word,label
Naloxone,I-Entity
reverses,O
the,O
antihypertensive,O
effect,O
of,O
clonidine,I-Entity
.,O
In,O
unanesthetized,O
",",O
spontaneously,O
hypertensive,I-Entity
rats,O
the,O
decrease,O
in,O
blood,O
pressure,O
and,O
heart,O
rate,O
produced,O
by,O
intravenous,O
clonidine,I-Entity
",",O
5,O
to,O
20,O
micrograms,O
/,O
kg,O
",",O
was,O
inhibited,O
or,O
reversed,O
by,O
nalozone,I-Entity
",",O
0.2,O
to,O
2,O
mg,O
/,O
kg,O
.,O
The,O
hypotensive,I-Entity
effect,O
of,O
100,O
mg,O
/,O
kg,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
was,O
also,O
partially,O
reversed,O
by,O
naloxone,I-Entity
.,O
Naloxone,I-Entity
alone,O
did,O
not,O
affect,O
either,O
blood,O
pressure,O
or,O
heart,O
rate,O
.,O
In,O
brain,O
membranes,O
from,O
spontaneously,O
hypertensive,I-Entity
rats,O
clonidine,I-Entity
",",O
10(-8,O
),O
to,O
10(-5,O
),O
M,O
",",O
did,O
not,O
influence,O
stereoselective,O
binding,O
of,O
[,B-Entity
3H]-naloxone,I-Entity
(,O
8,O
nM,O
),O
",",O
and,O
naloxone,I-Entity
",",O
10(-8,O
),O
to,O
10(-4,O
),O
M,O
",",O
did,O
not,O
influence,O
clonidine,I-Entity
-,O
suppressible,O
binding,O
of,O
[,B-Entity
3H]-dihydroergocryptine,I-Entity
(,O
1,O
nM,O
),O
.,O
These,O
findings,O
indicate,O
that,O
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
the,O
effects,O
of,O
central,O
alpha,O
-,O
adrenoceptor,O
stimulation,O
involve,O
activation,O
of,O
opiate,O
receptors,O
.,O
As,O
naloxone,I-Entity
and,O
clonidine,I-Entity
do,O
not,O
appear,O
to,O
interact,O
with,O
the,O
same,O
receptor,O
site,O
",",O
the,O
observed,O
functional,O
antagonism,O
suggests,O
the,O
release,O
of,O
an,O
endogenous,O
opiate,O
by,O
clonidine,I-Entity
or,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
and,O
the,O
possible,O
role,O
of,O
the,O
opiate,O
in,O
the,O
central,O
control,O
of,O
sympathetic,O
tone,O
.,O
Lidocaine,I-Entity
-,O
induced,O
cardiac,B-Entity
asystole,I-Entity
.,O
Intravenous,O
administration,O
of,O
a,O
single,O
50-mg,O
bolus,O
of,O
lidocaine,I-Entity
in,O
a,O
67-year,O
-,O
old,O
man,O
resulted,O
in,O
profound,O
depression,I-Entity
of,O
the,O
activity,O
of,O
the,O
sinoatrial,O
and,O
atrioventricular,O
nodal,O
pacemakers,O
.,O
The,O
patient,O
had,O
no,O
apparent,O
associated,O
conditions,O
which,O
might,O
have,O
predisposed,O
him,O
to,O
the,O
development,O
of,O
bradyarrhythmias,I-Entity
;,O
and,O
",",O
thus,O
",",O
this,O
probably,O
represented,O
a,O
true,O
idiosyncrasy,O
to,O
lidocaine,I-Entity
.,O
Suxamethonium,I-Entity
infusion,O
rate,O
and,O
observed,O
fasciculations,I-Entity
.,O
Suxamethonium,B-Entity
chloride,I-Entity
(,O
Sch,I-Entity
),O
was,O
administered,O
i.v,O
.,O
to,O
36,O
adult,O
males,O
at,O
six,O
rates,O
:,O
The,O
infusion,O
was,O
discontinued,O
either,O
when,O
there,O
was,O
no,O
muscular,O
response,O
to,O
tetanic,I-Entity
stimulation,O
of,O
the,O
ulnar,O
nerve,O
or,O
when,O
Sch,I-Entity
120,O
mg,O
was,O
exceeded,O
.,O
Fasciculations,I-Entity
in,O
six,O
areas,O
of,O
the,O
body,O
were,O
scored,O
from,O
0,O
to,O
3,O
and,O
summated,O
as,O
a,O
total,O
fasciculation,I-Entity
score,O
.,O
The,O
times,O
to,O
first,O
fasciculation,I-Entity
",",O
twitch,I-Entity
suppression,O
and,O
tetanus,I-Entity
suppression,O
were,O
inversely,O
related,O
to,O
the,O
infusion,O
rates,O
.,O
Fasciculations,I-Entity
in,O
the,O
six,O
areas,O
and,O
the,O
total,O
fasciculation,I-Entity
score,O
were,O
related,O
directly,O
to,O
the,O
rate,O
of,O
infusion,O
.,O
Total,O
fasciculation,I-Entity
scores,O
in,O
the,O
30-mg,O
bolus,O
group,O
and,O
the,O
5-mg,O
s-1,O
and,O
20-mg,O
s-1,O
infusion,O
groups,O
were,O
not,O
significantly,O
different,O
.,O
Galanthamine,B-Entity
hydrobromide,I-Entity
",",O
a,O
longer,O
acting,O
anticholinesterase,O
drug,O
",",O
in,O
the,O
treatment,O
of,O
the,O
central,O
effects,O
of,O
scopolamine,I-Entity
(,O
Hyoscine,I-Entity
),O
.,O
Galanthamine,B-Entity
hydrobromide,I-Entity
",",O
an,O
anticholinesterase,O
drug,O
capable,O
of,O
penetrating,O
the,O
blood,O
-,O
brain,O
barrier,O
",",O
was,O
used,O
in,O
a,O
patient,O
demonstrating,O
central,O
effects,O
of,O
scopolamine,I-Entity
(,O
hyoscine,I-Entity
),O
overdosage,I-Entity
.,O
It,O
is,O
longer,O
acting,O
than,O
physostigmine,I-Entity
and,O
is,O
used,O
in,O
anaesthesia,O
to,O
reverse,O
the,O
non,O
-,O
depolarizing,O
neuromuscular,O
block,O
.,O
However,O
",",O
studies,O
into,O
the,O
dose,O
necessary,O
to,O
combating,O
scopolamine,I-Entity
intoxication,O
are,O
indicated,O
.,O
Effects,O
of,O
uninephrectomy,O
and,O
high,O
protein,O
feeding,O
on,O
lithium,I-Entity
-,O
induced,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
in,O
rats,O
.,O
Rats,O
with,O
lithium,I-Entity
-,O
induced,O
nephropathy,I-Entity
were,O
subjected,O
to,O
high,O
protein,O
(,O
HP,O
),O
feeding,O
",",O
uninephrectomy,O
(,O
NX,O
),O
or,O
a,O
combination,O
of,O
these,O
",",O
in,O
an,O
attempt,O
to,O
induce,O
glomerular,O
hyperfiltration,O
and,O
further,O
progression,O
of,O
renal,B-Entity
failure,I-Entity
.,O
Newborn,O
female,O
Wistar,O
rats,O
were,O
fed,O
a,O
lithium,I-Entity
-,O
containing,O
diet,O
(,O
50,O
mmol,O
/,O
kg,O
),O
for,O
8,O
weeks,O
and,O
then,O
randomized,O
to,O
normal,O
diet,O
",",O
HP,O
diet,O
(,O
40,O
vs.,O
19%,O
),O
",",O
NX,O
or,O
HP+NX,O
for,O
another,O
8,O
weeks,O
.,O
Corresponding,O
non,O
-,O
lithium,I-Entity
pretreated,O
groups,O
were,O
generated,O
.,O
When,O
comparing,O
all,O
lithium,I-Entity
treated,O
versus,O
non,O
-,O
lithium,I-Entity
-,O
treated,O
groups,O
",",O
lithium,I-Entity
caused,O
a,O
reduction,O
in,O
glomerular,O
filtration,O
rate,O
(,O
GFR,O
),O
without,O
significant,O
changes,O
in,O
effective,O
renal,O
plasma,O
flow,O
(,O
as,O
determined,O
by,O
a,O
marker,O
secreted,O
into,O
the,O
proximal,O
tubules,O
),O
or,O
lithium,I-Entity
clearance,O
.,O
Consequently,O
",",O
lithium,I-Entity
pretreatment,O
caused,O
a,O
fall,O
in,O
filtration,O
fraction,O
and,O
an,O
increase,O
in,O
fractional,O
Li,I-Entity
excretion,O
.,O
Lithium,I-Entity
also,O
caused,O
proteinuria,I-Entity
and,O
systolic,O
hypertension,I-Entity
in,O
absence,O
of,O
glomerulosclerosis,I-Entity
.,O
HP,O
failed,O
to,O
accentuante,O
progression,O
of,O
renal,B-Entity
failure,I-Entity
and,O
in,O
fact,O
tended,O
to,O
increase,O
GFR,O
and,O
decrease,O
plasma,O
creatinine,I-Entity
levels,O
in,O
lithium,I-Entity
pretreated,O
rats,O
.,O
NX+HP,O
caused,O
a,O
further,O
rise,O
in,O
blood,O
pressure,O
in,O
Li,I-Entity
-,O
pretreated,O
rats,O
.,O
The,O
results,O
indicate,O
that,O
Li,I-Entity
-,O
induced,O
nephropathy,I-Entity
",",O
even,O
when,O
the,O
GFR,O
is,O
only,O
modestly,O
reduced,O
",",O
is,O
associated,O
with,O
proteinuria,I-Entity
and,O
arterial,O
systolic,O
hypertension,I-Entity
.,O
In,O
this,O
model,O
of,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
the,O
decline,O
in,O
GFR,O
is,O
not,O
accompanied,O
by,O
a,O
corresponding,O
fall,O
in,O
effective,O
renal,O
plasma,O
flow,O
",",O
which,O
may,O
be,O
the,O
functional,O
expression,O
of,O
the,O
formation,O
of,O
nonfiltrating,O
atubular,O
glomeruli,O
.,O
Treatment,O
of,O
Crohn,B-Entity
's,I-Entity
disease,I-Entity
with,O
fusidic,B-Entity
acid,I-Entity
:,O
an,O
antibiotic,O
with,O
immunosuppressive,O
properties,O
similar,O
to,O
cyclosporin,I-Entity
.,O
Fusidic,O
acid,O
is,O
an,O
antibiotic,O
with,O
T,O
-,O
cell,O
specific,O
immunosuppressive,O
effects,O
similar,O
to,O
those,O
of,O
cyclosporin,I-Entity
.,O
Because,O
of,O
the,O
need,O
for,O
the,O
development,O
of,O
new,O
treatments,O
for,O
Crohn,B-Entity
's,I-Entity
disease,I-Entity
",",O
a,O
pilot,O
study,O
was,O
undertaken,O
to,O
estimate,O
the,O
pharmacodynamics,O
and,O
tolerability,O
of,O
fusidic,B-Entity
acid,I-Entity
treatment,O
in,O
chronic,O
active,O
",",O
therapy,O
-,O
resistant,O
patients,O
.,O
Eight,O
Crohn,B-Entity
's,I-Entity
disease,I-Entity
patients,O
were,O
included,O
.,O
Fusidic,B-Entity
acid,I-Entity
was,O
administered,O
orally,O
in,O
a,O
dose,O
of,O
500,O
mg,O
t.d.s,O
.,O
Five,O
of,O
8,O
patients,O
(,O
63%,O
),O
improved,O
during,O
fusidic,B-Entity
acid,I-Entity
treatment,O
:,O
3,O
at,O
two,O
weeks,O
and,O
2,O
after,O
four,O
weeks,O
.,O
There,O
were,O
no,O
serious,O
clinical,O
side,O
effects,O
",",O
but,O
dose,O
reduction,O
was,O
required,O
in,O
two,O
patients,O
because,O
of,O
nausea,I-Entity
.,O
The,O
results,O
of,O
this,O
pilot,O
study,O
suggest,O
that,O
fusidic,B-Entity
acid,I-Entity
may,O
be,O
of,O
benefit,O
in,O
selected,O
chronic,O
active,O
Crohn,B-Entity
's,I-Entity
disease,I-Entity
patients,O
in,O
whom,O
conventional,O
treatment,O
is,O
ineffective,O
.,O
Because,O
there,O
seems,O
to,O
exist,O
a,O
scientific,O
rationale,O
for,O
the,O
use,O
of,O
fusidic,B-Entity
acid,I-Entity
at,O
the,O
cytokine,O
level,O
in,O
inflammatory,B-Entity
bowel,I-Entity
disease,I-Entity
",",O
we,O
suggest,O
that,O
the,O
role,O
of,O
this,O
treatment,O
should,O
be,O
further,O
investigated,O
.,O
Electrocardiographic,O
evidence,O
of,O
myocardial,B-Entity
injury,I-Entity
in,O
psychiatrically,O
hospitalized,O
cocaine,I-Entity
abusers,O
.,O
The,O
electrocardiograms,O
(,O
ECG,O
),O
of,O
99,O
cocaine,I-Entity
-,O
abusing,O
patients,O
were,O
compared,O
with,O
the,O
ECGs,O
of,O
50,O
schizophrenic,I-Entity
controls,O
.,O
Eleven,O
of,O
the,O
cocaine,I-Entity
abusers,O
and,O
none,O
of,O
the,O
controls,O
had,O
ECG,O
evidence,O
of,O
significant,O
myocardial,B-Entity
injury,I-Entity
defined,O
as,O
myocardial,B-Entity
infarction,I-Entity
",",O
ischemia,I-Entity
",",O
and,O
bundle,B-Entity
branch,I-Entity
block,I-Entity
.,O
Sulpiride,I-Entity
-,O
induced,O
tardive,B-Entity
dystonia,I-Entity
.,O
Sulpiride,I-Entity
is,O
a,O
selective,O
D2-receptor,O
antagonist,O
with,O
antipsychotic,O
and,O
antidepressant,I-Entity
properties,O
.,O
Although,O
initially,O
thought,O
to,O
be,O
free,O
of,O
extrapyramidal,O
side,O
effects,O
",",O
sulpiride,I-Entity
-,O
induced,O
tardive,B-Entity
dyskinesia,I-Entity
and,O
parkinsonism,I-Entity
have,O
been,O
reported,O
occasionally,O
.,O
We,O
studied,O
a,O
37-year,O
-,O
old,O
man,O
who,O
developed,O
persistent,O
segmental,O
dystonia,I-Entity
within,O
2,O
months,O
after,O
starting,O
sulpiride,I-Entity
therapy,O
.,O
We,O
could,O
not,O
find,O
any,O
previous,O
reports,O
of,O
sulpiride,I-Entity
-,O
induced,O
tardive,B-Entity
dystonia,I-Entity
.,O
Ocular,B-Entity
and,I-Entity
auditory,I-Entity
toxicity,I-Entity
in,O
hemodialyzed,O
patients,O
receiving,O
desferrioxamine,I-Entity
.,O
During,O
an,O
18-month,O
period,O
of,O
study,O
41,O
hemodialyzed,O
patients,O
receiving,O
desferrioxamine,I-Entity
(,O
10,O
-,O
40,O
mg,O
/,O
kg,O
BW/3,O
times,O
weekly,O
),O
for,O
the,O
first,O
time,O
were,O
monitored,O
for,O
detection,O
of,O
audiovisual,B-Entity
toxicity,I-Entity
.,O
6,O
patients,O
presented,O
clinical,O
symptoms,O
of,O
visual,B-Entity
or,I-Entity
auditory,I-Entity
toxicity,I-Entity
.,O
Visual,B-Entity
toxicity,I-Entity
was,O
of,O
retinal,O
origin,O
and,O
was,O
characterized,O
by,O
a,O
tritan,O
-,O
type,O
dyschromatopsy,I-Entity
",",O
sometimes,O
associated,O
with,O
a,B-Entity
loss,I-Entity
of,I-Entity
visual,I-Entity
acuity,I-Entity
and,O
pigmentary,B-Entity
retinal,I-Entity
deposits,I-Entity
.,O
Auditory,B-Entity
toxicity,I-Entity
was,O
characterized,O
by,O
a,O
mid-,O
to,O
high,O
-,O
frequency,O
neurosensorial,B-Entity
hearing,I-Entity
loss,I-Entity
and,O
the,O
lesion,O
was,O
of,O
the,O
cochlear,O
type,O
.,O
Desferrioxamine,I-Entity
withdrawal,O
resulted,O
in,O
a,O
complete,O
recovery,O
of,O
visual,O
function,O
in,O
1,O
patient,O
and,O
partial,O
recovery,O
in,O
3,O
",",O
and,O
a,O
complete,O
reversal,O
of,O
hearing,B-Entity
loss,I-Entity
in,O
3,O
patients,O
and,O
partial,O
recovery,O
in,O
3,O
.,O
This,O
toxicity,I-Entity
appeared,O
in,O
patients,O
receiving,O
the,O
higher,O
doses,O
of,O
desferrioxamine,I-Entity
or,O
coincided,O
with,O
the,O
normalization,O
of,O
ferritin,O
or,O
aluminium,I-Entity
serum,O
levels,O
.,O
The,O
data,O
indicate,O
that,O
audiovisual,B-Entity
toxicity,I-Entity
is,O
not,O
an,O
infrequent,O
complication,O
in,O
hemodialyzed,O
patients,O
receiving,O
desferrioxamine,I-Entity
.,O
Myasthenia,B-Entity
gravis,I-Entity
presenting,O
as,O
weakness,O
after,O
magnesium,I-Entity
administration,O
.,O
We,O
studied,O
a,O
patient,O
with,O
no,O
prior,O
history,O
of,O
neuromuscular,B-Entity
disease,I-Entity
who,O
became,O
virtually,O
quadriplegic,I-Entity
after,O
parenteral,O
magnesium,I-Entity
administration,O
for,O
preeclampsia,I-Entity
.,O
The,O
serum,O
magnesium,I-Entity
concentration,O
was,O
3.0,O
mEq,O
/,O
L,O
",",O
which,O
is,O
usually,O
well,O
tolerated,O
.,O
The,O
magnesium,I-Entity
was,O
stopped,O
and,O
she,O
recovered,O
over,O
a,O
few,O
days,O
.,O
While,O
she,O
was,O
weak,O
",",O
2-Hz,O
repetitive,O
stimulation,O
revealed,O
a,O
decrement,O
without,O
significant,O
facilitation,O
at,O
rapid,O
rates,O
or,O
after,O
exercise,O
",",O
suggesting,O
postsynaptic,B-Entity
neuromuscular,I-Entity
blockade,I-Entity
.,O
Her,O
acetylcholine,I-Entity
receptor,O
antibody,O
level,O
was,O
markedly,O
elevated,O
.,O
Although,O
paralysis,I-Entity
after,O
magnesium,I-Entity
administration,O
has,O
been,O
described,O
in,O
patients,O
with,O
known,O
myasthenia,B-Entity
gravis,I-Entity
",",O
it,O
has,O
not,O
previously,O
been,O
reported,O
to,O
be,O
the,O
initial,O
or,O
only,O
manifestation,O
of,O
the,O
disease,O
.,O
Patients,O
who,O
are,O
unusually,O
sensitive,O
to,O
the,O
neuromuscular,O
effects,O
of,O
magnesium,I-Entity
should,O
be,O
suspected,O
of,O
having,O
an,O
underlying,O
disorder,B-Entity
of,I-Entity
neuromuscular,I-Entity
transmission,I-Entity
.,O
Chloroacetaldehyde,I-Entity
and,O
its,O
contribution,O
to,O
urotoxicity,O
during,O
treatment,O
with,O
cyclophosphamide,I-Entity
or,O
ifosfamide,I-Entity
.,O
Based,O
on,O
clinical,O
data,O
",",O
indicating,O
that,O
chloroacetaldehyde,I-Entity
(,O
CAA,I-Entity
),O
is,O
an,O
important,O
metabolite,O
of,O
oxazaphosphorine,O
cytostatics,O
",",O
an,O
experimental,O
study,O
was,O
carried,O
out,O
in,O
order,O
to,O
elucidate,O
the,O
role,O
of,O
CAA,I-Entity
in,O
the,O
development,O
of,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
The,O
data,O
demonstrate,O
that,O
CAA,I-Entity
after,O
i.v,O
.,O
administration,O
does,O
not,O
contribute,O
to,O
bladder,B-Entity
damage,I-Entity
.,O
When,O
instilled,O
directly,O
into,O
the,O
bladder,O
",",O
CAA,I-Entity
exerts,O
urotoxic,O
effects,O
",",O
it,O
is,O
",",O
however,O
",",O
susceptible,O
to,O
detoxification,O
with,O
mesna,I-Entity
.,O
Source,O
of,O
pain,I-Entity
and,O
primitive,O
dysfunction,O
in,O
migraine,I-Entity
:,O
an,O
identical,O
site,O
?,O
Twenty,O
common,O
migraine,I-Entity
patients,O
received,O
a,O
one,O
sided,O
frontotemporal,O
application,O
of,O
nitroglycerin,I-Entity
(,O
10,O
patients,O
),O
or,O
placebo,O
ointment,O
(,O
10,O
patients,O
),O
in,O
a,O
double,O
blind,O
study,O
.,O
Early,O
onset,O
migraine,I-Entity
attacks,O
were,O
induced,O
by,O
nitroglycerin,I-Entity
in,O
seven,O
out,O
of,O
10,O
patients,O
versus,O
no,O
patient,O
in,O
the,O
placebo,O
group,O
.,O
Subsequently,O
20,O
migraine,I-Entity
patients,O
",",O
who,O
developed,O
an,O
early,O
onset,O
attack,O
with,O
frontotemporal,O
nitroglycerin,I-Entity
",",O
received,O
the,O
drug,O
in,O
a,O
second,O
induction,O
test,O
at,O
other,O
body,O
areas,O
.,O
No,O
early,O
onset,O
migraine,I-Entity
was,O
observed,O
.,O
Thus,O
the,O
migraine,I-Entity
-,O
inducing,O
effect,O
of,O
nitroglycerin,I-Entity
seems,O
to,O
depend,O
on,O
direct,O
stimulation,O
of,O
the,O
habitual,O
site,O
of,O
pain,I-Entity
",",O
suggesting,O
that,O
the,O
frontotemporal,O
region,O
is,O
of,O
crucial,O
importance,O
in,O
the,O
development,O
of,O
a,O
migraine,I-Entity
crisis,O
.,O
This,O
is,O
not,O
consistent,O
with,O
a,O
CNS,O
origin,O
of,O
migraine,I-Entity
attack,O
.,O
Clotiazepam,I-Entity
-,O
induced,O
acute,O
hepatitis,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
patient,O
who,O
developed,O
acute,O
hepatitis,I-Entity
with,O
extensive,B-Entity
hepatocellular,I-Entity
necrosis,I-Entity
",",O
7,O
months,O
after,O
the,O
onset,O
of,O
administration,O
of,O
clotiazepam,I-Entity
",",O
a,O
thienodiazepine,I-Entity
derivative,O
.,O
Clotiazepam,I-Entity
withdrawal,O
was,O
followed,O
by,O
prompt,O
recovery,O
.,O
The,O
administration,O
of,O
several,O
benzodiazepines,I-Entity
",",O
chemically,O
related,O
to,O
clotiazepam,I-Entity
",",O
did,O
not,O
interfere,O
with,O
recovery,O
and,O
did,O
not,O
induce,O
any,O
relapse,O
of,O
hepatitis,I-Entity
.,O
This,O
observation,O
shows,O
that,O
clotiazepam,I-Entity
can,O
induce,O
acute,O
hepatitis,I-Entity
and,O
suggests,O
that,O
there,O
is,O
no,O
cross,O
hepatotoxicity,I-Entity
between,O
clotiazepam,I-Entity
and,O
several,O
benzodiazepines,I-Entity
.,O
Arterial,O
hypertension,I-Entity
as,O
a,O
complication,O
of,O
prolonged,O
ketoconazole,I-Entity
treatment,O
.,O
Two,O
of,O
14,O
patients,O
with,O
Cushing,B-Entity
's,I-Entity
syndrome,I-Entity
treated,O
on,O
a,O
long,O
-,O
term,O
basis,O
with,O
ketoconazole,I-Entity
developed,O
sustained,O
hypertension,I-Entity
.,O
In,O
both,O
cases,O
normal,O
plasma,O
and,O
urinary,O
free,O
cortisol,I-Entity
levels,O
had,O
been,O
achieved,O
following,O
ketoconazole,I-Entity
therapy,O
",",O
yet,O
continuous,O
blood,O
pressure,O
monitoring,O
demonstrated,O
hypertension,I-Entity
31,O
(,O
patient,O
1,O
),O
and,O
52,O
weeks,O
(,O
patient,O
2,O
),O
after,O
treatment,O
.,O
In,O
patient,O
1,O
",",O
plasma,O
levels,O
of,O
deoxycorticosterone,I-Entity
and,O
11-deoxycortisol,I-Entity
were,O
elevated,O
.,O
In,O
patient,O
2,O
",",O
in,O
addition,O
to,O
an,O
increase,O
in,O
both,O
deoxycorticosterone,I-Entity
and,O
11-deoxycortisol,I-Entity
levels,O
",",O
plasma,O
aldosterone,I-Entity
values,O
were,O
raised,O
",",O
with,O
a,O
concomitant,O
suppression,O
of,O
renin,O
levels,O
.,O
Our,O
findings,O
show,O
that,O
long,O
-,O
term,O
treatment,O
with,O
high,O
doses,O
of,O
ketoconazole,I-Entity
may,O
induce,O
enzyme,O
blockade,O
leading,O
to,O
mineralocorticoid,O
-,O
related,O
hypertension,I-Entity
.,O
Effects,O
of,O
an,O
inhibitor,O
of,O
angiotensin,I-Entity
converting,O
enzyme,O
(,O
Captopril,I-Entity
),O
on,O
pulmonary,B-Entity
and,I-Entity
renal,I-Entity
insufficiency,I-Entity
due,O
to,O
intravascular,B-Entity
coagulation,I-Entity
in,O
the,O
rat,O
.,O
Induction,O
of,O
intravascular,B-Entity
coagulation,I-Entity
and,O
inhibition,O
of,O
fibrinolysis,O
by,O
injection,O
of,O
thrombin,O
and,O
tranexamic,B-Entity
acid,I-Entity
(,O
AMCA,I-Entity
),O
in,O
the,O
rat,O
gives,O
rise,O
to,O
pulmonary,B-Entity
and,I-Entity
renal,I-Entity
insufficiency,I-Entity
resembling,O
that,O
occurring,O
after,O
trauma,I-Entity
or,O
sepsis,I-Entity
in,O
man,O
.,O
Injection,O
of,O
Captopril,I-Entity
(,O
1,O
mg,O
/,O
kg,O
),O
",",O
an,O
inhibitor,O
of,O
angiotensin,I-Entity
converting,O
enzyme,O
(,O
ACE,O
),O
",",O
reduced,O
both,O
pulmonary,B-Entity
and,I-Entity
renal,I-Entity
insufficiency,I-Entity
in,O
this,O
rat,O
model,O
.,O
The,O
contents,O
of,O
albumin,O
in,O
the,O
lungs,O
were,O
not,O
changed,O
",",O
indicating,O
that,O
Captopril,I-Entity
did,O
not,O
influence,O
the,O
extravasation,O
of,O
protein,O
.,O
Renal,B-Entity
damage,I-Entity
as,O
reflected,O
by,O
an,O
increase,O
in,O
serum,O
urea,I-Entity
and,O
in,O
kidney,O
weight,O
was,O
prevented,O
by,O
Captopril,I-Entity
.,O
The,O
amount,O
of,O
fibrin,O
in,O
the,O
kidneys,O
was,O
also,O
considerably,O
lower,O
than,O
in,O
animals,O
which,O
received,O
thrombin,O
and,O
AMCA,I-Entity
alone,O
.,O
It,O
is,O
suggested,O
that,O
the,O
effects,O
of,O
Captopril,I-Entity
on,O
the,O
lungs,O
may,O
be,O
attributable,O
to,O
a,O
vasodilatory,O
effect,O
due,O
to,O
a,O
reduction,O
in,O
the,O
circulating,O
level,O
of,O
Angiotension,B-Entity
II,I-Entity
and,O
an,O
increase,O
in,O
prostacyclin,I-Entity
(,O
secondary,O
to,O
an,O
increase,O
in,O
bradykinin,I-Entity
),O
.,O
Captopril,I-Entity
may,O
",",O
by,O
the,O
same,O
mechanism,O
",",O
reduce,O
the,O
increase,O
in,O
glomerular,O
filtration,O
that,O
is,O
known,O
to,O
occur,O
after,O
an,O
injection,O
of,O
thrombin,O
",",O
thereby,O
diminishing,O
the,O
aggregation,O
of,O
fibrin,O
monomers,O
in,O
the,O
glomeruli,O
",",O
with,O
the,O
result,O
that,O
less,O
fibrin,O
will,O
be,O
deposited,O
and,O
thus,O
less,O
kidney,B-Entity
damage,I-Entity
will,O
be,O
produced,O
.,O
A,O
randomized,O
comparison,O
of,O
labetalol,I-Entity
and,O
nitroprusside,I-Entity
for,O
induced,O
hypotension,I-Entity
.,O
In,O
a,O
randomized,O
study,O
",",O
labetalol,I-Entity
-,O
induced,O
hypotension,I-Entity
and,O
nitroprusside,I-Entity
-,O
induced,O
hypotension,I-Entity
were,O
compared,O
in,O
20,O
patients,O
(,O
10,O
in,O
each,O
group,O
),O
scheduled,O
for,O
major,O
orthopedic,O
procedures,O
.,O
Each,O
patient,O
was,O
subjected,O
to,O
an,O
identical,O
anesthetic,O
protocol,O
and,O
similar,O
drug,O
-,O
induced,O
reductions,B-Entity
in,I-Entity
mean,I-Entity
arterial,I-Entity
blood,I-Entity
pressure,I-Entity
(,O
BP,O
),O
(,O
50,O
to,O
55,O
mmHg,O
),O
.,O
Nitroprusside,O
infusion,O
was,O
associated,O
with,O
a,O
significant,O
(,O
p,O
less,O
than,O
0.05,O
),O
increase,B-Entity
in,I-Entity
heart,I-Entity
rate,I-Entity
and,I-Entity
cardiac,I-Entity
output,I-Entity
;,O
rebound,O
hypertension,I-Entity
was,O
observed,O
in,O
three,O
patients,O
after,O
discontinuation,O
of,O
nitroprusside,I-Entity
.,O
Labetalol,I-Entity
administration,O
was,O
not,O
associated,O
with,O
any,O
of,O
these,O
findings,O
.,O
Arterial,O
PO2,I-Entity
decreased,O
in,O
both,O
groups,O
.,O
It,O
was,O
concluded,O
that,O
labetalol,I-Entity
offers,O
advantages,O
over,O
nitroprusside,I-Entity
.,O
Chronic,O
carbamazepine,I-Entity
treatment,O
in,O
the,O
rat,O
:,O
efficacy,O
",",O
toxicity,I-Entity
",",O
and,O
effect,O
on,O
plasma,O
and,O
tissue,O
folate,I-Entity
concentrations,O
.,O
Folate,I-Entity
depletion,O
has,O
often,O
been,O
a,O
problem,O
in,O
chronic,O
antiepileptic,O
drug,O
(,O
AED,O
),O
therapy,O
.,O
Carbamazepine,I-Entity
(,O
CBZ,I-Entity
),O
",",O
a,O
commonly,O
used,O
AED,O
",",O
has,O
been,O
implicated,O
in,O
some,O
clinical,O
studies,O
.,O
A,O
rat,O
model,O
was,O
developed,O
to,O
examine,O
the,O
effects,O
of,O
chronic,O
CBZ,I-Entity
treatment,O
on,O
folate,I-Entity
concentrations,O
in,O
the,O
rat,O
.,O
In,O
the,O
course,O
of,O
developing,O
this,O
model,O
",",O
a,O
common,O
vehicle,O
",",O
propylene,B-Entity
glycol,I-Entity
",",O
by,O
itself,O
in,O
high,O
doses,O
",",O
was,O
found,O
to,O
exhibit,O
protective,O
properties,O
against,O
induced,O
seizures,I-Entity
and,O
inhibited,O
weight,B-Entity
gain,I-Entity
.,O
Seizures,I-Entity
induced,O
by,O
hexafluorodiethyl,B-Entity
ether,I-Entity
(,O
HFDE,I-Entity
),O
were,O
also,O
found,O
to,O
be,O
a,O
more,O
sensitive,O
measure,O
of,O
protection,O
by,O
CBZ,I-Entity
than,O
seizures,I-Entity
induced,O
by,O
maximal,O
electroshock,O
(,O
MES,O
),O
.,O
Oral,O
administration,O
of,O
CBZ,I-Entity
as,O
an,O
aqueous,O
suspension,O
every,O
8,O
h,O
at,O
a,O
dose,O
of,O
250,O
mg,O
/,O
kg,O
was,O
continuously,O
protective,O
against,O
HFDE,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
was,O
minimally,O
toxic,O
as,O
measured,O
by,O
weight,B-Entity
gain,I-Entity
over,O
8,O
weeks,O
of,O
treatment,O
.,O
The,O
CBZ,I-Entity
levels,O
measured,O
in,O
plasma,O
and,O
brain,O
of,O
these,O
animals,O
",",O
however,O
",",O
were,O
below,O
those,O
normally,O
considered,O
protective,O
.,O
This,O
treatment,O
with,O
CBZ,I-Entity
had,O
no,O
apparent,O
adverse,O
effect,O
on,O
folate,I-Entity
concentrations,O
in,O
the,O
rat,O
",",O
and,O
",",O
indeed,O
",",O
the,O
folate,I-Entity
concentration,O
increased,O
in,O
liver,O
after,O
6,O
weeks,O
of,O
treatment,O
and,O
in,O
plasma,O
at,O
8,O
weeks,O
of,O
treatment,O
.,O
In,O
six,O
conscious,O
",",O
trained,O
dogs,O
",",O
maintained,O
on,O
a,O
normal,O
sodium,I-Entity
intake,O
of,O
2,O
to,O
4,O
mEq,O
/,O
kg,O
/,O
day,O
",",O
sympathetic,O
activity,O
was,O
assessed,O
as,O
the,O
release,O
rate,O
of,O
norepinephrine,I-Entity
and,O
epinephrine,I-Entity
during,O
15-minute,O
i.v,O
.,O
6%,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
respectively,O
",",O
but,O
no,O
tachycardia,I-Entity
and,O
no,O
augmentation,O
of,O
the,O
norepinephrine,I-Entity
release,O
rate,O
(,O
up,O
to,O
0.3,O
microgram,O
/,O
kg,O
/,O
min,O
),O
were,O
observed,O
",",O
which,O
is,O
in,O
contrast,O
to,O
comparable,O
hypotension,I-Entity
induced,O
by,O
hydralazine,I-Entity
or,O
nitroglycerin,I-Entity
.,O
The,O
release,O
rate,O
of,O
epinephrine,I-Entity
(,O
control,O
",",O
6.7,O
+,O
/-,O
Death,I-Entity
from,O
chemotherapy,O
in,O
gestational,B-Entity
trophoblastic,I-Entity
disease,I-Entity
.,O
Multiple,O
cytotoxic,O
drug,O
administration,O
is,O
the,O
generally,O
accepted,O
treatment,O
of,O
patients,O
with,O
a,O
high,O
-,O
risk,O
stage,O
of,O
choriocarcinoma,I-Entity
.,O
The,O
multiple,O
drug,O
schema,O
consisted,O
of,O
:,O
Etoposide,I-Entity
16.213,O
",",O
Methotrexate,I-Entity
",",O
Cyclophosphamide,I-Entity
",",O
Actomycin,B-Entity
-,I-Entity
D,I-Entity
",",O
and,O
Cisplatin,I-Entity
.,O
On,O
the,O
first,O
day,O
of,O
the,O
schedule,O
",",O
moderate,O
high,O
doses,O
of,O
Methotrexate,I-Entity
",",O
Etoposide,I-Entity
and,O
Cyclophosphamide,I-Entity
were,O
administered,O
.,O
Within,O
8,O
hours,O
after,O
initiation,O
of,O
therapy,O
the,O
patient,O
died,O
with,O
a,O
clinical,O
picture,O
resembling,O
massive,O
pulmonary,B-Entity
obstruction,I-Entity
due,O
to,O
choriocarcinomic,O
tissue,O
plugs,O
",",O
probably,O
originating,O
from,O
the,O
uterus,O
.,O
Formation,O
of,O
these,O
plugs,O
was,O
probably,O
due,O
to,O
extensive,O
tumor,I-Entity
necrosis,I-Entity
at,O
the,O
level,O
of,O
the,O
walls,O
of,O
the,O
major,O
uterine,O
veins,O
",",O
which,O
resulted,O
in,O
an,O
open,O
exchange,O
of,O
tumor,I-Entity
plugs,O
to,O
the,O
vascular,O
spaces,O
;,O
decrease,O
in,O
tumor,I-Entity
tissue,O
coherence,O
secondary,O
to,O
chemotherapy,O
may,O
have,O
further,O
contributed,O
to,O
the,O
formation,O
of,O
tumor,I-Entity
emboli,O
.,O
In,O
view,O
of,O
the,O
close,O
time,O
association,O
between,O
the,O
start,O
of,O
chemotherapy,O
and,O
the,O
acute,O
onset,O
of,O
massive,O
embolism,I-Entity
other,O
explanations,O
",",O
such,O
as,O
spontaneous,O
necrosis,I-Entity
",",O
must,O
be,O
considered,O
less,O
likely,O
.,O
Patients,O
with,O
large,O
pelvic,B-Entity
tumor,I-Entity
loads,O
are,O
",",O
according,O
to,O
existing,O
classifications,O
",",O
at,O
high,O
risk,O
to,O
die,O
and,O
to,O
develop,O
drug,O
resistance,O
.,O
Sexual,B-Entity
dysfunction,I-Entity
among,O
patients,O
with,O
arthritis,I-Entity
.,O
The,O
relationship,O
of,O
arthritis,I-Entity
and,O
sexual,B-Entity
dysfunction,I-Entity
was,O
investigated,O
among,O
169,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
",",O
osteoarthritis,I-Entity
and,O
spondyloarthropathy,I-Entity
",",O
130,O
of,O
whom,O
were,O
pair,O
-,O
matched,O
to,O
controls,O
.,O
Assessments,O
of,O
marital,O
happiness,O
and,O
depressed,B-Entity
mood,I-Entity
were,O
also,O
made,O
using,O
the,O
CES,O
-,O
D,O
and,O
the,O
Azrin,O
Marital,O
Happiness,O
Scale,O
(,O
AMHS,O
),O
.,O
Sexual,B-Entity
dysfunctions,I-Entity
were,O
found,O
to,O
be,O
common,O
among,O
patients,O
and,O
controls,O
",",O
the,O
majority,O
in,O
both,O
groups,O
reporting,O
one,O
or,O
more,O
dysfunctions,O
.,O
Impotence,I-Entity
was,O
more,O
common,O
among,O
male,O
patients,O
than,O
controls,O
and,O
was,O
found,O
to,O
be,O
associated,O
with,O
co,O
-,O
morbidity,O
and,O
the,O
taking,O
of,O
methotrexate,I-Entity
.,O
Depressed,B-Entity
mood,I-Entity
was,O
more,O
common,O
among,O
patients,O
and,O
was,O
associated,O
with,O
certain,O
sexual,O
difficulties,O
",",O
but,O
not,O
with,O
impotence,I-Entity
.,O
Marital,O
unhappiness,O
",",O
as,O
indicated,O
by,O
AMHS,O
scores,O
",",O
was,O
not,O
associated,O
with,O
arthritis,I-Entity
but,O
was,O
associated,O
with,O
sexual,B-Entity
dysfunction,I-Entity
",",O
sexual,O
dissatisfaction,O
and,O
being,O
female,O
.,O
Does,O
paracetamol,I-Entity
cause,O
urothelial,B-Entity
cancer,I-Entity
or,O
renal,B-Entity
papillary,I-Entity
necrosis,I-Entity
?,O
The,O
risk,O
of,O
developing,O
renal,B-Entity
papillary,I-Entity
necrosis,I-Entity
or,O
cancer,B-Entity
of,I-Entity
the,I-Entity
renal,I-Entity
pelvis,I-Entity
",",I-Entity
ureter,I-Entity
or,I-Entity
bladder,I-Entity
associated,O
with,O
consumption,O
of,O
either,O
phenacetin,I-Entity
or,O
paracetamol,I-Entity
was,O
calculated,O
from,O
data,O
acquired,O
by,O
questionnaire,O
from,O
381,O
cases,O
and,O
808,O
controls,O
.,O
The,O
risk,O
of,O
renal,B-Entity
papillary,I-Entity
necrosis,I-Entity
was,O
increased,O
nearly,O
20-fold,O
by,O
consumption,O
of,O
phenacetin,I-Entity
",",O
which,O
also,O
increased,O
the,O
risk,O
for,O
cancer,B-Entity
of,I-Entity
the,I-Entity
renal,I-Entity
pelvis,I-Entity
and,I-Entity
bladder,I-Entity
but,O
not,O
for,O
ureteric,B-Entity
cancer,I-Entity
.,O
By,O
contrast,O
",",O
we,O
were,O
unable,O
to,O
substantiate,O
an,O
increased,O
risk,O
from,O
paracetamol,I-Entity
consumption,O
for,O
renal,B-Entity
papillary,I-Entity
necrosis,I-Entity
or,O
any,O
of,O
these,O
cancers,I-Entity
although,O
there,O
was,O
a,O
suggestion,O
of,O
an,O
association,O
with,O
cancer,B-Entity
of,I-Entity
the,I-Entity
ureter,I-Entity
.,O
Dapsone,I-Entity
-,O
associated,O
Heinz,O
body,O
hemolytic,B-Entity
anemia,I-Entity
in,O
a,O
Cambodian,O
woman,O
with,O
hemoglobin,O
E,O
trait,O
.,O
A,O
Cambodian,O
woman,O
with,O
hemoglobin,O
E,O
trait,O
(,O
AE,O
),O
and,O
leprosy,I-Entity
developed,O
a,O
Heinz,O
body,O
hemolytic,B-Entity
anemia,I-Entity
while,O
taking,O
a,O
dose,O
of,O
dapsone,I-Entity
(,O
50,O
mg,O
/,O
day,O
),O
not,O
usually,O
associated,O
with,O
clinical,O
hemolysis,I-Entity
.,O
Her,O
red,O
blood,O
cells,O
(,O
RBCs,O
),O
had,O
increased,O
incubated,O
Heinz,O
body,O
formation,O
",",O
decreased,O
reduced,O
glutathione,I-Entity
(,O
GSH,I-Entity
),O
",",O
and,O
decreased,O
GSH,I-Entity
stability,O
.,O
The,O
pentose,B-Entity
phosphate,I-Entity
shunt,O
activity,O
of,O
the,O
dapsone,I-Entity
-,O
exposed,O
AE,O
RBCs,O
was,O
increased,O
compared,O
to,O
normal,O
RBCs,O
.,O
Although,O
the,O
AE,O
RBCs,O
from,O
an,O
individual,O
not,O
taking,O
dapsone,I-Entity
had,O
increased,O
incubated,O
Heinz,O
body,O
formation,O
",",O
the,O
GSH,I-Entity
content,O
and,O
GSH,I-Entity
stability,O
were,O
normal,O
.,O
The,O
pentose,B-Entity
phosphate,I-Entity
shunt,O
activity,O
of,O
the,O
non,O
-,O
dapsone,I-Entity
-,O
exposed,O
AE,O
RBCs,O
was,O
decreased,O
compared,O
to,O
normal,O
RBCs,O
.,O
Thus,O
",",O
AE,O
RBCs,O
appear,O
to,O
have,O
an,O
increased,O
sensitivity,O
to,O
oxidant,O
stress,O
both,O
in,O
vitro,O
and,O
in,O
vivo,O
",",O
since,O
dapsone,I-Entity
does,O
not,O
cause,O
hemolytic,B-Entity
anemia,I-Entity
at,O
this,O
dose,O
in,O
hematologically,O
normal,O
individuals,O
.,O
Given,O
the,O
influx,O
of,O
Southeast,O
Asians,O
into,O
the,O
United,O
States,O
",",O
oxidant,O
medications,O
should,O
be,O
used,O
with,O
caution,O
",",O
especially,O
if,O
an,O
infection,I-Entity
is,O
present,O
",",O
in,O
individuals,O
of,O
ethnic,O
backgrounds,O
that,O
have,O
an,O
increased,O
prevalence,O
of,O
hemoglobin,O
E.,O
Severe,O
complications,O
of,O
antianginal,O
drug,O
therapy,O
in,O
a,O
patient,O
identified,O
as,O
a,O
poor,O
metabolizer,O
of,O
metoprolol,I-Entity
",",O
propafenone,I-Entity
",",O
diltiazem,I-Entity
",",O
and,O
sparteine,I-Entity
.,O
A,O
47-year,O
-,O
old,O
patient,O
suffering,O
from,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
was,O
admitted,O
to,O
the,O
CCU,O
in,O
shock,I-Entity
with,O
III,O
.,O
AV,B-Entity
block,I-Entity
",",O
severe,O
hypotension,I-Entity
",",O
and,O
impairment,B-Entity
of,I-Entity
ventricular,I-Entity
function,I-Entity
.,O
One,O
week,O
prior,O
to,O
admission,O
a,O
therapy,O
with,O
standard,O
doses,O
of,O
metoprolol,I-Entity
(,O
100,O
mg,O
t.i.d,O
.,O
and,O
then,O
100,O
mg,O
b.i.d,O
.,O
),O
had,O
been,O
initiated,O
.,O
Two,O
days,O
before,O
admission,O
diltiazem,I-Entity
(,O
60,O
mg,O
b.i.d,O
.,O
),O
was,O
prescribed,O
in,O
addition,O
.,O
Analyses,O
of,O
a,O
blood,O
sample,O
revealed,O
unusually,O
high,O
plasma,O
concentrations,O
of,O
metoprolol,I-Entity
(,O
greater,O
than,O
3000,O
ng,O
/,O
ml,O
),O
and,O
diltiazem,I-Entity
(,O
526,O
ng,O
/,O
ml,O
),O
.,O
Three,O
months,O
later,O
the,O
patient,O
was,O
exposed,O
to,O
a,O
single,O
dose,O
of,O
metoprolol,I-Entity
",",O
diltiazem,I-Entity
",",O
propafenone,I-Entity
(,O
since,O
he,O
had,O
received,O
this,O
drug,O
in,O
the,O
past,O
),O
",",O
and,O
sparteine,I-Entity
(,O
as,O
a,O
probe,O
for,O
the,O
debrisoquine,I-Entity
/,O
sparteine,I-Entity
type,O
polymorphism,O
of,O
oxidative,O
drug,O
metabolism,O
),O
.,O
Therefore,O
",",O
patients,O
belonging,O
to,O
the,O
poor,O
-,O
metabolizer,O
phenotype,O
of,O
sparteine,I-Entity
/,O
debrisoquine,I-Entity
polymorphism,O
in,O
drug,O
metabolism,O
",",O
which,O
constitutes,O
6.4%,O
of,O
the,O
German,O
population,O
",",O
may,O
experience,O
adverse,B-Entity
drug,I-Entity
reactions,I-Entity
when,O
treated,O
with,O
standard,O
doses,O
of,O
one,O
of,O
these,O
drugs,O
alone,O
.,O
Triazolam,I-Entity
-,O
induced,O
brief,O
episodes,O
of,O
secondary,O
mania,I-Entity
in,O
a,O
depressed,I-Entity
patient,O
.,O
Large,O
doses,O
of,O
triazolam,I-Entity
repeatedly,O
induced,O
brief,O
episodes,O
of,O
mania,I-Entity
in,O
a,O
depressed,I-Entity
elderly,O
woman,O
.,O
Features,O
of,O
organic,B-Entity
mental,I-Entity
disorder,I-Entity
(,O
delirium,I-Entity
),O
were,O
not,O
present,O
.,O
Manic,I-Entity
excitement,O
was,O
coincident,O
with,O
the,O
duration,O
of,O
action,O
of,O
triazolam,I-Entity
.,O
The,O
possible,O
contribution,O
of,O
the,O
triazolo,I-Entity
group,O
to,O
changes,O
in,O
affective,O
status,O
is,O
discussed,O
.,O
On,O
the,O
mechanisms,O
of,O
the,O
development,O
of,O
tolerance,O
to,O
the,O
muscular,B-Entity
rigidity,I-Entity
produced,O
by,O
morphine,I-Entity
in,O
rats,O
.,O
The,O
development,O
of,O
tolerance,O
to,O
the,O
muscular,B-Entity
rigidity,I-Entity
produced,O
by,O
morphine,I-Entity
was,O
studied,O
in,O
rats,O
.,O
Saline,O
-,O
pretreated,O
controls,O
given,O
a,O
test,O
dose,O
of,O
morphine,I-Entity
(,O
20,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
showed,O
a,O
pronounced,O
rigidity,I-Entity
recorded,O
as,O
tonic,O
activity,O
in,O
the,O
electromyogram,O
.,O
Rats,O
treated,O
for,O
11,O
days,O
with,O
morphine,I-Entity
and,O
withdrawn,O
for,O
36,O
-,O
40,O
h,O
showed,O
differences,O
in,O
the,O
development,O
of,O
tolerance,O
:,O
about,O
half,O
of,O
the,O
animals,O
showed,O
a,O
rigidity,I-Entity
after,O
the,O
test,O
dose,O
of,O
morphine,I-Entity
that,O
was,O
not,O
significantly,O
less,O
than,O
in,O
the,O
controls,O
and,O
were,O
akinetic,I-Entity
(,O
A,O
group,O
),O
.,O
The,O
other,O
rats,O
showed,O
a,O
strong,O
decrease,O
in,O
the,O
rigidity,I-Entity
and,O
the,O
occurrence,O
of,O
stereotyped,O
(,O
S,O
),O
licking,O
and/or,O
gnawing,O
in,O
presence,O
of,O
akinetic,I-Entity
or,O
hyperkinetic,I-Entity
(,O
K,O
),O
behaviour,O
(,O
AS,O
/,O
KS,O
group,O
),O
",",O
suggesting,O
signs,O
of,O
dopaminergic,O
activation,O
.,O
The,O
rigidity,I-Entity
was,O
considerably,O
decreased,O
in,O
both,O
groups,O
after,O
20,O
days,O
',O
treatment,O
.,O
In,O
a,O
further,O
series,O
of,O
experiments,O
",",O
haloperidol,I-Entity
(,O
0.2,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
was,O
used,O
in,O
order,O
to,O
block,O
the,O
dopaminergic,O
activation,O
and,O
to,O
estimate,O
the,O
real,O
degree,O
of,O
the,O
tolerance,O
to,O
the,O
rigidity,I-Entity
without,O
any,O
dopaminergic,O
interference,O
.,O
Haloperidol,I-Entity
enhanced,O
the,O
rigidity,I-Entity
in,O
the,O
A,O
group,O
.,O
The,O
results,O
suggest,O
that,O
rigidity,I-Entity
",",O
which,O
is,O
assumed,O
to,O
be,O
due,O
to,O
an,O
action,O
of,O
morphine,I-Entity
in,O
the,O
striatum,O
",",O
can,O
be,O
antagonized,O
by,O
another,O
process,O
leading,O
to,O
dopaminergic,O
activation,O
in,O
the,O
striatum,O
.,O
The,O
rapid,O
alternations,O
of,O
rigidity,I-Entity
and,O
the,O
signs,O
of,O
dopaminergic,O
activation,O
observed,O
in,O
the,O
animals,O
of,O
the,O
AS,O
/,O
KS,O
group,O
might,O
be,O
due,O
to,O
rapid,O
shifts,O
in,O
the,O
predominance,O
of,O
various,O
DA,O
-,O
innervated,O
structures,O
.,O
Compression,B-Entity
neuropathy,I-Entity
of,I-Entity
the,I-Entity
radial,I-Entity
nerve,I-Entity
due,O
to,O
pentazocine,I-Entity
-,O
induced,O
fibrous,B-Entity
myopathy,I-Entity
.,O
Fibrous,B-Entity
myopathy,I-Entity
is,O
a,O
common,O
",",O
well,O
-,O
known,O
side,O
effect,O
of,O
repeated,O
pentazocine,I-Entity
injection,O
.,O
However,O
",",O
compression,B-Entity
neuropathy,I-Entity
due,O
to,O
fibrotic,O
muscle,O
affected,O
by,O
pentazocine,I-Entity
-,O
induced,O
myopathy,I-Entity
has,O
not,O
previously,O
been,O
reported,O
.,O
In,O
a,O
37-year,O
-,O
old,O
woman,O
with,O
documented,O
pentazocine,I-Entity
-,O
induced,O
fibrous,B-Entity
myopathy,I-Entity
of,O
triceps,O
and,O
deltoid,O
muscles,O
bilaterally,O
and,O
a,O
three,O
-,O
week,O
history,O
of,O
right,O
wrist,O
drop,O
",",O
electrodiagnostic,O
examination,O
showed,O
a,O
severe,O
but,O
partial,O
lesion,O
of,O
the,O
right,O
radial,O
nerve,O
distal,O
to,O
the,O
branches,O
to,O
the,O
triceps,O
",",O
in,O
addition,O
to,O
the,O
fibrous,B-Entity
myopathy,I-Entity
.,O
Recurrent,O
reversible,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
from,O
amphotericin,I-Entity
.,O
A,O
patient,O
with,O
cryptogenic,O
cirrhosis,I-Entity
and,O
disseminated,O
sporotrichosis,I-Entity
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
immediately,O
following,O
the,O
administration,O
of,O
amphotericin,B-Entity
B,I-Entity
on,O
four,O
separate,O
occasions,O
.,O
The,O
abruptness,O
of,O
the,O
renal,B-Entity
failure,I-Entity
and,O
its,O
reversibility,O
within,O
days,O
suggests,O
that,O
there,O
was,O
a,O
functional,O
component,O
to,O
the,O
renal,B-Entity
dysfunction,I-Entity
.,O
We,O
propose,O
that,O
amphotericin,I-Entity
",",O
in,O
the,O
setting,O
of,O
reduced,O
effective,O
arterial,O
volume,O
",",O
may,O
activate,O
tubuloglomerular,O
feedback,O
",",O
thereby,O
contributing,O
to,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
Pneumonitis,O
with,O
pleural,B-Entity
and,I-Entity
pericardial,I-Entity
effusion,I-Entity
and,O
neuropathy,I-Entity
during,O
amiodarone,I-Entity
therapy,O
.,O
A,O
patient,O
with,O
sinuatrial,B-Entity
disease,I-Entity
and,O
implanted,O
pacemaker,O
was,O
treated,O
with,O
amiodarone,I-Entity
(,O
maximum,O
dose,O
1000,O
mg,O
",",O
maintenance,O
dose,O
800,O
mg,O
daily,O
),O
for,O
10,O
months,O
",",O
for,O
control,O
of,O
supraventricular,B-Entity
tachyarrhythmias,I-Entity
.,O
He,O
developed,O
pneumonitis,I-Entity
",",O
pleural,B-Entity
and,I-Entity
pericardial,I-Entity
effusions,I-Entity
",",O
and,O
a,O
predominantly,O
proximal,B-Entity
motor,I-Entity
neuropathy,I-Entity
.,O
Immediate,O
but,O
gradual,O
improvement,O
followed,O
withdrawal,O
of,O
amiodarone,I-Entity
and,O
treatment,O
with,O
prednisolone,I-Entity
.,O
Review,O
of,O
this,O
and,O
previously,O
reported,O
cases,O
indicates,O
the,O
need,O
for,O
early,O
diagnosis,O
of,O
amiodarone,I-Entity
pneumonitis,I-Entity
",",O
immediate,O
withdrawal,O
of,O
amiodarone,I-Entity
",",O
and,O
prompt,O
but,O
continued,O
steroid,I-Entity
therapy,O
to,O
ensure,O
full,O
recovery,O
.,O
Indomethacin,I-Entity
-,O
induced,O
renal,B-Entity
insufficiency,I-Entity
:,O
recurrence,O
on,O
rechallenge,O
.,O
We,O
have,O
reported,O
a,O
case,O
of,O
acute,O
oliguric,O
renal,B-Entity
failure,I-Entity
with,O
hyperkalemia,I-Entity
in,O
a,O
patient,O
with,O
cirrhosis,I-Entity
",",O
ascites,I-Entity
",",O
and,O
cor,B-Entity
pulmonale,I-Entity
after,O
indomethacin,I-Entity
therapy,O
.,O
Prompt,O
restoration,O
of,O
renal,O
function,O
followed,O
drug,O
withdrawal,O
",",O
while,O
re,O
-,O
exposure,O
to,O
a,O
single,O
dose,O
of,O
indomethacin,I-Entity
caused,O
recurrence,O
of,O
acute,O
reversible,O
oliguria,I-Entity
.,O
Our,O
case,O
supports,O
the,O
hypothesis,O
that,O
endogenous,O
renal,O
prostaglandins,I-Entity
play,O
a,O
role,O
in,O
the,O
maintenance,O
of,O
renal,O
blood,O
flow,O
when,O
circulating,O
plasma,O
volume,O
is,O
diminished,O
.,O
Since,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
agents,O
interfere,O
with,O
this,O
compensatory,O
mechanism,O
and,O
may,O
cause,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
",",O
they,O
should,O
be,O
used,O
with,O
caution,O
in,O
such,O
patients,O
.,O
administration,O
of,O
flunitrazepam,I-Entity
in,O
volunteers,O
.,O
Flunitrazepam,I-Entity
0.5,O
",",O
1.0,O
or,O
2.0,O
mg,O
was,O
given,O
by,O
the,O
oral,O
or,O
i.m,O
.,O
Dizziness,I-Entity
was,O
less,O
marked,O
than,O
sedation,O
",",O
but,O
increased,O
with,O
the,O
dose,O
.,O
There,O
was,O
pain,I-Entity
on,O
i.m,O
.,O
injection,O
of,O
flunitrazepam,I-Entity
significantly,O
more,O
often,O
than,O
with,O
isotonic,O
saline,O
.,O
Changes,O
in,O
heart,O
size,O
during,O
long,O
-,O
term,O
timolol,I-Entity
treatment,O
after,O
myocardial,B-Entity
infarction,I-Entity
.,O
The,O
effect,O
of,O
long,O
-,O
term,O
timolol,I-Entity
treatment,O
on,O
heart,O
size,O
after,O
myocardial,B-Entity
infarction,I-Entity
was,O
evaluated,O
by,O
X,O
-,O
ray,O
in,O
a,O
double,O
-,O
blind,O
study,O
including,O
241,O
patients,O
(,O
placebo,O
126,O
",",O
timolol,I-Entity
115,O
),O
.,O
The,O
timolol,I-Entity
-,O
treated,O
patients,O
showed,O
a,O
small,O
but,O
significant,O
increase,O
in,O
heart,O
size,O
from,O
baseline,O
in,O
contrast,O
to,O
a,O
decrease,O
in,O
the,O
placebo,O
group,O
.,O
These,O
differences,O
may,O
be,O
caused,O
by,O
timolol,I-Entity
-,O
induced,O
bradycardia,I-Entity
and,O
a,O
compensatory,O
increase,O
in,O
end,O
-,O
diastolic,O
volume,O
.,O
The,O
timolol,I-Entity
-,O
related,O
increase,O
in,O
heart,O
size,O
was,O
observed,O
only,O
in,O
patients,O
with,O
normal,O
and,O
borderline,O
heart,O
size,O
.,O
In,O
patients,O
with,O
cardiomegaly,I-Entity
",",O
the,O
increase,O
in,O
heart,O
size,O
was,O
similar,O
in,O
both,O
groups,O
.,O
After,O
re,O
-,O
infarction,I-Entity
",",O
heart,O
size,O
increased,O
in,O
the,O
placebo,O
group,O
and,O
remained,O
unchanged,O
in,O
the,O
timolol,I-Entity
group,O
.,O
Vitamin,B-Entity
D3,I-Entity
toxicity,I-Entity
in,O
dairy,O
cows,O
.,O
Large,O
parenteral,O
doses,O
of,O
vitamin,B-Entity
D3,I-Entity
(,O
15,O
to,O
17.5,O
x,O
10(6,O
),O
IU,O
vitamin,B-Entity
D3,I-Entity
),O
were,O
associated,O
with,O
prolonged,O
hypercalcemia,I-Entity
",",O
hyperphosphatemia,I-Entity
",",O
and,O
large,O
increases,O
of,O
vitamin,B-Entity
D3,I-Entity
and,O
its,O
metabolites,O
in,O
the,O
blood,O
plasma,O
of,O
nonlactating,O
nonpregnant,O
and,O
pregnant,O
Jersey,O
cows,O
.,O
Calcium,I-Entity
concentrations,O
1,O
day,O
postpartum,O
were,O
higher,O
in,O
cows,O
treated,O
with,O
vitamin,B-Entity
D3,I-Entity
about,O
32,O
days,O
prepartum,O
(,O
8.8,O
mg/100,O
ml,O
),O
than,O
in,O
control,O
cows,O
(,O
5.5,O
mg/100,O
ml,O
),O
.,O
None,O
of,O
the,O
cows,O
treated,O
with,O
vitamin,B-Entity
D3,I-Entity
showed,O
signs,O
of,O
milk,B-Entity
fever,I-Entity
during,O
the,O
peripartal,O
period,O
;,O
however,O
",",O
22%,O
of,O
the,O
control,O
cows,O
developed,O
clinical,O
signs,O
of,O
milk,B-Entity
fever,I-Entity
during,O
this,O
period,O
.,O
Signs,O
of,O
vitamin,B-Entity
D3,I-Entity
toxicity,I-Entity
were,O
not,O
observed,O
in,O
nonlactating,O
nonpregnant,O
cows,O
;,O
however,O
",",O
pregnant,O
cows,O
commonly,O
developed,O
severe,O
signs,O
of,O
vitamin,B-Entity
D3,I-Entity
toxicity,I-Entity
and,O
10,O
of,O
17,O
cows,O
died,O
.,O
Because,O
of,O
the,O
extreme,O
toxicity,I-Entity
of,O
vitamin,B-Entity
D3,I-Entity
in,O
pregnant,O
Jersey,O
cows,O
and,O
the,O
low,O
margin,O
of,O
safety,O
between,O
doses,O
of,O
vitamin,B-Entity
D3,I-Entity
that,O
prevent,O
milk,B-Entity
fever,I-Entity
and,O
doses,O
that,O
induce,O
milk,B-Entity
fever,I-Entity
",",O
we,O
concluded,O
that,O
vitamin,B-Entity
D3,I-Entity
can,O
not,O
be,O
used,O
practically,O
to,O
prevent,O
milk,B-Entity
fever,I-Entity
when,O
injected,O
several,O
weeks,O
prepartum,O
.,O
Diseases,B-Entity
of,I-Entity
peripheral,I-Entity
nerves,I-Entity
as,O
seen,O
in,O
the,O
Nigerian,O
African,O
.,O
The,O
anatomical,O
and,O
aetiological,O
diagnoses,O
of,O
peripheral,B-Entity
nerve,I-Entity
disease,I-Entity
excluding,O
its,O
primary,O
benign,O
and,O
malignant,O
disorders,O
",",O
as,O
seen,O
in,O
358,O
Nigerians,O
are,O
presented,O
.,O
Sensori,B-Entity
-,I-Entity
motor,I-Entity
neuropathy,I-Entity
was,O
the,O
commonest,O
presentation,O
(,O
50%,O
),O
.,O
Guillain,B-Entity
-,I-Entity
Barr,I-Entity
syndrome,I-Entity
was,O
the,O
commonest,O
identifiable,O
cause,O
(,O
15.6%,O
),O
",",O
accounting,O
for,O
half,O
of,O
the,O
cases,O
with,O
motor,B-Entity
neuropathy,I-Entity
.,O
Peripheral,B-Entity
neuropathy,I-Entity
due,O
to,O
nutritional,B-Entity
deficiency,I-Entity
of,O
thiamine,I-Entity
and,O
riboflavin,I-Entity
was,O
common,O
(,O
10.1%,O
),O
and,O
presented,O
mainly,O
as,O
sensory,O
and,O
sensori,B-Entity
-,I-Entity
motor,I-Entity
neuropathy,I-Entity
.,O
Diabetes,B-Entity
mellitus,I-Entity
was,O
the,O
major,O
cause,O
of,O
autonomic,B-Entity
neuropathy,I-Entity
.,O
Isoniazid,I-Entity
was,O
the,O
most,O
frequent,O
agent,O
in,O
drug,O
-,O
induced,O
neuropathy,I-Entity
.,O
Migraine,I-Entity
(,O
20%,O
),O
was,O
not,O
an,O
uncommon,O
cause,O
of,O
cranial,B-Entity
neuropathy,I-Entity
although,O
malignancies,I-Entity
arising,O
from,O
the,O
reticuloendothelial,O
system,O
or,O
related,O
structures,O
of,O
the,O
head,O
and,O
neck,O
were,O
more,O
frequent,O
(,O
26%,O
),O
.,O
In,O
26.5%,O
of,O
all,O
the,O
cases,O
",",O
the,O
aetiology,O
of,O
the,O
neuropathy,I-Entity
was,O
undetermined,O
.,O
Heredofamilial,O
and,O
connective,B-Entity
tissue,I-Entity
disorders,I-Entity
were,O
rare,O
.,O
Some,O
of,O
the,O
factors,O
related,O
to,O
the,O
clinical,O
presentation,O
and,O
pathogenesis,O
of,O
the,O
neuropathies,I-Entity
are,O
briefly,O
discussed,O
.,O
A,O
double,O
-,O
blind,O
study,O
of,O
the,O
efficacy,O
and,O
safety,O
of,O
dothiepin,B-Entity
hydrochloride,I-Entity
in,O
the,O
treatment,O
of,O
major,O
depressive,B-Entity
disorder,I-Entity
.,O
In,O
a,O
6-week,O
double,O
-,O
blind,O
parallel,O
treatment,O
study,O
",",O
dothiepin,I-Entity
and,O
amitriptyline,I-Entity
were,O
compared,O
to,O
placebo,O
in,O
the,O
treatment,O
of,O
33,O
depressed,I-Entity
outpatients,O
.,O
Dothiepin,I-Entity
and,O
amitriptyline,I-Entity
were,O
equally,O
effective,O
in,O
alleviating,O
the,O
symptoms,O
of,O
depressive,B-Entity
illness,I-Entity
",",O
and,O
both,O
were,O
significantly,O
superior,O
to,O
placebo,O
.,O
The,O
overall,O
incidence,O
of,O
side,O
effects,O
and,O
the,O
frequency,O
and,O
severity,O
of,O
blurred,B-Entity
vision,I-Entity
",",O
dry,B-Entity
mouth,I-Entity
",",O
and,O
drowsiness,O
were,O
significantly,O
less,O
with,O
dothiepin,I-Entity
than,O
with,O
amitriptyline,I-Entity
.,O
Dothiepin,I-Entity
also,O
produced,O
fewer,O
CNS,O
and,O
cardiovascular,O
effects,O
.,O
Dothiepin,I-Entity
thus,O
was,O
found,O
to,O
be,O
an,O
effective,O
antidepressant,I-Entity
drug,O
associated,O
with,O
fewer,O
side,O
effects,O
than,O
amitriptyline,I-Entity
in,O
the,O
treatment,O
of,O
depressed,I-Entity
outpatients,O
.,O
Behavioral,O
effects,O
of,O
diazepam,I-Entity
and,O
propranolol,I-Entity
in,O
patients,O
with,O
panic,B-Entity
disorder,I-Entity
and,O
agoraphobia,I-Entity
.,O
The,O
effects,O
of,O
oral,O
doses,O
of,O
diazepam,I-Entity
(,O
single,O
dose,O
of,O
10,O
mg,O
and,O
a,O
median,O
dose,O
of,O
30,O
mg,O
/,O
day,O
for,O
2,O
weeks,O
),O
and,O
propranolol,I-Entity
(,O
single,O
dose,O
of,O
80,O
mg,O
and,O
a,O
median,O
dose,O
of,O
240,O
mg,O
/,O
day,O
for,O
2,O
weeks,O
),O
on,O
psychological,O
performance,O
of,O
patients,O
with,O
panic,B-Entity
disorders,I-Entity
and,O
agoraphobia,I-Entity
were,O
investigated,O
in,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
and,O
crossover,O
design,O
.,O
Both,O
drugs,O
impaired,B-Entity
immediate,I-Entity
free,I-Entity
recall,I-Entity
but,O
the,O
decrease,O
was,O
greater,O
for,O
diazepam,I-Entity
than,O
propranolol,I-Entity
.,O
Delayed,B-Entity
free,I-Entity
recall,I-Entity
was,I-Entity
also,I-Entity
impaired,I-Entity
but,O
the,O
two,O
drugs,O
did,O
not,O
differ,O
.,O
Patients,O
tapped,O
faster,O
after,O
propranolol,I-Entity
than,O
diazepam,I-Entity
and,O
they,O
were,O
more,O
sedated,O
after,O
diazepam,I-Entity
than,O
propranolol,I-Entity
.,O
Accumulation,O
of,O
drugs,O
was,O
not,O
reflected,O
in,O
prolonged,O
behavioral,B-Entity
impairment,I-Entity
.,O
Effect,O
of,O
aspirin,I-Entity
on,O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,I-Entity
-,O
induced,O
epithelial,O
proliferation,O
in,O
the,O
urinary,O
bladder,O
and,O
forestomach,O
of,O
the,O
rat,O
.,O
The,O
co,O
-,O
administration,O
of,O
aspirin,I-Entity
with,O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,I-Entity
(,O
FANFT,I-Entity
),O
to,O
rats,O
resulted,O
in,O
a,O
reduced,O
incidence,O
of,O
FANFT,I-Entity
-,O
induced,O
bladder,B-Entity
carcinomas,I-Entity
but,O
a,O
concomitant,O
induction,O
of,O
forestomach,B-Entity
tumors,I-Entity
.,O
An,O
autoradiographic,O
study,O
was,O
performed,O
on,O
male,O
F-344,O
rats,O
fed,O
diet,O
containing,O
FANFT,I-Entity
at,O
a,O
level,O
of,O
0.2%,O
and/or,O
aspirin,I-Entity
at,O
a,O
level,O
of,O
0.5%,O
to,O
evaluate,O
the,O
effect,O
of,O
aspirin,I-Entity
on,O
the,O
increased,O
cell,O
proliferation,O
induced,O
by,O
FANFT,I-Entity
in,O
the,O
forestomach,O
and,O
bladder,O
.,O
FANFT,I-Entity
-,O
induced,O
cell,O
proliferation,O
in,O
the,O
bladder,O
was,O
significantly,O
suppressed,O
by,O
aspirin,I-Entity
co,O
-,O
administration,O
after,O
4,O
weeks,O
but,O
not,O
after,O
12,O
weeks,O
.,O
In,O
the,O
forestomach,O
",",O
and,O
also,O
in,O
the,O
liver,O
",",O
aspirin,I-Entity
did,O
not,O
affect,O
the,O
FANFT,I-Entity
-,O
induced,O
increase,O
in,O
labeling,O
index,O
.,O
The,O
present,O
results,O
are,O
consistent,O
with,O
the,O
carcinogenicity,O
experiment,O
suggesting,O
that,O
different,O
mechanisms,O
are,O
involved,O
in,O
FANFT,I-Entity
carcinogenesis,I-Entity
in,O
the,O
bladder,O
and,O
forestomach,O
",",O
and,O
that,O
aspirin,I-Entity
's,O
effect,O
on,O
FANFT,I-Entity
in,O
the,O
forestomach,O
is,O
not,O
due,O
to,O
an,O
irritant,O
effect,O
associated,O
with,O
increased,O
cell,O
proliferation,O
.,O
Also,O
",",O
there,O
appears,O
to,O
be,O
an,O
adaptation,O
by,O
the,O
rats,O
to,O
the,O
chronic,O
ingestion,O
of,O
aspirin,I-Entity
.,O
Provocation,O
of,O
postural,O
hypotension,I-Entity
by,O
nitroglycerin,I-Entity
in,O
diabetic,B-Entity
autonomic,I-Entity
neuropathy,I-Entity
?,O
The,O
effect,O
of,O
nitroglycerin,I-Entity
on,O
heart,O
rate,O
and,O
systolic,O
blood,O
pressure,O
was,O
compared,O
in,O
5,O
normal,O
subjects,O
",",O
12,O
diabetic,I-Entity
subjects,O
without,O
autonomic,B-Entity
neuropathy,I-Entity
",",O
and,O
5,O
diabetic,I-Entity
subjects,O
with,O
autonomic,B-Entity
neuropathy,I-Entity
.,O
The,O
magnitude,O
and,O
time,O
course,O
of,O
the,O
increase,O
in,O
heart,O
rate,O
and,O
the,O
decrease,O
in,O
systolic,O
blood,O
pressure,O
after,O
nitroglycerin,I-Entity
were,O
similar,O
in,O
the,O
normal,O
and,O
diabetic,I-Entity
subjects,O
without,O
autonomic,B-Entity
neuropathy,I-Entity
",",O
whereas,O
a,O
lesser,O
increase,O
in,O
heart,O
rate,O
and,O
a,O
greater,O
decrease,O
in,O
systolic,O
blood,O
pressure,O
occurred,O
in,O
the,O
diabetic,I-Entity
subjects,O
with,O
autonomic,B-Entity
neuropathy,I-Entity
.,O
It,O
is,O
therefore,O
suggested,O
that,O
caution,O
should,O
be,O
exercised,O
when,O
prescribing,O
vasodilator,O
drugs,O
in,O
diabetic,I-Entity
patients,O
",",O
particularly,O
those,O
with,O
autonomic,B-Entity
neuropathy,I-Entity
.,O
Characterization,O
of,O
estrogen,I-Entity
-,O
induced,O
adenohypophyseal,B-Entity
tumors,I-Entity
in,O
the,O
Fischer,O
344,O
rat,O
.,O
Pituitary,B-Entity
tumors,I-Entity
were,O
induced,O
in,O
F344,O
female,O
rats,O
by,O
chronic,O
treatment,O
with,O
diethylstilbestrol,I-Entity
(,O
DES,I-Entity
",",O
8,O
-,O
10,O
mg,O
),O
implanted,O
subcutaneously,O
in,O
silastic,O
capsules,O
.,O
Over,O
a,O
range,O
of,O
1,O
-,O
150,O
days,O
of,O
DES,I-Entity
treatment,O
",",O
pairs,O
of,O
control,O
and,O
DES,I-Entity
-,O
treated,O
rats,O
were,O
sacrificed,O
",",O
and,O
their,O
pituitaries,O
dissociated,O
enzymatically,O
into,O
single,O
-,O
cell,O
preparations,O
.,O
The,O
cell,O
populations,O
were,O
examined,O
regarding,O
total,O
cell,O
recovery,O
correlated,O
with,O
gland,O
weight,O
",",O
intracellular,O
prolactin,O
(,O
PRL,O
),O
content,O
and,O
subsequent,O
release,O
in,O
primary,O
culture,O
",",O
immunocytochemical,O
PRL,O
staining,O
",",O
density,O
and/or,O
size,O
alterations,O
via,O
separation,O
on,O
Ficoll,O
-,O
Hypaque,O
and,O
by,O
unit,O
gravity,O
sedimentation,O
",",O
and,O
cell,O
cycle,O
analysis,O
",",O
after,O
acriflavine,I-Entity
DNA,O
staining,O
",",O
by,O
laser,O
flow,O
cytometry,O
.,O
Total,O
cell,O
yields,O
from,O
DES,I-Entity
-,O
treated,O
pituitaries,O
increased,O
from,O
1.3,O
times,O
control,O
yields,O
at,O
8,O
days,O
of,O
treatment,O
to,O
58.9,O
times,O
control,O
values,O
by,O
day,O
150,O
.,O
Intracellular,O
PRL,O
content,O
ranged,O
from,O
1.9,O
to,O
9.4,O
times,O
control,O
levels,O
",",O
and,O
PRL,O
release,O
in,O
vitro,O
was,O
significantly,O
and,O
consistently,O
higher,O
than,O
controls,O
",",O
after,O
at,O
least,O
8,O
days,O
of,O
DES,I-Entity
exposure,O
.,O
Beyond,O
8,O
days,O
of,O
DES,I-Entity
exposure,O
",",O
the,O
immunochemically,O
PRL,O
-,O
positive,O
proportion,O
of,O
cells,O
increased,O
to,O
over,O
50%,O
of,O
the,O
total,O
population,O
.,O
All,O
these,O
effects,O
of,O
DES,I-Entity
were,O
more,O
pronounced,O
among,O
previously,O
ovariectomized,O
animals,O
.,O
The,O
data,O
extend,O
the,O
findings,O
of,O
other,O
investigators,O
",",O
further,O
establishing,O
the,O
DES,I-Entity
-,O
induced,O
tumor,I-Entity
as,O
a,O
model,O
for,O
study,O
of,O
PRL,O
cellular,O
control,O
mechanisms,O
.,O
Triamterene,I-Entity
nephrolithiasis,I-Entity
complicating,O
dyazide,I-Entity
therapy,O
.,O
A,O
case,O
of,O
triamterene,I-Entity
nephrolithiasis,I-Entity
is,O
reported,O
in,O
a,O
man,O
after,O
4,O
years,O
of,O
hydrochlorothiazide,B-Entity
-,I-Entity
triamterene,I-Entity
therapy,O
for,O
hypertension,I-Entity
.,O
The,O
stone,O
passed,O
spontaneously,O
and,O
was,O
found,O
to,O
contain,O
a,O
triamterene,I-Entity
metabolite,O
admixed,O
with,O
uric,B-Entity
acid,I-Entity
salts,I-Entity
.,O
Factors,O
affecting,O
triamterene,I-Entity
nephrolithiasis,I-Entity
are,O
discussed,O
and,O
2,O
previously,O
reported,O
cases,O
are,O
reviewed,O
.,O
Metabolic,O
involvement,O
in,O
adriamycin,I-Entity
cardiotoxicity,I-Entity
.,O
The,O
cardiotoxic,I-Entity
effects,O
of,O
adriamycin,I-Entity
were,O
studied,O
in,O
mammalian,O
myocardial,O
cells,O
in,O
culture,O
as,O
a,O
model,O
system,O
.,O
Adriamycin,I-Entity
inhibited,O
cell,O
growth,O
and,O
the,O
rhythmic,O
contractions,O
characteristic,O
of,O
myocardial,O
cells,O
in,O
culture,O
.,O
A,O
possible,O
involvement,O
of,O
energy,O
metabolism,O
was,O
suggested,O
previously,O
",",O
and,O
in,O
this,O
study,O
the,O
adenylate,O
energy,O
charge,O
and,O
phosphorylcreatine,I-Entity
mole,O
fraction,O
were,O
determined,O
in,O
the,O
adriamycin,I-Entity
-,O
treated,O
cells,O
.,O
The,O
adenylate,O
energy,O
charge,O
was,O
found,O
to,O
be,O
significantly,O
decreased,O
",",O
while,O
the,O
phophorylcreatine,I-Entity
mole,O
fraction,O
was,O
unchanged,O
.,O
Such,O
disparity,O
suggests,O
an,O
inhibition,O
of,O
creatine,I-Entity
phosphokinase,O
.,O
The,O
addition,O
of,O
1,O
mM,O
adenosine,I-Entity
to,O
the,O
myocardial,O
cell,O
cultures,O
markedly,O
increases,O
the,O
ATP,I-Entity
concentration,O
through,O
a,O
pathway,O
reportedly,O
leading,O
to,O
a,O
compartmentalized,O
ATP,I-Entity
pool,O
.,O
In,O
the,O
adriamycin,I-Entity
-,O
treated,O
cells,O
",",O
the,O
addition,O
of,O
adenosine,I-Entity
increased,O
the,O
adenylate,O
charge,O
and,O
",",O
concomitant,O
with,O
this,O
inrcease,O
",",O
the,O
cells,O
',O
functional,O
integrity,O
",",O
in,O
terms,O
of,O
percentage,O
of,O
beating,O
cells,O
and,O
rate,O
of,O
contractions,O
",",O
was,O
maintained,O
.,O
Age,O
-,O
dependent,O
sensitivity,O
of,O
the,O
rat,O
to,O
neurotoxic,I-Entity
effects,O
of,O
streptomycin,I-Entity
.,O
Streptomycin,I-Entity
sulfate,O
(,O
300,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
was,O
injected,O
for,O
various,O
periods,O
into,O
preweanling,O
rats,O
and,O
for,O
3,O
weeks,O
into,O
weanling,O
rats,O
.,O
Abnormal,B-Entity
movements,I-Entity
and,O
deafness,I-Entity
occurred,O
only,O
in,O
rats,O
treated,O
during,O
the,O
preweaning,O
period,O
;,O
within,O
this,O
period,O
the,O
greatest,O
sensitivities,O
for,O
these,O
abnormalities,O
occurred,O
from,O
2,O
to,O
11,O
-,O
17,O
and,O
5,O
to,O
11,O
days,O
of,O
age,O
",",O
respectively,O
",",O
indicating,O
that,O
the,O
cochlea,O
is,O
more,O
sensitive,O
to,O
streptomycin,I-Entity
than,O
the,O
site,O
(,O
vestibular,O
or,O
central,O
),O
responsible,O
for,O
the,O
dyskinesias,I-Entity
.,O
Crescentic,O
fibrillary,O
glomerulonephritis,I-Entity
associated,O
with,O
intermittent,O
rifampin,I-Entity
therapy,O
for,O
pulmonary,B-Entity
tuberculosis,I-Entity
.,O
This,O
case,O
study,O
reveals,O
an,O
unusual,O
finding,O
of,O
rapidly,O
proliferative,O
crescentic,O
glomerulonephritis,I-Entity
in,O
a,O
patient,O
treated,O
with,O
rifampin,I-Entity
who,O
had,O
no,O
other,O
identifiable,O
causes,O
for,O
developing,O
this,O
disease,O
.,O
This,O
patient,O
underwent,O
a,O
10-month,O
regimen,O
of,O
rifampin,I-Entity
and,O
isoniazid,I-Entity
for,O
pulmonary,B-Entity
tuberculosis,I-Entity
and,O
was,O
discovered,O
to,O
have,O
developed,O
signs,O
of,O
severe,O
renal,B-Entity
failure,I-Entity
five,O
weeks,O
after,O
completion,O
of,O
therapy,O
.,O
Renal,O
biopsy,O
revealed,O
severe,O
glomerulonephritis,I-Entity
with,O
crescents,O
",",O
electron,O
dense,O
fibrillar,O
deposits,O
and,O
moderate,O
lymphocytic,O
interstitial,O
infiltrate,O
.,O
Other,O
possible,O
causes,O
of,O
rapidly,O
progressive,O
glomerulonephritis,I-Entity
were,O
investigated,O
and,O
ruled,O
out,O
.,O
This,O
report,O
documents,O
the,O
unusual,O
occurrence,O
of,O
rapidly,O
progressive,O
glomerulonephritis,I-Entity
with,O
crescents,O
and,O
fibrillar,O
glomerulonephritis,I-Entity
in,O
a,O
patient,O
treated,O
with,O
rifampin,I-Entity
.,O
Time,O
course,O
of,O
lipid,O
peroxidation,O
in,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephropathy,I-Entity
.,O
Reactive,O
oxygen,I-Entity
species,O
have,O
been,O
implicated,O
in,O
the,O
pathogenesis,O
of,O
acute,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN)-induced,I-Entity
nephropathy,I-Entity
",",O
with,O
antioxidants,O
significantly,O
reducing,O
the,O
proteinuria,I-Entity
.,O
The,O
temporal,O
relationship,O
between,O
lipid,O
peroxidation,O
in,O
the,O
kidney,O
and,O
proteinuria,I-Entity
was,O
examined,O
in,O
this,O
study,O
.,O
Rats,O
were,O
treated,O
with,O
a,O
single,O
IV,O
injection,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
",",O
(,O
PAN,I-Entity
",",O
7.5,O
mg,O
/,O
kg,O
),O
and,O
24,O
hour,O
urine,O
samples,O
were,O
obtained,O
prior,O
to,O
sacrifice,O
on,O
days,O
"3,5,7,10,17,27,41",O
(,O
N,O
=,O
5,O
-,O
10,O
per,O
group,O
),O
.,O
Tissue,O
lipid,O
peroxidation,O
was,O
measured,O
in,O
whole,O
homogenates,O
as,O
well,O
as,O
in,O
lipid,O
extracts,O
from,O
homogenates,O
as,O
thiobarbituric,B-Entity
acid,I-Entity
reactive,O
substances,O
.,O
Proteinuria,I-Entity
was,O
evident,O
at,O
day,O
5,O
",",O
peaked,O
at,O
day,O
7,O
and,O
persisted,O
to,O
day,O
27,O
.,O
This,O
study,O
supports,O
the,O
role,O
of,O
lipid,O
peroxidation,O
in,O
mediating,O
the,O
proteinuric,B-Entity
injury,I-Entity
in,O
PAN,I-Entity
nephropathy,I-Entity
.,O
Clomipramine,I-Entity
-,O
induced,O
sleep,B-Entity
disturbance,I-Entity
does,O
not,O
impair,O
its,O
prolactin,O
-,O
releasing,O
action,O
.,O
The,O
present,O
study,O
was,O
undertaken,O
to,O
examine,O
the,O
role,O
of,O
sleep,B-Entity
disturbance,I-Entity
",",O
induced,O
by,O
clomipramine,I-Entity
administration,O
",",O
on,O
the,O
secretory,O
rate,O
of,O
prolactin,O
(,O
PRL,O
),O
in,O
addition,O
to,O
the,O
direct,O
drug,O
effect,O
.,O
Each,O
subject,O
received,O
a,O
single,O
50,O
mg,O
dose,O
of,O
clomipramine,I-Entity
given,O
orally,O
2,O
hours,O
before,O
blood,O
collection,O
.,O
During,O
the,O
night,O
clomipramine,I-Entity
ingestion,O
altered,O
the,O
complete,O
sleep,O
architecture,O
in,O
that,O
it,O
suppressed,O
REM,O
sleep,O
and,O
the,O
sleep,O
cycles,O
and,O
induced,O
increased,O
wakefulness,O
.,O
10%,O
),O
",",O
it,O
can,O
be,O
concluded,O
that,O
the,O
observed,O
sleep,B-Entity
disturbance,I-Entity
did,O
not,O
interfere,O
with,O
the,O
drug,O
action,O
per,O
se,O
.,O
The,O
presence,O
of,O
REM,O
sleep,O
was,O
shown,O
not,O
to,O
be,O
a,O
determining,O
factor,O
either,O
for,O
secretory,O
pulse,O
amplitude,O
and,O
frequency,O
",",O
as,O
",",O
for,O
both,O
",",O
mean,O
nocturnal,O
values,O
were,O
similar,O
with,O
and,O
without,O
prior,O
clomipramine,I-Entity
ingestion,O
.,O
Angioedema,I-Entity
following,O
the,O
intravenous,O
administration,O
of,O
metoprolol,I-Entity
.,O
A,O
72-year,O
-,O
old,O
woman,O
was,O
admitted,O
to,O
the,O
hospital,O
with,O
"""",O
flash,O
"""",O
pulmonary,B-Entity
edema,I-Entity
",",O
preceded,O
by,O
chest,B-Entity
pain,I-Entity
",",O
requiring,O
intubation,O
.,O
Her,O
medical,O
history,O
included,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
with,O
previous,O
myocardial,B-Entity
infarctions,I-Entity
",",O
hypertension,I-Entity
",",O
and,O
diabetes,B-Entity
mellitus,I-Entity
.,O
A,O
history,O
of,O
angioedema,I-Entity
secondary,O
to,O
lisinopril,I-Entity
therapy,O
was,O
elicited,O
.,O
Current,O
medications,O
did,O
not,O
include,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitors,O
or,O
beta,O
-,O
blockers,O
.,O
During,O
the,O
first,O
day,O
of,O
hospitalization,O
(,O
while,O
intubated,O
),O
",",O
intravenous,O
metoprolol,I-Entity
was,O
given,O
",",O
resulting,O
in,O
severe,O
angioedema,I-Entity
.,O
The,O
angioedema,I-Entity
resolved,O
after,O
therapy,O
with,O
intravenous,O
steroids,I-Entity
and,O
diphenhydramine,I-Entity
hydrochloride,O
.,O
Effect,O
of,O
coniine,I-Entity
on,O
the,O
developing,O
chick,O
embryo,O
.,O
Coniine,I-Entity
",",O
an,O
alkaloid,O
from,O
Conium,O
maculatum,O
(,O
poison,O
hemlock,O
),O
",",O
has,O
been,O
shown,O
to,O
be,O
teratogenic,O
in,O
livestock,O
.,O
The,O
major,O
teratogenic,O
outcome,O
is,O
arthrogryposis,I-Entity
",",O
presumably,O
due,O
to,O
nicotinic,O
receptor,O
blockade,O
.,O
However,O
",",O
coniine,I-Entity
has,O
failed,O
to,O
produce,O
arthrogryposis,I-Entity
in,O
rats,O
or,O
mice,O
and,O
is,O
only,O
weakly,O
teratogenic,O
in,O
rabbits,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
and,O
compare,O
the,O
effects,O
of,O
coniine,I-Entity
and,O
nicotine,I-Entity
in,O
the,O
developing,O
chick,O
.,O
Concentrations,O
of,O
coniine,I-Entity
and,O
nicotine,I-Entity
sulfate,O
were,O
0.015%,O
",",O
0.03%,O
",",O
0.075%,O
",",O
0.15%,O
",",O
0.75%,O
",",O
1.5%,O
",",O
3%,O
",",O
and,O
6%,O
and,O
1%,O
",",O
5%,O
",",O
and,O
10%,O
",",O
respectively,O
.,O
Both,O
compounds,O
caused,O
deformations,I-Entity
and,O
lethality,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
All,O
concentrations,O
of,O
nicotine,I-Entity
sulfate,O
caused,O
some,O
lethality,O
but,O
a,O
no,O
effect,O
level,O
for,O
coniine,I-Entity
lethality,O
was,O
0.75%,O
.,O
The,O
deformations,I-Entity
caused,O
by,O
both,O
coniine,I-Entity
and,O
nicotine,I-Entity
sulfate,O
were,O
excessive,B-Entity
flexion,I-Entity
or,I-Entity
extension,I-Entity
of,I-Entity
one,I-Entity
or,I-Entity
more,I-Entity
toes,I-Entity
.,O
No,O
histopathological,O
alterations,O
or,O
differences,O
in,O
bone,O
formation,O
were,O
seen,O
in,O
the,O
limbs,O
or,O
toes,O
of,O
any,O
chicks,O
from,O
any,O
group,O
;,O
however,O
",",O
extensive,O
cranial,B-Entity
hemorrhage,I-Entity
occurred,O
in,O
all,O
nicotine,I-Entity
sulfate,O
-,O
treated,O
chicks,O
.,O
There,O
was,O
a,O
statistically,O
significant,O
(,O
P,O
<,O
or,O
=,O
0.01,O
),O
decrease,O
in,O
movement,O
in,O
coniine,I-Entity
and,O
nicotine,I-Entity
sulfate,O
treated,O
chicks,O
as,O
determined,O
by,O
ultrasound,O
.,O
Control,O
chicks,O
were,O
in,O
motion,O
an,O
average,O
of,O
33.67%,O
of,O
the,O
time,O
",",O
while,O
coniine,I-Entity
-,O
treated,O
chicks,O
were,O
only,O
moving,O
8.95%,O
of,O
a,O
5-min,O
interval,O
",",O
and,O
no,O
movement,O
was,O
observed,O
for,O
nicotine,I-Entity
sulfate,O
treated,O
chicks,O
.,O
In,O
summary,O
",",O
the,O
chick,O
embryo,O
provides,O
a,O
reliable,O
and,O
simple,O
experimental,O
animal,O
model,O
of,O
coniine,I-Entity
-,O
induced,O
arthrogryposis,I-Entity
.,O
Epidural,O
blood,O
flow,O
during,O
prostaglandin,B-Entity
E1,I-Entity
or,O
trimethaphan,I-Entity
induced,O
hypotension,I-Entity
.,O
To,O
evaluate,O
the,O
effect,O
of,O
prostaglandin,B-Entity
E1,I-Entity
(,O
PGE1,I-Entity
),O
or,O
trimethaphan,I-Entity
(,O
TMP,I-Entity
),O
induced,O
hypotension,I-Entity
on,O
epidural,O
blood,O
flow,O
(,O
EBF,O
),O
during,O
spinal,O
surgery,O
",",O
EBF,O
was,O
measured,O
using,O
the,O
heat,O
clearance,O
method,O
in,O
30,O
patients,O
who,O
underwent,O
postero,O
-,O
lateral,O
interbody,O
fusion,O
under,O
isoflurane,I-Entity
anaesthesia,O
.,O
An,O
initial,O
dose,O
of,O
0.1,O
microgram.kg-1.min-1,O
of,O
PGE1,I-Entity
(,O
15,O
patients,O
),O
",",O
or,O
10,O
micrograms.kg-1.min-1,O
of,O
TMP,I-Entity
(,O
15,O
patients,O
),O
was,O
administered,O
intravenously,O
after,O
the,O
dural,O
opening,O
and,O
the,O
dose,O
was,O
adjusted,O
to,O
maintain,O
the,O
mean,O
arterial,O
blood,O
pressure,O
(,O
MAP,O
),O
at,O
about,O
60,O
mmHg,O
.,O
The,O
hypotensive,I-Entity
drug,O
was,O
discontinued,O
at,O
the,O
completion,O
of,O
the,O
operative,O
procedure,O
.,O
After,O
starting,O
PGE1,I-Entity
or,O
TMP,I-Entity
",",O
MAP,O
and,O
rate,O
pressure,O
product,O
(,O
RPP,O
),O
decreased,O
significantly,O
compared,O
with,O
preinfusion,O
values,O
(,O
P,O
<,O
0.01,O
),O
",",O
and,O
the,O
degree,O
of,O
hypotension,I-Entity
due,O
to,O
PGE1,I-Entity
remained,O
constant,O
until,O
60,O
min,O
after,O
its,O
discontinuation,O
.,O
EBFF,O
did,O
not,O
change,O
during,O
PGE1,I-Entity
infusion,O
whereas,O
in,O
the,O
TMP,I-Entity
group,O
",",O
EBF,O
decreased,O
significantly,O
at,O
30,O
and,O
60,O
min,O
after,O
the,O
start,O
of,O
TMP,I-Entity
(,O
preinfusion,O
:,O
45.9,O
These,O
results,O
suggest,O
that,O
PGE1,I-Entity
may,O
be,O
preferable,O
to,O
TMP,I-Entity
for,O
hypotensive,I-Entity
anaesthesia,O
in,O
spinal,O
surgery,O
because,O
TMP,I-Entity
decreased,O
EBF,O
.,O
Immunohistochemical,O
studies,O
with,O
antibodies,O
to,O
neurofilament,O
proteins,O
on,O
axonal,B-Entity
damage,I-Entity
in,O
experimental,O
focal,O
lesions,O
in,O
rat,O
.,O
Immunohistochemistry,O
with,O
monoclonal,O
antibodies,O
against,O
neurofilament,O
(,O
NF,O
),O
proteins,O
of,O
middle,O
and,O
high,O
molecular,O
weight,O
class,O
",",O
NF,O
-,O
M,O
and,O
NF,O
-,O
H,O
",",O
was,O
used,O
to,O
study,O
axonal,B-Entity
injury,I-Entity
in,O
the,O
borderzone,O
of,O
focal,O
lesions,O
in,O
rats,O
.,O
Focal,O
injury,B-Entity
in,I-Entity
the,I-Entity
cortex,I-Entity
was,O
produced,O
by,O
infusion,O
of,O
lactate,I-Entity
at,O
acid,O
pH,O
or,O
by,O
stab,O
caused,O
by,O
needle,O
insertion,O
.,O
Infarcts,B-Entity
in,I-Entity
substantia,I-Entity
nigra,I-Entity
pars,I-Entity
reticulata,I-Entity
were,O
evoked,O
by,O
prolonged,O
pilocarpine,I-Entity
-,O
induced,O
status,B-Entity
epilepticus,I-Entity
.,O
These,O
immunohistochemical,O
changes,O
of,O
NFs,O
can,O
serve,O
as,O
a,O
marker,O
for,O
axonal,B-Entity
damage,I-Entity
in,O
various,O
experimental,O
traumatic,I-Entity
or,O
ischemic,O
lesions,O
.,O
Increase,O
of,O
Parkinson,B-Entity
disability,I-Entity
after,O
fluoxetine,I-Entity
medication,O
.,O
Depression,I-Entity
is,O
a,O
major,O
clinical,O
feature,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
We,O
report,O
the,O
increased,O
amount,O
of,O
motor,B-Entity
disability,I-Entity
in,O
four,O
patients,O
with,O
idiopathic,B-Entity
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
after,O
exposure,O
to,O
the,O
antidepressant,I-Entity
fluoxetine,I-Entity
.,O
The,O
possibility,O
of,O
a,O
clinically,O
relevant,O
dopamine,I-Entity
-,O
antagonistic,O
capacity,O
of,O
fluoxetine,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
patients,O
must,O
be,O
considered,O
.,O
Acetaminophen,I-Entity
-,O
induced,O
hypotension,I-Entity
.,O
Through,O
30,O
years,O
of,O
widespread,O
use,O
",",O
acetaminophen,I-Entity
has,O
been,O
shown,O
to,O
be,O
a,O
remarkably,O
safe,O
medication,O
in,O
therapeutic,O
dosages,O
.,O
The,O
potential,O
for,O
acetaminophen,I-Entity
to,O
produce,O
cardiovascular,B-Entity
toxicities,I-Entity
is,O
very,O
low,O
.,O
However,O
",",O
acetaminophen,I-Entity
has,O
been,O
demonstrated,O
to,O
produce,O
symptoms,O
of,O
anaphylaxis,I-Entity
",",O
including,O
hypotension,I-Entity
",",O
in,O
sensitive,O
individuals,O
.,O
This,O
article,O
describes,O
two,O
critically,B-Entity
ill,I-Entity
patients,O
in,O
whom,O
transient,O
episodes,O
of,O
hypotension,I-Entity
reproducibly,O
developed,O
after,O
administration,O
of,O
acetaminophen,I-Entity
.,O
Other,O
symptoms,O
of,O
allergic,B-Entity
reactions,I-Entity
were,O
not,O
clinically,O
detectable,O
.,O
The,O
hypotensive,I-Entity
episodes,O
were,O
severe,O
enough,O
to,O
require,O
vasopressor,O
administration,O
.,O
The,O
reports,O
illustrate,O
the,O
need,O
for,O
clinicians,O
to,O
consider,O
acetaminophen,I-Entity
in,O
patients,O
with,O
hypotension,I-Entity
of,O
unknown,O
origin,O
.,O
Acute,O
hepatitis,I-Entity
",",O
autoimmune,B-Entity
hemolytic,I-Entity
anemia,I-Entity
",",O
and,O
erythroblastocytopenia,I-Entity
induced,O
by,O
ceftriaxone,I-Entity
.,O
An,O
80-yr,O
-,O
old,O
man,O
developed,O
acute,O
hepatitis,I-Entity
shortly,O
after,O
ingesting,O
oral,O
ceftriaxone,I-Entity
.,O
Although,O
the,O
transaminases,O
gradually,O
returned,O
to,O
baseline,O
after,O
withholding,O
the,O
beta,B-Entity
lactam,I-Entity
antibiotic,O
",",O
there,O
was,O
a,O
gradual,O
increase,O
in,O
serum,O
bilirubin,I-Entity
and,O
a,O
decrease,O
in,O
hemoglobin,O
concentration,O
caused,O
by,O
an,O
autoimmune,B-Entity
hemolytic,I-Entity
anemia,I-Entity
and,O
erythroblastocytopenia,I-Entity
.,O
These,O
responded,O
to,O
systemic,O
steroids,I-Entity
and,O
immunoglobulins,O
.,O
Despite,O
the,O
widespread,O
use,O
of,O
these,O
agents,O
this,O
triad,O
of,O
side,O
effects,O
has,O
not,O
previously,O
been,O
reported,O
in,O
connection,O
with,O
beta,B-Entity
lactam,I-Entity
antibiotics,O
.,O
Conventional,O
agents,O
are,O
associated,O
with,O
unwanted,O
central,O
nervous,O
system,O
effects,O
",",O
including,O
extrapyramidal,B-Entity
symptoms,I-Entity
(,O
EPS,I-Entity
),O
",",O
tardive,B-Entity
dyskinesia,I-Entity
",",O
sedation,O
",",O
and,O
possible,O
impairment,O
of,O
some,O
cognitive,O
measures,O
",",O
as,O
well,O
as,O
cardiac,O
effects,O
",",O
orthostatic,B-Entity
hypotension,I-Entity
",",O
hepatic,O
changes,O
",",O
anticholinergic,O
side,O
effects,O
",",O
sexual,B-Entity
dysfunction,I-Entity
",",O
and,O
weight,B-Entity
gain,I-Entity
.,O
The,O
newer,O
atypical,O
agents,O
have,O
a,O
lower,O
risk,O
of,O
EPS,I-Entity
",",O
but,O
are,O
associated,O
in,O
varying,O
degrees,O
with,O
sedation,O
",",O
cardiovascular,O
effects,O
",",O
anticholinergic,O
effects,O
",",O
weight,B-Entity
gain,I-Entity
",",O
sexual,B-Entity
dysfunction,I-Entity
",",O
hepatic,O
effects,O
",",O
lowered,O
seizure,I-Entity
threshold,O
(,O
primarily,O
clozapine,I-Entity
),O
",",O
and,O
agranulocytosis,I-Entity
(,O
clozapine,I-Entity
only,O
),O
.,O
Effects,O
of,O
tetrandrine,I-Entity
and,O
fangchinoline,I-Entity
on,O
experimental,O
thrombosis,I-Entity
in,O
mice,O
and,O
human,O
platelet,B-Entity
aggregation,I-Entity
.,O
Tetrandrine,I-Entity
(,O
TET,I-Entity
),O
and,O
fangchinoline,I-Entity
(,O
FAN,I-Entity
),O
are,O
two,O
naturally,O
occurring,O
analogues,O
with,O
a,O
bisbenzylisoquinoline,I-Entity
structure,O
.,O
The,O
present,O
study,O
was,O
undertaken,O
to,O
investigate,O
the,O
effects,O
of,O
TET,I-Entity
and,O
FAN,I-Entity
on,O
the,O
experimental,O
thrombosis,I-Entity
induced,O
by,O
collagen,O
plus,O
epinephrine,I-Entity
(,O
EP,I-Entity
),O
in,O
mice,O
",",O
and,O
platelet,B-Entity
aggregation,I-Entity
and,O
blood,B-Entity
coagulation,I-Entity
in,O
vitro,O
.,O
In,O
the,O
in,O
vivo,O
study,O
",",O
the,O
administration,O
(,O
50,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
of,O
TET,I-Entity
and,O
FAN,I-Entity
in,O
mice,O
showed,O
the,O
inhibition,O
of,O
thrombosis,I-Entity
by,O
55%,O
and,O
35%,O
",",O
respectively,O
",",O
while,O
acetylsalicylic,B-Entity
acid,I-Entity
(,O
ASA,I-Entity
",",O
50,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
",",O
a,O
positive,O
control,O
",",O
showed,O
only,O
30%,O
inhibition,O
.,O
In,O
the,O
vitro,O
human,O
platelet,B-Entity
aggregations,I-Entity
induced,O
by,O
the,O
agonists,O
used,O
in,O
tests,O
",",O
TET,I-Entity
and,O
FAN,I-Entity
showed,O
the,O
inhibitions,O
dose,O
dependently,O
.,O
In,O
addition,O
",",O
neither,O
TET,I-Entity
nor,O
FAN,I-Entity
showed,O
any,O
anticoagulation,O
activities,O
in,O
the,O
measurement,O
of,O
the,O
activated,O
partial,O
thromboplastin,O
time,O
(,O
APTT,O
),O
",",O
prothrombin,O
time,O
(,O
PT,O
),O
and,O
thrombin,O
time,O
(,O
TT,O
),O
using,O
human,O
-,O
citrated,O
plasma,O
.,O
These,O
results,O
suggest,O
that,O
antithrombosis,O
of,O
TET,I-Entity
and,O
FAN,I-Entity
in,O
mice,O
may,O
be,O
mainly,O
related,O
to,O
the,O
antiplatelet,O
aggregation,O
activities,O
.,O
Gemcitabine,I-Entity
plus,O
vinorelbine,I-Entity
in,O
nonsmall,B-Entity
cell,I-Entity
lung,I-Entity
carcinoma,I-Entity
patients,O
age,O
70,O
years,O
or,O
older,O
or,O
patients,O
who,O
can,O
not,O
receive,O
cisplatin,I-Entity
.,O
Although,O
the,O
prevalence,O
of,O
nonsmall,B-Entity
cell,I-Entity
lung,I-Entity
carcinoma,I-Entity
(,O
NSCLC,I-Entity
),O
is,O
high,O
among,O
elderly,O
patients,O
",",O
few,O
data,O
are,O
available,O
regarding,O
the,O
efficacy,O
and,O
toxicity,I-Entity
of,O
chemotherapy,O
in,O
this,O
group,O
of,O
patients,O
.,O
Recent,O
reports,O
indicate,O
that,O
single,O
agent,O
therapy,O
with,O
vinorelbine,I-Entity
(,O
VNB,I-Entity
),O
or,O
gemcitabine,I-Entity
(,O
GEM,I-Entity
),O
may,O
obtain,O
a,O
response,O
rate,O
of,O
20,O
-,O
30%,O
in,O
elderly,O
patients,O
",",O
with,O
acceptable,O
toxicity,I-Entity
and,O
improvement,O
in,O
symptoms,O
and,O
quality,O
of,O
life,O
.,O
In,O
the,O
current,O
study,O
the,O
efficacy,O
and,O
toxicity,I-Entity
of,O
the,O
combination,O
of,O
GEM,I-Entity
and,O
VNB,I-Entity
in,O
elderly,O
patients,O
with,O
advanced,O
NSCLC,I-Entity
or,O
those,O
with,O
some,O
contraindication,O
to,O
receiving,O
cisplatin,I-Entity
were,O
assessed,O
.,O
METHODS,O
:,O
Forty,O
-,O
nine,O
patients,O
with,O
advanced,O
NSCLC,I-Entity
were,O
included,O
",",O
38,O
of,O
whom,O
were,O
age,O
>,O
/=,O
70,O
years,O
and,O
11,O
were,O
age,O
<,O
70,O
years,O
but,O
who,O
had,O
some,O
contraindication,O
to,O
receiving,O
cisplatin,I-Entity
.,O
All,O
patients,O
were,O
evaluable,O
for,O
response,O
and,O
toxicity,I-Entity
.,O
Treatment,O
was,O
comprised,O
of,O
VNB,I-Entity
",",O
25,O
mg,O
/,O
m(2,O
),O
",",O
plus,O
GEM,I-Entity
",",O
1000,O
mg,O
/,O
m(2,O
),O
",",O
both,O
on,O
Days,O
1,O
",",O
8,O
",",O
and,O
15,O
every,O
28,O
days,O
.,O
Toxicity,I-Entity
was,O
mild,O
.,O
Six,O
patients,O
(,O
12%,O
),O
had,O
World,O
Health,O
Organization,O
Grade,O
3,O
-,O
4,O
neutropenia,I-Entity
",",O
2,O
patients,O
(,O
4%,O
),O
had,O
Grade,O
3,O
-,O
4,O
thrombocytopenia,I-Entity
",",O
and,O
2,O
patients,O
(,O
4%,O
),O
had,O
Grade,O
3,O
neurotoxicity,I-Entity
.,O
Three,O
patients,O
with,O
severe,O
neutropenia,I-Entity
(,O
6%,O
),O
died,O
of,O
sepsis,I-Entity
.,O
The,O
median,O
age,O
of,O
those,O
patients,O
developing,O
Grade,O
3,O
-,O
4,O
neutropenia,I-Entity
was,O
significantly,O
higher,O
than,O
that,O
of,O
the,O
remaining,O
patients,O
(,O
75,O
years,O
vs.,O
72,O
years,O
;,O
P,O
=,O
0.047,O
),O
.,O
The,O
combination,O
of,O
GEM,I-Entity
and,O
VNB,I-Entity
is,O
moderately,O
active,O
and,O
well,O
tolerated,O
except,O
in,O
patients,O
age,O
>,O
/=,O
75,O
years,O
.,O
This,O
age,O
group,O
had,O
an,O
increased,O
risk,O
of,O
myelosuppression,I-Entity
.,O
New,O
chemotherapy,O
combinations,O
with,O
higher,O
activity,O
and,O
lower,O
toxicity,I-Entity
are,O
needed,O
for,O
elderly,O
patients,O
with,O
advanced,O
NSCLC,I-Entity
.,O
Warfarin,I-Entity
-,O
induced,O
artery,B-Entity
calcification,I-Entity
is,O
accelerated,O
by,O
growth,O
and,O
vitamin,B-Entity
D.,I-Entity
The,O
present,O
studies,O
demonstrate,O
that,O
growth,O
and,O
vitamin,B-Entity
D,I-Entity
treatment,O
enhance,O
the,O
extent,O
of,O
artery,B-Entity
calcification,I-Entity
in,O
rats,O
given,O
sufficient,O
doses,O
of,O
Warfarin,I-Entity
to,O
inhibit,O
gamma,O
-,O
carboxylation,O
of,O
matrix,O
Gla,O
protein,O
",",O
a,O
calcification,I-Entity
inhibitor,O
known,O
to,O
be,O
expressed,O
by,O
smooth,O
muscle,O
cells,O
and,O
macrophages,O
in,O
the,O
artery,O
wall,O
.,O
The,O
first,O
series,O
of,O
experiments,O
examined,O
the,O
influence,O
of,O
age,O
and,O
growth,O
status,O
on,O
artery,B-Entity
calcification,I-Entity
in,O
Warfarin,I-Entity
-,O
treated,O
rats,O
.,O
Treatment,O
for,O
2,O
weeks,O
with,O
Warfarin,I-Entity
caused,O
massive,O
focal,O
calcification,B-Entity
of,I-Entity
the,I-Entity
artery,I-Entity
media,O
in,O
20-day,O
-,O
old,O
rats,O
and,O
less,O
extensive,O
focal,O
calcification,I-Entity
in,O
42-day,O
-,O
old,O
rats,O
.,O
In,O
contrast,O
",",O
no,O
artery,B-Entity
calcification,I-Entity
could,O
be,O
detected,O
in,O
10-month,O
-,O
old,O
adult,O
rats,O
even,O
after,O
4,O
weeks,O
of,O
Warfarin,I-Entity
treatment,O
.,O
To,O
directly,O
examine,O
the,O
importance,O
of,O
growth,O
to,O
Warfarin,I-Entity
-,O
induced,O
artery,B-Entity
calcification,I-Entity
in,O
animals,O
of,O
the,O
same,O
age,O
",",O
20-day,O
-,O
old,O
rats,O
were,O
fed,O
for,O
2,O
weeks,O
either,O
an,O
ad,O
libitum,O
diet,O
or,O
a,O
6-g,O
/,O
d,O
restricted,O
diet,O
that,O
maintains,O
weight,O
but,O
prevents,O
growth,O
.,O
Concurrent,O
treatment,O
of,O
both,O
dietary,O
groups,O
with,O
Warfarin,I-Entity
produced,O
massive,O
focal,O
calcification,B-Entity
of,I-Entity
the,I-Entity
artery,I-Entity
media,O
in,O
the,O
ad,O
libitum,O
-,O
fed,O
rats,O
but,O
no,O
detectable,O
artery,B-Entity
calcification,I-Entity
in,O
the,O
restricted,O
-,O
diet,O
",",O
growth,O
-,O
inhibited,O
group,O
.,O
Although,O
the,O
explanation,O
for,O
the,O
association,O
between,O
artery,B-Entity
calcification,I-Entity
and,O
growth,O
status,O
can,O
not,O
be,O
determined,O
from,O
the,O
present,O
study,O
",",O
there,O
was,O
a,O
relationship,O
between,O
higher,O
serum,O
phosphate,I-Entity
and,O
susceptibility,O
to,O
artery,B-Entity
calcification,I-Entity
",",O
with,O
30%,O
higher,O
levels,O
of,O
serum,O
phosphate,I-Entity
in,O
young,O
",",O
ad,O
libitum,O
-,O
fed,O
rats,O
compared,O
with,O
either,O
of,O
the,O
groups,O
that,O
was,O
resistant,O
to,O
Warfarin,I-Entity
-,O
induced,O
artery,B-Entity
calcification,I-Entity
",",O
ie,O
",",O
the,O
10-month,O
-,O
old,O
rats,O
and,O
the,O
restricted,O
-,O
diet,O
",",O
growth,O
-,O
inhibited,O
young,O
rats,O
.,O
This,O
observation,O
suggests,O
that,O
increased,O
susceptibility,O
to,O
Warfarin,I-Entity
-,O
induced,O
artery,B-Entity
calcification,I-Entity
could,O
be,O
related,O
to,O
higher,O
serum,O
phosphate,I-Entity
levels,O
.,O
The,O
second,O
set,O
of,O
experiments,O
examined,O
the,O
possible,O
synergy,O
between,O
vitamin,B-Entity
D,I-Entity
and,O
Warfarin,I-Entity
in,O
artery,B-Entity
calcification,I-Entity
.,O
High,O
doses,O
of,O
vitamin,B-Entity
D,I-Entity
are,O
known,O
to,O
cause,O
calcification,B-Entity
of,I-Entity
the,I-Entity
artery,I-Entity
media,O
in,O
as,O
little,O
as,O
3,O
to,O
4,O
days,O
.,O
High,O
doses,O
of,O
the,O
vitamin,B-Entity
K,I-Entity
antagonist,O
Warfarin,I-Entity
are,O
also,O
known,O
to,O
cause,O
calcification,B-Entity
of,I-Entity
the,I-Entity
artery,I-Entity
media,O
",",O
but,O
at,O
treatment,O
times,O
of,O
2,O
weeks,O
or,O
longer,O
yet,O
not,O
at,O
1,O
week,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
investigated,O
the,O
synergy,O
between,O
these,O
2,O
treatments,O
and,O
found,O
that,O
concurrent,O
Warfarin,I-Entity
administration,O
dramatically,O
increased,O
the,O
extent,O
of,O
calcification,I-Entity
in,O
the,O
media,O
of,O
vitamin,B-Entity
D,I-Entity
-,O
treated,O
rats,O
at,O
3,O
and,O
4,O
days,O
.,O
There,O
was,O
a,O
close,O
parallel,O
between,O
the,O
effect,O
of,O
vitamin,B-Entity
D,I-Entity
dose,O
on,O
artery,B-Entity
calcification,I-Entity
and,O
the,O
effect,O
of,O
vitamin,B-Entity
D,I-Entity
dose,O
on,O
the,O
elevation,O
of,O
serum,O
calcium,I-Entity
",",O
which,O
suggests,O
that,O
vitamin,B-Entity
D,I-Entity
may,O
induce,O
artery,B-Entity
calcification,I-Entity
through,O
its,O
effect,O
on,O
serum,O
calcium,I-Entity
.,O
Because,O
Warfarin,I-Entity
treatment,O
had,O
no,O
effect,O
on,O
the,O
elevation,O
in,O
serum,O
calcium,I-Entity
produced,O
by,O
vitamin,B-Entity
D,I-Entity
",",O
the,O
synergy,O
between,O
Warfarin,I-Entity
and,O
vitamin,B-Entity
D,I-Entity
is,O
probably,O
best,O
explained,O
by,O
the,O
hypothesis,O
that,O
Warfarin,I-Entity
inhibits,O
the,O
activity,O
of,O
matrix,O
Gla,O
protein,O
as,O
a,O
calcification,I-Entity
inhibitor,O
.,O
High,O
levels,O
of,O
matrix,O
Gla,O
protein,O
are,O
found,O
at,O
sites,O
of,O
artery,B-Entity
calcification,I-Entity
in,O
rats,O
treated,O
with,O
vitamin,B-Entity
D,I-Entity
plus,O
Warfarin,I-Entity
",",O
and,O
chemical,O
analysis,O
showed,O
that,O
the,O
protein,O
that,O
accumulated,O
was,O
indeed,O
not,O
gamma,B-Entity
-,I-Entity
carboxylated,I-Entity
.,O
These,O
observations,O
indicate,O
that,O
although,O
the,O
gamma,B-Entity
-,I-Entity
carboxyglutamate,I-Entity
residues,O
of,O
matrix,O
Gla,O
protein,O
are,O
apparently,O
required,O
for,O
its,O
function,O
as,O
a,O
calcification,I-Entity
inhibitor,O
",",O
they,O
are,O
not,O
required,O
for,O
its,O
accumulation,O
at,O
calcification,I-Entity
sites,O
.,O
Antidepressant,I-Entity
-,O
induced,O
mania,I-Entity
in,O
bipolar,I-Entity
patients,O
:,O
identification,O
of,O
risk,O
factors,O
.,O
Concerns,O
about,O
possible,O
risks,O
of,O
switching,O
to,O
mania,I-Entity
associated,O
with,O
antidepressants,I-Entity
continue,O
to,O
interfere,O
with,O
the,O
establishment,O
of,O
an,O
optimal,O
treatment,O
paradigm,O
for,O
bipolar,B-Entity
depression,I-Entity
.,O
The,O
response,O
of,O
44,O
patients,O
meeting,O
DSM,O
-,O
IV,O
criteria,O
for,O
bipolar,B-Entity
disorder,I-Entity
to,O
naturalistic,O
treatment,O
was,O
assessed,O
for,O
at,O
least,O
6,O
weeks,O
using,O
the,O
Montgomery,O
-,O
Asberg,O
Depression,O
Rating,O
Scale,O
and,O
the,O
Bech,O
-,O
Rafaelson,O
Mania,O
Rating,O
Scale,O
.,O
Patients,O
who,O
experienced,O
a,O
manic,I-Entity
or,O
hypomanic,I-Entity
switch,O
were,O
compared,O
with,O
those,O
who,O
did,O
not,O
on,O
several,O
variables,O
including,O
age,O
",",O
sex,O
",",O
diagnosis,O
(,O
DSM,B-Entity
-,I-Entity
IV,I-Entity
bipolar,I-Entity
I,I-Entity
vs.,O
bipolar,B-Entity
II,I-Entity
),O
",",O
number,O
of,O
previous,O
manic,I-Entity
episodes,O
",",O
type,O
of,O
antidepressant,I-Entity
therapy,O
used,O
(,O
electroconvulsive,O
therapy,O
vs.,O
antidepressant,I-Entity
drugs,O
and,O
",",O
more,O
particularly,O
",",O
selective,O
serotonin,B-Entity
reuptake,I-Entity
inhibitors,I-Entity
[,O
SSRIs,I-Entity
],O
),O
",",O
use,O
and,O
type,O
of,O
mood,O
stabilizers,O
(,O
lithium,I-Entity
vs.,O
anticonvulsants,O
),O
",",O
and,O
temperament,O
of,O
the,O
patient,O
",",O
assessed,O
during,O
a,O
normothymic,O
period,O
using,O
the,O
hyperthymia,O
component,O
of,O
the,O
Semi,O
-,O
structured,O
Affective,O
Temperament,O
Interview,O
.,O
Switches,O
to,O
hypomania,I-Entity
or,O
mania,I-Entity
occurred,O
in,O
27%,O
of,O
all,O
patients,O
(,O
N,O
=,O
12,O
),O
(,O
and,O
in,O
24%,O
of,O
the,O
subgroup,O
of,O
patients,O
treated,O
with,O
SSRIs,I-Entity
[,O
8/33,O
],O
),O
;,O
16%,O
(,O
N,O
=,O
7,O
),O
experienced,O
manic,I-Entity
episodes,O
",",O
and,O
11%,O
(,O
N,O
=,O
5,O
),O
experienced,O
hypomanic,I-Entity
episodes,O
.,O
Sex,O
",",O
age,O
",",O
diagnosis,O
(,O
bipolar,B-Entity
I,I-Entity
vs.,O
bipolar,B-Entity
II,I-Entity
),O
",",O
and,O
additional,O
treatment,O
did,O
not,O
affect,O
the,O
risk,O
of,O
switching,O
.,O
In,O
contrast,O
",",O
mood,O
switches,O
were,O
less,O
frequent,O
in,O
patients,O
receiving,O
lithium,I-Entity
(,O
15%,O
",",O
4/26,O
),O
than,O
in,O
patients,O
not,O
treated,O
with,O
lithium,I-Entity
(,O
44%,O
",",O
8/18,O
;,O
p,O
=,O
.04,O
),O
.,O
The,O
number,O
of,O
previous,O
manic,I-Entity
episodes,O
did,O
not,O
affect,O
the,O
probability,O
of,O
switching,O
",",O
whereas,O
a,O
high,O
score,O
on,O
the,O
hyperthymia,O
component,O
of,O
the,O
Semistructured,O
Affective,O
Temperament,O
Interview,O
was,O
associated,O
with,O
a,O
greater,O
risk,O
of,O
switching,O
(,O
p,O
=,O
.008,O
),O
.,O
The,O
frequency,O
of,O
mood,O
switching,O
associated,O
with,O
acute,O
antidepressant,I-Entity
therapy,O
may,O
be,O
reduced,O
by,O
lithium,I-Entity
treatment,O
.,O
Caffeine,I-Entity
-,O
induced,O
cardiac,B-Entity
arrhythmia,I-Entity
:,O
an,O
unrecognised,O
danger,O
of,O
healthfood,O
products,O
.,O
We,O
describe,O
a,O
25-year,O
-,O
old,O
woman,O
with,O
pre,O
-,O
existing,O
mitral,B-Entity
valve,I-Entity
prolapse,I-Entity
who,O
developed,O
intractable,O
ventricular,B-Entity
fibrillation,I-Entity
after,O
consuming,O
a,O
"""",O
natural,O
energy,O
"""",O
guarana,O
health,O
drink,O
containing,O
a,O
high,O
concentration,O
of,O
caffeine,I-Entity
.,O
Bladder,O
retention,B-Entity
of,I-Entity
urine,I-Entity
as,O
a,O
result,O
of,O
continuous,O
intravenous,O
infusion,O
of,O
fentanyl,I-Entity
:,O
2,O
case,O
reports,O
.,O
Sedation,O
has,O
been,O
commonly,O
used,O
in,O
the,O
neonate,O
to,O
decrease,O
the,O
stress,O
and,O
pain,I-Entity
from,O
the,O
noxious,O
stimuli,O
and,O
invasive,O
procedures,O
in,O
the,O
neonatal,O
intensive,O
care,O
unit,O
",",O
as,O
well,O
as,O
to,O
facilitate,O
synchrony,O
between,O
ventilator,O
and,O
spontaneous,O
breaths,O
.,O
Fentanyl,I-Entity
",",O
an,O
opioid,O
analgesic,O
",",O
is,O
frequently,O
used,O
in,O
the,O
neonatal,O
intensive,O
care,O
unit,O
setting,O
for,O
these,O
very,O
purposes,O
.,O
Various,O
reported,O
side,O
effects,O
of,O
fentanyl,I-Entity
administration,O
include,O
chest,B-Entity
wall,I-Entity
rigidity,I-Entity
",",O
hypotension,I-Entity
",",O
respiratory,B-Entity
depression,I-Entity
",",O
and,O
bradycardia,I-Entity
.,O
Here,O
",",O
2,O
cases,O
of,O
urinary,B-Entity
bladder,I-Entity
retention,I-Entity
leading,O
to,O
renal,O
pelvocalyceal,O
dilatation,O
mimicking,O
hydronephrosis,I-Entity
as,O
a,O
result,O
of,O
continuous,O
infusion,O
of,O
fentanyl,I-Entity
are,O
reported,O
.,O
Combined,O
antiretroviral,O
therapy,O
causes,O
cardiomyopathy,I-Entity
and,O
elevates,O
plasma,O
lactate,I-Entity
in,O
transgenic,O
AIDS,I-Entity
mice,O
.,O
Highly,O
active,O
antiretroviral,O
therapy,O
(,O
HAART,O
),O
is,O
implicated,O
in,O
cardiomyopathy,I-Entity
(,O
CM,I-Entity
),O
and,O
in,O
elevated,O
plasma,O
lactate,I-Entity
(,O
LA,I-Entity
),O
in,O
AIDS,I-Entity
through,O
mechanisms,O
of,O
mitochondrial,B-Entity
dysfunction,I-Entity
.,O
To,O
determine,O
mitochondrial,O
events,O
from,O
HAART,O
in,O
vivo,O
",",O
8-week,O
-,O
old,O
hemizygous,O
transgenic,O
AIDS,I-Entity
mice,O
(,O
NL4,O
-,O
3Delta,O
gag,O
/,O
pol,O
;,O
TG,O
),O
and,O
wild,O
-,O
type,O
FVB,O
/,O
n,O
littermates,O
were,O
treated,O
with,O
the,O
HAART,O
combination,O
of,O
zidovudine,I-Entity
",",O
lamivudine,I-Entity
",",O
and,O
indinavir,I-Entity
or,O
vehicle,O
control,O
for,O
10,O
days,O
or,O
35,O
days,O
.,O
At,O
termination,O
of,O
the,O
experiments,O
",",O
mice,O
underwent,O
echocardiography,O
",",O
quantitation,O
of,O
abundance,O
of,O
molecular,O
markers,O
of,O
CM,I-Entity
(,O
ventricular,O
mRNA,O
encoding,O
atrial,O
natriuretic,O
factor,O
[,O
ANF,O
],O
and,O
sarcoplasmic,O
calcium,I-Entity
ATPase,O
[,O
SERCA2,O
],O
),O
",",O
and,O
determination,O
of,O
plasma,O
LA,I-Entity
.,O
Biochemically,O
",",O
LA,I-Entity
was,O
elevated,O
(,O
8.5,O
+,O
/-,O
Results,O
show,O
that,O
cumulative,O
HAART,O
caused,O
mitochondrial,O
CM,I-Entity
with,O
elevated,O
LA,I-Entity
in,O
AIDS,I-Entity
transgenic,O
mice,O
.,O
Oral,B-Entity
contraceptives,I-Entity
and,O
the,O
risk,O
of,O
myocardial,B-Entity
infarction,I-Entity
.,O
BACKGROUND,O
:,O
An,O
association,O
between,O
the,O
use,O
of,O
oral,B-Entity
contraceptives,I-Entity
and,O
the,O
risk,O
of,O
myocardial,B-Entity
infarction,I-Entity
has,O
been,O
found,O
in,O
some,O
",",O
but,O
not,O
all,O
",",O
studies,O
.,O
We,O
investigated,O
this,O
association,O
",",O
according,O
to,O
the,O
type,O
of,O
progestagen,I-Entity
included,O
in,O
third,O
-,O
generation,O
(,O
i.e.,O
",",O
desogestrel,I-Entity
or,O
gestodene,I-Entity
),O
and,O
second,O
-,O
generation,O
(,O
i.e.,O
",",O
levonorgestrel,I-Entity
),O
oral,B-Entity
contraceptives,I-Entity
",",O
the,O
dose,O
of,O
estrogen,I-Entity
",",O
and,O
the,O
presence,O
or,O
absence,O
of,O
prothrombotic,O
mutations,O
METHODS,O
:,O
In,O
a,O
nationwide,O
",",O
population,O
-,O
based,O
",",O
case,O
-,O
control,O
study,O
",",O
we,O
identified,O
and,O
enrolled,O
248,O
women,O
18,O
through,O
49,O
years,O
of,O
age,O
who,O
had,O
had,O
a,O
first,O
myocardial,B-Entity
infarction,I-Entity
between,O
1990,O
and,O
1995,O
and,O
925,O
control,O
women,O
who,O
had,O
not,O
had,O
a,O
myocardial,B-Entity
infarction,I-Entity
and,O
who,O
were,O
matched,O
for,O
age,O
",",O
calendar,O
year,O
of,O
the,O
index,O
event,O
",",O
and,O
area,O
of,O
residence,O
.,O
Subjects,O
supplied,O
information,O
on,O
oral,B-Entity
-,I-Entity
contraceptive,I-Entity
use,O
and,O
major,O
cardiovascular,O
risk,O
factors,O
.,O
An,O
analysis,O
for,O
factor,O
V,O
Leiden,O
and,O
the,O
G20210A,O
mutation,O
in,O
the,O
prothrombin,O
gene,O
was,O
conducted,O
in,O
217,O
patients,O
and,O
763,O
controls,O
RESULTS,O
:,O
The,O
odds,O
ratio,O
for,O
myocardial,B-Entity
infarction,I-Entity
among,O
women,O
who,O
used,O
any,O
type,O
of,O
combined,O
oral,B-Entity
contraceptive,I-Entity
",",O
as,O
compared,O
with,O
nonusers,O
",",O
was,O
2.0,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
1.5,O
to,O
2.8,O
),O
.,O
The,O
adjusted,O
odds,O
ratio,O
was,O
2.5,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
1.5,O
to,O
4.1,O
),O
among,O
women,O
who,O
used,O
second,O
-,O
generation,O
oral,B-Entity
contraceptives,I-Entity
and,O
1.3,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
0.7,O
to,O
2.5,O
),O
among,O
those,O
who,O
used,O
third,O
-,O
generation,O
oral,B-Entity
contraceptives,I-Entity
.,O
Among,O
women,O
who,O
used,O
oral,B-Entity
contraceptives,I-Entity
",",O
the,O
odds,O
ratio,O
was,O
2.1,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
1.5,O
to,O
3.0,O
),O
for,O
those,O
without,O
a,O
prothrombotic,O
mutation,O
and,O
1.9,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
0.6,O
to,O
5.5,O
),O
for,O
those,O
with,O
a,O
mutation,O
CONCLUSIONS,O
:,O
The,O
risk,O
of,O
myocardial,B-Entity
infarction,I-Entity
was,O
increased,O
among,O
women,O
who,O
used,O
second,O
-,O
generation,O
oral,B-Entity
contraceptives,I-Entity
.,O
The,O
results,O
with,O
respect,O
to,O
the,O
use,O
of,O
third,O
-,O
generation,O
oral,B-Entity
contraceptives,I-Entity
were,O
inconclusive,O
but,O
suggested,O
that,O
the,O
risk,O
was,O
lower,O
than,O
the,O
risk,O
associated,O
with,O
second,O
-,O
generation,O
oral,B-Entity
contraceptives,I-Entity
.,O
The,O
risk,O
of,O
myocardial,B-Entity
infarction,I-Entity
was,O
similar,O
among,O
women,O
who,O
used,O
oral,B-Entity
contraceptives,I-Entity
whether,O
or,O
not,O
they,O
had,O
a,O
prothrombotic,O
mutation,O
.,O
Effects,O
of,O
5-HT1B,O
receptor,O
ligands,O
microinjected,O
into,O
the,O
accumbal,O
shell,O
or,O
core,O
on,O
the,O
cocaine,I-Entity
-,O
induced,O
locomotor,B-Entity
hyperactivity,I-Entity
in,O
rats,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
examine,O
the,O
effect,O
of,O
5-HT1B,O
receptor,O
ligands,O
microinjected,O
into,O
the,O
subregions,O
of,O
the,O
nucleus,O
accumbens,O
(,O
the,O
shell,O
and,O
the,O
core,O
),O
on,O
the,O
locomotor,B-Entity
hyperactivity,I-Entity
induced,O
by,O
cocaine,I-Entity
in,O
rats,O
.,O
Male,O
Wistar,O
rats,O
were,O
implanted,O
bilaterally,O
with,O
cannulae,O
into,O
the,O
accumbens,O
shell,O
or,O
core,O
",",O
and,O
then,O
were,O
locally,O
injected,O
with,O
GR,B-Entity
55562,I-Entity
(,O
an,O
antagonist,O
of,O
5-HT1B,O
receptors,O
),O
or,O
CP,B-Entity
93129,I-Entity
(,O
an,O
agonist,O
of,O
5-HT1B,O
receptors,O
),O
.,O
Given,O
alone,O
to,O
any,O
accumbal,O
subregion,O
",",O
GR,B-Entity
55562,I-Entity
(,O
0.1,O
-,O
10,O
microg,O
/,O
side,O
),O
or,O
CP,B-Entity
93129,I-Entity
(,O
0.1,O
-,O
10,O
microg,O
/,O
side,O
),O
did,O
not,O
change,O
basal,O
locomotor,O
activity,O
.,O
Systemic,O
cocaine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
significantly,O
increased,O
the,O
locomotor,O
activity,O
of,O
rats,O
.,O
GR,B-Entity
55562,I-Entity
(,O
0.1,O
-,O
10,O
microg,O
/,O
side,O
),O
",",O
administered,O
intra,O
-,O
accumbens,O
shell,O
prior,O
to,O
cocaine,I-Entity
",",O
dose,O
-,O
dependently,O
attenuated,O
the,O
psychostimulant,O
-,O
induced,O
locomotor,B-Entity
hyperactivity,I-Entity
.,O
Such,O
attenuation,O
was,O
not,O
found,O
in,O
animals,O
which,O
had,O
been,O
injected,O
with,O
GR,B-Entity
55562,I-Entity
into,O
the,O
accumbens,O
core,O
.,O
When,O
injected,O
into,O
the,O
accumbens,O
shell,O
(,O
but,O
not,O
the,O
core,O
),O
before,O
cocaine,I-Entity
",",O
CP,B-Entity
93129,I-Entity
(,O
0.1,O
-,O
10,O
microg,O
/,O
side,O
),O
enhanced,O
the,O
locomotor,O
response,O
to,O
cocaine,I-Entity
;,O
the,O
maximum,O
effect,O
being,O
observed,O
after,O
10,O
microg,O
/,O
side,O
of,O
the,O
agonist,O
.,O
The,O
later,O
enhancement,O
was,O
attenuated,O
after,O
intra,O
-,O
accumbens,O
shell,O
treatment,O
with,O
GR,B-Entity
55562,I-Entity
(,O
1,O
microg,O
/,O
side,O
),O
.,O
Our,O
findings,O
indicate,O
that,O
cocaine,I-Entity
induced,O
hyperlocomotion,I-Entity
is,O
modified,O
by,O
5-HT1B,O
receptor,O
ligands,O
microinjected,O
into,O
the,O
accumbens,O
shell,O
",",O
but,O
not,O
core,O
",",O
this,O
modification,O
consisting,O
in,O
inhibitory,O
and,O
facilitatory,O
effects,O
of,O
the,O
5-HT1B,O
receptor,O
antagonist,O
(,O
GR,B-Entity
55562,I-Entity
),O
and,O
agonist,O
(,O
CP,B-Entity
93129,I-Entity
),O
",",O
respectively,O
.,O
Ticlopidine,I-Entity
-,O
induced,O
cholestatic,B-Entity
hepatitis,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
2,O
cases,O
of,O
ticlopidine,I-Entity
-,O
induced,O
cholestatic,B-Entity
hepatitis,I-Entity
",",O
investigate,O
its,O
mechanism,O
",",O
and,O
compare,O
the,O
observed,O
main,O
characteristics,O
with,O
those,O
of,O
the,O
published,O
cases,O
.,O
CASE,O
SUMMARIES,O
:,O
Two,O
patients,O
developed,O
prolonged,O
cholestatic,B-Entity
hepatitis,I-Entity
after,O
receiving,O
ticlopidine,I-Entity
following,O
percutaneous,O
coronary,O
angioplasty,O
",",O
with,O
complete,O
remission,O
during,O
the,O
follow,O
-,O
up,O
period,O
.,O
T,O
-,O
cell,O
stimulation,O
by,O
therapeutic,O
concentration,O
of,O
ticlopidine,I-Entity
was,O
demonstrated,O
in,O
vitro,O
in,O
the,O
patients,O
",",O
but,O
not,O
in,O
healthy,O
controls,O
.,O
DISCUSSION,O
:,O
Cholestatic,B-Entity
hepatitis,I-Entity
is,O
a,O
rare,O
complication,O
of,O
the,O
antiplatelet,O
agent,O
ticlopidine,I-Entity
;,O
several,O
cases,O
have,O
been,O
reported,O
but,O
few,O
in,O
the,O
English,O
literature,O
.,O
Our,O
patients,O
developed,O
jaundice,I-Entity
following,O
treatment,O
with,O
ticlopidine,I-Entity
and,O
showed,O
the,O
clinical,O
and,O
laboratory,O
characteristics,O
of,O
cholestatic,B-Entity
hepatitis,I-Entity
",",O
which,O
resolved,O
after,O
discontinuation,O
of,O
the,O
drug,O
.,O
Hepatitis,I-Entity
may,O
develop,O
weeks,O
after,O
discontinuation,O
of,O
the,O
drug,O
and,O
may,O
run,O
a,O
prolonged,O
course,O
",",O
but,O
complete,O
remission,O
was,O
observed,O
in,O
all,O
reported,O
cases,O
.,O
An,O
objective,O
causality,O
assessment,O
revealed,O
that,O
the,O
adverse,O
drug,O
event,O
was,O
probably,O
related,O
to,O
the,O
use,O
of,O
ticlopidine,I-Entity
.,O
The,O
mechanisms,O
of,O
this,O
ticlopidine,I-Entity
-,O
induced,O
cholestasis,I-Entity
are,O
unclear,O
.,O
Immune,O
mechanisms,O
may,O
be,O
involved,O
in,O
the,O
drug,O
's,O
hepatotoxicity,I-Entity
",",O
as,O
suggested,O
by,O
the,O
T,O
-,O
cell,O
stimulation,O
study,O
reported,O
here,O
.,O
Cholestatic,B-Entity
hepatitis,I-Entity
is,O
a,O
rare,O
adverse,O
effect,O
of,O
ticlopidine,I-Entity
that,O
may,O
be,O
immune,O
mediated,O
.,O
This,O
complication,O
will,O
be,O
observed,O
even,O
less,O
often,O
in,O
the,O
future,O
as,O
ticlopidine,I-Entity
is,O
being,O
replaced,O
by,O
the,O
newer,O
antiplatelet,O
agent,O
clopidogrel,I-Entity
.,O
Epithelial,O
sodium,I-Entity
channel,O
(,O
ENaC,O
),O
subunit,O
mRNA,O
and,O
protein,O
expression,O
in,O
rats,O
with,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
In,O
experimental,O
nephrotic,B-Entity
syndrome,I-Entity
",",O
urinary,O
sodium,I-Entity
excretion,O
is,O
decreased,O
during,O
the,O
early,O
phase,O
of,O
the,O
disease,O
.,O
The,O
rate,O
-,O
limiting,O
constituent,O
of,O
collecting,O
duct,O
sodium,I-Entity
transport,O
is,O
the,O
epithelial,O
sodium,I-Entity
channel,O
(,O
ENaC,O
),O
.,O
We,O
examined,O
the,O
abundance,O
of,O
ENaC,O
subunit,O
mRNAs,O
and,O
proteins,O
in,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN)-induced,I-Entity
nephrotic,B-Entity
syndrome,I-Entity
.,O
The,O
time,O
courses,O
of,O
urinary,O
sodium,I-Entity
excretion,O
",",O
plasma,O
aldosterone,I-Entity
concentration,O
and,O
proteinuria,I-Entity
were,O
studied,O
in,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
treated,O
with,O
a,O
single,O
dose,O
of,O
either,O
PAN,I-Entity
or,O
vehicle,O
.,O
The,O
kinetics,O
of,O
urinary,O
sodium,I-Entity
excretion,O
and,O
the,O
appearance,O
of,O
proteinuria,I-Entity
were,O
comparable,O
with,O
those,O
reported,O
previously,O
.,O
Sodium,I-Entity
retention,O
occurred,O
on,O
days,O
2,O
",",O
3,O
and,O
6,O
after,O
PAN,I-Entity
injection,O
.,O
A,O
significant,O
up,O
-,O
regulation,O
of,O
alphaENaC,O
and,O
betaENaC,O
mRNA,O
abundance,O
on,O
days,O
1,O
and,O
2,O
preceded,O
sodium,I-Entity
retention,O
on,O
days,O
2,O
and,O
3,O
.,O
Conversely,O
",",O
down,O
-,O
regulation,O
of,O
alphaENaC,O
",",O
betaENaC,O
and,O
gammaENaC,O
mRNA,O
expression,O
on,O
day,O
3,O
occurred,O
in,O
the,O
presence,O
of,O
high,O
aldosterone,I-Entity
concentrations,O
",",O
and,O
was,O
followed,O
by,O
a,O
return,O
of,O
sodium,I-Entity
excretion,O
to,O
control,O
values,O
.,O
The,O
amounts,O
of,O
alphaENaC,O
",",O
betaENaC,O
and,O
gammaENaC,O
proteins,O
were,O
not,O
increased,O
during,O
PAN,I-Entity
-,O
induced,O
sodium,I-Entity
retention,O
.,O
In,O
conclusion,O
",",O
ENaC,O
mRNA,O
expression,O
",",O
especially,O
alphaENaC,O
",",O
is,O
increased,O
in,O
the,O
very,O
early,O
phase,O
of,O
the,O
experimental,O
model,O
of,O
PAN,I-Entity
-,O
induced,O
nephrotic,B-Entity
syndrome,I-Entity
in,O
rats,O
",",O
but,O
appears,O
to,O
escape,O
from,O
the,O
regulation,O
by,O
aldosterone,I-Entity
after,O
day,O
3,O
.,O
NO,I-Entity
-,O
induced,O
migraine,I-Entity
attack,O
:,O
strong,O
increase,O
in,O
plasma,O
calcitonin,B-Entity
gene,I-Entity
-,I-Entity
related,I-Entity
peptide,I-Entity
(,O
CGRP,I-Entity
),O
concentration,O
and,O
negative,O
correlation,O
with,O
platelet,O
serotonin,I-Entity
release,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
changes,O
in,O
the,O
plasma,O
calcitonin,B-Entity
gene,I-Entity
-,I-Entity
related,I-Entity
peptide,I-Entity
(,O
CGRP,I-Entity
),O
concentration,O
and,O
platelet,O
serotonin,I-Entity
(,O
5-hydroxytriptamine,I-Entity
",",O
5-HT,I-Entity
),O
content,O
during,O
the,O
immediate,O
headache,I-Entity
and,O
the,O
delayed,O
genuine,O
migraine,I-Entity
attack,O
provoked,O
by,O
nitroglycerin,I-Entity
.,O
Fifteen,O
female,O
migraineurs,B-Entity
(,I-Entity
without,I-Entity
aura,I-Entity
),I-Entity
and,O
eight,O
controls,O
participated,O
in,O
the,O
study,O
.,O
Sublingual,O
nitroglycerin,I-Entity
(,O
0.5,O
mg,O
),O
was,O
administered,O
.,O
Blood,O
was,O
collected,O
from,O
the,O
antecubital,O
vein,O
four,O
times,O
:,O
60,O
min,O
before,O
and,O
after,O
the,O
nitroglycerin,I-Entity
application,O
",",O
and,O
60,O
and,O
120,O
min,O
after,O
the,O
beginning,O
of,O
the,O
migraine,I-Entity
attack,O
(,O
mean,O
344,O
and,O
404,O
min,O
;,O
12,O
subjects,O
),O
.,O
In,O
those,O
subjects,O
who,O
had,O
no,O
migraine,I-Entity
attack,O
(,O
11,O
subjects,O
),O
a,O
similar,O
time,O
schedule,O
was,O
used,O
.,O
Plasma,O
CGRP,I-Entity
concentration,O
increased,O
significantly,O
(,O
P<0.01,O
),O
during,O
the,O
migraine,I-Entity
attack,O
and,O
returned,O
to,O
baseline,O
after,O
the,O
cessation,O
of,O
the,O
migraine,I-Entity
.,O
In,O
addition,O
",",O
both,O
change,O
and,O
peak,O
",",O
showed,O
significant,O
positive,O
correlations,O
with,O
migraine,I-Entity
headache,I-Entity
intensity,O
(,O
P<0.001,O
),O
.,O
However,O
",",O
plasma,O
CGRP,I-Entity
concentrations,O
failed,O
to,O
change,O
during,O
immediate,O
headache,I-Entity
and,O
in,O
the,O
subjects,O
with,O
no,O
migraine,I-Entity
attack,O
.,O
Basal,O
CGRP,I-Entity
concentration,O
was,O
significantly,O
higher,O
and,O
platelet,O
5-HT,I-Entity
content,O
tended,O
to,O
be,O
lower,O
in,O
subjects,O
who,O
experienced,O
a,O
migraine,I-Entity
attack,O
.,O
Platelet,O
serotonin,I-Entity
content,O
decreased,O
significantly,O
(,O
P<0.01,O
),O
after,O
nitroglycerin,I-Entity
in,O
subjects,O
with,O
no,O
migraine,I-Entity
attack,O
but,O
no,O
consistent,O
change,O
was,O
observed,O
in,O
patients,O
with,O
migraine,I-Entity
attack,O
.,O
In,O
conclusion,O
",",O
the,O
fact,O
that,O
plasma,O
CGRP,I-Entity
concentration,O
correlates,O
with,O
the,O
timing,O
and,O
severity,O
of,O
a,O
migraine,I-Entity
headache,I-Entity
suggests,O
a,O
direct,O
relationship,O
between,O
CGRP,I-Entity
and,O
migraine,I-Entity
.,O
In,O
contrast,O
",",O
serotonin,I-Entity
release,O
from,O
platelets,O
does,O
not,O
provoke,O
migraine,I-Entity
",",O
it,O
may,O
even,O
counteract,O
the,O
headache,I-Entity
and,O
the,O
concomitant,O
CGRP,I-Entity
release,O
in,O
this,O
model,O
.,O
Coronary,B-Entity
aneurysm,I-Entity
after,O
implantation,O
of,O
a,O
paclitaxel,I-Entity
-,O
eluting,O
stent,O
.,O
Formation,O
of,O
coronary,B-Entity
aneurysm,I-Entity
is,O
a,O
rare,O
complication,O
of,O
stenting,O
with,O
bare,O
metal,O
stents,O
",",O
but,O
based,O
on,O
experimental,O
studies,O
drug,O
-,O
eluting,O
stents,O
may,O
induce,O
toxic,O
effects,O
on,O
the,O
vessel,O
wall,O
with,O
incomplete,O
stent,O
apposition,O
",",O
aneurysm,I-Entity
formation,O
and,O
with,O
the,O
potential,O
of,O
stent,O
thrombosis,I-Entity
or,O
vessel,B-Entity
rupture,I-Entity
.,O
We,O
present,O
a,O
43-year,O
-,O
old,O
man,O
who,O
developed,O
a,O
coronary,B-Entity
aneurysm,I-Entity
in,O
the,O
right,O
coronary,O
artery,O
6,O
months,O
after,O
receiving,O
a,O
paclitaxel,I-Entity
-,O
eluting,O
stent,O
.,O
The,O
patient,O
was,O
asymptomatic,O
and,O
the,O
aneurysm,I-Entity
was,O
detected,O
in,O
a,O
routine,O
control,O
.,O
Angiography,O
and,O
intracoronary,O
ultrasound,O
demonstrated,O
lack,O
of,O
contact,O
between,O
stent,O
and,O
vessel,O
wall,O
in,O
a,O
15-mm,O
long,O
segment,O
with,O
maximal,O
aneurysm,I-Entity
diameter,O
of,O
6.0,O
mm,O
.,O
Behavioral,O
effects,O
of,O
urotensin,B-Entity
-,I-Entity
II,I-Entity
centrally,O
administered,O
in,O
mice,O
.,O
Urotensin,B-Entity
-,I-Entity
II,I-Entity
(,O
U,B-Entity
-,I-Entity
II,I-Entity
),O
receptors,O
are,O
widely,O
distributed,O
in,O
the,O
central,O
nervous,O
system,O
.,O
Intracerebroventricular,O
(,O
i.c.v,O
.,O
),O
injection,O
of,O
U,B-Entity
-,I-Entity
II,I-Entity
causes,O
hypertension,I-Entity
and,O
bradycardia,I-Entity
and,O
stimulates,O
prolactin,O
and,O
thyrotropin,O
secretion,O
.,O
However,O
",",O
the,O
behavioral,O
effects,O
of,O
centrally,O
administered,O
U,B-Entity
-,I-Entity
II,I-Entity
have,O
received,O
little,O
attention,O
.,O
injections,O
of,O
U,B-Entity
-,I-Entity
II,I-Entity
on,O
behavioral,O
",",O
metabolic,O
",",O
and,O
endocrine,O
responses,O
in,O
mice,O
.,O
Administration,O
of,O
graded,O
doses,O
of,O
U,B-Entity
-,I-Entity
II,I-Entity
(,O
1,O
-,O
"10,000",O
ng,O
/,O
mouse,O
),O
provoked,O
:,O
(,O
1,O
),O
a,O
dose,O
-,O
dependent,O
reduction,O
in,O
the,O
number,O
of,O
head,O
dips,O
in,O
the,O
hole,O
-,O
board,O
test,O
;,O
(,O
2,O
),O
a,O
dose,O
-,O
dependent,O
reduction,O
in,O
the,O
number,O
of,O
entries,O
in,O
the,O
white,O
chamber,O
in,O
the,O
black,O
-,O
and,O
-,O
white,O
compartment,O
test,O
",",O
and,O
in,O
the,O
number,O
of,O
entries,O
in,O
the,O
central,O
platform,O
and,O
open,O
arms,O
in,O
the,O
plus,O
-,O
maze,O
test,O
;,O
and,O
(,O
3,O
),O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
duration,O
of,O
immobility,O
in,O
the,O
forced,O
-,O
swimming,O
test,O
and,O
tail,O
suspension,O
test,O
.,O
Intracerebroventricular,O
injection,O
of,O
U,B-Entity
-,I-Entity
II,I-Entity
also,O
caused,O
an,O
increase,O
in,O
:,O
food,O
intake,O
at,O
doses,O
of,O
100,O
and,O
"1,000",O
ng,O
/,O
mouse,O
",",O
water,O
intake,O
at,O
doses,O
of,O
100,O
-,O
"10,000",O
ng,O
/,O
mouse,O
",",O
and,O
horizontal,O
locomotion,O
activity,O
at,O
a,O
dose,O
of,O
"10,000",O
ng,O
/,O
mouse,O
.,O
Whatever,O
was,O
the,O
dose,O
",",O
the,O
central,O
administration,O
of,O
U,B-Entity
-,I-Entity
II,I-Entity
had,O
no,O
effect,O
on,O
body,O
temperature,O
",",O
nociception,O
",",O
apomorphine,I-Entity
-,O
induced,O
penile,B-Entity
erection,I-Entity
and,O
climbing,O
behavior,O
",",O
and,O
stress,O
-,O
induced,O
plasma,O
corticosterone,I-Entity
level,O
.,O
Taken,O
together,O
",",O
the,O
present,O
study,O
demonstrates,O
that,O
the,O
central,O
injection,O
of,O
U,B-Entity
-,I-Entity
II,I-Entity
at,O
doses,O
of,O
1,O
-,O
"10,000",O
ng,O
/,O
mouse,O
induces,O
anxiogenic-,O
and,O
depressant,O
-,O
like,O
effects,O
in,O
mouse,O
.,O
These,O
data,O
suggest,O
that,O
U,B-Entity
-,I-Entity
II,I-Entity
may,O
be,O
involved,O
in,O
some,O
aspects,O
of,O
psychiatric,B-Entity
disorders,I-Entity
.,O
Recurrent,O
dysphonia,I-Entity
and,O
acitretin,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
woman,O
complaining,O
of,O
dysphonia,I-Entity
while,O
she,O
was,O
treated,O
by,O
acitretin,I-Entity
.,O
Her,O
symptoms,O
totally,O
regressed,O
after,O
drug,O
withdrawal,O
and,O
reappeared,O
when,O
acitretin,I-Entity
was,O
reintroduced,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
case,O
of,O
acitretin,I-Entity
-,O
induced,O
dysphonia,I-Entity
.,O
Pharmacological,O
modulation,O
of,O
pain,I-Entity
-,O
related,O
brain,O
activity,O
during,O
normal,O
and,O
central,O
sensitization,O
states,O
in,O
humans,O
.,O
Abnormal,O
processing,O
of,O
somatosensory,O
inputs,O
in,O
the,O
central,O
nervous,O
system,O
(,O
central,O
sensitization,O
),O
is,O
the,O
mechanism,O
accounting,O
for,O
the,O
enhanced,O
pain,I-Entity
sensitivity,O
in,O
the,O
skin,O
surrounding,O
tissue,B-Entity
injury,I-Entity
(,O
secondary,B-Entity
hyperalgesia,I-Entity
),O
.,O
Secondary,B-Entity
hyperalgesia,I-Entity
shares,O
clinical,O
characteristics,O
with,O
neurogenic,B-Entity
hyperalgesia,I-Entity
in,O
patients,O
with,O
neuropathic,B-Entity
pain,I-Entity
.,O
Abnormal,O
brain,O
responses,O
to,O
somatosensory,O
stimuli,O
have,O
been,O
found,O
in,O
patients,O
with,O
hyperalgesia,I-Entity
as,O
well,O
as,O
in,O
normal,O
subjects,O
during,O
experimental,O
central,O
sensitization,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
effects,O
of,O
gabapentin,I-Entity
",",O
a,O
drug,O
effective,O
in,O
neuropathic,B-Entity
pain,I-Entity
patients,O
",",O
on,O
brain,O
processing,O
of,O
nociceptive,O
information,O
in,O
normal,O
and,O
central,O
sensitization,O
states,O
.,O
Using,O
functional,O
magnetic,O
resonance,O
imaging,O
(,O
fMRI,O
),O
in,O
normal,O
volunteers,O
",",O
we,O
studied,O
the,O
gabapentin,I-Entity
-,O
induced,O
modulation,O
of,O
brain,O
activity,O
in,O
response,O
to,O
nociceptive,O
mechanical,O
stimulation,O
of,O
normal,O
skin,O
and,O
capsaicin,I-Entity
-,O
induced,O
secondary,B-Entity
hyperalgesia,I-Entity
.,O
The,O
dose,O
of,O
gabapentin,I-Entity
was,O
"1,800",O
mg,O
per,O
os,O
",",O
in,O
a,O
single,O
administration,O
.,O
We,O
found,O
that,O
(,O
i,O
),O
gabapentin,I-Entity
reduced,O
the,O
activations,O
in,O
the,O
bilateral,O
operculoinsular,O
cortex,O
",",O
independently,O
of,O
the,O
presence,O
of,O
central,O
sensitization,O
;,O
(,O
ii,O
),O
gabapentin,I-Entity
reduced,O
the,O
activation,O
in,O
the,O
brainstem,O
",",O
only,O
during,O
central,O
sensitization,O
;,O
(,O
iii,O
),O
gabapentin,I-Entity
suppressed,O
stimulus,O
-,O
induced,O
deactivations,O
",",O
only,O
during,O
central,O
sensitization,O
;,O
this,O
effect,O
was,O
more,O
robust,O
than,O
the,O
effect,O
on,O
brain,O
activation,O
.,O
These,O
findings,O
indicate,O
that,O
gabapentin,I-Entity
has,O
a,O
measurable,O
antinociceptive,O
effect,O
and,O
a,O
stronger,O
antihyperalgesic,O
effect,O
most,O
evident,O
in,O
the,O
brain,O
areas,O
undergoing,O
deactivation,O
",",O
thus,O
supporting,O
the,O
concept,O
that,O
gabapentin,I-Entity
is,O
more,O
effective,O
in,O
modulating,O
nociceptive,O
transmission,O
when,O
central,O
sensitization,O
is,O
present,O
.,O
MDMA,I-Entity
polydrug,O
users,O
show,O
process,O
-,O
specific,O
central,O
executive,O
impairments,O
coupled,O
with,O
impaired,B-Entity
social,I-Entity
and,I-Entity
emotional,I-Entity
judgement,I-Entity
processes,I-Entity
.,O
In,O
recent,O
years,O
working,O
memory,B-Entity
deficits,I-Entity
have,O
been,O
reported,O
in,O
users,O
of,O
MDMA,I-Entity
(,O
"3,4-methylenedioxymethamphetamine",I-Entity
",",O
ecstasy,I-Entity
),O
.,O
The,O
current,O
study,O
aimed,O
to,O
assess,O
the,O
impact,O
of,O
MDMA,I-Entity
use,O
on,O
three,O
separate,O
central,O
executive,O
processes,O
(,O
set,O
shifting,O
",",O
inhibition,O
and,O
memory,O
updating,O
),O
and,O
also,O
on,O
"""",O
prefrontal,O
"""",O
mediated,O
social,O
and,O
emotional,O
judgement,O
processes,O
.,O
Fifteen,O
polydrug,O
ecstasy,I-Entity
users,O
and,O
15,O
polydrug,O
non,O
-,O
ecstasy,I-Entity
user,O
controls,O
completed,O
a,O
general,O
drug,O
use,O
questionnaire,O
",",O
the,O
Brixton,O
Spatial,O
Anticipation,O
task,O
(,O
set,O
shifting,O
),O
",",O
Backward,O
Digit,O
Span,O
procedure,O
(,O
memory,O
updating,O
),O
",",O
Inhibition,O
of,O
Return,O
(,O
inhibition,O
),O
",",O
an,O
emotional,O
intelligence,O
scale,O
",",O
the,O
Tromso,O
Social,O
Intelligence,O
Scale,O
and,O
the,O
Dysexecutive,O
Questionnaire,O
(,O
DEX,O
),O
.,O
Compared,O
with,O
MDMA,I-Entity
-,O
free,O
polydrug,O
controls,O
",",O
MDMA,I-Entity
polydrug,O
users,O
showed,O
impairments,O
in,O
set,O
shifting,O
and,O
memory,O
updating,O
",",O
and,O
also,O
in,O
social,O
and,O
emotional,O
judgement,O
processes,O
.,O
These,O
data,O
lend,O
further,O
support,O
to,O
the,O
proposal,O
that,O
cognitive,O
processes,O
mediated,O
by,O
the,O
prefrontal,O
cortex,O
may,O
be,O
impaired,O
by,O
recreational,O
ecstasy,I-Entity
use,O
.,O
Severe,O
citrate,I-Entity
toxicity,I-Entity
complicating,O
volunteer,O
apheresis,O
platelet,O
donation,O
.,O
We,O
report,O
a,O
case,O
of,O
severe,O
citrate,I-Entity
toxicity,I-Entity
during,O
volunteer,O
donor,O
apheresis,O
platelet,O
collection,O
.,O
Past,O
medical,O
history,O
was,O
remarkable,O
for,O
hypertension,I-Entity
",",O
hyperlipidemia,I-Entity
",",O
and,O
depression,I-Entity
.,O
Reported,O
medications,O
included,O
bumetanide,I-Entity
",",O
pravastatin,I-Entity
",",O
and,O
paroxetine,I-Entity
.,O
She,O
then,O
very,O
rapidly,O
developed,O
acute,O
onset,O
of,O
severe,O
facial,O
and,O
extremity,O
tetany,I-Entity
.,O
Empirical,O
treatment,O
with,O
intravenous,O
calcium,B-Entity
gluconate,I-Entity
was,O
initiated,O
",",O
and,O
muscle,B-Entity
contractions,I-Entity
slowly,O
subsided,O
over,O
approximately,O
10,O
to,O
15,O
minutes,O
.,O
The,O
events,O
are,O
consistent,O
with,O
a,O
severe,O
reaction,O
to,O
calcium,I-Entity
chelation,O
by,O
sodium,B-Entity
citrate,I-Entity
anticoagulant,O
resulting,O
in,O
symptomatic,O
systemic,O
hypocalcemia,I-Entity
.,O
Upon,O
additional,O
retrospective,O
analysis,O
",",O
it,O
was,O
noted,O
that,O
bumetanide,I-Entity
is,O
a,O
loop,B-Entity
diuretic,I-Entity
that,O
may,O
cause,O
significant,O
hypocalcemia,I-Entity
.,O
We,O
conclude,O
that,O
careful,O
screening,O
for,O
medications,O
and,O
underlying,O
conditions,O
predisposing,O
to,O
hypocalcemia,I-Entity
is,O
recommended,O
to,O
help,O
prevent,O
severe,O
reactions,O
due,O
to,O
citrate,I-Entity
toxicity,I-Entity
.,O
Laboratory,O
measurement,O
of,O
pre,O
-,O
procedure,O
serum,O
calcium,I-Entity
levels,O
in,O
selected,O
donors,O
may,O
identify,O
cases,O
requiring,O
heightened,O
vigilance,O
.,O
Proteinuria,I-Entity
after,O
conversion,O
to,O
sirolimus,I-Entity
in,O
renal,O
transplant,O
recipients,O
.,O
Sirolimus,I-Entity
(,O
SRL,I-Entity
),O
is,O
a,O
new,O
",",O
potent,O
immunosuppressive,O
agent,O
.,O
More,O
recently,O
",",O
proteinuria,I-Entity
has,O
been,O
reported,O
as,O
a,O
consequence,O
of,O
sirolimus,I-Entity
therapy,O
",",O
although,O
the,O
mechanism,O
has,O
remained,O
unclear,O
.,O
We,O
retrospectively,O
examined,O
the,O
records,O
of,O
25,O
renal,O
transplant,O
patients,O
",",O
who,O
developed,O
or,O
displayed,O
increased,O
proteinuria,I-Entity
after,O
SRL,I-Entity
conversion,O
.,O
The,O
patient,O
cohort,O
(,O
14,O
men,O
",",O
11,O
women,O
),O
was,O
treated,O
with,O
SRL,I-Entity
as,O
conversion,O
therapy,O
",",O
due,O
to,O
chronic,B-Entity
allograft,I-Entity
nephropathy,I-Entity
(,O
CAN,I-Entity
),O
(,O
n,O
=,O
15,O
),O
neoplasia,I-Entity
(,O
n,O
=,O
8),O
;,O
Kaposi,B-Entity
's,I-Entity
sarcoma,I-Entity
",",O
Four,O
skin,B-Entity
cancers,I-Entity
",",O
One,O
intestinal,B-Entity
tumors,I-Entity
",",O
One,O
renal,B-Entity
cell,I-Entity
carsinom,I-Entity
),O
or,O
BK,O
virus,O
nephropathy,I-Entity
(,O
n,O
=,O
2,O
),O
.,O
SRL,I-Entity
was,O
started,O
at,O
a,O
mean,O
of,O
78,O
+,O
/-,O
Mean,O
follow,O
-,O
up,O
on,O
SRL,I-Entity
therapy,O
was,O
20,O
+,O
/-,O
Proteinuria,I-Entity
increased,O
from,O
0.445,O
(,O
0,O
to,O
1.5,O
),O
Before,O
conversion,O
8,O
(,O
32%,O
),O
patients,O
had,O
no,O
proteinuria,I-Entity
",",O
whereas,O
afterwards,O
all,O
patients,O
had,O
proteinuria,I-Entity
.,O
In,O
28%,O
of,O
patients,O
proteinuria,I-Entity
remained,O
unchanged,O
",",O
whereas,O
it,O
increased,O
in,O
68%,O
of,O
patients,O
.,O
Twenty,O
-,O
eight,O
percent,O
of,O
patients,O
showed,O
increased,O
proteinuria,I-Entity
to,O
the,O
nephrotic,I-Entity
range,O
.,O
Biopsies,O
performed,O
in,O
five,O
patients,O
revealed,O
new,O
pathological,O
changes,O
:,O
One,O
membranoproliferative,B-Entity
glomerulopathy,I-Entity
and,O
interstitial,B-Entity
nephritis,I-Entity
.,O
Serum,O
creatinine,I-Entity
values,O
did,O
not,O
change,O
significantly,O
:,O
1.98,O
+,O
/-,O
0.8,O
mg,O
/,O
dL,O
before,O
SRL,I-Entity
therapy,O
and,O
2.53,O
+,O
/-,O
Five,O
patients,O
displayed,O
CAN,I-Entity
and,O
Kaposi,B-Entity
's,I-Entity
sarcoma,I-Entity
.,O
Mean,O
serum,O
creatinine,I-Entity
level,O
before,O
conversion,O
was,O
2.21,O
mg,O
/,O
dL,O
and,O
thereafter,O
",",O
4.93,O
mg,O
/,O
dL,O
(,O
P,O
=,O
.02,O
),O
.,O
Heavy,O
proteinuria,I-Entity
was,O
common,O
after,O
the,O
use,O
of,O
SRL,I-Entity
as,O
rescue,O
therapy,O
for,O
renal,O
transplantation,O
.,O
Therefore,O
",",O
conversion,O
should,O
be,O
considered,O
for,O
patients,O
who,O
have,O
not,O
developed,O
advanced,O
CAN,I-Entity
and,O
proteinuria,I-Entity
.,O
glomerular,O
pathology,O
under,O
SRL,I-Entity
treatment,O
requires,O
further,O
investigation,O
by,O
renal,O
biopsy,O
.,O
In,O
vitro,O
characterization,O
of,O
parasympathetic,O
and,O
sympathetic,O
responses,O
in,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
in,O
the,O
rat,O
.,O
In,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
in,O
the,O
rat,O
",",O
detrusor,O
function,O
is,O
impaired,O
and,O
the,O
expression,O
and,O
effects,O
of,O
muscarinic,O
receptors,O
altered,O
.,O
Whether,O
or,O
not,O
the,O
neuronal,O
transmission,O
may,O
be,O
affected,O
by,O
cystitis,I-Entity
was,O
presently,O
investigated,O
.,O
Responses,O
of,O
urinary,O
strip,O
preparations,O
from,O
control,O
and,O
cyclophosphamide,I-Entity
-,O
pretreated,O
rats,O
to,O
electrical,O
field,O
stimulation,O
and,O
to,O
agonists,O
were,O
assessed,O
in,O
the,O
absence,O
and,O
presence,O
of,O
muscarinic,O
",",O
adrenergic,O
and,O
purinergic,O
receptor,O
antagonists,O
.,O
Generally,O
",",O
atropine,I-Entity
reduced,O
contractions,O
",",O
but,O
in,O
contrast,O
to,O
controls,O
",",O
it,O
also,O
reduced,O
responses,O
to,O
low,O
electrical,O
field,O
stimulation,O
intensity,O
(,O
1,O
-,O
5,O
Hz,O
),O
in,O
inflamed,O
preparations,O
.,O
In,O
both,O
types,O
",",O
purinoceptor,O
desensitization,O
with,O
alpha,B-Entity
",",I-Entity
beta,I-Entity
-,I-Entity
methylene,I-Entity
adenosine-5'-triphosphate,I-Entity
(,O
alpha,B-Entity
",",I-Entity
beta,I-Entity
-,I-Entity
meATP,I-Entity
),O
caused,O
further,O
reductions,O
at,O
low,O
frequencies,O
(,O
<,O
10,O
Hz,O
),O
.,O
The,O
muscarinic,O
receptor,O
antagonists,O
atropine,I-Entity
",",O
4-diphenylacetoxy,B-Entity
-,I-Entity
N,I-Entity
-,I-Entity
methylpiperidine,I-Entity
(,O
4-DAMP,I-Entity
),O
(,O
',O
M(1)/M(3)/M(5)-selective,O
',O
),O
",",O
methoctramine,I-Entity
(,O
',O
M(2)-selective,O
',O
),O
and,O
pirenzepine,I-Entity
(,O
',O
M(1)-selective,O
',O
),O
antagonized,O
the,O
tonic,O
component,O
of,O
the,O
electrical,O
field,O
stimulation,O
-,O
evoked,O
contractile,O
response,O
more,O
potently,O
than,O
the,O
phasic,O
component,O
.,O
4-DAMP,I-Entity
inhibited,O
the,O
tonic,O
contractions,O
in,O
controls,O
more,O
potently,O
than,O
methoctramine,I-Entity
and,O
pirenzepine,I-Entity
.,O
In,O
inflamed,O
preparations,O
",",O
the,O
muscarinic,O
receptor,O
antagonism,O
on,O
the,O
phasic,O
component,O
of,O
the,O
electrical,O
field,O
stimulation,O
-,O
evoked,O
contraction,O
was,O
decreased,O
and,O
the,O
pirenzepine,I-Entity
and,O
4-DAMP,I-Entity
antagonism,O
on,O
the,O
tonic,O
component,O
was,O
much,O
less,O
efficient,O
than,O
in,O
controls,O
.,O
In,O
contrast,O
to,O
controls,O
",",O
methoctramine,I-Entity
increased,O
--,O
instead,O
of,O
decreased,O
--,O
the,O
tonic,O
responses,O
at,O
high,O
frequencies,O
.,O
While,O
contractions,O
to,O
carbachol,I-Entity
and,O
ATP,I-Entity
were,O
the,O
same,O
in,O
inflamed,O
and,O
in,O
control,O
strips,O
when,O
related,O
to,O
a,O
reference,O
potassium,I-Entity
response,O
",",O
isoprenaline,I-Entity
-,O
induced,O
relaxations,O
were,O
smaller,O
in,O
inflamed,O
strips,O
.,O
Thus,O
",",O
in,O
cystitis,I-Entity
substantial,O
changes,O
of,O
the,O
efferent,O
functional,O
responses,O
occur,O
.,O
Associations,O
between,O
use,O
of,O
benzodiazepines,I-Entity
or,O
related,O
drugs,O
and,O
health,O
",",O
physical,O
abilities,O
and,O
cognitive,O
function,O
:,O
a,O
non,O
-,O
randomised,O
clinical,O
study,O
in,O
the,O
elderly,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
associations,O
between,O
the,O
use,O
of,O
benzodiazepines,I-Entity
or,O
related,O
drugs,O
(,O
BZDs,I-Entity
/,O
RDs,O
),O
and,O
health,O
",",O
functional,O
abilities,O
and,O
cognitive,O
function,O
in,O
the,O
elderly,O
.,O
Of,O
these,O
",",O
nearly,O
half,O
(,O
n,O
=,O
78,O
),O
had,O
used,O
BZDs,I-Entity
/,O
RDs,O
before,O
admission,O
",",O
and,O
the,O
remainder,O
(,O
n,O
=,O
86,O
),O
were,O
non,O
-,O
users,O
.,O
Data,O
on,O
use,O
of,O
BZDs,I-Entity
/,O
RDs,O
before,O
admission,O
",",O
current,O
medications,O
and,O
discharge,O
diagnoses,O
were,O
collected,O
from,O
medical,O
records,O
.,O
The,O
residual,O
serum,O
concentrations,O
of,O
oxazepam,I-Entity
",",O
temazepam,I-Entity
and,O
zopiclone,I-Entity
were,O
analysed,O
.,O
Two,O
or,O
three,O
BZDs,I-Entity
/,O
RDs,O
were,O
concomitantly,O
taken,O
by,O
26%,O
of,O
users,O
(,O
n,O
=,O
20,O
),O
.,O
Long,O
-,O
term,O
use,O
of,O
these,O
drugs,O
was,O
associated,O
with,O
female,O
sex,O
and,O
use,O
of,O
a,O
higher,O
number,O
of,O
drugs,O
with,O
effects,O
on,O
the,O
CNS,O
",",O
which,O
tended,O
to,O
be,O
related,O
to,O
diagnosed,O
dementia,I-Entity
.,O
After,O
adjustment,O
for,O
these,O
variables,O
as,O
confounders,O
",",O
use,O
of,O
BZDs,I-Entity
/,O
RDs,O
was,O
not,O
associated,O
with,O
cognitive,O
function,O
as,O
measured,O
by,O
the,O
MMSE,O
.,O
However,O
",",O
use,O
of,O
BZDs,I-Entity
/,O
RDs,O
was,O
associated,O
with,O
dizziness,I-Entity
",",O
inability,B-Entity
to,I-Entity
sleep,I-Entity
after,O
awaking,O
at,O
night,O
and,O
tiredness,I-Entity
in,O
the,O
mornings,O
during,O
the,O
week,O
prior,O
to,O
admission,O
and,O
with,O
stronger,O
depressive,B-Entity
symptoms,I-Entity
measured,O
at,O
the,O
beginning,O
of,O
the,O
hospital,O
stay,O
.,O
Use,O
of,O
BZDs,I-Entity
/,O
RDs,O
tended,O
to,O
be,O
associated,O
with,O
a,O
reduced,O
ability,O
to,O
walk,O
and,O
shorter,O
night,O
-,O
time,O
sleep,O
during,O
the,O
week,O
prior,O
to,O
admission,O
.,O
A,O
higher,O
residual,O
serum,O
concentration,O
of,O
temazepam,I-Entity
correlated,O
with,O
a,O
lower,O
MMSE,O
sum,O
score,O
after,O
adjustment,O
for,O
confounding,O
variables,O
.,O
Acute,O
vocal,B-Entity
fold,I-Entity
palsy,I-Entity
after,O
acute,O
disulfiram,I-Entity
intoxication,O
.,O
Acute,O
peripheral,B-Entity
neuropathy,I-Entity
caused,O
by,O
a,O
disulfiram,I-Entity
overdose,I-Entity
is,O
very,O
rare,O
and,O
there,O
is,O
no,O
report,O
of,O
it,O
leading,O
to,O
vocal,B-Entity
fold,I-Entity
palsy,I-Entity
.,O
A,O
49-year,O
-,O
old,O
woman,O
was,O
transferred,O
to,O
our,O
department,O
because,O
of,O
quadriparesis,I-Entity
",",O
lancinating,O
pain,I-Entity
",",O
sensory,B-Entity
loss,I-Entity
",",O
and,O
paresthesia,I-Entity
of,O
the,O
distal,O
limbs,O
.,O
One,O
month,O
previously,O
",",O
she,O
had,O
taken,O
a,O
single,O
high,O
dose,O
of,O
disulfiram,I-Entity
(,O
130,O
tablets,O
of,O
ALCOHOL,I-Entity
STOP,O
TAB,O
",",O
Shin,O
-,O
Poong,O
Pharm,O
.,O
For,O
the,O
first,O
few,O
days,O
after,O
ingestion,O
",",O
she,O
was,O
in,O
a,O
confused,O
state,O
and,O
had,O
mild,O
to,O
moderate,O
ataxia,I-Entity
and,O
giddiness,I-Entity
.,O
She,O
noticed,O
hoarseness,I-Entity
and,O
distally,O
accentuated,O
motor,O
and,O
sensory,O
dysfunction,O
after,O
she,O
had,O
recovered,O
from,O
this,O
state,O
.,O
A,O
nerve,O
conduction,O
study,O
was,O
consistent,O
with,O
severe,O
sensorimotor,O
axonal,O
polyneuropathy,I-Entity
.,O
This,O
was,O
a,O
case,O
of,O
acute,O
palsy,I-Entity
of,O
the,O
recurrent,O
laryngeal,O
nerve,O
and,O
superimposed,O
severe,O
acute,O
sensorimotor,O
axonal,O
polyneuropathy,I-Entity
caused,O
by,O
high,O
-,O
dose,O
disulfiram,I-Entity
intoxication,O
.,O
Higher,O
optical,O
density,O
of,O
an,O
antigen,O
assay,O
predicts,O
thrombosis,I-Entity
in,O
patients,O
with,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
.,O
OBJECTIVES,O
:,O
To,O
correlate,O
optical,O
density,O
and,O
percent,O
inhibition,O
of,O
a,O
two,O
-,O
step,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
(,O
HIT,I-Entity
),O
antigen,O
assay,O
with,O
thrombosis,I-Entity
;,O
the,O
assay,O
utilizes,O
reaction,O
inhibition,O
characteristics,O
of,O
a,O
high,O
heparin,I-Entity
concentration,O
.,O
Patients,O
with,O
more,O
than,O
50%,O
decrease,O
in,O
platelet,O
count,O
or,O
thrombocytopenia,I-Entity
(,O
<,O
150,O
x,O
10(9)/L,O
),O
after,O
exposure,O
to,O
heparin,I-Entity
",",O
who,O
had,O
a,O
positive,O
two,O
-,O
step,O
antigen,O
assay,O
[,O
optical,O
density,O
(,O
OD,O
),O
0.4,O
and,O
>,O
50,O
inhibition,O
with,O
high,O
concentration,O
of,O
heparin,I-Entity
],O
were,O
included,O
in,O
the,O
study,O
.,O
Forty,O
of,O
94,O
HIT,I-Entity
patients,O
had,O
thrombosis,I-Entity
at,O
diagnosis,O
;,O
54/94,O
had,O
isolated,O
-,O
HIT,I-Entity
without,O
thrombosis,I-Entity
.,O
Eight,O
of,O
the,O
isolated,O
-,O
HIT,I-Entity
patients,O
developed,O
thrombosis,I-Entity
within,O
the,O
next,O
30,O
d,O
;,O
thus,O
",",O
a,O
total,O
of,O
48,O
patients,O
had,O
thrombosis,I-Entity
at,O
day,O
30,O
.,O
At,O
diagnosis,O
there,O
was,O
no,O
significant,O
difference,O
in,O
OD,O
between,O
HIT,I-Entity
patients,O
with,O
thrombosis,I-Entity
and,O
those,O
with,O
isolated,O
-,O
HIT,I-Entity
.,O
However,O
",",O
OD,O
was,O
significantly,O
higher,O
in,O
all,O
patients,O
with,O
thrombosis,I-Entity
(,O
n,O
=,O
48,O
",",O
1.34,O
+,O
/-,O
0.89,O
),O
",",O
including,O
isolated,O
-,O
HIT,I-Entity
patients,O
who,O
later,O
developed,O
thrombosis,I-Entity
within,O
30,O
d,O
(,O
n,O
=,O
8,O
",",O
1.84,O
+,O
/-,O
0.64,O
),O
as,O
compared,O
to,O
isolated,O
-,O
HIT,I-Entity
patients,O
who,O
did,O
not,O
develop,O
thrombosis,I-Entity
(,O
0.96,O
+,O
/-,O
The,O
Receiver,O
Operative,O
Characteristic,O
Curve,O
showed,O
that,O
OD,O
>,O
1.27,O
in,O
the,O
isolated,O
-,O
HIT,I-Entity
group,O
had,O
a,O
significantly,O
higher,O
chance,O
of,O
developing,O
thrombosis,I-Entity
by,O
day,O
30,O
.,O
Multivariate,O
analysis,O
showed,O
a,O
2.8-fold,O
increased,O
risk,O
of,O
thrombosis,I-Entity
in,O
females,O
.,O
Similarly,O
",",O
thrombotic,I-Entity
risk,O
increased,O
with,O
age,O
and,O
OD,O
values,O
.,O
CONCLUSION,O
:,O
Higher,O
OD,O
is,O
associated,O
with,O
significant,O
risk,O
of,O
subsequent,O
thrombosis,I-Entity
in,O
patients,O
with,O
isolated,O
-,O
HIT,I-Entity
;,O
percent,O
inhibition,O
",",O
however,O
",",O
was,O
not,O
predictive,O
.,O
Central,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
associated,O
with,O
clomiphene,I-Entity
-,O
induced,O
ovulation,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
central,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
associated,O
with,O
clomiphene,B-Entity
citrate,I-Entity
(,O
CC,I-Entity
),O
.,O
PATIENT(S,O
),O
:,O
A,O
36-year,O
-,O
old,O
woman,O
referred,O
from,O
the,O
infertility,I-Entity
clinic,O
for,O
blurred,B-Entity
vision,I-Entity
.,O
INTERVENTION(S,O
),O
:,O
Ophthalmic,O
examination,O
after,O
CC,I-Entity
therapy,O
.,O
MAIN,O
OUTCOME,O
MEASURE(S,O
),O
:,O
Central,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
after,O
ovulation,O
induction,O
with,O
CC,I-Entity
.,O
RESULT(S,O
),O
:,O
A,O
36-year,O
-,O
old,O
Chinese,O
woman,O
developed,O
central,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
after,O
eight,O
courses,O
of,O
CC,I-Entity
.,O
A,O
search,O
of,O
the,O
literature,O
on,O
the,O
thromboembolic,I-Entity
complications,O
of,O
CC,I-Entity
does,O
not,O
include,O
this,O
severe,O
ophthalmic,O
complication,O
",",O
although,O
mild,O
visual,B-Entity
disturbance,I-Entity
after,O
CC,I-Entity
intake,O
is,O
not,O
uncommon,O
.,O
CONCLUSION(S,O
),O
:,O
This,O
is,O
the,O
first,O
reported,O
case,O
of,O
central,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
after,O
treatment,O
with,O
CC,I-Entity
.,O
Extra,O
caution,O
is,O
warranted,O
in,O
treating,O
infertility,I-Entity
patients,O
with,O
CC,I-Entity
",",O
and,O
patients,O
should,O
be,O
well,O
informed,O
of,O
this,O
side,O
effect,O
before,O
commencement,O
of,O
therapy,O
.,O
Nicotine,I-Entity
-,O
induced,O
nystagmus,I-Entity
correlates,O
with,O
midpontine,O
activation,O
.,O
The,O
pathomechanism,O
of,O
nicotine,I-Entity
-,O
induced,O
nystagmus,I-Entity
(,O
NIN,I-Entity
),O
is,O
unknown,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
delineate,O
brain,O
structures,O
that,O
are,O
involved,O
in,O
NIN,I-Entity
generation,O
.,O
Eight,O
healthy,O
volunteers,O
inhaled,O
nicotine,I-Entity
in,O
darkness,O
during,O
a,O
functional,O
magnetic,O
resonance,O
imaging,O
(,O
fMRI,O
),O
experiment,O
;,O
eye,O
movements,O
were,O
registered,O
using,O
video,O
-,O
oculography,O
.,O
NIN,I-Entity
correlated,O
with,O
blood,O
oxygen,I-Entity
level,O
-,O
dependent,O
(,O
BOLD,O
),O
activity,O
levels,O
in,O
a,O
midpontine,O
site,O
in,O
the,O
posterior,O
basis,O
pontis,O
.,O
NIN,I-Entity
-,O
induced,O
midpontine,O
activation,O
may,O
correspond,O
to,O
activation,O
of,O
the,O
dorsomedial,O
pontine,O
nuclei,O
and,O
the,O
nucleus,O
reticularis,O
tegmenti,O
pontis,O
",",O
structures,O
known,O
to,O
participate,O
in,O
the,O
generation,O
of,O
multidirectional,O
saccades,O
and,O
smooth,O
pursuit,O
eye,O
movements,O
.,O
Protective,O
effect,O
of,O
verapamil,I-Entity
on,O
gastric,B-Entity
hemorrhagic,I-Entity
ulcers,I-Entity
in,O
severe,O
atherosclerotic,I-Entity
rats,O
.,O
Studies,O
concerning,O
with,O
pathogenesis,O
of,O
gastric,B-Entity
hemorrhage,I-Entity
and,O
mucosal,O
ulceration,O
produced,O
in,O
atherosclerotic,I-Entity
rats,O
are,O
lacking,O
.,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
examine,O
the,O
role,O
of,O
gastric,O
acid,O
back,O
-,O
diffusion,O
",",O
mast,O
cell,O
histamine,I-Entity
release,O
",",O
lipid,O
peroxide,O
(,O
LPO,O
),O
generation,O
and,O
mucosal,O
microvascular,O
permeability,O
in,O
modulating,O
gastric,B-Entity
hemorrhage,I-Entity
and,O
ulcer,I-Entity
in,O
rats,O
with,O
atherosclerosis,I-Entity
induced,O
by,O
coadministration,O
of,O
vitamin,B-Entity
D2,I-Entity
and,O
cholesterol,I-Entity
.,O
Additionally,O
",",O
the,O
protective,O
effect,O
of,O
verapamil,I-Entity
on,O
this,O
ulcer,I-Entity
model,O
was,O
evaluated,O
.,O
kg,O
of,O
corn,O
oil,O
containing,O
vitamin,B-Entity
D2,I-Entity
and,O
cholesterol,I-Entity
to,O
induce,O
atherosclerosis,I-Entity
.,O
Gastric,O
acid,O
back,O
-,O
diffusion,O
",",O
mucosal,O
LPO,O
generation,O
",",O
histamine,I-Entity
concentration,O
",",O
microvascular,O
permeability,O
",",O
luminal,I-Entity
hemoglobin,O
content,O
and,O
ulcer,I-Entity
areas,O
were,O
determined,O
.,O
Elevated,O
atherosclerotic,I-Entity
parameters,O
",",O
such,O
as,O
serum,O
calcium,I-Entity
",",O
total,O
cholesterol,I-Entity
and,O
low,O
-,O
density,O
lipoprotein,O
concentration,O
were,O
obtained,O
in,O
atherosclerotic,I-Entity
rats,O
.,O
Severe,O
gastric,O
ulcers,I-Entity
accompanied,O
with,O
increased,O
ulcerogenic,O
factors,O
",",O
including,O
gastric,O
acid,O
back,O
-,O
diffusion,O
",",O
histamine,I-Entity
release,O
",",O
LPO,O
generation,O
and,O
luminal,I-Entity
hemoglobin,O
content,O
were,O
also,O
observed,O
in,O
these,O
rats,O
.,O
Moreover,O
",",O
a,O
positive,O
correlation,O
of,O
histamine,I-Entity
to,O
gastric,B-Entity
hemorrhage,I-Entity
and,O
to,O
ulcer,I-Entity
was,O
found,O
in,O
those,O
atherosclerotic,I-Entity
rats,O
.,O
This,O
hemorrhagic,I-Entity
ulcer,I-Entity
and,O
various,O
ulcerogenic,O
parameters,O
were,O
dose,O
-,O
dependently,O
ameliorated,O
by,O
daily,O
intragastric,O
verapamil,I-Entity
.,O
Atherosclerosis,I-Entity
could,O
produce,O
gastric,B-Entity
hemorrhagic,I-Entity
ulcer,I-Entity
via,O
aggravation,O
of,O
gastric,O
acid,O
back,O
-,O
diffusion,O
",",O
LPO,O
generation,O
",",O
histamine,I-Entity
release,O
and,O
microvascular,O
permeability,O
that,O
could,O
be,O
ameliorated,O
by,O
verapamil,I-Entity
in,O
rats,O
.,O
Adriamycin,I-Entity
-,O
induced,O
autophagic,O
cardiomyocyte,O
death,I-Entity
plays,O
a,O
pathogenic,O
role,O
in,O
a,O
rat,O
model,O
of,O
heart,B-Entity
failure,I-Entity
.,O
The,O
mechanisms,O
underlying,O
heart,B-Entity
failure,I-Entity
induced,O
by,O
adriamycin,I-Entity
are,O
very,O
complicated,O
and,O
still,O
unclear,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
whether,O
autophagy,O
was,O
involved,O
in,O
the,O
progression,O
of,O
heart,B-Entity
failure,I-Entity
induced,O
by,O
adriamycin,I-Entity
",",O
so,O
that,O
we,O
can,O
develop,O
a,O
novel,O
treatment,O
strategy,O
for,O
heart,B-Entity
failure,I-Entity
.,O
METHODS,O
:,O
3-methyladenine,I-Entity
(,O
3MA,I-Entity
),O
",",O
a,O
specific,O
inhibitor,O
on,O
autophagy,O
was,O
used,O
in,O
a,O
heart,B-Entity
failure,I-Entity
model,O
of,O
rats,O
induced,O
by,O
adriamycin,I-Entity
.,O
Neonatal,O
cardiomyocytes,O
were,O
isolated,O
from,O
Sprague,O
-,O
Dawley,O
rat,O
hearts,O
and,O
randomly,O
divided,O
into,O
controls,O
",",O
an,O
adriamycin,I-Entity
-,O
treated,O
group,O
",",O
and,O
a,O
3MA,I-Entity
plus,O
adriamycin,I-Entity
-,O
treated,O
group,O
.,O
We,O
then,O
examined,O
the,O
morphology,O
",",O
expression,O
of,O
beclin,O
1,O
gene,O
",",O
mitochondrial,O
permeability,O
transition,O
(,O
MPT,O
),O
",",O
and,O
Na+-K+,I-Entity
ATPase,O
activity,O
in,O
vivo,O
.,O
RESULTS,O
:,O
3MA,I-Entity
significantly,O
improved,O
cardiac,O
function,O
and,O
reduced,O
mitochondrial,O
injury,O
.,O
Furthermore,O
",",O
adriamycin,I-Entity
induced,O
the,O
formation,O
of,O
autophagic,O
vacuoles,O
",",O
and,O
3MA,I-Entity
strongly,O
downregulated,O
the,O
expression,O
of,O
beclin,O
1,O
in,O
adriamycin,I-Entity
-,O
induced,O
failing,O
heart,O
and,O
inhibited,O
the,O
formation,O
of,O
autophagic,O
vacuoles,O
.,O
CONCLUSION,O
:,O
Autophagic,O
cardiomyocyte,O
death,I-Entity
plays,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
heart,B-Entity
failure,I-Entity
in,O
rats,O
induced,O
by,O
adriamycin,I-Entity
.,O
Mitochondrial,O
injury,O
may,O
be,O
involved,O
in,O
the,O
progression,O
of,O
heart,B-Entity
failure,I-Entity
caused,O
by,O
adriamycin,I-Entity
via,O
the,O
autophagy,O
pathway,O
.,O
Confusion,I-Entity
",",O
a,O
rather,O
serious,O
adverse,O
drug,O
reaction,O
with,O
valproic,B-Entity
acid,I-Entity
:,O
a,O
review,O
of,O
the,O
French,O
Pharmacovigilance,O
database,O
.,O
Confusion,I-Entity
is,O
an,O
adverse,O
drug,O
reaction,O
frequently,O
observed,O
with,O
valproic,B-Entity
acid,I-Entity
.,O
Using,O
the,O
French,O
Pharmacovigilance,O
database,O
",",O
we,O
selected,O
the,O
cases,O
of,O
confusion,I-Entity
reported,O
since,O
1985,O
with,O
valproic,B-Entity
acid,I-Entity
.,O
RESULTS,O
:,O
272,O
cases,O
of,O
confusion,I-Entity
were,O
reported,O
with,O
valproic,B-Entity
acid,I-Entity
:,O
153,O
women,O
and,O
119,O
men,O
.,O
Confusion,I-Entity
mostly,O
occurred,O
during,O
the,O
two,O
first,O
weeks,O
following,O
valproic,B-Entity
acid,I-Entity
exposure,O
(,O
39.7%,O
),O
.,O
This,O
work,O
shows,O
that,O
confusion,I-Entity
with,O
valproic,B-Entity
acid,I-Entity
is,O
a,O
serious,O
",",O
rather,O
frequent,O
but,O
reversible,O
adverse,O
drug,O
reaction,O
.,O
Learning,B-Entity
and,I-Entity
memory,I-Entity
deficits,I-Entity
in,O
ecstasy,I-Entity
users,O
and,O
their,O
neural,O
correlates,O
during,O
a,O
face,O
-,O
learning,O
task,O
.,O
It,O
has,O
been,O
consistently,O
shown,O
that,O
ecstasy,I-Entity
users,O
display,O
impairments,B-Entity
in,I-Entity
learning,I-Entity
and,I-Entity
memory,I-Entity
performance,O
.,O
In,O
addition,O
",",O
working,O
memory,O
processing,O
in,O
ecstasy,I-Entity
users,O
has,O
been,O
shown,O
to,O
be,O
associated,O
with,O
neural,O
alterations,O
in,O
hippocampal,O
and/or,O
cortical,O
regions,O
as,O
measured,O
by,O
functional,O
magnetic,O
resonance,O
imaging,O
(,O
fMRI,O
),O
.,O
Using,O
functional,O
imaging,O
and,O
a,O
face,O
-,O
learning,O
task,O
",",O
we,O
investigated,O
neural,O
correlates,O
of,O
encoding,O
and,O
recalling,O
face,O
-,O
name,O
associations,O
in,O
20,O
recreational,O
drug,O
users,O
whose,O
predominant,O
drug,O
use,O
was,O
ecstasy,I-Entity
and,O
20,O
controls,O
.,O
To,O
address,O
the,O
potential,O
confounding,O
effects,O
of,O
the,O
cannabis,I-Entity
use,O
of,O
the,O
ecstasy,I-Entity
using,O
group,O
",",O
a,O
second,O
analysis,O
included,O
14,O
previously,O
tested,O
cannabis,I-Entity
users,O
(,O
Nestor,O
",",O
L.,O
",",O
Roberts,O
",",O
G.,O
",",O
Garavan,O
",",O
H.,O
",",O
Hester,O
",",O
R.,O
",",O
2008,O
.,O
Deficits,B-Entity
in,I-Entity
learning,I-Entity
and,I-Entity
memory,I-Entity
:,O
parahippocampal,O
hyperactivity,I-Entity
and,O
frontocortical,O
hypoactivity,O
in,O
cannabis,I-Entity
users,O
.,O
Ecstasy,I-Entity
users,O
performed,O
significantly,O
worse,O
in,O
learning,O
and,O
memory,O
compared,O
to,O
controls,O
and,O
cannabis,I-Entity
users,O
.,O
A,O
conjunction,O
analysis,O
of,O
the,O
encode,O
and,O
recall,O
phases,O
of,O
the,O
task,O
revealed,O
ecstasy,I-Entity
-,O
specific,O
hyperactivity,I-Entity
in,O
bilateral,O
frontal,O
regions,O
",",O
left,O
temporal,O
",",O
right,O
parietal,O
",",O
bilateral,O
temporal,O
",",O
and,O
bilateral,O
occipital,O
brain,O
regions,O
.,O
Ecstasy,I-Entity
-,O
specific,O
hypoactivity,O
was,O
evident,O
in,O
the,O
right,O
dorsal,O
anterior,O
cingulated,O
cortex,O
(,O
ACC,O
),O
and,O
left,O
posterior,O
cingulated,O
cortex,O
.,O
In,O
both,O
ecstasy,I-Entity
and,O
cannabis,I-Entity
groups,O
brain,O
activation,O
was,O
decreased,O
in,O
the,O
right,O
medial,O
frontal,O
gyrus,O
",",O
left,O
parahippocampal,O
gyrus,O
",",O
left,O
dorsal,O
cingulate,O
gyrus,O
",",O
and,O
left,O
caudate,O
.,O
These,O
results,O
elucidated,O
ecstasy,I-Entity
-,O
related,O
deficits,O
",",O
only,O
some,O
of,O
which,O
might,O
be,O
attributed,O
to,O
cannabis,I-Entity
use,O
.,O
These,O
ecstasy,I-Entity
-,O
specific,O
effects,O
may,O
be,O
related,O
to,O
the,O
vulnerability,O
of,O
isocortical,O
and,O
allocortical,O
regions,O
to,O
the,O
neurotoxic,I-Entity
effects,O
of,O
ecstasy,I-Entity
.,O
Prolonged,O
elevation,O
of,O
plasma,O
argatroban,I-Entity
in,O
a,O
cardiac,O
transplant,O
patient,O
with,O
a,O
suspected,O
history,O
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
with,O
thrombosis,I-Entity
.,O
BACKGROUND,O
:,O
Direct,O
thrombin,O
inhibitors,O
(,O
DTIs,O
),O
provide,O
an,O
alternative,O
method,O
of,O
anticoagulation,O
for,O
patients,O
with,O
a,O
history,O
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
(,O
HIT,I-Entity
),O
or,O
HIT,I-Entity
with,O
thrombosis,I-Entity
(,O
HITT,I-Entity
),O
undergoing,O
cardiopulmonary,O
bypass,O
(,O
CPB,O
),O
.,O
In,O
the,O
following,O
report,O
",",O
a,O
65-year,O
-,O
old,O
critically,B-Entity
ill,I-Entity
patient,O
with,O
a,O
suspected,O
history,O
of,O
HITT,I-Entity
was,O
administered,O
argatroban,I-Entity
for,O
anticoagulation,O
on,O
bypass,O
during,O
heart,O
transplantation,O
.,O
The,O
patient,O
required,O
massive,O
transfusion,O
support,O
(,O
55,O
units,O
of,O
red,O
blood,O
cells,O
",",O
42,O
units,O
of,O
fresh,O
-,O
frozen,O
plasma,O
",",O
40,O
units,O
of,O
cryoprecipitate,O
",",O
40,O
units,O
of,O
platelets,O
",",O
and,O
three,O
doses,O
of,O
recombinant,O
Factor,O
VIIa,O
),O
for,O
severe,O
intraoperative,B-Entity
and,I-Entity
postoperative,I-Entity
bleeding,I-Entity
.,O
STUDY,O
DESIGN,O
AND,O
METHODS,O
:,O
Plasma,O
samples,O
from,O
before,O
and,O
after,O
CPB,O
were,O
analyzed,O
postoperatively,O
for,O
argatroban,I-Entity
concentration,O
using,O
a,O
modified,O
ecarin,O
clotting,O
time,O
(,O
ECT,O
),O
assay,O
.,O
Unexpectedly,O
high,O
concentrations,O
of,O
argatroban,I-Entity
were,O
measured,O
in,O
these,O
samples,O
(,O
range,O
",",O
0,O
-,O
32,O
microg,O
/,O
mL,O
),O
",",O
and,O
a,O
prolonged,O
plasma,O
argatroban,I-Entity
half,O
life,O
(,O
t(1/2,O
),O
),O
of,O
514,O
minutes,O
was,O
observed,O
(,O
published,O
elimination,O
t(1/2,O
),O
is,O
39,O
-,O
51,O
minutes,O
[,O
<,O
or,O
=,O
181,O
minutes,O
with,O
hepatic,B-Entity
impairment,I-Entity
],O
),O
.,O
Correlation,O
of,O
plasma,O
argatroban,I-Entity
concentration,O
versus,O
the,O
patient,O
's,O
coagulation,O
variables,O
and,O
clinical,O
course,O
suggest,O
that,O
prolonged,O
elevated,O
levels,O
of,O
plasma,O
argatroban,I-Entity
may,O
have,O
contributed,O
to,O
the,O
patient,O
's,O
extended,O
coagulopathy,I-Entity
.,O
This,O
is,O
the,O
first,O
report,O
to,O
measure,O
plasma,O
argatroban,I-Entity
concentration,O
in,O
the,O
context,O
of,O
CPB,O
and,O
extended,O
coagulopathy,I-Entity
.,O
Antituberculosis,I-Entity
therapy,O
-,O
induced,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
:,O
magnitude,O
",",O
profile,O
",",O
prognosis,O
",",O
and,O
predictors,O
of,O
outcome,O
.,O
Antituberculosis,I-Entity
therapy,O
(,O
ATT)-associated,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
(,O
ATT,O
-,O
ALF,I-Entity
),O
is,O
the,O
commonest,O
drug,O
-,O
induced,O
ALF,I-Entity
in,O
South,O
Asia,O
.,O
Prospective,O
studies,O
on,O
ATT,O
-,O
ALF,I-Entity
are,O
lacking,O
.,O
The,O
current,O
study,O
prospectively,O
evaluated,O
the,O
magnitude,O
",",O
clinical,O
course,O
",",O
outcome,O
",",O
and,O
prognostic,O
factors,O
in,O
ATT,O
-,O
ALF,I-Entity
.,O
From,O
January,O
1986,O
to,O
January,O
2009,O
",",O
1223,O
consecutive,O
ALF,I-Entity
patients,O
were,O
evaluated,O
:,O
ATT,O
alone,O
was,O
the,O
cause,O
in,O
70,O
(,O
5.7%,O
),O
patients,O
.,O
Another,O
15,O
(,O
1.2%,O
),O
had,O
ATT,O
and,O
simultaneous,O
hepatitis,B-Entity
virus,I-Entity
infection,I-Entity
.,O
In,O
44,O
(,O
62.8%,O
),O
patients,O
",",O
ATT,O
was,O
prescribed,O
empirically,O
without,O
definitive,O
evidence,O
of,O
tuberculosis,I-Entity
.,O
ATT,O
-,O
ALF,I-Entity
patients,O
were,O
younger,O
(,O
32.87,O
[,O
+,O
/-15.8,O
],O
years,O
),O
",",O
and,O
49,O
(,O
70%,O
),O
of,O
them,O
were,O
women,O
.,O
Most,O
had,O
hyperacute,O
presentation,O
;,O
the,O
median,O
icterus,I-Entity
encephalopathy,I-Entity
interval,O
was,O
4.5,O
(,O
0,O
-,O
30,O
),O
days,O
.,O
The,O
median,O
duration,O
of,O
ATT,O
before,O
ALF,I-Entity
was,O
30,O
(,O
7,O
-,O
350,O
),O
days,O
.,O
At,O
presentation,O
",",O
advanced,O
encephalopathy,I-Entity
and,O
cerebral,B-Entity
edema,I-Entity
were,O
present,O
in,O
51,O
(,O
76%,O
),O
and,O
29,O
(,O
41.4%,O
),O
patients,O
",",O
respectively,O
.,O
Gastrointestinal,B-Entity
bleed,I-Entity
",",O
seizures,I-Entity
",",O
infection,I-Entity
",",O
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
were,O
documented,O
in,O
seven,O
(,O
10%,O
),O
",",O
five,O
(,O
7.1%,O
),O
",",O
26,O
(,O
37.1%,O
),O
",",O
and,O
seven,O
(,O
10%,O
),O
patients,O
",",O
respectively,O
.,O
Compared,O
with,O
hepatitis,B-Entity
E,I-Entity
virus,O
(,O
HEV,O
),O
and,O
non,O
-,O
A,O
non,O
-,O
E,O
-,O
induced,O
ALF,I-Entity
",",O
ATT,O
-,O
ALF,I-Entity
patients,O
had,O
nearly,O
similar,O
presentations,O
except,O
for,O
older,O
age,O
and,O
less,O
elevation,O
of,O
liver,O
enzymes,O
.,O
The,O
mortality,O
rate,O
among,O
patients,O
with,O
ATT,O
-,O
ALF,I-Entity
was,O
high,O
(,O
67.1%,O
",",O
n,O
=,O
47,O
),O
",",O
and,O
only,O
23,O
(,O
32.9%,O
),O
patients,O
recovered,O
with,O
medical,O
treatment,O
.,O
In,O
multivariate,O
analysis,O
",",O
three,O
factors,O
independently,O
predicted,O
mortality,O
:,O
serum,O
bilirubin,I-Entity
(,O
>,O
or=10.8,O
mg,O
/,O
dL,O
),O
",",O
prothrombin,O
time,O
(,O
PT,O
),O
prolongation,O
(,O
>,O
or=26,O
seconds,O
),O
",",O
and,O
grade,O
III,O
/,O
IV,O
encephalopathy,I-Entity
at,O
presentation,O
.,O
CONCLUSION,O
:,O
ATT,O
-,O
ALF,I-Entity
constituted,O
5.7%,O
of,O
ALF,I-Entity
at,O
our,O
center,O
and,O
had,O
a,O
high,O
mortality,O
rate,O
.,O
Central,B-Entity
nervous,I-Entity
system,I-Entity
complications,I-Entity
during,O
treatment,O
of,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
in,O
a,O
single,O
pediatric,O
institution,O
.,O
Central,B-Entity
nervous,I-Entity
system,I-Entity
(,I-Entity
CNS,I-Entity
),I-Entity
complications,I-Entity
during,O
treatment,O
of,O
childhood,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
(,O
ALL,I-Entity
),O
remain,O
a,O
challenging,O
clinical,O
problem,O
.,O
This,O
study,O
analyzed,O
the,O
incidence,O
of,O
neurological,B-Entity
complications,I-Entity
during,O
ALL,I-Entity
treatment,O
in,O
a,O
single,O
pediatric,O
institution,O
",",O
focusing,O
on,O
clinical,O
",",O
radiological,O
",",O
and,O
electrophysiological,O
findings,O
.,O
Exclusion,O
criteria,O
included,O
CNS,O
leukemic,B-Entity
infiltration,I-Entity
at,O
diagnosis,O
",",O
therapy,O
-,O
related,O
peripheral,B-Entity
neuropathy,I-Entity
",",O
late,O
-,O
onset,O
encephalopathy,I-Entity
",",O
or,O
long,O
-,O
term,O
neurocognitive,B-Entity
defects,I-Entity
.,O
During,O
a,O
9-year,O
period,O
",",O
we,O
retrospectively,O
collected,O
27,O
neurological,O
events,O
(,O
11%,O
),O
in,O
as,O
many,O
patients,O
",",O
from,O
253,O
children,O
enrolled,O
in,O
the,O
ALL,I-Entity
front,O
-,O
line,O
protocol,O
.,O
CNS,O
complications,O
included,O
posterior,O
reversible,O
leukoencephalopathy,I-Entity
syndrome,O
(,O
n,O
=,O
10,O
),O
",",O
stroke,I-Entity
(,O
n,O
=,O
5,O
),O
",",O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
(,O
n,O
=,O
2,O
),O
",",O
high,O
-,O
dose,O
methotrexate,I-Entity
toxicity,I-Entity
(,O
n,O
=,O
2,O
),O
",",O
syndrome,O
of,O
inappropriate,B-Entity
antidiuretic,I-Entity
hormone,I-Entity
secretion,I-Entity
(,O
n,O
=,O
1,O
),O
",",O
and,O
other,O
unclassified,O
events,O
(,O
n,O
=,O
7,O
),O
.,O
In,O
conclusion,O
",",O
CNS,O
complications,O
are,O
frequent,O
events,O
during,O
ALL,I-Entity
therapy,O
",",O
and,O
require,O
rapid,O
detection,O
and,O
prompt,O
treatment,O
to,O
limit,O
permanent,O
damage,O
.,O
Safety,O
of,O
capecitabine,I-Entity
:,O
a,O
review,O
.,O
IMPORTANCE,O
OF,O
THE,O
FIELD,O
:,O
Fluoropyrimidines,I-Entity
",",O
in,O
particular,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
",",O
have,O
been,O
the,O
mainstay,O
of,O
treatment,O
for,O
several,O
solid,O
tumors,I-Entity
",",O
including,O
colorectal,B-Entity
",",I-Entity
breast,I-Entity
and,I-Entity
head,I-Entity
and,I-Entity
neck,I-Entity
cancers,I-Entity
",",O
for,O
>,O
40,O
years,O
.,O
This,O
article,O
reviews,O
the,O
pharmacology,O
and,O
efficacy,O
of,O
capecitabine,I-Entity
with,O
a,O
special,O
emphasis,O
on,O
its,O
safety,O
.,O
WHAT,O
THE,O
READER,O
WILL,O
GAIN,O
:,O
The,O
reader,O
will,O
gain,O
better,O
insight,O
into,O
the,O
safety,O
of,O
capecitabine,I-Entity
in,O
special,O
populations,O
such,O
as,O
patients,O
with,O
advanced,O
age,O
",",O
renal,B-Entity
and,I-Entity
kidney,I-Entity
disease,I-Entity
.,O
We,O
also,O
explore,O
different,O
dosing,O
and,O
schedules,O
of,O
capecitabine,I-Entity
administration,O
.,O
Capecitabine,I-Entity
is,O
an,O
oral,O
prodrug,O
of,O
5-FU,I-Entity
and,O
was,O
developed,O
to,O
fulfill,O
the,O
need,O
for,O
a,O
more,O
convenient,O
therapy,O
and,O
provide,O
an,O
improved,O
safety,O
/,O
efficacy,O
profile,O
.,O
It,O
has,O
shown,O
promising,O
results,O
alone,O
or,O
in,O
combination,O
with,O
other,O
chemotherapeutic,O
agents,O
in,O
colorectal,B-Entity
",",I-Entity
breast,I-Entity
",",I-Entity
pancreaticobiliary,I-Entity
",",I-Entity
gastric,I-Entity
",",I-Entity
renal,I-Entity
cell,I-Entity
and,I-Entity
head,I-Entity
and,I-Entity
neck,I-Entity
cancers,I-Entity
.,O
The,O
most,O
commonly,O
reported,O
toxic,O
effects,O
of,O
capecitabine,I-Entity
are,O
diarrhea,I-Entity
",",O
nausea,I-Entity
",",O
vomiting,I-Entity
",",O
stomatitis,I-Entity
and,O
hand,B-Entity
-,I-Entity
foot,I-Entity
syndrome,I-Entity
.,O
Capecitabine,I-Entity
has,O
a,O
well,O
-,O
established,O
safety,O
profile,O
and,O
can,O
be,O
given,O
safely,O
to,O
patients,O
with,O
advanced,O
age,O
",",O
hepatic,B-Entity
and,I-Entity
renal,I-Entity
dysfunctions,I-Entity
.,O
Effects,O
of,O
pallidal,O
neurotensin,I-Entity
on,O
haloperidol,I-Entity
-,O
induced,O
parkinsonian,B-Entity
catalepsy,I-Entity
:,O
behavioral,O
and,O
electrophysiological,O
studies,O
.,O
Previous,O
studies,O
have,O
indicated,O
that,O
the,O
globus,O
pallidus,O
receives,O
neurotensinergic,O
innervation,O
from,O
the,O
striatum,O
",",O
and,O
systemic,O
administration,O
of,O
a,O
neurotensin,I-Entity
analog,O
could,O
produce,O
antiparkinsonian,O
effects,O
.,O
The,O
present,O
study,O
aimed,O
to,O
investigate,O
the,O
effects,O
of,O
pallidal,O
neurotensin,I-Entity
on,O
haloperidol,I-Entity
-,O
induced,O
parkinsonian,B-Entity
symptoms,I-Entity
.,O
Bilateral,O
infusions,O
of,O
neurotensin,I-Entity
into,O
the,O
globus,O
pallidus,O
reversed,O
haloperidol,I-Entity
-,O
induced,O
parkinsonian,B-Entity
catalepsy,I-Entity
in,O
rats,O
.,O
Electrophysiological,O
recordings,O
showed,O
that,O
microinjection,O
of,O
neurotensin,I-Entity
induced,O
excitation,O
of,O
pallidal,O
neurons,O
in,O
the,O
presence,O
of,O
systemic,O
haloperidol,I-Entity
administration,O
.,O
The,O
neurotensin,B-Entity
type-1,I-Entity
receptor,I-Entity
antagonist,I-Entity
SR48692,I-Entity
blocked,O
both,O
the,O
behavioral,O
and,O
the,O
electrophysiological,O
effects,O
induced,O
by,O
neurotensin,I-Entity
.,O
CONCLUSION,O
:,O
Activation,O
of,O
pallidal,O
neurotensin,I-Entity
receptors,O
may,O
be,O
involved,O
in,O
neurotensin,I-Entity
-,O
induced,O
antiparkinsonian,O
effects,O
.,O
Antihypertensive,O
drugs,O
and,O
depression,I-Entity
:,O
a,O
reappraisal,O
.,O
new,O
referral,O
hypertensive,I-Entity
out,O
-,O
patients,O
and,O
46,O
new,O
referral,O
non,O
-,O
hypertensive,I-Entity
chronically,O
physically,O
ill,O
out,O
-,O
patients,O
completed,O
a,O
mood,O
rating,O
scale,O
at,O
regular,O
intervals,O
for,O
one,O
year,O
.,O
The,O
results,O
showed,O
a,O
high,O
prevalence,O
of,O
depression,I-Entity
in,O
both,O
groups,O
of,O
patients,O
",",O
with,O
no,O
preponderance,O
in,O
the,O
hypertensive,I-Entity
group,O
.,O
Hypertensive,I-Entity
patients,O
with,O
psychiatric,I-Entity
histories,O
had,O
a,O
higher,O
prevalence,O
of,O
depression,I-Entity
than,O
the,O
comparison,O
patients,O
.,O
This,O
was,O
accounted,O
for,O
by,O
a,O
significant,O
number,O
of,O
depressions,I-Entity
occurring,O
in,O
methyl,B-Entity
dopa,I-Entity
treated,O
patients,O
with,O
psychiatric,I-Entity
histories,O
.,O
Pulmonary,O
shunt,O
and,O
cardiovascular,O
responses,O
to,O
CPAP,O
during,O
nitroprusside,I-Entity
-,O
induced,O
hypotension,I-Entity
.,O
The,O
effects,O
of,O
continuous,O
positive,O
airway,O
pressure,O
(,O
CPAP,O
),O
on,O
cardiovascular,O
dynamics,O
and,O
pulmonary,O
shunt,O
(,O
QS,O
/,O
QT,O
),O
were,O
investigated,O
in,O
12,O
dogs,O
before,O
and,O
during,O
sodium,B-Entity
nitroprusside,I-Entity
infusion,O
that,O
decreased,O
mean,O
arterial,O
blood,O
pressure,O
40,O
-,O
50,O
per,O
cent,O
.,O
Before,O
nitroprusside,I-Entity
infusion,O
",",O
5,O
cm,O
H2O,I-Entity
CPAP,O
significantly,O
",",O
P,O
less,O
than,O
.05,O
",",O
decreased,O
arterial,O
blood,O
pressure,O
",",O
but,O
did,O
not,O
significantly,O
alter,O
heart,O
rate,O
",",O
cardiac,O
output,O
",",O
systemic,O
vascular,O
resistance,O
",",O
or,O
QS,O
/,O
QT,O
.,O
cm,O
H2O,I-Entity
CPAP,O
before,O
nitroprusside,I-Entity
infusion,O
produced,O
a,O
further,O
decrease,B-Entity
in,I-Entity
arterial,I-Entity
blood,I-Entity
pressure,I-Entity
and,O
significantly,O
increased,O
heart,O
rate,O
and,O
decreased,B-Entity
cardiac,I-Entity
output,I-Entity
and,O
QS,O
/,O
QT,O
.,O
Nitroprusside,I-Entity
caused,O
significant,O
decreases,B-Entity
in,I-Entity
arterial,I-Entity
blood,I-Entity
pressure,I-Entity
and,O
systemic,O
vascular,O
resistance,O
and,O
increases,O
in,O
heart,O
rate,O
",",O
but,O
did,O
not,O
change,O
cardiac,O
output,O
or,O
QS,O
/,O
QT,O
.,O
H2O,I-Entity
CPAP,O
during,O
nitroprusside,I-Entity
did,O
not,O
further,O
alter,O
any,O
of,O
the,O
above,O
-,O
mentioned,O
variables,O
.,O
However,O
",",O
10,O
cm,O
H2O,I-Entity
CPAP,O
decreased,O
arterial,O
blood,O
pressure,O
",",O
cardiac,O
output,O
",",O
and,O
QS,O
/,O
QT,O
.,O
These,O
data,O
indicate,O
that,O
nitroprusside,I-Entity
infusion,O
rates,O
that,O
decrease,O
mean,O
arterial,O
blood,O
pressure,O
by,O
40,O
-,O
50,O
per,O
cent,O
do,O
not,O
change,O
cardiac,O
output,O
or,O
QS,O
/,O
QT,O
.,O
During,O
nitroprusside,I-Entity
infusion,O
low,O
levels,O
of,O
CPAP,O
do,O
not,O
markedly,O
alter,O
cardiovascular,O
dynamics,O
",",O
but,O
high,O
levels,O
of,O
CPAP,O
(,O
10,O
cm,O
H2O,I-Entity
),O
",",O
while,O
decreasing,O
QS,O
/,O
QT,O
",",O
produce,O
marked,O
decreases,B-Entity
in,I-Entity
arterial,I-Entity
blood,I-Entity
pressure,I-Entity
and,I-Entity
cardiac,I-Entity
output,I-Entity
.,O
Mediation,O
of,O
enhanced,O
reflex,O
vagal,O
bradycardia,I-Entity
by,O
L,B-Entity
-,I-Entity
dopa,I-Entity
via,O
central,O
dopamine,I-Entity
formation,O
in,O
dogs,O
.,O
L,B-Entity
-,I-Entity
Dopa,I-Entity
(,O
5,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
decreased,O
blood,O
pressure,O
and,O
heart,O
rate,O
after,O
extracerebral,O
decarboxylase,O
inhibition,O
with,O
MK-486,I-Entity
(,O
25,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
in,O
anesthetize,O
MAO,I-Entity
-,O
inhibited,O
dogs,O
.,O
In,O
addition,O
",",O
reflex,O
bradycardia,I-Entity
caused,O
by,O
injected,O
norepinephrine,I-Entity
was,O
significantly,O
enhanced,O
by,O
L,B-Entity
-,I-Entity
dopa,I-Entity
",",O
DL,B-Entity
-,I-Entity
Threo,I-Entity
-,I-Entity
dihydroxyphenylserine,I-Entity
had,O
no,O
effect,O
on,O
blood,O
pressure,O
",",O
heart,O
rate,O
or,O
reflex,O
responses,O
to,O
norepinephrine,I-Entity
.,O
FLA-63,I-Entity
",",O
a,O
dopamine,I-Entity
-,O
beta,O
-,O
oxidase,O
inhibitor,O
",",O
did,O
not,O
have,O
any,O
effect,O
on,O
the,O
hypotension,I-Entity
",",O
bradycardia,I-Entity
or,O
reflex,O
-,O
enhancing,O
effect,O
of,O
L,B-Entity
-,I-Entity
dopa,I-Entity
.,O
Pimozide,I-Entity
did,O
not,O
affect,O
the,O
actions,O
of,O
L,B-Entity
-,I-Entity
dopa,I-Entity
on,O
blood,O
pressure,O
and,O
heart,O
rate,O
but,O
completely,O
blocked,O
the,O
enhancement,O
of,O
reflexes,O
.,O
Removal,O
of,O
the,O
carotid,O
sinuses,O
caused,O
an,O
elevation,O
blood,O
pressure,O
and,O
heart,O
rate,O
and,O
abolished,O
the,O
negative,O
chronotropic,O
effect,O
of,O
norepinephrine,I-Entity
.,O
However,O
",",O
L,B-Entity
-,I-Entity
dopa,I-Entity
restored,O
the,O
bradycardia,I-Entity
caused,O
by,O
norepinephrine,I-Entity
in,O
addition,O
to,O
decreasing,O
blood,O
pressure,O
and,O
heart,O
rate,O
.,O
5-HTP,I-Entity
(,O
5,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
decreased,O
blood,O
pressure,O
and,O
heart,O
rate,O
and,O
decreased,O
the,O
reflex,O
bradycardia,I-Entity
to,O
norepinephrine,I-Entity
.,O
It,O
is,O
concluded,O
that,O
L,B-Entity
-,I-Entity
dopa,I-Entity
enhances,O
reflex,O
bradycardia,I-Entity
through,O
central,O
alpha,O
-,O
receptor,O
stimulation,O
.,O
Furthermore,O
",",O
the,O
effects,O
are,O
mediated,O
through,O
dopamine,I-Entity
rather,O
than,O
norepinephrine,I-Entity
and,O
do,O
not,O
require,O
the,O
carotid,O
sinus,O
baroreceptors,O
.,O
Cocaine,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
:,O
clinical,O
observations,O
and,O
pathogenetic,O
considerations,O
.,O
Clinical,O
and,O
experimental,O
data,O
published,O
to,O
date,O
suggest,O
several,O
possible,O
mechanisms,O
by,O
which,O
cocaine,I-Entity
may,O
result,O
in,O
acute,B-Entity
myocardial,I-Entity
infarction,I-Entity
.,O
In,O
individuals,O
with,O
preexisting,O
",",O
high,O
-,O
grade,O
coronary,O
arterial,O
narrowing,O
",",O
acute,B-Entity
myocardial,I-Entity
infarction,I-Entity
may,O
result,O
from,O
an,O
increase,O
in,O
myocardial,O
oxygen,I-Entity
demand,O
associated,O
with,O
cocaine,I-Entity
-,O
induced,O
increase,O
in,O
rate,O
-,O
pressure,O
product,O
.,O
In,O
other,O
individuals,O
with,O
no,O
underlying,O
atherosclerotic,B-Entity
obstruction,I-Entity
",",O
coronary,B-Entity
occlusion,I-Entity
may,O
be,O
due,O
to,O
spasm,I-Entity
",",O
thrombus,I-Entity
",",O
or,O
both,O
.,O
With,O
regard,O
to,O
spasm,I-Entity
",",O
the,O
clinical,O
findings,O
are,O
largely,O
circumstantial,O
",",O
and,O
the,O
locus,O
of,O
cocaine,I-Entity
-,O
induced,O
vasoconstriction,O
remains,O
speculative,O
.,O
Although,O
certain,O
clinical,O
and,O
experimental,O
findings,O
support,O
the,O
hypothesis,O
that,O
spasm,I-Entity
involves,O
the,O
epicardial,O
",",O
medium,O
-,O
size,O
vessels,O
",",O
other,O
data,O
suggest,O
intramural,O
vasoconstriction,O
.,O
Diffuse,O
intramural,O
vasoconstriction,O
is,O
not,O
consistent,O
with,O
reports,O
of,O
segmental,O
",",O
discrete,O
infarction,I-Entity
.,O
The,O
finding,O
of,O
cocaine,I-Entity
-,O
induced,O
vasoconstriction,O
in,O
segments,O
of,O
(,O
noninnervated,O
),O
human,O
umbilical,O
artery,O
suggests,O
that,O
the,O
presence,O
or,O
absence,O
of,O
intact,O
innervation,O
is,O
not,O
sufficient,O
to,O
explain,O
the,O
discrepant,O
data,O
involving,O
the,O
possibility,O
of,O
alpha,O
-,O
mediated,O
effects,O
.,O
Finally,O
",",O
the,O
contribution,O
of,O
a,O
primary,O
",",O
thrombotic,I-Entity
effect,O
of,O
cocaine,I-Entity
has,O
not,O
been,O
excluded,O
.,O
Rabbit,B-Entity
syndrome,I-Entity
",",O
antidepressant,I-Entity
use,O
",",O
and,O
cerebral,O
perfusion,O
SPECT,O
scan,O
findings,O
.,O
The,O
rabbit,B-Entity
syndrome,I-Entity
is,O
an,O
extrapyramidal,O
side,O
effect,O
associated,O
with,O
chronic,O
neuroleptic,O
therapy,O
.,O
Its,O
occurrence,O
in,O
a,O
patient,O
being,O
treated,O
with,O
imipramine,I-Entity
is,O
described,O
",",O
representing,O
the,O
first,O
reported,O
case,O
of,O
this,O
syndrome,O
in,O
conjunction,O
with,O
antidepressants,I-Entity
.,O
Repeated,O
cerebral,O
perfusion,O
SPECT,O
scans,O
revealed,O
decreased,B-Entity
basal,I-Entity
ganglia,I-Entity
perfusion,I-Entity
while,O
the,O
movement,B-Entity
disorder,I-Entity
was,O
present,O
",",O
and,O
a,O
return,O
to,O
normal,O
perfusion,O
when,O
the,O
rabbit,B-Entity
syndrome,I-Entity
resolved,O
.,O
Acute,O
bronchodilating,O
effects,O
of,O
ipratropium,B-Entity
bromide,I-Entity
and,O
theophylline,I-Entity
in,O
chronic,B-Entity
obstructive,I-Entity
pulmonary,I-Entity
disease,I-Entity
.,O
The,O
bronchodilator,O
effects,O
of,O
a,O
single,O
dose,O
of,O
ipratropium,B-Entity
bromide,I-Entity
aerosol,O
(,O
36,O
micrograms,O
),O
and,O
short,O
-,O
acting,O
theophylline,I-Entity
tablets,O
(,O
dose,O
titrated,O
to,O
produce,O
serum,O
levels,O
of,O
10,O
-,O
20,O
micrograms,O
/,O
mL,O
),O
were,O
compared,O
in,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
crossover,O
study,O
in,O
21,O
patients,O
with,O
stable,O
",",O
chronic,B-Entity
obstructive,I-Entity
pulmonary,I-Entity
disease,I-Entity
.,O
Mean,O
peak,O
forced,O
expiratory,O
volume,O
in,O
1,O
second,O
(,O
FEV1,O
),O
increases,O
over,O
baseline,O
and,O
the,O
proportion,O
of,O
patients,O
attaining,O
at,O
least,O
a,O
15%,O
increase,O
in,O
the,O
FEV1,O
(,O
responders,O
),O
were,O
31%,O
and,O
90%,O
",",O
respectively,O
",",O
for,O
ipratropium,I-Entity
and,O
17%,O
and,O
50%,O
",",O
respectively,O
",",O
for,O
theophylline,I-Entity
.,O
The,O
average,O
FEV1,O
increases,O
during,O
the,O
6-hour,O
observation,O
period,O
were,O
18%,O
for,O
ipratropium,I-Entity
and,O
8%,O
for,O
theophylline,I-Entity
.,O
The,O
mean,O
duration,O
of,O
action,O
was,O
3.8,O
hours,O
with,O
ipratropium,I-Entity
and,O
2.4,O
hours,O
with,O
theophylline,I-Entity
.,O
While,O
side,O
effects,O
were,O
rare,O
",",O
those,O
experienced,O
after,O
theophylline,I-Entity
use,O
did,O
involve,O
the,O
cardiovascular,B-Entity
and,I-Entity
gastrointestinal,I-Entity
systems,I-Entity
.,O
These,O
results,O
show,O
that,O
ipratropium,I-Entity
is,O
a,O
more,O
potent,O
bronchodilator,O
than,O
oral,O
theophylline,I-Entity
in,O
patients,O
with,O
chronic,B-Entity
airflow,I-Entity
obstruction,I-Entity
.,O
Irreversible,O
damage,O
to,O
the,O
medullary,O
interstitium,O
in,O
experimental,O
analgesic,O
nephropathy,I-Entity
in,O
F344,O
rats,O
.,O
Renal,B-Entity
papillary,I-Entity
necrosis,I-Entity
(,O
RPN,I-Entity
),O
and,O
a,O
decreased,O
urinary,O
concentrating,O
ability,O
developed,O
during,O
continuous,O
long,O
-,O
term,O
treatment,O
with,O
aspirin,I-Entity
and,O
paracetamol,I-Entity
in,O
female,O
Fischer,O
344,O
rats,O
.,O
This,O
study,O
shows,O
that,O
prolonged,O
analgesic,O
treatment,O
in,O
Fischer,O
344,O
rats,O
causes,O
progressive,O
and,O
irreversible,O
damage,O
to,O
the,O
interstitial,O
matrix,O
and,O
type,O
1,O
interstitial,O
cells,O
leading,O
to,O
RPN,I-Entity
.,O
Less,O
frequent,O
lithium,I-Entity
administration,O
and,O
lower,O
urine,O
volume,O
.,O
This,O
study,O
was,O
designed,O
to,O
determine,O
whether,O
patients,O
maintained,O
on,O
a,O
regimen,O
of,O
lithium,I-Entity
on,O
a,O
once,O
-,O
per,O
-,O
day,O
schedule,O
have,O
lower,O
urine,O
volumes,O
than,O
do,O
patients,O
receiving,O
multiple,O
doses,O
per,O
day,O
.,O
This,O
was,O
a,O
cross,O
-,O
sectional,O
study,O
of,O
85,O
patients,O
from,O
a,O
lithium,I-Entity
clinic,O
who,O
received,O
different,O
dose,O
schedules,O
.,O
Patients,O
were,O
admitted,O
to,O
the,O
hospital,O
for,O
measurement,O
of,O
lithium,I-Entity
level,O
",",O
creatinine,I-Entity
clearance,O
",",O
urine,O
volume,O
",",O
and,O
maximum,O
osmolality,O
.,O
Multiple,O
daily,O
doses,O
of,O
lithium,I-Entity
were,O
associated,O
with,O
higher,O
urine,O
volumes,O
.,O
The,O
dosing,O
schedule,O
",",O
duration,O
of,O
lithium,I-Entity
treatment,O
",",O
and,O
daily,O
dose,O
of,O
lithium,I-Entity
did,O
not,O
affect,O
maximum,O
osmolality,O
or,O
creatinine,I-Entity
clearance,O
.,O
CONCLUSIONS,O
:,O
Urine,O
volume,O
can,O
be,O
reduced,O
by,O
giving,O
lithium,I-Entity
once,O
daily,O
and/or,O
by,O
lowering,O
the,O
total,O
daily,O
dose,O
.,O
Lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
seems,O
to,O
be,O
related,O
to,O
extrarenal,O
as,O
well,O
as,O
to,O
renal,O
effects,O
.,O
Effect,O
of,O
adriamycin,I-Entity
combined,O
with,O
whole,O
body,O
hyperthermia,I-Entity
on,O
tumor,I-Entity
and,O
normal,O
tissues,O
.,O
Thermal,O
enhancement,O
of,O
Adriamycin,I-Entity
-,O
mediated,O
antitumor,O
activity,O
and,O
normal,O
tissue,O
toxicities,I-Entity
by,O
whole,O
body,O
hyperthermia,I-Entity
were,O
compared,O
using,O
a,O
F344,O
rat,O
model,O
.,O
Antitumor,O
activity,O
was,O
studied,O
using,O
a,O
tumor,I-Entity
growth,O
delay,O
assay,O
.,O
Acute,O
normal,O
tissue,O
toxicities,I-Entity
(,O
i.e.,O
",",O
leukopenia,I-Entity
and,O
thrombocytopenia,I-Entity
),O
and,O
late,O
normal,O
tissue,O
toxicities,I-Entity
(,O
i.e.,O
",",O
myocardial,B-Entity
and,I-Entity
kidney,I-Entity
injury,I-Entity
),O
were,O
evaluated,O
by,O
functional,O
/,O
physiological,O
assays,O
and,O
by,O
morphological,O
techniques,O
.,O
Whole,O
body,O
hyperthermia,I-Entity
(,O
120,O
min,O
at,O
41.5,O
degrees,O
C,O
),O
enhanced,O
both,O
Adriamycin,I-Entity
-,O
mediated,O
antitumor,O
activity,O
and,O
toxic,O
side,O
effects,O
.,O
Thermal,O
enhancement,O
ratios,O
estimated,O
for,O
"""",O
acute,O
"""",O
hematological,O
changes,O
were,O
1.3,O
",",O
whereas,O
those,O
estimated,O
for,O
"""",O
late,O
"""",O
damage,O
(,O
based,O
on,O
morphological,O
cardiac,B-Entity
and,I-Entity
renal,I-Entity
lesions,I-Entity
),O
varied,O
between,O
2.4,O
and,O
4.3,O
.,O
Thus,O
",",O
while,O
whole,O
body,O
hyperthermia,I-Entity
enhances,O
Adriamycin,I-Entity
-,O
mediated,O
antitumor,O
effect,O
",",O
normal,O
tissue,O
toxicity,I-Entity
is,O
also,O
increased,O
",",O
and,O
the,O
potential,O
therapeutic,O
gain,O
of,O
the,O
combined,O
modality,O
treatment,O
is,O
eroded,O
.,O
Prazosin,I-Entity
-,O
induced,O
stress,B-Entity
incontinence,I-Entity
.,O
A,O
case,O
of,O
genuine,O
stress,B-Entity
incontinence,I-Entity
due,O
to,O
prazosin,I-Entity
",",O
a,O
common,O
antihypertensive,O
drug,O
",",O
is,O
presented,O
.,O
Prazosin,I-Entity
exerts,O
its,O
antihypertensive,O
effects,O
through,O
vasodilatation,O
caused,O
by,O
selective,O
blockade,O
of,O
postsynaptic,O
alpha-1,O
adrenergic,O
receptors,O
.,O
The,O
patient,O
's,O
clinical,O
course,O
is,O
described,O
and,O
correlated,O
with,O
initial,O
urodynamic,O
studies,O
while,O
on,O
prazosin,I-Entity
and,O
subsequent,O
studies,O
while,O
taking,O
verapamil,I-Entity
.,O
Her,O
incontinence,I-Entity
resolved,O
with,O
the,O
change,O
of,O
medication,O
.,O
Patients,O
who,O
present,O
with,O
stress,B-Entity
incontinence,I-Entity
while,O
taking,O
prazosin,I-Entity
should,O
change,O
their,O
antihypertensive,O
medication,O
before,O
considering,O
surgery,O
",",O
because,O
their,O
incontinence,I-Entity
may,O
resolve,O
spontaneously,O
with,O
a,O
change,O
in,O
drug,O
therapy,O
.,O
Myocardial,B-Entity
infarction,I-Entity
following,O
sublingual,O
administration,O
of,O
isosorbide,B-Entity
dinitrate,I-Entity
.,O
A,O
78-year,O
-,O
old,O
with,O
healed,O
septal,O
necrosis,I-Entity
suffered,O
a,O
recurrent,O
myocardial,B-Entity
infarction,I-Entity
of,O
the,O
anterior,O
wall,O
following,O
the,O
administration,O
of,O
isosorbide,B-Entity
dinitrate,I-Entity
5,O
mg,O
sublingually,O
.,O
After,O
detailing,O
the,O
course,O
of,O
events,O
",",O
we,O
discuss,O
the,O
role,O
of,O
paradoxical,O
coronary,O
spasm,I-Entity
and,O
hypotension,I-Entity
-,O
mediated,O
myocardial,B-Entity
ischemia,I-Entity
occurring,O
downstream,O
to,O
significant,O
coronary,B-Entity
arterial,I-Entity
stenosis,I-Entity
in,O
the,O
pathophysiology,O
of,O
acute,B-Entity
coronary,I-Entity
insufficiency,I-Entity
.,O
Fluoxetine,I-Entity
-,O
induced,O
akathisia,I-Entity
:,O
clinical,O
and,O
theoretical,O
implications,O
.,O
Five,O
patients,O
receiving,O
fluoxetine,I-Entity
for,O
the,O
treatment,O
of,O
obsessive,B-Entity
compulsive,I-Entity
disorder,I-Entity
or,O
major,B-Entity
depression,I-Entity
developed,O
akathisia,I-Entity
.,O
The,O
typical,O
fluoxetine,I-Entity
-,O
induced,O
symptoms,O
of,O
restlessness,O
",",O
constant,O
pacing,O
",",O
purposeless,O
movements,O
of,O
the,O
feet,O
and,O
legs,O
",",O
and,O
marked,O
anxiety,I-Entity
were,O
indistinguishable,O
from,O
those,O
of,O
neuroleptic,O
-,O
induced,O
akathisia,I-Entity
.,O
Three,O
patients,O
who,O
had,O
experienced,O
neuroleptic,O
-,O
induced,O
akathisia,I-Entity
in,O
the,O
past,O
reported,O
that,O
the,O
symptoms,O
of,O
fluoxetine,I-Entity
-,O
induced,O
akathisia,I-Entity
were,O
identical,O
",",O
although,O
somewhat,O
milder,O
.,O
Akathisia,I-Entity
appeared,O
to,O
be,O
a,O
common,O
side,O
effect,O
of,O
fluoxetine,I-Entity
and,O
generally,O
responded,O
well,O
to,O
treatment,O
with,O
the,O
beta,O
-,O
adrenergic,O
antagonist,O
propranolol,I-Entity
",",O
dose,O
reduction,O
",",O
or,O
both,O
.,O
The,O
authors,O
suggest,O
that,O
fluoxetine,I-Entity
-,O
induced,O
akathisia,I-Entity
may,O
be,O
caused,O
by,O
serotonergically,O
mediated,O
inhibition,O
of,O
dopaminergic,O
neurotransmission,O
and,O
that,O
the,O
pathophysiology,O
of,O
fluoxetine,I-Entity
-,O
induced,O
akathisia,I-Entity
and,O
tricyclic,O
antidepressant,I-Entity
-,O
induced,O
"""",O
jitteriness,O
"""",O
may,O
be,O
identical,O
.,O
Chronic,B-Entity
active,I-Entity
hepatitis,I-Entity
associated,O
with,O
diclofenac,B-Entity
sodium,I-Entity
therapy,O
.,O
Diclofenac,B-Entity
sodium,I-Entity
(,O
Voltarol,I-Entity
",",O
Geigy,O
Pharmaceuticals,O
),O
is,O
a,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
derivative,O
of,O
phenylacetic,B-Entity
acid,I-Entity
.,O
Although,O
generally,O
well,O
-,O
tolerated,O
",",O
asymptomatic,O
abnormalities,B-Entity
of,I-Entity
liver,I-Entity
function,I-Entity
have,O
been,O
recorded,O
and,O
",",O
less,O
commonly,O
",",O
severe,O
hepatitis,I-Entity
induced,O
by,O
diclofenac,I-Entity
.,O
The,O
patient,O
described,O
developed,O
chronic,B-Entity
active,I-Entity
hepatitis,I-Entity
after,O
six,O
months,O
therapy,O
with,O
diclofenac,B-Entity
sodium,I-Entity
which,O
progressed,O
despite,O
the,O
withdrawal,O
of,O
the,O
drug,O
",",O
a,O
finding,O
not,O
previously,O
reported,O
.,O
Stroke,I-Entity
associated,O
with,O
cocaine,I-Entity
use,O
.,O
We,O
describe,O
eight,O
patients,O
in,O
whom,O
cocaine,I-Entity
use,O
was,O
related,O
to,O
stroke,I-Entity
and,O
review,O
39,O
cases,O
from,O
the,O
literature,O
.,O
Stroke,I-Entity
followed,O
cocaine,I-Entity
use,O
by,O
inhalation,O
",",O
intranasal,O
",",O
intravenous,O
",",O
and,O
intramuscular,O
routes,O
.,O
Intracranial,B-Entity
aneurysms,I-Entity
or,O
arteriovenous,B-Entity
malformations,I-Entity
were,O
present,O
in,O
17,O
of,O
32,O
patients,O
studied,O
angiographically,O
or,O
at,O
autopsy,O
;,O
cerebral,B-Entity
vasculitis,I-Entity
was,O
present,O
in,O
two,O
patients,O
.,O
Cerebral,B-Entity
infarction,I-Entity
occurred,O
in,O
10,O
patients,O
(,O
22%,O
),O
",",O
intracerebral,B-Entity
hemorrhage,I-Entity
in,O
22,O
(,O
49%,O
),O
",",O
and,O
subarachnoid,B-Entity
hemorrhage,I-Entity
in,O
13,O
(,O
29%,O
),O
.,O
These,O
data,O
indicate,O
that,O
(,O
1,O
),O
the,O
apparent,O
incidence,O
of,O
stroke,I-Entity
related,O
to,O
cocaine,I-Entity
use,O
is,O
increasing,O
;,O
(,O
2,O
),O
cocaine,I-Entity
-,O
associated,O
stroke,I-Entity
occurs,O
primarily,O
in,O
young,O
adults,O
;,O
(,O
3,O
),O
stroke,I-Entity
may,O
follow,O
any,O
route,O
of,O
cocaine,I-Entity
administration,O
;,O
(,O
4,O
),O
stroke,I-Entity
after,O
cocaine,I-Entity
use,O
is,O
frequently,O
associated,O
with,O
intracranial,B-Entity
aneurysms,I-Entity
and,O
arteriovenous,B-Entity
malformations,I-Entity
;,O
and,O
(,O
5,O
),O
in,O
cocaine,I-Entity
-,O
associated,O
stroke,I-Entity
",",O
the,O
frequency,O
of,O
intracranial,B-Entity
hemorrhage,I-Entity
exceeds,O
that,O
of,O
cerebral,B-Entity
infarction,I-Entity
.,O
Glyburide,I-Entity
-,O
induced,O
hepatitis,I-Entity
.,O
Drug,O
-,O
induced,O
hepatotoxicity,I-Entity
",",O
although,O
common,O
",",O
has,O
been,O
reported,O
only,O
infrequently,O
with,O
sulfonylureas,I-Entity
.,O
For,O
glyburide,I-Entity
",",O
a,O
second,O
-,O
generation,O
sulfonylurea,I-Entity
",",O
only,O
two,O
brief,O
reports,O
of,O
hepatotoxicity,I-Entity
exist,O
.,O
Two,O
patients,O
with,O
type,B-Entity
II,I-Entity
diabetes,I-Entity
mellitus,I-Entity
developed,O
an,O
acute,B-Entity
hepatitis,I-Entity
-,I-Entity
like,I-Entity
syndrome,I-Entity
soon,O
after,O
initiation,O
of,O
glyburide,I-Entity
therapy,O
.,O
There,O
was,O
no,O
serologic,O
evidence,O
of,O
viral,B-Entity
infection,I-Entity
",",O
and,O
a,O
liver,O
biopsy,O
sample,O
showed,O
a,O
histologic,O
pattern,O
consistent,O
with,O
drug,B-Entity
-,I-Entity
induced,I-Entity
hepatitis,I-Entity
.,O
Both,O
patients,O
recovered,O
quickly,O
after,O
stopping,O
glyburide,I-Entity
therapy,O
and,O
have,O
remained,O
well,O
for,O
a,O
follow,O
-,O
up,O
period,O
of,O
1,O
year,O
.,O
Glyburide,I-Entity
can,O
produce,O
an,O
acute,B-Entity
hepatitis,I-Entity
-,I-Entity
like,I-Entity
illness,I-Entity
in,O
some,O
persons,O
.,O
Systolic,O
pressure,O
variation,O
is,O
greater,O
during,O
hemorrhage,I-Entity
than,O
during,O
sodium,B-Entity
nitroprusside,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
ventilated,O
dogs,O
.,O
The,O
systolic,O
pressure,O
variation,O
(,O
SPV,O
),O
",",O
which,O
is,O
the,O
difference,O
between,O
the,O
maximal,O
and,O
minimal,O
values,O
of,O
the,O
systolic,O
blood,O
pressure,O
(,O
SBP,O
),O
after,O
one,O
positive,O
-,O
pressure,O
breath,O
",",O
was,O
studied,O
in,O
ventilated,O
dogs,O
subjected,O
to,O
hypotension,I-Entity
.,O
Mean,O
arterial,O
pressure,O
was,O
decreased,O
to,O
50,O
mm,O
Hg,O
for,O
30,O
minutes,O
either,O
by,O
hemorrhage,I-Entity
(,O
HEM,I-Entity
",",O
n,O
=,O
7,O
),O
or,O
by,O
continuous,O
infusion,O
of,O
sodium,B-Entity
nitroprusside,I-Entity
(,O
SNP,I-Entity
",",O
n,O
=,O
7,O
),O
.,O
During,O
HEM,I-Entity
-,O
induced,O
hypotension,I-Entity
the,O
cardiac,O
output,O
was,O
significantly,O
lower,O
and,O
systemic,O
vascular,O
resistance,O
higher,O
compared,O
with,O
that,O
in,O
the,O
SNP,I-Entity
group,O
.,O
The,O
SPV,O
during,O
hypotension,I-Entity
was,O
15.7,O
+,O
/-,O
6.7,O
mm,O
Hg,O
in,O
the,O
HEM,I-Entity
group,O
",",O
compared,O
with,O
9.1,O
+,O
/-,O
2.0,O
mm,O
Hg,O
in,O
the,O
SNP,I-Entity
group,O
(,O
P,O
less,O
than,O
0.02,O
),O
.,O
3.8,O
mm,O
Hg,O
in,O
the,O
HEM,I-Entity
and,O
SNP,I-Entity
groups,O
",",O
respectively,O
",",O
during,O
hypotension,I-Entity
(,O
P,O
less,O
than,O
0.02,O
),O
.,O
It,O
is,O
concluded,O
that,O
increases,O
in,O
the,O
SPV,O
and,O
the,O
delta,O
down,O
are,O
characteristic,O
of,O
a,O
hypotensive,I-Entity
state,O
due,O
to,O
a,O
predominant,O
decrease,O
in,O
preload,O
.,O
They,O
are,O
thus,O
more,O
important,O
during,O
absolute,O
hypovolemia,I-Entity
than,O
during,O
deliberate,O
hypotension,I-Entity
.,O
Drug,O
-,O
induced,O
arterial,O
spasm,I-Entity
relieved,O
by,O
lidocaine,I-Entity
.,O
Following,O
major,O
intracranial,O
surgery,O
in,O
a,O
35-year,O
-,O
old,O
man,O
",",O
sodium,B-Entity
pentothal,I-Entity
was,O
intravenously,O
infused,O
to,O
minimize,O
cerebral,B-Entity
ischaemia,I-Entity
.,O
Intense,O
vasospasm,I-Entity
with,O
threatened,O
gangrene,I-Entity
arose,O
in,O
the,O
arm,O
used,O
for,O
the,O
infusion,O
.,O
Since,O
the,O
cranial,O
condition,O
precluded,O
use,O
of,O
more,O
usual,O
methods,O
",",O
lidocaine,I-Entity
was,O
given,O
intra,O
-,O
arterially,O
",",O
with,O
careful,O
cardiovascular,O
monitoring,O
",",O
to,O
counteract,O
the,O
vasospasm,I-Entity
.,O
Cerebral,O
blood,O
flow,O
and,O
metabolism,O
during,O
isoflurane,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
patients,O
subjected,O
to,O
surgery,O
for,O
cerebral,B-Entity
aneurysms,I-Entity
.,O
Cerebral,O
blood,O
flow,O
and,O
cerebral,O
metabolic,O
rate,O
for,O
oxygen,I-Entity
were,O
measured,O
during,O
isoflurane,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
10,O
patients,O
subjected,O
to,O
craniotomy,O
for,O
clipping,O
of,O
a,O
cerebral,B-Entity
aneurysm,I-Entity
.,O
Flow,O
and,O
metabolism,O
were,O
measured,O
5,O
-,O
13,O
days,O
after,O
the,O
subarachnoid,B-Entity
haemorrhage,I-Entity
by,O
a,O
modification,O
of,O
the,O
classical,O
Kety,O
-,O
Schmidt,O
technique,O
using,O
xenon-133,I-Entity
i.v,O
.,O
Anaesthesia,O
was,O
maintained,O
with,O
an,O
inspired,O
isoflurane,I-Entity
concentration,O
of,O
0.75%,O
(,O
plus,O
67%,O
nitrous,B-Entity
oxide,I-Entity
in,O
oxygen,I-Entity
),O
",",O
during,O
which,O
CBF,O
and,O
CMRO2,O
were,O
34.3,O
+,O
/-,O
Controlled,O
hypotension,I-Entity
to,O
an,O
average,O
MAP,O
of,O
50,O
-,O
55,O
mm,O
Hg,I-Entity
was,O
induced,O
by,O
increasing,O
the,O
dose,O
of,O
isoflurane,I-Entity
",",O
and,O
maintained,O
at,O
an,O
inspired,O
concentration,O
of,O
2.2,O
+,O
/-,O
After,O
the,O
clipping,O
of,O
the,O
aneurysm,I-Entity
the,O
isoflurane,I-Entity
concentration,O
was,O
reduced,O
to,O
0.75%,O
.,O
There,O
was,O
a,O
significant,O
increase,O
in,O
CBF,O
",",O
although,O
CMRO2,O
was,O
unchanged,O
",",O
compared,O
with,O
pre,O
-,O
hypotensive,I-Entity
values,O
.,O
These,O
changes,O
might,O
offer,O
protection,O
to,O
brain,O
tissue,O
during,O
periods,O
of,O
induced,O
hypotension,I-Entity
.,O
Allergic,B-Entity
reaction,I-Entity
to,O
5-fluorouracil,I-Entity
infusion,O
.,O
An,O
allergic,B-Entity
reaction,I-Entity
consisting,O
of,O
angioneurotic,B-Entity
edema,I-Entity
secondary,O
to,O
continuous,O
infusion,O
5-fluorouracil,I-Entity
occurred,O
in,O
a,O
patient,O
with,O
recurrent,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
oral,I-Entity
cavity,I-Entity
",",O
cirrhosis,I-Entity
",",O
and,O
cisplatin,I-Entity
-,O
induced,O
impaired,B-Entity
renal,I-Entity
function,I-Entity
.,O
Oral,O
diphenhydramine,I-Entity
and,O
prednisone,I-Entity
were,O
ineffective,O
in,O
preventing,O
the,O
recurrence,O
of,O
the,O
allergic,B-Entity
reaction,I-Entity
.,O
Amiodarone,I-Entity
-,O
induced,O
sinoatrial,B-Entity
block,I-Entity
.,O
We,O
observed,O
sinoatrial,B-Entity
block,I-Entity
due,O
to,O
chronic,O
amiodarone,I-Entity
administration,O
in,O
a,O
5-year,O
-,O
old,O
boy,O
with,O
primary,B-Entity
cardiomyopathy,I-Entity
",",O
Wolff,B-Entity
-,I-Entity
Parkinson,I-Entity
-,I-Entity
White,I-Entity
syndrome,I-Entity
and,O
supraventricular,B-Entity
tachycardia,I-Entity
.,O
Reduction,O
in,O
the,O
dosage,O
of,O
amiodarone,I-Entity
resulted,O
in,O
the,O
disappearance,O
of,O
the,O
sinoatrial,B-Entity
block,I-Entity
and,O
the,O
persistence,O
of,O
asymptomatic,O
sinus,B-Entity
bradycardia,I-Entity
.,O
Possible,O
teratogenicity,O
of,O
sulphasalazine,I-Entity
.,O
Three,O
infants,O
",",O
born,O
of,O
two,O
mothers,O
with,O
inflammatory,B-Entity
bowel,I-Entity
disease,I-Entity
who,O
received,O
treatment,O
with,O
sulphasalazine,I-Entity
throughout,O
pregnancy,O
",",O
were,O
found,O
to,O
have,O
major,O
congenital,B-Entity
anomalies,I-Entity
.,O
In,O
the,O
singleton,O
pregnancy,O
",",O
the,O
mother,O
had,O
ulcerative,B-Entity
colitis,I-Entity
",",O
and,O
the,O
infant,O
",",O
a,O
male,O
",",O
had,O
coarctation,B-Entity
of,I-Entity
the,I-Entity
aorta,I-Entity
and,O
a,O
ventricular,B-Entity
septal,I-Entity
defect,I-Entity
.,O
In,O
the,O
twin,O
pregnancy,O
",",O
the,O
mother,O
had,O
Crohn,B-Entity
's,I-Entity
disease,I-Entity
.,O
The,O
first,O
twin,O
",",O
a,O
female,O
",",O
had,O
a,O
left,O
Potter,B-Entity
-,I-Entity
type,I-Entity
IIa,I-Entity
polycystic,I-Entity
kidney,I-Entity
and,O
a,O
rudimentary,B-Entity
left,I-Entity
uterine,I-Entity
cornu,I-Entity
.,O
The,O
second,O
twin,O
",",O
a,O
male,O
",",O
had,O
some,O
features,O
of,O
Potter,B-Entity
's,I-Entity
facies,I-Entity
",",O
hypoplastic,B-Entity
lungs,I-Entity
",",O
absent,B-Entity
kidneys,I-Entity
and,I-Entity
ureters,I-Entity
",",O
and,O
talipes,B-Entity
equinovarus,I-Entity
.,O
Despite,O
reports,O
to,O
the,O
contrary,O
",",O
it,O
is,O
suggested,O
that,O
sulphasalazine,I-Entity
may,O
be,O
teratogenic,O
.,O
Veno,B-Entity
-,I-Entity
occlusive,I-Entity
liver,I-Entity
disease,I-Entity
after,O
dacarbazine,I-Entity
therapy,O
(,O
DTIC,I-Entity
),O
for,O
melanoma,I-Entity
.,O
A,O
case,O
of,O
veno,B-Entity
-,I-Entity
occlusive,I-Entity
disease,I-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
with,O
fatal,O
outcome,O
after,O
dacarbazine,I-Entity
(,O
DTIC,I-Entity
),O
therapy,O
for,O
melanoma,I-Entity
is,O
reported,O
.,O
There,O
was,O
a,O
fulminant,O
clinical,O
course,O
from,O
start,O
of,O
symptoms,O
until,O
death,I-Entity
.,O
At,O
autopsy,O
the,O
liver,O
was,O
enlarged,O
and,O
firm,O
with,O
signs,O
of,O
venous,B-Entity
congestion,I-Entity
.,O
Small-,O
and,O
medium,O
-,O
sized,O
hepatic,O
veins,O
were,O
blocked,O
by,O
thrombosis,I-Entity
.,O
A,O
case,O
of,O
tardive,B-Entity
dyskinesia,I-Entity
caused,O
by,O
metoclopramide,I-Entity
.,O
Abnormal,B-Entity
involuntary,I-Entity
movements,I-Entity
appeared,O
in,O
the,O
mouth,O
",",O
tongue,O
",",O
neck,O
and,O
abdomen,O
of,O
a,O
64-year,O
-,O
old,O
male,O
patient,O
after,O
he,O
took,O
metoclopramide,I-Entity
for,O
gastrointestinal,B-Entity
disorder,I-Entity
in,O
a,O
regimen,O
of,O
30,O
mg,O
per,O
day,O
for,O
a,O
total,O
of,O
about,O
260,O
days,O
.,O
When,O
the,O
metoclopramide,I-Entity
administration,O
was,O
discontinued,O
",",O
the,O
abnormal,B-Entity
movements,I-Entity
gradually,O
improved,O
to,O
a,O
considerable,O
extent,O
.,O
Attention,O
to,O
the,O
possible,O
induction,O
of,O
specific,O
tardive,B-Entity
dyskinesia,I-Entity
is,O
called,O
for,O
in,O
the,O
use,O
of,O
this,O
drug,O
.,O
Further,O
observations,O
on,O
the,O
electrophysiologic,O
effects,O
of,O
oral,O
amiodarone,I-Entity
therapy,O
.,O
A,O
case,O
is,O
presented,O
of,O
a,O
reversible,O
intra,B-Entity
-,I-Entity
Hisian,I-Entity
block,I-Entity
occurring,O
under,O
amiodarone,I-Entity
treatment,O
for,O
atrial,B-Entity
tachycardia,I-Entity
in,O
a,O
patient,O
without,O
clear,O
intraventricular,B-Entity
conduction,I-Entity
abnormalities,I-Entity
.,O
His,O
bundle,O
recordings,O
showed,O
an,O
atrial,B-Entity
tachycardia,I-Entity
with,O
intermittent,O
exit,O
block,O
and,O
greatly,O
prolonged,O
BH,O
and,O
HV,O
intervals,O
(,O
40,O
and,O
100,O
msec,O
",",O
respectively,O
),O
.,O
Thirty,O
days,O
after,O
amiodarone,I-Entity
discontinuation,O
",",O
His,O
bundle,O
electrograms,O
showed,O
atrial,B-Entity
flutter,I-Entity
without,O
intra,O
-,O
Hisian,O
or,O
infra,O
-,O
Hisian,O
delay,O
.,O
Amiodarone,I-Entity
should,O
be,O
used,O
with,O
caution,O
during,O
long,O
-,O
term,O
oral,O
therapy,O
in,O
patients,O
with,O
or,O
without,O
clear,O
intraventricular,O
conduction,O
defects,O
.,O
Busulfan,I-Entity
-,O
induced,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
A,O
case,O
of,O
a,O
busulfan,I-Entity
-,O
induced,O
hemorrhage,B-Entity
cystitis,I-Entity
is,O
reported,O
.,O
The,O
similarity,O
between,O
the,O
histologic,O
appearances,O
of,O
busulfan,I-Entity
cystitis,I-Entity
and,O
both,O
radiation,O
and,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
is,O
discussed,O
and,O
the,O
world,O
literature,O
reviewed,O
.,O
In,O
view,O
of,O
the,O
known,O
tendency,O
of,O
busulfan,I-Entity
to,O
induce,O
cellular,O
atypia,O
and,O
carcinoma,I-Entity
in,O
other,O
sites,O
",",O
periodic,O
urinary,O
cytology,O
is,O
suggested,O
in,O
patients,O
on,O
long,O
-,O
term,O
therapy,O
.,O
Rebound,O
hypertensive,I-Entity
after,O
sodium,B-Entity
nitroprusside,I-Entity
prevented,O
by,O
saralasin,I-Entity
in,O
rats,O
.,O
The,O
role,O
of,O
the,O
renin,O
--,O
angiotensin,I-Entity
system,O
in,O
the,O
maintenance,O
of,O
blood,O
pressure,O
during,O
halothane,I-Entity
anesthesia,O
and,O
sodium,B-Entity
nitroprusside,I-Entity
(,O
SNP)-induced,I-Entity
hypotension,I-Entity
was,O
evaluated,O
.,O
Control,O
rats,O
received,O
halothane,I-Entity
anesthesia,O
(,O
1,O
MAC,O
),O
for,O
one,O
hour,O
",",O
followed,O
by,O
SNP,I-Entity
infusion,O
",",O
40,O
microgram,O
/,O
kg,O
/,O
min,O
",",O
for,O
30,O
min,O
",",O
followed,O
by,O
a,O
30-min,O
recovery,O
period,O
.,O
A,O
second,O
group,O
of,O
rats,O
was,O
treated,O
identically,O
and,O
",",O
in,O
addition,O
",",O
received,O
an,O
infusion,O
of,O
saralasin,I-Entity
(,O
a,O
competitive,O
inhibitor,O
of,O
angiotensin,B-Entity
II,I-Entity
),O
throughout,O
the,O
experimental,O
period,O
.,O
In,O
each,O
group,O
",",O
SNP,I-Entity
infusion,O
resulted,O
in,O
an,O
initial,O
decrease,O
in,O
blood,O
pressure,O
from,O
86,O
torr,O
and,O
83,O
torr,O
",",O
respectively,O
",",O
to,O
48,O
torr,O
.,O
During,O
the,O
SNP,I-Entity
infusion,O
the,O
control,O
animals,O
demonstrated,O
a,O
progressive,O
increase,B-Entity
in,I-Entity
blood,I-Entity
pressure,I-Entity
to,O
61,O
torr,O
",",O
whereas,O
the,O
saralasin,I-Entity
-,O
treated,O
animals,O
showed,O
no,O
change,O
.,O
Following,O
discontinuation,O
of,O
SNP,I-Entity
",",O
blood,O
pressure,O
in,O
the,O
control,O
animals,O
rebounded,O
to,O
94,O
torr,O
",",O
as,O
compared,O
with,O
78,O
torr,O
in,O
the,O
saralasin,I-Entity
-,O
treated,O
rats,O
.,O
This,O
study,O
indicates,O
that,O
with,O
stable,O
halothane,I-Entity
anesthesia,O
",",O
the,O
partial,O
recovery,O
of,O
blood,O
pressure,O
during,O
SNP,I-Entity
infusion,O
and,O
the,O
post,O
-,O
SNP,I-Entity
rebound,O
of,O
blood,O
pressure,O
can,O
be,O
completely,O
blocked,O
by,O
saralasin,I-Entity
.,O
This,O
demonstrates,O
the,O
participation,O
of,O
the,O
renin,O
--,O
angiotensin,I-Entity
system,O
in,O
antagonizing,O
the,O
combined,O
hypotensive,I-Entity
effects,O
of,O
halothane,I-Entity
and,O
SNP,I-Entity
.,O
Toxic,B-Entity
hepatitis,I-Entity
induced,O
by,O
antithyroid,O
drugs,O
:,O
four,O
cases,O
including,O
one,O
with,O
cross,O
-,O
reactivity,O
between,O
carbimazole,I-Entity
and,O
benzylthiouracil,I-Entity
.,O
This,O
study,O
was,O
conducted,O
to,O
assess,O
the,O
occurrence,O
of,O
hepatic,B-Entity
adverse,I-Entity
effects,I-Entity
encountered,O
with,O
antithyroid,O
drugs,O
.,O
Retrospective,O
review,O
of,O
medical,O
records,O
of,O
236,O
patients,O
with,O
hyperthyroidism,I-Entity
admitted,O
in,O
our,O
department,O
(,O
in-,O
or,O
out,O
-,O
patients,O
),O
from,O
1986,O
to,O
1992,O
.,O
Four,O
patients,O
(,O
1.7%,O
),O
were,O
identified,O
with,O
toxic,B-Entity
hepatitis,I-Entity
which,O
could,O
reasonably,O
be,O
attributed,O
to,O
the,O
use,O
of,O
antithyroid,O
agent,O
.,O
Two,O
patients,O
had,O
a,O
cholestatic,B-Entity
hepatitis,I-Entity
induced,O
by,O
carbimazole,I-Entity
(,O
N,B-Entity
omercazole,I-Entity
),O
.,O
Two,O
others,O
had,O
a,O
mixed,O
(,O
cholestatic,I-Entity
and,O
cytolytic,O
),O
hepatitis,I-Entity
following,O
carbimazole,I-Entity
.,O
One,O
of,O
the,O
latter,O
two,O
patients,O
further,O
experienced,O
a,O
cytolytic,O
hepatitis,I-Entity
which,O
appeared,O
after,O
Benzylthiouracil,I-Entity
(,O
Basd,B-Entity
ne,I-Entity
),O
had,O
replaced,O
carbimazole,I-Entity
.,O
Biological,O
features,O
of,O
hepatitis,I-Entity
disappeared,O
in,O
all,O
cases,O
after,O
cessation,O
of,O
the,O
incriminated,O
drug,O
",",O
while,O
biliary,O
",",O
viral,O
and,O
immunological,O
searches,O
were,O
negative,O
.,O
Only,O
2,O
patients,O
of,O
our,O
retrospective,O
study,O
experienced,O
a,O
mild,O
or,O
severe,O
neutropenia,I-Entity
.,O
CONCLUSION,O
:,O
Toxic,B-Entity
hepatitis,I-Entity
is,O
a,O
potential,O
adverse,O
effect,O
of,O
antithyroid,O
drugs,O
which,O
warrants,O
",",O
as,O
for,O
haematological,O
disturbances,O
",",O
a,O
pre,O
-,O
therapeutic,O
determination,O
and,O
a,O
careful,O
follow,O
-,O
up,O
of,O
relevant,O
biological,O
markers,O
.,O
Moreover,O
",",O
hepatotoxicity,I-Entity
may,O
not,O
be,O
restricted,O
to,O
one,O
class,O
of,O
antithyroid,O
agents,O
.,O
Study,O
of,O
the,O
role,O
of,O
vitamin,B-Entity
B12,I-Entity
and,O
folinic,B-Entity
acid,I-Entity
supplementation,O
in,O
preventing,O
hematologic,O
toxicity,I-Entity
of,O
zidovudine,I-Entity
.,O
A,O
prospective,O
",",O
randomized,O
study,O
was,O
conducted,O
to,O
evaluate,O
the,O
role,O
of,O
vitamin,B-Entity
B12,I-Entity
and,O
folinic,B-Entity
acid,I-Entity
supplementation,O
in,O
preventing,O
zidovudine,I-Entity
(,O
ZDV)-induced,I-Entity
bone,B-Entity
marrow,I-Entity
suppression,I-Entity
.,O
Seventy,O
-,O
five,O
human,B-Entity
immunodeficiency,I-Entity
virus,I-Entity
(,I-Entity
HIV)-infected,I-Entity
patients,O
with,O
CD4,O
+,O
cell,O
counts,O
<,O
500/mm3,O
were,O
randomized,O
to,O
receive,O
either,O
ZDV,I-Entity
(,O
500,O
mg,O
daily,O
),O
alone,O
(,O
group,O
I,O
",",O
n,O
=,O
38,O
),O
or,O
in,O
combination,O
with,O
folinic,B-Entity
acid,I-Entity
(,O
15,O
mg,O
daily,O
),O
and,O
intramascular,O
vitamin,B-Entity
B12,I-Entity
(,O
1000,O
micrograms,O
monthly,O
),O
(,O
group,O
II,O
",",O
n,O
=,O
37,O
),O
.,O
Finally,O
",",O
15,O
patients,O
were,O
excluded,O
from,O
the,O
study,O
(,O
noncompliance,O
14,O
",",O
death,I-Entity
1,O
),O
;,O
thus,O
",",O
60,O
patients,O
(,O
31,O
in,O
group,O
I,O
and,O
29,O
in,O
group,O
II,O
),O
were,O
eligible,O
for,O
analysis,O
.,O
During,O
the,O
study,O
",",O
vitamin,B-Entity
B12,I-Entity
and,O
folate,I-Entity
levels,O
were,O
significantly,O
higher,O
in,O
group,O
II,O
patients,O
;,O
however,O
",",O
no,O
differences,O
in,O
hemoglobin,O
",",O
hematocrit,O
",",O
mean,O
corpuscular,O
volume,O
",",O
and,O
white,O
-,O
cell,O
",",O
neutrophil,O
and,O
platelet,O
counts,O
were,O
observed,O
between,O
groups,O
at,O
3,O
",",O
6,O
",",O
9,O
and,O
12,O
months,O
.,O
Severe,O
hematologic,O
toxicity,I-Entity
(,O
neutrophil,O
count,O
<,O
1000/mm3,O
and/or,O
hemoglobin,O
<,O
8,O
g,O
/,O
dl,O
),O
occurred,O
in,O
4,O
patients,O
assigned,O
to,O
group,O
I,O
and,O
7,O
assigned,O
to,O
group,O
II,O
.,O
There,O
was,O
no,O
correlation,O
between,O
vitamin,B-Entity
B12,I-Entity
or,O
folate,I-Entity
levels,O
and,O
development,O
of,O
myelosuppression,I-Entity
.,O
Vitamin,B-Entity
B12,I-Entity
and,O
folinic,B-Entity
acid,I-Entity
supplementation,O
of,O
ZDV,I-Entity
therapy,O
does,O
not,O
seem,O
useful,O
in,O
preventing,O
or,O
reducing,O
ZDV,I-Entity
-,O
induced,O
myelotoxicity,I-Entity
in,O
the,O
overall,O
treated,O
population,O
",",O
although,O
a,O
beneficial,O
effect,O
in,O
certain,O
subgroups,O
of,O
patients,O
can,O
not,O
be,O
excluded,O
.,O
Acute,O
confusion,I-Entity
induced,O
by,O
a,O
high,O
-,O
dose,O
infusion,O
of,O
5-fluorouracil,I-Entity
and,O
folinic,B-Entity
acid,I-Entity
.,O
A,O
61-year,O
-,O
old,O
man,O
was,O
treated,O
with,O
combination,O
chemotherapy,O
incorporating,O
cisplatinum,I-Entity
",",O
etoposide,I-Entity
",",O
high,O
-,O
dose,O
5-fluorouracil,I-Entity
(,O
"2,250",O
mg,O
/,O
m2/24,O
hours,O
),O
and,O
folinic,B-Entity
acid,I-Entity
for,O
an,O
inoperable,O
gastric,B-Entity
adenocarcinoma,I-Entity
.,O
He,O
developed,O
acute,O
neurologic,O
symptoms,O
of,O
mental,O
confusion,I-Entity
",",O
disorientation,I-Entity
and,O
irritability,I-Entity
",",O
and,O
then,O
lapsed,O
into,O
a,O
deep,O
coma,I-Entity
",",O
lasting,O
for,O
approximately,O
40,O
hours,O
during,O
the,O
first,O
dose,O
(,O
day,O
2,O
),O
of,O
5-fluorouracil,I-Entity
and,O
folinic,B-Entity
acid,I-Entity
infusion,O
.,O
This,O
complication,O
reappeared,O
on,O
day,O
25,O
during,O
the,O
second,O
dose,O
of,O
5-fluorouracil,I-Entity
and,O
folinic,B-Entity
acid,I-Entity
",",O
which,O
were,O
then,O
the,O
only,O
drugs,O
given,O
.,O
Because,O
folinic,B-Entity
acid,I-Entity
was,O
unlikely,O
to,O
be,O
associated,O
with,O
this,O
condition,O
",",O
neurotoxicity,I-Entity
due,O
to,O
high,O
-,O
dose,O
5-fluorouracil,I-Entity
was,O
highly,O
suspected,O
.,O
The,O
pathogenesis,O
of,O
5-fluorouracil,I-Entity
neurotoxicity,I-Entity
may,O
be,O
due,O
to,O
a,O
Krebs,O
cycle,O
blockade,O
by,O
fluoroacetate,I-Entity
and,O
fluorocitrate,I-Entity
",",O
thiamine,I-Entity
deficiency,O
",",O
or,O
dihydrouracil,I-Entity
dehydrogenase,O
deficiency,O
.,O
High,O
-,O
dose,O
5-fluorouracil,I-Entity
/,O
folinic,B-Entity
acid,I-Entity
infusion,O
therapy,O
has,O
recently,O
become,O
a,O
popular,O
regimen,O
for,O
various,O
cancers,I-Entity
.,O
Effect,O
of,O
switching,O
carbamazepine,I-Entity
to,O
oxcarbazepine,I-Entity
on,O
the,O
plasma,O
levels,O
of,O
neuroleptics,O
.,O
Carbamazepine,I-Entity
was,O
switched,O
to,O
its,O
10-keto,O
analogue,O
oxcarbazepine,I-Entity
among,O
six,O
difficult,O
-,O
to,O
-,O
treat,O
schizophrenic,I-Entity
or,O
organic,B-Entity
psychotic,I-Entity
patients,O
using,O
concomitantly,O
haloperidol,I-Entity
",",O
chlorpromazine,I-Entity
or,O
clozapine,I-Entity
.,O
This,O
change,O
resulted,O
within,O
2,O
-,O
4,O
weeks,O
in,O
the,O
50,O
-,O
200%,O
increase,O
in,O
the,O
plasma,O
levels,O
of,O
these,O
neuroleptics,O
and,O
the,O
appearance,O
of,O
extrapyramidal,B-Entity
symptoms,I-Entity
.,O
The,O
results,O
of,O
this,O
case,O
report,O
support,O
the,O
idea,O
that,O
in,O
contrast,O
with,O
carbamazepine,I-Entity
oxcarbazepine,I-Entity
does,O
not,O
induce,O
the,O
hepatic,O
microsomal,O
enzyme,O
systems,O
regulating,O
the,O
inactivation,O
of,O
antipsychotic,O
drugs,O
.,O
Erythema,B-Entity
multiforme,I-Entity
and,O
hypersensitivity,B-Entity
myocarditis,I-Entity
caused,O
by,O
ampicillin,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
erythema,B-Entity
multiforme,I-Entity
and,O
hypersensitivity,B-Entity
myocarditis,I-Entity
caused,O
by,O
ampicillin,I-Entity
.,O
A,O
13-year,O
-,O
old,O
boy,O
was,O
treated,O
with,O
ampicillin,I-Entity
and,O
gentamicin,I-Entity
because,O
of,O
suspected,O
septicemia,I-Entity
.,O
Medications,O
were,O
discontinued,O
when,O
erythema,B-Entity
multiforme,I-Entity
and,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
caused,O
by,O
myocarditis,I-Entity
occurred,O
.,O
The,O
patient,O
was,O
treated,O
with,O
methylprednisolone,I-Entity
and,O
gradually,O
improved,O
.,O
Macrophage,O
-,O
migration,O
inhibition,O
(,O
MIF,O
),O
test,O
with,O
ampicillin,I-Entity
was,O
positive,O
.,O
After,O
most,O
infections,I-Entity
causing,O
erythema,B-Entity
multiforme,I-Entity
and,O
myocarditis,I-Entity
were,O
ruled,O
out,O
",",O
a,O
drug,B-Entity
-,I-Entity
induced,I-Entity
allergic,I-Entity
reaction,I-Entity
was,O
suspected,O
.,O
Positive,O
MIF,O
test,O
for,O
ampicillin,I-Entity
showed,O
sensitization,O
of,O
the,O
patient,O
's,O
lymphocytes,O
to,O
ampicillin,I-Entity
.,O
Hypersensitivity,B-Entity
myocarditis,I-Entity
is,O
a,O
rare,O
and,O
dangerous,O
manifestation,O
of,O
allergy,I-Entity
to,O
penicillins,I-Entity
.,O
Immediate,O
allergic,B-Entity
reactions,I-Entity
to,O
amoxicillin,I-Entity
.,O
A,O
large,O
group,O
of,O
patients,O
with,O
suspected,O
allergic,B-Entity
reactions,I-Entity
to,O
beta,B-Entity
-,I-Entity
lactam,I-Entity
antibiotics,O
was,O
evaluated,O
.,O
A,O
detailed,O
clinical,O
history,O
",",O
together,O
with,O
skin,O
tests,O
",",O
RAST,O
(,O
radioallergosorbent,O
test,O
),O
",",O
and,O
controlled,O
challenge,O
tests,O
",",O
was,O
used,O
to,O
establish,O
whether,O
patients,O
allergic,I-Entity
to,O
beta,B-Entity
-,I-Entity
lactam,I-Entity
antibiotics,O
had,O
selective,O
immediate,O
allergic,I-Entity
responses,O
to,O
amoxicillin,I-Entity
(,O
AX,I-Entity
),O
or,O
were,O
cross,O
-,O
reacting,O
with,O
other,O
penicillin,I-Entity
derivatives,O
.,O
Skin,O
tests,O
were,O
performed,O
with,O
benzylpenicilloyl,B-Entity
-,I-Entity
poly,I-Entity
-,I-Entity
L,I-Entity
-,I-Entity
lysine,I-Entity
(,O
BPO,B-Entity
-,I-Entity
PLL,I-Entity
),O
",",O
benzylpenicilloate,I-Entity
",",O
benzylpenicillin,I-Entity
(,O
PG,I-Entity
),O
",",O
ampicillin,I-Entity
(,O
AMP,I-Entity
),O
",",O
and,O
AX,I-Entity
.,O
RAST,O
for,O
BPO,B-Entity
-,I-Entity
PLL,I-Entity
and,O
AX,I-Entity
-,O
PLL,O
was,O
done,O
.,O
When,O
both,O
skin,O
test,O
and,O
RAST,O
for,O
BPO,I-Entity
were,O
negative,O
",",O
single,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
challenge,O
tests,O
were,O
done,O
to,O
ensure,O
tolerance,O
of,O
PG,I-Entity
or,O
sensitivity,O
to,O
AX,I-Entity
.,O
A,O
total,O
of,O
177,O
patients,O
were,O
diagnosed,O
as,O
allergic,I-Entity
to,O
beta,B-Entity
-,I-Entity
lactam,I-Entity
antibiotics,O
.,O
We,O
selected,O
the,O
54,O
(,O
30.5%,O
),O
cases,O
of,O
immediate,O
AX,I-Entity
allergy,I-Entity
with,O
good,O
tolerance,O
of,O
PG,I-Entity
.,O
Anaphylaxis,I-Entity
was,O
seen,O
in,O
37,O
patients,O
(,O
69%,O
),O
",",O
the,O
other,O
17,O
(,O
31%,O
),O
having,O
urticaria,I-Entity
and/or,O
angioedema,I-Entity
.,O
All,O
the,O
patients,O
were,O
skin,O
test,O
negative,O
to,O
BPO,I-Entity
;,O
49,O
of,O
51,O
(,O
96%,O
),O
were,O
also,O
negative,O
to,O
MDM,I-Entity
",",O
and,O
44,O
of,O
46,O
(,O
96%,O
),O
to,O
PG,I-Entity
.,O
Skin,O
tests,O
with,O
AX,I-Entity
were,O
positive,O
in,O
34,O
(,O
63%,O
),O
patients,O
.,O
RAST,O
was,O
positive,O
for,O
AX,I-Entity
in,O
22,O
patients,O
(,O
41%,O
),O
and,O
to,O
BPO,I-Entity
in,O
just,O
5,O
(,O
9%,O
),O
.,O
None,O
of,O
the,O
sera,O
with,O
negative,O
RAST,O
for,O
AX,I-Entity
were,O
positive,O
to,O
BPO,I-Entity
.,O
Challenge,O
tests,O
with,O
AX,I-Entity
were,O
performed,O
in,O
23,O
subjects,O
(,O
43%,O
),O
to,O
establish,O
the,O
diagnosis,O
of,O
immediate,O
allergic,B-Entity
reaction,I-Entity
to,O
AX,I-Entity
",",O
and,O
in,O
15,O
cases,O
(,O
28%,O
),O
both,O
skin,O
test,O
and,O
RAST,O
for,O
AX,I-Entity
were,O
negative,O
.,O
PG,I-Entity
was,O
well,O
tolerated,O
by,O
all,O
54,O
patients,O
.,O
We,O
describe,O
the,O
largest,O
group,O
of,O
AX,I-Entity
-,O
allergic,I-Entity
patients,O
who,O
have,O
tolerated,O
PG,I-Entity
reported,O
so,O
far,O
.,O
Diagnosis,O
of,O
these,O
patients,O
can,O
be,O
achieved,O
only,O
if,O
specific,O
AX,I-Entity
-,O
related,O
reagents,O
are,O
employed,O
.,O
Persistent,O
paralysis,I-Entity
after,O
prolonged,O
use,O
of,O
atracurium,I-Entity
in,O
the,O
absence,O
of,O
corticosteroids,O
.,O
Reports,O
of,O
persistent,O
paralysis,I-Entity
after,O
the,O
discontinuance,O
of,O
these,O
drugs,O
have,O
most,O
often,O
involved,O
aminosteroid,O
-,O
based,O
NMBAs,O
such,O
as,O
vecuronium,B-Entity
bromide,I-Entity
",",O
especially,O
when,O
used,O
in,O
conjunction,O
with,O
corticosteroids,O
.,O
Atracurium,B-Entity
besylate,I-Entity
",",O
a,O
short,O
-,O
acting,O
benzylisoquinolinium,I-Entity
NMBA,O
that,O
is,O
eliminated,O
independently,O
of,O
renal,O
or,O
hepatic,O
function,O
",",O
has,O
also,O
been,O
associated,O
with,O
persistent,O
paralysis,I-Entity
",",O
but,O
only,O
when,O
used,O
with,O
corticosteroids,O
.,O
We,O
report,O
a,O
case,O
of,O
atracurium,I-Entity
-,O
related,O
paralysis,I-Entity
persisting,O
for,O
approximately,O
50,O
hours,O
in,O
a,O
patient,O
who,O
was,O
not,O
treated,O
with,O
corticosteroids,O
.,O
Habitual,O
use,O
of,O
acetaminophen,I-Entity
as,O
a,O
risk,O
factor,O
for,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
:,O
a,O
comparison,O
with,O
phenacetin,I-Entity
.,O
Six,O
epidemiologic,O
studies,O
in,O
the,O
United,O
States,O
and,O
Europe,O
indicate,O
that,O
habitual,O
use,O
of,O
phenacetin,I-Entity
is,O
associated,O
with,O
the,O
development,O
of,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
and,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
(,O
ESRD,I-Entity
),O
",",O
with,O
a,O
relative,O
risk,O
in,O
the,O
range,O
of,O
4,O
to,O
19,O
.,O
As,O
a,O
result,O
of,O
these,O
and,O
other,O
studies,O
",",O
phenacetin,I-Entity
has,O
now,O
been,O
withdrawn,O
from,O
the,O
market,O
in,O
most,O
countries,O
.,O
However,O
",",O
three,O
case,O
control,O
studies,O
",",O
one,O
each,O
in,O
North,O
Carolina,O
",",O
northern,O
Maryland,O
",",O
and,O
West,O
Berlin,O
",",O
Germany,O
",",O
showed,O
that,O
habitual,O
use,O
of,O
acetaminophen,I-Entity
is,O
also,O
associated,O
with,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
and,O
ESRD,I-Entity
",",O
with,O
a,O
relative,O
risk,O
in,O
the,O
range,O
of,O
2,O
to,O
4,O
.,O
These,O
studies,O
suggest,O
that,O
both,O
phenacetin,I-Entity
and,O
acetaminophen,I-Entity
may,O
contribute,O
to,O
the,O
burden,O
of,O
ESRD,I-Entity
",",O
with,O
the,O
risk,O
of,O
the,O
latter,O
being,O
somewhat,O
less,O
than,O
that,O
of,O
the,O
former,O
.,O
This,O
apparent,O
difference,O
in,O
risk,O
may,O
not,O
be,O
due,O
to,O
differences,O
in,O
nephrotoxic,I-Entity
potential,O
of,O
the,O
drugs,O
themselves,O
.,O
A,O
lower,O
relative,O
risk,O
would,O
be,O
expected,O
for,O
acetaminophen,I-Entity
if,O
the,O
risk,O
of,O
both,O
drugs,O
in,O
combination,O
with,O
other,O
analgesics,O
was,O
higher,O
than,O
the,O
risk,O
of,O
either,O
agent,O
alone,O
.,O
Thus,O
",",O
acetaminophen,I-Entity
has,O
been,O
used,O
both,O
as,O
a,O
single,O
agent,O
and,O
in,O
combination,O
with,O
other,O
analgesics,O
",",O
whereas,O
phenacetin,I-Entity
was,O
available,O
only,O
in,O
combinations,O
.,O
The,O
possibility,O
that,O
habitual,O
use,O
of,O
acetaminophen,I-Entity
alone,O
increases,O
the,O
risk,O
of,O
ESRD,I-Entity
has,O
not,O
been,O
clearly,O
demonstrated,O
",",O
but,O
can,O
not,O
be,O
dismissed,O
.,O
Reduction,O
of,O
heparan,B-Entity
sulphate,I-Entity
-,O
associated,O
anionic,O
sites,O
in,O
the,O
glomerular,O
basement,O
membrane,O
of,O
rats,O
with,O
streptozotocin,I-Entity
-,O
induced,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
Heparan,B-Entity
sulphate,I-Entity
-,O
associated,O
anionic,O
sites,O
in,O
the,O
glomerular,O
basement,O
membrane,O
were,O
studied,O
in,O
rats,O
8,O
months,O
after,O
induction,O
of,O
diabetes,I-Entity
by,O
streptozotocin,I-Entity
and,O
in,O
age-,O
adn,O
sex,O
-,O
matched,O
control,O
rats,O
",",O
employing,O
the,O
cationic,O
dye,O
cuprolinic,B-Entity
blue,I-Entity
.,O
The,O
heparan,B-Entity
sulphate,I-Entity
specificity,O
of,O
the,O
cuprolinic,B-Entity
blue,I-Entity
staining,O
was,O
demonstrated,O
by,O
glycosaminoglycan,I-Entity
-,O
degrading,O
enzymes,O
",",O
showing,O
that,O
pretreatment,O
of,O
the,O
sections,O
with,O
heparitinase,O
abolished,O
all,O
staining,O
",",O
whereas,O
chondroitinase,O
ABC,O
had,O
no,O
effect,O
.,O
The,O
majority,O
of,O
anionic,O
sites,O
(,O
74%,O
in,O
diabetic,I-Entity
and,O
81%,O
in,O
control,O
rats,O
),O
were,O
found,O
within,O
the,O
lamina,O
rara,O
externa,O
of,O
the,O
glomerular,O
basement,O
membrane,O
.,O
A,O
minority,O
of,O
anionic,O
sites,O
were,O
scattered,O
throughout,O
the,O
lamina,O
densa,O
and,O
lamina,O
rara,O
interna,O
",",O
and,O
were,O
significantly,O
smaller,O
than,O
those,O
in,O
the,O
lamina,O
rara,O
externa,O
of,O
the,O
glomerular,O
basement,O
membrane,O
(,O
p<0.001,O
and,O
p<0.01,O
for,O
diabetic,I-Entity
and,O
control,O
rats,O
",",O
respectively,O
),O
.,O
Diabetic,I-Entity
rats,O
progressively,O
developed,O
albuminuria,I-Entity
reaching,O
40.3,O
(,O
32.2,O
-,O
62.0,O
),O
At,O
the,O
same,O
time,O
",",O
the,O
number,O
of,O
heparan,B-Entity
sulphate,I-Entity
anionic,O
sites,O
and,O
the,O
total,O
anionic,O
site,O
surface,O
(,O
number,O
of,O
anionic,O
sites,O
x,O
mean,O
anionic,O
site,O
surface,O
),O
in,O
the,O
lamina,O
rara,O
externa,O
of,O
the,O
glomerular,O
basement,O
membrane,O
was,O
reduced,O
by,O
19%,O
(,O
p<0.021,O
),O
and,O
by,O
26%,O
(,O
p<0.02,O
),O
",",O
respectively,O
.,O
We,O
conclude,O
that,O
in,O
streptozotocin,I-Entity
-,O
diabetic,I-Entity
rats,O
with,O
an,O
increased,O
urinary,O
albumin,O
excretion,O
",",O
a,O
reduced,O
heparan,B-Entity
sulphate,I-Entity
charge,O
barrier,O
/,O
density,O
is,O
found,O
at,O
the,O
lamina,O
rara,O
externa,O
of,O
the,O
glomerular,O
basement,O
membrane,O
.,O
Effect,O
of,O
some,O
anticancer,O
drugs,O
and,O
combined,O
chemotherapy,O
on,O
renal,B-Entity
toxicity,I-Entity
.,O
The,O
nephrotoxic,I-Entity
action,O
of,O
anticancer,O
drugs,O
such,O
as,O
nitrogranulogen,I-Entity
(,O
NG,I-Entity
),O
",",O
methotrexate,I-Entity
(,O
MTX,I-Entity
),O
",",O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
and,O
cyclophosphamide,I-Entity
(,O
CY,I-Entity
),O
administered,O
alone,O
or,O
in,O
combination,O
[,O
MTX,I-Entity
+,O
5-FU,I-Entity
+,O
CY,I-Entity
(,O
CMF,O
),O
],O
was,O
evaluated,O
in,O
experiments,O
on,O
Wistar,O
rats,O
.,O
After,O
drug,O
administration,O
",",O
creatinine,I-Entity
concentrations,O
in,O
the,O
plasma,O
and,O
in,O
the,O
urine,O
of,O
the,O
rats,O
were,O
determined,O
",",O
as,O
well,O
as,O
creatinine,I-Entity
clearance,O
.,O
After,O
MTX,I-Entity
administration,O
a,O
significant,O
increase,O
(,O
p,O
=,O
0.0228,O
),O
in,O
the,O
plasma,O
creatinine,I-Entity
concentration,O
and,O
a,O
significant,O
(,O
p,O
=,O
0.0001,O
),O
decrease,O
in,O
creatinine,I-Entity
clearance,O
was,O
noted,O
compared,O
to,O
controls,O
.,O
After,O
the,O
administration,O
of,O
NG,I-Entity
",",O
5-FU,I-Entity
and,O
CY,I-Entity
neither,O
a,O
statistically,O
significant,O
increase,O
in,O
creatinine,I-Entity
concentration,O
nor,O
an,O
increase,O
in,O
creatinine,I-Entity
clearance,O
was,O
observed,O
compared,O
to,O
the,O
group,O
receiving,O
no,O
cytostatics,O
.,O
Following,O
polytherapy,O
according,O
to,O
the,O
CMF,O
regimen,O
",",O
a,O
statistically,O
significant,O
decrease,O
(,O
p,O
=,O
0.0343,O
),O
in,O
creatinine,I-Entity
clearance,O
was,O
found,O
",",O
but,O
creatinine,I-Entity
concentration,O
did,O
not,O
increase,O
significantly,O
compared,O
to,O
controls,O
.,O
CY,I-Entity
caused,O
hemorrhagic,B-Entity
cystitis,I-Entity
in,O
40%,O
of,O
rats,O
",",O
but,O
it,O
did,O
not,O
cause,O
this,O
complication,O
when,O
combined,O
with,O
5-FU,I-Entity
and,O
MTX,I-Entity
.,O
Histologic,O
changes,O
were,O
found,O
in,O
rat,O
kidneys,O
after,O
administration,O
of,O
MTX,I-Entity
",",O
CY,I-Entity
and,O
NG,I-Entity
",",O
while,O
no,O
such,O
change,O
was,O
observed,O
after,O
5-FU,I-Entity
and,O
joint,O
administration,O
of,O
MTX,I-Entity
+,O
5-FU,I-Entity
+,O
CY,I-Entity
compared,O
to,O
controls,O
.,O
Our,O
studies,O
indicate,O
that,O
nephrotoxicity,I-Entity
of,O
MTX,I-Entity
+,O
5-FU,I-Entity
+,O
CY,I-Entity
administered,O
jointly,O
is,O
lower,O
than,O
in,O
monotherapy,O
.,O
Lithium,I-Entity
-,O
associated,O
cognitive,B-Entity
and,I-Entity
functional,I-Entity
deficits,I-Entity
reduced,O
by,O
a,O
switch,O
to,O
divalproex,B-Entity
sodium,I-Entity
:,O
a,O
case,O
series,O
.,O
Lithium,I-Entity
remains,O
a,O
first,O
-,O
line,O
treatment,O
for,O
the,O
acute,O
and,O
maintenance,O
treatment,O
of,O
bipolar,B-Entity
disorder,I-Entity
.,O
Although,O
much,O
has,O
been,O
written,O
about,O
the,O
management,O
of,O
the,O
more,O
common,O
adverse,O
effects,O
of,O
lithium,I-Entity
",",O
such,O
as,O
polyuria,I-Entity
and,O
tremor,I-Entity
",",O
more,O
subtle,O
lithium,I-Entity
side,O
effects,O
such,O
as,O
cognitive,B-Entity
deficits,I-Entity
",",O
loss,B-Entity
of,I-Entity
creativity,I-Entity
",",O
and,O
functional,B-Entity
impairments,I-Entity
remain,O
understudied,O
.,O
This,O
report,O
summarizes,O
our,O
experience,O
in,O
switching,O
bipolar,I-Entity
patients,O
from,O
lithium,I-Entity
to,O
divalproex,B-Entity
sodium,I-Entity
to,O
alleviate,O
such,O
cognitive,B-Entity
and,I-Entity
functional,I-Entity
impairments,I-Entity
.,O
We,O
report,O
seven,O
cases,O
where,O
substitution,O
of,O
lithium,I-Entity
",",O
either,O
fully,O
or,O
partially,O
",",O
with,O
divalproex,B-Entity
sodium,I-Entity
was,O
extremely,O
helpful,O
in,O
reducing,O
the,O
cognitive,B-Entity
",",I-Entity
motivational,I-Entity
",",I-Entity
or,I-Entity
creative,I-Entity
deficits,I-Entity
attributed,O
to,O
lithium,I-Entity
in,O
our,O
bipolar,I-Entity
patients,O
.,O
In,O
this,O
preliminary,O
report,O
",",O
divalproex,B-Entity
sodium,I-Entity
was,O
a,O
superior,O
alternative,O
to,O
lithium,I-Entity
in,O
bipolar,I-Entity
patients,O
experiencing,O
cognitive,B-Entity
deficits,I-Entity
",",O
loss,B-Entity
of,I-Entity
creativity,I-Entity
",",O
and,O
functional,B-Entity
impairments,I-Entity
.,O
Treatment,O
of,O
previously,O
treated,O
metastatic,O
breast,B-Entity
cancer,I-Entity
by,O
mitoxantrone,I-Entity
and,O
48-hour,O
continuous,O
infusion,O
of,O
high,O
-,O
dose,O
5-FU,I-Entity
and,O
leucovorin,I-Entity
(,O
MFL,I-Entity
),O
:,O
low,O
palliative,O
benefit,O
and,O
high,O
treatment,O
-,O
related,O
toxicity,I-Entity
.,O
For,O
previously,O
treated,O
advanced,O
breast,B-Entity
cancer,I-Entity
",",O
there,O
is,O
no,O
standard,O
second,O
-,O
line,O
therapy,O
.,O
Combination,O
chemotherapy,O
with,O
mitoxantrone,I-Entity
",",O
high,O
-,O
dose,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
and,O
leucovorin,I-Entity
(,O
MFL,B-Entity
regimen,I-Entity
),O
had,O
been,O
reported,O
as,O
an,O
effective,O
and,O
well,O
tolerated,O
regimen,O
.,O
From,O
October,O
1993,O
to,O
November,O
1995,O
",",O
we,O
treated,O
13,O
patients,O
with,O
previously,O
chemotherapy,O
-,O
treated,O
metastatic,O
breast,B-Entity
cancer,I-Entity
by,O
mitoxantrone,I-Entity
",",O
12,O
mg,O
/,O
m2,O
",",O
on,O
day,O
1,O
and,O
continuous,O
infusion,O
of,O
5-FU,I-Entity
",",O
3000,O
mg,O
/,O
m2,O
",",O
together,O
with,O
leucovorin,I-Entity
",",O
300,O
mg,O
/,O
m2,O
",",O
for,O
48,O
h,O
from,O
day,O
1,O
to,O
2,O
.,O
Seven,O
patients,O
had,O
been,O
treated,O
with,O
anthracycline,I-Entity
.,O
Median,O
number,O
of,O
courses,O
of,O
MFL,B-Entity
regimen,I-Entity
given,O
was,O
six,O
and,O
the,O
median,O
cumulative,O
dose,O
of,O
mitoxantrone,I-Entity
was,O
68.35,O
mg,O
/,O
m2,O
.,O
Major,O
toxicities,I-Entity
were,O
cardiotoxicity,I-Entity
and,O
leukopenia,I-Entity
.,O
Eight,O
patients,O
were,O
dead,O
in,O
the,O
last,O
follow,O
-,O
up,O
;,O
two,O
of,O
them,O
died,O
of,O
treatment,O
-,O
related,O
toxicity,I-Entity
.,O
The,O
MFL,B-Entity
regimen,I-Entity
achieves,O
little,O
palliative,O
benefit,O
and,O
induces,O
severe,O
toxicity,I-Entity
at,O
a,O
fairly,O
high,O
rate,O
.,O
Administration,O
of,O
this,O
regimen,O
to,O
breast,B-Entity
cancer,I-Entity
patients,O
who,O
have,O
been,O
treated,O
by,O
chemotherapy,O
and,O
those,O
with,O
impaired,B-Entity
heart,I-Entity
function,I-Entity
requires,O
careful,O
attention,O
.,O
Upregulation,O
of,O
the,O
expression,O
of,O
vasopressin,I-Entity
gene,O
in,O
the,O
paraventricular,O
and,O
supraoptic,O
nuclei,O
of,O
the,O
lithium,I-Entity
-,O
induced,O
diabetes,B-Entity
insipidus,I-Entity
rat,O
.,O
The,O
expression,O
of,O
arginine,B-Entity
vasopressin,I-Entity
(,O
AVP,I-Entity
),O
gene,O
in,O
the,O
paraventricular,O
(,O
PVN,O
),O
and,O
supraoptic,O
nuclei,O
(,O
SON,O
),O
was,O
investigated,O
in,O
rats,O
with,O
lithium,I-Entity
(,O
Li)-induced,I-Entity
polyuria,I-Entity
",",O
using,O
in,O
situ,O
hybridization,O
histochemistry,O
and,O
radioimmunoassay,O
.,O
The,O
male,O
Wistar,O
rats,O
consuming,O
a,O
diet,O
that,O
contained,O
LiCl,I-Entity
(,O
60,O
mmol,O
/,O
kg,O
),O
for,O
4,O
weeks,O
developed,O
marked,O
polyuria,I-Entity
.,O
The,O
Li,I-Entity
-,O
treated,O
rats,O
produced,O
a,O
large,O
volume,O
of,O
hypotonic,O
urine,O
with,O
low,O
ionic,O
concentrations,O
.,O
Plasma,O
sodium,I-Entity
concentrations,O
were,O
found,O
to,O
be,O
slightly,O
increased,O
in,O
the,O
Li,I-Entity
-,O
treated,O
rats,O
compared,O
with,O
those,O
in,O
controls,O
.,O
Plasma,O
concentration,O
of,O
AVP,I-Entity
and,O
transcripts,O
of,O
AVP,I-Entity
gene,O
in,O
the,O
PVN,O
and,O
SON,O
were,O
significantly,O
increased,O
in,O
the,O
Li,I-Entity
-,O
treated,O
rats,O
compared,O
with,O
controls,O
.,O
These,O
results,O
suggest,O
that,O
dehydration,I-Entity
and/or,O
the,O
activation,O
of,O
visceral,O
afferent,O
inputs,O
may,O
contribute,O
to,O
the,O
elevation,O
of,O
plasma,O
AVP,I-Entity
and,O
the,O
upregulation,O
of,O
AVP,I-Entity
gene,O
expression,O
in,O
the,O
PVN,O
and,O
the,O
SON,O
of,O
the,O
Li,I-Entity
-,O
induced,O
diabetes,B-Entity
insipidus,I-Entity
rat,O
.,O
Suxamethonium,I-Entity
-,O
induced,O
cardiac,B-Entity
arrest,I-Entity
and,O
death,I-Entity
following,O
5,O
days,O
of,O
immobilization,O
.,O
The,O
present,O
report,O
describes,O
a,O
case,O
of,O
cardiac,B-Entity
arrest,I-Entity
and,O
subsequent,O
death,I-Entity
as,O
a,O
result,O
of,O
hyperkalaemia,I-Entity
following,O
the,O
use,O
of,O
suxamethonium,I-Entity
in,O
a,O
23-year,O
-,O
old,O
Malawian,O
woman,O
.,O
Five,O
days,O
after,O
the,O
onset,O
of,O
the,O
symptoms,O
of,O
meningitis,I-Entity
",",O
the,O
patient,O
aspirated,O
stomach,O
contents,O
and,O
needed,O
endotracheal,O
intubation,O
.,O
Forty,O
seconds,O
after,O
injection,O
of,O
suxamethonium,I-Entity
",",O
bradycardia,I-Entity
and,O
cardiac,B-Entity
arrest,I-Entity
occurred,O
.,O
The,O
serum,O
level,O
of,O
potassium,I-Entity
was,O
observed,O
to,O
be,O
8.4,O
mequiv,O
Apart,O
from,O
the,O
reduction,O
in,O
the,O
patient,O
's,O
level,O
of,O
consciousness,O
",",O
there,O
were,O
no,O
signs,O
of,O
motor,O
neurone,O
damage,O
or,O
of,O
any,O
of,O
the,O
other,O
known,O
predisposing,O
conditions,O
for,O
hyperkalaemia,I-Entity
following,O
the,O
administration,O
of,O
suxamethonium,I-Entity
.,O
It,O
is,O
postulated,O
that,O
her,O
death,I-Entity
was,O
caused,O
by,O
hypersensitivity,I-Entity
to,O
suxamethonium,I-Entity
",",O
associated,O
with,O
her,O
5-day,O
immobilization,O
.,O
An,O
unusual,O
toxic,O
reaction,O
to,O
axillary,O
block,O
by,O
mepivacaine,I-Entity
with,O
adrenaline,I-Entity
.,O
An,O
increase,B-Entity
in,I-Entity
blood,I-Entity
pressure,I-Entity
",",O
accompanied,O
by,O
atrial,B-Entity
fibrillation,I-Entity
",",O
agitation,I-Entity
",",O
incomprehensible,B-Entity
shouts,I-Entity
and,O
loss,B-Entity
of,I-Entity
consciousness,I-Entity
",",O
was,O
observed,O
in,O
an,O
elderly,O
",",O
ASA,O
classification,O
group,O
II,O
",",O
cardiovascularly,O
medicated,O
male,O
",",O
12,O
min,O
after,O
performance,O
of,O
axillary,O
block,O
with,O
mepivacaine,I-Entity
850,O
mg,O
containing,O
adrenaline,I-Entity
0.225,O
mg,O
",",O
for,O
correction,O
of,O
Dupuytren,B-Entity
's,I-Entity
contracture,I-Entity
.,O
After,O
intravenous,O
administration,O
of,O
labetalol,I-Entity
",",O
metoprolol,I-Entity
and,O
midazolam,I-Entity
the,O
patient,O
's,O
condition,O
improved,O
",",O
and,O
15,O
min,O
later,O
he,O
woke,O
up,O
.,O
The,O
block,O
was,O
successful,O
and,O
surgery,O
was,O
conducted,O
as,O
scheduled,O
despite,O
persisting,O
atrial,B-Entity
fibrillation,I-Entity
.,O
Both,O
the,O
temporal,O
relationship,O
of,O
events,O
and,O
the,O
response,O
to,O
treatment,O
suggest,O
that,O
a,O
rapid,O
systemic,O
absorption,O
of,O
mepivacaine,I-Entity
with,O
adrenaline,I-Entity
and/or,O
interaction,O
of,O
these,O
drugs,O
with,O
the,O
patient,O
's,O
cardiovascular,O
medications,O
were,O
responsible,O
for,O
the,O
perioperative,O
complications,O
.,O
Clinical,O
and,O
histopathologic,O
examination,O
of,O
renal,O
allografts,O
treated,O
with,O
tacrolimus,I-Entity
(,O
FK506,I-Entity
),O
for,O
at,O
least,O
one,O
year,O
.,O
We,O
clinically,O
and,O
pathologically,O
analyzed,O
renal,O
allografts,O
from,O
1,O
9,O
renal,O
transplant,O
patients,O
treated,O
with,O
tacrolimus,I-Entity
(,O
FK506,I-Entity
),O
for,O
more,O
than,O
1,O
year,O
.,O
The,O
main,O
pathologic,O
diagnoses,O
(,O
some,O
overlap,O
),O
were,O
acute,O
rejection,O
(,O
AR,O
;,O
n,O
=,O
4,O
),O
",",O
chronic,O
rejection,O
(,O
CR,O
;,O
n=5,O
),O
",",O
AR+CR,O
(,O
n,O
=,O
4,O
),O
",",O
recurrent,O
IgA,B-Entity
nephropathy,I-Entity
(,O
n,O
=,O
5,O
),O
",",O
normal,O
findings,O
(,O
n,O
=,O
2,O
),O
",",O
minimal,O
-,O
type,O
chronic,O
FK506,I-Entity
nephropathy,I-Entity
(,O
n,O
=,O
9,O
),O
",",O
and,O
mild,O
-,O
type,O
FK506,I-Entity
nephropathy,I-Entity
(,O
n,O
=,O
11,O
),O
.,O
Of,O
the,O
nonepisode,O
biopsies,O
",",O
7,O
and,O
4,O
biopsies,O
showed,O
minimal,O
-,O
type,O
and,O
mild,O
-,O
type,O
chronic,O
FK506,I-Entity
nephropathy,I-Entity
",",O
respectively,O
.,O
Chronic,O
FK506,I-Entity
nephropathy,I-Entity
consisted,O
of,O
rough,O
and,O
foamy,O
tubular,O
vacuolization,O
(,O
5,O
biopsies,O
),O
",",O
arteriolopathy,O
(,O
angiodegeneration,O
of,O
the,O
arteriolar,O
wall,O
;,O
20,O
biopsies,O
),O
",",O
focal,B-Entity
segmental,I-Entity
glomerulosclerosis,I-Entity
(,O
4,O
biopsies,O
),O
and,O
the,O
striped,O
form,O
of,O
interstitial,B-Entity
fibrosis,I-Entity
(,O
11,O
biopsies,O
),O
.,O
The,O
serum,O
creatinine,I-Entity
levels,O
of,O
patients,O
in,O
the,O
mild,O
-,O
type,O
chronic,O
FK506,I-Entity
nephropathy,I-Entity
group,O
",",O
which,O
included,O
7,O
episode,O
biopsies,O
",",O
were,O
statistically,O
higher,O
than,O
those,O
in,O
the,O
minimum,O
-,O
type,O
chronic,O
FK506-nephropathy,I-Entity
group,O
(,O
P,O
This,O
study,O
demonstrates,O
that,O
chronic,O
FK506,I-Entity
nephropathy,I-Entity
consists,O
primarily,O
of,O
arteriolopathy,O
manifesting,O
as,O
insudative,O
hyalinosis,O
of,O
the,O
arteriolar,O
wall,O
",",O
and,O
suggests,O
that,O
mild,O
-,O
type,O
chronic,O
FK506,I-Entity
nephropathy,I-Entity
is,O
a,O
condition,O
which,O
may,O
lead,O
to,O
deterioration,O
of,O
renal,O
allograft,O
function,O
.,O
Memory,O
facilitation,O
and,O
stimulation,O
of,O
endogenous,O
nerve,O
growth,O
factor,O
synthesis,O
by,O
the,O
acetylcholine,I-Entity
releaser,O
PG-9,I-Entity
.,O
The,O
effects,O
of,O
PG-9,I-Entity
(,O
3alpha,B-Entity
-,I-Entity
tropyl,I-Entity
2-(p,I-Entity
-,I-Entity
bromophenyl)propionate,I-Entity
),O
",",O
the,O
acetylcholine,I-Entity
releaser,O
",",O
on,O
memory,O
processes,O
and,O
nerve,O
growth,O
factor,O
(,O
NGF,O
),O
synthesis,O
were,O
evaluated,O
.,O
In,O
the,O
mouse,O
passive,O
-,O
avoidance,O
test,O
",",O
PG-9,I-Entity
(,O
10,O
-,O
30,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
",",O
administered,O
20,O
min,O
before,O
the,O
training,O
session,O
",",O
prevented,O
amnesia,I-Entity
induced,O
by,O
both,O
the,O
non,O
selective,O
antimuscarinic,O
drug,O
scopolamine,I-Entity
and,O
the,O
M1-selective,O
antagonist,O
S-(-)-ET-126,I-Entity
.,O
In,O
the,O
same,O
experimental,O
conditions,O
",",O
PG-9,I-Entity
(,O
5,O
-,O
20,O
microg,O
per,O
mouse,O
",",O
i.c.v,O
.,O
),O
was,O
also,O
able,O
to,O
prevent,O
antimuscarine,O
-,O
induced,O
amnesia,I-Entity
",",O
demonstrating,O
a,O
central,O
localization,O
of,O
the,O
activity,O
.,O
At,O
the,O
highest,O
effective,O
doses,O
",",O
PG-9,I-Entity
did,O
not,O
produce,O
any,O
collateral,O
symptoms,O
as,O
revealed,O
by,O
the,O
Irwin,O
test,O
",",O
and,O
it,O
did,O
not,O
modify,O
spontaneous,O
motility,O
and,O
inspection,O
activity,O
",",O
as,O
revealed,O
by,O
the,O
hole,O
-,O
board,O
test,O
.,O
PG-9,I-Entity
The,O
maximal,O
NGF,O
contents,O
obtained,O
by,O
PG-9,I-Entity
were,O
17.6-fold,O
of,O
the,O
control,O
value,O
.,O
During,O
culture,O
",",O
no,O
morphological,O
changes,O
were,O
found,O
at,O
effective,O
concentrations,O
of,O
PG-9,I-Entity
.,O
The,O
current,O
work,O
indicates,O
the,O
ability,O
of,O
PG-9,I-Entity
to,O
induce,O
beneficial,O
effects,O
on,O
cognitive,O
processes,O
and,O
stimulate,O
activity,O
of,O
NGF,O
synthesis,O
in,O
astroglial,O
cells,O
.,O
Therefore,O
",",O
PG-9,I-Entity
could,O
represent,O
a,O
potential,O
useful,O
drug,O
able,O
to,O
improve,O
the,O
function,O
of,O
impaired,O
cognitive,O
processes,O
.,O
Angioedema,I-Entity
due,O
to,O
ACE,B-Entity
inhibitors,I-Entity
:,O
common,O
and,O
inadequately,O
diagnosed,O
.,O
The,O
estimated,O
incidence,O
of,O
angioedema,I-Entity
during,O
angiotensin,B-Entity
-,I-Entity
converting,I-Entity
enzyme,I-Entity
(,I-Entity
ACE,I-Entity
),I-Entity
inhibitor,I-Entity
treatment,O
is,O
between,O
1,O
and,O
7,O
per,O
thousand,O
patients,O
.,O
Accumulation,O
of,O
atracurium,I-Entity
in,O
the,O
intravenous,O
line,O
led,O
to,O
recurarization,O
after,O
flushing,O
the,O
line,O
in,O
the,O
recovery,O
room,O
.,O
A,O
respiratory,B-Entity
arrest,I-Entity
with,O
severe,O
desaturation,I-Entity
and,O
bradycardia,I-Entity
occurred,O
.,O
Circumstances,O
leading,O
to,O
this,O
event,O
and,O
the,O
mechanisms,O
enabling,O
a,O
neuromuscular,B-Entity
blockade,I-Entity
to,O
occur,O
",",O
following,O
the,O
administration,O
of,O
a,O
small,O
dose,O
of,O
relaxant,O
",",O
are,O
discussed,O
.,O
Recurrent,O
use,O
of,O
newer,O
oral,B-Entity
contraceptives,I-Entity
and,O
the,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
.,O
The,O
epidemiological,O
studies,O
that,O
assessed,O
the,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
(,O
VTE,I-Entity
),O
associated,O
with,O
newer,O
oral,B-Entity
contraceptives,I-Entity
(,O
OC,I-Entity
),O
did,O
not,O
distinguish,O
between,O
patterns,O
of,O
OC,I-Entity
use,O
",",O
namely,O
first,O
-,O
time,O
users,O
",",O
repeaters,O
and,O
switchers,O
.,O
Data,O
from,O
a,O
Transnational,O
case,O
-,O
control,O
study,O
were,O
used,O
to,O
assess,O
the,O
risk,O
of,O
VTE,I-Entity
for,O
the,O
latter,O
patterns,O
of,O
use,O
",",O
while,O
accounting,O
for,O
duration,O
of,O
use,O
.,O
Over,O
the,O
period,O
1993,O
-,O
1996,O
",",O
551,O
cases,O
of,O
VTE,I-Entity
were,O
identified,O
in,O
Germany,O
and,O
the,O
UK,O
along,O
with,O
2066,O
controls,O
.,O
The,O
adjusted,O
rate,O
ratio,O
of,O
VTE,I-Entity
for,O
repeat,O
users,O
of,O
third,O
generation,O
OC,I-Entity
was,O
0.6,O
(,O
95%,O
CI:0.3,O
-,O
1.2,O
),O
relative,O
to,O
repeat,O
users,O
of,O
second,O
generation,O
pills,O
",",O
whereas,O
it,O
was,O
1.3,O
(,O
95%,O
CI:0.7,O
-,O
2.4,O
),O
for,O
switchers,O
from,O
second,O
to,O
third,O
generation,O
pills,O
relative,O
to,O
switchers,O
from,O
third,O
to,O
second,O
generation,O
pills,O
.,O
We,O
conclude,O
that,O
second,O
and,O
third,O
generation,O
agents,O
are,O
associated,O
with,O
equivalent,O
risks,O
of,O
VTE,I-Entity
when,O
the,O
same,O
agent,O
is,O
used,O
repeatedly,O
after,O
interruption,O
periods,O
or,O
when,O
users,O
are,O
switched,O
between,O
the,O
two,O
generations,O
of,O
pills,O
.,O
These,O
analyses,O
suggest,O
that,O
the,O
higher,O
risk,O
observed,O
for,O
the,O
newer,O
OC,I-Entity
in,O
other,O
studies,O
may,O
be,O
the,O
result,O
of,O
inadequate,O
comparisons,O
of,O
pill,O
users,O
with,O
different,O
patterns,O
of,O
pill,O
use,O
.,O
Development,O
of,O
apomorphine,I-Entity
-,O
induced,O
aggressive,B-Entity
behavior,I-Entity
:,O
comparison,O
of,O
adult,O
male,O
and,O
female,O
Wistar,O
rats,O
.,O
The,O
development,O
of,O
apomorphine,I-Entity
-,O
induced,O
(,O
1.0,O
mg,O
/,O
kg,O
s.c,O
.,O
once,O
daily,O
),O
aggressive,B-Entity
behavior,I-Entity
of,O
adult,O
male,O
and,O
female,O
Wistar,O
rats,O
obtained,O
from,O
the,O
same,O
breeder,O
was,O
studied,O
in,O
two,O
consecutive,O
sets,O
.,O
In,O
male,O
animals,O
",",O
repeated,O
apomorphine,I-Entity
treatment,O
induced,O
a,O
gradual,O
development,O
of,O
aggressive,B-Entity
behavior,I-Entity
as,O
evidenced,O
by,O
the,O
increased,O
intensity,O
of,O
aggressiveness,I-Entity
and,O
shortened,O
latency,O
before,O
the,O
first,O
attack,O
toward,O
the,O
opponent,O
.,O
In,O
female,O
rats,O
",",O
only,O
a,O
weak,O
tendency,O
toward,O
aggressiveness,I-Entity
was,O
found,O
.,O
In,O
conclusion,O
",",O
the,O
present,O
study,O
demonstrates,O
gender,O
differences,O
in,O
the,O
development,O
of,O
the,O
apomorphine,I-Entity
-,O
induced,O
aggressive,B-Entity
behavior,I-Entity
and,O
indicates,O
that,O
the,O
female,O
rats,O
do,O
not,O
fill,O
the,O
validation,O
criteria,O
for,O
use,O
in,O
this,O
method,O
.,O
Serotonergic,B-Entity
antidepressants,I-Entity
and,O
urinary,B-Entity
incontinence,I-Entity
.,O
Many,O
new,O
serotonergic,B-Entity
antidepressants,I-Entity
have,O
been,O
introduced,O
over,O
the,O
past,O
decade,O
.,O
Although,O
urinary,B-Entity
incontinence,I-Entity
is,O
listed,O
as,O
one,O
side,O
effect,O
of,O
these,O
drugs,O
in,O
their,O
package,O
inserts,O
there,O
is,O
only,O
one,O
report,O
in,O
the,O
literature,O
.,O
This,O
concerns,O
2,O
male,O
patients,O
who,O
experienced,O
incontinence,I-Entity
while,O
taking,O
venlafaxine,I-Entity
.,O
In,O
the,O
present,O
paper,O
the,O
authors,O
describe,O
2,O
female,O
patients,O
who,O
developed,O
incontinence,I-Entity
secondary,O
to,O
the,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitors,O
paroxetine,I-Entity
and,O
sertraline,I-Entity
",",O
as,O
well,O
as,O
a,O
third,O
who,O
developed,O
this,O
side,O
effect,O
on,O
venlafaxine,I-Entity
.,O
In,O
2,O
of,O
the,O
3,O
cases,O
the,O
patients,O
were,O
also,O
taking,O
lithium,B-Entity
carbonate,I-Entity
and,O
beta,O
-,O
blockers,O
",",O
both,O
of,O
which,O
could,O
have,O
contributed,O
to,O
the,O
incontinence,I-Entity
.,O
Animal,O
studies,O
suggest,O
that,O
incontinence,I-Entity
secondary,O
to,O
serotonergic,B-Entity
antidepressants,I-Entity
could,O
be,O
mediated,O
by,O
the,O
5HT4,O
receptors,O
found,O
on,O
the,O
bladder,O
.,O
Hypotension,I-Entity
following,O
the,O
initiation,O
of,O
tizanidine,I-Entity
in,O
a,O
patient,O
treated,O
with,O
an,O
angiotensin,I-Entity
converting,O
enzyme,O
inhibitor,O
for,O
chronic,O
hypertension,I-Entity
.,O
Centrally,O
acting,O
alpha-2,O
adrenergic,O
agonists,O
are,O
one,O
of,O
several,O
pharmacologic,O
agents,O
used,O
in,O
the,O
treatment,O
of,O
spasticity,I-Entity
related,O
to,O
disorders,B-Entity
of,I-Entity
the,I-Entity
central,I-Entity
nervous,I-Entity
system,I-Entity
.,O
In,O
addition,O
to,O
their,O
effects,O
on,O
spasticity,I-Entity
",",O
certain,O
adverse,O
cardiorespiratory,O
effects,O
have,O
been,O
reported,O
.,O
Adults,O
chronically,O
treated,O
with,O
angiotensin,I-Entity
converting,O
enzyme,O
inhibitors,O
may,O
have,O
a,O
limited,O
ability,O
to,O
respond,O
to,O
hypotension,I-Entity
when,O
the,O
sympathetic,O
response,O
is,O
simultaneously,O
blocked,O
.,O
The,O
authors,O
present,O
a,O
10-year,O
-,O
old,O
boy,O
chronically,O
treated,O
with,O
lisinopril,I-Entity
",",O
an,O
angiotensin,I-Entity
converting,O
enzyme,O
inhibitor,O
",",O
to,O
control,O
hypertension,I-Entity
who,O
developed,O
hypotension,I-Entity
following,O
the,O
addition,O
of,O
tizanidine,I-Entity
",",O
an,O
alpha-2,O
agonist,O
",",O
for,O
the,O
treatment,O
of,O
spasticity,I-Entity
.,O
The,O
possible,O
interaction,O
of,O
tizanidine,I-Entity
and,O
other,O
antihypertensive,O
agents,O
should,O
be,O
kept,O
in,O
mind,O
when,O
prescribing,O
therapy,O
to,O
treat,O
either,O
hypertension,I-Entity
or,O
spasticity,I-Entity
in,O
such,O
patients,O
.,O
Peritubular,O
capillary,O
basement,O
membrane,O
reduplication,O
in,O
allografts,O
and,O
native,O
kidney,B-Entity
disease,I-Entity
:,O
a,O
clinicopathologic,O
study,O
of,O
278,O
consecutive,O
renal,O
specimens,O
.,O
BACKGROUND,O
:,O
An,O
association,O
has,O
been,O
found,O
between,O
transplant,B-Entity
glomerulopathy,I-Entity
(,O
TG,I-Entity
),O
and,O
reduplication,O
of,O
peritubular,O
capillary,O
basement,O
membranes,O
(,O
PTCR,O
),O
.,O
In,O
addition,O
to,O
renal,O
allografts,O
with,O
TG,I-Entity
",",O
we,O
also,O
examined,O
grafts,O
with,O
acute,O
rejection,O
",",O
recurrent,O
glomerulonephritis,I-Entity
",",O
chronic,B-Entity
allograft,I-Entity
nephropathy,I-Entity
and,O
stable,O
grafts,O
(,O
"""",O
protocol,O
biopsies,O
"""",O
),O
.,O
Native,O
kidney,O
specimens,O
included,O
a,O
wide,O
range,O
of,O
glomerulopathies,I-Entity
as,O
well,O
as,O
cases,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
",",O
malignant,B-Entity
hypertension,I-Entity
",",O
acute,O
interstitial,B-Entity
nephritis,I-Entity
",",O
and,O
acute,B-Entity
tubular,I-Entity
necrosis,I-Entity
.,O
We,O
found,O
PTCR,O
in,O
14,O
of,O
15,O
cases,O
of,O
TG,I-Entity
",",O
in,O
7,O
transplant,O
biopsy,O
specimens,O
without,O
TG,I-Entity
",",O
and,O
in,O
13,O
of,O
143,O
native,O
kidney,O
biopsy,O
specimens,O
.,O
These,O
13,O
included,O
cases,O
of,O
malignant,B-Entity
hypertension,I-Entity
",",O
thrombotic,B-Entity
microangiopathy,I-Entity
",",O
lupus,B-Entity
nephritis,I-Entity
",",O
Henoch,B-Entity
-,I-Entity
Schonlein,I-Entity
nephritis,I-Entity
",",O
crescentic,O
glomerulonephritis,I-Entity
",",O
and,O
cocaine,I-Entity
-,O
related,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
Mild,O
PTCR,O
in,O
allografts,O
without,O
TG,I-Entity
did,O
not,O
predict,O
renal,B-Entity
failure,I-Entity
or,O
significant,O
proteinuria,I-Entity
after,O
follow,O
-,O
up,O
periods,O
of,O
between,O
3,O
months,O
and,O
1,O
year,O
.,O
CONCLUSIONS,O
:,O
We,O
conclude,O
that,O
in,O
transplants,O
",",O
there,O
is,O
a,O
strong,O
association,O
between,O
well,O
-,O
developed,O
PTCR,O
and,O
TG,I-Entity
",",O
while,O
the,O
significance,O
of,O
mild,O
PTCR,O
and,O
its,O
predictive,O
value,O
in,O
the,O
absence,O
of,O
TG,I-Entity
is,O
unclear,O
.,O
PTCR,O
also,O
occurs,O
in,O
certain,O
native,O
kidney,B-Entity
diseases,I-Entity
",",O
though,O
the,O
association,O
is,O
not,O
as,O
strong,O
as,O
that,O
for,O
TG,I-Entity
.,O
We,O
suggest,O
that,O
repeated,O
endothelial,B-Entity
injury,I-Entity
",",O
including,O
immunologic,B-Entity
injury,I-Entity
",",O
may,O
be,O
the,O
cause,O
of,O
this,O
lesion,O
both,O
in,O
allografts,O
and,O
native,O
kidneys,O
.,O
Conformationally,O
restricted,O
analogs,O
of,O
BD1008,I-Entity
and,O
an,O
antisense,O
oligodeoxynucleotide,I-Entity
targeting,O
sigma1,O
receptors,O
produce,O
anti,O
-,O
cocaine,I-Entity
effects,O
in,O
mice,O
.,O
Cocaine,I-Entity
's,O
ability,O
to,O
interact,O
with,O
sigma,O
receptors,O
suggests,O
that,O
these,O
proteins,O
mediate,O
some,O
of,O
its,O
behavioral,O
effects,O
.,O
Therefore,O
",",O
three,O
novel,O
sigma,O
receptor,O
ligands,O
with,O
antagonist,O
activity,O
were,O
evaluated,O
in,O
Swiss,O
Webster,O
mice,O
:,O
BD1018,I-Entity
(,O
"3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",I-Entity
),O
",",O
BD1063,I-Entity
(,O
"1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine",I-Entity
),O
",",O
and,O
LR132,I-Entity
(,O
"1R,2S-(+)-cis",O
-,O
"N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",O
),O
.,O
The,O
three,O
compounds,O
vary,O
in,O
their,O
affinities,O
for,O
sigma2,O
receptors,O
and,O
exhibit,O
negligible,O
affinities,O
for,O
dopamine,I-Entity
",",O
opioid,O
",",O
GABA(A,I-Entity
),O
and,O
NMDA,I-Entity
receptors,O
.,O
In,O
behavioral,O
studies,O
",",O
pre,O
-,O
treatment,O
of,O
mice,O
with,O
BD1018,I-Entity
",",O
BD1063,I-Entity
",",O
or,O
LR132,I-Entity
significantly,O
attenuated,O
cocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
and,O
lethality,O
.,O
Moreover,O
",",O
post,O
-,O
treatment,O
with,O
LR132,I-Entity
prevented,O
cocaine,I-Entity
-,O
induced,O
lethality,O
in,O
a,O
significant,O
proportion,O
of,O
animals,O
.,O
In,O
contrast,O
to,O
the,O
protection,O
provided,O
by,O
the,O
putative,O
antagonists,O
",",O
the,O
well,O
-,O
characterized,O
sigma,O
receptor,O
agonist,O
di,B-Entity
-,I-Entity
o,I-Entity
-,I-Entity
tolylguanidine,I-Entity
(,O
DTG,I-Entity
),O
and,O
the,O
novel,O
sigma,O
receptor,O
agonist,O
BD1031,I-Entity
(,O
"3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane",I-Entity
),O
each,O
worsened,O
the,O
behavioral,O
toxicity,I-Entity
of,O
cocaine,I-Entity
.,O
At,O
doses,O
where,O
alone,O
",",O
they,O
produced,O
no,O
significant,O
effects,O
on,O
locomotion,O
",",O
BD1018,I-Entity
",",O
BD1063,I-Entity
and,O
LR132,I-Entity
significantly,O
attenuated,O
the,O
locomotor,O
stimulatory,O
effects,O
of,O
cocaine,I-Entity
.,O
To,O
further,O
validate,O
the,O
hypothesis,O
that,O
the,O
anti,O
-,O
cocaine,I-Entity
effects,O
of,O
the,O
novel,O
ligands,O
involved,O
antagonism,O
of,O
sigma,O
receptors,O
",",O
an,O
antisense,O
oligodeoxynucleotide,I-Entity
against,O
sigma1,O
receptors,O
was,O
also,O
shown,O
to,O
significantly,O
attenuate,O
the,O
convulsive,I-Entity
and,O
locomotor,O
stimulatory,O
effects,O
of,O
cocaine,I-Entity
.,O
Together,O
",",O
the,O
data,O
suggests,O
that,O
functional,O
antagonism,O
of,O
sigma,O
receptors,O
is,O
capable,O
of,O
attenuating,O
a,O
number,O
of,O
cocaine,I-Entity
-,O
induced,O
behaviors,O
.,O
Pharmacokinetic,O
/,O
pharmacodynamic,O
assessment,O
of,O
the,O
effects,O
of,O
E4031,I-Entity
",",O
cisapride,I-Entity
",",O
terfenadine,I-Entity
and,O
terodiline,I-Entity
on,O
monophasic,O
action,O
potential,O
duration,O
in,O
dog,O
Torsades,B-Entity
de,I-Entity
pointes,I-Entity
(,O
TDP,I-Entity
),O
is,O
a,O
potentially,O
fatal,O
ventricular,B-Entity
tachycardia,I-Entity
associated,O
with,O
increases,O
in,O
QT,O
interval,O
and,O
monophasic,O
action,O
potential,O
duration,O
(,O
MAPD,O
),O
.,O
TDP,I-Entity
is,O
a,O
side,O
-,O
effect,O
that,O
has,O
led,O
to,O
withdrawal,O
of,O
several,O
drugs,O
from,O
the,O
market,O
(,O
e.g.,O
terfenadine,I-Entity
and,O
terodiline,I-Entity
),O
.,O
The,O
potential,O
of,O
compounds,O
to,O
cause,O
TDP,I-Entity
was,O
evaluated,O
by,O
monitoring,O
their,O
effects,O
on,O
MAPD,O
in,O
dog,O
.,O
Four,O
compounds,O
known,O
to,O
increase,O
QT,O
interval,O
and,O
cause,O
TDP,I-Entity
were,O
investigated,O
:,O
terfenadine,I-Entity
",",O
terodiline,I-Entity
",",O
cisapride,I-Entity
and,O
E4031,I-Entity
.,O
These,O
data,O
indicate,O
that,O
the,O
free,O
ED50,O
in,O
plasma,O
for,O
terfenadine,I-Entity
(,O
1.9,O
nM,O
),O
",",O
terodiline,I-Entity
(,O
76,O
nM,O
),O
",",O
cisapride,I-Entity
(,O
11,O
nM,O
),O
and,O
E4031,I-Entity
(,O
1.9,O
nM,O
),O
closely,O
correlate,O
with,O
the,O
free,O
concentration,O
in,O
man,O
causing,O
QT,O
effects,O
.,O
For,O
compounds,O
that,O
have,O
shown,O
TDP,I-Entity
in,O
the,O
clinic,O
(,O
terfenadine,I-Entity
",",O
terodiline,I-Entity
",",O
cisapride,I-Entity
),O
there,O
is,O
little,O
differentiation,O
between,O
the,O
dog,O
ED50,O
and,O
the,O
efficacious,O
free,O
plasma,O
concentrations,O
in,O
man,O
(,O
<,O
10-fold,O
),O
reflecting,O
their,O
limited,O
safety,O
margins,O
.,O
These,O
data,O
underline,O
the,O
need,O
to,O
maximize,O
the,O
therapeutic,O
ratio,O
with,O
respect,O
to,O
TDP,I-Entity
in,O
potential,O
development,O
candidates,O
and,O
the,O
importance,O
of,O
using,O
free,O
drug,O
concentrations,O
in,O
pharmacokinetic,O
/,O
pharmacodynamic,O
studies,O
.,O
Fatal,O
myeloencephalopathy,I-Entity
due,O
to,O
accidental,O
intrathecal,O
vincristin,I-Entity
administration,O
:,O
a,O
report,O
of,O
two,O
cases,O
.,O
We,O
report,O
on,O
two,O
fatal,O
cases,O
of,O
accidental,O
intrathecal,O
vincristine,I-Entity
instillation,O
in,O
a,O
5-year,O
old,O
girl,O
with,O
recurrent,O
acute,B-Entity
lymphoblastic,I-Entity
leucemia,I-Entity
and,O
a,O
57-year,O
old,O
man,O
with,O
lymphoblastic,B-Entity
lymphoma,I-Entity
.,O
The,O
girl,O
died,O
seven,O
days,O
",",O
the,O
man,O
four,O
weeks,O
after,O
intrathecal,O
injection,O
of,O
vincristine,I-Entity
.,O
Clinically,O
",",O
the,O
onset,O
was,O
characterized,O
by,O
the,O
signs,O
of,O
opistothonus,B-Entity
",",I-Entity
sensory,I-Entity
and,I-Entity
motor,I-Entity
dysfunction,I-Entity
and,O
ascending,O
paralysis,I-Entity
.,O
Histological,O
and,O
immunohistochemical,O
investigations,O
(,O
HE,O
-,O
LFB,O
",",O
CD-68,O
",",O
Neurofilament,O
),O
revealed,O
degeneration,B-Entity
of,I-Entity
myelin,I-Entity
and,I-Entity
axons,I-Entity
as,O
well,O
as,O
pseudocystic,B-Entity
transformation,I-Entity
in,O
areas,O
exposed,O
to,O
vincristine,I-Entity
",",O
accompanied,O
by,O
secondary,O
changes,O
with,O
numerous,O
prominent,O
macrophages,O
.,O
A,O
better,O
controlled,O
regimen,O
for,O
administering,O
vincristine,I-Entity
and,O
Intravenous,O
administration,O
of,O
prochlorperazine,I-Entity
by,O
15-minute,O
infusion,O
versus,O
2-minute,O
bolus,O
does,O
not,O
affect,O
the,O
incidence,O
of,O
akathisia,I-Entity
:,O
a,O
prospective,O
",",O
randomized,O
",",O
controlled,O
trial,O
.,O
STUDY,O
OBJECTIVE,O
:,O
We,O
sought,O
to,O
compare,O
the,O
rate,O
of,O
akathisia,I-Entity
after,O
administration,O
of,O
intravenous,O
prochlorperazine,I-Entity
as,O
a,O
2-minute,O
bolus,O
or,O
15-minute,O
infusion,O
.,O
Patients,O
aged,O
18,O
years,O
or,O
older,O
treated,O
with,O
prochlorperazine,I-Entity
for,O
headache,I-Entity
",",O
nausea,I-Entity
",",O
or,O
vomiting,I-Entity
were,O
eligible,O
for,O
inclusion,O
.,O
Study,O
participants,O
were,O
randomized,O
to,O
receive,O
10,O
mg,O
of,O
prochlorperazine,I-Entity
administered,O
intravenously,O
by,O
means,O
of,O
2-minute,O
push,O
(,O
bolus,O
group,O
),O
or,O
10,O
mg,O
diluted,O
in,O
50,O
mL,O
of,O
normal,O
saline,O
solution,O
administered,O
by,O
means,O
of,O
intravenous,O
infusion,O
during,O
a,O
15-minute,O
period,O
(,O
infusion,O
group,O
),O
.,O
The,O
main,O
outcome,O
was,O
the,O
number,O
of,O
study,O
participants,O
experiencing,O
akathisia,I-Entity
within,O
60,O
minutes,O
of,O
administration,O
.,O
Akathisia,O
was,O
defined,O
as,O
either,O
a,O
spontaneous,O
report,O
of,O
restlessness,O
or,O
agitation,I-Entity
or,O
a,O
change,O
of,O
2,O
or,O
more,O
in,O
the,O
patient,O
-,O
reported,O
akathisia,I-Entity
rating,O
scale,O
and,O
a,O
change,O
of,O
at,O
least,O
1,O
in,O
the,O
investigator,O
-,O
observed,O
akathisia,I-Entity
rating,O
scale,O
.,O
The,O
intensity,O
of,O
headache,I-Entity
and,O
nausea,I-Entity
was,O
measured,O
with,O
a,O
100-mm,O
visual,O
analog,O
scale,O
.,O
Seventy,O
-,O
three,O
percent,O
(,O
73/99,O
),O
of,O
the,O
study,O
participants,O
were,O
treated,O
for,O
headache,I-Entity
and,O
70%,O
(,O
70/99,O
),O
for,O
nausea,I-Entity
.,O
In,O
the,O
bolus,O
group,O
",",O
26.0%,O
(,O
13/50,O
),O
had,O
akathisia,I-Entity
compared,O
with,O
32.7%,O
(,O
16/49,O
),O
in,O
the,O
infusion,O
group,O
The,O
difference,O
between,O
the,O
bolus,O
and,O
infusion,O
groups,O
in,O
the,O
percentage,O
of,O
participants,O
who,O
saw,O
a,O
50%,O
reduction,O
in,O
their,O
headache,I-Entity
intensity,O
within,O
30,O
minutes,O
was,O
11.8%,O
(,O
95%,O
CI,O
-9.6%,O
to,O
33.3%,O
),O
.,O
The,O
difference,O
in,O
the,O
percentage,O
of,O
patients,O
with,O
a,O
50%,O
reduction,O
in,O
their,O
nausea,I-Entity
was,O
12.6%,O
(,O
95%,O
CI,O
-4.6%,O
to,O
29.8%,O
),O
.,O
A,O
50%,O
reduction,O
in,O
the,O
incidence,O
of,O
akathisia,I-Entity
when,O
prochlorperazine,I-Entity
was,O
administered,O
by,O
means,O
of,O
15-minute,O
intravenous,O
infusion,O
versus,O
a,O
2-minute,O
intravenous,O
push,O
was,O
not,O
detected,O
.,O
The,O
efficacy,O
of,O
prochlorperazine,I-Entity
in,O
the,O
treatment,O
of,O
headache,I-Entity
and,O
nausea,I-Entity
likewise,O
did,O
not,O
appear,O
to,O
be,O
affected,O
by,O
the,O
rate,O
of,O
administration,O
",",O
although,O
no,O
formal,O
statistical,O
comparisons,O
were,O
made,O
.,O
Antithymocyte,B-Entity
globulin,I-Entity
in,O
the,O
treatment,O
of,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
-,O
induced,O
aplastic,B-Entity
anemia,I-Entity
.,O
A,O
patient,O
who,O
received,O
antithymocyte,B-Entity
globulin,I-Entity
therapy,O
for,O
aplastic,B-Entity
anemia,I-Entity
due,O
to,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
therapy,O
is,O
described,O
.,O
Use,O
of,O
antithymocyte,B-Entity
globulin,I-Entity
may,O
be,O
the,O
optimal,O
treatment,O
of,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
-,O
induced,O
aplastic,B-Entity
anemia,I-Entity
.,O
The,O
relationship,O
between,O
hippocampal,O
acetylcholine,I-Entity
release,O
and,O
cholinergic,O
convulsant,O
sensitivity,O
in,O
withdrawal,O
seizure,I-Entity
-,O
prone,O
and,O
withdrawal,O
seizure,I-Entity
-,O
resistant,O
selected,O
mouse,O
lines,O
.,O
The,O
septo,O
-,O
hippocampal,O
cholinergic,O
pathway,O
has,O
been,O
implicated,O
in,O
epileptogenesis,O
",",O
and,O
genetic,O
factors,O
influence,O
the,O
response,O
to,O
cholinergic,O
agents,O
",",O
but,O
limited,O
data,O
are,O
available,O
on,O
cholinergic,O
involvement,O
in,O
alcohol,I-Entity
withdrawal,O
severity,O
.,O
Thus,O
",",O
the,O
relationship,O
between,O
cholinergic,O
activity,O
and,O
responsiveness,O
and,O
alcohol,I-Entity
withdrawal,O
was,O
investigated,O
in,O
a,O
genetic,O
animal,O
model,O
of,O
ethanol,I-Entity
withdrawal,O
severity,O
.,O
Cholinergic,O
convulsant,O
sensitivity,O
was,O
examined,O
in,O
alcohol,I-Entity
-,O
na,O
ve,O
Withdrawal,O
Seizure,I-Entity
-,O
Prone,O
(,O
WSP,O
),O
and,O
-,O
Resistant,O
(,O
WSR,O
),O
mice,O
.,O
Animals,O
were,O
administered,O
nicotine,I-Entity
",",O
carbachol,I-Entity
",",O
or,O
neostigmine,I-Entity
via,O
timed,O
tail,O
vein,O
infusion,O
",",O
and,O
the,O
latencies,O
to,O
onset,O
of,O
tremor,I-Entity
and,O
clonus,O
were,O
recorded,O
and,O
converted,O
to,O
threshold,O
dose,O
.,O
We,O
also,O
used,O
microdialysis,O
to,O
measure,O
basal,O
and,O
potassium,I-Entity
-,O
stimulated,O
acetylcholine,I-Entity
(,O
ACh,I-Entity
),O
release,O
in,O
the,O
CA1,O
region,O
of,O
the,O
hippocampus,O
.,O
Potassium,I-Entity
was,O
applied,O
by,O
reverse,O
dialysis,O
twice,O
",",O
separated,O
by,O
75,O
min,O
.,O
Hippocampal,O
ACh,I-Entity
also,O
was,O
measured,O
during,O
testing,O
for,O
handling,O
-,O
induced,O
convulsions,I-Entity
.,O
Sensitivity,O
to,O
several,O
convulsion,I-Entity
endpoints,O
induced,O
by,O
nicotine,I-Entity
",",O
carbachol,I-Entity
",",O
and,O
neostigmine,I-Entity
were,O
significantly,O
greater,O
in,O
WSR,O
versus,O
WSP,O
mice,O
.,O
In,O
microdialysis,O
experiments,O
",",O
the,O
lines,O
did,O
not,O
differ,O
in,O
basal,O
release,O
of,O
ACh,I-Entity
",",O
and,O
50,O
mM,O
KCl,I-Entity
increased,O
ACh,I-Entity
output,O
in,O
both,O
lines,O
of,O
mice,O
.,O
However,O
",",O
the,O
increase,O
in,O
release,O
of,O
ACh,I-Entity
produced,O
by,O
the,O
first,O
application,O
of,O
KCl,I-Entity
was,O
2-fold,O
higher,O
in,O
WSP,O
versus,O
WSR,O
mice,O
.,O
When,O
hippocampal,O
ACh,I-Entity
was,O
measured,O
during,O
testing,O
for,O
handling,O
-,O
induced,O
convulsions,I-Entity
",",O
extracellular,O
ACh,I-Entity
was,O
significantly,O
elevated,O
(,O
192%,O
),O
in,O
WSP,O
mice,O
",",O
but,O
was,O
nonsignificantly,O
elevated,O
(,O
59%,O
),O
in,O
WSR,O
mice,O
.,O
These,O
results,O
suggest,O
that,O
differences,O
in,O
cholinergic,O
activity,O
and,O
postsynaptic,O
sensitivity,O
to,O
cholinergic,O
convulsants,I-Entity
may,O
be,O
associated,O
with,O
ethanol,I-Entity
withdrawal,O
severity,O
and,O
implicate,O
cholinergic,O
mechanisms,O
in,O
alcohol,I-Entity
withdrawal,O
.,O
Specifically,O
",",O
WSP,O
mice,O
may,O
have,O
lower,O
sensitivity,O
to,O
cholinergic,O
convulsants,I-Entity
compared,O
with,O
WSR,O
because,O
of,O
postsynaptic,O
receptor,O
desensitization,O
brought,O
on,O
by,O
higher,O
activity,O
of,O
cholinergic,O
neurons,O
.,O
Prenatal,O
dexamethasone,I-Entity
programs,O
hypertension,I-Entity
and,O
renal,B-Entity
injury,I-Entity
in,O
the,O
rat,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
if,O
prenatal,O
dexamethasone,I-Entity
programmed,O
a,O
progressive,O
increase,B-Entity
in,I-Entity
blood,I-Entity
pressure,I-Entity
and,O
renal,B-Entity
injury,I-Entity
in,O
rats,O
.,O
Pregnant,O
rats,O
were,O
given,O
either,O
vehicle,O
or,O
2,O
daily,O
intraperitoneal,O
injections,O
of,O
dexamethasone,I-Entity
(,O
0.2,O
mg,O
/,O
kg,O
body,O
weight,O
),O
on,O
gestational,O
days,O
11,O
and,O
12,O
",",O
13,O
and,O
14,O
",",O
15,O
and,O
16,O
",",O
17,O
and,O
18,O
",",O
or,O
19,O
and,O
20,O
.,O
Offspring,O
of,O
rats,O
administered,O
dexamethasone,I-Entity
on,O
days,O
15,O
and,O
16,O
gestation,O
had,O
a,O
20%,O
reduction,B-Entity
in,I-Entity
glomerular,I-Entity
number,I-Entity
compared,O
with,O
control,O
at,O
6,O
to,O
9,O
months,O
of,O
age,O
(,O
22,O
527+/-509,O
versus,O
28,O
050+/-561,O
",",O
P<0.05,O
),O
",",O
which,O
was,O
comparable,O
to,O
the,O
percent,O
reduction,O
in,O
glomeruli,O
measured,O
at,O
3,O
weeks,O
of,O
age,O
.,O
Six-,O
to,O
9-month,O
old,O
rats,O
receiving,O
prenatal,O
dexamethasone,I-Entity
on,O
days,O
17,O
and,O
18,O
of,O
gestation,O
had,O
a,O
17%,O
reduction,O
in,O
glomeruli,O
(,O
23,O
380+/-587,O
),O
compared,O
with,O
control,O
rats,O
(,O
P<0.05,O
),O
.,O
Male,O
rats,O
that,O
received,O
prenatal,O
dexamethasone,I-Entity
on,O
days,O
15,O
and,O
16,O
",",O
17,O
and,O
18,O
",",O
and,O
13,O
and,O
14,O
of,O
gestation,O
had,O
elevated,B-Entity
blood,I-Entity
pressures,I-Entity
at,O
6,O
months,O
of,O
age,O
;,O
the,O
latter,O
group,O
did,O
not,O
have,O
a,O
reduction,B-Entity
in,I-Entity
glomerular,I-Entity
number,I-Entity
.,O
Adult,O
rats,O
given,O
dexamethasone,I-Entity
on,O
days,O
15,O
and,O
16,O
of,O
gestation,O
had,O
more,O
glomeruli,O
with,O
glomerulosclerosis,I-Entity
than,O
control,O
rats,O
.,O
This,O
study,O
shows,O
that,O
prenatal,O
dexamethasone,I-Entity
in,O
rats,O
results,O
in,O
a,O
reduction,B-Entity
in,I-Entity
glomerular,I-Entity
number,I-Entity
",",O
glomerulosclerosis,I-Entity
",",O
and,O
hypertension,I-Entity
when,O
administered,O
at,O
specific,O
points,O
during,O
gestation,O
.,O
Hypertension,I-Entity
was,O
observed,O
in,O
animals,O
that,O
had,O
a,O
reduction,O
in,O
glomeruli,O
as,O
well,O
as,O
in,O
a,O
group,O
that,O
did,O
not,O
have,O
a,O
reduction,B-Entity
in,I-Entity
glomerular,I-Entity
number,I-Entity
",",O
suggesting,O
that,O
a,O
reduction,B-Entity
in,I-Entity
glomerular,I-Entity
number,I-Entity
is,O
not,O
the,O
sole,O
cause,O
for,O
the,O
development,O
of,O
hypertension,I-Entity
.,O
The,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
in,O
women,O
prescribed,O
cyproterone,B-Entity
acetate,I-Entity
in,O
combination,O
with,O
ethinyl,B-Entity
estradiol,I-Entity
:,O
a,O
nested,O
cohort,O
analysis,O
and,O
case,O
-,O
control,O
study,O
.,O
Cyproterone,B-Entity
acetate,I-Entity
combined,O
with,O
ethinyl,B-Entity
estradiol,I-Entity
(,O
CPA,I-Entity
/,O
EE,I-Entity
),O
is,O
licensed,O
in,O
the,O
UK,O
for,O
the,O
treatment,O
of,O
women,O
with,O
acne,I-Entity
and,O
hirsutism,I-Entity
and,O
is,O
also,O
a,O
treatment,O
option,O
for,O
polycystic,B-Entity
ovary,I-Entity
syndrome,I-Entity
(,O
PCOS,I-Entity
),O
.,O
Previous,O
studies,O
have,O
demonstrated,O
an,O
increased,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
(,O
VTE,I-Entity
),O
associated,O
with,O
CPA,I-Entity
/,O
EE,I-Entity
compared,O
with,O
conventional,O
combined,O
oral,B-Entity
contraceptives,I-Entity
(,O
COCs,O
),O
.,O
Using,O
the,O
General,O
Practice,O
Research,O
Database,O
we,O
conducted,O
a,O
cohort,O
analysis,O
and,O
case,O
-,O
control,O
study,O
nested,O
within,O
a,O
population,O
of,O
women,O
aged,O
between,O
15,O
and,O
39,O
years,O
with,O
acne,I-Entity
",",O
hirsutism,I-Entity
or,O
PCOS,I-Entity
to,O
estimate,O
the,O
risk,O
of,O
VTE,I-Entity
associated,O
with,O
CPA,I-Entity
/,O
EE,I-Entity
.,O
The,O
age,O
-,O
adjusted,O
incidence,O
rate,O
ratio,O
for,O
CPA,I-Entity
/,O
EE,I-Entity
versus,O
conventional,O
COCs,O
was,O
2.20,O
[,O
95%,O
confidence,O
interval,O
(,O
CI,O
),O
1.35,O
-,O
3.58,O
],O
.,O
Using,O
as,O
the,O
reference,O
group,O
women,O
who,O
were,O
not,O
using,O
oral,O
contraception,O
",",O
had,O
no,O
recent,O
pregnancy,O
or,O
menopausal,O
symptoms,O
",",O
the,O
case,O
-,O
control,O
analysis,O
gave,O
an,O
adjusted,O
odds,O
ratio,O
(,O
OR(adj,O
),O
),O
of,O
7.44,O
(,O
95%,O
CI,O
3.67,O
-,O
15.08,O
),O
for,O
CPA,I-Entity
/,O
EE,I-Entity
use,O
compared,O
with,O
an,O
OR(adj,O
),O
of,O
2.58,O
(,O
95%,O
CI,O
1.60,O
-,O
4.18,O
),O
for,O
use,O
of,O
conventional,O
COCs,O
.,O
:,O
We,O
have,O
demonstrated,O
an,O
increased,O
risk,O
of,O
VTE,I-Entity
associated,O
with,O
the,O
use,O
of,O
CPA,I-Entity
/,O
EE,I-Entity
in,O
women,O
with,O
acne,I-Entity
",",O
hirsutism,I-Entity
or,O
PCOS,I-Entity
although,O
residual,O
confounding,O
by,O
indication,O
can,O
not,O
be,O
excluded,O
.,O
Pseudoacromegaly,I-Entity
induced,O
by,O
the,O
long,O
-,O
term,O
use,O
of,O
minoxidil,I-Entity
.,O
Acromegaly,I-Entity
is,O
an,O
endocrine,B-Entity
disorder,I-Entity
caused,O
by,O
chronic,O
excessive,O
growth,O
hormone,O
secretion,O
from,O
the,O
anterior,O
pituitary,O
gland,O
.,O
Significant,O
disfiguring,O
changes,O
occur,O
as,O
a,O
result,O
of,O
bone,O
",",O
cartilage,O
",",O
and,O
soft,O
tissue,O
hypertrophy,I-Entity
",",O
including,O
the,O
thickening,O
of,O
the,O
skin,O
",",O
coarsening,O
of,O
facial,O
features,O
",",O
and,O
cutis,B-Entity
verticis,I-Entity
gyrata,I-Entity
.,O
Pseudoacromegaly,I-Entity
",",O
on,O
the,O
other,O
hand,O
",",O
is,O
the,O
presence,O
of,O
similar,O
acromegaloid,O
features,O
in,O
the,O
absence,O
of,O
elevated,O
growth,O
hormone,O
or,O
insulin,O
-,O
like,O
growth,O
factor,O
levels,O
.,O
We,O
present,O
a,O
patient,O
with,O
pseudoacromegaly,I-Entity
that,O
resulted,O
from,O
the,O
long,O
-,O
term,O
use,O
of,O
minoxidil,I-Entity
at,O
an,O
unusually,O
high,O
dose,O
.,O
This,O
is,O
the,O
first,O
case,O
report,O
of,O
pseudoacromegaly,I-Entity
as,O
a,O
side,O
effect,O
of,O
minoxidil,I-Entity
use,O
.,O
Combined,O
androgen,O
blockade,O
-,O
induced,O
anemia,I-Entity
in,O
prostate,B-Entity
cancer,I-Entity
patients,O
without,O
bone,O
involvement,O
.,O
BACKGROUND,O
:,O
To,O
determine,O
the,O
onset,O
and,O
extent,O
of,O
combined,O
androgen,O
blockade,O
(,O
CAB)-induced,O
anemia,I-Entity
in,O
prostate,B-Entity
cancer,I-Entity
patients,O
without,O
bone,O
involvement,O
.,O
Forty,O
-,O
two,O
patients,O
with,O
biopsy,O
-,O
proven,O
prostatic,B-Entity
adenocarcinoma,I-Entity
[,O
26,O
with,O
stage,O
C,O
(,O
T3N0M0,O
),O
and,O
16,O
with,O
stage,O
D1,O
(,O
T3N1M0,O
),O
],O
were,O
included,O
in,O
this,O
study,O
.,O
All,O
patients,O
received,O
CAB,O
[,O
leuprolide,B-Entity
acetate,I-Entity
(,O
LHRH,B-Entity
-,I-Entity
A,I-Entity
),O
3.75,O
mg,O
",",O
intramuscularly,O
",",O
every,O
28,O
days,O
plus,O
250,O
mg,O
flutamide,I-Entity
",",O
tid,O
",",O
per,O
Os,O
],O
and,O
were,O
evaluated,O
for,O
anemia,I-Entity
by,O
physical,O
examination,O
and,O
laboratory,O
tests,O
at,O
baseline,O
and,O
4,O
subsequent,O
intervals,O
(,O
1,O
",",O
2,O
",",O
3,O
and,O
6,O
months,O
post,O
-,O
CAB,O
),O
.,O
Hb,O
",",O
PSA,O
and,O
Testosterone,I-Entity
measurements,O
were,O
recorded,O
.,O
Severe,O
and,O
clinically,O
evident,O
anemia,I-Entity
of,O
Hb,O
<,O
11,O
g,O
/,O
dl,O
with,O
clinical,O
symptoms,O
was,O
detected,O
in,O
6,O
patients,O
(,O
14.3%,O
),O
.,O
This,O
CAB,O
-,O
induced,O
anemia,I-Entity
was,O
normochromic,O
and,O
normocytic,O
.,O
At,O
six,O
months,O
post,O
-,O
CAB,O
",",O
patients,O
with,O
severe,O
anemia,I-Entity
had,O
a,O
Hb,O
mean,O
value,O
of,O
10.2,O
+,O
/-,O
SE,O
),O
",",O
whereas,O
the,O
other,O
patients,O
had,O
mild,O
anemia,I-Entity
with,O
Hb,O
mean,O
value,O
of,O
13.2,O
+,O
/-,O
The,O
development,O
of,O
severe,O
anemia,I-Entity
at,O
6,O
months,O
post,O
-,O
CAB,O
was,O
predictable,O
by,O
the,O
reduction,O
of,O
Hb,O
baseline,O
value,O
of,O
more,O
than,O
2.5,O
g,O
/,O
dl,O
after,O
3,O
months,O
of,O
CAB,O
(,O
p,O
=,O
0.01,O
),O
.,O
The,O
development,O
of,O
severe,O
CAB,O
-,O
induced,O
anemia,I-Entity
in,O
prostate,B-Entity
cancer,I-Entity
patients,O
did,O
not,O
correlate,O
with,O
T,O
baseline,O
values,O
(,O
T,O
<,O
3,O
Severe,O
and,O
clinically,O
evident,O
anemia,I-Entity
was,O
easily,O
corrected,O
by,O
subcutaneous,O
injections,O
(,O
3,O
times,O
/,O
week,O
for,O
1,O
month,O
),O
of,O
recombinant,O
erythropoietin,O
(,O
rHuEPO,O
-,O
beta,O
),O
.,O
Our,O
data,O
suggest,O
that,O
rHuEPO,O
-,O
beta,O
correctable,O
CAB,O
-,O
induced,O
anemia,I-Entity
occurs,O
in,O
14.3%,O
of,O
prostate,B-Entity
cancer,I-Entity
patients,O
after,O
6,O
months,O
of,O
therapy,O
.,O
Reversible,O
dilated,B-Entity
cardiomyopathy,I-Entity
related,O
to,O
amphotericin,B-Entity
B,I-Entity
therapy,O
.,O
We,O
describe,O
a,O
patient,O
who,O
developed,O
dilated,B-Entity
cardiomyopathy,I-Entity
and,O
clinical,O
congestive,O
heart,B-Entity
failure,I-Entity
after,O
2,O
months,O
of,O
therapy,O
with,O
amphotericin,B-Entity
B,I-Entity
(,O
AmB,I-Entity
),O
for,O
disseminated,O
coccidioidomycosis,I-Entity
.,O
His,O
echocardiographic,O
abnormalities,O
and,O
heart,B-Entity
failure,I-Entity
resolved,O
after,O
posaconazole,I-Entity
was,O
substituted,O
for,O
AmB.,I-Entity
It,O
is,O
important,O
to,O
recognize,O
the,O
rare,O
and,O
potentially,O
reversible,O
toxicity,I-Entity
of,O
AmB.,I-Entity
Risks,O
of,O
the,O
consumption,O
of,O
beverages,O
containing,O
quinine,I-Entity
.,O
Although,O
the,O
United,O
States,O
Food,O
and,O
Drug,O
Administration,O
banned,O
its,O
use,O
for,O
nocturnal,B-Entity
leg,I-Entity
cramps,I-Entity
due,O
to,O
lack,O
of,O
safety,O
and,O
efficacy,O
",",O
quinine,I-Entity
is,O
widely,O
available,O
in,O
beverages,O
including,O
tonic,O
water,O
and,O
bitter,O
lemon,O
.,O
Numerous,O
anecdotal,O
reports,O
suggest,O
that,O
products,O
containing,O
quinine,I-Entity
may,O
produce,O
neurological,B-Entity
complications,I-Entity
",",O
including,O
confusion,I-Entity
",",O
altered,O
mental,O
status,O
",",O
seizures,I-Entity
",",O
and,O
coma,I-Entity
",",O
particularly,O
in,O
older,O
women,O
.,O
Psychologists,O
need,O
to,O
inquire,O
about,O
consumption,O
of,O
quinine,I-Entity
-,O
containing,O
beverages,O
as,O
part,O
of,O
an,O
evaluation,O
process,O
.,O
Organophosphate,I-Entity
-,O
induced,O
convulsions,I-Entity
and,O
prevention,O
of,O
neuropathological,B-Entity
damages,I-Entity
.,O
Such,O
organophosphorus,I-Entity
(,O
OP,I-Entity
),O
compounds,O
as,O
diisopropylfluorophosphate,I-Entity
(,O
DFP,I-Entity
),O
",",O
sarin,I-Entity
and,O
soman,I-Entity
are,O
potent,O
inhibitors,O
of,O
acetylcholinesterases,O
(,O
AChEs,O
),O
and,O
butyrylcholinesterases,O
(,O
BChEs,O
),O
.,O
The,O
acute,O
toxicity,I-Entity
of,O
OPs,I-Entity
is,O
the,O
result,O
of,O
their,O
irreversible,O
binding,O
with,O
AChEs,O
in,O
the,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
",",O
which,O
elevates,O
acetylcholine,I-Entity
(,O
ACh,I-Entity
),O
levels,O
.,O
The,O
protective,O
action,O
of,O
subcutaneously,O
(,O
SC,O
),O
administered,O
antidotes,O
or,O
their,O
combinations,O
in,O
DFP,I-Entity
(,O
2.0,O
mg,O
/,O
kg,O
BW,O
),O
intoxication,O
was,O
studied,O
in,O
9,O
-,O
10-weeks,O
-,O
old,O
Han,O
-,O
Wistar,O
male,O
rats,O
.,O
The,O
rats,O
received,O
AChE,O
reactivator,O
pralidoxime-2-chloride,I-Entity
(,O
2PAM,I-Entity
),O
(,O
30.0,O
mg,O
/,O
kg,O
BW,O
),O
",",O
anticonvulsant,O
diazepam,I-Entity
(,O
2.0,O
mg,O
/,O
kg,O
BW,O
),O
",",O
A(1)-adenosine,I-Entity
receptor,O
agonist,O
N(6)-cyclopentyl,B-Entity
adenosine,I-Entity
(,O
CPA,I-Entity
),O
(,O
2.0,O
mg,O
/,O
kg,O
BW,O
),O
",",O
NMDA,I-Entity
-,O
receptor,O
antagonist,O
dizocilpine,B-Entity
maleate,I-Entity
(,O
+,O
-MK801,O
hydrogen,O
maleate,O
),O
(,O
2.0,O
mg,O
/,O
kg,O
BW,O
),O
or,O
their,O
combinations,O
with,O
cholinolytic,O
drug,O
atropine,B-Entity
sulfate,I-Entity
(,O
50.0,O
mg,O
/,O
kg,O
BW,O
),O
immediately,O
or,O
30,O
min,O
after,O
the,O
single,O
SC,O
injection,O
of,O
DFP,I-Entity
.,O
The,O
control,O
rats,O
received,O
atropine,B-Entity
sulfate,I-Entity
",",O
but,O
also,O
saline,O
and,O
olive,O
oil,O
instead,O
of,O
other,O
antidotes,O
and,O
DFP,I-Entity
",",O
respectively,O
.,O
All,O
rats,O
were,O
terminated,O
either,O
24,O
h,O
or,O
3,O
weeks,O
after,O
the,O
DFP,I-Entity
injection,O
.,O
The,O
rats,O
treated,O
with,O
DFP,I-Entity
-,O
atropine,I-Entity
showed,O
severe,O
typical,O
OP,I-Entity
-,O
induced,O
toxicity,I-Entity
signs,O
.,O
When,O
CPA,I-Entity
",",O
diazepam,I-Entity
or,O
2PAM,I-Entity
was,O
given,O
immediately,O
after,O
DFP,I-Entity
-,O
atropine,I-Entity
",",O
these,O
treatments,O
prevented,O
",",O
delayed,O
or,O
shortened,O
the,O
occurrence,O
of,O
serious,O
signs,O
of,O
poisoning,I-Entity
.,O
Atropine,I-Entity
-,O
MK801,I-Entity
did,O
not,O
offer,O
any,O
additional,O
protection,O
against,O
DFP,I-Entity
toxicity,I-Entity
.,O
In,O
conclusion,O
",",O
CPA,I-Entity
",",O
diazepam,I-Entity
and,O
2PAM,I-Entity
in,O
combination,O
with,O
atropine,I-Entity
prevented,O
the,O
occurrence,O
of,O
serious,O
signs,O
of,O
poisoning,I-Entity
and,O
thus,O
reduced,O
the,O
toxicity,I-Entity
of,O
DFP,I-Entity
in,O
rat,O
.,O
Differential,O
modulation,O
by,O
estrogen,I-Entity
of,O
alpha2-adrenergic,O
and,O
I1-imidazoline,I-Entity
receptor,O
-,O
mediated,O
hypotension,I-Entity
in,O
female,O
rats,O
.,O
We,O
have,O
recently,O
shown,O
that,O
estrogen,I-Entity
negatively,O
modulates,O
the,O
hypotensive,I-Entity
effect,O
of,O
clonidine,I-Entity
(,O
mixed,O
alpha2-/I1-receptor,O
agonist,O
),O
in,O
female,O
rats,O
and,O
implicates,O
the,O
cardiovascular,O
autonomic,O
control,O
in,O
this,O
interaction,O
.,O
The,O
present,O
study,O
investigated,O
whether,O
this,O
effect,O
of,O
estrogen,I-Entity
involves,O
interaction,O
with,O
alpha2-,O
and/or,O
I1-receptors,O
.,O
Changes,O
evoked,O
by,O
a,O
single,O
intraperitoneal,O
injection,O
of,O
rilmenidine,I-Entity
(,O
600,O
microg,O
/,O
kg,O
),O
or,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
(,O
100,O
mg,O
/,O
kg,O
),O
",",O
selective,O
I1-,O
and,O
alpha2-receptor,O
agonists,O
",",O
respectively,O
",",O
in,O
blood,O
pressure,O
",",O
hemodynamic,O
variability,O
",",O
and,O
locomotor,O
activity,O
were,O
assessed,O
in,O
radiotelemetered,O
sham,O
-,O
operated,O
and,O
ovariectomized,O
(,O
Ovx,O
),O
Sprague,O
-,O
Dawley,O
female,O
rats,O
with,O
or,O
without,O
12-wk,O
estrogen,I-Entity
replacement,O
.,O
In,O
sham,O
-,O
operated,O
rats,O
",",O
rilmenidine,I-Entity
or,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
elicited,O
similar,O
hypotension,I-Entity
that,O
lasted,O
at,O
least,O
5,O
h,O
and,O
was,O
associated,O
with,O
reductions,O
in,O
standard,O
deviation,O
of,O
mean,O
arterial,O
pressure,O
.,O
SDRR,O
was,O
reduced,O
only,O
by,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
.,O
Ovx,O
significantly,O
enhanced,O
the,O
hypotensive,I-Entity
response,O
to,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
",",O
in,O
contrast,O
to,O
no,O
effect,O
on,O
rilmenidine,I-Entity
hypotension,I-Entity
.,O
The,O
enhanced,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
hypotension,I-Entity
in,O
Ovx,O
rats,O
was,O
paralleled,O
with,O
further,O
reduction,O
in,O
SDRR,O
and,O
a,B-Entity
reduced,I-Entity
locomotor,I-Entity
activity,I-Entity
.,O
Estrogen,O
replacement,O
(,O
17beta,B-Entity
-,I-Entity
estradiol,I-Entity
subcutaneous,O
pellet,O
",",O
14.2,O
microg,O
/,O
day,O
",",O
12,O
wk,O
),O
of,O
Ovx,O
rats,O
restored,O
the,O
hemodynamic,O
and,O
locomotor,O
effects,O
of,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
to,O
sham,O
-,O
operated,O
levels,O
.,O
These,O
findings,O
suggest,O
that,O
estrogen,I-Entity
downregulates,O
alpha2-,O
but,O
not,O
I1-receptor,O
-,O
mediated,O
hypotension,I-Entity
and,O
highlight,O
a,O
role,O
for,O
the,O
cardiac,O
autonomic,O
control,O
in,O
alpha,B-Entity
-,I-Entity
methyldopa,I-Entity
-,O
estrogen,I-Entity
interaction,O
.,O
Cardioprotective,O
effect,O
of,O
tincture,B-Entity
of,I-Entity
Crataegus,I-Entity
on,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
Tincture,B-Entity
of,I-Entity
Crataegus,I-Entity
(,O
TCR,I-Entity
),O
",",O
an,O
alcoholic,B-Entity
extract,I-Entity
of,I-Entity
the,I-Entity
berries,I-Entity
of,I-Entity
hawthorn,I-Entity
(,O
Crataegus,B-Entity
oxycantha,I-Entity
),O
",",O
is,O
used,O
in,O
herbal,O
and,O
homeopathic,O
medicine,O
.,O
The,O
present,O
study,O
was,O
done,O
to,O
investigate,O
the,O
protective,O
effect,O
of,O
TCR,I-Entity
on,O
experimentally,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
Pretreatment,O
of,O
TCR,I-Entity
",",O
at,O
a,O
dose,O
of,O
0.5,O
mL/100,O
g,O
bodyweight,O
per,O
day,O
",",O
orally,O
for,O
30,O
days,O
",",O
prevented,O
the,O
increase,O
in,O
lipid,O
peroxidation,O
and,O
activity,O
of,O
marker,O
enzymes,O
observed,O
in,O
isoproterenol,I-Entity
-,O
induced,O
rats,O
(,O
85,O
mg,O
kg(-1,O
),O
s.,O
c.,O
for,O
2,O
days,O
at,O
an,O
interval,O
of,O
24,O
h,O
),O
.,O
TCR,I-Entity
prevented,O
the,O
isoproterenol,I-Entity
-,O
induced,O
decrease,O
in,O
antioxidant,O
enzymes,O
in,O
the,O
heart,O
and,O
increased,O
the,O
rate,O
of,O
ADP,I-Entity
-,O
stimulated,O
oxygen,I-Entity
uptake,O
and,O
respiratory,O
coupling,O
ratio,O
.,O
TCR,I-Entity
protected,O
against,O
pathological,O
changes,O
induced,O
by,O
isoproterenol,I-Entity
in,O
rat,O
heart,O
.,O
The,O
results,O
show,O
that,O
pretreatment,O
with,O
TCR,I-Entity
may,O
be,O
useful,O
in,O
preventing,O
the,O
damage,O
induced,O
by,O
isoproterenol,I-Entity
in,O
rat,O
heart,O
.,O
Safety,O
and,O
adverse,O
effects,O
associated,O
with,O
raloxifene,I-Entity
:,O
multiple,O
outcomes,O
of,O
raloxifene,I-Entity
evaluation,O
.,O
OBJECTIVE,O
:,O
To,O
examine,O
the,O
effect,O
of,O
raloxifene,I-Entity
on,O
major,O
adverse,O
events,O
that,O
occur,O
with,O
postmenopausal,O
estrogen,I-Entity
therapy,O
or,O
tamoxifen,I-Entity
.,O
The,O
Multiple,O
Outcomes,O
of,O
Raloxifene,I-Entity
Evaluation,O
",",O
a,O
multicenter,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
trial,O
",",O
enrolled,O
"7,705",O
postmenopausal,O
women,O
with,O
osteoporosis,I-Entity
.,O
Women,O
were,O
randomly,O
assigned,O
to,O
raloxifene,I-Entity
60,O
mg,O
/,O
d,O
or,O
120,O
mg,O
/,O
d,O
or,O
placebo,O
.,O
Outcomes,O
included,O
venous,B-Entity
thromboembolism,I-Entity
",",O
cataracts,I-Entity
",",O
gallbladder,B-Entity
disease,I-Entity
",",O
and,O
endometrial,B-Entity
hyperplasia,I-Entity
or,I-Entity
cancer,I-Entity
.,O
During,O
a,O
mean,O
follow,O
-,O
up,O
of,O
3.3,O
years,O
",",O
raloxifene,I-Entity
was,O
associated,O
with,O
an,O
increased,O
risk,O
for,O
venous,B-Entity
thromboembolism,I-Entity
(,O
relative,O
risk,O
[,O
RR,O
],O
2.1,O
;,O
95%,O
confidence,O
interval,O
[,O
CI,O
],O
1.2,O
-,O
3.8,O
),O
.,O
Risk,O
in,O
the,O
raloxifene,I-Entity
group,O
was,O
higher,O
than,O
in,O
the,O
placebo,O
group,O
for,O
the,O
first,O
2,O
years,O
",",O
but,O
decreased,O
to,O
about,O
the,O
same,O
rate,O
as,O
in,O
the,O
placebo,O
group,O
thereafter,O
.,O
Raloxifene,I-Entity
did,O
not,O
increase,O
risk,O
for,O
cataracts,I-Entity
(,O
RR,O
0.9,O
;,O
95%,O
CI,O
0.8,O
-,O
1.1,O
),O
",",O
gallbladder,B-Entity
disease,I-Entity
(,O
RR,O
1.0,O
;,O
95%,O
CI,O
0.7,O
-,O
1.3,O
),O
",",O
endometrial,B-Entity
hyperplasia,I-Entity
(,O
RR,O
1.3,O
;,O
95%,O
CI,O
0.4,O
-,O
5.1,O
),O
",",O
or,O
endometrial,B-Entity
cancer,I-Entity
(,O
RR,O
0.9,O
;,O
95%,O
CI,O
0.3,O
-,O
2.7,O
),O
.,O
Raloxifene,I-Entity
was,O
associated,O
with,O
an,O
increased,O
risk,O
for,O
venous,B-Entity
thromboembolism,I-Entity
",",O
but,O
there,O
was,O
no,O
increased,O
risk,O
for,O
cataracts,I-Entity
",",O
gallbladder,B-Entity
disease,I-Entity
",",O
endometrial,B-Entity
hyperplasia,I-Entity
",",O
or,O
endometrial,B-Entity
cancer,I-Entity
.,O
Ceftriaxone,I-Entity
-,O
associated,O
biliary,B-Entity
pseudolithiasis,I-Entity
in,O
paediatric,O
surgical,O
patients,O
.,O
It,O
is,O
well,O
known,O
that,O
ceftriaxone,I-Entity
leads,O
to,O
pseudolithiasis,I-Entity
in,O
some,O
patients,O
.,O
Clinical,O
and,O
experimental,O
studies,O
also,O
suggest,O
that,O
situations,O
causing,O
gallbladder,B-Entity
dysfunction,I-Entity
",",O
such,O
as,O
fasting,O
",",O
may,O
have,O
a,O
role,O
for,O
the,O
development,O
of,O
pseudolithiasis,I-Entity
.,O
In,O
this,O
study,O
",",O
we,O
prospectively,O
evaluated,O
the,O
incidence,O
and,O
clinical,O
importance,O
of,O
pseudolithiasis,I-Entity
in,O
paediatric,O
surgical,O
patients,O
receiving,O
ceftriaxone,I-Entity
treatment,O
",",O
who,O
often,O
had,O
to,O
fast,O
in,O
the,O
post,O
-,O
operative,O
period,O
.,O
Fifty,O
children,O
who,O
were,O
given,O
ceftriaxone,I-Entity
were,O
evaluated,O
by,O
serial,O
abdominal,O
sonograms,O
.,O
Comparison,O
of,O
the,O
patients,O
with,O
or,O
without,O
pseudolithiasis,I-Entity
revealed,O
no,O
significant,O
difference,O
with,O
respect,O
to,O
age,O
",",O
sex,O
",",O
duration,O
of,O
the,O
treatment,O
and,O
starvation,O
variables,O
.,O
After,O
cessation,O
of,O
the,O
treatment,O
",",O
pseudolithiasis,I-Entity
resolved,O
spontaneously,O
within,O
a,O
short,O
period,O
.,O
The,O
incidence,O
of,O
pseudolithiasis,I-Entity
is,O
not,O
affected,O
by,O
fasting,O
.,O
Evaluation,O
of,O
the,O
anticocaine,O
monoclonal,O
antibody,O
GNC92H2,I-Entity
as,O
an,O
immunotherapy,O
for,O
cocaine,B-Entity
overdose,I-Entity
.,O
The,O
illicit,O
use,O
of,O
cocaine,I-Entity
continues,O
in,O
epidemic,O
proportions,O
and,O
treatment,O
for,O
cocaine,B-Entity
overdose,I-Entity
remains,O
elusive,O
.,O
The,O
therapeutic,O
potential,O
of,O
the,O
anticocaine,O
antibody,O
GNC92H2,I-Entity
was,O
examined,O
using,O
a,O
model,O
of,O
cocaine,B-Entity
overdose,I-Entity
.,O
Swiss,O
albino,O
mice,O
prepared,O
with,O
intrajugular,O
catheters,O
were,O
tested,O
in,O
photocell,O
cages,O
after,O
administration,O
of,O
93,O
mg,O
/,O
kg,O
(,O
LD50,O
),O
of,O
cocaine,I-Entity
and,O
GNC92H2,I-Entity
infusions,O
ranging,O
from,O
30,O
to,O
190,O
mg,O
/,O
kg,O
.,O
GNC92H2,I-Entity
was,O
delivered,O
30,O
min,O
before,O
",",O
concomitantly,O
or,O
3,O
min,O
after,O
cocaine,I-Entity
treatment,O
.,O
Significant,O
blockade,O
of,O
cocaine,I-Entity
toxicity,I-Entity
was,O
observed,O
with,O
the,O
higher,O
dose,O
of,O
GNC92H2,I-Entity
(,O
190,O
mg,O
/,O
kg,O
),O
",",O
where,O
premorbid,O
behaviors,O
were,O
reduced,O
up,O
to,O
40%,O
",",O
seizures,I-Entity
up,O
to,O
77%,O
and,O
death,I-Entity
by,O
72%,O
.,O
Importantly,O
",",O
GNC92H2,I-Entity
prevented,O
death,I-Entity
even,O
post,O
-,O
cocaine,I-Entity
injection,O
.,O
The,O
results,O
support,O
the,O
important,O
potential,O
of,O
GNC92H2,I-Entity
as,O
a,O
therapeutic,O
tool,O
against,O
cocaine,B-Entity
overdose,I-Entity
.,O
The,O
effects,O
of,O
short,O
-,O
term,O
raloxifene,I-Entity
therapy,O
on,O
fibrinolysis,O
markers,O
:,O
TAFI,O
",",O
tPA,O
",",O
and,O
PAI-1,O
.,O
inhibitor-1,O
(,O
PAI-1,O
),O
levels,O
were,O
studied,O
for,O
the,O
evaluation,O
of,O
short,O
-,O
term,O
effects,O
of,O
raloxifene,I-Entity
administration,O
in,O
postmenopausal,O
women,O
.,O
METHODS,O
:,O
Thirty,O
-,O
nine,O
postmenopausal,O
women,O
with,O
osteopenia,I-Entity
or,O
osteoporosis,I-Entity
were,O
included,O
in,O
this,O
prospective,O
",",O
controlled,O
clinical,O
study,O
.,O
Twenty,O
-,O
five,O
women,O
were,O
given,O
raloxifene,B-Entity
hydrochloride,I-Entity
(,O
60,O
mg,O
/,O
day,O
),O
plus,O
calcium,I-Entity
(,O
500,O
mg,O
/,O
day,O
),O
.,O
Age,O
-,O
matched,O
controls,O
(,O
n,O
=,O
14,O
),O
were,O
given,O
only,O
calcium,I-Entity
.,O
RESULTS,O
:,O
Three,O
months,O
of,O
raloxifene,I-Entity
treatment,O
was,O
associated,O
with,O
a,O
significant,O
decrease,O
in,O
the,O
plasma,O
TAFI,O
antigen,O
concentrations,O
(,O
16%,O
change,O
",",O
P,O
<,O
0.01,O
),O
",",O
and,O
a,O
significant,O
increase,O
in,O
tPA,O
antigen,O
concentrations,O
(,O
25%,O
change,O
",",O
P,O
<,O
0.05,O
),O
.,O
A,O
significant,O
correlation,O
was,O
found,O
between,O
baseline,O
TAFI,O
antigen,O
concentrations,O
and,O
the,O
duration,O
of,O
amenorrhea,I-Entity
(,O
P,O
<,O
0.05,O
;,O
r,O
=,O
0.33,O
),O
.,O
:,O
We,O
suggest,O
that,O
the,O
increased,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
due,O
to,O
raloxifene,I-Entity
treatment,O
may,O
be,O
related,O
to,O
increased,O
tPA,O
levels,O
",",O
but,O
not,O
TAFI,O
levels,O
.,O
Ketoconazole,I-Entity
induced,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
without,O
concomitant,O
use,O
of,O
QT,O
interval,O
-,O
prolonging,O
drug,O
.,O
Ketoconazole,I-Entity
is,O
not,O
known,O
to,O
be,O
proarrhythmic,O
without,O
concomitant,O
use,O
of,O
QT,O
interval,O
-,O
prolonging,O
drugs,O
.,O
We,O
report,O
a,O
woman,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
who,O
developed,O
a,O
markedly,O
prolonged,B-Entity
QT,I-Entity
interval,I-Entity
and,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
(,O
TdP,I-Entity
),O
after,O
taking,O
ketoconazole,I-Entity
for,O
treatment,O
of,O
fungal,B-Entity
infection,I-Entity
.,O
Her,O
QT,O
interval,O
returned,O
to,O
normal,O
upon,O
withdrawal,O
of,O
ketoconazole,I-Entity
.,O
We,O
postulate,O
that,O
by,O
virtue,O
of,O
its,O
direct,O
blocking,O
action,O
on,O
IKr,O
",",O
ketoconazole,I-Entity
alone,O
may,O
prolong,O
QT,O
interval,O
and,O
induce,O
TdP.,I-Entity
This,O
calls,O
for,O
attention,O
when,O
ketoconazole,I-Entity
is,O
administered,O
to,O
patients,O
with,O
risk,O
factors,O
for,O
acquired,O
long,B-Entity
QT,I-Entity
syndrome,I-Entity
.,O
Pharmacological,O
evidence,O
for,O
the,O
potential,O
of,O
Daucus,O
carota,O
in,O
the,O
management,O
of,O
cognitive,B-Entity
dysfunctions,I-Entity
.,O
The,O
present,O
study,O
was,O
aimed,O
at,O
investigating,O
the,O
effects,O
of,O
Daucus,O
carota,O
seeds,O
on,O
cognitive,O
functions,O
",",O
total,O
serum,O
cholesterol,I-Entity
levels,O
and,O
brain,O
cholinesterase,O
activity,O
in,O
mice,O
.,O
The,O
ethanolic,O
extract,B-Entity
of,I-Entity
Daucus,I-Entity
carota,I-Entity
seeds,I-Entity
(,O
DCE,I-Entity
),O
was,O
administered,O
orally,O
in,O
three,O
doses,O
(,O
100,O
",",O
200,O
",",O
400,O
mg,O
/,O
kg,O
),O
for,O
seven,O
successive,O
days,O
to,O
different,O
groups,O
of,O
young,O
and,O
aged,O
mice,O
.,O
Diazepam-,I-Entity
",",O
scopolamine-,I-Entity
and,O
ageing,O
-,O
induced,O
amnesia,I-Entity
served,O
as,O
the,O
interoceptive,O
behavioral,O
models,O
.,O
DCE,I-Entity
(,O
200,O
",",O
400,O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
),O
showed,O
significant,O
improvement,O
in,O
memory,O
scores,O
of,O
young,O
and,O
aged,O
mice,O
.,O
The,O
extent,O
of,O
memory,O
improvement,O
evoked,O
by,O
DCE,I-Entity
was,O
23%,O
at,O
the,O
dose,O
of,O
200,O
mg,O
/,O
kg,O
and,O
35%,O
at,O
the,O
dose,O
of,O
400,O
mg,O
/,O
kg,O
in,O
young,O
mice,O
using,O
elevated,O
plus,O
maze,O
.,O
Furthermore,O
",",O
DCE,I-Entity
reversed,O
the,O
amnesia,I-Entity
induced,O
by,O
scopolamine,I-Entity
(,O
0.4,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
and,O
diazepam,I-Entity
(,O
1,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
Daucus,B-Entity
carota,I-Entity
extract,I-Entity
(,O
200,O
",",O
400,O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
),O
reduced,O
significantly,O
the,O
brain,O
acetylcholinesterase,O
activity,O
and,O
cholesterol,I-Entity
levels,O
in,O
young,O
and,O
aged,O
mice,O
.,O
The,O
extent,O
of,O
inhibition,O
of,O
brain,O
cholinesterase,O
activity,O
evoked,O
by,O
DCE,I-Entity
at,O
the,O
dose,O
of,O
400,O
mg,O
/,O
kg,O
was,O
22%,O
in,O
young,O
and,O
19%,O
in,O
aged,O
mice,O
.,O
There,O
was,O
a,O
remarkable,O
reduction,O
in,O
total,O
cholesterol,I-Entity
level,O
as,O
well,O
",",O
to,O
the,O
extent,O
of,O
23%,O
in,O
young,O
and,O
21%,O
in,O
aged,O
animals,O
with,O
this,O
dose,O
of,O
DCE,I-Entity
.,O
Therefore,O
",",O
DCE,I-Entity
may,O
prove,O
to,O
be,O
a,O
useful,O
remedy,O
for,O
the,O
management,O
of,O
cognitive,B-Entity
dysfunctions,I-Entity
on,O
account,O
of,O
its,O
multifarious,O
beneficial,O
effects,O
such,O
as,O
",",O
memory,O
improving,O
property,O
",",O
cholesterol,I-Entity
lowering,O
property,O
and,O
anticholinesterase,O
activity,O
.,O
Cauda,B-Entity
equina,I-Entity
syndrome,I-Entity
after,O
epidural,O
steroid,I-Entity
injection,O
:,O
a,O
case,O
report,O
.,O
Conventional,O
treatment,O
methods,O
of,O
lumbusacral,O
radiculopathy,I-Entity
are,O
physical,O
therapy,O
",",O
epidural,O
steroid,I-Entity
injections,O
",",O
oral,O
medications,O
",",O
and,O
spinal,O
manipulative,O
therapy,O
.,O
Cauda,B-Entity
equina,I-Entity
syndrome,I-Entity
is,O
a,O
rare,O
complication,O
of,O
epidural,O
anesthesia,O
.,O
The,O
following,O
case,O
is,O
a,O
report,O
of,O
cauda,B-Entity
equina,I-Entity
syndrome,I-Entity
possibly,O
caused,O
by,O
epidural,O
injection,O
of,O
triamcinolone,I-Entity
and,O
bupivacaine,I-Entity
.,O
A,O
50-year,O
-,O
old,O
woman,O
with,O
low,B-Entity
back,I-Entity
and,I-Entity
right,I-Entity
leg,I-Entity
pain,I-Entity
was,O
scheduled,O
for,O
epidural,O
steroid,I-Entity
injection,O
.,O
After,O
verifying,O
the,O
epidural,O
space,O
",",O
bupivacaine,I-Entity
and,O
triamcinolone,B-Entity
diacetate,I-Entity
were,O
injected,O
.,O
Three,O
hours,O
later,O
",",O
she,O
complained,O
of,O
perineal,O
numbness,I-Entity
and,O
lower,B-Entity
extremity,I-Entity
weakness,I-Entity
.,O
The,O
neurologic,O
evaluation,O
revealed,O
loss,B-Entity
of,I-Entity
sensation,I-Entity
in,O
the,O
saddle,O
area,O
and,O
medial,O
aspect,O
of,O
her,O
right,O
leg,O
.,O
Complications,O
associated,O
with,O
epidural,O
steroid,I-Entity
injections,O
are,O
rare,O
.,O
Clinical,O
examination,O
and,O
continued,O
vigilance,O
for,O
neurologic,B-Entity
deterioration,I-Entity
after,O
epidural,O
steroid,I-Entity
injections,O
is,O
important,O
.,O
High,O
-,O
dose,O
testosterone,I-Entity
is,O
associated,O
with,O
atherosclerosis,I-Entity
in,O
postmenopausal,O
women,O
.,O
OBJECTIVES,O
:,O
To,O
study,O
the,O
long,O
-,O
term,O
effects,O
of,O
androgen,O
treatment,O
on,O
atherosclerosis,I-Entity
in,O
postmenopausal,O
women,O
.,O
In,O
a,O
population,O
-,O
based,O
study,O
in,O
513,O
naturally,O
postmenopausal,O
women,O
aged,O
54,O
-,O
67,O
years,O
",",O
we,O
studied,O
the,O
association,O
between,O
self,O
-,O
reported,O
intramuscularly,O
administered,O
high,O
-,O
dose,O
estrogen,I-Entity
-,O
testosterone,I-Entity
therapy,O
(,O
estradiol-,B-Entity
and,I-Entity
testosterone,I-Entity
esters,I-Entity
),O
and,O
aortic,O
atherosclerosis,I-Entity
.,O
Aortic,O
atherosclerosis,I-Entity
was,O
diagnosed,O
by,O
radiographic,O
detection,O
of,O
calcified,O
deposits,O
in,O
the,O
abdominal,O
aorta,O
",",O
which,O
have,O
been,O
shown,O
to,O
reflect,O
intima,O
atherosclerosis,I-Entity
.,O
In,O
almost,O
half,O
of,O
these,O
women,O
severe,O
atherosclerosis,I-Entity
of,O
the,O
aorta,O
was,O
present,O
(,O
n=11,O
),O
",",O
while,O
in,O
women,O
without,O
hormone,O
use,O
severe,O
atherosclerosis,I-Entity
of,O
the,O
aorta,O
was,O
present,O
in,O
less,O
than,O
20%,O
(,O
OR,O
3.1,O
;,O
95%,O
CI,O
",",O
1.1,O
-,O
8.5,O
",",O
adjusted,O
for,O
age,O
",",O
years,O
since,O
menopause,O
",",O
smoking,O
",",O
and,O
body,O
mass,O
index,O
),O
.,O
The,O
association,O
remained,O
after,O
additional,O
adjustment,O
for,O
diabetes,I-Entity
",",O
cholesterol,I-Entity
level,O
",",O
systolic,O
blood,O
pressure,O
",",O
or,O
alcohol,I-Entity
use,O
.,O
CONCLUSION,O
:,O
Our,O
results,O
suggest,O
that,O
high,O
-,O
dose,O
testosterone,I-Entity
therapy,O
may,O
adversely,O
affect,O
atherosclerosis,I-Entity
in,O
postmenopausal,O
women,O
and,O
indicate,O
that,O
androgen,O
replacement,O
in,O
these,O
women,O
may,O
not,O
be,O
harmless,O
.,O
Sirolimus,I-Entity
-,O
associated,O
proteinuria,I-Entity
and,O
renal,B-Entity
dysfunction,I-Entity
.,O
Sirolimus,I-Entity
is,O
a,O
novel,O
immunosuppressant,O
with,O
potent,O
antiproliferative,O
actions,O
through,O
its,O
ability,O
to,O
inhibit,O
the,O
raptor,O
-,O
containing,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
protein,O
kinase,O
.,O
Sirolimus,I-Entity
represents,O
a,O
major,O
therapeutic,O
advance,O
in,O
the,O
prevention,O
of,O
acute,O
renal,O
allograft,O
rejection,O
and,O
chronic,O
allograft,O
nephropathy,I-Entity
.,O
Its,O
role,O
in,O
the,O
therapy,O
of,O
glomerulonephritis,I-Entity
",",O
autoimmunity,I-Entity
",",O
cystic,B-Entity
renal,I-Entity
diseases,I-Entity
and,O
renal,B-Entity
cancer,I-Entity
is,O
under,O
investigation,O
.,O
Because,O
sirolimus,I-Entity
does,O
not,O
share,O
the,O
vasomotor,O
renal,O
adverse,O
effects,O
exhibited,O
by,O
calcineurin,O
inhibitors,O
",",O
it,O
has,O
been,O
designated,O
a,O
',O
non,O
-,O
nephrotoxic,I-Entity
drug,O
',O
.,O
However,O
",",O
clinical,O
reports,O
suggest,O
that,O
",",O
under,O
some,O
circumstances,O
",",O
sirolimus,I-Entity
is,O
associated,O
with,O
proteinuria,I-Entity
and,O
acute,B-Entity
renal,I-Entity
dysfunction,I-Entity
.,O
A,O
common,O
risk,O
factor,O
appears,O
to,O
be,O
presence,O
of,O
pre,O
-,O
existing,O
chronic,B-Entity
renal,I-Entity
damage,I-Entity
.,O
The,O
mechanisms,O
of,O
sirolimus,I-Entity
-,O
associated,O
proteinuria,I-Entity
are,O
multifactorial,O
and,O
may,O
be,O
due,O
to,O
an,O
increase,O
in,O
glomerular,O
capillary,O
pressure,O
following,O
calcineurin,O
inhibitor,O
withdrawal,O
.,O
It,O
has,O
also,O
been,O
suggested,O
that,O
sirolimus,I-Entity
directly,O
causes,O
increased,O
glomerular,O
permeability,O
/,O
injury,O
",",O
but,O
evidence,O
for,O
this,O
mechanism,O
is,O
currently,O
inconclusive,O
.,O
The,O
acute,B-Entity
renal,I-Entity
dysfunction,I-Entity
associated,O
with,O
sirolimus,I-Entity
(,O
such,O
as,O
in,O
delayed,O
graft,O
function,O
),O
may,O
be,O
due,O
to,O
suppression,O
of,O
compensatory,O
renal,O
cell,O
proliferation,O
and,O
survival,O
/,O
repair,O
processes,O
.,O
Although,O
these,O
adverse,O
effects,O
occur,O
in,O
some,O
patients,O
",",O
their,O
occurrence,O
could,O
be,O
minimised,O
by,O
knowledge,O
of,O
the,O
molecular,O
effects,O
of,O
sirolimus,I-Entity
on,O
the,O
kidney,O
",",O
the,O
use,O
of,O
sirolimus,I-Entity
in,O
appropriate,O
patient,O
populations,O
",",O
close,O
monitoring,O
of,O
proteinuria,I-Entity
and,O
renal,O
function,O
",",O
use,O
of,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitors,O
or,O
angiotensin,B-Entity
II,I-Entity
receptor,O
blockers,O
if,O
proteinuria,I-Entity
occurs,O
and,O
withdrawal,O
if,O
needed,O
.,O
Further,O
long,O
-,O
term,O
analysis,O
of,O
renal,O
allograft,O
studies,O
using,O
sirolimus,I-Entity
as,O
de,O
novo,O
Progressive,O
myopathy,I-Entity
with,O
up,O
-,O
regulation,O
of,O
MHC,O
-,O
I,O
associated,O
with,O
statin,I-Entity
therapy,O
.,O
Statins,I-Entity
can,O
cause,O
a,O
necrotizing,O
myopathy,I-Entity
and,O
hyperCKaemia,I-Entity
which,O
is,O
reversible,O
on,O
cessation,O
of,O
the,O
drug,O
.,O
What,O
is,O
less,O
well,O
known,O
is,O
a,O
phenomenon,O
whereby,O
statins,I-Entity
may,O
induce,O
a,O
myopathy,I-Entity
",",O
which,O
persists,O
or,O
may,O
progress,O
after,O
stopping,O
the,O
drug,O
.,O
All,O
had,O
myofibre,O
necrosis,I-Entity
but,O
only,O
3,O
had,O
an,O
inflammatory,O
infiltrate,O
.,O
In,O
all,O
cases,O
there,O
was,O
diffuse,O
or,O
multifocal,O
up,O
-,O
regulation,O
of,O
MHC,O
-,O
I,O
expression,O
even,O
in,O
non,O
-,O
necrotic,I-Entity
fibres,O
.,O
Progressive,O
improvement,O
occurred,O
in,O
7,O
cases,O
after,O
commencement,O
of,O
prednisolone,I-Entity
and,O
methotrexate,I-Entity
",",O
and,O
in,O
one,O
case,O
spontaneously,O
.,O
These,O
observations,O
suggest,O
that,O
statins,I-Entity
may,O
initiate,O
an,O
immune,O
-,O
mediated,O
myopathy,I-Entity
that,O
persists,O
after,O
withdrawal,O
of,O
the,O
drug,O
and,O
responds,O
to,O
immunosuppressive,O
therapy,O
.,O
The,O
mechanism,O
of,O
this,O
myopathy,I-Entity
is,O
uncertain,O
but,O
may,O
involve,O
the,O
induction,O
by,O
statins,I-Entity
of,O
an,O
endoplasmic,O
reticulum,O
stress,O
response,O
with,O
associated,O
up,O
-,O
regulation,O
of,O
MHC,O
-,O
I,O
expression,O
and,O
antigen,O
presentation,O
by,O
muscle,O
fibres,O
.,O
Direct,O
inhibition,O
of,O
cardiac,O
hyperpolarization,O
-,O
activated,O
cyclic,B-Entity
nucleotide,I-Entity
-,O
gated,O
pacemaker,O
channels,O
by,O
clonidine,I-Entity
.,O
BACKGROUND,O
:,O
Inhibition,O
of,O
cardiac,O
sympathetic,O
tone,O
represents,O
an,O
important,O
strategy,O
for,O
treatment,O
of,O
cardiovascular,B-Entity
disease,I-Entity
",",O
including,O
arrhythmia,I-Entity
",",O
coronary,B-Entity
heart,I-Entity
disease,I-Entity
",",O
and,O
chronic,O
heart,B-Entity
failure,I-Entity
.,O
Activation,O
of,O
presynaptic,O
alpha2-adrenoceptors,O
is,O
the,O
most,O
widely,O
accepted,O
mechanism,O
of,O
action,O
of,O
the,O
antisympathetic,O
drug,O
clonidine,I-Entity
;,O
however,O
",",O
other,O
target,O
proteins,O
have,O
been,O
postulated,O
to,O
contribute,O
to,O
the,O
in,O
vivo,O
actions,O
of,O
clonidine,I-Entity
.,O
METHODS,O
AND,O
RESULTS,O
:,O
To,O
test,O
whether,O
clonidine,I-Entity
elicits,O
pharmacological,O
effects,O
independent,O
of,O
alpha2-adrenoceptors,O
",",O
we,O
have,O
generated,O
mice,O
with,O
a,O
targeted,O
deletion,O
of,O
all,O
3,O
alpha2-adrenoceptor,O
subtypes,O
(,O
alpha2ABC-/-,O
),O
.,O
Alpha2ABC-/-,O
mice,O
were,O
completely,O
unresponsive,O
to,O
the,O
analgesic,O
and,O
hypnotic,O
effects,O
of,O
clonidine,I-Entity
;,O
however,O
",",O
clonidine,I-Entity
significantly,O
lowered,O
heart,O
rate,O
in,O
alpha2ABC-/-,O
mice,O
by,O
up,O
to,O
150,O
bpm,O
.,O
Clonidine,I-Entity
-,O
induced,O
bradycardia,I-Entity
in,O
conscious,O
alpha2ABC-/-,O
mice,O
was,O
32.3%,O
(,O
10,O
microg,O
/,O
kg,O
),O
and,O
26.6%,O
(,O
100,O
microg,O
/,O
kg,O
),O
of,O
the,O
effect,O
in,O
wild,O
-,O
type,O
mice,O
.,O
A,O
similar,O
bradycardic,O
effect,O
of,O
clonidine,I-Entity
was,O
observed,O
in,O
isolated,O
spontaneously,O
beating,O
right,O
atria,O
from,O
alpha2ABC,O
-,O
knockout,O
and,O
wild,O
-,O
type,O
mice,O
.,O
Clonidine,I-Entity
inhibited,O
the,O
native,O
pacemaker,O
current,O
(,O
I(f,O
),O
),O
in,O
isolated,O
sinoatrial,O
node,O
pacemaker,O
cells,O
and,O
the,O
I(f)-generating,O
hyperpolarization,O
-,O
activated,O
cyclic,B-Entity
nucleotide,I-Entity
-,O
gated,O
(,O
HCN,O
),O
2,O
and,O
HCN4,O
channels,O
in,O
transfected,O
HEK293,O
cells,O
.,O
As,O
a,O
consequence,O
of,O
blocking,O
I(f,O
),O
",",O
clonidine,I-Entity
reduced,O
the,O
slope,O
of,O
the,O
diastolic,O
depolarization,O
and,O
the,O
frequency,O
of,O
pacemaker,O
potentials,O
in,O
sinoatrial,O
node,O
cells,O
from,O
wild,O
-,O
type,O
and,O
alpha2ABC,O
-,O
knockout,O
mice,O
.,O
Direct,O
inhibition,O
of,O
cardiac,O
HCN,O
pacemaker,O
channels,O
contributes,O
to,O
the,O
bradycardic,O
effects,O
of,O
clonidine,I-Entity
gene,O
-,O
targeted,O
mice,O
in,O
vivo,O
",",O
and,O
thus,O
",",O
clonidine,I-Entity
-,O
like,O
drugs,O
represent,O
novel,O
structures,O
for,O
future,O
HCN,O
channel,O
inhibitors,O
.,O
Influence,O
of,O
smoking,I-Entity
on,O
developing,O
cochlea,O
.,O
Does,O
smoking,I-Entity
during,O
pregnancy,O
affect,O
the,O
amplitudes,O
of,O
transient,O
evoked,O
otoacoustic,O
emissions,O
in,O
newborns,O
?,O
Maternal,O
tobacco,O
smoking,I-Entity
has,O
negative,O
effects,O
on,O
fetal,O
growth,O
.,O
The,O
influence,O
of,O
smoking,I-Entity
during,O
pregnancy,O
on,O
the,O
developing,O
cochlea,O
has,O
not,O
been,O
estimated,O
",",O
although,O
smoking,I-Entity
has,O
been,O
positively,O
associated,O
with,O
hearing,B-Entity
loss,I-Entity
in,O
adults,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
effects,O
of,O
maternal,O
smoking,I-Entity
on,O
transient,O
evoked,O
otoacoustic,O
emissions,O
(,O
TEOAEs,O
),O
of,O
healthy,O
neonates,O
.,O
This,O
study,O
was,O
undertaken,O
as,O
part,O
of,O
neonatal,O
screening,O
for,O
hearing,B-Entity
impairment,I-Entity
and,O
involved,O
both,O
ears,O
of,O
200,O
newborns,O
.,O
Newborns,O
whose,O
mothers,O
reported,O
smoking,I-Entity
during,O
pregnancy,O
(,O
n=200,O
ears,O
),O
were,O
compared,O
to,O
a,O
control,O
group,O
of,O
newborns,O
(,O
n=200,O
ears,O
),O
",",O
whose,O
mothers,O
were,O
non,O
-,O
smokers,O
.,O
However,O
",",O
by,O
comparing,O
each,O
subgroup,O
to,O
control,O
group,O
",",O
we,O
found,O
statistically,O
significant,O
decreases,B-Entity
of,I-Entity
TEOAEs,I-Entity
amplitudes,I-Entity
at,O
4000Hz,O
for,O
all,O
three,O
groups,O
.,O
In,O
utero,O
",",O
exposure,O
to,O
tobacco,O
smoking,I-Entity
seems,O
to,O
have,O
a,O
small,O
impact,O
on,O
outer,O
hair,O
cells,O
.,O
Further,O
studies,O
are,O
needed,O
in,O
order,O
to,O
establish,O
a,O
potential,O
negative,O
effect,O
of,O
maternal,O
smoking,I-Entity
on,O
the,O
neonate,O
's,O
hearing,O
acuity,O
.,O
Neuroinflammation,I-Entity
and,O
behavioral,B-Entity
abnormalities,I-Entity
after,O
neonatal,O
terbutaline,I-Entity
treatment,O
in,O
rats,O
:,O
implications,O
for,O
autism,I-Entity
.,O
Autism,I-Entity
is,O
a,O
neurodevelopmental,B-Entity
disorder,I-Entity
presenting,O
before,O
3,O
years,O
of,O
age,O
with,O
deficits,B-Entity
in,I-Entity
communication,I-Entity
and,I-Entity
social,I-Entity
skills,I-Entity
and,O
repetitive,B-Entity
behaviors,I-Entity
.,O
In,O
addition,O
to,O
genetic,O
influences,O
",",O
recent,O
studies,O
suggest,O
that,O
prenatal,O
drug,O
or,O
chemical,O
exposures,O
are,O
risk,O
factors,O
for,O
autism,I-Entity
.,O
Terbutaline,I-Entity
",",O
a,O
beta2-adrenoceptor,O
agonist,O
used,O
to,O
arrest,O
preterm,B-Entity
labor,I-Entity
",",O
has,O
been,O
associated,O
with,O
increased,O
concordance,O
for,O
autism,I-Entity
in,O
dizygotic,O
twins,O
.,O
We,O
studied,O
the,O
effects,O
of,O
terbutaline,I-Entity
on,O
microglial,O
activation,O
in,O
different,O
brain,O
regions,O
and,O
behavioral,O
outcomes,O
in,O
developing,O
rats,O
.,O
Newborn,O
rats,O
were,O
given,O
terbutaline,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
daily,O
on,O
postnatal,O
days,O
(,O
PN,O
),O
2,O
to,O
5,O
or,O
PN,O
11,O
to,O
14,O
and,O
examined,O
24,O
h,O
after,O
the,O
last,O
dose,O
and,O
at,O
PN,O
30,O
.,O
Immunohistochemical,O
studies,O
showed,O
that,O
administration,O
of,O
terbutaline,I-Entity
on,O
PN,O
2,O
to,O
5,O
produced,O
a,O
robust,O
increase,O
in,O
microglial,O
activation,O
on,O
PN,O
30,O
in,O
the,O
cerebral,O
cortex,O
",",O
as,O
well,O
as,O
in,O
cerebellar,O
and,O
cerebrocortical,O
white,O
matter,O
.,O
None,O
of,O
these,O
effects,O
occurred,O
in,O
animals,O
given,O
terbutaline,I-Entity
on,O
PN,O
11,O
to,O
14,O
.,O
In,O
behavioral,O
tests,O
",",O
animals,O
treated,O
with,O
terbutaline,I-Entity
on,O
PN,O
2,O
to,O
5,O
showed,O
consistent,O
patterns,O
of,O
hyper,O
-,O
reactivity,O
to,O
novelty,O
and,O
aversive,O
stimuli,O
when,O
assessed,O
in,O
a,O
novel,O
open,O
field,O
",",O
as,O
well,O
as,O
in,O
the,O
acoustic,O
startle,O
response,O
test,O
.,O
Our,O
findings,O
indicate,O
that,O
beta2-adrenoceptor,O
overstimulation,O
during,O
an,O
early,O
critical,O
period,O
results,O
in,O
microglial,O
activation,O
associated,O
with,O
innate,O
neuroinflammatory,O
pathways,O
and,O
behavioral,B-Entity
abnormalities,I-Entity
",",O
similar,O
to,O
those,O
described,O
in,O
autism,I-Entity
.,O
This,O
study,O
provides,O
a,O
useful,O
animal,O
model,O
for,O
understanding,O
the,O
neuropathological,O
processes,O
underlying,O
autism,B-Entity
spectrum,I-Entity
disorders,I-Entity
.,O
Acute,O
myocarditis,I-Entity
associated,O
with,O
clozapine,I-Entity
.,O
A,O
case,O
of,O
acute,O
myocarditis,I-Entity
associated,O
with,O
the,O
commencement,O
of,O
clozapine,I-Entity
is,O
described,O
",",O
highlighting,O
the,O
onset,O
",",O
course,O
and,O
possible,O
contributing,O
factors,O
.,O
There,O
is,O
an,O
urgent,O
need,O
to,O
raise,O
awareness,O
about,O
this,O
potentially,O
fatal,O
complication,O
of,O
clozapine,I-Entity
use,O
.,O
A,O
20-year,O
-,O
old,O
male,O
with,O
schizophrenia,I-Entity
developed,O
a,O
sudden,O
onset,O
of,O
myocarditis,I-Entity
after,O
commencement,O
of,O
clozapine,I-Entity
.,O
The,O
symptoms,O
occurred,O
around,O
2,O
weeks,O
after,O
starting,O
clozapine,I-Entity
in,O
an,O
inpatient,O
setting,O
.,O
Possible,O
contributing,O
factors,O
may,O
have,O
been,O
concomitant,O
antidepressant,I-Entity
use,O
and,O
unaccustomed,O
physical,O
activity,O
.,O
Myocarditis,I-Entity
is,O
an,O
increasingly,O
recognized,O
complication,O
associated,O
with,O
the,O
use,O
of,O
clozapine,I-Entity
.,O
Considering,O
that,O
clozapine,I-Entity
remains,O
the,O
gold,O
standard,O
in,O
treatment,O
of,O
resistant,O
psychosis,I-Entity
",",O
there,O
is,O
an,O
urgent,O
need,O
to,O
raise,O
awareness,O
among,O
medical,O
and,O
paramedical,O
staff,O
involved,O
in,O
the,O
care,O
of,O
these,O
patients,O
.,O
There,O
are,O
also,O
implications,O
for,O
recommendations,O
and,O
regulations,O
regarding,O
the,O
use,O
of,O
clozapine,I-Entity
.,O
Encephalopathy,I-Entity
induced,O
by,O
levetiracetam,I-Entity
added,O
to,O
valproate,I-Entity
.,O
BACKGROUND,O
:,O
We,O
report,O
on,O
the,O
manifestation,O
of,O
a,O
levetiracetam,I-Entity
(,O
LEV)-induced,I-Entity
encephalopathy,I-Entity
.,O
A,O
28-year,O
-,O
old,O
man,O
suffering,O
from,O
idiopathic,B-Entity
epilepsy,I-Entity
with,O
generalized,O
seizures,I-Entity
was,O
treated,O
with,O
LEV,I-Entity
(,O
3000,O
mg,O
),O
added,O
to,O
valproate,I-Entity
(,O
VPA,I-Entity
),O
(,O
2000,O
mg,O
),O
.,O
Frequency,O
of,O
generalized,O
tonic,B-Entity
-,I-Entity
clonic,I-Entity
seizures,I-Entity
increased,O
from,O
one,O
per,O
6,O
months,O
to,O
two,O
per,O
month,O
.,O
Neuropsychological,O
testing,O
showed,O
impaired,B-Entity
word,I-Entity
fluency,I-Entity
",",I-Entity
psychomotor,I-Entity
speed,I-Entity
and,I-Entity
working,I-Entity
memory,I-Entity
.,O
Following,O
discontinuation,O
of,O
LEV,I-Entity
",",O
EEG,O
and,O
neuropsychological,O
findings,O
improved,O
and,O
seizure,I-Entity
frequency,O
decreased,O
.,O
Norepinephrine,I-Entity
signaling,O
through,O
beta,O
-,O
adrenergic,O
receptors,O
is,O
critical,O
for,O
expression,O
of,O
cocaine,I-Entity
-,O
induced,O
anxiety,I-Entity
.,O
Cocaine,I-Entity
is,O
a,O
widely,O
abused,O
psychostimulant,O
that,O
has,O
both,O
rewarding,O
and,O
aversive,O
properties,O
.,O
While,O
the,O
mechanisms,O
underlying,O
cocaine,I-Entity
's,O
rewarding,O
effects,O
have,O
been,O
studied,O
extensively,O
",",O
less,O
attention,O
has,O
been,O
paid,O
to,O
the,O
unpleasant,O
behavioral,O
states,O
induced,O
by,O
cocaine,I-Entity
",",O
such,O
as,O
anxiety,I-Entity
.,O
:,O
In,O
this,O
study,O
",",O
we,O
evaluated,O
the,O
performance,O
of,O
dopamine,I-Entity
beta,O
-,O
hydroxylase,O
knockout,O
(,O
Dbh,O
-/-,O
),O
mice,O
",",O
which,O
lack,O
norepinephrine,I-Entity
(,O
NE,I-Entity
),O
",",O
in,O
the,O
elevated,O
plus,O
maze,O
(,O
EPM,O
),O
to,O
examine,O
the,O
contribution,O
of,O
noradrenergic,O
signaling,O
to,O
cocaine,I-Entity
-,O
induced,O
anxiety,I-Entity
.,O
We,O
found,O
that,O
cocaine,I-Entity
dose,O
-,O
dependently,O
increased,O
anxiety,I-Entity
-,O
like,O
behavior,O
in,O
control,O
(,O
Dbh,O
+,O
/-,O
mice,O
had,O
normal,O
baseline,O
performance,O
in,O
the,O
EPM,O
but,O
were,O
completely,O
resistant,O
to,O
the,O
anxiogenic,O
effects,O
of,O
cocaine,I-Entity
.,O
Cocaine,I-Entity
-,O
induced,O
anxiety,I-Entity
was,O
also,O
attenuated,O
in,O
Dbh,O
+,O
/-,O
mice,O
following,O
administration,O
of,O
disulfiram,I-Entity
",",O
a,O
dopamine,I-Entity
beta,O
-,O
hydroxylase,O
(,O
DBH,O
),O
inhibitor,O
.,O
In,O
experiments,O
using,O
specific,O
adrenergic,O
antagonists,O
",",O
we,O
found,O
that,O
pretreatment,O
with,O
the,O
beta,O
-,O
adrenergic,O
receptor,O
antagonist,O
propranolol,I-Entity
blocked,O
cocaine,I-Entity
-,O
induced,O
anxiety,I-Entity
-,O
like,O
behavior,O
in,O
Dbh,O
+,O
/-,O
and,O
wild,O
-,O
type,O
C57BL6/J,O
mice,O
",",O
while,O
the,O
alpha(1,O
),O
antagonist,O
prazosin,I-Entity
and,O
the,O
alpha(2,O
),O
antagonist,O
yohimbine,I-Entity
had,O
no,O
effect,O
.,O
These,O
results,O
indicate,O
that,O
noradrenergic,O
signaling,O
via,O
beta,O
-,O
adrenergic,O
receptors,O
is,O
required,O
for,O
cocaine,I-Entity
-,O
induced,O
anxiety,I-Entity
in,O
mice,O
.,O
Clonidine,I-Entity
for,O
attention,B-Entity
-,I-Entity
deficit,I-Entity
/,I-Entity
hyperactivity,I-Entity
disorder,I-Entity
:,O
OBJECTIVE,O
:,O
To,O
examine,O
the,O
safety,O
and,O
tolerability,O
of,O
clonidine,I-Entity
used,O
alone,O
or,O
with,O
methylphenidate,I-Entity
in,O
children,O
with,O
attention,B-Entity
-,I-Entity
deficit,I-Entity
/,I-Entity
hyperactivity,I-Entity
disorder,I-Entity
(,O
ADHD,I-Entity
),O
.,O
In,O
a,O
16-week,O
multicenter,O
",",O
double,O
-,O
blind,O
trial,O
",",O
122,O
children,O
with,O
ADHD,I-Entity
were,O
randomly,O
assigned,O
to,O
clonidine,I-Entity
(,O
n,O
=,O
31,O
),O
",",O
methylphenidate,I-Entity
(,O
n,O
=,O
29,O
),O
",",O
clonidine,I-Entity
and,O
methylphenidate,I-Entity
(,O
n,O
=,O
32,O
),O
",",O
or,O
placebo,O
(,O
Doses,O
were,O
flexibly,O
titrated,O
up,O
to,O
0.6,O
mg,O
/,O
day,O
for,O
clonidine,I-Entity
and,O
60,O
mg,O
/,O
day,O
for,O
methylphenidate,I-Entity
(,O
both,O
with,O
divided,O
dosing,O
),O
.,O
There,O
were,O
more,O
incidents,O
of,O
bradycardia,I-Entity
in,O
subjects,O
treated,O
with,O
clonidine,I-Entity
compared,O
with,O
those,O
not,O
treated,O
with,O
clonidine,I-Entity
(,O
17.5%,O
versus,O
3.4%,O
;,O
p,O
=,O
.02,O
),O
",",O
but,O
no,O
other,O
significant,O
group,O
differences,O
regarding,O
electrocardiogram,O
and,O
other,O
cardiovascular,O
outcomes,O
.,O
There,O
were,O
no,O
suggestions,O
of,O
interactions,O
between,O
clonidine,I-Entity
and,O
methylphenidate,I-Entity
regarding,O
cardiovascular,O
outcomes,O
.,O
Moderate,O
or,O
severe,O
adverse,O
events,O
were,O
more,O
common,O
in,O
subjects,O
on,O
clonidine,I-Entity
(,O
79.4%,O
versus,O
49.2%,O
;,O
p,O
=,O
.0006,O
),O
but,O
not,O
associated,O
with,O
higher,O
rates,O
of,O
early,O
study,O
withdrawal,O
.,O
Drowsiness,I-Entity
was,O
common,O
on,O
clonidine,I-Entity
",",O
but,O
generally,O
resolved,O
by,O
6,O
to,O
8,O
weeks,O
.,O
CONCLUSIONS,O
:,O
Clonidine,I-Entity
",",O
used,O
alone,O
or,O
with,O
methylphenidate,I-Entity
",",O
appears,O
safe,O
and,O
well,O
tolerated,O
in,O
childhood,O
ADHD,I-Entity
.,O
Physicians,O
prescribing,O
clonidine,I-Entity
should,O
monitor,O
for,O
bradycardia,I-Entity
and,O
advise,O
patients,O
about,O
the,O
high,O
likelihood,O
of,O
initial,O
drowsiness,I-Entity
.,O
Thalidomide,I-Entity
has,O
limited,O
single,O
-,O
agent,O
activity,O
in,O
relapsed,O
or,O
refractory,O
indolent,O
non,B-Entity
-,I-Entity
Hodgkin,I-Entity
lymphomas,I-Entity
:,O
a,O
phase,O
II,O
trial,O
of,O
the,O
Cancer,I-Entity
and,O
Leukemia,I-Entity
Group,O
B.,O
Thalidomide,I-Entity
is,O
an,O
immunomodulatory,O
agent,O
with,O
demonstrated,O
activity,O
in,O
multiple,B-Entity
myeloma,I-Entity
",",O
mantle,B-Entity
cell,I-Entity
lymphoma,I-Entity
and,O
lymphoplasmacytic,B-Entity
lymphoma,I-Entity
.,O
Its,O
activity,O
is,O
believed,O
to,O
be,O
due,O
modulation,O
of,O
the,O
tumour,I-Entity
milieu,O
",",O
including,O
downregulation,O
of,O
angiogenesis,O
and,O
inflammatory,O
cytokines,O
.,O
Between,O
July,O
2001,O
and,O
April,O
2004,O
",",O
24,O
patients,O
with,O
relapsed,O
/,O
refractory,O
indolent,O
lymphomas,I-Entity
received,O
thalidomide,I-Entity
200,O
mg,O
daily,O
with,O
escalation,O
by,O
100,O
mg,O
daily,O
every,O
1,O
-,O
2,O
weeks,O
as,O
tolerated,O
",",O
up,O
to,O
a,O
maximum,O
of,O
800,O
mg,O
daily,O
.,O
included,O
myelosuppression,I-Entity
",",O
fatigue,I-Entity
",",O
somnolence,I-Entity
/,O
depressed,B-Entity
mood,I-Entity
",",O
neuropathy,I-Entity
and,O
dyspnea,I-Entity
.,O
Of,O
concern,O
was,O
the,O
occurrence,O
of,O
four,O
thromboembolic,I-Entity
events,O
.,O
Our,O
results,O
failed,O
to,O
demonstrate,O
an,O
important,O
response,O
rate,O
to,O
single,O
agent,O
thalidomide,I-Entity
in,O
indolent,O
lymphomas,I-Entity
and,O
contrast,O
with,O
the,O
higher,O
activity,O
level,O
reported,O
with,O
the,O
second,O
generation,O
immunomodulatory,O
agent,O
",",O
lenalidomide,I-Entity
.,O
Intracavernous,O
epinephrine,I-Entity
:,O
a,O
minimally,O
invasive,O
treatment,O
for,O
priapism,I-Entity
in,O
the,O
emergency,O
department,O
.,O
Priapism,I-Entity
is,O
the,O
prolonged,O
erection,O
of,O
the,O
penis,O
in,O
the,O
absence,O
of,O
sexual,O
arousal,O
.,O
A,O
45-year,O
-,O
old,O
man,O
",",O
an,O
admitted,O
frequent,O
cocaine,I-Entity
user,O
",",O
presented,O
to,O
the,O
Emergency,O
Department,O
(,O
ED,O
),O
on,O
two,O
separate,O
occasions,O
with,O
a,O
history,O
of,O
priapism,I-Entity
after,O
cocaine,I-Entity
use,O
.,O
The,O
management,O
options,O
in,O
the,O
ED,O
",",O
as,O
exemplified,O
by,O
four,O
individual,O
case,O
reports,O
",",O
in,O
particular,O
the,O
use,O
of,O
a,O
minimally,O
invasive,O
method,O
of,O
intracorporal,O
epinephrine,I-Entity
instillation,O
",",O
are,O
discussed,O
.,O
Effect,O
of,O
green,B-Entity
tea,I-Entity
and,O
vitamin,B-Entity
E,I-Entity
combination,O
in,O
isoproterenol,I-Entity
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
The,O
present,O
study,O
was,O
aimed,O
to,O
investigate,O
the,O
combined,O
effects,O
of,O
green,B-Entity
tea,I-Entity
and,O
vitamin,B-Entity
E,I-Entity
on,O
heart,O
weight,O
",",O
body,O
weight,O
",",O
serum,O
marker,O
enzymes,O
",",O
lipid,O
peroxidation,O
",",O
endogenous,O
antioxidants,O
and,O
membrane,O
bound,O
ATPases,O
in,O
isoproterenol,I-Entity
(,O
ISO)-induced,I-Entity
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
Adult,O
male,O
albino,O
rats,O
",",O
treated,O
with,O
ISO,I-Entity
(,O
200,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
for,O
2,O
days,O
at,O
an,O
interval,O
of,O
24,O
h,O
caused,O
a,O
significant,O
(,O
P<0.05,O
),O
elevation,O
of,O
heart,O
weight,O
",",O
serum,O
marker,O
enzymes,O
",",O
lipid,O
peroxidation,O
and,O
Ca+2,I-Entity
ATPase,O
level,O
whereas,O
there,O
was,O
a,O
significant,O
(,O
P<0.05,O
),O
decrease,O
in,O
body,O
weight,O
",",O
endogenous,O
antioxidants,O
",",O
Na+/,I-Entity
K+,I-Entity
ATPase,O
and,O
Mg+2,I-Entity
ATPase,O
levels,O
.,O
Administration,O
of,O
green,B-Entity
tea,I-Entity
(,O
100,O
mg,O
/,O
kg,O
/,O
day,O
",",O
p.o,O
.,O
),O
and,O
vitamin,B-Entity
E,I-Entity
(,O
100,O
mg,O
/,O
kg,O
/,O
day,O
",",O
p.o,O
.,O
),O
together,O
for,O
30,O
consecutive,O
days,O
and,O
challenged,O
with,O
ISO,I-Entity
on,O
the,O
day,O
29th,O
and,O
30th,O
",",O
showed,O
a,O
significant,O
(,O
P<0.05,O
),O
decrease,O
in,O
heart,O
weight,O
",",O
serum,O
marker,O
enzymes,O
",",O
lipid,O
peroxidation,O
",",O
Ca+2,I-Entity
ATPase,O
and,O
a,O
significant,O
increase,O
in,O
the,O
body,O
weight,O
",",O
endogenous,O
antioxidants,O
",",O
Na+/K+,I-Entity
ATPase,O
and,O
Mg+2,I-Entity
ATPase,O
when,O
compared,O
with,O
ISO,I-Entity
treated,O
group,O
and,O
green,B-Entity
tea,I-Entity
or,O
vitamin,B-Entity
E,I-Entity
alone,O
treated,O
groups,O
.,O
These,O
findings,O
indicate,O
the,O
synergistic,O
protective,O
effect,O
of,O
green,B-Entity
tea,I-Entity
and,O
vitamin,B-Entity
E,I-Entity
during,O
ISO,I-Entity
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
Development,O
of,O
ocular,B-Entity
myasthenia,I-Entity
during,O
pegylated,B-Entity
interferon,I-Entity
and,O
ribavirin,I-Entity
treatment,O
for,O
chronic,B-Entity
hepatitis,I-Entity
C.,I-Entity
A,O
63-year,O
-,O
old,O
male,O
experienced,O
sudden,O
diplopia,I-Entity
after,O
9,O
weeks,O
of,O
administration,O
of,O
pegylated,B-Entity
interferon,I-Entity
(,I-Entity
IFN,I-Entity
),I-Entity
alpha-2b,I-Entity
and,O
ribavirin,I-Entity
for,O
chronic,B-Entity
hepatitis,I-Entity
C,I-Entity
(,O
CHC,I-Entity
),O
.,O
Ophthalmologic,O
examinations,O
showed,O
ptosis,B-Entity
on,I-Entity
the,I-Entity
right,I-Entity
upper,I-Entity
lid,I-Entity
and,O
restricted,B-Entity
right,I-Entity
eye,I-Entity
movement,I-Entity
without,O
any,O
other,O
neurological,O
signs,O
.,O
The,O
acetylcholine,I-Entity
receptor,O
antibody,O
titer,O
and,O
response,O
to,O
acetylcholinesterase,O
inhibitors,O
were,O
negative,O
",",O
and,O
the,O
results,O
of,O
thyroid,O
function,O
tests,O
were,O
normal,O
.,O
The,O
patient,O
's,O
ophthalmological,O
symptoms,O
improved,O
rapidly,O
3,O
weeks,O
after,O
discontinuation,O
of,O
pegylated,B-Entity
IFN,I-Entity
alpha-2b,I-Entity
and,O
ribavirin,I-Entity
.,O
The,O
ocular,B-Entity
myasthenia,I-Entity
associated,O
with,O
combination,O
therapy,O
of,O
pegylated,B-Entity
IFN,I-Entity
alpha-2b,I-Entity
and,O
ribavirin,I-Entity
for,O
CHC,I-Entity
is,O
very,O
rarely,O
reported,O
;,O
therefore,O
",",O
we,O
present,O
this,O
case,O
with,O
a,O
review,O
of,O
the,O
various,O
eye,O
complications,O
of,O
IFN,I-Entity
therapy,O
.,O
The,O
glycine,I-Entity
transporter-1,O
inhibitor,O
SSR103800,I-Entity
displays,O
a,O
selective,O
and,O
specific,O
antipsychotic,O
-,O
like,O
profile,O
in,O
normal,O
and,O
transgenic,O
mice,O
.,O
Schizophrenia,I-Entity
has,O
been,O
initially,O
associated,O
with,O
dysfunction,O
in,O
dopamine,I-Entity
neurotransmission,O
.,O
However,O
",",O
the,O
observation,O
that,O
antagonists,O
of,O
the,O
glutamate,I-Entity
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
produce,O
schizophrenic,I-Entity
-,O
like,O
symptoms,O
in,O
humans,O
has,O
led,O
to,O
the,O
idea,O
of,O
a,O
dysfunctioning,O
of,O
the,O
glutamatergic,O
system,O
via,O
its,O
NMDA,I-Entity
receptor,O
.,O
As,O
a,O
result,O
",",O
there,O
is,O
a,O
growing,O
interest,O
in,O
the,O
development,O
of,O
pharmacological,O
agents,O
with,O
potential,O
antipsychotic,O
properties,O
that,O
enhance,O
the,O
activity,O
of,O
the,O
glutamatergic,O
system,O
via,O
a,O
modulation,O
of,O
the,O
NMDA,I-Entity
receptor,O
.,O
Among,O
them,O
are,O
glycine,I-Entity
transporter-1,O
(,O
GlyT1,O
),O
inhibitors,O
such,O
as,O
SSR103800,I-Entity
",",O
which,O
indirectly,O
enhance,O
NMDA,I-Entity
receptor,O
function,O
by,O
increasing,O
the,O
glycine,I-Entity
(,O
a,O
co,O
-,O
agonist,O
for,O
the,O
NMDA,I-Entity
receptor,O
),O
levels,O
in,O
the,O
synapse,O
.,O
This,O
study,O
aimed,O
at,O
investigating,O
the,O
potential,O
antipsychotic,O
-,O
like,O
properties,O
of,O
SSR103800,I-Entity
",",O
with,O
a,O
particular,O
focus,O
on,O
models,O
of,O
hyperactivity,I-Entity
",",O
involving,O
either,O
drug,O
challenge,O
(,O
ie,O
",",O
amphetamine,I-Entity
and,O
MK-801,I-Entity
),O
or,O
transgenic,O
mice,O
(,O
ie,O
",",O
NMDA,I-Entity
Nr1(neo-/-,O
),O
and,O
DAT(-/-,O
),O
),O
.,O
Results,O
showed,O
that,O
SSR103800,I-Entity
(,O
10,O
-,O
30,O
mg,O
/,O
kg,O
p.o,O
.,O
),O
blocked,O
hyperactivity,I-Entity
induced,O
by,O
the,O
non,O
-,O
competitive,O
NMDA,I-Entity
receptor,O
antagonist,O
",",O
MK-801,I-Entity
and,O
partially,O
reversed,O
spontaneous,O
hyperactivity,I-Entity
of,O
NMDA,I-Entity
Nr1(neo-/-,O
),O
mice,O
.,O
In,O
contrast,O
",",O
SSR103800,I-Entity
failed,O
to,O
affect,O
hyperactivity,I-Entity
induced,O
by,O
amphetamine,I-Entity
or,O
naturally,O
observed,O
in,O
dopamine,I-Entity
transporter,O
(,O
DAT(-/-,O
),O
),O
knockout,O
mice,O
Importantly,O
",",O
both,O
classical,O
(,O
haloperidol,I-Entity
),O
and,O
atypical,O
(,O
olanzapine,I-Entity
",",O
clozapine,I-Entity
and,O
aripiprazole,I-Entity
),O
antipsychotics,O
were,O
effective,O
in,O
all,O
these,O
models,O
of,O
hyperactivity,I-Entity
.,O
However,O
",",O
unlike,O
these,O
latter,O
",",O
SSR103800,I-Entity
did,O
not,O
produce,O
catalepsy,I-Entity
(,O
retention,O
on,O
the,O
bar,O
test,O
),O
up,O
to,O
30,O
mg,O
/,O
kg,O
p.o,O
.,O
Together,O
these,O
findings,O
show,O
that,O
the,O
GlyT1,O
inhibitor,O
",",O
SSR103800,I-Entity
",",O
produces,O
antipsychotic,O
-,O
like,O
effects,O
",",O
which,O
differ,O
from,O
those,O
observed,O
with,O
compounds,O
primarily,O
targeting,O
the,O
dopaminergic,O
system,O
",",O
and,O
has,O
a,O
reduced,O
side,O
-,O
effect,O
potential,O
as,O
compared,O
with,O
these,O
latter,O
drugs,O
.,O
Phenylephrine,I-Entity
but,O
not,O
ephedrine,I-Entity
reduces,B-Entity
frontal,I-Entity
lobe,I-Entity
oxygenation,I-Entity
following,O
anesthesia,O
-,O
induced,O
hypotension,I-Entity
.,O
Vasopressor,O
agents,O
are,O
used,O
to,O
correct,O
anesthesia,O
-,O
induced,O
hypotension,I-Entity
.,O
We,O
describe,O
the,O
effect,O
of,O
phenylephrine,I-Entity
and,O
ephedrine,I-Entity
on,O
frontal,O
lobe,O
oxygenation,O
(,O
S(c)O(2,O
),O
),O
following,O
anesthesia,O
-,O
induced,O
hypotension,I-Entity
.,O
Following,O
induction,O
of,O
anesthesia,O
by,O
fentanyl,I-Entity
(,O
0.15,O
mg,O
kg(-1,O
),O
),O
and,O
propofol,I-Entity
(,O
2.0,O
mg,O
kg(-1,O
),O
),O
",",O
13,O
patients,O
received,O
phenylephrine,I-Entity
(,O
0.1,O
mg,O
iv,O
),O
and,O
12,O
patients,O
received,O
ephedrine,I-Entity
(,O
10,O
mg,O
iv,O
),O
to,O
restore,O
mean,O
arterial,O
pressure,O
(,O
MAP,O
),O
.,O
MAP,O
",",O
stroke,I-Entity
volume,O
(,O
SV,O
),O
",",O
cardiac,O
output,O
(,O
CO,O
),O
",",O
and,O
frontal,O
lobe,O
oxygenation,O
(,O
S(c)O(2,O
),O
),O
were,O
registered,O
.,O
Induction,O
of,O
anesthesia,O
was,O
followed,O
by,O
a,B-Entity
decrease,I-Entity
in,I-Entity
MAP,I-Entity
",",I-Entity
HR,I-Entity
",",I-Entity
SV,I-Entity
",",I-Entity
and,I-Entity
CO,I-Entity
concomitant,O
with,O
an,O
elevation,O
in,O
S(c)O(2,O
),O
.,O
After,O
administration,O
of,O
phenylephrine,I-Entity
",",O
MAP,O
increased,O
(,O
51,O
+,O
/-,O
The,O
administration,O
of,O
ephedrine,I-Entity
led,O
to,O
a,O
similar,O
increase,O
in,O
MAP,O
(,O
53,O
+,O
/-,O
The,O
utilization,O
of,O
phenylephrine,I-Entity
to,O
correct,O
hypotension,I-Entity
induced,O
by,O
anesthesia,O
has,O
a,O
negative,O
impact,O
on,O
S(c)O(2,O
),O
while,O
ephedrine,I-Entity
maintains,O
frontal,O
lobe,O
oxygenation,O
potentially,O
related,O
to,O
an,O
increase,O
in,O
CO,O
.,O
A,O
novel,O
",",O
multiple,O
symptom,O
model,O
of,O
obsessive,B-Entity
-,I-Entity
compulsive,I-Entity
-,I-Entity
like,I-Entity
behaviors,I-Entity
in,O
animals,O
.,O
Current,O
animal,O
models,O
of,O
obsessive,B-Entity
-,I-Entity
compulsive,I-Entity
disorder,I-Entity
(,O
OCD,I-Entity
),O
typically,O
involve,O
acute,O
",",O
drug,O
-,O
induced,O
symptom,O
provocation,O
or,O
a,O
genetic,O
association,O
with,O
stereotypies,O
or,O
anxiety,I-Entity
.,O
None,O
of,O
these,O
current,O
models,O
demonstrate,O
multiple,O
OCD,I-Entity
-,O
like,O
behaviors,O
.,O
Neonatal,O
rats,O
were,O
treated,O
with,O
the,O
tricyclic,O
antidepressant,I-Entity
clomipramine,I-Entity
or,O
vehicle,O
between,O
days,O
9,O
and,O
16,O
twice,O
daily,O
and,O
behaviorally,O
tested,O
in,O
adulthood,O
.,O
RESULTS,O
:,O
Clomipramine,I-Entity
exposure,O
in,O
immature,O
rats,O
produced,O
significant,O
behavioral,O
and,O
biochemical,O
changes,O
that,O
include,O
enhanced,O
anxiety,I-Entity
(,O
elevated,O
plus,O
maze,O
and,O
marble,O
burying,O
),O
",",O
behavioral,B-Entity
inflexibility,I-Entity
(,O
perseveration,O
in,O
the,O
spontaneous,O
alternation,O
task,O
and,O
impaired,O
reversal,O
learning,O
),O
",",O
working,O
memory,B-Entity
impairment,I-Entity
(,O
e.g.,O
",",O
win,O
-,O
shift,O
paradigm,O
),O
",",O
hoarding,I-Entity
",",O
and,O
corticostriatal,B-Entity
dysfunction,I-Entity
.,O
Dopamine,I-Entity
D2,O
receptors,O
were,O
elevated,O
in,O
the,O
striatum,O
",",O
whereas,O
serotonin,I-Entity
2C,O
",",O
but,O
not,O
serotonin,I-Entity
1A,O
",",O
receptors,O
were,O
elevated,O
in,O
the,O
orbital,O
frontal,O
cortex,O
.,O
This,O
is,O
the,O
first,O
demonstration,O
of,O
multiple,O
symptoms,O
consistent,O
with,O
an,O
OCD,I-Entity
-,O
like,O
profile,O
in,O
animals,O
.,O
Moreover,O
",",O
these,O
behaviors,O
are,O
accompanied,O
by,O
biochemical,O
changes,O
in,O
brain,O
regions,O
previously,O
identified,O
as,O
relevant,O
to,O
OCD,I-Entity
.,O
This,O
novel,O
model,O
of,O
OCD,I-Entity
demonstrates,O
that,O
drug,O
exposure,O
during,O
a,O
sensitive,O
period,O
can,O
program,O
disease,O
-,O
like,O
systems,O
permanently,O
",",O
which,O
could,O
have,O
implications,O
for,O
current,O
and,O
future,O
therapeutic,O
strategies,O
for,O
this,O
and,O
other,O
psychiatric,B-Entity
disorders,I-Entity
.,O
Late,O
recovery,O
of,O
renal,O
function,O
in,O
a,O
woman,O
with,O
the,O
hemolytic,B-Entity
uremic,I-Entity
syndrome,I-Entity
.,O
A,O
case,O
is,O
reported,O
of,O
the,O
hemolytic,B-Entity
uremic,I-Entity
syndrome,I-Entity
(,O
HUS,I-Entity
),O
in,O
a,O
woman,O
taking,O
oral,B-Entity
contraceptives,I-Entity
.,O
She,O
was,O
treated,O
with,O
heparin,I-Entity
",",O
dipyridamole,I-Entity
and,O
hemodialysis,O
;,O
and,O
after,O
more,O
than,O
three,O
months,O
",",O
her,O
urinary,O
output,O
rose,O
above,O
500,O
ml,O
;,O
and,O
six,O
months,O
after,O
the,O
onset,O
of,O
anuria,I-Entity
",",O
dialysis,O
treatment,O
was,O
stopped,O
.,O
This,O
case,O
emphasizes,O
the,O
possibility,O
that,O
HUS,I-Entity
in,O
adults,O
is,O
not,O
invariably,O
irreversible,O
and,O
that,O
",",O
despite,O
prolonged,O
oliguria,I-Entity
",",O
recovery,O
of,O
renal,O
function,O
can,O
be,O
obtained,O
.,O
Therefore,O
",",O
in,O
adult,O
patients,O
affected,O
by,O
HUS,I-Entity
",",O
dialysis,O
should,O
not,O
be,O
discontinued,O
prematurely,O
;,O
moreover,O
",",O
bilateral,O
nephrectomy,O
",",O
for,O
treatment,O
of,O
severe,O
hypertension,I-Entity
and,O
microangiopathic,B-Entity
hemolytic,I-Entity
anemia,I-Entity
",",O
should,O
be,O
performed,O
with,O
caution,O
.,O
Effects,O
of,O
acetylsalicylic,B-Entity
acid,I-Entity
",",O
dipyridamole,I-Entity
",",O
and,O
hydrocortisone,I-Entity
on,O
epinephrine,I-Entity
-,O
induced,O
myocardial,B-Entity
injury,I-Entity
in,O
dogs,O
.,O
A,O
reproducible,O
model,O
for,O
producing,O
diffuse,O
myocardial,B-Entity
injury,I-Entity
(,O
epinephrine,I-Entity
infusion,O
),O
has,O
been,O
developed,O
to,O
study,O
the,O
cardioprotective,O
effects,O
of,O
agents,O
or,O
maneuvers,O
which,O
might,O
alter,O
the,O
evolution,O
of,O
acute,O
myocardial,B-Entity
infarction,I-Entity
.,O
Infusions,O
of,O
epinephrine,I-Entity
(,O
4,O
mug,O
per,O
kilogram,O
per,O
minute,O
for,O
6,O
hours,O
),O
increased,O
radiocalcium,I-Entity
uptakes,O
into,O
intact,O
myocardium,O
and,O
each,O
of,O
its,O
subcellular,O
components,O
with,O
the,O
mitochondrial,O
fraction,O
showing,O
the,O
most,O
consistent,O
changes,O
when,O
compared,O
to,O
saline,O
-,O
infused,O
control,O
animals,O
(,O
"4,957",O
vs.,O
827,O
counts,O
per,O
minute,O
per,O
gram,O
of,O
dried,O
tissue,O
or,O
fraction,O
),O
.,O
Myocardial,O
concentrations,O
of,O
calcium,I-Entity
also,O
increased,O
significantly,O
(,O
12.0,O
vs.,O
5.0,O
mg.per,O
100,O
Gm,O
.,O
Infusions,O
of,O
calcium,B-Entity
chloride,I-Entity
sufficient,O
to,O
raise,O
serum,O
calcium,I-Entity
concentrations,O
2,O
mEq,O
.,O
per,O
liter,O
failed,O
to,O
increase,O
calcium,I-Entity
influx,O
into,O
the,O
myocardial,O
cell,O
.,O
Mitochondrial,O
radiocalcium,I-Entity
uptakes,O
were,O
significantly,O
decreased,O
in,O
animals,O
pretreated,O
with,O
acetylsalicylic,B-Entity
acid,I-Entity
or,O
dipyridamole,I-Entity
or,O
when,O
hydrocortisone,I-Entity
was,O
added,O
to,O
the,O
epinephrine,I-Entity
infusion,O
(,O
"2,682,2,803",O
",",O
and,O
"3,424",O
counts,O
per,O
minute,O
per,O
gram,O
of,O
dried,O
fraction,O
",",O
respectively,O
),O
.,O
Myocardial,O
calcium,I-Entity
concentrations,O
also,O
were,O
decreased,O
(,O
11.2,O
",",O
8.3,O
",",O
and,O
8.9,O
mg,O
.,O
Acetylsalicylic,B-Entity
acid,I-Entity
",",O
dipyridamole,I-Entity
",",O
and,O
hydrocortisone,I-Entity
all,O
appear,O
to,O
have,O
cardioprotective,O
effects,O
when,O
tested,O
in,O
this,O
model,O
.,O
Changes,O
in,O
depressive,I-Entity
status,O
associated,O
with,O
topical,O
beta,O
-,O
blockers,O
.,O
Depression,I-Entity
and,O
sexual,B-Entity
dysfunction,I-Entity
have,O
been,O
related,O
to,O
side,O
effects,O
of,O
topical,O
beta,O
-,O
blockers,O
.,O
We,O
performed,O
a,O
preliminary,O
study,O
in,O
order,O
to,O
determine,O
any,O
difference,O
between,O
a,O
non,O
selective,O
beta,O
-,O
blocker,O
(,O
timolol,I-Entity
),O
and,O
a,O
selective,O
beta,O
-,O
blocker,O
(,O
betaxolol,I-Entity
),O
regarding,O
CNS,O
side,O
effects,O
.,O
Eight,O
glaucomatous,I-Entity
patients,O
chronically,O
treated,O
with,O
timolol,I-Entity
0.5%/12h,O
",",O
suffering,O
from,O
depression,I-Entity
diagnosed,O
through,O
DMS,O
-,O
III,O
-,O
R,O
criteria,O
",",O
were,O
included,O
in,O
the,O
study,O
.,O
During,O
the,O
six,O
-,O
month,O
follow,O
up,O
",",O
depression,I-Entity
was,O
quantified,O
through,O
the,O
Beck,O
and,O
Zung,O
-,O
Conde,O
scales,O
every,O
two,O
months,O
.,O
In,O
a,O
double,O
blind,O
cross,O
-,O
over,O
study,O
with,O
control,O
group,O
",",O
the,O
patients,O
under,O
timolol,I-Entity
treatment,O
presented,O
higher,O
depression,I-Entity
values,O
measured,O
through,O
the,O
Beck,O
and,O
the,O
Zung,O
-,O
Conde,O
scales,O
(,O
p,O
These,O
results,O
suggest,O
that,O
betaxolol,I-Entity
could,O
be,O
less,O
of,O
a,O
depression,I-Entity
-,O
inducer,O
than,O
timolol,I-Entity
in,O
predisposed,O
patients,O
.,O
Long,O
-,O
term,O
follow,O
-,O
up,O
of,O
ifosfamide,I-Entity
renal,B-Entity
toxicity,I-Entity
in,O
children,O
treated,O
for,O
malignant,B-Entity
mesenchymal,I-Entity
tumors,I-Entity
:,O
an,O
International,O
Society,O
of,O
Pediatric,O
Oncology,O
report,O
.,O
The,O
renal,O
function,O
of,O
74,O
children,O
with,O
malignant,B-Entity
mesenchymal,I-Entity
tumors,I-Entity
in,O
complete,O
remission,O
and,O
who,O
have,O
received,O
the,O
same,O
ifosfamide,I-Entity
chemotherapy,O
protocol,O
(,O
International,O
Society,O
of,O
Pediatric,O
Oncology,O
Malignant,B-Entity
Mesenchymal,I-Entity
Tumor,I-Entity
Study,O
84,O
[,O
SIOP,O
MMT,O
84,O
],O
),O
were,O
studied,O
1,O
year,O
after,O
the,O
completion,O
of,O
treatment,O
.,O
Total,O
cumulative,O
doses,O
were,O
36,O
or,O
60,O
g,O
/,O
m2,O
of,O
ifosfamide,I-Entity
(,O
six,O
or,O
10,O
cycles,O
of,O
ifosfamide,B-Entity
",",I-Entity
vincristine,I-Entity
",",I-Entity
and,I-Entity
dactinomycin,I-Entity
[,O
IVA,I-Entity
],O
),O
.,O
None,O
of,O
them,O
had,O
received,O
cisplatin,I-Entity
chemotherapy,O
.,O
The,O
most,O
common,O
primary,O
tumor,I-Entity
site,O
was,O
the,O
head,O
and,O
neck,O
.,O
Renal,O
function,O
was,O
investigated,O
by,O
measuring,O
plasma,O
and,O
urinary,O
electrolytes,O
",",O
glucosuria,I-Entity
",",O
proteinuria,I-Entity
",",O
aminoaciduria,I-Entity
",",O
urinary,O
pH,O
",",O
osmolarity,O
",",O
creatinine,I-Entity
clearance,O
",",O
phosphate,I-Entity
tubular,O
reabsorption,O
",",O
beta,O
2,O
microglobulinuria,O
",",O
and,O
lysozymuria,O
.,O
Fifty,O
-,O
eight,O
patients,O
(,O
78%,O
),O
had,O
normal,O
renal,O
tests,O
",",O
whereas,O
16,O
patients,O
(,O
22%,O
),O
had,O
renal,B-Entity
abnormalities,I-Entity
.,O
the,O
first,O
included,O
four,O
patients,O
(,O
5%,O
of,O
the,O
total,O
population,O
),O
who,O
developed,O
major,O
toxicity,I-Entity
resulting,O
in,O
Fanconi,B-Entity
's,I-Entity
syndrome,I-Entity
(,O
TDFS,I-Entity
),O
;,O
and,O
the,O
second,O
group,O
included,O
five,O
patients,O
with,O
elevated,O
beta,O
2,O
microglobulinuria,O
and,O
low,O
phosphate,I-Entity
reabsorption,O
.,O
Severe,O
toxicity,I-Entity
was,O
correlated,O
with,O
the,O
higher,O
cumulative,O
dose,O
of,O
60,O
g,O
/,O
m2,O
of,O
ifosfamide,I-Entity
",",O
a,O
younger,O
age,O
(,O
less,O
than,O
2,O
1/2,O
years,O
old,O
),O
",",O
and,O
a,O
predominance,O
of,O
vesicoprostatic,O
tumor,I-Entity
involvement,O
.,O
This,O
low,O
percentage,O
(,O
5%,O
),O
of,O
TDFS,O
must,O
be,O
evaluated,O
with,O
respect,O
to,O
the,O
efficacy,O
of,O
ifosfamide,I-Entity
in,O
the,O
treatment,O
of,O
mesenchymal,B-Entity
tumors,I-Entity
in,O
children,O
.,O
Evidence,O
for,O
an,O
involvement,O
of,O
D1,O
and,O
D2,O
dopamine,I-Entity
receptors,O
in,O
mediating,O
nicotine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
in,O
rats,O
.,O
Previous,O
studies,O
have,O
suggested,O
that,O
repeated,O
exposure,O
of,O
rats,O
to,O
the,O
drug,O
or,O
to,O
the,O
experimental,O
environment,O
is,O
necessary,O
to,O
observe,O
nicotine,I-Entity
-,O
induced,O
locomotor,O
stimulation,O
.,O
In,O
the,O
present,O
study,O
the,O
role,O
of,O
habituation,O
to,O
the,O
experimental,O
environment,O
on,O
the,O
stimulant,O
effect,O
of,O
nicotine,I-Entity
in,O
rats,O
was,O
examined,O
.,O
In,O
addition,O
",",O
the,O
role,O
of,O
dopamine,I-Entity
receptors,O
in,O
mediating,O
nicotine,I-Entity
-,O
induced,O
locomotor,O
stimulation,O
was,O
investigated,O
by,O
examining,O
the,O
effects,O
of,O
selective,O
D1,O
and,O
D2,O
dopamine,I-Entity
receptor,O
antagonists,O
on,O
activity,O
induced,O
by,O
nicotine,I-Entity
.,O
Nicotine,I-Entity
(,O
1.0,O
mg,O
/,O
kg,O
),O
caused,O
a,O
significant,O
increase,B-Entity
in,I-Entity
locomotor,I-Entity
activity,I-Entity
in,O
rats,O
that,O
were,O
habituated,O
to,O
the,O
test,O
environment,O
",",O
but,O
had,O
only,O
a,O
weak,O
and,O
delayed,O
stimulant,O
action,O
in,O
rats,O
that,O
were,O
unfamiliar,O
with,O
the,O
test,O
environment,O
.,O
The,O
stimulant,O
action,O
of,O
nicotine,I-Entity
was,O
blocked,O
by,O
the,O
central,O
nicotinic,O
antagonist,O
mecamylamine,I-Entity
but,O
not,O
by,O
the,O
peripheral,O
nicotinic,O
blocker,O
hexamethonium,I-Entity
",",O
indicating,O
that,O
the,O
response,O
is,O
probably,O
mediated,O
by,O
central,O
nicotinic,O
receptors,O
.,O
Nicotine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
was,O
blocked,O
by,O
the,O
selective,O
D1,O
antagonist,O
SCH,B-Entity
23390,I-Entity
",",O
the,O
selective,O
D2,O
antagonist,O
raclopride,I-Entity
and,O
the,O
D1/D2,O
antagonist,O
fluphenazine,I-Entity
.,O
Pretreatment,O
with,O
the,O
D2,O
agonist,O
PHNO,I-Entity
enhanced,O
nicotine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
",",O
whereas,O
the,O
D1,O
agonist,O
SKF,B-Entity
38393,I-Entity
had,O
no,O
effect,O
.,O
The,O
results,O
indicate,O
that,O
acute,O
nicotine,I-Entity
injection,O
induces,O
a,O
pronounced,O
hyperactivity,I-Entity
in,O
rats,O
habituated,O
to,O
the,O
test,O
environment,O
.,O
The,O
effect,O
appears,O
to,O
be,O
mediated,O
by,O
central,O
nicotine,I-Entity
receptors,O
",",O
possibly,O
located,O
on,O
dopaminergic,O
neurons,O
",",O
and,O
also,O
requires,O
the,O
activation,O
of,O
both,O
D1,O
and,O
D2,O
dopamine,I-Entity
receptors,O
.,O
Neuropsychiatric,O
side,O
effects,O
after,O
the,O
use,O
of,O
mefloquine,I-Entity
.,O
This,O
study,O
describes,O
neuropsychiatric,O
side,O
effects,O
in,O
patients,O
after,O
treatment,O
with,O
mefloquine,I-Entity
.,O
Reactions,O
consisted,O
mainly,O
of,O
seizures,I-Entity
",",O
acute,O
psychoses,I-Entity
",",O
anxiety,B-Entity
neurosis,I-Entity
",",O
and,O
major,O
disturbances,B-Entity
of,I-Entity
sleep,I-Entity
-,I-Entity
wake,I-Entity
rhythm,I-Entity
.,O
In,O
a,O
risk,O
analysis,O
of,O
neuropsychiatric,O
side,O
effects,O
in,O
Germany,O
",",O
it,O
is,O
estimated,O
that,O
one,O
of,O
"8,000",O
mefloquine,I-Entity
users,O
suffers,O
from,O
such,O
reactions,O
.,O
The,O
incidence,O
calculation,O
revealed,O
that,O
one,O
of,O
215,O
therapeutic,O
users,O
had,O
reactions,O
",",O
compared,O
with,O
one,O
of,O
"13,000",O
in,O
the,O
prophylaxis,O
group,O
",",O
making,O
the,O
risk,O
of,O
neuropsychiatric,O
reactions,O
after,O
mefloquine,I-Entity
treatment,O
60,O
times,O
higher,O
than,O
after,O
prophylaxis,O
.,O
Therefore,O
",",O
certain,O
limitations,O
for,O
malaria,I-Entity
prophylaxis,O
and,O
treatment,O
with,O
mefloquine,I-Entity
are,O
recommended,O
.,O
Reduction,O
in,O
injection,O
pain,I-Entity
using,O
buffered,O
lidocaine,I-Entity
as,O
a,O
local,O
anesthetic,O
before,O
cardiac,O
catheterization,O
.,O
Previous,O
reports,O
have,O
suggested,O
that,O
pain,I-Entity
associated,O
with,O
the,O
injection,O
of,O
lidocaine,I-Entity
is,O
related,O
to,O
the,O
acidic,O
pH,O
of,O
the,O
solution,O
.,O
To,O
determine,O
if,O
the,O
addition,O
of,O
a,O
buffering,O
solution,O
to,O
adjust,O
the,O
pH,O
of,O
lidocaine,I-Entity
into,O
the,O
physiologic,O
range,O
would,O
reduce,O
pain,I-Entity
during,O
injection,O
",",O
we,O
performed,O
a,O
blinded,O
randomized,O
study,O
in,O
patients,O
undergoing,O
cardiac,O
catheterization,O
.,O
Twenty,O
patients,O
were,O
asked,O
to,O
quantify,O
the,O
severity,O
of,O
pain,I-Entity
after,O
receiving,O
standard,O
lidocaine,I-Entity
in,O
one,O
femoral,O
area,O
and,O
buffered,O
lidocaine,I-Entity
in,O
the,O
opposite,O
femoral,O
area,O
.,O
The,O
mean,O
pain,I-Entity
score,O
for,O
buffered,O
lidocaine,I-Entity
was,O
significantly,O
lower,O
than,O
the,O
mean,O
score,O
for,O
standard,O
lidocaine,I-Entity
(,O
2.7,O
+,O
/-,O
The,O
pH,O
adjustment,O
of,O
standard,O
lidocaine,I-Entity
can,O
be,O
accomplished,O
easily,O
in,O
the,O
catheterization,O
laboratory,O
before,O
injection,O
and,O
results,O
in,O
a,O
reduction,O
of,O
the,O
pain,I-Entity
occurring,O
during,O
the,O
infiltration,O
of,O
tissues,O
.,O
Randomized,O
",",O
double,O
-,O
blind,O
trial,O
of,O
mazindol,I-Entity
in,O
Duchenne,B-Entity
dystrophy,I-Entity
.,O
There,O
is,O
evidence,O
that,O
growth,O
hormone,O
may,O
be,O
related,O
to,O
the,O
progression,O
of,O
weakness,I-Entity
in,O
Duchenne,B-Entity
dystrophy,I-Entity
.,O
We,O
conducted,O
a,O
12-month,O
controlled,O
trial,O
of,O
mazindol,I-Entity
",",O
a,O
putative,O
growth,O
hormone,O
secretion,O
inhibitor,O
",",O
in,O
83,O
boys,O
with,O
Duchenne,B-Entity
dystrophy,I-Entity
.,O
Muscle,O
strength,O
",",O
contractures,O
",",O
functional,O
ability,O
and,O
pulmonary,O
function,O
were,O
tested,O
at,O
baseline,O
",",O
and,O
6,O
and,O
12,O
months,O
after,O
treatment,O
with,O
mazindol,I-Entity
(,O
3,O
mg,O
/,O
d,O
),O
or,O
placebo,O
.,O
The,O
study,O
was,O
designed,O
to,O
have,O
a,O
power,O
of,O
greater,O
than,O
0.90,O
to,O
detect,O
a,O
slowing,O
to,O
25%,O
of,O
the,O
expected,O
rate,O
of,O
progression,O
of,O
weakness,I-Entity
at,O
P,O
less,O
than,O
0.05,O
.,O
Mazindol,I-Entity
did,O
not,O
benefit,O
strength,O
at,O
any,O
point,O
in,O
the,O
study,O
.,O
Side,O
effects,O
attributable,O
to,O
mazindol,I-Entity
included,O
decreased,B-Entity
appetite,I-Entity
(,O
36%,O
),O
",",O
dry,B-Entity
mouth,I-Entity
(,O
10%,O
),O
",",O
behavioral,O
change,O
(,O
22%,O
),O
",",O
and,O
gastrointestinal,B-Entity
symptoms,I-Entity
(,O
18%,O
),O
;,O
mazindol,I-Entity
dosage,O
was,O
reduced,O
in,O
43%,O
of,O
patients,O
.,O
The,O
effect,O
of,O
mazindol,I-Entity
on,O
GH,O
secretion,O
was,O
estimated,O
indirectly,O
by,O
comparing,O
the,O
postabsorptive,O
IGF,O
-,O
I,O
levels,O
obtained,O
following,O
3,O
",",O
6,O
",",O
9,O
",",O
and,O
12,O
months,O
in,O
the,O
mazindol,I-Entity
treated,O
to,O
those,O
in,O
the,O
placebo,O
groups,O
.,O
Although,O
mazindol,I-Entity
-,O
treated,O
patients,O
gained,O
less,O
weight,O
and,O
height,O
than,O
placebo,O
-,O
treated,O
patients,O
",",O
no,O
significant,O
effect,O
on,O
IGF,O
-,O
I,O
levels,O
was,O
observed,O
.,O
Mazindol,I-Entity
doses,O
not,O
slow,O
the,O
progression,O
of,O
weakness,I-Entity
in,O
Duchenne,B-Entity
dystrophy,I-Entity
.,O
Pentoxifylline,I-Entity
(,O
Trental,I-Entity
),O
does,O
not,O
inhibit,O
dipyridamole,I-Entity
-,O
induced,O
coronary,O
hyperemia,I-Entity
:,O
implications,O
for,O
dipyridamole,I-Entity
-,O
thallium-201,I-Entity
myocardial,O
imaging,O
.,O
Dipyridamole,I-Entity
-,O
thallium-201,I-Entity
imaging,O
is,O
often,O
performed,O
in,O
patients,O
unable,O
to,O
exercise,O
because,O
of,O
peripheral,B-Entity
vascular,I-Entity
disease,I-Entity
.,O
Many,O
of,O
these,O
patients,O
are,O
taking,O
pentoxifylline,I-Entity
(,O
Trental,I-Entity
),O
",",O
a,O
methylxanthine,I-Entity
derivative,O
which,O
may,O
improve,O
intermittent,B-Entity
claudication,I-Entity
.,O
Whether,O
pentoxifylline,I-Entity
inhibits,O
dipyridamole,I-Entity
-,O
induced,O
coronary,O
hyperemia,I-Entity
like,O
other,O
methylxanthines,I-Entity
such,O
as,O
theophylline,I-Entity
and,O
should,O
be,O
stopped,O
prior,O
to,O
dipyridamole,I-Entity
-,O
thallium-201,I-Entity
imaging,O
is,O
unknown,O
.,O
Therefore,O
",",O
we,O
studied,O
the,O
hyperemic,O
response,O
to,O
dipyridamole,I-Entity
in,O
seven,O
open,O
-,O
chest,O
anesthetized,O
dogs,O
after,O
pretreatment,O
with,O
either,O
pentoxifylline,I-Entity
(,O
0,O
",",O
7.5,O
",",O
or,O
15,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
or,O
theophylline,I-Entity
(,O
3,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
.,O
Dipyridamole,I-Entity
significantly,O
increased,O
coronary,O
blood,O
flow,O
before,O
and,O
after,O
7.5,O
or,O
15,O
mm,O
/,O
kg,O
i.v,O
.,O
pentoxifylline,I-Entity
(,O
p,O
less,O
than,O
0.002,O
),O
.,O
Neither,O
dose,O
of,O
pentoxifylline,I-Entity
significantly,O
decreased,O
the,O
dipyridamole,I-Entity
-,O
induced,O
hyperemia,I-Entity
",",O
while,O
peak,O
coronary,O
blood,O
flow,O
was,O
significantly,O
lower,O
after,O
theophylline,I-Entity
(,O
p,O
less,O
than,O
0.01,O
),O
.,O
We,O
conclude,O
that,O
pentoxyifylline,I-Entity
does,O
not,O
inhibit,O
dipyridamole,I-Entity
-,O
induced,O
coronary,O
hyperemia,I-Entity
even,O
at,O
high,O
doses,O
.,O
Cause,O
of,O
death,I-Entity
among,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
:,O
a,O
rare,O
mortality,O
due,O
to,O
cerebral,B-Entity
haemorrhage,I-Entity
.,O
Causes,O
of,O
death,I-Entity
",",O
with,O
special,O
reference,O
to,O
cerebral,B-Entity
haemorrhage,I-Entity
",",O
among,O
240,O
patients,O
with,O
pathologically,O
verified,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
were,O
investigated,O
using,O
the,O
Annuals,O
of,O
the,O
Pathological,O
Autopsy,O
Cases,O
in,O
Japan,O
from,O
1981,O
to,O
1985,O
.,O
The,O
leading,O
causes,O
of,O
death,I-Entity
were,O
pneumonia,I-Entity
and,O
bronchitis,I-Entity
(,O
44.1%,O
),O
",",O
malignant,O
neoplasms,I-Entity
(,O
11.6%,O
),O
",",O
heart,B-Entity
diseases,I-Entity
(,O
4.1%,O
),O
",",O
cerebral,B-Entity
infarction,I-Entity
(,O
3.7%,O
),O
and,O
septicaemia,I-Entity
(,O
3.3%,O
),O
.,O
Cerebral,B-Entity
haemorrhage,I-Entity
was,O
the,O
11th,O
most,O
frequent,O
cause,O
of,O
death,I-Entity
",",O
accounting,O
for,O
only,O
0.8%,O
of,O
deaths,I-Entity
among,O
the,O
patients,O
",",O
whereas,O
it,O
was,O
the,O
5th,O
most,O
common,O
cause,O
of,O
death,I-Entity
among,O
the,O
Japanese,O
general,O
population,O
in,O
1985,O
.,O
The,O
low,O
incidence,O
of,O
cerebral,B-Entity
haemorrhage,I-Entity
as,O
a,O
cause,O
of,O
death,I-Entity
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
may,O
reflect,O
the,O
hypotensive,I-Entity
effect,O
of,O
levodopa,I-Entity
and,O
a,O
hypotensive,I-Entity
mechanism,O
due,O
to,O
reduced,O
noradrenaline,I-Entity
levels,O
in,O
the,O
parkinsonian,I-Entity
brain,O
.,O
Tolerance,O
and,O
antiviral,O
effect,O
of,O
ribavirin,I-Entity
in,O
patients,O
with,O
Argentine,B-Entity
hemorrhagic,I-Entity
fever,I-Entity
.,O
Tolerance,O
and,O
antiviral,O
effect,O
of,O
ribavirin,I-Entity
was,O
studied,O
in,O
6,O
patients,O
with,O
Argentine,B-Entity
hemorrhagic,I-Entity
fever,I-Entity
(,O
AHF,I-Entity
),O
of,O
more,O
than,O
8,O
days,O
of,O
evolution,O
.,O
Administration,O
of,O
ribavirin,I-Entity
resulted,O
in,O
a,O
neutralization,O
of,O
viremia,I-Entity
and,O
a,O
drop,O
of,O
endogenous,O
interferon,O
titers,O
.,O
The,O
average,O
time,O
of,O
death,I-Entity
was,O
delayed,O
.,O
A,O
reversible,O
anemia,I-Entity
was,O
the,O
only,O
adverse,O
effect,O
observed,O
.,O
From,O
these,O
results,O
",",O
we,O
conclude,O
that,O
ribavirin,I-Entity
has,O
an,O
antiviral,O
effect,O
in,O
advanced,O
cases,O
of,O
AHF,I-Entity
",",O
and,O
that,O
anemia,I-Entity
",",O
the,O
only,O
secondary,O
reaction,O
observed,O
",",O
can,O
be,O
easily,O
managed,O
.,O
The,O
possible,O
beneficial,O
effect,O
of,O
ribavirin,I-Entity
during,O
the,O
initial,O
days,O
of,O
AHF,I-Entity
is,O
discussed,O
.,O
Dipyridamole,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
.,O
Angina,I-Entity
and,O
ischemic,O
electrocardiographic,O
changes,O
occurred,O
after,O
administration,O
of,O
oral,O
dipyridamole,I-Entity
in,O
four,O
patients,O
awaiting,O
urgent,O
myocardial,O
revascularization,O
procedures,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
has,O
not,O
previously,O
been,O
reported,O
as,O
a,O
side,O
effect,O
of,O
preoperative,O
dipyridamole,I-Entity
therapy,O
",",O
although,O
dipyridamole,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
has,O
been,O
demonstrated,O
to,O
occur,O
in,O
animals,O
and,O
humans,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
.,O
Epicardial,O
coronary,O
collateral,O
vessels,O
were,O
demonstrated,O
in,O
all,O
four,O
patients,O
;,O
a,O
coronary,O
"""",O
steal,O
"""",O
phenomenon,O
may,O
be,O
the,O
mechanism,O
of,O
the,O
dipyridamole,I-Entity
-,O
induced,O
ischemia,I-Entity
observed,O
.,O
Nitroprusside,I-Entity
-,O
induced,O
hypotension,I-Entity
evokes,O
ACTH,O
secretion,O
which,O
is,O
primarily,O
mediated,O
by,O
enhanced,O
secretion,O
of,O
immunoreactive,O
corticotropin,O
-,O
releasing,O
factor,O
(,O
irCRF,O
),O
into,O
the,O
hypophysial,O
-,O
portal,O
circulation,O
.,O
Portal,O
plasma,O
concentrations,O
of,O
neither,O
arginine,B-Entity
vasopressin,I-Entity
nor,O
oxytocin,I-Entity
are,O
significantly,O
altered,O
in,O
this,O
paradigm,O
.,O
Application,O
of,O
a,O
delayed,O
feedback,O
signal,O
",",O
in,O
the,O
form,O
of,O
a,O
2-h,O
systemic,O
corticosterone,I-Entity
infusion,O
in,O
urethane,I-Entity
-,O
anesthetized,O
rats,O
with,O
pharmacological,O
blockade,O
of,O
glucocorticoid,O
synthesis,O
",",O
is,O
without,O
effect,O
on,O
the,O
resting,O
secretion,O
of,O
arginine,B-Entity
vasopressin,I-Entity
and,O
oxytocin,I-Entity
at,O
any,O
corticosterone,I-Entity
feedback,O
dose,O
tested,O
.,O
Resting,O
irCRF,O
levels,O
are,O
suppressed,O
only,O
at,O
the,O
highest,O
corticosterone,I-Entity
infusion,O
rate,O
",",O
which,O
resulted,O
in,O
systemic,O
corticosterone,I-Entity
levels,O
of,O
40,O
micrograms,O
/,O
dl,O
.,O
Suppression,O
of,O
irCRF,O
secretion,O
in,O
response,O
to,O
nitroprusside,I-Entity
-,O
induced,O
hypotension,I-Entity
is,O
observed,O
and,O
occurs,O
at,O
a,O
plasma,O
corticosterone,I-Entity
level,O
between,O
8,O
-,O
12,O
micrograms,O
/,O
dl,O
.,O
Noradrenergic,O
involvement,O
in,O
catalepsy,I-Entity
induced,O
by,O
delta,B-Entity
9-tetrahydrocannabinol,I-Entity
.,O
In,O
order,O
to,O
elucidate,O
the,O
role,O
of,O
the,O
catecholaminergic,O
system,O
in,O
the,O
cataleptogenic,O
effect,O
of,O
delta,B-Entity
9-tetrahydrocannabinol,I-Entity
(,O
THC,I-Entity
),O
",",O
the,O
effect,O
of,O
pretreatment,O
with,O
6-hydroxydopamine,I-Entity
(,O
6-OHDA,I-Entity
),O
or,O
with,O
desipramine,I-Entity
and,O
6-OHDA,I-Entity
and,O
lesions,O
of,O
the,O
locus,O
coeruleus,O
were,O
investigated,O
in,O
rats,O
.,O
The,O
cataleptogenic,O
effect,O
of,O
THC,I-Entity
was,O
significantly,O
reduced,O
in,O
rats,O
treated,O
with,O
6-OHDA,I-Entity
and,O
in,O
rats,O
with,O
lesions,O
of,O
the,O
locus,O
coeruleus,O
but,O
not,O
in,O
rats,O
treated,O
with,O
desipramine,I-Entity
and,O
6-OHDA,I-Entity
",",O
as,O
compared,O
with,O
control,O
rats,O
.,O
On,O
the,O
contrary,O
",",O
the,O
cataleptogenic,O
effect,O
of,O
haloperidol,I-Entity
was,O
significantly,O
reduced,O
in,O
rats,O
treated,O
with,O
desipramine,I-Entity
and,O
6-OHDA,I-Entity
but,O
not,O
in,O
rats,O
treated,O
with,O
6-OHDA,I-Entity
or,O
in,O
rats,O
with,O
lesions,O
of,O
the,O
locus,O
coeruleus,O
.,O
These,O
results,O
indicate,O
that,O
noradrenergic,O
neurons,O
have,O
an,O
important,O
role,O
in,O
the,O
manifestation,O
of,O
catalepsy,I-Entity
induced,O
by,O
THC,I-Entity
",",O
whereas,O
dopaminergic,O
neurons,O
are,O
important,O
in,O
catalepsy,I-Entity
induced,O
by,O
haloperidol,I-Entity
.,O
Intracranial,O
pressure,O
increases,O
during,O
alfentanil,I-Entity
-,O
induced,O
rigidity,I-Entity
.,O
Intracranial,O
pressure,O
(,O
ICP,O
),O
was,O
measured,O
during,O
alfentanil,I-Entity
-,O
induced,O
rigidity,I-Entity
in,O
rats,O
.,O
Ten,O
rats,O
had,O
arterial,O
",",O
central,O
venous,O
(,O
CVP,O
),O
",",O
and,O
subdural,O
cannulae,O
inserted,O
under,O
halothane,I-Entity
anesthesia,O
.,O
Following,O
instrumentation,O
",",O
halothane,I-Entity
was,O
discontinued,O
and,O
alfentanil,I-Entity
(,O
125,O
mu,O
/,O
kg,O
),O
administered,O
iv,O
during,O
emergence,O
from,O
halothane,I-Entity
anesthesia,O
.,O
In,O
the,O
five,O
rats,O
that,O
developed,O
somatic,B-Entity
rigidity,I-Entity
",",O
ICP,O
and,O
CVP,O
increased,O
significantly,O
above,O
baseline,O
(,O
delta,O
ICP,O
7.5,O
+,O
/-,O
These,O
variables,O
returned,O
to,O
baseline,O
when,O
rigidity,I-Entity
was,O
abolished,O
with,O
metocurine,I-Entity
.,O
In,O
five,O
rats,O
that,O
did,O
not,O
become,O
rigid,O
",",O
ICP,O
and,O
CVP,O
did,O
not,O
change,O
following,O
alfentanil,I-Entity
.,O
These,O
observations,O
suggest,O
that,O
rigidity,I-Entity
should,O
be,O
prevented,O
when,O
alfentanil,I-Entity
",",O
and,O
",",O
presumably,O
",",O
other,O
opiates,O
",",O
are,O
used,O
in,O
the,O
anesthetic,O
management,O
of,O
patients,O
with,O
ICP,O
problems,O
.,O
Adverse,O
cardiac,O
effects,O
during,O
induction,O
chemotherapy,O
treatment,O
with,O
cis,B-Entity
-,I-Entity
platin,I-Entity
and,O
5-fluorouracil,I-Entity
.,O
Survival,O
for,O
patients,O
with,O
advanced,O
head,B-Entity
and,I-Entity
neck,I-Entity
carcinoma,I-Entity
and,O
esophageal,B-Entity
carcinoma,I-Entity
is,O
poor,O
with,O
radiotherapy,O
and/or,O
surgery,O
.,O
In,O
the,O
present,O
study,O
",",O
cis,B-Entity
-,I-Entity
platin,I-Entity
(,O
80,O
-,O
120,O
mg,O
/,O
m2BSA,O
),O
and,O
5-FU,I-Entity
(,O
1000,O
mg,O
/,O
m2BSA,O
daily,O
as,O
a,O
continuous,O
infusion,O
during,O
5,O
days,O
),O
were,O
given,O
to,O
76,O
patients,O
before,O
radiotherapy,O
and,O
surgery,O
.,O
In,O
the,O
pre,O
-,O
treatment,O
evaluation,O
",",O
signs,O
of,O
cardiovascular,B-Entity
disease,I-Entity
were,O
found,O
in,O
33,O
patients,O
(,O
43%,O
),O
.,O
The,O
incidence,O
of,O
cardiotoxicity,I-Entity
was,O
not,O
higher,O
in,O
patients,O
with,O
signs,O
of,O
cardiovascular,B-Entity
disease,I-Entity
than,O
in,O
those,O
without,O
in,O
the,O
pre,O
-,O
treatment,O
evaluation,O
.,O
The,O
most,O
common,O
signs,O
of,O
cardiotoxicity,I-Entity
were,O
chest,B-Entity
pain,I-Entity
",",O
ST,O
-,O
T,O
wave,O
changes,O
and,O
atrial,B-Entity
fibrillation,I-Entity
.,O
This,O
was,O
followed,O
by,O
ventricular,B-Entity
fibrillation,I-Entity
in,O
one,O
patient,O
and,O
sudden,B-Entity
death,I-Entity
in,O
another,O
.,O
It,O
is,O
concluded,O
that,O
patients,O
on,O
5-FU,I-Entity
treatment,O
should,O
be,O
under,O
close,O
supervision,O
and,O
that,O
the,O
treatment,O
should,O
be,O
discontinued,O
if,O
chest,B-Entity
pain,I-Entity
or,O
tachyarrhythmia,I-Entity
is,O
observed,O
.,O
Verapamil,I-Entity
-,O
induced,O
carbamazepine,I-Entity
neurotoxicity,I-Entity
.,O
Two,O
patients,O
with,O
signs,O
of,O
carbamazepine,I-Entity
neurotoxicity,I-Entity
after,O
combined,O
treatment,O
with,O
verapamil,I-Entity
showed,O
complete,O
recovery,O
after,O
discontinuation,O
of,O
the,O
calcium,I-Entity
entry,O
blocker,O
.,O
Use,O
of,O
verapamil,I-Entity
in,O
combination,O
with,O
carbamazepine,I-Entity
should,O
either,O
be,O
avoided,O
or,O
prescribed,O
only,O
with,O
appropriate,O
adjustment,O
of,O
the,O
carbamazepine,I-Entity
dose,O
(,O
usually,O
reduction,O
of,O
the,O
carbamazepine,I-Entity
dose,O
by,O
one,O
half,O
),O
.,O
Serial,O
studies,O
of,O
auditory,B-Entity
neurotoxicity,I-Entity
in,O
patients,O
receiving,O
deferoxamine,I-Entity
therapy,O
.,O
Visual,B-Entity
and,I-Entity
auditory,I-Entity
neurotoxicity,I-Entity
was,O
previously,O
documented,O
in,O
42,O
of,O
89,O
patients,O
with,O
transfusion,O
-,O
dependent,O
anemia,I-Entity
who,O
were,O
receiving,O
iron,I-Entity
chelation,O
therapy,O
with,O
daily,O
subcutaneous,O
deferoxamine,I-Entity
.,O
Twenty,O
-,O
two,O
patients,O
in,O
the,O
affected,O
group,O
had,O
abnormal,B-Entity
audiograms,I-Entity
with,I-Entity
deficits,I-Entity
mostly,I-Entity
in,I-Entity
the,I-Entity
high,I-Entity
frequency,I-Entity
range,I-Entity
of,I-Entity
"4,000",I-Entity
to,I-Entity
"8,000",I-Entity
Hz,I-Entity
and,O
in,O
the,O
hearing,O
threshold,O
levels,O
of,O
30,O
to,O
100,O
decibels,O
.,O
When,O
deferoxamine,I-Entity
therapy,O
was,O
discontinued,O
and,O
serial,O
studies,O
were,O
performed,O
",",O
audiograms,O
in,O
seven,O
cases,O
reverted,O
to,O
normal,O
or,O
near,O
normal,O
within,O
two,O
to,O
three,O
weeks,O
",",O
and,O
nine,O
of,O
13,O
patients,O
with,O
symptoms,O
became,O
asymptomatic,O
.,O
Audiograms,O
from,O
15,O
patients,O
remained,O
abnormal,O
and,O
four,O
patients,O
required,O
hearing,O
aids,O
because,O
of,O
permanent,B-Entity
disability,I-Entity
.,O
Since,O
18,O
of,O
the,O
22,O
patients,O
were,O
initially,O
receiving,O
deferoxamine,I-Entity
doses,O
in,O
excess,O
of,O
the,O
commonly,O
recommended,O
50,O
mg,O
/,O
kg,O
per,O
dose,O
",",O
therapy,O
was,O
restarted,O
with,O
lower,O
doses,O
",",O
usually,O
50,O
mg,O
/,O
kg,O
per,O
dose,O
or,O
less,O
depending,O
on,O
the,O
degree,O
of,O
auditory,B-Entity
abnormality,I-Entity
",",O
and,O
with,O
the,O
exception,O
of,O
two,O
cases,O
no,O
further,O
toxicity,I-Entity
was,O
demonstrated,O
.,O
Auditory,O
deterioration,O
and,O
improvement,O
",",O
demonstrated,O
serially,O
in,O
individual,O
patients,O
receiving,O
and,O
not,O
receiving,O
deferoxamine,I-Entity
",",O
respectively,O
",",O
provided,O
convincing,O
evidence,O
for,O
a,O
cause,O
-,O
and,O
-,O
effect,O
relation,O
between,O
deferoxamine,I-Entity
administration,O
and,O
ototoxicity,I-Entity
.,O
Based,O
on,O
these,O
data,O
",",O
a,O
plan,O
of,O
management,O
was,O
developed,O
that,O
allows,O
effective,O
yet,O
safe,O
administration,O
of,O
deferoxamine,I-Entity
.,O
With,O
mild,O
toxicity,I-Entity
",",O
a,O
reduction,O
to,O
30,O
or,O
40,O
mg,O
/,O
kg,O
per,O
dose,O
should,O
result,O
in,O
a,O
reversal,O
of,O
the,O
abnormal,O
results,O
to,O
normal,O
within,O
four,O
weeks,O
.,O
Moderate,O
abnormalities,O
require,O
a,O
reduction,O
of,O
deferoxamine,I-Entity
to,O
25,O
mg,O
/,O
kg,O
per,O
dose,O
with,O
careful,O
monitoring,O
.,O
In,O
those,O
with,O
symptoms,O
of,O
hearing,B-Entity
loss,I-Entity
",",O
the,O
drug,O
should,O
be,O
stopped,O
for,O
four,O
weeks,O
",",O
and,O
when,O
the,O
audiogram,O
is,O
stable,O
or,O
improved,O
",",O
therapy,O
should,O
be,O
restarted,O
at,O
10,O
to,O
25,O
mg,O
/,O
kg,O
per,O
dose,O
.,O
Serial,O
audiograms,O
should,O
be,O
performed,O
every,O
six,O
months,O
in,O
those,O
without,O
problems,O
and,O
more,O
frequently,O
in,O
young,O
patients,O
with,O
normal,O
serum,O
ferritin,O
values,O
and,O
in,O
those,O
with,O
auditory,B-Entity
dysfunction,I-Entity
.,O
Flurbiprofen,I-Entity
in,O
the,O
treatment,O
of,O
juvenile,B-Entity
rheumatoid,I-Entity
arthritis,I-Entity
.,O
Thirty,O
-,O
four,O
patients,O
with,O
juvenile,B-Entity
rheumatoid,I-Entity
arthritis,I-Entity
",",O
who,O
were,O
treated,O
with,O
flurbiprofen,I-Entity
at,O
a,O
maximum,O
dose,O
of,O
4,O
mg,O
/,O
kg,O
/,O
day,O
",",O
had,O
statistically,O
significant,O
decreases,O
from,O
baseline,O
in,O
6,O
arthritis,I-Entity
indices,O
after,O
12,O
weeks,O
of,O
treatment,O
.,O
Improvements,O
were,O
seen,O
in,O
the,O
number,O
of,O
tender,B-Entity
joints,I-Entity
",",O
the,O
severity,O
of,O
swelling,I-Entity
and,O
tenderness,I-Entity
",",O
the,O
time,O
of,O
walk,O
50,O
feet,O
",",O
the,O
duration,O
of,O
morning,B-Entity
stiffness,I-Entity
and,O
the,O
circumference,O
of,O
the,O
left,O
knee,O
.,O
The,O
most,O
frequently,O
observed,O
side,O
effect,O
was,O
fecal,B-Entity
occult,I-Entity
blood,I-Entity
(,O
25%,O
of,O
patients,O
),O
;,O
however,O
",",O
there,O
was,O
no,O
other,O
evidence,O
of,O
gastrointestinal,B-Entity
(,I-Entity
GI,I-Entity
),I-Entity
bleeding,I-Entity
in,O
these,O
patients,O
.,O
One,O
patient,O
was,O
prematurely,O
discontinued,O
from,O
the,O
study,O
for,O
severe,O
headache,I-Entity
and,O
abdominal,B-Entity
pain,I-Entity
.,O
The,O
correlation,O
between,O
neurotoxic,I-Entity
esterase,O
inhibition,O
and,O
mipafox,I-Entity
-,O
induced,O
neuropathic,B-Entity
damage,I-Entity
in,O
rats,O
.,O
The,O
correlation,O
between,O
neuropathic,B-Entity
damage,I-Entity
and,O
inhibition,O
of,O
neurotoxic,I-Entity
esterase,O
or,O
neuropathy,I-Entity
target,O
enzyme,O
(,O
NTE,O
),O
was,O
examined,O
in,O
rats,O
acutely,O
exposed,O
to,O
Mipafox,I-Entity
(,O
N,B-Entity
",",I-Entity
N'-diisopropylphosphorodiamidofluoridate,I-Entity
),O
",",O
a,O
neurotoxic,I-Entity
organophosphate,I-Entity
.,O
Brain,O
and,O
spinal,O
cord,O
NTE,O
activities,O
were,O
measured,O
in,O
Long,O
-,O
Evans,O
male,O
rats,O
1,O
hr,O
post,O
-,O
exposure,O
to,O
various,O
dosages,O
of,O
Mipafox,I-Entity
(,O
ip,O
",",O
1,O
-,O
15,O
mg,O
/,O
kg,O
),O
.,O
These,O
data,O
were,O
correlated,O
with,O
histologically,O
scored,O
cervical,O
cord,B-Entity
damage,I-Entity
in,O
a,O
separate,O
group,O
of,O
similarly,O
dosed,O
rats,O
sampled,O
14,O
-,O
21,O
days,O
post,O
-,O
exposure,O
.,O
In,O
contrast,O
",",O
dosages,O
of,O
Mipafox,I-Entity
(,O
less,O
than,O
or,O
equal,O
to,O
5,O
mg,O
/,O
kg,O
),O
which,O
inhibited,O
mean,O
NTE,O
activity,O
in,O
spinal,O
cord,O
less,O
than,O
or,O
equal,O
to,O
61%,O
and,O
brain,O
less,O
than,O
or,O
equal,O
to,O
60%,O
produced,O
this,O
degree,O
of,O
cord,B-Entity
damage,I-Entity
in,O
only,O
9%,O
of,O
the,O
animals,O
.,O
These,O
data,O
indicate,O
that,O
a,O
critical,O
percentage,O
of,O
NTE,O
inhibition,O
in,O
brain,O
and,O
spinal,O
cord,O
sampled,O
shortly,O
after,O
Mipafox,I-Entity
exposure,O
can,O
predict,O
neuropathic,B-Entity
damage,I-Entity
in,O
rats,O
several,O
weeks,O
later,O
.,O
Cerebral,B-Entity
infarction,I-Entity
with,O
a,O
single,O
oral,O
dose,O
of,O
phenylpropanolamine,I-Entity
.,O
Phenylpropanolamine,I-Entity
(,O
PPA,I-Entity
),O
",",O
a,O
synthetic,O
sympathomimetic,O
that,O
is,O
structurally,O
similar,O
to,O
amphetamine,I-Entity
",",O
is,O
available,O
over,O
the,O
counter,O
in,O
anorectics,O
",",O
nasal,O
congestants,O
",",O
and,O
cold,O
preparations,O
.,O
Its,O
prolonged,O
use,O
or,O
overuse,O
has,O
been,O
associated,O
with,O
seizures,I-Entity
",",O
intracerebral,B-Entity
hemorrhage,I-Entity
",",O
neuropsychiatric,B-Entity
symptoms,I-Entity
",",O
and,O
nonhemorrhagic,O
cerebral,B-Entity
infarction,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
young,O
woman,O
who,O
suffered,O
a,O
cerebral,B-Entity
infarction,I-Entity
after,O
taking,O
a,O
single,O
oral,O
dose,O
of,O
PPA,I-Entity
.,O
Treatment,O
of,O
psoriasis,I-Entity
with,O
azathioprine,I-Entity
.,O
Azathioprine,I-Entity
treatment,O
benefited,O
19,O
(,O
66%,O
),O
out,O
of,O
29,O
patients,O
suffering,O
from,O
severe,O
psoriasis,I-Entity
.,O
Minimal,O
cholestasis,I-Entity
was,O
seen,O
in,O
two,O
cases,O
and,O
portal,O
fibrosis,I-Entity
of,O
a,O
reversible,O
degree,O
in,O
eight,O
.,O
Liver,O
biopsies,O
should,O
be,O
undertaken,O
at,O
regular,O
intervals,O
if,O
azathioprine,I-Entity
therapy,O
is,O
continued,O
so,O
that,O
structural,O
liver,B-Entity
damage,I-Entity
may,O
be,O
detected,O
at,O
an,O
early,O
and,O
reversible,O
stage,O
.,O
Maternal,O
lithium,I-Entity
and,O
neonatal,O
Ebstein,B-Entity
's,I-Entity
anomaly,I-Entity
:,O
evaluation,O
with,O
cross,O
-,O
sectional,O
echocardiography,O
.,O
Cross,O
-,O
sectional,O
echocardiography,O
was,O
used,O
to,O
evaluate,O
two,O
neonates,O
whose,O
mothers,O
ingested,O
lithium,I-Entity
during,O
pregnancy,O
.,O
In,O
one,O
infant,O
",",O
Ebstein,B-Entity
's,I-Entity
anomaly,I-Entity
of,O
the,O
tricuspid,O
valve,O
was,O
identified,O
.,O
In,O
the,O
other,O
infant,O
cross,O
-,O
sectional,O
echocardiography,O
provided,O
reassurance,O
that,O
the,O
infant,O
did,O
not,O
have,O
Ebstein,B-Entity
's,I-Entity
anomaly,I-Entity
.,O
Cross,O
-,O
sectional,O
echocardiographic,O
screening,O
of,O
newborns,O
exposed,O
to,O
lithium,I-Entity
during,O
gestation,O
can,O
provide,O
highly,O
accurate,O
",",O
noninvasive,O
assessment,O
of,O
the,O
presence,O
or,O
absence,O
of,O
lithium,I-Entity
-,O
induced,O
cardiac,B-Entity
malformations,I-Entity
.,O
Effects,O
of,O
training,O
on,O
the,O
extent,O
of,O
experimental,O
myocardial,B-Entity
infarction,I-Entity
in,O
aging,O
rats,O
.,O
The,O
effects,O
of,O
exercise,O
on,O
the,O
severity,O
of,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
were,O
studied,O
in,O
female,O
albino,O
rats,O
of,O
"20,40,60",O
and,O
80,O
weeks,O
of,O
age,O
.,O
The,O
occurrence,O
of,O
infarcts,I-Entity
were,O
confirmed,O
by,O
histological,O
methods,O
.,O
Elevations,O
in,O
the,O
serum,O
GOT,O
and,O
GPT,O
were,O
maximum,O
in,O
the,O
sedentary,O
-,O
isoproterenols,I-Entity
and,O
minimum,O
in,O
the,O
exercise,O
-,O
controls,O
.,O
Studies,O
dealing,O
with,O
myocardial,B-Entity
infarction,I-Entity
are,O
more,O
informative,O
when,O
dealt,O
with,O
age,O
.,O
Effect,O
of,O
polyethylene,B-Entity
glycol,I-Entity
400,I-Entity
on,O
adriamycin,I-Entity
toxicity,I-Entity
in,O
mice,O
.,O
The,O
effect,O
of,O
a,O
widely,O
used,O
organic,O
solvent,O
",",O
polyethylene,B-Entity
glycol,I-Entity
400,I-Entity
(,O
PEG,B-Entity
400,I-Entity
),O
",",O
on,O
the,O
toxic,O
action,O
of,O
an,O
acute,O
or,O
chronic,O
treatment,O
with,O
adriamycin,I-Entity
(,O
ADR,I-Entity
),O
was,O
evaluated,O
in,O
mice,O
.,O
PEG,B-Entity
400,I-Entity
impressively,O
decreased,O
both,O
acute,O
high,O
-,O
dose,O
and,O
chronic,O
low,O
-,O
dose,O
-,O
ADR,I-Entity
-,O
associated,O
lethality,O
.,O
Light,O
microscopic,O
analysis,O
showed,O
a,O
significant,O
protection,O
against,O
ADR,I-Entity
-,O
induced,O
cardiac,B-Entity
morphological,I-Entity
alterations,I-Entity
.,O
Such,O
treatment,O
did,O
not,O
diminish,O
the,O
ADR,I-Entity
antitumor,O
activity,O
in,O
L1210,B-Entity
leukemia,I-Entity
and,O
in,O
Ehrlich,B-Entity
ascites,I-Entity
tumor,I-Entity
.,O
Intra,O
-,O
arterial,O
BCNU,I-Entity
chemotherapy,O
for,O
treatment,O
of,O
malignant,B-Entity
gliomas,I-Entity
of,O
the,O
central,O
nervous,O
system,O
.,O
Because,O
of,O
the,O
rapid,O
systemic,O
clearance,O
of,O
BCNU,I-Entity
(,O
"1,3-bis-(2-chloroethyl)-1-nitrosourea",I-Entity
),O
",",O
intra,O
-,O
arterial,O
administration,O
should,O
provide,O
a,O
substantial,O
advantage,O
over,O
intravenous,O
administration,O
for,O
the,O
treatment,O
of,O
malignant,B-Entity
gliomas,I-Entity
.,O
Thirty,O
-,O
six,O
patients,O
were,O
treated,O
with,O
BCNU,I-Entity
every,O
6,O
to,O
8,O
weeks,O
",",O
either,O
by,O
transfemoral,O
catheterization,O
of,O
the,O
internal,O
carotid,O
or,O
vertebral,O
artery,O
or,O
through,O
a,O
fully,O
implantable,O
intracarotid,O
drug,O
delivery,O
system,O
",",O
beginning,O
with,O
a,O
dose,O
of,O
200,O
mg,O
/,O
sq,O
m,O
body,O
surface,O
area,O
.,O
Twelve,O
patients,O
with,O
Grade,O
III,O
or,O
IV,O
astrocytomas,I-Entity
were,O
treated,O
after,O
partial,O
resection,O
of,O
the,O
tumor,I-Entity
without,O
prior,O
radiation,O
therapy,O
.,O
After,O
two,O
to,O
seven,O
cycles,O
of,O
chemotherapy,O
",",O
nine,O
patients,O
showed,O
a,O
decrease,O
in,O
tumor,I-Entity
size,O
and,O
surrounding,O
edema,I-Entity
on,O
contrast,O
-,O
enhanced,O
computerized,O
tomography,O
scans,O
.,O
Twenty,O
-,O
four,O
patients,O
with,O
recurrent,O
Grade,O
I,O
to,O
IV,O
astrocytomas,I-Entity
",",O
whose,O
resection,O
and,O
irradiation,O
therapy,O
had,O
failed,O
",",O
received,O
two,O
to,O
eight,O
courses,O
of,O
intra,O
-,O
arterial,O
BCNU,I-Entity
therapy,O
.,O
The,O
catheterization,O
procedure,O
is,O
safe,O
",",O
with,O
no,O
immediate,O
complication,O
in,O
111,O
infusions,O
of,O
BCNU,I-Entity
.,O
A,O
delayed,O
complication,O
in,O
nine,O
patients,O
has,O
been,O
unilateral,O
loss,B-Entity
of,I-Entity
vision,I-Entity
secondary,O
to,O
a,O
retinal,B-Entity
vasculitis,I-Entity
.,O
The,O
frequency,O
of,O
visual,B-Entity
loss,I-Entity
decreased,O
after,O
the,O
concentration,O
of,O
the,O
ethanol,I-Entity
diluent,O
was,O
lowered,O
.,O
Blood,O
pressure,O
response,O
to,O
chronic,O
low,O
-,O
dose,O
intrarenal,O
noradrenaline,I-Entity
infusion,O
in,O
conscious,O
rats,O
.,O
Sodium,B-Entity
chloride,I-Entity
solution,O
(,O
0.9%,O
),O
or,O
noradrenaline,I-Entity
in,O
doses,O
of,O
4,O
",",O
12,O
and,O
36,O
Intrarenal,O
infusion,O
of,O
noradrenaline,I-Entity
caused,O
hypertension,I-Entity
at,O
doses,O
which,O
did,O
not,O
do,O
so,O
when,O
infused,O
intravenously,O
.,O
Intrarenal,O
compared,O
with,O
intravenous,O
infusion,O
of,O
noradrenaline,I-Entity
caused,O
higher,O
plasma,O
noradrenaline,I-Entity
concentrations,O
and,O
a,O
shift,O
of,O
the,O
plasma,O
noradrenaline,I-Entity
concentration,O
-,O
blood,O
pressure,O
effect,O
curve,O
towards,O
lower,O
plasma,O
noradrenaline,I-Entity
levels,O
.,O
These,O
results,O
suggest,O
that,O
hypertension,I-Entity
after,O
chronic,O
intrarenal,O
noradrenaline,I-Entity
infusion,O
is,O
produced,O
by,O
relatively,O
higher,O
levels,O
of,O
circulating,O
noradrenaline,I-Entity
and,O
by,O
triggering,O
of,O
an,O
additional,O
intrarenal,O
pressor,O
mechanism,O
.,O
Age,O
and,O
renal,O
clearance,O
of,O
cimetidine,I-Entity
.,O
In,O
35,O
patients,O
(,O
ages,O
20,O
to,O
86,O
yr,O
),O
receiving,O
cimetidine,I-Entity
therapeutically,O
two,O
serum,O
samples,O
and,O
all,O
urine,O
formed,O
in,O
the,O
interim,O
were,O
collected,O
for,O
analysis,O
of,O
cimetidine,I-Entity
by,O
high,O
-,O
pressure,O
liquid,O
chromatography,O
and,O
for,O
creatinine,I-Entity
.,O
Cimetidine,I-Entity
clearance,O
decreased,O
with,O
age,O
.,O
The,O
extrapolated,O
6-hr,O
serum,O
concentration,O
of,O
cimetidine,I-Entity
per,O
unit,O
dose,O
",",O
after,O
intravenous,O
cimetidine,I-Entity
",",O
increased,O
with,O
age,O
of,O
the,O
patients,O
.,O
The,O
ratio,O
of,O
cimetidine,I-Entity
clearance,O
to,O
creatinine,I-Entity
clearance,O
(,O
Rc,O
),O
averaged,O
4.8,O
+,O
/-,O
2.0,O
",",O
indicating,O
net,O
tubular,O
secretion,O
for,O
cimetidine,I-Entity
.,O
Rc,O
seemed,O
to,O
be,O
independent,O
of,O
age,O
and,O
decreased,O
with,O
increasing,O
serum,O
concentration,O
of,O
cimetidine,I-Entity
",",O
suggesting,O
that,O
secretion,O
of,O
cimetidine,I-Entity
is,O
a,O
saturable,O
process,O
.,O
There,O
was,O
only,O
one,O
case,O
of,O
dementia,I-Entity
possibly,O
due,O
to,O
cimetidine,I-Entity
(,O
with,O
a,O
drug,O
level,O
of,O
1.9,O
microgram,O
/,O
ml,O
6,O
hr,O
after,O
a,O
dose,O
),O
in,O
a,O
group,O
of,O
13,O
patients,O
without,O
liver,B-Entity
or,I-Entity
kidney,I-Entity
disease,I-Entity
who,O
had,O
cimetidine,I-Entity
levels,O
above,O
1.25,O
microgram,O
/,O
ml,O
.,O
Thus,O
",",O
high,O
cimetidine,I-Entity
levels,O
alone,O
do,O
not,O
always,O
induce,O
dementia,I-Entity
.,O
Development,O
of,O
clear,B-Entity
cell,I-Entity
adenocarcinoma,I-Entity
in,O
DES,I-Entity
-,O
exposed,O
offspring,O
under,O
observation,O
.,O
Two,O
cases,O
of,O
clear,B-Entity
cell,I-Entity
adenocarcinoma,I-Entity
of,I-Entity
the,I-Entity
vagina,I-Entity
detected,O
at,O
follow,O
-,O
up,O
in,O
young,O
women,O
exposed,O
in,O
utero,O
to,O
diethylstilbestrol,I-Entity
are,O
reported,O
.,O
One,O
patient,O
",",O
aged,O
23,O
",",O
had,O
been,O
followed,O
for,O
2,O
years,O
before,O
carcinoma,I-Entity
was,O
diagnosed,O
;,O
the,O
second,O
patient,O
",",O
aged,O
22,O
",",O
had,O
been,O
seen,O
on,O
a,O
regular,O
basis,O
for,O
5,O
years,O
",",O
8,O
months,O
.,O
In,O
both,O
instances,O
",",O
suspicion,O
of,O
the,O
presence,O
of,O
carcinoma,I-Entity
was,O
aroused,O
by,O
the,O
palpation,O
of,O
a,O
small,O
nodule,O
in,O
the,O
vaginal,O
fornix,O
.,O
Phenobarbitone,I-Entity
-,O
induced,O
enlargement,B-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
in,O
the,O
rat,O
:,O
its,O
relationship,O
to,O
carbon,B-Entity
tetrachloride,I-Entity
-,O
induced,O
cirrhosis,I-Entity
.,O
The,O
yield,O
of,O
severe,O
cirrhosis,B-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
(,O
defined,O
as,O
a,O
shrunken,O
finely,O
nodular,O
liver,O
with,O
micronodular,O
histology,O
",",O
ascites,I-Entity
greater,O
than,O
30,O
ml,O
",",O
plasma,O
albumin,O
less,O
than,O
2.2,O
g,O
/,O
dl,O
",",O
splenomegaly,I-Entity
2,O
-,O
3,O
times,O
normal,O
",",O
and,O
testicular,O
atrophy,I-Entity
approximately,O
half,O
normal,O
weight,O
),O
after,O
12,O
doses,O
of,O
carbon,B-Entity
tetrachloride,I-Entity
given,O
intragastrically,O
in,O
the,O
phenobarbitone,I-Entity
-,O
primed,O
rat,O
was,O
increased,O
from,O
25%,O
to,O
56%,O
by,O
giving,O
the,O
initial,O
"""",O
calibrating,O
"""",O
dose,O
of,O
carbon,B-Entity
tetrachloride,I-Entity
at,O
the,O
peak,O
of,O
the,O
phenobarbitone,I-Entity
-,O
induced,O
enlargement,B-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
.,O
At,O
this,O
point,O
it,O
was,O
assumed,O
that,O
the,O
cytochrome,O
P450/CCl4,I-Entity
toxic,O
state,O
was,O
both,O
maximal,O
and,O
stable,O
.,O
The,O
optimal,O
rat,O
size,O
to,O
begin,O
phenobarbitone,I-Entity
was,O
determined,O
as,O
100,O
g,O
",",O
and,O
this,O
size,O
as,O
a,O
group,O
had,O
a,O
mean,O
maximum,O
relative,O
liver,O
weight,O
increase,O
47%,O
greater,O
than,O
normal,O
rats,O
of,O
the,O
same,O
body,O
weight,O
.,O
The,O
optimal,O
time,O
for,O
the,O
initial,O
dose,O
of,O
carbon,B-Entity
tetrachloride,I-Entity
was,O
after,O
14,O
days,O
on,O
phenobarbitone,I-Entity
.,O
Attenuation,O
of,O
the,O
lithium,I-Entity
-,O
induced,O
diabetes,B-Entity
-,I-Entity
insipidus,I-Entity
-,I-Entity
like,I-Entity
syndrome,I-Entity
by,O
amiloride,I-Entity
in,O
rats,O
.,O
The,O
effect,O
of,O
amiloride,I-Entity
on,O
lithium,I-Entity
-,O
induced,O
polydipsia,I-Entity
and,O
polyuria,I-Entity
and,O
on,O
the,O
lithium,I-Entity
concentration,O
in,O
the,O
plasma,O
",",O
brain,O
",",O
kidney,O
",",O
thyroid,O
and,O
red,O
blood,O
cells,O
was,O
investigated,O
in,O
rats,O
",",O
chronically,O
treated,O
with,O
LiCl,I-Entity
.,O
Amiloride,I-Entity
reduced,O
the,O
drinking,O
and,O
urine,O
volume,O
of,O
rats,O
in,O
an,O
acute,O
(,O
6,O
or,O
12,O
h,O
),O
and,O
a,O
subacute,O
(,O
3,O
days,O
),O
experiment,O
.,O
6,O
h,O
after,O
the,O
administration,O
of,O
amiloride,I-Entity
",",O
a,O
reduction,O
was,O
observed,O
in,O
the,O
lithium,I-Entity
content,O
of,O
the,O
renal,O
medulla,O
but,O
not,O
in,O
the,O
other,O
organs,O
studied,O
.,O
At,O
12,O
h,O
",",O
all,O
the,O
tissues,O
showed,O
a,O
slight,O
increase,O
in,O
lithium,I-Entity
levels,O
.,O
After,O
3,O
days,O
of,O
combined,O
treatment,O
",",O
a,O
marked,O
elevation,O
in,O
plasma,O
and,O
tissue,O
lithium,I-Entity
levels,O
accompanied,O
a,O
reduction,O
in,O
water,O
intake,O
.,O
In,O
all,O
the,O
experiments,O
",",O
the,O
attenuation,O
of,O
the,O
lithium,I-Entity
-,O
induced,O
diabetes,B-Entity
-,I-Entity
insipidus,I-Entity
-,I-Entity
like,I-Entity
syndrome,I-Entity
by,O
amiloride,I-Entity
was,O
accompanied,O
by,O
a,O
reduction,O
of,O
the,O
ratio,O
between,O
the,O
lithium,I-Entity
concentration,O
in,O
the,O
renal,O
medulla,O
and,O
its,O
levels,O
in,O
the,O
blood,O
and,O
an,O
elevation,O
in,O
the,O
plasma,O
potassium,I-Entity
level,O
.,O
It,O
is,O
concluded,O
that,O
acute,O
amiloride,I-Entity
administration,O
to,O
lithium,I-Entity
-,O
treated,O
patients,O
suffering,O
from,O
polydipsia,I-Entity
and,O
polyuria,I-Entity
might,O
relieve,O
these,O
patients,O
but,O
prolonged,O
amiloride,I-Entity
supplementation,O
would,O
result,O
in,O
elevated,O
lithium,I-Entity
levels,O
and,O
might,O
be,O
hazardous,O
.,O
Safety,O
and,O
side,O
-,O
effects,O
of,O
alprazolam,I-Entity
.,O
Controlled,O
study,O
in,O
agoraphobia,I-Entity
with,O
panic,B-Entity
disorder,I-Entity
.,O
BACKGROUND,O
:,O
The,O
widespread,O
use,O
of,O
benzodiazepines,I-Entity
has,O
led,O
to,O
increasing,O
recognition,O
of,O
their,O
unwanted,O
effects,O
.,O
The,O
efficacy,O
of,O
alprazolam,I-Entity
and,O
placebo,O
in,O
panic,B-Entity
disorder,I-Entity
with,O
agoraphobia,I-Entity
",",O
and,O
the,O
side,O
-,O
effect,O
and,O
adverse,O
effect,O
profiles,O
of,O
both,O
drug,O
groups,O
were,O
measured,O
.,O
In,O
London,O
and,O
Toronto,O
154,O
patients,O
who,O
met,O
DSM,O
-,O
III,O
criteria,O
for,O
panic,B-Entity
disorder,I-Entity
with,O
agoraphobia,I-Entity
were,O
randomised,O
to,O
alprazolam,I-Entity
or,O
placebo,O
.,O
Mean,O
alprazolam,I-Entity
dose,O
was,O
5,O
mg,O
daily,O
.,O
Compared,O
with,O
placebo,O
subjects,O
",",O
alprazolam,I-Entity
patients,O
developed,O
more,O
adverse,O
reactions,O
(,O
21%,O
v.,O
0%,O
),O
of,O
depression,I-Entity
",",O
enuresis,I-Entity
",",O
disinhibition,O
and,O
aggression,I-Entity
;,O
and,O
more,O
side,O
-,O
effects,O
",",O
particularly,O
sedation,O
",",O
irritability,I-Entity
",",O
impaired,B-Entity
memory,I-Entity
",",O
weight,B-Entity
loss,I-Entity
and,O
ataxia,I-Entity
.,O
Alprazolam,I-Entity
caused,O
side,O
-,O
effects,O
and,O
adverse,O
effects,O
during,O
treatment,O
but,O
many,O
patients,O
were,O
willing,O
to,O
accept,O
these,O
.,O
Dup,B-Entity
753,I-Entity
prevents,O
the,O
development,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephrosis,I-Entity
.,O
The,O
appearance,O
of,O
nephrotic,B-Entity
syndromes,I-Entity
such,O
as,O
proteinuria,I-Entity
",",O
hypoalbuminemia,I-Entity
",",O
hypercholesterolemia,I-Entity
and,O
increase,O
in,O
blood,B-Entity
nitrogen,I-Entity
urea,I-Entity
",",O
induced,O
in,O
rats,O
by,O
injection,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
was,O
markedly,O
inhibited,O
by,O
oral,O
administration,O
of,O
Dup,B-Entity
753,I-Entity
(,O
losartan,I-Entity
),O
",",O
a,O
novel,O
angiotensin,B-Entity
II,I-Entity
receptor,O
antagonist,O
",",O
at,O
a,O
dose,O
of,O
1,O
or,O
2,O
mg,O
/,O
kg,O
per,O
day,O
.,O
The,O
results,O
suggest,O
a,O
possible,O
involvement,O
of,O
the,O
renin,O
-,O
angiotensin,I-Entity
system,O
in,O
the,O
development,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephrosis,I-Entity
.,O
Sodium,B-Entity
bicarbonate,I-Entity
alleviates,O
penile,B-Entity
pain,I-Entity
induced,O
by,O
intracavernous,O
injections,O
for,O
erectile,B-Entity
dysfunction,I-Entity
.,O
In,O
an,O
attempt,O
to,O
determine,O
whether,O
penile,B-Entity
pain,I-Entity
associated,O
with,O
intracorporeal,O
injections,O
could,O
be,O
due,O
to,O
the,O
acidity,O
of,O
the,O
medication,O
",",O
we,O
performed,O
a,O
randomized,O
study,O
comparing,O
the,O
incidence,O
of,O
penile,B-Entity
pain,I-Entity
following,O
intracorporeal,O
injections,O
with,O
or,O
without,O
the,O
addition,O
of,O
sodium,B-Entity
bicarbonate,I-Entity
to,O
the,O
intracorporeal,O
medications,O
.,O
A,O
total,O
of,O
38,O
consecutive,O
patients,O
who,O
presented,O
to,O
our,O
clinic,O
with,O
impotence,I-Entity
received,O
0.2,O
ml,O
.,O
of,O
a,O
combination,O
of,O
3,O
drugs,O
:,O
6,O
mg,O
.,O
papaverine,I-Entity
",",O
100,O
micrograms,O
.,O
phentolamine,I-Entity
and,O
10,O
micrograms,O
.,O
prostaglandin,B-Entity
E1,I-Entity
with,O
(,O
pH,O
7.05,O
),O
or,O
without,O
(,O
pH,O
4.17,O
),O
the,O
addition,O
of,O
sodium,B-Entity
bicarbonate,I-Entity
(,O
0.03,O
mEq,O
.,O
),O
.,O
Of,O
the,O
19,O
patients,O
without,O
sodium,B-Entity
bicarbonate,I-Entity
added,O
to,O
the,O
medication,O
11,O
(,O
58%,O
),O
complained,O
of,O
penile,B-Entity
pain,I-Entity
due,O
to,O
the,O
medication,O
",",O
while,O
only,O
1,O
of,O
the,O
19,O
men,O
(,O
5%,O
),O
who,O
received,O
sodium,B-Entity
bicarbonate,I-Entity
complained,O
of,O
penile,B-Entity
pain,I-Entity
.,O
From,O
these,O
data,O
we,O
conclude,O
that,O
the,O
penile,B-Entity
pain,I-Entity
following,O
intracorporeal,O
injections,O
is,O
most,O
likely,O
due,O
to,O
the,O
acidity,O
of,O
the,O
medication,O
",",O
which,O
can,O
be,O
overcome,O
by,O
elevating,O
the,O
pH,O
to,O
a,O
neutral,O
level,O
.,O
Prospective,O
study,O
of,O
the,O
long,O
-,O
term,O
effects,O
of,O
somatostatin,O
analog,O
(,O
octreotide,I-Entity
),O
on,O
gallbladder,O
function,O
and,O
gallstone,I-Entity
formation,O
in,O
Chinese,O
acromegalic,I-Entity
patients,O
.,O
This,O
article,O
reports,O
the,O
changes,O
in,O
gallbladder,O
function,O
examined,O
by,O
ultrasonography,O
in,O
20,O
Chinese,O
patients,O
with,O
active,O
acromegaly,I-Entity
treated,O
with,O
sc,O
injection,O
of,O
the,O
somatostatin,O
analog,O
octreotide,I-Entity
in,O
dosages,O
of,O
300,O
-,O
1500,O
micrograms,O
/,O
day,O
for,O
a,O
mean,O
of,O
24.2,O
+,O
/-,O
During,O
treatment,O
with,O
octreotide,I-Entity
",",O
17,O
patients,O
developed,O
sludge,O
",",O
10,O
had,O
gallstones,I-Entity
",",O
and,O
1,O
developed,O
acute,B-Entity
cholecystitis,I-Entity
requiring,O
surgery,O
.,O
In,O
8,O
patients,O
followed,O
for,O
24,O
weeks,O
",",O
gallbladder,O
contractility,O
remained,O
depressed,I-Entity
throughout,O
therapy,O
.,O
After,O
withdrawal,O
of,O
octreotide,I-Entity
in,O
10,O
patients,O
without,O
gallstones,I-Entity
",",O
8,O
patients,O
assessed,O
had,O
return,O
of,O
normal,O
gallbladder,O
contractility,O
within,O
1,O
month,O
.,O
In,O
8,O
of,O
the,O
remaining,O
10,O
patients,O
who,O
developed,O
gallstones,I-Entity
during,O
treatment,O
",",O
gallbladder,O
contractility,O
normalized,O
in,O
5,O
patients,O
(,O
3,O
of,O
whom,O
has,O
disappearance,O
of,O
their,O
stones,O
within,O
3,O
weeks,O
),O
",",O
and,O
remained,O
depressed,I-Entity
in,O
3,O
(,O
2,O
of,O
whom,O
had,O
stones,O
present,O
at,O
6,O
months,O
),O
.,O
Our,O
results,O
suggest,O
that,O
the,O
suppression,O
of,O
gallbladder,O
contractility,O
is,O
the,O
cause,O
of,O
the,O
successive,O
formation,O
of,O
bile,O
sludge,O
",",O
gallstones,I-Entity
",",O
and,O
cholecystitis,I-Entity
during,O
octreotide,I-Entity
therapy,O
in,O
Chinese,O
acromegalic,I-Entity
patients,O
.,O
It,O
is,O
therefore,O
very,O
important,O
to,O
follow,O
the,O
changes,O
of,O
gallbladder,O
function,O
during,O
long,O
-,O
term,O
octreotide,I-Entity
therapy,O
of,O
acromegalic,I-Entity
patients,O
.,O
Improvement,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
by,O
propranolol,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Seven,O
patients,O
suffering,O
from,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
with,O
severely,O
disabling,O
dyskinesia,I-Entity
received,O
low,O
-,O
dose,O
propranolol,I-Entity
as,O
an,O
adjunct,O
to,O
the,O
currently,O
used,O
medical,O
treatment,O
.,O
There,O
was,O
a,O
significant,O
40%,O
improvement,O
in,O
the,O
dyskinesia,I-Entity
score,O
without,O
increase,O
of,O
parkinsonian,I-Entity
motor,B-Entity
disability,I-Entity
.,O
Ballistic,O
and,O
choreic,O
dyskinesia,I-Entity
were,O
markedly,O
ameliorated,O
",",O
whereas,O
dystonia,I-Entity
was,O
not,O
.,O
This,O
study,O
suggests,O
that,O
administration,O
of,O
low,O
doses,O
of,O
beta,O
-,O
blockers,O
may,O
improve,O
levodopa,I-Entity
-,O
induced,O
ballistic,O
and,O
choreic,O
dyskinesia,I-Entity
in,O
PD,I-Entity
.,O
Morphological,O
features,O
of,O
encephalopathy,I-Entity
after,O
chronic,O
administration,O
of,O
the,O
antiepileptic,O
drug,O
valproate,I-Entity
to,O
rats,O
.,O
Long,O
-,O
term,O
intragastric,O
application,O
of,O
the,O
antiepileptic,O
drug,O
sodium,B-Entity
valproate,I-Entity
(,O
Vupral,O
"""",O
Polfa,O
"""",O
),O
at,O
the,O
effective,O
dose,O
of,O
200,O
mg,O
/,O
kg,O
b.,O
w.,O
once,O
daily,O
to,O
rats,O
for,O
1,O
",",O
3,O
",",O
6,O
",",O
9,O
and,O
12,O
months,O
revealed,O
neurological,B-Entity
disorders,I-Entity
indicating,O
cerebellum,B-Entity
damage,I-Entity
(,O
"""",O
valproate,I-Entity
encephalopathy,I-Entity
"""",O
),O
.,O
Lesions,O
of,O
the,O
capillary,O
included,O
necrosis,I-Entity
of,O
endothelial,O
cells,O
.,O
Reduced,O
size,O
of,O
capillary,O
lumen,O
and,O
occlusion,O
were,O
caused,O
by,O
swollen,O
endothelial,O
cells,O
which,O
had,O
luminal,I-Entity
protrusions,O
and,O
swollen,O
microvilli,O
.,O
Fragments,O
of,O
necrotic,I-Entity
endothelial,O
cells,O
were,O
in,O
the,O
vascular,O
lumens,O
and,O
in,O
these,O
there,O
was,O
loosening,O
and,O
breaking,O
of,O
tight,O
cellular,O
junctions,O
.,O
In,O
electron,O
micrographs,O
both,O
luminal,I-Entity
and,O
antiluminal,O
sides,O
of,O
the,O
BBB,O
of,O
the,O
cerebellar,O
cortex,O
had,O
similar,O
lesions,O
.,O
The,O
possible,O
influence,O
of,O
the,O
hepatic,B-Entity
damage,I-Entity
",",O
mainly,O
hyperammonemia,I-Entity
",",O
upon,O
the,O
development,O
of,O
valproate,I-Entity
encephalopathy,I-Entity
is,O
discussed,O
.,O
Macula,O
toxicity,I-Entity
after,O
intravitreal,O
amikacin,I-Entity
.,O
Although,O
intravitreal,O
aminoglycosides,I-Entity
have,O
substantially,O
improved,O
visual,O
prognosis,O
in,O
endophthalmitis,I-Entity
",",O
macular,O
infarction,I-Entity
may,O
impair,O
full,O
visual,O
recovery,O
.,O
METHODS,O
:,O
We,O
present,O
a,O
case,O
of,O
presumed,O
amikacin,I-Entity
retinal,B-Entity
toxicity,I-Entity
following,O
treatment,O
with,O
amikacin,I-Entity
and,O
vancomycin,I-Entity
for,O
alpha,O
-,O
haemolytic,O
streptococcal,B-Entity
endophthalmitis,I-Entity
.,O
Endophthalmitis,I-Entity
resolved,O
with,O
improvement,O
in,O
visual,O
acuity,O
to,O
6/24,O
at,O
three,O
months,O
.,O
Fundus,O
fluorescein,I-Entity
angiography,O
confirmed,O
macular,O
capillary,O
closure,O
and,O
telangiectasis,I-Entity
.,O
CONCLUSIONS,O
:,O
Currently,O
accepted,O
intravitreal,O
antibiotic,O
regimens,O
may,O
cause,O
retinal,B-Entity
toxicity,I-Entity
and,O
macular,O
ischaemia,I-Entity
.,O
Treatment,O
strategies,O
aimed,O
at,O
avoiding,O
retinal,B-Entity
toxicity,I-Entity
are,O
discussed,O
.,O
Iatrogenically,O
induced,O
intractable,O
atrioventricular,B-Entity
reentrant,I-Entity
tachycardia,I-Entity
after,O
verapamil,I-Entity
and,O
catheter,O
ablation,O
in,O
a,O
patient,O
with,O
Wolff,B-Entity
-,I-Entity
Parkinson,I-Entity
-,I-Entity
White,I-Entity
syndrome,I-Entity
and,O
idiopathic,B-Entity
dilated,I-Entity
cardiomyopathy,I-Entity
.,O
In,O
a,O
patient,O
with,O
WPW,B-Entity
syndrome,I-Entity
and,O
idiopathic,B-Entity
dilated,I-Entity
cardiomyopathy,I-Entity
",",O
intractable,O
atrioventricular,B-Entity
reentrant,I-Entity
tachycardia,I-Entity
(,O
AVRT,I-Entity
),O
was,O
iatrogenically,O
induced,O
.,O
QRS,O
without,O
preexcitation,O
",",O
caused,O
by,O
junctional,O
escape,O
beats,O
after,O
verapamil,I-Entity
or,O
unidirectional,O
antegrade,O
block,O
of,O
accessory,O
pathway,O
after,O
catheter,O
ablation,O
",",O
established,O
frequent,O
AVRT,I-Entity
attack,O
.,O
Epidemic,O
of,O
liver,B-Entity
disease,I-Entity
caused,O
by,O
hydrochlorofluorocarbons,I-Entity
used,O
as,O
ozone,I-Entity
-,O
sparing,O
substitutes,O
of,O
chlorofluorocarbons,I-Entity
.,O
BACKGROUND,O
:,O
Hydrochlorofluorocarbons,I-Entity
(,O
HCFCs,I-Entity
),O
are,O
used,O
increasingly,O
in,O
industry,O
as,O
substitutes,O
for,O
ozone,I-Entity
-,O
depleting,O
chlorofluorocarbons,I-Entity
(,O
CFCs,I-Entity
),O
.,O
Limited,O
studies,O
in,O
animals,O
indicate,O
potential,O
hepatotoxicity,I-Entity
of,O
some,O
of,O
these,O
compounds,O
.,O
We,O
investigated,O
an,O
epidemic,O
of,O
liver,B-Entity
disease,I-Entity
in,O
nine,O
industrial,O
workers,O
who,O
had,O
had,O
repeated,O
accidental,O
exposure,O
to,O
a,O
mixture,O
of,O
"1,1-dichloro-2,2,2-trifluoroethane",I-Entity
(,O
HCFC,B-Entity
123,I-Entity
),O
and,O
"1-chloro-1,2,2,2-tetrafluoroethane",I-Entity
(,O
HCFC,B-Entity
124,I-Entity
),O
.,O
Both,O
compounds,O
are,O
metabolised,O
in,O
the,O
same,O
way,O
as,O
"1-bromo-1-chloro-2,2,2-trifluoroethane",I-Entity
(,O
halothane,I-Entity
),O
to,O
form,O
reactive,O
trifluoroacetyl,I-Entity
halide,O
intermediates,O
",",O
which,O
have,O
been,O
implicated,O
in,O
the,O
hepatotoxicity,I-Entity
of,O
halothane,I-Entity
.,O
We,O
aimed,O
to,O
test,O
whether,O
HCFCs,B-Entity
123,I-Entity
and,I-Entity
124,I-Entity
can,O
result,O
in,O
serious,O
liver,B-Entity
disease,I-Entity
.,O
METHODS,O
:,O
For,O
one,O
severely,O
affected,O
worker,O
liver,O
biopsy,O
and,O
immunohistochemical,O
stainings,O
for,O
the,O
presence,O
of,O
trifluoroacetyl,I-Entity
protein,O
adducts,O
were,O
done,O
.,O
The,O
liver,O
biopsy,O
sample,O
showed,O
hepatocellular,O
necrosis,I-Entity
which,O
was,O
prominent,O
in,O
perivenular,O
zone,O
three,O
and,O
extended,O
focally,O
from,O
portal,O
tracts,O
to,O
portal,O
tracts,O
and,O
centrilobular,O
areas,O
(,O
bridging,O
necrosis,I-Entity
),O
.,O
Trifluoroacetyl,I-Entity
-,O
adducted,O
proteins,O
were,O
detected,O
in,O
surviving,O
hepatocytes,O
.,O
Autoantibodies,O
against,O
P450,O
2E1,O
or,O
P58,O
",",O
previously,O
associated,O
with,O
halothane,B-Entity
hepatitis,I-Entity
",",O
were,O
detected,O
in,O
the,O
serum,O
of,O
five,O
affected,O
workers,O
.,O
INTERPRETATION,O
:,O
Repeated,O
exposure,O
of,O
human,O
beings,O
to,O
HCFCs,B-Entity
123,I-Entity
and,I-Entity
124,I-Entity
can,O
result,O
in,O
serious,O
liver,B-Entity
injury,I-Entity
in,O
a,O
large,O
proportion,O
of,O
the,O
exposed,O
population,O
.,O
Although,O
the,O
exact,O
mechanism,O
of,O
hepatotoxicity,I-Entity
of,O
these,O
agents,O
is,O
not,O
known,O
",",O
the,O
results,O
suggest,O
that,O
trifluoroacetyl,I-Entity
-,O
altered,O
liver,O
proteins,O
are,O
involved,O
.,O
The,O
effect,O
of,O
different,O
anaesthetic,O
agents,O
in,O
hearing,B-Entity
loss,I-Entity
following,O
spinal,O
anaesthesia,O
.,O
The,O
cause,O
of,O
hearing,B-Entity
loss,I-Entity
after,O
spinal,O
anaesthesia,O
is,O
unknown,O
.,O
Up,O
until,O
now,O
",",O
the,O
only,O
factor,O
studied,O
has,O
been,O
the,O
effect,O
of,O
the,O
diameter,O
of,O
the,O
spinal,O
needle,O
on,O
post,O
-,O
operative,O
sensorineural,B-Entity
hearing,I-Entity
loss,I-Entity
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
describe,O
this,O
hearing,B-Entity
loss,I-Entity
and,O
to,O
investigate,O
other,O
factors,O
influencing,O
the,O
degree,O
of,O
hearing,B-Entity
loss,I-Entity
.,O
prilocaine,I-Entity
2%,O
;,O
and,O
the,O
other,O
received,O
3,O
mL,O
bupivacaine,I-Entity
0.5%,O
.,O
Patients,O
given,O
prilocaine,I-Entity
were,O
more,O
likely,O
to,O
develop,O
hearing,B-Entity
loss,I-Entity
(,O
10,O
out,O
of,O
22,O
),O
than,O
those,O
given,O
bupivacaine,I-Entity
(,O
4,O
out,O
of,O
22,O
),O
(,O
P,O
<,O
0.05,O
),O
.,O
The,O
average,O
hearing,B-Entity
loss,I-Entity
for,O
speech,O
frequencies,O
was,O
about,O
10,O
dB,O
after,O
prilocaine,I-Entity
and,O
15,O
dB,O
after,O
bupivacaine,I-Entity
.,O
None,O
of,O
the,O
patients,O
complained,O
of,O
subjective,O
hearing,B-Entity
loss,I-Entity
.,O
A,O
transient,O
neurological,B-Entity
deficit,I-Entity
following,O
intrathecal,O
injection,O
of,O
1%,O
hyperbaric,O
bupivacaine,I-Entity
for,O
unilateral,O
spinal,O
anaesthesia,O
.,O
We,O
describe,O
a,O
case,O
of,O
transient,O
neurological,B-Entity
deficit,I-Entity
that,O
occurred,O
after,O
unilateral,O
spinal,O
anaesthesia,O
with,O
8,O
mg,O
of,O
1%,O
hyperbaric,O
bupivacaine,I-Entity
slowly,O
injected,O
through,O
a,O
25-gauge,O
pencil,O
-,O
point,O
spinal,O
needle,O
.,O
The,O
surgery,O
and,O
anaesthesia,O
were,O
uneventful,O
",",O
but,O
3,O
days,O
after,O
surgery,O
",",O
the,O
patient,O
reported,O
an,O
area,O
of,O
hypoaesthesia,O
over,O
L3-L4,O
dermatomes,O
of,O
the,O
leg,O
which,O
had,O
been,O
operated,O
on,O
(,O
loss,B-Entity
of,I-Entity
pinprick,I-Entity
sensation,I-Entity
),O
without,O
reduction,O
in,O
muscular,O
strength,O
.,O
However,O
",",O
we,O
suggest,O
that,O
a,O
low,O
solution,O
concentration,O
should,O
be,O
preferred,O
for,O
unilateral,O
spinal,O
anaesthesia,O
with,O
a,O
hyperbaric,O
anaesthetic,O
solution,O
(,O
if,O
pencil,O
-,O
point,O
needle,O
and,O
slow,O
injection,O
rate,O
are,O
employed,O
),O
",",O
in,O
order,O
to,O
minimize,O
the,O
risk,O
of,O
a,O
localized,O
high,O
peak,O
anaesthetic,O
concentration,O
",",O
which,O
might,O
lead,O
to,O
a,O
transient,O
neurological,B-Entity
deficit,I-Entity
.,O
Pethidine,I-Entity
-,O
associated,O
seizure,I-Entity
in,O
a,O
healthy,O
adolescent,O
receiving,O
pethidine,I-Entity
for,O
postoperative,B-Entity
pain,I-Entity
control,O
.,O
A,O
healthy,O
17-year,O
-,O
old,O
male,O
received,O
standard,O
intermittent,O
doses,O
of,O
pethidine,I-Entity
via,O
a,O
patient,O
-,O
controlled,O
analgesia,O
(,O
PCA,O
),O
pump,O
for,O
management,O
of,O
postoperative,B-Entity
pain,I-Entity
control,O
.,O
postoperatively,O
he,O
developed,O
a,O
brief,O
self,O
-,O
limited,O
seizure,I-Entity
.,O
Both,O
plasma,O
pethidine,I-Entity
and,O
norpethidine,I-Entity
were,O
elevated,O
in,O
the,O
range,O
associated,O
with,O
clinical,O
manifestations,O
of,O
central,O
nervous,O
system,O
excitation,O
.,O
No,O
other,O
risk,O
factors,O
for,O
CNS,O
toxicity,I-Entity
were,O
identified,O
.,O
This,O
method,O
allowed,O
frequent,O
self,O
-,O
dosing,O
of,O
pethidine,I-Entity
at,O
short,O
time,O
intervals,O
and,O
rapid,O
accumulation,O
of,O
pethidine,I-Entity
and,O
norpethidine,I-Entity
.,O
The,O
routine,O
use,O
of,O
pethidine,I-Entity
via,O
PCA,O
even,O
for,O
a,O
brief,O
postoperative,O
analgesia,O
should,O
be,O
reconsidered,O
.,O
Drug,O
-,O
associated,O
acute,O
-,O
onset,O
vanishing,B-Entity
bile,I-Entity
duct,I-Entity
and,O
Stevens,B-Entity
-,I-Entity
Johnson,I-Entity
syndromes,I-Entity
in,O
a,O
child,O
.,O
Acute,O
vanishing,B-Entity
bile,I-Entity
duct,I-Entity
syndrome,O
is,O
a,O
rare,O
but,O
established,O
cause,O
of,O
progressive,O
cholestasis,I-Entity
in,O
adults,O
",",O
is,O
most,O
often,O
drug,O
or,O
toxin,O
related,O
",",O
and,O
is,O
of,O
unknown,O
pathogenesis,O
.,O
Stevens,B-Entity
-,I-Entity
Johnson,I-Entity
syndrome,I-Entity
is,O
a,O
well,O
-,O
recognized,O
immune,O
complex,O
-,O
mediated,O
hypersensitivity,I-Entity
reaction,O
that,O
affects,O
all,O
age,O
groups,O
",",O
is,O
drug,O
or,O
infection,I-Entity
induced,O
",",O
and,O
has,O
classic,O
systemic,O
",",O
mucosal,O
",",O
and,O
dermatologic,O
manifestations,O
.,O
A,O
previously,O
healthy,O
child,O
who,O
developed,O
acute,O
",",O
severe,O
",",O
rapidly,O
progressive,O
vanishing,B-Entity
bile,I-Entity
duct,I-Entity
syndrome,I-Entity
shortly,O
after,O
Stevens,B-Entity
-,I-Entity
Johnson,I-Entity
syndrome,I-Entity
is,O
described,O
;,O
this,O
was,O
temporally,O
associated,O
with,O
ibuprofen,I-Entity
use,O
.,O
Despite,O
therapy,O
with,O
ursodeoxycholic,B-Entity
acid,I-Entity
",",O
prednisone,I-Entity
",",O
and,O
then,O
tacrolimus,I-Entity
",",O
her,O
cholestatic,B-Entity
disease,I-Entity
was,O
unrelenting,O
",",O
with,O
cirrhosis,I-Entity
shown,O
by,O
biopsy,O
6,O
months,O
after,O
presentation,O
.,O
This,O
case,O
documents,O
acute,O
drug,O
-,O
related,O
vanishing,B-Entity
bile,I-Entity
duct,I-Entity
syndrome,I-Entity
in,O
the,O
pediatric,O
age,O
group,O
and,O
suggests,O
shared,O
immune,O
mechanisms,O
in,O
the,O
pathogenesis,O
of,O
both,O
Stevens,B-Entity
-,I-Entity
Johnson,I-Entity
syndrome,I-Entity
and,O
vanishing,B-Entity
bile,I-Entity
duct,I-Entity
syndrome,I-Entity
.,O
High,O
incidence,O
of,O
primary,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
associated,O
with,O
appetite,B-Entity
suppressants,I-Entity
in,O
Belgium,O
.,O
Primary,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
is,O
a,O
rare,O
",",O
progressive,O
and,O
incurable,O
disease,O
",",O
which,O
has,O
been,O
associated,O
with,O
the,O
intake,O
of,O
appetite,B-Entity
suppressant,I-Entity
drugs,O
.,O
The,O
importance,O
of,O
this,O
association,O
was,O
evaluated,O
in,O
Belgium,O
while,O
this,O
country,O
still,O
had,O
no,O
restriction,O
on,O
the,O
prescription,O
of,O
appetite,B-Entity
suppressants,I-Entity
.,O
Thirty,O
-,O
five,O
patients,O
with,O
primary,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
and,O
85,O
matched,O
controls,O
were,O
recruited,O
over,O
32,O
months,O
(,O
1992,O
-,O
1994,O
),O
in,O
Belgium,O
.,O
Exposure,O
to,O
appetite,B-Entity
-,I-Entity
suppressants,I-Entity
was,O
assessed,O
on,O
the,O
basis,O
of,O
hospital,O
records,O
and,O
standardized,O
interview,O
.,O
Twenty,O
-,O
three,O
of,O
the,O
patients,O
had,O
previously,O
taken,O
appetite,B-Entity
suppressants,I-Entity
",",O
mainly,O
fenfluramines,I-Entity
",",O
as,O
compared,O
with,O
only,O
5,O
of,O
the,O
controls,O
(,O
66,O
versus,O
6%,O
",",O
Five,O
patients,O
died,O
before,O
the,O
interview,O
",",O
all,O
of,O
them,O
had,O
taken,O
appetite,B-Entity
suppressants,I-Entity
.,O
In,O
8,O
patients,O
the,O
diagnosis,O
of,O
primary,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
was,O
uncertain,O
",",O
5,O
of,O
them,O
had,O
taken,O
appetite,B-Entity
suppressants,I-Entity
.,O
The,O
patients,O
who,O
had,O
been,O
exposed,O
to,O
appetite,B-Entity
suppressants,I-Entity
tended,O
to,O
be,O
on,O
average,O
more,O
severely,O
ill,O
",",O
and,O
to,O
have,O
a,O
shorter,O
median,O
delay,O
between,O
onset,O
of,O
symptoms,O
and,O
diagnosis,O
.,O
A,O
policy,O
of,O
unrestricted,O
prescription,O
of,O
appetite,B-Entity
suppressants,I-Entity
may,O
lead,O
to,O
a,O
high,O
incidence,O
of,O
associated,O
primary,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
.,O
Intake,O
of,O
appetite,B-Entity
suppressants,I-Entity
may,O
accelerate,O
the,O
progression,O
of,O
the,O
disease,O
.,O
Choreoathetoid,B-Entity
movements,I-Entity
associated,O
with,O
rapid,O
adjustment,O
to,O
methadone,I-Entity
.,O
Choreatiform,B-Entity
hyperkinesias,I-Entity
are,O
known,O
to,O
be,O
occasional,O
movement,B-Entity
abnormalities,I-Entity
during,O
intoxications,O
with,O
cocaine,I-Entity
but,O
not,O
opiates,O
.,O
This,O
is,O
a,O
case,O
report,O
of,O
euphoria,O
and,O
choreoathetoid,B-Entity
movements,I-Entity
both,O
transiently,O
induced,O
by,O
rapid,O
adjustment,O
to,O
the,O
selective,O
mu,O
-,O
opioid,O
receptor,O
agonist,O
methadone,I-Entity
in,O
an,O
inpatient,O
previously,O
abusing,O
heroine,I-Entity
and,O
cocaine,I-Entity
.,O
Cocaine,I-Entity
-,O
induced,O
mood,B-Entity
disorder,I-Entity
:,O
prevalence,O
rates,O
and,O
psychiatric,I-Entity
symptoms,O
in,O
an,O
outpatient,O
cocaine,I-Entity
-,O
dependent,O
sample,O
.,O
This,O
paper,O
attempts,O
to,O
examine,O
and,O
compare,O
prevalence,O
rates,O
and,O
symptom,O
patterns,O
of,O
DSM,O
substance,O
-,O
induced,O
and,O
other,O
mood,B-Entity
disorders,I-Entity
.,O
243,O
cocaine,I-Entity
-,O
dependent,O
outpatients,O
with,O
cocaine,I-Entity
-,O
induced,O
mood,B-Entity
disorder,I-Entity
(,O
CIMD,I-Entity
),O
",",O
other,O
mood,B-Entity
disorders,I-Entity
",",O
or,O
no,O
mood,B-Entity
disorder,I-Entity
were,O
compared,O
on,O
measures,O
of,O
psychiatric,I-Entity
symptoms,O
.,O
The,O
prevalence,O
rate,O
for,O
CIMD,I-Entity
was,O
12%,O
at,O
baseline,O
.,O
Introduction,O
of,O
the,O
DSM,O
-,O
IV,O
diagnosis,O
of,O
CIMD,I-Entity
did,O
not,O
substantially,O
affect,O
rates,O
of,O
the,O
other,O
depressive,B-Entity
disorders,I-Entity
.,O
Patients,O
with,O
CIMD,I-Entity
had,O
symptom,O
severity,O
levels,O
between,O
those,O
of,O
patients,O
with,O
and,O
without,O
a,O
mood,B-Entity
disorder,I-Entity
.,O
These,O
findings,O
suggest,O
some,O
validity,O
for,O
the,O
new,O
DSM,O
-,O
IV,O
diagnosis,O
of,O
CIMD,I-Entity
",",O
but,O
also,O
suggest,O
that,O
it,O
requires,O
further,O
specification,O
and,O
replication,O
.,O
Hemolysis,I-Entity
of,O
human,O
erythrocytes,O
induced,O
by,O
tamoxifen,I-Entity
is,O
related,O
to,O
disruption,O
of,O
membrane,O
structure,O
.,O
Tamoxifen,I-Entity
(,O
TAM,I-Entity
),O
",",O
the,O
antiestrogenic,O
drug,O
most,O
widely,O
prescribed,O
in,O
the,O
chemotherapy,O
of,O
breast,B-Entity
cancer,I-Entity
",",O
induces,O
changes,O
in,O
normal,O
discoid,O
shape,O
of,O
erythrocytes,O
and,O
hemolytic,B-Entity
anemia,I-Entity
.,O
This,O
work,O
evaluates,O
the,O
effects,O
of,O
TAM,I-Entity
on,O
isolated,O
human,O
erythrocytes,O
",",O
attempting,O
to,O
identify,O
the,O
underlying,O
mechanisms,O
on,O
TAM,I-Entity
-,O
induced,O
hemolytic,B-Entity
anemia,I-Entity
and,O
the,O
involvement,O
of,O
biomembranes,O
in,O
its,O
cytostatic,O
action,O
mechanisms,O
.,O
TAM,I-Entity
induces,O
hemolysis,I-Entity
of,O
erythrocytes,O
as,O
a,O
function,O
of,O
concentration,O
.,O
The,O
extension,O
of,O
hemolysis,I-Entity
is,O
variable,O
with,O
erythrocyte,O
samples,O
",",O
but,O
12.5,O
microM,O
TAM,I-Entity
induces,O
total,O
hemolysis,I-Entity
of,O
all,O
tested,O
suspensions,O
.,O
Despite,O
inducing,O
extensive,O
erythrocyte,O
lysis,O
",",O
TAM,I-Entity
does,O
not,O
shift,O
the,O
osmotic,O
fragility,O
curves,O
of,O
erythrocytes,O
.,O
The,O
hemolytic,I-Entity
effect,O
of,O
TAM,I-Entity
is,O
prevented,O
by,O
low,O
concentrations,O
of,O
alpha,B-Entity
-,I-Entity
tocopherol,I-Entity
(,O
alpha,B-Entity
-,I-Entity
T,I-Entity
),O
and,O
alpha,B-Entity
-,I-Entity
tocopherol,I-Entity
acetate,I-Entity
(,O
alpha,B-Entity
-,I-Entity
TAc,I-Entity
),O
(,O
inactivated,O
functional,O
hydroxyl,I-Entity
),O
indicating,O
that,O
TAM,I-Entity
-,O
induced,O
hemolysis,I-Entity
is,O
not,O
related,O
to,O
oxidative,O
membrane,O
damage,O
.,O
This,O
was,O
further,O
evidenced,O
by,O
absence,O
of,O
oxygen,I-Entity
consumption,O
and,O
hemoglobin,O
oxidation,O
both,O
determined,O
in,O
parallel,O
with,O
TAM,I-Entity
-,O
induced,O
hemolysis,I-Entity
.,O
Furthermore,O
",",O
it,O
was,O
observed,O
that,O
TAM,I-Entity
inhibits,O
the,O
peroxidation,O
of,O
human,O
erythrocytes,O
induced,O
by,O
AAPH,I-Entity
",",O
thus,O
ruling,O
out,O
TAM,I-Entity
-,O
induced,O
cell,O
oxidative,O
stress,O
.,O
Hemolysis,I-Entity
caused,O
by,O
TAM,I-Entity
was,O
not,O
preceded,O
by,O
the,O
leakage,O
of,O
K(+,I-Entity
),O
from,O
the,O
cells,O
",",O
also,O
excluding,O
a,O
colloid,O
-,O
osmotic,O
type,O
mechanism,O
of,O
hemolysis,I-Entity
",",O
according,O
to,O
the,O
effects,O
on,O
osmotic,O
fragility,O
curves,O
.,O
However,O
",",O
TAM,I-Entity
induces,O
release,O
of,O
peripheral,O
proteins,O
of,O
membrane,O
-,O
cytoskeleton,O
and,O
cytosol,O
proteins,O
essentially,O
bound,O
to,O
band,O
3,O
.,O
Either,O
alpha,B-Entity
-,I-Entity
T,I-Entity
or,O
alpha,B-Entity
-,I-Entity
TAc,I-Entity
increases,O
membrane,O
packing,O
and,O
prevents,O
TAM,I-Entity
partition,O
into,O
model,O
membranes,O
.,O
These,O
effects,O
suggest,O
that,O
the,O
protection,O
from,O
hemolysis,I-Entity
by,O
tocopherols,I-Entity
is,O
related,O
to,O
a,O
decreased,O
TAM,I-Entity
incorporation,O
in,O
condensed,O
membranes,O
and,O
the,O
structural,O
damage,O
of,O
the,O
erythrocyte,O
membrane,O
is,O
consequently,O
avoided,O
.,O
Therefore,O
",",O
TAM,I-Entity
-,O
induced,O
hemolysis,I-Entity
results,O
from,O
a,O
structural,O
perturbation,O
of,O
red,O
cell,O
membrane,O
",",O
leading,O
to,O
changes,O
in,O
the,O
framework,O
of,O
the,O
erythrocyte,O
membrane,O
and,O
its,O
cytoskeleton,O
caused,O
by,O
its,O
high,O
partition,O
in,O
the,O
membrane,O
.,O
These,O
defects,O
explain,O
the,O
abnormal,O
erythrocyte,O
shape,O
and,O
decreased,O
mechanical,O
stability,O
promoted,O
by,O
TAM,I-Entity
",",O
resulting,O
in,O
hemolytic,B-Entity
anemia,I-Entity
.,O
Additionally,O
",",O
since,O
membrane,O
leakage,O
is,O
a,O
final,O
stage,O
of,O
cytotoxicity,O
",",O
the,O
disruption,O
of,O
the,O
structural,O
characteristics,O
of,O
biomembranes,O
by,O
TAM,I-Entity
may,O
contribute,O
to,O
the,O
multiple,O
mechanisms,O
of,O
its,O
anticancer,O
action,O
.,O
Changes,O
of,O
sodium,I-Entity
and,O
ATP,I-Entity
affinities,O
of,O
the,O
cardiac,O
(,O
Na,I-Entity
",",O
K)-ATPase,I-Entity
during,O
and,O
after,O
nitric,B-Entity
oxide,I-Entity
deficient,O
hypertension,I-Entity
.,O
In,O
the,O
cardiovascular,O
system,O
",",O
NO,I-Entity
is,O
involved,O
in,O
the,O
regulation,O
of,O
a,O
variety,O
of,O
functions,O
.,O
Inhibition,O
of,O
NO,I-Entity
synthesis,O
induces,O
sustained,O
hypertension,I-Entity
.,O
In,O
several,O
models,O
of,O
hypertension,I-Entity
",",O
elevation,O
of,O
intracellular,O
sodium,I-Entity
level,O
was,O
documented,O
in,O
cardiac,O
tissue,O
.,O
To,O
assess,O
the,O
molecular,O
basis,O
of,O
disturbances,O
in,O
transmembraneous,O
transport,O
of,O
Na+,I-Entity
",",O
we,O
studied,O
the,O
response,O
of,O
cardiac,O
(,O
Na,I-Entity
",",O
K)-ATPase,I-Entity
to,O
NO,I-Entity
-,O
deficient,O
hypertension,I-Entity
induced,O
in,O
rats,O
by,O
NO,I-Entity
-,O
synthase,O
inhibition,O
with,O
40,O
mg,O
/,O
kg,O
/,O
day,O
N(G)-nitro,B-Entity
-,I-Entity
L,I-Entity
-,I-Entity
arginine,I-Entity
methyl,I-Entity
ester,I-Entity
(,O
L,B-Entity
-,I-Entity
NAME,I-Entity
),O
for,O
4,O
four,O
weeks,O
.,O
After,O
4-week,O
administration,O
of,O
L,B-Entity
-,I-Entity
NAME,I-Entity
",",O
the,O
systolic,O
blood,O
pressure,O
(,O
SBP,O
),O
increased,O
by,O
36%,O
.,O
When,O
activating,O
the,O
(,O
Na,I-Entity
",",O
K)-ATPase,I-Entity
with,O
its,O
substrate,O
ATP,I-Entity
",",O
no,O
changes,O
in,O
Km,O
and,O
Vmax,O
values,O
were,O
observed,O
in,O
NO,I-Entity
-,O
deficient,O
rats,O
.,O
During,O
activation,O
with,O
Na+,I-Entity
",",O
the,O
Vmax,O
remained,O
unchanged,O
",",O
however,O
the,O
K(Na,I-Entity
),O
increased,O
by,O
50%,O
",",O
indicating,O
a,O
profound,O
decrease,O
in,O
the,O
affinity,O
of,O
the,O
Na+-binding,I-Entity
site,O
in,O
NO,I-Entity
-,O
deficient,O
rats,O
.,O
After,O
recovery,O
from,O
hypertension,I-Entity
",",O
the,O
activity,O
of,O
(,O
Na,I-Entity
",",O
K)-ATPase,I-Entity
increased,O
",",O
due,O
to,O
higher,O
affinity,O
of,O
the,O
ATP,I-Entity
-,O
binding,O
site,O
",",O
as,O
revealed,O
from,O
the,O
lowered,O
Km,O
value,O
for,O
ATP,I-Entity
.,O
The,O
K(Na,I-Entity
),O
value,O
for,O
Na+,I-Entity
returned,O
to,O
control,O
value,O
.,O
Inhibition,O
of,O
NO,I-Entity
-,O
synthase,O
induced,O
a,O
reversible,O
hypertension,I-Entity
accompanied,O
by,O
depressed,I-Entity
Na+-extrusion,I-Entity
from,O
cardiac,O
cells,O
as,O
a,O
consequence,O
of,O
deteriorated,O
Na+-binding,I-Entity
properties,O
of,O
the,O
(,O
Na,I-Entity
",",O
K)-ATPase,I-Entity
.,O
After,O
recovery,O
of,O
blood,O
pressure,O
to,O
control,O
values,O
",",O
the,O
extrusion,O
of,O
Na+,I-Entity
from,O
cardiac,O
cells,O
was,O
normalized,O
",",O
as,O
revealed,O
by,O
restoration,O
of,O
the,O
(,O
Na,I-Entity
",",O
K)-ATPase,I-Entity
activity,O
.,O
Effects,O
of,O
long,O
-,O
term,O
pretreatment,O
with,O
isoproterenol,I-Entity
on,O
bromocriptine,I-Entity
-,O
induced,O
tachycardia,I-Entity
in,O
conscious,O
rats,O
.,O
It,O
has,O
been,O
shown,O
that,O
bromocriptine,I-Entity
-,O
induced,O
tachycardia,I-Entity
",",O
which,O
persisted,O
after,O
adrenalectomy,O
",",O
is,O
(,O
i,O
),O
mediated,O
by,O
central,O
dopamine,I-Entity
D2,O
receptor,O
activation,O
and,O
(,O
ii,O
),O
reduced,O
by,O
5-day,O
isoproterenol,I-Entity
pretreatment,O
",",O
supporting,O
therefore,O
the,O
hypothesis,O
that,O
this,O
effect,O
is,O
dependent,O
on,O
sympathetic,O
outflow,O
to,O
the,O
heart,O
.,O
This,O
study,O
was,O
conducted,O
to,O
examine,O
whether,O
prolonged,O
pretreatment,O
with,O
isoproterenol,I-Entity
could,O
abolish,O
bromocriptine,I-Entity
-,O
induced,O
tachycardia,I-Entity
in,O
conscious,O
rats,O
.,O
Isoproterenol,I-Entity
pretreatment,O
for,O
15,O
days,O
caused,O
cardiac,B-Entity
hypertrophy,I-Entity
without,O
affecting,O
baseline,O
blood,O
pressure,O
and,O
heart,O
rate,O
.,O
In,O
control,O
rats,O
",",O
intravenous,O
bromocriptine,I-Entity
(,O
150,O
microg,O
/,O
kg,O
),O
induced,O
significant,O
hypotension,I-Entity
and,O
tachycardia,I-Entity
.,O
Bromocriptine,I-Entity
-,O
induced,O
hypotension,I-Entity
was,O
unaffected,O
by,O
isoproterenol,I-Entity
pretreatment,O
",",O
while,O
tachycardia,I-Entity
was,O
reversed,O
to,O
significant,O
bradycardia,I-Entity
",",O
an,O
effect,O
that,O
was,O
partly,O
reduced,O
by,O
i.v,O
.,O
domperidone,I-Entity
(,O
0.5,O
mg,O
/,O
kg,O
),O
.,O
Neither,O
cardiac,O
vagal,O
nor,O
sympathetic,O
tone,O
was,O
altered,O
by,O
isoproterenol,I-Entity
pretreatment,O
.,O
In,O
isolated,O
perfused,O
heart,O
preparations,O
from,O
isoproterenol,I-Entity
-,O
pretreated,O
rats,O
",",O
the,O
isoproterenol,I-Entity
-,O
induced,O
maximal,O
increase,O
in,O
left,O
ventricular,O
systolic,O
pressure,O
was,O
significantly,O
reduced,O
",",O
compared,O
with,O
saline,O
-,O
pretreated,O
rats,O
(,O
the,O
EC50,O
of,O
the,O
isoproterenol,I-Entity
-,O
induced,O
increase,O
in,O
left,O
ventricular,O
systolic,O
pressure,O
was,O
enhanced,O
approximately,O
22-fold,O
),O
.,O
These,O
results,O
show,O
that,O
15-day,O
isoproterenol,I-Entity
pretreatment,O
not,O
only,O
abolished,O
but,O
reversed,O
bromocriptine,I-Entity
-,O
induced,O
tachycardia,I-Entity
to,O
bradycardia,I-Entity
",",O
an,O
effect,O
that,O
is,O
mainly,O
related,O
to,O
further,O
cardiac,O
beta,O
-,O
adrenoceptor,O
desensitization,O
rather,O
than,O
to,O
impairment,O
of,O
autonomic,O
regulation,O
of,O
the,O
heart,O
.,O
They,O
suggest,O
that,O
",",O
in,O
normal,O
conscious,O
rats,O
",",O
the,O
central,O
tachycardia,I-Entity
of,O
bromocriptine,I-Entity
appears,O
to,O
predominate,O
and,O
to,O
mask,O
the,O
bradycardia,I-Entity
of,O
this,O
agonist,O
at,O
peripheral,O
dopamine,I-Entity
D2,O
receptors,O
.,O
A,O
developmental,O
analysis,O
of,O
clonidine,I-Entity
's,O
effects,O
on,O
cardiac,O
rate,O
and,O
ultrasound,O
production,O
in,O
infant,O
rats,O
.,O
adrenoceptor,O
agonist,O
",",O
clonidine,I-Entity
.,O
Previous,O
investigations,O
have,O
determined,O
that,O
",",O
in,O
response,O
to,O
clonidine,I-Entity
",",O
ultrasound,O
production,O
increases,O
through,O
the,O
2nd,O
-,O
week,O
postpartum,O
and,O
decreases,O
thereafter,O
.,O
Given,O
that,O
sympathetic,O
neural,O
dominance,O
exhibits,O
a,O
similar,O
developmental,O
pattern,O
",",O
and,O
given,O
that,O
clonidine,I-Entity
induces,O
sympathetic,O
withdrawal,O
and,O
bradycardia,I-Entity
",",O
we,O
hypothesized,O
that,O
clonidine,I-Entity
's,O
developmental,O
effects,O
on,O
cardiac,O
rate,O
and,O
ultrasound,O
production,O
would,O
mirror,O
each,O
other,O
.,O
Therefore,O
",",O
in,O
the,O
present,O
experiment,O
",",O
the,O
effects,O
of,O
clonidine,I-Entity
administration,O
(,O
0.5,O
mg,O
/,O
kg,O
),O
on,O
cardiac,O
rate,O
and,O
ultrasound,O
production,O
were,O
examined,O
in,O
2-,O
",",O
8-,O
",",O
15-,O
",",O
and,O
20-day,O
-,O
old,O
rats,O
.,O
Age,O
-,O
related,O
changes,O
in,O
ultrasound,O
production,O
corresponded,O
with,O
changes,O
in,O
cardiovascular,O
variables,O
",",O
including,O
baseline,O
cardiac,O
rate,O
and,O
clonidine,I-Entity
-,O
induced,O
bradycardia,I-Entity
.,O
This,O
experiment,O
is,O
discussed,O
with,O
regard,O
to,O
the,O
hypothesis,O
that,O
ultrasound,O
production,O
is,O
the,O
acoustic,O
by,O
-,O
product,O
of,O
a,O
physiological,O
maneuver,O
that,O
compensates,O
for,O
clonidine,I-Entity
's,O
detrimental,O
effects,O
on,O
cardiovascular,O
function,O
.,O
Differential,O
effects,O
of,O
systemically,O
administered,O
ketamine,I-Entity
and,O
lidocaine,I-Entity
on,O
dynamic,O
and,O
static,O
hyperalgesia,I-Entity
induced,O
by,O
intradermal,O
capsaicin,I-Entity
in,O
humans,O
.,O
We,O
have,O
examined,O
the,O
effect,O
of,O
systemic,O
administration,O
of,O
ketamine,I-Entity
and,O
lidocaine,I-Entity
on,O
brush,O
-,O
evoked,O
(,O
dynamic,O
),O
pain,I-Entity
and,O
punctate,O
-,O
evoked,O
(,O
static,O
),O
hyperalgesia,I-Entity
induced,O
by,O
capsaicin,I-Entity
.,O
Capsaicin,I-Entity
100,O
micrograms,O
was,O
injected,O
intradermally,O
on,O
the,O
volar,O
forearm,O
followed,O
by,O
an,O
i.v,O
.,O
infusion,O
of,O
ketamine,I-Entity
(,O
bolus,O
0.1,O
mg,O
kg-1,O
over,O
10,O
min,O
followed,O
by,O
infusion,O
of,O
7,O
micrograms,O
kg-1,O
min-1,O
),O
",",O
lidocaine,I-Entity
5,O
mg,O
kg-1,O
or,O
saline,O
for,O
50,O
min,O
.,O
Infusion,O
started,O
15,O
min,O
after,O
injection,O
of,O
capsaicin,I-Entity
.,O
The,O
following,O
were,O
measured,O
:,O
spontaneous,O
pain,I-Entity
",",O
pain,I-Entity
evoked,O
by,O
punctate,O
and,O
brush,O
stimuli,O
(,O
VAS,O
),O
",",O
and,O
areas,O
of,O
brush,O
-,O
evoked,O
and,O
punctate,O
-,O
evoked,O
hyperalgesia,I-Entity
.,O
Ketamine,I-Entity
reduced,O
both,O
the,O
area,O
of,O
brush,O
-,O
evoked,O
and,O
punctate,O
-,O
evoked,O
hyperalgesia,I-Entity
significantly,O
and,O
it,O
tended,O
to,O
reduce,O
brush,O
-,O
evoked,O
pain,I-Entity
.,O
Lidocaine,I-Entity
reduced,O
the,O
area,O
of,O
punctate,O
-,O
evoked,O
hyperalgesia,I-Entity
significantly,O
.,O
It,O
tended,O
to,O
reduce,O
VAS,O
scores,O
of,O
spontaneous,O
pain,I-Entity
but,O
had,O
no,O
effect,O
on,O
evoked,O
pain,I-Entity
.,O
The,O
differential,O
effects,O
of,O
ketamine,I-Entity
and,O
lidocaine,I-Entity
on,O
static,O
and,O
dynamic,O
hyperalgesia,I-Entity
suggest,O
that,O
the,O
two,O
types,O
of,O
hyperalgesia,I-Entity
are,O
mediated,O
by,O
separate,O
mechanisms,O
and,O
have,O
a,O
distinct,O
pharmacology,O
.,O
Cyclosporine,I-Entity
and,O
tacrolimus,I-Entity
-,O
associated,O
thrombotic,B-Entity
microangiopathy,I-Entity
.,O
The,O
development,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
(,O
TMA,I-Entity
),O
associated,O
with,O
the,O
use,O
of,O
cyclosporine,I-Entity
has,O
been,O
well,O
documented,O
.,O
Treatments,O
have,O
included,O
discontinuation,O
or,O
reduction,O
of,O
cyclosporine,I-Entity
dose,O
with,O
or,O
without,O
concurrent,O
plasma,O
exchange,O
",",O
plasma,O
infusion,O
",",O
anticoagulation,O
",",O
and,O
intravenous,O
immunoglobulin,O
G,O
infusion,O
.,O
The,O
last,O
decade,O
has,O
seen,O
the,O
emergence,O
of,O
tacrolimus,I-Entity
as,O
a,O
potent,O
immunosuppressive,O
agent,O
with,O
mechanisms,O
of,O
action,O
virtually,O
identical,O
to,O
those,O
of,O
cyclosporine,I-Entity
.,O
As,O
a,O
result,O
",",O
switching,O
to,O
tacrolimus,I-Entity
has,O
been,O
reported,O
to,O
be,O
a,O
viable,O
therapeutic,O
option,O
in,O
the,O
setting,O
of,O
cyclosporine,I-Entity
-,O
induced,O
TMA,I-Entity
.,O
With,O
the,O
more,O
widespread,O
application,O
of,O
tacrolimus,I-Entity
in,O
organ,O
transplantation,O
",",O
tacrolimus,I-Entity
-,O
associated,O
TMA,I-Entity
has,O
also,O
been,O
recognized,O
.,O
However,O
",",O
literature,O
regarding,O
the,O
incidence,O
of,O
the,O
recurrence,O
of,O
TMA,I-Entity
in,O
patients,O
exposed,O
sequentially,O
to,O
cyclosporine,I-Entity
and,O
tacrolimus,I-Entity
is,O
limited,O
.,O
We,O
report,O
a,O
case,O
of,O
a,O
living,O
donor,O
renal,O
transplant,O
recipient,O
who,O
developed,O
cyclosporine,I-Entity
-,O
induced,O
TMA,I-Entity
that,O
responded,O
to,O
the,O
withdrawal,O
of,O
cyclosporine,I-Entity
in,O
conjunction,O
with,O
plasmapheresis,O
and,O
fresh,O
frozen,O
plasma,O
replacement,O
therapy,O
.,O
Introduction,O
of,O
tacrolimus,I-Entity
as,O
an,O
alternative,O
immunosuppressive,O
agent,O
resulted,O
in,O
the,O
recurrence,O
of,O
TMA,I-Entity
and,O
the,O
subsequent,O
loss,O
of,O
the,O
renal,O
allograft,O
.,O
Patients,O
who,O
are,O
switched,O
from,O
cyclosporine,I-Entity
to,O
tacrolimus,I-Entity
or,O
vice,O
versa,O
should,O
be,O
closely,O
monitored,O
for,O
the,O
signs,O
and,O
symptoms,O
of,O
recurrent,O
TMA,I-Entity
.,O
Repeated,O
transient,O
anuria,I-Entity
following,O
losartan,I-Entity
administration,O
in,O
a,O
patient,O
with,O
a,O
solitary,O
kidney,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
70-year,O
-,O
old,O
hypertensive,I-Entity
man,O
with,O
a,O
solitary,O
kidney,O
and,O
chronic,B-Entity
renal,I-Entity
insufficiency,I-Entity
who,O
developed,O
two,O
episodes,O
of,O
transient,O
anuria,I-Entity
after,O
losartan,I-Entity
administration,O
.,O
He,O
was,O
hospitalized,O
for,O
a,O
myocardial,B-Entity
infarction,I-Entity
with,O
pulmonary,B-Entity
edema,I-Entity
",",O
treated,O
with,O
high,O
-,O
dose,O
diuretics,O
.,O
Due,O
to,O
severe,O
systolic,B-Entity
dysfunction,I-Entity
losartan,I-Entity
was,O
prescribed,O
.,O
Surprisingly,O
",",O
the,O
first,O
dose,O
of,O
50,O
mg,O
of,O
losartan,I-Entity
resulted,O
in,O
a,O
sudden,O
anuria,I-Entity
",",O
which,O
lasted,O
eight,O
hours,O
despite,O
high,O
-,O
dose,O
furosemide,I-Entity
and,O
amine,I-Entity
infusion,O
.,O
One,O
week,O
later,O
",",O
by,O
mistake,O
",",O
losartan,I-Entity
was,O
prescribed,O
again,O
and,O
after,O
the,O
second,O
dose,O
of,O
50,O
mg,O
",",O
the,O
patient,O
developed,O
a,O
second,O
episode,O
of,O
transient,O
anuria,I-Entity
lasting,O
10,O
hours,O
.,O
During,O
these,O
two,O
episodes,O
",",O
his,O
blood,O
pressure,O
diminished,O
but,O
no,O
severe,O
hypotension,I-Entity
was,O
noted,O
.,O
Ultimately,O
",",O
an,O
arteriography,O
showed,O
a,O
70,O
-,O
80%,O
renal,B-Entity
artery,I-Entity
stenosis,I-Entity
.,O
In,O
this,O
patient,O
",",O
renal,B-Entity
artery,I-Entity
stenosis,I-Entity
combined,O
with,O
heart,B-Entity
failure,I-Entity
and,O
diuretic,O
therapy,O
certainly,O
resulted,O
in,O
a,O
strong,O
activation,O
of,O
the,O
renin,O
-,O
angiotensin,I-Entity
system,O
(,O
RAS,O
),O
.,O
Under,O
such,O
conditions,O
",",O
angiotensin,B-Entity
II,I-Entity
receptor,O
blockade,O
by,O
losartan,I-Entity
probably,O
induced,O
a,O
critical,O
fall,O
in,O
glomerular,O
filtration,O
pressure,O
.,O
This,O
case,O
report,O
highlights,O
the,O
fact,O
that,O
the,O
angiotensin,B-Entity
II,I-Entity
receptor,O
antagonist,O
losartan,I-Entity
can,O
cause,O
serious,O
unexpected,O
complications,O
in,O
patients,O
with,O
renovascular,B-Entity
disease,I-Entity
and,O
should,O
be,O
used,O
with,O
extreme,O
caution,O
in,O
this,O
setting,O
.,O
In,O
vivo,O
protection,O
of,O
dna,O
damage,O
associated,O
apoptotic,O
and,O
necrotic,I-Entity
cell,O
deaths,O
during,O
acetaminophen,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
",",O
amiodarone,I-Entity
-,O
induced,O
lung,B-Entity
toxicity,I-Entity
and,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
by,O
a,O
novel,O
IH636,B-Entity
grape,I-Entity
seed,I-Entity
proanthocyanidin,I-Entity
extract,I-Entity
.,O
Grape,B-Entity
seed,I-Entity
extract,I-Entity
",",O
primarily,O
a,O
mixture,O
of,O
proanthocyanidins,I-Entity
",",O
has,O
been,O
shown,O
to,O
modulate,O
a,O
wide,O
-,O
range,O
of,O
biological,O
",",O
pharmacological,O
and,O
toxicological,O
effects,O
which,O
are,O
mainly,O
cytoprotective,O
.,O
This,O
study,O
assessed,O
the,O
ability,O
of,O
IH636,B-Entity
grape,I-Entity
seed,I-Entity
proanthocyanidin,I-Entity
extract,I-Entity
(,O
GSPE,I-Entity
),O
to,O
prevent,O
acetaminophen,I-Entity
(,O
AAP)-induced,I-Entity
nephrotoxicity,I-Entity
",",O
amiodarone,I-Entity
(,O
AMI)-induced,I-Entity
lung,B-Entity
toxicity,I-Entity
",",O
and,O
doxorubicin,I-Entity
(,O
DOX)-induced,I-Entity
cardiotoxicity,I-Entity
in,O
mice,O
.,O
Experimental,O
design,O
consisted,O
of,O
four,O
groups,O
:,O
control,O
(,O
vehicle,O
alone,O
),O
",",O
GSPE,I-Entity
alone,O
",",O
drug,O
alone,O
and,O
GSPE+drug,I-Entity
.,O
For,O
the,O
cytoprotection,O
study,O
",",O
animals,O
were,O
orally,O
gavaged,O
100,O
mg,O
/,O
Kg,O
GSPE,I-Entity
for,O
7,O
-,O
10,O
days,O
followed,O
by,O
i.p,O
.,O
injections,O
of,O
organ,O
specific,O
three,O
drugs,O
(,O
AAP,I-Entity
:,O
500,O
mg,O
/,O
Kg,O
for,O
24,O
h,O
;,O
AMI,I-Entity
:,O
50,O
mg,O
/,O
Kg,O
/,O
day,O
for,O
four,O
days,O
;,O
DOX,I-Entity
:,O
20,O
mg,O
/,O
Kg,O
for,O
48,O
h,O
),O
.,O
Results,O
indicate,O
that,O
GSPE,I-Entity
preexposure,O
prior,O
to,O
AAP,I-Entity
",",O
AMI,I-Entity
and,O
DOX,I-Entity
",",O
provided,O
near,O
complete,O
protection,O
in,O
terms,O
of,O
serum,O
chemistry,O
changes,O
(,O
ALT,O
",",O
BUN,O
and,O
CPK,O
),O
",",O
and,O
significantly,O
reduced,O
DNA,O
fragmentation,O
.,O
Histopathological,O
examination,O
of,O
kidney,O
",",O
heart,O
and,O
lung,O
sections,O
revealed,O
moderate,O
to,O
massive,O
tissue,B-Entity
damage,I-Entity
with,O
a,O
variety,O
of,O
morphological,O
aberrations,O
by,O
all,O
the,O
three,O
drugs,O
in,O
the,O
absence,O
of,O
GSPE,I-Entity
preexposure,O
than,O
in,O
its,O
presence,O
.,O
GSPE+drug,I-Entity
exposed,O
tissues,O
exhibited,O
minor,O
residual,O
damage,O
or,O
near,O
total,O
recovery,O
.,O
Interestingly,O
",",O
all,O
the,O
drugs,O
",",O
such,O
as,O
",",O
AAP,I-Entity
",",O
AMI,I-Entity
and,O
DOX,I-Entity
induced,O
apoptotic,O
death,O
in,O
addition,O
to,O
necrosis,I-Entity
in,O
the,O
respective,O
organs,O
which,O
was,O
very,O
effectively,O
blocked,O
by,O
GSPE,I-Entity
.,O
Since,O
AAP,I-Entity
",",O
AMI,I-Entity
and,O
DOX,I-Entity
undergo,O
biotransformation,O
and,O
are,O
known,O
to,O
produce,O
damaging,O
radicals,O
in,O
vivo,O
",",O
the,O
protection,O
by,O
GSPE,I-Entity
may,O
be,O
linked,O
to,O
both,O
inhibition,O
of,O
metabolism,O
and/or,O
detoxification,O
of,O
cytotoxic,O
radicals,O
.,O
Additionally,O
",",O
this,O
may,O
have,O
been,O
the,O
first,O
report,O
on,O
AMI,I-Entity
-,O
induced,O
apoptotic,O
death,O
in,O
the,O
lung,O
tissue,O
.,O
Taken,O
together,O
",",O
these,O
events,O
undoubtedly,O
establish,O
GSPE,I-Entity
's,O
abundant,O
bioavailability,O
",",O
and,O
the,O
power,O
to,O
defend,O
multiple,O
target,O
organs,O
from,O
toxic,O
assaults,O
induced,O
by,O
structurally,O
diverse,O
and,O
functionally,O
different,O
entities,O
in,O
vivo,O
.,O
Palpebral,B-Entity
twitching,I-Entity
in,O
a,O
depressed,I-Entity
adolescent,O
on,O
citalopram,I-Entity
.,O
Current,O
estimates,O
suggest,O
that,O
between,O
0.4%,O
and,O
8.3%,O
of,O
children,O
and,O
adolescents,O
are,O
affected,O
by,O
major,B-Entity
depression,I-Entity
.,O
We,O
report,O
a,O
favorable,O
response,O
to,O
treatment,O
with,O
citalopram,I-Entity
by,O
a,O
15-year,O
-,O
old,O
boy,O
with,O
major,B-Entity
depression,I-Entity
who,O
exhibited,O
palpebral,B-Entity
twitching,I-Entity
during,O
his,O
first,O
2,O
weeks,O
of,O
treatment,O
.,O
This,O
may,O
have,O
been,O
a,O
side,O
effect,O
of,O
citalopram,I-Entity
as,O
it,O
remitted,O
with,O
redistribution,O
of,O
doses,O
.,O
Metamizol,I-Entity
potentiates,O
morphine,I-Entity
antinociception,O
but,O
not,O
constipation,I-Entity
after,O
chronic,O
treatment,O
.,O
This,O
work,O
evaluates,O
the,O
antinociceptive,O
and,O
constipating,I-Entity
effects,O
of,O
the,O
combination,O
of,O
3.2,O
mg,O
/,O
kg,O
s.c,O
.,O
morphine,I-Entity
with,O
177.8,O
mg,O
metamizol,I-Entity
in,O
acutely,O
and,O
chronically,O
treated,O
(,O
once,O
a,O
day,O
for,O
12,O
days,O
),O
rats,O
.,O
On,O
the,O
13th,O
day,O
",",O
antinociceptive,O
effects,O
were,O
assessed,O
using,O
a,O
model,O
of,O
inflammatory,O
nociception,O
",",O
pain,I-Entity
-,O
induced,O
functional,O
impairment,O
model,O
",",O
and,O
the,O
charcoal,I-Entity
meal,O
test,O
was,O
used,O
to,O
evaluate,O
the,O
intestinal,O
transit,O
.,O
Simultaneous,O
administration,O
of,O
morphine,I-Entity
with,O
metamizol,I-Entity
resulted,O
in,O
a,O
markedly,O
antinociceptive,O
potentiation,O
and,O
an,O
increasing,O
of,O
the,O
duration,O
of,O
action,O
after,O
a,O
single,O
(,O
298+/-7,O
vs.,O
139+/-36,O
units,O
area,O
(,O
ua,O
),O
;,O
P<0.001,O
),O
and,O
repeated,O
administration,O
(,O
280+/-17,O
vs.,O
131+/-22,O
Antinociceptive,O
effect,O
of,O
morphine,I-Entity
was,O
reduced,O
in,O
chronically,O
treated,O
rats,O
(,O
39+/-10,O
vs.,O
18+/-5,O
au,O
),O
while,O
the,O
combination,O
-,O
induced,O
antinociception,O
was,O
remained,O
similar,O
as,O
an,O
acute,O
treatment,O
(,O
298+/-7,O
vs.,O
280+/-17,O
au,O
),O
.,O
Acute,O
antinociceptive,O
effects,O
of,O
the,O
combination,O
were,O
partially,O
prevented,O
by,O
3.2,O
mg,O
/,O
kg,O
naloxone,I-Entity
s.c,O
.,O
In,O
independent,O
groups,O
",",O
morphine,I-Entity
inhibited,O
the,O
intestinal,O
transit,O
in,O
48+/-4%,O
and,O
38+/-4%,O
after,O
acute,O
and,O
chronic,O
treatment,O
",",O
respectively,O
",",O
suggesting,O
that,O
tolerance,O
did,O
not,O
develop,O
to,O
the,O
constipating,I-Entity
effects,O
.,O
The,O
combination,O
inhibited,O
intestinal,O
transit,O
similar,O
to,O
that,O
produced,O
by,O
morphine,I-Entity
regardless,O
of,O
the,O
time,O
of,O
treatment,O
",",O
suggesting,O
that,O
metamizol,I-Entity
did,O
not,O
potentiate,O
morphine,I-Entity
-,O
induced,O
constipation,I-Entity
.,O
These,O
findings,O
show,O
a,O
significant,O
interaction,O
between,O
morphine,I-Entity
and,O
metamizol,I-Entity
in,O
chronically,O
treated,O
rats,O
",",O
suggesting,O
that,O
this,O
combination,O
could,O
be,O
useful,O
for,O
the,O
treatment,O
of,O
chronic,B-Entity
pain,I-Entity
.,O
Ifosfamide,I-Entity
encephalopathy,I-Entity
presenting,O
with,O
asterixis,I-Entity
.,O
CNS,O
toxic,O
effects,O
of,O
the,O
antineoplastic,O
agent,O
ifosfamide,I-Entity
(,O
IFX,I-Entity
),O
are,O
frequent,O
and,O
include,O
a,O
variety,O
of,O
neurological,O
symptoms,O
that,O
can,O
limit,O
drug,O
use,O
.,O
We,O
report,O
a,O
case,O
of,O
a,O
51-year,O
-,O
old,O
man,O
who,O
developed,O
severe,O
",",O
disabling,O
negative,O
myoclonus,I-Entity
of,O
the,O
upper,O
and,O
lower,O
extremities,O
after,O
the,O
infusion,O
of,O
ifosfamide,I-Entity
for,O
plasmacytoma,I-Entity
.,O
Cranial,O
magnetic,O
resonance,O
imaging,O
and,O
extensive,O
laboratory,O
studies,O
failed,O
to,O
reveal,O
structural,B-Entity
lesions,I-Entity
of,I-Entity
the,I-Entity
brain,I-Entity
and,O
metabolic,B-Entity
abnormalities,I-Entity
.,O
An,O
electroencephalogram,O
showed,O
continuous,O
",",O
generalized,O
irregular,O
slowing,O
with,O
admixed,O
periodic,O
triphasic,O
waves,O
indicating,O
symptomatic,O
encephalopathy,I-Entity
.,O
The,O
administration,O
of,O
ifosfamide,I-Entity
was,O
discontinued,O
and,O
within,O
12,O
h,O
the,O
asterixis,I-Entity
resolved,O
completely,O
.,O
In,O
the,O
patient,O
described,O
",",O
the,O
presence,O
of,O
asterixis,I-Entity
during,O
infusion,O
of,O
ifosfamide,I-Entity
",",O
normal,O
laboratory,O
findings,O
and,O
imaging,O
studies,O
and,O
the,O
resolution,O
of,O
symptoms,O
following,O
the,O
discontinuation,O
of,O
the,O
drug,O
suggest,O
that,O
negative,O
myoclonus,I-Entity
is,O
associated,O
with,O
the,O
use,O
of,O
IFX,I-Entity
.,O
Sub,O
-,O
chronic,O
low,O
dose,O
gamma,B-Entity
-,I-Entity
vinyl,I-Entity
GABA,I-Entity
(,O
vigabatrin,I-Entity
),O
inhibits,O
cocaine,I-Entity
-,O
induced,O
increases,O
in,O
nucleus,O
accumbens,O
dopamine,I-Entity
.,O
RATIONALE,O
:,O
gamma,B-Entity
-,I-Entity
Vinyl,I-Entity
GABA,I-Entity
(,O
GVG,I-Entity
),O
irreversibly,O
inhibits,O
GABA,I-Entity
-,O
transaminase,O
.,O
This,O
non,O
-,O
receptor,O
mediated,O
inhibition,O
requires,O
de,O
novo,O
synthesis,O
for,O
restoration,O
of,O
functional,O
GABA,I-Entity
catabolism,O
.,O
Given,O
its,O
preclinical,O
success,O
for,O
treating,O
substance,B-Entity
abuse,I-Entity
and,O
the,O
increased,O
risk,O
of,O
visual,B-Entity
field,I-Entity
defects,I-Entity
(,O
VFD,I-Entity
),O
associated,O
with,O
cumulative,O
lifetime,O
exposure,O
",",O
we,O
explored,O
the,O
effects,O
of,O
sub,O
-,O
chronic,O
low,O
dose,O
GVG,I-Entity
on,O
cocaine,I-Entity
-,O
induced,O
increases,O
in,O
nucleus,O
accumbens,O
(,O
NAcc,O
),O
dopamine,I-Entity
(,O
DA,I-Entity
),O
.,O
Sub,O
-,O
chronic,O
GVG,I-Entity
exposure,O
inhibited,O
the,O
effect,O
of,O
cocaine,I-Entity
for,O
3,O
days,O
",",O
which,O
exceeded,O
in,O
magnitude,O
and,O
duration,O
the,O
identical,O
acute,O
dose,O
.,O
CONCLUSIONS,O
:,O
Sub,O
-,O
chronic,O
low,O
dose,O
GVG,I-Entity
potentiates,O
and,O
extends,O
the,O
inhibition,O
of,O
cocaine,I-Entity
-,O
induced,O
increases,O
in,O
dopamine,I-Entity
",",O
effectively,O
reducing,O
cumulative,O
exposures,O
and,O
the,O
risk,O
for,O
VFDS,O
.,O
Amount,O
of,O
bleeding,I-Entity
and,O
hematoma,I-Entity
size,O
in,O
the,O
collagenase,O
-,O
induced,O
intracerebral,B-Entity
hemorrhage,I-Entity
rat,O
model,O
.,O
The,O
aggravated,O
risk,O
on,O
intracerebral,B-Entity
hemorrhage,I-Entity
(,O
ICH,I-Entity
),O
with,O
drugs,O
used,O
for,O
stroke,I-Entity
patients,O
should,O
be,O
estimated,O
carefully,O
.,O
We,O
therefore,O
established,O
sensitive,O
quantification,O
methods,O
and,O
provided,O
a,O
rat,O
ICH,I-Entity
model,O
for,O
detection,O
of,O
ICH,I-Entity
deterioration,O
.,O
In,O
ICH,I-Entity
intrastriatally,O
induced,O
by,O
0.014-unit,O
",",O
0.070-unit,O
",",O
and,O
0.350-unit,O
collagenase,O
",",O
the,O
amount,O
of,O
bleeding,I-Entity
was,O
measured,O
using,O
a,O
hemoglobin,O
assay,O
developed,O
in,O
the,O
present,O
study,O
and,O
was,O
compared,O
with,O
the,O
morphologically,O
determined,O
hematoma,I-Entity
volume,O
.,O
The,O
blood,O
amounts,O
and,O
hematoma,I-Entity
volumes,O
were,O
significantly,O
correlated,O
",",O
and,O
the,O
hematoma,I-Entity
induced,O
by,O
0.014-unit,O
collagenase,O
was,O
adequate,O
to,O
detect,O
ICH,I-Entity
deterioration,O
.,O
In,O
ICH,I-Entity
induction,O
using,O
0.014-unit,O
collagenase,O
",",O
heparin,I-Entity
enhanced,O
the,O
hematoma,I-Entity
volume,O
3.4-fold,O
over,O
that,O
seen,O
in,O
control,O
ICH,I-Entity
animals,O
and,O
the,O
bleeding,I-Entity
7.6-fold,O
.,O
Data,O
suggest,O
that,O
this,O
sensitive,O
hemoglobin,O
assay,O
is,O
useful,O
for,O
ICH,I-Entity
detection,O
",",O
and,O
that,O
a,O
model,O
with,O
a,O
small,O
ICH,I-Entity
induced,O
with,O
a,O
low,O
-,O
dose,O
collagenase,O
should,O
be,O
used,O
for,O
evaluation,O
of,O
drugs,O
that,O
may,O
affect,O
ICH,I-Entity
.,O
Estradiol,I-Entity
reduces,O
seizure,I-Entity
-,O
induced,O
hippocampal,B-Entity
injury,I-Entity
in,O
ovariectomized,O
female,O
but,O
not,O
in,O
male,O
rats,O
.,O
Estrogens,O
protect,O
ovariectomized,O
rats,O
from,O
hippocampal,B-Entity
injury,I-Entity
induced,O
by,O
kainic,B-Entity
acid,I-Entity
-,O
induced,O
status,B-Entity
epilepticus,I-Entity
(,O
SE,I-Entity
),O
.,O
We,O
compared,O
the,O
effects,O
of,O
17beta,B-Entity
-,I-Entity
estradiol,I-Entity
in,O
adult,O
male,O
and,O
ovariectomized,O
female,O
rats,O
subjected,O
to,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
-,O
induced,O
SE,I-Entity
.,O
Rats,O
received,O
subcutaneous,O
injections,O
of,O
17beta,B-Entity
-,I-Entity
estradiol,I-Entity
(,O
2,O
microg,O
/,O
rat,O
),O
or,O
oil,O
once,O
daily,O
for,O
four,O
consecutive,O
days,O
.,O
SE,I-Entity
was,O
induced,O
20,O
h,O
following,O
the,O
second,O
injection,O
and,O
terminated,O
3,O
h,O
later,O
.,O
The,O
extent,O
of,O
silver,I-Entity
-,O
stained,O
CA3,O
and,O
CA1,O
hippocampal,O
neurons,O
was,O
evaluated,O
2,O
days,O
after,O
SE,I-Entity
.,O
17beta,B-Entity
-,I-Entity
Estradiol,I-Entity
did,O
not,O
alter,O
the,O
onset,O
of,O
first,O
clonus,O
in,O
ovariectomized,O
rats,O
but,O
accelerated,O
it,O
in,O
males,O
.,O
17beta,B-Entity
-,I-Entity
Estradiol,I-Entity
reduced,O
the,O
argyrophilic,O
neurons,O
in,O
the,O
CA1,O
and,O
CA3-C,O
sectors,O
of,O
ovariectomized,O
rats,O
.,O
In,O
males,O
",",O
estradiol,I-Entity
increased,O
the,O
total,O
damage,O
score,O
.,O
These,O
findings,O
suggest,O
that,O
the,O
effects,O
of,O
estradiol,I-Entity
on,O
seizure,I-Entity
threshold,O
and,O
damage,O
may,O
be,O
altered,O
by,O
sex,O
-,O
related,O
differences,O
in,O
the,O
hormonal,O
environment,O
.,O
Delirium,I-Entity
during,O
clozapine,I-Entity
treatment,O
:,O
incidence,O
and,O
associated,O
risk,O
factors,O
.,O
Incidence,O
and,O
risk,O
factors,O
for,O
delirium,I-Entity
during,O
clozapine,I-Entity
treatment,O
require,O
further,O
clarification,O
.,O
We,O
used,O
computerized,O
pharmacy,O
records,O
to,O
identify,O
all,O
adult,O
psychiatric,I-Entity
inpatients,O
treated,O
with,O
clozapine,I-Entity
(,O
1995,O
-,O
96,O
),O
",",O
reviewed,O
their,O
medical,O
records,O
to,O
score,O
incidence,O
and,O
severity,O
of,O
delirium,I-Entity
",",O
and,O
tested,O
associations,O
with,O
potential,O
risk,O
factors,O
.,O
23.3,O
days,O
",",O
and,O
given,O
clozapine,I-Entity
",",O
gradually,O
increased,O
to,O
an,O
average,O
daily,O
dose,O
of,O
282,O
+,O
/-,O
Delirium,I-Entity
was,O
diagnosed,O
in,O
14,O
(,O
10.1,O
%,O
incidence,O
",",O
or,O
1.48,O
cases,O
/,O
person,O
-,O
years,O
of,O
exposure,O
),O
;,O
71.4,O
%,O
of,O
cases,O
were,O
moderate,O
or,O
severe,O
.,O
Associated,O
factors,O
were,O
co,O
-,O
treatment,O
with,O
other,O
centrally,O
antimuscarinic,O
agents,O
",",O
poor,O
clinical,O
outcome,O
",",O
older,O
age,O
",",O
and,O
longer,O
hospitalization,O
(,O
by,O
17.5,O
days,O
",",O
increasing,O
cost,O
),O
;,O
sex,O
",",O
diagnosis,O
or,O
medical,O
co,O
-,O
morbidity,O
",",O
and,O
daily,O
clozapine,I-Entity
dose,O
",",O
which,O
fell,O
with,O
age,O
",",O
were,O
unrelated,O
.,O
Delirium,I-Entity
was,O
found,O
in,O
10,O
%,O
of,O
clozapine,I-Entity
-,O
treated,O
inpatients,O
",",O
particularly,O
in,O
older,O
patients,O
exposed,O
to,O
other,O
central,O
anticholinergics,O
.,O
Delirium,I-Entity
was,O
inconsistently,O
recognized,O
clinically,O
in,O
milder,O
cases,O
and,O
was,O
associated,O
with,O
increased,O
length,O
-,O
of,O
-,O
stay,O
and,O
higher,O
costs,O
",",O
and,O
inferior,O
clinical,O
outcome,O
.,O
Ketoconazole,I-Entity
-,O
induced,O
neurologic,B-Entity
sequelae,I-Entity
.,O
A,O
77-y,O
-,O
old,O
patient,O
developed,O
weakness,B-Entity
of,I-Entity
extremities,I-Entity
",",O
legs,B-Entity
paralysis,I-Entity
",",O
dysarthria,I-Entity
and,O
tremor,I-Entity
1,O
h,O
after,O
ingestion,O
of,O
200,O
mg,O
ketoconazole,I-Entity
for,O
the,O
first,O
time,O
in,O
his,O
life,O
.,O
All,O
complaints,O
faded,O
away,O
within,O
24,O
h.,O
Few,O
days,O
later,O
",",O
the,O
patient,O
used,O
another,O
200,O
mg,O
ketoconazole,I-Entity
tablet,O
",",O
and,O
within,O
an,O
hour,O
experienced,O
a,O
similar,O
clinical,O
picture,O
",",O
which,O
resolved,O
again,O
spontaneously,O
within,O
hours,O
.,O
This,O
case,O
illustrates,O
the,O
need,O
for,O
close,O
vigilance,O
in,O
adverse,B-Entity
drug,I-Entity
reactions,I-Entity
",",O
particularly,O
in,O
the,O
elderly,O
.,O
Noxious,O
chemical,O
stimulation,O
of,O
rat,O
facial,O
mucosa,O
increases,O
intracranial,O
blood,O
flow,O
through,O
a,O
trigemino,O
-,O
parasympathetic,O
reflex,O
--,O
an,O
experimental,O
model,O
for,O
vascular,B-Entity
dysfunctions,I-Entity
in,O
cluster,B-Entity
headache,I-Entity
.,O
Cluster,B-Entity
headache,I-Entity
is,O
characterized,O
by,O
typical,O
autonomic,O
dysfunctions,O
including,O
facial,O
and,O
intracranial,B-Entity
vascular,I-Entity
disturbances,I-Entity
.,O
Capsaicin,I-Entity
(,O
0.01,O
-,O
1,O
mm,O
),O
applied,O
to,O
oral,O
or,O
nasal,O
mucosa,O
induced,O
increases,B-Entity
in,I-Entity
dural,I-Entity
and,I-Entity
cortical,I-Entity
blood,I-Entity
flow,I-Entity
and,O
provoked,O
lacrimation,O
.,O
These,O
responses,O
were,O
blocked,O
by,O
systemic,O
pre,O
-,O
administration,O
of,O
hexamethonium,B-Entity
chloride,I-Entity
(,O
20,O
mg,O
/,O
kg,O
),O
.,O
The,O
evoked,O
increases,B-Entity
in,I-Entity
dural,I-Entity
blood,I-Entity
flow,I-Entity
were,O
also,O
abolished,O
by,O
topical,O
pre,O
-,O
administration,O
of,O
atropine,I-Entity
(,O
1,O
mm,O
),O
and,O
[,O
Lys1,O
",",O
"Pro2,5",O
",",O
"Arg3,4",O
",",O
Tyr6]-VIP,O
(,O
0.1,O
mm,O
),O
",",O
a,O
vasoactive,O
intestinal,O
polypeptide,O
(,O
VIP,O
),O
antagonist,O
",",O
onto,O
the,O
exposed,O
dura,O
mater,O
.,O
The,O
blood,O
flow,O
responses,O
seem,O
to,O
be,O
mediated,O
by,O
the,O
release,O
of,O
acetylcholine,I-Entity
and,O
VIP,O
within,O
the,O
meninges,O
.,O
Similar,O
mechanisms,O
may,O
be,O
involved,O
in,O
the,O
pathogenesis,O
of,O
cluster,B-Entity
headache,I-Entity
.,O
Recurrent,O
excitation,O
in,O
the,O
dentate,O
gyrus,O
of,O
a,O
murine,O
model,O
of,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
.,O
Similar,O
to,O
rats,O
",",O
systemic,O
pilocarpine,I-Entity
injection,O
causes,O
status,B-Entity
epilepticus,I-Entity
(,O
SE,I-Entity
),O
and,O
the,O
eventual,O
development,O
of,O
spontaneous,O
seizures,I-Entity
and,O
mossy,O
fiber,O
sprouting,O
in,O
C57BL/6,O
and,O
CD1,O
mice,O
",",O
but,O
the,O
physiological,O
correlates,O
of,O
these,O
events,O
have,O
not,O
been,O
identified,O
in,O
mice,O
.,O
Population,O
responses,O
in,O
granule,O
cells,O
of,O
the,O
dentate,O
gyrus,O
were,O
examined,O
in,O
transverse,O
slices,O
of,O
the,O
ventral,O
hippocampus,O
from,O
pilocarpine,I-Entity
-,O
treated,O
and,O
untreated,O
mice,O
.,O
In,O
Mg(2+)-free,I-Entity
bathing,O
medium,O
containing,O
bicuculline,I-Entity
",",O
conditions,O
designed,O
to,O
increase,O
excitability,O
in,O
the,O
slices,O
",",O
electrical,O
stimulation,O
of,O
the,O
hilus,O
resulted,O
in,O
a,O
single,O
population,O
spike,O
in,O
granule,O
cells,O
from,O
control,O
mice,O
and,O
pilocarpine,I-Entity
-,O
treated,O
mice,O
that,O
did,O
not,O
experience,O
SE,I-Entity
.,O
In,O
SE,I-Entity
survivors,O
",",O
similar,O
stimulation,O
resulted,O
in,O
a,O
population,O
spike,O
followed,O
",",O
at,O
a,O
variable,O
latency,O
",",O
by,O
negative,O
DC,O
shifts,O
and,O
repetitive,O
afterdischarges,O
of,O
3,O
-,O
60,O
s,O
duration,O
",",O
which,O
were,O
blocked,O
by,O
ionotropic,O
glutamate,I-Entity
receptor,O
antagonists,O
.,O
Focal,O
glutamate,I-Entity
photostimulation,O
of,O
the,O
granule,O
cell,O
layer,O
at,O
sites,O
distant,O
from,O
the,O
recording,O
pipette,O
resulted,O
in,O
population,O
responses,O
of,O
1,O
-,O
30,O
s,O
duration,O
in,O
slices,O
from,O
SE,I-Entity
survivors,O
but,O
not,O
other,O
groups,O
.,O
These,O
data,O
support,O
the,O
hypothesis,O
that,O
SE,I-Entity
-,O
induced,O
mossy,O
fiber,O
sprouting,O
and,O
synaptic,O
reorganization,O
are,O
relevant,O
characteristics,O
of,O
seizure,I-Entity
development,O
in,O
these,O
murine,O
strains,O
",",O
resembling,O
rat,O
models,O
of,O
human,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
.,O
The,O
alpha3,O
and,O
beta4,O
nicotinic,O
acetylcholine,I-Entity
receptor,O
subunits,O
are,O
necessary,O
for,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
hypolocomotion,I-Entity
in,O
mice,O
.,O
Binding,O
of,O
nicotine,I-Entity
to,O
nicotinic,O
acetylcholine,I-Entity
receptors,O
(,O
nAChRs,O
),O
elicits,O
a,O
series,O
of,O
dose,O
-,O
dependent,O
behaviors,O
that,O
go,O
from,O
altered,O
exploration,O
",",O
sedation,O
",",O
and,O
tremors,I-Entity
",",O
to,O
seizures,I-Entity
and,O
death,I-Entity
.,O
We,O
examined,O
the,O
role,O
of,O
the,O
beta4,O
subunits,O
in,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
hypolocomotion,I-Entity
in,O
beta4,O
homozygous,O
null,O
(,O
beta4,O
-/-,O
),O
and,O
alpha3,O
heterozygous,O
(,O
+,O
/-,O
mice,O
were,O
less,O
sensitive,O
to,O
the,O
effects,O
of,O
nicotine,I-Entity
both,O
at,O
low,O
doses,O
",",O
measured,O
as,O
decreased,O
exploration,O
in,O
an,O
open,O
field,O
",",O
and,O
at,O
high,O
doses,O
",",O
measured,O
as,O
sensitivity,O
to,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
mice,O
were,O
partially,O
resistant,O
to,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
when,O
compared,O
to,O
wild,O
-,O
type,O
littermates,O
.,O
Together,O
",",O
these,O
results,O
suggest,O
that,O
the,O
beta4,O
and,O
the,O
alpha3,O
subunits,O
are,O
mediators,O
of,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
hypolocomotion,I-Entity
.,O
Recurrent,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
induced,O
by,O
azithromycin,I-Entity
.,O
A,O
14-year,O
-,O
old,O
girl,O
is,O
reported,O
with,O
recurrent,O
",",O
azithromycin,I-Entity
-,O
induced,O
",",O
acute,O
interstitial,B-Entity
nephritis,I-Entity
.,O
Although,O
most,O
cases,O
of,O
antibiotic,O
induced,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
are,O
benign,O
and,O
self,O
-,O
limited,O
",",O
some,O
patients,O
are,O
at,O
risk,O
for,O
permanent,O
renal,B-Entity
injury,I-Entity
.,O
Valproate,I-Entity
-,O
induced,O
encephalopathy,I-Entity
.,O
Valproate,I-Entity
-,O
induced,O
encephalopathy,I-Entity
is,O
a,O
rare,O
syndrome,O
that,O
may,O
manifest,O
in,O
otherwise,O
normal,O
epileptic,I-Entity
individuals,O
.,O
It,O
is,O
usually,O
but,O
not,O
necessarily,O
associated,O
with,O
hyperammonemia,I-Entity
.,O
A,O
case,O
of,O
valproate,I-Entity
-,O
induced,O
encephalopathy,I-Entity
is,O
presented,O
.,O
Nitro,B-Entity
-,I-Entity
L,I-Entity
-,I-Entity
arginine,I-Entity
methyl,I-Entity
ester,I-Entity
:,O
a,O
potential,O
protector,O
against,O
gentamicin,I-Entity
ototoxicity,I-Entity
.,O
The,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
inhibitor,O
nitro,B-Entity
-,I-Entity
L,I-Entity
-,I-Entity
arginine,I-Entity
methyl,I-Entity
ester,I-Entity
(,O
L,B-Entity
-,I-Entity
NAME,I-Entity
),O
may,O
act,O
as,O
an,O
otoprotectant,O
against,O
high,B-Entity
-,I-Entity
frequency,I-Entity
hearing,I-Entity
loss,I-Entity
caused,O
by,O
gentamicin,I-Entity
",",O
but,O
further,O
studies,O
are,O
needed,O
to,O
confirm,O
this,O
.,O
Aminoglycoside,I-Entity
antibiotics,O
are,O
still,O
widely,O
used,O
by,O
virtue,O
of,O
their,O
efficacy,O
and,O
low,O
cost,O
.,O
Their,O
ototoxicity,I-Entity
is,O
a,O
serious,O
health,O
problem,O
and,O
",",O
as,O
their,O
ototoxic,I-Entity
mechanism,O
involves,O
the,O
production,O
of,O
NO,I-Entity
",",O
we,O
need,O
to,O
assess,O
the,O
use,O
of,O
NO,I-Entity
inhibitors,O
for,O
the,O
prevention,O
of,O
aminoglycoside,I-Entity
-,O
induced,O
sensorineural,B-Entity
hearing,I-Entity
loss,I-Entity
.,O
In,O
this,O
experimental,O
study,O
we,O
used,O
30,O
Sprague,O
-,O
Dawley,O
rats,O
",",O
27,O
of,O
which,O
had,O
gentamicin,I-Entity
instilled,O
into,O
the,O
middle,O
ear,O
.,O
The,O
otoprotectant,O
L,B-Entity
-,I-Entity
NAME,I-Entity
was,O
administered,O
topically,O
to,O
12/27,O
animals,O
.,O
Its,O
effect,O
was,O
determined,O
in,O
terms,O
of,O
attenuation,O
of,O
hearing,B-Entity
loss,I-Entity
",",O
measured,O
by,O
shifts,O
in,O
the,O
auditory,O
brainstem,O
response,O
threshold,O
.,O
L,B-Entity
-,I-Entity
NAME,I-Entity
reduced,O
gentamicin,I-Entity
-,O
induced,O
hearing,B-Entity
loss,I-Entity
in,O
the,O
high,O
-,O
frequency,O
range,O
",",O
but,O
gave,O
no,O
protection,O
in,O
the,O
middle,O
or,O
low,O
frequencies,O
.,O
Cerebral,B-Entity
vasculitis,I-Entity
following,O
oral,O
methylphenidate,I-Entity
intake,O
in,O
an,O
adult,O
:,O
a,O
case,O
report,O
.,O
Methylphenidate,I-Entity
is,O
structurally,O
and,O
functionally,O
similar,O
to,O
amphetamine,I-Entity
.,O
Cerebral,B-Entity
vasculitis,I-Entity
associated,O
with,O
amphetamine,B-Entity
abuse,I-Entity
is,O
well,O
documented,O
",",O
and,O
in,O
rare,O
cases,O
ischaemic,B-Entity
stroke,I-Entity
has,O
been,O
reported,O
after,O
methylphenidate,I-Entity
intake,O
in,O
children,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
63-year,O
-,O
old,O
female,O
who,O
was,O
treated,O
with,O
methylphenidate,I-Entity
due,O
to,O
hyperactivity,I-Entity
and,O
suffered,O
from,O
multiple,O
ischaemic,B-Entity
strokes,I-Entity
.,O
We,O
consider,O
drug,O
-,O
induced,O
cerebral,B-Entity
vasculitis,I-Entity
as,O
the,O
most,O
likely,O
cause,O
of,O
recurrent,O
ischaemic,B-Entity
strokes,I-Entity
in,O
the,O
absence,O
of,O
any,O
pathological,O
findings,O
during,O
the,O
diagnostic,O
work,O
-,O
up,O
.,O
We,O
conclude,O
that,O
methylphenidate,I-Entity
mediated,O
vasculitis,I-Entity
should,O
be,O
considered,O
in,O
patients,O
with,O
neurological,O
symptoms,O
and,O
a,O
history,O
of,O
methylphenidate,I-Entity
therapy,O
.,O
This,O
potential,O
side,O
-,O
effect,O
",",O
though,O
very,O
rare,O
",",O
represents,O
one,O
more,O
reason,O
to,O
be,O
very,O
restrictive,O
in,O
the,O
use,O
of,O
methylphenidate,I-Entity
.,O
Cerebral,B-Entity
haemorrhage,I-Entity
induced,O
by,O
warfarin,I-Entity
-,O
the,O
influence,O
of,O
drug,O
-,O
drug,O
interactions,O
.,O
PURPOSE,O
:,O
To,O
evaluate,O
the,O
frequency,O
",",O
severity,O
and,O
preventability,O
of,O
warfarin,I-Entity
-,O
induced,O
cerebral,B-Entity
haemorrhages,I-Entity
due,O
to,O
warfarin,I-Entity
and,O
warfarin,I-Entity
-,O
drug,O
interactions,O
in,O
patients,O
living,O
in,O
the,O
county,O
of,O
Osterg,O
tland,O
",",O
Sweden,O
.,O
All,O
patients,O
with,O
a,O
diagnosed,O
cerebral,B-Entity
haemorrhage,I-Entity
at,O
three,O
hospitals,O
during,O
the,O
period,O
2000,O
-,O
2002,O
were,O
identified,O
.,O
Medical,O
records,O
were,O
studied,O
retrospectively,O
to,O
evaluate,O
whether,O
warfarin,I-Entity
and,O
warfarin,I-Entity
-,O
drug,O
interactions,O
could,O
have,O
caused,O
the,O
cerebral,B-Entity
haemorrhage,I-Entity
.,O
Among,O
593,O
patients,O
with,O
cerebral,B-Entity
haemorrhage,I-Entity
",",O
59,O
(,O
10%,O
),O
were,O
assessed,O
as,O
related,O
to,O
warfarin,I-Entity
treatment,O
.,O
Of,O
the,O
59,O
cases,O
",",O
26,O
(,O
44%,O
),O
had,O
a,O
fatal,O
outcome,O
",",O
compared,O
to,O
136,O
(,O
25%,O
),O
among,O
the,O
non,O
-,O
warfarin,I-Entity
patients,O
(,O
p,O
<,O
0.01,O
),O
.,O
A,O
warfarin,I-Entity
-,O
drug,O
interaction,O
could,O
have,O
contributed,O
to,O
the,O
haemorrhage,I-Entity
in,O
24,O
(,O
41%,O
),O
of,O
the,O
warfarin,I-Entity
patients,O
and,O
in,O
7,O
of,O
these,O
(,O
12%,O
),O
the,O
bleeding,I-Entity
complication,O
was,O
considered,O
being,O
possible,O
to,O
avoid,O
.,O
Warfarin,I-Entity
-,O
induced,O
cerebral,B-Entity
haemorrhages,I-Entity
are,O
a,O
major,O
clinical,O
problem,O
with,O
a,O
high,O
fatality,O
rate,O
.,O
Almost,O
half,O
of,O
the,O
cases,O
was,O
related,O
to,O
a,O
warfarin,I-Entity
-,O
drug,O
interaction,O
.,O
A,O
significant,O
proportion,O
of,O
warfarin,I-Entity
-,O
related,O
cerebral,B-Entity
haemorrhages,I-Entity
might,O
have,O
been,O
prevented,O
if,O
greater,O
caution,O
had,O
been,O
taken,O
when,O
prescribing,O
drugs,O
known,O
to,O
interact,O
with,O
warfarin,I-Entity
.,O
Side,O
effects,O
of,O
postoperative,O
administration,O
of,O
methylprednisolone,I-Entity
and,O
gentamicin,I-Entity
into,O
the,O
posterior,O
sub,O
-,O
Tenon,O
's,O
space,O
.,O
To,O
assess,O
the,O
incidence,O
of,O
postoperative,O
emetic,O
side,O
effects,O
after,O
the,O
administration,O
of,O
methylprednisolone,I-Entity
and,O
gentamicin,I-Entity
into,O
the,O
posterior,O
sub,O
-,O
Tenon,O
's,O
space,O
at,O
the,O
end,O
of,O
routine,O
cataract,I-Entity
surgery,O
.,O
A,O
double,O
-,O
blind,O
double,O
-,O
armed,O
prospective,O
study,O
comprised,O
40,O
patients,O
who,O
had,O
uneventful,O
sutureless,O
phacoemulsification,O
under,O
sub,O
-,O
Tenon,O
's,O
local,O
infiltration,O
of,O
3,O
mL,O
of,O
plain,O
lignocaine,I-Entity
.,O
At,O
the,O
end,O
of,O
the,O
procedure,O
",",O
Group,O
A,O
(,O
n,O
=,O
20,O
),O
had,O
20,O
mg/0.5,O
mL,O
of,O
methylprednisolone,I-Entity
and,O
10,O
mg/0.5,O
mL,O
of,O
gentamicin,I-Entity
injected,O
into,O
the,O
posterior,O
sub,O
Postoperatively,O
",",O
all,O
patients,O
were,O
assessed,O
for,O
symptoms,O
of,O
nausea,B-Entity
",",I-Entity
vomiting,I-Entity
",",O
and,O
headache,I-Entity
.,O
Sixty,O
percent,O
in,O
Group,O
A,O
developed,O
postoperative,B-Entity
emetic,I-Entity
symptoms,I-Entity
",",O
headache,I-Entity
",",O
or,O
both,O
;,O
1,O
patient,O
in,O
Group,O
B,O
developed,O
symptoms,O
.,O
The,O
administration,O
of,O
methylprednisolone,I-Entity
and,O
gentamicin,I-Entity
in,O
the,O
posterior,O
sub,O
-,O
Tenon,O
's,O
space,O
was,O
related,O
to,O
a,O
high,O
incidence,O
of,O
side,O
effects,O
including,O
nausea,B-Entity
",",I-Entity
vomiting,I-Entity
",",O
and,O
headache,I-Entity
.,O
Cardiac,O
Angiography,O
in,O
Renally,O
Impaired,O
Patients,O
(,O
CARE,O
),O
study,O
:,O
a,O
randomized,O
double,O
-,O
blind,O
trial,O
of,O
contrast,O
-,O
induced,O
nephropathy,I-Entity
in,O
patients,O
with,O
chronic,B-Entity
kidney,I-Entity
disease,I-Entity
.,O
No,O
direct,O
comparisons,O
exist,O
of,O
the,O
renal,O
tolerability,O
of,O
the,O
low,O
-,O
osmolality,O
contrast,B-Entity
medium,I-Entity
iopamidol,I-Entity
with,O
that,O
of,O
the,O
iso,O
-,O
osmolality,O
contrast,B-Entity
medium,I-Entity
iodixanol,I-Entity
in,O
high,O
-,O
risk,O
patients,O
.,O
The,O
present,O
study,O
is,O
a,O
multicenter,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
comparison,O
of,O
iopamidol,I-Entity
and,O
iodixanol,I-Entity
in,O
patients,O
with,O
chronic,B-Entity
kidney,I-Entity
disease,I-Entity
(,O
estimated,O
glomerular,O
filtration,O
rate,O
",",O
20,O
to,O
59,O
mL,O
/,O
min,O
),O
who,O
underwent,O
cardiac,O
angiography,O
or,O
percutaneous,O
coronary,O
interventions,O
.,O
Serum,O
creatinine,I-Entity
(,O
SCr,O
),O
levels,O
and,O
estimated,O
glomerular,O
filtration,O
rate,O
were,O
assessed,O
at,O
baseline,O
and,O
2,O
to,O
5,O
days,O
after,O
receiving,O
medications,O
.,O
In,O
414,O
patients,O
",",O
contrast,O
volume,O
",",O
presence,O
of,O
diabetes,B-Entity
mellitus,I-Entity
",",O
use,O
of,O
N,B-Entity
-,I-Entity
acetylcysteine,I-Entity
",",O
mean,O
baseline,O
SCr,O
",",O
and,O
estimated,O
glomerular,O
filtration,O
rate,O
were,O
comparable,O
in,O
the,O
2,O
groups,O
.,O
>,O
or,O
=,O
0.5,O
mg,O
/,O
dL,O
occurred,O
in,O
4.4%,O
(,O
9,O
of,O
204,O
patients,O
),O
after,O
iopamidol,I-Entity
and,O
6.7%,O
(,O
14,O
of,O
210,O
patients,O
),O
after,O
iodixanol,I-Entity
(,O
P=0.39,O
),O
",",O
whereas,O
rates,O
of,O
SCr,O
increases,O
>,O
or,O
=,O
25%,O
were,O
9.8%,O
and,O
12.4%,O
",",O
respectively,O
(,O
P=0.44,O
),O
.,O
In,O
patients,O
with,O
diabetes,I-Entity
",",O
SCr,O
increases,O
>,O
or,O
=,O
0.5,O
mg,O
/,O
dL,O
were,O
5.1%,O
(,O
4,O
of,O
78,O
patients,O
),O
with,O
iopamidol,I-Entity
and,O
13.0%,O
(,O
12,O
of,O
92,O
patients,O
),O
with,O
iodixanol,I-Entity
(,O
P=0.11,O
),O
",",O
whereas,O
SCr,O
increases,O
>,O
or,O
=,O
25%,O
were,O
10.3%,O
and,O
15.2%,O
",",O
respectively,O
(,O
P=0.37,O
),O
.,O
Mean,O
post,O
-,O
SCr,O
increases,O
were,O
significantly,O
less,O
with,O
iopamidol,I-Entity
(,O
all,O
patients,O
:,O
0.07,O
versus,O
0.12,O
mg,O
/,O
dL,O
",",O
6.2,O
versus,O
10.6,O
micromol,O
/,O
L,O
",",O
P=0.03,O
;,O
patients,O
with,O
diabetes,I-Entity
:,O
0.07,O
versus,O
0.16,O
mg,O
/,O
dL,O
",",O
6.2,O
versus,O
14.1,O
micromol,O
/,O
L,O
",",O
P=0.01,O
),O
.,O
The,O
rate,O
of,O
contrast,O
-,O
induced,O
nephropathy,I-Entity
",",O
defined,O
by,O
multiple,O
end,O
points,O
",",O
is,O
not,O
statistically,O
different,O
after,O
the,O
intraarterial,O
administration,O
of,O
iopamidol,I-Entity
or,O
iodixanol,I-Entity
to,O
high,O
-,O
risk,O
patients,O
",",O
with,O
or,O
without,O
diabetes,B-Entity
mellitus,I-Entity
.,O
A,O
novel,O
compound,O
",",O
maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
",",O
attenuates,O
cognitive,B-Entity
deficits,I-Entity
and,O
shows,O
neuroprotective,O
effects,O
in,O
vitro,O
and,O
in,O
vivo,O
dementia,I-Entity
models,O
.,O
To,O
develop,O
a,O
novel,O
and,O
effective,O
drug,O
that,O
could,O
enhance,O
cognitive,O
function,O
and,O
neuroprotection,O
",",O
we,O
newly,O
synthesized,O
maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
by,O
the,O
esterification,O
of,O
maltol,I-Entity
and,O
p,B-Entity
-,I-Entity
coumaric,I-Entity
acid,I-Entity
.,O
In,O
the,O
present,O
study,O
",",O
we,O
investigated,O
whether,O
maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
could,O
improve,O
cognitive,B-Entity
decline,I-Entity
in,O
scopolamine,I-Entity
-,O
injected,O
rats,O
and,O
in,O
amyloid,B-Entity
beta,I-Entity
peptide(1,I-Entity
-,I-Entity
42)-infused,I-Entity
rats,O
.,O
Maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
was,O
found,O
to,O
attenuate,O
cognitive,B-Entity
deficits,I-Entity
in,O
both,O
rat,O
models,O
using,O
passive,O
avoidance,O
test,O
and,O
to,O
reduce,O
apoptotic,O
cell,O
death,O
observed,O
in,O
the,O
hippocampus,O
of,O
the,O
amyloid,B-Entity
beta,I-Entity
peptide(1,I-Entity
-,I-Entity
42)-infused,I-Entity
rats,O
.,O
We,O
also,O
examined,O
the,O
neuroprotective,O
effects,O
of,O
maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
in,O
vitro,O
using,O
SH,O
-,O
SY5Y,O
cells,O
.,O
Cells,O
were,O
pretreated,O
with,O
maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
",",O
before,O
exposed,O
to,O
amyloid,B-Entity
beta,I-Entity
peptide(1,I-Entity
-,I-Entity
42,I-Entity
),I-Entity
",",O
glutamate,I-Entity
or,O
H2O2,I-Entity
.,O
We,O
found,O
that,O
maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
significantly,O
decreased,O
apoptotic,O
cell,O
death,O
and,O
reduced,O
reactive,O
oxygen,O
species,O
",",O
cytochrome,O
c,O
release,O
",",O
and,O
caspase,O
3,O
activation,O
.,O
Taking,O
these,O
in,O
vitro,O
and,O
in,O
vivo,O
results,O
together,O
",",O
our,O
study,O
suggests,O
that,O
maltolyl,B-Entity
p,I-Entity
-,I-Entity
coumarate,I-Entity
is,O
a,O
potentially,O
effective,O
candidate,O
against,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
that,O
is,O
characterized,O
by,O
wide,O
spread,O
neuronal,B-Entity
death,I-Entity
and,O
progressive,O
decline,B-Entity
of,I-Entity
cognitive,I-Entity
function,I-Entity
.,O
Interaction,O
between,O
warfarin,I-Entity
and,O
levofloxacin,I-Entity
:,O
case,O
series,O
.,O
Warfarin,I-Entity
is,O
the,O
most,O
widely,O
used,O
oral,O
anticoagulant,O
and,O
is,O
indicated,O
for,O
many,O
clinical,O
conditions,O
.,O
Levofloxacin,I-Entity
",",O
a,O
fluoroquinolone,I-Entity
",",O
is,O
one,O
of,O
the,O
most,O
commonly,O
prescribed,O
antibiotics,O
in,O
clinical,O
practice,O
and,O
is,O
effective,O
against,O
Gram,O
-,O
positive,O
",",O
Gram,O
-,O
negative,O
",",O
and,O
atypical,O
bacteria,O
.,O
While,O
small,O
prospective,O
studies,O
have,O
not,O
revealed,O
any,O
significant,O
drug,O
-,O
drug,O
interaction,O
between,O
warfarin,I-Entity
and,O
levofloxacin,I-Entity
",",O
several,O
case,O
reports,O
have,O
indicated,O
that,O
levofloxacin,I-Entity
may,O
significantly,O
potentiate,O
the,O
anticoagulation,O
effect,O
of,O
warfarin,I-Entity
.,O
We,O
report,O
3,O
cases,O
of,O
serious,O
bleeding,I-Entity
complications,O
that,O
appear,O
to,O
be,O
the,O
result,O
of,O
the,O
interaction,O
between,O
warfarin,I-Entity
and,O
levofloxacin,I-Entity
.,O
Physicians,O
should,O
be,O
aware,O
of,O
this,O
potential,O
interaction,O
and,O
use,O
caution,O
when,O
prescribing,O
levofloxacin,I-Entity
to,O
patients,O
taking,O
warfarin,I-Entity
.,O
Mutations,O
associated,O
with,O
lamivudine,I-Entity
-,O
resistance,O
in,O
therapy,O
-,O
na,I-Entity
ve,O
hepatitis,B-Entity
B,I-Entity
virus,I-Entity
(,I-Entity
HBV,I-Entity
),I-Entity
infected,I-Entity
patients,O
with,O
and,O
without,O
HIV,B-Entity
co,I-Entity
-,I-Entity
infection,I-Entity
:,O
implications,O
for,O
antiretroviral,O
therapy,O
in,O
HBV,B-Entity
and,I-Entity
HIV,I-Entity
co,I-Entity
-,I-Entity
infected,I-Entity
South,O
African,O
patients,O
.,O
This,O
was,O
an,O
exploratory,O
study,O
to,O
investigate,O
lamivudine,I-Entity
-,O
resistant,O
hepatitis,B-Entity
B,I-Entity
virus,O
(,O
HBV,O
),O
strains,O
in,O
selected,O
lamivudine,I-Entity
-,O
na,I-Entity
ve,O
HBV,O
carriers,O
with,O
and,O
without,O
human,B-Entity
immunodeficiency,I-Entity
virus,I-Entity
(,I-Entity
HIV,I-Entity
),I-Entity
co,I-Entity
-,I-Entity
infection,I-Entity
in,O
South,O
African,O
patients,O
.,O
Thirty,O
-,O
five,O
lamivudine,I-Entity
-,O
na,I-Entity
ve,O
HBV,B-Entity
infected,I-Entity
patients,O
with,O
or,O
without,O
HIV,B-Entity
co,I-Entity
-,I-Entity
infection,I-Entity
were,O
studied,O
:,O
15,O
chronic,O
HBV,B-Entity
mono,I-Entity
-,I-Entity
infected,I-Entity
patients,O
and,O
20,O
HBV,B-Entity
-,I-Entity
HIV,I-Entity
co,I-Entity
-,I-Entity
infected,I-Entity
patients,O
.,O
The,O
latter,O
group,O
was,O
further,O
sub,O
-,O
divided,O
into,O
13,O
occult,O
HBV,O
(,O
HBsAg,I-Entity
-,O
negative,O
),O
and,O
7,O
overt,O
HBV,O
(,O
HBsAg-,I-Entity
positive,O
),O
patients,O
.,O
HBsAg,I-Entity
",",O
anti,O
-,O
HBs,O
",",O
anti,O
-,O
HBc,O
",",O
and,O
anti,O
-,O
HIV,O
1/2,O
were,O
determined,O
as,O
part,O
of,O
routine,O
diagnosis,O
using,O
Axsym,O
assays,O
(,O
Abbott,O
Laboratories,O
",",O
North,O
Chicago,O
",",O
IL,O
),O
.,O
Serum,O
samples,O
were,O
PCR,O
amplified,O
with,O
HBV,O
reverse,O
transcriptase,O
(,O
RT,O
),O
primers,O
",",O
followed,O
by,O
direct,O
sequencing,O
across,O
the,O
tyrosine,I-Entity
-,O
methionine,I-Entity
-,O
aspartate,I-Entity
-,O
aspartate,I-Entity
(,O
YMDD,O
),O
motif,O
of,O
the,O
major,O
catalytic,O
region,O
in,O
the,O
C,O
domain,O
of,O
the,O
HBV,O
RT,O
enzyme,O
.,O
HBV,O
lamivudine,I-Entity
-,O
resistant,O
strains,O
were,O
detected,O
in,O
3,O
of,O
15,O
mono,O
-,O
infected,O
chronic,O
hepatitis,B-Entity
B,I-Entity
patients,O
and,O
10,O
of,O
20,O
HBV,B-Entity
-,I-Entity
HIV,I-Entity
co,I-Entity
-,I-Entity
infected,I-Entity
patients,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
constitutes,O
the,O
first,O
report,O
of,O
HBV,O
lamivudine,I-Entity
-,O
resistant,O
strains,O
in,O
therapy,O
-,O
na,I-Entity
ve,O
HBV,B-Entity
-,I-Entity
HIV,I-Entity
co,I-Entity
-,I-Entity
infected,I-Entity
patients,O
.,O
It,O
remains,O
to,O
be,O
seen,O
whether,O
such,O
pre,O
-,O
existing,O
antiviral,O
mutations,O
could,O
result,O
in,O
widespread,O
emergence,O
of,O
HBV,O
resistant,O
strains,O
when,O
lamivudine,I-Entity
-,O
containing,O
highly,O
active,O
antiretroviral,O
(,O
ARV,O
),O
treatment,O
(,O
HAART,O
),O
regimens,O
become,O
widely,O
applied,O
in,O
South,O
Africa,O
",",O
as,O
this,O
is,O
likely,O
to,O
have,O
potential,O
implications,O
in,O
the,O
management,O
of,O
HBV,B-Entity
-,I-Entity
HIV,I-Entity
co,I-Entity
-,I-Entity
infected,I-Entity
patients,O
.,O
Sex,O
differences,O
in,O
NMDA,I-Entity
antagonist,O
enhancement,O
of,O
morphine,I-Entity
antihyperalgesia,O
in,O
a,O
capsaicin,I-Entity
model,O
of,O
persistent,O
pain,I-Entity
:,O
comparisons,O
to,O
two,O
models,O
of,O
acute,B-Entity
pain,I-Entity
.,O
In,O
acute,B-Entity
pain,I-Entity
models,O
",",O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
antagonists,O
enhance,O
the,O
antinociceptive,O
effects,O
of,O
morphine,I-Entity
to,O
a,O
greater,O
extent,O
in,O
males,O
than,O
females,O
.,O
The,O
purpose,O
of,O
this,O
investigation,O
was,O
to,O
extend,O
these,O
findings,O
to,O
a,O
persistent,O
pain,I-Entity
model,O
which,O
could,O
be,O
distinguished,O
from,O
acute,B-Entity
pain,I-Entity
models,O
on,O
the,O
basis,O
of,O
the,O
nociceptive,O
fibers,O
activated,O
",",O
neurochemical,O
substrates,O
",",O
and,O
duration,O
of,O
the,O
nociceptive,O
stimulus,O
.,O
To,O
this,O
end,O
",",O
persistent,O
hyperalgesia,I-Entity
was,O
induced,O
by,O
administration,O
of,O
capsaicin,I-Entity
in,O
the,O
tail,O
of,O
gonadally,O
intact,O
F344,O
rats,O
",",O
following,O
which,O
the,O
tail,O
was,O
immersed,O
in,O
a,O
mildly,O
noxious,O
thermal,O
stimulus,O
",",O
and,O
tail,O
-,O
withdrawal,O
latencies,O
measured,O
.,O
For,O
comparison,O
",",O
tests,O
were,O
conducted,O
in,O
two,O
acute,B-Entity
pain,I-Entity
models,O
",",O
the,O
hotplate,O
and,O
warm,O
water,O
tail,O
-,O
withdrawal,O
procedures,O
.,O
In,O
males,O
",",O
the,O
non,O
-,O
competitive,O
NMDA,I-Entity
antagonist,O
dextromethorphan,I-Entity
enhanced,O
the,O
antihyperalgesic,O
effect,O
of,O
low,O
to,O
moderate,O
doses,O
of,O
morphine,I-Entity
in,O
a,O
dose,O
-,O
and,O
time,O
-,O
dependent,O
manner,O
.,O
Enhancement,O
of,O
morphine,I-Entity
antinociception,O
by,O
dextromethorphan,I-Entity
was,O
seen,O
in,O
both,O
males,O
and,O
females,O
in,O
the,O
acute,B-Entity
pain,I-Entity
models,O
",",O
with,O
the,O
magnitude,O
of,O
this,O
effect,O
being,O
greater,O
in,O
males,O
.,O
These,O
findings,O
demonstrate,O
a,O
sexually,O
-,O
dimorphic,O
interaction,O
between,O
NMDA,I-Entity
antagonists,O
and,O
morphine,I-Entity
in,O
a,O
persistent,O
pain,I-Entity
model,O
that,O
can,O
be,O
distinguished,O
from,O
those,O
observed,O
in,O
acute,B-Entity
pain,I-Entity
models,O
.,O
Development,O
of,O
proteinuria,I-Entity
after,O
switch,O
to,O
sirolimus,I-Entity
-,O
based,O
immunosuppression,O
in,O
long,O
-,O
term,O
cardiac,O
transplant,O
patients,O
.,O
Calcineurin,O
-,O
inhibitor,O
therapy,O
can,O
lead,O
to,O
renal,B-Entity
dysfunction,I-Entity
in,O
heart,O
transplantation,O
patients,O
.,O
The,O
novel,O
immunosuppressive,O
(,O
IS,O
),O
drug,O
sirolmus,I-Entity
(,O
Srl,I-Entity
),O
lacks,O
nephrotoxic,I-Entity
effects,O
;,O
however,O
",",O
proteinuria,I-Entity
associated,O
with,O
Srl,I-Entity
has,O
been,O
reported,O
following,O
renal,O
transplantation,O
.,O
In,O
cardiac,O
transplantation,O
",",O
the,O
incidence,O
of,O
proteinuria,I-Entity
associated,O
with,O
Srl,I-Entity
is,O
unknown,O
.,O
In,O
this,O
study,O
",",O
long,O
-,O
term,O
cardiac,O
transplant,O
patients,O
were,O
switched,O
from,O
cyclosporine,I-Entity
to,O
Srl,I-Entity
-,O
based,O
IS,O
.,O
Concomitant,O
IS,O
consisted,O
of,O
mycophenolate,B-Entity
mofetil,I-Entity
steroids,I-Entity
.,O
Before,O
the,O
switch,O
",",O
11.5%,O
of,O
patients,O
had,O
high,O
-,O
grade,O
proteinuria,I-Entity
(,O
>,O
1.0,O
g,O
/,O
day,O
),O
;,O
this,O
increased,O
to,O
22.9%,O
postswitch,O
(,O
p,O
=,O
0.006,O
),O
.,O
ACE,B-Entity
inhibitor,I-Entity
and,O
angiotensin,B-Entity
-,I-Entity
releasing,I-Entity
blocker,I-Entity
(,O
ARB,I-Entity
),O
therapy,O
reduced,O
proteinuria,I-Entity
development,O
.,O
Patients,O
without,O
proteinuria,I-Entity
had,O
increased,O
renal,O
function,O
(,O
median,O
42.5,O
vs.,O
64.1,O
",",O
p,O
=,O
0.25,O
),O
",",O
whereas,O
patients,O
who,O
developed,O
high,O
-,O
grade,O
proteinuria,I-Entity
showed,O
decreased,O
renal,O
function,O
at,O
the,O
end,O
of,O
follow,O
-,O
up,O
(,O
median,O
39.6,O
vs.,O
29.2,O
",",O
p,O
=,O
0.125,O
),O
.,O
Thus,O
",",O
proteinuria,I-Entity
may,O
develop,O
in,O
cardiac,O
transplant,O
patients,O
after,O
switch,O
to,O
Srl,I-Entity
",",O
which,O
may,O
have,O
an,O
adverse,O
effect,O
on,O
renal,O
function,O
in,O
these,O
patients,O
.,O
Srl,I-Entity
should,O
be,O
used,O
with,O
ACEi,I-Entity
/,O
ARB,I-Entity
therapy,O
and,O
patients,O
monitored,O
for,O
proteinuria,I-Entity
and,O
increased,O
renal,B-Entity
dysfunction,I-Entity
.,O
Synthesis,O
of,O
N,B-Entity
-,I-Entity
pyrimidinyl-2-phenoxyacetamides,I-Entity
as,O
adenosine,I-Entity
A2A,O
receptor,O
antagonists,O
.,O
A,O
series,O
of,O
N,B-Entity
-,I-Entity
pyrimidinyl-2-phenoxyacetamide,I-Entity
adenosine,I-Entity
A(2A,O
),O
antagonists,O
is,O
described,O
.,O
>,O
100,O
),O
",",O
and,O
efficacy,O
(,O
MED,O
10,O
mg,O
/,O
kg,O
p.o,O
.,O
),O
in,O
the,O
rat,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
model,O
for,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Methamphetamine,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
and,O
microglial,O
activation,O
are,O
not,O
mediated,O
by,O
fractalkine,O
receptor,O
signaling,O
.,O
Methamphetamine,I-Entity
(,O
METH,I-Entity
),O
damages,O
dopamine,I-Entity
(,O
DA,I-Entity
),O
nerve,O
endings,O
by,O
a,O
process,O
that,O
has,O
been,O
linked,O
to,O
microglial,O
activation,O
but,O
the,O
signaling,O
pathways,O
that,O
mediate,O
this,O
response,O
have,O
not,O
yet,O
been,O
delineated,O
.,O
Neurosci,O
.,O
9,O
(,O
2006,O
),O
",",O
917,O
],O
recently,O
identified,O
the,O
microglial,O
-,O
specific,O
fractalkine,O
receptor,O
(,O
CX3CR1,O
),O
as,O
an,O
important,O
mediator,O
of,O
MPTP,I-Entity
-,O
induced,O
neurodegeneration,I-Entity
of,O
DA,I-Entity
neurons,O
.,O
Because,O
the,O
CNS,B-Entity
damage,I-Entity
caused,O
by,O
METH,I-Entity
and,O
MPTP,I-Entity
is,O
highly,O
selective,O
for,O
the,O
DA,I-Entity
neuronal,O
system,O
in,O
mouse,O
models,O
of,O
neurotoxicity,I-Entity
",",O
we,O
hypothesized,O
that,O
the,O
CX3CR1,O
plays,O
a,O
role,O
in,O
METH,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
and,O
microglial,O
activation,O
.,O
Mice,O
in,O
which,O
the,O
CX3CR1,O
gene,O
has,O
been,O
deleted,O
and,O
replaced,O
with,O
a,O
cDNA,O
encoding,O
enhanced,O
green,O
fluorescent,O
protein,O
(,O
eGFP,O
),O
were,O
treated,O
with,O
METH,I-Entity
and,O
examined,O
for,O
striatal,O
neurotoxicity,I-Entity
.,O
METH,I-Entity
depleted,O
DA,I-Entity
",",O
caused,O
microglial,O
activation,O
",",O
and,O
increased,O
body,O
temperature,O
in,O
CX3CR1,O
knockout,O
mice,O
to,O
the,O
same,O
extent,O
and,O
over,O
the,O
same,O
time,O
course,O
seen,O
in,O
wild,O
-,O
type,O
controls,O
.,O
The,O
effects,O
of,O
METH,I-Entity
in,O
CX3CR1,O
knockout,O
mice,O
were,O
not,O
gender,O
-,O
dependent,O
and,O
did,O
not,O
extend,O
beyond,O
the,O
striatum,O
.,O
Striatal,O
microglia,O
expressing,O
eGFP,O
constitutively,O
show,O
morphological,O
changes,O
after,O
METH,I-Entity
that,O
are,O
characteristic,O
of,O
activation,O
.,O
This,O
response,O
was,O
restricted,O
to,O
the,O
striatum,O
and,O
contrasted,O
sharply,O
with,O
unresponsive,O
eGFP,O
-,O
microglia,O
in,O
surrounding,O
brain,O
areas,O
that,O
are,O
not,O
damaged,O
by,O
METH,I-Entity
.,O
We,O
conclude,O
from,O
these,O
studies,O
that,O
CX3CR1,O
signaling,O
does,O
not,O
modulate,O
METH,I-Entity
neurotoxicity,I-Entity
or,O
microglial,O
activation,O
.,O
Furthermore,O
",",O
it,O
appears,O
that,O
striatal,O
-,O
resident,O
microglia,O
respond,O
to,O
METH,I-Entity
with,O
an,O
activation,O
cascade,O
and,O
then,O
return,O
to,O
a,O
surveying,O
state,O
without,O
undergoing,O
apoptosis,O
or,O
migration,O
.,O
Recovery,O
of,O
tacrolimus,I-Entity
-,O
associated,O
brachial,B-Entity
neuritis,I-Entity
after,O
conversion,O
to,O
everolimus,I-Entity
in,O
a,O
pediatric,O
renal,O
transplant,O
recipient,O
--,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
TAC,I-Entity
has,O
been,O
shown,O
to,O
be,O
a,O
potent,O
immunosuppressive,O
agent,O
for,O
solid,O
organ,O
transplantation,O
in,O
pediatrics,O
.,O
Neurotoxicity,I-Entity
is,O
a,O
potentially,O
serious,O
toxic,O
effect,O
.,O
It,O
is,O
characterized,O
by,O
encephalopathy,I-Entity
",",O
headaches,I-Entity
",",O
seizures,I-Entity
",",O
or,O
neurological,B-Entity
deficits,I-Entity
.,O
MRI,O
demonstrated,O
hyperintense,O
T2,O
signals,O
in,O
the,O
cervical,O
cord,O
and,O
right,O
brachial,O
plexus,O
roots,O
indicative,O
of,O
both,O
myelitis,I-Entity
and,O
right,O
brachial,B-Entity
plexitis,I-Entity
.,O
Symptoms,O
persisted,O
for,O
three,O
months,O
despite,O
TAC,I-Entity
dose,O
reduction,O
",",O
administration,O
of,O
IVIG,O
and,O
four,O
doses,O
of,O
methylprednisolone,I-Entity
pulse,O
therapy,O
.,O
Improvement,O
and,O
eventually,O
full,O
recovery,O
only,O
occurred,O
after,O
TAC,I-Entity
was,O
completely,O
discontinued,O
and,O
successfully,O
replaced,O
by,O
everolimus,I-Entity
.,O
Valvular,B-Entity
heart,I-Entity
disease,I-Entity
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
treated,O
with,O
pergolide,I-Entity
.,O
Valvular,B-Entity
heart,I-Entity
abnormalities,I-Entity
have,O
been,O
reported,O
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
treated,O
with,O
pergolide,I-Entity
.,O
OBJECTIVES,O
:,O
To,O
estimate,O
the,O
frequency,O
and,O
severity,O
of,O
valvular,B-Entity
heart,I-Entity
abnormality,I-Entity
and,O
its,O
possible,O
reversibility,O
after,O
drug,O
withdrawal,O
in,O
a,O
case,O
-,O
control,O
study,O
.,O
All,O
PD,I-Entity
patients,O
in,O
the,O
Amiens,O
area,O
treated,O
with,O
pergolide,I-Entity
were,O
invited,O
to,O
attend,O
a,O
cardiologic,O
assessment,O
including,O
transthoracic,O
echocardiography,O
.,O
Thirty,O
PD,I-Entity
patients,O
participated,O
in,O
the,O
study,O
.,O
A,O
second,O
echocardiography,O
was,O
performed,O
(,O
median,O
interval,O
:,O
13,O
months,O
),O
after,O
pergolide,I-Entity
withdrawal,O
(,O
n=10,O
patients,O
),O
.,O
Controls,O
were,O
age-,O
and,O
sex,O
-,O
matched,O
non,O
-,O
PD,I-Entity
patients,O
referred,O
to,O
the,O
cardiology,O
department,O
.,O
Compared,O
to,O
controls,O
",",O
aortic,B-Entity
regurgitation,I-Entity
(,O
OR,O
:,O
3.1,O
;,O
95%,O
IC,O
:,O
1.1,O
-,O
8.8,O
),O
and,O
mitral,B-Entity
regurgitation,I-Entity
(,O
OR,O
:,O
10.7,O
;,O
95%,O
IC,O
:,O
2.1,O
-,O
53,O
),O
were,O
more,O
frequent,O
in,O
PD,I-Entity
patients,O
(,O
tricuspid,O
:,O
NS,O
),O
.,O
The,O
number,O
of,O
affected,O
valves,O
(,O
n=2.4+/-0.7,O
),O
and,O
the,O
sum,O
of,O
regurgitation,O
grades,O
(,O
n=2.8+/-1.09,O
),O
were,O
higher,O
(,O
p=0.008,O
and,O
p=0.006,O
",",O
respectively,O
),O
in,O
the,O
pergolide,I-Entity
group,O
.,O
Severity,O
of,O
regurgitation,O
was,O
not,O
correlated,O
with,O
pergolide,I-Entity
cumulative,O
dose,O
.,O
A,O
restrictive,O
pattern,O
of,O
valvular,B-Entity
regurgitation,I-Entity
",",O
suggestive,O
of,O
the,O
role,O
of,O
pergolide,I-Entity
",",O
was,O
observed,O
in,O
12/30,O
(,O
40%,O
),O
patients,O
including,O
two,O
with,O
heart,B-Entity
failure,I-Entity
.,O
Pergolide,I-Entity
was,O
discontinued,O
in,O
10,O
patients,O
with,O
valvular,B-Entity
heart,I-Entity
disease,I-Entity
",",O
resulting,O
in,O
a,O
lower,O
regurgitation,O
grade,O
(,O
p=0.01,O
),O
at,O
the,O
second,O
transthoracic,O
echocardiography,O
and,O
the,O
two,O
patients,O
with,O
heart,B-Entity
failure,I-Entity
returned,O
to,O
nearly,O
normal,O
clinical,O
examination,O
.,O
This,O
study,O
supports,O
the,O
high,O
frequency,O
of,O
restrictive,O
valve,B-Entity
regurgitation,I-Entity
in,O
PD,I-Entity
patients,O
treated,O
with,O
pergolide,I-Entity
and,O
reveals,O
that,O
a,O
significant,O
improvement,O
is,O
usual,O
when,O
the,O
treatment,O
is,O
converted,O
to,O
non,O
-,O
ergot,O
dopamine,I-Entity
agonists,O
.,O
Adverse,O
effects,O
of,O
topical,O
papaverine,I-Entity
on,O
auditory,O
nerve,O
function,O
.,O
Papaverine,B-Entity
hydrochloride,I-Entity
is,O
a,O
direct,O
-,O
acting,O
vasodilator,O
used,O
to,O
manage,O
vasospasm,I-Entity
during,O
various,O
neurosurgical,O
operations,O
.,O
Transient,O
cranial,B-Entity
nerve,I-Entity
dysfunction,I-Entity
has,O
been,O
described,O
in,O
a,O
few,O
cases,O
with,O
topical,O
papaverine,I-Entity
.,O
METHODS,O
:,O
We,O
conducted,O
a,O
retrospective,O
review,O
of,O
70,O
consecutive,O
microvascular,O
decompression,O
operations,O
and,O
studied,O
those,O
patients,O
who,O
received,O
topical,O
papaverine,I-Entity
for,O
vasospasm,I-Entity
.,O
Topical,O
papaverine,I-Entity
was,O
used,O
as,O
a,O
direct,O
therapeutic,O
action,O
to,O
manage,O
vasospasm,I-Entity
in,O
a,O
total,O
of,O
11,O
patients,O
.,O
The,O
timing,O
of,O
papaverine,I-Entity
application,O
and,O
ongoing,O
operative,O
events,O
was,O
reviewed,O
relative,O
to,O
changes,O
in,O
neurophysiological,O
recordings,O
.,O
A,O
temporal,O
relationship,O
was,O
found,O
between,O
topical,O
papaverine,I-Entity
and,O
BAEP,O
changes,O
leading,O
to,O
complete,O
waveform,O
loss,O
.,O
The,O
average,O
temporal,O
delay,O
between,O
papaverine,I-Entity
and,O
the,O
onset,O
of,O
an,O
adverse,O
BAEP,O
change,O
was,O
5,O
min,O
.,O
In,O
10,O
of,O
11,O
patients,O
",",O
BAEP,O
waves,O
II,O
/,O
III,O
-,O
V,O
completely,O
disappeared,O
within,O
2,O
to,O
25,O
min,O
after,O
papaverine,I-Entity
.,O
One,O
patient,O
showed,O
no,O
recovery,O
of,O
later,O
waves,O
and,O
a,O
delayed,O
profound,O
sensorineural,B-Entity
hearing,I-Entity
loss,I-Entity
.,O
The,O
average,O
recovery,O
time,O
of,O
BAEP,O
waveforms,O
to,O
pre,O
-,O
papaverine,I-Entity
baseline,O
values,O
was,O
39,O
min,O
.,O
Topical,O
papaverine,I-Entity
for,O
the,O
treatment,O
of,O
vasospasm,I-Entity
was,O
associated,O
with,O
the,O
onset,O
of,O
a,O
transient,O
disturbance,O
in,O
neurophysiological,O
function,O
of,O
the,O
ascending,O
auditory,O
brainstem,O
pathway,O
.,O
The,O
complete,O
disappearance,O
of,O
BAEP,O
waveforms,O
with,O
a,O
consistent,O
temporal,O
delay,O
suggests,O
a,O
possible,O
adverse,B-Entity
effect,I-Entity
on,I-Entity
the,I-Entity
proximal,I-Entity
eighth,I-Entity
nerve,I-Entity
.,O
Recommendations,O
to,O
avoid,O
potential,O
cranial,B-Entity
nerve,I-Entity
deficits,I-Entity
from,O
papaverine,I-Entity
are,O
provided,O
.,O
Massive,O
proteinuria,I-Entity
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
after,O
oral,O
bisphosphonate,I-Entity
(,O
alendronate,I-Entity
),O
administration,O
in,O
a,O
patient,O
with,O
focal,B-Entity
segmental,I-Entity
glomerulosclerosis,I-Entity
.,O
A,O
61-year,O
-,O
old,O
Japanese,O
man,O
with,O
nephrotic,B-Entity
syndrome,I-Entity
due,O
to,O
focal,B-Entity
segmental,I-Entity
glomerulosclerosis,I-Entity
was,O
initially,O
responding,O
well,O
to,O
steroid,I-Entity
therapy,O
.,O
Within,O
14,O
days,O
of,O
the,O
oral,O
bisphosphonate,I-Entity
(,O
alendronate,B-Entity
sodium,I-Entity
),O
administration,O
",",O
the,O
amount,O
of,O
daily,O
urinary,O
protein,O
increased,O
rapidly,O
up,O
to,O
12.8,O
g,O
with,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
After,O
discontinuing,O
the,O
oral,O
alendronate,I-Entity
",",O
the,O
patient,O
underwent,O
six,O
cycles,O
of,O
hemodialysis,O
and,O
four,O
cycles,O
of,O
LDL,O
apheresis,O
.,O
Urinary,O
volume,O
and,O
serum,O
creatinine,I-Entity
levels,O
recovered,O
to,O
the,O
normal,O
range,O
",",O
with,O
urinary,O
protein,O
disappearing,O
completely,O
within,O
40,O
days,O
.,O
This,O
report,O
demonstrates,O
that,O
not,O
only,O
intravenous,O
",",O
but,O
also,O
oral,O
bisphosphonates,I-Entity
can,O
aggravate,O
proteinuria,I-Entity
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
Serum-,O
and,O
glucocorticoid,O
-,O
inducible,O
kinase,O
1,O
in,O
doxorubicin,I-Entity
-,O
induced,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
Doxorubicin,I-Entity
-,O
induced,O
nephropathy,I-Entity
leads,O
to,O
epithelial,O
sodium,I-Entity
channel,O
(,O
ENaC)-dependent,O
volume,B-Entity
retention,I-Entity
and,O
renal,O
fibrosis,I-Entity
.,O
The,O
aldosterone,I-Entity
-,O
sensitive,O
serum-,O
and,O
glucocorticoid,O
-,O
inducible,O
kinase,O
SGK1,O
has,O
been,O
shown,O
to,O
participate,O
in,O
the,O
stimulation,O
of,O
ENaC,O
and,O
to,O
mediate,O
renal,O
fibrosis,I-Entity
following,O
mineralocorticoid,O
and,O
salt,O
excess,O
.,O
The,O
present,O
study,O
was,O
performed,O
to,O
elucidate,O
the,O
role,O
of,O
SGK1,O
in,O
the,O
volume,B-Entity
retention,I-Entity
and,O
fibrosis,I-Entity
during,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
To,O
this,O
end,O
",",O
doxorubicin,I-Entity
(,O
15,O
mug,O
/,O
g,O
body,O
wt,O
),O
was,O
injected,O
intravenously,O
into,O
gene,O
-,O
targeted,O
mice,O
lacking,O
SGK1,O
(,O
sgk1(-/-,O
),O
),O
and,O
their,O
wild,O
-,O
type,O
littermates,O
(,O
sgk1(+/+,O
),O
),O
.,O
Doxorubicin,I-Entity
treatment,O
resulted,O
in,O
heavy,O
proteinuria,I-Entity
(,O
>,O
100,O
mg,O
protein,O
/,O
mg,O
crea,O
),O
in,O
15/44,O
of,O
sgk1(+/+,O
),O
and,O
15/44,O
of,O
sgk1(-/-,O
),O
mice,O
leading,O
to,O
severe,O
nephrotic,B-Entity
syndrome,I-Entity
with,O
ascites,I-Entity
",",O
lipidemia,I-Entity
",",O
and,O
hypoalbuminemia,I-Entity
in,O
both,O
genotypes,O
.,O
Plasma,O
aldosterone,I-Entity
levels,O
increased,O
in,O
nephrotic,I-Entity
mice,O
of,O
both,O
genotypes,O
and,O
was,O
followed,O
by,O
increased,O
SGK1,O
protein,O
expression,O
in,O
sgk1(+/+,O
),O
mice,O
.,O
Urinary,O
sodium,I-Entity
excretion,O
reached,O
signficantly,O
lower,O
values,O
in,O
sgk1(+/+,O
),O
mice,O
(,O
15,O
+,O
/-,O
5,O
mumol,O
/,O
mg,O
crea,O
),O
and,O
was,O
associated,O
with,O
a,O
significantly,O
higher,O
body,O
weight,B-Entity
gain,I-Entity
in,O
sgk1(+/+,O
),O
compared,O
with,O
sgk1(-/-,O
),O
mice,O
(,O
+,O
6.6,O
+,O
/-,O
During,O
the,O
course,O
of,O
nephrotic,B-Entity
syndrome,I-Entity
",",O
serum,O
urea,I-Entity
concentrations,O
increased,O
significantly,O
faster,O
in,O
sgk1(-/-,O
),O
mice,O
than,O
in,O
sgk1(+/+,O
),O
mice,O
leading,O
to,O
uremia,I-Entity
and,O
a,O
reduced,O
median,O
survival,O
in,O
sgk1(-/-,O
),O
mice,O
(,O
29,O
vs.,O
40,O
days,O
in,O
sgk1(+/+,O
),O
mice,O
),O
.,O
In,O
conclusion,O
",",O
gene,O
-,O
targeted,O
mice,O
lacking,O
SGK1,O
showed,O
blunted,O
volume,B-Entity
retention,I-Entity
",",O
yet,O
were,O
not,O
protected,O
against,O
renal,O
fibrosis,I-Entity
during,O
experimental,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
Severe,O
and,O
long,O
lasting,O
cholestasis,I-Entity
after,O
high,O
-,O
dose,O
co,B-Entity
-,I-Entity
trimoxazole,I-Entity
treatment,O
for,O
Pneumocystis,B-Entity
pneumonia,I-Entity
in,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
patients,O
--,O
a,O
report,O
of,O
two,O
cases,O
.,O
Pneumocystis,B-Entity
pneumonia,I-Entity
(,O
PCP,I-Entity
),O
",",O
a,O
common,O
opportunistic,B-Entity
infection,I-Entity
in,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
individuals,O
",",O
is,O
generally,O
treated,O
with,O
high,O
doses,O
of,O
co,B-Entity
-,I-Entity
trimoxazole,I-Entity
.,O
Here,O
",",O
we,O
report,O
two,O
cases,O
of,O
severely,O
immunocompromised,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
patients,O
who,O
developed,O
severe,O
intrahepatic,B-Entity
cholestasis,I-Entity
",",O
and,O
in,O
one,O
patient,O
lesions,O
mimicking,O
liver,B-Entity
abscess,I-Entity
formation,O
on,O
radiologic,O
exams,O
",",O
during,O
co,B-Entity
-,I-Entity
trimoxazole,I-Entity
treatment,O
for,O
PCP,I-Entity
.,O
Whereas,O
patient,O
1,O
showed,O
lesions,O
of,O
up,O
to,O
1,O
cm,O
readily,O
detectable,O
on,O
magnetic,O
resonance,O
imaging,O
under,O
prolonged,O
co,B-Entity
-,I-Entity
trimoxazole,I-Entity
treatment,O
",",O
therapy,O
of,O
patient,O
2,O
was,O
switched,O
early,O
.,O
Clinically,O
significant,O
proteinuria,I-Entity
following,O
the,O
administration,O
of,O
sirolimus,I-Entity
to,O
renal,O
transplant,O
recipients,O
.,O
Sirolimus,I-Entity
is,O
the,O
latest,O
immunosuppressive,O
agent,O
used,O
to,O
prevent,O
rejection,O
",",O
and,O
may,O
have,O
less,O
nephrotoxicity,I-Entity
than,O
calcineurin,O
inhibitor,O
(,O
CNI)-based,O
regimens,O
.,O
To,O
date,O
there,O
has,O
been,O
little,O
documentation,O
of,O
clinically,O
significant,O
proteinuria,I-Entity
linked,O
with,O
the,O
use,O
of,O
sirolimus,I-Entity
.,O
We,O
have,O
encountered,O
several,O
patients,O
who,O
developed,O
substantial,O
proteinuria,I-Entity
associated,O
with,O
sirolimus,I-Entity
use,O
.,O
In,O
each,O
patient,O
",",O
the,O
close,O
temporal,O
association,O
between,O
the,O
commencement,O
of,O
sirolimus,I-Entity
therapy,O
and,O
proteinuria,I-Entity
implicated,O
sirolimus,I-Entity
as,O
the,O
most,O
likely,O
etiology,O
of,O
the,O
proteinuria,I-Entity
.,O
METHODS,O
:,O
We,O
analyzed,O
the,O
clinical,O
and,O
laboratory,O
information,O
available,O
for,O
all,O
119,O
patients,O
transplanted,O
at,O
the,O
Washington,O
Hospital,O
Center,O
between,O
1999,O
-,O
2003,O
for,O
whom,O
sirolimus,I-Entity
was,O
a,O
component,O
of,O
their,O
immunosuppressant,O
regimen,O
.,O
In,O
these,O
patients,O
",",O
the,O
magnitude,O
of,O
proteinuria,I-Entity
was,O
assessed,O
on,O
morning,O
urine,O
samples,O
by,O
turbidometric,O
measurement,O
or,O
random,O
urine,O
protein,O
:,O
creatinine,I-Entity
ratios,O
",",O
an,O
estimate,O
of,O
grams,O
of,O
proteinuria,I-Entity
/,O
day,O
.,O
Laboratory,O
results,O
were,O
compared,O
between,O
prior,O
",",O
during,O
and,O
following,O
sirolimus,I-Entity
use,O
.,O
Twenty,O
-,O
eight,O
patients,O
(,O
24%,O
),O
developed,O
increased,O
proteinuria,I-Entity
from,O
baseline,O
during,O
their,O
post,O
-,O
transplantation,O
course,O
.,O
In,O
21,O
patients,O
an,O
alternative,O
cause,O
of,O
proteinuria,I-Entity
was,O
either,O
obvious,O
or,O
insufficient,O
data,O
was,O
available,O
to,O
be,O
conclusive,O
.,O
In,O
7,O
of,O
the,O
28,O
patients,O
there,O
was,O
a,O
striking,O
temporal,O
association,O
between,O
the,O
initiation,O
of,O
sirolimus,I-Entity
and,O
the,O
development,O
of,O
nephrotic,I-Entity
-,O
range,O
proteinuria,I-Entity
.,O
Proteinuria,I-Entity
correlated,O
most,O
strongly,O
with,O
sirolimus,I-Entity
therapy,O
when,O
compared,O
to,O
other,O
demographic,O
and,O
clinical,O
variables,O
.,O
In,O
most,O
patients,O
",",O
discontinuation,O
of,O
sirolimus,I-Entity
resulted,O
in,O
a,O
decrease,O
",",O
but,O
not,O
resolution,O
",",O
of,O
proteinuria,I-Entity
.,O
Sirolimus,I-Entity
induces,O
or,O
aggravates,O
pre,O
-,O
existing,O
proteinuria,I-Entity
in,O
an,O
unpredictable,O
subset,O
of,O
renal,O
allograft,O
recipients,O
.,O
Proteinuria,I-Entity
may,O
improve,O
",",O
but,O
does,O
not,O
resolve,O
",",O
when,O
sirolimus,I-Entity
is,O
withdrawn,O
.,O
Comparative,O
cognitive,O
and,O
subjective,O
side,O
effects,O
of,O
immediate,O
-,O
release,O
oxycodone,I-Entity
in,O
healthy,O
middle,O
-,O
aged,O
and,O
older,O
adults,O
.,O
This,O
study,O
measured,O
the,O
objective,O
and,O
subjective,O
neurocognitive,O
effects,O
of,O
a,O
single,O
10-mg,O
dose,O
of,O
immediate,O
-,O
release,O
oxycodone,I-Entity
in,O
healthy,O
",",O
older,O
(,O
>,O
65,O
years,O
),O
",",O
and,O
middle,O
-,O
aged,O
(,O
35,O
to,O
55,O
years,O
),O
adults,O
who,O
were,O
not,O
suffering,O
from,O
chronic,O
or,O
significant,O
daily,O
pain,I-Entity
.,O
Seventy,O
-,O
one,O
participants,O
completed,O
2,O
separate,O
study,O
days,O
and,O
were,O
blind,O
to,O
medication,O
condition,O
(,O
placebo,O
",",O
10-mg,O
oxycodone,I-Entity
),O
.,O
Plasma,O
oxycodone,I-Entity
concentration,O
peaked,O
between,O
60,O
and,O
90,O
minutes,O
postdose,O
(,O
P,O
<,O
.01,O
),O
and,O
pupil,O
size,O
",",O
an,O
indication,O
of,O
physiological,O
effects,O
of,O
the,O
medication,O
",",O
peaked,O
at,O
approximately,O
90,O
to,O
120,O
minutes,O
postdose,O
(,O
P,O
<,O
.01,O
),O
.,O
Significant,O
declines,B-Entity
in,I-Entity
simple,I-Entity
and,I-Entity
sustained,I-Entity
attention,I-Entity
",",I-Entity
working,I-Entity
memory,I-Entity
",",I-Entity
and,I-Entity
verbal,I-Entity
memory,I-Entity
were,O
observed,O
at,O
1,O
hour,O
postdose,O
compared,O
to,O
baseline,O
for,O
both,O
age,O
groups,O
with,O
a,O
trend,O
toward,O
return,O
to,O
baseline,O
by,O
5,O
hours,O
postdose,O
.,O
This,O
study,O
suggests,O
that,O
for,O
healthy,O
older,O
adults,O
who,O
are,O
not,O
suffering,O
from,O
chronic,B-Entity
pain,I-Entity
",",O
neurocognitive,O
and,O
pharmacodynamic,O
changes,O
in,O
response,O
to,O
a,O
10-mg,O
dose,O
of,O
immediate,O
-,O
release,O
oxycodone,I-Entity
are,O
similar,O
to,O
those,O
observed,O
for,O
middle,O
-,O
aged,O
adults,O
.,O
Study,O
findings,O
indicate,O
that,O
the,O
metabolism,O
",",O
neurocognitive,O
effects,O
",",O
and,O
physical,O
side,O
effects,O
of,O
oral,O
oxycodone,I-Entity
are,O
similar,O
for,O
healthy,O
middle,O
-,O
aged,O
and,O
older,O
adults,O
.,O
Normalizing,O
effects,O
of,O
modafinil,I-Entity
on,O
sleep,O
in,O
chronic,O
cocaine,I-Entity
users,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
the,O
effect,O
of,O
morning,O
-,O
dosed,O
modafinil,I-Entity
on,O
sleep,O
and,O
daytime,B-Entity
sleepiness,I-Entity
in,O
chronic,O
cocaine,I-Entity
users,O
.,O
Twenty,O
cocaine,I-Entity
-,O
dependent,O
participants,O
were,O
randomly,O
assigned,O
to,O
receive,O
modafinil,I-Entity
",",O
400,O
mg,O
(,O
N=10,O
),O
",",O
or,O
placebo,O
(,O
N=10,O
),O
every,O
morning,O
at,O
7:30,O
a.m.,O
for,O
16,O
days,O
in,O
an,O
inpatient,O
",",O
double,O
-,O
blind,O
randomized,O
trial,O
.,O
Progressive,O
abstinence,O
from,O
cocaine,I-Entity
was,O
associated,O
with,O
worsening,O
of,O
all,O
measured,O
polysomnographic,O
sleep,O
outcomes,O
.,O
Compared,O
with,O
placebo,O
",",O
modafinil,I-Entity
decreased,O
nighttime,O
sleep,O
latency,O
and,O
increased,O
slow,O
-,O
wave,O
sleep,O
time,O
in,O
cocaine,I-Entity
-,O
dependent,O
participants,O
.,O
The,O
effect,O
of,O
modafinil,I-Entity
interacted,O
with,O
the,O
abstinence,O
week,O
and,O
was,O
associated,O
with,O
longer,O
total,O
sleep,O
time,O
and,O
shorter,O
REM,O
sleep,O
latency,O
in,O
the,O
third,O
week,O
of,O
abstinence,O
.,O
Comparison,O
of,O
slow,O
-,O
wave,O
sleep,O
time,O
",",O
total,O
sleep,O
time,O
",",O
and,O
sleep,O
latency,O
in,O
cocaine,I-Entity
-,O
dependent,O
and,O
healthy,O
participants,O
revealed,O
a,O
normalizing,O
effect,O
of,O
modafinil,I-Entity
in,O
cocaine,I-Entity
-,O
dependent,O
participants,O
.,O
Modafinil,I-Entity
was,O
associated,O
with,O
increased,O
daytime,O
sleep,O
latency,O
",",O
as,O
measured,O
by,O
the,O
Multiple,O
Sleep,O
Latency,O
Test,O
",",O
and,O
a,O
nearly,O
significant,O
decrease,O
in,O
subjective,O
daytime,B-Entity
sleepiness,I-Entity
.,O
Morning,O
-,O
dosed,O
modafinil,I-Entity
promotes,O
nocturnal,O
sleep,O
",",O
normalizes,O
sleep,O
architecture,O
",",O
and,O
decreases,O
daytime,B-Entity
sleepiness,I-Entity
in,O
abstinent,O
cocaine,I-Entity
users,O
.,O
These,O
effects,O
may,O
be,O
relevant,O
in,O
the,O
treatment,O
of,O
cocaine,I-Entity
dependence,O
.,O
Efficacy,O
and,O
safety,O
of,O
asenapine,I-Entity
in,O
a,O
placebo-,O
and,O
haloperidol,I-Entity
-,O
controlled,O
trial,O
in,O
patients,O
with,O
acute,O
exacerbation,O
of,O
schizophrenia,I-Entity
.,O
Asenapine,I-Entity
is,O
approved,O
by,O
the,O
Food,O
and,O
Drugs,O
Administration,O
in,O
adults,O
for,O
acute,O
treatment,O
of,O
schizophrenia,I-Entity
or,O
of,O
manic,I-Entity
or,O
mixed,O
episodes,O
associated,O
with,O
bipolar,B-Entity
I,I-Entity
disorder,I-Entity
with,O
or,O
without,O
psychotic,I-Entity
features,O
.,O
In,O
a,O
double,O
-,O
blind,O
6-week,O
trial,O
",",O
458,O
patients,O
with,O
acute,O
schizophrenia,I-Entity
were,O
randomly,O
assigned,O
to,O
fixed,O
-,O
dose,O
treatment,O
with,O
asenapine,I-Entity
at,O
5,O
mg,O
twice,O
daily,O
(,O
BID,O
),O
",",O
asenapine,I-Entity
at,O
10,O
mg,O
BID,O
",",O
placebo,O
",",O
or,O
haloperidol,I-Entity
at,O
4,O
mg,O
BID,O
(,O
to,O
verify,O
assay,O
sensitivity,O
),O
.,O
With,O
last,O
observations,O
carried,O
forward,O
(,O
LOCF,O
),O
",",O
mean,O
Positive,O
and,O
Negative,O
Syndrome,O
Scale,O
total,O
score,O
reductions,O
from,O
baseline,O
to,O
endpoint,O
were,O
significantly,O
greater,O
with,O
asenapine,I-Entity
at,O
5,O
mg,O
BID,O
(,O
-16.2,O
),O
and,O
haloperidol,I-Entity
(,O
-15.4,O
),O
than,O
placebo,O
(,O
-10.7,O
;,O
both,O
P,O
<,O
0.05,O
),O
;,O
using,O
mixed,O
model,O
for,O
repeated,O
measures,O
(,O
MMRM,O
),O
",",O
changes,O
at,O
day,O
42,O
were,O
significantly,O
greater,O
with,O
asenapine,I-Entity
at,O
5,O
and,O
10,O
mg,O
BID,O
(,O
-21.3,O
and,O
-19.4,O
",",O
respectively,O
),O
and,O
haloperidol,I-Entity
(,O
-20.0,O
),O
than,O
placebo,O
(,O
-14.6,O
;,O
all,O
P,O
<,O
0.05,O
),O
.,O
On,O
the,O
Positive,O
and,O
Negative,O
Syndrome,O
Scale,O
positive,O
subscale,O
",",O
all,O
treatments,O
were,O
superior,O
to,O
placebo,O
with,O
LOCF,O
and,O
MMRM,O
;,O
asenapine,I-Entity
at,O
5,O
mg,O
BID,O
was,O
superior,O
to,O
placebo,O
on,O
the,O
negative,O
subscale,O
with,O
MMRM,O
and,O
on,O
the,O
general,O
psychopathology,O
subscale,O
with,O
LOCF,O
and,O
MMRM,O
.,O
Treatment,O
-,O
related,O
adverse,O
events,O
(,O
AEs,O
),O
occurred,O
in,O
44%,O
and,O
52%,O
",",O
57%,O
",",O
and,O
41%,O
of,O
the,O
asenapine,I-Entity
at,O
5,O
and,O
10,O
mg,O
BID,O
",",O
haloperidol,I-Entity
",",O
and,O
placebo,O
groups,O
",",O
respectively,O
.,O
Extrapyramidal,B-Entity
symptoms,I-Entity
reported,O
as,O
AEs,O
occurred,O
in,O
15%,O
and,O
18%,O
",",O
34%,O
",",O
and,O
10%,O
of,O
the,O
asenapine,I-Entity
at,O
5,O
and,O
10,O
mg,O
BID,O
",",O
haloperidol,I-Entity
",",O
and,O
placebo,O
groups,O
",",O
respectively,O
.,O
Post,O
hoc,O
analyses,O
indicated,O
that,O
efficacy,O
was,O
similar,O
with,O
asenapine,I-Entity
and,O
haloperidol,I-Entity
;,O
greater,O
contrasts,O
were,O
seen,O
in,O
AEs,O
",",O
especially,O
extrapyramidal,B-Entity
symptoms,I-Entity
.,O
Permeability,O
",",O
ultrastructural,O
changes,O
",",O
and,O
distribution,O
of,O
novel,O
proteins,O
in,O
the,O
glomerular,O
barrier,O
in,O
early,O
puromycin,B-Entity
aminonucleoside,I-Entity
nephrosis,I-Entity
.,O
BACKGROUND,O
/,O
AIMS,O
:,O
It,O
is,O
still,O
unclear,O
what,O
happens,O
in,O
the,O
glomerulus,O
when,O
proteinuria,I-Entity
starts,O
.,O
Using,O
puromycin,B-Entity
aminonucleoside,I-Entity
nephrosis,I-Entity
(,O
PAN,O
),O
rats,O
",",O
we,O
studied,O
early,O
ultrastructural,O
and,O
permeability,O
changes,O
in,O
relation,O
to,O
the,O
expression,O
of,O
the,O
podocyte,O
-,O
associated,O
molecules,O
nephrin,O
",",O
a,O
-,O
actinin,O
",",O
dendrin,O
",",O
and,O
plekhh2,O
",",O
the,O
last,O
two,O
of,O
which,O
were,O
only,O
recently,O
discovered,O
in,O
podocytes,O
.,O
By,O
day,O
2,O
",",O
some,O
patchy,O
foot,O
process,O
effacement,O
",",O
but,O
no,O
proteinuria,I-Entity
",",O
appeared,O
.,O
By,O
day,O
4,O
",",O
foot,O
process,O
effacement,O
was,O
complete,O
and,O
proteinuria,I-Entity
appeared,O
in,O
parallel,O
with,O
signs,O
of,O
size,O
barrier,O
damage,O
.,O
PAN,O
glomeruli,O
already,O
showed,O
significant,O
pathology,O
by,O
day,O
4,O
",",O
despite,O
relatively,O
mild,O
proteinuria,I-Entity
.,O
Twin,O
preterm,O
neonates,O
with,O
cardiac,B-Entity
toxicity,I-Entity
related,O
to,O
lopinavir,B-Entity
/,I-Entity
ritonavir,I-Entity
therapy,O
.,O
We,O
report,O
twin,O
neonates,O
who,O
were,O
born,O
prematurely,O
at,O
32,O
weeks,O
of,O
gestation,O
to,O
a,O
mother,O
with,O
human,B-Entity
immunodeficiency,I-Entity
virus,I-Entity
infection,I-Entity
.,O
One,O
of,O
the,O
twins,O
developed,O
complete,O
heart,B-Entity
block,I-Entity
and,O
dilated,B-Entity
cardiomyopathy,I-Entity
related,O
to,O
lopinavir,B-Entity
/,I-Entity
ritonavir,I-Entity
therapy,O
",",O
a,O
boosted,O
protease,O
-,O
inhibitor,O
agent,O
",",O
while,O
the,O
other,O
twin,O
developed,O
mild,O
bradycardia,I-Entity
.,O
We,O
recommend,O
caution,O
in,O
the,O
use,O
of,O
lopinavir,B-Entity
/,I-Entity
ritonavir,I-Entity
in,O
the,O
immediate,O
neonatal,O
period,O
.,O
Learning,O
of,O
rats,O
under,O
amnesia,I-Entity
caused,O
by,O
pentobarbital,I-Entity
.,O
Dissociated,O
learning,O
of,O
rats,O
in,O
the,O
normal,O
state,O
and,O
the,O
state,O
of,O
amnesia,I-Entity
produced,O
by,O
pentobarbital,I-Entity
(,O
15,O
mg,O
/,O
kg,O
",",O
ip,O
),O
was,O
carried,O
out,O
.,O
In,O
Group,O
1,O
the,O
rats,O
were,O
trained,O
under,O
the,O
influence,O
of,O
pentobarbital,I-Entity
to,O
run,O
to,O
the,O
same,O
shelf,O
as,O
in,O
the,O
normal,O
state,O
.,O
It,O
was,O
shown,O
that,O
memory,B-Entity
dissociation,I-Entity
occurred,O
in,O
both,O
groups,O
.,O
Differences,O
in,O
the,O
parameters,O
of,O
training,O
under,O
the,O
influence,O
of,O
pentobarbital,I-Entity
between,O
Groups,O
1,O
and,O
2,O
were,O
revealed,O
.,O
These,O
findings,O
show,O
that,O
the,O
brain,O
-,O
dissociated,O
state,O
induced,O
by,O
pentobarbital,I-Entity
is,O
formed,O
with,O
the,O
participation,O
of,O
the,O
mechanisms,O
of,O
information,O
perception,O
.,O
Angiosarcoma,B-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
associated,O
with,O
diethylstilbestrol,I-Entity
.,O
Angiosarcoma,B-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
occurred,O
in,O
a,O
76-year,O
-,O
old,O
man,O
who,O
had,O
been,O
treated,O
for,O
a,O
well,O
-,O
differentiated,O
adenocarcinoma,B-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
with,O
diethylstilbestrol,I-Entity
for,O
13,O
years,O
.,O
Angiosarcoma,I-Entity
was,O
also,O
present,O
within,O
pulmonary,O
and,O
renal,O
arteries,O
.,O
The,O
possibility,O
that,O
the,O
intraarterial,B-Entity
lesions,I-Entity
might,O
represent,O
independent,O
primary,O
tumors,I-Entity
is,O
considered,O
.,O
Role,O
of,O
xanthine,I-Entity
oxidase,O
in,O
dexamethasone,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
rats,O
.,O
1,O
.,O
Glucocorticoid,O
-,O
induced,O
hypertension,I-Entity
(,O
GC,O
-,O
HT,I-Entity
),O
in,O
the,O
rat,O
is,O
associated,O
with,O
nitric,B-Entity
oxide,I-Entity
-,O
redox,O
imbalance,O
.,O
We,O
studied,O
the,O
role,O
of,O
xanthine,I-Entity
oxidase,O
(,O
XO,O
),O
",",O
which,O
is,O
implicated,O
in,O
the,O
production,O
of,O
reactive,O
oxygen,O
species,O
",",O
in,O
dexamethasone,I-Entity
-,O
induced,O
hypertension,I-Entity
(,O
dex,I-Entity
-,O
HT,I-Entity
),O
.,O
Thirty,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
divided,O
randomly,O
into,O
four,O
treatment,O
groups,O
:,O
saline,O
",",O
dexamethasone,I-Entity
(,O
dex,I-Entity
),O
",",O
allopurinol,I-Entity
plus,O
saline,O
",",O
and,O
allopurinol,I-Entity
plus,O
dex,I-Entity
.,O
Thymus,O
weight,O
was,O
used,O
as,O
a,O
marker,O
of,O
glucocorticoid,O
activity,O
",",O
and,O
serum,O
urate,I-Entity
to,O
assess,O
XO,O
inhibition,O
.,O
Dex,I-Entity
increased,B-Entity
SBP,I-Entity
(,O
110,O
+,O
/-,O
3,O
mmHg,O
;,O
P,O
<,O
0.001,O
),O
and,O
decreased,B-Entity
thymus,I-Entity
(,I-Entity
P,I-Entity
<,I-Entity
0.001,I-Entity
),I-Entity
and,I-Entity
bodyweights,I-Entity
(,O
P,O
"""",O
<,O
0.01,O
),O
.,O
Allopurinol,I-Entity
decreased,O
serum,O
urate,I-Entity
from,O
76,O
+,O
/-,O
/,O
L,O
in,O
dex,I-Entity
-,O
treated,O
(,O
P,O
<,O
0.01,O
),O
groups,O
.,O
Allopurinol,I-Entity
did,O
not,O
prevent,O
dex,I-Entity
-,O
HT,I-Entity
.,O
This,O
",",O
together,O
with,O
our,O
previous,O
findings,O
that,O
allopurinol,I-Entity
failed,O
to,O
prevent,O
adrenocorticotrophic,O
hormone,O
induced,O
hypertension,I-Entity
",",O
suggests,O
that,O
XO,O
activity,O
is,O
not,O
a,O
major,O
determinant,O
of,O
GC,O
-,O
HT,I-Entity
in,O
the,O
rat,O
.,O
Extrapyramidal,O
side,O
effects,O
with,O
risperidone,I-Entity
and,O
haloperidol,I-Entity
at,O
comparable,O
D2,O
receptor,O
occupancy,O
levels,O
.,O
Risperidone,I-Entity
is,O
an,O
antipsychotic,O
drug,O
with,O
high,O
affinity,O
at,O
dopamine,I-Entity
D2,O
and,O
serotonin,B-Entity
5-HT2,I-Entity
receptors,O
.,O
Previous,O
clinical,O
studies,O
have,O
proposed,O
that,O
risperidone,I-Entity
's,O
pharmacologic,O
profile,O
may,O
produce,O
improved,O
efficacy,O
for,O
negative,O
psychotic,B-Entity
symptoms,I-Entity
and,O
decreased,O
propensity,O
for,O
extrapyramidal,O
side,O
effects,O
;,O
features,O
shared,O
by,O
so,O
-,O
called,O
',O
atypical,O
',O
neuroleptics,O
.,O
To,O
determine,O
if,O
routine,O
risperidone,I-Entity
treatment,O
is,O
associated,O
with,O
a,O
unique,O
degree,O
of,O
D2,O
receptor,O
occupancy,O
and,O
pattern,O
of,O
clinical,O
effects,O
",",O
we,O
used,O
[,O
123I]IBZM,O
SPECT,O
to,O
determine,O
D2,O
occupancy,O
in,O
subjects,O
treated,O
with,O
routine,O
clinical,O
doses,O
of,O
risperidone,I-Entity
(,O
n,O
=,O
12,O
),O
or,O
haloperidol,I-Entity
(,O
n,O
=,O
7,O
),O
.,O
Both,O
risperidone,I-Entity
and,O
haloperidol,I-Entity
produced,O
D2,O
occupancy,O
levels,O
between,O
approximately,O
60,O
and,O
90%,O
at,O
standard,O
clinical,O
doses,O
.,O
There,O
was,O
no,O
significant,O
difference,O
between,O
occupancy,O
levels,O
obtained,O
with,O
haloperidol,I-Entity
or,O
risperidone,I-Entity
.,O
Drug,B-Entity
-,I-Entity
induced,I-Entity
parkinsonism,I-Entity
was,O
observed,O
in,O
subjects,O
treated,O
with,O
risperidone,I-Entity
(,O
42%,O
),O
and,O
haloperidol,I-Entity
(,O
29%,O
),O
and,O
was,O
observed,O
at,O
occupancy,O
levels,O
above,O
60%,O
.,O
Based,O
on,O
these,O
observations,O
",",O
it,O
is,O
concluded,O
that,O
5-HT2,O
blockade,O
obtained,O
with,O
risperidone,I-Entity
at,O
D2,O
occupancy,O
rates,O
of,O
60%,O
and,O
above,O
does,O
not,O
appear,O
to,O
protect,O
against,O
the,O
risk,O
for,O
extrapyramidal,O
side,O
effects,O
.,O
Simvastatin,B-Entity
-,I-Entity
ezetimibe,I-Entity
-,O
induced,O
hepatic,B-Entity
failure,I-Entity
necessitating,O
liver,O
transplantation,O
.,O
A,O
reductase,O
inhibitor,O
(,O
statin,I-Entity
),O
therapy,O
.,O
However,O
",",O
hepatotoxic,I-Entity
events,O
have,O
not,O
been,O
widely,O
published,O
with,O
ezetimibe,I-Entity
or,O
the,O
combination,O
agent,O
simvastatin,B-Entity
-,I-Entity
ezetimibe,I-Entity
.,O
We,O
describe,O
a,O
70-year,O
-,O
old,O
Hispanic,O
woman,O
who,O
developed,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
necessitating,O
liver,O
transplantation,O
10,O
weeks,O
after,O
conversion,O
from,O
simvastatin,I-Entity
40,O
mg,O
/,O
day,O
to,O
simvastatin,B-Entity
10,I-Entity
mg,I-Entity
-,I-Entity
ezetimibe,I-Entity
40,I-Entity
mg,I-Entity
/,O
day,O
.,O
The,O
patient,O
's,O
lipid,O
panel,O
had,O
been,O
maintained,O
with,O
simvastatin,I-Entity
for,O
18,O
months,O
before,O
the,O
conversion,O
without,O
evidence,O
of,O
hepatotoxicity,I-Entity
.,O
Simvastatinezetimibe,I-Entity
and,O
escitalopram,I-Entity
(,O
which,O
she,O
was,O
taking,O
for,O
depression,I-Entity
),O
were,O
discontinued,O
",",O
and,O
other,O
potential,O
causes,O
of,O
hepatotoxicity,I-Entity
were,O
excluded,O
.,O
A,O
repeat,O
work,O
-,O
up,O
revealed,O
further,O
elevations,O
in,O
aminotransferase,O
levels,O
",",O
and,O
liver,O
biopsy,O
revealed,O
evidence,O
of,O
moderate,O
-,O
to,O
-,O
severe,O
drug,B-Entity
toxicity,I-Entity
.,O
Ezetimibe,I-Entity
undergoes,O
extensive,O
glucuronidation,O
by,O
uridine,B-Entity
diphosphate,I-Entity
glucoronosyltransferases,O
(,O
UGT,O
),O
in,O
the,O
intestine,O
and,O
liver,O
and,O
may,O
have,O
inhibited,O
the,O
glucuronidation,O
of,O
simvastatin,B-Entity
hydroxy,I-Entity
acid,I-Entity
",",O
resulting,O
in,O
increased,O
simvastatin,I-Entity
exposure,O
and,O
subsequent,O
hepatotoxicity,I-Entity
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
case,O
report,O
of,O
simvastatin,B-Entity
-,I-Entity
ezetimibe,I-Entity
-,O
induced,O
liver,B-Entity
failure,I-Entity
that,O
resulted,O
in,O
liver,O
transplantation,O
.,O
We,O
postulate,O
that,O
the,O
mechanism,O
of,O
the,O
simvastatinezetimibe,I-Entity
-,O
induced,O
hepatotoxicity,I-Entity
is,O
the,O
increased,O
simvastatin,I-Entity
exposure,O
by,O
ezetimibe,I-Entity
inhibition,O
of,O
UGT,O
enzymes,O
.,O
Clinicians,O
should,O
be,O
aware,O
of,O
potential,O
hepatotoxicity,I-Entity
with,O
simvastatin,B-Entity
-,I-Entity
ezetimibe,I-Entity
especially,O
in,O
elderly,O
patients,O
and,O
should,O
carefully,O
monitor,O
serum,O
aminotransferase,O
levels,O
when,O
starting,O
therapy,O
and,O
titrating,O
the,O
dosage,O
.,O
Oral,O
manifestations,O
of,O
"""",O
meth,B-Entity
mouth,I-Entity
"""",O
:,O
a,O
case,O
report,O
.,O
The,O
aim,O
of,O
the,O
documentation,O
of,O
this,O
clinical,O
case,O
is,O
to,O
make,O
clinicians,O
aware,O
of,O
"""",O
meth,B-Entity
mouth,I-Entity
"""",O
and,O
the,O
medical,O
risks,O
associated,O
with,O
this,O
serious,O
condition,O
.,O
Methamphetamine,I-Entity
is,O
a,O
very,O
addictive,O
",",O
powerful,O
stimulant,O
that,O
increases,O
wakefulness,O
and,O
physical,O
activity,O
and,O
can,O
produce,O
other,O
effects,O
such,O
as,O
cardiac,B-Entity
dysrhythmias,I-Entity
",",O
hypertension,I-Entity
",",O
hallucinations,I-Entity
",",O
and,O
violent,B-Entity
behavior,I-Entity
.,O
Dental,O
patients,O
abusing,O
methamphetamine,I-Entity
can,O
present,O
with,O
poor,O
oral,O
hygiene,O
",",O
xerostomia,I-Entity
",",O
rampant,O
caries,I-Entity
(,O
"""",O
meth,B-Entity
mouth,I-Entity
"""",O
),O
",",O
and,O
excessive,O
tooth,B-Entity
wear,I-Entity
.,O
Oral,O
rehabilitation,O
of,O
patients,O
using,O
methamphetamine,I-Entity
can,O
be,O
challenging,O
.,O
CASE,O
DESCRIPTION,O
:,O
A,O
30-year,O
-,O
old,O
Caucasian,O
woman,O
presented,O
with,O
dental,O
pain,I-Entity
",",O
bad,B-Entity
breath,I-Entity
",",O
and,O
self,O
-,O
reported,O
poor,O
esthetics,O
.,O
A,O
comprehensive,O
examination,O
including,O
her,O
medical,O
history,O
",",O
panoramic,O
radiograph,O
",",O
and,O
intraoral,O
examination,O
revealed,O
19,O
carious,B-Entity
lesions,I-Entity
",",O
which,O
is,O
not,O
very,O
common,O
for,O
a,O
healthy,O
adult,O
.,O
She,O
reported,O
her,O
use,O
of,O
methamphetamine,I-Entity
for,O
five,O
years,O
and,O
had,O
not,O
experienced,O
any,O
major,O
carious,B-Entity
episodes,I-Entity
before,O
she,O
started,O
using,O
the,O
drug,O
.,O
The,O
patient,O
's,O
medical,O
and,O
dental,O
histories,O
along,O
with,O
radiographic,O
and,O
clinical,O
findings,O
lead,O
to,O
a,O
diagnosis,O
of,O
"""",O
meth,B-Entity
mouth,I-Entity
.,O
This,O
clinical,O
case,O
showing,O
oral,O
manifestations,O
of,O
meth,B-Entity
mouth,I-Entity
was,O
presented,O
to,O
help,O
dental,O
practitioners,O
recognize,O
and,O
manage,O
patients,O
who,O
may,O
be,O
abusing,O
methamphetamines,I-Entity
.,O
Thyroxine,I-Entity
abuse,O
:,O
an,O
unusual,O
case,O
of,O
thyrotoxicosis,I-Entity
in,O
pregnancy,O
.,O
Eating,B-Entity
disorders,I-Entity
and,O
the,O
associated,O
behavioural,O
problems,O
and,O
drug,B-Entity
abuse,I-Entity
are,O
uncommon,O
in,O
pregnancy,O
.,O
This,O
case,O
illustrates,O
a,O
number,O
of,O
problems,O
that,O
may,O
be,O
encountered,O
in,O
women,O
with,O
eating,B-Entity
disorders,I-Entity
in,O
pregnancy,O
",",O
including,O
prolonged,O
and,O
recurrent,O
metabolic,O
disturbances,O
and,O
diuretic,O
abuse,O
.,O
In,O
particular,O
it,O
illustrates,O
the,O
derangements,O
of,O
thyroid,O
function,O
seen,O
in,O
pregnant,O
women,O
with,O
eating,B-Entity
disorders,I-Entity
and,O
reminds,O
us,O
that,O
when,O
a,O
cause,O
for,O
thyrotoxicosis,I-Entity
remains,O
obscure,O
",",O
thyroxine,I-Entity
abuse,O
should,O
be,O
considered,O
and,O
explored,O
.,O
Attenuation,O
of,O
methamphetamine,I-Entity
-,O
induced,O
nigrostriatal,O
dopaminergic,O
neurotoxicity,I-Entity
in,O
mice,O
by,O
lipopolysaccharide,I-Entity
pretreatment,O
.,O
Immunological,O
activation,O
has,O
been,O
proposed,O
to,O
play,O
a,O
role,O
in,O
methamphetamine,I-Entity
-,O
induced,O
dopaminergic,B-Entity
terminal,I-Entity
damage,I-Entity
.,O
In,O
this,O
study,O
",",O
we,O
examined,O
the,O
roles,O
of,O
lipopolysaccharide,I-Entity
",",O
a,O
pro,O
-,O
inflammatory,O
and,O
inflammatory,O
factor,O
",",O
treatment,O
in,O
modulating,O
the,O
methamphetamine,I-Entity
-,O
induced,O
nigrostriatal,O
dopamine,I-Entity
neurotoxicity,I-Entity
.,O
Lipopolysaccharide,I-Entity
pretreatment,O
did,O
not,O
affect,O
the,O
basal,O
body,O
temperature,O
or,O
methamphetamine,I-Entity
-,O
elicited,O
hyperthermia,I-Entity
three,O
days,O
later,O
.,O
Such,O
systemic,O
lipopolysaccharide,I-Entity
treatment,O
mitigated,O
methamphetamine,I-Entity
-,O
induced,O
striatal,O
dopamine,I-Entity
and,O
"3,4-dihydroxyphenylacetic",B-Entity
acid,I-Entity
depletions,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
As,O
the,O
most,O
potent,O
dose,O
(,O
1,O
mg,O
/,O
kg,O
),O
of,O
lipopolysaccharide,I-Entity
was,O
administered,O
two,O
weeks,O
",",O
one,O
day,O
before,O
or,O
after,O
the,O
methamphetamine,I-Entity
dosing,O
regimen,O
",",O
methamphetamine,I-Entity
-,O
induced,O
striatal,O
dopamine,I-Entity
and,O
"3,4-dihydroxyphenylacetic",B-Entity
acid,I-Entity
depletions,O
remained,O
unaltered,O
.,O
Moreover,O
",",O
systemic,O
lipopolysaccharide,I-Entity
pretreatment,O
(,O
1,O
mg,O
/,O
kg,O
),O
attenuated,O
local,O
methamphetamine,I-Entity
infusion,O
-,O
produced,O
dopamine,I-Entity
and,O
"3,4-dihydroxyphenylacetic",B-Entity
acid,I-Entity
depletions,O
in,O
the,O
striatum,O
",",O
indicating,O
that,O
the,O
protective,O
effect,O
of,O
lipopolysaccharide,I-Entity
is,O
less,O
likely,O
due,O
to,O
interrupted,O
peripheral,O
distribution,O
or,O
metabolism,O
of,O
methamphetamine,I-Entity
.,O
We,O
concluded,O
a,O
critical,O
time,O
window,O
for,O
systemic,O
lipopolysaccharide,I-Entity
pretreatment,O
in,O
exerting,O
effective,O
protection,O
against,O
methamphetamine,I-Entity
-,O
induced,O
nigrostriatal,O
dopamine,I-Entity
neurotoxicity,I-Entity
.,O
Effect,O
of,O
converting,O
enzyme,O
inhibition,O
on,O
the,O
course,O
of,O
adriamycin,I-Entity
-,O
induced,O
nephropathy,I-Entity
.,O
The,O
effect,O
of,O
the,O
converting,O
enzyme,O
inhibitor,O
(,O
CEI,O
),O
enalapril,I-Entity
was,O
assessed,O
in,O
Munich,O
-,O
Wistar,O
rats,O
with,O
established,O
adriamycin,I-Entity
nephrosis,I-Entity
.,O
Rats,O
were,O
given,O
a,O
single,O
dose,O
of,O
adriamycin,I-Entity
and,O
one,O
month,O
later,O
divided,O
into,O
four,O
groups,O
matched,O
for,O
albuminuria,I-Entity
",",O
blood,O
pressure,O
",",O
and,O
plasma,O
albumin,O
concentration,O
.,O
Groups,O
1,O
and,O
3,O
remained,O
untreated,O
while,O
groups,O
2,O
and,O
4,O
received,O
enalapril,I-Entity
.,O
These,O
short,O
-,O
term,O
studies,O
showed,O
that,O
enalapril,I-Entity
reduced,O
arterial,O
blood,O
pressure,O
(,O
101,O
+,O
/-,O
2,O
mm,O
Hg,O
",",O
P,O
less,O
than,O
0.05,O
),O
without,O
reducing,O
albuminuria,I-Entity
(,O
617,O
+,O
/-,O
50,O
vs.,O
570,O
+,O
/-,O
47,O
mg,O
/,O
day,O
),O
or,O
GFR,O
(,O
1.03,O
+,O
/-,O
Groups,O
3,O
and,O
4,O
were,O
studied,O
at,O
four,O
and,O
at,O
six,O
months,O
to,O
assess,O
the,O
effect,O
of,O
enalapril,I-Entity
on,O
progression,O
of,O
renal,B-Entity
injury,I-Entity
in,O
adriamycin,I-Entity
nephrosis,I-Entity
.,O
Chronic,O
enalapril,I-Entity
treatment,O
reduced,O
blood,O
pressure,O
without,O
reducing,O
albuminuria,I-Entity
in,O
group,O
4,O
.,O
Enalapril,I-Entity
treatment,O
blunted,O
but,O
did,O
not,O
prevent,O
reduction,O
in,O
GFR,O
in,O
group,O
4,O
(,O
0.86,O
+,O
/-,O
Reduction,O
in,O
GFR,O
was,O
associated,O
with,O
the,O
development,O
of,O
glomerular,B-Entity
sclerosis,I-Entity
in,O
both,O
treated,O
and,O
untreated,O
rats.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Butyrylcholinesterase,O
gene,O
mutations,O
in,O
patients,O
with,O
prolonged,O
apnea,I-Entity
after,O
succinylcholine,I-Entity
for,O
electroconvulsive,O
therapy,O
.,O
patients,O
undergoing,O
electroconvulsive,O
therapy,O
(,O
ECT,O
),O
often,O
receive,O
succinylcholine,I-Entity
as,O
part,O
of,O
the,O
anesthetic,O
procedure,O
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
assess,O
the,O
clinical,O
significance,O
of,O
genetic,O
variants,O
in,O
butyrylcholinesterase,O
gene,O
(,O
BCHE,O
),O
in,O
patients,O
with,O
a,O
suspected,O
prolonged,O
duration,O
of,O
action,O
of,O
succinylcholine,I-Entity
after,O
ECT,O
.,O
We,O
determined,O
the,O
BChE,O
activity,O
and,O
the,O
BCHE,O
genotype,O
using,O
molecular,O
genetic,O
methods,O
",",O
the,O
duration,O
of,O
apnea,I-Entity
",",O
time,O
to,O
sufficient,O
spontaneous,O
ventilation,O
and,O
whether,O
neuromuscular,O
monitoring,O
was,O
used,O
.,O
The,O
duration,O
of,O
apnea,I-Entity
was,O
compared,O
with,O
published,O
data,O
on,O
normal,O
subjects,O
.,O
The,O
duration,O
of,O
apnea,I-Entity
was,O
5,O
-,O
15,O
min,O
compared,O
with,O
3,O
-,O
5.3,O
min,O
from,O
the,O
literature,O
.,O
CONCLUSION,O
:,O
eleven,O
of,O
13,O
patients,O
with,O
a,O
prolonged,O
duration,O
of,O
action,O
of,O
succinylcholine,I-Entity
had,O
mutations,O
in,O
BCHE,O
",",O
indicating,O
that,O
this,O
is,O
the,O
possible,O
reason,O
for,O
a,O
prolonged,O
period,O
of,O
apnea,I-Entity
.,O
Ketamine,I-Entity
sedation,O
for,O
the,O
reduction,O
of,O
children,O
's,O
fractures,I-Entity
in,O
the,O
emergency,O
department,O
.,O
There,O
recently,O
has,O
been,O
a,O
resurgence,O
in,O
the,O
utilization,O
of,O
ketamine,I-Entity
",",O
a,O
unique,O
anesthetic,O
",",O
for,O
emergency,O
-,O
department,O
procedures,O
requiring,O
sedation,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
examine,O
the,O
safety,O
and,O
efficacy,O
of,O
ketamine,I-Entity
for,O
sedation,O
in,O
the,O
treatment,O
of,O
children,O
's,O
fractures,I-Entity
in,O
the,O
emergency,O
department,O
.,O
One,O
hundred,O
and,O
fourteen,O
children,O
(,O
average,O
age,O
",",O
5.3,O
years,O
;,O
range,O
",",O
twelve,O
months,O
to,O
ten,O
years,O
and,O
ten,O
months,O
),O
who,O
underwent,O
closed,O
reduction,O
of,O
an,O
isolated,O
fracture,I-Entity
or,O
dislocation,I-Entity
in,O
the,O
emergency,O
department,O
at,O
a,O
level,O
-,O
I,O
trauma,I-Entity
center,O
were,O
prospectively,O
evaluated,O
.,O
Ketamine,B-Entity
hydrochloride,I-Entity
was,O
administered,O
intravenously,O
(,O
at,O
a,O
dose,O
of,O
two,O
milligrams,O
per,O
kilogram,O
of,O
body,O
weight,O
),O
in,O
ninety,O
-,O
nine,O
of,O
the,O
patients,O
and,O
intramuscularly,O
(,O
at,O
a,O
dose,O
of,O
four,O
milligrams,O
per,O
kilogram,O
of,O
body,O
weight,O
),O
in,O
the,O
other,O
fifteen,O
.,O
Any,O
pain,I-Entity
during,O
the,O
reduction,O
was,O
rated,O
by,O
the,O
orthopaedic,O
surgeon,O
treating,O
the,O
patient,O
according,O
to,O
the,O
Children,O
's,O
Hospital,O
of,O
Eastern,O
Ontario,O
Pain,I-Entity
Scale,O
(,O
CHEOPS,O
),O
.,O
The,O
average,O
time,O
from,O
intravenous,O
administration,O
of,O
ketamine,I-Entity
to,O
manipulation,O
of,O
the,O
fracture,I-Entity
or,O
dislocation,I-Entity
was,O
one,O
minute,O
and,O
thirty,O
-,O
six,O
seconds,O
(,O
range,O
",",O
twenty,O
seconds,O
to,O
five,O
minutes,O
),O
",",O
and,O
the,O
average,O
time,O
from,O
intramuscular,O
administration,O
to,O
manipulation,O
was,O
four,O
minutes,O
and,O
forty,O
-,O
two,O
seconds,O
(,O
range,O
",",O
sixty,O
seconds,O
to,O
fifteen,O
minutes,O
),O
.,O
The,O
average,O
score,O
according,O
to,O
the,O
Children,O
's,O
Hospital,O
of,O
Eastern,O
Ontario,O
Pain,I-Entity
Scale,O
was,O
6.4,O
points,O
(,O
range,O
",",O
5,O
to,O
10,O
points,O
),O
",",O
reflecting,O
minimal,O
or,O
no,O
pain,I-Entity
during,O
fracture,I-Entity
reduction,O
.,O
Adequate,O
fracture,I-Entity
reduction,O
was,O
obtained,O
in,O
111,O
of,O
the,O
children,O
.,O
Minor,O
side,O
effects,O
included,O
nausea,I-Entity
(,O
thirteen,O
patients,O
),O
",",O
emesis,I-Entity
(,O
eight,O
of,O
the,O
thirteen,O
patients,O
with,O
nausea,I-Entity
),O
",",O
clumsiness,I-Entity
(,O
evident,O
as,O
ataxic,B-Entity
movements,I-Entity
in,O
ten,O
patients,O
),O
",",O
and,O
dysphoric,B-Entity
reaction,I-Entity
(,O
one,O
patient,O
),O
.,O
No,O
long,O
-,O
term,O
sequelae,O
were,O
noted,O
",",O
and,O
no,O
patients,O
had,O
hallucinations,I-Entity
or,O
nightmares,O
.,O
Ketamine,I-Entity
reliably,O
",",O
safely,O
",",O
and,O
quickly,O
provided,O
adequate,O
sedation,O
to,O
effectively,O
facilitate,O
the,O
reduction,O
of,O
children,O
's,O
fractures,I-Entity
in,O
the,O
emergency,O
department,O
at,O
our,O
institution,O
.,O
Ketamine,I-Entity
should,O
only,O
be,O
used,O
in,O
an,O
environment,O
such,O
as,O
the,O
emergency,O
department,O
",",O
where,O
proper,O
one,O
-,O
on,O
-,O
one,O
monitoring,O
is,O
used,O
and,O
board,O
-,O
certified,O
physicians,O
skilled,O
in,O
airway,O
management,O
are,O
directly,O
involved,O
in,O
the,O
care,O
of,O
the,O
patient,O
.,O
Prophylactic,O
use,O
of,O
lamivudine,I-Entity
with,O
chronic,O
immunosuppressive,O
therapy,O
for,O
rheumatologic,B-Entity
disorders,I-Entity
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
report,O
our,O
experience,O
concerning,O
the,O
effectiveness,O
of,O
the,O
prophylactic,O
administration,O
of,O
lamivudine,I-Entity
in,O
hepatitis,B-Entity
B,I-Entity
virus,I-Entity
surface,I-Entity
antigen,I-Entity
(,O
HBs,B-Entity
Ag,I-Entity
),O
positive,O
patients,O
with,O
rheumatologic,B-Entity
disease,I-Entity
.,O
From,O
June,O
2004,O
to,O
October,O
2006,O
",",O
11,O
HBs,B-Entity
Ag,I-Entity
positive,O
patients,O
with,O
rheumatologic,B-Entity
diseases,I-Entity
",",O
who,O
were,O
on,O
both,O
immunosuppressive,O
and,O
prophylactic,O
lamivudine,I-Entity
therapies,O
",",O
were,O
retrospectively,O
assessed,O
.,O
Liver,O
function,O
tests,O
",",O
hepatitis,B-Entity
B,I-Entity
virus,O
(,O
HBV,O
),O
serologic,O
markers,O
",",O
and,O
HBV,O
DNA,O
levels,O
of,O
the,O
patients,O
during,O
follow,O
-,O
up,O
were,O
obtained,O
from,O
hospital,O
file,O
records,O
.,O
Lamivudine,I-Entity
therapy,O
was,O
started,O
3,O
-,O
7,O
days,O
prior,O
to,O
immunosuppressive,O
therapy,O
in,O
all,O
patients,O
.,O
Shortly,O
after,O
treatment,O
their,O
tests,O
normalized,O
and,O
during,O
follow,O
-,O
up,O
period,O
none,O
of,O
the,O
patients,O
had,O
abnormal,B-Entity
liver,I-Entity
function,I-Entity
tests,O
.,O
Lamivudine,I-Entity
was,O
well,O
tolerated,O
and,O
was,O
continued,O
in,O
all,O
patients,O
.,O
Prophylactic,O
administration,O
of,O
lamivudine,I-Entity
in,O
patients,O
who,O
required,O
immunosuppressive,O
therapy,O
seems,O
to,O
be,O
safe,O
",",O
well,O
tolerated,O
and,O
effective,O
in,O
preventing,O
HBV,O
reactivation,O
.,O
OBJECTIVE,O
:,O
to,O
analyze,O
aspects,O
of,O
TEE,O
safety,O
associated,O
to,O
the,O
use,O
of,O
Midazolan,I-Entity
(,O
MZ,I-Entity
),O
and,O
Flumazenil,I-Entity
(,O
FL,I-Entity
),O
and,O
the,O
influence,O
of,O
the,O
clinical,O
variables,O
on,O
the,O
event,O
rate,O
.,O
METHOD,O
:,O
prospective,O
study,O
with,O
137,O
patients,O
that,O
underwent,O
TEE,O
with,O
MZ,I-Entity
associated,O
to,O
moderate,O
sedation,O
.,O
We,O
analyzed,O
the,O
following,O
events,O
:,O
complications,O
related,O
with,O
the,O
topical,O
anesthesia,O
",",O
with,O
MZ,I-Entity
use,O
and,O
with,O
the,O
procedure,O
.,O
Uni-,O
and,O
multivariate,O
analyses,O
were,O
used,O
to,O
test,O
the,O
influence,O
of,O
the,O
clinical,O
variables,O
:,O
age,O
",",O
sex,O
",",O
stroke,I-Entity
",",O
myocardiopathy,I-Entity
(,O
MP,I-Entity
),O
",",O
duration,O
of,O
the,O
test,O
",",O
mitral,B-Entity
regurgitation,I-Entity
(,O
MR,I-Entity
),O
and,O
the,O
MZ,I-Entity
dose,O
.,O
The,O
mean,O
doses,O
of,O
MZ,I-Entity
and,O
FL,I-Entity
were,O
4.3+/-1.9,O
mg,O
and,O
0.28+/-0.2,O
mg,O
",",O
respectively,O
.,O
Mild,O
hypoxia,I-Entity
(,O
SO2<90%,O
),O
was,O
the,O
most,O
common,O
event,O
(,O
11,O
patients,O
),O
;,O
3,O
patients,O
(,O
2%,O
),O
presented,O
transient,O
hypoxia,I-Entity
due,O
to,O
upper,O
airway,B-Entity
obstruction,I-Entity
by,O
probe,O
introduction,O
and,O
8,O
(,O
5.8%,O
),O
due,O
to,O
hypoxia,I-Entity
caused,O
by,O
MZ,I-Entity
use,O
.,O
Transient,O
hypotension,I-Entity
(,O
SAP<90mmHg,O
),O
occurred,O
in,O
1,O
patient,O
(,O
0.7%,O
),O
.,O
The,O
multivariate,O
analysis,O
showed,O
that,O
severe,O
MR,I-Entity
",",O
MP,I-Entity
(,O
EF<45%,O
),O
and,O
high,O
doses,O
of,O
MZ,I-Entity
(,O
>,O
5,O
mg,O
),O
were,O
associated,O
with,O
events,O
(,O
p<0.001,O
),O
.,O
The,O
EF,O
was,O
40%,O
",",O
in,O
the,O
group,O
with,O
MP,I-Entity
and,O
44%,O
in,O
the,O
group,O
with,O
severe,O
MR,I-Entity
and,O
it,O
can,O
be,O
a,O
factor,O
associated,O
with,O
clinical,O
events,O
in,O
the,O
last,O
group,O
.,O
Effects,O
of,O
calcium,I-Entity
channel,O
blockers,O
on,O
bupivacaine,I-Entity
-,O
induced,O
toxicity,I-Entity
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
investigate,O
the,O
influence,O
of,O
calcium,I-Entity
channel,O
blockers,O
on,O
bupivacaine,I-Entity
-,O
induced,O
acute,O
toxicity,I-Entity
.,O
For,O
each,O
of,O
the,O
three,O
tested,O
calcium,I-Entity
channel,O
blockers,O
(,O
diltiazem,I-Entity
",",O
verapamil,I-Entity
and,O
bepridil,I-Entity
),O
6,O
groups,O
of,O
mice,O
were,O
treated,O
by,O
two,O
different,O
doses,O
",",O
i.e.,O
2,O
and,O
10,O
mg,O
/,O
kg,O
/,O
i.p,O
.,O
",",O
or,O
an,O
equal,O
volume,O
of,O
saline,O
for,O
the,O
control,O
group,O
(,O
n,O
=,O
20,O
),O
;,O
15,O
minutes,O
later,O
",",O
all,O
the,O
animals,O
were,O
injected,O
with,O
a,O
single,O
50,O
mg,O
/,O
kg,O
/,O
i.p,O
.,O
dose,O
of,O
bupivacaine,I-Entity
.,O
The,O
local,O
anesthetic,O
-,O
induced,O
mortality,O
was,O
significantly,O
increased,O
by,O
the,O
three,O
different,O
calcium,I-Entity
channel,O
blockers,O
.,O
The,O
convulsant,O
activity,O
of,O
bupivacaine,I-Entity
was,O
not,O
significantly,O
modified,O
but,O
calcium,I-Entity
channel,O
blockers,O
decreased,O
the,O
time,O
of,O
latency,O
to,O
obtain,O
bupivacaine,I-Entity
-,O
induced,O
convulsions,I-Entity
;,O
this,O
effect,O
was,O
less,O
pronounced,O
with,O
bepridil,I-Entity
.,O
Selegiline,I-Entity
-,O
induced,O
postural,B-Entity
hypotension,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
:,O
a,O
longitudinal,O
study,O
on,O
the,O
effects,O
of,O
drug,O
withdrawal,O
.,O
The,O
United,O
Kingdom,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Research,O
Group,O
(,O
UKPDRG,O
),O
trial,O
found,O
an,O
increased,O
mortality,O
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
randomized,O
to,O
receive,O
10,O
mg,O
selegiline,I-Entity
per,O
day,O
and,O
L,B-Entity
-,I-Entity
dopa,I-Entity
compared,O
with,O
those,O
taking,O
L,B-Entity
-,I-Entity
dopa,I-Entity
alone,O
.,O
Recently,O
",",O
we,O
found,O
that,O
therapy,O
with,O
selegiline,I-Entity
and,O
L,B-Entity
-,I-Entity
dopa,I-Entity
was,O
associated,O
with,O
selective,O
systolic,B-Entity
orthostatic,I-Entity
hypotension,I-Entity
which,O
was,O
abolished,O
by,O
withdrawal,O
of,O
selegiline,I-Entity
.,O
The,O
aims,O
of,O
this,O
study,O
were,O
to,O
confirm,O
our,O
previous,O
findings,O
in,O
a,O
separate,O
cohort,O
of,O
patients,O
and,O
to,O
determine,O
the,O
time,O
course,O
of,O
the,O
cardiovascular,O
consequences,O
of,O
stopping,O
selegiline,I-Entity
in,O
the,O
expectation,O
that,O
this,O
might,O
shed,O
light,O
on,O
the,O
mechanisms,O
by,O
which,O
the,O
drug,O
causes,O
orthostatic,B-Entity
hypotension,I-Entity
.,O
The,O
cardiovascular,O
responses,O
to,O
standing,O
and,O
head,O
-,O
up,O
tilt,O
were,O
studied,O
repeatedly,O
in,O
PD,I-Entity
patients,O
receiving,O
selegiline,I-Entity
and,O
as,O
the,O
drug,O
was,O
withdrawn,O
.,O
Head,O
-,O
up,O
tilt,O
caused,O
systolic,B-Entity
orthostatic,I-Entity
hypotension,I-Entity
which,O
was,O
marked,O
in,O
six,O
of,O
20,O
PD,I-Entity
patients,O
on,O
selegiline,I-Entity
",",O
one,O
of,O
whom,O
lost,O
consciousness,O
with,O
unrecordable,O
blood,O
pressures,O
.,O
A,O
lesser,O
degree,O
of,O
orthostatic,B-Entity
hypotension,I-Entity
occurred,O
with,O
standing,O
.,O
Orthostatic,B-Entity
hypotension,I-Entity
was,O
ameliorated,O
4,O
days,O
after,O
withdrawal,O
of,O
selegiline,I-Entity
and,O
totally,O
abolished,O
7,O
days,O
after,O
discontinuation,O
of,O
the,O
drug,O
.,O
Stopping,O
selegiline,I-Entity
also,O
significantly,O
reduced,B-Entity
the,I-Entity
supine,I-Entity
systolic,I-Entity
and,I-Entity
diastolic,I-Entity
blood,I-Entity
pressures,I-Entity
consistent,O
with,O
a,O
previously,O
undescribed,O
supine,O
pressor,O
action,O
.,O
This,O
study,O
confirms,O
our,O
previous,O
finding,O
that,O
selegiline,I-Entity
in,O
combination,O
with,O
L,B-Entity
-,I-Entity
dopa,I-Entity
is,O
associated,O
with,O
selective,O
orthostatic,B-Entity
hypotension,I-Entity
.,O
The,O
possibilities,O
that,O
these,O
cardiovascular,O
findings,O
might,O
be,O
the,O
result,O
of,O
non,O
-,O
selective,O
inhibition,O
of,O
monoamine,O
oxidase,O
or,O
of,O
amphetamine,I-Entity
and,O
metamphetamine,I-Entity
are,O
discussed,O
.,O
Explicit,O
episodic,O
memory,O
for,O
sensory,O
-,O
discriminative,O
components,O
of,O
capsaicin,I-Entity
-,O
induced,O
pain,I-Entity
:,O
immediate,O
and,O
delayed,O
ratings,O
.,O
Pain,I-Entity
memory,O
is,O
thought,O
to,O
affect,O
future,O
pain,I-Entity
sensitivity,O
and,O
thus,O
contribute,O
to,O
clinical,O
pain,I-Entity
conditions,O
.,O
Systematic,O
investigations,O
of,O
the,O
human,O
capacity,O
to,O
remember,O
sensory,O
features,O
of,O
experimental,O
pain,I-Entity
are,O
sparse,O
.,O
In,O
order,O
to,O
address,O
long,O
-,O
term,O
pain,I-Entity
memory,O
",",O
nine,O
healthy,O
male,O
volunteers,O
received,O
intradermal,O
injections,O
of,O
three,O
doses,O
of,O
capsaicin,I-Entity
(,O
0.05,O
",",O
1,O
and,O
20,O
microg,O
",",O
separated,O
by,O
15,O
min,O
breaks,O
),O
",",O
each,O
given,O
three,O
times,O
in,O
a,O
balanced,O
design,O
across,O
three,O
sessions,O
at,O
one,O
week,O
intervals,O
.,O
Pain,I-Entity
rating,O
was,O
performed,O
using,O
a,O
computerized,O
visual,O
analogue,O
scale,O
(,O
0,O
-,O
100,O
),O
digitized,O
at,O
1/s,O
",",O
either,O
immediately,O
online,O
or,O
one,O
hour,O
or,O
one,O
day,O
after,O
injection,O
.,O
Subjects,O
also,O
recalled,O
their,O
pains,I-Entity
one,O
week,O
later,O
.,O
Capsaicin,I-Entity
injection,O
reliably,O
induced,O
a,O
dose,O
-,O
dependent,O
flare,O
(,O
p<0.001,O
),O
without,O
any,O
difference,O
within,O
or,O
across,O
sessions,O
.,O
The,O
strong,O
burning,O
pain,I-Entity
decayed,O
exponentially,O
within,O
a,O
few,O
minutes,O
.,O
Subjects,O
were,O
able,O
to,O
reliably,O
discriminate,O
pain,I-Entity
magnitude,O
and,O
duration,O
across,O
capsaicin,I-Entity
doses,O
(,O
both,O
p<0.001,O
),O
",",O
regardless,O
of,O
whether,O
first,O
-,O
time,O
ratings,O
were,O
requested,O
immediately,O
",",O
after,O
one,O
hour,O
or,O
after,O
one,O
day,O
.,O
Pain,I-Entity
recall,O
after,O
one,O
week,O
was,O
similarly,O
precise,O
(,O
magnitude,O
:,O
These,O
results,O
indicate,O
a,O
reliable,O
memory,O
for,O
magnitude,O
and,O
duration,O
of,O
experimentally,O
induced,O
pain,I-Entity
.,O
Reversibility,O
of,O
captopril,I-Entity
-,O
induced,O
renal,B-Entity
insufficiency,I-Entity
after,O
prolonged,O
use,O
in,O
an,O
unusual,O
case,O
of,O
renovascular,B-Entity
hypertension,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
severe,O
hypertension,I-Entity
with,O
an,O
occluded,O
renal,O
artery,O
to,O
a,O
solitary,O
kidney,O
",",O
who,O
developed,O
sudden,B-Entity
deterioration,I-Entity
of,I-Entity
renal,I-Entity
function,I-Entity
following,O
treatment,O
with,O
captopril,I-Entity
.,O
His,O
renal,O
function,O
remained,O
impaired,O
but,O
stable,O
during,O
2,O
years,O
',O
treatment,O
with,O
captopril,I-Entity
but,O
returned,O
to,O
pre,O
-,O
treatment,O
levels,O
soon,O
after,O
cessation,O
of,O
the,O
drug,O
.,O
This,O
indicates,O
reversibility,O
in,O
captopril,I-Entity
-,O
induced,O
renal,B-Entity
failure,I-Entity
even,O
after,O
its,O
prolonged,O
use,O
and,O
suggests,O
that,O
no,O
organic,O
damage,O
occurs,O
to,O
glomerular,O
arterioles,O
following,O
chronic,O
ACE,O
inhibition,O
.,O
Liver,B-Entity
disease,I-Entity
caused,O
by,O
propylthiouracil,I-Entity
.,O
This,O
report,O
presents,O
the,O
clinical,O
",",O
laboratory,O
",",O
and,O
light,O
and,O
electron,O
microscopic,O
observations,O
on,O
a,O
patient,O
with,O
chronic,B-Entity
active,I-Entity
(,I-Entity
aggressive,I-Entity
),I-Entity
hepatitis,I-Entity
caused,O
by,O
the,O
administration,O
of,O
propylthiouracil,I-Entity
.,O
This,O
is,O
an,O
addition,O
to,O
the,O
list,O
of,O
drugs,O
that,O
must,O
be,O
considered,O
in,O
the,O
evaluation,O
of,O
chronic,O
liver,B-Entity
disease,I-Entity
.,O
Capsaicin,I-Entity
-,O
induced,O
muscle,B-Entity
pain,I-Entity
alters,O
the,O
excitability,O
of,O
the,O
human,O
jaw,O
-,O
stretch,O
reflex,O
.,O
The,O
pathophysiology,O
of,O
painful,O
temporomandibular,B-Entity
disorders,I-Entity
is,O
not,O
fully,O
understood,O
",",O
but,O
evidence,O
suggests,O
that,O
muscle,B-Entity
pain,I-Entity
modulates,O
motor,O
function,O
in,O
characteristic,O
ways,O
.,O
This,O
study,O
tested,O
the,O
hypothesis,O
that,O
activation,O
of,O
nociceptive,B-Entity
muscle,I-Entity
afferent,O
fibers,O
would,O
be,O
linked,O
to,O
an,O
increased,O
excitability,O
of,O
the,O
human,O
jaw,O
-,O
stretch,O
reflex,O
and,O
whether,O
this,O
process,O
would,O
be,O
sensitive,O
to,O
length,O
and,O
velocity,O
of,O
the,O
stretch,O
.,O
Capsaicin,I-Entity
(,O
10,O
micro,O
g,O
),O
was,O
injected,O
into,O
the,O
masseter,O
muscle,O
to,O
induce,O
pain,I-Entity
in,O
11,O
healthy,O
volunteers,O
.,O
Short,O
-,O
latency,O
reflex,O
responses,O
were,O
evoked,O
in,O
the,O
masseter,O
and,O
temporalis,O
muscles,O
by,O
a,O
stretch,O
device,O
with,O
different,O
velocities,O
and,O
displacements,O
before,O
",",O
during,O
",",O
and,O
after,O
the,O
pain,I-Entity
.,O
The,O
normalized,O
reflex,O
amplitude,O
was,O
significantly,O
higher,O
during,O
pain,I-Entity
",",O
but,O
only,O
at,O
faster,O
stretches,O
in,O
the,O
painful,B-Entity
muscle,I-Entity
.,O
Increased,O
sensitivity,O
of,O
the,O
fusimotor,O
system,O
during,O
acute,O
muscle,B-Entity
pain,I-Entity
could,O
be,O
one,O
likely,O
mechanism,O
to,O
explain,O
the,O
findings,O
.,O
Repetitive,O
transcranial,O
magnetic,O
stimulation,O
for,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
In,O
a,O
placebo,O
-,O
controlled,O
",",O
single,O
-,O
blinded,O
",",O
crossover,O
study,O
",",O
we,O
assessed,O
the,O
effect,O
of,O
"""",O
real,O
"""",O
repetitive,O
transcranial,O
magnetic,O
stimulation,O
(,O
rTMS,O
),O
versus,O
"""",O
sham,O
"""",O
rTMS,O
(,O
placebo,O
),O
on,O
peak,O
dose,O
dyskinesias,I-Entity
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
.,O
Ten,O
patients,O
with,O
PD,I-Entity
and,O
prominent,O
dyskinesias,I-Entity
had,O
rTMS,O
(,O
"1,800",O
pulses,O
;,O
1,O
Hz,O
rate,O
),O
delivered,O
over,O
the,O
motor,O
cortex,O
for,O
4,O
consecutive,O
days,O
twice,O
",",O
once,O
real,O
stimuli,O
and,O
once,O
sham,O
stimulation,O
were,O
used,O
;,O
evaluations,O
were,O
done,O
at,O
the,O
baseline,O
and,O
1,O
day,O
after,O
the,O
end,O
of,O
each,O
of,O
the,O
treatment,O
series,O
.,O
Direct,O
comparison,O
between,O
sham,O
and,O
real,O
rTMS,O
effects,O
showed,O
no,O
significant,O
difference,O
in,O
clinician,O
-,O
assessed,O
dyskinesia,I-Entity
severity,O
.,O
However,O
",",O
comparison,O
with,O
the,O
baseline,O
showed,O
small,O
but,O
significant,O
reduction,O
in,O
dyskinesia,I-Entity
severity,O
following,O
real,O
rTMS,O
but,O
not,O
placebo,O
.,O
The,O
major,O
effect,O
was,O
on,O
dystonia,I-Entity
subscore,O
.,O
Similarly,O
",",O
in,O
patient,O
diaries,O
",",O
although,O
both,O
treatments,O
caused,O
reduction,O
in,O
subjective,O
dyskinesia,I-Entity
scores,O
during,O
the,O
days,O
of,O
intervention,O
",",O
the,O
effect,O
was,O
sustained,O
for,O
3,O
days,O
after,O
the,O
intervention,O
for,O
the,O
real,O
rTMS,O
only,O
.,O
Following,O
rTMS,O
",",O
no,O
side,O
effects,O
and,O
no,O
adverse,O
effects,O
on,O
motor,O
function,O
and,O
PD,I-Entity
symptoms,O
were,O
noted,O
.,O
The,O
results,O
suggest,O
the,O
existence,O
of,O
residual,O
beneficial,O
clinical,O
aftereffects,O
of,O
consecutive,O
daily,O
applications,O
of,O
low,O
-,O
frequency,O
rTMS,O
on,O
dyskinesias,I-Entity
in,O
PD,I-Entity
.,O
Disulfiram,I-Entity
-,O
like,O
syndrome,O
after,O
hydrogen,B-Entity
cyanamide,I-Entity
professional,O
skin,O
exposure,O
:,O
two,O
case,O
reports,O
in,O
France,O
.,O
Hydrogen,B-Entity
cyanamide,I-Entity
is,O
a,O
plant,O
growth,O
regulator,O
used,O
in,O
agriculture,O
to,O
induce,O
bud,O
break,O
in,O
fruit,O
trees,O
.,O
Contact,O
with,O
the,O
skin,O
can,O
result,O
in,O
percutaneous,O
absorption,O
of,O
the,O
substance,O
that,O
inhibits,O
aldehyde,I-Entity
dehydrogenase,O
and,O
can,O
induce,O
acetaldehyde,I-Entity
syndrome,O
in,O
case,O
of,O
alcohol,I-Entity
use,O
.,O
The,O
purpose,O
of,O
this,O
report,O
is,O
to,O
describe,O
two,O
cases,O
of,O
a,O
disulfiram,I-Entity
-,O
like,O
syndrome,O
following,O
occupational,O
exposure,O
to,O
hydrogen,B-Entity
cyanamide,I-Entity
.,O
The,O
first,O
case,O
involved,O
a,O
59-year,O
-,O
old,O
man,O
who,O
used,O
Dormex,I-Entity
",",O
which,O
contains,O
hydrogen,B-Entity
cyanamide,I-Entity
",",O
without,O
protection,O
after,O
consuming,O
a,O
large,O
amount,O
of,O
alcohol,I-Entity
during,O
a,O
meal,O
.,O
In,O
less,O
than,O
1,O
hour,O
after,O
the,O
ingestion,O
of,O
alcohol,I-Entity
",",O
he,O
developed,O
malaise,O
with,O
flushing,B-Entity
of,I-Entity
the,I-Entity
face,I-Entity
",",O
tachycardia,I-Entity
",",O
and,O
dyspnea,I-Entity
.,O
The,O
second,O
case,O
occurred,O
in,O
a,O
55-year,O
-,O
old,O
farmer,O
following,O
cutaneous,O
contact,O
with,O
Dormex,I-Entity
.,O
Five,O
hours,O
after,O
exposure,O
",",O
he,O
developed,O
disulfiram,I-Entity
-,O
like,O
syndrome,O
with,O
flushing,I-Entity
",",O
tachycardia,I-Entity
",",O
and,O
arterial,B-Entity
hypotension,I-Entity
after,O
consuming,O
three,O
glasses,O
of,O
wine,O
.,O
These,O
cases,O
confirm,O
the,O
necessity,O
of,O
avoiding,O
alcohol,I-Entity
consumption,O
as,O
recommended,O
in,O
the,O
instructions,O
for,O
use,O
of,O
Dormex,I-Entity
and,O
of,O
preventing,O
cutaneous,O
contact,O
during,O
use,O
.,O
Repeated,O
trimipramine,I-Entity
induces,O
dopamine,I-Entity
D2/D3,O
and,O
alpha1-adrenergic,O
up,O
-,O
regulation,O
.,O
Trimipramine,I-Entity
(,O
TRI,I-Entity
),O
",",O
which,O
shows,O
a,O
clinical,O
antidepressant,I-Entity
activity,O
",",O
is,O
chemically,O
related,O
to,O
imipramine,I-Entity
but,O
does,O
not,O
inhibit,O
the,O
reuptake,O
of,O
noradrenaline,I-Entity
and,O
5-hydroxytryptamine,I-Entity
",",O
nor,O
does,O
it,O
induce,O
beta,O
-,O
adrenergic,O
down,O
-,O
regulation,O
.,O
The,O
mechanism,O
of,O
its,O
antidepressant,I-Entity
activity,O
is,O
still,O
unknown,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
find,O
out,O
whether,O
TRI,I-Entity
given,O
repeatedly,O
was,O
able,O
to,O
induce,O
adaptive,O
changes,O
in,O
the,O
dopaminergic,O
and,O
alpha1-adrenergic,O
systems,O
",",O
demonstrated,O
by,O
us,O
previously,O
for,O
various,O
antidepressants,I-Entity
.,O
TRI,I-Entity
was,O
given,O
to,O
male,O
Wistar,O
rats,O
and,O
male,O
Albino,O
Swiss,O
mice,O
perorally,O
twice,O
daily,O
for,O
14,O
days,O
.,O
In,O
the,O
acute,O
experiment,O
TRI,I-Entity
(,O
given,O
i.p,O
.,O
),O
does,O
not,O
antagonize,O
the,O
reserpine,I-Entity
hypothermia,I-Entity
in,O
mice,O
and,O
does,O
not,O
potentiate,O
the,O
5-hydroxytryptophan,I-Entity
head,O
twitches,O
in,O
rats,O
.,O
TRI,I-Entity
given,O
repeatedly,O
to,O
rats,O
increases,O
the,O
locomotor,O
hyperactivity,I-Entity
induced,O
by,O
d,B-Entity
-,I-Entity
amphetamine,I-Entity
",",O
quinpirole,I-Entity
and,O
(,O
+,O
),O
-7-hydroxy,O
-,O
dipropyloaminotetralin,O
(,O
dopamine,I-Entity
D2,O
and,O
D3,O
effects,O
),O
.,O
The,O
stereotypies,O
induced,O
by,O
d,B-Entity
-,I-Entity
amphetamine,I-Entity
or,O
apomorphine,I-Entity
are,O
not,O
potentiated,O
by,O
TRI,I-Entity
.,O
It,O
increases,O
the,O
behaviour,O
stimulation,O
evoked,O
by,O
phenylephrine,I-Entity
(,O
given,O
intraventricularly,O
),O
in,O
rats,O
",",O
evaluated,O
in,O
the,O
open,O
field,O
test,O
as,O
well,O
as,O
the,O
aggressiveness,I-Entity
evoked,O
by,O
clonidine,I-Entity
in,O
mice,O
",",O
both,O
these,O
effects,O
being,O
mediated,O
by,O
an,O
alpha1-adrenergic,O
receptor,O
.,O
It,O
may,O
be,O
concluded,O
that,O
",",O
like,O
other,O
tricyclic,O
antidepressants,I-Entity
studied,O
previously,O
",",O
TRI,I-Entity
given,O
repeatedly,O
increases,O
the,O
responsiveness,O
of,O
brain,O
dopamine,I-Entity
D2,O
and,O
D3,O
(,O
locomotor,O
activity,O
but,O
not,O
stereotypy,O
),O
as,O
well,O
as,O
alpha1-adrenergic,O
receptors,O
to,O
their,O
agonists,O
.,O
A,O
question,O
arises,O
whether,O
the,O
reuptake,O
inhibition,O
is,O
of,O
any,O
importance,O
to,O
the,O
adaptive,O
changes,O
induced,O
by,O
repeated,O
antidepressants,I-Entity
",",O
suggested,O
to,O
be,O
responsible,O
for,O
the,O
antidepressant,I-Entity
activity,O
.,O
Ranitidine,I-Entity
-,O
induced,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
in,O
a,O
cadaveric,O
renal,O
allograft,O
.,O
Ranitidine,I-Entity
frequently,O
is,O
used,O
for,O
preventing,O
peptic,O
ulceration,O
after,O
renal,O
transplantation,O
.,O
This,O
drug,O
occasionally,O
has,O
been,O
associated,O
with,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
in,O
native,O
kidneys,O
.,O
We,O
report,O
a,O
case,O
of,O
ranitidine,I-Entity
-,O
induced,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
in,O
a,O
recipient,O
of,O
a,O
cadaveric,O
renal,O
allograft,O
presenting,O
with,O
acute,O
allograft,O
dysfunction,O
within,O
48,O
hours,O
of,O
exposure,O
to,O
the,O
drug,O
.,O
Late,O
",",O
late,O
doxorubicin,I-Entity
cardiotoxicity,I-Entity
.,O
Cardiac,B-Entity
toxicity,I-Entity
is,O
a,O
major,O
complication,O
which,O
limits,O
the,O
use,O
of,O
adriamycin,I-Entity
as,O
a,O
chemotherapeutic,O
agent,O
.,O
Cardiomyopathy,I-Entity
is,O
frequent,O
when,O
the,O
total,O
dose,O
exceeds,O
600,O
mg,O
/,O
m2,O
and,O
occurs,O
within,O
one,O
to,O
six,O
months,O
after,O
cessation,O
of,O
therapy,O
.,O
A,O
patient,O
is,O
reported,O
who,O
developed,O
progressive,O
cardiomyopathy,I-Entity
two,O
and,O
one,O
-,O
half,O
years,O
after,O
receiving,O
580,O
mg,O
/,O
m2,O
which,O
apparently,O
represents,O
late,O
",",O
late,O
cardiotoxicity,I-Entity
.,O
Acetazolamide,I-Entity
-,O
induced,O
nephrolithiasis,I-Entity
:,O
implications,O
for,O
treatment,O
of,O
neuromuscular,B-Entity
disorders,I-Entity
.,O
Carbonic,O
anhydrase,O
inhibitors,O
can,O
cause,O
nephrolithiasis,I-Entity
.,O
We,O
studied,O
20,O
patients,O
receiving,O
long,O
-,O
term,O
carbonic,O
anhydrase,O
inhibitor,O
treatment,O
for,O
periodic,O
paralysis,I-Entity
and,O
myotonia,I-Entity
.,O
Three,O
patients,O
on,O
acetazolamide,I-Entity
(,O
15%,O
),O
developed,O
renal,B-Entity
calculi,I-Entity
.,O
Extracorporeal,O
lithotripsy,O
successfully,O
removed,O
a,O
renal,B-Entity
calculus,I-Entity
in,O
one,O
patient,O
and,O
surgery,O
removed,O
a,O
staghorn,O
calculus,I-Entity
in,O
another,O
",",O
permitting,O
continued,O
treatment,O
.,O
Nephrolithiasis,I-Entity
is,O
a,O
complication,O
of,O
acetazolamide,I-Entity
but,O
does,O
not,O
preclude,O
its,O
use,O
.,O
Is,O
the,O
treatment,O
of,O
scabies,I-Entity
hazardous,O
?,O
Treatment,O
for,O
scabies,I-Entity
is,O
usually,O
initiated,O
by,O
general,O
practitioners,O
;,O
most,O
consider,O
lindane,I-Entity
(,O
gamma,B-Entity
benzene,I-Entity
hexachloride,I-Entity
),O
the,O
treatment,O
of,O
choice,O
.,O
Lindane,I-Entity
is,O
also,O
widely,O
used,O
as,O
an,O
agricultural,O
and,O
industrial,O
pesticide,O
",",O
and,O
as,O
a,O
result,O
the,O
toxic,O
profile,O
of,O
this,O
insecticide,O
is,O
well,O
understood,O
.,O
Evidence,O
is,O
accumulating,O
that,O
lindane,I-Entity
can,O
be,O
toxic,B-Entity
to,I-Entity
the,I-Entity
central,I-Entity
nervous,I-Entity
system,I-Entity
and,O
may,O
be,O
associated,O
with,O
aplastic,B-Entity
anaemia,I-Entity
.,O
Preparations,O
containing,O
lindane,I-Entity
continue,O
to,O
be,O
sold,O
over,O
the,O
counter,O
and,O
may,O
represent,O
a,O
hazard,O
to,O
poorly,O
informed,O
patients,O
.,O
This,O
literature,O
review,O
suggests,O
that,O
general,O
practitioners,O
should,O
prescribe,O
scabicides,O
with,O
increased,O
caution,O
for,O
certain,O
at,O
-,O
risk,O
groups,O
",",O
and,O
give,O
adequate,O
warnings,O
regarding,O
potential,O
toxicity,I-Entity
.,O
Anaesthetists,O
',O
nightmare,O
:,O
masseter,B-Entity
spasm,I-Entity
after,O
induction,O
in,O
an,O
undiagnosed,O
case,O
of,O
myotonia,B-Entity
congenita,I-Entity
.,O
We,O
report,O
an,O
undiagnosed,O
case,O
of,O
myotonia,B-Entity
congenita,I-Entity
in,O
a,O
24-year,O
-,O
old,O
previously,O
healthy,O
primigravida,O
",",O
who,O
developed,O
life,O
threatening,O
masseter,B-Entity
spasm,I-Entity
following,O
a,O
standard,O
dose,O
of,O
intravenous,O
suxamethonium,I-Entity
for,O
induction,O
of,O
anaesthesia,O
.,O
Toxicity,I-Entity
in,O
rhesus,O
monkeys,O
following,O
administration,O
of,O
the,O
8-aminoquinoline,I-Entity
8-[(4-amino,B-Entity
-,I-Entity
l,I-Entity
-,I-Entity
methylbutyl)amino]-,I-Entity
5-(l,I-Entity
-,I-Entity
hexyloxy)-6-methoxy-4-methylquinoline,I-Entity
(,O
WR242511,I-Entity
),O
.,O
INTRODUCTION,O
:,O
Many,O
substances,O
that,O
form,O
methemoglobin,O
(,O
MHb,O
),O
effectively,O
counter,O
cyanide,O
(,O
CN,O
),O
toxicity,I-Entity
.,O
Although,O
MHb,O
formers,O
are,O
generally,O
applied,O
as,O
treatments,O
for,O
CN,O
poisoning,I-Entity
",",O
it,O
has,O
been,O
proposed,O
that,O
a,O
stable,O
",",O
long,O
-,O
acting,O
MHb,O
former,O
could,O
serve,O
as,O
a,O
CN,O
pretreatment,O
.,O
Using,O
this,O
rationale,O
",",O
the,O
8-aminoquinoline,I-Entity
WR242511,I-Entity
",",O
a,O
potent,O
long,O
-,O
lasting,O
MHb,O
former,O
in,O
rodents,O
and,O
beagle,O
dogs,O
",",O
was,O
studied,O
in,O
the,O
rhesus,O
monkey,O
for,O
advanced,O
development,O
as,O
a,O
potential,O
CN,O
pretreatment,O
.,O
METHODS,O
:,O
In,O
this,O
study,O
",",O
WR242511,I-Entity
was,O
administered,O
intravenously,O
(,O
IV,O
),O
in,O
2,O
female,O
and,O
4,O
male,O
rhesus,O
monkeys,O
in,O
doses,O
of,O
3.5,O
and/or,O
7.0,O
mg,O
/,O
kg,O
;,O
a,O
single,O
male,O
also,O
received,O
WR242511,I-Entity
orally,O
(,O
PO,O
),O
at,O
7.0,O
mg,O
/,O
kg,O
.,O
The,O
selected,O
doses,O
of,O
WR242511,I-Entity
",",O
which,O
produced,O
significant,O
methemoglobinemia,I-Entity
in,O
beagle,O
dogs,O
in,O
earlier,O
studies,O
conducted,O
elsewhere,O
",",O
produced,O
very,O
little,O
MHb,O
(,O
mean,O
<,O
2.0%,O
),O
in,O
the,O
rhesus,O
monkey,O
.,O
Furthermore,O
",",O
transient,O
hemoglobinuria,I-Entity
was,O
noted,O
approximately,O
60,O
minutes,O
postinjection,O
of,O
WR242511,I-Entity
(,O
3.5,O
or,O
7.0,O
mg,O
/,O
kg,O
),O
",",O
and,O
2,O
lethalities,O
occurred,O
(,O
one,O
IV,O
and,O
one,O
PO,O
),O
following,O
the,O
7.0,O
mg,O
/,O
kg,O
dose,O
.,O
Myoglobinuria,I-Entity
was,O
also,O
observed,O
following,O
the,O
7.0,O
mg,O
/,O
kg,O
dose,O
.,O
Histopathology,O
analyses,O
in,O
the,O
2,O
animals,O
that,O
died,O
revealed,O
liver,B-Entity
and,I-Entity
kidney,I-Entity
toxicity,I-Entity
",",O
with,O
greater,O
severity,O
in,O
the,O
orally,O
-,O
treated,O
animal,O
.,O
These,O
data,O
demonstrate,O
direct,O
and/or,O
indirect,O
drug,O
-,O
induced,O
toxicity,I-Entity
.,O
It,O
is,O
concluded,O
that,O
WR242511,I-Entity
should,O
not,O
be,O
pursued,O
as,O
a,O
pretreatment,O
for,O
CN,O
poisoning,I-Entity
unless,O
the,O
anti,O
-,O
CN,O
characteristics,O
of,O
this,O
compound,O
can,O
be,O
successfully,O
dissociated,O
from,O
those,O
producing,O
undesirable,O
toxicity,I-Entity
.,O
Neuroplasticity,O
of,O
the,O
adult,O
primate,O
auditory,O
cortex,O
following,O
cochlear,O
hearing,B-Entity
loss,I-Entity
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
determine,O
if,O
changes,O
occur,O
in,O
this,O
tonotopic,O
organization,O
following,O
cochlear,O
hearing,B-Entity
loss,I-Entity
.,O
Following,O
recovery,O
",",O
the,O
monkeys,O
were,O
selectively,O
deafened,O
for,O
high,O
frequencies,O
using,O
kanamycin,I-Entity
and,O
furosemide,I-Entity
.,O
The,O
region,O
of,O
cortex,O
that,O
represents,O
the,O
low,O
frequencies,O
was,O
not,O
obviously,O
affected,O
by,O
the,O
cochlear,O
hearing,B-Entity
loss,I-Entity
.,O
The,O
site,O
of,O
common,O
side,O
effects,O
of,O
sumatriptan,I-Entity
.,O
Atypical,B-Entity
sensations,I-Entity
following,O
the,O
use,O
of,O
subcutaneous,O
sumatriptan,I-Entity
are,O
common,O
",",O
but,O
of,O
uncertain,O
origin,O
.,O
Two,O
patients,O
are,O
presented,O
with,O
tingling,B-Entity
or,I-Entity
burning,I-Entity
sensations,I-Entity
limited,O
to,O
areas,O
of,O
heat,O
exposure,O
or,O
sunburn,I-Entity
.,O
Tremor,I-Entity
side,O
effects,O
of,O
salbutamol,I-Entity
",",O
quantified,O
by,O
a,O
laser,O
pointer,O
technique,O
.,O
OBJECTIVE,O
:,O
To,O
study,O
tremor,I-Entity
side,O
effects,O
of,O
salbutamol,I-Entity
an,O
easily,O
applicable,O
",",O
quick,O
and,O
low,O
-,O
priced,O
method,O
is,O
needed,O
.,O
METHODS,O
:,O
Tremor,I-Entity
was,O
measured,O
using,O
a,O
laser,O
pointer,O
technique,O
.,O
To,O
determine,O
sensitivity,O
we,O
assessed,O
tremor,I-Entity
in,O
44,O
patients,O
with,O
obstructive,B-Entity
lung,I-Entity
disease,I-Entity
after,O
administration,O
of,O
cumulative,O
doses,O
of,O
salbutamol,I-Entity
.,O
In,O
another,O
series,O
of,O
measurements,O
",",O
reproducibility,O
and,O
reference,O
values,O
of,O
the,O
tremor,I-Entity
was,O
assessed,O
in,O
65,O
healthy,O
subjects,O
in,O
three,O
sessions,O
",",O
at,O
9,O
a.m.,O
",",O
4,O
p.m.,O
and,O
9,O
a.m.,O
",",O
respectively,O
",",O
1,O
week,O
later,O
.,O
Postural,O
tremor,I-Entity
was,O
measured,O
with,O
the,O
arm,O
horizontally,O
outstretched,O
rest,O
tremor,I-Entity
with,O
the,O
arm,O
supported,O
by,O
an,O
armrest,O
and,O
finally,O
tremor,I-Entity
was,O
measured,O
after,O
holding,O
a,O
2-kg,O
weight,O
until,O
exhaustion,O
.,O
Tremor,I-Entity
was,O
measured,O
simultaneously,O
by,O
two,O
independent,O
observers,O
.,O
Salbutamol,I-Entity
significantly,O
increased,O
tremor,I-Entity
severity,O
in,O
patients,O
in,O
a,O
dose,O
-,O
dependent,O
way,O
.,O
There,O
was,O
no,O
agreement,O
between,O
the,O
questionnaire,O
and,O
tremor,I-Entity
severity,O
(,O
r,O
=,O
0.093,O
;,O
P,O
=,O
0.53,O
),O
.,O
Postural,O
tremor,I-Entity
showed,O
no,O
significant,O
difference,O
between,O
the,O
first,O
and,O
third,O
session,O
(,O
P,O
=,O
0.07,O
),O
.,O
Support,O
of,O
the,O
arm,O
decreased,O
tremor,I-Entity
severity,O
",",O
exhaustion,O
increased,O
tremor,I-Entity
severity,O
significantly,O
.,O
DISCUSSION,O
:,O
Quantifying,O
tremor,I-Entity
by,O
using,O
an,O
inexpensive,O
laser,O
pointer,O
is,O
",",O
with,O
the,O
exception,O
of,O
children,O
(,O
<,O
12,O
years,O
),O
a,O
sensitive,O
and,O
reproducible,O
method,O
.,O
Increased,O
frequency,O
of,O
venous,B-Entity
thromboembolism,I-Entity
with,O
the,O
combination,O
of,O
docetaxel,I-Entity
and,O
thalidomide,I-Entity
in,O
patients,O
with,O
metastatic,O
androgen,O
-,O
independent,O
prostate,B-Entity
cancer,I-Entity
.,O
STUDY,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
frequency,O
of,O
venous,B-Entity
thromboembolism,I-Entity
(,O
VTE,I-Entity
),O
in,O
patients,O
with,O
advanced,O
androgen,O
-,O
independent,O
prostate,B-Entity
cancer,I-Entity
who,O
were,O
treated,O
with,O
docetaxel,I-Entity
alone,O
or,O
in,O
combination,O
with,O
thalidomide,I-Entity
.,O
PATIENTS,O
:,O
Seventy,O
men,O
",",O
aged,O
50,O
-,O
80,O
years,O
",",O
with,O
advanced,O
androgen,O
-,O
independent,O
prostate,B-Entity
cancer,I-Entity
.,O
Each,O
patient,O
received,O
either,O
intravenous,O
docetaxel,I-Entity
30,O
mg,O
/,O
m2/week,O
for,O
3,O
consecutive,O
weeks,O
",",O
followed,O
by,O
1,O
week,O
off,O
",",O
or,O
the,O
combination,O
of,O
continuous,O
oral,O
thalidomide,I-Entity
200,O
mg,O
every,O
evening,O
plus,O
the,O
same,O
docetaxel,I-Entity
regimen,O
.,O
This,O
4-week,O
cycle,O
was,O
repeated,O
until,O
there,O
was,O
evidence,O
of,O
excessive,O
toxicity,I-Entity
or,O
disease,O
progression,O
.,O
MEASUREMENTS,O
AND,O
MAIN,O
RESULTS,O
:,O
None,O
of,O
23,O
patients,O
who,O
received,O
docetaxel,I-Entity
alone,O
developed,O
VTE,I-Entity
",",O
whereas,O
9,O
of,O
47,O
patients,O
(,O
19%,O
),O
who,O
received,O
docetaxel,I-Entity
plus,O
thalidomide,I-Entity
developed,O
VTE,I-Entity
(,O
p=0.025,O
),O
.,O
The,O
addition,O
of,O
thalidomide,I-Entity
to,O
docetaxel,I-Entity
in,O
the,O
treatment,O
of,O
prostate,B-Entity
cancer,I-Entity
significantly,O
increases,O
the,O
frequency,O
of,O
VTE,I-Entity
.,O
Clinicians,O
should,O
be,O
aware,O
of,O
this,O
potential,O
complication,O
when,O
adding,O
thalidomide,I-Entity
to,O
chemotherapeutic,O
regimens,O
.,O
Sublingual,O
absorption,O
of,O
the,O
quaternary,B-Entity
ammonium,I-Entity
antiarrhythmic,O
agent,O
",",O
UM-272,I-Entity
.,O
UM-272,I-Entity
(,O
N,B-Entity
",",I-Entity
N,I-Entity
-,I-Entity
dimethylpropranolol,I-Entity
),O
",",O
a,O
quaternary,O
antiarrhythmic,O
agent,O
",",O
was,O
administered,O
sublingually,O
to,O
dogs,O
with,O
ouabain,I-Entity
-,O
induced,O
ventricular,B-Entity
tachycardias,I-Entity
.,O
Sublingual,O
UM-272,I-Entity
converted,O
ventricular,B-Entity
tachycardia,I-Entity
to,O
sinus,O
rhythm,O
in,O
all,O
5,O
dogs,O
.,O
Severe,O
thrombocytopenia,I-Entity
and,O
haemolytic,B-Entity
anaemia,I-Entity
associated,O
with,O
ciprofloxacin,I-Entity
:,O
a,O
case,O
report,O
with,O
fatal,O
outcome,O
.,O
Haematological,O
adverse,O
reactions,O
associated,O
with,O
fatal,O
outcome,O
are,O
rare,O
during,O
treatment,O
with,O
ciprofloxacin,I-Entity
.,O
A,O
30-year,O
old,O
Caucasian,O
man,O
reported,O
with,O
abdominal,B-Entity
pain,I-Entity
and,O
jaundice,I-Entity
after,O
3-day,O
administration,O
of,O
oral,O
ciprofloxacin,I-Entity
for,O
a,O
suspect,O
of,O
urinary,B-Entity
tract,I-Entity
infection,I-Entity
.,O
Clinical,O
evaluations,O
suggested,O
an,O
initial,O
diagnosis,O
of,O
severe,O
thrombocytopenia,I-Entity
and,O
haemolysis,I-Entity
.,O
The,O
patient,O
progressively,O
developed,O
petechiae,I-Entity
and,O
purpura,I-Entity
on,O
thorax,O
and,O
lower,O
limbs,O
.,O
An,O
accurate,O
autopsy,O
revealed,O
most,O
organs,O
with,O
diffuse,O
petechial,O
haemorrhages,I-Entity
.,O
No,O
signs,O
of,O
bone,B-Entity
marrow,I-Entity
depression,I-Entity
were,O
found,O
.,O
No,O
thrombi,I-Entity
or,O
signs,O
of,O
microangiopathies,I-Entity
were,O
observed,O
in,O
arterial,O
vessels,O
.,O
This,O
case,O
report,O
shows,O
that,O
ciprofloxacin,I-Entity
may,O
precipitate,O
life,O
-,O
threatening,O
thrombocytopenia,I-Entity
and,O
haemolytic,B-Entity
anaemia,I-Entity
",",O
even,O
in,O
the,O
early,O
phases,O
of,O
treatment,O
and,O
without,O
apparent,O
previous,O
exposures,O
.,O
Simvastatin,I-Entity
-,O
induced,O
bilateral,O
leg,O
compartment,B-Entity
syndrome,I-Entity
and,O
myonecrosis,I-Entity
associated,O
with,O
hypothyroidism,I-Entity
.,O
A,O
54-year,O
-,O
old,O
hypothyroid,I-Entity
male,O
taking,O
thyroxine,I-Entity
and,O
simvastatin,I-Entity
presented,O
with,O
bilateral,O
leg,O
compartment,B-Entity
syndrome,I-Entity
and,O
myonecrosis,I-Entity
.,O
Urgent,O
fasciotomies,O
were,O
performed,O
and,O
the,O
patient,O
made,O
an,O
uneventful,O
recovery,O
with,O
the,O
withdrawal,O
of,O
simvastatin,I-Entity
.,O
It,O
is,O
likely,O
that,O
this,O
complication,O
will,O
be,O
seen,O
more,O
often,O
with,O
the,O
increased,O
worldwide,O
use,O
of,O
this,O
drug,O
and,O
its,O
approval,O
for,O
all,O
arteriopathic,I-Entity
patients,O
.,O
Bile,B-Entity
duct,I-Entity
hamartoma,I-Entity
occurring,O
in,O
association,O
with,O
long,O
-,O
term,O
treatment,O
with,O
danazol,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
bile,B-Entity
duct,I-Entity
hamartoma,I-Entity
which,O
developed,O
in,O
a,O
patient,O
who,O
had,O
been,O
on,O
long,O
-,O
term,O
danazol,I-Entity
treatment,O
.,O
If,O
the,O
patient,O
develops,O
a,O
liver,B-Entity
mass,I-Entity
",",O
because,O
of,O
non,O
-,O
specific,O
clinical,O
features,O
and,O
imaging,O
appearances,O
",",O
biopsy,O
may,O
be,O
the,O
only,O
way,O
to,O
achieve,O
a,O
definitive,O
diagnosis,O
.,O
Granulomatous,B-Entity
hepatitis,I-Entity
due,O
to,O
combination,B-Entity
of,I-Entity
amoxicillin,I-Entity
and,I-Entity
clavulanic,I-Entity
acid,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
patient,O
with,O
amoxicillin,B-Entity
-,I-Entity
clavulanic,I-Entity
acid,I-Entity
-,O
induced,O
hepatitis,I-Entity
with,O
histologic,O
multiple,O
granulomas,I-Entity
.,O
This,O
type,O
of,O
lesion,O
broadens,O
the,O
spectrum,O
of,O
liver,B-Entity
injury,I-Entity
due,O
to,O
this,O
drug,O
combination,O
",",O
mainly,O
represented,O
by,O
a,O
benign,O
cholestatic,B-Entity
syndrome,I-Entity
.,O
The,O
association,O
of,O
granulomas,I-Entity
and,O
eosinophilia,I-Entity
favor,O
an,O
immunoallergic,O
mechanism,O
.,O
As,O
penicillin,I-Entity
derivatives,O
and,O
amoxicillin,I-Entity
alone,O
are,O
known,O
to,O
induce,O
such,O
types,O
of,O
lesions,O
",",O
the,O
amoxicillin,I-Entity
component,O
",",O
with,O
or,O
without,O
a,O
potentiating,O
effect,O
of,O
clavulanic,B-Entity
acid,I-Entity
",",O
might,O
have,O
a,O
major,O
role,O
.,O
Intracranial,B-Entity
aneurysms,I-Entity
and,O
cocaine,B-Entity
abuse,I-Entity
:,O
analysis,O
of,O
prognostic,O
indicators,O
.,O
The,O
outcome,O
of,O
subarachnoid,B-Entity
hemorrhage,I-Entity
associated,O
with,O
cocaine,B-Entity
abuse,I-Entity
is,O
reportedly,O
poor,O
.,O
METHODS,O
:,O
A,O
review,O
of,O
admissions,O
during,O
a,O
6-year,O
period,O
revealed,O
14,O
patients,O
with,O
cocaine,I-Entity
-,O
related,O
aneurysms,I-Entity
.,O
This,O
group,O
was,O
compared,O
with,O
a,O
control,O
group,O
of,O
135,O
patients,O
with,O
ruptured,B-Entity
aneurysms,I-Entity
and,O
no,O
history,O
of,O
cocaine,B-Entity
abuse,I-Entity
.,O
Age,O
at,O
presentation,O
",",O
time,O
of,O
ictus,O
after,O
intoxication,O
",",O
Hunt,O
and,O
Hess,O
grade,O
of,O
subarachnoid,B-Entity
hemorrhage,I-Entity
",",O
size,O
of,O
the,O
aneurysm,I-Entity
",",O
location,O
of,O
the,O
aneurysm,I-Entity
",",O
and,O
the,O
Glasgow,O
Outcome,O
Scale,O
score,O
were,O
assessed,O
and,O
compared,O
.,O
In,O
patients,O
in,O
the,O
study,O
group,O
",",O
all,O
aneurysms,I-Entity
were,O
located,O
in,O
the,O
anterior,O
circulation,O
.,O
The,O
majority,O
of,O
these,O
aneurysms,I-Entity
were,O
smaller,O
than,O
those,O
of,O
the,O
control,O
group,O
(,O
8,O
+,O
/-,O
0.007,O
),O
were,O
significant,O
predictors,O
of,O
outcome,O
for,O
the,O
patients,O
with,O
cocaine,I-Entity
-,O
related,O
aneurysms,I-Entity
.,O
CONCLUSION,O
:,O
Cocaine,I-Entity
use,O
predisposed,O
aneurysmal,B-Entity
rupture,I-Entity
at,O
a,O
significantly,O
earlier,O
age,O
and,O
in,O
much,O
smaller,O
aneurysms,I-Entity
.,O
Anti,O
-,O
epileptic,I-Entity
drugs,O
-,O
induced,O
de,O
novo,O
absence,B-Entity
seizures,I-Entity
.,O
The,O
authors,O
present,O
three,O
patients,O
with,O
de,O
novo,O
absence,B-Entity
epilepsy,I-Entity
after,O
administration,O
of,O
carbamazepine,I-Entity
and,O
vigabatrin,I-Entity
.,O
Despite,O
the,O
underlying,O
diseases,O
",",O
the,O
prognosis,O
for,O
drug,O
-,O
induced,O
de,O
novo,O
absence,B-Entity
seizure,I-Entity
is,O
good,O
because,O
it,O
subsides,O
rapidly,O
after,O
discontinuing,O
the,O
use,O
of,O
the,O
offending,O
drugs,O
.,O
The,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
-,O
transmitted,O
thalamocortical,O
circuitry,O
accounts,O
for,O
a,O
major,O
part,O
of,O
the,O
underlying,O
neurophysiology,O
of,O
the,O
absence,B-Entity
epilepsy,I-Entity
.,O
Because,O
drug,O
-,O
induced,O
de,O
novo,O
absence,B-Entity
seizure,I-Entity
is,O
rare,O
",",O
pro,O
-,O
absence,O
drugs,O
can,O
only,O
be,O
considered,O
a,O
promoting,O
factor,O
.,O
The,O
underlying,O
epileptogenecity,O
of,O
the,O
patients,O
or,O
the,O
synergistic,O
effects,O
of,O
the,O
accompanying,O
drugs,O
is,O
required,O
to,O
trigger,O
the,O
de,O
novo,O
absence,B-Entity
seizure,I-Entity
.,O
The,O
possibility,O
of,O
drug,O
-,O
induced,O
aggravation,O
should,O
be,O
considered,O
whenever,O
an,O
unexpected,O
increase,O
in,O
seizure,I-Entity
frequency,O
and/or,O
new,O
seizure,I-Entity
types,O
appear,O
following,O
a,O
change,O
in,O
drug,O
treatment,O
.,O
By,O
understanding,O
the,O
underlying,O
mechanism,O
of,O
absence,B-Entity
epilepsy,I-Entity
",",O
we,O
can,O
avoid,O
the,O
inappropriate,O
use,O
of,O
anticonvulsants,O
in,O
children,O
with,O
epilepsy,I-Entity
and,O
prevent,O
drug,O
-,O
induced,O
absence,B-Entity
seizures,I-Entity
.,O
Procainamide,I-Entity
-,O
induced,O
polymorphous,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
Seven,O
cases,O
of,O
procainamide,I-Entity
-,O
induced,O
polymorphous,O
ventricular,B-Entity
tachycardia,I-Entity
are,O
presented,O
.,O
In,O
four,O
patients,O
",",O
polymorphous,O
ventricular,B-Entity
tachycardia,I-Entity
appeared,O
after,O
intravenous,O
administration,O
of,O
200,O
to,O
400,O
mg,O
of,O
procainamide,I-Entity
for,O
the,O
treatment,O
of,O
sustained,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
In,O
the,O
remaining,O
three,O
patients,O
",",O
procainamide,I-Entity
was,O
administered,O
orally,O
for,O
treatment,O
of,O
chronic,O
premature,B-Entity
ventricular,I-Entity
contractions,I-Entity
or,O
atrial,B-Entity
flutter,I-Entity
.,O
These,O
patients,O
had,O
Q,B-Entity
-,I-Entity
T,I-Entity
prolongation,I-Entity
and,O
recurrent,O
syncope,I-Entity
due,O
to,O
polymorphous,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
In,O
four,O
patients,O
",",O
the,O
arrhythmia,I-Entity
was,O
rapidly,O
diagnosed,O
and,O
treated,O
with,O
disappearance,O
of,O
further,O
episodes,O
of,O
the,O
arrhythmia,I-Entity
.,O
In,O
two,O
patients,O
",",O
the,O
arrhythmia,I-Entity
degenerated,O
into,O
irreversible,O
ventricular,B-Entity
fibrillation,I-Entity
and,O
both,O
patients,O
died,O
.,O
In,O
the,O
seventh,O
patient,O
",",O
a,O
permanent,O
ventricular,O
pacemaker,O
was,O
inserted,O
and,O
",",O
despite,O
continuation,O
of,O
procainamide,I-Entity
therapy,O
",",O
polymorphous,O
ventricular,B-Entity
tachycardia,I-Entity
did,O
not,O
reoccur,O
.,O
These,O
seven,O
cases,O
demonstrate,O
that,O
procainamide,I-Entity
can,O
produce,O
an,O
acquired,O
prolonged,B-Entity
Q,I-Entity
-,I-Entity
T,I-Entity
syndrome,I-Entity
with,O
polymorphous,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
Role,O
of,O
activation,O
of,O
bradykinin,I-Entity
B2,O
receptors,O
in,O
disruption,O
of,O
the,O
blood,O
-,O
brain,O
barrier,O
during,O
acute,O
hypertension,I-Entity
.,O
Cellular,O
mechanisms,O
which,O
account,O
for,O
disruption,O
the,O
blood,O
-,O
brain,O
barrier,O
during,O
acute,O
hypertension,I-Entity
are,O
not,O
clear,O
.,O
The,O
goal,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
role,O
of,O
synthesis,O
/,O
release,O
of,O
bradykinin,I-Entity
to,O
activate,O
B2,O
receptors,O
in,O
disruption,O
of,O
the,O
blood,O
-,O
brain,O
barrier,O
during,O
acute,O
hypertension,I-Entity
.,O
Permeability,O
of,O
the,O
blood,O
-,O
brain,O
barrier,O
was,O
quantitated,O
by,O
clearance,O
of,O
fluorescent,O
-,O
labeled,O
dextran,I-Entity
before,O
and,O
during,O
phenylephrine,I-Entity
-,O
induced,O
acute,O
hypertension,I-Entity
in,O
rats,O
treated,O
with,O
vehicle,O
and,O
Hoe-140,I-Entity
(,O
0.1,O
microM,O
),O
.,O
Phenylephrine,I-Entity
infusion,O
increased,O
arterial,O
pressure,O
",",O
arteriolar,O
diameter,O
and,O
clearance,O
of,O
fluorescent,O
dextran,I-Entity
by,O
a,O
similar,O
magnitude,O
in,O
both,O
groups,O
.,O
These,O
findings,O
suggest,O
that,O
disruption,O
of,O
the,O
blood,O
-,O
brain,O
barrier,O
during,O
acute,O
hypertension,I-Entity
is,O
not,O
related,O
to,O
the,O
synthesis,O
/,O
release,O
of,O
bradykinin,I-Entity
to,O
activate,O
B2,O
receptors,O
.,O
5-azacytidine,I-Entity
potentiates,O
initiation,B-Entity
induced,I-Entity
by,I-Entity
carcinogens,I-Entity
in,O
rat,O
liver,O
.,O
To,O
test,O
the,O
validity,O
of,O
the,O
hypothesis,O
that,O
hypomethylation,O
of,O
DNA,O
plays,O
an,O
important,O
role,O
in,O
the,O
initiation,B-Entity
of,I-Entity
carcinogenic,I-Entity
process,I-Entity
",",O
5-azacytidine,I-Entity
(,O
5-AzC,I-Entity
),O
(,O
10,O
mg,O
/,O
kg,O
),O
",",O
an,O
inhibitor,O
of,O
DNA,O
methylation,O
",",O
was,O
given,O
to,O
rats,O
during,O
the,O
phase,O
of,O
repair,O
synthesis,O
induced,O
by,O
the,O
three,O
carcinogens,O
",",O
benzo[a]-pyrene,I-Entity
(,O
200,O
mg,O
/,O
kg,O
),O
",",O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
N,I-Entity
-,I-Entity
nitrosourea,I-Entity
(,O
60,O
mg,O
/,O
kg,O
),O
and,O
"1,2-dimethylhydrazine",I-Entity
(,O
"1,2-DMH",I-Entity
),O
The,O
initiated,O
hepatocytes,O
in,O
the,O
liver,O
were,O
assayed,O
as,O
the,O
gamma,O
-,O
glutamyltransferase,O
(,O
gamma,O
-,O
GT,O
),O
positive,O
foci,O
formed,O
following,O
a,O
2-week,O
selection,O
regimen,O
consisting,O
of,O
dietary,O
0.02%,O
2-acetylaminofluorene,I-Entity
coupled,O
with,O
a,O
necrogenic,O
dose,O
of,O
CCl4,I-Entity
.,O
The,O
results,O
obtained,O
indicate,O
that,O
with,O
all,O
three,O
carcinogens,O
",",O
administration,O
of,O
5-AzC,I-Entity
during,O
repair,O
synthesis,O
increased,O
the,O
incidence,O
of,O
initiated,O
hepatocytes,O
",",O
for,O
example,O
10,O
-,O
20,O
foci,O
/,O
cm2,O
in,O
5-AzC,I-Entity
and,O
carcinogen,O
-,O
treated,O
rats,O
compared,O
with,O
3,O
-,O
5,O
foci,O
/,O
cm2,O
in,O
rats,O
treated,O
with,O
carcinogen,O
only,O
.,O
Administration,O
of,O
[,B-Entity
3H]-5-azadeoxycytidine,I-Entity
during,O
the,O
repair,O
synthesis,O
induced,O
by,O
"1,2-DMH",I-Entity
further,O
showed,O
that,O
0.019,O
mol,O
%,O
of,O
cytosine,I-Entity
residues,O
in,O
DNA,O
were,O
substituted,O
by,O
the,O
analogue,O
",",O
indicating,O
that,O
incorporation,O
of,O
5-AzC,I-Entity
occurs,O
during,O
repair,O
synthesis,O
.,O
In,O
the,O
absence,O
of,O
the,O
carcinogen,O
",",O
5-AzC,I-Entity
given,O
after,O
a,O
two,O
thirds,O
partial,O
hepatectomy,O
",",O
when,O
its,O
incorporation,O
should,O
be,O
maximum,O
",",O
failed,O
to,O
induce,O
any,O
gamma,O
-,O
GT,O
positive,O
foci,O
.,O
Withdrawal,B-Entity
-,I-Entity
emergent,I-Entity
rabbit,I-Entity
syndrome,I-Entity
during,O
dose,O
reduction,O
of,O
risperidone,I-Entity
.,O
Rabbit,B-Entity
syndrome,I-Entity
(,O
RS,I-Entity
),O
is,O
a,O
rare,O
extrapyramidal,O
side,O
effect,O
caused,O
by,O
prolonged,O
neuroleptic,O
medication,O
.,O
Here,O
we,O
present,O
a,O
case,O
of,O
withdrawal,B-Entity
-,I-Entity
emergent,I-Entity
RS,I-Entity
",",O
which,O
is,O
the,O
first,O
of,O
its,O
kind,O
to,O
be,O
reported,O
.,O
The,O
patient,O
developed,O
RS,I-Entity
during,O
dose,O
reduction,O
of,O
risperidone,I-Entity
.,O
The,O
symptom,O
was,O
treated,O
successfully,O
with,O
trihexyphenidyl,I-Entity
anticholinergic,O
therapy,O
.,O
The,O
underlying,O
mechanism,O
of,O
withdrawal,B-Entity
-,I-Entity
emergent,I-Entity
RS,I-Entity
in,O
the,O
present,O
case,O
may,O
have,O
been,O
related,O
to,O
the,O
pharmacological,O
profile,O
of,O
risperidone,I-Entity
",",O
a,O
serotonin,I-Entity
-,O
dopamine,I-Entity
antagonist,O
",",O
suggesting,O
the,O
pathophysiologic,O
influence,O
of,O
the,O
serotonin,I-Entity
system,O
in,O
the,O
development,O
of,O
RS,I-Entity
.,O
Verapamil,I-Entity
withdrawal,O
as,O
a,O
possible,O
cause,O
of,O
myocardial,B-Entity
infarction,I-Entity
in,O
a,O
hypertensive,I-Entity
woman,O
with,O
a,O
normal,O
coronary,O
angiogram,O
.,O
Verapamil,I-Entity
is,O
an,O
effective,O
and,O
relatively,O
-,O
safe,O
antihypertensive,O
drug,O
.,O
Serious,O
adverse,O
effects,O
are,O
uncommon,O
and,O
mainly,O
have,O
been,O
related,O
to,O
the,O
depression,I-Entity
of,O
cardiac,O
contractility,O
and,O
conduction,O
",",O
especially,O
when,O
the,O
drug,O
is,O
combined,O
with,O
beta,O
-,O
blocking,O
agents,O
.,O
We,O
report,O
a,O
case,O
in,O
which,O
myocardial,B-Entity
infarction,I-Entity
coincided,O
with,O
the,O
introduction,O
of,O
captopril,I-Entity
and,O
the,O
withdrawal,O
of,O
verapamil,I-Entity
in,O
a,O
previously,O
asymptomatic,O
woman,O
with,O
severe,O
hypertension,I-Entity
.,O
Possible,O
mechanisms,O
that,O
involve,O
a,O
verapamil,I-Entity
-,O
related,O
increase,O
in,O
platelet,O
and/or,O
vascular,O
alpha,O
2-adrenoreceptor,O
affinity,O
for,O
catecholamines,I-Entity
are,O
discussed,O
.,O
Remission,O
induction,O
of,O
meningeal,B-Entity
leukemia,I-Entity
with,O
high,O
-,O
dose,O
intravenous,O
methotrexate,I-Entity
.,O
Twenty,O
children,O
with,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
who,O
developed,O
meningeal,B-Entity
disease,I-Entity
were,O
treated,O
with,O
a,O
high,O
-,O
dose,O
intravenous,O
methotrexate,I-Entity
regimen,O
that,O
was,O
designed,O
to,O
achieve,O
and,O
maintain,O
CSF,O
methotrexate,I-Entity
concentrations,O
of,O
10(-5,O
),O
The,O
methotrexate,I-Entity
was,O
administered,O
as,O
a,O
loading,O
dose,O
of,O
"6,000",O
mg,O
/,O
m2,O
for,O
a,O
period,O
of,O
one,O
hour,O
followed,O
by,O
an,O
infusion,O
of,O
"1,200",O
mg,O
/,O
m2/h,O
for,O
23,O
hours,O
.,O
Leucovorin,I-Entity
rescue,O
was,O
initiated,O
12,O
hours,O
after,O
the,O
end,O
of,O
the,O
infusion,O
with,O
a,O
loading,O
dose,O
of,O
200,O
mg,O
/,O
m2,O
followed,O
by,O
12,O
mg,O
/,O
m2,O
every,O
three,O
hours,O
for,O
six,O
doses,O
and,O
then,O
every,O
six,O
hours,O
until,O
the,O
plasma,O
methotrexate,I-Entity
level,O
decreased,O
to,O
less,O
than,O
1,O
X,O
10(-7,O
),O
mol,O
/,O
L.,O
The,O
mean,O
steady,O
-,O
state,O
plasma,O
and,O
CSF,O
methotrexate,I-Entity
concentrations,O
achieved,O
were,O
1.1,O
X,O
10(-3,O
),O
The,O
most,O
common,O
toxicities,I-Entity
encountered,O
were,O
transient,O
serum,O
transaminase,O
and,O
bilirubin,I-Entity
elevations,O
",",O
neutropenia,I-Entity
",",O
and,O
mucositis,I-Entity
.,O
One,O
patient,O
had,O
focal,O
seizures,I-Entity
and,O
transient,B-Entity
hemiparesis,I-Entity
but,O
recovered,O
completely,O
.,O
High,O
-,O
dose,O
intravenous,O
methotrexate,I-Entity
is,O
an,O
effective,O
treatment,O
for,O
the,O
induction,O
of,O
remission,O
after,O
meningeal,O
relapse,O
in,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
.,O
Hypersensitivity,I-Entity
to,O
carbamazepine,I-Entity
presenting,O
with,O
a,O
leukemoid,B-Entity
reaction,I-Entity
",",O
eosinophilia,I-Entity
",",O
erythroderma,I-Entity
",",O
and,O
renal,B-Entity
failure,I-Entity
.,O
We,O
report,O
a,O
patient,O
in,O
whom,O
hypersensitivity,I-Entity
to,O
carbamazepine,I-Entity
presented,O
with,O
generalized,O
erythroderma,I-Entity
",",O
a,O
severe,O
leukemoid,B-Entity
reaction,I-Entity
",",O
eosinophilia,I-Entity
",",O
hyponatremia,I-Entity
",",O
and,O
renal,B-Entity
failure,I-Entity
.,O
This,O
is,O
the,O
first,O
report,O
of,O
such,O
an,O
unusual,O
reaction,O
to,O
carbamazepine,I-Entity
.,O
The,O
interpeduncular,O
nucleus,O
regulates,O
nicotine,I-Entity
's,O
effects,O
on,O
free,O
-,O
field,O
activity,O
.,O
Partial,O
lesions,O
were,O
made,O
with,O
kainic,B-Entity
acid,I-Entity
in,O
the,O
interpeduncular,O
nucleus,O
of,O
the,O
ventral,O
midbrain,O
of,O
the,O
rat,O
.,O
Compared,O
with,O
sham,O
-,O
operated,O
controls,O
",",O
lesions,O
significantly,O
(,O
p,O
<,O
0.25,O
),O
blunted,O
the,O
early,O
(,O
<,O
60,O
min,O
),O
free,O
-,O
field,O
locomotor,B-Entity
hypoactivity,I-Entity
caused,O
by,O
nicotine,I-Entity
(,O
0.5,O
mg,O
kg(-1,O
),O
",",O
i.m,O
.,O
),O
",",O
enhanced,O
the,O
later,O
(,O
60,O
-,O
120,O
min,O
),O
nicotine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
",",O
and,O
raised,O
spontaneous,O
nocturnal,O
activity,O
.,O
Lesions,O
reduced,O
the,O
extent,O
of,O
immunohistological,O
staining,O
for,O
choline,I-Entity
acetyltransferase,O
in,O
the,O
interpeduncular,O
nucleus,O
(,O
p,O
<,O
0.025,O
),O
",",O
but,O
not,O
for,O
tyrosine,I-Entity
hydroxylase,O
in,O
the,O
surrounding,O
catecholaminergic,O
A10,O
region,O
.,O
We,O
conclude,O
that,O
the,O
interpeduncular,O
nucleus,O
mediates,O
nicotinic,O
depression,I-Entity
of,O
locomotor,O
activity,O
and,O
dampens,O
nicotinic,O
arousal,O
mechanisms,O
located,O
elsewhere,O
in,O
the,O
brain,O
.,O
Assessment,O
of,O
a,O
new,O
non,O
-,O
invasive,O
index,O
of,O
cardiac,O
performance,O
for,O
detection,O
of,O
dobutamine,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
.,O
Electrocardiography,O
has,O
a,O
very,O
low,O
sensitivity,O
in,O
detecting,O
dobutamine,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
.,O
To,O
assess,O
the,O
added,O
diagnostic,O
value,O
of,O
a,O
new,O
cardiac,O
performance,O
index,O
(,O
dP,O
/,O
dtejc,O
),O
measurement,O
",",O
based,O
on,O
brachial,O
artery,O
flow,O
changes,O
",",O
as,O
compared,O
to,O
standard,O
12-lead,O
ECG,O
",",O
for,O
detecting,O
dobutamine,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
",",O
using,O
Tc99m,B-Entity
-,I-Entity
Sestamibi,I-Entity
single,O
-,O
photon,O
emission,O
computed,O
tomography,O
as,O
the,O
gold,O
standard,O
of,O
comparison,O
to,O
assess,O
the,O
presence,O
or,O
absence,O
of,O
ischemia,I-Entity
.,O
:,O
The,O
study,O
group,O
comprised,O
40,O
patients,O
undergoing,O
Sestamibi,I-Entity
-,O
SPECT,O
/,O
dobutamine,I-Entity
stress,O
test,O
.,O
dtejc,O
were,O
performed,O
at,O
each,O
dobutamine,I-Entity
level,O
.,O
In,O
19,O
of,O
the,O
40,O
patients,O
perfusion,O
defects,O
compatible,O
with,O
ischemia,I-Entity
were,O
detected,O
on,O
SPECT,O
.,O
The,O
increase,O
in,O
dP,O
/,O
dtejc,O
during,O
infusion,O
of,O
dobutamine,I-Entity
in,O
this,O
group,O
was,O
severely,O
impaired,O
as,O
compared,O
to,O
the,O
non,O
-,O
ischemic,O
group,O
.,O
If,O
ECG,O
alone,O
is,O
used,O
for,O
specificity,O
",",O
the,O
combination,O
with,O
dP,O
/,O
dtejc,O
improved,O
the,O
sensitivity,O
of,O
the,O
test,O
and,O
could,O
be,O
a,O
cost,O
-,O
savings,O
alternative,O
to,O
cardiac,O
imaging,O
or,O
perfusion,O
studies,O
to,O
detect,O
myocardial,B-Entity
ischemia,I-Entity
",",O
especially,O
in,O
patients,O
unable,O
to,O
exercise,O
.,O
Acute,B-Entity
liver,I-Entity
failure,I-Entity
in,O
two,O
patients,O
with,O
regular,O
alcohol,I-Entity
consumption,O
ingesting,O
paracetamol,I-Entity
at,O
therapeutic,O
dosage,O
.,O
The,O
possible,O
role,O
of,O
alcohol,I-Entity
in,O
the,O
development,O
of,O
hepatotoxicity,I-Entity
associated,O
with,O
therapeutic,O
doses,O
of,O
paracetamol,I-Entity
(,O
acetaminophen,I-Entity
),O
is,O
currently,O
debated,O
.,O
We,O
describe,O
2,O
patients,O
who,O
were,O
regular,O
consumers,O
of,O
alcohol,I-Entity
and,O
who,O
developed,O
liver,B-Entity
failure,I-Entity
within,O
3,O
-,O
5,O
days,O
after,O
hospitalization,O
and,O
stopping,O
alcohol,I-Entity
consumption,O
while,O
being,O
treated,O
with,O
4,O
g,O
paracetamol,I-Entity
/,O
day,O
.,O
A,O
paracetamol,I-Entity
serum,O
level,O
obtained,O
in,O
one,O
of,O
these,O
patients,O
was,O
not,O
in,O
the,O
toxic,O
range,O
.,O
Possible,O
risk,O
factors,O
for,O
the,O
development,O
of,O
hepatotoxicity,I-Entity
in,O
patients,O
treated,O
with,O
therapeutic,O
doses,O
of,O
paracetamol,I-Entity
are,O
discussed,O
.,O
In,O
patients,O
with,O
risk,O
factors,O
",",O
e.g.,O
regular,O
consumption,O
of,O
alcohol,I-Entity
",",O
liver,B-Entity
failure,I-Entity
is,O
possible,O
when,O
therapeutic,O
doses,O
are,O
ingested,O
.,O
We,O
propose,O
that,O
the,O
paracetamol,I-Entity
dose,O
should,O
not,O
exceed,O
2,O
g,O
/,O
day,O
in,O
such,O
patients,O
and,O
that,O
their,O
liver,O
function,O
should,O
be,O
monitored,O
closely,O
while,O
being,O
treated,O
with,O
paracetamol,I-Entity
.,O
Cocaine,I-Entity
related,O
chest,B-Entity
pain,I-Entity
:,O
The,O
recreational,O
use,O
of,O
cocaine,I-Entity
is,O
on,O
the,O
increase,O
.,O
The,O
emergency,O
nurse,O
ought,O
to,O
be,O
familiar,O
with,O
some,O
of,O
the,O
cardiovascular,O
consequences,O
of,O
cocaine,I-Entity
use,O
.,O
In,O
particular,O
",",O
the,O
tendency,O
of,O
cocaine,I-Entity
to,O
produce,O
chest,B-Entity
pain,I-Entity
ought,O
to,O
be,O
in,O
the,O
mind,O
of,O
the,O
emergency,O
nurse,O
when,O
faced,O
with,O
a,O
young,O
victim,O
of,O
chest,B-Entity
pain,I-Entity
who,O
is,O
otherwise,O
at,O
low,O
risk,O
.,O
The,O
mechanism,O
of,O
chest,B-Entity
pain,I-Entity
related,O
to,O
cocaine,I-Entity
use,O
is,O
discussed,O
and,O
treatment,O
dilemmas,O
are,O
discussed,O
.,O
Finally,O
",",O
moral,O
issues,O
relating,O
to,O
the,O
testing,O
of,O
potential,O
cocaine,I-Entity
users,O
will,O
be,O
addressed,O
.,O
Severe,O
rhabdomyolysis,I-Entity
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
secondary,O
to,O
concomitant,O
use,O
of,O
simvastatin,I-Entity
",",O
amiodarone,I-Entity
",",O
and,O
atazanavir,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
a,O
severe,O
interaction,O
between,O
simvastatin,I-Entity
",",O
amiodarone,I-Entity
",",O
and,O
atazanavir,I-Entity
resulting,O
in,O
rhabdomyolysis,I-Entity
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
A,O
72-year,O
-,O
old,O
white,O
man,O
with,O
underlying,O
human,B-Entity
immunodeficiency,I-Entity
virus,I-Entity
",",O
atrial,B-Entity
fibrillation,I-Entity
",",O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
and,O
hyperlipidemia,I-Entity
presented,O
with,O
generalized,O
pain,I-Entity
",",O
fatigue,I-Entity
",",O
and,O
dark,O
orange,O
urine,O
for,O
3,O
days,O
.,O
The,O
patient,O
was,O
taking,O
80,O
mg,O
simvastatin,I-Entity
at,O
bedtime,O
(,O
initiated,O
27,O
days,O
earlier,O
),O
;,O
amiodarone,I-Entity
at,O
a,O
dose,O
of,O
400,O
mg,O
daily,O
for,O
7,O
days,O
",",O
then,O
200,O
mg,O
daily,O
(,O
initiated,O
19,O
days,O
earlier,O
),O
;,O
and,O
400,O
mg,O
atazanavir,I-Entity
daily,O
(,O
initiated,O
at,O
least,O
2,O
years,O
previously,O
),O
.,O
Laboratory,O
evaluation,O
revealed,O
"66,680",O
U,O
/,O
L,O
creatine,I-Entity
kinase,O
",",O
93,O
mg,O
/,O
dL,O
blood,B-Entity
urea,I-Entity
nitrogen,I-Entity
",",O
4.6,O
mg,O
/,O
dL,O
creatinine,I-Entity
",",O
1579,O
U,O
/,O
L,O
aspartate,I-Entity
aminotransferase,O
",",O
and,O
738,O
U,O
/,O
L,O
alanine,I-Entity
aminotransferase,O
.,O
Simvastatin,I-Entity
",",O
amiodarone,I-Entity
",",O
and,O
the,O
patient,O
's,O
human,B-Entity
immunodeficiency,I-Entity
virus,I-Entity
medications,O
were,O
all,O
temporarily,O
discontinued,O
and,O
the,O
patient,O
was,O
given,O
forced,O
alkaline,O
diuresis,O
and,O
started,O
on,O
dialysis,O
.,O
Nine,O
days,O
later,O
the,O
patient,O
's,O
creatine,I-Entity
kinase,O
had,O
dropped,O
to,O
1695,O
U,O
/,O
L,O
and,O
creatinine,I-Entity
was,O
3.3,O
mg,O
/,O
dL.,O
The,O
patient,O
was,O
discharged,O
and,O
continued,O
outpatient,O
dialysis,O
for,O
1,O
month,O
until,O
his,O
renal,O
function,O
recovered,O
.,O
The,O
risk,O
of,O
rhabdomyolysis,I-Entity
is,O
increased,O
in,O
the,O
presence,O
of,O
concomitant,O
drugs,O
that,O
inhibit,O
simvastatin,I-Entity
metabolism,O
.,O
Simvastatin,I-Entity
is,O
metabolized,O
by,O
CYP3A4,O
.,O
Amiodarone,I-Entity
and,O
atazanavir,I-Entity
are,O
recognized,O
CYP3A4,O
inhibitors,O
.,O
CONCLUSIONS,O
:,O
Pharmacokinetic,O
differences,O
in,O
statins,I-Entity
are,O
an,O
important,O
consideration,O
for,O
assessing,O
the,O
risk,O
of,O
potential,O
drug,O
interactions,O
.,O
In,O
patients,O
requiring,O
the,O
concurrent,O
use,O
of,O
statins,I-Entity
and,O
CYP3A4,O
inhibitors,O
",",O
pravastatin,I-Entity
",",O
fluvastatin,I-Entity
",",O
and,O
rosuvastatin,I-Entity
carry,O
the,O
lowest,O
risk,O
of,O
drug,O
interactions,O
;,O
atorvastatin,I-Entity
carries,O
moderate,O
risk,O
",",O
whereas,O
simvastatin,I-Entity
and,O
lovastatin,I-Entity
have,O
the,O
highest,O
risk,O
and,O
should,O
be,O
avoided,O
in,O
patients,O
taking,O
concomitant,O
CYP3A4,O
inhibitors,O
.,O
Phase,O
II,O
trial,O
of,O
vinorelbine,I-Entity
in,O
metastatic,O
squamous,B-Entity
cell,I-Entity
esophageal,I-Entity
carcinoma,I-Entity
.,O
European,O
Organization,O
for,O
Research,O
and,O
Treatment,O
of,O
Cancer,I-Entity
Gastrointestinal,O
Treat,O
Cancer,I-Entity
Cooperative,O
Group,O
.,O
PURPOSE,O
:,O
To,O
evaluate,O
the,O
response,O
rate,O
and,O
toxic,O
effects,O
of,O
vinorelbine,I-Entity
(,O
VNB,I-Entity
),O
administered,O
as,O
a,O
single,O
agent,O
in,O
metastatic,O
squamous,B-Entity
cell,I-Entity
esophageal,I-Entity
carcinoma,I-Entity
.,O
Thirty,O
patients,O
without,O
prior,O
chemotherapy,O
and,O
16,O
pretreated,O
with,O
cisplatin,I-Entity
-,O
based,O
chemotherapy,O
were,O
assessable,O
for,O
toxicity,I-Entity
and,O
response,O
.,O
VNB,I-Entity
was,O
administered,O
weekly,O
as,O
a,O
25-mg,O
/,O
m2,O
short,O
intravenous,O
(,O
i.v,O
.,O
),O
VNB,I-Entity
was,O
well,O
tolerated,O
and,O
zero,O
instances,O
of,O
WHO,O
grade,O
4,O
nonhematologic,O
toxicity,I-Entity
occurred,O
.,O
At,O
least,O
one,O
episode,O
of,O
grade,O
3,O
or,O
4,O
granulocytopenia,I-Entity
was,O
seen,O
in,O
59%,O
of,O
patients,O
.,O
A,O
grade,O
2,O
or,O
3,O
infection,I-Entity
occurred,O
in,O
16%,O
of,O
patients,O
",",O
but,O
no,O
toxic,O
deaths,I-Entity
occurred,O
.,O
Other,O
side,O
effects,O
were,O
rare,O
",",O
and,O
peripheral,B-Entity
neurotoxicity,I-Entity
has,O
been,O
minor,O
(,O
26%,O
grade,O
1,O
),O
.,O
CONCLUSION,O
:,O
These,O
data,O
indicate,O
that,O
VNB,I-Entity
is,O
an,O
active,O
agent,O
in,O
metastatic,O
esophageal,B-Entity
squamous,I-Entity
cell,I-Entity
carcinoma,I-Entity
.,O
Given,O
its,O
excellent,O
tolerance,O
profile,O
and,O
low,O
toxicity,I-Entity
",",O
further,O
evaluation,O
of,O
VNB,I-Entity
in,O
combination,O
therapy,O
is,O
warranted,O
.,O
Paclitaxel,I-Entity
",",O
cisplatin,I-Entity
",",O
and,O
gemcitabine,I-Entity
combination,O
chemotherapy,O
within,O
a,O
multidisciplinary,O
therapeutic,O
approach,O
in,O
metastatic,O
nonsmall,B-Entity
cell,I-Entity
lung,I-Entity
carcinoma,I-Entity
.,O
Cisplatin,I-Entity
-,O
based,O
chemotherapy,O
combinations,O
improve,O
quality,O
of,O
life,O
and,O
survival,O
in,O
advanced,O
nonsmall,B-Entity
cell,I-Entity
lung,I-Entity
carcinoma,I-Entity
(,O
NSCLC,I-Entity
),O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
feasibility,O
",",O
response,O
rate,O
",",O
and,O
toxicity,I-Entity
of,O
a,O
paclitaxel,I-Entity
",",O
cisplatin,I-Entity
",",O
and,O
gemcitabine,I-Entity
combination,O
to,O
treat,O
metastatic,O
NSCLC,I-Entity
.,O
Thirty,O
-,O
five,O
consecutive,O
chemotherapy,O
-,O
naive,O
patients,O
with,O
Stage,O
IV,O
NSCLC,I-Entity
and,O
an,O
Eastern,O
Cooperative,O
Oncology,O
Group,O
performance,O
status,O
of,O
0,O
-,O
2,O
were,O
treated,O
with,O
a,O
combination,O
of,O
paclitaxel,I-Entity
(,O
135,O
mg,O
/,O
m(2,O
),O
given,O
intravenously,O
in,O
3,O
hours,O
),O
on,O
Day,O
1,O
",",O
cisplatin,I-Entity
(,O
120,O
mg,O
/,O
m(2,O
),O
given,O
intravenously,O
in,O
6,O
hours,O
),O
on,O
Day,O
1,O
",",O
and,O
gemcitabine,I-Entity
(,O
800,O
mg,O
/,O
m(2,O
),O
given,O
intravenously,O
in,O
30,O
minutes,O
),O
on,O
Days,O
1,O
and,O
8,O
",",O
every,O
4,O
weeks,O
.,O
Although,O
responding,O
patients,O
were,O
scheduled,O
to,O
receive,O
consolidation,O
radiotherapy,O
and,O
24,O
patients,O
received,O
preplanned,O
second,O
-,O
line,O
chemotherapy,O
after,O
disease,O
progression,O
",",O
the,O
response,O
and,O
toxicity,I-Entity
rates,O
reported,O
refer,O
only,O
to,O
the,O
chemotherapy,O
regimen,O
given,O
.,O
All,O
the,O
patients,O
were,O
examined,O
for,O
toxicity,I-Entity
;,O
34,O
were,O
examinable,O
for,O
response,O
.,O
After,O
154,O
courses,O
of,O
therapy,O
",",O
the,O
median,O
dose,O
intensity,O
was,O
131,O
mg,O
/,O
m(2,O
),O
for,O
paclitaxel,I-Entity
(,O
97.3%,O
),O
",",O
117,O
mg,O
/,O
m(2,O
),O
for,O
cisplatin,I-Entity
(,O
97.3%,O
),O
",",O
and,O
1378,O
mg,O
/,O
m(2,O
),O
for,O
gemcitabine,I-Entity
(,O
86.2%,O
),O
.,O
World,O
Health,O
Organization,O
Grade,O
3,O
-,O
4,O
neutropenia,I-Entity
and,O
thrombocytopenia,I-Entity
occurred,O
in,O
39.9%,O
and,O
11.4%,O
of,O
patients,O
",",O
respectively,O
.,O
There,O
was,O
one,O
treatment,O
-,O
related,O
death,I-Entity
.,O
Nonhematologic,O
toxicities,I-Entity
were,O
mild,O
.,O
The,O
combination,O
of,O
paclitaxel,I-Entity
",",O
cisplatin,I-Entity
",",O
and,O
gemcitabine,I-Entity
is,O
well,O
tolerated,O
and,O
shows,O
high,O
activity,O
in,O
metastatic,O
NSCLC,I-Entity
.,O
This,O
treatment,O
merits,O
further,O
comparison,O
with,O
other,O
cisplatin,I-Entity
-,O
based,O
regimens,O
.,O
Evaluation,O
of,O
adverse,O
reactions,O
of,O
aponidine,B-Entity
hydrochloride,I-Entity
ophthalmic,O
solution,O
.,O
We,O
prospectively,O
evaluated,O
the,O
adverse,O
reactions,O
of,O
apraclonidine,I-Entity
in,O
20,O
normal,O
volunteers,O
by,O
instilling,O
a,O
single,O
drop,O
of,O
1%,O
apraclonidine,I-Entity
in,O
their,O
right,O
eyes,O
.,O
The,O
ocular,B-Entity
hypotensive,I-Entity
effects,O
were,O
statistically,O
significant,O
for,O
apraclonidine,I-Entity
-,O
treated,O
eyes,O
throughout,O
the,O
study,O
and,O
also,O
statistically,O
significant,O
for,O
contralateral,O
eyes,O
from,O
three,O
hours,O
after,O
topical,O
administration,O
of,O
1%,O
apraclonidine,I-Entity
.,O
Decreases,B-Entity
in,I-Entity
systolic,I-Entity
blood,I-Entity
pressure,I-Entity
were,O
statistically,O
",",O
but,O
not,O
clinically,O
",",O
significant,O
.,O
Conjunctival,B-Entity
blanching,I-Entity
and,O
mydriasis,I-Entity
were,O
commonly,O
found,O
.,O
While,O
the,O
elevations,O
of,O
the,O
upper,O
lid,O
margin,O
in,O
most,O
subjects,O
were,O
not,O
more,O
than,O
2,O
mm,O
and,O
did,O
not,O
cause,O
noticeable,O
change,O
in,O
appearance,O
",",O
one,O
subject,O
suffered,O
from,O
mechanical,O
entropion,I-Entity
and,O
marked,O
corneal,B-Entity
abrasion,I-Entity
3,O
hours,O
after,O
instillation,O
of,O
the,O
medication,O
.,O
Carmofur,I-Entity
-,O
induced,O
organic,B-Entity
mental,I-Entity
disorders,I-Entity
.,O
Organic,B-Entity
mental,I-Entity
disorder,I-Entity
was,O
observed,O
in,O
a,O
29-year,O
-,O
old,O
female,O
in,O
the,O
prognostic,O
period,O
after,O
the,O
onset,O
of,O
carmofur,I-Entity
-,O
induced,O
leukoencephalopathy,I-Entity
.,O
Symptoms,O
such,O
as,O
euphoria,O
",",O
emotional,O
lability,O
and,O
puerile,O
attitude,O
noted,O
in,O
the,O
patient,O
were,O
diagnosed,O
as,O
organic,B-Entity
personality,I-Entity
syndrome,I-Entity
according,O
to,O
the,O
criteria,O
defined,O
in,O
the,O
DSM,O
-,O
III,O
-,O
R.,O
It,O
is,O
referred,O
to,O
as,O
a,O
frontal,B-Entity
lobe,I-Entity
syndrome,I-Entity
.,O
Consequently,O
",",O
carmofur,I-Entity
-,O
induced,O
leukoencephalopathy,I-Entity
may,O
uncommonly,O
result,O
in,O
organic,B-Entity
personality,I-Entity
syndrome,I-Entity
in,O
the,O
residual,O
state,O
.,O
It,O
may,O
be,O
attributed,O
to,O
the,O
structural,B-Entity
damage,I-Entity
to,I-Entity
the,I-Entity
frontal,I-Entity
lobe,I-Entity
.,O
International,O
mexiletine,I-Entity
and,O
placebo,O
antiarrhythmic,O
coronary,O
trial,O
:,O
I.,O
Report,O
on,O
arrhythmia,I-Entity
and,O
other,O
findings,O
.,O
The,O
antiarrhythmic,O
effects,O
of,O
the,O
sustained,O
release,O
form,O
of,O
mexiletine,I-Entity
(,O
Mexitil,B-Entity
-,I-Entity
Perlongets,I-Entity
),O
were,O
evaluated,O
in,O
a,O
double,O
-,O
blind,O
placebo,O
trial,O
in,O
630,O
patients,O
with,O
recent,O
documented,O
myocardial,B-Entity
infarction,I-Entity
.,O
Large,O
differences,O
",",O
regarded,O
as,O
statistically,O
significant,O
",",O
between,O
the,O
mexiletine,I-Entity
and,O
placebo,O
groups,O
were,O
noted,O
in,O
that,O
end,O
point,O
at,O
months,O
1,O
and,O
4,O
",",O
but,O
only,O
trends,O
were,O
observed,O
at,O
month,O
12,O
.,O
These,O
differences,O
were,O
observed,O
even,O
though,O
the,O
serum,O
mexiletine,I-Entity
levels,O
obtained,O
in,O
this,O
study,O
were,O
generally,O
lower,O
than,O
those,O
observed,O
in,O
studies,O
that,O
have,O
used,O
the,O
regular,O
form,O
of,O
the,O
drug,O
.,O
There,O
were,O
more,O
deaths,I-Entity
in,O
the,O
mexiletine,I-Entity
group,O
(,O
7.6%,O
),O
than,O
in,O
the,O
placebo,O
group,O
(,O
4.8%,O
),O
;,O
the,O
difference,O
was,O
not,O
statistically,O
significant,O
.,O
Previously,O
recognized,O
side,O
effects,O
",",O
particularly,O
tremor,I-Entity
and,O
gastrointestinal,B-Entity
problems,I-Entity
",",O
were,O
more,O
frequent,O
in,O
the,O
mexiletine,I-Entity
group,O
than,O
in,O
the,O
placebo,O
group,O
.,O
Regional,O
localization,O
of,O
the,O
antagonism,O
of,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
by,O
intracerebral,O
calcitonin,I-Entity
injections,O
.,O
Calcitonin,I-Entity
receptors,O
are,O
found,O
in,O
the,O
brain,O
",",O
and,O
intracerebral,O
infusions,O
of,O
calcitonin,I-Entity
can,O
produce,O
behavioral,O
effects,O
.,O
Among,O
these,O
behavioral,O
effects,O
are,O
decreases,O
in,O
food,O
intake,O
and,O
decreases,O
in,O
amphetamine,I-Entity
-,O
induced,O
locomotor,O
activity,O
.,O
In,O
previous,O
experiments,O
we,O
found,O
that,O
decreases,O
in,O
food,O
intake,O
were,O
induced,O
by,O
local,O
administration,O
of,O
calcitonin,I-Entity
into,O
several,O
hypothalamic,O
sites,O
and,O
into,O
the,O
nucleus,O
accumbens,O
.,O
In,O
the,O
present,O
experiment,O
calcitonin,I-Entity
decreased,O
locomotor,O
activity,O
when,O
locally,O
injected,O
into,O
the,O
same,O
sites,O
where,O
it,O
decreases,O
food,O
intake,O
.,O
The,O
areas,O
where,O
calcitonin,I-Entity
is,O
most,O
effective,O
in,O
decreasing,O
locomotor,O
activity,O
are,O
located,O
in,O
the,O
hypothalamus,O
and,O
nucleus,O
accumbens,O
",",O
suggesting,O
that,O
these,O
areas,O
are,O
the,O
major,O
sites,O
of,O
action,O
of,O
calcitonin,I-Entity
in,O
inhibiting,O
amphetamine,I-Entity
-,O
induced,O
locomotor,O
activity,O
.,O
Fatal,O
intracranial,B-Entity
bleeding,I-Entity
associated,O
with,O
prehospital,O
use,O
of,O
epinephrine,I-Entity
.,O
We,O
present,O
a,O
case,O
of,O
paramedic,O
misjudgment,O
in,O
the,O
execution,O
of,O
a,O
protocol,O
for,O
the,O
treatment,O
of,O
allergic,B-Entity
reaction,I-Entity
in,O
a,O
case,O
of,O
pulmonary,B-Entity
edema,I-Entity
with,O
wheezing,I-Entity
.,O
The,O
sudden,O
onset,O
of,O
respiratory,B-Entity
distress,I-Entity
",",O
rash,I-Entity
",",O
and,O
a,O
history,O
of,O
a,O
new,O
medicine,O
led,O
the,O
two,O
paramedics,O
on,O
the,O
scene,O
to,O
administer,O
subcutaneous,O
epinephrine,I-Entity
.,O
Subsequently,O
",",O
acute,O
cardiac,B-Entity
arrest,I-Entity
and,O
fatal,O
subarachnoid,B-Entity
hemorrhage,I-Entity
occurred,O
.,O
Epinephrine,I-Entity
has,O
a,O
proven,O
role,O
in,O
cardiac,B-Entity
arrest,I-Entity
in,O
prehospital,O
care,O
;,O
however,O
",",O
use,O
by,O
paramedics,O
in,O
patients,O
with,O
suspected,O
allergic,B-Entity
reaction,I-Entity
and,O
severe,O
hypertension,I-Entity
should,O
be,O
viewed,O
with,O
caution,O
.,O
A,O
case,O
of,O
massive,O
rhabdomyolysis,I-Entity
following,O
molindone,I-Entity
administration,O
.,O
Rhabdomyolysis,I-Entity
is,O
a,O
potentially,O
lethal,O
syndrome,O
that,O
psychiatric,I-Entity
patients,O
seem,O
predisposed,O
to,O
develop,O
.,O
The,O
clinical,O
signs,O
and,O
symptoms,O
",",O
typical,O
laboratory,O
features,O
",",O
and,O
complications,O
of,O
rhabdomyolysis,I-Entity
are,O
presented,O
.,O
The,O
case,O
of,O
a,O
schizophrenic,I-Entity
patient,O
is,O
reported,O
to,O
illustrate,O
massive,O
rhabdomyolysis,I-Entity
and,O
subsequent,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
following,O
molindone,I-Entity
administration,O
.,O
Physicians,O
who,O
prescribe,O
molindone,I-Entity
should,O
be,O
aware,O
of,O
this,O
reaction,O
.,O
Cardiovascular,B-Entity
alterations,I-Entity
in,O
rat,O
fetuses,O
exposed,O
to,O
calcium,I-Entity
channel,O
blockers,O
.,O
Preclinical,O
toxicologic,O
investigation,O
suggested,O
that,O
a,O
new,O
calcium,I-Entity
channel,O
blocker,O
",",O
Ro,B-Entity
40,I-Entity
-,I-Entity
5967,I-Entity
",",O
induced,O
cardiovascular,B-Entity
alterations,I-Entity
in,O
rat,O
fetuses,O
exposed,O
to,O
this,O
agent,O
during,O
organogenesis,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
investigate,O
the,O
hypothesis,O
that,O
calcium,I-Entity
channel,O
blockers,O
in,O
general,O
induce,O
cardiovascular,B-Entity
malformations,I-Entity
indicating,O
a,O
pharmacologic,O
class,O
effect,O
.,O
We,O
studied,O
three,O
calcium,I-Entity
channel,O
blockers,O
of,O
different,O
structure,O
",",O
nifedipine,I-Entity
",",O
diltiazem,I-Entity
",",O
and,O
verapamil,I-Entity
",",O
along,O
with,O
the,O
new,O
agent,O
.,O
Pregnant,O
rats,O
were,O
administered,O
one,O
of,O
these,O
calcium,I-Entity
channel,O
blockers,O
during,O
the,O
period,O
of,O
cardiac,O
morphogenesis,O
and,O
the,O
offspring,O
examined,O
on,O
day,O
20,O
of,O
gestation,O
for,O
cardiovascular,B-Entity
malformations,I-Entity
.,O
A,O
low,O
incidence,O
of,O
cardiovascular,B-Entity
malformations,I-Entity
was,O
observed,O
after,O
exposure,O
to,O
each,O
of,O
the,O
four,O
calcium,I-Entity
channel,O
blockers,O
",",O
but,O
this,O
incidence,O
was,O
statistically,O
significant,O
only,O
for,O
verapamil,I-Entity
and,O
nifedipine,I-Entity
.,O
All,O
four,O
agents,O
were,O
associated,O
with,O
aortic,O
arch,O
branching,O
variants,O
",",O
although,O
significantly,O
increased,O
only,O
for,O
Ro,B-Entity
40,I-Entity
-,I-Entity
5967,I-Entity
and,O
verapamil,I-Entity
.,O
Differential,O
impact,O
of,O
immune,O
escape,O
mutations,O
G145R,O
and,O
P120,O
T,O
on,O
the,O
replication,O
of,O
lamivudine,I-Entity
-,O
resistant,O
hepatitis,B-Entity
B,I-Entity
virus,I-Entity
e,I-Entity
antigen,I-Entity
-,O
positive,O
and,O
-negative,O
strains,O
.,O
Immune,O
escape,O
variants,O
of,O
the,O
hepatitis,B-Entity
B,I-Entity
virus,O
(,O
HBV,O
),O
represent,O
an,O
emerging,O
clinical,O
challenge,O
",",O
because,O
they,O
can,O
be,O
associated,O
with,O
vaccine,O
escape,O
",",O
HBV,O
reactivation,O
",",O
and,O
failure,O
of,O
diagnostic,O
tests,O
.,O
We,O
therefore,O
systematically,O
analyzed,O
the,O
functional,O
impact,O
of,O
the,O
most,O
prevalent,O
immune,O
escape,O
variants,O
",",O
the,O
sG145R,O
and,O
sP120,O
T,O
mutants,O
",",O
on,O
the,O
viral,O
replication,O
efficacy,O
and,O
antiviral,O
drug,O
susceptibility,O
of,O
common,O
treatment,O
-,O
associated,O
mutants,O
with,O
resistance,O
to,O
lamivudine,I-Entity
(,O
LAM,I-Entity
),O
and/or,O
HBeAg,I-Entity
negativity,O
.,O
Replication,O
-,O
competent,O
HBV,O
strains,O
with,O
sG145R,O
or,O
sP120,O
T,O
and,O
LAM,I-Entity
resistance,O
(,O
rtM204I,O
or,O
rtL180M,O
/,O
rtM204V,O
),O
were,O
generated,O
on,O
an,O
HBeAg,I-Entity
-,O
positive,O
and,O
an,O
HBeAg,I-Entity
-,O
negative,O
background,O
with,O
precore,O
(,O
PC,O
),O
and,O
basal,O
core,O
promoter,O
(,O
BCP,O
),O
mutants,O
.,O
The,O
sG145R,O
mutation,O
strongly,O
reduced,O
HBsAg,I-Entity
levels,O
and,O
was,O
able,O
to,O
fully,O
restore,O
the,O
impaired,O
replication,O
of,O
LAM,I-Entity
-,O
resistant,O
HBV,O
mutants,O
to,O
the,O
levels,O
of,O
wild,O
-,O
type,O
HBV,O
",",O
and,O
PC,O
or,O
BCP,O
mutations,O
further,O
enhanced,O
viral,O
replication,O
.,O
Although,O
the,O
sP120,O
T,O
substitution,O
also,O
impaired,O
HBsAg,I-Entity
secretion,O
",",O
it,O
did,O
not,O
enhance,O
the,O
replication,O
of,O
LAM,I-Entity
-,O
resistant,O
clones,O
.,O
However,O
",",O
the,O
concomitant,O
occurrence,O
of,O
HBeAg,I-Entity
negativity,O
(,O
PC,O
/,O
BCP,O
),O
",",O
sP120,O
T,O
",",O
and,O
LAM,I-Entity
resistance,O
resulted,O
in,O
the,O
restoration,O
of,O
replication,O
to,O
levels,O
of,O
wild,O
-,O
type,O
HBV,O
.,O
In,O
all,O
clones,O
with,O
combined,O
immune,O
escape,O
and,O
LAM,I-Entity
resistance,O
mutations,O
",",O
the,O
nucleotide,I-Entity
analogues,O
adefovir,I-Entity
and,O
tenofovir,I-Entity
remained,O
effective,O
in,O
suppressing,O
viral,O
replication,O
in,O
vitro,O
.,O
The,O
effects,O
of,O
sevoflurane,I-Entity
on,O
lidocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
.,O
The,O
influence,O
of,O
sevoflurane,I-Entity
on,O
lidocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
was,O
studied,O
in,O
cats,O
.,O
The,O
convulsive,I-Entity
threshold,O
(,O
mean,O
+,O
/-,O
l(-1,O
),O
with,O
lidocaine,I-Entity
infusion,O
(,O
6,O
mg.kg(-1).min(-1,O
),O
),O
",",O
increasing,O
significantly,O
to,O
66.6,O
+,O
/-,O
l(-1,O
),O
when,O
the,O
end,O
-,O
tidal,O
concentration,O
of,O
sevoflurane,I-Entity
was,O
0.8%,O
.,O
l(-1,O
),O
),O
during,O
1.6%,O
sevoflurane,I-Entity
was,O
not,O
significant,O
from,O
that,O
during,O
0.8%,O
sevoflurane,I-Entity
",",O
indicating,O
a,O
celling,O
effect,O
.,O
There,O
was,O
no,O
significant,O
difference,O
in,O
the,O
convulsive,I-Entity
threshold,O
between,O
sevoflurane,I-Entity
and,O
enflurane,I-Entity
.,O
The,O
rise,O
in,O
blood,O
pressure,O
became,O
less,O
marked,O
when,O
higher,O
concentrations,O
of,O
sevoflurane,I-Entity
or,O
enflurane,I-Entity
were,O
administered,O
and,O
the,O
blood,O
pressure,O
at,O
convulsions,I-Entity
decreased,O
significantly,O
in,O
1.6%,O
sevoflurane,I-Entity
",",O
and,O
in,O
0.8%,O
and,O
1.6%,O
enflurane,I-Entity
.,O
However,O
",",O
there,O
was,O
no,O
significant,O
difference,O
in,O
the,O
lidocaine,I-Entity
concentrations,O
measured,O
when,O
the,O
systolic,O
blood,O
pressure,O
became,O
70,O
mmHg,O
.,O
Apamin,I-Entity
",",O
a,O
selective,O
blocker,O
of,O
calcium,I-Entity
-,O
dependent,O
potassium,I-Entity
channels,O
",",O
was,O
administered,O
intracerebroventricularly,O
in,O
rats,O
anesthetized,O
with,O
0.8%,O
sevoflurane,I-Entity
to,O
investigate,O
the,O
mechanism,O
of,O
the,O
anticonvulsive,O
effects,O
.,O
Apamin,I-Entity
(,O
10,O
ng,O
),O
had,O
a,O
tendency,O
to,O
decrease,O
the,O
convulsive,I-Entity
threshold,O
(,O
21.6,O
+,O
/-,O
It,O
is,O
suggested,O
that,O
sevoflurane,I-Entity
reduces,O
the,O
convulsive,I-Entity
effect,O
of,O
lidocaine,I-Entity
toxicity,I-Entity
but,O
carries,O
some,O
risk,O
due,O
to,O
circulatory,O
depression,I-Entity
.,O
Anti,O
-,O
oxidant,O
effects,O
of,O
atorvastatin,I-Entity
in,O
dexamethasone,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
the,O
rat,O
.,O
1,O
.,O
Dexamethasone,I-Entity
(,O
Dex)-induced,I-Entity
hypertension,I-Entity
is,O
characterized,O
by,O
endothelial,O
dysfunction,O
associated,O
with,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
deficiency,O
and,O
increased,O
superoxide,I-Entity
(,O
O2-,I-Entity
),O
production,O
.,O
Atorvastatin,I-Entity
(,O
Ato,I-Entity
),O
possesses,O
pleiotropic,O
properties,O
that,O
have,O
been,O
reported,O
to,O
improve,O
endothelial,O
function,O
through,O
increased,O
availability,O
of,O
NO,I-Entity
and,O
reduced,O
O2-,I-Entity
production,O
in,O
various,O
forms,O
of,O
hypertension,I-Entity
.,O
",",O
Ato,I-Entity
could,O
prevent,O
endothelial,O
NO,I-Entity
synthase,O
(,O
eNOS,O
),O
downregulation,O
and,O
the,O
increase,O
in,O
O2-,I-Entity
in,O
Sprague,O
-,O
Dawley,O
(,O
SD,O
),O
rats,O
",",O
thereby,O
reducing,O
blood,O
pressure,O
.,O
were,O
treated,O
with,O
Ato,I-Entity
(,O
50,O
mg,O
/,O
kg,O
per,O
day,O
in,O
drinking,O
water,O
),O
or,O
tap,O
water,O
for,O
15,O
days,O
.,O
Dexamethasone,I-Entity
(,O
10,O
microg,O
/,O
kg,O
per,O
day,O
",",O
s.c,O
.,O
),O
or,O
saline,O
was,O
started,O
after,O
4,O
days,O
in,O
Ato,I-Entity
-,O
treated,O
and,O
non,O
-,O
treated,O
rats,O
and,O
continued,O
for,O
11,O
-,O
13,O
days,O
.,O
Endothelial,O
function,O
was,O
assessed,O
by,O
acetylcholine,I-Entity
-,O
induced,O
vasorelaxation,O
and,O
phenylephrine,I-Entity
-,O
induced,O
vasoconstriction,O
in,O
aortic,O
segments,O
.,O
In,O
rats,O
treated,O
with,O
Dex,I-Entity
alone,O
",",O
SBP,O
was,O
increased,O
from,O
109,O
+,O
/-,O
In,O
the,O
Ato,I-Entity
+,O
Dex,I-Entity
group,O
",",O
SBP,O
was,O
increased,O
from,O
113,O
+,O
/-,O
<,O
0.001,O
),O
",",O
but,O
was,O
significantly,O
lower,O
than,O
SBP,O
in,O
the,O
group,O
treated,O
with,O
Dex,I-Entity
alone,O
(,O
P,O
<,O
0.05,O
),O
.,O
Endothelial,O
-,O
dependent,O
relaxation,O
and,O
eNOS,O
mRNA,O
expression,O
were,O
greater,O
in,O
the,O
Dex,I-Entity
+,O
Ato,I-Entity
group,O
than,O
in,O
the,O
Dex,I-Entity
only,O
group,O
(,O
P,O
<,O
0.05,O
and,O
P,O
Aortic,O
superoxide,I-Entity
production,O
was,O
lower,O
in,O
the,O
Dex,I-Entity
+,O
Ato,I-Entity
group,O
compared,O
with,O
the,O
group,O
treated,O
with,O
Dex,I-Entity
alone,O
(,O
P,O
<,O
0.0001,O
),O
.,O
Treatment,O
with,O
Ato,I-Entity
improved,O
endothelial,O
function,O
",",O
reduced,O
superoxide,I-Entity
production,O
and,O
reduced,O
SBP,O
in,O
Dex,I-Entity
-,O
treated,O
SD,O
rats,O
.,O
99mTc,B-Entity
-,I-Entity
glucarate,I-Entity
for,O
detection,O
of,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
Infarct,I-Entity
-,O
avid,O
radiopharmaceuticals,O
are,O
necessary,O
for,O
rapid,O
and,O
timely,O
diagnosis,O
of,O
acute,O
myocardial,B-Entity
infarction,I-Entity
.,O
The,O
animal,O
model,O
used,O
to,O
produce,O
infarction,I-Entity
implies,O
artery,O
ligation,O
but,O
chemical,O
induction,O
can,O
be,O
easily,O
obtained,O
with,O
isoproterenol,I-Entity
.,O
A,O
new,O
infarct,I-Entity
-,O
avid,O
radiopharmaceutical,O
based,O
on,O
glucaric,B-Entity
acid,I-Entity
was,O
prepared,O
in,O
the,O
hospital,O
radiopharmacy,O
of,O
the,O
INCMNSZ,O
.,O
99mTc,B-Entity
-,I-Entity
glucarate,I-Entity
was,O
easy,O
to,O
prepare,O
",",O
stable,O
for,O
96,O
h,O
and,O
was,O
used,O
to,O
study,O
its,O
biodistribution,O
in,O
rats,O
with,O
isoproterenol,I-Entity
-,O
induced,O
acute,O
myocardial,B-Entity
infarction,I-Entity
.,O
Histological,O
studies,O
demonstrated,O
that,O
the,O
rats,O
developed,O
an,O
infarct,I-Entity
18,O
h,O
after,O
isoproterenol,I-Entity
administration,O
.,O
Thirty,O
minutes,O
after,O
99mTc,B-Entity
-,I-Entity
glucarate,I-Entity
administration,O
the,O
standardised,O
heart,O
uptake,O
value,O
S(h)UV,O
was,O
4.7,O
in,O
infarcted,O
rat,O
heart,O
which,O
is,O
six,O
times,O
more,O
than,O
in,O
normal,O
rats,O
.,O
The,O
high,O
image,O
quality,O
suggests,O
that,O
high,O
contrast,O
images,O
can,O
be,O
obtained,O
in,O
humans,O
and,O
the,O
96,O
h,O
stability,O
makes,O
it,O
an,O
ideal,O
agent,O
to,O
detect,O
",",O
in,O
patients,O
",",O
early,O
cardiac,B-Entity
infarction,I-Entity
.,O
A,O
randomized,O
",",O
placebo,O
-,O
controlled,O
dose,O
-,O
comparison,O
trial,O
of,O
haloperidol,I-Entity
for,O
psychosis,I-Entity
and,O
disruptive,B-Entity
behaviors,I-Entity
in,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
.,O
OBJECTIVE,O
:,O
The,O
goal,O
of,O
this,O
study,O
was,O
to,O
compare,O
the,O
efficacy,O
and,O
side,O
effects,O
of,O
two,O
doses,O
of,O
haloperidol,I-Entity
and,O
placebo,O
in,O
the,O
treatment,O
of,O
psychosis,I-Entity
and,O
disruptive,B-Entity
behaviors,I-Entity
in,O
patients,O
with,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
.,O
In,O
a,O
6-week,O
random,O
-,O
assignment,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
(,O
phase,O
A,O
),O
",",O
haloperidol,I-Entity
",",O
2,O
-,O
3,O
mg,O
/,O
day,O
(,O
standard,O
dose,O
),O
",",O
and,O
haloperidol,I-Entity
",",O
0.50,O
-,O
0.75,O
mg,O
/,O
day,O
(,O
low,O
dose,O
),O
",",O
were,O
compared,O
in,O
71,O
outpatients,O
with,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
.,O
For,O
the,O
subsequent,O
6-week,O
double,O
-,O
blind,O
crossover,O
phase,O
(,O
phase,O
B,O
),O
",",O
patients,O
taking,O
standard-,O
or,O
low,O
-,O
dose,O
haloperidol,I-Entity
were,O
switched,O
to,O
placebo,O
",",O
and,O
patients,O
taking,O
placebo,O
were,O
randomly,O
assigned,O
to,O
standard-,O
or,O
low,O
-,O
dose,O
haloperidol,I-Entity
.,O
For,O
the,O
60,O
patients,O
who,O
completed,O
phase,O
A,O
",",O
standard,O
-,O
dose,O
haloperidol,I-Entity
was,O
efficacious,O
and,O
superior,O
to,O
both,O
low,O
-,O
dose,O
haloperidol,I-Entity
and,O
placebo,O
for,O
scores,O
on,O
the,O
Brief,O
Psychiatric,O
Rating,O
Scale,O
psychosis,I-Entity
factor,O
and,O
on,O
psychomotor,B-Entity
agitation,I-Entity
.,O
In,O
phase,O
A,O
",",O
extrapyramidal,B-Entity
signs,I-Entity
tended,O
to,O
be,O
greater,O
with,O
the,O
standard,O
dose,O
than,O
in,O
the,O
other,O
two,O
conditions,O
",",O
primarily,O
because,O
of,O
a,O
subgroup,O
(,O
20%,O
),O
who,O
developed,O
moderate,O
to,O
severe,O
signs,O
.,O
Low,O
-,O
dose,O
haloperidol,I-Entity
did,O
not,O
differ,O
from,O
placebo,O
on,O
any,O
measure,O
of,O
efficacy,O
or,O
side,O
effects,O
.,O
The,O
results,O
indicated,O
a,O
favorable,O
therapeutic,O
profile,O
for,O
haloperidol,I-Entity
in,O
doses,O
of,O
2,O
-,O
3,O
mg,O
/,O
day,O
",",O
although,O
a,O
subgroup,O
developed,O
moderate,O
to,O
severe,O
extrapyramidal,B-Entity
signs,I-Entity
.,O
The,O
narrow,O
therapeutic,O
window,O
observed,O
with,O
haloperidol,I-Entity
may,O
also,O
apply,O
to,O
other,O
neuroleptics,O
used,O
in,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
patients,O
with,O
psychosis,I-Entity
and,O
disruptive,B-Entity
behaviors,I-Entity
.,O
Individual,O
differences,O
in,O
renal,O
ACE,O
activity,O
in,O
healthy,O
rats,O
predict,O
susceptibility,O
to,O
adriamycin,I-Entity
-,O
induced,O
renal,B-Entity
damage,I-Entity
.,O
In,O
man,O
",",O
differences,O
in,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
(,O
ACE,O
),O
levels,O
",",O
related,O
to,O
ACE,O
(,O
I,O
/,O
D,O
),O
genotype,O
",",O
are,O
associated,O
with,O
renal,O
prognosis,O
.,O
Therefore,O
",",O
we,O
studied,O
the,O
predictive,O
effect,O
of,O
renal,O
ACE,O
activity,O
for,O
the,O
severity,O
of,O
renal,B-Entity
damage,I-Entity
induced,O
by,O
a,O
single,O
injection,O
of,O
adriamycin,I-Entity
in,O
rats,O
.,O
METHODS,O
:,O
Renal,O
ACE,O
activity,O
(,O
Hip,B-Entity
-,I-Entity
His,I-Entity
-,I-Entity
Leu,I-Entity
cleavage,O
by,O
cortical,O
homogenates,O
),O
was,O
determined,O
by,O
renal,O
biopsy,O
in,O
27,O
adult,O
male,O
Wistar,O
rats,O
.,O
After,O
1,O
week,O
of,O
recovery,O
",",O
proteinuria,I-Entity
was,O
induced,O
by,O
adriamycin,I-Entity
[,O
1.5,O
mg,O
/,O
kg,O
intravenously,O
(,O
i.v,O
.,O
),O
Proteinuria,I-Entity
was,O
measured,O
every,O
2,O
weeks,O
.,O
As,O
anticipated,O
",",O
adriamycin,I-Entity
elicited,O
nephrotic,I-Entity
range,O
proteinuria,I-Entity
",",O
renal,B-Entity
interstitial,I-Entity
damage,I-Entity
and,O
mild,O
focal,B-Entity
glomerulosclerosis,I-Entity
.,O
Baseline,O
renal,O
ACE,O
positively,O
correlated,O
with,O
the,O
relative,O
rise,O
in,O
proteinuria,I-Entity
after,O
adriamycin,I-Entity
(,O
r,O
=,O
0.62,O
",",O
P<0.01,O
),O
",",O
renal,O
interstitial,O
alpha,O
-,O
smooth,O
muscle,O
actin,O
(,O
r,O
=,O
0.49,O
",",O
P<0.05,O
),O
",",O
interstitial,O
macrophage,O
influx,O
(,O
r,O
=,O
0.56,O
",",O
P<0.05,O
),O
",",O
interstitial,O
collagen,O
III,O
(,O
r,O
=,O
0.53,O
",",O
P<0.05,O
),O
",",O
glomerular,O
alpha,O
-,O
smooth,O
muscle,O
actin,O
(,O
r,O
=,O
0.74,O
",",O
P<0.01,O
),O
and,O
glomerular,O
desmin,O
(,O
r,O
=,O
0.48,O
",",O
P<0.05,O
),O
.,O
ACE,O
did,O
not,O
correlate,O
with,O
focal,B-Entity
glomerulosclerosis,I-Entity
(,O
r,O
=,O
0.22,O
",",O
NS,O
),O
.,O
Individual,O
differences,O
in,O
renal,O
ACE,O
activity,O
predict,O
the,O
severity,O
of,O
adriamycin,I-Entity
-,O
induced,O
renal,B-Entity
damage,I-Entity
in,O
this,O
outbred,O
rat,O
strain,O
.,O
This,O
supports,O
the,O
assumption,O
that,O
differences,O
in,O
renal,O
ACE,O
activity,O
predispose,O
to,O
a,O
less,O
favourable,O
course,O
of,O
renal,B-Entity
damage,I-Entity
.,O
Clinical,O
nephrotoxicity,I-Entity
of,O
tobramycin,I-Entity
and,O
gentamicin,I-Entity
.,O
Nearly,O
3.2,O
million,O
people,O
in,O
this,O
country,O
receive,O
aminoglycoside,I-Entity
antibiotics,O
annually,O
.,O
Gentamicin,B-Entity
sulfate,I-Entity
and,O
tobramycin,B-Entity
sulfate,I-Entity
continue,O
to,O
demonstrate,O
ototoxicity,I-Entity
and,O
nephrotoxicity,I-Entity
in,O
both,O
animal,O
and,O
clinical,O
studies,O
.,O
In,O
this,O
study,O
",",O
62,O
patients,O
with,O
confirmed,O
initial,O
normal,O
renal,O
function,O
and,O
treated,O
with,O
2,O
to,O
5,O
mg,O
/,O
kg,O
/,O
day,O
of,O
gentamicin,B-Entity
sulfate,I-Entity
or,O
tobramycin,B-Entity
sulfate,I-Entity
for,O
a,O
minimum,O
of,O
seven,O
days,O
were,O
followed,O
up,O
prospectively,O
for,O
the,O
development,O
of,O
aminoglycoside,I-Entity
-,O
related,O
renal,B-Entity
failure,I-Entity
",",O
defined,O
as,O
at,O
least,O
a,O
one,O
-,O
third,O
reduction,O
in,O
renal,O
function,O
.,O
In,O
these,O
62,O
patients,O
",",O
no,O
other,O
causes,O
for,O
renal,B-Entity
failure,I-Entity
could,O
be,O
identified,O
.,O
Five,O
of,O
33,O
(,O
15%,O
),O
of,O
the,O
tobramycin,I-Entity
-,O
treated,O
patients,O
and,O
16,O
of,O
29,O
(,O
55.2%,O
),O
of,O
the,O
gentamicin,I-Entity
-,O
treated,O
patients,O
had,O
renal,B-Entity
failure,I-Entity
.,O
Thus,O
",",O
gentamicin,I-Entity
was,O
associated,O
with,O
renal,B-Entity
failure,I-Entity
more,O
than,O
three,O
times,O
as,O
often,O
as,O
was,O
tobramycin,I-Entity
.,O
Neuroprotective,O
action,O
of,O
MPEP,I-Entity
",",O
a,O
selective,O
mGluR5,O
antagonist,O
",",O
in,O
methamphetamine,I-Entity
-,O
induced,O
dopaminergic,O
neurotoxicity,I-Entity
is,O
associated,O
with,O
a,O
decrease,O
in,O
dopamine,I-Entity
outflow,O
and,O
inhibition,O
of,O
hyperthermia,I-Entity
in,O
rats,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
examine,O
the,O
role,O
of,O
metabotropic,O
glutamate,I-Entity
receptor,O
5,O
(,O
mGluR5,O
),O
in,O
the,O
toxic,O
action,O
of,O
methamphetamine,I-Entity
on,O
dopaminergic,O
neurones,O
in,O
rats,O
.,O
Methamphetamine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
sc,O
),O
",",O
administered,O
five,O
times,O
",",O
reduced,O
the,O
levels,O
of,O
dopamine,I-Entity
and,O
its,O
metabolites,O
in,O
striatal,O
tissue,O
when,O
measured,O
72,O
h,O
after,O
the,O
last,O
injection,O
.,O
A,O
selective,O
antagonist,O
of,O
mGluR5,O
",",O
2-methyl-6-(phenylethynyl)pyridine,I-Entity
(,O
MPEP,I-Entity
;,O
5,O
mg,O
/,O
kg,O
ip,O
),O
",",O
when,O
administered,O
five,O
times,O
immediately,O
before,O
each,O
methamphetamine,I-Entity
injection,O
reversed,O
the,O
above,O
-,O
mentioned,O
methamphetamine,I-Entity
effects,O
.,O
A,O
single,O
MPEP,I-Entity
(,O
5,O
mg,O
/,O
kg,O
ip,O
),O
injection,O
reduced,O
the,O
basal,O
extracellular,O
dopamine,I-Entity
level,O
in,O
the,O
striatum,O
",",O
as,O
well,O
as,O
dopamine,I-Entity
release,O
stimulated,O
either,O
by,O
methamphetamine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
sc,O
),O
or,O
by,O
intrastriatally,O
administered,O
veratridine,I-Entity
(,O
100,O
microM,O
),O
.,O
Moreover,O
",",O
it,O
transiently,O
diminished,O
the,O
methamphetamine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
sc)-induced,O
hyperthermia,I-Entity
and,O
reduced,O
basal,O
body,O
temperature,O
.,O
MPEP,I-Entity
administered,O
into,O
the,O
striatum,O
at,O
high,O
concentrations,O
(,O
500,O
microM,O
),O
increased,O
extracellular,O
dopamine,I-Entity
levels,O
",",O
while,O
lower,O
concentrations,O
(,O
50,O
-,O
100,O
microM,O
),O
were,O
devoid,O
of,O
any,O
effect,O
.,O
The,O
results,O
of,O
this,O
study,O
suggest,O
that,O
the,O
blockade,O
of,O
mGluR5,O
by,O
MPEP,I-Entity
may,O
protect,O
dopaminergic,O
neurones,O
against,O
methamphetamine,I-Entity
-,O
induced,O
toxicity,I-Entity
.,O
Neuroprotection,O
rendered,O
by,O
MPEP,I-Entity
may,O
be,O
associated,O
with,O
the,O
reduction,O
of,O
the,O
methamphetamine,I-Entity
-,O
induced,O
dopamine,I-Entity
efflux,O
in,O
the,O
striatum,O
due,O
to,O
the,O
blockade,O
of,O
extrastriatal,O
mGluR5,O
",",O
and,O
with,O
a,O
decrease,O
in,O
hyperthermia,I-Entity
.,O
Pharmacokinetics,O
of,O
desipramine,B-Entity
HCl,I-Entity
when,O
administered,O
with,O
cinacalcet,B-Entity
HCl,I-Entity
.,O
In,O
vitro,O
work,O
has,O
demonstrated,O
that,O
cinacalcet,I-Entity
is,O
a,O
strong,O
inhibitor,O
of,O
cytochrome,O
P450,O
isoenzyme,O
(,O
CYP,O
),O
2D6,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
effect,O
of,O
cinacalcet,I-Entity
on,O
CYP2D6,O
activity,O
",",O
using,O
desipramine,I-Entity
as,O
a,O
probe,O
substrate,O
",",O
in,O
healthy,O
subjects,O
.,O
Seventeen,O
subjects,O
who,O
were,O
genotyped,O
as,O
CYP2D6,O
extensive,O
metabolizers,O
were,O
enrolled,O
in,O
this,O
randomized,O
",",O
open,O
-,O
label,O
",",O
crossover,O
study,O
to,O
receive,O
a,O
single,O
oral,O
dose,O
of,O
desipramine,I-Entity
(,O
50,O
mg,O
),O
on,O
two,O
separate,O
occasions,O
",",O
once,O
alone,O
and,O
once,O
after,O
multiple,O
doses,O
of,O
cinacalcet,I-Entity
(,O
90,O
mg,O
for,O
7,O
days,O
),O
.,O
Relative,O
to,O
desipramine,I-Entity
alone,O
",",O
mean,O
AUC,O
and,O
C(max,O
),O
of,O
desipramine,I-Entity
increased,O
3.6-,O
and,O
1.8-fold,O
when,O
coadministered,O
with,O
cinacalcet,I-Entity
.,O
The,O
t,O
(,O
"1/2,z",O
),O
of,O
desipramine,I-Entity
was,O
longer,O
when,O
desipramine,I-Entity
was,O
coadministered,O
with,O
cinacalcet,I-Entity
(,O
21.0,O
versus,O
43.3,O
hs,O
),O
.,O
Fewer,O
subjects,O
reported,O
adverse,O
events,O
following,O
treatment,O
with,O
desipramine,I-Entity
alone,O
than,O
when,O
receiving,O
desipramine,I-Entity
with,O
cinacalcet,I-Entity
(,O
33,O
versus,O
86%,O
),O
",",O
the,O
most,O
frequent,O
of,O
which,O
(,O
nausea,I-Entity
and,O
headache,I-Entity
),O
have,O
been,O
reported,O
for,O
patients,O
treated,O
with,O
either,O
desipramine,I-Entity
or,O
cinacalcet,I-Entity
.,O
This,O
study,O
demonstrates,O
that,O
cinacalcet,I-Entity
is,O
a,O
strong,O
inhibitor,O
of,O
CYP2D6,O
.,O
These,O
data,O
suggest,O
that,O
during,O
concomitant,O
treatment,O
with,O
cinacalcet,I-Entity
",",O
dose,O
adjustment,O
may,O
be,O
necessary,O
for,O
drugs,O
that,O
demonstrate,O
a,O
narrow,O
therapeutic,O
index,O
and,O
are,O
metabolized,O
by,O
CYP2D6,O
.,O
Proteomic,O
analysis,O
of,O
striatal,O
proteins,O
in,O
the,O
rat,O
model,O
of,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
-,O
induced,O
dyskinesia,I-Entity
.,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
-,O
induced,O
dyskinesia,I-Entity
(,O
LID,I-Entity
),O
is,O
among,O
the,O
motor,O
complications,O
that,O
arise,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
patients,O
after,O
a,O
prolonged,O
treatment,O
with,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
.,O
To,O
this,O
day,O
",",O
transcriptome,O
analysis,O
has,O
been,O
performed,O
in,O
a,O
rat,O
model,O
of,O
LID,I-Entity
[,O
Neurobiol,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
investigated,O
the,O
changes,O
occurring,O
at,O
the,O
protein,O
level,O
in,O
striatal,O
samples,O
obtained,O
from,O
the,O
unilaterally,O
6-hydroxydopamine,I-Entity
-,O
lesion,O
rat,O
model,O
of,O
PD,I-Entity
treated,O
with,O
saline,O
",",O
L,B-Entity
-,I-Entity
DOPA,I-Entity
or,O
bromocriptine,I-Entity
using,O
two,O
-,O
dimensional,O
difference,O
gel,O
electrophoresis,O
and,O
mass,O
spectrometry,O
(,O
MS,O
),O
.,O
Rats,O
treated,O
with,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
were,O
allocated,O
to,O
two,O
groups,O
based,O
on,O
the,O
presence,O
or,O
absence,O
of,O
LID,I-Entity
.,O
Out,O
of,O
these,O
67,O
proteins,O
",",O
LID,I-Entity
significantly,O
changed,O
the,O
expression,O
level,O
of,O
five,O
proteins,O
:,O
alphabeta,O
-,O
crystalin,O
",",O
gamma,O
-,O
enolase,O
",",O
guanidoacetate,O
methyltransferase,O
",",O
vinculin,O
",",O
and,O
proteasome,O
alpha-2,O
subunit,O
.,O
In,O
conclusion,O
",",O
this,O
study,O
provides,O
new,O
insights,O
into,O
the,O
protein,O
changes,O
occurring,O
in,O
LID,I-Entity
.,O
Pseudo,O
-,O
allergic,B-Entity
reactions,I-Entity
to,O
corticosteroids,I-Entity
:,O
diagnosis,O
and,O
alternatives,O
.,O
Two,O
patients,O
treated,O
with,O
parenteral,O
paramethasone,I-Entity
(,O
Triniol,O
),O
and,O
dexamethasone,I-Entity
(,O
Sedionbel,O
),O
are,O
described,O
.,O
A,O
few,O
minutes,O
after,O
administration,O
of,O
the,O
drugs,O
",",O
they,O
presented,O
urticaria,I-Entity
(,O
patients,O
1,O
and,O
2,O
),O
and,O
conjunctivitis,I-Entity
(,O
patient,O
1,O
),O
.,O
Clinical,O
examinations,O
and,O
skin,O
",",O
oral,O
and,O
parenteral,O
challenges,O
with,O
different,O
corticosteroids,I-Entity
and,O
ELISA,O
tests,O
were,O
performed,O
.,O
In,O
the,O
two,O
patients,O
",",O
skin,O
and,O
ELISA,O
tests,O
with,O
paramethasone,I-Entity
were,O
negative,O
",",O
as,O
was,O
the,O
prick,O
test,O
with,O
each,O
of,O
its,O
excipients,O
.,O
We,O
also,O
carried,O
out,O
oral,O
and,O
parenteral,O
challenges,O
with,O
other,O
corticosteroids,I-Entity
and,O
found,O
intolerance,O
to,O
some,O
of,O
them,O
.,O
These,O
results,O
suggest,O
that,O
paramethasone,I-Entity
caused,O
pseudoallergic,O
reactions,O
in,O
our,O
patients,O
.,O
Corticosteroids,O
different,O
from,O
paramethasone,I-Entity
also,O
produced,O
hypersensitivity,I-Entity
reactions,O
in,O
these,O
patients,O
;,O
however,O
",",O
a,O
few,O
of,O
them,O
were,O
tolerated,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
report,O
of,O
a,O
pseudo,O
-,O
allergy,I-Entity
caused,O
by,O
paramethasone,I-Entity
.,O
Valproic,B-Entity
acid,I-Entity
induced,O
encephalopathy--19,I-Entity
new,O
cases,O
in,O
Germany,O
from,O
1994,O
to,O
2003,O
-,O
-a,O
side,O
effect,O
associated,O
to,O
VPA,I-Entity
-,O
therapy,O
not,O
only,O
in,O
young,O
children,O
.,O
Valproic,B-Entity
acid,I-Entity
(,O
VPA,I-Entity
),O
is,O
a,O
broad,O
-,O
spectrum,O
antiepileptic,O
drug,O
and,O
is,O
usually,O
well,O
-,O
tolerated,O
.,O
Rare,O
serious,O
complications,O
may,O
occur,O
in,O
some,O
patients,O
",",O
including,O
haemorrhagic,O
pancreatitis,I-Entity
",",O
bone,B-Entity
marrow,I-Entity
suppression,I-Entity
",",O
VPA,I-Entity
-,O
induced,O
hepatotoxicity,I-Entity
and,O
VPA,I-Entity
-,O
induced,O
encephalopathy,I-Entity
.,O
The,O
typical,O
signs,O
of,O
VPA,I-Entity
-,O
induced,O
encephalopathy,I-Entity
are,O
impaired,B-Entity
consciousness,I-Entity
",",O
sometimes,O
marked,O
EEG,O
background,O
slowing,O
",",O
increased,O
seizure,I-Entity
frequency,O
",",O
with,O
or,O
without,O
hyperammonemia,I-Entity
.,O
There,O
is,O
still,O
no,O
proof,O
of,O
causative,O
effect,O
of,O
VPA,I-Entity
in,O
patients,O
with,O
encephalopathy,I-Entity
",",O
but,O
only,O
of,O
an,O
association,O
with,O
an,O
assumed,O
causal,O
relation,O
.,O
We,O
report,O
19,O
patients,O
with,O
VPA,I-Entity
-,O
associated,O
encephalopathy,I-Entity
in,O
Germany,O
from,O
the,O
years,O
1994,O
to,O
2003,O
",",O
none,O
of,O
whom,O
had,O
been,O
published,O
previously,O
.,O
Haemolytic,B-Entity
-,I-Entity
uraemic,I-Entity
syndrome,I-Entity
after,O
treatment,O
with,O
metronidazole,I-Entity
.,O
This,O
paper,O
describes,O
the,O
clinical,O
features,O
of,O
six,O
children,O
who,O
developed,O
the,O
haemolytic,B-Entity
-,I-Entity
uraemic,I-Entity
syndrome,I-Entity
after,O
treatment,O
with,O
metronidazole,I-Entity
.,O
While,O
the,O
involvement,O
of,O
metronidazole,I-Entity
in,O
the,O
aetiology,O
of,O
the,O
haemolytic,B-Entity
-,I-Entity
uraemic,I-Entity
syndrome,I-Entity
is,O
not,O
established,O
firmly,O
",",O
the,O
action,O
of,O
this,O
drug,O
in,O
sensitizing,O
tissues,O
to,O
oxidation,O
injury,O
and,O
the,O
reported,O
evidence,O
of,O
oxidation,O
changes,O
in,O
the,O
haemolytic,B-Entity
-,I-Entity
uraemic,I-Entity
syndrome,I-Entity
suggest,O
a,O
possible,O
link,O
between,O
metronidazole,I-Entity
treatment,O
and,O
some,O
cases,O
of,O
the,O
haemolytic,B-Entity
-,I-Entity
uraemic,I-Entity
syndrome,I-Entity
.,O
Risk,O
factors,O
of,O
sensorineural,B-Entity
hearing,I-Entity
loss,I-Entity
in,O
preterm,O
infants,O
.,O
Among,O
547,O
preterm,O
infants,O
of,O
<,O
or,O
=,O
34,O
weeks,O
gestation,O
born,O
between,O
1987,O
and,O
1991,O
",",O
8,O
children,O
(,O
1.46%,O
),O
developed,O
severe,O
progressive,O
and,O
bilateral,O
sensorineural,B-Entity
hearing,I-Entity
loss,I-Entity
.,O
Perinatal,O
risk,O
factors,O
of,O
infants,O
with,O
hearing,B-Entity
loss,I-Entity
were,O
compared,O
with,O
those,O
of,O
two,O
control,O
groups,O
matched,O
for,O
gestation,O
and,O
birth,O
weight,O
and,O
for,O
perinatal,O
complications,O
.,O
Our,O
observations,O
demonstrated,O
an,O
association,O
of,O
hearing,B-Entity
loss,I-Entity
with,O
a,O
higher,O
incidence,O
of,O
perinatal,O
complications,O
.,O
Ototoxicity,I-Entity
appeared,O
closely,O
related,O
to,O
a,O
prolonged,O
administration,O
and,O
higher,O
total,O
dose,O
of,O
ototoxic,I-Entity
drugs,O
",",O
particularly,O
aminoglycosides,I-Entity
and,O
furosemide,I-Entity
.,O
Finally,O
",",O
we,O
strongly,O
recommend,O
to,O
prospectively,O
and,O
regularly,O
perform,O
audiologic,O
assessment,O
in,O
sick,O
preterm,O
children,O
as,O
hearing,B-Entity
loss,I-Entity
is,O
of,O
delayed,O
onset,O
and,O
in,O
most,O
cases,O
bilateral,O
and,O
severe,O
.,O
Pharmacokinetic,O
and,O
clinical,O
studies,O
in,O
patients,O
with,O
cimetidine,I-Entity
-,O
associated,O
mental,O
confusion,I-Entity
.,O
15,O
cases,O
of,O
cimetidine,I-Entity
-,O
associated,O
mental,O
confusion,I-Entity
have,O
been,O
reported,O
.,O
In,O
order,O
that,O
this,O
syndrome,O
might,O
be,O
investigated,O
changes,O
in,O
mental,O
status,O
(,O
M.S.,O
),O
were,O
correlated,O
with,O
serum,O
concentrations,O
and,O
renal,O
and,O
hepatic,O
function,O
in,O
36,O
patients,O
",",O
30,O
patients,O
had,O
no,O
M.S.,O
change,O
on,O
cimetidine,I-Entity
and,O
6,O
had,O
moderate,O
to,O
severe,O
changes,O
.,O
These,O
6,O
patients,O
had,O
both,O
renal,B-Entity
and,I-Entity
liver,I-Entity
dysfunction,I-Entity
(,O
P,O
less,O
than,O
0.05,O
),O
",",O
as,O
well,O
as,O
cimetidine,I-Entity
trough,O
-,O
concentrations,O
of,O
more,O
than,O
1.25,O
microgram,O
/,O
ml,O
(,O
P,O
less,O
than,O
0.05,O
),O
.,O
The,O
cerebrospinal,O
fluid,O
:,O
serum,O
ratio,O
of,O
cimetidine,I-Entity
concentrations,O
was,O
0.24:1,O
and,O
indicates,O
that,O
cimetidine,I-Entity
passes,O
the,O
blood,O
-,O
brain,O
barrier,O
;,O
it,O
also,O
raises,O
the,O
possibility,O
that,O
M.S.,O
changes,O
are,O
due,O
to,O
blockade,O
of,O
histamine,I-Entity
H2-receptors,O
in,O
the,O
central,O
nervous,O
system,O
.,O
Patients,O
likely,O
to,O
have,O
both,O
raised,O
trough,O
-,O
concentrations,O
and,O
mental,O
confusion,I-Entity
are,O
those,O
with,O
both,O
severe,O
renal,B-Entity
and,I-Entity
hepatic,I-Entity
dysfunction,I-Entity
.,O
They,O
should,O
be,O
closely,O
observed,O
and,O
should,O
be,O
given,O
reduced,O
doses,O
of,O
cimetidine,I-Entity
.,O
Different,O
lobular,O
distributions,O
of,O
altered,O
hepatocyte,O
tight,O
junctions,O
in,O
rat,O
models,O
of,O
intrahepatic,B-Entity
and,I-Entity
extrahepatic,I-Entity
cholestasis,I-Entity
.,O
Although,O
hepatocyte,O
TJs,O
are,O
impaired,O
in,O
cholestasis,I-Entity
",",O
attempts,O
to,O
localize,O
the,O
precise,O
site,O
of,O
hepatocyte,O
TJ,O
damage,O
by,O
freeze,O
-,O
fracture,O
electron,O
microscopy,O
have,O
produced,O
limited,O
information,O
.,O
We,O
used,O
rat,O
models,O
of,O
intrahepatic,B-Entity
cholestasis,I-Entity
by,O
ethinyl,B-Entity
estradiol,I-Entity
(,O
EE,I-Entity
),O
treatment,O
and,O
extrahepatic,B-Entity
cholestasis,I-Entity
by,O
bile,O
duct,O
ligation,O
(,O
BDL,O
),O
to,O
precisely,O
determine,O
the,O
site,O
of,O
TJ,O
damage,O
.,O
After,O
EE,I-Entity
treatment,O
",",O
changes,O
in,O
immunostaining,O
for,O
7H6,O
and,O
ZO-1,O
were,O
similar,O
to,O
those,O
seen,O
in,O
periportal,O
hepatocytes,O
after,O
BDL,O
",",O
but,O
distributed,O
more,O
diffusely,O
throughout,O
the,O
lobule,O
.,O
This,O
study,O
is,O
the,O
first,O
to,O
demonstrate,O
that,O
impairment,O
of,O
hepatocyte,O
TJs,O
occurs,O
heterogenously,O
in,O
the,O
liver,O
lobule,O
after,O
BDL,O
and,O
suggests,O
that,O
BDL,O
and,O
EE,I-Entity
treatments,O
produce,O
different,O
lobular,O
distributions,O
of,O
increased,O
paracellular,O
permeability,O
.,O
Long,O
term,O
audiological,O
evaluation,O
of,O
beta,B-Entity
-,I-Entity
thalassemic,I-Entity
patients,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
identify,O
the,O
incidence,O
and,O
to,O
monitor,O
the,O
progression,O
of,O
hearing,B-Entity
loss,I-Entity
in,O
children,O
and,O
young,O
adults,O
with,O
beta,B-Entity
-,I-Entity
thalassemia,I-Entity
major,O
.,O
Subjects,O
were,O
receiving,O
desferrioxamine,I-Entity
(,O
DFO,I-Entity
),O
chelation,O
treatment,O
with,O
a,O
mean,O
daily,O
dose,O
of,O
50,O
-,O
60,O
mg,O
/,O
kg,O
",",O
5,O
-,O
6,O
days,O
a,O
week,O
during,O
the,O
first,O
six,O
years,O
of,O
the,O
study,O
",",O
which,O
was,O
then,O
reduced,O
to,O
40,O
-,O
50,O
mg,O
/,O
kg,O
for,O
the,O
following,O
eight,O
years,O
.,O
Overall,O
",",O
21,O
out,O
of,O
104,O
patients,O
(,O
20.2%,O
),O
presented,O
with,O
high,O
frequency,O
sensorineural,B-Entity
hearing,I-Entity
loss,I-Entity
(,O
SNHL,I-Entity
),O
",",O
either,O
unilateral,O
or,O
bilateral,O
.,O
No,O
ototoxic,I-Entity
factor,O
",",O
other,O
than,O
DFO,I-Entity
",",O
was,O
present,O
in,O
any,O
of,O
the,O
patients,O
.,O
Patients,O
with,O
SNHL,I-Entity
presented,O
with,O
relatively,O
lower,O
serum,O
ferritin,O
levels,O
than,O
those,O
with,O
normal,O
hearing,O
",",O
however,O
",",O
no,O
statistically,O
significant,O
difference,O
was,O
observed,O
.,O
Subjects,O
with,O
SNHL,I-Entity
were,O
submitted,O
to,O
DFO,I-Entity
reduction,O
or,O
temporary,O
withdrawal,O
.,O
CONCLUSION,O
:,O
The,O
findings,O
are,O
indicative,O
of,O
DFO,I-Entity
's,O
contributing,O
role,O
in,O
the,O
development,O
of,O
hearing,B-Entity
impairment,I-Entity
.,O
Regular,O
audiologic,O
evaluation,O
is,O
imperative,O
in,O
all,O
thalassemic,I-Entity
patients,O
so,O
that,O
early,O
changes,O
may,O
be,O
recognized,O
and,O
treatment,O
may,O
be,O
judiciously,O
adjusted,O
in,O
order,O
to,O
prevent,O
or,O
reverse,O
hearing,B-Entity
impairment,I-Entity
.,O
Design,O
and,O
analysis,O
of,O
the,O
HYPREN,O
-,O
trial,O
:,O
safety,O
of,O
enalapril,I-Entity
and,O
prazosin,I-Entity
in,O
the,O
initial,O
treatment,O
phase,O
of,O
patients,O
with,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
.,O
Since,O
the,O
introduction,O
of,O
angiotensin,B-Entity
converting,I-Entity
enzyme,I-Entity
(,I-Entity
ACE,I-Entity
),I-Entity
inhibitors,I-Entity
into,O
the,O
adjunctive,O
treatment,O
of,O
patients,O
with,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
",",O
cases,O
of,O
severe,O
hypotension,I-Entity
",",O
especially,O
on,O
the,O
first,O
day,O
of,O
treatment,O
",",O
have,O
occasionally,O
been,O
reported,O
.,O
To,O
assess,O
the,O
safety,O
of,O
the,O
ACE,B-Entity
inhibitor,I-Entity
enalapril,I-Entity
a,O
multicenter,O
",",O
randomized,O
",",O
prazosin,I-Entity
-,O
controlled,O
trial,O
was,O
designed,O
that,O
compared,O
the,O
incidence,O
and,O
severity,O
of,O
symptomatic,O
hypotension,I-Entity
on,O
the,O
first,O
day,O
of,O
treatment,O
.,O
Trial,O
medication,O
was,O
2.5,O
mg,O
enalapril,I-Entity
or,O
0.5,O
prazosin,I-Entity
.,O
Patients,O
who,O
received,O
enalapril,I-Entity
experienced,O
clinically,O
and,O
statistically,O
significantly,O
less,O
symptomatic,O
hypotension,I-Entity
(,O
5.2%,O
),O
than,O
the,O
patients,O
who,O
received,O
prazosin,I-Entity
(,O
12.9%,O
),O
.,O
It,O
was,O
concluded,O
that,O
treatment,O
with,O
enalapril,I-Entity
was,O
well,O
tolerated,O
and,O
it,O
is,O
",",O
therefore,O
",",O
unreasonable,O
to,O
restrict,O
the,O
initiation,O
of,O
treatment,O
with,O
enalapril,I-Entity
to,O
inpatients,O
.,O
Antagonism,O
between,O
interleukin,O
3,O
and,O
erythropoietin,O
in,O
mice,O
with,O
azidothymidine,I-Entity
-,O
induced,O
anemia,I-Entity
and,O
in,O
bone,O
marrow,O
endothelial,O
cells,O
.,O
Azidothymidine,I-Entity
(,O
AZT)-induced,I-Entity
anemia,I-Entity
in,O
mice,O
can,O
be,O
reversed,O
by,O
the,O
administration,O
of,O
IGF,O
-,O
IL-3,O
(,O
fusion,O
protein,O
of,O
insulin,O
-,O
like,O
growth,O
factor,O
II,O
(,O
IGF,O
II,O
),O
and,O
interleukin,O
3,O
),O
.,O
Although,O
interleukin,O
3,O
(,O
IL-3,O
),O
and,O
erythropoietin,O
(,O
EPO,O
),O
are,O
known,O
to,O
act,O
synergistically,O
on,O
hematopoietic,O
cell,O
proliferation,O
in,O
vitro,O
",",O
injection,O
of,O
IGF,O
-,O
IL-3,O
and,O
EPO,O
in,O
AZT,I-Entity
-,O
treated,O
mice,O
resulted,O
in,O
a,O
reduction,O
of,O
red,O
cells,O
and,O
an,O
increase,O
of,O
plasma,O
EPO,O
levels,O
as,O
compared,O
to,O
animals,O
treated,O
with,O
IGF,O
-,O
IL-3,O
or,O
EPO,O
alone,O
.,O
There,O
was,O
a,O
significant,O
reduction,O
of,O
thymidine,I-Entity
incorporation,O
into,O
both,O
erythroid,O
and,O
endothelial,O
cells,O
in,O
cultures,O
pre,O
-,O
treated,O
with,O
IGF,O
-,O
IL-3,O
and,O
EPO,O
.,O
Endothelial,O
cell,O
culture,O
supernatants,O
separated,O
by,O
ultrafiltration,O
and,O
ultracentrifugation,O
from,O
cells,O
treated,O
with,O
EPO,O
and,O
IL-3,O
significantly,O
reduced,O
thymidine,I-Entity
incorporation,O
into,O
erythroid,O
cells,O
as,O
compared,O
to,O
identical,O
fractions,O
obtained,O
from,O
the,O
media,O
of,O
cells,O
cultured,O
with,O
EPO,O
alone,O
.,O
Interactive,O
effects,O
of,O
variations,O
in,O
[,O
Na]o,I-Entity
and,O
[,O
Ca]o,I-Entity
on,O
rat,O
atrial,O
spontaneous,O
frequency,O
.,O
The,O
effects,O
of,O
varying,O
the,O
extracellular,O
concentrations,O
of,O
Na,I-Entity
and,O
Ca,I-Entity
(,O
[,O
Na]o,I-Entity
and,O
[,O
Ca]o,I-Entity
),O
on,O
both,O
",",O
the,O
spontaneous,O
beating,O
and,O
the,O
negative,O
chronotropic,O
action,O
of,O
verapamil,I-Entity
",",O
were,O
studied,O
in,O
the,O
isolated,O
rat,O
atria,O
.,O
in,O
control,O
Krebs,O
-,O
Ringer,O
containing,O
137,O
mM,O
Na,I-Entity
and,O
1.35,O
mM,O
Ca,I-Entity
(,O
N,O
),O
.,O
3%,O
by,O
lowering,O
[,O
Na]o,I-Entity
to,O
78,O
mM,O
(,O
LNa,O
),O
",",O
23,O
[,O
Na]o,I-Entity
to,O
78,O
mM,O
and,O
[,O
Ca]o,I-Entity
to,O
0.675,O
mM,O
(,O
LNa+LCa,O
),O
and,O
31,O
+,O
/-,O
5%,O
by,O
lowering,O
[,O
Na]o,I-Entity
to,O
78,O
mM,O
plus,O
increasing,O
[,O
Ca]o,I-Entity
to,O
3.6,O
mM,O
(,O
LNa+HCa,O
),O
.,O
At,O
normal,O
[,O
Na]o,I-Entity
",",O
decrease,O
(,O
0.675,O
mM,O
),O
or,O
increase,O
(,O
3.6,O
mM,O
),O
of,O
[,O
Ca]o,I-Entity
did,O
not,O
modify,O
BF,O
;,O
a,O
reduction,O
of,O
ten,O
times,O
(,O
0.135,O
mM,O
of,O
normal,O
[,O
Ca]o,I-Entity
was,O
effective,O
to,O
reduce,O
BF,O
by,O
40,O
+,O
/-,O
Dose,O
-,O
dependent,O
bradycardia,I-Entity
induced,O
by,O
verapamil,I-Entity
was,O
potentiated,O
by,O
LNa,O
",",O
LCa,O
",",O
and,O
HCa,O
.,O
Independent,O
but,O
not,O
additive,O
effects,O
of,O
Na,I-Entity
and,O
Ca,I-Entity
are,O
shown,O
by,O
decreases,O
in,O
the,O
values,O
of,O
[,O
verapamil]o,I-Entity
needed,O
to,O
reduce,O
BF,O
by,O
30%,O
(,O
IC30,O
),O
with,O
the,O
following,O
order,O
of,O
inhibitory,O
potency,O
:,O
LNa,O
The,O
[,O
verapamil]o,I-Entity
that,O
arrested,O
atrial,O
beating,O
(,O
AC,O
),O
was,O
also,O
potentiated,O
with,O
the,O
order,O
LNa,O
=,O
The,O
results,O
indicate,O
that,O
rat,O
atrial,O
spontaneous,O
beating,O
is,O
more,O
dependent,O
on,O
[,O
Na]o,I-Entity
than,O
on,O
[,O
Ca]o,I-Entity
in,O
a,O
range,O
of,O
+,O
/-,O
Also,O
the,O
enhancement,O
of,O
verapamil,I-Entity
effects,O
on,O
atrial,O
beating,O
was,O
more,O
pronounced,O
at,O
LNa,O
than,O
at,O
LCa.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Sodium,I-Entity
status,O
influences,O
chronic,O
amphotericin,B-Entity
B,I-Entity
nephrotoxicity,I-Entity
in,O
rats,O
.,O
The,O
nephrotoxic,I-Entity
potential,O
of,O
amphotericin,B-Entity
B,I-Entity
(,O
5,O
mg,O
/,O
kg,O
per,O
day,O
intraperitoneally,O
for,O
3,O
weeks,O
),O
has,O
been,O
investigated,O
in,O
salt,O
-,O
depleted,O
",",O
normal,O
-,O
salt,O
",",O
and,O
salt,O
-,O
loaded,O
rats,O
.,O
In,O
salt,O
-,O
depleted,O
rats,O
",",O
amphotericin,B-Entity
B,I-Entity
decreased,O
creatinine,I-Entity
clearance,O
linearly,O
with,O
time,O
",",O
with,O
an,O
85%,O
reduction,O
by,O
week,O
3,O
.,O
In,O
contrast,O
",",O
in,O
normal,O
-,O
salt,O
rats,O
creatinine,I-Entity
clearance,O
was,O
decreased,O
but,O
to,O
a,O
lesser,O
extent,O
at,O
week,O
2,O
and,O
3,O
",",O
and,O
in,O
salt,O
-,O
loaded,O
rats,O
creatinine,I-Entity
clearance,O
did,O
not,O
change,O
for,O
2,O
weeks,O
and,O
was,O
decreased,O
by,O
43%,O
at,O
week,O
3,O
.,O
All,O
rats,O
in,O
the,O
sodium,I-Entity
-,O
depleted,O
group,O
had,O
histopathological,O
evidence,O
of,O
patchy,O
tubular,O
cytoplasmic,O
degeneration,O
in,O
tubules,O
that,O
was,O
not,O
observed,O
in,O
any,O
normal,O
-,O
salt,O
or,O
salt,O
-,O
loaded,O
rat,O
.,O
Concentrations,O
of,O
amphotericin,B-Entity
B,I-Entity
in,O
plasma,O
were,O
not,O
significantly,O
different,O
among,O
the,O
three,O
groups,O
at,O
any,O
time,O
during,O
the,O
study,O
.,O
However,O
",",O
at,O
the,O
end,O
of,O
3,O
weeks,O
",",O
amphotericin,B-Entity
B,I-Entity
levels,O
in,O
the,O
kidneys,O
and,O
liver,O
were,O
significantly,O
higher,O
in,O
salt,O
-,O
depleted,O
and,O
normal,O
-,O
salt,O
rats,O
than,O
those,O
in,O
salt,O
-,O
loaded,O
rats,O
",",O
with,O
plasma,O
/,O
kidney,O
ratios,O
of,O
21,O
",",O
14,O
",",O
and,O
8,O
in,O
salt,O
-,O
depleted,O
",",O
normal,O
-,O
salt,O
",",O
and,O
salt,O
-,O
loaded,O
rats,O
",",O
respectively,O
.,O
In,O
conclusion,O
",",O
reductions,O
in,O
creatinine,I-Entity
clearance,O
and,O
renal,O
amphotericin,B-Entity
B,I-Entity
accumulation,O
after,O
chronic,O
amphotericin,B-Entity
B,I-Entity
administration,O
were,O
enhanced,O
by,O
salt,O
depletion,O
and,O
attenuated,O
by,O
sodium,I-Entity
loading,O
in,O
rats,O
.,O
Reversible,O
inferior,B-Entity
colliculus,I-Entity
lesion,I-Entity
in,O
metronidazole,I-Entity
-,O
induced,O
encephalopathy,I-Entity
:,O
magnetic,O
resonance,O
findings,O
on,O
diffusion,O
-,O
weighted,O
and,O
fluid,O
attenuated,O
inversion,O
recovery,O
imaging,O
.,O
OBJECTIVE,O
:,O
This,O
is,O
to,O
present,O
reversible,O
inferior,B-Entity
colliculus,I-Entity
lesions,I-Entity
in,O
metronidazole,I-Entity
-,O
induced,O
encephalopathy,I-Entity
",",O
to,O
focus,O
on,O
the,O
diffusion,O
-,O
weighted,O
imaging,O
(,O
DWI,O
),O
and,O
fluid,O
attenuated,O
inversion,O
recovery,O
(,O
FLAIR,O
),O
imaging,O
.,O
From,O
November,O
2005,O
to,O
September,O
2007,O
",",O
8,O
patients,O
(,O
5,O
men,O
and,O
3,O
women,O
),O
were,O
diagnosed,O
as,O
having,O
metronidazole,I-Entity
-,O
induced,O
encephalopathy,I-Entity
(,O
age,O
range,O
;,O
43,O
-,O
78,O
years,O
),O
.,O
They,O
had,O
been,O
taking,O
metronidazole,I-Entity
(,O
total,O
dosage,O
",",O
45,O
-,O
120,O
g,O
;,O
duration,O
",",O
30,O
days,O
to,O
2,O
months,O
),O
to,O
treat,O
the,O
infection,I-Entity
in,O
various,O
organs,O
.,O
Follow,O
-,O
up,O
MRIs,O
were,O
performed,O
on,O
5,O
patients,O
from,O
third,O
to,O
14th,O
days,O
after,O
discontinuation,O
of,O
metronidazole,I-Entity
administration,O
.,O
All,O
the,O
lesions,O
in,O
dentate,O
",",O
inferior,O
colliculus,O
",",O
pons,O
",",O
and,O
medullas,O
had,O
been,O
resolved,O
completely,O
on,O
follow,O
-,O
up,O
MRIs,O
in,O
5,O
patients,O
",",O
but,O
in,O
1,O
patient,O
of,O
them,O
",",O
corpus,O
callosal,B-Entity
lesion,I-Entity
persisted,O
.,O
CONCLUSIONS,O
:,O
Reversible,O
inferior,B-Entity
colliculus,I-Entity
lesions,I-Entity
could,O
be,O
considered,O
as,O
the,O
characteristic,O
for,O
metronidazole,I-Entity
-,O
induced,O
encephalopathy,I-Entity
",",O
next,O
to,O
the,O
dentate,O
nucleus,O
involvement,O
.,O
infusions,O
of,O
morphine,I-Entity
and,O
regional,O
analgesia,O
by,O
extradural,O
block,O
.,O
The,O
incidence,O
of,O
postoperative,O
respiratory,O
apnoea,I-Entity
was,O
compared,O
between,O
five,O
patients,O
receiving,O
a,O
continuous,O
i.v,O
.,O
infusion,O
of,O
morphine,I-Entity
(,O
mean,O
73.6,O
mg,O
),O
and,O
five,O
patients,O
receiving,O
a,O
continuous,O
extradural,O
infusion,O
of,O
0.25%,O
bupivacaine,I-Entity
(,O
mean,O
192,O
mg,O
),O
in,O
the,O
24-h,O
period,O
following,O
upper,O
abdominal,O
surgery,O
.,O
Monitoring,O
consisted,O
of,O
airflow,O
detection,O
by,O
a,O
carbon,B-Entity
dioxide,I-Entity
analyser,O
",",O
chest,O
wall,O
movement,O
detected,O
by,O
pneumatic,O
capsules,O
",",O
and,O
continuous,O
electrocardiograph,O
recorded,O
with,O
a,O
Holter,O
ambulatory,O
monitor,O
.,O
Both,O
obstructive,B-Entity
(,I-Entity
P,I-Entity
less,I-Entity
than,I-Entity
0.05,I-Entity
),I-Entity
and,I-Entity
central,I-Entity
apnoea,I-Entity
(,O
P,O
less,O
than,O
0.05,O
),O
occurred,O
more,O
frequently,O
in,O
patients,O
who,O
had,O
a,O
morphine,I-Entity
infusion,O
.,O
There,O
was,O
also,O
a,O
higher,O
incidence,O
of,O
tachyarrhythmias,I-Entity
(,O
P,O
less,O
than,O
0.05,O
),O
and,O
ventricular,B-Entity
ectopic,I-Entity
beats,I-Entity
(,O
P,O
less,O
than,O
0.05,O
),O
in,O
the,O
morphine,I-Entity
infusion,O
group,O
.,O
Magnetic,O
resonance,O
volumetry,O
of,O
the,O
cerebellum,O
in,O
epileptic,I-Entity
patients,O
after,O
phenytoin,I-Entity
overdosages,I-Entity
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
relationship,O
between,O
phenytoin,I-Entity
medication,O
and,O
cerebellar,B-Entity
atrophy,I-Entity
in,O
patients,O
who,O
had,O
experienced,O
clinical,O
intoxication,O
.,O
Using,O
linear,O
regression,O
we,O
found,O
that,O
no,O
correlation,O
exists,O
between,O
seizure,I-Entity
duration,O
",",O
elevation,O
of,O
phenytoin,I-Entity
serum,O
levels,O
and,O
cerebellar,O
volume,O
.,O
However,O
",",O
multiple,O
regression,O
for,O
the,O
daily,O
dosage,O
",",O
duration,O
of,O
phenytoin,I-Entity
treatment,O
and,O
cerebellar,O
volume,O
revealed,O
a,O
correlation,O
of,O
these,O
parameters,O
.,O
We,O
conclude,O
that,O
phenytoin,I-Entity
overdosage,I-Entity
does,O
not,O
necessarily,O
result,O
in,O
cerebellar,B-Entity
atrophy,I-Entity
and,O
it,O
is,O
unlikely,O
that,O
phenytoin,I-Entity
medication,O
was,O
the,O
only,O
cause,O
of,O
cerebellar,B-Entity
atrophy,I-Entity
in,O
the,O
remaining,O
patients,O
.,O
Quantitative,O
morphometric,O
studies,O
of,O
the,O
cerebellum,O
provide,O
valuable,O
insights,O
into,O
the,O
pathogenesis,O
of,O
cerebellar,B-Entity
disorders,I-Entity
.,O
Evaluation,O
of,O
cardiac,O
troponin,O
I,O
and,O
T,O
levels,O
as,O
markers,O
of,O
myocardial,B-Entity
damage,I-Entity
in,O
doxorubicin,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
rats,O
",",O
and,O
their,O
relationship,O
with,O
echocardiographic,O
and,O
histological,O
findings,O
.,O
Cardiac,O
troponins,O
I,O
(,O
cTnI,O
),O
and,O
T,O
(,O
cTnT,O
),O
have,O
been,O
shown,O
to,O
be,O
highly,O
sensitive,O
and,O
specific,O
markers,O
of,O
myocardial,B-Entity
cell,I-Entity
injury,I-Entity
.,O
We,O
investigated,O
the,O
diagnostic,O
value,O
of,O
cTnI,O
and,O
cTnT,O
for,O
the,O
diagnosis,O
of,O
myocardial,B-Entity
damage,I-Entity
in,O
a,O
rat,O
model,O
of,O
doxorubicin,I-Entity
(,O
DOX)-induced,I-Entity
cardiomyopathy,I-Entity
",",O
and,O
we,O
examined,O
the,O
relationship,O
between,O
serial,O
cTnI,O
and,O
cTnT,O
with,O
the,O
development,O
of,O
cardiac,B-Entity
disorders,I-Entity
monitored,O
by,O
echocardiography,O
and,O
histological,O
examinations,O
in,O
this,O
model,O
.,O
Thirty,O
-,O
five,O
Wistar,O
rats,O
were,O
given,O
1.5,O
mg,O
/,O
kg,O
DOX,I-Entity
",",O
i.v,O
.,O
By,O
using,O
transthoracic,O
echocardiography,O
",",O
anterior,O
and,O
posterior,O
wall,O
thickness,O
",",O
LV,O
diameters,O
and,O
LV,O
fractional,O
shortening,O
(,O
FS,O
),O
were,O
measured,O
in,O
all,O
rats,O
before,O
DOX,I-Entity
or,O
saline,O
",",O
and,O
at,O
weeks,O
6,O
and,O
9,O
after,O
treatment,O
in,O
all,O
surviving,O
rats,O
.,O
Histology,O
was,O
performed,O
in,O
DOX,I-Entity
-,O
rats,O
at,O
6,O
and,O
9,O
weeks,O
after,O
the,O
last,O
DOX,I-Entity
dose,O
and,O
in,O
all,O
controls,O
.,O
Eighteen,O
of,O
the,O
DOX,I-Entity
rats,O
died,O
prematurely,O
of,O
general,O
toxicity,I-Entity
during,O
the,O
9-week,O
period,O
.,O
/,O
BW,O
significantly,O
increased,O
",",O
whereas,O
LV,O
FS,O
was,O
decreased,O
after,O
9,O
weeks,O
in,O
the,O
DOX,I-Entity
group,O
(,O
p<0.001,O
),O
.,O
Histological,O
evaluation,O
of,O
hearts,O
from,O
all,O
rats,O
given,O
DOX,I-Entity
revealed,O
significant,O
slight,O
degrees,O
of,O
perivascular,O
and,O
interstitial,O
fibrosis,I-Entity
.,O
Only,O
five,O
of,O
the,O
controls,O
exhibited,O
evidence,O
of,O
very,O
slight,O
perivascular,O
fibrosis,I-Entity
.,O
A,O
significant,O
rise,O
in,O
cTnT,O
was,O
found,O
in,O
DOX,I-Entity
rats,O
after,O
cumulative,O
doses,O
of,O
7.5,O
and,O
12,O
mg,O
/,O
kg,O
in,O
comparison,O
with,O
baseline,O
(,O
p<0.05,O
),O
.,O
/,O
kg,O
DOX,I-Entity
.,O
and,O
cTnT,O
levels,O
were,O
significantly,O
increased,O
in,O
DOX,I-Entity
rats,O
compared,O
with,O
controls,O
(,O
p=0.006,O
",",O
0.007,O
),O
.,O
cTnI,O
(,O
ng,O
/,O
ml,O
),O
",",O
CK,O
-,O
MB,O
mass,O
and,O
CK,O
remained,O
unchanged,O
in,O
DOX,I-Entity
rats,O
compared,O
with,O
controls,O
.,O
CONCLUSIONS,O
:,O
Among,O
markers,O
of,O
ischemic,B-Entity
injury,I-Entity
after,O
DOX,I-Entity
in,O
rats,O
",",O
cTnT,O
showed,O
the,O
greatest,O
ability,O
to,O
detect,O
myocardial,B-Entity
damage,I-Entity
assessed,O
by,O
echocardiographic,O
detection,O
and,O
histological,O
changes,O
.,O
Although,O
there,O
was,O
a,O
discrepancy,O
between,O
the,O
amount,O
of,O
cTnI,O
and,O
cTnT,O
after,O
DOX,I-Entity
",",O
probably,O
due,O
to,O
heterogeneity,O
in,O
cross,O
-,O
reactivities,O
of,O
mAbs,O
to,O
various,O
cTnI,O
and,O
cTnT,O
forms,O
",",O
it,O
is,O
likely,O
that,O
cTnT,O
in,O
rats,O
after,O
DOX,I-Entity
indicates,O
cell,O
damage,O
determined,O
by,O
the,O
magnitude,O
of,O
injury,O
induced,O
and,O
that,O
cTnT,O
should,O
be,O
a,O
useful,O
marker,O
for,O
the,O
prediction,O
of,O
experimentally,O
induced,O
cardiotoxicity,I-Entity
and,O
possibly,O
for,O
cardioprotective,O
experiments,O
.,O
Calcineurin,O
-,O
inhibitor,O
induced,O
pain,I-Entity
syndrome,O
(,O
CIPS,I-Entity
),O
:,O
a,O
severe,O
disabling,O
complication,O
after,O
organ,O
transplantation,O
.,O
Bone,O
pain,I-Entity
after,O
transplantation,O
is,O
a,O
frequent,O
complication,O
that,O
can,O
be,O
caused,O
by,O
several,O
diseases,O
.,O
Treatment,O
strategies,O
depend,O
on,O
the,O
correct,O
diagnosis,O
of,O
the,O
pain,I-Entity
.,O
Nine,O
patients,O
with,O
severe,O
pain,I-Entity
in,O
their,O
feet,O
",",O
which,O
was,O
registered,O
after,O
transplantation,O
",",O
were,O
investigated,O
.,O
Magnetic,O
resonance,O
imaging,O
demonstrated,O
bone,B-Entity
marrow,I-Entity
oedema,I-Entity
in,O
the,O
painful,O
bones,O
.,O
Pain,I-Entity
was,O
not,O
explained,O
by,O
other,O
diseases,O
causing,O
foot,O
pain,I-Entity
",",O
like,O
reflex,B-Entity
sympathetic,I-Entity
dystrophy,I-Entity
",",O
polyneuropathy,I-Entity
",",O
Morton,B-Entity
's,I-Entity
neuralgia,I-Entity
",",O
gout,I-Entity
",",O
osteoporosis,I-Entity
",",O
avascular,B-Entity
necrosis,I-Entity
",",O
intermittent,B-Entity
claudication,I-Entity
",",O
orthopaedic,O
foot,B-Entity
deformities,I-Entity
",",O
stress,B-Entity
fractures,I-Entity
",",O
and,O
hyperparathyroidism,I-Entity
.,O
The,O
reduction,O
of,O
cyclosporine-,I-Entity
or,O
tacrolimus,I-Entity
trough,O
levels,O
and,O
the,O
administration,O
of,O
calcium,I-Entity
channel,O
blockers,O
led,O
to,O
relief,O
of,O
pain,I-Entity
.,O
The,O
Calcineurin,O
-,O
inhibitor,O
Induced,O
Pain,I-Entity
Syndrome,O
(,O
CIPS,I-Entity
),O
is,O
a,O
rare,O
but,O
severe,O
side,O
effect,O
of,O
cyclosporine,I-Entity
or,O
tacrolimus,I-Entity
and,O
is,O
accurately,O
diagnosed,O
by,O
its,O
typical,O
presentation,O
",",O
magnetic,O
resonance,O
imaging,O
and,O
bone,O
scans,O
.,O
Incorrect,O
diagnosis,O
of,O
the,O
syndrome,O
will,O
lead,O
to,O
a,O
significant,O
reduction,O
of,O
life,O
quality,O
in,O
patients,O
suffering,O
from,O
CIPS,I-Entity
.,O
The,O
haemodynamic,O
effects,O
of,O
propofol,I-Entity
in,O
combination,O
with,O
ephedrine,I-Entity
in,O
elderly,O
patients,O
(,O
ASA,O
groups,O
3,O
and,O
4,O
),O
.,O
The,O
marked,O
vasodilator,O
and,O
negative,O
inotropic,O
effects,O
of,O
propofol,I-Entity
are,O
disadvantages,O
in,O
frail,O
elderly,O
patients,O
.,O
We,O
investigated,O
the,O
safety,O
and,O
efficacy,O
of,O
adding,O
different,O
doses,O
of,O
ephedrine,I-Entity
to,O
propofol,I-Entity
in,O
order,O
to,O
obtund,O
the,O
hypotensive,I-Entity
response,O
.,O
The,O
haemodynamic,O
effects,O
of,O
adding,O
15,O
",",O
20,O
or,O
25,O
mg,O
of,O
ephedrine,I-Entity
to,O
200,O
mg,O
of,O
propofol,I-Entity
were,O
compared,O
to,O
control,O
in,O
40,O
ASA,O
3/4,O
patients,O
over,O
60,O
years,O
presenting,O
for,O
genito,O
-,O
urinary,O
surgery,O
.,O
The,O
addition,O
of,O
ephedrine,I-Entity
to,O
propofol,I-Entity
appears,O
to,O
be,O
an,O
effective,O
method,O
of,O
obtunding,O
the,O
hypotensive,I-Entity
response,O
to,O
propofol,I-Entity
at,O
all,O
doses,O
used,O
in,O
this,O
study,O
.,O
However,O
",",O
marked,O
tachycardia,I-Entity
associated,O
with,O
the,O
use,O
of,O
ephedrine,I-Entity
in,O
combination,O
with,O
propofol,I-Entity
occurred,O
in,O
the,O
majority,O
of,O
patients,O
",",O
occasionally,O
reaching,O
high,O
levels,O
in,O
individual,O
patients,O
.,O
Due,O
to,O
the,O
risk,O
of,O
this,O
tachycardia,I-Entity
inducing,O
myocardial,B-Entity
ischemia,I-Entity
",",O
we,O
would,O
not,O
recommend,O
the,O
use,O
in,O
elderly,O
patients,O
of,O
any,O
of,O
the,O
ephedrine,I-Entity
/,O
propofol,I-Entity
/,O
mixtures,O
studied,O
.,O
Neurotoxicity,I-Entity
of,O
halogenated,B-Entity
hydroxyquinolines,I-Entity
:,O
clinical,O
analysis,O
of,O
cases,O
reported,O
outside,O
Japan,O
.,O
An,O
analysis,O
is,O
presented,O
of,O
220,O
cases,O
of,O
possible,O
neurotoxic,I-Entity
reactions,O
to,O
halogenated,B-Entity
hydroxyquinolines,I-Entity
reported,O
from,O
outside,O
Japan,O
.,O
In,O
80,O
cases,O
insufficient,O
information,O
was,O
available,O
for,O
adequate,O
comment,O
and,O
in,O
29,O
a,O
relationship,O
to,O
the,O
administration,O
of,O
clioquinol,I-Entity
could,O
be,O
excluded,O
.,O
Of,O
the,O
remainder,O
",",O
a,O
relationship,O
to,O
clioquinol,I-Entity
was,O
considered,O
probable,O
in,O
42,O
and,O
possible,O
in,O
69,O
cases,O
.,O
In,O
six,O
of,O
the,O
probable,O
cases,O
the,O
neurological,B-Entity
disturbance,I-Entity
consisted,O
of,O
an,O
acute,O
reversible,O
encephalopathy,I-Entity
usually,O
related,O
to,O
the,O
ingestion,O
of,O
a,O
high,O
dose,O
of,O
clioquinol,I-Entity
over,O
a,O
short,O
period,O
.,O
The,O
most,O
common,O
manifestation,O
",",O
observed,O
in,O
15,O
further,O
cases,O
",",O
was,O
isolated,O
optic,B-Entity
atrophy,I-Entity
.,O
This,O
was,O
most,O
frequently,O
found,O
in,O
children,O
",",O
many,O
of,O
whom,O
had,O
received,O
clioquinol,I-Entity
as,O
treatment,O
for,O
acrodermatitis,B-Entity
enteropathica,I-Entity
.,O
In,O
the,O
remaining,O
cases,O
",",O
a,O
combination,O
of,O
myelopathy,I-Entity
",",O
visual,B-Entity
disturbance,I-Entity
",",O
and,O
peripheral,B-Entity
neuropathy,I-Entity
was,O
the,O
most,O
common,O
manifestation,O
.,O
Isolated,O
myelopathy,I-Entity
or,O
peripheral,B-Entity
neuropathy,I-Entity
",",O
or,O
these,O
manifestations,O
occurring,O
together,O
",",O
were,O
infrequent,O
.,O
The,O
onset,O
of,O
all,O
manifestations,O
(,O
except,O
toxic,O
encephalopathy,I-Entity
),O
was,O
usually,O
subacute,O
",",O
with,O
subsequent,O
partial,O
recovery,O
.,O
The,O
full,O
syndrome,O
of,O
subacute,O
myelo,B-Entity
-,I-Entity
optic,I-Entity
neuropathy,I-Entity
was,O
more,O
frequent,O
in,O
women,O
",",O
but,O
they,O
tended,O
to,O
have,O
taken,O
greater,O
quantities,O
of,O
the,O
drug,O
.,O
Epileptic,B-Entity
seizures,I-Entity
following,O
cortical,O
application,O
of,O
fibrin,O
sealants,O
containing,O
tranexamic,B-Entity
acid,I-Entity
in,O
rats,O
.,O
Recently,O
",",O
synthetic,O
fibrinolysis,O
inhibitors,O
such,O
as,O
tranexamic,B-Entity
acid,I-Entity
(,O
tAMCA,I-Entity
),O
have,O
been,O
considered,O
as,O
substitutes,O
for,O
aprotinin,O
.,O
However,O
",",O
tAMCA,I-Entity
has,O
been,O
shown,O
to,O
cause,O
epileptic,B-Entity
seizures,I-Entity
.,O
We,O
wanted,O
to,O
study,O
whether,O
tAMCA,I-Entity
retains,O
its,O
convulsive,I-Entity
action,O
if,O
incorporated,O
into,O
a,O
FS,O
.,O
FS,O
containing,O
aprotinin,O
or,O
different,O
concentrations,O
of,O
tAMCA,I-Entity
(,O
0.5,O
-,O
47.5,O
mg,O
/,O
ml,O
),O
were,O
applied,O
to,O
the,O
pial,O
surface,O
of,O
the,O
cortex,O
of,O
anaesthetized,O
rats,O
.,O
FS,O
containing,O
tAMCA,I-Entity
caused,O
paroxysmal,O
brain,O
activity,O
which,O
was,O
associated,O
with,O
distinct,O
convulsive,I-Entity
behaviours,O
.,O
The,O
degree,O
of,O
these,O
seizures,I-Entity
increased,O
with,O
increasing,O
concentration,O
of,O
tAMCA,I-Entity
.,O
Thus,O
",",O
FS,O
containing,O
47.5,O
mg,O
/,O
ml,O
tAMCA,I-Entity
evoked,O
generalized,B-Entity
seizures,I-Entity
in,O
all,O
tested,O
rats,O
(,O
n=6,O
),O
while,O
the,O
lowest,O
concentration,O
of,O
tAMCA,I-Entity
(,O
0.5,O
mg,O
/,O
ml,O
),O
only,O
evoked,O
brief,O
episodes,O
of,O
jerk,O
-,O
correlated,O
convulsive,I-Entity
potentials,O
in,O
1,O
of,O
6,O
rats,O
.,O
INTERPRETATION,O
:,O
Tranexamic,B-Entity
acid,I-Entity
retains,O
its,O
convulsive,I-Entity
action,O
within,O
FS,O
.,O
Thus,O
",",O
use,O
of,O
FS,O
containing,O
tAMCA,I-Entity
for,O
surgery,O
within,O
or,O
close,O
to,O
the,O
CNS,O
may,O
pose,O
a,O
substantial,O
risk,O
to,O
the,O
patient,O
.,O
A,O
diet,O
promoting,O
sugar,B-Entity
dependency,I-Entity
causes,O
behavioral,B-Entity
cross,I-Entity
-,I-Entity
sensitization,I-Entity
to,O
a,O
low,O
dose,O
of,O
amphetamine,I-Entity
.,O
Previous,O
research,O
in,O
this,O
laboratory,O
has,O
shown,O
that,O
a,O
diet,O
of,O
intermittent,O
excessive,O
sugar,O
consumption,O
produces,O
a,O
state,O
with,O
neurochemical,O
and,O
behavioral,O
similarities,O
to,O
drug,B-Entity
dependency,I-Entity
.,O
The,O
present,O
study,O
examined,O
whether,O
female,O
rats,O
on,O
various,O
regimens,O
of,O
sugar,O
access,O
would,O
show,O
behavioral,B-Entity
cross,I-Entity
-,I-Entity
sensitization,I-Entity
to,O
a,O
low,O
dose,O
of,O
amphetamine,I-Entity
.,O
After,O
a,O
30-min,O
baseline,O
measure,O
of,O
locomotor,O
activity,O
(,O
day,O
0,O
),O
",",O
animals,O
were,O
maintained,O
on,O
a,O
cyclic,O
diet,O
of,O
12-h,O
deprivation,O
followed,O
by,O
12-h,O
access,O
to,O
10%,O
sucrose,I-Entity
solution,O
and,O
chow,O
pellets,O
(,O
12,O
h,O
access,O
starting,O
4,O
h,O
after,O
onset,O
of,O
the,O
dark,O
period,O
),O
for,O
21,O
days,O
.,O
Nine,O
days,O
later,O
locomotor,O
activity,O
was,O
measured,O
in,O
response,O
to,O
a,O
single,O
low,O
dose,O
of,O
amphetamine,I-Entity
(,O
0.5,O
mg,O
/,O
kg,O
),O
.,O
The,O
animals,O
that,O
had,O
experienced,O
cyclic,O
sucrose,I-Entity
and,O
chow,O
were,O
hyperactive,I-Entity
in,O
response,O
to,O
amphetamine,I-Entity
compared,O
with,O
four,O
control,O
groups,O
(,O
ad,O
libitum,O
10%,O
sucrose,I-Entity
and,O
chow,O
followed,O
by,O
amphetamine,I-Entity
injection,O
",",O
cyclic,O
chow,O
followed,O
by,O
amphetamine,I-Entity
injection,O
",",O
ad,O
libitum,O
chow,O
with,O
amphetamine,I-Entity
",",O
or,O
cyclic,O
10%,O
sucrose,I-Entity
and,O
chow,O
with,O
a,O
saline,O
injection,O
),O
.,O
These,O
results,O
suggest,O
that,O
a,O
diet,O
comprised,O
of,O
alternating,O
deprivation,O
and,O
access,O
to,O
a,O
sugar,O
solution,O
and,O
chow,O
produces,O
bingeing,O
on,O
sugar,O
that,O
leads,O
to,O
a,O
long,O
lasting,O
state,O
of,O
increased,O
sensitivity,O
to,O
amphetamine,I-Entity
",",O
possibly,O
due,O
to,O
a,O
lasting,O
alteration,O
in,O
the,O
dopamine,I-Entity
system,O
.,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
-,O
induced,O
angiopathy,I-Entity
in,O
rats,O
.,O
The,O
effect,O
of,O
high,O
dose,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
treatment,O
on,O
aortic,O
permeability,O
to,O
albumin,O
and,O
on,O
the,O
ultrastructure,O
of,O
the,O
vessel,O
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
treated,O
with,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
(,O
D,B-Entity
-,I-Entity
pen,I-Entity
),O
500,O
mg,O
/,O
kg,O
/,O
day,O
for,O
10,O
or,O
42,O
days,O
.,O
TEM,O
revealed,O
extensive,O
elastolysis,O
in,O
the,O
arterial,O
wall,O
of,O
D,B-Entity
-,I-Entity
pen,I-Entity
-,O
treated,O
rats,O
",",O
consistent,O
with,O
an,O
inhibitory,O
effect,O
on,O
crosslink,O
formation,O
.,O
The,O
aorta,O
/,O
serum,O
-,O
ratio,O
and,O
the,O
radioactive,O
build,O
-,O
up,O
24,O
and,O
48,O
hours,O
after,O
injection,O
of,O
131I,O
-,O
HSA,O
was,O
reduced,O
in,O
animals,O
treated,O
with,O
D,B-Entity
-,I-Entity
pen,I-Entity
for,O
42,O
days,O
",",O
indicating,O
an,O
impeded,O
transmural,O
transport,O
of,O
tracer,O
which,O
may,O
be,O
caused,O
by,O
a,O
steric,O
exclusion,O
effect,O
of,O
abundant,O
hyaluronate,I-Entity
.,O
The,O
endothelial,O
ultrastructure,O
was,O
unaffected,O
by,O
D,B-Entity
-,I-Entity
pen,I-Entity
",",O
and,O
no,O
differences,O
in,O
aortic,O
131I,O
-,O
HSA,O
radioactivity,O
or,O
aorta,O
/,O
serum,O
-,O
ratio,O
were,O
recorded,O
between,O
experimental,O
and,O
control,O
groups,O
10,O
minutes,O
after,O
tracer,O
injection,O
",",O
indicating,O
that,O
the,O
permeability,O
of,O
the,O
endothelial,O
barrier,O
to,O
albumin,O
remained,O
unaffected,O
by,O
D,B-Entity
-,I-Entity
pen,I-Entity
treatment,O
.,O
These,O
observations,O
support,O
the,O
hypothesis,O
that,O
treatment,O
with,O
high,O
doses,O
of,O
D,B-Entity
-,I-Entity
pen,I-Entity
may,O
induce,O
a,O
fibroproliferative,O
response,O
in,O
rat,O
aorta,O
",",O
possibly,O
by,O
an,O
inhibitory,O
effect,O
on,O
the,O
cross,O
-,O
linking,O
of,O
collagen,O
and,O
elastin,O
.,O
Brain,O
natriuretic,O
peptide,O
is,O
a,O
predictor,O
of,O
anthracycline,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Anthracyclines,I-Entity
are,O
effective,O
antineoplastic,O
drugs,O
",",O
but,O
they,O
frequently,O
cause,O
dose,O
-,O
related,O
cardiotoxicity,I-Entity
.,O
The,O
cardiotoxicity,I-Entity
of,O
conventional,O
anthracycline,I-Entity
therapy,O
highlights,O
a,O
need,O
to,O
search,O
for,O
methods,O
that,O
are,O
highly,O
sensitive,O
and,O
capable,O
of,O
predicting,O
cardiac,B-Entity
dysfunction,I-Entity
.,O
We,O
measured,O
the,O
plasma,O
level,O
of,O
brain,O
natriuretic,O
peptide,O
(,O
BNP,O
),O
to,O
determine,O
whether,O
BNP,O
might,O
serve,O
as,O
a,O
simple,O
diagnostic,O
indicator,O
of,O
anthracycline,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
patients,O
with,O
acute,B-Entity
leukemia,I-Entity
treated,O
with,O
a,O
daunorubicin,I-Entity
(,O
DNR)-containing,I-Entity
regimen,O
.,O
Thirteen,O
patients,O
with,O
acute,B-Entity
leukemia,I-Entity
were,O
treated,O
with,O
a,O
DNR,I-Entity
-,O
containing,O
regimen,O
.,O
Three,O
patients,O
developed,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
after,O
the,O
completion,O
of,O
chemotherapy,O
.,O
Five,O
patients,O
were,O
diagnosed,O
as,O
having,O
subclinical,O
heart,B-Entity
failure,I-Entity
after,O
the,O
completion,O
of,O
chemotherapy,O
.,O
The,O
plasma,O
levels,O
of,O
BNP,O
in,O
all,O
the,O
patients,O
with,O
clinical,O
and,O
subclinical,O
heart,B-Entity
failure,I-Entity
increased,O
above,O
the,O
normal,O
limit,O
(,O
40,O
pg,O
/,O
ml,O
),O
before,O
the,O
detection,O
of,O
clinical,O
or,O
subclinical,O
heart,B-Entity
failure,I-Entity
by,O
radionuclide,O
angiography,O
.,O
On,O
the,O
other,O
hand,O
",",O
BNP,O
did,O
not,O
increase,O
in,O
the,O
patients,O
without,O
heart,B-Entity
failure,I-Entity
given,O
DNR,I-Entity
",",O
even,O
at,O
more,O
than,O
700,O
mg,O
/,O
m(2,O
),O
.,O
The,O
plasma,O
level,O
of,O
ANP,O
did,O
not,O
always,O
increase,O
in,O
all,O
the,O
patients,O
with,O
clinical,O
and,O
subclinical,O
heart,B-Entity
failure,I-Entity
.,O
These,O
preliminary,O
results,O
suggest,O
that,O
BNP,O
may,O
be,O
useful,O
as,O
an,O
early,O
and,O
sensitive,O
indicator,O
of,O
anthracycline,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Antibacterial,O
medication,O
use,O
during,O
pregnancy,O
and,O
risk,O
of,O
birth,B-Entity
defects,I-Entity
:,O
National,O
Birth,B-Entity
Defects,I-Entity
Prevention,O
Study,O
.,O
OBJECTIVE,O
:,O
To,O
estimate,O
the,O
association,O
between,O
antibacterial,O
medications,O
and,O
selected,O
birth,B-Entity
defects,I-Entity
.,O
Population,O
-,O
based,O
",",O
multisite,O
",",O
case,O
-,O
control,O
study,O
of,O
women,O
who,O
had,O
pregnancies,O
affected,O
by,O
1,O
of,O
more,O
than,O
30,O
eligible,O
major,O
birth,B-Entity
defects,I-Entity
identified,O
via,O
birth,B-Entity
defect,I-Entity
surveillance,O
programs,O
in,O
10,O
states,O
(,O
n,O
=,O
13,O
155,O
),O
and,O
control,O
women,O
randomly,O
selected,O
from,O
the,O
same,O
geographical,O
regions,O
(,O
n,O
=,O
4941,O
),O
.,O
Odds,O
ratios,O
(,O
ORs,O
),O
measuring,O
the,O
association,O
between,O
antibacterial,O
use,O
and,O
selected,O
birth,B-Entity
defects,I-Entity
adjusted,O
for,O
potential,O
confounders,O
.,O
Sulfonamides,I-Entity
were,O
associated,O
with,O
anencephaly,I-Entity
(,O
adjusted,O
OR,O
[,O
AOR,O
],O
=,O
3.4,O
;,O
95%,O
confidence,O
interval,O
[,O
CI,O
],O
",",O
1.3,O
-,O
8.8,O
),O
",",O
hypoplastic,B-Entity
left,I-Entity
heart,I-Entity
syndrome,I-Entity
(,O
AOR,O
=,O
3.2,O
;,O
95%,O
CI,O
",",O
1.3,O
-,O
7.6,O
),O
",",O
coarctation,B-Entity
of,I-Entity
the,I-Entity
aorta,I-Entity
(,O
AOR,O
=,O
2.7,O
;,O
95%,O
CI,O
",",O
1.3,O
-,O
5.6,O
),O
",",O
choanal,B-Entity
atresia,I-Entity
(,O
AOR,O
=,O
8.0,O
;,O
95%,O
CI,O
",",O
2.7,O
-,O
23.5,O
),O
",",O
transverse,B-Entity
limb,I-Entity
deficiency,I-Entity
(,O
AOR,O
=,O
2.5,O
;,O
95%,O
CI,O
",",O
1.0,O
-,O
5.9,O
),O
",",O
and,O
diaphragmatic,B-Entity
hernia,I-Entity
(,O
AOR,O
=,O
2.4,O
;,O
95%,O
CI,O
",",O
1.1,O
-,O
5.4,O
),O
.,O
Nitrofurantoins,I-Entity
were,O
associated,O
with,O
anophthalmia,I-Entity
or,O
microphthalmos,I-Entity
(,O
AOR,O
=,O
3.7,O
;,O
95%,O
CI,O
",",O
1.1,O
-,O
12.2,O
),O
",",O
hypoplastic,B-Entity
left,I-Entity
heart,I-Entity
syndrome,I-Entity
(,O
AOR,O
=,O
4.2,O
;,O
95%,O
CI,O
",",O
1.9,O
-,O
9.1,O
),O
",",O
atrial,B-Entity
septal,I-Entity
defects,I-Entity
(,O
AOR,O
=,O
1.9,O
;,O
95%,O
CI,O
",",O
1.1,O
-,O
3.4,O
),O
",",O
and,O
cleft,B-Entity
lip,I-Entity
with,O
cleft,B-Entity
palate,I-Entity
(,O
AOR,O
=,O
2.1,O
;,O
Other,O
antibacterial,O
agents,O
that,O
showed,O
associations,O
included,O
erythromycins,I-Entity
(,O
2,O
defects,O
),O
",",O
penicillins,I-Entity
(,O
1,O
defect,O
),O
",",O
cephalosporins,I-Entity
(,O
1,O
defect,O
),O
",",O
and,O
quinolones,I-Entity
(,O
1,O
defect,O
),O
.,O
CONCLUSIONS,O
:,O
Reassuringly,O
",",O
penicillins,I-Entity
",",O
erythromycins,I-Entity
",",O
and,O
cephalosporins,I-Entity
",",O
although,O
used,O
commonly,O
by,O
pregnant,O
women,O
",",O
were,O
not,O
associated,O
with,O
many,O
birth,B-Entity
defects,I-Entity
.,O
Sulfonamides,I-Entity
and,O
nitrofurantoins,I-Entity
were,O
associated,O
with,O
several,O
birth,B-Entity
defects,I-Entity
",",O
indicating,O
a,O
need,O
for,O
additional,O
scrutiny,O
.,O
Incidence,O
of,O
neoplasms,I-Entity
in,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
exposed,O
to,O
different,O
treatment,O
regimens,O
.,O
Immunosuppressive,O
drugs,O
have,O
been,O
used,O
during,O
the,O
last,O
30,O
years,O
in,O
treatment,O
of,O
patients,O
with,O
severe,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
The,O
drugs,O
commonly,O
used,O
are,O
cyclophosphamide,I-Entity
and,O
chlorambucil,I-Entity
(,O
alkylating,B-Entity
agents,I-Entity
),O
",",O
azathioprine,I-Entity
(,O
purine,I-Entity
analogue,O
),O
",",O
and,O
methotrexate,I-Entity
(,O
folic,B-Entity
acid,I-Entity
analogue,O
),O
.,O
There,O
is,O
evidence,O
that,O
all,O
four,O
immunosuppressive,O
drugs,O
can,O
reduce,O
synovitis,I-Entity
",",O
but,O
disease,O
activity,O
almost,O
always,O
recurs,O
after,O
therapy,O
is,O
stopped,O
.,O
Patients,O
treated,O
with,O
alkylating,B-Entity
agents,I-Entity
have,O
an,O
increased,O
risk,O
of,O
development,O
of,O
acute,B-Entity
nonlymphocytic,I-Entity
leukemia,I-Entity
",",O
and,O
both,O
alkylating,B-Entity
agents,I-Entity
and,O
azathioprine,I-Entity
are,O
associated,O
with,O
the,O
development,O
of,O
non,B-Entity
-,I-Entity
Hodgkin,I-Entity
's,I-Entity
lymphoma,I-Entity
.,O
Cyclophosphamide,I-Entity
therapy,O
increases,O
the,O
risk,O
of,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
bladder,I-Entity
.,O
There,O
have,O
been,O
several,O
long,O
-,O
term,O
studies,O
of,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
treated,O
with,O
azathioprine,I-Entity
and,O
cyclophosphamide,I-Entity
and,O
the,O
incidence,O
of,O
most,O
of,O
the,O
common,O
cancers,I-Entity
is,O
not,O
increased,O
.,O
Data,O
on,O
the,O
possible,O
increased,O
risk,O
of,O
malignancy,I-Entity
in,O
rheumatoid,B-Entity
arthritis,I-Entity
are,O
still,O
being,O
collected,O
",",O
and,O
until,O
further,O
information,O
is,O
available,O
",",O
the,O
use,O
of,O
immunosuppressive,O
drugs,O
",",O
particularly,O
alkylating,B-Entity
agents,I-Entity
",",O
in,O
the,O
treatment,O
of,O
rheumatoid,B-Entity
arthritis,I-Entity
should,O
be,O
reserved,O
for,O
patients,O
with,O
severe,O
progressive,O
disease,O
or,O
life,O
-,O
threatening,O
complications,O
.,O
Patterns,O
of,O
hepatic,B-Entity
injury,I-Entity
induced,O
by,O
methyldopa,I-Entity
.,O
Twelve,O
patients,O
with,O
liver,B-Entity
disease,I-Entity
related,O
to,O
methyldopa,I-Entity
were,O
seen,O
between,O
1967,O
and,O
1977,O
.,O
Jaundice,I-Entity
with,O
tender,O
hepatomegaly,I-Entity
",",O
usually,O
preceded,O
by,O
symptoms,O
of,O
malaise,O
",",O
anorexia,I-Entity
",",O
nausea,I-Entity
and,O
vomiting,I-Entity
",",O
and,O
associated,O
with,O
upper,O
abdominal,B-Entity
pain,I-Entity
",",O
was,O
an,O
invariable,O
finding,O
in,O
all,O
patients,O
.,O
Biochemical,O
liver,O
function,O
tests,O
indicated,O
hepatocellular,O
necrosis,I-Entity
and,O
correlated,O
with,O
histopathological,O
evidence,O
of,O
hepatic,B-Entity
injury,I-Entity
",",O
the,O
spectrum,O
of,O
which,O
ranged,O
from,O
fatty,B-Entity
change,I-Entity
and,O
focal,O
hepatocellular,O
necrosis,I-Entity
to,O
massive,B-Entity
hepatic,I-Entity
necrosis,I-Entity
.,O
Most,O
patients,O
showed,O
moderate,O
to,O
severe,O
acute,B-Entity
hepatitis,I-Entity
or,O
chronic,B-Entity
active,I-Entity
hepatitis,I-Entity
with,O
associated,O
cholestasis,I-Entity
.,O
One,O
patient,O
died,O
",",O
having,O
presented,O
in,O
hepatic,B-Entity
failure,I-Entity
",",O
and,O
another,O
",",O
who,O
had,O
been,O
taking,O
methyldopa,I-Entity
for,O
7,O
years,O
",",O
showed,O
slower,O
clinical,O
and,O
biochemical,O
resolution,O
over,O
a,O
period,O
of,O
several,O
months,O
.,O
The,O
remaining,O
patient,O
in,O
the,O
series,O
developed,O
fulminant,B-Entity
hepatitis,I-Entity
when,O
the,O
drug,O
was,O
accidentally,O
recommenced,O
1,O
year,O
after,O
a,O
prior,O
episode,O
of,O
methyldopa,I-Entity
-,O
induced,O
hepatitis,I-Entity
.,O
In,O
this,O
latter,O
patient,O
",",O
and,O
in,O
2,O
others,O
",",O
the,O
causal,O
relationship,O
between,O
methyldopa,I-Entity
and,O
hepatic,B-Entity
dysfunction,I-Entity
was,O
proved,O
with,O
the,O
recurrence,O
of,O
hepatitis,I-Entity
within,O
2,O
weeks,O
of,O
re,O
-,O
exposure,O
to,O
the,O
drug,O
.,O
A,O
phase,O
I,O
/,O
II,O
study,O
of,O
paclitaxel,I-Entity
plus,O
cisplatin,I-Entity
as,O
first,O
-,O
line,O
therapy,O
for,O
head,B-Entity
and,I-Entity
neck,I-Entity
cancers,I-Entity
:,O
preliminary,O
results,O
.,O
Improved,O
outcomes,O
among,O
patients,O
with,O
head,B-Entity
and,I-Entity
neck,I-Entity
carcinomas,I-Entity
require,O
investigations,O
of,O
new,O
drugs,O
for,O
induction,O
therapy,O
.,O
Preliminary,O
results,O
of,O
an,O
Eastern,O
Cooperative,O
Oncology,O
Group,O
study,O
of,O
single,O
-,O
agent,O
paclitaxel,I-Entity
(,O
Taxol,I-Entity
;,O
Bristol,O
-,O
Myers,O
Squibb,O
Company,O
",",O
Princeton,O
",",O
NJ,O
),O
reported,O
a,O
37%,O
response,O
rate,O
in,O
patients,O
with,O
head,B-Entity
and,I-Entity
neck,I-Entity
cancer,I-Entity
",",O
and,O
the,O
paclitaxel,I-Entity
/,O
cisplatin,I-Entity
combination,O
has,O
been,O
used,O
successfully,O
and,O
has,O
significantly,O
improved,O
median,O
response,O
duration,O
in,O
ovarian,B-Entity
cancer,I-Entity
patients,O
.,O
We,O
initiated,O
a,O
phase,O
I,O
/,O
II,O
trial,O
to,O
determine,O
the,O
response,O
and,O
toxicity,I-Entity
of,O
escalating,O
paclitaxel,I-Entity
doses,O
combined,O
with,O
fixed,O
-,O
dose,O
cisplatin,I-Entity
with,O
granulocyte,O
colony,O
-,O
stimulating,O
factor,O
support,O
in,O
patients,O
with,O
untreated,O
locally,O
advanced,O
inoperable,O
head,B-Entity
and,I-Entity
neck,I-Entity
carcinoma,I-Entity
.,O
Primary,O
tumor,I-Entity
sites,O
were,O
oropharynx,O
",",O
10,O
patients,O
;,O
hypopharynx,O
",",O
four,O
;,O
larynx,O
",",O
two,O
;,O
oral,O
cavity,O
",",O
three,O
;,O
unknown,O
primary,O
",",O
two,O
;,O
and,O
nasal,O
cavity,O
and,O
parotid,O
gland,O
",",O
one,O
each,O
.,O
Of,O
20,O
patients,O
evaluable,O
for,O
toxicity,I-Entity
",",O
four,O
had,O
stage,O
III,O
and,O
16,O
had,O
stage,O
IV,O
disease,O
.,O
Treatment,O
",",O
given,O
every,O
21,O
days,O
for,O
a,O
maximum,O
of,O
three,O
cycles,O
",",O
consisted,O
of,O
paclitaxel,I-Entity
by,O
3-hour,O
infusion,O
followed,O
the,O
next,O
day,O
by,O
a,O
fixed,O
dose,O
of,O
cisplatin,I-Entity
(,O
75,O
mg,O
/,O
m2,O
),O
.,O
The,O
dose,O
levels,O
incorporate,O
escalating,O
paclitaxel,I-Entity
doses,O
",",O
and,O
intrapatient,O
escalations,O
within,O
a,O
given,O
dose,O
level,O
are,O
permitted,O
if,O
toxicity,I-Entity
permits,O
.,O
With,O
paclitaxel,I-Entity
doses,O
of,O
200,O
mg,O
/,O
m2,O
and,O
higher,O
",",O
granulocyte,O
colony,O
-,O
stimulating,O
factor,O
5,O
micrograms,O
/,O
kg,O
/,O
d,O
is,O
given,O
(,O
days,O
4,O
through,O
12,O
),O
.,O
Alopecia,I-Entity
",",O
paresthesias,I-Entity
",",O
and,O
arthralgias,I-Entity
/,O
myalgias,I-Entity
have,O
occurred,O
frequently,O
",",O
but,O
with,O
one,O
exception,O
(,O
a,O
grade,O
3,O
myalgia,I-Entity
),O
they,O
have,O
been,O
grade,O
1,O
or,O
2,O
.,O
No,O
dose,O
-,O
limiting,O
hematologic,O
toxicity,I-Entity
has,O
been,O
seen,O
.,O
Paclitaxel,I-Entity
/,O
cisplatin,I-Entity
is,O
an,O
effective,O
first,O
-,O
line,O
regimen,O
for,O
locoregionally,O
advanced,O
head,B-Entity
and,I-Entity
neck,I-Entity
cancer,I-Entity
and,O
continued,O
study,O
is,O
warranted,O
.,O
Results,O
thus,O
far,O
suggest,O
no,O
dose,O
-,O
response,O
effect,O
for,O
paclitaxel,I-Entity
doses,O
above,O
200,O
mg,O
/,O
m2,O
.,O
A,O
phase,O
I,O
study,O
of,O
4'-0-tetrahydropyranyladriamycin,I-Entity
.,O
A,O
Phase,O
I,O
study,O
of,O
intravenous,O
(,O
IV,O
),O
bolus,O
4'-0-tetrahydropyranyladriamycin,I-Entity
(,O
Pirarubicin,I-Entity
),O
was,O
done,O
in,O
55,O
patients,O
in,O
good,O
performance,O
status,O
with,O
refractory,O
tumors,I-Entity
.,O
Twenty,O
-,O
six,O
had,O
minimal,O
prior,O
therapy,O
(,O
good,O
risk,O
),O
",",O
23,O
had,O
extensive,O
prior,O
therapy,O
(,O
poor,O
risk,O
),O
",",O
and,O
six,O
had,O
renal,B-Entity
and/or,I-Entity
hepatic,I-Entity
dysfunction,I-Entity
.,O
The,O
dose,O
-,O
limiting,O
toxic,O
effect,O
was,O
transient,O
noncumulative,O
granulocytopenia,I-Entity
.,O
Less,O
frequent,O
toxic,O
effects,O
included,O
thrombocytopenia,I-Entity
",",O
anemia,I-Entity
",",O
nausea,I-Entity
",",O
mild,O
alopecia,I-Entity
",",O
phlebitis,I-Entity
",",O
and,O
mucositis,I-Entity
.,O
Myelosuppression,I-Entity
was,O
more,O
in,O
patients,O
with,O
hepatic,B-Entity
dysfunction,I-Entity
.,O
Pharmacokinetic,O
analyses,O
in,O
21,O
patients,O
revealed,O
Pirarubicin,I-Entity
plasma,O
T,O
1/2,O
alpha,O
(,O
+,O
/-,O
Adriamycinol,I-Entity
",",O
doxorubicin,I-Entity
",",O
adriamycinone,I-Entity
",",O
and,O
tetrahydropyranyladriamycinol,I-Entity
were,O
the,O
metabolites,O
detected,O
in,O
plasma,O
and,O
the,O
amount,O
of,O
doxorubicin,I-Entity
was,O
less,O
than,O
or,O
equal,O
to,O
10%,O
of,O
the,O
total,O
metabolites,O
.,O
Urinary,O
excretion,O
of,O
Pirarubicin,I-Entity
in,O
the,O
first,O
24,O
hours,O
was,O
less,O
than,O
or,O
equal,O
to,O
10%,O
.,O
Activity,O
was,O
noted,O
in,O
mesothelioma,I-Entity
",",O
leiomyosarcoma,I-Entity
",",O
and,O
basal,B-Entity
cell,I-Entity
carcinoma,I-Entity
.,O
Differential,O
effects,O
of,O
gamma,B-Entity
-,I-Entity
hexachlorocyclohexane,I-Entity
(,O
lindane,I-Entity
),O
on,O
pharmacologically,O
-,O
induced,O
seizures,I-Entity
.,O
Gamma,B-Entity
-,I-Entity
hexachlorocyclohexane,I-Entity
(,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
),O
",",O
the,O
active,O
ingredient,O
of,O
the,O
insecticide,O
lindane,I-Entity
",",O
has,O
been,O
shown,O
to,O
decrease,O
seizure,I-Entity
threshold,O
to,O
pentylenetrazol,O
(,O
PTZ,I-Entity
),O
3,O
h,O
after,O
exposure,O
to,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
and,O
conversely,O
increase,O
threshold,O
to,O
PTZ,I-Entity
-,O
induced,O
seizures,I-Entity
24,O
h,O
after,O
exposure,O
to,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
(,O
Vohland,O
et,O
al,O
.,O
1981,O
),O
.,O
In,O
this,O
study,O
",",O
the,O
severity,O
of,O
response,O
to,O
other,O
seizure,I-Entity
-,O
inducing,O
agents,O
was,O
tested,O
in,O
mice,O
1,O
and,O
24,O
h,O
after,O
intraperitoneal,O
administration,O
of,O
80,O
mg,O
/,O
kg,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
.,O
One,O
hour,O
after,O
the,O
administration,O
of,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
",",O
the,O
activity,O
of,O
seizure,I-Entity
-,O
inducing,O
agents,O
was,O
increased,O
",",O
regardless,O
of,O
their,O
mechanism,O
",",O
while,O
24,O
h,O
after,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
a,O
differential,O
response,O
was,O
observed,O
.,O
Seizure,I-Entity
activity,O
due,O
to,O
PTZ,I-Entity
and,O
picrotoxin,I-Entity
(,O
PTX,I-Entity
),O
was,O
significantly,O
decreased,O
;,O
however,O
",",O
seizure,I-Entity
activity,O
due,O
to,O
3-mercaptopropionic,B-Entity
acid,I-Entity
(,O
MPA,I-Entity
),O
",",O
bicuculline,I-Entity
(,O
BCC,I-Entity
),O
",",O
methyl,B-Entity
"6,7-dimethoxy-4-ethyl",I-Entity
-,I-Entity
B,I-Entity
-,I-Entity
carboline-3-carboxylate,I-Entity
(,O
DMCM,I-Entity
),O
",",O
or,O
strychnine,I-Entity
(,O
STR,I-Entity
),O
was,O
not,O
different,O
from,O
control,O
.,O
In,O
vitro,O
",",O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
",",O
pentylenetetrazol,I-Entity
and,O
picrotoxin,I-Entity
were,O
shown,O
to,O
inhibit,O
3H,B-Entity
-,I-Entity
TBOB,I-Entity
binding,O
in,O
mouse,O
whole,O
brain,O
",",O
with,O
IC50,O
values,O
of,O
4.6,O
",",O
404,O
and,O
9.4,O
microM,O
",",O
respectively,O
.,O
MPA,I-Entity
",",O
BCC,I-Entity
",",O
DMCM,I-Entity
",",O
and,O
STR,I-Entity
showed,O
no,O
inhibition,O
of,O
3H,B-Entity
-,I-Entity
TBOB,I-Entity
(,O
t,B-Entity
-,I-Entity
butyl,I-Entity
bicyclo,I-Entity
-,I-Entity
orthobenzoate,I-Entity
),O
binding,O
at,O
concentrations,O
of,O
100,O
micron,O
.,O
The,O
pharmacological,O
challenge,O
data,O
suggest,O
that,O
tolerance,O
may,O
occur,O
to,O
seizure,I-Entity
activity,O
induced,O
by,O
PTZ,I-Entity
and,O
PTX,I-Entity
24,O
h,O
after,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
",",O
since,O
the,O
response,O
to,O
only,O
these,O
two,O
seizure,I-Entity
-,O
inducing,O
agents,O
is,O
decreased,O
.,O
The,O
in,O
vitro,O
data,O
suggest,O
that,O
the,O
site,O
responsible,O
for,O
the,O
decrease,O
in,O
seizure,I-Entity
activity,O
24,O
h,O
after,O
gamma,B-Entity
-,I-Entity
HCH,I-Entity
may,O
be,O
the,O
GABA,I-Entity
-,O
A,O
receptor,O
-,O
linked,O
chloride,O
channel,O
.,O
Severe,O
ocular,B-Entity
and,I-Entity
orbital,I-Entity
toxicity,I-Entity
after,O
intracarotid,O
injection,O
of,O
carboplatin,I-Entity
for,O
recurrent,O
glioblastomas,I-Entity
.,O
Glioblastoma,I-Entity
is,O
a,O
malignant,B-Entity
tumor,I-Entity
that,O
occurs,O
in,O
the,O
cerebrum,O
during,O
adulthood,O
.,O
Therefore,O
",",O
patients,O
with,O
glioblastoma,I-Entity
sometimes,O
have,O
intracarotid,O
injection,O
of,O
carcinostatics,O
added,O
to,O
the,O
treatment,O
regimen,O
.,O
Generally,O
",",O
carboplatin,I-Entity
is,O
said,O
to,O
have,O
milder,O
side,O
effects,O
than,O
cisplatin,I-Entity
",",O
whose,O
ocular,B-Entity
and,I-Entity
orbital,I-Entity
toxicity,I-Entity
are,O
well,O
known,O
.,O
However,O
",",O
we,O
experienced,O
a,O
case,O
of,O
severe,O
ocular,B-Entity
and,I-Entity
orbital,I-Entity
toxicity,I-Entity
after,O
intracarotid,O
injection,O
of,O
carboplatin,I-Entity
",",O
which,O
is,O
infrequently,O
reported,O
.,O
A,O
58-year,O
-,O
old,O
man,O
received,O
an,O
intracarotid,O
injection,O
of,O
carboplatin,I-Entity
for,O
recurrent,O
glioblastomas,I-Entity
in,O
his,O
left,O
temporal,O
lobe,O
.,O
He,O
complained,O
of,O
pain,B-Entity
and,I-Entity
visual,I-Entity
disturbance,I-Entity
in,I-Entity
the,I-Entity
ipsilateral,I-Entity
eye,I-Entity
30,O
h,O
after,O
the,O
injection,O
.,O
Various,O
ocular,O
symptoms,O
and,O
findings,O
caused,O
by,O
carboplatin,I-Entity
toxicity,I-Entity
were,O
seen,O
.,O
He,O
was,O
treated,O
with,O
intravenous,O
administration,O
of,O
corticosteroids,O
and,O
glycerin,I-Entity
for,O
6,O
days,O
after,O
the,O
injection,O
.,O
Although,O
the,O
intraocular,O
pressure,O
elevation,O
caused,O
by,O
secondary,O
acute,O
angle,O
-,O
closure,O
glaucoma,I-Entity
decreased,O
and,O
ocular,B-Entity
pain,I-Entity
diminished,O
",",O
inexorable,O
papilledema,I-Entity
and,O
exudative,O
retinal,B-Entity
detachment,I-Entity
continued,O
for,O
3,O
weeks,O
.,O
Finally,O
",",O
6,O
weeks,O
later,O
",",O
diffuse,O
chorioretinal,B-Entity
atrophy,I-Entity
with,O
optic,B-Entity
atrophy,I-Entity
occurred,O
and,O
the,O
vision,O
in,O
his,O
left,O
eye,O
was,O
lost,O
.,O
CONCLUSION,O
:,O
When,O
performing,O
intracarotid,O
injection,O
of,O
carboplatin,I-Entity
",",O
we,O
must,O
be,O
aware,O
of,O
its,O
potentially,O
blinding,O
ocular,B-Entity
toxicity,I-Entity
.,O
Phase,O
II,O
study,O
of,O
the,O
amsacrine,I-Entity
analogue,O
CI-921,I-Entity
(,O
NSC,B-Entity
343499,I-Entity
),O
in,O
non,B-Entity
-,I-Entity
small,I-Entity
cell,I-Entity
lung,I-Entity
cancer,I-Entity
.,O
CI-921,I-Entity
(,O
NSC,B-Entity
343499,I-Entity
;,O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino,B-Entity
],I-Entity
"-N,5-dimethyl-",I-Entity
4-acridinecarboxamide,I-Entity
),O
is,O
a,O
topoisomerase,O
II,O
poison,O
with,O
high,O
experimental,O
antitumour,O
activity,O
.,O
It,O
was,O
administered,O
by,O
15,O
min,O
infusion,O
to,O
16,O
evaluable,O
patients,O
with,O
non,B-Entity
-,I-Entity
small,I-Entity
cell,I-Entity
lung,I-Entity
cancer,I-Entity
(,O
NSCLC,I-Entity
),O
(,O
7,O
with,O
no,O
prior,O
treatment,O
",",O
9,O
patients,O
in,O
relapse,O
following,O
surgery,O
/,O
radiotherapy,O
),O
at,O
a,O
dose,O
(,O
648,O
mg,O
/,O
m2,O
divided,O
over,O
3,O
days,O
",",O
repeated,O
every,O
3,O
weeks,O
),O
determined,O
by,O
phase,O
I,O
trial,O
.,O
The,O
histology,O
comprised,O
squamous,B-Entity
carcinoma,I-Entity
(,O
11,O
),O
",",O
adenocarcinoma,I-Entity
(,O
1,O
),O
",",O
mixed,O
histology,O
(,O
2,O
),O
",",O
bronchio,B-Entity
-,I-Entity
alveolar,I-Entity
carcinoma,I-Entity
(,O
1,O
),O
and,O
large,O
cell,O
undifferentiated,B-Entity
carcinoma,I-Entity
(,O
1,O
),O
.,O
Neutropenia,I-Entity
grade,O
greater,O
than,O
or,O
equal,O
to,O
3,O
was,O
seen,O
in,O
15,O
patients,O
",",O
infections,I-Entity
with,O
recovery,O
in,O
3,O
",",O
and,O
grand,O
mal,O
seizures,I-Entity
in,O
1,O
patient,O
.,O
Grade,O
less,O
than,O
or,O
equal,O
to,O
2,O
nausea,I-Entity
and,O
vomiting,I-Entity
occurred,O
in,O
66%,O
courses,O
and,O
phlebitis,I-Entity
in,O
the,O
infusion,O
arm,O
in,O
37%,O
.,O
1,O
patient,O
with,O
squamous,B-Entity
cell,I-Entity
carcinoma,I-Entity
achieved,O
a,O
partial,O
response,O
lasting,O
5,O
months,O
.,O
Further,O
testing,O
in,O
this,O
and,O
other,O
tumour,I-Entity
types,O
using,O
multiple,O
daily,O
schedules,O
is,O
warranted,O
.,O
Alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
prevents,O
mitochondrial,B-Entity
damage,I-Entity
and,O
neurotoxicity,I-Entity
in,O
experimental,O
chemotherapy,O
neuropathy,I-Entity
.,O
The,O
study,O
investigates,O
if,O
alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
is,O
neuroprotective,O
against,O
chemotherapy,O
induced,O
neurotoxicity,I-Entity
",",O
if,O
mitochondrial,B-Entity
damage,I-Entity
plays,O
a,O
critical,O
role,O
in,O
toxic,B-Entity
neurodegenerative,I-Entity
cascade,I-Entity
",",O
and,O
if,O
neuroprotective,O
effects,O
of,O
alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
depend,O
on,O
mitochondria,O
protection,O
.,O
We,O
used,O
an,O
in,O
vitro,O
model,O
of,O
chemotherapy,O
induced,O
peripheral,B-Entity
neuropathy,I-Entity
that,O
closely,O
mimic,O
the,O
in,O
vivo,O
condition,O
by,O
exposing,O
primary,O
cultures,O
of,O
dorsal,O
root,O
ganglion,O
(,O
DRG,O
),O
sensory,O
neurons,O
to,O
paclitaxel,I-Entity
and,O
cisplatin,I-Entity
",",O
two,O
widely,O
used,O
and,O
highly,O
effective,O
chemotherapeutic,O
drugs,O
.,O
This,O
approach,O
allowed,O
investigating,O
the,O
efficacy,O
of,O
alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
in,O
preventing,O
axonal,B-Entity
damage,I-Entity
and,O
apoptosis,O
and,O
the,O
function,O
and,O
ultrastructural,O
morphology,O
of,O
mitochondria,O
after,O
exposure,O
to,O
toxic,O
agents,O
and,O
alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
.,O
Our,O
results,O
demonstrate,O
that,O
both,O
cisplatin,I-Entity
and,O
paclitaxel,I-Entity
cause,O
early,O
mitochondrial,B-Entity
impairment,I-Entity
with,O
loss,O
of,O
membrane,O
potential,O
and,O
induction,O
of,O
autophagic,O
vacuoles,O
in,O
neurons,O
.,O
Alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
exerts,O
neuroprotective,O
effects,O
against,O
chemotherapy,O
induced,O
neurotoxicity,I-Entity
in,O
sensory,O
neurons,O
:,O
it,O
rescues,O
the,O
mitochondrial,B-Entity
toxicity,I-Entity
and,O
induces,O
the,O
expression,O
of,O
frataxin,O
",",O
an,O
essential,O
mitochondrial,O
protein,O
with,O
anti,O
-,O
oxidant,O
and,O
chaperone,O
properties,O
.,O
In,O
conclusion,O
mitochondrial,B-Entity
toxicity,I-Entity
is,O
an,O
early,O
common,O
event,O
both,O
in,O
paclitaxel,I-Entity
and,O
cisplatin,I-Entity
induced,O
neurotoxicity,I-Entity
.,O
Alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
protects,O
sensory,O
neurons,O
through,O
its,O
anti,O
-,O
oxidant,O
and,O
mitochondrial,O
regulatory,O
functions,O
",",O
possibly,O
inducing,O
the,O
expression,O
of,O
frataxin,O
.,O
These,O
findings,O
suggest,O
that,O
alpha,B-Entity
-,I-Entity
lipoic,I-Entity
acid,I-Entity
might,O
reduce,O
the,O
risk,O
of,O
developing,O
peripheral,B-Entity
nerve,I-Entity
toxicity,I-Entity
in,O
patients,O
undergoing,O
chemotherapy,O
and,O
encourage,O
further,O
confirmatory,O
clinical,O
trials,O
.,O
Optimising,O
stroke,I-Entity
prevention,O
in,O
non,O
-,O
valvular,O
atrial,B-Entity
fibrillation,I-Entity
.,O
Atrial,B-Entity
fibrillation,I-Entity
is,O
associated,O
with,O
substantial,O
morbidity,O
and,O
mortality,O
.,O
Pooled,O
data,O
from,O
trials,O
comparing,O
antithrombotic,O
treatment,O
with,O
placebo,O
have,O
shown,O
that,O
warfarin,I-Entity
reduces,O
the,O
risk,O
of,O
stroke,I-Entity
by,O
62%,O
",",O
and,O
that,O
aspirin,I-Entity
alone,O
reduces,O
the,O
risk,O
by,O
22%,O
.,O
Overall,O
",",O
in,O
high,O
-,O
risk,O
patients,O
",",O
warfarin,I-Entity
is,O
superior,O
to,O
aspirin,I-Entity
in,O
preventing,O
strokes,I-Entity
",",O
with,O
a,O
relative,O
risk,O
reduction,O
of,O
36%,O
.,O
Ximelagatran,I-Entity
",",O
an,O
oral,O
direct,O
thrombin,O
inhibitor,O
",",O
was,O
found,O
to,O
be,O
as,O
efficient,O
as,O
vitamin,B-Entity
K,I-Entity
antagonist,O
drugs,O
in,O
the,O
prevention,O
of,O
embolic,B-Entity
events,I-Entity
",",O
but,O
has,O
been,O
recently,O
withdrawn,O
because,O
of,O
abnormal,B-Entity
liver,I-Entity
function,I-Entity
tests,O
.,O
The,O
ACTIVE,O
-,O
W,O
(,O
Atrial,B-Entity
Fibrillation,I-Entity
Clopidogrel,I-Entity
Trial,O
with,O
Irbesartan,I-Entity
for,O
Prevention,O
of,O
Vascular,O
Events,O
),O
study,O
has,O
demonstrated,O
that,O
warfarin,I-Entity
is,O
superior,O
to,O
platelet,O
therapy,O
(,O
clopidogrel,I-Entity
plus,O
aspirin,I-Entity
),O
in,O
the,O
prevention,O
af,O
embolic,B-Entity
events,I-Entity
.,O
Idraparinux,I-Entity
",",O
a,O
Factor,O
Xa,O
inhibitor,O
",",O
is,O
being,O
evaluated,O
in,O
patients,O
with,O
atrial,B-Entity
fibrillation,I-Entity
.,O
Angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitors,O
and,O
angiotensin,B-Entity
II,I-Entity
receptor,O
-,O
blocking,O
drugs,O
hold,O
promise,O
in,O
atrial,B-Entity
fibrillation,I-Entity
through,O
cardiac,B-Entity
remodelling,I-Entity
.,O
Preliminary,O
studies,O
suggest,O
that,O
statins,I-Entity
could,O
interfere,O
with,O
the,O
risk,O
of,O
recurrence,O
after,O
electrical,O
cardioversion,O
.,O
Interaction,O
of,O
cyclosporin,B-Entity
A,I-Entity
with,O
antineoplastic,O
agents,O
.,O
A,O
synergistic,O
effect,O
of,O
etoposide,I-Entity
and,O
cyclosporin,B-Entity
A,I-Entity
was,O
observed,O
in,O
a,O
patient,O
with,O
acute,B-Entity
T,I-Entity
-,I-Entity
lymphocytic,I-Entity
leukemia,I-Entity
in,O
relapse,O
.,O
The,O
concomitant,O
administration,O
of,O
etoposide,I-Entity
and,O
cyclosporin,B-Entity
A,I-Entity
resulted,O
in,O
eradication,O
of,O
hitherto,O
refractory,O
leukemic,B-Entity
infiltration,I-Entity
of,O
bone,O
marrow,O
.,O
Severe,O
side,O
effects,O
in,O
terms,O
of,O
mental,O
confusion,I-Entity
and,O
progressive,O
hyperbilirubinemia,I-Entity
",",O
however,O
",",O
point,O
to,O
an,O
enhancement,O
not,O
only,O
of,O
antineoplastic,O
effects,O
but,O
also,O
of,O
toxicity,I-Entity
in,O
normal,O
tissues,O
.,O
This,O
report,O
demonstrates,O
for,O
the,O
first,O
time,O
that,O
the,O
pharmacodynamic,O
properties,O
of,O
cyclosporin,B-Entity
A,I-Entity
may,O
not,O
be,O
confined,O
strictly,O
to,O
suppression,O
of,O
normal,O
T,O
-,O
cell,O
functions,O
.,O
The,O
hematologic,O
effects,O
of,O
cefonicid,I-Entity
and,O
cefazedone,I-Entity
in,O
the,O
dog,O
:,O
a,O
potential,O
model,O
of,O
cephalosporin,I-Entity
hematotoxicity,I-Entity
in,O
man,O
.,O
Cephalosporin,I-Entity
antibiotics,O
cause,O
a,O
variety,O
of,O
hematologic,B-Entity
disturbances,I-Entity
in,O
man,O
",",O
the,O
pathogeneses,O
and,O
hematopathology,O
of,O
which,O
remain,O
poorly,O
characterized,O
.,O
There,O
is,O
a,O
need,O
for,O
a,O
well,O
-,O
defined,O
animal,O
model,O
in,O
which,O
these,O
blood,B-Entity
dyscrasias,I-Entity
can,O
be,O
studied,O
.,O
In,O
four,O
subacute,O
toxicity,I-Entity
studies,O
",",O
the,O
intravenous,O
administration,O
of,O
cefonicid,I-Entity
or,O
cefazedone,I-Entity
to,O
beagle,O
dogs,O
caused,O
a,O
dose,O
-,O
dependent,O
incidence,O
of,O
anemia,I-Entity
",",O
neutropenia,I-Entity
",",O
and,O
thrombocytopenia,I-Entity
after,O
1,O
-,O
3,O
months,O
of,O
treatment,O
.,O
A,O
nonregenerative,O
anemia,I-Entity
was,O
the,O
most,O
compromising,O
of,O
the,O
cytopenias,I-Entity
and,O
occurred,O
in,O
approximately,O
50%,O
of,O
dogs,O
receiving,O
400,O
-,O
500,O
mg,O
/,O
kg,O
cefonicid,I-Entity
or,O
540,O
-,O
840,O
mg,O
/,O
kg,O
cefazedone,I-Entity
.,O
All,O
three,O
cytopenias,I-Entity
were,O
completely,O
reversible,O
following,O
cessation,O
of,O
treatment,O
;,O
the,O
time,O
required,O
for,O
recovery,O
of,O
the,O
erythron,O
(,O
approximately,O
1,O
month,O
),O
was,O
considerably,O
longer,O
than,O
that,O
of,O
the,O
granulocytes,O
and,O
platelets,O
(,O
hours,O
to,O
a,O
few,O
days,O
),O
.,O
Upon,O
rechallenge,O
with,O
either,O
cephalosporin,I-Entity
",",O
the,O
hematologic,B-Entity
syndrome,I-Entity
was,O
reproduced,O
in,O
most,O
dogs,O
tested,O
;,O
cefonicid,I-Entity
(,O
but,O
not,O
cefazedone)-treated,I-Entity
dogs,O
showed,O
a,O
substantially,O
reduced,O
induction,O
period,O
(,O
15,O
+,O
/-,O
This,O
observation,O
",",O
along,O
with,O
the,O
rapid,O
rate,O
of,O
decline,O
in,O
red,O
cell,O
mass,O
parameters,O
of,O
affected,O
dogs,O
",",O
suggests,O
that,O
a,O
hemolytic,I-Entity
component,O
complicated,O
the,O
red,O
cell,O
production,O
problem,O
and,O
that,O
multiple,O
toxicologic,O
mechanisms,O
contributed,O
to,O
the,O
cytopenia,I-Entity
.,O
We,O
conclude,O
that,O
the,O
administration,O
of,O
high,O
doses,O
of,O
cefonicid,I-Entity
or,O
cefazedone,I-Entity
to,O
dogs,O
can,O
induce,O
hematotoxicity,I-Entity
similar,O
to,O
the,O
cephalosporin,I-Entity
-,O
induced,O
blood,B-Entity
dyscrasias,I-Entity
described,O
in,O
man,O
and,O
thus,O
provides,O
a,O
useful,O
model,O
for,O
studying,O
the,O
mechanisms,O
of,O
these,O
disorders,O
.,O
A,O
pyridoxine,I-Entity
-,O
dependent,O
behavioral,B-Entity
disorder,I-Entity
unmasked,O
by,O
isoniazid,I-Entity
.,O
A,O
3-year,O
-,O
old,O
girl,O
had,O
behavioral,B-Entity
deterioration,I-Entity
",",O
with,O
hyperkinesis,I-Entity
",",O
irritability,I-Entity
",",O
and,O
sleeping,B-Entity
difficulties,I-Entity
after,O
the,O
therapeutic,O
administration,O
of,O
isoniazid,I-Entity
.,O
The,O
administration,O
of,O
pharmacologic,O
doses,O
of,O
pyridoxine,B-Entity
hydrochloride,I-Entity
led,O
to,O
a,O
disappearance,O
of,O
symptoms,O
.,O
After,O
discontinuing,O
isoniazid,I-Entity
therapy,O
a,O
similar,O
pattern,O
of,O
behavior,O
was,O
noted,O
that,O
was,O
controlled,O
by,O
pyridoxine,I-Entity
.,O
A,O
placebo,O
had,O
no,O
effect,O
",",O
but,O
niacinamide,I-Entity
was,O
as,O
effective,O
as,O
pyridoxine,I-Entity
.,O
Periodic,O
withdrawal,O
of,O
pyridoxine,I-Entity
was,O
associated,O
with,O
return,O
of,O
the,O
hyperkinesis,I-Entity
.,O
The,O
level,O
of,O
pyridoxal,I-Entity
in,O
the,O
blood,O
was,O
normal,O
during,O
the,O
periods,O
of,O
relapse,O
.,O
Metabolic,O
studies,O
suggested,O
a,O
block,O
in,O
the,O
kynurenine,I-Entity
pathway,O
of,O
tryptophan,I-Entity
metabolism,O
.,O
The,O
patient,O
has,O
been,O
followed,O
for,O
six,O
years,O
and,O
has,O
required,O
pharmacologic,O
doses,O
of,O
pyridoxine,I-Entity
to,O
control,O
her,O
behavior,O
.,O
A,O
selective,O
dopamine,I-Entity
D4,O
receptor,O
antagonist,O
",",O
NRA0160,I-Entity
:,O
a,O
preclinical,O
neuropharmacological,O
profile,O
.,O
NRA0160,I-Entity
",",O
5,B-Entity
-,I-Entity
[,I-Entity
2-,I-Entity
(,I-Entity
4-,I-Entity
(,I-Entity
3,I-Entity
-,I-Entity
fluorobenzylidene,I-Entity
),I-Entity
piperidin-1-yl,I-Entity
),I-Entity
ethyl,I-Entity
],I-Entity
-,I-Entity
4,I-Entity
-(4-fluorophenyl,I-Entity
),I-Entity
thiazole-2-carboxamide,I-Entity
",",O
has,O
a,O
high,O
affinity,O
for,O
human,O
cloned,O
dopamine,I-Entity
D4.2,O
",",O
D4.4,O
and,O
D4.7,O
receptors,O
",",O
with,O
Ki,O
values,O
of,O
0.5,O
",",O
0.9,O
and,O
2.7,O
nM,O
",",O
respectively,O
.,O
NRA0160,I-Entity
is,O
over,O
"20,000fold",O
more,O
potent,O
at,O
the,O
dopamine,I-Entity
D4.2,O
receptor,O
compared,O
with,O
the,O
human,O
cloned,O
dopamine,I-Entity
D2L,O
receptor,O
.,O
NRA0160,I-Entity
has,O
negligible,O
affinity,O
for,O
the,O
human,O
cloned,O
dopamine,I-Entity
D3,O
receptor,O
(,O
Ki=39,O
nM,O
),O
",",O
rat,O
serotonin,I-Entity
(,O
5-HT)2A,I-Entity
receptors,O
(,O
Ki=180,O
nM,O
),O
and,O
rat,O
alpha1,O
adrenoceptor,O
(,O
Ki=237,O
nM,O
),O
.,O
NRA0160,I-Entity
and,O
clozapine,I-Entity
antagonized,O
locomotor,O
hyperactivity,I-Entity
induced,O
by,O
methamphetamine,I-Entity
(,O
MAP,I-Entity
),O
in,O
mice,O
.,O
NRA0160,I-Entity
and,O
clozapine,I-Entity
antagonized,O
MAP,I-Entity
-,O
induced,O
stereotyped,O
behavior,O
in,O
mice,O
",",O
although,O
their,O
effects,O
did,O
not,O
exceed,O
50%,O
inhibition,O
",",O
even,O
at,O
the,O
highest,O
dose,O
given,O
.,O
NRA0160,I-Entity
and,O
clozapine,I-Entity
significantly,O
induced,O
catalepsy,I-Entity
in,O
rats,O
",",O
although,O
their,O
effects,O
did,O
not,O
exceed,O
50%,O
induction,O
even,O
at,O
the,O
highest,O
dose,O
given,O
.,O
NRA0160,I-Entity
and,O
clozapine,I-Entity
significantly,O
reversed,O
the,O
disruption,O
of,O
prepulse,O
inhibition,O
(,O
PPI,O
),O
in,O
rats,O
produced,O
by,O
apomorphine,I-Entity
.,O
NRA0160,I-Entity
and,O
clozapine,I-Entity
significantly,O
shortened,O
the,O
phencyclidine,I-Entity
(,O
PCP)-induced,I-Entity
prolonged,O
swimming,O
latency,O
in,O
rats,O
in,O
a,O
water,O
maze,O
task,O
.,O
These,O
findings,O
suggest,O
that,O
NRA0160,I-Entity
may,O
have,O
unique,O
antipsychotic,O
activities,O
without,O
the,O
liability,O
of,O
motor,O
side,O
effects,O
typical,O
of,O
classical,O
antipsychotics,O
.,O
Prolonged,O
cholestasis,I-Entity
after,O
troleandomycin,I-Entity
-,O
induced,O
acute,O
hepatitis,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
patient,O
in,O
whom,O
troleandomycin,I-Entity
-,O
induced,O
hepatitis,I-Entity
was,O
followed,O
by,O
prolonged,O
anicteric,O
cholestasis,I-Entity
.,O
Jaundice,I-Entity
occurred,O
after,O
administration,O
of,O
troleandomycin,I-Entity
for,O
7,O
days,O
and,O
was,O
associated,O
with,O
hypereosinophilia,I-Entity
.,O
Jaundice,I-Entity
disappeared,O
within,O
3,O
months,O
but,O
was,O
followed,O
by,O
prolonged,O
anicteric,O
cholestasis,I-Entity
marked,O
by,O
pruritus,I-Entity
and,O
high,O
levels,O
of,O
alkaline,O
phosphatase,O
and,O
gammaglutamyltransferase,O
activities,O
.,O
Finally,O
",",O
pruritus,I-Entity
disappeared,O
within,O
19,O
months,O
",",O
and,O
liver,O
tests,O
returned,O
to,O
normal,O
27,O
months,O
after,O
the,O
onset,O
of,O
hepatitis,I-Entity
.,O
This,O
observation,O
demonstrates,O
that,O
prolonged,O
cholestasis,I-Entity
can,O
follow,O
troleandomycin,I-Entity
-,O
induced,O
acute,O
hepatitis,I-Entity
.,O
Lovastatin,I-Entity
and,O
simvastatin,I-Entity
are,O
the,O
2,O
best,O
-,O
known,O
members,O
of,O
the,O
class,O
of,O
hypolipidaemic,O
agents,O
known,O
as,O
HMG,O
CoA,O
reductase,O
inhibitors,O
.,O
Clinical,O
experience,O
with,O
lovastatin,I-Entity
includes,O
over,O
5000,O
patients,O
",",O
700,O
of,O
whom,O
have,O
been,O
treated,O
for,O
2,O
years,O
or,O
more,O
",",O
and,O
experience,O
with,O
simvastatin,I-Entity
includes,O
over,O
3500,O
patients,O
",",O
of,O
whom,O
350,O
have,O
been,O
treated,O
for,O
18,O
months,O
or,O
more,O
.,O
Lovastatin,I-Entity
has,O
been,O
marketed,O
in,O
the,O
United,O
States,O
for,O
over,O
6,O
months,O
.,O
Both,O
agents,O
show,O
substantial,O
clinical,O
efficacy,O
",",O
with,O
reductions,O
in,O
total,O
cholesterol,I-Entity
of,O
over,O
30%,O
and,O
in,O
LDL,O
-,O
cholesterol,I-Entity
of,O
40%,O
in,O
clinical,O
studies,O
.,O
Modest,O
increases,O
in,O
HDL,O
-,O
cholesterol,I-Entity
levels,O
of,O
about,O
10%,O
are,O
also,O
reported,O
.,O
Minor,O
elevations,O
of,O
creatine,I-Entity
kinase,O
levels,O
are,O
reported,O
in,O
about,O
5%,O
of,O
patients,O
.,O
Myopathy,I-Entity
",",O
associated,O
in,O
some,O
cases,O
with,O
myoglobinuria,I-Entity
",",O
and,O
in,O
2,O
cases,O
with,O
transient,O
renal,B-Entity
failure,I-Entity
",",O
has,O
been,O
rarely,O
reported,O
with,O
lovastatin,I-Entity
",",O
especially,O
in,O
patients,O
concomitantly,O
treated,O
with,O
cyclosporin,I-Entity
",",O
gemfibrozil,I-Entity
or,O
niacin,I-Entity
.,O
Lovastatin,I-Entity
and,O
simvastatin,I-Entity
are,O
both,O
effective,O
and,O
well,O
-,O
tolerated,O
agents,O
for,O
lowering,O
elevated,O
levels,O
of,O
serum,O
cholesterol,I-Entity
.,O
As,O
wider,O
use,O
confirms,O
their,O
safety,O
profile,O
",",O
they,O
will,O
gain,O
increasing,O
importance,O
in,O
the,O
therapeutic,O
approach,O
to,O
hypercholesterolaemia,I-Entity
and,O
its,O
consequences,O
.,O
Sulfasalazine,I-Entity
-,O
induced,O
lupus,B-Entity
erythematosus,I-Entity
.,O
Pneumonitis,I-Entity
",",O
bilateral,O
pleural,B-Entity
effusions,I-Entity
",",O
echocardiographic,O
evidence,O
of,O
cardiac,B-Entity
tamponade,I-Entity
",",O
and,O
positive,O
autoantibodies,O
developed,O
in,O
a,O
43-year,O
-,O
old,O
man,O
",",O
who,O
was,O
receiving,O
long,O
-,O
term,O
sulfasalazine,I-Entity
therapy,O
for,O
chronic,O
ulcerative,B-Entity
colitis,I-Entity
.,O
After,O
cessation,O
of,O
the,O
sulfasalazine,I-Entity
and,O
completion,O
of,O
a,O
six,O
-,O
week,O
course,O
of,O
corticosteroids,O
",",O
these,O
problems,O
resolved,O
over,O
a,O
period,O
of,O
four,O
to,O
six,O
months,O
.,O
It,O
is,O
suggested,O
that,O
the,O
patient,O
had,O
sulfasalazine,I-Entity
-,O
induced,O
lupus,I-Entity
",",O
which,O
manifested,O
with,O
serositis,I-Entity
and,O
pulmonary,O
parenchymal,O
involvement,O
in,O
the,O
absence,O
of,O
joint,O
symptoms,O
.,O
Physicians,O
who,O
use,O
sulfasalazine,I-Entity
to,O
treat,O
patients,O
with,O
inflammatory,B-Entity
bowel,I-Entity
disease,I-Entity
should,O
be,O
aware,O
of,O
the,O
signs,O
of,O
sulfasalazine,I-Entity
-,O
induced,O
lupus,B-Entity
syndrome,I-Entity
.,O
Optimization,O
of,O
levodopa,I-Entity
therapy,O
.,O
While,O
there,O
is,O
no,O
single,O
correct,O
starting,O
dose,O
for,O
levodopa,I-Entity
therapy,O
",",O
many,O
individuals,O
can,O
be,O
started,O
on,O
either,O
the,O
25/100,O
or,O
controlled,O
-,O
release,O
formula,O
",",O
following,O
the,O
general,O
rule,O
not,O
to,O
attempt,O
to,O
titrate,O
carbidopa,I-Entity
-,O
levodopa,I-Entity
to,O
the,O
point,O
of,O
"""",O
normality,O
",",O
"""",O
which,O
can,O
lead,O
to,O
toxicity,I-Entity
.,O
Following,O
the,O
initial,O
period,O
of,O
therapy,O
",",O
emerging,O
difficulties,O
require,O
a,O
reassessment,O
of,O
therapeutic,O
approaches,O
",",O
such,O
as,O
dosage,O
adjustment,O
or,O
introduction,O
of,O
a,O
dopamine,I-Entity
agonist,O
.,O
Other,O
possible,O
adverse,O
effects,O
--,O
such,O
as,O
gastrointestinal,B-Entity
disorders,I-Entity
",",O
orthostatic,B-Entity
hypotension,I-Entity
",",O
levodopa,I-Entity
-,O
induced,O
psychosis,I-Entity
",",O
sleep,B-Entity
disturbances,I-Entity
or,O
parasomnias,I-Entity
",",O
or,O
drug,O
interactions,O
--,O
also,O
require,O
carefully,O
monitored,O
individual,O
treatment,O
.,O
Nonpharmacologic,O
concerns,O
can,O
help,O
the,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
patient,O
achieve,O
and,O
maintain,O
optimal,O
functioning,O
",",O
including,O
daily,O
exercise,O
",",O
physical,O
therapy,O
",",O
and,O
involvement,O
with,O
support,O
groups,O
.,O
Alpha,O
and,O
beta,O
coma,I-Entity
in,O
drug,O
intoxication,O
uncomplicated,O
by,O
cerebral,B-Entity
hypoxia,I-Entity
.,O
Four,O
patients,O
who,O
were,O
rendered,O
comatose,I-Entity
or,O
stuporous,I-Entity
by,O
drug,O
intoxication,O
",",O
but,O
who,O
were,O
not,O
hypoxic,O
",",O
are,O
described,O
.,O
Three,O
patients,O
received,O
high,O
doses,O
of,O
chlormethiazole,I-Entity
for,O
alcohol,I-Entity
withdrawal,B-Entity
symptoms,I-Entity
",",O
and,O
one,O
took,O
a,O
suicidal,O
overdose,I-Entity
of,O
nitrazepam,I-Entity
.,O
The,O
patient,O
with,O
nitrazepam,I-Entity
overdose,I-Entity
and,O
two,O
of,O
those,O
with,O
chlormethiazole,I-Entity
intoxication,O
conformed,O
to,O
the,O
criteria,O
of,O
',O
alpha,O
coma,I-Entity
',O
",",O
showing,O
non,O
-,O
reactive,O
generalized,O
or,O
frontally,O
predominant,O
alpha,O
activity,O
in,O
the,O
EEG,O
.,O
The,O
fourth,O
patient,O
who,O
was,O
unconscious,O
after,O
chlormethiazole,I-Entity
administration,O
exhibite,O
generalized,O
non,O
-,O
reactive,O
activity,O
in,O
the,O
slow,O
beta,O
range,O
.,O
All,O
four,O
recovered,O
completely,O
without,O
neurological,B-Entity
sequelae,I-Entity
following,O
the,O
withdrawal,O
of,O
the,O
offending,O
agents,O
.,O
The,O
similarities,O
between,O
the,O
effects,O
of,O
structural,O
lesions,O
and,O
pharmacological,O
depression,I-Entity
of,O
the,O
brain,O
stem,O
reticular,O
formation,O
are,O
discussed,O
.,O
It,O
is,O
suggested,O
that,O
in,O
both,O
situations,O
disturbed,O
reticulo,O
-,O
thalamic,O
interactions,O
are,O
important,O
in,O
the,O
pathogenesis,O
of,O
alpha,O
coma,I-Entity
.,O
It,O
is,O
concluded,O
that,O
when,O
this,O
electroencephalographic,O
and,O
behavioural,O
picture,O
is,O
seen,O
in,O
drug,O
intoxication,O
",",O
in,O
the,O
absence,O
of,O
significant,O
hypoxaemia,I-Entity
",",O
a,O
favourable,O
outcome,O
may,O
be,O
anticipated,O
.,O
Omitting,O
fentanyl,I-Entity
reduces,O
nausea,I-Entity
and,O
vomiting,I-Entity
",",O
without,O
increasing,O
pain,I-Entity
",",O
after,O
sevoflurane,I-Entity
for,O
day,O
surgery,O
.,O
Despite,O
advantages,O
of,O
induction,O
and,O
maintenance,O
of,O
anaesthesia,O
with,O
sevoflurane,I-Entity
",",O
postoperative,B-Entity
nausea,I-Entity
and,I-Entity
vomiting,I-Entity
occurs,O
frequently,O
.,O
Fentanyl,I-Entity
is,O
a,O
commonly,O
used,O
supplement,O
that,O
may,O
contribute,O
to,O
this,O
",",O
although,O
it,O
may,O
also,O
improve,O
analgesia,O
.,O
This,O
double,O
-,O
blind,O
study,O
examined,O
the,O
incidence,O
and,O
severity,O
of,O
postoperative,B-Entity
nausea,I-Entity
and,I-Entity
vomiting,I-Entity
and,O
pain,I-Entity
in,O
the,O
first,O
24,O
h,O
after,O
sevoflurane,I-Entity
anaesthesia,O
in,O
216,O
adult,O
day,O
surgery,O
patients,O
.,O
Patients,O
were,O
randomly,O
allocated,O
to,O
either,O
receive,O
or,O
not,O
receive,O
1,O
1,O
fentanyl,I-Entity
",",O
while,O
a,O
third,O
group,O
received,O
dexamethasone,I-Entity
in,O
addition,O
to,O
fentanyl,I-Entity
.,O
Omission,O
of,O
fentanyl,I-Entity
did,O
not,O
reduce,O
the,O
overall,O
incidence,O
of,O
postoperative,B-Entity
nausea,I-Entity
and,I-Entity
vomiting,I-Entity
",",O
but,O
did,O
reduce,O
the,O
incidence,O
of,O
vomiting,I-Entity
and/or,O
moderate,O
to,O
severe,O
nausea,I-Entity
prior,O
to,O
discharge,O
from,O
20%,O
and,O
17%,O
with,O
fentanyl,I-Entity
and,O
fentanyl,I-Entity
-,O
dexamethasone,I-Entity
",",O
respectively,O
",",O
to,O
5%,O
(,O
P,O
=,O
0.013,O
),O
.,O
Dexamethasone,I-Entity
had,O
no,O
significant,O
effect,O
on,O
the,O
incidence,O
or,O
severity,O
of,O
postoperative,B-Entity
nausea,I-Entity
and,I-Entity
vomiting,I-Entity
.,O
Combining,O
the,O
two,O
fentanyl,I-Entity
groups,O
revealed,O
further,O
significant,O
benefits,O
from,O
the,O
avoidance,O
of,O
opioids,O
",",O
reducing,O
postoperative,B-Entity
nausea,I-Entity
and,I-Entity
vomiting,I-Entity
and,O
nausea,I-Entity
prior,O
to,O
discharge,O
from,O
35%,O
and,O
33%,O
to,O
22%,O
and,O
19%,O
(,O
P,O
=,O
0.049,O
and,O
P,O
=,O
0.035,O
),O
",",O
respectively,O
",",O
while,O
nausea,I-Entity
in,O
the,O
first,O
24,O
h,O
was,O
decreased,O
from,O
42%,O
to,O
27%,O
(,O
P,O
=,O
0.034,O
),O
.,O
Pain,I-Entity
severity,O
and,O
analgesic,O
requirements,O
were,O
unaffected,O
by,O
the,O
omission,O
of,O
fentanyl,I-Entity
.,O
Fentanyl,I-Entity
did,O
reduce,O
minor,O
intraoperative,O
movement,O
but,O
had,O
no,O
sevoflurane,I-Entity
-,O
sparing,O
effect,O
and,O
increased,O
respiratory,B-Entity
depression,I-Entity
",",O
hypotension,I-Entity
and,O
bradycardia,I-Entity
.,O
As,O
fentanyl,I-Entity
exacerbated,O
postoperative,B-Entity
nausea,I-Entity
and,I-Entity
vomiting,I-Entity
without,O
an,O
improvement,O
in,O
postoperative,B-Entity
pain,I-Entity
and,O
also,O
had,O
adverse,O
cardiorespiratory,O
effects,O
",",O
it,O
appears,O
to,O
be,O
an,O
unnecessary,O
and,O
possibly,O
detrimental,O
supplement,O
to,O
sevoflurane,I-Entity
in,O
day,O
surgery,O
.,O
Renal,B-Entity
Fanconi,I-Entity
syndrome,I-Entity
and,O
myopathy,I-Entity
after,O
liver,O
transplantation,O
:,O
drug,O
-,O
related,O
mitochondrial,B-Entity
cytopathy,I-Entity
?,O
We,O
describe,O
a,O
15-yr,O
-,O
old,O
girl,O
who,O
had,O
orthotopic,O
liver,O
transplantation,O
because,O
of,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Tacrolimus,I-Entity
",",O
MMF,I-Entity
",",O
and,O
steroids,I-Entity
were,O
given,O
as,O
immunosuppressant,O
.,O
Lamivudine,I-Entity
was,O
added,O
because,O
of,O
de,O
nova,O
hepatitis,B-Entity
B,I-Entity
infection,I-Entity
during,O
her,O
follow,O
-,O
up,O
.,O
Three,O
yr,O
after,O
transplantation,O
she,O
developed,O
renal,B-Entity
Fanconi,I-Entity
syndrome,I-Entity
with,O
severe,O
metabolic,B-Entity
acidosis,I-Entity
",",O
hypophosphatemia,I-Entity
",",O
glycosuria,I-Entity
",",O
and,O
aminoaciduria,I-Entity
.,O
Although,O
tacrolimus,I-Entity
was,O
suspected,O
to,O
be,O
the,O
cause,O
of,O
late,O
post,O
-,O
transplant,O
renal,O
acidosis,I-Entity
and,O
was,O
replaced,O
by,O
sirolimus,I-Entity
",",O
acidosis,I-Entity
",",O
and,O
electrolyte,O
imbalance,O
got,O
worse,O
.,O
Proximal,O
muscle,B-Entity
weakness,I-Entity
has,O
developed,O
during,O
her,O
follow,O
-,O
up,O
.,O
Fanconi,B-Entity
syndrome,I-Entity
",",O
as,O
well,O
as,O
myopathy,I-Entity
",",O
is,O
well,O
recognized,O
in,O
patients,O
with,O
mitochondrial,B-Entity
disorders,I-Entity
and,O
caused,O
by,O
depletion,O
of,O
mtDNA,O
.,O
We,O
suggest,O
that,O
our,O
patient,O
's,O
tubular,B-Entity
dysfunction,I-Entity
and,O
myopathy,I-Entity
may,O
have,O
resulted,O
from,O
mitochondrial,B-Entity
dysfunction,I-Entity
which,O
is,O
triggered,O
by,O
tacrolimus,I-Entity
and,O
augmented,O
by,O
lamivudine,I-Entity
.,O
Antipsychotic,O
-,O
like,O
profile,O
of,O
thioperamide,I-Entity
",",O
a,O
selective,O
H3-receptor,O
antagonist,O
in,O
mice,O
.,O
Experimental,O
and,O
clinical,O
evidence,O
points,O
to,O
a,O
role,O
of,O
central,O
histaminergic,O
system,O
in,O
the,O
pathogenesis,O
of,O
schizophrenia,I-Entity
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
study,O
the,O
effect,O
of,O
histamine,I-Entity
H(3)-receptor,O
ligands,O
on,O
neuroleptic,O
-,O
induced,O
catalepsy,I-Entity
",",O
apomorphine,I-Entity
-,O
induced,O
climbing,O
behavior,O
and,O
amphetamine,I-Entity
-,O
induced,O
locomotor,O
activities,O
in,O
mice,O
.,O
Catalepsy,I-Entity
was,O
induced,O
by,O
haloperidol,I-Entity
(,O
2,O
mg,O
/,O
kg,O
p.o,O
.,O
),O
",",O
while,O
apomorphine,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
and,O
amphetamine,I-Entity
(,O
2,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
(,B-Entity
R)-alpha,I-Entity
-,I-Entity
methylhistamine,I-Entity
(,O
RAMH,I-Entity
),O
(,O
5,O
microg,O
i.c.v,O
.,O
),O
and,O
thioperamide,I-Entity
(,O
THP,I-Entity
),O
(,O
15,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
",",O
per,O
se,O
did,O
not,O
cause,O
catalepsy,I-Entity
.,O
Administration,O
of,O
THP,I-Entity
(,O
3.75,O
",",O
7.5,O
and,O
15,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
1,O
h,O
prior,O
to,O
haloperidol,I-Entity
resulted,O
in,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
catalepsy,I-Entity
times,O
(,O
P,O
<,O
0.05,O
),O
.,O
However,O
",",O
pretreatment,O
with,O
RAMH,I-Entity
significantly,O
reversed,O
such,O
an,O
effect,O
of,O
THP,I-Entity
(,O
15,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
.,O
RAMH,I-Entity
per,O
se,O
showed,O
significant,O
reduction,O
in,O
locomotor,O
time,O
",",O
distance,O
traveled,O
and,O
average,O
speed,O
but,O
THP,I-Entity
(,O
15,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
On,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
",",O
THP,I-Entity
(,O
3.75,O
and,O
7.5,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
Pretreatment,O
with,O
RAMH,I-Entity
(,O
5,O
microg,O
i.c.v,O
.,O
),O
could,O
partially,O
reverse,O
such,O
effects,O
of,O
THP,I-Entity
(,O
3.75,O
mg,O
Climbing,O
behavior,O
induced,O
by,O
apomorphine,I-Entity
was,O
reduced,O
in,O
animals,O
treated,O
with,O
THP,I-Entity
.,O
Such,O
an,O
effect,O
was,O
",",O
however,O
",",O
reversed,O
in,O
presence,O
of,O
RAMH,I-Entity
.,O
THP,I-Entity
exhibited,O
an,O
antipsychotic,O
-,O
like,O
profile,O
by,O
potentiating,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
",",O
reducing,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
and,O
reducing,O
apomorphine,I-Entity
-,O
induced,O
climbing,O
in,O
mice,O
.,O
Such,O
effects,O
of,O
THP,I-Entity
were,O
reversed,O
by,O
RAMH,I-Entity
indicating,O
the,O
involvement,O
of,O
histamine,I-Entity
H(3)-receptors,O
.,O
Findings,O
suggest,O
a,O
potential,O
for,O
H(3)-receptor,O
antagonists,O
in,O
improving,O
the,O
refractory,O
cases,O
of,O
schizophrenia,I-Entity
.,O
Transient,O
platypnea,B-Entity
-,I-Entity
orthodeoxia,I-Entity
-,I-Entity
like,I-Entity
syndrome,I-Entity
induced,O
by,O
propafenone,I-Entity
overdose,I-Entity
in,O
a,O
young,O
woman,O
with,O
Ebstein,B-Entity
's,I-Entity
anomaly,I-Entity
.,O
In,O
this,O
report,O
we,O
describe,O
the,O
case,O
of,O
a,O
37-year,O
-,O
old,O
white,O
woman,O
with,O
Ebstein,B-Entity
's,I-Entity
anomaly,I-Entity
",",O
who,O
developed,O
a,O
rare,O
syndrome,O
called,O
platypnea,B-Entity
-,I-Entity
orthodeoxia,I-Entity
",",O
characterized,O
by,O
massive,O
right,O
-,O
to,O
-,O
left,O
interatrial,O
shunting,O
with,O
transient,O
profound,O
hypoxia,I-Entity
and,O
cyanosis,I-Entity
.,O
This,O
shunt,O
of,O
blood,O
via,O
a,O
patent,B-Entity
foramen,I-Entity
ovale,I-Entity
occurred,O
in,O
the,O
presence,O
of,O
a,O
normal,O
pulmonary,O
artery,O
pressure,O
",",O
and,O
was,O
probably,O
precipitated,O
by,O
a,O
propafenone,I-Entity
overdose,I-Entity
.,O
This,O
drug,O
caused,O
biventricular,B-Entity
dysfunction,I-Entity
",",O
due,O
to,O
its,O
negative,O
inotropic,O
effect,O
",",O
and,O
hypotension,I-Entity
",",O
due,O
to,O
its,O
peripheral,O
vasodilatory,O
effect,O
.,O
A,O
Phase,O
II,O
trial,O
of,O
cisplatin,I-Entity
plus,O
WR-2721,I-Entity
(,O
amifostine,I-Entity
),O
for,O
metastatic,O
breast,B-Entity
carcinoma,I-Entity
:,O
an,O
Eastern,O
Cooperative,O
Oncology,O
Group,O
Study,O
(,O
E8188,O
),O
.,O
Cisplatin,I-Entity
has,O
minimal,O
antitumor,O
activity,O
when,O
used,O
as,O
second-,O
or,O
third,O
-,O
line,O
treatment,O
of,O
metastatic,O
breast,B-Entity
carcinoma,I-Entity
.,O
Older,O
reports,O
suggest,O
an,O
objective,O
response,O
rate,O
of,O
8%,O
when,O
60,O
-,O
120,O
mg,O
/,O
m2,O
of,O
cisplatin,I-Entity
is,O
administered,O
every,O
3,O
-,O
4,O
weeks,O
.,O
Although,O
a,O
dose,O
-,O
response,O
effect,O
has,O
been,O
observed,O
with,O
cisplatin,I-Entity
",",O
the,O
dose,O
-,O
limiting,O
toxicities,I-Entity
associated,O
with,O
cisplatin,I-Entity
(,O
e.g.,O
",",O
nephrotoxicity,I-Entity
",",O
ototoxicity,I-Entity
",",O
and,O
neurotoxicity,I-Entity
),O
have,O
limited,O
its,O
use,O
as,O
a,O
treatment,O
for,O
breast,B-Entity
carcinoma,I-Entity
.,O
WR-2721,I-Entity
or,O
amifostine,I-Entity
initially,O
was,O
developed,O
to,O
protect,O
military,O
personnel,O
in,O
the,O
event,O
of,O
nuclear,O
war,O
.,O
Amifostine,I-Entity
subsequently,O
was,O
shown,O
to,O
protect,O
normal,O
tissues,O
from,O
the,O
toxic,O
effects,O
of,O
alkylating,B-Entity
agents,I-Entity
and,O
cisplatin,I-Entity
without,O
decreasing,O
the,O
antitumor,O
effect,O
of,O
the,O
chemotherapy,O
.,O
Early,O
trials,O
of,O
cisplatin,I-Entity
and,O
amifostine,I-Entity
also,O
suggested,O
that,O
the,O
incidence,O
and,O
severity,O
of,O
cisplatin,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
",",O
ototoxicity,I-Entity
",",O
and,O
neuropathy,I-Entity
were,O
reduced,O
.,O
METHODS,O
:,O
A,O
Phase,O
II,O
study,O
of,O
the,O
combination,O
of,O
cisplatin,I-Entity
plus,O
amifostine,I-Entity
was,O
conducted,O
in,O
patients,O
with,O
progressive,O
metastatic,O
breast,B-Entity
carcinoma,I-Entity
who,O
had,O
received,O
one,O
",",O
but,O
not,O
more,O
than,O
one,O
",",O
chemotherapy,O
regimen,O
for,O
metastatic,O
disease,O
.,O
Patients,O
received,O
amifostine,I-Entity
",",O
910,O
mg,O
/,O
m2,O
intravenously,O
over,O
15,O
minutes,O
.,O
After,O
completion,O
of,O
the,O
amifostine,I-Entity
infusion,O
",",O
cisplatin,I-Entity
120,O
mg,O
/,O
m2,O
was,O
administered,O
over,O
30,O
minutes,O
.,O
Intravenous,O
hydration,O
and,O
mannitol,I-Entity
was,O
administered,O
before,O
and,O
after,O
cisplatin,I-Entity
.,O
Neurologic,B-Entity
toxicity,I-Entity
was,O
reported,O
in,O
52%,O
of,O
patients,O
.,O
Seven,O
different,O
life,O
-,O
threatening,O
toxicities,I-Entity
were,O
observed,O
in,O
patients,O
while,O
receiving,O
treatment,O
.,O
The,O
combination,O
of,O
cisplatin,I-Entity
and,O
amifostine,I-Entity
in,O
this,O
study,O
resulted,O
in,O
an,O
overall,O
response,O
rate,O
of,O
16%,O
.,O
Neither,O
a,O
tumor,I-Entity
-,O
protective,O
effect,O
nor,O
reduced,O
toxicity,I-Entity
to,O
normal,O
tissues,O
was,O
observed,O
with,O
the,O
addition,O
of,O
amifostine,I-Entity
to,O
cisplatin,I-Entity
in,O
this,O
trial,O
.,O
Warfarin,I-Entity
-,O
induced,O
iliopsoas,O
hemorrhage,I-Entity
with,O
subsequent,O
femoral,B-Entity
nerve,I-Entity
palsy,I-Entity
.,O
We,O
present,O
the,O
case,O
of,O
a,O
28-year,O
-,O
old,O
man,O
on,O
chronic,O
warfarin,I-Entity
therapy,O
who,O
sustained,O
a,O
minor,O
muscle,B-Entity
tear,I-Entity
and,O
developed,O
increasing,O
pain,I-Entity
and,O
a,O
flexure,O
contracture,I-Entity
of,O
the,O
right,O
hip,O
.,O
Surgical,O
exploration,O
revealed,O
an,O
iliopsoas,O
hematoma,I-Entity
and,O
femoral,O
nerve,B-Entity
entrapment,I-Entity
",",O
resulting,O
in,O
a,O
femoral,B-Entity
nerve,I-Entity
palsy,I-Entity
and,O
partial,B-Entity
loss,I-Entity
of,I-Entity
quadriceps,I-Entity
functions,I-Entity
.,O
Anticoagulant,O
-,O
induced,O
femoral,B-Entity
nerve,I-Entity
palsy,I-Entity
represents,O
the,O
most,O
common,O
form,O
of,O
warfarin,I-Entity
-,O
induced,O
peripheral,B-Entity
neuropathy,I-Entity
;,O
it,O
is,O
characterized,O
by,O
severe,O
pain,I-Entity
in,O
the,O
inguinal,O
region,O
",",O
varying,O
degrees,O
of,O
motor,B-Entity
and,I-Entity
sensory,I-Entity
impairment,I-Entity
",",O
and,O
flexure,O
contracture,I-Entity
of,O
the,O
involved,O
extremity,O
.,O
Myasthenia,B-Entity
gravis,I-Entity
caused,O
by,O
penicillamine,I-Entity
and,O
chloroquine,I-Entity
therapy,O
for,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
We,O
have,O
described,O
a,O
unique,O
patient,O
who,O
had,O
reversible,O
and,O
dose,O
-,O
related,O
myasthenia,B-Entity
gravis,I-Entity
after,O
penicillamine,I-Entity
and,O
chloroquine,I-Entity
therapy,O
for,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
Although,O
acetylcholine,I-Entity
receptor,O
antibodies,O
were,O
not,O
detectable,O
",",O
the,O
time,O
course,O
was,O
consistent,O
with,O
an,O
autoimmune,O
process,O
.,O
Nephrotoxicity,I-Entity
of,O
combined,O
cephalothin,I-Entity
-,O
gentamicin,I-Entity
regimen,O
.,O
Two,O
patients,O
developed,O
acute,B-Entity
tubular,I-Entity
necrosis,I-Entity
",",O
characterized,O
clinically,O
by,O
acute,O
oliguric,B-Entity
renal,I-Entity
failure,I-Entity
",",O
while,O
they,O
were,O
receiving,O
a,O
combination,O
of,O
cephalothin,B-Entity
sodium,I-Entity
and,O
gentamicin,B-Entity
sulfate,I-Entity
therapy,O
.,O
Patients,O
who,O
are,O
given,O
this,O
drug,O
regimen,O
should,O
be,O
observed,O
very,O
carefully,O
for,O
early,O
signs,O
of,O
nephrotoxicity,I-Entity
.,O
Patients,O
with,O
renal,B-Entity
insufficiency,I-Entity
should,O
not,O
be,O
given,O
this,O
regimen,O
.,O
Components,O
of,O
lemon,O
essential,O
oil,O
attenuate,O
dementia,I-Entity
induced,O
by,O
scopolamine,I-Entity
.,O
The,O
anti,O
-,O
dementia,I-Entity
effects,O
of,O
s,B-Entity
-,I-Entity
limonene,I-Entity
and,O
s,B-Entity
-,I-Entity
perillyl,I-Entity
alcohol,I-Entity
were,O
observed,O
using,O
the,O
passive,O
avoidance,O
test,O
(,O
PA,O
),O
and,O
the,O
open,O
field,O
habituation,O
test,O
(,O
OFH,O
),O
.,O
These,O
lemon,O
essential,O
oils,O
showed,O
strong,O
ability,O
to,O
improve,O
memory,B-Entity
impaired,I-Entity
by,O
scopolamine,I-Entity
;,O
however,O
",",O
s,B-Entity
-,I-Entity
perillyl,I-Entity
alcohol,I-Entity
relieved,O
the,O
deficit,B-Entity
of,I-Entity
associative,I-Entity
memory,I-Entity
in,O
PA,O
only,O
",",O
and,O
did,O
not,O
improve,O
non,O
-,O
associative,O
memory,O
significantly,O
in,O
OFH,O
.,O
Analysis,O
of,O
neurotransmitter,O
concentration,O
in,O
some,O
brain,O
regions,O
on,O
the,O
test,O
day,O
showed,O
that,O
dopamine,I-Entity
concentration,O
of,O
the,O
vehicle,O
/,O
scopolamine,I-Entity
group,O
was,O
significantly,O
lower,O
than,O
that,O
of,O
the,O
vehicle,O
/,O
vehicle,O
group,O
",",O
but,O
this,O
phenomenon,O
was,O
reversed,O
when,O
s,B-Entity
-,I-Entity
limonene,I-Entity
or,O
s,B-Entity
-,I-Entity
perillyl,I-Entity
alcohol,I-Entity
were,O
administered,O
before,O
the,O
injection,O
of,O
scopolamine,I-Entity
.,O
The,O
selective,O
5-HT6,O
receptor,O
antagonist,O
Ro4368554,I-Entity
restores,O
memory,O
performance,O
in,O
cholinergic,O
and,O
serotonergic,O
models,O
of,O
memory,B-Entity
deficiency,I-Entity
in,O
the,O
rat,O
.,O
Antagonists,O
at,O
serotonin,I-Entity
type,O
6,O
(,O
5-HT(6,I-Entity
),O
),O
receptors,O
show,O
activity,O
in,O
models,O
of,O
learning,O
and,O
memory,O
.,O
Although,O
the,O
underlying,O
mechanism(s,O
),O
are,O
not,O
well,O
understood,O
",",O
these,O
effects,O
may,O
involve,O
an,O
increase,O
in,O
acetylcholine,I-Entity
(,O
ACh,I-Entity
),O
levels,O
.,O
The,O
present,O
study,O
sought,O
to,O
characterize,O
the,O
cognitive,O
-,O
enhancing,O
effects,O
of,O
the,O
5-HT(6,I-Entity
),O
antagonist,O
Ro4368554,I-Entity
(,O
3-benzenesulfonyl-7-(4-methyl,B-Entity
-,I-Entity
piperazin-1-yl)1H,I-Entity
-,I-Entity
indole,I-Entity
),O
in,O
a,O
rat,O
object,O
recognition,O
task,O
employing,O
a,O
cholinergic,O
(,O
scopolamine,I-Entity
pretreatment,O
),O
and,O
a,O
serotonergic-,O
(,O
tryptophan,I-Entity
(,O
TRP,I-Entity
),O
depletion,O
),O
deficient,O
model,O
",",O
and,O
compared,O
its,O
pattern,O
of,O
action,O
with,O
that,O
of,O
the,O
acetylcholinesterase,O
inhibitor,O
metrifonate,I-Entity
.,O
Initial,O
testing,O
in,O
a,O
time,O
-,O
dependent,O
forgetting,O
task,O
employing,O
a,O
24-h,O
delay,O
between,O
training,O
and,O
testing,O
showed,O
that,O
metrifonate,I-Entity
improved,O
object,O
recognition,O
(,O
at,O
10,O
and,O
30,O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
),O
",",O
whereas,O
Ro4368554,I-Entity
was,O
inactive,O
.,O
Both,O
",",O
Ro4368554,I-Entity
(,O
3,O
and,O
10,O
mg,O
/,O
kg,O
",",O
intraperitoneally,O
(,O
i.p,O
.,O
),O
),O
and,O
metrifonate,I-Entity
(,O
10,O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
",",O
respectively,O
),O
reversed,O
memory,B-Entity
deficits,I-Entity
induced,O
by,O
scopolamine,I-Entity
and,O
TRP,I-Entity
depletion,O
(,O
10,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
",",O
and,O
3,O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
In,O
conclusion,O
",",O
although,O
Ro4368554,I-Entity
did,O
not,O
improve,O
a,O
time,O
-,O
related,O
retention,O
deficit,O
",",O
it,O
reversed,O
a,O
cholinergic,O
and,O
a,O
serotonergic,O
memory,B-Entity
deficit,I-Entity
",",O
suggesting,O
that,O
both,O
mechanisms,O
may,O
be,O
involved,O
in,O
the,O
facilitation,O
of,O
object,O
memory,O
by,O
Ro4368554,I-Entity
and,O
",",O
possibly,O
",",O
other,O
5-HT(6,I-Entity
),O
receptor,O
antagonists,O
.,O
Lone,O
atrial,B-Entity
fibrillation,I-Entity
associated,O
with,O
creatine,I-Entity
monohydrate,O
supplementation,O
.,O
Atrial,B-Entity
fibrillation,I-Entity
in,O
young,O
patients,O
without,O
structural,O
heart,B-Entity
disease,I-Entity
is,O
rare,O
.,O
Therefore,O
",",O
when,O
the,O
arrhythmia,I-Entity
is,O
present,O
in,O
this,O
population,O
",",O
reversible,O
causes,O
must,O
be,O
identified,O
and,O
resolved,O
.,O
Thyroid,B-Entity
disorders,I-Entity
",",O
illicit,O
drug,O
or,O
stimulant,O
use,O
",",O
and,O
acute,B-Entity
alcohol,I-Entity
intoxication,I-Entity
are,O
among,O
these,O
causes,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
30-year,O
-,O
old,O
Caucasian,O
man,O
who,O
came,O
to,O
the,O
emergency,O
department,O
in,O
atrial,B-Entity
fibrillation,I-Entity
with,O
rapid,O
ventricular,O
response,O
.,O
His,O
medical,O
history,O
was,O
unremarkable,O
",",O
except,O
for,O
minor,O
fractures,I-Entity
of,O
the,O
fingers,O
and,O
foot,O
.,O
Thyroid,O
-,O
stimulating,O
hormone,O
",",O
magnesium,I-Entity
",",O
and,O
potassium,I-Entity
levels,O
were,O
within,O
normal,O
limits,O
",",O
urine,O
drug,O
screen,O
was,O
negative,O
",",O
and,O
alcohol,I-Entity
use,O
was,O
denied,O
.,O
However,O
",",O
when,O
the,O
patient,O
was,O
questioned,O
about,O
use,O
of,O
herbal,O
products,O
and,O
supplements,O
",",O
the,O
use,O
of,O
creatine,I-Entity
monohydrate,O
was,O
revealed,O
.,O
The,O
patient,O
was,O
admitted,O
to,O
the,O
hospital,O
",",O
anticoagulated,O
with,O
unfractionated,O
heparin,I-Entity
",",O
and,O
given,O
intravenous,O
diltiazem,I-Entity
for,O
rate,O
control,O
and,O
intravenous,O
amiodarone,I-Entity
for,O
rate,O
and,O
rhythm,O
control,O
.,O
When,O
discharged,O
less,O
than,O
24,O
hours,O
later,O
",",O
he,O
was,O
receiving,O
metoprolol,I-Entity
and,O
aspirin,I-Entity
",",O
with,O
follow,O
-,O
up,O
plans,O
for,O
echocardiography,O
and,O
nuclear,O
imaging,O
to,O
assess,O
perfusion,O
.,O
Exogenous,O
creatine,I-Entity
is,O
used,O
by,O
athletes,O
to,O
theoretically,O
improve,O
exercise,O
performance,O
.,O
Vegetarians,O
may,O
also,O
take,O
creatine,I-Entity
to,O
replace,O
what,O
they,O
are,O
not,O
consuming,O
from,O
meat,O
",",O
fish,O
",",O
and,O
other,O
animal,O
products,O
.,O
Previous,O
anecdotal,O
reports,O
have,O
linked,O
creatine,I-Entity
to,O
the,O
development,O
of,O
arrhythmia,I-Entity
.,O
Comparison,O
of,O
developmental,O
toxicity,I-Entity
of,O
selective,O
and,O
non,O
-,O
selective,O
cyclooxygenase-2,O
inhibitors,O
in,O
CRL:(WI)WUBR,O
Wistar,O
rats,O
--,O
DFU,I-Entity
and,O
piroxicam,I-Entity
study,O
.,O
Unlike,O
general,O
toxicity,I-Entity
data,O
",",O
their,O
prenatal,O
toxic,O
effects,O
were,O
not,O
extensively,O
studied,O
before,O
.,O
The,O
aim,O
of,O
the,O
experiment,O
was,O
to,O
evaluate,O
the,O
developmental,O
toxicity,I-Entity
of,O
the,O
non,O
-,O
selective,O
(,O
piroxicam,I-Entity
),O
and,O
selective,O
(,O
DFU,I-Entity
;,O
"5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl",B-Entity
),I-Entity
phenyl-2(5H)-furanon,I-Entity
),O
COX-2,O
inhibitors,O
.,O
Doses,O
were,O
set,O
at,O
0.3,O
",",O
3.0,O
and,O
30.0mg,O
/,O
kg,O
for,O
piroxicam,I-Entity
and,O
0.2,O
",",O
2.0,O
and,O
20.0mg,O
/,O
kg,O
for,O
DFU,I-Entity
.,O
The,O
pooled,O
statistical,O
analysis,O
for,O
ventricular,B-Entity
septal,I-Entity
(,I-Entity
VSD,I-Entity
),I-Entity
and,I-Entity
midline,I-Entity
(,I-Entity
MD,I-Entity
),I-Entity
defects,I-Entity
was,O
performed,O
for,O
rat,O
fetuses,O
exposed,O
to,O
piroxicam,I-Entity
",",O
selective,O
and,O
non,O
-,O
selective,O
COX-2,O
inhibitor,O
based,O
on,O
present,O
and,O
historic,O
data,O
.,O
RESULTS,O
:,O
Maternal,O
toxicity,I-Entity
",",O
intrauterine,B-Entity
growth,I-Entity
retardation,I-Entity
",",O
and,O
increase,B-Entity
of,I-Entity
external,I-Entity
and,I-Entity
skeletal,I-Entity
variations,I-Entity
were,O
found,O
in,O
rats,O
treated,O
with,O
the,O
highest,O
dose,O
of,O
piroxicam,I-Entity
.,O
Decrease,O
of,O
fetal,O
length,O
was,O
the,O
only,O
signs,O
of,O
the,O
DFU,I-Entity
developmental,O
toxicity,I-Entity
observed,O
in,O
pups,O
exposed,O
to,O
the,O
highest,O
compound,O
dose,O
.,O
Lack,O
of,O
teratogenicity,O
was,O
found,O
in,O
piroxicam,I-Entity
and,O
DFU,I-Entity
-,O
exposed,O
groups,O
.,O
Unlike,O
DFU,I-Entity
",",O
piroxicam,I-Entity
was,O
also,O
highly,O
toxic,O
to,O
the,O
dams,O
.,O
Prenatal,O
exposure,O
to,O
selective,O
COX-2,O
inhibitors,O
does,O
not,O
increase,O
the,O
risk,O
of,O
ventricular,B-Entity
septal,I-Entity
and,I-Entity
midline,I-Entity
defects,I-Entity
in,O
rat,O
when,O
compared,O
to,O
non,O
-,O
selective,O
drugs,O
and,O
historic,O
control,O
.,O
Protective,O
efficacy,O
of,O
neuroactive,O
steroids,I-Entity
against,O
cocaine,I-Entity
kindled,O
-,O
seizures,I-Entity
in,O
mice,O
.,O
Neuroactive,O
steroids,I-Entity
demonstrate,O
pharmacological,O
actions,O
that,O
have,O
relevance,O
for,O
a,O
host,O
of,O
neurological,B-Entity
and,I-Entity
psychiatric,I-Entity
disorders,I-Entity
.,O
They,O
offer,O
protection,O
against,O
seizures,I-Entity
in,O
a,O
range,O
of,O
models,O
and,O
seem,O
to,O
inhibit,O
certain,O
stages,O
of,O
drug,B-Entity
dependence,I-Entity
in,O
preclinical,O
assessments,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
evaluate,O
two,O
endogenous,O
and,O
one,O
synthetic,O
neuroactive,O
steroid,I-Entity
that,O
positively,O
modulate,O
the,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
(,O
GABA(A,I-Entity
),O
),O
receptor,O
against,O
the,O
increase,O
in,O
sensitivity,O
to,O
the,O
convulsant,O
effects,O
of,O
cocaine,I-Entity
engendered,O
by,O
repeated,O
cocaine,I-Entity
administration,O
(,O
seizure,I-Entity
kindling,O
),O
.,O
Allopregnanolone,I-Entity
(,O
3alpha,B-Entity
-,I-Entity
hydroxy-5alpha,I-Entity
-,I-Entity
pregnan-20-one,I-Entity
),O
",",O
pregnanolone,I-Entity
(,O
3alpha,B-Entity
-,I-Entity
hydroxy-5beta,I-Entity
-,I-Entity
pregnan-20-one,I-Entity
),O
and,O
ganaxolone,I-Entity
(,O
a,O
synthetic,O
derivative,O
of,O
allopregnanolone,I-Entity
3alpha,B-Entity
-,I-Entity
hydroxy-3beta,I-Entity
-,I-Entity
methyl-5alpha,I-Entity
-,I-Entity
pregnan-20-one,I-Entity
),O
were,O
tested,O
for,O
their,O
ability,O
to,O
suppress,O
the,O
expression,O
(,O
anticonvulsant,O
effect,O
),O
and,O
development,O
(,O
antiepileptogenic,O
effect,O
),O
of,O
cocaine,I-Entity
-,O
kindled,O
seizures,I-Entity
in,O
male,O
",",O
Swiss,O
-,O
Webster,O
mice,O
.,O
Kindled,O
seizures,I-Entity
were,O
induced,O
by,O
daily,O
administration,O
of,O
60,O
mg,O
/,O
kg,O
cocaine,I-Entity
for,O
5,O
days,O
.,O
All,O
of,O
these,O
positive,O
GABA(A,I-Entity
),O
modulators,O
suppressed,O
the,O
expression,O
of,O
kindled,O
seizures,I-Entity
",",O
whereas,O
only,O
allopregnanolone,I-Entity
and,O
ganaxolone,I-Entity
inhibited,O
the,O
development,O
of,O
kindling,O
.,O
Allopregnanolone,I-Entity
and,O
pregnanolone,I-Entity
",",O
but,O
not,O
ganaxolone,I-Entity
",",O
also,O
reduced,O
cumulative,O
lethality,O
associated,O
with,O
kindling,O
.,O
These,O
findings,O
demonstrate,O
that,O
some,O
neuroactive,O
steroids,I-Entity
attenuate,O
convulsant,O
and,O
sensitizing,O
properties,O
of,O
cocaine,I-Entity
and,O
add,O
to,O
a,O
growing,O
literature,O
on,O
their,O
potential,O
use,O
in,O
the,O
modulation,O
of,O
effects,O
of,O
drugs,O
of,O
abuse,O
.,O
Kidney,O
function,O
and,O
morphology,O
after,O
short,O
-,O
term,O
combination,O
therapy,O
with,O
cyclosporine,B-Entity
A,I-Entity
",",O
tacrolimus,I-Entity
and,O
sirolimus,I-Entity
in,O
the,O
rat,O
.,O
BACKGROUND,O
:,O
Sirolimus,I-Entity
(,O
SRL,I-Entity
),O
may,O
supplement,O
calcineurin,O
inhibitors,O
in,O
clinical,O
organ,O
transplantation,O
.,O
These,O
are,O
nephrotoxic,I-Entity
",",O
but,O
SRL,I-Entity
seems,O
to,O
act,O
differently,O
displaying,O
only,O
minor,O
nephrotoxic,I-Entity
effects,O
",",O
although,O
this,O
question,O
is,O
still,O
open,O
.,O
In,O
a,O
number,O
of,O
treatment,O
protocols,O
where,O
SRL,I-Entity
was,O
combined,O
with,O
a,O
calcineurin,O
inhibitor,O
indications,O
of,O
a,O
synergistic,O
nephrotoxic,I-Entity
effect,O
were,O
described,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
examine,O
further,O
the,O
renal,O
function,O
",",O
including,O
morphological,O
analysis,O
of,O
the,O
kidneys,O
of,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
treated,O
with,O
either,O
cyclosporine,B-Entity
A,I-Entity
(,O
CsA,I-Entity
),O
",",O
tacrolimus,I-Entity
(,O
FK506,I-Entity
),O
or,O
SRL,I-Entity
as,O
monotherapies,O
or,O
in,O
different,O
combinations,O
.,O
METHODS,O
:,O
For,O
a,O
period,O
of,O
2,O
weeks,O
",",O
CsA,I-Entity
15,O
mg,O
/,O
kg,O
/,O
day,O
(,O
given,O
orally,O
),O
",",O
FK506,I-Entity
3.0,O
mg,O
/,O
kg,O
/,O
day,O
(,O
given,O
orally,O
),O
or,O
SRL,I-Entity
0.4,O
mg,O
/,O
kg,O
/,O
day,O
(,O
given,O
intraperitoneally,O
),O
was,O
administered,O
once,O
a,O
day,O
as,O
these,O
doses,O
have,O
earlier,O
been,O
found,O
to,O
achieve,O
a,O
significant,O
immunosuppressive,O
effect,O
in,O
Sprague,O
-,O
Dawley,O
rats,O
.,O
The,O
morphological,O
analysis,O
of,O
the,O
kidneys,O
included,O
a,O
semi,O
-,O
quantitative,O
scoring,O
system,O
analysing,O
the,O
degree,O
of,O
striped,O
fibrosis,I-Entity
",",O
subcapsular,O
fibrosis,I-Entity
and,O
the,O
number,O
of,O
basophilic,O
tubules,O
",",O
plus,O
an,O
additional,O
stereological,O
analysis,O
of,O
the,O
total,O
grade,O
of,O
fibrosis,I-Entity
in,O
the,O
cortex,O
stained,O
with,O
Sirius,O
Red,O
.,O
CsA,I-Entity
",",O
FK506,I-Entity
and,O
SRL,I-Entity
all,O
significantly,O
decreased,O
the,O
GFR,O
.,O
A,O
further,O
deterioration,O
was,O
seen,O
when,O
CsA,I-Entity
was,O
combined,O
with,O
either,O
FK506,I-Entity
or,O
SRL,I-Entity
",",O
whereas,O
the,O
GFR,O
remained,O
unchanged,O
in,O
the,O
group,O
treated,O
with,O
FK506,I-Entity
plus,O
SRL,I-Entity
when,O
compared,O
with,O
treatment,O
with,O
any,O
of,O
the,O
single,O
substances,O
.,O
The,O
semi,O
-,O
quantitative,O
scoring,O
was,O
significantly,O
worst,O
in,O
the,O
group,O
treated,O
with,O
CsA,I-Entity
plus,O
SRL,I-Entity
(,O
P<0.001,O
compared,O
with,O
controls,O
),O
and,O
the,O
analysis,O
of,O
the,O
total,O
grade,O
of,O
fibrosis,I-Entity
also,O
showed,O
the,O
highest,O
proportion,O
in,O
the,O
same,O
group,O
and,O
was,O
significantly,O
different,O
from,O
controls,O
(,O
P<0.02,O
),O
.,O
The,O
FK506,I-Entity
plus,O
SRL,I-Entity
combination,O
showed,O
only,O
a,O
marginally,O
higher,O
degree,O
of,O
fibrosis,I-Entity
as,O
compared,O
with,O
controls,O
(,O
P=0.05,O
),O
.,O
This,O
rat,O
study,O
demonstrated,O
a,O
synergistic,O
nephrotoxic,I-Entity
effect,O
of,O
CsA,I-Entity
plus,O
SRL,I-Entity
",",O
whereas,O
FK506,I-Entity
plus,O
SRL,I-Entity
was,O
better,O
tolerated,O
.,O
Effect,O
of,O
fucoidan,I-Entity
treatment,O
on,O
collagenase,O
-,O
induced,O
intracerebral,B-Entity
hemorrhage,I-Entity
in,O
rats,O
.,O
Inflammatory,O
cells,O
are,O
postulated,O
to,O
mediate,O
some,O
of,O
the,O
brain,B-Entity
damage,I-Entity
following,O
ischemic,B-Entity
stroke,I-Entity
.,O
Intracerebral,B-Entity
hemorrhage,I-Entity
is,O
associated,O
with,O
more,O
inflammation,I-Entity
than,O
ischemic,B-Entity
stroke,I-Entity
.,O
We,O
tested,O
the,O
sulfated,O
polysaccharide,O
fucoidan,I-Entity
",",O
which,O
has,O
been,O
reported,O
to,O
reduce,O
inflammatory,O
brain,B-Entity
damage,I-Entity
",",O
in,O
a,O
rat,O
model,O
of,O
intracerebral,B-Entity
hemorrhage,I-Entity
induced,O
by,O
injection,O
of,O
bacterial,O
collagenase,O
into,O
the,O
caudate,O
nucleus,O
.,O
Rats,O
were,O
treated,O
with,O
seven,O
day,O
intravenous,O
infusion,O
of,O
fucoidan,I-Entity
(,O
30,O
micrograms,O
h-1,O
),O
or,O
vehicle,O
.,O
The,O
hematoma,I-Entity
was,O
assessed,O
in,O
vivo,O
by,O
magnetic,O
resonance,O
imaging,O
.,O
Fucoidan,I-Entity
-,O
treated,O
rats,O
exhibited,O
evidence,O
of,O
impaired,B-Entity
blood,I-Entity
clotting,I-Entity
and,O
hemodilution,I-Entity
",",O
had,O
larger,O
hematomas,I-Entity
",",O
and,O
tended,O
to,O
have,O
less,O
inflammation,I-Entity
in,O
the,O
vicinity,O
of,O
the,O
hematoma,I-Entity
after,O
three,O
days,O
.,O
They,O
showed,O
significantly,O
more,O
rapid,O
improvement,O
of,O
motor,O
function,O
in,O
the,O
first,O
week,O
following,O
hemorrhage,I-Entity
and,O
better,O
memory,O
retention,O
in,O
the,O
passive,O
avoidance,O
test,O
.,O
Acute,O
white,B-Entity
matter,I-Entity
edema,I-Entity
and,O
eventual,O
neuronal,B-Entity
loss,I-Entity
in,O
the,O
striatum,O
adjacent,O
to,O
the,O
hematoma,I-Entity
did,O
not,O
differ,O
between,O
the,O
two,O
groups,O
.,O
Investigation,O
of,O
more,O
specific,O
anti,O
-,O
inflammatory,O
agents,O
and,O
hemodiluting,O
agents,O
are,O
warranted,O
in,O
intracerebral,B-Entity
hemorrhage,I-Entity
.,O
Paracetamol,I-Entity
-,O
associated,O
coma,I-Entity
",",O
metabolic,B-Entity
acidosis,I-Entity
",",O
renal,B-Entity
and,I-Entity
hepatic,I-Entity
failure,I-Entity
.,O
A,O
case,O
of,O
metabolic,B-Entity
acidosis,I-Entity
",",O
acute,B-Entity
renal,I-Entity
failure,I-Entity
and,I-Entity
hepatic,I-Entity
failure,I-Entity
following,O
paracetamol,I-Entity
ingestion,O
is,O
presented,O
.,O
Hepatic,O
reactions,O
associated,O
with,O
ketoconazole,I-Entity
in,O
the,O
United,O
Kingdom,O
.,O
Ketoconazole,I-Entity
was,O
introduced,O
in,O
the,O
United,O
Kingdom,O
in,O
1981,O
.,O
By,O
November,O
1984,O
the,O
Committee,O
on,O
Safety,O
of,O
Medicines,O
had,O
received,O
82,O
reports,O
of,O
possible,O
hepatotoxicity,I-Entity
associated,O
with,O
the,O
drug,O
",",O
including,O
five,O
deaths,I-Entity
.,O
An,O
analysis,O
of,O
the,O
75,O
cases,O
that,O
had,O
been,O
adequately,O
followed,O
up,O
suggested,O
that,O
16,O
",",O
including,O
three,O
deaths,I-Entity
",",O
were,O
probably,O
related,O
to,O
treatment,O
with,O
the,O
drug,O
.,O
The,O
mean,O
age,O
of,O
patients,O
in,O
the,O
16,O
probable,O
cases,O
was,O
57.9,O
",",O
with,O
hepatotoxicity,I-Entity
being,O
more,O
common,O
in,O
women,O
.,O
The,O
average,O
duration,O
of,O
treatment,O
before,O
the,O
onset,O
of,O
jaundice,I-Entity
was,O
61,O
days,O
.,O
The,O
results,O
of,O
serum,O
liver,O
function,O
tests,O
suggested,O
hepatocellular,B-Entity
injury,I-Entity
in,O
10,O
(,O
63%,O
),O
;,O
the,O
rest,O
showed,O
a,O
mixed,O
pattern,O
.,O
In,O
contrast,O
",",O
the,O
results,O
of,O
histological,O
examination,O
of,O
the,O
liver,O
often,O
showed,O
evidence,O
of,O
cholestasis,I-Entity
.,O
Allergic,O
manifestations,O
such,O
as,O
rash,I-Entity
and,O
eosinophilia,I-Entity
were,O
rare,O
.,O
Hepatitis,I-Entity
was,O
usually,O
reversible,O
when,O
treatment,O
was,O
stopped,O
",",O
with,O
the,O
results,O
of,O
liver,O
function,O
tests,O
returning,O
to,O
normal,O
after,O
an,O
average,O
of,O
3.1,O
months,O
.,O
In,O
two,O
of,O
the,O
three,O
deaths,I-Entity
probably,O
associated,O
with,O
ketoconazole,I-Entity
treatment,O
the,O
drug,O
had,O
been,O
continued,O
after,O
the,O
onset,O
of,O
jaundice,I-Entity
and,O
other,O
symptoms,O
of,O
hepatitis,I-Entity
.,O
Clinical,O
and,O
biochemical,O
monitoring,O
at,O
regular,O
intervals,O
for,O
evidence,O
of,O
hepatitis,I-Entity
is,O
advised,O
during,O
long,O
term,O
treatment,O
with,O
ketoconazole,I-Entity
to,O
prevent,O
possible,O
serious,O
hepatic,B-Entity
injury,I-Entity
.,O
Combined,O
effects,O
of,O
prolonged,O
prostaglandin,B-Entity
E1-induced,I-Entity
hypotension,I-Entity
and,O
haemodilution,I-Entity
on,O
human,O
hepatic,O
function,O
.,O
Combined,O
effects,O
of,O
prolonged,O
prostaglandin,B-Entity
E1,I-Entity
(,O
PGE1)-induced,I-Entity
hypotension,I-Entity
and,O
haemodilution,I-Entity
on,O
hepatic,O
function,O
were,O
studied,O
in,O
30,O
patients,O
undergoing,O
hip,O
surgery,O
.,O
The,O
patients,O
were,O
randomly,O
allocated,O
to,O
one,O
of,O
three,O
groups,O
;,O
those,O
in,O
group,O
A,O
(,O
n,O
=,O
10,O
),O
were,O
subjected,O
to,O
controlled,O
hypotension,I-Entity
alone,O
",",O
those,O
in,O
group,O
B,O
(,O
n,O
=,O
10,O
),O
to,O
haemodilution,I-Entity
alone,O
and,O
those,O
in,O
group,O
C,O
(,O
n,O
=,O
10,O
),O
to,O
both,O
controlled,O
hypotension,I-Entity
and,O
haemodilution,I-Entity
.,O
Haemodilution,I-Entity
in,O
groups,O
B,O
and,O
C,O
was,O
produced,O
by,O
withdrawing,O
approximately,O
1000,O
mL,O
of,O
blood,O
and,O
replacing,O
it,O
with,O
the,O
same,O
amount,O
of,O
dextran,I-Entity
solution,O
",",O
and,O
final,O
haematocrit,O
values,O
were,O
21,O
or,O
22%,O
.,O
Controlled,O
hypotension,I-Entity
in,O
groups,O
A,O
and,O
C,O
was,O
induced,O
with,O
PGE1,I-Entity
to,O
maintain,O
mean,O
arterial,O
blood,O
pressure,O
at,O
55,O
mmHg,O
for,O
180,O
min,O
.,O
Measurements,O
included,O
arterial,O
ketone,O
body,O
ratio,O
(,O
AKBR,O
",",O
aceto,B-Entity
-,I-Entity
acetate/3-hydroxybutyrate,I-Entity
),O
and,O
clinical,O
hepatic,O
function,O
parameters,O
.,O
In,O
group,O
C,O
",",O
AKBR,O
showed,O
a,O
significant,O
decrease,O
at,O
120,O
min,O
(,O
-40%,O
),O
and,O
at,O
180,O
min,O
(,O
-49%,O
),O
after,O
the,O
start,O
of,O
hypotension,I-Entity
and,O
at,O
60,O
min,O
(,O
-32%,O
),O
after,O
recovery,O
of,O
normotension,O
",",O
and,O
SGOT,O
",",O
SGPT,O
",",O
LDH,O
and,O
total,O
bilirubin,I-Entity
showed,O
significant,O
increases,O
after,O
operation,O
.,O
The,O
results,O
suggest,O
that,O
a,O
prolonged,O
combination,O
of,O
more,O
than,O
120,O
min,O
of,O
PGE1-induced,I-Entity
hypotension,I-Entity
and,O
moderate,O
haemodilution,I-Entity
would,O
cause,O
impairment,B-Entity
of,I-Entity
hepatic,I-Entity
function,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
:,O
filling,O
the,O
bench,O
-,O
to,O
-,O
bedside,O
gap,O
.,O
Levodopa,I-Entity
is,O
the,O
most,O
effective,O
drug,O
for,O
the,O
treatment,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
However,O
",",O
the,O
long,O
-,O
term,O
use,O
of,O
this,O
dopamine,I-Entity
precursor,O
is,O
complicated,O
by,O
highly,O
disabling,O
fluctuations,O
and,O
dyskinesias,I-Entity
.,O
Although,O
preclinical,O
and,O
clinical,O
findings,O
suggest,O
pulsatile,O
stimulation,O
of,O
striatal,O
postsynaptic,O
receptors,O
as,O
a,O
key,O
mechanism,O
underlying,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
",",O
their,O
pathogenesis,O
is,O
still,O
unclear,O
.,O
In,O
recent,O
years,O
",",O
evidence,O
from,O
animal,O
models,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
has,O
provided,O
important,O
information,O
to,O
understand,O
the,O
effect,O
of,O
specific,O
receptor,O
and,O
post,O
-,O
receptor,O
molecular,O
mechanisms,O
underlying,O
the,O
development,O
of,O
dyskinetic,B-Entity
movements,I-Entity
.,O
Recent,O
preclinical,O
and,O
clinical,O
data,O
from,O
promising,O
lines,O
of,O
research,O
focus,O
on,O
the,O
differential,O
role,O
of,O
presynaptic,O
versus,O
postsynaptic,O
mechanisms,O
",",O
dopamine,I-Entity
receptor,O
subtypes,O
",",O
ionotropic,O
and,O
metabotropic,O
glutamate,I-Entity
receptors,O
",",O
and,O
non,O
-,O
dopaminergic,O
neurotransmitter,O
systems,O
in,O
the,O
pathophysiology,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
Prevention,O
of,O
seizures,I-Entity
and,O
reorganization,O
of,O
hippocampal,O
functions,O
by,O
transplantation,O
of,O
bone,O
marrow,O
cells,O
in,O
the,O
acute,O
phase,O
of,O
experimental,O
epilepsy,I-Entity
.,O
In,O
this,O
study,O
",",O
we,O
investigated,O
the,O
therapeutic,O
potential,O
of,O
bone,O
marrow,O
mononuclear,O
cells,O
(,O
BMCs,O
),O
in,O
a,O
model,O
of,O
epilepsy,I-Entity
induced,O
by,O
pilocarpine,I-Entity
in,O
rats,O
.,O
BMCs,O
obtained,O
from,O
green,O
fluorescent,O
protein,O
(,O
GFP,O
),O
transgenic,O
mice,O
or,O
rats,O
were,O
transplanted,O
intravenously,O
after,O
induction,O
of,O
status,B-Entity
epilepticus,I-Entity
(,O
SE,I-Entity
),O
.,O
Spontaneous,B-Entity
recurrent,I-Entity
seizures,I-Entity
(,O
SRS,I-Entity
),O
were,O
monitored,O
using,O
Racine,O
's,O
seizure,I-Entity
severity,O
scale,O
.,O
All,O
of,O
the,O
rats,O
in,O
the,O
saline,O
-,O
treated,O
epileptic,I-Entity
control,O
group,O
developed,O
SRS,I-Entity
",",O
whereas,O
none,O
of,O
the,O
BMC,O
-,O
treated,O
epileptic,I-Entity
animals,O
had,O
seizures,I-Entity
in,O
the,O
short,O
term,O
(,O
15,O
days,O
after,O
transplantation,O
),O
",",O
regardless,O
of,O
the,O
BMC,O
source,O
.,O
Over,O
the,O
long,O
-,O
term,O
chronic,O
phase,O
(,O
120,O
days,O
after,O
transplantation,O
),O
",",O
only,O
25%,O
of,O
BMC,O
-,O
treated,O
epileptic,I-Entity
animals,O
had,O
seizures,I-Entity
",",O
but,O
with,O
a,O
lower,O
frequency,O
and,O
duration,O
compared,O
to,O
the,O
epileptic,I-Entity
control,O
group,O
.,O
At,O
hippocampal,O
Schaeffer,O
collateral,O
-,O
CA1,O
synapses,O
",",O
long,O
-,O
term,O
potentiation,O
was,O
preserved,O
in,O
BMC,O
-,O
transplanted,O
rats,O
compared,O
to,O
epileptic,I-Entity
controls,O
.,O
cells,O
were,O
rarely,O
found,O
in,O
the,O
brains,O
of,O
transplanted,O
epileptic,I-Entity
rats,O
.,O
In,O
conclusion,O
",",O
treatment,O
with,O
BMCs,O
can,O
prevent,O
the,O
development,O
of,O
chronic,O
seizures,I-Entity
",",O
reduce,O
neuronal,B-Entity
loss,I-Entity
",",O
and,O
influence,O
the,O
reorganization,O
of,O
the,O
hippocampal,O
neuronal,O
network,O
.,O
Cardioprotective,O
effect,O
of,O
salvianolic,B-Entity
acid,I-Entity
A,I-Entity
on,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
evaluate,O
the,O
cardioprotective,O
potential,O
of,O
salvianolic,B-Entity
acid,I-Entity
A,I-Entity
on,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
Isoproterenol,I-Entity
-,O
treated,O
rats,O
showed,O
significant,O
increases,O
in,O
the,O
levels,O
of,O
lactate,I-Entity
dehydrogenase,O
",",O
aspartate,I-Entity
transaminase,O
",",O
creatine,I-Entity
kinase,O
and,O
malondialdehyde,I-Entity
and,O
significant,O
decreases,O
in,O
the,O
activities,O
of,O
superoxide,I-Entity
dismutase,O
",",O
catalase,O
and,O
glutathione,I-Entity
peroxidase,O
in,O
serum,O
and,O
heart,O
.,O
In,O
addition,O
",",O
mitochondrial,O
respiratory,B-Entity
dysfunction,I-Entity
characterized,O
by,O
decreased,O
respiratory,O
control,O
ratio,O
and,O
ADP,I-Entity
/,O
O,O
was,O
observed,O
in,O
isoproterenol,I-Entity
-,O
treated,O
rats,O
.,O
Administration,O
of,O
salvianolic,B-Entity
acid,I-Entity
A,I-Entity
for,O
a,O
period,O
of,O
8,O
days,O
significantly,O
attenuated,O
isoproterenol,I-Entity
-,O
induced,O
cardiac,B-Entity
dysfunction,I-Entity
and,O
myocardial,B-Entity
injury,I-Entity
and,O
improved,O
mitochondrial,O
respiratory,O
function,O
.,O
The,O
protective,O
role,O
of,O
salvianolic,B-Entity
acid,I-Entity
A,I-Entity
against,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
damage,I-Entity
was,O
further,O
confirmed,O
by,O
histopathological,O
examination,O
.,O
The,O
results,O
of,O
our,O
study,O
suggest,O
that,O
salvianolic,B-Entity
acid,I-Entity
A,I-Entity
possessing,O
antioxidant,O
activity,O
has,O
a,O
significant,O
protective,O
effect,O
against,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
.,O
Acute,O
effects,O
of,O
N-(2-propylpentanoyl)urea,I-Entity
on,O
hippocampal,O
amino,B-Entity
acid,I-Entity
neurotransmitters,O
in,O
pilocarpine,I-Entity
-,O
induced,O
seizure,I-Entity
in,O
rats,O
.,O
The,O
present,O
study,O
aimed,O
to,O
investigate,O
the,O
anticonvulsant,O
activity,O
as,O
well,O
as,O
the,O
effects,O
on,O
the,O
level,O
of,O
hippocampal,O
amino,B-Entity
acid,I-Entity
neurotransmitters,O
(,O
glutamate,I-Entity
",",O
aspartate,I-Entity
",",O
glycine,I-Entity
and,O
GABA,I-Entity
),O
of,O
N-(2-propylpentanoyl)urea,I-Entity
(,O
VPU,I-Entity
),O
in,O
comparison,O
to,O
its,O
parent,O
compound,O
",",O
valproic,B-Entity
acid,I-Entity
(,O
VPA,I-Entity
),O
.,O
VPU,I-Entity
was,O
more,O
potent,O
than,O
VPA,I-Entity
",",O
exhibiting,O
the,O
median,O
effective,O
dose,O
(,O
ED(50,O
),O
),O
of,O
49,O
mg,O
/,O
kg,O
in,O
protecting,O
rats,O
against,O
pilocarpine,I-Entity
-,O
induced,O
seizure,I-Entity
whereas,O
the,O
corresponding,O
value,O
for,O
VPA,I-Entity
was,O
322,O
mg,O
/,O
kg,O
.,O
In,O
vivo,O
microdialysis,O
demonstrated,O
that,O
an,O
intraperitoneal,O
administration,O
of,O
pilocarpine,I-Entity
induced,O
a,O
pronounced,O
increment,O
of,O
hippocampal,O
glutamate,I-Entity
and,O
aspartate,I-Entity
whereas,O
no,O
significant,O
change,O
was,O
observed,O
on,O
the,O
level,O
of,O
glycine,I-Entity
and,O
GABA,I-Entity
.,O
Pretreatment,O
with,O
either,O
VPU,I-Entity
(,O
50,O
and,O
100,O
mg,O
/,O
kg,O
),O
or,O
VPA,I-Entity
(,O
300,O
and,O
600,O
mg,O
/,O
kg,O
),O
completely,O
abolished,O
pilocarpine,I-Entity
-,O
evoked,O
increases,O
in,O
extracellular,O
glutamate,I-Entity
and,O
aspartate,I-Entity
.,O
In,O
addition,O
",",O
a,O
statistically,O
significant,O
reduction,O
was,O
also,O
observed,O
on,O
the,O
level,O
of,O
GABA,I-Entity
and,O
glycine,I-Entity
but,O
less,O
than,O
a,O
drastic,O
reduction,O
of,O
glutamate,I-Entity
and,O
aspartate,I-Entity
level,O
.,O
Based,O
on,O
the,O
finding,O
that,O
VPU,I-Entity
and,O
VPA,I-Entity
could,O
protect,O
the,O
animals,O
against,O
pilocarpine,I-Entity
-,O
induced,O
seizure,I-Entity
it,O
is,O
suggested,O
that,O
the,O
reduction,O
of,O
inhibitory,O
amino,B-Entity
acid,I-Entity
neurotransmitters,O
was,O
comparatively,O
minor,O
and,O
offset,O
by,O
a,O
pronounced,O
reduction,O
of,O
glutamate,I-Entity
and,O
aspartate,I-Entity
.,O
Therefore,O
",",O
like,O
VPA,I-Entity
",",O
the,O
finding,O
that,O
VPU,I-Entity
could,O
drastically,O
reduce,O
pilocarpine,I-Entity
-,O
induced,O
increases,O
in,O
glutamate,I-Entity
and,O
aspartate,I-Entity
should,O
account,O
",",O
at,O
least,O
partly,O
",",O
for,O
its,O
anticonvulsant,O
activity,O
observed,O
in,O
pilocarpine,I-Entity
-,O
induced,O
seizure,I-Entity
in,O
experimental,O
animals,O
.,O
Acute,O
hepatitis,I-Entity
attack,O
after,O
exposure,O
to,O
telithromycin,I-Entity
.,O
INTRODUCTION,O
:,O
Antibiotic,O
-,O
associated,O
hepatotoxicity,I-Entity
is,O
rare,O
.,O
With,O
widespread,O
use,O
of,O
antimicrobial,O
agents,O
",",O
however,O
",",O
hepatic,B-Entity
injury,I-Entity
occurs,O
frequently,O
",",O
and,O
among,O
adverse,B-Entity
drug,I-Entity
reactions,I-Entity
",",O
idiosyncratic,O
reactions,O
are,O
the,O
most,O
serious,O
.,O
Hospital,O
Emergency,O
Department,O
",",O
Istanbul,O
",",O
Turkey,O
",",O
with,O
5,O
days,O
',O
history,O
of,O
jaundice,I-Entity
",",O
malaise,O
",",O
nausea,I-Entity
",",O
and,O
vomiting,I-Entity
.,O
He,O
had,O
been,O
prescribed,O
telithromycin,I-Entity
400,O
mg,O
/,O
d,O
PO,O
to,O
treat,O
an,O
upper,B-Entity
respiratory,I-Entity
tract,I-Entity
infection,I-Entity
7,O
days,O
prior,O
.,O
Admission,O
laboratory,O
tests,O
were,O
as,O
follows,O
:,O
alanine,I-Entity
aminotransferase,O
",",O
67,O
U,O
/,O
L,O
(,O
reference,O
range,O
",",O
10,O
-,O
37,O
U,O
/,O
L,O
),O
;,O
aspartate,I-Entity
aminotransferase,O
",",O
98,O
U,O
/,O
L,O
(,O
10,O
-,O
40,O
U,O
/,O
L,O
),O
;,O
alkaline,O
phosphatase,O
",",O
513,O
U,O
/,O
L,O
(,O
0,O
-,O
270,O
U,O
/,O
L,O
),O
;,O
gamma,O
-,O
glutamyltransferase,O
",",O
32,O
U,O
/,O
L,O
(,O
7,O
-,O
49,O
U,O
/,O
L,O
),O
;,O
amylase,O
",",O
46,O
U,O
/,O
L,O
(,O
0,O
-,O
220,O
U,O
/,O
L,O
),O
;,O
total,O
bilirubin,I-Entity
",",O
20.1,O
mg,O
/,O
dL,O
(,O
0.2,O
-,O
1.0,O
mg,O
/,O
dL,O
),O
;,O
direct,O
bilirubin,I-Entity
",",O
14.8,O
mg,O
/,O
dL,O
(,O
0,O
-,O
0.3,O
mg,O
/,O
dL,O
),O
;,O
and,O
albumin,O
",",O
4.7,O
mg,O
/,O
dL,O
(,O
3.5,O
-,O
5.4,O
mg,O
/,O
dL,O
),O
.,O
No,O
toxin,O
",",O
alcohol,I-Entity
",",O
or,O
other,O
drugs,O
were,O
reported,O
.,O
The,O
patient,O
had,O
suffered,O
a,O
previous,O
episode,O
of,O
"""",O
acute,O
hepatitis,I-Entity
of,O
unknown,O
origin,O
",",O
"""",O
that,O
occurred,O
after,O
telithromycin,I-Entity
usage,O
.,O
Telithromycin,I-Entity
is,O
the,O
first,O
of,O
the,O
ketolide,O
antibacterials,O
to,O
receive,O
US,O
Food,O
and,O
Drug,O
Administration,O
approval,O
for,O
clinical,O
use,O
.,O
It,O
has,O
been,O
associated,O
with,O
infrequent,O
and,O
usually,O
reversible,O
severe,O
hepatic,B-Entity
dysfunction,I-Entity
.,O
Based,O
on,O
a,O
score,O
of,O
8,O
on,O
the,O
Naranjo,O
adverse,B-Entity
drug,I-Entity
reaction,I-Entity
probability,O
scale,O
",",O
telithromycin,I-Entity
was,O
the,O
probable,O
cause,O
of,O
acute,O
hepatitis,I-Entity
in,O
this,O
patient,O
",",O
and,O
pathological,O
findings,O
suggested,O
drug,O
-,O
induced,O
toxic,B-Entity
hepatitis,I-Entity
.,O
Recurrence,O
of,O
hepatitis,I-Entity
attack,O
might,O
have,O
been,O
avoided,O
if,O
the,O
initial,O
incident,O
had,O
been,O
communicated,O
to,O
the,O
attending,O
physician,O
who,O
prescribed,O
telithromycin,I-Entity
the,O
second,O
time,O
.,O
Here,O
we,O
report,O
a,O
case,O
of,O
acute,O
hepatitis,I-Entity
probably,O
associated,O
with,O
the,O
administration,O
of,O
telithromycin,I-Entity
.,O
Spironolactone,I-Entity
-,O
induced,O
renal,B-Entity
insufficiency,I-Entity
and,O
hyperkalemia,I-Entity
in,O
patients,O
with,O
heart,B-Entity
failure,I-Entity
.,O
A,O
previous,O
randomized,O
controlled,O
trial,O
evaluating,O
the,O
use,O
of,O
spironolactone,I-Entity
in,O
heart,B-Entity
failure,I-Entity
patients,O
reported,O
a,O
low,O
risk,O
of,O
hyperkalemia,I-Entity
(,O
2%,O
),O
and,O
renal,B-Entity
insufficiency,I-Entity
(,O
0%,O
),O
.,O
Because,O
treatments,O
for,O
heart,B-Entity
failure,I-Entity
have,O
changed,O
since,O
the,O
benefits,O
of,O
spironolactone,I-Entity
were,O
reported,O
",",O
the,O
prevalence,O
of,O
these,O
complications,O
may,O
differ,O
in,O
current,O
clinical,O
practice,O
.,O
We,O
therefore,O
sought,O
to,O
determine,O
the,O
prevalence,O
and,O
clinical,O
associations,O
of,O
hyperkalemia,I-Entity
and,O
renal,B-Entity
insufficiency,I-Entity
in,O
heart,B-Entity
failure,I-Entity
patients,O
treated,O
with,O
spironolactone,I-Entity
.,O
:,O
We,O
performed,O
a,O
case,O
control,O
study,O
of,O
heart,B-Entity
failure,I-Entity
patients,O
treated,O
with,O
spironolactone,I-Entity
in,O
our,O
clinical,O
practice,O
.,O
Cases,O
were,O
patients,O
who,O
developed,O
hyperkalemia,I-Entity
(,O
K(+,I-Entity
),O
>,O
5.0,O
mEq,O
/,O
L,O
),O
or,O
renal,B-Entity
insufficiency,I-Entity
(,O
Cr,I-Entity
>,O
or=2.5,O
mg,O
/,O
dL,O
),O
",",O
and,O
Sixty,O
-,O
seven,O
of,O
926,O
patients,O
(,O
7.2%,O
),O
required,O
discontinuation,O
of,O
spironolactone,I-Entity
due,O
to,O
hyperkalemia,I-Entity
(,O
n,O
=,O
33,O
),O
or,O
renal,B-Entity
failure,I-Entity
(,O
n,O
=,O
34,O
),O
.,O
Patients,O
who,O
developed,O
hyperkalemia,I-Entity
were,O
older,O
and,O
more,O
likely,O
to,O
have,O
diabetes,I-Entity
",",O
had,O
higher,O
baseline,O
serum,O
potassium,I-Entity
levels,O
and,O
lower,O
baseline,O
potassium,I-Entity
supplement,O
doses,O
",",O
and,O
were,O
more,O
likely,O
to,O
be,O
treated,O
with,O
beta,O
-,O
blockers,O
than,O
controls,O
(,O
n,O
=,O
134,O
),O
.,O
Patients,O
who,O
developed,O
renal,B-Entity
insufficiency,I-Entity
had,O
lower,O
baseline,O
body,O
weight,O
and,O
higher,O
baseline,O
serum,O
creatinine,I-Entity
",",O
required,O
higher,O
doses,O
of,O
loop,O
diuretics,O
",",O
and,O
were,O
more,O
likely,O
to,O
be,O
treated,O
with,O
thiazide,I-Entity
diuretics,O
than,O
controls,O
.,O
CONCLUSIONS,O
:,O
Spironolactone,I-Entity
-,O
induced,O
hyperkalemia,I-Entity
and,O
renal,B-Entity
insufficiency,I-Entity
are,O
more,O
common,O
in,O
our,O
clinical,O
experience,O
than,O
reported,O
previously,O
.,O
End,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
(,O
ESRD,I-Entity
),O
after,O
orthotopic,O
liver,O
transplantation,O
(,O
OLTX,O
),O
using,O
calcineurin,O
-,O
based,O
immunotherapy,O
:,O
The,O
calcineurin,O
inhibitors,O
cyclosporine,I-Entity
and,O
tacrolimus,I-Entity
are,O
both,O
known,O
to,O
be,O
nephrotoxic,I-Entity
.,O
Recently,O
",",O
however,O
",",O
we,O
have,O
had,O
an,O
increase,O
of,O
patients,O
who,O
are,O
presenting,O
after,O
OLTX,O
with,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
(,O
ESRD,I-Entity
),O
.,O
This,O
retrospective,O
study,O
examines,O
the,O
incidence,O
and,O
treatment,O
of,O
ESRD,I-Entity
and,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
(,O
CRF,I-Entity
),O
in,O
OLTX,O
patients,O
.,O
Patients,O
were,O
divided,O
into,O
three,O
groups,O
:,O
Controls,O
",",O
no,O
CRF,I-Entity
or,O
ESRD,I-Entity
",",O
n=748,O
;,O
CRF,I-Entity
",",O
sustained,O
serum,O
creatinine,I-Entity
>,O
2.5,O
mg,O
/,O
dl,O
",",O
n=41,O
;,O
and,O
ESRD,I-Entity
",",O
n=45,O
.,O
Groups,O
were,O
compared,O
for,O
preoperative,O
laboratory,O
variables,O
",",O
diagnosis,O
",",O
postoperative,O
variables,O
",",O
survival,O
",",O
type,O
of,O
ESRD,I-Entity
therapy,O
",",O
and,O
survival,O
from,O
onset,O
of,O
ESRD,I-Entity
.,O
At,O
13,O
years,O
after,O
OLTX,O
",",O
the,O
incidence,O
of,O
severe,O
renal,B-Entity
dysfunction,I-Entity
was,O
18.1%,O
(,O
CRF,I-Entity
8.6%,O
and,O
ESRD,I-Entity
9.5%,O
),O
.,O
Compared,O
with,O
control,O
patients,O
",",O
CRF,I-Entity
and,O
ESRD,I-Entity
patients,O
had,O
higher,O
preoperative,O
serum,O
creatinine,I-Entity
levels,O
",",O
a,O
greater,O
percentage,O
of,O
patients,O
with,O
hepatorenal,B-Entity
syndrome,I-Entity
",",O
higher,O
percentage,O
requirement,O
for,O
dialysis,O
in,O
the,O
first,O
3,O
months,O
postoperatively,O
",",O
and,O
a,O
higher,O
1-year,O
serum,O
creatinine,I-Entity
.,O
Multivariate,O
stepwise,O
logistic,O
regression,O
analysis,O
using,O
preoperative,O
and,O
postoperative,O
variables,O
identified,O
that,O
an,O
increase,O
of,O
serum,O
creatinine,I-Entity
compared,O
with,O
average,O
at,O
1,O
year,O
",",O
3,O
months,O
",",O
and,O
4,O
weeks,O
postoperatively,O
were,O
independent,O
risk,O
factors,O
for,O
the,O
development,O
of,O
CRF,I-Entity
or,O
ESRD,I-Entity
with,O
odds,O
ratios,O
of,O
2.6,O
",",O
2.2,O
",",O
and,O
1.6,O
",",O
respectively,O
.,O
Overall,O
survival,O
from,O
the,O
time,O
of,O
OLTX,O
was,O
not,O
significantly,O
different,O
among,O
groups,O
",",O
but,O
by,O
year,O
13,O
",",O
the,O
survival,O
of,O
the,O
patients,O
who,O
had,O
ESRD,I-Entity
was,O
only,O
28.2%,O
compared,O
with,O
54.6%,O
in,O
the,O
control,O
group,O
.,O
Patients,O
developing,O
ESRD,I-Entity
had,O
a,O
6-year,O
survival,O
after,O
onset,O
of,O
ESRD,I-Entity
of,O
27%,O
for,O
the,O
patients,O
receiving,O
hemodialysis,O
versus,O
71.4%,O
for,O
the,O
patients,O
developing,O
ESRD,I-Entity
who,O
subsequently,O
received,O
kidney,O
transplants,O
.,O
Patients,O
who,O
are,O
more,O
than,O
10,O
years,O
post,O
-,O
OLTX,O
have,O
CRF,I-Entity
and,O
ESRD,I-Entity
at,O
a,O
high,O
rate,O
.,O
The,O
development,O
of,O
ESRD,I-Entity
decreases,O
survival,O
",",O
particularly,O
in,O
those,O
patients,O
treated,O
with,O
dialysis,O
only,O
.,O
Patients,O
who,O
develop,O
ESRD,I-Entity
have,O
a,O
higher,O
preoperative,O
and,O
1-year,O
serum,O
creatinine,I-Entity
and,O
are,O
more,O
likely,O
to,O
have,O
hepatorenal,B-Entity
syndrome,I-Entity
.,O
However,O
",",O
an,O
increase,O
of,O
serum,O
creatinine,I-Entity
at,O
various,O
times,O
postoperatively,O
is,O
more,O
predictive,O
of,O
the,O
development,O
of,O
CRF,I-Entity
or,O
ESRD,I-Entity
.,O
Effect,O
of,O
intravenous,O
nimodipine,I-Entity
on,O
blood,O
pressure,O
and,O
outcome,O
after,O
acute,B-Entity
stroke,I-Entity
.,O
The,O
Intravenous,O
Nimodipine,I-Entity
West,O
European,O
Stroke,I-Entity
Trial,O
(,O
INWEST,O
),O
found,O
a,O
correlation,O
between,O
nimodipine,I-Entity
-,O
induced,O
reduction,B-Entity
in,I-Entity
blood,I-Entity
pressure,I-Entity
(,O
BP,O
),O
and,O
an,O
unfavorable,O
outcome,O
in,O
acute,B-Entity
stroke,I-Entity
.,O
We,O
sought,O
to,O
confirm,O
this,O
correlation,O
with,O
and,O
without,O
adjustment,O
for,O
prognostic,O
variables,O
and,O
to,O
investigate,O
outcome,O
in,O
subgroups,O
with,O
increasing,O
levels,O
of,O
BP,B-Entity
reduction,I-Entity
.,O
Patients,O
with,O
a,O
clinical,O
diagnosis,O
of,O
ischemic,B-Entity
stroke,I-Entity
(,O
within,O
24,O
hours,O
),O
were,O
consecutively,O
allocated,O
to,O
receive,O
placebo,O
(,O
n=100,O
),O
",",O
1,O
mg,O
/,O
h,O
(,O
low,O
-,O
dose,O
),O
nimodipine,I-Entity
(,O
n=101,O
),O
",",O
or,O
2,O
mg,O
/,O
h,O
(,O
high,O
-,O
dose,O
),O
nimodipine,I-Entity
(,O
n=94,O
),O
.,O
Nimodipine,I-Entity
treatment,O
resulted,O
in,O
a,O
statistically,O
significant,O
reduction,B-Entity
in,I-Entity
systolic,I-Entity
BP,I-Entity
(,O
SBP,O
),O
and,O
diastolic,O
BP,O
(,O
DBP,O
),O
from,O
baseline,O
compared,O
with,O
placebo,O
during,O
the,O
first,O
few,O
days,O
.,O
In,O
multivariate,O
analysis,O
",",O
a,O
significant,O
correlation,O
between,O
DBP,B-Entity
reduction,I-Entity
and,O
worsening,O
of,O
the,O
neurological,O
score,O
was,O
found,O
for,O
the,O
high,O
-,O
dose,O
group,O
(,O
beta=0.49,O
",",O
P=0,O
.,O
Patients,O
with,O
a,O
DBP,B-Entity
reduction,I-Entity
of,O
>,O
or,O
=,O
20%,O
in,O
the,O
high,O
-,O
dose,O
group,O
had,O
a,O
significantly,O
increased,O
adjusted,O
OR,O
for,O
the,O
compound,O
outcome,O
variable,O
death,I-Entity
or,O
dependency,O
(,O
n,O
/,O
N=25/26,O
",",O
OR,O
10,O
.,O
16,O
",",O
95%,O
CI,O
1.02,O
to,O
101.74,O
),O
and,O
death,I-Entity
alone,O
(,O
n,O
/,O
N=9/26,O
",",O
OR,O
4.336,O
",",O
95%,O
CI,O
1.131,O
16.619,O
),O
compared,O
with,O
all,O
placebo,O
patients,O
(,O
n,O
/,O
N=62/92,O
and,O
14/92,O
",",O
respectively,O
),O
.,O
DBP,O
",",O
but,O
not,O
SBP,O
",",O
reduction,O
was,O
associated,O
with,O
neurological,O
worsening,O
after,O
the,O
intravenous,O
administration,O
of,O
high,O
-,O
dose,O
nimodipine,I-Entity
after,O
acute,B-Entity
stroke,I-Entity
.,O
For,O
low,O
-,O
dose,O
nimodipine,I-Entity
",",O
the,O
results,O
were,O
not,O
conclusive,O
.,O
These,O
results,O
do,O
not,O
confirm,O
or,O
exclude,O
a,O
neuroprotective,O
property,O
of,O
nimodipine,I-Entity
.,O
Transient,B-Entity
neurologic,I-Entity
symptoms,I-Entity
after,O
spinal,O
anesthesia,O
:,O
a,O
lower,O
incidence,O
with,O
prilocaine,I-Entity
and,O
bupivacaine,I-Entity
than,O
with,O
lidocaine,I-Entity
.,O
Recent,O
evidence,O
suggests,O
that,O
transient,B-Entity
neurologic,I-Entity
symptoms,I-Entity
(,O
TNSs,I-Entity
),O
frequently,O
follow,O
lidocaine,I-Entity
spinal,O
anesthesia,O
but,O
are,O
infrequent,O
with,O
bupivacaine,I-Entity
.,O
However,O
",",O
identification,O
of,O
a,O
short,O
-,O
acting,O
local,O
anesthetic,O
to,O
substitute,O
for,O
lidocaine,I-Entity
for,O
brief,O
surgical,O
procedures,O
remains,O
an,O
important,O
goal,O
.,O
Prilocaine,I-Entity
is,O
an,O
amide,O
local,O
anesthetic,O
with,O
a,O
duration,O
of,O
action,O
similar,O
to,O
that,O
of,O
lidocaine,I-Entity
.,O
Accordingly,O
",",O
the,O
present,O
",",O
prospective,O
double,O
-,O
blind,O
study,O
compares,O
prilocaine,I-Entity
with,O
lidocaine,I-Entity
and,O
bupivacaine,I-Entity
with,O
respect,O
to,O
duration,O
of,O
action,O
and,O
relative,O
risk,O
of,O
TNSs,I-Entity
.,O
2%,O
lidocaine,I-Entity
in,O
7.5%,O
glucose,I-Entity
",",O
2%,O
prilocaine,I-Entity
in,O
7.5%,O
glucose,I-Entity
",",O
or,O
0.5%,O
bupivacaine,I-Entity
in,O
7.5%,O
glucose,I-Entity
.,O
In,O
the,O
evening,O
of,O
postoperative,O
day,O
1,O
",",O
patients,O
were,O
evaluated,O
for,O
TNSs,I-Entity
by,O
a,O
physician,O
unaware,O
of,O
the,O
drug,O
administered,O
and,O
the,O
details,O
of,O
the,O
anesthetic,O
procedure,O
.,O
Nine,O
of,O
30,O
patients,O
receiving,O
lidocaine,I-Entity
experienced,O
TNSs,I-Entity
",",O
1,O
of,O
30,O
patients,O
receiving,O
prilocaine,I-Entity
(,O
P,O
=,O
0.03,O
),O
had,O
them,O
",",O
and,O
none,O
of,O
30,O
patients,O
receiving,O
bupivacaine,I-Entity
had,O
TNSs,I-Entity
.,O
Times,O
to,O
ambulate,O
and,O
to,O
void,O
were,O
similar,O
after,O
lidocaine,I-Entity
and,O
prilocaine,I-Entity
(,O
150,O
vs.,O
165,O
min,O
and,O
238,O
vs.,O
253,O
min,O
",",O
respectively,O
),O
but,O
prolonged,O
after,O
bupivacaine,I-Entity
(,O
200,O
and,O
299,O
min,O
",",O
respectively,O
;,O
Prilocaine,I-Entity
may,O
be,O
preferable,O
to,O
lidocaine,I-Entity
for,O
short,O
surgical,O
procedures,O
because,O
it,O
has,O
a,O
similar,O
duration,O
of,O
action,O
but,O
a,O
lower,O
incidence,O
of,O
TNSs,I-Entity
.,O
The,O
role,O
of,O
nicotine,I-Entity
in,O
smoking,O
-,O
related,O
cardiovascular,B-Entity
disease,I-Entity
.,O
Nicotine,I-Entity
activates,O
the,O
sympathetic,O
nervous,O
system,O
and,O
in,O
this,O
way,O
could,O
contribute,O
to,O
cardiovascular,B-Entity
disease,I-Entity
.,O
Animal,O
studies,O
and,O
mechanistic,O
studies,O
indicate,O
that,O
nicotine,I-Entity
could,O
play,O
a,O
role,O
in,O
accelerating,O
atherosclerosis,I-Entity
",",O
but,O
evidence,O
among,O
humans,O
is,O
too,O
inadequate,O
to,O
be,O
definitive,O
about,O
such,O
an,O
effect,O
.,O
Almost,O
certainly,O
",",O
nicotine,I-Entity
via,O
its,O
hemodynamic,O
effects,O
contributes,O
to,O
acute,O
cardiovascular,O
events,O
",",O
although,O
current,O
evidence,O
suggests,O
that,O
the,O
effects,O
of,O
nicotine,I-Entity
are,O
much,O
less,O
important,O
than,O
are,O
the,O
prothrombotic,O
effects,O
of,O
cigarette,O
smoking,O
or,O
the,O
effects,O
of,O
carbon,B-Entity
monoxide,I-Entity
.,O
Nicotine,I-Entity
does,O
not,O
appear,O
to,O
enhance,O
thrombosis,I-Entity
among,O
humans,O
.,O
Clinical,O
studies,O
of,O
pipe,O
smokers,O
and,O
people,O
using,O
transdermal,O
nicotine,I-Entity
support,O
the,O
idea,O
that,O
toxins,O
other,O
than,O
nicotine,I-Entity
are,O
the,O
most,O
important,O
causes,O
of,O
acute,O
cardiovascular,O
events,O
.,O
Finally,O
",",O
the,O
dose,O
response,O
for,O
cardiovascular,O
events,O
of,O
nicotine,I-Entity
appears,O
to,O
be,O
flat,O
",",O
suggesting,O
that,O
if,O
nicotine,I-Entity
is,O
involved,O
",",O
adverse,O
effects,O
might,O
be,O
seen,O
with,O
relatively,O
low,O
-,O
level,O
cigarette,O
exposures,O
.,O
Seizure,I-Entity
resulting,O
from,O
a,O
venlafaxine,I-Entity
overdose,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
venlafaxine,I-Entity
overdose,I-Entity
.,O
A,O
40-year,O
-,O
old,O
woman,O
with,O
major,B-Entity
depression,I-Entity
took,O
an,O
overdose,I-Entity
of,O
venlafaxine,I-Entity
in,O
an,O
apparent,O
suicide,O
attempt,O
.,O
After,O
the,O
ingestion,O
of,O
26,O
venlafaxine,I-Entity
50-mg,O
tablets,O
",",O
the,O
patient,O
experienced,O
a,O
witnessed,O
generalized,O
seizure,I-Entity
.,O
She,O
was,O
admitted,O
to,O
the,O
medical,O
intensive,O
care,O
unit,O
",",O
venlafaxine,I-Entity
was,O
discontinued,O
",",O
and,O
no,O
further,O
sequelae,O
were,O
seen,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
venlafaxine,I-Entity
overdose,I-Entity
that,O
resulted,O
in,O
a,O
generalized,O
seizure,I-Entity
.,O
Based,O
on,O
nonoverdose,O
pharmacokinetics,O
and,O
pharmacodynamics,O
of,O
venlafaxine,I-Entity
and,O
the,O
potential,O
risks,O
of,O
available,O
interventions,O
",",O
no,O
emergent,O
therapy,O
was,O
instituted,O
.,O
The,O
venlafaxine,I-Entity
overdose,I-Entity
in,O
our,O
patient,O
resulted,O
in,O
a,O
single,O
episode,O
of,O
generalized,O
seizure,I-Entity
but,O
elicited,O
no,O
further,O
sequelae,O
.,O
Effect,O
of,O
nifedipine,I-Entity
on,O
renal,O
function,O
in,O
liver,O
transplant,O
recipients,O
receiving,O
tacrolimus,I-Entity
.,O
The,O
effect,O
of,O
nifedipine,I-Entity
on,O
renal,O
function,O
in,O
liver,O
transplant,O
recipients,O
who,O
were,O
receiving,O
tacrolimus,I-Entity
was,O
evaluated,O
between,O
January,O
1992,O
and,O
January,O
1996,O
.,O
Two,O
groups,O
of,O
patients,O
receiving,O
tacrolimus,I-Entity
were,O
compared,O
over,O
a,O
period,O
of,O
1,O
year,O
",",O
one,O
group,O
comprising,O
hypertensive,I-Entity
patients,O
who,O
were,O
receiving,O
nifedipine,I-Entity
",",O
and,O
the,O
other,O
comprising,O
nonhypertensive,O
patients,O
not,O
receiving,O
nifedipine,I-Entity
.,O
Nifedipine,I-Entity
significantly,O
improved,O
kidney,O
function,O
as,O
indicated,O
by,O
a,O
significant,O
lowering,O
of,O
serum,O
creatinine,I-Entity
levels,O
at,O
6,O
and,O
12,O
months,O
.,O
The,O
observed,O
positive,O
impact,O
of,O
nifedipine,I-Entity
on,O
reducing,O
the,O
nephrotoxicity,I-Entity
associated,O
with,O
tacrolimus,I-Entity
in,O
liver,O
transplant,O
recipients,O
should,O
be,O
an,O
important,O
factor,O
in,O
selecting,O
an,O
agent,O
to,O
treat,O
hypertension,I-Entity
in,O
this,O
population,O
.,O
Sinus,B-Entity
arrest,I-Entity
associated,O
with,O
continuous,O
-,O
infusion,O
cimetidine,I-Entity
.,O
The,O
administration,O
of,O
intermittent,O
intravenous,O
infusions,O
of,O
cimetidine,I-Entity
is,O
infrequently,O
associated,O
with,O
the,O
development,O
of,O
bradyarrhythmias,I-Entity
.,O
A,O
40-year,O
-,O
old,O
man,O
with,O
leukemia,I-Entity
and,O
no,O
history,O
of,O
cardiac,B-Entity
disease,I-Entity
developed,O
recurrent,O
",",O
brief,O
episodes,O
of,O
apparent,O
sinus,B-Entity
arrest,I-Entity
while,O
receiving,O
continuous,O
-,O
infusion,O
cimetidine,I-Entity
50,O
mg,O
/,O
hour,O
.,O
The,O
arrhythmias,I-Entity
were,O
temporally,O
related,O
to,O
cimetidine,I-Entity
administration,O
",",O
disappeared,O
after,O
dechallenge,O
",",O
and,O
did,O
not,O
recur,O
during,O
ranitidine,I-Entity
treatment,O
.,O
This,O
is,O
the,O
first,O
reported,O
case,O
of,O
sinus,B-Entity
arrest,I-Entity
associated,O
with,O
continuous,O
-,O
infusion,O
cimetidine,I-Entity
.,O
Composition,O
of,O
gall,B-Entity
bladder,I-Entity
stones,I-Entity
associated,O
with,O
octreotide,I-Entity
:,O
response,O
to,O
oral,O
ursodeoxycholic,B-Entity
acid,I-Entity
.,O
Octreotide,I-Entity
",",O
an,O
effective,O
treatment,O
for,O
acromegaly,I-Entity
",",O
induces,O
gall,B-Entity
bladder,I-Entity
stones,I-Entity
in,O
13,O
-,O
60%,O
of,O
patients,O
.,O
Because,O
knowledge,O
of,O
stone,O
composition,O
is,O
essential,O
for,O
studies,O
of,O
their,O
pathogenesis,O
",",O
treatment,O
",",O
and,O
prevention,O
",",O
this,O
was,O
investigated,O
by,O
direct,O
and,O
indirect,O
methods,O
in,O
14,O
octreotide,I-Entity
treated,O
acromegalic,I-Entity
patients,O
with,O
gall,B-Entity
stones,I-Entity
.,O
Chemical,O
analysis,O
of,O
gall,B-Entity
stones,I-Entity
retrieved,O
at,O
cholecystectomy,O
from,O
two,O
patients,O
",",O
showed,O
that,O
they,O
contained,O
71%,O
and,O
87%,O
cholesterol,I-Entity
by,O
weight,O
.,O
In,O
the,O
remaining,O
12,O
patients,O
",",O
localised,O
computed,O
tomography,O
of,O
the,O
gall,O
bladder,O
showed,O
that,O
eight,O
had,O
stones,O
with,O
maximum,O
attenuation,O
scores,O
of,O
<,O
100,O
Hounsfield,O
units,O
(,O
values,O
of,O
<,O
100,O
HU,O
predict,O
cholesterol,I-Entity
rich,O
",",O
dissolvable,O
stones,O
),O
.,O
All,O
six,O
patients,O
had,O
supersaturated,O
bile,O
(,O
mean,O
(,O
SEM,O
),O
cholesterol,I-Entity
saturation,O
index,O
of,O
1.19,O
(,O
0.08,O
),O
(,O
range,O
1.01,O
-,O
1.53,O
),O
),O
and,O
all,O
had,O
abnormally,O
rapid,O
cholesterol,I-Entity
microcrystal,O
nucleation,O
times,O
(,O
<,O
4,O
days,O
(,O
range,O
1,O
-,O
4,O
),O
),O
",",O
whilst,O
in,O
four,O
",",O
the,O
bile,O
contained,O
cholesterol,I-Entity
microcrystals,O
immediately,O
after,O
sampling,O
.,O
Of,O
the,O
12,O
patients,O
considered,O
for,O
oral,O
ursodeoxycholic,B-Entity
acid,I-Entity
(,O
UDCA,I-Entity
),O
treatment,O
",",O
two,O
had,O
a,O
blocked,O
cystic,O
duct,O
and,O
were,O
not,O
started,O
on,O
UDCA,I-Entity
while,O
one,O
was,O
lost,O
to,O
follow,O
up,O
.,O
n,O
=,O
2,O
),O
gall,B-Entity
stone,I-Entity
dissolution,O
",",O
suggesting,O
that,O
their,O
stones,O
were,O
cholesterol,I-Entity
rich,O
.,O
This,O
corresponds,O
",",O
by,O
actuarial,O
(,O
life,O
table,O
),O
analysis,O
",",O
to,O
a,O
combined,O
gall,B-Entity
stone,I-Entity
dissolution,O
rate,O
of,O
58.3,O
(,O
15.9%,O
),O
.,O
In,O
conclusion,O
",",O
octreotide,I-Entity
induced,O
gall,B-Entity
stones,I-Entity
are,O
generally,O
small,O
",",O
multiple,O
",",O
and,O
cholesterol,I-Entity
rich,O
although,O
",",O
in,O
common,O
with,O
spontaneous,O
gall,B-Entity
stone,I-Entity
disease,I-Entity
",",O
at,O
presentation,O
some,O
patients,O
will,O
have,O
a,O
blocked,O
cystic,O
duct,O
and,O
some,O
gall,B-Entity
stones,I-Entity
containing,O
calcium,I-Entity
.,O
Cardiovascular,B-Entity
complications,I-Entity
associated,O
with,O
terbutaline,I-Entity
treatment,O
for,O
preterm,B-Entity
labor,I-Entity
.,O
Severe,O
cardiovascular,B-Entity
complications,I-Entity
occurred,O
in,O
eight,O
of,O
160,O
patients,O
treated,O
with,O
terbutaline,I-Entity
for,O
preterm,B-Entity
labor,I-Entity
.,O
Neurologic,O
effects,O
of,O
subarachnoid,O
administration,O
of,O
2-chloroprocaine,B-Entity
-,I-Entity
CE,I-Entity
",",O
bupivacaine,I-Entity
",",O
and,O
low,O
pH,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
neurologic,O
consequences,O
of,O
deliberate,O
subarachnoid,O
injection,O
of,O
large,O
volumes,O
of,O
2-chloroprocaine,B-Entity
-,I-Entity
CE,I-Entity
in,O
experimental,O
animals,O
.,O
The,O
possible,O
role,O
of,O
low,O
pH,O
as,O
well,O
as,O
total,O
volume,O
as,O
potential,O
factors,O
in,O
causing,O
neurotoxicity,I-Entity
was,O
evaluated,O
.,O
The,O
65,O
dogs,O
in,O
the,O
study,O
received,O
injections,O
in,O
the,O
subarachnoid,O
space,O
as,O
follows,O
:,O
6,O
to,O
8,O
ml,O
of,O
bupivacaine,I-Entity
(,O
N,O
=,O
15,O
),O
",",O
2-chloroprocaine,B-Entity
-,I-Entity
CE,I-Entity
(,O
N,O
=,O
20,O
),O
",",O
low,O
pH,O
normal,O
saline,O
(,O
pH,O
3.0,O
),O
(,O
N,O
=,O
20,O
),O
",",O
or,O
normal,O
saline,O
(,O
N,O
=,O
10,O
),O
.,O
Of,O
the,O
20,O
animals,O
that,O
received,O
subarachnoid,O
injection,O
of,O
2-chloroprocaine,B-Entity
-,I-Entity
CE,I-Entity
seven,O
(,O
35%,O
),O
developed,O
hind,O
-,O
limb,O
paralysis,I-Entity
.,O
None,O
of,O
the,O
animals,O
that,O
received,O
bupivacaine,I-Entity
",",O
normal,O
saline,O
",",O
or,O
normal,O
saline,O
titrated,O
to,O
a,O
pH,O
3.0,O
developed,O
hind,O
-,O
limb,O
paralysis,I-Entity
.,O
Of,O
the,O
15,O
spinal,O
cords,O
of,O
the,O
animals,O
that,O
received,O
2-chloroprocaine,B-Entity
-,I-Entity
CE,I-Entity
",",O
13,O
showed,O
subpial,B-Entity
necrosis,I-Entity
;,O
the,O
nerve,O
roots,O
and,O
subarachnoid,O
vessels,O
were,O
normal,O
.,O
The,O
spinal,O
cords,O
of,O
the,O
animals,O
that,O
received,O
bupivacaine,I-Entity
",",O
low,O
pH,O
normal,O
saline,O
(,O
pH,O
3.0,O
),O
",",O
or,O
normal,O
saline,O
did,O
not,O
show,O
abnormal,O
findings,O
.,O
Early,O
adjuvant,O
adriamycin,I-Entity
in,O
superficial,O
bladder,B-Entity
carcinoma,I-Entity
.,O
A,O
multicenter,O
study,O
was,O
performed,O
in,O
110,O
patients,O
with,O
superficial,O
transitional,O
cell,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
bladder,I-Entity
.,O
Adriamycin,I-Entity
(,O
50,O
mg/50,O
ml,O
),O
was,O
administered,O
intravesically,O
within,O
24,O
h,O
after,O
transurethral,O
resection,O
of,O
TA,O
-,O
T1,O
(,O
O,O
-,O
A,O
),O
bladder,B-Entity
tumors,I-Entity
.,O
In,O
24,O
of,O
these,O
patients,O
chemical,O
cystitis,I-Entity
was,O
severe,O
enough,O
for,O
them,O
to,O
drop,O
out,O
of,O
the,O
study,O
.,O
Of,O
these,O
recurrences,O
",",O
27,O
were,O
T1,O
tumors,I-Entity
while,O
five,O
progressed,O
to,O
more,O
highly,O
invasive,O
lesions,O
.,O
In,O
patients,O
that,O
were,O
free,O
of,O
recurrence,O
during,O
the,O
first,O
year,O
",",O
80%,O
remained,O
tumor,I-Entity
-,O
free,O
during,O
the,O
2-,O
to,O
3-year,O
follow,O
-,O
up,O
period,O
.,O
The,O
beneficial,O
effect,O
of,O
Adriamycin,I-Entity
appears,O
obvious,O
and,O
might,O
be,O
related,O
to,O
the,O
drug,O
itself,O
",",O
the,O
early,O
and,O
repeated,O
instillations,O
after,O
TUR,O
",",O
or,O
both,O
.,O
Hyperkalemia,I-Entity
associated,O
with,O
sulindac,I-Entity
therapy,O
.,O
Hyperkalemia,I-Entity
has,O
recently,O
been,O
recognized,O
as,O
a,O
complication,O
of,O
nonsteroidal,O
antiinflammatory,O
agents,O
(,O
NSAID,O
),O
such,O
as,O
indomethacin,I-Entity
.,O
Several,O
recent,O
studies,O
have,O
stressed,O
the,O
renal,O
sparing,O
features,O
of,O
sulindac,I-Entity
",",O
owing,O
to,O
its,O
lack,O
of,O
interference,O
with,O
renal,O
prostacyclin,I-Entity
synthesis,O
.,O
We,O
describe,O
4,O
patients,O
in,O
whom,O
hyperkalemia,I-Entity
ranging,O
from,O
6.1,O
to,O
6.9,O
mEq,O
/,O
l,O
developed,O
within,O
3,O
to,O
8,O
days,O
of,O
sulindac,I-Entity
administration,O
.,O
In,O
all,O
of,O
them,O
normal,O
serum,O
potassium,I-Entity
levels,O
reached,O
within,O
2,O
to,O
4,O
days,O
of,O
stopping,O
sulindac,I-Entity
.,O
As,O
no,O
other,O
medications,O
known,O
to,O
effect,O
serum,O
potassium,I-Entity
had,O
been,O
given,O
concomitantly,O
",",O
this,O
course,O
of,O
events,O
is,O
suggestive,O
of,O
a,O
cause,O
-,O
and,O
-,O
effect,O
relationship,O
between,O
sulindac,I-Entity
and,O
hyperkalemia,I-Entity
.,O
These,O
observations,O
indicate,O
that,O
initial,O
hopes,O
that,O
sulindac,I-Entity
may,O
not,O
be,O
associated,O
with,O
the,O
adverse,O
renal,O
effects,O
of,O
other,O
NSAID,O
are,O
probably,O
not,O
justified,O
.,O
Ventricular,B-Entity
tachyarrhythmias,I-Entity
during,O
cesarean,O
section,O
after,O
ritodrine,I-Entity
therapy,O
:,O
This,O
case,O
illustrates,O
that,O
patients,O
receiving,O
ritodrine,I-Entity
for,O
preterm,B-Entity
labor,I-Entity
may,O
risk,O
interactions,O
between,O
the,O
residual,O
betamimetic,O
effects,O
of,O
ritodrine,I-Entity
and,O
the,O
effects,O
of,O
anesthetics,O
during,O
cesarean,O
section,O
.,O
Such,O
interactions,O
may,O
result,O
in,O
serious,O
cardiovascular,B-Entity
complications,I-Entity
even,O
after,O
cessation,O
of,O
an,O
infusion,O
of,O
ritodrine,I-Entity
.,O
Preoperative,O
assessment,O
should,O
focus,O
on,O
cardiovascular,O
status,O
and,O
serum,O
potassium,I-Entity
level,O
.,O
Careful,O
fluid,O
administration,O
and,O
cautious,O
use,O
of,O
titrated,O
doses,O
of,O
ephedrine,I-Entity
are,O
advised,O
.,O
After,O
delivery,O
of,O
the,O
infant,O
",",O
there,O
should,O
be,O
no,O
contraindication,O
to,O
the,O
use,O
of,O
an,O
alpha,O
-,O
adrenergic,O
vasopressor,O
such,O
as,O
phenylephrine,I-Entity
to,O
treat,O
hypotensive,I-Entity
patients,O
with,O
tachycardia,I-Entity
.,O
Immunohistochemical,O
",",O
electron,O
microscopic,O
and,O
morphometric,O
studies,O
of,O
estrogen,I-Entity
-,O
induced,O
rat,O
prolactinomas,I-Entity
after,O
bromocriptine,I-Entity
treatment,O
.,O
To,O
clarify,O
the,O
effects,O
of,O
bromocriptine,I-Entity
on,O
prolactinoma,I-Entity
cells,O
in,O
vivo,O
",",O
immunohistochemical,O
",",O
ultrastructural,O
and,O
morphometrical,O
analyses,O
were,O
applied,O
to,O
estrogen,I-Entity
-,O
induced,O
rat,O
prolactinoma,I-Entity
cells,O
1,O
h,O
and,O
6,O
h,O
after,O
injection,O
of,O
bromocriptine,I-Entity
(,O
3,O
mg,O
/,O
kg,O
of,O
body,O
weight,O
),O
.,O
Golgi,O
cisternae,O
in,O
the,O
prolactinoma,I-Entity
cells,O
.,O
These,O
findings,O
suggest,O
that,O
lowered,O
serum,O
prolactin,O
levels,O
in,O
the,O
early,O
phase,O
of,O
bromocriptine,I-Entity
treatment,O
may,O
result,O
from,O
an,O
impaired,O
secretion,O
of,O
prolactin,O
due,O
to,O
decreasing,O
numbers,O
of,O
cytoplasmic,O
microtubules,O
.,O
The,O
prolactinoma,I-Entity
cells,O
at,O
this,O
time,O
were,O
well,O
granulated,O
",",O
with,O
vesiculated,O
rough,O
endoplasmic,O
reticulum,O
and,O
markedly,O
dilated,O
Golgi,O
cisternae,O
.,O
Electron,O
microscopical,O
immunohistochemistry,O
revealed,O
positive,O
reaction,O
products,O
noted,O
on,O
the,O
secretory,O
granules,O
",",O
Golgi,O
cisternae,O
",",O
and,O
endoplasmic,O
reticulum,O
of,O
the,O
untreated,O
rat,O
prolactinoma,I-Entity
cells,O
.,O
However,O
",",O
only,O
secretory,O
granules,O
showed,O
the,O
positive,O
reaction,O
products,O
for,O
prolactin,O
6,O
h,O
after,O
bromocriptine,I-Entity
treatment,O
of,O
the,O
adenoma,I-Entity
cells,O
.,O
An,O
increase,O
in,O
the,O
volume,O
density,O
of,O
secretory,O
granules,O
and,O
a,O
decrease,O
in,O
the,O
volume,O
densities,O
of,O
rough,O
endoplasmic,O
reticulum,O
and,O
microtubules,O
was,O
determined,O
by,O
morphometric,O
analysis,O
",",O
suggesting,O
that,O
bromocriptine,I-Entity
inhibits,O
protein,O
synthesis,O
as,O
well,O
as,O
bringing,O
about,O
a,O
disturbance,O
of,O
the,O
prolactin,O
secretion,O
.,O
On,O
two,O
paradoxical,O
side,O
-,O
effects,O
of,O
prednisolone,I-Entity
in,O
rats,O
",",O
ribosomal,O
RNA,O
biosyntheses,O
",",O
and,O
a,O
mechanism,O
of,O
action,O
.,O
Liver,B-Entity
enlargement,I-Entity
and,O
muscle,B-Entity
wastage,I-Entity
occurred,O
in,O
Wistar,O
rats,O
following,O
the,O
subcutaneous,O
administration,O
of,O
prednisolone,I-Entity
.,O
This,O
view,O
supports,O
the,O
contention,O
that,O
the,O
liver,O
and,O
muscle,O
are,O
independent,O
sites,O
of,O
prednisolone,I-Entity
action,O
.,O
Possible,O
intramuscular,O
midazolam,I-Entity
-,O
associated,O
cardiorespiratory,B-Entity
arrest,I-Entity
and,O
death,I-Entity
.,O
Midazolam,B-Entity
hydrochloride,I-Entity
is,O
commonly,O
used,O
for,O
dental,O
or,O
endoscopic,O
procedures,O
.,O
Although,O
generally,O
consisted,O
safe,O
when,O
given,O
intramuscularly,O
",",O
intravenous,O
administration,O
is,O
known,O
to,O
cause,O
respiratory,B-Entity
and,I-Entity
cardiovascular,I-Entity
depression,I-Entity
.,O
This,O
report,O
describes,O
the,O
first,O
published,O
case,O
of,O
cardiorespiratory,B-Entity
arrest,I-Entity
and,O
death,I-Entity
associated,O
with,O
intramuscular,O
administration,O
of,O
midazolam,I-Entity
.,O
Information,O
regarding,O
midazolam,I-Entity
use,O
is,O
reviewed,O
to,O
provide,O
recommendation,O
for,O
safe,O
administration,O
.,O
Serial,O
epilepsy,I-Entity
caused,O
by,O
levodopa,B-Entity
/,I-Entity
carbidopa,I-Entity
administration,O
in,O
two,O
patients,O
on,O
hemodialysis,O
.,O
Two,O
patients,O
with,O
similar,O
clinical,O
features,O
are,O
presented,O
:,O
both,O
patients,O
had,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
",",O
on,O
hemodialysis,O
for,O
many,O
years,O
but,O
recently,O
begun,O
on,O
a,O
high,O
-,O
flux,O
dialyzer,O
;,O
both,O
had,O
been,O
receiving,O
a,O
carbidopa,B-Entity
/,I-Entity
levodopa,I-Entity
preparation,O
;,O
and,O
both,O
had,O
the,O
onset,O
of,O
hallucinosis,I-Entity
and,O
recurrent,O
seizures,I-Entity
",",O
which,O
were,O
refractory,O
to,O
anticonvulsants,O
.,O
The,O
first,O
patient,O
died,O
without,O
a,O
diagnosis,O
;,O
the,O
second,O
patient,O
had,O
a,O
dramatic,O
recovery,O
following,O
the,O
administration,O
of,O
vitamin,B-Entity
B6,I-Entity
.,O
Effect,O
of,O
L,B-Entity
-,I-Entity
alpha,I-Entity
-,I-Entity
glyceryl,I-Entity
-,I-Entity
phosphorylcholine,I-Entity
on,O
amnesia,I-Entity
caused,O
by,O
scopolamine,I-Entity
.,O
The,O
present,O
study,O
was,O
carried,O
out,O
to,O
test,O
the,O
effects,O
of,O
L,B-Entity
-,I-Entity
alpha,I-Entity
-,I-Entity
glycerylphosphorylcholine,I-Entity
(,O
L,B-Entity
-,I-Entity
alpha,I-Entity
-,I-Entity
GFC,I-Entity
),O
on,O
memory,B-Entity
impairment,I-Entity
induced,O
by,O
scopolamine,I-Entity
in,O
man,O
.,O
They,O
were,O
given,O
a,O
ten,O
day,O
pretreatment,O
with,O
either,O
L,B-Entity
-,I-Entity
alpha,I-Entity
-,I-Entity
GFC,I-Entity
or,O
placebo,O
",",O
p.o,O
.,O
",",O
and,O
on,O
the,O
eleventh,O
day,O
either,O
scopolamine,I-Entity
or,O
placebo,O
",",O
i.m,O
.,O
The,O
findings,O
of,O
this,O
study,O
indicate,O
that,O
the,O
drug,O
is,O
able,O
to,O
antagonize,O
impairment,B-Entity
of,I-Entity
attention,I-Entity
and,I-Entity
memory,I-Entity
induced,O
by,O
scopolamine,I-Entity
.,O
Seizures,I-Entity
induced,O
by,O
the,O
cocaine,I-Entity
metabolite,O
benzoylecgonine,I-Entity
in,O
rats,O
.,O
The,O
half,O
-,O
life,O
(,O
t1/2,O
),O
of,O
cocaine,I-Entity
is,O
relatively,O
short,O
",",O
but,O
some,O
of,O
the,O
consequences,O
of,O
its,O
use,O
",",O
such,O
as,O
seizures,I-Entity
and,O
strokes,I-Entity
",",O
can,O
occur,O
hours,O
after,O
exposure,O
.,O
This,O
led,O
us,O
to,O
hypothesize,O
that,O
a,O
metabolite,O
of,O
cocaine,I-Entity
may,O
be,O
responsible,O
for,O
some,O
of,O
those,O
delayed,O
sequelae,O
.,O
We,O
evaluated,O
the,O
potential,O
of,O
the,O
major,O
metabolite,O
of,O
cocaine,I-Entity
",",O
benzoylecgonine,I-Entity
(,O
BE,I-Entity
),O
",",O
to,O
cause,O
seizures,I-Entity
.,O
Two,O
separate,O
equimolar,O
doses,O
(,O
0.2,O
and,O
0.4,O
mumol,O
),O
of,O
either,O
cocaine,I-Entity
or,O
BE,I-Entity
were,O
injected,O
ventricularly,O
in,O
unanesthetized,O
juvenile,O
rats,O
.,O
Treated,O
rats,O
were,O
then,O
evaluated,O
for,O
incidence,O
",",O
latency,O
",",O
and,O
seizure,I-Entity
pattern,O
or,O
for,O
locomotor,O
activity,O
in,O
animals,O
without,O
seizures,I-Entity
.,O
BE,I-Entity
-,O
Induced,O
seizures,I-Entity
occurred,O
more,O
frequently,O
and,O
had,O
significantly,O
longer,O
latencies,O
than,O
those,O
induced,O
by,O
equimolar,O
amounts,O
of,O
cocaine,I-Entity
.,O
Whereas,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
were,O
best,O
characterized,O
as,O
brief,O
",",O
generalized,O
",",O
and,O
tonic,O
and,O
resulted,O
in,O
death,I-Entity
",",O
those,O
induced,O
by,O
BE,I-Entity
were,O
prolonged,O
",",O
often,O
multiple,O
and,O
mixed,O
in,O
type,O
",",O
and,O
rarely,O
resulted,O
in,O
death,I-Entity
.,O
Electrical,O
recordings,O
from,O
the,O
hippocampus,O
showed,O
a,O
rhythmic,O
progression,O
in,O
EEG,O
frequency,O
and,O
voltage,O
with,O
clinical,O
seizure,I-Entity
expression,O
.,O
BE,I-Entity
-,O
Injected,O
rats,O
that,O
did,O
not,O
have,O
seizures,I-Entity
had,O
significantly,O
more,O
locomotor,O
activity,O
than,O
cocaine,I-Entity
-,O
injected,O
animals,O
without,O
seizures,I-Entity
.,O
The,O
finding,O
that,O
cocaine-,I-Entity
and,O
BE,I-Entity
-,O
induced,O
seizures,I-Entity
differ,O
in,O
several,O
respects,O
suggests,O
more,O
than,O
one,O
mechanism,O
for,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
emphasizes,O
the,O
importance,O
of,O
a,O
cocaine,I-Entity
metabolite,O
",",O
BE,I-Entity
.,O
Protection,O
against,O
amphetamine,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
toward,O
striatal,O
dopamine,I-Entity
neurons,O
in,O
rodents,O
by,O
LY274614,I-Entity
",",O
an,O
excitatory,O
amino,B-Entity
acid,I-Entity
antagonist,O
.,O
LY274614,I-Entity
",",O
"3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr",B-Entity
oisoquinoline-3-,I-Entity
carboxylic,I-Entity
acid,I-Entity
",",O
has,O
been,O
described,O
as,O
a,O
potent,O
antagonist,O
of,O
the,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
subtype,O
of,O
glutamate,I-Entity
receptor,O
.,O
Here,O
its,O
ability,O
to,O
antagonize,O
the,O
prolonged,O
depletion,O
of,O
dopamine,I-Entity
in,O
the,O
striatum,O
by,O
amphetamine,I-Entity
in,O
iprindole,I-Entity
-,O
treated,O
rats,O
is,O
reported,O
.,O
dose,O
of,O
(,O
+,O
/-)-amphetamine,I-Entity
hemisulfate,O
",",O
given,O
to,O
rats,O
pretreated,O
with,O
iprindole,I-Entity
",",O
resulted,O
in,O
persistent,O
depletion,O
of,O
dopamine,I-Entity
in,O
the,O
striatum,O
1,O
week,O
later,O
.,O
This,O
prolonged,O
depletion,O
of,O
dopamine,I-Entity
in,O
the,O
striatum,O
was,O
antagonized,O
by,O
dizocilpine,I-Entity
(,O
MK-801,I-Entity
",",O
a,O
non,O
-,O
competitive,O
antagonist,O
of,O
NMDA,I-Entity
receptors,O
),O
or,O
by,O
LY274614,I-Entity
(,O
a,O
competitive,O
antagonist,O
of,O
NMDA,I-Entity
receptors,O
),O
.,O
The,O
protective,O
effect,O
of,O
LY274614,I-Entity
was,O
dose,O
-,O
dependent,O
",",O
being,O
maximum,O
at,O
10,O
-,O
40,O
mgkg,O
(,O
i.p,O
.,O
),O
.,O
A,O
10,O
mg,O
/,O
kg,O
dose,O
of,O
LY274614,I-Entity
was,O
effective,O
in,O
antagonizing,O
the,O
depletion,O
of,O
dopamine,I-Entity
in,O
the,O
striatum,O
",",O
when,O
given,O
as,O
long,O
as,O
8,O
hr,O
prior,O
to,O
amphetamine,I-Entity
but,O
not,O
when,O
given,O
24,O
hr,O
prior,O
to,O
amphetamine,I-Entity
.,O
Depletion,O
of,O
dopamine,I-Entity
in,O
the,O
striatum,O
was,O
also,O
antagonized,O
when,O
LY274614,I-Entity
was,O
given,O
after,O
the,O
injection,O
of,O
amphetamine,I-Entity
;,O
LY274614,I-Entity
protected,O
when,O
given,O
up,O
to,O
4,O
hr,O
after,O
but,O
not,O
when,O
given,O
8,O
or,O
24,O
hr,O
after,O
amphetamine,I-Entity
.,O
The,O
prolonged,O
depletion,O
of,O
dopamine,I-Entity
in,O
the,O
striatum,O
in,O
mice,O
",",O
given,O
multiple,O
injections,O
of,O
methamphetamine,I-Entity
",",O
was,O
also,O
antagonized,O
dose,O
-,O
dependently,O
and,O
completely,O
by,O
LY274614,I-Entity
.,O
The,O
data,O
strengthen,O
the,O
evidence,O
that,O
the,O
neurotoxic,I-Entity
effect,O
of,O
amphetamine,I-Entity
and,O
related,O
compounds,O
toward,O
nigrostriatal,O
dopamine,I-Entity
neurons,O
involves,O
NMDA,I-Entity
receptors,O
and,O
that,O
LY274614,I-Entity
is,O
an,O
NMDA,I-Entity
receptor,O
antagonist,O
with,O
long,O
-,O
lasting,O
in,O
vivo,O
effects,O
in,O
rats,O
.,O
Neonatal,O
pyridoxine,I-Entity
responsive,O
convulsions,I-Entity
due,O
to,O
isoniazid,I-Entity
therapy,O
.,O
A,O
17-day,O
-,O
old,O
infant,O
on,O
isoniazid,I-Entity
therapy,O
13,O
mg,O
/,O
kg,O
daily,O
from,O
birth,O
because,O
of,O
maternal,O
tuberculosis,I-Entity
was,O
admitted,O
after,O
4,O
days,O
of,O
clonic,B-Entity
fits,I-Entity
.,O
The,O
fits,I-Entity
ceased,O
within,O
4,O
hours,O
of,O
administering,O
intramuscular,O
pyridoxine,I-Entity
",",O
suggesting,O
an,O
aetiology,O
of,O
pyridoxine,I-Entity
deficiency,O
secondary,O
to,O
isoniazid,I-Entity
medication,O
.,O
Reversal,O
by,O
phenylephrine,I-Entity
of,O
the,O
beneficial,O
effects,O
of,O
intravenous,O
nitroglycerin,I-Entity
in,O
patients,O
with,O
acute,B-Entity
myocardial,I-Entity
infarction,I-Entity
.,O
Nitroglycerin,I-Entity
has,O
been,O
shown,O
to,O
reduce,O
ST,O
-,O
segment,O
elevation,O
during,O
acute,B-Entity
myocardial,I-Entity
infarction,I-Entity
",",O
an,O
effect,O
potentiated,O
in,O
the,O
dog,O
by,O
agents,O
that,O
reverse,O
nitroglycerin,I-Entity
-,O
induced,O
hypotension,I-Entity
.,O
Our,O
study,O
was,O
designed,O
to,O
determine,O
the,O
effects,O
of,O
combined,O
nitroglycerin,I-Entity
and,O
phenylephrine,I-Entity
therapy,O
.,O
Ten,O
patients,O
with,O
acute,O
transmural,O
myocardial,B-Entity
infarctions,I-Entity
received,O
intravenous,O
nitroglycerin,I-Entity
",",O
sufficient,O
to,O
reduce,O
mean,O
arterial,O
pressure,O
from,O
107,O
+,O
/-,O
SigmaST,O
",",O
the,O
sum,O
of,O
ST,O
-,O
segment,O
elevations,O
in,O
16,O
precordial,O
leads,O
",",O
decreased,O
(,O
P,O
less,O
than,O
0.02,O
),O
with,O
intravenous,O
nitroglycerin,I-Entity
.,O
Subsequent,O
addition,O
of,O
phenylephrine,I-Entity
infusion,O
",",O
sufficient,O
to,O
re,O
-,O
elevate,O
mean,O
arterial,O
pressure,O
to,O
106,O
+,O
/-,O
Our,O
results,O
suggest,O
that,O
addition,O
of,O
phenylephrine,I-Entity
to,O
nitroglycerin,I-Entity
is,O
not,O
beneficial,O
in,O
the,O
treatment,O
of,O
patients,O
with,O
acute,B-Entity
myocardial,I-Entity
infarction,I-Entity
.,O
Elevation,O
of,O
ADAM10,O
",",O
ADAM17,O
",",O
MMP-2,O
and,O
MMP-9,O
expression,O
with,O
media,O
degeneration,O
features,O
CaCl2-induced,I-Entity
thoracic,B-Entity
aortic,I-Entity
aneurysm,I-Entity
in,O
a,O
rat,O
model,O
.,O
This,O
study,O
was,O
designed,O
to,O
establish,O
a,O
rat,O
model,O
of,O
thoracic,B-Entity
aortic,I-Entity
aneurysm,I-Entity
(,O
TAA,I-Entity
),O
by,O
calcium,B-Entity
chloride,I-Entity
(,O
CaCl(2))-induced,I-Entity
arterial,B-Entity
injury,I-Entity
and,O
to,O
explore,O
the,O
potential,O
role,O
of,O
a,O
disintegrin,O
and,O
metalloproteinase,O
(,O
ADAM,O
),O
",",O
matrix,O
metalloproteinases,O
(,O
MMPs,O
),O
and,O
their,O
endogenous,O
inhibitors,O
(,O
TIMPs,O
),O
in,O
TAA,I-Entity
formation,O
.,O
Thoracic,O
aorta,O
of,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
was,O
exposed,O
to,O
0.5,O
M,O
CaCl(2,B-Entity
),I-Entity
or,O
normal,O
saline,O
(,O
NaCl,I-Entity
),O
.,O
After,O
12weeks,O
",",O
animals,O
were,O
euthanized,O
",",O
and,O
CaCl(2)-treated,I-Entity
",",O
CaCl(2)-untreated,I-Entity
(,O
n=12,O
),O
and,O
NaCl,I-Entity
-,O
treated,O
aortic,O
segments,O
(,O
n=12,O
),O
were,O
collected,O
for,O
histological,O
and,O
molecular,O
assessments,O
.,O
Despite,O
similar,O
external,O
diameters,O
among,O
CaCl(2)-treated,I-Entity
",",O
non,O
-,O
CaCl(2)-treated,I-Entity
and,O
NaCl,I-Entity
-,O
treated,O
segments,O
",",O
aneurymal,O
alteration,O
(,O
n=6,O
",",O
50%,O
),O
",",O
media,O
degeneration,O
with,O
regional,O
disruption,O
",",O
fragmentation,O
of,O
elastic,O
fiber,O
",",O
and,O
increased,O
collagen,O
deposition,O
(,O
n=12,O
",",O
100%,O
),O
were,O
demonstrated,O
in,O
CaCl(2)-treated,I-Entity
segments,O
.,O
MMP-2,O
",",O
MMP-9,O
",",O
ADAM-10,O
and,O
ADAM-17,O
mRNA,O
levels,O
were,O
increased,O
in,O
CaCl(2)-treated,I-Entity
segments,O
(,O
all,O
p<0.01,O
),O
",",O
with,O
trends,O
of,O
elevation,O
in,O
CaCl(2)-untreated,I-Entity
segments,O
",",O
as,O
compared,O
with,O
NaCl,I-Entity
-,O
treated,O
segments,O
.,O
Immunohistochemistry,O
displayed,O
significantly,O
increased,O
expressions,O
of,O
MMP-2,O
",",O
MMP-9,O
",",O
ADAM-10,O
and,O
ADAM-17,O
(,O
all,O
p<0.01,O
),O
in,O
intima,O
and,O
media,O
for,O
CaCl(2)-treated,I-Entity
segments,O
.,O
This,O
study,O
establishes,O
a,O
TAA,I-Entity
model,O
by,O
periarterial,O
CaCl(2,B-Entity
),I-Entity
exposure,O
in,O
rats,O
",",O
and,O
demonstrates,O
a,O
significant,O
elevation,O
of,O
expression,O
of,O
MMP-2,O
",",O
MMP-9,O
",",O
ADAM10,O
and,O
ADAM17,O
in,O
the,O
pathogenesis,O
of,O
vascular,O
remodeling,O
.,O
Twenty,O
-,O
three,O
hours,O
after,O
heart,O
transplantation,O
",",O
life,O
-,O
threatening,O
acute,O
right,B-Entity
heart,I-Entity
failure,I-Entity
was,O
diagnosed,O
in,O
a,O
patient,O
requiring,O
continuous,O
venovenous,O
hemodiafiltration,O
(,O
CVVHDF,O
),O
.,O
Increasing,O
doses,O
of,O
catecholamines,I-Entity
",",O
sedatives,O
",",O
and,O
muscle,O
relaxants,O
administered,O
through,O
a,O
central,O
venous,O
catheter,O
were,O
ineffective,O
.,O
However,O
",",O
a,O
bolus,O
of,O
epinephrine,I-Entity
injected,O
through,O
an,O
alternative,O
catheter,O
provoked,O
a,O
hypertensive,I-Entity
crisis,O
.,O
The,O
catheters,O
were,O
changed,O
",",O
and,O
hemodynamics,O
stabilized,O
at,O
lower,O
catecholamine,I-Entity
doses,O
.,O
Long,O
-,O
term,O
glutamate,I-Entity
supplementation,O
failed,O
to,O
protect,O
against,O
peripheral,B-Entity
neurotoxicity,I-Entity
of,O
paclitaxel,I-Entity
.,O
Toxic,O
peripheral,B-Entity
neuropathy,I-Entity
is,O
still,O
a,O
significant,O
limiting,O
factor,O
for,O
chemotherapy,O
with,O
paclitaxel,I-Entity
(,O
PAC,I-Entity
),O
",",O
although,O
glutamate,I-Entity
and,O
its,O
closely,O
related,O
amino,B-Entity
acid,I-Entity
glutamine,I-Entity
were,O
claimed,O
to,O
ameliorate,O
PAC,I-Entity
neurotoxicity,I-Entity
.,O
This,O
pilot,O
trial,O
aimed,O
to,O
evaluate,O
the,O
role,O
of,O
glutamate,I-Entity
supplementation,O
for,O
preventing,O
PAC,I-Entity
-,O
induced,O
peripheral,B-Entity
neuropathy,I-Entity
in,O
a,O
randomized,O
",",O
placebo,O
-,O
controlled,O
",",O
double,O
-,O
blinded,O
clinical,O
and,O
electro,O
-,O
diagnostic,O
study,O
.,O
Forty,O
-,O
three,O
ovarian,B-Entity
cancer,I-Entity
patients,O
were,O
available,O
for,O
analysis,O
following,O
six,O
cycles,O
of,O
the,O
same,O
PAC,I-Entity
-,O
containing,O
regimen,O
:,O
23,O
had,O
been,O
supplemented,O
by,O
glutamate,I-Entity
all,O
along,O
the,O
treatment,O
period,O
",",O
at,O
a,O
daily,O
dose,O
of,O
three,O
times,O
500,O
mg,O
(,O
group,O
G,O
),O
",",O
and,O
20,O
had,O
received,O
a,O
placebo,O
(,O
group,O
P,O
),O
.,O
There,O
was,O
no,O
significant,O
difference,O
in,O
the,O
frequency,O
of,O
signs,O
or,O
symptoms,O
between,O
the,O
two,O
groups,O
although,O
neurotoxicity,I-Entity
symptoms,O
presented,O
mostly,O
with,O
lower,O
scores,O
of,O
severity,O
in,O
group,O
G.,O
However,O
",",O
this,O
difference,O
reached,O
statistical,O
significance,O
only,O
with,O
regard,O
to,O
reported,O
pain,I-Entity
sensation,O
(,O
P,O
=,O
0.011,O
),O
.,O
This,O
pilot,O
study,O
leads,O
to,O
the,O
conclusion,O
that,O
glutamate,I-Entity
supplementation,O
at,O
the,O
chosen,O
regimen,O
fails,O
to,O
protect,O
against,O
peripheral,B-Entity
neurotoxicity,I-Entity
of,O
PAC,I-Entity
.,O
Attentional,O
modulation,O
of,O
perceived,O
pain,I-Entity
intensity,O
in,O
capsaicin,I-Entity
-,O
induced,O
secondary,O
hyperalgesia,I-Entity
.,O
Perceived,O
pain,I-Entity
intensity,O
is,O
modulated,O
by,O
attention,O
.,O
However,O
",",O
it,O
is,O
not,O
known,O
that,O
how,O
pain,I-Entity
intensity,O
ratings,O
are,O
affected,O
by,O
attention,O
in,O
capsaicin,I-Entity
-,O
induced,O
secondary,O
hyperalgesia,I-Entity
.,O
Here,O
we,O
show,O
that,O
perceived,O
pain,I-Entity
intensity,O
in,O
secondary,O
hyperalgesia,I-Entity
is,O
decreased,O
when,O
attention,O
is,O
distracted,O
away,O
from,O
the,O
painful,O
pinprick,O
stimulus,O
with,O
a,O
visual,O
task,O
.,O
Furthermore,O
",",O
it,O
was,O
found,O
that,O
the,O
magnitude,O
of,O
attentional,O
modulation,O
in,O
secondary,O
hyperalgesia,I-Entity
is,O
very,O
similar,O
to,O
that,O
of,O
capsaicin,I-Entity
-,O
untreated,O
",",O
control,O
condition,O
.,O
Our,O
findings,O
",",O
showing,O
no,O
interaction,O
between,O
capsaicin,I-Entity
treatment,O
and,O
attentional,O
modulation,O
suggest,O
that,O
capsaicin,I-Entity
-,O
induced,O
secondary,O
hyperalgesia,I-Entity
and,O
attention,O
might,O
affect,O
mechanical,O
pain,I-Entity
through,O
independent,O
mechanisms,O
.,O
Testosterone,I-Entity
-,O
dependent,O
hypertension,I-Entity
and,O
upregulation,O
of,O
intrarenal,O
angiotensinogen,O
in,O
Dahl,O
salt,I-Entity
-,O
sensitive,O
rats,O
.,O
Blood,O
pressure,O
(,O
BP,O
),O
is,O
more,O
salt,I-Entity
sensitive,O
in,O
men,O
than,O
in,O
premenopausal,O
women,O
.,O
In,O
Dahl,O
salt,I-Entity
-,O
sensitive,O
rats,O
(,O
DS,O
),O
",",O
high,O
-,O
salt,I-Entity
(,O
HS,O
),O
diet,O
increases,O
BP,O
more,O
in,O
males,O
than,O
females,O
.,O
In,O
contrast,O
to,O
the,O
systemic,O
renin,O
-,O
angiotensin,I-Entity
system,O
",",O
which,O
is,O
suppressed,O
in,O
response,O
to,O
HS,O
in,O
male,O
DS,O
",",O
intrarenal,O
angiotensinogen,O
expression,O
is,O
increased,O
",",O
and,O
intrarenal,O
levels,O
of,O
ANG,O
II,O
are,O
not,O
suppressed,O
.,O
In,O
this,O
study,O
",",O
the,O
hypothesis,O
was,O
tested,O
that,O
there,O
is,O
a,O
sexual,O
dimorphism,O
in,O
HS,O
-,O
induced,O
upregulation,O
of,O
intrarenal,O
angiotensinogen,O
mediated,O
by,O
testosterone,I-Entity
that,O
also,O
causes,O
increases,O
in,O
BP,O
and,O
renal,B-Entity
injury,I-Entity
.,O
On,O
a,O
low,O
-,O
salt,I-Entity
(,O
LS,O
),O
diet,O
",",O
male,O
DS,O
had,O
higher,O
levels,O
of,O
intrarenal,O
angiotensinogen,O
mRNA,O
than,O
females,O
.,O
HS,O
diet,O
for,O
4,O
wk,O
caused,O
a,O
progressive,O
increase,O
in,O
BP,O
",",O
protein,O
and,O
albumin,O
excretion,O
",",O
and,O
glomerular,B-Entity
sclerosis,I-Entity
in,O
male,O
DS,O
rats,O
",",O
which,O
were,O
attenuated,O
by,O
castration,O
.,O
Testosterone,I-Entity
replacement,O
in,O
castrated,O
DS,O
rats,O
increased,O
BP,O
",",O
renal,B-Entity
injury,I-Entity
",",O
and,O
upregulation,O
of,O
renal,O
angiotensinogen,O
associated,O
with,O
HS,O
diet,O
.,O
Testosterone,I-Entity
contributes,O
to,O
the,O
development,O
of,O
hypertension,I-Entity
and,O
renal,B-Entity
injury,I-Entity
in,O
male,O
DS,O
rats,O
on,O
HS,O
diet,O
possibly,O
through,O
upregulation,O
of,O
the,O
intrarenal,O
renin,O
-,O
angiotensin,I-Entity
system,O
.,O
Prenatal,O
protein,O
deprivation,O
alters,O
dopamine,I-Entity
-,O
mediated,O
behaviors,O
and,O
dopaminergic,O
and,O
glutamatergic,O
receptor,O
binding,O
.,O
Epidemiological,O
evidence,O
indicates,O
that,O
prenatal,O
nutritional,O
deprivation,O
may,O
increase,O
the,O
risk,O
of,O
schizophrenia,I-Entity
.,O
The,O
goal,O
of,O
these,O
studies,O
was,O
to,O
use,O
an,O
animal,O
model,O
to,O
examine,O
the,O
effects,O
of,O
prenatal,O
protein,O
deprivation,O
on,O
behaviors,O
and,O
receptor,O
binding,O
with,O
relevance,O
to,O
schizophrenia,I-Entity
.,O
We,O
report,O
that,O
prenatally,O
protein,O
deprived,O
(,O
PD,O
),O
female,O
rats,O
showed,O
an,O
increased,O
stereotypic,O
response,O
to,O
apomorphine,I-Entity
and,O
an,O
increased,O
locomotor,O
response,O
to,O
amphetamine,I-Entity
in,O
adulthood,O
.,O
No,O
changes,O
in,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
or,O
MK-801-induced,I-Entity
locomotion,O
were,O
seen,O
following,O
PD,O
.,O
In,O
addition,O
",",O
PD,O
female,O
rats,O
showed,O
increased,O
(,O
3)H,I-Entity
-,O
MK-801,I-Entity
binding,O
in,O
the,O
striatum,O
and,O
hippocampus,O
",",O
but,O
not,O
in,O
the,O
cortex,O
.,O
PD,O
female,O
rats,O
also,O
showed,O
increased,O
(,O
3)H,I-Entity
-,O
haloperidol,I-Entity
binding,O
and,O
decreased,O
dopamine,I-Entity
transporter,O
binding,O
in,O
striatum,O
.,O
No,O
statistically,O
significant,O
changes,O
in,O
behavior,O
or,O
receptor,O
binding,O
were,O
found,O
in,O
PD,O
males,O
with,O
the,O
exception,O
of,O
increased,O
(,O
3)H,I-Entity
-,O
MK-801,I-Entity
binding,O
in,O
cortex,O
.,O
This,O
animal,O
model,O
may,O
be,O
useful,O
to,O
explore,O
the,O
mechanisms,O
by,O
which,O
prenatal,O
nutritional,B-Entity
deficiency,I-Entity
enhances,O
risk,O
for,O
schizophrenia,I-Entity
in,O
humans,O
and,O
may,O
also,O
have,O
implications,O
for,O
developmental,O
processes,O
leading,O
to,O
differential,O
sensitivity,O
to,O
drugs,O
of,O
abuse,O
.,O
inhibitors,O
-,O
induced,O
proteinuria,I-Entity
:,O
mechanisms,O
",",O
significance,O
",",O
and,O
management,O
.,O
Massive,O
urinary,O
protein,O
excretion,O
has,O
been,O
observed,O
after,O
conversion,O
from,O
calcineurin,O
inhibitors,O
to,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
(,O
mToR,O
),O
inhibitors,O
",",O
especially,O
sirolimus,I-Entity
",",O
in,O
renal,O
transplant,O
recipients,O
with,O
chronic,B-Entity
allograft,I-Entity
nephropathy,I-Entity
.,O
Because,O
proteinuria,I-Entity
is,O
a,O
major,O
predictive,O
factor,O
of,O
poor,O
transplantation,O
outcome,O
",",O
many,O
studies,O
focused,O
on,O
this,O
adverse,O
event,O
during,O
the,O
past,O
years,O
.,O
Whether,O
proteinuria,I-Entity
was,O
due,O
to,O
sirolimus,I-Entity
or,O
only,O
a,O
consequence,O
of,O
calcineurin,O
inhibitors,O
withdrawal,O
remained,O
unsolved,O
until,O
high,O
range,O
proteinuria,I-Entity
has,O
been,O
observed,O
during,O
sirolimus,I-Entity
therapy,O
in,O
islet,O
transplantation,O
and,O
in,O
patients,O
who,O
received,O
sirolimus,I-Entity
de,O
novo,O
.,O
Podocyte,O
injury,O
and,O
focal,O
segmental,O
glomerulosclerosis,I-Entity
have,O
been,O
related,O
to,O
mToR,O
inhibition,O
in,O
some,O
patients,O
",",O
but,O
the,O
pathways,O
underlying,O
these,O
lesions,O
remain,O
hypothetic,O
.,O
We,O
discuss,O
herein,O
the,O
possible,O
mechanisms,O
and,O
the,O
significance,O
of,O
mToR,O
blockade,O
-,O
induced,O
proteinuria,I-Entity
.,O
Hypothalamic,O
prolactin,O
receptor,O
messenger,O
ribonucleic,B-Entity
acid,I-Entity
levels,O
",",O
prolactin,O
signaling,O
",",O
and,O
hyperprolactinemic,I-Entity
inhibition,O
of,O
pulsatile,O
luteinizing,O
hormone,O
secretion,O
are,O
dependent,O
on,O
estradiol,I-Entity
.,O
Hyperprolactinemia,I-Entity
can,O
reduce,O
fertility,O
and,O
libido,O
.,O
We,O
first,O
tested,O
whether,O
chronic,O
hyperprolactinemia,I-Entity
inhibited,O
two,O
neuroendocrine,O
parameters,O
necessary,O
for,O
female,O
fertility,O
:,O
pulsatile,O
LH,O
secretion,O
and,O
the,O
estrogen,I-Entity
-,O
induced,O
LH,O
surge,O
.,O
Chronic,O
hyperprolactinemia,I-Entity
induced,O
by,O
the,O
dopamine,I-Entity
antagonist,O
sulpiride,I-Entity
caused,O
a,O
40%,O
reduction,O
LH,O
pulse,O
frequency,O
in,O
ovariectomized,O
rats,O
",",O
but,O
only,O
in,O
the,O
presence,O
of,O
chronic,O
low,O
levels,O
of,O
estradiol,I-Entity
.,O
Sulpiride,I-Entity
did,O
not,O
affect,O
the,O
magnitude,O
of,O
a,O
steroid,I-Entity
-,O
induced,O
LH,O
surge,O
or,O
the,O
percentage,O
of,O
GnRH,O
neurons,O
activated,O
during,O
the,O
surge,O
.,O
Estradiol,I-Entity
is,O
known,O
to,O
influence,O
expression,O
of,O
the,O
long,O
form,O
of,O
prolactin,O
receptors,O
(,O
PRL,O
-,O
R,O
),O
and,O
components,O
of,O
prolactin,O
's,O
signaling,O
pathway,O
.,O
To,O
test,O
the,O
hypothesis,O
that,O
estrogen,I-Entity
increases,O
PRL,O
-,O
R,O
expression,O
and,O
sensitivity,O
to,O
prolactin,O
",",O
we,O
next,O
demonstrated,O
that,O
estradiol,I-Entity
greatly,O
augments,O
prolactin,O
-,O
induced,O
STAT5,O
activation,O
.,O
Lastly,O
",",O
we,O
measured,O
PRL,O
-,O
R,O
and,O
suppressor,O
of,O
cytokine,O
signaling,O
(,O
SOCS-1,O
and,O
-3,O
and,O
CIS,O
",",O
which,O
reflect,O
the,O
level,O
of,O
prolactin,O
signaling,O
),O
mRNAs,O
in,O
response,O
to,O
sulpiride,I-Entity
and,O
estradiol,I-Entity
.,O
Sulpiride,I-Entity
induced,O
only,O
SOCS-1,O
in,O
the,O
medial,O
preoptic,O
area,O
",",O
where,O
GnRH,O
neurons,O
are,O
regulated,O
",",O
but,O
in,O
the,O
arcuate,O
nucleus,O
and,O
choroid,O
plexus,O
",",O
PRL,O
-,O
R,O
",",O
SOCS-3,O
",",O
and,O
CIS,O
mRNA,O
levels,O
were,O
also,O
induced,O
.,O
Estradiol,I-Entity
enhanced,O
these,O
effects,O
on,O
SOCS-3,O
and,O
CIS,O
.,O
Interestingly,O
",",O
estradiol,I-Entity
also,O
induced,O
PRL,O
-,O
R,O
",",O
SOCS-3,O
",",O
and,O
CIS,O
mRNA,O
levels,O
independently,O
.,O
These,O
data,O
show,O
that,O
GnRH,O
pulse,O
frequency,O
is,O
inhibited,O
by,O
chronic,O
hyperprolactinemia,I-Entity
in,O
a,O
steroid,I-Entity
-,O
dependent,O
manner,O
.,O
They,O
also,O
provide,O
evidence,O
for,O
estradiol,I-Entity
-,O
dependent,O
and,O
brain,O
region,O
-,O
specific,O
regulation,O
of,O
PRL,O
-,O
R,O
expression,O
and,O
signaling,O
responses,O
by,O
prolactin,O
.,O
Estrogen,O
prevents,O
cholesteryl,B-Entity
ester,I-Entity
accumulation,O
in,O
macrophages,O
induced,O
by,O
the,O
HIV,O
protease,O
inhibitor,O
ritonavir,I-Entity
.,O
Individuals,O
with,O
HIV,O
can,O
now,O
live,O
long,O
lives,O
with,O
drug,O
therapy,O
that,O
often,O
includes,O
protease,O
inhibitors,O
such,O
as,O
ritonavir,I-Entity
.,O
Many,O
patients,O
",",O
however,O
",",O
develop,O
negative,O
long,O
-,O
term,O
side,O
effects,O
such,O
as,O
premature,B-Entity
atherosclerosis,I-Entity
.,O
We,O
have,O
previously,O
demonstrated,O
that,O
ritonavir,I-Entity
treatment,O
increases,O
atherosclerotic,B-Entity
lesion,I-Entity
formation,O
in,O
male,O
mice,O
to,O
a,O
greater,O
extent,O
than,O
in,O
female,O
mice,O
.,O
Furthermore,O
",",O
peripheral,O
blood,O
monocytes,O
isolated,O
from,O
ritonavir,I-Entity
-,O
treated,O
females,O
had,O
less,O
cholesteryl,B-Entity
ester,I-Entity
accumulation,O
.,O
In,O
the,O
present,O
study,O
",",O
we,O
have,O
investigated,O
the,O
molecular,O
mechanisms,O
by,O
which,O
female,O
hormones,O
influence,O
cholesterol,I-Entity
metabolism,O
in,O
macrophages,O
in,O
response,O
to,O
the,O
HIV,O
protease,O
inhibitor,O
ritonavir,I-Entity
.,O
Briefly,O
",",O
cells,O
were,O
differentiated,O
for,O
72,O
h,O
with,O
100,O
nM,O
PMA,O
to,O
obtain,O
a,O
macrophage,O
-,O
like,O
phenotype,O
in,O
the,O
presence,O
or,O
absence,O
of,O
1,O
nM,O
17beta,B-Entity
-,I-Entity
estradiol,I-Entity
(,O
E2,I-Entity
),O
",",O
100,O
nM,O
progesterone,I-Entity
or,O
vehicle,O
(,O
0.01%,O
ethanol,I-Entity
),O
.,O
Cells,O
were,O
then,O
treated,O
with,O
30,O
ng,O
/,O
ml,O
ritonavir,I-Entity
or,O
vehicle,O
in,O
the,O
presence,O
of,O
aggregated,O
LDL,O
for,O
24,O
h.,O
Cell,O
extracts,O
were,O
harvested,O
",",O
and,O
lipid,O
or,O
total,O
RNA,O
was,O
isolated,O
.,O
E2,I-Entity
decreased,O
the,O
accumulation,O
of,O
cholesteryl,B-Entity
esters,I-Entity
in,O
macrophages,O
following,O
ritonavir,I-Entity
treatment,O
.,O
Ritonavir,I-Entity
increased,O
the,O
expression,O
of,O
the,O
scavenger,O
receptor,O
",",O
CD36,O
mRNA,O
",",O
responsible,O
for,O
the,O
uptake,O
of,O
LDL,O
.,O
Additionally,O
",",O
ritonavir,I-Entity
treatment,O
selectively,O
increased,O
the,O
relative,O
levels,O
of,O
PPARgamma,O
mRNA,O
",",O
a,O
transcription,O
factor,O
responsible,O
for,O
the,O
regulation,O
of,O
CD36,O
mRNA,O
expression,O
.,O
Treatment,O
with,O
E2,I-Entity
",",O
however,O
",",O
failed,O
to,O
prevent,O
these,O
increases,O
at,O
the,O
mRNA,O
level,O
.,O
E2,I-Entity
did,O
",",O
however,O
",",O
significantly,O
suppress,O
CD36,O
protein,O
levels,O
as,O
measured,O
by,O
fluorescent,O
immunocytochemistry,O
.,O
This,O
data,O
suggests,O
that,O
E2,I-Entity
modifies,O
the,O
expression,O
of,O
CD36,O
at,O
the,O
level,O
of,O
protein,O
expression,O
in,O
monocyte,O
-,O
derived,O
macrophages,O
resulting,O
in,O
reduced,O
cholesteryl,B-Entity
ester,I-Entity
accumulation,O
following,O
ritonavir,I-Entity
treatment,O
.,O
Upregulation,O
of,O
brain,O
expression,O
of,O
P,O
-,O
glycoprotein,O
in,O
MRP2-deficient,O
TR(-,O
),O
rats,O
resembles,O
seizure,I-Entity
-,O
induced,O
up,O
-,O
regulation,O
of,O
this,O
drug,O
efflux,O
transporter,O
in,O
normal,O
rats,O
.,O
By,O
using,O
this,O
strategy,O
to,O
study,O
the,O
involvement,O
of,O
MRP2,O
in,O
brain,O
access,O
of,O
antiepileptic,O
drugs,O
(,O
AEDs,O
),O
",",O
we,O
recently,O
reported,O
that,O
phenytoin,I-Entity
is,O
a,O
substrate,O
for,O
MRP2,O
in,O
the,O
BBB,O
.,O
A,O
comparable,O
overexpression,O
of,O
Pgp,O
in,O
the,O
BBB,O
was,O
obtained,O
after,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
wild,O
-,O
type,O
Wistar,O
rats,O
.,O
Experiments,O
with,O
systemic,O
administration,O
of,O
the,O
Pgp,O
substrate,O
phenobarbital,I-Entity
and,O
the,O
selective,O
Pgp,O
inhibitor,O
tariquidar,I-Entity
in,O
TR(-,O
),O
rats,O
substantiated,O
that,O
Pgp,O
is,O
functional,O
and,O
compensates,O
for,O
the,O
lack,O
of,O
MRP2,O
in,O
the,O
BBB,O
.,O
Because,O
such,O
a,O
compensatory,O
mechanism,O
most,O
likely,O
occurs,O
to,O
reduce,O
injury,B-Entity
to,I-Entity
the,I-Entity
brain,I-Entity
from,O
cytotoxic,O
compounds,O
",",O
the,O
present,O
data,O
substantiate,O
the,O
concept,O
that,O
MRP2,O
performs,O
a,O
protective,O
role,O
in,O
the,O
BBB,O
.,O
Furthermore,O
",",O
our,O
data,O
suggest,O
that,O
TR(-,O
),O
rats,O
are,O
an,O
interesting,O
tool,O
to,O
study,O
consequences,O
of,O
overexpression,O
of,O
Pgp,O
in,O
the,O
BBB,O
on,O
access,O
of,O
drugs,O
in,O
the,O
brain,O
",",O
without,O
the,O
need,O
of,O
inducing,O
seizures,I-Entity
or,O
other,O
Pgp,O
-,O
enhancing,O
events,O
for,O
this,O
purpose,O
.,O
Use,O
of,O
chromosome,O
substitution,O
strains,O
to,O
identify,O
seizure,I-Entity
susceptibility,O
loci,O
in,O
mice,O
.,O
Seizure,I-Entity
susceptibility,O
varies,O
among,O
inbred,O
mouse,O
strains,O
.,O
Chromosome,O
substitution,O
strains,O
(,O
CSS,O
),O
",",O
in,O
which,O
a,O
single,O
chromosome,O
from,O
one,O
inbred,O
strain,O
(,O
donor,O
),O
has,O
been,O
transferred,O
onto,O
a,O
second,O
strain,O
(,O
host,O
),O
by,O
repeated,O
backcrossing,O
",",O
may,O
be,O
used,O
to,O
identify,O
quantitative,O
trait,O
loci,O
(,O
QTLs,O
),O
that,O
contribute,O
to,O
seizure,I-Entity
susceptibility,O
.,O
QTLs,O
for,O
susceptibility,O
to,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
",",O
a,O
model,O
of,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
",",O
have,O
not,O
been,O
reported,O
",",O
and,O
CSS,O
have,O
not,O
previously,O
been,O
used,O
to,O
localize,O
seizure,I-Entity
susceptibility,O
genes,O
.,O
CSS,O
panel,O
to,O
localize,O
genes,O
involved,O
in,O
susceptibility,O
to,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
A,O
/,O
J,O
were,O
tested,O
for,O
susceptibility,O
to,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
B6,O
mice,O
were,O
resistant,O
to,O
seizures,I-Entity
and,O
slower,O
to,O
reach,O
stages,O
compared,O
to,O
A,O
/,O
J,O
mice,O
.,O
CSS,O
mapping,O
suggests,O
seizure,I-Entity
susceptibility,O
loci,O
on,O
mouse,O
Chromosomes,O
10,O
and,O
18,O
.,O
This,O
approach,O
provides,O
a,O
framework,O
for,O
identifying,O
potentially,O
novel,O
homologous,O
candidate,O
genes,O
for,O
human,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
.,O
Investigation,O
of,O
mitochondrial,O
involvement,O
in,O
the,O
experimental,O
model,O
of,O
epilepsy,I-Entity
induced,O
by,O
pilocarpine,I-Entity
.,O
Mitochondrial,B-Entity
abnormalities,I-Entity
have,O
been,O
associated,O
with,O
several,O
aspects,O
of,O
epileptogenesis,O
",",O
such,O
as,O
energy,O
generation,O
",",O
control,O
of,O
cell,O
death,I-Entity
",",O
neurotransmitter,O
synthesis,O
",",O
and,O
free,O
radical,O
(,O
FR,O
),O
production,O
.,O
In,O
this,O
study,O
",",O
we,O
investigated,O
whether,O
increased,O
generation,O
of,O
FR,O
during,O
status,B-Entity
epilepticus,I-Entity
would,O
be,O
sufficient,O
to,O
provoke,O
abnormalities,O
in,O
mtDNA,O
and,O
in,O
the,O
expression,O
and,O
activity,O
of,O
cytochrome,O
c,O
oxidase,O
(,O
CCO,O
),O
",",O
complex,O
IV,O
of,O
the,O
respiratory,O
chain,O
",",O
in,O
the,O
chronic,O
phase,O
of,O
the,O
pilocarpine,I-Entity
model,O
of,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
.,O
Although,O
evidences,O
of,O
mitochondrial,B-Entity
abnormalities,I-Entity
were,O
found,O
in,O
previously,O
published,O
studies,O
",",O
our,O
results,O
do,O
not,O
suggest,O
that,O
the,O
FRs,O
",",O
generated,O
during,O
the,O
acute,O
phase,O
",",O
determined,O
important,O
abnormalities,O
in,O
mtDNA,O
",",O
in,O
expression,O
of,O
CCO,O
-,O
I,O
",",O
and,O
in,O
CCO,O
activity,O
.,O
Causes,O
of,O
acute,O
thrombotic,B-Entity
microangiopathy,I-Entity
in,O
patients,O
receiving,O
kidney,O
transplantation,O
.,O
Thrombotic,B-Entity
microangiopathy,I-Entity
is,O
a,O
well,O
-,O
known,O
problem,O
in,O
patients,O
following,O
renal,O
transplantation,O
.,O
In,O
postrenal,O
transplantation,O
",",O
thrombotic,B-Entity
microangiopathy,I-Entity
is,O
often,O
a,O
reflection,O
of,O
hemolytic,B-Entity
uremic,I-Entity
syndrome,I-Entity
.,O
We,O
aimed,O
to,O
determine,O
the,O
causes,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
in,O
a,O
population,O
of,O
renal,O
transplantation,O
recipients,O
and,O
discuss,O
the,O
literature,O
.,O
:,O
We,O
investigated,O
the,O
causes,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
during,O
a,O
1-year,O
period,O
",",O
from,O
June,O
2003,O
to,O
June,O
2004,O
",",O
at,O
the,O
King,O
Fahad,O
National,O
Guard,O
Hospital,O
in,O
Riyadh,O
",",O
Saudi,O
Arabia,O
",",O
by,O
reviewing,O
the,O
slides,O
of,O
all,O
transplant,O
biopsies,O
Five,O
cases,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
were,O
found,O
.,O
Three,O
cases,O
were,O
related,O
to,O
cyclosporine,I-Entity
",",O
and,O
1,O
case,O
was,O
secondary,O
to,O
both,O
cyclosporine,I-Entity
and,O
tacrolimus,I-Entity
.,O
The,O
fifth,O
case,O
had,O
features,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
related,O
to,O
an,O
antiphospholipid,B-Entity
syndrome,I-Entity
in,O
a,O
patient,O
with,O
systemic,B-Entity
lupus,I-Entity
erythematosus,I-Entity
.,O
In,O
the,O
literature,O
",",O
the,O
most,O
-,O
frequent,O
cause,O
of,O
hemolytic,B-Entity
uremic,I-Entity
syndrome,I-Entity
in,O
patients,O
following,O
renal,O
transplantation,O
is,O
recurrence,O
of,O
the,O
hemolytic,B-Entity
uremic,I-Entity
syndrome,I-Entity
.,O
cyclosporine,I-Entity
",",O
tacrolimus,I-Entity
),O
toxicity,I-Entity
",",O
procoagulant,O
status,O
",",O
and,O
antibody,O
-,O
mediated,O
rejection,O
.,O
We,O
found,O
that,O
the,O
most,O
-,O
frequent,O
cause,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
was,O
drug,O
related,O
",",O
secondary,O
mainly,O
to,O
cyclosporine,I-Entity
.,O
In,O
the,O
current,O
study,O
",",O
the,O
frequency,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
was,O
similar,O
to,O
the,O
percentage,O
reported,O
in,O
the,O
literature,O
(,O
20%,O
),O
.,O
Severe,O
reversible,O
left,B-Entity
ventricular,I-Entity
systolic,I-Entity
and,I-Entity
diastolic,I-Entity
dysfunction,I-Entity
due,O
to,O
accidental,O
iatrogenic,O
epinephrine,I-Entity
overdose,I-Entity
.,O
Catecholamine,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
due,O
to,O
chronic,O
excess,O
of,O
endogenous,O
catecholamines,I-Entity
has,O
been,O
recognized,O
for,O
decades,O
as,O
a,O
clinical,O
phenomenon,O
.,O
In,O
contrast,O
",",O
reports,O
of,O
myocardial,B-Entity
dysfunction,I-Entity
due,O
to,O
acute,O
iatrogenic,O
overdose,I-Entity
are,O
rare,O
.,O
A,O
35-year,O
-,O
old,O
woman,O
whose,O
cervix,O
uteri,O
was,O
inadvertently,O
injected,O
with,O
8,O
mg,O
of,O
epinephrine,I-Entity
developed,O
myocardial,B-Entity
stunning,I-Entity
that,O
was,O
characterized,O
by,O
severe,O
hemodynamic,O
compromise,O
",",O
profound,O
",",O
albeit,O
transient,O
",",O
left,B-Entity
ventricular,I-Entity
systolic,I-Entity
and,I-Entity
diastolic,I-Entity
dysfunction,I-Entity
",",O
and,O
only,O
modestly,O
elevated,O
biochemical,O
markers,O
of,O
myocardial,B-Entity
necrosis,I-Entity
.,O
Urinary,B-Entity
bladder,I-Entity
cancer,I-Entity
in,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
:,O
risks,O
and,O
relation,O
to,O
cyclophosphamide,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
assess,O
and,O
characterise,O
the,O
risk,O
of,O
bladder,B-Entity
cancer,I-Entity
",",O
and,O
its,O
relation,O
to,O
cyclophosphamide,I-Entity
",",O
in,O
patients,O
with,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
.,O
METHODS,O
:,O
In,O
the,O
population,O
based,O
",",O
nationwide,O
Swedish,O
Inpatient,O
Register,O
a,O
cohort,O
of,O
1065,O
patients,O
with,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
",",O
1969,O
-,O
95,O
",",O
was,O
identified,O
.,O
Through,O
linkage,O
with,O
the,O
Swedish,O
Cancer,I-Entity
Register,O
",",O
all,O
subjects,O
in,O
this,O
cohort,O
diagnosed,O
with,O
bladder,B-Entity
cancer,I-Entity
were,O
identified,O
.,O
Nested,O
within,O
the,O
cohort,O
",",O
a,O
matched,O
case,O
-,O
control,O
study,O
was,O
performed,O
to,O
estimate,O
the,O
association,O
between,O
cyclophosphamide,I-Entity
and,O
bladder,B-Entity
cancer,I-Entity
using,O
odds,O
ratios,O
(,O
ORs,O
),O
as,O
relative,O
risk,O
.,O
In,O
the,O
cohort,O
the,O
cumulative,O
risk,O
of,O
bladder,B-Entity
cancer,I-Entity
after,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
",",O
and,O
the,O
relative,O
prevalence,O
of,O
a,O
history,O
of,O
bladder,B-Entity
cancer,I-Entity
at,O
the,O
time,O
of,O
diagnosis,O
of,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
",",O
were,O
also,O
estimated,O
.,O
The,O
median,O
cumulative,O
doses,O
of,O
cyclophosphamide,I-Entity
among,O
cases,O
(,O
n,O
=,O
11,O
),O
and,O
controls,O
(,O
n,O
=,O
25,O
),O
were,O
113,O
g,O
and,O
25,O
g,O
",",O
respectively,O
.,O
The,O
risk,O
of,O
bladder,B-Entity
cancer,I-Entity
doubled,O
for,O
every,O
10,O
g,O
increment,O
in,O
cyclophosphamide,I-Entity
(,O
OR,O
=,O
2.0,O
",",O
95%,O
confidence,O
interval,O
(,O
CI,O
),O
0.8,O
to,O
4.9,O
),O
.,O
The,O
absolute,O
risk,O
for,O
bladder,B-Entity
cancer,I-Entity
in,O
the,O
cohort,O
reached,O
10%,O
16,O
years,O
after,O
diagnosis,O
of,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
",",O
and,O
a,O
history,O
of,O
bladder,B-Entity
cancer,I-Entity
was,O
(,O
non,O
-,O
significantly,O
),O
twice,O
as,O
common,O
as,O
expected,O
at,O
the,O
time,O
of,O
diagnosis,O
of,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
.,O
CONCLUSION,O
:,O
The,O
results,O
indicate,O
a,O
dose,O
-,O
response,O
relationship,O
between,O
cyclophosphamide,I-Entity
and,O
the,O
risk,O
of,O
bladder,B-Entity
cancer,I-Entity
",",O
high,O
cumulative,O
risks,O
in,O
the,O
entire,O
cohort,O
",",O
and,O
also,O
the,O
possibility,O
of,O
risk,O
factors,O
operating,O
even,O
before,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
.,O
L,B-Entity
-,I-Entity
arginine,I-Entity
transport,O
in,O
humans,O
with,O
cortisol,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
A,O
deficient,O
L,B-Entity
-,I-Entity
arginine,I-Entity
-,O
nitric,B-Entity
oxide,I-Entity
system,O
is,O
implicated,O
in,O
cortisol,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
We,O
investigate,O
whether,O
abnormalities,O
in,O
L,B-Entity
-,I-Entity
arginine,I-Entity
uptake,O
contribute,O
to,O
this,O
deficiency,O
.,O
Hydrocortisone,B-Entity
acetate,I-Entity
(,O
50,O
mg,O
),O
was,O
given,O
orally,O
every,O
6,O
hours,O
for,O
24,O
hours,O
after,O
a,O
5-day,O
fixed,O
-,O
salt,O
diet,O
(,O
150,O
mmol,O
/,O
d,O
),O
.,O
L,B-Entity
-,I-Entity
arginine,I-Entity
uptake,O
was,O
assessed,O
in,O
mononuclear,O
cells,O
incubated,O
with,O
L,B-Entity
-,I-Entity
arginine,I-Entity
(,O
1,O
to,O
300,O
micromol,O
/,O
L,O
),O
",",O
incorporating,O
100,O
nmol,O
/,O
L,O
[,B-Entity
3H]-l,I-Entity
-,I-Entity
arginine,I-Entity
for,O
a,O
period,O
of,O
5,O
minutes,O
at,O
37,O
degrees,O
C.,O
Forearm,O
[,B-Entity
3H]-L,I-Entity
-,I-Entity
arginine,I-Entity
extraction,O
was,O
calculated,O
after,O
infusion,O
of,O
[,B-Entity
3H]-L,I-Entity
-,I-Entity
arginine,I-Entity
into,O
the,O
brachial,O
artery,O
at,O
a,O
rate,O
of,O
100,O
nCi,O
/,O
min,O
for,O
80,O
minutes,O
.,O
Deep,O
forearm,O
venous,O
samples,O
were,O
collected,O
for,O
determination,O
of,O
L,B-Entity
-,I-Entity
arginine,I-Entity
extraction,O
.,O
Plasma,O
cortisol,I-Entity
concentrations,O
were,O
significantly,O
raised,O
during,O
the,O
active,O
phase,O
(,O
323+/-43,O
to,O
1082+/-245,O
mmol,O
/,O
Neither,O
L,B-Entity
-,I-Entity
arginine,I-Entity
transport,O
into,O
mononuclear,O
cells,O
(,O
placebo,O
vs,O
active,O
",",O
26.3+/-3.6,O
vs,O
29.0+/-2.1,O
pmol/10,O
000,O
cells,O
per,O
5,O
minutes,O
",",O
respectively,O
",",O
at,O
an,O
l,B-Entity
-,I-Entity
arginine,I-Entity
concentration,O
of,O
300,O
micromol,O
/,O
L,O
),O
nor,O
L,B-Entity
-,I-Entity
arginine,I-Entity
extraction,O
in,O
the,O
forearm,O
(,O
at,O
80,O
minutes,O
",",O
placebo,O
vs,O
active,O
",",O
1,O
868,O
904+/-434,O
962,O
vs,O
2,O
013,O
910+/-770,O
619,O
disintegrations,O
per,O
minute,O
),O
was,O
affected,O
by,O
cortisol,I-Entity
treatment,O
;,O
ie,O
",",O
that,O
L,B-Entity
-,I-Entity
arginine,I-Entity
uptake,O
is,O
not,O
affected,O
by,O
short,O
-,O
term,O
cortisol,I-Entity
treatment,O
.,O
We,O
conclude,O
that,O
cortisol,I-Entity
-,O
induced,O
increases,B-Entity
in,I-Entity
blood,I-Entity
pressure,I-Entity
are,O
not,O
associated,O
with,O
abnormalities,O
in,O
the,O
l,B-Entity
-,I-Entity
arginine,I-Entity
transport,O
system,O
.,O
MR,O
imaging,O
with,O
quantitative,O
diffusion,O
mapping,O
of,O
tacrolimus,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
in,O
organ,O
transplant,O
patients,O
.,O
Our,O
objective,O
was,O
to,O
investigate,O
brain,O
MR,O
imaging,O
findings,O
and,O
the,O
utility,O
of,O
diffusion,O
-,O
weighted,O
(,O
DW,O
),O
imaging,O
in,O
organ,O
transplant,O
patients,O
who,O
developed,O
neurologic,O
symptoms,O
during,O
tacrolimus,I-Entity
therapy,O
.,O
Brain,O
MR,O
studies,O
",",O
including,O
DW,O
imaging,O
",",O
were,O
prospectively,O
performed,O
in,O
14,O
organ,O
transplant,O
patients,O
receiving,O
tacrolimus,I-Entity
who,O
developed,O
neurologic,B-Entity
complications,I-Entity
.,O
Of,O
the,O
14,O
patients,O
",",O
5,O
(,O
35.7%,O
),O
had,O
white,B-Entity
matter,I-Entity
abnormalities,I-Entity
",",O
1,O
(,O
7.1%,O
),O
had,O
putaminal,B-Entity
hemorrhage,I-Entity
",",O
and,O
8,O
(,O
57.1%,O
),O
had,O
normal,O
findings,O
on,O
initial,O
MR,O
images,O
.,O
Among,O
the,O
5,O
patients,O
with,O
white,B-Entity
matter,I-Entity
abnormalities,I-Entity
",",O
4,O
patients,O
(,O
80.0%,O
),O
showed,O
higher,O
than,O
normal,O
ADC,O
values,O
on,O
initial,O
MR,O
images,O
",",O
and,O
all,O
showed,O
complete,O
resolution,O
on,O
follow,O
-,O
up,O
images,O
.,O
The,O
remaining,O
1,O
patient,O
(,O
20.0%,O
),O
showed,O
lower,O
than,O
normal,O
ADC,O
value,O
and,O
showed,O
incomplete,O
resolution,O
with,O
cortical,B-Entity
laminar,I-Entity
necrosis,I-Entity
.,O
Diffusion,O
-,O
weighted,O
imaging,O
may,O
be,O
useful,O
in,O
predicting,O
the,O
outcomes,O
of,O
the,O
lesions,O
of,O
tacrolimus,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
.,O
Octreotide,I-Entity
-,O
induced,O
hypoxemia,I-Entity
and,O
pulmonary,B-Entity
hypertension,I-Entity
in,O
premature,O
neonates,O
.,O
The,O
authors,O
report,O
2,O
cases,O
of,O
premature,O
neonates,O
who,O
had,O
enterocutaneous,O
fistula,I-Entity
complicating,O
necrotizing,B-Entity
enterocolitis,I-Entity
.,O
Pulmonary,B-Entity
hypertension,I-Entity
developed,O
after,O
administration,O
of,O
a,O
somatostatin,O
analogue,O
",",O
octreotide,I-Entity
",",O
to,O
enhance,O
resolution,O
of,O
the,O
fistula,I-Entity
.,O
Sequential,O
observations,O
of,O
exencephaly,I-Entity
and,O
subsequent,O
morphological,O
changes,O
by,O
mouse,O
exo,O
utero,O
development,O
system,O
:,O
analysis,O
of,O
the,O
mechanism,O
of,O
transformation,O
from,O
exencephaly,I-Entity
to,O
anencephaly,I-Entity
.,O
Anencephaly,I-Entity
has,O
been,O
suggested,O
to,O
develop,O
from,O
exencephaly,I-Entity
;,O
however,O
",",O
there,O
is,O
little,O
direct,O
experimental,O
evidence,O
to,O
support,O
this,O
",",O
and,O
the,O
mechanism,O
of,O
transformation,O
remains,O
unclear,O
.,O
We,O
observed,O
the,O
exencephaly,I-Entity
induced,O
by,O
5-azacytidine,I-Entity
at,O
embryonic,O
day,O
13.5,O
(,O
E13.5,O
),O
",",O
let,O
the,O
embryos,O
develop,O
exo,O
utero,O
until,O
E18.5,O
",",O
and,O
re,O
-,O
observed,O
the,O
same,O
embryos,O
at,O
E18.5,O
.,O
We,O
confirmed,O
several,O
cases,O
of,O
transformation,O
from,O
exencephaly,I-Entity
to,O
anencephaly,I-Entity
.,O
However,O
",",O
in,O
many,O
cases,O
",",O
the,O
exencephalic,I-Entity
brain,O
tissue,O
was,O
preserved,O
with,O
more,O
or,O
less,O
reduction,O
during,O
this,O
period,O
.,O
To,O
analyze,O
the,O
transformation,O
patterns,O
",",O
we,O
classified,O
the,O
exencephaly,I-Entity
by,O
size,O
and,O
shape,O
of,O
the,O
exencephalic,I-Entity
tissue,O
into,O
several,O
types,O
at,O
E13.5,O
and,O
E18.5,O
.,O
It,O
was,O
found,O
that,O
the,O
transformation,O
of,O
exencephalic,I-Entity
tissue,O
was,O
not,O
simply,O
size,O
-,O
dependent,O
",",O
and,O
all,O
cases,O
of,O
anencephaly,I-Entity
at,O
E18.5,O
resulted,O
from,O
embryos,O
with,O
a,O
large,O
amount,O
of,O
exencephalic,I-Entity
tissue,O
at,O
E13.5,O
.,O
Microscopic,O
observation,O
showed,O
the,O
configuration,O
of,O
exencephaly,I-Entity
at,O
E13.5,O
",",O
frequent,O
hemorrhaging,I-Entity
and,O
detachment,O
of,O
the,O
neural,O
plate,O
from,O
surface,O
ectoderm,O
in,O
the,O
exencephalic,I-Entity
head,O
at,O
E15.5,O
",",O
and,O
multiple,O
modes,O
of,O
reduction,O
in,O
the,O
exencephalic,I-Entity
tissue,O
at,O
E18.5,O
.,O
From,O
observations,O
of,O
the,O
vasculature,O
",",O
altered,O
distribution,O
patterns,O
of,O
vessels,O
were,O
identified,O
in,O
the,O
exencephalic,I-Entity
head,O
.,O
These,O
findings,O
suggest,O
that,O
overgrowth,O
of,O
the,O
exencephalic,I-Entity
neural,O
tissue,O
causes,O
the,O
altered,O
distribution,O
patterns,O
of,O
vessels,O
",",O
subsequent,O
peripheral,O
circulatory,B-Entity
failure,I-Entity
and/or,O
hemorrhaging,I-Entity
in,O
various,O
parts,O
of,O
the,O
exencephalic,I-Entity
head,O
",",O
leading,O
to,O
the,O
multiple,O
modes,O
of,O
tissue,O
reduction,O
during,O
transformation,O
from,O
exencephaly,I-Entity
to,O
anencephaly,I-Entity
.,O
Acute,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
:,O
differential,O
sensitivity,O
of,O
six,O
inbred,O
mouse,O
strains,O
.,O
Mature,O
male,O
and,O
female,O
mice,O
from,O
six,O
inbred,O
stains,O
were,O
tested,O
for,O
susceptibility,O
to,O
behavioral,O
seizures,I-Entity
induced,O
by,O
a,O
single,O
injection,O
of,O
cocaine,I-Entity
.,O
Cocaine,I-Entity
was,O
injected,O
ip,O
over,O
a,O
range,O
of,O
doses,O
(,O
50,O
-,O
100,O
mg,O
/,O
kg,O
),O
and,O
behavior,O
was,O
monitored,O
for,O
20,O
minutes,O
.,O
Seizure,I-Entity
end,O
points,O
included,O
latency,O
to,O
forelimb,O
or,O
hindlimb,O
clonus,O
",",O
latency,O
to,O
clonic,O
running,O
seizure,I-Entity
and,O
latency,O
to,O
jumping,O
bouncing,O
seizure,I-Entity
.,O
Additionally,O
",",O
levels,O
of,O
cocaine,I-Entity
determined,O
in,O
hippocampus,O
and,O
cortex,O
were,O
not,O
different,O
between,O
sensitive,O
and,O
resistant,O
strains,O
.,O
Additional,O
studies,O
of,O
these,O
murine,O
strains,O
may,O
be,O
useful,O
for,O
investigating,O
genetic,O
influences,O
on,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
Microangiopathic,B-Entity
hemolytic,I-Entity
anemia,I-Entity
complicating,O
FK506,I-Entity
(,O
tacrolimus,I-Entity
),O
therapy,O
.,O
We,O
describe,O
3,O
episodes,O
of,O
microangiopathic,B-Entity
hemolytic,I-Entity
anemia,I-Entity
(,O
MAHA,I-Entity
),O
in,O
2,O
solid,O
organ,O
recipients,O
under,O
FK506,I-Entity
(,O
tacrolimus,I-Entity
),O
therapy,O
.,O
In,O
both,O
cases,O
",",O
discontinuation,O
of,O
FK506,I-Entity
and,O
treatment,O
with,O
plasma,O
exchange,O
",",O
fresh,O
frozen,O
plasma,O
replacement,O
",",O
corticosteroids,I-Entity
",",O
aspirin,I-Entity
",",O
and,O
dipyridamole,I-Entity
led,O
to,O
resolution,O
of,O
MAHA,I-Entity
.,O
In,O
one,O
patient,O
",",O
reintroduction,O
of,O
FK506,I-Entity
led,O
to,O
rapid,O
recurrence,O
of,O
MAHA,I-Entity
.,O
FK506-associated,I-Entity
MAHA,I-Entity
is,O
probably,O
rare,O
but,O
physicians,O
must,O
be,O
aware,O
of,O
this,O
severe,O
complication,O
.,O
In,O
our,O
experience,O
and,O
according,O
to,O
the,O
literature,O
",",O
FK506,I-Entity
does,O
not,O
seem,O
to,O
cross,O
-,O
react,O
with,O
cyclosporin,B-Entity
A,I-Entity
(,O
CyA,I-Entity
),O
",",O
an,O
immuno,O
-,O
suppressive,O
drug,O
already,O
known,O
to,O
induce,O
MAHA,I-Entity
.,O
Variant,O
ventricular,B-Entity
tachycardia,I-Entity
in,O
desipramine,I-Entity
toxicity,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
variant,O
ventricular,B-Entity
tachycardia,I-Entity
induced,O
by,O
desipramine,I-Entity
toxicity,I-Entity
.,O
Unusual,O
features,O
of,O
the,O
arrhythmia,I-Entity
are,O
repetitive,O
group,O
beating,O
",",O
progressive,O
shortening,O
of,O
the,O
R,O
-,O
R,O
interval,O
",",O
progressive,O
widening,O
of,O
the,O
QRS,O
complex,O
with,O
eventual,O
failure,O
of,O
intraventricular,O
conduction,O
",",O
and,O
changes,O
in,O
direction,O
of,O
the,O
QRS,O
axis,O
.,O
Recognition,O
of,O
variant,O
ventricular,B-Entity
tachycardia,I-Entity
is,O
important,O
because,O
therapy,O
differs,O
from,O
that,O
of,O
classic,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
Desipramine,I-Entity
-,O
induced,O
delirium,I-Entity
at,O
"""",O
subtherapeutic,O
"""",O
concentrations,O
:,O
a,O
case,O
report,O
.,O
An,O
elderly,O
patient,O
treated,O
with,O
low,O
dose,O
Desipramine,I-Entity
developed,O
a,O
delirium,I-Entity
while,O
her,O
plasma,O
level,O
was,O
in,O
the,O
"""",O
subtherapeutic,O
"""",O
range,O
.,O
Delirium,I-Entity
",",O
which,O
may,O
be,O
induced,O
by,O
tricyclic,O
drug,O
therapy,O
in,O
the,O
elderly,O
",",O
can,O
be,O
caused,O
by,O
tricyclics,O
with,O
low,O
anticholinergic,O
potency,O
.,O
Therapeutic,O
ranges,O
for,O
antidepressants,I-Entity
that,O
have,O
been,O
derived,O
from,O
general,O
adult,O
population,O
studies,O
may,O
not,O
be,O
appropriate,O
for,O
the,O
elderly,O
.,O
Mouse,O
strain,O
-,O
dependent,O
effect,O
of,O
amantadine,I-Entity
on,O
motility,O
and,O
brain,O
biogenic,O
amines,I-Entity
.,O
The,O
effect,O
of,O
amantadine,B-Entity
hydrochloride,I-Entity
",",O
injected,O
i.p,O
.,O
in,O
6,O
increments,O
of,O
100,O
mg,O
/,O
kg,O
each,O
over,O
30,O
hr,O
",",O
on,O
mouse,O
motility,O
and,O
whole,O
brain,O
content,O
of,O
selected,O
biogenic,O
amines,I-Entity
and,O
major,O
metabolites,O
was,O
studied,O
in,O
4,O
strains,O
of,O
mice,O
.,O
Amantadine,I-Entity
treatment,O
produced,O
a,O
biphasic,O
effect,O
on,O
mouse,O
motility,O
.,O
The,O
initial,O
dose,O
of,O
amantadine,I-Entity
depressed,I-Entity
locomotor,O
activity,O
in,O
all,O
mouse,O
strains,O
studied,O
with,O
the,O
BALB,O
/,O
C,O
mice,O
being,O
the,O
most,O
sensitive,O
.,O
Subsequent,O
amantadine,I-Entity
treatments,O
produced,O
enhancement,O
of,O
motility,O
from,O
corresponding,O
control,O
in,O
all,O
mouse,O
strains,O
with,O
the,O
BALB,O
/,O
C,O
mice,O
being,O
the,O
least,O
sensitive,O
.,O
The,O
locomotor,O
activity,O
was,O
decreased,O
from,O
corresponding,O
controls,O
in,O
all,O
strains,O
studied,O
",",O
except,O
for,O
the,O
ICR,O
mice,O
",",O
during,O
an,O
overnight,O
drug,O
-,O
free,O
period,O
following,O
the,O
fourth,O
amantadine,I-Entity
treatment,O
.,O
Readministration,O
of,O
amantadine,I-Entity
",",O
after,O
a,O
drug,O
-,O
free,O
overnight,O
period,O
",",O
increased,O
motility,O
from,O
respective,O
saline,O
control,O
in,O
all,O
strains,O
with,O
exception,O
of,O
the,O
BALB,O
/,O
C,O
mice,O
where,O
suppression,B-Entity
of,I-Entity
motility,I-Entity
occurred,O
.,O
Treatment,O
with,O
amantadine,I-Entity
did,O
not,O
alter,O
whole,O
brain,O
dopamine,I-Entity
levels,O
but,O
decreased,O
the,O
amounts,O
of,O
"3,4-dihydroxyphenylacetic",B-Entity
acid,I-Entity
in,O
the,O
BALB,O
/,O
C,O
mice,O
compared,O
to,O
saline,O
control,O
.,O
Conversely,O
",",O
brain,O
normetanephrine,I-Entity
concentration,O
was,O
increased,O
from,O
saline,O
control,O
by,O
amantadine,I-Entity
in,O
the,O
BALB,O
/,O
C,O
mice,O
.,O
The,O
results,O
suggest,O
a,O
strain,O
-,O
dependent,O
effect,O
of,O
amantadine,I-Entity
on,O
motility,O
and,O
indicate,O
a,O
differential,O
response,O
to,O
the,O
acute,O
and,O
multiple,O
dose,O
regimens,O
used,O
.,O
The,O
BALB,O
/,O
C,O
mouse,O
was,O
the,O
most,O
sensitive,O
strain,O
and,O
could,O
serve,O
as,O
the,O
strain,O
of,O
choice,O
for,O
evaluating,O
the,O
side,O
effects,O
of,O
amantadine,I-Entity
.,O
The,O
biochemical,O
results,O
of,O
brain,O
biogenic,O
amines,I-Entity
of,O
BALB,O
/,O
C,O
mouse,O
strain,O
suggest,O
a,O
probable,O
decrease,O
of,O
catecholamine,I-Entity
turnover,O
rate,O
and/or,O
metabolism,O
by,O
monoamine,O
oxidase,O
and,O
a,O
resulting,O
increase,O
in,O
O,O
-,O
methylation,O
of,O
norepinephrine,I-Entity
which,O
may,O
account,O
for,O
a,O
behavioral,B-Entity
depression,I-Entity
caused,O
by,O
amantadine,I-Entity
in,O
the,O
BALB,O
/,O
C,O
mice,O
.,O
No,O
enhancement,O
by,O
phenobarbital,I-Entity
of,O
the,O
hepatocarcinogenicity,O
of,O
a,O
choline,I-Entity
-,O
devoid,O
diet,O
in,O
the,O
rat,O
.,O
An,O
experiment,O
was,O
performed,O
to,O
test,O
whether,O
inclusion,O
of,O
phenobarbital,I-Entity
in,O
a,O
choline,I-Entity
-,O
devoid,O
diet,O
would,O
increase,O
the,O
hepatocarcinogenicity,O
of,O
the,O
diet,O
.,O
semipurified,O
choline,I-Entity
-,O
devoid,O
or,O
choline,I-Entity
-,O
supplemented,O
diets,O
",",O
containing,O
or,O
not,O
0.06%,O
phenobarbital,I-Entity
.,O
No,O
hepatic,O
preneoplastic,O
nodules,O
or,O
hepatocellular,B-Entity
carcinomas,I-Entity
developed,O
in,O
rats,O
fed,O
the,O
plain,O
choline,I-Entity
-,O
supplemented,O
diet,O
",",O
while,O
one,O
preneoplastic,O
nodule,O
and,O
one,O
hepatocellular,B-Entity
carcinoma,I-Entity
developed,O
in,O
two,O
rats,O
fed,O
the,O
same,O
diet,O
containing,O
phenobarbital,I-Entity
.,O
The,O
incidence,O
of,O
preneoplastic,O
nodules,O
and,O
of,O
hepatocellular,B-Entity
carcinomas,I-Entity
was,O
10%,O
and,O
37%,O
",",O
respectively,O
",",O
in,O
rats,O
fed,O
the,O
plain,O
choline,I-Entity
-,O
devoid,O
diet,O
",",O
and,O
17%,O
and,O
30%,O
",",O
in,O
rats,O
fed,O
the,O
phenobarbital,I-Entity
-,O
containing,O
choline,I-Entity
-,O
devoid,O
diet,O
.,O
The,O
results,O
evinced,O
no,O
enhancement,O
of,O
the,O
hepatocarcinogenicity,O
of,O
the,O
choline,I-Entity
-,O
devoid,O
diet,O
by,O
phenobarbital,I-Entity
.,O
Effect,O
of,O
direct,O
intracoronary,O
administration,O
of,O
methylergonovine,I-Entity
in,O
patients,O
with,O
and,O
without,O
variant,B-Entity
angina,I-Entity
.,O
The,O
effects,O
of,O
intracoronary,O
administration,O
of,O
methylergonovine,I-Entity
were,O
studied,O
in,O
21,O
patients,O
with,O
variant,B-Entity
angina,I-Entity
and,O
22,O
patients,O
with,O
atypical,O
chest,B-Entity
pain,I-Entity
and,O
in,O
others,O
without,O
angina,B-Entity
pectoris,I-Entity
(,O
control,O
group,O
),O
.,O
Methylergonovine,I-Entity
was,O
administered,O
continuously,O
at,O
a,O
rate,O
of,O
10,O
micrograms,O
/,O
min,O
up,O
to,O
50,O
micrograms,O
.,O
In,O
all,O
patients,O
with,O
variant,B-Entity
angina,I-Entity
",",O
coronary,B-Entity
spasm,I-Entity
was,O
provoked,O
at,O
a,O
mean,O
dose,O
of,O
28,O
+,O
/-,O
In,O
the,O
control,O
group,O
neither,O
ischemic,O
ST,O
change,O
nor,O
localized,O
spasm,I-Entity
occurred,O
.,O
These,O
results,O
suggest,O
that,O
spasm,I-Entity
provocation,O
tests,O
",",O
which,O
use,O
an,O
intracoronary,O
injection,O
of,O
a,O
relatively,O
low,O
dose,O
of,O
methylergonovine,I-Entity
",",O
have,O
a,O
high,O
sensitivity,O
in,O
variant,B-Entity
angina,I-Entity
and,O
the,O
vasoreactivity,O
of,O
the,O
right,O
coronary,O
artery,O
may,O
be,O
greater,O
than,O
that,O
of,O
the,O
other,O
coronary,O
arteries,O
.,O
Dobutamine,I-Entity
stress,O
echocardiography,O
:,O
a,O
sensitive,O
indicator,O
of,O
diminished,O
myocardial,O
function,O
in,O
asymptomatic,O
doxorubicin,I-Entity
-,O
treated,O
long,O
-,O
term,O
survivors,O
of,O
childhood,O
cancer,I-Entity
.,O
Doxorubicin,I-Entity
is,O
an,O
effective,O
anticancer,O
chemotherapeutic,O
agent,O
known,O
to,O
cause,O
acute,O
and,O
chronic,O
cardiomyopathy,I-Entity
.,O
To,O
develop,O
a,O
more,O
sensitive,O
echocardiographic,O
screening,O
test,O
for,O
cardiac,B-Entity
damage,I-Entity
due,O
to,O
doxorubicin,I-Entity
",",O
a,O
cohort,O
study,O
was,O
performed,O
using,O
dobutamine,I-Entity
infusion,O
to,O
differentiate,O
asymptomatic,O
long,O
-,O
term,O
survivors,O
of,O
childhood,O
cancer,I-Entity
treated,O
with,O
doxorubicin,I-Entity
from,O
healthy,O
control,O
subjects,O
.,O
5,O
years,O
),O
treated,O
from,O
1.6,O
to,O
14.3,O
years,O
(,O
median,O
5.3,O
),O
before,O
this,O
study,O
with,O
27,O
to,O
532,O
mg,O
/,O
m2,O
of,O
doxorubicin,I-Entity
(,O
mean,O
196,O
),O
were,O
compared,O
with,O
echocardiographic,O
data,O
from,O
12,O
normal,O
age,O
-,O
matched,O
control,O
subjects,O
.,O
Graded,O
dobutamine,I-Entity
infusions,O
of,O
0.5,O
",",O
2.5,O
",",O
5,O
and,O
10,O
micrograms,O
/,O
kg,O
per,O
min,O
were,O
administered,O
.,O
Dobutamine,I-Entity
infusion,O
at,O
10,O
micrograms,O
The,O
most,O
important,O
findings,O
were,O
that,O
compared,O
with,O
values,O
in,O
control,O
subjects,O
",",O
end,O
-,O
systolic,O
left,O
ventricular,O
posterior,O
wall,O
dimension,O
and,O
percent,O
of,O
left,O
ventricular,O
posterior,O
wall,O
thickening,O
in,O
doxorubicin,I-Entity
-,O
treated,O
patients,O
were,O
decreased,O
at,O
baseline,O
study,O
and,O
these,O
findings,O
were,O
more,O
clearly,O
delineated,O
with,O
dobutamine,I-Entity
stimulation,O
.,O
End,O
-,O
systolic,O
left,O
ventricular,O
posterior,O
wall,O
dimension,O
at,O
baseline,O
for,O
the,O
doxorubicin,I-Entity
-,O
treated,O
group,O
was,O
11,O
+,O
/-,O
End,O
-,O
systolic,O
left,O
ventricular,O
posterior,O
wall,O
dimension,O
at,O
the,O
5-micrograms,O
/,O
kg,O
per,O
min,O
dobutamine,I-Entity
infusion,O
for,O
the,O
doxorubicin,I-Entity
-,O
treated,O
group,O
was,O
14.1,O
+,O
/-,O
Effects,O
of,O
aminophylline,I-Entity
on,O
the,O
threshold,O
for,O
initiating,O
ventricular,B-Entity
fibrillation,I-Entity
during,O
respiratory,B-Entity
failure,I-Entity
.,O
Cardiac,B-Entity
arrhythmias,I-Entity
have,O
frequently,O
been,O
reported,O
in,O
association,O
with,O
respiratory,B-Entity
failure,I-Entity
.,O
The,O
possible,O
additive,O
role,O
of,O
pharmacologic,O
agents,O
in,O
precipitating,O
cardiac,B-Entity
disturbances,I-Entity
in,O
patients,O
with,O
respiratory,B-Entity
failure,I-Entity
has,O
only,O
recently,O
been,O
emphasized,O
.,O
The,O
effects,O
of,O
aminophylline,I-Entity
on,O
the,O
ventricular,B-Entity
fibrillation,I-Entity
threshold,O
during,O
normal,O
acid,O
-,O
base,O
conditions,O
and,O
during,O
respiratory,B-Entity
failure,I-Entity
were,O
studied,O
in,O
anesthetized,O
open,O
chest,O
dogs,O
.,O
The,O
ventricular,B-Entity
fibrillation,I-Entity
threshold,O
was,O
measured,O
by,O
passing,O
a,O
gated,O
train,O
of,O
12,O
constant,O
current,O
pulses,O
through,O
the,O
ventricular,O
myocardium,O
during,O
the,O
vulnerable,O
period,O
of,O
the,O
cardiac,O
cycle,O
.,O
During,O
the,O
infusion,O
of,O
aminophylline,I-Entity
",",O
the,O
ventricular,B-Entity
fibrillation,I-Entity
threshold,O
was,O
reduced,O
by,O
30,O
to,O
40,O
percent,O
of,O
the,O
control,O
when,O
pH,O
and,O
partial,O
pressures,O
of,O
oxygen,I-Entity
(,O
PO2,I-Entity
),O
and,O
carbon,B-Entity
dioxide,I-Entity
(,O
CO2,I-Entity
),O
were,O
kept,O
within,O
normal,O
limits,O
.,O
When,O
respiratory,B-Entity
failure,I-Entity
was,O
produced,O
by,O
hypoventilation,I-Entity
(,O
pH,O
7.05,O
to,O
7.25,O
;,O
PC02,O
70,O
to,O
100,O
mm,O
P02,O
20,O
to,O
40,O
mm,O
Hg,O
),O
",",O
infusion,O
of,O
aminophylline,I-Entity
resulted,O
in,O
an,O
even,O
greater,O
decrease,O
in,O
ventricular,B-Entity
fibrillation,I-Entity
threshold,O
to,O
60,O
percent,O
of,O
the,O
control,O
level,O
.,O
These,O
experiments,O
suggest,O
that,O
although,O
many,O
factors,O
may,O
contribute,O
to,O
the,O
increased,O
incidence,O
of,O
ventricular,B-Entity
arrhythmias,I-Entity
in,O
respiratory,B-Entity
failure,I-Entity
",",O
pharmacologic,O
agents,O
",",O
particularly,O
aminophylline,I-Entity
",",O
may,O
play,O
a,O
significant,O
role,O
.,O
Case,O
report,O
:,O
acute,O
unintentional,O
carbachol,I-Entity
intoxication,O
.,O
INTRODUCTION,O
:,O
Intoxications,O
with,O
carbachol,I-Entity
",",O
a,O
muscarinic,O
cholinergic,O
receptor,O
agonist,O
are,O
rare,O
.,O
We,O
report,O
an,O
interesting,O
case,O
investigating,O
a,O
(,O
near,O
),O
fatal,O
poisoning,I-Entity
.,O
METHODS,O
:,O
The,O
son,O
of,O
an,O
84-year,O
-,O
old,O
male,O
discovered,O
a,O
newspaper,O
report,O
stating,O
clinical,O
success,O
with,O
plant,O
extracts,O
in,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
.,O
The,O
mode,O
of,O
action,O
was,O
said,O
to,O
be,O
comparable,O
to,O
that,O
of,O
the,O
synthetic,O
compound,O
',O
carbamylcholin,I-Entity
',O
;,O
that,O
is,O
",",O
carbachol,I-Entity
.,O
He,O
bought,O
25,O
g,O
of,O
carbachol,I-Entity
as,O
pure,O
substance,O
in,O
a,O
pharmacy,O
",",O
and,O
the,O
father,O
was,O
administered,O
400,O
to,O
500,O
mg,O
.,O
Carbachol,I-Entity
concentrations,O
in,O
serum,O
and,O
urine,O
on,O
day,O
1,O
and,O
RESULTS,O
:,O
Minutes,O
after,O
oral,O
administration,O
",",O
the,O
patient,O
developed,O
nausea,I-Entity
",",O
sweating,O
and,O
hypotension,I-Entity
",",O
and,O
finally,O
collapsed,O
.,O
Bradycardia,I-Entity
",",O
cholinergic,O
symptoms,O
and,O
asystole,I-Entity
occurred,O
.,O
Initial,O
cardiopulmonary,O
resuscitation,O
and,O
immediate,O
treatment,O
with,O
adrenaline,I-Entity
(,O
epinephrine,I-Entity
),O
",",O
atropine,I-Entity
and,O
furosemide,I-Entity
was,O
successful,O
.,O
Further,O
signs,O
were,O
hyperhidrosis,I-Entity
",",O
hypersalivation,I-Entity
",",O
bronchorrhoea,I-Entity
",",O
and,O
severe,O
miosis,I-Entity
;,O
the,O
electrocardiographic,O
finding,O
was,O
atrio,B-Entity
-,I-Entity
ventricular,I-Entity
dissociation,I-Entity
.,O
High,O
doses,O
of,O
atropine,I-Entity
(,O
up,O
to,O
50,O
mg,O
per,O
24,O
hours,O
),O
",",O
adrenaline,I-Entity
and,O
dopamine,I-Entity
were,O
necessary,O
.,O
However,O
",",O
increased,O
dyspnoea,I-Entity
and,O
bronchospasm,I-Entity
necessitated,O
reintubation,O
.,O
Respiratory,B-Entity
insufficiency,I-Entity
was,O
further,O
worsened,O
by,O
Proteus,B-Entity
mirabilis,I-Entity
infection,I-Entity
and,O
severe,O
bronchoconstriction,O
.,O
On,O
the,O
next,O
day,O
he,O
died,O
",",O
probably,O
as,O
a,O
result,O
of,O
heart,B-Entity
failure,I-Entity
.,O
Serum,O
samples,O
from,O
the,O
first,O
and,O
second,O
days,O
contained,O
3.6,O
and,O
1.9,O
mg,O
/,O
l,O
carbachol,I-Entity
",",O
respectively,O
.,O
For,O
the,O
first,O
time,O
",",O
an,O
analytical,O
method,O
for,O
the,O
determination,O
of,O
carbachol,I-Entity
in,O
plasma,O
and,O
urine,O
has,O
been,O
developed,O
.,O
The,O
analysed,O
carbachol,I-Entity
concentration,O
exceeded,O
the,O
supposed,O
serum,O
level,O
resulting,O
from,O
a,O
therapeutic,O
dose,O
by,O
a,O
factor,O
of,O
130,O
to,O
260,O
.,O
Especially,O
in,O
old,O
patients,O
",",O
intensivists,O
should,O
consider,O
intoxications,O
(,O
with,O
cholinergics,O
),O
as,O
a,O
cause,O
of,O
acute,B-Entity
cardiovascular,I-Entity
failure,I-Entity
.,O
Crossover,O
comparison,O
of,O
efficacy,O
and,O
preference,O
for,O
rizatriptan,I-Entity
10,O
mg,O
versus,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
in,O
migraine,I-Entity
.,O
Rizatriptan,I-Entity
is,O
a,O
selective,O
5-HT(1B/1D,I-Entity
),O
receptor,O
agonist,O
with,O
rapid,O
oral,O
absorption,O
and,O
early,O
onset,O
of,O
action,O
in,O
the,O
acute,O
treatment,O
of,O
migraine,I-Entity
.,O
This,O
randomized,O
double-,O
blind,O
crossover,O
outpatient,O
study,O
assessed,O
the,O
preference,O
for,O
1,O
rizatriptan,I-Entity
10,O
mg,O
tablet,O
to,O
2,O
ergotamine,I-Entity
1,O
mg,O
/,O
caffeine,I-Entity
100,O
mg,O
tablets,O
in,O
439,O
patients,O
treating,O
a,O
single,O
migraine,I-Entity
attack,O
with,O
each,O
therapy,O
.,O
Of,O
patients,O
expressing,O
a,O
preference,O
(,O
89.1%,O
),O
",",O
more,O
than,O
twice,O
as,O
many,O
preferred,O
rizatriptan,I-Entity
to,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
(,O
69.9,O
vs.,O
30.1%,O
",",O
p,O
<,O
or,O
=,O
0.001,O
),O
.,O
Faster,O
relief,O
of,O
headache,I-Entity
was,O
the,O
most,O
important,O
reason,O
for,O
preference,O
",",O
cited,O
by,O
67.3%,O
of,O
patients,O
preferring,O
rizatriptan,I-Entity
and,O
54.2%,O
of,O
patients,O
who,O
preferred,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
.,O
The,O
co,O
-,O
primary,O
endpoint,O
of,O
being,O
pain,I-Entity
free,O
at,O
2,O
h,O
was,O
also,O
in,O
favor,O
of,O
rizatriptan,I-Entity
.,O
Forty,O
-,O
nine,O
percent,O
of,O
patients,O
were,O
pain,I-Entity
free,O
2,O
h,O
after,O
rizatriptan,I-Entity
",",O
compared,O
with,O
24.3%,O
treated,O
with,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
(,O
p,O
<,O
or,O
=,O
0.001,O
),O
",",O
rizatriptan,I-Entity
being,O
superior,O
within,O
1,O
h,O
of,O
treatment,O
.,O
Headache,I-Entity
relief,O
at,O
2,O
h,O
was,O
75.9%,O
for,O
rizatriptan,I-Entity
and,O
47.3%,O
for,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
(,O
p,O
<,O
or,O
=,O
0.001,O
),O
",",O
with,O
rizatriptan,I-Entity
being,O
superior,O
to,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
within,O
30,O
min,O
of,O
dosing,O
.,O
Almost,O
36%,O
of,O
patients,O
taking,O
rizatriptan,I-Entity
were,O
pain,I-Entity
free,O
at,O
2,O
h,O
and,O
had,O
no,O
recurrence,O
or,O
need,O
for,O
additional,O
medication,O
within,O
24,O
h,O
",",O
compared,O
to,O
20%,O
of,O
patients,O
on,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
(,O
p,O
<,O
or,O
=,O
0.001,O
),O
.,O
Rizatriptan,I-Entity
was,O
also,O
superior,O
to,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
in,O
the,O
proportions,O
of,O
patients,O
with,O
no,O
nausea,I-Entity
",",O
vomiting,I-Entity
",",O
phonophobia,I-Entity
or,O
photophobia,I-Entity
and,O
for,O
patients,O
with,O
normal,O
function,O
2,O
h,O
after,O
drug,O
intake,O
(,O
More,O
patients,O
were,O
(,O
completely,O
",",O
very,O
or,O
somewhat,O
),O
satisfied,O
2,O
h,O
after,O
treatment,O
with,O
rizatriptan,I-Entity
(,O
69.8%,O
),O
than,O
at,O
2,O
h,O
after,O
treatment,O
with,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
(,O
38.6%,O
",",O
p,O
<,O
or,O
=,O
0.001,O
),O
.,O
Recurrence,O
rates,O
were,O
31.4%,O
with,O
rizatriptan,I-Entity
and,O
15.3%,O
with,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
.,O
The,O
most,O
common,O
adverse,O
events,O
(,O
incidence,O
>,O
or,O
=,O
5%,O
in,O
one,O
group,O
),O
after,O
rizatriptan,I-Entity
and,O
ergotamine,I-Entity
/,O
caffeine,I-Entity
",",O
respectively,O
",",O
were,O
dizziness,I-Entity
(,O
6.7,O
and,O
5.3%,O
),O
",",O
nausea,I-Entity
(,O
4.2,O
and,O
8.5%,O
),O
and,O
somnolence,I-Entity
(,O
5.5,O
and,O
2.3%,O
),O
.,O
Thrombotic,B-Entity
microangiopathy,I-Entity
and,O
renal,B-Entity
failure,I-Entity
associated,O
with,O
antineoplastic,O
chemotherapy,O
.,O
Five,O
patients,O
with,O
carcinoma,I-Entity
developed,O
thrombotic,B-Entity
microangiopathy,I-Entity
(,O
characterized,O
by,O
renal,B-Entity
insufficiency,I-Entity
",",O
microangiopathic,B-Entity
hemolytic,I-Entity
anemia,I-Entity
",",O
and,O
usually,O
thrombocytopenia,I-Entity
),O
after,O
treatment,O
with,O
cisplatin,I-Entity
",",O
bleomycin,I-Entity
",",O
and,O
a,O
vinca,B-Entity
alkaloid,I-Entity
.,O
One,O
patient,O
had,O
thrombotic,B-Entity
thrombocytopenic,I-Entity
purpura,I-Entity
",",O
three,O
the,O
hemolytic,B-Entity
-,I-Entity
uremic,I-Entity
syndrome,I-Entity
",",O
and,O
one,O
an,O
apparent,O
forme,O
fruste,O
of,O
one,O
of,O
these,O
disorders,O
.,O
Histologic,O
examination,O
of,O
the,O
renal,O
tissue,O
showed,O
evidence,O
of,O
intravascular,B-Entity
coagulation,I-Entity
",",O
primarily,O
affecting,O
the,O
small,O
arteries,O
",",O
arterioles,O
",",O
and,O
glomeruli,O
.,O
Because,O
each,O
patient,O
was,O
tumor,I-Entity
-,O
free,O
or,O
had,O
only,O
a,O
small,O
tumor,I-Entity
at,O
the,O
onset,O
of,O
this,O
syndrome,O
",",O
the,O
thrombotic,B-Entity
microangiopathy,I-Entity
may,O
have,O
been,O
induced,O
by,O
chemotherapy,O
.,O
Diagnosis,O
of,O
this,O
potentially,O
fatal,O
complication,O
may,O
be,O
delayed,O
or,O
missed,O
if,O
renal,O
tissue,O
or,O
the,O
peripheral,O
blood,O
smear,O
is,O
not,O
examined,O
",",O
because,O
renal,B-Entity
failure,I-Entity
may,O
be,O
ascribed,O
to,O
cisplatin,I-Entity
nephrotoxicity,I-Entity
and,O
the,O
anemia,I-Entity
and,O
thrombocytopenia,I-Entity
to,O
drug,O
-,O
induced,O
bone,B-Entity
marrow,I-Entity
suppression,I-Entity
.,O
Salvage,O
therapy,O
with,O
nelarabine,I-Entity
",",O
etoposide,I-Entity
",",O
and,O
cyclophosphamide,I-Entity
in,O
relapsed,O
/,O
refractory,O
paediatric,O
T,B-Entity
-,I-Entity
cell,I-Entity
lymphoblastic,I-Entity
leukaemia,I-Entity
and,I-Entity
lymphoma,I-Entity
.,O
A,O
combination,O
of,O
5,O
d,O
of,O
nelarabine,I-Entity
(,O
AraG,I-Entity
),O
with,O
5,O
d,O
of,O
etoposide,I-Entity
(,O
VP,I-Entity
),O
and,O
cyclophosphamide,I-Entity
(,O
CPM,I-Entity
),O
and,O
prophylactic,O
intrathecal,O
chemotherapy,O
was,O
used,O
as,O
salvage,O
therapy,O
in,O
seven,O
children,O
with,O
refractory,O
or,O
relapsed,O
T,B-Entity
-,I-Entity
cell,I-Entity
leukaemia,I-Entity
or,I-Entity
lymphoma,I-Entity
.,O
The,O
most,O
common,O
side,O
effects,O
attributable,O
to,O
the,O
AraG,I-Entity
included,O
Grade,O
2,O
and,O
3,O
sensory,O
and,O
motor,O
neuropathy,I-Entity
and,O
musculoskeletal,B-Entity
pain,I-Entity
.,O
Haematological,B-Entity
toxicity,I-Entity
was,O
greater,O
for,O
the,O
combination,O
than,O
AraG,I-Entity
alone,O
",",O
although,O
median,O
time,O
to,O
neutrophil,O
and,O
platelet,O
recovery,O
was,O
consistent,O
with,O
other,O
salvage,O
therapies,O
.,O
All,O
patients,O
had,O
some,O
response,O
to,O
the,O
combined,O
therapy,O
and,O
five,O
of,O
the,O
seven,O
went,O
into,O
complete,O
remission,O
after,O
one,O
or,O
two,O
courses,O
of,O
AraG,I-Entity
/,O
VP,I-Entity
/,O
CPM,I-Entity
.,O
Our,O
experience,O
supports,O
the,O
safety,O
of,O
giving,O
AraG,I-Entity
as,O
salvage,O
therapy,O
in,O
synchrony,O
with,O
etoposide,I-Entity
and,O
cyclophosphamide,I-Entity
",",O
although,O
neurological,B-Entity
toxicity,I-Entity
must,O
be,O
closely,O
monitored,O
.,O
The,O
3-week,O
sulphasalazine,I-Entity
syndrome,O
strikes,O
again,O
.,O
A,O
34-year,O
-,O
old,O
lady,O
developed,O
a,O
constellation,O
of,O
dermatitis,I-Entity
",",O
fever,I-Entity
",",O
lymphadenopathy,I-Entity
and,O
hepatitis,I-Entity
",",O
beginning,O
on,O
the,O
17th,O
day,O
of,O
a,O
course,O
of,O
oral,O
sulphasalazine,I-Entity
for,O
sero,O
-,O
negative,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
Cervical,O
and,O
inguinal,O
lymph,O
node,O
biopsies,O
showed,O
the,O
features,O
of,O
severe,O
necrotising,O
lymphadenitis,I-Entity
",",O
associated,O
with,O
erythrophagocytosis,O
and,O
prominent,O
eosinophilic,O
infiltrates,O
",",O
without,O
viral,O
inclusion,O
bodies,O
",",O
suggestive,O
of,O
an,O
adverse,B-Entity
drug,I-Entity
reaction,I-Entity
.,O
A,O
week,O
later,O
",",O
fulminant,O
drug,B-Entity
-,I-Entity
induced,I-Entity
hepatitis,I-Entity
",",O
associated,O
with,O
the,O
presence,O
of,O
anti,O
-,O
nuclear,O
autoantibodies,O
(,O
but,O
not,O
with,O
other,O
markers,O
of,O
autoimmunity,I-Entity
),O
",",O
and,O
accompanied,O
by,O
multi,B-Entity
-,I-Entity
organ,I-Entity
failure,I-Entity
and,O
sepsis,I-Entity
",",O
supervened,O
.,O
Post,O
-,O
mortem,O
examination,O
showed,O
evidence,O
of,O
massive,B-Entity
hepatocellular,I-Entity
necrosis,I-Entity
",",O
acute,O
hypersensitivity,O
myocarditis,I-Entity
",",O
focal,O
acute,O
tubulo,O
-,O
interstitial,O
nephritis,I-Entity
and,O
extensive,O
bone,B-Entity
marrow,I-Entity
necrosis,I-Entity
",",O
with,O
no,O
evidence,O
of,O
malignancy,I-Entity
.,O
It,O
is,O
thought,O
that,O
the,O
clinico,O
-,O
pathological,O
features,O
and,O
chronology,O
of,O
this,O
case,O
bore,O
the,O
hallmarks,O
of,O
the,O
so,O
-,O
called,O
"""",O
3-week,O
sulphasalazine,I-Entity
syndrome,O
"""",O
",",O
a,O
rare,O
",",O
but,O
often,O
fatal,O
",",O
immunoallergic,O
reaction,O
to,O
sulphasalazine,I-Entity
.,O
Bupropion,I-Entity
(,O
Zyban,I-Entity
),O
toxicity,I-Entity
.,O
Bupropion,I-Entity
is,O
a,O
monocyclic,O
antidepressant,I-Entity
structurally,O
related,O
to,O
amphetamine,I-Entity
.,O
Zyban,I-Entity
",",O
a,O
sustained,O
-,O
release,O
formulation,O
of,O
bupropion,B-Entity
hydrochloride,I-Entity
",",O
was,O
recently,O
released,O
in,O
Ireland,O
",",O
as,O
a,O
smoking,O
cessation,O
aid,O
.,O
In,O
the,O
initial,O
6,O
months,O
since,O
it,O
's,O
introduction,O
",",O
12,O
overdose,I-Entity
cases,O
have,O
been,O
reported,O
to,O
The,O
National,O
Poisons,O
Information,O
Centre,O
.,O
8,O
patients,O
developed,O
symptoms,O
of,O
toxicity,I-Entity
.,O
Common,O
features,O
included,O
tachycardia,I-Entity
",",O
drowsiness,O
",",O
hallucinations,I-Entity
and,O
convulsions,I-Entity
.,O
Two,O
patients,O
developed,O
severe,O
cardiac,B-Entity
arrhythmias,I-Entity
",",O
including,O
one,O
patient,O
who,O
was,O
resuscitated,O
following,O
a,O
cardiac,B-Entity
arrest,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
a,O
31,O
year,O
old,O
female,O
who,O
required,O
admission,O
to,O
the,O
Intensive,O
Care,O
Unit,O
for,O
ventilation,O
and,O
full,O
supportive,O
therapy,O
",",O
following,O
ingestion,O
of,O
13.5,O
g,O
bupropion,I-Entity
.,O
Recurrent,O
seizures,I-Entity
were,O
treated,O
with,O
diazepam,I-Entity
and,O
broad,O
complex,O
tachycardia,I-Entity
was,O
successfully,O
treated,O
with,O
adenosine,I-Entity
.,O
Zyban,I-Entity
caused,O
significant,O
neurological,B-Entity
and,I-Entity
cardiovascular,I-Entity
toxicity,I-Entity
in,O
overdose,I-Entity
.,O
Survey,O
of,O
complications,O
of,O
indocyanine,B-Entity
green,I-Entity
angiography,O
in,O
Japan,O
.,O
We,O
evaluated,O
the,O
safety,O
of,O
indocyanine,B-Entity
green,I-Entity
for,O
use,O
in,O
fundus,O
angiography,O
.,O
:,O
We,O
sent,O
a,O
questionnaire,O
concerning,O
complications,O
of,O
indocyanine,B-Entity
green,I-Entity
to,O
32,O
institutions,O
in,O
Japan,O
",",O
which,O
were,O
selected,O
on,O
the,O
basis,O
of,O
the,O
client,O
list,O
from,O
the,O
Topcon,O
Company,O
",",O
which,O
manufactures,O
the,O
indocyanine,B-Entity
green,I-Entity
fundus,O
camera,O
.,O
Ophthalmologists,O
at,O
15,O
institutions,O
responded,O
",",O
reporting,O
a,O
total,O
of,O
"3,774",O
indocyanine,B-Entity
green,I-Entity
angiograms,O
performed,O
on,O
"2,820",O
patients,O
between,O
June,O
1984,O
and,O
September,O
1992,O
.,O
Before,O
angiography,O
",",O
intradermal,O
or,O
intravenous,O
indocyanine,B-Entity
green,I-Entity
testing,O
",",O
or,O
both,O
was,O
performed,O
at,O
13,O
of,O
15,O
institutions,O
.,O
The,O
dosage,O
of,O
indocyanine,B-Entity
green,I-Entity
used,O
for,O
angiography,O
varied,O
from,O
25,O
to,O
75,O
mg,O
",",O
depending,O
upon,O
the,O
institution,O
.,O
There,O
were,O
13,O
cases,O
of,O
adverse,O
reactions,O
(,O
0.34%,O
),O
",",O
ten,O
of,O
which,O
were,O
mild,O
reactions,O
such,O
as,O
nausea,I-Entity
",",O
exanthema,I-Entity
",",O
urtication,I-Entity
",",O
itchiness,I-Entity
",",O
and,O
urgency,O
to,O
defecate,O
",",O
and,O
did,O
not,O
require,O
treatment,O
.,O
Also,O
recorded,O
were,O
one,O
case,O
of,O
pain,I-Entity
of,O
the,O
vein,O
",",O
which,O
required,O
treatment,O
",",O
and,O
two,O
cases,O
of,O
hypotension,I-Entity
.,O
The,O
two,O
hypotensive,I-Entity
patients,O
required,O
treatment,O
for,O
shock,I-Entity
.,O
A,O
comparison,O
of,O
frequency,O
of,O
adverse,O
reactions,O
to,O
indocyanine,B-Entity
green,I-Entity
with,O
the,O
previously,O
reported,O
frequency,O
of,O
such,O
reactions,O
to,O
fluorescein,B-Entity
sodium,I-Entity
indicated,O
that,O
indocyanine,B-Entity
green,I-Entity
is,O
a,O
safe,O
as,O
fluorescein,I-Entity
for,O
use,O
in,O
angiography,O
.,O
Bradykinin,I-Entity
receptors,O
antagonists,O
and,O
nitric,B-Entity
oxide,I-Entity
synthase,O
inhibitors,O
in,O
vincristine,I-Entity
and,O
streptozotocin,I-Entity
induced,O
hyperalgesia,I-Entity
in,O
chemotherapy,O
and,O
diabetic,B-Entity
neuropathy,I-Entity
rat,O
model,O
.,O
NO,I-Entity
synthase,O
(,O
L,O
-,O
NOArg,O
;,O
1.0,O
mg,O
/,O
kg,O
ip,O
),O
",",O
a,O
relatively,O
selective,O
inhibitor,O
of,O
inducible,O
NO,I-Entity
synthase,O
(,O
L,O
-,O
NIL,O
;,O
1.0,O
mg,O
/,O
kg,O
ip,O
),O
and,O
a,O
relatively,O
specific,O
inhibitor,O
of,O
neuronal,O
NO,I-Entity
synthase,O
(,O
7-NI,O
;,O
0.1,O
mg,O
/,O
kg,O
ip,O
),O
",",O
on,O
antihyperalgesic,O
action,O
of,O
selective,O
antagonists,O
of,O
B2,O
and,O
B1,O
receptors,O
:,O
D,O
-,O
"Arg-[Hyp3,Thi5,D",O
-,O
"Tic7,Oic8",O
],O
bradykinin,I-Entity
(,O
HOE,B-Entity
140,I-Entity
;,O
70,O
nmol,O
/,O
kg,O
ip,O
),O
or,O
des,B-Entity
Arg10,I-Entity
HOE,I-Entity
140,I-Entity
(,O
70,O
nmol,O
/,O
kg,O
ip,O
),O
respectively,O
",",O
in,O
model,O
of,O
diabetic,B-Entity
(,I-Entity
streptozotocin,I-Entity
-,I-Entity
induced,I-Entity
),I-Entity
and,I-Entity
toxic,I-Entity
(,I-Entity
vincristine,I-Entity
-,I-Entity
induced,I-Entity
),I-Entity
neuropathy,I-Entity
was,O
investigated,O
.,O
The,O
changes,O
in,O
pain,I-Entity
thresholds,O
were,O
determined,O
using,O
mechanical,O
stimuli,O
--,O
the,O
modification,O
of,O
the,O
classic,O
paw,O
withdrawal,O
test,O
described,O
by,O
Randall,O
-,O
Selitto,O
.,O
The,O
results,O
of,O
this,O
paper,O
confirm,O
that,O
inhibition,O
of,O
bradykinin,I-Entity
receptors,O
and,O
inducible,O
NO,I-Entity
synthase,O
but,O
not,O
neuronal,O
NO,I-Entity
synthase,O
activity,O
reduces,O
diabetic,B-Entity
hyperalgesia,I-Entity
.,O
both,O
HOE,B-Entity
140,I-Entity
and,O
des,B-Entity
Arg10,I-Entity
HOE,I-Entity
140,I-Entity
.,O
It,O
was,O
also,O
shown,O
that,O
both,O
products,O
of,O
inducible,O
NO,I-Entity
synthase,O
and,O
neuronal,O
NO,I-Entity
synthase,O
activation,O
as,O
well,O
as,O
bradykinin,I-Entity
are,O
involved,O
in,O
hyperalgesia,I-Entity
produced,O
by,O
vincristine,I-Entity
.,O
Moreover,O
",",O
L,O
-,O
NOArg,O
and,O
7-NI,O
but,O
not,O
L,O
-,O
NIL,O
intensify,O
antihyperalgesic,O
activity,O
of,O
HOE,B-Entity
140,I-Entity
or,O
des,B-Entity
-,I-Entity
Arg10HOE,I-Entity
140,I-Entity
in,O
toxic,B-Entity
neuropathy,I-Entity
.,O
Results,O
of,O
these,O
studies,O
suggest,O
that,O
B1,O
and,O
B2,O
receptors,O
are,O
engaged,O
in,O
transmission,O
of,O
nociceptive,O
stimuli,O
in,O
both,O
diabetic,B-Entity
and,I-Entity
toxic,I-Entity
neuropathy,I-Entity
.,O
In,O
streptozotocin,I-Entity
-,O
induced,O
hyperalgesia,I-Entity
",",O
inducible,O
NO,I-Entity
synthase,O
participates,O
in,O
pronociceptive,O
activity,O
of,O
bradykinin,I-Entity
",",O
whereas,O
in,O
vincristine,I-Entity
-,O
induced,O
hyperalgesia,I-Entity
bradykinin,I-Entity
seemed,O
to,O
activate,O
neuronal,O
NO,I-Entity
synthase,O
pathway,O
.,O
Therefore,O
",",O
concomitant,O
administration,O
of,O
small,O
doses,O
of,O
bradykinin,I-Entity
receptor,O
antagonists,O
and,O
NO,I-Entity
synthase,O
inhibitors,O
can,O
be,O
effective,O
in,O
alleviation,O
of,O
neuropathic,B-Entity
pain,I-Entity
",",O
even,O
in,O
hospital,O
care,O
.,O
Cardiac,B-Entity
toxicity,I-Entity
observed,O
in,O
association,O
with,O
high,O
-,O
dose,O
cyclophosphamide,I-Entity
-,O
based,O
chemotherapy,O
for,O
metastatic,O
breast,B-Entity
cancer,I-Entity
.,O
Cyclophosphamide,I-Entity
is,O
an,O
alkylating,O
agent,O
given,O
frequently,O
as,O
a,O
component,O
of,O
many,O
conditioning,O
regimens,O
.,O
In,O
high,O
doses,O
",",O
its,O
nonhematological,O
dose,O
-,O
limiting,O
toxicity,I-Entity
is,O
cardiomyopathy,I-Entity
.,O
We,O
combined,O
paclitaxel,I-Entity
",",O
melphalan,I-Entity
and,O
high,O
-,O
dose,O
cyclophosphamide,I-Entity
",",O
thiotepa,I-Entity
",",O
and,O
carboplatin,I-Entity
in,O
a,O
triple,O
sequential,O
high,O
-,O
dose,O
regimen,O
for,O
patients,O
with,O
metastatic,O
breast,B-Entity
cancer,I-Entity
.,O
Analysis,O
was,O
performed,O
on,O
61,O
women,O
with,O
chemotherapy,O
-,O
responsive,O
metastatic,O
breast,B-Entity
cancer,I-Entity
receiving,O
96-h,O
infusional,O
cyclophosphamide,I-Entity
as,O
part,O
of,O
a,O
triple,O
sequential,O
high,O
-,O
dose,O
regimen,O
to,O
assess,O
association,O
between,O
presence,O
of,O
peritransplant,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
(,O
CHF,I-Entity
),O
and,O
the,O
following,O
pretreatment,O
characteristics,O
:,O
presence,O
of,O
electrocardiogram,O
(,O
EKG,O
),O
abnormalities,O
",",O
age,O
",",O
hypertension,I-Entity
",",O
prior,O
cardiac,O
history,O
",",O
smoking,O
",",O
diabetes,B-Entity
mellitus,I-Entity
",",O
prior,O
use,O
of,O
anthracyclines,I-Entity
",",O
and,O
left,O
-,O
sided,O
chest,O
irradiation,O
.,O
Six,O
of,O
61,O
women,O
(,O
10%,O
),O
developed,O
clinically,O
reversible,O
grade,O
3,O
CHF,I-Entity
following,O
infusional,O
cyclophosphamide,I-Entity
with,O
a,O
median,O
percent,O
decline,O
in,O
ejection,O
fraction,O
of,O
31%,O
.,O
Incidence,O
of,O
transient,O
cyclophosphamide,I-Entity
-,O
related,O
cardiac,B-Entity
toxicity,I-Entity
(,O
10%,O
),O
is,O
comparable,O
to,O
previous,O
recorded,O
literature,O
.,O
Older,O
age,O
was,O
significantly,O
correlated,O
with,O
the,O
CHF,I-Entity
development,O
;,O
with,O
median,O
ages,O
for,O
the,O
entire,O
group,O
and,O
for,O
patients,O
developing,O
CHF,I-Entity
of,O
45,O
and,O
59,O
",",O
respectively,O
.,O
Routine,O
EKG,O
monitoring,O
during,O
infusional,O
cyclophosphamide,I-Entity
did,O
not,O
predict,O
CHF,I-Entity
development,O
.,O
Inappropriate,O
use,O
of,O
carbamazepine,I-Entity
and,O
vigabatrin,I-Entity
in,O
typical,O
absence,B-Entity
seizures,I-Entity
.,O
Carbamazepine,I-Entity
and,O
vigabatrin,I-Entity
are,O
contraindicated,O
in,O
typical,O
absence,B-Entity
seizures,I-Entity
.,O
Of,O
18,O
consecutive,O
referrals,O
of,O
children,O
with,O
resistant,O
typical,O
absences,O
only,O
",",O
eight,O
were,O
erroneously,O
treated,O
with,O
carbamazepine,I-Entity
either,O
as,O
monotherapy,O
or,O
as,O
an,O
add,O
-,O
on,O
.,O
Vigabatrin,I-Entity
was,O
also,O
used,O
in,O
the,O
treatment,O
of,O
two,O
children,O
.,O
Frequency,O
of,O
absences,O
increased,O
in,O
four,O
children,O
treated,O
with,O
carbamazepine,I-Entity
and,O
two,O
of,O
these,O
developed,O
myoclonic,B-Entity
jerks,I-Entity
",",O
which,O
resolved,O
on,O
withdrawal,O
of,O
carbamazepine,I-Entity
.,O
Absences,O
were,O
aggravated,O
in,O
both,O
cases,O
where,O
vigabatrin,I-Entity
was,O
added,O
on,O
to,O
concurrent,O
treatment,O
.,O
Optimal,O
control,O
of,O
the,O
absences,O
was,O
achieved,O
with,O
sodium,B-Entity
valproate,I-Entity
",",O
lamotrigine,I-Entity
",",O
or,O
ethosuximide,I-Entity
alone,O
or,O
in,O
combination,O
.,O
Hemolytic,B-Entity
anemia,I-Entity
associated,O
with,O
the,O
use,O
of,O
omeprazole,I-Entity
.,O
Omeprazole,I-Entity
is,O
the,O
first,O
drug,O
designed,O
to,O
block,O
the,O
final,O
step,O
in,O
the,O
acid,O
secretory,O
process,O
within,O
the,O
parietal,O
cell,O
.,O
It,O
has,O
been,O
shown,O
to,O
be,O
extremely,O
effective,O
in,O
the,O
treatment,O
of,O
peptic,B-Entity
ulcer,I-Entity
disease,I-Entity
",",O
reflux,B-Entity
esophagitis,I-Entity
",",O
and,O
the,O
Zollinger,B-Entity
-,I-Entity
Ellison,I-Entity
syndrome,I-Entity
.,O
Although,O
clinical,O
experience,O
with,O
omeprazole,I-Entity
is,O
still,O
limited,O
",",O
many,O
controlled,O
studies,O
have,O
established,O
the,O
short,O
-,O
term,O
safety,O
of,O
this,O
drug,O
.,O
We,O
report,O
the,O
first,O
case,O
of,O
a,O
serious,O
short,O
-,O
term,O
adverse,O
reaction,O
with,O
the,O
use,O
of,O
omeprazole,I-Entity
:,O
hemolytic,B-Entity
anemia,I-Entity
.,O
The,O
patient,O
developed,O
weakness,O
",",O
lethargy,I-Entity
",",O
and,O
shortness,B-Entity
of,I-Entity
breath,I-Entity
2,O
days,O
after,O
starting,O
therapy,O
with,O
omeprazole,I-Entity
.,O
Two,O
weeks,O
after,O
the,O
initiation,O
of,O
therapy,O
",",O
her,O
hematocrit,O
had,O
decreased,O
from,O
44.1%,O
to,O
20.4%,O
",",O
and,O
she,O
had,O
a,O
positive,O
direct,O
Coombs,O
antiglobulin,O
test,O
and,O
an,O
elevated,O
indirect,O
bilirubin,I-Entity
.,O
After,O
she,O
discontinued,O
the,O
omeprazole,I-Entity
",",O
her,O
hemoglobin,O
and,O
hematocrit,O
gradually,O
returned,O
to,O
normal,O
.,O
The,O
mechanism,O
by,O
which,O
omeprazole,I-Entity
caused,O
the,O
patient,O
's,O
hemolytic,B-Entity
anemia,I-Entity
is,O
uncertain,O
",",O
but,O
physicians,O
should,O
be,O
alerted,O
to,O
this,O
possible,O
adverse,O
effect,O
.,O
The,O
use,O
and,O
toxicity,I-Entity
of,O
didanosine,I-Entity
(,O
ddI,I-Entity
),O
in,O
HIV,B-Entity
antibody,I-Entity
-,I-Entity
positive,I-Entity
individuals,O
intolerant,O
to,O
zidovudine,I-Entity
(,O
AZT,I-Entity
),O
One,O
hundred,O
and,O
fifty,O
-,O
one,O
patients,O
intolerant,O
to,O
zidovudine,I-Entity
(,O
AZT,I-Entity
),O
received,O
didanosine,I-Entity
(,O
ddI,I-Entity
),O
to,O
a,O
maximum,O
dose,O
of,O
12.5,O
mg,O
/,O
kg,O
/,O
day,O
.,O
Seventy,O
patients,O
developed,O
major,O
opportunistic,B-Entity
infections,I-Entity
whilst,O
on,O
therapy,O
;,O
this,O
was,O
the,O
first,O
AIDS,I-Entity
diagnosis,O
in,O
17,O
.,O
+,O
lymphocyte,O
subset,O
count,O
were,O
observed,O
in,O
AIDS,I-Entity
patients,O
",",O
although,O
a,O
more,O
significant,O
rise,O
occurred,O
in,O
those,O
with,O
earlier,O
stages,O
of,O
disease,O
.,O
Adverse,O
reactions,O
possibly,O
attributable,O
to,O
didanosine,I-Entity
were,O
common,O
.,O
The,O
most,O
common,O
side,O
-,O
effect,O
was,O
diarrhoea,I-Entity
",",O
which,O
resulted,O
in,O
cessation,O
of,O
therapy,O
in,O
19,O
individuals,O
.,O
Peripheral,B-Entity
neuropathy,I-Entity
occurred,O
in,O
12,O
patients,O
and,O
pancreatitis,I-Entity
in,O
six,O
.,O
Thirteen,O
patients,O
developed,O
a,O
raised,O
serum,O
amylase,O
without,O
abdominal,B-Entity
pain,I-Entity
.,O
Seven,O
patients,O
developed,O
glucose,B-Entity
tolerance,I-Entity
curves,I-Entity
characteristic,O
of,O
diabetes,I-Entity
but,O
these,O
were,O
mild,O
",",O
did,O
not,O
require,O
treatment,O
and,O
returned,O
to,O
normal,O
on,O
ceasing,O
didanosine,I-Entity
.,O
Can,O
angiogenesis,O
be,O
a,O
target,O
of,O
treatment,O
for,O
ribavirin,I-Entity
associated,O
hemolytic,B-Entity
anemia,I-Entity
?,O
Recently,O
ribavirin,I-Entity
has,O
been,O
found,O
to,O
inhibit,O
angiogenesis,O
and,O
a,O
number,O
of,O
angiogenesis,O
inhibitors,O
such,O
as,O
sunitinib,I-Entity
and,O
sorafenib,I-Entity
have,O
been,O
found,O
to,O
cause,O
acute,O
hemolysis,I-Entity
.,O
We,O
aimed,O
to,O
investigate,O
whether,O
there,O
is,O
a,O
relation,O
between,O
hemoglobin,O
",",O
haptoglobin,O
and,O
angiogenesis,O
soluble,O
markers,O
which,O
are,O
modifiable,O
and,O
can,O
help,O
in,O
developing,O
strategies,O
against,O
anemia,I-Entity
.,O
METHODS,O
:,O
Fourteen,O
patients,O
chronically,B-Entity
infected,I-Entity
with,I-Entity
hepatitis,I-Entity
C,I-Entity
virus,I-Entity
were,O
treated,O
by,O
pegylated,B-Entity
interferon,I-Entity
alpha,I-Entity
2a,I-Entity
and,O
ribavirin,I-Entity
.,O
In,O
contrast,O
with,O
the,O
literature,O
",",O
serum,O
levels,O
of,O
angiogenesis,O
factors,O
did,O
not,O
change,O
significantly,O
by,O
pegylated,B-Entity
interferon,I-Entity
and,O
ribavirin,I-Entity
therapy,O
.,O
This,O
is,O
the,O
first,O
study,O
in,O
the,O
literature,O
investigating,O
a,O
link,O
between,O
angiogenesis,O
soluble,O
markers,O
and,O
ribavirin,I-Entity
induced,O
anemia,I-Entity
in,O
patients,O
with,O
hepatitis,B-Entity
C,I-Entity
and,O
we,O
could,O
not,O
find,O
any,O
relation,O
.,O
Future,O
research,O
with,O
larger,O
number,O
of,O
patients,O
is,O
needed,O
to,O
find,O
out,O
modifiable,O
factors,O
that,O
will,O
improve,O
the,O
safety,O
of,O
ribavirin,I-Entity
therapy,O
.,O
Cocaine,I-Entity
causes,O
memory,B-Entity
and,I-Entity
learning,I-Entity
impairments,I-Entity
in,O
rats,O
:,O
involvement,O
of,O
nuclear,O
factor,O
kappa,O
B,O
and,O
oxidative,O
stress,O
",",O
and,O
prevention,O
by,O
topiramate,I-Entity
.,O
Different,O
mechanisms,O
have,O
been,O
suggested,O
for,O
cocaine,I-Entity
toxicity,I-Entity
including,O
an,O
increase,O
in,O
oxidative,O
stress,O
but,O
the,O
association,O
between,O
oxidative,O
status,O
in,O
the,O
brain,O
and,O
cocaine,I-Entity
induced,O
-,O
behaviour,O
is,O
poorly,O
understood,O
.,O
Nuclear,O
factor,O
kappa,O
B,O
(,O
NFkappaB,O
),O
is,O
a,O
sensor,O
of,O
oxidative,O
stress,O
and,O
participates,O
in,O
memory,O
formation,O
that,O
could,O
be,O
involved,O
in,O
drug,O
toxicity,I-Entity
and,O
addiction,O
mechanisms,O
.,O
Therefore,O
NFkappaB,O
activity,O
",",O
oxidative,O
stress,O
",",O
neuronal,O
nitric,B-Entity
oxide,I-Entity
synthase,O
(,O
nNOS,O
),O
activity,O
",",O
spatial,O
learning,O
and,O
memory,O
as,O
well,O
as,O
the,O
effect,O
of,O
topiramate,I-Entity
",",O
a,O
previously,O
proposed,O
therapy,O
for,O
cocaine,B-Entity
addiction,I-Entity
",",O
were,O
evaluated,O
in,O
an,O
experimental,O
model,O
of,O
cocaine,I-Entity
administration,O
in,O
rats,O
.,O
NFkappaB,O
activity,O
was,O
decreased,O
in,O
the,O
frontal,O
cortex,O
of,O
cocaine,I-Entity
treated,O
rats,O
",",O
as,O
well,O
as,O
GSH,I-Entity
concentration,O
and,O
glutathione,I-Entity
peroxidase,O
activity,O
in,O
the,O
hippocampus,O
",",O
whereas,O
nNOS,O
activity,O
in,O
the,O
hippocampus,O
was,O
increased,O
.,O
Memory,O
retrieval,O
of,O
experiences,O
acquired,O
prior,O
to,O
cocaine,I-Entity
administration,O
was,O
impaired,O
and,O
negatively,O
correlated,O
with,O
NFkappaB,O
activity,O
in,O
the,O
frontal,O
cortex,O
.,O
In,O
contrast,O
",",O
learning,O
of,O
new,O
tasks,O
was,O
enhanced,O
and,O
correlated,O
with,O
the,O
increase,O
of,O
nNOS,O
activity,O
and,O
the,O
decrease,O
of,O
glutathione,I-Entity
peroxidase,O
.,O
These,O
results,O
provide,O
evidence,O
for,O
a,O
possible,O
mechanistic,O
role,O
of,O
oxidative,O
and,O
nitrosative,O
stress,O
and,O
NFkappaB,O
in,O
the,O
alterations,O
induced,O
by,O
cocaine,I-Entity
.,O
Topiramate,I-Entity
prevented,O
all,O
the,O
alterations,O
observed,O
",",O
showing,O
novel,O
neuroprotective,O
properties,O
.,O
Antinociceptive,O
and,O
antiamnesic,O
properties,O
of,O
the,O
presynaptic,O
cholinergic,O
amplifier,O
PG-9,I-Entity
.,O
The,O
antinociceptive,O
effect,O
of,O
3,B-Entity
alpha,I-Entity
-,I-Entity
tropyl,I-Entity
2-(p,I-Entity
-,I-Entity
bromophenyl)propionate,I-Entity
[,O
(,O
+,O
/-)-PG-9,I-Entity
],O
(,O
10,O
-,O
40,O
mg,O
kg-1,O
s.c,O
.,O
(,O
+,O
/-)-PG-9,I-Entity
antinociception,O
peaked,O
15,O
min,O
after,O
injection,O
and,O
then,O
slowly,O
diminished,O
.,O
The,O
antinociception,O
produced,O
by,O
(,O
+,O
/-)-PG-9,I-Entity
was,O
prevented,O
by,O
the,O
unselective,O
muscarinic,O
antagonist,O
atropine,I-Entity
",",O
the,O
M1-selective,O
antagonists,O
pirenzepine,I-Entity
and,O
dicyclomine,I-Entity
and,O
the,O
acetylcholine,I-Entity
depletor,O
hemicholinium-3,I-Entity
",",O
but,O
not,O
by,O
the,O
opioid,O
antagonist,O
naloxone,I-Entity
",",O
the,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acidB,I-Entity
antagonist,O
3-aminopropyl,B-Entity
-,I-Entity
diethoxy,I-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
phosphinic,I-Entity
acid,I-Entity
",",O
the,O
H3,O
agonist,O
R-(alpha)-methylhistamine,I-Entity
",",O
the,O
D2,O
antagonist,O
quinpirole,I-Entity
",",O
the,O
5-hydroxytryptamine4,I-Entity
antagonist,O
2-methoxy-4-amino-5-chlorobenzoic,B-Entity
acid,I-Entity
2-(diethylamino)ethyl,I-Entity
ester,I-Entity
hydrochloride,O
",",O
the,O
5-hydroxytryptamin1A,I-Entity
antagonist,O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine,I-Entity
hydrobromide,O
and,O
the,O
polyamines,O
depletor,O
reserpine,I-Entity
.,O
Based,O
on,O
these,O
data,O
",",O
it,O
can,O
be,O
postulated,O
that,O
(,O
+,O
/-)-PG-9,I-Entity
exerted,O
an,O
antinociceptive,O
effect,O
mediated,O
by,O
a,O
central,O
potentiation,O
of,O
cholinergic,O
transmission,O
.,O
(,O
+,O
/-)-PG-9,I-Entity
(,O
10,O
-,O
40,O
mg,O
kg-1,O
i.p,O
.,O
),O
was,O
able,O
to,O
prevent,O
amnesia,I-Entity
induced,O
by,O
scopolamine,I-Entity
(,O
1,O
mg,O
kg-1,O
i.p,O
.,O
),O
and,O
dicyclomine,I-Entity
(,O
2,O
mg,O
kg-1,O
i.p,O
.,O
),O
in,O
the,O
mouse,O
passive,O
-,O
avoidance,O
test,O
.,O
Affinity,O
profiles,O
of,O
(,O
+,O
/-)-PG-9,I-Entity
for,O
muscarinic,O
receptor,O
subtypes,O
",",O
determined,O
by,O
functional,O
studies,O
(,O
rabbit,O
vas,O
deferens,O
for,O
M1,O
",",O
guinea,O
pig,O
atrium,O
for,O
M2,O
",",O
",",O
have,O
shown,O
an,O
M4/M1,O
selectivity,O
ratio,O
of,O
10.2,O
that,O
might,O
be,O
responsible,O
for,O
the,O
antinociception,O
and,O
the,O
anti,O
-,O
amnesic,I-Entity
effect,O
induced,O
by,O
(,O
+,O
/-)-PG-9,I-Entity
through,O
an,O
increase,O
in,O
acetylcholine,I-Entity
extracellular,O
levels,O
.,O
In,O
the,O
antinociceptive,O
and,O
antiamnesic,O
dose,O
range,O
",",O
(,O
+,O
/-)-PG-9,I-Entity
did,O
not,O
impair,O
mouse,O
performance,O
evaluated,O
by,O
the,O
rota,O
-,O
rod,O
test,O
and,O
Animex,O
apparatus,O
.,O
Hyperbaric,O
oxygen,I-Entity
therapy,O
for,O
control,O
of,O
intractable,O
cyclophosphamide,I-Entity
-,O
induced,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
intractable,O
hemorrhagic,B-Entity
cystitis,I-Entity
due,O
to,O
cyclophosphamide,I-Entity
therapy,O
for,O
Wegener,B-Entity
's,I-Entity
granulomatosis,I-Entity
.,O
Conservative,O
treatment,O
",",O
including,O
bladder,O
irrigation,O
with,O
physiological,O
saline,O
and,O
instillation,O
of,O
prostaglandin,B-Entity
F2,I-Entity
alpha,I-Entity
",",O
failed,O
to,O
totally,O
control,O
hemorrhage,I-Entity
.,O
We,O
then,O
used,O
hyperbaric,O
oxygen,I-Entity
at,O
an,O
absolute,O
pressure,O
of,O
2,O
atm,O
",",O
5,O
days,O
a,O
week,O
for,O
8,O
consecutive,O
weeks,O
.,O
The,O
bleeding,I-Entity
ceased,O
completely,O
by,O
the,O
end,O
of,O
treatment,O
and,O
the,O
patient,O
remained,O
free,O
of,O
hematuria,I-Entity
thereafter,O
.,O
In,O
future,O
",",O
this,O
form,O
of,O
therapy,O
can,O
offer,O
a,O
safe,O
alternative,O
in,O
the,O
treatment,O
of,O
cyclophosphamide,I-Entity
-,O
induced,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
The,O
results,O
have,O
shown,O
that,O
the,O
degradation,O
product,O
p,B-Entity
-,I-Entity
choloroaniline,I-Entity
is,O
not,O
a,O
significant,O
factor,O
in,O
chlorhexidine,B-Entity
-,I-Entity
digluconate,I-Entity
associated,O
erosive,O
cystitis,I-Entity
.,O
A,O
high,O
percentage,O
of,O
kanamycin,I-Entity
-,O
colistin,I-Entity
and,O
povidone,B-Entity
-,I-Entity
iodine,I-Entity
irrigations,O
were,O
associated,O
with,O
erosive,O
cystitis,I-Entity
and,O
suggested,O
a,O
possible,O
complication,O
with,O
human,O
usage,O
.,O
Picloxydine,I-Entity
irrigations,O
appeared,O
to,O
have,O
a,O
lower,O
incidence,O
of,O
erosive,O
cystitis,I-Entity
but,O
further,O
studies,O
would,O
have,O
to,O
be,O
performed,O
before,O
it,O
could,O
be,O
recommended,O
for,O
use,O
in,O
urological,O
procedures,O
.,O
A,O
total,O
of,O
sixty,O
patients,O
were,O
trated,O
with,O
bromperidol,I-Entity
first,O
in,O
open,O
conditions,O
(,O
20,O
patients,O
),O
",",O
then,O
on,O
a,O
double,O
blind,O
basis,O
(,O
40,O
patients,O
),O
with,O
haloperidol,I-Entity
as,O
the,O
reference,O
substance,O
.,O
Nine,O
patients,O
exhibited,O
mild,O
to,O
moderate,O
extrapyramidal,B-Entity
concomitant,I-Entity
symptoms,I-Entity
;,O
no,O
other,O
side,O
effects,O
were,O
observed,O
.,O
In,O
the,O
double,O
blind,O
study,O
with,O
haloperidol,I-Entity
",",O
both,O
substances,O
were,O
found,O
to,O
be,O
highly,O
effective,O
in,O
the,O
treatment,O
of,O
psychotic,B-Entity
syndromes,I-Entity
belonging,I-Entity
predominantly,I-Entity
to,I-Entity
the,I-Entity
schizophrenia,I-Entity
group,I-Entity
.,O
Certain,O
clues,O
",",O
including,O
the,O
onset,O
of,O
action,O
",",O
seem,O
to,O
be,O
indicative,O
of,O
the,O
superiority,O
of,O
bromperidol,I-Entity
.,O
Curcumin,I-Entity
ameliorates,O
cognitive,B-Entity
dysfunction,I-Entity
and,O
oxidative,O
damage,O
in,O
phenobarbitone,I-Entity
and,O
carbamazepine,I-Entity
administered,O
rats,O
.,O
The,O
antiepileptic,O
drugs,O
",",O
phenobarbitone,I-Entity
and,O
carbamazepine,I-Entity
are,O
well,O
known,O
to,O
cause,O
cognitive,B-Entity
impairment,I-Entity
on,O
chronic,O
use,O
.,O
The,O
increase,O
in,O
free,O
radical,O
generation,O
has,O
been,O
implicated,O
as,O
one,O
of,O
the,O
important,O
mechanisms,O
of,O
cognitive,B-Entity
impairment,I-Entity
by,O
antiepileptic,O
drugs,O
.,O
Curcumin,I-Entity
has,O
shown,O
antioxidant,O
",",O
anti,O
-,O
inflammatory,O
and,O
neuro,O
-,O
protective,O
properties,O
.,O
Therefore,O
",",O
the,O
present,O
study,O
was,O
carried,O
out,O
to,O
investigate,O
the,O
effect,O
of,O
chronic,O
curcumin,I-Entity
administration,O
on,O
phenobarbitone-,I-Entity
and,O
carbamazepine,I-Entity
-,O
induced,O
cognitive,B-Entity
impairment,I-Entity
and,O
oxidative,O
stress,O
in,O
rats,O
.,O
Pharmacokinetic,O
interactions,O
of,O
curcumin,I-Entity
with,O
phenobarbitone,I-Entity
and,O
carbamazepine,I-Entity
were,O
also,O
studied,O
.,O
At,O
the,O
end,O
of,O
study,O
period,O
",",O
serum,O
phenobarbitone,I-Entity
and,O
carbamazepine,I-Entity
",",O
whole,O
brain,O
malondialdehyde,I-Entity
and,O
reduced,O
glutathione,I-Entity
levels,O
were,O
estimated,O
.,O
The,O
administration,O
of,O
phenobarbitone,I-Entity
and,O
carbamazepine,I-Entity
for,O
21days,O
caused,O
a,O
significant,O
impairment,B-Entity
of,I-Entity
learning,I-Entity
and,I-Entity
memory,I-Entity
as,O
well,O
as,O
an,O
increased,O
oxidative,O
stress,O
.,O
Concomitant,O
curcumin,I-Entity
administration,O
prevented,O
the,O
cognitive,B-Entity
impairment,I-Entity
and,O
decreased,O
the,O
increased,O
oxidative,O
stress,O
induced,O
by,O
these,O
antiepileptic,O
drugs,O
.,O
Curcumin,I-Entity
co,O
-,O
administration,O
did,O
not,O
cause,O
any,O
significant,O
alteration,O
in,O
the,O
serum,O
concentrations,O
of,O
both,O
phenobarbitone,I-Entity
as,O
well,O
as,O
carbamazepine,I-Entity
.,O
These,O
results,O
show,O
that,O
curcumin,I-Entity
has,O
beneficial,O
effect,O
in,O
mitigating,O
the,O
deterioration,B-Entity
of,I-Entity
cognitive,I-Entity
functions,I-Entity
and,O
oxidative,O
damage,O
in,O
rats,O
treated,O
with,O
phenobarbitone,I-Entity
and,O
carbamazepine,I-Entity
without,O
significantly,O
altering,O
their,O
serum,O
concentrations,O
.,O
The,O
findings,O
suggest,O
that,O
curcumin,I-Entity
can,O
be,O
considered,O
as,O
a,O
potential,O
safe,O
and,O
effective,O
adjuvant,O
to,O
phenobarbitone,I-Entity
and,O
carbamazepine,I-Entity
therapy,O
in,O
preventing,O
cognitive,B-Entity
impairment,I-Entity
associated,O
with,O
these,O
drugs,O
.,O
Pyrrolidine,B-Entity
dithiocarbamate,I-Entity
protects,O
the,O
piriform,O
cortex,O
in,O
the,O
pilocarpine,I-Entity
status,B-Entity
epilepticus,I-Entity
model,O
.,O
Pyrrolidine,B-Entity
dithiocarbamate,I-Entity
(,O
PDTC,I-Entity
),O
has,O
a,O
dual,O
mechanism,O
of,O
action,O
as,O
an,O
antioxidant,O
and,O
an,O
inhibitor,O
of,O
the,O
transcription,O
factor,O
kappa,O
-,O
beta,O
.,O
Both,O
",",O
production,O
of,O
reactive,O
oxygen,I-Entity
species,O
as,O
well,O
as,O
activation,O
of,O
NF,O
-,O
kappaB,O
have,O
been,O
implicated,O
in,O
severe,O
neuronal,B-Entity
damage,I-Entity
in,O
different,O
sub,O
-,O
regions,O
of,O
the,O
hippocampus,O
as,O
well,O
as,O
in,O
the,O
surrounding,O
cortices,O
.,O
The,O
effect,O
of,O
PDTC,I-Entity
on,O
status,B-Entity
epilepticus,I-Entity
-,O
associated,O
cell,O
loss,O
in,O
the,O
hippocampus,O
and,O
piriform,O
cortex,O
was,O
evaluated,O
in,O
the,O
rat,O
fractionated,O
pilocarpine,I-Entity
model,O
.,O
PDTC,I-Entity
before,O
and,O
following,O
status,B-Entity
epilepticus,I-Entity
significantly,O
increased,O
the,O
mortality,O
rate,O
to,O
100%,O
.,O
Administration,O
of,O
50,O
mg,O
/,O
kg,O
PDTC,I-Entity
(,O
low,O
-,O
dose,O
),O
did,O
not,O
exert,O
major,O
effects,O
on,O
the,O
development,O
of,O
a,O
status,B-Entity
epilepticus,I-Entity
or,O
the,O
mortality,O
rate,O
.,O
In,O
vehicle,O
-,O
treated,O
rats,O
",",O
status,B-Entity
epilepticus,I-Entity
caused,O
pronounced,O
neuronal,B-Entity
damage,I-Entity
in,O
the,O
piriform,O
cortex,O
comprising,O
both,O
pyramidal,O
cells,O
and,O
interneurons,O
.,O
Low,O
-,O
dose,O
PDTC,I-Entity
treatment,O
almost,O
completely,O
protected,O
from,O
lesions,O
in,O
the,O
piriform,O
cortex,O
.,O
A,O
significant,O
decrease,O
in,O
neuronal,O
density,O
of,O
the,O
hippocampal,O
hilar,O
formation,O
was,O
identified,O
in,O
vehicle-,O
and,O
PDTC,I-Entity
-,O
treated,O
rats,O
following,O
status,B-Entity
epilepticus,I-Entity
.,O
In,O
conclusion,O
",",O
the,O
NF,O
-,O
kappaB,O
inhibitor,O
and,O
antioxidant,O
PDTC,I-Entity
protected,O
the,O
piriform,O
cortex,O
",",O
whereas,O
it,O
did,O
not,O
affect,O
hilar,O
neuronal,B-Entity
loss,I-Entity
.,O
These,O
data,O
might,O
indicate,O
that,O
the,O
generation,O
of,O
reactive,O
oxygen,I-Entity
species,O
and,O
activation,O
of,O
NF,O
-,O
kappaB,O
plays,O
a,O
more,O
central,O
role,O
in,O
seizure,I-Entity
-,O
associated,O
neuronal,B-Entity
damage,I-Entity
in,O
the,O
temporal,O
cortex,O
as,O
compared,O
to,O
the,O
hippocampal,O
hilus,O
.,O
However,O
",",O
future,O
investigations,O
are,O
necessary,O
to,O
exactly,O
analyze,O
the,O
biochemical,O
mechanisms,O
by,O
which,O
PDTC,I-Entity
exerted,O
its,O
beneficial,O
effects,O
in,O
the,O
piriform,O
cortex,O
.,O
Safety,O
profile,O
of,O
a,O
nicotine,I-Entity
lozenge,O
compared,O
with,O
that,O
of,O
nicotine,I-Entity
gum,O
in,O
adult,O
smokers,O
with,O
underlying,O
medical,O
conditions,O
:,O
a,O
12-week,O
",",O
randomized,O
",",O
open,O
-,O
label,O
study,O
.,O
Nicotine,I-Entity
polacrilex,O
lozenges,O
deliver,O
25%,O
to,O
27%,O
more,O
nicotine,I-Entity
compared,O
with,O
equivalent,O
doses,O
of,O
nicotine,I-Entity
polacrilex,O
gum,O
.,O
The,O
increased,O
nicotine,I-Entity
exposure,O
from,O
the,O
lozenge,O
has,O
raised,O
questions,O
about,O
the,O
relative,O
safety,O
of,O
the,O
lozenge,O
and,O
gum,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
compare,O
the,O
safety,O
profiles,O
of,O
the,O
4-mg,O
nicotine,I-Entity
lozenge,O
and,O
4-mg,O
nicotine,I-Entity
gum,O
in,O
smokers,O
with,O
selected,O
label,O
-,O
restricted,O
diseases,O
.,O
This,O
was,O
a,O
multicenter,O
",",O
randomized,O
",",O
open,O
-,O
label,O
study,O
in,O
adult,O
smokers,O
with,O
heart,B-Entity
disease,I-Entity
",",O
hypertension,I-Entity
not,O
controlled,O
by,O
medication,O
",",O
and/or,O
diabetes,B-Entity
mellitus,I-Entity
.,O
Patients,O
were,O
randomized,O
in,O
a,O
1:1,O
ratio,O
to,O
receive,O
the,O
4-mg,O
nicotine,I-Entity
lozenge,O
or,O
4-mg,O
nicotine,I-Entity
gum,O
.,O
The,O
nicotine,I-Entity
lozenge,O
and,O
nicotine,I-Entity
gum,O
were,O
equally,O
well,O
tolerated,O
",",O
despite,O
increased,O
nicotine,I-Entity
exposure,O
from,O
the,O
lozenge,O
.,O
The,O
most,O
common,O
adverse,O
events,O
were,O
nausea,I-Entity
(,O
17.2%,O
and,O
16.1%,O
;,O
95%,O
CI,O
",",O
-3.7,O
to,O
6.0,O
),O
",",O
hiccups,I-Entity
(,O
10.7%,O
and,O
6.6%,O
;,O
95%,O
CI,O
",",O
0.5,O
to,O
7.8,O
),O
",",O
and,O
headache,I-Entity
(,O
8.7%,O
and,O
9.9%,O
;,O
95%,O
Cl,O
",",O
-5.0,O
to,O
2.6,O
),O
.,O
The,O
4-mg,O
nicotine,I-Entity
lozenge,O
and,O
4-mg,O
nicotine,I-Entity
gum,O
had,O
comparable,O
safety,O
profiles,O
in,O
these,O
patients,O
with,O
label,O
-,O
restricted,O
medical,O
conditions,O
.,O
Development,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
in,O
parkinsonian,I-Entity
monkeys,O
may,O
depend,O
upon,O
rate,O
of,O
symptom,O
onset,O
and/or,O
duration,O
of,O
symptoms,O
.,O
Levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
(,O
LIDs,I-Entity
),O
present,O
a,O
major,O
problem,O
for,O
the,O
long,O
-,O
term,O
management,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
patients,O
.,O
Due,O
to,O
the,O
interdependence,O
of,O
risk,O
factors,O
in,O
clinical,O
populations,O
",",O
it,O
is,O
difficult,O
to,O
independently,O
examine,O
factors,O
that,O
may,O
influence,O
the,O
development,O
of,O
LIDs,I-Entity
.,O
Using,O
macaque,O
monkeys,O
with,O
different,O
types,O
of,O
MPTP,I-Entity
-,O
induced,O
parkinsonism,I-Entity
",",O
the,O
current,O
study,O
evaluated,O
the,O
degree,O
to,O
which,O
rate,O
of,O
symptom,O
progression,O
",",O
symptom,O
severity,O
",",O
and,O
response,O
to,O
and,O
duration,O
of,O
levodopa,I-Entity
therapy,O
may,O
be,O
involved,O
in,O
the,O
development,O
of,O
LIDs,I-Entity
.,O
MPTP,I-Entity
exposure,O
",",O
rapid,O
symptom,O
onset,O
and,O
short,O
symptom,O
duration,O
prior,O
to,O
initiation,O
of,O
levodopa,I-Entity
therapy,O
developed,O
dyskinesia,I-Entity
between,O
11,O
and,O
24,O
days,O
of,O
daily,O
levodopa,I-Entity
administration,O
.,O
In,O
contrast,O
",",O
monkeys,O
with,O
long,O
-,O
term,O
MPTP,I-Entity
exposure,O
",",O
slow,O
symptom,O
progression,O
and/or,O
long,O
symptom,O
duration,O
prior,O
to,O
initiation,O
of,O
levodopa,I-Entity
therapy,O
were,O
more,O
resistant,O
to,O
developing,O
LIDs,I-Entity
(,O
e.g.,O
",",O
dyskinesia,I-Entity
developed,O
no,O
sooner,O
than,O
146,O
days,O
of,O
chronic,O
levodopa,I-Entity
administration,O
),O
.,O
All,O
animals,O
were,O
similarly,O
symptomatic,O
at,O
the,O
start,O
of,O
levodopa,I-Entity
treatment,O
and,O
had,O
similar,O
therapeutic,O
responses,O
to,O
the,O
drug,O
.,O
These,O
data,O
suggest,O
distinct,O
differences,O
in,O
the,O
propensity,O
to,O
develop,O
LIDs,I-Entity
in,O
monkeys,O
with,O
different,O
rates,O
of,O
symptom,O
progression,O
or,O
symptom,O
durations,O
prior,O
to,O
levodopa,I-Entity
and,O
demonstrate,O
the,O
value,O
of,O
these,O
models,O
for,O
further,O
studying,O
the,O
pathophysiology,O
of,O
LIDs,I-Entity
.,O
Propylthiouracil,I-Entity
-,O
induced,O
perinuclear,O
-,O
staining,O
antineutrophil,O
cytoplasmic,O
autoantibody,O
-,O
positive,O
vasculitis,I-Entity
in,O
conjunction,O
with,O
pericarditis,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
describe,O
a,O
case,O
of,O
propylthiouracil,I-Entity
-,O
induced,O
vasculitis,I-Entity
manifesting,O
with,O
pericarditis,I-Entity
.,O
METHODS,O
:,O
We,O
present,O
the,O
first,O
case,O
report,O
of,O
a,O
woman,O
with,O
hyperthyroidism,I-Entity
treated,O
with,O
propylthiouracil,I-Entity
in,O
whom,O
a,O
syndrome,O
of,O
pericarditis,I-Entity
",",O
fever,I-Entity
",",O
and,O
glomerulonephritis,I-Entity
developed,O
.,O
A,O
25-year,O
-,O
old,O
woman,O
with,O
Graves,B-Entity
',I-Entity
disease,I-Entity
had,O
a,O
febrile,B-Entity
illness,I-Entity
and,O
evidence,O
of,O
pericarditis,I-Entity
",",O
which,O
was,O
confirmed,O
by,O
biopsy,O
.,O
Propylthiouracil,I-Entity
therapy,O
was,O
withdrawn,O
",",O
and,O
she,O
was,O
treated,O
with,O
a,O
1-month,O
course,O
of,O
prednisone,I-Entity
",",O
which,O
alleviated,O
her,O
symptoms,O
.,O
A,O
literature,O
review,O
revealed,O
no,O
prior,O
reports,O
of,O
pericarditis,I-Entity
in,O
anti,O
-,O
MPO,O
pANCA,O
-,O
positive,O
vasculitis,I-Entity
associated,O
with,O
propylthio-,B-Entity
uracil,I-Entity
therapy,O
.,O
Pericarditis,I-Entity
may,O
be,O
the,O
initial,O
manifestation,O
of,O
drug,O
-,O
induced,O
vasculitis,I-Entity
attributable,O
to,O
propylthio-,B-Entity
uracil,I-Entity
therapy,O
.,O
Two,O
mouse,O
lines,O
selected,O
for,O
differential,O
sensitivities,O
to,O
beta,B-Entity
-,I-Entity
carboline,I-Entity
-,O
induced,O
seizures,I-Entity
are,O
also,O
differentially,O
sensitive,O
to,O
various,O
pharmacological,O
effects,O
of,O
other,O
GABA(A,I-Entity
),O
Two,O
mouse,O
lines,O
were,O
selectively,O
bred,O
according,O
to,O
their,O
sensitivity,O
(,O
BS,O
line,O
),O
or,O
resistance,O
(,O
BR,O
line,O
),O
to,O
seizures,I-Entity
induced,O
by,O
a,O
single,O
i.p,O
.,O
injection,O
of,O
methyl,B-Entity
beta,I-Entity
-,I-Entity
carboline-3-carboxylate,I-Entity
(,O
beta,B-Entity
-,I-Entity
CCM,I-Entity
),O
",",O
an,O
inverse,O
agonist,O
of,O
the,O
GABA(A,I-Entity
),O
receptor,O
benzodiazepine,I-Entity
site,O
.,O
Our,O
aim,O
was,O
to,O
characterize,O
both,O
lines,O
',O
sensitivities,O
to,O
various,O
physiological,O
effects,O
of,O
other,O
ligands,O
of,O
the,O
GABA(A,I-Entity
),O
receptor,O
.,O
We,O
measured,O
diazepam,I-Entity
-,O
induced,O
anxiolysis,O
with,O
the,O
elevated,O
plus,O
-,O
maze,O
test,O
",",O
diazepam,I-Entity
-,O
induced,O
sedation,O
by,O
recording,O
the,O
vigilance,O
states,O
",",O
and,O
picrotoxin-,I-Entity
and,O
pentylenetetrazol,I-Entity
-,O
induced,O
seizures,I-Entity
after,O
i.p,O
.,O
Results,O
presented,O
here,O
show,O
that,O
the,O
differential,O
sensitivities,O
of,O
BS,O
and,O
BR,O
lines,O
to,O
beta,B-Entity
-,I-Entity
CCM,I-Entity
can,O
be,O
extended,O
to,O
diazepam,I-Entity
",",O
picrotoxin,I-Entity
",",O
and,O
pentylenetetrazol,I-Entity
",",O
suggesting,O
a,O
genetic,O
selection,O
of,O
a,O
general,O
sensitivity,O
and,O
resistance,O
to,O
several,O
ligands,O
of,O
the,O
GABA(A,I-Entity
),O
receptor,O
.,O
Analgesic,O
effect,O
of,O
intravenous,O
ketamine,I-Entity
in,O
cancer,I-Entity
patients,O
on,O
morphine,I-Entity
therapy,O
:,O
a,O
randomized,O
",",O
controlled,O
",",O
double,O
-,O
blind,O
",",O
crossover,O
",",O
double,O
-,O
dose,O
study,O
.,O
Pain,I-Entity
not,O
responsive,O
to,O
morphine,I-Entity
is,O
often,O
problematic,O
.,O
Animal,O
and,O
clinical,O
studies,O
have,O
suggested,O
that,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
antagonists,O
",",O
such,O
as,O
ketamine,I-Entity
",",O
may,O
be,O
effective,O
in,O
improving,O
opioid,O
analgesia,O
in,O
difficult,O
pain,I-Entity
syndromes,O
",",O
such,O
as,O
neuropathic,B-Entity
pain,I-Entity
.,O
A,O
slow,O
bolus,O
of,O
subhypnotic,O
doses,O
of,O
ketamine,I-Entity
(,O
0.25,O
mg,O
/,O
kg,O
or,O
0.50,O
mg,O
/,O
kg,O
),O
was,O
given,O
to,O
10,O
cancer,I-Entity
patients,O
whose,O
pain,I-Entity
was,O
unrelieved,O
by,O
morphine,I-Entity
in,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
crossover,O
",",O
double,O
-,O
dose,O
study,O
.,O
Pain,I-Entity
intensity,O
on,O
a,O
0,O
to,O
10,O
numerical,O
scale,O
;,O
nausea,I-Entity
and,O
vomiting,I-Entity
",",O
drowsiness,O
",",O
confusion,I-Entity
",",O
and,O
dry,B-Entity
mouth,I-Entity
",",O
using,O
a,O
scale,O
from,O
0,O
to,O
3,O
(,O
not,O
at,O
all,O
",",O
slight,O
",",O
a,O
lot,O
",",O
awful,O
),O
;,O
Mini,O
-,O
Mental,O
State,O
Examination,O
(,O
MMSE,O
),O
(,O
0,O
-,O
30,O
),O
;,O
and,O
arterial,O
pressure,O
were,O
recorded,O
before,O
administration,O
of,O
drugs,O
(,O
T0,O
),O
and,O
after,O
30,O
minutes,O
(,O
T30,O
),O
",",O
60,O
minutes,O
(,O
T60,O
),O
",",O
120,O
minutes,O
(,O
T120,O
),O
",",O
and,O
180,O
minutes,O
(,O
T180,O
),O
.,O
Ketamine,I-Entity
",",O
but,O
not,O
saline,O
solution,O
",",O
significantly,O
reduced,O
the,O
pain,I-Entity
intensity,O
in,O
almost,O
all,O
the,O
patients,O
at,O
both,O
doses,O
.,O
Hallucinations,I-Entity
occurred,O
in,O
4,O
patients,O
",",O
and,O
an,O
unpleasant,O
sensation,O
(,O
"""",O
empty,O
head,O
"""",O
),O
was,O
also,O
reported,O
by,O
2,O
patients,O
.,O
These,O
episodes,O
reversed,O
after,O
the,O
administration,O
of,O
diazepam,I-Entity
1,O
mg,O
intravenously,O
.,O
Significant,O
increases,O
in,O
drowsiness,O
were,O
reported,O
in,O
patients,O
treated,O
with,O
ketamine,I-Entity
in,O
both,O
groups,O
and,O
were,O
more,O
marked,O
with,O
ketamine,I-Entity
0.50,O
mg,O
/,O
kg,O
.,O
A,O
significant,O
difference,O
in,O
MMSE,O
was,O
observed,O
at,O
T30,O
in,O
patients,O
who,O
received,O
0.50,O
mg,O
/,O
kg,O
of,O
ketamine,I-Entity
.,O
Ketamine,I-Entity
can,O
improve,O
morphine,I-Entity
analgesia,O
in,O
difficult,O
pain,I-Entity
syndromes,O
",",O
such,O
as,O
neuropathic,B-Entity
pain,I-Entity
.,O
This,O
observation,O
should,O
be,O
tested,O
in,O
studies,O
of,O
prolonged,O
ketamine,I-Entity
administration,O
.,O
Endocrine,O
screening,O
in,O
"1,022",O
men,O
with,O
erectile,B-Entity
dysfunction,I-Entity
:,O
clinical,O
significance,O
and,O
cost,O
-,O
effective,O
strategy,O
.,O
We,O
reviewed,O
the,O
results,O
of,O
serum,O
testosterone,I-Entity
and,O
prolactin,O
determination,O
in,O
"1,022",O
patients,O
referred,O
because,O
of,O
erectile,B-Entity
dysfunction,I-Entity
and,O
compared,O
the,O
data,O
with,O
history,O
",",O
results,O
of,O
physical,O
examination,O
",",O
other,O
etiological,O
investigations,O
and,O
effects,O
of,O
endocrine,O
therapy,O
to,O
refine,O
the,O
rules,O
of,O
cost,O
-,O
effective,O
endocrine,O
screening,O
and,O
to,O
pinpoint,O
actual,O
responsibility,O
for,O
hormonal,O
abnormalities,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
Testosterone,I-Entity
and,O
prolactin,O
were,O
determined,O
by,O
radioimmunoassay,O
.,O
Every,O
patient,O
was,O
screened,O
for,O
testosterone,I-Entity
and,O
451,O
were,O
screened,O
for,O
prolactin,O
on,O
the,O
basis,O
of,O
low,B-Entity
sexual,I-Entity
desire,I-Entity
",",O
gynecomastia,I-Entity
or,O
testosterone,I-Entity
less,O
than,O
4,O
ng./ml,O
.,O
Prolactin,O
results,O
were,O
compared,O
with,O
those,O
of,O
a,O
previous,O
personal,O
cohort,O
of,O
"1,340",O
patients,O
with,O
erectile,B-Entity
dysfunction,I-Entity
and,O
systematic,O
prolactin,O
determination,O
.,O
Main,O
clinical,O
criteria,O
tested,O
regarding,O
efficiency,O
in,O
hormone,O
determination,O
were,O
low,B-Entity
sexual,I-Entity
desire,I-Entity
",",O
small,O
testes,O
and,O
gynecomastia,I-Entity
.,O
Endocrine,O
therapy,O
consisted,O
of,O
testosterone,B-Entity
heptylate,I-Entity
or,O
human,O
chorionic,O
gonadotropin,O
for,O
hypogonadism,I-Entity
and,O
bromocriptine,I-Entity
for,O
hyperprolactinemia,I-Entity
.,O
Testosterone,I-Entity
was,O
less,O
than,O
3,O
ng./ml,O
.,O
The,O
prevalence,O
of,O
repeatedly,O
low,O
testosterone,I-Entity
increased,O
with,O
age,O
(,O
4%,O
before,O
age,O
50,O
years,O
and,O
9%,O
50,O
years,O
or,O
older,O
),O
.,O
Two,O
pituitary,B-Entity
tumors,I-Entity
were,O
discovered,O
after,O
testosterone,I-Entity
determination,O
.,O
Most,O
of,O
the,O
other,O
low,O
testosterone,I-Entity
levels,O
seemed,O
to,O
result,O
from,O
nonorganic,O
hypothalamic,B-Entity
dysfunction,I-Entity
because,O
of,O
normal,O
serum,O
luteinizing,O
hormone,O
and,O
prolactin,O
and,O
to,O
have,O
only,O
a,O
small,O
role,O
in,O
erectile,B-Entity
dysfunction,I-Entity
(,O
definite,O
improvement,O
in,O
only,O
16,O
of,O
44,O
[,O
36%,O
],O
after,O
androgen,O
therapy,O
",",O
normal,O
morning,O
or,O
nocturnal,O
erections,O
in,O
30%,O
and,O
definite,O
vasculogenic,O
contributions,O
in,O
42%,O
),O
.,O
Determining,O
testosterone,I-Entity
only,O
in,O
cases,O
of,O
low,B-Entity
sexual,I-Entity
desire,I-Entity
or,O
abnormal,O
physical,O
examination,O
would,O
have,O
missed,O
40%,O
of,O
the,O
cases,O
with,O
low,O
testosterone,I-Entity
",",O
including,O
37%,O
of,O
those,O
subsequently,O
improved,O
by,O
androgen,O
therapy,O
.,O
Only,O
1,O
prolactinoma,I-Entity
was,O
discovered,O
.,O
in,O
1.86%,O
of,O
"1,821",O
patients,O
",",O
prolactinomas,I-Entity
in,O
7,O
",",O
0.38%,O
),O
.,O
Bromocriptine,I-Entity
was,O
definitely,O
effective,O
in,O
cases,O
with,O
prolactin,O
greater,O
than,O
35,O
ng./ml,O
.,O
Testosterone,I-Entity
was,O
low,O
in,O
less,O
than,O
50%,O
of,O
cases,O
with,O
prolactin,O
greater,O
than,O
35,O
ng./ml,O
.,O
Low,O
prevalences,O
and,O
effects,O
of,O
low,O
testosterone,I-Entity
and,O
high,O
prolactin,O
in,O
erectile,B-Entity
dysfunction,I-Entity
can,O
not,O
justify,O
their,O
routine,O
determination,O
.,O
However,O
",",O
cost,O
-,O
effective,O
screening,O
strategies,O
recommended,O
so,O
far,O
missed,O
40,O
to,O
50%,O
of,O
cases,O
improved,O
with,O
endocrine,O
therapy,O
and,O
the,O
pituitary,B-Entity
tumors,I-Entity
.,O
We,O
now,O
advocate,O
that,O
before,O
age,O
50,O
years,O
testosterone,I-Entity
be,O
determined,O
only,O
in,O
cases,O
of,O
low,B-Entity
sexual,I-Entity
desire,I-Entity
and,O
abnormal,O
physical,O
examination,O
but,O
that,O
it,O
be,O
measured,O
in,O
all,O
men,O
older,O
than,O
50,O
years,O
.,O
Prolactin,O
should,O
be,O
determined,O
only,O
in,O
cases,O
of,O
low,B-Entity
sexual,I-Entity
desire,I-Entity
",",O
gynecomastia,I-Entity
and/or,O
testosterone,I-Entity
less,O
than,O
4,O
ng./ml,O
.,O
Thiopentone,I-Entity
pretreatment,O
for,O
propofol,I-Entity
injection,O
pain,I-Entity
in,O
ambulatory,O
patients,O
.,O
This,O
study,O
investigated,O
propofol,I-Entity
injection,O
pain,I-Entity
in,O
patients,O
undergoing,O
ambulatory,O
anaesthesia,O
.,O
In,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
trial,O
",",O
90,O
women,O
were,O
allocated,O
to,O
receive,O
one,O
of,O
three,O
treatments,O
prior,O
to,O
induction,O
of,O
anaesthesia,O
with,O
propofol,I-Entity
.,O
Patients,O
in,O
Group,O
C,O
received,O
2,O
ml,O
normal,O
saline,O
",",O
Group,O
L,O
",",O
2,O
ml,O
",",O
lidocaine,I-Entity
2%,O
(,O
40,O
mg,O
),O
and,O
Group,O
T,O
",",O
2,O
ml,O
thiopentone,I-Entity
2.5%,O
(,O
50,O
mg,O
),O
.,O
Venous,O
discomfort,O
was,O
assessed,O
with,O
a,O
visual,O
analogue,O
scale,O
(,O
VAS,O
),O
5,O
-,O
15,O
sec,O
after,O
commencing,O
propofol,I-Entity
administration,O
using,O
an,O
infusion,O
pump,O
(,O
rate,O
1000,O
micrograms.kg-1.min-1,O
),O
.,O
Loss,B-Entity
of,I-Entity
consciousness,I-Entity
occurred,O
in,O
60,O
-,O
90,O
sec,O
.,O
The,O
VAS,O
scores,O
for,O
recall,O
of,O
pain,I-Entity
in,O
the,O
recovery,O
room,O
were,O
correlated,O
with,O
the,O
VAS,O
scores,O
during,O
induction,O
(,O
r,O
=,O
0.7045,O
;,O
P,O
<,O
0.0001,O
),O
.,O
Assessing,O
their,O
overall,O
satisfaction,O
",",O
89.7%,O
would,O
choose,O
propofol,I-Entity
anaesthesia,O
again,O
.,O
We,O
conclude,O
that,O
lidocaine,I-Entity
reduces,O
the,O
incidence,O
and,O
severity,O
of,O
propofol,I-Entity
injection,O
pain,I-Entity
in,O
ambulatory,O
patients,O
whereas,O
thiopentone,I-Entity
only,O
reduces,O
its,O
severity,O
.,O
glycopyrrolate,I-Entity
and,O
atropine,I-Entity
in,O
the,O
prevention,O
of,O
bradycardia,I-Entity
and,O
arrhythmias,I-Entity
following,O
repeated,O
doses,O
of,O
suxamethonium,I-Entity
in,O
children,O
.,O
The,O
effectiveness,O
of,O
administration,O
of,O
glycopyrrolate,I-Entity
5,O
and,O
10,O
micrograms,O
kg-1,O
and,O
atropine,I-Entity
10,O
and,O
20,O
micrograms,O
kg-1,O
immediately,O
before,O
the,O
induction,O
of,O
anaesthesia,O
",",O
to,O
prevent,O
arrhythmia,I-Entity
and,O
bradycardia,I-Entity
following,O
repeated,O
doses,O
of,O
suxamethonium,I-Entity
in,O
children,O
",",O
was,O
studied,O
.,O
A,O
control,O
group,O
was,O
included,O
for,O
comparison,O
with,O
the,O
lower,O
dose,O
range,O
of,O
glycopyrrolate,I-Entity
and,O
atropine,I-Entity
.,O
A,O
frequency,O
of,O
bradycardia,I-Entity
of,O
50%,O
was,O
noted,O
in,O
the,O
control,O
group,O
",",O
but,O
this,O
was,O
not,O
significantly,O
different,O
from,O
the,O
frequency,O
with,O
the,O
active,O
drugs,O
.,O
Bradycardia,I-Entity
(,O
defined,O
as,O
a,O
decrease,O
in,O
heart,O
rate,O
to,O
less,O
than,O
50,O
beat,O
min-1,O
),O
was,O
prevented,O
when,O
the,O
larger,O
dose,O
of,O
either,O
active,O
drug,O
was,O
used,O
.,O
It,O
is,O
recommended,O
that,O
either,O
glycopyrrolate,I-Entity
10,O
micrograms,O
kg-1,O
or,O
atropine,I-Entity
20,O
micrograms,O
kg-1,O
i.v,O
.,O
should,O
immediately,O
precede,O
induction,O
of,O
anaesthesia,O
",",O
in,O
children,O
",",O
if,O
the,O
repeated,O
administration,O
of,O
suxamethonium,I-Entity
is,O
anticipated,O
.,O
Reduction,O
in,O
caffeine,I-Entity
toxicity,I-Entity
by,O
acetaminophen,I-Entity
.,O
A,O
patient,O
who,O
allegedly,O
consumed,O
100,O
tablets,O
of,O
an,O
over,O
-,O
the,O
-,O
counter,O
analgesic,O
containing,O
sodium,B-Entity
acetylsalicylate,I-Entity
",",O
caffeine,I-Entity
",",O
and,O
acetaminophen,I-Entity
displayed,O
no,O
significant,O
CNS,O
stimulation,O
despite,O
the,O
presence,O
of,O
175,O
micrograms,O
of,O
caffeine,I-Entity
per,O
mL,O
of,O
serum,O
.,O
Because,O
salicylates,O
have,O
been,O
reported,O
to,O
augment,O
the,O
stimulatory,O
effects,O
of,O
caffeine,I-Entity
on,O
the,O
CNS,O
",",O
attention,O
was,O
focused,O
on,O
the,O
possibility,O
that,O
the,O
presence,O
of,O
acetaminophen,I-Entity
(,O
52,O
micrograms,O
/,O
mL,O
),O
reduced,O
the,O
CNS,O
toxicity,I-Entity
of,O
caffeine,I-Entity
.,O
Studies,O
in,O
DBA/2J,O
mice,O
showed,O
that,O
:,O
1,O
),O
pretreatment,O
with,O
acetaminophen,I-Entity
(,O
100,O
mg,O
/,O
kg,O
),O
increased,O
the,O
interval,O
between,O
the,O
administration,O
of,O
caffeine,I-Entity
(,O
300,O
to,O
450,O
mg,O
/,O
kg,O
IP,O
),O
and,O
the,O
onset,O
of,O
fatal,O
convulsions,I-Entity
by,O
a,O
factor,O
of,O
about,O
two,O
;,O
and,O
2,O
),O
pretreatment,O
with,O
acetaminophen,I-Entity
(,O
75,O
mg,O
/,O
kg,O
),O
reduced,O
the,O
incidence,O
of,O
audiogenic,O
seizures,I-Entity
produced,O
in,O
the,O
presence,O
of,O
caffeine,I-Entity
(,O
12.5,O
to,O
75,O
mg,O
/,O
kg,O
IP,O
),O
.,O
The,O
frequency,O
of,O
sound,O
-,O
induced,O
seizures,I-Entity
after,O
12.5,O
or,O
25,O
mg,O
/,O
kg,O
caffeine,I-Entity
was,O
reduced,O
from,O
50,O
to,O
5%,O
by,O
acetaminophen,I-Entity
.,O
In,O
the,O
absence,O
of,O
caffeine,I-Entity
",",O
acetaminophen,I-Entity
(,O
up,O
to,O
300,O
mg,O
/,O
kg,O
),O
did,O
not,O
modify,O
the,O
seizures,I-Entity
induced,O
by,O
maximal,O
electroshock,O
and,O
did,O
not,O
alter,O
the,O
convulsant,O
dose,O
of,O
pentylenetetrezol,I-Entity
in,O
mice,O
(,O
tests,O
performed,O
by,O
the,O
Anticonvulsant,O
Screening,O
Project,O
of,O
NINCDS,O
),O
.,O
Acetaminophen,I-Entity
(,O
up,O
to,O
150,O
micrograms,O
/,O
mL,O
),O
did,O
not,O
retard,O
the,O
incorporation,O
of,O
radioactive,O
adenosine,I-Entity
into,O
ATP,I-Entity
in,O
slices,O
of,O
rat,O
cerebral,O
cortex,O
.,O
Thus,O
the,O
mechanism,O
by,O
which,O
acetaminophen,I-Entity
antagonizes,O
the,O
actions,O
of,O
caffeine,I-Entity
in,O
the,O
CNS,O
remains,O
unknown,O
.,O
Flestolol,I-Entity
:,O
Flestolol,I-Entity
(,O
ACC-9089,I-Entity
),O
is,O
a,O
nonselective,O
",",O
competitive,O
",",O
ultra,O
-,O
short,O
-,O
acting,O
beta,O
-,O
adrenergic,O
blocking,O
agent,O
",",O
without,O
any,O
intrinsic,O
sympathomimetic,O
activity,O
.,O
Flestolol,I-Entity
is,O
metabolized,O
by,O
plasma,O
esterases,O
and,O
has,O
an,O
elimination,O
half,O
-,O
life,O
of,O
approximately,O
6.5,O
minutes,O
.,O
In,O
long,O
-,O
term,O
infusion,O
studies,O
",",O
flestolol,I-Entity
was,O
well,O
tolerated,O
at,O
the,O
effective,O
beta,O
-,O
blocking,O
dose,O
(,O
5,O
micrograms,O
/,O
kg,O
/,O
min,O
),O
for,O
up,O
to,O
seven,O
days,O
.,O
Flestolol,I-Entity
blood,O
concentrations,O
increased,O
linearly,O
with,O
increasing,O
dose,O
and,O
good,O
correlation,O
exists,O
between,O
blood,O
concentrations,O
of,O
flestolol,I-Entity
and,O
beta,O
-,O
adrenergic,O
blockade,O
.,O
Flestolol,I-Entity
produced,O
a,O
dose,O
-,O
dependent,O
attenuation,O
of,O
isoproterenol,I-Entity
-,O
induced,O
tachycardia,I-Entity
.,O
Electrophysiologic,O
and,O
hemodynamic,O
effects,O
of,O
flestolol,I-Entity
are,O
similar,O
to,O
those,O
of,O
other,O
beta,O
blockers,O
.,O
In,O
contrast,O
with,O
other,O
beta,O
blockers,O
",",O
flestolol,I-Entity
-,O
induced,O
effects,O
reverse,O
rapidly,O
(,O
within,O
30,O
minutes,O
),O
following,O
discontinuation,O
because,O
of,O
its,O
short,O
half,O
-,O
life,O
.,O
Flestolol,I-Entity
effectively,O
reduced,O
heart,O
rate,O
in,O
patients,O
with,O
supraventricular,B-Entity
tachyarrhythmia,I-Entity
.,O
In,O
patients,O
with,O
unstable,B-Entity
angina,I-Entity
",",O
flestolol,I-Entity
infusion,O
was,O
found,O
to,O
be,O
safe,O
and,O
effective,O
in,O
controlling,O
chest,B-Entity
pain,I-Entity
.,O
It,O
is,O
concluded,O
that,O
flestolol,I-Entity
is,O
a,O
potent,O
",",O
well,O
-,O
tolerated,O
",",O
ultra,O
-,O
short,O
-,O
acting,O
beta,O
-,O
adrenergic,O
blocking,O
agent,O
.,O
Use,O
of,O
flestolol,I-Entity
in,O
the,O
critical,O
care,O
setting,O
is,O
currently,O
undergoing,O
investigation,O
.,O
Adverse,O
effect,O
of,O
the,O
calcium,I-Entity
channel,O
blocker,O
nitrendipine,I-Entity
on,O
nephrosclerosis,I-Entity
in,O
rats,O
with,O
renovascular,B-Entity
hypertension,I-Entity
.,O
The,O
effect,O
of,O
a,O
6-week,O
treatment,O
with,O
the,O
calcium,I-Entity
channel,O
blocker,O
nitrendipine,I-Entity
or,O
the,O
angiotensin,I-Entity
converting,O
enzyme,O
inhibitor,O
enalapril,I-Entity
on,O
blood,O
pressure,O
",",O
albuminuria,I-Entity
",",O
renal,O
hemodynamics,O
",",O
and,O
morphology,O
of,O
the,O
nonclipped,O
kidney,O
was,O
studied,O
in,O
rats,O
with,O
two,O
-,O
kidney,O
",",O
one,O
clip,O
renovascular,B-Entity
hypertension,I-Entity
.,O
Six,O
weeks,O
after,O
clipping,O
of,O
one,O
renal,O
artery,O
",",O
hypertensive,I-Entity
rats,O
(,O
178,O
+,O
/-,O
4,O
mm,O
Hg,O
),O
were,O
randomly,O
assigned,O
to,O
three,O
groups,O
:,O
untreated,O
hypertensive,I-Entity
controls,O
(,O
n,O
=,O
8),O
",",O
enalapril,I-Entity
-,O
treated,O
(,O
n,O
=,O
8),O
",",O
or,O
nitrendipine,I-Entity
-,O
treated,O
(,O
Enalapril,I-Entity
but,O
not,O
nitrendipine,I-Entity
reduced,O
blood,O
pressure,O
significantly,O
.,O
Renal,O
plasma,O
flow,O
increased,O
",",O
but,O
albumin,O
excretion,O
and,O
glomerulosclerosis,I-Entity
did,O
not,O
change,O
after,O
enalapril,I-Entity
treatment,O
.,O
In,O
contrast,O
",",O
in,O
the,O
nitrendipine,I-Entity
-,O
treated,O
group,O
albuminuria,I-Entity
increased,O
from,O
12.8,O
+,O
/-,O
9,O
mg/24,O
hr,O
in,O
the,O
hypertensive,I-Entity
controls,O
.,O
Furthermore,O
",",O
glomerulosclerosis,I-Entity
index,O
was,O
significantly,O
increased,O
in,O
the,O
nitrendipine,I-Entity
-,O
treated,O
group,O
compared,O
with,O
the,O
hypertensive,I-Entity
controls,O
(,O
0.38,O
+,O
/-,O
In,O
addition,O
",",O
glomerular,O
size,O
was,O
higher,O
in,O
the,O
nitrendipine,I-Entity
-,O
treated,O
group,O
(,O
14.9,O
+,O
/-,O
0.17,O
10(-3,O
),O
mm2,O
),O
but,O
lower,O
in,O
the,O
enalapril,I-Entity
-,O
treated,O
group,O
(,O
11.5,O
+,O
/-,O
mm2,O
),O
compared,O
with,O
the,O
hypertensive,I-Entity
controls,O
(,O
12.1,O
+,O
/-,O
Treatment,O
of,O
tinnitus,I-Entity
by,O
intratympanic,O
instillation,O
of,O
lignocaine,I-Entity
(,O
lidocaine,I-Entity
),O
2,O
per,O
cent,O
through,O
ventilation,O
tubes,O
.,O
Idiopathic,B-Entity
subjective,I-Entity
tinnitus,I-Entity
(,O
IST,I-Entity
),O
is,O
one,O
of,O
the,O
most,O
obscure,O
otological,O
pathologies,O
.,O
This,O
paper,O
presents,O
the,O
results,O
of,O
treating,O
IST,I-Entity
by,O
intratympanic,O
instillation,O
of,O
lignocaine,I-Entity
(,O
lidocaine,I-Entity
),O
2,O
per,O
cent,O
through,O
a,O
grommet,O
",",O
for,O
five,O
weekly,O
courses,O
.,O
Fifty,O
-,O
two,O
patients,O
suffering,O
from,O
intractable,O
tinnitus,I-Entity
entered,O
this,O
therapeutic,O
trial,O
",",O
but,O
only,O
nine,O
finished,O
all,O
five,O
courses,O
.,O
In,O
one,O
patient,O
",",O
the,O
tinnitus,I-Entity
was,O
almost,O
completely,O
abolished,O
",",O
but,O
in,O
all,O
the,O
nine,O
patients,O
the,O
decompensated,O
tinnitus,I-Entity
changed,O
to,O
a,O
compensated,O
one,O
.,O
Patients,O
should,O
be,O
warned,O
about,O
the,O
side,O
effects,O
of,O
vertigo,I-Entity
and,O
vomiting,I-Entity
",",O
which,O
subsides,O
gradually,O
with,O
every,O
new,O
instillation,O
",",O
and,O
that,O
the,O
tinnitus,I-Entity
may,O
not,O
disappear,O
but,O
will,O
be,O
alleviated,O
",",O
enabling,O
them,O
to,O
cope,O
more,O
easily,O
with,O
the,O
disease,O
and,O
lead,O
a,O
more,O
normal,O
life,O
.,O
Perhexiline,B-Entity
maleate,I-Entity
and,O
peripheral,B-Entity
neuropathy,I-Entity
.,O
Peripheral,B-Entity
neuropathy,I-Entity
has,O
been,O
noted,O
as,O
a,O
complication,O
of,O
therapy,O
with,O
perhexiline,B-Entity
maleate,I-Entity
",",O
a,O
drug,O
widely,O
used,O
in,O
France,O
(,O
and,O
in,O
clinical,O
trials,O
in,O
the,O
United,O
States,O
),O
for,O
the,O
prophylactic,O
treatment,O
of,O
angina,B-Entity
pectoris,I-Entity
.,O
In,O
24,O
patients,O
with,O
this,O
complication,O
",",O
the,O
marked,O
slowing,O
of,O
motor,O
nerve,O
conduction,O
velocity,O
and,O
the,O
electromyographic,O
changes,O
imply,O
mainly,O
a,O
demyelinating,B-Entity
disorder,I-Entity
.,O
The,O
underlying,O
mechanism,O
causing,O
the,O
neuropathy,I-Entity
is,O
not,O
yet,O
fully,O
known,O
",",O
although,O
some,O
evidence,O
indicates,O
that,O
it,O
may,O
be,O
a,O
lipid,O
storage,O
process,O
.,O
Effect,O
of,O
humoral,O
modulators,O
of,O
morphine,I-Entity
-,O
induced,O
increase,B-Entity
in,I-Entity
locomotor,I-Entity
activity,I-Entity
of,O
mice,O
.,O
The,O
effect,O
of,O
humoral,O
modulators,O
on,O
the,O
morphine,I-Entity
-,O
induced,O
increase,B-Entity
in,I-Entity
locomotor,I-Entity
activity,I-Entity
of,O
mice,O
was,O
studied,O
.,O
The,O
subcutaneous,O
administration,O
of,O
10,O
mg,O
/,O
kg,O
of,O
morphine,I-Entity
-,O
HC1,O
produced,O
a,O
marked,O
increase,B-Entity
in,I-Entity
locomotor,I-Entity
activity,I-Entity
in,O
mice,O
.,O
The,O
morphine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
was,O
potentiated,O
by,O
scopolamine,I-Entity
and,O
attenuated,O
by,O
physostigmine,I-Entity
.,O
In,O
contrast,O
",",O
both,O
methscopolamine,I-Entity
and,O
neostigmine,I-Entity
",",O
which,O
do,O
not,O
penetrate,O
the,O
blood,O
-,O
brain,O
barrier,O
",",O
had,O
no,O
effect,O
on,O
the,O
hyperactivity,I-Entity
produced,O
by,O
morphine,I-Entity
.,O
Pretreatment,O
of,O
mice,O
with,O
alpha,B-Entity
-,I-Entity
methyltyrosine,I-Entity
(,O
20,O
mg,O
/,O
kg,O
i.p,O
.,O
",",O
one,O
hour,O
),O
",",O
an,O
inhibitor,O
of,O
tyrosine,I-Entity
hydroxylase,O
",",O
significantly,O
decreased,O
the,O
activity,O
-,O
increasing,O
effects,O
of,O
morphine,I-Entity
.,O
On,O
the,O
other,O
hand,O
",",O
pretreatment,O
with,O
p,B-Entity
-,I-Entity
chlorophenylalamine,I-Entity
(,O
3,O
X,O
320,O
mg,O
/,O
kg,O
i.p,O
.,O
",",O
24,O
hr,O
),O
",",O
a,O
serotonin,I-Entity
depletor,O
",",O
caused,O
no,O
significant,O
change,O
in,O
the,O
hyperactivity,I-Entity
.,O
The,O
study,O
suggests,O
that,O
the,O
activity,O
-,O
increasing,O
effects,O
of,O
morphine,I-Entity
are,O
mediated,O
by,O
the,O
release,O
of,O
catecholamines,I-Entity
from,O
adrenergic,O
neurons,O
in,O
the,O
brain,O
.,O
And,O
the,O
results,O
are,O
consistent,O
with,O
the,O
hypothesis,O
that,O
morphine,I-Entity
acts,O
by,O
retarding,O
the,O
release,O
of,O
acetylcholine,I-Entity
at,O
some,O
central,O
cholinergic,O
synapses,O
.,O
It,O
is,O
also,O
suggested,O
from,O
collected,O
evidence,O
that,O
the,O
activity,O
-,O
increasing,O
effects,O
of,O
morphine,I-Entity
in,O
mice,O
are,O
mediated,O
by,O
mechanisms,O
different,O
from,O
those,O
which,O
mediate,O
the,O
activity,O
-,O
increasing,O
effects,O
of,O
morphine,I-Entity
in,O
rats,O
.,O
Mechanisms,O
of,O
FK,B-Entity
506-induced,I-Entity
hypertension,I-Entity
in,O
the,O
rat,O
.,O
-Tacrolimus,I-Entity
(,O
FK,B-Entity
506,I-Entity
),O
is,O
a,O
powerful,O
",",O
widely,O
used,O
immunosuppressant,O
.,O
The,O
clinical,O
utility,O
of,O
FK,B-Entity
506,I-Entity
is,O
complicated,O
by,O
substantial,O
hypertension,I-Entity
and,O
nephrotoxicity,I-Entity
.,O
To,O
clarify,O
the,O
mechanisms,O
of,O
FK,B-Entity
506-induced,I-Entity
hypertension,I-Entity
",",O
we,O
studied,O
the,O
chronic,O
effects,O
of,O
FK,B-Entity
506,I-Entity
on,O
the,O
synthesis,O
of,O
endothelin-1,O
(,O
ET-1,O
),O
",",O
the,O
expression,O
of,O
mRNA,O
of,O
ET-1,O
and,O
endothelin,O
-,O
converting,O
enzyme-1,O
(,O
ECE-1,O
),O
",",O
the,O
endothelial,O
nitric,B-Entity
oxide,I-Entity
synthase,O
(,O
eNOS,O
),O
activity,O
",",O
and,O
the,O
expression,O
of,O
mRNA,O
of,O
eNOS,O
and,O
C,O
-,O
type,O
natriuretic,O
peptide,O
(,O
CNP,O
),O
in,O
rat,O
blood,O
vessels,O
.,O
In,O
addition,O
",",O
the,O
effect,O
of,O
the,O
specific,O
endothelin,O
type,O
A,O
receptor,O
antagonist,O
FR,B-Entity
139317,I-Entity
on,O
FK,B-Entity
506-induced,I-Entity
hypertension,I-Entity
in,O
rats,O
was,O
studied,O
.,O
FK,B-Entity
506,I-Entity
",",O
5,O
mg,O
.,O
FK,B-Entity
506,I-Entity
decreased,O
eNOS,O
activity,O
and,O
the,O
levels,O
of,O
eNOS,O
mRNA,O
in,O
the,O
aorta,O
(,O
48%,O
and,O
55%,O
",",O
respectively,O
),O
.,O
The,O
administration,O
of,O
FR,B-Entity
139317,I-Entity
(,O
10,O
mg,O
.,O
d-1,O
),O
prevented,O
FK,B-Entity
506-induced,I-Entity
hypertension,I-Entity
in,O
rats,O
.,O
These,O
results,O
indicate,O
that,O
FK,B-Entity
506,I-Entity
may,O
increase,O
blood,O
pressure,O
not,O
only,O
by,O
increasing,O
ET-1,O
production,O
but,O
also,O
by,O
decreasing,O
NO,I-Entity
synthesis,O
in,O
the,O
vasculature,O
.,O
Suxamethonium,I-Entity
induced,O
prolonged,O
apnea,I-Entity
in,O
a,O
patient,O
receiving,O
electroconvulsive,O
therapy,O
.,O
Suxamethonium,I-Entity
causes,O
prolonged,O
apnea,I-Entity
in,O
patients,O
in,O
whom,O
pseudocholinesterase,O
enzyme,O
gets,O
deactivated,O
by,O
organophosphorus,B-Entity
(,I-Entity
OP,I-Entity
),I-Entity
poisons,I-Entity
.,O
Here,O
",",O
we,O
present,O
a,O
similar,O
incident,O
in,O
a,O
severely,O
depressed,I-Entity
patient,O
who,O
received,O
electroconvulsive,O
therapy,O
(,O
ECT,O
),O
.,O
Prolonged,O
apnea,I-Entity
in,O
our,O
case,O
ensued,O
because,O
the,O
information,O
about,O
suicidal,O
attempt,O
by,O
OP,B-Entity
compound,I-Entity
was,O
concealed,O
from,O
the,O
treating,O
team,O
.,O
The,O
effects,O
of,O
the,O
adjunctive,O
bupropion,I-Entity
on,O
male,O
sexual,B-Entity
dysfunction,I-Entity
induced,O
by,O
a,O
selective,B-Entity
serotonin,I-Entity
reuptake,I-Entity
inhibitor,I-Entity
:,O
a,O
double,O
-,O
blind,O
placebo,O
-,O
controlled,O
and,O
randomized,O
study,O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
safety,O
and,O
efficacy,O
of,O
adjunctive,O
bupropion,I-Entity
sustained,O
-,O
release,O
(,O
SR,O
),O
on,O
male,O
sexual,B-Entity
dysfunction,I-Entity
(,O
SD,I-Entity
),O
induced,O
by,O
a,O
selective,B-Entity
serotonin,I-Entity
reuptake,I-Entity
inhibitor,I-Entity
(,O
SSRI,I-Entity
),O
",",O
as,O
SD,I-Entity
is,O
a,O
common,O
side,O
-,O
effect,O
of,O
SSRIs,I-Entity
and,O
the,O
most,O
effective,O
treatments,O
have,O
yet,O
to,O
be,O
determined,O
.,O
The,O
randomized,O
sample,O
consisted,O
of,O
234,O
euthymic,O
men,O
who,O
were,O
receiving,O
some,O
type,O
of,O
SSRI,I-Entity
.,O
The,O
men,O
were,O
randomly,O
assigned,O
to,O
bupropion,I-Entity
SR,O
(,O
150,O
mg,O
twice,O
daily,O
",",O
117,O
),O
or,O
placebo,O
(,O
twice,O
daily,O
",",O
117,O
),O
for,O
12,O
weeks,O
.,O
Efficacy,O
was,O
evaluated,O
using,O
the,O
Clinical,O
Global,O
Impression,O
-,O
Sexual,O
Function,O
(,O
CGI,O
-,O
SF,O
;,O
the,O
primary,O
outcome,O
measure,O
),O
",",O
the,O
International,O
Index,O
of,O
Erectile,O
Function,O
(,O
IIEF,O
),O
",",O
Arizona,O
Sexual,O
Experience,O
Scale,O
(,O
ASEX,O
),O
",",O
and,O
Erectile,B-Entity
Dysfunction,I-Entity
Inventory,O
of,O
Treatment,O
Satisfaction,O
(,O
EDITS,O
),O
(,O
secondary,O
outcome,O
measures,O
),O
.,O
After,O
12,O
weeks,O
of,O
treatment,O
",",O
the,O
mean,O
(,O
sd,O
),O
scores,O
for,O
CGI,O
-,O
SF,O
were,O
significantly,O
lower,O
",",O
i.e.,O
better,O
",",O
in,O
patients,O
on,O
bupropion,I-Entity
SR,O
",",O
at,O
2.4,O
(,O
1.2,O
),O
",",O
than,O
in,O
the,O
placebo,O
group,O
",",O
at,O
3.9,O
(,O
1.1,O
),O
Men,O
who,O
received,O
bupropion,I-Entity
had,O
a,O
significant,O
increase,O
in,O
the,O
total,O
IIEF,O
score,O
(,O
54.4%,O
vs,O
1.2%,O
;,O
P=,O
0.003,O
),O
",",O
and,O
in,O
the,O
five,O
different,O
domains,O
of,O
the,O
IIEF,O
.,O
Total,O
ASEX,O
scores,O
were,O
significantly,O
lower,O
",",O
i.e.,O
better,O
",",O
among,O
men,O
who,O
received,O
bupropion,I-Entity
than,O
placebo,O
",",O
at,O
15.5,O
(,O
4.3,O
),O
vs,O
21.5,O
(,O
4.7,O
),O
(,O
P=,O
0.002,O
),O
.,O
The,O
EDITS,O
scores,O
were,O
67.4,O
(,O
10.2,O
),O
for,O
the,O
bupropion,I-Entity
and,O
36.3,O
(,O
11.7,O
),O
for,O
the,O
placebo,O
group,O
(,O
P=,O
0.001,O
),O
.,O
In,O
linear,O
regression,O
analyses,O
the,O
CGI,O
-,O
SF,O
score,O
was,O
not,O
affected,O
significantly,O
by,O
the,O
duration,O
of,O
SD,I-Entity
",",O
type,O
of,O
SSRI,I-Entity
used,O
and,O
age,O
.,O
Bupropion,I-Entity
is,O
an,O
effective,O
treatment,O
for,O
male,O
SD,I-Entity
induced,O
by,O
SSRIs,I-Entity
.,O
These,O
results,O
provide,O
empirical,O
support,O
for,O
conducting,O
a,O
further,O
study,O
of,O
bupropion,I-Entity
.,O
Lamivudine,I-Entity
for,O
the,O
prevention,O
of,O
hepatitis,B-Entity
B,I-Entity
virus,O
reactivation,O
in,O
hepatitis,B-Entity
-,I-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
(,O
HBSAG,I-Entity
),O
seropositive,O
cancer,I-Entity
patients,O
undergoing,O
cytotoxic,O
chemotherapy,O
.,O
Hepatitis,B-Entity
B,I-Entity
virus,O
(,O
HBV,O
),O
is,O
one,O
of,O
the,O
major,O
causes,O
of,O
chronic,O
liver,B-Entity
disease,I-Entity
worldwide,O
.,O
Cancer,I-Entity
patients,O
who,O
are,O
chronic,O
carriers,O
of,O
HBV,O
have,O
a,O
higher,O
hepatic,B-Entity
complication,I-Entity
rate,O
while,O
receiving,O
cytotoxic,O
chemotherapy,O
(,O
CT,O
),O
and,O
this,O
has,O
mainly,O
been,O
attributed,O
to,O
HBV,O
reactivation,O
.,O
In,O
this,O
study,O
",",O
cancer,I-Entity
patients,O
who,O
have,O
solid,O
and,O
hematological,B-Entity
malignancies,I-Entity
with,O
chronic,O
HBV,B-Entity
infection,I-Entity
received,O
the,O
antiviral,O
agent,O
lamivudine,I-Entity
prior,O
and,O
during,O
CT,O
compared,O
with,O
historical,O
control,O
group,O
who,O
did,O
not,O
receive,O
lamivudine,I-Entity
.,O
The,O
objectives,O
were,O
to,O
assess,O
the,O
efficacy,O
of,O
lamivudine,I-Entity
in,O
reducing,O
the,O
incidence,O
of,O
HBV,O
reactivation,O
",",O
and,O
diminishing,O
morbidity,O
and,O
mortality,O
during,O
CT,O
.,O
The,O
prophylactic,O
lamivudin,I-Entity
group,O
consisted,O
of,O
37,O
patients,O
who,O
received,O
prophylactic,O
lamivudine,I-Entity
treatment,O
.,O
The,O
historical,O
controls,O
consisted,O
of,O
50,O
consecutive,O
patients,O
who,O
underwent,O
CT,O
without,O
prophylactic,O
lamivudine,I-Entity
.,O
Of,O
our,O
control,O
group,O
(,O
n=,O
50,O
),O
",",O
21,O
patients,O
(,O
42%,O
),O
were,O
established,O
hepatitis,I-Entity
.,O
Twelve,O
(,O
24%,O
),O
of,O
them,O
were,O
evaluated,O
as,O
severe,O
hepatitis,I-Entity
.,O
In,O
the,O
prophylactic,O
lamivudine,I-Entity
group,O
severe,O
hepatitis,I-Entity
were,O
observed,O
only,O
in,O
1,O
patient,O
(,O
2.7%,O
),O
of,O
37,O
patients,O
(,O
p,O
<,O
0.006,O
),O
.,O
Comparison,O
of,O
the,O
mean,O
ALT,O
values,O
revealed,O
significantly,O
higher,O
mean,O
alanine,I-Entity
aminotransferase,O
(,O
ALT,O
),O
values,O
in,O
the,O
control,O
group,O
than,O
the,O
prophylactic,O
lamivudine,I-Entity
group,O
;,O
154:64,O
(,O
p,O
<,O
0.32,O
),O
.,O
Our,O
study,O
suggests,O
that,O
prophylactic,O
lamivudine,I-Entity
significantly,O
decreases,O
the,O
incidence,O
of,O
HBV,O
reactivation,O
and,O
overall,O
morbidity,O
in,O
cancer,I-Entity
patients,O
during,O
and,O
after,O
immunosuppressive,O
therapy,O
.,O
Further,O
studies,O
are,O
needed,O
to,O
determine,O
the,O
most,O
appropriate,O
nucleoside,I-Entity
or,O
nucleotide,I-Entity
analogue,O
for,O
antiviral,O
prophylaxis,O
during,O
CT,O
and,O
the,O
optimal,O
duration,O
of,O
administration,O
after,O
completion,O
of,O
CT,O
.,O
Ginsenoside,B-Entity
Rg1,I-Entity
restores,O
the,O
impairment,B-Entity
of,I-Entity
learning,I-Entity
induced,O
by,O
chronic,O
morphine,I-Entity
administration,O
in,O
rats,O
.,O
Rg1,I-Entity
",",O
as,O
a,O
ginsenoside,I-Entity
extracted,O
from,O
Panax,O
ginseng,O
",",O
could,O
ameliorate,O
spatial,O
learning,B-Entity
impairment,I-Entity
.,O
Previous,O
studies,O
have,O
demonstrated,O
that,O
Rg1,I-Entity
might,O
be,O
a,O
useful,O
agent,O
for,O
the,O
prevention,O
and,O
treatment,O
of,O
the,O
adverse,O
effects,O
of,O
morphine,I-Entity
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
the,O
effect,O
of,O
Rg1,I-Entity
on,O
learning,B-Entity
impairment,I-Entity
by,O
chronic,O
morphine,I-Entity
administration,O
and,O
the,O
mechanism,O
responsible,O
for,O
this,O
effect,O
.,O
Male,O
rats,O
were,O
subcutaneously,O
injected,O
with,O
morphine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
twice,O
a,O
day,O
at,O
12,O
hour,O
intervals,O
for,O
10,O
days,O
",",O
and,O
Rg1,I-Entity
(,O
30,O
mg,O
/,O
kg,O
),O
was,O
intraperitoneally,O
injected,O
2,O
hours,O
after,O
the,O
second,O
injection,O
of,O
morphine,I-Entity
once,O
a,O
day,O
for,O
10,O
days,O
.,O
The,O
results,O
showed,O
that,O
rats,O
treated,O
with,O
Morphine,I-Entity
/,O
Rg1,I-Entity
decreased,O
escape,O
latency,O
and,O
increased,O
the,O
time,O
spent,O
in,O
platform,O
quadrant,O
and,O
entering,O
frequency,O
.,O
By,O
implantation,O
of,O
electrodes,O
and,O
electrophysiological,O
recording,O
in,O
vivo,O
",",O
the,O
results,O
showed,O
that,O
Rg1,I-Entity
restored,O
the,O
long,O
-,O
term,O
potentiation,O
(,O
LTP,O
),O
impaired,O
by,O
morphine,I-Entity
in,O
both,O
freely,O
moving,O
and,O
anaesthetised,O
rats,O
.,O
The,O
electrophysiological,O
recording,O
in,O
vitro,O
showed,O
that,O
Rg1,I-Entity
restored,O
the,O
LTP,O
in,O
slices,O
from,O
the,O
rats,O
treated,O
with,O
morphine,I-Entity
",",O
but,O
not,O
changed,O
LTP,O
in,O
the,O
slices,O
from,O
normal,O
saline-,O
or,O
morphine,I-Entity
/,O
Rg1-treated,I-Entity
rats,O
;,O
this,O
restoration,O
could,O
be,O
inhibited,O
by,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
antagonist,O
MK801,I-Entity
.,O
We,O
conclude,O
that,O
Rg1,I-Entity
may,O
significantly,O
improve,O
the,O
spatial,O
learning,O
capacity,O
impaired,O
by,O
chonic,O
morphine,I-Entity
administration,O
and,O
restore,O
the,O
morphine,I-Entity
-,O
inhibited,O
LTP,O
.,O
This,O
effect,O
is,O
NMDA,I-Entity
receptor,O
dependent,O
.,O
A,O
study,O
on,O
the,O
effect,O
of,O
the,O
duration,O
of,O
subcutaneous,O
heparin,I-Entity
injection,O
on,O
bruising,I-Entity
and,O
pain,I-Entity
.,O
This,O
study,O
was,O
carried,O
out,O
to,O
determine,O
the,O
effect,O
of,O
injection,O
duration,O
on,O
bruising,I-Entity
and,O
pain,I-Entity
following,O
the,O
administration,O
of,O
the,O
subcutaneous,O
injection,O
of,O
heparin,I-Entity
.,O
Although,O
different,O
methods,O
to,O
prevent,O
bruising,I-Entity
and,O
pain,I-Entity
following,O
the,O
subcutaneous,O
injection,O
of,O
heparin,I-Entity
have,O
been,O
widely,O
studied,O
and,O
described,O
",",O
the,O
effect,O
of,O
injection,O
duration,O
on,O
the,O
occurrence,O
of,O
bruising,I-Entity
and,O
pain,I-Entity
is,O
little,O
documented,O
.,O
The,O
sample,O
for,O
the,O
study,O
consisted,O
of,O
50,O
patients,O
to,O
whom,O
subcutaneous,O
heparin,I-Entity
was,O
administered,O
.,O
Heparin,I-Entity
was,O
injected,O
over,O
10,O
seconds,O
on,O
the,O
right,O
abdominal,O
site,O
and,O
30,O
seconds,O
on,O
the,O
left,O
abdominal,O
site,O
.,O
Injections,O
areas,O
were,O
assessed,O
for,O
the,O
presence,O
of,O
bruising,I-Entity
at,O
48,O
and,O
72,O
hours,O
after,O
each,O
injection,O
.,O
Dimensions,O
of,O
the,O
bruising,I-Entity
on,O
the,O
heparin,I-Entity
applied,O
areas,O
were,O
measured,O
using,O
transparent,O
millimetric,O
measuring,O
paper,O
.,O
The,O
visual,O
analog,O
scale,O
(,O
VAS,O
),O
was,O
used,O
to,O
measure,O
pain,I-Entity
intensity,O
and,O
a,O
stop,O
-,O
watch,O
was,O
used,O
to,O
time,O
the,O
pain,I-Entity
period,O
.,O
The,O
percentage,O
of,O
bruising,I-Entity
occurrence,O
was,O
64%,O
with,O
the,O
injection,O
of,O
10,O
seconds,O
duration,O
and,O
42%,O
in,O
the,O
30-second,O
injection,O
.,O
It,O
was,O
determined,O
that,O
the,O
size,O
of,O
the,O
bruising,I-Entity
was,O
smaller,O
in,O
the,O
30-second,O
injection,O
.,O
Pain,I-Entity
intensity,O
and,O
pain,I-Entity
period,O
were,O
statistically,O
significantly,O
lower,O
for,O
the,O
30-second,O
injection,O
than,O
for,O
the,O
10-second,O
injection,O
.,O
CONCLUSIONS,O
:,O
It,O
was,O
determined,O
that,O
injection,O
duration,O
had,O
an,O
effect,O
on,O
bruising,I-Entity
and,O
pain,I-Entity
following,O
the,O
subcutaneous,O
administration,O
of,O
heparin,I-Entity
.,O
PRACTICE,O
:,O
When,O
administering,O
subcutaneous,O
heparin,I-Entity
injections,O
",",O
it,O
is,O
important,O
to,O
extend,O
the,O
duration,O
of,O
the,O
injection,O
.,O
Acute,O
reserpine,I-Entity
and,O
subchronic,O
haloperidol,I-Entity
treatments,O
change,O
synaptosomal,O
brain,O
glutamate,I-Entity
uptake,O
and,O
elicit,O
orofacial,B-Entity
dyskinesia,I-Entity
in,O
rats,O
.,O
Reserpine-,I-Entity
and,O
haloperidol,I-Entity
-,O
induced,O
orofacial,B-Entity
dyskinesia,I-Entity
are,O
putative,O
animal,O
models,O
of,O
tardive,B-Entity
dyskinesia,I-Entity
(,O
TD,I-Entity
),O
whose,O
pathophysiology,O
has,O
been,O
related,O
to,O
free,O
radical,O
generation,O
and,O
oxidative,O
stress,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
authors,O
induced,O
orofacial,B-Entity
dyskinesia,I-Entity
by,O
acute,O
reserpine,I-Entity
and,O
subchronic,O
haloperidol,I-Entity
administration,O
to,O
rats,O
.,O
Reserpine,I-Entity
injection,O
(,O
one,O
dose,O
of,O
1,O
mg,O
Haloperidol,I-Entity
administration,O
(,O
one,O
dose,O
of,O
12,O
mg,O
/,O
kg,O
once,O
a,O
week,O
s.c,O
.,O
),O
After,O
the,O
treatments,O
and,O
behavioral,O
observation,O
",",O
glutamate,I-Entity
uptake,O
by,O
segments,O
of,O
the,O
brain,O
was,O
analyzed,O
.,O
A,O
decreased,O
glutamate,I-Entity
uptake,O
was,O
observed,O
in,O
the,O
subcortical,O
parts,O
of,O
animals,O
treated,O
with,O
reserpine,I-Entity
and,O
haloperidol,I-Entity
",",O
compared,O
to,O
the,O
control,O
.,O
Importantly,O
",",O
a,O
decrease,O
in,O
glutamate,I-Entity
uptake,O
correlates,O
negatively,O
with,O
an,O
increase,O
in,O
the,O
incidence,O
of,O
orofacial,B-Entity
diskinesia,I-Entity
.,O
These,O
results,O
indicate,O
that,O
early,O
changes,O
in,O
glutamate,I-Entity
transport,O
may,O
be,O
related,O
to,O
the,O
development,O
of,O
vacuous,O
chewing,O
movements,O
in,O
rats,O
.,O
Acute,B-Entity
psychosis,I-Entity
due,O
to,O
treatment,O
with,O
phenytoin,I-Entity
in,O
a,O
nonepileptic,O
patient,O
.,O
The,O
development,O
of,O
psychosis,I-Entity
related,O
to,O
antiepileptic,O
drug,O
treatment,O
is,O
usually,O
attributed,O
to,O
the,O
interaction,O
between,O
the,O
epileptic,I-Entity
brain,O
substratum,O
and,O
the,O
antiepileptic,O
drugs,O
.,O
The,O
case,O
of,O
a,O
nonepileptic,O
patient,O
who,O
developed,O
psychosis,I-Entity
following,O
phenytoin,I-Entity
treatment,O
for,O
trigeminal,B-Entity
neuralgia,I-Entity
is,O
described,O
.,O
This,O
case,O
suggests,O
that,O
the,O
psychotic,B-Entity
symptoms,I-Entity
that,O
occur,O
following,O
phenytoin,I-Entity
treatment,O
in,O
some,O
epileptic,I-Entity
patients,O
may,O
be,O
the,O
direct,O
result,O
of,O
medication,O
",",O
unrelated,O
to,O
seizures,I-Entity
.,O
The,O
effect,O
of,O
treatment,O
with,O
gum,B-Entity
Arabic,I-Entity
on,O
gentamicin,I-Entity
nephrotoxicity,I-Entity
in,O
rats,O
:,O
a,O
preliminary,O
study,O
.,O
In,O
the,O
present,O
work,O
we,O
assessed,O
the,O
effect,O
of,O
treatment,O
of,O
rats,O
with,O
gum,B-Entity
Arabic,I-Entity
on,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
induced,O
by,O
gentamicin,I-Entity
(,O
GM,I-Entity
),O
nephrotoxicity,I-Entity
.,O
kg,O
of,O
distilled,O
water,O
and,O
5%,O
w,O
/,O
v,O
cellulose,O
",",O
10,O
days,O
),O
",",O
gum,B-Entity
Arabic,I-Entity
(,O
2,O
mL,O
/,O
kg,O
of,O
a,O
10%,O
w,O
/,O
v,O
aqueous,O
suspension,O
of,O
gum,B-Entity
Arabic,I-Entity
powder,O
",",O
orally,O
for,O
10,O
days,O
),O
",",O
or,O
gum,B-Entity
Arabic,I-Entity
concomitantly,O
with,O
GM,I-Entity
(,O
80mg,O
/,O
kg,O
/,O
day,O
intramuscularly,O
",",O
during,O
the,O
last,O
six,O
days,O
of,O
the,O
treatment,O
period,O
),O
.,O
Nephrotoxicity,I-Entity
was,O
assessed,O
by,O
measuring,O
the,O
concentrations,O
of,O
creatinine,I-Entity
and,O
urea,I-Entity
in,O
the,O
plasma,O
and,O
reduced,O
glutathione,I-Entity
(,O
GSH,I-Entity
),O
in,O
the,O
kidney,O
cortex,O
",",O
and,O
by,O
light,O
microscopic,O
examination,O
of,O
kidney,O
sections,O
.,O
The,O
results,O
indicated,O
that,O
concomitant,O
treatment,O
with,O
gum,B-Entity
Arabic,I-Entity
and,O
GM,I-Entity
significantly,O
increased,O
creatinine,I-Entity
and,O
urea,I-Entity
by,O
about,O
183,O
and,O
239%,O
",",O
respectively,O
(,O
compared,O
to,O
432,O
and,O
346%,O
",",O
respectively,O
",",O
in,O
rats,O
treated,O
with,O
cellulose,O
and,O
GM,I-Entity
),O
",",O
and,O
decreased,O
that,O
of,O
cortical,O
GSH,I-Entity
by,O
21%,O
(,O
compared,O
to,O
27%,O
in,O
the,O
cellulose,O
plus,O
GM,I-Entity
group,O
),O
The,O
GM,I-Entity
-,O
induced,O
proximal,O
tubular,B-Entity
necrosis,I-Entity
appeared,O
to,O
be,O
slightly,O
less,O
severe,O
in,O
rats,O
given,O
GM,I-Entity
together,O
with,O
gum,B-Entity
Arabic,I-Entity
than,O
in,O
those,O
given,O
GM,I-Entity
and,O
cellulose,O
.,O
It,O
could,O
be,O
inferred,O
that,O
gum,B-Entity
Arabic,I-Entity
treatment,O
has,O
induced,O
a,O
modest,O
amelioration,O
of,O
some,O
of,O
the,O
histological,O
and,O
biochemical,O
indices,O
of,O
GM,I-Entity
nephrotoxicity,I-Entity
.,O
Further,O
work,O
is,O
warranted,O
on,O
the,O
effect,O
of,O
the,O
treatments,O
on,O
renal,O
functional,O
aspects,O
in,O
models,O
of,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
",",O
and,O
on,O
the,O
mechanism(s,O
),O
involved,O
.,O
Visual,B-Entity
hallucinations,I-Entity
associated,O
with,O
zonisamide,I-Entity
.,O
Zonisamide,I-Entity
is,O
a,O
broad,O
-,O
spectrum,O
antiepileptic,O
drug,O
used,O
to,O
treat,O
various,O
types,O
of,O
seizures,I-Entity
.,O
Although,O
visual,B-Entity
hallucinations,I-Entity
have,O
not,O
been,O
reported,O
as,O
an,O
adverse,O
effect,O
of,O
this,O
agent,O
",",O
we,O
describe,O
three,O
patients,O
who,O
experienced,O
complex,O
visual,B-Entity
hallucinations,I-Entity
and,O
altered,O
mental,O
status,O
after,O
zonisamide,I-Entity
treatment,O
was,O
begun,O
or,O
its,O
dosage,O
increased,O
.,O
All,O
three,O
had,O
been,O
diagnosed,O
earlier,O
with,O
epilepsy,I-Entity
",",O
and,O
their,O
electroencephalogram,O
(,O
EEG,O
),O
During,O
monitoring,O
",",O
visual,B-Entity
hallucinations,I-Entity
did,O
not,O
correlate,O
with,O
EEG,O
readings,O
",",O
nor,O
did,O
video,O
recording,O
capture,O
any,O
of,O
the,O
described,O
events,O
.,O
None,O
of,O
the,O
patients,O
had,O
experienced,O
visual,B-Entity
hallucinations,I-Entity
before,O
this,O
event,O
.,O
The,O
only,O
recent,O
change,O
in,O
their,O
treatment,O
was,O
the,O
introduction,O
or,O
increased,O
dosage,O
of,O
zonisamide,I-Entity
.,O
Until,O
then,O
",",O
clinicians,O
need,O
to,O
be,O
aware,O
of,O
this,O
possible,O
complication,O
associated,O
with,O
zonisamide,I-Entity
.,O
GLEPP1,O
receptor,O
tyrosine,I-Entity
phosphatase,O
(,O
Ptpro,O
),O
in,O
rat,O
PAN,I-Entity
nephrosis,I-Entity
.,O
Glomerular,O
epithelial,O
protein,O
1,O
(,O
GLEPP1,O
),O
is,O
a,O
podocyte,O
receptor,O
membrane,O
protein,O
tyrosine,I-Entity
phosphatase,O
located,O
on,O
the,O
apical,O
cell,O
membrane,O
of,O
visceral,O
glomerular,O
epithelial,O
cell,O
and,O
foot,O
processes,O
.,O
To,O
better,O
understand,O
the,O
utility,O
of,O
GLEPP1,O
as,O
a,O
marker,O
of,O
glomerular,B-Entity
injury,I-Entity
",",O
the,O
amount,O
and,O
distribution,O
of,O
GLEPP1,O
protein,O
and,O
mRNA,O
were,O
examined,O
by,O
immunohistochemistry,O
",",O
Western,O
blot,O
and,O
RNase,O
protection,O
assay,O
in,O
a,O
model,O
of,O
podocyte,O
injury,O
in,O
the,O
rat,O
.,O
Puromycin,B-Entity
aminonucleoside,I-Entity
nephrosis,I-Entity
was,O
induced,O
by,O
single,O
intraperitoneal,O
injection,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
",",O
20,O
mg/100,O
g,O
BW,O
),O
.,O
Tissues,O
were,O
analyzed,O
at,O
0,O
",",O
5,O
",",O
7,O
",",O
11,O
",",O
21,O
",",O
45,O
",",O
80,O
and,O
126,O
days,O
after,O
PAN,I-Entity
injection,O
so,O
as,O
to,O
include,O
both,O
the,O
acute,O
phase,O
of,O
proteinuria,I-Entity
associated,O
with,O
foot,O
process,O
effacement,O
(,O
days,O
5,O
-,O
11,O
),O
and,O
the,O
chronic,O
phase,O
of,O
proteinuria,I-Entity
associated,O
with,O
glomerulosclerosis,I-Entity
(,O
days,O
45,O
-,O
126,O
),O
.,O
We,O
conclude,O
that,O
GLEPP1,O
expression,O
",",O
unlike,O
podocalyxin,O
",",O
reflects,O
podocyte,O
injury,O
induced,O
by,O
PAN,I-Entity
.,O
Ticlopidine,I-Entity
-,O
induced,O
aplastic,B-Entity
anemia,I-Entity
:,O
In,O
this,O
study,O
",",O
three,O
Chinese,O
patients,O
with,O
ticlopidine,I-Entity
-,O
induced,O
aplastic,B-Entity
anemia,I-Entity
were,O
reported,O
and,O
another,O
13,O
patients,O
in,O
the,O
English,O
literature,O
were,O
reviewed,O
.,O
Agranulocytosis,I-Entity
occurred,O
3,O
-,O
20,O
weeks,O
after,O
initiation,O
of,O
ticlopidine,I-Entity
",",O
so,O
frequent,O
examination,O
of,O
white,O
cell,O
count,O
during,O
treatment,O
is,O
recommended,O
.,O
There,O
seemed,O
to,O
be,O
no,O
direct,O
correlation,O
between,O
the,O
dose,O
or,O
duration,O
used,O
and,O
the,O
severity,O
of,O
bone,B-Entity
marrow,I-Entity
suppression,I-Entity
.,O
Treatment,O
for,O
ticlopidine,I-Entity
-,O
induced,O
aplastic,B-Entity
anemia,I-Entity
with,O
colony,O
-,O
stimulating,O
factors,O
seemed,O
to,O
have,O
little,O
effect,O
.,O
The,O
fact,O
that,O
5,O
of,O
the,O
6,O
patients,O
who,O
received,O
concurrent,O
calcium,I-Entity
channel,O
blockers,O
died,O
",",O
should,O
alert,O
clinicians,O
to,O
be,O
more,O
cautious,O
when,O
using,O
these,O
two,O
drugs,O
simultaneously,O
.,O
Facilitation,O
of,O
memory,O
retrieval,O
by,O
pre,O
-,O
test,O
morphine,I-Entity
and,O
its,O
state,O
dependency,O
in,O
the,O
step,O
-,O
through,O
type,O
passive,O
avoidance,O
learning,O
test,O
in,O
mice,O
.,O
Amnesia,I-Entity
produced,O
by,O
scopolamine,I-Entity
and,O
cycloheximide,I-Entity
were,O
reversed,O
by,O
morphine,I-Entity
given,O
30,O
min,O
before,O
the,O
test,O
trial,O
(,O
pre,O
-,O
test,O
),O
",",O
and,O
pre,O
-,O
test,O
morphine,I-Entity
also,O
facilitated,O
the,O
memory,O
retrieval,O
in,O
the,O
animals,O
administered,O
naloxone,I-Entity
during,O
the,O
training,O
trial,O
.,O
Similarly,O
",",O
pre,O
-,O
test,O
scopolamine,I-Entity
partially,O
reversed,O
the,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
",",O
but,O
not,O
significantly,O
;,O
and,O
pre,O
-,O
test,O
cycloheximide,I-Entity
failed,O
to,O
reverse,O
the,O
cycloheximide,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
These,O
results,O
suggest,O
that,O
the,O
facilitation,O
of,O
memory,O
retrieval,O
by,O
pre,O
-,O
test,O
morphine,I-Entity
might,O
be,O
the,O
direct,O
action,O
of,O
morphine,I-Entity
rather,O
than,O
a,O
state,O
dependent,O
effect,O
.,O
Apomorphine,I-Entity
",",O
a,O
nonselective,O
dopamine,B-Entity
agonist,I-Entity
",",O
was,O
selected,O
due,O
to,O
its,O
biphasic,O
behavioral,O
effects,O
",",O
its,O
ability,O
to,O
induce,O
hypothermia,I-Entity
",",O
and,O
to,O
produce,O
distinct,O
changes,O
to,O
dopamine,I-Entity
turnover,O
in,O
the,O
rodent,O
brain,O
.,O
From,O
such,O
experiments,O
there,O
is,O
evidence,O
that,O
characterization,O
and,O
detection,O
of,O
apomorphine,I-Entity
-,O
induced,O
activity,O
in,O
rodents,O
critically,O
depends,O
upon,O
the,O
test,O
conditions,O
employed,O
.,O
In,O
rats,O
",",O
detection,O
of,O
apomorphine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
was,O
facilitated,O
by,O
a,O
period,O
of,O
acclimatization,O
to,O
the,O
test,O
conditions,O
.,O
Moreover,O
",",O
test,O
conditions,O
can,O
impact,O
upon,O
other,O
physiological,O
responses,O
to,O
apomorphine,I-Entity
such,O
as,O
drug,O
-,O
induced,O
hypothermia,I-Entity
.,O
In,O
mice,O
",",O
apomorphine,I-Entity
produced,O
qualitatively,O
different,O
responses,O
under,O
novel,O
conditions,O
when,O
compared,O
to,O
those,O
behaviors,O
elicited,O
in,O
the,O
home,O
test,O
cage,O
.,O
By,O
contrast,O
",",O
apomorphine,I-Entity
-,O
induced,O
locomotion,O
was,O
more,O
prominent,O
in,O
the,O
novel,O
exploratory,O
box,O
.,O
Dopamine,I-Entity
turnover,O
ratios,O
(,O
DOPAC,I-Entity
:,O
DA,I-Entity
and,O
HVA,I-Entity
:,O
DA,I-Entity
),O
were,O
found,O
to,O
be,O
lower,O
in,O
those,O
animals,O
exposed,O
to,O
the,O
exploratory,O
box,O
when,O
compared,O
to,O
their,O
home,O
cage,O
counterparts,O
.,O
However,O
",",O
apomorphine,I-Entity
-,O
induced,O
reductions,O
in,O
striatal,O
dopamine,I-Entity
turnover,O
were,O
detected,O
in,O
both,O
novel,O
and,O
home,O
cage,O
environments,O
.,O
Famotidine,I-Entity
-,O
associated,O
delirium,I-Entity
.,O
Famotidine,I-Entity
is,O
a,O
histamine,O
H2-receptor,O
antagonist,O
used,O
in,O
inpatient,O
settings,O
for,O
prevention,O
of,O
stress,O
ulcers,I-Entity
and,O
is,O
showing,O
increasing,O
popularity,O
because,O
of,O
its,O
low,O
cost,O
.,O
Although,O
all,O
of,O
the,O
currently,O
available,O
H2-receptor,O
antagonists,O
have,O
shown,O
the,O
propensity,O
to,O
cause,O
delirium,I-Entity
",",O
only,O
two,O
previously,O
reported,O
cases,O
have,O
been,O
associated,O
with,O
famotidine,I-Entity
.,O
The,O
authors,O
report,O
on,O
six,O
cases,O
of,O
famotidine,I-Entity
-,O
associated,O
delirium,I-Entity
in,O
hospitalized,O
patients,O
who,O
cleared,O
completely,O
upon,O
removal,O
of,O
famotidine,I-Entity
.,O
The,O
pharmacokinetics,O
of,O
famotidine,I-Entity
are,O
reviewed,O
",",O
with,O
no,O
change,O
in,O
its,O
metabolism,O
in,O
the,O
elderly,O
population,O
seen,O
.,O
The,O
implications,O
of,O
using,O
famotidine,I-Entity
in,O
elderly,O
persons,O
are,O
discussed,O
.,O
Indomethacin,I-Entity
induced,O
hypotension,I-Entity
in,O
sodium,I-Entity
and,O
volume,O
depleted,O
rats,O
.,O
After,O
a,O
single,O
oral,O
dose,O
of,O
4,O
mg,O
/,O
kg,O
indomethacin,I-Entity
(,O
IDM,I-Entity
),O
to,O
sodium,I-Entity
and,O
volume,O
depleted,O
rats,O
plasma,O
renin,O
activity,O
(,O
PRA,O
),O
and,O
systolic,O
blood,O
pressure,O
fell,O
significantly,O
within,O
four,O
hours,O
.,O
In,O
sodium,I-Entity
repleted,O
animals,O
indomethacin,I-Entity
did,O
not,O
change,O
systolic,O
blood,O
pressure,O
(,O
BP,O
),O
although,O
plasma,O
renin,O
activity,O
was,O
decreased,O
.,O
Thus,O
",",O
indomethacin,I-Entity
by,O
inhibition,O
of,O
prostaglandin,I-Entity
synthesis,O
may,O
diminish,O
the,O
blood,O
pressure,O
maintaining,O
effect,O
of,O
the,O
stimulated,O
renin,O
-,O
angiotensin,I-Entity
system,O
in,O
sodium,I-Entity
and,O
volume,O
depletion,O
.,O
Late,O
-,O
onset,O
scleroderma,B-Entity
renal,I-Entity
crisis,I-Entity
induced,O
by,O
tacrolimus,I-Entity
and,O
prednisolone,I-Entity
:,O
a,O
case,O
report,O
.,O
Scleroderma,B-Entity
renal,I-Entity
crisis,I-Entity
(,O
SRC,I-Entity
),O
is,O
a,O
rare,O
complication,O
of,O
systemic,B-Entity
sclerosis,I-Entity
(,O
SSc,I-Entity
),O
but,O
can,O
be,O
severe,O
enough,O
to,O
require,O
temporary,O
or,O
permanent,O
renal,O
replacement,O
therapy,O
.,O
Moderate,O
to,O
high,O
dose,O
corticosteroid,I-Entity
use,O
is,O
recognized,O
as,O
a,O
major,O
risk,O
factor,O
for,O
SRC,I-Entity
.,O
Furthermore,O
",",O
there,O
have,O
been,O
reports,O
of,O
thrombotic,B-Entity
microangiopathy,I-Entity
precipitated,O
by,O
cyclosporine,I-Entity
in,O
patients,O
with,O
SSc,I-Entity
.,O
In,O
this,O
article,O
",",O
we,O
report,O
a,O
patient,O
with,O
SRC,I-Entity
induced,O
by,O
tacrolimus,I-Entity
and,O
corticosteroids,I-Entity
.,O
The,O
aim,O
of,O
this,O
work,O
is,O
to,O
call,O
attention,O
to,O
the,O
risk,O
of,O
tacrolimus,I-Entity
use,O
in,O
patients,O
with,O
SSc,I-Entity
.,O
The,O
risk,O
and,O
associated,O
factors,O
of,O
methamphetamine,I-Entity
psychosis,I-Entity
in,O
methamphetamine,I-Entity
-,O
dependent,O
patients,O
in,O
Malaysia,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
risk,O
of,O
lifetime,O
and,O
current,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
in,O
patients,O
with,O
methamphetamine,I-Entity
dependence,O
.,O
The,O
association,O
between,O
psychiatric,O
co,O
-,O
morbidity,O
and,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
was,O
also,O
studied,O
.,O
Patients,O
with,O
the,O
diagnosis,O
of,O
methamphetamine,I-Entity
based,O
on,O
DSM,O
-,O
IV,O
were,O
interviewed,O
using,O
the,O
Mini,O
International,O
Neuropsychiatric,O
Interview,O
(,O
M.I.N.I.,O
),O
for,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
and,O
other,O
Axis,O
I,O
psychiatric,B-Entity
disorders,I-Entity
.,O
Of,O
292,O
subjects,O
",",O
47.9%,O
of,O
the,O
subjects,O
had,O
a,O
past,O
history,O
of,O
psychotic,B-Entity
symptoms,I-Entity
and,O
13.0%,O
of,O
the,O
patients,O
were,O
having,O
current,O
psychotic,B-Entity
symptoms,I-Entity
.,O
Co,O
-,O
morbid,O
major,O
depressive,B-Entity
disorder,I-Entity
(,O
OR=7.18,O
",",O
95,O
CI=2.612,O
-,O
19.708,O
),O
",",O
bipolar,B-Entity
disorder,I-Entity
(,O
OR=13.807,O
",",O
95,O
CI=5.194,O
-,O
36.706,O
),O
",",O
antisocial,B-Entity
personality,I-Entity
disorder,I-Entity
(,O
OR=12.619,O
",",O
95,O
CI=6.702,O
-,O
23.759,O
),O
and,O
heavy,O
methamphetamine,I-Entity
uses,O
were,O
significantly,O
associated,O
with,O
lifetime,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
after,O
adjusted,O
for,O
other,O
factors,O
.,O
Major,B-Entity
depressive,I-Entity
disorder,I-Entity
(,O
OR=2.870,O
",",O
CI=1.154,O
-,O
7.142,O
),O
and,O
antisocial,B-Entity
personality,I-Entity
disorder,I-Entity
(,O
OR=3.299,O
",",O
95,O
CI=1.375,O
-,O
7.914,O
),O
were,O
the,O
only,O
factors,O
associated,O
with,O
current,O
psychosis,I-Entity
.,O
CONCLUSION,O
:,O
There,O
was,O
a,O
high,O
risk,O
of,O
psychosis,I-Entity
in,O
patients,O
with,O
methamphetamine,I-Entity
dependence,O
.,O
It,O
was,O
associated,O
with,O
co,O
-,O
morbid,O
affective,B-Entity
disorder,I-Entity
",",O
antisocial,B-Entity
personality,I-Entity
",",O
and,O
heavy,O
methamphetamine,I-Entity
use,O
.,O
It,O
is,O
recommended,O
that,O
all,O
cases,O
of,O
methamphetamine,I-Entity
dependence,O
should,O
be,O
screened,O
for,O
psychotic,B-Entity
symptoms,I-Entity
.,O
motor,O
cortical,O
plasticity,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
:,O
clues,O
from,O
dyskinetic,I-Entity
patients,O
.,O
The,O
plasticity,O
of,O
primary,O
motor,O
cortex,O
(,O
M1,O
),O
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
and,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
(,O
LIDs,I-Entity
),O
is,O
severely,O
impaired,O
.,O
This,O
study,O
demonstrates,O
that,O
the,O
deficient,O
sensorimotor,O
M1,O
plasticity,O
in,O
16,O
patients,O
with,O
LIDs,I-Entity
could,O
be,O
reinstated,O
by,O
a,O
single,O
session,O
of,O
real,O
inhibitory,O
cerebellar,O
stimulation,O
but,O
not,O
sham,O
stimulation,O
.,O
The,O
benefit,O
of,O
inhibitory,O
cerebellar,O
stimulation,O
on,O
LIDs,I-Entity
is,O
known,O
.,O
To,O
explore,O
whether,O
this,O
benefit,O
is,O
linked,O
to,O
the,O
restoration,O
of,O
sensorimotor,O
plasticity,O
of,O
M1,O
",",O
we,O
conducted,O
an,O
additional,O
study,O
looking,O
at,O
changes,O
in,O
LIDs,I-Entity
and,O
PAS,O
-,O
induced,O
plasticity,O
after,O
10,O
sessions,O
of,O
either,O
bilateral,O
",",O
real,O
inhibitory,O
cerebellar,O
stimulation,O
or,O
sham,O
stimulation,O
.,O
These,O
results,O
suggest,O
that,O
alterations,O
in,O
cerebellar,O
sensory,O
processing,O
function,O
",",O
occurring,O
secondary,O
to,O
abnormal,O
basal,O
ganglia,O
signals,O
reaching,O
it,O
",",O
may,O
be,O
an,O
important,O
element,O
contributing,O
to,O
the,O
maladaptive,O
sensorimotor,O
plasticity,O
of,O
M1,O
and,O
the,O
emergence,O
of,O
abnormal,B-Entity
involuntary,I-Entity
movements,I-Entity
.,O
The,O
function,O
of,O
P2X3,O
receptor,O
and,O
NK1,O
receptor,O
antagonists,O
on,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
in,O
rats,O
.,O
The,O
purpose,O
of,O
the,O
study,O
is,O
to,O
explore,O
the,O
function,O
of,O
P2X3,O
and,O
NK1,O
receptors,O
antagonists,O
on,O
cyclophosphamide,I-Entity
(,O
CYP)-induced,I-Entity
cystitis,I-Entity
in,O
rats,O
.,O
injected,O
with,O
CYP,I-Entity
(,O
150,O
mg,O
/,O
kg,O
),O
;,O
and,O
the,O
rats,O
in,O
the,O
intervention,O
group,O
were,O
i.p,O
.,O
injected,O
with,O
CYP,I-Entity
with,O
subsequently,O
perfusion,O
of,O
bladder,O
with,O
P2X3,O
and,O
NK1,O
receptors,O
',O
antagonists,O
",",O
Suramin,I-Entity
and,O
GR,B-Entity
82334,I-Entity
.,O
Spontaneous,O
pain,I-Entity
behaviors,O
following,O
the,O
administration,O
of,O
CYP,I-Entity
were,O
observed,O
.,O
RESULTS,O
:,O
Cyclophosphamide,I-Entity
treatment,O
increased,O
the,O
spontaneous,O
pain,I-Entity
behaviors,O
scores,O
.,O
Histological,O
changes,O
evident,O
in,O
model,O
and,O
intervention,O
groups,O
rats,O
',O
bladder,O
included,O
edema,I-Entity
",",O
vasodilation,O
",",O
and,O
infiltration,O
of,O
inflammatory,O
cells,O
.,O
In,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
",",O
the,O
expression,O
of,O
P2X3,O
and,O
NK1,O
receptors,O
increased,O
in,O
urothelium,O
and/or,O
suburothelium,O
.,O
Acute,O
hepatitis,I-Entity
associated,O
with,O
clopidogrel,I-Entity
:,O
a,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
Drug,O
-,O
induced,O
hepatotoxicity,I-Entity
is,O
a,O
common,O
cause,O
of,O
acute,O
hepatitis,I-Entity
",",O
and,O
the,O
recognition,O
of,O
the,O
responsible,O
drug,O
may,O
be,O
difficult,O
.,O
We,O
describe,O
a,O
case,O
of,O
clopidogrel,I-Entity
-,O
related,O
acute,O
hepatitis,I-Entity
.,O
Reports,O
about,O
cases,O
of,O
hepatotoxicity,I-Entity
due,O
to,O
clopidogrel,I-Entity
are,O
increasing,O
in,O
the,O
last,O
few,O
years,O
",",O
after,O
the,O
increased,O
use,O
of,O
this,O
drug,O
.,O
In,O
conclusion,O
",",O
we,O
believe,O
that,O
physicians,O
should,O
carefully,O
consider,O
the,O
risk,O
of,O
drug,O
-,O
induced,O
hepatic,B-Entity
injury,I-Entity
when,O
clopidogrel,I-Entity
is,O
prescribed,O
.,O
Bortezomib,I-Entity
and,O
dexamethasone,I-Entity
as,O
salvage,O
therapy,O
in,O
patients,O
with,O
relapsed,O
/,O
refractory,O
multiple,B-Entity
myeloma,I-Entity
:,O
analysis,O
of,O
long,O
-,O
term,O
clinical,O
outcomes,O
.,O
Bortezomib,I-Entity
(,O
bort)-dexamethasone,I-Entity
(,O
dex,I-Entity
),O
is,O
an,O
effective,O
therapy,O
for,O
relapsed,O
/,O
refractory,O
(,O
R,O
/,O
R,O
),O
multiple,B-Entity
myeloma,I-Entity
(,O
MM,I-Entity
),O
.,O
This,O
retrospective,O
study,O
investigated,O
the,O
combination,O
of,O
bort,I-Entity
(,O
1.3,O
mg,O
/,O
m(2,O
),O
on,O
days,O
1,O
",",O
4,O
",",O
8,O
",",O
and,O
11,O
every,O
3,O
weeks,O
),O
and,O
dex,I-Entity
(,O
20,O
mg,O
on,O
the,O
day,O
of,O
and,O
the,O
day,O
after,O
bort,I-Entity
),O
as,O
salvage,O
treatment,O
in,O
85,O
patients,O
with,O
R,O
/,O
R,O
MM,I-Entity
after,O
prior,O
autologous,O
stem,O
cell,O
transplantation,O
or,O
conventional,O
chemotherapy,O
.,O
Eighty,O
-,O
seven,O
percent,O
of,O
the,O
patients,O
had,O
received,O
immunomodulatory,O
drugs,O
included,O
in,O
some,O
line,O
of,O
therapy,O
before,O
bort,I-Entity
-,O
dex,I-Entity
.,O
The,O
median,O
number,O
of,O
bort,I-Entity
-,O
dex,I-Entity
cycles,O
was,O
6,O
",",O
up,O
to,O
a,O
maximum,O
of,O
12,O
cycles,O
.,O
The,O
most,O
relevant,O
adverse,O
event,O
was,O
peripheral,B-Entity
neuropathy,I-Entity
",",O
which,O
occurred,O
in,O
78,O
%,O
of,O
the,O
patients,O
(,O
grade,O
II,O
",",O
38,O
%,O
;,O
grade,O
III,O
",",O
21,O
%,O
),O
and,O
led,O
to,O
treatment,O
discontinuation,O
in,O
6,O
%,O
.,O
Prolonged,O
PFS,O
and,O
OS,O
were,O
observed,O
in,O
patients,O
achieving,O
CR,O
and,O
receiving,O
bort,I-Entity
-,O
dex,I-Entity
a,O
single,O
line,O
of,O
prior,O
therapy,O
.,O
Bort,I-Entity
-,O
dex,I-Entity
was,O
an,O
effective,O
salvage,O
treatment,O
for,O
MM,I-Entity
patients,O
",",O
particularly,O
for,O
those,O
in,O
first,O
relapse,O
.,O
Pubertal,O
exposure,O
to,O
Bisphenol,B-Entity
A,I-Entity
increases,O
anxiety,I-Entity
-,O
like,O
behavior,O
and,O
decreases,O
acetylcholinesterase,O
activity,O
of,O
hippocampus,O
in,O
adult,O
male,O
mice,O
.,O
The,O
negative,O
effects,O
of,O
Bisphenol,B-Entity
A,I-Entity
(,O
BPA,I-Entity
),O
on,O
neurodevelopment,O
and,O
behaviors,O
have,O
been,O
well,O
established,O
.,O
Acetylcholinesterase,O
(,O
AChE,O
),O
is,O
a,O
regulatory,O
enzyme,O
which,O
is,O
involved,O
in,O
anxiety,I-Entity
-,O
like,O
behavior,O
.,O
This,O
study,O
investigated,O
behavioral,O
phenotypes,O
and,O
AChE,O
activity,O
in,O
male,O
mice,O
following,O
BPA,I-Entity
exposure,O
during,O
puberty,O
.,O
On,O
postnatal,O
day,O
(,O
PND,O
),O
35,O
",",O
male,O
mice,O
were,O
exposed,O
to,O
50,O
mg,O
BPA,I-Entity
/,O
kg,O
diet,O
per,O
day,O
for,O
a,O
period,O
of,O
35,O
days,O
.,O
Results,O
from,O
our,O
behavioral,O
phenotyping,O
indicated,O
that,O
anxiety,I-Entity
-,O
like,O
behavior,O
was,O
increased,O
in,O
mice,O
exposed,O
to,O
BPA,I-Entity
.,O
AChE,O
activity,O
was,O
significantly,O
decreased,O
in,O
the,O
hippocampus,O
of,O
mice,O
with,O
BPA,I-Entity
compared,O
to,O
control,O
mice,O
",",O
whereas,O
no,O
difference,O
was,O
found,O
in,O
the,O
prefrontal,O
cortex,O
",",O
hypothalamus,O
and,O
cerebellum,O
.,O
Our,O
findings,O
showed,O
that,O
pubertal,O
BPA,I-Entity
exposure,O
increased,O
anxiety,I-Entity
-,O
like,O
behavior,O
",",O
which,O
may,O
be,O
associated,O
with,O
decreased,O
AChE,O
activity,O
of,O
the,O
hippocampus,O
in,O
adult,O
male,O
mice,O
.,O
Further,O
studies,O
are,O
necessary,O
to,O
investigate,O
the,O
cholinergic,O
signaling,O
of,O
the,O
hippocampus,O
in,O
PBE,O
induced,O
anxiety,I-Entity
-,O
like,O
behaviors,O
.,O
Biochemical,O
effects,O
of,O
Solidago,O
virgaurea,O
extract,O
on,O
experimental,O
cardiotoxicity,I-Entity
.,O
Cardiovascular,B-Entity
diseases,I-Entity
(,O
CVDs,I-Entity
),O
are,O
the,O
major,O
health,O
problem,O
of,O
advanced,O
as,O
well,O
as,O
developing,O
countries,O
of,O
the,O
world,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
protective,O
effect,O
of,O
the,O
Solidago,O
virgaurea,O
extract,O
on,O
isoproterenol,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
rats,O
.,O
The,O
subcutaneous,O
injection,O
of,O
isoproterenol,I-Entity
(,O
30,O
mg,O
/,O
kg,O
),O
into,O
rats,O
twice,O
at,O
an,O
interval,O
of,O
24,O
h,O
",",O
for,O
two,O
consecutive,O
days,O
",",O
led,O
to,O
a,O
significant,O
increase,O
in,O
serum,O
lactate,I-Entity
dehydrogenase,O
",",O
creatine,I-Entity
phosphokinase,O
",",O
alanine,I-Entity
transaminase,O
",",O
aspartate,I-Entity
transaminase,O
",",O
and,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
activities,O
",",O
total,O
cholesterol,I-Entity
",",O
triglycerides,I-Entity
",",O
free,O
serum,O
fatty,B-Entity
acid,I-Entity
",",O
cardiac,O
tissue,O
malondialdehyde,I-Entity
(,O
MDA,I-Entity
),O
",",O
and,O
nitric,B-Entity
oxide,I-Entity
levels,O
and,O
a,O
significant,O
decrease,O
in,O
levels,O
of,O
glutathione,I-Entity
and,O
superoxide,I-Entity
dismutase,O
in,O
cardiac,O
tissue,O
as,O
compared,O
to,O
the,O
normal,O
control,O
group,O
(,O
P,O
<,O
0.05,O
),O
.,O
Pretreatment,O
with,O
S.,O
virgaurea,O
extract,O
for,O
5,O
weeks,O
at,O
a,O
dose,O
of,O
250,O
mg,O
/,O
kg,O
followed,O
by,O
isoproterenol,I-Entity
injection,O
significantly,O
prevented,O
the,O
observed,O
alterations,O
.,O
Captopril,I-Entity
(,O
50,O
mg,O
/,O
kg,O
/,O
day,O
",",O
given,O
orally,O
),O
",",O
an,O
inhibitor,O
of,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
used,O
as,O
a,O
standard,O
cardioprotective,O
drug,O
",",O
was,O
used,O
as,O
a,O
positive,O
control,O
in,O
this,O
study,O
.,O
The,O
data,O
of,O
the,O
present,O
study,O
suggest,O
that,O
S.,O
virgaurea,O
extract,O
exerts,O
its,O
protective,O
effect,O
by,O
decreasing,O
MDA,I-Entity
level,O
and,O
increasing,O
the,O
antioxidant,O
status,O
in,O
isoproterenol,I-Entity
-,O
treated,O
rats,O
.,O
"""",O
Real,O
-,O
world,O
"""",O
data,O
on,O
the,O
efficacy,O
and,O
safety,O
of,O
lenalidomide,I-Entity
and,O
dexamethasone,I-Entity
in,O
patients,O
with,O
relapsed,O
/,O
refractory,O
multiple,B-Entity
myeloma,I-Entity
who,O
were,O
treated,O
according,O
to,O
the,O
standard,O
clinical,O
practice,O
:,O
a,O
study,O
of,O
the,O
Greek,O
Myeloma,I-Entity
Study,O
Group,O
.,O
Lenalidomide,I-Entity
and,O
dexamethasone,I-Entity
(,O
RD,I-Entity
),O
is,O
a,O
standard,O
of,O
care,O
for,O
relapsed,O
/,O
refractory,O
multiple,B-Entity
myeloma,I-Entity
(,O
RRMM,I-Entity
),O
",",O
but,O
there,O
is,O
limited,O
published,O
data,O
on,O
its,O
efficacy,O
and,O
safety,O
in,O
the,O
"""",O
real,O
world,O
"""",O
(,O
RW,O
),O
",",O
according,O
to,O
the,O
International,O
Society,O
of,O
Pharmacoeconomics,O
and,O
Outcomes,O
Research,O
definition,O
.,O
We,O
studied,O
212,O
RRMM,I-Entity
patients,O
who,O
received,O
RD,I-Entity
in,O
RW,O
.,O
Median,O
time,O
to,O
CR,O
when,O
RD,I-Entity
was,O
given,O
as,O
2nd,O
or,O
>,O
2(nd)-line,O
treatment,O
at,O
4,O
and,O
11,O
months,O
",",O
respectively,O
.,O
Quality,O
of,O
response,O
was,O
independent,O
of,O
previous,O
lines,O
of,O
therapies,O
or,O
previous,O
exposure,O
to,O
thalidomide,I-Entity
or,O
bortezomib,I-Entity
.,O
Median,O
duration,O
of,O
response,O
was,O
34.4,O
months,O
",",O
and,O
it,O
was,O
higher,O
in,O
patients,O
who,O
received,O
RD,I-Entity
until,O
progression,O
(,O
not,O
reached,O
versus,O
19,O
months,O
",",O
p,O
<,O
0.001,O
),O
.,O
Adverse,O
events,O
were,O
reported,O
in,O
68.9,O
%,O
of,O
patients,O
(,O
myelosuppression,I-Entity
in,O
49.4,O
%,O
),O
and,O
12.7,O
%,O
of,O
patients,O
needed,O
hospitalization,O
.,O
Peripheral,B-Entity
neuropathy,I-Entity
was,O
observed,O
only,O
in,O
2.5,O
%,O
of,O
patients,O
and,O
deep,B-Entity
vein,I-Entity
thrombosis,I-Entity
in,O
5.7,O
%,O
.,O
Performance,O
status,O
(,O
PS,O
),O
and,O
initial,O
lenalidomide,I-Entity
dose,O
predicted,O
for,O
treatment,O
discontinuation,O
.,O
Our,O
study,O
confirms,O
that,O
RD,I-Entity
is,O
effective,O
and,O
safe,O
in,O
RRMM,I-Entity
in,O
the,O
RW,O
;,O
it,O
produces,O
durable,O
responses,O
especially,O
in,O
patients,O
who,O
continue,O
on,O
treatment,O
till,O
progression,O
and,O
improves,O
humoral,O
immunity,O
even,O
in,O
patients,O
with,O
stable,O
disease,O
.,O
The,O
cytogenetic,O
action,O
of,O
ifosfamide,I-Entity
",",O
mesna,I-Entity
",",O
and,O
their,O
combination,O
on,O
peripheral,O
rabbit,O
lymphocytes,O
:,O
an,O
in,O
vivo,O
/,O
in,O
vitro,O
cytogenetic,O
study,O
.,O
Ifosfamide,I-Entity
(,O
IFO,I-Entity
),O
is,O
an,O
alkylating,O
nitrogen,I-Entity
mustard,O
",",O
administrated,O
as,O
an,O
antineoplasmic,O
agent,O
.,O
It,O
is,O
characterized,O
by,O
its,O
intense,O
urotoxic,O
action,O
",",O
leading,O
to,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
This,O
side,O
effect,O
of,O
IFO,I-Entity
raises,O
the,O
requirement,O
for,O
the,O
co,O
-,O
administration,O
with,O
sodium,B-Entity
2-sulfanylethanesulfonate,I-Entity
(,O
Mesna,I-Entity
),O
aiming,O
to,O
avoid,O
or,O
minimize,O
this,O
effect,O
.,O
IFO,I-Entity
and,O
Mesna,I-Entity
were,O
administrated,O
separately,O
on,O
rabbit,O
's,O
lymphocytes,O
in,O
vivo,O
",",O
which,O
were,O
later,O
developed,O
in,O
vitro,O
.,O
Mesna,I-Entity
's,O
action,O
",",O
in,O
conjunction,O
with,O
IFO,I-Entity
reduces,O
the,O
frequency,O
of,O
SCEs,O
",",O
in,O
comparison,O
with,O
the,O
SCEs,O
recordings,O
obtained,O
when,O
IFO,I-Entity
is,O
administered,O
alone,O
.,O
In,O
addition,O
to,O
this,O
",",O
when,O
high,O
concentrations,O
of,O
Mesna,I-Entity
were,O
administered,O
alone,O
significant,O
reductions,O
of,O
the,O
PRI,O
were,O
noted,O
",",O
than,O
with,O
IFO,I-Entity
acting,O
at,O
the,O
same,O
concentration,O
on,O
the,O
lymphocytes,O
.,O
Mesna,I-Entity
significantly,O
reduces,O
IFO,I-Entity
's,O
genotoxicity,I-Entity
",",O
while,O
when,O
administered,O
in,O
high,O
concentrations,O
it,O
acts,O
in,O
an,O
inhibitory,O
fashion,O
on,O
the,O
cytostatic,O
action,O
of,O
the,O
drug,O
.,O
Risk,O
factors,O
and,O
predictors,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
among,O
multiethnic,O
Malaysians,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Chronic,O
pulsatile,O
levodopa,I-Entity
therapy,O
for,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
leads,O
to,O
the,O
development,O
of,O
motor,O
fluctuations,O
and,O
dyskinesia,I-Entity
.,O
We,O
studied,O
the,O
prevalence,O
and,O
predictors,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
among,O
multiethnic,O
Malaysian,O
patients,O
with,O
PD,I-Entity
.,O
This,O
is,O
a,O
cross,O
-,O
sectional,O
study,O
involving,O
95,O
patients,O
with,O
PD,I-Entity
on,O
uninterrupted,O
levodopa,I-Entity
therapy,O
for,O
at,O
least,O
6,O
months,O
.,O
The,O
predictors,O
of,O
dyskinesia,I-Entity
were,O
determined,O
using,O
multivariate,O
logistic,O
regression,O
analysis,O
.,O
Dyskinesia,I-Entity
was,O
present,O
in,O
44%,O
(,O
n,O
=,O
42,O
),O
with,O
median,O
levodopa,I-Entity
therapy,O
of,O
3,O
years,O
.,O
Eighty,O
-,O
one,O
percent,O
of,O
patients,O
with,O
dyskinesia,I-Entity
had,O
clinical,O
fluctuations,O
.,O
Patients,O
with,O
dyskinesia,I-Entity
had,O
lower,O
onset,O
age,O
(,O
p,O
<,O
0.001,O
),O
",",O
longer,O
duration,O
of,O
levodopa,I-Entity
therapy,O
(,O
p,O
<,O
0.001,O
),O
",",O
higher,O
total,O
daily,O
levodopa,I-Entity
dose,O
(,O
p,O
<,O
0.001,O
),O
",",O
and,O
higher,O
total,O
UPDRS,O
scores,O
(,O
p,O
=,O
0.005,O
),O
than,O
patients,O
without,O
dyskinesia,I-Entity
.,O
The,O
three,O
significant,O
predictors,O
of,O
dyskinesia,I-Entity
were,O
duration,O
of,O
levodopa,I-Entity
therapy,O
",",O
onset,O
age,O
",",O
and,O
total,O
daily,O
levodopa,I-Entity
dose,O
.,O
The,O
prevalence,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
in,O
our,O
patients,O
was,O
44%,O
.,O
The,O
most,O
significant,O
predictors,O
were,O
duration,O
of,O
levodopa,I-Entity
therapy,O
",",O
total,O
daily,O
levodopa,I-Entity
dose,O
",",O
and,O
onset,O
age,O
.,O
An,O
unexpected,O
diagnosis,O
in,O
a,O
renal,O
-,O
transplant,O
patient,O
with,O
proteinuria,I-Entity
treated,O
with,O
everolimus,I-Entity
:,O
AL,I-Entity
amyloidosis,I-Entity
.,O
Proteinuria,I-Entity
is,O
an,O
expected,O
complication,O
in,O
transplant,O
patients,O
treated,O
with,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
inhibitors,O
(,O
mTOR,O
-,O
i,O
),O
.,O
However,O
",",O
clinical,O
suspicion,O
should,O
always,O
be,O
supported,O
by,O
histological,O
evidence,O
in,O
order,O
to,O
investigate,O
potential,O
alternate,O
diagnoses,O
such,O
as,O
acute,O
or,O
chronic,O
rejection,O
",",O
interstitial,O
fibrosis,I-Entity
and,O
tubular,O
atrophy,I-Entity
",",O
or,O
recurrent,O
or,O
de,O
novo,O
glomerulopathy,I-Entity
.,O
In,O
this,O
case,O
we,O
report,O
the,O
unexpected,O
diagnosis,O
of,O
amyloidosis,I-Entity
in,O
a,O
renal,O
-,O
transplant,O
patient,O
with,O
pre,O
-,O
transplant,O
monoclonal,O
gammapathy,O
of,O
undetermined,O
significance,O
who,O
developed,O
proteinuria,I-Entity
after,O
conversion,O
from,O
tacrolimus,I-Entity
to,O
everolimus,I-Entity
.,O
An,O
investigation,O
of,O
the,O
pattern,O
of,O
kidney,B-Entity
injury,I-Entity
in,O
HIV,O
-,O
positive,O
persons,O
exposed,O
to,O
tenofovir,B-Entity
disoproxil,I-Entity
fumarate,I-Entity
:,O
an,O
examination,O
of,O
a,O
large,O
population,O
database,O
(,O
MHRA,O
database,O
),O
.,O
The,O
potential,O
for,O
tenofovir,I-Entity
to,O
cause,O
a,O
range,O
of,O
kidney,O
syndromes,O
has,O
been,O
established,O
from,O
mechanistic,O
and,O
randomised,O
clinical,O
trials,O
.,O
We,O
undertook,O
a,O
descriptive,O
analysis,O
of,O
Yellow,O
Card,O
records,O
of,O
407,O
HIV,O
-,O
positive,O
persons,O
taking,O
tenofovir,B-Entity
disoproxil,I-Entity
fumarate,I-Entity
(,O
TDF,I-Entity
),O
as,O
part,O
of,O
their,O
antiretroviral,O
therapy,O
regimen,O
and,O
submitted,O
to,O
the,O
Medicines,O
and,O
Healthcare,O
Products,O
Regulatory,O
Agency,O
(,O
MHRA,O
),O
with,O
suspected,O
kidney,O
adverse,O
effects,O
.,O
Reports,O
that,O
satisfy,O
defined,O
criteria,O
were,O
classified,O
as,O
acute,B-Entity
kidney,I-Entity
injury,I-Entity
",",O
kidney,B-Entity
tubular,I-Entity
dysfunction,I-Entity
and,O
Fanconi,B-Entity
syndrome,I-Entity
.,O
Of,O
the,O
407,O
Yellow,O
Card,O
records,O
analysed,O
",",O
106,O
satisfied,O
criteria,O
for,O
TDF,I-Entity
-,O
related,O
kidney,B-Entity
disease,I-Entity
",",O
of,O
which,O
53,O
(,O
50%,O
),O
had,O
features,O
of,O
kidney,B-Entity
tubular,I-Entity
dysfunction,I-Entity
",",O
35,O
(,O
33%,O
),O
were,O
found,O
to,O
have,O
features,O
of,O
glomerular,B-Entity
dysfunction,I-Entity
and,O
18,O
(,O
17%,O
),O
had,O
Fanconi,B-Entity
syndrome,I-Entity
.,O
The,O
median,O
TDF,I-Entity
exposure,O
was,O
316,O
days,O
(,O
interquartile,O
range,O
120,O
-,O
740,O
),O
.,O
The,O
incidence,O
of,O
hospitalisation,O
for,O
TDF,I-Entity
kidney,O
adverse,O
effects,O
was,O
high,O
",",O
particularly,O
amongst,O
patients,O
with,O
features,O
of,O
Fanconi,B-Entity
syndrome,I-Entity
.,O
Cessation,O
of,O
TDF,I-Entity
was,O
associated,O
with,O
complete,O
restoration,O
of,O
kidney,O
function,O
in,O
up,O
half,O
of,O
the,O
patients,O
in,O
this,O
report,O
.,O
Incidence,O
of,O
postoperative,B-Entity
delirium,I-Entity
is,O
high,O
even,O
in,O
a,O
population,O
without,O
known,O
risk,O
factors,O
.,O
Postoperative,B-Entity
delirium,I-Entity
is,O
a,O
recognized,O
complication,O
in,O
populations,O
at,O
risk,O
.,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
assess,O
the,O
prevalence,O
of,O
early,O
postoperative,B-Entity
delirium,I-Entity
in,O
a,O
population,O
without,O
known,O
risk,O
factors,O
admitted,O
to,O
the,O
ICU,O
for,O
postoperative,O
monitoring,O
after,O
elective,O
major,O
surgery,O
.,O
Exclusion,O
criteria,O
were,O
any,O
preexisting,O
predisposing,O
factor,O
for,O
delirium,I-Entity
or,O
other,O
potentially,O
confounding,O
neurological,B-Entity
dysfunctions,I-Entity
.,O
Patients,O
were,O
assessed,O
daily,O
using,O
the,O
confusion,I-Entity
assessment,O
method,O
for,O
the,O
ICU,O
scale,O
for,O
3,O
days,O
after,O
the,O
surgical,O
procedure,O
.,O
Early,O
postoperative,B-Entity
delirium,I-Entity
incidence,O
risk,O
factors,O
were,O
then,O
assessed,O
through,O
three,O
different,O
multiple,O
regression,O
models,O
.,O
According,O
to,O
the,O
confusion,O
assessment,O
method,O
for,O
the,O
ICU,O
scale,O
",",O
28,O
%,O
of,O
patients,O
were,O
diagnosed,O
with,O
early,O
postoperative,B-Entity
delirium,I-Entity
.,O
The,O
use,O
of,O
thiopentone,I-Entity
was,O
significantly,O
associated,O
with,O
an,O
eight,O
-,O
fold,O
-,O
higher,O
risk,O
for,O
delirium,I-Entity
compared,O
to,O
propofol,I-Entity
(,O
57.1%,O
CONCLUSION,O
:,O
In,O
this,O
study,O
early,O
postoperative,B-Entity
delirium,I-Entity
was,O
found,O
to,O
be,O
a,O
very,O
common,O
complication,O
after,O
major,O
surgery,O
",",O
even,O
in,O
a,O
population,O
without,O
known,O
risk,O
factors,O
.,O
Thiopentone,I-Entity
was,O
independently,O
associated,O
with,O
an,O
increase,O
in,O
its,O
relative,O
risk,O
.,O
A,O
single,O
neurotoxic,I-Entity
dose,O
of,O
methamphetamine,I-Entity
induces,O
a,O
long,O
-,O
lasting,O
depressive,I-Entity
-,O
like,O
behaviour,O
in,O
mice,O
.,O
Methamphetamine,I-Entity
(,O
METH,I-Entity
),O
triggers,O
a,O
disruption,O
of,O
the,O
monoaminergic,O
system,O
and,O
METH,I-Entity
abuse,O
leads,O
to,O
negative,O
emotional,O
states,O
including,O
depressive,B-Entity
symptoms,I-Entity
during,O
drug,O
withdrawal,O
.,O
However,O
",",O
it,O
is,O
currently,O
unknown,O
if,O
the,O
acute,O
toxic,O
dosage,O
of,O
METH,I-Entity
also,O
causes,O
a,O
long,O
-,O
lasting,O
depressive,I-Entity
phenotype,O
and,O
persistent,O
monoaminergic,O
deficits,O
.,O
Thus,O
",",O
we,O
now,O
assessed,O
the,O
depressive,I-Entity
-,O
like,O
behaviour,O
in,O
mice,O
at,O
early,O
and,O
long,O
-,O
term,O
periods,O
following,O
a,O
single,O
high,O
METH,I-Entity
dose,O
(,O
30,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
METH,I-Entity
did,O
not,O
alter,O
the,O
motor,O
function,O
and,O
procedural,O
memory,O
of,O
mice,O
as,O
assessed,O
by,O
swimming,O
speed,O
and,O
escape,O
latency,O
to,O
find,O
the,O
platform,O
in,O
a,O
cued,O
version,O
of,O
the,O
water,O
maze,O
task,O
.,O
However,O
",",O
METH,I-Entity
significantly,O
increased,O
the,O
immobility,O
time,O
in,O
the,O
tail,O
suspension,O
test,O
at,O
3,O
and,O
49,O
days,O
post,O
-,O
administration,O
.,O
This,O
depressive,I-Entity
-,O
like,O
profile,O
induced,O
by,O
METH,I-Entity
was,O
accompanied,O
by,O
a,O
marked,O
depletion,O
of,O
frontostriatal,O
dopaminergic,O
and,O
serotonergic,O
neurotransmission,O
",",O
indicated,O
by,O
a,O
reduction,O
in,O
the,O
levels,O
of,O
dopamine,I-Entity
",",O
DOPAC,I-Entity
and,O
HVA,I-Entity
",",O
tyrosine,I-Entity
hydroxylase,O
and,O
serotonin,I-Entity
",",O
observed,O
at,O
both,O
3,O
and,O
49,O
days,O
post,O
-,O
administration,O
.,O
In,O
parallel,O
",",O
another,O
neurochemical,O
feature,O
of,O
depression,I-Entity
--,O
astroglial,O
dysfunction,O
--,O
was,O
unaffected,O
in,O
the,O
cortex,O
and,O
the,O
striatal,O
levels,O
of,O
the,O
astrocytic,O
protein,O
marker,O
",",O
glial,O
fibrillary,O
acidic,O
protein,O
",",O
were,O
only,O
transiently,O
increased,O
at,O
3,O
days,O
.,O
These,O
findings,O
demonstrate,O
for,O
the,O
first,O
time,O
that,O
a,O
single,O
high,O
dose,O
of,O
METH,I-Entity
induces,O
long,O
-,O
lasting,O
depressive,I-Entity
-,O
like,O
behaviour,O
in,O
mice,O
associated,O
with,O
a,O
persistent,O
disruption,O
of,O
frontostriatal,O
dopaminergic,O
and,O
serotonergic,O
homoeostasis,O
.,O
Linezolid,I-Entity
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
.,O
We,O
describe,O
a,O
case,O
of,O
progressive,O
loss,B-Entity
of,I-Entity
vision,I-Entity
associated,O
with,O
linezolid,I-Entity
therapy,O
.,O
A,O
45-year,O
-,O
old,O
male,O
patient,O
who,O
was,O
on,O
treatment,O
with,O
multiple,O
second,O
-,O
line,O
anti,O
-,O
tuberculous,O
drugs,O
including,O
linezolid,I-Entity
and,O
ethambutol,I-Entity
for,O
extensively,B-Entity
drug,I-Entity
-,I-Entity
resistant,I-Entity
tuberculosis,I-Entity
(,O
XDR,B-Entity
-,I-Entity
TB,I-Entity
),O
presented,O
to,O
us,O
with,O
painless,O
progressive,O
loss,B-Entity
of,I-Entity
vision,I-Entity
in,O
both,O
eyes,O
.,O
Color,O
vision,O
was,O
defective,O
and,O
fundus,O
examination,O
revealed,O
optic,B-Entity
disc,I-Entity
edema,I-Entity
in,O
both,O
eyes,O
.,O
Ethambutol,I-Entity
-,O
induced,O
toxic,B-Entity
optic,I-Entity
neuropathy,I-Entity
was,O
suspected,O
and,O
tablet,O
ethambutol,I-Entity
was,O
withdrawn,O
.,O
Deterioration,B-Entity
of,I-Entity
vision,I-Entity
occurred,O
despite,O
withdrawal,O
of,O
ethambutol,I-Entity
.,O
Discontinuation,O
of,O
linezolid,I-Entity
resulted,O
in,O
marked,O
improvement,O
of,O
vision,O
.,O
Our,O
report,O
emphasizes,O
the,O
need,O
for,O
monitoring,O
of,O
visual,O
function,O
in,O
patients,O
on,O
long,O
-,O
term,O
linezolid,I-Entity
treatment,O
.,O
Resuscitation,O
with,O
lipid,O
",",O
epinephrine,I-Entity
",",O
or,O
both,O
in,O
levobupivacaine,I-Entity
-,O
induced,O
cardiac,B-Entity
toxicity,I-Entity
in,O
newborn,O
piglets,O
.,O
The,O
optimal,O
dosing,O
regimens,O
of,O
lipid,O
emulsion,O
",",O
epinephrine,I-Entity
",",O
or,O
both,O
are,O
not,O
yet,O
determined,O
in,O
neonates,O
in,O
cases,O
of,O
local,O
anaesthetic,O
systemic,O
toxicity,I-Entity
(,O
LAST,O
),O
.,O
Newborn,O
piglets,O
received,O
levobupivacaine,I-Entity
until,O
cardiovascular,B-Entity
collapse,I-Entity
occurred,O
.,O
Standard,O
cardiopulmonary,O
resuscitation,O
was,O
started,O
and,O
electrocardiogram,O
(,O
ECG,O
),O
was,O
monitored,O
for,O
ventricular,B-Entity
tachycardia,I-Entity
",",O
fibrillation,I-Entity
",",O
or,O
QRS,O
prolongation,O
.,O
Piglets,O
were,O
then,O
randomly,O
allocated,O
to,O
four,O
groups,O
:,O
control,O
(,O
saline,O
),O
",",O
Intralipid,O
(,O
),O
alone,O
",",O
epinephrine,I-Entity
alone,O
",",O
or,O
a,O
combination,O
of,O
Intralipd,O
plus,O
epinephrine,I-Entity
.,O
The,O
number,O
of,O
ECG,O
abnormalities,O
was,O
zero,O
in,O
the,O
Intralipid,O
only,O
group,O
",",O
but,O
14,O
and,O
17,O
",",O
respectively,O
",",O
in,O
the,O
epinephrine,I-Entity
and,O
epinephrine,I-Entity
plus,O
lipid,O
groups,O
(,O
P<0.05,O
),O
.,O
Lipid,O
emulsion,O
with,O
or,O
without,O
epinephrine,I-Entity
",",O
or,O
epinephrine,I-Entity
alone,O
were,O
equally,O
effective,O
in,O
achieving,O
a,O
return,O
to,O
spontaneous,O
circulation,O
in,O
this,O
model,O
of,O
LAST,O
.,O
Epinephrine,I-Entity
alone,O
or,O
in,O
combination,O
with,O
lipid,O
was,O
associated,O
with,O
an,O
increased,O
number,O
of,O
ECG,O
abnormalities,O
compared,O
with,O
lipid,O
emulsion,O
alone,O
.,O
Incidence,O
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,B-Entity
type,I-Entity
II,I-Entity
and,O
postoperative,O
recovery,O
of,O
platelet,O
count,O
in,O
liver,O
graft,O
recipients,O
:,O
a,O
retrospective,O
cohort,O
analysis,O
.,O
Thrombocytopenia,I-Entity
in,O
patients,O
with,O
end,B-Entity
-,I-Entity
stage,I-Entity
liver,I-Entity
disease,I-Entity
is,O
a,O
common,O
disorder,O
caused,O
mainly,O
by,O
portal,B-Entity
hypertension,I-Entity
",",O
low,O
levels,O
of,O
thrombopoetin,O
",",O
and,O
endotoxemia,I-Entity
.,O
The,O
impact,O
of,O
immune,O
-,O
mediated,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,B-Entity
type,I-Entity
II,I-Entity
(,O
HIT,B-Entity
type,I-Entity
II,I-Entity
),O
as,O
a,O
cause,O
of,O
thrombocytopenia,I-Entity
after,O
liver,O
transplantation,O
is,O
not,O
yet,O
understood,O
",",O
with,O
few,O
literature,O
citations,O
reporting,O
contradictory,O
results,O
.,O
The,O
aim,O
of,O
our,O
study,O
was,O
to,O
demonstrate,O
the,O
perioperative,O
course,O
of,O
thrombocytopenia,I-Entity
after,O
liver,O
transplantation,O
and,O
determine,O
the,O
occurrence,O
of,O
clinical,O
HIT,B-Entity
type,I-Entity
II,I-Entity
.,O
We,O
retrospectively,O
evaluated,O
the,O
medical,O
records,O
of,O
205,O
consecutive,O
adult,O
patients,O
who,O
underwent,O
full,O
-,O
size,O
liver,O
transplantation,O
between,O
January,O
2006,O
and,O
December,O
2010,O
due,O
to,O
end,B-Entity
-,I-Entity
stage,I-Entity
or,I-Entity
malignant,I-Entity
liver,I-Entity
disease,I-Entity
.,O
Preoperative,O
platelet,O
count,O
",",O
postoperative,O
course,O
of,O
platelets,O
",",O
and,O
clinical,O
signs,O
of,O
HIT,B-Entity
type,I-Entity
II,I-Entity
were,O
analyzed,O
.,O
A,O
total,O
of,O
155,O
(,O
75.6%,O
),O
of,O
205,O
patients,O
had,O
thrombocytopenia,I-Entity
before,O
transplantation,O
",",O
significantly,O
influenced,O
by,O
Model,O
of,O
End,B-Entity
-,I-Entity
Stage,I-Entity
Liver,I-Entity
Disease,I-Entity
score,O
and,O
liver,B-Entity
cirrhosis,I-Entity
.,O
The,O
platelet,O
count,O
exceeded,O
"100,000/uL",O
in,O
most,O
of,O
the,O
patients,O
(,O
n,O
=,O
193,O
),O
at,O
a,O
medium,O
of,O
7,O
d.,O
Regarding,O
HIT,B-Entity
II,I-Entity
",",O
there,O
were,O
four,O
(,O
1.95%,O
),O
patients,O
with,O
a,O
background,O
of,O
HIT,B-Entity
type,I-Entity
II,I-Entity
.,O
The,O
incidence,O
of,O
HIT,I-Entity
in,O
patients,O
with,O
end,B-Entity
-,I-Entity
stage,I-Entity
hepatic,I-Entity
failure,I-Entity
is,O
",",O
with,O
about,O
1.95%,O
",",O
rare,O
.,O
For,O
further,O
reduction,O
of,O
HIT,B-Entity
type,I-Entity
II,I-Entity
",",O
the,O
use,O
of,O
intravenous,O
heparin,I-Entity
should,O
be,O
avoided,O
and,O
the,O
prophylactic,O
anticoagulation,O
should,O
be,O
performed,O
with,O
low,O
-,O
molecular,O
-,O
weight,O
heparin,I-Entity
after,O
normalization,O
of,O
platelet,O
count,O
.,O
Takotsubo,B-Entity
syndrome,I-Entity
(,O
or,O
apical,B-Entity
ballooning,I-Entity
syndrome,I-Entity
),O
secondary,O
to,O
Zolmitriptan,I-Entity
.,O
Takotsubo,B-Entity
syndrome,I-Entity
(,O
TS,I-Entity
),O
",",O
also,O
known,O
as,O
broken,B-Entity
heart,I-Entity
syndrome,I-Entity
",",O
is,O
characterized,O
by,O
left,O
ventricle,O
apical,O
ballooning,O
with,O
elevated,O
cardiac,O
biomarkers,O
and,O
electrocardiographic,O
changes,O
suggestive,O
of,O
an,O
acute,B-Entity
coronary,I-Entity
syndrome,I-Entity
(,O
ie,O
",",O
ST,O
-,O
segment,O
elevation,O
",",O
T,O
wave,O
inversions,O
",",O
and,O
pathologic,O
Q,O
waves,O
),O
.,O
We,O
report,O
a,O
case,O
of,O
54-year,O
-,O
old,O
woman,O
with,O
medical,O
history,O
of,O
mitral,B-Entity
valve,I-Entity
prolapse,I-Entity
and,O
migraines,I-Entity
",",O
who,O
was,O
admitted,O
to,O
the,O
hospital,O
for,O
substernal,O
chest,B-Entity
pain,I-Entity
and,O
electrocardiogram,O
demonstrated,O
1/2,O
mm,O
ST,O
-,O
segment,O
elevation,O
in,O
leads,O
II,O
",",O
III,O
",",O
aVF,O
",",O
V5,O
",",O
and,O
V6,O
and,O
positive,O
troponin,O
I.,O
Emergent,O
coronary,O
angiogram,O
revealed,O
normal,O
coronary,O
arteries,O
with,O
moderately,O
reduced,O
left,O
ventricular,O
ejection,O
fraction,O
with,O
wall,O
motion,O
abnormalities,O
consistent,O
with,O
TS,I-Entity
.,O
Detailed,O
history,O
obtained,O
retrospectively,O
revealed,O
that,O
the,O
patient,O
took,O
zolmitriptan,I-Entity
sparingly,O
only,O
when,O
she,O
had,O
migraines,I-Entity
.,O
But,O
before,O
this,O
event,O
",",O
she,O
was,O
taking,O
zolmitriptan,I-Entity
2,O
-,O
3,O
times,O
daily,O
for,O
several,O
days,O
because,O
of,O
a,O
persistent,O
migraine,B-Entity
headache,I-Entity
.,O
There,O
was,O
no,O
evidence,O
of,O
any,O
recent,O
stress,O
or,O
status,B-Entity
migrainosus,I-Entity
.,O
Extensive,O
literature,O
search,O
revealed,O
multiple,O
cases,O
of,O
coronary,B-Entity
artery,I-Entity
vasospasm,I-Entity
secondary,O
to,O
zolmitriptan,I-Entity
",",O
but,O
none,O
of,O
the,O
cases,O
were,O
associated,O
with,O
TS,I-Entity
.,O
Depression,I-Entity
",",O
impulsiveness,I-Entity
",",O
sleep,O
",",O
and,O
memory,O
in,O
past,O
and,O
present,O
polydrug,O
users,O
of,O
"3,4-methylenedioxymethamphetamine",I-Entity
(,O
MDMA,I-Entity
",",O
ecstasy,I-Entity
),O
.,O
RATIONALE,O
:,O
Ecstasy,I-Entity
(,O
"3,4-methylenedioxymethamphetamine",I-Entity
",",O
MDMA,I-Entity
),O
is,O
a,O
worldwide,O
recreational,O
drug,O
of,O
abuse,O
.,O
The,O
present,O
study,O
aimed,O
to,O
be,O
the,O
largest,O
to,O
date,O
in,O
sample,O
size,O
and,O
5HT,O
-,O
related,O
behaviors,O
;,O
the,O
first,O
to,O
compare,O
present,O
ecstasy,I-Entity
users,O
with,O
past,O
users,O
after,O
an,O
abstinence,O
of,O
4,O
or,O
more,O
years,O
",",O
and,O
the,O
first,O
to,O
include,O
robust,O
controls,O
for,O
other,O
recreational,O
substances,O
.,O
A,O
sample,O
of,O
997,O
participants,O
(,O
52,O
%,O
male,O
),O
was,O
recruited,O
to,O
four,O
control,O
groups,O
(,O
non,O
-,O
drug,O
(,O
ND,O
),O
",",O
alcohol,I-Entity
/,O
nicotine,I-Entity
(,O
AN,I-Entity
),O
",",O
cannabis,I-Entity
/,O
alcohol,I-Entity
/,O
nicotine,I-Entity
(,O
CAN,I-Entity
),O
",",O
non,O
-,O
ecstasy,I-Entity
polydrug,O
(,O
PD,O
),O
),O
",",O
and,O
two,O
ecstasy,I-Entity
polydrug,O
groups,O
(,O
present,O
(,O
MDMA,I-Entity
),O
and,O
past,O
users,O
(,O
EX,O
-,O
MDMA,I-Entity
),O
.,O
Participants,O
completed,O
a,O
drug,O
history,O
questionnaire,O
",",O
Beck,O
Depression,I-Entity
Inventory,O
",",O
Barratt,O
Impulsiveness,I-Entity
Scale,O
",",O
Pittsburgh,O
Sleep,O
Quality,O
Index,O
",",O
and,O
Wechsler,O
Memory,O
Scale,O
-,O
Revised,O
which,O
",",O
in,O
total,O
",",O
provided,O
13,O
psychometric,O
measures,O
.,O
While,O
the,O
CAN,I-Entity
and,O
PD,O
groups,O
tended,O
to,O
record,O
greater,O
deficits,O
than,O
the,O
non,O
-,O
drug,O
controls,O
",",O
the,O
MDMA,I-Entity
and,O
EX,O
-,O
MDMA,I-Entity
groups,O
recorded,O
greater,O
deficits,O
than,O
all,O
the,O
control,O
groups,O
on,O
ten,O
of,O
the,O
13,O
psychometric,O
measures,O
.,O
Strikingly,O
",",O
despite,O
prolonged,O
abstinence,O
(,O
mean,O
",",O
4.98,O
;,O
range,O
",",O
4,O
-,O
9,O
years,O
),O
",",O
past,O
ecstasy,I-Entity
users,O
showed,O
few,O
signs,O
of,O
recovery,O
.,O
Compared,O
with,O
present,O
ecstasy,I-Entity
users,O
",",O
the,O
past,O
users,O
showed,O
no,O
change,O
for,O
ten,O
measures,O
",",O
increased,O
impairment,O
for,O
two,O
measures,O
",",O
and,O
improvement,O
on,O
just,O
one,O
measure,O
.,O
Given,O
this,O
record,O
of,O
impaired,B-Entity
memory,I-Entity
and,O
clinically,O
significant,O
levels,O
of,O
depression,I-Entity
",",O
impulsiveness,I-Entity
",",O
and,O
sleep,B-Entity
disturbance,I-Entity
",",O
the,O
prognosis,O
for,O
the,O
current,O
generation,O
of,O
ecstasy,I-Entity
users,O
is,O
a,O
major,O
cause,O
for,O
concern,O
.,O
Association,O
of,O
common,O
genetic,O
variants,O
of,O
HOMER1,O
gene,O
with,O
levodopa,I-Entity
adverse,O
effects,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
patients,O
.,O
Levodopa,I-Entity
is,O
the,O
most,O
effective,O
symptomatic,O
therapy,O
for,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
",",O
but,O
its,O
chronic,O
use,O
could,O
lead,O
to,O
chronic,O
adverse,O
outcomes,O
",",O
such,O
as,O
motor,O
fluctuations,O
",",O
dyskinesia,I-Entity
and,O
visual,B-Entity
hallucinations,I-Entity
.,O
HOMER1,O
is,O
a,O
protein,O
with,O
pivotal,O
function,O
in,O
glutamate,I-Entity
transmission,O
",",O
which,O
has,O
been,O
related,O
to,O
the,O
pathogenesis,O
of,O
these,O
complications,O
.,O
This,O
study,O
investigates,O
whether,O
polymorphisms,O
in,O
the,O
HOMER1,O
gene,O
promoter,O
region,O
are,O
associated,O
with,O
the,O
occurrence,O
of,O
the,O
chronic,O
complications,O
of,O
levodopa,I-Entity
therapy,O
.,O
A,O
total,O
of,O
205,O
patients,O
with,O
idiopathic,B-Entity
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
were,O
investigated,O
.,O
The,O
rs4704559,O
G,O
allele,O
was,O
associated,O
with,O
a,O
lower,O
prevalence,O
of,O
dyskinesia,I-Entity
(,O
prevalence,O
ratio,O
(,O
PR)=0.615,O
",",O
95%,O
confidence,O
interval,O
(,O
CI,O
),O
0.426,O
-,O
0.887,O
",",O
P=0.009,O
),O
and,O
visual,B-Entity
hallucinations,I-Entity
(,O
PR=0.515,O
",",O
95%,O
CI,O
0.295,O
-,O
0.899,O
",",O
P=0.020,O
),O
.,O
Our,O
data,O
suggest,O
that,O
HOMER1,O
rs4704559,O
G,O
allele,O
has,O
a,O
protective,O
role,O
for,O
the,O
development,O
of,O
levodopa,I-Entity
adverse,O
effects,O
.,O
Crocin,I-Entity
improves,O
lipid,O
dysregulation,O
in,O
subacute,O
diazinon,I-Entity
exposure,O
through,O
ERK1/2,O
pathway,O
in,O
rat,O
liver,O
.,O
Diazinon,I-Entity
Yis,O
one,O
of,O
the,O
most,O
broadly,O
used,O
organophosphorus,I-Entity
insecticides,O
in,O
agriculture,O
.,O
It,O
has,O
been,O
shown,O
that,O
exposure,O
to,O
diazinon,I-Entity
may,O
interfere,O
with,O
lipid,O
metabolism,O
.,O
Moreover,O
",",O
the,O
hypolipidemic,O
effect,O
of,O
crocin,I-Entity
has,O
been,O
established,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
changes,O
in,O
the,O
regulation,O
of,O
lipid,O
metabolism,O
",",O
ERK,O
and,O
LDLr,O
expression,O
in,O
the,O
liver,O
of,O
rats,O
exposed,O
to,O
subacute,O
diazinon,I-Entity
.,O
Furthermore,O
ameliorating,O
effect,O
of,O
crocin,I-Entity
on,O
diazinon,I-Entity
induced,O
disturbed,O
cholesterol,I-Entity
homeostasis,O
was,O
studied,O
.,O
24,O
Rats,O
were,O
divided,O
into,O
4,O
groups,O
and,O
received,O
following,O
treatments,O
for,O
4,O
weeks,O
;,O
Corn,O
oil,O
(,O
control,O
),O
",",O
diazinon,I-Entity
(,O
15mg,O
/,O
kg,O
per,O
day,O
",",O
orally,O
),O
and,O
crocin,I-Entity
(,O
12.5,O
and,O
25mg,O
/,O
kg,O
per,O
day,O
",",O
intraperitoneally,O
),O
in,O
combination,O
with,O
diazinon,I-Entity
(,O
15,O
mg,O
/,O
kg,O
),O
.,O
The,O
levels,O
of,O
cholesterol,I-Entity
",",O
triglyceride,I-Entity
and,O
LDL,O
in,O
blood,O
of,O
rats,O
were,O
analyzed,O
.,O
RESULTS,O
:,O
Our,O
data,O
showed,O
that,O
subacute,O
exposure,O
to,O
diazinon,I-Entity
significantly,O
increased,O
concentrations,O
of,O
cholesterol,I-Entity
",",O
triglyceride,I-Entity
and,O
LDL,O
.,O
Moreover,O
diazinon,I-Entity
decreased,O
ERK1/2,O
protein,O
phosphorylation,O
and,O
LDLr,O
transcript,O
.,O
Crocin,I-Entity
reduced,O
inhibition,O
of,O
ERK,O
activation,O
and,O
diazinon,I-Entity
-,O
induced,O
hyperlipemia,I-Entity
and,O
increased,O
levels,O
of,O
LDLr,O
transcript,O
.,O
Crocin,I-Entity
may,O
be,O
considered,O
as,O
a,O
novel,O
protective,O
agent,O
in,O
diazinon,I-Entity
-,O
induced,O
hyperlipemia,I-Entity
through,O
modulating,O
of,O
ERK,O
pathway,O
and,O
increase,O
of,O
LDLr,O
expression,O
.,O
GEM,I-Entity
-,O
P,O
chemotherapy,O
is,O
active,O
in,O
the,O
treatment,O
of,O
relapsed,O
Hodgkin,B-Entity
lymphoma,I-Entity
.,O
Hodgkin,B-Entity
lymphoma,I-Entity
(,O
HL,I-Entity
),O
is,O
a,O
relatively,O
chemosensitive,O
malignancy,I-Entity
.,O
Regimens,O
commonly,O
used,O
often,O
require,O
inpatient,O
administration,O
and,O
can,O
be,O
difficult,O
to,O
deliver,O
due,O
to,O
toxicity,I-Entity
.,O
Gemcitabine,I-Entity
and,O
cisplatin,I-Entity
have,O
activity,O
in,O
HL,I-Entity
",",O
non,O
-,O
overlapping,O
toxicity,I-Entity
with,O
first,O
-,O
line,O
chemotherapeutics,O
",",O
and,O
may,O
be,O
delivered,O
in,O
an,O
outpatient,O
setting,O
.,O
In,O
this,O
retrospective,O
single,O
-,O
centre,O
analysis,O
",",O
patients,O
with,O
relapsed,O
or,O
refractory,O
HL,I-Entity
treated,O
with,O
gemcitabine,I-Entity
"1,000",O
mg,O
/,O
m(2,O
),O
day,O
(,O
D)1,O
",",O
D8,O
and,O
D15,O
;,O
methylprednisolone,I-Entity
"1,000",O
mg,O
D1,O
-,O
5,O
;,O
and,O
cisplatin,I-Entity
100,O
mg,O
/,O
m(2,O
),O
D15,O
",",O
every,O
28,O
days,O
(,O
GEM,I-Entity
-,O
P,O
),O
were,O
included,O
.,O
Demographic,O
",",O
survival,O
",",O
response,O
and,O
toxicity,I-Entity
data,O
were,O
recorded,O
.,O
One,O
hundred,O
and,O
twenty,O
-,O
two,O
cycles,O
of,O
GEM,I-Entity
-,O
P,O
were,O
administered,O
in,O
total,O
(,O
median,O
3,O
cycles,O
;,O
range,O
1,O
-,O
6,O
),O
.,O
patients,O
received,O
GEM,I-Entity
-,O
P,O
as,O
second,O
-,O
line,O
treatment,O
and,O
11/41,O
(,O
27,O
%,O
),O
as,O
third,O
-,O
line,O
therapy,O
.,O
Overall,O
response,O
rate,O
(,O
ORR,O
),O
to,O
GEM,I-Entity
-,O
P,O
in,O
the,O
entire,O
cohort,O
was,O
80,O
%,O
(,O
complete,O
response,O
(,O
CR,O
),O
37,O
%,O
",",O
partial,O
response,O
44,O
%,O
),O
with,O
14/15,O
CR,O
confirmed,O
as,O
a,O
metabolic,O
CR,O
on,O
PET,O
and,O
ORR,O
of,O
85,O
%,O
in,O
the,O
20,O
second,O
-,O
line,O
patients,O
.,O
3/4,O
toxicities,I-Entity
were,O
haematological,O
:,O
neutropenia,I-Entity
54,O
%,O
and,O
thrombocytopenia,I-Entity
51,O
%,O
.,O
Median,O
follow,O
-,O
up,O
from,O
the,O
start,O
of,O
GEM,I-Entity
-,O
P,O
was,O
4.5,O
years,O
.,O
Following,O
GEM,I-Entity
-,O
P,O
",",O
5-year,O
progression,O
-,O
free,O
survival,O
was,O
46,O
%,O
(,O
95,O
%,O
confidence,O
interval,O
(,O
CI,O
),O
",",O
30,O
-,O
62,O
%,O
),O
and,O
5-year,O
overall,O
survival,O
was,O
59,O
%,O
(,O
95,O
%,O
CI,O
",",O
43,O
-,O
74,O
%,O
),O
.,O
GEM,I-Entity
-,O
P,O
is,O
a,O
salvage,O
chemotherapy,O
with,O
relatively,O
high,O
response,O
rates,O
",",O
leading,O
to,O
successful,O
transplantation,O
in,O
appropriate,O
patients,O
",",O
in,O
the,O
treatment,O
of,O
relapsed,O
or,O
refractory,O
HL,I-Entity
.,O
Basal,O
functioning,O
of,O
the,O
hypothalamic,O
-,O
pituitary,O
-,O
adrenal,O
(,O
HPA,O
),O
axis,O
and,O
psychological,O
distress,O
in,O
recreational,O
ecstasy,I-Entity
polydrug,O
users,O
.,O
RATIONALE,O
:,O
Ecstasy,I-Entity
(,O
MDMA,I-Entity
),O
is,O
a,O
psychostimulant,O
drug,O
which,O
is,O
increasingly,O
associated,O
with,O
psychobiological,B-Entity
dysfunction,I-Entity
.,O
The,O
current,O
study,O
is,O
the,O
first,O
to,O
explore,O
the,O
effects,O
of,O
ecstasy,I-Entity
-,O
polydrug,O
use,O
on,O
psychological,O
distress,O
and,O
basal,O
functioning,O
of,O
the,O
HPA,O
axis,O
through,O
assessing,O
the,O
secretion,O
of,O
cortisol,I-Entity
across,O
the,O
diurnal,O
period,O
.,O
METHOD,O
:,O
Seventy,O
-,O
six,O
participants,O
(,O
21,O
nonusers,O
",",O
29,O
light,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
",",O
26,O
heavy,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
),O
completed,O
a,O
substance,O
use,O
inventory,O
and,O
measures,O
of,O
psychological,O
distress,O
at,O
baseline,O
",",O
then,O
two,O
consecutive,O
days,O
of,O
cortisol,I-Entity
sampling,O
(,O
on,O
awakening,O
",",O
30,O
min,O
post,O
awakening,O
",",O
between,O
1400,O
and,O
1600,O
hours,O
and,O
pre,O
bedtime,O
),O
.,O
Both,O
user,O
groups,O
exhibited,O
significantly,O
greater,O
levels,O
of,O
anxiety,I-Entity
and,O
depression,I-Entity
than,O
nonusers,O
.,O
On,O
day,O
1,O
",",O
all,O
participants,O
exhibited,O
a,O
typical,O
cortisol,I-Entity
profile,O
",",O
though,O
light,O
users,O
had,O
significantly,O
elevated,O
levels,O
pre,O
-,O
bed,O
.,O
On,O
day,O
2,O
",",O
heavy,O
users,O
demonstrated,O
elevated,O
levels,O
upon,O
awakening,O
and,O
all,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
demonstrated,O
elevated,O
pre,O
-,O
bed,O
levels,O
compared,O
to,O
non,O
-,O
users,O
.,O
Significant,O
between,O
group,O
differences,O
were,O
also,O
observed,O
in,O
afternoon,O
cortisol,I-Entity
levels,O
and,O
in,O
overall,O
cortisol,I-Entity
secretion,O
across,O
the,O
day,O
.,O
The,O
increases,O
in,O
anxiety,I-Entity
and,O
depression,I-Entity
are,O
in,O
line,O
with,O
previous,O
observations,O
in,O
recreational,O
ecstasy,I-Entity
-,O
polydrug,O
users,O
.,O
Dysregulated,O
diurnal,O
cortisol,I-Entity
may,O
be,O
indicative,O
of,O
inappropriate,O
anticipation,O
of,O
forthcoming,O
demands,O
and,O
hypersecretion,O
may,O
lead,O
to,O
the,O
increased,O
psychological,O
and,O
physical,O
morbidity,O
associated,O
with,O
heavy,O
recreational,O
use,O
of,O
ecstasy,I-Entity
.,O
Ifosfamide,I-Entity
related,O
encephalopathy,I-Entity
:,O
the,O
need,O
for,O
a,O
timely,O
EEG,O
evaluation,O
.,O
Ifosfamide,I-Entity
is,O
an,O
alkylating,O
agent,O
useful,O
in,O
the,O
treatment,O
of,O
a,O
wide,O
range,O
of,O
cancers,I-Entity
including,O
sarcomas,I-Entity
",",O
lymphoma,I-Entity
",",O
gynecologic,B-Entity
and,I-Entity
testicular,I-Entity
cancers,I-Entity
.,O
Encephalopathy,I-Entity
has,O
been,O
reported,O
in,O
10,O
-,O
40%,O
of,O
patients,O
receiving,O
high,O
-,O
dose,O
IV,O
ifosfamide,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
highlight,O
the,O
role,O
of,O
electroencephalogram,O
(,O
EEG,O
),O
in,O
the,O
early,O
detection,O
and,O
management,O
of,O
ifosfamide,I-Entity
related,O
encephalopathy,I-Entity
.,O
Retrospective,O
chart,O
review,O
including,O
clinical,O
data,O
and,O
EEG,O
recordings,O
was,O
done,O
on,O
five,O
patients,O
",",O
admitted,O
to,O
MD,O
Anderson,O
Cancer,I-Entity
Center,O
between,O
years,O
2009,O
and,O
2012,O
",",O
who,O
developed,O
ifosfamide,I-Entity
related,O
acute,O
encephalopathy,I-Entity
.,O
All,O
five,O
patients,O
experienced,O
symptoms,O
of,O
encephalopathy,I-Entity
soon,O
after,O
(,O
within,O
12,O
h-2,O
days,O
),O
receiving,O
ifosfamide,I-Entity
.,O
Two,O
patients,O
developed,O
generalized,O
convulsions,I-Entity
while,O
one,O
patient,O
developed,O
continuous,O
non,B-Entity
-,I-Entity
convulsive,I-Entity
status,I-Entity
epilepticus,I-Entity
(,O
NCSE,I-Entity
),O
that,O
required,O
ICU,O
admission,O
and,O
intubation,O
.,O
CONCLUSIONS,O
:,O
Severity,O
of,O
ifosfamide,I-Entity
related,O
encephalopathy,I-Entity
correlates,O
with,O
EEG,O
changes,O
.,O
We,O
suggest,O
a,O
timely,O
EEG,O
evaluation,O
for,O
patients,O
receiving,O
ifosfamide,I-Entity
who,O
develop,O
features,O
of,O
encephalopathy,I-Entity
.,O
Incidence,O
of,O
contrast,I-Entity
-,O
induced,O
nephropathy,I-Entity
in,O
hospitalised,O
patients,O
with,O
cancer,I-Entity
.,O
OBJECTIVES,O
:,O
To,O
determine,O
the,O
frequency,O
of,O
and,O
possible,O
factors,O
related,O
to,O
contrast,I-Entity
-,O
induced,O
nephropathy,I-Entity
(,O
CIN,O
),O
in,O
hospitalised,O
patients,O
with,O
cancer,I-Entity
.,O
Patients,O
with,O
risk,O
factors,O
for,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
were,O
excluded,O
.,O
Blood,O
samples,O
were,O
examined,O
the,O
day,O
before,O
contrast,I-Entity
-,O
enhanced,O
computed,O
tomography,O
(,O
CT,O
),O
and,O
serially,O
for,O
3,O
days,O
thereafter,O
.,O
CIN,O
was,O
defined,O
as,O
an,O
increase,O
in,O
serum,O
creatinine,I-Entity
(,O
Cr,I-Entity
),O
of,O
0.5,O
mg,O
/,O
dl,O
or,O
more,O
",",O
or,O
elevation,O
of,O
Cr,I-Entity
to,O
25,O
%,O
over,O
baseline,O
.,O
CIN,O
was,O
significantly,O
more,O
after,O
treatment,O
with,O
bevacizumab,I-Entity
/,O
irinotecan,I-Entity
(,O
P,O
=,O
0.021,O
),O
and,O
in,O
patients,O
with,O
hypertension,I-Entity
(,O
P,O
=,O
0.044,O
),O
.,O
CIN,O
developed,O
4.5-times,O
more,O
frequently,O
in,O
patients,O
with,O
cancer,I-Entity
who,O
had,O
undergone,O
recent,O
chemotherapy,O
.,O
Hypertension,I-Entity
and,O
the,O
combination,O
of,O
bevacizumab,I-Entity
/,O
irinotecan,I-Entity
may,O
be,O
additional,O
risk,O
factors,O
for,O
CIN,O
development,O
.,O
Contrast,I-Entity
-,O
induced,O
nephropathy,I-Entity
(,O
CIN,O
),O
is,O
a,O
concern,O
for,O
oncological,O
patients,O
undergoing,O
CT,O
.,O
.,O
Hypertension,I-Entity
and,O
treatment,O
with,O
bevacizumab,I-Entity
appear,O
to,O
be,O
additional,O
risk,O
factors,O
.,O
Syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
antidiuretic,I-Entity
hormone,I-Entity
secretion,O
associated,O
with,O
desvenlafaxine,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
anti,I-Entity
-,I-Entity
diuretic,I-Entity
hormone,I-Entity
(,O
SIADH,I-Entity
),O
secretion,O
associated,O
with,O
desvenlafaxine,I-Entity
.,O
A,O
57-year,O
old,O
female,O
with,O
hyponatraemia,I-Entity
.,O
Her,O
medications,O
included,O
desvenlafaxine,I-Entity
",",O
and,O
symptoms,O
included,O
nausea,I-Entity
",",O
anxiety,I-Entity
and,O
confusion,I-Entity
.,O
The,O
serum,O
sodium,I-Entity
at,O
this,O
time,O
was,O
120,O
mmol,O
/,O
L,O
",",O
serum,O
osmolality,O
was,O
263,O
mosmol,O
/,O
kg,O
",",O
urine,O
osmolality,O
410,O
mosmol,O
/,O
kg,O
and,O
urine,O
sodium,I-Entity
63,O
mmol,O
/,O
L,O
",",O
consistent,O
with,O
a,O
diagnosis,O
of,O
SIADH,I-Entity
.,O
Desvenlafaxine,I-Entity
was,O
ceased,O
and,O
fluid,O
restriction,O
implemented,O
.,O
After,O
4,O
days,O
the,O
sodium,I-Entity
increased,O
to,O
128,O
mmol,O
/,O
L,O
and,O
fluid,O
restriction,O
was,O
relaxed,O
.,O
During,O
her,O
further,O
3,O
weeks,O
inpatient,O
admission,O
the,O
serum,O
sodium,I-Entity
ranged,O
from,O
134,O
to,O
137,O
mmol,O
/,O
L,O
during,O
treatment,O
with,O
mirtazapine,I-Entity
.,O
SIADH,I-Entity
has,O
been,O
widely,O
reported,O
with,O
a,O
range,O
of,O
antidepressants,O
.,O
This,O
case,O
report,O
suggests,O
that,O
desvenlafaxine,I-Entity
might,O
cause,O
clinically,O
significant,O
hyponatremia,I-Entity
.,O
Clinicians,O
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
antidepressants,O
to,O
cause,O
hyponatremia,I-Entity
",",O
and,O
take,O
appropriate,O
corrective,O
action,O
where,O
necessary,O
.,O
Oxidative,O
stress,O
on,O
cardiotoxicity,I-Entity
after,O
treatment,O
with,O
single,O
and,O
multiple,O
doses,O
of,O
doxorubicin,I-Entity
.,O
The,O
mechanism,O
of,O
doxorubicin,I-Entity
(,O
DOX)-induced,I-Entity
cardiotoxicity,I-Entity
remains,O
controversial,O
.,O
Wistar,O
rats,O
(,O
n,O
=,O
66,O
),O
received,O
DOX,I-Entity
injections,O
intraperitoneally,O
and,O
were,O
randomly,O
assigned,O
to,O
2,O
experimental,O
protocols,O
:,O
(,O
1,O
),O
rats,O
were,O
killed,O
before,O
(,O
-24,O
h,O
",",O
n,O
=,O
8),O
and,O
24,O
h,O
after,O
(,O
+,O
24,O
h,O
",",O
n,O
=,O
8),O
a,O
single,O
dose,O
of,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
body,O
weight,O
),O
to,O
determine,O
the,O
DOX,I-Entity
acute,O
effect,O
and,O
(,O
2,O
),O
rats,O
(,O
n,O
=,O
58,O
),O
received,O
4,O
injections,O
of,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
body,O
weight,O
/,O
week,O
),O
and,O
were,O
killed,O
before,O
the,O
first,O
injection,O
(,O
M0,O
),O
and,O
1,O
week,O
after,O
each,O
injection,O
(,O
M1,O
",",O
M2,O
",",O
M3,O
",",O
and,O
M4,O
),O
to,O
determine,O
the,O
chronological,O
effects,O
.,O
Single,O
dose,O
of,O
DOX,I-Entity
was,O
associated,O
with,O
increased,O
cardiac,B-Entity
disarrangement,I-Entity
",",O
necrosis,I-Entity
",",O
and,O
DNA,O
damage,O
(,O
strand,O
breaks,O
(,O
SBs,O
),O
and,O
oxidized,O
pyrimidines,O
),O
and,O
decreased,O
TAP,O
.,O
The,O
chronological,O
study,O
showed,O
an,O
effect,O
of,O
a,O
cumulative,O
dose,O
on,O
body,O
weight,O
(,O
R,O
=,O
-0.99,O
",",O
p,O
=,O
0.011,O
),O
",",O
necrosis,I-Entity
(,O
R,O
=,O
1.00,O
",",O
p,O
=,O
0.004,O
),O
",",O
TAP,O
(,O
DNA,O
SBs,O
damage,O
was,O
negatively,O
associated,O
with,O
TAP,O
(,O
R,O
=,O
-0.98,O
",",O
p,O
=,O
0.018,O
),O
",",O
and,O
necrosis,I-Entity
Our,O
results,O
suggest,O
that,O
oxidative,O
damage,O
is,O
associated,O
with,O
acute,O
cardiotoxicity,I-Entity
induced,O
by,O
a,O
single,O
dose,O
of,O
DOX,I-Entity
only,O
.,O
Increased,O
resistance,O
to,O
the,O
oxidative,O
stress,O
is,O
plausible,O
for,O
the,O
multiple,O
dose,O
of,O
DOX,I-Entity
.,O
Thus,O
",",O
different,O
mechanisms,O
may,O
be,O
involved,O
in,O
acute,O
toxicity,I-Entity
versus,O
chronic,O
toxicity,I-Entity
.,O
Tacrolimus,I-Entity
-,O
related,O
seizure,I-Entity
after,O
pediatric,O
liver,O
transplantation,O
--,O
a,O
single,O
-,O
center,O
experience,O
.,O
To,O
identify,O
the,O
risk,O
factors,O
for,O
new,O
-,O
onset,O
seizures,I-Entity
after,O
pediatric,O
LT,O
and,O
to,O
assess,O
their,O
clinical,O
implications,O
and,O
long,O
-,O
term,O
prognosis,O
.,O
Patients,O
were,O
divided,O
into,O
seizures,I-Entity
group,O
and,O
a,O
non,O
-,O
seizures,I-Entity
group,O
.,O
Seizures,I-Entity
occurred,O
in,O
four,O
children,O
",",O
an,O
incidence,O
of,O
14.8%,O
.,O
All,O
exhibited,O
generalized,O
tonic,B-Entity
-,I-Entity
clonic,I-Entity
seizures,I-Entity
within,O
the,O
first,O
two,O
wk,O
after,O
LT,O
.,O
Univariate,O
analysis,O
showed,O
that,O
the,O
risk,O
factors,O
associated,O
with,O
seizures,I-Entity
after,O
pediatric,O
LT,O
included,O
gender,O
",",O
pediatric,O
end,B-Entity
-,I-Entity
stage,I-Entity
liver,I-Entity
disease,I-Entity
score,O
before,O
surgery,O
",",O
Child,O
-,O
Pugh,O
score,O
before,O
surgery,O
",",O
serum,O
total,O
bilirubin,I-Entity
after,O
surgery,O
",",O
and,O
trough,O
TAC,I-Entity
level,O
.,O
Multivariate,O
analysis,O
showed,O
that,O
trough,O
TAC,I-Entity
level,O
was,O
the,O
only,O
independent,O
risk,O
factor,O
associated,O
with,O
the,O
seizures,I-Entity
.,O
All,O
children,O
who,O
experienced,O
seizures,I-Entity
survived,O
with,O
good,O
graft,O
function,O
and,O
remained,O
seizure,I-Entity
-,O
free,O
without,O
anti,O
-,O
epileptic,I-Entity
drugs,O
over,O
a,O
mean,O
follow,O
-,O
up,O
period,O
of,O
33.7,O
+,O
14.6,O
months,O
.,O
High,O
trough,O
TAC,I-Entity
level,O
was,O
the,O
predominant,O
factor,O
that,O
contributed,O
to,O
seizures,I-Entity
in,O
the,O
early,O
post,O
-,O
operative,O
period,O
after,O
pediatric,O
LT,O
.,O
High,O
PELD,O
and,O
Child,O
-,O
Pugh,O
scores,O
before,O
LT,O
and,O
high,O
post,O
-,O
operative,O
serum,O
Tbil,O
may,O
be,O
contributory,O
risk,O
factors,O
for,O
TAC,I-Entity
-,O
related,O
seizures,I-Entity
.,O
The,O
flavonoid,I-Entity
apigenin,I-Entity
delays,O
forgetting,O
of,O
passive,O
avoidance,O
conditioning,O
in,O
rats,O
.,O
The,O
present,O
experiments,O
were,O
performed,O
to,O
study,O
the,O
effect,O
of,O
the,O
flavonoid,I-Entity
apigenin,I-Entity
(,O
20,O
mg,O
/,O
kg,O
intraperitoneally,O
(,O
i.p,O
.,O
),O
",",O
1,O
h,O
before,O
acquisition,O
),O
",",O
on,O
24,O
h,O
retention,O
performance,O
and,O
forgetting,O
of,O
a,O
step,O
-,O
through,O
passive,O
avoidance,O
task,O
",",O
in,O
young,O
male,O
Wistar,O
rats,O
.,O
There,O
were,O
no,O
differences,O
between,O
saline-,O
and,O
apigenin,I-Entity
-,O
treated,O
groups,O
in,O
the,O
24,O
h,O
retention,O
trial,O
.,O
Furthermore,O
",",O
apigenin,I-Entity
did,O
not,O
prevent,O
the,O
amnesia,I-Entity
induced,O
by,O
scopolamine,I-Entity
(,O
1mg,O
/,O
kg,O
",",O
i.p,O
.,O
The,O
saline-,O
and,O
apigenin,I-Entity
-,O
treated,O
rats,O
that,O
did,O
not,O
step,O
through,O
into,O
the,O
dark,O
compartment,O
during,O
the,O
cut,O
-,O
off,O
time,O
(,O
540,O
s,O
),O
were,O
retested,O
weekly,O
for,O
up,O
to,O
eight,O
weeks,O
.,O
In,O
the,O
saline,O
treated,O
group,O
",",O
the,O
first,O
significant,O
decline,O
in,O
passive,O
avoidance,O
response,O
was,O
observed,O
at,O
four,O
weeks,O
",",O
and,O
complete,O
memory,B-Entity
loss,I-Entity
was,O
found,O
five,O
weeks,O
after,O
the,O
acquisition,O
of,O
the,O
passive,O
avoidance,O
task,O
.,O
At,O
the,O
end,O
of,O
the,O
experimental,O
period,O
",",O
60%,O
of,O
the,O
animals,O
treated,O
with,O
apigenin,I-Entity
still,O
did,O
not,O
step,O
through,O
.,O
These,O
data,O
suggest,O
that,O
1,O
),O
apigenin,I-Entity
delays,O
the,O
long,O
-,O
term,O
forgetting,O
but,O
did,O
not,O
modulate,O
the,O
24,O
h,O
retention,O
of,O
fear,O
memory,O
and,O
2,O
),O
the,O
obtained,O
beneficial,O
effect,O
of,O
apigenin,I-Entity
on,O
the,O
passive,O
avoidance,O
conditioning,O
is,O
mediated,O
by,O
mechanisms,O
that,O
do,O
not,O
implicate,O
its,O
action,O
on,O
the,O
muscarinic,O
cholinergic,O
system,O
.,O
Cholecystokinin,B-Entity
-,I-Entity
octapeptide,I-Entity
restored,O
morphine,I-Entity
-,O
induced,O
hippocampal,O
long,O
-,O
term,O
potentiation,O
impairment,O
in,O
rats,O
.,O
Cholecystokinin,B-Entity
-,I-Entity
octapeptide,I-Entity
(,O
CCK-8,I-Entity
),O
",",O
which,O
is,O
a,O
typical,O
brain,O
-,O
gut,O
peptide,O
",",O
exerts,O
a,O
wide,O
range,O
of,O
biological,O
activities,O
on,O
the,O
central,O
nervous,O
system,O
.,O
We,O
have,O
previously,O
reported,O
that,O
CCK-8,I-Entity
significantly,O
alleviated,O
morphine,I-Entity
-,O
induced,O
amnesia,I-Entity
and,O
reversed,O
spine,O
density,O
decreases,O
in,O
the,O
CA1,O
region,O
of,O
the,O
hippocampus,O
in,O
morphine,I-Entity
-,O
treated,O
animals,O
.,O
Here,O
",",O
we,O
investigated,O
the,O
effects,O
of,O
CCK-8,I-Entity
on,O
long,O
-,O
term,O
potentiation,O
(,O
LTP,O
),O
in,O
the,O
lateral,O
perforant,O
path,O
(,O
LPP)-granule,O
cell,O
synapse,O
of,O
rat,O
dentate,O
gyrus,O
(,O
DG,O
),O
in,O
acute,O
saline,O
or,O
morphine,I-Entity
-,O
treated,O
rats,O
.,O
Acute,O
morphine,I-Entity
treatment,O
significantly,O
attenuated,O
hippocampal,O
LTP,O
and,O
CCK-8,I-Entity
(,O
1ug,O
",",O
i.c.v,O
.,O
),O
restored,O
the,O
amplitude,O
of,O
PS,O
that,O
was,O
attenuated,O
by,O
morphine,I-Entity
injection,O
.,O
Furthermore,O
",",O
microinjection,O
of,O
CCK-8,I-Entity
(,O
0.1,O
and,O
1ug,O
",",O
i.c.v,O
.,O
),O
also,O
significantly,O
augmented,O
hippocampal,O
LTP,O
in,O
saline,O
-,O
treated,O
(,O
1ml,O
/,O
kg,O
",",O
s.c,O
.,O
),O
rats,O
.,O
Pre,O
-,O
treatment,O
of,O
the,O
CCK2,O
receptor,O
antagonist,O
"L-365,260",O
(,O
10ug,O
",",O
i.c.v,O
),O
reversed,O
the,O
effects,O
of,O
CCK-8,I-Entity
",",O
but,O
the,O
CCK1,O
receptor,O
antagonist,O
"L-364,718",O
(,O
10ug,O
",",O
The,O
present,O
results,O
demonstrate,O
that,O
CCK-8,I-Entity
attenuates,O
the,O
effect,O
of,O
morphine,I-Entity
on,O
hippocampal,O
LTP,O
through,O
CCK2,O
receptors,O
and,O
suggest,O
an,O
ameliorative,O
function,O
of,O
CCK-8,I-Entity
on,O
morphine,I-Entity
-,O
induced,O
memory,B-Entity
impairment,I-Entity
.,O
Glial,O
activation,O
and,O
post,O
-,O
synaptic,O
neurotoxicity,I-Entity
:,O
the,O
key,O
events,O
in,O
Streptozotocin,I-Entity
(,O
ICV,O
),O
induced,O
memory,B-Entity
impairment,I-Entity
in,O
rats,O
.,O
In,O
the,O
present,O
study,O
the,O
role,O
of,O
glial,O
activation,O
and,O
post,O
synaptic,O
toxicity,I-Entity
in,O
ICV,O
Streptozotocin,I-Entity
(,O
STZ,I-Entity
),O
induced,O
memory,B-Entity
impaired,I-Entity
rats,O
was,O
explored,O
.,O
In,O
experiment,O
set,O
up,O
1,O
:,O
Memory,B-Entity
deficit,I-Entity
was,O
found,O
in,O
Morris,O
water,O
maze,O
test,O
on,O
14,O
-,O
16,O
days,O
after,O
STZ,I-Entity
(,O
ICV,O
;,O
3mg,O
/,O
Kg,O
),O
administration,O
.,O
STZ,I-Entity
causes,O
increased,O
expression,O
of,O
GFAP,O
",",O
CD11b,O
and,O
TNF,O
-,O
a,O
indicating,O
glial,O
activation,O
and,O
neuroinflammation,I-Entity
.,O
STZ,I-Entity
also,O
significantly,O
increased,O
the,O
level,O
of,O
ROS,O
",",O
nitrite,I-Entity
",",O
Ca(2,I-Entity
+,O
),O
and,O
reduced,O
the,O
mitochondrial,O
activity,O
in,O
synaptosomal,O
preparation,O
illustrating,O
free,O
radical,O
generation,O
and,O
excitotoxicity,I-Entity
.,O
Increased,O
expression,O
and,O
activity,O
of,O
Caspase-3,O
was,O
also,O
observed,O
in,O
STZ,I-Entity
treated,O
rat,O
which,O
specify,O
apoptotic,O
cell,O
death,O
in,O
hippocampus,O
and,O
cortex,O
.,O
STZ,I-Entity
treatment,O
showed,O
decrease,O
expression,O
of,O
post,O
synaptic,O
markers,O
CaMKIIa,O
and,O
PSD-95,O
",",O
while,O
",",O
expression,O
of,O
pre,O
synaptic,O
markers,O
(,O
synaptophysin,O
and,O
SNAP-25,O
),O
remains,O
unaltered,O
indicating,O
selective,O
post,O
synaptic,O
neurotoxicity,I-Entity
.,O
Oral,O
treatment,O
with,O
Memantine,I-Entity
(,O
10mg,O
/,O
kg,O
),O
and,O
Ibuprofen,I-Entity
(,O
50,O
mg,O
/,O
kg,O
),O
daily,O
for,O
13,O
days,O
attenuated,O
STZ,I-Entity
induced,O
glial,O
activation,O
",",O
apoptotic,O
cell,O
death,O
and,O
post,O
synaptic,O
neurotoxicity,I-Entity
in,O
rat,O
brain,O
.,O
Further,O
",",O
in,O
experiment,O
set,O
up,O
2,O
:,O
where,O
memory,O
function,O
was,O
not,O
affected,O
i.e.,O
7,O
-,O
9,O
days,O
after,O
STZ,I-Entity
treatment,O
.,O
The,O
level,O
of,O
GFAP,O
",",O
CD11b,O
",",O
TNF,O
-,O
a,O
",",O
ROS,O
and,O
nitrite,I-Entity
levels,O
were,O
increased,O
.,O
On,O
the,O
other,O
hand,O
",",O
apoptotic,O
marker,O
",",O
synaptic,O
markers,O
",",O
mitochondrial,O
activity,O
and,O
Ca(2,I-Entity
+,O
),O
levels,O
remained,O
unaffected,O
.,O
Collective,O
data,O
indicates,O
that,O
neuroinflammatory,I-Entity
process,O
and,O
oxidative,O
stress,O
occurs,O
earlier,O
to,O
apoptosis,O
and,O
does,O
not,O
affect,O
memory,O
function,O
.,O
Present,O
study,O
clearly,O
suggests,O
that,O
glial,O
activation,O
and,O
post,O
synaptic,O
neurotoxicity,I-Entity
are,O
the,O
key,O
factors,O
in,O
STZ,I-Entity
induced,O
memory,B-Entity
impairment,I-Entity
and,O
neuronal,O
cell,O
death,O
.,O
Comparison,O
of,O
effects,O
of,O
isotonic,O
sodium,B-Entity
chloride,I-Entity
with,O
diltiazem,I-Entity
in,O
prevention,O
of,O
contrast,I-Entity
-,O
induced,O
nephropathy,I-Entity
.,O
INTRODUCTION,O
AND,O
OBJECTIVE,O
:,O
Contrast,I-Entity
-,O
induced,O
nephropathy,I-Entity
(,O
CIN,O
),O
significantly,O
increases,O
the,O
morbidity,O
and,O
mortality,O
of,O
patients,O
.,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
investigate,O
and,O
compare,O
the,O
protective,O
effects,O
of,O
isotonic,O
sodium,B-Entity
chloride,I-Entity
with,O
sodium,B-Entity
bicarbonate,I-Entity
infusion,O
and,O
isotonic,O
sodium,B-Entity
chloride,I-Entity
infusion,O
with,O
diltiazem,I-Entity
",",O
a,O
calcium,I-Entity
channel,O
blocker,O
",",O
in,O
preventing,O
CIN,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
Our,O
study,O
included,O
patients,O
who,O
were,O
administered,O
30,O
-,O
60,O
mL,O
of,O
iodinated,O
contrast,I-Entity
agent,O
for,O
percutaneous,O
coronary,O
angiography,O
(,O
PCAG,O
),O
",",O
all,O
with,O
creatinine,I-Entity
values,O
between,O
1.1,O
and,O
3.1,O
mg,O
/,O
dL.,O
Patients,O
were,O
divided,O
into,O
three,O
groups,O
and,O
each,O
group,O
had,O
20,O
patients,O
.,O
The,O
first,O
group,O
of,O
patients,O
was,O
administered,O
isotonic,O
sodium,B-Entity
chloride,I-Entity
;,O
the,O
second,O
group,O
was,O
administered,O
a,O
solution,O
that,O
of,O
5%,O
dextrose,I-Entity
and,O
sodium,B-Entity
bicarbonate,I-Entity
",",O
while,O
the,O
third,O
group,O
was,O
administered,O
isotonic,O
sodium,B-Entity
chloride,I-Entity
before,O
and,O
after,O
the,O
contrast,I-Entity
injection,O
.,O
The,O
third,O
group,O
received,O
an,O
additional,O
injection,O
of,O
diltiazem,I-Entity
the,O
day,O
before,O
and,O
first,O
2,O
days,O
after,O
the,O
contrast,I-Entity
injection,O
.,O
All,O
of,O
the,O
patients,O
',O
plasma,O
blood,B-Entity
urea,I-Entity
nitrogen,I-Entity
(,O
BUN,I-Entity
),O
and,O
creatinine,I-Entity
levels,O
were,O
measured,O
on,O
the,O
second,O
and,O
seventh,O
day,O
after,O
the,O
administration,O
of,O
intravenous,O
contrast,I-Entity
material,O
.,O
The,O
basal,O
creatinine,I-Entity
levels,O
were,O
similar,O
for,O
all,O
three,O
groups,O
(,O
p,O
>,O
0.05,O
),O
.,O
Among,O
a,O
total,O
of,O
60,O
patients,O
included,O
in,O
the,O
study,O
",",O
16,O
patients,O
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
(,O
ARF,I-Entity
),O
on,O
the,O
second,O
day,O
after,O
contrast,I-Entity
material,O
was,O
injected,O
(,O
26.6%,O
),O
.,O
The,O
number,O
of,O
patients,O
who,O
developed,O
ARF,I-Entity
on,O
the,O
second,O
day,O
after,O
the,O
injection,O
in,O
the,O
first,O
group,O
was,O
five,O
(,O
25%,O
),O
",",O
in,O
the,O
second,O
group,O
was,O
six,O
(,O
30%,O
),O
and,O
the,O
third,O
group,O
was,O
five,O
(,O
25%,O
),O
(,O
p,O
>,O
0.05,O
),O
.,O
CONCLUSION,O
:,O
There,O
was,O
no,O
significant,O
difference,O
between,O
isotonic,O
sodium,B-Entity
chloride,I-Entity
",",O
sodium,B-Entity
bicarbonate,I-Entity
and,O
isotonic,O
sodium,B-Entity
chloride,I-Entity
with,O
diltiazem,I-Entity
application,O
in,O
prevention,O
of,O
CIN,O
.,O
Neurocognitive,O
and,O
neuroradiologic,O
central,O
nervous,O
system,O
late,O
effects,O
in,O
children,O
treated,O
on,O
Pediatric,O
Oncology,O
Group,O
(,O
POG,O
),O
P9605,O
(,O
standard,O
risk,O
),O
and,O
P9201,O
(,O
lesser,O
risk,O
),O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
protocols,O
(,O
ACCL0131,O
),O
:,O
a,O
methotrexate,I-Entity
consequence,O
?,O
Concerns,O
about,O
long,O
-,O
term,O
methotrexate,I-Entity
(,O
MTX,I-Entity
),O
neurotoxicity,I-Entity
in,O
the,O
1990s,O
led,O
to,O
modifications,O
in,O
intrathecal,O
(,O
IT,O
),O
therapy,O
",",O
leucovorin,O
rescue,O
",",O
and,O
frequency,O
of,O
systemic,O
MTX,I-Entity
administration,O
in,O
children,O
with,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
.,O
In,O
this,O
study,O
",",O
neurocognitive,O
outcomes,O
and,O
neuroradiologic,O
evidence,O
of,O
leukoencephalopathy,I-Entity
were,O
compared,O
in,O
children,O
treated,O
with,O
intense,O
central,O
nervous,O
system,O
(,O
CNS)-directed,O
therapy,O
(,O
P9605,O
),O
versus,O
those,O
receiving,O
fewer,O
CNS,O
-,O
directed,O
treatment,O
days,O
during,O
intensive,O
consolidation,O
(,O
P9201,O
),O
.,O
A,O
total,O
of,O
66,O
children,O
from,O
16,O
Pediatric,O
Oncology,O
Group,O
institutions,O
with,O
"""",O
standard,O
-,O
risk,O
"""",O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
",",O
1.00,O
to,O
9.99,O
years,O
at,O
diagnosis,O
",",O
without,O
evidence,O
of,O
CNS,O
leukemia,I-Entity
at,O
diagnosis,O
were,O
enrolled,O
on,O
ACCL0131,O
:,O
28,O
from,O
P9201,O
and,O
38,O
from,O
P9605,O
.,O
Significantly,O
more,O
P9605,O
patients,O
developed,O
leukoencephalopathy,I-Entity
compared,O
with,O
P9201,O
patients,O
(,O
68%,O
",",O
95%,O
confidence,O
interval,O
49%-83%,O
vs.,O
22%,O
",",O
95%,O
confidence,O
interval,O
5%-44%,O
;,O
P=0.001,O
),O
identified,O
as,O
late,O
as,O
7.7,O
years,O
after,O
the,O
end,O
of,O
treatment,O
.,O
Children,O
on,O
both,O
studies,O
had,O
significant,O
attention,B-Entity
problems,I-Entity
",",O
but,O
P9605,O
children,O
scored,O
below,O
average,O
on,O
more,O
neurocognitive,O
measures,O
than,O
those,O
treated,O
on,O
P9201,O
(,O
82%,O
",",O
14/17,O
measures,O
vs.,O
24%,O
",",O
4/17,O
measures,O
),O
.,O
This,O
supports,O
ongoing,O
concerns,O
about,O
intensive,O
MTX,I-Entity
exposure,O
as,O
a,O
major,O
contributor,O
to,O
CNS,O
late,O
effects,O
.,O
Tranexamic,B-Entity
acid,I-Entity
overdosage,O
-,O
induced,O
generalized,O
seizure,I-Entity
in,O
renal,B-Entity
failure,I-Entity
.,O
We,O
report,O
a,O
45-year,O
-,O
old,O
lady,O
with,O
chronic,B-Entity
kidney,I-Entity
disease,I-Entity
stage,O
4,O
due,O
to,O
chronic,O
tubulointerstial,B-Entity
disease,I-Entity
.,O
She,O
was,O
admitted,O
to,O
our,O
center,O
for,O
severe,O
anemia,I-Entity
due,O
to,O
menorrhagia,I-Entity
and,O
deterioration,B-Entity
of,I-Entity
renal,I-Entity
function,I-Entity
.,O
Tranexamic,B-Entity
acid,I-Entity
(,O
TNA,I-Entity
),O
1,O
g,O
8-hourly,O
was,O
administered,O
to,O
her,O
to,O
control,O
bleeding,I-Entity
per,O
vaginum,O
.,O
Two,O
hours,O
after,O
the,O
sixth,O
dose,O
of,O
TNA,I-Entity
",",O
she,O
had,O
an,O
episode,O
of,O
generalized,O
tonic,B-Entity
clonic,I-Entity
convulsions,I-Entity
.,O
TNA,I-Entity
was,O
discontinued,O
.,O
Investigations,O
of,O
the,O
patient,O
revealed,O
no,O
biochemical,O
or,O
structural,O
central,O
nervous,B-Entity
system,I-Entity
abnormalities,I-Entity
that,O
could,O
have,O
provoked,O
the,O
convulsions,I-Entity
.,O
She,O
had,O
no,O
further,O
episodes,O
of,O
convulsion,I-Entity
till,O
dis,O
-,O
charge,O
and,O
during,O
the,O
two,O
months,O
of,O
follow,O
-,O
up,O
.,O
Thus,O
",",O
the,O
precipitating,O
cause,O
of,O
convulsions,I-Entity
was,O
believed,O
to,O
be,O
an,O
overdose,I-Entity
of,O
TNA,I-Entity
.,O
Pre,O
-,O
treatment,O
of,O
bupivacaine,I-Entity
-,O
induced,O
cardiovascular,B-Entity
depression,I-Entity
using,O
different,O
lipid,O
formulations,O
of,O
propofol,I-Entity
.,O
Pre,O
-,O
treatment,O
with,O
lipid,O
emulsions,O
has,O
been,O
shown,O
to,O
increase,O
lethal,O
doses,O
of,O
bupivacaine,I-Entity
",",O
and,O
the,O
lipid,O
content,O
of,O
propofol,I-Entity
may,O
alleviate,O
bupivacaine,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
investigate,O
the,O
effects,O
of,O
propofol,I-Entity
in,O
intralipid,O
or,O
medialipid,O
emulsions,O
on,O
bupivacaine,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Rats,O
were,O
anaesthetised,O
with,O
ketamine,I-Entity
and,O
were,O
given,O
0.5,O
mg,O
/,O
kg,O
/,O
min,O
propofol,I-Entity
in,O
intralipid,O
(,O
Group,O
P,O
),O
",",O
propofol,I-Entity
in,O
medialipid,O
(,O
Group,O
L,O
),O
",",O
or,O
saline,O
(,O
Group,O
C,O
),O
over,O
20,O
min,O
.,O
bupivacaine,I-Entity
0.5%,O
was,O
infused,O
.,O
We,O
recorded,O
time,O
to,O
first,O
dysrhythmia,I-Entity
occurrence,O
",",O
respective,O
times,O
to,O
25%,O
and,O
50%,O
reduction,O
of,O
the,O
heart,O
rate,O
(,O
HR,O
),O
and,O
mean,O
arterial,O
pressure,O
",",O
and,O
time,O
to,O
asystole,I-Entity
and,O
total,O
amount,O
of,O
bupivacaine,I-Entity
consumption,O
.,O
Blood,O
and,O
tissue,O
samples,O
were,O
collected,O
following,O
asystole,I-Entity
.,O
The,O
time,O
to,O
first,O
dysrhythmia,I-Entity
occurrence,O
",",O
time,O
to,O
25%,O
and,O
50%,O
reductions,O
in,O
HR,O
",",O
and,O
time,O
to,O
asystole,I-Entity
were,O
longer,O
in,O
Group,O
P,O
than,O
the,O
other,O
groups,O
.,O
The,O
cumulative,O
bupivacaine,I-Entity
dose,O
given,O
at,O
those,O
time,O
points,O
was,O
higher,O
in,O
Group,O
P.,O
Plasma,O
bupivacaine,I-Entity
levels,O
were,O
significantly,O
lower,O
in,O
Group,O
P,O
than,O
in,O
Group,O
C.,O
Bupivacaine,I-Entity
levels,O
in,O
the,O
brain,O
and,O
heart,O
were,O
significantly,O
lower,O
in,O
Group,O
P,O
and,O
Group,O
L,O
than,O
in,O
Group,O
C.,O
CONCLUSION,O
:,O
We,O
conclude,O
that,O
pre,O
-,O
treatment,O
with,O
propofol,I-Entity
in,O
intralipid,O
",",O
compared,O
with,O
propofol,I-Entity
in,O
medialipid,O
or,O
saline,O
",",O
delayed,O
the,O
onset,O
of,O
bupivacaine,I-Entity
-,O
induced,O
cardiotoxic,I-Entity
effects,O
as,O
well,O
as,O
reduced,O
plasma,O
bupivacaine,I-Entity
levels,O
.,O
Further,O
studies,O
are,O
needed,O
to,O
explore,O
tissue,O
bupivacaine,I-Entity
levels,O
of,O
propofol,I-Entity
in,O
medialipid,O
and,O
adapt,O
these,O
results,O
to,O
clinical,O
practice,O
.,O
Drug,B-Entity
-,I-Entity
Induced,I-Entity
Acute,I-Entity
Liver,I-Entity
Injury,I-Entity
Within,O
12,O
Hours,O
After,O
Fluvastatin,I-Entity
Therapy,O
.,O
Although,O
statins,I-Entity
are,O
generally,O
well,O
-,O
tolerated,O
drugs,O
",",O
recent,O
cases,O
of,O
drug,B-Entity
-,I-Entity
induced,I-Entity
liver,I-Entity
injury,I-Entity
associated,O
with,O
their,O
use,O
have,O
been,O
reported,O
.,O
A,O
52-year,O
-,O
old,O
Chinese,O
man,O
reported,O
with,O
liver,B-Entity
damage,I-Entity
",",O
which,O
appeared,O
12,O
hours,O
after,O
beginning,O
treatment,O
with,O
fluvastatin,I-Entity
.,O
Patient,O
presented,O
with,O
complaints,O
of,O
increasing,O
nausea,I-Entity
",",O
anorexia,I-Entity
",",O
and,O
upper,O
abdominal,B-Entity
pain,I-Entity
.,O
His,O
laboratory,O
values,O
showed,O
elevated,O
creatine,I-Entity
kinase,O
and,O
transaminases,O
.,O
The,O
liver,O
biochemistries,O
eventually,O
normalized,O
within,O
3,O
weeks,O
of,O
stopping,O
the,O
fluvastatin,I-Entity
.,O
Therefore,O
",",O
when,O
prescribing,O
statins,O
",",O
the,O
possibility,O
of,O
hepatic,B-Entity
damage,I-Entity
should,O
be,O
taken,O
into,O
account,O
.,O
Fluconazole,I-Entity
associated,O
agranulocytosis,I-Entity
and,O
thrombocytopenia,I-Entity
.,O
CASE,O
:,O
We,O
describe,O
a,O
second,O
case,O
of,O
fluconazole,I-Entity
associated,O
agranulocytosis,I-Entity
with,O
thrombocytopenia,I-Entity
and,O
recovery,O
upon,O
discontinuation,O
of,O
therapy,O
.,O
The,O
patient,O
began,O
to,O
have,O
changes,O
in,O
white,O
blood,O
cells,O
and,O
platelets,O
within,O
48,O
h,O
of,O
administration,O
of,O
fluconazole,I-Entity
and,O
began,O
to,O
recover,O
with,O
48,O
h,O
of,O
discontinuation,O
.,O
This,O
case,O
highlights,O
that,O
drug,O
-,O
induced,O
blood,B-Entity
dyscrasias,I-Entity
can,O
occur,O
unexpectedly,O
as,O
a,O
result,O
of,O
treatment,O
with,O
a,O
commonly,O
used,O
drug,O
thought,O
to,O
be,O
"""",O
safe,O
"""",O
.,O
According,O
to,O
Naranjo,O
's,O
algorithm,O
the,O
likelihood,O
that,O
our,O
patient,O
's,O
agranulocytosis,I-Entity
and,O
thrombocytopenia,I-Entity
occurred,O
as,O
a,O
result,O
of,O
therapy,O
with,O
fluconazole,I-Entity
is,O
probable,O
",",O
with,O
a,O
total,O
of,O
six,O
points,O
.,O
In,O
particular,O
the,O
temporal,O
relationship,O
of,O
bone,B-Entity
marrow,I-Entity
suppression,I-Entity
to,O
the,O
initiation,O
of,O
fluconazole,I-Entity
and,O
the,O
abatement,O
of,O
symptoms,O
that,O
rapidly,O
reversed,O
immediately,O
following,O
discontinuation,O
.,O
Two,O
-,O
dimensional,O
speckle,O
tracking,O
echocardiography,O
combined,O
with,O
high,O
-,O
sensitive,O
cardiac,O
troponin,O
T,O
in,O
early,O
detection,O
and,O
prediction,O
of,O
cardiotoxicity,I-Entity
during,O
epirubicine,I-Entity
-,O
based,O
chemotherapy,O
.,O
To,O
investigate,O
whether,O
alterations,O
of,O
myocardial,B-Entity
strain,I-Entity
and,O
high,O
-,O
sensitive,O
cardiac,O
troponin,O
T,O
(,O
cTnT,O
),O
could,O
predict,O
future,O
cardiac,B-Entity
dysfunction,I-Entity
in,O
patients,O
after,O
epirubicin,I-Entity
exposure,O
.,O
METHODS,O
:,O
Seventy,O
-,O
five,O
patients,O
with,O
non,B-Entity
-,I-Entity
Hodgkin,I-Entity
lymphoma,I-Entity
treated,O
with,O
epirubicin,I-Entity
were,O
studied,O
.,O
Cardiotoxicity,I-Entity
was,O
defined,O
as,O
a,O
reduction,O
of,O
the,O
LVEF,O
of,O
>,O
5%,O
to,O
<,O
55%,O
with,O
symptoms,O
of,O
heart,B-Entity
failure,I-Entity
or,O
an,O
asymptomatic,O
reduction,O
of,O
the,O
LVEF,O
of,O
>,O
RESULTS,O
:,O
Fourteen,O
patients,O
(,O
18.67%,O
),O
developed,O
cardiotoxicity,I-Entity
after,O
treatment,O
.,O
AUC,O
=,O
0.757,O
;,O
P,O
=,O
0.005,O
),O
from,O
baseline,O
to,O
the,O
third,O
cycle,O
of,O
chemotherapy,O
predicted,O
later,O
cardiotoxicity,I-Entity
.,O
The,O
decrease,O
in,O
GLS,O
remained,O
the,O
only,O
independent,O
predictor,O
of,O
cardiotoxicity,I-Entity
(,O
P,O
=,O
0.000,O
),O
.,O
GLS,O
combined,O
with,O
cTnT,O
may,O
provide,O
a,O
reliable,O
and,O
non,O
-,O
invasive,O
method,O
to,O
predict,O
cardiac,B-Entity
dysfunction,I-Entity
in,O
patients,O
receiving,O
anthracycline,I-Entity
-,O
based,O
chemotherapy,O
.,O
Prevention,O
of,O
etomidate,I-Entity
-,O
induced,O
myoclonus,I-Entity
:,O
which,O
is,O
superior,O
:,O
Fentanyl,I-Entity
",",O
midazolam,I-Entity
",",O
or,O
a,O
combination,O
?,O
In,O
this,O
retrospective,O
comparative,O
study,O
",",O
we,O
aimed,O
to,O
compare,O
the,O
effectiveness,O
of,O
fentanyl,I-Entity
",",O
midazolam,I-Entity
",",O
and,O
a,O
combination,O
of,O
fentanyl,I-Entity
and,O
midazolam,I-Entity
to,O
prevent,O
etomidate,I-Entity
-,O
induced,O
myoclonus,I-Entity
.,O
Depending,O
on,O
the,O
drugs,O
that,O
would,O
be,O
given,O
before,O
the,O
induction,O
of,O
anesthesia,O
with,O
etomidate,I-Entity
",",O
the,O
patients,O
were,O
separated,O
into,O
4,O
groups,O
:,O
no,O
pretreatment,O
(,O
Group,O
NP,O
),O
",",O
fentanyl,I-Entity
1,O
ug.kg-1,O
(,O
Group,O
F,O
),O
",",O
midazolam,I-Entity
0.03,O
mg.kg-1,O
(,O
Group,O
M,O
),O
",",O
and,O
midazolam,I-Entity
0.015,O
mg.kg-1,O
+,O
fentanyl,I-Entity
Patients,O
who,O
received,O
the,O
same,O
anesthetic,O
procedure,O
were,O
selected,O
:,O
2,O
minutes,O
after,O
intravenous,O
injections,O
of,O
the,O
pretreatment,O
drugs,O
",",O
anesthesia,O
is,O
induced,O
with,O
0.3,O
mg.kg-1,O
etomidate,I-Entity
injected,O
intravenously,O
over,O
a,O
period,O
of,O
20,O
-,O
30,O
seconds,O
.,O
Myoclonic,B-Entity
movements,I-Entity
are,O
evaluated,O
",",O
which,O
were,O
observed,O
and,O
graded,O
according,O
to,O
clinical,O
severity,O
during,O
the,O
2,O
minutes,O
after,O
etomidate,I-Entity
injection,O
.,O
The,O
severity,O
of,O
pain,I-Entity
due,O
to,O
etomidate,I-Entity
injection,O
",",O
mean,O
arterial,O
pressure,O
",",O
heart,O
rate,O
",",O
and,O
adverse,O
effects,O
were,O
also,O
evaluated,O
.,O
Study,O
results,O
showed,O
that,O
myoclonus,I-Entity
incidence,O
was,O
85%,O
",",O
40%,O
",",O
70%,O
",",O
and,O
25%,O
in,O
Group,O
NP,O
",",O
Group,O
F,O
",",O
Group,O
M,O
",",O
and,O
Group,O
FM,O
",",O
respectively,O
",",O
and,O
were,O
significantly,O
lower,O
in,O
Group,O
F,O
and,O
Group,O
FM,O
.,O
CONCLUSIONS,O
:,O
We,O
conclude,O
that,O
pretreatment,O
with,O
fentanyl,I-Entity
or,O
combination,O
of,O
fentanyl,I-Entity
and,O
midazolam,I-Entity
was,O
effective,O
in,O
preventing,O
etomidate,I-Entity
-,O
induced,O
myoclonus,I-Entity
.,O
Cholestatic,I-Entity
presentation,O
of,O
yellow,O
phosphorus,I-Entity
poisoning,I-Entity
.,O
Yellow,O
phosphorus,I-Entity
",",O
a,O
component,O
of,O
certain,O
pesticide,O
pastes,O
and,O
fireworks,O
",",O
is,O
well,O
known,O
to,O
cause,O
hepatotoxicity,I-Entity
.,O
Poisoning,I-Entity
with,O
yellow,O
phosphorus,I-Entity
classically,O
manifests,O
with,O
acute,B-Entity
hepatitis,I-Entity
leading,O
to,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
which,O
may,O
need,O
liver,O
transplantation,O
.,O
We,O
present,O
a,O
case,O
of,O
yellow,O
phosphorus,I-Entity
poisoning,I-Entity
in,O
which,O
a,O
patient,O
presented,O
with,O
florid,O
clinical,O
features,O
of,O
cholestasis,I-Entity
highlighting,O
the,O
fact,O
that,O
cholestasis,I-Entity
can,O
rarely,O
be,O
a,O
presenting,O
feature,O
of,O
yellow,O
phosphorus,I-Entity
hepatotoxicity,I-Entity
.,O
Vasovagal,B-Entity
syncope,I-Entity
and,O
severe,O
bradycardia,I-Entity
following,O
intranasal,O
dexmedetomidine,I-Entity
for,O
pediatric,O
procedural,O
sedation,O
.,O
We,O
report,O
syncope,I-Entity
and,O
bradycardia,I-Entity
in,O
an,O
11-year,O
-,O
old,O
girl,O
following,O
administration,O
of,O
intranasal,O
dexmedetomidine,I-Entity
for,O
sedation,O
for,O
a,O
voiding,O
cystourethrogram,O
.,O
The,O
primary,O
abnormality,O
found,O
was,O
persistent,O
bradycardia,I-Entity
",",O
and,O
she,O
was,O
admitted,O
to,O
the,O
hospital,O
for,O
telemetric,O
observation,O
.,O
The,O
bradycardia,I-Entity
lasted,O
~2,O
h,O
",",O
and,O
further,O
cardiac,O
workup,O
revealed,O
no,O
underlying,O
abnormality,O
.,O
Paradoxical,O
severe,O
agitation,I-Entity
induced,O
by,O
add,O
-,O
on,O
high,O
-,O
doses,O
quetiapine,I-Entity
in,O
schizo,B-Entity
-,I-Entity
affective,I-Entity
disorder,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
35-year,O
-,O
old,O
patient,O
suffering,O
from,O
schizo,B-Entity
-,I-Entity
affective,I-Entity
disorder,I-Entity
since,O
the,O
age,O
of,O
19,O
years,O
",",O
treated,O
by,O
a,O
combination,O
of,O
first,O
-,O
generation,O
antipsychotics,O
",",O
zuclopenthixol,I-Entity
(,O
100,O
mg,O
/,O
day,O
),O
and,O
lithium,I-Entity
(,O
1200,O
mg,O
/,O
day,O
),O
(,O
serum,O
lithium=0.85,I-Entity
mEq,O
/,O
l,O
),O
.,O
This,O
patient,O
had,O
no,O
associated,O
personality,B-Entity
disorder,I-Entity
(,O
particularly,O
no,O
antisocial,B-Entity
disorder,I-Entity
),O
and,O
no,O
substance,B-Entity
abuse,I-Entity
disorder,I-Entity
.,O
Within,O
the,O
48,O
h,O
following,O
the,O
gradual,O
introduction,O
of,O
quetiapine,I-Entity
(,O
up,O
to,O
600,O
mg,O
/,O
day,O
),O
",",O
the,O
patient,O
presented,O
severe,O
agitation,I-Entity
without,O
an,O
environmental,O
explanation,O
",",O
contrasting,O
with,O
the,O
absence,O
of,O
a,O
history,O
of,O
aggressiveness,I-Entity
or,O
personality,B-Entity
disorder,I-Entity
.,O
The,O
diagnoses,O
of,O
manic,I-Entity
shift,O
and,O
akathisia,I-Entity
were,O
dismissed,O
.,O
The,O
withdrawal,O
and,O
the,O
gradual,O
reintroduction,O
of,O
quetiapine,I-Entity
2,O
weeks,O
later,O
",",O
which,O
led,O
to,O
another,O
severe,O
agitation,I-Entity
",",O
enabled,O
us,O
to,O
attribute,O
the,O
agitation,I-Entity
specifically,O
to,O
quetiapine,I-Entity
.,O
Antioxidant,O
effects,O
of,O
bovine,O
lactoferrin,O
on,O
dexamethasone,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
rat,O
.,O
Dexamethasone-,I-Entity
(,O
Dex-,I-Entity
),O
induced,O
hypertension,I-Entity
is,O
associated,O
with,O
enhanced,O
oxidative,O
stress,O
.,O
Lactoferrin,O
(,O
LF,O
),O
is,O
an,O
iron,I-Entity
-,O
binding,O
glycoprotein,O
with,O
antihypertensive,O
properties,O
.,O
In,O
this,O
study,O
",",O
we,O
investigated,O
the,O
effect,O
of,O
chronic,O
administration,O
of,O
LF,O
on,O
oxidative,O
stress,O
and,O
hypertension,I-Entity
upon,O
Dex,I-Entity
administration,O
.,O
Male,O
Wistar,O
rats,O
were,O
treated,O
by,O
Dex,I-Entity
(,O
30,O
u,O
In,O
a,O
prevention,O
study,O
",",O
rats,O
received,O
4,O
days,O
of,O
LF,O
treatment,O
followed,O
by,O
Dex,I-Entity
and,O
continued,O
during,O
the,O
test,O
period,O
.,O
Plasma,O
hydrogen,B-Entity
peroxide,I-Entity
(,O
H2O2,I-Entity
),O
concentration,O
and,O
ferric,O
reducing,O
antioxidant,O
power,O
(,O
FRAP,O
),O
value,O
were,O
determined,O
.,O
Dexamethasone,I-Entity
significantly,O
increased,O
SBP,O
and,O
plasma,O
H2O2,I-Entity
level,O
and,O
decreased,O
thymus,O
and,O
body,O
weights,O
.,O
LF,O
lowered,O
(,O
P,O
<,O
0.01,O
),O
and,O
dose,O
dependently,O
prevented,O
(,O
P,O
<,O
0.001,O
),O
Dex,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
LF,O
prevented,O
body,O
weight,B-Entity
loss,I-Entity
and,O
significantly,O
reduced,O
the,O
elevated,O
plasma,O
H2O2,I-Entity
and,O
increased,O
FRAP,O
values,O
.,O
Chronic,O
administration,O
of,O
LF,O
strongly,O
reduced,O
the,O
blood,O
pressure,O
and,O
production,O
of,O
ROS,O
and,O
improved,O
antioxidant,O
capacity,O
in,O
Dex,I-Entity
-,O
induced,O
hypertension,I-Entity
",",O
suggesting,O
the,O
role,O
of,O
inhibition,O
of,O
oxidative,O
stress,O
as,O
another,O
mechanism,O
of,O
antihypertensive,O
action,O
of,O
LF,O
.,O
The,O
association,O
between,O
tranexamic,B-Entity
acid,I-Entity
and,O
convulsive,I-Entity
seizures,I-Entity
after,O
cardiac,O
surgery,O
:,O
a,O
multivariate,O
analysis,O
in,O
11,O
529,O
patients,O
.,O
Because,O
of,O
a,O
lack,O
of,O
contemporary,O
data,O
regarding,O
seizures,I-Entity
after,O
cardiac,O
surgery,O
",",O
we,O
undertook,O
a,O
retrospective,O
analysis,O
of,O
prospectively,O
collected,O
data,O
from,O
11,O
529,O
patients,O
in,O
whom,O
cardiopulmonary,O
bypass,O
was,O
used,O
from,O
January,O
2004,O
to,O
December,O
2010,O
.,O
A,O
convulsive,I-Entity
seizure,I-Entity
was,O
defined,O
as,O
a,O
transient,O
episode,O
of,O
disturbed,O
brain,O
function,O
characterised,O
by,O
abnormal,B-Entity
involuntary,I-Entity
motor,I-Entity
movements,I-Entity
.,O
Multivariate,O
regression,O
analysis,O
was,O
performed,O
to,O
identify,O
independent,O
predictors,O
of,O
postoperative,O
seizures,I-Entity
.,O
A,O
total,O
of,O
100,O
(,O
0.9%,O
),O
patients,O
developed,O
postoperative,O
convulsive,I-Entity
seizures,I-Entity
.,O
Generalised,B-Entity
and,I-Entity
focal,I-Entity
seizures,I-Entity
were,O
identified,O
in,O
68,O
and,O
32,O
patients,O
",",O
respectively,O
.,O
),O
time,O
after,O
surgery,O
when,O
the,O
seizure,I-Entity
occurred,O
was,O
7,O
(,O
6,O
-,O
12,O
[,O
1,O
-,O
216,O
],O
),O
Independent,O
predictors,O
of,O
postoperative,O
seizures,I-Entity
included,O
age,O
",",O
female,O
sex,O
",",O
redo,O
cardiac,O
surgery,O
",",O
calcification,O
of,O
ascending,O
aorta,O
",",O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
",",O
deep,O
hypothermic,I-Entity
circulatory,O
arrest,O
",",O
duration,O
of,O
aortic,O
cross,O
-,O
clamp,O
and,O
tranexamic,B-Entity
acid,I-Entity
.,O
When,O
tested,O
in,O
a,O
multivariate,O
regression,O
analysis,O
",",O
tranexamic,B-Entity
acid,I-Entity
was,O
a,O
strong,O
independent,O
predictor,O
of,O
seizures,I-Entity
(,O
OR,O
14.3,O
",",O
95%,O
Patients,O
with,O
convulsive,I-Entity
seizures,I-Entity
had,O
2.5,O
times,O
higher,O
in,O
-,O
hospital,O
mortality,O
rates,O
and,O
twice,O
the,O
length,O
of,O
hospital,O
stay,O
compared,O
with,O
patients,O
without,O
convulsive,I-Entity
seizures,I-Entity
.,O
h,O
in,O
patients,O
with,O
convulsive,I-Entity
seizures,I-Entity
compared,O
with,O
26,O
(,O
22,O
-,O
69,O
[,O
14,O
-,O
1080,O
],O
),O
h,O
in,O
patients,O
without,O
seizures,I-Entity
(,O
p,O
<,O
0.001,O
),O
.,O
Convulsive,I-Entity
seizures,I-Entity
are,O
a,O
serious,O
postoperative,B-Entity
complication,I-Entity
after,O
cardiac,O
surgery,O
.,O
As,O
tranexamic,B-Entity
acid,I-Entity
is,O
the,O
only,O
modifiable,O
factor,O
",",O
its,O
administration,O
",",O
particularly,O
in,O
doses,O
exceeding,O
80,O
mg.kg(-1,O
),O
",",O
should,O
be,O
weighed,O
against,O
the,O
risk,O
of,O
postoperative,O
seizures,I-Entity
.,O
Dysfunctional,B-Entity
overnight,I-Entity
memory,I-Entity
consolidation,O
in,O
ecstasy,I-Entity
users,O
.,O
Previous,O
studies,O
indicate,O
that,O
ecstasy,I-Entity
users,O
have,O
marked,O
and,O
persistent,O
neurocognitive,O
and,O
sleep,B-Entity
-,I-Entity
related,I-Entity
impairments,I-Entity
.,O
We,O
extend,O
past,O
research,O
by,O
examining,O
overnight,O
memory,O
consolidation,O
among,O
regular,O
ecstasy,I-Entity
users,O
(,O
n=12,O
),O
and,O
drug,O
naive,O
healthy,O
controls,O
(,O
n=26,O
),O
.,O
Ecstasy,I-Entity
users,O
demonstrated,O
impaired,B-Entity
overnight,I-Entity
memory,I-Entity
consolidation,O
",",O
a,O
finding,O
that,O
was,O
more,O
pronounced,O
following,O
associative,O
interference,O
.,O
Additionally,O
",",O
ecstasy,I-Entity
users,O
demonstrated,O
impairments,O
on,O
tasks,O
recruiting,O
frontostriatal,O
and,O
hippocampal,O
neural,O
circuitry,O
",",O
in,O
the,O
domains,O
of,O
proactive,O
interference,O
memory,O
",",O
long,O
-,O
term,O
memory,O
",",O
encoding,O
",",O
working,O
memory,O
and,O
complex,O
planning,O
.,O
We,O
suggest,O
that,O
ecstasy,I-Entity
-,O
associated,O
dysfunction,O
in,O
fronto,O
-,O
temporal,O
circuitry,O
may,O
underlie,O
overnight,O
consolidation,O
memory,B-Entity
impairments,I-Entity
in,O
regular,O
ecstasy,I-Entity
users,O
.,O
Normoammonemic,O
encephalopathy,I-Entity
:,O
solely,O
valproate,I-Entity
induced,O
or,O
multiple,O
mechanisms,O
?,O
A,O
77-year,O
-,O
old,O
woman,O
presented,O
with,O
subacute,O
onset,O
progressive,O
confusion,I-Entity
",",O
aggression,I-Entity
",",O
auditory,B-Entity
hallucinations,I-Entity
and,O
delusions,I-Entity
.,O
In,O
the,O
preceding,O
months,O
",",O
the,O
patient,O
had,O
a,O
number,O
of,O
admissions,O
with,O
transient,O
unilateral,O
hemiparesis,I-Entity
with,O
facial,O
droop,O
",",O
and,O
had,O
been,O
started,O
on,O
valproate,I-Entity
for,O
presumed,O
hemiplegic,B-Entity
migraine,I-Entity
.,O
Valproate,I-Entity
was,O
withdrawn,O
soon,O
after,O
admission,O
and,O
her,O
cognitive,O
abilities,O
have,O
gradually,O
improved,O
over,O
3,O
months,O
of,O
follow,O
-,O
up,O
.,O
Valproate,I-Entity
levels,O
taken,O
prior,O
to,O
withdrawal,O
were,O
subtherapeutic,O
and,O
the,O
patient,O
was,O
normoammonaemic,O
.,O
EEG,O
undertaken,O
during,O
inpatient,O
stay,O
showed,O
changes,O
consistent,O
with,O
encephalopathy,I-Entity
",",O
and,O
low,O
titre,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
antibodies,O
were,O
present,O
in,O
this,O
patient,O
.,O
The,O
possible,O
aetiologies,O
of,O
valproate,I-Entity
-,O
induced,O
encephalopathy,I-Entity
and,O
NMDA,I-Entity
receptor,O
-,O
associated,O
encephalitis,I-Entity
present,O
a,O
diagnostic,O
dilemma,O
.,O
Cerebellar,B-Entity
and,I-Entity
oculomotor,I-Entity
dysfunction,I-Entity
induced,O
by,O
rapid,O
infusion,O
of,O
pethidine,I-Entity
.,O
Pethidine,I-Entity
is,O
an,O
opioid,O
that,O
gains,O
its,O
popularity,O
for,O
the,O
effective,O
pain,I-Entity
control,O
through,O
acting,O
on,O
the,O
opioid,O
-,O
receptors,O
.,O
However,O
",",O
rapid,O
pain,I-Entity
relief,O
sometimes,O
brings,O
about,O
unfavourable,O
side,O
effects,O
that,O
largely,O
limit,O
its,O
clinical,O
utility,O
.,O
Common,O
side,O
effects,O
include,O
nausea,I-Entity
",",O
vomiting,I-Entity
and,O
hypotension,I-Entity
.,O
In,O
patients,O
with,O
impaired,B-Entity
renal,I-Entity
and,I-Entity
liver,I-Entity
function,I-Entity
",",O
and,O
those,O
who,O
need,O
long,O
-,O
term,O
pain,I-Entity
control,O
",",O
pethidine,I-Entity
may,O
cause,O
excitatory,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
effects,O
through,O
its,O
neurotoxic,I-Entity
metabolite,O
",",O
norpethidine,I-Entity
",",O
resulting,O
in,O
irritability,I-Entity
and,O
seizure,I-Entity
attack,O
.,O
On,O
the,O
contrary,O
",",O
though,O
not,O
clinically,O
apparent,O
",",O
pethidine,I-Entity
potentially,O
causes,O
inhibitory,O
impacts,O
on,O
the,O
CNS,O
and,O
impairs,O
normal,O
cerebellar,O
and,O
oculomotor,O
function,O
in,O
the,O
short,O
term,O
.,O
In,O
this,O
case,O
report,O
",",O
we,O
highlight,O
opioid,O
's,O
inhibitory,O
side,O
effects,O
on,O
the,O
cerebellar,O
structure,O
that,O
causes,O
dysmetria,I-Entity
",",O
dysarthria,I-Entity
",",O
reduced,O
smooth,O
pursuit,O
gain,O
and,O
decreased,O
saccadic,O
velocity,O
.,O
Baboon,B-Entity
syndrome,I-Entity
induced,O
by,O
ketoconazole,I-Entity
.,O
A,O
27-year,O
-,O
old,O
male,O
patient,O
presented,O
with,O
a,O
maculopapular,B-Entity
eruption,I-Entity
on,O
the,O
flexural,O
areas,O
and,O
buttocks,O
after,O
using,O
oral,O
ketoconazole,I-Entity
.,O
The,O
patient,O
was,O
diagnosed,O
with,O
drug,O
-,O
induced,O
baboon,B-Entity
syndrome,I-Entity
based,O
on,O
his,O
history,O
",",O
which,O
included,O
prior,O
sensitivity,O
to,O
topical,O
ketoconazole,I-Entity
",",O
a,O
physical,O
examination,O
",",O
and,O
histopathological,O
findings,O
.,O
Baboon,B-Entity
syndrome,I-Entity
is,O
a,O
drug-,O
or,O
contact,O
allergen,O
-,O
related,O
maculopapular,B-Entity
eruption,I-Entity
that,O
typically,O
involves,O
the,O
flexural,O
and,O
gluteal,O
areas,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
ketoconazole,I-Entity
-,O
induced,O
baboon,B-Entity
syndrome,I-Entity
in,O
the,O
English,O
literature,O
.,O
A,O
Case,O
of,O
Sudden,B-Entity
Cardiac,I-Entity
Death,I-Entity
due,O
to,O
Pilsicainide,I-Entity
-,O
Induced,O
Torsades,B-Entity
de,I-Entity
Pointes,I-Entity
.,O
An,O
84-year,O
-,O
old,O
male,O
received,O
oral,O
pilsicainide,I-Entity
",",O
a,O
pure,O
sodium,I-Entity
channel,O
blocker,O
with,O
slow,O
recovery,O
kinetics,O
",",O
to,O
convert,O
his,O
paroxysmal,O
atrial,B-Entity
fibrillation,I-Entity
to,O
a,O
sinus,O
rhythm,O
;,O
the,O
patient,O
developed,O
sudden,B-Entity
cardiac,I-Entity
death,I-Entity
two,O
days,O
later,O
.,O
The,O
Holter,O
electrocardiogram,O
",",O
which,O
was,O
worn,O
by,O
chance,O
",",O
revealed,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
with,O
gradually,O
prolonged,O
QT,O
intervals,O
.,O
Although,O
the,O
patient,O
's,O
renal,O
function,O
was,O
not,O
highly,O
impaired,O
and,O
the,O
dose,O
of,O
pilsicainide,I-Entity
was,O
low,O
",",O
the,O
plasma,O
concentration,O
of,O
pilsicainide,I-Entity
may,O
have,O
been,O
high,O
",",O
which,O
can,O
produce,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
in,O
the,O
octogenarian,O
.,O
Although,O
the,O
oral,O
administration,O
of,O
class,O
IC,O
drugs,O
",",O
including,O
pilsicainide,I-Entity
",",O
is,O
effective,O
to,O
terminate,O
atrial,B-Entity
fibrillation,I-Entity
",",O
careful,O
consideration,O
must,O
be,O
taken,O
before,O
giving,O
these,O
drugs,O
to,O
octogenarians,O
.,O
All,B-Entity
-,I-Entity
trans,I-Entity
retinoic,I-Entity
acid,I-Entity
-,O
induced,O
inflammatory,O
myositis,I-Entity
in,O
a,O
patient,O
with,O
acute,B-Entity
promyelocytic,I-Entity
leukemia,I-Entity
.,O
All,B-Entity
-,I-Entity
trans,I-Entity
retinoic,I-Entity
acid,I-Entity
(,O
ATRA,I-Entity
),O
",",O
a,O
component,O
of,O
standard,O
therapy,O
for,O
acute,B-Entity
promyelocytic,I-Entity
leukemia,I-Entity
(,O
APL,I-Entity
),O
",",O
is,O
associated,O
with,O
potentially,O
serious,O
but,O
treatable,O
adverse,O
effects,O
involving,O
numerous,O
organ,O
systems,O
",",O
including,O
rare,O
skeletal,O
muscle,O
involvement,O
.,O
Only,O
a,O
handful,O
of,O
cases,O
of,O
ATRA,I-Entity
-,O
induced,O
myositis,I-Entity
in,O
children,O
have,O
been,O
reported,O
",",O
and,O
none,O
in,O
the,O
radiology,O
literature,O
.,O
We,O
present,O
such,O
a,O
case,O
in,O
a,O
15-year,O
-,O
old,O
boy,O
with,O
APL,I-Entity
",",O
where,O
recognition,O
of,O
imaging,O
findings,O
played,O
a,O
crucial,O
role,O
in,O
making,O
the,O
diagnosis,O
and,O
facilitated,O
prompt,O
",",O
effective,O
treatment,O
.,O
Tolerability,O
of,O
lomustine,I-Entity
in,O
combination,O
with,O
cyclophosphamide,I-Entity
in,O
dogs,O
with,O
lymphoma,I-Entity
.,O
This,O
retrospective,O
study,O
describes,O
toxicity,I-Entity
associated,O
with,O
a,O
protocol,O
of,O
lomustine,I-Entity
(,O
CCNU,I-Entity
),O
and,O
cyclophosphamide,I-Entity
(,O
CTX,I-Entity
),O
in,O
dogs,O
with,O
lymphoma,I-Entity
.,O
CCNU,I-Entity
was,O
administered,O
per,O
os,O
(,O
PO,O
),O
at,O
a,O
targeted,O
dosage,O
of,O
60,O
mg,O
/,O
m(2,O
),O
body,O
surface,O
area,O
on,O
day,O
0,O
",",O
CTX,I-Entity
was,O
administered,O
PO,O
at,O
a,O
targeted,O
dosage,O
of,O
250,O
mg,O
/,O
m(2,O
),O
divided,O
over,O
days,O
0,O
through,O
4,O
",",O
and,O
all,O
dogs,O
received,O
prophylactic,O
antibiotics,O
.,O
Neutropenia,I-Entity
was,O
the,O
principal,O
toxic,O
effect,O
",",O
and,O
the,O
overall,O
frequency,O
of,O
grade,O
4,O
neutropenia,I-Entity
after,O
the,O
first,O
treatment,O
of,O
CCNU,I-Entity
/,O
CTX,I-Entity
was,O
30%,O
(,O
95%,O
confidence,O
interval,O
",",O
19,O
-,O
43%,O
),O
.,O
The,O
mean,O
body,O
weight,O
of,O
dogs,O
with,O
grade,O
4,O
neutropenia,I-Entity
(,O
19.7,O
kg,O
+,O
13.4,O
kg,O
),O
was,O
significantly,O
less,O
than,O
the,O
mean,O
body,O
weight,O
of,O
dogs,O
that,O
did,O
not,O
develop,O
grade,O
4,O
neutropenia,I-Entity
(,O
31.7,O
kg,O
+,O
12.4,O
kg,O
;,O
P,O
=,O
.005,O
),O
.,O
One,O
dog,O
(,O
3%,O
),O
developed,O
hematologic,O
changes,O
suggestive,O
of,O
hepatotoxicity,I-Entity
.,O
No,O
dogs,O
had,O
evidence,O
of,O
either,O
renal,B-Entity
toxicity,I-Entity
or,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
On,O
the,O
basis,O
of,O
the,O
findings,O
reported,O
herein,O
",",O
a,O
dose,O
of,O
60,O
mg,O
/,O
m(2,O
),O
of,O
CCNU,I-Entity
combined,O
with,O
250,O
mg,O
/,O
m(2,O
),O
of,O
CTX,I-Entity
(,O
divided,O
over,O
5,O
days,O
),O
4,O
wk,O
is,O
tolerable,O
in,O
tumor,I-Entity
-,O
bearing,O
dogs,O
.,O
Nelarabine,I-Entity
neurotoxicity,I-Entity
with,O
concurrent,O
intrathecal,O
chemotherapy,O
:,O
Severe,O
nelarabine,I-Entity
neurotoxicity,I-Entity
in,O
a,O
patient,O
who,O
received,O
concurrent,O
intrathecal,O
A,O
37-year,O
-,O
old,O
Caucasian,O
woman,O
with,O
a,O
history,O
of,O
T,B-Entity
-,I-Entity
cell,I-Entity
lymphoblastic,I-Entity
lymphoma,I-Entity
was,O
admitted,O
for,O
relapsed,O
disease,O
.,O
She,O
developed,O
relapsed,O
disease,O
10,O
months,O
later,O
with,O
leukemic,I-Entity
involvement,O
.,O
She,O
was,O
re,O
-,O
induced,O
with,O
nelarabine,I-Entity
1500,O
mg,O
/,O
m(2,O
),O
on,O
days,O
1,O
",",O
3,O
",",O
and,O
5,O
with,O
1,O
dose,O
of,O
IT,O
cytarabine,I-Entity
100,O
mg,O
on,O
day,O
2,O
as,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
prophylaxis,O
.,O
At,O
the,O
time,O
of,O
treatment,O
",",O
she,O
was,O
on,O
continuous,O
renal,O
replacement,O
therapy,O
due,O
to,O
sequelae,O
of,O
tumor,B-Entity
lysis,I-Entity
syndrome,I-Entity
(,O
TLS,I-Entity
),O
.,O
She,O
received,O
a,O
second,O
cycle,O
of,O
nelarabine,I-Entity
without,O
additional,O
IT,O
prophylaxis,O
one,O
month,O
later,O
.,O
Predominantly,O
sensory,O
",",O
though,O
also,O
motor,O
and,O
autonomic,O
",",O
peripheral,B-Entity
neuropathy,I-Entity
started,O
in,O
her,O
feet,O
",",O
ascended,O
proximally,O
to,O
the,O
mid,O
-,O
thoracic,O
region,O
",",O
and,O
eventually,O
included,O
her,O
distal,O
upper,O
extremities,O
.,O
Nelarabine,I-Entity
was,O
felt,O
to,O
be,O
the,O
cause,O
of,O
her,O
symptoms,O
.,O
Her,O
neuropathy,I-Entity
stabilized,O
and,O
showed,O
slight,O
improvement,O
and,O
ultimately,O
received,O
an,O
unrelated,O
",",O
reduced,O
-,O
intensity,O
allogeneic,O
transplant,O
while,O
in,O
complete,O
remission,O
",",O
but,O
relapsed,O
disease,O
10,O
weeks,O
later,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
published,O
case,O
report,O
of,O
severe,O
neurotoxicity,I-Entity
caused,O
by,O
nelarabine,I-Entity
in,O
a,O
patient,O
who,O
received,O
concurrent,O
IT,O
chemotherapy,O
.,O
Valproate,I-Entity
-,O
induced,O
hyperammonemic,I-Entity
encephalopathy,I-Entity
in,O
a,O
renal,O
transplanted,O
patient,O
.,O
Neurological,B-Entity
complications,I-Entity
after,O
renal,O
transplantation,O
constitute,O
an,O
important,O
cause,O
of,O
morbidity,O
and,O
mortality,O
.,O
Valproate,I-Entity
-,O
induced,O
hyperammonemic,I-Entity
encephalopathy,I-Entity
is,O
an,O
uncommon,O
but,O
serious,O
effect,O
of,O
valproate,I-Entity
treatment,O
.,O
Here,O
",",O
we,O
describe,O
the,O
case,O
of,O
a,O
15-year,O
-,O
old,O
girl,O
who,O
was,O
on,O
a,O
long,O
-,O
term,O
therapy,O
with,O
valproate,I-Entity
due,O
to,O
epilepsy,I-Entity
and,O
revealed,O
impaired,B-Entity
consciousness,I-Entity
with,O
hyperammonemia,I-Entity
12,O
days,O
after,O
renal,O
transplantation,O
.,O
After,O
withdraw,O
of,O
valproate,I-Entity
",",O
patients,O
',O
symptoms,O
resolved,O
within,O
24,O
h.,O
Clinicians,O
should,O
increase,O
their,O
awareness,O
for,O
potential,O
complication,O
of,O
valproate,I-Entity
",",O
especially,O
in,O
transplanted,O
patients,O
.,O
Necrotising,B-Entity
fasciitis,I-Entity
after,O
bortezomib,I-Entity
and,O
dexamethasone,I-Entity
-,O
containing,O
regimen,O
in,O
an,O
elderly,O
patient,O
of,O
Waldenstrom,B-Entity
macroglobulinaemia,I-Entity
.,O
Bortezomib,I-Entity
and,O
high,O
-,O
dose,O
dexamethasone,I-Entity
-,O
containing,O
regimens,O
are,O
considered,O
to,O
be,O
generally,O
tolerable,O
with,O
few,O
severe,O
bacterial,B-Entity
infections,I-Entity
in,O
patients,O
with,O
B,O
-,O
cell,O
malignancies,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
a,O
76-year,O
-,O
old,O
man,O
with,O
Waldenstrom,B-Entity
macroglobulinaemia,I-Entity
who,O
suffered,O
necrotising,B-Entity
fasciitis,I-Entity
without,O
neutropenia,I-Entity
after,O
the,O
combination,O
treatment,O
with,O
bortezomib,I-Entity
",",O
high,O
-,O
dose,O
dexamethasone,I-Entity
and,O
rituximab,O
.,O
Physicians,O
should,O
recognise,O
the,O
possibility,O
of,O
fatal,O
bacterial,B-Entity
infections,I-Entity
related,O
to,O
bortezomib,I-Entity
plus,O
high,O
-,O
dose,O
dexamethasone,I-Entity
in,O
elderly,O
patients,O
",",O
and,O
we,O
believe,O
this,O
case,O
warrants,O
further,O
investigation,O
.,O
An,O
integrated,O
characterization,O
of,O
serological,O
",",O
pathological,O
",",O
and,O
functional,O
events,O
in,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Many,O
efficacious,O
cancer,I-Entity
treatments,O
cause,O
significant,O
cardiac,O
morbidity,O
",",O
yet,O
biomarkers,O
or,O
functional,O
indices,O
of,O
early,O
damage,O
",",O
which,O
would,O
allow,O
monitoring,O
and,O
intervention,O
",",O
are,O
lacking,O
.,O
In,O
this,O
study,O
",",O
we,O
have,O
utilized,O
a,O
rat,O
model,O
of,O
progressive,O
doxorubicin,I-Entity
(,O
DOX)-induced,I-Entity
cardiomyopathy,I-Entity
",",O
applying,O
multiple,O
approaches,O
",",O
including,O
cardiac,O
magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
",",O
to,O
provide,O
the,O
most,O
comprehensive,O
characterization,O
to,O
date,O
of,O
the,O
timecourse,O
of,O
serological,O
",",O
pathological,O
",",O
and,O
functional,O
events,O
underlying,O
this,O
toxicity,I-Entity
.,O
Hannover,O
Wistar,O
rats,O
were,O
dosed,O
with,O
1.25,O
mg,O
/,O
kg,O
DOX,I-Entity
weekly,O
for,O
8,O
weeks,O
followed,O
by,O
a,O
4,O
week,O
off,O
-,O
dosing,O
"""",O
recovery,O
"""",O
period,O
.,O
Electron,O
microscopy,O
of,O
the,O
myocardium,O
revealed,O
subcellular,B-Entity
degeneration,I-Entity
and,O
marked,O
mitochondrial,O
changes,O
after,O
a,O
single,O
dose,O
.,O
Histopathological,O
analysis,O
revealed,O
progressive,O
cardiomyocyte,B-Entity
degeneration,I-Entity
",",O
hypertrophy,I-Entity
/,O
cytomegaly,O
",",O
and,O
extensive,O
vacuolation,O
after,O
two,O
doses,O
.,O
Extensive,O
replacement,O
fibrosis,I-Entity
(,O
quantified,O
by,O
Sirius,O
red,O
staining,O
),O
developed,O
during,O
the,O
off,O
-,O
dosing,O
period,O
.,O
Functional,O
indices,O
assessed,O
by,O
cardiac,O
MRI,O
(,O
including,O
left,O
ventricular,O
ejection,O
fraction,O
(,O
LVEF,O
),O
",",O
cardiac,O
output,O
",",O
and,O
E,O
/,O
A,O
ratio,O
),O
declined,O
progressively,O
",",O
reaching,O
statistical,O
significance,O
after,O
two,O
doses,O
and,O
culminating,O
in,O
"""",O
clinical,O
"""",O
LV,B-Entity
dysfunction,I-Entity
by,O
12,O
weeks,O
.,O
Troponin,O
I,O
levels,O
positively,O
correlated,O
with,O
delayed,O
and,O
peak,O
gadolinium,I-Entity
contrast,O
enhancement,O
",",O
histopathological,O
grading,O
",",O
and,O
diastolic,B-Entity
dysfunction,I-Entity
.,O
In,O
summary,O
",",O
subcellular,O
cardiomyocyte,B-Entity
degeneration,I-Entity
was,O
the,O
earliest,O
marker,O
",",O
followed,O
by,O
progressive,O
functional,O
decline,O
and,O
histopathological,O
manifestations,O
.,O
However,O
",",O
all,O
indices,O
predated,O
"""",O
clinical,O
"""",O
LV,B-Entity
dysfunction,I-Entity
and,O
thus,O
warrant,O
further,O
evaluation,O
as,O
predictive,O
biomarkers,O
.,O
Intradermal,O
glutamate,I-Entity
and,O
capsaicin,I-Entity
injections,O
:,O
intra-,O
and,O
interindividual,O
variability,O
of,O
provoked,O
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
.,O
Intradermal,O
injections,O
of,O
glutamate,I-Entity
and,O
capsaicin,I-Entity
are,O
attractive,O
to,O
use,O
in,O
human,O
experimental,O
pain,I-Entity
models,O
because,O
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
mimic,O
isolated,O
aspects,O
of,O
clinical,O
pain,B-Entity
disorders,I-Entity
.,O
Twenty,O
healthy,O
male,O
volunteers,O
(,O
mean,O
age,O
24,O
years,O
;,O
range,O
18,O
-,O
38,O
years,O
),O
received,O
intradermal,O
injections,O
of,O
glutamate,I-Entity
and,O
capsaicin,I-Entity
in,O
the,O
volar,O
forearm,O
.,O
Magnitudes,O
of,O
secondary,O
pinprick,O
hyperalgesia,I-Entity
and,O
brush,O
-,O
evoked,O
allodynia,I-Entity
were,O
investigated,O
using,O
von,O
Frey,O
filaments,O
(,O
gauges,O
10,O
",",O
15,O
",",O
60,O
and,O
100,O
g,O
),O
and,O
brush,O
strokes,O
.,O
Areas,O
of,O
secondary,B-Entity
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
were,O
quantified,O
immediately,O
after,O
injection,O
and,O
after,O
15,O
",",O
30,O
and,O
60,O
min,O
.,O
Secondary,O
pinprick,O
hyperalgesia,I-Entity
was,O
observed,O
as,O
a,O
marked,O
increase,O
in,O
the,O
visual,O
analogue,O
scale,O
(,O
VAS,O
),O
response,O
to,O
von,O
Frey,O
gauges,O
60,O
and,O
100,O
g,O
<,O
0.001,O
),O
after,O
glutamate,I-Entity
injection,O
.,O
For,O
capsaicin,I-Entity
",",O
secondary,O
pinprick,O
hyperalgesia,I-Entity
was,O
detected,O
with,O
all,O
von,O
Frey,O
gauges,O
(,O
P,O
<,O
0.001,O
),O
.,O
Glutamate,I-Entity
evoked,O
reproducible,O
VAS,O
response,O
to,O
all,O
von,O
Frey,O
gauges,O
(,O
ICC,O
>,O
0.60,O
),O
and,O
brush,O
strokes,O
(,O
ICC,O
>,O
0.83,O
),O
.,O
Capsaicin,I-Entity
injection,O
was,O
reproducible,O
for,O
secondary,B-Entity
hyperalgesia,I-Entity
(,O
ICC,O
>,O
0.70,O
),O
and,O
allodynia,I-Entity
Intra,O
-,O
individual,O
variability,O
was,O
generally,O
lower,O
for,O
the,O
VAS,O
response,O
to,O
von,O
Frey,O
and,O
brush,O
compared,O
with,O
areas,O
of,O
secondary,B-Entity
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
.,O
In,O
conclusion,O
",",O
glutamate,I-Entity
and,O
capsaicin,I-Entity
yield,O
reproducible,O
hyperalgesic,I-Entity
and,O
allodynic,I-Entity
responses,O
",",O
and,O
the,O
present,O
model,O
is,O
well,O
suited,O
for,O
basic,O
research,O
",",O
as,O
well,O
as,O
for,O
assessing,O
the,O
modulation,O
of,O
central,O
phenomena,O
.,O
Ocular,O
-,O
specific,O
ER,O
stress,O
reduction,O
rescues,O
glaucoma,I-Entity
in,O
murine,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
.,O
Administration,O
of,O
glucocorticoids,O
induces,O
ocular,B-Entity
hypertension,I-Entity
in,O
some,O
patients,O
.,O
If,O
untreated,O
",",O
these,O
patients,O
can,O
develop,O
a,O
secondary,O
glaucoma,I-Entity
that,O
resembles,O
primary,B-Entity
open,I-Entity
-,I-Entity
angle,I-Entity
glaucoma,I-Entity
(,O
POAG,I-Entity
),O
.,O
The,O
underlying,O
pathology,O
of,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
is,O
not,O
fully,O
understood,O
",",O
due,O
in,O
part,O
to,O
lack,O
of,O
an,O
appropriate,O
animal,O
model,O
.,O
Here,O
",",O
we,O
developed,O
a,O
murine,O
model,O
of,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
that,O
exhibits,O
glaucoma,I-Entity
features,O
that,O
are,O
observed,O
in,O
patients,O
.,O
Treatment,O
of,O
WT,O
mice,O
with,O
topical,O
ocular,O
0.1%,O
dexamethasone,I-Entity
led,O
to,O
elevation,O
of,O
intraocular,O
pressure,O
(,O
IOP,O
),O
",",O
functional,O
and,O
structural,O
loss,O
of,O
retinal,B-Entity
ganglion,I-Entity
cells,O
",",O
and,O
axonal,B-Entity
degeneration,I-Entity
",",O
resembling,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
in,O
human,O
patients,O
.,O
Furthermore,O
",",O
dexamethasone,I-Entity
-,O
induced,O
ocular,B-Entity
hypertension,I-Entity
was,O
associated,O
with,O
chronic,O
ER,O
stress,O
of,O
the,O
trabecular,O
meshwork,O
(,O
TM,O
),O
.,O
Similar,O
to,O
patients,O
",",O
withdrawal,O
of,O
dexamethasone,I-Entity
treatment,O
reduced,O
elevated,O
IOP,O
and,O
ER,O
stress,O
in,O
this,O
animal,O
model,O
.,O
Dexamethasone,I-Entity
induced,O
the,O
transcriptional,O
factor,O
CHOP,O
",",O
a,O
marker,O
for,O
chronic,O
ER,O
stress,O
",",O
in,O
the,O
anterior,O
segment,O
tissues,O
",",O
and,O
Chop,O
deletion,O
reduced,O
ER,O
stress,O
in,O
these,O
tissues,O
and,O
prevented,O
dexamethasone,I-Entity
-,O
induced,O
ocular,B-Entity
hypertension,I-Entity
.,O
Furthermore,O
",",O
reduction,O
of,O
ER,O
stress,O
in,O
the,O
TM,O
with,O
sodium,B-Entity
4-phenylbutyrate,I-Entity
prevented,O
dexamethasone,I-Entity
-,O
induced,O
ocular,B-Entity
hypertension,I-Entity
in,O
WT,O
mice,O
.,O
Our,O
data,O
indicate,O
that,O
ER,O
stress,O
contributes,O
to,O
glucocorticoid,O
-,O
induced,O
ocular,B-Entity
hypertension,I-Entity
and,O
suggest,O
that,O
reducing,O
ER,O
stress,O
has,O
potential,O
as,O
a,O
therapeutic,O
strategy,O
for,O
treating,O
glucocorticoid,O
-,O
induced,O
glaucoma,I-Entity
.,O
Effects,O
of,O
ginsenosides,I-Entity
on,O
opioid,O
-,O
induced,O
hyperalgesia,I-Entity
in,O
mice,O
.,O
Opioid,O
-,O
induced,O
hyperalgesia,I-Entity
(,O
OIH,I-Entity
),O
is,O
characterized,O
by,O
nociceptive,O
sensitization,O
caused,O
by,O
the,O
cessation,O
of,O
chronic,O
opioid,O
use,O
.,O
OIH,I-Entity
can,O
limit,O
the,O
clinical,O
use,O
of,O
opioid,O
analgesics,O
and,O
complicate,O
withdrawal,O
from,O
opioid,B-Entity
addiction,I-Entity
.,O
In,O
this,O
study,O
",",O
we,O
investigated,O
the,O
effects,O
of,O
Re,B-Entity
",",I-Entity
Rg1,I-Entity
",",I-Entity
and,I-Entity
Rb1,I-Entity
ginsenosides,I-Entity
",",O
the,O
bioactive,O
components,O
of,O
ginseng,O
",",O
on,O
OIH,I-Entity
.,O
OIH,I-Entity
was,O
achieved,O
in,O
mice,O
after,O
subcutaneous,O
administration,O
of,O
morphine,I-Entity
for,O
7,O
consecutive,O
days,O
three,O
times,O
per,O
day,O
.,O
During,O
withdrawal,O
(,O
days,O
8,O
and,O
9,O
),O
",",O
these,O
mice,O
were,O
administered,O
Re,I-Entity
",",O
Rg1,I-Entity
",",O
or,O
Rb1,I-Entity
intragastrically,O
two,O
times,O
per,O
day,O
.,O
On,O
the,O
test,O
day,O
(,O
day,O
10,O
),O
",",O
mice,O
were,O
subjected,O
to,O
the,O
thermal,O
sensitivity,O
test,O
and,O
the,O
acetic,B-Entity
acid,I-Entity
-,O
induced,O
writhing,O
test,O
.,O
Re,I-Entity
(,O
300,O
mg,O
/,O
kg,O
),O
inhibited,O
OIH,I-Entity
in,O
both,O
the,O
thermal,O
sensitivity,O
test,O
and,O
the,O
acetic,B-Entity
acid,I-Entity
-,O
induced,O
writhing,O
test,O
.,O
However,O
",",O
the,O
Rg1,B-Entity
and,I-Entity
Rb1,I-Entity
ginsenosides,I-Entity
failed,O
to,O
prevent,O
OIH,I-Entity
in,O
either,O
test,O
.,O
Furthermore,O
",",O
Rg1,I-Entity
showed,O
a,O
tendency,O
to,O
aggravate,O
OIH,I-Entity
in,O
the,O
acetic,B-Entity
acid,I-Entity
-,O
induced,O
writhing,O
test,O
.,O
Our,O
data,O
suggested,O
that,O
the,O
ginsenoside,B-Entity
Re,I-Entity
",",O
but,O
not,O
Rg1,I-Entity
or,O
Rb1,I-Entity
",",O
may,O
contribute,O
toward,O
reversal,O
of,O
OIH,I-Entity
.,O
A,O
comparison,O
of,O
severe,O
hemodynamic,O
disturbances,O
between,O
dexmedetomidine,I-Entity
and,O
propofol,I-Entity
for,O
sedation,O
in,O
neurocritical,O
care,O
patients,O
.,O
Dexmedetomidine,I-Entity
and,O
propofol,I-Entity
are,O
commonly,O
used,O
sedatives,O
in,O
neurocritical,O
care,O
as,O
they,O
allow,O
for,O
frequent,O
neurologic,O
examinations,O
.,O
The,O
primary,O
objective,O
of,O
this,O
study,O
is,O
to,O
compare,O
the,O
prevalence,O
of,O
severe,O
hemodynamic,O
effects,O
in,O
neurocritical,O
care,O
patients,O
receiving,O
dexmedetomidine,I-Entity
and,O
propofol,I-Entity
.,O
INTERVENTIONS,O
:,O
Continuous,O
sedation,O
with,O
dexmedetomidine,I-Entity
or,O
propofol,I-Entity
.,O
A,O
total,O
of,O
342,O
patients,O
(,O
105,O
dexmedetomidine,I-Entity
and,O
237,O
propofol,I-Entity
),O
were,O
included,O
in,O
the,O
analysis,O
",",O
with,O
190,O
matched,O
(,O
95,O
in,O
each,O
group,O
),O
by,O
propensity,O
score,O
.,O
The,O
primary,O
outcome,O
of,O
this,O
study,O
was,O
a,O
composite,O
of,O
severe,O
hypotension,I-Entity
(,O
mean,O
arterial,O
pressure,O
<,O
60,O
mm,O
Hg,O
),O
and,O
bradycardia,I-Entity
(,O
heart,O
rate,O
<,O
50,O
beats,O
/,O
min,O
),O
during,O
sedative,O
infusion,O
.,O
When,O
analyzed,O
separately,O
",",O
no,O
differences,O
could,O
be,O
found,O
in,O
the,O
prevalence,O
of,O
severe,O
hypotension,I-Entity
or,O
bradycardia,I-Entity
in,O
either,O
the,O
unmatched,O
or,O
matched,O
cohorts,O
.,O
Severe,O
hypotension,I-Entity
and,O
bradycardia,I-Entity
occur,O
at,O
similar,O
prevalence,O
in,O
neurocritical,O
care,O
patients,O
who,O
receive,O
dexmedetomidine,I-Entity
or,O
propofol,I-Entity
.,O
Providers,O
should,O
similarly,O
consider,O
the,O
likelihood,O
of,O
hypotension,I-Entity
or,O
bradycardia,I-Entity
before,O
starting,O
either,O
sedative,O
.,O
Hydroxytyrosol,I-Entity
ameliorates,O
oxidative,O
stress,O
and,O
mitochondrial,B-Entity
dysfunction,I-Entity
in,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
rats,O
with,O
breast,B-Entity
cancer,I-Entity
.,O
Oxidative,O
stress,O
is,O
involved,O
in,O
several,O
processes,O
including,O
cancer,I-Entity
",",O
aging,O
and,O
cardiovascular,B-Entity
disease,I-Entity
",",O
and,O
has,O
been,O
shown,O
to,O
potentiate,O
the,O
therapeutic,O
effect,O
of,O
drugs,O
such,O
as,O
doxorubicin,I-Entity
.,O
Doxorubicin,I-Entity
causes,O
significant,O
cardiotoxicity,I-Entity
characterized,O
by,O
marked,O
increases,O
in,O
oxidative,O
stress,O
and,O
mitochondrial,B-Entity
dysfunction,I-Entity
.,O
Herein,O
",",O
we,O
investigate,O
whether,O
doxorubicin,I-Entity
-,O
associated,O
chronic,O
cardiac,B-Entity
toxicity,I-Entity
can,O
be,O
ameliorated,O
with,O
the,O
antioxidant,O
hydroxytyrosol,I-Entity
in,O
rats,O
with,O
breast,B-Entity
cancer,I-Entity
.,O
Thirty,O
-,O
six,O
rats,O
bearing,O
breast,B-Entity
tumors,I-Entity
induced,O
chemically,O
were,O
divided,O
into,O
4,O
groups,O
:,O
control,O
",",O
hydroxytyrosol,I-Entity
(,O
0.5mg,O
/,O
kg,O
",",O
5days,O
/,O
week,O
),O
",",O
doxorubicin,I-Entity
(,O
1mg,O
/,O
kg,O
/,O
week,O
),O
",",O
and,O
doxorubicin,I-Entity
plus,O
hydroxytyrosol,I-Entity
.,O
Cardiac,B-Entity
disturbances,I-Entity
at,O
the,O
cellular,O
and,O
mitochondrial,O
level,O
",",O
mitochondrial,O
electron,O
transport,O
chain,O
complexes,O
I,O
-,O
IV,O
and,O
apoptosis,O
-,O
inducing,O
factor,O
",",O
and,O
oxidative,O
stress,O
markers,O
have,O
been,O
analyzed,O
.,O
Hydroxytyrosol,I-Entity
improved,O
the,O
cardiac,B-Entity
disturbances,I-Entity
enhanced,O
by,O
doxorubicin,I-Entity
by,O
significantly,O
reducing,O
the,O
percentage,O
of,O
altered,O
mitochondria,O
and,O
oxidative,O
damage,O
.,O
These,O
results,O
suggest,O
that,O
hydroxytyrosol,I-Entity
improve,O
the,O
mitochondrial,O
electron,O
transport,O
chain,O
.,O
This,O
study,O
demonstrates,O
that,O
hydroxytyrosol,I-Entity
protect,O
rat,O
heart,B-Entity
damage,I-Entity
provoked,O
by,O
doxorubicin,I-Entity
decreasing,O
oxidative,O
damage,O
and,O
mitochondrial,O
alterations,O
.,O
Amiodarone,I-Entity
-,O
induced,O
myxoedema,B-Entity
coma,I-Entity
.,O
A,O
62-year,O
-,O
old,O
man,O
was,O
found,O
to,O
have,O
bradycardia,I-Entity
",",O
hypothermia,I-Entity
and,O
respiratory,B-Entity
failure,I-Entity
3,O
weeks,O
after,O
initiation,O
of,O
amiodarone,I-Entity
therapy,O
for,O
atrial,B-Entity
fibrillation,I-Entity
.,O
0.3,O
-,O
5,O
uIU,O
/,O
mL,O
),O
and,O
free,O
thyroxine,I-Entity
(,O
FT4,O
),O
was,O
<,O
0.2,O
ng,O
/,O
dL,O
(,O
nl,O
.,O
He,O
received,O
intravenous,O
fluids,O
",",O
vasopressor,O
therapy,O
and,O
stress,O
dose,O
steroids,I-Entity
;,O
he,O
was,O
intubated,O
and,O
admitted,O
to,O
the,O
intensive,O
care,O
unit,O
.,O
He,O
received,O
500,O
ug,O
of,O
intravenous,O
levothyroxine,I-Entity
in,O
the,O
first,O
18,O
h,O
of,O
therapy,O
",",O
and,O
150,O
ug,O
intravenous,O
daily,O
thereafter,O
.,O
The,O
patient,O
was,O
maintained,O
on,O
levothyroxine,I-Entity
175,O
(,O
g,O
POorally,O
daily,O
.,O
The,O
24,O
hour,O
excretion,O
of,O
iodine,I-Entity
was,O
3657,O
(,O
mcg,O
(,O
25,O
-,O
756,O
(,O
mcg,O
),O
.,O
The,O
only,O
two,O
cases,O
of,O
amiodarone,I-Entity
-,O
induced,O
myxoedema,B-Entity
coma,I-Entity
in,O
the,O
literature,O
report,O
patient,O
death,O
despite,O
supportive,O
therapy,O
and,O
thyroid,O
hormone,O
replacement,O
.,O
This,O
case,O
represents,O
the,O
most,O
thoroughly,O
investigated,O
case,O
of,O
amiodarone,I-Entity
-,O
induced,O
myxoedema,B-Entity
coma,I-Entity
with,O
a,O
history,O
significant,O
for,O
subclinical,O
thyroid,B-Entity
disease,I-Entity
.,O
Use,O
of,O
argatroban,I-Entity
and,O
catheter,O
-,O
directed,O
thrombolysis,I-Entity
with,O
alteplase,O
in,O
an,O
oncology,O
patient,O
with,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
with,O
thrombosis,I-Entity
.,O
The,O
case,O
of,O
an,O
oncology,O
patient,O
who,O
developed,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
with,O
thrombosis,I-Entity
(,O
HITT,I-Entity
),O
and,O
was,O
treated,O
with,O
argatroban,I-Entity
plus,O
catheter,O
-,O
directed,O
thrombolysis,I-Entity
(,O
CDT,O
),O
with,O
alteplase,O
is,O
presented,O
.,O
A,O
63-year,O
-,O
old,O
Caucasian,O
man,O
with,O
renal,O
amyloidosis,I-Entity
undergoing,O
peripheral,O
blood,O
stem,O
cell,O
collection,O
for,O
an,O
autologous,O
stem,O
cell,O
transplant,O
developed,O
extensive,O
bilateral,O
upper,B-Entity
-,I-Entity
extremity,I-Entity
deep,I-Entity
venous,I-Entity
thrombosis,I-Entity
(,O
DVT,I-Entity
),O
and,O
pulmonary,B-Entity
embolism,I-Entity
secondary,O
to,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
.,O
infusion,O
of,O
argatroban,I-Entity
was,O
initiated,O
",",O
and,O
the,O
patient,O
was,O
managed,O
on,O
the,O
general,O
medical,O
floor,O
.,O
After,O
one,O
week,O
of,O
therapy,O
",",O
he,O
was,O
transferred,O
to,O
the,O
intensive,O
care,O
unit,O
with,O
cardiopulmonary,O
compromise,O
related,O
to,O
superior,B-Entity
vena,I-Entity
cava,I-Entity
(,I-Entity
SVC,I-Entity
),I-Entity
syndrome,I-Entity
.,O
A,O
percutaneous,O
mechanical,O
thrombectomy,O
and,O
CDT,O
with,O
alteplase,O
were,O
attempted,O
",",O
but,O
the,O
procedure,O
was,O
aborted,O
due,O
to,O
epistaxis,I-Entity
.,O
The,O
epistaxis,I-Entity
resolved,O
the,O
next,O
day,O
",",O
and,O
the,O
patient,O
was,O
restarted,O
on,O
argatroban,I-Entity
.,O
Postthrombectomy,O
continuous,O
CDT,O
with,O
alteplase,O
was,O
commenced,O
while,O
argatroban,I-Entity
was,O
withheld,O
",",O
and,O
complete,O
patency,O
of,O
the,O
SVC,O
and,O
central,O
veins,O
was,O
achieved,O
after,O
three,O
days,O
of,O
therapy,O
.,O
Alteplase,O
was,O
discontinued,O
",",O
and,O
the,O
patient,O
was,O
reinitiated,O
on,O
argatroban,I-Entity
;,O
ultimately,O
",",O
he,O
was,O
transitioned,O
to,O
warfarin,I-Entity
for,O
long,O
-,O
term,O
anticoagulation,O
.,O
Although,O
the,O
patient,O
recovered,O
",",O
he,O
experienced,O
permanent,O
vision,B-Entity
and,I-Entity
hearing,I-Entity
loss,I-Entity
",",O
as,O
well,O
as,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
.,O
A,O
63-year,O
-,O
old,O
man,O
with,O
renal,O
amyloidosis,I-Entity
and,O
SVC,B-Entity
syndrome,I-Entity
secondary,O
to,O
HITT,I-Entity
was,O
successfully,O
treated,O
with,O
argatroban,I-Entity
and,O
CDT,O
with,O
alteplase,O
.,O
Effects,O
of,O
dehydroepiandrosterone,I-Entity
in,O
amphetamine,I-Entity
-,O
induced,O
schizophrenia,I-Entity
models,O
in,O
mice,O
.,O
OBJECTIVE,O
:,O
To,O
examine,O
the,O
effects,O
of,O
dehydroepiandrosterone,I-Entity
(,O
DHEA,I-Entity
),O
on,O
animal,O
models,O
of,O
schizophrenia,I-Entity
.,O
METHODS,O
:,O
Seventy,O
Swiss,O
albino,O
female,O
mice,O
(,O
25,O
-,O
35,O
g,O
),O
were,O
divided,O
into,O
4,O
groups,O
:,O
amphetamine,I-Entity
-,O
free,O
(,O
control,O
),O
",",O
amphetamine,I-Entity
",",O
50,O
",",O
and,O
100,O
mg,O
/,O
kg,O
DHEA,I-Entity
.,O
The,O
DHEA,I-Entity
was,O
administered,O
intraperitoneally,O
(,O
ip,O
),O
for,O
5,O
days,O
.,O
Amphetamine,I-Entity
(,O
3,O
mg,O
/,O
kg,O
ip,O
),O
induced,O
hyper,I-Entity
locomotion,O
",",O
apomorphine,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
subcutaneously,O
[,O
sc,O
],O
),O
induced,O
climbing,O
",",O
and,O
haloperidol,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
sc,O
),O
induced,O
catalepsy,I-Entity
tests,O
were,O
used,O
as,O
animal,O
models,O
of,O
schizophrenia,I-Entity
.,O
Statistical,O
analysis,O
was,O
carried,O
out,O
using,O
Kruskal,O
-,O
Wallis,O
test,O
for,O
hyper,I-Entity
locomotion,O
",",O
and,O
one,O
-,O
way,O
ANOVA,O
for,O
climbing,O
and,O
catalepsy,I-Entity
tests,O
.,O
In,O
the,O
amphetamine,I-Entity
-,O
induced,O
locomotion,O
test,O
",",O
there,O
were,O
significant,O
increases,O
in,O
all,O
movements,O
compared,O
with,O
the,O
amphetamine,I-Entity
-,O
free,O
group,O
.,O
Both,O
DHEA,I-Entity
50,O
mg,O
/,O
kg,O
(,O
p<0.05,O
),O
",",O
and,O
100,O
mg,O
/,O
kg,O
(,O
p<0.01,O
),O
significantly,O
decreased,O
all,O
movements,O
compared,O
with,O
the,O
amphetamine,I-Entity
-,O
induced,O
locomotion,O
group,O
.,O
There,O
was,O
a,O
significant,O
difference,O
between,O
groups,O
in,O
the,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
test,O
(,O
p<0.05,O
),O
.,O
There,O
was,O
no,O
significant,O
difference,O
between,O
groups,O
in,O
terms,O
of,O
total,O
climbing,O
time,O
in,O
the,O
apomorphine,I-Entity
-,O
induced,O
climbing,O
test,O
(,O
p>0.05,O
),O
.,O
We,O
observed,O
that,O
DHEA,I-Entity
reduced,O
locomotor,O
activity,O
and,O
increased,O
catalepsy,I-Entity
at,O
both,O
doses,O
",",O
while,O
it,O
had,O
no,O
effect,O
on,O
climbing,O
behavior,O
.,O
We,O
suggest,O
that,O
DHEA,I-Entity
displays,O
typical,O
neuroleptic,O
-,O
like,O
effects,O
",",O
and,O
may,O
be,O
used,O
in,O
the,O
treatment,O
of,O
schizophrenia,I-Entity
.,O
Availability,O
of,O
human,O
induced,O
pluripotent,O
stem,O
cell,O
-,O
derived,O
cardiomyocytes,O
in,O
assessment,O
of,O
drug,O
potential,O
for,O
QT,B-Entity
prolongation,I-Entity
.,O
Field,O
potential,O
duration,O
(,O
FPD,O
),O
in,O
human,O
-,O
induced,O
pluripotent,O
stem,O
cell,O
-,O
derived,O
cardiomyocytes,O
(,O
hiPS,O
-,O
CMs,O
),O
",",O
which,O
can,O
express,O
QT,O
interval,O
in,O
an,O
electrocardiogram,O
",",O
is,O
reported,O
to,O
be,O
a,O
useful,O
tool,O
to,O
predict,O
K(+,I-Entity
),O
channel,O
and,O
Ca(2,I-Entity
+,O
),O
channel,O
blocker,O
effects,O
on,O
QT,O
interval,O
.,O
However,O
",",O
there,O
is,O
no,O
report,O
showing,O
that,O
this,O
technique,O
can,O
be,O
used,O
to,O
predict,O
multichannel,O
blocker,O
potential,O
for,O
QT,B-Entity
prolongation,I-Entity
.,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
show,O
that,O
FPD,O
from,O
MEA,O
(,O
Multielectrode,O
array,O
),O
of,O
hiPS,O
-,O
CMs,O
can,O
detect,O
QT,B-Entity
prolongation,I-Entity
induced,O
by,O
multichannel,O
blockers,O
.,O
IKr,O
and,O
IKs,O
blockers,O
concentration,O
-,O
dependently,O
prolonged,O
corrected,O
FPD,O
(,O
FPDc,O
),O
",",O
whereas,O
Ca(2,I-Entity
+,O
),O
channel,O
blockers,O
concentration,O
-,O
dependently,O
shortened,O
FPDc,O
.,O
Also,O
",",O
the,O
multichannel,O
blockers,O
Amiodarone,I-Entity
",",O
Paroxetine,I-Entity
",",O
Terfenadine,I-Entity
and,O
Citalopram,I-Entity
prolonged,O
FPDc,O
in,O
a,O
concentration,O
dependent,O
manner,O
.,O
Finally,O
",",O
the,O
IKr,O
blockers,O
",",O
Terfenadine,I-Entity
and,O
Citalopram,I-Entity
",",O
which,O
are,O
reported,O
to,O
cause,O
Torsade,B-Entity
de,I-Entity
Pointes,I-Entity
(,O
TdP,I-Entity
),O
in,O
clinical,O
practice,O
",",O
produced,O
early,O
afterdepolarization,O
(,O
EAD,O
),O
.,O
This,O
study,O
also,O
shows,O
that,O
this,O
assay,O
can,O
help,O
detect,O
EAD,O
for,O
drugs,O
with,O
TdP,I-Entity
potential,O
.,O
Dermal,O
developmental,O
toxicity,I-Entity
of,O
N,O
-,O
phenylimide,O
herbicides,O
in,O
rats,O
.,O
BACKGROUND,O
:,O
S-53482,I-Entity
and,O
S-23121,I-Entity
are,O
N,O
-,O
phenylimide,O
herbicides,O
and,O
produced,O
embryolethality,I-Entity
",",O
teratogenicity,I-Entity
(,O
mainly,O
ventricular,B-Entity
septal,I-Entity
defects,I-Entity
and,O
wavy,O
ribs,O
),O
",",O
and,O
growth,B-Entity
retardation,I-Entity
in,O
rats,O
in,O
conventional,O
oral,O
developmental,O
toxicity,I-Entity
studies,O
.,O
Our,O
objective,O
in,O
this,O
study,O
was,O
to,O
investigate,O
whether,O
the,O
compounds,O
induce,O
developmental,O
toxicity,I-Entity
via,O
the,O
dermal,O
route,O
",",O
which,O
is,O
more,O
relevant,O
to,O
occupational,O
exposure,O
",",O
hence,O
better,O
addressing,O
human,O
health,O
risks,O
.,O
S-53482,I-Entity
was,O
administered,O
dermally,O
to,O
rats,O
at,O
30,O
",",O
100,O
",",O
and,O
300,O
mg,O
/,O
kg,O
during,O
organogenesis,O
",",O
and,O
S-23121,I-Entity
was,O
administered,O
at,O
200,O
",",O
400,O
",",O
and,O
800,O
mg,O
/,O
kg,O
(,O
the,O
maximum,O
applicable,O
dose,O
level,O
),O
.,O
RESULTS,O
:,O
Dermal,O
exposure,O
of,O
rats,O
to,O
S-53482,I-Entity
at,O
300,O
mg,O
/,O
kg,O
produced,O
patterns,O
of,O
developmental,O
toxicity,I-Entity
similar,O
to,O
those,O
resulting,O
from,O
oral,O
exposure,O
.,O
Toxicity,I-Entity
included,O
embryolethality,I-Entity
",",O
teratogenicity,I-Entity
",",O
and,O
growth,B-Entity
retardation,I-Entity
.,O
Dermal,O
administration,O
of,O
S-23121,I-Entity
at,O
800,O
mg,O
/,O
kg,O
resulted,O
in,O
an,O
increased,O
incidence,O
of,O
embryonic,B-Entity
death,I-Entity
and,O
ventricular,B-Entity
septal,I-Entity
defect,I-Entity
",",O
but,O
retarded,O
fetal,O
growth,O
was,O
not,O
observed,O
as,O
it,O
was,O
following,O
oral,O
exposure,O
to,O
S-23121,I-Entity
.,O
CONCLUSIONS,O
:,O
Based,O
on,O
the,O
results,O
",",O
S-53482,I-Entity
and,O
S-23121,I-Entity
were,O
teratogenic,I-Entity
when,O
administered,O
dermally,O
to,O
pregnant,O
rats,O
as,O
were,O
the,O
compounds,O
administered,O
orally,O
.,O
Rates,O
of,O
Renal,B-Entity
Toxicity,I-Entity
in,O
Cancer,I-Entity
Patients,O
Receiving,O
Cisplatin,I-Entity
With,O
and,O
Without,O
Mannitol,I-Entity
.,O
Cisplatin,I-Entity
is,O
a,O
widely,O
used,O
antineoplastic,O
.,O
One,O
of,O
the,O
major,O
complications,O
of,O
cisplatin,I-Entity
use,O
is,O
dose,O
-,O
limiting,O
nephrotoxicity,I-Entity
.,O
There,O
are,O
many,O
strategies,O
to,O
prevent,O
this,O
toxicity,I-Entity
",",O
including,O
the,O
use,O
of,O
mannitol,I-Entity
as,O
a,O
nephroprotectant,O
in,O
combination,O
with,O
hydration,O
.,O
OBJECTIVE,O
:,O
We,O
aimed,O
to,O
evaluate,O
the,O
rates,O
of,O
cisplatin,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
in,O
cancer,I-Entity
patients,O
receiving,O
single,O
-,O
agent,O
cisplatin,I-Entity
with,O
and,O
without,O
mannitol,I-Entity
.,O
This,O
single,O
-,O
center,O
retrospective,O
analysis,O
was,O
a,O
quasi,O
experiment,O
created,O
by,O
the,O
national,O
mannitol,I-Entity
shortage,O
.,O
Data,O
were,O
collected,O
on,O
adult,O
cancer,I-Entity
patients,O
receiving,O
single,O
-,O
agent,O
cisplatin,I-Entity
as,O
an,O
outpatient,O
from,O
January,O
2011,O
to,O
September,O
2012,O
.,O
The,O
primary,O
outcome,O
was,O
acute,B-Entity
kidney,I-Entity
injury,I-Entity
(,O
AKI,I-Entity
),O
.,O
We,O
evaluated,O
143,O
patients,O
who,O
received,O
single,O
-,O
agent,O
cisplatin,I-Entity
;,O
97.2%,O
of,O
patients,O
had,O
head,B-Entity
and,I-Entity
neck,I-Entity
cancer,I-Entity
as,O
their,O
primary,O
malignancy,I-Entity
.,O
Patients,O
who,O
did,O
not,O
receive,O
mannitol,I-Entity
were,O
more,O
likely,O
to,O
develop,O
nephrotoxicity,I-Entity
:,O
odds,O
ratio,O
[,O
OR,O
],O
=,O
2.646,O
(,O
95%,O
CI,O
=,O
1.008,O
",",O
6.944,O
;,O
P,O
=,O
0.048,O
),O
.,O
Patients,O
who,O
received,O
the,O
100,O
mg,O
/,O
m(2,O
),O
dosing,O
and,O
patients,O
who,O
had,O
a,O
history,O
of,O
hypertension,I-Entity
also,O
had,O
a,O
higher,O
likelihood,O
of,O
developing,O
nephrotoxicity,I-Entity
:,O
OR,O
=,O
11.494,O
(,O
95%,O
CI,O
=,O
4.149,O
",",O
32.258,O
;,O
CONCLUSIONS,O
:,O
When,O
limited,O
quantities,O
of,O
mannitol,I-Entity
are,O
available,O
",",O
it,O
should,O
preferentially,O
be,O
given,O
to,O
patients,O
at,O
particularly,O
high,O
risk,O
of,O
nephrotoxicity,I-Entity
.,O
Our,O
analysis,O
suggests,O
that,O
those,O
patients,O
receiving,O
the,O
dosing,O
schedule,O
of,O
100,O
mg,O
/,O
m(2,O
),O
cisplatin,I-Entity
every,O
3,O
weeks,O
and,O
those,O
with,O
hypertension,I-Entity
are,O
at,O
the,O
greatest,O
risk,O
of,O
nephrotoxicity,I-Entity
and,O
would,O
benefit,O
from,O
the,O
addition,O
of,O
mannitol,I-Entity
.,O
Metformin,I-Entity
protects,O
against,O
seizures,I-Entity
",",O
learning,B-Entity
and,I-Entity
memory,I-Entity
impairments,I-Entity
and,O
oxidative,O
damage,O
induced,O
by,O
pentylenetetrazole,I-Entity
-,O
induced,O
kindling,O
in,O
mice,O
.,O
Cognitive,B-Entity
impairment,I-Entity
",",O
the,O
most,O
common,O
and,O
severe,O
comorbidity,O
of,O
epilepsy,I-Entity
",",O
greatly,O
diminishes,O
the,O
quality,O
of,O
life,O
.,O
However,O
",",O
current,O
therapeutic,O
interventions,O
for,O
epilepsy,I-Entity
can,O
also,O
cause,O
untoward,O
cognitive,O
effects,O
.,O
Thus,O
",",O
there,O
is,O
an,O
urgent,O
need,O
for,O
new,O
kinds,O
of,O
agents,O
targeting,O
both,O
seizures,I-Entity
and,O
cognition,B-Entity
deficits,I-Entity
.,O
Oxidative,O
stress,O
is,O
considered,O
to,O
play,O
an,O
important,O
role,O
in,O
epileptogenesis,O
and,O
cognitive,B-Entity
deficits,I-Entity
",",O
and,O
antioxidants,O
have,O
a,O
putative,O
antiepileptic,O
potential,O
.,O
Metformin,I-Entity
",",O
the,O
most,O
commonly,O
prescribed,O
antidiabetic,O
oral,O
drug,O
",",O
has,O
antioxidant,O
properties,O
.,O
This,O
study,O
was,O
designed,O
to,O
evaluate,O
the,O
ameliorative,O
effects,O
of,O
metformin,I-Entity
on,O
seizures,I-Entity
",",O
cognitive,B-Entity
impairment,I-Entity
and,O
brain,O
oxidative,O
stress,O
markers,O
observed,O
in,O
pentylenetetrazole,I-Entity
-,O
induced,O
kindling,O
animals,O
.,O
Male,O
C57BL/6,O
mice,O
were,O
administered,O
with,O
subconvulsive,O
dose,O
of,O
pentylenetetrazole,I-Entity
(,O
37,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
every,O
other,O
day,O
for,O
14,O
injections,O
.,O
Metformin,I-Entity
was,O
injected,O
intraperitoneally,O
in,O
dose,O
of,O
200mg,O
/,O
kg,O
along,O
with,O
alternate,O
-,O
day,O
PTZ,I-Entity
.,O
We,O
found,O
that,O
metformin,I-Entity
suppressed,O
the,O
progression,O
of,O
kindling,O
",",O
ameliorated,O
the,O
cognitive,B-Entity
impairment,I-Entity
and,O
decreased,O
brain,O
oxidative,O
stress,O
.,O
Thus,O
the,O
present,O
study,O
concluded,O
that,O
metformin,I-Entity
may,O
be,O
a,O
potential,O
agent,O
for,O
the,O
treatment,O
of,O
epilepsy,I-Entity
as,O
well,O
as,O
a,O
protective,O
medicine,O
against,O
cognitive,B-Entity
impairment,I-Entity
induced,O
by,O
seizures,I-Entity
.,O
P53,O
inhibition,O
exacerbates,O
late,O
-,O
stage,O
anthracycline,I-Entity
cardiotoxicity,I-Entity
.,O
AIMS,O
:,O
Doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
is,O
an,O
effective,O
anti,O
-,O
cancer,I-Entity
therapeutic,O
",",O
but,O
is,O
associated,O
with,O
both,O
acute,O
and,O
late,O
-,O
stage,O
cardiotoxicity,I-Entity
.,O
Children,O
are,O
particularly,O
sensitive,O
to,O
DOX,I-Entity
-,O
induced,O
heart,B-Entity
failure,I-Entity
.,O
Here,O
",",O
the,O
impact,O
of,O
p53,O
inhibition,O
on,O
acute,O
vs.,O
late,O
-,O
stage,O
DOX,I-Entity
cardiotoxicity,I-Entity
was,O
examined,O
in,O
a,O
juvenile,O
model,O
.,O
littermates,O
received,O
weekly,O
DOX,I-Entity
injections,O
for,O
5,O
weeks,O
(,O
25,O
mg,O
/,O
kg,O
cumulative,O
dose,O
),O
.,O
One,O
week,O
after,O
the,O
last,O
DOX,I-Entity
treatment,O
(,O
acute,O
stage,O
),O
",",O
MHC,O
-,O
CB7,O
mice,O
exhibited,O
improved,O
cardiac,O
function,O
and,O
lower,O
levels,O
of,O
cardiomyocyte,O
apoptosis,O
when,O
compared,O
with,O
the,O
NON,O
-,O
TXG,O
mice,O
.,O
Surprisingly,O
",",O
by,O
13,O
weeks,O
following,O
the,O
last,O
DOX,I-Entity
treatment,O
(,O
late,O
stage,O
),O
",",O
MHC,O
-,O
CB7,O
exhibited,O
a,O
progressive,O
decrease,O
in,O
cardiac,O
function,O
and,O
higher,O
rates,O
of,O
cardiomyocyte,O
apoptosis,O
when,O
compared,O
with,O
NON,O
-,O
TXG,O
mice,O
.,O
p53,O
inhibition,O
blocked,O
transient,O
DOX,I-Entity
-,O
induced,O
STAT3,O
activation,O
in,O
MHC,O
-,O
CB7,O
mice,O
",",O
which,O
was,O
associated,O
with,O
enhanced,O
induction,O
of,O
the,O
DNA,O
repair,O
proteins,O
Ku70,O
and,O
Ku80,O
.,O
Mice,O
with,O
cardiomyocyte,O
-,O
restricted,O
deletion,O
of,O
STAT3,O
exhibited,O
worse,O
cardiac,O
function,O
",",O
higher,O
levels,O
of,O
cardiomyocyte,O
apoptosis,O
",",O
and,O
a,O
greater,O
induction,O
of,O
Ku70,O
and,O
Ku80,O
in,O
response,O
to,O
DOX,I-Entity
treatment,O
during,O
the,O
acute,O
stage,O
when,O
compared,O
with,O
control,O
animals,O
.,O
CONCLUSION,O
:,O
These,O
data,O
support,O
a,O
model,O
wherein,O
a,O
p53-dependent,O
cardioprotective,O
pathway,O
",",O
mediated,O
via,O
STAT3,O
activation,O
",",O
mitigates,O
DOX,I-Entity
-,O
induced,O
myocardial,O
stress,O
during,O
drug,O
delivery,O
.,O
Furthermore,O
",",O
these,O
data,O
suggest,O
an,O
explanation,O
as,O
to,O
how,O
p53,O
inhibition,O
can,O
result,O
in,O
cardioprotection,O
during,O
drug,O
treatment,O
and,O
",",O
paradoxically,O
",",O
enhanced,O
cardiotoxicity,I-Entity
long,O
after,O
the,O
cessation,O
of,O
drug,O
treatment,O
.,O
Metronidazole,I-Entity
-,O
induced,O
encephalopathy,I-Entity
:,O
an,O
uncommon,O
scenario,O
.,O
Metronidazole,I-Entity
can,O
produce,O
neurological,O
complications,O
although,O
it,O
is,O
not,O
a,O
common,O
scenario,O
.,O
We,O
present,O
a,O
case,O
where,O
a,O
patient,O
developed,O
features,O
of,O
encephalopathy,I-Entity
following,O
prolonged,O
metronidazole,I-Entity
intake,O
.,O
The,O
diagnosis,O
of,O
metronidazole,I-Entity
toxicity,I-Entity
was,O
made,O
by,O
the,O
MRI,O
findings,O
and,O
supported,O
clinically,O
.,O
Aconitine,I-Entity
-,O
induced,O
Ca2,I-Entity
+,O
overload,O
causes,O
arrhythmia,I-Entity
and,O
triggers,O
apoptosis,O
through,O
p38,O
MAPK,O
signaling,O
pathway,O
in,O
rats,O
.,O
Aconitine,I-Entity
is,O
a,O
major,O
bioactive,O
diterpenoid,O
alkaloid,O
with,O
high,O
content,O
derived,O
from,O
herbal,O
aconitum,O
plants,O
.,O
Emerging,O
evidence,O
indicates,O
that,O
voltage,O
-,O
dependent,O
Na(+,I-Entity
),O
channels,O
have,O
pivotal,O
roles,O
in,O
the,O
cardiotoxicity,I-Entity
of,O
aconitine,I-Entity
.,O
However,O
",",O
no,O
reports,O
are,O
available,O
on,O
the,O
role,O
of,O
Ca(2,I-Entity
+,O
),O
in,O
aconitine,I-Entity
poisoning,I-Entity
.,O
In,O
this,O
study,O
",",O
we,O
explored,O
the,O
importance,O
of,O
pathological,O
Ca(2,I-Entity
+,O
),O
signaling,O
in,O
aconitine,I-Entity
poisoning,I-Entity
in,O
vitro,O
and,O
in,O
vivo,O
.,O
We,O
found,O
that,O
Ca(2,I-Entity
+,O
),O
overload,O
lead,O
to,O
accelerated,O
beating,O
rhythm,O
in,O
adult,O
rat,O
ventricular,O
myocytes,O
and,O
caused,O
arrhythmia,I-Entity
in,O
conscious,O
freely,O
moving,O
rats,O
.,O
To,O
investigate,O
effects,O
of,O
aconitine,I-Entity
on,O
myocardial,B-Entity
injury,I-Entity
",",O
we,O
performed,O
cytotoxicity,I-Entity
assay,O
in,O
neonatal,O
rat,O
ventricular,O
myocytes,O
(,O
NRVMs,O
),O
",",O
as,O
well,O
as,O
measured,O
lactate,I-Entity
dehydrogenase,O
level,O
in,O
the,O
culture,O
medium,O
of,O
NRVMs,O
and,O
activities,O
of,O
serum,O
cardiac,O
enzymes,O
in,O
rats,O
.,O
The,O
results,O
showed,O
that,O
aconitine,I-Entity
resulted,O
in,O
myocardial,B-Entity
injury,I-Entity
and,O
reduced,O
NRVMs,O
viability,O
dose,O
-,O
dependently,O
.,O
transferase,O
-,O
mediated,O
dUTP,I-Entity
-,O
biotin,I-Entity
nick,O
end,O
labeling,O
assay,O
.,O
The,O
results,O
showed,O
that,O
aconitine,I-Entity
stimulated,O
apoptosis,O
time,O
-,O
dependently,O
.,O
The,O
expression,O
analysis,O
of,O
Ca(2,I-Entity
+,O
),O
handling,O
proteins,O
demonstrated,O
that,O
aconitine,I-Entity
promoted,O
Ca(2,I-Entity
+,O
),O
overload,O
through,O
the,O
expression,O
regulation,O
of,O
Ca(2,I-Entity
+,O
),O
handling,O
proteins,O
.,O
Hence,O
",",O
our,O
results,O
suggest,O
that,O
aconitine,I-Entity
significantly,O
aggravates,O
Ca(2,I-Entity
+,O
),O
overload,O
and,O
causes,O
arrhythmia,I-Entity
and,O
finally,O
promotes,O
apoptotic,O
development,O
via,O
phosphorylation,O
of,O
P38,O
mitogen,O
-,O
activated,O
protein,O
kinase,O
.,O
Chronic,O
treatment,O
with,O
metformin,I-Entity
suppresses,O
toll,O
-,O
like,O
receptor,O
4,O
signaling,O
and,O
attenuates,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
following,O
myocardial,B-Entity
infarction,I-Entity
.,O
Acute,O
treatment,O
with,O
metformin,I-Entity
has,O
a,O
protective,O
effect,O
in,O
myocardial,B-Entity
infarction,I-Entity
by,O
suppression,O
of,O
inflammatory,O
responses,O
due,O
to,O
activation,O
of,O
AMP,I-Entity
-,O
activated,O
protein,O
kinase,O
(,O
AMPK,O
),O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
effect,O
of,O
chronic,O
pre,O
-,O
treatment,O
with,O
metformin,I-Entity
on,O
cardiac,B-Entity
dysfunction,I-Entity
and,O
toll,O
-,O
like,O
receptor,O
4,O
(,O
TLR4,O
),O
activities,O
following,O
myocardial,B-Entity
infarction,I-Entity
and,O
their,O
relation,O
with,O
AMPK,O
were,O
assessed,O
.,O
Male,O
Wistar,O
rats,O
were,O
randomly,O
assigned,O
to,O
one,O
of,O
5,O
groups,O
(,O
n=6,O
),O
:,O
normal,O
control,O
and,O
groups,O
were,O
injected,O
isoproterenol,I-Entity
after,O
chronic,O
pre,O
-,O
treatment,O
with,O
0,O
",",O
25,O
",",O
50,O
",",O
or,O
100mg,O
/,O
kg,O
of,O
metformin,I-Entity
twice,O
daily,O
for,O
14,O
days,O
.,O
Isoproterenol,I-Entity
(,O
100mg,O
/,O
kg,O
),O
was,O
injected,O
subcutaneously,O
on,O
the,O
13th,O
and,O
14th,O
days,O
to,O
induce,O
acute,B-Entity
myocardial,I-Entity
infarction,I-Entity
.,O
Isoproterenol,I-Entity
alone,O
decreased,O
left,O
ventricular,O
systolic,O
pressure,O
and,O
myocardial,O
contractility,O
indexed,O
as,O
LVdp,O
/,O
dtmax,O
and,O
LVdp,O
/,O
dtmin,O
.,O
The,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
was,O
significantly,O
lower,O
in,O
the,O
groups,O
treated,O
with,O
25,O
and,O
50mg,O
/,O
kg,O
of,O
metformin,I-Entity
.,O
Metfromin,O
markedly,O
lowered,O
isoproterenol,I-Entity
-,O
induced,O
elevation,O
in,O
the,O
levels,O
of,O
TLR4,O
mRNA,O
",",O
myeloid,O
differentiation,O
protein,O
88,O
(,O
MyD88,O
),O
",",O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
(,O
TNF,O
-,O
a,O
),O
",",O
and,O
interleukin,O
6,O
(,O
IL-6,O
),O
in,O
the,O
heart,O
tissues,O
.,O
kg,O
of,O
metformin,I-Entity
",",O
slightly,O
by,O
50mg,O
/,O
kg,O
",",O
but,O
not,O
by,O
100mg,O
Chronic,O
pre,O
-,O
treatment,O
with,O
metformin,I-Entity
reduces,O
post,O
-,O
myocardial,B-Entity
infarction,I-Entity
cardiac,O
dysfunction,O
and,O
suppresses,O
inflammatory,O
responses,O
",",O
possibly,O
through,O
inhibition,O
of,O
TLR4,O
activities,O
.,O
Neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
induced,O
by,O
combination,O
therapy,O
with,O
tetrabenazine,I-Entity
and,O
tiapride,I-Entity
in,O
a,O
Japanese,O
patient,O
with,O
Huntington,B-Entity
's,I-Entity
disease,I-Entity
at,O
the,O
terminal,O
stage,O
of,O
recurrent,O
breast,B-Entity
cancer,I-Entity
.,O
We,O
herein,O
describe,O
the,O
case,O
of,O
an,O
81-year,O
-,O
old,O
Japanese,O
woman,O
with,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
that,O
occurred,O
36,O
days,O
after,O
the,O
initiation,O
of,O
combination,O
therapy,O
with,O
tiapride,I-Entity
(,O
75,O
mg,O
/,O
day,O
),O
and,O
tetrabenazine,I-Entity
(,O
12.5,O
mg,O
/,O
day,O
),O
for,O
Huntington,B-Entity
's,I-Entity
disease,I-Entity
.,O
The,O
patient,O
had,O
been,O
treated,O
with,O
tiapride,I-Entity
or,O
tetrabenazine,I-Entity
alone,O
without,O
any,O
adverse,O
effects,O
before,O
the,O
administration,O
of,O
the,O
combination,O
therapy,O
.,O
She,O
also,O
had,O
advanced,O
breast,B-Entity
cancer,I-Entity
when,O
the,O
combination,O
therapy,O
was,O
initiated,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
the,O
occurrence,O
of,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
due,O
to,O
combination,O
therapy,O
with,O
tetrabenazine,I-Entity
and,O
tiapride,I-Entity
has,O
not,O
been,O
previously,O
reported,O
.,O
Tetrabenazine,I-Entity
should,O
be,O
administered,O
very,O
carefully,O
in,O
combination,O
with,O
other,O
neuroleptic,B-Entity
drugs,I-Entity
",",O
particularly,O
in,O
patients,O
with,O
a,O
worsening,O
general,O
condition,O
.,O
A,O
metoprolol,I-Entity
-,O
terbinafine,I-Entity
combination,O
induced,O
bradycardia,I-Entity
.,O
To,O
report,O
a,O
sinus,B-Entity
bradycardia,I-Entity
induced,O
by,O
metoprolol,I-Entity
and,O
terbinafine,I-Entity
drug,O
-,O
drug,O
interaction,O
and,O
its,O
management,O
.,O
A,O
63,O
year,O
-,O
old,O
Caucasian,O
man,O
on,O
metoprolol,I-Entity
200,O
mg,O
/,O
day,O
for,O
stable,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
was,O
prescribed,O
a,O
90-day,O
course,O
of,O
oral,O
terbinafine,I-Entity
250,O
mg,O
/,O
day,O
for,O
onychomycosis,I-Entity
.,O
On,O
the,O
49th,O
day,O
of,O
terbinafine,I-Entity
therapy,O
",",O
he,O
was,O
brought,O
to,O
the,O
emergency,O
room,O
for,O
a,O
decrease,O
of,O
his,O
global,O
health,O
status,O
",",O
confusion,I-Entity
and,O
falls,O
.,O
The,O
electrocardiogram,O
revealed,O
a,O
37,O
beats,O
/,O
min,O
sinus,B-Entity
bradycardia,I-Entity
.,O
A,O
score,O
of,O
7,O
on,O
the,O
Naranjo,O
adverse,B-Entity
drug,I-Entity
reaction,I-Entity
probability,O
scale,O
indicates,O
a,O
probable,O
relationship,O
between,O
the,O
patient,O
's,O
sinus,B-Entity
bradycardia,I-Entity
and,O
the,O
drug,O
interaction,O
between,O
metoprolol,I-Entity
and,O
terbinafine,I-Entity
.,O
The,O
heart,O
rate,O
ameliorated,O
first,O
with,O
a,O
decrease,O
in,O
the,O
dose,O
of,O
metoprolol,I-Entity
.,O
It,O
was,O
subsequently,O
changed,O
to,O
bisoprolol,I-Entity
and,O
the,O
heart,O
rate,O
remained,O
normal,O
.,O
By,O
inhibiting,O
the,O
cytochrome,O
P450,O
2D6,O
",",O
terbinafine,I-Entity
had,O
decreased,O
metoprolol,I-Entity
's,O
clearance,O
",",O
leading,O
in,O
metoprolol,I-Entity
accumulation,O
which,O
has,O
resulted,O
in,O
clinically,O
significant,O
sinus,B-Entity
bradycardia,I-Entity
.,O
Optochiasmatic,O
and,O
peripheral,B-Entity
neuropathy,I-Entity
due,O
to,O
ethambutol,I-Entity
overtreatment,O
.,O
Ethambutol,I-Entity
is,O
known,O
to,O
cause,O
optic,B-Entity
neuropathy,I-Entity
and,O
",",O
more,O
rarely,O
",",O
axonal,O
polyneuropathy,I-Entity
.,O
We,O
characterize,O
the,O
clinical,O
",",O
neurophysiological,O
",",O
and,O
neuroimaging,O
findings,O
in,O
a,O
72-year,O
-,O
old,O
man,O
who,O
developed,O
visual,B-Entity
loss,I-Entity
and,O
paresthesias,I-Entity
after,O
11,O
weeks,O
of,O
exposure,O
to,O
a,O
supratherapeutic,O
dose,O
of,O
ethambutol,I-Entity
.,O
This,O
case,O
demonstrates,O
the,O
selective,O
vulnerability,O
of,O
the,O
anterior,O
visual,O
pathways,O
and,O
peripheral,O
nerves,O
to,O
ethambutol,I-Entity
toxicity,I-Entity
.,O
Testosterone,I-Entity
ameliorates,O
streptozotocin,I-Entity
-,O
induced,O
memory,B-Entity
impairment,I-Entity
in,O
male,O
rats,O
.,O
AIM,O
:,O
To,O
study,O
the,O
effects,O
of,O
testosterone,I-Entity
on,O
streptozotocin,I-Entity
(,O
STZ)-induced,I-Entity
memory,B-Entity
impairment,I-Entity
in,O
male,O
rats,O
.,O
Adult,O
male,O
Wistar,O
rats,O
were,O
intracerebroventricularly,O
(,O
icv,O
),O
infused,O
with,O
STZ,I-Entity
(,O
750,O
ug,O
),O
on,O
d,O
1,O
and,O
d,O
3,O
",",O
and,O
a,O
passive,O
avoidance,O
task,O
was,O
assessed,O
2,O
weeks,O
after,O
the,O
first,O
injection,O
of,O
STZ,I-Entity
.,O
Testosterone,I-Entity
(,O
1,O
mg.kg(-1).d(-1,O
),O
",",O
sc,O
),O
",",O
the,O
androgen,I-Entity
receptor,O
antagonist,O
flutamide,I-Entity
(,O
10,O
mg.kg(-1).d(-1,O
),O
",",O
ip,O
),O
",",O
the,O
estrogen,I-Entity
receptor,O
antagonist,O
tamoxifen,I-Entity
(,O
1,O
mg.kg(-1).d(-1,O
),O
",",O
ip,O
),O
or,O
the,O
aromatase,O
inhibitor,O
letrozole,I-Entity
(,O
4,O
mg.kg(-1).d(-1,O
),O
",",O
ip,O
),O
were,O
administered,O
for,O
6,O
d,O
after,O
the,O
first,O
injection,O
of,O
STZ,I-Entity
.,O
STZ,I-Entity
administration,O
and,O
castration,O
markedly,O
decreased,O
both,O
STL1,O
(,O
the,O
short,O
memory,O
),O
and,O
STL2,O
(,O
the,O
long,O
memory,O
),O
in,O
passive,O
avoidance,O
tests,O
.,O
Testosterone,I-Entity
replacement,O
almost,O
restored,O
the,O
STL1,O
and,O
STL2,O
in,O
castrated,O
rats,O
",",O
and,O
significantly,O
prolonged,O
the,O
STL1,O
and,O
STL2,O
in,O
STZ,I-Entity
-,O
treated,O
rats,O
.,O
Administration,O
of,O
flutamide,I-Entity
",",O
letrozole,I-Entity
or,O
tamoxifen,I-Entity
significantly,O
impaired,B-Entity
the,I-Entity
memory,I-Entity
in,O
intact,O
rats,O
",",O
and,O
significantly,O
attenuated,O
the,O
testosterone,I-Entity
replacement,O
in,O
improving,O
STZ-,I-Entity
and,O
castration,O
-,O
induced,O
memory,B-Entity
impairment,I-Entity
.,O
Testosterone,I-Entity
administration,O
ameliorates,O
STZ-,I-Entity
and,O
castration,O
-,O
induced,O
memory,B-Entity
impairment,I-Entity
in,O
male,O
Wistar,O
rats,O
.,O
Behavioral,O
and,O
neurochemical,O
studies,O
in,O
mice,O
pretreated,O
with,O
garcinielliptone,B-Entity
FC,I-Entity
in,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
Garcinielliptone,B-Entity
FC,I-Entity
(,O
GFC,I-Entity
),O
isolated,O
from,O
hexanic,O
fraction,O
seed,O
extract,O
of,O
species,O
Platonia,O
insignis,O
Mart,O
.,O
It,O
is,O
widely,O
used,O
in,O
folk,O
medicine,O
to,O
treat,O
skin,B-Entity
diseases,I-Entity
in,O
both,O
humans,O
and,O
animals,O
as,O
well,O
as,O
the,O
seed,O
decoction,O
has,O
been,O
used,O
to,O
treat,O
diarrheas,I-Entity
and,O
inflammatory,B-Entity
diseases,I-Entity
.,O
However,O
",",O
there,O
is,O
no,O
research,O
on,O
GFC,I-Entity
effects,O
in,O
the,O
central,O
nervous,O
system,O
of,O
rodents,O
.,O
The,O
present,O
study,O
aimed,O
to,O
evaluate,O
the,O
GFC,I-Entity
effects,O
at,O
doses,O
of,O
25,O
",",O
50,O
or,O
75,O
mg,O
/,O
kg,O
on,O
seizure,I-Entity
parameters,O
to,O
determine,O
their,O
anticonvulsant,O
activity,O
and,O
its,O
effects,O
on,O
amino,B-Entity
acid,I-Entity
(,O
r,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
(,O
GABA,I-Entity
),O
",",O
glutamine,I-Entity
",",O
aspartate,I-Entity
and,O
glutathione,I-Entity
),O
levels,O
as,O
well,O
as,O
on,O
acetylcholinesterase,O
(,O
AChE,O
),O
activity,O
in,O
mice,O
hippocampus,O
after,O
seizures,I-Entity
.,O
GFC,I-Entity
produced,O
an,O
increased,O
latency,O
to,O
first,O
seizure,I-Entity
",",O
at,O
doses,O
25mg,O
/,O
kg,O
(,O
20.12,O
+,O
2.20,O
min,O
),O
",",O
50mg,O
/,O
kg,O
(,O
20.95,O
+,O
2.21,O
min,O
),O
or,O
75,O
mg,O
/,O
kg,O
(,O
23.43,O
+,O
1.99,O
min,O
),O
when,O
compared,O
with,O
seized,O
mice,O
.,O
In,O
addition,O
",",O
GABA,I-Entity
content,O
of,O
mice,O
hippocampus,O
treated,O
with,O
GFC75,O
plus,O
P400,O
showed,O
an,O
increase,O
of,O
46.90%,O
when,O
compared,O
with,O
seized,O
mice,O
.,O
In,O
aspartate,I-Entity
",",O
glutamine,I-Entity
and,O
glutamate,I-Entity
levels,O
detected,O
a,O
decrease,O
of,O
5.21%,O
",",O
13.55%,O
and,O
21.80%,O
",",O
respectively,O
in,O
mice,O
hippocampus,O
treated,O
with,O
GFC75,O
plus,O
P400,O
when,O
compared,O
with,O
seized,O
mice,O
.,O
The,O
results,O
indicate,O
that,O
GFC,I-Entity
can,O
exert,O
anticonvulsant,O
activity,O
and,O
reduce,O
the,O
frequency,O
of,O
installation,O
of,O
pilocarpine,I-Entity
-,O
induced,O
status,B-Entity
epilepticus,I-Entity
",",O
as,O
demonstrated,O
by,O
increase,O
in,O
latency,O
to,O
first,O
seizure,I-Entity
and,O
decrease,O
in,O
mortality,O
rate,O
of,O
animals,O
.,O
In,O
conclusion,O
",",O
our,O
data,O
suggest,O
that,O
GFC,I-Entity
may,O
influence,O
in,O
epileptogenesis,O
and,O
promote,O
anticonvulsant,O
actions,O
in,O
pilocarpine,I-Entity
model,O
by,O
modulating,O
the,O
GABA,I-Entity
and,O
glutamate,I-Entity
contents,O
and,O
of,O
AChE,O
activity,O
in,O
seized,O
mice,O
hippocampus,O
.,O
Standard,O
operating,O
procedures,O
for,O
antibiotic,O
therapy,O
and,O
the,O
occurrence,O
of,O
acute,B-Entity
kidney,I-Entity
injury,I-Entity
:,O
a,O
prospective,O
",",O
clinical,O
",",O
non,O
-,O
interventional,O
",",O
observational,O
study,O
.,O
Acute,B-Entity
kidney,I-Entity
injury,I-Entity
(,O
AKI,I-Entity
),O
occurs,O
in,O
7%,O
of,O
hospitalized,O
and,O
66%,O
of,O
Intensive,O
Care,O
Unit,O
(,O
ICU,O
),O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
",",O
whether,O
there,O
is,O
an,O
association,O
between,O
adherence,O
to,O
guidelines,O
(,O
standard,O
operating,O
procedures,O
(,O
SOP,O
),O
),O
for,O
potentially,O
nephrotoxic,I-Entity
antibiotics,O
and,O
the,O
occurrence,O
of,O
AKI,I-Entity
.,O
163,O
of,O
these,O
had,O
therapy,O
with,O
vancomycin,I-Entity
",",O
gentamicin,I-Entity
",",O
or,O
tobramycin,I-Entity
;,O
were,O
>,O
18,O
years,O
;,O
and,O
treated,O
in,O
the,O
ICU,O
for,O
>,O
24,O
hours,O
.,O
AKI,I-Entity
was,O
defined,O
according,O
to,O
RIFLE,O
criteria,O
.,O
Development,O
of,O
AKI,I-Entity
was,O
compared,O
between,O
groups,O
with,O
exact,O
Chi2-test,O
and,O
multivariate,O
logistic,O
regression,O
analysis,O
(,O
two,O
-,O
sided,O
P,O
<,O
0.05,O
),O
.,O
AKI,I-Entity
occurred,O
significantly,O
more,O
often,O
in,O
LAG,O
with,O
36%,O
versus,O
21%,O
in,O
HAG,O
(,O
P,O
=,O
0.035,O
),O
.,O
Basic,O
characteristics,O
were,O
comparable,O
",",O
except,O
an,O
increased,O
rate,O
of,O
soft,O
tissue,O
infections,I-Entity
in,O
LAG,O
.,O
Multivariate,O
analysis,O
revealed,O
an,O
odds,O
ratio,O
of,O
2.5-fold,O
for,O
LAG,O
to,O
develop,O
AKI,I-Entity
compared,O
with,O
HAG,O
(,O
95%,O
confidence,O
interval,O
1.195,O
to,O
5.124,O
",",O
P,O
=,O
0.039,O
),O
.,O
CONCLUSION,O
:,O
Low,O
adherence,O
to,O
SOPs,O
for,O
potentially,O
nephrotoxic,I-Entity
antibiotics,O
was,O
associated,O
with,O
a,O
higher,O
occurrence,O
of,O
AKI,I-Entity
.,O
Rhabdomyolysis,I-Entity
in,O
a,O
hepatitis,B-Entity
C,I-Entity
virus,I-Entity
infected,I-Entity
patient,O
treated,O
with,O
telaprevir,I-Entity
and,O
simvastatin,I-Entity
.,O
A,O
46-year,O
old,O
man,O
with,O
a,O
chronic,O
hepatitis,B-Entity
C,I-Entity
virus,I-Entity
infection,I-Entity
received,O
triple,O
therapy,O
with,O
ribavirin,I-Entity
",",O
pegylated,B-Entity
interferon,I-Entity
and,O
telaprevir,I-Entity
.,O
The,O
patient,O
also,O
received,O
simvastatin,I-Entity
.,O
One,O
month,O
after,O
starting,O
the,O
antiviral,O
therapy,O
",",O
the,O
patient,O
was,O
admitted,O
to,O
the,O
hospital,O
because,O
he,O
developed,O
rhabdomyolysis,I-Entity
.,O
At,O
admission,O
simvastatin,I-Entity
and,O
all,O
antiviral,O
drugs,O
were,O
discontinued,O
because,O
toxicity,I-Entity
due,O
to,O
a,O
drug,O
-,O
drug,O
interaction,O
was,O
suspected,O
.,O
The,O
creatine,I-Entity
kinase,O
peaked,O
at,O
"62,246",O
IU,O
/,O
L,O
and,O
the,O
patient,O
was,O
treated,O
with,O
intravenous,O
normal,O
saline,O
.,O
Fourteen,O
days,O
after,O
hospitalization,O
",",O
creatine,I-Entity
kinase,O
level,O
had,O
returned,O
to,O
230,O
IU,O
/,O
L,O
and,O
the,O
patient,O
was,O
discharged,O
.,O
Telaprevir,I-Entity
was,O
considered,O
the,O
probable,O
causative,O
agent,O
of,O
an,O
interaction,O
with,O
simvastatin,I-Entity
according,O
to,O
the,O
Drug,O
Interaction,O
Probability,O
Scale,O
.,O
The,O
interaction,O
is,O
due,O
to,O
inhibition,O
of,O
CYP3A4-mediated,O
simvastatin,I-Entity
clearance,O
.,O
Simvastatin,I-Entity
plasma,O
concentration,O
increased,O
30,O
times,O
in,O
this,O
patient,O
and,O
statin,I-Entity
induced,O
muscle,B-Entity
toxicity,I-Entity
is,O
related,O
to,O
the,O
concentration,O
of,O
the,O
statin,I-Entity
in,O
blood,O
.,O
In,O
conclusion,O
",",O
with,O
this,O
case,O
we,O
illustrate,O
that,O
telaprevir,I-Entity
as,O
well,O
as,O
statins,I-Entity
are,O
susceptible,O
to,O
clinical,O
relevant,O
drug,O
-,O
drug,O
interactions,O
.,O
Combination,O
of,O
bortezomib,I-Entity
",",O
thalidomide,I-Entity
",",O
and,O
dexamethasone,I-Entity
(,O
VTD,O
),O
as,O
a,O
consolidation,O
therapy,O
after,O
autologous,O
stem,O
cell,O
transplantation,O
for,O
symptomatic,O
multiple,B-Entity
myeloma,I-Entity
in,O
Japanese,O
patients,O
.,O
Consolidation,O
therapy,O
for,O
patients,O
with,O
multiple,B-Entity
myeloma,I-Entity
(,O
MM,I-Entity
),O
has,O
been,O
widely,O
adopted,O
to,O
improve,O
treatment,O
response,O
following,O
autologous,O
stem,O
cell,O
transplantation,O
.,O
In,O
this,O
study,O
",",O
we,O
retrospectively,O
analyzed,O
the,O
safety,O
and,O
efficacy,O
of,O
combination,O
regimen,O
of,O
bortezomib,I-Entity
",",O
thalidomide,I-Entity
",",O
and,O
dexamethasone,I-Entity
(,O
VTD,O
),O
as,O
consolidation,O
therapy,O
in,O
24,O
Japanese,O
patients,O
with,O
newly,O
diagnosed,O
MM,I-Entity
.,O
VTD,O
consisted,O
of,O
bortezomib,I-Entity
at,O
a,O
dose,O
of,O
1.3,O
mg,O
/,O
m(2,O
),O
and,O
dexamethasone,I-Entity
at,O
a,O
dose,O
of,O
40,O
mg,O
/,O
day,O
on,O
days,O
1,O
",",O
8,O
",",O
15,O
",",O
and,O
22,O
of,O
a,O
35-day,O
cycle,O
",",O
with,O
daily,O
oral,O
thalidomide,I-Entity
at,O
a,O
dose,O
of,O
100,O
mg,O
/,O
day,O
.,O
Grade,O
3,O
-,O
4,O
neutropenia,I-Entity
and,O
thrombocytopenia,I-Entity
were,O
documented,O
in,O
four,O
and,O
three,O
patients,O
(,O
17,O
and,O
13,O
%,O
),O
",",O
respectively,O
",",O
but,O
drug,O
dose,O
reduction,O
due,O
to,O
cytopenia,I-Entity
was,O
not,O
required,O
in,O
any,O
case,O
.,O
Peripheral,B-Entity
neuropathy,I-Entity
was,O
common,O
(,O
63,O
%,O
),O
",",O
but,O
severe,O
grade,O
3,O
-,O
4,O
peripheral,B-Entity
neuropathy,I-Entity
was,O
not,O
observed,O
.,O
Conversion,O
to,O
sirolimus,I-Entity
ameliorates,O
cyclosporine,I-Entity
-,O
induced,O
nephropathy,I-Entity
in,O
the,O
rat,O
:,O
focus,O
on,O
serum,O
",",O
urine,O
",",O
gene,O
",",O
and,O
protein,O
renal,O
expression,O
biomarkers,O
.,O
Protocols,O
of,O
conversion,O
from,O
cyclosporin,B-Entity
A,I-Entity
(,O
CsA,I-Entity
),O
to,O
sirolimus,I-Entity
(,O
SRL,I-Entity
),O
have,O
been,O
widely,O
used,O
in,O
immunotherapy,O
after,O
transplantation,O
to,O
prevent,O
CsA,I-Entity
-,O
induced,O
nephropathy,I-Entity
",",O
but,O
the,O
molecular,O
mechanisms,O
underlying,O
these,O
protocols,O
remain,O
nuclear,O
.,O
This,O
study,O
aimed,O
to,O
identify,O
the,O
molecular,O
pathways,O
and,O
putative,O
biomarkers,O
of,O
CsA,I-Entity
-,O
to,O
-,O
SRL,I-Entity
conversion,O
in,O
a,O
rat,O
model,O
.,O
Four,O
animal,O
groups,O
(,O
n,O
=,O
6,O
),O
were,O
tested,O
during,O
9,O
weeks,O
:,O
control,O
",",O
CsA,I-Entity
",",O
SRL,I-Entity
",",O
and,O
conversion,O
(,O
CsA,I-Entity
for,O
3,O
weeks,O
followed,O
by,O
SRL,I-Entity
for,O
6,O
weeks,O
),O
.,O
Renal,B-Entity
lesions,I-Entity
were,O
analyzed,O
in,O
hematoxylin,I-Entity
and,O
eosin,I-Entity
",",O
periodic,O
acid,O
-,O
Schiff,O
",",O
and,O
Masson,O
's,O
trichrome,O
stains,O
.,O
SRL,I-Entity
-,O
treated,O
rats,O
presented,O
proteinuria,I-Entity
and,O
NGAL,O
(,O
serum,O
and,O
urinary,O
),O
as,O
the,O
best,O
markers,O
of,O
renal,B-Entity
impairment,I-Entity
.,O
Short,O
CsA,I-Entity
treatment,O
presented,O
slight,O
or,O
even,O
absent,O
kidney,B-Entity
lesions,I-Entity
and,O
TGF,O
-,O
b,O
",",O
NF-,O
kb,O
",",O
mTOR,O
",",O
PCNA,O
",",O
TP53,O
",",O
KIM-1,O
",",O
and,O
CTGF,O
as,O
relevant,O
gene,O
and,O
protein,O
changes,O
.,O
Prolonged,O
CsA,I-Entity
exposure,O
aggravated,O
renal,B-Entity
damage,I-Entity
",",O
without,O
clear,O
changes,O
on,O
the,O
traditional,O
markers,O
",",O
but,O
with,O
changes,O
in,O
serums,O
TGF-,O
b,O
and,O
IL-7,O
",",O
TBARs,O
clearance,O
",",O
and,O
kidney,O
TGF,O
-,O
b,O
and,O
mTOR,O
.,O
Conversion,O
to,O
SRL,I-Entity
prevented,O
CsA,I-Entity
-,O
induced,O
renal,B-Entity
damage,I-Entity
evolution,O
(,O
absent,O
/,O
mild,O
grade,O
lesions,O
),O
",",O
while,O
NGAL,O
(,O
serum,O
versus,O
urine,O
),O
seems,O
to,O
be,O
a,O
feasible,O
biomarker,O
of,O
CsA,I-Entity
replacement,O
to,O
SRL,I-Entity
.,O
cisplatin,I-Entity
-,O
induced,O
acute,B-Entity
renal,I-Entity
injury,I-Entity
.,O
Cisplatin,I-Entity
treatment,O
has,O
been,O
adopted,O
in,O
some,O
chemotherapies,O
;,O
however,O
",",O
this,O
drug,O
can,O
induce,O
acute,B-Entity
kidney,I-Entity
injury,I-Entity
due,O
its,O
ability,O
to,O
negatively,O
affect,O
renal,O
function,O
",",O
augment,O
serum,O
levels,O
of,O
creatinine,I-Entity
and,O
urea,I-Entity
",",O
increase,O
the,O
acute,B-Entity
tubular,I-Entity
necrosis,I-Entity
score,O
and,O
up,O
-,O
regulate,O
cytokines,O
(,O
e.g.,O
",",O
IL-1b,O
and,O
TNF,O
-,O
a,O
),O
.,O
The,O
kinin,O
B2,O
receptor,O
has,O
been,O
associated,O
with,O
the,O
inflammation,I-Entity
process,O
",",O
as,O
well,O
as,O
the,O
regulation,O
of,O
cytokine,O
expression,O
",",O
and,O
its,O
deletion,O
resulted,O
in,O
an,O
improvement,O
in,O
the,O
diabetic,B-Entity
nephropathy,I-Entity
status,O
.,O
To,O
examine,O
the,O
role,O
of,O
the,O
kinin,O
B2,O
receptor,O
in,O
cisplatin,I-Entity
-,O
induced,O
acute,B-Entity
kidney,I-Entity
injury,I-Entity
",",O
kinin,O
B2,O
receptor,O
knockout,O
mice,O
were,O
challenged,O
with,O
cisplatin,I-Entity
.,O
Additionally,O
",",O
WT,O
mice,O
were,O
treated,O
with,O
a,O
B2,O
receptor,O
antagonist,O
after,O
cisplatin,I-Entity
administration,O
.,O
B2,O
receptor,O
-,O
deficient,O
mice,O
were,O
less,O
sensitive,O
to,O
this,O
drug,O
than,O
the,O
WT,O
mice,O
",",O
as,O
shown,O
by,O
reduced,O
weight,B-Entity
loss,I-Entity
",",O
better,O
preservation,O
of,O
kidney,O
function,O
",",O
down,O
regulation,O
of,O
inflammatory,O
cytokines,O
and,O
less,O
acute,B-Entity
tubular,I-Entity
necrosis,I-Entity
.,O
Moreover,O
",",O
treatment,O
with,O
the,O
kinin,O
B2,O
receptor,O
antagonist,O
effectively,O
reduced,O
the,O
levels,O
of,O
serum,O
creatinine,I-Entity
and,O
blood,O
urea,I-Entity
after,O
cisplatin,I-Entity
administration,O
.,O
Thus,O
",",O
our,O
data,O
suggest,O
that,O
the,O
kinin,O
B2,O
receptor,O
is,O
involved,O
in,O
cisplatin,I-Entity
-,O
induced,O
acute,B-Entity
kidney,I-Entity
injury,I-Entity
by,O
mediating,O
the,O
necrotic,I-Entity
process,O
and,O
the,O
expression,O
of,O
inflammatory,O
cytokines,O
",",O
thus,O
resulting,O
in,O
declined,O
renal,O
function,O
.,O
These,O
results,O
highlight,O
the,O
kinin,O
B2,O
receptor,O
antagonist,O
treatment,O
in,O
amelioration,O
of,O
nephrotoxicity,I-Entity
induced,O
by,O
cisplatin,I-Entity
therapy,O
.,O
Safety,O
and,O
efficacy,O
of,O
fluocinolone,B-Entity
acetonide,I-Entity
intravitreal,O
implant,O
(,O
0.59,O
mg,O
),O
in,O
birdshot,B-Entity
retinochoroidopathy,I-Entity
.,O
PURPOSE,O
:,O
To,O
report,O
the,O
treatment,O
outcomes,O
of,O
the,O
fluocinolone,B-Entity
acetonide,I-Entity
intravitreal,O
implant,O
(,O
0.59,O
mg,O
),O
in,O
patients,O
with,O
birdshot,B-Entity
retinochoroidopathy,I-Entity
whose,O
disease,O
is,O
refractory,O
or,O
intolerant,O
to,O
conventional,O
immunomodulatory,O
therapy,O
.,O
A,O
retrospective,O
case,O
series,O
involving,O
11,O
birdshot,B-Entity
retinochoroidopathy,I-Entity
patients,O
(,O
11,O
eyes,O
),O
.,O
Eleven,O
patients,O
(,O
11,O
eyes,O
),O
underwent,O
surgery,O
for,O
fluocinolone,B-Entity
acetonide,I-Entity
implant,O
(,O
0.59,O
mg,O
),O
.,O
Treatment,O
outcomes,O
of,O
interest,O
were,O
noted,O
at,O
baseline,O
",",O
before,O
fluocinolone,B-Entity
acetonide,I-Entity
implant,O
",",O
and,O
then,O
at,O
6,O
months,O
",",O
1,O
year,O
",",O
2,O
years,O
",",O
3,O
years,O
",",O
and,O
beyond,O
3,O
years,O
.,O
Disease,O
activity,O
markers,O
",",O
including,O
signs,O
of,O
ocular,O
inflammation,I-Entity
",",O
evidence,O
of,O
retinal,B-Entity
vasculitis,I-Entity
",",O
Swedish,O
interactive,O
threshold,O
algorithm,O
-,O
short,O
wavelength,O
automated,O
perimetry,O
Humphrey,O
visual,O
field,O
analysis,O
",",O
electroretinographic,O
parameters,O
",",O
and,O
optical,O
coherence,O
tomography,O
were,O
recorded,O
.,O
Data,O
on,O
occurrence,O
of,O
cataract,I-Entity
and,O
raised,B-Entity
intraocular,I-Entity
pressure,I-Entity
were,O
collected,O
in,O
all,O
eyes,O
.,O
RESULTS,O
:,O
Intraocular,O
inflammation,I-Entity
was,O
present,O
in,O
54.5,O
",",O
9.9,O
",",O
11.1,O
",",O
and,O
0%,O
of,O
patients,O
at,O
baseline,O
",",O
6,O
months,O
",",O
1,O
year,O
",",O
2,O
years,O
",",O
3,O
years,O
",",O
and,O
beyond,O
3,O
years,O
after,O
receiving,O
the,O
implant,O
",",O
respectively,O
.,O
Active,O
vasculitis,I-Entity
was,O
noted,O
in,O
36.3%,O
patients,O
at,O
baseline,O
and,O
0%,O
at,O
3,O
years,O
of,O
follow,O
-,O
up,O
.,O
More,O
than,O
20%,O
(,O
47.61,O
-,O
67.2%,O
),O
reduction,O
in,O
central,O
retinal,O
thickness,O
was,O
noted,O
in,O
all,O
patients,O
with,O
cystoid,B-Entity
macular,I-Entity
edema,I-Entity
at,O
6,O
months,O
",",O
1,O
year,O
",",O
2,O
years,O
",",O
and,O
3,O
years,O
postimplant,O
.,O
Adverse,O
events,O
included,O
increased,B-Entity
intraocular,I-Entity
pressure,I-Entity
(,O
54.5%,O
),O
and,O
cataract,I-Entity
formation,O
(,O
100%,O
),O
.,O
The,O
data,O
suggest,O
that,O
fluocinolone,B-Entity
acetonide,I-Entity
implant,O
(,O
0.59,O
mg,O
),O
helps,O
to,O
control,O
inflammation,I-Entity
in,O
otherwise,O
treatment,O
-,O
refractory,O
cases,O
of,O
birdshot,B-Entity
retinochoroidopathy,I-Entity
.,O
It,O
is,O
associated,O
with,O
significant,O
side,O
effects,O
of,O
cataract,I-Entity
and,O
ocular,B-Entity
hypertension,I-Entity
requiring,O
treatment,O
.,O
Optimal,O
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
to,O
decrease,O
fasciculation,I-Entity
and,O
myalgia,I-Entity
following,O
succinylcholine,I-Entity
administration,O
.,O
Succinylcholine,I-Entity
commonly,O
produces,O
frequent,O
adverse,O
effects,O
",",O
including,O
muscle,B-Entity
fasciculation,I-Entity
and,O
myalgia,I-Entity
.,O
The,O
current,O
study,O
identified,O
the,O
optimal,O
dose,O
of,O
rocuronium,I-Entity
to,O
prevent,O
succinylcholine,I-Entity
-,O
induced,O
fasciculation,I-Entity
and,O
myalgia,I-Entity
and,O
evaluated,O
the,O
influence,O
of,O
rocuronium,I-Entity
on,O
the,O
speed,O
of,O
onset,O
produced,O
by,O
succinylcholine,I-Entity
.,O
/,O
kg,O
rocuronium,I-Entity
as,O
a,O
precurarizing,O
dose,O
.,O
All,O
patients,O
received,O
succinylcholine,I-Entity
1.5,O
mg,O
/,O
kg,O
at,O
2,O
minutes,O
after,O
the,O
precurarization,O
",",O
and,O
were,O
assessed,O
the,O
incidence,O
and,O
severity,O
of,O
fasciculations,I-Entity
",",O
while,O
myalgia,I-Entity
was,O
assessed,O
at,O
24,O
hours,O
after,O
surgery,O
.,O
The,O
incidence,O
and,O
severity,O
of,O
visible,O
muscle,B-Entity
fasciculation,I-Entity
was,O
significantly,O
less,O
with,O
increasing,O
the,O
amount,O
of,O
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
(,O
P,O
<,O
0.001,O
),O
.,O
Those,O
of,O
myalgia,I-Entity
tend,O
to,O
decrease,O
according,O
to,O
increasing,O
the,O
amount,O
of,O
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
",",O
but,O
there,O
was,O
no,O
significance,O
(,O
P,O
=,O
0.072,O
),O
.,O
The,O
onset,O
time,O
of,O
succinylcholine,I-Entity
was,O
significantly,O
longer,O
with,O
increasing,O
the,O
amount,O
of,O
precurarizing,O
dose,O
of,O
rocuronium,I-Entity
(,O
P,O
<,O
0.001,O
),O
.,O
Precurarization,O
with,O
0.04,O
mg,O
/,O
kg,O
rocuronium,I-Entity
was,O
the,O
optimal,O
dose,O
considering,O
the,O
reduction,O
in,O
the,O
incidence,O
and,O
severity,O
of,O
fasciculation,I-Entity
and,O
myalgia,I-Entity
with,O
acceptable,O
onset,O
time,O
",",O
and,O
the,O
safe,O
and,O
effective,O
precurarization,O
.,O
Absence,O
of,O
PKC,O
-,O
alpha,O
attenuates,O
lithium,I-Entity
-,O
induced,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
.,O
Lithium,I-Entity
",",O
an,O
effective,O
antipsychotic,O
",",O
induces,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
(,O
NDI,I-Entity
),O
in,O
40%,O
of,O
patients,O
.,O
The,O
decreased,O
capacity,O
to,O
concentrate,O
urine,O
is,O
likely,O
due,O
to,O
lithium,I-Entity
acutely,O
disrupting,O
the,O
cAMP,I-Entity
pathway,O
and,O
chronically,O
reducing,O
urea,I-Entity
transporter,O
(,O
UT,O
-,O
A1,O
),O
and,O
water,O
channel,O
(,O
AQP2,O
),O
expression,O
in,O
the,O
inner,O
medulla,O
.,O
Targeting,O
an,O
alternative,O
signaling,O
pathway,O
",",O
such,O
as,O
PKC,O
-,O
mediated,O
signaling,O
",",O
may,O
be,O
an,O
effective,O
method,O
of,O
treating,O
lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
.,O
),O
controls,O
were,O
treated,O
with,O
lithium,I-Entity
for,O
0,O
",",O
3,O
or,O
5,O
days,O
.,O
Animals,O
were,O
also,O
treated,O
with,O
lithium,I-Entity
for,O
6,O
weeks,O
.,O
Lithium,I-Entity
-,O
treated,O
WT,O
mice,O
had,O
19-fold,O
increased,O
urine,O
output,O
whereas,O
treated,O
PKCa,O
KO,O
animals,O
had,O
a,O
4-fold,O
increase,O
in,O
output,O
.,O
AQP2,O
and,O
UT,O
-,O
A1,O
expression,O
was,O
lowered,O
in,O
6,O
week,O
lithium,I-Entity
-,O
treated,O
WT,O
animals,O
whereas,O
in,O
treated,O
PKCa,O
KO,O
mice,O
",",O
AQP2,O
was,O
only,O
reduced,O
by,O
2-fold,O
and,O
UT,O
-,O
A1,O
expression,O
was,O
unaffected,O
.,O
Urinary,O
sodium,I-Entity
",",O
potassium,I-Entity
and,O
calcium,I-Entity
were,O
elevated,O
in,O
lithium,I-Entity
-,O
fed,O
WT,O
but,O
not,O
in,O
lithium,I-Entity
-,O
fed,O
PKCa,O
KO,O
mice,O
.,O
Our,O
data,O
show,O
that,O
ablation,O
of,O
PKCa,O
preserves,O
AQP2,O
and,O
UT,O
-,O
A1,O
protein,O
expression,O
and,O
localization,O
in,O
lithium,I-Entity
-,O
induced,O
NDI,I-Entity
",",O
and,O
prevents,O
the,O
development,O
of,O
the,O
severe,O
polyuria,I-Entity
associated,O
with,O
lithium,I-Entity
therapy,O
.,O
Is,O
Dysguesia,I-Entity
Going,O
to,O
be,O
a,O
Rare,O
or,O
a,O
Common,O
Side,O
-,O
effect,O
of,O
Amlodipine,I-Entity
?,O
A,O
very,O
rare,O
side,O
-,O
effect,O
of,O
amlodipine,I-Entity
is,O
dysguesia,I-Entity
.,O
We,O
report,O
a,O
case,O
about,O
a,O
female,O
with,O
essential,O
hypertension,I-Entity
on,O
drug,O
treatment,O
with,O
amlodipine,I-Entity
developed,O
loss,B-Entity
of,I-Entity
taste,I-Entity
sensation,I-Entity
.,O
We,O
conclude,O
that,O
amlodipine,I-Entity
can,O
cause,O
dysguesia,I-Entity
.,O
Here,O
",",O
we,O
describe,O
the,O
clinical,O
presentation,O
and,O
review,O
the,O
relevant,O
literature,O
on,O
amlodipine,I-Entity
and,O
dysguesia,I-Entity
.,O
Rhabdomyolysis,I-Entity
in,O
association,O
with,O
simvastatin,I-Entity
and,O
dosage,O
increment,O
in,O
clarithromycin,I-Entity
.,O
Clarithromycin,I-Entity
is,O
the,O
most,O
documented,O
cytochrome,O
P450,O
3A4,O
(,O
CYP3A4,O
),O
inhibitor,O
to,O
cause,O
an,O
adverse,O
interaction,O
with,O
simvastatin,I-Entity
.,O
This,O
particular,O
case,O
is,O
of,O
interest,O
as,O
rhabdomyolysis,I-Entity
only,O
occurred,O
after,O
an,O
increase,O
in,O
the,O
dose,O
of,O
clarithromycin,I-Entity
.,O
The,O
patient,O
developed,O
raised,O
cardiac,O
biomarkers,O
without,O
any,O
obvious,O
cardiac,O
issues,O
",",O
a,O
phenomenon,O
that,O
has,O
been,O
linked,O
to,O
rhabdomyolysis,I-Entity
previously,O
.,O
To,O
date,O
",",O
there,O
has,O
been,O
no,O
reported,O
effect,O
of,O
rhabdomyolysis,I-Entity
on,O
the,O
structure,O
and,O
function,O
of,O
cardiac,O
muscle,O
.,O
Clinicians,O
need,O
to,O
be,O
aware,O
of,O
prescribing,O
concomitant,O
medications,O
that,O
increase,O
the,O
risk,O
of,O
myopathy,I-Entity
or,O
inhibit,O
the,O
CYP3A4,O
enzyme,O
.,O
Our,O
case,O
suggests,O
that,O
troponin,O
elevation,O
could,O
be,O
associated,O
with,O
statin,I-Entity
induced,O
rhabdomyolysis,I-Entity
",",O
which,O
may,O
warrant,O
further,O
studies,O
.,O
Val204Asp,O
),O
causes,O
loss,O
of,O
activity,O
and,O
prolonged,O
apnea,I-Entity
with,O
suxamethonium,I-Entity
.,O
Butyrylcholinesterase,B-Entity
deficiency,I-Entity
is,O
characterized,O
by,O
prolonged,O
apnea,I-Entity
after,O
the,O
use,O
of,O
muscle,O
relaxants,O
(,O
suxamethonium,I-Entity
or,O
mivacurium,I-Entity
),O
in,O
patients,O
who,O
have,O
mutations,O
in,O
the,O
BCHE,O
gene,O
.,O
Here,O
",",O
we,O
report,O
a,O
case,O
of,O
prolonged,O
neuromuscular,O
block,O
after,O
administration,O
of,O
suxamethonium,I-Entity
leading,O
to,O
the,O
discovery,O
of,O
a,O
novel,O
BCHE,O
variant,O
(,O
c.695T,O
>,O
A,O
",",O
p,O
.,O
Low,O
activity,O
of,O
patient,O
plasma,O
butyrylcholinesterase,O
with,O
butyrylthiocholine,I-Entity
(,O
BTC,I-Entity
),O
and,O
benzoylcholine,I-Entity
",",O
and,O
values,O
of,O
dibucaine,I-Entity
and,O
fluoride,I-Entity
numbers,O
fit,O
with,O
heterozygous,O
atypical,O
silent,O
genotype,O
.,O
BChE,O
displays,O
a,O
pure,O
Michaelian,O
behavior,O
with,O
BTC,I-Entity
as,O
the,O
substrate,O
.,O
Both,O
catalytic,O
parameters,O
Km,O
=,O
265,O
uM,O
for,O
BTC,I-Entity
",",O
two,O
times,O
higher,O
than,O
that,O
of,O
the,O
atypical,O
enzyme,O
",",O
and,O
a,O
low,O
Vmax,O
are,O
consistent,O
with,O
the,O
absence,O
of,O
activity,O
against,O
suxamethonium,I-Entity
.,O
Val204Asp,O
is,O
disruption,O
of,O
hydrogen,I-Entity
bonding,O
between,O
Gln223,O
and,O
Glu441,O
",",O
leading,O
Ser198,O
and,O
His438,O
to,O
move,O
away,O
from,O
each,O
other,O
with,O
subsequent,O
disruption,O
of,O
the,O
catalytic,O
triad,O
functionality,O
regardless,O
of,O
the,O
type,O
of,O
substrate,O
.,O
Delayed,O
anemia,I-Entity
after,O
treatment,O
with,O
injectable,O
artesunate,I-Entity
in,O
the,O
Democratic,O
Republic,O
of,O
the,O
Congo,O
:,O
a,O
manageable,O
issue,O
.,O
Cases,O
of,O
delayed,O
hemolytic,B-Entity
anemia,I-Entity
have,O
been,O
described,O
after,O
treatment,O
with,O
injectable,O
artesunate,I-Entity
",",O
the,O
current,O
World,O
Health,O
Organization,O
(,O
WHO)-recommended,O
first,O
-,O
line,O
drug,O
for,O
the,O
treatment,O
of,O
severe,O
malaria,I-Entity
.,O
>,O
5,O
years,O
of,O
age,O
),O
were,O
followed,O
-,O
up,O
after,O
treatment,O
with,O
injectable,O
artesunate,I-Entity
for,O
severe,O
malaria,I-Entity
in,O
hospitals,O
and,O
health,O
centers,O
of,O
the,O
Democratic,O
Republic,O
of,O
the,O
Congo,O
.,O
All,O
cases,O
of,O
delayed,O
anemia,I-Entity
were,O
clinically,O
manageable,O
and,O
resolved,O
within,O
one,O
month,O
.,O
Regulation,O
of,O
signal,O
transducer,O
and,O
activator,O
of,O
transcription,O
3,O
and,O
apoptotic,O
pathways,O
by,O
betaine,I-Entity
attenuates,O
isoproterenol,I-Entity
-,O
induced,O
acute,O
myocardial,B-Entity
injury,I-Entity
in,O
rats,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
investigate,O
the,O
cardioprotective,O
effects,O
of,O
betaine,I-Entity
on,O
acute,O
myocardial,B-Entity
ischemia,I-Entity
induced,O
experimentally,O
in,O
rats,O
focusing,O
on,O
regulation,O
of,O
signal,O
transducer,O
and,O
activator,O
of,O
transcription,O
3,O
(,O
STAT3,O
),O
and,O
apoptotic,O
pathways,O
as,O
the,O
potential,O
mechanism,O
underlying,O
the,O
drug,O
effect,O
.,O
Male,O
Sprague,O
Dawley,O
rats,O
were,O
treated,O
with,O
betaine,I-Entity
(,O
100,O
",",O
200,O
",",O
and,O
400,O
mg,O
/,O
kg,O
),O
orally,O
for,O
40,O
days,O
.,O
Acute,O
myocardial,B-Entity
ischemic,I-Entity
injury,I-Entity
was,O
induced,O
in,O
rats,O
by,O
subcutaneous,O
injection,O
of,O
isoproterenol,I-Entity
(,O
85,O
mg,O
/,O
kg,O
),O
",",O
for,O
two,O
consecutive,O
days,O
.,O
Oral,O
administration,O
of,O
betaine,I-Entity
(,O
200,O
and,O
400,O
mg,O
/,O
kg,O
),O
significantly,O
reduced,O
the,O
level,O
of,O
cardiac,O
marker,O
enzyme,O
in,O
the,O
serum,O
and,O
prevented,O
left,O
ventricular,B-Entity
remodeling,I-Entity
.,O
Western,O
blot,O
analysis,O
showed,O
that,O
isoproterenol,I-Entity
-,O
induced,O
phosphorylation,O
of,O
STAT3,O
was,O
maintained,O
or,O
further,O
enhanced,O
by,O
betaine,I-Entity
treatment,O
in,O
myocardium,O
.,O
Furthermore,O
",",O
betaine,I-Entity
(,O
200,O
and,O
400,O
mg,O
/,O
kg,O
),O
treatment,O
increased,O
the,O
ventricular,O
expression,O
of,O
Bcl-2,O
and,O
reduced,O
the,O
level,O
of,O
Bax,O
",",O
therefore,O
causing,O
a,O
significant,O
increase,O
in,O
the,O
ratio,O
of,O
Bcl-2/Bax,O
.,O
The,O
protective,O
role,O
of,O
betaine,I-Entity
on,O
myocardial,B-Entity
damage,I-Entity
was,O
further,O
confirmed,O
by,O
histopathological,O
examination,O
.,O
In,O
summary,O
",",O
our,O
results,O
showed,O
that,O
betaine,I-Entity
pretreatment,O
attenuated,O
isoproterenol,I-Entity
-,O
induced,O
acute,O
myocardial,B-Entity
ischemia,I-Entity
via,O
the,O
regulation,O
of,O
STAT3,O
and,O
apoptotic,O
pathways,O
.,O
Quetiapine,I-Entity
-,O
induced,O
neutropenia,I-Entity
in,O
a,O
bipolar,I-Entity
patient,O
with,O
hepatocellular,B-Entity
carcinoma,I-Entity
.,O
OBJECTIVE,O
:,O
Quetiapine,I-Entity
is,O
a,O
dibenzothiazepine,O
derivative,O
",",O
similar,O
to,O
clozapine,I-Entity
",",O
which,O
has,O
the,O
highest,O
risk,O
of,O
causing,O
blood,B-Entity
dyscrasias,I-Entity
",",O
especially,O
neutropenia,I-Entity
.,O
There,O
are,O
some,O
case,O
reports,O
about,O
this,O
side,O
effect,O
of,O
quetiapine,I-Entity
",",O
but,O
possible,O
risk,O
factors,O
are,O
seldom,O
discussed,O
and,O
identified,O
.,O
A,O
case,O
of,O
a,O
patient,O
with,O
hepatocellular,B-Entity
carcinoma,I-Entity
that,O
developed,O
neutropenia,I-Entity
after,O
treatment,O
with,O
quetiapine,I-Entity
is,O
described,O
here,O
.,O
CASE,O
REPORT,O
:,O
A,O
62-year,O
-,O
old,O
Taiwanese,O
widow,O
with,O
bipolar,B-Entity
disorder,I-Entity
was,O
diagnosed,O
with,O
hepatocellular,B-Entity
carcinoma,I-Entity
at,O
age,O
60,O
.,O
She,O
developed,O
leucopenia,I-Entity
after,O
being,O
treated,O
with,O
quetiapine,I-Entity
.,O
After,O
quetiapine,I-Entity
was,O
discontinued,O
",",O
her,O
white,O
blood,O
cell,O
count,O
returned,O
to,O
normal,O
.,O
CONCLUSIONS,O
:,O
Although,O
neutropenia,I-Entity
is,O
not,O
a,O
common,O
side,O
effect,O
of,O
quetiapine,I-Entity
",",O
physicians,O
should,O
be,O
cautious,O
about,O
its,O
presentation,O
and,O
associated,O
risk,O
factors,O
.,O
Hepatic,B-Entity
dysfunction,I-Entity
may,O
be,O
one,O
of,O
the,O
possible,O
risk,O
factors,O
",",O
and,O
concomitant,O
fever,I-Entity
may,O
be,O
a,O
diagnostic,O
marker,O
for,O
adverse,O
reaction,O
to,O
quetiapine,I-Entity
.,O
Lateral,O
antebrachial,O
cutaneous,O
neuropathy,I-Entity
after,O
steroid,I-Entity
injection,O
at,O
lateral,O
epicondyle,O
.,O
This,O
report,O
aimed,O
to,O
present,O
a,O
case,O
of,O
lateral,O
antebrachial,O
cutaneous,O
neuropathy,I-Entity
(,O
LACNP,O
),O
that,O
occurred,O
after,O
a,O
steroid,I-Entity
injection,O
in,O
the,O
lateral,O
epicondyle,O
to,O
treat,O
lateral,B-Entity
epicondylitis,I-Entity
in,O
a,O
40-year,O
-,O
old,O
woman,O
.,O
A,O
40-year,O
-,O
old,O
woman,O
presented,O
with,O
decreased,O
sensation,O
and,O
paresthesia,I-Entity
over,O
her,O
right,O
lateral,O
forearm,O
;,O
the,O
paresthesia,I-Entity
had,O
occurred,O
after,O
a,O
steroid,I-Entity
injection,O
in,O
the,O
right,O
lateral,O
epicondyle,O
3,O
months,O
before,O
.,O
Her,O
sensation,O
of,O
light,O
touch,O
and,O
pain,I-Entity
was,O
diminished,O
over,O
the,O
lateral,O
side,O
of,O
the,O
right,O
forearm,O
and,O
wrist,O
area,O
.,O
This,O
report,O
describes,O
the,O
case,O
of,O
a,O
woman,O
with,O
LACNP,O
that,O
developed,O
after,O
a,O
steroid,I-Entity
injection,O
for,O
the,O
treatment,O
of,O
lateral,B-Entity
epicondylitis,I-Entity
.,O
Curcumin,I-Entity
prevents,O
maleate,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
:,O
relation,O
to,O
hemodynamic,O
alterations,O
",",O
oxidative,O
stress,O
",",O
mitochondrial,O
oxygen,I-Entity
consumption,O
and,O
activity,O
of,O
respiratory,O
complex,O
I.,O
The,O
potential,O
protective,O
effect,O
of,O
the,O
dietary,O
antioxidant,O
curcumin,I-Entity
(,O
120,O
mg,O
/,O
Kg,O
/,O
day,O
for,O
6,O
days,O
),O
against,O
the,O
renal,B-Entity
injury,I-Entity
induced,O
by,O
maleate,I-Entity
was,O
evaluated,O
.,O
Tubular,O
proteinuria,I-Entity
and,O
oxidative,O
stress,O
were,O
induced,O
by,O
a,O
single,O
injection,O
of,O
maleate,I-Entity
(,O
400,O
mg,O
/,O
kg,O
),O
in,O
rats,O
.,O
Maleate,I-Entity
-,O
induced,O
renal,B-Entity
injury,I-Entity
included,O
increase,O
in,O
renal,O
vascular,O
resistance,O
and,O
in,O
the,O
urinary,O
excretion,O
of,O
total,O
protein,O
",",O
glucose,I-Entity
",",O
sodium,I-Entity
",",O
neutrophil,O
gelatinase,O
-,O
associated,O
lipocalin,O
(,O
NGAL,O
),O
and,O
N,O
-,O
acetyl,O
b,O
-,O
D,O
-,O
glucosaminidase,O
(,O
NAG,O
),O
",",O
upregulation,O
of,O
kidney,B-Entity
injury,I-Entity
molecule,O
(,O
KIM)-1,O
",",O
decrease,O
in,O
renal,O
blood,O
flow,O
and,O
claudin-2,O
expression,O
besides,O
of,O
necrosis,I-Entity
and,O
apoptosis,O
of,O
tubular,O
cells,O
on,O
24,O
h.,O
Oxidative,O
stress,O
was,O
determined,O
by,O
measuring,O
the,O
oxidation,O
of,O
lipids,O
and,O
proteins,O
and,O
diminution,O
in,O
renal,O
Nrf2,O
levels,O
.,O
Maleate,I-Entity
induced,O
cell,O
damage,O
and,O
reactive,O
oxygen,I-Entity
species,O
(,O
ROS,O
),O
production,O
in,O
LLC,O
-,O
PK1,O
cells,O
in,O
culture,O
.,O
In,O
addition,O
",",O
maleate,I-Entity
treatment,O
reduced,O
oxygen,I-Entity
consumption,O
in,O
ADP,I-Entity
-,O
stimulated,O
mitochondria,O
and,O
diminished,O
respiratory,O
control,O
index,O
when,O
using,O
malate,I-Entity
/,O
glutamate,I-Entity
as,O
substrate,O
.,O
All,O
the,O
above,O
-,O
described,O
alterations,O
were,O
prevented,O
by,O
curcumin,I-Entity
.,O
It,O
is,O
concluded,O
that,O
curcumin,I-Entity
is,O
able,O
to,O
attenuate,O
in,O
vivo,O
maleate,I-Entity
-,O
induced,O
nephropathy,I-Entity
and,O
in,O
vitro,O
cell,O
damage,O
.,O
The,O
in,O
vivo,O
protection,O
was,O
associated,O
to,O
the,O
prevention,O
of,O
oxidative,O
stress,O
and,O
preservation,O
of,O
mitochondrial,O
oxygen,I-Entity
consumption,O
and,O
activity,O
of,O
respiratory,O
complex,O
I,O
",",O
and,O
the,O
in,O
vitro,O
protection,O
was,O
associated,O
to,O
the,O
prevention,O
of,O
ROS,O
production,O
.,O
Incidence,O
of,O
solid,O
tumours,I-Entity
among,O
pesticide,O
applicators,O
exposed,O
to,O
the,O
organophosphate,I-Entity
insecticide,O
diazinon,I-Entity
in,O
the,O
Agricultural,O
Health,O
Study,O
:,O
an,O
updated,O
analysis,O
.,O
OBJECTIVE,O
:,O
Diazinon,I-Entity
",",O
a,O
common,O
organophosphate,I-Entity
insecticide,O
with,O
genotoxic,O
properties,O
",",O
was,O
previously,O
associated,O
with,O
lung,B-Entity
cancer,I-Entity
in,O
the,O
Agricultural,O
Health,O
Study,O
(,O
AHS,O
),O
cohort,O
",",O
but,O
few,O
other,O
epidemiological,O
studies,O
have,O
examined,O
diazinon,I-Entity
-,O
associated,O
cancer,I-Entity
risk,O
.,O
We,O
used,O
updated,O
diazinon,I-Entity
exposure,O
and,O
cancer,I-Entity
incidence,O
information,O
to,O
evaluate,O
solid,O
tumour,I-Entity
risk,O
in,O
the,O
AHS,O
.,O
Male,O
pesticide,O
applicators,O
in,O
Iowa,O
and,O
North,O
Carolina,O
reported,O
lifetime,O
diazinon,I-Entity
use,O
at,O
enrolment,O
(,O
1993,O
-,O
1997,O
),O
and,O
follow,O
-,O
up,O
(,O
1998,O
-,O
2005,O
),O
;,O
cancer,I-Entity
incidence,O
was,O
assessed,O
through,O
2010(North,O
Carolina)/2011(Iowa,O
),O
.,O
Among,O
applicators,O
with,O
usage,O
information,O
sufficient,O
to,O
evaluate,O
exposure,O
-,O
response,O
patterns,O
",",O
we,O
used,O
Poisson,O
regression,O
to,O
estimate,O
adjusted,O
rate,O
ratios,O
(,O
RRs,O
),O
and,O
95%,O
CI,O
for,O
cancer,I-Entity
sites,O
with,O
>,O
10,O
exposed,O
cases,O
for,O
both,O
lifetime,O
(,O
LT,O
),O
exposure,O
days,O
and,O
intensity,O
-,O
weighted,O
(,O
IW,O
),O
lifetime,O
exposure,O
days,O
(,O
accounting,O
for,O
factors,O
impacting,O
exposure,O
),O
.,O
We,O
observed,O
elevated,O
lung,B-Entity
cancer,I-Entity
risks,O
(,O
N=283,O
),O
among,O
applicators,O
with,O
the,O
greatest,O
number,O
of,O
LT,O
(,O
RR=1.60,O
;,O
95%,O
CI,O
1.11,O
to,O
2.31,O
;,O
Ptrend=0.02,O
),O
and,O
IW,O
days,O
of,O
diazinon,I-Entity
use,O
(,O
RR=1.41,O
;,O
95%,O
CI,O
0.98,O
to,O
2.04,O
;,O
Ptrend=0.08,O
),O
.,O
Kidney,B-Entity
cancer,I-Entity
(,O
N=94,O
),O
risks,O
were,O
non,O
-,O
significantly,O
elevated,O
(,O
RRLT,O
days=1.77,O
;,O
95%,O
CI,O
0.90,O
to,O
3.51,O
;,O
Ptrend=0.09,O
;,O
RRIW,O
days,O
1.37,O
;,O
95%,O
CI,O
0.64,O
to,O
2.92,O
;,O
Ptrend=0.50,O
),O
",",O
as,O
were,O
risks,O
for,O
aggressive,O
prostate,B-Entity
cancer,I-Entity
(,O
N=656,O
),O
.,O
Our,O
updated,O
evaluation,O
of,O
diazinon,I-Entity
provides,O
additional,O
evidence,O
of,O
an,O
association,O
with,O
lung,B-Entity
cancer,I-Entity
risk,O
.,O
Newly,O
identified,O
links,O
to,O
kidney,B-Entity
cancer,I-Entity
and,O
associations,O
with,O
aggressive,O
prostate,B-Entity
cancer,I-Entity
require,O
further,O
evaluation,O
.,O
Associations,O
of,O
Ozone,I-Entity
and,O
PM2.5,O
Concentrations,O
With,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Among,O
Participants,O
in,O
the,O
Agricultural,O
Health,O
Study,O
.,O
This,O
study,O
describes,O
associations,O
of,O
ozone,I-Entity
and,O
fine,O
particulate,B-Entity
matter,I-Entity
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
observed,O
among,O
farmers,O
in,O
North,O
Carolina,O
and,O
Iowa,O
.,O
:,O
We,O
used,O
logistic,O
regression,O
to,O
determine,O
the,O
associations,O
of,O
these,O
pollutants,O
with,O
self,O
-,O
reported,O
",",O
doctor,O
-,O
diagnosed,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
We,O
observed,O
positive,O
associations,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
with,O
ozone,I-Entity
(,O
odds,O
ratio,O
=,O
1.39,O
;,O
95%,O
CI,O
:,O
0.98,O
to,O
1.98,O
),O
and,O
fine,O
particulate,B-Entity
matter,I-Entity
(,O
odds,O
ratio,O
=,O
1.34,O
;,O
95%,O
CI,O
:,O
0.93,O
to,O
1.93,O
),O
in,O
North,O
Carolina,O
but,O
not,O
in,O
Iowa,O
.,O
The,O
plausibility,O
of,O
an,O
effect,O
of,O
ambient,O
concentrations,O
of,O
these,O
pollutants,O
on,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
risk,O
is,O
supported,O
by,O
experimental,O
data,O
demonstrating,O
damage,O
to,O
dopaminergic,O
neurons,O
at,O
relevant,O
concentrations,O
.,O
Low,O
functional,O
programming,O
of,O
renal,O
AT2R,O
mediates,O
the,O
developmental,O
origin,O
of,O
glomerulosclerosis,I-Entity
in,O
adult,O
offspring,O
induced,O
by,O
prenatal,O
caffeine,I-Entity
exposure,O
.,O
UNASSIGNED,O
:,O
Our,O
previous,O
study,O
has,O
indicated,O
that,O
prenatal,O
caffeine,I-Entity
exposure,O
(,O
PCE,O
),O
could,O
induce,O
intrauterine,B-Entity
growth,I-Entity
retardation,I-Entity
(,O
IUGR,I-Entity
),O
of,O
offspring,O
.,O
Recent,O
research,O
suggested,O
that,O
IUGR,I-Entity
is,O
a,O
risk,O
factor,O
for,O
glomerulosclerosis,I-Entity
.,O
However,O
",",O
whether,O
PCE,O
could,O
induce,O
glomerulosclerosis,I-Entity
and,O
its,O
underlying,O
mechanisms,O
remain,O
unknown,O
.,O
This,O
study,O
aimed,O
to,O
demonstrate,O
the,O
induction,O
to,O
glomerulosclerosis,I-Entity
in,O
adult,O
offspring,O
by,O
PCE,O
and,O
its,O
intrauterine,O
programming,O
mechanisms,O
.,O
A,O
rat,O
model,O
of,O
IUGR,I-Entity
was,O
established,O
by,O
PCE,O
",",O
male,O
fetuses,O
and,O
adult,O
offspring,O
at,O
the,O
age,O
of,O
postnatal,O
week,O
24,O
were,O
euthanized,O
.,O
The,O
results,O
revealed,O
that,O
the,O
adult,O
offspring,O
kidneys,O
in,O
the,O
PCE,O
group,O
exhibited,O
glomerulosclerosis,I-Entity
as,O
well,O
as,O
interstitial,B-Entity
fibrosis,I-Entity
",",O
accompanied,O
by,O
elevated,O
levels,O
of,O
serum,O
creatinine,I-Entity
and,O
urine,O
protein,O
.,O
Renal,O
angiotensin,B-Entity
II,I-Entity
receptor,O
type,O
2,O
(,O
AT2R,O
),O
gene,O
expression,O
in,O
adult,O
offspring,O
was,O
reduced,O
by,O
PCE,O
",",O
whereas,O
the,O
renal,O
angiotensin,B-Entity
II,I-Entity
receptor,O
type,O
1a,O
(,O
AT1aR)/AT2R,O
expression,O
ratio,O
was,O
increased,O
.,O
Moreover,O
",",O
AT2R,O
gene,O
and,O
protein,O
expressions,O
in,O
fetal,O
kidneys,O
were,O
inhibited,O
by,O
PCE,O
",",O
associated,O
with,O
the,O
repression,O
of,O
the,O
gene,O
expression,O
of,O
glial,O
-,O
cell,O
-,O
line,O
-,O
derived,O
neurotrophic,O
factor,O
(,O
GDNF)/tyrosine,I-Entity
kinase,O
receptor,O
(,O
c,O
-,O
Ret,O
),O
signaling,O
pathway,O
.,O
These,O
results,O
demonstrated,O
that,O
PCE,O
could,O
induce,O
dysplasia,B-Entity
of,I-Entity
fetal,I-Entity
kidneys,I-Entity
as,O
well,O
as,O
glomerulosclerosis,I-Entity
of,O
adult,O
offspring,O
",",O
and,O
the,O
low,O
functional,O
programming,O
of,O
renal,O
AT2R,O
might,O
mediate,O
the,O
developmental,O
origin,O
of,O
adult,O
glomerulosclerosis,I-Entity
.,O
"1,3-Butadiene",I-Entity
",",O
CML,I-Entity
and,O
the,O
t(9:22,O
),O
Epidemiological,O
studies,O
of,O
"1,3-butadiene",I-Entity
have,O
suggest,O
that,O
exposures,O
to,O
humans,O
are,O
associated,O
with,O
chronic,B-Entity
myeloid,I-Entity
leukemia,I-Entity
(,O
CML,I-Entity
),O
.,O
CML,I-Entity
has,O
a,O
well,O
-,O
documented,O
association,O
with,O
ionizing,O
radiation,O
",",O
but,O
reports,O
of,O
associations,O
with,O
chemical,O
exposures,O
have,O
been,O
questioned,O
.,O
Ionizing,O
radiation,O
is,O
capable,O
of,O
inducing,O
the,O
requisite,O
CML,I-Entity
-,O
associated,O
t(9:22,O
),O
translocation,O
(,O
Philadelphia,B-Entity
chromosome,I-Entity
),O
in,O
appropriate,O
cells,O
in,O
vitro,O
We,O
have,O
proposed,O
that,O
"1,3-butadiene",I-Entity
metabolites,O
be,O
so,O
tested,O
as,O
a,O
reality,O
check,O
on,O
the,O
epidemiological,O
reports,O
.,O
Conditions,O
that,O
will,O
be,O
required,O
for,O
studies,O
of,O
"1,3-butadiene",I-Entity
are,O
discussed,O
.,O
Cancer,I-Entity
incidence,O
and,O
metolachlor,I-Entity
use,O
in,O
the,O
Agricultural,O
Health,O
Study,O
:,O
Metolachlor,I-Entity
",",O
a,O
widely,O
used,O
herbicide,O
",",O
is,O
classified,O
as,O
a,O
Group,O
C,O
carcinogen,O
by,O
the,O
U.S.,O
Environmental,O
Protection,O
Agency,O
based,O
on,O
increased,O
liver,B-Entity
neoplasms,I-Entity
in,O
female,O
rats,O
.,O
Epidemiologic,O
studies,O
of,O
the,O
health,O
effects,O
of,O
metolachlor,I-Entity
have,O
been,O
limited,O
.,O
We,O
evaluated,O
cancer,I-Entity
incidence,O
through,O
2010/2011,O
(,O
NC,O
/,O
IA,O
),O
for,O
"49,616",O
applicators,O
",",O
53%,O
of,O
whom,O
reported,O
ever,O
using,O
metolachlor,I-Entity
.,O
We,O
used,O
Poisson,O
regression,O
to,O
evaluate,O
relations,O
between,O
two,O
metrics,O
of,O
metolachlor,I-Entity
use,O
(,O
lifetime,O
days,O
",",O
intensity,O
-,O
weighted,O
lifetime,O
days,O
),O
and,O
cancer,I-Entity
incidence,O
.,O
We,O
saw,O
no,O
association,O
between,O
metolachlor,I-Entity
use,O
and,O
incidence,O
of,O
all,O
cancers,I-Entity
combined,O
(,O
n,O
=,O
"5,701",O
with,O
a,O
5-year,O
lag,O
),O
or,O
most,O
site,O
-,O
specific,O
cancers,I-Entity
.,O
For,O
liver,B-Entity
cancer,I-Entity
",",O
in,O
analyses,O
restricted,O
to,O
exposed,O
workers,O
",",O
elevations,O
observed,O
at,O
higher,O
categories,O
of,O
use,O
were,O
not,O
statistically,O
significant,O
.,O
However,O
",",O
trends,O
for,O
both,O
lifetime,O
and,O
intensity,O
-,O
weighted,O
lifetime,O
days,O
of,O
metolachor,I-Entity
use,O
were,O
positive,O
and,O
statistically,O
significant,O
with,O
an,O
unexposed,O
reference,O
group,O
.,O
A,O
similar,O
pattern,O
was,O
observed,O
for,O
follicular,B-Entity
cell,I-Entity
lymphoma,I-Entity
",",O
but,O
no,O
other,O
lymphoma,I-Entity
subtypes,O
.,O
An,O
earlier,O
suggestion,O
of,O
increased,O
lung,B-Entity
cancer,I-Entity
risk,O
at,O
high,O
levels,O
of,O
metolachlor,I-Entity
use,O
in,O
this,O
cohort,O
was,O
not,O
confirmed,O
in,O
this,O
update,O
.,O
This,O
suggestion,O
of,O
an,O
association,O
between,O
metolachlor,I-Entity
and,O
liver,B-Entity
cancer,I-Entity
among,O
pesticide,O
applicators,O
is,O
a,O
novel,O
finding,O
and,O
echoes,O
observation,O
of,O
increased,O
liver,B-Entity
neoplasms,I-Entity
in,O
some,O
animal,O
studies,O
.,O
However,O
",",O
our,O
findings,O
for,O
both,O
liver,B-Entity
cancer,I-Entity
and,O
follicular,O
cell,O
lymphoma,I-Entity
warrant,O
follow,O
-,O
up,O
to,O
better,O
differentiate,O
effects,O
of,O
metolachlor,I-Entity
use,O
from,O
other,O
factors,O
.,O
Mechanisms,O
Underlying,O
Latent,O
Disease,O
Risk,O
Associated,O
with,O
Early,O
-,O
Life,O
Arsenic,I-Entity
Millions,O
of,O
individuals,O
worldwide,O
",",O
particularly,O
those,O
living,O
in,O
rural,O
and,O
developing,O
areas,O
",",O
are,O
exposed,O
to,O
harmful,O
levels,O
of,O
inorganic,B-Entity
arsenic,I-Entity
(,O
iAs,I-Entity
),O
in,O
their,O
drinking,O
water,O
.,O
Inorganic,B-Entity
As,I-Entity
exposure,O
during,O
key,O
developmental,O
periods,O
is,O
associated,O
with,O
a,O
variety,O
of,O
adverse,O
health,O
effects,O
including,O
those,O
that,O
are,O
evident,O
in,O
adulthood,O
.,O
There,O
is,O
considerable,O
interest,O
in,O
identifying,O
the,O
molecular,O
mechanisms,O
that,O
relate,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
to,O
the,O
development,O
of,O
these,O
latent,O
diseases,O
",",O
particularly,O
in,O
relationship,O
to,O
cancer,I-Entity
.,O
This,O
work,O
summarizes,O
research,O
on,O
the,O
molecular,O
mechanisms,O
that,O
underlie,O
the,O
increased,O
risk,O
of,O
cancer,I-Entity
development,O
in,O
adulthood,O
that,O
is,O
associated,O
with,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
.,O
DISCUSSION,O
:,O
Epigenetic,O
reprogramming,O
that,O
imparts,O
functional,O
changes,O
in,O
gene,O
expression,O
",",O
the,O
development,O
of,O
cancer,I-Entity
stem,O
cells,O
",",O
and,O
immunomodulation,O
are,O
plausible,O
underlying,O
mechanisms,O
by,O
which,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
elicits,O
latent,O
carcinogenic,O
effects,O
.,O
Evidence,O
is,O
mounting,O
that,O
relates,O
early,O
-,O
life,O
iAs,I-Entity
exposure,O
and,O
cancer,I-Entity
development,O
later,O
in,O
life,O
.,O
On,O
the,O
antiarrhythmic,O
activity,O
of,O
one,O
N,O
-,O
substituted,O
piperazine,I-Entity
derivative,O
of,O
trans-2-amino-3-hydroxy-1,B-Entity
",",I-Entity
2,I-Entity
",",I-Entity
3,I-Entity
",",I-Entity
4-tetrahydroanaphthalene,I-Entity
.,O
The,O
antiarrhythmic,O
activity,O
of,O
the,O
compound,O
"N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine",B-Entity
hydrochloride,I-Entity
",",O
referred,O
to,O
as,O
P11,I-Entity
",",O
is,O
studied,O
on,O
anaesthesized,O
cats,O
and,O
Wistar,O
albino,O
rats,O
",",O
as,O
well,O
as,O
on,O
non,O
-,O
anaesthesized,O
rabbits,O
.,O
Four,O
types,O
of,O
experimental,O
arrhythmia,I-Entity
are,O
used,O
--,O
with,O
BaCl2,I-Entity
",",O
with,O
chloroform,I-Entity
-,O
adrenaline,I-Entity
",",O
with,O
strophantine,B-Entity
G,I-Entity
and,O
with,O
aconitine,I-Entity
.,O
The,O
compound,O
P11,I-Entity
is,O
introduced,O
in,O
doses,O
of,O
0.25,O
and,O
0.50,O
mg,O
/,O
kg,O
intravenously,O
and,O
10,O
mg,O
/,O
kg,O
orally,O
.,O
The,O
compound,O
manifests,O
antiarrhythmic,O
activity,O
in,O
all,O
models,O
of,O
experimental,O
arrhythmia,I-Entity
used,O
",",O
causing,O
greatest,O
inhibition,O
on,O
the,O
arrhythmia,I-Entity
induced,O
by,O
chloroform,I-Entity
-,O
adrenaline,I-Entity
(,O
in,O
90,O
per,O
cent,O
),O
and,O
with,O
BaCl2,I-Entity
(,O
in,O
84,O
per,O
cent,O
),O
.,O
Experimental,O
progressive,O
muscular,B-Entity
dystrophy,I-Entity
and,O
its,O
treatment,O
with,O
high,O
doses,O
anabolizing,O
agents,O
.,O
We,O
are,O
still,O
a,O
long,O
way,O
from,O
discovering,O
an,O
unequivocal,O
pathogenetic,O
interpretation,O
of,O
progressive,O
muscular,B-Entity
dystrophy,I-Entity
in,O
man,O
.,O
Myopathy,I-Entity
due,O
to,O
lack,O
of,O
vitamin,B-Entity
E,I-Entity
and,O
myopathy,I-Entity
induced,O
by,O
certain,O
viruses,O
have,O
much,O
in,O
common,O
anatomically,O
and,O
pathologically,O
with,O
the,O
human,O
form,O
.,O
The,O
authors,O
induced,O
myodystrophy,I-Entity
in,O
the,O
rat,O
by,O
giving,O
it,O
a,O
diet,O
lacking,O
in,O
vitamin,B-Entity
E.,I-Entity
The,O
pharmacological,O
characteristics,O
of,O
vitamin,B-Entity
E,I-Entity
and,O
the,O
degenerative,O
changes,O
brought,O
about,O
by,O
its,O
deficiency,O
",",O
especially,O
in,O
the,O
muscles,O
",",O
are,O
illustrated,O
.,O
It,O
is,O
thus,O
confirmed,O
that,O
the,O
histological,O
characteristics,O
of,O
myopathic,I-Entity
rat,O
muscle,O
induced,O
experimentally,O
are,O
extraordinarily,O
similar,O
to,O
those,O
of,O
human,O
myopathy,I-Entity
as,O
confirmed,O
during,O
biopsies,O
performed,O
at,O
the,O
Orthopaedic,O
Traumatological,O
Centre,O
",",O
Florence,O
.,O
The,O
encouraging,O
results,O
obtained,O
in,O
various,O
authoratative,O
departments,O
in,O
myopathic,I-Entity
patients,O
by,O
using,O
anabolizing,O
steroids,I-Entity
have,O
encouraged,O
the,O
authors,O
to,O
investigate,O
the,O
beneficial,O
effects,O
of,O
one,O
anabolizing,O
agent,O
(,O
Dianabol,I-Entity
",",O
CIBA,I-Entity
),O
at,O
high,O
doses,O
in,O
rats,O
rendered,O
myopathic,I-Entity
by,O
a,O
diet,O
deficient,O
in,O
vitamin,B-Entity
E.,I-Entity
In,O
this,O
way,O
they,O
obtained,O
appreciable,O
changes,O
in,O
body,O
weight,O
(,O
increased,O
from,O
50,O
to,O
70,O
g,O
after,O
forty,O
days,O
at,O
a,O
dose,O
of,O
5,O
mg,O
per,O
day,O
of,O
anabolizing,O
agent,O
),O
",",O
but,O
most,O
of,O
all,O
they,O
found,O
histological,O
changes,O
due,O
to,O
"""",O
regenerative,O
"""",O
changes,O
in,O
the,O
muscle,O
tissue,O
",",O
which,O
however,O
maintained,O
its,O
myopathic,I-Entity
characteristics,O
in,O
the,O
control,O
animals,O
that,O
were,O
not,O
treated,O
with,O
the,O
anabolizing,O
agent,O
.,O
The,O
authors,O
conclude,O
by,O
affirming,O
the,O
undoubted,O
efficacy,O
of,O
the,O
anabolizing,O
steroids,I-Entity
in,O
experimental,O
myopathic,B-Entity
disease,I-Entity
",",O
but,O
they,O
have,O
reservations,O
as,O
to,O
the,O
transfer,O
of,O
the,O
results,O
into,O
the,O
human,O
field,O
",",O
where,O
high,O
dosage,O
can,O
not,O
be,O
carried,O
out,O
continuously,O
because,O
of,O
the,O
effects,O
of,O
the,O
drug,O
on,O
virility,O
;,O
because,O
the,O
tissue,O
injury,O
too,O
often,O
occurs,O
at,O
an,O
irreversible,O
stage,O
vis,O
-,O
a,O
-,O
vis,O
the,O
"""",O
regeneration,O
"""",O
of,O
the,O
muscle,O
tissue,O
;,O
and,O
finally,O
because,O
the,O
dystrophic,O
injurious,O
agent,O
is,O
certainly,O
not,O
the,O
lack,O
of,O
vitamin,B-Entity
E,I-Entity
but,O
something,O
as,O
yet,O
unknown,O
.,O
Fetal,O
risks,O
due,O
to,O
warfarin,I-Entity
therapy,O
during,O
pregnancy,O
.,O
Two,O
mothers,O
with,O
heart,O
valve,O
prosthesis,O
were,O
treated,O
with,O
warfarin,I-Entity
during,O
pregnancy,O
.,O
In,O
the,O
first,O
case,O
a,O
caesarean,O
section,O
was,O
done,O
one,O
week,O
after,O
replacement,O
of,O
warfarin,I-Entity
with,O
heparin,I-Entity
.,O
The,O
baby,O
died,O
of,O
cerebral,B-Entity
and,I-Entity
pulmonary,I-Entity
hemorrhage,I-Entity
.,O
The,O
baby,O
showed,O
warfarin,I-Entity
-,O
induced,O
embryopathy,I-Entity
with,O
nasal,B-Entity
hypoplasia,I-Entity
and,O
stippled,B-Entity
epiphyses,I-Entity
(,O
chondrodysplasia,B-Entity
punctata,I-Entity
),O
.,O
Nasal,B-Entity
hypoplasia,I-Entity
with,O
or,O
without,O
stippled,B-Entity
epiphyses,I-Entity
has,O
now,O
been,O
reported,O
in,O
11,O
infants,O
born,O
to,O
mothers,O
treated,O
with,O
warfarin,I-Entity
during,O
the,O
first,O
trimester,O
",",O
and,O
a,O
causal,O
association,O
is,O
probable,O
.,O
Isradipine,I-Entity
treatment,O
for,O
hypertension,I-Entity
in,O
general,O
practice,O
in,O
Hong,O
Kong,O
.,O
A,O
6-week,O
open,O
study,O
of,O
the,O
introduction,O
of,O
isradipine,I-Entity
treatment,O
was,O
conducted,O
in,O
general,O
practice,O
in,O
Hong,O
Kong,O
.,O
303,O
Chinese,O
patients,O
with,O
mild,O
to,O
moderate,O
hypertension,I-Entity
entered,O
the,O
study,O
.,O
The,O
main,O
side,O
-,O
effects,O
were,O
headache,I-Entity
",",O
dizziness,I-Entity
",",O
palpitation,I-Entity
and,O
flushing,I-Entity
and,O
these,O
were,O
not,O
more,O
frequent,O
than,O
reported,O
in,O
other,O
studies,O
with,O
isradipine,I-Entity
or,O
with,O
placebo,O
.,O
Similar,O
reductions,O
occurred,O
in,O
standing,O
blood,O
pressure,O
and,O
there,O
was,O
no,O
evidence,O
of,O
postural,B-Entity
hypotension,I-Entity
.,O
Tachyphylaxis,O
to,O
systemic,O
but,O
not,O
to,O
airway,O
responses,O
during,O
prolonged,O
therapy,O
with,O
high,O
dose,O
inhaled,O
salbutamol,I-Entity
in,O
asthmatics,I-Entity
.,O
High,O
doses,O
of,O
inhaled,O
salbutamol,I-Entity
produce,O
substantial,O
improvements,O
in,O
airway,O
response,O
in,O
patients,O
with,O
asthma,I-Entity
",",O
and,O
are,O
associated,O
with,O
dose,O
-,O
dependent,O
systemic,O
beta,O
-,O
adrenoceptor,O
responses,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
whether,O
tachyphylaxis,O
occurs,O
during,O
prolonged,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,I-Entity
.,O
Twelve,O
asthmatic,I-Entity
patients,O
(,O
FEV1,O
",",O
81,O
were,O
given,O
a,O
14-day,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,I-Entity
(,O
HDS,O
),O
",",O
"4,000",O
micrograms,O
daily,O
",",O
low,O
dose,O
inhaled,O
salbutamol,I-Entity
(,O
LDS,O
),O
",",O
800,O
micrograms,O
daily,O
",",O
or,O
placebo,O
(,O
PI,O
),O
by,O
metered,O
-,O
dose,O
inhaler,O
in,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
crossover,O
design,O
.,O
During,O
the,O
14-day,O
run,O
-,O
in,O
and,O
during,O
washout,O
periods,O
",",O
inhaled,O
beta,O
-,O
agonists,O
were,O
withheld,O
and,O
ipratropium,B-Entity
bromide,I-Entity
was,O
substituted,O
for,O
rescue,O
purposes,O
.,O
chronotropic,O
(,O
HR,O
),O
",",O
tremor,I-Entity
",",O
and,O
metabolic,O
(,O
K,I-Entity
",",O
Glu,I-Entity
),O
responses,O
were,O
measured,O
at,O
each,O
step,O
(,O
from,O
100,O
to,O
"4,000",O
micrograms,O
),O
.,O
DRC,O
for,O
HR,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
K,I-Entity
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
and,O
Glu,I-Entity
(,O
p,O
less,O
than,O
0.005,O
),O
were,O
attenuated,O
after,O
treatment,O
with,O
HDS,O
compared,O
with,O
PI,O
.,O
There,O
were,O
also,O
differences,O
between,O
HDS,O
and,O
LDS,O
for,O
HR,O
(,O
p,O
less,O
than,O
0.001,O
),O
and,O
Glu,I-Entity
(,O
p,O
less,O
than,O
0.05,O
),O
responses,O
.,O
Frequency,O
and,O
severity,O
of,O
subjective,O
adverse,O
effects,O
were,O
also,O
reduced,O
after,O
HDS,O
:,O
tremor,I-Entity
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
palpitations,I-Entity
(,O
p,O
less,O
than,O
0.001).(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Increased,O
anxiogenic,O
effects,O
of,O
caffeine,I-Entity
in,O
panic,B-Entity
disorders,I-Entity
.,O
The,O
effects,O
of,O
oral,O
administration,O
of,O
caffeine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
on,O
behavioral,O
ratings,O
",",O
somatic,O
symptoms,O
",",O
blood,O
pressure,O
and,O
plasma,O
levels,O
of,O
3-methoxy-4-hydroxyphenethyleneglycol,I-Entity
(,O
MHPG,I-Entity
),O
and,O
cortisol,I-Entity
were,O
determined,O
in,O
17,O
healthy,O
subjects,O
and,O
21,O
patients,O
meeting,O
DSM,O
-,O
III,O
criteria,O
for,O
agoraphobia,I-Entity
with,O
panic,B-Entity
attacks,I-Entity
or,O
panic,B-Entity
disorder,I-Entity
.,O
Caffeine,I-Entity
produced,O
significantly,O
greater,O
increases,O
in,O
subject,O
-,O
rated,O
anxiety,I-Entity
",",O
nervousness,O
",",O
fear,O
",",O
nausea,I-Entity
",",O
palpitations,I-Entity
",",O
restlessness,I-Entity
",",O
and,O
tremors,I-Entity
in,O
the,O
patients,O
compared,O
with,O
healthy,O
subjects,O
.,O
In,O
the,O
patients,O
",",O
but,O
not,O
the,O
healthy,O
subjects,O
",",O
these,O
symptoms,O
were,O
significantly,O
correlated,O
with,O
plasma,O
caffeine,I-Entity
levels,O
.,O
Seventy,O
-,O
one,O
percent,O
of,O
the,O
patients,O
reported,O
that,O
the,O
behavioral,O
effects,O
of,O
caffeine,I-Entity
were,O
similar,O
to,O
those,O
experienced,O
during,O
panic,B-Entity
attacks,I-Entity
.,O
Caffeine,I-Entity
did,O
not,O
alter,O
plasma,O
MHPG,I-Entity
levels,O
in,O
either,O
the,O
healthy,O
subjects,O
or,O
patients,O
.,O
Caffeine,I-Entity
increased,O
plasma,O
cortisol,I-Entity
levels,O
equally,O
in,O
the,O
patient,O
and,O
healthy,O
groups,O
.,O
Because,O
caffeine,I-Entity
is,O
an,O
adenosine,I-Entity
receptor,O
antagonist,O
",",O
these,O
results,O
suggest,O
that,O
some,O
panic,B-Entity
disorder,I-Entity
patients,O
may,O
have,O
abnormalities,B-Entity
in,I-Entity
neuronal,I-Entity
systems,I-Entity
involving,O
adenosine,I-Entity
.,O
Patients,O
with,O
anxiety,B-Entity
disorders,I-Entity
may,O
benefit,O
by,O
avoiding,O
caffeine,I-Entity
-,O
containing,O
foods,O
and,O
beverages,O
.,O
intestinal,O
polypeptide,O
:,O
decrease,O
with,O
heart,B-Entity
failure,I-Entity
.,O
Myocardial,O
levels,O
of,O
VIP,O
were,O
assayed,O
before,O
and,O
after,O
the,O
development,O
of,O
heart,B-Entity
failure,I-Entity
in,O
two,O
canine,O
models,O
.,O
In,O
the,O
first,O
",",O
cobalt,I-Entity
cardiomyopathy,I-Entity
was,O
induced,O
in,O
eight,O
dogs,O
;,O
VIP,O
(,O
by,O
radioimmunoassay,O
),O
decreased,O
from,O
35,O
+,O
/-,O
In,O
six,O
dogs,O
with,O
doxorubicin,I-Entity
-,O
induced,O
heart,B-Entity
failure,I-Entity
",",O
VIP,O
decreased,O
from,O
31,O
+,O
/-,O
In,O
addition,O
",",O
VIP,O
content,O
of,O
left,O
ventricular,O
muscle,O
of,O
resected,O
failing,O
hearts,O
in,O
10,O
patients,O
receiving,O
a,O
heart,O
transplant,O
was,O
compared,O
with,O
the,O
papillary,O
muscles,O
in,O
14,O
patients,O
(,O
five,O
with,O
rheumatic,B-Entity
disease,I-Entity
",",O
nine,O
with,O
myxomatous,B-Entity
degeneration,I-Entity
),O
receiving,O
mitral,O
valve,O
prostheses,O
.,O
The,O
lowest,O
myocardial,O
VIP,O
concentration,O
was,O
found,O
in,O
the,O
hearts,O
of,O
patients,O
with,O
coronary,B-Entity
disease,I-Entity
(,O
one,O
patient,O
receiving,O
a,O
transplant,O
and,O
three,O
receiving,O
mitral,O
prostheses,O
),O
(,O
6.3,O
+,O
/-,O
The,O
hearts,O
without,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
(,O
average,O
ejection,O
fraction,O
of,O
this,O
group,O
62%,O
+,O
/-,O
7.9,O
pg,O
/,O
mg,O
protein,O
",",O
and,O
this,O
was,O
greater,O
than,O
in,O
hearts,O
of,O
the,O
patients,O
with,O
coronary,B-Entity
disease,I-Entity
and,O
the,O
hearts,O
of,O
patients,O
receiving,O
a,O
transplant,O
(,O
P,O
less,O
than,O
0.05,O
),O
.,O
Myocardial,O
catecholamines,I-Entity
were,O
also,O
determined,O
in,O
14,O
subjects,O
;,O
a,O
weak,O
correlation,O
(,O
r,O
=,O
0.57,O
",",O
P,O
less,O
than,O
0.05,O
),O
between,O
the,O
tissue,O
concentrations,O
of,O
VIP,O
and,O
norepinephrine,I-Entity
was,O
noted.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Interstrain,O
variation,O
in,O
acute,O
toxic,O
response,O
to,O
caffeine,I-Entity
among,O
inbred,O
mice,O
.,O
Acute,O
toxic,O
dosage,O
-,O
dependent,O
behavioral,O
effects,O
of,O
caffeine,I-Entity
were,O
compared,O
in,O
adult,O
males,O
from,O
seven,O
inbred,O
mouse,O
strains,O
(,O
A,O
/,O
J,O
",",O
BALB,O
/,O
cJ,O
",",O
CBA,O
/,O
J,O
",",O
C3H,O
/,O
HeJ,O
",",O
C57BL/6J,O
",",O
DBA/2J,O
",",O
SWR,O
/,O
J,O
),O
.,O
C57BL/6J,O
",",O
chosen,O
as,O
a,O
"""",O
prototypic,O
"""",O
mouse,O
strain,O
",",O
was,O
used,O
to,O
determine,O
behavioral,O
responses,O
to,O
a,O
broad,O
range,O
(,O
5,O
-,O
500,O
mg,O
/,O
kg,O
),O
of,O
caffeine,I-Entity
doses,O
.,O
Five,O
phenotypic,O
characteristics,O
--,O
locomotor,O
activity,O
",",O
righting,O
ability,O
",",O
clonic,B-Entity
seizure,I-Entity
induction,O
",",O
stress,O
-,O
induced,O
lethality,O
",",O
death,O
without,O
external,O
stress,O
--,O
were,O
scored,O
at,O
various,O
caffeine,I-Entity
doses,O
in,O
drug,O
-,O
naive,O
animals,O
under,O
empirically,O
optimized,O
",",O
rigidly,O
constant,O
experimental,O
conditions,O
.,O
Mice,O
(,O
n,O
=,O
12,O
for,O
each,O
point,O
),O
received,O
single,O
IP,O
injections,O
of,O
a,O
fixed,O
volume,O
/,O
g,O
body,O
weight,O
of,O
physiological,O
saline,O
carrier,O
with,O
or,O
without,O
caffeine,I-Entity
in,O
doses,O
ranging,O
from,O
125,O
-,O
500,O
mg,O
/,O
kg,O
.,O
In,O
the,O
same,O
animals,O
the,O
occurrence,O
of,O
clonic,B-Entity
seizures,I-Entity
was,O
scored,O
as,O
to,O
time,O
of,O
onset,O
and,O
severity,O
for,O
20,O
min,O
after,O
drug,O
administration,O
.,O
When,O
these,O
proceeded,O
to,O
tonic,B-Entity
seizures,I-Entity
",",O
death,O
occurred,O
in,O
less,O
than,O
20,O
min,O
.,O
Animals,O
surviving,O
for,O
20,O
min,O
were,O
immediately,O
stressed,O
by,O
a,O
swim,O
test,O
in,O
25,O
degrees,O
C,O
water,O
",",O
and,O
death,O
-,O
producing,O
tonic,B-Entity
seizures,I-Entity
were,O
scored,O
for,O
2,O
min,O
.,O
In,O
other,O
animals,O
locomotor,O
activity,O
was,O
measured,O
15,O
or,O
60,O
min,O
after,O
caffeine,I-Entity
administration,O
.,O
By,O
any,O
single,O
behavioral,O
criterion,O
or,O
a,O
combination,O
of,O
these,O
criteria,O
",",O
marked,O
differences,O
in,O
response,O
to,O
toxic,O
caffeine,I-Entity
doses,O
were,O
observed,O
between,O
strains,O
.,O
These,O
results,O
indicate,O
that,O
behavioral,O
toxicity,I-Entity
testing,O
of,O
alkylxanthines,I-Entity
in,O
a,O
single,O
mouse,O
strain,O
may,O
be,O
misleading,O
and,O
suggest,O
that,O
toxic,O
responses,O
of,O
the,O
central,O
nervous,O
system,O
to,O
this,O
class,O
of,O
compounds,O
are,O
genetically,O
influenced,O
in,O
mammals,O
.,O
Invasive,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
renal,I-Entity
pelvis,I-Entity
following,O
cyclophosphamide,I-Entity
therapy,O
for,O
nonmalignant,O
disease,O
.,O
A,O
47-year,O
-,O
old,O
woman,O
with,O
right,O
hydroureteronephrosis,I-Entity
due,O
to,O
ureterovesical,O
junction,O
obstruction,O
had,O
gross,O
hematuria,I-Entity
after,O
being,O
treated,O
for,O
five,O
years,O
wtih,O
cyclophosphamide,I-Entity
for,O
cerebral,B-Entity
vasculitis,I-Entity
.,O
A,O
right,O
nephroureterectomy,O
was,O
required,O
for,O
control,O
of,O
bleeding,I-Entity
.,O
The,O
pathology,O
specimen,O
contained,O
clinically,O
occult,O
invasive,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
renal,I-Entity
pelvis,I-Entity
.,O
Although,O
the,O
ability,O
of,O
cyclophosphamide,I-Entity
to,O
cause,O
hemorrhagic,B-Entity
cystitis,I-Entity
and,O
urine,O
cytologic,O
abnormalities,O
indistinguishable,O
from,O
high,O
grade,O
carcinoma,I-Entity
is,O
well,O
known,O
",",O
it,O
is,O
less,O
widely,O
appreciated,O
that,O
it,O
is,O
also,O
associated,O
with,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
urinary,I-Entity
tract,I-Entity
.,O
Twenty,O
carcinomas,B-Entity
of,I-Entity
the,I-Entity
urinary,I-Entity
bladder,I-Entity
and,O
one,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
prostate,I-Entity
have,O
been,O
reported,O
in,O
association,O
with,O
its,O
use,O
.,O
The,O
present,O
case,O
is,O
the,O
first,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
renal,I-Entity
pelvis,I-Entity
reported,O
in,O
association,O
with,O
cyclophosphamide,I-Entity
treatment,O
.,O
It,O
is,O
the,O
third,O
urinary,B-Entity
tract,I-Entity
cancer,I-Entity
reported,O
in,O
association,O
with,O
cyclophosphamide,I-Entity
treatment,O
for,O
nonmalignant,O
disease,O
.,O
The,O
association,O
of,O
the,O
tumor,I-Entity
with,O
preexisting,O
hydroureteronephrosis,I-Entity
suggests,O
that,O
stasis,O
prolonged,O
and,O
intensified,O
exposure,O
of,O
upper,O
urinary,O
tract,O
epithelium,O
to,O
cyclophosphamide,I-Entity
.,O
Patients,O
who,O
are,O
candidates,O
for,O
long,O
-,O
term,O
cyclophosphamide,I-Entity
treatment,O
should,O
be,O
routinely,O
evaluated,O
for,O
obstructive,B-Entity
uropathy,I-Entity
.,O
Ascending,O
dose,O
tolerance,O
study,O
of,O
intramuscular,O
carbetocin,I-Entity
administered,O
after,O
normal,O
vaginal,O
birth,O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
maximum,O
tolerated,O
dose,O
(,O
MTD,O
),O
of,O
carbetocin,I-Entity
(,O
a,O
long,O
-,O
acting,O
synthetic,O
analogue,O
of,O
oxytocin,I-Entity
),O
",",O
when,O
administered,O
immediately,O
after,O
vaginal,O
delivery,O
at,O
term,O
.,O
Carbetocin,I-Entity
was,O
given,O
as,O
an,O
intramuscular,O
injection,O
immediately,O
after,O
the,O
birth,O
of,O
the,O
infant,O
in,O
45,O
healthy,O
women,O
with,O
normal,O
singleton,O
pregnancies,O
who,O
delivered,O
vaginally,O
at,O
term,O
.,O
Dosage,O
groups,O
of,O
15,O
",",O
30,O
",",O
50,O
",",O
75,O
",",O
100,O
",",O
125,O
",",O
150,O
",",O
175,O
or,O
200,O
microg,O
carbetocin,I-Entity
were,O
assigned,O
to,O
blocks,O
of,O
three,O
women,O
according,O
to,O
the,O
continual,O
reassessment,O
method,O
(,O
CRM,O
),O
.,O
Recorded,O
were,O
dose,O
-,O
limiting,O
adverse,O
events,O
:,O
hyper-,B-Entity
or,I-Entity
hypotension,I-Entity
(,O
three,O
),O
",",O
severe,O
abdominal,B-Entity
pain,I-Entity
(,O
0,O
),O
",",O
vomiting,I-Entity
(,O
0,O
),O
and,O
retained,B-Entity
placenta,I-Entity
(,O
four,O
),O
.,O
Serious,O
adverse,O
events,O
occurred,O
in,O
seven,O
women,O
:,O
six,O
cases,O
with,O
blood,B-Entity
loss,I-Entity
>,O
or,O
=,O
1000,O
ml,O
",",O
four,O
cases,O
of,O
manual,O
placenta,O
removal,O
",",O
five,O
cases,O
of,O
additional,O
oxytocics,O
administration,O
and,O
five,O
cases,O
of,O
blood,O
transfusion,O
.,O
Maximum,O
blood,B-Entity
loss,I-Entity
was,O
greatest,O
at,O
the,O
upper,O
and,O
lower,O
dose,O
levels,O
",",O
and,O
lowest,O
in,O
the,O
70,O
-,O
125,O
microg,O
dose,O
range,O
.,O
Four,O
out,O
of,O
six,O
cases,O
with,O
blood,B-Entity
loss,I-Entity
>,O
or,O
=,O
1000,O
ml,O
occurred,O
in,O
the,O
200,O
microg,O
group,O
.,O
The,O
MTD,O
was,O
calculated,O
to,O
be,O
at,O
200,O
microg,O
carbetocin,I-Entity
.,O
A,O
pilot,O
study,O
to,O
assess,O
the,O
safety,O
of,O
dobutamine,I-Entity
stress,O
echocardiography,O
in,O
the,O
emergency,O
department,O
evaluation,O
of,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
.,O
STUDY,O
OBJECTIVE,O
:,O
Chest,B-Entity
pain,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
use,O
poses,O
a,O
diagnostic,O
dilemma,O
.,O
Dobutamine,I-Entity
stress,O
echocardiography,O
(,O
DSE,O
),O
is,O
a,O
widely,O
available,O
and,O
sensitive,O
test,O
for,O
evaluating,O
cardiac,O
ischemia,I-Entity
.,O
Because,O
of,O
the,O
theoretical,O
concern,O
regarding,O
administration,O
of,O
dobutamine,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
use,O
",",O
we,O
conducted,O
a,O
pilot,O
study,O
to,O
assess,O
the,O
safety,O
of,O
DSE,O
in,O
emergency,O
department,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
.,O
Patients,O
were,O
eligible,O
for,O
DSE,O
if,O
they,O
had,O
used,O
cocaine,I-Entity
within,O
24,O
hours,O
preceding,O
the,O
onset,O
of,O
chest,B-Entity
pain,I-Entity
and,O
had,O
a,O
normal,O
ECG,O
and,O
tropinin,O
I,O
level,O
.,O
Patients,O
exhibiting,O
signs,O
of,O
continuing,O
cocaine,I-Entity
toxicity,I-Entity
were,O
excluded,O
from,O
the,O
study,O
.,O
Two,O
patients,O
had,O
inadequate,O
resting,O
images,O
",",O
one,O
DSE,O
was,O
terminated,O
because,O
of,O
inferior,O
hypokinesis,I-Entity
",",O
another,O
DSE,O
was,O
terminated,O
because,O
of,O
a,O
rate,O
-,O
related,O
atrial,O
conduction,O
deficit,O
",",O
and,O
1,O
patient,O
did,O
not,O
reach,O
the,O
target,O
heart,O
rate,O
.,O
None,O
of,O
the,O
patients,O
experienced,O
signs,O
of,O
exaggerated,O
adrenergic,O
response,O
",",O
which,O
was,O
defined,O
as,O
a,O
systolic,O
blood,O
pressure,O
of,O
greater,O
than,O
200,O
mm,O
Hg,O
or,O
the,O
occurrence,O
of,O
tachydysrhythmias,I-Entity
(,O
excluding,O
sinus,B-Entity
tachycardia,I-Entity
),O
.,O
Further,O
suggesting,O
lack,O
of,O
exaggerated,O
adrenergic,O
response,O
",",O
13,O
(,O
65%,O
),O
of,O
20,O
patients,O
required,O
supplemental,O
atropine,I-Entity
to,O
reach,O
their,O
target,O
heart,O
rates,O
.,O
No,O
exaggerated,O
adrenergic,O
response,O
was,O
detected,O
when,O
dobutamine,I-Entity
was,O
administered,O
to,O
patients,O
with,O
cocaine,I-Entity
-,O
related,O
chest,B-Entity
pain,I-Entity
.,O
Amiodarone,I-Entity
-,O
induced,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
during,O
bladder,O
irrigation,O
:,O
an,O
unusual,O
presentation,O
--,O
a,O
case,O
report,O
.,O
The,O
authors,O
present,O
a,O
case,O
of,O
early,O
(,O
within,O
4,O
days,O
),O
development,O
of,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
(,O
TdP,I-Entity
),O
associated,O
with,O
oral,O
amiodarone,I-Entity
therapy,O
.,O
Consistent,O
with,O
other,O
reports,O
this,O
case,O
of,O
TdP,I-Entity
occurred,O
in,O
the,O
context,O
of,O
multiple,O
exacerbating,O
factors,O
including,O
hypokalemia,I-Entity
and,O
digoxin,I-Entity
excess,O
.,O
Transient,O
prolongation,O
of,O
the,O
QT,O
during,O
bladder,O
irrigation,O
prompted,O
the,O
episode,O
of,O
TdP.,I-Entity
It,O
is,O
well,O
known,O
that,O
bradycardia,I-Entity
exacerbates,O
acquired,O
TdP.,I-Entity
The,O
authors,O
speculate,O
that,O
the,O
increased,O
vagal,O
tone,O
during,O
bladder,O
irrigation,O
",",O
a,O
vagal,O
maneuver,O
",",O
in,O
the,O
context,O
of,O
amiodarone,I-Entity
therapy,O
resulted,O
in,O
amiodarone,I-Entity
-,O
induced,O
proarrhythmia,I-Entity
.,O
In,O
the,O
absence,O
of,O
amiodarone,I-Entity
therapy,O
",",O
a,O
second,O
bladder,O
irrigation,O
did,O
not,O
induce,O
TdP,I-Entity
despite,O
hypokalemia,I-Entity
and,O
hypomagnesemia,I-Entity
.,O
Acute,B-Entity
renal,I-Entity
insufficiency,I-Entity
after,O
high,O
-,O
dose,O
melphalan,I-Entity
in,O
patients,O
with,O
primary,B-Entity
systemic,I-Entity
amyloidosis,I-Entity
during,O
stem,O
cell,O
transplantation,O
.,O
Patients,O
with,O
primary,B-Entity
systemic,I-Entity
amyloidosis,I-Entity
(,O
AL,I-Entity
),O
have,O
a,O
poor,O
prognosis,O
.,O
High,O
-,O
dose,O
intravenous,O
melphalan,I-Entity
followed,O
by,O
peripheral,O
blood,O
stem,O
cell,O
transplant,O
(,O
PBSCT,O
),O
appears,O
to,O
be,O
the,O
most,O
promising,O
therapy,O
",",O
but,O
treatment,O
mortality,O
can,O
be,O
high,O
.,O
The,O
authors,O
have,O
noted,O
the,O
development,O
of,O
acute,B-Entity
renal,I-Entity
insufficiency,I-Entity
immediately,O
after,O
melphalan,I-Entity
conditioning,O
.,O
METHODS,O
:,O
Consecutive,O
AL,I-Entity
patients,O
who,O
underwent,O
PBSCT,O
were,O
studied,O
retrospectively,O
.,O
Acute,B-Entity
renal,I-Entity
insufficiency,I-Entity
(,O
ARI,I-Entity
),O
after,O
high,O
-,O
dose,O
melphalan,I-Entity
was,O
defined,O
by,O
a,O
minimum,O
increase,O
of,O
0.5,O
mg,O
/,O
dL,O
(,O
44,O
micromol,O
/,O
L,O
),O
in,O
the,O
serum,O
creatinine,I-Entity
level,O
that,O
is,O
greater,O
than,O
50%,O
of,O
baseline,O
immediately,O
after,O
conditioning,O
.,O
Of,O
the,O
80,O
patients,O
studied,O
",",O
ARI,I-Entity
developed,O
in,O
18.8%,O
of,O
the,O
patients,O
after,O
high,O
-,O
dose,O
melphalan,I-Entity
.,O
Univariate,O
analysis,O
identified,O
age,O
",",O
hypoalbuminemia,I-Entity
",",O
heavy,O
proteinuria,I-Entity
",",O
diuretic,O
use,O
",",O
and,O
urine,O
sediment,O
score,O
(,O
>,O
3,O
),O
as,O
risk,O
factors,O
.,O
Patients,O
who,O
had,O
ARI,I-Entity
after,O
high,O
-,O
dose,O
melphalan,I-Entity
underwent,O
dialysis,O
more,O
often,O
(,O
P,O
=,O
0.007,O
),O
",",O
and,O
had,O
a,O
worse,O
1-year,O
survival,O
(,O
P,O
=,O
0.03,O
),O
.,O
The,O
timing,O
of,O
renal,B-Entity
injury,I-Entity
strongly,O
suggests,O
melphalan,I-Entity
as,O
the,O
causative,O
agent,O
.,O
Ongoing,O
tubular,B-Entity
injury,I-Entity
may,O
be,O
a,O
prerequisite,O
for,O
renal,B-Entity
injury,I-Entity
by,O
melphalan,I-Entity
as,O
evidenced,O
by,O
the,O
active,O
urinary,O
sediment,O
.,O
Development,O
of,O
ARI,I-Entity
adversely,O
affected,O
the,O
outcome,O
after,O
PBSCT,O
.,O
Effective,O
preventive,O
measures,O
may,O
help,O
decrease,O
the,O
treatment,O
mortality,O
of,O
PBSCT,O
in,O
AL,I-Entity
patients,O
.,O
Impaired,B-Entity
fear,I-Entity
recognition,I-Entity
in,O
regular,O
recreational,O
cocaine,I-Entity
users,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
conduct,O
the,O
first,O
investigation,O
of,O
facial,O
expression,O
recognition,O
performance,O
in,O
recreational,O
cocaine,I-Entity
users,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
Three,O
groups,O
",",O
comprised,O
of,O
21,O
cocaine,I-Entity
naive,O
participants,O
(,O
CN,O
),O
",",O
30,O
occasional,O
cocaine,I-Entity
(,O
OC,O
),O
",",O
and,O
48,O
regular,O
recreational,O
cocaine,I-Entity
(,O
RC,O
),O
users,O
",",O
were,O
compared,O
.,O
There,O
were,O
no,O
group,O
differences,O
in,O
psychopathology,O
or,O
"""",O
eyes,O
task,O
"""",O
performance,O
",",O
but,O
the,O
RC,O
group,O
",",O
who,O
otherwise,O
had,O
similar,O
illicit,O
substance,O
use,O
histories,O
to,O
the,O
OC,O
group,O
",",O
exhibited,O
impaired,B-Entity
fear,I-Entity
recognition,I-Entity
accuracy,O
compared,O
to,O
the,O
OC,O
and,O
CN,O
groups,O
.,O
The,O
selective,O
deficit,B-Entity
in,I-Entity
fear,I-Entity
recognition,I-Entity
accuracy,O
manifested,O
by,O
the,O
RC,O
group,O
can,O
not,O
be,O
explained,O
by,O
the,O
subacute,O
effects,O
of,O
cocaine,I-Entity
",",O
or,O
ecstasy,I-Entity
",",O
because,O
recent,O
and,O
less,O
recent,O
users,O
of,O
these,O
drugs,O
within,O
this,O
group,O
were,O
similarly,O
impaired,O
.,O
Possible,O
parallels,O
between,O
RC,O
users,O
and,O
psychopaths,I-Entity
with,O
respect,O
to,O
impaired,B-Entity
fear,I-Entity
recognition,I-Entity
",",O
amygdala,B-Entity
dysfunction,I-Entity
",",O
and,O
etiology,O
are,O
discussed,O
.,O
Corneal,B-Entity
ulcers,I-Entity
associated,O
with,O
aerosolized,O
crack,B-Entity
cocaine,I-Entity
use,O
.,O
We,O
report,O
4,O
cases,O
of,O
corneal,B-Entity
ulcers,I-Entity
associated,O
with,O
drug,B-Entity
abuse,I-Entity
.,O
The,O
pathogenesis,O
of,O
these,O
ulcers,I-Entity
and,O
management,O
of,O
these,O
patients,O
are,O
also,O
reviewed,O
.,O
METHODS,O
:,O
Review,O
of,O
all,O
cases,O
of,O
corneal,B-Entity
ulcers,I-Entity
associated,O
with,O
drug,B-Entity
abuse,I-Entity
seen,O
at,O
our,O
institution,O
from,O
July,O
2006,O
to,O
December,O
2006,O
.,O
RESULTS,O
:,O
Four,O
patients,O
with,O
corneal,B-Entity
ulcers,I-Entity
associated,O
with,O
crack,B-Entity
cocaine,I-Entity
use,O
were,O
reviewed,O
.,O
All,O
corneal,B-Entity
ulcers,I-Entity
were,O
cultured,O
",",O
and,O
the,O
patients,O
were,O
admitted,O
to,O
the,O
hospital,O
for,O
intensive,O
topical,O
antibiotic,O
treatment,O
.,O
Each,O
patient,O
received,O
comprehensive,O
health,O
care,O
",",O
including,O
medical,O
and,O
substance,B-Entity
abuse,I-Entity
consultations,O
.,O
The,O
infections,I-Entity
responded,O
to,O
antibiotic,O
treatment,O
.,O
Two,O
patients,O
needed,O
a,O
lateral,O
tarsorrhaphy,O
for,O
persistent,O
epithelial,B-Entity
defects,I-Entity
.,O
CONCLUSIONS,O
:,O
Aerosolized,O
crack,B-Entity
cocaine,I-Entity
use,O
can,O
be,O
associated,O
with,O
the,O
development,O
of,O
corneal,B-Entity
ulcers,I-Entity
.,O
Drug,B-Entity
abuse,I-Entity
provides,O
additional,O
challenges,O
for,O
management,O
.,O
Not,O
only,O
treatment,O
of,O
their,O
infections,I-Entity
but,O
also,O
the,O
overall,O
poor,O
health,O
of,O
the,O
patients,O
and,O
increased,O
risk,O
of,O
noncompliance,O
need,O
to,O
be,O
addressed,O
.,O
Comprehensive,O
care,O
may,O
provide,O
the,O
patient,O
the,O
opportunity,O
to,O
discontinue,O
their,O
substance,B-Entity
abuse,I-Entity
",",O
improve,O
their,O
overall,O
health,O
",",O
and,O
prevent,O
future,O
corneal,O
complications,O
.,O
Levetiracetam,I-Entity
as,O
an,O
adjunct,O
to,O
phenobarbital,I-Entity
treatment,O
in,O
cats,O
with,O
suspected,O
idiopathic,B-Entity
epilepsy,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
assess,O
pharmacokinetics,O
",",O
efficacy,O
",",O
and,O
tolerability,O
of,O
oral,O
levetiracetam,I-Entity
administered,O
as,O
an,O
adjunct,O
to,O
phenobarbital,I-Entity
treatment,O
in,O
cats,O
with,O
poorly,O
controlled,O
suspected,O
idiopathic,B-Entity
epilepsy,I-Entity
.,O
ANIMALS,O
:,O
12,O
cats,O
suspected,O
to,O
have,O
idiopathic,B-Entity
epilepsy,I-Entity
that,O
was,O
poorly,O
controlled,O
with,O
phenobarbital,I-Entity
or,O
that,O
had,O
unacceptable,O
adverse,O
effects,O
when,O
treated,O
with,O
phenobarbital,I-Entity
.,O
Cats,O
were,O
treated,O
with,O
levetiracetam,I-Entity
(,O
20,O
mg,O
/,O
kg,O
[,O
9.1,O
mg,O
/,O
lb,O
],O
",",O
PO,O
",",O
q,O
8,O
h,O
),O
.,O
After,O
a,O
minimum,O
of,O
1,O
week,O
of,O
treatment,O
",",O
serum,O
levetiracetam,I-Entity
concentrations,O
were,O
measured,O
before,O
and,O
2,O
",",O
4,O
",",O
and,O
6,O
hours,O
after,O
drug,O
administration,O
",",O
and,O
maximum,O
and,O
minimum,O
serum,O
concentrations,O
and,O
elimination,O
half,O
-,O
life,O
were,O
calculated,O
.,O
Seizure,I-Entity
frequencies,O
before,O
and,O
after,O
initiation,O
of,O
levetiracetam,I-Entity
treatment,O
were,O
compared,O
",",O
and,O
adverse,O
effects,O
were,O
recorded,O
.,O
Median,O
maximum,O
serum,O
levetiracetam,I-Entity
concentration,O
was,O
25.5,O
microg,O
/,O
mL,O
",",O
median,O
minimum,O
serum,O
levetiracetam,I-Entity
concentration,O
was,O
8.3,O
microg,O
/,O
mL,O
",",O
and,O
median,O
elimination,O
half,O
-,O
life,O
was,O
2.9,O
hours,O
.,O
Median,O
seizure,I-Entity
frequency,O
prior,O
to,O
treatment,O
with,O
levetiracetam,I-Entity
(,O
2.1,O
seizures,I-Entity
/,O
mo,O
),O
was,O
significantly,O
higher,O
than,O
median,O
seizure,I-Entity
frequency,O
after,O
initiation,O
of,O
levetiracetam,I-Entity
treatment,O
(,O
0.42,O
seizures,I-Entity
/,O
mo,O
),O
",",O
and,O
7,O
of,O
10,O
cats,O
were,O
classified,O
as,O
having,O
responded,O
to,O
levetiracetam,I-Entity
treatment,O
(,O
ie,O
",",O
reduction,O
in,O
seizure,I-Entity
frequency,O
of,O
>,O
or=50%,O
),O
.,O
Two,O
cats,O
had,O
transient,O
lethargy,I-Entity
and,O
inappetence,I-Entity
.,O
Results,O
suggested,O
that,O
levetiracetam,I-Entity
is,O
well,O
tolerated,O
in,O
cats,O
and,O
may,O
be,O
useful,O
as,O
an,O
adjunct,O
to,O
phenobarbital,I-Entity
treatment,O
in,O
cats,O
with,O
idiopathic,B-Entity
epilepsy,I-Entity
.,O
Bilateral,O
haemorrhagic,B-Entity
infarction,I-Entity
of,I-Entity
the,I-Entity
globus,I-Entity
pallidus,I-Entity
after,O
cocaine,I-Entity
and,O
alcohol,I-Entity
intoxication,O
.,O
Cocaine,I-Entity
is,O
a,O
risk,O
factor,O
for,O
both,O
ischemic,B-Entity
and,I-Entity
haemorrhagic,I-Entity
stroke,I-Entity
.,O
We,O
present,O
the,O
case,O
of,O
a,O
31-year,O
-,O
old,O
man,O
with,O
bilateral,O
ischemia,B-Entity
of,I-Entity
the,I-Entity
globus,I-Entity
pallidus,I-Entity
after,O
excessive,O
alcohol,I-Entity
and,O
intranasal,O
cocaine,I-Entity
use,O
.,O
Drug,O
-,O
related,O
globus,B-Entity
pallidus,I-Entity
infarctions,I-Entity
are,O
most,O
often,O
associated,O
with,O
heroin,I-Entity
.,O
Bilateral,O
basal,B-Entity
ganglia,I-Entity
infarcts,I-Entity
after,O
the,O
use,O
of,O
cocaine,I-Entity
",",O
without,O
concurrent,O
heroin,I-Entity
use,O
",",O
have,O
never,O
been,O
reported,O
.,O
In,O
our,O
patient,O
",",O
transient,O
cardiac,B-Entity
arrhythmia,I-Entity
or,O
respiratory,B-Entity
dysfunction,I-Entity
related,O
to,O
cocaine,I-Entity
and/or,O
ethanol,I-Entity
use,O
were,O
the,O
most,O
likely,O
causes,O
of,O
cerebral,B-Entity
hypoperfusion,I-Entity
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
after,O
high,O
-,O
dose,O
methotrexate,I-Entity
therapy,O
in,O
a,O
patient,O
with,O
ileostomy,O
.,O
High,O
-,O
dose,O
methotrexate,I-Entity
(,O
HD,O
-,O
MTX,I-Entity
),O
is,O
an,O
important,O
treatment,O
for,O
Burkitt,B-Entity
lymphoma,I-Entity
",",O
but,O
can,O
cause,O
hepatic,B-Entity
and,I-Entity
renal,I-Entity
toxicity,I-Entity
when,O
its,O
clearance,O
is,O
delayed,O
.,O
We,O
report,O
a,O
case,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
after,O
HD,O
-,O
MTX,I-Entity
therapy,O
in,O
a,O
patient,O
with,O
ileostomy,O
",",O
The,O
patient,O
was,O
a,O
3-year,O
-,O
old,O
boy,O
who,O
had,O
received,O
a,O
living,O
-,O
related,O
liver,O
transplantation,O
for,O
congenital,O
biliary,B-Entity
atresia,I-Entity
.,O
At,O
day,O
833,O
after,O
the,O
transplantation,O
",",O
he,O
was,O
diagnosed,O
with,O
PTLD,I-Entity
(,O
post,B-Entity
-,I-Entity
transplantation,I-Entity
lymphoproliferative,I-Entity
disorder,I-Entity
",",O
Burkitt,B-Entity
-,I-Entity
type,I-Entity
malignant,I-Entity
lymphoma,I-Entity
),O
.,O
Subsequent,O
HD,O
-,O
MTX,I-Entity
therapy,O
caused,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
that,O
required,O
continuous,O
hemodialysis,O
.,O
We,O
supposed,O
that,O
intravascular,O
hypovolemia,I-Entity
due,O
to,O
substantial,O
drainage,O
from,O
the,O
ileostoma,O
caused,O
acute,B-Entity
prerenal,I-Entity
failure,I-Entity
.,O
After,O
recovery,O
of,O
his,O
renal,O
function,O
",",O
we,O
could,O
safely,O
treat,O
the,O
patient,O
with,O
HD,O
-,O
MTX,I-Entity
therapy,O
by,O
controlling,O
drainage,O
from,O
ileostoma,O
with,O
total,O
parenteral,O
nutrition,O
.,O
Antithrombotic,O
drug,O
use,O
",",O
cerebral,B-Entity
microbleeds,I-Entity
",",O
and,O
intracerebral,B-Entity
hemorrhage,I-Entity
:,O
a,O
systematic,O
review,O
of,O
published,O
and,O
unpublished,O
studies,O
.,O
BACKGROUND,O
AND,O
PURPOSE,O
:,O
Cerebral,B-Entity
microbleeds,I-Entity
(,O
MB,I-Entity
),O
are,O
potential,O
risk,O
factors,O
for,O
intracerebral,B-Entity
hemorrhage,I-Entity
(,O
ICH,I-Entity
),O
",",O
but,O
it,O
is,O
unclear,O
if,O
they,O
are,O
a,O
contraindication,O
to,O
using,O
antithrombotic,O
drugs,O
.,O
Insights,O
could,O
be,O
gained,O
by,O
pooling,O
data,O
on,O
MB,I-Entity
frequency,O
stratified,O
by,O
antithrombotic,O
use,O
in,O
cohorts,O
with,O
ICH,I-Entity
and,O
ischemic,B-Entity
stroke,I-Entity
(,O
IS)/transient,B-Entity
ischemic,I-Entity
attack,I-Entity
(,O
TIA,I-Entity
),O
.,O
:,O
We,O
performed,O
a,O
systematic,O
review,O
of,O
published,O
and,O
unpublished,O
data,O
from,O
cohorts,O
with,O
stroke,I-Entity
or,O
TIA,I-Entity
to,O
compare,O
the,O
presence,O
of,O
MB,I-Entity
in,O
:,O
(,O
1,O
),O
antithrombotic,O
users,O
vs,O
nonantithrombotic,O
users,O
with,O
ICH,I-Entity
;,O
(,O
2,O
),O
antithrombotic,O
users,O
vs,O
nonusers,O
with,O
IS,I-Entity
/,O
TIA,I-Entity
;,O
and,O
(,O
3,O
),O
ICH,I-Entity
vs,O
ischemic,I-Entity
events,O
stratified,O
by,O
antithrombotic,O
use,O
.,O
We,O
also,O
analyzed,O
published,O
and,O
unpublished,O
follow,O
-,O
up,O
data,O
to,O
determine,O
the,O
risk,O
of,O
ICH,I-Entity
in,O
antithrombotic,O
users,O
with,O
MB,I-Entity
.,O
In,O
a,O
pooled,O
analysis,O
of,O
1460,O
ICH,I-Entity
and,O
3817,O
IS,I-Entity
/,O
TIA,I-Entity
",",O
MB,I-Entity
were,O
more,O
frequent,O
in,O
ICH,I-Entity
vs,O
IS,I-Entity
/,O
TIA,I-Entity
in,O
all,O
treatment,O
groups,O
",",O
but,O
the,O
excess,O
increased,O
from,O
2.8,O
(,O
odds,O
ratio,O
;,O
range,O
",",O
2.3,O
-,O
3.5,O
),O
in,O
nonantithrombotic,O
users,O
to,O
5.7,O
(,O
range,O
",",O
3.4,O
-,O
9.7,O
),O
in,O
antiplatelet,O
users,O
and,O
8.0,O
(,O
range,O
",",O
3.5,O
-,O
17.8,O
),O
in,O
warfarin,I-Entity
users,O
(,O
P,O
difference=0.01,O
),O
.,O
There,O
was,O
also,O
an,O
excess,O
of,O
MB,I-Entity
in,O
warfarin,I-Entity
users,O
vs,O
nonusers,O
with,O
ICH,I-Entity
(,O
OR,O
",",O
2.7,O
;,O
95%,O
CI,O
",",O
1.6,O
-,O
4.4,O
;,O
P<0.001,O
),O
but,O
none,O
in,O
warfarin,I-Entity
users,O
with,O
IS,I-Entity
/,O
TIA,I-Entity
(,O
OR,O
",",O
1.3,O
;,O
95%,O
CI,O
",",O
0.9,O
-,O
1.7,O
;,O
P=0.33,O
;,O
P,O
difference=0.01,O
),O
.,O
There,O
was,O
a,O
smaller,O
excess,O
of,O
MB,I-Entity
in,O
antiplatelet,O
users,O
vs,O
nonusers,O
with,O
ICH,I-Entity
(,O
OR,O
",",O
1.7,O
;,O
95%,O
CI,O
",",O
1.3,O
-,O
2.3,O
;,O
P<0.001,O
),O
",",O
but,O
findings,O
were,O
similar,O
for,O
antiplatelet,O
users,O
with,O
IS,I-Entity
/,O
TIA,I-Entity
(,O
OR,O
",",O
1.4,O
;,O
95%,O
CI,O
",",O
1.2,O
-,O
1.7,O
;,O
P<0.001,O
;,O
P,O
difference=0.25,O
),O
.,O
In,O
pooled,O
follow,O
-,O
up,O
data,O
for,O
768,O
antithrombotic,O
users,O
",",O
presence,O
of,O
MB,I-Entity
at,O
baseline,O
was,O
associated,O
with,O
a,O
substantially,O
increased,O
risk,O
of,O
subsequent,O
ICH,I-Entity
(,O
OR,O
",",O
12.1,O
;,O
95%,O
CI,O
",",O
3.4,O
-,O
42.5,O
;,O
P<0.001,O
),O
.,O
The,O
excess,O
of,O
MB,I-Entity
in,O
warfarin,I-Entity
users,O
with,O
ICH,I-Entity
compared,O
to,O
other,O
groups,O
suggests,O
that,O
MB,I-Entity
increase,O
the,O
risk,O
of,O
warfarin,I-Entity
-,O
associated,O
ICH,I-Entity
.,O
Verapamil,I-Entity
stimulation,O
test,O
in,O
hyperprolactinemia,I-Entity
:,O
loss,O
of,O
prolactin,O
response,O
in,O
anatomic,O
or,O
functional,O
stalk,O
effect,O
.,O
Verapamil,I-Entity
stimulation,O
test,O
was,O
previously,O
investigated,O
as,O
a,O
tool,O
for,O
differential,O
diagnosis,O
of,O
hyperprolactinemia,I-Entity
",",O
but,O
with,O
conflicting,O
results,O
.,O
Macroprolactinemia,I-Entity
was,O
never,O
considered,O
in,O
those,O
previous,O
studies,O
.,O
Here,O
",",O
we,O
aimed,O
to,O
re,O
-,O
investigate,O
the,O
diagnostic,O
value,O
of,O
verapamil,I-Entity
in,O
a,O
population,O
who,O
were,O
all,O
screened,O
for,O
macroprolactinemia,I-Entity
.,O
Prolactin,O
responses,O
to,O
verapamil,I-Entity
in,O
65,O
female,O
patients,O
(,O
age,O
:,O
29.9,O
+,O
/-,O
8.1,O
years,O
),O
with,O
hyperprolactinemia,I-Entity
were,O
tested,O
in,O
a,O
descriptive,O
",",O
matched,O
case,O
-,O
control,O
study,O
.,O
METHODS,O
:,O
Verapamil,I-Entity
80,O
mg,O
",",O
p.o,O
.,O
Verapamil,I-Entity
responsiveness,O
was,O
determined,O
by,O
peak,O
percent,O
change,O
in,O
basal,O
prolactin,O
levels,O
(,O
PRL,O
),O
.,O
Verapamil,I-Entity
significantly,O
increased,O
PRL,O
levels,O
in,O
healthy,O
controls,O
(,O
N.,O
8,O
",",O
PRL,O
:,O
183%,O
),O
",",O
macroprolactinoma,I-Entity
(,O
N.,O
8,O
",",O
PRL,O
:,O
7%,O
),O
",",O
microprolactinoma,I-Entity
(,O
N.,O
19,O
",",O
PRL,O
:,O
21%,O
),O
",",O
macroprolactinemia,I-Entity
but,O
not,O
in,O
pseudoprolactinoma,I-Entity
(,O
N.,O
8,O
",",O
PRL,O
:,O
0.8%,O
),O
",",O
and,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
(,O
N.,O
7,O
",",O
ROC,O
curve,O
analysis,O
revealed,O
that,O
unresponsiveness,O
to,O
verapamil,I-Entity
defined,O
as,O
PRL,O
<,O
0.001,O
",",O
CI,O
:,O
0.768,O
-,O
0.942,O
),O
associated,O
with,O
pseudoprolactinoma,I-Entity
or,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
",",O
respectively,O
.,O
CONCLUSION,O
:,O
Verapamil,I-Entity
responsiveness,O
is,O
not,O
a,O
reliable,O
finding,O
for,O
the,O
differential,O
diagnosis,O
of,O
hyperprolactinemia,I-Entity
.,O
However,O
",",O
verapamil,I-Entity
unresponsiveness,O
discriminates,O
stalk,O
effect,O
(,O
i.e.,O
",",O
anatomically,O
or,O
functionally,O
inhibited,O
dopaminergic,O
tonus,O
),O
from,O
other,O
causes,O
of,O
hyperprolactinemia,I-Entity
with,O
varying,O
degrees,O
of,O
responsiveness,O
.,O
The,O
effect,O
of,O
clonidine,I-Entity
",",O
naphazoline,I-Entity
and,O
xylometazoline,I-Entity
on,O
analgesia,O
induced,O
by,O
morphine,I-Entity
",",O
codeine,I-Entity
",",O
fentanyl,I-Entity
and,O
pentazocine,I-Entity
",",O
and,O
on,O
cataleptic,I-Entity
effect,O
of,O
morphine,I-Entity
",",O
codine,I-Entity
and,O
fentanyl,I-Entity
was,O
studied,O
in,O
rats,O
.,O
The,O
biochemical,O
assays,O
on,O
the,O
influence,O
of,O
four,O
analgesics,O
on,O
the,O
brain,O
concentration,O
and,O
turnover,O
of,O
noradrenaline,I-Entity
(,O
NA,I-Entity
),O
were,O
also,O
performed,O
.,O
It,O
was,O
found,O
that,O
three,O
drugs,O
stimulating,O
central,O
NA,I-Entity
receptors,O
failed,O
to,O
affect,O
the,O
analgesic,O
ED50,O
of,O
all,O
antinociceptive,O
agents,O
and,O
they,O
enhanced,O
catalepsy,I-Entity
induced,O
by,O
morphine,I-Entity
and,O
fentanyl,I-Entity
.,O
Codeine,I-Entity
catalepsy,I-Entity
was,O
increased,O
by,O
clonidine,I-Entity
and,O
decreased,O
by,O
naphazoline,I-Entity
and,O
xylometazoline,I-Entity
.,O
The,O
brain,O
concentration,O
of,O
NA,I-Entity
was,O
not,O
changed,O
by,O
morphine,I-Entity
and,O
fentanyl,I-Entity
",",O
but,O
one,O
of,O
the,O
doses,O
of,O
codeine,I-Entity
(,O
45,O
mg,O
/,O
kg,O
),O
slightly,O
enhanced,O
it,O
.,O
Pentazocine,I-Entity
dose,O
-,O
dependently,O
decreased,O
the,O
brain,O
level,O
of,O
NA,I-Entity
.,O
The,O
rate,O
of,O
NA,I-Entity
turnover,O
was,O
not,O
altered,O
by,O
analgesics,O
except,O
for,O
the,O
higher,O
dose,O
of,O
fentanyl,I-Entity
(,O
0.2,O
mg,O
/,O
kg,O
),O
following,O
which,O
the,O
disappearance,O
of,O
NA,I-Entity
from,O
the,O
brain,O
was,O
diminished,O
.,O
It,O
is,O
suggested,O
that,O
in,O
rats,O
the,O
brain,O
NA,I-Entity
plays,O
a,O
less,O
important,O
function,O
than,O
the,O
other,O
monoamines,I-Entity
in,O
the,O
behavioural,O
activity,O
of,O
potent,O
analgesics,O
.,O
Modification,O
by,O
propranolol,I-Entity
of,O
cardiovascular,O
effects,O
of,O
induced,O
hypoglycaemia,I-Entity
.,O
The,O
cardiovascular,O
effects,O
of,O
hypoglycaemia,I-Entity
",",O
with,O
and,O
without,O
beta,O
-,O
blockade,O
",",O
were,O
compared,O
in,O
fourteen,O
healthy,O
men,O
.,O
Eight,O
received,O
insulin,O
alone,O
",",O
and,O
eight,O
",",O
including,O
two,O
of,O
the,O
original,O
insulin,O
-,O
only,O
group,O
",",O
were,O
given,O
propranolol,I-Entity
and,O
insulin,O
.,O
In,O
the,O
insulin,O
-,O
group,O
the,O
period,O
of,O
hypoglycaemia,I-Entity
was,O
associated,O
with,O
an,O
increase,O
in,O
heart,O
-,O
rate,O
and,O
a,O
fall,O
in,O
diastolic,O
blood,O
-,O
pressure,O
.,O
In,O
the,O
propranolol,I-Entity
-,O
insulin,O
group,O
there,O
was,O
a,O
significant,O
fall,O
in,O
heart,O
-,O
rate,O
in,O
most,O
subjects,O
and,O
an,O
increase,O
in,O
diastolic,O
pressure,O
.,O
/,O
T,O
changes,O
occurred,O
in,O
the,O
insulin,O
-,O
group,O
but,O
in,O
none,O
of,O
the,O
propranolol,I-Entity
-,O
insulin,O
group,O
.,O
Hypertension,I-Entity
in,O
diabetics,I-Entity
prone,O
to,O
hypoglycaemia,I-Entity
attacks,O
should,O
not,O
be,O
treated,O
with,O
beta,O
-,O
blockers,O
because,O
these,O
drugs,O
may,O
cause,O
a,O
sharp,O
rise,O
in,O
blood,O
-,O
pressure,O
in,O
such,O
patients,O
.,O
Prevention,O
and,O
treatment,O
of,O
endometrial,B-Entity
disease,I-Entity
in,O
climacteric,O
women,O
receiving,O
oestrogen,I-Entity
therapy,O
.,O
The,O
treatment,O
regimens,O
are,O
described,O
in,O
74,O
patients,O
with,O
endometrial,B-Entity
disease,I-Entity
among,O
850,O
climacteric,O
women,O
receiving,O
oestrogen,I-Entity
therapy,O
.,O
Cystic,O
hyperplasia,I-Entity
was,O
associated,O
with,O
unopposed,O
oestrogen,I-Entity
therapy,O
without,O
progestagen,I-Entity
.,O
Two,O
courses,O
of,O
21,O
days,O
of,O
5,O
mg,O
norethisterone,I-Entity
daily,O
caused,O
reversion,O
to,O
normal,O
in,O
all,O
57,O
cases,O
of,O
cystic,O
hyperplasia,I-Entity
and,O
6,O
of,O
the,O
8,O
cases,O
of,O
atypical,O
hyperplasia,I-Entity
.,O
4,O
cases,O
of,O
endometrial,B-Entity
carcinoma,I-Entity
referred,O
from,O
elsewhere,O
demonstrated,O
the,O
problems,O
of,O
inappropriate,O
and,O
unsupervised,O
unopposed,O
oestrogen,I-Entity
therapy,O
and,O
the,O
difficulty,O
in,O
distinguishing,O
severe,O
hyperplasia,I-Entity
from,O
malignancy,I-Entity
.,O
Cyclical,O
low,O
-,O
dose,O
oestrogen,I-Entity
therapy,O
with,O
7,O
-,O
-13,O
days,O
of,O
progestagen,I-Entity
does,O
not,O
seem,O
to,O
increase,O
the,O
risk,O
of,O
endometrial,B-Entity
hyperplasia,I-Entity
or,O
carcinoma,I-Entity
.,O
Pure,B-Entity
red,I-Entity
cell,I-Entity
aplasia,I-Entity
",",O
toxic,B-Entity
dermatitis,I-Entity
and,O
lymphadenopathy,I-Entity
in,O
a,O
patient,O
taking,O
diphenylhydantoin,I-Entity
.,O
A,O
patient,O
taking,O
diphenylhydantoin,I-Entity
for,O
3,O
weeks,O
developed,O
a,O
generalized,O
skin,B-Entity
rash,I-Entity
",",O
lymphadenopathy,I-Entity
and,O
pure,B-Entity
red,I-Entity
cell,I-Entity
aplasia,I-Entity
.,O
Skin,B-Entity
rash,I-Entity
is,O
a,O
well,O
-,O
known,O
complication,O
of,O
diphenylhydantoin,I-Entity
treatment,O
as,O
is,O
benign,O
and,O
malignant,O
lymphadenopathy,I-Entity
.,O
Pure,B-Entity
red,I-Entity
cell,I-Entity
aplasia,I-Entity
associated,O
with,O
diphenylhydantoin,I-Entity
medication,O
has,O
been,O
reported,O
in,O
3,O
patients,O
.,O
The,O
exact,O
mechanism,O
by,O
which,O
diphenylhydantoin,I-Entity
exerts,O
its,O
toxic,O
effects,O
is,O
not,O
known,O
.,O
In,O
this,O
patient,O
the,O
time,O
relation,O
between,O
the,O
ingestion,O
of,O
diphenylhydantoin,I-Entity
and,O
the,O
occurrence,O
of,O
the,O
skin,B-Entity
rash,I-Entity
",",O
lymphadenopathy,I-Entity
and,O
pure,B-Entity
red,I-Entity
cell,I-Entity
aplasia,I-Entity
is,O
very,O
suggestive,O
of,O
a,O
direct,O
connection,O
.,O
Continuous,O
infusion,O
tobramycin,I-Entity
combined,O
with,O
carbenicillin,I-Entity
for,O
infections,I-Entity
in,O
cancer,I-Entity
patients,O
.,O
The,O
cure,O
rate,O
of,O
infections,I-Entity
in,O
cancer,I-Entity
patients,O
is,O
adversely,O
affected,O
by,O
neutropenia,I-Entity
(,O
less,O
than,O
"1,000/mm3",O
),O
.,O
In,O
particular,O
",",O
patients,O
with,O
severe,O
neutropenia,I-Entity
(,O
less,O
than,O
100/mm3,O
),O
have,O
shown,O
a,O
poor,O
response,O
to,O
antibiotics,O
.,O
To,O
overcome,O
the,O
adverse,O
effects,O
of,O
neutropenia,I-Entity
",",O
tobramycin,I-Entity
was,O
given,O
by,O
continuous,O
infusion,O
and,O
combined,O
with,O
intermittent,O
carbenicillin,I-Entity
.,O
Tobramycin,I-Entity
was,O
given,O
to,O
a,O
total,O
daily,O
dose,O
of,O
300,O
mg,O
/,O
m2,O
and,O
carbenicillin,I-Entity
was,O
given,O
at,O
a,O
dose,O
of,O
5,O
gm,O
every,O
four,O
hours,O
.,O
There,O
were,O
125,O
infectious,O
episodes,O
in,O
116,O
cancer,I-Entity
patients,O
receiving,O
myelosuppressive,O
chemotherapy,O
.,O
Pneumonia,I-Entity
was,O
the,O
most,O
common,O
infection,I-Entity
and,O
61%,O
of,O
59,O
episodes,O
were,O
cured,O
.,O
Gram,O
-,O
negative,O
bacilli,O
were,O
the,O
most,O
common,O
causative,O
organisms,O
and,O
69%,O
of,O
these,O
infections,I-Entity
were,O
cured,O
.,O
The,O
most,O
common,O
pathogen,O
was,O
Klebsiella,O
pneumoniae,I-Entity
and,O
this,O
",",O
together,O
with,O
Escherichia,O
coli,O
and,O
Pseudomonas,O
aeruginosa,O
",",O
accounted,O
for,O
74%,O
of,O
all,O
gram,B-Entity
-,I-Entity
negative,I-Entity
bacillary,I-Entity
infections,I-Entity
.,O
Response,O
was,O
not,O
influenced,O
by,O
the,O
initial,O
neutrophil,O
count,O
",",O
with,O
a,O
62%,O
cure,O
rate,O
for,O
39,O
episodes,O
associated,O
with,O
severe,O
neutropenia,I-Entity
.,O
Azotemia,I-Entity
was,O
the,O
major,O
side,O
effect,O
recognized,O
",",O
and,O
it,O
occurred,O
in,O
11%,O
of,O
episodes,O
.,O
Major,O
azotemia,I-Entity
(,O
serum,O
creatinine,I-Entity
greater,O
than,O
2.5,O
mg,O
/,O
dl,O
or,O
BUN,O
greater,O
than,O
50,O
mg,O
/,O
dl,O
),O
occurred,O
in,O
only,O
2%,O
.,O
Azotemia,I-Entity
was,O
not,O
related,O
to,O
duration,O
of,O
therapy,O
or,O
serum,O
tobramycin,I-Entity
concentration,O
.,O
This,O
antibiotic,O
regimen,O
showed,O
both,O
therapeutic,O
efficacy,O
and,O
acceptable,O
renal,B-Entity
toxicity,I-Entity
for,O
these,O
patients,O
.,O
Recurrent,O
subarachnoid,B-Entity
hemorrhage,I-Entity
associated,O
with,O
aminocaproic,B-Entity
acid,I-Entity
therapy,O
and,O
acute,B-Entity
renal,I-Entity
artery,I-Entity
thrombosis,I-Entity
.,O
Epsilon,B-Entity
aminocaproic,I-Entity
acid,I-Entity
(,O
EACA,I-Entity
),O
has,O
been,O
used,O
to,O
prevent,O
rebleeding,O
in,O
patients,O
with,O
subarachnoid,B-Entity
hemorrhage,I-Entity
(,O
SAH,I-Entity
),O
.,O
Although,O
this,O
agent,O
does,O
decrease,O
the,O
frequency,O
of,O
rebleeding,O
",",O
several,O
reports,O
have,O
described,O
thrombotic,I-Entity
complications,O
of,O
EACA,I-Entity
therapy,O
.,O
These,O
complications,O
have,O
included,O
clinical,O
deterioration,O
and,O
intracranial,B-Entity
vascular,I-Entity
thrombosis,I-Entity
in,O
patients,O
with,O
SAH,I-Entity
",",O
arteriolar,O
and,O
capillary,O
fibrin,O
thrombi,I-Entity
in,O
patients,O
with,O
fibrinolytic,O
syndromes,O
treated,O
with,O
EACA,I-Entity
",",O
or,O
other,O
thromboembolic,B-Entity
phenomena,I-Entity
.,O
Since,O
intravascular,O
fibrin,O
thrombi,I-Entity
are,O
often,O
observed,O
in,O
patients,O
with,O
fibrinolytic,O
disorders,O
",",O
EACA,I-Entity
should,O
not,O
be,O
implicated,O
in,O
the,O
pathogenesis,O
of,O
fibrin,O
thrombi,I-Entity
in,O
patients,O
with,O
disseminated,B-Entity
intravascular,I-Entity
coagulation,I-Entity
or,O
other,O
"""",O
consumption,B-Entity
coagulopathies,I-Entity
.,O
"""",O
This,O
report,O
describes,O
subtotal,O
infarction,I-Entity
of,O
the,O
kidney,O
due,O
to,O
thrombosis,B-Entity
of,I-Entity
a,I-Entity
normal,I-Entity
renal,I-Entity
artery,I-Entity
.,O
This,O
occlusion,O
occurred,O
after,O
EACA,I-Entity
therapy,O
in,O
a,O
patient,O
with,O
SAH,I-Entity
and,O
histopathological,O
documentation,O
of,O
recurrent,O
SAH,I-Entity
.,O
The,O
corresponding,O
clinical,O
event,O
was,O
characterized,O
by,O
marked,O
hypertension,I-Entity
and,O
abrupt,O
neurological,O
deterioration,O
.,O
Long,O
-,O
term,O
propranolol,I-Entity
therapy,O
in,O
pregnancy,O
:,O
maternal,O
and,O
fetal,O
outcome,O
.,O
Propranolol,I-Entity
",",O
a,O
beta,O
-,O
adrenergic,O
blocking,O
agent,O
",",O
has,O
found,O
an,O
important,O
position,O
in,O
the,O
practice,O
of,O
medicine,O
.,O
Ten,O
patients,O
and,O
12,O
pregnancies,O
are,O
reported,O
where,O
chronic,O
propranolol,I-Entity
has,O
been,O
administered,O
.,O
Five,O
patients,O
with,O
serial,O
pregnancies,O
with,O
and,O
without,O
propranolol,I-Entity
therapy,O
are,O
also,O
examined,O
.,O
We,O
conclude,O
that,O
previously,O
reported,O
hypoglycemia,I-Entity
",",O
hyperbilirubinemia,I-Entity
",",O
polycythemia,I-Entity
",",O
neonatal,B-Entity
apnea,I-Entity
",",O
and,O
bradycardia,I-Entity
are,O
not,O
invariable,O
and,O
can,O
not,O
be,O
statistically,O
correlated,O
with,O
chronic,O
propranolol,I-Entity
therapy,O
.,O
Growth,B-Entity
retardation,I-Entity
",",O
however,O
",",O
appears,O
to,O
be,O
significant,O
in,O
both,O
of,O
our,O
series,O
.,O
Use,O
of,O
propranolol,I-Entity
in,O
the,O
treatment,O
of,O
idiopathic,B-Entity
orthostatic,I-Entity
hypotension,I-Entity
.,O
Five,O
patients,O
with,O
idiopathic,B-Entity
orthostatic,I-Entity
hypotension,I-Entity
who,O
had,O
physiologic,O
and,O
biochemical,O
evidence,O
of,O
severe,O
autonomic,O
dysfunction,O
were,O
included,O
in,O
the,O
study,O
.,O
They,O
all,O
exhibited,O
markedly,O
reduced,O
plasma,O
catecholamines,I-Entity
and,O
plasma,O
renin,O
activity,O
in,O
both,O
recumbent,O
and,O
upright,O
positions,O
and,O
had,O
marked,O
hypersensitivity,I-Entity
to,O
the,O
pressor,O
effects,O
of,O
infused,O
norepinephrine,I-Entity
.,O
Treatment,O
with,O
propanolol,I-Entity
administered,O
intravenously,O
(,O
1,O
-,O
5,O
mg,O
),O
produced,O
increases,O
in,O
supine,O
and,O
upright,O
blood,O
pressure,O
in,O
4,O
of,O
the,O
5,O
individuals,O
with,O
rises,O
ranging,O
from,O
11/6,O
to,O
22/11,O
mmHg,O
.,O
Chronic,O
oral,O
administration,O
of,O
propranolol,I-Entity
(,O
40,O
-,O
160,O
mg,O
/,O
day,O
),O
also,O
elevated,O
the,O
blood,O
pressures,O
of,O
these,O
individuals,O
with,O
increases,O
in,O
the,O
order,O
of,O
20,O
-,O
35/15,O
-,O
25,O
mmg,O
being,O
observed,O
.,O
In,O
1,O
patient,O
",",O
marked,O
hypertension,I-Entity
was,O
induced,O
by,O
propranolol,I-Entity
and,O
the,O
drug,O
had,O
to,O
be,O
withdrawn,O
.,O
Hemodynamic,O
measurements,O
in,O
1,O
of,O
the,O
patients,O
demonstrated,O
an,O
increase,O
in,O
total,O
peripheral,O
resistance,O
and,O
essentially,O
no,O
change,O
in,O
cardiac,O
output,O
following,O
propranolol,I-Entity
therapy,O
.,O
The,O
studies,O
suggest,O
that,O
propranolol,I-Entity
is,O
a,O
useful,O
drug,O
in,O
selected,O
patients,O
with,O
severe,O
idiopathic,B-Entity
orthostatic,I-Entity
hypotension,I-Entity
.,O
Total,O
intravenous,O
anesthesia,O
with,O
etomidate,I-Entity
.,O
An,O
investigation,O
was,O
undertaken,O
to,O
determine,O
the,O
dosage,O
of,O
etomidate,I-Entity
required,O
to,O
maintain,O
sleep,O
in,O
adults,O
undergoing,O
surgery,O
under,O
regional,O
local,O
anesthesia,O
.,O
Premedication,O
of,O
diazepam,I-Entity
10,O
mg,O
and,O
atropine,I-Entity
0.5,O
mg,O
was,O
given,O
",",O
and,O
sleep,O
was,O
induced,O
and,O
maintained,O
by,O
intermittent,O
intravenous,O
injections,O
of,O
etomidate,I-Entity
0.1/mg,O
/,O
kg,O
",",O
given,O
whenever,O
the,O
patient,O
would,O
open,O
his,O
eyes,O
on,O
request,O
.,O
A,O
mean,O
overall,O
dose,O
of,O
etomidate,I-Entity
17.4,O
microgram,O
/,O
kg,O
/,O
min,O
.,O
The,O
investigation,O
was,O
discontinued,O
after,O
18,O
patients,O
because,O
of,O
the,O
frequency,O
and,O
intensity,O
of,O
side,O
-,O
effects,O
",",O
particularly,O
pain,I-Entity
and,O
myoclonia,I-Entity
",",O
which,O
caused,O
the,O
technique,O
to,O
be,O
abandoned,O
in,O
two,O
cases,O
.,O
It,O
is,O
considered,O
unlikely,O
that,O
etomidate,I-Entity
will,O
prove,O
to,O
be,O
the,O
hypnotic,O
of,O
choice,O
for,O
a,O
totally,O
intravenous,O
anesthetic,O
technique,O
in,O
adults,O
because,O
of,O
the,O
high,O
incidence,O
of,O
myoclonia,I-Entity
after,O
prolonged,O
administration,O
.,O
A,O
method,O
for,O
the,O
measurement,O
of,O
tremor,I-Entity
",",O
and,O
a,O
comparison,O
of,O
the,O
effects,O
of,O
tocolytic,O
beta,O
-,O
mimetics,O
.,O
A,O
method,O
permitting,O
measurement,O
of,O
finger,O
tremor,I-Entity
as,O
a,O
displacement,O
-,O
time,O
curve,O
is,O
described,O
",",O
using,O
a,O
test,O
system,O
with,O
simple,O
amplitude,O
calibration,O
.,O
By,O
means,O
of,O
a,O
computer,O
program,O
",",O
periods,O
and,O
amplitudes,O
of,O
tremor,I-Entity
oscillations,O
were,O
calculated,O
and,O
classified,O
.,O
The,O
actions,O
of,O
fenoterol,B-Entity
-,I-Entity
hydrobromide,I-Entity
",",O
ritodrin,B-Entity
-,I-Entity
HCl,I-Entity
and,O
placebo,O
given,O
to,O
10,O
healthy,O
subjects,O
by,O
intravenous,O
infusion,O
in,O
a,O
double,O
-,O
blind,O
crossover,O
study,O
were,O
tested,O
by,O
this,O
method,O
.,O
At,O
therapeutic,O
doses,O
both,O
substances,O
raised,O
the,O
mean,O
tremor,I-Entity
amplitude,O
to,O
about,O
three,O
times,O
the,O
control,O
level,O
.,O
After,O
the,O
end,O
of,O
fenoterol,B-Entity
-,I-Entity
hydrobromide,I-Entity
infusion,O
",",O
tremor,I-Entity
amplitudes,O
decreased,O
significantly,O
faster,O
than,O
those,O
following,O
ritodrin,B-Entity
-,I-Entity
HCl,I-Entity
infusion,O
.,O
Bilateral,O
retinal,B-Entity
artery,I-Entity
and,I-Entity
choriocapillaris,I-Entity
occlusion,I-Entity
following,O
the,O
injection,O
of,O
long,O
-,O
acting,O
corticosteroid,I-Entity
suspensions,O
in,O
combination,O
with,O
other,O
drugs,O
:,O
I.,O
Clinical,O
studies,O
.,O
Two,O
well,O
-,O
documented,O
cases,O
of,O
bilateral,O
retinal,B-Entity
artery,I-Entity
and,I-Entity
choriocapillaris,I-Entity
occlusions,I-Entity
with,O
blindness,I-Entity
following,O
head,O
and,O
neck,O
soft,O
-,O
tissue,O
injection,O
with,O
methylprednisolone,B-Entity
acetate,I-Entity
in,O
combination,O
with,O
lidocaine,I-Entity
",",O
epinephrine,I-Entity
",",O
or,O
penicillin,I-Entity
are,O
reported,O
.,O
The,O
acute,O
observations,O
included,O
hazy,O
sensorium,O
",",O
superior,O
gaze,O
palsy,I-Entity
",",O
pupillary,B-Entity
abnormalities,I-Entity
",",O
and,O
conjunctival,O
hemorrhages,I-Entity
with,O
edema,I-Entity
.,O
Follow,O
-,O
up,O
changes,O
showed,O
marked,O
visual,B-Entity
loss,I-Entity
",",O
constricted,O
visual,O
fields,O
",",O
optic,O
nerve,O
pallor,O
",",O
vascular,O
attenuation,O
",",O
and,O
chorioretinal,B-Entity
atrophy,I-Entity
.,O
Cephalothin,I-Entity
-,O
induced,O
immune,O
hemolytic,B-Entity
anemia,I-Entity
.,O
A,O
patient,O
with,O
renal,B-Entity
disease,I-Entity
developed,O
Coombs,O
-,O
positive,O
hemolytic,B-Entity
anemia,I-Entity
while,O
receiving,O
cephalothin,I-Entity
therapy,O
.,O
An,O
anti,O
-,O
cephalothin,I-Entity
IgG,O
antibody,O
was,O
detected,O
in,O
the,O
patient,O
's,O
serum,O
and,O
in,O
the,O
eluates,O
from,O
her,O
erythrocytes,O
.,O
In,O
addition,O
",",O
nonimmunologic,O
binding,O
of,O
normal,O
and,O
patient,O
's,O
serum,O
proteins,O
to,O
her,O
own,O
and,O
cephalothin,I-Entity
-,O
coated,O
normal,O
red,O
cells,O
was,O
demonstrated,O
.,O
Skin,O
tests,O
and,O
in,O
vitro,O
lymphocyte,O
stimulation,O
revealed,O
that,O
the,O
patient,O
was,O
sensitized,O
to,O
cephalothin,I-Entity
and,O
also,O
to,O
ampicillin,I-Entity
.,O
Careful,O
investigation,O
of,O
drug,O
-,O
induced,O
hemolytic,B-Entity
anemias,I-Entity
reveals,O
the,O
complexity,O
of,O
the,O
immune,O
mechanisms,O
involved,O
.,O
Kaliuretic,O
effect,O
of,O
L,B-Entity
-,I-Entity
dopa,I-Entity
treatment,O
in,O
parkinsonian,I-Entity
patients,O
.,O
Hypokalemia,I-Entity
",",O
sometimes,O
severe,O
",",O
was,O
observed,O
in,O
some,O
L,B-Entity
-,I-Entity
dopa,I-Entity
-,O
treated,O
parkinsonian,I-Entity
patients,O
.,O
The,O
influence,O
of,O
L,B-Entity
-,I-Entity
dopa,I-Entity
on,O
the,O
renal,O
excretion,O
of,O
potassium,I-Entity
was,O
studied,O
in,O
3,O
patients,O
with,O
hypokalemia,I-Entity
and,O
in,O
5,O
normokalemic,O
patients,O
by,O
determination,O
of,O
renal,O
plasma,O
flow,O
",",O
glomerular,O
filtration,O
rate,O
",",O
plasma,O
concentration,O
of,O
potassium,I-Entity
and,O
sodium,I-Entity
as,O
well,O
as,O
urinary,O
excretion,O
of,O
potassium,I-Entity
",",O
sodium,I-Entity
and,O
aldosterone,I-Entity
.,O
L,B-Entity
-,I-Entity
Dopa,I-Entity
intake,O
was,O
found,O
to,O
cause,O
an,O
increased,O
excretion,O
of,O
potassium,I-Entity
",",O
and,O
sometimes,O
also,O
of,O
sodium,I-Entity
",",O
in,O
the,O
hypokalemic,O
but,O
not,O
in,O
the,O
normokalemic,O
patients,O
.,O
It,O
is,O
not,O
known,O
why,O
this,O
effect,O
occurred,O
in,O
some,O
individuals,O
but,O
not,O
in,O
others,O
",",O
but,O
our,O
results,O
indicate,O
a,O
correlation,O
between,O
aldosterone,I-Entity
production,O
and,O
this,O
renal,O
effect,O
of,O
L,B-Entity
-,I-Entity
dopa,I-Entity
.,O
Phenytoin,I-Entity
encephalopathy,I-Entity
as,O
probable,O
idiosyncratic,O
reaction,O
:,O
case,O
report,O
.,O
A,O
case,O
of,O
phenytoin,I-Entity
(,O
DPH,I-Entity
),O
encephalopathy,I-Entity
with,O
increasing,O
seizures,I-Entity
and,O
EEG,O
and,O
mental,O
changes,O
is,O
described,O
.,O
Despite,O
adequate,O
oral,O
dosage,O
of,O
DPH,I-Entity
(,O
5,O
mg,O
/,O
kg,O
/,O
daily,O
),O
the,O
plasma,O
level,O
was,O
very,O
low,O
(,O
2.8,O
microgramg,O
/,O
ml,O
),O
.,O
The,O
encephalopathy,I-Entity
was,O
probably,O
an,O
idiosyncratic,O
and,O
not,O
toxic,O
or,O
allergic,O
reaction,O
.,O
In,O
fact,O
the,O
concentration,O
of,O
free,O
DPH,I-Entity
was,O
normal,O
",",O
the,O
patient,O
presented,O
a,O
retarded,O
morbilliform,O
rash,I-Entity
during,O
DPH,I-Entity
treatment,O
",",O
the,O
protidogram,O
was,O
normal,O
",",O
and,O
an,O
intradermic,O
DPH,I-Entity
injection,O
had,O
no,O
local,O
effect,O
.,O
The,O
authors,O
conclude,O
that,O
in,O
a,O
patient,O
starting,O
DPH,I-Entity
treatment,O
an,O
unexpected,O
increase,O
in,O
seizures,I-Entity
",",O
with,O
EEG,O
and,O
mental,O
changes,O
occurring,O
simultaneously,O
",",O
should,O
alert,O
the,O
physician,O
to,O
the,O
possible,O
need,O
for,O
eliminating,O
DPH,I-Entity
from,O
the,O
therapeutic,O
regimen,O
",",O
even,O
if,O
plasma,O
concentrations,O
are,O
low,O
.,O
Effects,O
of,O
exercise,O
on,O
the,O
severity,O
of,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
.,O
The,O
effect,O
of,O
exercise,O
on,O
the,O
severity,O
of,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
was,O
studied,O
in,O
male,O
rats,O
.,O
The,O
exercise,O
-,O
isoproterenol,I-Entity
(,O
E-1,O
),O
and,O
exercise,O
control,O
(,O
EC,O
),O
groups,O
exercised,O
daily,O
for,O
thirty,O
days,O
on,O
a,O
treadmill,O
at,O
1,O
mph,O
",",O
2%,O
grade,O
while,O
animals,O
of,O
the,O
sedentary,O
-,O
isoproterenol,I-Entity
(,O
S,O
-,O
I,O
),O
group,O
remained,O
sedentary,O
.,O
Forty,O
-,O
eight,O
hours,O
after,O
the,O
final,O
exercise,O
period,O
",",O
S,O
-,O
I,O
and,O
E,O
-,O
I,O
animals,O
received,O
a,O
single,O
subcutaneous,O
injection,O
of,O
isoproterenol,I-Entity
(,O
250,O
mg,O
/,O
kg,O
body,O
weight,O
),O
.,O
Animals,O
of,O
the,O
S,O
-,O
I,O
group,O
exhibited,O
significantly,O
(,O
Pp,O
less,O
than,O
0.05,O
),O
greater,O
mortality,O
from,O
the,O
effects,O
of,O
isoproterenol,I-Entity
than,O
animals,O
of,O
the,O
E,O
-,O
I,O
group,O
.,O
Serum,O
CPK,O
activity,O
for,O
E,O
-,O
I,O
animals,O
was,O
significantly,O
(,O
p,O
less,O
than,O
0.05,O
),O
greater,O
than,O
for,O
animals,O
in,O
the,O
S,O
-,O
I,O
and,O
EC,O
groups,O
twenty,O
hours,O
following,O
isoproterenol,I-Entity
injection,O
.,O
No,O
statistically,O
significant,O
differences,O
were,O
observed,O
between,O
the,O
two,O
isoproterenol,I-Entity
treated,O
groups,O
for,O
severity,O
of,O
the,O
induced,O
lesions,O
",",O
changes,O
in,O
heart,O
weight,O
",",O
or,O
heart,O
weight,O
to,O
body,O
weight,O
ratios,O
.,O
The,O
results,O
indicated,O
that,O
exercise,O
reduced,O
the,O
mortality,O
associated,O
with,O
the,O
effects,O
of,O
large,O
dosages,O
of,O
isoproterenol,I-Entity
but,O
had,O
little,O
on,O
the,O
severity,O
of,O
the,O
infarction,I-Entity
.,O
Effect,O
of,O
D,B-Entity
-,I-Entity
Glucarates,I-Entity
on,O
basic,O
antibiotic,O
-,O
induced,O
renal,B-Entity
damage,I-Entity
in,O
rats,O
.,O
Dehydrated,I-Entity
rats,O
regularly,O
develop,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
following,O
single,O
injection,O
of,O
aminoglycoside,I-Entity
antibiotics,O
combined,O
with,O
dextran,O
or,O
of,O
antibiotics,O
only,O
.,O
Oral,O
administration,O
of,O
"2,5-di",B-Entity
-,I-Entity
O,I-Entity
-,I-Entity
acetyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
"glucaro-1,4",I-Entity
-,I-Entity
"6,3-dilactone",I-Entity
protected,O
rats,O
against,O
renal,B-Entity
failure,I-Entity
induced,O
by,O
kanamycin,I-Entity
-,O
dextran,O
.,O
The,O
protective,O
effect,O
was,O
prevalent,O
among,O
D,B-Entity
-,I-Entity
glucarates,I-Entity
",",O
and,O
also,O
to,O
other,O
saccharic,B-Entity
acid,I-Entity
",",O
hexauronic,B-Entity
acids,I-Entity
and,O
hexaaldonic,B-Entity
acids,I-Entity
",",O
although,O
to,O
a,O
lesser,O
degree,O
",",O
but,O
not,O
to,O
a,O
hexaaldose,O
",",O
sugar,B-Entity
alcohols,I-Entity
",",O
substances,O
inthe,O
TCA,I-Entity
cycle,O
and,O
other,O
acidic,O
compounds,O
.,O
D,B-Entity
-,I-Entity
Glucarates,I-Entity
were,O
effective,O
against,O
renal,B-Entity
damage,I-Entity
induced,O
by,O
peptide,O
antibiotics,O
as,O
well,O
as,O
various,O
aminoglycoside,I-Entity
antibitocis,O
.,O
Dose,O
-,O
responses,O
were,O
observed,O
in,O
the,O
protective,O
effect,O
of,O
D,B-Entity
-,I-Entity
Glucarates,I-Entity
.,O
With,O
a,O
D,B-Entity
-,I-Entity
glucarate,I-Entity
of,O
a,O
fixed,O
size,O
of,O
dose,O
",",O
approximately,O
the,O
same,O
degree,O
of,O
protection,O
was,O
obtained,O
against,O
renal,B-Entity
damages,I-Entity
induced,O
by,O
different,O
basic,O
antibiotics,O
despite,O
large,O
disparities,O
in,O
administration,O
doses,O
of,O
different,O
antibiotics,O
.,O
D,B-Entity
-,I-Entity
Glucarates,I-Entity
had,O
the,O
ability,O
to,O
prevent,O
renal,B-Entity
damage,I-Entity
but,O
not,O
to,O
cure,O
it,O
.,O
Rats,O
excreted,O
acidic,O
urine,O
when,O
they,O
were,O
spared,O
from,O
renal,B-Entity
lesions,I-Entity
by,O
monosaccharides,I-Entity
.,O
The,O
reduction,O
effect,O
of,O
D,B-Entity
-,I-Entity
glucarates,I-Entity
against,O
nephrotoxicity,I-Entity
of,O
basic,O
antibiotics,O
was,O
discussed,O
.,O
Paraplegia,I-Entity
following,O
intrathecal,O
methotrexate,I-Entity
:,O
report,O
of,O
a,O
case,O
and,O
review,O
of,O
the,O
literature,O
.,O
A,O
patient,O
who,O
developed,O
paraplegia,I-Entity
following,O
the,O
intrathecal,O
instillation,O
of,O
methotrexate,I-Entity
is,O
discribed,O
.,O
The,O
following,O
factors,O
appear,O
to,O
predispose,O
to,O
the,O
development,O
of,O
this,O
complication,O
:,O
abnormal,O
cerebrospinal,O
dynamics,O
related,O
to,O
the,O
presence,O
of,O
central,B-Entity
nervous,I-Entity
system,I-Entity
leukemia,I-Entity
",",O
and,O
epidural,O
cerebrospinal,O
leakage,O
;,O
elevated,O
cerebrospinal,O
fluid,O
methothexate,I-Entity
concentration,O
related,O
to,O
abnormal,O
cerebrospinal,O
fluid,O
dynamics,O
and,O
to,O
inappropriately,O
high,O
methotrexate,I-Entity
doses,O
based,O
on,O
body,O
surface,O
area,O
calculations,O
in,O
older,O
children,O
and,O
adults,O
;,O
the,O
presence,O
of,O
neurotoxic,I-Entity
preservatives,O
in,O
commercially,O
available,O
methotrexate,I-Entity
preparations,O
and,O
diluents,O
;,O
and,O
the,O
use,O
of,O
methotrexate,I-Entity
diluents,O
of,O
unphysiologic,O
pH,O
",",O
ionic,O
content,O
and,O
osmolarity,O
.,O
The,O
role,O
of,O
methotrexate,I-Entity
contaminants,O
",",O
local,O
folate,B-Entity
deficiency,I-Entity
",",O
and,O
cranial,O
irradiation,O
in,O
the,O
pathogenesis,O
of,O
intrathecal,O
methotrexate,I-Entity
toxicity,I-Entity
is,O
unclear,O
.,O
The,O
incidence,O
of,O
neurotoxicity,I-Entity
may,O
be,O
reduced,O
by,O
employing,O
lower,O
doses,O
of,O
methotrexate,I-Entity
in,O
the,O
presence,O
of,O
central,B-Entity
nervous,I-Entity
system,I-Entity
leukemia,I-Entity
",",O
in,O
older,O
children,O
and,O
adults,O
",",O
and,O
in,O
the,O
presence,O
of,O
epidural,O
leakage,O
.,O
Only,O
preservative,O
-,O
free,O
methotrexate,I-Entity
in,O
Elliott,O
's,O
B,O
Solution,O
at,O
a,O
concentration,O
of,O
not,O
more,O
than,O
1,O
mg,O
/,O
ml,O
should,O
be,O
used,O
for,O
intrathecal,O
administration,O
.,O
Periodic,O
monitoring,O
of,O
cerebruspinal,O
fluid,O
methotrexate,I-Entity
levels,O
may,O
be,O
predictive,O
of,O
the,O
development,O
of,O
serious,O
neurotoxicity,I-Entity
.,O
Centrally,O
mediated,O
cardiovascular,O
effects,O
of,O
intracisternal,O
application,O
of,O
carbachol,I-Entity
in,O
anesthetized,O
rats,O
.,O
injection,O
of,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
in,O
anesthetized,O
rats,O
was,O
analyzed,O
.,O
injection,O
of,O
guanethidine,I-Entity
(,O
5,O
mg,O
),O
",",O
hexamethonium,I-Entity
(,O
10,O
mg,O
),O
or,O
phentolamine,I-Entity
(,O
5,O
mg,O
),O
",",O
and,O
conversely,O
",",O
potentiated,O
by,O
i.v,O
.,O
desmethylimipramine,I-Entity
(,O
0.3,O
mg,O
),O
",",O
while,O
propranolol,I-Entity
(,O
0.5,O
mg,O
),O
i.v,O
.,O
selectively,O
inhibited,O
the,O
enlargement,B-Entity
of,I-Entity
pulse,I-Entity
pressure,I-Entity
and,O
the,O
tachycardia,I-Entity
following,O
i.c,O
.,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
.,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
was,O
almost,O
completely,O
blocked,O
by,O
i.c,O
.,O
atropine,I-Entity
(,O
3,O
mug,O
),O
or,O
hexamethonium,I-Entity
(,O
500,O
mug,O
),O
",",O
and,O
significantly,O
reduced,O
by,O
i.c,O
.,O
chlorpromazine,I-Entity
(,O
50,O
mug,O
),O
but,O
desmethylimipramine,I-Entity
(,O
30,O
mug,O
),O
.,O
carbachol,I-Entity
(,O
1,O
mug,O
),O
remained,O
unchanged,O
after,O
sectioning,O
of,O
the,O
bilateral,O
cervical,O
vagal,O
nerves,O
but,O
disappeared,O
after,O
sectioning,O
of,O
the,O
spinal,O
cord,O
(,O
C7-C8,O
),O
.,O
carbachol,I-Entity
ortral,O
and,O
peripheral,O
adrenergic,O
mechanisms,O
",",O
and,O
that,O
the,O
sympathetic,O
trunk,O
is,O
the,O
main,O
pathway,O
.,O
Hyperglycemic,I-Entity
effect,O
of,O
amino,I-Entity
compounds,O
structurally,O
related,O
to,O
caproate,I-Entity
in,O
rats,O
.,O
The,O
chronic,O
feeding,O
of,O
small,O
amounts,O
(,O
0.3,O
-,O
3%,O
of,O
diet,O
weight,O
),O
of,O
certain,O
amino,I-Entity
derivatives,O
of,O
caproate,I-Entity
resulted,O
in,O
hyperglycemia,I-Entity
",",O
an,O
elevated,O
glucose,I-Entity
tolerance,O
curve,O
and,O
",",O
occasionally,O
",",O
glucosuria,I-Entity
.,O
Effective,O
compounds,O
included,O
norleucine,I-Entity
",",O
norvaline,I-Entity
",",O
glutamate,I-Entity
",",O
epsilon,B-Entity
-,I-Entity
aminocaproate,I-Entity
",",O
methionine,I-Entity
",",O
and,O
leucine,I-Entity
.,O
Fatty,B-Entity
liver,I-Entity
induced,O
by,O
tetracycline,I-Entity
in,O
the,O
rat,O
.,O
Dose,O
-,O
response,O
relationships,O
",",O
biochemical,O
mechanisms,O
",",O
and,O
sex,O
differences,O
in,O
the,O
experimental,O
fatty,B-Entity
liver,I-Entity
induced,O
by,O
tetracycline,I-Entity
were,O
studied,O
in,O
the,O
intact,O
rat,O
and,O
with,O
the,O
isolated,O
perfused,O
rat,O
liver,O
in,O
vitro,O
.,O
In,O
the,O
intact,O
male,O
and,O
female,O
rat,O
",",O
no,O
direct,O
relationship,O
was,O
observed,O
between,O
dose,O
of,O
tetracycline,I-Entity
and,O
hepatic,O
accumulation,O
of,O
triglyceride,I-Entity
.,O
With,O
provision,O
of,O
adequate,O
oleic,B-Entity
acid,I-Entity
as,O
a,O
substrate,O
for,O
the,O
isolated,O
perfused,O
liver,O
",",O
a,O
direct,O
relationship,O
was,O
observed,O
between,O
dose,O
of,O
tetracycline,I-Entity
and,O
both,O
accumulation,O
of,O
triglyceride,I-Entity
in,O
the,O
liver,O
and,O
depression,I-Entity
of,O
output,O
of,O
triglyceride,I-Entity
by,O
livers,O
from,O
male,O
and,O
female,O
rats,O
.,O
Marked,O
differences,O
were,O
observed,O
between,O
female,O
and,O
male,O
rats,O
with,O
regard,O
to,O
base,O
line,O
(,O
control,O
),O
hepatic,O
concentration,O
of,O
triglyceride,I-Entity
and,O
output,O
of,O
triglyceride,I-Entity
.,O
Accumulation,O
of,O
hepatic,O
triglyceride,I-Entity
",",O
as,O
a,O
per,O
cent,O
of,O
control,O
values,O
",",O
in,O
response,O
to,O
graded,O
doses,O
of,O
tetracycline,I-Entity
",",O
did,O
not,O
differ,O
significantly,O
between,O
male,O
",",O
female,O
and,O
pregnant,O
rat,O
livers,O
.,O
However,O
",",O
livers,O
from,O
female,O
",",O
and,O
especially,O
pregnant,O
female,O
rats,O
",",O
were,O
strikingly,O
resistant,O
to,O
the,O
effects,O
of,O
tetracycline,I-Entity
on,O
depression,I-Entity
of,O
output,O
of,O
triglyceride,I-Entity
under,O
these,O
experimental,O
conditions,O
.,O
These,O
differences,O
between,O
the,O
sexes,O
could,O
not,O
be,O
related,O
to,O
altered,O
disposition,O
of,O
tetracycline,I-Entity
or,O
altered,O
uptake,O
of,O
oleic,B-Entity
acid,I-Entity
.,O
Depressed,O
hepatic,O
secretion,O
of,O
triglyceride,I-Entity
accounted,O
only,O
for,O
30,O
to,O
50%,O
of,O
accumulated,O
hepatic,O
triglyceride,I-Entity
",",O
indicating,O
that,O
additional,O
mechanisms,O
must,O
be,O
involved,O
in,O
the,O
production,O
of,O
the,O
triglyceride,I-Entity
-,O
rich,O
fatty,B-Entity
liver,I-Entity
in,O
response,O
to,O
tetracycline,I-Entity
.,O
Fatal,O
myeloencephalopathy,I-Entity
due,O
to,O
intrathecal,O
vincristine,I-Entity
administration,O
.,O
Vincristine,I-Entity
was,O
accidentally,O
given,O
intrathecally,O
to,O
a,O
child,O
with,O
leukaemia,I-Entity
",",O
producing,O
sensory,B-Entity
and,I-Entity
motor,I-Entity
dysfunction,I-Entity
followed,O
by,O
encephalopathy,I-Entity
and,O
death,O
.,O
Separate,O
times,O
for,O
administering,O
vincristine,I-Entity
and,O
intrathecal,O
therapy,O
is,O
recommended,O
.,O
Progesterone,I-Entity
potentiation,O
of,O
bupivacaine,I-Entity
arrhythmogenicity,O
in,O
pentobarbital,I-Entity
-,O
anesthetized,O
rats,O
and,O
beating,O
rat,O
heart,O
cell,O
cultures,O
.,O
The,O
effects,O
of,O
progesterone,I-Entity
treatment,O
on,O
bupivacaine,I-Entity
arrhythmogenicity,O
in,O
beating,O
rat,O
heart,O
myocyte,O
cultures,O
and,O
on,O
anesthetized,O
rats,O
were,O
determined,O
.,O
After,O
determining,O
the,O
bupivacaine,I-Entity
AD50,O
(,O
the,O
concentration,O
of,O
bupivacaine,I-Entity
that,O
caused,O
50%,O
of,O
all,O
beating,O
rat,O
heart,O
myocyte,O
cultures,O
to,O
become,O
arrhythmic,I-Entity
),O
",",O
we,O
determined,O
the,O
effect,O
of,O
1-hour,O
progesterone,I-Entity
HCl,I-Entity
exposure,O
on,O
myocyte,O
contractile,O
rhythm,O
.,O
Each,O
concentration,O
of,O
progesterone,I-Entity
(,O
6.25,O
",",O
12.5,O
",",O
25,O
",",O
and,O
50,O
micrograms,O
/,O
ml,O
),O
caused,O
a,O
significant,O
and,O
concentration,O
-,O
dependent,O
reduction,O
in,O
the,O
AD50,O
for,O
bupivacaine,I-Entity
.,O
Estradiol,I-Entity
treatment,O
also,O
increased,O
the,O
arrhythmogenicity,O
of,O
bupivacaine,I-Entity
in,O
myocyte,O
cultures,O
",",O
but,O
was,O
only,O
one,O
fourth,O
as,O
potent,O
as,O
progesterone,I-Entity
.,O
Neither,O
progesterone,I-Entity
nor,O
estradiol,I-Entity
effects,O
on,O
bupivacaine,I-Entity
arrhythmogenicity,O
were,O
potentiated,O
by,O
epinephrine,I-Entity
.,O
Chronic,O
progesterone,I-Entity
pretreatment,O
(,O
5,O
mg,O
/,O
kg,O
/,O
day,O
for,O
21,O
days,O
),O
caused,O
a,O
significant,O
increase,O
in,O
bupivacaine,I-Entity
arrhythmogenicity,O
in,O
intact,O
pentobarbital,I-Entity
-,O
anesthetized,O
rats,O
.,O
There,O
was,O
a,O
significant,O
decrease,O
in,O
the,O
time,O
to,O
onset,O
of,O
arrhythmia,I-Entity
as,O
compared,O
with,O
control,O
nonprogesterone,O
-,O
treated,O
rats,O
(,O
6.2,O
+,O
/-,O
The,O
results,O
of,O
this,O
study,O
indicate,O
that,O
progesterone,I-Entity
can,O
potentiate,O
bupivacaine,I-Entity
arrhythmogenicity,O
both,O
in,O
vivo,O
and,O
in,O
vitro,O
.,O
Potentiation,O
of,O
bupivacaine,I-Entity
arrhythmia,I-Entity
in,O
myocyte,O
cultures,O
suggests,O
that,O
this,O
effect,O
is,O
at,O
least,O
partly,O
mediated,O
at,O
the,O
myocyte,O
level,O
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
occurring,O
during,O
intravenous,O
desferrioxamine,I-Entity
therapy,O
:,O
recovery,O
after,O
haemodialysis,O
.,O
A,O
patient,O
with,O
transfusion,O
-,O
dependent,O
thalassemia,I-Entity
was,O
undergoing,O
home,O
intravenous,O
desferrioxamine,I-Entity
(,O
DFX,I-Entity
),O
treatment,O
by,O
means,O
of,O
a,O
totally,O
implanted,O
system,O
because,O
of,O
his,O
poor,O
compliance,O
with,O
the,O
nightly,O
subcutaneous,O
therapy,O
.,O
Due,O
to,O
an,O
accidental,O
malfunctioning,O
of,O
the,O
infusion,O
pump,O
",",O
the,O
patient,O
was,O
inadvertently,O
administered,O
a,O
toxic,O
dosage,O
of,O
the,O
drug,O
which,O
caused,O
renal,B-Entity
insufficiency,I-Entity
.,O
Given,O
the,O
progressive,O
deterioration,O
of,O
the,O
symptoms,O
and,O
of,O
the,O
laboratory,O
values,O
",",O
despite,O
adequate,O
medical,O
treatment,O
",",O
a,O
decision,O
was,O
made,O
to,O
introduce,O
haemodialytical,O
therapy,O
in,O
order,O
to,O
remove,O
the,O
drug,O
and,O
therapy,O
reduce,O
the,O
nephrotoxicity,I-Entity
.,O
From,O
the,O
results,O
obtained,O
",",O
haemodialysis,O
can,O
therefore,O
be,O
suggested,O
as,O
a,O
useful,O
therapy,O
in,O
rare,O
cases,O
of,O
progressive,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
caused,O
by,O
desferrioxamine,I-Entity
.,O
Neuroleptic,I-Entity
-,O
associated,O
hyperprolactinemia,I-Entity
.,O
Can,O
it,O
be,O
treated,O
with,O
bromocriptine,I-Entity
?,O
Six,O
stable,O
psychiatric,O
outpatients,O
with,O
hyperprolactinemia,I-Entity
and,O
amenorrhea,I-Entity
/,O
oligomenorrhea,I-Entity
associated,O
with,O
their,O
neuroleptic,B-Entity
medications,I-Entity
were,O
treated,O
with,O
bromocriptine,I-Entity
.,O
Daily,O
dosages,O
of,O
5,O
-,O
10,O
mg,O
corrected,O
the,O
hyperprolactinemia,I-Entity
and,O
restored,O
menstruation,O
in,O
four,O
of,O
the,O
six,O
patients,O
.,O
One,O
woman,O
",",O
however,O
",",O
developed,O
worsened,O
psychiatric,B-Entity
symptoms,I-Entity
while,O
taking,O
bromocriptine,I-Entity
",",O
and,O
it,O
was,O
discontinued,O
.,O
Thus,O
",",O
three,O
of,O
six,O
patients,O
had,O
their,O
menstrual,O
irregularity,O
successfully,O
corrected,O
with,O
bromocriptine,I-Entity
.,O
This,O
suggests,O
that,O
bromocriptine,I-Entity
should,O
be,O
further,O
evaluated,O
as,O
potential,O
therapy,O
for,O
neuroleptic,I-Entity
-,O
associated,O
hyperprolactinemia,I-Entity
and,O
amenorrhea,I-Entity
/,O
galactorrhea,I-Entity
.,O
Ethacrynic,B-Entity
acid,I-Entity
-,O
induced,O
convulsions,I-Entity
and,O
brain,O
neurotransmitters,O
in,O
mice,O
.,O
Intracerebroventricular,O
injection,O
of,O
ethacrynic,B-Entity
acid,I-Entity
(,O
50%,O
convulsive,I-Entity
dose,O
;,O
50,O
micrograms,O
/,O
mouse,O
),O
accelerated,O
the,O
synthesis,O
/,O
turnover,O
of,O
5-hydroxytryptamine,I-Entity
(,O
5-HT,I-Entity
),O
but,O
suppressed,O
the,O
synthesis,O
of,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
and,O
acetylcholine,I-Entity
in,O
mouse,O
brain,O
.,O
These,O
effects,O
were,O
completely,O
antagonized,O
by,O
pretreatment,O
with,O
a,O
glutamate,I-Entity
/,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
antagonist,O
",",O
aminophosphonovaleric,B-Entity
acid,I-Entity
.,O
In,O
ethacrynic,B-Entity
acid,I-Entity
-,O
induced,O
convulsions,I-Entity
",",O
these,O
neurotransmitter,O
systems,O
may,O
be,O
differentially,O
modulated,O
",",O
probably,O
through,O
activation,O
of,O
glutaminergic,O
neurons,O
in,O
the,O
brain,O
.,O
Pharmacology,O
of,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acidA,I-Entity
receptor,O
complex,O
after,O
the,O
in,O
vivo,O
administration,O
of,O
the,O
anxioselective,O
and,O
anticonvulsant,O
beta,B-Entity
-,I-Entity
carboline,I-Entity
derivative,O
abecarnil,I-Entity
.,O
In,O
rodents,O
",",O
the,O
effect,O
of,O
the,O
beta,B-Entity
-,I-Entity
carboline,I-Entity
derivative,O
isopropyl-6-,B-Entity
benzyloxy-4-methoxymethyl,I-Entity
-,I-Entity
beta,I-Entity
-,I-Entity
carboline-3-carboxylate,I-Entity
(,O
abecarrnil,I-Entity
),O
",",O
a,O
new,O
ligand,O
for,O
benzodiazepine,I-Entity
receptors,O
possessing,O
anxiolytic,O
and,O
anticonvulsant,O
properties,O
",",O
was,O
evaluated,O
on,O
the,O
function,O
of,O
central,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
(,O
GABA)A,I-Entity
receptor,O
complex,O
",",O
both,O
in,O
vitro,O
and,O
in,O
vivo,O
.,O
Added,O
in,O
vitro,O
to,O
rat,O
cortical,O
membrane,O
preparation,O
",",O
abecarnil,I-Entity
increased,O
[,O
3H]GABA,I-Entity
binding,O
",",O
enhanced,O
muscimol,I-Entity
-,O
stimulated,O
36Cl-,O
uptake,O
and,O
reduced,O
the,O
binding,O
of,O
t-[35S]butylbicyclophosphorothionate,I-Entity
(,O
[,B-Entity
35S]TBPS,I-Entity
),O
.,O
These,O
effects,O
were,O
similar,O
to,O
those,O
induced,O
by,O
diazepam,I-Entity
",",O
whereas,O
the,O
partial,O
agonist,O
Ro,B-Entity
16,I-Entity
-,I-Entity
6028,I-Entity
(,O
tert,B-Entity
-,I-Entity
"butyl-(S)-8-bromo-11,12,13,13a",I-Entity
-,I-Entity
tetrahydro-9-oxo-9H-,I-Entity
"imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate",I-Entity
),O
showed,O
very,O
weak,O
efficacy,O
in,O
these,O
biochemical,O
tests,O
.,O
injection,O
to,O
rats,O
",",O
abecarnil,I-Entity
and,O
diazepam,I-Entity
decreased,O
in,O
a,O
time,O
-,O
dependent,O
and,O
dose,O
-,O
related,O
(,O
0.25,O
-,O
20,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
manner,O
[,B-Entity
35S]TBPS,I-Entity
binding,O
measured,O
ex,O
vivo,O
in,O
the,O
cerebral,O
cortex,O
.,O
Moreover,O
",",O
both,O
drugs,O
at,O
the,O
dose,O
of,O
0.5,O
mg,O
/,O
kg,O
antagonized,O
completely,O
the,O
convulsant,O
activity,O
and,O
the,O
increase,O
of,O
[,B-Entity
35S]TBPS,I-Entity
binding,O
induced,O
by,O
isoniazide,I-Entity
(,O
350,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
as,O
well,O
as,O
the,O
increase,O
of,O
[,B-Entity
35S]TBPS,I-Entity
binding,O
induced,O
by,O
foot,O
-,O
shock,O
stress,O
.,O
To,O
better,O
correlate,O
the,O
biochemical,O
and,O
the,O
pharmacological,O
effects,O
",",O
we,O
studied,O
the,O
action,O
of,O
abecarnil,I-Entity
on,O
[,B-Entity
35S]TBPS,I-Entity
binding,O
",",O
exploratory,O
motility,O
and,O
on,O
isoniazid,I-Entity
-,O
induced,O
biochemical,O
and,O
pharmacological,O
effects,O
in,O
mice,O
.,O
In,O
these,O
animals,O
",",O
abecarnil,I-Entity
produced,O
a,O
paralleled,O
dose,O
-,O
dependent,O
(,O
0.05,O
-,O
1,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
reduction,O
of,O
both,O
motor,O
behavior,O
and,O
cortical,O
[,O
35S]TBPS,O
binding,O
.,O
kg,O
of,O
this,O
beta,B-Entity
-,I-Entity
carboline,I-Entity
reduced,O
markedly,O
the,O
increase,O
of,O
[,B-Entity
35S]TBPS,I-Entity
binding,O
and,O
the,O
convulsions,I-Entity
induced,O
by,O
isoniazid,I-Entity
(,O
200,O
mg,O
/,O
kg,O
s.c.).(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Recurrent,O
myocardial,B-Entity
infarction,I-Entity
in,O
a,O
postpartum,O
patient,O
receiving,O
bromocriptine,I-Entity
.,O
Myocardial,B-Entity
infarction,I-Entity
in,O
puerperium,O
is,O
infrequently,O
reported,O
.,O
Spasm,I-Entity
",",O
coronary,O
dissection,O
",",O
or,O
atheromatous,O
etiology,O
has,O
been,O
described,O
.,O
Bromocriptine,I-Entity
has,O
been,O
implicated,O
in,O
several,O
previous,O
case,O
reports,O
of,O
myocardial,B-Entity
infarction,I-Entity
in,O
the,O
puerperium,O
.,O
Although,O
generally,O
regarded,O
as,O
"""",O
safe,O
",",O
"""",O
possible,O
serious,O
cardiac,O
effects,O
of,O
bromocriptine,I-Entity
should,O
be,O
acknowledged,O
.,O
Asterixis,I-Entity
induced,O
by,O
carbamazepine,I-Entity
therapy,O
.,O
There,O
are,O
very,O
few,O
reports,O
about,O
asterixis,I-Entity
as,O
a,O
side,O
effect,O
of,O
treatment,O
with,O
psychopharmacologic,O
agents,O
.,O
In,O
this,O
report,O
we,O
present,O
four,O
patients,O
treated,O
with,O
a,O
combination,O
of,O
different,O
psychotropic,O
drugs,O
",",O
in,O
whom,O
asterixis,I-Entity
was,O
triggered,O
either,O
by,O
adding,O
carbamazepine,I-Entity
(,O
CBZ,I-Entity
),O
to,O
a,O
treatment,O
regimen,O
",",O
or,O
by,O
increasing,O
its,O
dosage,O
.,O
Neither,O
dosage,O
nor,O
serum,O
levels,O
of,O
CBZ,I-Entity
were,O
in,O
a,O
higher,O
range,O
.,O
We,O
consider,O
asterixis,I-Entity
to,O
be,O
an,O
easily,O
overlooked,O
sign,O
of,O
neurotoxicity,I-Entity
",",O
which,O
may,O
occur,O
even,O
at,O
low,O
or,O
moderate,O
dosage,O
levels,O
",",O
if,O
certain,O
drugs,O
as,O
lithium,I-Entity
or,O
clozapine,I-Entity
are,O
used,O
in,O
combination,O
with,O
CBZ,I-Entity
.,O
Pharmacodynamics,O
of,O
the,O
hypotensive,I-Entity
effect,O
of,O
levodopa,I-Entity
in,O
parkinsonian,I-Entity
patients,O
.,O
levodopa,I-Entity
were,O
examined,O
in,O
parkinsonian,I-Entity
patients,O
with,O
stable,O
and,O
fluctuating,O
responses,O
to,O
levodopa,I-Entity
.,O
The,O
magnitude,O
of,O
the,O
hypotensive,I-Entity
effect,O
of,O
levodopa,I-Entity
was,O
concentration,O
dependent,O
and,O
was,O
fit,O
to,O
an,O
Emax,O
model,O
in,O
fluctuating,O
responders,O
.,O
Stable,O
responders,O
demonstrated,O
a,O
small,O
hypotensive,I-Entity
response,O
.,O
Baseline,O
blood,O
pressures,O
were,O
higher,O
in,O
fluctuating,O
patients,O
;,O
a,O
higher,O
baseline,O
blood,O
pressure,O
correlated,O
with,O
greater,O
hypotensive,I-Entity
effects,O
.,O
Antiparkinsonian,O
effects,O
of,O
levodopa,I-Entity
temporally,O
correlated,O
with,O
blood,O
pressure,O
changes,O
.,O
Phenylalanine,I-Entity
",",O
a,O
large,O
neutral,O
amino,B-Entity
acid,I-Entity
(,O
LNAA,O
),O
competing,O
with,O
levodopa,I-Entity
for,O
transport,O
across,O
the,O
blood,O
-,O
brain,O
barrier,O
",",O
reduced,O
the,O
hypotensive,I-Entity
and,O
antiparkinsonian,O
effects,O
of,O
levodopa,I-Entity
.,O
We,O
conclude,O
that,O
levodopa,I-Entity
has,O
a,O
central,O
hypotensive,I-Entity
action,O
that,O
parallels,O
the,O
motor,O
effects,O
in,O
fluctuating,O
patients,O
.,O
The,O
hypotensive,I-Entity
effect,O
appears,O
to,O
be,O
related,O
to,O
the,O
higher,O
baseline,O
blood,O
pressure,O
we,O
observed,O
in,O
fluctuating,O
patients,O
relative,O
to,O
stable,O
patients,O
.,O
Syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
secretion,I-Entity
of,I-Entity
antidiuretic,I-Entity
hormone,I-Entity
after,O
infusional,O
vincristine,I-Entity
.,O
A,O
77-year,O
-,O
old,O
woman,O
with,O
refractory,O
multiple,B-Entity
myeloma,I-Entity
was,O
treated,O
with,O
a,O
4-day,O
continuous,O
intravenous,O
infusion,O
of,O
vincristine,I-Entity
and,O
doxorubicin,I-Entity
and,O
4,O
days,O
of,O
oral,O
dexamethasone,I-Entity
.,O
Nine,O
days,O
after,O
her,O
second,O
cycle,O
she,O
presented,O
with,O
lethargy,I-Entity
and,O
weakness,I-Entity
associated,O
with,O
hyponatremia,I-Entity
.,O
Evaluation,O
revealed,O
the,O
syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
secretion,I-Entity
of,I-Entity
antidiuretic,I-Entity
hormone,I-Entity
",",O
which,O
was,O
attributed,O
to,O
the,O
vincristine,I-Entity
infusion,O
.,O
After,O
normal,O
serum,O
sodium,I-Entity
levels,O
returned,O
",",O
further,O
doxorubicin,I-Entity
and,O
dexamethasone,I-Entity
chemotherapy,O
without,O
vincristine,I-Entity
did,O
not,O
produce,O
this,O
complication,O
.,O
Heart,B-Entity
failure,I-Entity
:,O
to,O
digitalise,O
or,O
not,O
?,O
Despite,O
extensive,O
clinical,O
experience,O
the,O
role,O
of,O
digoxin,I-Entity
is,O
still,O
not,O
well,O
defined,O
.,O
In,O
patients,O
with,O
atrial,B-Entity
fibrillation,I-Entity
digoxin,I-Entity
is,O
beneficial,O
for,O
ventricular,O
rate,O
control,O
.,O
For,O
patients,O
in,O
sinus,O
rhythm,O
and,O
heart,B-Entity
failure,I-Entity
the,O
situation,O
is,O
less,O
clear,O
.,O
Digoxin,I-Entity
has,O
a,O
narrow,O
therapeutic,O
:,O
toxic,O
ratio,O
and,O
concentrations,O
are,O
affected,O
by,O
a,O
number,O
of,O
drugs,O
.,O
Also,O
",",O
digoxin,I-Entity
has,O
undesirable,O
effects,O
such,O
as,O
increasing,O
peripheral,O
resistance,O
and,O
myocardial,O
demands,O
",",O
and,O
causing,O
arrhythmias,I-Entity
.,O
More,O
convincing,O
evidence,O
is,O
required,O
showing,O
that,O
digoxin,I-Entity
improves,O
symptoms,O
or,O
exercise,O
capacity,O
.,O
Pooled,O
analysis,O
of,O
the,O
effects,O
of,O
other,O
inotropic,O
drugs,O
shows,O
an,O
excess,O
mortality,O
and,O
there,O
is,O
a,O
possibility,O
that,O
digoxin,I-Entity
may,O
increase,O
mortality,O
after,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
.,O
Angiotensin,I-Entity
-,O
converting,O
enzyme,O
(,O
ACE,O
),O
inhibitors,O
should,O
be,O
used,O
first,O
as,O
they,O
are,O
safer,O
",",O
do,O
not,O
require,O
blood,O
level,O
monitoring,O
",",O
modify,O
progression,O
of,O
disease,O
",",O
relieve,O
symptoms,O
",",O
improve,O
exercise,O
tolerance,O
and,O
reduce,O
mortality,O
.,O
Caution,O
should,O
be,O
exercised,O
in,O
using,O
digoxin,I-Entity
until,O
large,O
mortality,O
trials,O
are,O
completed,O
showing,O
either,O
benefit,O
or,O
harm,O
.,O
Until,O
then,O
digoxin,I-Entity
should,O
be,O
considered,O
a,O
third,O
-,O
line,O
therapy,O
.,O
Intravascular,O
hemolysis,I-Entity
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
following,O
intermittent,O
rifampin,I-Entity
therapy,O
.,O
Renal,B-Entity
failure,I-Entity
is,O
a,O
rare,O
complication,O
associated,O
with,O
the,O
use,O
of,O
rifampin,I-Entity
.,O
Intravascular,O
hemolysis,I-Entity
leading,O
to,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
following,O
rifampin,I-Entity
therapy,O
is,O
extremely,O
rare,O
.,O
Two,O
patients,O
with,O
leprosy,I-Entity
who,O
developed,O
hemolysis,I-Entity
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
following,O
rifampin,I-Entity
are,O
reported,O
.,O
Zidovudine,I-Entity
-,O
induced,O
hepatitis,I-Entity
.,O
A,O
case,O
of,O
acute,O
hepatitis,I-Entity
induced,O
by,O
zidovudine,I-Entity
in,O
a,O
38-year,O
-,O
old,O
patient,O
with,O
AIDS,I-Entity
is,O
presented,O
.,O
The,O
mechanism,O
whereby,O
the,O
hepatitis,I-Entity
was,O
induced,O
is,O
not,O
known,O
.,O
However,O
",",O
the,O
patient,O
tolerated,O
well,O
an,O
alternative,O
reverse,O
transcriptase,O
inhibitor,O
",",O
2'3,B-Entity
',I-Entity
dideoxyinosine,I-Entity
.,O
Physicians,O
caring,O
for,O
patients,O
with,O
AIDS,I-Entity
should,O
be,O
aware,O
of,O
this,O
hitherto,O
rarely,O
reported,O
complication,O
.,O
Thoracic,B-Entity
hematomyelia,I-Entity
secondary,O
to,O
coumadin,I-Entity
anticoagulant,O
therapy,O
:,O
a,O
case,O
report,O
.,O
A,O
case,O
of,O
thoracic,B-Entity
hematomyelia,I-Entity
secondary,O
to,O
anticoagulant,O
therapy,O
is,O
presented,O
.,O
Mania,I-Entity
associated,O
with,O
fluoxetine,I-Entity
treatment,O
in,O
adolescents,O
.,O
Fluoxetine,I-Entity
",",O
a,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitor,O
",",O
is,O
gaining,O
increased,O
acceptance,O
in,O
the,O
treatment,O
of,O
adolescent,O
depression,I-Entity
.,O
Generally,O
safe,O
and,O
well,O
tolerated,O
by,O
adults,O
",",O
fluoxetine,I-Entity
has,O
been,O
reported,O
to,O
induce,O
mania,I-Entity
.,O
The,O
cases,O
of,O
five,O
depressed,I-Entity
adolescents,O
",",O
14,O
-,O
16,O
years,O
of,O
age,O
",",O
who,O
developed,O
mania,I-Entity
during,O
pharmacotherapy,O
with,O
fluoxetine,I-Entity
",",O
are,O
reported,O
here,O
.,O
Apparent,O
risk,O
factors,O
for,O
the,O
development,O
of,O
mania,I-Entity
or,O
hypomania,I-Entity
during,O
fluoxetine,I-Entity
pharmacotherapy,O
in,O
this,O
population,O
were,O
the,O
combination,O
of,O
attention,B-Entity
-,I-Entity
deficit,I-Entity
hyperactivity,I-Entity
disorder,I-Entity
and,O
affective,O
instability,O
;,O
major,O
depression,I-Entity
with,O
psychotic,I-Entity
features,O
;,O
a,O
family,O
history,O
of,O
affective,B-Entity
disorder,I-Entity
",",O
especially,O
bipolar,B-Entity
disorder,I-Entity
;,O
and,O
a,O
diagnosis,O
of,O
bipolar,B-Entity
disorder,I-Entity
.,O
Further,O
study,O
is,O
needed,O
to,O
determine,O
the,O
optimal,O
dosage,O
and,O
to,O
identify,O
risk,O
factors,O
that,O
increase,O
individual,O
vulnerability,O
to,O
fluoxetine,I-Entity
induced,O
mania,I-Entity
in,O
adolescents,O
.,O
Gemfibrozil,I-Entity
-,O
lovastatin,I-Entity
therapy,O
for,O
primary,O
hyperlipoproteinemias,I-Entity
.,O
The,O
specific,O
aim,O
of,O
this,O
retrospective,O
",",O
observational,O
study,O
was,O
to,O
assess,O
safety,O
and,O
efficacy,O
of,O
long,O
-,O
term,O
(,O
21,O
months,O
/,O
patient,O
),O
",",O
open,O
-,O
label,O
",",O
gemfibrozil,I-Entity
-,O
lovastatin,I-Entity
treatment,O
in,O
80,O
patients,O
with,O
primary,O
mixed,O
hyperlipidemia,I-Entity
(,O
68%,O
of,O
whom,O
had,O
atherosclerotic,B-Entity
vascular,I-Entity
disease,I-Entity
),O
.,O
Because,O
ideal,O
lipid,O
targets,O
were,O
not,O
reached,O
(,O
low,O
-,O
density,O
lipoprotein,O
(,O
LDL,O
),O
cholesterol,I-Entity
less,O
than,O
130,O
mg,O
/,O
dl,O
",",O
high,O
-,O
density,O
lipoprotein,O
(,O
HDL,O
),O
cholesterol,I-Entity
greater,O
than,O
35,O
mg,O
/,O
dl,O
",",O
or,O
total,O
cholesterol,I-Entity
/,O
HDL,O
cholesterol,I-Entity
less,O
than,O
4.5,O
mg,O
/,O
dl,O
),O
with,O
diet,O
plus,O
a,O
single,O
drug,O
",",O
gemfibrozil,I-Entity
(,O
1.2,O
g,O
/,O
day)-lovastatin,I-Entity
(,O
primarily,O
20,O
or,O
40,O
mg,O
),O
treatment,O
was,O
given,O
.,O
Follow,O
-,O
up,O
visits,O
were,O
scheduled,O
with,O
2-drug,O
therapy,O
every,O
6,O
to,O
8,O
weeks,O
",",O
an,O
average,O
of,O
10.3,O
visits,O
per,O
patient,O
",",O
with,O
741,O
batteries,O
of,O
6,O
liver,O
function,O
tests,O
and,O
714,O
creatine,I-Entity
phosphokinase,O
levels,O
measured,O
.,O
Of,O
the,O
714,O
creatine,I-Entity
phosphokinase,O
levels,O
",",O
9%,O
were,O
high,O
;,O
only,O
1,O
(,O
0.1%,O
),O
was,O
greater,O
than,O
or,O
equal,O
to,O
3,O
times,O
the,O
upper,O
normal,O
limit,O
.,O
With,O
2-drug,O
therapy,O
",",O
mean,O
total,O
cholesterol,I-Entity
decreased,O
22%,O
from,O
255,O
to,O
200,O
mg,O
/,O
dl,O
",",O
triglyceride,I-Entity
levels,O
decreased,O
35%,O
from,O
236,O
to,O
154,O
mg,O
/,O
dl,O
",",O
LDL,O
cholesterol,I-Entity
decreased,O
26%,O
from,O
176,O
to,O
131,O
mg,O
/,O
dl,O
",",O
and,O
the,O
total,O
cholesterol,I-Entity
/,O
HDL,O
cholesterol,I-Entity
ratio,O
decreased,O
24%,O
from,O
7.1,O
to,O
5.4,O
",",O
all,O
p,O
less,O
than,O
or,O
equal,O
to,O
0.0001,O
.,O
Myositis,I-Entity
",",O
attributable,O
to,O
the,O
drug,O
combination,O
and,O
symptomatic,O
enough,O
to,O
discontinue,O
it,O
",",O
occurred,O
in,O
3%,O
of,O
patients,O
",",O
and,O
in,O
1%,O
with,O
concurrent,O
high,O
creatine,I-Entity
phosphokinase,O
(,O
769,O
U,O
/,O
liter,O
),O
;,O
no,O
patients,O
had,O
rhabdomyolysis,I-Entity
or,O
myoglobinuria.(ABSTRACT,I-Entity
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Hepatocellular,B-Entity
carcinoma,I-Entity
in,O
Fanconi,B-Entity
's,I-Entity
anemia,I-Entity
treated,O
with,O
androgen,I-Entity
and,O
corticosteroid,I-Entity
.,O
The,O
case,O
of,O
an,O
11-year,O
-,O
old,O
boy,O
is,O
reported,O
who,O
was,O
known,O
to,O
have,O
Fanconi,B-Entity
's,I-Entity
anemia,I-Entity
for,O
3,O
years,O
and,O
was,O
treated,O
with,O
androgens,I-Entity
",",O
corticosteroids,I-Entity
and,O
transfusions,O
.,O
Two,O
weeks,O
before,O
his,O
death,O
he,O
was,O
readmitted,O
because,O
of,O
aplastic,O
crisis,O
with,O
septicemia,I-Entity
and,O
marked,O
abnormalities,O
in,O
liver,O
function,O
and,O
died,O
of,O
hemorrhagic,B-Entity
bronchopneumonia,I-Entity
.,O
At,O
autopsy,O
peliosis,I-Entity
and,O
multiple,O
hepatic,B-Entity
tumors,I-Entity
were,O
found,O
which,O
histologically,O
proved,O
to,O
be,O
well,O
-,O
differentiated,O
hepatocellular,B-Entity
carcinoma,I-Entity
.,O
This,O
case,O
contributes,O
to,O
the,O
previous,O
observations,O
that,O
non,O
-,O
metastasizing,O
hepatic,B-Entity
neoplasms,I-Entity
and,O
peliosis,I-Entity
can,O
develop,O
in,O
patients,O
with,O
androgen-,I-Entity
and,O
corticosteroid,I-Entity
-,O
treated,O
Fanconi,B-Entity
's,I-Entity
anemia,I-Entity
.,O
Chronic,O
lesion,O
of,O
rostral,O
ventrolateral,O
medulla,O
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
We,O
studied,O
the,O
effects,O
of,O
chronic,O
selective,O
neuronal,O
lesion,O
of,O
rostral,O
ventrolateral,O
medulla,O
on,O
mean,O
arterial,O
pressure,O
",",O
heart,O
rate,O
",",O
and,O
neurogenic,O
tone,O
in,O
conscious,O
",",O
unrestrained,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartic,I-Entity
acid,I-Entity
.,O
The,O
restimulation,O
of,O
this,O
area,O
with,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartic,I-Entity
acid,I-Entity
15,O
days,O
postlesion,O
failed,O
to,O
produce,O
a,O
pressor,O
response,O
.,O
The,O
ganglionic,O
blocker,O
trimethaphan,I-Entity
(,O
5,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
The,O
trimethaphan,I-Entity
-,O
induced,O
hypotension,I-Entity
was,O
accompanied,O
by,O
a,O
significant,O
bradycardia,I-Entity
in,O
lesioned,O
rats,O
(,O
-32,O
13,O
beats,O
per,O
minute,O
),O
but,O
a,O
tachycardia,I-Entity
in,O
sham,O
rats,O
(,O
+,O
33,O
+,O
/-,O
Therefore,O
",",O
rostral,O
ventrolateral,O
medulla,O
neurons,O
appear,O
to,O
play,O
a,O
significant,O
role,O
in,O
maintaining,O
hypertension,I-Entity
in,O
conscious,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
Spinal,O
or,O
suprabulbar,O
structures,O
could,O
be,O
responsible,O
for,O
the,O
gradual,O
recovery,O
of,O
the,O
hypertension,I-Entity
in,O
the,O
lesioned,O
rats,O
.,O
Damage,B-Entity
of,I-Entity
substantia,I-Entity
nigra,I-Entity
pars,I-Entity
reticulata,I-Entity
during,O
pilocarpine,I-Entity
-,O
induced,O
status,B-Entity
epilepticus,I-Entity
in,O
the,O
rat,O
:,O
immunohistochemical,O
study,O
of,O
neurons,O
",",O
astrocytes,O
and,O
serum,O
-,O
protein,O
extravasation,O
.,O
The,O
substantia,O
nigra,O
has,O
a,O
gating,O
function,O
controlling,O
the,O
spread,O
of,O
epileptic,B-Entity
seizure,I-Entity
activity,O
.,O
Additionally,O
",",O
in,O
models,O
of,O
prolonged,B-Entity
status,I-Entity
epilepticus,I-Entity
the,O
pars,O
reticulata,O
of,O
substantia,O
nigra,O
(,O
SNR,O
),O
suffers,O
from,O
a,O
massive,O
lesion,O
which,O
may,O
arise,O
from,O
a,O
massive,O
metabolic,B-Entity
derangement,I-Entity
and,O
hyperexcitation,O
developing,O
in,O
the,O
activated,O
SNR,O
.,O
In,O
this,O
study,O
",",O
status,B-Entity
epilepticus,I-Entity
was,O
induced,O
by,O
systemic,O
injection,O
of,O
pilocarpine,I-Entity
in,O
rats,O
.,O
Animals,O
surviving,O
20,O
",",O
30,O
",",O
40,O
",",O
60,O
min,O
",",O
2,O
",",O
3,O
",",O
6,O
hours,O
",",O
1,O
",",O
2,O
",",O
and,O
3,O
days,O
after,O
induction,O
of,O
status,B-Entity
epilepticus,I-Entity
were,O
perfusion,O
-,O
fixed,O
",",O
and,O
brains,O
processed,O
for,O
immunohistochemical,O
staining,O
of,O
SNR,O
.,O
Nissl,O
-,O
staining,O
and,O
antibodies,O
against,O
the,O
neuron,O
-,O
specific,O
calcium,I-Entity
-,O
binding,O
protein,O
",",O
parvalbumin,O
",",O
served,O
to,O
detect,O
neuronal,B-Entity
damage,I-Entity
in,O
SNR,O
.,O
Antibodies,O
against,O
the,O
astroglia,O
-,O
specific,O
cytoskeletal,O
protein,O
",",O
glial,O
fibrillary,O
acidic,O
protein,O
(,O
GFAP,O
),O
",",O
and,O
against,O
the,O
glial,O
calcium,I-Entity
-,O
binding,O
protein,O
",",O
S-100,O
protein,O
",",O
were,O
used,O
to,O
assess,O
the,O
status,O
of,O
astrocytes,O
.,O
Immunohistochemical,O
staining,O
for,O
serum,O
-,O
albumin,O
and,O
immunoglobulins,O
in,O
brain,O
tissue,O
was,O
taken,O
as,O
indicator,O
of,O
blood,O
-,O
brain,O
barrier,O
disturbances,O
and,O
vasogenic,B-Entity
edema,I-Entity
formation,O
.,O
Immunohistochemical,O
staining,O
indicated,O
loss,O
of,O
GFAP,O
-,O
staining,O
already,O
at,O
30,O
min,O
after,O
induction,O
of,O
seizures,I-Entity
in,O
an,O
oval,O
focus,O
situated,O
in,O
the,O
center,O
of,O
SNR,O
while,O
sparing,O
medial,O
and,O
lateral,O
aspects,O
.,O
By,O
2,O
hours,O
",",O
parvalbumin,O
-,O
staining,O
changed,O
in,O
the,O
central,O
SNR,O
indicating,O
neuronal,B-Entity
damage,I-Entity
",",O
and,O
Nissl,O
-,O
staining,O
visualized,O
some,O
neuronal,O
distortion,O
.,O
By,O
6,O
h,O
",",O
vasogenic,B-Entity
edema,I-Entity
covered,O
the,O
lesioned,B-Entity
SNR,I-Entity
.,O
In,O
a,O
further,O
group,O
of,O
animals,O
surviving,O
1,O
to,O
5,O
days,O
",",O
conventional,O
paraffin,O
-,O
sections,O
confirmed,O
the,O
neuronal,O
and,O
glial,O
damage,B-Entity
of,I-Entity
SNR,I-Entity
.,O
Both,O
cell,O
elements,O
may,O
suffer,O
in,O
common,O
from,O
metabolic,O
disturbance,O
and,O
neurotransmitter,B-Entity
dysfunction,I-Entity
as,O
occur,O
during,O
massive,O
status,B-Entity
epilepticus,I-Entity
.,O
Reduced,O
cardiotoxicity,I-Entity
of,O
doxorubicin,I-Entity
given,O
in,O
the,O
form,O
of,O
N-(2-hydroxypropyl)methacrylamide,I-Entity
conjugates,O
:,O
and,O
experimental,O
study,O
in,O
the,O
rat,O
.,O
A,O
rat,O
model,O
was,O
used,O
to,O
evaluate,O
the,O
general,O
acute,O
toxicity,I-Entity
and,O
the,O
late,O
cardiotoxicity,I-Entity
of,O
4,O
mg,O
/,O
kg,O
doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
given,O
either,O
as,O
free,O
drug,O
or,O
in,O
the,O
form,O
of,O
three,O
N-(2-hydroxypropyl)methacrylamide,I-Entity
(,O
HPMA,I-Entity
),O
In,O
these,O
HPMA,I-Entity
copolymers,O
",",O
DOX,I-Entity
was,O
covalently,O
bound,O
via,O
peptide,O
linkages,O
that,O
were,O
either,O
non,O
-,O
biodegradable,O
(,O
Gly,O
-,O
Gly,O
),O
or,O
degradable,O
by,O
lysosomal,O
proteinases,O
(,O
Gly,B-Entity
-,I-Entity
Phe,I-Entity
-,I-Entity
Leu,I-Entity
-,I-Entity
Gly,I-Entity
),O
.,O
In,O
addition,O
",",O
one,O
biodegradable,O
conjugate,O
containing,O
galactosamine,I-Entity
was,O
used,O
;,O
this,O
residue,O
was,O
targeted,O
to,O
the,O
liver,O
.,O
administration,O
of,O
free,O
and,O
polymer,O
-,O
bound,O
DOX,I-Entity
",",O
all,O
animals,O
showed,O
a,O
transient,O
reduction,O
in,O
body,O
weight,O
.,O
However,O
",",O
the,O
maximal,O
reduction,O
in,O
body,O
weight,O
seen,O
in,O
animals,O
that,O
received,O
polymer,O
-,O
bound,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
),O
was,O
significantly,O
lower,O
than,O
that,O
observed,O
in,O
those,O
that,O
received,O
free,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
),O
or,O
a,O
mixture,O
of,O
the,O
unmodified,O
parent,O
HPMA,I-Entity
copolymer,O
and,O
free,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
;,O
P,O
less,O
than,O
0.01,O
),O
.,O
Throughout,O
the,O
study,O
(,O
20,O
weeks,O
),O
",",O
deaths,O
related,O
to,O
cardiotoxicity,I-Entity
were,O
observed,O
only,O
in,O
animals,O
that,O
received,O
either,O
free,O
DOX,I-Entity
or,O
the,O
mixture,O
of,O
HPMA,I-Entity
copolymer,O
and,O
free,O
DOX,I-Entity
;,O
in,O
these,O
cases,O
",",O
histological,O
investigations,O
revealed,O
marked,O
changes,O
in,O
the,O
heart,O
that,O
were,O
consistent,O
with,O
DOX,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Sequential,O
measurements,O
of,O
cardiac,O
output,O
in,O
surviving,O
animals,O
that,O
received,O
either,O
free,O
DOX,I-Entity
or,O
the,O
mixture,O
of,O
HPMA,I-Entity
copolymer,O
and,O
free,O
DOX,I-Entity
showed,O
a,O
reduction,O
of,O
approximately,O
30%,O
in,O
function,O
beginning,O
at,O
the,O
4th,O
week,O
after,O
drug,O
administration,O
.,O
Animals,O
that,O
were,O
given,O
the,O
HPMA,I-Entity
copolymer,O
conjugates,O
containing,O
DOX,I-Entity
exhibited,O
no,O
significant,O
change,O
in,O
cardiac,O
output,O
throughout,O
the,O
study,O
(,O
P,O
less,O
than,O
0.05,O
),O
.,O
In,O
addition,O
",",O
no,O
significant,O
histological,O
change,O
was,O
observed,O
in,O
the,O
heart,O
of,O
animals,O
that,O
received,O
DOX,I-Entity
in,O
the,O
form,O
of,O
HPMA,I-Entity
copolymer,O
conjugates,O
and,O
were,O
killed,O
at,O
the,O
end,O
of,O
the,O
study,O
.,O
Topical,O
0.025%,O
capsaicin,I-Entity
in,O
chronic,O
post,B-Entity
-,I-Entity
herpetic,I-Entity
neuralgia,I-Entity
:,O
efficacy,O
",",O
predictors,O
of,O
response,O
and,O
long,O
-,O
term,O
course,O
.,O
In,O
order,O
to,O
evaluate,O
the,O
efficacy,O
",",O
time,O
-,O
course,O
of,O
action,O
and,O
predictors,O
of,O
response,O
to,O
topical,O
capsaicin,I-Entity
",",O
39,O
patients,O
with,O
chronic,O
post,B-Entity
-,I-Entity
herpetic,I-Entity
neuralgia,I-Entity
(,O
PHN,I-Entity
),O
",",O
median,O
duration,O
24,O
months,O
",",O
were,O
treated,O
with,O
0.025%,O
capsaicin,I-Entity
cream,O
for,O
8,O
weeks,O
.,O
During,O
therapy,O
the,O
patients,O
rated,O
their,O
pain,I-Entity
on,O
a,O
visual,O
analogue,O
scale,O
(,O
VAS,O
),O
and,O
a,O
verbal,O
outcome,O
scale,O
.,O
Nineteen,O
patients,O
(,O
48.7%,O
),O
substantially,O
improved,O
after,O
the,O
8-week,O
trial,O
;,O
5,O
(,O
12.8%,O
),O
discontinued,O
therapy,O
due,O
to,O
side,O
-,O
effects,O
such,O
as,O
intolerable,O
capsaicin,I-Entity
-,O
induced,O
burning,O
sensations,O
(,O
4,O
),O
or,O
mastitis,I-Entity
(,O
1,O
),O
;,O
15,O
(,O
38.5%,O
),O
reported,O
no,O
benefit,O
.,O
Treatment,O
effect,O
was,O
not,O
dependent,O
on,O
patient,O
's,O
age,O
",",O
duration,O
or,O
localization,O
of,O
PHN,I-Entity
(,O
trigeminal,O
involvement,O
was,O
excluded,O
),O
",",O
sensory,B-Entity
disturbance,I-Entity
or,O
pain,I-Entity
character,O
.,O
Treatment,O
response,O
was,O
not,O
correlated,O
with,O
the,O
incidence,O
",",O
time,O
-,O
course,O
or,O
severity,O
of,O
capsaicin,I-Entity
-,O
induced,O
burning,O
.,O
If,O
confirmed,O
in,O
controlled,O
trials,O
",",O
the,O
long,O
-,O
term,O
results,O
of,O
this,O
open,O
",",O
non,O
-,O
randomized,O
study,O
might,O
indicate,O
that,O
the,O
analgesic,O
effect,O
of,O
capsaicin,I-Entity
in,O
PHN,I-Entity
is,O
mediated,O
by,O
both,O
interference,O
with,O
neuropeptide,O
metabolism,O
and,O
morphological,O
changes,O
(,O
perhaps,O
degeneration,O
),O
of,O
nociceptive,O
afferents,O
.,O
Serotonin,I-Entity
reuptake,O
inhibitors,O
",",O
paranoia,I-Entity
",",O
and,O
the,O
ventral,O
basal,O
ganglia,O
.,O
Antidepressants,O
have,O
previously,O
been,O
associated,O
with,O
paranoid,I-Entity
reactions,O
in,O
psychiatric,O
patients,O
.,O
Five,O
cases,O
of,O
paranoid,I-Entity
exacerbation,O
with,O
the,O
serotonin,I-Entity
reuptake,O
inhibitors,O
fluoxetine,I-Entity
and,O
amitriptyline,I-Entity
are,O
reported,O
here,O
.,O
Elements,O
common,O
to,O
these,O
cases,O
included,O
a,O
history,O
of,O
paranoid,I-Entity
symptomatology,O
and,O
the,O
concomitant,O
occurrence,O
of,O
depressive,B-Entity
and,I-Entity
psychotic,I-Entity
symptoms,I-Entity
.,O
Complicated,O
depressive,B-Entity
disorders,I-Entity
(,O
including,O
atypicality,O
of,O
course,O
and,O
symptomatology,O
",",O
chronicity,O
",",O
psychosis,I-Entity
",",O
bipolarity,O
",",O
and,O
secondary,O
onset,O
in,O
the,O
course,O
of,O
a,O
primary,O
psychosis,I-Entity
),O
may,O
present,O
particular,O
vulnerability,O
to,O
paranoid,I-Entity
exacerbations,O
associated,O
with,O
serotonin,I-Entity
reuptake,O
inhibitors,O
.,O
Although,O
the,O
pharmacology,O
and,O
neurobiology,O
of,O
paranoia,I-Entity
remain,O
cryptic,O
",",O
several,O
mechanisms,O
",",O
including,O
5HT3,O
receptor,O
-,O
mediated,O
dopamine,I-Entity
release,O
",",O
beta,O
-,O
noradrenergic,O
receptor,O
downregulation,O
",",O
or,O
GABAB,O
receptor,O
upregulation,O
acting,O
in,O
the,O
vicinity,O
of,O
the,O
ventral,O
basal,O
ganglia,O
(,O
possibly,O
in,O
lateral,O
orbitofrontal,O
or,O
anterior,O
cingulate,O
circuits,O
),O
",",O
might,O
apply,O
to,O
this,O
phenomenon,O
.,O
These,O
cases,O
call,O
attention,O
to,O
possible,O
paranoid,I-Entity
exacerbations,O
with,O
serotonin,I-Entity
reuptake,O
blockers,O
in,O
select,O
patients,O
and,O
raise,O
neurobiological,O
considerations,O
regarding,O
paranoia,I-Entity
.,O
Five,O
cases,O
of,O
encephalitis,I-Entity
during,O
treatment,O
of,O
loiasis,I-Entity
with,O
diethylcarbamazine,I-Entity
.,O
Five,O
cases,O
of,O
encephalitis,I-Entity
following,O
treatment,O
with,O
diethylcarbamazine,I-Entity
(,O
DEC,I-Entity
),O
were,O
observed,O
in,O
Congolese,O
patients,O
with,O
Loa,O
loa,O
filariasis,I-Entity
.,O
The,O
notable,O
fact,O
was,O
that,O
this,O
complication,O
occurred,O
in,O
three,O
patients,O
hospitalized,O
before,O
treatment,O
began,O
",",O
with,O
whom,O
particularly,O
strict,O
therapeutic,O
precautions,O
were,O
taken,O
",",O
i.e.,O
",",O
initial,O
dose,O
less,O
than,O
10,O
mg,O
of,O
DEC,I-Entity
",",O
very,O
gradual,O
dose,O
increases,O
",",O
and,O
associated,O
anti,O
-,O
allergic,O
treatment,O
.,O
The,O
relationship,O
between,O
the,O
occurrence,O
of,O
encephalitis,I-Entity
and,O
the,O
decrease,O
in,O
microfilaremia,I-Entity
is,O
evident,O
.,O
Delirium,I-Entity
in,O
an,O
elderly,O
woman,O
possibly,O
associated,O
with,O
administration,O
of,O
misoprostol,I-Entity
.,O
Misoprostol,I-Entity
has,O
been,O
associated,O
with,O
adverse,O
reactions,O
",",O
including,O
gastrointestinal,O
symptoms,O
",",O
gynecologic,O
problems,O
",",O
and,O
headache,I-Entity
.,O
We,O
present,O
a,O
case,O
in,O
which,O
an,O
89-year,O
-,O
old,O
woman,O
in,O
a,O
long,O
-,O
term,O
care,O
facility,O
became,O
confused,O
after,O
the,O
initiation,O
of,O
misoprostol,I-Entity
therapy,O
.,O
Her,O
delirium,I-Entity
significantly,O
improved,O
after,O
misoprostol,I-Entity
was,O
discontinued,O
and,O
her,O
mental,O
status,O
returned,O
to,O
normal,O
within,O
a,O
week,O
.,O
Because,O
no,O
other,O
factors,O
related,O
to,O
this,O
patient,O
changed,O
significantly,O
",",O
the,O
delirium,I-Entity
experienced,O
by,O
this,O
patient,O
possibly,O
resulted,O
from,O
misoprostol,I-Entity
therapy,O
.,O
Hepatocellular,O
oxidant,O
stress,O
following,O
intestinal,O
ischemia,I-Entity
-,O
reperfusion,B-Entity
injury,I-Entity
.,O
Reperfusion,O
of,O
ischemic,I-Entity
intestine,O
results,O
in,O
acute,O
liver,B-Entity
dysfunction,I-Entity
characterized,O
by,O
hepatocellular,O
enzyme,O
release,O
into,O
plasma,O
",",O
reduction,O
in,O
bile,O
flow,O
rate,O
",",O
and,O
neutrophil,O
sequestration,O
within,O
the,O
liver,O
.,O
The,O
pathophysiology,O
underlying,O
this,O
acute,O
hepatic,B-Entity
injury,I-Entity
is,O
unknown,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
whether,O
oxidants,O
are,O
associated,O
with,O
the,O
hepatic,B-Entity
injury,I-Entity
and,O
to,O
determine,O
the,O
relative,O
value,O
of,O
several,O
indirect,O
methods,O
of,O
assessing,O
oxidant,O
exposure,O
in,O
vivo,O
.,O
Rats,O
were,O
subjected,O
to,O
a,O
standardized,O
intestinal,O
ischemia,I-Entity
-,O
reperfusion,B-Entity
injury,I-Entity
.,O
Hepatic,O
tissue,O
was,O
assayed,O
for,O
lipid,O
peroxidation,O
products,O
and,O
oxidized,B-Entity
and,I-Entity
reduced,I-Entity
glutathione,I-Entity
.,O
There,O
was,O
no,O
change,O
in,O
hepatic,O
tissue,O
total,O
glutathione,I-Entity
following,O
intestinal,O
ischemia,I-Entity
-,O
reperfusion,B-Entity
injury,I-Entity
.,O
Oxidized,B-Entity
glutathione,I-Entity
(,O
GSSG,I-Entity
),O
increased,O
significantly,O
following,O
30,O
and,O
60,O
min,O
of,O
reperfusion,O
.,O
An,O
increase,O
in,O
GSSG,I-Entity
within,O
hepatic,O
tissue,O
during,O
intestinal,O
reperfusion,O
suggests,O
exposure,O
of,O
hepatocytes,O
to,O
an,O
oxidant,O
stress,O
.,O
These,O
data,O
also,O
suggest,O
that,O
the,O
measurement,O
of,O
tissue,O
GSSG,I-Entity
may,O
be,O
a,O
more,O
sensitive,O
indicator,O
of,O
oxidant,O
stress,O
than,O
measurement,O
of,O
products,O
of,O
lipid,O
peroxidation,O
.,O
Diphenhydramine,I-Entity
prevents,O
the,O
haemodynamic,O
changes,O
of,O
cimetidine,I-Entity
in,O
ICU,O
patients,O
.,O
Cimetidine,I-Entity
",",O
a,O
histamine,I-Entity
2,O
(,O
H2,O
),O
antagonist,O
",",O
produces,O
a,O
decrease,O
in,O
arterial,O
pressure,O
due,O
to,O
vasodilatation,O
",",O
especially,O
in,O
critically,O
ill,O
patients,O
.,O
This,O
may,O
be,O
because,O
cimetidine,I-Entity
acts,O
as,O
a,O
histamine,I-Entity
agonist,O
.,O
We,O
",",O
therefore,O
",",O
investigated,O
the,O
effects,O
of,O
the,O
histamine,I-Entity
1(H1,O
),O
receptor,O
antagonist,O
",",O
diphenhydramine,I-Entity
",",O
on,O
the,O
haemodynamic,O
changes,O
observed,O
after,O
cimetidine,I-Entity
in,O
ICU,O
patients,O
.,O
In,O
a,O
random,O
fashion,O
",",O
they,O
received,O
cimetidine,I-Entity
200,O
mg,O
iv,O
on,O
one,O
day,O
",",O
and,O
on,O
the,O
other,O
",",O
a,O
pretreatment,O
of,O
diphenhydramine,I-Entity
40,O
mg,O
iv,O
with,O
cimetidine,I-Entity
200,O
mg,O
iv,O
.,O
11.4,O
mmHg,O
(,O
P,O
less,O
than,O
0.01,O
),O
two,O
minutes,O
after,O
cimetidine,I-Entity
.,O
We,O
conclude,O
that,O
an,O
H1,O
antagonist,O
may,O
be,O
useful,O
in,O
preventing,O
hypotension,I-Entity
caused,O
by,O
iv,O
cimetidine,I-Entity
",",O
since,O
the,O
vasodilating,O
activity,O
of,O
cimetidine,I-Entity
is,O
mediated,O
",",O
in,O
part,O
",",O
through,O
the,O
H1,O
receptor,O
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
due,O
to,O
rifampicin,I-Entity
.,O
A,O
23-year,O
-,O
old,O
male,O
patient,O
with,O
bacteriologically,O
proven,O
pulmonary,B-Entity
tuberculosis,I-Entity
was,O
treated,O
with,O
the,O
various,O
regimens,O
of,O
antituberculosis,O
drugs,O
for,O
nearly,O
15,O
months,O
.,O
Rifampicin,I-Entity
was,O
administered,O
thrice,O
as,O
one,O
of,O
the,O
3,O
-,O
4,O
drug,O
regimen,O
and,O
each,O
time,O
he,O
developed,O
untoward,O
side,O
effects,O
like,O
nausea,I-Entity
",",O
vomiting,I-Entity
and,O
fever,I-Entity
with,O
chills,O
and,O
rigors,O
.,O
Severe,O
polyneuropathy,I-Entity
and,O
motor,O
loss,O
after,O
intrathecal,O
thiotepa,I-Entity
combination,O
chemotherapy,O
:,O
Two,O
cases,O
of,O
severe,O
delayed,O
neurologic,B-Entity
toxicity,I-Entity
related,O
to,O
the,O
administration,O
of,O
intrathecal,O
(,O
IT,O
),O
combination,O
chemotherapy,O
including,O
thiotepa,I-Entity
(,O
TSPA,I-Entity
),O
are,O
presented,O
.,O
Both,O
cases,O
developed,O
axonal,B-Entity
neuropathy,I-Entity
with,O
motor,O
predominance,O
in,O
the,O
lower,O
extremities,O
1,O
and,O
6,O
months,O
after,O
IT,O
chemotherapy,O
was,O
administered,O
.,O
Neurologic,B-Entity
toxicities,I-Entity
have,O
been,O
described,O
with,O
IT,O
-,O
methotrexate,I-Entity
",",O
IT,O
-,O
cytosine,B-Entity
arabinoside,I-Entity
and,O
IT,O
-,O
TSPA,I-Entity
.,O
To,O
our,O
knowledge,O
",",O
however,O
",",O
axonal,B-Entity
neuropathy,I-Entity
In,O
spite,O
of,O
the,O
fact,O
that,O
TSPA,I-Entity
is,O
a,O
useful,O
IT,O
agent,O
",",O
its,O
combination,O
with,O
MTX,I-Entity
",",O
ara,B-Entity
-,I-Entity
C,I-Entity
and,O
radiotherapy,O
could,O
cause,O
severe,O
neurotoxicity,I-Entity
.,O
This,O
unexpected,O
complication,O
indicates,O
the,O
need,O
for,O
further,O
toxicology,O
research,O
on,O
IT,O
-,O
TSPA,I-Entity
.,O
Effects,O
of,O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
on,O
large,O
epicardial,O
and,O
small,O
coronary,O
arteries,O
in,O
conscious,O
dogs,O
.,O
bolus,O
administration,O
of,O
cromakalim,I-Entity
(,O
1,O
-,O
10,O
micrograms,O
/,O
kg,O
),O
and,O
pinacidil,I-Entity
(,O
3,O
-,O
100,O
micrograms,O
/,O
kg,O
),O
on,O
large,O
(,O
circumflex,O
artery,O
),O
and,O
small,O
coronary,O
arteries,O
and,O
on,O
systemic,O
hemodynamics,O
were,O
investigated,O
in,O
chronically,O
instrumented,O
conscious,O
dogs,O
and,O
compared,O
to,O
those,O
of,O
nitroglycerin,I-Entity
(,O
0.03,O
-,O
10,O
micrograms,O
/,O
kg,O
),O
.,O
Nitroglycerin,I-Entity
",",O
up,O
to,O
0.3,O
micrograms,O
/,O
kg,O
",",O
selectively,O
increased,O
circumflex,O
artery,O
diameter,O
(,O
CxAD,O
),O
without,O
simultaneously,O
affecting,O
any,O
other,O
cardiac,O
or,O
systemic,O
hemodynamic,O
parameter,O
.,O
In,O
contrast,O
",",O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
at,O
all,O
doses,O
and,O
nitroglycerin,I-Entity
at,O
doses,O
higher,O
than,O
0.3,O
micrograms,O
/,O
kg,O
simultaneously,O
and,O
dose,O
-,O
dependently,O
increased,O
CxAD,O
",",O
coronary,O
blood,O
flow,O
and,O
heart,O
rate,O
and,O
decreased,O
coronary,O
vascular,O
resistance,O
and,O
aortic,O
pressure,O
.,O
Cromakalim,I-Entity
was,O
approximately,O
8-,O
to,O
9.5-fold,O
more,O
potent,O
than,O
pinacidil,I-Entity
in,O
increasing,O
CxAD,O
.,O
Vasodilation,O
of,O
large,O
and,O
small,O
coronary,O
vessels,O
and,O
hypotension,I-Entity
induced,O
by,O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
were,O
not,O
affected,O
by,O
prior,O
combined,O
beta,B-Entity
adrenergic,I-Entity
and,I-Entity
muscarinic,I-Entity
receptors,I-Entity
blockade,I-Entity
but,O
drug,O
-,O
induced,O
tachycardia,I-Entity
was,O
abolished,O
.,O
When,O
circumflex,O
artery,O
blood,O
flow,O
was,O
maintained,O
constant,O
",",O
the,O
increases,O
in,O
CxAD,O
induced,O
by,O
cromakalim,I-Entity
(,O
10,O
micrograms,O
/,O
kg,O
),O
",",O
pinacidil,I-Entity
(,O
30,O
micrograms,O
/,O
kg,O
),O
and,O
nitroglycerin,I-Entity
(,O
10,O
micrograms,O
/,O
kg,O
),O
were,O
reduced,O
by,O
68,O
+,O
/-,O
Thus,O
",",O
whereas,O
nitroglycerin,I-Entity
preferentially,O
and,O
flow,O
-,O
independently,O
dilates,O
large,O
coronary,O
arteries,O
",",O
cromakalim,I-Entity
and,O
pinacidil,I-Entity
dilate,O
both,O
large,O
and,O
small,O
coronary,O
arteries,O
and,O
this,O
effect,O
is,O
not,O
dependent,O
upon,O
the,O
simultaneous,O
beta,O
adrenoceptors,O
-,O
mediated,O
rise,O
in,O
myocardial,O
metabolic,O
demand,O
.,O
Finally,O
",",O
two,O
mechanisms,O
at,O
least,O
",",O
direct,O
vasodilation,O
and,O
flow,O
dependency,O
",",O
are,O
involved,O
in,O
the,O
cromakalim-,I-Entity
and,O
pinacidil,I-Entity
-,O
induced,O
increase,O
in,O
CxAD,O
.,O
Mefenamic,B-Entity
acid,I-Entity
-,O
induced,O
neutropenia,I-Entity
and,O
renal,B-Entity
failure,I-Entity
in,O
elderly,O
females,O
with,O
hypothyroidism,I-Entity
.,O
We,O
report,O
mefenamic,B-Entity
acid,I-Entity
-,O
induced,O
non,O
-,O
oliguric,O
renal,B-Entity
failure,I-Entity
and,O
severe,O
neutropenia,I-Entity
occurring,O
simultaneously,O
in,O
two,O
elderly,O
females,O
.,O
The,O
neutropenia,I-Entity
was,O
due,O
to,O
maturation,O
arrest,O
of,O
the,O
myeloid,O
series,O
in,O
one,O
patient,O
.,O
Both,O
patients,O
were,O
also,O
hypothyroid,I-Entity
",",O
but,O
it,O
is,O
not,O
clear,O
whether,O
this,O
was,O
a,O
predisposing,O
factor,O
to,O
the,O
development,O
of,O
these,O
adverse,O
reactions,O
.,O
However,O
",",O
it,O
would,O
seem,O
prudent,O
not,O
to,O
use,O
mefenamic,B-Entity
acid,I-Entity
in,O
hypothyroid,I-Entity
patients,O
until,O
the,O
hypothyroidism,I-Entity
has,O
been,O
corrected,O
.,O
Etiology,O
of,O
hypercalcemia,I-Entity
in,O
hemodialysis,O
patients,O
on,O
calcium,B-Entity
carbonate,I-Entity
therapy,O
.,O
Fourteen,O
of,O
39,O
dialysis,O
patients,O
(,O
36%,O
),O
became,O
hypercalcemic,I-Entity
after,O
switching,O
to,O
calcium,B-Entity
carbonate,I-Entity
as,O
their,O
principal,O
phosphate,I-Entity
binder,O
.,O
In,O
order,O
to,O
identify,O
risk,O
factors,O
associated,O
with,O
the,O
development,O
of,O
hypercalcemia,I-Entity
",",O
indirect,O
parameters,O
of,O
intestinal,O
calcium,I-Entity
reabsorption,O
and,O
bone,O
turnover,O
rate,O
in,O
these,O
14,O
patients,O
were,O
compared,O
with,O
results,O
in,O
14,O
eucalcemic,O
patients,O
matched,O
for,O
age,O
",",O
sex,O
",",O
length,O
of,O
time,O
on,O
dialysis,O
",",O
and,O
etiology,O
of,O
renal,B-Entity
disease,I-Entity
.,O
In,O
addition,O
to,O
experiencing,O
hypercalcemic,I-Entity
episodes,O
with,O
peak,O
calcium,I-Entity
values,O
of,O
2.7,O
to,O
3.8,O
mmol,O
/,O
L,O
(,O
10.7,O
to,O
15.0,O
mg,O
/,O
dL,O
),O
",",O
patients,O
in,O
the,O
hypercalcemic,I-Entity
group,O
exhibited,O
a,O
significant,O
increase,O
in,O
the,O
mean,O
calcium,I-Entity
concentration,O
obtained,O
during,O
6,O
months,O
before,O
the,O
switch,O
",",O
compared,O
with,O
the,O
mean,O
value,O
obtained,O
during,O
the,O
7,O
months,O
of,O
observation,O
after,O
the,O
switch,O
(,O
2.4,O
+,O
/-,O
In,O
contrast,O
",",O
eucalcemic,O
patients,O
exhibited,O
no,O
change,O
in,O
mean,O
calcium,I-Entity
values,O
over,O
the,O
same,O
time,O
period,O
(,O
2.3,O
+,O
/-,O
CaCO3,I-Entity
dosage,O
",",O
calculated,O
dietary,O
calcium,I-Entity
intake,O
",",O
and,O
circulating,O
levels,O
of,O
vitamin,B-Entity
D,I-Entity
metabolites,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Physical,O
activity,O
index,O
and,O
predialysis,O
serum,O
bicarbonate,I-Entity
levels,O
also,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Methyldopa,I-Entity
-,O
induced,O
hemolytic,B-Entity
anemia,I-Entity
in,O
a,O
15,O
year,O
old,O
presenting,O
as,O
near,O
-,O
syncope,I-Entity
.,O
Methyldopa,I-Entity
is,O
an,O
antihypertensive,O
medication,O
which,O
is,O
available,O
generically,O
and,O
under,O
the,O
trade,O
name,O
Aldomet,I-Entity
that,O
is,O
widely,O
prescribed,O
in,O
the,O
adult,O
population,O
and,O
infrequently,O
used,O
in,O
children,O
.,O
Methyldopa,I-Entity
causes,O
an,O
autoimmune,B-Entity
hemolytic,I-Entity
anemia,I-Entity
in,O
a,O
small,O
percentage,O
of,O
patients,O
who,O
take,O
the,O
drug,O
.,O
We,O
report,O
a,O
case,O
of,O
methyldopa,I-Entity
-,O
induced,O
hemolytic,B-Entity
anemia,I-Entity
in,O
a,O
15-year,O
-,O
old,O
boy,O
who,O
presented,O
to,O
the,O
emergency,B-Entity
department,I-Entity
with,O
near,O
-,O
syncope,I-Entity
.,O
The,O
boy,O
had,O
been,O
treated,O
with,O
intravenous,O
methyldopa,I-Entity
during,O
a,O
trauma,I-Entity
admission,O
seven,O
weeks,O
prior,O
to,O
presentation,O
.,O
Transfusion,O
and,O
corticosteroid,I-Entity
therapy,O
resulted,O
in,O
a,O
complete,O
recovery,O
of,O
the,O
patient,O
.,O
A,O
brief,O
review,O
of,O
autoimmune,O
and,O
drug,O
-,O
induced,O
hemolytic,B-Entity
anemias,I-Entity
is,O
provided,O
.,O
The,O
long,O
-,O
term,O
safety,O
of,O
danazol,I-Entity
in,O
women,O
with,O
hereditary,B-Entity
angioedema,I-Entity
.,O
Although,O
the,O
short,O
-,O
term,O
safety,O
(,O
less,O
than,O
or,O
equal,O
to,O
6,O
months,O
),O
of,O
danazol,I-Entity
has,O
been,O
established,O
in,O
a,O
variety,O
of,O
settings,O
",",O
no,O
information,O
exists,O
as,O
to,O
its,O
long,O
-,O
term,O
safety,O
.,O
We,O
therefore,O
investigated,O
the,O
long,O
-,O
term,O
safety,O
of,O
danazol,I-Entity
by,O
performing,O
a,O
retrospective,O
chart,O
review,O
of,O
60,O
female,O
patients,O
with,O
hereditary,B-Entity
angioedema,I-Entity
treated,O
with,O
danazol,I-Entity
for,O
a,O
continuous,O
period,O
of,O
6,O
months,O
or,O
longer,O
.,O
Menstrual,B-Entity
abnormalities,I-Entity
(,O
79%,O
),O
",",O
weight,B-Entity
gain,I-Entity
(,O
60%,O
),O
",",O
muscle,B-Entity
cramps,I-Entity
/,O
myalgias,I-Entity
(,O
40%,O
),O
",",O
and,O
transaminase,O
elevations,O
(,O
40%,O
),O
were,O
the,O
most,O
common,O
adverse,O
reactions,O
.,O
We,O
conclude,O
that,O
",",O
despite,O
a,O
relatively,O
high,O
incidence,O
of,O
adverse,O
reactions,O
",",O
danazol,I-Entity
has,O
proven,O
to,O
be,O
remarkably,O
safe,O
over,O
the,O
long,O
-,O
term,O
in,O
this,O
group,O
of,O
patients,O
.,O
Patient,O
tolerance,O
study,O
of,O
topical,O
chlorhexidine,B-Entity
diphosphanilate,I-Entity
:,O
a,O
new,O
topical,O
agent,O
for,O
burns,I-Entity
.,O
Effective,O
topical,O
antimicrobial,O
agents,O
decrease,O
infection,I-Entity
and,O
mortality,O
in,O
burn,I-Entity
patients,O
.,O
Chlorhexidine,B-Entity
phosphanilate,I-Entity
(,O
CHP,I-Entity
),O
",",O
a,O
new,O
broad,O
-,O
spectrum,O
antimicrobial,O
agent,O
",",O
has,O
been,O
evaluated,O
as,O
a,O
topical,O
burn,I-Entity
wound,O
dressing,O
in,O
cream,O
form,O
",",O
but,O
preliminary,O
clinical,O
trials,O
reported,O
that,O
it,O
was,O
painful,O
upon,O
application,O
.,O
This,O
study,O
compared,O
various,O
concentrations,O
of,O
CHP,I-Entity
to,O
determine,O
if,O
a,O
tolerable,O
concentration,O
could,O
be,O
identified,O
with,O
retention,O
of,O
antimicrobial,O
efficacy,O
.,O
Twenty,O
-,O
nine,O
burn,I-Entity
patients,O
",",O
each,O
with,O
two,O
similar,O
burns,I-Entity
which,O
could,O
be,O
separately,O
treated,O
",",O
were,O
given,O
pairs,O
of,O
treatments,O
at,O
successive,O
12-h,O
intervals,O
over,O
a,O
3-day,O
period,O
.,O
One,O
burn,I-Entity
site,O
was,O
treated,O
with,O
each,O
of,O
four,O
different,O
CHP,I-Entity
concentrations,O
",",O
from,O
0.25,O
per,O
cent,O
to,O
2,O
per,O
cent,O
",",O
their,O
vehicle,O
",",O
and,O
1,O
per,O
cent,O
silver,B-Entity
sulphadiazine,I-Entity
(,O
AgSD,I-Entity
),O
cream,O
",",O
an,O
antimicrobial,O
agent,O
frequently,O
used,O
for,O
topical,O
treatment,O
of,O
burn,I-Entity
wounds,O
.,O
The,O
other,O
site,O
was,O
always,O
treated,O
with,O
AgSD,I-Entity
cream,O
.,O
There,O
was,O
a,O
direct,O
relationship,O
between,O
CHP,I-Entity
concentration,O
and,O
patients,O
',O
ratings,O
of,O
pain,I-Entity
on,O
an,O
analogue,O
scale,O
.,O
The,O
0.25,O
per,O
cent,O
CHP,I-Entity
cream,O
was,O
closest,O
to,O
AgSD,I-Entity
in,O
pain,I-Entity
tolerance,O
;,O
however,O
",",O
none,O
of,O
the,O
treatments,O
differed,O
statistically,O
from,O
AgSD,I-Entity
or,O
from,O
each,O
other,O
.,O
In,O
addition,O
",",O
ease,O
of,O
application,O
of,O
CHP,I-Entity
creams,O
was,O
less,O
satisfactory,O
than,O
that,O
of,O
AgSD,I-Entity
.,O
It,O
was,O
concluded,O
that,O
formulations,O
at,O
or,O
below,O
0.5,O
per,O
cent,O
CHP,I-Entity
may,O
prove,O
acceptable,O
for,O
wound,O
care,O
",",O
but,O
the,O
vehicle,O
system,O
needs,O
pharmaceutical,O
improvement,O
to,O
render,O
it,O
more,O
tolerable,O
and,O
easier,O
to,O
use,O
.,O
Dose,O
-,O
dependent,O
neurotoxicity,I-Entity
of,O
high,O
-,O
dose,O
busulfan,I-Entity
in,O
children,O
:,O
a,O
clinical,O
and,O
pharmacological,O
study,O
.,O
Busulfan,I-Entity
is,O
known,O
to,O
be,O
neurotoxic,I-Entity
in,O
animals,O
and,O
humans,O
",",O
but,O
its,O
acute,O
neurotoxicity,I-Entity
remains,O
poorly,O
characterized,O
in,O
children,O
.,O
We,O
report,O
here,O
a,O
retrospective,O
study,O
of,O
123,O
children,O
(,O
median,O
age,O
",",O
6.5,O
years,O
),O
receiving,O
high,O
-,O
dose,O
busulfan,I-Entity
in,O
combined,O
chemotherapy,O
before,O
bone,O
marrow,O
transplantation,O
for,O
malignant,O
solid,O
tumors,I-Entity
",",O
brain,B-Entity
tumors,I-Entity
excluded,O
.,O
Busulfan,I-Entity
was,O
given,O
p.o,O
.,O
Ninety,O
-,O
six,O
patients,O
were,O
not,O
given,O
anticonvulsive,O
prophylaxis,O
;,O
7,O
(,O
7.5%,O
),O
developed,O
seizures,I-Entity
during,O
the,O
4,O
days,O
of,O
the,O
busulfan,I-Entity
course,O
or,O
within,O
24,O
h,O
after,O
the,O
last,O
dosing,O
.,O
When,O
the,O
total,O
busulfan,I-Entity
dose,O
was,O
taken,O
into,O
account,O
",",O
there,O
was,O
a,O
significant,O
difference,O
in,O
terms,O
of,O
neurotoxicity,I-Entity
incidence,O
among,O
patients,O
under,O
16,O
mg,O
/,O
kg,O
(,O
1,O
of,O
57,O
",",O
1.7%,O
),O
and,O
patients,O
under,O
600,O
mg,O
/,O
m2,O
(,O
6,O
of,O
39,O
",",O
15.4%,O
),O
(,O
P,O
less,O
than,O
0.02,O
),O
.,O
Twenty,O
-,O
seven,O
patients,O
were,O
given,O
a,O
600-mg,O
/,O
m2,O
busulfan,I-Entity
total,O
dose,O
with,O
continuous,O
i.v,O
.,O
infusion,O
of,O
clonazepam,I-Entity
;,O
none,O
had,O
any,O
neurological,B-Entity
symptoms,I-Entity
.,O
Busulfan,I-Entity
levels,O
were,O
measured,O
by,O
a,O
gas,O
chromatographic,O
-,O
mass,O
spectrometry,O
assay,O
in,O
the,O
plasma,O
and,O
cerebrospinal,O
fluid,O
of,O
9,O
children,O
without,O
central,B-Entity
nervous,I-Entity
system,I-Entity
disease,I-Entity
under,O
600,O
mg,O
/,O
m2,O
busulfan,I-Entity
with,O
clonazepam,I-Entity
:,O
busulfan,I-Entity
cerebrospinal,O
fluid,O
:,O
plasma,O
ratio,O
was,O
1.39,O
.,O
This,O
was,O
significantly,O
different,O
(,O
P,O
less,O
than,O
0.02,O
),O
from,O
the,O
cerebrospinal,O
fluid,O
:,O
plasma,O
ratio,O
previously,O
defined,O
in,O
children,O
receiving,O
a,O
16-mg,O
/,O
kg,O
total,O
dose,O
of,O
busulfan,I-Entity
.,O
This,O
study,O
shows,O
that,O
busulfan,I-Entity
neurotoxicity,I-Entity
is,O
dose,O
-,O
dependent,O
in,O
children,O
and,O
efficiently,O
prevented,O
by,O
clonazepam,I-Entity
.,O
A,O
busulfan,I-Entity
dose,O
calculated,O
on,O
the,O
basis,O
of,O
body,O
surface,O
area,O
",",O
resulting,O
in,O
higher,O
doses,O
in,O
young,O
children,O
",",O
was,O
followed,O
by,O
increased,O
neurotoxicity,I-Entity
",",O
close,O
to,O
neurotoxicity,I-Entity
incidence,O
observed,O
in,O
adults,O
.,O
Since,O
plasma,O
pharmacokinetic,O
studies,O
showed,O
a,O
faster,O
busulfan,I-Entity
clearance,O
in,O
children,O
than,O
in,O
adults,O
",",O
this,O
new,O
dose,O
may,O
approximate,O
more,O
closely,O
the,O
adult,O
systemic,O
exposure,O
obtained,O
after,O
the,O
usual,O
16-mg,O
/,O
kg,O
total,O
dose,O
",",O
with,O
potential,O
inferences,O
in,O
terms,O
of,O
anticancer,O
or,O
myeloablative,O
effects,O
.,O
The,O
busulfan,I-Entity
dose,O
in,O
children,O
and,O
infants,O
undergoing,O
bone,O
marrow,O
transplantation,O
should,O
be,O
reconsidered,O
on,O
the,O
basis,O
of,O
pharmacokinetic,O
studies,O
.,O
Histamine,I-Entity
antagonists,O
and,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
cardiac,O
surgical,O
patients,O
.,O
Hemodynamic,O
effects,O
and,O
histamine,I-Entity
release,O
by,O
bolus,O
injection,O
of,O
0.35,O
mg,O
/,O
kg,O
of,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
were,O
studied,O
in,O
24,O
patients,O
.,O
H1-,O
and,O
H2-histamine,I-Entity
antagonists,O
or,O
placebo,O
were,O
given,O
before,O
dosing,O
with,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
in,O
a,O
randomized,O
double,O
-,O
blind,O
fashion,O
to,O
four,O
groups,O
:,O
group,O
1,O
-,O
-placebo,O
;,O
group,O
2,O
-,O
-cimetidine,I-Entity
",",O
4,O
mg,O
/,O
kg,O
",",O
plus,O
placebo,O
;,O
group,O
3,O
-,O
-chlorpheniramine,I-Entity
",",O
0.1,O
mg,O
/,O
kg,O
",",O
plus,O
placebo,O
;,O
and,O
group,O
4,O
-,O
-cimetidine,I-Entity
plus,O
chlorpheniramine,I-Entity
.,O
Histamine,I-Entity
release,O
occurred,O
in,O
most,O
patients,O
",",O
the,O
highest,O
level,O
2,O
minutes,O
after,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
dosing,O
.,O
Group,O
1,O
had,O
a,O
moderate,O
negative,O
correlation,O
between,O
plasma,O
histamine,I-Entity
change,O
and,O
systemic,O
vascular,O
resistance,O
(,O
r,O
=,O
0.58,O
;,O
P,O
less,O
than,O
0.05,O
),O
not,O
present,O
in,O
group,O
4,O
.,O
These,O
data,O
demonstrate,O
that,O
the,O
hemodynamic,O
changes,O
associated,O
with,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
dosing,O
are,O
only,O
partially,O
explained,O
by,O
histamine,I-Entity
release,O
.,O
Convulsant,O
effect,O
of,O
lindane,I-Entity
and,O
regional,O
brain,O
concentration,O
of,O
GABA,I-Entity
and,O
dopamine,I-Entity
.,O
Lindane,I-Entity
(,O
gamma,B-Entity
-,I-Entity
hexachlorocyclohexane,I-Entity
),O
is,O
an,O
organochlorine,O
insecticide,O
with,O
known,O
neurotoxic,I-Entity
effects,O
.,O
Its,O
mechanism,O
of,O
action,O
is,O
not,O
well,O
understood,O
although,O
it,O
has,O
been,O
proposed,O
that,O
lindane,I-Entity
acts,O
as,O
a,O
non,O
-,O
competitive,O
antagonist,O
at,O
the,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
(,O
GABA)-A,I-Entity
receptor,O
.,O
We,O
studied,O
the,O
effect,O
of,O
lindane,I-Entity
(,O
150,O
mg,O
/,O
kg,O
),O
on,O
the,O
GABAergic,O
and,O
dopaminergic,O
systems,O
by,O
measuring,O
the,O
concentration,O
of,O
GABA,I-Entity
",",O
dopamine,I-Entity
and,O
its,O
metabolites,O
in,O
7,O
brain,O
areas,O
at,O
the,O
onset,O
of,O
seizures,I-Entity
.,O
All,O
animals,O
suffered,O
tonic,O
convulsions,I-Entity
at,O
18.3,O
1.4,O
min,O
after,O
lindane,I-Entity
administration,O
.,O
The,O
concentration,O
of,O
GABA,I-Entity
was,O
only,O
slightly,O
but,O
significantly,O
decreased,O
in,O
the,O
colliculi,O
without,O
modifications,O
in,O
the,O
other,O
areas,O
.,O
The,O
concentration,O
of,O
dopamine,I-Entity
was,O
increased,O
in,O
the,O
mesencephalon,O
and,O
that,O
of,O
its,O
metabolite,O
DOPAC,I-Entity
was,O
also,O
increased,O
in,O
the,O
mesencephalon,O
and,O
the,O
striatum,O
.,O
Two,O
cases,O
of,O
propylthiouracil,I-Entity
-,O
associated,O
acute,O
hepatitis,I-Entity
",",O
one,O
case,O
of,O
fatal,O
methimazole,I-Entity
-,O
associated,O
hepatocellular,B-Entity
necrosis,I-Entity
and,O
one,O
case,O
of,O
propylthiouracil,I-Entity
-,O
associated,O
lupus,B-Entity
-,I-Entity
like,I-Entity
syndrome,I-Entity
are,O
described,O
.,O
It,O
is,O
concluded,O
that,O
in,O
most,O
circumstances,O
131I,O
is,O
the,O
therapy,O
of,O
choice,O
for,O
hyperthyroidism,I-Entity
.,O
Anticonvulsant,O
actions,O
of,O
MK-801,I-Entity
on,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
of,O
status,B-Entity
epilepticus,I-Entity
in,O
rats,O
.,O
MK-801,I-Entity
",",O
a,O
noncompetitive,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
antagonist,O
",",O
was,O
tested,O
for,O
anticonvulsant,O
effects,O
in,O
rats,O
using,O
two,O
seizure,I-Entity
models,O
",",O
coadministration,O
of,O
lithium,I-Entity
and,O
pilocarpine,I-Entity
and,O
administration,O
of,O
a,O
high,O
dose,O
of,O
pilocarpine,I-Entity
alone,O
.,O
First,O
",",O
pretreatment,O
with,O
MK-801,I-Entity
produced,O
an,O
effective,O
and,O
dose,O
-,O
dependent,O
anticonvulsant,O
action,O
with,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
but,O
not,O
with,O
rats,O
treated,O
with,O
pilocarpine,I-Entity
alone,O
",",O
suggesting,O
that,O
different,O
biochemical,O
mechanisms,O
control,O
seizures,I-Entity
in,O
these,O
two,O
models,O
.,O
Second,O
",",O
the,O
anticonvulsant,O
effect,O
of,O
MK-801,I-Entity
in,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
only,O
occurred,O
after,O
initial,O
periods,O
of,O
seizure,I-Entity
activity,O
.,O
This,O
observation,O
is,O
suggested,O
to,O
be,O
an,O
in,O
vivo,O
demonstration,O
of,O
the,O
conclusion,O
derived,O
from,O
in,O
vitro,O
experiments,O
that,O
MK-801,I-Entity
binding,O
requires,O
agonist,O
-,O
induced,O
opening,O
of,O
the,O
channel,O
sites,O
of,O
the,O
NMDA,I-Entity
receptor,O
.,O
Third,O
",",O
although,O
it,O
is,O
relatively,O
easy,O
to,O
block,O
seizures,I-Entity
induced,O
by,O
lithium,I-Entity
and,O
pilocarpine,I-Entity
by,O
administration,O
of,O
anticonvulsants,O
prior,O
to,O
pilocarpine,I-Entity
",",O
it,O
is,O
more,O
difficult,O
to,O
terminate,O
ongoing,O
status,B-Entity
epilepticus,I-Entity
and,O
block,O
the,O
lethality,O
of,O
the,O
seizures,I-Entity
.,O
Administration,O
of,O
MK-801,I-Entity
30,O
or,O
60,O
min,O
after,O
pilocarpine,I-Entity
",",O
i.e.,O
",",O
during,O
status,B-Entity
epilepticus,I-Entity
",",O
gradually,O
reduced,O
electrical,O
and,O
behavioral,O
seizure,I-Entity
activity,O
and,O
greatly,O
enhanced,O
the,O
survival,O
rate,O
.,O
These,O
results,O
suggest,O
that,O
activation,O
of,O
NMDA,I-Entity
receptors,O
plays,O
an,O
important,O
role,O
in,O
status,B-Entity
epilepticus,I-Entity
and,O
brain,B-Entity
damage,I-Entity
in,O
the,O
lithium,I-Entity
-,O
pilocarpine,I-Entity
model,O
.,O
This,O
was,O
further,O
supported,O
by,O
results,O
showing,O
that,O
nonconvulsive,O
doses,O
of,O
NMDA,I-Entity
and,O
pilocarpine,I-Entity
were,O
synergistic,O
",",O
resulting,O
in,O
status,B-Entity
epilepticus,I-Entity
and,O
subsequent,O
mortality,O
.,O
Nifedipine,I-Entity
induced,O
bradycardia,I-Entity
in,O
a,O
patient,O
with,O
autonomic,B-Entity
neuropathy,I-Entity
.,O
An,O
80,O
year,O
old,O
diabetic,I-Entity
male,O
with,O
evidence,O
of,O
peripheral,B-Entity
and,I-Entity
autonomic,I-Entity
neuropathy,I-Entity
was,O
admitted,O
with,O
chest,B-Entity
pain,I-Entity
.,O
He,O
was,O
found,O
to,O
have,O
atrial,B-Entity
flutter,I-Entity
at,O
a,O
ventricular,O
rate,O
of,O
70/min,O
which,O
slowed,O
down,O
to,O
30,O
-,O
40/min,O
when,O
nifedipine,I-Entity
(,O
60,O
mg,O
),O
in,O
3,O
divided,O
doses,O
",",O
during,O
which,O
he,O
was,O
paced,O
at,O
a,O
rate,O
of,O
70/min,O
.,O
This,O
is,O
inconsistent,O
with,O
the,O
well,O
-,O
established,O
finding,O
that,O
nifedipine,I-Entity
induces,O
tachycardia,I-Entity
in,O
normally,O
innervated,O
hearts,O
.,O
However,O
",",O
in,O
hearts,O
deprived,O
of,O
compensatory,O
sympathetic,O
drive,O
",",O
it,O
may,O
lead,O
to,O
bradycardia,I-Entity
.,O
The,O
effect,O
of,O
haloperidol,I-Entity
in,O
cocaine,I-Entity
and,O
amphetamine,I-Entity
intoxication,O
.,O
The,O
effectiveness,O
of,O
haloperidol,I-Entity
pretreatment,O
in,O
preventing,O
the,O
toxic,O
effects,O
of,O
high,O
doses,O
of,O
amphetamine,I-Entity
and,O
cocaine,I-Entity
was,O
studied,O
in,O
rats,O
.,O
injection,O
of,O
amphetamine,I-Entity
75,O
mg,O
/,O
kg,O
(,O
100%,O
death,O
rate,O
),O
or,O
cocaine,I-Entity
70,O
mg,O
/,O
kg,O
(,O
82%,O
death,O
rate,O
),O
.,O
Haloperidol,I-Entity
failed,O
to,O
prevent,O
amphetamine,I-Entity
-,O
induced,O
seizures,I-Entity
",",O
but,O
did,O
lower,O
the,O
mortality,O
rate,O
at,O
most,O
doses,O
tested,O
.,O
Haloperidol,I-Entity
decreased,O
the,O
incidence,O
of,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
at,O
the,O
two,O
highest,O
doses,O
",",O
but,O
the,O
lowering,O
of,O
the,O
mortality,O
rate,O
did,O
not,O
reach,O
statistical,O
significance,O
at,O
any,O
dose,O
.,O
These,O
data,O
suggest,O
a,O
protective,O
role,O
for,O
the,O
central,O
dopamine,I-Entity
blocker,O
haloperidol,I-Entity
against,O
death,O
from,O
high,O
-,O
dose,O
amphetamine,I-Entity
exposure,O
without,O
reducing,O
the,O
incidence,O
of,O
seizures,I-Entity
.,O
In,O
contrast,O
",",O
haloperidol,I-Entity
demonstrated,O
an,O
ability,O
to,O
reduce,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
without,O
significantly,O
reducing,O
mortality,O
.,O
Autoradiographic,O
evidence,O
of,O
estrogen,I-Entity
binding,O
sites,O
in,O
nuclei,O
of,O
diethylstilbesterol,I-Entity
induced,O
hamster,O
renal,B-Entity
carcinomas,I-Entity
.,O
Estrogen,I-Entity
binding,O
sites,O
were,O
demonstrated,O
by,O
autoradiography,O
in,O
one,O
transplantable,O
and,O
five,O
primary,O
diethylstilbesterol,I-Entity
induced,O
renal,B-Entity
carcinomas,I-Entity
in,O
three,O
hamsters,O
.,O
Radiolabelling,O
",",O
following,O
the,O
in,O
vivo,O
injection,O
of,O
3H-17,O
beta,O
estradiol,I-Entity
",",O
was,O
increased,O
only,O
over,O
the,O
nuclei,O
of,O
tumor,I-Entity
cells,O
;,O
stereologic,O
analysis,O
revealed,O
a,O
4.5-,O
to,O
6.7-times,O
higher,O
concentration,O
of,O
reduced,O
silver,I-Entity
grains,O
over,O
nuclei,O
than,O
cytoplasm,O
of,O
these,O
cells,O
.,O
Despite,O
rapid,O
tubular,O
excretion,O
of,O
estradiol,I-Entity
which,O
peaked,O
in,O
less,O
than,O
1,O
This,O
is,O
the,O
first,O
published,O
report,O
documenting,O
the,O
preferential,O
in,O
vivo,O
binding,O
of,O
estrogen,I-Entity
to,O
nuclei,O
of,O
cells,O
in,O
estrogen,I-Entity
induced,O
hamster,O
renal,B-Entity
carcinomas,I-Entity
.,O
Bradycardia,I-Entity
due,O
to,O
biperiden,I-Entity
.,O
In,O
a,O
38-year,O
-,O
old,O
male,O
patient,O
suffering,O
from,O
a,O
severe,O
postzosteric,I-Entity
trigeminal,B-Entity
neuralgia,I-Entity
",",O
intravenous,O
application,O
of,O
10,O
mg,O
biperiden,B-Entity
lactate,I-Entity
led,O
to,O
a,O
long,O
-,O
lasting,O
paradoxical,O
reaction,O
characterized,O
by,O
considerable,O
bradycardia,I-Entity
",",O
dysarthria,I-Entity
",",O
and,O
dysphagia,I-Entity
.,O
The,O
heart,O
rate,O
was,O
back,O
to,O
normal,O
within,O
12,O
hours,O
upon,O
administration,O
of,O
orciprenaline,I-Entity
under,O
cardiac,O
monitoring,O
in,O
an,O
intensive,O
care,O
unit,O
.,O
Bradycardia,I-Entity
induced,O
by,O
biperiden,I-Entity
is,O
attributed,O
to,O
the,O
speed,O
of,O
injection,O
and,O
to,O
a,O
dose,O
-,O
related,O
dual,O
effect,O
of,O
atropine,I-Entity
-,O
like,O
drugs,O
on,O
muscarine,I-Entity
receptors,O
.,O
Deliberate,O
hypotension,I-Entity
induced,O
by,O
labetalol,I-Entity
with,O
halothane,I-Entity
",",O
enflurane,I-Entity
or,O
isoflurane,I-Entity
for,O
middle,O
-,O
ear,O
surgery,O
.,O
The,O
feasibility,O
of,O
using,O
labetalol,I-Entity
",",O
an,O
alpha-,O
and,O
beta,O
-,O
adrenergic,O
blocking,O
agent,O
",",O
as,O
a,O
hypotensive,I-Entity
agent,O
in,O
combination,O
with,O
inhalation,O
anaesthetics,O
(,O
halothane,I-Entity
",",O
enflurane,I-Entity
or,O
isoflurane,I-Entity
),O
was,O
studied,O
in,O
23,O
adult,O
patients,O
undergoing,O
middle,O
-,O
ear,O
surgery,O
.,O
10,O
min,O
in,O
the,O
halothane,I-Entity
(,O
H,I-Entity
),O
group,O
",",O
from,O
79,O
+,O
/-,O
11,O
min,O
in,O
the,O
enflurane,I-Entity
(,O
E,I-Entity
),O
group,O
",",O
and,O
from,O
80,O
+,O
/-,O
15,O
min,O
in,O
the,O
isoflurane,I-Entity
(,O
I,I-Entity
),O
group,O
.,O
The,O
mean,O
H,I-Entity
concentration,O
during,O
hypotension,I-Entity
in,O
the,O
inspiratory,O
gas,O
was,O
0.7,O
+,O
/-,O
0.1,O
vol%,O
",",O
the,O
mean,O
E,I-Entity
concentration,O
1.6,O
+,O
/-,O
I,I-Entity
concentration,O
1.0,O
+,O
/-,O
In,O
addition,O
",",O
the,O
patients,O
received,O
fentanyl,I-Entity
and,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
.,O
The,O
initial,O
dose,O
of,O
labetalol,I-Entity
for,O
lowering,O
blood,O
pressure,O
was,O
similar,O
",",O
0.52,O
-,O
0.59,O
mg,O
/,O
kg,O
",",O
in,O
all,O
the,O
groups,O
.,O
During,O
hypotension,I-Entity
",",O
the,O
heart,O
rate,O
was,O
stable,O
without,O
tachy-,B-Entity
or,I-Entity
bradycardia,I-Entity
.,O
The,O
operating,O
conditions,O
regarding,O
bleeding,I-Entity
were,O
estimated,O
in,O
a,O
double,O
-,O
blind,O
manner,O
",",O
and,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
groups,O
.,O
During,O
hypotension,I-Entity
",",O
the,O
serum,O
creatinine,I-Entity
concentration,O
rose,O
significantly,O
in,O
all,O
groups,O
from,O
the,O
values,O
before,O
hypotension,I-Entity
and,O
returned,O
postoperatively,O
to,O
the,O
initial,O
level,O
in,O
the,O
other,O
groups,O
",",O
except,O
the,O
isoflurane,I-Entity
group,O
.,O
After,O
hypotension,I-Entity
there,O
was,O
no,O
rebound,O
phenomenon,O
in,O
either,O
blood,O
pressure,O
or,O
heart,O
rate,O
.,O
These,O
results,O
indicate,O
that,O
labetalol,I-Entity
induces,O
easily,O
adjustable,O
hypotension,I-Entity
without,O
compensatory,O
tachycardia,I-Entity
and,O
rebound,O
hypertension,I-Entity
.,O
Convulsion,I-Entity
following,O
intravenous,O
fluorescein,I-Entity
angiography,O
.,O
Tonic,B-Entity
-,I-Entity
clonic,I-Entity
seizures,I-Entity
followed,O
intravenous,O
fluorescein,I-Entity
injection,O
for,O
fundus,O
angiography,O
in,O
a,O
47-year,O
-,O
old,O
male,O
.,O
Despite,O
precautions,O
this,O
adverse,O
reaction,O
recurred,O
on,O
re,O
-,O
exposure,O
to,O
intravenous,O
fluorescein,I-Entity
.,O
Pharmacology,O
of,O
ACC-9653,I-Entity
(,O
phenytoin,I-Entity
prodrug,O
),O
.,O
ACC-9653,I-Entity
",",O
the,O
disodium,B-Entity
phosphate,I-Entity
ester,I-Entity
of,O
"3-hydroxymethyl-5,5-diphenylhydantoin",I-Entity
",",O
is,O
a,O
prodrug,O
of,O
phenytoin,I-Entity
with,O
advantageous,O
physicochemical,O
properties,O
.,O
ACC-9653,I-Entity
is,O
rapidly,O
converted,O
enzymatically,O
to,O
phenytoin,I-Entity
in,O
vivo,O
.,O
ACC-9653,I-Entity
and,O
phenytoin,B-Entity
sodium,I-Entity
have,O
equivalent,O
anticonvulsant,O
activity,O
against,O
seizures,I-Entity
induced,O
by,O
maximal,O
electroshock,O
(,O
MES,O
),O
in,O
mice,O
following,O
i.p,O
.,O
ACC-9653,I-Entity
and,O
8,O
mg,O
/,O
kg,O
for,O
i.v,O
.,O
phenytoin,B-Entity
sodium,I-Entity
.,O
ACC-9653,I-Entity
and,O
phenytoin,B-Entity
sodium,I-Entity
have,O
similar,O
antiarrhythmic,O
activity,O
against,O
ouabain,I-Entity
-,O
induced,O
ventricular,B-Entity
tachycardia,I-Entity
in,O
anesthetized,O
dogs,O
.,O
The,O
total,O
doses,O
of,O
ACC-9653,I-Entity
or,O
phenytoin,B-Entity
sodium,I-Entity
necessary,O
to,O
convert,O
the,O
arrhythmia,I-Entity
to,O
a,O
normal,O
sinus,O
rhythm,O
were,O
24,O
+,O
/-,O
Only,O
phenytoin,B-Entity
sodium,I-Entity
displayed,O
in,O
vitro,O
antiarrhythmic,O
activity,O
against,O
strophanthidin,I-Entity
-,O
induced,O
arrhythmias,I-Entity
in,O
guinea,O
pig,O
right,O
atria,O
.,O
In,O
anesthetized,O
dogs,O
",",O
a,O
high,O
dose,O
of,O
ACC-9653,I-Entity
(,O
31,O
mg,O
/,O
kg,O
),O
was,O
infused,O
over,O
15,O
",",O
20,O
",",O
and,O
30,O
min,O
and,O
the,O
responses,O
were,O
compared,O
to,O
an,O
equimolar,O
dose,O
of,O
phenytoin,B-Entity
sodium,I-Entity
(,O
21,O
mg,O
/,O
kg,O
),O
.,O
The,O
ACC-9653,I-Entity
and,O
phenytoin,B-Entity
sodium,I-Entity
treatments,O
produced,O
similar,O
marked,O
reductions,O
in,O
diastolic,O
blood,O
pressure,O
and,O
contractile,O
force,O
(,O
LVdP,O
/,O
dt,O
),O
.,O
The,O
maximum,O
effects,O
of,O
each,O
treatment,O
occurred,O
at,O
the,O
time,O
of,O
maximum,O
phenytoin,B-Entity
sodium,I-Entity
levels,O
.,O
Acute,O
toxicity,I-Entity
studies,O
of,O
ACC-9653,I-Entity
and,O
phenytoin,B-Entity
sodium,I-Entity
were,O
carried,O
out,O
in,O
mice,O
",",O
rats,O
",",O
rabbits,O
",",O
and,O
dogs,O
by,O
i.v,O
.,O
Importantly,O
",",O
the,O
local,O
irritation,O
of,O
ACC-9653,I-Entity
was,O
markedly,O
less,O
than,O
phenytoin,B-Entity
sodium,I-Entity
following,O
i.m,O
.,O
Phenytoin,I-Entity
induced,O
fatal,O
hepatic,B-Entity
injury,I-Entity
.,O
A,O
61,O
year,O
old,O
female,O
developed,O
fatal,O
hepatic,B-Entity
failure,I-Entity
after,O
phenytoin,I-Entity
administration,O
.,O
A,O
typical,O
multisystem,O
clinical,O
pattern,O
precedes,O
the,O
manifestations,O
of,O
hepatic,B-Entity
injury,I-Entity
.,O
The,O
hematologic,O
",",O
biochemical,O
and,O
pathologic,O
features,O
indicate,O
a,O
mixed,O
hepatocellular,B-Entity
damage,I-Entity
due,O
to,O
drug,B-Entity
hypersensitivity,I-Entity
.,O
In,O
a,O
patient,O
receiving,O
phenytoin,I-Entity
who,O
presents,O
a,O
viral,O
-,O
like,O
illness,O
",",O
early,O
recognition,O
and,O
discontinuation,O
of,O
the,O
drug,O
are,O
mandatory,O
.,O
Treatment,O
of,O
lethal,O
pertussis,B-Entity
vaccine,I-Entity
reaction,O
with,O
histamine,I-Entity
H1,O
antagonists,O
.,O
We,O
studied,O
mortality,O
after,O
pertussis,I-Entity
immunization,O
in,O
the,O
mouse,O
.,O
Without,O
treatment,O
",",O
73,O
of,O
92,O
animals,O
(,O
80%,O
),O
died,O
after,O
injection,O
of,O
bovine,O
serum,O
albumin,O
(,O
BSA,O
),O
on,O
day,O
+,O
7,O
of,O
pertussis,I-Entity
immunization,O
.,O
After,O
pretreatment,O
with,O
3,O
mg,O
of,O
cyproheptadine,I-Entity
",",O
2,O
mg,O
mianserin,I-Entity
",",O
or,O
2,O
mg,O
chlorpheniramine,I-Entity
",",O
only,O
5,O
of,O
105,O
animals,O
(,O
5%,O
),O
died,O
after,O
receiving,O
BSA,O
on,O
day,O
+,O
7,O
(,O
p,O
less,O
than,O
0.001,O
),O
.,O
Blockade,O
of,O
histamine,I-Entity
H1,O
receptors,O
may,O
reduce,O
mortality,O
in,O
pertussis,I-Entity
immunization,O
-,O
induced,O
encephalopathy,I-Entity
in,O
mice,O
.,O
Support,O
for,O
adrenaline,I-Entity
-,O
hypertension,I-Entity
hypothesis,O
:,O
18,O
hour,O
pressor,O
effect,O
after,O
6,O
hours,O
adrenaline,I-Entity
infusion,O
.,O
In,O
a,O
double,O
blind,O
",",O
crossover,O
study,O
6,O
h,O
infusions,O
of,O
adrenaline,I-Entity
(,O
15,O
ng,O
/,O
kg,O
/,O
min,O
;,O
1,O
ng,O
=,O
5.458,O
pmol,O
),O
",",O
noradrenaline,I-Entity
(,O
30,O
ng,O
/,O
kg,O
/,O
min,O
;,O
1,O
ng,O
=,O
5.911,O
pmol,O
),O
",",O
and,O
a,O
5%,O
dextrose,I-Entity
solution,O
(,O
5.4,O
ml,O
/,O
h,O
),O
",",O
were,O
given,O
to,O
ten,O
healthy,O
volunteers,O
in,O
random,O
order,O
2,O
weeks,O
apart,O
.,O
Adrenaline,I-Entity
",",O
but,O
not,O
noradrenaline,I-Entity
",",O
caused,O
a,O
delayed,O
and,O
protracted,O
pressor,O
effect,O
.,O
Over,O
the,O
total,O
postinfusion,O
period,O
systolic,O
and,O
diastolic,O
arterial,O
pressure,O
were,O
6,O
(,O
SEM,O
2)%,O
and,O
7,O
(,O
2)%,O
",",O
respectively,O
",",O
higher,O
than,O
after,O
dextrose,I-Entity
infusion,O
(,O
ANOVA,O
",",O
p,O
less,O
than,O
0.001,O
),O
.,O
Thus,O
",",O
"""",O
stress,O
"""",O
levels,O
of,O
adrenaline,I-Entity
(,O
230,O
pg,O
/,O
ml,O
),O
for,O
6,O
h,O
cause,O
a,O
delayed,O
and,O
protracted,O
pressor,O
effect,O
.,O
These,O
findings,O
are,O
strong,O
support,O
for,O
the,O
adrenaline,I-Entity
-,O
hypertension,I-Entity
hypothesis,O
in,O
man,O
.,O
Effect,O
of,O
alkylxanthines,I-Entity
on,O
gentamicin,I-Entity
-,O
induced,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
in,O
the,O
rat,O
.,O
Adenosine,I-Entity
antagonists,O
have,O
been,O
previously,O
shown,O
to,O
be,O
of,O
benefit,O
in,O
some,O
ischaemic,I-Entity
and,O
nephrotoxic,I-Entity
models,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
(,O
ARF,I-Entity
),O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
effects,O
of,O
three,O
alkylxanthines,I-Entity
with,O
different,O
potencies,O
as,O
adenosine,I-Entity
antagonists,O
8-phenyltheophylline,I-Entity
",",O
theophylline,I-Entity
and,O
enprofylline,I-Entity
",",O
were,O
examined,O
in,O
rats,O
developing,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
after,O
4,O
daily,O
injections,O
of,O
gentamicin,I-Entity
(,O
200,O
mg,O
kg-1,O
),O
.,O
Renal,O
function,O
was,O
assessed,O
by,O
biochemical,O
(,O
plasma,O
urea,I-Entity
and,O
creatinine,I-Entity
),O
",",O
functional,O
(,O
urine,O
analysis,O
and,O
[,O
3H]inulin,O
and,O
[,O
14C]p,B-Entity
-,I-Entity
aminohippuric,I-Entity
acid,I-Entity
clearances,O
),O
and,O
morphological,O
(,O
degree,O
of,O
necrosis,I-Entity
),O
indices,O
.,O
However,O
",",O
any,O
improvement,O
produced,O
by,O
drug,O
treatment,O
was,O
largely,O
a,O
result,O
of,O
a,O
beneficial,O
effect,O
exerted,O
by,O
its,O
vehicle,O
(,O
polyethylene,B-Entity
glycol,I-Entity
and,O
NaOH,I-Entity
),O
.,O
The,O
lack,O
of,O
any,O
consistent,O
protective,O
effect,O
noted,O
with,O
the,O
alkylxanthines,I-Entity
tested,O
in,O
the,O
present,O
study,O
indicates,O
that,O
adenosine,I-Entity
plays,O
little,O
",",O
if,O
any,O
",",O
pathophysiological,O
role,O
in,O
gentamicin,I-Entity
-,O
induced,O
ARF,I-Entity
.,O
Adverse,O
ocular,O
reactions,O
possibly,O
associated,O
with,O
isotretinoin,I-Entity
.,O
A,O
total,O
of,O
261,O
adverse,O
ocular,O
reactions,O
occurred,O
in,O
237,O
patients,O
who,O
received,O
isotretinoin,I-Entity
",",O
a,O
commonly,O
used,O
drug,O
in,O
the,O
treatment,O
of,O
severe,O
cystic,O
acne,I-Entity
.,O
Blepharoconjunctivitis,I-Entity
",",O
subjective,O
complaints,O
of,O
dry,B-Entity
eyes,I-Entity
",",O
blurred,B-Entity
vision,I-Entity
",",O
contact,O
lens,O
intolerance,O
",",O
and,O
photodermatitis,I-Entity
are,O
reversible,O
side,O
effects,O
.,O
More,O
serious,O
ocular,O
adverse,O
reactions,O
include,O
papilledema,I-Entity
",",O
pseudotumor,B-Entity
cerebri,I-Entity
",",O
and,O
white,O
or,O
gray,O
subepithelial,O
corneal,B-Entity
opacities,I-Entity
;,O
all,O
of,O
these,O
are,O
reversible,O
if,O
the,O
drug,O
is,O
discontinued,O
.,O
Isotretinoin,I-Entity
is,O
contraindicated,O
in,O
pregnancy,O
because,O
of,O
the,O
many,O
reported,O
congenital,B-Entity
abnormalities,I-Entity
after,O
maternal,O
use,O
(,O
including,O
microphthalmos,I-Entity
",",O
orbital,O
hypertelorism,I-Entity
",",O
and,O
optic,B-Entity
nerve,I-Entity
hypoplasia,I-Entity
),O
.,O
Procaterol,I-Entity
and,O
terbutaline,I-Entity
in,O
bronchial,B-Entity
asthma,I-Entity
.,O
Procaterol,I-Entity
",",O
a,O
new,O
beta-2,O
adrenoceptor,O
stimulant,O
",",O
was,O
studied,O
in,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
",",O
cross,O
-,O
over,O
trial,O
in,O
patients,O
with,O
bronchial,B-Entity
asthma,I-Entity
.,O
Oral,O
procaterol,I-Entity
50,O
micrograms,O
b.d,O
.,O
",",O
procaterol,I-Entity
100,O
micrograms,O
b.d,O
.,O
terbutaline,I-Entity
5,O
mg,O
t.i.d,O
.,O
The,O
best,O
clinical,O
effect,O
was,O
found,O
with,O
terbutaline,I-Entity
.,O
Both,O
anti,O
-,O
asthmatic,I-Entity
and,O
tremorgenic,I-Entity
effects,O
of,O
procaterol,I-Entity
were,O
dose,O
-,O
related,O
.,O
Procaterol,I-Entity
appeared,O
effective,O
in,O
the,O
doses,O
tested,O
",",O
and,O
a,O
twice,O
daily,O
regimen,O
would,O
appear,O
to,O
be,O
suitable,O
with,O
this,O
drug,O
.,O
Subacute,O
effects,O
of,O
propranolol,I-Entity
and,O
B,O
24/76,O
on,O
isoproterenol,I-Entity
-,O
induced,O
rat,O
heart,B-Entity
hypertrophy,I-Entity
in,O
correlation,O
with,O
blood,O
pressure,O
.,O
24/76,O
i.e.,O
"1-(2,4-dichlorophenoxy)-3[2",O
-,O
"3,4-dimethoxyphenyl)ethanolamino]-prop",O
an-2-ol,O
",",O
which,O
is,O
characterized,O
by,O
beta,O
1-adrenoceptor,O
blocking,O
and,O
beta,O
2-adrenoceptor,O
stimulating,O
properties,O
with,O
propranolol,I-Entity
.,O
The,O
studies,O
were,O
performed,O
using,O
an,O
experimental,O
model,O
of,O
isoproterenol,I-Entity
-,O
induced,O
heart,B-Entity
hypertrophy,I-Entity
in,O
rats,O
.,O
A,O
correlation,O
of,O
the,O
blood,O
pressure,O
was,O
neither,O
found,O
in,O
the,O
development,O
nor,O
in,O
the,O
attempt,O
to,O
suppress,O
the,O
development,O
of,O
heart,B-Entity
hypertrophy,I-Entity
with,O
the,O
two,O
beta,O
-,O
receptor,O
blockers,O
.,O
Both,O
beta,O
-,O
blockers,O
influenced,O
the,O
development,O
of,O
hypertrophy,I-Entity
to,O
a,O
different,O
",",O
but,O
not,O
reproducible,O
extent,O
.,O
It,O
was,O
possible,O
to,O
suppress,O
the,O
increased,O
ornithine,I-Entity
decarboxylase,O
activity,O
with,O
both,O
beta,O
-,O
blockers,O
in,O
hypertrophied,B-Entity
hearts,I-Entity
",",O
but,O
there,O
was,O
no,O
effect,O
on,O
the,O
heart,O
mass,O
.,O
Neither,O
propranolol,I-Entity
nor,O
B,O
24/76,O
could,O
stop,O
the,O
changes,O
in,O
the,O
characteristic,O
myosin,O
isoenzyme,O
pattern,O
of,O
the,O
hypertrophied,I-Entity
rat,O
heart,O
.,O
Thus,O
",",O
the,O
investigations,O
did,O
not,O
provide,O
any,O
evidence,O
that,O
the,O
beta,O
-,O
receptor,O
blockers,O
propranolol,I-Entity
and,O
B,O
24/76,O
have,O
the,O
potency,O
to,O
prevent,O
isoproterenol,I-Entity
from,O
producing,O
heart,B-Entity
hypertrophy,I-Entity
.,O
Comparison,O
of,O
the,O
effect,O
of,O
oxitropium,B-Entity
bromide,I-Entity
and,O
of,O
slow,O
-,O
release,O
theophylline,I-Entity
on,O
nocturnal,O
asthma,I-Entity
.,O
The,O
effects,O
of,O
a,O
new,O
inhaled,O
antimuscarinic,O
drug,O
",",O
oxitropium,B-Entity
bromide,I-Entity
",",O
and,O
of,O
a,O
slow,O
-,O
release,O
theophylline,I-Entity
preparation,O
upon,O
nocturnal,O
asthma,I-Entity
were,O
compared,O
in,O
a,O
placebo,O
-,O
controlled,O
double,O
-,O
blind,O
study,O
.,O
Two,O
samples,O
were,O
studied,O
:,O
12,O
patients,O
received,O
oxitropium,I-Entity
at,O
600,O
micrograms,O
(,O
6,O
subjects,O
),O
or,O
at,O
400,O
micrograms,O
t.i.d,O
.,O
(,O
6,O
subjects,O
),O
whereas,O
11,O
received,O
theophylline,I-Entity
at,O
300,O
mg,O
b.i.d,O
.,O
No,O
significant,O
difference,O
was,O
noticed,O
between,O
results,O
obtained,O
with,O
either,O
active,O
drug,O
",",O
as,O
well,O
as,O
with,O
either,O
dosage,O
of,O
oxitropium,I-Entity
.,O
No,O
subject,O
reported,O
side,O
effects,O
of,O
oxitropium,I-Entity
",",O
as,O
compared,O
to,O
three,O
subjects,O
reporting,O
nausea,I-Entity
",",O
vomiting,I-Entity
and,O
tremors,I-Entity
after,O
theophylline,I-Entity
.,O
Oxitropium,I-Entity
proves,O
to,O
be,O
a,O
valuable,O
alternative,O
to,O
theophylline,I-Entity
in,O
nocturnal,O
asthma,I-Entity
",",O
since,O
it,O
is,O
equally,O
potent,O
",",O
safer,O
and,O
does,O
not,O
require,O
the,O
titration,O
of,O
dosage,O
.,O
Penicillin,I-Entity
anaphylaxis,I-Entity
.,O
A,O
case,O
of,O
oral,O
penicillin,I-Entity
anaphylaxis,I-Entity
is,O
described,O
",",O
and,O
the,O
terminology,O
",",O
occurrence,O
",",O
clinical,O
manifestations,O
",",O
pathogenesis,O
",",O
prevention,O
",",O
and,O
treatment,O
of,O
anaphylaxis,I-Entity
are,O
reviewed,O
.,O
Emergency,O
physicians,O
should,O
be,O
aware,O
of,O
oral,O
penicillin,I-Entity
anaphylaxis,I-Entity
in,O
order,O
to,O
prevent,O
its,O
occurrence,O
by,O
prescribing,O
the,O
antibiotic,O
judiciously,O
and,O
knowledgeably,O
and,O
to,O
offer,O
optimal,O
medical,O
therapy,O
once,O
this,O
life,O
-,O
threatening,O
reaction,O
has,O
begun,O
.,O
Reversible,O
valproic,B-Entity
acid,I-Entity
-,O
induced,O
dementia,I-Entity
:,O
a,O
case,O
report,O
.,O
Reversible,O
valproic,B-Entity
acid,I-Entity
-,O
induced,O
dementia,I-Entity
was,O
documented,O
in,O
a,O
21-year,O
-,O
old,O
man,O
with,O
epilepsy,I-Entity
who,O
had,O
a,O
3-year,O
history,O
of,O
insidious,O
progressive,O
decline,O
in,O
global,O
cognitive,O
abilities,O
documented,O
by,O
serial,O
neuropsychological,O
studies,O
.,O
Possible,O
pathophysiological,O
mechanisms,O
which,O
may,O
have,O
been,O
operative,O
in,O
this,O
case,O
include,O
:,O
a,O
direct,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
toxic,O
effect,O
of,O
valproic,B-Entity
acid,I-Entity
;,O
a,O
paradoxical,O
epileptogenic,O
effect,O
secondary,O
to,O
the,O
drug,O
;,O
and,O
an,O
indirect,O
CNS,O
toxic,O
effect,O
mediated,O
through,O
valproic,B-Entity
acid,I-Entity
-,O
induced,O
hyperammonemia,I-Entity
.,O
Reversal,O
of,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
of,O
passive,O
avoidance,O
by,O
pre-,O
and,O
post,O
-,O
training,O
naloxone,I-Entity
.,O
In,O
a,O
series,O
of,O
five,O
experiments,O
",",O
the,O
modulating,O
role,O
of,O
naloxone,I-Entity
on,O
a,O
scopolamine,I-Entity
-,O
induced,O
retention,B-Entity
deficit,I-Entity
in,O
a,O
passive,O
avoidance,O
paradigm,O
was,O
investigated,O
in,O
mice,O
.,O
Scopolamine,I-Entity
",",O
but,O
not,O
methyl,B-Entity
scopolamine,I-Entity
(,O
1,O
and,O
3,O
mg,O
/,O
kg,O
),O
",",O
induced,O
an,O
amnesia,I-Entity
as,O
measured,O
by,O
latency,O
and,O
duration,O
parameters,O
.,O
Naloxone,I-Entity
(,O
0.3,O
",",O
1,O
",",O
3,O
",",O
and,O
10,O
mg,O
/,O
kg,O
),O
injected,O
prior,O
to,O
training,O
attenuated,O
the,O
retention,B-Entity
deficit,I-Entity
with,O
a,O
peak,O
of,O
activity,O
at,O
3,O
mg,O
/,O
kg,O
.,O
The,O
effect,O
of,O
naloxone,I-Entity
could,O
be,O
antagonized,O
with,O
morphine,I-Entity
(,O
1,O
",",O
3,O
",",O
and,O
10,O
mg,O
/,O
kg,O
),O
",",O
demonstrating,O
the,O
opioid,O
specificity,O
of,O
the,O
naloxone,I-Entity
effect,O
.,O
Post,O
-,O
training,O
administration,O
of,O
naloxone,I-Entity
(,O
3,O
mg,O
/,O
kg,O
),O
as,O
a,O
single,O
or,O
as,O
a,O
split,O
dose,O
also,O
attenuated,O
the,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
Control,O
experiments,O
indicated,O
that,O
neither,O
an,O
increase,O
in,O
pain,I-Entity
sensitivity,O
(,O
pre,O
-,O
training,O
naloxone,I-Entity
),O
nor,O
an,O
induced,O
aversive,O
state,O
(,O
post,O
-,O
training,O
naloxone,I-Entity
),O
appear,O
to,O
be,O
responsible,O
for,O
the,O
influence,O
of,O
naloxone,I-Entity
on,O
the,O
scopolamine,I-Entity
-,O
induced,O
retention,B-Entity
deficit,I-Entity
.,O
Electron,O
microscopic,O
investigations,O
of,O
the,O
cyclophosphamide,I-Entity
-,O
induced,O
lesions,B-Entity
of,I-Entity
the,I-Entity
urinary,I-Entity
bladder,I-Entity
of,O
the,O
rat,O
and,O
their,O
prevention,O
by,O
mesna,I-Entity
.,O
Fully,O
developed,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
is,O
characterized,O
by,O
nearly,O
complete,O
detachment,O
of,O
the,O
urothelium,O
",",O
severe,O
submucosal,O
edema,I-Entity
owing,O
to,O
damage,O
to,O
the,O
microvascular,O
bed,O
and,O
focal,O
muscle,O
necroses,I-Entity
.,O
The,O
initial,O
response,O
to,O
the,O
primary,O
attack,O
by,O
the,O
cyclophosphamide,I-Entity
metabolites,O
seems,O
to,O
be,O
fragmentation,O
of,O
the,O
luminal,I-Entity
membrane,O
.,O
Subsequent,O
breaks,O
in,O
the,O
lateral,O
cell,O
membranes,O
of,O
the,O
superficial,O
cells,O
and,O
in,O
all,O
the,O
plasma,O
membranes,O
of,O
the,O
intermediate,O
and,O
basal,O
cells,O
",",O
intercellular,O
and,O
intracellular,O
edema,I-Entity
and,O
disintegration,O
of,O
the,O
desmosomes,O
and,O
hemidesmosomes,O
lead,O
to,O
progressive,O
degeneration,O
and,O
detachment,O
of,O
the,O
epithelial,O
cells,O
with,O
exposure,O
and,O
splitting,O
of,O
the,O
basal,O
membrane,O
.,O
These,O
changes,O
can,O
be,O
effectively,O
prevented,O
by,O
mesna,I-Entity
.,O
Increase,O
in,O
intragastric,O
pressure,O
during,O
suxamethonium,I-Entity
-,O
induced,O
muscle,B-Entity
fasciculations,I-Entity
in,O
children,O
:,O
inhibition,O
by,O
alfentanil,I-Entity
.,O
Changes,O
in,O
intragastric,O
pressure,O
after,O
the,O
administration,O
of,O
suxamethonium,I-Entity
1.5,O
mg,O
kg-1,O
i.v,O
.,O
were,O
studied,O
in,O
32,O
children,O
(,O
mean,O
age,O
6.9,O
yr,O
),O
pretreated,O
with,O
either,O
physiological,O
saline,O
or,O
alfentanil,I-Entity
50,O
micrograms,O
kg-1,O
.,O
Anaesthesia,O
was,O
induced,O
with,O
thiopentone,I-Entity
5,O
mg,O
kg-1,O
.,O
The,O
incidence,O
and,O
intensity,O
of,O
muscle,B-Entity
fasciculations,I-Entity
caused,O
by,O
suxamethonium,I-Entity
were,O
significantly,O
greater,O
in,O
the,O
control,O
than,O
in,O
the,O
alfentanil,I-Entity
group,O
.,O
The,O
intragastric,O
pressure,O
during,O
muscle,B-Entity
fasciculations,I-Entity
was,O
significantly,O
higher,O
in,O
the,O
control,O
group,O
(,O
16,O
+,O
/-,O
0.7,O
(,O
SEM,O
),O
cm,O
H2O,I-Entity
),O
than,O
in,O
the,O
alfentanil,I-Entity
group,O
(,O
7.7,O
+,O
/-,O
(,O
SEM,O
),O
cm,O
H2O,I-Entity
),O
.,O
The,O
increase,O
in,O
intragastric,O
pressure,O
was,O
directly,O
related,O
to,O
the,O
intensity,O
of,O
muscle,B-Entity
fasciculations,I-Entity
(,O
regression,O
line,O
:,O
y,O
=,O
0.5,O
+,O
4.78x,O
with,O
r,O
of,O
0.78,O
),O
.,O
It,O
is,O
concluded,O
that,O
intragastric,O
pressure,O
increases,O
significantly,O
during,O
muscle,B-Entity
fasciculations,I-Entity
caused,O
by,O
suxamethonium,I-Entity
in,O
healthy,O
children,O
.,O
Alfentanil,I-Entity
50,O
micrograms,O
kg-1,O
effectively,O
inhibits,O
the,O
incidence,O
and,O
intensity,O
of,O
suxamethonium,I-Entity
-,O
induced,O
muscle,B-Entity
fasciculations,I-Entity
;,O
moreover,O
",",O
intragastric,O
pressure,O
remains,O
at,O
its,O
control,O
value,O
.,O
Acute,O
insulin,O
treatment,O
normalizes,O
the,O
resistance,O
to,O
the,O
cardiotoxic,I-Entity
effect,O
of,O
isoproterenol,I-Entity
in,O
streptozotocin,I-Entity
diabetic,I-Entity
rats,O
.,O
A,O
morphometric,O
study,O
of,O
isoproterenol,I-Entity
induced,O
myocardial,O
fibrosis,I-Entity
.,O
The,O
acute,O
effect,O
of,O
insulin,O
treatment,O
on,O
the,O
earlier,O
reported,O
protective,O
effect,O
of,O
streptozotocin,I-Entity
diabetes,I-Entity
against,O
the,O
cardiotoxic,I-Entity
effect,O
of,O
high,O
doses,O
of,O
isoproterenol,I-Entity
(,O
ISO,I-Entity
),O
was,O
investigated,O
in,O
rats,O
.,O
Thirty,O
to,O
135,O
min,O
after,O
the,O
injection,O
of,O
crystalline,O
insulin,O
",",O
ISO,I-Entity
was,O
given,O
subcutaneously,O
and,O
when,O
ISO,I-Entity
induced,O
fibrosis,I-Entity
in,O
the,O
myocardium,O
was,O
morphometrically,O
analyzed,O
7,O
days,O
later,O
",",O
a,O
highly,O
significant,O
correlation,O
(,O
r,O
=,O
0.83,O
",",O
2,O
p,O
=,O
0.006,O
),O
to,O
the,O
slope,O
of,O
the,O
fall,O
in,O
blood,O
glucose,I-Entity
after,O
insulin,O
treatment,O
appeared,O
.,O
The,O
myocardial,O
content,O
of,O
catecholamines,I-Entity
was,O
estimated,O
in,O
these,O
8,O
day,O
diabetic,I-Entity
rats,O
.,O
The,O
norepinephrine,I-Entity
content,O
was,O
significantly,O
increased,O
while,O
epinephrine,I-Entity
remained,O
unchanged,O
.,O
An,O
enhanced,O
sympathetic,O
nervous,O
system,O
activity,O
with,O
a,O
consequent,O
down,O
regulation,O
of,O
the,O
myocardial,O
beta,O
-,O
adrenergic,O
receptors,O
could,O
",",O
therefore,O
",",O
explain,O
this,O
catecholamine,I-Entity
resistance,O
.,O
The,O
rapid,O
reversion,O
after,O
insulin,O
treatment,O
excludes,O
the,O
possibility,O
that,O
streptozotocin,I-Entity
in,O
itself,O
causes,O
the,O
ISO,I-Entity
resistance,O
and,O
points,O
towards,O
a,O
direct,O
insulin,O
effect,O
on,O
myocardial,O
catecholamine,I-Entity
sensitivity,O
in,O
diabetic,I-Entity
rats,O
.,O
The,O
phenomenon,O
described,O
might,O
elucidate,O
pathogenetic,O
mechanisms,O
behind,O
toxic,O
myocardial,O
cell,O
degeneration,O
and,O
may,O
possibly,O
have,O
relevance,O
for,O
acute,O
cardiovascular,O
complications,O
in,O
diabetic,I-Entity
patients,O
.,O
Differential,O
effects,O
of,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
on,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
in,O
rats,O
.,O
The,O
muscarinic,O
cholinergic,O
agonist,O
pilocarpine,I-Entity
induces,O
in,O
rats,O
seizures,I-Entity
and,O
status,B-Entity
epilepticus,I-Entity
followed,O
by,O
widespread,O
damage,O
to,O
the,O
forebrain,O
.,O
anti,O
-,O
inflammatory,O
drugs,O
",",O
sodium,B-Entity
salicylate,I-Entity
",",O
phenylbutazone,I-Entity
",",O
indomethacin,I-Entity
",",O
ibuprofen,I-Entity
and,O
mefenamic,B-Entity
acid,I-Entity
",",O
on,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
.,O
Pretreatment,O
of,O
rats,O
with,O
sodium,B-Entity
salicylate,I-Entity
",",O
ED50,O
103,O
mg,O
/,O
kg,O
(,O
60,O
-,O
174,O
),O
",",O
and,O
phenylbutazone,I-Entity
",",O
59,O
mg,O
/,O
kg,O
(,O
50,O
-,O
70,O
),O
converted,O
the,O
non,O
-,O
convulsant,O
dose,O
of,O
pilocarpine,I-Entity
",",O
200,O
mg,O
/,O
kg,O
",",O
to,O
a,O
convulsant,O
one,O
.,O
Indomethacin,I-Entity
",",O
1,O
-,O
10,O
mg,O
/,O
kg,O
",",O
and,O
ibuprofen,I-Entity
",",O
10,O
-,O
100,O
mg,O
/,O
kg,O
",",O
failed,O
to,O
modulate,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
.,O
Mefenamic,B-Entity
acid,I-Entity
",",O
26,O
(,O
22,O
-,O
30,O
),O
mg,O
/,O
kg,O
",",O
prevented,O
seizures,I-Entity
and,O
protected,O
rats,O
from,O
seizure,I-Entity
-,O
related,O
brain,B-Entity
damage,I-Entity
induced,O
by,O
pilocarpine,I-Entity
",",O
380,O
mg,O
/,O
kg,O
.,O
These,O
results,O
indicate,O
that,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
differentially,O
modulate,O
the,O
threshold,O
for,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
Acute,B-Entity
neurologic,I-Entity
dysfunction,I-Entity
after,O
high,O
-,O
dose,O
etoposide,I-Entity
therapy,O
for,O
malignant,B-Entity
glioma,I-Entity
.,O
Etoposide,I-Entity
(,O
VP-16,B-Entity
-,I-Entity
213,I-Entity
),O
has,O
been,O
used,O
in,O
the,O
treatment,O
of,O
many,O
solid,O
tumors,I-Entity
and,O
hematologic,B-Entity
malignancies,I-Entity
.,O
When,O
used,O
in,O
high,O
doses,O
and,O
in,O
conjunction,O
with,O
autologous,O
bone,O
marrow,O
transplantation,O
",",O
this,O
agent,O
has,O
activity,O
against,O
several,O
treatment,O
-,O
resistant,O
cancers,I-Entity
including,O
malignant,B-Entity
glioma,I-Entity
.,O
In,O
six,O
of,O
eight,O
patients,O
(,O
75%,O
),O
who,O
we,O
treated,O
for,O
recurrent,O
or,O
resistant,O
glioma,I-Entity
",",O
sudden,O
severe,O
neurologic,B-Entity
deterioration,I-Entity
occurred,O
.,O
This,O
developed,O
a,O
median,O
of,O
9,O
days,O
after,O
initiation,O
of,O
high,O
-,O
dose,O
etoposide,I-Entity
therapy,O
.,O
Significant,O
clinical,O
manifestations,O
have,O
included,O
confusion,I-Entity
",",O
papilledema,I-Entity
",",O
somnolence,I-Entity
",",O
exacerbation,O
of,O
motor,B-Entity
deficits,I-Entity
",",O
and,O
sharp,O
increase,O
in,O
seizure,I-Entity
activity,O
.,O
These,O
abnormalities,O
resolved,O
rapidly,O
after,O
initiation,O
of,O
high,O
-,O
dose,O
intravenous,O
dexamethasone,I-Entity
therapy,O
.,O
brain,O
scans,O
demonstrated,O
stability,O
in,O
tumor,I-Entity
size,O
and,O
peritumor,O
edema,I-Entity
when,O
compared,O
with,O
pretransplant,O
scans,O
.,O
This,O
complication,O
appears,O
to,O
represent,O
a,O
significant,O
new,O
toxicity,I-Entity
of,O
high,O
-,O
dose,O
etoposide,I-Entity
therapy,O
for,O
malignant,B-Entity
glioma,I-Entity
.,O
Progressive,O
bile,B-Entity
duct,I-Entity
injury,I-Entity
after,O
thiabendazole,I-Entity
administration,O
.,O
A,O
27-yr,O
-,O
old,O
man,O
developed,O
jaundice,I-Entity
2,O
wk,O
after,O
exposure,O
to,O
thiabendazole,I-Entity
.,O
Cholestasis,I-Entity
persisted,O
for,O
3,O
yr,O
",",O
at,O
which,O
time,O
a,O
liver,O
transplant,O
was,O
performed,O
.,O
Prominent,O
fibrosis,I-Entity
and,O
hepatocellular,O
regeneration,O
were,O
also,O
present,O
;,O
however,O
",",O
the,O
lobular,O
architecture,O
was,O
preserved,O
.,O
This,O
case,O
represents,O
an,O
example,O
of,O
"""",O
idiosyncratic,O
"""",O
drug,B-Entity
-,I-Entity
induced,I-Entity
liver,I-Entity
damage,I-Entity
in,O
which,O
the,O
primary,O
target,O
of,O
injury,O
is,O
the,O
bile,O
duct,O
.,O
An,O
autoimmune,O
pathogenesis,O
of,O
the,O
bile,B-Entity
duct,I-Entity
destruction,I-Entity
is,O
suggested,O
.,O
Differential,O
effects,O
of,O
"1,4-dihydropyridine",I-Entity
calcium,B-Entity
channel,I-Entity
blockers,I-Entity
:,O
therapeutic,O
implications,O
.,O
Increasing,O
recognition,O
of,O
the,O
importance,O
of,O
calcium,I-Entity
in,O
the,O
pathogenesis,O
of,O
cardiovascular,B-Entity
disease,I-Entity
has,O
stimulated,O
research,O
into,O
the,O
use,O
of,O
calcium,B-Entity
channel,I-Entity
blocking,I-Entity
agents,I-Entity
for,O
treatment,O
of,O
a,O
variety,O
of,O
cardiovascular,B-Entity
diseases,I-Entity
.,O
Clinical,O
applications,O
of,O
calcium,B-Entity
channel,I-Entity
blockers,I-Entity
parallel,O
their,O
tissue,O
selectivity,O
.,O
In,O
contrast,O
to,O
verapamil,I-Entity
and,O
diltiazem,I-Entity
",",O
which,O
are,O
roughly,O
equipotent,O
in,O
their,O
actions,O
on,O
the,O
heart,O
and,O
vascular,O
smooth,O
muscle,O
",",O
the,O
dihydropyridine,I-Entity
calcium,B-Entity
channel,I-Entity
blockers,I-Entity
are,O
a,O
group,O
of,O
potent,O
peripheral,O
vasodilator,O
agents,O
that,O
exert,O
minimal,O
electrophysiologic,O
effects,O
on,O
cardiac,O
nodal,O
or,O
conduction,O
tissue,O
.,O
As,O
the,O
first,O
dihydropyridine,I-Entity
available,O
for,O
use,O
in,O
the,O
United,O
States,O
",",O
nifedipine,I-Entity
controls,O
angina,I-Entity
and,O
hypertension,I-Entity
with,O
minimal,O
depression,O
of,O
cardiac,O
function,O
.,O
Additional,O
members,O
of,O
this,O
group,O
of,O
calcium,B-Entity
channel,I-Entity
blockers,I-Entity
have,O
been,O
studied,O
for,O
a,O
variety,O
of,O
indications,O
for,O
which,O
they,O
may,O
offer,O
advantages,O
over,O
current,O
therapy,O
.,O
Once,O
or,O
twice,O
daily,O
dosage,O
possible,O
with,O
nitrendipine,I-Entity
and,O
nisoldipine,I-Entity
offers,O
a,O
convenient,O
administration,O
schedule,O
",",O
which,O
encourages,O
patient,O
compliance,O
in,O
long,O
-,O
term,O
therapy,O
of,O
hypertension,I-Entity
.,O
The,O
coronary,O
vasodilating,O
properties,O
of,O
nisoldipine,I-Entity
have,O
led,O
to,O
the,O
investigation,O
of,O
this,O
agent,O
for,O
use,O
in,O
angina,I-Entity
.,O
Selectivity,O
for,O
the,O
cerebrovascular,O
bed,O
makes,O
nimodipine,I-Entity
potentially,O
useful,O
in,O
the,O
treatment,O
of,O
subarachnoid,B-Entity
hemorrhage,I-Entity
",",O
migraine,B-Entity
headache,I-Entity
",",O
dementia,I-Entity
",",O
and,O
stroke,I-Entity
.,O
In,O
general,O
",",O
the,O
dihydropyridine,I-Entity
calcium,B-Entity
channel,I-Entity
blockers,I-Entity
are,O
usually,O
well,O
tolerated,O
",",O
with,O
headache,I-Entity
",",O
facial,O
flushing,I-Entity
",",O
palpitations,I-Entity
",",O
edema,I-Entity
",",O
nausea,I-Entity
",",O
anorexia,I-Entity
",",O
and,O
dizziness,I-Entity
being,O
the,O
more,O
common,O
adverse,O
effects,O
.,O
The,O
enhancement,O
of,O
aminonucleoside,I-Entity
nephrosis,I-Entity
by,O
the,O
co,O
-,O
administration,O
of,O
protamine,O
.,O
An,O
experimental,O
model,O
of,O
focal,B-Entity
segmental,I-Entity
glomerular,I-Entity
sclerosis,I-Entity
(,O
FSGS,I-Entity
),O
was,O
developed,O
in,O
rats,O
by,O
the,O
combined,O
administration,O
of,O
puromycin,B-Entity
-,I-Entity
aminonucleoside,I-Entity
(,O
AMNS,I-Entity
),O
and,O
protamine,B-Entity
sulfate,I-Entity
(,O
PS,I-Entity
),O
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
",",O
uninephrectomized,O
three,O
weeks,O
before,O
",",O
received,O
daily,O
injections,O
of,O
subcutaneous,O
AMNS,I-Entity
(,O
1,O
mg/100,O
g,O
body,O
wt,O
),O
and,O
intravenous,O
PS,I-Entity
(,O
2,O
separated,O
doses,O
of,O
2.5,O
mg/100,O
g,O
body,O
wt,O
),O
for,O
four,O
days,O
.,O
They,O
developed,O
nephrotic,B-Entity
syndrome,I-Entity
and,O
finally,O
renal,B-Entity
failure,I-Entity
.,O
The,O
time,O
-,O
course,O
curve,O
of,O
creatinine,I-Entity
clearance,O
dropped,O
and,O
showed,O
significant,O
difference,O
(,O
P,O
less,O
than,O
0.01,O
),O
from,O
that,O
of,O
each,O
control,O
group,O
",",O
such,O
as,O
",",O
AMNS,I-Entity
alone,O
",",O
PS,I-Entity
alone,O
or,O
saline,O
injected,O
.,O
Their,O
glomeruli,O
showed,O
changes,O
of,O
progressive,O
FSGS,I-Entity
.,O
The,O
ultrastructural,O
studies,O
in,O
the,O
initial,O
stage,O
revealed,O
significant,O
lack,O
of,O
particles,O
of,O
perfused,O
ruthenium,I-Entity
red,O
on,O
the,O
lamina,O
rara,O
externa,O
and,O
marked,O
changes,O
in,O
epithelial,O
cell,O
cytoplasm,O
.,O
Therefore,O
",",O
it,O
is,O
suggested,O
that,O
the,O
administration,O
of,O
PS,I-Entity
enhances,O
the,O
toxicity,I-Entity
of,O
AMNS,I-Entity
on,O
the,O
glomerulus,O
and,O
readily,O
produces,O
progressive,O
FSGS,I-Entity
in,O
rats,O
resulting,O
in,O
the,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
.,O
Theophylline,I-Entity
neurotoxicity,I-Entity
in,O
pregnant,O
rats,O
.,O
The,O
purpose,O
of,O
this,O
investigation,O
was,O
to,O
determine,O
whether,O
the,O
neurotoxicity,I-Entity
of,O
theophylline,I-Entity
is,O
altered,O
in,O
advanced,O
pregnancy,O
.,O
Sprague,O
-,O
Dawley,O
rats,O
that,O
were,O
20,O
days,O
pregnant,O
and,O
nonpregnant,O
rats,O
of,O
the,O
same,O
age,O
and,O
strain,O
received,O
infusions,O
of,O
aminophylline,I-Entity
until,O
onset,O
of,O
maximal,O
seizures,I-Entity
which,O
occurred,O
after,O
28,O
and,O
30,O
minutes,O
respectively,O
.,O
Theophylline,I-Entity
concentrations,O
at,O
this,O
endpoint,O
in,O
serum,O
(,O
total,O
),O
and,O
CSF,O
were,O
similar,O
but,O
serum,O
(,O
free,O
),O
and,O
brain,O
concentrations,O
were,O
slightly,O
different,O
in,O
pregnant,O
rats,O
.,O
Theophylline,I-Entity
serum,O
protein,O
binding,O
determined,O
by,O
equilibrium,O
dialysis,O
was,O
lower,O
in,O
pregnant,O
rats,O
.,O
Fetal,O
serum,O
concentrations,O
at,O
onset,O
of,O
seizures,I-Entity
in,O
the,O
mother,O
were,O
similar,O
to,O
maternal,O
brain,O
and,O
CSF,O
concentrations,O
and,O
correlated,O
significantly,O
with,O
the,O
former,O
.,O
It,O
is,O
concluded,O
that,O
advanced,O
pregnancy,O
has,O
a,O
negligible,O
effect,O
on,O
the,O
neurotoxic,I-Entity
response,O
to,O
theophylline,I-Entity
in,O
rats,O
.,O
Hyperkalemia,I-Entity
induced,O
by,O
indomethacin,I-Entity
and,O
naproxen,I-Entity
and,O
reversed,O
by,O
fludrocortisone,I-Entity
.,O
We,O
have,O
described,O
a,O
patient,O
with,O
severe,O
rheumatoid,B-Entity
arthritis,I-Entity
and,O
a,O
history,O
of,O
mefenamic,B-Entity
acid,I-Entity
nephropathy,I-Entity
in,O
whom,O
hyperkalemia,I-Entity
and,O
inappropriate,O
hypoaldosteronism,I-Entity
were,O
caused,O
by,O
both,O
indomethacin,I-Entity
and,O
naproxen,I-Entity
",",O
without,O
major,O
decline,O
in,O
renal,O
function,O
.,O
It,O
is,O
likely,O
that,O
preexisting,O
renal,B-Entity
disease,I-Entity
predisposed,O
this,O
patient,O
to,O
type,B-Entity
IV,I-Entity
renal,I-Entity
tubular,I-Entity
acidosis,I-Entity
with,O
prostaglandin,I-Entity
synthetase,O
inhibitors,O
.,O
Because,O
he,O
was,O
unable,O
to,O
discontinue,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
therapy,O
",",O
fludrocortisone,I-Entity
was,O
added,O
",",O
correcting,O
the,O
hyperkalemia,I-Entity
and,O
allowing,O
indomethacin,I-Entity
therapy,O
to,O
be,O
continued,O
safely,O
.,O
Hypotension,I-Entity
as,O
a,O
manifestation,O
of,O
cardiotoxicity,I-Entity
in,O
three,O
patients,O
receiving,O
cisplatin,I-Entity
and,O
5-fluorouracil,I-Entity
.,O
Cardiac,O
symptoms,O
",",O
including,O
hypotension,I-Entity
",",O
developed,O
in,O
three,O
patients,O
with,O
advanced,O
colorectal,B-Entity
carcinoma,I-Entity
while,O
being,O
treated,O
with,O
cisplatin,I-Entity
(,O
CDDP,I-Entity
),O
and,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
.,O
In,O
two,O
patients,O
",",O
hypotension,I-Entity
was,O
associated,O
with,O
severe,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
.,O
The,O
presentation,O
and,O
cardiac,O
evaluation,O
(,O
hemodynamic,O
",",O
echocardiographic,O
",",O
and,O
scintigraphic,O
),O
of,O
these,O
patients,O
suggest,O
new,O
manifestations,O
of,O
5-FU,I-Entity
cardiotoxicity,I-Entity
that,O
may,O
be,O
influenced,O
by,O
CDDP,I-Entity
.,O
Fatal,O
aplastic,B-Entity
anemia,I-Entity
in,O
a,O
patient,O
treated,O
with,O
carbamazepine,I-Entity
.,O
A,O
case,O
of,O
fatal,O
aplastic,B-Entity
anemia,I-Entity
due,O
to,O
carbamazepine,I-Entity
treatment,O
in,O
an,O
epileptic,I-Entity
woman,O
is,O
reported,O
.,O
Despite,O
concerns,O
of,O
fatal,O
bone,B-Entity
marrow,I-Entity
toxicity,I-Entity
due,O
to,O
carbamazepine,I-Entity
",",O
this,O
is,O
only,O
the,O
fourth,O
documented,O
and,O
published,O
report,O
.,O
Carbamazepine,I-Entity
is,O
a,O
safe,O
drug,O
",",O
but,O
physicians,O
and,O
patients,O
should,O
be,O
aware,O
of,O
the,O
exceedingly,O
rare,O
but,O
potentially,O
fatal,O
side,O
effects,O
",",O
better,O
prevented,O
by,O
clinical,O
than,O
by,O
laboratory,O
monitoring,O
.,O
Participation,O
of,O
a,O
bulbospinal,O
serotonergic,O
pathway,O
in,O
the,O
rat,O
brain,O
in,O
clonidine,I-Entity
-,O
induced,O
hypotension,I-Entity
and,O
bradycardia,I-Entity
.,O
The,O
effects,O
of,O
microinjection,O
of,O
clonidine,I-Entity
(,O
1,O
-,O
10,O
micrograms,O
in,O
1,O
microliter,O
),O
into,O
a,O
region,O
adjacent,O
to,O
the,O
ventrolateral,O
surface,O
of,O
the,O
medulla,O
oblongata,O
on,O
cardiovascular,O
function,O
were,O
assessed,O
in,O
urethane,I-Entity
-,O
anesthetized,O
rats,O
.,O
Intramedullary,O
administration,O
of,O
clonidine,I-Entity
",",O
but,O
not,O
saline,O
vehicle,O
",",O
caused,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
both,O
the,O
mean,O
arterial,O
pressure,O
and,O
the,O
heart,O
rate,O
.,O
The,O
clonidine,I-Entity
-,O
induced,O
hypotension,I-Entity
was,O
antagonized,O
by,O
prior,O
spinal,O
transection,O
",",O
but,O
not,O
bilateral,O
vagotomy,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
clonidine,I-Entity
-,O
induced,O
bradycardia,I-Entity
was,O
antagonized,O
by,O
prior,O
bilateral,O
vagotomy,O
",",O
but,O
not,O
spinal,O
transection,O
.,O
Furthermore,O
",",O
selective,O
destruction,O
of,O
the,O
spinal,O
5-HT,I-Entity
nerves,O
",",O
produced,O
by,O
bilateral,O
spinal,O
injection,O
of,O
"5,7-dihydroxytryptamine",I-Entity
",",O
reduced,O
the,O
magnitude,O
of,O
the,O
vasodepressor,O
or,O
the,O
bradycardiac,I-Entity
responses,O
to,O
clonidine,I-Entity
microinjected,O
into,O
the,O
area,O
near,O
the,O
ventrolateral,O
surface,O
of,O
the,O
medulla,O
oblongata,O
in,O
rats,O
.,O
The,O
data,O
indicate,O
that,O
a,O
bulbospinal,O
serotonergic,O
pathway,O
is,O
involved,O
in,O
development,O
of,O
clonidine,I-Entity
-,O
induced,O
hypotension,I-Entity
and,O
bradycardia,I-Entity
.,O
The,O
induced,O
hypotension,I-Entity
is,O
brought,O
about,O
by,O
a,O
decrease,O
in,O
sympathetic,O
efferent,O
activity,O
",",O
whereas,O
the,O
induced,O
bradycardia,I-Entity
was,O
due,O
to,O
an,O
increase,O
in,O
vagal,O
efferent,O
activity,O
.,O
Hypertension,I-Entity
in,O
neuroblastoma,I-Entity
induced,O
by,O
imipramine,I-Entity
.,O
Hypertension,I-Entity
is,O
a,O
well,O
-,O
known,O
finding,O
in,O
some,O
patients,O
with,O
neuroblastoma,I-Entity
.,O
However,O
",",O
it,O
has,O
not,O
previously,O
been,O
described,O
in,O
association,O
with,O
the,O
use,O
of,O
Imipramine,I-Entity
.,O
We,O
report,O
the,O
occurrence,O
of,O
severe,O
hypertension,I-Entity
(,O
blood,O
pressure,O
190/160,O
),O
in,O
a,O
4-year,O
-,O
old,O
girl,O
with,O
neuroblastoma,I-Entity
who,O
was,O
given,O
Imipramine,I-Entity
to,O
control,O
a,O
behavior,B-Entity
disorder,I-Entity
.,O
It,O
was,O
determined,O
later,O
that,O
this,O
patient,O
's,O
tumor,I-Entity
was,O
recurring,O
at,O
the,O
time,O
of,O
her,O
hypertensive,I-Entity
episode,O
.,O
Since,O
she,O
had,O
no,O
blood,O
pressure,O
elevation,O
at,O
initial,O
diagnosis,O
and,O
none,O
following,O
discontinuation,O
of,O
the,O
Imipramine,I-Entity
(,O
when,O
she,O
was,O
in,O
florid,O
relapse,O
),O
",",O
we,O
believe,O
that,O
this,O
drug,O
rather,O
than,O
her,O
underlying,O
disease,O
alone,O
caused,O
her,O
hypertension,I-Entity
.,O
The,O
mechanism,O
for,O
this,O
reaction,O
is,O
believed,O
to,O
be,O
increased,O
levels,O
of,O
vasoactive,O
catecholamines,I-Entity
due,O
to,O
interference,O
of,O
their,O
physiologic,O
inactivation,O
by,O
Imipramine,I-Entity
.,O
From,O
this,O
experience,O
",",O
we,O
urge,O
extreme,O
caution,O
in,O
the,O
use,O
of,O
tricyclic,O
antidepressants,O
in,O
children,O
with,O
active,O
neuroblastoma,I-Entity
.,O
Rechallenge,O
of,O
patients,O
who,O
developed,O
oral,B-Entity
candidiasis,I-Entity
or,O
hoarseness,I-Entity
with,O
beclomethasone,B-Entity
dipropionate,I-Entity
.,O
Of,O
158,O
asthmatic,I-Entity
patients,O
who,O
were,O
placed,O
on,O
inhaled,O
beclomethasone,I-Entity
",",O
15,O
(,O
9.5%,O
),O
developed,O
either,O
hoarseness,I-Entity
(,O
8),O
",",O
oral,O
thrush,I-Entity
(,O
6,O
),O
",",O
or,O
both,O
(,O
1,O
),O
.,O
When,O
their,O
adverse,O
reactions,O
subsided,O
",",O
seven,O
of,O
these,O
15,O
patients,O
were,O
rechallenged,O
with,O
inhaled,O
beclomethasone,I-Entity
.,O
These,O
included,O
five,O
cases,O
who,O
developed,O
hoarseness,I-Entity
and,O
three,O
who,O
developed,O
Candidiasis,I-Entity
.,O
Oral,O
thrush,I-Entity
did,O
not,O
recur,O
",",O
but,O
60%,O
(,O
3/5,O
),O
of,O
patients,O
with,O
hoarseness,I-Entity
had,O
recurrence,O
.,O
We,O
conclude,O
that,O
patients,O
may,O
be,O
restarted,O
on,O
inhaled,O
beclomethasone,I-Entity
when,O
clinically,O
indicated,O
;,O
however,O
",",O
because,O
of,O
the,O
high,O
recurrence,O
rate,O
",",O
patients,O
who,O
develop,O
hoarseness,I-Entity
should,O
not,O
be,O
re,O
-,O
challenged,O
.,O
Concomitant,O
use,O
of,O
oral,O
prednisone,I-Entity
and,O
topical,O
beclomethasone,I-Entity
may,O
increase,O
the,O
risk,O
of,O
developing,O
hoarseness,I-Entity
or,O
candidiasis,I-Entity
.,O
Cyclophosphamide,I-Entity
cardiotoxicity,I-Entity
:,O
an,O
analysis,O
of,O
dosing,O
as,O
a,O
risk,O
factor,O
.,O
Patients,O
who,O
undergo,O
bone,O
marrow,O
transplantation,O
are,O
generally,O
immunosuppressed,O
with,O
a,O
dose,O
of,O
cyclophosphamide,I-Entity
(,O
CYA,I-Entity
),O
which,O
is,O
usually,O
calculated,O
based,O
on,O
the,O
patient,O
's,O
weight,O
.,O
At,O
these,O
high,O
doses,O
of,O
CYA,I-Entity
",",O
serious,O
cardiotoxicity,I-Entity
may,O
occur,O
",",O
but,O
definitive,O
risk,O
factors,O
for,O
the,O
development,O
of,O
such,O
cardiotoxicity,I-Entity
have,O
not,O
been,O
described,O
.,O
Since,O
chemotherapeutic,O
agent,O
toxicity,I-Entity
generally,O
correlates,O
with,O
dose,O
per,O
body,O
surface,O
area,O
",",O
we,O
retrospectively,O
calculated,O
the,O
dose,O
of,O
CYA,I-Entity
in,O
patients,O
transplanted,O
at,O
our,O
institution,O
to,O
determine,O
whether,O
the,O
incidence,O
of,O
CYA,I-Entity
cardiotoxicity,I-Entity
correlated,O
with,O
the,O
dose,O
per,O
body,O
surface,O
area,O
.,O
Eighty,O
patients,O
who,O
were,O
to,O
receive,O
CYA,I-Entity
50,O
mg,O
/,O
kg,O
/,O
d,O
for,O
four,O
days,O
as,O
preparation,O
for,O
marrow,O
grafting,O
underwent,O
a,O
total,O
of,O
84,O
transplants,O
for,O
aplastic,B-Entity
anemia,I-Entity
",",O
Wiskott,B-Entity
-,I-Entity
Aldrich,I-Entity
syndrome,I-Entity
",",O
or,O
severe,B-Entity
combined,I-Entity
immunodeficiency,I-Entity
syndrome,I-Entity
.,O
Fourteen,O
of,O
84,O
(,O
17%,O
),O
patients,O
had,O
symptoms,O
and,O
signs,O
consistent,O
with,O
CYA,I-Entity
cardiotoxicity,I-Entity
within,O
ten,O
days,O
of,O
receiving,O
1,O
to,O
4,O
doses,O
of,O
CYA,I-Entity
.,O
Six,O
of,O
the,O
14,O
patients,O
died,O
with,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
.,O
The,O
dose,O
of,O
CYA,I-Entity
per,O
body,O
surface,O
area,O
was,O
calculated,O
for,O
all,O
patients,O
and,O
the,O
patients,O
were,O
divided,O
into,O
two,O
groups,O
based,O
on,O
daily,O
CYA,I-Entity
dose,O
:,O
Group,O
1,O
",",O
CYA,I-Entity
less,O
than,O
or,O
equal,O
to,O
1.55,O
g,O
/,O
m2/d,O
;,O
Group,O
2,O
",",O
CYA,I-Entity
greater,O
than,O
1.55,O
Cardiotoxicity,I-Entity
that,O
was,O
thought,O
to,O
be,O
related,O
to,O
CYA,I-Entity
occurred,O
in,O
1/32,O
(,O
3%,O
),O
of,O
patients,O
in,O
Group,O
1,O
and,O
in,O
13/52,O
(,O
25%,O
),O
patients,O
in,O
Group,O
2,O
(,O
P,O
less,O
than,O
0.025,O
),O
.,O
Congestive,B-Entity
heart,I-Entity
failure,I-Entity
caused,O
or,O
contributed,O
to,O
death,O
in,O
0/32,O
patients,O
in,O
Group,O
1,O
v,O
6/52,O
(,O
12%,O
),O
of,O
patients,O
in,O
Group,O
2,O
(,O
P,O
less,O
than,O
0.25,O
),O
.,O
We,O
conclude,O
that,O
the,O
CYA,I-Entity
cardiotoxicity,I-Entity
correlates,O
with,O
CYA,I-Entity
dosage,O
as,O
calculated,O
by,O
body,O
surface,O
area,O
",",O
and,O
that,O
patients,O
with,O
aplastic,B-Entity
anemia,I-Entity
and,O
immunodeficiencies,I-Entity
can,O
be,O
effectively,O
prepared,O
for,O
bone,O
marrow,O
grafting,O
at,O
a,O
CYA,I-Entity
dose,O
of,O
1.55,O
g,O
/,O
m2/d,O
for,O
four,O
days,O
with,O
a,O
lower,O
incidence,O
of,O
cardiotoxicity,I-Entity
than,O
patients,O
whose,O
CYA,I-Entity
dosage,O
is,O
calculated,O
based,O
on,O
weight,O
.,O
This,O
study,O
reaffirms,O
the,O
principle,O
that,O
drug,O
toxicity,I-Entity
correlates,O
with,O
dose,O
per,O
body,O
surface,O
area,O
.,O
Studies,O
of,O
risk,O
factors,O
for,O
aminoglycoside,I-Entity
nephrotoxicity,I-Entity
.,O
The,O
epidemiology,O
of,O
aminoglycoside,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
is,O
not,O
fully,O
understood,O
.,O
Experimental,O
studies,O
in,O
healthy,O
human,O
volunteers,O
indicate,O
aminoglycosides,I-Entity
cause,O
proximal,O
tubular,O
damage,O
in,O
most,O
patients,O
",",O
but,O
rarely,O
",",O
if,O
ever,O
",",O
cause,O
glomerular,B-Entity
or,I-Entity
tubular,I-Entity
dysfunction,I-Entity
.,O
Clinical,O
trials,O
of,O
aminoglycosides,I-Entity
in,O
seriously,O
ill,O
patients,O
indicate,O
that,O
the,O
relative,O
risk,O
for,O
developing,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
during,O
therapy,O
ranges,O
from,O
8,O
to,O
10,O
and,O
that,O
the,O
attributable,O
risk,O
is,O
70%,O
to,O
80%,O
.,O
Further,O
analysis,O
of,O
these,O
data,O
suggests,O
that,O
the,O
duration,O
of,O
therapy,O
",",O
plasma,O
aminoglycoside,I-Entity
levels,O
",",O
liver,B-Entity
disease,I-Entity
",",O
advanced,O
age,O
",",O
high,O
initial,O
estimated,O
creatinine,I-Entity
clearance,O
and,O
",",O
possibly,O
",",O
female,O
gender,O
all,O
increase,O
the,O
risk,O
for,O
nephrotoxicity,I-Entity
.,O
Other,O
causes,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
",",O
such,O
as,O
shock,I-Entity
",",O
appear,O
to,O
have,O
an,O
additive,O
effect,O
.,O
These,O
models,O
may,O
also,O
be,O
useful,O
in,O
developing,O
insights,O
into,O
the,O
pathophysiology,O
of,O
aminoglycoside,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
.,O
Flurothyl,I-Entity
seizure,I-Entity
thresholds,O
in,O
mice,O
treated,O
neonatally,O
with,O
a,O
single,O
injection,O
of,O
monosodium,B-Entity
glutamate,I-Entity
(,O
MSG,I-Entity
),O
:,O
evaluation,O
of,O
experimental,O
parameters,O
in,O
flurothyl,I-Entity
seizure,I-Entity
testing,O
.,O
Monosodium,B-Entity
glutamate,I-Entity
(,O
MSG,I-Entity
),O
administration,O
to,O
neonatal,O
rodents,O
produces,O
convulsions,I-Entity
and,O
results,O
in,O
numerous,O
biochemical,O
and,O
behavioral,O
deficits,O
.,O
These,O
studies,O
were,O
undertaken,O
to,O
determine,O
if,O
neonatal,O
administration,O
of,O
MSG,I-Entity
produced,O
permanent,O
alterations,O
in,O
seizure,I-Entity
susceptibility,O
",",O
since,O
previous,O
investigations,O
were,O
inconclusive,O
.,O
A,O
flurothyl,I-Entity
ether,I-Entity
seizure,I-Entity
screening,O
technique,O
was,O
used,O
to,O
evaluate,O
seizure,I-Entity
susceptibility,O
in,O
adult,O
mice,O
that,O
received,O
neonatal,O
injections,O
of,O
MSG,I-Entity
(,O
4,O
mg,O
/,O
g,O
and,O
1,O
mg,O
/,O
g,O
),O
.,O
MSG,I-Entity
treatment,O
resulted,O
in,O
significant,O
reductions,O
in,O
whole,O
brain,O
weight,O
but,O
did,O
not,O
alter,O
seizure,I-Entity
threshold,O
.,O
A,O
naloxone,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
challenge,O
was,O
also,O
ineffective,O
in,O
altering,O
the,O
seizure,I-Entity
thresholds,O
of,O
either,O
control,O
of,O
MSG,I-Entity
-,O
treated,O
mice,O
.,O
Flurothyl,I-Entity
ether,I-Entity
produced,O
hypothermia,I-Entity
which,O
was,O
correlated,O
with,O
the,O
duration,O
of,O
flurothyl,I-Entity
exposure,O
;,O
however,O
",",O
the,O
relationship,O
of,O
hypothermia,I-Entity
to,O
seizure,I-Entity
induction,O
was,O
unclear,O
.,O
Flurothyl,I-Entity
seizure,I-Entity
testing,O
proved,O
to,O
be,O
a,O
rapid,O
and,O
reliable,O
technique,O
with,O
which,O
to,O
evaluate,O
seizure,I-Entity
susceptibility,O
.,O
Susceptibility,O
to,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
in,O
rats,O
after,O
microinjection,O
of,O
isoniazid,I-Entity
or,O
gamma,B-Entity
-,I-Entity
vinyl,I-Entity
-,I-Entity
GABA,I-Entity
into,O
the,O
substantia,O
nigra,O
.,O
Pilocarpine,I-Entity
",",O
given,O
intraperitoneally,O
to,O
rats,O
",",O
reproduces,O
the,O
neuropathological,O
sequelae,O
of,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
and,O
provides,O
a,O
relevant,O
animal,O
model,O
for,O
studying,O
mechanisms,O
of,O
buildup,O
of,O
convulsive,I-Entity
activity,O
and,O
pathways,O
operative,O
in,O
the,O
generalization,O
and,O
propagation,O
of,O
seizures,I-Entity
within,O
the,O
forebrain,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
effects,O
of,O
manipulating,O
the,O
activity,O
of,O
the,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
(,O
GABA)-mediated,I-Entity
synaptic,O
inhibition,O
within,O
the,O
substantia,O
nigra,O
on,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
in,O
rats,O
",",O
were,O
investigated,O
.,O
In,O
animals,O
pretreated,O
with,O
microinjections,O
of,O
isoniazid,I-Entity
",",O
150,O
micrograms,O
",",O
an,O
inhibitor,O
of,O
activity,O
of,O
the,O
GABA,I-Entity
-,O
synthesizing,O
enzyme,O
",",O
L,B-Entity
-,I-Entity
glutamic,I-Entity
acid,I-Entity
decarboxylase,O
",",O
into,O
the,O
substantia,O
nigra,O
pars,O
reticulata,O
(,O
SNR,O
),O
",",O
bilaterally,O
",",O
non,O
-,O
convulsant,O
doses,O
of,O
pilocarpine,I-Entity
",",O
100,O
and,O
200,O
mg,O
/,O
kg,O
",",O
resulted,O
in,O
severe,O
motor,O
limbic,O
seizures,I-Entity
and,O
status,B-Entity
epilepticus,I-Entity
.,O
Electroencephalographic,O
and,O
behavioral,O
monitoring,O
revealed,O
a,O
profound,O
reduction,O
of,O
the,O
threshold,O
for,O
pilocarpine,I-Entity
-,O
induced,O
convulsions,I-Entity
.,O
Morphological,O
analysis,O
of,O
frontal,O
forebrain,O
sections,O
with,O
light,O
microscopy,O
revealed,O
seizure,I-Entity
-,O
related,O
damage,O
to,O
the,O
hippocampal,O
formation,O
",",O
thalamus,O
",",O
amygdala,O
",",O
olfactory,O
cortex,O
",",O
substantia,O
nigra,O
and,O
neocortex,O
",",O
which,O
is,O
typically,O
observed,O
with,O
pilocarpine,I-Entity
in,O
doses,O
exceeding,O
350,O
mg,O
/,O
kg,O
.,O
Bilateral,O
intrastriatal,O
injections,O
of,O
isoniazid,I-Entity
did,O
not,O
augment,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
",",O
200,O
mg,O
/,O
kg,O
.,O
Application,O
of,O
an,O
irreversible,O
inhibitor,O
of,O
GABA,I-Entity
transaminase,O
",",O
gamma,B-Entity
-,I-Entity
vinyl,I-Entity
-,I-Entity
GABA,I-Entity
(,O
D,B-Entity
",",I-Entity
L-4-amino,I-Entity
-,I-Entity
hex-5-enoic,I-Entity
acid,I-Entity
),O
",",O
5,O
micrograms,O
",",O
into,O
the,O
SNR,O
",",O
bilaterally,O
",",O
suppressed,O
the,O
appearance,O
of,O
electrographic,O
and,O
behavioral,O
seizures,I-Entity
produced,O
by,O
pilocarpine,I-Entity
",",O
380,O
mg,O
/,O
kg,O
.,O
This,O
treatment,O
was,O
also,O
sufficient,O
to,O
protect,O
animals,O
from,O
the,O
occurrence,O
of,O
brain,B-Entity
damage,I-Entity
.,O
Microinjections,O
of,O
gamma,B-Entity
-,I-Entity
vinyl,I-Entity
-,I-Entity
GABA,I-Entity
",",O
5,O
micrograms,O
",",O
into,O
the,O
dorsal,O
striatum,O
",",O
bilaterally,O
",",O
failed,O
to,O
prevent,O
the,O
development,O
of,O
convulsions,I-Entity
produced,O
by,O
pilocarpine,I-Entity
",",O
380,O
mg,O
/,O
kg,O
.,O
The,O
results,O
demonstrate,O
that,O
the,O
threshold,O
for,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
rats,O
is,O
subjected,O
to,O
the,O
regulation,O
of,O
the,O
GABA,I-Entity
-,O
mediated,O
synaptic,O
inhibition,O
within,O
the,O
substantia,O
nigra,O
.,O
Non,O
-,O
invasive,O
detection,O
of,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
by,O
body,O
surface,O
electrocardiographic,O
mapping,O
after,O
dipyridamole,I-Entity
infusion,O
.,O
Electrocardiographic,O
changes,O
after,O
dipyridamole,I-Entity
infusion,O
(,O
0.568,O
mg,O
/,O
kg/4,O
min,O
),O
were,O
studied,O
in,O
41,O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
and,O
compared,O
with,O
those,O
after,O
submaximal,O
treadmill,O
exercise,O
by,O
use,O
of,O
the,O
body,O
surface,O
mapping,O
technique,O
.,O
Patients,O
were,O
divided,O
into,O
three,O
groups,O
;,O
19,O
patients,O
without,O
myocardial,B-Entity
infarction,I-Entity
(,O
non,O
-,O
MI,I-Entity
group,O
),O
",",O
14,O
with,O
anterior,B-Entity
infarction,I-Entity
(,O
ANT,B-Entity
-,I-Entity
MI,I-Entity
),O
and,O
eight,O
with,O
inferior,B-Entity
infarction,I-Entity
(,O
INF,B-Entity
-,I-Entity
MI,I-Entity
),O
.,O
After,O
dipyridamole,I-Entity
",",O
ischemic,I-Entity
ST,O
-,O
segment,O
depression,I-Entity
(,O
0.05,O
mV,O
or,O
more,O
),O
was,O
observed,O
in,O
84%,O
of,O
the,O
non,O
-,O
MI,I-Entity
group,O
",",O
29%,O
of,O
the,O
ANT,B-Entity
-,I-Entity
MI,I-Entity
group,O
",",O
63%,O
of,O
the,O
INF,B-Entity
-,I-Entity
MI,I-Entity
group,O
and,O
61%,O
of,O
the,O
total,O
population,O
.,O
Exercise,O
-,O
induced,O
ST,O
depression,I-Entity
was,O
observed,O
in,O
84%,O
of,O
the,O
non,O
-,O
MI,I-Entity
group,O
",",O
43%,O
of,O
the,O
ANT,B-Entity
-,I-Entity
MI,I-Entity
group,O
",",O
38%,O
of,O
the,O
INF,B-Entity
-,I-Entity
MI,I-Entity
group,O
and,O
61%,O
of,O
the,O
total,O
.,O
For,O
individual,O
patients,O
",",O
there,O
were,O
no,O
obvious,O
differences,O
between,O
the,O
body,O
surface,O
distribution,O
of,O
ST,O
depression,I-Entity
in,O
both,O
tests,O
.,O
The,O
increase,O
in,O
pressure,O
rate,O
product,O
after,O
dipyridamole,I-Entity
was,O
significantly,O
less,O
than,O
that,O
during,O
the,O
treadmill,O
exercise,O
.,O
The,O
data,O
suggest,O
that,O
the,O
dipyridamole,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
is,O
caused,O
by,O
the,O
inhomogenous,O
distribution,O
of,O
myocardial,O
blood,O
flow,O
.,O
We,O
conclude,O
that,O
the,O
dipyridamole,I-Entity
ECG,O
test,O
is,O
as,O
useful,O
as,O
the,O
exercise,O
ECG,O
test,O
for,O
the,O
assessment,O
of,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
.,O
Bradycardia,I-Entity
after,O
high,O
-,O
dose,O
intravenous,O
methylprednisolone,I-Entity
therapy,O
.,O
In,O
5,O
consecutive,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
who,O
received,O
intravenous,O
high,O
-,O
dose,O
methylprednisolone,I-Entity
(,O
MP,I-Entity
),O
therapy,O
(,O
1,O
g,O
daily,O
for,O
2,O
or,O
3,O
consecutive,O
days,O
),O
",",O
a,O
decline,O
in,O
pulse,O
rate,O
was,O
observed,O
",",O
most,O
pronounced,O
on,O
day,O
4,O
.,O
In,O
one,O
of,O
the,O
5,O
patients,O
the,O
bradycardia,I-Entity
was,O
associated,O
with,O
complaints,O
of,O
substernal,O
pressure,O
.,O
Electrocardiographic,O
registrations,O
showed,O
sinus,B-Entity
bradycardia,I-Entity
in,O
all,O
cases,O
.,O
Careful,O
observation,O
of,O
patients,O
receiving,O
high,O
-,O
dose,O
MP,I-Entity
is,O
recommended,O
.,O
High,O
-,O
dose,O
MP,I-Entity
may,O
be,O
contraindicated,O
in,O
patients,O
with,O
known,O
heart,B-Entity
disease,I-Entity
.,O
Two,O
cases,O
of,O
downbeat,B-Entity
nystagmus,I-Entity
and,O
oscillopsia,I-Entity
associated,O
with,O
carbamazepine,I-Entity
.,O
Downbeat,B-Entity
nystagmus,I-Entity
is,O
often,O
associated,O
with,O
structural,O
lesions,O
at,O
the,O
craniocervical,O
junction,O
",",O
but,O
has,O
occasionally,O
been,O
reported,O
as,O
a,O
manifestation,O
of,O
metabolic,O
imbalance,O
or,O
drug,O
intoxication,O
.,O
We,O
recorded,O
the,O
eye,O
movements,O
of,O
two,O
patients,O
with,O
reversible,O
downbeat,B-Entity
nystagmus,I-Entity
related,O
to,O
carbamazepine,I-Entity
therapy,O
.,O
The,O
nystagmus,I-Entity
of,O
both,O
patients,O
resolved,O
after,O
reduction,O
of,O
the,O
serum,O
carbamazepine,I-Entity
levels,O
.,O
In,O
patients,O
with,O
downbeat,B-Entity
nystagmus,I-Entity
who,O
are,O
taking,O
anticonvulsant,O
medications,O
",",O
consideration,O
should,O
be,O
given,O
to,O
reduction,O
in,O
dose,O
before,O
further,O
investigation,O
is,O
undertaken,O
.,O
Improvement,O
by,O
denopamine,I-Entity
(,O
TA-064,I-Entity
),O
of,O
pentobarbital,I-Entity
-,O
induced,O
cardiac,B-Entity
failure,I-Entity
in,O
the,O
dog,O
heart,O
-,O
lung,O
preparation,O
.,O
The,O
efficacy,O
of,O
denopamine,I-Entity
",",O
an,O
orally,O
active,O
beta,O
1-adrenoceptor,O
agonist,O
",",O
in,O
improving,O
cardiac,B-Entity
failure,I-Entity
was,O
assessed,O
in,O
dog,O
heart,O
-,O
lung,O
preparations,O
.,O
Cardiac,O
functions,O
depressed,O
by,O
pentobarbital,I-Entity
(,O
118,O
+,O
/-,O
SD,O
),O
such,O
that,O
cardiac,O
output,O
and,O
maximum,O
rate,O
of,O
rise,O
of,O
left,O
ventricular,O
pressure,O
(,O
LV,O
dP,O
/,O
dt,O
max,O
),O
had,O
been,O
reduced,O
by,O
about,O
35%,O
and,O
26%,O
of,O
the,O
respective,O
controls,O
were,O
improved,O
by,O
denopamine,I-Entity
(,O
10,O
-,O
300,O
micrograms,O
),O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
With,O
100,O
micrograms,O
denopamine,I-Entity
",",O
almost,O
complete,O
restoration,O
of,O
cardiac,O
performance,O
was,O
attained,O
",",O
associated,O
with,O
a,O
slight,O
increase,O
in,O
heart,O
rate,O
.,O
No,O
arrhythmias,I-Entity
were,O
induced,O
by,O
these,O
doses,O
of,O
denopamine,I-Entity
.,O
The,O
results,O
warrant,O
clinical,O
trials,O
of,O
denopamine,I-Entity
in,O
the,O
treatment,O
of,O
cardiac,B-Entity
failure,I-Entity
.,O
Clonazepam,I-Entity
monotherapy,O
for,O
epilepsy,I-Entity
in,O
childhood,O
.,O
Sixty,O
patients,O
(,O
age,O
-,O
range,O
one,O
month,O
to,O
14,O
years,O
),O
with,O
other,O
types,O
of,O
epilepsy,I-Entity
than,O
infantile,B-Entity
spasms,I-Entity
were,O
treated,O
with,O
clonazepam,I-Entity
.,O
Disappearance,O
of,O
seizures,I-Entity
and,O
normalization,O
of,O
abnormal,O
EEG,O
with,O
disappearance,O
of,O
seizures,I-Entity
were,O
recognized,O
in,O
77%,O
and,O
50%,O
",",O
respectively,O
.,O
Seizures,I-Entity
disappeared,O
in,O
71%,O
of,O
the,O
patients,O
with,O
generalized,O
seizures,I-Entity
and,O
89%,O
of,O
partial,O
seizures,I-Entity
.,O
The,O
incidence,O
of,O
side,O
effects,O
such,O
as,O
drowsiness,I-Entity
and,O
ataxia,I-Entity
was,O
only,O
5%,O
.,O
Postmarketing,O
study,O
of,O
timolol,I-Entity
-,O
hydrochlorothiazide,I-Entity
antihypertensive,O
therapy,O
.,O
A,O
postmarketing,O
surveillance,O
study,O
was,O
conducted,O
to,O
determine,O
the,O
safety,O
and,O
efficacy,O
of,O
a,O
fixed,O
-,O
ratio,O
combination,O
containing,O
10,O
mg,O
of,O
timolol,B-Entity
maleate,I-Entity
and,O
25,O
mg,O
of,O
hydrochlorothiazide,I-Entity
",",O
administered,O
twice,O
daily,O
for,O
one,O
month,O
to,O
hypertensive,I-Entity
patients,O
.,O
Mean,O
systolic,O
blood,O
pressure,O
decreased,O
25,O
mmHg,O
and,O
mean,O
diastolic,O
blood,O
pressure,O
declined,O
15,O
mmHg,O
after,O
one,O
month,O
of,O
timolol,I-Entity
-,O
hydrochlorothiazide,I-Entity
therapy,O
(,O
P,O
less,O
than,O
0.01,O
",",O
both,O
comparisons,O
),O
.,O
The,O
antihypertensive,O
effect,O
of,O
the,O
drug,O
was,O
greater,O
in,O
patients,O
with,O
more,O
severe,O
hypertension,I-Entity
.,O
Overall,O
",",O
"1,453",O
patients,O
experienced,O
a,O
total,O
of,O
"2,658",O
adverse,O
events,O
",",O
the,O
most,O
common,O
being,O
fatigue,I-Entity
",",O
dizziness,I-Entity
",",O
and,O
weakness,I-Entity
.,O
Salicylate,I-Entity
nephropathy,I-Entity
in,O
the,O
Gunn,O
rat,O
:,O
potential,O
role,O
of,O
prostaglandins,I-Entity
.,O
We,O
examined,O
the,O
potential,O
role,O
of,O
prostaglandins,I-Entity
in,O
the,O
development,O
of,O
analgesic,O
nephropathy,I-Entity
in,O
the,O
Gunn,O
strain,O
of,O
rat,O
.,O
The,O
homozygous,O
Gunn,O
rats,O
have,O
unconjugated,O
hyperbilirubinemia,I-Entity
due,O
to,O
the,O
absence,O
of,O
glucuronyl,I-Entity
transferase,O
",",O
leading,O
to,O
marked,O
bilirubin,I-Entity
deposition,O
in,O
renal,O
medulla,O
and,O
papilla,O
.,O
These,O
rats,O
are,O
also,O
highly,O
susceptible,O
to,O
develop,O
papillary,B-Entity
necrosis,I-Entity
with,O
analgesic,O
administration,O
.,O
Four,O
groups,O
of,O
rats,O
(,O
n,O
=,O
7,O
),O
were,O
studied,O
:,O
jj,O
and,O
jJ,O
rats,O
treated,O
either,O
with,O
aspirin,I-Entity
300,O
mg,O
/,O
kg,O
every,O
other,O
day,O
or,O
sham,O
-,O
treated,O
.,O
After,O
one,O
week,O
",",O
slices,O
of,O
cortex,O
",",O
outer,O
and,O
inner,O
medulla,O
from,O
one,O
kidney,O
were,O
incubated,O
in,O
buffer,O
and,O
prostaglandin,I-Entity
synthesis,O
was,O
determined,O
by,O
radioimmunoassay,O
.,O
A,O
marked,O
corticomedullary,O
gradient,O
of,O
prostaglandin,I-Entity
synthesis,O
was,O
observed,O
in,O
all,O
groups,O
.,O
PGE2,I-Entity
synthesis,O
was,O
significantly,O
higher,O
in,O
outer,O
medulla,O
",",O
but,O
not,O
cortex,O
or,O
inner,O
medulla,O
",",O
of,O
jj,O
(,O
38,O
+,O
/-,O
Aspirin,I-Entity
treatment,O
reduced,O
PGE2,I-Entity
synthesis,O
in,O
all,O
regions,O
",",O
but,O
outer,O
medullary,O
PGE2,I-Entity
remained,O
higher,O
in,O
jj,O
(,O
18,O
+,O
/-,O
PGF2,B-Entity
alpha,I-Entity
was,O
also,O
significantly,O
higher,O
in,O
the,O
outer,O
medulla,O
of,O
jj,O
rats,O
with,O
and,O
without,O
aspirin,I-Entity
administration,O
(,O
p,O
less,O
than,O
0.05,O
),O
.,O
The,O
changes,O
in,O
renal,O
prostaglandin,I-Entity
synthesis,O
were,O
accompanied,O
by,O
evidence,O
of,O
renal,B-Entity
damage,I-Entity
in,O
aspirin,I-Entity
-,O
treated,O
jj,O
but,O
not,O
jJ,O
rats,O
as,O
evidenced,O
by,O
:,O
increased,O
incidence,O
and,O
severity,O
of,O
hematuria,I-Entity
(,O
p,O
less,O
than,O
0.01,O
),O
;,O
increased,O
serum,O
creatinine,I-Entity
(,O
p,O
less,O
than,O
0.05,O
),O
;,O
and,O
increase,O
in,O
outer,O
medullary,O
histopathologic,O
lesions,O
(,O
p,O
less,O
than,O
0.005,O
compared,O
to,O
either,O
sham,O
-,O
treated,O
jj,O
or,O
aspirin,I-Entity
-,O
treated,O
jJ,O
),O
.,O
These,O
results,O
suggest,O
that,O
enhanced,O
prostaglandin,I-Entity
synthesis,O
contributes,O
to,O
maintenance,O
of,O
renal,O
function,O
and,O
morphological,O
integrity,O
",",O
and,O
that,O
inhibition,O
of,O
prostaglandin,I-Entity
synthesis,O
may,O
lead,O
to,O
pathological,B-Entity
renal,I-Entity
medullary,I-Entity
lesions,I-Entity
and,O
deterioration,B-Entity
of,I-Entity
renal,I-Entity
function,I-Entity
.,O
Prophylactic,O
lidocaine,I-Entity
in,O
the,O
early,O
phase,O
of,O
suspected,O
myocardial,B-Entity
infarction,I-Entity
.,O
Four,O
hundred,O
two,O
patients,O
with,O
suspected,O
myocardial,B-Entity
infarction,I-Entity
seen,O
within,O
6,O
hours,O
of,O
the,O
onset,O
of,O
symptoms,O
entered,O
a,O
double,O
-,O
blind,O
randomized,O
trial,O
of,O
lidocaine,I-Entity
vs,O
placebo,O
.,O
During,O
the,O
1,O
hour,O
after,O
administration,O
of,O
the,O
drug,O
the,O
incidence,O
of,O
ventricular,B-Entity
fibrillation,I-Entity
or,O
sustained,O
ventricular,B-Entity
tachycardia,I-Entity
among,O
the,O
204,O
patients,O
with,O
acute,O
myocardial,B-Entity
infarction,I-Entity
was,O
low,O
",",O
1.5%,O
.,O
Lidocaine,I-Entity
",",O
given,O
in,O
a,O
300,O
mg,O
dose,O
intramuscularly,O
followed,O
by,O
100,O
mg,O
intravenously,O
",",O
did,O
not,O
prevent,O
sustained,O
ventricular,B-Entity
tachycardia,I-Entity
",",O
although,O
there,O
was,O
a,O
significant,O
reduction,O
in,O
the,O
number,O
of,O
patients,O
with,O
warning,O
arrhythmias,I-Entity
between,O
15,O
and,O
45,O
minutes,O
after,O
the,O
administration,O
of,O
lidocaine,I-Entity
(,O
p,O
less,O
than,O
0.05,O
),O
.,O
The,O
average,O
plasma,O
lidocaine,I-Entity
level,O
10,O
minutes,O
after,O
administration,O
for,O
patients,O
without,O
a,O
myocardial,B-Entity
infarction,I-Entity
was,O
significantly,O
higher,O
than,O
that,O
for,O
patients,O
with,O
an,O
acute,O
infarction,I-Entity
.,O
The,O
mean,O
plasma,O
lidocaine,I-Entity
level,O
of,O
patients,O
on,O
beta,O
-,O
blocking,O
agents,O
was,O
no,O
different,O
from,O
that,O
in,O
patients,O
not,O
on,O
beta,O
blocking,O
agents,O
.,O
During,O
the,O
1-hour,O
study,O
period,O
",",O
the,O
incidence,O
of,O
central,O
nervous,O
system,O
side,O
effects,O
was,O
significantly,O
greater,O
in,O
the,O
lidocaine,I-Entity
group,O
",",O
hypotension,I-Entity
occurred,O
in,O
11,O
patients,O
",",O
nine,O
of,O
whom,O
had,O
received,O
lidocaine,I-Entity
",",O
and,O
four,O
patients,O
died,O
from,O
asystole,I-Entity
",",O
three,O
of,O
whom,O
had,O
had,O
lidocaine,I-Entity
.,O
We,O
can,O
not,O
advocate,O
the,O
administration,O
of,O
lidocaine,I-Entity
prophylactically,O
in,O
the,O
early,O
hours,O
of,O
suspected,O
myocardial,B-Entity
infarction,I-Entity
.,O
Evidence,O
for,O
a,O
cholinergic,O
role,O
in,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
Experiments,O
in,O
mice,O
tested,O
previous,O
evidence,O
that,O
activation,O
of,O
cholinergic,O
systems,O
promotes,O
catalepsy,I-Entity
and,O
that,O
cholinergic,O
mechanisms,O
need,O
to,O
be,O
intact,O
for,O
full,O
expression,O
of,O
neuroleptic,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
Large,O
doses,O
of,O
the,O
cholinomimetic,O
",",O
pilocarpine,I-Entity
",",O
could,O
induce,O
catalepsy,I-Entity
when,O
peripheral,O
cholinergic,O
receptors,O
were,O
blocked,O
.,O
Low,O
doses,O
of,O
pilocarpine,I-Entity
caused,O
a,O
pronounced,O
enhancement,O
of,O
the,O
catalepsy,I-Entity
that,O
was,O
induced,O
by,O
the,O
dopaminergic,O
blocker,O
",",O
haloperidol,I-Entity
.,O
A,O
muscarinic,O
receptor,O
blocker,O
",",O
atropine,I-Entity
",",O
disrupted,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
Intracranial,O
injection,O
of,O
an,O
acetylcholine,I-Entity
-,O
synthesis,O
inhibitor,O
",",O
hemicholinium,I-Entity
",",O
prevented,O
the,O
catalepsy,I-Entity
that,O
is,O
usually,O
induced,O
by,O
haloperidol,I-Entity
.,O
These,O
findings,O
suggest,O
the,O
hypothesis,O
that,O
the,O
catalepsy,I-Entity
that,O
is,O
produced,O
by,O
neuroleptics,I-Entity
such,O
as,O
haloperidol,I-Entity
is,O
actually,O
mediated,O
by,O
intrinsic,O
central,O
cholinergic,O
systems,O
.,O
Alternatively,O
",",O
activation,O
of,O
central,O
cholinergic,O
systems,O
could,O
promote,O
catalepsy,I-Entity
by,O
suppression,O
of,O
dopaminergic,O
systems,O
.,O
Cardiovascular,B-Entity
dysfunction,I-Entity
and,O
hypersensitivity,I-Entity
to,O
sodium,B-Entity
pentobarbital,I-Entity
induced,O
by,O
chronic,O
barium,B-Entity
chloride,I-Entity
ingestion,O
.,O
Barium,I-Entity
-,O
supplemented,O
Long,O
-,O
Evans,O
hooded,O
rats,O
were,O
characterized,O
by,O
a,O
persistent,O
hypertension,I-Entity
that,O
was,O
evident,O
after,O
1,O
month,O
of,O
barium,I-Entity
(,O
100,O
micrograms,O
/,O
ml,O
mineral,O
fortified,O
water,O
),O
treatment,O
.,O
myocardial,O
excitability,O
",",O
contractility,O
",",O
and,O
metabolic,O
characteristics,O
at,O
16,O
months,O
revealed,O
other,O
significant,O
barium,I-Entity
-,O
induced,O
disturbances,B-Entity
within,I-Entity
the,I-Entity
cardiovascular,I-Entity
system,I-Entity
.,O
The,O
most,O
distinctive,O
aspect,O
of,O
the,O
barium,I-Entity
effect,O
was,O
a,O
demonstrated,O
hypersensitivity,I-Entity
of,O
the,O
cardiovascular,O
system,O
to,O
sodium,B-Entity
pentobarbital,I-Entity
.,O
Under,O
barbiturate,I-Entity
anesthesia,O
",",O
virtually,O
all,O
of,O
the,O
myocardial,O
contractile,O
indices,O
were,O
depressed,O
significantly,O
in,O
barium,I-Entity
-,O
exposed,O
rats,O
relative,O
to,O
the,O
corresponding,O
control,O
-,O
fed,O
rats,O
.,O
The,O
lack,O
of,O
a,O
similar,O
response,O
to,O
ketamine,I-Entity
and,O
xylazine,I-Entity
anesthesia,O
revealed,O
that,O
the,O
cardiovascular,O
actions,O
of,O
sodium,B-Entity
pentobarbital,I-Entity
in,O
barium,I-Entity
-,O
treated,O
rats,O
were,O
linked,O
specifically,O
to,O
this,O
anesthetic,O
",",O
and,O
were,O
not,O
representative,O
of,O
a,O
generalized,O
anesthetic,O
response,O
.,O
Other,O
myocardial,O
pathophysiologic,O
and,O
metabolic,O
changes,O
induced,O
by,O
barium,I-Entity
were,O
manifest,O
",",O
irrespective,O
of,O
the,O
anesthetic,O
employed,O
.,O
The,O
contractile,O
element,O
shortening,O
velocity,O
of,O
the,O
cardiac,O
muscle,O
fibers,O
was,O
significantly,O
slower,O
in,O
both,O
groups,O
of,O
barium,I-Entity
-,O
treated,O
rats,O
relative,O
to,O
the,O
control,O
groups,O
",",O
irrespective,O
of,O
the,O
anesthetic,O
regimen,O
.,O
Similarly,O
",",O
significant,O
disturbances,O
in,O
myocardial,O
energy,O
metabolism,O
were,O
detected,O
in,O
the,O
barium,I-Entity
-,O
exposed,O
rats,O
which,O
were,O
consistent,O
with,O
the,O
reduced,O
contractile,O
element,O
shortening,O
velocity,O
.,O
In,O
addition,O
",",O
the,O
excitability,O
of,O
the,O
cardiac,O
conduction,O
system,O
was,O
depressed,O
preferentially,O
in,O
the,O
atrioventricular,O
nodal,O
region,O
of,O
hearts,O
from,O
barium,I-Entity
-,O
exposed,O
rats,O
.,O
Overall,O
",",O
the,O
altered,O
cardiac,O
contractility,O
and,O
excitability,O
characteristics,O
",",O
the,O
myocardial,O
metabolic,B-Entity
disturbances,I-Entity
",",O
and,O
the,O
hypersensitivity,I-Entity
of,O
the,O
cardiovascular,O
system,O
to,O
sodium,B-Entity
pentobarbital,I-Entity
suggest,O
the,O
existence,O
of,O
a,O
heretofore,O
undescribed,O
cardiomyopathic,B-Entity
disorder,I-Entity
induced,O
by,O
chronic,O
barium,I-Entity
exposure,O
.,O
These,O
experimental,O
findings,O
represent,O
the,O
first,O
indication,O
that,O
life,O
-,O
long,O
barium,I-Entity
ingestion,O
may,O
have,O
significant,O
adverse,O
effects,O
on,O
the,O
mammalian,O
cardiovascular,O
system,O
.,O
Propranolol,I-Entity
antagonism,O
of,O
phenylpropanolamine,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
Phenylpropanolamine,I-Entity
(,O
PPA,I-Entity
),O
overdose,I-Entity
can,O
cause,O
severe,O
hypertension,I-Entity
",",O
intracerebral,B-Entity
hemorrhage,I-Entity
",",O
and,O
death,O
.,O
We,O
studied,O
the,O
efficacy,O
and,O
safety,O
of,O
propranolol,I-Entity
in,O
the,O
treatment,O
of,O
PPA,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
Subjects,O
received,O
propranolol,I-Entity
either,O
by,O
mouth,O
for,O
48,O
hours,O
before,O
PPA,I-Entity
or,O
as,O
a,O
rapid,O
intravenous,O
infusion,O
after,O
PPA,I-Entity
.,O
PPA,I-Entity
",",O
75,O
mg,O
alone,O
",",O
increased,O
blood,O
pressure,O
(,O
31,O
+,O
/-,O
5,O
mm,O
Hg,O
diastolic,O
),O
",",O
and,O
propranolol,I-Entity
pretreatment,O
antagonized,O
this,O
increase,O
(,O
12,O
+,O
/-,O
Intravenous,O
propranolol,I-Entity
after,O
PPA,I-Entity
also,O
decreased,O
blood,O
pressure,O
.,O
Left,O
ventricular,O
function,O
(,O
assessed,O
by,O
echocardiography,O
),O
showed,O
that,O
PPA,I-Entity
increased,O
the,O
stroke,I-Entity
volume,O
30%,O
(,O
from,O
62.5,O
+,O
/-,O
Intravenous,O
propranolol,I-Entity
reversed,O
these,O
effects,O
.,O
Systemic,O
vascular,O
resistance,O
was,O
increased,O
by,O
PPA,I-Entity
28%,O
(,O
from,O
1710,O
+,O
/-,O
sec,O
/,O
cm5,O
),O
and,O
was,O
further,O
increased,O
by,O
propranolol,I-Entity
22%,O
(,O
to,O
2660,O
+,O
/-,O
We,O
conclude,O
that,O
PPA,I-Entity
increases,O
blood,O
pressure,O
by,O
increasing,O
systemic,O
vascular,O
resistance,O
and,O
cardiac,O
output,O
",",O
and,O
that,O
propranolol,I-Entity
antagonizes,O
this,O
increase,O
by,O
reversing,O
the,O
effect,O
of,O
PPA,I-Entity
on,O
cardiac,O
output,O
.,O
That,O
propranolol,I-Entity
antagonizes,O
the,O
pressor,O
effect,O
of,O
PPA,I-Entity
is,O
in,O
contrast,O
to,O
the,O
interaction,O
in,O
which,O
propranolol,I-Entity
enhances,O
the,O
pressor,O
effect,O
of,O
norepinephrine,I-Entity
.,O
This,O
is,O
probably,O
because,O
PPA,I-Entity
has,O
less,O
beta,O
2,O
activity,O
than,O
does,O
norepinephrine,I-Entity
.,O
Mesangial,O
function,O
and,O
glomerular,B-Entity
sclerosis,I-Entity
in,O
rats,O
with,O
aminonucleoside,I-Entity
nephrosis,I-Entity
.,O
The,O
possible,O
relationship,O
between,O
mesangial,B-Entity
dysfunction,I-Entity
and,O
development,O
of,O
glomerular,B-Entity
sclerosis,I-Entity
was,O
studied,O
in,O
the,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
model,O
.,O
Five,O
male,O
Wistar,O
rats,O
received,O
repeated,O
subcutaneous,O
PAN,I-Entity
injections,O
;,O
five,O
controls,O
received,O
saline,O
only,O
.,O
After,O
4,O
weeks,O
the,O
PAN,I-Entity
rats,O
were,O
severely,O
proteinuric,I-Entity
(,O
190,O
+,O
/-,O
80,O
mg/24,O
hr,O
),O
",",O
and,O
all,O
rats,O
were,O
given,O
colloidal,O
carbon,I-Entity
(,O
CC,O
),O
intravenously,O
.,O
At,O
5,O
months,O
glomerular,B-Entity
sclerosis,I-Entity
was,O
found,O
in,O
7.6,O
+,O
/-,O
3.4%,O
of,O
the,O
glomeruli,O
of,O
PAN,I-Entity
rats,O
;,O
glomeruli,O
of,O
the,O
controls,O
were,O
normal,O
.,O
Glomeruli,O
of,O
PAN,I-Entity
rats,O
contained,O
significantly,O
more,O
CC,O
than,O
glomeruli,O
of,O
controls,O
.,O
Glomeruli,O
with,O
sclerosis,I-Entity
contained,O
significantly,O
more,O
CC,O
than,O
non,O
-,O
sclerotic,O
glomeruli,O
in,O
the,O
same,O
kidneys,O
.,O
Since,O
mesangial,O
CC,O
clearance,O
from,O
the,O
mesangium,O
did,O
not,O
change,O
during,O
chronic,O
PAN,I-Entity
treatment,O
",",O
we,O
conclude,O
that,O
this,O
preferential,O
CC,O
localization,O
within,O
the,O
lesions,O
is,O
caused,O
by,O
an,O
increased,O
CC,O
uptake,O
shortly,O
after,O
injection,O
in,O
apparent,O
vulnerable,O
areas,O
where,O
sclerosis,I-Entity
will,O
develop,O
subsequently,O
.,O
Cluster,O
analysis,O
showed,O
a,O
random,O
distribution,O
of,O
lesions,O
in,O
the,O
PAN,I-Entity
glomeruli,O
in,O
concordance,O
with,O
the,O
random,O
localization,O
of,O
mesangial,O
areas,O
with,O
dysfunction,O
in,O
this,O
model,O
.,O
Similar,O
to,O
the,O
remnant,O
kidney,O
model,O
in,O
PAN,I-Entity
nephrosis,I-Entity
the,O
development,O
of,O
glomerular,B-Entity
sclerosis,I-Entity
may,O
be,O
related,O
to,O
"""",O
mesangial,O
overloading,O
.,O
"""",O
Relationship,O
between,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
hippocampal,O
nicotinic,O
receptors,O
.,O
Using,O
mice,O
derived,O
from,O
a,O
classical,O
F2,O
and,O
backcross,O
genetic,O
design,O
",",O
a,O
relationship,O
between,O
nicotine,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
alpha,O
-,O
bungarotoxin,O
nicotinic,O
receptor,O
concentration,O
was,O
found,O
.,O
Mice,O
sensitive,O
to,O
the,O
convulsant,O
effects,O
of,O
nicotine,I-Entity
had,O
greater,O
alpha,O
-,O
bungarotoxin,O
binding,O
in,O
the,O
hippocampus,O
than,O
seizure,I-Entity
insensitive,O
mice,O
.,O
The,O
binding,O
sites,O
from,O
seizure,I-Entity
sensitive,O
and,O
resistant,O
mice,O
were,O
equally,O
affected,O
by,O
treatment,O
with,O
dithiothreitol,I-Entity
",",O
trypsin,O
or,O
heat,O
.,O
Thus,O
it,O
appears,O
that,O
the,O
difference,O
between,O
seizure,I-Entity
sensitive,O
and,O
insensitive,O
animals,O
may,O
be,O
due,O
to,O
a,O
difference,O
in,O
hippocampal,O
nicotinic,O
receptor,O
concentration,O
as,O
measured,O
with,O
alpha,O
-,O
bungarotoxin,O
binding,O
.,O
The,O
role,O
of,O
p,B-Entity
-,I-Entity
aminophenol,I-Entity
in,O
acetaminophen,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
:,O
effect,O
of,O
bis(p,B-Entity
-,I-Entity
nitrophenyl,I-Entity
),I-Entity
phosphate,I-Entity
on,O
acetaminophen,I-Entity
and,O
p,B-Entity
-,I-Entity
aminophenol,I-Entity
nephrotoxicity,I-Entity
and,O
metabolism,O
in,O
Fischer,O
344,O
rats,O
.,O
Acetaminophen,I-Entity
(,O
APAP,I-Entity
),O
produces,O
proximal,O
tubular,B-Entity
necrosis,I-Entity
in,O
Fischer,O
344,O
(,O
F344,O
),O
rats,O
.,O
Recently,O
",",O
p,B-Entity
-,I-Entity
aminophenol,I-Entity
(,O
PAP,I-Entity
),O
",",O
a,O
known,O
potent,O
nephrotoxicant,O
",",O
was,O
identified,O
as,O
a,O
metabolite,O
of,O
APAP,I-Entity
in,O
F344,O
rats,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
determine,O
if,O
PAP,I-Entity
formation,O
is,O
a,O
requisite,O
step,O
in,O
APAP,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
.,O
Therefore,O
",",O
the,O
effect,O
of,O
bis(p,B-Entity
-,I-Entity
nitrophenyl,I-Entity
),I-Entity
phosphate,I-Entity
(,O
BNPP,I-Entity
),O
",",O
an,O
acylamidase,O
inhibitor,O
",",O
on,O
APAP,I-Entity
and,O
PAP,I-Entity
nephrotoxicity,I-Entity
and,O
metabolism,O
was,O
determined,O
.,O
BNPP,I-Entity
(,O
1,O
to,O
8,O
mM,O
),O
reduced,O
APAP,I-Entity
deacetylation,O
and,O
covalent,O
binding,O
in,O
F344,O
renal,O
cortical,O
homogenates,O
in,O
a,O
concentration,O
-,O
dependent,O
manner,O
.,O
Pretreatment,O
of,O
animals,O
with,O
BNPP,I-Entity
prior,O
to,O
APAP,I-Entity
or,O
PAP,I-Entity
administration,O
resulted,O
in,O
marked,O
reduction,O
of,O
APAP,I-Entity
(,O
900,O
mg,O
/,O
kg,O
),O
nephrotoxicity,I-Entity
but,O
not,O
PAP,I-Entity
nephrotoxicity,I-Entity
.,O
This,O
result,O
was,O
not,O
due,O
to,O
altered,O
disposition,O
of,O
either,O
APAP,I-Entity
or,O
acetylated,O
metabolites,O
in,O
plasma,O
or,O
renal,O
cortical,O
and,O
hepatic,O
tissue,O
.,O
Rather,O
",",O
BNPP,I-Entity
pretreatment,O
reduced,O
the,O
fraction,O
of,O
APAP,I-Entity
excreted,O
as,O
PAP,I-Entity
by,O
64,O
and,O
75%,O
after,O
APAP,I-Entity
doses,O
of,O
750,O
and,O
900,O
mg,O
/,O
kg,O
.,O
BNPP,I-Entity
did,O
not,O
alter,O
the,O
excretion,O
of,O
APAP,I-Entity
or,O
any,O
of,O
its,O
non,O
-,O
deacetylated,O
metabolites,O
nor,O
did,O
BNPP,I-Entity
alter,O
excretion,O
of,O
PAP,I-Entity
or,O
its,O
metabolites,O
after,O
PAP,I-Entity
doses,O
of,O
150,O
and,O
300,O
mg,O
/,O
kg,O
.,O
Therefore,O
",",O
the,O
BNPP,I-Entity
-,O
induced,O
reduction,O
in,O
APAP,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
appears,O
to,O
be,O
due,O
to,O
inhibition,O
of,O
APAP,I-Entity
deacetylation,O
.,O
It,O
is,O
concluded,O
that,O
PAP,I-Entity
formation,O
",",O
in,O
vivo,O
",",O
accounts,O
",",O
at,O
least,O
in,O
part,O
",",O
for,O
APAP,I-Entity
-,O
induced,O
renal,B-Entity
tubular,I-Entity
necrosis,I-Entity
.,O
Morphine,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
newborn,O
infants,O
.,O
Two,O
neonates,O
suffered,O
from,O
generalized,O
seizures,I-Entity
during,O
the,O
course,O
of,O
intravenous,O
morphine,B-Entity
sulfate,I-Entity
for,O
post,O
-,O
operative,O
analgesia,O
.,O
They,O
received,O
morphine,I-Entity
in,O
doses,O
of,O
32,O
micrograms,O
/,O
kg,O
/,O
hr,O
and,O
40,O
micrograms,O
/,O
kg,O
/,O
hr,O
larger,O
than,O
a,O
group,O
of,O
10,O
neonates,O
who,O
received,O
6,O
-,O
24,O
micrograms,O
/,O
kg,O
/,O
hr,O
and,O
had,O
no,O
seizures,I-Entity
.,O
Plasma,O
concentrations,O
of,O
morphine,I-Entity
in,O
these,O
neonates,O
was,O
excessive,O
(,O
60,O
and,O
90,O
mg,O
/,O
ml,O
),O
.,O
Other,O
known,O
reasons,O
for,O
seizures,I-Entity
were,O
ruled,O
out,O
and,O
the,O
convulsions,I-Entity
stopped,O
a,O
few,O
hours,O
after,O
cessation,O
of,O
morphine,I-Entity
and,O
did,O
not,O
reoccur,O
in,O
the,O
subsequent,O
8,O
months,O
.,O
It,O
is,O
suggested,O
that,O
post,O
-,O
operative,O
intravenous,O
morphine,I-Entity
should,O
not,O
exceed,O
20,O
micrograms,O
/,O
kg,O
/,O
ml,O
in,O
neonates,O
.,O
Effect,O
of,O
vincristine,B-Entity
sulfate,I-Entity
on,O
Pseudomonas,B-Entity
infections,I-Entity
in,O
monkeys,O
.,O
Leukocytosis,I-Entity
was,O
observed,O
in,O
all,O
monkeys,O
.,O
Intravenous,O
or,O
intratracheal,O
inoculation,O
of,O
2.0,O
to,O
2.5,O
mg,O
of,O
vincristine,B-Entity
sulfate,I-Entity
was,O
followed,O
by,O
leukopenia,I-Entity
in,O
4,O
to,O
5,O
days,O
.,O
Pseudomonas,O
organisms,O
in,O
monkeys,O
given,O
vincristine,B-Entity
sulfate,I-Entity
4,O
days,O
previously,O
resulted,O
in,O
fatal,O
infection,I-Entity
in,O
11,O
of,O
14,O
monkeys,O
",",O
whereas,O
none,O
of,O
four,O
receiving,O
Pseudomonas,O
alone,O
died,O
.,O
These,O
studies,O
suggest,O
that,O
an,O
antimetabolite,O
-,O
induced,O
leukopenia,I-Entity
predisposes,O
to,O
severe,O
Pseudomonas,O
sepsis,I-Entity
and,O
that,O
such,O
monkeys,O
may,O
serve,O
as,O
a,O
biological,O
model,O
for,O
study,O
of,O
comparative,O
efficacy,O
of,O
antimicrobial,O
agents,O
.,O
Central,O
excitatory,O
actions,O
of,O
flurazepam,I-Entity
.,O
Toxic,O
actions,O
of,O
flurazepam,I-Entity
(,O
FZP,I-Entity
),O
were,O
studied,O
in,O
cats,O
",",O
mice,O
and,O
rats,O
.,O
High,O
doses,O
caused,O
an,O
apparent,O
central,O
excitation,O
",",O
most,O
clearly,O
seen,O
as,O
clonic,O
convulsions,I-Entity
",",O
superimposed,O
on,O
general,O
depression,I-Entity
.,O
Following,O
a,O
lethal,O
dose,O
",",O
death,O
was,O
always,O
associated,O
with,O
convulsions,I-Entity
.,O
Comparing,O
the,O
relative,O
sensitivity,O
to,O
central,O
depression,I-Entity
and,O
excitation,O
revealed,O
that,O
rats,O
were,O
least,O
likely,O
to,O
have,O
convulsions,I-Entity
at,O
doses,O
that,O
did,O
not,O
first,O
cause,O
loss,B-Entity
of,I-Entity
consciousness,I-Entity
",",O
while,O
cats,O
most,O
clearly,O
showed,O
marked,O
central,O
excitatory,O
actions,O
.,O
Signs,O
of,O
FZP,I-Entity
toxocity,I-Entity
in,O
cats,O
included,O
excessive,O
salivation,I-Entity
",",O
extreme,O
apprehensive,O
behavior,O
",",O
retching,O
",",O
muscle,B-Entity
tremors,I-Entity
and,O
convulsions,I-Entity
.,O
An,O
interaction,O
between,O
FZP,I-Entity
and,O
pentylenetetrazol,I-Entity
(,O
PTZ,I-Entity
),O
was,O
shown,O
by,O
pretreating,O
mice,O
with,O
FZP,I-Entity
before,O
PTZ,I-Entity
challenge,O
.,O
As,O
a,O
function,O
of,O
dose,O
",",O
FZP,I-Entity
first,O
protected,O
against,O
convulsions,I-Entity
and,O
death,O
.,O
At,O
higher,O
doses,O
",",O
however,O
",",O
convulsions,I-Entity
again,O
emerged,O
.,O
These,O
doses,O
of,O
FZP,I-Entity
were,O
lower,O
than,O
those,O
that,O
would,O
alone,O
cause,O
convulsions,I-Entity
.,O
These,O
results,O
may,O
be,O
relevant,O
to,O
the,O
use,O
of,O
FZP,I-Entity
in,O
clinical,O
situations,O
in,O
which,O
there,O
is,O
increased,O
neural,O
excitability,O
",",O
such,O
as,O
epilepsy,I-Entity
or,O
sedative,O
-,O
hypnotic,O
drug,O
withdrawal,O
.,O
We,O
compared,O
the,O
effects,O
of,O
single,O
doses,O
of,O
50,O
mg,O
atenolol,I-Entity
(,O
cardioselective,O
),O
",",O
40,O
mg,O
propranolol,I-Entity
(,O
nonselective,O
),O
",",O
and,O
placebo,O
on,O
both,O
exercise-,O
and,O
isoproterenol,I-Entity
-,O
induced,O
tachycardia,I-Entity
in,O
two,O
experiments,O
involving,O
nine,O
normal,O
subjects,O
.,O
7,O
bpm,O
after,O
atenolol,I-Entity
and,O
138,O
+,O
/-,O
6,O
bpm,O
after,O
propranolol,I-Entity
",",O
The,O
effects,O
on,O
isoproterenol,I-Entity
tachycardia,I-Entity
were,O
determined,O
before,O
and,O
after,O
atropine,I-Entity
(,O
0.04,O
mg,O
/,O
kg,O
IV,O
),O
.,O
Isoproterenol,I-Entity
sensitivity,O
was,O
determined,O
as,O
the,O
intravenous,O
dose,O
that,O
increased,O
heart,O
rate,O
by,O
25,O
bpm,O
(,O
CD25,O
),O
and,O
this,O
was,O
increased,O
from,O
1.8,O
+,O
/-,O
8.3,O
micrograms,O
after,O
propranolol,I-Entity
and,O
8.3,O
+,O
/-,O
1.7,O
micrograms,O
after,O
atenolol,I-Entity
.,O
After,O
atropine,I-Entity
the,O
CD25,O
was,O
unchanged,O
after,O
placebo,O
(,O
2.3,O
+,O
/-,O
0.3,O
micrograms,O
),O
and,O
atenolol,I-Entity
(,O
7.7,O
+,O
/-,O
1.3,O
micrograms,O
),O
;,O
it,O
was,O
reduced,O
after,O
propranolol,I-Entity
(,O
24.8,O
+,O
/-,O
5.0,O
micrograms,O
),O
",",O
but,O
remained,O
different,O
from,O
atenolol,I-Entity
.,O
This,O
change,O
with,O
propranolol,I-Entity
sensitivity,O
was,O
calculated,O
as,O
the,O
apparent,O
Ka,O
",",O
this,O
was,O
unchanged,O
by,O
atropine,I-Entity
(,O
11.7,O
+,O
/-,O
These,O
data,O
are,O
consistent,O
with,O
the,O
hypothesis,O
that,O
exercise,O
-,O
induced,O
tachycardia,I-Entity
results,O
largely,O
from,O
beta,O
1-receptor,O
activation,O
that,O
is,O
blocked,O
by,O
both,O
cardioselective,O
and,O
nonselective,O
drugs,O
",",O
whereas,O
isoproterenol,I-Entity
activates,O
both,O
beta,O
1-,O
and,O
beta,O
2-receptors,O
so,O
that,O
after,O
cardioselective,O
blockade,O
there,O
remains,O
a,O
beta,O
2-component,O
that,O
can,O
be,O
blocked,O
with,O
a,O
nonselective,O
drug,O
.,O
Hormones,O
and,O
risk,O
of,O
breast,B-Entity
cancer,I-Entity
.,O
It,O
was,O
hypothesized,O
that,O
progestins,I-Entity
could,O
equilibrate,O
the,O
effects,O
of,O
the,O
estrogenic,O
stimulation,O
on,O
the,O
mammary,O
and,O
endometrial,O
target,O
tissues,O
of,O
women,O
on,O
hormonal,O
replacement,O
therapy,O
.,O
The,O
treatment,O
schedule,O
consisted,O
of,O
conjugated,B-Entity
estrogens,I-Entity
(,O
Premarin,I-Entity
),O
1.25,O
mg,O
/,O
day,O
for,O
21,O
days,O
and,O
Medroxyprogesterone,B-Entity
acetate,I-Entity
10,O
mg,O
/,O
day,O
for,O
10,O
days,O
in,O
each,O
month,O
.,O
Mastodynia,I-Entity
was,O
reported,O
by,O
21,O
patients,O
",",O
and,O
physical,O
examination,O
revealed,O
a,O
light,O
increase,O
in,O
breast,O
firmness,O
in,O
12,O
women,O
and,O
a,O
moderate,O
increase,O
in,O
breast,O
nodularity,O
in,O
2,O
women,O
.,O
Themography,O
confirmed,O
the,O
existence,O
of,O
an,O
excessive,O
breast,O
stimulation,O
in,O
1,O
women,O
who,O
complained,O
of,O
moderate,O
mastodynia,I-Entity
and,O
in,O
5,O
of,O
the,O
7,O
women,O
who,O
complained,O
of,O
severe,O
mastodynia,I-Entity
.,O
Normalization,O
was,O
obtained,O
by,O
halving,O
the,O
estrogen,I-Entity
dose,O
.,O
Early,O
infections,I-Entity
in,O
kidney,O
",",O
heart,O
",",O
and,O
liver,O
transplant,O
recipients,O
on,O
cyclosporine,I-Entity
.,O
Eighty,O
-,O
one,O
renal,O
",",O
seventeen,O
heart,O
",",O
and,O
twenty,O
-,O
four,O
liver,O
transplant,O
patients,O
were,O
followed,O
for,O
infection,I-Entity
.,O
Seventeen,O
renal,O
patients,O
received,O
azathioprine,I-Entity
(,O
Aza,I-Entity
),O
and,O
prednisone,I-Entity
as,O
part,O
of,O
a,O
randomized,O
trial,O
of,O
immunosuppression,O
with,O
21,O
cyclosporine,I-Entity
-,O
and,O
-,O
prednisone,I-Entity
-,O
treated,O
renal,O
transplant,O
patients,O
.,O
All,O
others,O
received,O
cyclosporine,I-Entity
and,O
prednisone,I-Entity
.,O
The,O
randomized,O
Aza,I-Entity
patients,O
had,O
more,O
overall,O
infections,I-Entity
(,O
P,O
less,O
than,O
0.05,O
),O
and,O
more,O
nonviral,O
infections,I-Entity
(,O
P,O
less,O
than,O
0.02,O
),O
than,O
the,O
randomized,O
cyclosporine,I-Entity
patients,O
.,O
Heart,O
and,O
liver,O
patients,O
had,O
more,O
infections,I-Entity
than,O
cyclosporine,I-Entity
renal,O
patients,O
but,O
fewer,O
infections,I-Entity
than,O
the,O
Aza,I-Entity
renal,O
patients,O
.,O
There,O
were,O
no,O
infectious,O
deaths,O
in,O
renal,O
transplant,O
patients,O
on,O
cyclosporine,I-Entity
or,O
Aza,I-Entity
",",O
but,O
infection,I-Entity
played,O
a,O
major,O
role,O
in,O
3,O
out,O
of,O
6,O
cardiac,O
transplant,O
deaths,O
and,O
in,O
8,O
out,O
of,O
9,O
liver,O
transplant,O
deaths,O
.,O
Renal,O
patients,O
on,O
cyclosporine,I-Entity
had,O
the,O
fewest,O
bacteremias,I-Entity
.,O
Analysis,O
of,O
site,O
of,O
infection,I-Entity
showed,O
a,O
preponderance,O
of,O
abdominal,B-Entity
infections,I-Entity
in,O
liver,O
patients,O
",",O
intrathoracic,O
infections,I-Entity
in,O
heart,O
patients,O
",",O
and,O
urinary,B-Entity
tract,I-Entity
infections,I-Entity
in,O
renal,O
patients,O
.,O
Pulmonary,O
infections,I-Entity
were,O
less,O
common,O
in,O
cyclosporine,I-Entity
-,O
treated,O
renal,O
patients,O
than,O
in,O
Aza,I-Entity
-,O
treated,O
patients,O
(,O
P,O
less,O
than,O
0.05,O
),O
.,O
Aza,I-Entity
patients,O
had,O
significantly,O
more,O
staphylococcal,B-Entity
infections,I-Entity
than,O
all,O
other,O
transplant,O
groups,O
(,O
P,O
less,O
than,O
0.005,O
),O
",",O
and,O
systemic,O
fungal,B-Entity
infections,I-Entity
occurred,O
only,O
in,O
the,O
liver,O
transplant,O
group,O
.,O
Cytomegalovirus,O
(,O
CMV,O
),O
shedding,O
or,O
serological,O
rises,O
in,O
antibody,O
titer,O
",",O
or,O
both,O
occurred,O
in,O
78%,O
of,O
cyclosporine,I-Entity
patients,O
and,O
76%,O
of,O
Aza,I-Entity
patients,O
.,O
Of,O
the,O
cyclosporine,I-Entity
patients,O
",",O
15%,O
had,O
symptoms,O
related,O
to,O
CMV,B-Entity
infection,I-Entity
.,O
Serological,O
evidence,O
for,O
Epstein,B-Entity
Barr,I-Entity
Virus,I-Entity
infection,I-Entity
was,O
found,O
in,O
20%,O
of,O
65,O
cyclosporine,I-Entity
patients,O
studied,O
.,O
Three,O
had,O
associated,O
symptoms,O
",",O
and,O
one,O
developed,O
a,O
lymphoma,I-Entity
.,O
Structure,O
-,O
activity,O
and,O
dose,O
-,O
effect,O
relationships,O
of,O
the,O
antagonism,O
of,O
picrotoxin,I-Entity
-,O
induced,O
seizures,I-Entity
by,O
cholecystokinin,I-Entity
",",O
fragments,O
and,O
analogues,O
of,O
cholecystokinin,I-Entity
in,O
mice,O
.,O
Intraperitoneal,O
administration,O
of,O
cholecystokinin,B-Entity
octapeptide,I-Entity
sulphate,O
ester,O
(,O
CCK-8-SE,I-Entity
),O
and,O
nonsulphated,O
cholecystokinin,B-Entity
octapeptide,I-Entity
(,O
CCK-8-NS,I-Entity
),O
enhanced,O
the,O
latency,O
of,O
seizures,I-Entity
induced,O
by,O
picrotoxin,I-Entity
in,O
mice,O
.,O
The,O
analogues,O
CCK-8-SE,I-Entity
and,O
CCK-8-NS,I-Entity
(,O
dose,O
range,O
0.2,O
-,O
6.4,O
mumol,O
/,O
kg,O
),O
and,O
caerulein,I-Entity
dose,O
range,O
0.1,O
-,O
0.8,O
mumol,O
/,O
kg,O
),O
showed,O
bell,O
-,O
shaped,O
dose,O
-,O
effect,O
curves,O
",",O
with,O
the,O
greatest,O
maximum,O
inhibition,O
for,O
CCK-8-NS,I-Entity
.,O
The,O
peptide,O
CCK-5,O
-,O
8,O
had,O
weak,O
anticonvulsant,O
activity,O
in,O
comparison,O
to,O
the,O
octapeptides,O
",",O
3.2,O
mumol,O
/,O
kg,O
and,O
larger,O
doses,O
of,O
the,O
reference,O
drug,O
",",O
diazepam,I-Entity
",",O
totally,O
prevented,O
picrotoxin,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
mortality,O
.,O
The,O
maximum,O
effect,O
of,O
the,O
peptides,O
tested,O
was,O
less,O
than,O
that,O
of,O
diazepam,I-Entity
.,O
Experiments,O
with,O
analogues,O
and,O
derivatives,O
of,O
CCK-5,O
-,O
8,O
demonstrated,O
that,O
the,O
effectiveness,O
of,O
the,O
beta,O
-,O
alanyl,O
derivatives,O
of,O
CCK-5,O
-,O
8,O
were,O
enhanced,O
and,O
that,O
they,O
were,O
equipotent,O
with,O
CCK-8-SE,I-Entity
.,O
Of,O
the,O
CCK-2,O
-,O
8,O
analogues,O
",",O
Ser(SO3H)7-Ac,O
-,O
CCK-2,O
-,O
8-SE,O
and,O
Thr(SO3H)7-Ac,O
-,O
CCK-2,O
-,O
8-SE,O
and,O
Hyp(SO3H)-Ac,O
-,O
CCK-2,O
-,O
8-SE,O
were,O
slightly,O
more,O
active,O
than,O
CCK-8-SE,I-Entity
.,O
Vasopressin,I-Entity
as,O
a,O
possible,O
contributor,O
to,O
hypertension,I-Entity
.,O
The,O
role,O
of,O
vasopressin,I-Entity
as,O
a,O
pressor,O
agent,O
to,O
the,O
hypertensive,I-Entity
process,O
was,O
examined,O
.,O
Vasopressin,I-Entity
plays,O
a,O
major,O
role,O
in,O
the,O
pathogenesis,O
of,O
DOCA,I-Entity
-,O
salt,O
hypertension,I-Entity
",",O
since,O
the,O
elevation,O
of,O
blood,O
pressure,O
was,O
not,O
substantial,O
in,O
the,O
rats,O
with,O
lithium,I-Entity
-,O
treated,O
diabetes,B-Entity
insipidus,I-Entity
after,O
DOCA,I-Entity
-,O
salt,O
treatment,O
.,O
Administration,O
of,O
DDAVP,I-Entity
which,O
has,O
antidiuretic,O
action,O
but,O
minimal,O
vasopressor,O
effect,O
failed,O
to,O
increase,O
blood,O
pressure,O
to,O
the,O
levels,O
observed,O
after,O
administration,O
of,O
AVP,O
.,O
Furthermore,O
",",O
the,O
pressor,O
action,O
of,O
vasopressin,I-Entity
appears,O
to,O
be,O
important,O
in,O
the,O
development,O
of,O
this,O
model,O
of,O
hypertension,I-Entity
",",O
since,O
the,O
enhanced,O
pressor,O
responsiveness,O
to,O
the,O
hormone,O
was,O
observed,O
in,O
the,O
initial,O
stage,O
of,O
hypertension,I-Entity
.,O
Increased,O
secretion,O
of,O
vasopressin,I-Entity
from,O
neurohypophysis,O
also,O
promotes,O
the,O
function,O
of,O
the,O
hormone,O
as,O
a,O
pathogenetic,O
factor,O
in,O
hypertension,I-Entity
.,O
An,O
unproportional,O
release,O
of,O
vasopressin,I-Entity
compared,O
to,O
plasma,O
osmolality,O
may,O
be,O
induced,O
by,O
the,O
absence,O
of,O
an,O
adjusting,O
control,O
of,O
angiotensin,I-Entity
II,O
forming,O
and,O
receptor,O
binding,O
capacity,O
for,O
sodium,I-Entity
balance,O
in,O
the,O
brain,O
.,O
However,O
",",O
the,O
role,O
of,O
vasopressin,I-Entity
remains,O
to,O
be,O
determined,O
in,O
human,O
essential,O
hypertension,I-Entity
.,O
Toxic,B-Entity
hepatitis,I-Entity
induced,O
by,O
disulfiram,I-Entity
in,O
a,O
non,O
-,O
alcoholic,O
.,O
A,O
reversible,O
toxic,B-Entity
liver,I-Entity
damage,I-Entity
was,O
observed,O
in,O
a,O
non,O
-,O
alcoholic,O
woman,O
treated,O
with,O
disulfiram,I-Entity
.,O
Atrial,B-Entity
thrombosis,I-Entity
involving,O
the,O
heart,O
of,O
F-344,O
rats,O
ingesting,O
quinacrine,B-Entity
hydrochloride,I-Entity
.,O
Quinacrine,B-Entity
hydrochloride,I-Entity
is,O
toxic,O
for,O
the,O
heart,O
of,O
F-344,O
rats,O
.,O
Rats,O
treated,O
with,O
500,O
ppm,O
quinacrine,B-Entity
hydrochloride,I-Entity
in,O
the,O
diet,O
all,O
developed,O
a,O
high,O
incidence,O
of,O
left,O
atrial,B-Entity
thrombosis,I-Entity
.,O
The,O
lesion,O
was,O
associated,O
with,O
cardiac,B-Entity
hypertrophy,I-Entity
and,O
dilatation,O
and,O
focal,O
myocardial,B-Entity
degeneration,I-Entity
.,O
Rats,O
died,O
from,O
cardiac,B-Entity
hypertrophy,I-Entity
with,O
severe,O
acute,O
and,O
chronic,O
congestion,O
of,O
the,O
lungs,O
",",O
liver,O
",",O
and,O
other,O
organs,O
.,O
Seventy,O
percent,O
of,O
rats,O
given,O
250,O
ppm,O
quinacrine,B-Entity
hydrochloride,I-Entity
and,O
"1,000",O
ppm,O
sodium,B-Entity
nitrite,I-Entity
simultaneously,O
in,O
the,O
diet,O
had,O
thrombosis,I-Entity
of,O
the,O
atria,O
of,O
the,O
heart,O
",",O
while,O
untreated,O
control,O
rats,O
in,O
this,O
laboratory,O
did,O
not,O
have,O
atrial,B-Entity
thrombosis,I-Entity
.,O
Sodium,B-Entity
nitrite,I-Entity
in,O
combination,O
with,O
quinacrine,B-Entity
hydrochloride,I-Entity
appeared,O
to,O
have,O
no,O
additional,O
effect,O
.,O
Alternating,B-Entity
sinus,I-Entity
rhythm,I-Entity
and,O
intermittent,O
sinoatrial,B-Entity
block,I-Entity
induced,O
by,O
propranolol,I-Entity
.,O
Alternating,B-Entity
sinus,I-Entity
rhythm,I-Entity
and,O
intermittent,O
sinoatrial,B-Entity
(,I-Entity
S,I-Entity
-,I-Entity
A,I-Entity
),I-Entity
block,I-Entity
was,O
observed,O
in,O
a,O
57-year,O
-,O
old,O
woman,O
",",O
under,O
treatment,O
for,O
angina,I-Entity
with,O
80,O
mg,O
propranolol,I-Entity
daily,O
.,O
Following,O
these,O
basic,O
sinus,O
cycles,O
",",O
alternating,B-Entity
rhythm,I-Entity
started,O
with,O
the,O
longer,O
P,O
-,O
P,O
interval,O
.,O
In,O
one,O
recording,O
a,O
short,O
period,O
of,O
regular,O
sinus,O
rhythm,O
with,O
intermittent,O
2/1,O
S,B-Entity
-,I-Entity
A,I-Entity
block,I-Entity
was,O
observed,O
.,O
Atropine,I-Entity
1,O
mg,O
given,O
intravenously,O
resulted,O
in,O
shortening,O
of,O
all,O
P,O
-,O
P,O
intervals,O
without,O
changing,O
the,O
rhythm,O
.,O
The,O
abnormal,O
rhythm,O
disappeared,O
with,O
the,O
withdrawal,O
of,O
propranolol,I-Entity
and,O
when,O
the,O
drug,O
was,O
restarted,O
a,O
2/1,O
S,B-Entity
-,I-Entity
A,I-Entity
block,I-Entity
was,O
seen,O
.,O
This,O
was,O
accepted,O
as,O
evidence,O
for,O
propranolol,I-Entity
being,O
the,O
cause,O
of,O
this,O
conduction,B-Entity
disorder,I-Entity
.,O
Antitumor,O
effect,O
",",O
cardiotoxicity,I-Entity
",",O
and,O
nephrotoxicity,I-Entity
of,O
doxorubicin,I-Entity
in,O
the,O
IgM,O
solid,O
immunocytoma,I-Entity
-,O
bearing,O
LOU,O
/,O
M,O
/,O
WSL,O
rat,O
.,O
Antitumor,O
activity,O
",",O
cardiotoxicity,I-Entity
",",O
and,O
nephrotoxicity,I-Entity
induced,O
by,O
doxorubicin,I-Entity
were,O
studied,O
in,O
LOU,O
/,O
M,O
/,O
WSL,O
inbred,O
rats,O
each,O
bearing,O
a,O
transplantable,O
solid,O
IgM,O
immunocytoma,I-Entity
.,O
Animals,O
with,O
a,O
tumor,I-Entity
(,O
diameter,O
",",O
15.8,O
+,O
/-,O
3.3,O
mm,O
),O
were,O
treated,O
with,O
iv,O
injections,O
of,O
doxorubicin,I-Entity
on,O
5,O
consecutive,O
days,O
",",O
followed,O
by,O
1,O
weekly,O
injection,O
for,O
7,O
weeks,O
(,O
dose,O
range,O
",",O
0.015,O
-,O
4.0,O
Tumor,I-Entity
regression,O
was,O
observed,O
with,O
0.5,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
.,O
Complete,O
disappearance,O
of,O
the,O
tumor,I-Entity
was,O
induced,O
with,O
1.0,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
.,O
Histologic,O
evidence,O
of,O
cardiotoxicity,I-Entity
scored,O
as,O
grade,O
III,O
was,O
only,O
observed,O
at,O
a,O
dose,O
of,O
1.0,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
.,O
Light,O
microscopic,O
evidence,O
of,O
renal,B-Entity
damage,I-Entity
was,O
seen,O
above,O
a,O
dose,O
of,O
0.5,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
",",O
which,O
resulted,O
in,O
albuminuria,I-Entity
and,O
very,O
low,O
serum,O
albumin,O
levels,O
.,O
In,O
the,O
group,O
that,O
received,O
1.0,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
",",O
the,O
serum,O
albumin,O
level,O
decreased,O
from,O
33.6,O
+,O
/-,O
Ascites,I-Entity
and,O
hydrothorax,I-Entity
were,O
observed,O
simultaneously,O
.,O
The,O
same,O
experiments,O
were,O
performed,O
with,O
non,O
-,O
tumor,I-Entity
-,O
bearing,O
rats,O
",",O
in,O
which,O
no,O
major,O
differences,O
were,O
observed,O
.,O
In,O
conclusion,O
",",O
antitumor,O
activity,O
",",O
cardiotoxicity,I-Entity
",",O
and,O
nephrotoxicity,I-Entity
were,O
studied,O
simultaneously,O
in,O
the,O
same,O
LOU,O
/,O
M,O
/,O
WSL,O
rat,O
.,O
Albuminuria,I-Entity
due,O
to,O
renal,B-Entity
damage,I-Entity
led,O
to,O
extremely,O
low,O
serum,O
albumin,O
levels,O
",",O
so,O
ascites,I-Entity
and,O
hydrothorax,I-Entity
were,O
not,O
necessarily,O
a,O
consequence,O
of,O
the,O
observed,O
cardiomyopathy,I-Entity
.,O
Intraoperative,O
bradycardia,I-Entity
and,O
hypotension,I-Entity
associated,O
with,O
timolol,I-Entity
and,O
pilocarpine,I-Entity
eye,O
drops,O
.,O
A,O
69-yr,O
-,O
old,O
man,O
",",O
who,O
was,O
concurrently,O
being,O
treated,O
with,O
pilocarpine,B-Entity
nitrate,I-Entity
and,O
timolol,B-Entity
maleate,I-Entity
eye,O
drops,O
",",O
developed,O
a,O
bradycardia,I-Entity
and,O
became,O
hypotensive,I-Entity
during,O
halothane,I-Entity
anaesthesia,O
.,O
Both,O
timolol,I-Entity
and,O
pilocarpine,I-Entity
were,O
subsequently,O
identified,O
in,O
a,O
24-h,O
collection,O
of,O
urine,O
.,O
Timolol,I-Entity
(,O
but,O
not,O
pilocarpine,I-Entity
),O
was,O
detected,O
in,O
a,O
sample,O
of,O
plasma,O
removed,O
during,O
surgery,O
;,O
the,O
plasma,O
concentration,O
of,O
timolol,I-Entity
(,O
2.6,O
ng,O
ml-1,O
),O
was,O
consistent,O
with,O
partial,O
beta,O
-,O
adrenoceptor,O
blockade,O
.,O
It,O
is,O
postulated,O
that,O
this,O
action,O
may,O
have,O
been,O
enhanced,O
during,O
halothane,I-Entity
anaesthesia,O
with,O
resultant,O
bradycardia,I-Entity
and,O
hypotension,I-Entity
.,O
Pilocarpine,I-Entity
may,O
have,O
had,O
a,O
contributory,O
effect,O
.,O
Succinylcholine,I-Entity
apnoea,I-Entity
:,O
attempted,O
reversal,O
with,O
anticholinesterases,O
.,O
Anticholinesterases,O
were,O
administered,O
in,O
an,O
attempt,O
to,O
antagonize,O
prolonged,O
neuromuscular,B-Entity
blockade,I-Entity
following,O
the,O
administration,O
of,O
succinylcholine,I-Entity
in,O
a,O
patient,O
later,O
found,O
to,O
be,O
homozygous,O
for,O
atypical,O
plasma,O
cholinesterase,O
.,O
Edrophonium,I-Entity
10,O
mg,O
",",O
given,O
74,O
min,O
after,O
succinylcholine,I-Entity
",",O
when,O
train,O
-,O
of,O
-,O
four,O
stimulation,O
was,O
characteristic,O
of,O
phase,O
II,O
block,O
",",O
produced,O
partial,O
antagonism,O
which,O
was,O
not,O
sustained,O
.,O
Repeated,O
doses,O
of,O
edrophonium,I-Entity
to,O
70,O
mg,O
and,O
neostigmine,I-Entity
to,O
2.5,O
mg,O
did,O
not,O
antagonize,O
or,O
augment,O
the,O
block,O
.,O
Spontaneous,O
respiration,O
recommenced,O
200,O
min,O
after,O
succinylcholine,I-Entity
administration,O
.,O
It,O
is,O
concluded,O
that,O
anticholinesterases,O
are,O
only,O
partially,O
effective,O
in,O
restoring,O
neuromuscular,O
function,O
in,O
succinylcholine,I-Entity
apnoea,I-Entity
despite,O
muscle,O
twitch,O
activity,O
typical,O
of,O
phase,O
II,O
block,O
.,O
Effect,O
of,O
doxorubicin,I-Entity
on,O
[,B-Entity
omega,I-Entity
-,I-Entity
I-131]heptadecanoic,I-Entity
acid,I-Entity
myocardial,O
scintigraphy,O
and,O
echocardiography,O
in,O
dogs,O
.,O
The,O
effects,O
of,O
serial,O
treatment,O
with,O
doxorubicin,I-Entity
on,O
dynamic,O
myocardial,O
scintigraphy,O
with,O
[,B-Entity
omega,I-Entity
-,I-Entity
I-131]heptadecanoic,I-Entity
acid,I-Entity
(,O
I-131,B-Entity
HA,I-Entity
),O
",",O
and,O
on,O
global,O
left,O
-,O
ventricular,O
function,O
determined,O
echocardiographically,O
",",O
were,O
studied,O
in,O
a,O
group,O
of,O
nine,O
mongrel,O
dogs,O
.,O
Total,O
extractable,O
myocardial,O
lipid,O
was,O
compared,O
postmortem,O
between,O
a,O
group,O
of,O
control,O
dogs,O
and,O
doxorubicin,I-Entity
-,O
treated,O
dogs,O
.,O
A,O
significant,O
and,O
then,O
progressive,O
fall,O
in,O
global,O
LV,O
function,O
was,O
observed,O
at,O
a,O
cumulative,O
doxorubicin,I-Entity
dose,O
of,O
4,O
mg,O
/,O
kg,O
.,O
A,O
significant,O
increase,O
in,O
the,O
myocardial,O
t1/2,O
of,O
the,O
I-131,B-Entity
HA,I-Entity
was,O
observed,O
only,O
at,O
a,O
higher,O
cumulative,O
dose,O
",",O
10,O
mg,O
/,O
kg,O
.,O
No,O
significant,O
alteration,O
in,O
total,O
extractable,O
myocardial,O
lipids,O
was,O
observed,O
between,O
control,O
dogs,O
and,O
those,O
treated,O
with,O
doxorubicin,I-Entity
.,O
Our,O
findings,O
suggest,O
that,O
the,O
changes,O
leading,O
to,O
an,O
alteration,O
of,O
myocardial,O
dynamic,O
imaging,O
with,O
I-131,B-Entity
HA,I-Entity
are,O
not,O
the,O
initiating,O
factor,O
in,O
doxorubicin,I-Entity
cardiotoxicity,I-Entity
.,O
Hemodynamics,O
and,O
myocardial,O
metabolism,O
under,O
deliberate,O
hypotension,I-Entity
.,O
Coronary,O
blood,O
flow,O
",",O
cardiac,O
work,O
and,O
metabolism,O
were,O
studied,O
in,O
dogs,O
under,O
sodium,B-Entity
nitroprusside,I-Entity
(,O
SNP,I-Entity
),O
and,O
trimetaphan,I-Entity
(,O
TMP,I-Entity
),O
deliberate,O
hypotension,I-Entity
(,O
20%,O
and,O
Regarding,O
the,O
effects,O
of,O
drug,O
-,O
induced,O
hypotension,I-Entity
on,O
coronary,O
blood,O
flow,O
",",O
aortic,O
and,O
coronary,O
sinus,O
metabolic,O
data,O
(,O
pH,O
",",O
pO2,O
",",O
pCO2,O
),O
we,O
could,O
confirm,O
that,O
nitroprusside,I-Entity
hypotension,I-Entity
could,O
be,O
safely,O
used,O
to,O
30%,O
mean,O
blood,O
pressure,O
decrease,O
from,O
control,O
",",O
trimetaphan,I-Entity
hypotension,I-Entity
to,O
20%,O
mean,O
blood,O
pressure,O
decrease,O
.,O
Cardiac,O
work,O
was,O
significantly,O
reduced,O
during,O
SNP,I-Entity
hypotension,I-Entity
.,O
Myocardial,O
O2,I-Entity
consumption,O
and,O
O2,I-Entity
availability,O
were,O
directly,O
dependent,O
on,O
the,O
coronary,O
perfusion,O
.,O
Evidence,O
for,O
a,O
selective,O
brain,O
noradrenergic,O
involvement,O
in,O
the,O
locomotor,O
stimulant,O
effects,O
of,O
amphetamine,I-Entity
in,O
the,O
rat,O
.,O
Male,O
rats,O
received,O
the,O
noradrenaline,I-Entity
neurotoxin,O
DSP4,I-Entity
(,O
50,O
mg,O
/,O
kg,O
),O
7,O
days,O
prior,O
to,O
injection,O
of,O
D,B-Entity
-,I-Entity
amphetamine,I-Entity
(,O
10,O
or,O
40,O
mumol,O
/,O
kg,O
i.p,O
.,O
),O
.,O
The,O
hyperactivity,I-Entity
induced,O
by,O
D,B-Entity
-,I-Entity
amphetamine,I-Entity
(,O
10,O
mumol,O
/,O
kg,O
),O
was,O
significantly,O
reduced,O
by,O
DSP4,I-Entity
pretreatment,O
.,O
However,O
",",O
the,O
increased,O
rearings,O
and,O
the,O
amphetamine,I-Entity
-,O
induced,O
stereotypies,I-Entity
were,O
not,O
blocked,O
by,O
pretreatment,O
with,O
DSP4,I-Entity
.,O
The,O
reduction,O
of,O
amphetamine,I-Entity
hyperactivity,I-Entity
induced,O
by,O
DSP4,I-Entity
was,O
blocked,O
by,O
pretreatment,O
with,O
the,O
noradrenaline,I-Entity
-,O
uptake,O
blocking,O
agent,O
",",O
desipramine,I-Entity
",",O
which,O
prevents,O
the,O
neurotoxic,I-Entity
action,O
of,O
DSP4,I-Entity
.,O
The,O
present,O
results,O
suggest,O
a,O
selective,O
involvement,O
of,O
central,O
noradrenergic,O
neurones,O
in,O
the,O
locomotor,O
stimulant,O
effect,O
of,O
amphetamine,I-Entity
in,O
the,O
rat,O
.,O
Accelerated,B-Entity
junctional,I-Entity
rhythms,I-Entity
during,O
oral,O
verapamil,I-Entity
therapy,O
.,O
This,O
study,O
examined,O
the,O
frequency,O
of,O
atrioventricular,O
(,O
AV,O
),O
dissociation,O
and,O
accelerated,B-Entity
junctional,I-Entity
rhythms,I-Entity
in,O
59,O
patients,O
receiving,O
oral,O
verapamil,I-Entity
.,O
Accelerated,B-Entity
junctional,I-Entity
rhythms,I-Entity
and,O
AV,O
dissociation,O
were,O
frequent,O
in,O
patients,O
with,O
supraventricular,B-Entity
tachyarrhythmias,I-Entity
",",O
particularly,O
AV,O
nodal,O
reentry,O
.,O
Verapamil,I-Entity
administration,O
to,O
these,O
patients,O
led,O
to,O
an,O
asymptomatic,O
increase,O
in,O
activity,O
of,O
these,O
junctional,O
pacemakers,O
.,O
In,O
patients,O
with,O
various,O
chest,B-Entity
pain,I-Entity
syndromes,O
",",O
verapamil,I-Entity
neither,O
increased,O
the,O
frequency,O
of,O
junctional,O
rhythms,O
nor,O
suppressed,O
their,O
role,O
as,O
escape,O
rhythms,O
under,O
physiologically,O
appropriate,O
circumstances,O
.,O
Treatment,O
of,O
ovarian,B-Entity
cancer,I-Entity
with,O
a,O
combination,O
of,O
cis,B-Entity
-,I-Entity
platinum,I-Entity
",",O
adriamycin,I-Entity
",",O
cyclophosphamide,I-Entity
and,O
hexamethylmelamine,I-Entity
.,O
During,O
the,O
last,O
2,O
1/2,O
years,O
",",O
38,O
patients,O
with,O
ovarian,B-Entity
cancer,I-Entity
were,O
treated,O
with,O
a,O
combination,O
of,O
cisplatinum,I-Entity
(,O
CPDD,I-Entity
),O
",",O
50,O
mg,O
/,O
m2,O
",",O
adriamycin,I-Entity
",",O
30,O
mg,O
/,O
m2,O
",",O
cyclophosphamide,I-Entity
",",O
300,O
mg,O
/,O
m2,O
",",O
on,O
day,O
1,O
;,O
and,O
hexamethylmelamine,I-Entity
(,O
HMM,I-Entity
),O
",",O
6,O
mg,O
/,O
kg,O
daily,O
",",O
for,O
14,O
days,O
.,O
14,O
of,O
the,O
38,O
patients,O
were,O
previously,O
treated,O
with,O
chemotherapy,O
",",O
1,O
with,O
radiation,O
",",O
6,O
with,O
both,O
chemotherapy,O
and,O
radiation,O
",",O
and,O
17,O
did,O
not,O
have,O
any,O
treatment,O
before,O
CPDD,I-Entity
combination,O
.,O
Hematologic,B-Entity
toxicity,I-Entity
was,O
moderate,O
and,O
with,O
reversible,O
anemia,I-Entity
developing,O
in,O
71%,O
of,O
patients,O
.,O
Gastrointestinal,O
side,O
effects,O
from,O
CPDD,I-Entity
were,O
universal,O
.,O
HMM,I-Entity
gastrointestinal,B-Entity
toxicity,I-Entity
necessitated,O
discontinuation,O
of,O
the,O
drug,O
in,O
5,O
patients,O
.,O
Severe,O
nephrotoxicity,I-Entity
was,O
observed,O
in,O
2,O
patients,O
but,O
was,O
reversible,O
.,O
Nontraumatic,O
dissecting,B-Entity
aneurysm,I-Entity
of,O
the,O
basilar,O
artery,O
.,O
A,O
case,O
of,O
nontraumatic,O
dissecting,B-Entity
aneurysm,I-Entity
of,O
the,O
basilar,O
artery,O
in,O
association,O
with,O
hypertension,I-Entity
",",O
smoke,O
",",O
and,O
oral,B-Entity
contraceptives,I-Entity
is,O
reported,O
in,O
a,O
young,O
female,O
patient,O
with,O
a,O
locked,B-Entity
-,I-Entity
in,I-Entity
syndrome,I-Entity
.,O
Propylthiouracil,I-Entity
-,O
induced,O
hepatic,B-Entity
damage,I-Entity
.,O
Two,O
cases,O
of,O
propylthiouracil,I-Entity
-,O
induced,O
liver,B-Entity
damage,I-Entity
have,O
been,O
observed,O
.,O
The,O
first,O
case,O
is,O
of,O
an,O
acute,O
type,O
of,O
damage,O
",",O
proven,O
by,O
rechallenge,O
;,O
the,O
second,O
presents,O
a,O
clinical,O
and,O
histologic,O
picture,O
resembling,O
chronic,B-Entity
active,I-Entity
hepatitis,I-Entity
",",O
with,O
spontaneous,O
remission,O
.,O
Studies,O
on,O
the,O
bradycardia,I-Entity
induced,O
by,O
bepridil,I-Entity
.,O
Bepridil,I-Entity
",",O
a,O
novel,O
active,O
compound,O
for,O
prophylactic,O
treatment,O
of,O
anginal,B-Entity
attacks,I-Entity
",",O
induced,O
persistent,O
bradycardia,I-Entity
and,O
a,O
non,O
-,O
specific,O
anti,O
-,O
tachycardial,I-Entity
effect,O
",",O
the,O
mechanisms,O
of,O
which,O
were,O
investigated,O
in,O
vitro,O
and,O
in,O
vivo,O
.,O
In,O
vitro,O
perfusion,O
of,O
bepridil,I-Entity
in,O
the,O
life,O
-,O
support,O
medium,O
for,O
isolated,O
sino,O
-,O
atrial,O
tissue,O
from,O
rabbit,O
heart,O
",",O
caused,O
a,O
reduction,O
in,O
action,O
potential,O
(,O
AP,O
),O
spike,O
frequency,O
(,O
recorded,O
by,O
KCl,I-Entity
microelectrodes,O
),O
starting,O
at,O
doses,O
of,O
5,O
X,O
10(-6,O
),O
M.,O
Bepridil,I-Entity
at,O
a,O
dose,O
of,O
5,O
X,O
10(-6,O
),O
In,O
vivo,O
injection,O
of,O
bepridil,I-Entity
at,O
a,O
dose,O
of,O
5,O
mg,O
/,O
kg,O
(,O
i.v,O
.,O
),O
It,O
is,O
concluded,O
that,O
bepridil,I-Entity
reduces,O
heart,O
rate,O
by,O
acting,O
directly,O
on,O
the,O
sinus,O
node,O
.,O
This,O
effect,O
",",O
which,O
results,O
in,O
a,O
flattening,O
of,O
the,O
phase,O
0,O
and,O
phase,O
4,O
slope,O
",",O
together,O
with,O
a,O
longer,O
AP,O
duration,O
",",O
may,O
be,O
due,O
to,O
an,O
increase,O
in,O
the,O
time,O
constants,O
of,O
slow,O
inward,O
ionic,O
currents,O
(,O
already,O
demonstrated,O
elsewhere,O
),O
",",O
but,O
also,O
to,O
an,O
increased,O
time,O
constant,O
for,O
deactivation,O
of,O
the,O
outward,O
potassium,I-Entity
current,O
(,O
Ip,O
),O
.,O
Hepatitis,I-Entity
and,O
renal,B-Entity
tubular,I-Entity
acidosis,I-Entity
after,O
anesthesia,O
with,O
methoxyflurane,I-Entity
.,O
A,O
69-year,O
-,O
old,O
man,O
operated,O
for,O
acute,B-Entity
cholecystitis,I-Entity
under,O
methoxyflurane,I-Entity
anesthesia,O
developed,O
postoperatively,O
a,O
hepatic,B-Entity
insufficiency,I-Entity
syndrome,I-Entity
and,O
renal,B-Entity
tubular,I-Entity
acidosis,I-Entity
.,O
Massive,O
bleeding,I-Entity
appeared,O
during,O
surgery,O
which,O
lasted,O
for,O
six,O
hours,O
.,O
Pituitary,O
response,O
to,O
luteinizing,O
hormone,O
-,O
releasing,O
hormone,O
during,O
haloperidol,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
.,O
The,O
effects,O
of,O
a,O
6-hour,O
infusion,O
with,O
haloperidol,I-Entity
on,O
serum,O
prolactin,O
and,O
luteinizing,O
hormone,O
(,O
LH,O
),O
Control,O
patients,O
received,O
infusions,O
of,O
0.9%,O
NaCl,I-Entity
solution,O
.,O
During,O
the,O
course,O
of,O
haloperidol,I-Entity
infusions,O
",",O
significant,O
hyperprolactinemia,I-Entity
was,O
found,O
",",O
together,O
with,O
an,O
abolished,O
pituitary,O
response,O
to,O
LH,O
-,O
RH,O
",",O
as,O
compared,O
with,O
responses,O
of,O
control,O
subjects,O
.,O
Antirifampicin,O
antibodies,O
in,O
acute,O
rifampicin,I-Entity
-,O
associated,O
renal,B-Entity
failure,I-Entity
.,O
5,O
patients,O
with,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
(,O
3,O
with,O
thrombopenia,I-Entity
and,O
hemolysis,I-Entity
),O
induced,O
by,O
the,O
reintroduction,O
of,O
rifampicin,I-Entity
are,O
described,O
.,O
Antibodies,O
suggested,O
to,O
be,O
of,O
the,O
IgM,O
class,O
were,O
detected,O
in,O
all,O
3,O
patients,O
with,O
hematological,B-Entity
disorders,I-Entity
.,O
The,O
pattern,O
of,O
non,O
-,O
specific,O
acute,B-Entity
tubular,I-Entity
necrosis,I-Entity
found,O
in,O
the,O
2,O
biopsied,O
patients,O
",",O
indistinguishable,O
from,O
that,O
of,O
ischemic,O
origin,O
",",O
raised,O
the,O
possibility,O
of,O
a,O
vascular,O
-,O
mediated,O
damage,O
.,O
Cardiovascular,O
effects,O
of,O
hypotension,I-Entity
induced,O
by,O
adenosine,B-Entity
triphosphate,I-Entity
and,O
sodium,B-Entity
nitroprusside,I-Entity
on,O
dogs,O
with,O
denervated,O
hearts,O
.,O
Adenosine,B-Entity
triphosphate,I-Entity
(,O
ATP,I-Entity
),O
and,O
sodium,B-Entity
nitroprusside,I-Entity
(,O
SNP,I-Entity
),O
are,O
administered,O
to,O
patients,O
to,O
induce,O
and,O
control,O
hypotension,I-Entity
during,O
anesthesia,O
.,O
SNP,I-Entity
is,O
authorized,O
for,O
clinical,O
use,O
in,O
USA,O
and,O
UK,O
",",O
and,O
ATP,I-Entity
is,O
clinically,O
used,O
in,O
other,O
countries,O
such,O
as,O
Japan,O
.,O
ATP,I-Entity
(,O
10,O
dogs,O
),O
or,O
SNP,I-Entity
(,O
10,O
dogs,O
),O
was,O
administered,O
to,O
reduce,O
mean,O
arterial,O
pressure,O
by,O
30%,O
to,O
70%,O
of,O
control,O
.,O
Before,O
",",O
during,O
and,O
after,O
induced,O
hypotension,I-Entity
",",O
we,O
measured,O
major,O
cardiovascular,O
parameters,O
.,O
Hypotension,I-Entity
induced,O
by,O
ATP,I-Entity
was,O
accompanied,O
by,O
significant,O
decreases,O
in,O
mean,O
pulmonary,O
arterial,O
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
central,O
venous,O
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
left,O
ventricular,O
end,O
-,O
diastolic,O
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
total,O
peripheral,O
resistance,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
rate,O
pressure,O
product,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
total,O
body,O
oxygen,I-Entity
consumption,O
(,O
p,O
less,O
than,O
0.05,O
),O
",",O
and,O
heart,O
rate,O
(,O
p,O
less,O
than,O
0.001,O
),O
;,O
all,O
these,O
variables,O
returned,O
normal,O
within,O
30,O
min,O
after,O
ATP,I-Entity
was,O
stopped,O
.,O
During,O
hypotension,I-Entity
produced,O
by,O
SNP,I-Entity
similar,O
decreases,O
were,O
observed,O
in,O
mean,O
pulmonary,O
arterial,O
pressure,O
(,O
p,O
less,O
than,O
0.01,O
),O
",",O
central,O
venous,O
pressure,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
left,O
ventricular,O
end,O
-,O
diastolic,O
pressure,O
(,O
p,O
less,O
than,O
0.01,O
),O
",",O
total,O
peripheral,O
resistance,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
rate,O
pressure,O
product,O
(,O
p,O
less,O
than,O
0.001,O
),O
",",O
and,O
oxygen,I-Entity
content,O
difference,O
between,O
arterial,O
and,O
mixed,O
venous,O
blood,O
(,O
p,O
less,O
than,O
0.05,O
),O
",",O
while,O
heart,O
rate,O
(,O
p,O
less,O
than,O
0.001,O
),O
and,O
cardiac,O
output,O
(,O
p,O
less,O
than,O
0.05,O
),O
were,O
increased,O
.,O
Recoveries,O
of,O
heart,O
rate,O
and,O
left,O
ventricular,O
end,O
-,O
diastolic,O
pressure,O
were,O
not,O
shown,O
within,O
60,O
min,O
after,O
SNP,I-Entity
had,O
been,O
stopped,O
.,O
Both,O
ATP,I-Entity
and,O
SNP,I-Entity
should,O
act,O
on,O
the,O
pacemaker,O
tissue,O
of,O
the,O
heart,O
.,O
Comparative,O
study,O
:,O
Endografine,I-Entity
(,O
diatrizoate,I-Entity
),O
",",O
Vasurix,B-Entity
polyvidone,I-Entity
(,O
acetrizoate,I-Entity
),O
",",O
Dimer,B-Entity
-,I-Entity
X,I-Entity
(,O
iocarmate,I-Entity
),O
and,O
Hexabrix,I-Entity
(,O
ioxaglate,I-Entity
),O
in,O
hysterosalpingography,O
.,O
Side,O
effects,O
of,O
hysterosalpingography,O
with,O
Dimer,B-Entity
-,I-Entity
X,I-Entity
",",O
Hexabrix,I-Entity
",",O
Vasurix,B-Entity
polyvidone,I-Entity
and,O
Endografine,I-Entity
in,O
142,O
consecutive,O
patients,O
",",O
receiving,O
one,O
of,O
the,O
four,O
tested,O
media,O
were,O
evaluated,O
from,O
replies,O
to,O
postal,O
questionnaires,O
.,O
The,O
Dimer,B-Entity
-,I-Entity
X,I-Entity
group,O
had,O
a,O
higher,O
incidence,O
of,O
nausea,I-Entity
and,O
dizziness,I-Entity
.,O
The,O
Endografine,I-Entity
group,O
had,O
a,O
higher,O
incidence,O
of,O
abdominal,B-Entity
pain,I-Entity
.,O
Hexabrix,I-Entity
and,O
Vasurix,B-Entity
polyvidone,I-Entity
are,O
considered,O
the,O
best,O
contrast,B-Entity
media,I-Entity
for,O
hysterosalpingography,O
and,O
perhaps,O
because,O
of,O
its,O
low,O
toxicity,I-Entity
Hexabrix,I-Entity
should,O
be,O
preferred,O
.,O
Post,O
-,O
suxamethonium,I-Entity
pains,I-Entity
in,O
Nigerian,O
surgical,O
patients,O
.,O
Contrary,O
to,O
an,O
earlier,O
report,O
by,O
Coxon,O
",",O
scoline,I-Entity
pain,I-Entity
occurs,O
in,O
African,O
negroes,O
.,O
About,O
62%,O
of,O
the,O
out,O
-,O
patients,O
developed,O
scoline,I-Entity
pain,I-Entity
as,O
compared,O
with,O
about,O
26%,O
among,O
the,O
in,O
-,O
patients,O
.,O
The,O
abolition,O
of,O
muscle,O
fasciculations,I-Entity
(,O
by,O
0.075mg,O
/,O
kg,O
dose,O
of,O
Fazadinium,I-Entity
),O
did,O
not,O
influence,O
the,O
occurrence,O
of,O
scoline,I-Entity
pain,I-Entity
.,O
Neither,O
the,O
type,O
of,O
induction,O
agent,O
(,O
Althesin,I-Entity
or,O
Thiopentone,I-Entity
),O
nor,O
the,O
salt,O
preparation,O
of,O
suxamethonium,I-Entity
used,O
(,O
chloride,I-Entity
or,O
bromide,I-Entity
),O
",",O
affected,O
the,O
incidence,O
of,O
scoline,I-Entity
pain,I-Entity
.,O
Medial,O
changes,O
in,O
arterial,O
spasm,I-Entity
induced,O
by,O
L,B-Entity
-,I-Entity
norepinephrine,I-Entity
.,O
In,O
the,O
media,O
of,O
the,O
saphenous,O
artery,O
and,O
its,O
distal,O
branch,O
",",O
vasoconstriction,O
induced,O
by,O
L,B-Entity
-,I-Entity
norepinephrine,I-Entity
produced,O
many,O
cell,O
-,O
to,O
-,O
cell,O
hernias,I-Entity
within,O
15,O
minutes,O
.,O
The,O
experimental,O
data,O
are,O
discussed,O
in,O
relation,O
to,O
medial,O
changes,O
observed,O
in,O
other,O
instances,O
of,O
arterial,O
spasm,I-Entity
.,O
Abnormalities,O
of,O
the,O
pupil,O
and,O
visual,O
-,O
evoked,O
potential,O
in,O
quinine,I-Entity
amblyopia,I-Entity
.,O
Total,O
blindness,I-Entity
with,O
a,O
transient,O
tonic,B-Entity
pupillary,I-Entity
response,O
",",O
denervation,O
supersensitivity,O
",",O
and,O
abnormal,O
visual,O
-,O
evoked,O
potentials,O
developed,O
in,O
a,O
54-year,O
-,O
old,O
man,O
after,O
the,O
use,O
of,O
quinine,B-Entity
sulfate,I-Entity
for,O
leg,B-Entity
cramps,I-Entity
.,O
A,O
transient,O
tonic,B-Entity
pupillary,I-Entity
response,O
",",O
denervation,O
supersensitivity,O
",",O
and,O
abnormal,O
visual,O
-,O
evoked,O
potentials,O
in,O
quinine,I-Entity
toxicity,I-Entity
",",O
to,O
our,O
knowledge,O
",",O
have,O
not,O
been,O
previously,O
reported,O
.,O
Suxamethonium,I-Entity
-,O
induced,O
jaw,B-Entity
stiffness,I-Entity
and,O
myalgia,I-Entity
associated,O
with,O
atypical,O
cholinesterase,O
:,O
case,O
report,O
.,O
An,O
11-year,O
-,O
old,O
boy,O
was,O
given,O
halothane,I-Entity
",",O
nitrous,B-Entity
oxide,I-Entity
and,O
oxygen,I-Entity
",",O
pancuronium,I-Entity
0.4,O
mg,O
and,O
suxamethonium,I-Entity
100,O
mg,O
for,O
induction,O
of,O
anaesthesia,O
.,O
In,O
response,O
to,O
this,O
a,O
marked,O
jaw,B-Entity
stiffness,I-Entity
occurred,O
which,O
lasted,O
for,O
two,O
minutes,O
and,O
the,O
anaesthesia,O
were,O
terminated,O
.,O
Four,O
hours,O
of,O
apnoea,I-Entity
ensued,O
and,O
he,O
suffered,O
generalized,O
severe,O
myalgia,I-Entity
lasting,O
for,O
one,O
week,O
.,O
He,O
was,O
found,O
to,O
have,O
atypical,O
plasma,O
cholinesterase,O
with,O
a,O
dibucaine,I-Entity
number,O
of,O
12,O
",",O
indicating,O
homozygocity,O
.,O
The,O
case,O
shows,O
that,O
prolonged,B-Entity
jaw,I-Entity
rigidity,I-Entity
and,O
myalgia,I-Entity
may,O
occur,O
after,O
suxamethonium,I-Entity
in,O
patients,O
with,O
atypical,O
cholinesterase,O
despite,O
pretreatment,O
with,O
pancuronium,I-Entity
.,O
Indomethacin,I-Entity
-,O
induced,O
hyperkalemia,I-Entity
in,O
three,O
patients,O
with,O
gouty,B-Entity
arthritis,I-Entity
.,O
We,O
describe,O
three,O
patients,O
in,O
whom,O
severe,O
",",O
life,O
-,O
threatening,O
hyperkalemia,I-Entity
and,O
renal,B-Entity
insufficiency,I-Entity
developed,O
after,O
treatment,O
of,O
acute,O
gouty,B-Entity
arthritis,I-Entity
with,O
indomethacin,I-Entity
.,O
This,O
complication,O
may,O
result,O
from,O
an,O
inhibition,O
of,O
prostaglandin,I-Entity
synthesis,O
and,O
consequent,O
hyporeninemic,B-Entity
hypoaidosteronism,I-Entity
.,O
Careful,O
attention,O
to,O
renal,O
function,O
and,O
potassium,I-Entity
balance,O
in,O
patients,O
receiving,O
indomethacin,I-Entity
or,O
other,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
agents,O
",",O
particularly,O
in,O
those,O
patients,O
with,O
diabetes,B-Entity
mellitus,I-Entity
or,O
preexisting,O
renal,B-Entity
disease,I-Entity
",",O
will,O
help,O
prevent,O
this,O
potentially,O
serious,O
complication,O
.,O
Etomidate,I-Entity
:,O
a,O
foreshortened,O
clinical,O
trial,O
.,O
A,O
clinical,O
evaluation,O
of,O
etomidate,I-Entity
for,O
outpatient,O
cystoscopy,O
was,O
embarked,O
upon,O
.,O
Unpremedicated,O
patients,O
were,O
given,O
fentanyl,I-Entity
1,O
microgram,O
/,O
kg,O
followed,O
by,O
etomidate,I-Entity
0.3,O
mg,O
/,O
kg,O
.,O
Anaesthesia,O
was,O
maintained,O
with,O
intermittent,O
etomidate,I-Entity
in,O
2,O
-,O
4,O
mg,O
doses,O
.,O
Venous,O
pain,I-Entity
occurred,O
in,O
68%,O
of,O
patients,O
and,O
50%,O
had,O
redness,O
",",O
pain,I-Entity
or,O
swelling,I-Entity
related,O
to,O
the,O
injection,O
site,O
",",O
in,O
some,O
cases,O
lasting,O
up,O
to,O
three,O
weeks,O
after,O
anaesthesia,O
.,O
Skeletal,O
movements,O
occurred,O
in,O
50%,O
of,O
patients,O
;,O
30%,O
experienced,O
respiratory,B-Entity
upset,I-Entity
",",O
one,O
sufficiently,O
severe,O
to,O
necessitate,O
abandoning,O
the,O
technique,O
.,O
Nausea,I-Entity
and,O
vomiting,I-Entity
occurred,O
in,O
40%,O
and,O
25%,O
had,O
disturbing,O
emergence,O
psychoses,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
are,O
improved,O
by,O
fluoxetine,I-Entity
.,O
We,O
evaluated,O
the,O
severity,O
of,O
motor,B-Entity
disability,I-Entity
and,O
dyskinesias,I-Entity
in,O
seven,O
levodopa,I-Entity
-,O
responsive,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
after,O
an,O
acute,O
challenge,O
with,O
the,O
mixed,O
dopamine,I-Entity
agonist,O
",",O
apomorphine,I-Entity
",",O
before,O
and,O
after,O
the,O
administration,O
of,O
fluoxetine,I-Entity
(,O
20,O
mg,O
twice,O
per,O
day,O
),O
for,O
11,O
+,O
/-,O
After,O
fluoxetine,I-Entity
treatment,O
",",O
there,O
was,O
a,O
significant,O
47%,O
improvement,O
(,O
p,O
<,O
0.05,O
),O
of,O
apomorphine,I-Entity
-,O
induced,O
dyskinesias,I-Entity
without,O
modification,O
of,O
parkinsonian,I-Entity
motor,B-Entity
disability,I-Entity
.,O
The,O
dyskinesias,I-Entity
were,O
reduced,O
predominantly,O
in,O
the,O
lower,O
limbs,O
during,O
the,O
onset,O
and,O
disappearance,O
of,O
dystonic,B-Entity
dyskinesias,I-Entity
(,O
onset-,O
and,O
end,O
-,O
of,O
-,O
dose,O
dyskinesias,I-Entity
),O
and,O
in,O
the,O
upper,O
limbs,O
during,O
choreic,B-Entity
mid,I-Entity
-,I-Entity
dose,I-Entity
dyskinesias,I-Entity
.,O
The,O
results,O
suggest,O
that,O
increased,O
brain,O
serotoninergic,O
transmission,O
with,O
fluoxetine,I-Entity
may,O
reduce,O
levodopa-,I-Entity
or,O
dopamine,I-Entity
agonist,O
-,O
induced,O
dyskinesias,I-Entity
without,O
aggravating,O
parkinsonian,I-Entity
motor,B-Entity
disability,I-Entity
.,O
A,O
large,O
population,O
-,O
based,O
follow,O
-,O
up,O
study,O
of,O
trimethoprim,B-Entity
-,I-Entity
sulfamethoxazole,I-Entity
",",O
trimethoprim,I-Entity
",",O
and,O
cephalexin,I-Entity
for,O
uncommon,O
serious,O
drug,B-Entity
toxicity,I-Entity
.,O
We,O
conducted,O
a,O
population,O
-,O
based,O
45-day,O
follow,O
-,O
up,O
study,O
of,O
"232,390",O
people,O
who,O
were,O
prescribed,O
trimethoprim,B-Entity
-,I-Entity
sulfamethoxazole,I-Entity
(,O
TMP,B-Entity
-,I-Entity
SMZ,I-Entity
),O
",",O
"266,951",O
prescribed,O
trimethoprim,I-Entity
alone,O
",",O
and,O
"196,397",O
prescribed,O
cephalexin,I-Entity
",",O
to,O
estimate,O
the,O
risk,O
of,O
serious,O
liver,B-Entity
",",I-Entity
blood,I-Entity
",",I-Entity
skin,I-Entity
",",I-Entity
and,I-Entity
renal,I-Entity
disorders,I-Entity
resulting,O
in,O
referral,O
or,O
hospitalization,O
associated,O
with,O
these,O
drugs,O
.,O
The,O
risk,O
of,O
clinically,O
important,O
idiopathic,O
liver,B-Entity
disease,I-Entity
was,O
similar,O
for,O
persons,O
prescribed,O
TMP,B-Entity
-,I-Entity
SMZ,I-Entity
(,O
"5.2/100,000",O
),O
and,O
those,O
prescribed,O
trimethoprim,I-Entity
alone,O
(,O
"3.8/100,000",O
),O
.,O
The,O
risk,O
for,O
those,O
prescribed,O
cephalexin,I-Entity
was,O
somewhat,O
lower,O
(,O
"2.0/100,000",O
),O
.,O
Only,O
five,O
patients,O
experienced,O
blood,O
disorders,O
",",O
one,O
of,O
whom,O
was,O
exposed,O
to,O
TMP,B-Entity
-,I-Entity
SMZ,I-Entity
;,O
of,O
seven,O
with,O
erythema,B-Entity
multiforme,I-Entity
and,O
Stevens,B-Entity
-,I-Entity
Johnson,I-Entity
syndrome,I-Entity
",",O
four,O
were,O
exposed,O
to,O
TMP,B-Entity
-,I-Entity
SMZ,I-Entity
.,O
The,O
one,O
case,O
of,O
toxic,B-Entity
epidermal,I-Entity
necrolysis,I-Entity
occurred,O
in,O
a,O
patient,O
who,O
took,O
cephalexin,I-Entity
.,O
Finally,O
",",O
only,O
five,O
cases,O
of,O
acute,O
parenchymal,O
renal,B-Entity
disease,I-Entity
occurred,O
",",O
none,O
likely,O
to,O
be,O
caused,O
by,O
a,O
study,O
drug,O
.,O
Clinical,O
safety,O
of,O
lidocaine,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
myocardial,B-Entity
infarction,I-Entity
.,O
STUDY,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
safety,O
of,O
lidocaine,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
.,O
Patients,O
with,O
cocaine,I-Entity
-,O
associated,O
MI,I-Entity
who,O
received,O
lidocaine,I-Entity
in,O
the,O
emergency,O
department,O
.,O
Of,O
29,O
patients,O
who,O
received,O
lidocaine,I-Entity
in,O
the,O
setting,O
of,O
cocaine,I-Entity
-,O
associated,O
MI,I-Entity
",",O
no,O
patient,O
died,O
;,O
exhibited,O
bradydysrhythmias,I-Entity
",",O
ventricular,B-Entity
tachycardia,I-Entity
",",O
or,O
ventricular,B-Entity
fibrillation,I-Entity
;,O
or,O
experienced,O
seizures,I-Entity
after,O
administration,O
of,O
lidocaine,I-Entity
(,O
95%,O
confidence,O
interval,O
",",O
0%,O
to,O
11%,O
),O
.,O
CONCLUSION,O
:,O
Despite,O
theoretical,O
concerns,O
that,O
lidocaine,I-Entity
may,O
enhance,O
cocaine,I-Entity
toxicity,I-Entity
",",O
the,O
use,O
of,O
lidocaine,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
MI,I-Entity
was,O
not,O
associated,O
with,O
significant,O
cardiovascular,B-Entity
or,I-Entity
central,I-Entity
nervous,I-Entity
system,I-Entity
toxicity,I-Entity
.,O
Paclitaxel,I-Entity
3-hour,O
infusion,O
given,O
alone,O
and,O
combined,O
with,O
carboplatin,I-Entity
:,O
preliminary,O
results,O
of,O
dose,O
-,O
escalation,O
trials,O
.,O
Paclitaxel,I-Entity
(,O
Taxol,I-Entity
;,O
Bristol,O
-,O
Myers,O
Squibb,O
Company,O
",",O
Princeton,O
",",O
NJ,O
),O
by,O
3-hour,O
infusion,O
was,O
combined,O
with,O
carboplatin,I-Entity
in,O
a,O
phase,O
I,O
/,O
II,O
study,O
directed,O
to,O
patients,O
with,O
non,B-Entity
-,I-Entity
small,I-Entity
cell,I-Entity
lung,I-Entity
cancer,I-Entity
.,O
Carboplatin,I-Entity
was,O
given,O
at,O
a,O
fixed,O
target,O
area,O
under,O
the,O
concentration,O
-,O
time,O
curve,O
of,O
6.0,O
by,O
the,O
Calvert,O
formula,O
",",O
whereas,O
paclitaxel,I-Entity
was,O
escalated,O
in,O
patient,O
cohorts,O
from,O
150,O
mg,O
/,O
m2,O
(,O
dose,O
level,O
I,O
),O
to,O
175,O
",",O
200,O
",",O
225,O
",",O
and,O
250,O
mg,O
/,O
m2,O
.,O
The,O
225,O
mg,O
/,O
m2,O
level,O
was,O
expanded,O
for,O
the,O
phase,O
II,O
study,O
since,O
the,O
highest,O
level,O
achieved,O
(,O
250,O
mg,O
/,O
m2,O
),O
required,O
modification,O
because,O
of,O
nonhematologic,O
toxicities,I-Entity
(,O
arthralgia,I-Entity
and,O
sensory,B-Entity
neuropathy,I-Entity
),O
.,O
Toxicities,I-Entity
were,O
compared,O
with,O
a,O
cohort,O
of,O
patients,O
in,O
a,O
phase,O
I,O
trial,O
of,O
paclitaxel,I-Entity
alone,O
at,O
identical,O
dose,O
levels,O
.,O
Carboplatin,I-Entity
did,O
not,O
appear,O
to,O
add,O
to,O
the,O
hematologic,B-Entity
toxicities,I-Entity
observed,O
",",O
and,O
the,O
paclitaxel,I-Entity
/,O
carboplatin,I-Entity
combination,O
could,O
be,O
dosed,O
every,O
3,O
weeks,O
.,O
The,O
dose,O
-,O
dependent,O
effect,O
of,O
misoprostol,I-Entity
on,O
indomethacin,I-Entity
-,O
induced,O
renal,B-Entity
dysfunction,I-Entity
in,O
well,O
compensated,O
cirrhosis,I-Entity
.,O
Misoprostol,I-Entity
(,O
200,O
micrograms,O
),O
has,O
been,O
shown,O
to,O
acutely,O
counteract,O
the,O
indomethacin,I-Entity
-,O
induced,O
renal,B-Entity
dysfunction,I-Entity
in,O
well,O
compensated,O
cirrhotic,I-Entity
patients,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
if,O
the,O
prophylactic,O
value,O
of,O
misoprostol,I-Entity
was,O
dose,O
-,O
dependent,O
.,O
Parameters,O
of,O
renal,O
hemodynamics,O
and,O
tubular,O
sodium,I-Entity
and,O
water,O
handling,O
were,O
assessed,O
by,O
clearance,O
techniques,O
in,O
26,O
well,O
compensated,O
cirrhotic,I-Entity
patients,O
before,O
and,O
after,O
an,O
oral,O
combination,O
of,O
50,O
mg,O
of,O
indomethacin,I-Entity
and,O
various,O
doses,O
of,O
misoprostol,I-Entity
.,O
The,O
200-micrograms,O
dose,O
was,O
able,O
to,O
totally,O
abolish,O
the,O
deleterious,O
renal,O
effects,O
of,O
indomethacin,I-Entity
",",O
whereas,O
the,O
800-micrograms,O
dose,O
resulted,O
in,O
significant,O
worsening,O
of,O
renal,O
hemodynamics,O
and,O
sodium,I-Entity
retention,O
.,O
These,O
results,O
suggest,O
that,O
the,O
renal,O
protective,O
effects,O
of,O
misoprostol,I-Entity
is,O
dose,O
-,O
dependent,O
.,O
However,O
",",O
until,O
this,O
apparent,O
ability,O
of,O
200,O
micrograms,O
of,O
misoprostol,I-Entity
to,O
prevent,O
the,O
adverse,O
effects,O
of,O
indomethacin,I-Entity
on,O
renal,O
function,O
is,O
confirmed,O
with,O
chronic,O
frequent,O
dosing,O
",",O
it,O
would,O
be,O
prudent,O
to,O
avoid,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
therapy,O
in,O
patients,O
with,O
cirrhosis,I-Entity
.,O
Increased,O
frequency,O
and,O
severity,O
of,O
angio,B-Entity
-,I-Entity
oedema,I-Entity
related,O
to,O
long,O
-,O
term,O
therapy,O
with,O
angiotensin,B-Entity
-,I-Entity
converting,I-Entity
enzyme,I-Entity
inhibitor,I-Entity
in,O
two,O
patients,O
.,O
Adverse,O
reactions,O
to,O
drugs,O
are,O
well,O
recognized,O
as,O
a,O
cause,O
of,O
acute,O
or,O
chronic,O
urticaria,I-Entity
",",O
and,O
angio,B-Entity
-,I-Entity
oedema,I-Entity
.,O
Angiotensin,B-Entity
-,I-Entity
converting,I-Entity
enzyme,I-Entity
(,I-Entity
ACE,I-Entity
),I-Entity
inhibitors,I-Entity
",",O
used,O
to,O
treat,O
hypertension,I-Entity
and,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
",",O
were,O
introduced,O
in,O
Europe,O
in,O
the,O
middle,O
of,O
the,O
eighties,O
",",O
and,O
the,O
use,O
of,O
these,O
drugs,O
has,O
increased,O
progressively,O
.,O
Soon,O
after,O
the,O
introduction,O
of,O
ACE,B-Entity
inhibitors,I-Entity
",",O
acute,O
bouts,O
of,O
angio,B-Entity
-,I-Entity
oedema,I-Entity
were,O
reported,O
in,O
association,O
with,O
the,O
use,O
of,O
these,O
drugs,O
.,O
We,O
wish,O
to,O
draw,O
attention,O
to,O
the,O
possibility,O
of,O
adverse,O
reactions,O
to,O
ACE,B-Entity
inhibitors,I-Entity
after,O
long,O
-,O
term,O
use,O
and,O
in,O
patients,O
with,O
pre,O
-,O
existing,O
angio,B-Entity
-,I-Entity
oedema,I-Entity
.,O
Myoclonus,I-Entity
associated,O
with,O
lorazepam,I-Entity
therapy,O
in,O
very,O
-,O
low,O
-,O
birth,O
-,O
weight,O
infants,O
.,O
Lorazepam,I-Entity
is,O
being,O
used,O
with,O
increasing,O
frequency,O
as,O
a,O
sedative,O
in,O
the,O
newborn,O
and,O
the,O
young,O
infant,O
.,O
Concern,O
has,O
been,O
raised,O
with,O
regard,O
to,O
the,O
safety,O
of,O
lorazepam,I-Entity
in,O
this,O
age,O
group,O
",",O
especially,O
in,O
very,O
-,O
low,O
-,O
birth,O
-,O
weight,O
(,O
VLBW,O
;,O
<,O
"1,500",O
g,O
),O
infants,O
.,O
Three,O
young,O
infants,O
",",O
all,O
of,O
birth,O
weight,O
<,O
"1,500",O
g,O
",",O
experienced,O
myoclonus,I-Entity
following,O
the,O
intravenous,O
administration,O
of,O
lorazepam,I-Entity
.,O
The,O
potential,O
neurotoxic,I-Entity
effects,O
of,O
the,O
drug,O
(,O
and,O
its,O
vehicle,O
),O
in,O
this,O
population,O
are,O
discussed,O
.,O
Injectable,O
lorazepam,I-Entity
should,O
be,O
used,O
with,O
caution,O
in,O
VLBW,O
infants,O
.,O
right,O
ventricular,O
pacing,O
during,O
cardiopulmonary,O
resuscitation,O
of,O
pediatric,O
patients,O
with,O
acute,O
cardiomyopathy,I-Entity
.,O
We,O
describe,O
the,O
cardiopulmonary,O
resuscitation,O
efforts,O
on,O
five,O
patients,O
who,O
presented,O
in,O
acute,O
circulatory,B-Entity
failure,I-Entity
from,O
myocardial,B-Entity
dysfunction,I-Entity
.,O
Three,O
patients,O
had,O
acute,O
viral,O
myocarditis,I-Entity
",",O
one,O
had,O
a,O
carbamazepine,I-Entity
-,O
induced,O
acute,O
eosinophilic,B-Entity
myocarditis,I-Entity
",",O
and,O
one,O
had,O
cardiac,O
hemosiderosis,O
resulting,O
in,O
acute,O
cardiogenic,B-Entity
shock,I-Entity
.,O
An,O
introducer,O
sheath,O
",",O
a,O
pacemaker,O
",",O
and,O
sterile,O
pacing,O
wires,O
were,O
made,O
readily,O
available,O
for,O
the,O
patients,O
",",O
should,O
the,O
need,O
arise,O
to,O
terminate,O
resistant,O
cardiac,O
dysrhythmias,I-Entity
.,O
All,O
patients,O
developed,O
cardiocirculatory,O
arrest,O
associated,O
with,O
extreme,O
hypotension,I-Entity
and,O
dysrhythmias,I-Entity
within,O
the,O
first,O
48,O
hours,O
of,O
their,O
admission,O
to,O
the,O
pediatric,O
intensive,O
care,O
unit,O
(,O
PICU,O
),O
.,O
These,O
patients,O
had,O
a,O
second,O
event,O
of,O
cardiac,B-Entity
arrest,I-Entity
",",O
resulting,O
in,O
death,O
",",O
within,O
10,O
to,O
60,O
minutes,O
.,O
We,O
conclude,O
that,O
cardiac,O
pacing,O
during,O
resuscitative,O
efforts,O
in,O
pediatric,O
patients,O
suffering,O
from,O
acute,O
myocardial,B-Entity
dysfunction,I-Entity
may,O
not,O
have,O
long,O
-,O
term,O
value,O
in,O
and,O
of,O
itself,O
;,O
however,O
",",O
if,O
temporary,O
hemodynamic,O
stability,O
is,O
achieved,O
by,O
this,O
procedure,O
",",O
it,O
may,O
provide,O
additional,O
time,O
needed,O
to,O
institute,O
other,O
therapeutic,O
modalities,O
.,O
Efficacy,O
and,O
safety,O
of,O
granisetron,I-Entity
",",O
a,O
selective,O
5-hydroxytryptamine-3,I-Entity
receptor,O
antagonist,O
",",O
in,O
the,O
prevention,O
of,O
nausea,I-Entity
and,O
vomiting,I-Entity
induced,O
by,O
high,O
-,O
dose,O
cisplatin,I-Entity
.,O
PURPOSE,O
:,O
To,O
assess,O
the,O
antiemetic,O
effects,O
and,O
safety,O
profile,O
of,O
four,O
different,O
doses,O
of,O
granisetron,I-Entity
(,O
Kytril,I-Entity
;,O
SmithKline,O
Beecham,O
Pharmaceuticals,O
",",O
Philadelphia,O
",",O
PA,O
),O
when,O
administered,O
as,O
a,O
single,O
intravenous,O
(,O
IV,O
),O
dose,O
for,O
prophylaxis,O
of,O
cisplatin,I-Entity
-,O
induced,O
nausea,I-Entity
and,O
vomiting,I-Entity
.,O
One,O
hundred,O
eighty,O
-,O
four,O
chemotherapy,O
-,O
naive,O
patients,O
receiving,O
high,O
-,O
dose,O
cisplatin,I-Entity
(,O
81,O
to,O
120,O
mg,O
/,O
m2,O
),O
were,O
randomized,O
to,O
receive,O
one,O
of,O
four,O
granisetron,I-Entity
doses,O
(,O
5,O
",",O
10,O
",",O
20,O
",",O
or,O
40,O
micrograms,O
/,O
kg,O
),O
administered,O
before,O
chemotherapy,O
.,O
Patients,O
were,O
observed,O
on,O
an,O
inpatient,O
basis,O
for,O
18,O
to,O
24,O
hours,O
",",O
and,O
vital,O
signs,O
",",O
nausea,I-Entity
",",O
vomiting,I-Entity
",",O
retching,O
",",O
and,O
appetite,O
were,O
assessed,O
.,O
After,O
granisetron,I-Entity
doses,O
of,O
5,O
",",O
10,O
",",O
20,O
",",O
and,O
40,O
micrograms,O
/,O
kg,O
",",O
a,O
major,O
response,O
(,O
<,O
or,O
=,O
two,O
vomiting,I-Entity
or,O
retching,O
episodes,O
",",O
and,O
no,O
antiemetic,O
rescue,O
),O
was,O
recorded,O
in,O
23%,O
",",O
57%,O
",",O
58%,O
",",O
and,O
60%,O
of,O
patients,O
",",O
respectively,O
",",O
and,O
a,O
complete,O
response,O
(,O
no,O
vomiting,I-Entity
or,O
retching,O
",",O
and,O
no,O
antiemetic,O
rescue,O
),O
in,O
18%,O
",",O
41%,O
",",O
40%,O
",",O
and,O
47%,O
of,O
patients,O
",",O
respectively,O
.,O
There,O
was,O
a,O
statistically,O
longer,O
time,O
to,O
first,O
episode,O
of,O
nausea,I-Entity
(,O
P,O
=,O
.0015,O
),O
and,O
vomiting,I-Entity
(,O
P,O
=,O
.0001,O
),O
",",O
and,O
fewer,O
patients,O
were,O
administered,O
additional,O
antiemetic,O
medication,O
in,O
the,O
10-micrograms,O
/,O
kg,O
dosing,O
groups,O
than,O
in,O
the,O
5-micrograms,O
/,O
kg,O
dosing,O
group,O
.,O
As,O
granisetron,I-Entity
dose,O
increased,O
",",O
appetite,O
return,O
increased,O
(,O
P,O
=,O
.040,O
),O
.,O
Headache,I-Entity
was,O
the,O
most,O
frequently,O
reported,O
adverse,O
event,O
(,O
20%,O
),O
.,O
A,O
single,O
10-,O
",",O
20-,O
",",O
or,O
40-micrograms,O
/,O
kg,O
dose,O
of,O
granisetron,I-Entity
was,O
effective,O
in,O
controlling,O
vomiting,I-Entity
in,O
57%,O
to,O
60%,O
of,O
patients,O
who,O
received,O
cisplatin,I-Entity
at,O
doses,O
greater,O
than,O
81,O
mg,O
/,O
m2,O
and,O
totally,O
prevented,O
vomiting,I-Entity
in,O
40%,O
to,O
47%,O
of,O
patients,O
.,O
Granisetron,I-Entity
was,O
well,O
tolerated,O
at,O
all,O
doses,O
.,O
Adverse,O
interaction,O
between,O
clonidine,I-Entity
and,O
verapamil,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
two,O
cases,O
of,O
a,O
possible,O
adverse,O
interaction,O
between,O
clonidine,I-Entity
and,O
verapamil,I-Entity
resulting,O
in,O
atrioventricular,B-Entity
(,I-Entity
AV,I-Entity
),I-Entity
block,I-Entity
in,O
both,O
patients,O
and,O
severe,O
hypotension,I-Entity
in,O
one,O
patient,O
.,O
A,O
54-year,O
-,O
old,O
woman,O
with,O
hyperaldosteronism,I-Entity
was,O
treated,O
with,O
verapamil,I-Entity
480,O
mg,O
/,O
d,O
and,O
spironolactone,I-Entity
100,O
mg,O
/,O
d,O
.,O
After,O
the,O
addition,O
of,O
a,O
minimal,O
dose,O
of,O
clonidine,I-Entity
(,O
0.15,O
mg,O
bid,O
),O
",",O
she,O
developed,O
complete,O
AV,B-Entity
block,I-Entity
and,O
severe,O
hypotension,I-Entity
",",O
which,O
resolved,O
upon,O
cessation,O
of,O
all,O
medications,O
.,O
A,O
65-year,O
-,O
old,O
woman,O
was,O
treated,O
with,O
extended,O
-,O
release,O
verapamil,I-Entity
240,O
mg,O
/,O
d,O
.,O
After,O
the,O
addition,O
of,O
clonidine,I-Entity
0.15,O
mg,O
bid,O
she,O
developed,O
complete,O
AV,B-Entity
block,I-Entity
",",O
which,O
resolved,O
after,O
all,O
therapy,O
was,O
stopped,O
.,O
DISCUSSION,O
:,O
An,O
adverse,O
interaction,O
between,O
clonidine,I-Entity
and,O
verapamil,I-Entity
has,O
not,O
been,O
reported,O
previously,O
.,O
Caution,O
is,O
recommended,O
in,O
combining,O
clonidine,I-Entity
and,O
verapamil,I-Entity
therapy,O
",",O
even,O
in,O
patients,O
who,O
do,O
not,O
have,O
sinus,O
or,O
AV,O
node,O
dysfunction,O
.,O
Pharmacological,O
studies,O
on,O
a,O
new,O
dihydrothienopyridine,B-Entity
calcium,I-Entity
antagonist,O
",",O
S-312-d,I-Entity
.,O
S-312,I-Entity
",",O
S-312-d,I-Entity
",",O
but,O
not,O
S-312-l,I-Entity
",",O
L,O
-,O
type,O
calcium,I-Entity
channel,O
antagonists,O
",",O
showed,O
anticonvulsant,O
effects,O
on,O
the,O
audiogenic,B-Entity
tonic,I-Entity
convulsions,I-Entity
in,O
DBA/2,O
mice,O
;,O
and,O
their,O
ED50,O
values,O
were,O
18.4,O
(,O
12.8,O
-,O
27.1,O
),O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
and,O
15.0,O
(,O
10.2,O
-,O
23.7,O
),O
mg,O
/,O
kg,O
",",O
p.o,O
.,O
",",O
respectively,O
",",O
while,O
that,O
of,O
flunarizine,I-Entity
was,O
34.0,O
(,O
26.0,O
-,O
44.8,O
Although,O
moderate,O
anticonvulsant,O
effects,O
of,O
S-312-d,I-Entity
in,O
higher,O
doses,O
were,O
observed,O
against,O
the,O
clonic,O
convulsions,I-Entity
induced,O
by,O
pentylenetetrazole,I-Entity
(,O
85,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
or,O
bemegride,I-Entity
(,O
40,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
",",O
no,O
effects,O
were,O
observed,O
in,O
convulsions,I-Entity
induced,O
by,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
",",O
picrotoxin,I-Entity
",",O
or,O
electroshock,O
in,O
Slc,O
:,O
ddY,O
mice,O
.,O
S-312-d,I-Entity
may,O
be,O
useful,O
in,O
the,O
therapy,O
of,O
certain,O
types,O
of,O
human,O
epilepsy,I-Entity
.,O
Transmural,O
myocardial,B-Entity
infarction,I-Entity
with,O
sumatriptan,I-Entity
.,O
For,O
sumatriptan,I-Entity
",",O
tightness,O
in,O
the,O
chest,O
caused,O
by,O
an,O
unknown,O
mechanism,O
has,O
been,O
reported,O
in,O
3,O
-,O
5%,O
of,O
users,O
.,O
We,O
describe,O
a,O
47-year,O
-,O
old,O
woman,O
with,O
an,O
acute,O
myocardial,B-Entity
infarction,I-Entity
after,O
administration,O
of,O
sumatriptan,I-Entity
6,O
mg,O
subcutaneously,O
for,O
cluster,B-Entity
headache,I-Entity
.,O
The,O
patient,O
had,O
no,O
history,O
of,O
underlying,O
ischaemic,B-Entity
heart,I-Entity
disease,I-Entity
or,O
Prinzmetal,B-Entity
's,I-Entity
angina,I-Entity
.,O
Flumazenil,I-Entity
induces,O
seizures,I-Entity
and,O
death,O
in,O
mixed,O
cocaine,I-Entity
-,O
diazepam,I-Entity
intoxications,O
.,O
Administration,O
of,O
the,O
benzodiazepine,I-Entity
antagonist,O
flumazenil,I-Entity
may,O
unmask,O
seizures,I-Entity
in,O
mixed,O
cocaine,I-Entity
-,O
benzodiazepine,I-Entity
intoxication,O
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
received,O
100,O
mg,O
/,O
kg,O
cocaine,I-Entity
IP,O
alone,O
",",O
5,O
mg,O
/,O
kg,O
diazepam,I-Entity
alone,O
",",O
or,O
a,O
combination,O
of,O
diazepam,I-Entity
and,O
cocaine,I-Entity
.,O
Three,O
minutes,O
later,O
",",O
groups,O
were,O
challenged,O
with,O
vehicle,O
or,O
flumazenil,I-Entity
5,O
or,O
10,O
mg,O
/,O
kg,O
IP,O
.,O
Animal,O
behavior,O
",",O
seizures,I-Entity
(,O
time,O
to,O
and,O
incidence,O
),O
",",O
death,O
(,O
time,O
to,O
and,O
incidence,O
),O
",",O
and,O
cortical,O
EEG,O
tracings,O
were,O
recorded,O
.,O
Administration,O
of,O
flumazenil,I-Entity
to,O
animals,O
after,O
they,O
had,O
received,O
a,O
combination,O
dose,O
of,O
cocaine,I-Entity
and,O
diazepam,I-Entity
.,O
In,O
group,O
1,O
",",O
animals,O
received,O
cocaine,I-Entity
followed,O
by,O
vehicle,O
.,O
This,O
resulted,O
in,O
100%,O
developing,O
seizures,I-Entity
and,O
death,O
.,O
Group,O
2,O
received,O
diazepam,I-Entity
alone,O
followed,O
by,O
vehicle,O
.,O
Group,O
3,O
received,O
diazepam,I-Entity
followed,O
by,O
5,O
mg,O
/,O
kg,O
flumazenil,I-Entity
.,O
Animals,O
became,O
somnolent,O
after,O
diazepam,I-Entity
and,O
then,O
active,O
after,O
flumazenil,I-Entity
administration,O
.,O
In,O
group,O
4,O
",",O
a,O
combination,O
of,O
cocaine,I-Entity
and,O
diazepam,I-Entity
was,O
administered,O
simultaneously,O
.,O
This,O
resulted,O
in,O
no,O
overt,O
or,O
EEG,O
-,O
detectable,O
seizures,I-Entity
and,O
a,O
50%,O
incidence,O
of,O
death,O
.,O
Group,O
5,O
received,O
a,O
similar,O
combination,O
of,O
cocaine,I-Entity
and,O
diazepam,I-Entity
",",O
followed,O
later,O
by,O
5,O
mg,O
/,O
kg,O
flumazenil,I-Entity
.,O
This,O
resulted,O
in,O
an,O
increased,O
incidence,O
of,O
seizures,I-Entity
",",O
90%,O
(,O
P,O
<,O
.01,O
),O
",",O
and,O
death,O
",",O
100%,O
Group,O
6,O
received,O
cocaine,I-Entity
and,O
diazepam,I-Entity
followed,O
by,O
10,O
mg,O
/,O
kg,O
flumazenil,I-Entity
.,O
This,O
also,O
resulted,O
in,O
an,O
increased,O
incidence,O
of,O
seizures,I-Entity
",",O
90%,O
CONCLUSION,O
:,O
Flumazenil,I-Entity
can,O
unmask,O
seizures,I-Entity
and,O
increase,O
the,O
incidence,O
of,O
death,O
in,O
a,O
model,O
of,O
combined,O
cocaine,I-Entity
-,O
diazepam,I-Entity
intoxications,O
.,O
Mechanisms,O
for,O
protective,O
effects,O
of,O
free,O
radical,O
scavengers,O
on,O
gentamicin,I-Entity
-,O
mediated,O
nephropathy,I-Entity
in,O
rats,O
.,O
Studies,O
were,O
performed,O
to,O
examine,O
the,O
mechanisms,O
for,O
the,O
protective,O
effects,O
of,O
free,O
radical,O
scavengers,O
on,O
gentamicin,I-Entity
(,O
GM)-mediated,I-Entity
nephropathy,I-Entity
.,O
Administration,O
of,O
GM,I-Entity
at,O
40,O
mg,O
/,O
kg,O
sc,O
for,O
13,O
days,O
to,O
rats,O
induced,O
a,O
significant,O
reduction,O
in,O
renal,O
blood,O
flow,O
(,O
RBF,O
),O
and,O
inulin,O
clearance,O
(,O
CIn,O
),O
as,O
well,O
as,O
marked,O
tubular,B-Entity
damage,I-Entity
.,O
A,O
significant,O
reduction,O
in,O
urinary,O
guanosine,B-Entity
"3',5'-cyclic",I-Entity
monophosphate,I-Entity
(,O
cGMP,I-Entity
),O
excretion,O
and,O
a,O
significant,O
increase,O
in,O
renal,O
cortical,O
renin,O
and,O
endothelin-1,O
contents,O
were,O
also,O
observed,O
in,O
GM,I-Entity
-,O
mediated,O
nephropathy,I-Entity
.,O
Superoxide,I-Entity
dismutase,O
(,O
SOD,O
),O
or,O
dimethylthiourea,I-Entity
(,O
DMTU,I-Entity
),O
significantly,O
lessened,O
the,O
GM,I-Entity
-,O
induced,O
decrement,O
in,O
CIn,O
.,O
The,O
SOD,O
-,O
induced,O
increase,O
in,O
glomerular,O
filtration,O
rate,O
was,O
associated,O
with,O
a,O
marked,O
improvement,O
in,O
RBF,O
",",O
an,O
increase,O
in,O
urinary,O
cGMP,I-Entity
excretion,O
",",O
and,O
a,O
decrease,O
in,O
renal,O
renin,O
and,O
endothelin-1,O
content,O
.,O
SOD,O
did,O
not,O
attenuate,O
the,O
tubular,B-Entity
damage,I-Entity
.,O
In,O
contrast,O
",",O
DMTU,I-Entity
significantly,O
reduced,O
the,O
tubular,B-Entity
damage,I-Entity
and,O
lipid,O
peroxidation,O
",",O
but,O
it,O
did,O
not,O
affect,O
renal,O
hemodynamics,O
and,O
vasoactive,O
substances,O
.,O
Neither,O
SOD,O
nor,O
DMTU,I-Entity
affected,O
the,O
renal,O
cortical,O
GM,I-Entity
content,O
in,O
GM,I-Entity
-,O
treated,O
rats,O
.,O
These,O
results,O
suggest,O
that,O
1,O
),O
both,O
SOD,O
and,O
DMTU,I-Entity
have,O
protective,O
effects,O
on,O
GM,I-Entity
-,O
mediated,O
nephropathy,I-Entity
",",O
2,O
),O
the,O
mechanisms,O
for,O
the,O
protective,O
effects,O
differ,O
for,O
SOD,O
and,O
DMTU,I-Entity
",",O
and,O
3,O
),O
superoxide,I-Entity
anions,O
play,O
a,O
critical,O
role,O
in,O
GM,I-Entity
-,O
induced,O
renal,O
vasoconstriction,O
.,O
Assessment,O
of,O
cardiomyocyte,O
DNA,O
synthesis,O
during,O
hypertrophy,I-Entity
in,O
adult,O
mice,O
.,O
The,O
ability,O
of,O
cardiomyocytes,O
to,O
synthesize,O
DNA,O
in,O
response,O
to,O
experimentally,O
induced,O
cardiac,B-Entity
hypertrophy,I-Entity
was,O
assessed,O
in,O
adult,O
mice,O
.,O
Isoproterenol,I-Entity
delivered,O
by,O
osmotic,O
minipump,O
implantation,O
in,O
adult,O
C3Heb,O
/,O
FeJ,O
mice,O
resulted,O
in,O
a,O
46%,O
increase,O
in,O
heart,O
weight,O
and,O
a,O
19.3%,O
increase,O
in,O
cardiomyocyte,O
area,O
.,O
No,O
DNA,O
synthesis,O
",",O
as,O
assessed,O
by,O
autoradiographic,O
analysis,O
of,O
isolated,O
cardiomyocytes,O
",",O
was,O
observed,O
in,O
control,O
or,O
hypertrophic,B-Entity
hearts,I-Entity
.,O
To,O
determine,O
whether,O
the,O
capacity,O
for,O
reactive,O
DNA,O
synthesis,O
was,O
also,O
subject,O
to,O
genetic,O
regulation,O
",",O
cardiac,B-Entity
hypertrophy,I-Entity
was,O
induced,O
in,O
the,O
strains,O
of,O
mice,O
comprising,O
the,O
extremes,O
of,O
the,O
nuclear,O
number,O
survey,O
.,O
These,O
data,O
indicate,O
that,O
adult,O
mouse,O
atrial,O
and,O
ventricular,O
cardiomyocytes,O
do,O
not,O
synthesize,O
DNA,O
in,O
response,O
to,O
isoproterenol,I-Entity
-,O
induced,O
cardiac,B-Entity
hypertrophy,I-Entity
.,O
Central,O
cardiovascular,O
effects,O
of,O
AVP,I-Entity
and,O
ANP,O
in,O
normotensive,O
and,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
compare,O
influence,O
of,O
central,O
arginine,B-Entity
vasopressin,I-Entity
(,O
AVP,I-Entity
),O
and,O
of,O
atrial,O
natriuretic,O
peptide,O
(,O
ANP,O
),O
on,O
control,O
of,O
arterial,O
blood,O
pressure,O
(,O
MAP,O
),O
and,O
heart,O
rate,O
(,O
HR,O
),O
in,O
normotensive,O
(,O
WKY,O
),O
and,O
spontaneously,O
hypertensive,I-Entity
(,O
SHR,O
),O
rats,O
.,O
injections,O
of,O
either,O
vehicle,O
or,O
1,O
",",O
10,O
and,O
50,O
ng,O
of,O
AVP,I-Entity
and,O
25,O
",",O
125,O
and,O
500,O
ng,O
of,O
ANP,O
.,O
Sensitivity,O
of,O
cardiac,O
component,O
of,O
baroreflex,O
(,O
CCB,O
),O
",",O
expressed,O
as,O
a,O
slope,O
of,O
the,O
regression,O
line,O
was,O
determined,O
from,O
relationships,O
between,O
systolic,O
arterial,O
pressure,O
(,O
SAP,O
),O
and,O
HR,O
period,O
(,O
HRp,O
),O
during,O
phenylephrine,I-Entity
(,O
Phe)-induced,I-Entity
hypertension,I-Entity
and,O
sodium,B-Entity
nitroprusside,I-Entity
(,O
SN)-induced,I-Entity
hypotension,I-Entity
.,O
CCB,O
was,O
measured,O
before,O
and,O
after,O
administration,O
of,O
either,O
vehicle,O
",",O
AVP,I-Entity
",",O
ANP,O
",",O
or,O
both,O
peptides,O
together,O
.,O
Increases,O
of,O
MAP,O
occurred,O
after,O
LV,O
administration,O
of,O
1,O
",",O
10,O
and,O
50,O
ng,O
of,O
AVP,I-Entity
in,O
WKY,O
and,O
of,O
10,O
and,O
50,O
ng,O
in,O
SHR,O
.,O
ANP,O
did,O
not,O
cause,O
significant,O
changes,O
in,O
MAP,O
in,O
both,O
strains,O
as,O
compared,O
to,O
vehicle,O
",",O
but,O
it,O
abolished,O
AVP,I-Entity
-,O
induced,O
MAP,O
increase,O
in,O
WKY,O
and,O
SHR,O
.,O
CCB,O
was,O
reduced,O
in,O
WKY,O
and,O
SHR,O
after,O
LV,O
administration,O
of,O
AVP,I-Entity
during,O
SN,I-Entity
-,O
induced,O
hypotension,I-Entity
.,O
In,O
SHR,O
but,O
not,O
in,O
WKY,O
administration,O
of,O
ANP,O
",",O
AVP,I-Entity
and,O
ANP,O
+,O
AVP,I-Entity
decreased,O
CCB,O
during,O
Phe,I-Entity
-,O
induced,O
MAP,O
elevation,O
.,O
The,O
results,O
indicate,O
that,O
centrally,O
applied,O
AVP,I-Entity
and,O
ANP,O
exert,O
differential,O
effects,O
on,O
blood,O
pressure,O
and,O
baroreflex,O
control,O
of,O
heart,O
rate,O
in,O
WKY,O
and,O
SHR,O
and,O
suggest,O
interaction,O
of,O
these,O
two,O
peptides,O
in,O
blood,O
pressure,O
regulation,O
at,O
the,O
level,O
of,O
central,O
nervous,O
system,O
.,O
Cutaneous,O
exposure,O
to,O
warfarin,I-Entity
-,O
like,O
anticoagulant,O
causing,O
an,O
intracerebral,B-Entity
hemorrhage,I-Entity
:,O
a,O
case,O
report,O
.,O
A,O
case,O
of,O
intercerebral,O
hematoma,I-Entity
due,O
to,O
warfarin,I-Entity
-,O
induced,O
coagulopathy,I-Entity
is,O
presented,O
.,O
The,O
39-year,O
-,O
old,O
woman,O
had,O
spread,O
a,O
warfarin,I-Entity
-,O
type,O
rat,O
poison,O
around,O
her,O
house,O
weekly,O
using,O
her,O
bare,O
hands,O
",",O
with,O
no,O
washing,O
post,O
application,O
.,O
Percutaneous,O
absorption,O
of,O
warfarin,I-Entity
causing,O
coagulopathy,I-Entity
",",O
reported,O
three,O
times,O
in,O
the,O
past,O
",",O
is,O
a,O
significant,O
risk,O
if,O
protective,O
measures,O
",",O
such,O
as,O
gloves,O
",",O
are,O
not,O
used,O
.,O
An,O
adverse,O
drug,O
interaction,O
with,O
piroxicam,I-Entity
",",O
which,O
she,O
took,O
occasionally,O
",",O
may,O
have,O
exacerbated,O
the,O
coagulopathy,I-Entity
.,O
Pediatric,O
heart,O
transplantation,O
without,O
chronic,O
maintenance,O
steroids,I-Entity
.,O
Indications,O
for,O
transplantation,O
were,O
idiopathic,B-Entity
cardiomyopathy,I-Entity
(,O
52%,O
),O
",",O
congenital,B-Entity
heart,I-Entity
disease,I-Entity
(,O
35%,O
),O
with,O
and,O
without,O
prior,O
repair,O
(,O
71%,O
and,O
29%,O
",",O
respectively,O
),O
",",O
hypertrophic,B-Entity
cardiomyopathy,I-Entity
(,O
5%,O
),O
",",O
valvular,B-Entity
heart,I-Entity
disease,I-Entity
(,O
3%,O
),O
",",O
and,O
doxorubicin,I-Entity
cardiomyopathy,I-Entity
(,O
5%,O
),O
.,O
Patients,O
were,O
managed,O
with,O
cyclosporine,I-Entity
and,O
azathioprine,I-Entity
.,O
Steroids,I-Entity
were,O
given,O
to,O
39%,O
of,O
patients,O
for,O
refractory,O
rejection,O
",",O
but,O
weaning,O
was,O
always,O
attempted,O
and,O
generally,O
successful,O
(,O
64%,O
),O
.,O
Five,O
patients,O
(,O
14%,O
),O
received,O
maintenance,O
steroids,I-Entity
.,O
There,O
have,O
been,O
no,O
deaths,O
related,O
to,O
rejection,O
or,O
infection,I-Entity
.,O
Freedom,O
from,O
serious,O
infections,I-Entity
was,O
83%,O
at,O
1,O
month,O
and,O
65%,O
at,O
1,O
year,O
.,O
Cytomegalovirus,B-Entity
infections,I-Entity
were,O
treated,O
successfully,O
with,O
ganciclovir,I-Entity
in,O
11,O
patients,O
.,O
Twenty,O
-,O
one,O
patients,O
(,O
60%,O
),O
have,O
undergone,O
annual,O
catheterizations,O
and,O
no,O
sign,O
of,O
graft,O
atherosclerosis,I-Entity
has,O
been,O
observed,O
.,O
Seizures,I-Entity
occurred,O
in,O
five,O
patients,O
(,O
14%,O
),O
and,O
hypertension,I-Entity
was,O
treated,O
in,O
10,O
patients,O
(,O
28%,O
),O
.,O
No,O
patient,O
was,O
disabled,O
and,O
no,O
lymphoproliferative,B-Entity
disorder,I-Entity
was,O
observed.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Delirium,I-Entity
during,O
fluoxetine,I-Entity
treatment,O
.,O
Only,O
a,O
few,O
reports,O
exist,O
",",O
however,O
",",O
on,O
the,O
relationship,O
between,O
the,O
serum,O
concentrations,O
of,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitors,O
(,O
SSRIs,O
),O
and,O
their,O
toxic,O
effects,O
.,O
In,O
some,O
cases,O
",",O
a,O
high,O
serum,O
concentration,O
of,O
citalopram,I-Entity
(,O
>,O
600,O
nmol,O
/,O
L,O
),O
in,O
elderly,O
patients,O
has,O
been,O
associated,O
with,O
increased,O
somnolence,I-Entity
and,O
movement,B-Entity
difficulties,I-Entity
.,O
Widespread,O
cognitive,B-Entity
disorders,I-Entity
",",O
such,O
as,O
delirium,I-Entity
",",O
have,O
not,O
been,O
previously,O
linked,O
with,O
high,O
blood,O
levels,O
of,O
SSRIs,O
.,O
In,O
this,O
report,O
",",O
we,O
describe,O
a,O
patient,O
with,O
acute,O
hyperkinetic,I-Entity
delirium,I-Entity
connected,O
with,O
a,O
high,O
serum,O
total,O
fluoxetine,I-Entity
(,O
fluoxetine,I-Entity
plus,O
desmethylfluoxetine,I-Entity
),O
concentration,O
.,O
Pulmonary,B-Entity
edema,I-Entity
and,O
shock,I-Entity
after,O
high,O
-,O
dose,O
aracytine,B-Entity
-,I-Entity
C,I-Entity
for,O
lymphoma,I-Entity
;,O
possible,O
role,O
of,O
TNF,O
-,O
alpha,O
and,O
PAF,O
.,O
Four,O
out,O
of,O
23,O
consecutive,O
patients,O
treated,O
with,O
high,O
-,O
dose,O
Ara,B-Entity
-,I-Entity
C,I-Entity
for,O
lymphomas,I-Entity
in,O
our,O
institution,O
developed,O
a,O
strikingly,O
similar,O
syndrome,O
during,O
the,O
perfusion,O
.,O
It,O
was,O
characterized,O
by,O
the,O
onset,O
of,O
fever,I-Entity
",",O
diarrhea,I-Entity
",",O
shock,I-Entity
",",O
pulmonary,B-Entity
edema,I-Entity
",",O
acute,B-Entity
renal,I-Entity
failure,I-Entity
",",O
metabolic,B-Entity
acidosis,I-Entity
",",O
weight,B-Entity
gain,I-Entity
and,O
leukocytosis,I-Entity
.,O
Thorough,O
bacteriological,O
screening,O
failed,O
to,O
provide,O
evidence,O
of,O
infection,I-Entity
.,O
Sequential,O
biological,O
assays,O
of,O
IL-1,O
",",O
IL-2,O
",",O
TNF,O
and,O
PAF,O
were,O
performed,O
during,O
Ara,B-Entity
-,I-Entity
C,I-Entity
infusion,O
to,O
ten,O
patients,O
",",O
including,O
the,O
four,O
who,O
developed,O
the,O
syndrome,O
.,O
As,O
TNF,O
and,O
PAF,O
are,O
thought,O
to,O
be,O
involved,O
in,O
the,O
development,O
of,O
septic,O
shock,I-Entity
and,O
adult,B-Entity
respiratory,I-Entity
distress,I-Entity
syndrome,I-Entity
",",O
we,O
hypothesize,O
that,O
high,O
-,O
dose,O
Ara,B-Entity
-,I-Entity
C,I-Entity
may,O
be,O
associated,O
with,O
cytokine,O
release,O
.,O
Protective,O
effect,O
of,O
clentiazem,I-Entity
against,O
epinephrine,I-Entity
-,O
induced,O
cardiac,B-Entity
injury,I-Entity
in,O
rats,O
.,O
We,O
investigated,O
the,O
effects,O
of,O
clentiazem,I-Entity
",",O
a,O
"1,5-benzothiazepine",I-Entity
calcium,I-Entity
antagonist,O
",",O
on,O
epinephrine,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
in,O
rats,O
.,O
With,O
2-week,O
chronic,O
epinephrine,I-Entity
infusion,O
",",O
16,O
of,O
30,O
rats,O
died,O
within,O
4,O
days,O
",",O
and,O
severe,O
ischemic,B-Entity
lesions,I-Entity
and,O
fibrosis,I-Entity
of,O
the,O
left,O
ventricles,O
were,O
observed,O
.,O
In,O
epinephrine,I-Entity
-,O
treated,O
rats,O
",",O
left,O
atrial,O
and,O
left,O
ventricular,O
papillary,O
muscle,O
contractile,O
responses,O
to,O
isoproterenol,I-Entity
were,O
reduced,O
",",O
but,O
responses,O
to,O
calcium,I-Entity
were,O
normal,O
or,O
enhanced,O
compared,O
to,O
controls,O
.,O
Treatment,O
with,O
clentiazem,I-Entity
prevented,O
epinephrine,I-Entity
-,O
induced,O
death,O
(,O
P,O
<,O
.05,O
),O
",",O
and,O
attenuated,O
the,O
ventricular,O
ischemic,B-Entity
lesions,I-Entity
and,O
fibrosis,I-Entity
",",O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
Left,O
atrial,O
and,O
left,O
ventricular,O
papillary,O
muscle,O
contractile,O
responses,O
to,O
isoproterenol,I-Entity
were,O
reduced,O
compared,O
to,O
controls,O
in,O
groups,O
treated,O
with,O
clentiazem,I-Entity
alone,O
",",O
but,O
combined,O
with,O
epinephrine,I-Entity
",",O
clentiazem,I-Entity
restored,O
left,O
atrial,O
responses,O
and,O
enhanced,O
left,O
ventricular,O
papillary,O
responses,O
to,O
isoproterenol,I-Entity
.,O
On,O
the,O
other,O
hand,O
clentiazem,I-Entity
did,O
not,O
prevent,O
epinephrine,I-Entity
-,O
induced,O
down,O
-,O
regulation,O
of,O
alpha,O
and,O
beta,O
adrenoceptors,O
.,O
Interestingly,O
",",O
clentiazem,I-Entity
",",O
infused,O
alone,O
",",O
resulted,O
in,O
decreased,O
adrenergic,O
receptor,O
densities,O
in,O
the,O
left,O
ventricle,O
.,O
Clentiazem,I-Entity
also,O
did,O
not,O
prevent,O
the,O
enhanced,O
responses,O
to,O
calcium,I-Entity
seen,O
in,O
the,O
epinephrine,I-Entity
-,O
treated,O
animals,O
",",O
although,O
the,O
high,O
dose,O
of,O
clentiazem,I-Entity
partially,O
attenuated,O
the,O
maximal,O
response,O
to,O
calcium,I-Entity
compared,O
to,O
epinephrine,I-Entity
-,O
treated,O
animals,O
.,O
In,O
conclusion,O
",",O
clentiazem,I-Entity
attenuated,O
epinephrine,I-Entity
-,O
induced,O
cardiac,B-Entity
injury,I-Entity
",",O
possibly,O
through,O
its,O
effect,O
on,O
the,O
adrenergic,O
pathway,O
.,O
Cocaine,I-Entity
induced,O
myocardial,B-Entity
ischemia,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
myocardial,B-Entity
ischemia,I-Entity
induced,O
by,O
cocaine,I-Entity
.,O
The,O
ischemia,I-Entity
probably,O
induced,O
by,O
coronary,B-Entity
artery,I-Entity
spasm,I-Entity
was,O
reversed,O
by,O
nitroglycerin,I-Entity
and,O
calcium,I-Entity
blocking,O
agents,O
.,O
Doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
monitored,O
by,O
ECG,O
in,O
freely,O
moving,O
mice,O
.,O
In,O
laboratory,O
animals,O
",",O
histology,O
is,O
most,O
commonly,O
used,O
to,O
study,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
With,O
this,O
model,O
we,O
investigated,O
the,O
effect,O
of,O
chronic,O
doxorubicin,I-Entity
administration,O
on,O
the,O
ECG,O
of,O
freely,O
moving,O
BALB,O
/,O
c,O
mice,O
and,O
the,O
efficacy,O
of,O
ICRF-187,I-Entity
as,O
a,O
protective,O
agent,O
.,O
11.8,O
ms,O
in,O
week,O
10,O
(,O
7,O
weekly,O
doses,O
of,O
4,O
mg,O
/,O
kg,O
doxorubicin,I-Entity
given,O
i.v,O
.,O
After,O
sacrifice,O
the,O
hearts,O
of,O
doxorubicin,I-Entity
-,O
treated,O
animals,O
were,O
enlarged,O
and,O
the,O
atria,O
were,O
hypertrophic,I-Entity
.,O
As,O
this,O
schedule,O
exerted,O
more,O
toxicity,I-Entity
than,O
needed,O
to,O
investigate,O
protective,O
agents,O
",",O
the,O
protection,O
of,O
ICRF-187,I-Entity
was,O
determined,O
using,O
a,O
dose,O
schedule,O
with,O
lower,O
general,O
toxicity,I-Entity
(,O
6,O
weekly,O
doses,O
of,O
4,O
mg,O
/,O
kg,O
doxorubicin,I-Entity
given,O
i.v,O
.,O
On,O
this,O
schedule,O
",",O
the,O
animals,O
',O
hearts,O
appeared,O
normal,O
after,O
sacrifice,O
and,O
ICRF-187,I-Entity
(,O
50,O
mg,O
/,O
kg,O
given,O
i.p,O
.,O
1,O
h,O
before,O
doxorubicin,I-Entity
),O
provided,O
almost,O
full,O
protection,O
.,O
The,O
results,O
indicate,O
that,O
this,O
new,O
model,O
is,O
very,O
sensitive,O
and,O
enables,O
monitoring,O
of,O
the,O
development,O
of,O
cardiotoxicity,I-Entity
with,O
time,O
.,O
These,O
findings,O
result,O
in,O
a,O
model,O
that,O
allows,O
the,O
testing,O
of,O
protectors,O
against,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
as,O
demonstrated,O
by,O
the,O
protection,O
provided,O
by,O
ICRF-187,I-Entity
.,O
Epinephrine,I-Entity
dysrhythmogenicity,O
is,O
not,O
enhanced,O
by,O
subtoxic,O
bupivacaine,I-Entity
in,O
dogs,O
.,O
Since,O
bupivacaine,I-Entity
and,O
epinephrine,I-Entity
may,O
both,O
precipitate,O
dysrhythmias,I-Entity
",",O
circulating,O
bupivacaine,I-Entity
during,O
regional,O
anesthesia,O
could,O
potentiate,O
dysrhythmogenic,O
effects,O
of,O
epinephrine,I-Entity
.,O
We,O
therefore,O
examined,O
whether,O
bupivacaine,I-Entity
alters,O
the,O
dysrhythmogenicity,O
of,O
subsequent,O
administration,O
of,O
epinephrine,I-Entity
in,O
conscious,O
",",O
healthy,O
dogs,O
and,O
in,O
anesthetized,O
dogs,O
with,O
myocardial,B-Entity
infarction,I-Entity
.,O
Forty,O
-,O
one,O
conscious,O
dogs,O
received,O
10,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
.,O
Seventeen,O
animals,O
responded,O
with,O
ventricular,B-Entity
tachycardia,I-Entity
(,O
VT,I-Entity
),O
within,O
3,O
min,O
.,O
After,O
3,O
h,O
",",O
these,O
responders,O
randomly,O
received,O
1,O
or,O
2,O
mg,O
/,O
kg,O
bupivacaine,I-Entity
or,O
saline,O
over,O
5,O
min,O
",",O
followed,O
by,O
10,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
.,O
In,O
the,O
bupivacaine,I-Entity
groups,O
",",O
epinephrine,I-Entity
caused,O
fewer,O
prodysrhythmic,O
effects,O
than,O
without,O
bupivacaine,I-Entity
.,O
VT,I-Entity
appeared,O
in,O
fewer,O
dogs,O
and,O
at,O
a,O
later,O
time,O
",",O
and,O
there,O
were,O
more,O
sinoatrial,O
beats,O
and,O
less,O
ectopies,O
.,O
Epinephrine,I-Entity
shortened,O
QT,O
less,O
after,O
bupivacaine,I-Entity
than,O
in,O
control,O
animals,O
.,O
One,O
day,O
after,O
experimental,O
myocardial,B-Entity
infarction,I-Entity
",",O
six,O
additional,O
halothane,I-Entity
-,O
anesthetized,O
dogs,O
received,O
4,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
until,O
VT,I-Entity
appeared,O
.,O
After,O
45,O
min,O
",",O
1,O
mg,O
/,O
kg,O
bupivacaine,I-Entity
was,O
injected,O
over,O
5,O
min,O
",",O
again,O
followed,O
by,O
4,O
micrograms.kg-1.min-1,O
epinephrine,I-Entity
.,O
In,O
these,O
dogs,O
",",O
the,O
prodysrhythmic,O
response,O
to,O
epinephrine,I-Entity
was,O
also,O
mitigated,O
by,O
preceding,O
bupivacaine,I-Entity
.,O
Bupivacaine,I-Entity
antagonizes,O
epinephrine,I-Entity
dysrhythmogenicity,O
in,O
conscious,O
dogs,O
susceptible,O
to,O
VT,I-Entity
and,O
in,O
anesthetized,O
dogs,O
with,O
spontaneous,O
postinfarct,O
dysrhythmias,I-Entity
.,O
There,O
is,O
no,O
evidence,O
that,O
systemic,O
subtoxic,O
bupivacaine,I-Entity
administration,O
enhances,O
the,O
dysrhythmogenicity,O
of,O
subsequent,O
epinephrine,I-Entity
.,O
Milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
induced,O
by,O
"1,25(OH)2D",I-Entity
in,O
a,O
patient,O
with,O
hypoparathyroidism,I-Entity
.,O
Milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
was,O
first,O
described,O
70,O
years,O
ago,O
in,O
the,O
context,O
of,O
the,O
treatment,O
of,O
peptic,B-Entity
ulcer,I-Entity
disease,I-Entity
with,O
large,O
amounts,O
of,O
calcium,I-Entity
and,O
alkali,I-Entity
.,O
Although,O
with,O
current,O
ulcer,I-Entity
therapy,O
(,O
H-2,O
blockers,O
",",O
omeprazole,I-Entity
",",O
and,O
sucralfate,I-Entity
),O
",",O
the,O
frequency,O
of,O
milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
has,O
decreased,O
significantly,O
",",O
the,O
classic,O
triad,O
of,O
hypercalcemia,I-Entity
",",O
alkalosis,I-Entity
",",O
and,O
renal,B-Entity
impairment,I-Entity
remains,O
the,O
hallmark,O
of,O
the,O
syndrome,O
.,O
Milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
can,O
present,O
serious,O
and,O
occasionally,O
life,O
-,O
threatening,O
illness,O
unless,O
diagnosed,O
and,O
treated,O
appropriately,O
.,O
This,O
article,O
presents,O
a,O
patient,O
with,O
hypoparathyroidism,I-Entity
who,O
was,O
treated,O
with,O
calcium,B-Entity
carbonate,I-Entity
and,O
calcitriol,I-Entity
resulting,O
in,O
two,O
admissions,O
to,O
the,O
hospital,O
for,O
milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
.,O
The,O
patient,O
was,O
successfully,O
treated,O
with,O
intravenous,O
pamidronate,I-Entity
on,O
his,O
first,O
admission,O
and,O
with,O
hydrocortisone,I-Entity
on,O
the,O
second,O
.,O
This,O
illustrates,O
intravenous,O
pamidronate,I-Entity
as,O
a,O
valuable,O
therapeutic,O
tool,O
when,O
milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
presents,O
as,O
hypercalcemic,B-Entity
emergency,I-Entity
.,O
Encephalopathy,I-Entity
during,O
amitriptyline,I-Entity
therapy,O
:,O
are,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
and,O
serotonin,B-Entity
syndrome,I-Entity
spectrum,O
disorders,O
?,O
This,O
report,O
describes,O
a,O
case,O
of,O
encephalopathy,I-Entity
developed,O
in,O
the,O
course,O
of,O
amitriptyline,I-Entity
therapy,O
",",O
during,O
a,O
remission,O
of,O
unipolar,B-Entity
depression,I-Entity
.,O
This,O
patient,O
could,O
have,O
been,O
diagnosed,O
as,O
having,O
either,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
(,O
NMS,I-Entity
),O
or,O
serotonin,B-Entity
syndrome,I-Entity
(,O
SS,I-Entity
),O
.,O
The,O
major,O
determinant,O
of,O
the,O
symptoms,O
may,O
have,O
been,O
dopamine,I-Entity
/,O
serotonin,I-Entity
imbalance,O
in,O
the,O
central,O
nervous,O
system,O
.,O
The,O
NMS,I-Entity
-,O
like,O
encephalopathy,I-Entity
that,O
develops,O
in,O
association,O
with,O
the,O
use,O
of,O
antidepressants,O
indicates,O
that,O
NMS,I-Entity
and,O
SS,I-Entity
are,O
spectrum,O
disorders,O
induced,O
by,O
drugs,O
with,O
both,O
antidopaminergic,O
and,O
serotonergic,O
effects,O
.,O
Genetic,O
separation,O
of,O
tumor,I-Entity
growth,O
and,O
hemorrhagic,I-Entity
phenotypes,O
in,O
an,O
estrogen,I-Entity
-,O
induced,O
tumor,I-Entity
.,O
Chronic,O
administration,O
of,O
estrogen,I-Entity
to,O
the,O
Fischer,O
344,O
(,O
F344,O
),O
rat,O
induces,O
growth,O
of,O
large,O
",",O
hemorrhagic,I-Entity
pituitary,B-Entity
tumors,I-Entity
.,O
Ten,O
weeks,O
of,O
diethylstilbestrol,I-Entity
(,O
DES,I-Entity
),O
treatment,O
caused,O
female,O
F344,O
rat,O
pituitaries,O
to,O
grow,O
to,O
an,O
average,O
of,O
109.2,O
+,O
/-,O
1.4,O
mg,O
for,O
untreated,O
rats,O
",",O
and,O
to,O
become,O
highly,O
hemorrhagic,I-Entity
.,O
The,O
same,O
DES,I-Entity
treatment,O
produced,O
no,O
significant,O
growth,O
(,O
8.9,O
+,O
/-,O
An,O
F1,O
hybrid,O
of,O
F344,O
and,O
BN,O
exhibited,O
significant,O
pituitary,O
growth,O
after,O
10,O
weeks,O
of,O
DES,I-Entity
treatment,O
with,O
an,O
average,O
mass,O
of,O
26.3,O
+,O
/-,O
Surprisingly,O
",",O
the,O
F1,O
hybrid,O
tumors,I-Entity
were,O
not,O
hemorrhagic,I-Entity
and,O
had,O
hemoglobin,O
content,O
and,O
outward,O
appearance,O
identical,O
to,O
that,O
of,O
BN,O
.,O
However,O
",",O
while,O
DES,I-Entity
-,O
induced,O
pituitary,O
growth,O
exhibited,O
quantitative,O
",",O
additive,O
inheritance,O
",",O
the,O
hemorrhagic,I-Entity
phenotype,O
exhibited,O
recessive,O
",",O
epistatic,O
inheritance,O
.,O
Only,O
5,O
of,O
the,O
160,O
F2,O
pituitaries,O
exhibited,O
the,O
hemorrhagic,I-Entity
phenotype,O
;,O
36,O
of,O
the,O
160,O
F2,O
pituitaries,O
were,O
in,O
the,O
F344,O
range,O
of,O
mass,O
",",O
but,O
31,O
of,O
these,O
were,O
not,O
hemorrhagic,I-Entity
",",O
indicating,O
that,O
the,O
hemorrhagic,I-Entity
phenotype,O
is,O
not,O
merely,O
a,O
consequence,O
of,O
extensive,O
growth,O
.,O
The,O
hemorrhagic,I-Entity
F2,O
pituitaries,O
were,O
all,O
among,O
the,O
most,O
massive,O
",",O
indicating,O
that,O
some,O
of,O
the,O
genes,O
regulate,O
both,O
phenotypes,O
.,O
Increased,O
expression,O
of,O
neuronal,O
nitric,B-Entity
oxide,I-Entity
synthase,O
in,O
bladder,O
afferent,O
pathways,O
following,O
chronic,O
bladder,B-Entity
irritation,I-Entity
.,O
Immunocytochemical,O
techniques,O
were,O
used,O
to,O
examine,O
alterations,O
in,O
the,O
expression,O
of,O
neuronal,O
nitric,B-Entity
oxide,I-Entity
synthase,O
(,O
NOS,O
),O
in,O
bladder,O
pathways,O
following,O
acute,O
and,O
chronic,O
irritation,B-Entity
of,I-Entity
the,I-Entity
urinary,I-Entity
tract,I-Entity
of,O
the,O
rat,O
.,O
Chemical,O
cystitis,I-Entity
was,O
induced,O
by,O
cyclophosphamide,I-Entity
(,O
CYP,I-Entity
),O
which,O
is,O
metabolized,O
to,O
acrolein,I-Entity
",",O
an,O
irritant,O
eliminated,O
in,O
the,O
urine,O
.,O
Injection,O
of,O
CYP,I-Entity
(,O
n,O
=,O
10,O
",",O
75,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
Fos,O
-,O
IR,O
in,O
the,O
spinal,O
cord,O
was,O
not,O
changed,O
in,O
rats,O
receiving,O
chronic,O
CYP,I-Entity
treatment,O
(,O
In,O
control,O
animals,O
and,O
in,O
animals,O
treated,O
acutely,O
with,O
CYP,I-Entity
",",O
only,O
small,O
numbers,O
of,O
NOS,O
-,O
IR,O
cells,O
(,O
0.5,O
-,O
0.7,O
cell,O
profiles,O
/,O
sections,O
),O
were,O
detected,O
in,O
the,O
L6-S1,O
dorsal,O
root,O
ganglia,O
(,O
DRG,O
),O
.,O
Chronic,O
CYP,I-Entity
administration,O
significantly,O
(,O
P,O
<,O
or,O
=,O
.002,O
),O
increased,O
bladder,O
weight,O
by,O
60%,O
and,O
increased,O
(,O
7-,O
to,O
11-fold,O
),O
the,O
numbers,O
of,O
NOS,O
-,O
immunoreactive,O
(,O
IR,O
),O
afferent,O
neurons,O
in,O
the,O
L6-S1,O
DRG,O
.,O
Bladder,O
afferent,O
cells,O
in,O
the,O
L6-S1,O
DRG,O
labeled,O
by,O
Fluorogold,O
(,O
40,O
microliters,O
),O
injected,O
into,O
the,O
bladder,O
wall,O
did,O
not,O
exhibit,O
NOS,O
-,O
IR,O
in,O
control,O
animals,O
;,O
however,O
",",O
following,O
chronic,O
CYP,I-Entity
administration,O
",",O
a,O
significant,O
percentage,O
of,O
bladder,O
afferent,O
neurons,O
were,O
NOS,O
-,O
IR,O
:,O
Effects,O
of,O
a,O
new,O
calcium,I-Entity
antagonist,O
",",O
CD-832,I-Entity
",",O
on,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
in,O
dogs,O
with,O
partial,O
coronary,B-Entity
stenosis,I-Entity
.,O
Effects,O
of,O
CD-832,I-Entity
on,O
isoproterenol,I-Entity
(,O
ISO)-induced,I-Entity
myocardial,B-Entity
ischemia,I-Entity
were,O
studied,O
in,O
dogs,O
with,O
partial,O
coronary,B-Entity
stenosis,I-Entity
of,O
the,O
left,O
circumflex,O
coronary,O
artery,O
and,O
findings,O
were,O
compared,O
with,O
those,O
for,O
nifedipine,I-Entity
or,O
diltiazem,I-Entity
.,O
In,O
the,O
presence,O
of,O
coronary,B-Entity
artery,I-Entity
stenosis,I-Entity
",",O
3-min,O
periods,O
of,O
intracoronary,O
ISO,I-Entity
infusion,O
(,O
10,O
ng,O
/,O
kg,O
/,O
min,O
),O
increased,O
heart,O
rate,O
and,O
maximal,O
rate,O
of,O
left,O
ventricular,O
pressure,O
rise,O
",",O
which,O
resulted,O
in,O
a,O
decrease,O
in,O
percentage,O
segmental,O
shortening,O
and,O
ST,O
-,O
segment,O
elevation,O
of,O
the,O
epicardial,O
electrocardiogram,O
.,O
After,O
the,O
control,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
was,O
performed,O
",",O
equihypotensive,O
doses,O
of,O
CD-832,I-Entity
(,O
3,O
and,O
10,O
micrograms,O
/,O
kg,O
/,O
min,O
",",O
n,O
=,O
7,O
),O
",",O
nifedipine,I-Entity
(,O
1,O
and,O
3,O
micrograms,O
/,O
kg,O
/,O
min,O
",",O
n,O
=,O
9,O
),O
or,O
diltiazem,I-Entity
(,O
10,O
and,O
30,O
micrograms,O
/,O
kg,O
/,O
min,O
",",O
n,O
=,O
7,O
),O
were,O
infused,O
5,O
min,O
before,O
and,O
during,O
the,O
second,O
and,O
third,O
ISO,I-Entity
infusion,O
.,O
Both,O
CD-832,I-Entity
and,O
diltiazem,I-Entity
",",O
but,O
not,O
nifedipine,I-Entity
",",O
significantly,O
reduced,O
the,O
increase,O
in,O
heart,O
rate,O
induced,O
by,O
ISO,I-Entity
infusion,O
.,O
In,O
contrast,O
to,O
nifedipine,I-Entity
",",O
CD-832,I-Entity
(,O
10,O
micrograms,O
/,O
<,O
.01,O
),O
at,O
3,O
min,O
after,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
.,O
Diltiazem,I-Entity
(,O
30,O
micrograms,O
/,O
kg,O
/,O
min,O
),O
also,O
prevented,O
the,O
decrease,O
in,O
percentage,O
segmental,O
shortening,O
from,O
34,O
+,O
/-,O
.01,O
),O
at,O
3,O
min,O
after,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
.,O
These,O
data,O
show,O
that,O
CD-832,I-Entity
improves,O
myocardial,B-Entity
ischemia,I-Entity
during,O
ISO,I-Entity
infusion,O
with,O
stenosis,I-Entity
and,O
suggest,O
that,O
the,O
negative,O
chronotropic,O
property,O
of,O
CD-832,I-Entity
plays,O
a,O
major,O
role,O
in,O
the,O
beneficial,O
effects,O
of,O
CD-832,I-Entity
.,O
The,O
effect,O
of,O
recombinant,O
human,O
insulin,O
-,O
like,O
growth,O
factor,O
-,O
I,O
on,O
chronic,O
puromycin,B-Entity
aminonucleoside,I-Entity
nephropathy,I-Entity
in,O
rats,O
.,O
We,O
recently,O
demonstrated,O
that,O
recombinant,O
hGH,O
exacerbates,O
renal,O
functional,O
and,O
structural,O
injury,O
in,O
chronic,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
nephropathy,I-Entity
",",O
an,O
experimental,O
model,O
of,O
glomerular,B-Entity
disease,I-Entity
.,O
IGF,O
-,O
I,O
is,O
a,O
safer,O
alternative,O
for,O
the,O
treatment,O
of,O
growth,B-Entity
failure,I-Entity
in,O
rats,O
with,O
chronic,O
PAN,I-Entity
nephropathy,I-Entity
.,O
The,O
glomerulopathy,I-Entity
was,O
induced,O
by,O
seven,O
serial,O
injections,O
of,O
PAN,I-Entity
over,O
12,O
wk,O
.,O
rhIGF,O
-,O
I,O
improved,O
weight,O
gain,O
by,O
14%,O
(,O
p,O
<,O
0.05,O
),O
",",O
without,O
altering,O
hematocrit,O
or,O
blood,O
pressure,O
in,O
rats,O
with,O
renal,B-Entity
disease,I-Entity
.,O
I,O
treatment,O
in,O
rats,O
with,O
chronic,O
PAN,I-Entity
nephropathy,I-Entity
.,O
0.06,O
mL,O
/,O
min/100,O
g,O
of,O
body,O
weight,O
in,O
untreated,O
PAN,I-Entity
nephropathy,I-Entity
animals,O
",",O
p,O
The,O
improvement,O
in,O
GFR,O
was,O
not,O
associated,O
with,O
enhanced,O
glomerular,B-Entity
hypertrophy,I-Entity
or,O
increased,O
segmental,O
glomerulosclerosis,I-Entity
",",O
tubulointerstitial,B-Entity
injury,I-Entity
",",O
or,O
renal,O
cortical,O
malondialdehyde,I-Entity
content,O
.,O
In,O
rats,O
with,O
PAN,I-Entity
nephropathy,I-Entity
",",O
administration,O
of,O
rhIGF,O
-,O
I,O
increased,O
IGF,O
-,O
I,O
and,O
GH,O
receptor,O
gene,O
expression,O
",",O
without,O
altering,O
the,O
steady,O
state,O
level,O
of,O
IGF,O
-,O
I,O
receptor,O
mRNA,O
.,O
In,O
normal,O
rats,O
with,O
intact,O
kidneys,O
",",O
rhIGF,O
-,O
I,O
administration,O
(,O
n,O
=,O
4,O
),O
did,O
not,O
alter,O
weight,O
gain,O
",",O
blood,O
pressure,O
",",O
proteinuria,I-Entity
",",O
GFR,O
",",O
glomerular,O
planar,O
area,O
",",O
renal,O
cortical,O
malondialdehyde,I-Entity
content,O
",",O
or,O
glomerular,O
or,O
tubulointerstitial,B-Entity
damage,I-Entity
",",O
compared,O
with,O
untreated,O
animals,O
(,O
n,O
=,O
4,O
),O
.,O
We,O
conclude,O
that,O
:,O
1,O
),O
administration,O
of,O
rhIGF,O
-,O
I,O
improves,O
growth,O
and,O
GFR,O
in,O
rats,O
with,O
chronic,O
PAN,I-Entity
nephropathy,I-Entity
and,O
2,O
),O
unlike,O
rhGH,O
",",O
long,O
-,O
term,O
use,O
of,O
rhIGF,O
-,O
I,O
does,O
not,O
worsen,O
renal,O
functional,O
and,O
structural,O
injury,O
in,O
this,O
disease,O
model,O
.,O
Nefiracetam,I-Entity
(,O
DM-9384,I-Entity
),O
reverses,O
apomorphine,I-Entity
-,O
induced,O
amnesia,I-Entity
of,O
a,O
passive,O
avoidance,O
response,O
:,O
Nefiracetam,I-Entity
is,O
a,O
novel,O
pyrrolidone,I-Entity
derivative,O
which,O
attenuates,O
scopolamine,I-Entity
-,O
induced,O
learning,B-Entity
and,I-Entity
post,I-Entity
-,I-Entity
training,I-Entity
consolidation,I-Entity
deficits,I-Entity
.,O
Given,O
that,O
apomorphine,I-Entity
inhibits,O
passive,O
avoidance,O
retention,O
when,O
given,O
during,O
training,O
or,O
in,O
a,O
defined,O
10,O
-,O
12h,O
post,O
-,O
training,O
period,O
",",O
we,O
evaluated,O
the,O
ability,O
of,O
nefiracetam,I-Entity
to,O
attenuate,O
amnesia,I-Entity
induced,O
by,O
dopaminergic,O
agonism,O
.,O
A,O
step,O
-,O
down,O
passive,O
avoidance,O
paradigm,O
was,O
employed,O
and,O
nefiracetam,I-Entity
(,O
3,O
mg,O
/,O
kg,O
),O
and,O
apomorphine,I-Entity
(,O
0.5,O
mg,O
/,O
kg,O
),O
were,O
given,O
alone,O
or,O
in,O
combination,O
during,O
training,O
and,O
at,O
the,O
10,O
-,O
12h,O
post,O
-,O
training,O
period,O
of,O
consolidation,O
.,O
Co,O
-,O
administration,O
of,O
nefiracetam,I-Entity
and,O
apomorphine,I-Entity
during,O
training,O
or,O
10h,O
thereafter,O
produced,O
no,O
significant,O
anti,O
-,O
amnesic,O
effect,O
.,O
However,O
",",O
administration,O
of,O
nefiracetam,I-Entity
during,O
training,O
completely,O
reversed,O
the,O
amnesia,I-Entity
induced,O
by,O
apomorphine,I-Entity
at,O
the,O
10h,O
post,O
-,O
training,O
time,O
and,O
the,O
converse,O
was,O
also,O
true,O
.,O
These,O
effects,O
were,O
not,O
mediated,O
by,O
a,O
dopaminergic,O
mechanism,O
as,O
nefiracetam,I-Entity
",",O
at,O
millimolar,O
concentrations,O
",",O
failed,O
to,O
displace,O
either,O
[,O
3H]SCH,B-Entity
23390,I-Entity
or,O
[,O
3H]spiperone,I-Entity
binding,O
from,O
D1,O
or,O
D2,O
dopamine,I-Entity
receptor,O
subtypes,O
",",O
respectively,O
.,O
It,O
is,O
suggested,O
that,O
nefiracetam,I-Entity
augments,O
molecular,O
processes,O
in,O
the,O
early,O
stages,O
of,O
events,O
which,O
ultimately,O
lead,O
to,O
consolidation,O
of,O
memory,O
.,O
Human,O
corticotropin,I-Entity
-,O
releasing,O
hormone,O
and,O
thyrotropin,I-Entity
-,O
releasing,O
hormone,O
modulate,O
the,O
hypercapnic,I-Entity
ventilatory,O
response,O
in,O
humans,O
.,O
Human,O
corticotropin,I-Entity
-,O
releasing,O
hormone,O
(,O
hCRH,O
),O
and,O
thyrotropin,I-Entity
-,O
releasing,O
hormone,O
(,O
TRH,O
),O
are,O
known,O
to,O
stimulate,O
ventilation,O
after,O
i.v,O
.,O
Two,O
subsequent,O
CO2-rebreathing,I-Entity
tests,O
were,O
performed,O
in,O
healthy,O
young,O
volunteers,O
.,O
During,O
the,O
first,O
test,O
0.9%,O
NaCl,I-Entity
was,O
given,O
i.v,O
.,O
Nine,O
subjects,O
received,O
0.9%,O
NaCl,I-Entity
i.v,O
.,O
The,O
CO2-response,I-Entity
curves,O
for,O
the,O
two,O
tests,O
were,O
compared,O
within,O
the,O
same,O
subject,O
.,O
In,O
the,O
hCRH,O
group,O
a,O
marked,O
parallel,O
shift,O
of,O
the,O
CO2-response,I-Entity
curve,O
to,O
the,O
left,O
was,O
observed,O
after,O
hCRH,O
(,O
P,O
<,O
0.01,O
),O
.,O
hCRH,O
and,O
TRH,O
caused,O
a,O
reduction,O
in,O
the,O
CO2,I-Entity
threshold,O
.,O
The,O
CO2-response,I-Entity
curves,O
in,O
the,O
control,O
group,O
were,O
nearly,O
identical,O
.,O
The,O
results,O
indicate,O
an,O
additive,O
effect,O
of,O
both,O
releasing,O
hormones,O
on,O
the,O
hypercapnic,I-Entity
ventilatory,O
response,O
in,O
humans,O
",",O
presumably,O
independent,O
of,O
central,O
chemosensitivity,O
.,O
Lamivudine,I-Entity
is,O
effective,O
in,O
suppressing,O
hepatitis,B-Entity
B,I-Entity
virus,O
DNA,O
in,O
Chinese,O
hepatitis,B-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
carriers,O
:,O
a,O
placebo,O
-,O
controlled,O
trial,O
.,O
Lamivudine,I-Entity
is,O
a,O
novel,O
"2',3'-dideoxy",B-Entity
cytosine,I-Entity
analogue,O
that,O
has,O
potent,O
inhibitory,O
effects,O
on,O
hepatitis,B-Entity
B,I-Entity
virus,O
replication,O
in,O
vitro,O
and,O
in,O
vivo,O
.,O
We,O
performed,O
a,O
single,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
study,O
to,O
assess,O
its,O
effectiveness,O
and,O
safety,O
in,O
Chinese,O
hepatitis,B-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
(,O
HBsAg,I-Entity
),O
carriers,O
.,O
Forty,O
-,O
two,O
Chinese,O
HBsAg,I-Entity
carriers,O
were,O
randomized,O
to,O
receive,O
placebo,O
(,O
6,O
patients,O
),O
or,O
lamivudine,I-Entity
orally,O
in,O
dosages,O
of,O
25,O
mg,O
",",O
100,O
mg,O
",",O
or,O
300,O
mg,O
daily,O
(,O
12,O
patients,O
for,O
each,O
dosage,O
),O
.,O
All,O
36,O
patients,O
receiving,O
lamivudine,I-Entity
had,O
a,O
decrease,O
in,O
hepatitis,B-Entity
B,I-Entity
virus,O
(,O
HBV,O
),O
DNA,O
values,O
of,O
>,O
90%,O
(,O
P,O
<,O
.001,O
compared,O
with,O
placebo,O
),O
.,O
Although,O
25,O
mg,O
of,O
lamivudine,I-Entity
was,O
slightly,O
less,O
effective,O
than,O
100,O
mg,O
(,O
P,O
=,O
.011,O
),O
and,O
300,O
mg,O
(,O
P,O
=,O
.005,O
),O
",",O
it,O
still,O
induced,O
94%,O
suppression,O
of,O
HBV,O
DNA,O
after,O
the,O
fourth,O
week,O
of,O
therapy,O
.,O
There,O
was,O
no,O
change,O
in,O
the,O
hepatitis,B-Entity
B,I-Entity
e,O
antigen,O
status,O
or,O
in,O
aminotransferase,O
levels,O
.,O
In,O
conclusion,O
",",O
a,O
4-week,O
course,O
of,O
lamivudine,I-Entity
was,O
safe,O
and,O
effective,O
in,O
suppression,O
of,O
HBV,O
DNA,O
in,O
Chinese,O
HBsAg,I-Entity
carriers,O
.,O
Studies,O
with,O
long,O
-,O
term,O
lamivudine,I-Entity
administration,O
should,O
be,O
performed,O
to,O
determine,O
if,O
prolonged,O
suppression,O
of,O
HBV,O
DNA,O
can,O
be,O
achieved,O
.,O
Population,O
-,O
based,O
study,O
of,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
associated,O
with,O
various,O
oral,B-Entity
contraceptives,I-Entity
.,O
BACKGROUND,O
:,O
Four,O
studies,O
published,O
since,O
December,O
",",O
1995,O
",",O
reported,O
that,O
the,O
incidence,O
of,O
venous,B-Entity
thromboembolism,I-Entity
(,O
VTE,I-Entity
),O
was,O
higher,O
in,O
women,O
who,O
used,O
oral,B-Entity
contraceptives,I-Entity
(,O
OCs,I-Entity
),O
containing,O
the,O
third,O
-,O
generation,O
progestagens,I-Entity
gestodene,I-Entity
or,O
desogestrel,I-Entity
than,O
in,O
users,O
of,O
OCs,I-Entity
containing,O
second,O
-,O
generation,O
progestagens,I-Entity
.,O
The,O
aim,O
of,O
our,O
study,O
was,O
to,O
re,O
-,O
examine,O
the,O
association,O
between,O
risk,O
of,O
VTE,I-Entity
and,O
OC,I-Entity
use,O
with,O
a,O
different,O
study,O
design,O
and,O
analysis,O
to,O
avoid,O
some,O
of,O
the,O
bias,O
and,O
confounding,O
of,O
the,O
earlier,O
studies,O
.,O
All,O
women,O
who,O
had,O
a,O
recorded,O
diagnosis,O
of,O
deep,B-Entity
-,I-Entity
vein,I-Entity
thrombosis,I-Entity
",",O
venous,B-Entity
thrombosis,I-Entity
not,O
otherwise,O
specified,O
",",O
or,O
pulmonary,O
embolus,O
during,O
the,O
study,O
period,O
",",O
and,O
who,O
had,O
been,O
treated,O
with,O
an,O
anticoagulant,O
were,O
identified,O
as,O
potential,O
cases,O
of,O
VTE,I-Entity
.,O
We,O
did,O
a,O
cohort,O
analysis,O
to,O
estimate,O
and,O
compare,O
incidence,O
of,O
VTE,I-Entity
in,O
users,O
of,O
the,O
main,O
OC,I-Entity
preparations,O
",",O
and,O
a,O
nested,O
case,O
-,O
control,O
study,O
to,O
calculate,O
the,O
odds,O
ratios,O
of,O
VTE,I-Entity
associated,O
with,O
use,O
of,O
different,O
types,O
of,O
OC,I-Entity
",",O
after,O
adjustment,O
for,O
potential,O
confounding,O
factors,O
.,O
In,O
the,O
case,O
-,O
control,O
study,O
",",O
we,O
matched,O
cases,O
to,O
controls,O
by,O
exact,O
year,O
of,O
birth,O
",",O
practice,O
",",O
and,O
current,O
use,O
of,O
OCs,I-Entity
.,O
We,O
used,O
a,O
multiple,O
logistic,O
regression,O
model,O
that,O
included,O
body,O
-,O
mass,O
index,O
",",O
number,O
of,O
cycles,O
",",O
change,O
in,O
type,O
of,O
OC,I-Entity
prescribed,O
within,O
3,O
months,O
of,O
the,O
event,O
",",O
previous,O
pregnancy,O
",",O
and,O
concurrent,O
disease,O
.,O
FINDINGS,O
:,O
85,O
women,O
met,O
the,O
inclusion,O
criteria,O
for,O
VTE,I-Entity
",",O
two,O
of,O
whom,O
were,O
users,O
of,O
progestagen,I-Entity
-,O
only,O
OCs,I-Entity
.,O
Of,O
the,O
83,O
cases,O
of,O
VTE,I-Entity
associated,O
with,O
use,O
of,O
combined,O
OCs,I-Entity
",",O
43,O
were,O
recorded,O
as,O
deep,B-Entity
-,I-Entity
vein,I-Entity
thrombosis,I-Entity
",",O
35,O
as,O
pulmonary,O
thrombosis,I-Entity
",",O
and,O
five,O
as,O
venous,B-Entity
thrombosis,I-Entity
not,O
otherwise,O
specified,O
.,O
The,O
crude,O
rate,O
of,O
VTE,I-Entity
per,O
"10,000",O
woman,O
-,O
years,O
was,O
4.10,O
in,O
current,O
users,O
of,O
any,O
OC,I-Entity
",",O
3.10,O
in,O
users,O
of,O
second,O
-,O
generation,O
OCs,I-Entity
",",O
and,O
4.96,O
in,O
users,O
of,O
third,O
-,O
generation,O
preparations,O
.,O
After,O
adjustment,O
for,O
age,O
",",O
the,O
rate,O
ratio,O
of,O
VTE,I-Entity
in,O
users,O
of,O
third,O
-,O
generation,O
relative,O
to,O
second,O
-,O
generation,O
OCs,I-Entity
was,O
1.68,O
(,O
95%,O
CI,O
1.04,O
-,O
2.75,O
),O
.,O
Logistic,O
regression,O
showed,O
no,O
significant,O
difference,O
in,O
the,O
risk,O
of,O
VTE,I-Entity
between,O
users,O
of,O
third,O
-,O
generation,O
and,O
second,O
-,O
generation,O
OCs,I-Entity
.,O
Among,O
users,O
of,O
third,O
-,O
generation,O
progestagens,I-Entity
",",O
the,O
risk,O
of,O
VTE,I-Entity
was,O
higher,O
in,O
users,O
of,O
desogestrel,I-Entity
with,O
20,O
g,O
ethinyloestradiol,I-Entity
than,O
in,O
users,O
of,O
gestodene,I-Entity
or,O
desogestrel,I-Entity
with,O
30,O
g,O
ethinyloestradiol,I-Entity
.,O
With,O
all,O
second,O
-,O
generation,O
OCs,I-Entity
as,O
the,O
reference,O
",",O
the,O
odds,O
ratios,O
for,O
VTE,I-Entity
were,O
3.49,O
(,O
1.21,O
-,O
10.12,O
),O
for,O
desogestrel,I-Entity
plus,O
20,O
g,O
ethinyloestradiol,I-Entity
and,O
1.18,O
(,O
0.66,O
-,O
2.17,O
),O
for,O
the,O
other,O
third,O
-,O
generation,O
progestagens,I-Entity
.,O
The,O
previously,O
reported,O
increase,O
in,O
odds,O
ratio,O
associated,O
with,O
third,O
-,O
generation,O
OCs,I-Entity
when,O
compared,O
with,O
second,O
-,O
generation,O
products,O
is,O
likely,O
to,O
have,O
been,O
the,O
result,O
of,O
residual,O
confounding,O
by,O
age,O
.,O
The,O
increased,O
odds,O
ratio,O
associated,O
with,O
products,O
containing,O
20,O
micrograms,O
ethinyloestradiol,I-Entity
and,O
desogestrel,I-Entity
compared,O
with,O
the,O
30,O
micrograms,O
product,O
is,O
biologically,O
implausible,O
",",O
and,O
is,O
likely,O
to,O
be,O
the,O
result,O
of,O
preferential,O
prescribing,O
and,O
",",O
thus,O
",",O
confounding,O
.,O
MK-801,I-Entity
augments,O
pilocarpine,I-Entity
-,O
induced,O
electrographic,O
seizure,I-Entity
but,O
protects,O
against,O
brain,B-Entity
damage,I-Entity
in,O
rats,O
The,O
authors,O
examined,O
the,O
anticonvulsant,O
effects,O
of,O
MK-801,I-Entity
on,O
the,O
pilocarpine,I-Entity
-,O
induced,O
seizure,I-Entity
model,O
.,O
Intraperitoneal,O
injection,O
of,O
pilocarpine,I-Entity
(,O
400,O
mg,O
/,O
kg,O
),O
induced,O
tonic,B-Entity
and,I-Entity
clonic,I-Entity
seizure,I-Entity
.,O
Scopolamine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
and,O
pentobarbital,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
prevented,O
development,O
of,O
pilocarpine,I-Entity
-,O
induced,O
behavioral,O
seizure,I-Entity
but,O
MK-801,I-Entity
(,O
0.5,O
mg,O
/,O
kg,O
),O
did,O
not,O
.,O
An,O
electrical,O
seizure,I-Entity
measured,O
with,O
hippocampal,O
EEG,O
appeared,O
in,O
the,O
pilocarpine,I-Entity
-,O
treated,O
group,O
.,O
Scopolamine,I-Entity
and,O
pentobarbital,I-Entity
blocked,O
the,O
pilocarpine,I-Entity
-,O
induced,O
electrographic,O
seizure,I-Entity
",",O
MK-801,I-Entity
treatment,O
augmented,O
the,O
electrographic,O
seizure,I-Entity
induced,O
by,O
pilocarpine,I-Entity
.,O
Brain,B-Entity
damage,I-Entity
was,O
assessed,O
by,O
examining,O
the,O
hippocampus,O
microscopically,O
.,O
Pilocarpine,I-Entity
produced,O
neuronal,B-Entity
death,I-Entity
in,O
the,O
hippocampus,O
",",O
which,O
showed,O
pyknotic,O
changes,O
.,O
Pentobarbital,I-Entity
",",O
scopolamine,I-Entity
and,O
MK-801,I-Entity
protected,O
the,O
brain,B-Entity
damage,I-Entity
by,O
pilocarpine,I-Entity
",",O
though,O
in,O
the,O
MK-801-treated,I-Entity
group,O
",",O
the,O
pyramidal,O
cells,O
of,O
hippocampus,O
appeared,O
darker,O
than,O
normal,O
.,O
These,O
results,O
indicate,O
that,O
status,B-Entity
epilepticus,I-Entity
induced,O
by,O
pilocarpine,I-Entity
is,O
initiated,O
by,O
cholinergic,O
overstimulation,O
and,O
propagated,O
by,O
glutamatergic,O
transmission,O
",",O
the,O
elevation,O
of,O
which,O
may,O
cause,O
brain,B-Entity
damage,I-Entity
through,O
an,O
excitatory,O
NMDA,I-Entity
receptor,O
-,O
mediated,O
mechanism,O
.,O
Paclitaxel,I-Entity
",",O
5-fluorouracil,I-Entity
",",O
and,O
folinic,B-Entity
acid,I-Entity
in,O
metastatic,O
breast,B-Entity
cancer,I-Entity
:,O
5-Fluorouracil,I-Entity
plus,O
folinic,B-Entity
acid,I-Entity
and,O
paclitaxel,I-Entity
(,O
Taxol,I-Entity
;,O
Bristol,O
-,O
Myers,O
Squibb,O
Company,O
",",O
Princeton,O
",",O
NJ,O
),O
are,O
effective,O
salvage,O
therapies,O
for,O
metastatic,O
breast,B-Entity
cancer,I-Entity
patients,O
.,O
Paclitaxel,I-Entity
and,O
5-fluorouracil,I-Entity
have,O
additive,O
cytotoxicity,I-Entity
in,O
MCF-7,O
cell,O
lines,O
.,O
We,O
performed,O
a,O
phase,O
II,O
trial,O
of,O
paclitaxel,I-Entity
175,O
mg,O
/,O
m2,O
over,O
3,O
hours,O
on,O
day,O
I,O
followed,O
by,O
folinic,B-Entity
acid,I-Entity
300,O
mg,O
over,O
1,O
hour,O
before,O
5-fluorouracil,I-Entity
350,O
mg,O
/,O
m2,O
on,O
days,O
1,O
to,O
3,O
every,O
28,O
days,O
(,O
TFL,O
),O
in,O
women,O
with,O
metastatic,O
breast,B-Entity
cancer,I-Entity
.,O
Analysis,O
is,O
reported,O
on,O
37,O
patients,O
with,O
a,O
minimum,O
of,O
6,O
months,O
follow,O
-,O
up,O
who,O
received,O
a,O
total,O
of,O
192,O
cycles,O
of,O
TFL,O
:,O
nine,O
cycles,O
(,O
5%,O
),O
were,O
associated,O
with,O
grade,O
3/4,O
neutropenia,I-Entity
requiring,O
hospitalization,O
;,O
seven,O
(,O
4%,O
),O
cycles,O
in,O
two,O
patients,O
required,O
granulocyte,B-Entity
colony,I-Entity
-,I-Entity
stimulating,I-Entity
factor,I-Entity
due,O
to,O
neutropenia,I-Entity
;,O
no,O
patient,O
required,O
platelet,O
transfusions,O
.,O
Grade,O
3/4,O
nonhematologic,O
toxicities,I-Entity
were,O
uncommon,O
.,O
Of,O
the,O
19,O
evaluable,O
patients,O
with,O
prior,O
doxorubicin,I-Entity
exposure,O
",",O
11,O
(,O
58%,O
),O
responded,O
compared,O
with,O
nine,O
of,O
15,O
(,O
60%,O
),O
without,O
prior,O
doxorubicin,I-Entity
.,O
Plasma,O
paclitaxel,I-Entity
concentrations,O
were,O
measured,O
at,O
the,O
completion,O
of,O
paclitaxel,I-Entity
infusion,O
and,O
at,O
24,O
hours,O
in,O
19,O
patients,O
.,O
TFL,O
is,O
an,O
active,O
",",O
well,O
-,O
tolerated,O
regimen,O
in,O
metastatic,O
breast,B-Entity
cancer,I-Entity
.,O
Efficacy,O
and,O
proarrhythmia,I-Entity
with,O
the,O
use,O
of,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
for,O
sustained,O
ventricular,B-Entity
tachyarrhythmias,I-Entity
.,O
This,O
study,O
prospectively,O
evaluated,O
the,O
clinical,O
efficacy,O
",",O
the,O
incidence,O
of,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
",",O
and,O
the,O
presumable,O
risk,O
factors,O
for,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
in,O
patients,O
treated,O
with,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
for,O
sustained,O
ventricular,B-Entity
tachyarrhythmias,I-Entity
.,O
Eighty,O
-,O
one,O
consecutive,O
patients,O
(,O
54,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
and,O
20,O
with,O
dilated,B-Entity
cardiomyopathy,I-Entity
),O
with,O
inducible,O
sustained,O
ventricular,B-Entity
tachycardia,I-Entity
or,O
ventricular,B-Entity
fibrillation,I-Entity
received,O
oral,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
to,O
prevent,O
induction,O
of,O
the,O
ventricular,B-Entity
tachyarrhythmia,I-Entity
.,O
During,O
oral,O
loading,O
with,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
",",O
continuous,O
electrocardiographic,O
(,O
ECG,O
),O
monitoring,O
was,O
performed,O
.,O
Those,O
patients,O
in,O
whom,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
prevented,O
induction,O
of,O
ventricular,B-Entity
tachycardia,I-Entity
or,O
ventricular,B-Entity
fibrillation,I-Entity
were,O
discharged,O
with,O
the,O
drug,O
and,O
followed,O
up,O
on,O
an,O
outpatient,O
basis,O
for,O
21,O
+,O
/-,O
Induction,O
of,O
the,O
ventricular,B-Entity
tachyarrhythmia,I-Entity
was,O
prevented,O
by,O
oral,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
in,O
35,O
(,O
43%,O
),O
patients,O
;,O
the,O
ventricular,B-Entity
tachyarrhythmia,I-Entity
remained,O
inducible,O
in,O
40,O
(,O
49%,O
),O
patients,O
;,O
and,O
two,O
(,O
2.5%,O
),O
patients,O
did,O
not,O
tolerate,O
even,O
40,O
mg,O
of,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
once,O
daily,O
.,O
Four,O
(,O
5%,O
),O
patients,O
had,O
from,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
during,O
the,O
initial,O
oral,O
treatment,O
with,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
.,O
Neither,O
ECG,O
[,O
sinus,O
-,O
cycle,O
length,O
(,O
SCL,O
),O
",",O
QT,O
or,O
QTc,O
interval,O
",",O
or,O
U,O
wave,O
],O
nor,O
clinical,O
parameters,O
identified,O
patients,O
at,O
risk,O
for,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
.,O
However,O
",",O
the,O
oral,O
dose,O
of,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
was,O
significantly,O
lower,O
in,O
patients,O
with,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
(,O
200,O
+,O
/-,O
Risk,O
factors,O
associated,O
with,O
the,O
development,O
of,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
were,O
the,O
appearance,O
of,O
an,O
U,O
wave,O
(,O
p,O
=,O
0.049,O
),O
",",O
female,O
gender,O
(,O
p,O
=,O
0.015,O
),O
",",O
and,O
significant,O
dose,O
-,O
corrected,O
changes,O
of,O
SCL,O
",",O
QT,O
interval,O
",",O
and,O
QTc,O
interval,O
(,O
During,O
follow,O
-,O
up,O
",",O
seven,O
(,O
20%,O
),O
patients,O
had,O
a,O
nonfatal,O
ventricular,B-Entity
tachycardia,I-Entity
recurrence,O
",",O
and,O
two,O
(,O
6%,O
),O
One,O
female,O
patient,O
with,O
stable,O
cardiac,B-Entity
disease,I-Entity
had,O
recurrent,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
after,O
2,O
years,O
of,O
successful,O
treatment,O
with,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
.,O
Torsades,B-Entity
de,I-Entity
pointes,I-Entity
occurred,O
early,O
during,O
treatment,O
even,O
with,O
low,O
doses,O
of,O
oral,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
.,O
Pronounced,O
changes,O
in,O
the,O
surface,O
ECG,O
(,O
cycle,O
length,O
",",O
QT,O
",",O
and,O
QTc,O
),O
in,O
relation,O
to,O
the,O
dose,O
of,O
oral,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
might,O
identify,O
a,O
subgroup,O
of,O
patients,O
with,O
an,O
increased,O
risk,O
for,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
.,O
Other,O
ECG,O
parameters,O
before,O
the,O
application,O
of,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
did,O
not,O
identify,O
patients,O
at,O
increased,O
risk,O
for,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
.,O
Recurrence,O
rates,O
of,O
ventricular,B-Entity
tachyarrhythmias,I-Entity
are,O
high,O
despite,O
complete,O
suppression,O
of,O
the,O
arrhythmia,I-Entity
during,O
programmed,O
stimulation,O
.,O
Therefore,O
programmed,O
electrical,O
stimulation,O
in,O
the,O
case,O
of,O
d,B-Entity
",",I-Entity
l,I-Entity
-,I-Entity
sotalol,I-Entity
seems,O
to,O
be,O
of,O
limited,O
prognostic,O
value,O
.,O
Chronic,O
hyperprolactinemia,I-Entity
and,O
changes,O
in,O
dopamine,I-Entity
neurons,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
induce,O
hyperprolactinemia,I-Entity
in,O
rats,O
for,O
extended,O
periods,O
of,O
time,O
and,O
examine,O
its,O
effects,O
on,O
dopaminergic,O
systems,O
in,O
the,O
brain,O
.,O
Hyperprolactinemia,I-Entity
was,O
induced,O
by,O
treatment,O
with,O
haloperidol,I-Entity
",",O
a,O
dopamine,I-Entity
receptor,O
antagonist,O
",",O
and,O
Palkovits,O
',O
microdissection,O
technique,O
in,O
combination,O
with,O
high,O
-,O
performance,O
liquid,O
chromatography,O
was,O
used,O
to,O
measure,O
neurotransmitter,O
concentrations,O
in,O
several,O
areas,O
of,O
the,O
brain,O
.,O
After,O
6,O
months,O
of,O
hyperprolactinemia,I-Entity
",",O
dopamine,I-Entity
(,O
DA,I-Entity
),O
concentrations,O
in,O
the,O
median,O
eminence,O
(,O
ME,O
),O
increased,O
by,O
84%,O
over,O
the,O
control,O
group,O
.,O
Nine,O
months,O
of,O
hyperprolactinemia,I-Entity
produced,O
a,O
50%,O
increase,O
in,O
DA,I-Entity
concentrations,O
in,O
the,O
ME,O
over,O
the,O
control,O
group,O
.,O
However,O
",",O
DA,I-Entity
response,O
was,O
lost,O
if,O
a,O
9-month,O
long,O
haloperidol,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
was,O
followed,O
by,O
a,O
1,O
1/2,O
month,O
-,O
long,O
extremely,O
high,O
increase,O
in,O
serum,O
PRL,O
levels,O
produced,O
by,O
implantation,O
of,O
MMQ,O
cells,O
under,O
the,O
kidney,O
capsule,O
.,O
There,O
was,O
no,O
change,O
in,O
the,O
levels,O
of,O
DA,I-Entity
",",O
norepinephrine,I-Entity
(,O
NE,I-Entity
),O
",",O
serotonin,I-Entity
(,O
5-HT,I-Entity
),O
",",O
or,O
their,O
metabolites,O
in,O
the,O
arcuate,O
nucleus,O
(,O
AN,O
),O
",",O
medial,O
preoptic,O
area,O
(,O
MPA,O
),O
",",O
caudate,O
putamen,O
(,O
CP,O
),O
",",O
substantia,O
nigra,O
(,O
SN,O
),O
",",O
and,O
zona,O
incerta,O
(,O
ZI,O
),O
",",O
except,O
for,O
a,O
decrease,O
in,O
5-hydroxyindoleacetic,B-Entity
acid,I-Entity
(,O
5-HIAA,I-Entity
),O
in,O
the,O
AN,O
after,O
6-months,O
of,O
hyperprolactinemia,I-Entity
and,O
an,O
increase,O
in,O
DA,I-Entity
concentrations,O
in,O
the,O
AN,O
after,O
9-months,O
of,O
hyperprolactinemia,I-Entity
.,O
These,O
results,O
demonstrate,O
that,O
hyperprolactinemia,I-Entity
specifically,O
affects,O
TIDA,O
neurons,O
and,O
these,O
effects,O
vary,O
",",O
depending,O
on,O
the,O
duration,O
and,O
intensity,O
of,O
hyperprolactinemia,I-Entity
.,O
The,O
age,O
-,O
related,O
decrease,O
in,O
hypothalamic,O
dopamine,I-Entity
function,O
may,O
be,O
associated,O
with,O
increases,O
in,O
PRL,O
secretion,O
.,O
Treatment,O
-,O
related,O
disseminated,O
necrotizing,O
leukoencephalopathy,I-Entity
with,O
characteristic,O
contrast,O
enhancement,O
of,O
the,O
white,O
matter,O
.,O
This,O
report,O
describes,O
unique,O
contrast,O
enhancement,O
of,O
the,O
white,O
matter,O
on,O
T1-weighted,O
magnetic,O
resonance,O
images,O
of,O
two,O
patients,O
with,O
disseminated,O
necrotizing,O
leukoencephalopathy,I-Entity
",",O
which,O
developed,O
from,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
treated,O
with,O
high,O
-,O
dose,O
methotrexate,I-Entity
.,O
Necropsy,O
of,O
the,O
first,O
case,O
revealed,O
loss,B-Entity
of,I-Entity
myelination,I-Entity
and,O
necrosis,I-Entity
of,O
the,O
white,O
matter,O
.,O
Possible,O
mechanisms,O
causing,O
such,O
a,O
leukoencephalopathy,I-Entity
are,O
discussed,O
.,O
Thrombotic,I-Entity
complications,O
in,O
acute,B-Entity
promyelocytic,I-Entity
leukemia,I-Entity
during,O
all,B-Entity
-,I-Entity
trans,I-Entity
-,I-Entity
retinoic,I-Entity
acid,I-Entity
therapy,O
.,O
A,O
case,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
",",O
due,O
to,O
occlusion,B-Entity
of,I-Entity
renal,I-Entity
vessels,I-Entity
in,O
a,O
patient,O
with,O
acute,B-Entity
promyelocytic,I-Entity
leukemia,I-Entity
(,O
APL,I-Entity
),O
treated,O
with,O
all,B-Entity
-,I-Entity
trans,I-Entity
-,I-Entity
retinoic,I-Entity
acid,I-Entity
(,O
ATRA,I-Entity
),O
and,O
tranexamic,B-Entity
acid,I-Entity
has,O
been,O
described,O
recently,O
.,O
We,O
report,O
a,O
case,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
in,O
an,O
APL,I-Entity
patient,O
treated,O
with,O
ATRA,I-Entity
alone,O
.,O
This,O
case,O
further,O
supports,O
the,O
concern,O
about,O
thromboembolic,I-Entity
complications,O
associated,O
with,O
ATRA,I-Entity
therapy,O
in,O
APL,I-Entity
patients,O
.,O
The,O
patients,O
",",O
a,O
43-year,O
-,O
old,O
man,O
",",O
presented,O
all,O
the,O
signs,O
and,O
symptoms,O
of,O
APL,I-Entity
and,O
was,O
included,O
in,O
a,O
treatment,O
protocol,O
with,O
ATRA,I-Entity
.,O
After,O
10,O
days,O
of,O
treatment,O
",",O
he,O
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
that,O
was,O
completely,O
reversible,O
after,O
complete,O
remission,O
of,O
APL,I-Entity
was,O
achieved,O
and,O
therapy,O
discontinued,O
.,O
We,O
conclude,O
that,O
ATRA,I-Entity
is,O
a,O
valid,O
therapeutic,O
choice,O
for,O
patients,O
with,O
APL,I-Entity
",",O
although,O
the,O
procoagulant,O
tendency,O
is,O
not,O
completely,O
corrected,O
.,O
Thrombotic,I-Entity
events,O
",",O
however,O
",",O
could,O
be,O
avoided,O
by,O
using,O
low,O
-,O
dose,O
heparin,I-Entity
.,O
Pupillary,O
changes,O
associated,O
with,O
the,O
development,O
of,O
stimulant,O
-,O
induced,O
mania,I-Entity
:,O
a,O
case,O
report,O
.,O
A,O
30-year,O
-,O
old,O
cocaine,I-Entity
-,O
dependent,O
man,O
who,O
was,O
a,O
subject,O
in,O
a,O
study,O
evaluating,O
the,O
anticraving,O
efficacy,O
of,O
the,O
stimulant,O
medication,O
diethylpropion,I-Entity
(,O
DEP,I-Entity
),O
became,O
manic,I-Entity
during,O
his,O
second,O
week,O
on,O
the,O
study,O
drug,O
.,O
Pupillometric,O
changes,O
while,O
on,O
DEP,I-Entity
",",O
especially,O
changes,O
in,O
the,O
total,O
power,O
of,O
pupillary,B-Entity
oscillation,I-Entity
",",O
were,O
dramatically,O
different,O
than,O
those,O
observed,O
in,O
the,O
eight,O
other,O
study,O
subjects,O
who,O
did,O
not,O
become,O
manic,I-Entity
.,O
The,O
large,O
changes,O
in,O
total,O
power,O
of,O
pupillary,B-Entity
oscillation,I-Entity
occurred,O
a,O
few,O
days,O
before,O
the,O
patient,O
became,O
fully,O
manic,I-Entity
.,O
Such,O
medication,O
-,O
associated,O
changes,O
in,O
the,O
total,O
power,O
of,O
pupillary,B-Entity
oscillation,I-Entity
might,O
be,O
of,O
utility,O
in,O
identifying,O
persons,O
at,O
risk,O
for,O
manic,I-Entity
-,O
like,O
adverse,O
effects,O
during,O
the,O
medical,O
use,O
of,O
psychomotor,O
stimulants,O
or,O
sympathomimetic,O
agents,O
.,O
OBJECTIVE,O
:,O
We,O
wanted,O
to,O
test,O
whether,O
assessment,O
of,O
both,O
a,O
central,O
pain,I-Entity
-,O
related,O
signal,O
(,O
chemo,O
-,O
somatosensory,O
evoked,O
potential,O
",",O
CSSEP,O
),O
and,O
a,O
concomitantly,O
recorded,O
peripheral,O
signal,O
(,O
negative,O
mucosal,O
potential,O
",",O
NMP,O
),O
allows,O
for,O
separation,O
of,O
central,O
and,O
peripheral,O
effects,O
of,O
NSAIDs,O
.,O
For,O
this,O
purpose,O
",",O
experimental,O
conditions,O
were,O
created,O
in,O
which,O
NSAIDs,O
had,O
previously,O
been,O
observed,O
to,O
produce,O
effects,O
on,O
phasic,O
and,O
tonic,O
pain,I-Entity
by,O
either,O
central,O
or,O
peripheral,O
mechanisms,O
.,O
According,O
to,O
a,O
double,O
-,O
blind,O
",",O
randomised,O
",",O
controlled,O
",",O
threefold,O
cross,O
-,O
over,O
design,O
",",O
18,O
healthy,O
subjects,O
(,O
11,O
males,O
",",O
7,O
females,O
;,O
mean,O
age,O
26,O
years,O
),O
received,O
either,O
placebo,O
",",O
400,O
mg,O
ibuprofen,I-Entity
",",O
or,O
800,O
mg,O
ibuprofen,I-Entity
.,O
Phasic,O
pain,I-Entity
was,O
applied,O
by,O
means,O
of,O
short,O
pulses,O
of,O
CO2,I-Entity
to,O
the,O
nasal,O
mucosa,O
(,O
stimulus,O
duration,O
500,O
ms,O
",",O
interval,O
approximately,O
60,O
s,O
),O
",",O
and,O
tonic,O
pain,I-Entity
was,O
induced,O
in,O
the,O
nasal,O
cavity,O
by,O
means,O
of,O
dry,O
air,O
of,O
controlled,O
temperature,O
",",O
humidity,O
and,O
flow,O
rate,O
(,O
22,O
degrees,O
C,O
",",O
0%,O
relative,O
humidity,O
",",O
145,O
ml.s-1,O
),O
.,O
Both,O
CSSEPs,O
as,O
central,O
and,O
NMPs,O
as,O
peripheral,O
correlates,O
of,O
pain,I-Entity
were,O
obtained,O
in,O
response,O
to,O
the,O
CO2,I-Entity
stimuli,O
.,O
Additionally,O
",",O
the,O
subjects,O
rated,O
the,O
intensity,O
of,O
both,O
phasic,O
and,O
tonic,O
pain,I-Entity
by,O
means,O
of,O
visual,O
analogue,O
scales,O
.,O
As,O
described,O
earlier,O
",",O
administration,O
of,O
ibuprofen,I-Entity
was,O
followed,O
by,O
a,O
decrease,O
in,O
tonic,O
pain,I-Entity
but,O
-,O
relative,O
to,O
placebo,O
-,O
an,O
increase,O
in,O
correlates,O
of,O
phasic,O
pain,I-Entity
",",O
indicating,O
a,O
specific,O
effect,O
of,O
ibuprofen,I-Entity
on,O
the,O
interaction,O
between,O
the,O
pain,I-Entity
stimuli,O
under,O
these,O
special,O
experimental,O
conditions,O
.,O
The,O
major,O
advantage,O
of,O
this,O
pain,I-Entity
model,O
is,O
the,O
possibility,O
of,O
obtaining,O
peripheral,O
pain,I-Entity
-,O
related,O
activity,O
directly,O
using,O
a,O
non,O
-,O
invasive,O
technique,O
in,O
humans,O
.,O
Acute,O
severe,O
depression,I-Entity
following,O
peri,O
-,O
operative,O
ondansetron,I-Entity
.,O
A,O
41-year,O
-,O
old,O
woman,O
with,O
a,O
strong,O
history,O
of,O
postoperative,B-Entity
nausea,I-Entity
and,I-Entity
vomiting,I-Entity
presented,O
for,O
abdominal,O
hysterectomy,O
3,O
months,O
after,O
a,O
previous,O
anaesthetic,O
where,O
ondansetron,I-Entity
prophylaxis,O
had,O
been,O
used,O
.,O
She,O
had,O
developed,O
a,O
severe,O
acute,O
major,B-Entity
depression,I-Entity
disorder,I-Entity
almost,O
immediately,O
thereafter,O
",",O
possibly,O
related,O
to,O
the,O
use,O
of,O
a,O
serotonin,I-Entity
antagonist,O
.,O
Nine,O
years,O
before,O
she,O
had,O
experienced,O
a,O
self,O
-,O
limited,O
puerperal,O
depressive,B-Entity
episode,I-Entity
.,O
Anaesthesia,O
with,O
a,O
propofol,I-Entity
infusion,O
and,O
avoidance,O
of,O
serotonin,I-Entity
antagonists,O
provided,O
a,O
nausea,I-Entity
-,O
free,O
postoperative,O
course,O
without,O
exacerbation,O
of,O
the,O
depression,B-Entity
disorder,I-Entity
.,O
Hypertensive,I-Entity
response,O
during,O
dobutamine,I-Entity
stress,O
echocardiography,O
.,O
Among,O
"3,129",O
dobutamine,I-Entity
stress,O
echocardiographic,O
studies,O
",",O
a,O
hypertensive,I-Entity
response,O
",",O
defined,O
as,O
systolic,O
blood,O
pressure,O
(,O
BP,O
),O
>,O
or,O
=,O
220,O
mm,O
Hg,O
and/or,O
diastolic,O
BP,O
>,O
or,O
=,O
110,O
mm,O
Hg,O
",",O
occurred,O
in,O
30,O
patients,O
(,O
1%,O
),O
.,O
Patients,O
with,O
this,O
response,O
more,O
often,O
had,O
a,O
history,O
of,O
hypertension,I-Entity
and,O
had,O
higher,O
resting,O
systolic,O
and,O
diastolic,O
BP,O
before,O
dobutamine,I-Entity
infusion,O
.,O
Continuously,O
nebulized,O
albuterol,I-Entity
in,O
severe,O
exacerbations,O
of,O
asthma,I-Entity
in,O
adults,O
:,O
a,O
case,O
-,O
controlled,O
study,O
.,O
A,O
retrospective,O
",",O
case,O
-,O
controlled,O
analysis,O
comparing,O
patients,O
admitted,O
to,O
a,O
medical,O
intensive,O
care,O
unit,O
with,O
severe,O
exacerbations,O
of,O
asthma,I-Entity
who,O
received,O
continuously,O
nebulized,O
albuterol,I-Entity
(,O
CNA,O
),O
versus,O
intermittent,O
albuterol,I-Entity
(,O
INA,O
),O
treatments,O
is,O
reported,O
.,O
Forty,O
matched,O
pairs,O
of,O
patients,O
with,O
asthma,I-Entity
are,O
compared,O
.,O
The,O
incidence,O
of,O
cardiac,B-Entity
dysrhythmias,I-Entity
was,O
similar,O
between,O
groups,O
.,O
Symptomatic,O
hypokalemia,I-Entity
did,O
not,O
occur,O
.,O
Hyperosmolar,B-Entity
nonketotic,I-Entity
coma,I-Entity
precipitated,O
by,O
lithium,I-Entity
-,O
induced,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
.,O
A,O
45-year,O
-,O
old,O
man,O
",",O
with,O
a,O
10-year,O
history,O
of,O
manic,B-Entity
depression,I-Entity
treated,O
with,O
lithium,I-Entity
",",O
was,O
admitted,O
with,O
hyperosmolar,B-Entity
",",I-Entity
nonketotic,I-Entity
coma,I-Entity
.,O
He,O
gave,O
a,O
five,O
-,O
year,O
history,O
of,O
polyuria,I-Entity
and,O
polydipsia,I-Entity
",",O
during,O
which,O
time,O
urinalysis,O
had,O
been,O
negative,O
for,O
glucose,I-Entity
.,O
After,O
recovery,O
from,O
hyperglycaemia,I-Entity
",",O
he,O
remained,O
polyuric,I-Entity
despite,O
normal,O
blood,O
glucose,I-Entity
concentrations,O
;,O
water,O
deprivation,O
testing,O
indicated,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
",",O
likely,O
to,O
be,O
lithium,I-Entity
-,O
induced,O
.,O
We,O
hypothesize,O
that,O
when,O
this,O
man,O
developed,O
type,B-Entity
2,I-Entity
diabetes,I-Entity
",",O
chronic,O
polyuria,I-Entity
due,O
to,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
was,O
sufficient,O
to,O
precipitate,O
hyperosmolar,O
dehydration,I-Entity
.,O
Effects,O
of,O
the,O
intracoronary,O
infusion,O
of,O
cocaine,I-Entity
on,O
left,O
ventricular,O
systolic,O
and,O
diastolic,O
function,O
in,O
humans,O
.,O
In,O
dogs,O
",",O
a,O
large,O
amount,O
of,O
intravenous,O
cocaine,I-Entity
causes,O
a,O
profound,O
deterioration,B-Entity
of,I-Entity
left,I-Entity
ventricular,I-Entity
(,I-Entity
LV,I-Entity
),I-Entity
systolic,I-Entity
function,I-Entity
and,O
an,O
increase,O
in,O
LV,O
end,O
-,O
diastolic,O
pressure,O
.,O
This,O
study,O
was,O
done,O
to,O
assess,O
the,O
influence,O
of,O
a,O
high,O
intracoronary,O
cocaine,I-Entity
concentration,O
on,O
LV,O
systolic,O
and,O
diastolic,O
function,O
in,O
humans,O
.,O
METHODS,O
AND,O
RESULTS,O
:,O
In,O
20,O
patients,O
(,O
14,O
men,O
and,O
6,O
women,O
aged,O
39,O
to,O
72,O
years,O
),O
referred,O
for,O
cardiac,O
catheterization,O
for,O
the,O
evaluation,O
of,O
chest,B-Entity
pain,I-Entity
",",O
we,O
measured,O
heart,O
rate,O
",",O
systemic,O
arterial,O
pressure,O
",",O
LV,O
pressure,O
and,O
its,O
first,O
derivative,O
(,O
dP,O
/,O
dt,O
),O
",",O
and,O
LV,O
volumes,O
and,O
ejection,O
fraction,O
before,O
and,O
during,O
the,O
final,O
2,O
to,O
3,O
minutes,O
of,O
a,O
15-minute,O
intracoronary,O
infusion,O
of,O
saline,O
(,O
n=10,O
",",O
control,O
subjects,O
),O
or,O
cocaine,B-Entity
hydrochloride,I-Entity
1,O
mg,O
/,O
min,O
(,O
n=10,O
),O
.,O
With,O
cocaine,I-Entity
",",O
the,O
drug,O
concentration,O
in,O
blood,O
obtained,O
from,O
the,O
coronary,O
sinus,O
was,O
3.0+/-0.4,O
(,O
mean+/-SD,O
),O
/,O
L,O
",",O
similar,O
in,O
magnitude,O
to,O
the,O
blood,O
cocaine,I-Entity
concentration,O
reported,O
in,O
abusers,O
dying,O
of,O
cocaine,I-Entity
intoxication,O
.,O
Cocaine,I-Entity
induced,O
no,O
significant,O
change,O
in,O
heart,O
rate,O
",",O
LV,O
dP,O
/,O
dt,O
(,O
positive,O
or,O
negative,O
),O
",",O
or,O
LV,O
end,O
-,O
diastolic,O
volume,O
",",O
but,O
it,O
caused,O
an,O
increase,O
in,O
systolic,O
and,O
mean,O
arterial,O
pressures,O
",",O
LV,O
end,O
-,O
diastolic,O
pressure,O
",",O
and,O
LV,O
end,O
-,O
systolic,O
volume,O
",",O
as,O
well,O
as,O
a,O
decrease,O
in,O
LV,O
ejection,O
fraction,O
.,O
In,O
humans,O
",",O
the,O
intracoronary,O
infusion,O
of,O
cocaine,I-Entity
sufficient,O
in,O
amount,O
to,O
achieve,O
a,O
high,O
drug,O
concentration,O
in,O
coronary,O
sinus,O
blood,O
causes,O
a,O
deterioration,B-Entity
of,I-Entity
LV,I-Entity
systolic,I-Entity
and,I-Entity
diastolic,I-Entity
performance,I-Entity
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
",",O
paradoxical,O
thromboembolism,I-Entity
",",O
and,O
other,O
side,O
effects,O
of,O
heparin,I-Entity
therapy,O
.,O
Although,O
several,O
new,O
anticoagulant,O
drugs,O
are,O
in,O
development,O
",",O
heparin,I-Entity
remains,O
the,O
drug,O
of,O
choice,O
for,O
most,O
anticoagulation,O
needs,O
.,O
The,O
clinical,O
effects,O
of,O
heparin,I-Entity
are,O
meritorious,O
",",O
but,O
side,O
effects,O
do,O
exist,O
.,O
Important,O
untoward,O
effects,O
of,O
heparin,I-Entity
therapy,O
including,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
",",O
heparin,I-Entity
-,O
associated,O
osteoporosis,I-Entity
",",O
eosinophilia,I-Entity
",",O
skin,B-Entity
reactions,I-Entity
",",O
allergic,B-Entity
reactions,I-Entity
other,O
than,O
thrombocytopenia,I-Entity
and,O
alopecia,I-Entity
will,O
be,O
discussed,O
in,O
this,O
article,O
.,O
Nonopaque,O
crystal,O
deposition,O
causing,O
ureteric,B-Entity
obstruction,I-Entity
in,O
patients,O
with,O
HIV,O
undergoing,O
indinavir,I-Entity
therapy,O
.,O
We,O
describe,O
the,O
unique,O
CT,O
features,O
of,O
ureteric,B-Entity
calculi,I-Entity
in,O
six,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
patients,O
receiving,O
indinavir,I-Entity
",",O
the,O
most,O
commonly,O
used,O
HIV,O
protease,O
inhibitor,O
",",O
which,O
is,O
associated,O
with,O
an,O
increased,O
incidence,O
of,O
urolithiasis,I-Entity
.,O
CONCLUSION,O
:,O
Ureteric,B-Entity
obstruction,I-Entity
caused,O
by,O
precipitated,O
indinavir,I-Entity
crystals,O
may,O
be,O
difficult,O
to,O
diagnose,O
with,O
unenhanced,O
CT,O
.,O
contrast,O
material,O
to,O
enable,O
diagnosis,O
of,O
ureteric,B-Entity
stones,I-Entity
or,I-Entity
obstruction,I-Entity
in,O
patients,O
with,O
HIV,B-Entity
infection,I-Entity
who,O
receive,O
indinavir,I-Entity
therapy,O
.,O
Ischemic,B-Entity
colitis,I-Entity
and,O
sumatriptan,I-Entity
use,O
.,O
Sumatriptan,B-Entity
succinate,I-Entity
",",O
a,O
serotonin-1,I-Entity
(,O
5-hydroxytryptamine-1,I-Entity
),O
receptor,O
agonist,O
",",O
is,O
an,O
antimigraine,O
drug,O
that,O
is,O
reported,O
to,O
act,O
by,O
selectively,O
constricting,O
intracranial,O
arteries,O
.,O
Cases,O
have,O
been,O
published,O
of,O
coronary,B-Entity
vasospasm,I-Entity
",",O
myocardial,B-Entity
ischemia,I-Entity
",",O
and,O
myocardial,B-Entity
infarction,I-Entity
occurring,O
after,O
sumatriptan,I-Entity
use,O
.,O
We,O
report,O
on,O
the,O
development,O
of,O
8,O
serious,O
cases,O
of,O
ischemic,B-Entity
colitis,I-Entity
in,O
patients,O
with,O
migraine,I-Entity
treated,O
with,O
sumatriptan,I-Entity
.,O
51,O
patients,O
with,O
medically,O
refractory,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
underwent,O
stereotactic,O
posteromedial,O
pallidotomy,O
between,O
August,O
1993,O
and,O
February,O
1997,O
for,O
treatment,O
of,O
bradykinesia,I-Entity
",",O
rigidity,I-Entity
",",O
and,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
Clinical,O
assessment,O
as,O
well,O
as,O
blinded,O
ratings,O
of,O
Unified,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Rating,O
Scale,O
(,O
UPDRS,O
),O
85,O
percent,O
of,O
patients,O
with,O
dyskinesias,I-Entity
were,O
relieved,O
of,O
symptoms,O
",",O
regardless,O
of,O
whether,O
the,O
pallidotomies,O
were,O
performed,O
with,O
the,O
Gamma,O
Knife,O
or,O
radiofrequency,O
methods,O
.,O
About,O
2/3,O
of,O
the,O
patients,O
in,O
both,O
Gamma,O
Knife,O
and,O
radiofrequency,O
groups,O
showed,O
improvements,O
in,O
bradykinesia,I-Entity
and,O
rigidity,I-Entity
",",O
although,O
when,O
considered,O
as,O
a,O
group,O
neither,O
the,O
Gamma,O
Knife,O
nor,O
the,O
radiofrequency,O
group,O
showed,O
statistically,O
significant,O
improvements,O
in,O
UPDRS,O
scores,O
.,O
One,O
patient,O
in,O
the,O
Gamma,O
Knife,O
group,O
(,O
3.4%,O
),O
developed,O
a,O
homonymous,B-Entity
hemianopsia,I-Entity
9,O
months,O
following,O
treatment,O
and,O
5,O
patients,O
(,O
27.7%,O
),O
in,O
the,O
radiofrequency,O
group,O
became,O
transiently,O
confused,O
postoperatively,O
.,O
Gamma,O
Knife,O
pallidotomy,O
is,O
as,O
effective,O
as,O
radiofrequency,O
pallidotomy,O
in,O
controlling,O
certain,O
of,O
the,O
symptoms,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
It,O
may,O
be,O
the,O
only,O
practical,O
technique,O
available,O
in,O
certain,O
patients,O
",",O
such,O
as,O
those,O
who,O
take,O
anticoagulants,O
",",O
have,O
bleeding,I-Entity
diatheses,O
or,O
serious,O
systemic,O
medical,O
illnesses,O
.,O
Neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
and,O
methylphenidate,I-Entity
.,O
A,O
1-year,O
-,O
old,O
female,O
presented,O
with,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
probably,O
caused,O
by,O
methylphenidate,I-Entity
.,O
She,O
had,O
defects,O
in,O
the,O
supratentorial,O
brain,O
including,O
the,O
basal,O
ganglia,O
and,O
the,O
striatum,O
(,O
multicystic,B-Entity
encephalomalacia,I-Entity
),O
due,O
to,O
severe,O
perinatal,O
hypoxic,B-Entity
-,I-Entity
ischemic,I-Entity
encephalopathy,I-Entity
",",O
which,O
was,O
considered,O
to,O
be,O
a,O
possible,O
predisposing,O
factor,O
causing,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
.,O
However,O
",",O
methylphenidate,I-Entity
is,O
a,O
dopamine,I-Entity
agonist,O
via,O
the,O
inhibition,O
of,O
uptake,O
of,O
dopamine,I-Entity
",",O
and,O
therefore,O
dopaminergic,O
systems,O
in,O
the,O
brainstem,O
(,O
mainly,O
the,O
midbrain,O
),O
and,O
the,O
spinal,O
cord,O
were,O
unlikely,O
to,O
participate,O
in,O
the,O
onset,O
of,O
this,O
syndrome,O
.,O
A,O
relative,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
-,O
ergic,O
deficiency,O
might,O
occur,O
because,O
diazepam,I-Entity
",",O
a,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
-,O
mimetic,O
agent,O
",",O
was,O
strikingly,O
effective,O
.,O
This,O
is,O
the,O
first,O
reported,O
patient,O
with,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
probably,O
caused,O
by,O
methylphenidate,I-Entity
.,O
Differential,O
effects,O
of,O
17alpha,B-Entity
-,I-Entity
ethinylestradiol,I-Entity
on,O
the,O
neutral,O
and,O
acidic,O
pathways,O
of,O
bile,B-Entity
salt,I-Entity
synthesis,O
in,O
the,O
rat,O
.,O
Effects,O
of,O
17alpha,B-Entity
-,I-Entity
ethinylestradiol,I-Entity
(,O
EE,I-Entity
),O
on,O
the,O
neutral,O
and,O
acidic,O
biosynthetic,O
pathways,O
of,O
bile,B-Entity
salt,I-Entity
(,O
BS,I-Entity
),O
synthesis,O
were,O
evaluated,O
in,O
rats,O
with,O
an,O
intact,O
enterohepatic,O
circulation,O
and,O
in,O
rats,O
with,O
long,O
-,O
term,O
bile,O
diversion,O
to,O
induce,O
BS,I-Entity
synthesis,O
.,O
For,O
this,O
purpose,O
",",O
bile,B-Entity
salt,I-Entity
pool,O
composition,O
",",O
synthesis,O
of,O
individual,O
BS,I-Entity
in,O
vivo,O
",",O
hepatic,O
activities,O
",",O
and,O
expression,O
levels,O
of,O
cholesterol,I-Entity
7alpha,O
-,O
hydroxylase,O
(,O
CYP7A,O
),O
",",O
and,O
sterol,I-Entity
27-hydroxylase,O
(,O
CYP27,O
),O
",",O
as,O
well,O
as,O
of,O
other,O
enzymes,O
involved,O
in,O
BS,I-Entity
synthesis,O
",",O
were,O
analyzed,O
in,O
rats,O
treated,O
with,O
EE,I-Entity
(,O
5,O
mg,O
/,O
kg,O
",",O
3,O
days,O
),O
or,O
its,O
vehicle,O
.,O
BS,I-Entity
pool,O
size,O
was,O
decreased,O
by,O
27%,O
but,O
total,O
BS,I-Entity
synthesis,O
was,O
not,O
affected,O
by,O
EE,I-Entity
in,O
intact,O
rats,O
.,O
Synthesis,O
of,O
cholate,I-Entity
was,O
reduced,O
by,O
68%,O
in,O
EE,I-Entity
-,O
treated,O
rats,O
",",O
while,O
that,O
of,O
chenodeoxycholate,I-Entity
was,O
increased,O
by,O
60%,O
.,O
The,O
recently,O
identified,O
Delta22-isomer,O
of,O
beta,O
-,O
muricholate,O
contributed,O
for,O
5.4%,O
and,O
18.3,O
%,O
(,O
P,O
<,O
0.01,O
),O
to,O
the,O
pool,O
in,O
control,O
and,O
EE,I-Entity
-,O
treated,O
rats,O
",",O
respectively,O
",",O
but,O
could,O
not,O
be,O
detected,O
in,O
bile,O
after,O
exhaustion,O
of,O
the,O
pool,O
.,O
A,O
clear,O
reduction,O
of,O
BS,I-Entity
synthesis,O
was,O
found,O
in,O
bile,O
-,O
diverted,O
rats,O
treated,O
with,O
EE,I-Entity
",",O
yet,O
biliary,O
BS,I-Entity
composition,O
was,O
only,O
minimally,O
affected,O
.,O
Activity,O
of,O
CYP7A,O
was,O
decreased,O
by,O
EE,I-Entity
in,O
both,O
intact,O
and,O
bile,O
-,O
diverted,O
rats,O
",",O
whereas,O
the,O
activity,O
of,O
the,O
CYP27,O
was,O
not,O
affected,O
.,O
Hepatic,O
mRNA,O
levels,O
of,O
CYP7A,O
were,O
significantly,O
reduced,O
by,O
EE,I-Entity
in,O
bile,O
-,O
diverted,O
rats,O
only,O
;,O
CYP27,O
mRNA,O
levels,O
were,O
not,O
affected,O
by,O
EE,I-Entity
.,O
In,O
addition,O
",",O
mRNA,O
levels,O
of,O
sterol,I-Entity
12alpha,O
-,O
hydroxylase,O
and,O
lithocholate,O
6beta,O
-,O
hydroxylase,O
were,O
increased,O
by,O
bile,O
diversion,O
and,O
suppressed,O
by,O
EE,I-Entity
.,O
This,O
study,O
shows,O
that,O
17alpha,B-Entity
-,I-Entity
ethinylestradiol,I-Entity
(,O
EE)-induced,I-Entity
intrahepatic,B-Entity
cholestasis,I-Entity
in,O
rats,O
is,O
associated,O
with,O
selective,O
inhibition,O
of,O
the,O
neutral,O
pathway,O
of,O
bile,B-Entity
salt,I-Entity
(,O
BS,I-Entity
),O
synthesis,O
.,O
Simultaneous,O
impairment,O
of,O
other,O
enzymes,O
in,O
the,O
BS,I-Entity
biosynthetic,O
pathways,O
may,O
contribute,O
to,O
overall,O
effects,O
of,O
EE,I-Entity
on,O
BS,I-Entity
synthesis,O
.,O
Glibenclamide,I-Entity
-,O
sensitive,O
hypotension,I-Entity
produced,O
by,O
helodermin,I-Entity
assessed,O
in,O
the,O
rat,O
.,O
The,O
effects,O
of,O
helodermin,I-Entity
",",O
a,O
basic,O
35-amino,B-Entity
acid,I-Entity
peptide,O
isolated,O
from,O
the,O
venom,O
of,O
a,O
lizard,O
salivary,O
gland,O
",",O
on,O
arterial,O
blood,O
pressure,O
and,O
heart,O
rate,O
were,O
examined,O
in,O
the,O
rat,O
",",O
focusing,O
on,O
the,O
possibility,O
that,O
activation,O
of,O
ATP,I-Entity
sensitive,O
K+,I-Entity
(,O
K(ATP,I-Entity
),O
),O
channels,O
is,O
involved,O
in,O
the,O
responses,O
.,O
Helodermin,I-Entity
produced,O
hypotension,I-Entity
in,O
a,O
dose,O
-,O
dependent,O
manner,O
with,O
approximately,O
similar,O
potency,O
and,O
duration,O
to,O
VIP,O
.,O
Hypotension,I-Entity
induced,O
by,O
both,O
peptides,O
was,O
significantly,O
attenuated,O
by,O
glibenclamide,I-Entity
",",O
which,O
abolished,O
a,O
levcromakalim,I-Entity
-,O
produced,O
decrease,O
in,O
arterial,O
blood,O
pressure,O
.,O
Oxyhemoglobin,O
did,O
not,O
affect,O
helodermin,I-Entity
-,O
induced,O
hypotension,I-Entity
",",O
whereas,O
it,O
shortened,O
the,O
duration,O
of,O
acetylcholine,I-Entity
(,O
ACh)-produced,I-Entity
hypotension,I-Entity
.,O
These,O
findings,O
suggest,O
that,O
helodermin,I-Entity
-,O
produced,O
hypotension,I-Entity
is,O
partly,O
attributable,O
to,O
the,O
activation,O
of,O
glibenclamide,I-Entity
-,O
sensitive,O
K+,I-Entity
channels,O
(,O
K(ATP,I-Entity
),O
channels,O
),O
",",O
which,O
presumably,O
exist,O
on,O
arterial,O
smooth,O
muscle,O
cells,O
.,O
EDRF,O
(,O
endothelium,O
-,O
derived,O
relaxing,O
factor)/nitric,B-Entity
oxide,I-Entity
does,O
not,O
seem,O
to,O
play,O
an,O
important,O
role,O
in,O
the,O
peptide,O
-,O
produced,O
hypotension,I-Entity
.,O
Long,O
-,O
term,O
efficacy,O
and,O
adverse,O
event,O
of,O
nifedipine,I-Entity
sustained,O
-,O
release,O
tablets,O
for,O
cyclosporin,B-Entity
A,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
patients,O
with,O
psoriasis,I-Entity
.,O
Thirteen,O
psoriatic,I-Entity
patients,O
with,O
hypertension,I-Entity
during,O
the,O
course,O
of,O
cyclosporin,B-Entity
A,I-Entity
therapy,O
were,O
treated,O
for,O
25,O
months,O
with,O
a,O
calcium,I-Entity
channel,O
blocker,O
",",O
sustained,O
-,O
release,O
nifedipine,I-Entity
",",O
to,O
study,O
the,O
clinical,O
antihypertensive,O
effects,O
and,O
adverse,O
events,O
during,O
treatment,O
with,O
both,O
drugs,O
.,O
Seven,O
of,O
the,O
13,O
patients,O
had,O
exhibited,O
a,O
subclinical,O
hypertensive,I-Entity
state,O
before,O
cyclosporin,B-Entity
A,I-Entity
therapy,O
.,O
Both,O
systolic,O
and,O
diastolic,O
blood,O
pressures,O
of,O
these,O
13,O
patients,O
were,O
decreased,O
significantly,O
after,O
4,O
weeks,O
of,O
nifedipine,I-Entity
therapy,O
",",O
and,O
blood,O
pressure,O
was,O
maintained,O
within,O
the,O
normal,O
range,O
thereafter,O
for,O
25,O
months,O
.,O
The,O
adverse,O
events,O
during,O
combined,O
therapy,O
with,O
cyclosporin,B-Entity
A,I-Entity
and,O
nifedipine,I-Entity
included,O
an,O
increase,O
in,O
blood,B-Entity
urea,I-Entity
nitrogen,I-Entity
levels,O
in,O
9,O
of,O
the,O
13,O
patients,O
and,O
development,O
of,O
gingival,B-Entity
hyperplasia,I-Entity
in,O
2,O
of,O
the,O
13,O
patients,O
.,O
Our,O
findings,O
indicate,O
that,O
sustained,O
-,O
release,O
nifedipine,I-Entity
is,O
useful,O
for,O
hypertensive,I-Entity
psoriatic,I-Entity
patients,O
under,O
long,O
-,O
term,O
treatment,O
with,O
cyclosporin,B-Entity
A,I-Entity
",",O
but,O
that,O
these,O
patients,O
should,O
be,O
monitored,O
for,O
gingival,B-Entity
hyperplasia,I-Entity
.,O
Torsade,B-Entity
de,I-Entity
pointes,I-Entity
ventricular,B-Entity
tachycardia,I-Entity
during,O
low,O
dose,O
intermittent,O
dobutamine,I-Entity
treatment,O
in,O
a,O
patient,O
with,O
dilated,B-Entity
cardiomyopathy,I-Entity
and,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
.,O
The,O
authors,O
describe,O
the,O
case,O
of,O
a,O
56-year,O
-,O
old,O
woman,O
with,O
chronic,O
",",O
severe,O
heart,B-Entity
failure,I-Entity
secondary,O
to,O
dilated,B-Entity
cardiomyopathy,I-Entity
and,O
absence,O
of,O
significant,O
ventricular,B-Entity
arrhythmias,I-Entity
who,O
developed,O
QT,B-Entity
prolongation,I-Entity
and,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
ventricular,B-Entity
tachycardia,I-Entity
during,O
one,O
cycle,O
of,O
intermittent,O
low,O
dose,O
(,O
2.5,O
mcg,O
/,O
kg,O
per,O
min,O
),O
dobutamine,I-Entity
.,O
This,O
report,O
of,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
ventricular,B-Entity
tachycardia,I-Entity
during,O
intermittent,O
dobutamine,I-Entity
supports,O
the,O
hypothesis,O
that,O
unpredictable,O
fatal,O
arrhythmias,I-Entity
may,O
occur,O
even,O
with,O
low,O
doses,O
and,O
in,O
patients,O
with,O
no,O
history,O
of,O
significant,O
rhythm,O
disturbances,O
.,O
The,O
mechanisms,O
of,O
proarrhythmic,O
effects,O
of,O
Dubutamine,I-Entity
are,O
discussed,O
.,O
Positive,O
skin,O
tests,O
in,O
late,O
reactions,O
to,O
radiographic,O
contrast,B-Entity
media,I-Entity
.,O
In,O
the,O
last,O
few,O
years,O
delayed,O
reactions,O
several,O
hours,O
after,O
the,O
injection,O
of,O
radiographic,O
and,O
contrast,B-Entity
materials,I-Entity
(,O
PRC,I-Entity
),O
have,O
been,O
described,O
with,O
increasing,O
frequency,O
.,O
The,O
authors,O
report,O
two,O
observations,O
on,O
patients,O
with,O
delayed,O
reactions,O
in,O
whom,O
intradermoreactions,O
(,O
IDR,O
),O
and,O
patch,O
tests,O
to,O
a,O
series,O
of,O
ionic,O
and,O
non,O
ionic,O
PRC,I-Entity
were,O
studied,O
.,O
After,O
angiography,O
by,O
the,O
venous,O
route,O
in,O
patient,O
n,O
degree,O
1,O
a,O
biphasic,O
reaction,O
with,O
an,O
immediate,O
reaction,O
(,O
dyspnea,I-Entity
",",O
loss,B-Entity
of,I-Entity
consciousness,I-Entity
),O
and,O
delayed,O
macro,B-Entity
-,I-Entity
papular,I-Entity
rash,I-Entity
appeared,O
",",O
whilst,O
patient,O
n,O
degree,O
2,O
developed,O
a,O
generalised,O
sensation,O
of,O
heat,O
",",O
persistent,O
pain,I-Entity
at,O
the,O
site,O
of,O
injection,O
immediately,O
and,O
a,O
generalised,O
macro,O
-,O
papular,O
reaction,O
after,O
24,O
hours,O
.,O
The,O
skin,O
tests,O
revealed,O
positive,O
delayed,O
reactions,O
of,O
24,O
hours,O
and,O
48,O
hours,O
by,O
IDR,O
and,O
patch,O
tests,O
to,O
only,O
some,O
PRC,I-Entity
with,O
common,O
chains,O
in,O
their,O
structures,O
.,O
The,O
positive,O
skin,O
tests,O
are,O
in,O
favour,O
of,O
immunological,O
reactions,O
and,O
may,O
help,O
in,O
diagnosis,O
of,O
allergy,I-Entity
in,O
the,O
patients,O
.,O
Risk,O
of,O
transient,O
hyperammonemic,B-Entity
encephalopathy,I-Entity
in,O
cancer,I-Entity
patients,O
who,O
received,O
continuous,O
infusion,O
of,O
5-fluorouracil,I-Entity
with,O
the,O
complication,O
of,O
dehydration,I-Entity
and,O
infection,I-Entity
.,O
From,O
1986,O
to,O
1998,O
",",O
29,O
cancer,I-Entity
patients,O
who,O
had,O
32,O
episodes,O
of,O
transient,O
hyperammonemic,B-Entity
encephalopathy,I-Entity
related,O
to,O
continuous,O
infusion,O
of,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
were,O
identified,O
.,O
None,O
of,O
the,O
patients,O
had,O
decompensated,O
liver,B-Entity
disease,I-Entity
.,O
Onset,O
of,O
hyperammonemic,B-Entity
encephalopathy,I-Entity
varied,O
from,O
0.5,O
to,O
5,O
days,O
(,O
mean,O
:,O
2.6,O
+,O
/-,O
Plasma,O
ammonium,I-Entity
level,O
ranged,O
from,O
248,O
to,O
2387,O
microg%,O
(,O
mean,O
:,O
626,O
+,O
/-,O
Among,O
the,O
32,O
episodes,O
",",O
26,O
(,O
81%,O
),O
had,O
various,O
degrees,O
of,O
azotemia,I-Entity
",",O
18,O
(,O
56%,O
),O
occurred,O
during,O
bacterial,B-Entity
infections,I-Entity
and,O
14,O
(,O
44%,O
),O
without,O
infection,I-Entity
occurred,O
during,O
periods,O
of,O
dehydration,I-Entity
.,O
Higher,O
plasma,O
ammonium,I-Entity
levels,O
and,O
more,O
rapid,O
onset,O
of,O
hyperammonemia,I-Entity
were,O
seen,O
in,O
18,O
patients,O
with,O
bacterial,B-Entity
infections,I-Entity
(,O
p=0.003,O
and,O
0.0006,O
",",O
respectively,O
),O
and,O
in,O
nine,O
patients,O
receiving,O
high,O
daily,O
doses,O
(,O
2600,O
or,O
1800,O
mg,O
/,O
m2,O
),O
of,O
5-FU,I-Entity
(,O
p=0.0001,O
and,O
In,O
25,O
out,O
of,O
32,O
episodes,O
(,O
78%,O
),O
",",O
plasma,O
ammonium,I-Entity
levels,O
and,O
mental,O
status,O
returned,O
to,O
normal,O
within,O
2,O
days,O
after,O
adequate,O
management,O
.,O
In,O
conclusion,O
",",O
hyperammonemic,B-Entity
encephalopathy,I-Entity
can,O
occur,O
in,O
patients,O
receiving,O
continuous,O
infusion,O
of,O
5-FU,I-Entity
.,O
Azotemia,I-Entity
",",O
body,O
fluid,O
insufficiency,O
and,O
bacterial,B-Entity
infections,I-Entity
were,O
frequently,O
found,O
in,O
these,O
patients,O
.,O
It,O
is,O
therefore,O
important,O
to,O
recognize,O
this,O
condition,O
in,O
patients,O
receiving,O
continuous,O
infusion,O
of,O
5-FU,I-Entity
.,O
The,O
effects,O
of,O
quinine,I-Entity
and,O
4-aminopyridine,I-Entity
on,O
conditioned,O
place,O
preference,O
and,O
changes,O
in,O
motor,O
activity,O
induced,O
by,O
morphine,I-Entity
in,O
rats,O
The,O
effects,O
of,O
two,O
unselective,O
potassium,I-Entity
(,O
K(+)-,I-Entity
),O
channel,O
blockers,O
",",O
quinine,I-Entity
(,O
12.5,O
",",O
25,O
and,O
50,O
mg,O
/,O
kg,O
),O
and,O
4-aminopyridine,I-Entity
(,O
1,O
and,O
2,O
mg,O
/,O
kg,O
),O
",",O
on,O
conditioned,O
place,O
preference,O
and,O
biphasic,O
changes,O
in,O
motor,O
activity,O
induced,O
by,O
morphine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
were,O
tested,O
in,O
Wistar,O
rats,O
.,O
Quinine,I-Entity
is,O
known,O
to,O
block,O
voltage-,O
",",O
calcium-,I-Entity
and,O
ATP,I-Entity
-,O
sensitive,O
K(+)-channels,I-Entity
while,O
4-aminopyridine,I-Entity
is,O
known,O
to,O
block,O
voltage,O
-,O
sensitive,O
K(+)-channels,I-Entity
.,O
In,O
the,O
counterbalanced,O
method,O
",",O
quinine,I-Entity
attenuated,O
morphine,I-Entity
-,O
induced,O
place,O
preference,O
",",O
whereas,O
4-aminopyridine,I-Entity
was,O
ineffective,O
.,O
In,O
the,O
motor,O
activity,O
test,O
measured,O
with,O
an,O
Animex,O
-,O
activity,O
meter,O
neither,O
of,O
the,O
K(+)-channel,I-Entity
blockers,O
affected,O
morphine,I-Entity
-,O
induced,O
hypoactivity,I-Entity
",",O
but,O
both,O
K(+)-channel,I-Entity
blockers,O
prevented,O
morphine,I-Entity
-,O
induced,O
secondary,O
hyperactivity,I-Entity
.,O
These,O
results,O
suggest,O
the,O
involvement,O
of,O
quinine,I-Entity
-,O
sensitive,O
but,O
not,O
4-aminopyridine,I-Entity
-,O
sensitive,O
K(+)-channels,I-Entity
in,O
morphine,I-Entity
reward,O
.,O
It,O
is,O
also,O
suggested,O
that,O
the,O
blockade,O
of,O
K(+)-channels,I-Entity
sensitive,O
to,O
these,O
blockers,O
is,O
not,O
sufficient,O
to,O
prevent,O
morphine,I-Entity
-,O
induced,O
hypoactivity,I-Entity
whereas,O
morphine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
seems,O
to,O
be,O
connected,O
to,O
both,O
quinine-,I-Entity
and,O
4-aminopyridine,I-Entity
-,O
sensitive,O
K(+)-channels,I-Entity
.,O
Nociceptin,I-Entity
/,O
orphanin,B-Entity
FQ,I-Entity
and,O
nocistatin,I-Entity
on,O
learning,B-Entity
and,I-Entity
memory,I-Entity
impairment,I-Entity
induced,O
by,O
scopolamine,I-Entity
in,O
mice,O
Nociceptin,I-Entity
",",O
also,O
known,O
as,O
orphanin,B-Entity
FQ,I-Entity
",",O
is,O
an,O
endogenous,O
ligand,O
for,O
the,O
orphan,O
opioid,O
receptor,O
-,O
like,O
receptor,O
1,O
(,O
ORL1,O
),O
and,O
involves,O
in,O
various,O
functions,O
in,O
the,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
.,O
On,O
the,O
other,O
hand,O
",",O
nocistatin,I-Entity
is,O
recently,O
isolated,O
from,O
the,O
same,O
precursor,O
as,O
nociceptin,I-Entity
and,O
blocks,O
nociceptin,I-Entity
-,O
induced,O
allodynia,I-Entity
and,O
hyperalgesia,I-Entity
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
investigate,O
whether,O
nociceptin,I-Entity
/,O
orphanin,B-Entity
FQ,I-Entity
and,O
nocistatin,I-Entity
could,O
modulate,O
impairment,B-Entity
of,I-Entity
learning,I-Entity
and,I-Entity
memory,I-Entity
induced,O
by,O
scopolamine,I-Entity
",",O
a,O
muscarinic,O
cholinergic,O
receptor,O
antagonist,O
",",O
using,O
spontaneous,O
alternation,O
of,O
Y,O
-,O
maze,O
and,O
step,O
-,O
down,O
type,O
passive,O
avoidance,O
tasks,O
in,O
mice,O
.,O
While,O
nocistatin,I-Entity
(,O
0.5,O
-,O
5.0,O
nmol,O
mouse-1,O
",",O
i.c.v,O
.,O
),O
administered,O
30,O
min,O
before,O
spontaneous,O
alternation,O
performance,O
or,O
the,O
training,O
session,O
of,O
the,O
passive,O
avoidance,O
task,O
",",O
had,O
no,O
effect,O
on,O
spontaneous,O
alternation,O
or,O
passive,O
avoidance,O
behaviours,O
",",O
a,O
lower,O
per,O
cent,O
alternation,O
and,O
shorter,O
median,O
step,O
-,O
down,O
latency,O
in,O
the,O
retention,O
test,O
were,O
obtained,O
in,O
nociceptin,I-Entity
(,O
1.5,O
and/or,O
5.0,O
nmol,O
mouse-1,O
",",O
Administration,O
of,O
nocistatin,I-Entity
(,O
1.5,O
and/or,O
5.0,O
nmol,O
mouse-1,O
",",O
i.c.v,O
.,O
),O
30,O
min,O
before,O
spontaneous,O
alternation,O
performance,O
or,O
the,O
training,O
session,O
of,O
the,O
passive,O
avoidance,O
task,O
",",O
attenuated,O
the,O
scopolamine,I-Entity
-,O
induced,O
impairment,O
of,O
spontaneous,O
alternation,O
and,O
passive,O
avoidance,O
behaviours,O
.,O
These,O
results,O
indicated,O
that,O
nocistatin,I-Entity
",",O
a,O
new,O
biologically,O
active,O
peptide,O
",",O
ameliorates,O
impairments,O
of,O
spontaneous,O
alternation,O
and,O
passive,O
avoidance,O
induced,O
by,O
scopolamine,I-Entity
",",O
and,O
suggested,O
that,O
these,O
peptides,O
play,O
opposite,O
roles,O
in,O
learning,O
and,O
memory,O
.,O
Meloxicam,I-Entity
-,O
induced,O
liver,B-Entity
toxicity,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
female,O
patient,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
who,O
developed,O
acute,O
cytolytic,O
hepatitis,I-Entity
due,O
to,O
meloxicam,I-Entity
.,O
Recently,O
introduced,O
in,O
Belgium,O
",",O
meloxicam,I-Entity
is,O
the,O
first,O
nonsteroidal,O
antiinflammatory,O
drug,O
with,O
selective,O
action,O
on,O
the,O
inducible,O
form,O
of,O
cyclooxygenase,O
2,O
.,O
The,O
acute,O
cytolytic,O
hepatitis,I-Entity
occurred,O
rapidly,O
after,O
meloxicam,I-Entity
administration,O
and,O
was,O
associated,O
with,O
the,O
development,O
of,O
antinuclear,O
antibodies,O
suggesting,O
a,O
hypersensitivity,I-Entity
mechanism,O
.,O
This,O
first,O
case,O
of,O
meloxicam,I-Entity
related,O
liver,B-Entity
toxicity,I-Entity
demonstrates,O
the,O
potential,O
of,O
this,O
drug,O
to,O
induce,O
hepatic,B-Entity
damage,I-Entity
.,O
Induction,O
of,O
apoptosis,O
by,O
remoxipride,I-Entity
metabolites,O
in,O
HL60,O
and,O
CD34+/CD19-,O
human,O
bone,O
marrow,O
progenitor,O
cells,O
:,O
potential,O
relevance,O
to,O
remoxipride,I-Entity
-,O
induced,O
aplastic,B-Entity
anemia,I-Entity
.,O
The,O
antipsychotic,O
agent,O
",",O
remoxipride,I-Entity
[,O
(,B-Entity
S)-(-)-3-bromo,I-Entity
-,I-Entity
"N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz",I-Entity
amide,I-Entity
],O
has,O
been,O
associated,O
with,O
acquired,O
aplastic,B-Entity
anemia,I-Entity
.,O
We,O
have,O
examined,O
the,O
ability,O
of,O
remoxipride,I-Entity
",",O
three,O
pyrrolidine,I-Entity
ring,O
metabolites,O
and,O
five,O
aromatic,O
ring,O
metabolites,O
of,O
the,O
parent,O
compound,O
to,O
induce,O
apoptosis,O
in,O
HL60,O
cells,O
and,O
human,O
bone,O
marrow,O
progenitor,O
(,O
HBMP,O
),O
cells,O
.,O
Apoptosis,O
was,O
assessed,O
by,O
fluorescence,O
microscopy,O
in,O
Hoechst,B-Entity
33342-,I-Entity
and,O
propidium,B-Entity
iodide,I-Entity
stained,O
cell,O
samples,O
.,O
The,O
catechol,I-Entity
and,O
hydroquinone,I-Entity
metabolites,O
",",O
NCQ436,I-Entity
and,O
NCQ344,I-Entity
",",O
induced,O
apoptosis,O
in,O
HL60,O
and,O
HBMP,O
cells,O
in,O
a,O
time-,O
and,O
concentration,O
dependent,O
manner,O
",",O
while,O
the,O
phenols,I-Entity
",",O
NCR181,O
",",O
FLA873,O
",",O
and,O
FLA797,I-Entity
",",O
and,O
the,O
derivatives,O
formed,O
by,O
oxidation,O
of,O
the,O
pyrrolidine,I-Entity
ring,O
",",O
FLA838,O
",",O
NCM001,O
",",O
and,O
NCL118,O
",",O
had,O
no,O
effect,O
.,O
No,O
necrosis,I-Entity
was,O
observed,O
in,O
cells,O
treated,O
with,O
NCQ436,I-Entity
but,O
NCQ344,I-Entity
had,O
a,O
biphasic,O
effect,O
in,O
both,O
cell,O
types,O
",",O
inducing,O
apoptosis,O
at,O
lower,O
concentrations,O
and,O
necrosis,I-Entity
at,O
higher,O
concentrations,O
.,O
These,O
data,O
show,O
that,O
the,O
catechol,I-Entity
and,O
hydroquinone,I-Entity
metabolites,O
of,O
remoxipride,I-Entity
have,O
direct,O
toxic,O
effects,O
in,O
HL60,O
and,O
HBMP,O
cells,O
",",O
leading,O
to,O
apoptosis,O
",",O
while,O
the,O
phenol,I-Entity
metabolites,O
were,O
inactive,O
.,O
Similarly,O
",",O
benzene,I-Entity
-,O
derived,O
catechol,I-Entity
and,O
hydroquinone,I-Entity
",",O
but,O
not,O
phenol,I-Entity
",",O
induce,O
apoptosis,O
in,O
HBMP,O
cells,O
We,O
propose,O
that,O
remoxipride,I-Entity
and,O
benzene,I-Entity
may,O
induce,O
aplastic,B-Entity
anemia,I-Entity
via,O
production,O
of,O
similar,O
reactive,O
metabolites,O
and,O
that,O
the,O
ability,O
of,O
NCQ436,I-Entity
and,O
NCQ344,I-Entity
to,O
induce,O
apoptosis,O
in,O
HBMP,O
cells,O
may,O
contribute,O
to,O
the,O
mechanism,O
underlying,O
acquired,O
aplastic,B-Entity
anemia,I-Entity
that,O
has,O
been,O
associated,O
with,O
remoxipride,I-Entity
.,O
Synthesis,O
and,O
preliminary,O
pharmacological,O
investigations,O
of,O
"1-(1,2-dihydro-2-acenaphthylenyl)piperazine",I-Entity
derivatives,O
as,O
potential,O
atypical,O
antipsychotic,O
agents,O
in,O
mice,O
.,O
The,O
synthesis,O
and,O
preliminary,O
pharmacological,O
evaluation,O
of,O
a,O
series,O
of,O
potential,O
atypical,O
antipsychotic,O
agents,O
based,O
on,O
the,O
structure,O
of,O
"1-(1,2-dihydro-2-acenaphthylenyl)piperazine",I-Entity
(,O
7,O
),O
is,O
described,O
.,O
Compound,O
7e,O
",",O
"5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy",B-Entity
dro-1H-,I-Entity
indol-2-one,I-Entity
",",O
from,O
this,O
series,O
showed,O
significant,O
affinities,O
at,O
the,O
5-HT1A,O
and,O
5-HT2A,O
receptors,O
and,O
moderate,O
affinity,O
at,O
the,O
D2,O
receptor,O
.,O
7e,O
exhibits,O
a,O
high,O
reversal,O
of,O
catalepsy,I-Entity
induced,O
by,O
haloperidol,I-Entity
indicating,O
its,O
atypical,O
antipsychotic,O
nature,O
.,O
Sub,O
-,O
chronic,O
inhibition,O
of,O
nitric,B-Entity
-,I-Entity
oxide,I-Entity
synthesis,O
modifies,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
and,O
the,O
number,O
of,O
NADPH,I-Entity
-,O
diaphorase,O
neurons,O
in,O
mice,O
.,O
NG,B-Entity
-,I-Entity
nitro,I-Entity
-,I-Entity
L,I-Entity
-,I-Entity
arginine,I-Entity
(,O
L,B-Entity
-,I-Entity
NOARG,I-Entity
),O
",",O
an,O
inhibitor,O
of,O
nitric,B-Entity
-,I-Entity
oxide,I-Entity
synthase,O
(,O
NOS,O
),O
",",O
induces,O
catalepsy,I-Entity
in,O
mice,O
.,O
This,O
effect,O
undergoes,O
rapid,O
tolerance,O
",",O
showing,O
a,O
significant,O
decrease,O
after,O
2,O
days,O
of,O
sub,O
-,O
chronic,O
L,B-Entity
-,I-Entity
NOARG,I-Entity
treatment,O
.,O
Nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
has,O
been,O
shown,O
to,O
influence,O
dopaminergic,O
neurotransmission,O
in,O
the,O
striatum,O
.,O
Neuroleptic,O
drugs,O
such,O
as,O
haloperidol,I-Entity
",",O
which,O
block,O
dopamine,I-Entity
receptors,O
",",O
also,O
cause,O
catalepsy,I-Entity
in,O
rodents,O
.,O
To,O
investigate,O
the,O
effects,O
of,O
subchronic,O
L,B-Entity
-,I-Entity
NOARG,I-Entity
treatment,O
in,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
and,O
the,O
number,O
of,O
NOS,O
neurons,O
in,O
areas,O
related,O
to,O
motor,O
control,O
.,O
Male,O
albino,O
Swiss,O
mice,O
were,O
treated,O
sub,O
-,O
chronically,O
(,O
twice,O
a,O
day,O
for,O
4,O
days,O
),O
with,O
L,B-Entity
-,I-Entity
NOARG,I-Entity
(,O
40,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
or,O
haloperidol,I-Entity
(,O
1,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
.,O
Catalepsy,I-Entity
was,O
evaluated,O
at,O
the,O
beginning,O
and,O
the,O
end,O
of,O
the,O
treatments,O
.,O
Reduced,O
nicotinamide,B-Entity
adenine,I-Entity
dinucleotide,I-Entity
phosphate,I-Entity
-,O
diaphorase,O
(,O
NADPH,I-Entity
-,O
d,O
),O
L,B-Entity
-,I-Entity
NOARG,I-Entity
sub,O
-,O
chronic,O
administration,O
produced,O
tolerance,O
of,O
L,B-Entity
-,I-Entity
NOARG,I-Entity
and,O
of,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
It,O
also,O
induced,O
an,O
increase,O
in,O
the,O
number,O
of,O
NADPH,I-Entity
-,O
d,O
-,O
positive,O
cells,O
in,O
the,O
dorsal,O
part,O
of,O
the,O
caudate,O
and,O
accumbens,O
nuclei,O
compared,O
with,O
haloperidol,I-Entity
and,O
in,O
the,O
pedunculopontine,O
tegmental,O
nucleus,O
compared,O
with,O
saline,O
.,O
In,O
contrast,O
",",O
there,O
was,O
a,O
decrease,O
in,O
NADPH,I-Entity
-,O
d,O
neuron,O
number,O
in,O
the,O
substantia,O
nigra,O
",",O
pars,O
compacta,O
in,O
both,O
haloperidol,I-Entity
-,O
treated,O
and,O
L,B-Entity
-,I-Entity
NOARG,I-Entity
-,O
treated,O
animals,O
.,O
CONCLUSIONS,O
:,O
The,O
results,O
give,O
further,O
support,O
to,O
the,O
hypothesis,O
that,O
NO,I-Entity
plays,O
a,O
role,O
in,O
motor,O
behavior,O
control,O
and,O
suggest,O
that,O
it,O
may,O
take,O
part,O
in,O
the,O
synaptic,O
changes,O
produced,O
by,O
antipsychotic,O
treatment,O
.,O
Prolonged,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
occurs,O
in,O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
after,O
both,O
dobutamine,I-Entity
and,O
exercise,O
induced,O
myocardial,B-Entity
ischaemia,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
determine,O
whether,O
pharmacological,O
stress,O
leads,O
to,O
prolonged,O
but,O
reversible,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
in,O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
similar,O
to,O
that,O
seen,O
after,O
exercise,O
.,O
A,O
randomised,O
crossover,O
study,O
of,O
recovery,O
time,O
of,O
systolic,O
and,O
diastolic,O
left,O
ventricular,O
function,O
after,O
exercise,O
and,O
dobutamine,I-Entity
induced,O
ischaemia,I-Entity
.,O
SUBJECTS,O
:,O
10,O
patients,O
with,O
stable,B-Entity
angina,I-Entity
",",O
angiographically,O
proven,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
and,O
normal,O
left,O
ventricular,O
function,O
.,O
INTERVENTIONS,O
:,O
Treadmill,O
exercise,O
and,O
dobutamine,I-Entity
stress,O
were,O
performed,O
on,O
different,O
days,O
.,O
There,O
was,O
no,O
difference,O
in,O
the,O
maximum,O
double,O
product,O
(,O
p,O
=,O
0.53,O
),O
or,O
ST,O
depression,I-Entity
(,O
p,O
=,O
0.63,O
),O
with,O
either,O
form,O
of,O
stress,O
.,O
After,O
exercise,O
",",O
ejection,O
fraction,O
was,O
reduced,O
at,O
15,O
and,O
30,O
minutes,O
compared,O
with,O
baseline,O
(,O
mean,O
(,O
SEM,O
),O
",",O
-5.6,O
(,O
1.5)%,O
",",O
p,O
<,O
0.05,O
;,O
and,O
-6.1,O
(,O
2.2)%,O
",",O
p,O
<,O
0,O
.,O
01,O
),O
",",O
and,O
at,O
30,O
and,O
45,O
minutes,O
after,O
dobutamine,I-Entity
(,O
-10.8,O
(,O
1.8)%,O
and,O
-5,O
.,O
Regional,O
analysis,O
showed,O
a,O
reduction,O
in,O
the,O
worst,O
affected,O
segment,O
15,O
and,O
30,O
minutes,O
after,O
exercise,O
(,O
-27.9,O
(,O
7.2)%,O
and,O
-28.6,O
(,O
5.7)%,O
",",O
both,O
p,O
<,O
0.01,O
),O
",",O
and,O
at,O
30,O
minutes,O
after,O
dobutamine,I-Entity
In,O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
dobutamine,I-Entity
induced,O
ischaemia,I-Entity
results,O
in,O
prolonged,O
reversible,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
",",O
presumed,O
to,O
be,O
myocardial,B-Entity
stunning,I-Entity
",",O
similar,O
to,O
that,O
seen,O
after,O
exercise,O
.,O
Dobutamine,I-Entity
induced,O
ischaemia,I-Entity
could,O
therefore,O
be,O
used,O
to,O
study,O
the,O
pathophysiology,O
of,O
this,O
phenomenon,O
further,O
in,O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
.,O
Anorexigens,O
and,O
pulmonary,B-Entity
hypertension,I-Entity
in,O
the,O
United,O
States,O
:,O
results,O
from,O
the,O
surveillance,O
of,O
North,O
American,O
pulmonary,B-Entity
hypertension,I-Entity
.,O
BACKGROUND,O
:,O
The,O
use,O
of,O
appetite,O
suppressants,O
in,O
Europe,O
has,O
been,O
associated,O
with,O
the,O
development,O
of,O
primary,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
(,O
PPH,I-Entity
),O
.,O
Recently,O
",",O
fenfluramine,I-Entity
appetite,O
suppressants,O
became,O
widely,O
used,O
in,O
the,O
United,O
States,O
but,O
were,O
withdrawn,O
in,O
September,O
1997,O
because,O
of,O
concerns,O
over,O
adverse,O
effects,O
.,O
:,O
We,O
conducted,O
a,O
prospective,O
surveillance,O
study,O
on,O
patients,O
diagnosed,O
with,O
pulmonary,B-Entity
hypertension,I-Entity
at,O
12,O
large,O
referral,O
centers,O
in,O
North,O
America,O
.,O
Data,O
collected,O
on,O
patients,O
seen,O
from,O
September,O
1,O
",",O
1996,O
",",O
to,O
December,O
31,O
",",O
1997,O
",",O
included,O
the,O
cause,O
of,O
the,O
pulmonary,B-Entity
hypertension,I-Entity
and,O
its,O
severity,O
.,O
Patients,O
with,O
no,O
identifiable,O
cause,O
of,O
pulmonary,B-Entity
hypertension,I-Entity
were,O
classed,O
as,O
PPH,I-Entity
.,O
A,O
history,O
of,O
drug,O
exposure,O
also,O
was,O
taken,O
with,O
special,O
attention,O
on,O
the,O
use,O
of,O
antidepressants,O
",",O
anorexigens,O
",",O
and,O
amphetamines,I-Entity
.,O
Five,O
hundred,O
seventy,O
-,O
nine,O
patients,O
were,O
studied,O
",",O
205,O
with,O
PPH,I-Entity
and,O
374,O
with,O
pulmonary,B-Entity
hypertension,I-Entity
from,O
other,O
causes,O
(,O
secondary,O
pulmonary,B-Entity
hypertension,I-Entity
[,O
SPH,O
],O
),O
.,O
However,O
",",O
of,O
the,O
medications,O
surveyed,O
",",O
only,O
the,O
fenfluramines,I-Entity
had,O
a,O
significant,O
preferential,O
association,O
with,O
PPH,I-Entity
as,O
compared,O
with,O
SPH,O
(,O
adjusted,O
odds,O
ratio,O
for,O
use,O
>,O
6,O
months,O
",",O
7.5,O
;,O
95%,O
confidence,O
interval,O
",",O
1.7,O
to,O
32.4,O
),O
.,O
The,O
magnitude,O
of,O
the,O
association,O
with,O
PPH,I-Entity
",",O
the,O
increase,O
of,O
association,O
with,O
increasing,O
duration,O
of,O
use,O
",",O
and,O
the,O
specificity,O
for,O
fenfluramines,I-Entity
are,O
consistent,O
with,O
previous,O
studies,O
indicating,O
that,O
fenfluramines,I-Entity
are,O
causally,O
related,O
to,O
PPH,I-Entity
.,O
The,O
high,O
prevalence,O
of,O
anorexigen,O
use,O
in,O
patients,O
with,O
SPH,O
also,O
raises,O
the,O
possibility,O
that,O
these,O
drugs,O
precipitate,O
pulmonary,B-Entity
hypertension,I-Entity
in,O
patients,O
with,O
underlying,O
conditions,O
associated,O
with,O
SPH,O
.,O
Clinical,O
aspects,O
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
and,O
thrombosis,I-Entity
and,O
other,O
side,O
effects,O
of,O
heparin,I-Entity
therapy,O
.,O
Heparin,I-Entity
",",O
first,O
used,O
to,O
prevent,O
the,O
clotting,O
of,O
blood,O
in,O
vitro,O
",",O
has,O
been,O
clinically,O
used,O
to,O
treat,O
thrombosis,I-Entity
for,O
more,O
than,O
50,O
years,O
.,O
Although,O
several,O
new,O
anticoagulant,O
drugs,O
are,O
in,O
development,O
",",O
heparin,I-Entity
remains,O
the,O
anticoagulant,O
of,O
choice,O
to,O
treat,O
acute,O
thrombotic,I-Entity
episodes,O
.,O
The,O
clinical,O
effects,O
of,O
heparin,I-Entity
are,O
meritorious,O
",",O
but,O
side,O
effects,O
do,O
exist,O
.,O
Bleeding,I-Entity
is,O
the,O
primary,O
untoward,O
effect,O
of,O
heparin,I-Entity
.,O
Major,O
bleeding,I-Entity
is,O
of,O
primary,O
concern,O
in,O
patients,O
receiving,O
heparin,I-Entity
therapy,O
.,O
However,O
",",O
additional,O
important,O
untoward,O
effects,O
of,O
heparin,I-Entity
therapy,O
include,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
",",O
heparin,I-Entity
-,O
associated,O
osteoporosis,I-Entity
",",O
eosinophilia,I-Entity
",",O
skin,B-Entity
reactions,I-Entity
",",O
allergic,B-Entity
reactions,I-Entity
other,O
than,O
thrombocytopenia,I-Entity
",",O
alopecia,I-Entity
",",O
transaminasemia,O
",",O
hyperkalemia,I-Entity
",",O
hypoaldosteronism,I-Entity
",",O
and,O
priapism,I-Entity
.,O
These,O
side,O
effects,O
are,O
relatively,O
rare,O
in,O
a,O
given,O
individual,O
",",O
but,O
given,O
the,O
extremely,O
widespread,O
use,O
of,O
heparin,I-Entity
",",O
some,O
are,O
quite,O
common,O
",",O
particularly,O
HITT,I-Entity
and,O
osteoporosis,I-Entity
.,O
Although,O
reasonable,O
incidences,O
of,O
many,O
of,O
these,O
side,O
effects,O
can,O
be,O
"""",O
softly,O
"""",O
deduced,O
from,O
current,O
reports,O
dealing,O
with,O
unfractionated,O
heparin,I-Entity
",",O
at,O
present,O
the,O
incidences,O
of,O
these,O
side,O
effects,O
with,O
newer,O
low,O
molecular,O
weight,O
heparins,I-Entity
appear,O
to,O
be,O
much,O
less,O
common,O
.,O
A,O
case,O
of,O
bilateral,O
optic,B-Entity
neuropathy,I-Entity
in,O
a,O
patient,O
on,O
tacrolimus,I-Entity
(,O
FK506,I-Entity
),O
therapy,O
after,O
liver,O
transplantation,O
.,O
PURPOSE,O
:,O
To,O
report,O
a,O
case,O
of,O
bilateral,O
optic,B-Entity
neuropathy,I-Entity
in,O
a,O
patient,O
receiving,O
tacrolimus,I-Entity
(,O
FK,B-Entity
506,I-Entity
",",O
Prograf,O
;,O
Fujisawa,O
USA,O
",",O
Inc,O
",",O
Deerfield,O
",",O
Illinois,O
),O
for,O
immunosuppression,O
after,O
orthotropic,O
liver,O
transplantation,O
.,O
In,O
a,O
58-year,O
-,O
old,O
man,O
receiving,O
tacrolimus,I-Entity
after,O
orthotropic,O
liver,O
transplantation,O
",",O
serial,O
neuro,O
-,O
ophthalmologic,O
examinations,O
and,O
laboratory,O
studies,O
were,O
performed,O
.,O
The,O
patient,O
had,O
episodic,O
deterioration,O
of,O
vision,O
in,O
both,O
eyes,O
",",O
with,O
clinical,O
features,O
resembling,O
ischemic,B-Entity
optic,I-Entity
neuropathies,I-Entity
.,O
Deterioration,B-Entity
of,I-Entity
vision,I-Entity
occurred,O
despite,O
discontinuation,O
of,O
the,O
tacrolimus,I-Entity
.,O
Tacrolimus,I-Entity
and,O
other,O
immunosuppressive,O
agents,O
may,O
be,O
associated,O
with,O
optic,B-Entity
nerve,I-Entity
toxicity,I-Entity
.,O
Hypercalcemia,I-Entity
",",O
arrhythmia,I-Entity
",",O
and,O
mood,O
stabilizers,O
.,O
Recent,O
findings,O
in,O
a,O
bipolar,I-Entity
patient,O
receiving,O
maintenance,O
lithium,I-Entity
therapy,O
who,O
developed,O
hypercalcemia,I-Entity
and,O
severe,O
bradyarrhythmia,I-Entity
prompted,O
the,O
authors,O
to,O
conduct,O
a,O
retrospective,O
study,O
of,O
bipolar,I-Entity
patients,O
with,O
lithium,I-Entity
-,O
associated,O
hypercalcemia,I-Entity
.,O
A,O
printout,O
of,O
all,O
cases,O
of,O
hypercalcemia,I-Entity
that,O
presented,O
during,O
a,O
1-year,O
period,O
was,O
generated,O
.,O
After,O
eliminating,O
spurious,O
hypercalcemias,I-Entity
or,O
those,O
associated,O
with,O
intravenous,O
fluids,O
",",O
the,O
authors,O
identified,O
18,O
non,O
-,O
lithium,I-Entity
-,O
treated,O
patients,O
with,O
hypercalcemias,I-Entity
related,O
to,O
malignancies,I-Entity
and,O
other,O
medical,O
conditions,O
(,O
group,O
A,O
),O
and,O
12,O
patients,O
with,O
lithium,I-Entity
-,O
associated,O
hypercalcemia,I-Entity
(,O
group,O
B,O
),O
.,O
Thus,O
",",O
two,O
control,O
groups,O
were,O
generated,O
:,O
group,O
C1,O
",",O
which,O
included,O
age-,O
and,O
sex,O
-,O
comparable,O
lithium,I-Entity
-,O
treated,O
bipolar,I-Entity
normocalcemic,O
patients,O
",",O
and,O
group,O
C2,O
",",O
which,O
included,O
bipolar,I-Entity
normocalcemic,O
patients,O
treated,O
with,O
anticonvulsant,O
mood,O
stabilizers,O
.,O
Patients,O
with,O
hypercalcemia,I-Entity
resulting,O
from,O
medical,O
diseases,O
and,O
bipolar,I-Entity
patients,O
with,O
lithium,I-Entity
-,O
associated,O
hypercalcemia,I-Entity
had,O
significantly,O
higher,O
frequencies,O
of,O
conduction,O
defects,O
.,O
Attenuation,O
of,O
nephrotoxicity,I-Entity
by,O
a,O
novel,O
lipid,O
nanosphere,O
(,O
NS-718,O
),O
incorporating,O
amphotericin,B-Entity
B.,I-Entity
NS-718,O
",",O
a,O
lipid,O
nanosphere,O
incorporating,O
amphotericin,B-Entity
B,I-Entity
",",O
is,O
effective,O
against,O
pathogenic,O
fungi,O
and,O
has,O
low,O
toxicity,I-Entity
.,O
We,O
compared,O
the,O
toxicity,I-Entity
of,O
NS-718,O
with,O
that,O
of,O
Fungizone,I-Entity
(,O
amphotericin,B-Entity
B,I-Entity
-,I-Entity
sodium,I-Entity
deoxycholate,I-Entity
;,O
D,B-Entity
-,I-Entity
AmB,I-Entity
),O
in,O
vitro,O
using,O
renal,O
cell,O
cultures,O
and,O
in,O
vivo,O
by,O
biochemical,O
analysis,O
",",O
histopathological,O
study,O
of,O
the,O
kidney,O
and,O
pharmacokinetic,O
study,O
of,O
amphotericin,B-Entity
B,I-Entity
following,O
intravenous,O
infusion,O
of,O
the,O
formulation,O
in,O
rats,O
.,O
Incubation,O
with,O
NS-718,O
resulted,O
in,O
significantly,O
less,O
damage,O
of,O
cultured,O
human,O
renal,O
proximal,O
tubular,O
epithelial,O
cells,O
compared,O
with,O
D,B-Entity
-,I-Entity
AmB.,I-Entity
Serum,O
blood,O
urea,I-Entity
and,O
creatinine,I-Entity
concentrations,O
increased,O
significantly,O
in,O
rats,O
given,O
an,O
iv,O
infusion,O
of,O
D,B-Entity
-,I-Entity
AmB,I-Entity
3,O
mg,O
/,O
kg,O
but,O
not,O
in,O
those,O
given,O
the,O
same,O
dose,O
of,O
NS-718,O
.,O
Histopathological,O
examination,O
of,O
the,O
kidney,O
showed,O
tubular,B-Entity
necrosis,I-Entity
in,O
D,B-Entity
-,I-Entity
AmB,I-Entity
-,O
treated,O
rats,O
but,O
no,O
change,O
in,O
NS-718-treated,O
rats,O
.,O
Amphotericin,B-Entity
B,I-Entity
concentrations,O
in,O
the,O
kidney,O
in,O
NS-718-treated,O
rats,O
were,O
higher,O
than,O
those,O
in,O
D,B-Entity
-,I-Entity
AmB,I-Entity
-,O
treated,O
rats,O
.,O
Our,O
in,O
vitro,O
and,O
in,O
vivo,O
results,O
suggest,O
that,O
incorporation,O
of,O
amphotericin,B-Entity
B,I-Entity
into,O
lipid,O
nanospheres,O
of,O
NS-718,O
attenuates,O
the,O
nephrotoxicity,I-Entity
of,O
amphotericin,B-Entity
B.,I-Entity
Patterns,O
of,O
sulfadiazine,I-Entity
acute,B-Entity
nephrotoxicity,I-Entity
.,O
Sulfadiazine,I-Entity
acute,B-Entity
nephrotoxicity,I-Entity
is,O
reviving,O
specially,O
because,O
of,O
its,O
use,O
in,O
toxoplasmosis,I-Entity
in,O
HIV,O
-,O
positive,O
patients,O
.,O
Under,O
treatment,O
with,O
sulfadiazine,I-Entity
they,O
developed,O
oliguria,I-Entity
",",O
abdominal,B-Entity
pain,I-Entity
",",O
renal,B-Entity
failure,I-Entity
and,O
showed,O
multiple,O
radiolucent,O
renal,B-Entity
calculi,I-Entity
in,O
echography,O
.,O
A,O
nephrostomy,O
tube,O
had,O
to,O
be,O
placed,O
in,O
one,O
of,O
the,O
patients,O
for,O
ureteral,B-Entity
lithiasis,I-Entity
in,O
a,O
single,O
functional,O
kidney,O
.,O
Treatment,O
with,O
sulfadiazine,I-Entity
requires,O
exquisite,O
control,O
of,O
renal,O
function,O
",",O
an,O
increase,O
in,O
water,O
ingestion,O
and,O
possibly,O
the,O
alcalinization,O
of,O
the,O
urine,O
.,O
Downbeat,B-Entity
nystagmus,I-Entity
associated,O
with,O
intravenous,O
patient,O
-,O
controlled,O
administration,O
of,O
morphine,I-Entity
.,O
This,O
case,O
documents,O
a,O
patient,O
who,O
developed,O
dizziness,I-Entity
with,O
downbeating,B-Entity
nystagmus,I-Entity
while,O
receiving,O
a,O
relatively,O
large,O
dose,O
of,O
IV,O
patient,O
-,O
controlled,O
analgesia,O
morphine,I-Entity
.,O
Although,O
there,O
have,O
been,O
case,O
reports,O
of,O
epidural,O
morphine,I-Entity
with,O
these,O
symptoms,O
and,O
signs,O
",",O
this,O
has,O
not,O
been,O
previously,O
documented,O
with,O
IV,O
or,O
patient,O
-,O
controlled,O
analgesia,O
morphine,I-Entity
.,O
Hemodynamic,O
and,O
antiadrenergic,O
effects,O
of,O
dronedarone,I-Entity
and,O
amiodarone,I-Entity
in,O
animals,O
with,O
a,O
healed,O
myocardial,B-Entity
infarction,I-Entity
.,O
The,O
hemodynamic,O
and,O
antiadrenergic,O
effects,O
of,O
dronedarone,I-Entity
",",O
a,O
noniodinated,O
compound,O
structurally,O
related,O
to,O
amiodarone,I-Entity
",",O
were,O
compared,O
with,O
those,O
of,O
amiodarone,I-Entity
after,O
prolonged,O
oral,O
administration,O
",",O
both,O
at,O
rest,O
and,O
during,O
sympathetic,O
stimulation,O
in,O
conscious,O
dogs,O
with,O
a,O
healed,O
myocardial,B-Entity
infarction,I-Entity
.,O
All,O
dogs,O
(,O
n,O
=,O
6,O
),O
randomly,O
received,O
orally,O
dronedarone,I-Entity
(,O
10,O
and,O
30,O
mg,O
/,O
kg,O
),O
",",O
amiodarone,I-Entity
(,O
10,O
and,O
30,O
mg,O
/,O
kg,O
),O
",",O
and,O
placebo,O
twice,O
daily,O
for,O
7,O
days,O
",",O
with,O
a,O
3-week,O
washout,O
between,O
consecutive,O
treatments,O
.,O
Heart,O
rate,O
(,O
HR,O
),O
",",O
mean,O
arterial,O
pressure,O
(,O
MBP,O
),O
",",O
positive,O
rate,O
of,O
increase,O
of,O
left,O
ventricular,O
pressure,O
(,O
+,O
LVdP,O
/,O
dt,O
),O
",",O
echocardiographically,O
assessed,O
left,O
ventricular,O
ejection,O
fraction,O
(,O
LVEF,O
),O
",",O
and,O
fractional,O
shortening,O
(,O
FS,O
),O
",",O
as,O
well,O
as,O
chronotropic,O
response,O
to,O
isoproterenol,I-Entity
and,O
exercise,O
-,O
induced,O
sympathetic,O
stimulation,O
were,O
evaluated,O
under,O
baseline,O
and,O
posttreatment,O
conditions,O
.,O
Resting,O
values,O
of,O
LVEF,O
",",O
FS,O
",",O
+,O
LVdP,O
/,O
dt,O
",",O
and,O
MBP,O
remained,O
unchanged,O
whatever,O
the,O
drug,O
and,O
the,O
dosing,O
regimen,O
",",O
whereas,O
resting,O
HR,O
was,O
significantly,O
and,O
dose,O
-,O
dependently,O
lowered,O
after,O
dronedarone,I-Entity
and,O
to,O
a,O
lesser,O
extent,O
after,O
amiodarone,I-Entity
.,O
Both,O
dronedarone,I-Entity
and,O
amiodarone,I-Entity
significantly,O
reduced,O
the,O
exercise,O
-,O
induced,O
tachycardia,I-Entity
and,O
",",O
at,O
the,O
highest,O
dose,O
",",O
decreased,O
the,O
isoproterenol,I-Entity
-,O
induced,O
tachycardia,I-Entity
.,O
Thus,O
",",O
dronedarone,I-Entity
and,O
amiodarone,I-Entity
displayed,O
a,O
similar,O
level,O
of,O
antiadrenergic,O
effect,O
and,O
did,O
not,O
impair,O
the,O
resting,O
left,O
ventricular,O
function,O
.,O
Consequently,O
",",O
dronedarone,I-Entity
might,O
be,O
particularly,O
suitable,O
for,O
the,O
treatment,O
and,O
prevention,O
of,O
various,O
clinical,O
arrhythmias,I-Entity
",",O
without,O
compromising,O
the,O
left,O
ventricular,O
function,O
.,O
Phase,O
2,O
trial,O
of,O
liposomal,O
doxorubicin,I-Entity
(,O
40,O
mg,O
/,O
m(2,O
),O
),O
in,O
platinum,I-Entity
/,O
paclitaxel,I-Entity
-,O
refractory,O
ovarian,B-Entity
and,I-Entity
fallopian,I-Entity
tube,I-Entity
cancers,I-Entity
and,O
primary,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
peritoneum,I-Entity
.,O
Several,O
studies,O
have,O
demonstrated,O
liposomal,O
doxorubicin,I-Entity
(,O
Doxil,I-Entity
),O
to,O
be,O
an,O
active,O
antineoplastic,O
agent,O
in,O
platinum,I-Entity
-,O
resistant,O
ovarian,B-Entity
cancer,I-Entity
",",O
with,O
dose,O
limiting,O
toxicity,I-Entity
of,O
the,O
standard,O
dosing,O
regimen,O
(,O
50,O
mg,O
/,O
m(2,O
),O
q,O
4,O
weeks,O
),O
being,O
severe,O
erythrodysesthesia,I-Entity
(,O
"""",O
hand,B-Entity
-,I-Entity
foot,I-Entity
syndrome,I-Entity
"""",O
),O
and,O
stomatitis,I-Entity
.,O
We,O
wished,O
to,O
develop,O
a,O
more,O
tolerable,O
liposomal,O
doxorubicin,I-Entity
treatment,O
regimen,O
and,O
document,O
its,O
level,O
of,O
activity,O
in,O
a,O
well,O
-,O
defined,O
patient,O
population,O
with,O
platinum,I-Entity
/,O
paclitaxel,I-Entity
-,O
refractory,O
disease,O
.,O
Patients,O
with,O
ovarian,B-Entity
or,I-Entity
fallopian,I-Entity
tube,I-Entity
cancers,I-Entity
or,O
primary,O
peritoneal,B-Entity
carcinoma,I-Entity
with,O
platinum,I-Entity
/,O
paclitaxel,I-Entity
-,O
refractory,O
disease,O
(,O
stable,O
or,O
progressive,O
disease,O
following,O
treatment,O
with,O
these,O
agents,O
or,O
previous,O
objective,O
response,O
<3,O
months,O
in,O
duration,O
),O
were,O
treated,O
with,O
liposomal,O
doxorubicin,I-Entity
at,O
a,O
dose,O
of,O
40,O
mg,O
/,O
m(2,O
),O
q,O
4,O
weeks,O
.,O
Six,O
(,O
12%,O
),O
and,O
4,O
(,O
8%,O
),O
patients,O
experienced,O
grade,O
2,O
hand,B-Entity
-,I-Entity
foot,I-Entity
syndrome,I-Entity
and,O
stomatitis,I-Entity
",",O
respectively,O
(,O
no,O
episodes,O
of,O
grade,O
3,O
),O
.,O
One,O
patient,O
developed,O
grade,O
3,O
diarrhea,I-Entity
requiring,O
hospitalization,O
for,O
hydration,O
.,O
The,O
median,O
number,O
of,O
courses,O
of,O
liposomal,O
doxorubicin,I-Entity
administered,O
on,O
this,O
protocol,O
was,O
2,O
(,O
range,O
:,O
1,O
-,O
12,O
),O
.,O
This,O
modified,O
liposomal,O
doxorubicin,I-Entity
regimen,O
results,O
in,O
less,O
toxicity,I-Entity
(,O
stomatitis,I-Entity
",",O
hand,B-Entity
-,I-Entity
foot,I-Entity
syndrome,I-Entity
),O
than,O
the,O
standard,O
FDA,O
-,O
approved,O
dose,O
schedule,O
.,O
Definite,O
",",O
although,O
limited,O
",",O
antineoplastic,O
activity,O
is,O
observed,O
in,O
patients,O
with,O
well,O
-,O
defined,O
platinum-,I-Entity
and,O
paclitaxel,I-Entity
-,O
refractory,O
ovarian,B-Entity
cancer,I-Entity
.,O
Efficacy,O
of,O
olanzapine,I-Entity
in,O
acute,O
bipolar,B-Entity
mania,I-Entity
:,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
study,O
.,O
The,O
Olanzipine,I-Entity
HGGW,O
Study,O
Group,O
.,O
We,O
compared,O
the,O
efficacy,O
and,O
safety,O
of,O
olanzapine,I-Entity
vs,O
placebo,O
for,O
the,O
treatment,O
of,O
acute,O
bipolar,B-Entity
mania,I-Entity
.,O
A,O
total,O
of,O
115,O
patients,O
with,O
a,O
DSM,O
-,O
IV,O
diagnosis,O
of,O
bipolar,B-Entity
disorder,I-Entity
",",O
manic,I-Entity
or,O
mixed,O
",",O
were,O
randomized,O
to,O
olanzapine,I-Entity
",",O
5,O
to,O
20,O
mg,O
/,O
d,O
(,O
n,O
=,O
55,O
),O
",",O
or,O
placebo,O
(,O
n,O
=,O
60,O
),O
.,O
The,O
primary,O
efficacy,O
measure,O
was,O
the,O
Young,O
-,O
Mania,I-Entity
Rating,O
Scale,O
(,O
Y,O
-,O
MRS,O
),O
total,O
score,O
.,O
Safety,O
was,O
assessed,O
using,O
adverse,O
events,O
",",O
Extrapyramidal,B-Entity
Symptom,I-Entity
(,O
EPS,I-Entity
),O
rating,O
scales,O
",",O
laboratory,O
values,O
",",O
electrocardiograms,O
",",O
vital,O
signs,O
",",O
and,O
weight,O
change,O
.,O
Olanzapine,I-Entity
-,O
treated,O
patients,O
demonstrated,O
a,O
statistically,O
significant,O
greater,O
mean,O
(,O
+,O
/-,O
Olanzapine,I-Entity
-,O
treated,O
patients,O
demonstrated,O
a,O
higher,O
rate,O
of,O
response,O
(,O
65%,O
vs,O
43%,O
",",O
respectively,O
;,O
P,O
=,O
.02,O
),O
and,O
euthymia,O
(,O
There,O
were,O
no,O
statistically,O
significant,O
differences,O
in,O
EPSs,I-Entity
between,O
groups,O
.,O
However,O
",",O
olanzapine,I-Entity
-,O
treated,O
patients,O
had,O
a,O
statistically,O
significant,O
greater,O
mean,O
(,O
+,O
/-,O
SD,O
),O
weight,B-Entity
gain,I-Entity
than,O
placebo,O
-,O
treated,O
patients,O
(,O
2.1,O
+,O
/-,O
2.3,O
kg,O
",",O
respectively,O
),O
and,O
also,O
experienced,O
more,O
treatment,O
-,O
emergent,O
somnolence,I-Entity
(,O
21,O
patients,O
[,O
38.2%,O
],O
vs,O
5,O
[,O
8.3%,O
],O
",",O
respectively,O
),O
.,O
CONCLUSION,O
:,O
Olanzapine,I-Entity
demonstrated,O
greater,O
efficacy,O
than,O
placebo,O
in,O
the,O
treatment,O
of,O
acute,O
bipolar,B-Entity
mania,I-Entity
and,O
was,O
generally,O
well,O
tolerated,O
.,O
The,O
effect,O
of,O
pupil,B-Entity
dilation,I-Entity
with,O
tropicamide,I-Entity
on,O
vision,O
and,O
driving,O
simulator,O
performance,O
.,O
To,O
assess,O
the,O
effect,O
of,O
pupil,B-Entity
dilation,I-Entity
on,O
vision,O
and,O
driving,O
ability,O
.,O
METHODS,O
:,O
A,O
series,O
of,O
tests,O
on,O
various,O
parameters,O
of,O
visual,O
function,O
and,O
driving,O
simulator,O
performance,O
were,O
performed,O
on,O
12,O
healthy,O
drivers,O
",",O
before,O
and,O
after,O
pupil,B-Entity
dilation,I-Entity
using,O
guttae,O
tropicamide,I-Entity
1%,O
.,O
RESULTS,O
:,O
Pupillary,B-Entity
dilation,I-Entity
resulted,O
in,O
a,O
statistically,O
significant,O
deterioration,O
in,O
CT,O
and,O
HCVA,O
only,O
.,O
Pupillary,B-Entity
dilation,I-Entity
may,O
lead,O
to,O
a,O
decrease,O
in,O
vision,O
and,O
daylight,O
driving,O
performance,O
in,O
young,O
people,O
.,O
A,O
case,O
of,O
isotretinoin,B-Entity
embryopathy,I-Entity
with,O
bilateral,O
anotia,I-Entity
and,O
Taussig,B-Entity
-,I-Entity
Bing,I-Entity
malformation,I-Entity
.,O
We,O
report,O
a,O
newborn,O
infant,O
with,O
multiple,O
congenital,O
anomalies,O
(,O
anotia,I-Entity
and,O
Taussig,B-Entity
-,I-Entity
Bing,I-Entity
malformation,I-Entity
),O
due,O
to,O
exposure,O
to,O
isotretinoin,I-Entity
within,O
the,O
first,O
trimester,O
.,O
In,O
this,O
paper,O
we,O
aim,O
to,O
draw,O
to,O
the,O
fact,O
that,O
caution,O
is,O
needed,O
when,O
prescribing,O
vitamin,B-Entity
A,I-Entity
-,O
containing,O
drugs,O
to,O
women,O
of,O
childbearing,O
years,O
.,O
Effect,O
of,O
methoxamine,I-Entity
on,O
maximum,O
urethral,O
pressure,O
in,O
women,O
with,O
genuine,O
stress,B-Entity
incontinence,I-Entity
:,O
a,O
placebo,O
-,O
controlled,O
",",O
double,O
-,O
blind,O
crossover,O
study,O
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
evaluate,O
the,O
potential,O
role,O
for,O
a,O
selective,O
alpha1-adrenoceptor,O
agonist,O
in,O
the,O
treatment,O
of,O
urinary,B-Entity
stress,I-Entity
incontinence,I-Entity
.,O
Half,O
log,O
incremental,O
doses,O
of,O
intravenous,O
methoxamine,I-Entity
or,O
placebo,O
(,O
saline,O
),O
were,O
administered,O
to,O
a,O
group,O
of,O
women,O
with,O
genuine,O
stress,B-Entity
incontinence,I-Entity
while,O
measuring,O
maximum,O
urethral,O
pressure,O
(,O
MUP,O
),O
",",O
blood,O
pressure,O
",",O
heart,O
rate,O
",",O
and,O
symptomatic,O
side,O
effects,O
.,O
Methoxamine,I-Entity
evoked,O
non,O
-,O
significant,O
increases,O
in,O
MUP,O
and,O
diastolic,O
blood,O
pressure,O
but,O
caused,O
a,B-Entity
significant,I-Entity
rise,I-Entity
in,I-Entity
systolic,I-Entity
blood,I-Entity
pressure,I-Entity
and,O
significant,O
fall,O
in,O
heart,O
rate,O
at,O
maximum,O
dosage,O
.,O
Systemic,O
side,O
effects,O
including,O
piloerection,O
",",O
headache,I-Entity
",",O
and,O
cold,O
extremities,O
were,O
experienced,O
in,O
all,O
subjects,O
.,O
The,O
results,O
indicate,O
that,O
the,O
clinical,O
usefulness,O
of,O
direct,O
",",O
peripherally,O
acting,O
sub,O
-,O
type,O
-,O
selective,O
alpha1-adrenoceptor,O
agonists,O
in,O
the,O
medical,O
treatment,O
of,O
stress,B-Entity
incontinence,I-Entity
may,O
be,O
limited,O
by,O
associated,O
piloerection,O
and,O
cardiovascular,O
side,O
effects,O
.,O
Toleration,O
of,O
high,O
doses,O
of,O
angiotensin,B-Entity
-,I-Entity
converting,I-Entity
enzyme,I-Entity
inhibitors,I-Entity
in,O
patients,O
with,O
chronic,O
heart,B-Entity
failure,I-Entity
:,O
results,O
from,O
the,O
ATLAS,O
trial,O
.,O
The,O
Assessment,O
of,O
Treatment,O
with,O
Lisinopril,I-Entity
and,O
Survival,O
.,O
BACKGROUND,O
:,O
Treatment,O
with,O
angiotensin,B-Entity
-,I-Entity
converting,I-Entity
enzyme,I-Entity
(,I-Entity
ACE,I-Entity
),I-Entity
inhibitors,I-Entity
reduces,O
mortality,O
and,O
morbidity,O
in,O
patients,O
with,O
chronic,O
heart,B-Entity
failure,I-Entity
(,O
CHF,I-Entity
),O
",",O
but,O
most,O
affected,O
patients,O
are,O
not,O
receiving,O
these,O
agents,O
or,O
are,O
being,O
treated,O
with,O
doses,O
lower,O
than,O
those,O
found,O
to,O
be,O
efficacious,O
in,O
trials,O
",",O
primarily,O
because,O
of,O
concerns,O
about,O
the,O
safety,O
and,O
tolerability,O
of,O
these,O
agents,O
",",O
especially,O
at,O
the,O
recommended,O
doses,O
.,O
The,O
present,O
study,O
examines,O
the,O
safety,O
and,O
tolerability,O
of,O
high-,O
compared,O
with,O
low,O
-,O
dose,O
lisinopril,I-Entity
in,O
CHF,I-Entity
.,O
The,O
Assessment,O
of,O
Lisinopril,I-Entity
and,O
Survival,O
study,O
was,O
a,O
multicenter,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
trial,O
in,O
which,O
patients,O
with,O
or,O
without,O
previous,O
ACE,B-Entity
inhibitor,I-Entity
treatment,O
were,O
stabilized,O
receiving,O
medium,O
-,O
dose,O
lisinopril,I-Entity
(,O
12.5,O
or,O
15.0,O
mg,O
once,O
daily,O
[,O
OD,O
],O
),O
for,O
2,O
to,O
4,O
weeks,O
and,O
then,O
randomized,O
to,O
high-,O
(,O
35.0,O
or,O
32.5,O
mg,O
OD,O
),O
or,O
low,O
-,O
dose,O
(,O
5.0,O
or,O
2.5,O
mg,O
OD,O
),O
groups,O
.,O
Patients,O
with,O
New,O
York,O
Heart,O
Association,O
classes,O
II,O
to,O
IV,O
CHF,I-Entity
and,O
left,O
ventricular,O
ejection,O
fractions,O
of,O
no,O
greater,O
than,O
0.30,O
(,O
n,O
=,O
3164,O
),O
were,O
randomized,O
and,O
followed,O
up,O
for,O
a,O
median,O
of,O
46,O
months,O
.,O
We,O
examined,O
the,O
occurrence,O
of,O
adverse,O
events,O
and,O
the,O
need,O
for,O
discontinuation,O
and,O
dose,O
reduction,O
during,O
treatment,O
",",O
with,O
a,O
focus,O
on,O
hypotension,I-Entity
and,O
renal,B-Entity
dysfunction,I-Entity
.,O
Of,O
405,O
patients,O
not,O
previously,O
receiving,O
an,O
ACE,B-Entity
inhibitor,I-Entity
",",O
doses,O
in,O
only,O
4.2%,O
could,O
not,O
be,O
titrated,O
to,O
the,O
medium,O
doses,O
required,O
for,O
randomization,O
because,O
of,O
symptoms,O
possibly,O
related,O
to,O
hypotension,I-Entity
(,O
2.0%,O
),O
or,O
because,O
of,O
renal,B-Entity
dysfunction,I-Entity
or,O
hyperkalemia,I-Entity
(,O
2.3%,O
),O
.,O
Subgroups,O
presumed,O
to,O
be,O
at,O
higher,O
risk,O
for,O
ACE,B-Entity
inhibitor,I-Entity
intolerance,O
(,O
blood,O
pressure,O
",",O
<,O
creatinine,I-Entity
",",O
>,O
or,O
=,O
132.6,O
micromol,O
/,O
L,O
[,O
>,O
or,O
=,O
1.5,O
mg,O
/,O
dL,O
],O
;,O
age,O
",",O
>,O
or,O
=,O
70,O
years,O
;,O
and,O
patients,O
with,O
diabetes,I-Entity
),O
generally,O
tolerated,O
the,O
high,O
-,O
dose,O
strategy,O
.,O
These,O
findings,O
demonstrate,O
that,O
ACE,B-Entity
inhibitor,I-Entity
therapy,O
in,O
most,O
patients,O
with,O
CHF,I-Entity
can,O
be,O
successfully,O
titrated,O
to,O
and,O
maintained,O
at,O
high,O
doses,O
",",O
and,O
that,O
more,O
aggressive,O
use,O
of,O
these,O
agents,O
is,O
warranted,O
.,O
Cocaine,I-Entity
",",O
ethanol,I-Entity
",",O
and,O
cocaethylene,I-Entity
cardiotoxity,I-Entity
in,O
an,O
animal,O
model,O
of,O
cocaine,B-Entity
and,I-Entity
ethanol,I-Entity
abuse,I-Entity
.,O
Simultaneous,O
abuse,B-Entity
of,I-Entity
cocaine,I-Entity
and,I-Entity
ethanol,I-Entity
affects,O
12,O
million,O
Americans,O
annually,O
.,O
Their,O
combined,O
cardiac,B-Entity
toxicity,I-Entity
may,O
be,O
due,O
to,O
independent,O
effects,O
of,O
each,O
drug,O
;,O
however,O
",",O
they,O
may,O
also,O
be,O
due,O
to,O
cocaethylene,I-Entity
(,O
CE,I-Entity
),O
",",O
a,O
cocaine,I-Entity
metabolite,O
formed,O
only,O
in,O
the,O
presence,O
of,O
ethanol,I-Entity
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
delineate,O
the,O
role,O
of,O
CE,I-Entity
in,O
the,O
combined,O
cardiotoxicity,I-Entity
of,O
cocaine,I-Entity
and,O
ethanol,I-Entity
in,O
a,O
model,O
simulating,O
their,O
abuse,O
.,O
Twenty,O
-,O
three,O
dogs,O
were,O
randomized,O
to,O
receive,O
either,O
1,O
),O
three,O
intravenous,O
(,O
IV,O
),O
boluses,O
of,O
cocaine,I-Entity
7.5,O
mg,O
/,O
kg,O
with,O
ethanol,I-Entity
(,O
1,O
g,O
/,O
kg,O
),O
as,O
an,O
IV,O
infusion,O
(,O
C+E,O
",",O
n,O
=,O
8),O
",",O
2,O
),O
three,O
cocaine,I-Entity
boluses,O
only,O
(,O
C,O
",",O
n,O
=,O
6,O
),O
",",O
3,O
),O
ethanol,I-Entity
infusion,O
only,O
(,O
E,O
",",O
n,O
=,O
5,O
),O
",",O
or,O
4,O
),O
placebo,O
boluses,O
and,O
infusion,O
(,O
n,O
=,O
4,O
),O
.,O
Two,O
of,O
eight,O
dogs,O
in,O
the,O
C+E,O
group,O
experienced,O
cardiovascular,B-Entity
collapse,I-Entity
.,O
The,O
most,O
dramatic,O
hemodynamic,O
changes,O
occurred,O
after,O
each,O
cocaine,I-Entity
bolus,O
in,O
the,O
C+E,O
and,O
C,O
only,O
groups,O
;,O
however,O
",",O
persistent,O
hemodynamic,O
changes,O
occurred,O
in,O
the,O
C+E,O
group,O
.,O
Peak,O
CE,I-Entity
levels,O
were,O
associated,O
with,O
a,O
45%,O
(,O
SD,O
+,O
/-,O
22%,O
to,O
69%,O
),O
decrease,B-Entity
in,I-Entity
cardiac,I-Entity
output,I-Entity
(,O
p,O
<,O
0.05,O
),O
",",O
a,O
56%,O
(,O
SD,O
+,O
/-,O
Ventricular,B-Entity
arrhythmias,I-Entity
were,O
primarily,O
observed,O
in,O
the,O
C+E,O
group,O
",",O
in,O
which,O
four,O
of,O
eight,O
dogs,O
experienced,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
Cocaine,I-Entity
and,O
ethanol,I-Entity
in,O
combination,O
were,O
more,O
toxic,O
than,O
either,O
substance,O
alone,O
.,O
Co,O
-,O
administration,O
resulted,O
in,O
prolonged,O
cardiac,B-Entity
toxicity,I-Entity
and,O
was,O
dysrhythmogenic,O
.,O
Peak,O
serum,O
cocaethylene,I-Entity
concentrations,O
were,O
associated,O
with,O
prolonged,O
myocardial,B-Entity
depression,I-Entity
.,O
Worsening,O
of,O
Parkinsonism,I-Entity
after,O
the,O
use,O
of,O
veralipride,I-Entity
for,O
treatment,O
of,O
menopause,O
:,O
case,O
report,O
.,O
We,O
describe,O
a,O
female,O
patient,O
with,O
stable,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
who,O
has,O
shown,O
a,O
marked,O
worsening,O
of,O
her,O
motor,O
functions,O
following,O
therapy,O
of,O
menopause,O
related,O
symptoms,O
with,O
veralipride,I-Entity
",",O
as,O
well,O
as,O
the,O
improvement,O
of,O
her,O
symptoms,O
back,O
to,O
baseline,O
after,O
discontinuation,O
of,O
the,O
drug,O
.,O
We,O
emphasize,O
the,O
anti,O
-,O
dopaminergic,O
effect,O
of,O
veralipride,I-Entity
.,O
Viracept,I-Entity
and,O
irregular,B-Entity
heartbeat,I-Entity
warning,O
.,O
A,O
group,O
of,O
doctors,O
in,O
Boston,O
warn,O
that,O
the,O
protease,O
inhibitor,O
Viracept,I-Entity
may,O
cause,O
an,O
irregular,B-Entity
heart,I-Entity
beat,I-Entity
",",O
known,O
as,O
bradycardia,I-Entity
",",O
in,O
people,O
with,O
HIV,O
.,O
Bradycardia,I-Entity
occurred,O
in,O
a,O
45-year,O
-,O
old,O
male,O
patient,O
who,O
was,O
Viracept,I-Entity
in,O
combination,O
with,O
other,O
anti,O
-,O
HIV,O
drugs,O
.,O
Frequency,O
of,O
appearance,O
of,O
myeloperoxidase,O
-,O
antineutrophil,O
cytoplasmic,O
antibody,O
(,O
MPO,O
-,O
ANCA,O
),O
in,O
Graves,B-Entity
',I-Entity
disease,I-Entity
patients,O
treated,O
with,O
propylthiouracil,I-Entity
and,O
the,O
relationship,O
between,O
MPO,O
-,O
ANCA,O
and,O
clinical,O
manifestations,O
.,O
OBJECTIVE,O
:,O
Myeloperoxidase,O
antineutrophil,O
cytoplasmic,O
antibody,O
(,O
MPO,O
-,O
ANCA)-positive,O
vasculitis,I-Entity
has,O
been,O
reported,O
in,O
patients,O
with,O
Graves,B-Entity
',I-Entity
disease,I-Entity
who,O
were,O
treated,O
with,O
propylthiouracil,I-Entity
(,O
PTU,I-Entity
),O
.,O
The,O
appearance,O
of,O
MPO,O
-,O
ANCA,O
in,O
these,O
cases,O
was,O
suspected,O
of,O
being,O
related,O
to,O
PTU,I-Entity
because,O
the,O
titres,O
of,O
MPO,O
-,O
ANCA,O
decreased,O
when,O
PTU,I-Entity
was,O
stopped,O
.,O
Nevertheless,O
",",O
there,O
have,O
been,O
no,O
studies,O
on,O
the,O
temporal,O
relationship,O
between,O
the,O
appearance,O
of,O
MPO,O
-,O
ANCA,O
and,O
vasculitis,I-Entity
during,O
PTU,I-Entity
therapy,O
",",O
or,O
on,O
the,O
incidence,O
of,O
MPO,O
-,O
ANCA,O
in,O
untreated,O
Graves,B-Entity
',I-Entity
disease,I-Entity
patients,O
.,O
Therefore,O
",",O
we,O
sought,O
to,O
address,O
these,O
parameters,O
in,O
patients,O
with,O
Graves,B-Entity
',I-Entity
disease,I-Entity
.,O
We,O
investigated,O
102,O
untreated,O
patients,O
with,O
hyperthyroidism,I-Entity
due,O
to,O
Graves,B-Entity
',I-Entity
disease,I-Entity
for,O
the,O
presence,O
of,O
MPO,O
-,O
ANCA,O
",",O
and,O
for,O
the,O
development,O
vasculitis,I-Entity
after,O
starting,O
PTU,I-Entity
therapy,O
.,O
Twenty,O
-,O
nine,O
of,O
them,O
were,O
later,O
excluded,O
because,O
of,O
adverse,O
effects,O
of,O
PTU,I-Entity
or,O
because,O
the,O
observation,O
period,O
was,O
less,O
than,O
3,O
months,O
.,O
Before,O
treatment,O
",",O
the,O
MPO,O
-,O
ANCA,O
titres,O
of,O
all,O
102,O
untreated,O
Graves,B-Entity
',I-Entity
disease,I-Entity
patients,O
were,O
within,O
the,O
reference,O
range,O
(,O
below,O
10,O
U,O
/,O
ml,O
),O
.,O
Three,O
(,O
4.1%,O
),O
of,O
the,O
73,O
patients,O
were,O
positive,O
for,O
MPO,O
-,O
ANCA,O
at,O
13,O
",",O
16,O
and,O
17,O
months,O
",",O
respectively,O
",",O
after,O
the,O
start,O
of,O
PTU,I-Entity
therapy,O
.,O
In,O
two,O
of,O
them,O
",",O
the,O
MPO,O
-,O
ANCA,O
titres,O
transiently,O
increased,O
to,O
12.8,O
and,O
15.0,O
U,O
/,O
ml,O
",",O
respectively,O
",",O
despite,O
continued,O
PTU,I-Entity
therapy,O
",",O
but,O
no,O
vasculitic,B-Entity
disorders,I-Entity
developed,O
.,O
In,O
the,O
third,O
patient,O
",",O
the,O
MPO,O
-,O
ANCA,O
titre,O
increased,O
to,O
204,O
U,O
/,O
ml,O
and,O
she,O
developed,O
a,O
higher,O
fever,I-Entity
",",O
oral,B-Entity
ulcers,I-Entity
and,O
polyarthralgia,I-Entity
",",O
but,O
the,O
symptoms,O
resolved,O
2,O
weeks,O
after,O
stopping,O
PTU,I-Entity
therapy,O
",",O
and,O
the,O
MPO,O
-,O
ANCA,O
titre,O
decreased,O
to,O
20.7,O
U,O
/,O
ml,O
by,O
4,O
months,O
after,O
discontinuing,O
PTU,I-Entity
.,O
PTU,I-Entity
therapy,O
may,O
be,O
related,O
to,O
the,O
appearance,O
of,O
MPO,O
-,O
ANCA,O
",",O
but,O
MPO,O
-,O
ANCA,O
does,O
not,O
appear,O
to,O
be,O
closely,O
related,O
to,O
vasculitis,I-Entity
.,O
Prevalence,O
of,O
heart,B-Entity
disease,I-Entity
in,O
asymptomatic,O
chronic,O
cocaine,I-Entity
users,O
.,O
To,O
determine,O
the,O
prevalence,O
of,O
heart,B-Entity
disease,I-Entity
in,O
outpatient,O
young,O
asymptomatic,O
chronic,O
cocaine,I-Entity
users,O
",",O
35,O
cocaine,I-Entity
users,O
and,O
32,O
age,O
-,O
matched,O
controls,O
underwent,O
resting,O
and,O
exercise,O
electrocardiography,O
(,O
ECG,O
),O
and,O
Doppler,O
echocardiography,O
.,O
Findings,O
consistent,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
were,O
detected,O
in,O
12,O
(,O
34%,O
),O
patients,O
and,O
3,O
(,O
9%,O
),O
controls,O
(,O
p,O
=,O
0.01,O
),O
.,O
Finally,O
",",O
resting,O
and,O
peak,O
exercise,O
abnormal,B-Entity
left,I-Entity
ventricular,I-Entity
filling,I-Entity
was,O
detected,O
in,O
38,O
and,O
35%,O
of,O
patients,O
as,O
compared,O
to,O
19,O
and,O
9%,O
of,O
controls,O
",",O
respectively,O
(,O
p,O
=,O
0.11,O
and,O
0.02,O
",",O
respectively,O
),O
.,O
We,O
conclude,O
that,O
coronary,B-Entity
artery,I-Entity
or,I-Entity
myocardial,I-Entity
disease,I-Entity
is,O
common,O
(,O
38%,O
),O
in,O
young,O
asymptomatic,O
chronic,O
cocaine,I-Entity
users,O
.,O
Cardioprotective,O
effects,O
of,O
Picrorrhiza,O
kurroa,O
against,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,O
stress,O
in,O
rats,O
.,O
The,O
cardioprotective,O
effect,O
of,O
the,O
ethanol,I-Entity
extract,O
of,O
Picrorrhiza,O
kurroa,O
rhizomes,O
and,O
roots,O
(,O
PK,O
),O
on,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
with,O
respect,O
to,O
lipid,O
metabolism,O
in,O
serum,O
and,O
heart,O
tissue,O
has,O
been,O
investigated,O
.,O
day(-1,O
),O
for,O
15,O
days,O
),O
significantly,O
prevented,O
the,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
and,O
maintained,O
the,O
rats,O
at,O
near,O
normal,O
status,O
.,O
Phase,O
2,O
early,O
afterdepolarization,O
as,O
a,O
trigger,O
of,O
polymorphic,O
ventricular,B-Entity
tachycardia,I-Entity
in,O
acquired,O
long,B-Entity
-,I-Entity
QT,I-Entity
syndrome,I-Entity
:,O
direct,O
evidence,O
from,O
intracellular,O
recordings,O
in,O
the,O
intact,O
left,O
ventricular,O
wall,O
.,O
This,O
study,O
examined,O
the,O
role,O
of,O
phase,O
2,O
early,O
afterdepolarization,O
(,O
EAD,O
),O
in,O
producing,O
a,O
trigger,O
to,O
initiate,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
(,O
TdP,I-Entity
),O
with,O
QT,B-Entity
prolongation,I-Entity
induced,O
by,O
dl,O
-,O
sotalol,I-Entity
and,O
azimilide,I-Entity
.,O
The,O
contribution,O
of,O
transmural,O
dispersion,O
of,O
repolarization,O
(,O
TDR,O
),O
to,O
transmural,O
propagation,O
of,O
EAD,O
and,O
the,O
maintenance,O
of,O
TdP,I-Entity
was,O
also,O
evaluated,O
.,O
-,O
Sotalol,I-Entity
preferentially,O
prolonged,O
action,O
potential,O
duration,O
(,O
APD,O
),O
in,O
M,O
cells,O
dose,O
-,O
dependently,O
(,O
1,O
to,O
100,O
micromol,O
/,O
L,O
),O
",",O
leading,O
to,O
QT,B-Entity
prolongation,I-Entity
and,O
an,O
increase,O
in,O
TDR,O
.,O
Azimilide,I-Entity
",",O
however,O
",",O
significantly,O
prolonged,O
APD,O
and,O
QT,O
interval,O
at,O
concentrations,O
from,O
0.1,O
to,O
10,O
Unlike,O
dl,O
-,O
sotalol,I-Entity
",",O
azimilide,I-Entity
(,O
>,O
3,O
micromol,O
/,O
L,O
),O
increased,O
epicardial,O
APD,O
markedly,O
",",O
causing,O
a,O
diminished,O
TDR,O
.,O
Although,O
both,O
dl,O
-,O
sotalol,I-Entity
and,O
azimilide,I-Entity
rarely,O
induced,O
EADs,O
in,O
canine,O
left,O
ventricles,O
",",O
they,O
produced,O
frequent,O
EADs,O
in,O
rabbits,O
",",O
in,O
which,O
more,O
pronounced,O
QT,B-Entity
prolongation,I-Entity
was,O
seen,O
.,O
An,O
increase,O
in,O
TDR,O
by,O
dl,O
-,O
sotalol,I-Entity
facilitated,O
transmural,O
propagation,O
of,O
EADs,O
that,O
initiated,O
multiple,O
episodes,O
of,O
spontaneous,O
TdP,I-Entity
in,O
3,O
of,O
6,O
rabbit,O
left,O
ventricles,O
.,O
Of,O
note,O
",",O
although,O
azimilide,I-Entity
(,O
3,O
to,O
10,O
micromol,O
/,O
L,O
),O
increased,O
APD,O
more,O
than,O
dl,O
-,O
sotalol,I-Entity
",",O
its,O
EADs,O
often,O
failed,O
to,O
propagate,O
transmurally,O
",",O
probably,O
because,O
of,O
a,O
diminished,O
TDR,O
.,O
This,O
study,O
provides,O
the,O
first,O
direct,O
evidence,O
from,O
intracellular,O
action,O
potential,O
recordings,O
that,O
phase,O
2,O
EAD,O
can,O
be,O
generated,O
from,O
intact,O
ventricular,O
wall,O
and,O
produce,O
a,O
trigger,O
to,O
initiate,O
the,O
onset,O
of,O
TdP,I-Entity
under,O
QT,B-Entity
prolongation,I-Entity
.,O
Prenatal,O
cocaine,I-Entity
exposure,O
and,O
cranial,O
sonographic,O
findings,O
in,O
preterm,B-Entity
infants,I-Entity
.,O
Prenatal,O
cocaine,I-Entity
exposure,O
has,O
been,O
linked,O
with,O
subependymal,O
hemorrhage,I-Entity
and,O
the,O
formation,O
of,O
cysts,I-Entity
that,O
are,O
detectable,O
on,O
cranial,O
sonography,O
in,O
neonates,O
born,O
at,O
term,O
.,O
We,O
sought,O
to,O
determine,O
if,O
prenatal,O
cocaine,I-Entity
exposure,O
increases,O
the,O
incidence,O
of,O
subependymal,B-Entity
cysts,I-Entity
in,O
preterm,B-Entity
infants,I-Entity
.,O
METHODS,O
:,O
We,O
retrospectively,O
reviewed,O
the,O
medical,O
records,O
and,O
cranial,O
sonograms,O
obtained,O
during,O
a,O
1-year,O
period,O
on,O
122,O
premature,B-Entity
(,I-Entity
<,I-Entity
36,I-Entity
weeks,I-Entity
of,I-Entity
gestation,I-Entity
),I-Entity
infants,I-Entity
.,O
Infants,O
were,O
categorized,O
into,O
1,O
of,O
2,O
groups,O
:,O
those,O
exposed,O
to,O
cocaine,I-Entity
and,O
those,O
not,O
exposed,O
to,O
cocaine,I-Entity
.,O
Infants,O
were,O
assigned,O
to,O
the,O
cocaine,I-Entity
-,O
exposed,O
group,O
if,O
there,O
was,O
a,O
maternal,O
history,O
of,O
cocaine,B-Entity
abuse,I-Entity
during,O
pregnancy,O
or,O
if,O
maternal,O
or,O
neonatal,O
urine,O
toxicology,O
results,O
were,O
positive,O
at,O
the,O
time,O
of,O
delivery,O
.,O
The,O
incidence,O
of,O
subependymal,B-Entity
cysts,I-Entity
in,O
the,O
117,O
remaining,O
infants,O
was,O
14%,O
(,O
16,O
of,O
117,O
),O
.,O
The,O
incidence,O
of,O
subependymal,B-Entity
cysts,I-Entity
in,O
infants,O
exposed,O
to,O
cocaine,I-Entity
prenatally,O
was,O
44%,O
(,O
8,O
of,O
18,O
),O
compared,O
with,O
8%,O
(,O
8,O
of,O
99,O
),O
in,O
the,O
unexposed,O
group,O
(,O
p,O
We,O
found,O
an,O
increased,O
incidence,O
of,O
subependymal,B-Entity
cyst,I-Entity
formation,O
in,O
preterm,B-Entity
infants,I-Entity
who,O
were,O
exposed,O
to,O
cocaine,I-Entity
prenatally,O
.,O
Thalidomide,I-Entity
neuropathy,I-Entity
in,O
patients,O
treated,O
for,O
metastatic,O
prostate,B-Entity
cancer,I-Entity
.,O
We,O
prospectively,O
evaluated,O
thalidomide,I-Entity
-,O
induced,O
neuropathy,I-Entity
using,O
electrodiagnostic,O
studies,O
.,O
Sixty,O
-,O
seven,O
men,O
with,O
metastatic,O
androgen,I-Entity
-,O
independent,O
prostate,B-Entity
cancer,I-Entity
in,O
an,O
open,O
-,O
label,O
trial,O
of,O
oral,O
thalidomide,I-Entity
underwent,O
neurologic,O
examinations,O
and,O
nerve,O
conduction,O
studies,O
(,O
NCS,O
),O
prior,O
to,O
and,O
at,O
3-month,O
intervals,O
during,O
treatment,O
.,O
Thalidomide,I-Entity
was,O
discontinued,O
in,O
55,O
patients,O
for,O
lack,O
of,O
therapeutic,O
response,O
.,O
Of,O
67,O
patients,O
initially,O
enrolled,O
",",O
24,O
remained,O
on,O
thalidomide,I-Entity
for,O
3,O
months,O
",",O
8,O
remained,O
at,O
6,O
months,O
",",O
and,O
3,O
remained,O
at,O
9,O
months,O
.,O
Six,O
patients,O
developed,O
neuropathy,I-Entity
.,O
Neuropathy,I-Entity
may,O
thus,O
be,O
a,O
common,O
complication,O
of,O
thalidomide,I-Entity
in,O
older,O
patients,O
.,O
The,O
SNAP,O
index,O
can,O
be,O
used,O
to,O
monitor,O
peripheral,B-Entity
neuropathy,I-Entity
",",O
but,O
not,O
for,O
early,O
detection,O
.,O
Overexpression,O
of,O
copper,I-Entity
/,O
zinc,I-Entity
-,O
superoxide,I-Entity
dismutase,O
protects,O
from,O
kanamycin,I-Entity
-,O
induced,O
hearing,B-Entity
loss,I-Entity
.,O
The,O
participation,O
of,O
reactive,O
oxygen,I-Entity
species,O
in,O
aminoglycoside,I-Entity
-,O
induced,O
ototoxicity,I-Entity
has,O
been,O
deduced,O
from,O
observations,O
that,O
aminoglycoside,I-Entity
-,O
iron,I-Entity
complexes,O
catalyze,O
the,O
formation,O
of,O
superoxide,I-Entity
radicals,O
in,O
vitro,O
and,O
that,O
antioxidants,O
attenuate,O
ototoxicity,I-Entity
in,O
vivo,O
.,O
We,O
therefore,O
hypothesized,O
that,O
overexpression,O
of,O
Cu,I-Entity
/,O
Zn,I-Entity
-,O
superoxide,I-Entity
dismutase,O
(,O
h,O
-,O
SOD1,O
),O
should,O
protect,O
transgenic,O
mice,O
from,O
ototoxicity,I-Entity
.,O
Transgenic,O
and,O
nontransgenic,O
littermates,O
received,O
kanamycin,I-Entity
(,O
400,O
mg,O
/,O
kg,O
body,O
weight,O
/,O
day,O
),O
for,O
10,O
days,O
beginning,O
on,O
day,O
10,O
after,O
birth,O
.,O
In,O
nontransgenic,O
animals,O
",",O
the,O
threshold,O
in,O
the,O
kanamycin,I-Entity
-,O
treated,O
group,O
was,O
45,O
-,O
50,O
dB,O
higher,O
than,O
in,O
saline,O
-,O
injected,O
controls,O
.,O
In,O
the,O
transgenic,O
group,O
",",O
kanamycin,I-Entity
increased,O
the,O
threshold,O
by,O
only,O
15,O
dB,O
over,O
the,O
respective,O
controls,O
.,O
The,O
protection,O
by,O
overexpression,O
of,O
superoxide,I-Entity
dismutase,O
supports,O
the,O
hypothesis,O
that,O
oxidant,O
stress,O
plays,O
a,O
significant,O
role,O
in,O
aminoglycoside,I-Entity
-,O
induced,O
ototoxicity,I-Entity
.,O
Prednisone,I-Entity
induces,O
anxiety,I-Entity
and,O
glial,O
cerebral,O
changes,O
in,O
rats,O
.,O
OBJECTIVE,O
:,O
To,O
assess,O
whether,O
prednisone,I-Entity
(,O
PDN,I-Entity
),O
produces,O
anxiety,I-Entity
and/or,O
cerebral,O
glial,O
changes,O
in,O
rats,O
.,O
The,O
moderate,O
-,O
dose,O
group,O
received,O
5,O
mg,O
/,O
kg,O
/,O
day,O
PDN,I-Entity
released,O
from,O
a,O
subcutaneous,O
implant,O
.,O
In,O
the,O
high,O
-,O
dose,O
group,O
",",O
implants,O
containing,O
PDN,I-Entity
equivalent,O
to,O
60,O
mg,O
/,O
kg,O
/,O
day,O
were,O
applied,O
.,O
In,O
the,O
control,O
group,O
implants,O
contained,O
no,O
PDN,I-Entity
.,O
Anxiety,I-Entity
was,O
assessed,O
using,O
an,O
open,O
field,O
and,O
elevated,O
plus,O
-,O
maze,O
devices,O
.,O
Anxiety,I-Entity
was,O
documented,O
in,O
both,O
groups,O
of,O
PDN,I-Entity
treated,O
rats,O
compared,O
with,O
controls,O
.,O
The,O
magnitude,O
of,O
transformation,O
of,O
the,O
microglia,O
assessed,O
by,O
the,O
number,O
of,O
intersections,O
was,O
significantly,O
higher,O
in,O
the,O
PDN,I-Entity
groups,O
than,O
in,O
controls,O
in,O
the,O
prefrontal,O
cortex,O
(,O
moderate,O
-,O
dose,O
",",O
24.1,O
;,O
high,O
-,O
dose,O
",",O
23.6,O
;,O
controls,O
18.7,O
;,O
The,O
number,O
of,O
stained,O
microglia,O
cells,O
was,O
significantly,O
higher,O
in,O
the,O
PDN,I-Entity
treated,O
groups,O
in,O
the,O
prefrontal,O
cortex,O
than,O
in,O
controls,O
(,O
moderate,O
-,O
dose,O
",",O
29.1,O
;,O
high,O
-,O
dose,O
",",O
28.4,O
;,O
control,O
",",O
17.7,O
cells,O
per,O
field,O
;,O
p,O
<,O
0.01,O
),O
.,O
CONCLUSION,O
:,O
Subacute,O
exposure,O
to,O
PDN,I-Entity
induced,O
anxiety,I-Entity
and,O
reactivity,O
of,O
microglia,O
.,O
The,O
relevance,O
of,O
these,O
features,O
for,O
patients,O
using,O
PDN,I-Entity
remains,O
to,O
be,O
elucidated,O
.,O
Phase,O
II,O
study,O
of,O
carboplatin,I-Entity
and,O
liposomal,O
doxorubicin,I-Entity
in,O
patients,O
with,O
recurrent,O
squamous,B-Entity
cell,I-Entity
carcinoma,I-Entity
of,I-Entity
the,I-Entity
cervix,I-Entity
.,O
The,O
activity,O
of,O
the,O
combination,O
of,O
carboplatin,I-Entity
and,O
liposomal,O
doxorubicin,I-Entity
was,O
tested,O
in,O
a,O
Phase,O
II,O
study,O
of,O
patients,O
with,O
recurrent,O
cervical,B-Entity
carcinoma,I-Entity
.,O
METHODS,O
:,O
The,O
combination,O
of,O
carboplatin,I-Entity
(,O
area,O
under,O
the,O
concentration,O
curve,O
[,O
AUC,O
],O
",",O
5,O
),O
and,O
liposomal,O
doxorubicin,I-Entity
(,O
Doxil,I-Entity
;,O
starting,O
dose,O
",",O
40,O
mg,O
/,O
m(2,O
),O
),O
was,O
administered,O
intravenously,O
every,O
28,O
days,O
to,O
37,O
patients,O
with,O
recurrent,O
squamous,B-Entity
cell,I-Entity
cervical,I-Entity
carcinoma,I-Entity
to,O
determine,O
antitumor,O
activity,O
and,O
toxicity,I-Entity
profile,O
.,O
Twenty,O
-,O
nine,O
patients,O
were,O
assessable,O
for,O
response,O
",",O
and,O
35,O
patients,O
were,O
assessable,O
for,O
toxicity,I-Entity
.,O
The,O
main,O
toxic,O
effect,O
was,O
myelosuppression,I-Entity
",",O
with,O
Grade,O
3,O
and,O
4,O
neutropenia,I-Entity
in,O
16,O
patients,O
",",O
anemia,I-Entity
in,O
12,O
patients,O
",",O
thrombocytopenia,I-Entity
in,O
11,O
patients,O
",",O
and,O
neutropenic,B-Entity
fever,I-Entity
in,O
3,O
patients,O
.,O
Four,O
patients,O
had,O
five,O
infusion,O
-,O
related,O
reactions,O
during,O
the,O
infusion,O
of,O
liposomal,O
doxorubicin,I-Entity
",",O
leading,O
to,O
treatment,O
discontinuation,O
in,O
three,O
patients,O
.,O
Grade,O
>,O
or,O
=,O
2,O
nonhematologic,O
toxicity,I-Entity
included,O
nausea,I-Entity
in,O
17,O
patients,O
",",O
emesis,I-Entity
in,O
14,O
patients,O
",",O
fatigue,I-Entity
in,O
9,O
patients,O
",",O
mucositis,I-Entity
and/or,O
stomatitis,I-Entity
in,O
8,O
patients,O
",",O
constipation,I-Entity
in,O
6,O
patients,O
",",O
weight,B-Entity
loss,I-Entity
in,O
5,O
patients,O
",",O
hand,B-Entity
-,I-Entity
foot,I-Entity
syndrome,I-Entity
in,O
2,O
patients,O
",",O
and,O
skin,B-Entity
reactions,I-Entity
in,O
3,O
patients,O
.,O
The,O
combination,O
of,O
carboplatin,I-Entity
and,O
liposomal,O
doxorubicin,I-Entity
has,O
modest,O
activity,O
in,O
patients,O
with,O
recurrent,O
cervical,B-Entity
carcinoma,I-Entity
.,O
Antimicrobial,O
-,O
induced,O
mania,I-Entity
(,O
antibiomania,I-Entity
),O
:,O
a,O
review,O
of,O
spontaneous,O
reports,O
.,O
The,O
authors,O
reviewed,O
reported,O
cases,O
of,O
antibiotic,O
-,O
induced,O
manic,I-Entity
episodes,O
by,O
means,O
of,O
a,O
MEDLINE,O
and,O
PsychLit,O
search,O
for,O
reports,O
of,O
antibiotic,O
-,O
induced,O
mania,I-Entity
.,O
Twenty,O
-,O
one,O
reports,O
of,O
antimicrobial,O
-,O
induced,O
mania,I-Entity
were,O
found,O
in,O
the,O
literature,O
.,O
There,O
were,O
6,O
cases,O
implicating,O
clarithromycin,I-Entity
",",O
13,O
implicating,O
isoniazid,I-Entity
",",O
and,O
1,O
case,O
each,O
implicating,O
erythromycin,I-Entity
and,O
amoxicillin,I-Entity
.,O
Of,O
these,O
",",O
clarithromycin,I-Entity
was,O
implicated,O
in,O
23,O
(,O
27.6%,O
),O
cases,O
",",O
ciprofloxacin,I-Entity
in,O
12,O
(,O
14.4%,O
),O
cases,O
",",O
and,O
ofloxacin,I-Entity
in,O
10,O
(,O
12%,O
),O
cases,O
.,O
Cotrimoxazole,I-Entity
",",O
metronidazole,I-Entity
",",O
and,O
erythromycin,I-Entity
were,O
involved,O
in,O
15,O
reported,O
manic,I-Entity
episodes,O
.,O
Cases,O
reported,O
by,O
the,O
FDA,O
showed,O
clarithromycin,I-Entity
and,O
ciprofloxacin,I-Entity
to,O
be,O
the,O
most,O
frequently,O
associated,O
with,O
the,O
development,O
of,O
mania,I-Entity
.,O
Patients,O
have,O
an,O
increased,O
risk,O
of,O
developing,O
mania,I-Entity
while,O
being,O
treated,O
with,O
antimicrobials,O
.,O
Further,O
research,O
clearly,O
is,O
required,O
to,O
determine,O
the,O
incidence,O
of,O
antimicrobial,O
-,O
induced,O
mania,I-Entity
",",O
the,O
relative,O
risk,O
factors,O
of,O
developing,O
an,O
antimicrobial,O
-,O
induced,O
manic,I-Entity
episode,O
among,O
various,O
demographic,O
populations,O
",",O
and,O
the,O
incidence,O
of,O
patients,O
who,O
continue,O
to,O
have,O
persistent,O
affective,O
disorders,O
once,O
the,O
initial,O
episode,O
",",O
which,O
occurs,O
while,O
the,O
patient,O
is,O
taking,O
antibiotics,O
",",O
subsides,O
.,O
The,O
authors,O
elected,O
to,O
name,O
this,O
syndrome,O
"""",O
antibiomania,I-Entity
.,O
"""",O
Levodopa,I-Entity
-,O
induced,O
ocular,B-Entity
dyskinesias,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
ocular,B-Entity
dyskinesias,I-Entity
are,O
very,O
uncommon,O
.,O
Usually,O
they,O
occur,O
simultaneously,O
with,O
limb,O
peak,O
-,O
dose,O
choreatic,B-Entity
dyskinesias,I-Entity
.,O
We,O
report,O
on,O
a,O
patient,O
with,O
leftward,O
and,O
upward,O
deviations,O
of,O
gaze,O
during,O
the,O
peak,O
effect,O
of,O
levodopa,I-Entity
",",O
and,O
hypothesize,O
that,O
a,O
severe,O
dopaminergic,O
denervation,O
in,O
the,O
caudate,O
nucleus,O
is,O
needed,O
for,O
the,O
appearance,O
of,O
these,O
levodopa,I-Entity
-,O
induce,O
ocular,B-Entity
dyskinesias,I-Entity
.,O
A,O
comparison,O
of,O
glyceryl,B-Entity
trinitrate,I-Entity
with,O
diclofenac,I-Entity
for,O
the,O
treatment,O
of,O
primary,O
dysmenorrhea,I-Entity
:,O
an,O
open,O
",",O
randomized,O
",",O
cross,O
-,O
over,O
trial,O
.,O
Primary,O
dysmenorrhea,I-Entity
is,O
a,O
syndrome,O
characterized,O
by,O
painful,O
uterine,O
contractility,O
caused,O
by,O
a,O
hypersecretion,O
of,O
endometrial,O
prostaglandins,I-Entity
;,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
are,O
the,O
first,O
choice,O
for,O
its,O
treatment,O
.,O
However,O
",",O
in,O
vivo,O
and,O
in,O
vitro,O
studies,O
have,O
demonstrated,O
that,O
myometrial,O
cells,O
are,O
also,O
targets,O
of,O
the,O
relaxant,O
effects,O
of,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
the,O
efficacy,O
of,O
glyceryl,B-Entity
trinitrate,I-Entity
(,O
GTN,I-Entity
),O
",",O
an,O
NO,I-Entity
donor,O
",",O
in,O
the,O
resolution,O
of,O
primary,O
dysmenorrhea,I-Entity
in,O
comparison,O
with,O
diclofenac,I-Entity
(,O
DCF,I-Entity
),O
.,O
A,O
total,O
of,O
24,O
patients,O
with,O
the,O
diagnosis,O
of,O
severe,O
primary,O
dysmenorrhea,I-Entity
were,O
studied,O
during,O
two,O
consecutive,O
menstrual,O
cycles,O
.,O
cross,O
-,O
over,O
",",O
controlled,O
design,O
",",O
patients,O
were,O
randomized,O
to,O
receive,O
either,O
DCF,I-Entity
per,O
os,O
or,O
GTN,I-Entity
patches,O
the,O
first,O
days,O
of,O
menses,O
",",O
when,O
menstrual,O
cramps,O
became,O
unendurable,O
.,O
Patients,O
received,O
up,O
to,O
3,O
doses,O
/,O
day,O
of,O
50,O
mg,O
DCF,I-Entity
or,O
2.5,O
mg/24,O
h,O
transdermal,O
GTN,I-Entity
for,O
the,O
first,O
3,O
days,O
of,O
the,O
cycle,O
",",O
according,O
to,O
their,O
needs,O
.,O
The,O
difference,O
in,O
pain,I-Entity
intensity,O
score,O
(,O
DPI,O
),O
was,O
the,O
main,O
outcome,O
variable,O
.,O
Both,O
treatments,O
significantly,O
reduced,O
DPI,O
by,O
the,O
30th,O
minute,O
(,O
GTN,I-Entity
",",O
-12.8,O
DCF,I-Entity
",",O
-18.9,O
However,O
",",O
DCF,I-Entity
continued,O
to,O
be,O
effective,O
in,O
reducing,O
pelvic,B-Entity
pain,I-Entity
for,O
two,O
hours,O
",",O
whereas,O
GTN,I-Entity
scores,O
remained,O
more,O
or,O
less,O
stable,O
after,O
30,O
min,O
and,O
significantly,O
higher,O
than,O
those,O
for,O
DFC,O
(,O
after,O
one,O
hour,O
:,O
GTN,I-Entity
",",O
-12.8,O
16.6,O
and,O
after,O
two,O
hours,O
:,O
GTN,I-Entity
",",O
-23.7,O
Low,B-Entity
back,I-Entity
pain,I-Entity
was,O
also,O
relieved,O
by,O
both,O
drugs,O
.,O
Headache,I-Entity
was,O
significantly,O
increased,O
by,O
GTN,I-Entity
but,O
not,O
by,O
DCF,I-Entity
.,O
Eight,O
patients,O
stopped,O
using,O
GTN,I-Entity
because,O
headache,I-Entity
--,O
attributed,O
to,O
its,O
use,O
--,O
became,O
intolerable,O
.,O
These,O
findings,O
indicate,O
that,O
GTN,I-Entity
has,O
a,O
reduced,O
efficacy,O
and,O
tolerability,O
by,O
comparison,O
with,O
DCF,I-Entity
in,O
the,O
treatment,O
of,O
primary,O
dysmenorrhea,I-Entity
.,O
Temocapril,I-Entity
",",O
a,O
long,O
-,O
acting,O
non,O
-,O
SH,O
group,O
angiotensin,I-Entity
converting,O
enzyme,O
inhibitor,O
",",O
modulates,O
glomerular,B-Entity
injury,I-Entity
in,O
chronic,O
puromycin,B-Entity
aminonucleoside,I-Entity
nephrosis,I-Entity
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
whether,O
chronic,O
administration,O
of,O
temocapril,I-Entity
",",O
a,O
long,O
-,O
acting,O
non,O
-,O
SH,O
group,O
angiotensin,I-Entity
converting,O
enzyme,O
(,O
ACE,O
),O
inhibitor,O
",",O
reduced,O
proteinuria,I-Entity
",",O
inhibited,O
glomerular,O
hypertrophy,I-Entity
and,O
prevented,O
glomerulosclerosis,I-Entity
in,O
chronic,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
-,O
induced,O
nephrotic,I-Entity
rats,O
.,O
Nephrosis,I-Entity
was,O
induced,O
by,O
injection,O
of,O
PAN,I-Entity
(,O
15mg/100,O
g,O
body,O
weight,O
),O
in,O
male,O
Sprague,O
-,O
Dawley,O
(,O
SD,O
),O
rats,O
.,O
Four,O
groups,O
were,O
used,O
",",O
i,O
),O
the,O
PAN,I-Entity
group,O
(,O
14,O
),O
",",O
ii,O
),O
PAN,I-Entity
/,O
temocapril,I-Entity
(,O
13,O
),O
",",O
iii,O
),O
temocapril,I-Entity
(,O
14,O
),O
and,O
iv,O
),O
untreated,O
controls,O
(,O
15,O
),O
.,O
Temocapril,I-Entity
(,O
8,O
mg,O
/,O
kg,O
/,O
day,O
),O
was,O
administered,O
to,O
the,O
rats,O
which,O
were,O
killed,O
at,O
weeks,O
4,O
",",O
14,O
or,O
20,O
.,O
Systolic,O
BP,O
in,O
the,O
PAN,I-Entity
group,O
was,O
significantly,O
high,O
at,O
4,O
",",O
14,O
and,O
20,O
weeks,O
",",O
but,O
was,O
normal,O
in,O
the,O
PAN,I-Entity
/,O
temocapril,I-Entity
group,O
.,O
Urinary,O
protein,O
excretion,O
in,O
the,O
PAN,I-Entity
group,O
increased,O
significantly,O
",",O
peaking,O
at,O
8,O
days,O
",",O
then,O
decreased,O
at,O
4,O
weeks,O
",",O
but,O
rose,O
again,O
significantly,O
at,O
14,O
and,O
20,O
weeks,O
.,O
Temocapril,I-Entity
did,O
not,O
attenuate,O
proteinuria,I-Entity
at,O
8,O
days,O
",",O
but,O
it,O
did,O
markedly,O
lower,O
it,O
from,O
weeks,O
4,O
to,O
20,O
.,O
The,O
glomerulosclerosis,I-Entity
index,O
(,O
GSI,O
),O
was,O
6.21,O
%,O
at,O
4,O
weeks,O
and,O
respectively,O
25.35,O
%,O
and,O
30.49,O
%,O
at,O
14,O
and,O
20,O
weeks,O
in,O
the,O
PAN,I-Entity
group,O
.,O
The,O
ratio,O
of,O
glomerular,O
tuft,O
area,O
to,O
the,O
area,O
of,O
Bowman,O
's,O
capsules,O
(,O
GT,O
/,O
BC,O
),O
in,O
the,O
PAN,I-Entity
group,O
was,O
significantly,O
increased,O
",",O
but,O
it,O
was,O
significantly,O
lower,O
in,O
the,O
PAN,I-Entity
/,O
temocapril,I-Entity
group,O
.,O
It,O
appears,O
that,O
temocapril,I-Entity
was,O
effective,O
in,O
retarding,O
renal,O
progression,O
and,O
protected,O
renal,O
function,O
in,O
PAN,I-Entity
neprotic,I-Entity
rats,O
.,O
Pulmonary,B-Entity
hypertension,I-Entity
after,O
ibuprofen,I-Entity
prophylaxis,O
in,O
very,O
preterm,O
infants,O
.,O
We,O
report,O
three,O
cases,O
of,O
severe,O
hypoxaemia,I-Entity
after,O
ibuprofen,I-Entity
administration,O
during,O
a,O
randomised,O
controlled,O
trial,O
of,O
prophylactic,O
treatment,O
of,O
patent,B-Entity
ductus,I-Entity
arteriosus,I-Entity
with,O
ibuprofen,I-Entity
in,O
premature,O
infants,O
born,O
at,O
less,O
than,O
28,O
weeks,O
of,O
gestation,O
.,O
Hypoxaemia,I-Entity
resolved,O
quickly,O
on,O
inhaled,O
nitric,B-Entity
oxide,I-Entity
therapy,O
.,O
We,O
suggest,O
that,O
investigators,O
involved,O
in,O
similar,O
trials,O
pay,O
close,O
attention,O
to,O
pulmonary,O
pressure,O
if,O
hypoxaemia,I-Entity
occurs,O
after,O
prophylactic,O
administration,O
of,O
ibuprofen,I-Entity
.,O
Hyponatremia,I-Entity
and,O
syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
anti,I-Entity
-,I-Entity
diuretic,I-Entity
hormone,I-Entity
reported,O
with,O
the,O
use,O
of,O
Vincristine,I-Entity
:,O
an,O
over,O
-,O
representation,O
of,O
Asians,O
?,O
This,O
retrospective,O
study,O
used,O
a,O
pharmaceutical,O
company,O
's,O
global,O
safety,O
database,O
to,O
determine,O
the,O
reporting,O
rate,O
of,O
hyponatremia,I-Entity
and/or,O
syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
secretion,I-Entity
of,I-Entity
anti,I-Entity
-,I-Entity
diuretic,I-Entity
hormone,I-Entity
(,O
SIADH,I-Entity
),O
among,O
vincristine,I-Entity
-,O
treated,O
patients,O
and,O
to,O
explore,O
the,O
possibility,O
of,O
at,O
-,O
risk,O
population,O
subgroups,O
.,O
METHOD,O
:,O
We,O
searched,O
the,O
Eli,O
Lilly,O
and,O
Company,O
's,O
computerized,O
adverse,O
event,O
database,O
for,O
all,O
reported,O
cases,O
of,O
hyponatremia,I-Entity
and/or,O
SIADH,I-Entity
as,O
of,O
1,O
November,O
1999,O
that,O
had,O
been,O
reported,O
during,O
the,O
use,O
of,O
vincristine,I-Entity
.,O
A,O
total,O
of,O
76,O
cases,O
of,O
hyponatremia,I-Entity
and/or,O
SIADH,I-Entity
associated,O
with,O
vincristine,I-Entity
use,O
were,O
identified,O
.,O
Approximately,O
75%,O
of,O
the,O
patients,O
were,O
receiving,O
treatment,O
for,O
leukemia,I-Entity
or,O
lymphoma,I-Entity
.,O
CONCLUSION,O
:,O
Our,O
data,O
suggest,O
that,O
Asian,O
patients,O
may,O
be,O
at,O
increased,O
risk,O
of,O
hyponatremia,I-Entity
and/or,O
SIADH,I-Entity
associated,O
with,O
vincristine,I-Entity
use,O
.,O
Although,O
the,O
overall,O
reported,O
rate,O
of,O
SIADH,I-Entity
associated,O
with,O
vincristine,I-Entity
is,O
very,O
low,O
",",O
physicians,O
caring,O
for,O
Asian,O
oncology,O
patients,O
should,O
be,O
aware,O
of,O
this,O
potential,O
serious,O
but,O
reversible,O
adverse,O
event,O
.,O
Delayed,O
toxicity,I-Entity
of,O
cyclophosphamide,I-Entity
on,O
the,O
bladder,O
of,O
DBA/2,O
and,O
C57BL/6,O
female,O
mouse,O
.,O
The,O
present,O
study,O
describes,O
the,O
delayed,O
development,O
of,O
a,O
severe,O
bladder,O
pathology,O
in,O
a,O
susceptible,O
strain,O
of,O
mice,O
(,O
DBA/2,O
),O
but,O
not,O
in,O
a,O
resistant,O
strain,O
(,O
C57BL/6,O
),O
when,O
both,O
were,O
treated,O
with,O
a,O
single,O
300,O
mg,O
/,O
kg,O
dose,O
of,O
cyclophosphamide,I-Entity
(,O
CY,I-Entity
),O
.,O
Inbred,O
DBA/2,O
and,O
C57BL/6,O
female,O
mice,O
were,O
injected,O
with,O
CY,I-Entity
",",O
and,O
the,O
effect,O
of,O
the,O
drug,O
on,O
the,O
bladder,O
was,O
assessed,O
during,O
100,O
days,O
by,O
light,O
microscopy,O
using,O
different,O
staining,O
procedures,O
",",O
and,O
after,O
30,O
days,O
by,O
conventional,O
electron,O
microscopy,O
.,O
Early,O
CY,I-Entity
toxicity,I-Entity
caused,O
a,O
typical,O
haemorrhagic,I-Entity
cystitis,I-Entity
in,O
both,O
strains,O
that,O
was,O
completely,O
repaired,O
in,O
about,O
7,O
-,O
10,O
days,O
.,O
After,O
30,O
days,O
of,O
CY,I-Entity
injection,O
ulcerous,O
and,O
non,O
-,O
ulcerous,O
forms,O
of,O
chronic,O
cystitis,I-Entity
appeared,O
in,O
86%,O
of,O
DBA/2,O
mice,O
but,O
only,O
in,O
4%,O
of,O
C57BL/6,O
mice,O
.,O
Delayed,O
cystitis,I-Entity
was,O
characterized,O
by,O
infiltration,O
and,O
transepithelial,O
passage,O
into,O
the,O
lumen,O
of,O
inflammatory,O
cells,O
and,O
by,O
frequent,O
exfoliation,O
of,O
the,O
urothelium,O
.,O
Delayed,O
cystitis,I-Entity
still,O
persisted,O
in,O
DBA/2,O
mice,O
100,O
days,O
after,O
treatment,O
.,O
These,O
results,O
indicate,O
that,O
delayed,O
toxicity,I-Entity
of,O
CY,I-Entity
in,O
female,O
DBA/2,O
mice,O
causes,O
a,O
bladder,O
pathology,O
that,O
is,O
not,O
observed,O
in,O
C57BL/6,O
mice,O
.,O
This,O
pathology,O
resembles,O
interstitial,B-Entity
cystitis,I-Entity
in,O
humans,O
and,O
could,O
perhaps,O
be,O
used,O
as,O
an,O
animal,O
model,O
for,O
studies,O
on,O
the,O
disease,O
.,O
High,O
-,O
dose,O
5-fluorouracil,I-Entity
/,O
folinic,B-Entity
acid,I-Entity
in,O
combination,O
with,O
three,O
-,O
weekly,O
mitomycin,B-Entity
C,I-Entity
in,O
the,O
treatment,O
of,O
advanced,O
gastric,B-Entity
cancer,I-Entity
.,O
BACKGROUND,O
:,O
The,O
24-hour,O
continuous,O
infusion,O
of,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
and,O
folinic,B-Entity
acid,I-Entity
(,O
FA,I-Entity
),O
as,O
part,O
of,O
several,O
new,O
multidrug,O
chemotherapy,O
regimens,O
in,O
advanced,O
gastric,B-Entity
cancer,I-Entity
(,O
AGC,I-Entity
),O
has,O
shown,O
to,O
be,O
effective,O
",",O
with,O
low,O
toxicity,I-Entity
.,O
In,O
a,O
previous,O
phase,O
II,O
study,O
with,O
3-weekly,O
bolus,O
5-FU,I-Entity
",",O
FA,I-Entity
and,O
mitomycin,B-Entity
C,I-Entity
(,O
MMC,I-Entity
),O
we,O
found,O
a,O
low,O
toxicity,I-Entity
rate,O
and,O
response,O
rates,O
comparable,O
to,O
those,O
of,O
regimens,O
such,O
as,O
ELF,O
",",O
FAM,O
or,O
FAMTX,O
",",O
and,O
a,O
promising,O
median,O
overall,O
survival,O
.,O
In,O
order,O
to,O
improve,O
this,O
MMC,I-Entity
-,O
dependent,O
schedule,O
we,O
initiated,O
a,O
phase,O
II,O
study,O
with,O
high,O
-,O
dose,O
5-FU,I-Entity
/,O
FA,I-Entity
and,O
3-weekly,O
bolus,O
MMC,I-Entity
.,O
From,O
February,O
",",O
1998,O
to,O
September,O
",",O
2000,O
we,O
recruited,O
33,O
patients,O
with,O
AGC,I-Entity
to,O
receive,O
weekly,O
24-hour,O
5-FU,I-Entity
"2,600",O
mg,O
/,O
m(2,O
),O
preceded,O
by,O
2-hour,O
FA,I-Entity
500,O
mg,O
/,O
m(2,O
),O
for,O
6,O
weeks,O
",",O
followed,O
by,O
a,O
2-week,O
rest,O
period,O
.,O
MMC,I-Entity
10,O
mg,O
/,O
m(2,O
),O
was,O
added,O
in,O
3-weekly,O
intervals,O
.,O
18,O
patients,O
had,O
a,O
primary,O
AGC,I-Entity
",",O
and,O
15,O
showed,O
a,O
relapsed,O
AGC,I-Entity
.,O
The,O
worst,O
toxicities,I-Entity
(,O
%,O
),O
observed,O
were,O
(,O
CTC,O
-,O
NCI,O
1/2/3,O
),O
:,O
leukopenia,I-Entity
45.5/18.2/6.1,O
",",O
thrombocytopenia,I-Entity
33.3/9.1/6.1,O
",",O
vomitus,I-Entity
24.2/9.1/0,O
",",O
diarrhea,I-Entity
36.4/6.1/3.0,O
",",O
stomatitis,I-Entity
18.2/9.1/0,O
",",O
hand,B-Entity
-,I-Entity
foot,I-Entity
syndrome,I-Entity
12.1/0/0,O
.,O
Two,O
patients,O
developed,O
hemolytic,B-Entity
-,I-Entity
uremic,I-Entity
syndrome,I-Entity
(,O
HUS,I-Entity
),O
.,O
High,O
-,O
dose,O
5-FU,I-Entity
/,O
FA,I-Entity
/,O
MMC,I-Entity
is,O
an,O
effective,O
and,O
well,O
-,O
tolerated,O
outpatient,O
regimen,O
for,O
AGC,I-Entity
(,O
objective,O
response,O
rate,O
54.6%,O
),O
.,O
It,O
may,O
serve,O
as,O
an,O
alternative,O
to,O
cisplatin,I-Entity
-,O
containing,O
regimens,O
;,O
however,O
",",O
it,O
has,O
to,O
be,O
considered,O
that,O
possibly,O
HUS,I-Entity
may,O
occur,O
.,O
Persistent,O
sterile,O
leukocyturia,I-Entity
is,O
associated,O
with,O
impaired,B-Entity
renal,I-Entity
function,I-Entity
in,O
human,B-Entity
immunodeficiency,I-Entity
virus,I-Entity
type,I-Entity
1-infected,I-Entity
children,O
treated,O
with,O
indinavir,I-Entity
.,O
BACKGROUND,O
:,O
Prolonged,O
administration,O
of,O
indinavir,I-Entity
is,O
associated,O
with,O
the,O
occurrence,O
of,O
a,O
variety,O
of,O
renal,O
complications,O
in,O
adults,O
.,O
A,O
prospective,O
study,O
to,O
monitor,O
indinavir,I-Entity
-,O
related,O
nephrotoxicity,I-Entity
in,O
a,O
cohort,O
of,O
30,O
human,B-Entity
immunodeficiency,I-Entity
virus,I-Entity
type,I-Entity
1-infected,I-Entity
children,O
treated,O
with,O
indinavir,I-Entity
.,O
METHODS,O
:,O
Urinary,O
pH,O
",",O
albumin,O
",",O
creatinine,I-Entity
",",O
the,O
presence,O
of,O
erythrocytes,O
",",O
leukocytes,O
",",O
bacteria,O
and,O
crystals,O
",",O
and,O
culture,O
were,O
analyzed,O
every,O
3,O
months,O
for,O
96,O
weeks,O
.,O
Serum,O
creatinine,I-Entity
levels,O
were,O
routinely,O
determined,O
at,O
the,O
same,O
time,O
points,O
.,O
Steady,O
-,O
state,O
pharmacokinetics,O
of,O
indinavir,I-Entity
were,O
done,O
at,O
week,O
4,O
after,O
the,O
initiation,O
of,O
indinavir,I-Entity
.,O
The,O
cumulative,O
incidence,O
of,O
persistent,O
sterile,O
leukocyturia,I-Entity
(,O
>,O
or,O
=,O
75,O
cells/,O
micro,O
L,O
in,O
at,O
least,O
2,O
consecutive,O
visits,O
),O
after,O
96,O
weeks,O
was,O
53%,O
.,O
Persistent,O
sterile,O
leukocyturia,I-Entity
was,O
frequently,O
associated,O
with,O
a,O
mild,O
increase,O
in,O
the,O
urine,O
albumin,O
/,O
creatinine,I-Entity
ratio,O
and,O
by,O
microscopic,O
hematuria,I-Entity
.,O
The,O
cumulative,O
incidence,O
of,O
serum,O
creatinine,I-Entity
levels,O
>,O
50%,O
above,O
normal,O
was,O
33%,O
after,O
96,O
weeks,O
.,O
Children,O
with,O
persistent,O
sterile,O
leukocyturia,I-Entity
more,O
frequently,O
had,O
serum,O
creatinine,I-Entity
levels,O
of,O
50%,O
above,O
normal,O
than,O
those,O
children,O
without,O
persistent,O
sterile,O
leukocyturia,I-Entity
.,O
In,O
children,O
younger,O
than,O
5.6,O
years,O
",",O
persistent,O
sterile,O
leukocyturia,I-Entity
was,O
significantly,O
more,O
frequent,O
than,O
in,O
older,O
children,O
.,O
A,O
higher,O
cumulative,O
incidence,O
of,O
persistent,O
leukocyturia,I-Entity
was,O
found,O
in,O
children,O
with,O
an,O
area,O
under,O
the,O
curve,O
>,O
19,O
mg,O
/,O
L,O
x,O
h,O
or,O
a,O
peak,O
serum,O
level,O
of,O
indinavir,I-Entity
>,O
12,O
mg,O
In,O
4,O
children,O
",",O
indinavir,I-Entity
was,O
discontinued,O
because,O
of,O
nephrotoxicity,I-Entity
.,O
Subsequently,O
",",O
the,O
serum,O
creatinine,I-Entity
levels,O
decreased,O
",",O
the,O
urine,O
albumin,O
/,O
creatinine,I-Entity
ratios,O
returned,O
to,O
zero,O
",",O
and,O
the,O
leukocyturia,I-Entity
disappeared,O
within,O
3,O
months,O
.,O
Children,O
treated,O
with,O
indinavir,I-Entity
have,O
a,O
high,O
cumulative,O
incidence,O
of,O
persistent,O
sterile,O
leukocyturia,I-Entity
.,O
Children,O
with,O
persistent,O
sterile,O
leukocyturia,I-Entity
more,O
frequently,O
had,O
an,O
increase,O
in,O
serum,O
creatinine,I-Entity
levels,O
of,O
>,O
50%,O
above,O
normal,O
.,O
The,O
impairment,B-Entity
of,I-Entity
the,I-Entity
renal,I-Entity
function,I-Entity
in,O
these,O
children,O
occurred,O
in,O
the,O
absence,O
of,O
clinical,O
symptoms,O
of,O
nephrolithiasis,I-Entity
.,O
Indinavir,I-Entity
-,O
associated,O
nephrotoxicity,I-Entity
must,O
be,O
monitored,O
closely,O
",",O
especially,O
in,O
children,O
with,O
risk,O
factors,O
such,O
as,O
persistent,O
sterile,O
leukocyturia,I-Entity
",",O
age,O
<,O
5.6,O
years,O
",",O
an,O
area,O
under,O
the,O
curve,O
of,O
indinavir,I-Entity
>,O
19,O
mg,O
/,O
L,O
x,O
h,O
",",O
and,O
a,O
C(max,O
),O
Utility,O
of,O
troponin,O
I,O
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
.,O
Baseline,O
electrocardiogram,O
abnormalities,O
and,O
market,O
elevations,O
not,O
associated,O
with,O
myocardial,B-Entity
necrosis,I-Entity
make,O
accurate,O
diagnosis,O
of,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
difficult,O
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
assess,O
outcomes,O
based,O
on,O
troponin,O
positivity,O
in,O
patients,O
with,O
cocaine,I-Entity
chest,B-Entity
pain,I-Entity
admitted,O
for,O
exclusion,O
of,O
MI,I-Entity
.,O
Outcomes,O
were,O
examined,O
in,O
patients,O
admitted,O
for,O
possible,O
MI,I-Entity
after,O
cocaine,I-Entity
use,O
.,O
All,O
patients,O
underwent,O
a,O
rapid,O
rule,O
-,O
in,O
protocol,O
that,O
included,O
serial,O
sampling,O
of,O
creatine,I-Entity
kinase,O
(,O
CK,O
),O
",",O
CK,O
-,O
MB,O
",",O
and,O
cardiac,O
troponin,O
I,O
(,O
cTnI,O
),O
over,O
eight,O
hours,O
.,O
Outcomes,O
included,O
CK,O
-,O
MB,O
MI,I-Entity
(,O
CK,O
-,O
MB,O
>,O
or=,O
4,O
",",O
cardiac,B-Entity
death,I-Entity
",",O
and,O
significant,O
coronary,B-Entity
disease,I-Entity
(,O
>,O
or=50%,O
),O
.,O
Of,O
the,O
246,O
admitted,O
patients,O
",",O
34,O
(,O
14%,O
),O
met,O
CK,O
-,O
MB,O
criteria,O
for,O
MI,I-Entity
and,O
38,O
(,O
16%,O
),O
Three,O
of,O
the,O
four,O
patients,O
without,O
significant,O
disease,O
who,O
had,O
cTnI,O
elevations,O
met,O
CK,O
-,O
MB,O
criteria,O
for,O
MI,I-Entity
",",O
and,O
the,O
other,O
had,O
a,O
peak,O
CK,O
-,O
MB,O
level,O
of,O
13,O
ng,O
/,O
mL.,O
Sensitivities,O
",",O
specificities,O
",",O
and,O
positive,O
and,O
negative,O
likelihood,O
ratios,O
for,O
predicting,O
cardiac,B-Entity
death,I-Entity
or,O
significant,O
disease,O
were,O
high,O
for,O
both,O
CK,O
-,O
MB,O
MI,I-Entity
and,O
cTnI,O
and,O
were,O
not,O
significantly,O
different,O
.,O
CONCLUSIONS,O
:,O
Most,O
patients,O
with,O
cTnI,O
elevations,O
meet,O
CK,O
-,O
MB,O
criteria,O
for,O
MI,I-Entity
",",O
as,O
well,O
as,O
have,O
a,O
high,O
incidence,O
of,O
underlying,O
significant,O
disease,O
.,O
Troponin,O
appears,O
to,O
have,O
an,O
equivalent,O
diagnostic,O
accuracy,O
compared,O
with,O
CK,O
-,O
MB,O
for,O
diagnosing,O
necrosis,I-Entity
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
and,O
suspected,O
MI,I-Entity
.,O
Acute,O
interstitial,B-Entity
nephritis,I-Entity
due,O
to,O
nicergoline,I-Entity
(,O
Sermion,I-Entity
),O
.,O
We,O
report,O
a,O
case,O
of,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
(,O
AIN,I-Entity
),O
due,O
to,O
nicergoline,I-Entity
(,O
Sermion,I-Entity
),O
.,O
A,O
50-year,O
-,O
old,O
patient,O
admitted,O
to,O
our,O
hospital,O
for,O
fever,I-Entity
and,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
Before,O
admission,O
",",O
he,O
had,O
been,O
taking,O
nicergoline,I-Entity
and,O
bendazac,B-Entity
lysine,I-Entity
due,O
to,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
at,O
ophthalmologic,O
department,O
.,O
Thereafter,O
",",O
he,O
experienced,O
intermittent,O
fever,I-Entity
and,O
skin,B-Entity
rash,I-Entity
.,O
On,O
admission,O
",",O
clinical,O
symptoms,O
(,O
i.e.,O
arthralgia,I-Entity
and,O
fever,I-Entity
),O
and,O
laboratory,O
findings,O
(,O
i.e.,O
eosinophilia,I-Entity
and,O
renal,B-Entity
failure,I-Entity
),O
suggested,O
AIN,I-Entity
",",O
and,O
which,O
was,O
confirmed,O
by,O
pathologic,O
findings,O
on,O
renal,O
biopsy,O
.,O
A,O
lymphocyte,O
transformation,O
test,O
demonstrated,O
a,O
positive,O
result,O
against,O
nicergoline,I-Entity
.,O
Treatment,O
was,O
consisted,O
of,O
withdrawal,O
of,O
nicergoline,I-Entity
and,O
intravenous,O
methylprednisolone,I-Entity
",",O
and,O
his,O
renal,O
function,O
was,O
completely,O
recovered,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
report,O
of,O
nicergoline,I-Entity
-,O
associated,O
AIN,I-Entity
.,O
Neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
complicated,O
by,O
massive,O
intestinal,O
bleeding,I-Entity
in,O
a,O
patient,O
with,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
.,O
A,O
patient,O
with,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
(,O
CRF,I-Entity
),O
developed,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
(,O
NMS,I-Entity
),O
after,O
administration,O
of,O
risperidone,I-Entity
and,O
levomepromazine,I-Entity
.,O
In,O
addition,O
to,O
the,O
typical,O
symptoms,O
of,O
NMS,I-Entity
",",O
massive,O
intestinal,O
bleeding,I-Entity
was,O
observed,O
during,O
the,O
episode,O
.,O
This,O
report,O
suggests,O
that,O
NMS,I-Entity
in,O
a,O
patient,O
with,O
CRF,I-Entity
may,O
be,O
complicated,O
by,O
intestinal,O
bleeding,I-Entity
and,O
needs,O
special,O
caution,O
for,O
this,O
complication,O
.,O
Adrenaline,I-Entity
-,O
induced,O
hypertension,I-Entity
was,O
used,O
to,O
destroy,O
the,O
BBB,O
",",O
which,O
was,O
evaluated,O
using,O
triphenyltetrazolium,I-Entity
(,O
TTC,I-Entity
),O
staining,O
of,O
the,O
brain,O
slices,O
just,O
after,O
giving,O
adrenaline,I-Entity
for,O
30,O
s.,O
In,O
normal,O
rats,O
",",O
the,O
whole,O
brain,O
sections,O
exhibited,O
complete,O
staining,O
with,O
TTC,I-Entity
.,O
After,O
adrenaline,I-Entity
infusion,O
for,O
30,O
s,O
",",O
there,O
were,O
large,O
unstained,O
areas,O
in,O
the,O
left,O
brain,O
in,O
right,O
-,O
pawed,O
animals,O
",",O
and,O
vice,O
versa,O
in,O
left,O
-,O
pawed,O
animals,O
.,O
Similar,O
results,O
were,O
obtained,O
in,O
seizure,I-Entity
-,O
induced,O
breakdown,O
of,O
BBB,O
.,O
Carvedilol,I-Entity
protects,O
against,O
doxorubicin,I-Entity
-,O
induced,O
mitochondrial,O
cardiomyopathy,I-Entity
.,O
Several,O
cytopathic,O
mechanisms,O
have,O
been,O
suggested,O
to,O
mediate,O
the,O
dose,O
-,O
limiting,O
cumulative,O
and,O
irreversible,O
cardiomyopathy,I-Entity
caused,O
by,O
doxorubicin,I-Entity
.,O
Recent,O
evidence,O
indicates,O
that,O
oxidative,O
stress,O
and,O
mitochondrial,B-Entity
dysfunction,I-Entity
are,O
key,O
factors,O
in,O
the,O
pathogenic,O
process,O
.,O
The,O
objective,O
of,O
this,O
investigation,O
was,O
to,O
test,O
the,O
hypothesis,O
that,O
carvedilol,I-Entity
",",O
a,O
nonselective,O
beta,O
-,O
adrenergic,O
receptor,O
antagonist,O
with,O
potent,O
antioxidant,O
properties,O
",",O
protects,O
against,O
the,O
cardiac,O
and,O
hepatic,O
mitochondrial,O
bioenergetic,O
dysfunction,O
associated,O
with,O
subchronic,O
doxorubicin,I-Entity
toxicity,I-Entity
.,O
Heart,O
and,O
liver,O
mitochondria,O
were,O
isolated,O
from,O
rats,O
treated,O
for,O
7,O
weeks,O
with,O
doxorubicin,I-Entity
(,O
2,O
mg,O
/,O
kg,O
sc,O
/,O
week,O
),O
",",O
carvedilol,I-Entity
(,O
1,O
mg,O
/,O
kg,O
ip,O
/,O
week,O
),O
",",O
or,O
the,O
combination,O
of,O
the,O
two,O
drugs,O
.,O
Heart,O
mitochondria,O
isolated,O
from,O
doxorubicin,I-Entity
-,O
treated,O
rats,O
exhibited,O
depressed,O
rates,O
for,O
state,O
3,O
respiration,O
(,O
336,O
+,O
/-,O
Mitochondrial,O
calcium,I-Entity
-,O
loading,O
capacity,O
and,O
the,O
activity,O
of,O
NADH,O
-,O
dehydrogenase,O
were,O
also,O
suppressed,O
in,O
cardiac,O
mitochondria,O
from,O
doxorubicin,I-Entity
-,O
treated,O
rats,O
.,O
Doxorubicin,I-Entity
treatment,O
also,O
caused,O
a,O
decrease,O
in,O
RCR,O
for,O
liver,O
mitochondria,O
(,O
3.9,O
+,O
/-,O
Coadministration,O
of,O
carvedilol,I-Entity
decreased,O
the,O
extent,O
of,O
cellular,O
vacuolization,O
in,O
cardiac,O
myocytes,O
and,O
prevented,O
the,O
inhibitory,O
effect,O
of,O
doxorubicin,I-Entity
on,O
mitochondrial,O
respiration,O
in,O
both,O
heart,O
and,O
liver,O
.,O
Carvedilol,I-Entity
also,O
prevented,O
the,O
decrease,O
in,O
mitochondrial,O
Ca(2,I-Entity
+,O
),O
loading,O
capacity,O
and,O
the,O
inhibition,O
of,O
the,O
respiratory,O
complexes,O
of,O
heart,O
mitochondria,O
caused,O
by,O
doxorubicin,I-Entity
.,O
Carvedilol,I-Entity
by,O
itself,O
did,O
not,O
affect,O
any,O
of,O
the,O
parameters,O
measured,O
for,O
heart,O
or,O
liver,O
mitochondria,O
.,O
It,O
is,O
concluded,O
that,O
this,O
protection,O
by,O
carvedilol,I-Entity
against,O
both,O
the,O
structural,O
and,O
functional,O
cardiac,O
tissue,O
damage,O
may,O
afford,O
significant,O
clinical,O
advantage,O
in,O
minimizing,O
the,O
dose,O
-,O
limiting,O
mitochondrial,B-Entity
dysfunction,I-Entity
and,O
cardiomyopathy,I-Entity
that,O
accompanies,O
long,O
-,O
term,O
doxorubicin,I-Entity
therapy,O
in,O
cancer,I-Entity
patients,O
.,O
Cocaine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
is,O
more,O
influenced,O
by,O
adenosine,I-Entity
receptor,O
agonists,O
than,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
The,O
influence,O
of,O
adenosine,I-Entity
receptor,O
agonists,O
and,O
antagonists,O
on,O
cocaine,I-Entity
-,O
and,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
was,O
examined,O
in,O
mice,O
.,O
All,O
adenosine,I-Entity
receptor,O
agonists,O
significantly,O
decreased,B-Entity
the,I-Entity
locomotor,I-Entity
activity,I-Entity
in,O
mice,O
",",O
and,O
the,O
effects,O
were,O
dose,O
-,O
dependent,O
.,O
It,O
seems,O
that,O
adenosine,I-Entity
A1,O
and,O
A2,O
receptors,O
might,O
be,O
involved,O
in,O
this,O
reaction,O
.,O
Moreover,O
",",O
all,O
adenosine,I-Entity
receptor,O
agonists,O
:,O
2-p-(2-carboxyethyl)phenethylamino-5'-N,B-Entity
-,I-Entity
ethylcarboxamidoadenosine,I-Entity
(,O
CGS,B-Entity
21680,I-Entity
),O
",",O
A2A,O
receptor,O
agonist,O
",",O
N6-cyclopentyladenosine,I-Entity
(,O
CPA,I-Entity
),O
",",O
A1,O
receptor,O
agonist,O
",",O
and,O
5'-N,B-Entity
-,I-Entity
ethylcarboxamidoadenosine,I-Entity
(,O
NECA,I-Entity
),O
",",O
A2/A1,O
receptor,O
agonist,O
significantly,O
and,O
dose,O
-,O
dependently,O
decreased,O
cocaine,I-Entity
-,O
induced,O
locomotor,O
activity,O
.,O
CPA,I-Entity
reduced,O
cocaine,I-Entity
action,O
at,O
the,O
doses,O
which,O
",",O
given,O
alone,O
",",O
did,O
not,O
influence,O
motility,O
",",O
while,O
CGS,B-Entity
21680,I-Entity
and,O
NECA,I-Entity
decreased,O
the,O
action,O
of,O
cocaine,I-Entity
at,O
the,O
doses,O
which,O
",",O
given,O
alone,O
",",O
decreased,O
locomotor,O
activity,O
in,O
animals,O
.,O
These,O
results,O
suggest,O
the,O
involvement,O
of,O
both,O
adenosine,I-Entity
receptors,O
in,O
the,O
action,O
of,O
cocaine,I-Entity
although,O
agonists,O
of,O
A1,O
receptors,O
seem,O
to,O
have,O
stronger,O
influence,O
on,O
it,O
.,O
The,O
selective,O
blockade,O
of,O
A2,O
adenosine,I-Entity
receptor,O
by,O
DMPX,I-Entity
(,O
"3,7-dimethyl-1-propargylxanthine",I-Entity
),O
significantly,O
enhanced,O
cocaine,I-Entity
-,O
induced,O
locomotor,O
activity,O
of,O
animals,O
.,O
Caffeine,I-Entity
had,O
similar,O
action,O
but,O
the,O
effect,O
was,O
not,O
significant,O
.,O
CPT,I-Entity
(,O
8-cyclopentyltheophylline)--A1,I-Entity
receptor,O
antagonist,O
",",O
did,O
not,O
show,O
any,O
influence,O
in,O
this,O
test,O
.,O
Similarly,O
",",O
all,O
adenosine,I-Entity
receptor,O
agonists,O
decreased,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
",",O
but,O
at,O
the,O
higher,O
doses,O
than,O
those,O
which,O
were,O
active,O
in,O
cocaine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
The,O
selective,O
blockade,O
of,O
A2,O
adenosine,I-Entity
receptors,O
(,O
DMPX,I-Entity
),O
and,O
non,O
-,O
selective,O
blockade,O
of,O
adenosine,I-Entity
receptors,O
(,O
caffeine,I-Entity
),O
significantly,O
increased,O
the,O
action,O
of,O
amphetamine,I-Entity
in,O
the,O
locomotor,O
activity,O
test,O
.,O
Our,O
results,O
have,O
shown,O
that,O
all,O
adenosine,I-Entity
receptor,O
agonists,O
(,O
A1,O
and,O
A2,O
),O
reduce,O
cocaine-,I-Entity
and,O
amphetamine,I-Entity
-,O
induced,O
locomotor,O
activity,O
and,O
indicate,O
that,O
cocaine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
is,O
more,O
influenced,O
by,O
adenosine,I-Entity
receptor,O
agonists,O
(,O
particularly,O
A1,O
receptors,O
),O
than,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
Amiodarone,I-Entity
and,O
the,O
risk,O
of,O
bradyarrhythmia,I-Entity
requiring,O
permanent,O
pacemaker,O
in,O
elderly,O
patients,O
with,O
atrial,B-Entity
fibrillation,I-Entity
and,O
prior,O
myocardial,B-Entity
infarction,I-Entity
.,O
OBJECTIVES,O
:,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
the,O
use,O
of,O
amiodarone,I-Entity
in,O
patients,O
with,O
atrial,B-Entity
fibrillation,I-Entity
(,O
AF,I-Entity
),O
increases,O
the,O
risk,O
of,O
bradyarrhythmia,I-Entity
requiring,O
a,O
permanent,O
pacemaker,O
.,O
Reports,O
of,O
severe,O
bradyarrhythmia,I-Entity
during,O
amiodarone,I-Entity
therapy,O
are,O
infrequent,O
and,O
limited,O
to,O
studies,O
assessing,O
the,O
therapy,O
's,O
use,O
in,O
the,O
management,O
of,O
patients,O
with,O
ventricular,B-Entity
arrhythmias,I-Entity
.,O
METHODS,O
:,O
A,O
study,O
cohort,O
of,O
"8,770",O
patients,O
age,O
>,O
or,O
=,O
65,O
years,O
with,O
a,O
new,O
diagnosis,O
of,O
AF,I-Entity
was,O
identified,O
from,O
a,O
provincewide,O
database,O
of,O
Quebec,O
residents,O
with,O
a,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
between,O
1991,O
and,O
1999,O
.,O
Using,O
a,O
nested,O
case,O
-,O
control,O
design,O
",",O
477,O
cases,O
of,O
bradyarrhythmia,I-Entity
requiring,O
a,O
permanent,O
pacemaker,O
were,O
matched,O
(,O
1:4,O
),O
to,O
"1,908",O
controls,O
.,O
Multivariable,O
logistic,O
regression,O
was,O
used,O
to,O
estimate,O
the,O
odds,O
ratio,O
(,O
OR,O
),O
of,O
pacemaker,O
insertion,O
associated,O
with,O
amiodarone,I-Entity
use,O
",",O
controlling,O
for,O
baseline,O
risk,O
factors,O
and,O
exposure,O
to,O
sotalol,I-Entity
",",O
Class,O
I,O
antiarrhythmic,O
agents,O
",",O
beta,O
-,O
blockers,O
",",O
calcium,I-Entity
channel,O
blockers,O
",",O
and,O
digoxin,I-Entity
.,O
RESULTS,O
:,O
amiodarone,I-Entity
use,O
was,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
pacemaker,O
insertion,O
(,O
OR,O
:,O
2.14,O
",",O
95%,O
confidence,O
interval,O
[,O
CI,O
],O
:,O
1.30,O
to,O
3.54,O
),O
.,O
Digoxin,I-Entity
was,O
the,O
only,O
other,O
medication,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
pacemaker,O
insertion,O
(,O
OR,O
:,O
1.78,O
",",O
95%,O
CI,O
:,O
1.37,O
to,O
2.31,O
),O
.,O
This,O
study,O
suggests,O
that,O
the,O
use,O
of,O
amiodarone,I-Entity
in,O
elderly,O
patients,O
with,O
AF,I-Entity
and,O
a,O
previous,O
MI,I-Entity
increases,O
the,O
risk,O
of,O
bradyarrhythmia,I-Entity
requiring,O
a,O
permanent,O
pacemaker,O
.,O
The,O
finding,O
of,O
an,O
augmented,O
risk,O
of,O
pacemaker,O
insertion,O
in,O
elderly,O
women,O
receiving,O
amiodarone,I-Entity
requires,O
further,O
investigation,O
.,O
Indomethacin,I-Entity
-,O
induced,O
morphologic,O
changes,O
in,O
the,O
rat,O
urinary,O
bladder,O
epithelium,O
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
morphologic,O
changes,O
in,O
rat,O
urothelium,O
induced,O
by,O
indomethacin,I-Entity
.,O
Nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
-,O
induced,O
cystitis,I-Entity
is,O
a,O
poorly,O
recognized,O
and,O
under,O
-,O
reported,O
condition,O
.,O
In,O
addition,O
to,O
tiaprofenic,B-Entity
acid,I-Entity
",",O
indomethacin,I-Entity
has,O
been,O
reported,O
to,O
be,O
associated,O
with,O
this,O
condition,O
.,O
Three,O
groups,O
were,O
established,O
:,O
a,O
control,O
group,O
(,O
n,O
=,O
10,O
),O
",",O
a,O
high,O
-,O
dose,O
group,O
(,O
n,O
=,O
10,O
),O
",",O
treated,O
with,O
one,O
intraperitoneal,O
injection,O
of,O
indomethacin,I-Entity
20,O
mg,O
/,O
kg,O
",",O
and,O
a,O
therapeutic,O
dose,O
group,O
(,O
n,O
=,O
10,O
),O
in,O
which,O
oral,O
indomethacin,I-Entity
was,O
administered,O
3.25,O
mg,O
/,O
kg,O
body,O
weight,O
daily,O
for,O
3,O
weeks,O
.,O
When,O
compared,O
with,O
the,O
control,O
group,O
",",O
both,O
indomethacin,I-Entity
groups,O
revealed,O
statistically,O
increased,O
numbers,O
of,O
mast,O
cells,O
in,O
the,O
mucosa,O
(,O
P,O
<,O
0.0001,O
),O
and,O
penetration,O
of,O
lanthanum,B-Entity
nitrate,I-Entity
through,O
intercellular,O
areas,O
of,O
the,O
epithelium,O
.,O
Indomethacin,I-Entity
resulted,O
in,O
histopathologic,O
findings,O
typical,O
of,O
interstitial,B-Entity
cystitis,I-Entity
",",O
such,O
as,O
leaky,O
bladder,O
epithelium,O
and,O
mucosal,O
mastocytosis,I-Entity
.,O
The,O
true,O
incidence,O
of,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
-,O
induced,O
cystitis,I-Entity
in,O
humans,O
must,O
be,O
clarified,O
by,O
prospective,O
clinical,O
trials,O
.,O
An,O
open,O
-,O
label,O
phase,O
II,O
study,O
of,O
low,O
-,O
dose,O
thalidomide,I-Entity
in,O
androgen,I-Entity
-,O
independent,O
prostate,B-Entity
cancer,I-Entity
.,O
The,O
antiangiogenic,O
effects,O
of,O
thalidomide,I-Entity
have,O
been,O
assessed,O
in,O
clinical,O
trials,O
in,O
patients,O
with,O
various,O
solid,O
and,O
haematological,B-Entity
malignancies,I-Entity
.,O
Thalidomide,I-Entity
blocks,O
the,O
activity,O
of,O
angiogenic,O
agents,O
including,O
bFGF,O
",",O
VEGF,O
and,O
IL-6,O
.,O
We,O
undertook,O
an,O
open,O
-,O
label,O
study,O
using,O
thalidomide,I-Entity
100,O
mg,O
once,O
daily,O
for,O
up,O
to,O
6,O
months,O
in,O
20,O
men,O
with,O
androgen,I-Entity
-,O
independent,O
prostate,B-Entity
cancer,I-Entity
.,O
Patients,O
underwent,O
regular,O
measurement,O
of,O
prostate,O
-,O
specific,O
antigen,O
(,O
PSA,O
),O
",",O
urea,I-Entity
and,O
electrolytes,O
",",O
serum,O
bFGF,O
and,O
VEGF,O
.,O
Adverse,O
effects,O
included,O
constipation,I-Entity
",",O
morning,O
drowsiness,I-Entity
",",O
dizziness,I-Entity
and,O
rash,I-Entity
",",O
and,O
resulted,O
in,O
withdrawal,O
from,O
the,O
study,O
by,O
three,O
men,O
.,O
Evidence,O
of,O
peripheral,B-Entity
sensory,I-Entity
neuropathy,I-Entity
was,O
found,O
in,O
nine,O
of,O
13,O
men,O
before,O
treatment,O
.,O
In,O
the,O
seven,O
men,O
who,O
completed,O
six,O
months,O
on,O
thalidomide,I-Entity
",",O
subclinical,O
evidence,O
of,O
peripheral,B-Entity
neuropathy,I-Entity
was,O
found,O
in,O
four,O
before,O
treatment,O
",",O
but,O
in,O
all,O
seven,O
at,O
repeat,O
testing,O
.,O
The,O
findings,O
indicate,O
that,O
thalidomide,I-Entity
may,O
be,O
an,O
option,O
for,O
patients,O
who,O
have,O
failed,O
other,O
forms,O
of,O
therapy,O
",",O
provided,O
close,O
follow,O
-,O
up,O
is,O
maintained,O
for,O
development,O
of,O
peripheral,B-Entity
neuropathy,I-Entity
.,O
Central,B-Entity
nervous,I-Entity
system,I-Entity
toxicity,I-Entity
following,O
the,O
administration,O
of,O
levobupivacaine,I-Entity
for,O
lumbar,O
plexus,O
block,O
:,O
Central,B-Entity
nervous,I-Entity
system,I-Entity
and,I-Entity
cardiac,I-Entity
toxicity,I-Entity
following,O
the,O
administration,O
of,O
local,O
anesthetics,O
is,O
a,O
recognized,O
complication,O
of,O
regional,O
anesthesia,O
.,O
Levobupivacaine,I-Entity
",",O
the,O
pure,O
S(-,O
),O
enantiomer,O
of,O
bupivacaine,I-Entity
",",O
was,O
developed,O
to,O
improve,O
the,O
cardiac,O
safety,O
profile,O
of,O
bupivacaine,I-Entity
.,O
We,O
describe,O
2,O
cases,O
of,O
grand,B-Entity
mal,I-Entity
seizures,I-Entity
following,O
accidental,O
intravascular,O
injection,O
of,O
levobupivacaine,I-Entity
.,O
Immediately,O
after,O
the,O
administration,O
of,O
levobupivacaine,I-Entity
0.5%,O
with,O
epinephrine,I-Entity
2.5,O
microgram,O
/,O
mL,O
",",O
the,O
patients,O
developed,O
grand,B-Entity
mal,I-Entity
seizures,I-Entity
",",O
despite,O
negative,O
aspiration,O
for,O
blood,O
and,O
no,O
clinical,O
signs,O
of,O
intravenous,O
epinephrine,I-Entity
administration,O
.,O
The,O
seizures,I-Entity
were,O
successfully,O
treated,O
with,O
sodium,B-Entity
thiopental,I-Entity
in,O
addition,O
to,O
succinylcholine,I-Entity
in,O
1,O
patient,O
.,O
Neither,O
patient,O
developed,O
signs,O
of,O
cardiovascular,B-Entity
toxicity,I-Entity
.,O
Both,O
patients,O
were,O
treated,O
preoperatively,O
with,O
beta,O
-,O
adrenergic,O
antagonist,O
medications,O
",",O
which,O
may,O
have,O
masked,O
the,O
cardiovascular,O
signs,O
of,O
the,O
unintentional,O
intravascular,O
administration,O
of,O
levobupivacaine,I-Entity
with,O
epinephrine,I-Entity
.,O
Although,O
levobupivacaine,I-Entity
may,O
have,O
a,O
safer,O
cardiac,B-Entity
toxicity,I-Entity
profile,O
than,O
racemic,O
bupivacaine,I-Entity
",",O
if,O
adequate,O
amounts,O
of,O
levobupivacaine,I-Entity
reach,O
the,O
circulation,O
",",O
it,O
will,O
result,O
in,O
convulsions,I-Entity
.,O
Plasma,O
concentrations,O
sufficient,O
to,O
result,O
in,O
central,B-Entity
nervous,I-Entity
system,I-Entity
toxicity,I-Entity
did,O
not,O
produce,O
manifestations,O
of,O
cardiac,B-Entity
toxicity,I-Entity
in,O
these,O
2,O
patients,O
.,O
Anaesthetic,O
complications,O
associated,O
with,O
myotonia,B-Entity
congenita,I-Entity
:,O
case,O
study,O
and,O
comparison,O
with,O
other,O
myotonic,B-Entity
disorders,I-Entity
.,O
Myotonia,B-Entity
congenita,I-Entity
(,O
MC,I-Entity
),O
is,O
caused,O
by,O
a,O
defect,O
in,O
the,O
skeletal,O
muscle,O
chloride,I-Entity
channel,O
function,O
",",O
which,O
may,O
cause,O
sustained,B-Entity
membrane,I-Entity
depolarisation,I-Entity
.,O
We,O
describe,O
a,O
previously,O
healthy,O
32-year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
life,O
-,O
threatening,O
muscle,B-Entity
spasm,I-Entity
and,O
secondary,O
ventilation,O
difficulties,O
following,O
a,O
preoperative,O
injection,O
of,O
suxamethonium,I-Entity
.,O
The,O
muscle,B-Entity
spasms,I-Entity
disappeared,O
spontaneously,O
and,O
the,O
surgery,O
proceeded,O
without,O
further,O
problems,O
.,O
When,O
subsequently,O
questioned,O
",",O
she,O
reported,O
minor,O
symptoms,O
suggesting,O
a,O
myotonic,B-Entity
condition,I-Entity
.,O
Myotonia,I-Entity
was,O
found,O
on,O
clinical,O
examination,O
and,O
EMG,O
.,O
The,O
diagnosis,O
MC,I-Entity
was,O
confirmed,O
genetically,O
.,O
We,O
give,O
a,O
brief,O
overview,O
of,O
ion,B-Entity
channel,I-Entity
disorders,I-Entity
including,O
malignant,B-Entity
hyperthermia,I-Entity
and,O
their,O
anaesthetic,O
considerations,O
.,O
Respiratory,O
pattern,O
in,O
a,O
rat,O
model,O
of,O
epilepsy,I-Entity
.,O
Apnea,I-Entity
is,O
known,O
to,O
occur,O
during,O
seizures,I-Entity
",",O
but,O
systematic,O
studies,O
of,O
ictal,O
respiratory,O
changes,O
in,O
adults,O
are,O
few,O
.,O
Here,O
we,O
sought,O
to,O
generate,O
information,O
with,O
regard,O
to,O
the,O
interictal,O
period,O
in,O
animals,O
with,O
pilocarpine,I-Entity
-,O
induced,O
epilepsy,I-Entity
.,O
METHODS,O
:,O
Twelve,O
rats,O
(,O
six,O
chronically,O
epileptic,I-Entity
animals,O
and,O
six,O
controls,O
),O
were,O
anesthetized,O
",",O
given,O
tracheotomies,O
",",O
and,O
subjected,O
to,O
hyperventilation,I-Entity
or,O
hypoventilation,O
conditions,O
.,O
The,O
hyperventilation,I-Entity
maneuver,O
caused,O
a,O
decrease,O
in,O
spontaneous,O
ventilation,O
in,O
pilocarpine,I-Entity
-,O
treated,O
and,O
control,O
rats,O
.,O
Although,O
VE,O
had,O
a,O
similar,O
decrease,O
in,O
both,O
groups,O
",",O
in,O
the,O
epileptic,I-Entity
group,O
",",O
the,O
decrease,O
in,O
VE,O
was,O
due,O
to,O
a,O
significant,O
(,O
p,O
<,O
0.05,O
),O
increase,O
in,O
TE,O
peak,O
in,O
relation,O
to,O
that,O
of,O
the,O
control,O
animals,O
.,O
In,O
the,O
epileptic,I-Entity
group,O
",",O
the,O
increase,O
in,O
VE,O
was,O
mediated,O
by,O
a,O
significant,O
(,O
p,O
<,O
0.05,O
),O
decrease,O
in,O
TE,O
peak,O
compared,O
with,O
the,O
control,O
group,O
.,O
CONCLUSIONS,O
:,O
The,O
data,O
indicate,O
that,O
pilocarpine,I-Entity
-,O
treated,O
animals,O
have,O
an,O
altered,O
ability,O
to,O
react,O
to,O
(,O
or,O
compensate,O
for,O
),O
blood,O
gas,O
changes,O
with,O
changes,O
in,O
ventilation,O
and,O
suggest,O
that,O
it,O
is,O
centrally,O
determined,O
.,O
We,O
speculate,O
on,O
the,O
possible,O
relation,O
of,O
the,O
current,O
findings,O
on,O
treating,O
different,O
epilepsy,I-Entity
-,O
associated,O
conditions,O
.,O
Increased,O
serum,O
soluble,O
Fas,O
in,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
due,O
to,O
paracetamol,I-Entity
overdose,I-Entity
.,O
Experimental,O
studies,O
have,O
suggested,O
that,O
apoptosis,O
via,O
the,O
Fas,O
/,O
Fas,O
Ligand,O
signaling,O
system,O
may,O
play,O
an,O
important,O
role,O
in,O
the,O
development,O
of,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
soluble,O
form,O
of,O
Fas,O
in,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
.,O
METHODOLOGY,O
:,O
Serum,O
levels,O
of,O
sFas,O
(,O
soluble,O
Fas,O
),O
were,O
measured,O
by,O
ELISA,O
in,O
24,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
and,O
10,O
normal,O
control,O
subjects,O
.,O
Serum,O
levels,O
of,O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
and,O
interferon,O
-,O
gamma,O
were,O
also,O
determined,O
by,O
ELISA,O
.,O
Serum,O
sFas,O
was,O
significantly,O
increased,O
in,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
(,O
median,O
",",O
26.8,O
U,O
/,O
mL,O
;,O
range,O
",",O
6.9,O
-,O
52.7,O
U,O
/,O
mL,O
),O
compared,O
to,O
the,O
normal,O
controls,O
(,O
median,O
",",O
8.6,O
U,O
/,O
mL,O
;,O
range,O
",",O
6.5,O
-,O
12.0,O
U,O
/,O
mL,O
",",O
P,O
<,O
0.0001,O
),O
.,O
Levels,O
were,O
significantly,O
greater,O
in,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
due,O
to,O
paracetamol,I-Entity
overdose,I-Entity
(,O
median,O
",",O
28.7,O
U,O
/,O
mL,O
;,O
range,O
",",O
12.8,O
-,O
52.7,O
U,O
/,O
mL,O
",",O
n,O
=,O
17,O
),O
than,O
those,O
due,O
to,O
non,O
-,O
A,O
to,O
E,O
hepatitis,I-Entity
(,O
median,O
",",O
12.5,O
U,O
/,O
mL,O
;,O
range,O
",",O
6.9,O
-,O
46.0,O
U,O
/,O
mL,O
",",O
A,O
significant,O
correlation,O
was,O
observed,O
between,O
serum,O
sFas,O
levels,O
and,O
aspartate,I-Entity
aminotransferase,O
(,O
r,O
=,O
0.613,O
",",O
P,O
<,O
0.01,O
),O
.,O
The,O
increased,O
concentration,O
of,O
sFas,O
in,O
serum,O
of,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
may,O
reflect,O
activation,O
of,O
Fas,O
-,O
mediated,O
apoptosis,O
in,O
the,O
liver,O
and,O
this,O
together,O
with,O
increased,O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
may,O
be,O
an,O
important,O
factor,O
in,O
liver,O
cell,O
loss,O
.,O
Bilateral,O
subthalamic,O
nucleus,O
stimulation,O
for,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
High,O
frequency,O
stimulation,O
of,O
the,O
subthalamic,O
nucleus,O
(,O
STN,O
),O
is,O
known,O
to,O
ameliorate,O
the,O
signs,O
and,O
symptoms,O
of,O
advanced,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
METHOD,O
:,O
Twenty,O
-,O
three,O
patients,O
suffering,O
from,O
severe,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
Stages,O
III,O
-,O
V,O
on,O
Hoehn,O
and,O
Yahr,O
scale,O
),O
and,O
",",O
particularly,O
bradykinesia,I-Entity
",",O
rigidity,I-Entity
",",O
and,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
underwent,O
bilateral,O
implantation,O
of,O
electrodes,O
in,O
the,O
STN,O
.,O
Preoperative,O
and,O
postoperative,O
assessments,O
of,O
these,O
patients,O
at,O
1,O
",",O
3,O
",",O
6,O
and,O
12,O
months,O
follow,O
-,O
up,O
",",O
in,O
"""",O
on,O
"""",O
and,O
"""",O
off,O
"""",O
drug,O
conditions,O
",",O
was,O
carried,O
out,O
using,O
Unified,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Rating,O
Scale,O
",",O
Hoehn,O
and,O
Yahr,O
staging,O
",",O
England,O
activities,O
of,O
daily,O
living,O
score,O
and,O
video,O
recordings,O
.,O
(,O
Unified,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Rating,O
Scale,O
parts,O
II,O
and,O
III,O
),O
off,O
medication,O
improved,O
by,O
62%,O
and,O
61%,O
respectively,O
(,O
p<0.0005,O
),O
.,O
The,O
subscores,O
for,O
the,O
akinesia,I-Entity
",",O
rigidity,I-Entity
",",O
tremor,I-Entity
and,O
gait,O
also,O
improved,O
.,O
The,O
average,O
levodopa,I-Entity
dose,O
decreased,O
from,O
813,O
mg,O
to,O
359,O
mg,O
.,O
Bilateral,O
subthalamic,O
nucleus,O
stimulation,O
is,O
an,O
effective,O
treatment,O
for,O
advanced,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
It,O
reduces,O
the,O
severity,O
of,O
"""",O
off,O
"""",O
phase,O
symptoms,O
",",O
improves,O
the,O
axial,O
symptoms,O
and,O
reduces,O
levodopa,I-Entity
requirements,O
.,O
The,O
reduction,O
in,O
the,O
levodopa,I-Entity
dose,O
is,O
useful,O
in,O
controlling,O
drug,B-Entity
-,I-Entity
induced,I-Entity
dyskinesias,I-Entity
.,O
Ocular,O
motility,O
changes,O
after,O
subtenon,O
carboplatin,I-Entity
chemotherapy,O
for,O
retinoblastoma,I-Entity
.,O
Focal,O
subtenon,O
carboplatin,I-Entity
injections,O
have,O
recently,O
been,O
used,O
as,O
a,O
presumably,O
toxicity,I-Entity
-,O
free,O
adjunct,O
to,O
systemic,O
chemotherapy,O
for,O
intraocular,O
retinoblastoma,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
our,O
clinical,O
experience,O
with,O
abnormal,B-Entity
ocular,I-Entity
motility,I-Entity
in,O
patients,O
treated,O
with,O
subtenon,O
carboplatin,I-Entity
chemotherapy,O
.,O
:,O
We,O
noted,O
abnormal,B-Entity
ocular,I-Entity
motility,I-Entity
in,O
10,O
consecutive,O
patients,O
with,O
retinoblastoma,I-Entity
who,O
had,O
received,O
subtenon,O
carboplatin,I-Entity
.,O
During,O
ocular,O
manipulation,O
under,O
general,O
anesthesia,O
",",O
we,O
assessed,O
their,O
eyes,O
by,O
forced,O
duction,O
testing,O
",",O
comparing,O
ocular,O
motility,O
after,O
tumor,I-Entity
control,O
with,O
ocular,O
motility,O
at,O
diagnosis,O
.,O
Limitation,O
of,O
ocular,O
motility,O
was,O
detected,O
in,O
all,O
12,O
eyes,O
of,O
10,O
patients,O
treated,O
for,O
intraocular,O
retinoblastoma,I-Entity
with,O
1,O
to,O
6,O
injections,O
of,O
subtenon,O
carboplatin,I-Entity
as,O
part,O
of,O
multimodality,O
therapy,O
.,O
Histopathological,O
examination,O
revealed,O
many,O
lipophages,O
in,O
the,O
periorbital,O
fat,O
surrounding,O
the,O
optic,O
nerve,O
in,O
1,O
eye,O
",",O
indicative,O
of,O
phagocytosis,O
of,O
previously,O
existing,O
fat,O
cells,O
and,O
suggesting,O
prior,O
fat,O
necrosis,I-Entity
.,O
The,O
enucleations,O
were,O
technically,O
difficult,O
and,O
hazardous,O
for,O
globe,O
rupture,I-Entity
because,O
of,O
extensive,O
orbital,O
soft,O
tissue,O
adhesions,O
.,O
Subtenon,O
carboplatin,I-Entity
chemotherapy,O
is,O
associated,O
with,O
significant,O
fibrosis,I-Entity
of,O
orbital,O
soft,O
tissues,O
",",O
leading,O
to,O
mechanical,O
restriction,O
of,O
eye,O
movements,O
and,O
making,O
subsequent,O
enucleation,O
difficult,O
.,O
Subtenon,O
carboplatin,I-Entity
is,O
not,O
free,O
of,O
toxicity,I-Entity
",",O
and,O
its,O
use,O
is,O
best,O
restricted,O
to,O
specific,O
indications,O
.,O
Ethambutol,I-Entity
and,O
optic,B-Entity
neuropathy,I-Entity
.,O
PURPOSE,O
:,O
To,O
demonstrate,O
the,O
association,O
between,O
ethambutol,I-Entity
and,O
optic,B-Entity
neuropathy,I-Entity
.,O
METHOD,O
:,O
Thirteen,O
patients,O
who,O
developed,O
optic,B-Entity
neuropathy,I-Entity
after,O
being,O
treated,O
with,O
ethambutol,I-Entity
for,O
tuberculosis,B-Entity
of,I-Entity
the,I-Entity
lung,I-Entity
or,I-Entity
lymph,I-Entity
node,I-Entity
at,O
Siriraj,O
Hospital,O
between,O
1997,O
and,O
2001,O
were,O
retrospectively,O
reviewed,O
.,O
RESULTS,O
:,O
All,O
patients,O
had,O
optic,B-Entity
neuropathy,I-Entity
between,O
1,O
to,O
6,O
months,O
(,O
mean,O
=,O
2.9,O
months,O
),O
after,O
starting,O
ethambutol,I-Entity
therapy,O
at,O
a,O
dosage,O
ranging,O
from,O
13,O
to,O
20,O
mg,O
/,O
kg,O
/,O
day,O
(,O
mean,O
=,O
17,O
mg,O
/,O
kg,O
/,O
day,O
),O
.,O
Of,O
6,O
patients,O
with,O
irreversible,O
visual,B-Entity
impairment,I-Entity
",",O
4,O
patients,O
had,O
diabetes,B-Entity
mellitus,I-Entity
",",O
glaucoma,I-Entity
and,O
a,O
history,O
of,O
heavy,O
smoking,O
.,O
CONCLUSION,O
:,O
Early,O
recognition,O
of,O
optic,B-Entity
neuropathy,I-Entity
should,O
be,O
considered,O
in,O
patients,O
with,O
ethambutol,I-Entity
therapy,O
.,O
A,O
low,O
dose,O
and,O
prompt,O
discontinuation,O
of,O
the,O
drug,O
is,O
recommended,O
particularly,O
in,O
individuals,O
with,O
diabetes,B-Entity
mellitus,I-Entity
",",O
glaucoma,I-Entity
or,O
who,O
are,O
heavy,O
smokers,O
.,O
Treatment,O
of,O
compensatory,O
gustatory,B-Entity
hyperhidrosis,I-Entity
with,O
topical,O
glycopyrrolate,I-Entity
.,O
Gustatory,B-Entity
hyperhidrosis,I-Entity
is,O
facial,O
sweating,I-Entity
usually,O
associated,O
with,O
the,O
eating,O
of,O
hot,O
spicy,O
food,O
or,O
even,O
smelling,O
this,O
food,O
.,O
Current,O
options,O
of,O
treatment,O
include,O
oral,O
anticholinergic,O
drugs,O
",",O
the,O
topical,O
application,O
of,O
anticholinergics,O
or,O
aluminum,B-Entity
chloride,I-Entity
",",O
and,O
the,O
injection,O
of,O
botulinum,O
toxin,O
.,O
Thirteen,O
patients,O
have,O
been,O
treated,O
to,O
date,O
with,O
1.5%,O
or,O
2%,O
topical,O
glycopyrrolate,I-Entity
.,O
All,O
patients,O
had,O
gustatory,B-Entity
hyperhidrosis,I-Entity
",",O
which,O
interfered,O
with,O
their,O
social,O
activities,O
",",O
after,O
transthroacic,O
endoscopic,O
sympathectomy,O
",",O
and,O
which,O
was,O
associated,O
with,O
compensatory,O
focal,O
hyperhidrosis,I-Entity
.,O
After,O
applying,O
topical,O
glycopyrrolate,I-Entity
",",O
the,O
subjective,O
effect,O
was,O
excellent,O
(,O
no,O
sweating,I-Entity
after,O
eating,O
hot,O
spicy,O
food,O
),O
in,O
10,O
patients,O
(,O
77%,O
),O
",",O
and,O
fair,O
(,O
clearly,O
reduced,O
sweating,I-Entity
),O
in,O
3,O
patients,O
(,O
23%,O
),O
.,O
Adverse,O
effects,O
included,O
a,O
mildly,O
dry,B-Entity
mouth,I-Entity
and,O
a,O
sore,B-Entity
throat,I-Entity
in,O
2,O
patients,O
(,O
2%,O
glycopyrrolate,I-Entity
),O
",",O
a,O
light,O
headache,I-Entity
in,O
1,O
patient,O
(,O
1.5%,O
glycopyrrolate,I-Entity
),O
.,O
The,O
topical,O
application,O
of,O
a,O
glycopyrrolate,I-Entity
pad,O
appeared,O
to,O
be,O
safe,O
",",O
efficacious,O
",",O
well,O
tolerated,O
",",O
and,O
a,O
convenient,O
method,O
of,O
treatment,O
for,O
moderate,O
to,O
severe,O
symptoms,O
of,O
gustatory,B-Entity
hyperhidrosis,I-Entity
in,O
post,O
transthoracic,O
endoscopic,O
sympathectomy,O
or,O
sympathicotomy,O
patients,O
",",O
with,O
few,O
side,O
effects,O
.,O
Pharmacological,O
characteristics,O
and,O
side,O
effects,O
of,O
a,O
new,O
galenic,O
formulation,O
of,O
propofol,I-Entity
without,O
soyabean,O
oil,O
.,O
We,O
compared,O
the,O
pharmacokinetics,O
",",O
pharmacodynamics,O
and,O
safety,O
profile,O
of,O
a,O
new,O
galenic,O
formulation,O
of,O
propofol,I-Entity
(,O
AM149,O
1%,O
),O
",",O
which,O
does,O
not,O
contain,O
soyabean,O
oil,O
",",O
with,O
a,O
standard,O
formulation,O
of,O
propofol,I-Entity
(,O
Disoprivan,I-Entity
1%,O
),O
.,O
In,O
a,O
randomised,O
",",O
double,O
-,O
blind,O
",",O
cross,O
-,O
over,O
study,O
",",O
30,O
healthy,O
volunteers,O
received,O
a,O
single,O
intravenous,O
bolus,O
injection,O
of,O
2.5,O
mg.kg-1,O
propofol,I-Entity
.,O
Plasma,O
propofol,I-Entity
levels,O
were,O
measured,O
for,O
48,O
h,O
following,O
drug,O
administration,O
and,O
evaluated,O
according,O
to,O
a,O
three,O
-,O
compartment,O
model,O
.,O
The,O
pharmacodynamic,O
parameters,O
assessed,O
included,O
induction,O
and,O
emergence,O
times,O
",",O
respiratory,O
and,O
cardiovascular,O
effects,O
",",O
and,O
pain,I-Entity
on,O
injection,O
.,O
Owing,O
to,O
a,O
high,O
incidence,O
of,O
thrombophlebitis,I-Entity
",",O
the,O
study,O
was,O
terminated,O
prematurely,O
and,O
only,O
the,O
data,O
of,O
the,O
two,O
parallel,O
treatment,O
groups,O
(,O
15,O
patients,O
in,O
each,O
group,O
),O
were,O
analysed,O
.,O
Pain,I-Entity
on,O
injection,O
(,O
80,O
vs.,O
20%,O
",",O
p,O
<,O
0.01,O
),O
and,O
thrombophlebitis,I-Entity
(,O
93.3,O
vs.,O
6.6%,O
",",O
p,O
<,O
0.001,O
),O
occurred,O
more,O
frequently,O
with,O
AM149,O
than,O
with,O
Disoprivan,I-Entity
.,O
Although,O
both,O
formulations,O
had,O
similar,O
pharmacokinetic,O
and,O
pharmacodynamic,O
profiles,O
the,O
new,O
formulation,O
is,O
not,O
suitable,O
for,O
clinical,O
use,O
due,O
to,O
the,O
high,O
incidence,O
of,O
thrombophlebitis,I-Entity
produced,O
.,O
Vinorelbine,I-Entity
-,O
related,O
cardiac,O
events,O
:,O
a,O
meta,O
-,O
analysis,O
of,O
randomized,O
clinical,O
trials,O
.,O
Several,O
cases,O
of,O
cardiac,O
adverse,O
reactions,O
related,O
to,O
vinorelbine,I-Entity
(,O
VNR,I-Entity
),O
have,O
been,O
reported,O
in,O
the,O
literature,O
.,O
In,O
order,O
to,O
quantify,O
the,O
incidence,O
of,O
these,O
cardiac,O
events,O
",",O
we,O
performed,O
a,O
meta,O
-,O
analysis,O
of,O
clinical,O
trials,O
comparing,O
VNR,I-Entity
with,O
other,O
chemotherapeutic,O
agents,O
in,O
the,O
treatment,O
of,O
various,O
malignancies,I-Entity
.,O
Randomized,O
clinical,O
trials,O
comparing,O
VNR,I-Entity
with,O
other,O
drugs,O
in,O
the,O
treatment,O
of,O
cancer,I-Entity
were,O
searched,O
in,O
Medline,O
",",O
Embase,O
",",O
Evidence,O
-,O
based,O
Medicine,O
Reviews,O
databases,O
and,O
the,O
Cochrane,O
library,O
from,O
1987,O
to,O
2002,O
.,O
We,O
found,O
19,O
trials,O
",",O
involving,O
2441,O
patients,O
treated,O
by,O
VNR,I-Entity
and,O
2050,O
control,O
patients,O
.,O
The,O
incidence,O
of,O
cardiac,O
events,O
with,O
VNR,I-Entity
was,O
1.19%,O
[,O
95%,O
confidence,O
interval,O
(,O
CI,O
),O
(,O
0.75,O
;,O
1.67,O
),O
],O
.,O
There,O
was,O
no,O
difference,O
in,O
the,O
risk,O
of,O
cardiac,O
events,O
between,O
VNR,I-Entity
and,O
other,O
drugs,O
[,O
odds,O
ratio,O
:,O
0.92,O
",",O
95%,O
CI,O
(,O
0.54,O
;,O
1.55,O
),O
],O
.,O
The,O
risk,O
of,O
VNR,I-Entity
cardiac,O
events,O
was,O
similar,O
to,O
vindesine,I-Entity
(,O
VDS,I-Entity
),O
and,O
other,O
cardiotoxic,I-Entity
drugs,O
[,O
fluorouracil,I-Entity
",",O
anthracyclines,I-Entity
",",O
gemcitabine,I-Entity
(,O
GEM,I-Entity
),O
em,O
leader,O
],O
.,O
Even,O
if,O
it,O
did,O
not,O
reach,O
statistical,O
significance,O
because,O
of,O
a,O
few,O
number,O
of,O
cases,O
",",O
the,O
risk,O
was,O
lower,O
in,O
trials,O
excluding,O
patients,O
with,O
cardiac,O
history,O
",",O
and,O
seemed,O
to,O
be,O
higher,O
in,O
trials,O
including,O
patients,O
with,O
pre,O
-,O
existing,O
cardiac,B-Entity
diseases,I-Entity
.,O
Vinorelbine,I-Entity
-,O
related,O
cardiac,O
events,O
concern,O
about,O
1%,O
of,O
treated,O
patients,O
in,O
clinical,O
trials,O
.,O
However,O
",",O
the,O
risk,O
associated,O
with,O
VNR,I-Entity
seems,O
to,O
be,O
similar,O
to,O
that,O
of,O
other,O
chemotherapeutic,O
agents,O
in,O
the,O
same,O
indications,O
.,O
MRI,O
findings,O
of,O
hypoxic,O
cortical,O
laminar,O
necrosis,I-Entity
in,O
a,O
child,O
with,O
hemolytic,B-Entity
anemia,I-Entity
crisis,O
.,O
We,O
present,O
magnetic,O
resonance,O
imaging,O
findings,O
of,O
a,O
5-year,O
-,O
old,O
girl,O
who,O
had,O
a,O
rapidly,O
installing,O
hemolytic,B-Entity
anemia,I-Entity
crisis,O
induced,O
by,O
trimethoprim,B-Entity
-,I-Entity
sulfomethoxazole,I-Entity
",",O
resulting,O
in,O
cerebral,B-Entity
anoxia,I-Entity
leading,O
to,O
permanent,O
damage,O
.,O
Magnetic,O
Resonance,O
imaging,O
revealed,O
cortical,O
laminar,O
necrosis,I-Entity
in,O
arterial,O
border,O
zones,O
in,O
both,O
cerebral,O
hemispheres,O
",",O
ischemic,O
changes,O
in,O
subcortical,O
white,O
matter,O
of,O
left,O
cerebral,O
hemisphere,O
",",O
and,O
in,O
the,O
left,O
putamen,O
.,O
Although,O
cortical,O
laminar,O
necrosis,I-Entity
is,O
a,O
classic,O
entity,O
in,O
adulthood,O
related,O
to,O
conditions,O
of,O
energy,O
depletions,O
",",O
there,O
are,O
few,O
reports,O
available,O
in,O
children,O
.,O
The,O
natural,O
history,O
of,O
Vigabatrin,I-Entity
associated,O
visual,B-Entity
field,I-Entity
defects,I-Entity
in,O
patients,O
electing,O
to,O
continue,O
their,O
medication,O
.,O
PURPOSE,O
:,O
To,O
determine,O
the,O
natural,O
history,O
of,O
visual,B-Entity
field,I-Entity
defects,I-Entity
in,O
a,O
group,O
of,O
patients,O
known,O
to,O
have,O
Vigabatrin,I-Entity
-,O
associated,O
changes,O
who,O
elected,O
to,O
continue,O
the,O
medication,O
because,O
of,O
good,O
seizure,I-Entity
control,O
.,O
All,O
patients,O
taking,O
Vigabatrin,I-Entity
alone,O
or,O
in,O
combination,O
with,O
other,O
antiepileptic,O
drugs,O
for,O
at,O
least,O
5,O
years,O
(,O
range,O
5,O
-,O
12,O
years,O
),O
were,O
entered,O
into,O
a,O
visual,O
surveillance,O
programme,O
.,O
Following,O
already,O
published,O
methodology,O
(,O
Eye,O
2002,O
;,O
16;567,O
-,O
571,O
),O
monocular,O
mean,O
radial,O
degrees,O
(,O
MRDs,O
),O
to,O
the,O
I/4e,O
isopter,O
on,O
Goldmann,O
perimetry,O
was,O
calculated,O
for,O
the,O
right,O
eye,O
at,O
the,O
time,O
of,O
discovery,O
of,O
a,O
visual,B-Entity
field,I-Entity
defect,I-Entity
and,O
again,O
after,O
not,O
less,O
than,O
18,O
months,O
follow,O
-,O
up,O
.,O
Only,O
one,O
patient,O
demonstrated,O
a,O
deterioration,B-Entity
in,I-Entity
visual,I-Entity
field,I-Entity
during,O
the,O
study,O
period,O
and,O
discontinued,O
treatment,O
.,O
Established,O
visual,B-Entity
field,I-Entity
defects,I-Entity
presumed,O
to,O
be,O
due,O
to,O
Vigabatrin,I-Entity
therapy,O
did,O
not,O
usually,O
progress,O
in,O
spite,O
of,O
continuing,O
use,O
of,O
the,O
medication,O
.,O
These,O
data,O
give,O
support,O
to,O
the,O
hypothesis,O
that,O
the,O
pathogenesis,O
of,O
Vigabatrin,I-Entity
-,O
associated,O
visual,B-Entity
field,I-Entity
defects,I-Entity
may,O
be,O
an,O
idiosyncratic,O
adverse,O
drug,O
reaction,O
rather,O
than,O
dose,O
-,O
dependent,O
toxicity,I-Entity
.,O
Induction,O
of,O
rosaceiform,O
dermatitis,I-Entity
during,O
treatment,O
of,O
facial,B-Entity
inflammatory,I-Entity
dermatoses,I-Entity
with,O
tacrolimus,I-Entity
ointment,O
.,O
Tacrolimus,I-Entity
ointment,O
is,O
increasingly,O
used,O
for,O
anti,O
-,O
inflammatory,O
treatment,O
of,O
sensitive,O
areas,O
such,O
as,O
the,O
face,O
",",O
and,O
recent,O
observations,O
indicate,O
that,O
the,O
treatment,O
is,O
effective,O
in,O
steroid,I-Entity
-,O
aggravated,O
rosacea,I-Entity
and,O
perioral,B-Entity
dermatitis,I-Entity
.,O
We,O
report,O
on,O
rosaceiform,O
dermatitis,I-Entity
as,O
a,O
complication,O
of,O
treatment,O
with,O
tacrolimus,I-Entity
ointment,O
.,O
Six,O
adult,O
patients,O
with,O
inflammatory,B-Entity
facial,I-Entity
dermatoses,I-Entity
were,O
treated,O
with,O
tacrolimus,I-Entity
ointment,O
because,O
of,O
the,O
ineffectiveness,O
of,O
standard,O
treatments,O
.,O
Within,O
2,O
to,O
3,O
weeks,O
of,O
initially,O
effective,O
and,O
well,O
-,O
tolerated,O
treatment,O
",",O
3,O
patients,O
with,O
a,O
history,O
of,O
rosacea,I-Entity
and,O
1,O
with,O
a,O
history,O
of,O
acne,I-Entity
experienced,O
sudden,O
worsening,O
with,O
pustular,O
rosaceiform,O
lesions,O
.,O
In,O
1,O
patient,O
with,O
eyelid,O
eczema,I-Entity
",",O
rosaceiform,O
periocular,B-Entity
dermatitis,I-Entity
gradually,O
appeared,O
after,O
3,O
weeks,O
of,O
treatment,O
.,O
In,O
1,O
patient,O
with,O
atopic,B-Entity
dermatitis,I-Entity
",",O
telangiectatic,O
and,O
papular,B-Entity
rosacea,I-Entity
insidiously,O
appeared,O
after,O
5,O
months,O
of,O
treatment,O
.,O
Our,O
observations,O
suggest,O
that,O
the,O
spectrum,O
of,O
rosaceiform,O
dermatitis,I-Entity
as,O
a,O
complication,O
of,O
treatment,O
with,O
tacrolimus,I-Entity
ointment,O
is,O
heterogeneous,O
.,O
A,O
variety,O
of,O
factors,O
",",O
such,O
as,O
vasoactive,O
properties,O
of,O
tacrolimus,I-Entity
",",O
proliferation,O
of,O
Demodex,O
due,O
to,O
local,O
immunosuppression,O
",",O
and,O
the,O
occlusive,O
properties,O
of,O
the,O
ointment,O
",",O
may,O
be,O
involved,O
in,O
the,O
observed,O
phenomena,O
.,O
Structural,O
abnormalities,O
in,O
the,O
brains,O
of,O
human,O
subjects,O
who,O
use,O
methamphetamine,I-Entity
.,O
We,O
visualize,O
",",O
for,O
the,O
first,O
time,O
",",O
the,O
profile,O
of,O
structural,B-Entity
deficits,I-Entity
in,I-Entity
the,I-Entity
human,I-Entity
brain,I-Entity
associated,O
with,O
chronic,O
methamphetamine,I-Entity
(,O
MA,I-Entity
),O
abuse,O
.,O
Studies,O
of,O
human,O
subjects,O
who,O
have,O
used,O
MA,I-Entity
chronically,O
have,O
revealed,O
deficits,O
in,O
dopaminergic,O
and,O
serotonergic,O
systems,O
and,O
cerebral,O
metabolic,B-Entity
abnormalities,I-Entity
.,O
Using,O
magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
and,O
new,O
computational,O
brain,O
-,O
mapping,O
techniques,O
",",O
we,O
determined,O
the,O
pattern,O
of,O
structural,O
brain,O
alterations,O
associated,O
with,O
chronic,O
MA,I-Entity
abuse,O
in,O
human,O
subjects,O
and,O
related,O
these,O
deficits,O
to,O
cognitive,B-Entity
impairment,I-Entity
.,O
We,O
used,O
high,O
-,O
resolution,O
MRI,O
and,O
surface,O
-,O
based,O
computational,O
image,O
analyses,O
to,O
map,O
regional,O
abnormalities,B-Entity
in,I-Entity
the,I-Entity
cortex,I-Entity
",",I-Entity
hippocampus,I-Entity
",",I-Entity
white,I-Entity
matter,I-Entity
",",I-Entity
and,I-Entity
ventricles,I-Entity
in,O
22,O
human,O
subjects,O
who,O
used,O
MA,I-Entity
and,O
21,O
age,O
-,O
matched,O
",",O
healthy,O
controls,O
.,O
Cortical,O
maps,O
revealed,O
severe,O
gray,O
-,O
matter,O
deficits,O
in,O
the,O
cingulate,O
",",O
limbic,O
",",O
and,O
paralimbic,O
cortices,O
of,O
MA,I-Entity
abusers,O
(,O
averaging,O
11.3%,O
below,O
control,O
;,O
On,O
average,O
",",O
MA,I-Entity
abusers,O
had,O
7.8%,O
smaller,O
hippocampal,O
volumes,O
than,O
control,O
subjects,O
(,O
p,O
<,O
0.01,O
;,O
left,O
",",O
p,O
=,O
0.01,O
;,O
right,O
",",O
p,O
<,O
0.05,O
),O
and,O
significant,O
white,O
-,O
matter,O
hypertrophy,I-Entity
(,O
7.0%,O
;,O
MRI,O
-,O
based,O
maps,O
suggest,O
that,O
chronic,O
methamphetamine,I-Entity
abuse,O
causes,O
a,O
selective,O
pattern,O
of,O
cerebral,O
deterioration,O
that,O
contributes,O
to,O
impaired,B-Entity
memory,I-Entity
performance,I-Entity
.,O
MA,I-Entity
may,O
selectively,O
damage,O
the,O
medial,O
temporal,O
lobe,O
and,O
",",O
consistent,O
with,O
metabolic,O
studies,O
",",O
the,O
cingulate,O
-,O
limbic,O
cortex,O
",",O
inducing,O
neuroadaptation,O
",",O
neuropil,O
reduction,O
",",O
or,O
cell,O
death,O
.,O
Prominent,O
white,O
-,O
matter,O
hypertrophy,I-Entity
may,O
result,O
from,O
altered,O
myelination,O
and,O
adaptive,O
glial,O
changes,O
",",O
including,O
gliosis,I-Entity
secondary,O
to,O
neuronal,B-Entity
damage,I-Entity
.,O
These,O
brain,O
substrates,O
may,O
help,O
account,O
for,O
the,O
symptoms,O
of,O
MA,I-Entity
abuse,O
",",O
providing,O
therapeutic,O
targets,O
for,O
drug,O
-,O
induced,O
brain,B-Entity
injury,I-Entity
.,O
Disruption,O
of,O
hepatic,O
lipid,O
homeostasis,O
in,O
mice,O
after,O
amiodarone,I-Entity
treatment,O
is,O
associated,O
with,O
peroxisome,O
proliferator,O
-,O
activated,O
receptor,O
-,O
alpha,O
target,O
gene,O
activation,O
.,O
Amiodarone,I-Entity
",",O
an,O
efficacious,O
and,O
widely,O
used,O
antiarrhythmic,O
agent,O
",",O
has,O
been,O
reported,O
to,O
cause,O
hepatotoxicity,I-Entity
in,O
some,O
patients,O
.,O
To,O
gain,O
insight,O
into,O
the,O
mechanism,O
of,O
this,O
unwanted,O
effect,O
",",O
mice,O
were,O
administered,O
various,O
doses,O
of,O
amiodarone,I-Entity
and,O
examined,O
for,O
changes,O
in,O
hepatic,O
histology,O
and,O
gene,O
regulation,O
.,O
Amiodarone,I-Entity
induced,O
hepatomegaly,I-Entity
",",O
hepatocyte,O
microvesicular,O
lipid,O
accumulation,O
",",O
and,O
a,O
significant,O
decrease,O
in,O
serum,O
triglycerides,I-Entity
and,O
glucose,I-Entity
.,O
Northern,O
blot,O
analysis,O
of,O
hepatic,O
RNA,O
revealed,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
expression,O
of,O
a,O
number,O
of,O
genes,O
critical,O
for,O
fatty,B-Entity
acid,I-Entity
oxidation,O
",",O
lipoprotein,O
assembly,O
",",O
and,O
lipid,O
transport,O
.,O
The,O
absence,O
of,O
induction,O
of,O
these,O
genes,O
as,O
well,O
as,O
hepatomegaly,I-Entity
in,O
PPARalpha,O
knockout,O
[,O
PPARalpha-/-,O
],O
mice,O
indicated,O
that,O
the,O
effects,O
of,O
amiodarone,I-Entity
were,O
dependent,O
upon,O
the,O
presence,O
of,O
a,O
functional,O
PPARalpha,O
gene,O
.,O
Compared,O
to,O
wild,O
-,O
type,O
mice,O
",",O
treatment,O
of,O
PPARalpha-/-,O
mice,O
with,O
amiodarone,I-Entity
resulted,O
in,O
an,O
increased,O
rate,O
and,O
extent,O
of,O
total,O
body,O
weight,B-Entity
loss,I-Entity
.,O
The,O
inability,O
of,O
amiodarone,I-Entity
to,O
directly,O
activate,O
either,O
human,O
or,O
mouse,O
PPARalpha,O
transiently,O
expressed,O
in,O
human,O
HepG2,O
hepatoma,I-Entity
cells,O
indicates,O
that,O
the,O
effects,O
of,O
amiodarone,I-Entity
on,O
the,O
function,O
of,O
this,O
receptor,O
were,O
indirect,O
.,O
Based,O
upon,O
these,O
results,O
",",O
we,O
conclude,O
that,O
amiodarone,I-Entity
disrupts,O
hepatic,O
lipid,O
homeostasis,O
and,O
that,O
the,O
increased,O
expression,O
of,O
PPARalpha,O
target,O
genes,O
is,O
secondary,O
to,O
this,O
toxic,O
effect,O
.,O
These,O
results,O
provide,O
important,O
new,O
mechanistic,O
information,O
regarding,O
the,O
hepatotoxic,I-Entity
effects,O
of,O
amiodarone,I-Entity
and,O
indicate,O
that,O
PPARalpha,O
protects,O
against,O
amiodarone,I-Entity
-,O
induced,O
hepatotoxicity,I-Entity
.,O
Safety,O
and,O
compliance,O
with,O
once,O
-,O
daily,O
niacin,B-Entity
extended,I-Entity
-,I-Entity
release,I-Entity
/,I-Entity
lovastatin,I-Entity
as,O
initial,O
therapy,O
in,O
the,O
Impact,O
of,O
Medical,O
Subspecialty,O
on,O
Patient,O
Compliance,O
to,O
Treatment,O
(,O
IMPACT,O
),O
study,O
.,O
Niacin,B-Entity
extended,I-Entity
-,I-Entity
release,I-Entity
/,I-Entity
lovastatin,I-Entity
is,O
a,O
new,O
combination,O
product,O
approved,O
for,O
treatment,O
of,O
primary,O
hypercholesterolemia,I-Entity
and,O
mixed,O
dyslipidemia,I-Entity
.,O
This,O
open,O
-,O
labeled,O
",",O
multicenter,O
study,O
evaluated,O
the,O
safety,O
of,O
bedtime,O
niacin,B-Entity
extended,I-Entity
-,I-Entity
release,I-Entity
/,I-Entity
lovastatin,I-Entity
when,O
dosed,O
as,O
initial,O
therapy,O
and,O
patient,O
compliance,O
to,O
treatment,O
in,O
various,O
clinical,O
practice,O
settings,O
.,O
A,O
total,O
of,O
"4,499",O
patients,O
with,O
dyslipidemia,I-Entity
requiring,O
drug,O
intervention,O
was,O
enrolled,O
at,O
"1,081",O
sites,O
.,O
Patients,O
were,O
treated,O
with,O
1,O
tablet,O
(,O
500,O
mg,O
of,O
niacin,I-Entity
extended,O
-,O
release/20,O
mg,O
of,O
lovastatin,I-Entity
),O
once,O
nightly,O
for,O
4,O
weeks,O
and,O
then,O
2,O
tablets,O
for,O
8,O
weeks,O
.,O
Patients,O
also,O
received,O
dietary,O
counseling,O
",",O
educational,O
materials,O
",",O
and,O
reminders,O
to,O
call,O
a,O
toll,O
-,O
free,O
number,O
that,O
provided,O
further,O
education,O
about,O
dyslipidemia,I-Entity
and,O
niacin,B-Entity
extended,I-Entity
-,I-Entity
release,I-Entity
/,I-Entity
lovastatin,I-Entity
.,O
Primary,O
end,O
points,O
were,O
study,O
compliance,O
",",O
increases,O
in,O
liver,O
transaminases,O
to,O
>,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
",",O
and,O
clinical,O
myopathy,I-Entity
.,O
Compliance,O
to,O
niacin,B-Entity
extended,I-Entity
-,I-Entity
release,I-Entity
/,I-Entity
lovastatin,I-Entity
was,O
77%,O
",",O
with,O
"3,245",O
patients,O
completing,O
the,O
study,O
.,O
Flushing,I-Entity
was,O
the,O
most,O
common,O
adverse,O
event,O
",",O
reported,O
by,O
18%,O
of,O
patients,O
and,O
leading,O
to,O
discontinuation,O
by,O
6%,O
.,O
Incidence,O
of,O
increased,O
aspartate,I-Entity
aminotransferase,O
and/or,O
alanine,I-Entity
aminotransferase,O
>,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
was,O
<,O
0.3%,O
.,O
An,O
increase,O
of,O
creatine,I-Entity
phosphokinase,O
to,O
>,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
occurred,O
in,O
0.24%,O
of,O
patients,O
",",O
and,O
no,O
cases,O
of,O
drug,O
-,O
induced,O
myopathy,I-Entity
were,O
observed,O
.,O
Niacin,B-Entity
extended,I-Entity
-,I-Entity
release,I-Entity
/,I-Entity
lovastatin,I-Entity
"1,000/40",O
mg,O
",",O
dosed,O
as,O
initial,O
therapy,O
",",O
was,O
associated,O
with,O
good,O
compliance,O
and,O
safety,O
and,O
had,O
very,O
low,O
incidences,O
of,O
increased,O
liver,O
and,O
muscle,O
enzymes,O
.,O
Protective,O
effect,O
of,O
Terminalia,B-Entity
chebula,I-Entity
against,O
experimental,O
myocardial,B-Entity
injury,I-Entity
induced,O
by,O
isoproterenol,I-Entity
.,O
Cardioprotective,O
effect,O
of,O
ethanolic,B-Entity
extract,I-Entity
of,I-Entity
Terminalia,I-Entity
chebula,I-Entity
fruits,I-Entity
(,O
500,O
mg,O
/,O
kg,O
body,O
wt,O
),O
was,O
examined,O
in,O
isoproterenol,I-Entity
(,O
200,O
mg,O
/,O
kg,O
body,O
wt,O
),O
induced,O
myocardial,B-Entity
damage,I-Entity
in,O
rats,O
.,O
In,O
isoproterenol,I-Entity
administered,O
rats,O
",",O
the,O
level,O
of,O
lipid,O
peroxides,I-Entity
increased,O
significantly,O
in,O
the,O
serum,O
and,O
heart,O
.,O
Histopathological,O
examination,O
was,O
carried,O
out,O
to,O
confirm,O
the,O
myocardial,O
necrosis,I-Entity
.,O
T.,B-Entity
chebula,I-Entity
extract,I-Entity
pretreatment,O
was,O
found,O
to,O
ameliorate,O
the,O
effect,O
of,O
isoproterenol,I-Entity
on,O
lipid,O
peroxide,I-Entity
formation,O
and,O
retained,O
the,O
activities,O
of,O
the,O
diagnostic,O
marker,O
enzymes,O
.,O
A,O
case,O
of,O
postoperative,O
anxiety,I-Entity
due,O
to,O
low,O
dose,O
droperidol,I-Entity
used,O
with,O
patient,O
-,O
controlled,O
analgesia,O
.,O
Postoperatively,O
",",O
she,O
was,O
given,O
a,O
patient,O
-,O
controlled,O
analgesia,O
device,O
delivering,O
boluses,O
of,O
diamorphine,I-Entity
0.5,O
mg,O
and,O
droperidol,I-Entity
0.025,O
mg,O
.,O
The,O
diagnosis,O
of,O
droperidol,I-Entity
-,O
induced,O
psychological,B-Entity
disturbance,I-Entity
was,O
not,O
made,O
straight,O
away,O
although,O
on,O
subsequent,O
close,O
questioning,O
the,O
patient,O
gave,O
a,O
very,O
clear,O
history,O
.,O
After,O
she,O
had,O
received,O
a,O
total,O
of,O
only,O
0.9,O
mg,O
droperidol,I-Entity
",",O
a,O
syringe,O
containing,O
diamorphine,I-Entity
only,O
was,O
substituted,O
and,O
her,O
unease,O
resolved,O
completely,O
.,O
Accurate,O
patient,O
history,O
contributes,O
to,O
differentiating,O
diabetes,B-Entity
insipidus,I-Entity
:,O
a,O
case,O
study,O
.,O
The,O
case,O
discussed,O
herein,O
initially,O
appeared,O
to,O
be,O
neurogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
(,O
DI,I-Entity
),O
secondary,O
to,O
a,O
traumatic,B-Entity
brain,I-Entity
injury,I-Entity
.,O
The,O
nursing,O
staff,O
",",O
by,O
reviewing,O
the,O
patient,O
's,O
health,O
history,O
with,O
his,O
family,O
",",O
discovered,O
a,O
history,O
of,O
polydipsia,I-Entity
and,O
long,O
-,O
standing,O
lithium,I-Entity
use,O
.,O
Lithium,I-Entity
is,O
implicated,O
in,O
drug,O
-,O
induced,O
nephrogenic,B-Entity
DI,I-Entity
",",O
and,O
because,O
the,O
patient,O
had,O
not,O
received,O
lithium,I-Entity
since,O
being,O
admitted,O
to,O
the,O
hospital,O
",",O
his,O
treatment,O
changed,O
to,O
focus,O
on,O
nephrogenic,B-Entity
DI,I-Entity
.,O
By,O
combining,O
information,O
from,O
the,O
patient,O
history,O
",",O
the,O
physical,O
examination,O
",",O
and,O
radiologic,O
and,O
laboratory,O
studies,O
",",O
the,O
critical,O
care,O
team,O
demonstrated,O
that,O
the,O
patient,O
had,O
been,O
self,O
-,O
treating,O
his,O
lithium,I-Entity
-,O
induced,O
nephrogenic,B-Entity
DI,I-Entity
and,O
developed,O
neurogenic,B-Entity
DI,I-Entity
secondary,O
to,O
brain,B-Entity
trauma,I-Entity
.,O
Thus,O
successful,O
treatment,O
required,O
that,O
nephrogenic,O
and,O
neurogenic,B-Entity
DI,I-Entity
be,O
treated,O
concomitantly,O
.,O
Factors,O
contributing,O
to,O
ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
Interferon,I-Entity
and,O
ribavirin,I-Entity
combination,O
therapy,O
for,O
chronic,B-Entity
hepatitis,I-Entity
C,I-Entity
produces,O
hemolytic,B-Entity
anemia,I-Entity
.,O
This,O
study,O
was,O
conducted,O
to,O
identify,O
the,O
factors,O
contributing,O
to,O
ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
METHODS,O
:,O
Eighty,O
-,O
eight,O
patients,O
with,O
chronic,B-Entity
hepatitis,I-Entity
C,I-Entity
who,O
received,O
interferon,B-Entity
-,I-Entity
alpha-2b,I-Entity
at,O
a,O
dose,O
of,O
6,O
MU,O
administered,O
intramuscularly,O
for,O
24,O
weeks,O
in,O
combination,O
with,O
ribavirin,I-Entity
administered,O
orally,O
at,O
a,O
dose,O
of,O
600,O
mg,O
or,O
800,O
mg,O
participated,O
in,O
the,O
study,O
.,O
A,O
hemoglobin,O
concentration,O
of,O
<,O
10,O
g,O
/,O
dL,O
was,O
defined,O
as,O
ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
Ribavirin,I-Entity
-,O
induced,O
anemia,I-Entity
occurred,O
in,O
18,O
(,O
20.5%,O
),O
patients,O
during,O
treatment,O
.,O
A,O
2,O
g,O
/,O
dL,O
decrease,O
in,O
hemoglobin,O
concentrations,O
in,O
patients,O
with,O
anemia,I-Entity
was,O
observed,O
at,O
week,O
2,O
after,O
the,O
start,O
of,O
treatment,O
.,O
A,O
significant,O
relationship,O
was,O
observed,O
between,O
the,O
rate,O
of,O
reduction,O
of,O
hemoglobin,O
concentrations,O
at,O
week,O
2,O
and,O
the,O
severity,O
of,O
anemia,I-Entity
(,O
P,O
<,O
0.01,O
),O
.,O
Such,O
factors,O
as,O
sex,O
(,O
female,O
),O
",",O
age,O
(,O
>,O
or,O
=,O
60,O
years,O
old,O
),O
",",O
and,O
the,O
ribavirin,I-Entity
dose,O
by,O
body,O
weight,O
(,O
12,O
mg,O
/,O
kg,O
or,O
more,O
),O
were,O
significant,O
by,O
univariate,O
analysis,O
.,O
Careful,O
administration,O
is,O
necessary,O
in,O
patients,O
>,O
or,O
=,O
60,O
years,O
old,O
",",O
in,O
female,O
patients,O
",",O
and,O
in,O
patients,O
receiving,O
a,O
ribavirin,I-Entity
dose,O
of,O
12,O
mg,O
/,O
kg,O
or,O
more,O
.,O
Oxidative,O
damage,O
precedes,O
nitrative,O
damage,O
in,O
adriamycin,I-Entity
-,O
induced,O
cardiac,O
mitochondrial,B-Entity
injury,I-Entity
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
determine,O
if,O
elevated,O
reactive,O
oxygen,I-Entity
(,O
ROS)/nitrogen,I-Entity
species,O
(,O
RNS,O
),O
reported,O
to,O
be,O
present,O
in,O
adriamycin,I-Entity
(,O
ADR)-induced,I-Entity
cardiotoxicity,I-Entity
actually,O
resulted,O
in,O
cardiomyocyte,O
B6C3,O
mice,O
were,O
treated,O
with,O
a,O
single,O
dose,O
of,O
20,O
mg,O
/,O
kg,O
ADR,I-Entity
.,O
Ultrastructural,O
damage,O
and,O
levels,O
of,O
4-hydroxy-2-nonenal,I-Entity
(,O
4HNE)-protein,I-Entity
adducts,O
and,O
3-nitrotyrosine,I-Entity
(,O
3NT,I-Entity
),O
were,O
analyzed,O
.,O
Analysis,O
of,O
4HNE,I-Entity
protein,O
adducts,O
by,O
immunogold,O
electron,O
microscopy,O
showed,O
appearance,O
of,O
4HNE,I-Entity
protein,O
adducts,O
in,O
mitochondria,O
as,O
early,O
as,O
3,O
hours,O
",",O
with,O
a,O
peak,O
at,O
6,O
hours,O
and,O
subsequent,O
decline,O
at,O
24,O
hours,O
.,O
3NT,I-Entity
levels,O
were,O
significantly,O
increased,O
in,O
all,O
subcellular,O
compartments,O
at,O
6,O
hours,O
and,O
subsequently,O
declined,O
at,O
24,O
hours,O
.,O
Our,O
data,O
showed,O
ADR,I-Entity
induced,O
4HNE,I-Entity
-,O
protein,O
adducts,O
in,O
mitochondria,O
at,O
the,O
same,O
time,O
point,O
as,O
when,O
mitochondrial,B-Entity
injury,I-Entity
initially,O
appeared,O
.,O
These,O
results,O
document,O
for,O
the,O
first,O
time,O
in,O
vivo,O
that,O
mitochondrial,B-Entity
oxidative,I-Entity
damage,I-Entity
precedes,O
nitrative,O
damage,O
.,O
The,O
progressive,O
nature,O
of,O
mitochondrial,B-Entity
injury,I-Entity
suggests,O
that,O
mitochondria,O
",",O
not,O
other,O
subcellular,O
organelles,O
",",O
are,O
the,O
major,O
site,O
of,O
intracellular,O
injury,O
.,O
Sotalol,I-Entity
-,O
induced,O
coronary,B-Entity
spasm,I-Entity
in,O
a,O
patient,O
with,O
dilated,B-Entity
cardiomyopathy,I-Entity
associated,O
with,O
sustained,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
A,O
54-year,O
-,O
old,O
man,O
with,O
severe,O
left,O
ventricular,B-Entity
dysfunction,I-Entity
due,O
to,O
dilated,B-Entity
cardiomyopathy,I-Entity
was,O
referred,O
to,O
our,O
hospital,O
for,O
symptomatic,O
incessant,O
sustained,O
ventricular,B-Entity
tachycardia,I-Entity
(,O
VT,I-Entity
),O
.,O
After,O
the,O
administration,O
of,O
nifekalant,B-Entity
hydrochloride,I-Entity
",",O
sustained,O
VT,I-Entity
was,O
terminated,O
.,O
An,O
alternate,O
class,O
III,O
agent,O
",",O
sotalol,I-Entity
",",O
was,O
also,O
effective,O
for,O
the,O
prevention,O
of,O
VT,I-Entity
.,O
However,O
",",O
one,O
month,O
after,O
switching,O
over,O
nifekalant,I-Entity
to,O
sotalol,I-Entity
",",O
a,O
short,O
duration,O
of,O
ST,O
elevation,O
was,O
documented,O
in,O
ECG,O
monitoring,O
at,O
almost,O
the,O
same,O
time,O
for,O
three,O
consecutive,O
days,O
.,O
ST,O
elevation,O
with,O
chest,O
discomfort,O
disappeared,O
since,O
he,O
began,O
taking,O
long,O
-,O
acting,O
diltiazem,I-Entity
.,O
Coronary,B-Entity
vasospasm,I-Entity
may,O
be,O
induced,O
by,O
the,O
non,O
-,O
selective,O
beta,O
-,O
blocking,O
properties,O
of,O
sotalol,I-Entity
.,O
Effects,O
of,O
the,O
antidepressant,O
trazodone,I-Entity
",",O
a,O
5-HT,I-Entity
2A/2C,O
receptor,O
antagonist,O
",",O
on,O
dopamine,I-Entity
-,O
dependent,O
behaviors,O
in,O
rats,O
.,O
RATIONALE,O
:,O
5-Hydroxytryptamine,I-Entity
",",O
via,O
stimulation,O
of,O
5-HT,I-Entity
2C,O
receptors,O
",",O
exerts,O
a,O
tonic,O
inhibitory,O
influence,O
on,O
dopaminergic,O
neurotransmission,O
",",O
whereas,O
activation,O
of,O
5-HT,I-Entity
2A,O
receptors,O
enhances,O
stimulated,O
DAergic,O
neurotransmission,O
.,O
The,O
antidepressant,O
trazodone,I-Entity
is,O
a,O
5-HT,I-Entity
2A/2C,O
receptor,O
antagonist,O
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
effect,O
of,O
trazodone,I-Entity
treatment,O
on,O
behaviors,O
dependent,O
on,O
the,O
functional,O
status,O
of,O
the,O
nigrostriatal,O
DAergic,O
system,O
.,O
The,O
effect,O
of,O
pretreatment,O
with,O
trazodone,I-Entity
on,O
dexamphetamine-,I-Entity
and,O
apomorphine,I-Entity
-,O
induced,O
oral,B-Entity
stereotypies,I-Entity
",",O
on,O
catalepsy,I-Entity
induced,O
by,O
haloperidol,I-Entity
and,O
apomorphine,I-Entity
(,O
0.05,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
",",O
on,O
ergometrine,I-Entity
-,O
induced,O
wet,O
dog,O
shake,O
(,O
WDS,O
),O
behavior,O
and,O
fluoxetine,I-Entity
-,O
induced,O
penile,O
erections,O
was,O
studied,O
in,O
rats,O
.,O
We,O
also,O
investigated,O
whether,O
trazodone,I-Entity
induces,O
catalepsy,I-Entity
in,O
rats,O
.,O
Trazodone,I-Entity
at,O
2.5,O
-,O
20,O
mg,O
did,O
not,O
induce,O
catalepsy,I-Entity
",",O
and,O
did,O
not,O
antagonize,O
apomorphine,I-Entity
(,O
1.5,O
and,O
3,O
mg,O
/,O
kg,O
),O
stereotypy,O
and,O
apomorphine,I-Entity
(,O
0.05,O
mg,O
/,O
kg)-induced,O
catalepsy,I-Entity
.,O
trazodone,I-Entity
enhanced,O
dexamphetamine,I-Entity
stereotypy,O
",",O
and,O
antagonized,O
haloperidol,I-Entity
catalepsy,I-Entity
",",O
ergometrine,I-Entity
-,O
induced,O
WDS,O
behavior,O
and,O
fluoxetine,I-Entity
-,O
induced,O
penile,O
erections,O
.,O
Trazodone,I-Entity
at,O
30,O
",",O
40,O
and,O
50,O
mg,O
induced,O
catalepsy,I-Entity
and,O
antagonized,O
apomorphine,I-Entity
and,O
dexamphetamine,I-Entity
stereotypies,O
.,O
Our,O
results,O
indicate,O
that,O
trazodone,I-Entity
at,O
2.5,O
-,O
20,O
mg,O
/,O
kg,O
does,O
not,O
block,O
pre-,O
and,O
postsynaptic,O
striatal,O
D2,O
DA,O
receptors,O
",",O
while,O
at,O
30,O
",",O
40,O
and,O
50,O
mg,O
/,O
kg,O
it,O
blocks,O
postsynaptic,O
striatal,O
D2,O
DA,O
receptors,O
.,O
Furthermore,O
",",O
at,O
5,O
",",O
10,O
and,O
20,O
mg,O
/,O
kg,O
",",O
trazodone,I-Entity
blocks,O
5-HT,I-Entity
2A,O
and,O
5-HT,I-Entity
2C,O
receptors,O
.,O
We,O
suggest,O
that,O
trazodone,I-Entity
(,O
5,O
",",O
10,O
and,O
20,O
mg,O
/,O
kg,O
),O
",",O
by,O
blocking,O
the,O
5-HT,I-Entity
2C,O
receptors,O
",",O
releases,O
the,O
nigrostriatal,O
DAergic,O
neurons,O
from,O
tonic,O
inhibition,O
caused,O
by,O
5-HT,I-Entity
",",O
and,O
thereby,O
potentiates,O
dexamphetamine,I-Entity
stereotypy,O
and,O
antagonizes,O
haloperidol,I-Entity
catalepsy,I-Entity
.,O
Swallowing,B-Entity
abnormalities,I-Entity
and,O
dyskinesia,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Gastrointestinal,B-Entity
abnormalities,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
have,O
been,O
known,O
for,O
almost,O
two,O
centuries,O
",",O
but,O
many,O
aspects,O
concerning,O
their,O
pathophysiology,O
have,O
not,O
been,O
completely,O
clarified,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
characterize,O
the,O
oropharyngeal,O
dynamics,O
in,O
PD,I-Entity
patients,O
with,O
and,O
without,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
.,O
Fifteen,O
dyskinetic,I-Entity
",",O
12,O
nondyskinetic,O
patients,O
",",O
and,O
a,O
control,O
group,O
were,O
included,O
.,O
Patients,O
were,O
asked,O
about,O
dysphagia,I-Entity
and,O
evaluated,O
with,O
the,O
Unified,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Rating,O
Scale,O
Parts,O
II,O
and,O
III,O
and,O
the,O
Hoehn,O
and,O
Yahr,O
scale,O
.,O
Deglutition,O
was,O
assessed,O
using,O
modified,O
barium,I-Entity
swallow,O
with,O
videofluoroscopy,O
.,O
Nondyskinetic,O
patients,O
",",O
but,O
not,O
the,O
dyskinetic,I-Entity
ones,O
",",O
showed,O
less,O
oropharyngeal,O
swallowing,O
efficiency,O
(,O
OPSE,O
),O
for,O
liquid,O
food,O
than,O
controls,O
(,O
Dunnett,O
",",O
P,O
=,O
0.02,O
),O
.,O
Dyskinetic,I-Entity
patients,O
tended,O
to,O
have,O
a,O
greater,O
OPSE,O
than,O
nondyskinetic,O
(,O
Dunnett,O
",",O
P,O
=,O
0.06,O
),O
.,O
Patients,O
who,O
were,O
using,O
a,O
higher,O
dose,O
of,O
levodopa,I-Entity
had,O
a,O
greater,O
OPSE,O
and,O
a,O
trend,O
toward,O
a,O
smaller,O
oral,O
transit,O
time,O
(,O
Pearson,O
's,O
correlation,O
",",O
P,O
=,O
0.01,O
and,O
0.08,O
",",O
respectively,O
),O
.,O
Neither,O
the,O
report,O
of,O
dysphagia,I-Entity
nor,O
any,O
of,O
the,O
PD,I-Entity
severity,O
parameters,O
correlated,O
to,O
the,O
videofluoroscopic,O
variables,O
.,O
In,O
the,O
current,O
study,O
",",O
dyskinetic,I-Entity
patients,O
performed,O
better,O
in,O
swallowing,O
function,O
",",O
which,O
could,O
be,O
explained,O
on,O
the,O
basis,O
of,O
a,O
greater,O
levodopa,I-Entity
dose,O
.,O
Our,O
results,O
suggest,O
a,O
role,O
for,O
levodopa,I-Entity
in,O
the,O
oral,O
phase,O
of,O
deglutition,O
and,O
confirm,O
that,O
dysphagia,I-Entity
is,O
not,O
a,O
good,O
predictor,O
of,O
deglutition,O
alterations,O
in,O
PD,I-Entity
.,O
Inhibition,O
of,O
nuclear,O
factor,O
-,O
kappaB,O
activation,O
attenuates,O
tubulointerstitial,B-Entity
nephritis,I-Entity
induced,O
by,O
gentamicin,I-Entity
.,O
:,O
Animals,O
treated,O
with,O
gentamicin,I-Entity
can,O
show,O
residual,O
areas,O
of,O
interstitial,O
fibrosis,I-Entity
in,O
the,O
renal,O
cortex,O
.,O
kinases,O
and,O
macrophages,O
in,O
the,O
renal,O
cortex,O
and,O
structural,O
and,O
functional,O
renal,O
changes,O
of,O
rats,O
treated,O
with,O
gentamicin,I-Entity
or,O
gentamicin,I-Entity
+,O
pyrrolidine,B-Entity
dithiocarbamate,I-Entity
(,O
PDTC,I-Entity
),O
",",O
an,O
NF,O
-,O
kappaB,O
inhibitor,O
.,O
METHODS,O
:,O
38,O
female,O
Wistar,O
rats,O
were,O
injected,O
with,O
gentamicin,I-Entity
",",O
40,O
mg,O
/,O
kg,O
",",O
twice,O
a,O
day,O
for,O
9,O
days,O
",",O
38,O
with,O
gentamicin,I-Entity
+,O
PDTC,I-Entity
",",O
and,O
28,O
with,O
0.15,O
M,O
NaCl,I-Entity
solution,O
.,O
Gentamicin,I-Entity
-,O
treated,O
rats,O
presented,O
a,O
transitory,O
increase,O
in,O
plasma,O
creatinine,I-Entity
levels,O
.,O
Increased,O
ED-1,O
",",O
MAP,O
kinases,O
and,O
NF,O
-,O
kappaB,O
staining,O
were,O
also,O
observed,O
in,O
the,O
renal,O
cortex,O
from,O
all,O
gentamicin,I-Entity
-,O
treated,O
rats,O
compared,O
to,O
control,O
(,O
p,O
<,O
0.05,O
),O
.,O
The,O
animals,O
killed,O
on,O
day,O
30,O
also,O
presented,O
fibrosis,I-Entity
in,O
the,O
renal,O
cortex,O
despite,O
the,O
recovery,O
of,O
renal,O
function,O
.,O
Treatment,O
with,O
PDTC,I-Entity
reduced,O
the,O
functional,O
and,O
structural,O
changes,O
induced,O
by,O
gentamicin,I-Entity
.,O
These,O
data,O
show,O
that,O
inhibition,O
of,O
NF,O
-,O
kappaB,O
activation,O
attenuates,O
tubulointerstitial,B-Entity
nephritis,I-Entity
induced,O
by,O
gentamicin,I-Entity
.,O
Glucose,I-Entity
metabolism,O
in,O
patients,O
with,O
schizophrenia,I-Entity
treated,O
with,O
atypical,O
antipsychotic,O
agents,O
:,O
a,O
frequently,O
sampled,O
intravenous,O
glucose,I-Entity
tolerance,O
test,O
and,O
minimal,O
model,O
analysis,O
.,O
While,O
the,O
incidence,O
of,O
new,O
-,O
onset,O
diabetes,B-Entity
mellitus,I-Entity
may,O
be,O
increasing,O
in,O
patients,O
with,O
schizophrenia,I-Entity
treated,O
with,O
certain,O
atypical,O
antipsychotic,O
agents,O
",",O
it,O
remains,O
unclear,O
whether,O
atypical,O
agents,O
are,O
directly,O
affecting,O
glucose,I-Entity
metabolism,O
or,O
simply,O
increasing,O
known,O
risk,O
factors,O
for,O
diabetes,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
study,O
the,O
2,O
drugs,O
most,O
clearly,O
implicated,O
(,O
clozapine,I-Entity
and,O
olanzapine,I-Entity
),O
and,O
risperidone,I-Entity
using,O
a,O
frequently,O
sampled,O
intravenous,O
glucose,I-Entity
tolerance,O
test,O
.,O
A,O
cross,O
-,O
sectional,O
design,O
in,O
stable,O
",",O
treated,O
patients,O
with,O
schizophrenia,I-Entity
evaluated,O
using,O
a,O
frequently,O
sampled,O
intravenous,O
glucose,I-Entity
tolerance,O
test,O
and,O
the,O
Bergman,O
minimal,O
model,O
analysis,O
.,O
Patients,O
Fifty,O
subjects,O
signed,O
informed,O
consent,O
and,O
41,O
underwent,O
the,O
frequently,O
sampled,O
intravenous,O
glucose,I-Entity
tolerance,O
test,O
.,O
Thirty,O
-,O
six,O
nonobese,O
subjects,O
with,O
schizophrenia,I-Entity
or,O
schizoaffective,B-Entity
disorder,I-Entity
",",O
matched,O
by,O
body,O
mass,O
index,O
and,O
treated,O
with,O
either,O
clozapine,I-Entity
",",O
olanzapine,I-Entity
",",O
or,O
risperidone,I-Entity
",",O
were,O
included,O
in,O
the,O
analysis,O
.,O
Fasting,O
plasma,O
glucose,I-Entity
and,O
fasting,O
serum,O
insulin,O
levels,O
",",O
insulin,B-Entity
sensitivity,I-Entity
index,O
",",O
homeostasis,O
model,O
assessment,O
of,O
insulin,B-Entity
resistance,I-Entity
",",O
and,O
glucose,I-Entity
effectiveness,O
.,O
28.9,O
months,O
(,O
clozapine,I-Entity
),O
",",O
29.5,O
+,O
/-,O
17.5,O
months,O
(,O
olanzapine,I-Entity
),O
",",O
and,O
40.9,O
+,O
/-,O
33.7,O
(,O
risperidone,I-Entity
),O
.,O
Fasting,O
serum,O
insulin,O
concentrations,O
differed,O
among,O
groups,O
(,O
F(33,O
),O
=,O
3.35,O
;,O
P,O
=,O
.047,O
),O
(,O
clozapine,I-Entity
>,O
olanzapine,I-Entity
>,O
risperidone,I-Entity
),O
with,O
significant,O
differences,O
between,O
clozapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(33,O
),O
=,O
2.32,O
;,O
P,O
=,O
.03,O
),O
and,O
olanzapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(33,O
),O
=,O
2.15,O
;,O
P,O
=,O
.04,O
),O
.,O
There,O
was,O
a,O
significant,O
difference,O
in,O
insulin,B-Entity
sensitivity,I-Entity
index,O
among,O
groups,O
(,O
F(33,O
),O
=,O
10.66,O
;,O
P<.001,O
),O
(,O
clozapine,I-Entity
<,O
olanzapine,I-Entity
<,O
risperidone,I-Entity
),O
",",O
with,O
subjects,O
who,O
received,O
clozapine,I-Entity
and,O
olanzapine,I-Entity
exhibiting,O
significant,O
insulin,B-Entity
resistance,I-Entity
compared,O
with,O
subjects,O
who,O
were,O
treated,O
with,O
risperidone,I-Entity
(,O
clozapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
-4.29,O
;,O
P<.001,O
;,O
olanzapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
-3.62,O
;,O
P,O
=,O
.001,O
[,O
P<.001,O
],O
),O
.,O
The,O
homeostasis,O
model,O
assessment,O
of,O
insulin,B-Entity
resistance,I-Entity
also,O
differed,O
significantly,O
among,O
groups,O
(,O
F(33,O
),O
=,O
4.92,O
;,O
P,O
=,O
.01,O
),O
(,O
clozapine,I-Entity
>,O
olanzapine,I-Entity
>,O
risperidone,I-Entity
),O
(,O
clozapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
2.94,O
;,O
P,O
=,O
.006,O
;,O
olanzapine,I-Entity
vs,O
risperidone,I-Entity
",",O
t(33,O
),O
=,O
2.42,O
;,O
P,O
=,O
.02,O
),O
.,O
There,O
was,O
a,O
significant,O
difference,O
among,O
groups,O
in,O
glucose,I-Entity
effectiveness,O
(,O
F(30,O
),O
=,O
4.18,O
;,O
P,O
=,O
.02,O
),O
(,O
clozapine,I-Entity
<,O
olanzapine,I-Entity
<,O
risperidone,I-Entity
),O
with,O
significant,O
differences,O
between,O
clozapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(30,O
),O
=,O
-2.59,O
;,O
P,O
=,O
.02,O
),O
and,O
olanzapine,I-Entity
and,O
risperidone,I-Entity
(,O
t(30,O
),O
=,O
-2.34,O
",",O
P,O
=,O
.03,O
),O
.,O
Both,O
nonobese,O
clozapine-,I-Entity
and,O
olanzapine,I-Entity
-,O
treated,O
groups,O
displayed,O
significant,O
insulin,B-Entity
resistance,I-Entity
and,O
impairment,O
of,O
glucose,I-Entity
effectiveness,O
compared,O
with,O
risperidone,I-Entity
-,O
treated,O
subjects,O
.,O
Patients,O
taking,O
clozapine,I-Entity
and,O
olanzapine,I-Entity
must,O
be,O
examined,O
for,O
insulin,B-Entity
resistance,I-Entity
and,O
its,O
consequences,O
.,O
Focal,O
cerebral,B-Entity
ischemia,I-Entity
in,O
rats,O
:,O
effect,O
of,O
phenylephrine,I-Entity
-,O
induced,O
hypertension,I-Entity
during,O
reperfusion,O
.,O
After,O
180,O
min,O
of,O
temporary,O
middle,B-Entity
cerebral,I-Entity
artery,I-Entity
occlusion,I-Entity
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
",",O
the,O
effect,O
of,O
phenylephrine,I-Entity
-,O
induced,O
hypertension,I-Entity
on,O
ischemic,B-Entity
brain,I-Entity
injury,I-Entity
and,O
blood,O
-,O
brain,O
barrier,O
permeability,O
was,O
determined,O
.,O
Blood,O
pressure,O
was,O
manipulated,O
by,O
one,O
of,O
the,O
following,O
schedules,O
during,O
120,O
min,O
of,O
reperfusion,O
:,O
Control,O
",",O
normotensive,O
reperfusion,O
;,O
90/hypertension,I-Entity
(,O
90/HTN,I-Entity
),O
",",O
blood,O
pressure,O
was,O
increased,O
by,O
35,O
mm,O
Hg,O
during,O
the,O
initial,O
90,O
min,O
of,O
reperfusion,O
only,O
;,O
15/hypertension,I-Entity
(,O
15/HTN,I-Entity
),O
",",O
normotensive,O
reperfusion,O
for,O
30,O
min,O
followed,O
by,O
15,O
min,O
of,O
hypertension,I-Entity
and,O
75,O
min,O
of,O
normotension,O
.,O
Part,O
A,O
",",O
for,O
eight,O
rats,O
in,O
each,O
group,O
brain,B-Entity
injury,I-Entity
was,O
evaluated,O
by,O
staining,O
tissue,O
using,O
"2,3,5-triphenyltetrazolium",B-Entity
chloride,I-Entity
and,O
edema,I-Entity
was,O
evaluated,O
by,O
microgravimetry,O
.,O
Brain,B-Entity
injury,I-Entity
(,O
percentage,O
of,O
the,O
ischemic,B-Entity
hemisphere,I-Entity
),O
was,O
less,O
in,O
the,O
15/HTN,I-Entity
group,O
(,O
16,O
+,O
/-,O
SD,O
),O
versus,O
the,O
90/HTN,I-Entity
group,O
(,O
30,O
+,O
/-,O
Specific,O
gravity,O
was,O
greater,O
in,O
the,O
15/HTN,I-Entity
group,O
(,O
1.043,O
+,O
/-,O
0.002,O
),O
versus,O
the,O
90/HTN,I-Entity
(,O
1.036,O
+,O
/-,O
0.003,O
),O
and,O
control,O
(,O
1.037,O
+,O
/-,O
Evans,B-Entity
Blue,I-Entity
(,O
mug,O
g-1,O
of,O
brain,O
tissue,O
),O
was,O
greater,O
in,O
the,O
90/HTN,I-Entity
group,O
(,O
24.4,O
+,O
/-,O
4.1,O
),O
",",O
which,O
was,O
in,O
turn,O
greater,O
than,O
the,O
15/HTN,I-Entity
group,O
(,O
7.3,O
+,O
/-,O
This,O
study,O
supports,O
a,O
hypothesis,O
that,O
during,O
reperfusion,O
",",O
a,O
short,O
interval,O
of,O
hypertension,I-Entity
decreases,O
brain,B-Entity
injury,I-Entity
and,O
edema,I-Entity
;,O
and,O
that,O
sustained,O
hypertension,I-Entity
increases,O
the,O
risk,O
of,O
vasogenic,B-Entity
edema,I-Entity
.,O
People,O
aged,O
over,O
75,O
in,O
atrial,B-Entity
fibrillation,I-Entity
on,O
warfarin,I-Entity
:,O
the,O
rate,O
of,O
major,O
hemorrhage,I-Entity
and,O
stroke,I-Entity
in,O
more,O
than,O
500,O
patient,O
-,O
years,O
of,O
follow,O
-,O
up,O
.,O
OBJECTIVES,O
:,O
To,O
determine,O
the,O
incidence,O
of,O
major,O
hemorrhage,I-Entity
and,O
stroke,I-Entity
in,O
people,O
aged,O
76,O
and,O
older,O
with,O
atrial,B-Entity
fibrillation,I-Entity
on,O
adjusted,O
-,O
dose,O
warfarin,I-Entity
who,O
had,O
been,O
recently,O
been,O
admitted,O
to,O
hospital,O
.,O
Two,O
hundred,O
thirty,O
-,O
five,O
patients,O
aged,O
76,O
and,O
older,O
admitted,O
to,O
a,O
major,O
healthcare,O
network,O
between,O
July,O
1,O
",",O
2001,O
",",O
and,O
June,O
30,O
",",O
2002,O
",",O
with,O
atrial,B-Entity
fibrillation,I-Entity
on,O
warfarin,I-Entity
were,O
enrolled,O
.,O
Information,O
regarding,O
major,O
bleeding,I-Entity
episodes,O
",",O
strokes,I-Entity
",",O
and,O
warfarin,I-Entity
use,O
was,O
obtained,O
from,O
patients,O
",",O
relatives,O
",",O
primary,O
physicians,O
",",O
and,O
medical,O
records,O
.,O
Total,O
follow,O
-,O
up,O
on,O
warfarin,I-Entity
was,O
530,O
years,O
(,O
mean,O
28,O
months,O
),O
.,O
There,O
were,O
53,O
major,O
hemorrhages,I-Entity
",",O
for,O
an,O
annual,O
rate,O
of,O
10.0%,O
",",O
including,O
24,O
(,O
45.3%,O
),O
life,O
-,O
threatening,O
and,O
five,O
(,O
9.4%,O
),O
fatal,O
bleeds,O
.,O
The,O
annual,O
stroke,I-Entity
rate,O
after,O
initiation,O
of,O
warfarin,I-Entity
was,O
2.6%,O
.,O
The,O
rate,O
of,O
major,O
hemorrhage,I-Entity
was,O
high,O
in,O
this,O
old,O
",",O
frail,O
group,O
",",O
but,O
excluding,O
fatalities,O
",",O
resulted,O
in,O
no,O
long,O
-,O
term,O
sequelae,O
",",O
and,O
the,O
stroke,I-Entity
rate,O
on,O
warfarin,I-Entity
was,O
low,O
",",O
demonstrating,O
how,O
effective,O
warfarin,I-Entity
treatment,O
is,O
.,O
Safety,O
of,O
celecoxib,I-Entity
in,O
patients,O
with,O
adverse,O
skin,B-Entity
reactions,I-Entity
to,O
acetaminophen,I-Entity
(,O
paracetamol,I-Entity
),O
and,O
nimesulide,I-Entity
associated,O
or,O
not,O
with,O
common,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
.,O
BACKGROUND,O
:,O
Acetaminophen,I-Entity
(,O
paracetamol,I-Entity
--,O
P,I-Entity
),O
and,O
Nimesulide,I-Entity
(,O
N,I-Entity
),O
are,O
widely,O
used,O
analgesic,O
-,O
antipyretic,O
/,O
anti,O
-,O
inflammatory,O
drugs,O
.,O
The,O
rate,O
of,O
adverse,O
hypersensitivity,I-Entity
reactions,O
to,O
these,O
agents,O
is,O
generally,O
low,O
.,O
Celecoxib,I-Entity
(,O
CE,I-Entity
),O
is,O
a,O
novel,O
drug,O
",",O
with,O
high,O
selectivity,O
and,O
affinity,O
for,O
COX-2,O
enzyme,O
.,O
We,O
evaluated,O
the,O
tolerability,O
of,O
CE,I-Entity
in,O
a,O
group,O
of,O
patients,O
with,O
documented,O
history,O
of,O
adverse,O
cutaneous,B-Entity
reactions,I-Entity
to,O
P,I-Entity
and,O
N,I-Entity
associated,O
or,O
not,O
to,O
classic,O
NSAIDs,O
.,O
:,O
We,O
studied,O
9,O
patients,O
with,O
hypersensitivity,I-Entity
to,O
P,I-Entity
and,O
N,I-Entity
with,O
or,O
without,O
associated,O
reactions,O
to,O
classic,O
NSAIDs,O
.,O
The,O
diagnosis,O
of,O
P,I-Entity
and,O
N,I-Entity
-,O
induced,O
skin,B-Entity
reactions,I-Entity
was,O
based,O
in,O
vivo,O
challenge,O
.,O
After,O
three,O
days,O
",",O
a,O
cumulative,O
dosage,O
of,O
200,O
mg,O
of,O
CE,I-Entity
in,O
refracted,O
doses,O
were,O
given,O
.,O
The,O
challenge,O
was,O
considered,O
positive,O
if,O
one,O
or,O
more,O
of,O
the,O
following,O
appeared,O
:,O
erythema,I-Entity
",",O
rush,O
or,O
urticaria,I-Entity
-,O
angioedema,I-Entity
.,O
No,O
reaction,O
was,O
observed,O
with,O
placebo,O
and,O
eight,O
patients,O
(,O
88.8%,O
),O
tolerated,O
CE,I-Entity
.,O
Only,O
one,O
patient,O
developed,O
a,O
moderate,O
angioedema,I-Entity
of,O
the,O
lips,O
.,O
CONCLUSION,O
:,O
Only,O
one,O
hypersensitivity,I-Entity
reaction,O
to,O
CE,I-Entity
was,O
documented,O
among,O
9,O
P,I-Entity
and,O
N,I-Entity
-,O
highly,O
NSAIDs,O
intolerant,O
patients,O
.,O
Thus,O
",",O
we,O
conclude,O
that,O
CE,I-Entity
is,O
a,O
reasonably,O
safe,O
alternative,O
to,O
be,O
used,O
in,O
subjects,O
who,O
do,O
not,O
tolerate,O
P,I-Entity
and,O
N.,I-Entity
Case,O
-,O
control,O
study,O
of,O
regular,O
analgesic,O
and,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
use,O
and,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
.,O
Studies,O
on,O
the,O
association,O
between,O
the,O
long,O
-,O
term,O
use,O
of,O
aspirin,I-Entity
and,O
other,O
analgesic,O
and,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,O
),O
and,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
(,O
ESRD,I-Entity
),O
have,O
given,O
conflicting,O
results,O
.,O
In,O
order,O
to,O
examine,O
this,O
association,O
",",O
a,O
case,O
-,O
control,O
study,O
with,O
incident,O
cases,O
of,O
ESRD,I-Entity
was,O
carried,O
out,O
.,O
METHODS,O
:,O
The,O
cases,O
were,O
all,O
patients,O
entering,O
the,O
local,O
dialysis,O
program,O
because,O
of,O
ESRD,I-Entity
in,O
the,O
study,O
area,O
between,O
June,O
1,O
",",O
1995,O
and,O
November,O
30,O
",",O
1997,O
.,O
They,O
were,O
classified,O
according,O
to,O
the,O
underlying,O
disease,O
",",O
which,O
had,O
presumably,O
led,O
them,O
to,O
ESRD,I-Entity
.,O
For,O
specific,O
groups,O
of,O
drugs,O
",",O
the,O
risks,O
were,O
1.56,O
(,O
1.05,O
-,O
2.30,O
),O
for,O
aspirin,I-Entity
",",O
1.03,O
(,O
0.60,O
-,O
1.76,O
),O
for,O
pyrazolones,I-Entity
",",O
0.80,O
(,O
0.39,O
-,O
1.63,O
),O
for,O
paracetamol,I-Entity
",",O
and,O
0.94,O
(,O
0.57,O
-,O
1.56,O
),O
for,O
nonaspirin,O
NSAIDs,O
.,O
The,O
risk,O
of,O
ESRD,I-Entity
associated,O
with,O
aspirin,I-Entity
was,O
related,O
to,O
the,O
cumulated,O
dose,O
and,O
duration,O
of,O
use,O
",",O
and,O
it,O
was,O
particularly,O
high,O
among,O
the,O
subset,O
of,O
patients,O
with,O
vascular,O
nephropathy,I-Entity
as,O
underlying,O
disease,O
[,O
2.35,O
(,O
1.17,O
-,O
4.72,O
),O
],O
.,O
CONCLUSION,O
:,O
Our,O
data,O
indicate,O
that,O
long,O
-,O
term,O
use,O
of,O
nonaspirin,O
analgesic,O
drugs,O
and,O
NSAIDs,O
is,O
not,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
ESRD,I-Entity
.,O
However,O
",",O
the,O
chronic,O
use,O
of,O
aspirin,I-Entity
may,O
increase,O
the,O
risk,O
of,O
ESRD,I-Entity
.,O
Two,O
cases,O
of,O
amisulpride,I-Entity
overdose,I-Entity
:,O
a,O
cause,O
for,O
prolonged,B-Entity
QT,I-Entity
syndrome,I-Entity
.,O
Two,O
cases,O
of,O
deliberate,O
self,O
-,O
poisoning,I-Entity
with,O
5,O
g,O
and,O
3.6,O
g,O
of,O
amisulpride,I-Entity
",",O
respectively,O
",",O
are,O
reported,O
.,O
In,O
both,O
cases,O
",",O
QT,B-Entity
prolongation,I-Entity
and,O
hypocalcaemia,I-Entity
were,O
noted,O
.,O
The,O
QT,B-Entity
prolongation,I-Entity
appeared,O
to,O
respond,O
to,O
administration,O
of,O
i.v,O
.,O
calcium,B-Entity
gluconate,I-Entity
.,O
Growth,O
-,O
associated,O
protein,O
43,O
expression,O
in,O
hippocampal,O
molecular,O
layer,O
of,O
chronic,O
epileptic,I-Entity
rats,O
treated,O
with,O
cycloheximide,I-Entity
.,O
GAP43,O
has,O
been,O
thought,O
to,O
be,O
linked,O
with,O
mossy,O
fiber,O
sprouting,O
(,O
MFS,O
),O
in,O
various,O
experimental,O
models,O
of,O
epilepsy,I-Entity
.,O
To,O
investigate,O
how,O
GAP43,O
expression,O
(,O
GAP43-ir,O
),O
correlates,O
with,O
MFS,O
",",O
we,O
assessed,O
the,O
intensity,O
(,O
densitometry,O
),O
and,O
extension,O
(,O
width,O
),O
of,O
GAP43-ir,O
in,O
the,O
inner,O
molecular,O
layer,O
of,O
the,O
dentate,O
gyrus,O
(,O
IML,O
),O
of,O
rats,O
subject,O
to,O
status,B-Entity
epilepticus,I-Entity
induced,O
by,O
pilocarpine,I-Entity
(,O
Pilo,I-Entity
),O
",",O
previously,O
injected,O
or,O
not,O
with,O
cycloheximide,I-Entity
(,O
CHX,I-Entity
),O
",",O
which,O
has,O
been,O
shown,O
to,O
inhibit,O
MFS,O
.,O
CHX,I-Entity
was,O
injected,O
before,O
the,O
Pilo,I-Entity
injection,O
in,O
adult,O
Wistar,O
rats,O
.,O
The,O
Pilo,I-Entity
group,O
was,O
injected,O
with,O
the,O
same,O
drugs,O
",",O
except,O
for,O
CHX,I-Entity
.,O
RESULTS,O
:,O
Densitometry,O
showed,O
no,O
significant,O
difference,O
regarding,O
GAP43-ir,O
in,O
the,O
IML,O
between,O
Pilo,I-Entity
",",O
CHX+Pilo,I-Entity
",",O
and,O
control,O
groups,O
.,O
However,O
",",O
the,O
results,O
of,O
the,O
width,O
of,O
the,O
GAP43-ir,O
band,O
in,O
the,O
IML,O
showed,O
that,O
CHX+Pilo,I-Entity
and,O
control,O
animals,O
had,O
a,O
significantly,O
larger,O
band,O
(,O
p,O
=,O
0.03,O
),O
as,O
compared,O
with,O
that,O
in,O
the,O
Pilo,I-Entity
group,O
.,O
Our,O
current,O
finding,O
that,O
animals,O
in,O
the,O
CHX+Pilo,I-Entity
group,O
have,O
a,O
GAP43-ir,O
band,O
in,O
the,O
IML,O
",",O
similar,O
to,O
that,O
of,O
controls,O
",",O
reinforces,O
prior,O
data,O
on,O
the,O
blockade,O
of,O
MFS,O
in,O
these,O
animals,O
.,O
The,O
change,O
in,O
GAP43-ir,O
present,O
in,O
Pilo,I-Entity
-,O
treated,O
animals,O
was,O
a,O
thinning,O
of,O
the,O
band,O
to,O
a,O
very,O
narrow,O
layer,O
just,O
above,O
the,O
granule,O
cell,O
layer,O
that,O
is,O
likely,O
to,O
be,O
associated,O
with,O
the,O
loss,O
of,O
hilar,O
cell,O
projections,O
that,O
express,O
GAP-43,O
.,O
Nicotine,I-Entity
antagonizes,O
caffeine-,I-Entity
but,O
not,O
pentylenetetrazole,I-Entity
-,O
induced,O
anxiogenic,O
effect,O
in,O
mice,O
.,O
Nicotine,I-Entity
and,O
caffeine,I-Entity
are,O
widely,O
consumed,O
licit,O
psychoactive,O
drugs,O
worldwide,O
.,O
Although,O
some,O
studies,O
in,O
experimental,O
animals,O
indicate,O
clear,O
pharmacological,O
interactions,O
between,O
them,O
",",O
no,O
studies,O
have,O
shown,O
a,O
specific,O
interaction,O
on,O
anxiety,I-Entity
responses,O
.,O
The,O
present,O
study,O
investigates,O
the,O
effects,O
of,O
nicotine,I-Entity
on,O
anxiety,I-Entity
induced,O
by,O
caffeine,I-Entity
and,O
another,O
anxiogenic,O
drug,O
",",O
pentylenetetrazole,I-Entity
",",O
in,O
mice,O
.,O
test,O
was,O
used,O
to,O
evaluate,O
the,O
effects,O
of,O
drugs,O
on,O
anxiety,I-Entity
.,O
Adult,O
male,O
Swiss,O
Webster,O
mice,O
(,O
25,O
-,O
32,O
g,O
),O
were,O
given,O
nicotine,I-Entity
(,O
0.05,O
-,O
0.25,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
or,O
saline,O
10,O
min,O
before,O
caffeine,I-Entity
(,O
70,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
or,O
pentylenetetrazole,I-Entity
(,O
15,O
and,O
30,O
mg,O
Nicotine,I-Entity
(,O
0.05,O
-,O
0.25,O
mg,O
/,O
kg,O
),O
itself,O
did,O
not,O
produce,O
any,O
significant,O
effect,O
in,O
the,O
EPM,O
test,O
",",O
whereas,O
caffeine,I-Entity
(,O
70,O
mg,O
/,O
kg,O
),O
and,O
pentylenetetrazole,I-Entity
(,O
30,O
mg,O
/,O
kg,O
),O
produced,O
an,O
anxiogenic,O
effect,O
",",O
apparent,O
with,O
decreases,O
in,O
open,O
-,O
arm,O
time,O
and,O
entry,O
.,O
Nicotine,I-Entity
(,O
0.25,O
mg,O
/,O
kg,O
),O
pretreatment,O
blocked,O
the,O
caffeine-,I-Entity
but,O
not,O
pentylenetetrazole,I-Entity
-,O
induced,O
anxiety,I-Entity
.,O
Our,O
results,O
suggest,O
that,O
the,O
antagonistic,O
effect,O
of,O
nicotine,I-Entity
on,O
caffeine,I-Entity
-,O
induced,O
anxiety,I-Entity
is,O
specific,O
to,O
caffeine,I-Entity
",",O
instead,O
of,O
a,O
non,O
-,O
specific,O
anxiolytic,O
effect,O
.,O
Thus,O
",",O
it,O
may,O
extend,O
the,O
current,O
findings,O
on,O
the,O
interaction,O
between,O
nicotine,I-Entity
and,O
caffeine,I-Entity
.,O
Hormone,O
therapy,O
(,O
HT,O
),O
is,O
widely,O
used,O
for,O
controlling,O
menopausal,B-Entity
symptoms,I-Entity
.,O
It,O
has,O
also,O
been,O
used,O
for,O
the,O
management,O
and,O
prevention,O
of,O
cardiovascular,B-Entity
disease,I-Entity
",",O
osteoporosis,I-Entity
and,O
dementia,I-Entity
in,O
older,O
women,O
but,O
the,O
evidence,O
supporting,O
its,O
use,O
for,O
these,O
indications,O
is,O
largely,O
observational,O
.,O
To,O
assess,O
the,O
effect,O
of,O
long,O
-,O
term,O
HT,O
on,O
mortality,O
",",O
heart,B-Entity
disease,I-Entity
",",O
venous,B-Entity
thromboembolism,I-Entity
",",O
stroke,I-Entity
",",O
transient,B-Entity
ischaemic,I-Entity
attacks,I-Entity
",",O
breast,B-Entity
cancer,I-Entity
",",O
colorectal,B-Entity
cancer,I-Entity
",",O
ovarian,B-Entity
cancer,I-Entity
",",O
endometrial,B-Entity
cancer,I-Entity
",",O
gallbladder,B-Entity
disease,I-Entity
",",O
cognitive,O
function,O
",",O
dementia,I-Entity
",",O
fractures,I-Entity
and,O
quality,O
of,O
life,O
.,O
SELECTION,O
CRITERIA,O
:,O
Randomised,O
double,O
-,O
blind,O
trials,O
of,O
HT,O
(,O
oestrogens,I-Entity
with,O
or,O
without,O
progestogens,I-Entity
),O
versus,O
placebo,O
",",O
taken,O
for,O
at,O
least,O
one,O
year,O
by,O
perimenopausal,O
or,O
postmenopausal,O
women,O
.,O
In,O
relatively,O
healthy,O
women,O
",",O
combined,O
continuous,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
or,O
coronary,O
event,O
(,O
after,O
one,O
year,O
's,O
use,O
),O
",",O
stroke,I-Entity
(,O
after,O
3,O
years,O
),O
",",O
breast,B-Entity
cancer,I-Entity
(,O
after,O
5,O
years,O
),O
and,O
gallbladder,B-Entity
disease,I-Entity
.,O
Long,O
-,O
term,O
oestrogen,I-Entity
-,O
only,O
HT,O
also,O
significantly,O
increased,O
the,O
risk,O
of,O
stroke,I-Entity
and,O
gallbladder,B-Entity
disease,I-Entity
.,O
Overall,O
",",O
the,O
only,O
statistically,O
significant,O
benefits,O
of,O
HT,O
were,O
a,O
decreased,O
incidence,O
of,O
fractures,I-Entity
and,O
colon,B-Entity
cancer,I-Entity
with,O
long,O
-,O
term,O
use,O
.,O
Among,O
relatively,O
healthy,O
women,O
over,O
65,O
years,O
taking,O
continuous,O
combined,O
HT,O
",",O
there,O
was,O
a,O
statistically,O
significant,O
increase,O
in,O
the,O
incidence,O
of,O
dementia,I-Entity
.,O
Among,O
women,O
with,O
cardiovascular,B-Entity
disease,I-Entity
",",O
long,O
-,O
term,O
use,O
of,O
combined,O
continuous,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
.,O
However,O
",",O
one,O
trial,O
analysed,O
subgroups,O
of,O
2839,O
relatively,O
healthy,O
50,O
to,O
59,O
year,O
-,O
old,O
women,O
taking,O
combined,O
continuous,O
HT,O
and,O
1637,O
taking,O
oestrogen,I-Entity
-,O
only,O
HT,O
",",O
versus,O
similar,O
-,O
sized,O
placebo,O
groups,O
.,O
The,O
only,O
significantly,O
increased,O
risk,O
reported,O
was,O
for,O
venous,B-Entity
thromboembolism,I-Entity
in,O
women,O
taking,O
combined,O
continuous,O
HT,O
;,O
their,O
absolute,O
risk,O
remained,O
very,O
low,O
.,O
HT,O
is,O
not,O
indicated,O
for,O
the,O
routine,O
management,O
of,O
chronic,B-Entity
disease,I-Entity
.,O
Drug,B-Entity
-,I-Entity
induced,I-Entity
liver,I-Entity
injury,I-Entity
:,O
an,O
analysis,O
of,O
461,O
incidences,O
submitted,O
to,O
the,O
Spanish,O
registry,O
over,O
a,O
10-year,O
period,O
.,O
Progress,O
in,O
the,O
understanding,O
of,O
susceptibility,O
factors,O
to,O
drug,B-Entity
-,I-Entity
induced,I-Entity
liver,I-Entity
injury,I-Entity
(,O
DILI,I-Entity
),O
and,O
outcome,O
predictability,O
are,O
hampered,O
by,O
the,O
lack,O
of,O
systematic,O
programs,O
to,O
detect,O
bona,O
fide,O
cases,O
.,O
A,O
cooperative,O
network,O
was,O
created,O
in,O
1994,O
in,O
Spain,O
to,O
identify,O
all,O
suspicions,O
of,O
DILI,I-Entity
following,O
a,O
prospective,O
structured,O
report,O
form,O
.,O
The,O
liver,B-Entity
damage,I-Entity
was,O
characterized,O
according,O
to,O
hepatocellular,O
",",O
cholestatic,I-Entity
",",O
and,O
mixed,O
laboratory,O
criteria,O
and,O
to,O
histologic,O
criteria,O
when,O
available,O
.,O
Since,O
April,O
1994,O
to,O
August,O
2004,O
",",O
461,O
out,O
of,O
570,O
submitted,O
cases,O
",",O
involving,O
505,O
drugs,O
",",O
were,O
deemed,O
to,O
be,O
related,O
to,O
DILI,I-Entity
.,O
The,O
antiinfective,O
group,O
of,O
drugs,O
was,O
the,O
more,O
frequently,O
incriminated,O
",",O
amoxicillin,B-Entity
-,I-Entity
clavulanate,I-Entity
accounting,O
for,O
the,O
12.8%,O
of,O
the,O
whole,O
series,O
.,O
Indeed,O
",",O
the,O
incidence,O
of,O
liver,O
transplantation,O
and,O
death,O
in,O
this,O
group,O
was,O
11.7%,O
if,O
patients,O
had,O
jaundice,I-Entity
at,O
presentation,O
",",O
whereas,O
the,O
corresponding,O
figure,O
was,O
3.8%,O
in,O
nonjaundiced,O
patients,O
(,O
P,O
<,O
.04,O
),O
.,O
Factors,O
associated,O
with,O
the,O
development,O
of,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
were,O
female,O
sex,O
(,O
OR,O
=,O
25,O
;,O
95%,O
CI,O
:,O
4.1,O
-,O
151,O
;,O
P,O
95%,O
CI,O
:,O
1.6,O
-,O
37,O
;,O
P,O
<,O
.009,O
),O
",",O
and,O
higher,O
baseline,O
plasma,O
bilirubin,I-Entity
value,O
(,O
OR,O
=,O
1.15,O
;,O
95%,O
CI,O
:,O
1.09,O
-,O
1.22,O
;,O
P,O
Patients,O
with,O
drug,O
-,O
induced,O
hepatocellular,O
jaundice,I-Entity
have,O
11.7%,O
chance,O
of,O
progressing,O
to,O
death,O
or,O
transplantation,O
.,O
Amoxicillin,B-Entity
-,I-Entity
clavulanate,I-Entity
stands,O
out,O
as,O
the,O
most,O
common,O
drug,O
related,O
to,O
DILI,I-Entity
.,O
Morphological,O
evaluation,O
of,O
the,O
effect,O
of,O
d,B-Entity
-,I-Entity
ribose,I-Entity
on,O
adriamycin,I-Entity
-,O
evoked,O
cardiotoxicity,I-Entity
in,O
rats,O
.,O
The,O
influence,O
of,O
d,B-Entity
-,I-Entity
ribose,I-Entity
on,O
adriamycin,I-Entity
-,O
induced,O
myocardiopathy,I-Entity
in,O
rats,O
was,O
studied,O
.,O
Adriamycin,I-Entity
in,O
the,O
cumulative,O
dose,O
of,O
25,O
mg,O
/,O
kg,O
evoked,O
fully,O
developed,O
cardiac,B-Entity
toxicity,I-Entity
.,O
D,B-Entity
-,I-Entity
ribose,I-Entity
in,O
the,O
multiple,O
doses,O
of,O
200,O
mg,O
/,O
kg,O
did,O
not,O
influence,O
ADR,I-Entity
cardiotoxicity,I-Entity
.,O
In,O
vivo,O
evidences,O
suggesting,O
the,O
role,O
of,O
oxidative,O
stress,O
in,O
pathogenesis,O
of,O
vancomycin,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
:,O
protection,O
by,O
erdosteine,I-Entity
.,O
The,O
aims,O
of,O
this,O
study,O
were,O
to,O
examine,O
vancomycin,I-Entity
(,O
VCM)-induced,I-Entity
oxidative,O
stress,O
that,O
promotes,O
production,O
of,O
reactive,O
oxygen,I-Entity
species,O
(,O
ROS,O
),O
and,O
to,O
investigate,O
the,O
role,O
of,O
erdosteine,I-Entity
",",O
an,O
expectorant,O
agent,O
",",O
which,O
has,O
also,O
antioxidant,O
properties,O
",",O
on,O
kidney,O
tissue,O
against,O
the,O
possible,O
VCM,I-Entity
-,O
induced,O
renal,B-Entity
impairment,I-Entity
in,O
rats,O
.,O
Rats,O
were,O
divided,O
into,O
three,O
groups,O
:,O
sham,O
",",O
VCM,I-Entity
and,O
VCM,I-Entity
plus,O
erdosteine,I-Entity
.,O
VCM,I-Entity
was,O
administrated,O
intraperitoneally,O
(,O
i.p,O
.,O
),O
Erdosteine,I-Entity
was,O
administered,O
orally,O
.,O
VCM,I-Entity
administration,O
to,O
control,O
rats,O
significantly,O
increased,O
renal,O
malondialdehyde,I-Entity
(,O
MDA,I-Entity
),O
and,O
urinary,O
(,O
NAG,O
",",O
a,O
marker,O
of,O
renal,B-Entity
tubular,I-Entity
injury,I-Entity
),O
excretion,O
but,O
decreased,O
superoxide,I-Entity
dismutase,O
(,O
SOD,O
),O
and,O
catalase,O
(,O
CAT,O
),O
activities,O
.,O
Erdosteine,I-Entity
administration,O
with,O
VCM,I-Entity
injections,O
caused,O
significantly,O
decreased,O
renal,O
MDA,I-Entity
and,O
urinary,O
NAG,O
excretion,O
",",O
and,O
increased,O
SOD,O
activity,O
",",O
but,O
not,O
CAT,O
activity,O
in,O
renal,O
tissue,O
when,O
compared,O
with,O
VCM,I-Entity
alone,O
.,O
Erdosteine,I-Entity
showed,O
histopathological,O
protection,O
against,O
VCM,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
.,O
There,O
were,O
a,O
significant,O
dilatation,O
of,O
tubular,O
lumens,O
",",O
extensive,O
epithelial,O
cell,O
vacuolization,O
",",O
atrophy,I-Entity
",",O
desquamation,I-Entity
",",O
and,O
necrosis,I-Entity
in,O
VCM,I-Entity
-,O
treated,O
rats,O
more,O
than,O
those,O
of,O
the,O
control,O
and,O
the,O
erdosteine,I-Entity
groups,O
.,O
Erdosteine,I-Entity
caused,O
a,O
marked,O
reduction,O
in,O
the,O
extent,O
of,O
tubular,O
damage,O
.,O
It,O
is,O
concluded,O
that,O
oxidative,O
tubular,O
damage,O
plays,O
an,O
important,O
role,O
in,O
the,O
VCM,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
and,O
the,O
modulation,O
of,O
oxidative,O
stress,O
with,O
erdosteine,I-Entity
reduces,O
the,O
VCM,I-Entity
-,O
induced,O
kidney,B-Entity
damage,I-Entity
both,O
at,O
the,O
biochemical,O
and,O
histological,O
levels,O
.,O
Does,O
domperidone,I-Entity
potentiate,O
mirtazapine,I-Entity
-,O
associated,O
restless,B-Entity
legs,I-Entity
syndrome,I-Entity
?,O
There,O
is,O
now,O
evidence,O
to,O
suggest,O
a,O
central,O
role,O
for,O
the,O
dopaminergic,O
system,O
in,O
restless,B-Entity
legs,I-Entity
syndrome,I-Entity
(,O
RLS,I-Entity
),O
.,O
For,O
example,O
",",O
the,O
symptoms,O
of,O
RLS,I-Entity
can,O
be,O
dramatically,O
improved,O
by,O
levodopa,I-Entity
and,O
dopamine,I-Entity
agonists,O
",",O
whereas,O
central,O
dopamine,I-Entity
D2,O
receptor,O
antagonists,O
can,O
induce,O
or,O
aggravate,O
RLS,I-Entity
symptoms,O
.,O
To,O
our,O
knowledge,O
",",O
there,O
is,O
no,O
previous,O
report,O
regarding,O
whether,O
domperidone,I-Entity
",",O
a,O
peripheral,O
dopamine,I-Entity
D2,O
receptor,O
antagonist,O
",",O
can,O
also,O
induce,O
or,O
aggravate,O
symptoms,O
of,O
RLS,I-Entity
.,O
Mirtazapine,I-Entity
",",O
the,O
first,O
noradrenergic,O
and,O
specific,O
serotonergic,O
antidepressant,O
(,O
NaSSA,O
),O
",",O
has,O
been,O
associated,O
with,O
RLS,I-Entity
in,O
several,O
recent,O
publications,O
.,O
The,O
authors,O
report,O
here,O
a,O
depressed,O
patient,O
comorbid,O
with,O
postprandial,B-Entity
dyspepsia,I-Entity
who,O
developed,O
RLS,I-Entity
after,O
mirtazapine,I-Entity
had,O
been,O
added,O
to,O
his,O
domperidone,I-Entity
therapy,O
.,O
Our,O
patient,O
started,O
to,O
have,O
symptoms,O
of,O
RLS,I-Entity
only,O
after,O
he,O
had,O
been,O
treated,O
with,O
mirtazapine,I-Entity
",",O
and,O
his,O
RLS,I-Entity
symptoms,O
resolved,O
completely,O
upon,O
discontinuation,O
of,O
his,O
mirtazapine,I-Entity
.,O
Such,O
a,O
temporal,O
relationship,O
between,O
the,O
use,O
of,O
mirtazapine,I-Entity
and,O
the,O
symptoms,O
of,O
RLS,I-Entity
in,O
our,O
patient,O
did,O
not,O
support,O
a,O
potentiating,O
effect,O
of,O
domperione,I-Entity
on,O
mirtazapine,I-Entity
-,O
associated,O
RLS,I-Entity
.,O
However,O
",",O
physicians,O
should,O
be,O
aware,O
of,O
the,O
possibility,O
that,O
mirtazapine,I-Entity
can,O
be,O
associated,O
with,O
RLS,I-Entity
in,O
some,O
individuals,O
",",O
especially,O
those,O
receiving,O
concomitant,O
dopamine,I-Entity
D2,O
receptor,O
antagonists,O
.,O
Antiandrogenic,O
therapy,O
can,O
cause,O
coronary,B-Entity
arterial,I-Entity
disease,I-Entity
.,O
AIM,O
:,O
To,O
study,O
the,O
change,O
of,O
lipid,O
metabolism,O
by,O
antiandrogen,O
therapy,O
in,O
patients,O
with,O
prostate,B-Entity
cancer,I-Entity
.,O
We,O
studied,O
with,O
a,O
2.5,O
years,O
follow,O
-,O
up,O
the,O
changes,O
in,O
plasma,O
cholesterols,I-Entity
(,O
C,I-Entity
),O
",",O
triglycerides,I-Entity
(,O
TG,I-Entity
),O
",",O
lipoproteins,O
(,O
LP,O
),O
",",O
and,O
apolipoproteins,O
(,O
Apo,O
),O
fi,O
les,O
in,O
24,O
patients,O
of,O
mean,O
age,O
60,O
years,O
with,O
low,O
risk,O
prostate,B-Entity
cancer,I-Entity
(,O
stage,O
:,O
T1cN0M0,O
",",O
Gleason,O
score,O
:,O
2,O
-,O
5,O
),O
during,O
treatment,O
with,O
cyproterone,B-Entity
acetate,I-Entity
(,O
CPA,I-Entity
),O
without,O
surgical,O
management,O
or,O
radiation,O
therapy,O
.,O
Significant,O
decreases,O
of,O
HDL,O
-,O
C,O
",",O
Apo,O
A,O
-,O
I,O
and,O
Apo,O
A,O
-,O
II,O
and,O
an,O
increase,O
of,O
triglyceride,I-Entity
levels,O
in,O
VLDL,O
were,O
induced,O
by,O
CPA,I-Entity
.,O
After,O
a,O
period,O
of,O
2.5,O
years,O
on,O
CPA,I-Entity
treatment,O
",",O
four,O
patients,O
out,O
of,O
twenty,O
-,O
four,O
were,O
found,O
to,O
be,O
affected,O
by,O
coronary,B-Entity
heart,I-Entity
disease,I-Entity
.,O
Ischaemic,O
coronary,B-Entity
arteriosclerosis,I-Entity
with,O
an,O
incidence,O
rate,O
of,O
16.6%,O
as,O
caused,O
by,O
prolonged,O
CPA,I-Entity
therapy,O
is,O
mediated,O
through,O
changes,O
in,O
HDL,O
cholesterol,I-Entity
",",O
Apo,O
A,O
-,O
I,O
and,O
Apo,O
pro,O
fi,O
les,O
",",O
other,O
than,O
the,O
well,O
-,O
known,O
hyperglyceridemic,B-Entity
effect,I-Entity
caused,O
by,O
estrogen,I-Entity
.,O
5-Fluorouracil,I-Entity
cardiotoxicity,I-Entity
induced,O
by,O
alpha,B-Entity
-,I-Entity
fluoro,I-Entity
-,I-Entity
beta,I-Entity
-,I-Entity
alanine,I-Entity
.,O
Cardiotoxicity,I-Entity
is,O
a,O
rare,O
complication,O
occurring,O
during,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
treatment,O
for,O
malignancies,I-Entity
.,O
We,O
herein,O
report,O
the,O
case,O
of,O
a,O
70-year,O
-,O
old,O
man,O
with,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
",",O
in,O
whom,O
a,O
high,O
serum,O
level,O
of,O
alpha,B-Entity
-,I-Entity
fluoro,I-Entity
-,I-Entity
beta,I-Entity
-,I-Entity
alanine,I-Entity
(,O
FBAL,I-Entity
),O
was,O
observed,O
.,O
The,O
patient,O
",",O
who,O
had,O
unresectable,O
colon,B-Entity
cancer,I-Entity
metastases,O
to,O
the,O
liver,O
and,O
lung,O
",",O
was,O
referred,O
to,O
us,O
for,O
chemotherapy,O
from,O
an,O
affiliated,O
hospital,O
;,O
he,O
had,O
no,O
cardiac,O
history,O
.,O
After,O
admission,O
",",O
the,O
patient,O
received,O
a,O
continuous,O
intravenous,O
infusion,O
of,O
5-FU,I-Entity
(,O
1000,O
mg,O
/,O
day,O
),O
",",O
during,O
which,O
precordial,B-Entity
pain,I-Entity
with,O
right,B-Entity
bundle,I-Entity
branch,I-Entity
block,I-Entity
occurred,O
concomitantly,O
with,O
a,O
high,O
serum,O
FBAL,I-Entity
concentration,O
of,O
1955,O
ng,O
/,O
ml,O
.,O
Both,O
the,O
precordial,B-Entity
pain,I-Entity
and,O
the,O
electrocardiographic,O
changes,O
disappeared,O
spontaneously,O
after,O
the,O
discontinuation,O
of,O
5-FU,I-Entity
.,O
As,O
the,O
precordial,B-Entity
pain,I-Entity
in,O
this,O
patient,O
was,O
considered,O
to,O
have,O
been,O
due,O
to,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
",",O
the,O
administration,O
of,O
5-FU,I-Entity
was,O
abandoned,O
.,O
Instead,O
",",O
oral,O
administration,O
of,O
S-1,O
(,O
a,O
derivative,O
of,O
5-FU,I-Entity
),O
",",O
at,O
200,O
mg,O
/,O
day,O
twice,O
a,O
week,O
",",O
was,O
instituted,O
",",O
because,O
S-1,O
has,O
a,O
strong,O
inhibitory,O
effect,O
on,O
dihydropyrimidine,I-Entity
dehydrogenase,O
",",O
which,O
catalyzes,O
the,O
degradative,O
of,O
5-FU,I-Entity
into,O
FBAL,I-Entity
.,O
The,O
serum,O
FBAL,I-Entity
concentration,O
subsequently,O
decreased,O
to,O
352,O
ng,O
/,O
ml,O
",",O
the,O
same,O
as,O
the,O
value,O
measured,O
on,O
the,O
first,O
day,O
of,O
S-1,O
administration,O
.,O
Thereafter,O
",",O
no,O
cardiac,B-Entity
symptoms,I-Entity
were,O
observed,O
.,O
The,O
experience,O
of,O
this,O
case,O
",",O
together,O
with,O
a,O
review,O
of,O
the,O
literature,O
",",O
suggests,O
that,O
FBAL,I-Entity
is,O
related,O
to,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
S-1,O
may,O
be,O
administered,O
safely,O
to,O
patients,O
with,O
5-FU,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
The,O
influence,O
of,O
the,O
time,O
interval,O
between,O
monoHER,I-Entity
and,O
doxorubicin,I-Entity
administration,O
on,O
the,O
protection,O
against,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
mice,O
.,O
Despite,O
its,O
well,O
-,O
known,O
cardiotoxicity,I-Entity
",",O
the,O
anthracyclin,O
doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
continues,O
to,O
be,O
an,O
effective,O
and,O
widely,O
used,O
chemotherapeutic,O
agent,O
.,O
DOX,I-Entity
-,O
induced,O
cardiac,B-Entity
damage,I-Entity
presumably,O
results,O
from,O
the,O
formation,O
of,O
free,O
radicals,O
by,O
DOX,I-Entity
.,O
Reactive,O
oxygen,I-Entity
species,O
particularly,O
affect,O
the,O
cardiac,O
myocytes,O
because,O
these,O
cells,O
seem,O
to,O
have,O
a,O
relatively,O
poor,O
antioxidant,O
defense,O
system,O
.,O
The,O
semisynthetic,O
flavonoid,I-Entity
monohydroxyethylrutoside,I-Entity
(,O
monoHER,I-Entity
),O
showed,O
cardioprotection,O
against,O
DOX,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
through,O
its,O
radical,O
scavenging,O
and,O
iron,I-Entity
chelating,O
properties,O
.,O
Because,O
of,O
the,O
relatively,O
short,O
final,O
half,O
-,O
life,O
of,O
monoHER,I-Entity
(,O
about,O
30,O
min,O
),O
",",O
it,O
is,O
expected,O
that,O
the,O
time,O
interval,O
between,O
monoHER,I-Entity
and,O
DOX,I-Entity
might,O
be,O
of,O
influence,O
on,O
the,O
cardioprotective,O
effect,O
of,O
monoHER,I-Entity
.,O
Six,O
groups,O
of,O
6,O
BALB,O
/,O
c,O
mice,O
were,O
treated,O
with,O
saline,O
",",O
DOX,I-Entity
alone,O
or,O
DOX,I-Entity
(,O
4,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
preceded,O
by,O
monoHER,I-Entity
(,O
500,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
with,O
an,O
interval,O
of,O
10,O
",",O
30,O
",",O
60,O
or,O
120,O
min,O
.,O
Their,O
cardiac,O
tissues,O
were,O
processed,O
for,O
light,O
microscopy,O
",",O
after,O
which,O
cardiomyocyte,B-Entity
damage,I-Entity
was,O
evaluated,O
according,O
to,O
Billingham,O
(,O
in,O
Cancer,I-Entity
Treat,O
Rep,O
62(6):865,O
-,O
872,O
",",O
1978,O
),O
.,O
Microscopic,O
evaluation,O
revealed,O
that,O
treatment,O
with,O
DOX,I-Entity
alone,O
induced,O
significant,O
cardiac,B-Entity
damage,I-Entity
in,O
comparison,O
to,O
the,O
saline,O
control,O
group,O
(,O
P<0.001,O
),O
.,O
The,O
number,O
of,O
damaged,O
cardiomyocytes,O
was,O
9.6-fold,O
(,O
95%,O
CI,O
4.4,O
-,O
21.0,O
),O
higher,O
in,O
mice,O
treated,O
with,O
DOX,I-Entity
alone,O
than,O
that,O
in,O
animals,O
of,O
the,O
control,O
group,O
.,O
The,O
ratio,O
of,O
aberrant,O
cardiomyocytes,O
in,O
mice,O
treated,O
with,O
DOX,I-Entity
preceded,O
by,O
monoHER,I-Entity
and,O
those,O
in,O
mice,O
treated,O
with,O
saline,O
ranged,O
from,O
1.6,O
to,O
2.8,O
(,O
mean,O
2.2,O
",",O
95%,O
CI,O
1.2,O
-,O
4.1,O
",",O
P=0.019,O
),O
.,O
The,O
mean,O
protective,O
effect,O
by,O
adding,O
monoHER,I-Entity
before,O
DOX,I-Entity
led,O
to,O
a,O
significant,O
4.4-fold,O
reduction,O
(,O
P<0.001,O
",",O
95%,O
CI,O
2.3,O
-,O
8.2,O
),O
of,O
abnormal,O
cardiomyocytes,O
.,O
This,O
protective,O
effect,O
did,O
not,O
depend,O
on,O
the,O
time,O
interval,O
between,O
monoHER,I-Entity
and,O
DOX,I-Entity
administration,O
(,O
P=0.345,O
),O
.,O
CONCLUSION,O
:,O
The,O
results,O
indicate,O
that,O
in,O
an,O
outpatient,O
clinical,O
setting,O
monoHER,I-Entity
may,O
be,O
administered,O
shortly,O
before,O
DOX,I-Entity
.,O
Clinical,O
evaluation,O
of,O
adverse,O
effects,O
during,O
bepridil,I-Entity
administration,O
for,O
atrial,B-Entity
fibrillation,I-Entity
and,I-Entity
flutter,I-Entity
.,O
Bepridil,B-Entity
hydrochloride,I-Entity
(,O
Bpd,I-Entity
),O
has,O
attracted,O
attention,O
as,O
an,O
effective,O
drug,O
for,O
atrial,B-Entity
fibrillation,I-Entity
(,O
AF,I-Entity
),O
and,O
atrial,B-Entity
flutter,I-Entity
(,O
AFL,I-Entity
),O
.,O
However,O
",",O
serious,O
adverse,O
effects,O
",",O
including,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
(,O
Tdp,I-Entity
),O
",",O
have,O
been,O
reported,O
.,O
Adverse,O
effects,O
of,O
Bpd,I-Entity
requiring,O
discontinuation,O
of,O
treatment,O
were,O
evaluated,O
.,O
Bpd,I-Entity
was,O
administered,O
to,O
459,O
patients,O
(,O
361,O
males,O
",",O
63+/-12,O
years,O
old,O
),O
comprising,O
378,O
AF,I-Entity
and,O
81,O
AFL,I-Entity
cases,O
.,O
There,O
was,O
marked,O
QT,B-Entity
prolongation,I-Entity
greater,O
than,O
0.55,O
s,O
in,O
13,O
patients,O
",",O
bradycardia,I-Entity
less,O
than,O
40,O
beats,O
/,O
min,O
in,O
6,O
patients,O
",",O
dizziness,I-Entity
and,O
general,O
fatigue,I-Entity
in,O
1,O
patient,O
each,O
.,O
In,O
4,O
of,O
13,O
patients,O
with,O
QT,B-Entity
prolongation,I-Entity
",",O
Tdp,I-Entity
occurred,O
.,O
The,O
major,O
triggering,O
factors,O
of,O
Tdp,I-Entity
were,O
hypokalemia,I-Entity
and,O
sudden,O
decrease,O
in,O
heart,O
rate,O
.,O
There,O
were,O
no,O
differences,O
in,O
the,O
clinical,O
backgrounds,O
of,O
the,O
patients,O
with,O
and,O
without,O
Tdp,I-Entity
other,O
than,O
LAD,O
and,O
age,O
",",O
which,O
were,O
larger,O
and,O
older,O
in,O
the,O
patients,O
with,O
Tdp,I-Entity
.,O
CONCLUSION,O
:,O
Careful,O
observation,O
of,O
serum,O
potassium,I-Entity
concentration,O
and,O
the,O
ECG,O
should,O
always,O
be,O
done,O
during,O
Bpd,I-Entity
administration,O
",",O
particularly,O
in,O
elderly,O
patients,O
.,O
Enhanced,O
isoproterenol,I-Entity
-,O
induced,O
cardiac,B-Entity
hypertrophy,I-Entity
in,O
transgenic,O
rats,O
with,O
low,O
brain,O
angiotensinogen,O
.,O
We,O
have,O
previously,O
shown,O
that,O
a,O
permanent,O
deficiency,O
in,O
the,O
brain,O
renin,O
-,O
angiotensin,I-Entity
system,O
(,O
RAS,O
),O
may,O
increase,O
the,O
sensitivity,O
of,O
the,O
baroreflex,O
control,O
of,O
heart,O
rate,O
.,O
agonist,O
isoproterenol,I-Entity
(,O
Iso,I-Entity
),O
.,O
In,O
isolated,O
hearts,O
",",O
Iso,I-Entity
induced,O
a,O
significantly,O
greater,O
increase,O
in,O
left,O
ventricular,O
(,O
LV,O
),O
pressure,O
and,O
maximal,O
contraction,O
(,O
+,O
dP,O
/,O
dt(max,O
),O
),O
in,O
the,O
TGR,O
than,O
in,O
the,O
Sprague,O
-,O
Dawley,O
(,O
SD,O
),O
rats,O
.,O
LV,B-Entity
hypertrophy,I-Entity
induced,O
by,O
Iso,I-Entity
treatment,O
was,O
significantly,O
higher,O
in,O
TGR,O
than,O
in,O
SD,O
rats,O
(,O
in,O
g,O
LV,O
wt/100,O
The,O
greater,O
LV,B-Entity
hypertrophy,I-Entity
in,O
TGR,O
rats,O
was,O
associated,O
with,O
more,O
pronounced,O
downregulation,O
of,O
beta,O
-,O
AR,O
and,O
upregulation,O
of,O
LV,O
beta,O
-,O
AR,O
kinase-1,O
mRNA,O
levels,O
compared,O
with,O
those,O
in,O
SD,O
rats,O
.,O
The,O
decrease,O
in,O
the,O
heart,O
rate,O
(,O
HR,O
),O
induced,O
by,O
the,O
beta,O
-,O
AR,O
antagonist,O
metoprolol,I-Entity
in,O
conscious,O
rats,O
was,O
significantly,O
attenuated,O
in,O
TGR,O
compared,O
with,O
SD,O
rats,O
(,O
-9.9,O
1.5%,O
),O
",",O
whereas,O
the,O
effect,O
of,O
parasympathetic,O
blockade,O
by,O
atropine,I-Entity
on,O
HR,O
was,O
similar,O
in,O
both,O
strains,O
.,O
These,O
results,O
indicate,O
that,O
TGR,O
are,O
more,O
sensitive,O
to,O
beta,O
-,O
AR,O
agonist,O
-,O
induced,O
cardiac,B-Entity
inotropic,I-Entity
response,O
and,O
hypertrophy,I-Entity
",",O
possibly,O
due,O
to,O
chronically,O
low,O
sympathetic,O
outflow,O
directed,O
to,O
the,O
heart,O
.,O
Drug,O
-,O
induced,O
long,B-Entity
QT,I-Entity
syndrome,I-Entity
in,O
injection,O
drug,O
users,O
receiving,O
methadone,I-Entity
:,O
high,O
frequency,O
in,O
hospitalized,O
patients,O
and,O
risk,O
factors,O
.,O
Drug,O
-,O
induced,O
long,B-Entity
QT,I-Entity
syndrome,I-Entity
is,O
a,O
serious,O
adverse,O
drug,O
reaction,O
.,O
Methadone,I-Entity
prolongs,O
the,O
QT,O
interval,O
in,O
vitro,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
In,O
the,O
inpatient,O
setting,O
",",O
the,O
frequency,O
of,O
QT,B-Entity
interval,I-Entity
prolongation,I-Entity
with,O
methadone,I-Entity
treatment,O
",",O
its,O
dose,O
dependence,O
",",O
and,O
the,O
importance,O
of,O
cofactors,O
such,O
as,O
drug,O
-,O
drug,O
interactions,O
remain,O
unknown,O
.,O
:,O
We,O
performed,O
a,O
systematic,O
",",O
retrospective,O
study,O
comparing,O
active,O
or,O
former,O
intravenous,O
drug,O
users,O
receiving,O
methadone,I-Entity
and,O
those,O
not,O
receiving,O
methadone,I-Entity
among,O
all,O
patients,O
hospitalized,O
over,O
a,O
5-year,O
period,O
in,O
a,O
tertiary,O
care,O
hospital,O
.,O
A,O
total,O
of,O
167,O
patients,O
receiving,O
methadone,I-Entity
fulfilled,O
the,O
inclusion,O
criteria,O
and,O
were,O
compared,O
with,O
a,O
control,O
group,O
of,O
80,O
injection,O
drug,O
users,O
not,O
receiving,O
methadone,I-Entity
.,O
In,O
addition,O
to,O
methadone,I-Entity
dose,O
",",O
15,O
demographic,O
",",O
biological,O
",",O
and,O
pharmacological,O
variables,O
were,O
considered,O
as,O
potential,O
risk,O
factors,O
for,O
QT,B-Entity
prolongation,I-Entity
.,O
Among,O
167,O
methadone,I-Entity
maintenance,O
patients,O
",",O
the,O
prevalence,O
of,O
QTc,O
prolongation,O
to,O
0.50,O
second((1/2,O
),O
),O
or,O
longer,O
was,O
16.2%,O
compared,O
with,O
0%,O
in,O
80,O
control,O
subjects,O
.,O
Six,O
patients,O
(,O
3.6%,O
),O
in,O
the,O
methadone,I-Entity
group,O
presented,O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
.,O
QTc,O
length,O
was,O
weakly,O
but,O
significantly,O
associated,O
with,O
methadone,I-Entity
daily,O
dose,O
(,O
Spearman,O
rank,O
correlation,O
coefficient,O
",",O
0.20,O
;,O
P<.01,O
),O
.,O
Multivariate,O
regression,O
analysis,O
allowed,O
attribution,O
of,O
31.8%,O
of,O
QTc,O
variability,O
to,O
methadone,I-Entity
dose,O
",",O
cytochrome,O
P-450,O
3A4,O
drug,O
-,O
drug,O
interactions,O
",",O
hypokalemia,I-Entity
",",O
and,O
altered,O
liver,O
function,O
.,O
QT,B-Entity
interval,I-Entity
prolongation,I-Entity
in,O
methadone,I-Entity
maintenance,O
patients,O
hospitalized,O
in,O
a,O
tertiary,O
care,O
center,O
is,O
a,O
frequent,O
finding,O
.,O
Methadone,I-Entity
dose,O
",",O
presence,O
of,O
cytochrome,O
P-450,O
3A4,O
inhibitors,O
",",O
potassium,I-Entity
level,O
",",O
and,O
liver,O
function,O
contribute,O
to,O
QT,B-Entity
prolongation,I-Entity
.,O
Long,B-Entity
QT,I-Entity
syndrome,I-Entity
can,O
occur,O
with,O
low,O
doses,O
of,O
methadone,I-Entity
.,O
Mechanisms,O
of,O
hypertension,I-Entity
induced,O
by,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
deficiency,O
:,O
focus,O
on,O
venous,O
function,O
.,O
Loss,O
of,O
endothelial,O
cell,O
-,O
derived,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
in,O
hypertension,I-Entity
is,O
a,O
hallmark,O
of,O
arterial,B-Entity
dysfunction,I-Entity
.,O
Experimental,O
hypertension,I-Entity
created,O
by,O
the,O
removal,O
of,O
NO,I-Entity
",",O
however,O
",",O
involves,O
mechanisms,O
in,O
addition,O
to,O
decreased,O
arterial,O
vasodilator,O
activity,O
.,O
We,O
hypothesized,O
that,O
increased,O
venous,O
smooth,O
muscle,O
(,O
venomotor,O
),O
tone,O
plays,O
a,O
role,O
in,O
Nomega,B-Entity
-,I-Entity
nitro,I-Entity
-,I-Entity
L,I-Entity
-,I-Entity
arginine,I-Entity
(,O
LNNA,I-Entity
),O
hypertension,I-Entity
through,O
these,O
mechanisms,O
.,O
Rats,O
were,O
treated,O
with,O
the,O
NO,I-Entity
synthase,O
inhibitor,O
LNNA,I-Entity
(,O
0.5,O
g,O
/,O
L,O
in,O
drinking,O
water,O
),O
for,O
2,O
weeks,O
.,O
5,O
mm,O
Hg,O
in,O
LNNA,I-Entity
rats,O
(,O
P<0.05,O
),O
.,O
Maximal,O
contraction,O
to,O
norepinephrine,I-Entity
was,O
modestly,O
reduced,O
in,O
arteries,O
from,O
LNNA,I-Entity
compared,O
with,O
control,O
rats,O
whereas,O
the,O
maximum,O
contraction,O
to,O
ET-1,O
was,O
significantly,O
reduced,O
(,O
54%,O
control,O
),O
.,O
Maximum,O
contraction,O
of,O
vena,O
cava,O
to,O
norepinephrine,I-Entity
(,O
37%,O
control,O
),O
also,O
was,O
reduced,O
but,O
no,O
change,O
in,O
response,O
to,O
ET-1,O
was,O
observed,O
.,O
Mean,O
circulatory,O
filling,O
pressure,O
",",O
an,O
in,O
vivo,O
measure,O
of,O
venomotor,O
tone,O
",",O
was,O
not,O
elevated,O
in,O
LNNA,I-Entity
hypertension,I-Entity
at,O
1,O
or,O
2,O
weeks,O
after,O
LNNA,I-Entity
.,O
The,O
superoxide,I-Entity
scavenger,O
tempol,I-Entity
(,O
30,O
",",O
100,O
",",O
and,O
300,O
micromol,O
kg(-1,O
),O
",",O
IV,O
),O
did,O
not,O
change,O
arterial,O
pressure,O
in,O
control,O
rats,O
but,O
caused,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
LNNA,I-Entity
rats,O
(,O
-18,O
+,O
/-,O
Similarly,O
",",O
ganglionic,O
blockade,O
with,O
hexamethonium,I-Entity
caused,O
a,O
significantly,O
greater,O
fall,O
in,O
LNNA,I-Entity
hypertensive,I-Entity
rats,O
(,O
76,O
+,O
/-,O
Carotid,O
arteries,O
",",O
vena,O
cava,O
",",O
and,O
sympathetic,O
ganglia,O
from,O
LNNA,I-Entity
rats,O
had,O
higher,O
basal,O
levels,O
of,O
superoxide,I-Entity
compared,O
with,O
those,O
from,O
control,O
rats,O
.,O
These,O
data,O
suggest,O
that,O
while,O
NO,I-Entity
deficiency,O
increases,O
oxidative,O
stress,O
and,O
sympathetic,O
activity,O
in,O
both,O
arterial,O
and,O
venous,O
vessels,O
",",O
the,O
impact,O
on,O
veins,O
does,O
not,O
make,O
a,O
major,O
contribution,O
to,O
this,O
form,O
of,O
hypertension,I-Entity
.,O
Association,O
of,O
DRD2,O
polymorphisms,O
and,O
chlorpromazine,I-Entity
-,O
induced,O
extrapyramidal,B-Entity
syndrome,I-Entity
in,O
Chinese,O
schizophrenic,I-Entity
patients,O
.,O
Extrapyramidal,B-Entity
syndrome,I-Entity
(,O
EPS,I-Entity
),O
is,O
most,O
commonly,O
affected,O
by,O
typical,O
antipsychotic,O
drugs,O
that,O
have,O
a,O
high,O
affinity,O
with,O
the,O
D2,O
receptor,O
.,O
Recently,O
",",O
many,O
research,O
groups,O
have,O
reported,O
on,O
the,O
positive,O
relationship,O
between,O
the,O
genetic,O
variations,O
in,O
the,O
DRD2,O
gene,O
and,O
the,O
therapeutic,O
response,O
in,O
schizophrenia,I-Entity
patients,O
as,O
a,O
result,O
of,O
the,O
role,O
of,O
variations,O
in,O
the,O
receptor,O
in,O
modulating,O
receptor,O
expression,O
.,O
In,O
this,O
study,O
",",O
we,O
evaluate,O
the,O
role,O
DRD2,O
plays,O
in,O
chlorpromazine,I-Entity
-,O
induced,O
EPS,I-Entity
in,O
schizophrenic,I-Entity
patients,O
.,O
:,O
We,O
identified,O
seven,O
SNP(single,O
nucleotide,O
polymorphism,O
),O
(,O
-141Cins,O
>,O
del,O
",",O
TaqIB,O
",",O
TaqID,O
",",O
Ser311Cys,O
",",O
rs6275,O
",",O
rs6277,O
and,O
TaqIA,O
),O
in,O
the,O
DRD2,O
gene,O
in,O
146,O
schizophrenic,I-Entity
inpatients,O
(,O
59,O
with,O
EPS,I-Entity
and,O
87,O
without,O
EPS,I-Entity
according,O
to,O
the,O
Simpson,O
-,O
Angus,O
Scale,O
),O
treated,O
with,O
chlorpromazine,I-Entity
after,O
8,O
weeks,O
.,O
CONCLUSION,O
:,O
Our,O
results,O
did,O
not,O
lend,O
strong,O
support,O
to,O
the,O
view,O
that,O
the,O
genetic,O
variation,O
of,O
the,O
DRD2,O
gene,O
plays,O
a,O
major,O
role,O
in,O
the,O
individually,O
variable,O
adverse,O
effect,O
induced,O
by,O
chlorpromazine,I-Entity
",",O
at,O
least,O
in,O
Chinese,O
patients,O
with,O
schizophrenia,I-Entity
.,O
Our,O
results,O
confirmed,O
a,O
previous,O
study,O
on,O
the,O
relationship,O
between,O
DRD2,O
and,O
EPS,I-Entity
in,O
Caucasians,O
.,O
Physical,O
training,O
decreases,O
susceptibility,O
to,O
subsequent,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
the,O
rat,O
.,O
Regular,O
motor,O
activity,O
has,O
many,O
benefits,O
for,O
mental,O
and,O
physical,O
condition,O
but,O
its,O
implications,O
for,O
epilepsy,I-Entity
are,O
still,O
controversial,O
.,O
In,O
order,O
to,O
elucidate,O
this,O
problem,O
",",O
we,O
have,O
studied,O
the,O
effect,O
of,O
long,O
-,O
term,O
physical,O
activity,O
on,O
susceptibility,O
to,O
subsequent,O
seizures,I-Entity
.,O
Thereafter,O
",",O
seizures,I-Entity
were,O
induced,O
by,O
pilocarpine,I-Entity
injections,O
in,O
trained,O
and,O
non,O
-,O
trained,O
control,O
groups,O
.,O
During,O
the,O
acute,O
period,O
of,O
status,B-Entity
epilepticus,I-Entity
",",O
we,O
measured,O
:,O
(,O
1,O
),O
the,O
latency,O
of,O
the,O
first,O
motor,O
sign,O
",",O
(,O
2,O
),O
the,O
intensity,O
of,O
seizures,I-Entity
",",O
(,O
3,O
),O
the,O
time,O
when,O
it,O
occurred,O
within,O
the,O
6-h,O
observation,O
period,O
",",O
and,O
(,O
4,O
),O
the,O
time,O
when,O
the,O
acute,O
period,O
ended,O
.,O
All,O
these,O
behavioral,O
parameters,O
showed,O
statistically,O
significant,O
changes,O
suggesting,O
that,O
regular,O
physical,O
exercises,O
decrease,O
susceptibility,O
to,O
subsequently,O
induced,O
seizures,I-Entity
and,O
ameliorate,O
the,O
course,O
of,O
experimentally,O
induced,O
status,B-Entity
epilepticus,I-Entity
.,O
Tonic,O
dopaminergic,O
stimulation,O
impairs,B-Entity
associative,I-Entity
learning,I-Entity
in,O
healthy,O
subjects,O
.,O
Endogenous,O
dopamine,I-Entity
plays,O
a,O
central,O
role,O
in,O
salience,O
coding,O
during,O
associative,O
learning,O
.,O
Administration,O
of,O
the,O
dopamine,I-Entity
precursor,O
levodopa,I-Entity
enhances,O
learning,O
in,O
healthy,O
subjects,O
and,O
stroke,I-Entity
patients,O
.,O
Because,O
levodopa,I-Entity
increases,O
both,O
phasic,O
and,O
tonic,O
dopaminergic,O
neurotransmission,O
",",O
the,O
critical,O
mechanism,O
mediating,O
the,O
enhancement,O
of,O
learning,O
is,O
unresolved,O
.,O
Subjects,O
received,O
the,O
tonically,O
stimulating,O
dopamine,I-Entity
-,O
receptor,O
agonist,O
pergolide,I-Entity
(,O
0.1,O
mg,O
),O
vs,O
placebo,O
120,O
min,O
before,O
training,O
on,O
each,O
training,O
day,O
.,O
The,O
dopamine,I-Entity
agonist,O
significantly,O
impaired,B-Entity
novel,I-Entity
word,I-Entity
learning,I-Entity
compared,O
to,O
placebo,O
.,O
Subjects,O
treated,O
with,O
pergolide,I-Entity
also,O
showed,O
restricted,O
emotional,O
responses,O
compared,O
to,O
the,O
PLACEBO,O
group,O
.,O
The,O
extent,O
of,O
',O
flattened,O
',O
affect,O
with,O
pergolide,I-Entity
was,O
related,O
to,O
the,O
degree,O
of,O
learning,O
inhibition,O
.,O
These,O
findings,O
suggest,O
that,O
tonic,O
occupation,O
of,O
dopamine,I-Entity
receptors,O
impairs,O
learning,O
by,O
competition,O
with,O
phasic,O
dopamine,I-Entity
signals,O
.,O
Thus,O
",",O
phasic,O
signaling,O
seems,O
to,O
be,O
the,O
critical,O
mechanism,O
by,O
which,O
dopamine,I-Entity
enhances,O
associative,O
learning,O
in,O
healthy,O
subjects,O
and,O
stroke,I-Entity
patients,O
.,O
Minocycline,I-Entity
-,O
induced,O
vasculitis,I-Entity
fulfilling,O
the,O
criteria,O
of,O
polyarteritis,B-Entity
nodosa,I-Entity
.,O
A,O
47-year,O
-,O
old,O
man,O
who,O
had,O
been,O
taking,O
minocycline,I-Entity
for,O
palmoplantar,B-Entity
pustulosis,I-Entity
developed,O
fever,I-Entity
",",O
myalgias,I-Entity
",",O
polyneuropathy,I-Entity
",",O
and,O
testicular,B-Entity
pain,I-Entity
",",O
with,O
elevated,O
C,O
-,O
reactive,O
protein,O
(,O
CRP,O
),O
.,O
These,O
manifestations,O
met,O
the,O
American,O
College,O
of,O
Rheumatology,O
1990,O
criteria,O
for,O
the,O
classification,O
of,O
polyarteritis,B-Entity
nodosa,I-Entity
.,O
Stopping,O
minocycline,I-Entity
led,O
to,O
amelioration,O
of,O
symptoms,O
and,O
normalization,O
of,O
CRP,O
level,O
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
second,O
case,O
of,O
minocycline,I-Entity
-,O
induced,O
vasculitis,I-Entity
satisfying,O
the,O
criteria,O
.,O
Differential,O
diagnosis,O
for,O
drug,O
-,O
induced,O
disease,O
is,O
invaluable,O
even,O
for,O
patients,O
with,O
classical,O
polyarteritis,B-Entity
nodosa,I-Entity
.,O
Intramuscular,O
hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
combined,O
with,O
lamivudine,I-Entity
in,O
prevention,O
of,O
hepatitis,B-Entity
B,I-Entity
recurrence,O
after,O
liver,O
transplantation,O
.,O
BACKGROUND,O
:,O
Combined,O
hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
(,O
HBIg,O
),O
and,O
lamivudine,I-Entity
in,O
prophylaxis,O
of,O
the,O
recurrence,O
of,O
hepatitis,B-Entity
B,I-Entity
after,O
liver,O
transplantation,O
has,O
significantly,O
improved,O
the,O
survival,O
of,O
HBsAg,I-Entity
positive,O
patients,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
evaluate,O
the,O
outcomes,O
of,O
liver,O
transplantation,O
for,O
patients,O
with,O
hepatitis,B-Entity
B,I-Entity
virus,O
(,O
HBV,O
),O
.,O
A,O
retrospective,O
chart,O
analysis,O
and,O
a,O
review,O
of,O
the,O
organ,O
transplant,O
database,O
identified,O
51,O
patients,O
(,O
43,O
men,O
and,O
8,O
women,O
),O
transplanted,O
for,O
benign,O
HBV,O
-,O
related,O
cirrhotic,B-Entity
diseases,I-Entity
between,O
June,O
2002,O
and,O
December,O
2004,O
who,O
had,O
survived,O
more,O
than,O
3,O
months,O
.,O
A,O
daily,O
oral,O
dose,O
of,O
100,O
mg,O
lamivudine,I-Entity
for,O
2,O
weeks,O
before,O
transplantation,O
for,O
10,O
patients,O
enabled,O
57.1%,O
(,O
4/7,O
),O
and,O
62.5%,O
(,O
5/8,O
),O
of,O
HBV,O
-,O
DNA,O
and,O
HBeAg,I-Entity
positive,O
patients,O
respectively,O
to,O
convert,O
to,O
be,O
negative,O
.,O
Lamivudine,I-Entity
combined,O
with,O
intramuscular,O
HBIg,O
can,O
effectively,O
prevent,O
allograft,O
from,O
the,O
recurrence,O
of,O
HBV,O
after,O
liver,O
transplantation,O
.,O
Anticonvulsant,O
effect,O
of,O
eslicarbazepine,B-Entity
acetate,I-Entity
(,O
BIA,B-Entity
2,I-Entity
-,I-Entity
093,I-Entity
),O
on,O
seizures,I-Entity
induced,O
by,O
microperfusion,O
of,O
picrotoxin,I-Entity
in,O
the,O
hippocampus,O
of,O
freely,O
moving,O
rats,O
.,O
Eslicarbazepine,B-Entity
acetate,I-Entity
(,O
BIA,B-Entity
2,I-Entity
-,I-Entity
093,I-Entity
",",O
"S-(-)-10-acetoxy-10,11-dihydro-5H",B-Entity
-,I-Entity
dibenzo,I-Entity
/,I-Entity
b,I-Entity
",",I-Entity
f,I-Entity
/,I-Entity
azepine-5-carboxamide,I-Entity
),O
is,O
a,O
novel,O
antiepileptic,O
drug,O
",",O
now,O
in,O
Phase,O
III,O
clinical,O
trials,O
",",O
designed,O
with,O
the,O
aim,O
of,O
improving,O
efficacy,O
and,O
safety,O
in,O
comparison,O
with,O
the,O
structurally,O
related,O
drugs,O
carbamazepine,I-Entity
(,O
CBZ,I-Entity
),O
and,O
oxcarbazepine,I-Entity
(,O
OXC,I-Entity
),O
.,O
We,O
have,O
studied,O
the,O
effects,O
of,O
oral,O
treatment,O
with,O
eslicarbazepine,B-Entity
acetate,I-Entity
on,O
a,O
whole,O
-,O
animal,O
model,O
in,O
which,O
partial,O
seizures,I-Entity
can,O
be,O
elicited,O
repeatedly,O
on,O
different,O
days,O
without,O
changes,O
in,O
threshold,O
or,O
seizure,I-Entity
patterns,O
.,O
In,O
the,O
animals,O
treated,O
with,O
threshold,O
doses,O
of,O
picrotoxin,I-Entity
",",O
the,O
average,O
number,O
of,O
seizures,I-Entity
was,O
2.3+/-1.2,O
",",O
and,O
average,O
seizure,I-Entity
duration,O
was,O
39.5+/-8.4s,O
.,O
Pre,O
-,O
treatment,O
with,O
a,O
dose,O
of,O
30,O
mg,O
/,O
kg,O
2h,O
before,O
picrotoxin,I-Entity
microperfusion,O
prevented,O
seizures,I-Entity
in,O
the,O
75%,O
of,O
the,O
rats,O
.,O
Lower,O
doses,O
(,O
3,O
and,O
10mg,O
/,O
kg,O
),O
did,O
not,O
suppress,O
seizures,I-Entity
",",O
however,O
",",O
after,O
administration,O
of,O
10mg,O
/,O
kg,O
",",O
significant,O
reductions,O
in,O
seizures,I-Entity
duration,O
(,O
24.3+/-6.8s,O
),O
and,O
seizure,I-Entity
number,O
(,O
1.6+/-0.34,O
),O
were,O
found,O
.,O
No,O
adverse,O
effects,O
of,O
eslicarbazepine,B-Entity
acetate,I-Entity
were,O
observed,O
in,O
the,O
behavioral,O
/,O
EEG,O
patterns,O
studied,O
",",O
including,O
sleep,O
/,O
wakefulness,O
cycle,O
",",O
at,O
the,O
doses,O
studied,O
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
associated,O
with,O
prolonged,O
intake,O
of,O
slimming,O
pills,O
containing,O
anthraquinones,I-Entity
.,O
Chinese,B-Entity
herbal,I-Entity
medicine,O
preparations,O
are,O
widely,O
available,O
and,O
often,O
regarded,O
by,O
the,O
public,O
as,O
natural,O
and,O
safe,O
remedies,O
for,O
a,O
variety,O
of,O
medical,O
conditions,O
.,O
Nephropathy,I-Entity
caused,O
by,O
Chinese,B-Entity
herbs,I-Entity
has,O
previously,O
been,O
reported,O
",",O
usually,O
involving,O
the,O
use,O
of,O
aristolochic,B-Entity
acids,I-Entity
.,O
We,O
report,O
a,O
23-year,O
-,O
old,O
woman,O
who,O
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
following,O
prolonged,O
use,O
of,O
a,O
proprietary,O
Chinese,B-Entity
herbal,I-Entity
slimming,O
pill,O
that,O
contained,O
anthraquinone,I-Entity
derivatives,O
",",O
extracted,O
from,O
Rhizoma,O
Rhei,O
(,O
rhubarb,O
),O
.,O
The,O
renal,B-Entity
injury,I-Entity
was,O
probably,O
aggravated,O
by,O
the,O
concomitant,O
intake,O
of,O
a,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drug,O
",",O
diclofenac,I-Entity
.,O
Renal,O
pathology,O
was,O
that,O
of,O
hypocellular,O
interstitial,O
fibrosis,I-Entity
.,O
Spontaneous,O
renal,O
recovery,O
occurred,O
upon,O
cessation,O
of,O
the,O
slimming,O
pills,O
",",O
but,O
mild,O
interstitial,O
fibrosis,I-Entity
and,O
tubular,O
atrophy,I-Entity
was,O
still,O
evident,O
histologically,O
4,O
months,O
later,O
.,O
Although,O
a,O
causal,O
relationship,O
between,O
the,O
use,O
of,O
an,O
anthraquinone,I-Entity
-,O
containing,O
herbal,O
agent,O
and,O
renal,B-Entity
injury,I-Entity
remains,O
to,O
be,O
proven,O
",",O
phytotherapy,O
-,O
associated,O
interstitial,O
nephropathy,I-Entity
should,O
be,O
considered,O
in,O
patients,O
who,O
present,O
with,O
unexplained,O
renal,B-Entity
failure,I-Entity
.,O
Chloroacetaldehyde,I-Entity
as,O
a,O
sulfhydryl,I-Entity
reagent,O
:,O
the,O
role,O
of,O
critical,O
thiol,I-Entity
groups,O
in,O
ifosfamide,I-Entity
nephropathy,I-Entity
.,O
Chloroacetaldehyde,I-Entity
(,O
CAA,I-Entity
),O
is,O
a,O
metabolite,O
of,O
the,O
alkylating,O
agent,O
ifosfamide,I-Entity
(,O
IFO,I-Entity
),O
and,O
putatively,O
responsible,O
for,O
renal,B-Entity
damage,I-Entity
following,O
anti,O
-,O
tumor,I-Entity
therapy,O
with,O
IFO,I-Entity
.,O
Depletion,O
of,O
sulfhydryl,I-Entity
(,O
SH,I-Entity
),O
In,O
this,O
work,O
the,O
effect,O
of,O
CAA,I-Entity
on,O
human,O
proximal,O
tubule,O
cells,O
in,O
primary,O
culture,O
(,O
hRPTEC,O
),O
was,O
investigated,O
.,O
Toxicity,I-Entity
of,O
CAA,I-Entity
was,O
determined,O
by,O
protein,O
content,O
",",O
cell,O
number,O
",",O
LDH,O
release,O
",",O
trypan,B-Entity
blue,I-Entity
exclusion,O
assay,O
and,O
caspase-3,O
activity,O
.,O
Free,O
thiols,I-Entity
were,O
measured,O
by,O
the,O
method,O
of,O
Ellman,O
.,O
CAA,I-Entity
reduced,O
hRPTEC,O
cell,O
number,O
and,O
protein,O
",",O
induced,O
a,O
loss,O
in,O
free,O
intracellular,O
thiols,I-Entity
and,O
an,O
increase,O
in,O
necrosis,I-Entity
markers,O
.,O
CAA,I-Entity
but,O
not,O
acrolein,I-Entity
inhibited,O
the,O
cysteine,I-Entity
B.,O
Caspase,O
activation,O
by,O
cisplatin,I-Entity
was,O
inhibited,O
by,O
CAA,I-Entity
.,O
In,O
cells,O
stained,O
with,O
fluorescent,O
dyes,O
targeting,O
lysosomes,O
",",O
CAA,I-Entity
induced,O
an,O
increase,O
in,O
lysosomal,O
size,O
and,O
lysosomal,O
leakage,O
.,O
The,O
effects,O
of,O
CAA,I-Entity
on,O
cysteine,I-Entity
protease,O
activities,O
and,O
thiols,I-Entity
could,O
be,O
reproduced,O
in,O
cell,O
lysate,O
.,O
Acidification,O
",",O
which,O
slowed,O
the,O
reaction,O
of,O
CAA,I-Entity
with,O
thiol,I-Entity
donors,O
",",O
could,O
also,O
attenuate,O
effects,O
of,O
CAA,I-Entity
on,O
necrosis,I-Entity
markers,O
",",O
thiol,I-Entity
depletion,O
and,O
cysteine,I-Entity
protease,O
inhibition,O
in,O
living,O
cells,O
.,O
Thus,O
",",O
CAA,I-Entity
directly,O
reacts,O
with,O
cellular,O
protein,O
and,O
non,O
-,O
protein,O
thiols,I-Entity
",",O
mediating,O
its,O
toxicity,I-Entity
on,O
hRPTEC,O
.,O
Therefore,O
",",O
urinary,O
acidification,O
could,O
be,O
an,O
option,O
to,O
prevent,O
IFO,I-Entity
nephropathy,I-Entity
in,O
patients,O
.,O
Stereological,O
methods,O
reveal,O
the,O
robust,O
size,O
and,O
stability,O
of,O
ectopic,O
hilar,O
granule,O
cells,O
after,O
pilocarpine,I-Entity
-,O
induced,O
status,B-Entity
epilepticus,I-Entity
in,O
the,O
adult,O
rat,O
.,O
Following,O
status,B-Entity
epilepticus,I-Entity
in,O
the,O
rat,O
",",O
dentate,O
granule,O
cell,O
neurogenesis,O
increases,O
greatly,O
",",O
and,O
many,O
of,O
the,O
new,O
neurons,O
appear,O
to,O
develop,O
ectopically,O
",",O
in,O
the,O
hilar,O
region,O
of,O
the,O
hippocampal,O
formation,O
.,O
It,O
has,O
been,O
suggested,O
that,O
the,O
ectopic,O
hilar,O
granule,O
cells,O
could,O
contribute,O
to,O
the,O
spontaneous,O
seizures,I-Entity
that,O
ultimately,O
develop,O
after,O
status,B-Entity
epilepticus,I-Entity
.,O
To,O
quantify,O
this,O
population,O
",",O
the,O
total,O
number,O
of,O
ectopic,O
hilar,O
granule,O
cells,O
was,O
estimated,O
using,O
unbiased,O
stereology,O
at,O
different,O
times,O
after,O
pilocarpine,I-Entity
-,O
induced,O
status,B-Entity
epilepticus,I-Entity
.,O
The,O
results,O
indicate,O
that,O
the,O
size,O
of,O
the,O
hilar,O
ectopic,O
granule,O
cell,O
population,O
after,O
status,B-Entity
epilepticus,I-Entity
is,O
substantial,O
",",O
and,O
stable,O
over,O
time,O
.,O
Interestingly,O
",",O
the,O
size,O
of,O
the,O
population,O
appears,O
to,O
be,O
correlated,O
with,O
the,O
frequency,O
of,O
behavioral,O
seizures,I-Entity
",",O
because,O
animals,O
with,O
more,O
ectopic,O
granule,O
cells,O
in,O
the,O
hilus,O
have,O
more,O
frequent,O
behavioral,O
seizures,I-Entity
.,O
The,O
results,O
provide,O
new,O
insight,O
into,O
the,O
potential,O
role,O
of,O
ectopic,O
hilar,O
granule,O
cells,O
in,O
the,O
pilocarpine,I-Entity
model,O
of,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
.,O
A,O
prospective,O
",",O
open,O
-,O
label,O
trial,O
of,O
galantamine,I-Entity
in,O
autistic,B-Entity
disorder,I-Entity
.,O
Post,O
-,O
mortem,O
studies,O
have,O
reported,O
abnormalities,O
of,O
the,O
cholinergic,O
system,O
in,O
autism,I-Entity
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
use,O
of,O
galantamine,I-Entity
",",O
an,O
acetylcholinesterase,O
inhibitor,O
and,O
nicotinic,O
receptor,O
modulator,O
",",O
in,O
the,O
treatment,O
of,O
interfering,O
behaviors,O
in,O
children,O
with,O
autism,I-Entity
.,O
Thirteen,O
medication,O
-,O
free,O
children,O
with,O
autism,I-Entity
(,O
mean,O
age,O
",",O
8.8,O
+,O
/-,O
3.5,O
years,O
),O
participated,O
in,O
a,O
12-week,O
",",O
open,O
-,O
label,O
trial,O
of,O
galantamine,I-Entity
.,O
Patients,O
showed,O
a,O
significant,O
reduction,O
in,O
parent,O
-,O
rated,O
irritability,I-Entity
and,O
social,O
withdrawal,O
on,O
the,O
ABC,O
as,O
well,O
as,O
significant,O
improvements,O
in,O
emotional,O
lability,O
and,O
inattention,O
on,O
the,O
Conners,O
',O
Parent,O
Rating,O
Scale,O
--,O
Revised,O
.,O
Overall,O
",",O
galantamine,I-Entity
was,O
well,O
-,O
tolerated,O
",",O
with,O
no,O
significant,O
adverse,O
effects,O
apart,O
from,O
headaches,I-Entity
in,O
one,O
patient,O
.,O
In,O
this,O
open,O
trial,O
",",O
galantamine,I-Entity
was,O
well,O
-,O
tolerated,O
and,O
appeared,O
to,O
be,O
beneficial,O
for,O
the,O
treatment,O
of,O
interfering,O
behaviors,O
in,O
children,O
with,O
autism,I-Entity
",",O
particularly,O
aggression,I-Entity
",",O
behavioral,B-Entity
dyscontrol,I-Entity
",",O
and,O
inattention,I-Entity
.,O
Randomized,O
comparison,O
of,O
olanzapine,I-Entity
versus,O
risperidone,I-Entity
for,O
the,O
treatment,O
of,O
first,O
-,O
episode,O
schizophrenia,I-Entity
:,O
4-month,O
outcomes,O
.,O
OBJECTIVE,O
:,O
The,O
authors,O
compared,O
4-month,O
treatment,O
outcomes,O
for,O
olanzapine,I-Entity
versus,O
risperidone,I-Entity
in,O
patients,O
with,O
first,O
-,O
episode,O
schizophrenia,I-Entity
spectrum,O
disorders,O
.,O
One,O
hundred,O
twelve,O
subjects,O
(,O
70%,O
male,O
;,O
mean,O
age=23.3,O
years,O
[,O
SD,O
=,O
5.1,O
],O
),O
with,O
first,O
-,O
episode,O
schizophrenia,I-Entity
(,O
75%,O
),O
",",O
schizophreniform,B-Entity
disorder,I-Entity
(,O
17%,O
),O
",",O
or,O
schizoaffective,B-Entity
disorder,I-Entity
(,O
8%,O
),O
were,O
randomly,O
assigned,O
to,O
treatment,O
with,O
olanzapine,I-Entity
(,O
2.5,O
-,O
20,O
mg,O
/,O
day,O
),O
or,O
risperidone,I-Entity
(,O
1,O
-,O
6,O
mg,O
/,O
day,O
),O
.,O
Response,O
rates,O
did,O
not,O
significantly,O
differ,O
between,O
olanzapine,I-Entity
(,O
43.7%,O
",",O
95%,O
CI=28.8%-58.6%,O
),O
and,O
risperidone,I-Entity
(,O
54.3%,O
",",O
95%,O
CI=39.9%-68.7%,O
),O
.,O
Among,O
those,O
responding,O
to,O
treatment,O
",",O
more,O
subjects,O
in,O
the,O
olanzapine,I-Entity
group,O
(,O
40.9%,O
",",O
95%,O
CI=16.8%-65.0%,O
),O
than,O
in,O
the,O
risperidone,I-Entity
group,O
(,O
18.9%,O
",",O
95%,O
CI=0%-39.2%,O
),O
had,O
subsequent,O
ratings,O
not,O
meeting,O
response,O
criteria,O
.,O
Negative,O
symptom,O
outcomes,O
and,O
measures,O
of,O
parkinsonism,I-Entity
and,O
akathisia,I-Entity
did,O
not,O
differ,O
between,O
medications,O
.,O
Extrapyramidal,B-Entity
symptom,I-Entity
severity,O
scores,O
were,O
1.4,O
(,O
95%,O
CI=1.2,O
-,O
1.6,O
),O
with,O
risperidone,I-Entity
and,O
1.2,O
(,O
95%,O
CI=1.0,O
-,O
1.4,O
),O
with,O
olanzapine,I-Entity
.,O
Significantly,O
more,O
weight,B-Entity
gain,I-Entity
occurred,O
with,O
olanzapine,I-Entity
than,O
with,O
risperidone,I-Entity
:,O
the,O
increase,O
in,O
weight,O
at,O
4,O
months,O
relative,O
to,O
baseline,O
weight,O
was,O
17.3%,O
(,O
95%,O
CI=14.2%-20.5%,O
),O
with,O
olanzapine,I-Entity
and,O
11.3%,O
(,O
95%,O
CI=8.4%-14.3%,O
),O
with,O
risperidone,I-Entity
.,O
Body,O
mass,O
index,O
at,O
baseline,O
and,O
at,O
4,O
months,O
was,O
24.3,O
(,O
95%,O
CI=22.8,O
-,O
25.7,O
),O
versus,O
28.2,O
(,O
95%,O
CI=26.7,O
-,O
29.7,O
),O
with,O
olanzapine,I-Entity
and,O
23.9,O
(,O
95%,O
CI=22.5,O
-,O
25.3,O
),O
versus,O
26.7,O
(,O
95%,O
CI=25.2,O
-,O
28.2,O
),O
with,O
risperidone,I-Entity
.,O
CONCLUSIONS,O
:,O
Clinical,O
outcomes,O
with,O
risperidone,I-Entity
were,O
equal,O
to,O
those,O
with,O
olanzapine,I-Entity
",",O
and,O
response,O
may,O
be,O
more,O
stable,O
.,O
Olanzapine,I-Entity
may,O
have,O
an,O
advantage,O
for,O
motor,O
side,O
effects,O
.,O
Both,O
medications,O
caused,O
substantial,O
rapid,O
weight,B-Entity
gain,I-Entity
",",O
but,O
weight,B-Entity
gain,I-Entity
was,O
greater,O
with,O
olanzapine,I-Entity
.,O
Early,O
paracentral,O
visual,B-Entity
field,I-Entity
loss,I-Entity
in,O
patients,O
taking,O
hydroxychloroquine,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
review,O
the,O
natural,O
history,O
and,O
ocular,O
and,O
systemic,O
adverse,O
effects,O
of,O
patients,O
taking,O
hydroxychloroquine,B-Entity
sulfate,I-Entity
who,O
attended,O
an,O
ophthalmic,O
screening,O
program,O
.,O
RESULTS,O
:,O
Records,O
of,O
262,O
patients,O
who,O
were,O
taking,O
hydroxychloroquine,I-Entity
and,O
screened,O
in,O
the,O
Department,O
of,O
Ophthalmology,O
were,O
reviewed,O
.,O
Thirty,O
-,O
five,O
patients,O
(,O
13.4%,O
),O
had,O
visual,B-Entity
field,I-Entity
abnormalities,I-Entity
",",O
which,O
were,O
attributed,O
to,O
hydroxychloroquine,I-Entity
treatment,O
in,O
4,O
patients,O
(,O
1.5%,O
),O
.,O
The,O
current,O
study,O
used,O
a,O
protocol,O
of,O
visual,O
acuity,O
and,O
color,O
vision,O
assessment,O
",",O
funduscopy,O
",",O
and,O
Humphrey,O
10,O
-,O
2,O
visual,O
field,O
testing,O
and,O
shows,O
that,O
visual,B-Entity
field,I-Entity
defects,I-Entity
appeared,O
before,O
any,O
corresponding,O
changes,O
in,O
any,O
other,O
tested,O
clinical,O
parameters,O
;,O
the,O
defects,O
were,O
reproducible,O
and,O
the,O
test,O
parameters,O
were,O
reliable,O
.,O
Patients,O
taking,O
hydroxychloroquine,I-Entity
can,O
demonstrate,O
a,O
toxic,O
reaction,O
in,O
the,O
retina,O
despite,O
the,O
absence,O
of,O
known,O
risk,O
factors,O
.,O
Peri,O
-,O
operative,O
atrioventricular,B-Entity
block,I-Entity
as,O
a,O
result,O
of,O
chemotherapy,O
with,O
epirubicin,I-Entity
and,O
paclitaxel,I-Entity
.,O
A,O
47-year,O
-,O
old,O
woman,O
presented,O
for,O
mastectomy,O
and,O
immediate,O
latissimus,O
dorsi,O
flap,O
reconstruction,O
having,O
been,O
diagnosed,O
with,O
carcinoma,B-Entity
of,I-Entity
the,I-Entity
breast,I-Entity
6,O
months,O
previously,O
.,O
In,O
the,O
preceding,O
months,O
she,O
had,O
received,O
neo,O
-,O
adjuvant,O
chemotherapy,O
with,O
epirubicin,I-Entity
",",O
paclitaxel,I-Entity
(,O
Taxol,I-Entity
),O
and,O
cyclophosphamide,I-Entity
.,O
She,O
was,O
found,O
to,O
be,O
bradycardic,I-Entity
at,O
pre,O
-,O
operative,O
assessment,O
but,O
had,O
no,O
cardiac,O
symptoms,O
.,O
Second,O
degree,O
Mobitz,O
type,O
II,O
atrioventricular,B-Entity
block,I-Entity
was,O
diagnosed,O
on,O
electrocardiogram,O
",",O
and,O
temporary,O
transvenous,O
ventricular,O
pacing,O
instituted,O
in,O
the,O
peri,O
-,O
operative,O
period,O
.,O
We,O
discuss,O
how,O
evidence,O
-,O
based,O
guidelines,O
would,O
not,O
have,O
been,O
helpful,O
in,O
this,O
case,O
",",O
and,O
how,O
chemotherapy,O
can,O
exhibit,O
substantial,O
cardiotoxicity,I-Entity
that,O
may,O
develop,O
over,O
many,O
years,O
.,O
Risks,O
and,O
benefits,O
of,O
COX-2,B-Entity
inhibitors,I-Entity
vs,O
non,O
-,O
selective,O
NSAIDs,O
:,O
does,O
their,O
cardiovascular,O
risk,O
exceed,O
their,O
gastrointestinal,O
benefit,O
?,O
The,O
risk,O
of,O
acute,B-Entity
myocardial,I-Entity
infarction,I-Entity
(,O
AMI,I-Entity
),O
with,O
COX-2,B-Entity
inhibitors,I-Entity
may,O
offset,O
their,O
gastrointestinal,O
(,O
GI,O
),O
benefit,O
compared,O
with,O
non,O
-,O
selective,O
(,O
NS,O
),O
non,B-Entity
-,I-Entity
steroidal,I-Entity
anti,I-Entity
-,I-Entity
inflammatory,I-Entity
drugs,I-Entity
(,O
NSAIDs,O
),O
.,O
We,O
aimed,O
to,O
compare,O
the,O
risks,O
of,O
hospitalization,O
for,O
AMI,I-Entity
and,O
GI,B-Entity
bleeding,I-Entity
among,O
elderly,O
patients,O
using,O
COX-2,B-Entity
inhibitors,I-Entity
",",O
NS,O
-,O
NSAIDs,O
and,O
acetaminophen,I-Entity
.,O
METHODS,O
:,O
We,O
conducted,O
a,O
retrospective,O
cohort,O
study,O
using,O
administrative,O
data,O
of,O
patients,O
>,O
or,O
=,O
65,O
years,O
of,O
age,O
who,O
filled,O
a,O
prescription,O
for,O
NSAID,O
or,O
acetaminophen,I-Entity
during,O
1999,O
-,O
2002,O
.,O
Person,O
-,O
years,O
of,O
exposure,O
among,O
non,O
-,O
users,O
of,O
aspirin,I-Entity
were,O
:,O
"75,761",O
to,O
acetaminophen,I-Entity
",",O
"42,671",O
to,O
rofecoxib,I-Entity
"65,860",O
to,O
celecoxib,I-Entity
",",O
and,O
"37,495",O
to,O
NS,O
-,O
NSAIDs,O
.,O
Among,O
users,O
of,O
aspirin,I-Entity
",",O
they,O
were,O
:,O
"14,671",O
to,O
rofecoxib,I-Entity
",",O
"22,875",O
to,O
celecoxib,I-Entity
",",O
"9,832",O
to,O
NS,O
-,O
NSAIDs,O
and,O
"38,048",O
to,O
acetaminophen,I-Entity
.,O
Among,O
non,O
-,O
users,O
of,O
aspirin,I-Entity
",",O
the,O
adjusted,O
hazard,O
ratios,O
(,O
95%,O
confidence,O
interval,O
),O
of,O
hospitalization,O
for,O
AMI,I-Entity
/,O
GI,O
vs,O
the,O
acetaminophen,I-Entity
(,O
with,O
no,O
aspirin,I-Entity
),O
group,O
were,O
:,O
rofecoxib,I-Entity
1.27,O
(,O
1.13,O
",",O
1.42,O
),O
",",O
celecoxib,I-Entity
0.93,O
(,O
0.83,O
",",O
1.03,O
),O
",",O
naproxen,I-Entity
1.59,O
(,O
1.31,O
",",O
1.93,O
),O
",",O
diclofenac,I-Entity
1.17,O
(,O
0.99,O
",",O
1.38,O
),O
and,O
ibuprofen,I-Entity
1.05,O
(,O
0.74,O
",",O
1.51,O
),O
.,O
Among,O
users,O
of,O
aspirin,I-Entity
",",O
they,O
were,O
:,O
rofecoxib,I-Entity
1.73,O
(,O
1.52,O
",",O
1.98,O
),O
",",O
celecoxib,I-Entity
1.34,O
(,O
1.19,O
",",O
1.52,O
),O
",",O
ibuprofen,I-Entity
1.51,O
(,O
0.95,O
",",O
2.41,O
),O
",",O
diclofenac,I-Entity
1.69,O
(,O
1.35,O
",",O
2.10,O
),O
",",O
naproxen,I-Entity
1.35,O
(,O
0.97,O
",",O
1.88,O
),O
and,O
acetaminophen,I-Entity
1.29,O
(,O
1.17,O
",",O
1.42,O
),O
.,O
Among,O
non,O
-,O
users,O
of,O
aspirin,I-Entity
",",O
naproxen,I-Entity
seemed,O
to,O
carry,O
the,O
highest,O
risk,O
for,O
AMI,I-Entity
/,O
GI,B-Entity
bleeding,I-Entity
.,O
The,O
AMI,I-Entity
/,O
GI,O
toxicity,I-Entity
of,O
celecoxib,I-Entity
was,O
similar,O
to,O
that,O
of,O
acetaminophen,I-Entity
and,O
seemed,O
to,O
be,O
better,O
than,O
those,O
of,O
rofecoxib,I-Entity
and,O
NS,O
-,O
NSAIDs,O
.,O
Among,O
users,O
of,O
aspirin,I-Entity
",",O
both,O
celecoxib,I-Entity
and,O
naproxen,I-Entity
seemed,O
to,O
be,O
the,O
least,O
toxic,O
.,O
Quinine,I-Entity
-,O
induced,O
arrhythmia,I-Entity
in,O
a,O
patient,O
with,O
severe,B-Entity
malaria,I-Entity
.,O
It,O
was,O
reported,O
that,O
there,O
was,O
a,O
case,O
of,O
severe,B-Entity
malaria,I-Entity
patient,O
with,O
jaundice,I-Entity
who,O
presented,O
with,O
arrhythmia,I-Entity
(,O
premature,B-Entity
ventricular,I-Entity
contraction,I-Entity
),O
while,O
getting,O
quinine,I-Entity
infusion,O
was,O
reported,O
.,O
A,O
man,O
",",O
25,O
years,O
old,O
",",O
was,O
admitted,O
to,O
hospital,O
with,O
high,O
fever,I-Entity
",",O
chill,I-Entity
",",O
vomiting,I-Entity
",",O
jaundice,I-Entity
.,O
On,O
admission,O
",",O
laboratory,O
examination,O
showed,O
Plasmodium,O
falciparum,O
(,O
+,O
+,O
+,O
+,O
),O
",",O
total,O
bilirubin,I-Entity
8.25,O
mg,O
/,O
dL,O
",",O
conjugated,O
bilirubin,I-Entity
4.36,O
mg,O
/,O
dL,O
",",O
unconjugated,O
bilirubin,I-Entity
3.89,O
mg,O
/,O
dL,O
",",O
potassium,I-Entity
3.52,O
meq,O
/,O
L,O
Patient,O
was,O
diagnosed,O
as,O
severe,B-Entity
malaria,I-Entity
with,O
jaundice,I-Entity
and,O
got,O
quinine,I-Entity
infusion,O
in,O
dextrose,I-Entity
5%,O
500,O
mg/8,O
hour,O
.,O
On,O
the,O
second,O
day,O
the,O
patient,O
had,O
vomitus,I-Entity
",",O
diarrhea,I-Entity
",",O
tinnitus,I-Entity
",",O
loss,B-Entity
of,I-Entity
hearing,I-Entity
.,O
After,O
30,O
hours,O
of,O
quinine,I-Entity
infusion,O
the,O
patient,O
felt,O
palpitation,I-Entity
and,O
electrocardiography,O
(,O
ECG,O
),O
recording,O
showed,O
premature,B-Entity
ventricular,I-Entity
contraction,I-Entity
(,O
PVC,I-Entity
),O
>,O
5,O
x,O
/,O
minute,O
",",O
trigemini,O
",",O
constant,O
type,O
--,O
sinoatrial,B-Entity
block,I-Entity
",",O
positive,O
U,O
wave,O
.,O
He,O
was,O
treated,O
with,O
lidocaine,I-Entity
50,O
mg,O
intravenously,O
followed,O
by,O
infusion,O
1500,O
mg,O
in,O
dextrose,I-Entity
5%/24,O
hour,O
and,O
potassium,B-Entity
aspartate,I-Entity
tablet,O
.,O
Quinine,I-Entity
infusion,O
was,O
discontinued,O
and,O
changed,O
with,O
sulfate,O
quinine,I-Entity
tablets,O
.,O
Three,O
hours,O
later,O
the,O
patient,O
felt,O
better,O
",",O
the,O
frequency,O
of,O
PVC,I-Entity
reduced,O
to,O
4,O
-,O
5,O
x,O
/,O
minute,O
and,O
on,O
the,O
third,O
day,O
ECG,O
was,O
normal,O
",",O
potassium,I-Entity
level,O
was,O
3.34,O
meq,O
/,O
L.,O
Quinine,I-Entity
",",O
like,O
quinidine,I-Entity
",",O
is,O
a,O
chincona,O
alkaloid,O
that,O
has,O
anti,O
-,O
arrhythmic,I-Entity
property,O
",",O
although,O
it,O
also,O
pro,O
-,O
arrhythmic,I-Entity
that,O
can,O
cause,O
various,O
arrhythmias,I-Entity
",",O
including,O
severe,O
arrhythmia,I-Entity
such,O
as,O
multiple,O
PVC,I-Entity
.,O
Administration,O
of,O
parenteral,O
quinine,I-Entity
must,O
be,O
done,O
carefully,O
and,O
with,O
good,O
observation,O
because,O
of,O
its,O
pro,O
-,O
arrhythmic,I-Entity
effect,O
",",O
especially,O
in,O
older,O
patients,O
who,O
have,O
heart,B-Entity
diseases,I-Entity
or,O
patients,O
with,O
electrolyte,B-Entity
disorder,I-Entity
(,O
hypokalemia,I-Entity
),O
which,O
frequently,O
occurs,O
due,O
to,O
vomiting,I-Entity
and,O
or,O
diarrhea,I-Entity
in,O
malaria,I-Entity
cases,O
.,O
Penicillamine,I-Entity
-,O
related,O
lichenoid,B-Entity
dermatitis,I-Entity
and,O
utility,O
of,O
zinc,B-Entity
acetate,I-Entity
in,O
a,O
Wilson,B-Entity
disease,I-Entity
patient,O
with,O
hepatic,O
presentation,O
",",O
anxiety,I-Entity
and,O
SPECT,O
abnormalities,O
.,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
is,O
an,O
autosomal,O
recessive,O
disorder,O
of,O
hepatic,O
copper,I-Entity
metabolism,O
with,O
consequent,O
copper,I-Entity
accumulation,O
and,O
toxicity,I-Entity
in,O
many,O
tissues,O
and,O
consequent,O
hepatic,B-Entity
",",I-Entity
neurologic,I-Entity
and,I-Entity
psychiatric,I-Entity
disorders,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
with,O
chronic,B-Entity
liver,I-Entity
disease,I-Entity
;,O
moreover,O
",",O
in,O
our,O
patient,O
",",O
presenting,O
also,O
with,O
high,O
levels,O
of,O
state,O
anxiety,I-Entity
without,O
depression,I-Entity
",",O
99mTc,O
-,O
ECD,O
-,O
SPECT,O
showed,O
cortical,O
hypoperfusion,O
in,O
frontal,O
lobes,O
",",O
more,O
marked,O
on,O
the,O
left,O
frontal,O
lobe,O
.,O
During,O
the,O
follow,O
-,O
up,O
of,O
our,O
patient,O
",",O
penicillamine,I-Entity
was,O
interrupted,O
after,O
the,O
appearance,O
of,O
a,O
lichenoid,B-Entity
dermatitis,I-Entity
",",O
and,O
zinc,B-Entity
acetate,I-Entity
permitted,O
to,O
continue,O
the,O
successful,O
treatment,O
of,O
the,O
patient,O
without,O
side,O
-,O
effects,O
.,O
In,O
our,O
case,O
the,O
therapy,O
with,O
zinc,B-Entity
acetate,I-Entity
represented,O
an,O
effective,O
treatment,O
for,O
a,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
patient,O
in,O
which,O
penicillamine,I-Entity
-,O
related,O
side,O
effects,O
appeared,O
.,O
The,O
safety,O
of,O
the,O
zinc,B-Entity
acetate,I-Entity
allowed,O
us,O
to,O
avoid,O
other,O
potentially,O
toxic,O
chelating,O
drugs,O
;,O
this,O
observation,O
is,O
in,O
line,O
with,O
the,O
growing,O
evidence,O
on,O
the,O
efficacy,O
of,O
the,O
drug,O
in,O
the,O
treatment,O
of,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Since,O
most,O
of,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
penicillamine,I-Entity
-,O
treated,O
patients,O
do,O
not,O
seem,O
to,O
develop,O
this,O
skin,B-Entity
lesion,I-Entity
",",O
it,O
could,O
be,O
conceivable,O
that,O
a,O
specific,O
genetic,O
factor,O
is,O
involved,O
in,O
drug,O
response,O
.,O
Further,O
studies,O
are,O
needed,O
for,O
a,O
better,O
clarification,O
of,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
therapy,O
",",O
and,O
in,O
particular,O
to,O
differentiate,O
specific,O
therapies,O
for,O
different,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
phenotypes,O
.,O
A,O
dramatic,O
drop,B-Entity
in,I-Entity
blood,I-Entity
pressure,I-Entity
following,O
prehospital,O
GTN,I-Entity
administration,O
.,O
A,O
male,O
in,O
his,O
sixties,O
with,O
no,O
history,O
of,O
cardiac,O
chest,B-Entity
pain,I-Entity
awoke,O
with,O
chest,B-Entity
pain,I-Entity
following,O
an,O
afternoon,O
sleep,O
.,O
The,O
patient,O
's,O
observations,O
were,O
within,O
normal,O
limits,O
",",O
he,O
was,O
administered,O
oxygen,I-Entity
via,O
a,O
face,O
mask,O
and,O
glyceryl,B-Entity
trinitrate,I-Entity
(,O
GTN,I-Entity
),O
.,O
Several,O
minutes,O
after,O
the,O
GTN,I-Entity
the,O
patient,O
experienced,O
a,O
sudden,O
drop,B-Entity
in,I-Entity
blood,I-Entity
pressure,I-Entity
and,O
heart,O
rate,O
",",O
this,O
was,O
rectified,O
by,O
atropine,B-Entity
sulphate,I-Entity
and,O
a,O
fluid,O
challenge,O
.,O
Prehospital,O
care,O
providers,O
who,O
are,O
managing,O
any,O
patient,O
with,O
a,O
syncopal,B-Entity
episode,I-Entity
that,O
fails,O
to,O
recover,O
within,O
a,O
reasonable,O
time,O
frame,O
should,O
consider,O
the,O
Bezold,O
-,O
Jarisch,O
reflex,O
as,O
the,O
cause,O
and,O
manage,O
the,O
patient,O
accordingly,O
.,O
Acute,B-Entity
encephalopathy,I-Entity
and,O
cerebral,B-Entity
vasospasm,I-Entity
after,O
multiagent,O
chemotherapy,O
including,O
PEG,B-Entity
-,I-Entity
asparaginase,I-Entity
and,O
intrathecal,O
cytarabine,I-Entity
for,O
the,O
treatment,O
of,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
.,O
A,O
7-year,O
-,O
old,O
girl,O
with,O
an,O
unusual,O
reaction,O
to,O
induction,O
chemotherapy,O
for,O
precursor,O
B,O
-,O
cell,O
acute,B-Entity
lymphoblastic,I-Entity
leukemia,I-Entity
(,O
ALL,I-Entity
),O
is,O
described,O
.,O
The,O
patient,O
developed,O
acute,B-Entity
encephalopathy,I-Entity
evidenced,O
by,O
behavioral,O
changes,O
",",O
aphasia,I-Entity
",",O
incontinence,I-Entity
",",O
visual,B-Entity
hallucinations,I-Entity
",",O
and,O
right,O
-,O
sided,O
weakness,I-Entity
with,O
diffuse,O
cerebral,B-Entity
vasospasm,I-Entity
on,O
magnetic,O
resonance,O
angiography,O
after,O
the,O
administration,O
of,O
intrathecal,O
cytarabine,I-Entity
.,O
Vincristine,I-Entity
",",O
dexamethasone,I-Entity
",",O
and,O
polyethylene,B-Entity
glycol,I-Entity
-,I-Entity
asparaginase,I-Entity
were,O
also,O
administered,O
before,O
the,O
episode,O
as,O
part,O
of,O
induction,O
therapy,O
.,O
Comparison,O
of,O
valsartan,I-Entity
/,O
hydrochlorothiazide,I-Entity
combination,O
therapy,O
at,O
doses,O
up,O
to,O
320/25,O
mg,O
versus,O
monotherapy,O
:,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
study,O
followed,O
by,O
long,O
-,O
term,O
combination,O
therapy,O
in,O
hypertensive,I-Entity
adults,O
.,O
One,O
third,O
of,O
patients,O
treated,O
for,O
hypertension,I-Entity
attain,O
adequate,O
blood,O
pressure,O
(,O
BP,O
),O
control,O
",",O
and,O
multidrug,O
regimens,O
are,O
often,O
required,O
.,O
Given,O
the,O
lifelong,O
nature,O
of,O
hypertension,I-Entity
",",O
there,O
is,O
a,O
need,O
to,O
evaluate,O
the,O
long,O
-,O
term,O
efficacy,O
and,O
tolerability,O
of,O
higher,O
doses,O
of,O
combination,O
anti,O
-,O
hypertensive,I-Entity
therapies,O
.,O
This,O
study,O
investigated,O
the,O
efficacy,O
and,O
tolerability,O
of,O
valsartan,I-Entity
(,O
VAL,I-Entity
),O
or,O
hydrochlorothiazide,I-Entity
(,O
HCTZ)-monotherapy,I-Entity
and,O
higher,O
-,O
dose,O
combinations,O
in,O
patients,O
with,O
essential,B-Entity
hypertension,I-Entity
.,O
Patients,O
with,O
essential,B-Entity
hypertension,I-Entity
(,O
mean,O
sitting,O
diastolic,O
BP,O
[,O
MSDBP,O
],O
",",O
>,O
or,O
=,O
95,O
mm,O
Hg,O
and,O
<,O
110,O
mm,O
Hg,O
),O
were,O
randomized,O
to,O
1,O
of,O
8,O
treatment,O
groups,O
:,O
VAL,I-Entity
160,O
or,O
320,O
mg,O
;,O
HCTZ,I-Entity
12.5,O
or,O
25,O
mg,O
;,O
VAL,I-Entity
/,O
HCTZ,I-Entity
160/12.5,O
",",O
320/12.5,O
",",O
or,O
320/25,O
mg,O
;,O
or,O
placebo,O
.,O
VAL,I-Entity
/,O
HCTZ,I-Entity
320/12.5,O
and,O
320/25,O
mg,O
were,O
further,O
investigated,O
in,O
a,O
54-week,O
",",O
open,O
-,O
label,O
extension,O
.,O
All,O
active,O
treatments,O
were,O
associated,O
with,O
significantly,O
reduced,O
MSSBP,O
and,O
MSDBP,O
during,O
the,O
core,O
8-week,O
study,O
",",O
with,O
each,O
monotherapy,O
significantly,O
contributing,O
to,O
the,O
overall,O
effect,O
of,O
combination,O
therapy,O
(,O
VAL,I-Entity
and,O
HCTZ,I-Entity
",",O
P,O
The,O
mean,O
reduction,O
in,O
MSSBP,O
/,O
MSDBP,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
320/25,O
mg,O
was,O
24.7/16.6,O
mm,O
Hg,O
",",O
compared,O
with,O
5.9/7.0,O
mm,O
Hg,O
with,O
placebo,O
.,O
The,O
reduction,O
in,O
MSSBP,O
was,O
significantly,O
greater,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
320/25,O
mg,O
compared,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
160/12.5,O
mg,O
(,O
P,O
<,O
0.002,O
),O
.,O
The,O
incidence,O
of,O
hypokalemia,I-Entity
was,O
lower,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
combinations,O
(,O
1.8%-6.1%,O
),O
than,O
with,O
HCTZ,I-Entity
monotherapies,O
(,O
7.1%-13.3%,O
),O
.,O
The,O
efficacy,O
and,O
tolerability,O
of,O
VAL,I-Entity
/,O
HCTZ,I-Entity
combinations,O
were,O
maintained,O
during,O
the,O
extension,O
(,O
797,O
patients,O
),O
.,O
In,O
this,O
study,O
population,O
",",O
combination,O
therapies,O
with,O
VAL,I-Entity
/,O
HCTZ,I-Entity
were,O
associated,O
with,O
significantly,O
greater,O
BP,O
reductions,O
compared,O
with,O
either,O
monotherapy,O
",",O
were,O
well,O
tolerated,O
",",O
and,O
were,O
associated,O
with,O
less,O
hypokalemia,I-Entity
than,O
HCTZ,I-Entity
alone,O
.,O
Succimer,I-Entity
chelation,O
improves,O
learning,O
",",O
attention,O
",",O
and,O
arousal,O
regulation,O
in,O
lead,I-Entity
-,O
exposed,O
rats,O
but,O
produces,O
lasting,O
cognitive,B-Entity
impairment,I-Entity
in,O
the,O
absence,O
of,O
lead,I-Entity
exposure,O
.,O
BACKGROUND,O
:,O
There,O
is,O
growing,O
pressure,O
for,O
clinicians,O
to,O
prescribe,O
chelation,O
therapy,O
at,O
only,O
slightly,O
elevated,O
blood,O
lead,I-Entity
levels,O
.,O
However,O
",",O
very,O
few,O
studies,O
have,O
evaluated,O
whether,O
chelation,O
improves,O
cognitive,O
outcomes,O
in,O
Pb,I-Entity
-,O
exposed,O
children,O
",",O
or,O
whether,O
these,O
agents,O
have,O
adverse,O
effects,O
that,O
may,O
affect,O
brain,O
development,O
in,O
the,O
absence,O
of,O
Pb,I-Entity
exposure,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
answer,O
these,O
questions,O
",",O
using,O
a,O
rodent,O
model,O
of,O
early,O
childhood,O
Pb,I-Entity
exposure,O
and,O
treatment,O
with,O
succimer,I-Entity
",",O
a,O
widely,O
used,O
chelating,O
agent,O
for,O
the,O
treatment,O
of,O
Pb,B-Entity
poisoning,I-Entity
.,O
Pb,I-Entity
exposure,O
produced,O
lasting,O
impairments,B-Entity
in,I-Entity
learning,I-Entity
",",I-Entity
attention,I-Entity
",",I-Entity
inhibitory,I-Entity
control,I-Entity
",",I-Entity
and,I-Entity
arousal,I-Entity
regulation,I-Entity
",",O
paralleling,O
the,O
areas,O
of,O
dysfunction,O
seen,O
in,O
Pb,I-Entity
-,O
exposed,O
children,O
.,O
Succimer,I-Entity
treatment,O
of,O
the,O
Pb,I-Entity
-,O
exposed,O
rats,O
significantly,O
improved,O
learning,O
",",O
attention,O
",",O
and,O
arousal,O
regulation,O
",",O
although,O
the,O
efficacy,O
of,O
the,O
treatment,O
varied,O
as,O
a,O
function,O
of,O
the,O
Pb,I-Entity
exposure,O
level,O
and,O
the,O
specific,O
functional,O
deficit,O
.,O
In,O
contrast,O
",",O
succimer,I-Entity
treatment,O
of,O
rats,O
not,O
previously,O
exposed,O
to,O
Pb,I-Entity
produced,O
lasting,O
and,O
pervasive,O
cognitive,B-Entity
and,I-Entity
affective,I-Entity
dysfunction,I-Entity
comparable,O
in,O
magnitude,O
to,O
that,O
produced,O
by,O
the,O
higher,O
Pb,I-Entity
exposure,O
regimen,O
.,O
These,O
are,O
the,O
first,O
data,O
",",O
to,O
our,O
knowledge,O
",",O
to,O
show,O
that,O
treatment,O
with,O
any,O
chelating,O
agent,O
can,O
alleviate,O
cognitive,B-Entity
deficits,I-Entity
due,O
to,O
Pb,I-Entity
exposure,O
.,O
These,O
findings,O
suggest,O
that,O
it,O
may,O
be,O
possible,O
to,O
identify,O
a,O
succimer,I-Entity
treatment,O
protocol,O
that,O
improves,O
cognitive,O
outcomes,O
in,O
Pb,I-Entity
-,O
exposed,O
children,O
.,O
However,O
",",O
they,O
also,O
suggest,O
that,O
succimer,I-Entity
treatment,O
should,O
be,O
strongly,O
discouraged,O
for,O
children,O
who,O
do,O
not,O
have,O
elevated,O
tissue,O
levels,O
of,O
Pb,I-Entity
or,O
other,O
heavy,O
metals,O
.,O
Caffeine,I-Entity
challenge,O
test,O
in,O
panic,B-Entity
disorder,I-Entity
and,O
depression,I-Entity
with,O
panic,B-Entity
attacks,I-Entity
.,O
Our,O
aim,O
was,O
to,O
observe,O
if,O
patients,O
with,O
panic,B-Entity
disorder,I-Entity
(,O
PD,I-Entity
),O
and,O
patients,O
with,O
major,B-Entity
depression,I-Entity
with,O
panic,B-Entity
attacks,I-Entity
(,O
MDP,I-Entity
),O
(,O
Diagnostic,O
and,O
Statistical,O
Manual,O
of,O
Mental,B-Entity
Disorders,I-Entity
",",O
Fourth,O
Edition,O
criteria,O
),O
respond,O
in,O
a,O
similar,O
way,O
to,O
the,O
induction,O
of,O
panic,B-Entity
attacks,I-Entity
by,O
an,O
oral,O
caffeine,I-Entity
challenge,O
test,O
.,O
We,O
randomly,O
selected,O
29,O
patients,O
with,O
PD,I-Entity
",",O
27,O
with,O
MDP,I-Entity
",",O
25,O
with,O
major,B-Entity
depression,I-Entity
without,O
panic,B-Entity
attacks,I-Entity
(,O
MD,I-Entity
),O
",",O
and,O
28,O
healthy,O
volunteers,O
.,O
In,O
a,O
randomized,O
double,O
-,O
blind,O
experiment,O
performed,O
in,O
2,O
occasions,O
7,O
days,O
apart,O
",",O
480,O
mg,O
caffeine,I-Entity
and,O
a,O
caffeine,I-Entity
-,O
free,O
(,O
placebo,O
),O
solution,O
were,O
administered,O
in,O
a,O
coffee,O
form,O
and,O
anxiety,I-Entity
scales,O
were,O
applied,O
before,O
and,O
after,O
each,O
test,O
.,O
A,O
total,O
of,O
58.6%,O
(,O
n,O
=,O
17,O
),O
of,O
patients,O
with,O
PD,I-Entity
",",O
44.4%,O
(,O
n,O
=,O
12,O
),O
of,O
patients,O
with,O
MDP,I-Entity
",",O
12.0%,O
(,O
n,O
=,O
3,O
),O
of,O
patients,O
with,O
MD,I-Entity
",",O
and,O
7.1%,O
(,O
n=,O
2,O
),O
of,O
control,O
subjects,O
had,O
a,O
panic,B-Entity
attack,I-Entity
after,O
the,O
480-mg,O
caffeine,I-Entity
challenge,O
test,O
(,O
chi(2)(3,O
),O
=,O
16.22,O
",",O
P,O
=,O
.001,O
),O
.,O
The,O
patients,O
with,O
PD,I-Entity
and,O
MDP,I-Entity
were,O
more,O
sensitive,O
to,O
caffeine,I-Entity
than,O
were,O
patients,O
with,O
MD,I-Entity
and,O
healthy,O
volunteers,O
.,O
No,O
panic,B-Entity
attack,I-Entity
was,O
observed,O
after,O
the,O
caffeine,I-Entity
-,O
free,O
solution,O
intake,O
.,O
The,O
patients,O
with,O
MD,I-Entity
had,O
a,O
lower,O
heart,O
rate,O
response,O
to,O
the,O
test,O
than,O
all,O
the,O
other,O
groups,O
(,O
2-way,O
analysis,O
of,O
variance,O
",",O
group,O
by,O
time,O
interaction,O
with,O
Greenhouse,O
-,O
Geisser,O
correction,O
:,O
"F(3,762",O
),O
=,O
2.85,O
",",O
P,O
=,O
.026,O
),O
.,O
Our,O
data,O
suggest,O
that,O
there,O
is,O
an,O
association,O
between,O
panic,B-Entity
attacks,I-Entity
",",O
no,O
matter,O
if,O
associated,O
with,O
PD,I-Entity
or,O
MDP,I-Entity
",",O
and,O
hyperreactivity,O
to,O
an,O
oral,O
caffeine,I-Entity
challenge,O
test,O
.,O
Mitral,O
annuloplasty,O
as,O
a,O
ventricular,O
restoration,O
method,O
for,O
the,O
failing,B-Entity
left,I-Entity
ventricle,I-Entity
:,O
a,O
pilot,O
study,O
.,O
Undersized,O
mitral,O
annuloplasty,O
(,O
MAP,O
),O
is,O
effective,O
in,O
patients,O
with,O
dilated,B-Entity
cardiomyopathy,I-Entity
and,O
functional,O
mitral,B-Entity
regurgitation,I-Entity
(,O
MR,I-Entity
),O
since,O
",",O
as,O
well,O
as,O
addressing,O
the,O
MR,I-Entity
",",O
the,O
MAP,O
may,O
also,O
reshape,O
the,O
dilated,O
left,O
ventricular,O
(,O
LV,O
),O
base,O
.,O
However,O
",",O
the,O
direct,O
benefits,O
of,O
this,O
possible,O
reshaping,O
on,O
LV,O
function,O
in,O
the,O
absence,O
of,O
underlying,O
MR,I-Entity
remain,O
incompletely,O
understood,O
.,O
The,O
study,O
aim,O
was,O
to,O
identify,O
these,O
benefits,O
in,O
a,O
canine,O
model,O
of,O
acute,O
heart,B-Entity
failure,I-Entity
.,O
Acute,O
heart,B-Entity
failure,I-Entity
was,O
induced,O
by,O
propranolol,I-Entity
and,O
volume,O
loading,O
after,O
weaning,O
from,O
cardiopulmonary,O
bypass,O
;,O
an,O
absence,O
of,O
MR,I-Entity
was,O
confirmed,O
by,O
echocardiography,O
.,O
Data,O
were,O
acquired,O
at,O
baseline,O
",",O
after,O
induction,O
of,O
acute,O
heart,B-Entity
failure,I-Entity
",",O
and,O
after,O
MAP,O
.,O
:,O
The,O
data,O
acquired,O
suggest,O
that,O
isolated,O
MAP,O
may,O
have,O
certain,O
benefits,O
on,O
LV,O
dimension,O
/,O
function,O
in,O
acute,O
heart,B-Entity
failure,I-Entity
",",O
even,O
in,O
the,O
absence,O
of,O
MR,I-Entity
.,O
However,O
",",O
further,O
investigations,O
are,O
warranted,O
in,O
a,O
model,O
of,O
chronic,O
heart,B-Entity
failure,I-Entity
.,O
Piperacillin,B-Entity
/,I-Entity
tazobactam,I-Entity
-,O
induced,O
seizure,I-Entity
rapidly,O
reversed,O
by,O
high,O
flux,O
hemodialysis,O
in,O
a,O
patient,O
on,O
peritoneal,O
dialysis,O
.,O
Despite,O
popular,O
use,O
of,O
piperacillin,I-Entity
",",O
the,O
dire,O
neurotoxicity,I-Entity
associated,O
with,O
piperacillin,I-Entity
still,O
goes,O
unrecognized,O
",",O
leading,O
to,O
a,O
delay,O
in,O
appropriate,O
management,O
.,O
We,O
report,O
a,O
57-year,O
-,O
old,O
woman,O
with,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
receiving,O
continuous,O
ambulatory,O
peritoneal,O
dialysis,O
(,O
CAPD,O
),O
",",O
who,O
developed,O
slurred,O
speech,O
",",O
tremor,I-Entity
",",O
bizarre,O
behavior,O
",",O
progressive,O
mental,O
confusion,I-Entity
",",O
and,O
2,O
episodes,O
of,O
generalized,O
tonic,B-Entity
-,I-Entity
clonic,I-Entity
seizure,I-Entity
(,O
GTCS,I-Entity
),O
after,O
5,O
doses,O
of,O
piperacillin,B-Entity
/,I-Entity
tazobactam,I-Entity
(,O
2,O
g/250,O
mg,O
),O
were,O
given,O
for,O
bronchiectasis,I-Entity
with,O
secondary,B-Entity
infection,I-Entity
.,O
The,O
laboratory,O
data,O
revealed,O
normal,O
plasma,O
electrolyte,O
and,O
ammonia,I-Entity
levels,O
but,O
leukocytosis,I-Entity
.,O
Neurologic,O
examinations,O
showed,O
dysarthria,I-Entity
and,O
bilateral,O
Babinski,O
sign,O
.,O
Despite,O
the,O
use,O
of,O
antiepileptic,O
agents,O
",",O
another,O
GTCS,I-Entity
episode,O
recurred,O
after,O
the,O
sixth,O
dose,O
of,O
piperacillin,B-Entity
/,I-Entity
tazobactam,I-Entity
.,O
Brain,O
magnetic,O
resonance,O
imaging,O
did,O
not,O
demonstrate,O
acute,O
infarction,I-Entity
and,O
organic,B-Entity
brain,I-Entity
lesions,I-Entity
.,O
Piperacillin,I-Entity
-,O
induced,O
encephalopathy,I-Entity
should,O
be,O
considered,O
in,O
any,O
uremic,I-Entity
patients,O
with,O
unexplained,O
neurological,O
manifestations,O
.,O
CAPD,O
is,O
inefficient,O
in,O
removing,O
piperacillin,I-Entity
",",O
whereas,O
hemodialysis,O
can,O
rapidly,O
terminate,O
the,O
piperacillin,I-Entity
-,O
induced,O
encephalopathy,I-Entity
.,O
Frequency,O
of,O
transient,O
ipsilateral,O
vocal,B-Entity
cord,I-Entity
paralysis,I-Entity
in,O
patients,O
undergoing,O
carotid,O
endarterectomy,O
under,O
local,O
anesthesia,O
.,O
Temporary,O
ipsilateral,O
vocal,B-Entity
nerve,I-Entity
palsies,I-Entity
due,O
to,O
local,O
anesthetics,O
have,O
been,O
described,O
",",O
however,O
.,O
Such,O
complications,O
are,O
most,O
important,O
in,O
situations,O
where,O
there,O
is,O
a,O
pre,O
-,O
existing,O
contralateral,O
paralysis,I-Entity
.,O
Anesthesia,O
was,O
performed,O
by,O
injecting,O
20,O
to,O
40,O
mL,O
of,O
a,O
mixture,O
of,O
long,O
-,O
acting,O
(,O
ropivacaine,I-Entity
),O
and,O
short,O
-,O
acting,O
(,O
prilocaine,I-Entity
),O
anesthetic,O
.,O
Twelve,O
patients,O
(,O
43%,O
),O
were,O
found,O
to,O
have,O
intraoperative,O
ipsilateral,O
vocal,B-Entity
cord,I-Entity
paralysis,I-Entity
.,O
There,O
were,O
no,O
significant,O
differences,O
in,O
operating,O
time,O
or,O
volume,O
or,O
frequency,O
of,O
anesthetic,O
administration,O
in,O
patients,O
with,O
temporary,O
vocal,B-Entity
cord,I-Entity
paralysis,I-Entity
compared,O
with,O
those,O
without,O
.,O
CONCLUSION,O
:,O
Local,O
anesthesia,O
led,O
to,O
temporary,O
ipsilateral,O
vocal,B-Entity
cord,I-Entity
paralysis,I-Entity
in,O
almost,O
half,O
of,O
these,O
patients,O
.,O
Because,O
pre,O
-,O
existing,O
paralysis,I-Entity
is,O
of,O
a,O
relevant,O
frequency,O
(,O
up,O
to,O
3%,O
),O
",",O
a,O
preoperative,O
evaluation,O
of,O
vocal,O
cord,O
function,O
before,O
carotid,O
endarterectomy,O
under,O
local,O
anesthesia,O
is,O
recommended,O
to,O
avoid,O
intraoperative,O
bilateral,O
paralysis,I-Entity
.,O
In,O
patients,O
with,O
preoperative,O
contralateral,O
vocal,B-Entity
cord,I-Entity
paralysis,I-Entity
",",O
surgery,O
under,O
general,O
anesthesia,O
should,O
be,O
considered,O
.,O
Neuroprotective,O
effects,O
of,O
melatonin,I-Entity
upon,O
the,O
offspring,O
cerebellar,O
cortex,O
in,O
the,O
rat,O
model,O
of,O
BCNU,I-Entity
-,O
induced,O
cortical,B-Entity
dysplasia,I-Entity
.,O
Cortical,B-Entity
dysplasia,I-Entity
is,O
a,O
malformation,O
characterized,O
by,O
defects,O
in,O
proliferation,O
",",O
migration,O
and,O
maturation,O
.,O
This,O
study,O
was,O
designed,O
to,O
evaluate,O
the,O
alterations,O
in,O
offspring,O
rat,O
cerebellum,O
induced,O
by,O
maternal,O
exposure,O
to,O
"carmustine-[1,3-bis",B-Entity
(,I-Entity
2-chloroethyl)-1-nitrosoure,I-Entity
],O
(,O
BCNU,I-Entity
),O
and,O
to,O
investigate,O
the,O
effects,O
of,O
exogenous,O
melatonin,I-Entity
upon,O
cerebellar,O
BCNU,I-Entity
-,O
induced,O
cortical,B-Entity
dysplasia,I-Entity
",",O
using,O
histological,O
and,O
biochemical,O
analyses,O
.,O
Pregnant,O
Wistar,O
rats,O
were,O
assigned,O
to,O
five,O
groups,O
:,O
intact,O
-,O
control,O
",",O
saline,O
-,O
control,O
",",O
melatonin,I-Entity
-,O
treated,O
",",O
BCNU,I-Entity
-,O
exposed,O
and,O
BCNU,I-Entity
-,O
exposed,O
plus,O
melatonin,I-Entity
.,O
Rats,O
were,O
exposed,O
to,O
BCNU,I-Entity
on,O
embryonic,O
day,O
15,O
and,O
melatonin,I-Entity
was,O
given,O
until,O
delivery,O
.,O
Immuno,O
/,O
histochemistry,O
and,O
electron,O
microscopy,O
were,O
carried,O
out,O
on,O
the,O
offspring,O
cerebellum,O
",",O
and,O
levels,O
of,O
malondialdehyde,I-Entity
and,O
superoxide,I-Entity
dismutase,O
were,O
determined,O
.,O
Histopathologically,O
",",O
typical,O
findings,O
were,O
observed,O
in,O
the,O
cerebella,O
from,O
the,O
control,O
groups,O
",",O
but,O
the,O
findings,O
consistent,O
with,O
early,O
embryonic,O
development,O
were,O
noted,O
in,O
BCNU,I-Entity
-,O
exposed,O
cortical,B-Entity
dysplasia,I-Entity
group,O
.,O
There,O
was,O
a,O
marked,O
increase,O
in,O
the,O
number,O
of,O
TUNEL,O
positive,O
cells,O
and,O
nestin,O
positive,O
cells,O
in,O
BCNU,I-Entity
-,O
exposed,O
group,O
",",O
but,O
a,O
decreased,O
immunoreactivity,O
to,O
glial,O
fibrillary,O
acidic,O
protein,O
",",O
synaptophysin,O
and,O
transforming,O
growth,O
factor,O
beta1,O
was,O
observed,O
",",O
indicating,O
a,O
delayed,O
maturation,O
",",O
and,O
melatonin,I-Entity
significantly,O
reversed,O
these,O
changes,O
.,O
Malondialdehyde,I-Entity
level,O
in,O
BCNU,I-Entity
-,O
exposed,O
group,O
was,O
higher,O
than,O
those,O
in,O
control,O
groups,O
and,O
melatonin,I-Entity
decreased,O
malondialdehyde,I-Entity
levels,O
in,O
BCNU,I-Entity
group,O
(,O
P<0.01,O
),O
",",O
while,O
there,O
were,O
no,O
significant,O
differences,O
in,O
the,O
superoxide,I-Entity
dismutase,O
levels,O
between,O
these,O
groups,O
.,O
These,O
data,O
suggest,O
that,O
exposure,O
of,O
animals,O
to,O
BCNU,I-Entity
during,O
pregnancy,O
leads,O
to,O
delayed,O
maturation,O
of,O
offspring,O
cerebellum,O
and,O
melatonin,I-Entity
protects,O
the,O
cerebellum,O
against,O
the,O
effects,O
of,O
BCNU,I-Entity
.,O
Myo,B-Entity
-,I-Entity
inositol-1-phosphate,I-Entity
(,O
MIP,I-Entity
),O
Lithium,I-Entity
and,O
valproate,I-Entity
are,O
the,O
prototypic,O
mood,O
stabilizers,O
and,O
have,O
diverse,O
structures,O
and,O
targets,O
.,O
Both,O
drugs,O
influence,O
inositol,I-Entity
metabolism,O
.,O
Lithium,I-Entity
inhibits,O
IMPase,O
and,O
valproate,I-Entity
inhibits,O
MIP,I-Entity
synthase,O
.,O
This,O
study,O
shows,O
that,O
MIP,I-Entity
synthase,O
inhibition,O
does,O
not,O
replicate,O
or,O
augment,O
the,O
effects,O
of,O
lithium,I-Entity
in,O
the,O
inositol,I-Entity
sensitive,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
model,O
.,O
This,O
lack,O
of,O
effects,O
may,O
stem,O
from,O
the,O
low,O
contribution,O
of,O
de,O
-,O
novo,O
synthesis,O
to,O
cellular,O
inositol,I-Entity
supply,O
or,O
to,O
the,O
inhibition,O
of,O
the,O
de,O
-,O
novo,O
synthesis,O
by,O
lithium,I-Entity
itself,O
.,O
Non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
-,O
associated,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
with,O
granular,O
tubular,O
basement,O
membrane,O
deposits,O
.,O
Acute,B-Entity
tubulo,I-Entity
-,I-Entity
interstitial,I-Entity
nephritis,I-Entity
(,O
ATIN,I-Entity
),O
is,O
an,O
important,O
cause,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
resulting,O
from,O
a,O
variety,O
of,O
insults,O
",",O
including,O
immune,O
complex,O
-,O
mediated,O
tubulo,B-Entity
-,I-Entity
interstitial,I-Entity
injury,I-Entity
",",O
but,O
drugs,O
such,O
as,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,O
),O
are,O
a,O
far,O
more,O
frequent,O
cause,O
.,O
Overall,O
",",O
as,O
an,O
entity,O
",",O
ATIN,I-Entity
remains,O
under,O
-,O
diagnosed,O
",",O
as,O
symptoms,O
resolve,O
spontaneously,O
if,O
the,O
medication,O
is,O
stopped,O
.,O
We,O
report,O
on,O
a,O
14-year,O
-,O
old,O
boy,O
who,O
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
2,O
weeks,O
after,O
aortic,O
valve,O
surgery,O
.,O
He,O
was,O
put,O
on,O
aspirin,I-Entity
following,O
surgery,O
and,O
took,O
ibuprofen,I-Entity
for,O
fever,I-Entity
for,O
nearly,O
a,O
week,O
prior,O
to,O
presentation,O
.,O
He,O
then,O
presented,O
to,O
the,O
emergency,O
department,O
feeling,O
quite,O
ill,O
and,O
was,O
found,O
to,O
have,O
a,O
blood,B-Entity
urea,I-Entity
nitrogen,I-Entity
(,O
BUN,I-Entity
),O
concentration,O
of,O
of,O
147,O
mg,O
/,O
dl,O
",",O
creatinine,I-Entity
of,O
15.3,O
mg,O
/,O
dl,O
and,O
serum,O
potassium,I-Entity
of,O
8.7,O
mEq,O
/,O
l,O
.,O
A,O
kidney,O
biopsy,O
showed,O
inflammatory,O
infiltrate,O
consistent,O
with,O
ATIN,I-Entity
.,O
He,O
needed,O
dialysis,O
for,O
2,O
weeks,O
and,O
was,O
treated,O
successfully,O
with,O
steroids,I-Entity
for,O
6,O
months,O
.,O
His,O
renal,O
recovery,O
and,O
disappearance,O
of,O
proteinuria,I-Entity
took,O
a,O
year,O
.,O
In,O
conclusion,O
",",O
this,O
is,O
a,O
first,O
report,O
of,O
NSAIDs,O
-,O
associated,O
ATIN,I-Entity
",",O
showing,O
deposits,O
of,O
granular,O
immune,O
complex,O
present,O
only,O
in,O
the,O
TBM,O
and,O
not,O
in,O
the,O
glomeruli,O
.,O
Rifampicin,I-Entity
-,O
associated,O
segmental,O
necrotizing,O
glomerulonephritis,I-Entity
in,O
staphylococcal,B-Entity
endocarditis,I-Entity
.,O
necrotising,O
glomerulonephritis,I-Entity
has,O
been,O
reported,O
as,O
complication,O
of,O
rifampicin,I-Entity
therapy,O
in,O
patients,O
receiving,O
treatment,O
for,O
tuberculosis,I-Entity
.,O
Changing,O
epidemiology,O
of,O
infections,I-Entity
such,O
as,O
infective,B-Entity
endocarditis,I-Entity
(,O
IE,I-Entity
),O
has,O
led,O
to,O
an,O
increase,O
in,O
the,O
use,O
of,O
rifampicin,I-Entity
for,O
Staphylococcal,B-Entity
infections,I-Entity
.,O
We,O
describe,O
a,O
case,O
of,O
a,O
patient,O
with,O
Staphylococcal,B-Entity
IE,I-Entity
who,O
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
secondary,O
to,O
a,O
segmental,O
necrotising,O
glomerulonephritis,I-Entity
while,O
being,O
treated,O
with,O
rifampicin,I-Entity
",",O
and,O
review,O
the,O
literature,O
regarding,O
this,O
complication,O
of,O
rifampicin,I-Entity
therapy,O
.,O
Rate,O
of,O
YMDD,O
motif,O
mutants,O
in,O
lamivudine,I-Entity
-,O
untreated,O
Iranian,O
patients,O
with,O
chronic,B-Entity
hepatitis,I-Entity
B,I-Entity
virus,I-Entity
infection,I-Entity
.,O
Lamivudine,I-Entity
is,O
used,O
for,O
the,O
treatment,O
of,O
chronic,B-Entity
hepatitis,I-Entity
B,I-Entity
patients,O
.,O
Recent,O
studies,O
show,O
that,O
the,O
YMDD,O
motif,O
mutants,O
(,O
resistant,O
hepatitis,B-Entity
B,I-Entity
virus,O
),O
occur,O
as,O
natural,O
genome,O
variability,O
in,O
lamivudine,I-Entity
-,O
untreated,O
chronic,B-Entity
hepatitis,I-Entity
B,I-Entity
patients,O
.,O
In,O
this,O
study,O
we,O
aimed,O
to,O
determine,O
the,O
rate,O
of,O
YMDD,O
motif,O
mutants,O
in,O
lamivudine,I-Entity
-,O
untreated,O
chronic,B-Entity
hepatitis,I-Entity
B,I-Entity
patients,O
in,O
Iran,O
.,O
A,O
total,O
of,O
77,O
chronic,B-Entity
hepatitis,I-Entity
B,I-Entity
patients,O
who,O
had,O
not,O
been,O
treated,O
with,O
lamivudine,I-Entity
were,O
included,O
in,O
the,O
study,O
.,O
All,O
patients,O
were,O
also,O
tested,O
for,O
liver,O
enzymes,O
",",O
anti,O
-,O
HCV,O
",",O
HBeAg,I-Entity
",",O
and,O
anti,O
-,O
HBe,O
.,O
HBeAg,I-Entity
was,O
positive,O
in,O
40%,O
and,O
anti,O
-,O
HBe,O
in,O
60%,O
of,O
the,O
patients,O
.,O
YMDD,O
motif,O
mutants,O
were,O
not,O
detected,O
in,O
any,O
of,O
the,O
patients,O
despite,O
the,O
liver,O
enzyme,O
levels,O
and,O
the,O
presence,O
of,O
HBeAg,I-Entity
or,O
anti,O
-,O
HBe,O
.,O
CONCLUSION,O
:,O
Although,O
the,O
natural,O
occurrence,O
of,O
YMDD,O
motif,O
mutants,O
in,O
lamivudine,I-Entity
-,O
untreated,O
patients,O
with,O
chronic,B-Entity
hepatitis,I-Entity
B,I-Entity
has,O
been,O
reported,O
",",O
these,O
mutants,O
were,O
not,O
detected,O
in,O
Iranian,O
lamivudine,I-Entity
-,O
untreated,O
chronic,B-Entity
hepatitis,I-Entity
B,I-Entity
patients,O
.,O
Branch,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
and,O
fluoxetine,I-Entity
.,O
A,O
case,O
of,O
branch,O
retinal,B-Entity
vein,I-Entity
occlusion,I-Entity
associated,O
with,O
fluoxetine,I-Entity
-,O
induced,O
secondary,O
hypertension,I-Entity
is,O
described,O
.,O
Although,O
an,O
infrequent,O
complication,O
of,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitor,O
therapy,O
",",O
it,O
is,O
important,O
that,O
ophthalmologists,O
are,O
aware,O
that,O
these,O
agents,O
can,O
cause,O
hypertension,I-Entity
because,O
this,O
class,O
of,O
drugs,O
is,O
widely,O
prescribed,O
.,O
The,O
differential,O
effects,O
of,O
bupivacaine,I-Entity
and,O
lidocaine,I-Entity
on,O
prostaglandin,B-Entity
E2,I-Entity
release,O
",",O
cyclooxygenase,O
gene,O
expression,O
and,O
pain,I-Entity
in,O
a,O
clinical,O
pain,I-Entity
model,O
.,O
In,O
addition,O
to,O
blocking,O
nociceptive,O
input,O
from,O
surgical,O
sites,O
",",O
long,O
-,O
acting,O
local,O
anesthetics,O
might,O
directly,O
modulate,O
inflammation,I-Entity
.,O
In,O
the,O
present,O
study,O
",",O
we,O
describe,O
the,O
proinflammatory,O
effects,O
of,O
bupivacaine,I-Entity
on,O
local,O
prostaglandin,B-Entity
E2,I-Entity
(,O
PGE2,I-Entity
),O
production,O
and,O
cyclooxygenase,O
(,O
COX,O
),O
gene,O
expression,O
that,O
increases,O
postoperative,B-Entity
pain,I-Entity
in,O
human,O
subjects,O
.,O
METHODS,O
:,O
Subjects,O
(,O
n,O
=,O
114,O
),O
undergoing,O
extraction,O
of,O
impacted,O
third,O
molars,O
received,O
either,O
2%,O
lidocaine,I-Entity
or,O
0.5%,O
bupivacaine,I-Entity
before,O
surgery,O
and,O
either,O
rofecoxib,I-Entity
50,O
mg,O
or,O
placebo,O
orally,O
90,O
min,O
before,O
surgery,O
and,O
for,O
the,O
following,O
48,O
h.,O
Oral,O
mucosal,O
biopsies,O
were,O
taken,O
before,O
surgery,O
and,O
48,O
h,O
after,O
surgery,O
.,O
After,O
extraction,O
",",O
a,O
microdialysis,O
probe,O
was,O
placed,O
at,O
the,O
surgical,O
site,O
for,O
PGE2,I-Entity
and,O
thromboxane,B-Entity
B2,I-Entity
(,O
TXB2,I-Entity
),O
measurements,O
.,O
The,O
bupivacaine,I-Entity
/,O
rofecoxib,I-Entity
group,O
reported,O
significantly,O
less,O
pain,I-Entity
",",O
as,O
assessed,O
by,O
a,O
visual,O
analog,O
scale,O
",",O
compared,O
with,O
the,O
other,O
three,O
treatment,O
groups,O
over,O
the,O
first,O
4,O
h.,O
However,O
",",O
the,O
bupivacaine,I-Entity
/,O
placebo,O
group,O
reported,O
significantly,O
more,O
pain,I-Entity
at,O
24,O
h,O
and,O
PGE2,I-Entity
levels,O
during,O
the,O
first,O
4,O
h,O
were,O
significantly,O
higher,O
than,O
the,O
other,O
three,O
treatment,O
groups,O
.,O
Moreover,O
",",O
bupivacaine,I-Entity
significantly,O
increased,O
COX-2,O
gene,O
expression,O
at,O
48,O
h,O
as,O
compared,O
with,O
the,O
lidocaine,I-Entity
/,O
placebo,O
group,O
.,O
Thromboxane,I-Entity
levels,O
were,O
not,O
significantly,O
affected,O
by,O
any,O
of,O
the,O
treatments,O
",",O
indicating,O
that,O
the,O
effects,O
seen,O
were,O
attributable,O
to,O
inhibition,O
of,O
COX-2,O
",",O
but,O
not,O
COX-1,O
.,O
These,O
results,O
suggest,O
that,O
bupivacaine,I-Entity
stimulates,O
COX-2,O
gene,O
expression,O
after,O
tissue,B-Entity
injury,I-Entity
",",O
which,O
is,O
associated,O
with,O
higher,O
PGE2,I-Entity
production,O
and,O
pain,I-Entity
after,O
the,O
local,O
anesthetic,O
effect,O
dissipates,O
.,O
p75NTR,O
expression,O
in,O
rat,O
urinary,O
bladder,O
sensory,O
neurons,O
and,O
spinal,O
cord,O
with,O
cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
.,O
Previous,O
studies,O
have,O
examined,O
the,O
expression,O
and,O
regulation,O
of,O
tyrosine,I-Entity
kinase,O
receptors,O
(,O
Trks,O
),O
in,O
micturition,O
reflexes,O
with,O
urinary,B-Entity
bladder,I-Entity
inflammation,I-Entity
.,O
The,O
present,O
studies,O
examine,O
the,O
expression,O
and,O
regulation,O
of,O
another,O
receptor,O
known,O
to,O
bind,O
NGF,O
",",O
p75(NTR,O
),O
",",O
after,O
various,O
durations,O
of,O
bladder,B-Entity
inflammation,I-Entity
induced,O
by,O
cyclophosphamide,I-Entity
(,O
CYP,I-Entity
),O
.,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
increased,O
(,O
P,O
<,O
or,O
=,O
0.001,O
),O
The,O
number,O
of,O
p75(NTR)-immunoreactive,O
(,O
-IR,O
),O
cells,O
in,O
the,O
lumbosacral,O
dorsal,O
root,O
ganglia,O
(,O
DRG,O
),O
also,O
increased,O
(,O
P,O
<,O
or,O
=,O
0.05,O
),O
with,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
(,O
acute,O
",",O
intermediate,O
",",O
and,O
chronic,O
),O
.,O
Quantitative,O
",",O
real,O
-,O
time,O
polymerase,O
chain,O
reaction,O
also,O
demonstrated,O
significant,O
increases,O
(,O
P,O
<,O
or,O
=,O
0.01,O
),O
in,O
p75(NTR,O
),O
mRNA,O
in,O
DRG,O
with,O
intermediate,O
and,O
chronic,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
.,O
In,O
bladder,O
afferent,O
cells,O
in,O
DRG,O
",",O
p75(NTR)-IR,O
was,O
also,O
increased,O
(,O
P,O
<,O
or,O
=,O
0.01,O
),O
with,O
cystitis,I-Entity
.,O
These,O
studies,O
demonstrate,O
that,O
p75(NTR,O
),O
expression,O
in,O
micturition,O
reflexes,O
is,O
present,O
constitutively,O
and,O
modified,O
by,O
bladder,B-Entity
inflammation,I-Entity
.,O
Azathioprine,I-Entity
-,O
induced,O
suicidal,O
erythrocyte,O
death,O
.,O
Azathioprine,I-Entity
is,O
widely,O
used,O
as,O
an,O
immunosuppressive,O
drug,O
.,O
The,O
side,O
effects,O
of,O
azathioprine,I-Entity
include,O
anemia,I-Entity
",",O
which,O
has,O
been,O
attributed,O
to,O
bone,O
marrow,O
suppression,O
.,O
Alternatively,O
",",O
anemia,I-Entity
could,O
result,O
from,O
accelerated,O
suicidal,O
erythrocyte,O
death,O
or,O
eryptosis,O
",",O
which,O
is,O
characterized,O
by,O
exposure,O
of,O
phosphatidylserine,I-Entity
(,O
PS,I-Entity
),O
at,O
the,O
erythrocyte,O
surface,O
and,O
by,O
cell,O
shrinkage,O
.,O
METHODS,O
:,O
The,O
present,O
experiments,O
explored,O
whether,O
azathioprine,I-Entity
influences,O
eryptosis,O
.,O
According,O
to,O
annexin,O
V,O
binding,O
",",O
erythrocytes,O
from,O
patients,O
indeed,O
showed,O
a,O
significant,O
increase,O
of,O
PS,I-Entity
exposure,O
within,O
1,O
week,O
of,O
treatment,O
with,O
azathioprine,I-Entity
.,O
In,O
a,O
second,O
series,O
",",O
cytosolic,O
Ca2,I-Entity
+,O
activity,O
(,O
Fluo3,I-Entity
fluorescence,O
),O
",",O
cell,O
volume,O
(,O
forward,O
scatter,O
),O
",",O
and,O
PS,I-Entity
-,O
exposure,O
(,O
annexin,O
V,O
binding,O
),O
were,O
determined,O
by,O
FACS,O
analysis,O
in,O
erythrocytes,O
from,O
healthy,O
volunteers,O
.,O
Exposure,O
to,O
azathioprine,I-Entity
(,O
>,O
or,O
=,O
2,O
microg,O
/,O
mL,O
),O
for,O
48,O
hours,O
increased,O
cytosolic,O
Ca2,I-Entity
+,O
activity,O
and,O
annexin,O
V,O
binding,O
and,O
decreased,O
forward,O
scatter,O
.,O
The,O
effect,O
of,O
azathioprine,I-Entity
on,O
both,O
annexin,O
V,O
binding,O
and,O
forward,O
scatter,O
was,O
significantly,O
blunted,O
in,O
the,O
nominal,O
absence,O
of,O
extracellular,O
Ca2,I-Entity
+,O
.,O
Azathioprine,I-Entity
triggers,O
suicidal,O
erythrocyte,O
death,O
",",O
an,O
effect,O
presumably,O
contributing,O
to,O
azathioprine,I-Entity
-,O
induced,O
anemia,I-Entity
.,O
BACKGROUND,O
:,O
Spinal,O
anaesthesia,O
is,O
widely,O
employed,O
in,O
clinical,O
practice,O
but,O
has,O
the,O
main,O
drawback,O
of,O
post,O
-,O
spinal,O
block,O
hypotension,I-Entity
.,O
In,O
the,O
lateral,O
position,O
with,O
operative,O
side,O
down,O
",",O
patients,O
recived,O
10,O
mg,O
(,O
2mls,O
),O
of,O
0.5%,O
hyperbaric,O
bupivacaine,I-Entity
through,O
a,O
25-gauge,O
spinal,O
needle,O
.,O
Blood,O
pressure,O
",",O
heart,O
rate,O
",",O
respiratory,O
rate,O
and,O
oxygen,I-Entity
saturation,O
were,O
monitored,O
over,O
1,O
hour,O
.,O
RESULTS,O
:,O
Three,O
patients,O
(,O
8.1%,O
),O
in,O
the,O
unilateral,O
group,O
and,O
5,O
(,O
13.5%,O
),O
in,O
the,O
conventional,O
group,O
developed,O
hypotension,I-Entity
",",O
P=,O
0.71,O
.,O
Four,O
(,O
10.8%,O
),O
patients,O
in,O
the,O
conventional,O
group,O
and,O
1,O
(,O
2.7%,O
),O
in,O
the,O
unilateral,O
group,O
",",O
P=,O
0.17,O
required,O
epinephrine,I-Entity
infusion,O
to,O
treat,O
hypotension,I-Entity
.,O
The,O
mean,O
respiratory,O
rate,O
and,O
oxygen,I-Entity
saturations,O
in,O
the,O
two,O
groups,O
were,O
similar,O
.,O
Also,O
",",O
the,O
type,O
of,O
spinal,O
block,O
instituted,O
affected,O
neither,O
the,O
respiratory,O
rate,O
nor,O
the,O
arterial,O
oxygen,I-Entity
saturation,O
.,O
Spectrum,O
of,O
adverse,O
events,O
after,O
generic,O
HAART,O
in,O
southern,O
Indian,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
patients,O
.,O
To,O
determine,O
the,O
incidence,O
of,O
clinically,O
significant,O
adverse,O
events,O
after,O
long,O
-,O
term,O
",",O
fixed,O
-,O
dose,O
",",O
generic,O
highly,O
active,O
antiretroviral,O
therapy,O
(,O
HAART,O
),O
use,O
among,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
individuals,O
in,O
South,O
India,O
",",O
we,O
examined,O
the,O
experiences,O
of,O
3154,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
individuals,O
who,O
received,O
a,O
minimum,O
of,O
3,O
months,O
of,O
generic,O
HAART,O
between,O
February,O
1996,O
and,O
December,O
2006,O
at,O
a,O
tertiary,O
HIV,O
care,O
referral,O
center,O
in,O
South,O
India,O
.,O
The,O
most,O
common,O
regimens,O
were,O
3TC,I-Entity
+,O
d4,B-Entity
T,I-Entity
+,O
nevirapine,I-Entity
(,O
NVP,I-Entity
),O
(,O
54.8%,O
),O
",",O
zidovudine,I-Entity
(,O
AZT,I-Entity
),O
+,O
3TC,I-Entity
+,O
NVP,I-Entity
(,O
14.5%,O
),O
",",O
3TC,I-Entity
+,O
d4,B-Entity
T,I-Entity
+,O
efavirenz,I-Entity
(,O
EFV,I-Entity
),O
(,O
20.1%,O
),O
",",O
and,O
AZT,I-Entity
+,O
3TC,I-Entity
+,O
EFV,I-Entity
(,O
5.4%,O
),O
.,O
The,O
most,O
common,O
adverse,O
events,O
and,O
median,O
CD4,O
at,O
time,O
of,O
event,O
were,O
rash,I-Entity
(,O
15.2%,O
;,O
CD4,O
",",O
285,O
cells,O
/,O
microL,O
),O
and,O
peripheral,B-Entity
neuropathy,I-Entity
(,O
9.0%,O
and,O
348,O
cells,O
/,O
microL,O
),O
.,O
Clinically,O
significant,O
anemia,I-Entity
(,O
hemoglobin,O
<,O
7,O
g,O
/,O
dL,O
),O
was,O
observed,O
in,O
5.4%,O
of,O
patients,O
(,O
CD4,O
",",O
165,O
cells,O
/,O
microL,O
),O
and,O
hepatitis,I-Entity
(,O
clinical,O
jaundice,I-Entity
with,O
alanine,I-Entity
aminotransferase,O
>,O
5,O
times,O
upper,O
limits,O
of,O
normal,O
),O
in,O
3.5%,O
of,O
patients,O
(,O
CD4,O
",",O
260,O
cells,O
/,O
microL,O
),O
.,O
Women,O
were,O
significantly,O
more,O
likely,O
to,O
experience,O
lactic,B-Entity
acidosis,I-Entity
",",O
while,O
men,O
were,O
significantly,O
more,O
likely,O
to,O
experience,O
immune,B-Entity
reconstitution,I-Entity
syndrome,I-Entity
(,O
p,O
<,O
0.05,O
),O
.,O
Among,O
the,O
patients,O
with,O
1,O
year,O
of,O
follow,O
-,O
up,O
",",O
NVP,I-Entity
therapy,O
was,O
significantly,O
associated,O
with,O
developing,O
rash,I-Entity
and,O
d4,B-Entity
T,I-Entity
therapy,O
with,O
developing,O
peripheral,B-Entity
neuropathy,I-Entity
(,O
p,O
<,O
0.05,O
),O
.,O
Anemia,I-Entity
and,O
hepatitis,I-Entity
often,O
occur,O
within,O
12,O
weeks,O
of,O
initiating,O
generic,O
HAART,O
.,O
Frequent,O
and,O
early,O
monitoring,O
for,O
these,O
toxicities,I-Entity
is,O
warranted,O
in,O
developing,O
countries,O
where,O
generic,O
HAART,O
is,O
increasingly,O
available,O
.,O
Thalidomide,I-Entity
and,O
sensory,B-Entity
neurotoxicity,I-Entity
:,O
a,O
neurophysiological,O
study,O
.,O
Recent,O
studies,O
confirmed,O
a,O
high,O
incidence,O
of,O
sensory,B-Entity
axonal,I-Entity
neuropathy,I-Entity
in,O
patients,O
treated,O
with,O
different,O
doses,O
of,O
thalidomide,I-Entity
.,O
The,O
study,O
's,O
aims,O
were,O
to,O
measure,O
variations,O
in,O
sural,O
nerve,O
sensory,O
action,O
potential,O
(,O
SAP,O
),O
amplitude,O
in,O
patients,O
with,O
refractory,O
cutaneous,B-Entity
lupus,I-Entity
erythematosus,I-Entity
(,O
CLE,I-Entity
),O
treated,O
with,O
thalidomide,I-Entity
and,O
use,O
these,O
findings,O
to,O
identify,O
the,O
neurotoxic,I-Entity
potential,O
of,O
thalidomide,I-Entity
and,O
the,O
recovery,O
capacity,O
of,O
sensory,O
fibres,O
after,O
discontinuation,O
of,O
treatment,O
.,O
Clinical,O
and,O
electrophysiological,O
data,O
in,O
12,O
female,O
patients,O
with,O
CLE,I-Entity
during,O
treatment,O
with,O
thalidomide,I-Entity
and,O
up,O
to,O
47,O
months,O
after,O
discontinuation,O
of,O
treatment,O
were,O
analysed,O
.,O
Five,O
patients,O
complained,O
of,O
paresthesias,I-Entity
and,O
leg,O
cramps,I-Entity
.,O
After,O
thalidomide,I-Entity
treatment,O
",",O
sural,O
SAP,O
amplitude,O
recovered,O
in,O
3,O
patients,O
.,O
At,O
detection,O
of,O
reduction,O
in,O
sural,O
nerve,O
SAP,O
amplitude,O
",",O
the,O
median,O
thalidomide,I-Entity
cumulative,O
dose,O
was,O
21.4,O
g.,O
The,O
threshold,O
neurotoxic,I-Entity
dosage,O
is,O
lower,O
than,O
previously,O
reported,O
.,O
This,O
electrophysiological,O
parameter,O
provides,O
information,O
about,O
subclinical,O
neurotoxic,I-Entity
potential,O
of,O
thalidomide,I-Entity
but,O
is,O
not,O
helpful,O
in,O
predicting,O
the,O
appearance,O
of,O
sensory,O
symptoms,O
.,O
Amiodarone,I-Entity
-,O
related,O
pulmonary,B-Entity
mass,I-Entity
and,O
unique,O
membranous,B-Entity
glomerulonephritis,I-Entity
in,O
a,O
patient,O
with,O
valvular,B-Entity
heart,I-Entity
disease,I-Entity
:,O
Diagnostic,O
pitfall,O
and,O
new,O
findings,O
.,O
Amiodarone,I-Entity
is,O
an,O
anti,O
-,O
arrhythmic,I-Entity
drug,O
for,O
life,O
-,O
threatening,O
tachycardia,I-Entity
",",O
but,O
various,O
adverse,O
effects,O
have,O
been,O
reported,O
.,O
Reported,O
herein,O
is,O
an,O
autopsy,O
case,O
of,O
valvular,B-Entity
heart,I-Entity
disease,I-Entity
",",O
in,O
a,O
patient,O
who,O
developed,O
a,O
lung,B-Entity
mass,I-Entity
(,O
1.5,O
cm,O
in,O
diameter,O
),O
and,O
proteinuria,I-Entity
(,O
2.76,O
g,O
/,O
day,O
),O
after,O
treatment,O
with,O
amiodarone,I-Entity
for,O
a,O
long,O
time,O
.,O
The,O
lung,B-Entity
mass,I-Entity
was,O
highly,O
suspected,O
to,O
be,O
lung,B-Entity
cancer,I-Entity
on,O
CT,O
and,O
positron,O
emission,O
tomography,O
",",O
but,O
histologically,O
the,O
lesion,O
was,O
composed,O
of,O
lymphoplasmacytic,O
infiltrates,O
in,O
alveolar,O
walls,O
and,O
intra,O
-,O
alveolar,O
accumulation,O
of,O
foamy,O
macrophages,O
containing,O
characteristic,O
myelinoid,O
bodies,O
",",O
indicating,O
that,O
it,O
was,O
an,O
amiodarone,I-Entity
-,O
related,O
lesion,O
.,O
In,O
addition,O
",",O
the,O
lung,O
tissue,O
had,O
unevenly,O
distributed,O
hemosiderin,I-Entity
deposition,O
",",O
and,O
abnormally,O
tortuous,O
capillaries,O
were,O
seen,O
in,O
the,O
mass,O
and,O
in,O
heavily,O
hemosiderotic,I-Entity
lung,O
portions,O
outside,O
the,O
mass,O
.,O
Autoimmune,B-Entity
diseases,I-Entity
",",O
viral,B-Entity
hepatitis,I-Entity
",",O
malignant,O
neoplasms,I-Entity
or,O
other,O
diseases,O
with,O
a,O
known,O
relationship,O
to,O
membranous,B-Entity
glomerulonephritis,I-Entity
were,O
not,O
found,O
.,O
The,O
present,O
case,O
highlights,O
the,O
possibility,O
that,O
differential,O
diagnosis,O
between,O
an,O
amiodarone,I-Entity
-,O
related,O
pulmonary,B-Entity
lesion,I-Entity
and,O
a,O
neoplasm,I-Entity
can,O
be,O
very,O
difficult,O
radiologically,O
",",O
and,O
suggests,O
that,O
membranous,B-Entity
glomerulonephritis,I-Entity
might,O
be,O
another,O
possible,O
complication,O
of,O
amiodarone,I-Entity
treatment,O
.,O
Risk,O
of,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
associated,O
with,O
initial,O
sulphonylurea,I-Entity
treatment,O
of,O
patients,O
with,O
type,B-Entity
2,I-Entity
diabetes,I-Entity
:,O
a,O
matched,O
case,O
-,O
control,O
study,O
.,O
This,O
study,O
sought,O
to,O
assess,O
the,O
risk,O
of,O
developing,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
(,O
CAD,I-Entity
),O
associated,O
with,O
initial,O
treatment,O
of,O
type,B-Entity
2,I-Entity
diabetes,I-Entity
with,O
different,O
sulphonylureas,I-Entity
.,O
METHODS,O
:,O
In,O
type,B-Entity
2,I-Entity
diabetic,I-Entity
patients,O
",",O
cases,O
who,O
developed,O
CAD,I-Entity
were,O
compared,O
retrospectively,O
with,O
controls,O
that,O
did,O
not,O
.,O
The,O
20-year,O
risk,O
of,O
CAD,I-Entity
at,O
diagnosis,O
of,O
diabetes,I-Entity
",",O
using,O
the,O
UKPDS,O
risk,O
engine,O
",",O
was,O
used,O
to,O
match,O
cases,O
with,O
controls,O
.,O
The,O
76,O
cases,O
of,O
CAD,I-Entity
were,O
compared,O
with,O
152,O
controls,O
.,O
The,O
hazard,O
of,O
developing,O
CAD,I-Entity
(,O
95%,O
CI,O
),O
associated,O
with,O
initial,O
treatment,O
increased,O
by,O
2.4-fold,O
(,O
1.3,O
-,O
4.3,O
",",O
P=0.004,O
),O
with,O
glibenclamide,I-Entity
;,O
2-fold,O
(,O
0.9,O
-,O
4.6,O
",",O
P=0.099,O
),O
with,O
glipizide,I-Entity
;,O
2.9-fold,O
(,O
1.6,O
-,O
5.1,O
",",O
P=0.000,O
),O
with,O
either,O
",",O
and,O
was,O
unchanged,O
with,O
metformin,I-Entity
.,O
The,O
hazard,O
decreased,O
0.3-fold,O
(,O
0.7,O
-,O
1.7,O
",",O
P=0.385,O
),O
with,O
glimepiride,I-Entity
",",O
0.4-fold,O
(,O
0.7,O
-,O
1.3,O
",",O
P=0.192,O
),O
with,O
gliclazide,I-Entity
",",O
and,O
0.4-fold,O
(,O
0.7,O
-,O
1.1,O
",",O
P=0.09,O
),O
with,O
either,O
.,O
CONCLUSIONS,O
:,O
Initiating,O
treatment,O
of,O
type,B-Entity
2,I-Entity
diabetes,I-Entity
with,O
glibenclamide,I-Entity
or,O
glipizide,I-Entity
is,O
associated,O
with,O
increased,O
risk,O
of,O
CAD,I-Entity
in,O
comparison,O
to,O
gliclazide,I-Entity
or,O
glimepiride,I-Entity
.,O
If,O
confirmed,O
",",O
this,O
may,O
be,O
important,O
because,O
most,O
Indian,O
patients,O
receive,O
the,O
cheaper,O
older,O
sulphonylureas,I-Entity
",",O
and,O
present,O
guidelines,O
do,O
not,O
distinguish,O
between,O
individual,O
agents,O
.,O
Reduced,O
progression,O
of,O
adriamycin,I-Entity
nephropathy,I-Entity
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
treated,O
by,O
losartan,I-Entity
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
antihypertensive,O
effects,O
of,O
angiotensin,B-Entity
II,I-Entity
type-1,O
receptor,O
blocker,O
",",O
losartan,I-Entity
",",O
and,O
its,O
potential,O
in,O
slowing,O
down,O
renal,B-Entity
disease,I-Entity
progression,O
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
(,O
SHR,O
),O
with,O
adriamycin,I-Entity
(,O
ADR,I-Entity
),O
nephropathy,I-Entity
.,O
Groups,O
ADR(6,I-Entity
),O
",",O
ADR+LOS(6,I-Entity
),O
and,O
ADR(12,I-Entity
),O
",",O
and,O
ADR+LOS(12,I-Entity
),O
received,O
ADR,I-Entity
(,O
2,O
mg,O
/,O
kg,O
/,O
b.w,O
.,O
Group,O
ADR+LOS(6,I-Entity
),O
received,O
losartan,I-Entity
(,O
10,O
mg,O
/,O
kg,O
/,O
b.w./day,O
by,O
gavages,O
),O
for,O
6,O
weeks,O
and,O
group,O
ADR+LOS(12,I-Entity
),O
for,O
12,O
weeks,O
after,O
second,O
injection,O
of,O
ADR,I-Entity
.,O
Short,O
-,O
term,O
losartan,I-Entity
treatment,O
",",O
besides,O
antihypertensive,O
effect,O
",",O
improved,O
glomerular,O
filtration,O
rate,O
and,O
ameliorated,O
glomerulosclerosis,I-Entity
resulting,O
in,O
decreased,O
proteinuria,I-Entity
.,O
Prolonged,O
treatment,O
with,O
losartan,I-Entity
showed,O
further,O
reduction,O
of,O
glomerulosclerosis,I-Entity
associated,O
with,O
reduced,O
progression,O
of,O
tubular,O
atrophy,I-Entity
and,O
interstitial,B-Entity
fibrosis,I-Entity
",",O
thus,O
preventing,O
heavy,O
proteinuria,I-Entity
and,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
.,O
Losartan,I-Entity
reduced,O
uraemia,I-Entity
and,O
increased,O
urea,I-Entity
clearance,O
in,O
advanced,O
ADR,I-Entity
nephropathy,I-Entity
in,O
SHR,O
.,O
Histological,O
examination,O
showed,O
that,O
losartan,I-Entity
could,O
prevent,O
tubular,O
atrophy,I-Entity
",",O
interstitial,O
infiltration,O
and,O
fibrosis,I-Entity
in,O
ADR,I-Entity
nephropathy,I-Entity
.,O
CONCLUSION,O
:,O
Losartan,I-Entity
reduces,O
the,O
rate,O
of,O
progression,O
of,O
ADR,I-Entity
-,O
induced,O
focal,B-Entity
segmental,I-Entity
glomerulosclerosis,I-Entity
to,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
in,O
SHR,O
.,O
The,O
risks,O
of,O
aprotinin,O
and,O
tranexamic,B-Entity
acid,I-Entity
in,O
cardiac,O
surgery,O
:,O
a,O
one,O
-,O
year,O
follow,O
-,O
up,O
of,O
1188,O
consecutive,O
patients,O
.,O
BACKGROUND,O
:,O
Our,O
aim,O
was,O
to,O
investigate,O
postoperative,O
complications,O
and,O
mortality,O
after,O
administration,O
of,O
aprotinin,O
compared,O
to,O
tranexamic,B-Entity
acid,I-Entity
in,O
an,O
unselected,O
",",O
consecutive,O
cohort,O
.,O
During,O
the,O
first,O
5,O
mo,O
",",O
596,O
patients,O
received,O
aprotinin,O
(,O
Group,O
A,O
),O
;,O
in,O
the,O
next,O
5,O
mo,O
",",O
592,O
patients,O
were,O
treated,O
with,O
tranexamic,B-Entity
acid,I-Entity
(,O
Group,O
T,O
),O
.,O
Postoperatively,O
",",O
a,O
significantly,O
higher,O
incidence,O
of,O
seizures,I-Entity
was,O
found,O
in,O
Group,O
T,O
(,O
4.6%,O
vs,O
1.2%,O
",",O
P,O
Persistent,O
atrial,O
fibrillation,O
(,O
7.9%,O
vs,O
2.3%,O
",",O
P,O
=,O
0.020,O
),O
and,O
renal,B-Entity
failure,I-Entity
(,O
9.7%,O
vs,O
1.7%,O
",",O
P,O
=,O
0.002,O
),O
were,O
also,O
more,O
common,O
in,O
Group,O
T,O
",",O
in,O
the,O
primary,O
valve,O
surgery,O
subgroup,O
.,O
On,O
the,O
contrary,O
",",O
among,O
primary,O
coronary,O
artery,O
bypass,O
surgery,O
patients,O
",",O
there,O
were,O
more,O
acute,O
myocardial,B-Entity
infarctions,I-Entity
and,O
renal,B-Entity
dysfunction,I-Entity
in,O
Group,O
A,O
(,O
5.8%,O
vs,O
2.0%,O
",",O
P,O
=,O
0.027,O
;,O
22.5%,O
vs,O
15.2%,O
",",O
P,O
=,O
0.036,O
",",O
respectively,O
),O
.,O
Administration,O
of,O
aprotinin,O
should,O
be,O
avoided,O
in,O
coronary,O
artery,O
bypass,O
graft,O
and,O
high,O
risk,O
patients,O
",",O
whereas,O
administration,O
of,O
tranexamic,B-Entity
acid,I-Entity
is,O
not,O
recommended,O
in,O
valve,O
surgery,O
.,O
The,O
biological,O
properties,O
of,O
the,O
optical,O
isomers,O
of,O
propranolol,I-Entity
and,O
their,O
effects,O
on,O
cardiac,B-Entity
arrhythmias,I-Entity
.,O
1,O
.,O
The,O
optical,O
isomers,O
of,O
propranolol,I-Entity
have,O
been,O
compared,O
for,O
their,O
beta,O
-,O
blocking,O
and,O
antiarrhythmic,O
activities.2,O
.,O
In,O
blocking,O
the,O
positive,O
inotropic,O
and,O
chronotropic,O
responses,O
to,O
isoprenaline,I-Entity
",",O
(,O
+,O
),O
-propranolol,I-Entity
had,O
less,O
than,O
one,O
hundredth,O
the,O
potency,O
of,O
(,O
-)-propranolol,I-Entity
.,O
At,O
dose,O
levels,O
of,O
(,O
+,O
),O
-propranolol,I-Entity
which,O
attenuated,O
the,O
responses,O
to,O
isoprenaline,I-Entity
",",O
there,O
was,O
a,O
significant,O
prolongation,O
of,O
the,O
PR,O
interval,O
of,O
the,O
electrocardiogram.3,O
.,O
The,O
metabolic,O
responses,O
to,O
isoprenaline,I-Entity
in,O
dogs,O
(,O
an,O
increase,O
in,O
circulating,O
glucose,I-Entity
",",O
lactate,I-Entity
and,O
free,O
fatty,B-Entity
acids,I-Entity
),O
were,O
all,O
blocked,O
by,O
(,O
-)-propranolol,I-Entity
.,O
-Propranolol,I-Entity
had,O
no,O
effect,O
on,O
fatty,B-Entity
acid,I-Entity
mobilization,O
but,O
significantly,O
reduced,O
the,O
increments,O
in,O
both,O
lactate,I-Entity
and,O
glucose.4,I-Entity
.,O
Both,O
isomers,O
of,O
propranolol,I-Entity
possessed,O
similar,O
depressant,O
potency,O
on,O
isolated,O
atrial,O
muscle,O
taken,O
from,O
guinea,O
-,O
pigs.5,O
.,O
The,O
isomers,O
of,O
propranolol,I-Entity
exhibited,O
similar,O
local,O
anaesthetic,O
potencies,O
on,O
an,O
isolated,O
frog,O
nerve,O
preparation,O
at,O
a,O
level,O
approximately,O
three,O
times,O
that,O
of,O
procaine,I-Entity
.,O
Both,O
isomers,O
of,O
propranolol,I-Entity
were,O
capable,O
of,O
preventing,O
adrenaline,I-Entity
-,O
induced,O
cardiac,B-Entity
arrhythmias,I-Entity
in,O
cats,O
anaesthetized,O
with,O
halothane,I-Entity
",",O
but,O
the,O
mean,O
dose,O
of,O
(,O
-)-propranolol,I-Entity
was,O
0.09+/-0.02,O
mg,O
/,O
kg,O
whereas,O
that,O
of,O
(,O
+,O
),O
-propranolol,I-Entity
was,O
4.2+/-1.2,O
mg,O
/,O
kg,O
.,O
-propranolol,I-Entity
there,O
was,O
a,O
significant,O
prolongation,O
of,O
the,O
PR,O
interval,O
of,O
the,O
electrocardiogram,O
.,O
Blockade,O
of,O
arrhythmias,I-Entity
with,O
both,O
isomers,O
was,O
surmountable,O
by,O
increasing,O
the,O
dose,O
of,O
adrenaline.7,I-Entity
.,O
Both,O
isomers,O
of,O
propranolol,I-Entity
were,O
also,O
capable,O
of,O
reversing,O
ventricular,B-Entity
tachycardia,I-Entity
caused,O
by,O
ouabain,I-Entity
in,O
anaesthetized,O
cats,O
and,O
dogs,O
.,O
The,O
dose,O
of,O
(,O
-)-propranolol,I-Entity
was,O
significantly,O
smaller,O
than,O
that,O
of,O
(,O
+,O
),O
-propranolol,I-Entity
in,O
both,O
species,O
but,O
much,O
higher,O
than,O
that,O
required,O
to,O
produce,O
evidence,O
of,O
beta,O
-,O
blockade.8,O
.,O
Topotecan,I-Entity
in,O
combination,O
with,O
radiotherapy,O
in,O
unresectable,O
glioblastoma,I-Entity
:,O
a,O
phase,O
2,O
study,O
.,O
Improving,O
glioblastoma,B-Entity
multiforme,I-Entity
(,O
GBM,I-Entity
),O
treatment,O
with,O
radio,O
-,O
chemotherapy,O
remains,O
a,O
challenge,O
.,O
Topotecan,I-Entity
is,O
an,O
attractive,O
option,O
as,O
it,O
exhibits,O
growth,O
inhibition,O
of,O
human,O
glioma,I-Entity
as,O
well,O
as,O
brain,O
penetration,O
.,O
The,O
present,O
study,O
assessed,O
the,O
combination,O
of,O
radiotherapy,O
(,O
60,O
Gy/30,O
fractions/40,O
days,O
),O
and,O
topotecan,I-Entity
(,O
0.9,O
mg,O
/,O
m(2)/day,O
on,O
days,O
1,O
-,O
5,O
on,O
weeks,O
1,O
",",O
3,O
and,O
5,O
),O
in,O
50,O
adults,O
with,O
histologically,O
proven,O
and,O
untreated,O
GBM,I-Entity
.,O
The,O
incidence,O
of,O
non,O
-,O
hematological,O
toxicities,I-Entity
was,O
low,O
and,O
grade,O
3,O
-,O
4,O
hematological,O
toxicities,I-Entity
were,O
reported,O
in,O
20,O
patients,O
(,O
mainly,O
lymphopenia,I-Entity
and,O
neutropenia,I-Entity
),O
.,O
Topotecan,I-Entity
in,O
combination,O
with,O
radiotherapy,O
was,O
well,O
tolerated,O
.,O
However,O
",",O
while,O
response,O
and,O
stabilization,O
concerned,O
one,O
-,O
third,O
of,O
the,O
patients,O
",",O
the,O
study,O
did,O
not,O
show,O
increased,O
benefits,O
in,O
terms,O
of,O
survival,O
in,O
patients,O
with,O
unresectable,O
GBM,I-Entity
.,O
Long,O
-,O
term,O
lithium,I-Entity
therapy,O
leading,O
to,O
hyperparathyroidism,I-Entity
:,O
a,O
case,O
report,O
.,O
This,O
paper,O
reviews,O
the,O
effect,O
of,O
chronic,O
lithium,I-Entity
therapy,O
on,O
serum,O
calcium,I-Entity
level,O
and,O
parathyroid,O
glands,O
",",O
its,O
pathogenesis,O
",",O
and,O
treatment,O
options,O
.,O
We,O
examined,O
the,O
case,O
of,O
a,O
lithium,I-Entity
-,O
treated,O
patient,O
who,O
had,O
recurrent,O
hypercalcemia,I-Entity
to,O
better,O
understand,O
the,O
disease,O
process,O
.,O
CONCLUSION,O
:,O
Primary,B-Entity
hyperparathyroidism,I-Entity
is,O
a,O
rare,O
but,O
potentially,O
life,O
-,O
threatening,O
side,O
effect,O
of,O
long,O
-,O
term,O
lithium,I-Entity
therapy,O
.,O
PRACTICAL,O
IMPLICATIONS,O
:,O
As,O
much,O
as,O
15%,O
of,O
lithium,I-Entity
-,O
treated,O
patients,O
become,O
hypercalcemic,I-Entity
.,O
By,O
routinely,O
monitoring,O
serum,O
calcium,I-Entity
levels,O
",",O
healthcare,O
providers,O
can,O
improve,O
the,O
quality,O
of,O
life,O
of,O
this,O
patient,O
group,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
compare,O
surgical,O
conditions,O
",",O
including,O
the,O
amount,O
of,O
intraoperative,O
bleeding,I-Entity
as,O
well,O
as,O
intraoperative,O
blood,O
pressure,O
",",O
during,O
functional,O
endoscopic,O
sinus,O
surgery,O
(,O
FESS,O
),O
using,O
flexible,O
reinforced,O
laryngeal,O
mask,O
airway,O
(,O
FRLMA,O
),O
versus,O
endotracheal,O
tube,O
(,O
ETT,O
),O
in,O
maintaining,O
controlled,O
hypotension,I-Entity
anesthesia,O
induced,O
by,O
propofol,I-Entity
-,O
remifentanil,I-Entity
total,O
i.v,O
.,O
METHODS,O
:,O
Sixty,O
normotensive,O
American,O
Society,O
of,O
Anesthesiologists,O
I,O
-,O
II,O
adult,O
patients,O
undergoing,O
FESS,O
under,O
controlled,O
hypotension,I-Entity
anesthesia,O
caused,O
by,O
propofol,I-Entity
-,O
remifentanil,I-Entity
-,O
TIVA,O
were,O
randomly,O
assigned,O
into,O
two,O
groups,O
:,O
group,O
I,O
",",O
FRLMA,O
;,O
group,O
II,O
",",O
ETT,O
.,O
Hemorrhage,I-Entity
was,O
measured,O
and,O
the,O
visibility,O
of,O
the,O
operative,O
field,O
was,O
evaluated,O
according,O
to,O
a,O
six,O
-,O
point,O
scale,O
.,O
Controlled,O
hypotension,I-Entity
was,O
achieved,O
within,O
a,O
shorter,O
period,O
using,O
laryngeal,O
mask,O
using,O
lower,O
rates,O
of,O
remifentanil,I-Entity
infusion,O
and,O
lower,O
total,O
dose,O
of,O
remifentanil,I-Entity
.,O
In,O
summary,O
",",O
our,O
results,O
indicate,O
that,O
airway,O
management,O
using,O
FRLMA,O
during,O
controlled,O
hypotension,I-Entity
anesthesia,O
provided,O
better,O
surgical,O
conditions,O
in,O
terms,O
of,O
quality,O
of,O
operative,O
field,O
and,O
blood,O
loss,O
and,O
allowed,O
for,O
convenient,O
induced,O
hypotension,I-Entity
with,O
low,O
doses,O
of,O
remifentanil,I-Entity
during,O
TIVA,O
in,O
patients,O
undergoing,O
FESS,O
.,O
Nonalcoholic,B-Entity
fatty,I-Entity
liver,I-Entity
disease,I-Entity
during,O
valproate,I-Entity
therapy,O
.,O
Valproic,B-Entity
acid,I-Entity
(,O
VPA,I-Entity
),O
is,O
effective,O
for,O
the,O
treatment,O
of,O
many,O
types,O
of,O
epilepsy,I-Entity
",",O
but,O
its,O
use,O
can,O
be,O
associated,O
with,O
an,O
increase,O
in,O
body,O
weight,O
.,O
We,O
report,O
a,O
case,O
of,O
nonalcoholic,B-Entity
fatty,I-Entity
liver,I-Entity
disease,I-Entity
(,O
NAFLD,I-Entity
),O
arising,O
in,O
a,O
child,O
who,O
developed,O
obesity,I-Entity
during,O
VPA,I-Entity
treatment,O
.,O
Laboratory,O
data,O
revealed,O
hyperinsulinemia,I-Entity
with,O
insulin,B-Entity
resistance,I-Entity
.,O
After,O
the,O
withdrawal,O
of,O
VPA,I-Entity
therapy,O
",",O
our,O
patient,O
showed,O
a,O
significant,O
weight,B-Entity
loss,I-Entity
",",O
a,O
decrease,O
of,O
body,O
mass,O
index,O
",",O
and,O
normalization,O
of,O
metabolic,O
and,O
endocrine,O
parameters,O
;,O
moreover,O
",",O
ultrasound,O
measurements,O
showed,O
a,O
complete,O
normalization,O
.,O
The,O
present,O
case,O
suggests,O
that,O
obesity,I-Entity
",",O
hyperinsulinemia,I-Entity
",",O
insulin,B-Entity
resistance,I-Entity
",",O
and,O
long,O
-,O
term,O
treatment,O
with,O
VPA,I-Entity
may,O
be,O
all,O
associated,O
with,O
the,O
development,O
of,O
NAFLD,I-Entity
;,O
this,O
side,O
effect,O
is,O
reversible,O
after,O
VPA,I-Entity
withdrawal,O
.,O
Carbimazole,I-Entity
induced,O
ANCA,B-Entity
positive,I-Entity
vasculitis,I-Entity
.,O
Anti,B-Entity
-,I-Entity
thyroid,I-Entity
drugs,I-Entity
",",O
like,O
carbimazole,I-Entity
and,O
propylthiouracil,I-Entity
(,O
PTU,I-Entity
),O
are,O
commonly,O
prescribed,O
for,O
the,O
treatment,O
of,O
hyperthyroidism,I-Entity
.,O
One,O
should,O
be,O
aware,O
of,O
the,O
side,O
effects,O
of,O
antithyroid,B-Entity
medications,I-Entity
.,O
Antineutrophil,B-Entity
cytoplasmic,I-Entity
antibody,I-Entity
(,I-Entity
ANCA)--associated,I-Entity
vasculitis,I-Entity
is,O
a,O
potentially,O
life,O
-,O
threatening,O
adverse,O
effect,O
of,O
antithyroidmedications,I-Entity
.,O
We,O
report,O
a,O
patient,O
with,O
Graves,B-Entity
',I-Entity
disease,I-Entity
who,O
developed,O
ANCA,O
positive,O
carbimazole,I-Entity
induced,O
vasculitis,I-Entity
.,O
The,O
episode,O
was,O
characterized,O
by,O
a,O
vasculitic,I-Entity
skin,B-Entity
rash,I-Entity
associated,O
with,O
large,O
joint,O
arthritis,I-Entity
",",O
pyrexia,I-Entity
and,O
parotiditis,I-Entity
but,O
no,O
renal,O
or,O
pulmonary,O
involvement,O
.,O
He,O
was,O
referred,O
to,O
us,O
for,O
neurological,O
evaluation,O
because,O
he,O
had,O
difficulty,O
in,O
getting,O
up,O
from,O
squatting,O
position,O
and,O
was,O
suspected,O
to,O
have,O
myositis,I-Entity
.,O
Carbimazole,I-Entity
and,O
methimazole,I-Entity
have,O
a,O
lower,O
incidence,O
of,O
reported,O
ANCA,O
positive,O
side,O
effects,O
than,O
PUT,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
this,O
is,O
the,O
first,O
ANCA,O
positive,O
carbimazole,I-Entity
induced,O
vasculitis,I-Entity
case,O
reported,O
from,O
India,O
.,O
Aspirin,I-Entity
for,O
the,O
primary,O
prevention,O
of,O
cardiovascular,O
events,O
:,O
an,O
update,O
of,O
the,O
evidence,O
for,O
the,O
U.S.,O
Preventive,O
Services,O
Task,O
Force,O
.,O
Coronary,B-Entity
heart,I-Entity
disease,I-Entity
and,O
cerebrovascular,B-Entity
disease,I-Entity
are,O
leading,O
causes,O
of,O
death,O
in,O
the,O
United,O
States,O
.,O
In,O
2002,O
",",O
the,O
U.S.,O
Preventive,O
Services,O
Task,O
Force,O
(,O
USPSTF,O
),O
strongly,O
recommended,O
that,O
clinicians,O
discuss,O
aspirin,I-Entity
with,O
adults,O
who,O
are,O
at,O
increased,O
risk,O
for,O
coronary,B-Entity
heart,I-Entity
disease,I-Entity
.,O
PURPOSE,O
:,O
To,O
determine,O
the,O
benefits,O
and,O
harms,O
of,O
taking,O
aspirin,I-Entity
for,O
the,O
primary,O
prevention,O
of,O
myocardial,B-Entity
infarctions,I-Entity
",",O
strokes,I-Entity
",",O
and,O
death,O
.,O
STUDY,O
SELECTION,O
:,O
English,O
-,O
language,O
randomized,O
",",O
controlled,O
trials,O
(,O
RCTs,O
),O
;,O
case,O
-,O
control,O
studies,O
;,O
meta,O
-,O
analyses,O
;,O
and,O
systematic,O
reviews,O
of,O
aspirin,I-Entity
versus,O
control,O
for,O
the,O
primary,O
prevention,O
of,O
cardiovascular,B-Entity
disease,I-Entity
(,O
CVD,I-Entity
),O
were,O
selected,O
to,O
answer,O
the,O
following,O
questions,O
:,O
Does,O
aspirin,I-Entity
decrease,O
coronary,O
heart,O
events,O
",",O
strokes,I-Entity
",",O
death,O
from,O
coronary,O
heart,O
events,O
or,O
stroke,I-Entity
",",O
or,O
all,O
-,O
cause,O
mortality,O
in,O
adults,O
without,O
known,O
CVD,I-Entity
?,O
Does,O
aspirin,I-Entity
increase,O
gastrointestinal,B-Entity
bleeding,I-Entity
or,O
hemorrhagic,B-Entity
strokes,I-Entity
?,O
DATA,O
SYNTHESIS,O
:,O
New,O
evidence,O
from,O
1,O
good,O
-,O
quality,O
RCT,O
",",O
1,O
good,O
-,O
quality,O
meta,O
-,O
analysis,O
",",O
and,O
2,O
fair,O
-,O
quality,O
subanalyses,O
of,O
RCTs,O
demonstrates,O
that,O
aspirin,I-Entity
use,O
reduces,O
the,O
number,O
of,O
CVD,I-Entity
events,O
in,O
patients,O
without,O
known,O
CVD,I-Entity
.,O
Men,O
in,O
these,O
studies,O
experienced,O
fewer,O
myocardial,B-Entity
infarctions,I-Entity
and,O
women,O
experienced,O
fewer,O
ischemic,O
strokes,I-Entity
.,O
Aspirin,I-Entity
does,O
not,O
seem,O
to,O
affect,O
CVD,I-Entity
mortality,O
or,O
all,O
-,O
cause,O
mortality,O
in,O
either,O
men,O
or,O
women,O
.,O
The,O
use,O
of,O
aspirin,I-Entity
for,O
primary,O
prevention,O
increases,O
the,O
risk,O
for,O
major,O
bleeding,I-Entity
events,O
",",O
primarily,O
gastrointestinal,B-Entity
bleeding,I-Entity
events,O
",",O
in,O
both,O
men,O
and,O
women,O
.,O
Men,O
have,O
an,O
increased,O
risk,O
for,O
hemorrhagic,B-Entity
strokes,I-Entity
with,O
aspirin,I-Entity
use,O
.,O
A,O
new,O
RCT,O
and,O
meta,O
-,O
analysis,O
suggest,O
that,O
the,O
risk,O
for,O
hemorrhagic,B-Entity
strokes,I-Entity
in,O
women,O
is,O
not,O
statistically,O
significantly,O
increased,O
.,O
New,O
evidence,O
on,O
aspirin,I-Entity
for,O
the,O
primary,O
prevention,O
of,O
CVD,I-Entity
is,O
limited,O
.,O
The,O
dose,O
of,O
aspirin,I-Entity
used,O
in,O
the,O
RCTs,O
varied,O
",",O
which,O
prevented,O
the,O
estimation,O
of,O
the,O
most,O
appropriate,O
dose,O
for,O
primary,O
prevention,O
.,O
Aspirin,I-Entity
reduces,O
the,O
risk,O
for,O
myocardial,B-Entity
infarction,I-Entity
in,O
men,O
and,O
strokes,I-Entity
in,O
women,O
.,O
Aspirin,I-Entity
use,O
increases,O
the,O
risk,O
for,O
serious,O
bleeding,I-Entity
events,O
.,O
Reducing,O
harm,O
associated,O
with,O
anticoagulation,O
:,O
practical,O
considerations,O
of,O
argatroban,I-Entity
therapy,O
in,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
.,O
Argatroban,I-Entity
is,O
a,O
hepatically,O
metabolized,O
",",O
direct,O
thrombin,O
inhibitor,O
used,O
for,O
prophylaxis,O
or,O
treatment,O
of,O
thrombosis,I-Entity
in,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
(,O
HIT,I-Entity
),O
and,O
for,O
patients,O
with,O
or,O
at,O
risk,O
of,O
HIT,I-Entity
undergoing,O
percutaneous,O
coronary,O
intervention,O
(,O
PCI,O
),O
.,O
The,O
objective,O
of,O
this,O
review,O
is,O
to,O
summarize,O
practical,O
considerations,O
of,O
argatroban,I-Entity
therapy,O
in,O
HIT,I-Entity
.,O
The,O
US,O
FDA,O
-,O
recommended,O
argatroban,I-Entity
dose,O
in,O
HIT,I-Entity
is,O
2,O
microg,O
/,O
kg,O
/,O
min,O
(,O
reduced,O
in,O
patients,O
with,O
hepatic,B-Entity
impairment,I-Entity
and,O
in,O
paediatric,O
patients,O
),O
",",O
adjusted,O
to,O
achieve,O
activated,O
partial,O
thromboplastin,O
times,O
(,O
aPTTs,O
),O
1.5,O
-,O
3,O
times,O
baseline,O
(,O
not,O
>,O
100,O
seconds,O
),O
.,O
Contemporary,O
experiences,O
indicate,O
that,O
reduced,O
doses,O
are,O
also,O
needed,O
in,O
patients,O
with,O
conditions,O
associated,O
with,O
hepatic,O
hypoperfusion,O
",",O
e.g.,O
heart,B-Entity
failure,I-Entity
",",O
yet,O
are,O
unnecessary,O
for,O
renal,B-Entity
dysfunction,I-Entity
",",O
adult,O
age,O
",",O
sex,O
",",O
race,O
/,O
ethnicity,O
or,O
obesity,I-Entity
.,O
Argatroban,I-Entity
0.5,O
-,O
1.2,O
For,O
PCI,O
",",O
argatroban,I-Entity
has,O
not,O
been,O
investigated,O
in,O
hepatically,O
impaired,O
patients,O
;,O
dose,O
adjustment,O
is,O
unnecessary,O
for,O
adult,O
age,O
",",O
sex,O
",",O
race,O
/,O
ethnicity,O
or,O
obesity,I-Entity
",",O
and,O
lesser,O
doses,O
may,O
be,O
adequate,O
with,O
concurrent,O
glycoprotein,O
IIb,O
/,O
IIIa,O
inhibition,O
.,O
Argatroban,I-Entity
prolongs,O
the,O
International,O
Normalized,O
Ratio,O
",",O
and,O
published,O
approaches,O
for,O
monitoring,O
the,O
argatroban,I-Entity
-,O
to,O
-,O
warfarin,I-Entity
transition,O
should,O
be,O
followed,O
.,O
Major,O
bleeding,I-Entity
with,O
argatroban,I-Entity
is,O
0,O
-,O
10%,O
in,O
the,O
non,O
-,O
interventional,O
setting,O
and,O
0,O
-,O
5.8%,O
periprocedurally,O
.,O
Argatroban,I-Entity
has,O
no,O
specific,O
antidote,O
",",O
and,O
if,O
excessive,O
anticoagulation,O
occurs,O
",",O
argatroban,I-Entity
infusion,O
should,O
be,O
stopped,O
or,O
reduced,O
.,O
Improved,O
familiarity,O
of,O
healthcare,O
professionals,O
with,O
argatroban,I-Entity
therapy,O
in,O
HIT,I-Entity
",",O
including,O
in,O
special,O
populations,O
and,O
during,O
PCI,O
",",O
may,O
facilitate,O
reduction,O
of,O
harm,O
associated,O
with,O
HIT,I-Entity
(,O
e.g.,O
fewer,O
thromboses,O
),O
or,O
its,O
treatment,O
(,O
e.g.,O
fewer,O
argatroban,I-Entity
medication,O
errors,O
),O
.,O
Rhabdomyolysis,I-Entity
and,O
brain,O
ischemic,B-Entity
stroke,I-Entity
in,O
a,O
heroin,I-Entity
-,O
dependent,O
male,O
under,O
methadone,I-Entity
maintenance,O
therapy,O
.,O
OBJECTIVE,O
:,O
There,O
are,O
several,O
complications,O
associated,O
with,O
heroin,B-Entity
abuse,I-Entity
",",O
some,O
of,O
which,O
are,O
life,O
-,O
threatening,O
.,O
Methadone,I-Entity
may,O
aggravate,O
this,O
problem,O
.,O
A,O
33-year,O
-,O
old,O
man,O
presented,O
with,O
rhabdomyolysis,I-Entity
and,O
cerebral,O
ischemic,B-Entity
stroke,I-Entity
after,O
intravenous,O
heroin,I-Entity
.,O
He,O
had,O
used,O
heroin,I-Entity
since,O
age,O
20,O
",",O
and,O
had,O
used,O
150,O
mg,O
methadone,I-Entity
daily,O
for,O
6,O
months,O
.,O
He,O
was,O
found,O
unconsciousness,I-Entity
at,O
home,O
and,O
was,O
sent,O
to,O
our,O
hospital,O
.,O
In,O
the,O
ICU,O
",",O
we,O
found,O
rhabdomyolysis,I-Entity
",",O
acute,B-Entity
renal,I-Entity
failure,I-Entity
and,O
acute,O
respiratory,B-Entity
failure,I-Entity
.,O
After,O
transfer,O
to,O
an,O
internal,O
ward,O
",",O
we,O
noted,O
aphasia,I-Entity
and,O
weakness,I-Entity
of,O
his,O
left,O
limbs,O
.,O
After,O
MRI,O
",",O
we,O
found,O
cerebral,B-Entity
ischemic,I-Entity
infarction,I-Entity
.,O
Those,O
using,O
methadone,I-Entity
and,O
heroin,I-Entity
simultaneously,O
may,O
increase,O
risk,O
of,O
rhabdomyolysis,I-Entity
and,O
ischemic,B-Entity
stroke,I-Entity
.,O
Patients,O
under,O
methadone,I-Entity
maintenance,O
therapy,O
should,O
be,O
warned,O
regarding,O
these,O
serious,O
adverse,O
events,O
.,O
Hypotheses,O
of,O
heroin,I-Entity
-,O
related,O
rhabdomyolysis,I-Entity
and,O
stroke,I-Entity
in,O
heroin,I-Entity
abusers,O
are,O
discussed,O
.,O
Increased,O
vulnerability,O
to,O
6-hydroxydopamine,I-Entity
lesion,O
and,O
reduced,O
development,O
of,O
dyskinesias,I-Entity
in,O
mice,O
lacking,O
CB1,O
cannabinoid,O
receptors,O
.,O
Motor,O
impairment,O
",",O
dopamine,I-Entity
(,O
DA,I-Entity
),O
neuronal,O
activity,O
and,O
proenkephalin,I-Entity
(,O
PENK,I-Entity
),O
gene,O
expression,O
in,O
the,O
caudate,O
-,O
putamen,O
(,O
CPu,O
),O
were,O
measured,O
in,O
6-OHDA,I-Entity
-,O
lesioned,O
and,O
treated,O
(,O
L,B-Entity
-,I-Entity
DOPA+benserazide,I-Entity
),O
A,O
lesion,O
induced,O
by,O
6-OHDA,I-Entity
produced,O
more,O
severe,O
motor,O
deterioration,O
in,O
CB1,O
KO,O
mice,O
accompanied,O
by,O
more,O
loss,O
of,O
DA,I-Entity
neurons,O
and,O
increased,O
PENK,I-Entity
gene,O
expression,O
in,O
the,O
CPu,O
.,O
CB1,O
KO,O
mice,O
exhibited,O
higher,O
MDA,I-Entity
levels,O
and,O
iNOS,O
protein,O
expression,O
in,O
the,O
CPu,O
and,O
Cg,O
compared,O
to,O
WT,O
mice,O
.,O
Treatment,O
with,O
L,B-Entity
-,I-Entity
DOPA+benserazide,I-Entity
(,O
12,O
weeks,O
),O
resulted,O
in,O
less,O
severe,O
dyskinesias,I-Entity
in,O
CB1,O
KO,O
than,O
in,O
WT,O
mice,O
.,O
The,O
results,O
revealed,O
that,O
the,O
lack,O
of,O
cannabinoid,O
CB1,O
receptors,O
increased,O
the,O
severity,O
of,O
motor,O
impairment,O
and,O
DA,I-Entity
lesion,O
",",O
and,O
reduced,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
These,O
results,O
suggest,O
that,O
activation,O
of,O
CB1,O
receptors,O
offers,O
neuroprotection,O
against,O
dopaminergic,O
lesion,O
and,O
the,O
development,O
of,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
Animal,O
model,O
of,O
mania,I-Entity
induced,O
by,O
ouabain,I-Entity
:,O
Evidence,O
of,O
oxidative,O
stress,O
in,O
submitochondrial,O
particles,O
of,O
the,O
rat,O
brain,O
.,O
The,O
intracerebroventricular,O
(,O
ICV,O
),O
administration,O
of,O
ouabain,I-Entity
(,O
a,O
Na(+)/K(+)-ATPase,I-Entity
inhibitor,O
),O
in,O
rats,O
has,O
been,O
suggested,O
to,O
mimic,O
some,O
symptoms,O
of,O
human,O
bipolar,B-Entity
mania,I-Entity
.,O
Clinical,O
studies,O
have,O
shown,O
that,O
bipolar,B-Entity
disorder,I-Entity
may,O
be,O
related,O
to,O
mitochondrial,B-Entity
dysfunction,I-Entity
.,O
Herein,O
",",O
we,O
investigated,O
the,O
behavioral,O
and,O
biochemical,O
effects,O
induced,O
by,O
the,O
ICV,O
administration,O
of,O
ouabain,I-Entity
in,O
rats,O
.,O
To,O
achieve,O
this,O
aim,O
",",O
the,O
effects,O
of,O
ouabain,I-Entity
injection,O
immediately,O
after,O
and,O
7,O
days,O
following,O
a,O
single,O
ICV,O
administration,O
(,O
at,O
concentrations,O
of,O
10(-2,O
),O
and,O
10(-3)M,O
),O
on,O
locomotion,O
was,O
measured,O
using,O
the,O
open,O
-,O
field,O
test,O
.,O
Additionally,O
",",O
thiobarbituric,B-Entity
acid,I-Entity
reactive,O
substances,O
(,O
TBARSs,O
),O
and,O
superoxide,I-Entity
production,O
were,O
measured,O
in,O
submitochondrial,O
particles,O
of,O
the,O
prefrontal,O
cortex,O
",",O
hippocampus,O
",",O
striatum,O
and,O
amygdala,O
.,O
Our,O
findings,O
demonstrated,O
that,O
ouabain,I-Entity
at,O
10(-2,O
),O
and,O
10(-3)M,O
induced,O
hyperlocomotion,I-Entity
in,O
rats,O
",",O
and,O
this,O
response,O
remained,O
up,O
to,O
7,O
days,O
following,O
a,O
single,O
ICV,O
injection,O
.,O
In,O
addition,O
",",O
we,O
observed,O
that,O
the,O
persistent,O
increase,O
in,O
the,O
rat,O
spontaneous,O
locomotion,O
is,O
associated,O
with,O
increased,O
TBARS,O
levels,O
and,O
superoxide,I-Entity
generation,O
in,O
submitochondrial,O
particles,O
in,O
the,O
prefrontal,O
cortex,O
",",O
striatum,O
and,O
amygdala,O
.,O
In,O
conclusion,O
",",O
ouabain,I-Entity
-,O
induced,O
mania,I-Entity
-,O
like,O
behavior,O
may,O
provide,O
a,O
useful,O
animal,O
model,O
to,O
test,O
the,O
hypothesis,O
of,O
the,O
involvement,O
of,O
oxidative,O
stress,O
in,O
bipolar,B-Entity
disorder,I-Entity
.,O
Intraoperative,O
dialysis,O
during,O
liver,O
transplantation,O
with,O
citrate,I-Entity
dialysate,O
.,O
Liver,O
transplantation,O
for,O
acutely,O
ill,O
patients,O
with,O
fulminant,B-Entity
liver,I-Entity
failure,I-Entity
carries,O
high,O
intraoperative,O
and,O
immediate,O
postoperative,O
risks,O
.,O
These,O
are,O
increased,O
with,O
the,O
presence,O
of,O
concomitant,O
acute,B-Entity
kidney,I-Entity
injury,I-Entity
(,O
AKI,I-Entity
),O
and,O
intraoperative,O
dialysis,O
is,O
sometimes,O
required,O
to,O
allow,O
the,O
transplant,O
to,O
proceed,O
.,O
The,O
derangements,O
in,O
the,O
procoagulant,O
and,O
anticoagulant,O
pathways,O
during,O
fulminant,B-Entity
liver,I-Entity
failure,I-Entity
can,O
lead,O
to,O
difficulties,O
with,O
anticoagulation,O
during,O
dialysis,O
",",O
especially,O
when,O
continued,O
in,O
the,O
operating,O
room,O
.,O
Systemic,O
anticoagulation,O
is,O
unsafe,O
and,O
regional,O
citrate,I-Entity
anticoagulation,O
in,O
the,O
absence,O
of,O
a,O
functional,O
liver,O
carries,O
the,O
risk,O
of,O
citrate,I-Entity
toxicity,I-Entity
.,O
Citrate,I-Entity
dialysate,O
",",O
a,O
new,O
dialysate,O
with,O
citric,B-Entity
acid,I-Entity
can,O
be,O
used,O
for,O
anticoagulation,O
in,O
patients,O
who,O
can,O
not,O
tolerate,O
heparin,I-Entity
or,O
regional,O
citrate,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
a,O
40-year,O
-,O
old,O
female,O
with,O
acetaminophen,I-Entity
-,O
induced,O
fulminant,B-Entity
liver,I-Entity
failure,I-Entity
with,O
associated,O
AKI,I-Entity
who,O
underwent,O
intraoperative,O
dialytic,O
support,O
during,O
liver,O
transplantation,O
anticoagulated,O
with,O
citrate,I-Entity
dialysate,O
during,O
the,O
entire,O
procedure,O
.,O
The,O
patient,O
tolerated,O
the,O
procedure,O
well,O
without,O
any,O
signs,O
of,O
citrate,I-Entity
toxicity,I-Entity
and,O
maintained,O
adequate,O
anticoagulation,O
for,O
patency,O
of,O
the,O
dialysis,O
circuit,O
.,O
Citrate,I-Entity
dialysate,O
is,O
a,O
safe,O
alternative,O
for,O
intradialytic,O
support,O
of,O
liver,O
transplantation,O
in,O
fulminant,B-Entity
liver,I-Entity
failure,I-Entity
.,O
Delirium,I-Entity
in,O
a,O
patient,O
with,O
toxic,O
flecainide,I-Entity
plasma,O
concentrations,O
:,O
the,O
role,O
of,O
a,O
pharmacokinetic,O
drug,O
interaction,O
with,O
paroxetine,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
describe,O
a,O
case,O
of,O
flecainide,I-Entity
-,O
induced,O
delirium,I-Entity
associated,O
with,O
a,O
pharmacokinetic,O
drug,O
interaction,O
with,O
paroxetine,I-Entity
.,O
A,O
69-year,O
-,O
old,O
white,O
female,O
presented,O
to,O
the,O
emergency,O
department,O
with,O
a,O
history,O
of,O
confusion,I-Entity
and,O
paranoia,I-Entity
over,O
the,O
past,O
several,O
days,O
.,O
On,O
admission,O
the,O
patient,O
was,O
taking,O
carvedilol,I-Entity
12,O
mg,O
twice,O
daily,O
",",O
warfarin,I-Entity
2,O
mg,O
/,O
day,O
",",O
folic,B-Entity
acid,I-Entity
1,O
mg,O
/,O
day,O
",",O
levothyroxine,I-Entity
100,O
microg,O
/,O
day,O
",",O
pantoprazole,I-Entity
40,O
mg,O
/,O
day,O
",",O
paroxetine,I-Entity
40,O
mg,O
/,O
day,O
",",O
and,O
flecainide,I-Entity
100,O
mg,O
twice,O
daily,O
.,O
Flecainide,I-Entity
had,O
been,O
started,O
2,O
weeks,O
prior,O
for,O
atrial,B-Entity
fibrillation,I-Entity
.,O
Laboratory,O
test,O
findings,O
on,O
admission,O
were,O
notable,O
only,O
for,O
a,O
flecainide,I-Entity
plasma,O
concentration,O
of,O
1360,O
microg,O
/,O
L,O
(,O
reference,O
range,O
200,O
-,O
1000,O
),O
.,O
A,O
metabolic,O
drug,O
interaction,O
between,O
flecainide,I-Entity
and,O
paroxetine,I-Entity
",",O
which,O
the,O
patient,O
had,O
been,O
taking,O
for,O
more,O
than,O
5,O
years,O
",",O
was,O
considered,O
.,O
Paroxetine,I-Entity
was,O
discontinued,O
and,O
the,O
dose,O
of,O
flecainide,I-Entity
was,O
reduced,O
to,O
50,O
mg,O
twice,O
daily,O
.,O
Her,O
delirium,I-Entity
resolved,O
3,O
days,O
later,O
.,O
DISCUSSION,O
:,O
Flecainide,I-Entity
and,O
pharmacologically,O
similar,O
agents,O
that,O
interact,O
with,O
sodium,I-Entity
channels,O
may,O
cause,O
delirium,I-Entity
in,O
susceptible,O
patients,O
.,O
A,O
MEDLINE,O
search,O
(,O
1966-January,O
2009,O
),O
revealed,O
one,O
in,O
vivo,O
pharmacokinetic,O
study,O
on,O
the,O
interaction,O
between,O
flecainide,I-Entity
",",O
a,O
CYP2D6,O
substrate,O
",",O
and,O
paroxetine,I-Entity
",",O
a,O
CYP2D6,O
inhibitor,O
",",O
as,O
well,O
as,O
3,O
case,O
reports,O
of,O
flecainide,I-Entity
-,O
induced,O
delirium,I-Entity
.,O
According,O
to,O
the,O
Naranjo,O
probability,O
scale,O
",",O
flecainide,I-Entity
was,O
the,O
probable,O
cause,O
of,O
the,O
patient,O
's,O
delirium,I-Entity
;,O
the,O
Horn,O
Drug,O
Interaction,O
Probability,O
Scale,O
indicates,O
a,O
possible,O
pharmacokinetic,O
drug,O
interaction,O
between,O
flecainide,I-Entity
and,O
paroxetine,I-Entity
.,O
Supratherapeutic,O
flecainide,I-Entity
plasma,O
concentrations,O
may,O
cause,O
delirium,I-Entity
.,O
Because,O
toxicity,I-Entity
may,O
occur,O
when,O
flecainide,I-Entity
is,O
prescribed,O
with,O
paroxetine,I-Entity
and,O
other,O
potent,O
CYP2D6,O
inhibitors,O
",",O
flecainide,I-Entity
plasma,O
concentrations,O
should,O
be,O
monitored,O
closely,O
with,O
commencement,O
of,O
CYP2D6,O
inhibitors,O
.,O
Efficacy,O
of,O
everolimus,I-Entity
(,O
RAD001,I-Entity
),O
in,O
patients,O
with,O
advanced,O
NSCLC,I-Entity
previously,O
treated,O
with,O
chemotherapy,O
alone,O
or,O
with,O
chemotherapy,O
and,O
EGFR,O
inhibitors,O
.,O
BACKGROUND,O
:,O
Treatment,O
options,O
are,O
scarce,O
in,O
pretreated,O
advanced,O
non,B-Entity
-,I-Entity
small,I-Entity
-,I-Entity
cell,I-Entity
lung,I-Entity
cancer,I-Entity
(,O
NSCLC,I-Entity
),O
patients,O
.,O
RAD001,I-Entity
",",O
an,O
oral,O
inhibitor,O
of,O
the,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
(,O
mTOR,O
),O
",",O
has,O
shown,O
phase,O
I,O
efficacy,O
in,O
NSCLC,I-Entity
.,O
METHODS,O
:,O
Stage,O
IIIb,O
or,O
IV,O
NSCLC,I-Entity
patients,O
",",O
with,O
two,O
or,O
fewer,O
prior,O
chemotherapy,O
regimens,O
",",O
one,O
platinum,I-Entity
based,O
(,O
stratum,O
1,O
),O
or,O
both,O
chemotherapy,O
and,O
epidermal,O
growth,O
factor,O
receptor,O
tyrosine,I-Entity
kinase,O
inhibitors,O
(,O
stratum,O
2,O
),O
",",O
received,O
RAD001,I-Entity
10,O
mg,O
/,O
day,O
until,O
progression,O
or,O
unacceptable,O
toxicity,I-Entity
.,O
Analyses,O
of,O
markers,O
associated,O
with,O
the,O
mTOR,O
pathway,O
were,O
carried,O
out,O
on,O
archival,O
tumor,I-Entity
from,O
a,O
subgroup,O
using,O
immunohistochemistry,O
(,O
IHC,O
),O
and,O
direct,O
mutation,O
sequencing,O
.,O
Common,O
>,O
or,O
=,O
grade,O
3,O
events,O
were,O
fatigue,I-Entity
",",O
dyspnea,I-Entity
",",O
stomatitis,I-Entity
",",O
anemia,I-Entity
",",O
and,O
thrombocytopenia,I-Entity
.,O
Pneumonitis,I-Entity
",",O
probably,O
or,O
possibly,O
related,O
",",O
mainly,O
grade,O
1/2,O
",",O
occurred,O
in,O
25%,O
.,O
RAD001,I-Entity
10,O
mg,O
/,O
day,O
was,O
well,O
tolerated,O
",",O
showing,O
modest,O
clinical,O
activity,O
in,O
pretreated,O
NSCLC,I-Entity
.,O
Evaluation,O
of,O
RAD001,I-Entity
plus,O
standard,O
therapy,O
for,O
metastatic,O
NSCLC,I-Entity
continues,O
.,O
Posttransplant,O
anemia,I-Entity
:,O
the,O
role,O
of,O
sirolimus,I-Entity
.,O
Posttransplant,O
anemia,I-Entity
is,O
a,O
common,O
problem,O
that,O
may,O
hinder,O
patients,O
',O
quality,O
of,O
life,O
.,O
A,O
variety,O
of,O
factors,O
have,O
been,O
identified,O
that,O
increase,O
the,O
risk,O
of,O
posttransplant,O
anemia,I-Entity
",",O
of,O
which,O
the,O
level,O
of,O
renal,O
function,O
is,O
most,O
important,O
.,O
Sirolimus,I-Entity
",",O
a,O
mammalian,O
target,O
of,O
rapamycin,I-Entity
inhibitor,O
",",O
has,O
been,O
implicated,O
as,O
playing,O
a,O
special,O
role,O
in,O
posttransplant,O
anemia,I-Entity
.,O
This,O
review,O
considers,O
anemia,I-Entity
associated,O
with,O
sirolimus,I-Entity
",",O
including,O
its,O
presentation,O
",",O
mechanisms,O
",",O
and,O
management,O
.,O
Coronary,O
computerized,O
tomography,O
angiography,O
for,O
rapid,O
discharge,O
of,O
low,O
-,O
risk,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
.,O
Most,O
patients,O
presenting,O
to,O
emergency,O
departments,O
(,O
EDs,O
),O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
are,O
admitted,O
for,O
at,O
least,O
12,O
hours,O
and,O
receive,O
a,O
"""",O
rule,O
out,O
acute,B-Entity
coronary,I-Entity
syndrome,I-Entity
"""",O
protocol,O
",",O
often,O
with,O
noninvasive,O
testing,O
prior,O
to,O
discharge,O
.,O
In,O
patients,O
without,O
cocaine,I-Entity
use,O
",",O
coronary,O
computerized,O
tomography,O
angiography,O
(,O
CTA,O
),O
has,O
been,O
shown,O
to,O
be,O
useful,O
for,O
identifying,O
a,O
group,O
of,O
patients,O
at,O
low,O
risk,O
for,O
cardiac,O
events,O
who,O
can,O
be,O
safely,O
discharged,O
.,O
It,O
is,O
unclear,O
whether,O
a,O
coronary,O
CTA,O
strategy,O
would,O
be,O
efficacious,O
in,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
",",O
as,O
coronary,B-Entity
vasospasm,I-Entity
may,O
account,O
for,O
some,O
of,O
the,O
ischemia,I-Entity
.,O
We,O
studied,O
whether,O
a,O
negative,O
coronary,O
CTA,O
in,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
could,O
identify,O
a,O
subset,O
safe,O
for,O
discharge,O
.,O
:,O
We,O
prospectively,O
evaluated,O
the,O
safety,O
of,O
coronary,O
CTA,O
for,O
low,O
-,O
risk,O
patients,O
who,O
presented,O
to,O
the,O
ED,O
with,O
cocaineassociated,O
chest,B-Entity
pain,I-Entity
(,O
self,O
-,O
reported,O
or,O
positive,O
urine,O
test,O
),O
.,O
Patients,O
with,O
negative,O
coronary,O
CTA,O
(,O
maximal,O
stenosis,I-Entity
less,O
than,O
50%,O
),O
were,O
discharged,O
.,O
The,O
main,O
outcome,O
was,O
30-day,O
cardiovascular,O
death,O
or,O
myocardial,B-Entity
infarction,I-Entity
.,O
A,O
total,O
of,O
59,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
chest,B-Entity
pain,I-Entity
were,O
evaluated,O
.,O
Six,O
patients,O
had,O
coronary,B-Entity
stenosis,I-Entity
>,O
During,O
the,O
30-day,O
follow,O
-,O
up,O
period,O
",",O
no,O
patients,O
died,O
of,O
a,O
cardiovascular,O
event,O
(,O
0%,O
;,O
95%,O
CI,O
",",O
0,O
-,O
6.1%,O
),O
and,O
no,O
patient,O
sustained,O
a,O
nonfatal,O
myocardial,B-Entity
infarction,I-Entity
(,O
0%,O
;,O
95%,O
CI,O
",",O
0,O
-,O
6.1%,O
),O
.,O
Although,O
cocaine,I-Entity
-,O
associated,O
myocardial,B-Entity
ischemia,I-Entity
can,O
result,O
from,O
coronary,O
vasoconstriction,O
",",O
patients,O
with,O
cocaine,I-Entity
associated,O
chest,B-Entity
pain,I-Entity
",",O
a,O
non,O
-,O
ischemic,I-Entity
ECG,O
",",O
and,O
a,O
TIMI,O
risk,O
score,O
Late,O
fulminant,O
posterior,B-Entity
reversible,I-Entity
encephalopathy,I-Entity
syndrome,I-Entity
after,O
liver,O
transplant,O
.,O
Posterior,B-Entity
leukoencephalopathy,I-Entity
due,O
to,O
calcineurin,O
-,O
inhibitor,O
-,O
related,O
neurotoxicity,I-Entity
is,O
a,O
rare,O
but,O
severe,O
complication,O
that,O
results,O
from,O
treatment,O
with,O
immunosuppressive,O
agents,O
(,O
primarily,O
those,O
administered,O
after,O
a,O
liver,O
or,O
kidney,O
transplant,O
),O
.,O
:,O
We,O
report,O
the,O
case,O
of,O
a,O
46-year,O
-,O
old,O
woman,O
who,O
received,O
a,O
liver,O
transplant,O
in,O
our,O
center,O
as,O
treatment,O
for,O
alcoholic,B-Entity
cirrhosis,I-Entity
and,O
in,O
whom,O
either,O
a,O
fulminant,O
course,O
of,O
posterior,B-Entity
leukoencephalopathy,I-Entity
or,O
posterior,B-Entity
reversible,I-Entity
encephalopathy,I-Entity
syndrome,I-Entity
developed,O
110,O
days,O
after,O
transplant,O
.,O
Switching,O
the,O
immunosuppressive,O
regimen,O
from,O
tacrolimus,I-Entity
to,O
cyclosporine,I-Entity
did,O
not,O
improve,O
the,O
clinical,O
situation,O
.,O
Posterior,B-Entity
reversible,I-Entity
encephalopathy,I-Entity
syndrome,I-Entity
after,O
liver,O
transplant,O
is,O
rare,O
.,O
Prolonged,O
hypothermia,I-Entity
as,O
a,O
bridge,O
to,O
recovery,O
for,O
cerebral,B-Entity
edema,I-Entity
and,O
intracranial,B-Entity
hypertension,I-Entity
associated,O
with,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
.,O
BACKGROUND,O
:,O
To,O
review,O
evidence,O
-,O
based,O
treatment,O
options,O
in,O
patients,O
with,O
cerebral,B-Entity
edema,I-Entity
complicating,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
(,O
FHF,I-Entity
),O
and,O
discuss,O
the,O
potential,O
applications,O
of,O
hypothermia,I-Entity
.,O
METHOD,O
:,O
Case,O
-,O
based,O
observations,O
from,O
a,O
medical,O
intensive,O
care,O
unit,O
(,O
MICU,O
),O
in,O
a,O
tertiary,O
care,O
facility,O
in,O
a,O
27-year,O
-,O
old,O
female,O
with,O
FHF,I-Entity
from,O
acetaminophen,I-Entity
and,O
resultant,O
cerebral,B-Entity
edema,I-Entity
.,O
Our,O
patient,O
was,O
admitted,O
to,O
the,O
MICU,O
after,O
being,O
found,O
unresponsive,O
with,O
presumed,O
toxicity,I-Entity
from,O
acetaminophen,I-Entity
which,O
was,O
ingested,O
over,O
a,O
2-day,O
period,O
.,O
Initial,O
evaluation,O
confirmed,O
FHF,I-Entity
from,O
acetaminophen,I-Entity
and,O
cerebral,B-Entity
edema,I-Entity
.,O
The,O
patient,O
was,O
treated,O
with,O
hyperosmolar,O
therapy,O
",",O
hyperventilation,I-Entity
",",O
sedation,O
",",O
and,O
chemical,O
paralysis,I-Entity
.,O
We,O
then,O
initiated,O
therapeutic,O
hypothermia,I-Entity
which,O
was,O
continued,O
for,O
5,O
days,O
.,O
At,O
re,O
-,O
warming,O
",",O
patient,O
had,O
resolution,O
of,O
her,O
cerebral,B-Entity
edema,I-Entity
and,O
intracranial,B-Entity
hypertension,I-Entity
.,O
In,O
patients,O
with,O
FHF,I-Entity
and,O
cerebral,B-Entity
edema,I-Entity
from,O
acetaminophen,I-Entity
overdose,I-Entity
",",O
prolonged,O
therapeutic,O
hypothermia,I-Entity
could,O
potentially,O
be,O
used,O
as,O
a,O
life,O
saving,O
therapy,O
and,O
a,O
bridge,O
to,O
hepatic,O
and,O
neurological,O
recovery,O
.,O
A,O
clinical,O
trial,O
of,O
hypothermia,I-Entity
in,O
patients,O
with,O
this,O
condition,O
is,O
warranted,O
.,O
Binasal,B-Entity
visual,I-Entity
field,I-Entity
defects,I-Entity
are,O
not,O
specific,O
to,O
vigabatrin,I-Entity
.,O
This,O
study,O
investigated,O
the,O
visual,B-Entity
defects,I-Entity
associated,O
with,O
the,O
antiepileptic,O
drug,O
vigabatrin,I-Entity
(,O
VGB,I-Entity
),O
.,O
Two,O
hundred,O
four,O
people,O
with,O
epilepsy,I-Entity
were,O
grouped,O
on,O
the,O
basis,O
of,O
antiepileptic,O
drug,O
therapy,O
(,O
current,O
",",O
previous,O
",",O
or,O
no,O
exposure,O
to,O
VGB,I-Entity
),O
.,O
Groups,O
were,O
matched,O
with,O
respect,O
to,O
age,O
",",O
gender,O
",",O
and,O
seizure,I-Entity
frequency,O
.,O
Bilateral,O
visual,O
field,O
constriction,O
was,O
observed,O
in,O
59%,O
of,O
patients,O
currently,O
taking,O
VGB,I-Entity
",",O
43%,O
of,O
patients,O
who,O
previously,O
took,O
VGB,I-Entity
",",O
and,O
24%,O
of,O
patients,O
with,O
no,O
exposure,O
to,O
VGB,I-Entity
.,O
Assessment,O
of,O
retinal,O
function,O
revealed,O
abnormal,O
responses,O
in,O
48%,O
of,O
current,O
VGB,I-Entity
users,O
and,O
22%,O
of,O
prior,O
VGB,I-Entity
users,O
",",O
but,O
in,O
none,O
of,O
the,O
patients,O
without,O
previous,O
exposure,O
to,O
VGB,I-Entity
.,O
Bilateral,B-Entity
visual,I-Entity
field,I-Entity
abnormalities,I-Entity
are,O
common,O
in,O
the,O
treated,O
epilepsy,I-Entity
population,O
",",O
irrespective,O
of,O
drug,O
history,O
.,O
Assessment,O
by,O
conventional,O
static,O
perimetry,O
may,O
neither,O
be,O
sufficiently,O
sensitive,O
nor,O
specific,O
to,O
reliably,O
identify,O
retinal,B-Entity
toxicity,I-Entity
associated,O
with,O
VGB,I-Entity
.,O
Smoking,O
of,O
crack,B-Entity
cocaine,I-Entity
as,O
a,O
risk,O
factor,O
for,O
HIV,B-Entity
infection,I-Entity
among,O
people,O
who,O
use,O
injection,O
drugs,O
.,O
Little,O
is,O
known,O
about,O
the,O
possible,O
role,O
that,O
smoking,O
crack,B-Entity
cocaine,I-Entity
has,O
on,O
the,O
incidence,O
of,O
HIV,B-Entity
infection,I-Entity
.,O
Given,O
the,O
increasing,O
use,O
of,O
crack,B-Entity
cocaine,I-Entity
",",O
we,O
sought,O
to,O
examine,O
whether,O
use,O
of,O
this,O
illicit,O
drug,O
has,O
become,O
a,O
risk,O
factor,O
for,O
HIV,B-Entity
infection,I-Entity
.,O
To,O
determine,O
whether,O
the,O
risk,O
of,O
HIV,B-Entity
seroconversion,I-Entity
among,O
daily,O
smokers,O
of,O
crack,B-Entity
cocaine,I-Entity
changed,O
over,O
time,O
",",O
we,O
used,O
Cox,O
proportional,O
hazards,O
regression,O
and,O
divided,O
the,O
study,O
into,O
3,O
periods,O
:,O
May,O
1,O
",",O
1996-Nov,O
.,O
30,O
",",O
1999,O
(,O
period,O
1,O
),O
",",O
Dec.,O
1,O
",",O
1999-Nov,O
.,O
30,O
",",O
2002,O
(,O
period,O
2,O
),O
",",O
and,O
Dec.,O
1,O
",",O
2002-Dec,O
.,O
30,O
",",O
2005,O
(,O
period,O
3,O
),O
.,O
Of,O
these,O
",",O
137,O
acquired,O
HIV,B-Entity
infection,I-Entity
during,O
follow,O
-,O
up,O
.,O
The,O
mean,O
proportion,O
of,O
participants,O
who,O
reported,O
daily,O
smoking,O
of,O
crack,B-Entity
cocaine,I-Entity
increased,O
from,O
11.6%,O
in,O
period,O
1,O
to,O
39.7%,O
in,O
period,O
3,O
.,O
After,O
adjusting,O
for,O
potential,O
confounders,O
",",O
we,O
found,O
that,O
the,O
risk,O
of,O
HIV,B-Entity
seroconversion,I-Entity
among,O
participants,O
who,O
were,O
daily,O
smokers,O
of,O
crack,B-Entity
cocaine,I-Entity
increased,O
over,O
time,O
(,O
period,O
1,O
:,O
hazard,O
ratio,O
[,O
HR,O
],O
1.03,O
",",O
95%,O
confidence,O
interval,O
[,O
CI,O
],O
0.57,O
-,O
1.85,O
;,O
period,O
2,O
:,O
HR,O
1.68,O
",",O
95%,O
INTERPRETATION,O
:,O
Smoking,O
of,O
crack,B-Entity
cocaine,I-Entity
was,O
found,O
to,O
be,O
an,O
independent,O
risk,O
factor,O
for,O
HIV,B-Entity
seroconversion,I-Entity
among,O
people,O
who,O
were,O
injection,O
drug,O
users,O
.,O
This,O
finding,O
points,O
to,O
the,O
urgent,O
need,O
for,O
evidence,O
-,O
based,O
public,O
health,O
initiatives,O
targeted,O
at,O
people,O
who,O
smoke,O
crack,B-Entity
cocaine,I-Entity
.,O
Fluoxetine,I-Entity
improves,O
the,O
memory,B-Entity
deficits,I-Entity
caused,O
by,O
the,O
chemotherapy,O
agent,O
5-fluorouracil,I-Entity
.,O
Cancer,I-Entity
patients,O
who,O
have,O
been,O
treated,O
with,O
systemic,O
adjuvant,O
chemotherapy,O
have,O
described,O
experiencing,O
deteriorations,O
in,O
cognition,O
.,O
A,O
widely,O
used,O
chemotherapeutic,O
agent,O
",",O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
",",O
readily,O
crosses,O
the,O
blood,O
-,O
brain,O
barrier,O
and,O
so,O
could,O
have,O
a,O
direct,O
effect,O
on,O
brain,O
function,O
.,O
In,O
contrast,O
reports,O
indicate,O
that,O
hippocampal,O
dependent,O
neurogenesis,O
and,O
cognition,O
are,O
enhanced,O
by,O
the,O
SSRI,I-Entity
antidepressant,O
Fluoxetine,I-Entity
.,O
In,O
this,O
investigation,O
the,O
behavioural,O
effects,O
of,O
chronic,O
(,O
two,O
week,O
),O
treatment,O
with,O
5-FU,I-Entity
and,O
(,O
three,O
weeks,O
),O
with,O
Fluoxetine,I-Entity
either,O
separately,O
or,O
in,O
combination,O
with,O
5-FU,I-Entity
were,O
tested,O
on,O
adult,O
Lister,O
hooded,O
rats,O
.,O
Behavioural,O
effects,O
were,O
tested,O
using,O
a,O
context,O
dependent,O
conditioned,O
emotional,O
response,O
test,O
(,O
CER,O
),O
which,O
showed,O
that,O
animals,O
treated,O
with,O
5-FU,I-Entity
had,O
a,O
significant,O
reduction,O
in,O
freezing,O
time,O
compared,O
to,O
controls,O
.,O
Animals,O
treated,O
only,O
with,O
5-FU,I-Entity
showed,O
significant,O
deficits,O
in,O
their,O
ability,O
to,O
carry,O
out,O
the,O
OLR,O
task,O
but,O
co,O
administration,O
of,O
Fluoxetine,I-Entity
improved,O
their,O
performance,O
.,O
5-FU,I-Entity
chemotherapy,O
caused,O
a,O
significant,O
reduction,O
in,O
the,O
number,O
of,O
proliferating,O
cells,O
in,O
the,O
sub,O
granular,O
zone,O
of,O
the,O
dentate,O
gyrus,O
compared,O
to,O
controls,O
.,O
This,O
reduction,O
was,O
eliminated,O
when,O
Fluoxetine,I-Entity
was,O
co,O
administered,O
with,O
5-FU,I-Entity
.,O
Fluoxetine,I-Entity
on,O
its,O
own,O
had,O
no,O
effect,O
on,O
proliferating,O
cell,O
number,O
or,O
behaviour,O
.,O
These,O
findings,O
suggest,O
that,O
5-FU,I-Entity
can,O
negatively,O
affect,O
both,O
cell,O
proliferation,O
and,O
hippocampal,O
dependent,O
working,O
memory,O
and,O
that,O
these,O
deficits,O
can,O
be,O
reversed,O
by,O
the,O
simultaneous,O
administration,O
of,O
the,O
antidepressant,O
Fluoxetine,I-Entity
.,O
Liver,O
-,O
specific,O
ablation,O
of,O
integrin,O
-,O
linked,O
kinase,O
in,O
mice,O
results,O
in,O
enhanced,O
and,O
prolonged,O
cell,O
proliferation,O
and,O
hepatomegaly,I-Entity
after,O
phenobarbital,I-Entity
administration,O
.,O
This,O
study,O
investigates,O
the,O
role,O
of,O
ILK,O
in,O
liver,O
enlargement,O
induced,O
by,O
phenobarbital,I-Entity
(,O
PB,I-Entity
),O
.,O
liver-/-,O
mice,O
were,O
given,O
PB,I-Entity
(,O
0.1%,O
in,O
drinking,O
water,O
),O
for,O
10,O
days,O
.,O
Livers,O
were,O
harvested,O
on,O
2,O
",",O
5,O
",",O
and,O
10,O
days,O
during,O
PB,I-Entity
administration,O
.,O
There,O
were,O
slightly,O
increased,O
proliferating,O
cell,O
nuclear,O
antigen,O
-,O
positive,O
cells,O
in,O
the,O
ILK,O
/,O
liver-/-,O
animals,O
at,O
day,O
2,O
as,O
compared,O
to,O
WT,O
after,O
PB,I-Entity
administration,O
.,O
/,O
liver-/-,O
mice,O
also,O
showed,O
increased,O
expression,O
of,O
key,O
genes,O
involved,O
in,O
hepatocyte,O
proliferation,O
at,O
different,O
time,O
points,O
during,O
PB,I-Entity
administration,O
.,O
Lack,O
of,O
ILK,O
in,O
the,O
hepatocytes,O
imparts,O
prolonged,O
proliferative,O
response,O
not,O
only,O
to,O
stimuli,O
related,O
to,O
liver,O
regeneration,O
but,O
also,O
to,O
xenobiotic,O
chemical,O
mitogens,O
",",O
such,O
as,O
PB,I-Entity
.,O
Decreased,O
Expression,O
of,O
Na,I-Entity
/,O
K,I-Entity
-,O
ATPase,O
",",O
NHE3,O
",",O
NBC1,O
",",O
AQP1,O
and,O
OAT,O
in,O
Gentamicin,I-Entity
-,O
induced,O
Nephropathy,I-Entity
.,O
The,O
present,O
study,O
was,O
aimed,O
to,O
determine,O
whether,O
there,O
is,O
an,O
altered,O
regulation,O
of,O
tubular,O
transporters,O
in,O
gentamicin,I-Entity
-,O
induced,O
nephropathy,I-Entity
.,O
Sprague,O
-,O
Dawley,O
male,O
rats,O
(,O
200~250,O
g,O
),O
were,O
subcutaneously,O
injected,O
with,O
gentamicin,I-Entity
(,O
100,O
mg,O
/,O
kg,O
per,O
day,O
),O
for,O
7,O
days,O
",",O
and,O
the,O
expression,O
of,O
tubular,O
transporters,O
was,O
determined,O
by,O
immunoblotting,O
and,O
immunohistochemistry,O
.,O
Gentamicin,I-Entity
-,O
treated,O
rats,O
exhibited,O
significantly,O
decreased,O
creatinine,I-Entity
clearance,O
along,O
with,O
increased,O
plasma,O
creatinine,I-Entity
levels,O
.,O
Accordingly,O
",",O
the,O
fractional,O
excretion,O
of,O
sodium,I-Entity
increased,O
.,O
Immunoblotting,O
and,O
immunohistochemistry,O
revealed,O
decreased,O
expression,O
of,O
Na(+)/K(+)-ATPase,I-Entity
",",O
NHE3,O
",",O
NBC1,O
",",O
and,O
AQP1,O
in,O
the,O
kidney,O
of,O
gentamicin,I-Entity
-,O
treated,O
rats,O
.,O
Gentamicin,I-Entity
-,O
induced,O
nephropathy,I-Entity
may,O
at,O
least,O
in,O
part,O
be,O
causally,O
related,O
with,O
a,O
decreased,O
expression,O
of,O
Na(+)/K(+)-ATPase,I-Entity
",",O
NHE3,O
",",O
NBC1,O
",",O
AQP1,O
and,O
OAT,O
.,O
Longitudinal,O
association,O
of,O
alcohol,I-Entity
use,O
with,O
HIV,B-Entity
disease,I-Entity
progression,O
and,O
psychological,O
health,O
of,O
women,O
with,O
HIV,O
.,O
We,O
evaluated,O
the,O
association,O
of,O
alcohol,I-Entity
consumption,O
and,O
depression,I-Entity
",",O
and,O
their,O
effects,O
on,O
HIV,B-Entity
disease,I-Entity
progression,O
among,O
women,O
with,O
HIV,O
.,O
The,O
participants,O
had,O
physical,O
examination,O
",",O
medical,O
record,O
extraction,O
",",O
and,O
venipuncture,O
",",O
CD4+T,O
-,O
cell,O
counts,O
determination,O
",",O
measurement,O
of,O
depression,I-Entity
symptoms,O
(,O
using,O
the,O
self,O
-,O
report,O
Center,O
for,O
Epidemiological,O
Studies,O
-,O
Depression,I-Entity
Scale,O
),O
",",O
and,O
alcohol,I-Entity
use,O
assessment,O
at,O
enrollment,O
",",O
and,O
semiannually,O
until,O
March,O
2000,O
.,O
There,O
was,O
no,O
significant,O
association,O
between,O
level,O
of,O
alcohol,I-Entity
use,O
and,O
CD4,O
+,O
T,O
-,O
cell,O
counts,O
.,O
When,O
participants,O
were,O
stratified,O
by,O
antiretroviral,O
therapy,O
(,O
ART,O
),O
use,O
",",O
the,O
association,O
between,O
alcohol,I-Entity
and,O
CD4,O
+,O
T,O
-,O
cell,O
did,O
not,O
reach,O
statistical,O
significance,O
.,O
The,O
association,O
between,O
alcohol,I-Entity
consumption,O
and,O
depression,I-Entity
was,O
significant,O
(,O
p<0.001,O
),O
.,O
Depression,I-Entity
had,O
a,O
significant,O
negative,O
effect,O
on,O
CD4,O
+,O
T,O
-,O
cell,O
counts,O
over,O
time,O
regardless,O
of,O
ART,O
use,O
.,O
Our,O
findings,O
suggest,O
that,O
alcohol,I-Entity
consumption,O
has,O
a,O
direct,O
association,O
with,O
depression,I-Entity
.,O
Moreover,O
",",O
depression,I-Entity
is,O
associated,O
with,O
HIV,B-Entity
disease,I-Entity
progression,O
.,O
Our,O
findings,O
have,O
implications,O
for,O
the,O
provision,O
of,O
alcohol,I-Entity
use,O
interventions,O
and,O
psychological,O
resources,O
to,O
improve,O
the,O
health,O
of,O
women,O
with,O
HIV,O
.,O
Chemokine,O
CCL2,O
and,O
its,O
receptor,O
CCR2,O
are,O
increased,O
in,O
the,O
hippocampus,O
following,O
pilocarpine,I-Entity
-,O
induced,O
status,B-Entity
epilepticus,I-Entity
.,O
Neuroinflammation,I-Entity
occurs,O
after,O
seizures,I-Entity
and,O
is,O
implicated,O
in,O
epileptogenesis,O
.,O
CCR2,O
is,O
a,O
chemokine,O
receptor,O
for,O
CCL2,O
and,O
their,O
interaction,O
mediates,O
monocyte,O
infiltration,O
in,O
the,O
neuroinflammatory,I-Entity
cascade,O
triggered,O
in,O
different,O
brain,O
pathologies,O
.,O
In,O
this,O
work,O
CCR2,O
and,O
CCL2,O
expression,O
were,O
examined,O
following,O
status,B-Entity
epilepticus,I-Entity
(,O
SE,I-Entity
),O
induced,O
by,O
pilocarpine,I-Entity
injection,O
.,O
METHODS,O
:,O
SE,I-Entity
was,O
induced,O
by,O
pilocarpine,I-Entity
injection,O
.,O
Control,O
rats,O
were,O
injected,O
with,O
saline,O
instead,O
of,O
pilocarpine,I-Entity
.,O
Five,O
days,O
after,O
SE,I-Entity
",",O
CCR2,O
staining,O
in,O
neurons,O
and,O
glial,O
cells,O
was,O
examined,O
using,O
imunohistochemical,O
analyses,O
.,O
Increased,O
CCR2,O
was,O
observed,O
in,O
the,O
hippocampus,O
after,O
SE,I-Entity
.,O
Seizures,I-Entity
also,O
resulted,O
in,O
alterations,O
to,O
the,O
cell,O
types,O
expressing,O
CCR2,O
.,O
Increased,O
numbers,O
of,O
neurons,O
that,O
expressed,O
CCR2,O
was,O
observed,O
following,O
SE,I-Entity
.,O
Microglial,O
cells,O
were,O
more,O
closely,O
apposed,O
to,O
the,O
CCR2-labeled,O
cells,O
in,O
SE,I-Entity
rats,O
.,O
In,O
addition,O
",",O
rats,O
that,O
experienced,O
SE,I-Entity
exhibited,O
CCR2-labeling,O
in,O
populations,O
of,O
hypertrophied,I-Entity
astrocytes,O
",",O
especially,O
in,O
CA1,O
and,O
dentate,O
gyrus,O
.,O
Examination,O
of,O
CCL2,O
expression,O
showed,O
that,O
it,O
was,O
elevated,O
in,O
the,O
hippocampus,O
following,O
SE,I-Entity
.,O
CONCLUSION,O
:,O
The,O
data,O
show,O
that,O
CCR2,O
and,O
CCL2,O
are,O
up,O
-,O
regulated,O
in,O
the,O
hippocampus,O
after,O
pilocarpine,I-Entity
-,O
induced,O
SE,I-Entity
.,O
Seizures,I-Entity
also,O
result,O
in,O
changes,O
to,O
CCR2,O
receptor,O
expression,O
in,O
neurons,O
and,O
astrocytes,O
.,O
These,O
changes,O
might,O
be,O
involved,O
in,O
detrimental,O
neuroplasticity,O
and,O
neuroinflammatory,I-Entity
changes,O
that,O
occur,O
following,O
seizures,I-Entity
.,O
Metallothionein,I-Entity
induction,O
reduces,O
caspase-3,O
activity,O
and,O
TNFalpha,O
levels,O
with,O
preservation,O
of,O
cognitive,O
function,O
and,O
intact,O
hippocampal,O
neurons,O
in,O
carmustine,I-Entity
-,O
treated,O
rats,O
.,O
On,O
the,O
other,O
hand,O
",",O
induction,O
of,O
metallothionein,I-Entity
(,O
MT,I-Entity
),O
by,O
ZnSO(4,B-Entity
),I-Entity
and,O
its,O
role,O
in,O
neuroprotection,O
has,O
been,O
documented,O
.,O
The,O
present,O
study,O
aimed,O
to,O
explore,O
the,O
effect,O
of,O
MT,I-Entity
induction,O
on,O
carmustine,I-Entity
(,O
BCNU)-induced,I-Entity
hippocampal,O
cognitive,B-Entity
dysfunction,I-Entity
in,O
rats,O
.,O
A,O
total,O
of,O
60,O
male,O
Wistar,O
albino,O
rats,O
were,O
randomly,O
divided,O
into,O
four,O
groups,O
(,O
15/group,O
),O
:,O
The,O
control,O
group,O
injected,O
with,O
single,O
doses,O
of,O
normal,O
saline,O
(,O
i.c.v,O
),O
followed,O
24,O
h,O
later,O
by,O
BCNU,I-Entity
solvent,O
(,O
i.v,O
),O
.,O
The,O
second,O
group,O
administered,O
ZnSO(4,B-Entity
),I-Entity
(,O
0.1,O
micromol/10,O
microl,O
normal,O
saline,O
",",O
i.c.v,O
",",O
once,O
),O
then,O
BCNU,I-Entity
solvent,O
(,O
i.v,O
),O
after,O
24,O
h.,O
Third,O
group,O
received,O
BCNU,I-Entity
(,O
20,O
mg,O
/,O
kg,O
",",O
i.v,O
",",O
once,O
),O
Fourth,O
group,O
received,O
a,O
single,O
dose,O
of,O
ZnSO(4,B-Entity
),I-Entity
(,O
0.1,O
micromol/10,O
microl,O
normal,O
saline,O
",",O
i.c.v,O
),O
then,O
BCNU,I-Entity
(,O
20,O
mg,O
/,O
kg,O
",",O
i.v,O
",",O
once,O
),O
after,O
24,O
h.,O
The,O
obtained,O
data,O
revealed,O
that,O
BCNU,I-Entity
administration,O
resulted,O
in,O
deterioration,B-Entity
of,I-Entity
learning,I-Entity
and,I-Entity
short,I-Entity
-,I-Entity
term,I-Entity
memory,I-Entity
(,O
STM,O
),O
",",O
as,O
measured,O
by,O
using,O
radial,O
arm,O
water,O
maze,O
",",O
accompanied,O
with,O
decreased,O
hippocampal,O
glutathione,I-Entity
reductase,O
(,O
GR,O
),O
activity,O
and,O
reduced,O
glutathione,I-Entity
(,O
GSH,I-Entity
),O
content,O
.,O
Also,O
",",O
BCNU,I-Entity
administration,O
increased,O
serum,O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
(,O
TNFalpha,O
),O
",",O
hippocampal,O
MT,I-Entity
and,O
malondialdehyde,I-Entity
(,O
MDA,I-Entity
),O
contents,O
as,O
well,O
as,O
caspase-3,O
activity,O
in,O
addition,O
to,O
histological,O
alterations,O
.,O
ZnSO(4,B-Entity
),I-Entity
pretreatment,O
counteracted,O
BCNU,I-Entity
-,O
induced,O
inhibition,O
of,O
GR,O
and,O
depletion,O
of,O
GSH,I-Entity
and,O
resulted,O
in,O
significant,O
reduction,O
in,O
the,O
levels,O
of,O
MDA,I-Entity
and,O
TNFalpha,O
as,O
well,O
as,O
the,O
activity,O
of,O
caspase-3,O
.,O
The,O
histological,O
features,O
were,O
improved,O
in,O
hippocampus,O
of,O
rats,O
treated,O
with,O
ZnSO(4,B-Entity
),I-Entity
+,O
BCNU,I-Entity
compared,O
to,O
only,O
BCNU,I-Entity
-,O
treated,O
animals,O
.,O
In,O
conclusion,O
",",O
MT,I-Entity
induction,O
halts,O
BCNU,I-Entity
-,O
induced,O
hippocampal,O
toxicity,I-Entity
as,O
it,O
prevented,O
GR,O
inhibition,O
and,O
GSH,I-Entity
depletion,O
and,O
counteracted,O
the,O
increased,O
levels,O
of,O
TNFalpha,O
",",O
MDA,I-Entity
and,O
caspase-3,O
activity,O
with,O
subsequent,O
preservation,O
of,O
cognition,O
.,O
Fatal,O
carbamazepine,I-Entity
induced,O
fulminant,B-Entity
eosinophilic,I-Entity
(,O
hypersensitivity,I-Entity
),O
myocarditis,I-Entity
:,O
emphasis,O
on,O
anatomical,O
and,O
histological,O
characteristics,O
",",O
mechanisms,O
and,O
genetics,O
of,O
drug,B-Entity
hypersensitivity,I-Entity
and,O
differential,O
diagnosis,O
.,O
The,O
most,O
severe,O
adverse,O
reactions,O
to,O
carbamazepine,I-Entity
have,O
been,O
observed,O
in,O
the,O
haemopoietic,O
system,O
",",O
the,O
liver,O
and,O
the,O
cardiovascular,O
system,O
.,O
A,O
frequently,O
fatal,O
",",O
although,O
exceptionally,O
rare,O
side,O
effect,O
of,O
carbamazepine,I-Entity
is,O
necrotizing,O
eosinophilic,O
(,O
hypersensitivity,I-Entity
),O
myocarditis,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
hypersensitivity,I-Entity
myocarditis,I-Entity
secondary,O
to,O
administration,O
of,O
carbamazepine,I-Entity
.,O
Acute,O
hypersensitivity,I-Entity
myocarditis,I-Entity
was,O
not,O
suspected,O
clinically,O
",",O
and,O
the,O
diagnosis,O
was,O
made,O
post,O
-,O
mortem,O
.,O
Clinically,O
",",O
death,O
was,O
due,O
to,O
cardiogenic,B-Entity
shock,I-Entity
.,O
To,O
best,O
of,O
our,O
knowledge,O
this,O
is,O
the,O
second,O
case,O
of,O
fatal,O
carbamazepine,I-Entity
induced,O
myocarditis,I-Entity
reported,O
in,O
English,O
literature,O
.,O
Neuropsychiatric,O
behaviors,O
in,O
the,O
MPTP,I-Entity
marmoset,O
model,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Neuropsychiatric,O
symptoms,O
are,O
increasingly,O
recognised,O
as,O
a,O
significant,O
problem,O
in,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
.,O
These,O
symptoms,O
may,O
be,O
due,O
to,O
',O
sensitisation,O
',O
following,O
repeated,O
levodopa,I-Entity
treatment,O
or,O
a,O
direct,O
effect,O
of,O
dopamine,I-Entity
on,O
the,O
disease,O
state,O
.,O
The,O
levodopa,I-Entity
-,O
treated,O
MPTP,I-Entity
-,O
lesioned,O
marmoset,O
was,O
used,O
as,O
a,O
model,O
of,O
neuropsychiatric,B-Entity
symptoms,I-Entity
in,O
PD,I-Entity
patients,O
.,O
Here,O
we,O
compare,O
the,O
time,O
course,O
of,O
levodopa,I-Entity
-,O
induced,O
motor,O
fluctuations,O
and,O
neuropsychiatric,B-Entity
-,I-Entity
like,I-Entity
behaviors,I-Entity
to,O
determine,O
the,O
relationship,O
between,O
duration,O
of,O
treatment,O
and,O
onset,O
of,O
symptoms,O
.,O
Marmosets,O
were,O
administered,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",I-Entity
(,O
2.0,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
for,O
five,O
days,O
",",O
resulting,O
in,O
stable,O
parkinsonism,I-Entity
.,O
Levodopa,I-Entity
(,O
15,O
mg,O
/,O
kg,O
and,O
benserazide,I-Entity
",",O
3.75,O
mg,O
/,O
kg,O
),O
Animals,O
were,O
evaluated,O
for,O
parkinsonian,B-Entity
disability,I-Entity
",",O
dyskinesia,I-Entity
and,O
on,O
-,O
time,O
(,O
motor,O
fluctuations,O
),O
and,O
neuropsychiatric,B-Entity
-,I-Entity
like,I-Entity
behaviors,I-Entity
on,O
Day,O
0,O
(,O
prior,O
to,O
levodopa,I-Entity
),O
and,O
on,O
Days,O
1,O
",",O
7,O
",",O
13,O
",",O
27,O
and,O
30,O
of,O
treatment,O
using,O
post,O
hoc,O
DVD,O
analysis,O
by,O
a,O
trained,O
rater,O
",",O
blind,O
to,O
the,O
treatment,O
day,O
.,O
The,O
neuropsychiatric,B-Entity
-,I-Entity
like,I-Entity
behavior,I-Entity
rating,O
scale,O
demonstrated,O
high,O
interrater,O
reliability,O
between,O
three,O
trained,O
raters,O
of,O
differing,O
professional,O
backgrounds,O
.,O
As,O
anticipated,O
",",O
animals,O
exhibited,O
a,O
progressive,O
increase,O
in,O
levodopa,I-Entity
-,O
induced,O
motor,O
fluctuations,O
",",O
dyskinesia,I-Entity
and,O
wearing,O
-,O
off,O
",",O
that,O
correlated,O
with,O
the,O
duration,O
of,O
levodopa,I-Entity
therapy,O
.,O
In,O
contrast,O
",",O
levodopa,I-Entity
-,O
induced,O
neuropsychiatric,B-Entity
-,I-Entity
like,I-Entity
behaviors,I-Entity
were,O
present,O
on,O
Day,O
1,O
of,O
levodopa,I-Entity
treatment,O
and,O
their,O
severity,O
did,O
not,O
correlate,O
with,O
duration,O
of,O
treatment,O
.,O
The,O
data,O
suggest,O
that,O
neuropsychiatric,B-Entity
disorders,I-Entity
in,O
PD,I-Entity
are,O
more,O
likely,O
an,O
interaction,O
between,O
levodopa,I-Entity
and,O
the,O
disease,O
state,O
than,O
a,O
consequence,O
of,O
sensitisation,O
to,O
repeated,O
dopaminergic,O
therapy,O
.,O
Contrast,B-Entity
medium,I-Entity
nephrotoxicity,I-Entity
after,O
renal,O
artery,O
and,O
coronary,O
angioplasty,O
.,O
Renal,B-Entity
dysfunction,I-Entity
induced,O
by,O
iodinated,O
contrast,B-Entity
medium,I-Entity
(,O
CM,I-Entity
),O
administration,O
can,O
minimize,O
the,O
benefit,O
of,O
the,O
interventional,O
procedure,O
in,O
patients,O
undergoing,O
renal,O
angioplasty,O
(,O
PTRA,O
),O
.,O
To,O
compare,O
the,O
susceptibility,O
to,O
nephrotoxic,I-Entity
effect,O
of,O
CM,I-Entity
in,O
patients,O
undergoing,O
PTRA,O
with,O
that,O
of,O
patients,O
submitted,O
to,O
percutaneous,O
coronary,O
intervention,O
(,O
PCI,O
),O
.,O
A,O
total,O
of,O
33,O
patients,O
successfully,O
treated,O
with,O
PTRA,O
(,O
PTRA,O
group,O
",",O
mean,O
age,O
70+/-12,O
years,O
",",O
23,O
female,O
",",O
basal,O
creatinine,I-Entity
1.46+/-0.79,O
",",O
range,O
0.7,O
-,O
4.9,O
mg,O
/,O
dl,O
),O
were,O
compared,O
with,O
33,O
patients,O
undergoing,O
successful,O
PCI,O
(,O
PCI,O
group,O
),O
",",O
matched,O
for,O
basal,O
creatinine,I-Entity
(,O
1.44+/-0.6,O
",",O
range,O
0.7,O
-,O
3.4,O
mg,O
/,O
dl,O
),O
",",O
gender,O
",",O
and,O
age,O
.,O
serum,O
creatinine,I-Entity
was,O
measured,O
.,O
RESULTS,O
:,O
Postprocedural,O
creatinine,I-Entity
level,O
decreased,O
nonsignificantly,O
in,O
the,O
PTRA,O
group,O
(,O
1.46+/-0.8,O
vs.,O
1.34+/-0.5,O
mg,O
/,O
dl,O
",",O
Changes,O
in,O
serum,O
creatinine,I-Entity
after,O
intervention,O
(,O
after,O
-,O
before,O
),O
were,O
significantly,O
different,O
between,O
the,O
PTRA,O
and,O
PCI,O
groups,O
(,O
-0.12+/-0.5,O
vs.,O
0.13+/-0.3,O
",",O
P=0.014,O
),O
.,O
This,O
difference,O
was,O
not,O
related,O
to,O
either,O
a,O
different,O
clinical,O
risk,O
profile,O
or,O
to,O
the,O
volume,O
of,O
CM,I-Entity
administered,O
.,O
CONCLUSION,O
:,O
In,O
this,O
preliminary,O
study,O
patients,O
submitted,O
to,O
PTRA,O
showed,O
a,O
lower,O
susceptibility,O
to,O
renal,B-Entity
damage,I-Entity
induced,O
by,O
CM,I-Entity
administration,O
than,O
PCI,O
patients,O
.,O
The,O
effectiveness,O
of,O
PTRA,O
on,O
renal,O
function,O
seems,O
to,O
be,O
barely,O
influenced,O
by,O
CM,I-Entity
toxicity,I-Entity
.,O
Medical,O
and,O
psychiatric,O
outcomes,O
for,O
patients,O
transplanted,O
for,O
acetaminophen,I-Entity
-,O
induced,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
:,O
a,O
case,O
-,O
control,O
study,O
.,O
Acetaminophen,I-Entity
-,O
induced,O
hepatotoxicity,I-Entity
is,O
the,O
most,O
common,O
cause,O
of,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
(,O
ALF,I-Entity
),O
in,O
the,O
UK,O
.,O
:,O
We,O
compared,O
the,O
severity,O
of,O
pretransplant,O
illness,O
",",O
psychiatric,O
co,O
-,O
morbidity,O
",",O
medical,O
and,O
psychosocial,O
outcomes,O
of,O
all,O
patients,O
who,O
had,O
undergone,O
liver,O
transplantation,O
(,O
LT,O
),O
emergently,O
between,O
1999,O
-,O
2004,O
for,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
(,O
n=36,O
),O
with,O
age-,O
and,O
sex,O
-,O
matched,O
patients,O
undergoing,O
emergent,O
LT,O
for,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
(,O
n=35,O
),O
and,O
elective,O
LT,O
for,O
chronic,B-Entity
liver,I-Entity
disease,I-Entity
(,O
CLD,I-Entity
",",O
n=34,O
),O
.,O
Acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
patients,O
undergoing,O
LT,O
had,O
a,O
greater,O
severity,O
of,O
pre,O
-,O
LT,O
illness,O
reflected,O
by,O
higher,O
Acute,O
Physiology,O
and,O
Chronic,O
Health,O
Evaluation,O
II,O
Twenty,O
(,O
56%,O
),O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
patients,O
had,O
a,O
formal,O
psychiatric,O
diagnosis,O
before,O
LT,O
(,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF=0/35,I-Entity
",",O
CLD=2/34,I-Entity
;,O
P<0.01,O
for,O
all,O
),O
and,O
nine,O
(,O
25%,O
),O
had,O
a,O
previous,O
suicide,O
attempt,O
.,O
During,O
follow,O
-,O
up,O
(,O
median,O
5,O
years,O
),O
",",O
there,O
were,O
no,O
significant,O
differences,O
in,O
rejection,O
(,O
acute,O
and,O
chronic,O
),O
",",O
graft,O
failure,O
or,O
survival,O
between,O
the,O
groups,O
(,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
1,O
year,O
87%,O
",",O
5,O
years,O
75%,O
;,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
88%,O
",",O
78%,O
;,O
CLD,I-Entity
93%,O
",",O
82%,O
:,O
P>0.6,O
log,O
rank,O
),O
.,O
Two,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
patients,O
reattempted,O
suicide,O
post,O
-,O
LT,O
(,O
one,O
died,O
8,O
years,O
post,O
-,O
LT,O
),O
.,O
Despite,O
a,O
high,O
prevalence,O
of,O
psychiatric,O
disturbance,O
",",O
outcomes,O
for,O
patients,O
transplanted,O
emergently,O
for,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
were,O
comparable,O
to,O
those,O
transplanted,O
for,O
non,O
-,O
acetaminophen,I-Entity
-,O
induced,O
ALF,I-Entity
and,O
electively,O
for,O
CLD,I-Entity
.,O
Studies,O
of,O
synergy,O
between,O
morphine,I-Entity
and,O
a,O
novel,O
sodium,I-Entity
channel,O
blocker,O
",",O
CNSB002,I-Entity
",",O
in,O
rat,O
models,O
of,O
inflammatory,O
and,O
neuropathic,B-Entity
pain,I-Entity
.,O
This,O
study,O
determined,O
the,O
antihyperalgesic,O
effect,O
of,O
CNSB002,I-Entity
",",O
a,O
sodium,I-Entity
channel,O
blocker,O
with,O
antioxidant,O
properties,O
given,O
alone,O
and,O
in,O
combinations,O
with,O
morphine,I-Entity
in,O
rat,O
models,O
of,O
inflammatory,O
and,O
neuropathic,B-Entity
pain,I-Entity
.,O
Dose,O
response,O
curves,O
for,O
nonsedating,O
doses,O
of,O
morphine,I-Entity
and,O
CNSB002,I-Entity
given,O
intraperitoneally,O
alone,O
and,O
together,O
in,O
combinations,O
were,O
constructed,O
for,O
antihyperalgesic,O
effect,O
using,O
paw,O
withdrawal,O
from,O
noxious,O
heat,O
in,O
two,O
rat,O
pain,I-Entity
models,O
:,O
carrageenan,I-Entity
-,O
induced,O
paw,O
inflammation,I-Entity
and,O
streptozotocin,I-Entity
(,O
STZ)-induced,I-Entity
diabetic,B-Entity
neuropathy,I-Entity
.,O
The,O
maximum,O
nonsedating,O
doses,O
were,O
:,O
morphine,I-Entity
",",O
3.2,O
mg,O
/,O
kg,O
;,O
CNSB002,I-Entity
10.0,O
mg,O
/,O
kg,O
;,O
5.0,O
mg,O
/,O
kg,O
CNSB002,I-Entity
with,O
morphine,I-Entity
3.2,O
mg,O
/,O
kg,O
in,O
combination,O
.,O
The,O
doses,O
calculated,O
to,O
cause,O
50%,O
reversal,O
of,O
hyperalgesia,I-Entity
(,O
ED50,O
),O
were,O
7.54,O
(,O
1.81,O
),O
and,O
4.83,O
(,O
1.54,O
),O
in,O
the,O
carrageenan,I-Entity
model,O
and,O
44.18,O
(,O
1.37,O
),O
and,O
9.14,O
(,O
1.24,O
),O
in,O
the,O
STZ,I-Entity
-,O
induced,O
neuropathy,I-Entity
model,O
for,O
CNSB002,I-Entity
and,O
morphine,I-Entity
",",O
respectively,O
(,O
mg,O
/,O
kg,O
;,O
mean,O
",",O
SEM,O
),O
.,O
The,O
ED50,O
values,O
for,O
morphine,I-Entity
when,O
given,O
in,O
combination,O
with,O
CNSB002,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
were,O
less,O
than,O
the,O
maximum,O
nonsedating,O
dose,O
:,O
0.56,O
(,O
1.55,O
),O
in,O
the,O
carrageenan,I-Entity
model,O
and,O
1.37,O
(,O
1.23,O
),O
in,O
the,O
neuropathy,I-Entity
model,O
(,O
mg,O
/,O
kg,O
;,O
mean,O
",",O
SEM,O
),O
.,O
The,O
antinociception,O
after,O
morphine,I-Entity
(,O
3.2,O
mg,O
/,O
kg,O
),O
was,O
increased,O
by,O
co,O
-,O
administration,O
with,O
CNSB002,I-Entity
from,O
28.0,O
and,O
31.7%,O
to,O
114.6,O
and,O
56.9%,O
reversal,O
of,O
hyperalgesia,I-Entity
in,O
the,O
inflammatory,O
and,O
neuropathic,I-Entity
models,O
",",O
respectively,O
(,O
P,O
<,O
0.01,O
;,O
one,O
-,O
way,O
analysis,O
of,O
variance,O
-,O
significantly,O
greater,O
than,O
either,O
drug,O
given,O
alone,O
),O
.,O
The,O
maximum,O
antihyperalgesic,O
effect,O
achievable,O
with,O
nonsedating,O
doses,O
of,O
morphine,I-Entity
may,O
be,O
increased,O
significantly,O
when,O
the,O
drug,O
is,O
used,O
in,O
combination,O
with,O
CNSB002,I-Entity
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
:,O
a,O
practical,O
review,O
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
(,O
HIT,I-Entity
),O
remains,O
under,O
-,O
recognized,O
despite,O
its,O
potentially,O
devastating,O
outcomes,O
.,O
It,O
begins,O
when,O
heparin,I-Entity
exposure,O
stimulates,O
the,O
formation,O
of,O
heparin,I-Entity
-,O
platelet,O
factor,O
4,O
antibodies,O
",",O
which,O
in,O
turn,O
triggers,O
the,O
release,O
of,O
procoagulant,O
platelet,O
particles,O
.,O
Thrombosis,I-Entity
and,O
thrombocytopenia,I-Entity
that,O
follow,O
comprise,O
the,O
2,O
hallmark,O
traits,O
of,O
HIT,I-Entity
",",O
with,O
the,O
former,O
largely,O
responsible,O
for,O
significant,O
vascular,O
complications,O
.,O
The,O
prevalence,O
of,O
HIT,I-Entity
varies,O
among,O
several,O
subgroups,O
",",O
with,O
greater,O
incidence,O
in,O
surgical,O
as,O
compared,O
with,O
medical,O
populations,O
.,O
HIT,I-Entity
must,O
be,O
acknowledged,O
for,O
its,O
intense,O
predilection,O
for,O
thrombosis,I-Entity
and,O
suspected,O
whenever,O
thrombosis,I-Entity
occurs,O
after,O
heparin,I-Entity
exposure,O
.,O
The,O
treatment,O
of,O
HIT,I-Entity
mandates,O
an,O
immediate,O
cessation,O
of,O
all,O
heparin,I-Entity
exposure,O
and,O
the,O
institution,O
of,O
an,O
antithrombotic,O
therapy,O
",",O
most,O
commonly,O
using,O
a,O
direct,B-Entity
thrombin,I-Entity
inhibitor,I-Entity
.,O
Current,O
"""",O
diagnostic,O
"""",O
tests,O
",",O
which,O
primarily,O
include,O
functional,O
and,O
antigenic,O
assays,O
",",O
have,O
more,O
of,O
a,O
confirmatory,O
than,O
diagnostic,O
role,O
in,O
the,O
management,O
of,O
HIT,I-Entity
.,O
Special,O
attention,O
must,O
be,O
paid,O
to,O
cardiac,O
patients,O
who,O
are,O
often,O
exposed,O
to,O
heparin,I-Entity
multiple,O
times,O
during,O
their,O
course,O
of,O
treatment,O
.,O
Direct,B-Entity
thrombin,I-Entity
inhibitors,I-Entity
are,O
appropriate,O
",",O
evidence,O
-,O
based,O
alternatives,O
to,O
heparin,I-Entity
in,O
patients,O
with,O
a,O
history,O
of,O
HIT,I-Entity
",",O
who,O
need,O
to,O
undergo,O
percutaneous,O
coronary,O
intervention,O
.,O
As,O
heparin,I-Entity
remains,O
one,O
of,O
the,O
most,O
frequently,O
used,O
medications,O
today,O
with,O
potential,O
for,O
HIT,I-Entity
with,O
every,O
heparin,I-Entity
exposure,O
",",O
a,O
close,O
vigilance,O
of,O
platelet,O
counts,O
must,O
be,O
practiced,O
whenever,O
heparin,I-Entity
is,O
initiated,O
.,O
Abductor,O
paralysis,I-Entity
after,O
botox,I-Entity
injection,O
for,O
adductor,B-Entity
spasmodic,I-Entity
dysphonia,I-Entity
.,O
Botulinum,O
toxin,O
(,O
Botox,I-Entity
),O
injections,O
into,O
the,O
thyroarytenoid,O
muscles,O
are,O
the,O
current,O
standard,O
of,O
care,O
for,O
adductor,B-Entity
spasmodic,I-Entity
dysphonia,I-Entity
(,O
ADSD,I-Entity
),O
.,O
Reported,O
adverse,O
effects,O
include,O
a,O
period,O
of,O
breathiness,O
",",O
throat,B-Entity
pain,I-Entity
",",O
and,O
difficulty,O
with,O
swallowing,O
liquids,O
.,O
Here,O
we,O
report,O
multiple,O
cases,O
of,O
bilateral,O
abductor,O
paralysis,I-Entity
following,O
Botox,I-Entity
injections,O
for,O
ADSD,I-Entity
",",O
a,O
complication,O
previously,O
unreported,O
.,O
Patients,O
that,O
received,O
Botox,I-Entity
injections,O
for,O
spasmodic,B-Entity
dysphonia,I-Entity
between,O
January,O
2000,O
and,O
October,O
2009,O
were,O
evaluated,O
.,O
Patients,O
with,O
ADSD,I-Entity
were,O
identified,O
.,O
For,O
patients,O
with,O
bilateral,O
abductor,O
paralysis,I-Entity
",",O
age,O
",",O
sex,O
",",O
paralytic,O
Botox,I-Entity
dose,O
",",O
prior,O
Botox,I-Entity
dose,O
",",O
and,O
course,O
following,O
paralysis,I-Entity
were,O
noted,O
.,O
From,O
a,O
database,O
of,O
452,O
patients,O
receiving,O
Botox,I-Entity
",",O
352,O
patients,O
had,O
been,O
diagnosed,O
with,O
ADSD,I-Entity
.,O
Of,O
these,O
352,O
patients,O
",",O
eight,O
patients,O
suffered,O
bilateral,O
abductor,O
paralysis,I-Entity
",",O
and,O
two,O
suffered,O
this,O
complication,O
twice,O
.,O
Most,O
patients,O
had,O
received,O
treatments,O
prior,O
to,O
abductor,O
paralysis,I-Entity
and,O
continued,O
receiving,O
after,O
paralysis,I-Entity
.,O
The,O
incidence,O
of,O
abductor,O
paralysis,I-Entity
after,O
Botox,I-Entity
injection,O
for,O
ADSD,I-Entity
was,O
0.34%,O
.,O
Bilateral,O
abductor,O
paralysis,I-Entity
is,O
a,O
rare,O
complication,O
of,O
Botox,I-Entity
injections,O
for,O
ADSD,I-Entity
",",O
causing,O
difficulty,O
with,O
breathing,O
upon,O
exertion,O
.,O
The,O
likely,O
mechanism,O
of,O
paralysis,I-Entity
is,O
diffusion,O
of,O
Botox,I-Entity
around,O
the,O
muscular,O
process,O
of,O
the,O
arytenoid,O
to,O
the,O
posterior,O
cricoarytenoid,O
muscles,O
.,O
The,O
paralysis,I-Entity
is,O
temporary,O
",",O
and,O
watchful,O
waiting,O
with,O
restriction,O
of,O
activity,O
is,O
the,O
recommended,O
management,O
.,O
Mitochondrial,B-Entity
impairment,I-Entity
contributes,O
to,O
cocaine,I-Entity
-,O
induced,O
cardiac,B-Entity
dysfunction,I-Entity
:,O
Prevention,O
by,O
the,O
targeted,O
antioxidant,O
MitoQ.,I-Entity
The,O
goal,O
of,O
this,O
study,O
was,O
to,O
assess,O
mitochondrial,O
function,O
and,O
ROS,O
production,O
in,O
an,O
experimental,O
model,O
of,O
cocaine,I-Entity
-,O
induced,O
cardiac,B-Entity
dysfunction,I-Entity
.,O
We,O
hypothesized,O
that,O
cocaine,B-Entity
abuse,I-Entity
may,O
lead,O
to,O
altered,O
mitochondrial,O
function,O
that,O
in,O
turn,O
may,O
cause,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
.,O
Seven,O
days,O
of,O
cocaine,I-Entity
administration,O
to,O
rats,O
led,O
to,O
an,O
increased,O
oxygen,I-Entity
consumption,O
detected,O
in,O
cardiac,O
fibers,O
",",O
specifically,O
through,O
complex,O
I,O
and,O
complex,O
III,O
.,O
In,O
parallel,O
there,O
was,O
a,O
decrease,O
in,O
ATP,I-Entity
synthesis,O
",",O
whereas,O
no,O
difference,O
was,O
observed,O
in,O
subsarcolemmal,O
mitochondria,O
.,O
This,O
uncoupling,O
effect,O
on,O
oxidative,O
phosphorylation,O
was,O
not,O
detectable,O
after,O
short,O
-,O
term,O
exposure,O
to,O
cocaine,I-Entity
",",O
suggesting,O
that,O
these,O
mitochondrial,B-Entity
abnormalities,I-Entity
were,O
a,O
late,O
rather,O
than,O
a,O
primary,O
event,O
in,O
the,O
pathological,O
response,O
to,O
cocaine,I-Entity
.,O
MitoQ,I-Entity
",",O
a,O
mitochondrial,O
-,O
targeted,O
antioxidant,O
",",O
was,O
shown,O
to,O
completely,O
prevent,O
these,O
mitochondrial,B-Entity
abnormalities,I-Entity
as,O
well,O
as,O
cardiac,B-Entity
dysfunction,I-Entity
characterized,O
here,O
by,O
a,O
diastolic,B-Entity
dysfunction,I-Entity
studied,O
with,O
a,O
conductance,O
catheter,O
to,O
obtain,O
pressure,O
-,O
volume,O
data,O
.,O
Taken,O
together,O
",",O
these,O
results,O
extend,O
previous,O
studies,O
and,O
demonstrate,O
that,O
cocaine,I-Entity
-,O
induced,O
cardiac,B-Entity
dysfunction,I-Entity
may,O
be,O
due,O
to,O
a,O
mitochondrial,B-Entity
defect,I-Entity
.,O
Trimethoprim,I-Entity
-,O
induced,O
immune,O
hemolytic,B-Entity
anemia,I-Entity
in,O
a,O
pediatric,O
oncology,O
patient,O
presenting,O
as,O
an,O
acute,O
hemolytic,O
transfusion,O
reaction,O
.,O
A,O
10-year,O
-,O
old,O
male,O
with,O
acute,B-Entity
leukemia,I-Entity
presented,O
with,O
post,O
-,O
chemotherapy,O
anemia,I-Entity
.,O
During,O
red,O
cell,O
transfusion,O
",",O
he,O
developed,O
hemoglobinuria,I-Entity
.,O
Drug,O
-,O
induced,O
immune,O
hemolytic,B-Entity
anemia,I-Entity
was,O
suspected,O
because,O
of,O
positive,O
direct,O
antiglobulin,O
test,O
",",O
negative,O
eluate,O
",",O
and,O
microspherocytes,O
on,O
smear,O
pre-,O
and,O
post,O
-,O
transfusion,O
.,O
Drug,O
studies,O
using,O
the,O
indirect,O
antiglobulin,O
test,O
were,O
strongly,O
positive,O
with,O
trimethoprim,I-Entity
and,O
trimethoprim,B-Entity
-,I-Entity
sulfamethoxazole,I-Entity
but,O
negative,O
with,O
sulfamethoxazole,I-Entity
.,O
Other,O
causes,O
of,O
anemia,I-Entity
should,O
be,O
considered,O
in,O
patients,O
with,O
worse,O
-,O
than,O
-,O
expected,O
anemia,I-Entity
after,O
chemotherapy,O
.,O
Furthermore,O
",",O
hemolysis,I-Entity
during,O
transfusion,O
is,O
not,O
always,O
a,O
transfusion,O
reaction,O
.,O
Blockade,O
of,O
endothelial,O
-,O
mesenchymal,O
transition,O
by,O
a,O
Smad3,O
inhibitor,O
delays,O
the,O
early,O
development,O
of,O
streptozotocin,I-Entity
-,O
induced,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
OBJECTIVE,O
:,O
A,O
multicenter,O
",",O
controlled,O
trial,O
showed,O
that,O
early,O
blockade,O
of,O
the,O
renin,O
-,O
angiotensin,I-Entity
system,O
in,O
patients,O
with,O
type,B-Entity
1,I-Entity
diabetes,I-Entity
and,O
normoalbuminuria,O
did,O
not,O
retard,O
the,O
progression,O
of,O
nephropathy,I-Entity
",",O
suggesting,O
that,O
other,O
mechanism(s,O
),O
are,O
involved,O
in,O
the,O
pathogenesis,O
of,O
early,O
diabetic,B-Entity
nephropathy,I-Entity
(,O
diabetic,B-Entity
nephropathy,I-Entity
),O
.,O
We,O
have,O
previously,O
demonstrated,O
that,O
endothelial,O
-,O
mesenchymal,O
-,O
transition,O
(,O
EndoMT,O
),O
contributes,O
to,O
the,O
early,O
development,O
of,O
renal,O
interstitial,O
fibrosis,I-Entity
independently,O
of,O
microalbuminuria,O
in,O
mice,O
with,O
streptozotocin,I-Entity
(,O
STZ)-induced,I-Entity
diabetes,I-Entity
.,O
In,O
the,O
present,O
study,O
",",O
we,O
hypothesized,O
that,O
blocking,O
EndoMT,O
reduces,O
the,O
early,O
development,O
of,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
Blocking,O
studies,O
using,O
receptor,O
for,O
AGE,O
siRNA,O
and,O
a,O
specific,O
inhibitor,O
of,O
Smad3,O
(,O
SIS3,O
),O
were,O
performed,O
in,O
MMECs,O
and,O
in,O
STZ,I-Entity
-,O
induced,O
diabetic,B-Entity
nephropathy,I-Entity
in,O
Tie2-Cre;Loxp,O
-,O
EGFP,O
mice,O
.,O
/,O
Western,O
blotting,O
showed,O
that,O
Smad3,O
was,O
activated,O
by,O
AGEs,O
but,O
was,O
inhibited,O
by,O
SIS3,O
in,O
MMECs,O
and,O
in,O
STZ,I-Entity
-,O
induced,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
Confocal,O
microscopy,O
and,O
real,O
-,O
time,O
PCR,O
further,O
demonstrated,O
that,O
SIS3,O
abrogated,O
EndoMT,O
",",O
reduced,O
renal,O
fibrosis,I-Entity
",",O
and,O
retarded,O
progression,O
of,O
nephropathy,I-Entity
.,O
EndoMT,O
is,O
a,O
novel,O
pathway,O
leading,O
to,O
early,O
development,O
of,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
Blockade,O
of,O
EndoMT,O
by,O
SIS3,O
may,O
provide,O
a,O
new,O
strategy,O
to,O
retard,O
the,O
progression,O
of,O
diabetic,B-Entity
nephropathy,I-Entity
and,O
other,O
diabetes,B-Entity
complications,I-Entity
.,O
Cytostatic,O
and,O
anti,O
-,O
angiogenic,O
effects,O
of,O
temsirolimus,I-Entity
in,O
refractory,O
mantle,B-Entity
cell,I-Entity
lymphoma,I-Entity
.,O
Mantle,B-Entity
cell,I-Entity
lymphoma,I-Entity
(,O
MCL,I-Entity
),O
is,O
a,O
rare,O
and,O
aggressive,O
type,O
of,O
B,B-Entity
-,I-Entity
cell,I-Entity
non,I-Entity
-,I-Entity
Hodgkin,I-Entity
's,I-Entity
lymphoma,I-Entity
.,O
However,O
",",O
a,O
38%,O
remission,O
rate,O
has,O
been,O
recently,O
reported,O
in,O
refractory,O
MCL,I-Entity
treated,O
with,O
temsirolimus,I-Entity
",",O
a,O
mTOR,O
inhibitor,O
.,O
Here,O
we,O
had,O
the,O
opportunity,O
to,O
study,O
a,O
case,O
of,O
refractory,O
MCL,I-Entity
who,O
had,O
tumor,I-Entity
regression,O
two,O
months,O
after,O
temsirolimus,I-Entity
treatment,O
",",O
and,O
a,O
progression,O
-,O
free,O
survival,O
of,O
10,O
months,O
.,O
In,O
this,O
case,O
",",O
lymph,O
node,O
biopsies,O
were,O
performed,O
before,O
and,O
six,O
months,O
after,O
temsirolimus,I-Entity
therapy,O
.,O
Comparison,O
of,O
the,O
two,O
biopsies,O
showed,O
that,O
temsirolimus,I-Entity
inhibited,O
tumor,I-Entity
cell,O
proliferation,O
through,O
cell,O
cycle,O
arrest,O
",",O
but,O
did,O
not,O
induce,O
any,O
change,O
in,O
the,O
number,O
of,O
apoptotic,O
tumor,I-Entity
cells,O
.,O
Apart,O
from,O
this,O
cytostatic,O
effect,O
",",O
temsirolimus,I-Entity
had,O
an,O
antiangiogenic,O
effect,O
with,O
decrease,O
of,O
tumor,I-Entity
microvessel,O
density,O
and,O
of,O
VEGF,O
expression,O
.,O
Moreover,O
",",O
numerous,O
patchy,O
",",O
well,O
-,O
limited,O
fibrotic,O
areas,O
",",O
compatible,O
with,O
post,O
-,O
necrotic,I-Entity
tissue,O
repair,O
",",O
were,O
found,O
after,O
6-month,O
temsirolimus,I-Entity
therapy,O
.,O
Thus,O
",",O
temsirolimus,I-Entity
reduced,O
tumor,I-Entity
burden,O
through,O
associated,O
cytostatic,O
and,O
anti,O
-,O
angiogenic,O
effects,O
.,O
This,O
dual,O
effect,O
of,O
temsirolimus,I-Entity
on,O
tumor,I-Entity
tissue,O
could,O
contribute,O
to,O
its,O
recently,O
reported,O
efficiency,O
in,O
refractory,O
MCL,I-Entity
resistant,O
to,O
conventional,O
chemotherapy,O
.,O
Syncope,I-Entity
caused,O
by,O
hyperkalemia,I-Entity
during,O
use,O
of,O
a,O
combined,O
therapy,O
with,O
the,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitor,O
and,O
spironolactone,I-Entity
.,O
A,O
76,O
year,O
-,O
old,O
woman,O
with,O
a,O
history,O
of,O
coronary,O
artery,O
bypass,O
grafting,O
and,O
prior,O
myocardial,B-Entity
infarction,I-Entity
was,O
transferred,O
to,O
the,O
emergency,O
room,O
with,O
loss,B-Entity
of,I-Entity
consciousness,I-Entity
due,O
to,O
marked,O
bradycardia,I-Entity
caused,O
by,O
hyperkalemia,I-Entity
.,O
The,O
concentration,O
of,O
serum,O
potassium,I-Entity
was,O
high,O
",",O
and,O
normal,O
sinus,O
rhythm,O
was,O
restored,O
after,O
correction,O
of,O
the,O
serum,O
potassium,I-Entity
level,O
.,O
The,O
cause,O
of,O
hyperkalemia,I-Entity
was,O
considered,O
to,O
be,O
several,O
doses,O
of,O
spiranolactone,I-Entity
",",O
an,O
aldosterone,I-Entity
antagonist,O
",",O
in,O
addition,O
to,O
the,O
long,O
-,O
term,O
intake,O
of,O
ramipril,I-Entity
",",O
an,O
ACE,O
inhibitor,O
.,O
Clinicians,O
should,O
be,O
alert,O
to,O
the,O
possibility,O
of,O
hyperkalemia,I-Entity
",",O
especially,O
in,O
elderly,O
patients,O
using,O
ACE,O
/,O
ARB,O
in,O
combination,O
with,O
potassium,I-Entity
sparing,O
agents,O
and,O
who,O
have,O
mild,O
renal,B-Entity
disturbance,I-Entity
.,O
Diffuse,O
skeletal,O
pain,I-Entity
after,O
administration,O
of,O
alendronate,I-Entity
.,O
Osteoporosis,I-Entity
is,O
caused,O
by,O
bone,O
resorption,O
in,O
excess,O
of,O
bone,O
formation,O
",",O
and,O
bisphosphonates,I-Entity
",",O
are,O
used,O
to,O
inhibit,O
bone,O
resorption,O
.,O
Alendronate,I-Entity
",",O
a,O
biphosphonate,I-Entity
",",O
is,O
effective,O
for,O
both,O
the,O
treatment,O
and,O
prevention,O
of,O
osteoporosis,I-Entity
in,O
postmenopausal,O
women,O
.,O
Musculoskeletal,B-Entity
pain,I-Entity
may,O
be,O
an,O
important,O
side,O
effect,O
in,O
these,O
patients,O
.,O
We,O
presented,O
a,O
patient,O
admitted,O
to,O
our,O
out,O
-,O
patient,O
clinic,O
with,O
diffuse,O
skeletal,O
pain,I-Entity
after,O
three,O
consecutive,O
administration,O
of,O
alendronate,I-Entity
.,O
We,O
conclude,O
that,O
patients,O
with,O
osteoporosis,I-Entity
can,O
report,O
pain,I-Entity
",",O
and,O
bisphosphonate,I-Entity
-,O
related,O
pain,I-Entity
should,O
also,O
be,O
considered,O
before,O
ascribing,O
this,O
complaint,O
to,O
osteoporosis,I-Entity
.,O
Cerebrospinal,O
fluid,O
penetration,O
of,O
high,O
-,O
dose,O
daptomycin,I-Entity
in,O
suspected,O
Staphylococcus,O
aureus,O
meningitis,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
methicillin,I-Entity
-,O
sensitive,O
Staphylococcus,O
aureus,O
(,O
MSSA,O
),O
bacteremia,I-Entity
with,O
suspected,O
MSSA,O
meningitis,I-Entity
treated,O
with,O
high,O
-,O
dose,O
daptomycin,I-Entity
assessed,O
with,O
concurrent,O
serum,O
and,O
cerebrospinal,O
fluid,O
(,O
CSF,O
),O
concentrations,O
.,O
A,O
54-year,O
-,O
old,O
male,O
presented,O
to,O
the,O
emergency,O
department,O
with,O
generalized,O
weakness,I-Entity
and,O
presumed,O
health,O
-,O
care,O
-,O
associated,O
pneumonia,I-Entity
shown,O
on,O
chest,O
radiograph,O
.,O
Treatment,O
was,O
empirically,O
initiated,O
with,O
vancomycin,I-Entity
",",O
levofloxacin,I-Entity
",",O
and,O
piperacillin,I-Entity
/,O
tazobactam,I-Entity
.,O
Blood,O
cultures,O
revealed,O
S.,O
aureus,O
susceptible,O
to,O
oxacillin,I-Entity
.,O
Empiric,O
antibiotic,O
treatment,O
was,O
narrowed,O
to,O
nafcillin,I-Entity
on,O
day,O
4,O
.,O
On,O
day,O
8,O
",",O
the,O
patient,O
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
(,O
serum,O
creatinine,I-Entity
1.9,O
mg,O
/,O
dL,O
",",O
increased,O
from,O
1.2,O
mg,O
/,O
dL,O
the,O
previous,O
day,O
and,O
0.8,O
mg,O
/,O
dL,O
on,O
admission,O
),O
.,O
The,O
patient,O
's,O
Glasgow,O
Coma,O
Score,O
was,O
3,O
",",O
with,O
normal,O
findings,O
shown,O
on,O
computed,O
tomography,O
scan,O
of,O
the,O
head,O
72,O
hours,O
following,O
an,O
episode,O
of,O
cardiac,B-Entity
arrest,I-Entity
on,O
day,O
10,O
.,O
The,O
patient,O
experienced,O
relapsing,O
MSSA,O
bacteremia,I-Entity
on,O
day,O
9,O
",",O
increasing,O
the,O
suspicion,O
for,O
a,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
infection,I-Entity
.,O
Nafcillin,I-Entity
was,O
discontinued,O
and,O
daptomycin,I-Entity
9,O
mg,O
/,O
kg,O
daily,O
was,O
initiated,O
for,O
suspected,O
meningitis,I-Entity
and,O
was,O
continued,O
until,O
the,O
patient,O
's,O
death,O
on,O
day,O
16,O
.,O
Daptomycin,I-Entity
serum,O
and,O
CSF,O
trough,O
concentrations,O
were,O
11.21,O
ug,O
/,O
mL,O
and,O
0.52,O
Creatine,I-Entity
kinase,O
levels,O
were,O
normal,O
prior,O
to,O
daptomycin,I-Entity
therapy,O
and,O
were,O
not,O
reassessed,O
.,O
Daptomycin,I-Entity
was,O
initiated,O
in,O
our,O
patient,O
secondary,O
to,O
possible,O
nafcillin,I-Entity
-,O
induced,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
and,O
relapsing,O
bacteremia,I-Entity
.,O
High,O
-,O
dose,O
daptomycin,I-Entity
may,O
be,O
an,O
alternative,O
option,O
for,O
MSSA,O
bacteremia,I-Entity
with,O
or,O
without,O
a,O
CNS,O
source,O
in,O
patients,O
who,O
have,O
failed,O
or,O
can,O
not,O
tolerate,O
standard,O
therapy,O
.,O
Further,O
clinical,O
evaluation,O
in,O
patients,O
with,O
confirmed,O
meningitis,I-Entity
is,O
warranted,O
.,O
The,O
role,O
of,O
nitric,B-Entity
oxide,I-Entity
in,O
convulsions,I-Entity
induced,O
by,O
lindane,I-Entity
in,O
rats,O
.,O
Lindane,I-Entity
is,O
an,O
organochloride,O
pesticide,O
and,O
scabicide,O
.,O
It,O
evokes,O
convulsions,I-Entity
mainly,O
trough,O
the,O
blockage,O
of,O
GABA(A,I-Entity
),O
receptors,O
.,O
Nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
",",O
gaseous,O
neurotransmitter,O
",",O
has,O
contradictor,O
role,O
in,O
epileptogenesis,O
due,O
to,O
opposite,O
effects,O
of,O
L,B-Entity
-,I-Entity
arginine,I-Entity
",",O
precursor,O
of,O
NO,I-Entity
syntheses,O
(,O
NOS,O
),O
",",O
and,O
L,B-Entity
-,I-Entity
NAME,I-Entity
(,O
NOS,O
inhibitor,O
),O
observed,O
in,O
different,O
epilepsy,I-Entity
models,O
.,O
The,O
aim,O
of,O
the,O
current,O
study,O
was,O
to,O
determine,O
the,O
effects,O
of,O
NO,I-Entity
on,O
the,O
behavioral,O
and,O
EEG,O
characteristics,O
of,O
lindane,I-Entity
-,O
induced,O
epilepsy,I-Entity
in,O
male,O
Wistar,O
albino,O
rats,O
.,O
The,O
administration,O
of,O
L,B-Entity
-,I-Entity
arginine,I-Entity
(,O
600,O
",",O
800,O
and,O
1000,O
mg,O
/,O
in,O
dose,O
-,O
dependent,O
manner,O
significantly,O
increased,O
convulsion,I-Entity
incidence,O
and,O
severity,O
and,O
shortened,O
latency,O
time,O
to,O
first,O
convulsion,I-Entity
elicited,O
by,O
lower,O
lindane,I-Entity
dose,O
(,O
4,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
On,O
the,O
contrary,O
",",O
pretreatment,O
with,O
L,B-Entity
-,I-Entity
NAME,I-Entity
(,O
500,O
",",O
700,O
and,O
900,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
decreased,O
convulsion,I-Entity
incidence,O
and,O
severity,O
and,O
prolonged,O
latency,O
time,O
to,O
convulsion,I-Entity
following,O
injection,O
with,O
a,O
convulsive,I-Entity
dose,O
of,O
lindane,I-Entity
(,O
8,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
EEG,O
analyses,O
showed,O
increase,O
of,O
number,O
and,O
duration,O
of,O
ictal,O
periods,O
in,O
EEG,O
of,O
rats,O
receiving,O
l,B-Entity
-,I-Entity
arginine,I-Entity
prior,O
to,O
lindane,I-Entity
and,O
decrease,O
of,O
this,O
number,O
in,O
rats,O
pretreated,O
with,O
L,B-Entity
-,I-Entity
NAME,I-Entity
.,O
These,O
results,O
support,O
the,O
conclusion,O
that,O
NO,I-Entity
plays,O
a,O
role,O
of,O
endogenous,O
convulsant,O
in,O
rat,O
model,O
of,O
lindane,I-Entity
seizures,I-Entity
.,O
Long,O
-,O
term,O
oral,O
galactose,I-Entity
treatment,O
prevents,O
cognitive,B-Entity
deficits,I-Entity
in,O
male,O
Wistar,O
rats,O
treated,O
intracerebroventricularly,O
with,O
streptozotocin,I-Entity
.,O
Basic,O
and,O
clinical,O
research,O
has,O
demonstrated,O
that,O
dementia,I-Entity
of,O
sporadic,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
(,O
sAD,O
),O
type,O
is,O
associated,O
with,O
dysfunction,O
of,O
the,O
insulin,O
-,O
receptor,O
(,O
IR,O
),O
system,O
followed,O
by,O
decreased,O
glucose,I-Entity
transport,O
via,O
glucose,I-Entity
transporter,O
GLUT4,O
and,O
decreased,O
glucose,I-Entity
metabolism,O
in,O
brain,O
cells,O
.,O
An,O
alternative,O
source,O
of,O
energy,O
is,O
d,B-Entity
-,I-Entity
galactose,I-Entity
(,O
the,O
C-4-epimer,O
of,O
d,B-Entity
-,I-Entity
glucose,I-Entity
),O
which,O
is,O
transported,O
into,O
the,O
brain,O
by,O
insulin,O
-,O
independent,O
GLUT3,O
transporter,O
where,O
it,O
might,O
be,O
metabolized,O
to,O
glucose,I-Entity
via,O
the,O
Leloir,O
pathway,O
.,O
Exclusively,O
parenteral,O
daily,O
injections,O
of,O
galactose,I-Entity
induce,O
memory,B-Entity
deterioration,I-Entity
in,O
rodents,O
and,O
are,O
used,O
to,O
generate,O
animal,O
aging,O
model,O
",",O
but,O
the,O
effects,O
of,O
oral,O
galactose,I-Entity
treatment,O
on,O
cognitive,O
functions,O
have,O
never,O
been,O
tested,O
.,O
We,O
have,O
investigated,O
the,O
effects,O
of,O
continuous,O
daily,O
oral,O
galactose,I-Entity
(,O
200,O
mg,O
/,O
kg,O
/,O
day,O
),O
treatment,O
on,O
cognitive,B-Entity
deficits,I-Entity
in,O
streptozotocin,I-Entity
-,O
induced,O
(,O
STZ,I-Entity
-,O
icv,O
),O
rat,O
model,O
of,O
sAD,O
",",O
tested,O
by,O
Morris,O
Water,O
Maze,O
and,O
Passive,O
Avoidance,O
test,O
",",O
respectively,O
.,O
One,O
month,O
of,O
oral,O
galactose,I-Entity
treatment,O
initiated,O
immediately,O
after,O
the,O
STZ,I-Entity
-,O
icv,O
administration,O
",",O
successfully,O
prevented,O
development,O
of,O
the,O
STZ,I-Entity
-,O
icv,O
-,O
induced,O
cognitive,B-Entity
deficits,I-Entity
.,O
Beneficial,O
effect,O
of,O
oral,O
galactose,I-Entity
was,O
independent,O
of,O
the,O
rat,O
age,O
and,O
of,O
the,O
galactose,I-Entity
dose,O
ranging,O
from,O
100,O
to,O
300,O
mg,O
Additionally,O
",",O
oral,O
galactose,I-Entity
administration,O
led,O
to,O
the,O
appearance,O
of,O
galactose,I-Entity
in,O
the,O
blood,O
.,O
The,O
increase,O
of,O
galactose,I-Entity
concentration,O
in,O
the,O
cerebrospinal,O
fluid,O
was,O
several,O
times,O
lower,O
after,O
oral,O
than,O
after,O
parenteral,O
administration,O
of,O
the,O
same,O
galactose,I-Entity
dose,O
.,O
Oral,O
galactose,I-Entity
exposure,O
might,O
have,O
beneficial,O
effects,O
on,O
learning,O
and,O
memory,O
ability,O
and,O
could,O
be,O
worth,O
investigating,O
for,O
improvement,O
of,O
cognitive,B-Entity
deficits,I-Entity
associated,O
with,O
glucose,B-Entity
hypometabolism,I-Entity
in,O
AD,I-Entity
.,O
Tricuspid,B-Entity
valve,I-Entity
regurgitation,I-Entity
and,O
lithium,B-Entity
carbonate,I-Entity
toxicity,I-Entity
in,O
a,O
newborn,O
infant,O
.,O
A,O
newborn,O
with,O
massive,O
tricuspid,B-Entity
regurgitation,I-Entity
",",O
atrial,B-Entity
flutter,I-Entity
",",O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
",",O
and,O
a,O
high,O
serum,O
lithium,I-Entity
level,O
is,O
described,O
.,O
This,O
is,O
the,O
first,O
patient,O
to,O
initially,O
manifest,O
tricuspid,B-Entity
regurgitation,I-Entity
and,O
atrial,B-Entity
flutter,I-Entity
",",O
and,O
the,O
11th,O
described,O
patient,O
with,O
cardiac,B-Entity
disease,I-Entity
among,O
infants,O
exposed,O
to,O
lithium,I-Entity
compounds,O
in,O
the,O
first,O
trimester,O
of,O
pregnancy,O
.,O
Lithium,B-Entity
carbonate,I-Entity
may,O
be,O
a,O
factor,O
in,O
the,O
increasing,O
incidence,O
of,O
congenital,B-Entity
heart,I-Entity
disease,I-Entity
when,O
taken,O
during,O
early,O
pregnancy,O
.,O
It,O
also,O
causes,O
neurologic,B-Entity
depression,I-Entity
",",O
cyanosis,I-Entity
",",O
and,O
cardiac,B-Entity
arrhythmia,I-Entity
when,O
consumed,O
prior,O
to,O
delivery,O
.,O
Phenobarbital,I-Entity
-,O
induced,O
dyskinesia,I-Entity
in,O
a,O
neurologically,B-Entity
-,I-Entity
impaired,I-Entity
child,O
.,O
A,O
2-year,O
-,O
old,O
child,O
with,O
known,O
neurologic,B-Entity
impairment,I-Entity
developed,O
a,O
dyskinesia,I-Entity
soon,O
after,O
starting,O
phenobarbital,I-Entity
therapy,O
for,O
seizures,I-Entity
.,O
Known,O
causes,O
of,O
movement,B-Entity
disorders,I-Entity
were,O
eliminated,O
after,O
evaluation,O
.,O
On,O
repeat,O
challenge,O
with,O
phenobarbital,I-Entity
",",O
the,O
dyskinesia,I-Entity
recurred,O
.,O
Phenobarbital,I-Entity
should,O
be,O
added,O
to,O
the,O
list,O
of,O
anticonvulsant,O
drugs,O
that,O
can,O
cause,O
movement,B-Entity
disorders,I-Entity
.,O
Acute,O
changes,O
of,O
blood,O
ammonia,I-Entity
may,O
predict,O
short,O
-,O
term,O
adverse,O
effects,O
of,O
valproic,B-Entity
acid,I-Entity
.,O
Valproic,B-Entity
acid,I-Entity
(,O
VPA,I-Entity
),O
was,O
given,O
to,O
24,O
epileptic,I-Entity
patients,O
who,O
were,O
already,O
being,O
treated,O
with,O
other,O
antiepileptic,O
drugs,O
.,O
A,O
standardized,O
loading,O
dose,O
of,O
VPA,I-Entity
was,O
administered,O
",",O
and,O
venous,O
blood,O
was,O
sampled,O
at,O
0,O
",",O
1,O
",",O
2,O
",",O
3,O
",",O
and,O
4,O
hours,O
.,O
Ammonia,I-Entity
(,O
NH3,I-Entity
),O
was,O
higher,O
in,O
patients,O
who,O
",",O
during,O
continuous,O
therapy,O
",",O
complained,O
of,O
drowsiness,I-Entity
(,O
7,O
patients,O
),O
than,O
in,O
those,O
who,O
were,O
symptom,O
-,O
free,O
(,O
17,O
patients,O
),O
",",O
although,O
VPA,I-Entity
plasma,O
levels,O
were,O
similar,O
in,O
both,O
groups,O
.,O
By,O
measuring,O
VPA,I-Entity
-,O
induced,O
changes,O
of,O
blood,O
NH3,I-Entity
content,O
",",O
it,O
may,O
be,O
possible,O
to,O
identify,O
patients,O
at,O
higher,O
risk,O
of,O
obtundation,O
when,O
VPA,I-Entity
is,O
given,O
chronically,O
.,O
Calcitonin,O
injection,O
resulted,O
in,O
a,O
potentiation,O
of,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
and,O
a,O
partial,O
prevention,O
of,O
apomorphine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
Moreover,O
calcitonin,O
induced,O
a,O
significant,O
decrease,O
in,O
nigral,O
GAD,O
activity,O
but,O
no,O
change,O
in,O
striatal,O
DA,I-Entity
and,O
DOPAC,I-Entity
concentration,O
or,O
GAD,O
activity,O
.,O
The,O
results,O
are,O
discussed,O
in,O
view,O
of,O
a,O
primary,O
action,O
of,O
calcitonin,O
on,O
the,O
striatonigral,O
GABAergic,O
pathway,O
mediating,O
the,O
DA,I-Entity
-,O
related,O
behavioral,O
messages,O
of,O
striatal,O
origin,O
.,O
Development,O
of,O
isoproterenol,I-Entity
-,O
induced,O
cardiac,B-Entity
hypertrophy,I-Entity
.,O
The,O
development,O
of,O
cardiac,B-Entity
hypertrophy,I-Entity
was,O
studied,O
in,O
adult,O
female,O
Wistar,O
rats,O
following,O
daily,O
subcutaneous,O
injections,O
of,O
isoproterenol,I-Entity
(,O
ISO,I-Entity
),O
(,O
0.3,O
mg,O
/,O
kg,O
body,O
weight,O
),O
.,O
A,O
time,O
course,O
was,O
established,O
for,O
the,O
change,O
in,O
tissue,O
mass,O
",",O
RNA,O
and,O
DNA,O
content,O
",",O
as,O
well,O
as,O
hydroxyproline,I-Entity
content,O
.,O
The,O
total,O
content,O
of,O
hydroxyproline,I-Entity
remained,O
stable,O
during,O
the,O
first,O
2,O
days,O
of,O
treatment,O
but,O
increased,O
46%,O
after,O
4,O
days,O
of,O
therapy,O
.,O
Ventricular,O
DNA,O
content,O
was,O
unchanged,O
during,O
the,O
early,O
stage,O
(,O
1,O
-,O
4,O
days,O
),O
of,O
hypertrophic,I-Entity
growth,O
but,O
increased,O
to,O
a,O
new,O
steady,O
-,O
state,O
level,O
19%,O
above,O
the,O
controls,O
after,O
8,O
days,O
of,O
treatment,O
.,O
Intraventricular,O
pressures,O
and,O
coronary,O
flow,O
measures,O
were,O
similar,O
for,O
control,O
and,O
experimental,O
animals,O
following,O
4,O
days,O
of,O
developed,O
hypertrophy,I-Entity
.,O
However,O
",",O
dP,O
/,O
dt,O
in,O
the,O
ISO,I-Entity
-,O
treated,O
hearts,O
was,O
slightly,O
but,O
significantly,O
(,O
P,O
less,O
than,O
0.05,O
),O
elevated,O
.,O
These,O
data,O
indicate,O
that,O
the,O
adaptive,O
response,O
to,O
ISO,I-Entity
shows,O
an,O
early,O
hypertrophic,I-Entity
phase,O
(,O
1,O
-,O
4,O
days,O
),O
characterized,O
by,O
a,O
substantial,O
increase,O
in,O
RNA,O
content,O
and,O
cardiac,O
mass,O
in,O
the,O
absence,O
of,O
changes,O
in,O
DNA,O
.,O
However,O
",",O
prolonged,O
stimulation,O
(,O
8,O
-,O
12,O
days,O
),O
appears,O
to,O
represent,O
a,O
complex,O
integration,O
of,O
both,O
cellular,O
hypertrophy,I-Entity
and,O
hyperplasia,I-Entity
within,O
the,O
heart,O
.,O
Co,O
-,O
carcinogenic,I-Entity
effect,O
of,O
retinyl,B-Entity
acetate,I-Entity
on,O
forestomach,B-Entity
carcinogenesis,I-Entity
of,O
male,O
F344,O
rats,O
induced,O
with,O
butylated,B-Entity
hydroxyanisole,I-Entity
.,O
The,O
potential,O
modifying,O
effect,O
of,O
retinyl,B-Entity
acetate,I-Entity
(,O
RA,I-Entity
),O
on,O
butylated,B-Entity
hydroxyanisole,I-Entity
(,O
BHA)-induced,I-Entity
rat,O
forestomach,B-Entity
tumorigenesis,I-Entity
was,O
examined,O
.,O
Male,O
F344,O
rats,O
",",O
5,O
weeks,O
of,O
age,O
",",O
were,O
maintained,O
on,O
diet,O
containing,O
1%,O
or,O
2%,O
BHA,I-Entity
by,O
weight,O
and,O
simultaneously,O
on,O
drinking,O
water,O
supplemented,O
with,O
RA,I-Entity
at,O
various,O
concentrations,O
(,O
w,O
/,O
v,O
),O
for,O
52,O
weeks,O
.,O
In,O
groups,O
given,O
2%,O
BHA,I-Entity
",",O
although,O
marked,O
hyperplastic,O
changes,O
of,O
the,O
forestomach,O
epithelium,O
were,O
observed,O
in,O
all,O
animals,O
",",O
co,O
-,O
administration,O
of,O
0.25%,O
RA,I-Entity
significantly,O
(,O
P,O
less,O
than,O
0.05,O
),O
increased,O
the,O
incidence,O
of,O
forestomach,B-Entity
tumors,I-Entity
(,O
squamous,B-Entity
cell,I-Entity
papilloma,I-Entity
and,O
carcinoma,I-Entity
),O
to,O
60%,O
(,O
9/15,O
",",O
2,O
rats,O
with,O
carcinoma,I-Entity
),O
from,O
15%,O
(,O
3/20,O
",",O
one,O
rat,O
with,O
carcinoma,I-Entity
),O
in,O
the,O
group,O
given,O
RA,I-Entity
-,O
free,O
water,O
.,O
In,O
rats,O
given,O
1%,O
BHA,I-Entity
",",O
RA,I-Entity
co,O
-,O
administered,O
at,O
a,O
dose,O
of,O
0.05,O
",",O
0.1,O
",",O
0.2,O
or,O
0.25%,O
showed,O
a,O
dose,O
-,O
dependent,O
enhancing,O
effect,O
on,O
the,O
development,O
of,O
the,O
BHA,I-Entity
-,O
induced,O
epithelial,B-Entity
hyperplasia,I-Entity
.,O
Tumors,I-Entity
",",O
all,O
papillomas,I-Entity
",",O
were,O
induced,O
in,O
3,O
rats,O
(,O
17%,O
),O
with,O
0.25%,O
RA,I-Entity
and,O
in,O
one,O
rat,O
(,O
10%,O
),O
with,O
0.05%,O
RA,I-Entity
co,O
-,O
administration,O
.,O
RA,I-Entity
alone,O
did,O
not,O
induce,O
hyperplastic,O
changes,O
in,O
the,O
forestomach,O
.,O
These,O
findings,O
indicate,O
that,O
RA,I-Entity
acted,O
as,O
a,O
co,O
-,O
carcinogen,O
in,O
the,O
BHA,I-Entity
forestomach,B-Entity
carcinogenesis,I-Entity
of,O
the,O
rat,O
.,O
Ketanserin,I-Entity
pretreatment,O
reverses,O
alfentanil,I-Entity
-,O
induced,O
muscle,B-Entity
rigidity,I-Entity
.,O
Systemic,O
pretreatment,O
with,O
ketanserin,I-Entity
",",O
a,O
relatively,O
specific,O
type-2,O
serotonin,I-Entity
receptor,O
antagonist,O
",",O
significantly,O
attenuated,O
the,O
muscle,B-Entity
rigidity,I-Entity
produced,O
in,O
rats,O
by,O
the,O
potent,O
short,O
-,O
acting,O
opiate,O
agonist,O
alfentanil,I-Entity
.,O
Following,O
placement,O
of,O
subcutaneous,O
electrodes,O
in,O
each,O
animal,O
's,O
left,O
gastrocnemius,O
muscle,O
",",O
rigidity,I-Entity
was,O
assessed,O
by,O
analyzing,O
root,O
-,O
mean,O
-,O
square,O
electromyographic,O
activity,O
.,O
Intraperitoneal,O
ketanserin,I-Entity
administration,O
at,O
doses,O
of,O
0.63,O
and,O
2.5,O
mg,O
/,O
kg,O
prevented,O
the,O
alfentanil,I-Entity
-,O
induced,O
increase,O
in,O
electromyographic,O
activity,O
compared,O
with,O
animals,O
pretreated,O
with,O
saline,O
.,O
Chlordiazepoxide,I-Entity
at,O
doses,O
up,O
to,O
10,O
mg,O
/,O
kg,O
failed,O
to,O
significantly,O
influence,O
the,O
rigidity,I-Entity
produced,O
by,O
alfentanil,I-Entity
.,O
Despite,O
the,O
absence,O
of,O
rigidity,I-Entity
",",O
animals,O
that,O
received,O
ketanserin,I-Entity
(,O
greater,O
than,O
0.31,O
followed,O
by,O
alfentanil,I-Entity
were,O
motionless,O
",",O
flaccid,O
",",O
and,O
less,O
responsive,O
to,O
external,O
stimuli,O
than,O
were,O
animals,O
receiving,O
alfentanil,I-Entity
alone,O
.,O
Rats,O
that,O
received,O
ketanserin,I-Entity
and,O
alfentanil,I-Entity
exhibited,O
less,O
rearing,O
and,O
exploratory,O
behavior,O
at,O
the,O
end,O
of,O
the,O
60-min,O
recording,O
period,O
than,O
did,O
animals,O
that,O
received,O
ketanserin,I-Entity
alone,O
.,O
These,O
results,O
",",O
in,O
combination,O
with,O
previous,O
work,O
",",O
suggest,O
that,O
muscle,B-Entity
rigidity,I-Entity
",",O
a,O
clinically,O
relevant,O
side,O
-,O
effect,O
of,O
parenteral,O
narcotic,O
administration,O
",",O
may,O
be,O
partly,O
mediated,O
via,O
serotonergic,O
pathways,O
.,O
Pretreatment,O
with,O
type-2,O
serotonin,I-Entity
antagonists,O
may,O
be,O
clinically,O
useful,O
in,O
attenuating,O
opiate,O
-,O
induced,O
rigidity,I-Entity
",",O
although,O
further,O
studies,O
will,O
be,O
necessary,O
to,O
assess,O
the,O
interaction,O
of,O
possibly,O
enhanced,O
CNS,O
",",O
cardiovascular,B-Entity
",",I-Entity
and,I-Entity
respiratory,I-Entity
depression,I-Entity
.,O
Glycopyrronium,I-Entity
requirements,O
for,O
antagonism,O
of,O
the,O
muscarinic,O
side,O
effects,O
of,O
edrophonium,I-Entity
.,O
We,O
have,O
compared,O
",",O
in,O
60,O
adult,O
patients,O
",",O
the,O
cardiovascular,O
effects,O
of,O
glycopyrronium,I-Entity
5,O
micrograms,O
kg-1,O
and,O
10,O
micrograms,O
kg-1,O
given,O
either,O
simultaneously,O
or,O
1,O
min,O
before,O
edrophonium,I-Entity
1,O
mg,O
kg-1,O
.,O
Use,O
of,O
glycopyrronium,I-Entity
5,O
micrograms,O
kg-1,O
provided,O
greater,O
cardiovascular,O
stability,O
and,O
",",O
given,O
1,O
min,O
before,O
the,O
edrophonium,I-Entity
",",O
was,O
sufficient,O
to,O
minimize,O
early,O
",",O
edrophonium,I-Entity
-,O
induced,O
bradycardias,I-Entity
.,O
This,O
low,O
dose,O
of,O
glycopyrronium,I-Entity
provided,O
good,O
control,O
of,O
oropharyngeal,O
secretions,O
.,O
Involvement,O
of,O
locus,O
coeruleus,O
and,O
noradrenergic,O
neurotransmission,O
in,O
fentanyl,I-Entity
-,O
induced,O
muscular,B-Entity
rigidity,I-Entity
in,O
the,O
rat,O
.,O
Whereas,O
muscular,B-Entity
rigidity,I-Entity
is,O
a,O
well,O
-,O
known,O
side,O
effect,O
that,O
is,O
associated,O
with,O
high,O
-,O
dose,O
fentanyl,I-Entity
anesthesia,O
",",O
a,O
paucity,O
of,O
information,O
exists,O
with,O
regard,O
to,O
its,O
underlying,O
mechanism(s,O
),O
.,O
We,O
investigated,O
in,O
this,O
study,O
the,O
possible,O
engagement,O
of,O
locus,O
coeruleus,O
of,O
the,O
pons,O
in,O
this,O
phenomenon,O
",",O
using,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
anesthetized,O
with,O
ketamine,I-Entity
.,O
Under,O
proper,O
control,O
of,O
respiration,O
",",O
body,O
temperature,O
and,O
end,O
-,O
tidal,O
CO2,I-Entity
",",O
intravenous,O
administration,O
of,O
fentanyl,I-Entity
(,O
50,O
or,O
100,O
micrograms,O
/,O
kg,O
),O
consistently,O
promoted,O
an,O
increase,O
in,O
electromyographic,O
activity,O
recorded,O
from,O
the,O
gastrocnemius,O
and,O
abdominal,O
rectus,O
muscles,O
.,O
Such,O
an,O
induced,O
muscular,B-Entity
rigidity,I-Entity
by,O
the,O
narcotic,O
agent,O
was,O
significantly,O
antagonized,O
or,O
even,O
reduced,O
by,O
prior,O
electrolytic,O
lesions,O
of,O
the,O
locus,O
coeruleus,O
or,O
pretreatment,O
with,O
the,O
alpha,O
-,O
adrenoceptor,O
blocker,O
",",O
prazosin,I-Entity
.,O
Microinjection,O
of,O
fentanyl,I-Entity
(,O
2.5,O
micrograms/50,O
nl,O
),O
directly,O
into,O
this,O
pontine,O
nucleus,O
",",O
on,O
the,O
other,O
hand,O
",",O
elicited,O
discernible,O
electromyographic,O
excitation,O
.,O
It,O
is,O
speculated,O
that,O
the,O
induction,O
of,O
muscular,B-Entity
rigidity,I-Entity
by,O
fentanyl,I-Entity
may,O
involve,O
the,O
coerulospinal,O
noradrenergic,O
fibers,O
to,O
the,O
spinal,O
motoneurons,O
.,O
Cerebral,B-Entity
sinus,I-Entity
thrombosis,I-Entity
as,O
a,O
potential,O
hazard,O
of,O
antifibrinolytic,O
treatment,O
in,O
menorrhagia,I-Entity
.,O
We,O
describe,O
a,O
42-year,O
-,O
old,O
woman,O
who,O
developed,O
superior,O
sagittal,B-Entity
and,I-Entity
left,I-Entity
transverse,I-Entity
sinus,I-Entity
thrombosis,I-Entity
associated,O
with,O
prolonged,O
epsilon,B-Entity
-,I-Entity
aminocaproic,I-Entity
acid,I-Entity
therapy,O
for,O
menorrhagia,I-Entity
.,O
This,O
antifibrinolytic,O
agent,O
has,O
been,O
used,O
in,O
women,O
with,O
menorrhagia,I-Entity
to,O
promote,O
clotting,O
and,O
reduce,O
blood,B-Entity
loss,I-Entity
.,O
Although,O
increased,O
risk,O
of,O
thromboembolic,B-Entity
disease,I-Entity
has,O
been,O
reported,O
during,O
treatment,O
with,O
epsilon,B-Entity
-,I-Entity
aminocaproic,I-Entity
acid,I-Entity
",",O
cerebral,B-Entity
sinus,I-Entity
thrombosis,I-Entity
has,O
not,O
been,O
previously,O
described,O
.,O
Careful,O
use,O
of,O
epsilon,B-Entity
-,I-Entity
aminocaproic,I-Entity
acid,I-Entity
therapy,O
is,O
recommended,O
.,O
Hemorrhagic,B-Entity
cystitis,I-Entity
complicating,O
bone,O
marrow,O
transplantation,O
.,O
Hemorrhagic,B-Entity
cystitis,I-Entity
is,O
a,O
potentially,O
serious,O
complication,O
of,O
high,O
-,O
dose,O
cyclophosphamide,I-Entity
therapy,O
administered,O
before,O
bone,O
marrow,O
transplantation,O
.,O
In,O
an,O
attempt,O
to,O
obviate,O
the,O
inconvenience,O
of,O
bladder,O
irrigation,O
",",O
we,O
conducted,O
a,O
feasibility,O
trial,O
of,O
uroprophylaxis,O
with,O
mesna,I-Entity
",",O
which,O
neutralizes,O
the,O
hepatic,O
metabolite,O
of,O
cyclophosphamide,I-Entity
that,O
causes,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
Of,O
97,O
patients,O
who,O
received,O
standard,O
prophylaxis,O
",",O
4,O
had,O
symptomatic,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
In,O
contrast,O
",",O
two,O
of,O
four,O
consecutive,O
patients,O
who,O
received,O
mesna,I-Entity
uroprophylaxis,O
before,O
allogeneic,O
bone,O
marrow,O
transplantation,O
had,O
severe,O
hemorrhagic,B-Entity
cystitis,I-Entity
for,O
at,O
least,O
2,O
weeks,O
.,O
Because,O
of,O
this,O
suboptimal,O
result,O
",",O
we,O
resumed,O
the,O
use,O
of,O
bladder,O
irrigation,O
and,O
forced,O
hydration,O
to,O
minimize,O
the,O
risk,O
of,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
Reversal,O
of,O
central,O
benzodiazepine,I-Entity
effects,O
by,O
flumazenil,I-Entity
after,O
intravenous,O
conscious,O
sedation,O
with,O
diazepam,I-Entity
and,O
opioids,O
:,O
report,O
of,O
a,O
double,O
-,O
blind,O
multicenter,O
study,O
.,O
The,O
Flumazenil,I-Entity
in,O
Intravenous,O
Conscious,O
Sedation,O
with,O
Diazepam,I-Entity
Multicenter,O
Study,O
Group,O
II,O
.,O
The,O
efficacy,O
and,O
safety,O
of,O
a,O
new,O
benzodiazepine,I-Entity
antagonist,O
",",O
flumazenil,I-Entity
",",O
were,O
assessed,O
in,O
a,O
double,O
-,O
blind,O
multicenter,O
study,O
.,O
Flumazenil,I-Entity
(,O
mean,O
dose,O
",",O
0.76,O
mg,O
),O
or,O
placebo,O
(,O
mean,O
dose,O
",",O
8.9,O
ml,O
),O
was,O
administered,O
intravenously,O
to,O
130,O
and,O
67,O
patients,O
",",O
respectively,O
",",O
who,O
had,O
been,O
given,O
diazepam,I-Entity
in,O
conjunction,O
with,O
an,O
opioid,O
(,O
fentanyl,I-Entity
",",O
meperidine,I-Entity
",",O
or,O
morphine,I-Entity
),O
for,O
the,O
induction,O
and,O
maintenance,O
of,O
intravenous,O
conscious,O
sedation,O
for,O
diagnostic,O
or,O
therapeutic,O
surgical,O
procedures,O
.,O
The,O
group,O
assessable,O
for,O
efficacy,O
comprised,O
122,O
patients,O
treated,O
with,O
flumazenil,I-Entity
and,O
64,O
patients,O
given,O
placebo,O
.,O
After,O
5,O
minutes,O
",",O
80/115,O
(,O
70%,O
),O
flumazenil,I-Entity
-,O
treated,O
patients,O
",",O
compared,O
with,O
21/63,O
(,O
33%,O
),O
placebo,O
-,O
treated,O
patients,O
",",O
were,O
completely,O
awake,O
and,O
alert,O
",",O
as,O
indicated,O
by,O
a,O
score,O
of,O
5,O
on,O
the,O
Observer,O
's,O
Assessment,O
of,O
Alertness,O
/,O
Sedation,O
Scale,O
.,O
Flumazenil,I-Entity
-,O
treated,O
patients,O
also,O
performed,O
significantly,O
better,O
on,O
the,O
Finger,O
-,O
to,O
-,O
Nose,O
Test,O
and,O
the,O
recall,O
of,O
pictures,O
shown,O
at,O
the,O
5-minute,O
assessment,O
.,O
Flumazenil,I-Entity
was,O
well,O
tolerated,O
",",O
with,O
no,O
serious,O
adverse,O
effects,O
reported,O
.,O
Thirty,O
-,O
nine,O
(,O
30%,O
),O
of,O
flumazenil,I-Entity
-,O
treated,O
patients,O
",",O
compared,O
with,O
17,O
(,O
25%,O
),O
of,O
placebo,O
-,O
treated,O
patients,O
had,O
one,O
or,O
more,O
drug,O
-,O
related,O
adverse,O
experiences,O
.,O
The,O
most,O
common,O
adverse,O
effects,O
were,O
nausea,I-Entity
and,O
vomiting,I-Entity
in,O
the,O
flumazenil,I-Entity
group,O
and,O
nausea,I-Entity
and,O
injection,O
-,O
site,O
pain,I-Entity
in,O
the,O
placebo,O
group,O
.,O
Flumazenil,I-Entity
was,O
found,O
to,O
promptly,O
reverse,O
sedation,O
induced,O
by,O
diazepam,I-Entity
in,O
the,O
presence,O
of,O
opioids,O
.,O
Hepatic,O
adenomas,I-Entity
and,O
focal,B-Entity
nodular,I-Entity
hyperplasia,I-Entity
of,O
the,O
liver,O
in,O
young,O
women,O
on,O
oral,B-Entity
contraceptives,I-Entity
:,O
case,O
reports,O
.,O
Two,O
cases,O
of,O
hepatic,O
adenoma,I-Entity
and,O
one,O
of,O
focal,B-Entity
nodular,I-Entity
hyperplasia,I-Entity
presumably,O
associated,O
with,O
the,O
use,O
of,O
oral,B-Entity
contraceptives,I-Entity
",",O
are,O
reported,O
.,O
Histologic,O
differences,O
and,O
clinical,O
similarities,O
between,O
hepatic,O
adenoma,I-Entity
and,O
focal,B-Entity
nodular,I-Entity
hyperplasia,I-Entity
of,O
the,O
liver,O
are,O
discussed,O
.,O
Arterial,O
thromboembolism,I-Entity
in,O
patients,O
receiving,O
systemic,O
heparin,I-Entity
therapy,O
:,O
a,O
complication,O
associated,O
with,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
.,O
Arterial,O
thromboembolism,I-Entity
is,O
a,O
recognized,O
complication,O
of,O
systemic,O
heparin,I-Entity
therapy,O
.,O
Characteristic,O
of,O
the,O
entity,O
is,O
arterial,B-Entity
occlusion,I-Entity
by,O
platelet,O
-,O
fibrin,O
thrombi,I-Entity
with,O
distal,O
ischemia,I-Entity
occurring,O
four,O
to,O
twenty,O
days,O
after,O
the,O
initiation,O
of,O
heparin,I-Entity
therapy,O
",",O
preceded,O
by,O
profound,O
thrombocytopenia,I-Entity
with,O
platelet,O
counts,O
in,O
the,O
range,O
of,O
"30,000",O
to,O
"40,000",O
per,O
cubic,O
millimeter,O
.,O
The,O
clinically,O
apparent,O
occlusion,O
may,O
be,O
preceded,O
by,O
gastrointestinal,B-Entity
and,I-Entity
musculoskeletal,I-Entity
symptoms,I-Entity
that,O
appear,O
to,O
be,O
ischemic,I-Entity
in,O
origin,O
",",O
and,O
might,O
serve,O
to,O
warn,O
the,O
clinician,O
of,O
these,O
complications,O
.,O
Previous,O
reports,O
of,O
these,O
phenomena,O
as,O
well,O
as,O
recent,O
studies,O
of,O
the,O
effect,O
of,O
heparin,I-Entity
are,O
reviewed,O
.,O
The,O
common,O
factor,O
relating,O
thromboembolism,I-Entity
and,O
thrombocytopenia,I-Entity
is,O
heparin,I-Entity
-,O
induced,O
platelet,B-Entity
aggregation,I-Entity
.,O
Appropriate,O
treatment,O
consists,O
of,O
discontinuation,O
of,O
heparin,I-Entity
",",O
and,O
anticoagulation,O
with,O
sodium,B-Entity
warfarin,I-Entity
if,O
necessary,O
.,O
Long,O
-,O
term,O
prognosis,O
for,O
transplant,O
-,O
free,O
survivors,O
of,O
paracetamol,I-Entity
-,O
induced,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
.,O
BACKGROUND,O
:,O
The,O
prognosis,O
for,O
transplant,O
-,O
free,O
survivors,O
of,O
paracetamol,I-Entity
-,O
induced,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
remains,O
unknown,O
.,O
AIM,O
:,O
To,O
examine,O
whether,O
paracetamol,I-Entity
-,O
induced,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
increases,O
long,O
-,O
term,O
mortality,O
.,O
We,O
followed,O
up,O
all,O
transplant,O
-,O
free,O
survivors,O
of,O
paracetamol,I-Entity
-,O
induced,O
acute,B-Entity
liver,I-Entity
injury,I-Entity
",",O
hospitalized,O
in,O
a,O
Danish,O
national,O
referral,O
centre,O
during,O
1984,O
-,O
2004,O
.,O
We,O
compared,O
age,O
-,O
specific,O
mortality,O
rates,O
from,O
1,O
year,O
post,O
-,O
discharge,O
through,O
2008,O
between,O
those,O
in,O
whom,O
the,O
liver,B-Entity
injury,I-Entity
led,O
to,O
an,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
and,O
those,O
in,O
whom,O
it,O
did,O
not,O
.,O
On,O
average,O
",",O
age,O
-,O
specific,O
mortality,O
rates,O
were,O
slightly,O
higher,O
for,O
the,O
101,O
patients,O
whose,O
paracetamol,I-Entity
-,O
induced,O
liver,B-Entity
injury,I-Entity
had,O
caused,O
an,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
(,O
adjusted,O
mortality,O
rate,O
ratio,O
=,O
1.70,O
",",O
95%,O
CI,O
1.02,O
-,O
2.85,O
),O
",",O
but,O
the,O
association,O
was,O
age,O
-,O
dependent,O
",",O
and,O
no,O
survivors,O
of,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
died,O
of,O
liver,B-Entity
disease,I-Entity
",",O
whereas,O
suicides,O
were,O
frequent,O
in,O
both,O
groups,O
.,O
These,O
observations,O
speak,O
against,O
long,O
-,O
term,O
effects,O
of,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
.,O
More,O
likely,O
",",O
the,O
elevated,O
mortality,O
rate,O
ratio,O
resulted,O
from,O
incomplete,O
adjustment,O
for,O
the,O
greater,O
prevalence,O
of,O
substance,B-Entity
abuse,I-Entity
among,O
survivors,O
of,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
.,O
CONCLUSIONS,O
:,O
Paracetamol,I-Entity
-,O
induced,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
did,O
not,O
affect,O
long,O
-,O
term,O
mortality,O
.,O
Clinical,O
follow,O
-,O
up,O
may,O
be,O
justified,O
by,O
the,O
cause,O
of,O
the,O
liver,B-Entity
failure,I-Entity
",",O
but,O
not,O
by,O
the,O
liver,B-Entity
failure,I-Entity
itself,O
.,O
Serotonin,I-Entity
6,O
receptor,O
gene,O
is,O
associated,O
with,O
methamphetamine,I-Entity
-,O
induced,O
psychosis,I-Entity
in,O
a,O
Japanese,O
population,O
.,O
Altered,O
serotonergic,O
neural,O
transmission,O
is,O
hypothesized,O
to,O
be,O
a,O
susceptibility,O
factor,O
for,O
psychotic,B-Entity
disorders,I-Entity
such,O
as,O
schizophrenia,I-Entity
.,O
The,O
serotonin,I-Entity
6,O
(,O
5-HT6,I-Entity
),O
receptor,O
is,O
therapeutically,O
targeted,O
by,O
several,O
second,O
generation,O
antipsychotics,O
",",O
such,O
as,O
clozapine,I-Entity
and,O
olanzapine,I-Entity
",",O
and,O
d,B-Entity
-,I-Entity
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
in,O
rats,O
is,O
corrected,O
with,O
the,O
use,O
of,O
a,O
selective,O
5-HT6,I-Entity
receptor,O
antagonist,O
.,O
In,O
addition,O
",",O
the,O
disrupted,O
prepulse,O
inhibition,O
induced,O
by,O
d,B-Entity
-,I-Entity
amphetamine,I-Entity
or,O
phencyclidine,I-Entity
was,O
restored,O
by,O
5-HT6,I-Entity
receptor,O
antagonist,O
in,O
an,O
animal,O
study,O
using,O
rats,O
.,O
These,O
animal,O
models,O
were,O
considered,O
to,O
reflect,O
the,O
positive,O
symptoms,O
of,O
schizophrenia,I-Entity
",",O
and,O
the,O
above,O
evidence,O
suggests,O
that,O
altered,O
5-HT6,I-Entity
receptors,O
are,O
involved,O
in,O
the,O
pathophysiology,O
of,O
psychotic,B-Entity
disorders,I-Entity
.,O
The,O
symptoms,O
of,O
methamphetamine,I-Entity
(,O
METH)-induced,I-Entity
psychosis,I-Entity
are,O
similar,O
to,O
those,O
of,O
paranoid,B-Entity
type,I-Entity
schizophrenia,I-Entity
.,O
Therefore,O
",",O
we,O
conducted,O
an,O
analysis,O
of,O
the,O
association,O
of,O
the,O
5-HT6,I-Entity
gene,O
(,O
HTR6,O
),O
with,O
METH,I-Entity
-,O
induced,O
psychosis,I-Entity
.,O
Using,O
five,O
tagging,O
SNPs,O
(,O
rs6693503,O
",",O
rs1805054,O
",",O
rs4912138,O
",",O
rs3790757,O
and,O
rs9659997,O
),O
",",O
we,O
conducted,O
a,O
genetic,O
association,O
analysis,O
of,O
case,O
-,O
control,O
samples,O
(,O
197,O
METH,I-Entity
-,O
induced,O
psychosis,I-Entity
patients,O
and,O
337,O
controls,O
),O
in,O
the,O
Japanese,O
population,O
.,O
The,O
age,O
and,O
sex,O
of,O
the,O
control,O
subjects,O
did,O
not,O
differ,O
from,O
those,O
of,O
the,O
methamphetamine,I-Entity
dependence,O
patients,O
.,O
rs6693503,O
was,O
associated,O
with,O
METH,I-Entity
-,O
induced,O
psychosis,I-Entity
patients,O
in,O
the,O
allele,O
/,O
genotype,O
-,O
wise,O
analysis,O
.,O
In,O
the,O
haplotype,O
-,O
wise,O
analysis,O
",",O
we,O
detected,O
an,O
association,O
between,O
two,O
markers,O
(,O
rs6693503,O
and,O
rs1805054,O
),O
and,O
three,O
markers,O
(,O
rs6693503,O
",",O
rs1805054,O
and,O
rs4912138,O
),O
in,O
HTR6,O
and,O
METH,I-Entity
-,O
induced,O
psychosis,I-Entity
patients,O
",",O
respectively,O
.,O
CONCLUSION,O
:,O
HTR6,O
may,O
play,O
an,O
important,O
role,O
in,O
the,O
pathophysiology,O
of,O
METH,I-Entity
-,O
induced,O
psychosis,I-Entity
in,O
the,O
Japanese,O
population,O
.,O
Effect,O
of,O
increasing,O
intraperitoneal,O
infusion,O
rates,O
on,O
bupropion,B-Entity
hydrochloride,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
mice,O
.,O
BACKGROUND,O
:,O
It,O
is,O
not,O
known,O
if,O
there,O
is,O
a,O
relationship,O
between,O
input,O
rate,O
and,O
incidence,O
of,O
bupropion,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
This,O
is,O
important,O
",",O
since,O
different,O
controlled,O
release,O
formulations,O
of,O
bupropion,I-Entity
release,O
the,O
active,O
drug,O
at,O
different,O
rates,O
.,O
METHODS,O
:,O
We,O
investigated,O
the,O
effect,O
of,O
varying,O
the,O
intraperitoneal,O
infusion,O
rates,O
of,O
bupropion,B-Entity
HCl,I-Entity
120,O
mg,O
/,O
kg,O
",",O
a,O
known,O
convulsive,I-Entity
dose,O
50,O
(,O
CD50,O
),O
",",O
on,O
the,O
incidence,O
and,O
severity,O
of,O
bupropion,I-Entity
-,O
induced,O
convulsions,I-Entity
in,O
the,O
Swiss,O
albino,O
mice,O
.,O
A,O
total,O
of,O
69,O
mice,O
",",O
approximately,O
7,O
weeks,O
of,O
age,O
",",O
and,O
weighing,O
21.0,O
to,O
29.1,O
g,O
were,O
randomly,O
assigned,O
to,O
bupropion,B-Entity
HCl,I-Entity
120,O
mg,O
/,O
kg,O
treatment,O
by,O
intraperitoneal,O
(,O
IP,O
),O
administration,O
in,O
7,O
groups,O
(,O
9,O
to,O
10,O
animals,O
per,O
group,O
),O
.,O
Bupropion,B-Entity
HCl,I-Entity
was,O
infused,O
through,O
a,O
surgically,O
implanted,O
IP,O
dosing,O
catheter,O
with,O
infusions,O
in,O
each,O
group,O
of,O
0,O
min,O
",",O
15,O
min,O
",",O
30,O
min,O
",",O
60,O
min,O
",",O
90,O
min,O
",",O
120,O
min,O
",",O
and,O
240,O
min,O
.,O
The,O
number,O
",",O
time,O
of,O
onset,O
",",O
duration,O
and,O
the,O
intensity,O
of,O
the,O
convulsions,I-Entity
or,O
absence,O
of,O
convulsions,I-Entity
were,O
recorded,O
.,O
The,O
results,O
showed,O
that,O
IP,O
administration,O
of,O
bupropion,B-Entity
HCl,I-Entity
120,O
mg,O
/,O
kg,O
by,O
bolus,O
injection,O
induced,O
convulsions,I-Entity
in,O
6,O
out,O
of,O
10,O
mice,O
(,O
60%,O
of,O
convulsing,O
mice,O
),O
in,O
group,O
1,O
.,O
Logistic,O
regression,O
analysis,O
revealed,O
that,O
infusion,O
time,O
was,O
significant,O
(,O
p,O
=,O
0.0004,O
;,O
odds,O
ratio,O
=,O
0.974,O
),O
and,O
increasing,O
the,O
IP,O
infusion,O
time,O
of,O
bupropion,B-Entity
HCl,I-Entity
120,O
mg,O
/,O
kg,O
was,O
associated,O
with,O
a,O
91%,O
reduced,O
odds,O
of,O
convulsions,I-Entity
at,O
infusion,O
times,O
of,O
15,O
to,O
90,O
min,O
compared,O
to,O
bolus,O
injection,O
.,O
Further,O
increase,O
in,O
infusion,O
time,O
resulted,O
in,O
further,O
reduction,O
in,O
the,O
odds,O
of,O
convulsions,I-Entity
to,O
99.8%,O
reduction,O
at,O
240,O
min,O
.,O
In,O
conclusion,O
",",O
the,O
demonstration,O
of,O
an,O
inverse,O
relationship,O
between,O
infusion,O
time,O
of,O
a,O
fixed,O
and,O
convulsive,I-Entity
dose,O
of,O
bupropion,I-Entity
and,O
the,O
risk,O
of,O
convulsions,I-Entity
in,O
a,O
prospective,O
study,O
is,O
novel,O
.,O
Detailed,O
spectral,O
profile,O
analysis,O
of,O
penicillin,I-Entity
-,O
induced,O
epileptiform,B-Entity
activity,I-Entity
in,O
anesthetized,O
rats,O
.,O
Penicillin,I-Entity
model,O
is,O
a,O
widely,O
used,O
experimental,O
model,O
for,O
epilepsy,I-Entity
research,O
.,O
In,O
the,O
present,O
study,O
we,O
aimed,O
to,O
portray,O
a,O
detailed,O
spectral,O
analysis,O
of,O
penicillin,I-Entity
-,O
induced,O
epileptiform,B-Entity
activity,I-Entity
in,O
comparison,O
with,O
basal,O
brain,O
activity,O
in,O
anesthetized,O
Wistar,O
rats,O
.,O
urethane,I-Entity
and,O
connected,O
to,O
an,O
electrocorticogram,O
setup,O
.,O
After,O
a,O
short,O
period,O
of,O
basal,O
activity,O
recording,O
",",O
epileptic,I-Entity
focus,O
was,O
induced,O
by,O
injecting,O
400IU/2,O
microl,O
penicillin,B-Entity
-,I-Entity
G,I-Entity
potassium,I-Entity
into,O
the,O
left,O
lateral,O
ventricle,O
while,O
the,O
cortical,O
activity,O
was,O
continuously,O
recorded,O
.,O
Basal,O
activity,O
",",O
latent,O
period,O
and,O
the,O
penicillin,I-Entity
-,O
induced,O
epileptiform,B-Entity
activity,I-Entity
periods,O
were,O
then,O
analyzed,O
using,O
both,O
conventional,O
methods,O
and,O
spectral,O
analysis,O
.,O
Our,O
results,O
show,O
that,O
the,O
most,O
affected,O
frequency,O
bands,O
were,O
delta,O
",",O
theta,O
",",O
beta-2,O
and,O
gamma-2,O
bands,O
during,O
the,O
epileptiform,B-Entity
activity,I-Entity
and,O
there,O
were,O
marked,O
differences,O
in,O
terms,O
of,O
spectral,O
densities,O
between,O
three,O
investigated,O
episodes,O
(,O
basal,O
activity,O
",",O
latent,O
period,O
and,O
epileptiform,B-Entity
activity,I-Entity
),O
.,O
Our,O
results,O
may,O
help,O
to,O
analyze,O
novel,O
data,O
obtained,O
using,O
similar,O
experimental,O
models,O
and,O
the,O
simple,O
analysis,O
method,O
described,O
here,O
can,O
be,O
used,O
in,O
similar,O
studies,O
to,O
investigate,O
the,O
basic,O
neuronal,O
mechanism,O
of,O
this,O
or,O
other,O
types,O
of,O
experimental,O
epilepsies,I-Entity
.,O
High,O
dose,O
dexmedetomidine,I-Entity
as,O
the,O
sole,O
sedative,O
for,O
pediatric,O
MRI,O
.,O
This,O
large,O
-,O
scale,O
retrospective,O
review,O
evaluates,O
the,O
sedation,O
profile,O
of,O
dexmedetomidine,I-Entity
.,O
AIM,O
:,O
To,O
determine,O
the,O
hemodynamic,O
responses,O
",",O
efficacy,O
and,O
adverse,O
events,O
associated,O
with,O
the,O
use,O
of,O
high,O
dose,O
dexmedetomidine,I-Entity
as,O
the,O
sole,O
sedative,O
for,O
magnetic,O
resonance,O
imaging,O
(,O
MRI,O
),O
studies,O
.,O
Dexmedetomidine,I-Entity
has,O
been,O
used,O
at,O
our,O
institution,O
since,O
2005,O
to,O
provide,O
sedation,O
for,O
pediatric,O
radiological,O
imaging,O
studies,O
.,O
Over,O
time,O
",",O
an,O
effective,O
protocol,O
utilizing,O
high,O
dose,O
dexmedetomidine,I-Entity
as,O
the,O
sole,O
sedative,O
agent,O
has,O
evolved,O
.,O
Data,O
were,O
analyzed,O
from,O
all,O
747,O
consecutive,O
patients,O
who,O
received,O
dexmedetomidine,I-Entity
for,O
MRI,O
sedation,O
from,O
April,O
2005,O
to,O
April,O
2007,O
.,O
Since,O
2005,O
",",O
the,O
10-min,O
loading,O
dose,O
of,O
our,O
dexmedetomidine,I-Entity
protocol,O
increased,O
from,O
2,O
to,O
3,O
microg.kg(-1,O
),O
",",O
and,O
the,O
infusion,O
rate,O
increased,O
from,O
1,O
to,O
1.5,O
to,O
2,O
microg.kg(-1).h(-1,O
),O
.,O
The,O
current,O
sedation,O
protocol,O
progressively,O
increased,O
the,O
rate,O
of,O
successful,O
sedation,O
(,O
able,O
to,O
complete,O
the,O
imaging,O
study,O
),O
when,O
using,O
dexmedetomidine,I-Entity
alone,O
from,O
91.8%,O
to,O
97.6%,O
(,O
P,O
=,O
0.009,O
),O
",",O
reducing,O
the,O
requirement,O
for,O
adjuvant,O
pentobarbital,I-Entity
in,O
the,O
event,O
of,O
sedation,O
failure,O
with,O
dexmedetomidine,I-Entity
alone,O
and,O
decreased,O
the,O
mean,O
recovery,O
time,O
by,O
10,O
min,O
(,O
P,O
Although,O
dexmedetomidine,I-Entity
sedation,O
was,O
associated,O
with,O
a,O
16%,O
incidence,O
of,O
bradycardia,I-Entity
",",O
all,O
concomitant,O
mean,O
arterial,O
blood,O
pressures,O
were,O
within,O
20%,O
of,O
age,O
-,O
adjusted,O
normal,O
range,O
and,O
oxygen,I-Entity
saturations,O
were,O
95%,O
or,O
higher,O
.,O
CONCLUSION,O
:,O
Dexmedetomidine,I-Entity
in,O
high,O
doses,O
provides,O
adequate,O
sedation,O
for,O
pediatric,O
MRI,O
studies,O
.,O
While,O
use,O
of,O
high,O
dose,O
dexmedetomidine,I-Entity
is,O
associated,O
with,O
decreases,O
in,O
heart,O
rate,O
and,O
blood,O
pressure,O
outside,O
the,O
established,O
',O
awake,O
',O
norms,O
",",O
this,O
deviation,O
is,O
generally,O
within,O
20%,O
of,O
norms,O
",",O
and,O
is,O
not,O
associated,O
with,O
adverse,O
sequelae,O
.,O
Dexmedetomidine,I-Entity
is,O
useful,O
as,O
the,O
sole,O
sedative,O
for,O
pediatric,O
MRI,O
.,O
Methamphetamine,I-Entity
causes,O
alterations,O
in,O
the,O
MAP,O
kinase,O
-,O
related,O
pathways,O
in,O
the,O
brains,O
of,O
mice,O
that,O
display,O
increased,O
aggressiveness,I-Entity
.,O
Aggressive,B-Entity
behaviors,I-Entity
have,O
been,O
reported,O
in,O
patients,O
who,O
suffer,O
from,O
some,O
psychiatric,B-Entity
disorders,I-Entity
",",O
and,O
are,O
common,O
in,O
methamphetamine,I-Entity
(,O
METH,I-Entity
),O
abusers,O
.,O
Herein,O
",",O
we,O
report,O
that,O
multiple,O
(,O
but,O
not,O
single,O
),O
injections,O
of,O
METH,I-Entity
significantly,O
increased,O
aggressiveness,I-Entity
in,O
male,O
CD-1,O
mice,O
.,O
This,O
increase,O
in,O
aggressiveness,I-Entity
was,O
not,O
secondary,O
to,O
METH,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
Analysis,O
of,O
protein,O
expression,O
using,O
antibody,O
microarrays,O
and,O
Western,O
blotting,O
revealed,O
differential,O
changes,O
in,O
MAP,O
kinase,O
-,O
related,O
pathways,O
after,O
multiple,O
and,O
single,O
METH,I-Entity
injections,O
.,O
There,O
were,O
statistically,O
significant,O
(,O
p<0.05,O
),O
decreases,O
in,O
MEK1,O
",",O
Erk2p,O
",",O
GSK3alpha,O
",",O
14,O
-,O
3,O
-,O
3e,O
",",O
and,O
MEK7,O
in,O
the,O
striata,O
of,O
mice,O
after,O
multiple,O
injections,O
of,O
METH,I-Entity
.,O
MEK1,O
was,O
significantly,O
decreased,O
also,O
after,O
a,O
single,O
injection,O
of,O
METH,I-Entity
",",O
but,O
to,O
a,O
much,O
lesser,O
degree,O
than,O
after,O
multiple,O
injections,O
of,O
METH,I-Entity
.,O
In,O
the,O
frontal,O
cortex,O
",",O
there,O
was,O
a,O
statistically,O
significant,O
decrease,O
in,O
GSK3alpha,O
after,O
multiple,O
(,O
but,O
not,O
single,O
),O
injections,O
of,O
METH,I-Entity
.,O
These,O
findings,O
suggest,O
that,O
alterations,O
in,O
MAP,O
kinase,O
-,O
related,O
pathways,O
in,O
the,O
prefronto,O
-,O
striatal,O
circuitries,O
might,O
be,O
involved,O
in,O
the,O
manifestation,O
of,O
aggressive,B-Entity
behaviors,I-Entity
in,O
mice,O
.,O
Lamotrigine,I-Entity
associated,O
with,O
exacerbation,O
or,O
de,O
novo,O
myoclonus,I-Entity
in,O
idiopathic,B-Entity
generalized,I-Entity
epilepsies,I-Entity
.,O
Five,O
patients,O
with,O
idiopathic,B-Entity
generalized,I-Entity
epilepsies,I-Entity
(,O
IGE,I-Entity
),O
treated,O
with,O
lamotrigine,I-Entity
(,O
LTG,I-Entity
),O
experienced,O
exacerbation,O
or,O
de,O
novo,O
appearance,O
of,O
myoclonic,B-Entity
jerks,I-Entity
(,O
MJ,I-Entity
),O
.,O
In,O
three,O
patients,O
",",O
LTG,I-Entity
exacerbated,O
MJ,I-Entity
in,O
a,O
dose,O
-,O
dependent,O
manner,O
with,O
early,O
aggravation,O
during,O
titration,O
.,O
MJ,I-Entity
disappeared,O
when,O
LTG,I-Entity
dose,O
was,O
decreased,O
by,O
25,O
to,O
50%,O
.,O
In,O
two,O
patients,O
",",O
LTG,I-Entity
exacerbated,O
MJ,I-Entity
in,O
a,O
delayed,O
but,O
more,O
severe,O
manner,O
",",O
with,O
myoclonic,B-Entity
status,I-Entity
that,O
only,O
ceased,O
after,O
LTG,I-Entity
withdrawal,O
.,O
rTMS,O
of,O
supplementary,O
motor,O
area,O
modulates,O
therapy,O
-,O
induced,O
dyskinesias,I-Entity
in,O
Parkinson,B-Entity
disease,I-Entity
.,O
The,O
neural,O
mechanisms,O
and,O
circuitry,O
involved,O
in,O
levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
are,O
unclear,O
.,O
Using,O
repetitive,O
transcranial,O
magnetic,O
stimulation,O
(,O
rTMS,O
),O
over,O
the,O
supplementary,O
motor,O
area,O
(,O
SMA,O
),O
in,O
a,O
group,O
of,O
patients,O
with,O
advanced,O
Parkinson,B-Entity
disease,I-Entity
",",O
the,O
authors,O
investigated,O
whether,O
modulation,O
of,O
SMA,O
excitability,O
may,O
result,O
in,O
a,O
modification,O
of,O
a,O
dyskinetic,I-Entity
state,O
induced,O
by,O
continuous,O
apomorphine,I-Entity
infusion,O
.,O
rTMS,O
at,O
1,O
Hz,O
was,O
observed,O
to,O
markedly,O
reduce,O
drug,B-Entity
-,I-Entity
induced,I-Entity
dyskinesias,I-Entity
",",O
whereas,O
5-Hz,O
rTMS,O
induced,O
a,O
slight,O
but,O
not,O
significant,O
increase,O
.,O
Assessment,O
of,O
the,O
onset,O
and,O
persistence,O
of,O
amnesia,I-Entity
during,O
procedural,O
sedation,O
with,O
propofol,I-Entity
.,O
To,O
assess,O
patients,O
',O
ability,O
to,O
repeat,O
and,O
recall,O
words,O
presented,O
to,O
them,O
while,O
undergoing,O
procedural,O
sedation,O
with,O
propofol,I-Entity
",",O
and,O
correlate,O
their,O
recall,O
with,O
their,O
level,O
of,O
awareness,O
as,O
measured,O
by,O
bispectral,O
index,O
(,O
BIS,O
),O
monitoring,O
.,O
This,O
was,O
a,O
prospective,O
",",O
single,O
-,O
intervention,O
study,O
of,O
consenting,O
adult,O
patients,O
undergoing,O
procedural,O
sedation,O
with,O
propofol,I-Entity
between,O
December,O
28,O
",",O
2002,O
",",O
and,O
October,O
31,O
",",O
2003,O
.,O
The,O
mean,O
highest,O
BIS,O
score,O
corresponding,O
to,O
the,O
inability,B-Entity
to,I-Entity
repeat,I-Entity
words,I-Entity
was,O
81.5,O
(,O
95%,O
CI,O
=,O
78.1,O
to,O
84.8,O
),O
.,O
Furthermore,O
",",O
patients,O
had,O
no,O
recall,O
of,O
words,O
repeated,O
prior,O
to,O
procedural,O
sedation,O
in,O
BIS,O
ranges,O
associated,O
with,O
recall,O
after,O
procedural,O
sedation,O
",",O
suggestive,O
of,O
retrograde,B-Entity
amnesia,I-Entity
.,O
Assessment,O
of,O
perinatal,O
hepatitis,B-Entity
B,I-Entity
and,O
rubella,I-Entity
prevention,O
in,O
New,O
Hampshire,O
delivery,O
hospitals,O
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
current,O
performance,O
on,O
recommended,O
perinatal,O
hepatitis,B-Entity
B,I-Entity
and,O
rubella,I-Entity
prevention,O
practices,O
in,O
New,O
Hampshire,O
.,O
Assessment,O
was,O
done,O
on,O
the,O
following,O
:,O
prenatal,O
screening,O
for,O
hepatitis,B-Entity
B,I-Entity
and,O
rubella,I-Entity
",",O
administration,O
of,O
the,O
hepatitis,B-Entity
B,I-Entity
vaccine,O
birth,O
dose,O
to,O
all,O
infants,O
",",O
administration,O
of,O
hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
to,O
infants,O
who,O
were,O
born,O
to,O
hepatitis,B-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
-,O
positive,O
mothers,O
",",O
rubella,I-Entity
immunity,O
",",O
and,O
administration,O
of,O
in,O
-,O
hospital,O
postpartum,O
rubella,I-Entity
vaccine,O
to,O
rubella,I-Entity
nonimmune,O
women,O
.,O
RESULTS,O
:,O
Prenatal,O
screening,O
rates,O
for,O
hepatitis,B-Entity
B,I-Entity
(,O
98.8%,O
),O
and,O
rubella,I-Entity
(,O
99.4%,O
),O
were,O
high,O
.,O
Hepatitis,B-Entity
B,I-Entity
vaccine,O
birth,O
dose,O
was,O
administered,O
to,O
76.2%,O
of,O
all,O
infants,O
.,O
All,O
infants,O
who,O
were,O
born,O
to,O
hepatitis,B-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
-,O
positive,O
mothers,O
also,O
received,O
hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
.,O
Multivariate,O
logistic,O
regression,O
showed,O
that,O
the,O
month,O
of,O
delivery,O
and,O
infant,O
birth,O
weight,O
were,O
independent,O
predictors,O
of,O
hepatitis,B-Entity
B,I-Entity
vaccination,O
.,O
Women,O
who,O
were,O
born,O
between,O
1971,O
and,O
1975,O
had,O
the,O
highest,O
rate,O
of,O
rubella,I-Entity
nonimmunity,O
(,O
9.5%,O
),O
.,O
In,O
-,O
hospital,O
postpartum,O
rubella,I-Entity
vaccine,O
administration,O
was,O
documented,O
for,O
75.6%,O
of,O
nonimmune,O
women,O
.,O
This,O
study,O
documents,O
good,O
compliance,O
in,O
New,O
Hampshire,O
's,O
birthing,O
hospitals,O
with,O
national,O
guidelines,O
for,O
perinatal,O
hepatitis,B-Entity
B,I-Entity
and,O
rubella,I-Entity
prevention,O
and,O
highlights,O
potential,O
areas,O
for,O
improvement,O
.,O
Doxorubicin,I-Entity
is,O
an,O
anti,O
-,O
tumor,I-Entity
agent,O
that,O
represses,O
cardiac,O
-,O
specific,O
gene,O
expression,O
and,O
induces,O
myocardial,O
cell,O
apoptosis,O
.,O
Doxorubicin,I-Entity
depletes,O
cardiac,O
p300,O
",",O
a,O
transcriptional,O
coactivator,O
that,O
is,O
required,O
for,O
the,O
maintenance,O
of,O
the,O
differentiated,O
phenotype,O
of,O
cardiac,O
myocytes,O
.,O
However,O
",",O
the,O
role,O
of,O
p300,O
in,O
protection,O
against,O
doxorubicin,I-Entity
-,O
induced,O
apoptosis,O
is,O
unknown,O
.,O
Transgenic,O
mice,O
overexpressing,O
p300,O
in,O
the,O
heart,O
and,O
wild,O
-,O
type,O
mice,O
were,O
subjected,O
to,O
doxorubicin,I-Entity
treatment,O
.,O
Doxorubicin,I-Entity
induced,O
myocardial,O
cell,O
apoptosis,O
in,O
wild,O
-,O
type,O
mice,O
but,O
not,O
in,O
transgenic,O
mice,O
.,O
These,O
findings,O
demonstrate,O
that,O
overexpression,O
of,O
p300,O
protects,O
cardiac,O
myocytes,O
from,O
doxorubicin,I-Entity
-,O
induced,O
apoptosis,O
and,O
reduces,O
the,O
extent,O
of,O
acute,O
heart,B-Entity
failure,I-Entity
in,O
adult,O
mice,O
in,O
vivo,O
.,O
Mitochondrial,O
DNA,O
and,O
its,O
respiratory,O
chain,O
products,O
are,O
defective,O
in,O
doxorubicin,I-Entity
nephrosis,I-Entity
.,O
Doxorubicin,I-Entity
induces,O
a,O
self,O
-,O
perpetuating,O
nephropathy,I-Entity
characterized,O
by,O
early,O
glomerular,B-Entity
and,I-Entity
late,I-Entity
-,I-Entity
onset,I-Entity
tubular,I-Entity
lesions,I-Entity
in,O
rats,O
.,O
We,O
investigated,O
the,O
potential,O
role,O
of,O
mitochondrial,B-Entity
injury,I-Entity
in,O
the,O
onset,O
of,O
these,O
lesions,O
.,O
Rats,O
were,O
treated,O
with,O
intravenous,O
doxorubicin,I-Entity
(,O
1,O
mg,O
kg(-1,O
),O
Glomerular,B-Entity
and,I-Entity
tubular,I-Entity
injury,I-Entity
was,O
monitored,O
and,O
correlated,O
to,O
the,O
activity,O
or,O
expression,O
of,O
respiratory,O
chain,O
components,O
.,O
Finally,O
",",O
we,O
quantified,O
both,O
nuclear,O
and,O
mitochondrial,O
DNA,O
(,O
mtDNA,O
),O
as,O
well,O
as,O
superoxide,I-Entity
production,O
and,O
the,O
4834,O
base,O
pair,O
',O
common,O
',O
mtDNA,O
deletion,O
.,O
The,O
',O
long,O
-,O
term,O
',O
group,O
had,O
significant,O
glomerular,B-Entity
and,I-Entity
tubular,I-Entity
lesions,I-Entity
",",O
depressed,O
activities,O
of,O
mtDNA,O
-,O
encoded,O
NADH,O
dehydrogenase,O
and,O
cytochrome,O
-,O
c,O
oxidase,O
(,O
COX,O
),O
and,O
increased,O
citrate,I-Entity
synthase,O
activity,O
.,O
In,O
',O
short,O
-,O
term,O
',O
rats,O
",",O
there,O
were,O
fewer,O
tubular,B-Entity
lesions,I-Entity
",",O
but,O
similar,O
numbers,O
of,O
glomerular,B-Entity
lesions,I-Entity
activity,O
.,O
Among,O
all,O
animals,O
",",O
glomerular,B-Entity
and,I-Entity
tubular,I-Entity
injury,I-Entity
were,O
inversely,O
correlated,O
with,O
mtDNA,O
levels,O
",",O
mtDNA,O
-,O
encoded,O
respiratory,O
chain,O
activities,O
and,O
with,O
the,O
expression,O
of,O
the,O
mtDNA,O
-,O
encoded,O
respiratory,O
chain,O
subunit,O
COX,O
-,O
I.,O
Injury,O
was,O
positively,O
correlated,O
with,O
superoxide,I-Entity
production,O
and,O
the,O
activities,O
of,O
nucleus,O
-,O
encoded,O
mitochondrial,O
or,O
cytoplasmic,O
enzymes,O
.,O
These,O
results,O
suggest,O
an,O
important,O
role,O
for,O
quantitative,O
and,O
qualitative,O
mtDNA,O
alterations,O
through,O
the,O
reduction,O
of,O
mtDNA,O
-,O
encoded,O
respiratory,O
chain,O
function,O
and,O
induction,O
of,O
superoxide,I-Entity
in,O
doxorubicin,I-Entity
-,O
induced,O
renal,B-Entity
lesions,I-Entity
.,O
Amphotericin,B-Entity
B,I-Entity
-,O
induced,O
seizures,I-Entity
in,O
a,O
patient,O
with,O
AIDS,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
multiple,O
episodes,O
of,O
seizure,I-Entity
activity,O
in,O
an,O
AIDS,I-Entity
patent,O
following,O
amphotericin,B-Entity
B,I-Entity
infusion,O
.,O
A,O
46-year,O
-,O
old,O
African,O
-,O
American,O
man,O
experienced,O
recurrent,O
grand,B-Entity
mal,I-Entity
seizures,I-Entity
during,O
intravenous,O
infusion,O
of,O
amphotericin,B-Entity
B,I-Entity
",",O
then,O
petit,O
mal,O
seizures,I-Entity
as,O
the,O
infusion,O
was,O
stopped,O
and,O
the,O
drug,O
concentrations,O
decreased,O
with,O
time,O
.,O
The,O
patients,O
concurrent,O
medications,O
included,O
didanosine,I-Entity
",",O
hydroxyzine,I-Entity
",",O
promethazine,I-Entity
",",O
hydrocortisone,I-Entity
",",O
and,O
prochlorperazine,I-Entity
.,O
Despite,O
administration,O
of,O
phenytoin,I-Entity
and,O
lorazepam,I-Entity
",",O
the,O
seizures,I-Entity
persisted,O
and,O
occurred,O
only,O
during,O
amphotercin,B-Entity
B,I-Entity
administration,O
.,O
DISCUSSION,O
:,O
AIDS,I-Entity
and,O
cryptococcal,B-Entity
meningitis,I-Entity
",",O
both,O
of,O
which,O
the,O
patient,O
had,O
",",O
can,O
potentially,O
cause,O
seizures,I-Entity
.,O
The,O
patient,O
had,O
a,O
history,O
of,O
alcohol,B-Entity
abuse,I-Entity
;,O
alcohol,I-Entity
intake,O
as,O
well,O
as,O
withdrawal,O
can,O
also,O
cause,O
seizures,I-Entity
.,O
Didanosine,I-Entity
also,O
has,O
a,O
potential,O
for,O
inducing,O
seizures,I-Entity
.,O
However,O
",",O
these,O
other,O
potential,O
causes,O
of,O
seizure,I-Entity
were,O
ruled,O
out,O
.,O
The,O
time,O
course,O
of,O
events,O
suggested,O
that,O
amphotericin,B-Entity
B,I-Entity
was,O
the,O
cause,O
of,O
the,O
seizures,I-Entity
in,O
this,O
AIDS,I-Entity
patient,O
.,O
CONCLUSIONS,O
:,O
Amphotericin,B-Entity
B,I-Entity
seems,O
to,O
be,O
the,O
probable,O
cause,O
of,O
the,O
seizures,I-Entity
.,O
To,O
date,O
",",O
only,O
three,O
cases,O
of,O
seizures,I-Entity
associated,O
with,O
amphotericin,B-Entity
B,I-Entity
have,O
been,O
reported,O
in,O
the,O
literature,O
",",O
but,O
healthcare,O
providers,O
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
this,O
rare,O
adverse,O
effect,O
.,O
Therapeutic,O
drug,O
monitoring,O
of,O
tobramycin,I-Entity
:,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
effect,O
of,O
dosage,O
regimen,O
(,O
once,O
-,O
daily,O
vs.,O
twice,O
-,O
daily,O
),O
of,O
tobramicyn,I-Entity
on,O
steady,O
-,O
state,O
serum,O
concentrations,O
and,O
toxicity,I-Entity
.,O
tobramycin,I-Entity
(,O
4,O
mg,O
/,O
kg,O
/,O
day,O
),O
were,O
randomised,O
to,O
two,O
groups,O
.,O
Group,O
OD,O
(,O
n,O
=,O
22,O
),O
received,O
a,O
once,O
-,O
daily,O
dose,O
of,O
tobramycin,I-Entity
and,O
group,O
TD,O
(,O
n,O
=,O
21,O
),O
received,O
the,O
same,O
dose,O
divided,O
into,O
two,O
doses,O
daily,O
.,O
Tobramycin,I-Entity
serum,O
concentrations,O
(,O
peak,O
and,O
trough,O
),O
were,O
measured,O
by,O
enzyme,O
multiplied,O
immunoassay,O
.,O
Increased,O
serum,O
creatinine,I-Entity
was,O
observed,O
in,O
73%,O
of,O
patients,O
in,O
OD,O
versus,O
57%,O
of,O
patients,O
in,O
TD,O
",",O
without,O
evidence,O
of,O
nephrotoxicity,I-Entity
.,O
In,O
TD,O
group,O
",",O
three,O
patients,O
developed,O
decreased,B-Entity
auditory,I-Entity
function,I-Entity
",",O
of,O
which,O
one,O
presented,O
with,O
an,O
auditory,B-Entity
loss,I-Entity
of,O
-30,O
dB,O
",",O
whereas,O
in,O
the,O
OD,O
group,O
only,O
one,O
patient,O
presented,O
decreased,B-Entity
auditory,I-Entity
function,I-Entity
.,O
This,O
small,O
study,O
suggests,O
that,O
a,O
once,O
-,O
daily,O
dosing,O
regimen,O
of,O
tobramycin,I-Entity
is,O
at,O
least,O
as,O
effective,O
as,O
and,O
is,O
no,O
more,O
and,O
possibly,O
less,O
toxic,O
than,O
the,O
twice,O
-,O
daily,O
regimen,O
.,O
Chronic,O
effects,O
of,O
a,O
novel,O
synthetic,O
anthracycline,I-Entity
derivative,O
(,O
SM-5887,I-Entity
),O
on,O
normal,O
heart,O
and,O
doxorubicin,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
in,O
beagle,O
dogs,O
.,O
This,O
study,O
was,O
designed,O
to,O
investigate,O
the,O
chronic,O
cardiotoxic,I-Entity
potential,O
of,O
SM-5887,I-Entity
and,O
a,O
possible,O
deteriorating,O
effect,O
of,O
SM-5887,I-Entity
on,O
low,O
-,O
grade,O
cardiotoxicity,I-Entity
pre,O
-,O
induced,O
by,O
doxorubicin,I-Entity
in,O
beagle,O
dogs,O
.,O
In,O
the,O
chronic,O
treatment,O
",",O
beagle,O
dogs,O
of,O
each,O
sex,O
were,O
given,O
intravenously,O
once,O
every,O
3,O
weeks,O
",",O
either,O
a,O
sublethal,O
dose,O
of,O
doxorubicin,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
),O
or,O
SM-5887,I-Entity
(,O
2.5,O
mg,O
/,O
kg,O
),O
.,O
Animals,O
which,O
received,O
over,O
six,O
courses,O
of,O
doxorubicin,I-Entity
demonstrated,O
the,O
electrocardiogram,O
(,O
ECG,O
),O
changes,O
",",O
decrease,O
of,O
blood,O
pressure,O
and,O
high,O
-,O
grade,O
histopathological,O
cardiomyopathy,I-Entity
",",O
while,O
animals,O
which,O
were,O
terminally,O
sacrificed,O
after,O
the,O
SM-5887,I-Entity
administration,O
did,O
not,O
show,O
any,O
changes,O
in,O
ECG,O
",",O
blood,O
pressure,O
and,O
histopathological,O
examinations,O
.,O
To,O
examine,O
a,O
possibly,O
deteriorating,O
cardiotoxic,I-Entity
effect,O
of,O
SM-5887,I-Entity
",",O
low,O
-,O
grade,O
cardiomyopathy,I-Entity
was,O
induced,O
in,O
dogs,O
by,O
four,O
courses,O
of,O
doxorubicin,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
),O
.,O
Nine,O
weeks,O
after,O
pre,O
-,O
treatment,O
",",O
dogs,O
were,O
given,O
four,O
courses,O
of,O
either,O
doxorubicin,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
),O
or,O
SM-5887,I-Entity
(,O
2.5,O
mg,O
/,O
kg,O
),O
once,O
every,O
3,O
weeks,O
.,O
The,O
low,O
-,O
grade,O
cardiotoxic,I-Entity
changes,O
were,O
enhanced,O
by,O
the,O
additional,O
doxorubicin,I-Entity
treatment,O
.,O
On,O
the,O
contrary,O
",",O
the,O
SM-5887,I-Entity
treatment,O
did,O
not,O
progress,O
the,O
grade,O
of,O
cardiomyopathy,I-Entity
.,O
In,O
conclusion,O
",",O
SM-5887,I-Entity
does,O
not,O
have,O
any,O
potential,O
of,O
chronic,O
cardiotoxicity,I-Entity
and,O
deteriorating,O
effect,O
on,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
in,O
dogs,O
.,O
Posteroventral,O
medial,O
pallidotomy,O
in,O
advanced,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
medial,O
pallidotomy,O
sometimes,O
produces,O
striking,O
improvement,O
in,O
patients,O
with,O
advanced,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
",",O
but,O
the,O
studies,O
to,O
date,O
have,O
involved,O
small,O
numbers,O
of,O
patients,O
and,O
short,O
-,O
term,O
follow,O
-,O
up,O
.,O
METHODS,O
:,O
Forty,O
patients,O
with,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
underwent,O
serial,O
",",O
detailed,O
assessments,O
both,O
after,O
drug,O
withdrawal,O
(,O
"""",O
off,O
"""",O
period,O
),O
and,O
while,O
taking,O
their,O
optimal,O
medical,O
regimens,O
(,O
"""",O
on,O
"""",O
period,O
),O
.,O
The,O
percent,O
improvements,O
at,O
six,O
months,O
were,O
as,O
follows,O
:,O
off,O
-,O
period,O
score,O
for,O
overall,O
motor,O
function,O
",",O
28,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
19,O
to,O
38,O
percent,O
),O
",",O
with,O
most,O
of,O
the,O
improvement,O
in,O
the,O
contralateral,O
limbs,O
;,O
off,O
-,O
period,O
score,O
for,O
activities,O
of,O
daily,O
living,O
",",O
29,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
19,O
to,O
39,O
percent,O
),O
;,O
on,O
-,O
period,O
score,O
for,O
contralateral,O
dyskinesias,I-Entity
",",O
82,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
72,O
to,O
91,O
percent,O
),O
;,O
and,O
on,O
-,O
period,O
score,O
for,O
ipsilateral,O
dyskinesias,I-Entity
",",O
44,O
percent,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
29,O
to,O
59,O
percent,O
),O
.,O
The,O
improvements,O
in,O
dyskinesias,I-Entity
and,O
the,O
total,O
scores,O
for,O
off,O
-,O
period,O
parkinsonism,I-Entity
",",O
contralateral,O
bradykinesia,I-Entity
",",O
and,O
rigidity,I-Entity
were,O
sustained,O
in,O
the,O
11,O
patients,O
examined,O
at,O
two,O
years,O
.,O
The,O
improvement,O
in,O
ipsilateral,O
dyskinesias,I-Entity
was,O
lost,O
after,O
one,O
year,O
",",O
and,O
the,O
improvements,O
in,O
postural,O
stability,O
and,O
gait,O
lasted,O
only,O
three,O
to,O
six,O
months,O
.,O
In,O
late,O
-,O
stage,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
",",O
pallidotomy,O
significantly,O
reduces,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
and,O
off,O
-,O
period,O
disability,O
.,O
Neuropeptide,O
-,O
Y,O
immunoreactivity,O
in,O
the,O
pilocarpine,I-Entity
model,O
of,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
.,O
Neuropeptide,O
-,O
Y,O
(,O
NPY,O
),O
is,O
expressed,O
by,O
granule,O
cells,O
and,O
mossy,O
fibres,O
of,O
the,O
hippocampal,O
dentate,O
gyrus,O
during,O
experimental,O
temporal,B-Entity
lobe,I-Entity
epilepsy,I-Entity
(,O
TLE,I-Entity
),O
.,O
This,O
expression,O
may,O
represent,O
an,O
endogenous,O
damping,O
mechanism,O
since,O
NPY,O
has,O
been,O
shown,O
to,O
block,O
seizure,I-Entity
-,O
like,O
events,O
following,O
high,O
-,O
frequency,O
stimulation,O
in,O
hippocampal,O
slices,O
.,O
The,O
pilocarpine,I-Entity
(,O
PILO,I-Entity
),O
model,O
of,O
epilepsy,I-Entity
is,O
characterized,O
by,O
an,O
acute,O
period,O
of,O
status,B-Entity
epilepticus,I-Entity
followed,O
by,O
spontaneous,O
recurrent,O
seizures,I-Entity
and,O
related,O
brain,B-Entity
damage,I-Entity
.,O
PILO,I-Entity
-,O
injected,O
animals,O
exhibited,O
NPY,O
immunoreactivity,O
in,O
the,O
region,O
of,O
the,O
mossy,O
fibre,O
terminals,O
",",O
in,O
the,O
dentate,O
gyrus,O
inner,O
molecular,O
layer,O
and,O
",",O
in,O
a,O
few,O
cases,O
",",O
within,O
presumed,O
granule,O
cells,O
.,O
In,O
addition,O
",",O
PILO,I-Entity
injected,O
animals,O
exhibited,O
a,O
reduction,O
in,O
the,O
number,O
of,O
NPY,O
-,O
immunoreactive,O
interneurons,O
compared,O
with,O
controls,O
.,O
The,O
results,O
demonstrate,O
that,O
changes,O
in,O
NPY,O
expression,O
",",O
including,O
expression,O
in,O
the,O
granule,O
cells,O
and,O
mossy,O
fibres,O
and,O
the,O
loss,O
of,O
vulnerable,O
NPY,O
neurons,O
",",O
are,O
present,O
in,O
the,O
PILO,I-Entity
model,O
of,O
TLE,I-Entity
.,O
During,O
the,O
follow,O
-,O
up,O
",",O
3,O
patients,O
(,O
12%,O
),O
developed,O
steroid,I-Entity
-,O
induced,O
elevated,B-Entity
intraocular,I-Entity
pressure,I-Entity
(,O
IOP,O
),O
that,O
resolved,O
after,O
corticosteroid,I-Entity
therapy,O
was,O
discontinued,O
.,O
The,O
transient,O
steroid,I-Entity
-,O
induced,O
IOP,B-Entity
rise,I-Entity
did,O
not,O
seem,O
to,O
cause,O
functional,O
impairment,O
.,O
Liposomal,O
daunorubicin,I-Entity
in,O
advanced,O
Kaposi,B-Entity
's,I-Entity
sarcoma,I-Entity
:,O
a,O
phase,O
II,O
study,O
.,O
We,O
report,O
a,O
non,O
-,O
randomized,O
Phase,O
II,O
clinical,O
trial,O
to,O
assess,O
the,O
efficacy,O
and,O
safety,O
of,O
liposomal,O
daunorubicin,I-Entity
(,O
DaunoXome,O
),O
in,O
the,O
treatment,O
of,O
AIDS,I-Entity
related,O
Kaposi,B-Entity
's,I-Entity
sarcoma,I-Entity
.,O
Eleven,O
homosexual,O
men,O
with,O
advanced,O
Kaposi,B-Entity
's,I-Entity
sarcoma,I-Entity
were,O
entered,O
in,O
the,O
trial,O
.,O
Changes,O
in,O
size,O
",",O
colour,O
and,O
associated,O
oedema,I-Entity
of,O
selected,O
',O
target,O
',O
lesions,O
were,O
measured,O
.,O
Clinical,O
",",O
biochemical,O
and,O
haematological,O
toxicities,I-Entity
were,O
assessed,O
.,O
Stabilization,O
of,O
Kaposi,B-Entity
's,I-Entity
sarcoma,I-Entity
occurred,O
in,O
the,O
remaining,O
six,O
",",O
maintained,O
until,O
the,O
end,O
of,O
the,O
trial,O
period,O
in,O
four,O
.,O
The,O
drug,O
was,O
generally,O
well,O
tolerated,O
",",O
with,O
few,O
mild,O
symptoms,O
of,O
toxicity,I-Entity
.,O
The,O
main,O
problem,O
encountered,O
was,O
haematological,O
toxicity,I-Entity
",",O
with,O
three,O
subjects,O
experiencing,O
severe,O
neutropenia,I-Entity
(,O
neutrophil,O
count,O
<,O
0.5,O
x,O
10(9)/l,O
),O
.,O
There,O
was,O
no,O
evidence,O
of,O
cardiotoxicity,I-Entity
.,O
In,O
this,O
small,O
patient,O
sample,O
",",O
liposomal,O
daunorubicin,I-Entity
was,O
an,O
effective,O
and,O
well,O
tolerated,O
agent,O
in,O
the,O
treatment,O
of,O
Kaposi,B-Entity
's,I-Entity
sarcoma,I-Entity
.,O
Failure,O
of,O
ancrod,O
in,O
the,O
treatment,O
of,O
heparin,I-Entity
-,O
induced,O
arterial,O
thrombosis,I-Entity
.,O
The,O
morbidity,O
and,O
mortality,O
associated,O
with,O
heparin,I-Entity
-,O
induced,O
thrombosis,I-Entity
remain,O
high,O
despite,O
numerous,O
empirical,O
therapies,O
.,O
Ancrod,O
has,O
been,O
used,O
successfully,O
for,O
prophylaxis,O
against,O
development,O
of,O
thrombosis,I-Entity
in,O
patients,O
with,O
heparin,I-Entity
induced,O
platelet,B-Entity
aggregation,I-Entity
who,O
require,O
brief,O
reexposure,O
to,O
heparin,I-Entity
",",O
but,O
its,O
success,O
in,O
patients,O
who,O
have,O
developed,O
the,O
thrombosis,I-Entity
syndrome,O
is,O
not,O
well,O
defined,O
.,O
The,O
authors,O
present,O
a,O
case,O
of,O
failure,O
of,O
ancrod,O
treatment,O
in,O
a,O
patient,O
with,O
heparin,I-Entity
-,O
induced,O
thrombosis,I-Entity
.,O
Seizure,I-Entity
after,O
flumazenil,I-Entity
administration,O
in,O
a,O
pediatric,O
patient,O
.,O
Flumazenil,I-Entity
is,O
a,O
benzodiazepine,I-Entity
receptor,O
antagonist,O
used,O
to,O
reverse,O
sedation,O
and,O
respiratory,B-Entity
depression,I-Entity
induced,O
by,O
benzodiazepines,I-Entity
.,O
Seizures,I-Entity
and,O
cardiac,B-Entity
arrhythmias,I-Entity
have,O
complicated,O
its,O
use,O
in,O
adult,O
patients,O
.,O
Overdose,I-Entity
patients,O
who,O
have,O
coingested,O
tricyclic,O
antidepressants,O
have,O
a,O
higher,O
risk,O
of,O
these,O
complications,O
.,O
Little,O
information,O
exists,O
concerning,O
adverse,O
effects,O
of,O
flumazenil,I-Entity
in,O
children,O
.,O
We,O
report,O
the,O
occurrence,O
of,O
a,O
generalized,O
tonic,B-Entity
-,I-Entity
clonic,I-Entity
seizure,I-Entity
in,O
a,O
pediatric,O
patient,O
following,O
the,O
administration,O
of,O
flumazenil,I-Entity
.,O
Remodelling,O
of,O
nerve,O
structure,O
in,O
experimental,O
isoniazid,I-Entity
neuropathy,I-Entity
in,O
the,O
rat,O
.,O
The,O
neuropathy,I-Entity
caused,O
by,O
a,O
single,O
dose,O
of,O
isoniazid,I-Entity
in,O
rats,O
was,O
studied,O
with,O
a,O
computer,O
-,O
assisted,O
morphometric,O
method,O
.,O
Selective,O
injection,O
of,O
iopentol,I-Entity
",",O
iohexol,I-Entity
and,O
metrizoate,I-Entity
into,O
the,O
left,O
coronary,O
artery,O
of,O
the,O
dog,O
.,O
Induction,O
of,O
ventricular,B-Entity
fibrillation,I-Entity
and,O
decrease,O
of,O
aortic,O
pressure,O
.,O
In,O
twenty,O
beagle,O
dogs,O
selective,O
injections,O
were,O
made,O
into,O
the,O
left,O
coronary,O
artery,O
with,O
iopentol,I-Entity
",",O
iohexol,I-Entity
and,O
metrizoate,I-Entity
in,O
doses,O
of,O
4,O
ml,O
",",O
8,O
ml,O
and,O
16,O
ml,O
.,O
Thirty,O
-,O
six,O
iopentol,I-Entity
injections,O
",",O
35,O
iohexol,I-Entity
injections,O
and,O
37,O
metrizoate,I-Entity
injections,O
were,O
made,O
.,O
Frequencies,O
of,O
ventricular,B-Entity
fibrillation,I-Entity
were,O
significantly,O
lower,O
(,O
p,O
less,O
than,O
0.05,O
),O
after,O
iopentol,I-Entity
(,O
0%,O
),O
and,O
iohexol,I-Entity
(,O
3%,O
),O
than,O
after,O
metrizoate,I-Entity
(,O
22%,O
),O
.,O
Iopentol,I-Entity
and,O
iohexol,I-Entity
also,O
produced,O
significantly,O
less,O
decrease,O
in,O
aortic,O
blood,O
pressure,O
than,O
metrizoate,I-Entity
at,O
the,O
different,O
doses,O
.,O
Magnetic,O
resonance,O
imaging,O
of,O
cerebral,O
venous,B-Entity
thrombosis,I-Entity
secondary,O
to,O
"""",O
low,O
-,O
dose,O
"""",O
birth,O
control,O
pills,O
.,O
The,O
clinical,O
and,O
radiographic,O
features,O
of,O
cerebral,O
deep,B-Entity
venous,I-Entity
thrombosis,I-Entity
in,O
a,O
21-year,O
-,O
old,O
white,O
woman,O
are,O
presented,O
.,O
The,O
only,O
known,O
risk,O
factor,O
was,O
"""",O
low,O
-,O
dose,O
"""",O
oral,B-Entity
contraceptive,I-Entity
pills,O
.,O
Relation,O
of,O
perfusion,O
defects,O
observed,O
with,O
myocardial,O
contrast,O
echocardiography,O
to,O
the,O
severity,O
of,O
coronary,B-Entity
stenosis,I-Entity
:,O
correlation,O
with,O
thallium-201,I-Entity
single,O
-,O
photon,O
emission,O
tomography,O
.,O
It,O
has,O
been,O
previously,O
shown,O
that,O
myocardial,O
contrast,O
echocardiography,O
is,O
a,O
valuable,O
technique,O
for,O
delineating,O
regions,O
of,O
myocardial,O
underperfusion,O
secondary,O
to,O
coronary,B-Entity
occlusion,I-Entity
and,O
to,O
critical,O
coronary,B-Entity
stenoses,I-Entity
in,O
the,O
presence,O
of,O
hyperemic,I-Entity
stimulation,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
myocardial,O
contrast,O
echocardiography,O
performed,O
with,O
a,O
stable,O
solution,O
of,O
sonicated,O
albumin,O
could,O
detect,O
regions,O
of,O
myocardial,O
underperfusion,O
resulting,O
from,O
various,O
degrees,O
of,O
coronary,B-Entity
stenosis,I-Entity
.,O
The,O
perfusion,O
defect,O
produced,O
in,O
16,O
open,O
chest,O
dogs,O
was,O
compared,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
measured,O
by,O
the,O
postmortem,O
dual,O
-,O
perfusion,O
technique,O
and,O
with,O
thallium-201,I-Entity
single,O
-,O
photon,O
emission,O
tomography,O
(,O
SPECT,O
),O
.,O
During,O
a,O
transient,O
(,O
20-s,O
),O
coronary,B-Entity
occlusion,I-Entity
",",O
a,O
perfusion,O
defect,O
was,O
observed,O
with,O
contrast,O
echocardiography,O
in,O
14,O
of,O
the,O
15,O
dogs,O
in,O
which,O
the,O
occlusion,O
was,O
produced,O
.,O
During,O
dipyridamole,I-Entity
-,O
induced,O
hyperemia,I-Entity
",",O
12,O
of,O
the,O
16,O
dogs,O
with,O
a,O
partial,O
coronary,B-Entity
stenosis,I-Entity
had,O
a,O
visible,O
area,O
of,O
hypoperfusion,O
by,O
contrast,O
echocardiography,O
.,O
The,O
four,O
dogs,O
without,O
a,O
perfusion,O
defect,O
had,O
a,O
stenosis,O
that,O
resulted,O
in,O
a,O
mild,O
(,O
0%,O
to,O
50%,O
),O
reduction,O
in,O
dipyridamole,I-Entity
-,O
induced,O
hyperemia,I-Entity
.,O
Thallium-201,I-Entity
SPECT,O
demonstrated,O
a,O
perfusion,O
defect,O
in,O
all,O
14,O
dogs,O
analyzed,O
during,O
dipyridamole,I-Entity
-,O
induced,O
hyperemia,I-Entity
;,O
the,O
size,O
of,O
the,O
perfusion,O
defect,O
correlated,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
(,O
r,O
=,O
0.58,O
;,O
p,O
less,O
than,O
0.03,O
),O
and,O
with,O
the,O
perfusion,O
defect,O
by,O
contrast,O
echocardiography,O
(,O
r,O
=,O
0.58,O
;,O
p,O
less,O
than,O
0.03,O
),O
.,O
Thus,O
",",O
myocardial,O
contrast,O
echocardiography,O
can,O
be,O
used,O
to,O
visualize,O
and,O
quantitate,O
the,O
amount,O
of,O
jeopardized,O
myocardium,O
during,O
moderate,O
to,O
severe,O
degrees,O
of,O
coronary,B-Entity
stenosis,I-Entity
.,O
The,O
results,O
obtained,O
show,O
a,O
correlation,O
with,O
the,O
anatomic,O
area,O
at,O
risk,O
similar,O
to,O
that,O
obtained,O
with,O
thallium-201,I-Entity
SPECT,O
.,O
Potential,O
deleterious,O
effect,O
of,O
furosemide,I-Entity
in,O
radiocontrast,O
nephropathy,I-Entity
.,O
The,O
purpose,O
of,O
the,O
study,O
was,O
to,O
determine,O
the,O
efficacy,O
of,O
furosemide,I-Entity
in,O
addition,O
to,O
intravenous,O
fluids,O
in,O
the,O
prevention,O
of,O
radiocontrast,O
nephropathy,I-Entity
.,O
18,O
patients,O
",",O
referred,O
to,O
a,O
radiocontrast,O
study,O
",",O
considered,O
at,O
risk,O
because,O
of,O
preexisting,O
renal,B-Entity
insufficiency,I-Entity
",",O
were,O
enrolled,O
in,O
a,O
prospective,O
",",O
randomized,O
",",O
controlled,O
trial,O
",",O
performed,O
at,O
the,O
secondary,O
care,O
center,O
of,O
a,O
"1,100-bed",O
private,O
university,O
hospital,O
.,O
In,O
addition,O
to,O
fluids,O
",",O
the,O
treatment,O
group,O
received,O
furosemide,I-Entity
(,O
mean,O
dose,O
110,O
mg,O
),O
intravenously,O
30,O
min,O
prior,O
to,O
the,O
injection,O
of,O
contrast,O
material,O
.,O
Renal,B-Entity
function,I-Entity
significantly,I-Entity
deteriorated,I-Entity
in,O
the,O
group,O
pretreated,O
with,O
furosemide,I-Entity
(,O
p,O
<,O
0.005,O
by,O
ANOVA,O
),O
",",O
with,O
a,O
rise,O
in,O
serum,O
creatinine,I-Entity
from,O
145,O
+,O
/-,O
Renal,B-Entity
failure,I-Entity
was,O
associated,O
with,O
weight,B-Entity
loss,I-Entity
in,O
the,O
furosemide,I-Entity
-,O
treated,O
group,O
.,O
Furosemide,I-Entity
may,O
be,O
deleterious,O
in,O
the,O
prevention,O
of,O
radiocontrast,O
nephropathy,I-Entity
.,O
The,O
renal,O
pathology,O
in,O
a,O
case,O
of,O
lithium,I-Entity
-,O
induced,O
diabetes,B-Entity
insipidus,I-Entity
.,O
A,O
case,O
of,O
lithium,I-Entity
-,O
induced,O
diabetes,B-Entity
insipidus,I-Entity
is,O
reported,O
.,O
It,O
is,O
suggested,O
that,O
these,O
changes,O
represent,O
a,O
specific,O
toxic,O
effect,O
of,O
lithium,I-Entity
",",O
reported,O
here,O
for,O
the,O
first,O
time,O
in,O
man,O
.,O
Etiologic,O
factors,O
in,O
the,O
pathogenesis,O
of,O
liver,B-Entity
tumors,I-Entity
associated,O
with,O
oral,B-Entity
contraceptives,I-Entity
.,O
Within,O
the,O
last,O
several,O
years,O
",",O
previously,O
rare,O
liver,B-Entity
tumors,I-Entity
have,O
been,O
seen,O
in,O
young,O
women,O
using,O
oral,B-Entity
contraceptive,I-Entity
steroids,I-Entity
.,O
The,O
Registry,O
for,O
Liver,B-Entity
Tumors,I-Entity
Associated,O
with,O
Oral,B-Entity
Contraceptives,I-Entity
at,O
the,O
University,O
of,O
California,O
",",O
Irvine,O
",",O
has,O
clearly,O
identified,O
27,O
cases,O
.,O
Common,O
to,O
these,O
71,O
cases,O
has,O
been,O
a,O
histopathologic,O
diagnosis,O
of,O
focal,B-Entity
nodular,I-Entity
hyperplasia,I-Entity
",",O
adenoma,I-Entity
",",O
hamartoma,I-Entity
",",O
and,O
hepatoma,I-Entity
.,O
Significant,O
statistical,O
etiologic,O
factors,O
include,O
prolonged,O
uninterrupted,O
usage,O
of,O
oral,B-Entity
contraceptive,I-Entity
steroids,I-Entity
.,O
Eight,O
deaths,O
and,O
liver,O
rupture,I-Entity
in,O
18,O
patients,O
attest,O
to,O
the,O
seriousness,O
of,O
this,O
new,O
potentially,O
lethal,O
adverse,O
phenomenon,O
.,O
Graft,B-Entity
-,I-Entity
versus,I-Entity
-,I-Entity
host,I-Entity
disease,I-Entity
prophylaxis,O
with,O
everolimus,I-Entity
and,O
tacrolimus,I-Entity
is,O
associated,O
with,O
a,O
high,O
incidence,O
of,O
sinusoidal,B-Entity
obstruction,I-Entity
syndrome,I-Entity
and,O
microangiopathy,I-Entity
:,O
results,O
of,O
the,O
EVTAC,O
trial,O
.,O
A,O
calcineurin,O
inhibitor,O
combined,O
with,O
methotrexate,I-Entity
is,O
the,O
standard,O
prophylaxis,O
for,O
graft,B-Entity
-,I-Entity
versus,I-Entity
-,I-Entity
host,I-Entity
disease,I-Entity
(,O
GVHD,I-Entity
),O
after,O
allogeneic,O
hematopoietic,O
stem,O
cell,O
transplantation,O
(,O
HSCT,O
),O
.,O
Everolimus,I-Entity
",",O
a,O
derivative,O
of,O
sirolimus,I-Entity
",",O
seems,O
to,O
mediate,O
antileukemia,O
effects,O
.,O
We,O
report,O
on,O
a,O
combination,O
of,O
everolimus,I-Entity
and,O
tacrolimus,I-Entity
in,O
24,O
patients,O
(,O
median,O
age,O
",",O
62,O
years,O
),O
with,O
either,O
myelodysplastic,B-Entity
syndrome,I-Entity
(,O
MDS,I-Entity
;,O
n,O
=,O
17,O
),O
or,O
acute,B-Entity
myeloid,I-Entity
leukemia,I-Entity
(,O
AML,I-Entity
;,O
n,O
=,O
7,O
),O
undergoing,O
intensive,O
conditioning,O
followed,O
by,O
HSCT,O
from,O
related,O
(,O
n,O
=,O
4,O
),O
or,O
unrelated,O
(,O
n,O
=,O
20,O
),O
donors,O
.,O
All,O
patients,O
engrafted,O
",",O
and,O
only,O
1,O
patient,O
experienced,O
grade,O
IV,O
mucositis,I-Entity
.,O
Nine,O
patients,O
(,O
37%,O
),O
developed,O
acute,O
grade,O
II,O
-,O
IV,O
GVHD,I-Entity
",",O
and,O
11,O
of,O
17,O
evaluable,O
patients,O
(,O
64%,O
),O
developed,O
chronic,O
extensive,O
GVHD,I-Entity
.,O
Transplantation,B-Entity
-,I-Entity
associated,I-Entity
microangiopathy,I-Entity
(,O
TMA,I-Entity
),O
occurred,O
in,O
7,O
patients,O
(,O
29%,O
),O
",",O
with,O
2,O
cases,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
The,O
study,O
was,O
terminated,O
prematurely,O
because,O
an,O
additional,O
6,O
patients,O
(,O
25%,O
),O
developed,O
sinusoidal,B-Entity
obstruction,I-Entity
syndrome,I-Entity
(,O
SOS,I-Entity
),O
",",O
which,O
was,O
fatal,O
in,O
2,O
cases,O
.,O
Although,O
this,O
new,O
combination,O
appears,O
to,O
be,O
effective,O
as,O
a,O
prophylactic,O
regimen,O
for,O
acute,O
GVHD,I-Entity
",",O
the,O
incidence,O
of,O
TMA,I-Entity
and,O
SOS,I-Entity
is,O
considerably,O
higher,O
than,O
seen,O
with,O
other,O
regimens,O
.,O
Effect,O
of,O
some,O
convulsants,O
on,O
the,O
protective,O
activity,O
of,O
loreclezole,I-Entity
and,O
its,O
combinations,O
with,O
valproate,I-Entity
or,O
clonazepam,I-Entity
in,O
amygdala,O
-,O
kindled,O
rats,O
.,O
Loreclezole,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
exerted,O
a,O
significant,O
protective,O
action,O
in,O
amygdala,O
-,O
kindled,O
rats,O
",",O
reducing,O
both,O
seizure,I-Entity
and,O
afterdischarge,O
durations,O
.,O
The,O
combinations,O
of,O
loreclezole,I-Entity
(,O
2.5,O
mg,O
/,O
kg,O
),O
with,O
valproate,I-Entity
",",O
clonazepam,I-Entity
",",O
or,O
carbamazepine,I-Entity
(,O
applied,O
at,O
their,O
subprotective,O
doses,O
),O
also,O
exhibited,O
antiseizure,O
effect,O
in,O
this,O
test,O
.,O
Among,O
several,O
chemoconvulsants,O
",",O
bicuculline,I-Entity
",",O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartic,I-Entity
acid,I-Entity
and,O
BAY,B-Entity
k-8644,I-Entity
(,O
the,O
opener,O
of,O
L,O
-,O
type,O
calcium,I-Entity
channels,O
),O
reversed,O
the,O
protective,O
activity,O
of,O
loreclezole,I-Entity
alone,O
and,O
its,O
combination,O
with,O
valproate,I-Entity
.,O
On,O
the,O
other,O
hand,O
",",O
bicuculline,I-Entity
",",O
aminophylline,I-Entity
and,O
BAY,B-Entity
k-8644,I-Entity
inhibited,O
the,O
anticonvulsive,O
action,O
of,O
loreclezole,I-Entity
combined,O
with,O
clonazepam,I-Entity
.,O
The,O
results,O
support,O
the,O
hypothesis,O
that,O
the,O
protective,O
activity,O
of,O
loreclezole,I-Entity
and,O
its,O
combinations,O
with,O
other,O
antiepileptics,O
may,O
involve,O
potentiation,O
of,O
GABAergic,O
neurotransmission,O
and,O
blockade,O
of,O
L,O
-,O
type,O
of,O
calcium,I-Entity
channels,O
.,O
Acute,B-Entity
liver,I-Entity
failure,I-Entity
with,O
concurrent,O
bupropion,I-Entity
and,O
carbimazole,I-Entity
therapy,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
fatal,O
liver,B-Entity
failure,I-Entity
possibly,O
associated,O
with,O
concurrent,O
use,O
of,O
bupropion,I-Entity
and,O
carbimazole,I-Entity
.,O
A,O
41-year,O
-,O
old,O
Chinese,O
man,O
with,O
a,O
history,O
of,O
hyperthyroidism,I-Entity
had,O
been,O
treated,O
with,O
carbimazole,I-Entity
and,O
propranolol,I-Entity
for,O
the,O
past,O
5,O
years,O
.,O
He,O
received,O
a,O
10-day,O
course,O
of,O
bupropion,I-Entity
as,O
an,O
aid,O
for,O
smoking,O
cessation,O
10,O
weeks,O
prior,O
to,O
presentation,O
.,O
He,O
developed,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
with,O
rapid,O
deterioration,O
of,O
renal,O
function,O
.,O
Liver,O
biopsy,O
showed,O
evidence,O
of,O
nonspecific,O
drug,B-Entity
-,I-Entity
induced,I-Entity
acute,I-Entity
liver,I-Entity
injury,I-Entity
.,O
His,O
condition,O
was,O
further,O
complicated,O
by,O
sepsis,I-Entity
and,O
coagulopathy,I-Entity
.,O
The,O
likelihood,O
that,O
bupropion,I-Entity
induced,O
hepatotoxicity,I-Entity
in,O
our,O
patient,O
was,O
possible,O
",",O
based,O
on,O
the,O
Naranjo,O
probability,O
scale,O
.,O
DISCUSSION,O
:,O
Although,O
there,O
is,O
increasing,O
evidence,O
of,O
hepatotoxicity,I-Entity
induced,O
by,O
bupropion,I-Entity
",",O
this,O
is,O
the,O
first,O
case,O
of,O
fatality,O
that,O
could,O
have,O
resulted,O
from,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
in,O
a,O
patient,O
receiving,O
bupropion,I-Entity
while,O
on,O
concomitant,O
treatment,O
with,O
carbimazole,I-Entity
.,O
Clinicians,O
should,O
be,O
aware,O
of,O
the,O
possibility,O
of,O
acute,B-Entity
liver,I-Entity
insult,I-Entity
induced,O
by,O
bupropion,I-Entity
given,O
concurrently,O
with,O
other,O
hepatotoxic,I-Entity
drugs,O
.,O
Hormone,O
therapy,O
(,O
HT,O
),O
is,O
widely,O
used,O
for,O
controlling,O
menopausal,O
symptoms,O
and,O
has,O
also,O
been,O
used,O
for,O
the,O
management,O
and,O
prevention,O
of,O
cardiovascular,B-Entity
disease,I-Entity
",",O
osteoporosis,I-Entity
and,O
dementia,I-Entity
in,O
older,O
women,O
.,O
To,O
assess,O
the,O
effect,O
of,O
long,O
-,O
term,O
HT,O
on,O
mortality,O
",",O
cardiovascular,O
outcomes,O
",",O
cancer,I-Entity
",",O
gallbladder,B-Entity
disease,I-Entity
",",O
cognition,O
",",O
fractures,I-Entity
and,O
quality,O
of,O
life,O
.,O
We,O
searched,O
the,O
following,O
databases,O
to,O
November,O
2007,O
:,O
Trials,O
Register,O
of,O
the,O
Cochrane,O
Menstrual,B-Entity
Disorders,I-Entity
and,O
Subfertility,O
Group,O
",",O
Cochrane,O
Central,O
Register,O
of,O
Controlled,O
Trials,O
",",O
MEDLINE,O
",",O
EMBASE,O
",",O
Biological,O
Abstracts,O
.,O
HT,O
included,O
oestrogens,I-Entity
",",O
with,O
or,O
without,O
progestogens,I-Entity
",",O
via,O
oral,O
",",O
transdermal,O
",",O
subcutaneous,O
or,O
transnasal,O
routes,O
.,O
In,O
relatively,O
healthy,O
women,O
",",O
combined,O
continuous,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,B-Entity
thrombo,I-Entity
-,I-Entity
embolism,I-Entity
or,O
coronary,O
event,O
(,O
after,O
one,O
year,O
's,O
use,O
),O
",",O
stroke,I-Entity
(,O
after,O
three,O
years,O
),O
",",O
breast,B-Entity
cancer,I-Entity
and,O
gallbladder,B-Entity
disease,I-Entity
.,O
Long,O
-,O
term,O
oestrogen,I-Entity
-,O
only,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,B-Entity
thrombo,I-Entity
-,I-Entity
embolism,I-Entity
",",O
stroke,I-Entity
and,O
gallbladder,B-Entity
disease,I-Entity
(,O
after,O
one,O
to,O
two,O
years,O
",",O
three,O
years,O
and,O
seven,O
years,O
',O
use,O
respectively,O
),O
",",O
but,O
did,O
not,O
significantly,O
increase,O
the,O
risk,O
of,O
breast,B-Entity
cancer,I-Entity
.,O
The,O
only,O
statistically,O
significant,O
benefits,O
of,O
HT,O
were,O
a,O
decreased,O
incidence,O
of,O
fractures,I-Entity
and,O
(,O
for,O
combined,O
HT,O
),O
colon,B-Entity
cancer,I-Entity
",",O
with,O
long,O
-,O
term,O
use,O
.,O
Among,O
women,O
aged,O
over,O
65,O
who,O
were,O
relatively,O
healthy,O
(,O
i.e.,O
generally,O
fit,O
",",O
without,O
overt,O
disease,O
),O
and,O
taking,O
continuous,O
combined,O
HT,O
",",O
there,O
was,O
a,O
statistically,O
significant,O
increase,O
in,O
the,O
incidence,O
of,O
dementia,I-Entity
.,O
Among,O
women,O
with,O
cardiovascular,B-Entity
disease,I-Entity
",",O
long,O
-,O
term,O
use,O
of,O
combined,O
continuous,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,B-Entity
thrombo,I-Entity
-,I-Entity
embolism,I-Entity
.,O
One,O
trial,O
analysed,O
subgroups,O
of,O
2839,O
relatively,O
healthy,O
50,O
to,O
59,O
year,O
old,O
women,O
taking,O
combined,O
continuous,O
HT,O
and,O
1637,O
taking,O
oestrogen,I-Entity
-,O
only,O
HT,O
",",O
versus,O
similar,O
-,O
sized,O
placebo,O
groups,O
.,O
The,O
only,O
significantly,O
increased,O
risk,O
reported,O
was,O
for,O
venous,B-Entity
thrombo,I-Entity
-,I-Entity
embolism,I-Entity
in,O
women,O
taking,O
combined,O
continuous,O
HT,O
:,O
their,O
absolute,O
risk,O
remained,O
low,O
",",O
at,O
less,O
than,O
1/500,O
.,O
Passage,O
of,O
mannitol,I-Entity
into,O
the,O
brain,O
around,O
gliomas,I-Entity
:,O
a,O
potential,O
cause,O
of,O
rebound,O
phenomenon,O
.,O
Widespread,O
use,O
of,O
mannitol,I-Entity
to,O
reduce,O
brain,B-Entity
edema,I-Entity
and,O
lower,O
elevated,B-Entity
ICP,I-Entity
in,O
brain,B-Entity
tumor,I-Entity
patients,O
continues,O
to,O
be,O
afflicted,O
by,O
the,O
so,O
-,O
called,O
rebound,O
phenomenon,O
.,O
Leakage,O
of,O
mannitol,I-Entity
into,O
the,O
brain,O
parenchyma,O
through,O
an,O
altered,O
BBB,O
and,O
secondary,O
reversal,O
of,O
osmotic,O
gradient,O
is,O
considered,O
the,O
major,O
cause,O
of,O
rebound,O
.,O
As,O
a,O
contribution,O
to,O
this,O
issue,O
we,O
decided,O
to,O
research,O
the,O
possible,O
passage,O
of,O
mannitol,I-Entity
into,O
the,O
brain,O
after,O
administration,O
to,O
21,O
brain,B-Entity
tumor,I-Entity
patients,O
.,O
METHODS,O
:,O
Mannitol,I-Entity
(,O
18%,O
solution,O
;,O
1,O
g,O
/,O
kg,O
),O
was,O
administered,O
as,O
a,O
bolus,O
to,O
patients,O
(,O
ten,O
had,O
malignant,B-Entity
glioma,I-Entity
",",O
seven,O
brain,O
metastases,I-Entity
and,O
four,O
meningioma,I-Entity
),O
about,O
30,O
minutes,O
before,O
craniotomy,O
.,O
During,O
resection,O
",",O
a,O
sample,O
of,O
the,O
surrounding,O
edematous,I-Entity
white,O
matter,O
was,O
taken,O
at,O
the,O
same,O
time,O
as,O
a,O
10,O
ml,O
venous,O
blood,O
sample,O
.,O
Mannitol,I-Entity
concentrations,O
were,O
measured,O
in,O
plasma,O
and,O
white,O
matter,O
by,O
a,O
modified,O
version,O
of,O
the,O
enzyme,O
assay,O
of,O
Blonquist,O
et,O
al,O
.,O
In,O
most,O
glioma,I-Entity
patients,O
",",O
mannitol,I-Entity
concentrations,O
in,O
white,O
matter,O
were,O
2,O
to,O
6,O
times,O
higher,O
than,O
in,O
plasma,O
(,O
mean,O
3.5,O
times,O
),O
.,O
In,O
meningioma,I-Entity
and,O
metastases,I-Entity
patients,O
plasma,O
concentrations,O
of,O
mannitol,I-Entity
were,O
higher,O
than,O
white,O
matter,O
concentrations,O
except,O
in,O
three,O
cases,O
with,O
infiltration,O
by,O
neoplastic,O
cells,O
.,O
The,O
results,O
of,O
our,O
study,O
show,O
that,O
even,O
after,O
a,O
single,O
bolus,O
",",O
mannitol,I-Entity
may,O
leak,O
through,O
the,O
altered,O
BBB,O
near,O
gliomas,I-Entity
",",O
reversing,O
the,O
initial,O
plasma,O
-,O
to,O
-,O
blood,O
osmotic,O
gradient,O
",",O
aggravating,O
peritumoral,O
edema,I-Entity
and,O
promoting,O
rebound,O
of,O
ICP,O
.,O
Can,O
lidocaine,I-Entity
reduce,O
succinylcholine,I-Entity
induced,O
postoperative,B-Entity
myalgia,I-Entity
?,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
the,O
effect,O
of,O
lidocaine,I-Entity
pretreatment,O
on,O
reduction,O
of,O
succinylcholine,I-Entity
-,O
induced,O
myalgia,I-Entity
in,O
patients,O
undergoing,O
general,O
anesthesia,O
for,O
gynecological,O
surgery,O
.,O
Group,O
PS,O
",",O
the,O
control,O
group,O
",",O
received,O
normal,O
saline,O
and,O
succinylcholine,I-Entity
1.5,O
mg,O
x,O
kg(-1,O
),O
;,O
Group,O
LS,O
",",O
lidocaine,I-Entity
1.5,O
mg,O
x,O
kg(-1,O
),O
and,O
succinylcholine,I-Entity
1.5,O
mg,O
x,O
kg(-1,O
),O
;,O
Group,O
PR,O
",",O
normal,O
saline,O
and,O
rocuronium,I-Entity
0.6,O
mg,O
x,O
kg(-1,O
),O
.,O
Morphine,I-Entity
0.1,O
mg,O
x,O
kg(-1,O
),O
thiopental,I-Entity
iv,O
.,O
followed,O
by,O
succinylcholine,I-Entity
(,O
Group,O
PS,O
",",O
LS,O
),O
or,O
rocuronium,I-Entity
(,O
Group,O
PR,O
),O
for,O
tracheal,O
intubation,O
.,O
Following,O
administration,O
of,O
these,O
agents,O
",",O
the,O
presence,O
",",O
and,O
degree,O
of,O
fasciculation,I-Entity
were,O
assessed,O
visually,O
on,O
a,O
four,O
point,O
scale,O
by,O
one,O
investigator,O
who,O
was,O
blinded,O
to,O
the,O
drug,O
administered,O
.,O
Twenty,O
-,O
four,O
hours,O
later,O
",",O
any,O
myalgia,I-Entity
experienced,O
was,O
assessed,O
according,O
to,O
a,O
structured,O
questionaire,O
and,O
graded,O
by,O
a,O
four,O
point,O
scale,O
by,O
one,O
investigator,O
blinded,O
to,O
the,O
intraoperative,O
management,O
.,O
The,O
results,O
indicate,O
that,O
muscle,B-Entity
fasciculation,I-Entity
was,O
not,O
found,O
in,O
Group,O
PR,O
while,O
the,O
patients,O
in,O
Group,O
LS,O
had,O
a,O
lower,O
incidence,O
of,O
muscle,B-Entity
fasciculation,I-Entity
than,O
those,O
in,O
Group,O
PS,O
(,O
p,O
At,O
24,O
h,O
",",O
the,O
incidence,O
of,O
myalgia,I-Entity
was,O
higher,O
in,O
Group,O
PS,O
than,O
in,O
Group,O
LS,O
and,O
PR,O
(,O
A,O
correlation,O
was,O
not,O
found,O
between,O
the,O
incidence,O
of,O
myalgia,I-Entity
and,O
the,O
occurrence,O
of,O
muscle,B-Entity
fasciculation,I-Entity
.,O
In,O
conclusion,O
",",O
where,O
succinylcholine,I-Entity
is,O
used,O
",",O
lidocaine,I-Entity
is,O
proven,O
to,O
be,O
the,O
useful,O
pretreatment,O
agent,O
for,O
the,O
reduction,O
of,O
postoperative,B-Entity
myalgia,I-Entity
.,O
Open,O
-,O
label,O
assessment,O
of,O
levofloxacin,I-Entity
for,O
the,O
treatment,O
of,O
acute,O
bacterial,O
sinusitis,I-Entity
in,O
adults,O
.,O
PURPOSE,O
:,O
To,O
evaluate,O
the,O
efficacy,O
and,O
safety,O
of,O
levofloxacin,I-Entity
(,O
500,O
mg,O
orally,O
once,O
daily,O
for,O
10,O
to,O
14,O
days,O
),O
in,O
treating,O
adult,O
outpatients,O
with,O
acute,O
bacterial,O
sinusitis,I-Entity
.,O
Adverse,O
events,O
considered,O
to,O
be,O
related,O
to,O
levofloxacin,I-Entity
administration,O
were,O
reported,O
by,O
29,O
patients,O
(,O
9%,O
),O
.,O
The,O
most,O
common,O
drug,O
-,O
related,O
adverse,O
events,O
were,O
diarrhea,I-Entity
",",O
flatulence,I-Entity
",",O
and,O
nausea,I-Entity
;,O
most,O
adverse,O
events,O
were,O
mild,O
to,O
moderate,O
in,O
severity,O
.,O
The,O
results,O
of,O
this,O
study,O
indicate,O
that,O
levofloxacin,I-Entity
500,O
mg,O
once,O
daily,O
is,O
an,O
effective,O
and,O
safe,O
treatment,O
for,O
acute,O
bacterial,O
sinusitis,I-Entity
.,O
Clinical,O
evaluation,O
on,O
combined,O
administration,O
of,O
oral,O
prostacyclin,I-Entity
analogue,O
beraprost,I-Entity
and,O
phosphodiesterase,O
inhibitor,O
cilostazol,I-Entity
.,O
Among,O
various,O
oral,O
antiplatelets,O
",",O
a,O
combination,O
of,O
a,O
novel,O
prostacyclin,I-Entity
analogue,O
beraprost,I-Entity
(,O
BPT,I-Entity
),O
and,O
a,O
potent,O
phosphodiesterase,O
inhibitor,O
cilostazol,I-Entity
(,O
CLZ,I-Entity
),O
may,O
result,O
in,O
untoward,O
clinical,O
effects,O
due,O
to,O
possible,O
synergistic,O
elevation,O
of,O
intracellular,O
cAMP,I-Entity
(,O
cyclic,B-Entity
adenosine,I-Entity
"3',5'-monophosphate",I-Entity
),O
.,O
Twelve,O
healthy,O
volunteers,O
were,O
assigned,O
to,O
take,O
BPT,I-Entity
/,O
CLZ,I-Entity
in,O
the,O
following,O
schedule,O
;,O
BPT,I-Entity
:,O
40,O
micrograms,O
at,O
day,O
1,O
and,O
120,O
micrograms,O
t.i.d,O
.,O
from,O
day,O
7,O
to,O
14,O
",",O
CLZ,I-Entity
:,O
200,O
mg,O
t.i.d,O
.,O
At,O
various,O
time,O
intervals,O
",",O
physical,O
examination,O
and,O
blood,O
collection,O
for,O
ex,O
vivo,O
platelet,B-Entity
aggregation,I-Entity
and,O
determination,O
of,O
intraplatelet,O
cAMP,I-Entity
were,O
performed,O
.,O
Seven,O
out,O
of,O
12,O
subjects,O
experienced,O
headache,I-Entity
of,O
a,O
short,O
duration,O
accompanying,O
facial,B-Entity
flush,I-Entity
in,O
one,O
and,O
nausea,I-Entity
in,O
one,O
",",O
especially,O
after,O
ingestion,O
of,O
CLZ,I-Entity
.,O
Intraplatelet,O
cAMP,I-Entity
content,O
was,O
gradually,O
but,O
significantly,O
increased,O
to,O
9.84,O
+,O
/-,O
In,O
conclusion,O
",",O
the,O
combined,O
administration,O
of,O
BPT,I-Entity
/,O
CLZ,I-Entity
is,O
safe,O
at,O
doses,O
used,O
in,O
the,O
study,O
",",O
though,O
the,O
beneficial,O
clinical,O
effect,O
of,O
the,O
combined,O
administration,O
has,O
yet,O
to,O
be,O
elucidated,O
.,O
Gastrointestinal,O
tolerability,O
of,O
etoricoxib,I-Entity
in,O
rheumatoid,B-Entity
arthritis,I-Entity
patients,O
:,O
results,O
of,O
the,O
etoricoxib,I-Entity
vs,O
diclofenac,B-Entity
sodium,I-Entity
gastrointestinal,O
tolerability,O
and,O
effectiveness,O
trial,O
(,O
EDGE,O
-,O
II,O
),O
.,O
OBJECTIVE,O
:,O
A,O
randomised,O
",",O
double,O
-,O
blind,O
study,O
to,O
compare,O
the,O
gastrointestinal,O
(,O
GI,O
),O
tolerability,O
",",O
safety,O
and,O
efficacy,O
of,O
etoricoxib,I-Entity
and,O
diclofenac,I-Entity
in,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
(,O
RA,I-Entity
),O
.,O
A,O
total,O
of,O
4086,O
patients,O
(,O
mean,O
age,O
60.8,O
years,O
),O
diagnosed,O
with,O
RA,I-Entity
were,O
enrolled,O
and,O
received,O
etoricoxib,I-Entity
90,O
mg,O
daily,O
(,O
n,O
=,O
2032,O
),O
or,O
diclofenac,I-Entity
75,O
mg,O
twice,O
daily,O
(,O
n,O
=,O
2054,O
),O
.,O
Use,O
of,O
gastroprotective,O
agents,O
and,O
low,O
-,O
dose,O
aspirin,I-Entity
was,O
allowed,O
.,O
General,O
safety,O
was,O
also,O
assessed,O
",",O
including,O
adjudicated,O
thrombotic,B-Entity
cardiovascular,I-Entity
event,O
data,O
.,O
;,O
maximum,O
),O
duration,O
of,O
treatment,O
was,O
19.3,O
(,O
10.3,O
;,O
32.9,O
),O
and,O
19.1,O
(,O
10.4,O
;,O
33.1,O
),O
months,O
in,O
the,O
etoricoxib,I-Entity
and,O
diclofenac,I-Entity
groups,O
",",O
respectively,O
.,O
The,O
cumulative,O
discontinuation,O
rate,O
due,O
to,O
GI,B-Entity
AEs,I-Entity
was,O
significantly,O
lower,O
with,O
etoricoxib,I-Entity
than,O
diclofenac,I-Entity
(,O
5.2,O
vs,O
8.5,O
events,O
per,O
100,O
patient,O
-,O
years,O
",",O
respectively,O
;,O
hazard,O
ratio,O
0.62,O
(,O
95%,O
CI,O
:,O
0.47,O
",",O
0.81,O
;,O
p,O
<,O
The,O
incidence,O
of,O
discontinuations,O
for,O
hypertension,I-Entity
-,O
related,O
and,O
oedema,I-Entity
-,O
related,O
AEs,O
were,O
significantly,O
higher,O
with,O
etoricoxib,I-Entity
(,O
2.5%,O
and,O
1.1%,O
respectively,O
),O
compared,O
with,O
diclofenac,I-Entity
(,O
1.5%,O
and,O
0.4%,O
respectively,O
;,O
p<0.001,O
for,O
hypertension,I-Entity
and,O
p<0.01,O
for,O
oedema,I-Entity
),O
.,O
Etoricoxib,I-Entity
and,O
diclofenac,I-Entity
treatment,O
resulted,O
in,O
similar,O
efficacy,O
(,O
PGADS,O
mean,O
changes,O
from,O
baseline,O
-0.62,O
vs,O
-0.58,O
",",O
respectively,O
),O
.,O
Etoricoxib,I-Entity
90,O
mg,O
demonstrated,O
a,O
significantly,O
lower,O
risk,O
for,O
discontinuing,O
treatment,O
due,O
to,O
GI,B-Entity
AEs,I-Entity
compared,O
with,O
diclofenac,I-Entity
150,O
mg,O
.,O
Discontinuations,O
from,O
renovascular,O
AEs,O
",",O
although,O
less,O
common,O
than,O
discontinuations,O
from,O
GI,B-Entity
AEs,I-Entity
",",O
were,O
significantly,O
higher,O
with,O
etoricoxib,I-Entity
.,O
Placebo,O
-,O
level,O
incidence,O
of,O
extrapyramidal,B-Entity
symptoms,I-Entity
(,O
EPS,I-Entity
),O
with,O
quetiapine,I-Entity
in,O
controlled,O
studies,O
of,O
patients,O
with,O
bipolar,B-Entity
mania,I-Entity
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
extrapyramidal,B-Entity
symptoms,I-Entity
(,O
EPS,I-Entity
),O
",",O
including,O
akathisia,I-Entity
",",O
with,O
quetiapine,I-Entity
in,O
patients,O
with,O
bipolar,B-Entity
mania,I-Entity
.,O
Two,O
studies,O
evaluated,O
quetiapine,I-Entity
monotherapy,O
(,O
up,O
to,O
800,O
mg,O
/,O
day,O
),O
(,O
n,O
=,O
209,O
),O
versus,O
placebo,O
(,O
n,O
=,O
198,O
),O
",",O
with,O
lithium,I-Entity
or,O
haloperidol,I-Entity
monotherapy,O
as,O
respective,O
active,O
controls,O
.,O
Two,O
studies,O
evaluated,O
quetiapine,I-Entity
(,O
up,O
to,O
800,O
mg,O
/,O
day,O
),O
in,O
combination,O
with,O
a,O
mood,O
stabilizer,O
(,O
lithium,I-Entity
or,O
divalproex,I-Entity
",",O
QTP,I-Entity
+,O
Li,I-Entity
/,O
DVP,I-Entity
),O
(,O
n,O
=,O
196,O
),O
compared,O
to,O
placebo,O
and,O
mood,O
stabilizer,O
(,O
PBO,O
+,O
Li,I-Entity
/,O
DVP,I-Entity
),O
(,O
n,O
=,O
203,O
),O
.,O
Extrapyramidal,B-Entity
symptoms,I-Entity
were,O
evaluated,O
using,O
the,O
Simpson,O
-,O
Angus,O
Scale,O
(,O
SAS,O
),O
",",O
the,O
Barnes,O
Akathisia,O
Rating,O
Scale,O
(,O
BARS,O
),O
",",O
adverse,O
event,O
reports,O
and,O
anticholinergic,O
drug,O
usage,O
.,O
The,O
incidence,O
of,O
EPS,I-Entity
-,O
related,O
adverse,O
events,O
",",O
including,O
akathisia,I-Entity
",",O
was,O
no,O
different,O
with,O
quetiapine,I-Entity
monotherapy,O
(,O
12.9%,O
),O
than,O
with,O
placebo,O
(,O
13.1%,O
),O
.,O
Similarly,O
",",O
EPS,I-Entity
-,O
related,O
adverse,O
events,O
with,O
QTP,I-Entity
+,O
Li,I-Entity
/,O
DVP,I-Entity
(,O
21.4%,O
),O
were,O
no,O
different,O
than,O
with,O
PBO,O
+,O
Li,I-Entity
/,O
DVP,I-Entity
(,O
19.2%,O
),O
.,O
Adverse,O
events,O
related,O
to,O
EPS,I-Entity
occurred,O
in,O
59.6%,O
of,O
patients,O
treated,O
with,O
haloperidol,I-Entity
(,O
n,O
=,O
99,O
),O
monotherapy,O
",",O
whereas,O
26.5%,O
of,O
patients,O
treated,O
with,O
lithium,I-Entity
(,O
n,O
=,O
98,O
),O
monotherapy,O
experienced,O
adverse,O
events,O
related,O
to,O
EPS,I-Entity
.,O
The,O
incidence,O
of,O
akathisia,I-Entity
was,O
low,O
and,O
similar,O
with,O
quetiapine,I-Entity
monotherapy,O
(,O
3.3%,O
),O
and,O
placebo,O
(,O
6.1%,O
),O
",",O
and,O
with,O
QTP,I-Entity
+,O
Li,I-Entity
/,O
DVP,I-Entity
(,O
3.6%,O
),O
and,O
PBO,O
+,O
Li,I-Entity
/,O
DVP,I-Entity
(,O
4.9%,O
),O
.,O
Lithium,I-Entity
was,O
associated,O
with,O
a,O
significantly,O
higher,O
incidence,O
(,O
p,O
<,O
0.05,O
),O
of,O
tremor,I-Entity
(,O
18.4%,O
),O
than,O
quetiapine,I-Entity
(,O
5.6%,O
),O
;,O
cerebellar,O
tremor,I-Entity
",",O
which,O
is,O
a,O
known,O
adverse,O
effect,O
of,O
lithium,I-Entity
",",O
may,O
have,O
contributed,O
to,O
the,O
elevated,O
rate,O
of,O
tremor,I-Entity
in,O
patients,O
receiving,O
lithium,I-Entity
therapy,O
.,O
Haloperidol,I-Entity
induced,O
a,O
significantly,O
higher,O
incidence,O
(,O
p,O
<,O
0.001,O
),O
of,O
akathisia,I-Entity
(,O
33.3%,O
versus,O
5.9%,O
),O
",",O
tremor,I-Entity
(,O
30.3%,O
versus,O
7.8%,O
),O
",",O
and,O
extrapyramidal,B-Entity
syndrome,I-Entity
(,O
35.4%,O
versus,O
5.9%,O
),O
than,O
quetiapine,I-Entity
.,O
No,O
significant,O
differences,O
were,O
observed,O
between,O
quetiapine,I-Entity
and,O
placebo,O
on,O
SAS,O
and,O
BARS,O
scores,O
.,O
Anticholinergic,O
use,O
was,O
low,O
and,O
similar,O
with,O
quetiapine,I-Entity
or,O
placebo,O
.,O
In,O
bipolar,B-Entity
mania,I-Entity
",",O
the,O
incidence,O
of,O
EPS,I-Entity
",",O
including,O
akathisia,I-Entity
",",O
with,O
quetiapine,I-Entity
therapy,O
is,O
similar,O
to,O
that,O
with,O
placebo,O
.,O
Contribution,O
of,O
the,O
sympathetic,O
nervous,O
system,O
to,O
salt,O
-,O
sensitivity,O
in,O
lifetime,O
captopril,I-Entity
-,O
treated,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
OBJECTIVE,O
:,O
To,O
test,O
the,O
hypothesis,O
that,O
",",O
in,O
lifetime,O
captopril,I-Entity
-,O
treated,O
spontaneously,O
hypertensive,I-Entity
rats,O
(,O
SHR,O
),O
",",O
the,O
sympathetic,O
nervous,O
system,O
contributes,O
importantly,O
to,O
the,O
hypertensive,I-Entity
effect,O
of,O
dietary,B-Entity
sodium,I-Entity
chloride,I-Entity
supplementation,O
.,O
Male,O
SHR,O
(,O
aged,O
6,O
weeks,O
),O
that,O
had,O
been,O
treated,O
from,O
conception,O
onward,O
with,O
either,O
captopril,I-Entity
or,O
vehicle,O
remained,O
on,O
a,O
basal,O
sodium,B-Entity
chloride,I-Entity
diet,O
or,O
were,O
fed,O
a,O
high,O
sodium,B-Entity
chloride,I-Entity
diet,O
.,O
After,O
2,O
weeks,O
",",O
the,O
rats,O
were,O
subjected,O
to,O
ganglionic,O
blockade,O
and,O
2,O
days,O
later,O
",",O
an,O
infusion,O
of,O
clonidine,I-Entity
.,O
Lifetime,O
captopril,I-Entity
treatment,O
significantly,O
lowered,O
mean,O
arterial,O
pressure,O
in,O
both,O
groups,O
.,O
Intravenous,O
infusion,O
of,O
the,O
ganglionic,O
blocker,O
hexamethonium,I-Entity
resulted,O
in,O
a,O
rapid,O
decline,O
in,O
MAP,O
that,O
eliminated,O
the,O
dietary,B-Entity
sodium,I-Entity
chloride,I-Entity
-,O
induced,O
increase,B-Entity
in,I-Entity
MAP,I-Entity
in,O
both,O
groups,O
.,O
Infusion,O
of,O
the,O
central,O
nervous,O
system,O
alpha2-adrenergic,B-Entity
receptor,I-Entity
agonist,I-Entity
clonidine,I-Entity
also,O
resulted,O
in,O
a,O
greater,O
reduction,O
in,O
MAP,O
in,O
both,O
groups,O
of,O
SHR,O
that,O
were,O
fed,O
the,O
high,O
(,O
compared,O
with,O
the,O
basal,O
),O
sodium,B-Entity
chloride,I-Entity
diet,O
.,O
In,O
both,O
lifetime,O
captopril,I-Entity
-,O
treated,O
and,O
control,O
SHR,O
",",O
the,O
sympathetic,O
nervous,O
system,O
contributes,O
to,O
the,O
pressor,O
effects,O
of,O
a,O
high,O
sodium,B-Entity
chloride,I-Entity
diet,O
.,O
Dose,O
-,O
related,O
beneficial,O
and,O
adverse,O
effects,O
of,O
dietary,O
corticosterone,I-Entity
on,O
organophosphorus,I-Entity
-,O
induced,O
delayed,O
neuropathy,I-Entity
in,O
chickens,O
.,O
Tri,B-Entity
-,I-Entity
ortho,I-Entity
-,I-Entity
tolyl,I-Entity
phosphate,I-Entity
(,O
TOTP,I-Entity
),O
",",O
360,O
mg,O
/,O
kg,O
",",O
po,O
",",O
and,O
"0,0'-diisopropyl",B-Entity
phosphorofluoridate,I-Entity
(,O
DFP,I-Entity
),O
",",O
1,O
mg,O
/,O
kg,O
sc,O
",",O
were,O
administered,O
to,O
adult,O
White,O
Leghorn,O
chickens,O
24,O
hr,O
after,O
they,O
were,O
placed,O
on,O
diets,O
containing,O
0,O
to,O
300,O
ppm,O
corticosterone,I-Entity
.,O
Supplemented,O
diets,O
were,O
continued,O
until,O
clinical,O
signs,O
and,O
lesions,O
of,O
delayed,O
neuropathy,I-Entity
appeared,O
.,O
Although,O
low,O
concentrations,O
(,O
less,O
than,O
or,O
equal,O
to,O
50,O
ppm,O
),O
of,O
corticosterone,I-Entity
had,O
beneficial,O
effects,O
on,O
TOTP,I-Entity
-,O
induced,O
neuropathy,I-Entity
",",O
greater,O
than,O
or,O
equal,O
to,O
200,O
ppm,O
exacerbated,O
clinical,O
signs,O
in,O
chickens,O
given,O
either,O
TOTP,I-Entity
or,O
DFP,I-Entity
.,O
Neurotoxic,I-Entity
esterase,O
activities,O
24,O
hr,O
after,O
TOTP,I-Entity
or,O
DFP,I-Entity
were,O
less,O
than,O
20%,O
of,O
values,O
measured,O
in,O
chickens,O
not,O
given,O
organophosphorous,I-Entity
compounds,O
.,O
corticosterone,I-Entity
without,O
TOTP,I-Entity
or,O
DFP,I-Entity
had,O
significantly,O
elevated,O
activity,O
of,O
plasma,O
cholinesterase,O
and,O
significantly,O
inhibited,O
activity,O
of,O
liver,O
carboxylesterase,O
.,O
Degenerating,B-Entity
myelinated,I-Entity
fibers,I-Entity
were,O
also,O
evident,O
in,O
distal,O
levels,O
of,O
the,O
peripheral,O
nerves,O
of,O
chickens,O
given,O
TOTP,I-Entity
or,O
DFP,I-Entity
.,O
In,O
vivo,O
characterization,O
of,O
a,O
dual,O
adenosine,B-Entity
A2A,I-Entity
/,I-Entity
A1,I-Entity
receptor,I-Entity
antagonist,I-Entity
in,O
animal,O
models,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
The,O
in,O
vivo,O
characterization,O
of,O
a,O
dual,O
adenosine,B-Entity
A(2A)/A(1,I-Entity
),I-Entity
receptor,I-Entity
antagonist,I-Entity
in,O
several,O
animal,O
models,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
is,O
described,O
.,O
nM,O
),O
that,O
has,O
excellent,O
activity,O
",",O
after,O
oral,O
administration,O
",",O
across,O
a,O
number,O
of,O
animal,O
models,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
including,O
mouse,O
and,O
rat,O
models,O
of,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
",",O
mouse,O
model,O
of,O
reserpine,I-Entity
-,O
induced,O
akinesia,I-Entity
",",O
rat,O
6-hydroxydopamine,I-Entity
(,O
6-OHDA,I-Entity
),O
lesion,O
model,O
of,O
drug,O
-,O
induced,O
rotation,O
",",O
and,O
MPTP,I-Entity
-,O
treated,O
non,O
-,O
human,O
primate,O
model,O
.,O
An,O
extremely,O
rare,O
case,O
of,O
delusional,B-Entity
parasitosis,I-Entity
in,O
a,O
chronic,B-Entity
hepatitis,I-Entity
C,I-Entity
patient,O
during,O
pegylated,B-Entity
interferon,I-Entity
alpha-2b,I-Entity
and,O
ribavirin,I-Entity
treatment,O
.,O
During,O
treatment,O
of,O
chronic,B-Entity
hepatitis,I-Entity
C,I-Entity
patients,O
with,O
interferon,O
and,O
ribavirin,I-Entity
",",O
a,O
lot,O
of,O
side,O
effects,O
are,O
described,O
.,O
Twenty,O
-,O
three,O
percent,O
to,O
44%,O
of,O
patients,O
develop,O
depression,I-Entity
.,O
A,O
minority,O
of,O
patients,O
evolve,O
to,O
psychosis,I-Entity
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
no,O
cases,O
of,O
psychogenic,B-Entity
parasitosis,I-Entity
occurring,O
during,O
interferon,O
therapy,O
have,O
been,O
described,O
in,O
the,O
literature,O
.,O
We,O
present,O
a,O
49-year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
delusional,B-Entity
parasitosis,I-Entity
during,O
treatment,O
with,O
pegylated,B-Entity
interferon,I-Entity
alpha-2b,I-Entity
weekly,O
and,O
ribavirin,I-Entity
.,O
All,O
the,O
complaints,O
disappeared,O
after,O
stopping,O
pegylated,B-Entity
interferon,I-Entity
alpha-2b,I-Entity
and,O
reappeared,O
after,O
restarting,O
it,O
.,O
Possible,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
related,O
to,O
concomitant,O
treatment,O
with,O
paroxetine,I-Entity
and,O
alprazolam,I-Entity
.,O
A,O
74-year,O
-,O
old,O
man,O
with,O
depressive,B-Entity
symptoms,I-Entity
was,O
admitted,O
to,O
a,O
psychiatric,I-Entity
hospital,O
due,O
to,O
insomnia,I-Entity
",",O
loss,B-Entity
of,I-Entity
appetite,I-Entity
",",O
exhaustion,O
",",O
and,O
agitation,I-Entity
.,O
Medical,O
treatment,O
was,O
initiated,O
at,O
a,O
daily,O
dose,O
of,O
20,O
mg,O
paroxetine,I-Entity
and,O
1.2,O
mg,O
alprazolam,I-Entity
.,O
On,O
the,O
10th,O
day,O
of,O
paroxetine,I-Entity
and,O
alprazolam,I-Entity
treatment,O
",",O
the,O
patient,O
exhibited,O
marked,O
psychomotor,B-Entity
retardation,I-Entity
",",O
disorientation,O
",",O
and,O
severe,O
muscle,B-Entity
rigidity,I-Entity
with,O
tremors,I-Entity
.,O
The,O
patient,O
had,O
a,O
fever,I-Entity
(,O
38.2,O
degrees,O
C,O
),O
",",O
fluctuating,O
blood,O
pressure,O
(,O
between,O
165/90,O
and,O
130/70,O
mg,O
mm,O
Hg,O
),O
",",O
and,O
severe,O
extrapyramidal,B-Entity
symptoms,I-Entity
.,O
Laboratory,O
tests,O
showed,O
an,O
elevation,O
of,O
creatine,I-Entity
phosphokinase,O
(,O
2218,O
IU,O
/,O
L,O
),O
",",O
aspartate,I-Entity
aminotransferase,O
(,O
134,O
IU,O
/,O
L,O
),O
",",O
alanine,I-Entity
aminotransferase,O
(,O
78,O
IU,O
/,O
L,O
),O
",",O
and,O
BUN,O
(,O
27.9,O
mg,O
/,O
ml,O
),O
levels,O
.,O
The,O
patient,O
received,O
bromocriptine,I-Entity
and,O
diazepam,I-Entity
to,O
treat,O
his,O
symptoms,O
.,O
7,O
days,O
later,O
",",O
the,O
fever,I-Entity
disappeared,O
and,O
the,O
patient,O
's,O
serum,O
CPK,O
levels,O
were,O
normalized,O
(,O
175,O
IU,O
/,O
L,O
),O
.,O
This,O
patient,O
presented,O
with,O
symptoms,O
of,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
(,O
NMS,I-Entity
),O
",",O
thus,O
demonstrating,O
that,O
NMS,I-Entity
-,O
like,O
symptoms,O
can,O
occur,O
after,O
combined,O
paroxetine,I-Entity
and,O
alprazolam,I-Entity
treatment,O
.,O
The,O
adverse,O
drug,O
reaction,O
score,O
obtained,O
by,O
the,O
Naranjo,O
algorithm,O
was,O
6,O
in,O
our,O
case,O
",",O
indicating,O
a,O
probable,O
relationship,O
between,O
the,O
patient,O
's,O
NMS,I-Entity
-,O
like,O
adverse,O
symptoms,O
and,O
the,O
combined,O
treatment,O
used,O
in,O
this,O
case,O
.,O
Several,O
risk,O
factors,O
for,O
NMS,I-Entity
should,O
be,O
noted,O
in,O
elderly,O
depressive,I-Entity
patients,O
whose,O
symptoms,O
often,O
include,O
dehydration,I-Entity
",",O
agitation,I-Entity
",",O
malnutrition,I-Entity
",",O
and,O
exhaustion,O
.,O
Careful,O
therapeutic,O
intervention,O
is,O
necessary,O
in,O
cases,O
involving,O
elderly,O
patients,O
who,O
suffer,O
from,O
depression,I-Entity
.,O
Pilocarpine,I-Entity
seizures,I-Entity
cause,O
age,O
-,O
dependent,O
impairment,B-Entity
in,I-Entity
auditory,I-Entity
location,I-Entity
discrimination,I-Entity
.,O
Children,O
who,O
have,O
status,B-Entity
epilepticus,I-Entity
have,O
continuous,O
or,O
rapidly,O
repeating,O
seizures,I-Entity
that,O
may,O
be,O
life,O
-,O
threatening,O
and,O
may,O
cause,O
life,O
-,O
long,O
changes,O
in,O
brain,O
and,O
behavior,O
.,O
The,O
extent,O
to,O
which,O
status,B-Entity
epilepticus,I-Entity
causes,O
deficits,B-Entity
in,I-Entity
auditory,I-Entity
discrimination,I-Entity
is,O
unknown,O
.,O
A,O
naturalistic,O
auditory,O
location,O
discrimination,O
method,O
was,O
used,O
to,O
evaluate,O
this,O
question,O
using,O
an,O
animal,O
model,O
of,O
status,B-Entity
epilepticus,I-Entity
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
injected,O
with,O
saline,O
on,O
postnatal,O
day,O
(,O
P,O
),O
20,O
",",O
or,O
a,O
convulsant,O
dose,O
of,O
pilocarpine,I-Entity
on,O
P20,O
or,O
P45,O
.,O
Pilocarpine,I-Entity
on,O
either,O
day,O
induced,O
status,B-Entity
epilepticus,I-Entity
;,O
status,B-Entity
epilepticus,I-Entity
at,O
P45,O
resulted,O
in,O
CA3,O
cell,O
loss,O
and,O
spontaneous,O
seizures,I-Entity
",",O
whereas,O
P20,O
rats,O
had,O
no,O
cell,O
loss,O
or,O
spontaneous,O
seizures,I-Entity
.,O
In,O
status,B-Entity
epilepticus,I-Entity
(,O
P20,O
),O
rats,O
",",O
acquisition,O
of,O
the,O
sound,O
-,O
source,O
location,O
discrimination,O
was,O
moderately,O
impaired,O
.,O
Status,B-Entity
epilepticus,I-Entity
(,O
P45,O
),O
rats,O
failed,O
to,O
acquire,O
either,O
sound,O
-,O
source,O
location,O
or,O
sound,O
-,O
silence,O
discriminations,O
.,O
Status,B-Entity
epilepticus,I-Entity
in,O
rat,O
causes,O
an,O
age,O
-,O
dependent,O
",",O
long,O
-,O
term,O
impairment,B-Entity
in,I-Entity
auditory,I-Entity
discrimination,I-Entity
.,O
This,O
impairment,O
may,O
explain,O
one,O
cause,O
of,O
impaired,B-Entity
auditory,I-Entity
location,I-Entity
discrimination,I-Entity
in,O
humans,O
.,O
Cardiovascular,O
risk,O
with,O
cyclooxygenase,B-Entity
inhibitors,I-Entity
:,O
general,O
problem,O
with,O
substance,O
specific,O
differences,O
?,O
Randomised,O
clinical,O
trials,O
and,O
observational,O
studies,O
have,O
shown,O
an,O
increased,O
risk,O
of,O
myocardial,B-Entity
infarction,I-Entity
",",O
stroke,I-Entity
",",O
hypertension,I-Entity
and,O
heart,B-Entity
failure,I-Entity
during,O
treatment,O
with,O
cyclooxygenase,B-Entity
inhibitors,I-Entity
.,O
Cyclooxygenase,B-Entity
inhibitors,I-Entity
cause,O
complex,O
changes,O
in,O
renal,O
",",O
vascular,O
and,O
cardiac,O
prostanoid,O
profiles,O
thereby,O
increasing,O
vascular,O
resistance,O
and,O
fluid,O
retention,O
.,O
A,O
comparison,O
of,O
individual,O
selective,O
and,O
unselective,O
cyclooxygenase,B-Entity
inhibitors,I-Entity
suggests,O
substance,O
-,O
specific,O
differences,O
",",O
which,O
may,O
depend,O
on,O
differences,O
in,O
pharmacokinetic,O
parameters,O
or,O
inhibitory,O
potency,O
and,O
may,O
be,O
contributed,O
by,O
prostaglandin,I-Entity
-,O
independent,O
effects,O
.,O
Diagnostic,O
markers,O
such,O
as,O
N,B-Entity
-,I-Entity
terminal,I-Entity
pro,I-Entity
brain,I-Entity
natriuretic,I-Entity
peptide,I-Entity
(,O
NT,B-Entity
-,I-Entity
proBNP,I-Entity
),O
or,O
high,O
-,O
sensitive,O
C,O
-,O
reactive,O
protein,O
might,O
help,O
in,O
the,O
early,O
identification,O
of,O
patients,O
at,O
risk,O
",",O
thus,O
avoiding,O
the,O
occurrence,O
of,O
serious,O
cardiovascular,B-Entity
toxicity,I-Entity
.,O
Predictors,O
of,O
decreased,B-Entity
renal,I-Entity
function,I-Entity
in,O
patients,O
with,O
heart,B-Entity
failure,I-Entity
during,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitor,O
therapy,O
:,O
results,O
from,O
the,O
studies,O
of,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
(,O
SOLVD,O
),O
BACKGROUND,O
:,O
Although,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitor,O
therapy,O
reduces,O
mortality,O
rates,O
in,O
patients,O
with,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
(,O
CHF,I-Entity
),O
",",O
it,O
may,O
also,O
cause,O
decreased,B-Entity
renal,I-Entity
function,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
quantify,O
specific,O
clinical,O
predictors,O
of,O
reduction,B-Entity
in,I-Entity
renal,I-Entity
function,I-Entity
in,O
patients,O
with,O
CHF,I-Entity
who,O
are,O
prescribed,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
inhibitor,O
therapy,O
.,O
We,O
analyzed,O
data,O
from,O
the,O
Studies,O
of,O
Left,B-Entity
Ventricular,I-Entity
Dysfunction,I-Entity
(,O
SOLVD,O
),O
",",O
a,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
of,O
enalapril,I-Entity
for,O
the,O
treatment,O
of,O
CHF,I-Entity
.,O
There,O
were,O
3379,O
patients,O
randomly,O
assigned,O
to,O
enalapril,I-Entity
with,O
a,O
median,O
follow,O
-,O
up,O
of,O
974,O
days,O
and,O
3379,O
patients,O
randomly,O
assigned,O
to,O
placebo,O
with,O
a,O
mean,O
follow,O
-,O
up,O
of,O
967,O
days,O
.,O
Decreased,B-Entity
renal,I-Entity
function,I-Entity
was,O
defined,O
as,O
a,O
rise,O
in,O
serum,O
creatinine,I-Entity
>,O
/=0.5,O
mg,O
/,O
dL,O
(,O
44,O
micromol,O
/,O
L,O
),O
from,O
baseline,O
.,O
We,O
used,O
time,O
-,O
to,O
-,O
event,O
analysis,O
to,O
identify,O
potential,O
predictors,O
of,O
decrease,O
in,O
renal,O
function,O
including,O
age,O
",",O
baseline,O
ejection,O
fraction,O
",",O
baseline,O
creatinine,I-Entity
",",O
low,O
systolic,O
blood,O
pressure,O
(,O
<,O
100,O
mm,O
Hg,O
),O
",",O
history,O
of,O
hypertension,I-Entity
",",O
diabetes,I-Entity
",",O
and,O
use,O
of,O
antiplatelet,O
",",O
diuretic,I-Entity
",",O
and,O
beta,O
-,O
blocker,O
therapy,O
.,O
Patients,O
randomly,O
assigned,O
to,O
enalapril,I-Entity
had,O
a,O
33%,O
greater,O
likelihood,O
of,O
decreased,B-Entity
renal,I-Entity
function,I-Entity
than,O
controls,O
(,O
P,O
=,O
.003,O
),O
.,O
By,O
multivariate,O
analysis,O
",",O
in,O
both,O
the,O
placebo,O
and,O
enalapril,I-Entity
groups,O
older,O
age,O
",",O
diuretic,I-Entity
therapy,O
",",O
and,O
diabetes,I-Entity
were,O
associated,O
with,O
decreased,B-Entity
renal,I-Entity
function,I-Entity
",",O
whereas,O
beta,O
-,O
blocker,O
therapy,O
and,O
higher,O
ejection,O
fraction,O
were,O
renoprotective,O
.,O
Older,O
age,O
was,O
associated,O
with,O
a,O
greater,O
risk,O
of,O
developing,O
decreased,B-Entity
renal,I-Entity
function,I-Entity
in,O
both,O
groups,O
",",O
but,O
significantly,O
more,O
so,O
in,O
the,O
enalapril,I-Entity
group,O
(,O
enalapril,I-Entity
:,O
risk,O
ratio,O
[,O
RR,O
],O
1.42,O
per,O
10,O
years,O
",",O
95%,O
confidence,O
interval,O
[,O
CI,O
],O
1.32,O
-,O
1.52,O
with,O
enalapril,I-Entity
;,O
placebo,O
:,O
RR,O
1.18,O
",",O
95%,O
CI,O
1.12,O
-,O
1.25,O
),O
.,O
Diuretic,I-Entity
therapy,O
was,O
likewise,O
associated,O
with,O
a,O
greater,O
risk,O
of,O
decreased,B-Entity
renal,I-Entity
function,I-Entity
in,O
the,O
enalapril,I-Entity
group,O
(,O
RR,O
1.89,O
",",O
95%,O
CI,O
1.70,O
-,O
2.08,O
),O
than,O
in,O
the,O
placebo,O
group,O
(,O
RR,O
1.35,O
",",O
95%,O
CI,O
1.09,O
-,O
1.66,O
),O
.,O
Conversely,O
",",O
enalapril,I-Entity
had,O
a,O
relative,O
renoprotective,O
effect,O
(,O
RR,O
1.33,O
",",O
95%,O
CI,O
1.13,O
-,O
1.53,O
),O
compared,O
with,O
placebo,O
(,O
RR,O
1.96,O
",",O
95%,O
CI,O
1.57,O
-,O
2.44,O
),O
in,O
patients,O
with,O
diabetes,I-Entity
.,O
A,O
lower,O
risk,O
of,O
renal,B-Entity
impairment,I-Entity
was,O
seen,O
in,O
both,O
groups,O
with,O
beta,O
-,O
blocker,O
therapy,O
(,O
RR,O
0.70,O
",",O
95%,O
CI,O
0.57,O
-,O
0.85,O
),O
and,O
higher,O
baseline,O
ejection,O
fraction,O
(,O
RR,O
0.93,O
per,O
5%,O
increment,O
",",O
95%,O
CI,O
0.91,O
-,O
0,O
.,O
Enalapril,I-Entity
use,O
caused,O
a,O
33%,O
increase,O
in,O
the,O
risk,O
of,O
decreased,B-Entity
renal,I-Entity
function,I-Entity
in,O
patients,O
with,O
CHF,I-Entity
.,O
Diuretic,I-Entity
use,O
and,O
advanced,O
age,O
increased,O
this,O
risk,O
.,O
Diabetes,I-Entity
was,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
renal,B-Entity
impairment,I-Entity
in,O
all,O
patients,O
with,O
CHF,I-Entity
",",O
but,O
this,O
risk,O
was,O
reduced,O
in,O
the,O
enalapril,I-Entity
group,O
compared,O
with,O
the,O
placebo,O
group,O
.,O
Pemoline,I-Entity
induced,O
acute,O
choreoathetosis,I-Entity
:,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
Pemoline,I-Entity
is,O
an,O
oxazolidine,I-Entity
derivative,O
that,O
is,O
structurally,O
different,O
from,O
amphetamines,I-Entity
and,O
used,O
in,O
the,O
treatment,O
of,O
attention,B-Entity
deficit,I-Entity
disorder,I-Entity
.,O
Pemoline,I-Entity
has,O
not,O
been,O
commonly,O
associated,O
in,O
the,O
literature,O
as,O
a,O
cause,O
of,O
acute,O
movement,B-Entity
disorders,I-Entity
.,O
The,O
following,O
case,O
describes,O
two,O
children,O
acutely,O
poisoned,O
with,O
pemoline,I-Entity
who,O
experienced,O
profound,O
choreoathetosis,I-Entity
.,O
Two,O
",",O
3-year,O
-,O
old,O
male,O
",",O
identical,O
twin,O
siblings,O
presented,O
to,O
the,O
emergency,O
department,O
after,O
found,O
playing,O
with,O
a,O
an,O
empty,O
bottle,O
of,O
pemoline,I-Entity
originally,O
containing,O
59,O
tablets,O
.,O
The,O
children,O
had,O
a,O
medical,O
history,O
significant,O
for,O
attention,B-Entity
deficit,I-Entity
disorder,I-Entity
previously,O
treated,O
with,O
methylphenidate,I-Entity
without,O
success,O
.,O
This,O
was,O
their,O
first,O
day,O
of,O
pemoline,I-Entity
therapy,O
.,O
The,O
choreoathetoid,I-Entity
movements,O
began,O
45,O
min,O
to,O
1,O
h,O
after,O
ingestion,O
.,O
The,O
children,O
gave,O
no,O
history,O
of,O
prior,O
movement,B-Entity
disorders,I-Entity
and,O
there,O
was,O
no,O
family,O
history,O
of,O
movement,B-Entity
disorders,I-Entity
.,O
The,O
children,O
received,O
gastrointestinal,O
decontamination,O
and,O
high,O
doses,O
of,O
intravenous,O
benzodiazepines,I-Entity
in,O
an,O
attempt,O
to,O
control,O
the,O
choreoathetoid,I-Entity
movements,O
.,O
Despite,O
treatment,O
",",O
the,O
children,O
continued,O
to,O
have,O
choreoathetosis,I-Entity
for,O
approximately,O
24,O
hours,O
.,O
Pemoline,I-Entity
associated,O
movement,B-Entity
disorder,I-Entity
has,O
been,O
rarely,O
reported,O
in,O
the,O
acute,O
toxicology,O
literature,O
.,O
The,O
possibility,O
of,O
choreoathetoid,I-Entity
movements,O
should,O
be,O
considered,O
in,O
patients,O
presenting,O
after,O
pemoline,I-Entity
overdose,I-Entity
.,O
Continuous,O
subcutaneous,O
administration,O
of,O
mesna,I-Entity
to,O
prevent,O
ifosfamide,I-Entity
-,O
induced,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
Hemorrhagic,B-Entity
cystitis,I-Entity
is,O
a,O
major,O
potential,O
toxicity,I-Entity
of,O
ifosfamide,I-Entity
that,O
can,O
be,O
prevented,O
by,O
administering,O
mesna,I-Entity
along,O
with,O
the,O
cytotoxic,O
agent,O
.,O
Mesna,I-Entity
is,O
generally,O
administered,O
by,O
the,O
intravenous,O
route,O
",",O
although,O
experience,O
with,O
oral,O
delivery,O
of,O
the,O
drug,O
has,O
increased,O
.,O
The,O
continuous,O
subcutaneous,O
administration,O
of,O
mesna,I-Entity
has,O
the,O
advantage,O
of,O
not,O
requiring,O
intravenous,O
access,O
.,O
In,O
addition,O
",",O
subcutaneous,O
delivery,O
of,O
the,O
neutralizing,O
agent,O
will,O
not,O
be,O
associated,O
with,O
the,O
risk,O
of,O
inadequate,O
urinary,O
mesna,I-Entity
concentrations,O
",",O
such,O
as,O
in,O
a,O
patient,O
taking,O
oral,O
mesna,I-Entity
who,O
experiences,O
severe,O
ifosfamide,I-Entity
-,O
induced,O
emesis,I-Entity
and,O
is,O
unable,O
to,O
absorb,O
the,O
drug,O
.,O
Limited,O
clinical,O
experience,O
with,O
continuous,O
subcutaneous,O
mesna,I-Entity
administration,O
suggests,O
it,O
is,O
a,O
safe,O
",",O
practical,O
",",O
and,O
economic,O
method,O
of,O
drug,O
delivery,O
that,O
permits,O
ifosfamide,I-Entity
to,O
be,O
administered,O
successfully,O
in,O
the,O
outpatient,O
setting,O
.,O
Modification,O
of,O
drug,O
action,O
by,O
hyperammonemia,I-Entity
.,O
Pretreatment,O
with,O
ammonium,B-Entity
acetate,I-Entity
(,O
NH4Ac,I-Entity
),O
(,O
6,O
mmol,O
/,O
kg,O
s.c,O
.,O
),O
approximately,O
doubled,O
the,O
time,O
morphine,I-Entity
-,O
treated,O
mice,O
remained,O
on,O
a,O
hot,O
surface,O
and,O
similarly,O
increased,O
muscular,O
incoordination,I-Entity
by,O
diazepam,I-Entity
",",O
but,O
NH4Ac,I-Entity
treatment,O
alone,O
had,O
no,O
effect,O
.,O
Thus,O
",",O
hyperammonemia,I-Entity
is,O
capable,O
of,O
altering,O
drug,O
action,O
and,O
must,O
be,O
considered,O
along,O
with,O
impaired,O
drug,O
metabolism,O
in,O
enhanced,O
drug,O
responses,O
associated,O
with,O
liver,B-Entity
disease,I-Entity
.,O
Experiments,O
in,O
vitro,O
showed,O
that,O
acetylcholine,I-Entity
-,O
induced,O
catecholamine,I-Entity
release,O
from,O
bovine,O
adrenal,O
medulla,O
is,O
depressed,O
as,O
much,O
as,O
50%,O
by,O
0.3,O
mM,O
NH4Ac,I-Entity
and,O
KCl,I-Entity
-,O
induced,O
contractions,O
of,O
guinea,O
-,O
pig,O
ileum,O
were,O
inhibited,O
20%,O
by,O
5,O
mM,O
NH4Ac,I-Entity
.,O
Addition,O
of,O
excess,O
calcium,I-Entity
reversed,O
the,O
depression,I-Entity
in,O
both,O
tissues,O
",",O
but,O
calcium,I-Entity
-,O
independent,O
catecholamine,I-Entity
release,O
by,O
acetaldehyde,I-Entity
was,O
not,O
blocked,O
by,O
NH4Ac,I-Entity
.,O
These,O
results,O
suggested,O
that,O
ammonia,I-Entity
blocks,O
calcium,I-Entity
channels,O
.,O
Parallels,O
in,O
the,O
actions,O
of,O
NH4Ac,I-Entity
and,O
the,O
calcium,I-Entity
channel,O
blocker,O
verapamil,I-Entity
support,O
this,O
concept,O
.,O
Both,O
verapamil,I-Entity
(,O
10,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
and,O
NH4Ac,I-Entity
pretreatment,O
enhanced,O
morphine,I-Entity
analgesia-,I-Entity
and,O
diazepam,I-Entity
-,O
induced,O
muscular,O
incoordination,I-Entity
and,O
antagonized,O
amphetamine,I-Entity
-,O
induced,O
motor,O
activity,O
",",O
and,O
neither,O
verapamil,I-Entity
nor,O
NH4Ac,I-Entity
affected,O
the,O
convulsant,O
action,O
of,O
metrazol,I-Entity
.,O
The,O
data,O
suggest,O
that,O
hyperammonemia,I-Entity
exerts,O
a,O
calcium,I-Entity
channel,O
blocking,O
action,O
which,O
enhances,O
the,O
effects,O
of,O
central,O
nervous,O
system,O
depressants,O
and,O
certain,O
opioid,O
analgesics,O
.,O
Risk,O
of,O
nephropathy,I-Entity
after,O
consumption,O
of,O
nonionic,O
contrast,B-Entity
media,I-Entity
by,O
children,O
undergoing,O
cardiac,O
angiography,O
:,O
a,O
prospective,O
study,O
.,O
Despite,O
increasing,O
reports,O
on,O
nonionic,O
contrast,B-Entity
media,I-Entity
-,O
induced,O
nephropathy,I-Entity
(,O
CIN,I-Entity
),O
in,O
hospitalized,O
adult,O
patients,O
during,O
cardiac,O
procedures,O
",",O
the,O
studies,O
in,O
pediatrics,O
are,O
limited,O
",",O
with,O
even,O
less,O
focus,O
on,O
possible,O
predisposing,O
factors,O
and,O
preventive,O
measures,O
for,O
patients,O
undergoing,O
cardiac,O
angiography,O
.,O
This,O
prospective,O
study,O
determined,O
the,O
incidence,O
of,O
CIN,I-Entity
for,O
two,O
nonionic,O
contrast,B-Entity
media,I-Entity
(,O
CM,I-Entity
),O
",",O
iopromide,I-Entity
and,O
iohexol,I-Entity
",",O
among,O
80,O
patients,O
younger,O
than,O
18,O
years,O
and,O
compared,O
the,O
rates,O
for,O
this,O
complication,O
in,O
relation,O
to,O
the,O
type,O
and,O
dosage,O
of,O
CM,I-Entity
and,O
the,O
presence,O
of,O
cyanosis,I-Entity
.,O
The,O
80,O
patients,O
in,O
the,O
study,O
consecutively,O
received,O
either,O
iopromide,I-Entity
(,O
group,O
A,O
",",O
n,O
=,O
40,O
),O
or,O
iohexol,I-Entity
Serum,O
sodium,I-Entity
(,O
Na,I-Entity
),O
",",O
potassium,I-Entity
(,O
K,I-Entity
),O
",",O
and,O
creatinine,I-Entity
(,O
Cr,I-Entity
),O
were,O
measured,O
24,O
h,O
before,O
angiography,O
as,O
baseline,O
values,O
",",O
then,O
measured,O
again,O
at,O
12-,O
",",O
24-,O
",",O
and,O
48-h,O
intervals,O
after,O
CM,I-Entity
use,O
.,O
Urine,O
samples,O
for,O
Na,I-Entity
and,O
Cr,I-Entity
also,O
were,O
checked,O
at,O
the,O
same,O
intervals,O
.,O
Risk,O
of,O
renal,B-Entity
failure,I-Entity
",",O
Injury,B-Entity
to,I-Entity
the,I-Entity
kidney,I-Entity
",",O
Failure,B-Entity
of,I-Entity
kidney,I-Entity
function,I-Entity
",",O
Loss,B-Entity
of,I-Entity
kidney,I-Entity
function,I-Entity
",",O
and,O
End,O
-,O
stage,O
renal,B-Entity
damage,I-Entity
(,O
RIFLE,O
criteria,O
),O
were,O
used,O
to,O
define,O
CIN,I-Entity
and,O
its,O
incidence,O
in,O
the,O
study,O
population,O
.,O
Accordingly,O
",",O
among,O
the,O
15,O
CIN,I-Entity
patients,O
(,O
18.75%,O
),O
",",O
7.5%,O
of,O
the,O
patients,O
in,O
group,O
A,O
had,O
increased,O
risk,O
and,O
3.75%,O
had,O
renal,B-Entity
injury,I-Entity
",",O
whereas,O
5%,O
of,O
group,O
B,O
had,O
increased,O
risk,O
and,O
2.5%,O
had,O
renal,B-Entity
injury,I-Entity
.,O
Whereas,O
33.3%,O
of,O
the,O
patients,O
with,O
CIN,I-Entity
were,O
among,O
those,O
who,O
received,O
the,O
proper,O
dosage,O
of,O
CM,I-Entity
",",O
the,O
percentage,O
increased,O
to,O
66.6%,O
among,O
those,O
who,O
received,O
larger,O
doses,O
",",O
with,O
a,O
significant,O
difference,O
in,O
the,O
incidence,O
of,O
CIN,I-Entity
related,O
to,O
the,O
different,O
dosages,O
of,O
CM,I-Entity
(,O
p,O
=,O
0.014,O
),O
.,O
Among,O
the,O
15,O
patients,O
with,O
CIN,I-Entity
",",O
6,O
had,O
cyanotic,O
congenital,B-Entity
heart,I-Entity
diseases,I-Entity
",",O
but,O
the,O
incidence,O
did,O
not,O
differ,O
significantly,O
from,O
that,O
for,O
the,O
noncyanotic,O
patients,O
(,O
p,O
=,O
0.243,O
),O
.,O
Although,O
clinically,O
silent,O
",",O
CIN,I-Entity
is,O
not,O
rare,O
in,O
pediatrics,O
.,O
The,O
incidence,O
depends,O
on,O
dosage,O
but,O
not,O
on,O
the,O
type,O
of,O
consumed,O
nonionic,O
CM,I-Entity
",",O
nor,O
on,O
the,O
presence,O
of,O
cyanosis,I-Entity
",",O
and,O
although,O
CIN,I-Entity
usually,O
is,O
reversible,O
",",O
more,O
concern,O
is,O
needed,O
for,O
the,O
prevention,O
of,O
such,O
a,O
complication,O
in,O
children,O
.,O
A,O
case,O
of,O
ventricular,B-Entity
tachycardia,I-Entity
related,O
to,O
caffeine,I-Entity
pretreatment,O
.,O
Suboptimal,O
seizure,I-Entity
duration,O
is,O
commonly,O
encountered,O
in,O
electroconvulsive,O
therapy,O
practice,O
",",O
especially,O
in,O
older,O
patients,O
with,O
higher,O
seizure,I-Entity
thresholds,O
.,O
Intravenous,O
caffeine,I-Entity
is,O
commonly,O
used,O
to,O
improve,O
seizure,I-Entity
duration,O
and,O
quality,O
in,O
such,O
patients,O
and,O
is,O
generally,O
well,O
tolerated,O
aside,O
from,O
occasional,O
reports,O
of,O
relatively,O
benign,O
ventricular,B-Entity
ectopy,I-Entity
.,O
We,O
describe,O
a,O
patient,O
with,O
no,O
previous,O
history,O
of,O
cardiac,B-Entity
disease,I-Entity
or,O
arrhythmia,I-Entity
who,O
developed,O
sustained,O
bigeminy,O
and,O
2,O
brief,O
runs,O
of,O
ventricular,B-Entity
tachycardia,I-Entity
after,O
caffeine,I-Entity
administration,O
.,O
Although,O
intravenous,O
caffeine,I-Entity
is,O
generally,O
well,O
tolerated,O
",",O
the,O
clinician,O
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
unpredictable,O
and,O
serious,O
ventricular,B-Entity
arrhythmias,I-Entity
.,O
Optical,O
coherence,O
tomography,O
can,O
measure,O
axonal,O
loss,O
in,O
patients,O
with,O
ethambutol,I-Entity
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
.,O
PURPOSE,O
:,O
To,O
map,O
and,O
identify,O
the,O
pattern,O
",",O
in,O
vivo,O
",",O
of,O
axonal,B-Entity
degeneration,I-Entity
in,O
ethambutol,I-Entity
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
using,O
optical,O
coherence,O
tomography,O
(,O
OCT,O
),O
.,O
Ethambutol,I-Entity
is,O
an,O
antimycobacterial,O
agent,O
often,O
used,O
to,O
treat,O
tuberculosis,I-Entity
.,O
A,O
serious,O
complication,O
of,O
ethambutol,I-Entity
is,O
an,O
optic,B-Entity
neuropathy,I-Entity
that,O
impairs,O
visual,O
acuity,O
",",O
contrast,O
sensitivity,O
",",O
and,O
color,O
vision,O
.,O
However,O
",",O
early,O
on,O
",",O
when,O
the,O
toxic,O
optic,B-Entity
neuropathy,I-Entity
is,O
mild,O
and,O
partly,O
reversible,O
",",O
the,O
funduscopic,O
findings,O
are,O
often,O
subtle,O
and,O
easy,O
to,O
miss,O
.,O
METHODS,O
:,O
Three,O
subjects,O
with,O
a,O
history,O
of,O
ethambutol,I-Entity
(,O
EMB)-induced,I-Entity
optic,B-Entity
neuropathy,I-Entity
of,O
short-,O
",",O
intermediate-,O
",",O
and,O
long,O
-,O
term,O
visual,B-Entity
deficits,I-Entity
were,O
administered,O
a,O
full,O
neuro,O
-,O
ophthalmologic,O
examination,O
including,O
visual,O
acuity,O
",",O
color,O
vision,O
",",O
contrast,O
sensitivity,O
",",O
and,O
fundus,O
examination,O
.,O
In,O
all,O
subjects,O
with,O
history,O
of,O
EMB,I-Entity
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
",",O
there,O
was,O
a,O
mean,O
loss,O
of,O
72%,O
nerve,O
fiber,O
layer,O
thickness,O
in,O
the,O
temporal,O
quadrant,O
(,O
patient,O
A,O
",",O
with,O
eventual,O
recovery,O
of,O
visual,O
acuity,O
and,O
fields,O
",",O
58%,O
loss,O
;,O
patient,O
B,O
",",O
with,O
intermediate,O
visual,B-Entity
deficits,I-Entity
",",O
68%,O
loss,O
;,O
patient,O
C,O
",",O
with,O
chronic,O
visual,B-Entity
deficits,I-Entity
",",O
90%,O
loss,O
),O
",",O
with,O
an,O
average,O
mean,O
optic,O
nerve,O
thickness,O
of,O
26+/-16,O
microm,O
.,O
In,O
both,O
sets,O
(,O
four,O
),O
of,O
eyes,O
of,O
the,O
subjects,O
with,O
persistent,O
visual,B-Entity
deficits,I-Entity
(,O
patients,O
B,O
and,O
C,O
),O
",",O
there,O
was,O
an,O
average,O
loss,O
of,O
79%,O
of,O
nerve,O
fiber,O
thickness,O
in,O
the,O
temporal,O
quadrant,O
.,O
The,O
OCT,O
results,O
in,O
these,O
patients,O
with,O
EMB,I-Entity
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
show,O
considerable,O
loss,O
especially,O
of,O
the,O
temporal,O
fibers,O
.,O
This,O
is,O
consistent,O
with,O
prior,O
histopathological,O
studies,O
that,O
show,O
predominant,O
loss,O
of,O
parvo,O
-,O
cellular,O
axons,O
(,O
or,O
small,O
-,O
caliber,O
axons,O
),O
within,O
the,O
papillo,O
-,O
macular,O
bundle,O
in,O
toxic,O
or,O
hereditary,O
optic,B-Entity
neuropathies,I-Entity
.,O
OCT,O
can,O
be,O
a,O
valuable,O
tool,O
in,O
the,O
quantitative,O
analysis,O
of,O
optic,B-Entity
neuropathies,I-Entity
.,O
Additionally,O
",",O
in,O
terms,O
of,O
management,O
of,O
EMB,I-Entity
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
",",O
it,O
is,O
important,O
to,O
properly,O
manage,O
ethambutol,I-Entity
dosing,O
in,O
patients,O
with,O
renal,B-Entity
impairment,I-Entity
and,O
to,O
achieve,O
proper,O
transition,O
to,O
a,O
maintenance,O
dose,O
once,O
an,O
appropriate,O
loading,O
dose,O
has,O
been,O
reached,O
.,O
Effects,O
of,O
the,O
cyclooxygenase-2,O
specific,O
inhibitor,O
valdecoxib,I-Entity
versus,O
nonsteroidal,O
antiinflammatory,O
agents,O
and,O
placebo,O
on,O
cardiovascular,O
thrombotic,I-Entity
events,O
in,O
patients,O
with,O
arthritis,I-Entity
.,O
There,O
have,O
been,O
concerns,O
that,O
the,O
risk,O
of,O
cardiovascular,O
thrombotic,I-Entity
events,O
may,O
be,O
higher,O
with,O
cyclooxygenase,O
(,O
COX)-2-specific,O
inhibitors,O
than,O
nonselective,O
nonsteroidal,O
antiinflammatory,O
drugs,O
(,O
NSAIDs,O
),O
.,O
We,O
evaluated,O
cardiovascular,O
event,O
data,O
for,O
valdecoxib,I-Entity
",",O
a,O
new,O
COX-2-specific,O
inhibitor,O
in,O
approximately,O
8000,O
patients,O
with,O
osteoarthritis,I-Entity
and,O
rheumatoid,B-Entity
arthritis,I-Entity
treated,O
with,O
this,O
agent,O
in,O
randomized,O
clinical,O
trials,O
.,O
The,O
incidence,O
of,O
cardiovascular,O
thrombotic,I-Entity
events,O
(,O
cardiac,O
",",O
cerebrovascular,O
and,O
peripheral,O
vascular,O
",",O
or,O
arterial,O
thrombotic,I-Entity
),O
was,O
determined,O
by,O
analyzing,O
pooled,O
valdecoxib,I-Entity
(,O
10,O
-,O
80,O
mg,O
daily,O
),O
",",O
nonselective,O
NSAID,O
(,O
diclofenac,I-Entity
75,O
mg,O
bid,O
",",O
ibuprofen,I-Entity
800,O
mg,O
tid,O
",",O
or,O
naproxen,I-Entity
500,O
mg,O
bid,O
),O
and,O
placebo,O
data,O
from,O
10,O
randomized,O
osteoarthritis,I-Entity
and,O
rheumatoid,B-Entity
arthritis,I-Entity
trials,O
that,O
were,O
6,O
-,O
52,O
weeks,O
in,O
duration,O
.,O
in,O
users,O
of,O
low,O
-,O
dose,O
(,O
<,O
or,O
=,O
325,O
mg,O
daily,O
),O
aspirin,I-Entity
(,O
n,O
=,O
1051,O
),O
and,O
nonusers,O
of,O
aspirin,I-Entity
(,O
n,O
=,O
6883,O
),O
.,O
Crude,O
and,O
exposure,O
-,O
adjusted,O
incidences,O
of,O
thrombotic,I-Entity
events,O
were,O
similar,O
for,O
valdecoxib,I-Entity
",",O
NSAIDs,O
",",O
and,O
placebo,O
.,O
The,O
risk,O
of,O
serious,O
thrombotic,I-Entity
events,O
was,O
also,O
similar,O
for,O
each,O
valdecoxib,I-Entity
dose,O
.,O
Thrombotic,I-Entity
risk,O
was,O
consistently,O
higher,O
for,O
users,O
of,O
aspirin,I-Entity
users,O
than,O
nonusers,O
of,O
aspirin,I-Entity
(,O
placebo,O
",",O
1.4%,O
vs.,O
0%,O
;,O
valdecoxib,I-Entity
",",O
1.7%,O
vs.,O
0.2%,O
;,O
NSAIDs,O
",",O
1.9%,O
vs.,O
0.5%,O
),O
.,O
The,O
rates,O
of,O
events,O
in,O
users,O
of,O
aspirin,I-Entity
were,O
similar,O
for,O
all,O
3,O
treatment,O
groups,O
and,O
across,O
valdecoxib,I-Entity
doses,O
.,O
valdecoxib,I-Entity
doses,O
was,O
not,O
associated,O
with,O
an,O
increased,O
incidence,O
of,O
thrombotic,I-Entity
events,O
relative,O
to,O
nonselective,O
NSAIDs,O
or,O
placebo,O
in,O
osteoarthritis,I-Entity
and,O
rheumatoid,B-Entity
arthritis,I-Entity
patients,O
in,O
controlled,O
clinical,O
trials,O
.,O
A,O
randomized,O
",",O
placebo,O
-,O
controlled,O
",",O
crossover,O
study,O
of,O
ephedrine,I-Entity
for,O
SSRI,O
-,O
induced,O
female,O
sexual,B-Entity
dysfunction,I-Entity
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
ephedrine,I-Entity
",",O
an,O
alpha-,O
and,O
beta,O
-,O
adrenergic,O
agonist,O
previously,O
shown,O
to,O
enhance,O
genital,O
blood,O
flow,O
in,O
women,O
",",O
has,O
beneficial,O
effects,O
in,O
reversing,O
antidepressant,O
-,O
induced,O
sexual,B-Entity
dysfunction,I-Entity
.,O
Nineteen,O
sexually,B-Entity
dysfunctional,I-Entity
women,O
receiving,O
either,O
fluoxetine,I-Entity
",",O
sertraline,I-Entity
",",O
or,O
paroxetine,I-Entity
participated,O
in,O
an,O
eight,O
-,O
week,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
",",O
cross,O
-,O
over,O
study,O
of,O
the,O
effects,O
of,O
ephedrine,I-Entity
(,O
50,O
mg,O
),O
on,O
self,O
-,O
report,O
measures,O
of,O
sexual,O
desire,O
",",O
arousal,O
",",O
orgasm,O
",",O
and,O
sexual,O
satisfaction,O
.,O
Although,O
there,O
were,O
significant,O
improvements,O
relative,O
to,O
baseline,O
in,O
sexual,O
desire,O
and,O
orgasm,O
intensity,O
/,O
pleasure,O
on,O
50,O
mg,O
ephedrine,I-Entity
1-hr,O
prior,O
to,O
sexual,O
activity,O
",",O
significant,O
improvements,O
in,O
these,O
measures,O
",",O
as,O
well,O
as,O
in,O
sexual,O
arousal,O
and,O
orgasmic,O
ability,O
also,O
were,O
noted,O
with,O
placebo,O
.,O
Erectile,B-Entity
dysfunction,I-Entity
occurs,O
following,O
substantia,O
nigra,O
lesions,O
in,O
the,O
rat,O
.,O
Erectile,O
function,O
was,O
assessed,O
6,O
weeks,O
following,O
uni-,O
and,O
bilateral,O
injections,O
of,O
6-hydroxydopamine,I-Entity
in,O
the,O
substantia,O
nigra,O
nucleus,O
of,O
the,O
brain,O
.,O
Behavioral,O
apomorphine,I-Entity
-,O
induced,O
penile,O
erections,O
were,O
reduced,O
(,O
5/8,O
),O
and,O
increased,O
(,O
3/8,O
),O
in,O
uni-,O
and,O
bilateral,O
lesioned,O
animals,O
.,O
Concentration,O
of,O
dopamine,I-Entity
and,O
its,O
metabolites,O
were,O
decreased,O
in,O
the,O
striatum,O
of,O
substantia,O
nigra,O
lesioned,O
rats,O
.,O
Lesions,O
of,O
the,O
substantia,O
nigra,O
are,O
therefore,O
associated,O
with,O
erectile,B-Entity
dysfunction,I-Entity
in,O
rats,O
and,O
may,O
serve,O
as,O
a,O
model,O
to,O
study,O
erectile,B-Entity
dysfunction,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Potential,O
therapeutic,O
use,O
of,O
the,O
selective,O
dopamine,I-Entity
D1,O
receptor,O
agonist,O
",",O
A-86929,I-Entity
:,O
an,O
acute,O
study,O
in,O
parkinsonian,I-Entity
levodopa,I-Entity
-,O
primed,O
monkeys,O
.,O
The,O
clinical,O
utility,O
of,O
dopamine,I-Entity
(,O
DA,I-Entity
),O
D1,O
receptor,O
agonists,O
in,O
the,O
treatment,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
is,O
still,O
unclear,O
.,O
The,O
therapeutic,O
use,O
of,O
selective,O
DA,I-Entity
D1,O
receptor,O
agonists,O
such,O
as,O
SKF-82958,I-Entity
(,O
"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze",B-Entity
pine,I-Entity
hydrobromide,I-Entity
),O
and,O
A-77636,I-Entity
(,O
[,B-Entity
1R,I-Entity
",",I-Entity
3S,I-Entity
],I-Entity
"3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo",I-Entity
pyran,I-Entity
hydrochloride,I-Entity
),O
seems,O
limited,O
because,O
of,O
their,O
duration,O
of,O
action,O
",",O
which,O
is,O
too,O
short,O
for,O
SKF-82958,I-Entity
(,O
<,O
1,O
hr,O
),O
and,O
too,O
long,O
for,O
A-77636,I-Entity
(,O
>,O
20,O
We,O
therefore,O
conducted,O
the,O
present,O
acute,O
dose,O
-,O
response,O
study,O
in,O
four,O
"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",I-Entity
(,O
MPTP)-exposed,I-Entity
cynomolgus,O
monkeys,O
primed,O
to,O
exhibit,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
to,O
evaluate,O
the,O
locomotor,O
and,O
dyskinetic,I-Entity
effects,O
on,O
challenge,O
with,O
four,O
doses,O
(,O
from,O
0.03,O
to,O
1.0,O
mg,O
/,O
kg,O
),O
of,O
A-86929,I-Entity
(,O
[,B-Entity
"-]-[5aR,11bS]-4,5,5a,6,7,11b",I-Entity
-,I-Entity
hexahydro-2-propyl-3-thia-5-+,I-Entity
+,I-Entity
+,I-Entity
azacyclopent-1-,I-Entity
ena[c]phenathrene-9,I-Entity
-,I-Entity
10-diol,I-Entity
),O
",",O
a,O
selective,O
and,O
full,O
DA,I-Entity
D1-like,O
receptor,O
agonist,O
with,O
an,O
intermediate,O
duration,O
of,O
action,O
.,O
Levodopa,I-Entity
and,O
the,O
DA,I-Entity
D2-like,O
receptor,O
agonist,O
",",O
LY-171555,I-Entity
(,O
[,B-Entity
4aR,I-Entity
-,I-Entity
"trans]-4,4a,5,6,7,8,8a,9-o",I-Entity
-,I-Entity
dihydro-5n,I-Entity
-,I-Entity
propyl-2H,I-Entity
-,I-Entity
pyrazo,I-Entity
lo-3,I-Entity
-,I-Entity
4-quinoline,I-Entity
hydrochloride,I-Entity
),O
were,O
also,O
used,O
for,O
comparison,O
.,O
Acute,O
administration,O
of,O
A-86929,I-Entity
was,O
as,O
efficacious,O
in,O
alleviating,O
MPTP,I-Entity
-,O
induced,O
parkinsonism,I-Entity
as,O
levodopa,I-Entity
and,O
LY-171555,I-Entity
",",O
but,O
was,O
less,O
likely,O
to,O
reproduce,O
the,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
in,O
these,O
animals,O
than,O
with,O
either,O
LY-171555,I-Entity
or,O
subsequent,O
challenge,O
of,O
levodopa,I-Entity
.,O
Selective,O
stimulation,O
of,O
the,O
DA,I-Entity
D1,O
receptor,O
may,O
provide,O
better,O
integration,O
of,O
neural,O
inputs,O
transmitted,O
to,O
the,O
internal,O
segment,O
of,O
the,O
globus,O
pallidus,O
(,O
referred,O
to,O
as,O
the,O
basal,O
ganglia,O
output,O
),O
compared,O
with,O
levodopa,I-Entity
and,O
selective,O
DA,I-Entity
D2,O
receptor,O
agonist,O
.,O
Potent,O
DA,I-Entity
D1,O
receptor,O
agents,O
with,O
an,O
intermediate,O
duration,O
of,O
efficacy,O
such,O
as,O
A-86929,I-Entity
(,O
approximately,O
4,O
hr,O
at,O
higher,O
doses,O
tested,O
),O
are,O
potential,O
therapeutic,O
tools,O
in,O
PD,I-Entity
and,O
merit,O
further,O
attention,O
.,O
Deaths,O
from,O
local,O
anesthetic,O
-,O
induced,O
convulsions,I-Entity
in,O
mice,O
.,O
Median,O
convulsant,O
(,O
CD50,O
),O
and,O
median,O
lethal,O
(,O
LD50,O
),O
doses,O
of,O
three,O
representative,O
local,O
anesthetics,O
were,O
determined,O
in,O
adult,O
mice,O
to,O
evaluate,O
the,O
threat,O
to,O
life,O
of,O
local,O
anesthetic,O
-,O
induced,O
convulsions,I-Entity
.,O
The,O
CD50,O
and,O
LD50,O
",",O
respectively,O
",",O
were,O
57.7,O
and,O
58.7,O
mg,O
/,O
kg,O
for,O
bupivacaine,I-Entity
",",O
111.0,O
and,O
133.1,O
mg,O
/,O
kg,O
for,O
lidocaine,I-Entity
",",O
and,O
243.4,O
and,O
266.5,O
mg,O
/,O
kg,O
for,O
chloroprocaine,I-Entity
.,O
When,O
given,O
intraperitoneally,O
",",O
bupivacaine,I-Entity
thus,O
was,O
only,O
about,O
twice,O
as,O
toxic,O
as,O
lidocaine,I-Entity
and,O
four,O
times,O
as,O
toxic,O
as,O
chloroprocaine,I-Entity
.,O
Convulsions,I-Entity
always,O
preceded,O
death,O
",",O
except,O
after,O
precipitous,O
cardiopulmonary,B-Entity
arrest,I-Entity
from,O
extreme,O
doses,O
.,O
A,O
CD50,O
dose,O
of,O
local,O
anesthetic,O
(,O
causing,O
convulsions,I-Entity
in,O
50%,O
of,O
mice,O
),O
was,O
fatal,O
in,O
90%,O
of,O
bupivacaine,I-Entity
-,O
induced,O
seizures,I-Entity
",",O
in,O
57%,O
of,O
the,O
chloroprocaine,I-Entity
group,O
",",O
and,O
in,O
6%,O
of,O
the,O
lidocaine,I-Entity
group,O
.,O
The,O
narrow,O
gap,O
between,O
convulsant,O
and,O
lethal,O
doses,O
of,O
local,O
anesthetics,O
indicates,O
that,O
untreated,O
convulsions,I-Entity
present,O
much,O
more,O
of,O
a,O
threat,O
to,O
life,O
than,O
heretofore,O
appreciated,O
.,O
Myoclonic,B-Entity
",",I-Entity
atonic,I-Entity
",",I-Entity
and,I-Entity
absence,I-Entity
seizures,I-Entity
following,O
institution,O
of,O
carbamazepine,I-Entity
therapy,O
in,O
children,O
.,O
Five,O
children,O
",",O
aged,O
3,O
to,O
11,O
years,O
",",O
treated,O
with,O
carbamazepine,I-Entity
for,O
epilepsy,I-Entity
",",O
had,O
an,O
acute,O
aberrant,O
reaction,O
characterized,O
by,O
the,O
onset,O
of,O
myoclonic,B-Entity
",",I-Entity
atypical,I-Entity
absence,I-Entity
and/or,I-Entity
atonic,I-Entity
(,I-Entity
minor,I-Entity
motor,I-Entity
),I-Entity
seizures,I-Entity
within,O
a,O
few,O
days,O
.,O
When,O
the,O
carbamazepine,I-Entity
was,O
discontinued,O
",",O
two,O
of,O
the,O
children,O
returned,O
to,O
their,O
former,O
state,O
very,O
quickly,O
",",O
two,O
had,O
the,O
minor,O
motor,O
seizures,I-Entity
resolve,O
in,O
3,O
and,O
6,O
months,O
",",O
and,O
one,O
had,O
the,O
seizures,I-Entity
persist,O
.,O
The,O
child,O
in,O
whom,O
the,O
seizures,I-Entity
persisted,O
was,O
later,O
found,O
to,O
have,O
ceroid,B-Entity
lipofuscinosis,I-Entity
.,O
Naloxone,I-Entity
reversal,O
of,O
hypotension,I-Entity
due,O
to,O
captopril,I-Entity
overdose,I-Entity
.,O
The,O
hemodynamic,O
effects,O
of,O
captopril,I-Entity
and,O
other,O
angiotensin,B-Entity
-,I-Entity
converting,I-Entity
enzyme,I-Entity
inhibitors,I-Entity
may,O
be,O
mediated,O
by,O
the,O
endogenous,O
opioid,O
system,O
.,O
The,O
opioid,O
antagonist,O
naloxone,I-Entity
has,O
been,O
shown,O
to,O
block,O
or,O
reverse,O
the,O
hypotensive,I-Entity
actions,O
of,O
captopril,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
an,O
intentional,O
captopril,I-Entity
overdose,I-Entity
",",O
manifested,O
by,O
marked,O
hypotension,I-Entity
",",O
that,O
resolved,O
promptly,O
with,O
the,O
administration,O
of,O
naloxone,I-Entity
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
captopril,I-Entity
-,O
induced,O
hypotension,I-Entity
treated,O
with,O
naloxone,I-Entity
.,O
Our,O
experience,O
demonstrates,O
a,O
possible,O
role,O
of,O
naloxone,I-Entity
in,O
the,O
reversal,O
of,O
hypotension,I-Entity
resulting,O
from,O
captopril,I-Entity
.,O
Carbamazepine,I-Entity
-,O
induced,O
cardiac,B-Entity
dysfunction,I-Entity
.,O
A,O
patient,O
with,O
sinus,O
bradycardia,I-Entity
and,O
atrioventricular,B-Entity
block,I-Entity
",",O
induced,O
by,O
carbamazepine,I-Entity
",",O
prompted,O
an,O
extensive,O
literature,O
review,O
of,O
all,O
previously,O
reported,O
cases,O
.,O
From,O
the,O
analysis,O
of,O
these,O
cases,O
",",O
two,O
distinct,O
forms,O
of,O
carbamazepine,I-Entity
-,O
associated,O
cardiac,B-Entity
dysfunction,I-Entity
emerged,O
.,O
One,O
patient,O
group,O
developed,O
sinus,B-Entity
tachycardias,I-Entity
in,O
the,O
setting,O
of,O
a,O
massive,O
carbamazepine,I-Entity
overdose,I-Entity
.,O
The,O
second,O
group,O
consisted,O
almost,O
exclusively,O
of,O
elderly,O
women,O
who,O
developed,O
potentially,O
life,O
-,O
threatening,O
bradyarrhythmias,I-Entity
or,O
atrioventricular,B-Entity
conduction,I-Entity
delay,I-Entity
",",O
associated,O
with,O
either,O
therapeutic,O
or,O
modestly,O
elevated,O
carbamazepine,I-Entity
serum,O
levels,O
.,O
Because,O
carbamazepine,I-Entity
is,O
widely,O
used,O
in,O
the,O
treatment,O
of,O
many,O
neurologic,O
and,O
psychiatric,I-Entity
conditions,O
",",O
the,O
recognition,O
of,O
the,O
latter,O
syndrome,O
has,O
important,O
implications,O
for,O
the,O
use,O
of,O
this,O
drug,O
in,O
elderly,O
patients,O
.,O
Glutamatergic,O
neurotransmission,O
mediated,O
by,O
NMDA,I-Entity
receptors,O
in,O
the,O
inferior,O
colliculus,O
can,O
modulate,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
Functional,O
evidence,O
relating,O
the,O
IC,O
to,O
motor,O
behavior,O
derives,O
from,O
experiments,O
showing,O
that,O
activation,O
of,O
the,O
IC,O
by,O
electrical,O
stimulation,O
or,O
excitatory,O
amino,B-Entity
acid,I-Entity
microinjection,O
causes,O
freezing,O
",",O
escape,O
-,O
like,O
behavior,O
",",O
and,O
immobility,O
.,O
The,O
present,O
study,O
examined,O
the,O
influence,O
of,O
excitatory,O
amino,B-Entity
acid,I-Entity
-,O
mediated,O
mechanisms,O
in,O
the,O
IC,O
on,O
the,O
catalepsy,I-Entity
induced,O
by,O
the,O
dopamine,I-Entity
receptor,O
blocker,O
haloperidol,I-Entity
administered,O
Haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
was,O
challenged,O
with,O
prior,O
intracollicular,O
microinjections,O
of,O
glutamate,I-Entity
NMDA,I-Entity
receptor,O
antagonists,O
",",O
MK-801,I-Entity
(,O
15,O
or,O
30,O
mmol/0.5,O
microl,O
),O
and,O
AP7,I-Entity
(,O
10,O
or,O
20,O
nmol/0.5,O
microl,O
),O
",",O
or,O
of,O
the,O
NMDA,I-Entity
receptor,O
agonist,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
d,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
",",O
20,O
or,O
30,O
nmol/0.5,O
microl,O
),O
.,O
The,O
results,O
showed,O
that,O
intracollicular,O
microinjection,O
of,O
MK-801,I-Entity
and,O
AP7,I-Entity
previous,O
to,O
systemic,O
injections,O
of,O
haloperidol,I-Entity
significantly,O
attenuated,O
the,O
catalepsy,I-Entity
",",O
as,O
indicated,O
by,O
a,O
reduced,O
latency,O
to,O
step,O
down,O
from,O
a,O
horizontal,O
bar,O
.,O
Accordingly,O
",",O
intracollicular,O
microinjection,O
of,O
NMDA,I-Entity
increased,O
the,O
latency,O
to,O
step,O
down,O
the,O
bar,O
.,O
These,O
findings,O
suggest,O
that,O
glutamate,I-Entity
-,O
mediated,O
mechanisms,O
in,O
the,O
neural,O
circuits,O
at,O
the,O
IC,O
level,O
influence,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
and,O
participate,O
in,O
the,O
regulation,O
of,O
motor,O
activity,O
.,O
Metabotropic,O
glutamate,I-Entity
7,O
receptor,O
subtype,O
modulates,O
motor,O
symptoms,O
in,O
rodent,O
models,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Metabotropic,O
glutamate,I-Entity
(,O
mGlu,O
),O
receptors,O
modulate,O
synaptic,O
transmission,O
in,O
the,O
central,O
nervous,O
system,O
and,O
represent,O
promising,O
therapeutic,O
targets,O
for,O
symptomatic,O
treatment,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
.,O
Among,O
the,O
eight,O
mGlu,O
receptor,O
subtypes,O
",",O
mGlu7,O
receptor,O
is,O
prominently,O
expressed,O
in,O
the,O
basal,O
ganglia,O
",",O
but,O
its,O
role,O
in,O
restoring,O
motor,O
function,O
in,O
animal,O
models,O
of,O
PD,I-Entity
is,O
not,O
known,O
.,O
The,O
effects,O
of,O
N,B-Entity
",",I-Entity
"N'-dibenzhydrylethane-1,2-diamine",I-Entity
dihydrochloride,I-Entity
(,O
AMN082,I-Entity
),O
",",O
the,O
first,O
selective,O
allosteric,O
activator,O
of,O
mGlu7,O
receptors,O
",",O
were,O
thus,O
tested,O
in,O
different,O
rodent,O
models,O
of,O
PD,I-Entity
.,O
Here,O
",",O
we,O
show,O
that,O
oral,O
(,O
5,O
mg,O
/,O
kg,O
),O
or,O
intrastriatal,O
administration,O
(,O
0.1,O
and,O
0.5,O
nmol,O
),O
of,O
AMN082,I-Entity
reverses,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
in,O
rats,O
.,O
AMN082,I-Entity
(,O
2.5,O
and,O
5,O
mg,O
/,O
kg,O
),O
reduces,O
apomorphine,I-Entity
-,O
induced,O
rotations,O
in,O
unilateral,O
6-hydroxydopamine,I-Entity
(,O
6-OHDA)-lesioned,I-Entity
rats,O
.,O
In,O
a,O
more,O
complex,O
task,O
commonly,O
used,O
to,O
evaluate,O
major,O
akinetic,I-Entity
symptoms,O
of,O
PD,I-Entity
patients,O
",",O
5,O
mg,O
/,O
kg,O
AMN082,I-Entity
reverses,O
the,O
increased,O
reaction,O
time,O
to,O
respond,O
to,O
a,O
cue,O
of,O
bilateral,O
6-OHDA,I-Entity
-,O
lesioned,O
rats,O
.,O
In,O
addition,O
",",O
AMN082,I-Entity
reduces,O
the,O
duration,O
of,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
in,O
a,O
mGlu7,O
receptor,O
-,O
dependent,O
manner,O
in,O
wild,O
-,O
type,O
but,O
not,O
mGlu7,O
receptor,O
knockout,O
mice,O
.,O
Higher,O
doses,O
of,O
AMN082,I-Entity
(,O
10,O
and,O
20,O
mg,O
/,O
kg,O
p.o,O
.,O
),O
have,O
no,O
effect,O
on,O
the,O
same,O
models,O
of,O
PD,I-Entity
.,O
Overall,O
these,O
findings,O
suggest,O
that,O
mGlu7,O
receptor,O
activation,O
can,O
reverse,O
motor,O
dysfunction,O
associated,O
with,O
reduced,O
dopamine,I-Entity
activity,O
.,O
Nimodipine,I-Entity
prevents,O
memory,B-Entity
impairment,I-Entity
caused,O
by,O
nitroglycerin,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
adult,O
mice,O
.,O
Hypotension,I-Entity
and,O
a,O
resultant,O
decrease,O
in,O
cerebral,O
blood,O
flow,O
have,O
been,O
implicated,O
in,O
the,O
development,O
of,O
cognitive,B-Entity
dysfunction,I-Entity
.,O
We,O
tested,O
the,O
hypothesis,O
that,O
nimodipine,I-Entity
(,O
NIMO,I-Entity
),O
administered,O
at,O
the,O
onset,O
of,O
nitroglycerin,I-Entity
(,O
NTG)-induced,I-Entity
hypotension,I-Entity
would,O
preserve,O
long,O
-,O
term,O
associative,O
memory,O
.,O
Ninety,O
-,O
six,O
Swiss,O
-,O
Webster,O
mice,O
(,O
30,O
-,O
35,O
g,O
",",O
6,O
-,O
8,O
wk,O
),O
",",O
were,O
randomized,O
into,O
6,O
groups,O
1,O
),O
saline,O
(,O
control,O
),O
",",O
2,O
),O
NTG,I-Entity
immediately,O
after,O
learning,O
",",O
3,O
),O
NTG,I-Entity
3,O
h,O
after,O
learning,O
",",O
4,O
),O
NTG,I-Entity
and,O
NIMO,I-Entity
",",O
5,O
),O
vehicle,O
",",O
and,O
6,O
),O
NIMO,I-Entity
alone,O
.,O
The,O
extent,O
of,O
hypotension,I-Entity
and,O
changes,O
in,O
brain,O
tissue,O
oxygenation,O
(,O
PbtO(2,O
),O
),O
and,O
in,O
cerebral,O
blood,O
flow,O
were,O
studied,O
in,O
a,O
separate,O
group,O
of,O
animals,O
.,O
Mice,O
subjected,O
to,O
hypotensive,I-Entity
episodes,O
showed,O
a,O
significant,O
decrease,O
in,O
latency,O
time,O
(,O
178,O
+,O
/-,O
156,O
s,O
),O
compared,O
with,O
those,O
injected,O
with,O
saline,O
",",O
NTG,I-Entity
+,O
NIMO,I-Entity
",",O
or,O
delayed,O
NTG,I-Entity
(,O
580,O
+,O
/-,O
In,O
a,O
separate,O
group,O
of,O
mice,O
not,O
subjected,O
to,O
behavioral,O
studies,O
",",O
the,O
same,O
dose,O
of,O
NTG,I-Entity
(,O
n,O
=,O
3,O
),O
and,O
NTG,I-Entity
+,O
NIMO,I-Entity
(,O
n,O
=,O
3,O
),O
caused,O
mean,O
arterial,O
blood,O
pressure,O
to,O
decrease,O
from,O
85.9,O
+,O
/-,O
Mean,O
arterial,O
blood,O
pressure,O
in,O
mice,O
treated,O
with,O
NIMO,I-Entity
alone,O
decreased,O
from,O
88.1,O
+,O
/-,O
5.2,O
mm,O
Hg,O
sem,O
in,O
the,O
NTG,I-Entity
group,O
and,O
from,O
38.6,O
+,O
/-,O
2.0,O
mm,O
Hg,O
sem,O
in,O
the,O
NTG,I-Entity
+,O
NIMO,I-Entity
groups,O
",",O
respectively,O
.,O
In,O
a,O
PA,O
retention,O
paradigm,O
",",O
the,O
injection,O
of,O
NTG,I-Entity
immediately,O
after,O
learning,O
produced,O
a,O
significant,O
impairment,O
of,O
long,O
-,O
term,O
associative,O
memory,O
in,O
mice,O
",",O
whereas,O
delayed,O
induced,O
hypotension,I-Entity
had,O
no,O
effect,O
.,O
NIMO,I-Entity
attenuated,O
the,O
disruption,O
in,O
consolidation,O
of,O
long,O
-,O
term,O
memory,O
caused,O
by,O
NTG,I-Entity
but,O
did,O
not,O
improve,O
latency,O
in,O
the,O
absence,O
of,O
hypotension,I-Entity
.,O
The,O
observed,O
effect,O
of,O
NIMO,I-Entity
may,O
have,O
been,O
attributable,O
to,O
the,O
preservation,O
of,O
calcium,I-Entity
homeostasis,O
during,O
hypotension,I-Entity
",",O
because,O
there,O
were,O
no,O
differences,O
in,O
the,O
PbtO(2,O
),O
indices,O
among,O
groups,O
.,O
Fatal,O
haemopericardium,I-Entity
and,O
gastrointestinal,B-Entity
haemorrhage,I-Entity
due,O
to,O
possible,O
interaction,O
of,O
cranberry,O
juice,O
with,O
warfarin,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
fatal,O
internal,O
haemorrhage,I-Entity
in,O
an,O
elderly,O
man,O
who,O
consumed,O
only,O
cranberry,O
juice,O
for,O
two,O
weeks,O
while,O
maintaining,O
his,O
usual,O
dosage,O
of,O
warfarin,I-Entity
.,O
We,O
propose,O
that,O
naturally,O
occurring,O
compounds,O
such,O
as,O
flavonoids,I-Entity
",",O
which,O
are,O
present,O
in,O
fruit,O
juices,O
",",O
may,O
increase,O
the,O
potency,O
of,O
warfarin,I-Entity
by,O
competing,O
for,O
the,O
enzymes,O
that,O
normally,O
inactivate,O
warfarin,I-Entity
.,O
Isoproterenol,I-Entity
induces,O
primary,O
loss,O
of,O
dystrophin,O
in,O
rat,O
hearts,O
:,O
correlation,O
with,O
myocardial,B-Entity
injury,I-Entity
.,O
The,O
mechanism,O
of,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
damage,I-Entity
is,O
unknown,O
",",O
but,O
a,O
mismatch,O
of,O
oxygen,I-Entity
supply,O
vs.,O
demand,O
following,O
coronary,O
hypotension,I-Entity
and,O
myocardial,B-Entity
hyperactivity,I-Entity
is,O
the,O
best,O
explanation,O
for,O
the,O
complex,O
morphological,O
alterations,O
observed,O
.,O
Severe,O
alterations,O
in,O
the,O
structural,O
integrity,O
of,O
the,O
sarcolemma,O
of,O
cardiomyocytes,O
have,O
been,O
demonstrated,O
to,O
be,O
caused,O
by,O
isoproterenol,I-Entity
.,O
Taking,O
into,O
account,O
that,O
the,O
sarcolemmal,O
integrity,O
is,O
stabilized,O
by,O
the,O
dystrophin,O
-,O
glycoprotein,O
complex,O
(,O
DGC,O
),O
that,O
connects,O
actin,O
and,O
laminin,O
in,O
contractile,O
machinery,O
and,O
extracellular,O
matrix,O
and,O
by,O
integrins,O
",",O
this,O
study,O
tests,O
the,O
hypothesis,O
that,O
isoproterenol,I-Entity
affects,O
sarcolemmal,O
stability,O
through,O
changes,O
in,O
the,O
DGC,O
and,O
integrins,O
.,O
We,O
found,O
different,O
sensitivity,O
of,O
the,O
DGC,O
and,O
integrin,O
to,O
isoproterenol,I-Entity
subcutaneous,O
administration,O
.,O
In,O
conclusion,O
",",O
administration,O
of,O
isoproterenol,I-Entity
to,O
rats,O
results,O
in,O
primary,O
loss,O
of,O
dystrophin,O
",",O
the,O
most,O
sensitive,O
among,O
the,O
structural,O
proteins,O
that,O
form,O
the,O
DGC,O
that,O
connects,O
the,O
extracellular,O
matrix,O
and,O
the,O
cytoskeleton,O
in,O
cardiomyocyte,O
.,O
These,O
changes,O
",",O
related,O
to,O
ischaemic,B-Entity
injury,I-Entity
",",O
explain,O
the,O
severe,O
alterations,O
in,O
the,O
structural,O
integrity,O
of,O
the,O
sarcolemma,O
of,O
cardiomyocytes,O
and,O
hence,O
severe,O
and,O
irreversible,O
injury,O
induced,O
by,O
isoproterenol,I-Entity
.,O
High,O
fat,I-Entity
diet,O
-,O
fed,O
obese,I-Entity
rats,O
are,O
highly,O
sensitive,O
to,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Often,O
",",O
chemotherapy,O
by,O
doxorubicin,I-Entity
(,O
Adriamycin,I-Entity
),O
is,O
limited,O
due,O
to,O
life,O
threatening,O
cardiotoxicity,I-Entity
in,O
patients,O
during,O
and,O
posttherapy,O
.,O
Recently,O
",",O
we,O
have,O
shown,O
that,O
moderate,O
diet,O
restriction,O
remarkably,O
protects,O
against,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
This,O
cardioprotection,O
is,O
accompanied,O
by,O
decreased,O
cardiac,O
oxidative,O
stress,O
and,O
triglycerides,I-Entity
and,O
increased,O
cardiac,O
fatty,O
-,O
acid,O
oxidation,O
",",O
ATP,I-Entity
synthesis,O
",",O
and,O
upregulated,O
JAK,O
/,O
STAT3,O
pathway,O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
investigated,O
whether,O
a,O
physiological,O
intervention,O
by,O
feeding,O
40%,O
high,O
fat,I-Entity
diet,O
(,O
HFD,O
),O
",",O
which,O
induces,O
obesity,I-Entity
in,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
(,O
250,O
-,O
275,O
g,O
),O
",",O
sensitizes,O
to,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
A,O
LD(10,O
),O
dose,O
(,O
8,O
mg,O
doxorubicin,I-Entity
/,O
kg,O
",",O
ip,O
),O
administered,O
on,O
day,O
43,O
of,O
the,O
HFD,O
feeding,O
regimen,O
led,O
to,O
higher,O
cardiotoxicity,I-Entity
",",O
cardiac,B-Entity
dysfunction,I-Entity
",",O
lipid,O
peroxidation,O
",",O
and,O
80%,O
mortality,O
in,O
the,O
obese,I-Entity
(,O
OB,I-Entity
),O
rats,O
in,O
the,O
absence,O
of,O
any,O
significant,O
renal,B-Entity
or,I-Entity
hepatic,I-Entity
toxicity,I-Entity
.,O
Doxorubicin,I-Entity
toxicokinetics,O
studies,O
revealed,O
no,O
change,O
in,O
accumulation,O
of,O
doxorubicin,I-Entity
and,O
doxorubicinol,I-Entity
(,O
toxic,O
metabolite,O
),O
in,O
the,O
normal,O
diet,O
-,O
fed,O
(,O
ND,O
),O
and,O
OB,I-Entity
hearts,O
.,O
Mechanistic,O
studies,O
revealed,O
that,O
OB,I-Entity
rats,O
are,O
sensitized,O
due,O
to,O
:,O
(,O
1,O
),O
higher,O
oxyradical,O
stress,O
leading,O
to,O
upregulation,O
of,O
uncoupling,O
proteins,O
2,O
and,O
3,O
",",O
(,O
2,O
),O
downregulation,O
of,O
cardiac,O
peroxisome,O
proliferators,O
activated,O
receptor,O
-,O
alpha,O
",",O
(,O
3,O
),O
decreased,O
plasma,O
adiponectin,O
levels,O
",",O
(,O
4,O
),O
decreased,O
cardiac,O
fatty,O
-,O
acid,O
oxidation,O
(,O
666.9+/-14.0,O
nmol,O
/,O
min,O
/,O
g,O
heart,O
in,O
ND,O
versus,O
400.2+/-11.8,O
nmol,O
/,O
min,O
/,O
g,O
heart,O
in,O
OB,I-Entity
),O
",",O
(,O
5,O
),O
decreased,O
mitochondrial,O
AMP,I-Entity
-,O
alpha2,O
protein,O
kinase,O
",",O
and,O
(,O
6,O
),O
86%,O
drop,O
in,O
cardiac,O
ATP,I-Entity
levels,O
accompanied,O
by,O
decreased,O
ATP,I-Entity
/,O
ADP,I-Entity
ratio,O
after,O
doxorubicin,I-Entity
administration,O
.,O
In,O
conclusion,O
",",O
HFD,O
-,O
induced,O
obese,I-Entity
rats,O
are,O
highly,O
sensitized,O
to,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
by,O
substantially,O
downregulating,O
cardiac,O
mitochondrial,O
ATP,I-Entity
generation,O
",",O
increasing,O
oxidative,O
stress,O
and,O
downregulating,O
the,O
JAK,O
/,O
STAT3,O
pathway,O
.,O
Complete,O
atrioventricular,B-Entity
block,I-Entity
secondary,O
to,O
lithium,I-Entity
therapy,O
.,O
Sinus,B-Entity
node,I-Entity
dysfunction,I-Entity
has,O
been,O
reported,O
most,O
frequently,O
among,O
the,O
adverse,O
cardiovascular,O
effects,O
of,O
lithium,I-Entity
.,O
In,O
the,O
present,O
case,O
",",O
complete,O
atrioventricular,B-Entity
(,I-Entity
AV,I-Entity
),I-Entity
block,I-Entity
with,O
syncopal,B-Entity
attacks,I-Entity
developed,O
secondary,O
to,O
lithium,I-Entity
therapy,O
",",O
necessitating,O
permanent,O
pacemaker,O
implantation,O
.,O
Serum,O
lithium,I-Entity
levels,O
remained,O
under,O
or,O
within,O
the,O
therapeutic,O
range,O
during,O
the,O
syncopal,B-Entity
attacks,I-Entity
.,O
Lithium,I-Entity
should,O
be,O
used,O
with,O
extreme,O
caution,O
",",O
especially,O
in,O
patients,O
with,O
mild,O
disturbance,O
of,O
AV,O
conduction,O
.,O
Neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
induced,O
by,O
ziprasidone,I-Entity
on,O
the,O
second,O
day,O
of,O
treatment,O
.,O
Neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
(,O
NMS,I-Entity
),O
is,O
the,O
rarest,O
and,O
most,O
serious,O
of,O
the,O
neuroleptic,O
-,O
induced,O
movement,B-Entity
disorders,I-Entity
.,O
We,O
describe,O
a,O
case,O
of,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
(,O
NMS,I-Entity
),O
associated,O
with,O
the,O
use,O
of,O
ziprasidone,I-Entity
.,O
Although,O
conventional,O
neuroleptics,O
are,O
more,O
frequently,O
associated,O
with,O
NMS,I-Entity
",",O
atypical,O
antipsychotic,O
drugs,O
like,O
ziprasidone,I-Entity
may,O
also,O
be,O
a,O
cause,O
.,O
The,O
patient,O
is,O
a,O
24-year,O
-,O
old,O
male,O
with,O
a,O
history,O
of,O
schizophrenia,I-Entity
who,O
developed,O
signs,O
and,O
symptoms,O
of,O
NMS,I-Entity
after,O
2,O
days,O
of,O
treatment,O
with,O
an,O
80-mg,O
/,O
day,O
dose,O
of,O
orally,O
administrated,O
ziprasidone,I-Entity
.,O
NMS,I-Entity
due,O
to,O
ziprasidone,I-Entity
reported,O
in,O
the,O
literature,O
.,O
Role,O
of,O
mangiferin,I-Entity
on,O
biochemical,O
alterations,O
and,O
antioxidant,O
status,O
in,O
isoproterenol,I-Entity
-,O
induced,O
myocardial,B-Entity
infarction,I-Entity
in,O
rats,O
.,O
The,O
current,O
study,O
dealt,O
with,O
the,O
protective,O
role,O
of,O
mangiferin,I-Entity
",",O
a,O
polyphenol,I-Entity
from,O
Mangifera,O
indica,O
Linn,O
.,O
(,O
Anacardiaceae,O
),O
",",O
on,O
isoproterenol,I-Entity
(,O
ISPH)-induced,I-Entity
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
in,O
rats,O
through,O
its,O
antioxidative,O
mechanism,O
.,O
Subcutaneous,O
injection,O
of,O
ISPH,I-Entity
(,O
200,O
mg,O
/,O
kg,O
body,O
weight,O
in,O
1,O
ml,O
saline,O
),O
to,O
rats,O
for,O
2,O
consecutive,O
days,O
caused,O
myocardial,B-Entity
damage,I-Entity
in,O
rat,O
heart,O
",",O
which,O
was,O
determined,O
by,O
the,O
increased,O
activity,O
of,O
serum,O
lactate,I-Entity
dehydrogenase,O
(,O
LDH,O
),O
and,O
creatine,I-Entity
phosphokinase,O
isoenzymes,O
(,O
CK,O
-,O
MB,O
),O
",",O
increased,O
uric,B-Entity
acid,I-Entity
level,O
and,O
reduced,O
plasma,O
iron,I-Entity
binding,O
capacity,O
.,O
The,O
protective,O
role,O
of,O
mangiferin,I-Entity
was,O
analyzed,O
by,O
triphenyl,B-Entity
tetrazolium,I-Entity
chloride,I-Entity
(,O
TTC,I-Entity
),O
test,O
used,O
for,O
macroscopic,O
enzyme,O
mapping,O
assay,O
of,O
the,O
ischemic,B-Entity
myocardium,I-Entity
.,O
The,O
heart,O
tissue,O
antioxidant,O
enzymes,O
such,O
as,O
superoxide,I-Entity
dismutase,O
",",O
catalase,O
",",O
glutathione,I-Entity
peroxidase,O
",",O
glutathione,I-Entity
transferase,O
and,O
glutathione,I-Entity
reductase,O
activities,O
",",O
non,O
-,O
enzymic,O
antioxidants,O
such,O
as,O
cerruloplasmin,O
",",O
Vitamin,B-Entity
C,I-Entity
",",O
Vitamin,B-Entity
E,I-Entity
and,O
glutathione,I-Entity
levels,O
were,O
altered,O
in,O
MI,I-Entity
rats,O
.,O
Upon,O
pretreatment,O
with,O
mangiferin,I-Entity
(,O
100,O
mg,O
/,O
kg,O
body,O
weight,O
suspended,O
in,O
2,O
ml,O
of,O
dimethyl,B-Entity
sulphoxide,I-Entity
),O
given,O
intraperitoneally,O
for,O
28,O
days,O
to,O
MI,I-Entity
rats,O
protected,O
the,O
above,O
-,O
mentioned,O
parameters,O
to,O
fall,O
from,O
the,O
normal,O
levels,O
.,O
Activities,O
of,O
heart,O
tissue,O
enzymic,O
antioxidants,O
and,O
serum,O
non,O
-,O
enzymic,O
antioxidants,O
levels,O
rose,O
significantly,O
upon,O
mangiferin,I-Entity
administration,O
as,O
compared,O
to,O
ISPH,I-Entity
-,O
induced,O
MI,I-Entity
rats,O
.,O
From,O
the,O
present,O
study,O
it,O
is,O
concluded,O
that,O
mangiferin,I-Entity
exerts,O
a,O
beneficial,O
effect,O
against,O
ISPH,I-Entity
-,O
induced,O
MI,I-Entity
due,O
to,O
its,O
antioxidant,O
potential,O
",",O
which,O
regulated,O
the,O
tissues,O
defense,O
system,O
against,O
cardiac,B-Entity
damage,I-Entity
.,O
Remifentanil,I-Entity
pretreatment,O
reduces,O
myoclonus,I-Entity
after,O
etomidate,I-Entity
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
compare,O
the,O
effect,O
of,O
pretreatment,O
with,O
remifentanil,I-Entity
1,O
microg,O
/,O
kg,O
and,O
the,O
effect,O
of,O
gender,O
on,O
the,O
incidence,O
of,O
myoclonus,I-Entity
after,O
anesthesia,O
induction,O
with,O
etomidate,I-Entity
.,O
Sixty,O
patients,O
were,O
pretreated,O
in,O
a,O
randomized,O
double,O
-,O
blinded,O
fashion,O
with,O
remifentanil,I-Entity
1,O
microg,O
/,O
kg,O
or,O
placebo,O
.,O
Two,O
minutes,O
after,O
remifentanil,I-Entity
or,O
placebo,O
injection,O
",",O
etomidate,I-Entity
0.3,O
mg,O
/,O
kg,O
was,O
given,O
.,O
Myoclonus,I-Entity
was,O
recorded,O
with,O
a,O
scale,O
of,O
0,O
to,O
3,O
.,O
The,O
grade,O
of,O
sedation,O
(,O
none,O
",",O
mild,O
",",O
moderate,O
",",O
severe,O
),O
",",O
nausea,I-Entity
",",O
pruritus,I-Entity
",",O
and,O
apnea,I-Entity
were,O
recorded,O
after,O
injection,O
of,O
both,O
drugs,O
.,O
The,O
incidence,O
of,O
myoclonus,I-Entity
was,O
significantly,O
lower,O
in,O
the,O
remifentanil,I-Entity
group,O
(,O
6.7%,O
),O
than,O
in,O
the,O
placebo,O
group,O
(,O
70%,O
),O
None,O
of,O
the,O
patients,O
experienced,O
sedation,O
",",O
apnea,I-Entity
",",O
nausea,I-Entity
",",O
or,O
pruritus,I-Entity
after,O
injection,O
of,O
both,O
drugs,O
.,O
In,O
the,O
placebo,O
group,O
",",O
male,O
patients,O
were,O
associated,O
with,O
significantly,O
increased,O
incidence,O
of,O
myoclonus,I-Entity
after,O
etomidate,I-Entity
administration,O
.,O
CONCLUSION,O
:,O
Pretreatment,O
with,O
remifentanil,I-Entity
1,O
microg,O
/,O
kg,O
reduced,O
myoclonus,I-Entity
after,O
etomidate,I-Entity
induction,O
without,O
side,O
effects,O
such,O
as,O
sedation,O
",",O
apnea,I-Entity
",",O
nausea,I-Entity
",",O
or,O
pruritus,I-Entity
.,O
Men,O
experience,O
increased,O
incidence,O
of,O
myoclonus,I-Entity
than,O
women,O
after,O
etomidate,I-Entity
administration,O
.,O
Daidzein,I-Entity
activates,O
choline,I-Entity
acetyltransferase,O
from,O
MC,O
-,O
IXC,O
cells,O
and,O
improves,O
drug,O
-,O
induced,O
amnesia,I-Entity
.,O
The,O
choline,I-Entity
acetyltransferase,O
(,O
ChAT,O
),O
activator,O
",",O
which,O
enhances,O
cholinergic,O
transmission,O
via,O
an,O
augmentation,O
of,O
the,O
enzymatic,O
production,O
of,O
acetylcholine,I-Entity
(,O
ACh,I-Entity
),O
",",O
is,O
an,O
important,O
factor,O
in,O
the,O
treatment,O
of,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
(,O
AD,I-Entity
),O
.,O
Via,O
the,O
sequential,O
isolation,O
of,O
Pueraria,O
thunbergiana,O
",",O
the,O
active,O
component,O
was,O
ultimately,O
identified,O
as,O
daidzein,I-Entity
(,O
"4',7-dihydroxy",B-Entity
-,I-Entity
isoflavone,I-Entity
),O
.,O
In,O
order,O
to,O
investigate,O
the,O
effects,O
of,O
daidzein,I-Entity
from,O
Pueraria,O
thunbergiana,O
on,O
scopolamine,I-Entity
-,O
induced,O
impairments,B-Entity
of,I-Entity
learning,I-Entity
and,I-Entity
memory,I-Entity
",",O
we,O
conducted,O
a,O
series,O
of,O
in,O
vivo,O
tests,O
.,O
Administration,O
of,O
daidzein,I-Entity
(,O
4.5,O
mg,O
/,O
kg,O
body,O
weight,O
),O
to,O
mice,O
was,O
shown,O
significantly,O
to,O
reverse,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
",",O
according,O
to,O
the,O
results,O
of,O
a,O
Y,O
-,O
maze,O
test,O
.,O
Injections,O
of,O
scopolamine,I-Entity
into,O
mice,O
resulted,O
in,O
impaired,O
performance,O
on,O
Y,O
-,O
maze,O
tests,O
(,O
a,O
37%,O
decreases,O
in,O
alternation,O
behavior,O
),O
.,O
By,O
way,O
of,O
contrast,O
",",O
mice,O
treated,O
with,O
daidzein,I-Entity
prior,O
to,O
the,O
scopolamine,I-Entity
injections,O
were,O
noticeably,O
protected,O
from,O
this,O
performance,O
impairment,O
(,O
an,O
approximately,O
12%-21%,O
decrease,O
in,O
alternation,O
behavior,O
),O
.,O
These,O
results,O
indicate,O
that,O
daidzein,I-Entity
might,O
play,O
a,O
role,O
in,O
acetylcholine,I-Entity
biosynthesis,O
as,O
a,O
ChAT,O
activator,O
",",O
and,O
that,O
it,O
also,O
ameliorates,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
Possible,O
azithromycin,I-Entity
-,O
associated,O
hiccups,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
persistent,O
hiccups,I-Entity
associated,O
by,O
azithromycin,I-Entity
therapy,O
.,O
A,O
76-year,O
-,O
old,O
man,O
presented,O
with,O
persistent,O
hiccups,I-Entity
after,O
beginning,O
azithromycin,I-Entity
for,O
the,O
treatment,O
of,O
pharyngitis,I-Entity
.,O
Hiccups,I-Entity
were,O
persistent,O
and,O
exhausting,O
.,O
Discontinuation,O
of,O
azithromycin,I-Entity
and,O
therapy,O
with,O
baclofen,I-Entity
finally,O
resolved,O
hiccups,I-Entity
.,O
No,O
organic,O
cause,O
of,O
hiccups,I-Entity
was,O
identified,O
despite,O
extensive,O
investigation,O
.,O
DISCUSSION,O
:,O
Pharmacotherapeutic,O
agents,O
have,O
been,O
uncommonly,O
associated,O
with,O
hiccups,I-Entity
.,O
Corticosteroids,O
(,O
dexamethasone,I-Entity
and,O
methylprednisolone,I-Entity
),O
",",O
benzodiazepines,I-Entity
(,O
midazolam,I-Entity
),O
and,O
general,O
anaesthesia,O
have,O
been,O
the,O
specific,O
agents,O
mentioned,O
most,O
frequently,O
in,O
the,O
literature,O
as,O
being,O
associated,O
with,O
the,O
development,O
of,O
hiccups,I-Entity
.,O
Few,O
cases,O
of,O
drug,O
-,O
induced,O
hiccups,I-Entity
have,O
been,O
reported,O
related,O
to,O
macrolide,I-Entity
antimicrobials,O
.,O
Using,O
the,O
Naranjo,O
adverse,O
effect,O
reaction,O
probability,O
scale,O
this,O
event,O
could,O
be,O
classified,O
as,O
possible,O
(,O
score,O
5,O
points,O
),O
",",O
mostly,O
because,O
of,O
the,O
close,O
temporal,O
sequence,O
",",O
previous,O
reports,O
on,O
this,O
reaction,O
with,O
other,O
macrolides,I-Entity
and,O
the,O
absence,O
of,O
any,O
alternative,O
explanation,O
for,O
hiccups,I-Entity
.,O
Our,O
hypothesis,O
is,O
that,O
a,O
vagal,O
mechanism,O
mediated,O
by,O
azithromycin,I-Entity
could,O
be,O
the,O
pathogenesis,O
of,O
hiccups,I-Entity
in,O
our,O
patient,O
.,O
Diagnosis,O
of,O
drug,O
-,O
induced,O
hiccups,I-Entity
is,O
difficult,O
and,O
often,O
achieved,O
only,O
by,O
a,O
process,O
of,O
elimination,O
.,O
However,O
",",O
macrolide,I-Entity
antimicrobials,O
have,O
been,O
reported,O
to,O
be,O
associated,O
with,O
hiccups,I-Entity
and,O
vagal,O
mechanism,O
could,O
explain,O
the,O
development,O
of,O
this,O
side,O
-,O
effect,O
.,O
Time,O
trends,O
in,O
warfarin,I-Entity
-,O
associated,O
hemorrhage,I-Entity
.,O
The,O
annual,O
incidence,O
of,O
warfarin,I-Entity
-,O
related,O
bleeding,I-Entity
at,O
Brigham,O
and,O
Women,O
's,O
Hospital,O
increased,O
from,O
"0.97/1,000",O
patient,O
admissions,O
in,O
the,O
first,O
time,O
period,O
(,O
January,O
1995,O
to,O
October,O
1998,O
),O
to,O
"1.19/1,000",O
patient,O
admissions,O
in,O
the,O
second,O
time,O
period,O
(,O
November,O
1998,O
to,O
August,O
2002,O
),O
of,O
this,O
study,O
.,O
The,O
proportion,O
of,O
patients,O
with,O
major,O
and,O
intracranial,B-Entity
bleeding,I-Entity
increased,O
from,O
20.2%,O
and,O
1.9%,O
",",O
respectively,O
",",O
in,O
the,O
first,O
time,O
period,O
",",O
to,O
33.3%,O
and,O
7.8%,O
",",O
respectively,O
",",O
in,O
the,O
second,O
.,O
Fatal,O
haemorrhagic,B-Entity
myocarditis,I-Entity
secondary,O
to,O
cyclophosphamide,I-Entity
therapy,O
.,O
Haemorrhagic,B-Entity
myocarditis,I-Entity
is,O
a,O
rare,O
but,O
important,O
complication,O
of,O
cyclophosphamide,I-Entity
therapy,O
.,O
Glyceryl,B-Entity
trinitrate,I-Entity
induces,O
attacks,O
of,O
migraine,B-Entity
without,I-Entity
aura,I-Entity
in,O
sufferers,O
of,O
migraine,B-Entity
with,I-Entity
aura,I-Entity
.,O
Migraine,B-Entity
with,I-Entity
aura,I-Entity
and,O
migraine,B-Entity
without,I-Entity
aura,I-Entity
have,O
the,O
same,O
pain,I-Entity
phase,O
",",O
thus,O
indicating,O
that,O
migraine,B-Entity
with,I-Entity
aura,I-Entity
and,O
migraine,B-Entity
without,I-Entity
aura,I-Entity
share,O
a,O
common,O
pathway,O
of,O
nociception,O
.,O
In,O
recent,O
years,O
",",O
increasing,O
evidence,O
has,O
suggested,O
that,O
the,O
messenger,O
molecule,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
is,O
involved,O
in,O
pain,I-Entity
mechanisms,O
of,O
migraine,B-Entity
without,I-Entity
aura,I-Entity
.,O
In,O
order,O
to,O
clarify,O
whether,O
the,O
same,O
is,O
true,O
for,O
migraine,B-Entity
with,I-Entity
aura,I-Entity
",",O
in,O
the,O
present,O
study,O
we,O
examined,O
the,O
headache,I-Entity
response,O
to,O
intravenous,O
infusion,O
of,O
glyceryl,B-Entity
trinitrate,I-Entity
(,O
GTN,I-Entity
),O
(,O
0.5,O
microg,O
/,O
kg,O
/,O
min,O
for,O
20,O
min,O
),O
in,O
12,O
sufferers,O
of,O
migraine,B-Entity
with,I-Entity
aura,I-Entity
.,O
The,O
specific,O
aim,O
was,O
to,O
elucidate,O
whether,O
an,O
aura,O
and/or,O
an,O
attack,O
of,O
migraine,B-Entity
without,I-Entity
aura,I-Entity
could,O
be,O
induced,O
.,O
Headache,I-Entity
was,O
more,O
severe,O
in,O
migraineurs,I-Entity
than,O
in,O
the,O
controls,O
during,O
and,O
immediately,O
after,O
GTN,I-Entity
infusion,O
(,O
p=0.037,O
),O
as,O
well,O
as,O
during,O
the,O
following,O
11,O
h,O
(,O
p,O
=,O
0.008,O
),O
.,O
In,O
the,O
controls,O
",",O
the,O
GTN,I-Entity
-,O
induced,O
headache,I-Entity
gradually,O
disappeared,O
",",O
whereas,O
in,O
migraineurs,I-Entity
peak,O
headache,I-Entity
intensity,O
occurred,O
at,O
a,O
mean,O
time,O
of,O
240,O
min,O
post,O
-,O
infusion,O
.,O
At,O
this,O
time,O
the,O
induced,O
headache,I-Entity
in,O
6,O
of,O
12,O
migraineurs,I-Entity
fulfilled,O
the,O
diagnostic,O
criteria,O
for,O
migraine,B-Entity
without,I-Entity
aura,I-Entity
of,O
the,O
International,O
Headache,I-Entity
Society,O
.,O
The,O
results,O
therefore,O
suggest,O
that,O
NO,I-Entity
is,O
involved,O
in,O
the,O
pain,I-Entity
mechanisms,O
of,O
migraine,B-Entity
with,I-Entity
aura,I-Entity
.,O
Since,O
cortical,O
spreading,O
depression,I-Entity
has,O
been,O
shown,O
to,O
liberate,O
NO,I-Entity
in,O
animals,O
",",O
this,O
finding,O
may,O
help,O
our,O
understanding,O
of,O
the,O
coupling,O
between,O
cortical,O
spreading,O
depression,I-Entity
and,O
headache,I-Entity
in,O
migraine,B-Entity
with,I-Entity
aura,I-Entity
.,O
Stroke,I-Entity
and,O
cocaine,I-Entity
or,O
amphetamine,I-Entity
use,O
.,O
The,O
association,O
of,O
cocaine,I-Entity
and,O
amphetamine,I-Entity
use,O
with,O
hemorrhagic,O
and,O
ischemic,I-Entity
stroke,I-Entity
is,O
based,O
almost,O
solely,O
on,O
data,O
from,O
case,O
series,O
.,O
The,O
limited,O
number,O
of,O
epidemiologic,O
studies,O
of,O
stroke,I-Entity
and,O
use,O
of,O
cocaine,I-Entity
and/or,O
amphetamine,I-Entity
have,O
been,O
done,O
in,O
settings,O
that,O
serve,O
mostly,O
the,O
poor,O
and/or,O
minorities,O
.,O
We,O
attempted,O
to,O
identify,O
all,O
incident,O
strokes,I-Entity
in,O
women,O
ages,O
15,O
-,O
44,O
years,O
during,O
a,O
3-year,O
period,O
using,O
hospital,O
admission,O
and,O
discharge,O
records,O
",",O
emergency,O
department,O
logs,O
",",O
and,O
payment,O
requests,O
for,O
out,O
-,O
of,O
-,O
plan,O
hospitalizations,O
.,O
There,O
were,O
347,O
confirmed,O
stroke,I-Entity
cases,O
and,O
"1,021",O
controls,O
.,O
The,O
univariate,O
matched,O
odds,O
ratio,O
for,O
stroke,I-Entity
in,O
women,O
who,O
admitted,O
to,O
using,O
cocaine,I-Entity
and/or,O
amphetamine,I-Entity
was,O
8.5,O
(,O
95%,O
confidence,O
interval,O
=,O
3.6,O
-,O
20.0,O
),O
.,O
After,O
further,O
adjustment,O
for,O
potential,O
confounders,O
",",O
the,O
odds,O
ratio,O
in,O
women,O
who,O
reported,O
using,O
cocaine,I-Entity
and/or,O
amphetamine,I-Entity
was,O
7.0,O
(,O
95%,O
confidence,O
interval,O
=,O
2.8,O
-,O
17.9,O
),O
.,O
The,O
use,O
of,O
cocaine,I-Entity
and/or,O
amphetamine,I-Entity
is,O
a,O
strong,O
risk,O
factor,O
for,O
stroke,I-Entity
in,O
this,O
socioeconomically,O
heterogeneous,O
",",O
insured,O
urban,O
population,O
.,O
Prevention,O
of,O
breast,B-Entity
cancer,I-Entity
with,O
tamoxifen,I-Entity
:,O
preliminary,O
findings,O
from,O
the,O
Italian,O
randomised,O
trial,O
among,O
hysterectomised,O
women,O
.,O
Italian,O
Tamoxifen,I-Entity
Prevention,O
Study,O
.,O
Tamoxifen,I-Entity
is,O
a,O
candidate,O
chemopreventive,O
agent,O
in,O
breast,B-Entity
cancer,I-Entity
",",O
although,O
the,O
drug,O
may,O
be,O
associated,O
with,O
the,O
development,O
of,O
endometrial,B-Entity
cancer,I-Entity
.,O
Therefore,O
we,O
did,O
a,O
trial,O
in,O
hysterectomised,O
women,O
of,O
tamoxifen,I-Entity
as,O
a,O
chemopreventive,O
.,O
In,O
October,O
",",O
1992,O
",",O
we,O
started,O
a,O
double,O
-,O
blind,O
placebo,O
-,O
controlled,O
",",O
randomised,O
trial,O
of,O
tamoxifen,I-Entity
in,O
women,O
(,O
mainly,O
in,O
Italy,O
),O
who,O
did,O
not,O
have,O
breast,B-Entity
cancer,I-Entity
and,O
who,O
had,O
had,O
a,O
hysterectomy,O
.,O
Women,O
were,O
randomised,O
to,O
receive,O
tamoxifen,I-Entity
20,O
mg,O
per,O
day,O
or,O
placebo,O
",",O
both,O
orally,O
for,O
5,O
years,O
.,O
The,O
primary,O
endpoints,O
are,O
the,O
occurrence,O
of,O
and,O
deaths,O
from,O
breast,B-Entity
cancer,I-Entity
.,O
41,O
cases,O
of,O
breast,B-Entity
cancer,I-Entity
occurred,O
so,O
far,O
;,O
there,O
have,O
been,O
no,O
deaths,O
from,O
breast,B-Entity
cancer,I-Entity
.,O
There,O
is,O
no,O
difference,O
in,O
breast,B-Entity
-,I-Entity
cancer,I-Entity
frequency,O
between,O
the,O
placebo,O
(,O
22,O
cases,O
),O
and,O
tamoxifen,I-Entity
(,O
19,O
),O
arms,O
.,O
There,O
is,O
a,O
statistically,O
significant,O
reduction,O
of,O
breast,B-Entity
cancer,I-Entity
among,O
women,O
receiving,O
tamoxifen,I-Entity
who,O
also,O
used,O
hormone,O
-,O
replacement,O
therapy,O
during,O
the,O
trial,O
:,O
among,O
390,O
women,O
on,O
such,O
therapy,O
and,O
allocated,O
to,O
placebo,O
",",O
we,O
found,O
eight,O
cases,O
of,O
breast,B-Entity
cancer,I-Entity
compared,O
with,O
one,O
case,O
among,O
362,O
women,O
allocated,O
to,O
tamoxifen,I-Entity
.,O
Compared,O
with,O
the,O
placebo,O
group,O
",",O
there,O
was,O
a,O
significantly,O
increased,O
risk,O
of,O
vascular,B-Entity
events,I-Entity
and,O
hypertriglyceridaemia,I-Entity
among,O
women,O
on,O
tamoxifen,I-Entity
.,O
Although,O
this,O
preliminary,O
analysis,O
has,O
low,O
power,O
",",O
in,O
this,O
cohort,O
of,O
women,O
at,O
low,O
-,O
to,O
-,O
normal,O
risk,O
of,O
breast,B-Entity
cancer,I-Entity
",",O
the,O
postulated,O
protective,O
effects,O
of,O
tamoxifen,I-Entity
are,O
not,O
yet,O
apparent,O
.,O
Women,O
using,O
hormone,O
-,O
replacement,O
therapy,O
appear,O
to,O
have,O
benefited,O
from,O
use,O
of,O
tamoxifen,I-Entity
.,O
There,O
were,O
no,O
deaths,O
from,O
breast,B-Entity
cancer,I-Entity
recorded,O
in,O
women,O
in,O
the,O
study,O
.,O
It,O
is,O
essential,O
to,O
continue,O
follow,O
-,O
up,O
to,O
quantify,O
the,O
long,O
-,O
term,O
risks,O
and,O
benefits,O
of,O
tamoxifen,I-Entity
therapy,O
.,O
A,O
measure,O
of,O
pupillary,B-Entity
oscillation,I-Entity
as,O
a,O
marker,O
of,O
cocaine,I-Entity
-,O
induced,O
paranoia,I-Entity
.,O
Cocaine,I-Entity
-,O
induced,O
paranoia,I-Entity
(,O
CIP,I-Entity
),O
remains,O
an,O
important,O
drug,O
-,O
induced,O
model,O
of,O
idiopathic,O
paranoia,I-Entity
for,O
which,O
no,O
psychophysiologic,O
marker,O
has,O
yet,O
emerged,O
.,O
Measures,O
of,O
pupillary,B-Entity
oscillation,I-Entity
were,O
able,O
to,O
significantly,O
distinguish,O
a,O
group,O
of,O
abstinent,O
crack,B-Entity
cocaine,I-Entity
abusers,O
endorsing,O
past,O
CIP,I-Entity
(,O
n,O
=,O
32,O
),O
from,O
another,O
group,O
of,O
crack,I-Entity
addicts,O
who,O
denied,O
past,O
CIP,I-Entity
(,O
n,O
=,O
29,O
),O
.,O
Seizures,I-Entity
induced,O
by,O
combined,O
levomepromazine,I-Entity
-,O
fluvoxamine,I-Entity
treatment,O
.,O
We,O
report,O
a,O
case,O
of,O
combined,O
levomepromazine,I-Entity
-,O
fluvoxamine,I-Entity
treatment,O
-,O
induced,O
seizures,I-Entity
.,O
It,O
seems,O
that,O
combined,O
treatment,O
of,O
fluvoxamine,I-Entity
with,O
phenothiazines,I-Entity
may,O
possess,O
proconvulsive,O
activity,O
.,O
Why,O
may,O
epsilon,B-Entity
-,I-Entity
aminocaproic,I-Entity
acid,I-Entity
(,O
EACA,I-Entity
),O
induce,O
myopathy,I-Entity
in,O
man,O
?,O
A,O
case,O
of,O
necrotizing,B-Entity
myopathy,I-Entity
due,O
to,O
a,O
short,O
epsilon,B-Entity
-,I-Entity
aminocaproic,I-Entity
acid,I-Entity
(,O
EACA,I-Entity
),O
treatment,O
in,O
a,O
72,O
year,O
-,O
old,O
patient,O
with,O
subarachnoid,B-Entity
haemorrhage,I-Entity
(,O
SAH,I-Entity
),O
is,O
described,O
.,O
Comparison,O
of,O
the,O
effectiveness,O
of,O
ranitidine,I-Entity
and,O
cimetidine,I-Entity
in,O
inhibiting,O
acid,O
secretion,O
in,O
patients,O
with,O
gastric,O
hypersecretory,O
states,O
.,O
The,O
H2-histamine,I-Entity
receptor,O
antagonists,O
ranitidine,I-Entity
and,O
cimetidine,I-Entity
were,O
compared,O
for,O
their,O
abilities,O
to,O
control,O
gastric,O
acid,O
hypersecretion,O
on,O
a,O
short-,O
and,O
long,O
-,O
term,O
basis,O
in,O
22,O
patients,O
with,O
gastric,O
acid,O
hypersecretory,O
states,O
.,O
Nineteen,O
patients,O
had,O
Zollinger,B-Entity
-,I-Entity
Ellison,I-Entity
syndrome,I-Entity
",",O
one,O
patient,O
had,O
systemic,B-Entity
mastocytosis,I-Entity
",",O
and,O
two,O
patients,O
had,O
idiopathic,O
hypersecretion,O
.,O
The,O
rates,O
of,O
onset,O
of,O
the,O
action,O
of,O
cimetidine,I-Entity
and,O
ranitidine,I-Entity
were,O
the,O
same,O
.,O
However,O
",",O
ranitidine,I-Entity
was,O
threefold,O
more,O
potent,O
than,O
cimetidine,I-Entity
both,O
in,O
acute,O
inhibition,O
studies,O
and,O
in,O
the,O
median,O
maintenance,O
dose,O
needed,O
(,O
1.2,O
g,O
per,O
day,O
for,O
ranitidine,I-Entity
and,O
3.6,O
g,O
per,O
day,O
for,O
cimetidine,I-Entity
),O
.,O
Sixty,O
percent,O
of,O
the,O
males,O
developed,O
breast,O
changes,O
or,O
impotence,I-Entity
while,O
taking,O
cimetidine,I-Entity
and,O
in,O
all,O
cases,O
these,O
changes,O
disappeared,O
when,O
cimetidine,I-Entity
was,O
replaced,O
by,O
ranitidine,I-Entity
.,O
Treatment,O
with,O
high,O
doses,O
of,O
cimetidine,I-Entity
(,O
one,O
to,O
60,O
months,O
;,O
median,O
",",O
11,O
months,O
),O
or,O
ranitidine,I-Entity
(,O
two,O
to,O
31,O
months,O
;,O
median,O
",",O
14,O
months,O
),O
was,O
not,O
associated,O
with,O
hepatic,B-Entity
or,I-Entity
hematologic,I-Entity
toxicity,I-Entity
or,O
alterations,O
of,O
serum,O
gastrin,O
concentrations,O
",",O
but,O
ranitidine,I-Entity
therapy,O
was,O
associated,O
with,O
a,O
significantly,O
lower,O
serum,O
creatinine,I-Entity
level,O
than,O
seen,O
with,O
cimetidine,I-Entity
therapy,O
.,O
Both,O
are,O
safe,O
at,O
high,O
doses,O
",",O
but,O
ranitidine,I-Entity
is,O
threefold,O
more,O
potent,O
and,O
does,O
not,O
cause,O
the,O
antiandrogen,O
side,O
effects,O
frequently,O
seen,O
with,O
high,O
doses,O
of,O
cimetidine,I-Entity
.,O
A,O
catch,O
in,O
the,O
Reye,I-Entity
.,O
Twenty,O
-,O
six,O
cases,O
of,O
Reye,B-Entity
syndrome,I-Entity
from,O
The,O
Children,O
's,O
Hospital,O
",",O
Camperdown,O
",",O
Australia,O
",",O
occurring,O
between,O
1973,O
and,O
1982,O
were,O
reviewed,O
.,O
Of,O
these,O
",",O
20,O
cases,O
met,O
the,O
US,O
Public,O
Health,O
Service,O
Centers,O
for,O
Disease,O
Control,O
criteria,O
for,O
the,O
diagnosis,O
of,O
Reye,B-Entity
syndrome,I-Entity
.,O
Aspirin,I-Entity
or,O
salicylate,I-Entity
ingestion,O
had,O
occurred,O
in,O
only,O
one,O
of,O
the,O
20,O
cases,O
(,O
5%,O
),O
",",O
and,O
paracetamol,I-Entity
(,O
acetaminophen,I-Entity
),O
had,O
been,O
administered,O
in,O
only,O
six,O
of,O
the,O
cases,O
(,O
30%,O
),O
.,O
Pathologic,O
confirmation,O
of,O
the,O
diagnosis,O
of,O
Reye,B-Entity
syndrome,I-Entity
was,O
accomplished,O
in,O
90%,O
of,O
the,O
cases,O
.,O
The,O
incidence,O
of,O
Reye,B-Entity
syndrome,I-Entity
in,O
New,O
South,O
Wales,O
",",O
Australia,O
",",O
is,O
estimated,O
from,O
this,O
study,O
to,O
be,O
approximately,O
nine,O
cases,O
per,O
1,O
million,O
children,O
compared,O
with,O
recent,O
US,O
data,O
of,O
ten,O
to,O
20,O
cases,O
per,O
1,O
million,O
children,O
and,O
three,O
to,O
seven,O
cases,O
per,O
1,O
million,O
children,O
in,O
Great,O
Britain,O
.,O
The,O
mortality,O
for,O
these,O
Reye,B-Entity
syndrome,I-Entity
cases,O
in,O
Australia,O
was,O
45%,O
as,O
compared,O
with,O
a,O
32%,O
case,O
-,O
fatality,O
rate,O
in,O
the,O
United,O
States,O
.,O
In,O
Australia,O
",",O
the,O
pediatric,O
usage,O
of,O
aspirin,I-Entity
has,O
been,O
extremely,O
low,O
for,O
the,O
past,O
25,O
years,O
(,O
less,O
than,O
1%,O
of,O
total,O
dosage,O
units,O
sold,O
),O
",",O
with,O
paracetamol,I-Entity
(,O
acetaminophen,I-Entity
),O
dominating,O
the,O
pediatric,O
analgesic,O
and,O
antipyretic,O
market,O
.,O
Reye,B-Entity
syndrome,I-Entity
may,O
be,O
disappearing,O
from,O
Australia,O
despite,O
a,O
total,O
lack,O
of,O
association,O
with,O
salicylates,I-Entity
or,O
aspirin,I-Entity
ingestion,O
",",O
since,O
there,O
were,O
no,O
cases,O
found,O
at,O
The,O
Children,O
's,O
Hospital,O
in,O
1983,O
",",O
1984,O
",",O
or,O
1985,O
.,O
St.,B-Entity
Anthony,I-Entity
's,I-Entity
fire,I-Entity
",",O
then,O
and,O
now,O
:,O
a,O
case,O
report,O
and,O
historical,O
review,O
.,O
A,O
rare,O
case,O
of,O
morbid,O
vasospasm,I-Entity
",",O
together,O
with,O
striking,O
angiographic,O
findings,O
",",O
is,O
described,O
secondary,O
to,O
the,O
ingestion,O
of,O
methysergide,I-Entity
by,O
a,O
48-year,O
-,O
old,O
woman,O
.,O
A,O
discussion,O
of,O
the,O
history,O
of,O
ergot,I-Entity
includes,O
its,O
original,O
discovery,O
",",O
the,O
epidemics,O
of,O
gangrene,I-Entity
that,O
it,O
has,O
caused,O
through,O
the,O
ages,O
and,O
its,O
past,O
and,O
present,O
role,O
in,O
the,O
management,O
of,O
migraine,B-Entity
headache,I-Entity
.,O
Despite,O
the,O
advent,O
of,O
calcium,I-Entity
channel,O
blockers,O
and,O
beta,O
-,O
adrenergic,O
antagonists,O
",",O
ergot,I-Entity
preparations,O
continue,O
to,O
play,O
a,O
major,O
role,O
in,O
migraine,I-Entity
therapy,O
",",O
so,O
that,O
the,O
danger,O
of,O
St.,B-Entity
Anthony,I-Entity
's,I-Entity
fire,I-Entity
persists,O
.,O
Beta-2-adrenoceptor,O
-,O
mediated,O
hypokalemia,I-Entity
and,O
its,O
abolishment,O
by,O
oxprenolol,I-Entity
.,O
The,O
time,O
course,O
and,O
concentration,O
-,O
effect,O
relationship,O
of,O
terbutaline,I-Entity
-,O
induced,O
hypokalemia,I-Entity
was,O
studied,O
",",O
using,O
computer,O
-,O
aided,O
pharmacokinetic,O
-,O
dynamic,O
modeling,O
.,O
Subsequently,O
we,O
investigated,O
the,O
efficacy,O
of,O
oxprenolol,I-Entity
in,O
antagonizing,O
such,O
hypokalemia,I-Entity
",",O
together,O
with,O
the,O
pharmacokinetic,O
interaction,O
between,O
both,O
drugs,O
.,O
Six,O
healthy,O
subjects,O
were,O
given,O
a,O
0.5,O
mg,O
subcutaneous,O
dose,O
of,O
terbutaline,I-Entity
on,O
two,O
occasions,O
:,O
1,O
hour,O
after,O
oral,O
administration,O
of,O
a,O
placebo,O
and,O
1,O
hour,O
after,O
80,O
mg,O
oxprenolol,I-Entity
orally,O
.,O
In,O
the,O
7-hour,O
period,O
after,O
terbutaline,I-Entity
administration,O
",",O
plasma,O
samples,O
were,O
taken,O
for,O
determination,O
of,O
plasma,O
potassium,I-Entity
levels,O
and,O
drug,O
concentrations,O
.,O
The,O
sigmoid,O
Emax,O
model,O
offered,O
a,O
good,O
description,O
of,O
the,O
relation,O
between,O
terbutaline,I-Entity
concentrations,O
and,O
potassium,I-Entity
effects,O
.,O
Oxprenolol,I-Entity
caused,O
decreases,O
of,O
65%,O
and,O
56%,O
of,O
terbutaline,I-Entity
volume,O
of,O
distribution,O
and,O
clearance,O
",",O
respectively,O
",",O
and,O
an,O
increase,O
of,O
130%,O
of,O
its,O
AUC,O
.,O
In,O
spite,O
of,O
higher,O
terbutaline,I-Entity
concentrations,O
after,O
oxprenolol,I-Entity
pretreatment,O
",",O
the,O
hypokalemia,I-Entity
was,O
almost,O
completely,O
antagonized,O
by,O
the,O
beta,O
2-blocking,O
action,O
.,O
Midline,O
B3,O
serotonin,I-Entity
nerves,O
in,O
rat,O
medulla,O
are,O
involved,O
in,O
hypotensive,I-Entity
effect,O
of,O
methyldopa,I-Entity
.,O
Previous,O
experiments,O
in,O
this,O
laboratory,O
have,O
shown,O
that,O
microinjection,O
of,O
methyldopa,I-Entity
onto,O
the,O
ventrolateral,O
cells,O
of,O
the,O
B3,O
serotonin,I-Entity
neurons,O
in,O
the,O
medulla,O
elicits,O
a,O
hypotensive,I-Entity
response,O
mediated,O
by,O
a,O
projection,O
descending,O
into,O
the,O
spinal,O
cord,O
.,O
The,O
present,O
experiments,O
were,O
designed,O
to,O
investigate,O
the,O
role,O
of,O
the,O
midline,O
cells,O
of,O
the,O
B3,O
serotonin,I-Entity
neurons,O
in,O
the,O
medulla,O
",",O
coinciding,O
with,O
the,O
raphe,O
magnus,O
.,O
In,O
spontaneously,O
hypertensive,I-Entity
",",O
stroke,I-Entity
-,O
prone,O
rats,O
",",O
microinjection,O
of,O
methyldopa,I-Entity
into,O
the,O
area,O
of,O
the,O
midline,O
B3,O
serotonin,I-Entity
cell,O
group,O
in,O
the,O
ventral,O
medulla,O
caused,O
a,O
potent,O
hypotension,I-Entity
of,O
30,O
-,O
40,O
mm,O
Hg,O
",",O
which,O
was,O
maximal,O
2,O
-,O
3,O
h,O
after,O
administration,O
and,O
was,O
abolished,O
by,O
the,O
serotonin,I-Entity
neurotoxin,O
"5,7-dihydroxytryptamine",I-Entity
(,O
"5,7-DHT",I-Entity
),O
injected,O
intracerebroventricularly,O
.,O
However,O
",",O
intraspinal,O
injection,O
of,O
"5,7-DHT",I-Entity
to,O
produce,O
a,O
more,O
selective,O
lesion,O
of,O
only,O
descending,O
serotonin,I-Entity
projections,O
in,O
the,O
spinal,O
cord,O
did,O
not,O
affect,O
this,O
hypotension,I-Entity
.,O
Further,O
",",O
"5,7-DHT",I-Entity
lesion,O
of,O
serotonin,I-Entity
nerves,O
travelling,O
in,O
the,O
median,O
forebrain,O
bundle,O
",",O
one,O
of,O
the,O
main,O
ascending,O
pathways,O
from,O
the,O
B3,O
serotonin,I-Entity
cells,O
",",O
did,O
not,O
affect,O
the,O
fall,O
in,O
blood,O
pressure,O
associated,O
with,O
a,O
midline,O
B3,O
serotonin,I-Entity
methyldopa,I-Entity
injection,O
.,O
It,O
is,O
concluded,O
therefore,O
that,O
",",O
unlike,O
the,O
ventrolateral,O
B3,O
cells,O
which,O
mediate,O
a,O
methyldopa,I-Entity
-,O
induced,O
hypotension,I-Entity
via,O
descending,O
projections,O
",",O
the,O
midline,O
serotonin,I-Entity
B3,O
cells,O
in,O
the,O
medulla,O
contribute,O
to,O
the,O
hypotensive,I-Entity
action,O
of,O
methyldopa,I-Entity
",",O
either,O
by,O
way,O
of,O
an,O
ascending,O
projection,O
which,O
does,O
not,O
pass,O
through,O
the,O
median,O
forebrain,O
bundle,O
",",O
or,O
through,O
a,O
projection,O
restricted,O
to,O
the,O
caudal,O
brainstem,O
.,O
Yohimbine,I-Entity
treatment,O
of,O
sexual,B-Entity
side,I-Entity
effects,I-Entity
induced,O
by,O
serotonin,I-Entity
reuptake,O
blockers,O
.,O
:,O
Preclinical,O
and,O
clinical,O
studies,O
suggest,O
that,O
yohimbine,I-Entity
facilitates,O
sexual,O
behavior,O
and,O
may,O
be,O
helpful,O
in,O
the,O
treatment,O
of,O
male,B-Entity
impotence,I-Entity
.,O
A,O
single,O
case,O
report,O
suggests,O
that,O
yohimbine,I-Entity
may,O
be,O
used,O
to,O
treat,O
the,O
sexual,B-Entity
side,I-Entity
effects,I-Entity
of,O
clomipramine,I-Entity
.,O
This,O
study,O
evaluated,O
yohimbine,I-Entity
as,O
a,O
treatment,O
for,O
the,O
sexual,B-Entity
side,I-Entity
effects,I-Entity
caused,O
by,O
serotonin,I-Entity
reuptake,O
blockers,O
.,O
METHOD,O
:,O
Six,O
patients,O
with,O
either,O
obsessive,B-Entity
compulsive,I-Entity
disorder,I-Entity
",",O
trichotillomania,I-Entity
",",O
anxiety,I-Entity
",",O
or,O
affective,B-Entity
disorders,I-Entity
who,O
suffered,O
sexual,B-Entity
side,I-Entity
effects,I-Entity
after,O
treatment,O
with,O
serotonin,I-Entity
reuptake,O
blockers,O
were,O
given,O
yohimbine,I-Entity
on,O
a,O
p.r.n,O
.,O
Various,O
doses,O
of,O
yohimbine,I-Entity
were,O
used,O
to,O
determine,O
the,O
ideal,O
dose,O
for,O
each,O
patient,O
.,O
Five,O
of,O
the,O
six,O
patients,O
experienced,O
improved,O
sexual,O
functioning,O
after,O
taking,O
yohimbine,I-Entity
.,O
One,O
patient,O
who,O
failed,O
to,O
comply,O
with,O
yohimbine,I-Entity
treatment,O
had,O
no,O
therapeutic,O
effects,O
.,O
Side,O
effects,O
of,O
yohimbine,I-Entity
included,O
excessive,O
sweating,O
",",O
increased,O
anxiety,I-Entity
",",O
and,O
a,O
wound,O
-,O
up,O
feeling,O
in,O
some,O
patients,O
.,O
The,O
results,O
of,O
this,O
study,O
indicate,O
that,O
yohimbine,I-Entity
may,O
be,O
an,O
effective,O
treatment,O
for,O
the,O
sexual,B-Entity
side,I-Entity
effects,I-Entity
caused,O
by,O
serotonin,I-Entity
reuptake,O
blockers,O
.,O
Future,O
controlled,O
studies,O
are,O
needed,O
to,O
further,O
investigate,O
the,O
effectiveness,O
and,O
safety,O
of,O
yohimbine,I-Entity
for,O
this,O
indication,O
.,O
Hypersensitivity,I-Entity
immune,O
reaction,O
as,O
a,O
mechanism,O
for,O
dilevalol,I-Entity
-,O
associated,O
hepatitis,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
assess,O
lymphocyte,O
reactivity,O
to,O
dilevalol,I-Entity
and,O
to,O
serum,O
containing,O
putative,O
ex,O
vivo,O
dilevalol,I-Entity
antigens,O
or,O
metabolites,O
in,O
a,O
case,O
of,O
dilevalol,I-Entity
-,O
induced,O
liver,B-Entity
injury,I-Entity
.,O
A,O
58-year,O
-,O
old,O
woman,O
with,O
a,O
clinical,O
diagnosis,O
of,O
dilevalol,I-Entity
-,O
induced,O
liver,B-Entity
injury,I-Entity
.,O
Peripheral,O
blood,O
mononuclear,O
cells,O
collected,O
from,O
the,O
patient,O
were,O
cultured,O
in,O
the,O
presence,O
of,O
a,O
solution,O
of,O
dilevalol,I-Entity
and,O
also,O
with,O
sera,O
collected,O
from,O
a,O
volunteer,O
before,O
and,O
after,O
dilevalol,I-Entity
intake,O
.,O
No,O
lymphocyte,O
proliferation,O
was,O
observed,O
either,O
in,O
the,O
patient,O
or,O
in,O
the,O
healthy,O
volunteer,O
in,O
the,O
presence,O
of,O
dilevalol,I-Entity
solutions,O
.,O
A,O
significant,O
proliferative,O
response,O
to,O
serum,O
collected,O
after,O
dilevalol,I-Entity
intake,O
was,O
observed,O
in,O
the,O
case,O
of,O
the,O
patient,O
compared,O
with,O
the,O
proliferative,O
response,O
to,O
the,O
serum,O
collected,O
before,O
the,O
drug,O
intake,O
.,O
The,O
methodology,O
used,O
allowed,O
the,O
detection,O
of,O
lymphocyte,O
sensitization,O
to,O
sera,O
containing,O
ex,O
vivo,O
-,O
prepared,O
dilevalol,I-Entity
antigens,O
",",O
suggesting,O
the,O
involvement,O
of,O
an,O
immunologic,O
mechanism,O
in,O
dilevalol,I-Entity
-,O
induced,O
liver,B-Entity
injury,I-Entity
.,O
Reversible,O
myocardial,B-Entity
hypertrophy,I-Entity
induced,O
by,O
tacrolimus,I-Entity
in,O
a,O
pediatric,O
heart,O
transplant,O
recipient,O
:,O
case,O
report,O
.,O
Tacrolimus,I-Entity
is,O
a,O
potent,O
immunosuppressant,O
that,O
is,O
frequently,O
used,O
in,O
organ,O
transplantation,O
.,O
However,O
",",O
adverse,O
effects,O
include,O
cardiac,B-Entity
toxicity,I-Entity
.,O
Herein,O
we,O
describe,O
transient,O
myocardial,B-Entity
hypertrophy,I-Entity
induced,O
by,O
tacrolimus,I-Entity
after,O
heart,O
transplantation,O
.,O
The,O
hypertrophy,I-Entity
caused,O
no,O
clinical,O
symptoms,O
but,O
was,O
noted,O
because,O
of,O
elevation,O
of,O
plasma,O
brain,O
natriuretic,O
peptide,O
concentration,O
and,O
confirmed,O
at,O
echocardiography,O
.,O
Initially,O
",",O
allograft,O
rejection,O
was,O
feared,O
;,O
however,O
",",O
myocardial,O
biopsy,O
samples,O
revealed,O
only,O
interstitial,O
edema,I-Entity
and,O
mild,O
myocardial,B-Entity
hypertrophy,I-Entity
;,O
neither,O
cellular,O
nor,O
humoral,O
rejection,O
was,O
detected,O
.,O
The,O
blood,O
tacrolimus,I-Entity
concentration,O
was,O
higher,O
than,O
usual,O
at,O
that,O
time,O
;,O
thus,O
",",O
tacrolimus,I-Entity
dosage,O
was,O
reduced,O
.,O
Myocardial,B-Entity
hypertrophy,I-Entity
completely,O
resolved,O
upon,O
reducing,O
the,O
target,O
concentration,O
of,O
tacrolimus,I-Entity
and,O
did,O
not,O
recur,O
",",O
as,O
confirmed,O
at,O
echocardiography,O
and,O
myocardial,O
biopsy,O
.,O
Thus,O
",",O
we,O
conclude,O
that,O
tacrolimus,I-Entity
induces,O
reversible,O
myocardial,B-Entity
hypertrophy,I-Entity
.,O
In,O
patients,O
receiving,O
tacrolimus,I-Entity
therapy,O
",",O
blood,O
concentration,O
should,O
be,O
carefully,O
controlled,O
and,O
extreme,O
attention,O
paid,O
to,O
cardiac,O
involvement,O
.,O
Comparison,O
of,O
unilateral,O
pallidotomy,O
and,O
subthalamotomy,O
findings,O
in,O
advanced,O
idiopathic,B-Entity
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
A,O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
pilot,O
study,O
to,O
compare,O
the,O
results,O
of,O
stereotactic,O
unilateral,O
pallidotomy,O
and,O
subthalamotomy,O
in,O
advanced,O
idiopathic,B-Entity
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
refractory,O
to,O
medical,O
treatment,O
was,O
designed,O
.,O
3.5,O
years,O
),O
",",O
disabling,O
motor,O
fluctuations,O
(,O
Hoehn,O
_,O
Yahr,O
stage,O
3,O
-,O
5,O
in,O
off,O
-,O
drug,O
phases,O
),O
and,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
were,O
selected,O
.,O
All,O
patients,O
had,O
bilateral,O
symptoms,O
and,O
their,O
levodopa,I-Entity
equivalent,O
dosing,O
were,O
analysed,O
.,O
Clinical,O
evaluation,O
included,O
the,O
use,O
of,O
the,O
Unified,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Rating,O
Scale,O
(,O
UPDRS,O
),O
",",O
Hoehn_Yahr,O
score,O
and,O
Schwab,O
England,O
activities,O
of,O
daily,O
living,O
(,O
ADL,O
),O
score,O
in,O
',O
on'-,O
and,O
',O
off'-drug,O
conditions,O
before,O
surgery,O
and,O
6,O
months,O
after,O
surgery,O
.,O
There,O
was,O
statistically,O
significant,O
improvement,O
in,O
all,O
contralateral,O
major,O
parkinsonian,I-Entity
motor,O
signs,O
in,O
all,O
patients,O
followed,O
for,O
6,O
months,O
.,O
Levodopa,I-Entity
equivalent,O
daily,O
intake,O
was,O
significantly,O
reduced,O
in,O
the,O
STN,O
group,O
.,O
Complications,O
were,O
observed,O
in,O
two,O
patients,O
:,O
one,O
had,O
a,O
left,O
homonymous,B-Entity
hemianopsia,I-Entity
after,O
pallidotomy,O
and,O
another,O
one,O
developed,O
left,O
hemiballistic,O
movements,O
3,O
days,O
after,O
subthalamotomy,O
which,O
partly,O
improved,O
within,O
1,O
month,O
with,O
Valproate,I-Entity
1000,O
mg,O
/,O
day,O
.,O
The,O
findings,O
of,O
this,O
study,O
suggest,O
that,O
lesions,O
of,O
the,O
unilateral,O
STN,O
and,O
GPi,O
are,O
equally,O
effective,O
treatment,O
for,O
patients,O
with,O
advanced,O
PD,I-Entity
refractory,O
to,O
medical,O
treatment,O
.,O
Protective,O
effects,O
of,O
antithrombin,O
on,O
puromycin,B-Entity
aminonucleoside,I-Entity
nephrosis,I-Entity
in,O
rats,O
.,O
We,O
investigated,O
the,O
effects,O
of,O
antithrombin,O
",",O
a,O
plasma,O
inhibitor,O
of,O
coagulation,O
factors,O
",",O
in,O
rats,O
with,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephrosis,I-Entity
",",O
which,O
is,O
an,O
experimental,O
model,O
of,O
human,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
Antithrombin,O
(,O
50,O
or,O
500,O
IU,O
/,O
kg,O
/,O
i.v,O
.,O
),O
was,O
administered,O
to,O
rats,O
once,O
a,O
day,O
for,O
10,O
days,O
immediately,O
after,O
the,O
injection,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
50,O
mg,O
/,O
kg,O
/,O
i.v,O
.,O
),O
.,O
Treatment,O
with,O
antithrombin,O
attenuated,O
the,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
hematological,B-Entity
abnormalities,I-Entity
.,O
Puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
renal,B-Entity
dysfunction,I-Entity
and,O
hyperlipidemia,I-Entity
were,O
also,O
suppressed,O
.,O
Histopathological,O
examination,O
revealed,O
severe,O
renal,B-Entity
damage,I-Entity
such,O
as,O
proteinaceous,O
casts,O
in,O
tubuli,O
and,O
tubular,O
expansion,O
in,O
the,O
kidney,O
of,O
control,O
rats,O
",",O
while,O
an,O
improvement,O
of,O
the,O
damage,O
was,O
seen,O
in,O
antithrombin,O
-,O
treated,O
rats,O
.,O
In,O
addition,O
",",O
antithrombin,O
treatment,O
markedly,O
suppressed,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
apoptosis,O
of,O
renal,O
tubular,O
epithelial,O
cells,O
.,O
Furthermore,O
",",O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
increases,O
in,O
renal,O
cytokine,O
content,O
were,O
also,O
decreased,O
.,O
These,O
findings,O
suggest,O
that,O
thrombin,O
plays,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
Treatment,O
with,O
antithrombin,O
may,O
be,O
clinically,O
effective,O
in,O
patients,O
with,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
Reverse,O
or,O
inverted,O
left,B-Entity
ventricular,I-Entity
apical,I-Entity
ballooning,I-Entity
syndrome,I-Entity
(,O
reverse,O
Takotsubo,B-Entity
cardiomyopathy,I-Entity
),O
in,O
a,O
young,O
woman,O
in,O
the,O
setting,O
of,O
amphetamine,I-Entity
use,O
.,O
Transient,O
left,B-Entity
ventricular,I-Entity
apical,I-Entity
ballooning,I-Entity
syndrome,I-Entity
was,O
first,O
described,O
in,O
Japan,O
as,O
"""",O
Takotsubo,B-Entity
cardiomyopathy,I-Entity
.,O
One,O
of,O
the,O
rarest,O
is,O
the,O
reverse,O
type,O
of,O
this,O
syndrome,O
",",O
with,O
hyperdynamic,O
apex,O
and,O
complete,O
akinesia,I-Entity
of,O
the,O
base,O
(,O
as,O
opposed,O
to,O
the,O
classic,O
apical,B-Entity
ballooning,I-Entity
),O
.,O
In,O
this,O
article,O
",",O
we,O
report,O
an,O
interesting,O
case,O
of,O
a,O
young,O
woman,O
who,O
presented,O
with,O
this,O
rare,O
type,O
of,O
reverse,O
apical,B-Entity
ballooning,I-Entity
syndrome,I-Entity
occurring,O
after,O
amphetamine,I-Entity
use,O
.,O
Attenuated,O
disruption,O
of,O
prepulse,O
inhibition,O
by,O
dopaminergic,O
stimulation,O
after,O
maternal,O
deprivation,O
and,O
adolescent,O
corticosterone,I-Entity
treatment,O
in,O
rats,O
.,O
The,O
development,O
of,O
schizophrenia,I-Entity
may,O
include,O
an,O
early,O
neurodevelopmental,O
stress,O
component,O
which,O
increases,O
vulnerability,O
to,O
later,O
stressful,O
life,O
events,O
",",O
in,O
combination,O
leading,O
to,O
overt,O
disease,O
.,O
We,O
investigated,O
the,O
effect,O
of,O
an,O
early,O
stress,O
",",O
in,O
the,O
form,O
of,O
maternal,O
deprivation,O
",",O
combined,O
with,O
a,O
later,O
stress,O
",",O
simulated,O
by,O
chronic,O
periadolescent,O
corticosterone,I-Entity
treatment,O
",",O
on,O
behaviour,O
in,O
rats,O
.,O
Acute,O
treatment,O
with,O
apomorphine,I-Entity
caused,O
disruption,O
of,O
prepulse,O
inhibition,O
(,O
PPI,O
),O
in,O
controls,O
and,O
in,O
rats,O
that,O
had,O
undergone,O
either,O
maternal,O
deprivation,O
or,O
corticosterone,I-Entity
treatment,O
",",O
but,O
was,O
surprisingly,O
absent,O
in,O
rats,O
that,O
had,O
undergone,O
the,O
combined,O
early,O
and,O
late,O
stress,O
.,O
Amphetamine,I-Entity
treatment,O
significantly,O
disrupted,O
PPI,O
in,O
both,O
non,O
-,O
deprived,O
groups,O
",",O
but,O
was,O
absent,O
in,O
both,O
maternally,O
deprived,O
groups,O
.,O
The,O
serotonin-1A,I-Entity
receptor,O
agonist,O
",",O
8-OH,B-Entity
-,I-Entity
DPAT,I-Entity
",",O
induced,O
a,O
significant,O
disruption,O
of,O
PPI,O
in,O
all,O
groups,O
.,O
Amphetamine,I-Entity
-,O
induced,O
locomotor,B-Entity
hyperactivity,I-Entity
was,O
similar,O
in,O
all,O
groups,O
.,O
These,O
results,O
show,O
an,O
inhibitory,O
interaction,O
of,O
early,O
stress,O
",",O
caused,O
by,O
maternal,O
deprivation,O
",",O
combined,O
with,O
',O
adolescent,O
',O
stress,O
",",O
simulated,O
by,O
corticosterone,I-Entity
treatment,O
",",O
on,O
dopaminergic,O
regulation,O
of,O
PPI,O
.,O
The,O
altered,O
effects,O
of,O
apomorphine,I-Entity
and,O
amphetamine,I-Entity
could,O
indicate,O
differential,O
changes,O
in,O
dopamine,I-Entity
receptor,O
signalling,O
leading,O
to,O
functional,O
desensitisation,O
",",O
or,O
altered,O
modulation,O
of,O
sensory,O
gating,O
in,O
the,O
nucleus,O
accumbens,O
by,O
limbic,O
structures,O
such,O
as,O
the,O
hippocampus,O
.,O
Peripheral,O
iron,B-Entity
dextran,I-Entity
induced,O
degeneration,B-Entity
of,I-Entity
dopaminergic,I-Entity
neurons,I-Entity
in,O
rat,O
substantia,O
nigra,O
.,O
Iron,I-Entity
accumulation,O
is,O
considered,O
to,O
be,O
involved,O
in,O
the,O
pathogenesis,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
To,O
demonstrate,O
the,O
relationship,O
between,O
peripheral,O
iron,I-Entity
overload,O
and,O
dopaminergic,O
neuron,O
loss,O
in,O
rat,O
substantia,O
nigra,O
(,O
SN,O
),O
",",O
in,O
the,O
present,O
study,O
we,O
used,O
fast,O
cyclic,O
voltammetry,O
",",O
tyrosine,I-Entity
hydroxylase,O
(,O
TH,O
),O
immunohistochemistry,O
",",O
Perls,O
',O
iron,I-Entity
staining,O
",",O
and,O
high,O
performance,O
liquid,O
chromatography,O
-,O
electrochemical,O
detection,O
to,O
study,O
the,O
degeneration,B-Entity
of,I-Entity
dopaminergic,I-Entity
neurons,I-Entity
and,O
increased,O
iron,I-Entity
content,O
in,O
the,O
SN,O
of,O
iron,B-Entity
dextran,I-Entity
overloaded,O
animals,O
.,O
The,O
findings,O
showed,O
that,O
peripheral,O
iron,B-Entity
dextran,I-Entity
overload,O
increased,O
the,O
iron,I-Entity
staining,O
positive,O
cells,O
and,O
reduced,O
the,O
number,O
of,O
TH,O
-,O
immunoreactive,O
neurons,O
in,O
the,O
SN,O
.,O
As,O
a,O
result,O
",",O
dopamine,I-Entity
release,O
and,O
content,O
",",O
as,O
well,O
as,O
its,O
metabolites,O
contents,O
were,O
decreased,O
in,O
caudate,O
putamen,O
.,O
These,O
results,O
suggest,O
that,O
peripheral,O
iron,B-Entity
dextran,I-Entity
can,O
increase,O
the,O
iron,I-Entity
level,O
in,O
the,O
SN,O
",",O
where,O
excessive,O
iron,I-Entity
causes,O
the,O
degeneration,B-Entity
of,I-Entity
dopaminergic,I-Entity
neurons,I-Entity
.,O
The,O
chronic,O
iron,I-Entity
overload,O
may,O
be,O
more,O
destructive,O
to,O
dopaminergic,O
neurons,O
than,O
the,O
acute,O
iron,I-Entity
overload,O
.,O
Warfarin,I-Entity
-,O
induced,O
leukocytoclastic,B-Entity
vasculitis,I-Entity
.,O
Skin,O
reactions,O
associated,O
with,O
oral,O
coumarin,I-Entity
-,O
derived,O
anticoagulants,O
are,O
an,O
uncommon,O
occurrence,O
.,O
Leukocytoclastic,B-Entity
vasculitis,I-Entity
(,O
LV,I-Entity
),O
is,O
primarily,O
a,O
cutaneous,B-Entity
small,I-Entity
vessel,I-Entity
vasculitis,I-Entity
",",O
though,O
systemic,O
involvement,O
may,O
be,O
encountered,O
.,O
We,O
report,O
4,O
patients,O
with,O
late,O
-,O
onset,O
LV,I-Entity
probably,O
due,O
to,O
warfarin,I-Entity
.,O
All,O
4,O
patients,O
presented,O
with,O
skin,B-Entity
eruptions,I-Entity
that,O
developed,O
after,O
receiving,O
warfarin,I-Entity
for,O
several,O
years,O
.,O
The,O
results,O
of,O
skin,B-Entity
lesion,I-Entity
biopsies,O
were,O
available,O
in,O
3,O
patients,O
",",O
confirming,O
LV,B-Entity
Cutaneous,I-Entity
lesions,I-Entity
resolved,O
in,O
all,O
patients,O
after,O
warfarin,I-Entity
was,O
discontinued,O
.,O
In,O
2,O
of,O
the,O
4,O
patients,O
",",O
rechallenge,O
with,O
warfarin,I-Entity
led,O
to,O
recurrence,O
of,O
the,O
lesions,O
.,O
LV,I-Entity
may,O
be,O
a,O
late,O
-,O
onset,O
adverse,O
reaction,O
associated,O
with,O
warfarin,I-Entity
therapy,O
.,O
The,O
activation,O
of,O
spinal,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
receptors,O
may,O
contribute,O
to,O
degeneration,O
of,O
spinal,O
motor,O
neurons,O
induced,O
by,O
neuraxial,O
morphine,I-Entity
after,O
a,O
noninjurious,O
interval,O
of,O
spinal,B-Entity
cord,I-Entity
ischemia,I-Entity
.,O
We,O
investigated,O
the,O
relationship,O
between,O
the,O
degeneration,O
of,O
spinal,O
motor,O
neurons,O
and,O
activation,O
of,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
d,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptors,O
after,O
neuraxial,O
morphine,I-Entity
following,O
a,O
noninjurious,O
interval,O
of,O
aortic,B-Entity
occlusion,I-Entity
in,O
rats,O
.,O
Spinal,B-Entity
cord,I-Entity
ischemia,I-Entity
was,O
induced,O
by,O
aortic,B-Entity
occlusion,I-Entity
for,O
6,O
min,O
with,O
a,O
balloon,O
catheter,O
.,O
In,O
a,O
microdialysis,O
study,O
",",O
10,O
muL,O
of,O
saline,O
(,O
group,O
C,O
;,O
n,O
=,O
8),O
or,O
30,O
mug,O
of,O
morphine,I-Entity
(,O
group,O
M,O
;,O
n,O
=,O
8),O
was,O
injected,O
intrathecally,O
(,O
IT,O
),O
0.5,O
h,O
after,O
reflow,O
",",O
and,O
30,O
mug,O
of,O
morphine,I-Entity
(,O
group,O
SM,O
;,O
Second,O
",",O
we,O
investigated,O
the,O
effect,O
of,O
IT,O
MK-801,I-Entity
(,O
30,O
mug,O
),O
on,O
the,O
histopathologic,O
changes,O
in,O
the,O
spinal,O
cord,O
after,O
morphine,I-Entity
-,O
induced,O
spastic,B-Entity
paraparesis,I-Entity
.,O
After,O
IT,O
morphine,I-Entity
",",O
the,O
cerebrospinal,O
fluid,O
(,O
CSF,O
),O
glutamate,I-Entity
concentration,O
was,O
increased,O
in,O
group,O
M,O
relative,O
to,O
both,O
baseline,O
and,O
group,O
C,O
(,O
P,O
<,O
0.05,O
),O
.,O
IT,O
MK-801,I-Entity
significantly,O
reduced,O
the,O
number,O
of,O
dark,O
-,O
stained,O
alpha,O
-,O
motoneurons,O
after,O
morphine,I-Entity
-,O
induced,O
spastic,B-Entity
paraparesis,I-Entity
compared,O
with,O
the,O
saline,O
group,O
.,O
These,O
data,O
indicate,O
that,O
IT,O
morphine,I-Entity
induces,O
spastic,B-Entity
paraparesis,I-Entity
with,O
a,O
concomitant,O
increase,O
in,O
CSF,O
glutamate,I-Entity
",",O
which,O
is,O
involved,O
in,O
NMDA,I-Entity
receptor,O
activation,O
.,O
We,O
suggest,O
that,O
opioids,O
may,O
be,O
neurotoxic,I-Entity
in,O
the,O
setting,O
of,O
spinal,B-Entity
cord,I-Entity
ischemia,I-Entity
via,O
NMDA,I-Entity
receptor,O
activation,O
.,O
Reduced,O
sodium,I-Entity
channel,O
density,O
",",O
altered,O
voltage,O
dependence,O
of,O
inactivation,O
",",O
and,O
increased,O
susceptibility,O
to,O
seizures,I-Entity
in,O
mice,O
lacking,O
sodium,I-Entity
channel,O
beta,O
2-subunits,O
.,O
Sodium,I-Entity
channel,O
beta,O
-,O
subunits,O
modulate,O
channel,O
gating,O
",",O
assembly,O
",",O
and,O
cell,O
surface,O
expression,O
in,O
heterologous,O
cell,O
systems,O
.,O
We,O
generated,O
beta2(-/-,O
),O
mice,O
to,O
investigate,O
the,O
role,O
of,O
beta2,O
in,O
control,O
of,O
sodium,I-Entity
channel,O
density,O
",",O
localization,O
",",O
and,O
function,O
in,O
neurons,O
in,O
vivo,O
.,O
Measurements,O
of,O
[,O
(,O
3)H]saxitoxin,I-Entity
(,O
STX,I-Entity
),O
binding,O
showed,O
a,O
significant,O
reduction,O
in,O
the,O
level,O
of,O
plasma,O
membrane,O
sodium,I-Entity
channels,O
in,O
beta2(-/-,O
),O
neurons,O
.,O
The,O
loss,O
of,O
beta2,O
resulted,O
in,O
negative,O
shifts,O
in,O
the,O
voltage,O
dependence,O
of,O
inactivation,O
as,O
well,O
as,O
significant,O
decreases,O
in,O
sodium,I-Entity
current,O
density,O
in,O
acutely,O
dissociated,O
hippocampal,O
neurons,O
.,O
The,O
integral,O
of,O
the,O
compound,O
action,O
potential,O
in,O
optic,O
nerve,O
was,O
significantly,O
reduced,O
",",O
and,O
the,O
threshold,O
for,O
action,O
potential,O
generation,O
was,O
increased,O
",",O
indicating,O
a,O
reduction,O
in,O
the,O
level,O
of,O
functional,O
plasma,O
membrane,O
sodium,I-Entity
channels,O
.,O
In,O
contrast,O
",",O
the,O
conduction,O
velocity,O
",",O
the,O
number,O
and,O
size,O
of,O
axons,O
in,O
the,O
optic,O
nerve,O
",",O
and,O
the,O
specific,O
localization,O
of,O
Na(v)1.6,I-Entity
channels,O
in,O
the,O
nodes,O
of,O
Ranvier,O
were,O
unchanged,O
.,O
beta2(-/-,O
),O
mice,O
displayed,O
increased,O
susceptibility,O
to,O
seizures,I-Entity
",",O
as,O
indicated,O
by,O
reduced,O
latency,O
and,O
threshold,O
for,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
",",O
but,O
seemed,O
normal,O
in,O
other,O
neurological,O
tests,O
.,O
Our,O
observations,O
show,O
that,O
beta2-subunits,O
play,O
an,O
important,O
role,O
in,O
the,O
regulation,O
of,O
sodium,I-Entity
channel,O
density,O
and,O
function,O
in,O
neurons,O
in,O
vivo,O
and,O
are,O
required,O
for,O
normal,O
action,O
potential,O
generation,O
and,O
control,O
of,O
excitability,O
.,O
Screening,O
for,O
stimulant,O
use,O
in,O
adult,O
emergency,O
department,O
seizure,I-Entity
patients,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
prevalence,O
of,O
positive,O
plasma,O
drug,O
screening,O
for,O
cocaine,I-Entity
or,O
amphetamine,I-Entity
in,O
adult,O
emergency,O
department,O
seizure,I-Entity
patients,O
.,O
This,O
prospective,O
study,O
evaluated,O
consecutive,O
eligible,O
seizure,I-Entity
patients,O
who,O
had,O
a,O
plasma,O
sample,O
collected,O
as,O
part,O
of,O
their,O
clinical,O
evaluation,O
.,O
Plasma,O
was,O
tested,O
for,O
amphetamine,I-Entity
and,O
the,O
cocaine,I-Entity
metabolite,O
benzoylecgonine,I-Entity
Plasma,O
samples,O
with,O
benzoylecgonine,I-Entity
greater,O
than,O
150,O
ng,O
/,O
mL,O
or,O
an,O
amphetamine,I-Entity
greater,O
than,O
500,O
ng,O
/,O
mL,O
were,O
defined,O
as,O
positive,O
.,O
Patient,O
demographics,O
",",O
history,O
of,O
underlying,O
drug,O
or,O
alcohol,I-Entity
-,O
related,O
seizure,I-Entity
disorder,O
",",O
estimated,O
time,O
from,O
seizure,I-Entity
to,O
sample,O
collection,O
",",O
history,O
or,O
suspicion,O
of,O
cocaine,B-Entity
or,I-Entity
amphetamine,I-Entity
abuse,I-Entity
",",O
results,O
of,O
clinical,O
urine,O
testing,O
for,O
drugs,O
of,O
abuse,O
",",O
and,O
assay,O
results,O
were,O
recorded,O
without,O
patient,O
identifiers,O
.,O
Fourteen,O
of,O
248,O
(,O
5.6%,O
",",O
95%,O
CI,O
2.7%-8.5%,O
),O
plasma,O
samples,O
were,O
positive,O
by,O
immunoassay,O
testing,O
for,O
benzoylecgonine,I-Entity
and,O
no,O
samples,O
(,O
0%,O
",",O
95%,O
CI,O
0,O
-,O
1.2%,O
),O
were,O
positive,O
for,O
amphetamine,I-Entity
.,O
Positive,O
test,O
results,O
were,O
more,O
common,O
in,O
patient,O
visits,O
where,O
there,O
was,O
a,O
history,O
or,O
suspicion,O
of,O
cocaine,B-Entity
or,I-Entity
amphetamine,I-Entity
abuse,I-Entity
(,O
p,O
During,O
this,O
study,O
period,O
",",O
routine,O
plasma,O
screening,O
for,O
cocaine,I-Entity
and,O
amphetamines,I-Entity
in,O
adult,O
seizure,I-Entity
patients,O
had,O
a,O
low,O
yield,O
.,O
As,O
a,O
result,O
",",O
routine,O
plasma,O
screening,O
would,O
yield,O
few,O
cases,O
of,O
stimulant,O
drug,O
in,O
which,O
there,O
was,O
neither,O
a,O
history,O
nor,O
suspicion,O
of,O
drug,B-Entity
abuse,I-Entity
in,O
this,O
population,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
explore,O
the,O
functional,O
anatomy,O
of,O
the,O
globus,O
pallidus,O
internus,O
(,O
GPi,O
),O
by,O
studying,O
the,O
effects,O
of,O
unilateral,O
pallidotomy,O
on,O
parkinsonian,I-Entity
',O
off,O
',O
signs,O
and,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
(,O
LID,I-Entity
),O
.,O
We,O
found,O
significant,O
positive,O
correlations,O
between,O
the,O
preoperative,O
levodopa,I-Entity
responsiveness,O
of,O
motor,O
signs,O
and,O
the,O
levodopa,I-Entity
responsiveness,O
of,O
scores,O
in,O
timed,O
tests,O
(,O
Core,O
Assessment,O
Program,O
for,O
Intracerebral,O
Transplantations,O
),O
in,O
the,O
contralateral,O
limbs,O
and,O
the,O
improvement,O
in,O
these,O
scores,O
after,O
surgery,O
",",O
whereas,O
there,O
was,O
no,O
correlation,O
with,O
the,O
improvement,O
in,O
LID,I-Entity
.,O
0.0001,O
",",O
r,O
=,O
0.8,O
),O
between,O
the,O
volume,O
of,O
the,O
ventral,O
lesion,O
in,O
the,O
GPi,O
and,O
the,O
improvement,O
in,O
LID,I-Entity
in,O
the,O
contralateral,O
limbs,O
",",O
whereas,O
there,O
was,O
no,O
correlation,O
between,O
the,O
ventral,O
volume,O
and,O
the,O
improvement,O
in,O
parkinsonian,I-Entity
',O
off,O
',O
signs,O
.,O
The,O
volumes,O
of,O
the,O
total,O
lesion,O
cylinder,O
and,O
the,O
dorsal,O
lesion,O
did,O
not,O
correlate,O
with,O
the,O
outcome,O
of,O
either,O
dyskinesias,I-Entity
or,O
parkinsonian,I-Entity
',O
off,O
',O
signs,O
.,O
The,O
differential,O
predictive,O
value,O
of,O
levodopa,I-Entity
responsiveness,O
for,O
the,O
outcome,O
of,O
parkinsonian,I-Entity
',O
off,O
',O
signs,O
and,O
LID,I-Entity
and,O
the,O
different,O
correlations,O
of,O
ventral,O
lesion,O
volume,O
with,O
dyskinesias,I-Entity
and,O
parkinsonian,I-Entity
',O
off,O
',O
signs,O
indicate,O
that,O
different,O
anatomical,O
or,O
pathophysiological,O
substrates,O
may,O
be,O
responsible,O
for,O
the,O
generation,O
of,O
parkinsonian,I-Entity
',O
off,O
',O
signs,O
and,O
dyskinesias,I-Entity
.,O
Whereas,O
cells,O
in,O
a,O
wider,O
area,O
of,O
the,O
GPi,O
may,O
be,O
implicated,O
in,O
parkinsonism,I-Entity
",",O
the,O
ventral,O
GPi,O
seems,O
to,O
be,O
crucial,O
for,O
the,O
manifestation,O
of,O
LID,I-Entity
.,O
We,O
suggest,O
that,O
our,O
observations,O
are,O
additional,O
proof,O
of,O
the,O
functional,O
somatotopy,O
of,O
the,O
systems,O
within,O
the,O
GPi,O
that,O
mediate,O
parkinsonism,I-Entity
and,O
dyskinesias,I-Entity
",",O
especially,O
along,O
the,O
dorsoventral,O
trajectory,O
used,O
in,O
pallidotomy,O
.,O
Pain,I-Entity
responses,O
in,O
methadone,I-Entity
-,O
maintained,O
opioid,O
abusers,O
.,O
Providing,O
pain,I-Entity
management,O
for,O
known,O
opioid,O
abusers,O
is,O
a,O
challenging,O
clinical,O
task,O
",",O
in,O
part,O
because,O
little,O
is,O
known,O
about,O
their,O
pain,I-Entity
experience,O
and,O
analgesic,O
requirements,O
.,O
This,O
study,O
was,O
designed,O
to,O
describe,O
pain,I-Entity
tolerance,O
and,O
analgesic,O
response,O
in,O
a,O
sample,O
of,O
opioid,B-Entity
addicts,I-Entity
stabilized,O
in,O
methadone,I-Entity
-,O
maintenance,O
(,O
MM,O
),O
treatment,O
(,O
n,O
=,O
60,O
),O
in,O
comparison,O
to,O
matched,O
nondependent,O
control,O
subjects,O
(,O
n,O
=,O
60,O
),O
.,O
By,O
using,O
a,O
placebo,O
-,O
controlled,O
",",O
two,O
-,O
way,O
factorial,O
design,O
",",O
tolerance,O
to,O
cold,O
-,O
pressor,O
(,O
CP,O
),O
pain,I-Entity
was,O
examined,O
",",O
both,O
before,O
and,O
after,O
oral,O
administration,O
of,O
therapeutic,O
doses,O
of,O
common,O
opioid,O
(,O
hydromorphone,I-Entity
2,O
mg,O
),O
and,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
(,O
ketorolac,I-Entity
10,O
mg,O
),O
analgesic,O
agents,O
.,O
Results,O
showed,O
that,O
MM,O
individuals,O
were,O
significantly,O
less,O
tolerant,O
of,O
CP,O
pain,I-Entity
than,O
control,O
subjects,O
",",O
replicating,O
previous,O
work,O
.,O
These,O
data,O
indicate,O
that,O
MM,O
opioid,O
abusers,O
represent,O
a,O
pain,B-Entity
-,I-Entity
intolerant,I-Entity
subset,O
of,O
clinical,O
patients,O
.,O
Their,O
complaints,O
of,O
pain,I-Entity
should,O
be,O
evaluated,O
seriously,O
and,O
managed,O
aggressively,O
.,O
Although,O
an,O
indicator,O
of,O
renal,B-Entity
tubular,I-Entity
dysfunction,I-Entity
",",O
an,O
increased,O
urinary,O
N,O
-,O
acetyl,O
-,O
beta,O
Puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
was,O
administered,O
to,O
Sprague,O
Dawley,O
rats,O
to,O
induce,O
proteinuria,I-Entity
.,O
Following,O
intravenous,O
PAN,I-Entity
urine,O
volume,O
and,O
urine,O
NAG,O
activity,O
increased,O
significantly,O
by,O
day,O
two,O
",",O
but,O
returned,O
to,O
normal,O
by,O
day,O
four,O
.,O
Peak,O
urine,O
NAG,O
activity,O
and,O
a,O
change,O
in,O
NAG,O
isoenzyme,O
pattern,O
coincided,O
with,O
both,O
the,O
peak,O
proteinuria,I-Entity
and,O
the,O
reduction,O
in,O
intracellular,O
protein,O
and,O
NAG,O
droplets,O
(,O
day,O
six,O
onwards,O
),O
.,O
Over,O
expression,O
of,O
vascular,O
endothelial,O
growth,O
factor,O
and,O
its,O
receptor,O
during,O
the,O
development,O
of,O
estrogen,I-Entity
-,O
induced,O
rat,O
pituitary,B-Entity
tumors,I-Entity
may,O
mediate,O
estrogen,I-Entity
-,O
initiated,O
tumor,I-Entity
angiogenesis,O
.,O
Estrogens,I-Entity
",",O
which,O
have,O
been,O
associated,O
with,O
several,O
types,O
of,O
human,O
and,O
animal,O
cancers,I-Entity
",",O
can,O
induce,O
tumor,I-Entity
angiogenesis,O
in,O
the,O
pituitary,O
of,O
Fischer,O
344,O
rats,O
.,O
The,O
mechanistic,O
details,O
of,O
tumor,I-Entity
angiogenesis,O
induction,O
",",O
during,O
estrogen,I-Entity
carcinogenesis,I-Entity
",",O
are,O
still,O
unknown,O
.,O
To,O
elucidate,O
the,O
role,O
of,O
estrogen,I-Entity
in,O
the,O
regulation,O
of,O
tumor,I-Entity
angiogenesis,O
in,O
the,O
pituitary,O
of,O
female,O
rats,O
",",O
the,O
density,O
of,O
blood,O
vessels,O
was,O
analysed,O
using,O
factor,O
VIII,O
related,O
antigen,O
(,O
FVIIIRAg,O
),O
immunohistochemistry,O
and,O
the,O
expression,O
of,O
vascular,O
endothelial,O
growth,O
factor,O
/,O
vascular,O
permeability,O
factor,O
(,O
VEGF,O
/,O
VPF,O
),O
was,O
examined,O
by,O
Western,O
blot,O
and,O
immunohistochemical,O
analysis,O
.,O
The,O
results,O
demonstrated,O
that,O
17beta,B-Entity
-,I-Entity
estradiol,I-Entity
(,O
E2,I-Entity
),O
induces,O
neovascularization,O
",",O
as,O
well,O
as,O
the,O
growth,O
and,O
enlargement,O
of,O
blood,O
vessels,O
after,O
7,O
days,O
of,O
exposure,O
.,O
The,O
high,O
tumor,I-Entity
angiogenic,O
potential,O
was,O
associated,O
with,O
an,O
elevated,O
VEGF,O
/,O
VPF,O
protein,O
expression,O
in,O
the,O
E2,I-Entity
exposed,O
pituitary,O
of,O
ovariectomized,O
(,O
OVEX,O
),O
rats,O
.,O
After,O
15,O
days,O
of,O
E2,I-Entity
exposure,O
",",O
VEGF,O
/,O
VPF,O
protein,O
expression,O
",",O
in,O
the,O
non,O
-,O
endothelial,O
cell,O
population,O
",",O
sharply,O
declined,O
and,O
was,O
restricted,O
to,O
the,O
blood,O
vessels,O
.,O
Furthermore,O
",",O
immunohistochemical,O
studies,O
demonstrated,O
that,O
VEGFR-2,O
(,O
flk-1/KDR,O
),O
",",O
expression,O
was,O
elevated,O
significantly,O
in,O
the,O
endothelial,O
cells,O
of,O
microblood,O
vessels,O
after,O
7,O
days,O
of,O
E2,I-Entity
exposure,O
.,O
These,O
findings,O
suggest,O
that,O
over,O
expression,O
of,O
VEGF,O
and,O
its,O
receptor,O
(,O
VEGFR-2,O
),O
may,O
play,O
an,O
important,O
role,O
in,O
the,O
initial,O
step,O
of,O
the,O
regulation,O
of,O
estrogen,I-Entity
induced,O
tumor,I-Entity
angiogenesis,O
in,O
the,O
rat,O
pituitary,O
.,O
Pravastatin,I-Entity
-,O
associated,O
myopathy,I-Entity
.,O
A,O
case,O
of,O
acute,O
inflammatory,B-Entity
myopathy,I-Entity
associated,O
with,O
the,O
use,O
of,O
pravastatin,I-Entity
",",O
a,O
new,O
hydrophilic,O
3-hydroxy-3,O
The,O
patient,O
",",O
a,O
69-year,O
-,O
old,O
man,O
was,O
affected,O
by,O
non,B-Entity
-,I-Entity
insulin,I-Entity
-,I-Entity
dependent,I-Entity
diabetes,I-Entity
mellitus,I-Entity
and,O
hypertension,I-Entity
.,O
He,O
assumed,O
pravastatin,I-Entity
(,O
20,O
mg,O
/,O
day,O
),O
because,O
of,O
hypercholesterolemia,I-Entity
.,O
He,O
was,O
admitted,O
with,O
acute,O
myopathy,I-Entity
of,O
the,O
lower,O
limbs,O
which,O
resolved,O
in,O
a,O
few,O
days,O
after,O
pravastatin,I-Entity
discontinuation,O
.,O
A,O
previously,O
unknown,O
hypothyroidism,I-Entity
",",O
probably,O
due,O
to,O
chronic,O
autoimmune,B-Entity
thyroiditis,I-Entity
",",O
was,O
evidenced,O
.,O
While,O
lovastatin,I-Entity
and,O
simvastatin,I-Entity
have,O
been,O
associated,O
with,O
toxic,O
myopathy,I-Entity
",",O
pravastatin,I-Entity
-,O
associated,O
myopathy,I-Entity
could,O
represent,O
a,O
distinct,O
",",O
inflammatory,O
entity,O
.,O
Dose,O
-,O
effect,O
and,O
structure,O
-,O
function,O
relationships,O
in,O
doxorubicin,I-Entity
cardiomyopathy,I-Entity
.,O
The,O
cardiomyopathy,I-Entity
(,O
CM,I-Entity
),O
produced,O
by,O
the,O
anticancer,O
drug,O
doxorubicin,I-Entity
(,O
DXR,I-Entity
),O
(,O
Adriamycin,I-Entity
),O
provides,O
a,O
unique,O
opportunity,O
to,O
analyze,O
dose,O
-,O
effect,O
and,O
structure,O
-,O
function,O
relationships,O
during,O
development,O
of,O
myocardial,B-Entity
disease,I-Entity
.,O
We,O
measured,O
the,O
degree,O
of,O
morphologic,O
damage,O
by,O
ultrastructural,O
examination,O
of,O
endomyocardial,O
biopsy,O
and,O
the,O
degree,O
of,O
performance,O
abnormally,O
by,O
right,O
heart,O
catheterization,O
in,O
patients,O
receiving,O
DXR,I-Entity
.,O
Morphologic,O
damage,O
was,O
variable,O
but,O
was,O
proportional,O
to,O
the,O
total,O
cumulative,O
DXR,I-Entity
dose,O
between,O
100,O
and,O
600,O
mg,O
/,O
m2,O
.,O
In,O
DXR,I-Entity
-,O
CM,I-Entity
myocardial,B-Entity
damage,I-Entity
is,O
proportional,O
to,O
the,O
degree,O
of,O
cytotoxic,O
insult,O
(,O
DXR,I-Entity
dose,O
),O
while,O
myocardial,O
function,O
is,O
preserved,O
until,O
a,O
critical,O
dose,O
or,O
degree,O
of,O
damage,O
is,O
reached,O
",",O
after,O
which,O
myocardial,O
performance,O
deteriorates,O
rapidly,O
.,O
Fatal,O
aplastic,B-Entity
anemia,I-Entity
following,O
topical,O
administration,O
of,O
ophthalmic,O
chloramphenicol,I-Entity
.,O
A,O
73-year,O
-,O
old,O
woman,O
died,O
of,O
aplastic,B-Entity
anemia,I-Entity
less,O
than,O
two,O
months,O
after,O
undergoing,O
cataract,I-Entity
extraction,O
and,O
beginning,O
topical,O
therapy,O
with,O
chloramphenicol,I-Entity
.,O
The,O
first,O
signs,O
of,O
pancytopenia,I-Entity
began,O
within,O
one,O
month,O
of,O
the,O
surgery,O
.,O
The,O
pattern,O
of,O
the,O
aplastic,B-Entity
anemia,I-Entity
was,O
associated,O
with,O
an,O
idiosyncratic,O
response,O
to,O
chloramphenicol,I-Entity
.,O
This,O
was,O
the,O
second,O
report,O
of,O
fatal,O
aplastic,B-Entity
anemia,I-Entity
after,O
topical,O
treatment,O
with,O
chloramphenicol,I-Entity
for,O
ocular,O
conditions,O
",",O
although,O
two,O
cases,O
of,O
reversible,O
bone,B-Entity
marrow,I-Entity
hypoplasia,I-Entity
have,O
also,O
been,O
reported,O
.,O
Any,O
other,O
suspected,O
cases,O
of,O
ocular,B-Entity
toxicity,I-Entity
associated,O
with,O
topically,O
applied,O
chloramphenicol,I-Entity
should,O
be,O
reported,O
to,O
the,O
National,O
Registry,O
of,O
Drug,O
-,O
Induced,O
Ocular,O
Side,O
Effects,O
",",O
Oregon,O
Health,O
Sciences,O
University,O
",",O
Portland,O
",",O
OR,O
97201,O
.,O
Bradycardia,I-Entity
due,O
to,O
trihexyphenidyl,B-Entity
hydrochloride,I-Entity
.,O
A,O
chronic,O
schizophrenic,I-Entity
patient,O
was,O
treated,O
with,O
an,O
anticholinergic,O
drug,O
",",O
trihexyphenidyl,B-Entity
hydrochloride,I-Entity
.,O
The,O
patient,O
developed,O
",",O
paradoxically,O
",",O
sinus,O
bradycardia,I-Entity
.,O
The,O
reaction,O
was,O
specific,O
to,O
trihexyphenidyl,I-Entity
and,O
not,O
to,O
other,O
anticholinergic,O
drugs,O
.,O
This,O
antidyskinetic,O
drug,O
is,O
widely,O
used,O
in,O
clinical,O
psychiatric,I-Entity
practice,O
and,O
physicians,O
should,O
be,O
aware,O
of,O
this,O
side,O
effect,O
.,O
Experimental,O
cyclosporine,I-Entity
nephrotoxicity,I-Entity
:,O
risk,O
of,O
concomitant,O
chemotherapy,O
.,O
The,O
role,O
of,O
cyclosporine,I-Entity
(,O
CSA,I-Entity
),O
alone,O
or,O
in,O
combination,O
with,O
various,O
chemotherapeutics,O
in,O
the,O
development,O
of,O
renal,B-Entity
toxicity,I-Entity
was,O
evaluated,O
in,O
rats,O
.,O
Administration,O
of,O
20,O
mg,O
/,O
kg,O
/,O
day,O
CSA,I-Entity
for,O
4,O
weeks,O
caused,O
renal,O
functional,O
and,O
structural,O
changes,O
similar,O
to,O
those,O
reported,O
in,O
man,O
.,O
The,O
combined,O
administration,O
of,O
CSA,I-Entity
and,O
various,O
chemotherapeutic,O
drugs,O
with,O
a,O
nephrotoxic,I-Entity
potential,O
",",O
such,O
as,O
gentamicin,I-Entity
(,O
at,O
therapeutic,O
doses,O
),O
",",O
amphothericin,B-Entity
B,I-Entity
and,O
ketoconazole,I-Entity
",",O
which,O
are,O
frequently,O
used,O
in,O
immunosuppressed,O
patients,O
",",O
did,O
not,O
aggravate,O
the,O
CSA,I-Entity
induced,O
toxicity,I-Entity
in,O
the,O
rat,O
model,O
.,O
Gentamicin,I-Entity
at,O
toxic,O
doses,O
",",O
however,O
",",O
increased,O
CSA,I-Entity
nephrotoxicity,I-Entity
.,O
Thus,O
",",O
the,O
nephrotoxicity,I-Entity
induced,O
by,O
CSA,I-Entity
has,O
a,O
different,O
pathogenetic,O
mechanism,O
.,O
Receptor,O
mechanisms,O
of,O
nicotine,I-Entity
-,O
induced,O
locomotor,B-Entity
hyperactivity,I-Entity
in,O
chronic,O
nicotine,I-Entity
-,O
treated,O
rats,O
.,O
Rats,O
were,O
pretreated,O
with,O
saline,O
or,O
nicotine,I-Entity
(,O
1.5,O
mg,O
/,O
kg,O
per,O
day,O
),O
by,O
subcutaneously,O
implanting,O
each,O
animal,O
with,O
an,O
Alzet,O
osmotic,O
mini,O
-,O
pump,O
which,O
continuously,O
released,O
saline,O
or,O
nicotine,I-Entity
for,O
1,O
",",O
5,O
and,O
14,O
days,O
.,O
At,O
the,O
end,O
of,O
each,O
pretreatment,O
period,O
",",O
animals,O
were,O
used,O
for,O
(,O
i,O
),O
determining,O
their,O
locomotor,O
response,O
to,O
acutely,O
injected,O
nicotine,I-Entity
(,O
0.2,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
and,O
(,O
ii,O
),O
measuring,O
the,O
density,O
of,O
L-[3H]nicotine,I-Entity
and,O
[,O
3H]spiperone,I-Entity
binding,O
sites,O
in,O
the,O
striatum,O
.,O
We,O
observed,O
no,O
changes,O
in,O
nicotine,I-Entity
-,O
induced,O
locomotor,O
response,O
",",O
striatal,O
L-[3H]nicotine,I-Entity
and,O
[,O
3H]spiperone,I-Entity
binding,O
in,O
the,O
animals,O
pretreated,O
with,O
nicotine,I-Entity
for,O
1,O
day,O
.,O
In,O
rats,O
which,O
were,O
pretreated,O
with,O
nicotine,I-Entity
for,O
5,O
days,O
",",O
there,O
was,O
a,O
significant,O
increase,O
in,O
the,O
nicotine,I-Entity
-,O
stimulated,O
locomotor,O
response,O
which,O
was,O
associated,O
with,O
an,O
increase,O
in,O
the,O
number,O
of,O
L-[3H]nicotine,I-Entity
binding,O
sites,O
and,O
also,O
with,O
an,O
elevated,O
dopamine,I-Entity
(,O
DA,I-Entity
),O
level,O
in,O
the,O
striatum,O
.,O
The,O
number,O
of,O
striatal,O
[,O
3H]spiperone,I-Entity
binding,O
sites,O
was,O
not,O
affected,O
.,O
In,O
animals,O
pretreated,O
with,O
nicotine,I-Entity
for,O
14,O
days,O
",",O
the,O
nicotine,I-Entity
-,O
induced,O
locomotor,O
response,O
remained,O
to,O
be,O
potentiated,O
.,O
However,O
",",O
this,O
response,O
was,O
correlated,O
with,O
an,O
elevated,O
number,O
of,O
striatal,O
[,O
3H]spiperone,I-Entity
binding,O
sites,O
",",O
whereas,O
the,O
number,O
of,O
striatal,O
L-[3H]nicotine,I-Entity
binding,O
sites,O
and,O
the,O
striatal,O
DA,I-Entity
level,O
were,O
normal,O
.,O
These,O
results,O
suggest,O
that,O
chronic,O
nicotine,I-Entity
-,O
treated,O
rats,O
develop,O
locomotor,B-Entity
hyperactivity,I-Entity
in,O
response,O
to,O
nicotine,I-Entity
initially,O
due,O
to,O
increases,O
of,O
both,O
the,O
density,O
of,O
nicotinic,O
receptors,O
and,O
DA,I-Entity
concentration,O
",",O
followed,O
by,O
inducing,O
DA,I-Entity
receptor,O
supersensitivity,O
in,O
the,O
striatum,O
.,O
Hydrocortisone,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
humans,O
:,O
pressor,O
responsiveness,O
and,O
sympathetic,O
function,O
.,O
Oral,O
hydrocortisone,I-Entity
increases,O
blood,O
pressure,O
and,O
enhances,O
pressor,O
responsiveness,O
in,O
normal,O
human,O
subjects,O
.,O
We,O
studied,O
the,O
effects,O
of,O
1,O
week,O
of,O
oral,O
hydrocortisone,I-Entity
(,O
200,O
mg,O
/,O
day,O
),O
on,O
blood,O
pressure,O
",",O
cardiac,O
output,O
",",O
total,O
peripheral,O
resistance,O
",",O
forearm,O
vascular,O
resistance,O
",",O
and,O
norepinephrine,I-Entity
spillover,O
to,O
plasma,O
in,O
eight,O
healthy,O
male,O
volunteers,O
.,O
3.4,O
",",O
p,O
less,O
than,O
0.01,O
),O
",",O
associated,O
with,O
an,O
increased,B-Entity
cardiac,I-Entity
output,I-Entity
(,O
5.85,O
-,O
7.73,O
l,O
/,O
min,O
",",O
SED,O
+,O
/-,O
The,O
rise,O
in,O
forearm,O
vascular,O
resistance,O
accompanying,O
intra,O
-,O
arterial,O
norepinephrine,I-Entity
(,O
25,O
",",O
50,O
",",O
and,O
100,O
ng,O
/,O
min,O
),O
was,O
also,O
significantly,O
greater,O
after,O
hydrocortisone,I-Entity
",",O
increasing,O
from,O
an,O
average,O
of,O
14.9,O
+,O
/-,O
5.5,O
R,O
units,O
after,O
hydrocortisone,I-Entity
A,O
shift,O
to,O
the,O
left,O
in,O
the,O
dose,O
-,O
response,O
relation,O
and,O
fall,O
in,O
threshold,O
suggested,O
increased,O
sensitivity,O
to,O
norepinephrine,I-Entity
after,O
treatment,O
.,O
Measurement,O
of,O
resting,O
norepinephrine,I-Entity
spillover,O
rate,O
to,O
plasma,O
and,O
norepinephrine,I-Entity
uptake,O
indicated,O
that,O
overall,O
resting,O
sympathetic,O
nervous,O
system,O
activity,O
was,O
not,O
increased,O
.,O
The,O
rise,B-Entity
in,I-Entity
resting,I-Entity
blood,I-Entity
pressure,I-Entity
with,O
hydrocortisone,I-Entity
is,O
associated,O
with,O
an,O
increased,B-Entity
cardiac,I-Entity
output,I-Entity
(,O
presumably,O
due,O
to,O
increased,O
blood,O
volume).(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Effects,O
of,O
suprofen,I-Entity
on,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
.,O
Although,O
suprofen,I-Entity
has,O
been,O
associated,O
with,O
the,O
development,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
in,O
greater,O
than,O
100,O
subjects,O
",",O
the,O
mechanism,O
of,O
damage,O
remains,O
unclear,O
.,O
The,O
direct,O
nephrotoxic,I-Entity
effects,O
of,O
a,O
single,O
dose,O
of,O
15,O
mg,O
of,O
suprofen,I-Entity
were,O
compared,O
in,O
the,O
recirculating,O
isolated,O
rat,O
kidney,O
perfused,O
with,O
cell,O
-,O
free,O
buffer,O
with,O
or,O
without,O
the,O
addition,O
of,O
5,O
mg,O
/,O
dL,O
of,O
uric,B-Entity
acid,I-Entity
.,O
There,O
were,O
no,O
significant,O
differences,O
in,O
renal,O
sodium,I-Entity
excretion,O
",",O
oxygen,I-Entity
consumption,O
",",O
or,O
urinary,O
flow,O
rates,O
in,O
kidneys,O
perfused,O
with,O
suprofen,I-Entity
compared,O
with,O
the,O
drug,O
-,O
free,O
control,O
groups,O
.,O
In,O
contrast,O
",",O
a,O
significant,O
decline,O
in,O
glomerular,O
filtration,O
rate,O
was,O
found,O
after,O
the,O
introduction,O
of,O
suprofen,I-Entity
to,O
the,O
kidney,O
perfused,O
with,O
uric,B-Entity
acid,I-Entity
;,O
no,O
changes,O
were,O
found,O
with,O
suprofen,I-Entity
in,O
the,O
absence,O
of,O
uric,B-Entity
acid,I-Entity
.,O
A,O
significant,O
decrease,O
in,O
the,O
baseline,O
excretion,O
rate,O
of,O
uric,B-Entity
acid,I-Entity
was,O
found,O
in,O
rats,O
given,O
suprofen,I-Entity
",",O
compared,O
with,O
drug,O
-,O
free,O
controls,O
.,O
However,O
",",O
the,O
fractional,O
excretion,O
of,O
uric,B-Entity
acid,I-Entity
was,O
unchanged,O
between,O
the,O
groups,O
over,O
the,O
experimental,O
period,O
.,O
In,O
summary,O
",",O
suprofen,I-Entity
causes,O
acute,B-Entity
declines,I-Entity
in,I-Entity
renal,I-Entity
function,I-Entity
",",O
most,O
likely,O
by,O
directly,O
altering,O
the,O
intrarenal,O
distribution,O
of,O
uric,B-Entity
acid,I-Entity
.,O
Cocaine,I-Entity
-,O
induced,O
brainstem,O
seizures,I-Entity
and,O
behavior,O
.,O
electrical,O
current,O
stimulations,O
and,O
by,O
acute,O
and,O
chronic,O
administration,O
of,O
cocaine,I-Entity
.,O
Cocaine,I-Entity
(,O
40,O
mg,O
/,O
kg,O
),O
was,O
injected,O
subcutaneously,O
for,O
an,O
acute,O
experiment,O
and,O
subsequent,O
20,O
mg,O
/,O
kg,O
doses,O
twice,O
daily,O
for,O
3,O
days,O
in,O
a,O
chronic,O
study,O
.,O
Cocaine,I-Entity
generated,O
more,O
abnormal,O
behaviors,O
in,O
the,O
brainstem,O
perturbation,O
group,O
",",O
especially,O
the,O
electrically,O
perturbated,O
subjects,O
.,O
The,O
abnormal,O
behaviors,O
were,O
yawning,O
",",O
retrocollis,O
",",O
hyperactivity,I-Entity
",",O
hypersensitivity,I-Entity
",",O
"""",O
beating,O
drum,O
"""",O
behavior,O
",",O
squealing,O
",",O
head,O
bobbing,O
",",O
circling,O
",",O
sniffing,O
",",O
abnormal,O
posturing,O
",",O
and,O
facial,O
twitching,O
.,O
Hypersensitivity,I-Entity
to,O
various,O
auditory,O
",",O
tactile,O
",",O
and,O
visual,O
stimulation,O
was,O
present,O
and,O
shifts,O
in,O
the,O
brainstem,O
ambient,O
power,O
spectral,O
frequency,O
occurred,O
in,O
response,O
to,O
tactile,O
stimulation,O
.,O
Cocaine,I-Entity
was,O
found,O
to,O
activate,O
the,O
discharge,O
system,O
and,O
thus,O
induce,O
abnormal,O
behaviors,O
that,O
are,O
generated,O
at,O
the,O
discharge,O
site,O
and,O
at,O
distant,O
sites,O
to,O
which,O
the,O
discharge,O
propagates,O
.,O
Increased,O
sulfation,O
and,O
decreased,O
7alpha,O
-,O
hydroxylation,O
of,O
deoxycholic,B-Entity
acid,I-Entity
in,O
ethinyl,B-Entity
estradiol,I-Entity
-,O
induced,O
cholestasis,I-Entity
in,O
rats,O
.,O
Deoxycholic,B-Entity
acid,I-Entity
conjugation,O
",",O
transport,O
capacity,O
",",O
and,O
metabolism,O
were,O
compared,O
in,O
control,O
and,O
ethinyl,B-Entity
estradiol,I-Entity
-,O
treated,O
rats,O
.,O
Control,O
rats,O
were,O
found,O
to,O
have,O
a,O
lower,O
capacity,O
to,O
transport,O
deoxycholic,B-Entity
acid,I-Entity
than,O
taurodeoxycholic,B-Entity
acid,I-Entity
",",O
and,O
both,O
were,O
decreased,O
by,O
ethinyl,B-Entity
estradiol,I-Entity
treatment,O
.,O
During,O
[,O
24,O
-,O
14C]sodium,B-Entity
deoxycholate,I-Entity
infusion,O
",",O
[,O
14C]biliary,O
bile,B-Entity
acid,I-Entity
secretion,O
increased,O
",",O
but,O
bile,O
flow,O
did,O
not,O
change,O
significantly,O
in,O
either,O
control,O
or,O
ethinyl,B-Entity
estradiol,I-Entity
-,O
treated,O
rats,O
.,O
Ethinyl,B-Entity
estradiol,I-Entity
-,O
treated,O
animals,O
excreted,O
significantly,O
less,O
14C,O
as,O
taurocholic,B-Entity
acid,I-Entity
than,O
did,O
control,O
animals,O
",",O
consistent,O
with,O
an,O
impairment,O
of,O
7alpha,O
-,O
hydroxylation,O
of,O
taurodeoxycholic,B-Entity
acid,I-Entity
.,O
Ethinyl,B-Entity
estradiol,I-Entity
treatment,O
did,O
not,O
impair,O
conjugation,O
of,O
deoxycholic,B-Entity
acid,I-Entity
",",O
but,O
did,O
result,O
in,O
an,O
increase,O
in,O
sulfation,O
of,O
taurodeoxycholic,B-Entity
acid,I-Entity
from,O
1.5%,O
in,O
controls,O
to,O
nearly,O
4.0%,O
(,O
P,O
less,O
than,O
0.01,O
),O
.,O
These,O
results,O
are,O
consistent,O
with,O
the,O
hypothesis,O
that,O
the,O
rat,O
has,O
a,O
poorer,O
tolerance,O
for,O
deoxycholic,B-Entity
acid,I-Entity
than,O
do,O
certain,O
other,O
species,O
.,O
Furthermore,O
",",O
the,O
rat,O
converts,O
deoxycholic,B-Entity
acid,I-Entity
",",O
a,O
poor,O
choleretic,O
",",O
to,O
taurocholic,B-Entity
acid,I-Entity
",",O
a,O
good,O
choleretic,O
.,O
When,O
this,O
conversion,O
is,O
impaired,O
with,O
ethinyl,B-Entity
estradiol,I-Entity
treatment,O
",",O
sulfation,O
may,O
be,O
an,O
important,O
alternate,O
pathway,O
for,O
excretion,O
of,O
this,O
potentially,O
harmful,O
bile,B-Entity
acid,I-Entity
.,O
Effects,O
of,O
ouabain,I-Entity
on,O
myocardial,O
oxygen,I-Entity
supply,O
and,O
demand,O
in,O
patients,O
with,O
chronic,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
.,O
A,O
hemodynamic,O
",",O
volumetric,O
",",O
and,O
metabolic,O
study,O
in,O
patients,O
without,O
heart,B-Entity
failure,I-Entity
.,O
The,O
effects,O
of,O
digitalis,B-Entity
glycosides,I-Entity
on,O
myocardial,O
oxygen,I-Entity
supply,O
and,O
demand,O
are,O
of,O
particular,O
interest,O
in,O
the,O
presence,O
of,O
obstructive,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
but,O
have,O
not,O
been,O
measured,O
previously,O
in,O
man,O
.,O
We,O
assessed,O
the,O
effects,O
of,O
ouabain,I-Entity
(,O
0.015,O
mg,O
/,O
kg,O
body,O
weight,O
),O
on,O
hemodynamic,O
",",O
volumetric,O
",",O
and,O
metabolic,O
parameters,O
in,O
11,O
patients,O
with,O
severe,O
chronic,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
without,O
clinical,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
.,O
Because,O
the,O
protocol,O
was,O
long,O
and,O
involved,O
interventions,O
which,O
might,O
affect,O
the,O
determinations,O
",",O
we,O
also,O
studied,O
in,O
nine,O
patients,O
using,O
an,O
identical,O
protocol,O
except,O
that,O
ouabain,I-Entity
administration,O
was,O
omitted,O
.,O
Left,O
ventricular,O
end,O
-,O
diastolic,O
pressure,O
and,O
left,O
ventricular,O
end,O
-,O
diastolic,O
volume,O
fell,O
in,O
each,O
patient,O
given,O
ouabain,I-Entity
",",O
even,O
though,O
they,O
were,O
initially,O
elevated,O
in,O
only,O
two,O
patients,O
.,O
Left,O
ventricular,O
end,O
-,O
diastolic,O
pressure,O
fell,O
from,O
11.5+/-1.4,O
(,O
mean+/-SE,O
),O
to,O
5.6+/-0.9,O
mm,O
Hg,O
(,O
P,O
less,O
than,O
0.001,O
),O
and,O
left,O
ventricular,O
end,O
-,O
diastolic,O
volume,O
fell,O
from,O
100+/-17,O
to,O
82+/-12,O
ml,O
/,O
m2,O
(,O
P,O
less,O
than,O
0.01,O
),O
1,O
h,O
after,O
ouabain,I-Entity
infusion,O
was,O
completed,O
.,O
No,O
significant,O
change,O
in,O
myocardial,O
oxygen,I-Entity
consumption,O
occurred,O
after,O
ouabain,I-Entity
administration,O
but,O
this,O
may,O
be,O
related,O
to,O
a,O
greater,O
decrease,O
in,O
mean,O
arterial,O
pressure,O
in,O
the,O
ouabain,I-Entity
patients,O
than,O
in,O
the,O
control,O
patients,O
.,O
We,O
conclude,O
that,O
in,O
patients,O
with,O
chronic,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
who,O
are,O
not,O
in,O
clinical,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
left,B-Entity
ventricular,I-Entity
end,I-Entity
-,I-Entity
diastolic,I-Entity
volume,I-Entity
falls,I-Entity
after,O
ouabain,I-Entity
administration,O
even,O
when,O
it,O
is,O
initially,O
normal,O
.,O
Though,O
this,O
fall,O
would,O
be,O
associated,O
with,O
a,O
decrease,O
in,O
wall,O
tension,O
",",O
and,O
",",O
therefore,O
",",O
of,O
myocardial,O
oxygen,I-Entity
consumption,O
",",O
it,O
may,O
not,O
be,O
of,O
sufficient,O
magnitude,O
to,O
prevent,O
a,O
net,O
increase,O
in,O
myocardial,O
oxygen,I-Entity
consumption,O
.,O
Prolongation,B-Entity
of,I-Entity
the,I-Entity
QT,I-Entity
interval,I-Entity
related,O
to,O
cisapride,I-Entity
-,O
diltiazem,I-Entity
interaction,O
.,O
Cisapride,I-Entity
",",O
a,O
cytochrome,O
P450,O
3A4,O
(,O
CYP3A4,O
),O
substrate,O
",",O
is,O
widely,O
prescribed,O
for,O
the,O
treatment,O
of,O
gastrointestinal,B-Entity
motility,I-Entity
disorders,I-Entity
.,O
Prolongation,B-Entity
of,I-Entity
QT,I-Entity
interval,I-Entity
",",O
torsades,B-Entity
de,I-Entity
pointes,I-Entity
",",O
and,O
sudden,B-Entity
cardiac,I-Entity
death,I-Entity
have,O
been,O
reported,O
after,O
concomitant,O
administration,O
with,O
erythromycin,I-Entity
or,O
azole,I-Entity
antifungal,O
agents,O
",",O
but,O
not,O
with,O
other,O
CYP3A4,O
inhibitors,O
.,O
A,O
possible,O
drug,O
interaction,O
occurred,O
in,O
a,O
45-year,O
-,O
old,O
woman,O
who,O
was,O
taking,O
cisapride,I-Entity
for,O
gastroesophageal,B-Entity
reflux,I-Entity
disorder,I-Entity
and,O
diltiazem,I-Entity
",",O
an,O
agent,O
that,O
has,O
inhibitory,O
effect,O
on,O
CYP3A4,O
",",O
for,O
hypertension,I-Entity
.,O
The,O
patient,O
was,O
in,O
near,O
syncope,I-Entity
and,O
had,O
QT,B-Entity
-,I-Entity
interval,I-Entity
prolongation,I-Entity
.,O
After,O
discontinuing,O
cisapride,I-Entity
",",O
the,O
QT,O
interval,O
returned,O
to,O
normal,O
and,O
symptoms,O
did,O
not,O
recur,O
.,O
We,O
suggest,O
that,O
caution,O
be,O
taken,O
when,O
cisapride,I-Entity
is,O
prescribed,O
with,O
any,O
potent,O
inhibitor,O
of,O
CYP3A4,O
",",O
including,O
diltiazem,I-Entity
.,O
Paclitaxel,I-Entity
combined,O
with,O
carboplatin,I-Entity
in,O
the,O
first,O
-,O
line,O
treatment,O
of,O
advanced,O
ovarian,B-Entity
cancer,I-Entity
.,O
In,O
a,O
phase,O
I,O
study,O
to,O
determine,O
the,O
maximum,O
tolerated,O
dose,O
of,O
paclitaxel,I-Entity
(,O
Taxol,I-Entity
;,O
Bristol,O
-,O
Myers,O
Squibb,O
Company,O
",",O
Princeton,O
",",O
NJ,O
),O
given,O
as,O
a,O
3-hour,O
infusion,O
in,O
combination,O
with,O
carboplatin,I-Entity
administered,O
every,O
21,O
days,O
to,O
women,O
with,O
advanced,O
ovarian,B-Entity
cancer,I-Entity
",",O
paclitaxel,I-Entity
doses,O
were,O
escalated,O
as,O
follows,O
:,O
level,O
1,O
",",O
135,O
mg,O
/,O
m2,O
;,O
level,O
2,O
",",O
160,O
mg,O
/,O
m2,O
;,O
level,O
3,O
",",O
185,O
mg,O
/,O
m2,O
;,O
and,O
level,O
"4,210",O
mg,O
/,O
m2,O
.,O
The,O
fixed,O
dose,O
of,O
carboplatin,I-Entity
at,O
levels,O
1,O
through,O
4,O
was,O
given,O
to,O
achieve,O
an,O
area,O
under,O
the,O
concentration,O
-,O
time,O
curve,O
(,O
AUC,O
),O
of,O
5,O
using,O
the,O
Calvert,O
formula,O
.,O
In,O
levels,O
5,O
and,O
6,O
the,O
carboplatin,I-Entity
dose,O
was,O
targeted,O
at,O
AUCs,O
of,O
6,O
and,O
7.5,O
",",O
respectively,O
",",O
combined,O
with,O
a,O
fixed,O
paclitaxel,I-Entity
dose,O
of,O
185,O
mg,O
/,O
m2,O
.,O
The,O
dose,O
-,O
limiting,O
toxicity,I-Entity
of,O
the,O
combination,O
was,O
myelosuppression,I-Entity
(,O
leukopenia,I-Entity
",",O
granulocytopenia,I-Entity
",",O
and,O
thrombocytopenia,I-Entity
),O
.,O
Neurotoxicity,I-Entity
was,O
largely,O
moderate,O
.,O
We,O
conclude,O
that,O
the,O
combination,O
of,O
paclitaxel,I-Entity
185,O
mg,O
/,O
m2,O
administered,O
as,O
a,O
3-hour,O
infusion,O
followed,O
immediately,O
by,O
a,O
1-hour,O
infusion,O
of,O
carboplatin,I-Entity
at,O
an,O
AUC,O
of,O
6,O
can,O
be,O
administered,O
safely,O
in,O
a,O
21-day,O
schedule,O
in,O
the,O
outpatient,O
setting,O
.,O
The,O
recommended,O
dose,O
for,O
phase,O
III,O
studies,O
is,O
paclitaxel,I-Entity
185,O
mg,O
/,O
m2,O
and,O
carboplatin,I-Entity
AUC,O
6,O
.,O
Treatment,O
of,O
tacrolimus,I-Entity
-,O
related,O
adverse,O
effects,O
by,O
conversion,O
to,O
cyclosporine,I-Entity
in,O
liver,O
transplant,O
recipients,O
.,O
When,O
tacrolimus,I-Entity
side,O
effects,O
persist,O
despite,O
dose,O
reduction,O
",",O
conversion,O
to,O
cyclosporine,I-Entity
-,O
based,O
immunosuppression,O
(,O
CyA,O
),O
is,O
necessary,O
.,O
We,O
characterized,O
tacrolimus,I-Entity
side,O
effects,O
that,O
warranted,O
discontinuation,O
of,O
the,O
drug,O
",",O
and,O
outcomes,O
after,O
conversion,O
.,O
Of,O
388,O
liver,O
recipients,O
who,O
received,O
tacrolimus,I-Entity
as,O
primary,O
immunosuppression,O
",",O
70,O
required,O
conversion,O
to,O
CyA.,O
We,O
recorded,O
indication,O
for,O
conversion,O
",",O
whether,O
conversion,O
was,O
early,O
or,O
late,O
after,O
transplantation,O
",",O
tacrolimus,I-Entity
dose,O
and,O
trough,O
blood,O
level,O
at,O
conversion,O
",",O
and,O
incidence,O
of,O
rejection,O
after,O
conversion,O
.,O
Indications,O
for,O
early,O
conversion,O
were,O
neurotoxicity,I-Entity
(,O
20,O
),O
",",O
(,B-Entity
insulin,I-Entity
-,I-Entity
dependent,I-Entity
),I-Entity
diabetes,I-Entity
mellitus,I-Entity
(,O
IDDM,I-Entity
),O
(,O
5,O
),O
",",O
nephrotoxicity,I-Entity
(,O
3,O
),O
",",O
gastrointestinal,B-Entity
(,I-Entity
GI,I-Entity
),I-Entity
toxicity,I-Entity
(,O
6,O
),O
",",O
and,O
cardiomyopathy,I-Entity
(,O
1,O
),O
",",O
and,O
for,O
late,O
conversion,O
were,O
neurotoxicity,I-Entity
(,O
15,O
),O
",",O
IDDM,I-Entity
(,O
12,O
),O
",",O
nephrotoxicity,I-Entity
(,O
3,O
),O
",",O
GI,B-Entity
toxicity,I-Entity
(,O
5,O
),O
",",O
hepatotoxicity,I-Entity
(,O
6,O
),O
",",O
post,B-Entity
-,I-Entity
transplant,I-Entity
lmphoproliferate,I-Entity
disease,I-Entity
(,O
PTLD,I-Entity
),O
(,O
2,O
),O
",",O
cardiomyopathy,I-Entity
(,O
1,O
),O
",",O
hemolytic,B-Entity
anemia,I-Entity
(,O
1,O
),O
",",O
and,O
pruritus,I-Entity
(,O
1,O
),O
.,O
When,O
tacrolimus,I-Entity
side,O
effects,O
are,O
unresponsive,O
to,O
dose,O
reduction,O
",",O
conversion,O
to,O
CyA,O
can,O
be,O
accomplished,O
safely,O
",",O
with,O
no,O
increased,O
risk,O
of,O
rejection,O
and,O
excellent,O
long,O
-,O
term,O
outcome,O
.,O
Relative,O
efficacy,O
and,O
toxicity,I-Entity
of,O
netilmicin,I-Entity
and,O
tobramycin,I-Entity
in,O
oncology,O
patients,O
.,O
We,O
prospectively,O
compared,O
the,O
efficacy,O
and,O
safety,O
of,O
netilmicin,B-Entity
sulfate,I-Entity
or,O
tobramycin,B-Entity
sulfate,I-Entity
in,O
conjunction,O
with,O
piperacillin,B-Entity
sodium,I-Entity
in,O
118,O
immunocompromised,O
patients,O
with,O
presumed,O
severe,O
infections,I-Entity
.,O
Nephrotoxicity,I-Entity
occurred,O
in,O
a,O
similar,O
proportion,O
in,O
patients,O
treated,O
with,O
netilmicin,I-Entity
and,O
tobramycin,I-Entity
(,O
17%,O
vs,O
11%,O
),O
.,O
Ototoxicity,I-Entity
occurred,O
in,O
four,O
(,O
9.5%,O
),O
of,O
42,O
netilmicin,I-Entity
and,O
piperacillin,I-Entity
and,O
in,O
12,O
(,O
22%,O
),O
of,O
54,O
tobramycin,I-Entity
and,O
piperacillin,I-Entity
-,O
treated,O
patients,O
.,O
Of,O
those,O
evaluated,O
with,O
posttherapy,O
audiograms,O
",",O
three,O
of,O
four,O
netilmicin,I-Entity
and,O
piperacillin,I-Entity
-,O
treated,O
patients,O
had,O
auditory,O
thresholds,O
return,O
to,O
baseline,O
compared,O
with,O
one,O
of,O
nine,O
tobramycin,I-Entity
and,O
piperacillin,I-Entity
-,O
treated,O
patients,O
.,O
The,O
number,O
of,O
greater,O
than,O
or,O
equal,O
to,O
15-dB,O
increases,O
in,O
auditory,O
threshold,O
as,O
a,O
proportion,O
of,O
total,O
greater,O
than,O
or,O
equal,O
to,O
15-dB,O
changes,O
(,O
increases,O
and,O
decreases,O
),O
was,O
significantly,O
lower,O
in,O
netilmicin,I-Entity
and,O
piperacillin-,I-Entity
vs,O
tobramycin,I-Entity
and,O
piperacillin,I-Entity
-,O
treated,O
patients,O
(,O
18,O
of,O
78,O
vs,O
67,O
of,O
115,O
),O
.,O
We,O
conclude,O
that,O
aminoglycoside,I-Entity
-,O
associated,O
ototoxicity,I-Entity
was,O
less,O
severe,O
and,O
more,O
often,O
reversible,O
with,O
netilmicin,I-Entity
than,O
with,O
tobramycin,I-Entity
.,O
Effect,O
of,O
prostaglandin,I-Entity
synthetase,O
inhibitors,O
on,O
experimentally,O
induced,O
convulsions,I-Entity
in,O
rats,O
.,O
To,O
investigate,O
the,O
relationship,O
of,O
prostaglandins,I-Entity
(,O
PGs,I-Entity
),O
to,O
seizure,I-Entity
induction,O
",",O
the,O
effects,O
of,O
six,O
PG,O
synthetase,O
inhibitors,O
on,O
convulsions,I-Entity
induced,O
by,O
flurothyl,I-Entity
",",O
picrotoxin,I-Entity
",",O
pentetrazol,I-Entity
(,O
PTZ,I-Entity
),O
",",O
electroshock,O
or,O
bicuculline,I-Entity
were,O
evaluated,O
.,O
Ibuprofen,I-Entity
",",O
sulindac,I-Entity
",",O
mefenamic,B-Entity
acid,I-Entity
",",O
and,O
low,O
dose,O
meclofenamic,B-Entity
acid,I-Entity
increased,O
the,O
latency,O
-,O
to,O
-,O
onset,O
in,O
the,O
flurothyl,I-Entity
and/or,O
PTZ,I-Entity
models,O
;,O
the,O
electroshock,O
",",O
picrotoxin,I-Entity
and,O
bicuculline,I-Entity
models,O
were,O
not,O
significantly,O
affected,O
by,O
any,O
of,O
the,O
pretreatment,O
agents,O
.,O
These,O
results,O
suggest,O
that,O
PGs,I-Entity
are,O
involved,O
in,O
the,O
mechanism(s,O
),O
underlying,O
fluorthyl-,I-Entity
and,O
PTZ,I-Entity
-,O
induced,O
convulsions,I-Entity
",",O
but,O
not,O
picrotoxin-,I-Entity
",",O
electroshock-,O
",",O
or,O
bicuculline,I-Entity
-,O
induced,O
convulsions,I-Entity
.,O
Angiotensin,O
-,O
converting,O
enzyme,O
(,O
ACE,O
),O
inhibitor,O
-,O
associated,O
angioedema,I-Entity
of,O
the,O
stomach,O
and,O
small,O
intestine,O
:,O
a,O
case,O
report,O
.,O
This,O
is,O
a,O
case,O
report,O
on,O
a,O
45-year,O
old,O
African,O
-,O
American,O
female,O
with,O
newly,O
diagnosed,O
hypertension,I-Entity
",",O
who,O
was,O
started,O
on,O
a,O
combination,O
pill,O
of,O
amlodipine,I-Entity
/,O
benazapril,I-Entity
10/5,O
mg,O
.,O
The,O
very,O
next,O
day,O
",",O
she,O
presented,O
at,O
the,O
emergency,O
room,O
(,O
ER,O
),O
with,O
abdominal,B-Entity
pain,I-Entity
",",O
nausea,I-Entity
and,O
vomiting,I-Entity
.,O
Angiotensin,O
-,O
converting,O
enzyme,O
inhibitor,O
(,O
ACEI)-induced,O
angioedema,I-Entity
was,O
suspected,O
",",O
and,O
anti,O
-,O
hypertensive,I-Entity
medications,O
were,O
discontinued,O
.,O
Her,O
symptoms,O
improved,O
within,O
the,O
next,O
24,O
hours,O
",",O
and,O
repeat,O
CT,O
after,O
72,O
hours,O
revealed,O
marked,O
improvement,O
in,O
stomach,O
and,O
small,O
bowel,O
thickening,O
and,O
resolution,O
of,O
ascites,I-Entity
.,O
The,O
recognition,O
of,O
angiotensin,I-Entity
-,O
converting,O
enzyme,O
(,O
ACE,O
),O
and,O
angiotensin,I-Entity
receptor,O
blocker,O
(,O
ARB,O
),O
intestinal,B-Entity
angioedema,I-Entity
constitutes,O
a,O
challenge,O
to,O
primary,O
care,O
physicians,O
",",O
internists,O
",",O
emergency,O
room,O
personal,O
and,O
surgeons,O
.,O
Valproic,B-Entity
acid,I-Entity
I,O
:,O
time,O
course,O
of,O
lipid,O
peroxidation,O
biomarkers,O
",",O
liver,B-Entity
toxicity,I-Entity
",",O
and,O
valproic,B-Entity
acid,I-Entity
metabolite,O
levels,O
in,O
rats,O
.,O
A,O
single,O
dose,O
of,O
valproic,B-Entity
acid,I-Entity
(,O
VPA,I-Entity
),O
",",O
which,O
is,O
a,O
widely,O
used,O
antiepileptic,O
drug,O
",",O
is,O
associated,O
with,O
oxidative,O
stress,O
in,O
rats,O
",",O
as,O
recently,O
demonstrated,O
by,O
elevated,O
levels,O
of,O
15-F(2t)-isoprostane,I-Entity
(,O
15-F(2t)-IsoP,I-Entity
),O
.,O
To,O
determine,O
whether,O
there,O
was,O
a,O
temporal,O
relationship,O
between,O
VPA,I-Entity
-,O
associated,O
oxidative,O
stress,O
and,O
hepatotoxicity,I-Entity
",",O
adult,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
treated,O
ip,O
with,O
VPA,I-Entity
(,O
500,O
mg,O
/,O
kg,O
),O
or,O
0.9%,O
saline,O
(,O
vehicle,O
),O
once,O
daily,O
for,O
2,O
",",O
4,O
",",O
7,O
",",O
10,O
",",O
or,O
14,O
days,O
.,O
Oxidative,O
stress,O
was,O
assessed,O
by,O
determining,O
plasma,O
and,O
liver,O
levels,O
of,O
15-F(2t)-IsoP,I-Entity
",",O
lipid,B-Entity
hydroperoxides,I-Entity
(,O
LPO,I-Entity
),O
",",O
and,O
thiobarbituric,B-Entity
acid,I-Entity
reactive,I-Entity
substances,I-Entity
(,O
TBARs,I-Entity
),O
.,O
Plasma,O
and,O
liver,O
15-F(2t)-IsoP,I-Entity
were,O
elevated,O
and,O
reached,O
a,O
plateau,O
after,O
day,O
2,O
of,O
VPA,I-Entity
treatment,O
compared,O
to,O
control,O
.,O
Liver,O
LPO,I-Entity
levels,O
were,O
not,O
elevated,O
until,O
day,O
7,O
of,O
treatment,O
(,O
1.8-fold,O
versus,O
control,O
",",O
p,O
<,O
0.05,O
),O
.,O
Liver,O
and,O
plasma,O
TBARs,I-Entity
were,O
not,O
increased,O
until,O
14,O
days,O
(,O
2-fold,O
vs.,O
control,O
",",O
p,O
<,O
0.05,O
),O
.,O
Liver,B-Entity
toxicity,I-Entity
was,O
evaluated,O
based,O
on,O
serum,O
levels,O
of,O
alpha,O
-,O
glutathione,I-Entity
S,O
-,O
transferase,O
(,O
alpha,O
-,O
GST,O
),O
and,O
by,O
histology,O
.,O
Serum,O
alpha,O
-,O
GST,O
levels,O
were,O
significantly,O
elevated,O
by,O
day,O
4,O
",",O
which,O
corresponded,O
to,O
hepatotoxicity,I-Entity
as,O
shown,O
by,O
the,O
increasing,O
incidence,O
of,O
inflammation,I-Entity
of,O
the,O
liver,O
capsule,O
",",O
necrosis,I-Entity
",",O
and,O
steatosis,I-Entity
throughout,O
the,O
study,O
.,O
The,O
liver,O
levels,O
of,O
beta,O
-,O
oxidation,O
metabolites,O
of,O
VPA,I-Entity
were,O
decreased,O
by,O
day,O
14,O
",",O
while,O
the,O
levels,O
of,O
4-ene,B-Entity
-,I-Entity
VPA,I-Entity
and,O
(,O
"E)-2,4-diene",B-Entity
-,I-Entity
VPA,I-Entity
were,O
not,O
elevated,O
throughout,O
the,O
study,O
.,O
Overall,O
",",O
these,O
findings,O
indicate,O
that,O
VPA,I-Entity
treatment,O
results,O
in,O
oxidative,O
stress,O
",",O
as,O
measured,O
by,O
levels,O
of,O
15-F(2t)-IsoP,I-Entity
",",O
which,O
precedes,O
the,O
onset,O
of,O
necrosis,I-Entity
",",O
steatosis,I-Entity
",",O
and,O
elevated,O
levels,O
of,O
serum,O
alpha,O
-,O
GST,O
.,O
Pheochromocytoma,I-Entity
unmasked,O
by,O
amisulpride,I-Entity
and,O
tiapride,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
describe,O
the,O
unmasking,O
of,O
pheochromocytoma,I-Entity
in,O
a,O
patient,O
treated,O
with,O
amisulpride,I-Entity
and,O
tiapride,I-Entity
.,O
A,O
42-year,O
-,O
old,O
white,O
man,O
developed,O
acute,O
hypertension,I-Entity
with,O
severe,O
headache,I-Entity
and,O
vomiting,I-Entity
2,O
hours,O
after,O
the,O
first,O
doses,O
of,O
amisulpride,I-Entity
100,O
mg,O
and,O
tiapride,I-Entity
100,O
mg,O
.,O
Both,O
drugs,O
were,O
immediately,O
discontinued,O
",",O
and,O
the,O
patient,O
recovered,O
after,O
subsequent,O
nicardipine,I-Entity
and,O
verapamil,I-Entity
treatment,O
.,O
Abdominal,O
ultrasound,O
showed,O
an,O
adrenal,O
mass,O
",",O
and,O
postoperative,O
histologic,O
examination,O
confirmed,O
the,O
diagnosis,O
of,O
pheochromocytoma,I-Entity
.,O
DISCUSSION,O
:,O
Drug,O
-,O
induced,O
symptoms,O
of,O
pheochromocytoma,I-Entity
are,O
often,O
associated,O
with,O
the,O
use,O
of,O
substituted,O
benzamide,I-Entity
drugs,O
",",O
but,O
the,O
underlying,O
mechanism,O
is,O
unknown,O
.,O
In,O
our,O
case,O
",",O
use,O
of,O
the,O
Naranjo,O
probability,O
scale,O
indicated,O
a,O
possible,O
relationship,O
between,O
the,O
hypertensive,I-Entity
crisis,O
and,O
amisulpride,I-Entity
and,O
tiapride,I-Entity
therapy,O
.,O
As,O
of,O
March,O
24,O
",",O
2005,O
",",O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
amisulpride-,I-Entity
and,O
tiapride,I-Entity
-,O
induced,O
hypertensive,I-Entity
crisis,O
in,O
a,O
patient,O
with,O
pheochromocytoma,I-Entity
.,O
Physicians,O
and,O
other,O
healthcare,O
professionals,O
should,O
be,O
aware,O
of,O
this,O
potential,O
adverse,O
effect,O
of,O
tiapride,I-Entity
and,O
amisulpride,I-Entity
.,O
Quantitative,O
drug,O
levels,O
in,O
stimulant,O
psychosis,I-Entity
:,O
relationship,O
to,O
symptom,O
severity,O
",",O
catecholamines,I-Entity
and,O
hyperkinesia,I-Entity
.,O
To,O
examine,O
the,O
relationship,O
between,O
quantitative,O
stimulant,O
drug,O
levels,O
",",O
catecholamines,I-Entity
",",O
and,O
psychotic,B-Entity
symptoms,I-Entity
",",O
nineteen,O
patients,O
in,O
a,O
psychiatric,I-Entity
emergency,O
service,O
with,O
a,O
diagnosis,O
of,O
amphetamine-,I-Entity
or,O
cocaine,I-Entity
-,O
induced,O
psychosis,I-Entity
were,O
interviewed,O
",",O
and,O
plasma,O
and,O
urine,O
were,O
collected,O
for,O
quantitative,O
assays,O
of,O
stimulant,O
drug,O
and,O
catecholamine,I-Entity
metabolite,O
levels,O
.,O
Methamphetamine,I-Entity
or,O
amphetamine,I-Entity
levels,O
were,O
related,O
to,O
several,O
psychopathology,O
scores,O
and,O
the,O
global,O
hyperkinesia,I-Entity
rating,O
.,O
HVA,O
levels,O
were,O
related,O
to,O
global,O
hyperkinesia,I-Entity
but,O
not,O
to,O
psychopathology,O
ratings,O
.,O
Although,O
many,O
other,O
factors,O
such,O
as,O
sensitization,O
may,O
play,O
a,O
role,O
",",O
intensity,O
of,O
stimulant,O
-,O
induced,O
psychotic,B-Entity
symptoms,I-Entity
and,O
stereotypies,I-Entity
appears,O
to,O
be,O
at,O
least,O
in,O
part,O
dose,O
-,O
related,O
.,O
Delayed,O
asystolic,I-Entity
cardiac,B-Entity
arrest,I-Entity
after,O
diltiazem,I-Entity
overdose,I-Entity
;,O
resuscitation,O
with,O
high,O
dose,O
intravenous,O
calcium,I-Entity
.,O
A,O
51,O
year,O
old,O
man,O
took,O
a,O
mixed,O
overdose,I-Entity
including,O
1.8,O
-,O
3.6,O
g,O
of,O
diltiazem,I-Entity
",",O
paracetamol,I-Entity
",",O
aspirin,I-Entity
",",O
isosorbide,I-Entity
nitrate,I-Entity
",",O
and,O
alcohol,I-Entity
.,O
He,O
initially,O
presented,O
to,O
hospital,O
after,O
six,O
hours,O
with,O
mild,O
hypotension,I-Entity
and,O
was,O
treated,O
with,O
activated,O
charcoal,O
and,O
intravenous,O
fluids,O
.,O
Eighteen,O
hours,O
after,O
the,O
overdose,I-Entity
he,O
had,O
two,O
generalised,O
tonic,B-Entity
-,I-Entity
clonic,I-Entity
seizures,I-Entity
.,O
The,O
patient,O
remained,O
unresponsive,O
with,O
junctional,O
bradycardia,I-Entity
",",O
unrecordable,O
blood,O
pressure,O
",",O
and,O
then,O
became,O
asystolic,I-Entity
.,O
He,O
was,O
resuscitated,O
with,O
high,O
dose,O
(,O
13.5,O
g,O
),O
intravenous,O
calcium,I-Entity
and,O
adrenaline,I-Entity
(,O
epinephrine,I-Entity
),O
.,O
This,O
case,O
suggests,O
there,O
is,O
a,O
role,O
for,O
aggressive,O
high,O
dose,O
intravenous,O
calcium,I-Entity
therapy,O
in,O
severe,O
diltiazem,I-Entity
overdose,I-Entity
",",O
particularly,O
with,O
the,O
onset,O
of,O
asystole,I-Entity
.,O
It,O
should,O
be,O
considered,O
early,O
in,O
cases,O
of,O
cardiac,B-Entity
arrest,I-Entity
after,O
diltiazem,I-Entity
overdose,I-Entity
.,O
The,O
case,O
also,O
highlights,O
the,O
problems,O
with,O
delayed,O
toxicity,I-Entity
when,O
whole,O
bowel,O
irrigation,O
is,O
not,O
administered,O
.,O
Renal,B-Entity
papillary,I-Entity
necrosis,I-Entity
due,O
to,O
naproxen,I-Entity
.,O
A,O
31-year,O
-,O
old,O
man,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
",",O
who,O
had,O
previously,O
been,O
treated,O
with,O
sulindac,I-Entity
",",O
fenoprofen,B-Entity
calcium,I-Entity
",",O
high,O
dose,O
salicylates,I-Entity
and,O
gold,I-Entity
salts,O
",",O
developed,O
renal,B-Entity
papillary,I-Entity
necrosis,I-Entity
(,O
RPN,I-Entity
),O
4,O
months,O
after,O
institution,O
of,O
naproxen,I-Entity
therapy,O
.,O
No,O
other,O
factor,O
predisposing,O
to,O
RPN,I-Entity
could,O
be,O
discovered,O
.,O
Sulindac,I-Entity
was,O
substituted,O
for,O
naproxen,I-Entity
and,O
no,O
further,O
adverse,O
renal,O
effects,O
occurred,O
over,O
the,O
next,O
12,O
months,O
.,O
We,O
review,O
previous,O
reports,O
linking,O
RPN,I-Entity
to,O
antiinflammatory,O
drug,O
use,O
and,O
discuss,O
possible,O
advantages,O
of,O
sulindac,I-Entity
in,O
patients,O
who,O
have,O
experienced,O
renal,B-Entity
toxicity,I-Entity
from,O
other,O
antiinflammatory,O
agents,O
.,O
Adverse,O
interaction,O
between,O
beta,B-Entity
-,I-Entity
adrenergic,I-Entity
blocking,I-Entity
drugs,I-Entity
and,O
verapamil,I-Entity
--,O
report,O
of,O
three,O
cases,O
.,O
Three,O
patients,O
with,O
ischaemic,B-Entity
heart,I-Entity
disease,I-Entity
developed,O
profound,O
cardiac,B-Entity
failure,I-Entity
",",O
hypotension,I-Entity
and,O
bradycardia,I-Entity
during,O
combined,O
therapy,O
with,O
verapamil,I-Entity
and,O
beta,B-Entity
-,I-Entity
adrenergic,I-Entity
blocking,I-Entity
drugs,I-Entity
.,O
Simultaneously,O
administration,O
of,O
beta,B-Entity
-,I-Entity
adrenergic,I-Entity
blocking,I-Entity
drugs,I-Entity
and,O
verapamil,I-Entity
may,O
result,O
in,O
profound,O
adverse,O
interactions,O
and,O
should,O
only,O
be,O
administered,O
with,O
great,O
caution,O
.,O
Adverse,O
reactions,O
to,O
bendrofluazide,I-Entity
and,O
propranolol,I-Entity
for,O
the,O
treatment,O
of,O
mild,O
hypertension,I-Entity
.,O
Report,O
of,O
Medical,O
Research,O
Council,O
Working,O
Party,O
on,O
Mild,O
to,O
Moderate,O
Hypertension,I-Entity
.,O
Participants,O
in,O
the,O
Medical,O
Research,O
Council,O
treatment,O
trial,O
for,O
mild,O
hypertension,I-Entity
are,O
randomly,O
allocated,O
to,O
one,O
of,O
four,O
treatment,O
groups,O
:,O
bendrofluazide,I-Entity
",",O
propranolol,I-Entity
",",O
or,O
a,O
placebo,O
for,O
either,O
of,O
these,O
drugs,O
.,O
The,O
results,O
show,O
an,O
association,O
between,O
bendrofluazide,I-Entity
treatment,O
and,O
impotence,I-Entity
",",O
and,O
impotence,I-Entity
also,O
occurred,O
more,O
frequently,O
in,O
patients,O
taking,O
propranolol,I-Entity
than,O
in,O
those,O
taking,O
placebos,O
.,O
Other,O
adverse,O
reactions,O
significantly,O
linked,O
with,O
active,O
drugs,O
include,O
impaired,B-Entity
glucose,I-Entity
tolerance,I-Entity
in,O
men,O
and,O
women,O
and,O
gout,I-Entity
in,O
men,O
",",O
associated,O
with,O
bendrofluazide,I-Entity
treatment,O
",",O
and,O
Raynaud,B-Entity
's,I-Entity
phenomenon,I-Entity
and,O
dyspnoea,I-Entity
in,O
men,O
and,O
women,O
taking,O
propranolol,I-Entity
.,O
No,O
corneal,B-Entity
disease,I-Entity
is,O
known,O
to,O
have,O
occurred,O
in,O
the,O
propranolol,I-Entity
group,O
.,O
Mean,O
serum,O
potassium,I-Entity
level,O
fell,O
",",O
and,O
urea,I-Entity
and,O
uric,B-Entity
acid,I-Entity
levels,O
rose,O
",",O
in,O
men,O
and,O
women,O
taking,O
bendrofluazide,I-Entity
.,O
In,O
the,O
propranolol,I-Entity
group,O
",",O
serum,O
potassium,I-Entity
and,O
uric,B-Entity
acid,I-Entity
levels,O
rose,O
in,O
both,O
sexes,O
",",O
but,O
the,O
urea,I-Entity
level,O
rose,O
significantly,O
in,O
women,O
only,O
.,O
Dexmedetomidine,I-Entity
and,O
cardiac,O
protection,O
for,O
non,O
-,O
cardiac,O
surgery,O
:,O
a,O
meta,O
-,O
analysis,O
of,O
randomised,O
controlled,O
trials,O
.,O
We,O
conducted,O
a,O
systematic,O
review,O
of,O
the,O
effects,O
of,O
dexmedetomidine,I-Entity
on,O
cardiac,O
outcomes,O
following,O
non,O
-,O
cardiac,O
surgery,O
.,O
We,O
included,O
prospective,O
",",O
randomised,O
peri,O
-,O
operative,O
studies,O
of,O
dexmedetomidine,I-Entity
that,O
reported,O
mortality,O
",",O
cardiac,O
morbidity,O
or,O
adverse,O
drug,O
events,O
.,O
Dexmedetomidine,I-Entity
was,O
associated,O
with,O
a,O
trend,O
towards,O
improved,O
cardiac,O
outcomes,O
;,O
all,O
-,O
cause,O
mortality,O
(,O
OR,O
0.27,O
",",O
95%,O
CI,O
0.01,O
-,O
7.13,O
",",O
p,O
=,O
0.44,O
),O
",",O
non,O
-,O
fatal,O
myocardial,B-Entity
infarction,I-Entity
(,O
OR,O
0.26,O
",",O
95%,O
CI,O
0.04,O
-,O
1.60,O
",",O
p,O
=,O
0.14,O
),O
",",O
and,O
myocardial,B-Entity
ischaemia,I-Entity
(,O
OR,O
0.65,O
",",O
95%,O
CI,O
0.26,O
-,O
1.63,O
",",O
Peri,O
-,O
operative,O
hypotension,I-Entity
(,O
26%,O
",",O
OR,O
3.80,O
",",O
95%,O
CI,O
1.91,O
-,O
7.54,O
",",O
p,O
=,O
0.0001,O
),O
and,O
bradycardia,I-Entity
(,O
17%,O
",",O
OR,O
5.45,O
",",O
95%,O
CI,O
2.98,O
-,O
9.95,O
",",O
p,O
An,O
anticholinergic,O
did,O
not,O
reduce,O
the,O
incidence,O
of,O
bradycardia,I-Entity
(,O
p,O
=,O
0.43,O
),O
.,O
A,O
randomised,O
placebo,O
-,O
controlled,O
trial,O
of,O
dexmedetomidine,I-Entity
is,O
warranted,O
.,O
Differential,O
diagnosis,O
of,O
high,O
serum,O
creatine,I-Entity
kinase,O
levels,O
in,O
systemic,B-Entity
lupus,I-Entity
erythematosus,I-Entity
.,O
We,O
report,O
the,O
clinical,O
and,O
bioptic,O
findings,O
for,O
a,O
57-year,O
-,O
old,O
woman,O
with,O
severe,O
chloroquine,I-Entity
-,O
induced,O
myopathy,I-Entity
.,O
Since,O
1989,O
",",O
she,O
had,O
been,O
suffering,O
from,O
systemic,B-Entity
lupus,I-Entity
erythematosus,I-Entity
(,O
SLE,I-Entity
),O
with,O
renal,B-Entity
involvement,I-Entity
and,O
undergone,O
periods,O
of,O
treatment,O
with,O
azathioprine,I-Entity
and,O
cyclophosphamide,I-Entity
.,O
Additional,O
therapy,O
with,O
chloroquine,I-Entity
(,O
CQ,I-Entity
),O
was,O
started,O
because,O
of,O
arthralgia,I-Entity
.,O
At,O
the,O
same,O
time,O
",",O
slightly,O
increased,O
creatine,I-Entity
kinase,O
(,O
CK,O
),O
Myositis,I-Entity
was,O
suspected,O
",",O
and,O
the,O
patient,O
was,O
treated,O
with,O
steroids,I-Entity
.,O
The,O
CK,O
increase,O
persisted,O
",",O
however,O
",",O
and,O
she,O
developed,O
progressive,O
muscular,B-Entity
weakness,I-Entity
and,O
muscular,B-Entity
atrophy,I-Entity
.,O
The,O
neurological,O
and,O
electrophysiological,O
findings,O
were,O
not,O
typical,O
of,O
myositis,I-Entity
.,O
Thus,O
",",O
muscle,O
biopsy,O
of,O
the,O
deltoid,O
muscle,O
was,O
performed,O
in,O
order,O
to,O
exclude,O
polymyositis,I-Entity
or,O
toxic,O
myopathy,I-Entity
.,O
As,O
it,O
revealed,O
chloroquine,I-Entity
-,O
induced,O
myopathy,I-Entity
",",O
medication,O
was,O
stopped,O
.,O
Discriminating,O
between,O
primary,O
SLE,I-Entity
-,O
induced,O
affection,B-Entity
of,I-Entity
the,I-Entity
musculoskeletal,I-Entity
system,I-Entity
and,O
drug,O
-,O
induced,O
side,O
effects,O
is,O
important,O
for,O
appropriate,O
treatment,O
of,O
SLE,I-Entity
patients,O
.,O
Intravenous,O
ribavirin,I-Entity
treatment,O
for,O
severe,O
adenovirus,B-Entity
disease,I-Entity
in,O
immunocompromised,O
children,O
.,O
The,O
incidence,O
of,O
severe,O
adenovirus,B-Entity
disease,I-Entity
in,O
pediatrics,O
is,O
increasing,O
in,O
association,O
with,O
growing,O
numbers,O
of,O
immunocompromised,O
children,O
",",O
where,O
case,O
fatality,O
rates,O
as,O
high,O
as,O
50%,O
to,O
80%,O
have,O
been,O
reported,O
.,O
There,O
are,O
no,O
approved,O
antiviral,O
agents,O
with,O
proven,O
efficacy,O
for,O
the,O
treatment,O
of,O
severe,O
adenovirus,B-Entity
disease,I-Entity
",",O
nor,O
are,O
there,O
any,O
prospective,O
randomized,O
",",O
controlled,O
trials,O
of,O
potentially,O
useful,O
anti,O
-,O
adenovirus,O
therapies,O
.,O
Apparent,O
clinical,O
success,O
in,O
the,O
treatment,O
of,O
severe,O
adenovirus,B-Entity
disease,I-Entity
is,O
limited,O
to,O
a,O
few,O
case,O
reports,O
and,O
small,O
series,O
.,O
Experience,O
is,O
greatest,O
with,O
intravenous,O
ribavirin,I-Entity
and,O
cidofovir,I-Entity
.,O
Ribavirin,I-Entity
",",O
a,O
guanosine,I-Entity
analogue,O
",",O
has,O
broad,O
antiviral,O
activity,O
against,O
both,O
RNA,O
and,O
DNA,O
viruses,O
",",O
including,O
documented,O
activity,O
against,O
adenovirus,O
in,O
vitro,O
.,O
Ribavirin,I-Entity
is,O
licensed,O
in,O
aerosol,O
form,O
for,O
the,O
treatment,O
of,O
respiratory,B-Entity
syncytial,I-Entity
virus,I-Entity
infection,I-Entity
",",O
and,O
orally,O
in,O
combination,O
with,O
interferon,O
to,O
treat,O
hepatitis,B-Entity
C.,I-Entity
Intravenous,O
ribavirin,I-Entity
is,O
the,O
treatment,O
of,O
choice,O
for,O
infection,B-Entity
with,I-Entity
hemorrhagic,I-Entity
fever,I-Entity
viruses,I-Entity
.,O
The,O
most,O
common,O
adverse,O
effect,O
of,O
intravenous,O
ribavirin,I-Entity
is,O
reversible,O
mild,O
anemia,I-Entity
.,O
The,O
use,O
of,O
cidofovir,I-Entity
in,O
severe,O
adenovirus,B-Entity
infection,I-Entity
has,O
been,O
limited,O
by,O
adverse,O
effects,O
",",O
the,O
most,O
significant,O
of,O
which,O
is,O
nephrotoxicity,I-Entity
.,O
OBJECTIVE,O
:,O
We,O
report,O
our,O
experience,O
with,O
intravenous,O
ribavirin,I-Entity
therapy,O
for,O
severe,O
adenovirus,B-Entity
disease,I-Entity
in,O
a,O
series,O
of,O
immunocompromised,O
children,O
and,O
review,O
the,O
literature,O
.,O
:,O
We,O
retrospectively,O
reviewed,O
the,O
medical,O
records,O
of,O
5,O
children,O
treated,O
with,O
intravenous,O
ribavirin,I-Entity
for,O
documented,O
severe,O
adenovirus,B-Entity
disease,I-Entity
.,O
Two,O
patients,O
developed,O
adenovirus,O
hemorrhagic,B-Entity
cystitis,I-Entity
after,O
cardiac,O
and,O
bone,O
marrow,O
transplants,O
",",O
respectively,O
.,O
The,O
bone,O
marrow,O
transplant,O
patient,O
also,O
received,O
intravenous,O
cidofovir,I-Entity
for,O
progressive,O
disseminated,O
disease,O
.,O
An,O
additional,O
3,O
children,O
developed,O
adenovirus,B-Entity
pneumonia,I-Entity
;,O
2,O
were,O
neonates,O
",",O
1,O
of,O
whom,O
had,O
partial,O
DiGeorge,B-Entity
syndrome,I-Entity
.,O
Intravenous,O
ribavirin,I-Entity
was,O
administered,O
on,O
a,O
compassionate,O
-,O
use,O
protocol,O
.,O
RESULTS,O
:,O
Complete,O
clinical,O
recovery,O
followed,O
later,O
by,O
viral,O
clearance,O
was,O
observed,O
in,O
2,O
children,O
:,O
the,O
cardiac,O
transplant,O
recipient,O
with,O
adenovirus,O
hemorrhagic,B-Entity
cystitis,I-Entity
and,O
the,O
immunocompetent,O
neonate,O
with,O
adenovirus,B-Entity
pneumonia,I-Entity
.,O
The,O
remaining,O
3,O
children,O
died,O
of,O
adenovirus,B-Entity
disease,I-Entity
.,O
Intravenous,O
ribavirin,I-Entity
therapy,O
was,O
well,O
tolerated,O
.,O
Use,O
of,O
cidofovir,I-Entity
in,O
1,O
child,O
was,O
associated,O
with,O
progressive,B-Entity
renal,I-Entity
failure,I-Entity
and,O
neutropenia,I-Entity
.,O
Our,O
series,O
of,O
patients,O
is,O
representative,O
of,O
the,O
spectrum,O
of,O
immunocompromised,O
children,O
at,O
greatest,O
risk,O
for,O
severe,O
adenovirus,B-Entity
disease,I-Entity
",",O
namely,O
solid,O
-,O
organ,O
and,O
bone,O
marrow,O
transplant,O
recipients,O
",",O
neonates,O
",",O
and,O
children,O
with,O
immunodeficiency,I-Entity
.,O
Although,O
intravenous,O
ribavirin,I-Entity
was,O
not,O
effective,O
for,O
all,O
children,O
with,O
severe,O
adenovirus,B-Entity
disease,I-Entity
in,O
this,O
series,O
or,O
in,O
the,O
literature,O
",",O
therapy,O
is,O
unlikely,O
to,O
be,O
of,O
benefit,O
if,O
begun,O
late,O
in,O
the,O
course,O
of,O
the,O
infection,I-Entity
.,O
Early,O
identification,O
",",O
eg,O
by,O
polymerase,O
chain,O
reaction,O
of,O
those,O
patients,O
at,O
risk,O
of,O
disseminated,O
adenovirus,B-Entity
disease,I-Entity
may,O
permit,O
earlier,O
antiviral,O
treatment,O
and,O
better,O
evaluation,O
of,O
therapeutic,O
response,O
.,O
Two,O
of,O
5,O
children,O
with,O
severe,O
adenovirus,B-Entity
disease,I-Entity
treated,O
with,O
intravenous,O
ribavirin,I-Entity
recovered,O
.,O
The,O
availability,O
of,O
newer,O
rapid,O
diagnostic,O
techniques,O
",",O
such,O
as,O
polymerase,O
chain,O
reaction,O
",",O
may,O
make,O
earlier,O
",",O
more,O
effective,O
treatment,O
of,O
adenovirus,B-Entity
infection,I-Entity
possible,O
.,O
Given,O
the,O
seriousness,O
and,O
increasing,O
prevalence,O
of,O
adenovirus,B-Entity
disease,I-Entity
in,O
certain,O
hosts,O
",",O
especially,O
children,O
",",O
a,O
large,O
",",O
multicenter,O
clinical,O
trial,O
of,O
potentially,O
useful,O
anti,O
-,O
adenoviral,O
therapies,O
",",O
such,O
as,O
intravenous,O
ribavirin,I-Entity
",",O
is,O
clearly,O
required,O
to,O
demonstrate,O
the,O
most,O
effective,O
and,O
least,O
toxic,O
therapy,O
.,O
Hepatotoxicity,I-Entity
of,O
amiodarone,I-Entity
.,O
Amiodarone,I-Entity
has,O
proved,O
very,O
effective,O
in,O
the,O
treatment,O
of,O
otherwise,O
resistant,O
cardiac,O
tachyarrhythmias,I-Entity
.,O
The,O
use,O
of,O
amiodarone,I-Entity
has,O
",",O
however,O
",",O
been,O
limited,O
due,O
to,O
its,O
serious,O
side,O
-,O
effects,O
.,O
A,O
patient,O
with,O
cholestatic,B-Entity
hepatitis,I-Entity
due,O
to,O
amiodarone,I-Entity
treatment,O
is,O
presented,O
below,O
and,O
a,O
review,O
of,O
the,O
hepatotoxicity,I-Entity
of,O
amiodarone,I-Entity
is,O
given,O
.,O
It,O
is,O
concluded,O
that,O
solid,O
evidence,O
exists,O
of,O
hepatic,B-Entity
injury,I-Entity
due,O
to,O
amiodarone,I-Entity
treatment,O
",",O
including,O
steatosis,I-Entity
",",O
alterations,O
resembling,O
alcoholic,B-Entity
hepatitis,I-Entity
",",O
cholestatic,B-Entity
hepatitis,I-Entity
and,O
micronodular,O
cirrhosis,B-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
.,O
Patients,O
receiving,O
amiodarone,I-Entity
should,O
be,O
regularly,O
screened,O
with,O
respect,O
to,O
hepatic,O
enzyme,O
levels,O
.,O
Therapy,O
should,O
be,O
discontinued,O
on,O
the,O
suspicion,O
of,O
cholestatic,B-Entity
injury,I-Entity
or,O
hepatomegaly,I-Entity
.,O
Catalepsy,I-Entity
induced,O
by,O
combinations,O
of,O
ketamine,I-Entity
and,O
morphine,I-Entity
:,O
potentiation,O
",",O
antagonism,O
",",O
tolerance,O
and,O
cross,O
-,O
tolerance,O
in,O
the,O
rat,O
.,O
Previous,O
studies,O
demonstrated,O
that,O
both,O
ketamine,I-Entity
and,O
morphine,I-Entity
induced,O
analgesia,I-Entity
and,O
catalepsy,I-Entity
in,O
the,O
rat,O
.,O
Pre,O
-,O
treatment,O
with,O
ketamine,I-Entity
produced,O
cross,O
-,O
tolerance,O
to,O
morphine,I-Entity
",",O
whereas,O
pretreatment,O
with,O
morphine,I-Entity
did,O
not,O
induce,O
cross,O
-,O
tolerance,O
to,O
ketamine,I-Entity
but,O
rather,O
augmented,O
the,O
cataleptic,I-Entity
response,O
;,O
this,O
augmentation,O
was,O
attributed,O
to,O
residual,O
morphine,I-Entity
in,O
the,O
brain,O
.,O
The,O
present,O
studies,O
explored,O
the,O
duration,O
of,O
the,O
loss,O
of,O
righting,O
reflex,O
induced,O
by,O
sub,O
-,O
effective,O
doses,O
of,O
ketamine,I-Entity
and,O
morphine,I-Entity
",",O
administered,O
simultaneously,O
.,O
There,O
was,O
mutual,O
potentiation,O
between,O
sub,O
-,O
effective,O
doses,O
of,O
ketamine,I-Entity
and,O
morphine,I-Entity
",",O
but,O
sub,O
-,O
effective,O
doses,O
of,O
ketamine,I-Entity
partly,O
antagonized,O
fully,O
-,O
effective,O
doses,O
of,O
morphine,I-Entity
.,O
Latency,O
to,O
the,O
loss,O
of,O
righting,O
reflex,O
",",O
rigidity,I-Entity
and,O
behavior,O
on,O
recovery,O
",",O
reflected,O
the,O
relative,O
predominance,O
of,O
ketamine,I-Entity
or,O
morphine,I-Entity
in,O
each,O
combination,O
.,O
Naloxone,I-Entity
inhibited,O
the,O
induced,O
cataleptic,I-Entity
effects,O
.,O
The,O
degree,O
and,O
time,O
course,O
of,O
development,O
of,O
tolerance,O
to,O
daily,O
administration,O
of,O
sub,O
-,O
effective,O
dose,O
combinations,O
of,O
ketamine,I-Entity
and,O
morphine,I-Entity
were,O
similar,O
.,O
Rats,O
",",O
tolerant,O
to,O
ketamine,I-Entity
-,O
dominant,O
combinations,O
",",O
were,O
cross,O
-,O
tolerant,O
to,O
both,O
drugs,O
",",O
while,O
those,O
tolerant,O
to,O
morphine,I-Entity
-,O
dominant,O
combinations,O
were,O
cross,O
-,O
tolerant,O
to,O
morphine,I-Entity
but,O
showed,O
either,O
no,O
cross,O
-,O
tolerance,O
or,O
an,O
augmented,O
response,O
to,O
ketamine,I-Entity
.,O
While,O
the,O
mutual,O
potentiation,O
",",O
antagonism,O
and,O
tolerance,O
suggest,O
common,O
mechanisms,O
for,O
the,O
induced,O
catalepsy,I-Entity
",",O
differences,O
in,O
latency,O
",",O
rigidity,I-Entity
and,O
behavior,O
",",O
asymmetry,O
of,O
cross,O
-,O
tolerance,O
and,O
a,O
widely,O
-,O
different,O
ID50,O
for,O
naloxone,I-Entity
would,O
argue,O
against,O
an,O
action,O
at,O
a,O
single,O
opioid,O
site,O
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
in,O
patients,O
with,O
AIDS,I-Entity
on,O
tenofovir,I-Entity
while,O
receiving,O
prolonged,O
vancomycin,I-Entity
course,O
for,O
osteomyelitis,I-Entity
.,O
Renal,B-Entity
failure,I-Entity
developed,O
after,O
a,O
prolonged,O
course,O
of,O
vancomycin,I-Entity
therapy,O
in,O
2,O
patients,O
who,O
were,O
receiving,O
tenofovir,B-Entity
disoproxil,I-Entity
fumarate,I-Entity
as,O
part,O
of,O
an,O
antiretroviral,O
regimen,O
.,O
Tenofovir,I-Entity
has,O
been,O
implicated,O
in,O
the,O
development,O
of,O
Fanconi,B-Entity
syndrome,I-Entity
and,O
renal,B-Entity
insufficiency,I-Entity
because,O
of,O
its,O
effects,O
on,O
the,O
proximal,O
renal,O
tubule,O
.,O
Vancomycin,I-Entity
nephrotoxicity,I-Entity
is,O
infrequent,O
but,O
may,O
result,O
from,O
coadministration,O
with,O
a,O
nephrotoxic,I-Entity
agent,O
.,O
Clinicians,O
should,O
be,O
aware,O
that,O
tenofovir,I-Entity
may,O
raise,O
the,O
risk,O
of,O
renal,B-Entity
failure,I-Entity
during,O
prolonged,O
administration,O
of,O
vancomycin,I-Entity
.,O
Delayed,O
leukoencephalopathy,I-Entity
with,O
stroke,I-Entity
-,O
like,O
presentation,O
in,O
chemotherapy,O
recipients,O
.,O
A,O
transient,O
leukoencephalopathy,I-Entity
mimicking,O
cerebrovascular,B-Entity
accident,I-Entity
has,O
been,O
described,O
as,O
a,O
complication,O
of,O
chemotherapy,O
",",O
most,O
commonly,O
in,O
recipients,O
of,O
intrathecal,O
methotrexate,I-Entity
for,O
childhood,O
leukaemia,I-Entity
.,O
METHODS,O
:,O
We,O
reviewed,O
the,O
medical,O
literature,O
for,O
single,O
reports,O
and,O
case,O
series,O
of,O
patients,O
presenting,O
with,O
stroke,I-Entity
-,O
like,O
episodes,O
while,O
receiving,O
systemic,O
or,O
intrathecal,O
chemotherapy,O
.,O
Patients,O
with,O
cerebrovascular,B-Entity
accidents,I-Entity
were,O
excluded,O
.,O
We,O
identified,O
27,O
reports,O
of,O
toxic,O
leukoencephalopathy,I-Entity
in,O
patients,O
treated,O
with,O
methotrexate,I-Entity
(,O
intrathecal,O
",",O
systemic,O
),O
",",O
5-fluorouracil,I-Entity
and,O
its,O
derivative,O
carmofur,I-Entity
",",O
and,O
capecitabine,I-Entity
.,O
Diffusion,O
weighted,O
imaging,O
(,O
DWI,O
),O
of,O
all,O
patients,O
revealed,O
well,O
demarcated,O
hyperintense,O
lesions,B-Entity
within,I-Entity
the,I-Entity
subcortical,I-Entity
white,I-Entity
matter,I-Entity
of,O
the,O
cerebral,O
hemispheres,O
and,O
the,O
corpus,O
callosum,O
",",O
corresponding,O
to,O
areas,O
of,O
decreased,O
proton,O
diffusion,O
on,O
apparent,O
diffusion,O
coefficient,O
(,O
ADC,O
),O
maps,O
(,O
available,O
in,O
21/27,O
patients,O
),O
.,O
However,O
",",O
fluid,O
attenuated,O
inversion,O
recovery,O
(,O
FLAIR,O
),O
sequences,O
frequently,O
revealed,O
persistent,O
white,B-Entity
matter,I-Entity
abnormalities,I-Entity
.,O
CONCLUSIONS,O
:,O
Several,O
pathophysiological,O
models,O
of,O
delayed,O
leukoencephalopathy,I-Entity
after,O
exposure,O
to,O
intrathecal,O
or,O
systemic,O
chemotherapy,O
have,O
been,O
proposed,O
.,O
DWI,O
findings,O
in,O
this,O
cohort,O
are,O
indicative,O
of,O
cytotoxic,B-Entity
oedema,I-Entity
within,I-Entity
cerebral,I-Entity
white,I-Entity
matter,I-Entity
and,O
lend,O
support,O
to,O
an,O
at,O
least,O
partially,O
reversible,O
metabolic,O
derangement,O
as,O
the,O
basis,O
for,O
this,O
syndrome,O
.,O
Down,O
-,O
regulation,O
of,O
norepinephrine,I-Entity
transporter,O
function,O
induced,O
by,O
chronic,O
administration,O
of,O
desipramine,I-Entity
linking,O
to,O
the,O
alteration,O
of,O
sensitivity,O
of,O
local,O
-,O
anesthetics,O
-,O
induced,O
convulsions,I-Entity
and,O
the,O
counteraction,O
by,O
co,O
-,O
administration,O
with,O
local,O
anesthetics,O
.,O
Alterations,O
of,O
norepinephrine,I-Entity
transporter,O
(,O
NET,O
),O
function,O
by,O
chronic,O
inhibition,O
of,O
NET,O
in,O
relation,O
to,O
sensitization,O
to,O
seizures,I-Entity
induce,O
by,O
cocaine,I-Entity
and,O
local,O
anesthetics,O
were,O
studied,O
in,O
mice,O
.,O
Daily,O
administration,O
of,O
desipramine,I-Entity
",",O
an,O
inhibitor,O
of,O
the,O
NET,O
",",O
for,O
5,O
days,O
decreased,O
[,O
(,O
3)H]norepinephrine,I-Entity
uptake,O
in,O
the,O
P2,O
fractions,O
of,O
hippocampus,O
but,O
not,O
cortex,O
",",O
striatum,O
or,O
amygdalae,O
.,O
Co,O
-,O
administration,O
of,O
lidocaine,I-Entity
",",O
bupivacaine,I-Entity
or,O
tricaine,I-Entity
with,O
desipramine,I-Entity
reversed,O
this,O
effect,O
.,O
Daily,O
treatment,O
of,O
cocaine,I-Entity
increased,O
[,O
(,O
3)H]norepinephrine,I-Entity
uptake,O
into,O
the,O
hippocampus,O
.,O
Daily,O
administration,O
of,O
desipramine,I-Entity
increased,O
the,O
incidence,O
of,O
appearance,O
of,O
lidocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
and,O
decreased,O
that,O
of,O
cocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
.,O
Co,O
-,O
administration,O
of,O
lidocaine,I-Entity
with,O
desipramine,I-Entity
reversed,O
the,O
changes,O
of,O
convulsive,I-Entity
activity,O
of,O
lidocaine,I-Entity
and,O
cocaine,I-Entity
induced,O
by,O
repeated,O
administration,O
of,O
desipramine,I-Entity
.,O
These,O
results,O
suggest,O
that,O
down,O
-,O
regulation,O
of,O
hippocampal,O
NET,O
induced,O
by,O
chronic,O
administration,O
of,O
desipramine,I-Entity
may,O
be,O
relevant,O
to,O
desipramine,I-Entity
-,O
induced,O
sensitization,O
of,O
lidocaine,I-Entity
convulsions,I-Entity
.,O
Inhibition,O
of,O
Na(+,I-Entity
),O
channels,O
by,O
local,O
anesthetics,O
may,O
regulate,O
desipramine,I-Entity
-,O
induced,O
down,O
-,O
regulation,O
of,O
NET,O
function,O
.,O
Repeated,O
administration,O
of,O
cocaine,I-Entity
induces,O
up,O
-,O
regulation,O
of,O
hippocampal,O
NET,O
function,O
.,O
Desipramine,I-Entity
-,O
induced,O
sensitization,O
of,O
lidocaine,I-Entity
seizures,I-Entity
may,O
have,O
a,O
mechanism,O
distinct,O
from,O
kindling,O
resulting,O
from,O
repeated,O
administration,O
of,O
cocaine,I-Entity
.,O
Definition,O
and,O
management,O
of,O
anemia,I-Entity
in,O
patients,O
infected,B-Entity
with,I-Entity
hepatitis,I-Entity
C,I-Entity
virus,I-Entity
.,O
Chronic,B-Entity
infection,I-Entity
with,I-Entity
hepatitis,I-Entity
C,I-Entity
virus,I-Entity
(,O
HCV,O
),O
can,O
progress,O
to,O
cirrhosis,I-Entity
",",O
hepatocellular,B-Entity
carcinoma,I-Entity
",",O
and,O
end,B-Entity
-,I-Entity
stage,I-Entity
liver,I-Entity
disease,I-Entity
.,O
The,O
current,O
best,O
treatment,O
for,O
HCV,B-Entity
infection,I-Entity
is,O
combination,O
therapy,O
with,O
pegylated,O
interferon,I-Entity
and,O
ribavirin,I-Entity
.,O
Although,O
this,O
regimen,O
produces,O
sustained,O
virologic,O
responses,O
(,O
SVRs,O
),O
in,O
approximately,O
50%,O
of,O
patients,O
",",O
it,O
can,O
be,O
associated,O
with,O
a,O
potentially,O
dose,O
-,O
limiting,O
hemolytic,B-Entity
anemia,I-Entity
.,O
Hemoglobin,O
concentrations,O
decrease,O
mainly,O
as,O
a,O
result,O
of,O
ribavirin,I-Entity
-,O
induced,O
hemolysis,I-Entity
",",O
and,O
this,O
anemia,I-Entity
can,O
be,O
problematic,O
in,O
patients,O
with,O
HCV,B-Entity
infection,I-Entity
",",O
especially,O
those,O
who,O
have,O
comorbid,O
renal,B-Entity
or,I-Entity
cardiovascular,I-Entity
disorders,I-Entity
.,O
In,O
general,O
",",O
anemia,I-Entity
can,O
increase,O
the,O
risk,O
of,O
morbidity,O
and,O
mortality,O
",",O
and,O
may,O
have,O
negative,O
effects,O
on,O
cerebral,O
function,O
and,O
quality,O
of,O
life,O
.,O
Although,O
ribavirin,I-Entity
-,O
associated,O
anemia,I-Entity
can,O
be,O
reversed,O
by,O
dose,O
reduction,O
or,O
discontinuation,O
",",O
this,O
approach,O
compromises,O
outcomes,O
by,O
significantly,O
decreasing,O
SVR,O
rates,O
.,O
Recombinant,O
human,O
erythropoietin,O
has,O
been,O
used,O
to,O
manage,O
ribavirin,I-Entity
-,O
associated,O
anemia,I-Entity
but,O
has,O
other,O
potential,O
disadvantages,O
.,O
Viramidine,I-Entity
",",O
a,O
liver,O
-,O
targeting,O
prodrug,O
of,O
ribavirin,I-Entity
",",O
has,O
the,O
potential,O
to,O
maintain,O
the,O
virologic,O
efficacy,O
of,O
ribavirin,I-Entity
while,O
decreasing,O
the,O
risk,O
of,O
hemolytic,B-Entity
anemia,I-Entity
in,O
patients,O
with,O
chronic,B-Entity
hepatitis,I-Entity
C.,I-Entity
Calcium,B-Entity
carbonate,I-Entity
toxicity,I-Entity
:,O
the,O
updated,O
milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
;,O
report,O
of,O
3,O
cases,O
and,O
review,O
of,O
the,O
literature,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
3,O
patients,O
with,O
calcium,B-Entity
carbonate,I-Entity
-,O
induced,O
hypercalcemia,I-Entity
and,O
gain,O
insights,O
into,O
the,O
cause,O
and,O
management,O
of,O
the,O
milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
.,O
METHODS,O
:,O
We,O
report,O
the,O
clinical,O
and,O
laboratory,O
data,O
in,O
3,O
patients,O
who,O
presented,O
with,O
severe,O
hypercalcemia,I-Entity
(,O
corrected,O
serum,O
calcium,I-Entity
>,O
or,O
=,O
14,O
mg,O
/,O
dL,O
),O
and,O
review,O
the,O
pertinent,O
literature,O
on,O
milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
.,O
The,O
3,O
patients,O
had,O
acute,B-Entity
renal,I-Entity
insufficiency,I-Entity
",",O
relative,O
metabolic,B-Entity
alkalosis,I-Entity
",",O
and,O
low,O
parathyroid,O
hormone,O
(,O
PTH,O
),O
",",O
PTH,O
-,O
related,O
peptide,O
",",O
and,O
"1,25-dihydroxyvitamin",B-Entity
D,I-Entity
concentrations,O
.,O
Treatment,O
included,O
aggressive,O
hydration,O
and,O
varied,O
amounts,O
of,O
furosemide,I-Entity
.,O
The,O
2,O
patients,O
with,O
the,O
higher,O
serum,O
calcium,I-Entity
concentrations,O
received,O
pamidronate,I-Entity
intravenously,O
(,O
60,O
and,O
30,O
mg,O
",",O
respectively,O
),O
",",O
which,O
caused,O
severe,O
hypocalcemia,I-Entity
.,O
Of,O
the,O
3,O
patients,O
",",O
2,O
were,O
ingesting,O
acceptable,O
doses,O
of,O
elemental,O
calcium,I-Entity
(,O
1,O
g,O
and,O
2,O
g,O
daily,O
",",O
respectively,O
),O
in,O
the,O
form,O
of,O
calcium,B-Entity
carbonate,I-Entity
.,O
In,O
addition,O
to,O
our,O
highlighted,O
cases,O
",",O
we,O
review,O
the,O
history,O
",",O
classification,O
",",O
pathophysiologic,O
features,O
",",O
and,O
treatment,O
of,O
milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
and,O
summarize,O
the,O
cases,O
reported,O
from,O
early,O
1995,O
to,O
November,O
2003,O
.,O
Milk,B-Entity
-,I-Entity
alkali,I-Entity
syndrome,I-Entity
may,O
be,O
a,O
common,O
cause,O
of,O
unexplained,O
hypercalcemia,I-Entity
and,O
can,O
be,O
precipitated,O
by,O
small,O
amounts,O
of,O
orally,O
ingested,O
calcium,B-Entity
carbonate,I-Entity
in,O
susceptible,O
persons,O
.,O
Treatment,O
with,O
hydration,O
",",O
furosemide,I-Entity
",",O
and,O
discontinuation,O
of,O
the,O
calcium,I-Entity
and,O
vitamin,B-Entity
D,I-Entity
source,O
is,O
adequate,O
.,O
Pamidronate,I-Entity
treatment,O
is,O
associated,O
with,O
considerable,O
risk,O
for,O
hypocalcemia,I-Entity
",",O
even,O
in,O
cases,O
of,O
initially,O
severe,O
hypercalcemia,I-Entity
.,O
Management,O
strategies,O
for,O
ribavirin,I-Entity
-,O
induced,O
hemolytic,B-Entity
anemia,I-Entity
in,O
the,O
treatment,O
of,O
hepatitis,B-Entity
C,I-Entity
:,O
clinical,O
and,O
economic,O
implications,O
.,O
Recently,O
published,O
studies,O
have,O
demonstrated,O
increased,O
efficacy,O
and,O
cost,O
-,O
effectiveness,O
of,O
combination,O
therapy,O
with,O
interferon,O
and,O
alpha-2b,O
/,O
ribavirin,I-Entity
compared,O
with,O
interferon,B-Entity
-,I-Entity
alpha,I-Entity
monotherapy,O
in,O
the,O
treatment,O
of,O
chronic,B-Entity
hepatitis,I-Entity
C,I-Entity
(,O
CHC,I-Entity
),O
.,O
Combination,O
therapy,O
is,O
associated,O
with,O
a,O
clinically,O
important,O
adverse,O
effect,O
:,O
ribavirin,I-Entity
-,O
induced,O
hemolytic,B-Entity
anemia,I-Entity
(,O
RIHA,I-Entity
),O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
direct,O
health,O
-,O
care,O
costs,O
and,O
management,O
of,O
RIHA,I-Entity
during,O
treatment,O
of,O
CHC,I-Entity
in,O
a,O
clinical,O
trial,O
setting,O
.,O
A,O
systematic,O
literature,O
review,O
was,O
conducted,O
to,O
synthesize,O
information,O
on,O
the,O
incidence,O
and,O
management,O
of,O
RIHA,I-Entity
.,O
Decision,O
-,O
analytic,O
techniques,O
were,O
used,O
to,O
estimate,O
the,O
cost,O
of,O
treating,O
RIHA,I-Entity
.,O
RESULTS,O
:,O
RIHA,I-Entity
",",O
defined,O
as,O
a,O
reduction,O
in,O
hemoglobin,O
to,O
less,O
than,O
100,O
g,O
/,O
L,O
",",O
occurs,O
in,O
approximately,O
7%,O
to,O
9%,O
of,O
patients,O
treated,O
with,O
combination,O
therapy,O
.,O
The,O
standard,O
of,O
care,O
for,O
management,O
of,O
RIHA,I-Entity
is,O
reduction,O
or,O
discontinuation,O
of,O
the,O
ribavirin,I-Entity
dosage,O
.,O
We,O
estimated,O
the,O
direct,O
cost,O
of,O
treating,O
clinically,O
significant,O
RIHA,I-Entity
to,O
be,O
170,O
per,O
patient,O
receiving,O
combination,O
therapy,O
per,O
48-week,O
treatment,O
course,O
(,O
range,O
68-,O
692,O
),O
.,O
The,O
direct,O
cost,O
of,O
treating,O
clinically,O
significant,O
RIHA,I-Entity
is,O
1%,O
(,O
170/,O
"16,459",O
),O
of,O
drug,O
treatment,O
costs,O
.,O
Questions,O
remain,O
about,O
the,O
optimal,O
dose,O
of,O
ribavirin,I-Entity
and,O
the,O
incidence,O
of,O
RIHA,I-Entity
in,O
a,O
real,O
-,O
world,O
population,O
.,O
Despite,O
these,O
uncertainties,O
",",O
this,O
initial,O
evaluation,O
of,O
the,O
direct,O
cost,O
of,O
treating,O
RIHA,I-Entity
provides,O
an,O
estimate,O
of,O
the,O
cost,O
and,O
management,O
implications,O
of,O
this,O
clinically,O
important,O
adverse,O
effect,O
.,O
Effects,O
of,O
amine,I-Entity
pretreatment,O
on,O
ketamine,I-Entity
catatonia,I-Entity
in,O
pinealectomized,O
or,O
hypophysectomized,O
animals,O
.,O
The,O
present,O
studies,O
were,O
designed,O
to,O
clarify,O
the,O
role,O
of,O
catecholamines,I-Entity
and,O
pineal,O
idolamines,O
on,O
ketamine,I-Entity
-,O
induced,O
catatonia,I-Entity
in,O
the,O
intact,O
",",O
pinealectomized,O
or,O
hypophysectomized,O
chick,O
and,O
rat,O
.,O
In,O
the,O
pinealectomized,O
chick,O
",",O
pretreatment,O
with,O
dopamine,I-Entity
increased,O
the,O
duration,O
of,O
catatonia,I-Entity
(,O
DOC,O
),O
after,O
ketamine,I-Entity
",",O
but,O
pretreatment,O
with,O
norepinephrine,I-Entity
did,O
not,O
.,O
Serotonin,I-Entity
and,O
N,B-Entity
-,I-Entity
acetyl,I-Entity
serotonin,I-Entity
which,O
augmented,O
ketamine,I-Entity
DOC,O
",",O
did,O
not,O
do,O
so,O
in,O
the,O
absence,O
of,O
the,O
pineal,O
gland,O
",",O
whereas,O
melatonin,I-Entity
potentiated,O
the,O
ketamine,I-Entity
DOC,O
in,O
both,O
the,O
intact,O
and,O
pinealectomized,O
chick,O
.,O
Ketamine,I-Entity
was,O
more,O
potent,O
in,O
the,O
hypophysectomized,O
chick,O
and,O
the,O
circadian,O
rhythm,O
noted,O
in,O
the,O
intact,O
chick,O
was,O
absent,O
;,O
furthermore,O
",",O
melatonin,I-Entity
did,O
not,O
augment,O
the,O
ketamine,I-Entity
DOC,O
whereas,O
dopamine,I-Entity
continued,O
to,O
do,O
so,O
.,O
This,O
study,O
did,O
not,O
demonstrate,O
a,O
species,O
difference,O
regarding,O
the,O
role,O
of,O
the,O
amines,I-Entity
on,O
the,O
pineal,O
in,O
spite,O
of,O
the,O
immature,O
blood,O
-,O
brain,O
barrier,O
in,O
the,O
young,O
chick,O
and,O
the,O
intact,O
barrier,O
in,O
the,O
rat,O
.,O
In,O
addition,O
",",O
these,O
data,O
indicate,O
a,O
direct,O
role,O
of,O
the,O
pituitary,O
in,O
the,O
augmentation,O
of,O
ketamine,I-Entity
DOC,O
induced,O
by,O
melatonin,I-Entity
.,O
Furthermore,O
",",O
dopamine,I-Entity
appeared,O
to,O
act,O
on,O
systems,O
more,O
closely,O
involved,O
with,O
the,O
induction,O
of,O
ketamine,I-Entity
catatonia,I-Entity
rather,O
than,O
directly,O
on,O
the,O
pituitary,O
.,O
Multicenter,O
",",O
double,O
-,O
blind,O
",",O
multiple,O
-,O
dose,O
",",O
parallel,O
-,O
groups,O
efficacy,O
and,O
safety,O
trial,O
of,O
azelastine,I-Entity
",",O
chlorpheniramine,I-Entity
",",O
and,O
placebo,O
in,O
the,O
treatment,O
of,O
spring,B-Entity
allergic,I-Entity
rhinitis,I-Entity
.,O
Azelastine,I-Entity
",",O
a,O
novel,O
antiallergic,O
medication,O
",",O
was,O
compared,O
with,O
chlorpheniramine,B-Entity
maleate,I-Entity
and,O
placebo,O
for,O
efficacy,O
and,O
safety,O
in,O
the,O
treatment,O
of,O
spring,B-Entity
allergic,I-Entity
rhinitis,I-Entity
in,O
a,O
multicenter,O
",",O
double,O
-,O
blind,O
",",O
multiple,O
-,O
dose,O
",",O
parallel,O
-,O
groups,O
study,O
.,O
Subjects,O
ranged,O
in,O
age,O
from,O
18,O
to,O
60,O
years,O
of,O
age,O
and,O
had,O
at,O
least,O
a,O
2-year,O
history,O
of,O
spring,B-Entity
allergic,I-Entity
rhinitis,I-Entity
",",O
confirmed,O
by,O
positive,O
skin,O
test,O
to,O
spring,O
aeroallergens,O
.,O
Medications,O
were,O
given,O
four,O
times,O
daily,O
;,O
the,O
azelastine,I-Entity
groups,O
received,O
0.5,O
",",O
1.0,O
",",O
or,O
2.0,O
mg,O
in,O
the,O
morning,O
and,O
evening,O
with,O
placebo,O
in,O
the,O
early,O
and,O
late,O
afternoon,O
;,O
the,O
chlorpheniramine,I-Entity
group,O
received,O
4.0,O
mg,O
four,O
times,O
daily,O
.,O
Symptoms,O
relief,O
in,O
the,O
group,O
receiving,O
the,O
highest,O
concentration,O
of,O
azelastine,I-Entity
(,O
2.0,O
mg,O
twice,O
daily,O
),O
was,O
statistically,O
greater,O
than,O
in,O
the,O
placebo,O
group,O
during,O
all,O
weeks,O
of,O
the,O
study,O
.,O
Lower,O
doses,O
of,O
azelastine,I-Entity
were,O
statistically,O
more,O
effective,O
than,O
placebo,O
only,O
during,O
portions,O
of,O
the,O
first,O
3,O
weeks,O
of,O
the,O
study,O
.,O
In,O
contrast,O
",",O
although,O
the,O
chlorpheniramine,I-Entity
group,O
did,O
have,O
fewer,O
symptoms,O
than,O
the,O
placebo,O
group,O
during,O
the,O
study,O
",",O
the,O
difference,O
never,O
reached,O
statistical,O
significance,O
during,O
any,O
week,O
of,O
the,O
study,O
.,O
Drowsiness,I-Entity
and,O
altered,B-Entity
taste,I-Entity
perception,I-Entity
were,O
increased,O
significantly,O
over,O
placebo,O
only,O
in,O
the,O
high,O
-,O
dose,O
azelastine,I-Entity
group,O
.,O
Azelastine,I-Entity
appears,O
to,O
be,O
a,O
safe,O
",",O
efficacious,O
medication,O
for,O
seasonal,B-Entity
allergic,I-Entity
rhinitis,I-Entity
.,O
One,O
case,O
of,O
acute,O
hypercalcaemia,I-Entity
and,O
two,O
of,O
recurrent,O
nephrolithiasis,I-Entity
are,O
reported,O
in,O
patients,O
who,O
had,O
regularly,O
consumed,O
large,O
amounts,O
of,O
calcium,B-Entity
carbon,I-Entity
-,I-Entity
ate,I-Entity
-,O
sodium,B-Entity
bicarbonate,I-Entity
powders,O
for,O
more,O
than,O
20,O
years,O
.,O
Prolonged,O
paralysis,I-Entity
due,O
to,O
nondepolarizing,B-Entity
neuromuscular,I-Entity
blocking,I-Entity
agents,I-Entity
and,O
corticosteroids,I-Entity
.,O
The,O
long,O
-,O
term,O
use,O
of,O
nondepolarizing,B-Entity
neuromuscular,I-Entity
blocking,I-Entity
agents,I-Entity
(,O
ND,B-Entity
-,I-Entity
NMBA,I-Entity
),O
has,O
recently,O
been,O
implicated,O
as,O
a,O
cause,O
of,O
prolonged,O
muscle,B-Entity
weakness,I-Entity
",",O
although,O
the,O
site,O
of,O
the,O
lesion,O
and,O
the,O
predisposing,O
factors,O
have,O
been,O
unclear,O
.,O
We,O
report,O
3,O
patients,O
(,O
age,O
37,O
-,O
52,O
years,O
),O
with,O
acute,O
respiratory,B-Entity
insufficiency,I-Entity
who,O
developed,O
prolonged,O
weakness,I-Entity
following,O
the,O
discontinuation,O
of,O
ND,B-Entity
-,I-Entity
NMBAs,I-Entity
.,O
Two,O
patients,O
also,O
received,O
intravenous,O
corticosteroids,I-Entity
.,O
Renal,O
function,O
was,O
normal,O
but,O
hepatic,O
function,O
was,O
impaired,O
in,O
all,O
patients,O
",",O
and,O
all,O
had,O
acidosis,I-Entity
.,O
The,O
serum,O
vecuronium,I-Entity
level,O
measured,O
in,O
1,O
patient,O
14,O
days,O
after,O
the,O
drug,O
had,O
been,O
discontinued,O
was,O
172,O
ng,O
/,O
mL.,O
A,O
muscle,O
biopsy,O
in,O
this,O
patient,O
showed,O
loss,B-Entity
of,I-Entity
thick,I-Entity
",",I-Entity
myosin,I-Entity
filaments,I-Entity
.,O
The,O
weakness,I-Entity
in,O
these,O
patients,O
is,O
due,O
to,O
pathology,B-Entity
at,I-Entity
both,I-Entity
the,I-Entity
neuromuscular,I-Entity
junction,I-Entity
(,O
most,O
likely,O
due,O
to,O
ND,B-Entity
-,I-Entity
NMBA,I-Entity
),O
and,O
muscle,O
(,O
most,O
likely,O
due,O
to,O
corticosteroids,I-Entity
),O
.,O
Hepatic,B-Entity
dysfunction,I-Entity
and,O
acidosis,I-Entity
are,O
contributing,O
risk,O
factors,O
.,O
Prostaglandin,B-Entity
E2-induced,I-Entity
bladder,B-Entity
hyperactivity,I-Entity
in,O
normal,O
",",O
conscious,O
rats,O
:,O
involvement,O
of,O
tachykinins,I-Entity
?,O
In,O
normal,O
conscious,O
rats,O
investigated,O
by,O
continuous,O
cystometry,O
",",O
intravesically,O
instilled,O
prostaglandin,B-Entity
(,I-Entity
PG,I-Entity
),I-Entity
E2,I-Entity
facilitated,O
micturition,O
and,O
increased,O
basal,O
intravesical,O
pressure,O
.,O
The,O
effect,O
was,O
attenuated,O
by,O
both,O
the,O
NK1,O
receptor,O
selective,O
antagonist,O
RP,B-Entity
"67,580",I-Entity
and,O
the,O
NK2,O
receptor,O
selective,O
antagonist,O
SR,B-Entity
"48,968",I-Entity
",",O
given,O
intra,O
-,O
arterially,O
",",O
suggesting,O
that,O
it,O
was,O
mediated,O
by,O
stimulation,O
of,O
both,O
NK1,O
and,O
NK2,O
receptors,O
.,O
Intra,O
-,O
arterially,O
given,O
PGE2,I-Entity
produced,O
a,O
distinct,O
increase,O
in,O
bladder,O
pressure,O
before,O
initiating,O
a,O
micturition,O
reflex,O
",",O
indicating,O
that,O
the,O
PG,I-Entity
had,O
a,O
direct,O
contractant,O
effect,O
on,O
the,O
detrusor,O
smooth,O
muscle,O
.,O
The,O
effect,O
of,O
intra,O
-,O
arterial,O
PGE2,I-Entity
could,O
not,O
be,O
blocked,O
by,O
intra,O
-,O
arterial,O
RP,B-Entity
"67,580",I-Entity
or,O
SR,B-Entity
"48,968",I-Entity
",",O
which,O
opens,O
the,O
possibility,O
that,O
the,O
micturition,O
reflex,O
elicited,O
by,O
intra,O
-,O
arterial,O
PGE2,I-Entity
was,O
mediated,O
by,O
pathways,O
other,O
than,O
the,O
reflex,O
initiated,O
when,O
the,O
PG,I-Entity
was,O
given,O
intravesically,O
.,O
The,O
present,O
results,O
thus,O
suggest,O
that,O
intra,O
-,O
arterial,O
PGE2,I-Entity
",",O
given,O
near,O
the,O
bladder,O
",",O
may,O
initiate,O
micturition,O
in,O
the,O
normal,O
rat,O
chiefly,O
by,O
directly,O
contracting,O
the,O
smooth,O
muscle,O
of,O
the,O
detrusor,O
.,O
However,O
",",O
when,O
given,O
intravesically,O
",",O
PGE2,I-Entity
may,O
stimulate,O
micturition,O
by,O
releasing,O
tachykinins,I-Entity
from,O
nerves,O
in,O
and/or,O
immediately,O
below,O
the,O
urothelium,O
.,O
These,O
tachykinins,I-Entity
",",O
in,O
turn,O
",",O
initiate,O
a,O
micturition,O
reflex,O
by,O
stimulating,O
NK1,O
and,O
NK2,O
receptors,O
.,O
Prostanoids,I-Entity
may,O
",",O
via,O
release,O
of,O
tachykinins,I-Entity
",",O
contribute,O
to,O
both,O
urge,O
and,O
bladder,B-Entity
hyperactivity,I-Entity
seen,O
in,O
inflammatory,O
conditions,O
of,O
the,O
lower,O
urinary,O
tract,O
.,O
Thiazide,I-Entity
diuretics,O
",",O
hypokalemia,I-Entity
and,O
cardiac,B-Entity
arrhythmias,I-Entity
.,O
Thiazide,I-Entity
diuretics,O
are,O
widely,O
accepted,O
as,O
the,O
cornerstone,O
of,O
antihypertensive,O
treatment,O
programs,O
.,O
Hypokalemia,I-Entity
is,O
a,O
commonly,O
encountered,O
metabolic,O
consequence,O
of,O
chronic,O
thiazide,I-Entity
therapy,O
.,O
We,O
treated,O
38,O
patients,O
(,O
22,O
low,O
renin,O
",",O
16,O
normal,O
renin,O
),O
with,O
moderate,O
diastolic,B-Entity
hypertension,I-Entity
with,O
hydrochlorothiazide,I-Entity
(,O
HCTC,I-Entity
),O
administered,O
on,O
a,O
twice,O
daily,O
schedule,O
.,O
The,O
serum,O
K,I-Entity
during,O
the,O
control,O
period,O
was,O
4.5,O
+,O
/-,O
/,O
l,O
an,O
on,O
50,O
",",O
100,O
",",O
150,O
and,O
200,O
mg,O
HCTZ,I-Entity
daily,O
3.9,O
Corresponding,O
figures,O
for,O
whole,O
body,O
K,I-Entity
were,O
4107,O
+,O
/-,O
In,O
13,O
patients,O
we,O
observed,O
the,O
effects,O
of,O
HCTZ,I-Entity
therapy,O
(,O
100,O
mg,O
daily,O
),O
on,O
the,O
occurrence,O
of,O
PVC,O
's,O
during,O
rest,O
as,O
well,O
as,O
during,O
static,O
and,O
dynamic,O
exercise,O
.,O
Corresponding,O
figures,O
during,O
HCTZ,I-Entity
therapy,O
100,O
mg,O
daily,O
were,O
1.4,O
+,O
/-,O
K+,I-Entity
observed,O
r,O
=,O
0.72,O
",",O
p,O
less,O
than,O
0.001,O
.,O
In,O
conclusion,O
we,O
found,O
that,O
thiazide,I-Entity
diuretics,O
cause,O
hypokalemia,I-Entity
and,O
depletion,O
of,O
body,O
potassium,I-Entity
.,O
The,O
more,O
profound,O
hypokalemia,I-Entity
",",O
the,O
greater,O
the,O
propensity,O
for,O
the,O
occurrence,O
of,O
PVC,O
's,O
.,O
Diuretics,O
",",O
potassium,I-Entity
and,O
arrhythmias,I-Entity
in,O
hypertensive,I-Entity
coronary,B-Entity
disease,I-Entity
.,O
It,O
has,O
been,O
proposed,O
that,O
modest,O
changes,O
in,O
plasma,O
potassium,I-Entity
can,O
alter,O
the,O
tendency,O
towards,O
cardiac,B-Entity
arrhythmias,I-Entity
.,O
If,O
this,O
were,O
so,O
",",O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
might,O
be,O
especially,O
susceptible,O
.,O
Thus,O
",",O
myocardial,O
electrical,O
excitability,O
was,O
measured,O
in,O
patients,O
with,O
mild,O
essential,O
hypertension,I-Entity
and,O
known,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
after,O
8,O
weeks,O
of,O
treatment,O
with,O
a,O
potassium,I-Entity
-,O
conserving,O
diuretic,O
(,O
amiloride,I-Entity
),O
and,O
a,O
similar,O
period,O
on,O
a,O
potassium,I-Entity
-,O
losing,O
diuretic,O
(,O
chlorthalidone,I-Entity
),O
in,O
a,O
randomised,O
study,O
.,O
Plasma,O
potassium,I-Entity
concentrations,O
were,O
on,O
average,O
1,O
mmol,O
/,O
L,O
lower,O
during,O
the,O
chlorthalidone,I-Entity
phase,O
compared,O
to,O
amiloride,I-Entity
therapy,O
.,O
Blood,O
pressure,O
and,O
volume,O
states,O
as,O
assessed,O
by,O
bodyweight,O
",",O
plasma,O
renin,O
and,O
noradrenaline,I-Entity
(,O
norepinephrine,I-Entity
),O
Compared,O
to,O
amiloride,I-Entity
treatment,O
",",O
the,O
chlorthalidone,I-Entity
phase,O
was,O
associated,O
with,O
an,O
increased,O
frequency,O
of,O
ventricular,B-Entity
ectopic,I-Entity
beats,I-Entity
(,O
24-hour,O
Holter,O
monitoring,O
),O
and,O
a,O
higher,O
Lown,O
grading,O
",",O
increased,O
upslope,O
and,O
duration,O
of,O
the,O
monophasic,O
action,O
potential,O
",",O
prolonged,O
ventricular,O
effective,O
refractory,O
period,O
",",O
and,O
increased,O
electrical,O
instability,O
during,O
programmed,O
ventricular,O
stimulation,O
.,O
The,O
above,O
results,O
indicate,O
that,O
because,O
potassium,I-Entity
-,O
losing,O
diuretic,O
therapy,O
can,O
increase,O
myocardial,O
electrical,O
excitability,O
in,O
patients,O
with,O
ischaemic,B-Entity
heart,I-Entity
disease,I-Entity
",",O
even,O
minor,O
falls,O
in,O
plasma,O
potassium,I-Entity
concentrations,O
are,O
probably,O
best,O
avoided,O
in,O
such,O
patients,O
.,O
GABA,I-Entity
involvement,O
in,O
naloxone,I-Entity
induced,O
reversal,O
of,O
respiratory,B-Entity
paralysis,I-Entity
produced,O
by,O
thiopental,I-Entity
.,O
No,O
agent,O
is,O
yet,O
available,O
to,O
reverse,O
respiratory,B-Entity
paralysis,I-Entity
produced,O
by,O
CNS,O
depressants,O
",",O
such,O
as,O
general,O
anesthetics,O
.,O
In,O
this,O
study,O
naloxone,I-Entity
reversed,O
respiratory,B-Entity
paralysis,I-Entity
induced,O
by,O
thiopental,I-Entity
in,O
rats,O
.,O
thiopental,I-Entity
produced,O
anesthesia,O
without,O
altering,O
respiratory,O
rate,O
",",O
increased,O
GABA,I-Entity
",",O
decreased,O
glutamate,I-Entity
",",O
and,O
had,O
no,O
effect,O
on,O
aspartate,I-Entity
or,O
glycine,I-Entity
levels,O
compared,O
to,O
controls,O
in,O
rat,O
cortex,O
and,O
brain,O
stem,O
.,O
Pretreatment,O
of,O
rats,O
with,O
thiosemicarbazide,I-Entity
for,O
30,O
minutes,O
abolished,O
the,O
anesthetic,O
action,O
as,O
well,O
as,O
the,O
respiratory,O
depressant,O
action,O
of,O
thiopental,I-Entity
.,O
thiopental,I-Entity
produced,O
respiratory,B-Entity
arrest,I-Entity
with,O
further,O
increase,O
in,O
GABA,I-Entity
and,O
decrease,O
in,O
glutamate,I-Entity
again,O
in,O
cortex,O
and,O
brain,O
stem,O
without,O
affecting,O
any,O
of,O
the,O
amino,B-Entity
acids,I-Entity
studied,O
in,O
four,O
regions,O
of,O
rat,O
brain,O
.,O
Naloxone,I-Entity
(,O
2.5,O
mg,O
/,O
kg,O
",",O
i.v,O
.,O
),O
reversed,O
respiratory,B-Entity
paralysis,I-Entity
",",O
glutamate,I-Entity
and,O
GABA,I-Entity
levels,O
to,O
control,O
values,O
in,O
brain,O
stem,O
and,O
cortex,O
with,O
no,O
changes,O
in,O
caudate,O
or,O
cerebellum,O
.,O
These,O
data,O
suggest,O
naloxone,I-Entity
reverses,O
respiratory,B-Entity
paralysis,I-Entity
produced,O
by,O
thiopental,I-Entity
and,O
involves,O
GABA,I-Entity
in,O
its,O
action,O
.,O
National,O
project,O
on,O
the,O
prevention,O
of,O
mother,O
-,O
to,O
-,O
infant,O
infection,B-Entity
by,I-Entity
hepatitis,I-Entity
B,I-Entity
virus,I-Entity
in,O
Japan,O
.,O
In,O
Japan,O
",",O
a,O
nationwide,O
prevention,O
program,O
against,O
mother,O
-,O
to,O
-,O
infant,O
infection,B-Entity
by,I-Entity
hepatitis,I-Entity
B,I-Entity
virus,I-Entity
(,O
HBV,O
),O
started,O
in,O
1985,O
.,O
This,O
program,O
consists,O
of,O
double,O
screenings,O
of,O
pregnant,O
women,O
and,O
prophylactic,O
treatment,O
to,O
the,O
infants,O
born,O
to,O
both,O
hepatitis,B-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
(,O
HBsAg,I-Entity
),O
and,O
hepatitis,B-Entity
B,I-Entity
e,I-Entity
antigen,I-Entity
(,O
HBeAg,I-Entity
),O
positive,O
mothers,O
.,O
These,O
infants,O
are,O
treated,O
with,O
two,O
injections,O
of,O
hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
(,O
HBIG,O
),O
and,O
at,O
least,O
three,O
injections,O
of,O
plasma,O
derived,O
hepatitis,B-Entity
B,I-Entity
vaccine,I-Entity
.,O
93.4%,O
pregnant,O
women,O
had,O
the,O
chance,O
to,O
be,O
examined,O
for,O
HBsAg,I-Entity
",",O
and,O
the,O
positive,O
rate,O
was,O
1.4,O
to,O
1.5%,O
.,O
The,O
HBeAg,I-Entity
positive,O
rate,O
in,O
HBsAg,I-Entity
positive,O
was,O
23,O
to,O
26%,O
.,O
The,O
HBsAg,I-Entity
positive,O
rate,O
in,O
neonates,O
and,O
in,O
infants,O
before,O
two,O
months,O
were,O
3%,O
and,O
2%,O
respectively,O
.,O
Nociceptive,O
effects,O
induced,O
by,O
intrathecal,O
administration,O
of,O
prostaglandin,B-Entity
D2,I-Entity
",",I-Entity
E2,I-Entity
",",I-Entity
or,I-Entity
F2,I-Entity
alpha,I-Entity
to,O
conscious,O
mice,O
.,O
The,O
effects,O
of,O
intrathecal,O
administration,O
of,O
prostaglandins,I-Entity
on,O
pain,I-Entity
responses,O
in,O
conscious,O
mice,O
were,O
evaluated,O
by,O
using,O
hot,O
plate,O
and,O
acetic,B-Entity
acid,I-Entity
writhing,O
tests,O
.,O
Prostaglandin,B-Entity
D2,I-Entity
(,O
0.5,O
-,O
3,O
ng,O
/,O
mouse,O
),O
had,O
a,O
hyperalgesic,I-Entity
action,O
on,O
the,O
response,O
to,O
a,O
hot,O
plate,O
during,O
a,O
3,O
-,O
60,O
min,O
period,O
after,O
injection,O
.,O
Prostaglandin,B-Entity
E2,I-Entity
showed,O
a,O
hyperalgesic,I-Entity
effect,O
at,O
doses,O
of,O
1,O
pg,I-Entity
to,O
10,O
ng,O
/,O
mouse,O
",",O
but,O
the,O
effect,O
lasted,O
shorter,O
(,O
3,O
-,O
30,O
min,O
),O
than,O
that,O
of,O
prostaglandin,B-Entity
D2,I-Entity
.,O
Similar,O
results,O
were,O
obtained,O
by,O
acetic,B-Entity
acid,I-Entity
writhing,O
tests,O
.,O
The,O
hyperalgesic,I-Entity
effect,O
of,O
prostaglandin,B-Entity
D2,I-Entity
was,O
blocked,O
by,O
simultaneous,O
injection,O
of,O
a,O
substance,O
P,O
antagonist,O
(,O
greater,O
than,O
or,O
equal,O
to,O
100,O
ng,O
),O
but,O
not,O
by,O
AH6809,I-Entity
",",O
a,O
prostanoid,O
EP1-receptor,O
antagonist,O
.,O
Conversely,O
",",O
prostaglandin,B-Entity
E2-induced,I-Entity
hyperalgesia,I-Entity
was,O
blocked,O
by,O
AH6809,I-Entity
(,O
greater,O
than,O
or,O
equal,O
to,O
500,O
ng,O
),O
but,O
not,O
by,O
the,O
substance,O
P,O
antagonist,O
.,O
Prostaglandin,B-Entity
F2,I-Entity
alpha,I-Entity
had,O
little,O
effect,O
on,O
pain,I-Entity
responses,O
.,O
These,O
results,O
demonstrate,O
that,O
both,O
prostaglandin,B-Entity
D2,I-Entity
and,O
prostaglandin,B-Entity
E2,I-Entity
exert,O
hyperalgesia,I-Entity
in,O
the,O
spinal,O
cord,O
",",O
but,O
in,O
different,O
ways,O
.,O
Swallowing,O
-,O
induced,O
atrial,B-Entity
tachyarrhythmia,I-Entity
triggered,O
by,O
salbutamol,I-Entity
:,O
case,O
report,O
and,O
review,O
of,O
the,O
literature,O
.,O
On,O
electrocardiogram,O
",",O
episodes,O
of,O
atrial,B-Entity
tachyarrhythmia,I-Entity
were,O
recorded,O
immediately,O
after,O
swallowing,O
;,O
24-hour,O
Holter,O
monitoring,O
recorded,O
several,O
events,O
.,O
The,O
arrhythmia,I-Entity
resolved,O
after,O
therapy,O
with,O
atenolol,I-Entity
",",O
but,O
recurred,O
a,O
year,O
later,O
.,O
The,O
patient,O
noticed,O
that,O
before,O
these,O
episodes,O
he,O
had,O
been,O
using,O
an,O
inhalator,O
of,O
salbutamol,I-Entity
.,O
After,O
stopping,O
the,O
beta,O
-,O
agonist,O
",",O
and,O
after,O
a,O
week,O
with,O
the,O
atenolol,I-Entity
",",O
the,O
arrhythmia,I-Entity
disappeared,O
.,O
DISCUSSION,O
:,O
Swallowing,O
-,O
induced,O
atrial,B-Entity
tachyarrhythmia,I-Entity
(,O
SIAT,I-Entity
),O
is,O
a,O
rare,O
phenomenon,O
.,O
Fewer,O
than,O
50,O
cases,O
of,O
SIAT,I-Entity
have,O
been,O
described,O
in,O
the,O
literature,O
.,O
This,O
article,O
summarizes,O
all,O
the,O
cases,O
published,O
",",O
creating,O
a,O
comprehensive,O
review,O
of,O
the,O
current,O
knowledge,O
and,O
approach,O
to,O
SIAT,I-Entity
.,O
It,O
discusses,O
demographics,O
",",O
clinical,O
characteristics,O
and,O
types,O
of,O
arrhythmia,I-Entity
",",O
postulated,O
mechanisms,O
of,O
SIAT,I-Entity
",",O
and,O
different,O
treatment,O
possibilities,O
such,O
as,O
medications,O
",",O
surgery,O
",",O
and,O
radiofrequency,O
catheter,O
ablation,O
(,O
RFCA,O
),O
.,O
CONCLUSION,O
:,O
Salbutamol,I-Entity
is,O
presented,O
here,O
as,O
a,O
possible,O
trigger,O
for,O
SIAT,I-Entity
.,O
Although,O
it,O
is,O
difficult,O
to,O
define,O
causality,O
in,O
a,O
case,O
report,O
",",O
it,O
is,O
logical,O
to,O
think,O
that,O
a,O
beta,O
-,O
agonist,O
like,O
salbutamol,I-Entity
(,O
known,O
to,O
induce,O
tachycardia,I-Entity
),O
may,O
be,O
the,O
trigger,O
of,O
adrenergic,O
reflexes,O
originating,O
in,O
the,O
esophagus,O
while,O
swallowing,O
and,O
that,O
a,O
beta,O
-,O
blocker,O
such,O
as,O
atenolol,I-Entity
(,O
that,O
blocks,O
the,O
adrenergic,O
activity,O
),O
may,O
relieve,O
it,O
.,O
Coenzyme,B-Entity
Q10,I-Entity
treatment,O
ameliorates,O
acute,O
cisplatin,I-Entity
nephrotoxicity,I-Entity
in,O
mice,O
.,O
The,O
nephroprotective,O
effect,O
of,O
coenzyme,B-Entity
Q10,I-Entity
was,O
investigated,O
in,O
mice,O
with,O
acute,B-Entity
renal,I-Entity
injury,I-Entity
induced,O
by,O
a,O
single,O
i.p,O
.,O
injection,O
of,O
cisplatin,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
.,O
Coenzyme,B-Entity
Q10,I-Entity
treatment,O
(,O
10,O
mg,O
/,O
kg,O
/,O
day,O
",",O
i.p,O
.,O
),O
was,O
applied,O
for,O
6,O
consecutive,O
days,O
",",O
starting,O
1,O
day,O
before,O
cisplatin,I-Entity
administration,O
.,O
Coenzyme,B-Entity
Q10,I-Entity
significantly,O
reduced,O
blood,B-Entity
urea,I-Entity
nitrogen,I-Entity
and,O
serum,O
creatinine,I-Entity
levels,O
which,O
were,O
increased,O
by,O
cisplatin,I-Entity
.,O
Coenzyme,B-Entity
Q10,I-Entity
significantly,O
compensated,O
deficits,O
in,O
the,O
antioxidant,O
defense,O
mechanisms,O
(,O
reduced,B-Entity
glutathione,I-Entity
level,O
and,O
superoxide,I-Entity
dismutase,O
activity,O
),O
",",O
suppressed,O
lipid,O
peroxidation,O
",",O
decreased,O
the,O
elevations,O
of,O
tumor,I-Entity
necrosis,I-Entity
factor,O
-,O
alpha,O
",",O
nitric,B-Entity
oxide,I-Entity
and,O
platinum,I-Entity
ion,O
concentration,O
",",O
and,O
attenuated,O
the,O
reductions,O
of,O
selenium,I-Entity
and,O
zinc,I-Entity
ions,O
in,O
renal,O
tissue,O
resulted,O
from,O
cisplatin,I-Entity
administration,O
.,O
Also,O
",",O
histopathological,O
renal,B-Entity
tissue,I-Entity
damage,I-Entity
mediated,O
by,O
cisplatin,I-Entity
was,O
ameliorated,O
by,O
coenzyme,B-Entity
Q10,I-Entity
treatment,O
.,O
Immunohistochemical,O
analysis,O
revealed,O
that,O
coenzyme,B-Entity
Q10,I-Entity
significantly,O
decreased,O
the,O
cisplatin,I-Entity
-,O
induced,O
overexpression,O
of,O
inducible,O
nitric,B-Entity
oxide,I-Entity
synthase,O
",",O
nuclear,O
factor,O
-,O
kappaB,O
",",O
caspase-3,O
and,O
p53,O
in,O
renal,O
tissue,O
.,O
It,O
was,O
concluded,O
that,O
coenzyme,B-Entity
Q10,I-Entity
represents,O
a,O
potential,O
therapeutic,O
option,O
to,O
protect,O
against,O
acute,O
cisplatin,I-Entity
nephrotoxicity,I-Entity
commonly,O
encountered,O
in,O
clinical,O
practice,O
.,O
Metformin,I-Entity
prevents,O
experimental,O
gentamicin,I-Entity
-,O
induced,O
nephropathy,I-Entity
by,O
a,O
mitochondria,O
-,O
dependent,O
pathway,O
.,O
The,O
antidiabetic,O
drug,O
metformin,I-Entity
can,O
diminish,O
apoptosis,O
induced,O
by,O
oxidative,O
stress,O
in,O
endothelial,O
cells,O
and,O
prevent,O
vascular,B-Entity
dysfunction,I-Entity
even,O
in,O
nondiabetic,O
patients,O
.,O
Here,O
we,O
tested,O
whether,O
it,O
has,O
a,O
beneficial,O
effect,O
in,O
a,O
rat,O
model,O
of,O
gentamicin,I-Entity
toxicity,I-Entity
.,O
Mitochondrial,O
analysis,O
",",O
respiration,O
intensity,O
",",O
levels,O
of,O
reactive,O
oxygen,I-Entity
species,O
",",O
permeability,O
transition,O
",",O
and,O
cytochrome,O
c,O
release,O
were,O
assessed,O
3,O
and,O
6,O
days,O
after,O
gentamicin,I-Entity
administration,O
.,O
Metformin,I-Entity
treatment,O
fully,O
blocked,O
gentamicin,I-Entity
-,O
mediated,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
Metformin,I-Entity
also,O
protected,O
the,O
kidney,O
from,O
histological,O
damage,O
6,O
days,O
after,O
gentamicin,I-Entity
administration,O
.,O
These,O
in,O
vivo,O
markers,O
of,O
kidney,B-Entity
dysfunction,I-Entity
and,O
their,O
correction,O
by,O
metformin,I-Entity
were,O
complemented,O
by,O
in,O
vitro,O
studies,O
of,O
mitochondrial,O
function,O
.,O
We,O
found,O
that,O
gentamicin,I-Entity
treatment,O
depleted,O
respiratory,O
components,O
(,O
cytochrome,O
c,O
",",O
NADH,O
),O
",",O
probably,O
due,O
to,O
the,O
opening,O
of,O
mitochondrial,O
transition,O
pores,O
.,O
These,O
injuries,O
",",O
partly,O
mediated,O
by,O
a,O
rise,O
in,O
reactive,O
oxygen,I-Entity
species,O
from,O
the,O
electron,O
transfer,O
chain,O
",",O
were,O
significantly,O
decreased,O
by,O
metformin,I-Entity
.,O
Thus,O
",",O
our,O
study,O
suggests,O
that,O
pleiotropic,O
effects,O
of,O
metformin,I-Entity
can,O
lessen,O
gentamicin,I-Entity
nephrotoxicity,I-Entity
and,O
improve,O
mitochondrial,O
homeostasis,O
.,O
Sedation,O
depth,O
during,O
spinal,O
anesthesia,O
and,O
the,O
development,O
of,O
postoperative,B-Entity
delirium,I-Entity
in,O
elderly,O
patients,O
undergoing,O
hip,B-Entity
fracture,I-Entity
repair,O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
whether,O
limiting,O
intraoperative,O
sedation,O
depth,O
during,O
spinal,O
anesthesia,O
for,O
hip,B-Entity
fracture,I-Entity
repair,O
in,O
elderly,O
patients,O
can,O
decrease,O
the,O
prevalence,O
of,O
postoperative,B-Entity
delirium,I-Entity
.,O
:,O
We,O
performed,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
controlled,O
trial,O
at,O
an,O
academic,O
medical,O
center,O
of,O
elderly,O
patients,O
(,O
>,O
or=65,O
years,O
),O
without,O
preoperative,O
delirium,I-Entity
or,O
severe,O
dementia,I-Entity
who,O
underwent,O
hip,B-Entity
fracture,I-Entity
repair,O
under,O
spinal,O
anesthesia,O
with,O
propofol,I-Entity
sedation,O
.,O
Postoperative,B-Entity
delirium,I-Entity
was,O
assessed,O
as,O
defined,O
by,O
Diagnostic,O
and,O
Statistical,O
Manual,O
of,O
Mental,B-Entity
Disorders,I-Entity
(,O
Third,O
Edition,O
Revised,O
),O
criteria,O
using,O
the,O
Confusion,O
Assessment,O
Method,O
beginning,O
at,O
any,O
time,O
from,O
the,O
second,O
day,O
after,O
surgery,O
.,O
The,O
prevalence,O
of,O
postoperative,B-Entity
delirium,I-Entity
was,O
significantly,O
lower,O
in,O
the,O
light,O
sedation,O
group,O
(,O
11/57,O
[,O
19%,O
],O
vs,O
23/57,O
[,O
40%,O
],O
in,O
the,O
deep,O
sedation,O
group,O
;,O
P=.02,O
),O
",",O
indicating,O
that,O
1,O
incident,O
of,O
delirium,I-Entity
will,O
be,O
prevented,O
for,O
every,O
4.7,O
patients,O
treated,O
with,O
light,O
sedation,O
.,O
SD,O
number,O
of,O
days,O
of,O
delirium,I-Entity
during,O
hospitalization,O
was,O
lower,O
in,O
the,O
light,O
sedation,O
group,O
than,O
in,O
the,O
deep,O
sedation,O
group,O
(,O
0.5+/-1.5,O
days,O
vs,O
1.4+/-4.0,O
days,O
;,O
P=.01,O
),O
.,O
The,O
use,O
of,O
light,O
propofol,I-Entity
sedation,O
decreased,O
the,O
prevalence,O
of,O
postoperative,B-Entity
delirium,I-Entity
by,O
50%,O
compared,O
with,O
deep,O
sedation,O
.,O
Limiting,O
depth,O
of,O
sedation,O
during,O
spinal,O
anesthesia,O
is,O
a,O
simple,O
",",O
safe,O
",",O
and,O
cost,O
-,O
effective,O
intervention,O
for,O
preventing,O
postoperative,B-Entity
delirium,I-Entity
in,O
elderly,O
patients,O
that,O
could,O
be,O
widely,O
and,O
readily,O
adopted,O
.,O
Sorafenib,I-Entity
-,O
induced,O
acute,O
myocardial,B-Entity
infarction,I-Entity
due,O
to,O
coronary,B-Entity
artery,I-Entity
spasm,I-Entity
.,O
A,O
65-year,O
-,O
old,O
man,O
with,O
advanced,O
renal,B-Entity
cell,I-Entity
carcinoma,I-Entity
was,O
admitted,O
due,O
to,O
continuing,O
chest,B-Entity
pain,I-Entity
at,O
rest,O
.,O
Two,O
weeks,O
before,O
his,O
admission,O
",",O
sorafenib,I-Entity
had,O
been,O
started,O
.,O
He,O
was,O
diagnosed,O
with,O
non,O
-,O
ST,O
-,O
elevation,O
myocardial,B-Entity
infarction,I-Entity
by,O
laboratory,O
data,O
and,O
electrocardiogram,O
.,O
Enhanced,O
heart,O
magnetic,O
resonance,O
imaging,O
also,O
showed,O
subendocardial,B-Entity
infarction,I-Entity
.,O
Coronary,B-Entity
artery,I-Entity
spasm,I-Entity
was,O
induced,O
by,O
a,O
provocative,O
test,O
.,O
Cessation,O
of,O
sorafenib,I-Entity
and,O
administration,O
of,O
Ca,I-Entity
-,O
channel,O
blocker,O
and,O
nitrates,I-Entity
ameliorated,O
his,O
symptoms,O
",",O
but,O
relapse,O
occurred,O
after,O
resumption,O
of,O
sorafenib,I-Entity
.,O
Addition,O
of,O
oral,O
nicorandil,I-Entity
reduced,O
his,O
symptoms,O
and,O
maintained,O
stable,B-Entity
angina,I-Entity
status,O
.,O
We,O
report,O
the,O
first,O
case,O
of,O
sorafenib,I-Entity
-,O
induced,O
coronary,B-Entity
artery,I-Entity
spasm,I-Entity
.,O
Sorafenib,I-Entity
is,O
a,O
multikinase,O
inhibitor,O
that,O
targets,O
signaling,O
pathways,O
necessary,O
for,O
cellular,O
proliferation,O
and,O
survival,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
Rho,O
/,O
ROCK,O
pathway,O
has,O
an,O
important,O
role,O
in,O
the,O
pathogenesis,O
of,O
coronary,B-Entity
artery,I-Entity
spasm,I-Entity
.,O
Our,O
report,O
may,O
show,O
an,O
adverse,O
effect,O
on,O
the,O
Rho,O
/,O
ROCK,O
pathway,O
by,O
sorafenib,I-Entity
use,O
.,O
Anxiogenic,O
potential,O
of,O
ciprofloxacin,I-Entity
and,O
norfloxacin,I-Entity
in,O
rats,O
.,O
The,O
possible,O
anxiogenic,O
effects,O
of,O
fluoroquinolones,I-Entity
",",O
namely,O
ciprofloxacin,I-Entity
and,O
norfloxacin,I-Entity
",",O
were,O
investigated,O
in,O
adult,O
Charles,O
Foster,O
albino,O
rats,O
of,O
either,O
sex,O
",",O
weighing,O
150,O
-,O
200,O
g.,O
METHODS,O
:,O
The,O
results,O
indicate,O
that,O
ciprofloxacin-,I-Entity
and,O
norfloxacin,I-Entity
-,O
treated,O
rats,O
showed,O
anxious,B-Entity
behaviour,I-Entity
in,O
comparison,O
to,O
control,O
rats,O
in,O
all,O
the,O
parameters,O
studied,O
.,O
However,O
",",O
ciprofloxacin-,I-Entity
and,O
norfloxacin,I-Entity
-,O
treated,O
rats,O
did,O
not,O
differ,O
significantly,O
from,O
each,O
other,O
in,O
various,O
behavioural,O
parameters,O
.,O
CONCLUSION,O
:,O
The,O
present,O
experimental,O
findings,O
substantiate,O
the,O
clinically,O
observed,O
anxiogenic,O
potential,O
of,O
ciprofloxacin,I-Entity
and,O
norfloxacin,I-Entity
.,O
Myocardial,O
Fas,O
ligand,O
expression,O
increases,O
susceptibility,O
to,O
AZT,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
.,O
BACKGROUND,O
:,O
Dilated,B-Entity
cardiomyopathy,I-Entity
(,O
DCM,I-Entity
),O
and,O
myocarditis,I-Entity
occur,O
in,O
many,O
HIV,B-Entity
-,I-Entity
infected,I-Entity
individuals,O
",",O
resulting,O
in,O
symptomatic,O
heart,B-Entity
failure,I-Entity
in,O
up,O
to,O
5%,O
of,O
patients,O
.,O
Highly,O
active,O
antiretroviral,O
therapy,O
(,O
HAART,O
),O
has,O
significantly,O
reduced,O
morbidity,O
and,O
mortality,O
of,O
acquired,B-Entity
immunodeficiency,I-Entity
syndrome,I-Entity
(,O
AIDS,I-Entity
),O
",",O
but,O
has,O
resulted,O
in,O
an,O
increase,O
in,O
cardiac,B-Entity
and,I-Entity
skeletal,I-Entity
myopathies,I-Entity
.,O
In,O
order,O
to,O
investigate,O
whether,O
the,O
HAART,O
component,O
zidovudine,I-Entity
(,O
"3'-azido-2',3'-deoxythymidine",I-Entity
;,O
AZT,I-Entity
),O
triggers,O
the,O
Fas,O
-,O
dependent,O
cell,O
-,O
death,O
pathway,O
and,O
cause,O
cytoskeletal,O
disruption,O
in,O
a,O
murine,O
model,O
of,O
DCM,I-Entity
",",O
8-week,O
-,O
old,O
transgenic,O
(,O
expressing,O
Fas,O
ligand,O
in,O
the,O
myocardium,O
:,O
FasL,O
Tg,O
),O
and,O
non,O
-,O
transgenic,O
(,O
NTg,O
),O
mice,O
received,O
water,O
ad,O
libitum,O
containing,O
different,O
concentrations,O
of,O
AZT,I-Entity
(,O
0,O
",",O
0.07,O
",",O
0.2,O
",",O
and,O
0.7,O
mg,O
/,O
ml,O
),O
.,O
In,O
contrast,O
",",O
AZT,I-Entity
-,O
treated,O
FasL,O
Tg,O
mice,O
developed,O
cardiac,B-Entity
dilation,I-Entity
and,O
depressed,O
cardiac,O
function,O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
",",O
with,O
concomitant,O
inflammatory,O
infiltration,O
of,O
both,O
ventricles,O
.,O
The,O
expression,O
of,O
Fas,O
ligand,O
in,O
the,O
myocardium,O
",",O
as,O
identified,O
in,O
HIV,O
-,O
positive,O
patients,O
",",O
might,O
increase,O
the,O
susceptibility,O
to,O
HAART,O
-,O
induced,O
cardiomyopathy,I-Entity
due,O
to,O
activation,O
of,O
apoptotic,O
pathways,O
",",O
resulting,O
in,O
cardiac,B-Entity
dilation,I-Entity
and,I-Entity
dysfunction,I-Entity
.,O
Valproate,I-Entity
-,O
induced,O
chorea,I-Entity
and,O
encephalopathy,I-Entity
in,O
atypical,O
nonketotic,B-Entity
hyperglycinemia,I-Entity
.,O
Nonketotic,B-Entity
hyperglycinemia,I-Entity
is,O
a,O
disorder,B-Entity
of,I-Entity
amino,I-Entity
acid,I-Entity
metabolism,I-Entity
in,O
which,O
a,O
defect,O
in,O
the,O
glycine,I-Entity
cleavage,O
system,O
leads,O
to,O
an,O
accumulation,O
of,O
glycine,I-Entity
in,O
the,O
brain,O
and,O
other,O
body,O
compartments,O
.,O
In,O
the,O
classical,O
form,O
it,O
presents,O
as,O
neonatal,O
apnea,I-Entity
",",O
intractable,O
seizures,I-Entity
",",O
and,O
hypotonia,I-Entity
",",O
followed,O
by,O
significant,O
psychomotor,B-Entity
retardation,I-Entity
.,O
An,O
important,O
subset,O
of,O
children,O
with,O
nonketotic,B-Entity
hyperglycinemia,I-Entity
are,O
atypical,O
variants,O
who,O
present,O
in,O
a,O
heterogeneous,O
manner,O
.,O
This,O
report,O
describes,O
a,O
patient,O
with,O
mild,O
language,B-Entity
delay,I-Entity
and,O
mental,B-Entity
retardation,I-Entity
",",O
who,O
was,O
found,O
to,O
have,O
nonketotic,B-Entity
hyperglycinemia,I-Entity
following,O
her,O
presentation,O
with,O
acute,O
encephalopathy,I-Entity
and,O
chorea,I-Entity
shortly,O
after,O
initiation,O
of,O
valproate,I-Entity
therapy,O
.,O
Microinjection,O
of,O
ritanserin,I-Entity
into,O
the,O
CA1,O
region,O
of,O
hippocampus,O
improves,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
in,O
adult,O
male,O
rats,O
.,O
The,O
effect,O
of,O
ritanserin,I-Entity
(,O
5-HT2,O
antagonist,O
),O
on,O
scopolamine,I-Entity
(,O
muscarinic,O
cholinergic,O
antagonist)-induced,O
amnesia,I-Entity
in,O
Morris,O
water,O
maze,O
(,O
MWM,O
),O
was,O
investigated,O
.,O
One,O
week,O
later,O
",",O
they,O
received,O
repeatedly,O
vehicles,O
(,O
saline,O
",",O
DMSO,I-Entity
",",O
saline+DMSO,I-Entity
),O
",",O
scopolamine,I-Entity
(,O
2,O
microg/0.5,O
microl,O
saline,O
/,O
side,O
;,O
30,O
min,O
before,O
training,O
),O
",",O
ritanserin,I-Entity
(,O
2,O
",",O
4,O
and,O
8,O
microg/0.5,O
microl,O
DMSO,I-Entity
/,O
side,O
;,O
20,O
min,O
before,O
training,O
),O
and,O
scopolamine,I-Entity
(,O
2,O
microg/0.5,O
microl,O
;,O
30,O
min,O
before,O
ritanserin,I-Entity
injection)+ritanserin,I-Entity
(,O
4,O
microg/0.5,O
microl,O
DMSO,I-Entity
),O
through,O
cannulae,O
each,O
day,O
.,O
The,O
results,O
showed,O
a,O
significant,O
increase,O
in,O
escape,O
latencies,O
and,O
traveled,O
distances,O
to,O
find,O
platform,O
in,O
scopolamine,I-Entity
-,O
treated,O
group,O
as,O
compared,O
to,O
saline,O
group,O
.,O
Ritanserin,I-Entity
-,O
treated,O
rats,O
(,O
4,O
microg/0.5,O
microl,O
/,O
side,O
),O
showed,O
a,O
significant,O
decrease,O
in,O
the,O
mentioned,O
parameters,O
as,O
compared,O
to,O
DMSO,I-Entity
-,O
treated,O
group,O
.,O
However,O
",",O
scopolamine,I-Entity
and,O
ritanserin,I-Entity
co,O
-,O
administration,O
resulted,O
in,O
a,O
significant,O
decrease,O
in,O
escape,O
latencies,O
and,O
traveled,O
distances,O
as,O
compared,O
to,O
the,O
scopolamine,I-Entity
-,O
treated,O
rats,O
.,O
Our,O
findings,O
show,O
that,O
microinjection,O
of,O
ritanserin,I-Entity
into,O
the,O
CA1,O
region,O
of,O
the,O
hippocampus,O
improves,O
the,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
Hypoxia,I-Entity
in,O
renal,B-Entity
disease,I-Entity
with,O
proteinuria,I-Entity
and/or,O
glomerular,O
hypertension,I-Entity
.,O
In,O
this,O
study,O
",",O
we,O
developed,O
a,O
new,O
hypoxia,I-Entity
-,O
responsive,O
reporter,O
vector,O
using,O
a,O
hypoxia,I-Entity
-,O
responsive,O
element,O
of,O
the,O
5,O
',O
vascular,O
endothelial,O
growth,O
factor,O
untranslated,O
region,O
and,O
generated,O
a,O
novel,O
hypoxia,I-Entity
-,O
sensing,O
transgenic,O
rat,O
.,O
We,O
then,O
applied,O
this,O
animal,O
model,O
to,O
the,O
detection,O
of,O
tubulointerstitial,O
hypoxia,I-Entity
in,O
the,O
diseased,B-Entity
kidney,I-Entity
.,O
With,O
this,O
model,O
",",O
we,O
were,O
able,O
to,O
identify,O
diffuse,O
cortical,O
hypoxia,I-Entity
in,O
the,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephrotic,B-Entity
syndrome,I-Entity
and,O
focal,O
and,O
segmental,O
hypoxia,I-Entity
in,O
the,O
remnant,O
kidney,O
model,O
.,O
Expression,O
of,O
the,O
hypoxia,I-Entity
-,O
responsive,O
transgene,O
increased,O
throughout,O
the,O
observation,O
period,O
",",O
reaching,O
2.2-fold,O
at,O
2,O
weeks,O
in,O
the,O
puromycin,B-Entity
aminonucleoside,I-Entity
model,O
and,O
2.6-fold,O
at,O
4,O
weeks,O
in,O
the,O
remnant,O
kidney,O
model,O
",",O
whereas,O
that,O
of,O
vascular,O
endothelial,O
growth,O
factor,O
showed,O
a,O
mild,O
decrease,O
",",O
reflecting,O
distinct,O
behaviors,O
of,O
the,O
two,O
genes,O
.,O
The,O
degree,O
of,O
hypoxia,I-Entity
showed,O
a,O
positive,O
correlation,O
with,O
microscopic,O
tubulointerstitial,B-Entity
injury,I-Entity
in,O
both,O
models,O
.,O
Finally,O
",",O
we,O
identified,O
the,O
localization,O
of,O
proliferating,O
cell,O
nuclear,O
antigen,O
-,O
positive,O
",",O
ED-1-positive,O
",",O
and,O
terminal,O
dUTP,O
nick,O
-,O
end,O
labeled,O
-,O
positive,O
cells,O
in,O
the,O
hypoxic,I-Entity
cortical,O
area,O
in,O
the,O
remnant,O
kidney,O
model,O
.,O
We,O
propose,O
here,O
a,O
possible,O
pathological,O
tie,O
between,O
chronic,O
tubulointerstitial,O
hypoxia,I-Entity
and,O
progressive,O
glomerular,B-Entity
diseases,I-Entity
.,O
Consensus,O
statement,O
concerning,O
cardiotoxicity,I-Entity
occurring,O
during,O
haematopoietic,O
stem,O
cell,O
transplantation,O
in,O
the,O
treatment,O
of,O
autoimmune,B-Entity
diseases,I-Entity
",",O
with,O
special,O
reference,O
to,O
systemic,B-Entity
sclerosis,I-Entity
and,O
multiple,B-Entity
sclerosis,I-Entity
.,O
Autologous,O
haematopoietic,O
stem,O
cell,O
transplantation,O
is,O
now,O
a,O
feasible,O
and,O
effective,O
treatment,O
for,O
selected,O
patients,O
with,O
severe,O
autoimmune,B-Entity
diseases,I-Entity
.,O
This,O
is,O
primarily,O
due,O
to,O
complications,O
related,O
to,O
either,O
the,O
stage,O
of,O
the,O
disease,O
at,O
transplant,O
or,O
due,O
to,O
infections,I-Entity
.,O
The,O
number,O
of,O
deaths,O
related,O
to,O
cardiac,B-Entity
toxicity,I-Entity
is,O
low,O
.,O
However,O
",",O
caution,O
is,O
required,O
when,O
cyclophosphamide,I-Entity
or,O
anthracyclines,I-Entity
such,O
as,O
mitoxantrone,I-Entity
are,O
used,O
in,O
patients,O
with,O
a,O
possible,O
underlying,O
heart,B-Entity
damage,I-Entity
",",O
for,O
example,O
",",O
systemic,B-Entity
sclerosis,I-Entity
patients,O
.,O
The,O
object,O
of,O
the,O
meeting,O
was,O
to,O
analyse,O
existing,O
data,O
",",O
both,O
published,O
or,O
available,O
",",O
in,O
the,O
European,O
Group,O
for,O
Blood,O
and,O
Marrow,O
Transplantation,O
autoimmune,B-Entity
disease,I-Entity
database,O
",",O
and,O
to,O
propose,O
a,O
safe,O
approach,O
to,O
such,O
patients,O
.,O
Immunohistochemical,O
study,O
on,O
inducible,O
type,O
of,O
nitric,B-Entity
oxide,I-Entity
(,O
iNOS,O
),O
",",O
basic,O
fibroblast,O
growth,O
factor,O
(,O
bFGF,O
),O
and,O
tumor,I-Entity
growth,O
factor,O
-,O
beta1,O
(,O
TGF,O
-,O
beta1,O
),O
in,O
arteritis,I-Entity
induced,O
in,O
rats,O
by,O
fenoldopam,I-Entity
and,O
theophylline,I-Entity
",",O
vasodilators,O
.,O
Arteritis,I-Entity
induced,O
in,O
rats,O
by,O
vasodilators,O
",",O
fenoldopam,I-Entity
and,O
theophylline,I-Entity
",",O
was,O
examined,O
immunohistochemically,O
for,O
expressions,O
of,O
inducible,O
type,O
of,O
nitric,B-Entity
oxide,I-Entity
synthase,O
(,O
iNOS,O
),O
",",O
basic,O
fibroblast,O
growth,O
factor,O
(,O
bFGF,O
),O
and,O
tumor,I-Entity
growth,O
factor,O
-,O
beta1,O
(,O
TGF,O
-,O
beta1,O
),O
.,O
Rats,O
were,O
administered,O
fenoldopam,I-Entity
for,O
24,O
hours,O
by,O
intravenous,O
infusion,O
with,O
or,O
without,O
following,O
repeated,O
daily,O
oral,O
administrations,O
of,O
theophylline,I-Entity
.,O
Irrespective,O
of,O
theophylline,I-Entity
administration,O
",",O
iNOS,O
antigens,O
were,O
remarkably,O
abundant,O
in,O
ED-1-positive,O
cells,O
on,O
day,O
5,O
and,O
8,O
post,O
-,O
fenoldopam,I-Entity
-,O
infusion,O
(,O
DPI,O
),O
;,O
bFGF,O
antigens,O
were,O
remarkably,O
abundant,O
in,O
ED-1-positive,O
cells,O
on,O
1,O
and,O
3,O
DPI,O
;,O
TGF,O
-,O
beta1,O
antigens,O
were,O
observed,O
in,O
ED-1-positive,O
cells,O
on,O
and,O
after,O
5,O
DPI,O
.,O
These,O
results,O
suggest,O
that,O
the,O
peak,O
expression,O
of,O
iNOS,O
antigen,O
was,O
followed,O
by,O
that,O
of,O
bFGF,O
antigen,O
",",O
and,O
bFGF,O
may,O
have,O
a,O
suppressive,O
effect,O
on,O
iNOS,O
expression,O
in,O
these,O
rat,O
arteritis,I-Entity
models,O
.,O
Low,B-Entity
-,I-Entity
molecular,I-Entity
-,I-Entity
weight,I-Entity
heparin,I-Entity
for,O
the,O
treatment,O
of,O
patients,O
with,O
mechanical,O
heart,O
valves,O
.,O
Unfractionated,B-Entity
heparin,I-Entity
(,O
UH,I-Entity
),O
is,O
currently,O
the,O
substitute,O
for,O
selected,O
patients,O
.,O
Low,B-Entity
-,I-Entity
molecular,I-Entity
-,I-Entity
weight,I-Entity
heparin,I-Entity
(,O
LMWH,I-Entity
),O
offers,O
theoretical,O
advantages,O
over,O
UH,I-Entity
",",O
but,O
is,O
not,O
currently,O
considered,O
in,O
clinical,O
guidelines,O
as,O
an,O
alternative,O
to,O
UH,I-Entity
in,O
patients,O
with,O
prosthetic,O
valves,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
review,O
the,O
data,O
accumulated,O
so,O
far,O
on,O
the,O
use,O
of,O
LMWH,I-Entity
in,O
this,O
patient,O
population,O
and,O
to,O
discuss,O
its,O
applicability,O
in,O
common,O
practice,O
.,O
METHODS,O
:,O
For,O
this,O
paper,O
",",O
the,O
current,O
medical,O
literature,O
on,O
LMWH,I-Entity
in,O
patients,O
with,O
mechanical,O
heart,O
valves,O
was,O
extensively,O
reviewed,O
.,O
Data,O
to,O
establish,O
the,O
thromboembolic,I-Entity
risk,O
were,O
incomplete,O
.,O
The,O
incidence,O
rate,O
of,O
thromboembolism,I-Entity
was,O
0.9%,O
for,O
all,O
the,O
studies,O
and,O
0.5,O
",",O
0,O
",",O
20,O
",",O
and,O
0%,O
in,O
groups,O
a,O
",",O
b,O
",",O
c,O
",",O
and,O
d,O
",",O
respectively,O
;,O
for,O
hemorrhage,I-Entity
",",O
the,O
overall,O
rate,O
was,O
3.4%,O
(,O
3.8,O
",",O
2.6,O
",",O
10,O
",",O
and,O
0%,O
for,O
the,O
respective,O
groups,O
),O
.,O
In,O
patients,O
with,O
mechanical,O
heart,O
valves,O
",",O
short,O
-,O
term,O
LMWH,I-Entity
therapy,O
compares,O
favorably,O
with,O
UH,I-Entity
.,O
Data,O
on,O
mid-,O
and,O
long,O
-,O
term,O
LMWH,I-Entity
administration,O
in,O
these,O
patients,O
are,O
sparse,O
.,O
Further,O
randomized,O
studies,O
are,O
needed,O
to,O
confirm,O
the,O
safety,O
and,O
precise,O
indications,O
for,O
the,O
use,O
of,O
LMWH,I-Entity
in,O
patients,O
with,O
mechanical,O
heart,O
valves,O
.,O
Topiramate,I-Entity
-,O
induced,O
nephrolithiasis,I-Entity
.,O
Topiramate,I-Entity
is,O
a,O
recently,O
developed,O
antiepileptic,O
medication,O
that,O
is,O
becoming,O
more,O
widely,O
prescribed,O
because,O
of,O
its,O
efficacy,O
in,O
treating,O
refractory,B-Entity
seizures,I-Entity
.,O
Urologists,O
should,O
be,O
aware,O
that,O
this,O
medication,O
can,O
cause,O
metabolic,B-Entity
acidosis,I-Entity
in,O
patients,O
secondary,O
to,O
inhibition,O
of,O
carbonic,O
anhydrase,O
.,O
These,O
factors,O
can,O
lead,O
to,O
the,O
development,O
of,O
calcium,B-Entity
phosphate,I-Entity
nephrolithiasis,I-Entity
.,O
We,O
report,O
the,O
first,O
two,O
cases,O
of,O
topiramate,I-Entity
-,O
induced,O
nephrolithiasis,I-Entity
in,O
the,O
urologic,O
literature,O
.,O
Spironolactone,I-Entity
:,O
is,O
it,O
a,O
novel,O
drug,O
for,O
the,O
prevention,O
of,O
amphotericin,B-Entity
B,I-Entity
-,O
related,O
hypokalemia,I-Entity
in,O
cancer,I-Entity
patients,O
?,O
OBJECTIVE,O
:,O
Nephrotoxicity,I-Entity
is,O
the,O
major,O
adverse,O
effect,O
of,O
amphotericin,B-Entity
B,I-Entity
(,O
AmB,I-Entity
),O
",",O
often,O
limiting,O
administration,O
of,O
full,O
dosage,O
.,O
Selective,O
distal,O
tubular,O
epithelial,O
toxicity,I-Entity
seems,O
to,O
be,O
responsible,O
for,O
the,O
profound,O
potassium,I-Entity
wasting,O
that,O
is,O
a,O
major,O
clinical,O
side,O
effect,O
of,O
treatment,O
with,O
AmB.,I-Entity
Potassium,I-Entity
depletion,O
also,O
potentiates,O
the,O
tubular,O
toxicity,I-Entity
of,O
AmB.,I-Entity
This,O
study,O
was,O
designed,O
to,O
assess,O
the,O
ability,O
of,O
spironolactone,I-Entity
to,O
reduce,O
potassium,I-Entity
requirements,O
and,O
to,O
prevent,O
hypokalemia,I-Entity
in,O
neutropenic,I-Entity
patients,O
on,O
AmB,I-Entity
treatment,O
.,O
In,O
this,O
study,O
26,O
patients,O
with,O
various,O
hematological,B-Entity
disorders,I-Entity
were,O
randomized,O
to,O
receive,O
either,O
intravenous,O
AmB,I-Entity
alone,O
or,O
AmB,I-Entity
and,O
oral,O
spironolactone,I-Entity
100,O
mg,O
twice,O
daily,O
when,O
developing,O
a,O
proven,O
or,O
suspected,O
fungal,B-Entity
infection,I-Entity
.,O
Patients,O
receiving,O
concomitant,O
AmB,I-Entity
and,O
spironolactone,I-Entity
had,O
significantly,O
higher,O
plasma,O
potassium,I-Entity
levels,O
than,O
those,O
receiving,O
AmB,I-Entity
alone,O
(,O
P,O
=,O
0.0027,O
),O
.,O
Those,O
patients,O
receiving,O
AmB,I-Entity
and,O
spironolactone,I-Entity
required,O
significantly,O
less,O
potassium,I-Entity
supplementation,O
to,O
maintain,O
their,O
plasma,O
potassium,I-Entity
within,O
the,O
normal,O
range,O
(,O
P,O
=,O
0.022,O
),O
.,O
Moreover,O
",",O
urinary,O
potassium,I-Entity
losses,O
were,O
significantly,O
less,O
in,O
patients,O
receiving,O
AmB,I-Entity
and,O
spironolactone,I-Entity
than,O
those,O
receiving,O
AmB,I-Entity
alone,O
(,O
P,O
=,O
0.040,O
),O
.,O
This,O
study,O
showed,O
that,O
spironolactone,I-Entity
can,O
reduce,O
potassium,I-Entity
requirements,O
and,O
prevent,O
hypokalemia,I-Entity
by,O
reducing,O
urinary,O
potassium,I-Entity
loss,O
in,O
neutropenic,I-Entity
patients,O
on,O
AmB,I-Entity
treatment,O
.,O
Dopamine,I-Entity
D2,O
receptor,O
signaling,O
controls,O
neuronal,O
cell,O
death,O
induced,O
by,O
muscarinic,O
and,O
glutamatergic,O
drugs,O
.,O
Dopamine,I-Entity
(,O
DA,I-Entity
),O
",",O
through,O
D1/D2,O
receptor,O
-,O
mediated,O
signaling,O
",",O
plays,O
a,O
major,O
role,O
in,O
the,O
control,O
of,O
epileptic,B-Entity
seizures,I-Entity
arising,O
in,O
the,O
limbic,O
system,O
.,O
Excitotoxicity,I-Entity
leading,O
to,O
neuronal,O
cell,O
death,O
in,O
the,O
affected,O
areas,O
is,O
a,O
major,O
consequence,O
of,O
seizures,I-Entity
at,O
the,O
cellular,O
level,O
.,O
In,O
this,O
respect,O
",",O
little,O
is,O
known,O
about,O
the,O
role,O
of,O
DA,I-Entity
receptors,O
in,O
the,O
occurrence,O
of,O
epilepsy,I-Entity
-,O
induced,O
neuronal,O
cell,O
death,O
.,O
Here,O
we,O
analyze,O
the,O
occurrence,O
of,O
seizures,I-Entity
and,O
neurotoxicity,I-Entity
in,O
D2R,O
-/-,O
mice,O
treated,O
with,O
the,O
cholinergic,O
agonist,O
pilocarpine,I-Entity
.,O
We,O
compared,O
these,O
results,O
with,O
those,O
previously,O
obtained,O
with,O
kainic,B-Entity
acid,I-Entity
(,O
KA,I-Entity
),O
",",O
a,O
potent,O
glutamate,I-Entity
agonist,O
.,O
Importantly,O
",",O
D2R,O
-/-,O
mice,O
develop,O
seizures,I-Entity
at,O
doses,O
of,O
both,O
drugs,O
that,O
are,O
not,O
epileptogenic,O
for,O
WT,O
littermates,O
and,O
show,O
greater,O
neurotoxicity,I-Entity
.,O
However,O
",",O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
result,O
in,O
a,O
more,O
widespread,O
neuronal,O
death,O
in,O
both,O
WT,O
and,O
D2R,O
-/-,O
brains,O
in,O
comparison,O
to,O
KA,I-Entity
.,O
Thus,O
",",O
the,O
absence,O
of,O
D2R,O
lowers,O
the,O
threshold,O
for,O
seizures,I-Entity
induced,O
by,O
both,O
glutamate,I-Entity
and,O
acetylcholine,I-Entity
.,O
Moreover,O
",",O
the,O
dopaminergic,O
control,O
of,O
epilepsy,I-Entity
-,O
induced,O
neurodegeneration,I-Entity
seems,O
to,O
be,O
mediated,O
by,O
distinct,O
interactions,O
of,O
D2R,O
signaling,O
with,O
these,O
two,O
neurotransmitters,O
.,O
Treatment,O
of,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
with,O
a,O
dopamine,I-Entity
agonist,O
in,O
children,O
.,O
Risperidone,I-Entity
",",O
a,O
potent,O
antagonist,O
of,O
both,O
serotonergic,O
(,O
5HT2A,O
),O
and,O
dopaminergic,O
D2,O
receptors,O
is,O
associated,O
with,O
hyperprolactinemia,I-Entity
in,O
adults,O
and,O
children,O
.,O
Chronically,O
elevated,O
prolactin,O
levels,O
in,O
children,O
with,O
prolactinomas,I-Entity
may,O
be,O
associated,O
with,O
arrested,O
growth,O
and,O
development,O
resulting,O
in,O
either,O
delayed,B-Entity
puberty,I-Entity
or,O
short,O
stature,O
.,O
These,O
possibilities,O
stress,O
the,O
importance,O
of,O
developing,O
a,O
safe,O
and,O
effective,O
approach,O
to,O
drug,O
-,O
induced,O
hyperprolactinemia,I-Entity
in,O
youth,O
.,O
We,O
report,O
the,O
successful,O
treatment,O
of,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
with,O
cabergoline,I-Entity
in,O
youth,O
.,O
:,O
We,O
undertook,O
a,O
retrospective,O
case,O
review,O
of,O
four,O
children,O
with,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
treated,O
with,O
cabergoline,I-Entity
.,O
Four,O
males,O
(,O
age,O
6,O
-,O
11,O
years,O
),O
with,O
Diagnostic,O
and,O
Statistical,O
Manual,O
of,O
Mental,B-Entity
Disorders,I-Entity
(,O
fourth,O
edition,O
),O
bipolar,B-Entity
disorder,I-Entity
or,O
psychoses,I-Entity
",",O
with,O
risperidone,I-Entity
-,O
induced,O
elevations,O
in,O
serum,O
prolactin,O
levels,O
(,O
57.5,O
-,O
129,O
ng,O
/,O
mL,O
",",O
normal,O
5,O
-,O
15,O
ng,O
/,O
mL,O
),O
",",O
were,O
treated,O
with,O
cabergoline,I-Entity
10.9,O
ng,O
/,O
mL,O
),O
",",O
the,O
cabergoline,I-Entity
dose,O
was,O
reduced,O
to,O
1,O
mg,O
/,O
week,O
in,O
three,O
of,O
four,O
subjects,O
.,O
The,O
mean,O
duration,O
of,O
therapy,O
with,O
cabergoline,I-Entity
was,O
523.5,O
+,O
/-,O
129.7,O
days,O
",",O
and,O
the,O
mean,O
duration,O
of,O
therapy,O
with,O
risperidone,I-Entity
was,O
788.5,O
+,O
/-,O
Cabergoline,I-Entity
was,O
well,O
tolerated,O
without,O
adverse,O
effects,O
.,O
Cabergoline,I-Entity
may,O
be,O
useful,O
for,O
the,O
treatment,O
of,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
in,O
youth,O
;,O
however,O
",",O
further,O
research,O
is,O
needed,O
.,O
Cholestatic,B-Entity
jaundice,I-Entity
associated,O
with,O
the,O
use,O
of,O
metformin,I-Entity
.,O
We,O
report,O
a,O
patient,O
who,O
developed,O
cholestatic,B-Entity
jaundice,I-Entity
shortly,O
after,O
initiation,O
of,O
treatment,O
with,O
metformin,B-Entity
hydrochloride,I-Entity
.,O
A,O
percutaneous,O
liver,O
biopsy,O
was,O
obtained,O
showing,O
marked,O
cholestasis,I-Entity
",",O
with,O
portal,O
edema,I-Entity
",",O
ductular,O
proliferation,O
",",O
and,O
acute,O
inflammation,I-Entity
.,O
Metformin,B-Entity
hydrochloride,I-Entity
was,O
discontinued,O
",",O
and,O
the,O
patient,O
's,O
jaundice,I-Entity
resolved,O
slowly,O
over,O
a,O
period,O
of,O
several,O
months,O
.,O
Given,O
the,O
onset,O
of,O
his,O
jaundice,I-Entity
2,O
wk,O
after,O
the,O
initiation,O
of,O
metformin,I-Entity
",",O
we,O
believe,O
that,O
this,O
case,O
represents,O
an,O
example,O
of,O
metformin,I-Entity
-,O
associated,O
hepatotoxicity,I-Entity
",",O
the,O
first,O
such,O
case,O
reported,O
.,O
Electro,O
-,O
oculography,O
",",O
electroretinography,O
",",O
visual,O
evoked,O
potentials,O
",",O
and,O
multifocal,O
electroretinography,O
in,O
patients,O
with,O
vigabatrin,I-Entity
-,O
attributed,O
visual,B-Entity
field,I-Entity
constriction,I-Entity
.,O
Symptomatic,O
visual,B-Entity
field,I-Entity
constriction,I-Entity
thought,O
to,O
be,O
associated,O
with,O
vigabatrin,I-Entity
has,O
been,O
reported,O
.,O
The,O
current,O
study,O
investigated,O
the,O
visual,O
fields,O
and,O
visual,O
electrophysiology,O
of,O
eight,O
patients,O
with,O
known,O
vigabatrin,I-Entity
-,O
attributed,O
visual,B-Entity
field,I-Entity
loss,I-Entity
",",O
three,O
of,O
whom,O
were,O
reported,O
previously,O
.,O
Six,O
of,O
the,O
patients,O
were,O
no,O
longer,O
receiving,O
vigabatrin,I-Entity
.,O
Seven,O
patients,O
showed,O
marked,O
visual,B-Entity
field,I-Entity
constriction,I-Entity
with,O
some,O
sparing,O
of,O
the,O
temporal,O
visual,O
field,O
.,O
Marked,O
visual,B-Entity
field,I-Entity
constriction,I-Entity
appears,O
to,O
be,O
associated,O
with,O
vigabatrin,I-Entity
therapy,O
.,O
The,O
field,O
defects,O
and,O
some,O
electrophysiological,O
abnormalities,O
persist,O
when,O
vigabatrin,I-Entity
therapy,O
is,O
withdrawn,O
.,O
Conversion,O
to,O
rapamycin,I-Entity
immunosuppression,O
in,O
renal,O
transplant,O
recipients,O
:,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
evaluate,O
the,O
effects,O
of,O
RAPA,I-Entity
conversion,O
in,O
patients,O
undergoing,O
cyclosporine,I-Entity
(,O
CsA,I-Entity
),O
or,O
tacrolimus,I-Entity
(,O
Tac,I-Entity
),O
toxicity,I-Entity
.,O
Twenty,O
renal,O
transplant,O
recipients,O
were,O
switched,O
to,O
fixed,O
dose,O
rapamycin,I-Entity
(,O
RAPA,I-Entity
),O
(,O
5,O
mg,O
/,O
day,O
),O
0,O
to,O
204,O
months,O
posttransplant,O
.,O
The,O
indications,O
for,O
switch,O
were,O
chronic,O
CsA,I-Entity
or,O
Tac,I-Entity
nephrotoxicity,I-Entity
(,O
12,O
),O
",",O
acute,O
CsA,I-Entity
or,O
Tac,I-Entity
toxicity,I-Entity
(,O
3,O
),O
",",O
severe,O
facial,B-Entity
dysmorphism,I-Entity
(,O
2,O
),O
",",O
posttransplant,B-Entity
lymphoproliferative,I-Entity
disorder,I-Entity
(,O
PTLD,I-Entity
),O
in,O
remission,O
(,O
2,O
),O
",",O
and,O
hepatotoxicity,I-Entity
in,O
1,O
.,O
In,O
the,O
12,O
patients,O
switched,O
because,O
of,O
chronic,O
nephrotoxicity,I-Entity
there,O
was,O
a,O
significant,O
decrease,O
in,O
serum,O
creatinine,I-Entity
[,O
233+/-34,O
to,O
210+/-56,O
micromol,O
/,O
liter,O
(,O
P<0.05,O
),O
at,O
6,O
months,O
],O
.,O
Facial,B-Entity
dysmorphism,I-Entity
improved,O
in,O
two,O
patients,O
.,O
No,O
relapse,O
of,O
PTLD,I-Entity
was,O
observed,O
.,O
Five,O
patients,O
developed,O
pneumonia,I-Entity
(,O
two,O
Pneumocystis,B-Entity
carinii,I-Entity
pneumonia,I-Entity
",",O
one,O
infectious,B-Entity
mononucleosis,I-Entity
with,O
polyclonal,O
PTLD,I-Entity
lung,O
infiltrate,O
),O
and,O
two,O
had,O
bronchiolitis,B-Entity
obliterans,I-Entity
.,O
RAPA,I-Entity
was,O
discontinued,O
in,O
four,O
patients,O
",",O
because,O
of,O
pneumonia,I-Entity
in,O
two,O
",",O
PTLD,I-Entity
in,O
one,O
",",O
and,O
oral,O
aphtous,B-Entity
ulcers,I-Entity
in,O
one,O
.,O
RAPA,I-Entity
levels,O
were,O
high,O
(,O
>,O
15,O
ng,O
/,O
ml,O
),O
in,O
7,O
of,O
13,O
(,O
54%,O
),O
patients,O
.,O
RAPA,I-Entity
conversion,O
provides,O
adequate,O
immunosuppression,O
to,O
enable,O
CsA,I-Entity
withdrawal,O
.,O
However,O
",",O
when,O
converting,O
patients,O
to,O
RAPA,I-Entity
drug,O
levels,O
should,O
be,O
monitored,O
to,O
avoid,O
over,O
-,O
immunosuppression,O
and,O
adequate,O
antiviral,O
and,O
Pneumocystis,B-Entity
carinii,I-Entity
pneumonia,I-Entity
prophylaxis,O
should,O
be,O
given,O
.,O
Worsening,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
by,O
motor,O
and,O
mental,O
tasks,O
.,O
Ten,O
patients,O
who,O
had,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
with,O
disabling,O
dyskinesia,I-Entity
were,O
included,O
in,O
this,O
study,O
to,O
evaluate,O
the,O
role,O
of,O
mental,O
(,O
mental,O
calculation,O
),O
and,O
motor,O
(,O
flexion,O
/,O
extension,O
of,O
right,O
fingers,O
",",O
flexion,O
/,O
extension,O
of,O
left,O
fingers,O
",",O
flexion,O
/,O
extension,O
of,O
the,O
neck,O
",",O
speaking,O
aloud,O
),O
tasks,O
on,O
the,O
worsening,O
of,O
peak,O
-,O
dose,O
dyskinesia,I-Entity
following,O
administration,O
of,O
an,O
effective,O
single,O
dose,O
of,O
apomorphine,I-Entity
.,O
Compared,O
with,O
the,O
score,O
at,O
rest,O
(,O
1.3+/-0.3,O
),O
",",O
a,O
significant,O
aggravation,O
of,O
the,O
dyskinesia,I-Entity
score,O
was,O
observed,O
during,O
speaking,O
aloud,O
(,O
5.2+/-1.1,O
",",O
p<0.05,O
),O
",",O
movements,O
of,O
right,O
(,O
4.5+/-1.0,O
",",O
p<0.05,O
),O
and,O
left,O
(,O
3.7+/-0.8,O
",",O
p<0.05,O
),O
fingers,O
",",O
movements,O
of,O
the,O
neck,O
(,O
5.1+/-1.0,O
",",O
p<0.05,O
),O
",",O
and,O
mental,O
calculation,O
(,O
3.1+/-1.0,O
",",O
p<0.05,O
),O
.,O
These,O
results,O
suggest,O
that,O
activation,O
tasks,O
such,O
as,O
"""",O
speaking,O
aloud,O
"""",O
could,O
be,O
used,O
for,O
objective,O
assessment,O
of,O
dyskinesia,I-Entity
severity,O
.,O
Structural,B-Entity
and,I-Entity
functional,I-Entity
impairment,I-Entity
of,I-Entity
mitochondria,I-Entity
in,O
adriamycin,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
in,O
mice,O
:,O
suppression,O
of,O
cytochrome,O
c,O
oxidase,O
II,O
gene,O
expression,O
.,O
The,O
use,O
of,O
adriamycin,I-Entity
(,O
ADR,I-Entity
),O
in,O
cancer,I-Entity
chemotherapy,O
has,O
been,O
limited,O
due,O
to,O
its,O
cumulative,O
cardiovascular,B-Entity
toxicity,I-Entity
.,O
Earlier,O
observations,O
that,O
ADR,I-Entity
interacts,O
with,O
mitochondrial,O
cytochrome,O
c,O
oxidase,O
(,O
COX,O
),O
and,O
suppresses,O
its,O
enzyme,O
activity,O
led,O
us,O
to,O
investigate,O
ADR,I-Entity
's,O
action,O
on,O
the,O
cardiovascular,O
functions,O
and,O
heart,O
mitochondrial,O
morphology,O
in,O
Balb,O
-,O
c,O
mice,O
i.p,O
.,O
treated,O
with,O
ADR,I-Entity
for,O
several,O
weeks,O
.,O
Our,O
results,O
indicated,O
that,O
1,O
),O
treatment,O
of,O
mice,O
with,O
ADR,I-Entity
caused,O
cardiovascular,B-Entity
arrhythmias,I-Entity
characterized,O
by,O
bradycardia,I-Entity
",",O
extension,O
of,O
ventricular,O
depolarization,O
time,O
(,O
tQRS,O
),O
",",O
and,O
failure,O
of,O
QRS,O
at,O
high,O
concentrations,O
(,O
10,O
-,O
14,O
mg,O
/,O
kg,O
body,O
weight,O
cumulative,O
dose,O
),O
;,O
2,O
),O
the,O
heart,O
mitochondria,O
underwent,O
swelling,I-Entity
",",O
fusion,O
",",O
dissolution,O
",",O
and/or,O
disruption,O
of,O
mitochondrial,O
cristae,O
after,O
several,O
weeks,O
of,O
treatment,O
.,O
Such,O
abnormalities,O
were,O
not,O
observed,O
in,O
the,O
mitochondria,O
of,O
liver,O
tissue,O
;,O
and,O
3,O
),O
among,O
the,O
three,O
genes,O
of,O
COX,O
enzyme,O
examined,O
",",O
only,O
COXII,O
gene,O
expression,O
was,O
suppressed,O
by,O
ADR,I-Entity
treatment,O
",",O
mainly,O
after,O
8,O
weeks,O
in,O
both,O
heart,O
and,O
liver,O
.,O
Knowing,O
that,O
heart,O
mitochondria,O
represent,O
almost,O
40%,O
of,O
heart,O
muscle,O
by,O
weight,O
",",O
we,O
conclude,O
that,O
the,O
deteriorating,O
effects,O
of,O
ADR,I-Entity
on,O
cardiovascular,O
function,O
involve,O
mitochondrial,B-Entity
structural,I-Entity
and,I-Entity
functional,I-Entity
impairment,I-Entity
.,O
Enhanced,O
bradycardia,I-Entity
induced,O
by,O
beta,O
-,O
adrenoceptor,O
antagonists,O
in,O
rats,O
pretreated,O
with,O
isoniazid,I-Entity
.,O
High,O
doses,O
of,O
isoniazid,I-Entity
increase,O
hypotension,I-Entity
induced,O
by,O
vasodilators,O
and,O
change,O
the,O
accompanying,O
reflex,O
tachycardia,I-Entity
to,O
bradycardia,I-Entity
",",O
an,O
interaction,O
attributed,O
to,O
decreased,O
synthesis,O
of,O
brain,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid,I-Entity
(,O
GABA,I-Entity
),O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
possible,O
enhancement,O
by,O
isoniazid,I-Entity
of,O
bradycardia,I-Entity
induced,O
by,O
beta,O
-,O
adrenoceptor,O
antagonists,O
was,O
determined,O
in,O
rats,O
anaesthetised,O
with,O
chloralose,I-Entity
-,O
urethane,I-Entity
.,O
Isoniazid,I-Entity
significantly,O
increased,O
bradycardia,I-Entity
after,O
propranolol,I-Entity
",",O
pindolol,I-Entity
",",O
labetalol,I-Entity
and,O
atenolol,I-Entity
",",O
as,O
well,O
as,O
after,O
clonidine,I-Entity
",",O
but,O
not,O
after,O
hexamethonium,I-Entity
or,O
carbachol,I-Entity
.,O
Enhancement,O
was,O
not,O
observed,O
in,O
rats,O
pretreated,O
with,O
methylatropine,I-Entity
or,O
previously,O
vagotomised,O
.,O
These,O
results,O
are,O
compatible,O
with,O
interference,O
by,O
isoniazid,I-Entity
with,O
GABAergic,O
inhibition,O
of,O
cardiac,O
parasympathetic,O
tone,O
.,O
Epileptogenic,O
activity,O
of,O
folic,B-Entity
acid,I-Entity
after,O
drug,O
induces,O
SLE,I-Entity
(,O
folic,B-Entity
acid,I-Entity
and,O
epilepsy,I-Entity
),O
OBJECTIVE,O
:,O
To,O
study,O
the,O
effect,O
of,O
folic,B-Entity
acid,I-Entity
-,O
containing,O
multivitamin,O
supplementation,O
in,O
epileptic,I-Entity
women,O
before,O
and,O
during,O
pregnancy,O
in,O
order,O
to,O
determine,O
the,O
rate,O
of,O
structural,O
birth,B-Entity
defects,I-Entity
and,O
epilepsy,I-Entity
-,O
related,O
side,O
effects,O
.,O
Of,O
60,O
epileptic,I-Entity
women,O
with,O
periconceptional,O
folic,B-Entity
acid,I-Entity
(,O
0.8,O
mg)-containing,O
multivitamin,O
supplementation,O
",",O
no,O
one,O
developed,O
epilepsy,I-Entity
-,O
related,O
side,O
effects,O
during,O
the,O
periconception,O
period,O
.,O
One,O
epileptic,I-Entity
woman,O
delivered,O
a,O
newborn,O
with,O
cleft,B-Entity
lip,I-Entity
and,I-Entity
palate,I-Entity
.,O
Another,O
patient,O
exhibited,O
with,O
a,O
cluster,O
of,O
seizures,I-Entity
after,O
the,O
periconception,O
period,O
using,O
another,O
multivitamin,O
.,O
This,O
22-year,O
-,O
old,O
epileptic,I-Entity
woman,O
was,O
treated,O
continuously,O
by,O
carbamazepine,I-Entity
and,O
a,O
folic,B-Entity
acid,I-Entity
(,O
1,O
mg)-containing,O
multivitamin,O
from,O
the,O
20th,O
week,O
of,O
gestation,O
.,O
She,O
developed,O
status,B-Entity
epilepticus,I-Entity
and,O
later,O
symptoms,O
of,O
systemic,B-Entity
lupus,I-Entity
erythematodes,I-Entity
.,O
Her,O
pregnancy,O
ended,O
with,O
stillbirth,I-Entity
.,O
The,O
epileptic,I-Entity
pregnant,O
patient,O
's,O
autoimmune,B-Entity
disease,I-Entity
(,O
probably,O
drug,O
-,O
induced,O
lupus,I-Entity
),O
could,O
damage,O
the,O
blood,O
-,O
brain,O
barrier,O
",",O
therefore,O
the,O
therapeutic,O
dose,O
(,O
>,O
or,O
=,O
1,O
mg,O
),O
of,O
folic,B-Entity
acid,I-Entity
triggered,O
a,O
cluster,O
of,O
seizures,I-Entity
.,O
Physiological,O
dose,O
(,O
<,O
1,O
mg,O
),O
of,O
folic,B-Entity
acid,I-Entity
both,O
in,O
healthy,O
and,O
60,O
epileptic,I-Entity
women,O
",",O
all,O
without,O
any,O
autoimmune,B-Entity
disease,I-Entity
",",O
did,O
not,O
increase,O
the,O
risk,O
for,O
epileptic,B-Entity
seizures,I-Entity
.,O
Effects,O
of,O
cisapride,I-Entity
on,O
symptoms,O
and,O
postcibal,O
small,O
-,O
bowel,O
motor,O
function,O
in,O
patients,O
with,O
irritable,B-Entity
bowel,I-Entity
syndrome,I-Entity
.,O
BACKGROUND,O
:,O
Irritable,B-Entity
bowel,I-Entity
syndrome,I-Entity
is,O
a,O
common,O
cause,O
of,O
abdominal,B-Entity
pain,I-Entity
and,O
discomfort,O
and,O
may,O
be,O
related,O
to,O
disordered,B-Entity
gastrointestinal,I-Entity
motility,I-Entity
.,O
Our,O
aim,O
was,O
to,O
assess,O
the,O
effects,O
of,O
long,O
-,O
term,O
treatment,O
with,O
a,O
prokinetic,O
agent,O
",",O
cisapride,I-Entity
",",O
on,O
postprandial,O
jejunal,O
motility,O
and,O
symptoms,O
in,O
the,O
irritable,B-Entity
bowel,I-Entity
syndrome,I-Entity
(,O
IBS,I-Entity
),O
.,O
METHODS,O
:,O
Thirty,O
-,O
eight,O
patients,O
with,O
IBS,I-Entity
(,O
constipation,I-Entity
-,O
predominant,O
",",O
n,O
=,O
17,O
;,O
diarrhoea,I-Entity
-,O
predominant,O
",",O
n,O
=,O
21,O
),O
underwent,O
24-h,O
ambulatory,O
jejunal,O
manometry,O
before,O
and,O
after,O
12,O
week,O
's,O
treatment,O
[,O
cisapride,I-Entity
",",O
5,O
mg,O
three,O
times,O
daily,O
(,O
n,O
=,O
19,O
),O
or,O
placebo,O
In,O
diarrhoea,I-Entity
-,O
predominant,O
patients,O
significant,O
differences,O
in,O
contraction,O
characteristics,O
were,O
observed,O
between,O
the,O
cisapride,I-Entity
and,O
placebo,O
groups,O
.,O
In,O
cisapride,I-Entity
-,O
treated,O
diarrhoea,I-Entity
-,O
predominant,O
patients,O
the,O
mean,O
contraction,O
amplitude,O
was,O
higher,O
(,O
29.3,O
+,O
/-,O
2.6,O
mm,O
Hg,O
",",O
cisapride,I-Entity
versus,O
placebo,O
(,O
P,O
<,O
0.001,O
),O
;,O
pretreatment,O
",",O
25.7,O
+,O
/-,O
0.2,O
sec,O
",",O
cisapride,I-Entity
versus,O
placebo,O
(,O
P,O
<,O
0.001,O
),O
;,O
pretreatment,O
",",O
3.1,O
+,O
/-,O
0.4,O
cont./min,O
",",O
cisapride,I-Entity
versus,O
placebo,O
(,O
P,O
No,O
significant,O
differences,O
in,O
jejunal,O
motility,O
were,O
found,O
in,O
the,O
constipation,I-Entity
-,O
predominant,O
IBS,I-Entity
group,O
.,O
Symptom,O
scores,O
relating,O
to,O
the,O
severity,O
of,O
constipation,I-Entity
were,O
lower,O
in,O
cisapride,I-Entity
-,O
treated,O
constipation,I-Entity
-,O
predominant,O
IBS,I-Entity
patients,O
[,O
score,O
",",O
54,O
+,O
/-,O
14,O
mm,O
",",O
cisapride,I-Entity
versus,O
placebo,O
(,O
P,O
<,O
0.05,O
),O
;,O
pretreatment,O
",",O
62,O
+,O
/-,O
Diarrhoea,I-Entity
-,O
predominant,O
IBS,I-Entity
patients,O
had,O
a,O
higher,O
pain,I-Entity
score,O
after,O
cisapride,I-Entity
therapy,O
[,O
score,O
",",O
55,O
+,O
/-,O
12,O
mm,O
",",O
cisapride,I-Entity
versus,O
placebo,O
(,O
P,O
<,O
0.05,O
),O
;,O
pretreatment,O
",",O
67,O
+,O
/-,O
CONCLUSION,O
:,O
Cisapride,I-Entity
affects,O
jejunal,O
contraction,O
characteristics,O
and,O
some,O
symptoms,O
in,O
IBS,I-Entity
.,O
Clarithromycin,I-Entity
-,O
induced,O
ventricular,B-Entity
tachycardia,I-Entity
.,O
Clarithromycin,I-Entity
is,O
a,O
relatively,O
new,O
macrolide,I-Entity
antibiotic,O
that,O
offers,O
twice,O
-,O
daily,O
dosing,O
.,O
It,O
differs,O
from,O
erythromycin,I-Entity
only,O
in,O
the,O
methylation,O
of,O
the,O
hydroxyl,O
group,O
at,O
position,O
6,O
.,O
Although,O
the,O
side,O
-,O
effect,O
profile,O
of,O
erythromycin,I-Entity
is,O
established,O
",",O
including,O
gastroenteritis,I-Entity
and,O
interactions,O
with,O
other,O
drugs,O
subject,O
to,O
hepatic,O
mixed,O
-,O
function,O
oxidase,O
metabolism,O
",",O
experience,O
with,O
the,O
newer,O
macrolides,I-Entity
is,O
still,O
being,O
recorded,O
.,O
Cardiotoxicity,I-Entity
has,O
been,O
demonstrated,O
after,O
both,O
intravenous,O
and,O
oral,O
administration,O
of,O
erythromycin,I-Entity
but,O
has,O
never,O
been,O
reported,O
with,O
the,O
newer,O
macrolides,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
ventricular,B-Entity
dysrhythmias,I-Entity
that,O
occurred,O
after,O
six,O
therapeutic,O
doses,O
of,O
clarithromycin,I-Entity
.,O
The,O
dysrhythmias,I-Entity
resolved,O
after,O
discontinuation,O
of,O
the,O
drug,O
.,O
Persistent,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
following,O
lithium,I-Entity
therapy,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
patient,O
who,O
developed,O
severe,O
hypernatraemic,O
dehydration,I-Entity
following,O
a,O
head,B-Entity
injury,I-Entity
.,O
Ten,O
years,O
previously,O
he,O
had,O
been,O
diagnosed,O
to,O
have,O
lithium,I-Entity
-,O
induced,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
",",O
and,O
lithium,I-Entity
therapy,O
had,O
been,O
discontinued,O
.,O
He,O
remained,O
thirsty,O
and,O
polyuric,I-Entity
despite,O
cessation,O
of,O
lithium,I-Entity
and,O
investigations,O
on,O
admission,O
showed,O
him,O
to,O
have,O
normal,O
osmoregulated,O
thirst,O
and,O
vasopressin,I-Entity
secretion,O
",",O
with,O
clear,O
evidence,O
of,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
.,O
Lithium,I-Entity
induced,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
is,O
considered,O
to,O
be,O
reversible,O
on,O
cessation,O
of,O
therapy,O
but,O
polyuria,I-Entity
persisted,O
in,O
this,O
patient,O
for,O
ten,O
years,O
after,O
lithium,I-Entity
was,O
stopped,O
.,O
We,O
discuss,O
the,O
possible,O
renal,O
mechanisms,O
and,O
the,O
implications,O
for,O
management,O
of,O
patients,O
with,O
lithium,I-Entity
-,O
induced,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
.,O
Late,O
cardiotoxicity,I-Entity
after,O
treatment,O
for,O
a,O
malignant,O
bone,B-Entity
tumor,I-Entity
.,O
Cardiac,O
function,O
was,O
assessed,O
in,O
long,O
-,O
term,O
survivors,O
of,O
malignant,O
bone,B-Entity
tumors,I-Entity
who,O
were,O
treated,O
according,O
to,O
Rosen,B-Entity
's,I-Entity
T5,I-Entity
or,I-Entity
T10,I-Entity
protocol,I-Entity
",",O
both,O
including,O
doxorubicin,I-Entity
.,O
Cumulative,O
doses,O
of,O
doxorubicin,I-Entity
were,O
225,O
-,O
550,O
mg,O
/,O
m2,O
(,O
median,O
dose,O
360,O
),O
.,O
Eighteen,O
of,O
31,O
(,O
58%,O
),O
patients,O
showed,O
cardiac,B-Entity
toxicity,I-Entity
",",O
defined,O
as,O
having,O
one,O
or,O
more,O
of,O
the,O
following,O
abnormalities,O
:,O
late,O
potentials,O
",",O
complex,O
ventricular,B-Entity
arrhythmias,I-Entity
",",O
left,O
ventricular,B-Entity
dilation,I-Entity
",",O
decreased,O
shortening,O
fraction,O
",",O
or,O
decreased,O
ejection,O
fraction,O
.,O
The,O
incidence,O
of,O
cardiac,B-Entity
abnormalities,I-Entity
increased,O
with,O
length,O
of,O
follow,O
-,O
up,O
(,O
P,O
<,O
or,O
=,O
.05,O
),O
.,O
No,O
correlation,O
could,O
be,O
demonstrated,O
between,O
cumulative,O
dose,O
of,O
doxorubicin,I-Entity
and,O
cardiac,O
status,O
",",O
except,O
for,O
heart,O
rate,O
variability,O
.,O
The,O
incidence,O
of,O
doxorubicin,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
is,O
high,O
and,O
increases,O
with,O
follow,O
-,O
up,O
",",O
irrespective,O
of,O
cumulative,O
dose,O
.,O
The,O
results,O
of,O
our,O
study,O
suggest,O
that,O
heart,O
rate,O
variability,O
and,O
LVPW,O
index,O
could,O
be,O
sensitive,O
indicators,O
for,O
cardiotoxicity,I-Entity
.,O
Venous,B-Entity
complications,I-Entity
of,O
midazolam,I-Entity
versus,O
diazepam,I-Entity
.,O
Although,O
some,O
studies,O
have,O
suggested,O
fewer,O
venous,B-Entity
complications,I-Entity
are,O
associated,O
with,O
midazolam,I-Entity
than,O
with,O
diazepam,I-Entity
for,O
endoscopic,O
procedures,O
",",O
this,O
variable,O
has,O
not,O
been,O
well,O
documented,O
.,O
We,O
prospectively,O
evaluated,O
the,O
incidence,O
of,O
venous,B-Entity
complications,I-Entity
after,O
intravenous,O
injection,O
of,O
diazepam,I-Entity
or,O
midazolam,I-Entity
in,O
122,O
consecutive,O
patients,O
undergoing,O
colonoscopy,O
and,O
esophagogastroduodenoscopy,O
.,O
Overall,O
",",O
venous,B-Entity
complications,I-Entity
were,O
more,O
frequent,O
with,O
diazepam,I-Entity
(,O
22,O
of,O
62,O
patients,O
),O
than,O
with,O
midazolam,I-Entity
(,O
4,O
of,O
60,O
patients,O
),O
(,O
p,O
<,O
0.001,O
),O
.,O
A,O
palpable,O
venous,O
cord,O
was,O
present,O
in,O
23%,O
(,O
14,O
of,O
62,O
),O
of,O
patients,O
in,O
the,O
diazepam,I-Entity
group,O
",",O
compared,O
with,O
2%,O
(,O
1,O
of,O
60,O
patients,O
),O
in,O
the,O
midazolam,I-Entity
group,O
(,O
p,O
Pain,I-Entity
at,O
the,O
injection,O
site,O
occurred,O
in,O
35%,O
(,O
22,O
of,O
62,O
),O
of,O
patients,O
in,O
the,O
diazepam,I-Entity
group,O
compared,O
with,O
7%,O
(,O
4,O
of,O
60,O
patients,O
),O
in,O
the,O
midazolam,I-Entity
group,O
Swelling,I-Entity
and,O
warmth,O
at,O
the,O
injection,O
site,O
were,O
not,O
significantly,O
different,O
between,O
the,O
two,O
groups,O
.,O
Smoking,O
",",O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
use,O
",",O
intravenous,O
catheter,O
site,O
",",O
dwell,O
time,O
of,O
the,O
needle,O
",",O
alcohol,I-Entity
use,O
",",O
and,O
pain,I-Entity
during,O
the,O
injection,O
had,O
no,O
effect,O
on,O
the,O
incidence,O
of,O
venous,B-Entity
complications,I-Entity
.,O
Tetany,I-Entity
and,O
rhabdomyolysis,I-Entity
due,O
to,O
surreptitious,O
furosemide,I-Entity
--,O
importance,O
of,O
magnesium,I-Entity
supplementation,O
.,O
Diuretics,O
may,O
induce,O
hypokalemia,I-Entity
",",O
hypocalcemia,I-Entity
and,O
hypomagnesemia,I-Entity
.,O
While,O
severe,O
hypokalemia,I-Entity
may,O
cause,O
muscle,B-Entity
weakness,I-Entity
",",O
severe,O
hypomagnesemia,I-Entity
is,O
associated,O
with,O
muscle,B-Entity
spasms,I-Entity
and,O
tetany,I-Entity
which,O
can,O
not,O
be,O
corrected,O
by,O
potassium,I-Entity
and,O
calcium,I-Entity
supplementation,O
alone,O
(,O
"1,2",O
),O
.,O
Surreptitious,O
diuretic,O
ingestion,O
has,O
been,O
described,O
",",O
mainly,O
in,O
women,O
who,O
are,O
concerned,O
that,O
they,O
are,O
obese,I-Entity
or,O
edematous,I-Entity
.,O
Symptomatic,O
hypokalemia,I-Entity
has,O
been,O
reported,O
in,O
such,O
patients,O
(,O
3,O
-,O
7,O
),O
and,O
in,O
one,O
case,O
hypocalcemia,I-Entity
was,O
observed,O
(,O
8),O
",",O
but,O
the,O
effects,O
of,O
magnesium,I-Entity
depletion,O
were,O
not,O
noted,O
in,O
these,O
patients,O
.,O
Loss,O
of,O
glutamate,I-Entity
decarboxylase,O
mRNA,O
-,O
containing,O
neurons,O
in,O
the,O
rat,O
dentate,O
gyrus,O
following,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
In,O
situ,O
hybridization,O
methods,O
were,O
used,O
to,O
determine,O
if,O
glutamic,B-Entity
acid,I-Entity
decarboxylase,O
(,O
GAD,O
),O
mRNA,O
-,O
containing,O
neurons,O
within,O
the,O
hilus,O
of,O
the,O
dentate,O
gyrus,O
are,O
vulnerable,O
to,O
seizure,I-Entity
-,O
induced,O
damage,O
in,O
a,O
model,O
of,O
chronic,O
seizures,I-Entity
.,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
injected,O
intraperitoneally,O
with,O
pilocarpine,I-Entity
",",O
and,O
the,O
hippocampal,O
formation,O
was,O
studied,O
histologically,O
at,O
1,O
",",O
2,O
",",O
4,O
",",O
and,O
8,O
week,O
intervals,O
after,O
pilocarpine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
In,O
situ,O
hybridization,O
histochemistry,O
",",O
using,O
a,O
digoxigenin,I-Entity
-,O
labeled,O
GAD,O
cRNA,O
probe,O
",",O
demonstrated,O
a,O
substantial,O
decrease,O
in,O
the,O
number,O
of,O
GAD,O
mRNA,O
-,O
containing,O
neurons,O
in,O
the,O
hilus,O
of,O
the,O
dentate,O
gyrus,O
in,O
the,O
pilocarpine,I-Entity
-,O
treated,O
rats,O
as,O
compared,O
to,O
controls,O
at,O
all,O
time,O
intervals,O
.,O
Additional,O
neuronanatomical,O
studies,O
",",O
including,O
cresyl,B-Entity
violet,I-Entity
staining,O
",",O
neuronal,B-Entity
degeneration,I-Entity
methods,O
",",O
and,O
histochemical,O
localization,O
of,O
glial,O
fibrillary,O
acidic,O
protein,O
",",O
suggested,O
that,O
the,O
decrease,O
in,O
the,O
number,O
of,O
GAD,O
mRNA,O
-,O
containing,O
neurons,O
was,O
related,O
to,O
neuronal,B-Entity
loss,I-Entity
rather,O
than,O
to,O
a,O
decrease,O
in,O
GAD,O
mRNA,O
levels,O
.,O
The,O
results,O
indicate,O
that,O
",",O
in,O
this,O
model,O
",",O
a,O
subpopulation,O
of,O
GAD,O
mRNA,O
-,O
containing,O
neurons,O
within,O
the,O
dentate,O
gyrus,O
is,O
selectively,O
vulnerable,O
to,O
seizure,I-Entity
-,O
induced,O
damage,O
.,O
Such,O
differential,O
vulnerability,O
appears,O
to,O
be,O
another,O
indication,O
of,O
the,O
heterogeneity,O
of,O
GABA,I-Entity
neurons,O
.,O
Protective,O
effect,O
of,O
misoprostol,I-Entity
on,O
indomethacin,I-Entity
induced,O
renal,B-Entity
dysfunction,I-Entity
in,O
elderly,O
patients,O
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
possible,O
protective,O
effects,O
of,O
misoprostol,I-Entity
on,O
renal,O
function,O
in,O
hospitalized,O
elderly,O
patients,O
treated,O
with,O
indomethacin,I-Entity
.,O
Forty,O
-,O
five,O
hospitalized,O
elderly,O
patients,O
(,O
>,O
65,O
years,O
old,O
),O
who,O
required,O
therapy,O
with,O
nonsteroidal,O
antiinflammatory,O
drugs,O
(,O
NSAID,O
),O
were,O
randomly,O
assigned,O
to,O
receive,O
either,O
indomethacin,I-Entity
",",O
150,O
mg,O
/,O
day,O
(,O
Group,O
A,O
),O
",",O
or,O
indomethacin,I-Entity
150,O
mg,O
/,O
day,O
plus,O
misoprostol,I-Entity
at,O
0.6,O
mg,O
/,O
day,O
(,O
Group,O
B,O
),O
.,O
Laboratory,O
variables,O
of,O
renal,O
function,O
[,O
serum,O
creatinine,I-Entity
",",O
blood,B-Entity
urea,I-Entity
nitrogen,I-Entity
(,O
BUN,I-Entity
),O
and,O
electrolytes,O
],O
were,O
evaluated,O
before,O
initiation,O
of,O
therapy,O
and,O
every,O
2,O
days,O
",",O
until,O
termination,O
of,O
the,O
study,O
(,O
a,O
period,O
of,O
at,O
least,O
6,O
days,O
),O
.,O
Response,O
to,O
treatment,O
was,O
estimated,O
by,O
the,O
visual,O
analog,O
scale,O
for,O
severity,O
of,O
pain,I-Entity
.,O
Forty,O
-,O
two,O
patients,O
completed,O
the,O
study,O
",",O
22,O
in,O
Group,O
A,O
and,O
20,O
in,O
Group,O
B.,O
BUN,I-Entity
and,O
creatinine,I-Entity
increased,O
by,O
>,O
50%,O
of,O
baseline,O
levels,O
in,O
54,O
and,O
45%,O
of,O
Group,O
A,O
patients,O
",",O
respectively,O
",",O
compared,O
to,O
only,O
20,O
and,O
10%,O
of,O
Group,O
B,O
patients,O
(,O
p,O
<,O
0.05,O
),O
.,O
Potassium,I-Entity
(,O
K,I-Entity
),O
increment,O
of,O
0.6,O
The,O
mean,O
increments,O
in,O
BUN,I-Entity
",",O
creatinine,I-Entity
",",O
and,O
K,I-Entity
were,O
reduced,O
by,O
63,O
",",O
80,O
",",O
and,O
42%,O
",",O
respectively,O
",",O
in,O
Group,O
B,O
patients,O
compared,O
to,O
Group,O
A.,O
Response,O
to,O
treatment,O
did,O
not,O
differ,O
significantly,O
between,O
the,O
2,O
groups,O
.,O
CONCLUSION,O
:,O
Hospitalized,O
elderly,O
patients,O
are,O
at,O
risk,O
for,O
developing,O
indomethacin,I-Entity
related,O
renal,B-Entity
dysfunction,I-Entity
.,O
Addition,O
of,O
misoprostol,I-Entity
can,O
minimize,O
this,O
renal,B-Entity
impairment,I-Entity
without,O
affecting,O
pain,I-Entity
control,O
.,O
Nephrotoxic,I-Entity
effects,O
of,O
aminoglycoside,I-Entity
treatment,O
on,O
renal,O
protein,O
reabsorption,O
and,O
accumulation,O
.,O
To,O
quantify,O
the,O
effects,O
of,O
gentamicin,I-Entity
",",O
kanamycin,I-Entity
and,O
netilmicin,I-Entity
on,O
renal,O
protein,O
reabsorption,O
and,O
accumulation,O
",",O
these,O
drugs,O
were,O
administered,O
to,O
rats,O
intraperitoneally,O
(,O
30,O
mg,O
/,O
kg,O
/,O
day,O
),O
for,O
7,O
",",O
14,O
or,O
21,O
days,O
.,O
Scanning,O
electron,O
microscopy,O
of,O
the,O
glomerular,O
endothelia,O
",",O
urinary,O
measurements,O
of,O
sodium,I-Entity
",",O
potassium,I-Entity
",",O
endogenous,O
lysozyme,O
",",O
N,O
-,O
acetyl,O
-,O
beta,O
-,O
D,O
-,O
glucosaminidase,O
(,O
NAG,O
),O
as,O
well,O
as,O
clearance,O
and,O
accumulation,O
experiments,O
after,O
i.v,O
.,O
Gentamicin,I-Entity
administration,O
decreased,O
diameter,O
",",O
density,O
and,O
shape,O
of,O
endothelial,O
fenestrae,O
.,O
Kanamycin,I-Entity
and,O
netilmicin,I-Entity
appeared,O
to,O
have,O
no,O
effect,O
at,O
the,O
dose,O
used,O
.,O
All,O
three,O
aminoglycosides,I-Entity
decreased,O
GFR,O
and,O
increased,O
urinary,O
excretion,O
of,O
sodium,I-Entity
and,O
potassium,I-Entity
.,O
While,O
gentamicin,I-Entity
and,O
kanamycin,I-Entity
decreased,O
the,O
percentage,O
reabsorption,O
and,O
accumulation,O
of,O
lysozyme,O
after,O
i.v,O
.,O
administration,O
of,O
egg,O
-,O
white,O
lysozyme,O
netilmicin,I-Entity
had,O
no,O
effect,O
.,O
Daily,O
excretion,O
of,O
total,O
protein,O
",",O
endogenous,O
lysozyme,O
and,O
NAG,O
increased,O
only,O
after,O
treatment,O
with,O
kanamycin,I-Entity
and,O
gentamicin,I-Entity
.,O
Thus,O
",",O
aminoglycosides,I-Entity
may,O
act,O
as,O
nephrotoxicants,O
at,O
glomerular,O
and/or,O
tubular,O
level,O
inducing,O
impairment,B-Entity
of,I-Entity
renal,I-Entity
reabsorption,I-Entity
and,O
accumulation,O
of,O
proteins,O
.,O
Pharmacology,O
of,O
GYKI-41,B-Entity
099,I-Entity
(,O
chlorpropanol,I-Entity
",",O
Tobanum,I-Entity
),O
a,O
new,O
potent,O
beta,O
-,O
adrenergic,O
antagonist,O
.,O
The,O
compound,O
GYKI-41,B-Entity
099,I-Entity
",",O
as,O
a,O
beta,O
-,O
adrenergic,O
antagonist,O
",",O
is,O
3,O
-,O
8,O
times,O
more,O
potent,O
than,O
propranolol,I-Entity
in,O
vitro,O
and,O
in,O
vivo,O
.,O
Its,O
antiarrhythmic,O
effectiveness,O
surpasses,O
that,O
of,O
propranolol,I-Entity
and,O
pindolol,I-Entity
inhibiting,O
the,O
ouabain,I-Entity
arrhythmia,I-Entity
in,O
dogs,O
and,O
cats,O
.,O
GYKI-41,B-Entity
900,I-Entity
has,O
a,O
negligible,O
cardiodepressant,O
activity,O
;,O
it,O
is,O
not,O
cardioselective,O
.,O
There,O
was,O
a,O
prolonged,O
elimination,O
of,O
the,O
radioactivity,O
after,O
the,O
injection,O
of,O
14C-41,B-Entity
099,I-Entity
to,O
rats,O
and,O
dogs,O
.,O
Chorea,I-Entity
associated,O
with,O
oral,B-Entity
contraception,I-Entity
.,O
Three,O
patients,O
developed,O
chorea,I-Entity
while,O
receiving,O
oral,B-Entity
contraceptives,I-Entity
.,O
Two,O
were,O
young,O
patients,O
whose,O
chorea,I-Entity
developed,O
long,O
after,O
treatment,O
had,O
been,O
started,O
and,O
disappeared,O
soon,O
after,O
it,O
had,O
been,O
discontinued,O
.,O
The,O
third,O
patient,O
had,O
acute,O
amphetamine,I-Entity
-,O
induced,O
chorea,I-Entity
after,O
prolonged,O
oral,B-Entity
contraception,I-Entity
.,O
Prolonged,O
administration,O
of,O
female,O
sex,O
hormones,O
is,O
a,O
possible,O
cause,O
of,O
chorea,I-Entity
in,O
women,O
who,O
have,O
not,O
previously,O
had,O
chorea,I-Entity
or,O
rheumatic,B-Entity
fever,I-Entity
.,O
Reversal,O
of,O
ammonia,I-Entity
coma,I-Entity
in,O
rats,O
by,O
L,B-Entity
-,I-Entity
dopa,I-Entity
:,O
a,O
peripheral,O
effect,O
.,O
Ammonia,I-Entity
coma,I-Entity
was,O
produced,O
in,O
rats,O
within,O
10,O
to,O
15,O
minutes,O
of,O
an,O
intraperitonealinjection,O
of,O
1.7,O
mmol,O
NH4CL,I-Entity
.,O
This,O
coma,I-Entity
was,O
prevented,O
with,O
1.68,O
mmol,O
L,B-Entity
-,I-Entity
dopa,I-Entity
given,O
by,O
gastric,O
intubation,O
15,O
minutes,O
before,O
the,O
ammonium,B-Entity
salt,I-Entity
injection,O
.,O
The,O
effect,O
of,O
L,B-Entity
-,I-Entity
dopa,I-Entity
was,O
correlated,O
with,O
a,O
decrease,O
in,O
blood,O
and,O
brain,O
ammonia,I-Entity
",",O
an,O
increase,O
in,O
brain,O
dopamine,I-Entity
",",O
and,O
an,O
increase,O
in,O
renal,O
excretion,O
of,O
ammonia,I-Entity
and,O
urea,I-Entity
.,O
Intraventricular,O
infusion,O
of,O
dopamine,I-Entity
sufficient,O
to,O
raise,O
the,O
brain,O
dopamine,I-Entity
to,O
the,O
same,O
extent,O
did,O
not,O
prevent,O
the,O
ammonia,I-Entity
coma,I-Entity
nor,O
affect,O
the,O
blood,O
and,O
brain,O
ammonia,I-Entity
concentrations,O
.,O
Bilateral,O
nephrectomy,O
eliminated,O
the,O
beneficial,O
effect,O
of,O
L,B-Entity
-,I-Entity
dopa,I-Entity
on,O
blood,O
and,O
brain,O
ammonia,I-Entity
and,O
the,O
ammonia,I-Entity
coma,I-Entity
was,O
not,O
prevented,O
.,O
Thus,O
",",O
the,O
reduction,O
in,O
blood,O
and,O
brain,O
ammonia,I-Entity
and,O
the,O
prevention,O
of,O
ammonia,I-Entity
coma,I-Entity
after,O
L,B-Entity
-,I-Entity
dopa,I-Entity
",",O
can,O
be,O
accounted,O
for,O
by,O
the,O
peripheral,O
effect,O
of,O
dopamine,I-Entity
on,O
renal,O
function,O
rather,O
than,O
its,O
central,O
action,O
.,O
These,O
results,O
provide,O
a,O
reasonable,O
explanation,O
for,O
the,O
beneficial,O
effects,O
observed,O
in,O
some,O
encephalopathic,I-Entity
patients,O
receiving,O
L,B-Entity
-,I-Entity
dopa,I-Entity
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
after,O
liver,O
transplantation,O
.,O
Unfractionated,B-Entity
heparin,I-Entity
sodium,I-Entity
(,O
UFH,I-Entity
),O
or,O
low,B-Entity
-,I-Entity
molecular,I-Entity
weight,I-Entity
heparin,I-Entity
(,O
LMWH,O
),O
is,O
used,O
in,O
anticoagulant,O
protocols,O
at,O
several,O
institutions,O
to,O
prevent,O
thrombosis,I-Entity
after,O
liver,O
transplantation,O
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
(,O
HIT,I-Entity
),O
is,O
an,O
adverse,O
immune,O
-,O
mediated,O
reaction,O
to,O
heparin,I-Entity
",",O
resulting,O
in,O
platelet,O
count,O
decreases,O
of,O
more,O
than,O
50%,O
.,O
The,O
frequencies,O
of,O
HIT,I-Entity
after,O
liver,O
transplantation,O
and,O
platelet,O
factor,O
4/heparin,I-Entity
-,O
reactive,O
antibody,O
(,O
HIT,I-Entity
antibody,O
),O
positivity,O
in,O
liver,O
transplantation,O
patients,O
",",O
however,O
",",O
are,O
unknown,O
.,O
We,O
started,O
LMWH,O
(,O
25,O
IU,O
/,O
kg,O
/,O
h,O
),O
on,O
postoperative,O
day,O
(,O
POD,O
),O
1,O
",",O
switching,O
to,O
UFH,I-Entity
(,O
5000,O
U,O
/,O
d,O
),O
on,O
POD,O
2,O
or,O
3,O
.,O
The,O
dose,O
of,O
UFH,I-Entity
was,O
changed,O
according,O
to,O
the,O
activated,O
clotting,O
time,O
level,O
.,O
HIT,I-Entity
antibody,O
levels,O
were,O
measured,O
the,O
day,O
before,O
surgery,O
and,O
on,O
POD,O
7,O
and,O
14,O
.,O
Two,O
patients,O
developed,O
hepatic,O
artery,O
thrombosis,I-Entity
on,O
POD,O
11,O
and,O
19,O
",",O
respectively,O
",",O
although,O
they,O
were,O
HIT,I-Entity
antibody,O
-,O
negative,O
and,O
their,O
platelet,O
counts,O
were,O
stable,O
.,O
The,O
heparin,I-Entity
-,O
induced,O
platelet,B-Entity
aggregation,I-Entity
test,O
was,O
negative,O
in,O
these,O
patients,O
.,O
The,O
percentage,O
of,O
HIT,I-Entity
antibody,O
-,O
positive,O
patients,O
was,O
0.5%,O
preoperatively,O
",",O
5.6%,O
on,O
POD,O
7,O
",",O
and,O
5.6%,O
on,O
POD,O
14,O
.,O
None,O
of,O
the,O
subjects,O
/,O
patients,O
developed,O
UFH,I-Entity
-,O
related,O
HIT,I-Entity
.,O
In,O
our,O
series,O
",",O
the,O
occurrence,O
of,O
HIT,I-Entity
after,O
liver,O
transplantation,O
was,O
uncommon,O
.,O
PTU,I-Entity
-,O
associated,O
vasculitis,I-Entity
in,O
a,O
girl,O
with,O
Turner,B-Entity
Syndrome,I-Entity
and,O
Graves,B-Entity
',I-Entity
disease,I-Entity
.,O
Palpable,O
purpura,I-Entity
is,O
a,O
concerning,O
clinical,O
finding,O
in,O
pediatric,O
patients,O
and,O
can,O
have,O
many,O
causes,O
",",O
including,O
infectious,O
and,O
autoimmune,O
processes,O
.,O
A,O
rare,O
cause,O
",",O
drug,O
-,O
induced,O
vasculitis,I-Entity
",",O
may,O
result,O
from,O
the,O
production,O
of,O
antineutrophil,O
cytoplasmic,O
antibodies,O
(,O
ANCAs,O
),O
in,O
response,O
to,O
a,O
medication,O
.,O
We,O
report,O
a,O
girl,O
with,O
Turner,B-Entity
syndrome,I-Entity
and,O
Graves,B-Entity
',I-Entity
disease,I-Entity
who,O
presented,O
with,O
palpable,O
purpuric,B-Entity
lesions,I-Entity
.,O
The,O
diagnosis,O
of,O
propylthiouracil,I-Entity
(,O
PTU)-associated,I-Entity
vasculitis,I-Entity
was,O
made,O
by,O
observation,O
of,O
consistent,O
clinical,O
features,O
",",O
the,O
detection,O
of,O
elevated,O
ANA,O
and,O
ANCA,O
in,O
the,O
blood,O
",",O
and,O
the,O
observed,O
clinical,O
resolution,O
of,O
symptoms,O
following,O
withdrawal,O
of,O
PTU,I-Entity
.,O
Subsequent,O
treatment,O
of,O
persistent,O
hyperthyroidism,I-Entity
with,O
radioablation,O
did,O
not,O
result,O
in,O
an,O
exacerbation,O
of,O
the,O
vasculitis,I-Entity
",",O
a,O
complication,O
described,O
in,O
prior,O
case,O
reports,O
.,O
Succinylcholine,I-Entity
-,O
induced,O
masseter,B-Entity
muscle,I-Entity
rigidity,I-Entity
during,O
bronchoscopic,O
removal,O
of,O
a,O
tracheal,O
foreign,O
body,O
.,O
Masseter,B-Entity
muscle,I-Entity
rigidity,I-Entity
during,O
general,O
anesthesia,O
is,O
considered,O
an,O
early,O
warning,O
sign,O
of,O
a,O
possible,O
episode,O
of,O
malignant,B-Entity
hyperthermia,I-Entity
.,O
The,O
decision,O
whether,O
to,O
continue,O
or,O
discontinue,O
the,O
procedure,O
depends,O
on,O
the,O
urgency,O
of,O
the,O
surgery,O
and,O
severity,O
of,O
masseter,B-Entity
muscle,I-Entity
rigidity,I-Entity
.,O
Here,O
",",O
we,O
describe,O
a,O
case,O
of,O
severe,O
masseter,B-Entity
muscle,I-Entity
rigidity,I-Entity
(,O
jaw,B-Entity
of,I-Entity
steel,I-Entity
),O
after,O
succinylcholine,I-Entity
(,O
Sch,I-Entity
),O
administration,O
during,O
general,O
anesthetic,O
management,O
for,O
rigid,O
bronchoscopic,O
removal,O
of,O
a,O
tracheal,O
foreign,O
body,O
.,O
Anesthesia,O
was,O
continued,O
uneventfully,O
with,O
propofol,I-Entity
infusion,O
while,O
all,O
facilities,O
were,O
available,O
to,O
detect,O
and,O
treat,O
malignant,B-Entity
hyperthermia,I-Entity
.,O
Minor,O
neurological,B-Entity
dysfunction,I-Entity
",",O
cognitive,O
development,O
",",O
and,O
somatic,O
development,O
at,O
the,O
age,O
of,O
3,O
to,O
7,O
years,O
after,O
dexamethasone,I-Entity
treatment,O
in,O
very,O
-,O
low,O
birth,O
-,O
weight,O
infants,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
assess,O
minor,O
neurological,B-Entity
dysfunction,I-Entity
",",O
cognitive,O
development,O
",",O
and,O
somatic,O
development,O
after,O
dexamethasone,I-Entity
therapy,O
in,O
very,O
-,O
low,O
-,O
birthweight,O
infants,O
.,O
Thirty,O
-,O
three,O
children,O
after,O
dexamethasone,I-Entity
treatment,O
were,O
matched,O
to,O
33,O
children,O
without,O
dexamethasone,I-Entity
treatment,O
.,O
Dexamethasone,I-Entity
was,O
started,O
between,O
the,O
7th,O
and,O
the,O
28th,O
day,O
of,O
life,O
over,O
7,O
days,O
with,O
a,O
total,O
dose,O
of,O
2.35,O
mg,O
/,O
kg,O
/,O
day,O
.,O
Exclusion,O
criteria,O
were,O
asphyxia,I-Entity
",",O
malformations,I-Entity
",",O
major,O
surgical,O
interventions,O
",",O
small,O
for,O
gestational,O
age,O
",",O
intraventricular,O
haemorrhage,I-Entity
grades,O
III,O
and,O
IV,O
",",O
periventricular,B-Entity
leukomalacia,I-Entity
",",O
and,O
severe,O
psychomotor,B-Entity
retardation,I-Entity
.,O
Each,O
child,O
was,O
examined,O
by,O
a,O
neuropediatrician,O
for,O
minor,O
neurological,B-Entity
dysfunctions,I-Entity
and,O
tested,O
by,O
a,O
psychologist,O
for,O
cognitive,O
development,O
with,O
a,O
Kaufman,O
Assessment,O
Battery,O
for,O
Children,O
and,O
a,O
Draw,O
-,O
a,O
-,O
Man,O
Test,O
.,O
After,O
dexamethasone,I-Entity
treatment,O
",",O
children,O
showed,O
a,O
higher,O
rate,O
of,O
minor,O
neurological,B-Entity
dysfunctions,I-Entity
.,O
Further,O
long,O
-,O
term,O
follow,O
-,O
up,O
studies,O
will,O
be,O
necessary,O
to,O
fully,O
evaluate,O
the,O
impact,O
of,O
dexamethasone,I-Entity
on,O
neurological,O
and,O
cognitive,O
development,O
.,O
Force,O
overflow,O
and,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
We,O
assessed,O
force,O
coordination,O
of,O
the,O
hand,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
and,O
its,O
relationship,O
to,O
motor,O
complications,O
of,O
levodopa,I-Entity
therapy,O
",",O
particularly,O
to,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
(,O
LID,I-Entity
),O
.,O
We,O
studied,O
two,O
groups,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
patients,O
with,O
(,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
+,O
LID,I-Entity
",",O
n,O
=,O
23,O
),O
and,O
without,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
(,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
-,O
LID,I-Entity
",",O
n,O
=,O
10,O
),O
",",O
and,O
age,O
-,O
matched,O
healthy,O
controls,O
.,O
The,O
motor,O
score,O
of,O
the,O
Unified,O
Parkinson,B-Entity
's,I-Entity
Disease,I-Entity
Rating,O
Scale,O
",",O
a,O
dyskinesia,I-Entity
score,O
and,O
force,O
in,O
a,O
grip,O
-,O
lift,O
paradigm,O
were,O
assessed,O
ON,O
and,O
OFF,O
levodopa,I-Entity
.,O
A,O
pathological,O
increase,O
of,O
forces,O
was,O
seen,O
in,O
ON,O
-,O
state,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
+,O
LID,I-Entity
only,O
.,O
In,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
+,O
LID,I-Entity
",",O
the,O
force,O
involved,O
in,O
pressing,O
down,O
the,O
object,O
before,O
lifting,O
was,O
significantly,O
increased,O
by,O
levodopa,I-Entity
(,O
by,O
61%,O
",",O
P,O
<,O
0.05,O
),O
.,O
In,O
contrast,O
",",O
no,O
excessive,O
force,O
was,O
found,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
-,O
LID,I-Entity
.,O
Peak,O
grip,O
force,O
in,O
ON,O
-,O
state,O
was,O
140%,O
(,O
P,O
<,O
0.05,O
),O
higher,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
+,O
LID,I-Entity
than,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
-,O
LID,I-Entity
",",O
while,O
static,O
grip,O
force,O
was,O
increased,O
by,O
138%,O
(,O
P,O
<,O
0.01,O
),O
between,O
groups,O
.,O
Severity,O
of,O
peak,O
-,O
dose,O
dyskinesias,I-Entity
was,O
strongly,O
correlated,O
with,O
grip,O
force,O
in,O
ON,O
-,O
state,O
(,O
r,O
=,O
0.79,O
with,O
peak,O
force,O
",",O
P,O
<,O
0.01,O
),O
.,O
Force,O
excess,O
was,O
only,O
observed,O
in,O
patients,O
with,O
LID,I-Entity
and,O
motor,O
fluctuations,O
.,O
A,O
close,O
relationship,O
was,O
seen,O
between,O
the,O
overshooting,O
of,O
forces,O
and,O
dyskinesias,I-Entity
in,O
the,O
ON,O
-,O
drug,O
condition,O
.,O
We,O
postulate,O
that,O
both,O
LID,I-Entity
and,O
grip,O
force,O
excess,O
share,O
common,O
pathophysiological,O
mechanisms,O
related,O
to,O
motor,O
fluctuations,O
.,O
Postinfarction,O
ventricular,B-Entity
septal,I-Entity
defect,I-Entity
associated,O
with,O
long,O
-,O
term,O
steroid,I-Entity
therapy,O
.,O
Two,O
cases,O
of,O
postinfarction,O
ventricular,B-Entity
septal,I-Entity
rupture,I-Entity
in,O
patients,O
on,O
long,O
-,O
term,O
steroid,I-Entity
therapy,O
are,O
presented,O
and,O
the,O
favourable,O
outcome,O
in,O
both,O
cases,O
described,O
.,O
A,O
possible,O
association,O
between,O
steroid,I-Entity
therapy,O
and,O
subsequent,O
postinfarction,O
septal,B-Entity
rupture,I-Entity
is,O
discussed,O
.,O
Angioedema,I-Entity
associated,O
with,O
droperidol,I-Entity
administration,O
.,O
Angioedema,I-Entity
",",O
also,O
known,O
as,O
angioneurotic,B-Entity
edema,I-Entity
or,O
Quincke,B-Entity
's,I-Entity
disease,I-Entity
",",O
is,O
a,O
well,O
-,O
demarcated,O
",",O
localized,O
edema,I-Entity
involving,O
the,O
subcutaneous,O
tissues,O
that,O
may,O
cause,O
upper,B-Entity
-,I-Entity
airway,I-Entity
obstruction,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
previously,O
healthy,O
19-year,O
-,O
old,O
man,O
with,O
no,O
known,O
drug,B-Entity
allergies,I-Entity
in,O
whom,O
angioedema,I-Entity
with,O
significant,O
tongue,B-Entity
swelling,I-Entity
and,O
protrusion,O
developed,O
within,O
10,O
minutes,O
of,O
the,O
administration,O
of,O
a,O
single,O
IV,O
dose,O
of,O
droperidol,I-Entity
.,O
Clarithromycin,I-Entity
-,O
associated,O
visual,B-Entity
hallucinations,I-Entity
in,O
a,O
patient,O
with,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
on,O
continuous,O
ambulatory,O
peritoneal,O
dialysis,O
.,O
Visual,B-Entity
hallucinations,I-Entity
are,O
a,O
rare,O
event,O
in,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
and,O
not,O
related,O
to,O
uremia,I-Entity
per,O
se,O
.,O
Unreported,O
in,O
the,O
literature,O
is,O
visual,B-Entity
hallucinations,I-Entity
occurring,O
in,O
association,O
with,O
the,O
new,O
macrolide,I-Entity
antibiotic,O
",",O
clarithromycin,I-Entity
.,O
We,O
describe,O
such,O
a,O
case,O
in,O
a,O
patient,O
with,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
(,O
ESRD,I-Entity
),O
maintained,O
on,O
continuous,O
ambulatory,O
peritoneal,O
dialysis,O
(,O
CAPD,O
),O
.,O
The,O
combination,O
of,O
a,O
relatively,O
high,O
dose,O
of,O
clarithromycin,I-Entity
in,O
face,O
of,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
in,O
a,O
functionally,O
anephric,O
patient,O
",",O
with,O
underlying,O
aluminum,I-Entity
intoxication,O
",",O
may,O
have,O
facilitated,O
the,O
appearance,O
of,O
this,O
neurotoxic,I-Entity
side,O
effect,O
.,O
It,O
is,O
important,O
to,O
understand,O
the,O
pharmacokinetics,O
of,O
medications,O
in,O
face,O
of,O
chronic,B-Entity
renal,I-Entity
failure,I-Entity
",",O
the,O
possibility,O
of,O
drug,O
interactions,O
",",O
and,O
how,O
these,O
factors,O
should,O
help,O
guide,O
medication,O
therapy,O
in,O
the,O
ESRD,I-Entity
patient,O
.,O
Acute,O
renal,B-Entity
toxicity,I-Entity
of,O
doxorubicin,I-Entity
(,O
adriamycin)-loaded,I-Entity
cyanoacrylate,I-Entity
nanoparticles,O
.,O
Acute,O
doxorubicin,I-Entity
-,O
loaded,O
nanoparticle,O
(,O
DXNP,O
),O
renal,B-Entity
toxicity,I-Entity
was,O
explored,O
in,O
both,O
normal,O
rats,O
and,O
rats,O
with,O
experimental,O
glomerulonephritis,I-Entity
.,O
In,O
normal,O
rats,O
",",O
2/6,O
rats,O
given,O
free,O
doxorubicin,I-Entity
(,O
DX,I-Entity
),O
(,O
5,O
mg,O
/,O
kg,O
),O
died,O
within,O
one,O
week,O
",",O
whereas,O
all,O
control,O
animals,O
and,O
all,O
rats,O
having,O
received,O
free,O
NP,O
or,O
DXNP,O
survived,O
.,O
A,O
3,O
times,O
higher,O
proteinuria,I-Entity
appeared,O
in,O
animals,O
treated,O
with,O
DXNP,O
than,O
in,O
those,O
treated,O
with,O
DX,I-Entity
.,O
Free,O
NP,O
did,O
not,O
provoke,O
any,O
proteinuria,I-Entity
.,O
Two,O
hr,O
post,O
-,O
injection,O
",",O
DXNP,O
was,O
2.7,O
times,O
more,O
concentrated,O
in,O
kidneys,O
than,O
free,O
DX,I-Entity
(,O
p,O
<,O
0.025,O
),O
.,O
In,O
rats,O
with,O
immune,O
experimental,O
glomerulonephritis,I-Entity
",",O
5/6,O
rats,O
given,O
DX,I-Entity
died,O
within,O
7,O
days,O
",",O
in,O
contrast,O
to,O
animals,O
treated,O
by,O
DXNP,O
",",O
NP,O
",",O
or,O
untreated,O
",",O
which,O
all,O
survived,O
.,O
Proteinuria,I-Entity
appeared,O
in,O
all,O
series,O
",",O
but,O
was,O
2,O
-,O
5,O
times,O
more,O
intense,O
(,O
p,O
>,O
0.001,O
),O
and,O
prolonged,O
after,O
doxorubicin,I-Entity
treatment,O
(,O
400,O
-,O
700,O
mg,O
/,O
day,O
),O
",",O
without,O
significant,O
difference,O
between,O
DXNP,O
and,O
DX,I-Entity
.,O
These,O
results,O
demonstrate,O
that,O
",",O
in,O
these,O
experimental,O
conditions,O
",",O
DXNP,O
killed,O
less,O
animals,O
than,O
free,O
DX,I-Entity
",",O
despite,O
of,O
an,O
enhanced,O
renal,B-Entity
toxicity,I-Entity
of,O
the,O
former,O
.,O
Both,O
effects,O
(,O
better,O
survival,O
and,O
nephrosis,I-Entity
),O
are,O
most,O
probably,O
related,O
to,O
an,O
enhanced,O
capture,O
of,O
DXNP,O
by,O
cells,O
of,O
the,O
mononuclear,O
phagocyte,O
system,O
",",O
including,O
mesangial,O
cells,O
.,O
Etoposide,I-Entity
-,O
related,O
myocardial,B-Entity
infarction,I-Entity
.,O
The,O
occurrence,O
of,O
a,O
myocardial,B-Entity
infarction,I-Entity
is,O
reported,O
after,O
chemotherapy,O
containing,O
etoposide,I-Entity
",",O
in,O
a,O
man,O
with,O
no,O
risk,O
factors,O
for,O
coronary,B-Entity
heart,I-Entity
disease,I-Entity
.,O
Subjective,O
assessment,O
of,O
sexual,B-Entity
dysfunction,I-Entity
of,O
patients,O
on,O
long,O
-,O
term,O
administration,O
of,O
digoxin,I-Entity
.,O
Various,O
data,O
suggest,O
that,O
male,O
patients,O
who,O
have,O
received,O
digoxin,I-Entity
on,O
a,O
longterm,O
basis,O
have,O
increased,O
levels,O
of,O
serum,O
estrogen,I-Entity
and,O
decreased,O
levels,O
of,O
plasma,O
testosterone,I-Entity
and,O
luteinizing,O
hormone,O
(,O
LH,O
),O
.,O
This,O
study,O
was,O
undertaken,O
to,O
investigate,O
the,O
links,O
between,O
the,O
long,O
-,O
term,O
administration,O
of,O
digoxin,I-Entity
therapy,O
and,O
sexual,O
behavior,O
",",O
and,O
the,O
effect,O
of,O
digoxin,I-Entity
on,O
plasma,O
levels,O
of,O
estradiol,I-Entity
",",O
testosterone,I-Entity
",",O
and,O
LH,O
.,O
The,O
patients,O
of,O
the,O
study,O
and,O
control,O
group,O
(,O
without,O
digoxin,I-Entity
),O
were,O
of,O
similar,O
cardiac,O
functional,O
capacity,O
and,O
age,O
(,O
25,O
-,O
40,O
years,O
),O
and,O
were,O
randomly,O
selected,O
from,O
the,O
rheumatic,B-Entity
heart,I-Entity
disease,I-Entity
patients,O
.,O
The,O
findings,O
support,O
the,O
reports,O
concerning,O
digoxin,I-Entity
effect,O
on,O
plasma,O
estradiol,I-Entity
",",O
testosterone,I-Entity
",",O
and,O
LH,O
.,O
Tests,O
used,O
to,O
evaluate,O
the,O
changes,O
in,O
sexual,O
behavior,O
showed,O
a,O
significant,O
decrease,B-Entity
in,I-Entity
sexual,I-Entity
desire,I-Entity
",",O
sexual,O
excitement,O
phase,O
(,O
erection,O
),O
",",O
and,O
frequency,O
of,O
sexual,O
relations,O
in,O
the,O
study,O
group,O
.,O
Fatal,O
aplastic,B-Entity
anemia,I-Entity
due,O
to,O
indomethacin,I-Entity
--,O
lymphocyte,O
transformation,O
tests,O
in,O
vitro,O
.,O
Although,O
indomethacin,I-Entity
has,O
been,O
implicated,O
as,O
a,O
possible,O
cause,O
of,O
aplastic,B-Entity
anemia,I-Entity
on,O
the,O
basis,O
of,O
a,O
few,O
clinical,O
observations,O
",",O
its,O
role,O
has,O
not,O
been,O
definitely,O
established,O
.,O
A,O
case,O
of,O
fatal,O
aplastic,B-Entity
anemia,I-Entity
is,O
described,O
in,O
which,O
no,O
drugs,O
other,O
than,O
allopurinol,I-Entity
and,O
indomethacin,I-Entity
were,O
given,O
.,O
Indomethacin,I-Entity
was,O
first,O
given,O
four,O
weeks,O
prior,O
to,O
the,O
onset,O
of,O
symptoms,O
.,O
A,O
positive,O
lymphocyte,O
transformation,O
test,O
with,O
indomethacin,I-Entity
in,O
vitro,O
further,O
substantiates,O
the,O
potential,O
role,O
of,O
this,O
drug,O
in,O
causing,O
aplastic,B-Entity
anemia,I-Entity
in,O
a,O
susceptible,O
patient,O
.,O
Plasma,O
and,O
urinary,O
lipids,O
and,O
lipoproteins,O
during,O
the,O
development,O
of,O
nephrotic,B-Entity
syndrome,I-Entity
induced,O
in,O
the,O
rat,O
by,O
puromycin,B-Entity
aminonucleoside,I-Entity
.,O
This,O
study,O
was,O
undertaken,O
to,O
ascertain,O
whether,O
the,O
alterations,O
of,O
plasma,O
lipoproteins,O
found,O
in,O
nephrotic,B-Entity
syndrome,I-Entity
induced,O
by,O
puromycin,B-Entity
aminonucleoside,I-Entity
were,O
due,O
to,O
nephrotic,B-Entity
syndrome,I-Entity
per,O
se,O
",",O
or,O
",",O
at,O
least,O
in,O
part,O
",",O
to,O
the,O
aminonucleoside,I-Entity
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
changes,O
in,O
plasma,O
and,O
urinary,O
lipoproteins,O
during,O
the,O
administration,O
of,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
20,O
mg,O
/,O
kg,O
for,O
7,O
days,O
),O
and,O
the,O
subsequent,O
development,O
of,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
Since,O
massive,O
albuminuria,I-Entity
occurred,O
after,O
6,O
days,O
of,O
treatment,O
",",O
the,O
time,O
-,O
course,O
study,O
was,O
divided,O
into,O
two,O
stages,O
:,O
pre,O
-,O
nephrotic,I-Entity
stage,O
(,O
day,O
1,O
-,O
5,O
),O
and,O
nephrotic,I-Entity
stage,O
(,O
day,O
6,O
-,O
11,O
),O
.,O
In,O
pre,O
-,O
nephrotic,I-Entity
stage,O
the,O
plasma,O
level,O
of,O
fatty,B-Entity
acids,I-Entity
",",O
triacylglycerol,I-Entity
and,O
VLDL,O
decreased,O
while,O
that,O
of,O
phospholipid,O
",",O
cholesteryl,B-Entity
esters,I-Entity
and,O
HDL,O
remained,O
constant,O
.,O
At,O
the,O
beginning,O
of,O
nephrotic,I-Entity
stage,O
(,O
day,O
6,O
),O
the,O
concentration,O
of,O
plasma,O
albumin,O
dropped,O
to,O
a,O
very,O
low,O
level,O
",",O
while,O
that,O
of,O
apolipoprotein,O
A,O
-,O
I,O
increased,O
abruptly,O
(,O
4-fold,O
increase,O
),O
and,O
continued,O
to,O
rise,O
",",O
although,O
less,O
steeply,O
",",O
in,O
the,O
following,O
days,O
.,O
In,O
the,O
pre,O
-,O
nephrotic,I-Entity
stage,O
lipoproteinuria,O
was,O
negligible,O
",",O
while,O
in,O
the,O
early,O
nephrotic,I-Entity
stage,O
the,O
urinary,O
loss,O
of,O
plasma,O
lipoproteins,O
consisted,O
mainly,O
of,O
HDL,O
.,O
These,O
observations,O
indicate,O
that,O
puromycin,B-Entity
aminonucleoside,I-Entity
alters,O
plasma,O
lipoproteins,O
by,O
lowering,O
VLDL,O
and,O
increasing,O
HDL,O
.,O
It,O
is,O
likely,O
that,O
the,O
early,O
and,O
striking,O
increase,O
of,O
plasma,O
HDL,O
found,O
in,O
nephrotic,I-Entity
rats,O
is,O
related,O
to,O
a,O
direct,O
effect,O
of,O
the,O
drug,O
on,O
HDL,O
metabolism,O
.,O
Circulating,O
lysosomal,O
enzymes,O
and,O
acute,B-Entity
hepatic,I-Entity
necrosis,I-Entity
.,O
The,O
activities,O
of,O
the,O
lysosomal,O
enzymes,O
acid,O
and,O
neutral,O
protease,O
",",O
N,O
-,O
acetylglucosaminidase,O
",",O
and,O
acid,O
phosphatase,O
were,O
measured,O
in,O
the,O
serum,O
of,O
patients,O
with,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
.,O
(,O
cathepsin,O
D,O
),O
activity,O
was,O
increased,O
about,O
tenfold,O
in,O
patients,O
who,O
died,O
and,O
nearly,O
fourfold,O
in,O
those,O
who,O
survived,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
after,O
paracetamol,I-Entity
overdose,I-Entity
",",O
whereas,O
activities,O
were,O
increased,O
equally,O
in,O
patients,O
with,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
due,O
to,O
viral,B-Entity
hepatitis,I-Entity
whether,O
or,O
not,O
they,O
survived,O
.,O
A,O
correlation,O
was,O
found,O
between,O
serum,O
acid,O
protease,O
activity,O
and,O
prothrombin,O
time,O
",",O
and,O
the,O
increase,O
in,O
cathepsin,O
D,O
activity,O
was,O
sustained,O
over,O
several,O
days,O
compared,O
with,O
aspartate,I-Entity
aminotransferase,O
",",O
which,O
showed,O
a,O
sharp,O
early,O
peak,O
and,O
then,O
a,O
fall,O
.,O
Transketolase,O
abnormality,O
in,O
tolazamide,I-Entity
-,O
induced,O
Wernicke,B-Entity
's,I-Entity
encephalopathy,I-Entity
.,O
We,O
studied,O
a,O
thiamine,I-Entity
-,O
dependent,O
enzyme,O
",",O
transketolase,O
",",O
from,O
fibroblasts,O
of,O
a,O
diabetic,I-Entity
patient,O
who,O
developed,O
Wernicke,B-Entity
's,I-Entity
encephalopathy,I-Entity
when,O
treated,O
with,O
tolazamide,I-Entity
",",O
in,O
order,O
to,O
delineate,O
if,O
this,O
patient,O
also,O
had,O
transketolase,O
abnormality,O
[,O
high,O
Km,O
for,O
thiamine,B-Entity
pyrophosphate,I-Entity
(,O
TPP,I-Entity
),O
],O
",",O
as,O
previously,O
reported,O
in,O
postalcoholic,O
Wernicke,B-Entity
-,I-Entity
Korsakoff,I-Entity
syndrome,I-Entity
.,O
In,O
addition,O
to,O
this,O
patient,O
",",O
we,O
also,O
studied,O
this,O
enzyme,O
from,O
three,O
diabetic,I-Entity
kindreds,O
without,O
any,O
history,O
of,O
Wernicke,B-Entity
's,I-Entity
encephalopathy,I-Entity
and,O
from,O
four,O
normal,O
controls,O
.,O
We,O
found,O
that,O
the,O
above,O
-,O
mentioned,O
patient,O
and,O
one,O
of,O
the,O
diabetic,I-Entity
kindreds,O
with,O
no,O
history,O
of,O
Wernicke,B-Entity
's,I-Entity
encephalopathy,I-Entity
had,O
abnormal,O
transketolase,O
as,O
determined,O
by,O
its,O
Km,O
for,O
TPP,I-Entity
.,O
These,O
data,O
suggest,O
a,O
similarity,O
between,O
postalcoholic,O
Wernicke,B-Entity
-,I-Entity
Korsakoff,I-Entity
syndrome,I-Entity
and,O
the,O
patient,O
with,O
tolazamide,I-Entity
-,O
induced,O
Wernicke,B-Entity
's,I-Entity
encephalopathy,I-Entity
from,O
the,O
standpoint,O
of,O
transketolase,O
abnormality,O
.,O
Mechanisms,O
of,O
myocardial,B-Entity
ischemia,I-Entity
induced,O
by,O
epinephrine,I-Entity
:,O
comparison,O
with,O
exercise,O
-,O
induced,O
ischemia,I-Entity
.,O
The,O
role,O
of,O
epinephrine,I-Entity
in,O
eliciting,O
myocardial,B-Entity
ischemia,I-Entity
was,O
examined,O
in,O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
.,O
Objective,O
signs,O
of,O
ischemia,I-Entity
and,O
factors,O
increasing,O
myocardial,O
oxygen,I-Entity
consumption,O
were,O
compared,O
during,O
epinephrine,I-Entity
infusion,O
and,O
supine,O
bicycle,O
exercise,O
.,O
Both,O
epinephrine,I-Entity
and,O
exercise,O
produced,O
myocardial,B-Entity
ischemia,I-Entity
as,O
evidenced,O
by,O
ST,O
segment,O
depression,I-Entity
and,O
angina,I-Entity
.,O
However,O
",",O
the,O
mechanisms,O
of,O
myocardial,B-Entity
ischemia,I-Entity
induced,O
by,O
epinephrine,I-Entity
were,O
significantly,O
different,O
from,O
those,O
of,O
exercise,O
.,O
Exercise,O
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
was,O
marked,O
predominantly,O
by,O
increased,O
heart,O
rate,O
and,O
rate,O
-,O
pressure,O
product,O
with,O
a,O
minor,O
contribution,O
of,O
end,O
-,O
diastolic,O
volume,O
",",O
while,O
epinephrine,I-Entity
-,O
induced,O
ischemia,I-Entity
was,O
characterized,O
by,O
a,O
marked,O
increase,O
in,O
contractility,O
and,O
a,O
less,O
pronounced,O
increase,O
in,O
heart,O
rate,O
and,O
rate,O
-,O
pressure,O
product,O
.,O
These,O
findings,O
indicate,O
that,O
ischemia,I-Entity
produced,O
by,O
epinephrine,I-Entity
",",O
as,O
may,O
occur,O
during,O
states,O
of,O
emotional,O
distress,O
",",O
has,O
a,O
mechanism,O
distinct,O
from,O
that,O
due,O
to,O
physical,O
exertion,O
.,O
Transient,O
contralateral,B-Entity
rotation,I-Entity
following,O
unilateral,O
substantia,B-Entity
nigra,I-Entity
lesion,I-Entity
reflects,O
susceptibility,O
of,O
the,O
nigrostriatal,O
system,O
to,O
exhaustion,O
by,O
amphetamine,I-Entity
.,O
Following,O
unilateral,O
6-OHDA,I-Entity
induced,O
SN,B-Entity
lesion,I-Entity
",",O
a,O
transient,O
period,O
of,O
contralateral,B-Entity
rotation,I-Entity
has,O
been,O
reported,O
to,O
precede,O
the,O
predominant,O
ipsilateral,B-Entity
circling,I-Entity
.,O
In,O
order,O
to,O
clarify,O
the,O
nature,O
of,O
this,O
initial,O
contralateral,B-Entity
rotation,I-Entity
we,O
examined,O
the,O
effect,O
of,O
the,O
duration,O
of,O
recovery,O
period,O
after,O
the,O
lesion,O
",",O
on,O
amphetamine,I-Entity
-,O
induced,O
rotational,B-Entity
behavior,I-Entity
.,O
Such,O
contralateral,B-Entity
rotation,I-Entity
may,O
result,O
from,O
either,O
degeneration,O
-,O
induced,O
breakdown,O
of,O
the,O
DA,O
pool,O
",",O
or,O
lesion,O
-,O
induced,O
increase,O
of,O
DA,O
turnover,O
in,O
the,O
spared,O
neurons,O
.,O
A,O
substantial,O
degree,O
of,O
contralateral,O
preference,O
was,O
still,O
evident,O
when,O
amphetamine,I-Entity
was,O
administered,O
for,O
the,O
first,O
time,O
24,O
days,O
after,O
lesioning,O
",",O
indicating,O
involvement,O
of,O
spared,O
cells,O
in,O
the,O
contralateral,B-Entity
rotation,I-Entity
.,O
However,O
",",O
regardless,O
of,O
the,O
duration,O
of,O
recovery,O
(,O
and,O
irrespective,O
of,O
either,O
lesion,O
volume,O
",",O
amphetamine,I-Entity
dose,O
",",O
or,O
post,O
-,O
lesion,O
motor,O
exercise,O
),O
",",O
amphetamine,I-Entity
-,O
induced,O
rotation,I-Entity
tended,O
to,O
become,O
gradually,O
more,O
ipsilateral,O
as,O
the,O
observation,O
session,O
progressed,O
",",O
and,O
all,O
rats,O
circled,O
ipsilaterally,O
to,O
the,O
lesion,O
in,O
response,O
to,O
further,O
amphetamine,I-Entity
injections,O
.,O
These,O
findings,O
suggest,O
that,O
amphetamine,I-Entity
has,O
an,O
irreversible,O
effect,O
on,O
the,O
post,O
-,O
lesion,O
DA,O
pool,O
contributing,O
to,O
contralateral,B-Entity
rotation,I-Entity
.,O
Thyroid,O
function,O
and,O
urine,O
-,O
concentrating,O
ability,O
during,O
lithium,I-Entity
treatment,O
.,O
It,O
has,O
been,O
suggested,O
that,O
adenylate,O
cyclase,O
inhibition,O
may,O
be,O
important,O
in,O
the,O
development,O
of,O
both,O
nephrogenic,B-Entity
diabetes,I-Entity
insipidus,I-Entity
and,O
hypothyroidism,I-Entity
during,O
lithium,I-Entity
treatment,O
.,O
We,O
measured,O
serum,O
thyroxine,I-Entity
and,O
urine,O
-,O
concentrating,O
ability,O
(,O
Umax,O
),O
in,O
response,O
to,O
desmopressin,O
(,O
DDAVP,O
),O
in,O
85,O
patients,O
receiving,O
lithium,I-Entity
.,O
Hypothyroidism,I-Entity
developed,O
in,O
eight,O
patients,O
while,O
they,O
were,O
taking,O
lithium,I-Entity
.,O
Impaired,O
Umax,O
was,O
found,O
in,O
both,O
euthyroid,O
and,O
hypothyroid,I-Entity
patients,O
while,O
some,O
hypothyroid,I-Entity
patients,O
concentrated,O
their,O
urine,O
well,O
.,O
It,O
is,O
concluded,O
that,O
the,O
dominant,O
mechanisms,O
by,O
which,O
lithium,I-Entity
exerts,O
these,O
two,O
effects,O
are,O
different,O
.,O
Sensitivity,O
of,O
erythroid,O
progenitor,O
colonies,O
to,O
erythropoietin,O
in,O
azidothymidine,I-Entity
treated,O
immunodeficient,I-Entity
mice,O
.,O
The,O
anaemia,I-Entity
induced,O
by,O
3'-azido-3'dideoxythymidine,I-Entity
(,O
AZT,I-Entity
),O
is,O
poorly,O
understood,O
.,O
We,O
have,O
used,O
a,O
murine,O
model,O
of,O
AIDS,I-Entity
",",O
infection,I-Entity
of,O
female,O
C57BL/6,O
mice,O
with,O
LP,O
-,O
BM5,O
murine,O
leukaemia,I-Entity
(,O
MuLV,O
),O
virus,O
",",O
to,O
determine,O
if,O
AZT,I-Entity
-,O
induced,O
anaemia,I-Entity
is,O
due,O
",",O
in,O
part,O
",",O
to,O
decreased,O
responsiveness,O
of,O
erythropoietic,O
precursors,O
(,O
BFU,O
-,O
e,O
),O
to,O
erythropoietin,O
(,O
EPO,O
),O
.,O
Mice,O
in,O
the,O
early,O
stage,O
of,O
LP,O
-,O
BM5,O
MuLV,O
disease,O
were,O
given,O
AZT,I-Entity
in,O
their,O
drinking,O
water,O
at,O
1.0,O
and,O
2.5,O
mg,O
/,O
ml,O
.,O
AZT,I-Entity
produced,O
anaemia,I-Entity
in,O
both,O
groups,O
",",O
in,O
a,O
dose,O
-,O
dependent,O
fashion,O
.,O
Despite,O
the,O
anaemia,I-Entity
",",O
the,O
number,O
of,O
splenic,O
and,O
bone,O
marrow,O
BFU,O
-,O
e,O
in,O
AZT,I-Entity
treated,O
mice,O
increased,O
up,O
to,O
five,O
-,O
fold,O
over,O
levels,O
observed,O
in,O
infected,O
untreated,O
animals,O
after,O
15,O
d,O
of,O
treatment,O
.,O
Colony,O
formation,O
by,O
splenic,O
and,O
bone,O
marrow,O
BFUe,O
was,O
stimulated,O
at,O
lower,O
concentrations,O
of,O
EPO,O
in,O
mice,O
receiving,O
AZT,I-Entity
for,O
15,O
d,O
than,O
for,O
infected,O
",",O
untreated,O
mice,O
.,O
The,O
mean,O
plasma,O
levels,O
of,O
EPO,O
observed,O
in,O
AZT,I-Entity
treated,O
mice,O
were,O
appropriate,O
for,O
the,O
degree,O
of,O
anaemia,I-Entity
observed,O
when,O
compared,O
with,O
phenylhydrazine,I-Entity
(,O
PHZ,I-Entity
),O
treated,O
mice,O
.,O
The,O
numbers,O
of,O
BFU,O
-,O
e,O
and,O
the,O
percentage,O
of,O
bone,O
marrow,O
erythroblasts,O
observed,O
were,O
comparable,O
in,O
AZT,I-Entity
and,O
PHZ,I-Entity
treated,O
mice,O
with,O
similar,O
degrees,O
of,O
anaemia,I-Entity
.,O
However,O
",",O
reticulocytosis,I-Entity
was,O
inappropriate,O
for,O
the,O
degree,O
of,O
anaemia,I-Entity
observed,O
in,O
AZT,I-Entity
treated,O
infected,O
mice,O
.,O
AZT,I-Entity
-,O
induced,O
peripheral,O
anaemia,I-Entity
in,O
the,O
face,O
of,O
increased,O
numbers,O
of,O
BFU,O
-,O
e,O
and,O
increased,O
levels,O
of,O
plasma,O
EPO,O
suggest,O
a,O
lesion,O
in,O
terminal,O
differentiation,O
.,O
Detection,O
of,O
abnormal,O
cardiac,O
adrenergic,O
neuron,O
activity,O
in,O
adriamycin,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
with,O
iodine-125-metaiodobenzylguanidine,I-Entity
.,O
Radiolabeled,B-Entity
metaiodobenzylguanidine,I-Entity
(,O
MIBG,I-Entity
),O
",",O
an,O
analog,O
of,O
norepinephrine,I-Entity
(,O
NE,I-Entity
),O
",",O
serves,O
as,O
an,O
index,O
of,O
adrenergic,O
neuron,O
integrity,O
and,O
function,O
.,O
Using,O
a,O
rat,O
model,O
of,O
adriamycin,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
",",O
we,O
tested,O
the,O
hypothesis,O
that,O
abnormal,O
cardiac,O
adrenergic,O
neuron,O
activity,O
may,O
appear,O
and,O
be,O
exacerbated,O
dose,O
-,O
dependently,O
in,O
adriamycin,I-Entity
cardiomyopathy,I-Entity
.,O
The,O
degree,O
of,O
vacuolar,B-Entity
degeneration,I-Entity
of,I-Entity
myocardial,I-Entity
cells,I-Entity
was,O
analyzed,O
in,O
relation,O
to,O
the,O
duration,O
of,O
adriamycin,I-Entity
treatment,O
(,O
2,O
mg,O
/,O
kg,O
",",O
once,O
a,O
week,O
),O
.,O
Myocardial,O
accumulation,O
of,O
[,O
125I]MIBG,I-Entity
4,O
hr,O
after,O
intravenous,O
injection,O
did,O
not,O
differ,O
between,O
the,O
controls,O
and,O
the,O
groups,O
treated,O
3,O
wk,O
or,O
less,O
.,O
In,O
the,O
5-wk,O
group,O
",",O
MIBG,I-Entity
accumulation,O
in,O
the,O
right,O
and,O
left,O
ventricular,O
wall,O
was,O
35%,O
and,O
27%,O
of,O
that,O
in,O
controls,O
",",O
respectively,O
(,O
p,O
less,O
than,O
0.001,O
),O
.,O
In,O
the,O
8-wk,O
group,O
",",O
MIBG,I-Entity
accumulation,O
in,O
the,O
right,O
and,O
left,O
ventricular,O
wall,O
was,O
18%,O
and,O
14%,O
of,O
that,O
in,O
controls,O
",",O
respectively,O
(,O
p,O
less,O
than,O
0.001,O
),O
.,O
Thus,O
",",O
MIBG,I-Entity
accumulation,O
in,O
the,O
myocardium,O
decreased,O
in,O
an,O
adriamycin,I-Entity
dose,O
-,O
dependent,O
manner,O
.,O
The,O
appearance,O
of,O
impaired,O
cardiac,O
adrenergic,O
neuron,O
activity,O
in,O
the,O
presence,O
of,O
slight,O
myocardial,B-Entity
impairment,I-Entity
(,O
scattered,O
or,O
focal,O
vacuolar,B-Entity
degeneration,I-Entity
),O
indicates,O
that,O
MIBG,I-Entity
scintigraphy,O
may,O
be,O
a,O
useful,O
method,O
for,O
detection,O
of,O
adriamycin,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
.,O
Amnestic,B-Entity
syndrome,I-Entity
associated,O
with,O
propranolol,I-Entity
toxicity,I-Entity
:,O
a,O
case,O
report,O
.,O
An,O
elderly,O
woman,O
developed,O
an,O
Alzheimer,I-Entity
-,O
like,O
subacute,O
dementia,I-Entity
as,O
a,O
result,O
of,O
propranolol,I-Entity
toxicity,I-Entity
.,O
There,O
is,O
evidence,O
that,O
cerebral,O
reactions,O
to,O
drug,O
toxicity,I-Entity
can,O
exhibit,O
patterns,O
that,O
suggest,O
highly,O
selective,O
involvement,O
of,O
functional,O
subdivisions,O
of,O
the,O
brain,O
.,O
Biphasic,O
response,O
of,O
the,O
SA,O
node,O
of,O
the,O
dog,O
heart,O
in,O
vivo,O
to,O
selective,O
administration,O
of,O
ketamine,I-Entity
.,O
Effect,O
of,O
ketamine,I-Entity
on,O
the,O
SA,O
node,O
of,O
the,O
dog,O
heart,O
was,O
studied,O
in,O
vivo,O
using,O
a,O
selective,O
perfusion,O
technique,O
of,O
the,O
SA,O
node,O
artery,O
.,O
Injections,O
of,O
ketamine,I-Entity
in,O
doses,O
from,O
100,O
microgram,O
to,O
3,O
mg,O
into,O
the,O
artery,O
produced,O
a,O
depression,I-Entity
of,O
the,O
SA,O
nodal,O
activity,O
by,O
a,O
direct,O
action,O
.,O
This,O
depression,I-Entity
was,O
followed,O
by,O
the,O
sudden,O
appearance,O
of,O
a,O
stimulatory,O
phase,O
.,O
Bilateral,O
vagotomy,O
and,O
sympathectomy,O
or,O
prior,O
administration,O
of,O
a,O
ganglion,O
blocker,O
failed,O
to,O
inhibit,O
the,O
occurrence,O
of,O
the,O
ketamine,I-Entity
-,O
induced,O
tachycardia,I-Entity
",",O
while,O
it,O
was,O
completely,O
abolished,O
in,O
the,O
reserpinized,O
dogs,O
or,O
by,O
a,O
prior,O
injection,O
of,O
a,O
beta,O
-,O
blocking,O
agent,O
into,O
the,O
SA,O
node,O
artery,O
.,O
This,O
may,O
indicate,O
that,O
an,O
activation,O
of,O
the,O
peripheral,O
adrenergic,O
mechanism,O
plays,O
an,O
important,O
role,O
in,O
the,O
induction,O
of,O
the,O
excitatory,O
effect,O
of,O
ketamine,I-Entity
injected,O
in,O
the,O
SA,O
node,O
artery,O
.,O
The,O
use,O
of,O
serum,O
cholinesterase,O
in,O
succinylcholine,I-Entity
apnoea,I-Entity
.,O
Fifteen,O
patients,O
demonstrating,O
unexpected,O
prolonged,O
apnoea,I-Entity
lasting,O
several,O
hours,O
after,O
succinylcholine,I-Entity
have,O
been,O
treated,O
by,O
a,O
new,O
preparation,O
of,O
human,O
serum,O
cholinesterase,O
.,O
It,O
is,O
therefore,O
supposed,O
that,O
other,O
unknown,O
variants,O
of,O
serum,O
cholinesterase,O
exist,O
which,O
can,O
not,O
hydrolyze,O
succinylcholine,I-Entity
.,O
The,O
use,O
of,O
serum,O
cholinesterase,O
in,O
succinylcholine,I-Entity
apnoea,I-Entity
provided,O
considerable,O
relief,O
to,O
both,O
patient,O
and,O
anaesthetist,O
.,O
Orthostatic,B-Entity
hypotension,I-Entity
occurs,O
following,O
alpha,O
2-adrenoceptor,O
blockade,O
in,O
chronic,O
prazosin,I-Entity
-,O
pretreated,O
conscious,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
1,O
.,O
Studies,O
were,O
performed,O
to,O
evaluate,O
whether,O
chronic,O
prazosin,I-Entity
treatment,O
alters,O
the,O
alpha,O
2-adrenoceptor,O
function,O
for,O
orthostatic,O
control,O
of,O
arterial,O
blood,O
pressure,O
in,O
conscious,O
spontaneously,O
hypertensive,I-Entity
rats,O
(,O
SHR,O
),O
.,O
Conscious,O
SHR,O
(,O
male,O
300,O
-,O
350,O
g,O
),O
were,O
subjected,O
to,O
90,O
degrees,O
head,O
-,O
up,O
tilts,O
for,O
60,O
s,O
following,O
acute,O
administration,O
of,O
prazosin,I-Entity
(,O
0.1,O
mg,O
kg-1,O
i.p,O
.,O
),O
or,O
rauwolscine,I-Entity
(,O
3,O
mg,O
kg-1,O
i.v,O
.,O
),O
.,O
Orthostatic,B-Entity
hypotension,I-Entity
was,O
determined,O
by,O
the,O
average,O
decrease,O
(,O
%,O
),O
in,O
mean,O
arterial,O
pressure,O
(,O
MAP,O
femoral,O
),O
over,O
the,O
60-s,O
tilt,O
period,O
.,O
The,O
basal,O
MAP,O
of,O
conscious,O
SHR,O
was,O
reduced,O
to,O
a,O
similar,O
extent,O
by,O
prazosin,I-Entity
(,O
-23%(-)-26%,O
MAP,O
),O
and,O
rauwolscine,I-Entity
(,O
-16%(-)-33%,O
MAP,O
),O
.,O
However,O
",",O
the,O
head,O
-,O
up,O
tilt,O
induced,O
orthostatic,B-Entity
hypotension,I-Entity
in,O
the,O
SHR,O
treated,O
with,O
prazosin,I-Entity
(,O
-16%,O
MAP,O
",",O
n,O
=,O
6,O
),O
",",O
but,O
not,O
in,O
the,O
SHR,O
treated,O
with,O
rauwolscine,I-Entity
(,O
less,O
than,O
+,O
2%,O
MAP,O
",",O
n,O
=,O
6,O
),O
.,O
Conscious,O
SHR,O
were,O
treated,O
for,O
4,O
days,O
with,O
prazosin,I-Entity
at,O
2,O
mg,O
kg-1,O
day-1,O
i.p,O
.,O
MAP,O
in,O
conscious,O
SHR,O
after,O
chronic,O
prazosin,I-Entity
treatment,O
was,O
14%,O
lower,O
than,O
in,O
the,O
untreated,O
SHR,O
(,O
n,O
=,O
8),O
.,O
Head,O
-,O
up,O
tilts,O
in,O
these,O
rats,O
did,O
not,O
produce,O
orthostatic,B-Entity
hypotension,I-Entity
when,O
performed,O
either,O
prior,O
to,O
or,O
after,O
acute,O
dosing,O
of,O
prazosin,I-Entity
(,O
0.1,O
mg,O
kg-1,O
i.p,O
.,O
),O
.,O
Conversely,O
",",O
administration,O
of,O
rauwolscine,I-Entity
(,O
3,O
mg,O
kg-1,O
i.v,O
.,O
),O
in,O
chronic,O
prazosin,I-Entity
treated,O
SHR,O
decreased,O
the,O
basal,O
MAP,O
by,O
12,O
-,O
31%,O
(,O
n,O
=,O
4,O
),O
",",O
and,O
subsequent,O
tilts,O
induced,O
further,O
drops,O
of,O
MAP,O
by,O
19,O
-,O
23%,O
in,O
these,O
rats,O
.,O
The,O
pressor,O
responses,O
and,O
bradycardia,I-Entity
to,O
the,O
alpha,O
1-agonist,O
cirazoline,I-Entity
(,O
0.6,O
and,O
2,O
micrograms,O
kg-1,O
i.v,O
.,O
),O
",",O
the,O
alpha,O
2-agonist,O
Abbott-53693,I-Entity
(,O
1,O
and,O
3,O
micrograms,O
kg-1,O
i.v,O
.,O
),O
",",O
and,O
noradrenaline,I-Entity
(,O
0.1,O
and,O
1.0,O
micrograms,O
kg-1,O
i.v,O
.,O
),O
were,O
determined,O
in,O
conscious,O
SHR,O
with,O
and,O
without,O
chronic,O
prazosin,I-Entity
pretreatment,O
.,O
Both,O
the,O
pressor,O
and,O
bradycardia,I-Entity
effects,O
of,O
cirazoline,I-Entity
were,O
abolished,O
in,O
chronic,O
prazosin,I-Entity
treated,O
SHR,O
(,O
n,O
=,O
4,O
),O
as,O
compared,O
to,O
the,O
untreated,O
SHR,O
(,O
n,O
=,O
4,O
),O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
pressor,O
effects,O
of,O
Abbott-53693,I-Entity
were,O
similar,O
in,O
both,O
groups,O
of,O
SHR,O
",",O
but,O
the,O
accompanying,O
bradycardia,I-Entity
was,O
greater,O
in,O
SHR,O
with,O
chronic,O
prazosin,I-Entity
treatment,O
than,O
without,O
such,O
treatment,O
.,O
Furthermore,O
",",O
the,O
bradycardia,I-Entity
that,O
accompanied,O
the,O
noradrenaline,I-Entity
-,O
induced,O
pressor,O
effect,O
in,O
SHR,O
was,O
similar,O
with,O
and,O
without,O
chronic,O
prazosin,I-Entity
treatment,O
despite,O
a,O
47,O
-,O
71%,O
reduction,O
of,O
the,O
pressor,O
effect,O
in,O
chronic,O
alpha,O
1-receptor,O
blocked,O
SHR.(ABSTRACT,O
TRUNCATED,O
AT,O
400,O
WORDS,O
),O
Coexistence,O
of,O
cerebral,B-Entity
venous,I-Entity
sinus,I-Entity
and,I-Entity
internal,I-Entity
carotid,I-Entity
artery,I-Entity
thrombosis,I-Entity
associated,O
with,O
exogenous,O
sex,O
hormones,O
.,O
A,O
forty,O
-,O
six,O
year,O
-,O
old,O
premenopausal,O
woman,O
developed,O
headache,I-Entity
",",O
nausea,I-Entity
and,O
vomiting,I-Entity
",",O
left,O
hemiparesis,I-Entity
and,O
seizure,I-Entity
two,O
days,O
after,O
parenteral,O
use,O
of,O
progesterone,I-Entity
and,O
estradiol,I-Entity
.,O
Diabetes,B-Entity
mellitus,I-Entity
(,O
DM,I-Entity
),O
was,O
found,O
during,O
admission,O
.,O
Computed,O
tomography,O
showed,O
a,O
hemorrhagic,B-Entity
infarct,I-Entity
in,O
the,O
right,O
frontal,O
lobe,O
and,O
increased,O
density,O
in,O
the,O
superior,O
sagittal,O
sinus,O
(,O
SSS,O
),O
.,O
Left,O
carotid,O
angiography,O
found,O
occlusion,B-Entity
of,I-Entity
the,I-Entity
left,I-Entity
internal,I-Entity
carotid,I-Entity
artery,I-Entity
(,O
ICA,O
),O
.,O
Right,O
carotid,O
angiograms,O
failed,O
to,O
show,O
the,O
SSS,O
and,O
inferior,O
sagittal,O
sinus,O
",",O
suggestive,O
of,O
venous,B-Entity
sinus,I-Entity
thrombosis,I-Entity
.,O
Coexistence,O
of,O
the,O
cerebral,B-Entity
artery,I-Entity
and,I-Entity
the,I-Entity
venous,I-Entity
sinus,I-Entity
occlusion,I-Entity
has,O
been,O
described,O
infrequently,O
.,O
In,O
this,O
case,O
",",O
the,O
authors,O
postulate,O
that,O
the,O
use,O
of,O
estradiol,I-Entity
and,O
progesterone,I-Entity
and,O
the,O
underlying,O
DM,I-Entity
increased,O
vascular,O
thrombogenicity,O
",",O
which,O
provided,O
a,O
common,O
denominator,O
for,O
thrombosis,B-Entity
of,I-Entity
both,I-Entity
the,I-Entity
ICA,I-Entity
and,I-Entity
the,I-Entity
venous,I-Entity
sinus,I-Entity
.,O
Chloroquine,I-Entity
related,O
complete,O
heart,B-Entity
block,I-Entity
with,O
blindness,I-Entity
:,O
case,O
report,O
.,O
A,O
27-year,O
old,O
African,O
woman,O
with,O
history,O
of,O
regular,O
chloroquine,I-Entity
ingestion,O
presented,O
with,O
progressive,O
deterioration,B-Entity
of,I-Entity
vision,I-Entity
",",O
easy,O
fatiguability,I-Entity
",",O
dyspnoea,I-Entity
",",O
dizziness,I-Entity
progressing,O
to,O
syncopal,B-Entity
attacks,I-Entity
.,O
Ophthalmological,O
assessment,O
revealed,O
features,O
of,O
chloroquine,I-Entity
retinopathy,I-Entity
",",O
cardiac,O
assessment,O
revealed,O
features,O
of,O
heart,B-Entity
failure,I-Entity
and,O
a,O
complete,O
heart,B-Entity
block,I-Entity
with,O
right,B-Entity
bundle,I-Entity
branch,I-Entity
block,I-Entity
pattern,O
.,O
The,O
heart,B-Entity
block,I-Entity
was,O
treated,O
by,O
pacemaker,O
insertion,O
and,O
the,O
heart,B-Entity
failure,I-Entity
resolved,O
spontaneously,O
following,O
chloroquine,I-Entity
discontinuation,O
.,O
She,O
however,O
remains,O
blind,I-Entity
.,O
Systemic,O
toxicity,I-Entity
and,O
resuscitation,O
in,O
bupivacaine-,I-Entity
",",O
levobupivacaine-,I-Entity
",",O
or,O
ropivacaine,I-Entity
-,O
infused,O
rats,O
.,O
We,O
compared,O
the,O
systemic,O
toxicity,I-Entity
of,O
bupivacaine,I-Entity
",",O
levobupivacaine,I-Entity
",",O
and,O
ropivacaine,I-Entity
in,O
anesthetized,O
rats,O
.,O
Bupivacaine,I-Entity
",",O
levobupivacaine,I-Entity
",",O
or,O
ropivacaine,I-Entity
was,O
infused,O
at,O
a,O
rate,O
of,O
2,O
mg,O
.,O
When,O
asystole,I-Entity
was,O
recorded,O
",",O
drug,O
infusion,O
was,O
stopped,O
and,O
a,O
resuscitation,O
sequence,O
was,O
begun,O
.,O
Epinephrine,I-Entity
0.01,O
mg,O
/,O
kg,O
was,O
administered,O
at,O
1-min,O
intervals,O
while,O
external,O
cardiac,O
compressions,O
were,O
applied,O
.,O
The,O
cumulative,O
doses,O
of,O
levobupivacaine,I-Entity
and,O
ropivacaine,I-Entity
that,O
produced,O
seizures,I-Entity
were,O
similar,O
and,O
were,O
larger,O
than,O
those,O
of,O
bupivacaine,I-Entity
.,O
The,O
cumulative,O
doses,O
of,O
levobupivacaine,I-Entity
that,O
produced,O
dysrhythmias,I-Entity
and,O
asystole,I-Entity
were,O
smaller,O
than,O
the,O
corresponding,O
doses,O
of,O
ropivacaine,I-Entity
",",O
but,O
they,O
were,O
larger,O
than,O
those,O
of,O
bupivacaine,I-Entity
.,O
However,O
",",O
a,O
smaller,O
dose,O
of,O
epinephrine,I-Entity
was,O
required,O
in,O
the,O
Ropivacaine,I-Entity
group,O
than,O
in,O
the,O
other,O
groups,O
.,O
We,O
conclude,O
that,O
the,O
systemic,O
toxicity,I-Entity
of,O
levobupivacaine,I-Entity
is,O
intermediate,O
between,O
that,O
of,O
ropivacaine,I-Entity
and,O
bupivacaine,I-Entity
when,O
administered,O
at,O
the,O
same,O
rate,O
and,O
that,O
ropivacaine,I-Entity
-,O
induced,O
cardiac,B-Entity
arrest,I-Entity
appears,O
to,O
be,O
more,O
susceptible,O
to,O
treatment,O
than,O
that,O
induced,O
by,O
bupivacaine,I-Entity
or,O
levobupivacaine,I-Entity
.,O
22-oxacalcitriol,I-Entity
suppresses,O
secondary,B-Entity
hyperparathyroidism,I-Entity
without,O
inducing,O
low,B-Entity
bone,I-Entity
turnover,I-Entity
in,O
dogs,O
with,O
renal,B-Entity
failure,I-Entity
.,O
Calcitriol,I-Entity
therapy,O
suppresses,O
serum,O
levels,O
of,O
parathyroid,O
hormone,O
(,O
PTH,O
),O
in,O
patients,O
with,O
renal,B-Entity
failure,I-Entity
but,O
has,O
several,O
drawbacks,O
",",O
including,O
hypercalcemia,I-Entity
and/or,O
marked,O
suppression,B-Entity
of,I-Entity
bone,I-Entity
turnover,I-Entity
",",O
which,O
may,O
lead,O
to,O
adynamic,B-Entity
bone,I-Entity
disease,I-Entity
.,O
A,O
new,O
vitamin,B-Entity
D,I-Entity
analogue,O
",",O
22-oxacalcitriol,I-Entity
(,O
OCT,I-Entity
),O
",",O
has,O
been,O
shown,O
to,O
have,O
promising,O
characteristics,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
the,O
effects,O
of,O
OCT,I-Entity
on,O
serum,O
PTH,O
levels,O
and,O
bone,O
turnover,O
in,O
states,O
of,O
normal,O
or,O
impaired,B-Entity
renal,I-Entity
function,I-Entity
.,O
The,O
animals,O
received,O
supplemental,O
phosphate,I-Entity
to,O
enhance,O
PTH,O
secretion,O
.,O
Fourteen,O
weeks,O
after,O
the,O
start,O
of,O
phosphate,I-Entity
supplementation,O
",",O
half,O
of,O
the,O
Nx,O
and,O
Sham,O
dogs,O
received,O
doses,O
of,O
OCT,I-Entity
(,O
three,O
times,O
per,O
week,O
),O
;,O
the,O
other,O
half,O
were,O
given,O
vehicle,O
for,O
60,O
weeks,O
.,O
Biochemical,O
and,O
hormonal,O
indices,O
of,O
calcium,I-Entity
and,O
bone,O
metabolism,O
were,O
measured,O
throughout,O
the,O
study,O
",",O
and,O
bone,O
biopsies,O
were,O
done,O
at,O
baseline,O
",",O
60,O
weeks,O
after,O
OCT,I-Entity
or,O
vehicle,O
treatment,O
",",O
and,O
at,O
the,O
end,O
of,O
the,O
crossover,O
period,O
.,O
In,O
Nx,O
dogs,O
",",O
OCT,I-Entity
significantly,O
decreased,O
serum,O
PTH,O
levels,O
soon,O
after,O
the,O
induction,O
of,O
renal,B-Entity
insufficiency,I-Entity
.,O
In,O
long,O
-,O
standing,O
secondary,B-Entity
hyperparathyroidism,I-Entity
",",O
OCT,I-Entity
(,O
0.03,O
microg,O
/,O
kg,O
),O
stabilized,O
serum,O
PTH,O
levels,O
during,O
the,O
first,O
months,O
.,O
These,O
effects,O
were,O
accompanied,O
by,O
episodes,O
of,O
hypercalcemia,I-Entity
and,O
hyperphosphatemia,I-Entity
.,O
In,O
animals,O
with,O
normal,O
renal,O
function,O
",",O
OCT,I-Entity
induced,O
a,O
transient,O
decrease,O
in,O
serum,O
PTH,O
levels,O
at,O
a,O
dose,O
of,O
0.1,O
microg,O
/,O
kg,O
",",O
which,O
was,O
not,O
sustained,O
with,O
lowering,O
of,O
the,O
doses,O
.,O
In,O
Nx,O
dogs,O
",",O
OCT,I-Entity
reversed,O
abnormal,O
bone,O
formation,O
",",O
such,O
as,O
woven,B-Entity
osteoid,I-Entity
and,O
fibrosis,I-Entity
",",O
but,O
did,O
not,O
significantly,O
alter,O
the,O
level,O
of,O
bone,O
turnover,O
.,O
In,O
addition,O
",",O
OCT,I-Entity
improved,O
mineralization,O
lag,O
time,O
",",O
(,O
that,O
is,O
",",O
the,O
rate,O
at,O
which,O
osteoid,O
mineralizes,O
),O
in,O
both,O
Nx,O
and,O
Sham,O
dogs,O
.,O
These,O
results,O
indicate,O
that,O
even,O
though,O
OCT,I-Entity
does,O
not,O
completely,O
prevent,O
the,O
occurrence,O
of,O
hypercalcemia,I-Entity
in,O
experimental,O
dogs,O
with,O
renal,B-Entity
insufficiency,I-Entity
",",O
it,O
may,O
be,O
of,O
use,O
in,O
the,O
management,O
of,O
secondary,B-Entity
hyperparathyroidism,I-Entity
because,O
it,O
does,O
not,O
induce,O
low,B-Entity
bone,I-Entity
turnover,I-Entity
and,O
",",O
therefore,O
",",O
does,O
not,O
increase,O
the,O
risk,O
of,O
adynamic,B-Entity
bone,I-Entity
disease,I-Entity
.,O
Chemotherapy,O
of,O
advanced,O
inoperable,O
non,B-Entity
-,I-Entity
small,I-Entity
cell,I-Entity
lung,I-Entity
cancer,I-Entity
with,O
paclitaxel,I-Entity
:,O
a,O
phase,O
II,O
trial,O
.,O
Paclitaxel,I-Entity
(,O
Taxol,I-Entity
;,O
Bristol,O
-,O
Myers,O
Squibb,O
Company,O
",",O
Princeton,O
",",O
NJ,O
),O
has,O
demonstrated,O
significant,O
antineoplastic,O
activity,O
against,O
different,O
tumor,I-Entity
types,O
",",O
notably,O
ovarian,B-Entity
and,I-Entity
breast,I-Entity
carcinoma,I-Entity
.,O
Two,O
phase,O
II,O
trials,O
of,O
24-hour,O
paclitaxel,I-Entity
infusions,O
in,O
chemotherapy,O
-,O
naive,O
patients,O
with,O
stage,O
IIIB,O
or,O
IV,O
non,B-Entity
-,I-Entity
small,I-Entity
cell,I-Entity
lung,I-Entity
cancer,I-Entity
(,O
NSCLC,I-Entity
),O
reported,O
response,O
rates,O
of,O
21%,O
and,O
24%,O
.,O
Leukopenia,I-Entity
was,O
dose,O
limiting,O
:,O
as,O
many,O
as,O
62.5%,O
of,O
patients,O
experienced,O
grade,O
4,O
leukopenia,I-Entity
.,O
We,O
investigated,O
the,O
efficacy,O
and,O
toxicity,I-Entity
of,O
a,O
3-hour,O
paclitaxel,I-Entity
infusion,O
in,O
a,O
phase,O
II,O
trial,O
in,O
patients,O
with,O
inoperable,O
stage,O
IIIB,O
or,O
IV,O
NSCLC,I-Entity
.,O
Most,O
patients,O
(,O
72.4%,O
),O
had,O
stage,O
IV,O
NSCLC,I-Entity
.,O
Paclitaxel,I-Entity
Hematologic,O
toxicities,I-Entity
were,O
mild,O
:,O
only,O
one,O
patient,O
(,O
2%,O
),O
developed,O
grade,O
3,O
or,O
4,O
neutropenia,I-Entity
",",O
while,O
29%,O
had,O
grade,O
1,O
or,O
2,O
.,O
Grade,O
1,O
or,O
2,O
polyneuropathy,I-Entity
affected,O
56%,O
of,O
patients,O
while,O
only,O
one,O
(,O
2%,O
),O
experienced,O
severe,O
polyneuropathy,I-Entity
.,O
Similarly,O
",",O
grade,O
1,O
or,O
2,O
myalgia,I-Entity
/,O
arthralgia,I-Entity
was,O
observed,O
in,O
63.2%,O
of,O
patients,O
",",O
but,O
only,O
14.3%,O
experienced,O
grade,O
3,O
or,O
4,O
.,O
Nausea,I-Entity
and,O
vomiting,I-Entity
were,O
infrequent,O
",",O
with,O
14%,O
of,O
patients,O
experiencing,O
grade,O
1,O
or,O
2,O
and,O
only,O
2%,O
experiencing,O
grade,O
3,O
or,O
4,O
.,O
Paclitaxel,I-Entity
is,O
thus,O
an,O
active,O
single,O
agent,O
in,O
this,O
patient,O
population,O
",",O
with,O
a,O
3-hour,O
infusion,O
proving,O
comparably,O
effective,O
to,O
a,O
24-hour,O
infusion,O
and,O
superior,O
in,O
terms,O
of,O
the,O
incidence,O
of,O
hematologic,O
and,O
nonhematologic,O
toxicity,I-Entity
.,O
Further,O
phase,O
II,O
studies,O
with,O
paclitaxel,I-Entity
combined,O
with,O
other,O
drugs,O
active,O
against,O
NSCLC,I-Entity
are,O
indicated,O
",",O
and,O
phase,O
III,O
studies,O
comparing,O
paclitaxel,I-Entity
with,O
standard,O
chemotherapy,O
remain,O
to,O
be,O
completed,O
.,O
Cerebral,B-Entity
hemorrhage,I-Entity
associated,O
with,O
phenylpropanolamine,I-Entity
in,O
combination,O
with,O
caffeine,I-Entity
.,O
Phenylpropanolamine,I-Entity
(,O
PPA,I-Entity
),O
is,O
a,O
drug,O
that,O
has,O
been,O
associated,O
with,O
serious,O
side,O
effects,O
including,O
stroke,I-Entity
.,O
It,O
is,O
often,O
combined,O
with,O
caffeine,I-Entity
in,O
diet,O
preparations,O
and,O
"""",O
look,O
-,O
alike,O
"""",O
pills,O
.,O
In,O
order,O
to,O
determine,O
if,O
PPA,I-Entity
/,O
caffeine,I-Entity
can,O
lead,O
to,O
stroke,I-Entity
in,O
normotensive,O
and/or,O
hypertensive,I-Entity
rats,O
",",O
we,O
administered,O
the,O
combination,O
in,O
six,O
times,O
the,O
allowed,O
human,O
dose,O
calculated,O
on,O
a,O
per,O
weight,O
basis,O
for,O
the,O
rats,O
two,O
times,O
per,O
day,O
for,O
five,O
days,O
.,O
Subarachnoid,B-Entity
and,I-Entity
cerebral,I-Entity
hemorrhage,I-Entity
was,O
noted,O
in,O
18%,O
of,O
the,O
hypertensive,I-Entity
rats,O
.,O
A,O
single,O
PPA,I-Entity
/,O
caffeine,I-Entity
administration,O
(,O
same,O
dose,O
),O
lead,O
to,O
acute,O
hypertension,I-Entity
in,O
both,O
the,O
normotensive,O
and,O
hypertensive,I-Entity
animals,O
.,O
These,O
results,O
suggest,O
that,O
PPA,I-Entity
/,O
caffeine,I-Entity
can,O
lead,O
to,O
cerebral,B-Entity
hemorrhage,I-Entity
in,O
previously,O
hypertensive,I-Entity
animals,O
when,O
administered,O
in,O
greater,O
than,O
the,O
allowed,O
dosage,O
.,O
Long,O
-,O
term,O
efficacy,O
and,O
toxicity,I-Entity
of,O
high,O
-,O
dose,O
amiodarone,I-Entity
therapy,O
for,O
ventricular,B-Entity
tachycardia,I-Entity
or,O
ventricular,B-Entity
fibrillation,I-Entity
.,O
Amiodarone,I-Entity
was,O
administered,O
to,O
154,O
patients,O
who,O
had,O
sustained,O
",",O
symptomatic,O
ventricular,B-Entity
tachycardia,I-Entity
(,O
VT,I-Entity
),O
(,O
n,O
=,O
118,O
),O
or,O
a,O
cardiac,B-Entity
arrest,I-Entity
(,O
n,O
=,O
36,O
),O
and,O
who,O
were,O
refractory,O
to,O
conventional,O
antiarrhythmic,O
drugs,O
.,O
Sixty,O
-,O
nine,O
percent,O
of,O
patients,O
continued,O
treatment,O
with,O
amiodarone,I-Entity
and,O
had,O
no,O
recurrence,O
of,O
symptomatic,O
VT,I-Entity
or,O
ventricular,B-Entity
fibrillation,I-Entity
(,O
VF,I-Entity
),O
over,O
a,O
follow,O
-,O
up,O
of,O
6,O
to,O
52,O
months,O
(,O
mean,O
+,O
/-,O
Six,O
percent,O
of,O
the,O
patients,O
had,O
a,O
nonfatal,O
recurrence,O
of,O
VT,I-Entity
and,O
were,O
successfully,O
managed,O
by,O
continuing,O
amiodarone,I-Entity
at,O
a,O
higher,O
dose,O
or,O
by,O
the,O
addition,O
of,O
a,O
conventional,O
antiarrhythmic,O
drug,O
.,O
Adverse,O
effects,O
forced,O
a,O
reduction,O
in,O
the,O
dose,O
of,O
amiodarone,I-Entity
in,O
41%,O
and,O
discontinuation,O
of,O
amiodarone,I-Entity
in,O
10%,O
of,O
patients,O
.,O
The,O
most,O
common,O
symptomatic,O
adverse,O
reactions,O
were,O
tremor,I-Entity
or,O
ataxia,I-Entity
(,O
35%,O
),O
",",O
nausea,I-Entity
and,O
anorexia,I-Entity
(,O
8%,O
),O
",",O
visual,B-Entity
halos,I-Entity
or,I-Entity
blurring,I-Entity
(,O
6%,O
),O
",",O
thyroid,B-Entity
function,I-Entity
abnormalities,I-Entity
(,O
6%,O
),O
and,O
pulmonary,B-Entity
interstitial,I-Entity
infiltrates,I-Entity
(,O
5%,O
),O
.,O
Although,O
large,O
-,O
dose,O
amiodarone,I-Entity
is,O
highly,O
effective,O
in,O
the,O
long,O
-,O
term,O
treatment,O
of,O
VT,I-Entity
or,O
VF,I-Entity
refractory,O
to,O
conventional,O
antiarrhythmic,O
drugs,O
",",O
it,O
causes,O
significant,O
toxicity,I-Entity
in,O
approximately,O
50%,O
of,O
patients,O
.,O
However,O
",",O
when,O
the,O
dose,O
is,O
adjusted,O
based,O
on,O
clinical,O
response,O
or,O
the,O
development,O
of,O
adverse,O
effects,O
",",O
75%,O
of,O
patients,O
with,O
VT,I-Entity
or,O
VF,I-Entity
can,O
be,O
successfully,O
managed,O
with,O
amiodarone,I-Entity
.,O
Effect,O
of,O
calcium,B-Entity
chloride,I-Entity
and,O
4-aminopyridine,I-Entity
therapy,O
on,O
desipramine,I-Entity
toxicity,I-Entity
in,O
rats,O
.,O
Hypotension,I-Entity
is,O
a,O
major,O
contributor,O
to,O
mortality,O
in,O
tricyclic,O
antidepressant,O
overdose,I-Entity
.,O
Recent,O
data,O
suggest,O
that,O
tricyclic,O
antidepressants,O
inhibit,O
calcium,I-Entity
influx,O
in,O
some,O
tissues,O
.,O
This,O
study,O
addressed,O
the,O
potential,O
role,O
of,O
calcium,I-Entity
channel,O
blockade,O
in,O
tricyclic,O
antidepressant,O
-,O
induced,O
hypotension,I-Entity
.,O
Two,O
interventions,O
were,O
studied,O
that,O
have,O
been,O
shown,O
previously,O
to,O
improve,O
blood,O
pressure,O
with,O
calcium,I-Entity
channel,O
blocker,O
overdose,I-Entity
.,O
CaCl2,I-Entity
and,O
4-aminopyridine,I-Entity
.,O
Anesthetized,O
rats,O
received,O
the,O
tricyclic,O
antidepressant,O
desipramine,I-Entity
IP,O
to,O
produce,O
hypotension,I-Entity
",",O
QRS,O
prolongation,O
",",O
and,O
bradycardia,I-Entity
.,O
min,O
later,O
",",O
animals,O
received,O
CaCl2,I-Entity
",",O
NaHCO3,I-Entity
",",O
or,O
saline,O
.,O
In,O
a,O
second,O
experiment,O
",",O
rats,O
received,O
tricyclic,O
antidepressant,O
desipramine,I-Entity
IP,O
followed,O
in,O
15,O
min,O
by,O
4-aminopyridine,I-Entity
or,O
saline,O
.,O
NaHCO3,I-Entity
briefly,O
(,O
5,O
min,O
),O
reversed,O
hypotension,I-Entity
and,O
QRS,O
prolongation,O
.,O
CaCl2,I-Entity
and,O
4-aminopyridine,I-Entity
failed,O
to,O
improve,O
blood,O
pressure,O
.,O
The,O
incidence,O
of,O
ventricular,B-Entity
arrhythmias,I-Entity
(,O
p,O
=,O
0.004,O
),O
and,O
seizures,I-Entity
(,O
p,O
=,O
0.03,O
),O
in,O
the,O
CaCl2,I-Entity
group,O
was,O
higher,O
than,O
the,O
other,O
groups,O
.,O
CONCLUSION,O
:,O
The,O
administration,O
of,O
CaCl2,I-Entity
or,O
4-aminopyridine,I-Entity
did,O
not,O
reverse,O
tricyclic,O
antidepressant,O
-,O
induced,O
hypotension,I-Entity
in,O
rats,O
.,O
CaCl2,I-Entity
therapy,O
may,O
possibly,O
worsen,O
both,O
cardiovascular,B-Entity
and,I-Entity
central,I-Entity
nervous,I-Entity
system,I-Entity
toxicity,I-Entity
.,O
These,O
findings,O
do,O
not,O
support,O
a,O
role,O
for,O
calcium,I-Entity
channel,O
inhibition,O
in,O
the,O
pathogenesis,O
of,O
tricyclic,O
antidepressant,O
-,O
induced,O
hypotension,I-Entity
.,O
Phase,O
I,O
trial,O
of,O
13-cis,B-Entity
-,I-Entity
retinoic,I-Entity
acid,I-Entity
in,O
children,O
with,O
neuroblastoma,I-Entity
following,O
bone,O
marrow,O
transplantation,O
.,O
PURPOSE,O
:,O
Treatment,O
of,O
neuroblastoma,I-Entity
cell,O
lines,O
with,O
13-cis,B-Entity
-,I-Entity
retinoic,I-Entity
acid,I-Entity
(,O
cis,B-Entity
-,I-Entity
RA,I-Entity
),O
can,O
cause,O
sustained,O
inhibition,O
of,O
proliferation,O
.,O
Since,O
cis,B-Entity
-,I-Entity
RA,I-Entity
has,O
demonstrated,O
clinical,O
responses,O
in,O
neuroblastoma,I-Entity
patients,O
",",O
it,O
may,O
be,O
effective,O
in,O
preventing,O
relapse,O
after,O
cytotoxic,O
therapy,O
.,O
This,O
phase,O
I,O
trial,O
was,O
designed,O
to,O
determine,O
the,O
maximal,O
-,O
tolerated,O
dosage,O
(,O
MTD,O
),O
",",O
toxicities,I-Entity
",",O
and,O
pharmacokinetics,O
of,O
cis,B-Entity
-,I-Entity
RA,I-Entity
administered,O
on,O
an,O
intermittent,O
schedule,O
in,O
children,O
with,O
neuroblastoma,I-Entity
following,O
bone,O
marrow,O
transplantation,O
(,O
BMT,O
),O
.,O
PATIENTS,O
AND,O
METHODS,O
:,O
Fifty,O
-,O
one,O
assessable,O
patients,O
",",O
2,O
to,O
12,O
years,O
of,O
age,O
",",O
were,O
treated,O
with,O
oral,O
cis,B-Entity
-,I-Entity
RA,I-Entity
administered,O
in,O
two,O
equally,O
divided,O
doses,O
daily,O
for,O
2,O
weeks,O
",",O
followed,O
by,O
a,O
2-week,O
rest,O
period,O
",",O
for,O
up,O
to,O
12,O
courses,O
.,O
The,O
dose,O
was,O
escalated,O
from,O
100,O
to,O
200,O
mg,O
/,O
m2/d,O
until,O
dose,O
-,O
limiting,O
toxicity,I-Entity
(,O
DLT,O
),O
was,O
observed,O
.,O
The,O
MTD,O
of,O
cis,B-Entity
-,I-Entity
RA,I-Entity
was,O
160,O
mg,O
/,O
m2/d,O
.,O
Dose,O
-,O
limiting,O
toxicities,I-Entity
in,O
six,O
of,O
nine,O
patients,O
at,O
200,O
mg,O
/,O
m2/d,O
included,O
hypercalcemia,I-Entity
(,O
n,O
=,O
3,O
),O
",",O
rash,I-Entity
(,O
n,O
=,O
2,O
),O
",",O
and,O
anemia,I-Entity
/,O
thrombocytopenia,I-Entity
/,O
emesis,I-Entity
/,O
rash,I-Entity
(,O
n,O
=,O
1,O
),O
.,O
All,O
toxicities,I-Entity
resolved,O
after,O
cis,B-Entity
-,I-Entity
RA,I-Entity
was,O
discontinued,O
.,O
Three,O
complete,O
responses,O
were,O
observed,O
in,O
marrow,O
metastases,I-Entity
.,O
The,O
MTD,O
of,O
cis,B-Entity
-,I-Entity
RA,I-Entity
given,O
on,O
this,O
intermittent,O
schedule,O
was,O
160,O
mg,O
/,O
m2/d,O
.,O
Serum,O
levels,O
known,O
to,O
be,O
effective,O
against,O
neuroblastoma,I-Entity
in,O
vitro,O
were,O
achieved,O
at,O
this,O
dose,O
.,O
The,O
DLT,O
included,O
hypercalcemia,I-Entity
",",O
and,O
may,O
be,O
predicted,O
by,O
serum,O
cis,B-Entity
-,I-Entity
RA,I-Entity
levels,O
.,O
Monitoring,O
of,O
serum,O
calcium,I-Entity
and,O
cis,B-Entity
-,I-Entity
RA,I-Entity
levels,O
is,O
indicated,O
in,O
future,O
trials,O
.,O
Effect,O
of,O
calcium,B-Entity
chloride,I-Entity
on,O
gross,O
behavioural,O
changes,O
produced,O
by,O
carbachol,I-Entity
and,O
eserine,I-Entity
in,O
cats,O
.,O
The,O
effect,O
of,O
calcium,B-Entity
chloride,I-Entity
injected,O
into,O
the,O
cerebral,O
ventricles,O
of,O
group,O
-,O
housed,O
unanaesthetized,O
cats,O
upon,O
vocalization,O
(,O
rage,O
",",O
hissing,O
and,O
snarling,O
),O
",",O
fighting,O
(,O
attack,O
with,O
paws,O
and,O
claws,O
",",O
defense,O
with,O
paws,O
and,O
claws,O
and,O
biting,O
),O
",",O
mydriasis,I-Entity
",",O
tremor,I-Entity
and,O
clonic,B-Entity
-,I-Entity
tonic,I-Entity
convulsions,I-Entity
produced,O
by,O
carbachol,I-Entity
and,O
eserine,I-Entity
injected,O
similarly,O
was,O
investigated,O
.,O
Calcium,B-Entity
chloride,I-Entity
depressed,O
or,O
almost,O
completely,O
abolished,O
the,O
vocalization,O
and,O
fighting,O
due,O
to,O
carbachol,I-Entity
and,O
eserine,I-Entity
.,O
On,O
the,O
other,O
hand,O
",",O
mydriasis,I-Entity
",",O
tremor,I-Entity
and,O
clonic,B-Entity
-,I-Entity
tonic,I-Entity
convulsions,I-Entity
evoked,O
by,O
carbachol,I-Entity
and,O
eserine,I-Entity
were,O
not,O
significantly,O
changed,O
by,O
calcium,B-Entity
chloride,I-Entity
.,O
It,O
is,O
apparent,O
that,O
calcium,B-Entity
chloride,I-Entity
can,O
"""",O
dissociate,O
"""",O
vocalization,O
and,O
fighting,O
from,O
autonomic,O
and,O
motor,O
phenomena,O
such,O
as,O
mydriasis,I-Entity
",",O
tremor,I-Entity
and,O
clonic,B-Entity
-,I-Entity
tonic,I-Entity
convulsions,I-Entity
caused,O
by,O
carbachol,I-Entity
and,O
eserine,I-Entity
.,O
Calcium,B-Entity
chloride,I-Entity
inhibited,O
the,O
vocalization,O
and,O
fighting,O
produced,O
by,O
carbachol,I-Entity
and,O
eserine,I-Entity
most,O
probably,O
by,O
a,O
nonspecific,O
stabilizing,O
action,O
on,O
central,O
muscarinic,O
cholinoceptive,O
sites,O
.,O
These,O
results,O
further,O
support,O
the,O
view,O
that,O
calcium,I-Entity
ions,O
in,O
excess,O
have,O
an,O
atropine,I-Entity
-,O
like,O
action,O
also,O
in,O
the,O
central,O
nervous,O
system,O
.,O
Multiple,O
side,O
effects,O
of,O
penicillamine,I-Entity
therapy,O
in,O
one,O
patient,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
Skin,B-Entity
rashes,I-Entity
",",O
proteinuria,I-Entity
",",O
systemic,B-Entity
lupus,I-Entity
erythematosus,I-Entity
",",O
polymyositis,I-Entity
and,O
myasthenia,B-Entity
gravis,I-Entity
have,O
all,O
been,O
recorded,O
as,O
complications,O
of,O
penicillamine,I-Entity
therapy,O
in,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
The,O
skin,B-Entity
lesion,I-Entity
resembled,O
elastosis,B-Entity
perforans,I-Entity
serpiginosa,I-Entity
",",O
which,O
has,O
been,O
reported,O
as,O
a,O
rare,O
side,O
effect,O
in,O
patients,O
with,O
Wilson,B-Entity
's,I-Entity
disease,I-Entity
but,O
not,O
in,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
treated,O
with,O
penicillamine,I-Entity
.,O
Electrocardiographic,O
changes,O
and,O
cardiac,B-Entity
arrhythmias,I-Entity
in,O
patients,O
receiving,O
psychotropic,O
drugs,O
.,O
Eight,O
patients,O
had,O
cardiac,O
manifestations,O
that,O
were,O
life,O
-,O
threatening,O
in,O
five,O
while,O
taking,O
psychotropic,O
drugs,O
",",O
either,O
phenothiazines,I-Entity
or,O
tricyclic,O
antidepressants,O
.,O
Although,O
most,O
patients,O
were,O
receiving,O
several,O
drugs,O
",",O
Mellaril,I-Entity
(,O
thioridazine,I-Entity
),O
appeared,O
to,O
be,O
responsible,O
for,O
five,O
cases,O
of,O
ventricular,B-Entity
tachycardia,I-Entity
",",O
one,O
of,O
which,O
was,O
fatal,O
in,O
a,O
35,O
year,O
old,O
woman,O
.,O
Supraventricular,B-Entity
tachycardia,I-Entity
developed,O
in,O
one,O
patient,O
receiving,O
Thorazine,I-Entity
(,O
chlorpromazine,I-Entity
),O
.,O
Aventyl,I-Entity
(,O
nortriptyline,I-Entity
),O
and,O
Elavil,I-Entity
(,O
amitriptyline,I-Entity
),O
each,O
produced,O
left,B-Entity
bundle,I-Entity
branch,I-Entity
block,I-Entity
in,O
a,O
73,O
year,O
old,O
woman,O
.,O
The,O
ventricular,B-Entity
arrhythmias,I-Entity
responded,O
to,O
intravenous,O
administration,O
of,O
lidocaine,I-Entity
and,O
to,O
direct,O
current,O
electric,O
shock,O
;,O
ventricular,O
pacing,O
was,O
required,O
in,O
some,O
instances,O
and,O
intravenous,O
administration,O
of,O
propranolol,I-Entity
combined,O
with,O
ventricular,O
pacing,O
in,O
one,O
.,O
The,O
tachyarrhythmias,I-Entity
generally,O
subsided,O
within,O
48,O
hours,O
after,O
administration,O
of,O
the,O
drugs,O
was,O
stopped,O
.,O
Five,O
of,O
the,O
eight,O
patients,O
were,O
50,O
years,O
of,O
age,O
or,O
younger,O
;,O
only,O
one,O
clearly,O
had,O
antecedent,O
heart,B-Entity
disease,I-Entity
.,O
Major,O
cardiac,B-Entity
arrhythmias,I-Entity
are,O
a,O
potential,O
hazard,O
in,O
patients,O
without,O
heart,B-Entity
disease,I-Entity
who,O
are,O
receiving,O
customary,O
therapeutic,O
doses,O
of,O
psychotropic,O
drugs,O
.,O
A,O
prospective,O
clinical,O
trial,O
is,O
suggested,O
to,O
quantify,O
the,O
risk,O
of,O
cardiac,B-Entity
complications,I-Entity
to,O
patients,O
receiving,O
phenothiazines,I-Entity
or,O
tricyclic,O
antidepressant,O
drugs,O
.,O
Serotonergic,O
drugs,O
",",O
benzodiazepines,I-Entity
and,O
baclofen,I-Entity
block,O
muscimol,I-Entity
-,O
induced,O
myoclonic,B-Entity
jerks,I-Entity
in,O
a,O
strain,O
of,O
mice,O
.,O
In,O
male,O
Swiss,O
mice,O
",",O
muscimol,I-Entity
produced,O
myoclonic,B-Entity
jerks,I-Entity
.,O
Increasing,O
the,O
brain,O
serotonin,I-Entity
levels,O
by,O
the,O
administration,O
of,O
5-hydroxytryptophan,I-Entity
(,O
80,O
-,O
160,O
mg,O
/,O
kg,O
),O
in,O
combination,O
with,O
a,O
peripheral,O
decarboxylase,O
inhibitor,O
resulted,O
in,O
an,O
inhibition,O
of,O
the,O
muscimol,I-Entity
effect,O
.,O
l,B-Entity
-,I-Entity
dopa,I-Entity
(,O
80,O
-,O
160,O
mg,O
/,O
kg,O
),O
was,O
without,O
effect,O
.,O
In,O
doses,O
of,O
3,O
-,O
10,O
mg,O
/,O
kg,O
",",O
the,O
serotonin,I-Entity
receptor,O
agonist,O
MK-212,I-Entity
caused,O
a,O
dose,O
-,O
dependent,O
blockade,O
of,O
the,O
response,O
of,O
muscimol,I-Entity
.,O
Of,O
the,O
benzodiazepines,I-Entity
",",O
clonazepam,I-Entity
(,O
0.1,O
-,O
0.3,O
mg,O
/,O
kg,O
),O
was,O
found,O
to,O
be,O
several,O
fold,O
more,O
potent,O
than,O
diazepam,I-Entity
(,O
0.3,O
-,O
3,O
mg,O
/,O
kg,O
),O
in,O
blocking,O
the,O
myoclonic,B-Entity
jerks,I-Entity
.,O
While,O
(,O
-)-baclofen,I-Entity
(,O
1,O
-,O
3,O
mg,O
/,O
kg,O
),O
proved,O
to,O
be,O
an,O
effective,O
antagonist,O
of,O
muscimol,I-Entity
",",O
its,O
(,O
+,O
),O
Considering,O
the,O
fact,O
that,O
5-HTP,I-Entity
and,O
the,O
benzodiazepines,I-Entity
have,O
been,O
found,O
to,O
be,O
beneficial,O
in,O
the,O
management,O
of,O
clinical,O
myoclonus,I-Entity
",",O
the,O
muscimol,I-Entity
-,O
induced,O
myoclonus,I-Entity
seems,O
to,O
be,O
a,O
satisfactory,O
animal,O
model,O
that,O
may,O
prove,O
useful,O
for,O
the,O
development,O
of,O
new,O
drug,O
treatments,O
for,O
this,O
condition,O
.,O
Our,O
present,O
study,O
indicated,O
the,O
possible,O
value,O
of,O
MK-212,I-Entity
and,O
(,O
-)-baclofen,I-Entity
in,O
the,O
management,O
of,O
clinical,O
myoclonus,I-Entity
.,O
Hyperglycemic,B-Entity
acidotic,I-Entity
coma,I-Entity
and,O
death,O
in,O
Kearns,B-Entity
-,I-Entity
Sayre,I-Entity
syndrome,I-Entity
.,O
This,O
paper,O
presents,O
the,O
clinical,O
and,O
metabolic,O
findings,O
in,O
two,O
young,O
boys,O
with,O
long,O
-,O
standing,O
Kearns,B-Entity
-,I-Entity
Sayre,I-Entity
syndrome,I-Entity
.,O
Following,O
short,O
exposure,O
to,O
oral,O
prednisone,I-Entity
",",O
both,O
boys,O
developed,O
lethargy,I-Entity
",",O
increasing,O
somnolence,I-Entity
",",O
polydipsia,I-Entity
",",O
polyphagia,I-Entity
",",O
and,O
polyuria,I-Entity
.,O
Both,O
presented,O
in,O
the,O
emergency,O
room,O
with,O
profound,O
coma,I-Entity
",",O
hypotension,I-Entity
",",O
severe,O
hyperglycemia,I-Entity
",",O
and,O
acidosis,I-Entity
.,O
Nonketotic,O
lactic,B-Entity
acidosis,I-Entity
was,O
present,O
in,O
one,O
and,O
ketosis,I-Entity
without,O
a,O
known,O
serum,O
lactate,I-Entity
level,O
was,O
present,O
in,O
the,O
other,O
.,O
Respiratory,B-Entity
failure,I-Entity
rapidly,O
ensued,O
and,O
both,O
patients,O
expired,O
in,O
spite,O
of,O
efforts,O
at,O
resuscitation,O
.,O
We,O
believe,O
these,O
two,O
cases,O
represent,O
a,O
newly,O
described,O
and,O
catastrophic,O
metabolic,B-Entity
-,I-Entity
endocrine,I-Entity
failure,I-Entity
in,O
the,O
Kearns,B-Entity
-,I-Entity
Sayre,I-Entity
syndrome,I-Entity
.,O
Effects,O
of,O
active,O
constituents,O
of,O
Crocus,O
sativus,O
L.,O
",",O
crocin,I-Entity
on,O
streptozocin,I-Entity
-,O
induced,O
model,O
of,O
sporadic,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
in,O
male,O
rats,O
.,O
BACKGROUND,O
:,O
The,O
involvement,O
of,O
water,O
-,O
soluble,O
carotenoids,I-Entity
",",O
crocins,I-Entity
",",O
as,O
the,O
main,O
and,O
active,O
components,O
of,O
Crocus,O
sativus,O
L.,O
extract,O
in,O
learning,O
and,O
memory,O
processes,O
has,O
been,O
proposed,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
effect,O
of,O
crocins,I-Entity
on,O
sporadic,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
induced,O
by,O
intracerebroventricular,O
(,O
icv,O
),O
streptozocin,I-Entity
(,O
STZ,I-Entity
),O
in,O
male,O
rats,O
was,O
investigated,O
.,O
Male,O
adult,O
Wistar,O
rats,O
(,O
n,O
=,O
90,O
and,O
260,O
-,O
290,O
g,O
),O
were,O
divided,O
into,O
1,O
",",O
control,O
;,O
2,O
and,O
3,O
",",O
crocins,I-Entity
(,O
15,O
and,O
30,O
mg,O
/,O
kg,O
),O
;,O
4,O
",",O
STZ,I-Entity
;,O
5,O
and,O
6,O
",",O
STZ,I-Entity
+,O
crocins,I-Entity
(,O
15,O
and,O
30,O
mg,O
/,O
kg,O
),O
groups,O
.,O
In,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
groups,O
",",O
rats,O
were,O
injected,O
with,O
STZ,I-Entity
-,O
icv,O
bilaterally,O
(,O
3,O
mg,O
/,O
kg,O
),O
in,O
first,O
day,O
and,O
3,O
days,O
later,O
",",O
a,O
similar,O
STZ,I-Entity
-,O
icv,O
application,O
was,O
repeated,O
.,O
In,O
STZ,I-Entity
+,O
crocin,I-Entity
animal,O
groups,O
",",O
crocin,I-Entity
was,O
applied,O
in,O
doses,O
of,O
15,O
and,O
30,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
Prescription,O
of,O
crocin,I-Entity
in,O
each,O
dose,O
was,O
repeated,O
once,O
for,O
two,O
days,O
.,O
It,O
was,O
found,O
out,O
that,O
crocin,I-Entity
(,O
30,O
mg,O
/,O
kg)-treated,O
STZ,I-Entity
-,O
injected,O
rats,O
show,O
higher,O
correct,O
choices,O
and,O
lower,O
errors,O
in,O
Y,O
-,O
maze,O
than,O
vehicle,O
-,O
treated,O
STZ,I-Entity
-,O
injected,O
rats,O
.,O
In,O
addition,O
",",O
crocin,I-Entity
in,O
the,O
mentioned,O
dose,O
could,O
significantly,O
attenuated,O
learning,B-Entity
and,I-Entity
memory,I-Entity
impairment,I-Entity
in,O
treated,O
STZ,I-Entity
-,O
injected,O
group,O
in,O
passive,O
avoidance,O
test,O
.,O
Therefore,O
",",O
these,O
results,O
demonstrate,O
the,O
effectiveness,O
of,O
crocin,I-Entity
(,O
30,O
mg,O
/,O
kg,O
),O
in,O
antagonizing,O
the,O
cognitive,B-Entity
deficits,I-Entity
caused,O
by,O
STZ,I-Entity
-,O
icv,O
in,O
rats,O
and,O
its,O
potential,O
in,O
the,O
treatment,O
of,O
neurodegenerative,B-Entity
diseases,I-Entity
such,O
as,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
.,O
Rosaceiform,O
dermatitis,I-Entity
associated,O
with,O
topical,O
tacrolimus,I-Entity
treatment,O
.,O
We,O
describe,O
herein,O
3,O
patients,O
who,O
developed,O
rosacea,I-Entity
-,O
like,O
dermatitis,I-Entity
eruptions,I-Entity
while,O
using,O
0.03%,O
or,O
0.1%,O
tacrolimus,I-Entity
ointment,O
for,O
facial,B-Entity
dermatitis,I-Entity
.,O
Skin,O
biopsy,O
specimens,O
showed,O
telangiectasia,I-Entity
and,O
noncaseating,O
epithelioid,O
granulomatous,O
tissue,O
formation,O
in,O
the,O
papillary,O
to,O
mid,O
dermis,O
.,O
Continuous,O
topical,O
use,O
of,O
immunomodulators,O
such,O
as,O
tacrolimus,I-Entity
or,O
pimecrolimus,I-Entity
should,O
be,O
regarded,O
as,O
a,O
potential,O
cause,O
of,O
rosaceiform,O
dermatitis,I-Entity
",",O
although,O
many,O
cases,O
have,O
not,O
been,O
reported,O
.,O
poly,B-Entity
-,I-Entity
L,I-Entity
-,I-Entity
lactid,I-Entity
acid,I-Entity
nanoparticles,O
was,O
used,O
as,O
a,O
model,O
of,O
colloidal,O
drug,O
delivery,O
system,O
",",O
able,O
to,O
trespass,O
the,O
BBB,O
.,O
Tacrine,I-Entity
",",O
administered,O
in,O
LiCl,I-Entity
pre,O
-,O
treated,O
rats,O
",",O
induces,O
electrocorticographic,O
seizures,I-Entity
and,O
delayed,O
hippocampal,B-Entity
damage,I-Entity
.,O
The,O
toxic,O
effects,O
of,O
tacrine,I-Entity
-,O
loaded,O
poly,B-Entity
-,I-Entity
L,I-Entity
-,I-Entity
lactid,I-Entity
acid,I-Entity
nanoparticles,O
(,O
5mg,O
/,O
kg,O
),O
",",O
a,O
saline,O
solution,O
of,O
tacrine,I-Entity
(,O
5mg,O
/,O
kg,O
),O
and,O
an,O
empty,O
colloidal,O
nanoparticle,O
suspension,O
were,O
compared,O
following,O
i.p,O
.,O
administration,O
in,O
LiCl,I-Entity
-,O
pre,O
-,O
treated,O
Wistar,O
rats,O
.,O
All,O
the,O
animals,O
treated,O
with,O
tacrine,I-Entity
-,O
loaded,O
nanoparticles,O
showed,O
an,O
earlier,O
outcome,O
of,O
CNS,O
adverse,O
symptoms,O
",",O
i.e.,O
epileptic,I-Entity
onset,O
",",O
with,O
respect,O
to,O
those,O
animals,O
treated,O
with,O
the,O
free,O
compound,O
(,O
10,O
min,O
vs.,O
22,O
min,O
respectively,O
),O
.,O
In,O
addition,O
",",O
tacrine,I-Entity
-,O
loaded,O
nanoparticles,O
administration,O
induced,O
damage,B-Entity
of,I-Entity
neuronal,I-Entity
cells,I-Entity
in,O
CA1,O
field,O
of,O
the,O
hippocampus,O
in,O
all,O
treated,O
animals,O
",",O
while,O
the,O
saline,O
solution,O
of,O
tacrine,I-Entity
only,O
in,O
60%,O
of,O
animals,O
.,O
In,O
conclusion,O
",",O
the,O
evaluation,O
of,O
time,O
-,O
to,O
-,O
onset,O
of,O
symptoms,O
and,O
the,O
severity,O
of,O
neurodegenerative,O
processes,O
induced,O
by,O
the,O
tacrine,I-Entity
-,O
lithium,I-Entity
model,O
of,O
epilepsy,I-Entity
in,O
the,O
rat,O
",",O
could,O
be,O
used,O
to,O
evaluate,O
preliminarily,O
the,O
capability,O
of,O
a,O
drug,O
delivery,O
system,O
to,O
trespass,O
(,O
or,O
not,O
),O
the,O
BBB,O
in,O
vivo,O
.,O
The,O
antiarrhythmic,O
effect,O
and,O
possible,O
ionic,O
mechanisms,O
of,O
pilocarpine,I-Entity
on,O
animal,O
models,O
.,O
This,O
study,O
was,O
designed,O
to,O
evaluate,O
the,O
effects,O
of,O
pilocarpine,I-Entity
and,O
explore,O
the,O
underlying,O
ionic,O
mechanism,O
",",O
using,O
both,O
aconitine,I-Entity
-,O
induced,O
rat,O
and,O
ouabain,I-Entity
-,O
induced,O
guinea,O
pig,O
arrhythmia,I-Entity
models,O
.,O
Confocal,O
microscopy,O
was,O
used,O
to,O
measure,O
intracellular,O
free,O
-,O
calcium,I-Entity
concentrations,O
(,O
[,O
Ca(2+)](i,I-Entity
),O
),O
in,O
isolated,O
myocytes,O
.,O
The,O
current,O
data,O
showed,O
that,O
pilocarpine,I-Entity
significantly,O
delayed,O
onset,O
of,O
arrhythmias,I-Entity
",",O
decreased,O
the,O
time,O
course,O
of,O
ventricular,B-Entity
tachycardia,I-Entity
and,I-Entity
fibrillation,I-Entity
",",O
reduced,O
arrhythmia,I-Entity
score,O
",",O
and,O
increased,O
the,O
survival,O
time,O
of,O
arrhythmic,I-Entity
rats,O
and,O
guinea,O
pigs,O
.,O
[,O
Ca(2+)](i,I-Entity
),O
overload,O
induced,O
by,O
aconitine,I-Entity
or,O
ouabain,I-Entity
was,O
reduced,O
in,O
isolated,O
myocytes,O
pretreated,O
with,O
pilocarpine,I-Entity
.,O
Moreover,O
",",O
M(3)-muscarinic,O
acetylcholine,I-Entity
receptor,O
(,O
mAChR,O
),O
antagonist,O
4-DAMP,I-Entity
(,O
4-diphenylacetoxy,B-Entity
-,I-Entity
N,I-Entity
-,I-Entity
methylpiperidine,I-Entity
-,I-Entity
methiodide,I-Entity
),O
partially,O
abolished,O
the,O
beneficial,O
effects,O
of,O
pilocarpine,I-Entity
.,O
These,O
data,O
suggest,O
that,O
pilocarpine,I-Entity
produced,O
antiarrhythmic,O
actions,O
on,O
arrhythmic,I-Entity
rat,O
and,O
guinea,O
pig,O
models,O
induced,O
by,O
aconitine,I-Entity
or,O
ouabain,I-Entity
via,O
stimulating,O
the,O
cardiac,O
M(3)-mAChR.,O
The,O
mechanism,O
may,O
be,O
related,O
to,O
the,O
improvement,O
of,O
Ca(2,I-Entity
+,O
),O
handling,O
.,O
Disulfiram,I-Entity
-,O
induced,O
transient,O
optic,B-Entity
and,I-Entity
peripheral,I-Entity
neuropathy,I-Entity
:,O
a,O
case,O
report,O
.,O
AIM,O
:,O
To,O
report,O
a,O
case,O
of,O
optic,B-Entity
and,I-Entity
peripheral,I-Entity
neuropathy,I-Entity
after,O
chronic,O
use,O
of,O
disulfiram,I-Entity
for,O
alcohol,B-Entity
dependence,I-Entity
management,O
.,O
A,O
57-year,O
-,O
old,O
male,O
presented,O
with,O
gradual,O
loss,B-Entity
of,I-Entity
vision,I-Entity
in,O
both,O
eyes,O
with,O
intermittent,O
headaches,I-Entity
for,O
2,O
months,O
.,O
He,O
also,O
complained,O
of,O
paraesthesia,I-Entity
with,O
numbness,I-Entity
in,O
both,O
feet,O
.,O
Visual,O
field,O
testing,O
confirmed,O
bilateral,O
central,O
-,O
caecal,O
scotomata,I-Entity
.,O
He,O
had,O
been,O
taking,O
disulfiram,I-Entity
for,O
alcohol,B-Entity
dependence,I-Entity
for,O
the,O
preceding,O
3,O
years,O
.,O
Disulfiram,I-Entity
discontinuation,O
lead,O
to,O
an,O
immediate,O
symptomatic,O
improvement,O
.,O
Physicians,O
initiating,O
long,O
-,O
term,O
disulfiram,I-Entity
therapy,O
should,O
be,O
aware,O
of,O
these,O
adverse,O
effects,O
.,O
Sustained,O
clinical,O
improvement,O
of,O
a,O
patient,O
with,O
decompensated,O
hepatitis,B-Entity
B,I-Entity
virus,O
-,O
related,O
cirrhosis,I-Entity
after,O
treatment,O
with,O
lamivudine,I-Entity
monotherapy,O
.,O
Hepatitis,B-Entity
B,I-Entity
virus,I-Entity
(,I-Entity
HBV,I-Entity
),I-Entity
infection,I-Entity
",",O
which,O
causes,O
liver,B-Entity
cirrhosis,I-Entity
and,O
hepatocellular,B-Entity
carcinoma,I-Entity
",",O
remains,O
a,O
major,O
health,O
problem,O
in,O
Asian,O
countries,O
.,O
In,O
this,O
report,O
",",O
we,O
encountered,O
a,O
patient,O
with,O
decompensated,O
HBV,O
-,O
related,O
cirrhosis,I-Entity
who,O
exhibited,O
the,O
dramatic,O
improvements,O
after,O
antiviral,O
therapy,O
.,O
However,O
",",O
the,O
administration,O
of,O
lamivudine,I-Entity
",",O
a,O
reverse,O
transcriptase,O
inhibitor,O
",",O
for,O
23,O
months,O
dramatically,O
improved,O
her,O
liver,O
severity,O
.,O
Moreover,O
",",O
both,O
hepatitis,B-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
and,I-Entity
e,I-Entity
antigen,I-Entity
were,O
observed,O
to,O
have,O
disappeared,O
in,O
this,O
patient,O
.,O
The,O
administration,O
of,O
lamivudine,I-Entity
to,O
patients,O
with,O
HBV,O
-,O
related,O
cirrhosis,I-Entity
",",O
like,O
our,O
present,O
case,O
",",O
should,O
be,O
considered,O
as,O
an,O
initial,O
medical,O
therapeutic,O
option,O
",",O
especially,O
in,O
countries,O
where,O
liver,O
transplantation,O
is,O
not,O
reliably,O
available,O
.,O
Dual,O
effects,O
of,O
melatonin,I-Entity
on,O
barbiturate,I-Entity
-,O
induced,O
narcosis,I-Entity
in,O
rats,O
.,O
Melatonin,I-Entity
affects,O
the,O
circadian,O
sleep,O
/,O
wake,O
cycle,O
",",O
but,O
it,O
is,O
not,O
clear,O
whether,O
it,O
may,O
influence,O
drug,O
-,O
induced,O
narcosis,I-Entity
.,O
Sodium,B-Entity
thiopenthal,I-Entity
was,O
administered,O
intraperitoneally,O
into,O
male,O
rats,O
pre,O
-,O
treated,O
with,O
melatonin,I-Entity
(,O
0.05,O
",",O
0.5,O
",",O
5,O
and,O
50,O
mg,O
/,O
kg,O
),O
.,O
Melatonin,I-Entity
pre,O
-,O
treatment,O
affected,O
in,O
a,O
dual,O
manner,O
barbiturate,I-Entity
narcosis,I-Entity
",",O
however,O
",",O
no,O
dose,O
-,O
effect,O
correlation,O
was,O
found,O
.,O
In,O
particular,O
",",O
low,O
doses,O
reduced,O
the,O
latency,O
to,O
and,O
prolonged,O
the,O
duration,O
of,O
barbiturate,I-Entity
narcosis,I-Entity
.,O
In,O
contrast,O
",",O
the,O
highest,O
dose,O
of,O
melatonin,I-Entity
(,O
50,O
mg,O
/,O
kg,O
),O
caused,O
a,O
paradoxical,O
increase,O
in,O
the,O
latency,O
and,O
produced,O
a,O
sustained,O
reduction,O
of,O
the,O
duration,O
of,O
narcosis,I-Entity
",",O
and,O
a,O
reduction,O
in,O
mortality,O
rate,O
.,O
Melatonin,I-Entity
0.5,O
and,O
5,O
mg,O
/,O
kg,O
influenced,O
the,O
duration,O
but,O
not,O
the,O
latency,O
of,O
ketamine-,I-Entity
or,O
diazepam,I-Entity
-,O
induced,O
narcosis,I-Entity
.,O
Thus,O
",",O
the,O
dual,O
action,O
of,O
melatonin,I-Entity
on,O
pharmacological,O
narcosis,I-Entity
seems,O
to,O
be,O
specific,O
for,O
the,O
barbiturate,I-Entity
mechanism,O
of,O
action,O
.,O
Effects,O
of,O
NIK-247,I-Entity
on,O
cholinesterase,O
and,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
The,O
effects,O
of,O
NIK-247,I-Entity
on,O
cholinesterase,O
",",O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
and,O
spontaneous,O
movement,O
were,O
examined,O
and,O
compared,O
with,O
those,O
of,O
the,O
well,O
-,O
known,O
cholinesterase,O
inhibitors,O
tacrine,I-Entity
and,O
E-2020,I-Entity
.,O
NIK-247,I-Entity
",",O
tacrine,I-Entity
and,O
E-2020,I-Entity
all,O
strongly,O
inhibited,O
acetylcholinesterase,O
(,O
AChE,O
),O
in,O
human,O
red,O
blood,O
cells,O
(,O
IC50s,O
=,O
1.0,O
x,O
10(-6,O
),O
",",O
2.9,O
x,O
10(-7,O
),O
and,O
3.7,O
x,O
10(-8,O
),O
In,O
addition,O
",",O
NIK-247,I-Entity
and,O
tacrine,I-Entity
",",O
but,O
not,O
E-2020,I-Entity
",",O
strongly,O
inhibited,O
butyrylcholinestrase,O
(,O
BuChE,O
),O
Moreover,O
",",O
the,O
inhibitory,O
effect,O
of,O
NIK-247,I-Entity
on,O
AChE,O
was,O
reversible,O
.,O
significantly,O
improved,O
the,O
amnesia,I-Entity
induced,O
by,O
scopolamine,I-Entity
(,O
0.5,O
mg,O
/,O
kg,O
s.c,O
.,O
),O
These,O
findings,O
suggest,O
that,O
NIK-247,I-Entity
at,O
a,O
low,O
dose,O
(,O
0.1,O
-,O
1,O
mg,O
/,O
kg,O
p.o,O
.,O
),O
improves,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
but,O
does,O
not,O
affect,O
spontaneous,O
movement,O
.,O
The,O
findings,O
suggest,O
that,O
NIK-247,I-Entity
may,O
be,O
a,O
useful,O
drug,O
for,O
the,O
treatment,O
of,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
.,O
Nightmares,O
and,O
hallucinations,I-Entity
after,O
long,O
-,O
term,O
intake,O
of,O
tramadol,I-Entity
combined,O
with,O
antidepressants,O
.,O
Tramadol,I-Entity
is,O
a,O
weak,O
opioid,O
with,O
effects,O
on,O
adrenergic,O
and,O
serotonergic,O
neurotransmission,O
that,O
is,O
used,O
to,O
treat,O
cancer,I-Entity
pain,I-Entity
and,O
chronic,O
non,O
malignant,O
pain,I-Entity
.,O
This,O
drug,O
was,O
initiated,O
in,O
association,O
with,O
paroxetine,I-Entity
and,O
dosulepine,B-Entity
hydrochloride,I-Entity
in,O
a,O
tetraparetic,I-Entity
patient,O
with,O
chronic,B-Entity
pain,I-Entity
.,O
Fifty,O
-,O
six,O
days,O
after,O
initiation,O
of,O
the,O
treatment,O
the,O
patient,O
presented,O
hallucinations,I-Entity
that,O
only,O
stopped,O
after,O
the,O
withdrawal,O
of,O
psycho,O
-,O
active,O
drugs,O
and,O
tramadol,I-Entity
.,O
The,O
case,O
report,O
questions,O
the,O
long,O
term,O
use,O
of,O
pain,I-Entity
killers,O
combined,O
with,O
psycho,O
-,O
active,O
drugs,O
in,O
chronic,O
non,O
malignant,O
pain,I-Entity
",",O
especially,O
if,O
pain,I-Entity
is,O
under,O
control,O
.,O
Apparent,O
cure,O
of,O
rheumatoid,B-Entity
arthritis,I-Entity
by,O
bone,O
marrow,O
transplantation,O
.,O
We,O
describe,O
the,O
induction,O
of,O
sustained,O
remissions,O
and,O
possible,O
cure,O
of,O
severe,O
erosive,O
rheumatoid,B-Entity
arthritis,I-Entity
(,O
RA,I-Entity
),O
by,O
bone,O
marrow,O
transplantation,O
(,O
BMT,O
),O
in,O
2,O
patients,O
.,O
BMT,O
was,O
used,O
to,O
treat,O
severe,O
aplastic,B-Entity
anemia,I-Entity
which,O
was,O
caused,O
by,O
gold,I-Entity
in,O
one,O
case,O
and,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
in,O
the,O
other,O
.,O
In,O
the,O
8,O
and,O
6,O
years,O
since,O
the,O
transplants,O
(,O
representing,O
8,O
and,O
4,O
years,O
since,O
cessation,O
of,O
all,O
immunosuppressive,O
therapy,O
",",O
respectively,O
),O
",",O
the,O
RA,I-Entity
in,O
each,O
case,O
has,O
been,O
completely,O
quiescent,O
.,O
Although,O
short,O
term,O
remission,O
of,O
severe,O
RA,I-Entity
following,O
BMT,O
has,O
been,O
reported,O
",",O
these,O
are,O
the,O
first,O
cases,O
for,O
which,O
prolonged,O
followup,O
has,O
been,O
available,O
.,O
This,O
experience,O
raises,O
the,O
question,O
of,O
the,O
role,O
of,O
BMT,O
itself,O
as,O
a,O
therapeutic,O
option,O
for,O
patients,O
with,O
uncontrolled,O
destructive,O
synovitis,I-Entity
.,O
Urinary,O
enzymes,O
and,O
protein,O
patterns,O
as,O
indicators,O
of,O
injury,B-Entity
to,I-Entity
different,I-Entity
regions,I-Entity
of,I-Entity
the,I-Entity
kidney,I-Entity
.,O
Acute,B-Entity
experimental,I-Entity
models,I-Entity
of,I-Entity
renal,I-Entity
damage,I-Entity
to,O
the,O
proximal,O
tubular,O
",",O
glomerular,O
",",O
and,O
papillary,O
regions,O
of,O
the,O
rat,O
were,O
produced,O
by,O
administration,O
of,O
hexachloro-1:3-butadiene,I-Entity
(,O
HCBD,I-Entity
),O
",",O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
),O
",",O
and,O
2-bromoethylamine,I-Entity
(,O
BEA,I-Entity
),O
",",O
respectively,O
.,O
Several,O
routine,O
indicators,O
of,O
nephrotoxicity,I-Entity
",",O
the,O
enzymes,O
alkaline,O
phosphatase,O
and,O
N,O
-,O
acetyl,O
-,O
beta,O
-,O
glucosaminidase,O
",",O
and,O
the,O
molecular,O
weight,O
of,O
protein,B-Entity
excretion,I-Entity
were,O
determined,O
on,O
urine,O
samples,O
.,O
Tubular,O
damage,O
produced,O
by,O
HCBD,I-Entity
or,O
BEA,I-Entity
was,O
discriminated,O
both,O
quantitatively,O
and,O
qualitatively,O
from,O
glomerular,B-Entity
damage,I-Entity
produced,O
by,O
PAN,I-Entity
.,O
The,O
latter,O
was,O
characterized,O
by,O
a,O
pronounced,O
increase,O
in,O
protein,B-Entity
excretion,I-Entity
",",O
especially,O
proteins,O
with,O
molecular,O
weight,O
greater,O
than,O
"40,000",O
Da,O
.,O
In,O
contrast,O
",",O
protein,B-Entity
excretion,I-Entity
in,O
tubular,O
damage,O
was,O
raised,O
only,O
slightly,O
and,O
characterized,O
by,O
excretion,B-Entity
of,I-Entity
proteins,I-Entity
of,O
a,O
wide,O
range,O
of,O
molecular,O
weights,O
.,O
Proximal,O
tubular,O
damage,O
caused,O
by,O
HCBD,I-Entity
and,O
papillary,O
damage,O
caused,O
by,O
BEA,I-Entity
were,O
distinguished,O
both,O
by,O
conventional,O
urinalysis,O
(,O
volume,O
and,O
specific,O
gravity,O
),O
and,O
by,O
measurement,O
of,O
the,O
two,O
urinary,O
enzymes,O
.,O
Alkaline,O
phosphatase,O
and,O
glucose,I-Entity
were,O
markedly,O
and,O
transiently,O
elevated,O
in,O
proximal,O
tubular,O
damage,O
and,O
N,O
-,O
acetyl,O
-,O
beta,O
-,O
glucosaminidase,O
showed,O
a,O
sustained,O
elevation,O
in,O
papillary,O
damage,O
.,O
It,O
is,O
concluded,O
that,O
both,O
selective,O
urinary,O
enzymes,O
and,O
the,O
molecular,O
weight,O
pattern,O
of,O
urinary,O
proteins,O
can,O
be,O
used,O
to,O
provide,O
diagnostic,O
information,O
about,O
the,O
possible,O
site,O
of,O
renal,B-Entity
damage,I-Entity
.,O
Neuromuscular,B-Entity
blockade,I-Entity
with,O
magnesium,B-Entity
sulfate,I-Entity
and,O
nifedipine,I-Entity
.,O
A,O
patient,O
who,O
received,O
tocolysis,O
with,O
nifedipine,I-Entity
developed,O
neuromuscular,B-Entity
blockade,I-Entity
after,O
500,O
mg,O
of,O
magnesium,B-Entity
sulfate,I-Entity
was,O
administered,O
.,O
This,O
reaction,O
demonstrates,O
that,O
nifedipine,I-Entity
can,O
seriously,O
potentiate,O
the,O
toxicity,I-Entity
of,O
magnesium,I-Entity
.,O
Ifosfamide,I-Entity
continuous,O
infusion,O
without,O
mesna,I-Entity
.,O
Twenty,O
patients,O
received,O
27,O
courses,O
of,O
ifosfamide,I-Entity
administered,O
as,O
a,O
24-hour,O
continuous,O
infusion,O
for,O
14,O
days,O
without,O
Mesna,I-Entity
.,O
The,O
goal,O
of,O
the,O
study,O
was,O
to,O
deliver,O
a,O
dose,O
rate,O
and,O
total,O
cumulative,O
dose,O
of,O
ifosfamide,I-Entity
that,O
would,O
be,O
comparable,O
to,O
standard,O
bolus,O
or,O
short,O
-,O
term,O
infusions,O
administered,O
with,O
Mesna,I-Entity
.,O
Four,O
patients,O
developed,O
transient,O
microscopic,O
hematuria,I-Entity
at,O
400,O
",",O
450,O
",",O
and,O
500,O
mg,O
/,O
m2/d,O
.,O
There,O
were,O
no,O
instances,O
of,O
macroscopic,O
hematuria,I-Entity
.,O
At,O
550,O
mg,O
/,O
m2/d,O
",",O
three,O
patients,O
experienced,O
nonurologic,O
toxicity,I-Entity
;,O
confusion,I-Entity
(,O
1,O
),O
",",O
nausea,I-Entity
(,O
1,O
),O
",",O
and,O
Grade,O
2,O
leukopenia,I-Entity
(,O
1,O
),O
.,O
The,O
frequency,O
and,O
predictability,O
of,O
hematuria,I-Entity
are,O
not,O
precise,O
",",O
and,O
at,O
least,O
daily,O
monitoring,O
by,O
urine,O
Hematest,O
is,O
essential,O
",",O
adding,O
Mesna,I-Entity
to,O
the,O
infusate,O
in,O
patients,O
with,O
persistent,O
hematuria,I-Entity
.,O
The,O
protracted,O
infusion,O
schedule,O
for,O
ifosfamide,I-Entity
permits,O
convenient,O
outpatient,O
administration,O
without,O
Mesna,I-Entity
and,O
reduces,O
the,O
drug,O
cost,O
of,O
clinical,O
usage,O
of,O
this,O
agent,O
by,O
up,O
to,O
890,O
per,O
cycle,O
.,O
Myocardial,B-Entity
infarction,I-Entity
in,O
pregnancy,O
associated,O
with,O
clomiphene,B-Entity
citrate,I-Entity
for,O
ovulation,O
induction,O
:,O
a,O
case,O
report,O
.,O
BACKGROUND,O
:,O
Clomiphene,B-Entity
citrate,I-Entity
(,O
CC,I-Entity
),O
is,O
commonly,O
prescribed,O
for,O
ovulation,O
induction,O
.,O
Thromboembolism,I-Entity
is,O
a,O
rare,O
but,O
life,O
-,O
threatening,O
complication,O
that,O
has,O
been,O
reported,O
after,O
ovulation,O
induction,O
with,O
CC,I-Entity
.,O
coronary,B-Entity
thrombosis,I-Entity
or,O
thromboembolism,I-Entity
with,O
subsequent,O
clot,O
lysis,O
has,O
been,O
suggested,O
as,O
one,O
of,O
the,O
most,O
common,O
causes,O
of,O
myocardial,B-Entity
infarction,I-Entity
(,O
MI,I-Entity
),O
during,O
pregnancy,O
",",O
with,O
a,O
subsequently,O
normal,O
coronary,O
angiogram,O
.,O
A,O
33-year,O
-,O
old,O
woman,O
with,O
a,O
5-week,O
gestation,O
had,O
recently,O
received,O
CC,I-Entity
for,O
ovulation,O
induction,O
and,O
presented,O
with,O
chest,B-Entity
pain,I-Entity
.,O
An,O
electrocardiogram,O
showed,O
a,O
lateral,O
and,O
anterior,O
wall,O
myocardial,B-Entity
infarction,I-Entity
.,O
At,O
the,O
time,O
of,O
admission,O
",",O
the,O
patient,O
was,O
at,O
high,O
risk,O
of,O
radiation,B-Entity
injury,I-Entity
to,O
the,O
fetus,O
",",O
so,O
a,O
coronary,O
angiogram,O
was,O
postponed,O
until,O
the,O
second,O
trimester,O
.,O
This,O
appears,O
to,O
be,O
the,O
first,O
reported,O
case,O
documenting,O
a,O
possible,O
association,O
between,O
CC,I-Entity
and,O
myocardial,B-Entity
infarction,I-Entity
.,O
Thrombosis,I-Entity
might,O
be,O
a,O
rare,O
but,O
hazardous,O
complication,O
of,O
CC,I-Entity
.,O
Hepatonecrosis,I-Entity
and,O
cholangitis,I-Entity
related,O
to,O
long,O
-,O
term,O
phenobarbital,I-Entity
therapy,O
:,O
an,O
autopsy,O
report,O
of,O
two,O
patients,O
.,O
Phenobarbital,I-Entity
(,O
PB,I-Entity
),O
has,O
a,O
reputation,O
for,O
safety,O
",",O
and,O
it,O
is,O
commonly,O
believed,O
that,O
PB,I-Entity
-,O
related,O
increases,O
in,O
serum,O
aminotransferase,O
levels,O
do,O
not,O
indicate,O
or,O
predict,O
the,O
development,O
of,O
significant,O
chronic,O
liver,B-Entity
disease,I-Entity
.,O
Here,O
we,O
report,O
of,O
two,O
adult,O
patients,O
with,O
a,O
long,O
history,O
of,O
epilepsy,I-Entity
treated,O
with,O
PB,I-Entity
who,O
died,O
suddenly,O
:,O
one,O
as,O
consequence,O
of,O
cardiac,B-Entity
arrest,I-Entity
",",O
the,O
other,O
of,O
acute,O
bronchopneumonia,I-Entity
.,O
At,O
autopsy,O
",",O
analysis,O
of,O
liver,O
parenchyma,O
revealed,O
rich,O
portal,O
inflammatory,O
infiltrate,O
",",O
which,O
consisted,O
of,O
mixed,O
eosinophil,O
and,O
monocyte,O
cells,O
",",O
associated,O
with,O
several,O
foci,O
of,O
necrosis,I-Entity
surrounded,O
by,O
a,O
hard,O
ring,O
of,O
non,O
-,O
specific,O
granulomatous,O
tissue,O
.,O
Our,O
findings,O
illustrate,O
that,O
PB,I-Entity
may,O
be,O
associated,O
with,O
chronic,O
liver,B-Entity
damage,I-Entity
",",O
which,O
may,O
lead,O
to,O
more,O
serious,O
and,O
deleterious,O
consequences,O
.,O
For,O
this,O
reason,O
",",O
each,O
clinician,O
should,O
recognize,O
this,O
entity,O
in,O
the,O
differential,O
diagnosis,O
of,O
PB,I-Entity
-,O
related,O
asymptomatic,O
chronic,B-Entity
hepatic,I-Entity
enzyme,I-Entity
dysfunction,I-Entity
.,O
Ethambutol,I-Entity
-,O
associated,O
optic,B-Entity
neuropathy,I-Entity
.,O
Ethambutol,I-Entity
is,O
used,O
in,O
the,O
treatment,O
of,O
tuberculosis,I-Entity
",",O
which,O
is,O
still,O
prevalent,O
in,O
Southeast,O
Asia,O
",",O
and,O
can,O
be,O
associated,O
with,O
permanent,O
visual,B-Entity
loss,I-Entity
.,O
We,O
report,O
3,O
cases,O
which,O
presented,O
with,O
bitemporal,B-Entity
hemianopia,I-Entity
.,O
Three,O
patients,O
with,O
ethambutol,I-Entity
-,O
associated,O
toxic,O
optic,B-Entity
neuropathy,I-Entity
are,O
described,O
.,O
All,O
3,O
patients,O
had,O
loss,B-Entity
of,I-Entity
central,I-Entity
visual,I-Entity
acuity,I-Entity
",",I-Entity
colour,I-Entity
vision,I-Entity
(,I-Entity
Ishihara,I-Entity
),I-Entity
and,I-Entity
visual,I-Entity
field,I-Entity
.,O
The,O
visual,B-Entity
field,I-Entity
loss,I-Entity
had,O
a,O
bitemporal,O
flavour,O
",",O
suggesting,O
involvement,O
of,O
the,O
optic,O
chiasm,O
.,O
Despite,O
stopping,O
ethambutol,I-Entity
on,O
diagnosis,O
",",O
visual,O
function,O
continued,O
to,O
deteriorate,O
for,O
a,O
few,O
months,O
.,O
All,O
3,O
patients,O
had,O
some,O
permanent,O
loss,B-Entity
of,I-Entity
visual,I-Entity
function,I-Entity
.,O
Ethambutol,I-Entity
usage,O
is,O
associated,O
with,O
permanent,O
visual,B-Entity
loss,I-Entity
and,O
should,O
be,O
avoided,O
if,O
possible,O
or,O
used,O
with,O
caution,O
and,O
proper,O
ophthalmological,O
follow,O
-,O
up,O
.,O
The,O
author,O
postulates,O
that,O
in,O
cases,O
of,O
ethambutol,I-Entity
associated,O
chiasmopathy,O
",",O
ethambutol,I-Entity
may,O
initially,O
affect,O
the,O
optic,O
nerves,O
and,O
subsequently,O
progress,O
to,O
involve,O
the,O
optic,O
chiasm,O
.,O
Tolerability,O
of,O
nimesulide,I-Entity
and,O
paracetamol,I-Entity
in,O
patients,O
with,O
NSAID,I-Entity
-,O
induced,O
urticaria,I-Entity
/,O
angioedema,I-Entity
.,O
Previous,O
studies,O
evaluated,O
the,O
tolerance,O
of,O
nimesulide,I-Entity
and,O
paracetamol,I-Entity
in,O
subjects,O
with,O
cutaneous,O
",",O
respiratory,O
and,O
anaphylactoid,O
reactions,O
induced,O
by,O
nonsteroidal,B-Entity
anti,I-Entity
-,I-Entity
inflammatory,I-Entity
drugs,I-Entity
(,O
NSAIDs,I-Entity
),O
.,O
In,O
this,O
study,O
we,O
investigated,O
tolerability,O
and,O
reliability,O
of,O
nimesulide,I-Entity
and,O
paracetamol,I-Entity
in,O
a,O
very,O
large,O
number,O
of,O
patients,O
with,O
an,O
exclusive,O
well,O
-,O
documented,O
history,O
of,O
NSAID,I-Entity
-,O
induced,O
urticaria,I-Entity
/,O
angioedema,I-Entity
.,O
Furthermore,O
",",O
we,O
evaluated,O
whether,O
some,O
factors,O
have,O
the,O
potential,O
to,O
increase,O
the,O
risk,O
of,O
reaction,O
to,O
paracetamol,I-Entity
and,O
nimesulide,I-Entity
.,O
A,O
single,O
-,O
placebo,O
-,O
controlled,O
oral,O
challenge,O
procedure,O
with,O
nimesulide,I-Entity
or,O
paracetamol,I-Entity
was,O
applied,O
to,O
829,O
patients,O
with,O
a,O
history,O
of,O
NSAID,I-Entity
-,O
induced,O
urticaria,I-Entity
/,O
angioedema,I-Entity
.,O
patients,O
experienced,O
reactions,O
to,O
nimesulide,I-Entity
or,O
paracetamol,I-Entity
.,O
Of,O
the,O
715,O
patients,O
tested,O
with,O
nimesulide,I-Entity
62,O
(,O
8.6%,O
),O
showed,O
a,O
positive,O
test,O
",",O
while,O
of,O
114,O
subjects,O
submitted,O
to,O
the,O
challenge,O
with,O
paracetamol,I-Entity
",",O
13,O
(,O
9.6%,O
),O
did,O
not,O
tolerate,O
this,O
drug,O
.,O
Furthermore,O
",",O
18.28%,O
of,O
patients,O
with,O
a,O
history,O
of,O
chronic,O
urticaria,I-Entity
and,O
11.8%,O
of,O
subjects,O
with,O
an,O
history,O
of,O
NSAID,I-Entity
-,O
induced,O
urticaria,I-Entity
/,O
angioedema,I-Entity
or,O
angioedema,I-Entity
alone,O
(,O
with,O
or,O
without,O
chronic,O
urticaria,I-Entity
),O
resulted,O
to,O
be,O
intolerant,O
to,O
alternative,O
drugs,O
.,O
Taken,O
together,O
",",O
our,O
results,O
confirm,O
the,O
good,O
tolerability,O
of,O
nimesulide,I-Entity
and,O
paracetamol,I-Entity
in,O
patients,O
who,O
experienced,O
urticaria,I-Entity
/,O
angioedema,I-Entity
caused,O
by,O
NSAIDs,I-Entity
.,O
However,O
",",O
the,O
risk,O
of,O
reaction,O
to,O
these,O
alternative,O
study,O
drugs,O
is,O
statistically,O
increased,O
by,O
a,O
history,O
of,O
chronic,O
urticaria,I-Entity
and,O
",",O
above,O
all,O
",",O
by,O
a,O
history,O
of,O
NSAID,I-Entity
-,O
induced,O
angioedema,I-Entity
.,O
Effects,O
of,O
verapamil,I-Entity
on,O
atrial,B-Entity
fibrillation,I-Entity
and,O
its,O
electrophysiological,O
determinants,O
in,O
dogs,O
.,O
Atrial,B-Entity
tachycardia,I-Entity
-,O
induced,O
remodeling,O
promotes,O
the,O
occurrence,O
and,O
maintenance,O
of,O
atrial,B-Entity
fibrillation,I-Entity
(,O
AF,I-Entity
),O
and,O
decreases,O
L,O
-,O
type,O
Ca(2,I-Entity
+,O
),O
current,O
.,O
There,O
is,O
also,O
a,O
clinical,O
suggestion,O
that,O
acute,O
L,O
-,O
type,O
Ca(2,I-Entity
),O
channel,O
blockade,O
can,O
promote,O
AF,I-Entity
",",O
consistent,O
with,O
an,O
AF,I-Entity
promoting,O
effect,O
of,O
Ca(2,I-Entity
+,O
),O
channel,O
inhibition,O
.,O
METHODS,O
:,O
To,O
evaluate,O
the,O
potential,O
mechanisms,O
of,O
AF,I-Entity
promotion,O
by,O
Ca(2,I-Entity
+,O
),O
channel,O
blockers,O
",",O
we,O
administered,O
verapamil,I-Entity
to,O
morphine,I-Entity
-,O
chloralose,I-Entity
anesthetized,O
dogs,O
.,O
Diltiazem,I-Entity
was,O
used,O
as,O
a,O
comparison,O
drug,O
and,O
autonomic,O
blockade,O
with,O
atropine,I-Entity
and,O
nadolol,I-Entity
was,O
applied,O
in,O
some,O
experiments,O
.,O
Epicardial,O
mapping,O
with,O
240,O
epicardial,O
electrodes,O
was,O
used,O
to,O
evaluate,O
activation,O
during,O
AF,I-Entity
.,O
RESULTS,O
:,O
Verapamil,I-Entity
caused,O
AF,I-Entity
promotion,O
in,O
six,O
dogs,O
",",O
increasing,O
mean,O
duration,O
of,O
AF,I-Entity
induced,O
by,O
burst,O
pacing,O
",",O
from,O
8+/-4,O
s,O
(,O
mean+/-S.E.,O
),O
to,O
95+/-39,O
s,O
(,O
P<0.01,O
vs.,O
control,O
),O
at,O
a,O
loading,O
dose,O
of,O
0.1,O
mg,O
/,O
kg,O
and,O
228+/-101,O
s,O
(,O
P<0.0005,O
vs.,O
control,O
),O
at,O
a,O
dose,O
of,O
0.2,O
mg,O
/,O
kg,O
.,O
Underlying,O
electrophysiological,O
mechanisms,O
were,O
studied,O
in,O
detail,O
in,O
five,O
additional,O
dogs,O
under,O
control,O
conditions,O
and,O
in,O
the,O
presence,O
of,O
the,O
higher,O
dose,O
of,O
verapamil,I-Entity
.,O
In,O
these,O
experiments,O
",",O
verapamil,I-Entity
shortened,O
mean,O
effective,O
refractory,O
period,O
(,O
ERP,O
),O
from,O
122+/-5,O
to,O
114+/-4,O
ms,O
(,O
P<0.02,O
),O
at,O
a,O
cycle,O
length,O
of,O
300,O
ms,O
",",O
decreased,O
ERP,O
heterogeneity,O
(,O
from,O
15+/-1,O
to,O
10+/-1%,O
",",O
P<0.05,O
),O
",",O
heterogeneously,O
accelerated,O
atrial,O
conduction,O
and,O
decreased,O
the,O
cycle,O
length,O
of,O
AF,I-Entity
(,O
94+/-4,O
to,O
84+/-3,O
ms,O
",",O
P<0.005,O
),O
.,O
Diltiazem,I-Entity
did,O
not,O
affect,O
ERP,O
",",O
AF,I-Entity
cycle,O
length,O
or,O
AF,I-Entity
duration,O
",",O
but,O
produced,O
conduction,O
acceleration,O
similar,O
to,O
that,O
caused,O
by,O
verapamil,I-Entity
(,O
n=5,O
),O
.,O
In,O
the,O
presence,O
of,O
autonomic,O
blockade,O
",",O
verapamil,I-Entity
failed,O
to,O
promote,O
AF,I-Entity
and,O
increased,O
",",O
rather,O
than,O
decreasing,O
",",O
refractoriness,O
.,O
Neither,O
verapamil,I-Entity
nor,O
diltiazem,I-Entity
affected,O
atrial,O
conduction,O
in,O
the,O
presence,O
of,O
autonomic,O
blockade,O
.,O
Epicardial,O
mapping,O
suggested,O
that,O
verapamil,I-Entity
promoted,O
AF,I-Entity
by,O
increasing,O
the,O
number,O
of,O
simultaneous,O
wavefronts,O
reflected,O
by,O
separate,O
zones,O
of,O
reactivation,O
in,O
each,O
cycle,O
.,O
:,O
Verapamil,I-Entity
promotes,O
AF,I-Entity
in,O
normal,O
dogs,O
by,O
promoting,O
multiple,O
circuit,O
reentry,O
",",O
an,O
effect,O
dependent,O
on,O
intact,O
autonomic,O
tone,O
and,O
not,O
shared,O
by,O
diltiazem,I-Entity
.,O
Hypotension,I-Entity
",",O
bradycardia,I-Entity
",",O
and,O
asystole,I-Entity
after,O
high,O
-,O
dose,O
intravenous,O
methylprednisolone,I-Entity
in,O
a,O
monitored,O
patient,O
.,O
We,O
report,O
a,O
case,O
of,O
hypotension,I-Entity
",",O
bradycardia,I-Entity
",",O
and,O
asystole,I-Entity
after,O
intravenous,O
administration,O
of,O
high,O
-,O
dose,O
methylprednisolone,I-Entity
in,O
a,O
73-year,O
-,O
old,O
patient,O
who,O
underwent,O
electrocardiographic,O
(,O
ECG,O
),O
monitoring,O
throughout,O
the,O
episode,O
.,O
There,O
was,O
a,O
history,O
of,O
ischemic,I-Entity
cardiac,B-Entity
disease,I-Entity
9,O
years,O
earlier,O
.,O
The,O
patient,O
was,O
admitted,O
with,O
a,O
pulmonary,B-Entity
-,I-Entity
renal,I-Entity
syndrome,I-Entity
with,O
hemoptysis,I-Entity
",",O
rapidly,O
progressive,O
renal,B-Entity
failure,I-Entity
",",O
and,O
hypoxemia,I-Entity
that,O
required,O
mechanical,O
ventilation,O
in,O
the,O
intensive,O
care,O
unit,O
.,O
The,O
ECG,O
showed,O
a,O
junctional,O
rhythm,O
without,O
ventricular,B-Entity
arrhythmia,I-Entity
.,O
This,O
study,O
reviews,O
the,O
current,O
proposed,O
mechanisms,O
of,O
sudden,B-Entity
death,I-Entity
after,O
a,O
high,O
dose,O
of,O
intravenous,O
methylprednisolone,I-Entity
(,O
IVMP,I-Entity
),O
.,O
Rapid,O
infusion,O
and,O
underlying,O
cardiac,B-Entity
disease,I-Entity
were,O
important,O
risk,O
factors,O
in,O
the,O
case,O
reported,O
here,O
",",O
and,O
the,O
authors,O
discount,O
ventricular,B-Entity
arrhythmia,I-Entity
as,O
the,O
main,O
mechanism,O
.,O
Lifetime,O
treatment,O
of,O
mice,O
with,O
azidothymidine,I-Entity
(,O
AZT,I-Entity
),O
produces,O
myelodysplasia,I-Entity
.,O
AZT,I-Entity
has,O
induced,O
a,O
macrocytic,B-Entity
anemia,I-Entity
in,O
AIDS,I-Entity
patients,O
on,O
long,O
term,O
AZT,I-Entity
therapy,O
.,O
It,O
is,O
generally,O
assumed,O
that,O
DNA,O
elongation,O
is,O
stopped,O
by,O
the,O
insertion,O
of,O
AZT,I-Entity
into,O
the,O
chain,O
in,O
place,O
of,O
thymidine,I-Entity
thus,O
preventing,O
the,O
phosphate,I-Entity
hydroxyl,O
linkages,O
and,O
therefore,O
suppresses,O
hemopoietic,O
progenitor,O
cell,O
proliferation,O
in,O
an,O
early,O
stage,O
of,O
differentiation,O
.,O
CBA,O
/,O
Ca,O
male,O
mice,O
started,O
on,O
AZT,I-Entity
0.75,O
mg,O
/,O
ml,O
H2O,O
at,O
84,O
days,O
of,O
age,O
and,O
kept,O
on,O
it,O
for,O
687,O
days,O
when,O
dosage,O
reduced,O
to,O
0.5,O
mg,O
/,O
ml,O
H2O,O
for,O
a,O
group,O
",",O
another,O
group,O
removed,O
from,O
AZT,I-Entity
to,O
see,O
recovery,O
",",O
and,O
third,O
group,O
remained,O
on,O
0.75,O
mg,O
.,O
Histological,O
examination,O
on,O
9,O
of,O
10,O
mice,O
with,O
such,O
thrombocytopenia,I-Entity
showed,O
changes,O
compatible,O
with,O
myelodysplastic,B-Entity
syndrome,I-Entity
(,O
MDS,I-Entity
),O
.,O
There,O
were,O
two,O
cases,O
of,O
hypocellular,O
myelodysplasia,I-Entity
",",O
two,O
cases,O
of,O
hypersegmented,O
myelodysplastic,I-Entity
granulocytosis,O
",",O
two,O
cases,O
of,O
hypercellular,O
marrow,O
with,O
abnormal,O
megakaryocytes,O
with,O
bizarre,O
nuclei,O
",",O
one,O
case,O
of,O
megakaryocytic,O
myelosis,O
associated,O
with,O
a,O
hyperplastic,B-Entity
marrow,I-Entity
",",O
dysmyelopoiesis,I-Entity
and,O
a,O
hypocellular,B-Entity
marrow,I-Entity
and,O
two,O
cases,O
of,O
myelodysplasia,I-Entity
with,O
dyserythropoiesis,I-Entity
",",O
hemosiderosis,I-Entity
and,O
a,O
hypocellular,B-Entity
marrow,I-Entity
.,O
Above,O
mentioned,O
AZT,I-Entity
incorporation,O
may,O
have,O
induced,O
an,O
ineffective,O
hemopoiesis,O
in,O
the,O
primitive,O
hemopoietic,O
progenitor,O
cells,O
",",O
which,O
is,O
known,O
to,O
be,O
seen,O
commonly,O
in,O
the,O
myelodysplastic,B-Entity
syndrome,I-Entity
.,O
Influence,O
of,O
diet,O
free,O
of,O
NAD,I-Entity
-,O
precursors,O
on,O
acetaminophen,I-Entity
hepatotoxicity,I-Entity
in,O
mice,O
.,O
Recently,O
",",O
we,O
demonstrated,O
the,O
hepatoprotective,O
effects,O
of,O
nicotinic,B-Entity
acid,I-Entity
amide,I-Entity
",",O
a,O
selective,O
inhibitor,O
of,O
poly(ADP,B-Entity
-,I-Entity
ribose,I-Entity
),I-Entity
polymerase,O
(,O
PARP,O
;,O
EC,O
2.4.2.30,O
),O
on,O
mice,O
suffering,O
from,O
acetaminophen,I-Entity
(,O
AAP)-hepatitis,I-Entity
",",O
suggesting,O
that,O
the,O
AAP,I-Entity
-,O
induced,O
liver,B-Entity
injury,I-Entity
involves,O
a,O
step,O
which,O
depends,O
on,O
adenoribosylation,O
.,O
The,O
present,O
study,O
investigates,O
the,O
effects,O
of,O
a,O
diet,O
free,O
of,O
precursors,O
of,O
NAD,I-Entity
",",O
the,O
substrate,O
on,O
which,O
PARP,O
acts,O
",",O
in,O
female,O
NMRI,O
mice,O
with,O
AAP,I-Entity
hepatitis,I-Entity
and,O
evaluates,O
the,O
influence,O
of,O
simultaneous,O
ethanol,I-Entity
consumption,O
in,O
these,O
animals,O
.,O
Liver,B-Entity
injuries,I-Entity
were,O
quantified,O
as,O
serum,O
activities,O
of,O
glutamate,I-Entity
-,O
oxaloacetate,I-Entity
transaminase,O
(,O
GOT,O
),O
and,O
glutamate,I-Entity
-,O
pyruvate,I-Entity
transaminase,O
(,O
GPT,O
),O
.,O
While,O
AAP,I-Entity
caused,O
a,O
117-fold,O
elevation,O
of,O
serum,O
transaminase,O
activities,O
in,O
mice,O
kept,O
on,O
a,O
standard,O
laboratory,O
diet,O
",",O
which,O
was,O
significantly,O
exacerbated,O
by,O
ethanol,I-Entity
and,O
inhibited,O
by,O
nicotinic,B-Entity
acid,I-Entity
amide,I-Entity
(,O
NAA,I-Entity
),O
",",O
adverse,O
effects,O
were,O
noted,O
in,O
animals,O
fed,O
a,O
diet,O
free,O
of,O
precursors,O
of,O
NAD,I-Entity
.,O
In,O
these,O
animals,O
",",O
only,O
minor,O
increases,O
of,O
serum,O
transaminase,O
activities,O
were,O
measured,O
in,O
the,O
presence,O
of,O
AAP,I-Entity
",",O
and,O
unlike,O
the,O
exacerbation,O
caused,O
by,O
ethanol,I-Entity
in,O
mice,O
on,O
a,O
standard,O
diet,O
",",O
the,O
liver,B-Entity
damage,I-Entity
was,O
inhibited,O
by,O
50%,O
by,O
ethanol,I-Entity
.,O
A,O
further,O
64%,O
reduction,O
of,O
hepatitis,I-Entity
was,O
observed,O
",",O
when,O
NAA,I-Entity
was,O
given,O
to,O
ethanol,I-Entity
/,O
AAP,I-Entity
-,O
mice,O
.,O
Our,O
results,O
provide,O
evidence,O
that,O
the,O
AAP,I-Entity
-,O
induced,O
hepatitis,I-Entity
and,O
its,O
exacerbation,O
by,O
ethanol,I-Entity
can,O
either,O
be,O
reduced,O
by,O
end,O
-,O
product,O
inhibition,O
of,O
PARP,O
by,O
NAA,I-Entity
or,O
by,O
dietary,O
depletion,O
of,O
the,O
enzyme,O
's,O
substrate,O
NAD,I-Entity
.,O
We,O
see,O
the,O
main,O
application,O
of,O
NAA,I-Entity
as,O
for,O
the,O
combinational,O
use,O
in,O
pharmaceutical,O
preparations,O
of,O
acetaminophen,I-Entity
in,O
order,O
to,O
avoid,O
hepatic,B-Entity
damage,I-Entity
in,O
patients,O
treated,O
with,O
this,O
widely,O
used,O
analgesic,O
.,O
Antiarrhythmic,O
plasma,O
concentrations,O
of,O
cibenzoline,I-Entity
on,O
canine,O
ventricular,B-Entity
arrhythmias,I-Entity
.,O
Using,O
two,O
-,O
stage,O
coronary,O
ligation-,O
",",O
digitalis-,I-Entity
",",O
and,O
adrenaline,I-Entity
-,O
induced,O
canine,O
ventricular,B-Entity
arrhythmias,I-Entity
",",O
antiarrhythmic,O
effects,O
of,O
cibenzoline,I-Entity
were,O
examined,O
and,O
the,O
minimum,O
effective,O
plasma,O
concentration,O
for,O
each,O
arrhythmia,I-Entity
model,O
was,O
determined,O
.,O
Cibenzoline,I-Entity
suppressed,O
all,O
the,O
arrhythmias,I-Entity
",",O
and,O
the,O
minimum,O
effective,O
plasma,O
concentrations,O
for,O
arrhythmias,I-Entity
induced,O
by,O
24-h,O
coronary,O
ligation,O
",",O
48-h,O
coronary,O
ligation,O
",",O
digitalis,I-Entity
",",O
and,O
adrenaline,I-Entity
were,O
1.9,O
+,O
/-,O
The,O
concentration,O
for,O
adrenaline,I-Entity
-,O
induced,O
arrhythmia,I-Entity
was,O
significantly,O
higher,O
than,O
those,O
for,O
the,O
other,O
types,O
of,O
arrhythmias,I-Entity
.,O
This,O
pharmacological,O
profile,O
is,O
similar,O
to,O
those,O
of,O
mexiletine,I-Entity
and,O
tocainide,I-Entity
",",O
and,O
all,O
three,O
drugs,O
have,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
stimulant,O
action,O
.,O
Because,O
cibenzoline,I-Entity
had,O
only,O
weak,O
hypotensive,I-Entity
and,O
sinus,O
node,O
depressive,I-Entity
effects,O
and,O
was,O
found,O
to,O
be,O
orally,O
active,O
when,O
given,O
to,O
coronary,O
ligation,O
arrhythmia,I-Entity
dogs,O
",",O
its,O
clinical,O
usefulness,O
is,O
expected,O
.,O
Immunopathology,O
of,O
penicillamine,I-Entity
-,O
induced,O
glomerular,B-Entity
disease,I-Entity
.,O
Four,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
developed,O
heavy,O
proteinuria,I-Entity
after,O
five,O
to,O
12,O
months,O
of,O
treatment,O
with,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
.,O
The,O
findings,O
were,O
similar,O
to,O
those,O
in,O
early,O
membranous,B-Entity
glomerulonephritis,I-Entity
",",O
differences,O
being,O
observed,O
however,O
in,O
the,O
results,O
of,O
staining,O
for,O
the,O
early,O
-,O
acting,O
complement,O
components,O
C1q,O
and,O
C4,O
.,O
Ventricular,B-Entity
fibrillation,I-Entity
from,O
diatrizoate,I-Entity
with,O
and,O
without,O
chelating,O
agents,O
.,O
The,O
toxicity,I-Entity
of,O
Renografin,B-Entity
76%,I-Entity
was,O
compared,O
with,O
that,O
of,O
Hypaque,B-Entity
76%,I-Entity
by,O
selective,O
injection,O
of,O
each,O
into,O
the,O
right,O
coronary,O
artery,O
of,O
dogs,O
.,O
Renografin,I-Entity
contains,O
the,O
chelating,O
agents,O
sodium,B-Entity
citrate,I-Entity
and,O
disodium,B-Entity
edetate,I-Entity
",",O
while,O
Hypaque,I-Entity
contains,O
calcium,B-Entity
disodium,I-Entity
edetate,I-Entity
and,O
no,O
sodium,B-Entity
citrate,I-Entity
.,O
Ventricular,B-Entity
fibrillation,I-Entity
occurred,O
significantly,O
more,O
often,O
with,O
Renografin,I-Entity
",",O
suggesting,O
that,O
chelating,O
agents,O
contribute,O
to,O
toxicity,I-Entity
in,O
coronary,O
angiography,O
.,O
Rapid,O
reversal,O
of,O
anticoagulation,O
reduces,O
hemorrhage,I-Entity
volume,O
in,O
a,O
mouse,O
model,O
of,O
warfarin,I-Entity
-,O
associated,O
intracerebral,B-Entity
hemorrhage,I-Entity
.,O
Warfarin,I-Entity
-,O
associated,O
intracerebral,B-Entity
hemorrhage,I-Entity
(,O
W,O
-,O
ICH,I-Entity
),O
is,O
a,O
severe,O
type,O
of,O
stroke,I-Entity
.,O
There,O
is,O
no,O
consensus,O
on,O
the,O
optimal,O
treatment,O
for,O
W,O
-,O
ICH,I-Entity
.,O
Using,O
a,O
mouse,O
model,O
",",O
we,O
tested,O
whether,O
the,O
rapid,O
reversal,O
of,O
anticoagulation,O
using,O
human,O
prothrombin,B-Entity
complex,I-Entity
concentrate,I-Entity
(,O
PCC,I-Entity
),O
can,O
reduce,O
hemorrhagic,O
blood,O
volume,O
.,O
Male,O
CD-1,O
mice,O
were,O
treated,O
with,O
warfarin,I-Entity
(,O
2,O
mg,O
/,O
kg,O
over,O
24,O
h,O
),O
",",O
resulting,O
in,O
a,O
mean,O
(,O
+,O
/-s.d,O
.,O
),O
First,O
",",O
we,O
showed,O
that,O
an,O
intravenous,O
administration,O
of,O
human,O
PCC,I-Entity
rapidly,O
reversed,O
anticoagulation,O
in,O
mice,O
.,O
Second,O
",",O
a,O
stereotactic,O
injection,O
of,O
collagenase,O
was,O
administered,O
to,O
induce,O
hemorrhage,I-Entity
in,O
the,O
right,O
striatum,O
.,O
Forty,O
-,O
five,O
minutes,O
later,O
",",O
the,O
animals,O
were,O
randomly,O
treated,O
with,O
PCC,I-Entity
(,O
100,O
U,O
/,O
kg,O
),O
or,O
saline,O
i.v,O
.,O
Twenty,O
-,O
four,O
hours,O
after,O
hemorrhage,I-Entity
induction,O
",",O
hemorrhagic,O
blood,O
volume,O
was,O
quantified,O
using,O
a,O
photometric,O
hemoglobin,O
assay,O
.,O
The,O
mean,O
hemorrhagic,O
blood,O
volume,O
was,O
reduced,O
in,O
PCC,I-Entity
-,O
treated,O
animals,O
(,O
6.5+/-3.1,O
microL,O
),O
compared,O
with,O
saline,O
controls,O
(,O
15.3+/-11.2,O
microL,O
",",O
P=0.015,O
),O
.,O
In,O
the,O
saline,O
group,O
",",O
45%,O
of,O
the,O
mice,O
developed,O
large,O
hematomas,I-Entity
(,O
i.e.,O
",",O
>,O
15,O
microL,O
),O
.,O
In,O
contrast,O
",",O
such,O
extensive,O
lesions,O
were,O
never,O
found,O
in,O
the,O
PCC,I-Entity
group,O
.,O
We,O
provide,O
experimental,O
data,O
suggesting,O
PCC,I-Entity
to,O
be,O
an,O
effective,O
acute,O
treatment,O
for,O
W,O
-,O
ICH,I-Entity
in,O
terms,O
of,O
reducing,O
hemorrhagic,O
blood,O
volume,O
.,O
Future,O
studies,O
are,O
needed,O
to,O
assess,O
the,O
therapeutic,O
potential,O
emerging,O
from,O
our,O
finding,O
for,O
human,O
W,O
-,O
ICH,I-Entity
.,O
Impact,O
of,O
alcohol,I-Entity
exposure,O
after,O
pregnancy,O
recognition,O
on,O
ultrasonographic,O
fetal,O
growth,O
measures,O
.,O
BACKGROUND,O
:,O
More,O
than,O
3,O
decades,O
after,O
Jones,O
and,O
Smith,O
(,O
1973,O
),O
reported,O
on,O
the,O
devastation,O
caused,O
by,O
alcohol,I-Entity
exposure,O
on,O
fetal,O
development,O
",",O
the,O
rates,O
of,O
heavy,O
drinking,O
during,O
pregnancy,O
remain,O
relatively,O
unchanged,O
.,O
Early,O
identification,O
of,O
fetal,O
alcohol,I-Entity
exposure,O
and,O
maternal,O
abstinence,O
led,O
to,O
better,O
infant,O
outcomes,O
.,O
This,O
study,O
examined,O
the,O
utility,O
of,O
biometry,O
for,O
detecting,O
alcohol,I-Entity
-,O
related,O
fetal,O
growth,B-Entity
impairment,I-Entity
.,O
METHODS,O
:,O
We,O
obtained,O
fetal,O
ultrasound,O
measures,O
from,O
routine,O
ultrasound,O
examinations,O
for,O
167,O
pregnant,O
hazardous,O
drinkers,O
who,O
were,O
enrolled,O
in,O
a,O
brief,O
alcohol,I-Entity
intervention,O
study,O
.,O
Because,O
intensity,O
of,O
alcohol,I-Entity
consumption,O
is,O
associated,O
with,O
poorer,O
fetal,O
outcomes,O
",",O
separate,O
analyses,O
were,O
conducted,O
for,O
the,O
heavy,O
(,O
average,O
of,O
>,O
or=5,O
drinks,O
per,O
drinking,O
day,O
),O
alcohol,I-Entity
consumers,O
.,O
Analyses,O
of,O
covariance,O
were,O
used,O
to,O
determine,O
whether,O
there,O
were,O
differences,O
between,O
groups,O
after,O
controlling,O
for,O
influences,O
of,O
gestational,O
age,O
and,O
drug,B-Entity
abuse,I-Entity
.,O
When,O
women,O
reportedly,O
quit,O
drinking,O
early,O
in,O
their,O
pregnancies,O
",",O
fetal,O
growth,O
measures,O
were,O
not,O
significantly,O
different,O
from,O
a,O
non,O
-,O
alcohol,I-Entity
-,O
exposed,O
group,O
",",O
regardless,O
of,O
prior,O
drinking,O
patterns,O
.,O
Any,O
alcohol,I-Entity
consumption,O
postpregnancy,O
recognition,O
among,O
the,O
heavy,O
drinkers,O
resulted,O
in,O
reduced,B-Entity
cerebellar,I-Entity
growth,I-Entity
as,O
well,O
as,O
decreased,B-Entity
cranial,I-Entity
to,I-Entity
body,I-Entity
growth,I-Entity
in,O
comparison,O
with,O
women,O
who,O
either,O
quit,O
drinking,O
or,O
who,O
were,O
nondrinkers,O
.,O
Amphetamine,I-Entity
abuse,O
was,O
predictive,O
of,O
larger,O
cranial,O
to,O
body,O
growth,O
ratios,O
.,O
Although,O
the,O
reliance,O
on,O
self,O
-,O
reported,O
drinking,O
is,O
a,O
limitation,O
in,O
this,O
study,O
",",O
these,O
findings,O
support,O
the,O
benefits,O
of,O
early,O
abstinence,O
and,O
the,O
potential,O
for,O
ultrasound,O
examinations,O
in,O
the,O
detection,O
of,O
fetal,O
alcohol,I-Entity
effects,O
.,O
Urinary,O
symptoms,O
and,O
quality,O
of,O
life,O
changes,O
in,O
Thai,O
women,O
with,O
overactive,B-Entity
bladder,I-Entity
after,O
tolterodine,I-Entity
treatment,O
.,O
OBJECTIVES,O
:,O
To,O
study,O
the,O
urinary,O
symptoms,O
and,O
quality,O
of,O
life,O
changes,O
in,O
Thai,O
women,O
with,O
overactive,B-Entity
bladder,I-Entity
(,O
OAB,I-Entity
),O
after,O
tolterodine,I-Entity
treatment,O
.,O
MATERIAL,O
AND,O
METHOD,O
:,O
Thirty,O
women,O
(,O
aged,O
30,O
-,O
77,O
years,O
),O
diagnosed,O
as,O
having,O
OAB,I-Entity
at,O
the,O
Gynecology,O
Clinic,O
",",O
King,O
Chulalongkorn,O
Memorial,O
Hospital,O
from,O
January,O
to,O
April,O
2004,O
were,O
included,O
in,O
the,O
present,O
study,O
.,O
Tolterodine,I-Entity
2,O
mg,O
",",O
twice,O
daily,O
was,O
given,O
.,O
The,O
number,O
of,O
nocturia,I-Entity
episodes,O
decreased,O
from,O
5.4,O
+,O
/-,O
The,O
most,O
common,O
side,O
effect,O
was,O
dry,B-Entity
month,I-Entity
in,O
5,O
cases,O
(,O
16.7%,O
),O
with,O
2,O
cases,O
reporting,O
a,O
moderate,O
degree,O
and,O
1,O
case,O
with,O
severe,O
degree,O
.,O
Only,O
one,O
case,O
(,O
3.3%,O
),O
withdrew,O
from,O
the,O
present,O
study,O
due,O
to,O
a,O
severe,O
dry,B-Entity
mouth,I-Entity
.,O
Tolterodine,I-Entity
was,O
well,O
tolerated,O
and,O
its,O
effects,O
improved,O
the,O
quality,O
of,O
life,O
in,O
Thai,O
women,O
with,O
OAB,I-Entity
.,O
Absence,O
of,O
acute,O
cerebral,O
vasoconstriction,O
after,O
cocaine,I-Entity
-,O
associated,O
subarachnoid,B-Entity
hemorrhage,I-Entity
.,O
Cocaine,I-Entity
use,O
has,O
been,O
associated,O
with,O
neurovascular,B-Entity
complications,I-Entity
",",O
including,O
arterial,O
vasoconstriction,O
and,O
vasculitis,I-Entity
.,O
However,O
",",O
there,O
are,O
few,O
studies,O
of,O
angiographic,O
effects,O
of,O
cocaine,I-Entity
on,O
human,O
cerebral,O
arteries,O
.,O
Information,O
on,O
these,O
effects,O
could,O
be,O
obtained,O
from,O
angiograms,O
of,O
patients,O
with,O
cocaine,I-Entity
-,O
associated,O
subarachnoid,B-Entity
hemorrhage,I-Entity
(,O
SAH,I-Entity
),O
who,O
underwent,O
angiography,O
shortly,O
after,O
cocaine,I-Entity
use,O
.,O
METHODS,O
:,O
We,O
screened,O
patients,O
with,O
SAH,I-Entity
retrospectively,O
and,O
identified,O
those,O
with,O
positive,O
urine,O
toxicology,O
for,O
cocaine,I-Entity
or,O
its,O
metabolites,O
.,O
Quantitative,O
arterial,O
diameter,O
measurements,O
from,O
angiograms,O
of,O
these,O
patients,O
were,O
compared,O
to,O
measurements,O
from,O
control,O
patients,O
with,O
SAH,I-Entity
who,O
were,O
matched,O
for,O
factors,O
known,O
to,O
influence,O
arterial,O
diameter,O
.,O
RESULTS,O
:,O
Thirteen,O
patients,O
with,O
positive,O
cocaine,I-Entity
toxicology,O
were,O
compared,O
to,O
26,O
controls,O
.,O
No,O
quantitative,O
evidence,O
for,O
narrowing,O
of,O
large,O
cerebral,O
arteries,O
or,O
qualitative,O
angiographic,O
evidence,O
for,O
distal,O
narrowing,O
or,O
vasculitis,I-Entity
could,O
be,O
found,O
in,O
patients,O
who,O
underwent,O
angiography,O
after,O
aneurysmal,I-Entity
SAH,I-Entity
associated,O
with,O
cocaine,I-Entity
use,O
.,O
Atrial,B-Entity
fibrillation,I-Entity
following,O
chemotherapy,O
for,O
stage,O
IIIE,O
diffuse,O
large,O
B,O
-,O
cell,O
gastric,B-Entity
lymphoma,I-Entity
in,O
a,O
patient,O
with,O
myotonic,B-Entity
dystrophy,I-Entity
(,O
Steinert,B-Entity
's,I-Entity
disease,I-Entity
),O
.,O
The,O
authors,O
describe,O
the,O
unusual,O
association,O
between,O
diffuse,O
B,O
-,O
cell,O
gastric,B-Entity
lymphoma,I-Entity
and,O
myotonic,B-Entity
dystrophy,I-Entity
",",O
the,O
most,O
common,O
form,O
of,O
adult,O
muscular,B-Entity
dystrophy,I-Entity
",",O
and,O
sudden,O
atrial,B-Entity
fibrillation,I-Entity
following,O
one,O
cycle,O
of,O
doxorubicin,I-Entity
-,O
based,O
chemotherapy,O
in,O
the,O
same,O
patient,O
.,O
Atrial,B-Entity
fibrillation,I-Entity
or,O
other,O
cardiac,B-Entity
arrhythmias,I-Entity
are,O
unusual,O
complications,O
in,O
patients,O
treated,O
with,O
chemotherapy,O
.,O
The,O
cardiac,B-Entity
toxicity,I-Entity
intrinsically,O
associated,O
with,O
the,O
aggressive,O
chemotherapy,O
employed,O
could,O
function,O
as,O
a,O
triggering,O
factor,O
for,O
the,O
arrhythmia,I-Entity
in,O
the,O
predisposed,O
myocardium,O
of,O
this,O
patient,O
.,O
A,O
phase,O
II,O
study,O
of,O
thalidomide,I-Entity
in,O
advanced,O
metastatic,O
renal,B-Entity
cell,I-Entity
carcinoma,I-Entity
.,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
toxicity,I-Entity
and,O
activity,O
of,O
thalidomide,I-Entity
in,O
patients,O
with,O
advanced,O
metastatic,O
renal,B-Entity
cell,I-Entity
cancer,I-Entity
and,O
to,O
measure,O
changes,O
of,O
one,O
angiogenic,O
factor,O
",",O
vascular,O
endothelial,O
growth,O
factor,O
(,O
VEGF)165,O
",",O
with,O
therapy,O
.,O
29,O
patients,O
were,O
enrolled,O
on,O
a,O
study,O
of,O
thalidomide,I-Entity
using,O
an,O
intra,O
-,O
patient,O
dose,O
escalation,O
schedule,O
.,O
Patients,O
began,O
thalidomide,I-Entity
at,O
400,O
mg,O
/,O
d,O
and,O
escalated,O
as,O
tolerated,O
to,O
1200,O
mg,O
/,O
d,O
by,O
day,O
54,O
.,O
RESULTS,O
:,O
24,O
patients,O
were,O
evaluable,O
for,O
response,O
with,O
one,O
partial,O
response,O
of,O
11,O
months,O
duration,O
of,O
a,O
patient,O
with,O
hepatic,O
and,O
pulmonary,O
metastases,I-Entity
(,O
4%,O
),O
",",O
one,O
minor,O
response,O
",",O
and,O
2,O
patients,O
stable,O
for,O
over,O
6,O
months,O
.,O
Somnolence,I-Entity
and,O
constipation,I-Entity
were,O
prominent,O
toxicities,I-Entity
and,O
most,O
patients,O
could,O
not,O
tolerate,O
the,O
1200,O
mg,O
/,O
day,O
dose,O
level,O
.,O
CONCLUSION,O
:,O
These,O
results,O
are,O
consistent,O
with,O
a,O
low,O
level,O
of,O
activity,O
of,O
thalidomide,I-Entity
in,O
renal,B-Entity
cell,I-Entity
carcinoma,I-Entity
.,O
The,O
dose,O
-,O
response,O
relationship,O
",",O
if,O
any,O
",",O
of,O
thalidomide,I-Entity
for,O
renal,B-Entity
cell,I-Entity
carcinoma,I-Entity
is,O
unclear,O
.,O
The,O
striatum,O
as,O
a,O
target,O
for,O
anti,O
-,O
rigor,O
effects,O
of,O
an,O
antagonist,O
of,O
mGluR1,O
",",O
but,O
not,O
an,O
agonist,O
of,O
group,O
II,O
metabotropic,O
glutamate,I-Entity
receptors,O
.,O
Haloperidol,I-Entity
(,O
1,O
mg,O
/,O
kg,O
ip,O
),O
induced,O
parkinsonian,I-Entity
-,O
like,O
muscle,B-Entity
rigidity,I-Entity
",",O
measured,O
as,O
an,O
increased,O
resistance,O
of,O
a,O
rat,O
's,O
hind,O
foot,O
to,O
passive,O
flexion,O
and,O
extension,O
at,O
the,O
ankle,O
joint,O
.,O
(,B-Entity
"RS)-1-aminoindan-1,5-dicarboxylic",I-Entity
acid,I-Entity
(,O
AIDA,I-Entity
;,O
0.5,O
-,O
15,O
microg/0.5,O
microl,O
),O
",",O
a,O
potent,O
and,O
selective,O
mGluR1,O
antagonist,O
",",O
or,O
(,B-Entity
"2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate",I-Entity
(,O
"2R,4R",B-Entity
-,I-Entity
APDC,I-Entity
;,O
7.5,O
-,O
15,O
microg/0.5,O
microl,O
),O
",",O
a,O
selective,O
group,O
II,O
agonist,O
",",O
was,O
injected,O
bilaterally,O
into,O
the,O
striatum,O
of,O
haloperidol,I-Entity
-,O
treated,O
animals,O
.,O
AIDA,I-Entity
in,O
doses,O
of,O
7.5,O
-,O
15,O
microg/0.5,O
microl,O
diminished,O
the,O
haloperidol,I-Entity
-,O
induced,O
muscle,B-Entity
rigidity,I-Entity
.,O
In,O
contrast,O
",",O
"2R,4R",B-Entity
-,I-Entity
APDC,I-Entity
injections,O
were,O
ineffective,O
.,O
The,O
present,O
results,O
may,O
suggest,O
that,O
the,O
blockade,O
of,O
striatal,O
mGluR1,O
",",O
but,O
not,O
the,O
stimulation,O
of,O
group,O
II,O
mGluRs,O
",",O
may,O
ameliorate,O
parkinsonian,I-Entity
muscle,B-Entity
rigidity,I-Entity
.,O
Acute,O
cholestatic,B-Entity
hepatitis,I-Entity
after,O
exposure,O
to,O
isoflurane,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
acute,O
cholestatic,B-Entity
hepatitis,I-Entity
following,O
exposure,O
to,O
the,O
inhalational,O
anesthetic,O
isoflurane,I-Entity
.,O
A,O
70-year,O
-,O
old,O
healthy,O
woman,O
from,O
Iraq,O
developed,O
acute,O
cholestatic,B-Entity
hepatitis,I-Entity
3,O
weeks,O
following,O
repair,O
of,O
the,O
right,O
rotator,O
cuff,O
under,O
general,O
anesthesia,O
.,O
There,O
was,O
no,O
evidence,O
for,O
viral,O
",",O
autoimmune,O
",",O
or,O
metabolic,O
causes,O
of,O
hepatitis,I-Entity
.,O
No,O
other,O
medications,O
were,O
involved,O
except,O
for,O
dipyrone,I-Entity
for,O
analgesia,I-Entity
.,O
The,O
alanine,I-Entity
aminotransferase,O
was,O
elevated,O
to,O
a,O
peak,O
concentration,O
of,O
1533,O
U,O
/,O
L,O
and,O
the,O
serum,O
bilirubin,I-Entity
reached,O
a,O
peak,O
of,O
17.0,O
mg,O
/,O
dL.,O
Accidental,O
reexposure,O
by,O
the,O
patient,O
to,O
dipyrone,I-Entity
was,O
uneventful,O
.,O
The,O
clinical,O
and,O
histologic,O
picture,O
of,O
this,O
case,O
resembles,O
halothane,B-Entity
hepatitis,I-Entity
",",O
which,O
has,O
a,O
significant,O
mortality,O
rate,O
.,O
Isoflurane,I-Entity
",",O
a,O
common,O
anesthetic,O
agent,O
",",O
can,O
cause,O
severe,O
cholestatic,B-Entity
hepatitis,I-Entity
.,O
Calcitonin,O
gene,O
-,O
related,O
peptide,O
levels,O
during,O
nitric,B-Entity
oxide,I-Entity
-,O
induced,O
headache,I-Entity
in,O
patients,O
with,O
chronic,O
tension,B-Entity
-,I-Entity
type,I-Entity
headache,I-Entity
.,O
It,O
has,O
been,O
proposed,O
that,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
induced,O
headache,I-Entity
in,O
primary,B-Entity
headaches,I-Entity
may,O
be,O
associated,O
with,O
release,O
of,O
calcitonin,O
gene,O
-,O
related,O
peptide,O
(,O
CGRP,O
),O
.,O
In,O
the,O
present,O
study,O
we,O
aimed,O
to,O
investigate,O
plasma,O
levels,O
of,O
CGRP,O
during,O
headache,I-Entity
induced,O
by,O
the,O
NO,I-Entity
donor,O
glyceryl,B-Entity
trinitrate,I-Entity
(,O
GTN,I-Entity
),O
in,O
16,O
patients,O
with,O
chronic,O
tension,B-Entity
-,I-Entity
type,I-Entity
headache,I-Entity
and,O
16,O
healthy,O
controls,O
.,O
The,O
subjects,O
were,O
randomly,O
allocated,O
to,O
receive,O
0.5,O
microg,O
/,O
kg,O
/,O
min,O
GTN,I-Entity
or,O
placebo,O
over,O
20,O
min,O
on,O
two,O
headache,I-Entity
-,O
free,O
days,O
.,O
Both,O
patients,O
and,O
controls,O
developed,O
significantly,O
stronger,O
immediate,O
headache,I-Entity
on,O
the,O
GTN,I-Entity
day,O
than,O
on,O
the,O
placebo,O
day,O
and,O
the,O
headache,I-Entity
was,O
significantly,O
more,O
pronounced,O
in,O
patients,O
than,O
in,O
controls,O
.,O
There,O
was,O
no,O
difference,O
between,O
the,O
area,O
under,O
the,O
CGRP,O
curve,O
(,O
AUCCGRP,O
),O
on,O
GTN,I-Entity
vs.,O
placebo,O
day,O
in,O
either,O
patients,O
(,O
P=0.65,O
),O
or,O
controls,O
(,O
P=0.48,O
),O
.,O
The,O
AUCCGRP,O
recorded,O
on,O
the,O
GTN,I-Entity
day,O
did,O
not,O
differ,O
between,O
patients,O
and,O
controls,O
(,O
P=0.36,O
),O
.,O
Both,O
in,O
patients,O
and,O
controls,O
",",O
CGRP,O
levels,O
changed,O
significantly,O
over,O
time,O
",",O
on,O
both,O
the,O
GTN,I-Entity
and,O
placebo,O
days,O
(,O
P,O
<,O
0.05,O
),O
.,O
The,O
present,O
study,O
indicates,O
that,O
NO,I-Entity
-,O
induced,O
immediate,O
headache,I-Entity
is,O
not,O
associated,O
with,O
release,O
of,O
CGRP,O
.,O
Myocardial,B-Entity
ischemia,I-Entity
due,O
to,O
coronary,B-Entity
artery,I-Entity
spasm,I-Entity
during,O
dobutamine,I-Entity
stress,O
echocardiography,O
.,O
Dobutamine,I-Entity
stress,O
echocardiography,O
(,O
DSE,O
),O
is,O
a,O
useful,O
and,O
safe,O
provocation,O
test,O
for,O
myocardial,B-Entity
ischemia,I-Entity
.,O
Until,O
now,O
",",O
the,O
test,O
has,O
been,O
focused,O
only,O
on,O
the,O
organic,O
lesion,O
in,O
the,O
coronary,O
artery,O
",",O
and,O
positive,O
DSE,O
has,O
indicated,O
the,O
presence,O
of,O
significant,O
fixed,O
coronary,B-Entity
artery,I-Entity
stenosis,I-Entity
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
is,O
to,O
examine,O
whether,O
myocardial,B-Entity
ischemia,I-Entity
due,O
to,O
coronary,B-Entity
spasm,I-Entity
is,O
induced,O
by,O
dobutamine,I-Entity
.,O
We,O
performed,O
DSE,O
on,O
51,O
patients,O
with,O
coronary,B-Entity
spastic,I-Entity
angina,I-Entity
but,O
without,O
significant,O
fixed,O
coronary,B-Entity
artery,I-Entity
stenosis,I-Entity
.,O
All,O
patients,O
had,O
anginal,I-Entity
attacks,O
at,O
rest,O
with,O
ST,O
elevation,O
on,O
the,O
electrocardiogram,O
(,O
variant,B-Entity
angina,I-Entity
),O
.,O
Coronary,O
spasm,O
was,O
induced,O
by,O
intracoronary,O
injection,O
of,O
acetylcholine,I-Entity
",",O
and,O
no,O
fixed,O
coronary,B-Entity
artery,I-Entity
stenosis,I-Entity
was,O
documented,O
on,O
angiograms,O
in,O
all,O
patients,O
.,O
DSE,O
was,O
performed,O
with,O
intravenous,O
dobutamine,I-Entity
infusion,O
with,O
an,O
incremental,O
doses,O
of,O
5,O
",",O
10,O
",",O
20,O
",",O
30,O
",",O
and,O
40,O
microg,O
/,O
kg,O
/,O
min,O
every,O
5,O
minutes,O
.,O
All,O
7,O
patients,O
(,O
13.7%,O
),O
had,O
chest,B-Entity
pain,I-Entity
during,O
asynergy,O
",",O
and,O
both,O
chest,B-Entity
pain,I-Entity
and,O
electrocardiographic,O
changes,O
were,O
preceded,O
by,O
asynergy,O
.,O
These,O
findings,O
indicate,O
that,O
dobutamine,I-Entity
can,O
provoke,O
coronary,B-Entity
spasm,I-Entity
in,O
some,O
patients,O
with,O
coronary,B-Entity
spastic,I-Entity
angina,I-Entity
.,O
When,O
DSE,O
is,O
performed,O
to,O
evaluate,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
not,O
only,O
fixed,O
coronary,B-Entity
stenosis,I-Entity
",",O
but,O
also,O
coronary,B-Entity
spasm,I-Entity
should,O
be,O
considered,O
as,O
a,O
genesis,O
of,O
asynergy,O
.,O
Nitric,B-Entity
oxide,I-Entity
synthase,O
expression,O
in,O
the,O
course,O
of,O
lead,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
We,O
recently,O
showed,O
elevated,O
reactive,O
oxygen,I-Entity
species,O
(,O
ROS,O
),O
",",O
reduced,O
urinary,O
excretion,O
of,O
NO,I-Entity
metabolites,O
(,O
NOx,O
),O
",",O
and,O
increased,O
NO,I-Entity
sequestration,O
as,O
nitrotyrosine,I-Entity
in,O
various,O
tissues,O
in,O
rats,O
with,O
lead,I-Entity
-,O
induced,O
hypertension,I-Entity
.,O
This,O
study,O
was,O
designed,O
to,O
discern,O
whether,O
the,O
reduction,O
in,O
urinary,O
NOx,O
in,O
lead,I-Entity
-,O
induced,O
hypertension,I-Entity
is,O
",",O
in,O
part,O
",",O
due,O
to,O
depressed,O
NO,I-Entity
synthase,O
(,O
NOS,O
),O
expression,O
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
randomly,O
assigned,O
to,O
a,O
lead,I-Entity
-,O
treated,O
group,O
(,O
given,O
lead,B-Entity
acetate,I-Entity
",",O
100,O
ppm,O
",",O
in,O
drinking,O
water,O
and,O
regular,O
rat,O
chow,O
),O
",",O
a,O
group,O
given,O
lead,I-Entity
and,O
vitamin,B-Entity
E,I-Entity
-,O
fortified,O
chow,O
",",O
or,O
a,O
normal,O
control,O
group,O
given,O
either,O
regular,O
food,O
and,O
water,O
or,O
vitamin,B-Entity
E,I-Entity
-,O
fortified,O
food,O
for,O
12,O
weeks,O
.,O
Tail,O
blood,O
pressure,O
",",O
urinary,O
NOx,O
excretion,O
",",O
plasma,O
malondialdehyde,I-Entity
(,O
MDA,I-Entity
),O
",",O
and,O
endothelial,O
and,O
inducible,O
NOS,O
(,O
eNOS,O
and,O
iNOS,O
),O
isotypes,O
in,O
the,O
aorta,O
and,O
kidney,O
were,O
measured,O
.,O
The,O
lead,I-Entity
-,O
treated,O
group,O
exhibited,O
a,O
rise,O
in,O
blood,O
pressure,O
and,O
plasma,O
MDA,I-Entity
concentration,O
",",O
a,O
fall,O
in,O
urinary,O
NOx,O
excretion,O
",",O
and,O
a,O
paradoxical,O
rise,O
in,O
vascular,O
and,O
renal,O
tissue,O
eNOS,O
and,O
iNOS,O
expression,O
.,O
Vitamin,B-Entity
E,I-Entity
supplementation,O
ameliorated,O
hypertension,I-Entity
",",O
lowered,O
plasma,O
MDA,I-Entity
concentration,O
",",O
and,O
raised,O
urinary,O
NOx,O
excretion,O
while,O
significantly,O
lowering,O
vascular,O
",",O
but,O
not,O
renal,O
",",O
tissue,O
eNOS,O
and,O
iNOS,O
expression,O
.,O
Vitamin,B-Entity
E,I-Entity
supplementation,O
had,O
no,O
effect,O
on,O
either,O
blood,O
pressure,O
",",O
plasma,O
MDA,I-Entity
",",O
or,O
NOS,O
expression,O
in,O
the,O
control,O
group,O
.,O
The,O
study,O
also,O
revealed,O
significant,O
inhibition,O
of,O
NOS,O
enzymatic,O
activity,O
by,O
lead,I-Entity
in,O
cell,O
-,O
free,O
preparations,O
.,O
In,O
conclusion,O
",",O
lead,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
this,O
model,O
was,O
associated,O
with,O
a,O
compensatory,O
upregulation,O
of,O
renal,O
and,O
vascular,O
eNOS,O
and,O
iNOS,O
expression,O
.,O
NO,I-Entity
inactivation,O
",",O
lead,I-Entity
-,O
associated,O
inhibition,O
of,O
NOS,O
activity,O
",",O
and,O
perhaps,O
stimulatory,O
actions,O
of,O
increased,O
shear,O
stress,O
associated,O
with,O
hypertension,I-Entity
.,O
Risk,O
for,O
valvular,B-Entity
heart,I-Entity
disease,I-Entity
among,O
users,O
of,O
fenfluramine,I-Entity
and,O
dexfenfluramine,I-Entity
who,O
underwent,O
echocardiography,O
before,O
use,O
of,O
medication,O
.,O
Because,O
uncontrolled,O
echocardiographic,O
surveys,O
suggested,O
that,O
up,O
to,O
30%,O
to,O
38%,O
of,O
users,O
of,O
fenfluramine,I-Entity
and,O
dexfenfluramine,I-Entity
had,O
valvular,B-Entity
disease,I-Entity
",",O
these,O
drugs,O
were,O
withdrawn,O
from,O
the,O
market,O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
risk,O
for,O
new,O
or,O
worsening,O
valvular,B-Entity
abnormalities,I-Entity
among,O
users,O
of,O
fenfluramine,I-Entity
or,O
dexfenfluramine,I-Entity
who,O
underwent,O
echocardiography,O
before,O
they,O
began,O
to,O
take,O
these,O
medications,O
.,O
PATIENTS,O
:,O
46,O
patients,O
who,O
used,O
fenfluramine,I-Entity
or,O
dexfenfluramine,I-Entity
for,O
14,O
days,O
or,O
more,O
and,O
had,O
echocardiograms,O
obtained,O
before,O
therapy,O
.,O
The,O
primary,O
outcome,O
was,O
new,O
or,O
worsening,O
valvulopathy,I-Entity
",",O
defined,O
as,O
progression,O
of,O
either,O
aortic,B-Entity
or,I-Entity
mitral,I-Entity
regurgitation,I-Entity
by,O
at,O
least,O
one,O
degree,O
of,O
severity,O
and,O
disease,O
that,O
met,O
U.S.,O
Food,O
and,O
Drug,O
Administration,O
criteria,O
(,O
at,O
least,O
mild,O
aortic,B-Entity
regurgitation,I-Entity
or,O
moderate,O
mitral,B-Entity
regurgitation,I-Entity
),O
.,O
RESULTS,O
:,O
Two,O
patients,O
(,O
4.3%,O
[,O
95%,O
CI,O
",",O
0.6%,O
to,O
14.8%,O
],O
),O
receiving,O
fenfluramine,I-Entity
-,O
phentermine,I-Entity
developed,O
valvular,B-Entity
heart,I-Entity
disease,I-Entity
.,O
One,O
had,O
baseline,O
bicuspid,B-Entity
aortic,I-Entity
valve,I-Entity
and,O
mild,O
aortic,B-Entity
regurgitation,I-Entity
that,O
progressed,O
to,O
moderate,O
regurgitation,O
.,O
The,O
second,O
patient,O
developed,O
new,O
moderate,O
aortic,B-Entity
insufficiency,I-Entity
.,O
Users,O
of,O
diet,O
medications,O
are,O
at,O
risk,O
for,O
valvular,B-Entity
heart,I-Entity
disease,I-Entity
.,O
Carboplatin,I-Entity
toxic,O
effects,O
on,O
the,O
peripheral,O
nervous,O
system,O
of,O
the,O
rat,O
.,O
BACKGROUND,O
:,O
The,O
most,O
striking,O
of,O
carboplatin,I-Entity
's,O
advantages,O
(,O
CBDCA,I-Entity
),O
over,O
cisplatin,I-Entity
(,O
CDDP,I-Entity
),O
is,O
its,O
markedly,O
reduced,O
rate,O
of,O
neurotoxic,I-Entity
effects,O
.,O
However,O
",",O
the,O
use,O
of,O
CBDCA,I-Entity
higher,O
-,O
intensity,O
schedules,O
and,O
the,O
association,O
with,O
other,O
neurotoxic,I-Entity
drugs,O
in,O
polychemotherapy,O
may,O
cause,O
some,O
concern,O
about,O
its,O
safety,O
with,O
respect,O
to,O
peripheral,B-Entity
nervous,I-Entity
system,I-Entity
damage,I-Entity
.,O
Two,O
different,O
schedules,O
of,O
CBDCA,I-Entity
administration,O
(,O
10,O
mg,O
/,O
kg,O
and,O
15,O
mg,O
/,O
kg,O
i.p,O
.,O
Neurotoxicity,I-Entity
was,O
assessed,O
for,O
behavioral,O
(,O
tail,O
-,O
flick,O
test,O
),O
",",O
neurophysiological,O
(,O
nerve,O
conduction,O
velocity,O
in,O
the,O
tail,O
nerve,O
),O
",",O
morphological,O
",",O
morphometrical,O
and,O
analytical,O
effects,O
.,O
CBDCA,I-Entity
administration,O
induced,O
dose,O
-,O
dependent,O
peripheral,B-Entity
neurotoxicity,I-Entity
.,O
Pain,I-Entity
perception,O
and,O
nerve,O
conduction,O
velocity,O
in,O
the,O
tail,O
were,O
significantly,O
impaired,O
",",O
particularly,O
after,O
the,O
high,O
-,O
dose,O
treatment,O
.,O
The,O
dorsal,O
root,O
ganglia,O
sensory,O
neurons,O
and,O
",",O
to,O
a,O
lesser,O
extent,O
",",O
satellite,O
cells,O
showed,O
the,O
same,O
changes,O
as,O
those,O
induced,O
by,O
CDDP,I-Entity
",",O
mainly,O
affecting,O
the,O
nucleus,O
and,O
nucleolus,O
of,O
ganglionic,O
sensory,O
neurons,O
.,O
Moreover,O
",",O
significant,O
amounts,O
of,O
platinum,I-Entity
were,O
detected,O
in,O
the,O
dorsal,O
root,O
ganglia,O
and,O
kidney,O
after,O
CBDCA,I-Entity
treatment,O
.,O
CBDCA,I-Entity
is,O
neurotoxic,I-Entity
in,O
our,O
model,O
",",O
and,O
the,O
type,O
of,O
pathological,O
changes,O
it,O
induces,O
are,O
so,O
closely,O
similar,O
to,O
those,O
caused,O
by,O
CDDP,I-Entity
that,O
it,O
is,O
probable,O
that,O
neurotoxicity,I-Entity
is,O
induced,O
in,O
the,O
two,O
drugs,O
by,O
the,O
same,O
mechanism,O
.,O
This,O
model,O
can,O
be,O
used,O
alone,O
or,O
in,O
combination,O
with,O
other,O
drugs,O
to,O
explore,O
the,O
effect,O
of,O
CBDCA,I-Entity
on,O
the,O
peripheral,O
nervous,O
system,O
.,O
Iatrogenic,O
risks,O
of,O
endometrial,B-Entity
carcinoma,I-Entity
after,O
treatment,O
for,O
breast,B-Entity
cancer,I-Entity
in,O
a,O
large,O
French,O
case,O
-,O
control,O
study,O
.,O
Since,O
tamoxifen,I-Entity
is,O
widely,O
used,O
in,O
breast,B-Entity
cancer,I-Entity
treatment,O
and,O
has,O
been,O
proposed,O
for,O
the,O
prevention,O
of,O
breast,B-Entity
cancer,I-Entity
",",O
its,O
endometrial,O
iatrogenic,O
effects,O
must,O
be,O
carefully,O
examined,O
.,O
We,O
have,O
investigated,O
the,O
association,O
between,O
endometrial,B-Entity
cancer,I-Entity
and,O
tamoxifen,I-Entity
use,O
or,O
other,O
treatments,O
in,O
women,O
treated,O
for,O
breast,B-Entity
cancer,I-Entity
in,O
a,O
case,O
-,O
control,O
study,O
.,O
Cases,O
of,O
endometrial,B-Entity
cancer,I-Entity
diagnosed,O
after,O
breast,B-Entity
cancer,I-Entity
(,O
n,O
=,O
135,O
),O
and,O
467,O
controls,O
matched,O
for,O
age,O
",",O
year,O
of,O
diagnosis,O
of,O
breast,B-Entity
cancer,I-Entity
and,O
hospital,O
and,O
survival,O
time,O
with,O
an,O
intact,O
uterus,O
were,O
included,O
.,O
Women,O
who,O
had,O
received,O
tamoxifen,I-Entity
were,O
significantly,O
more,O
likely,O
to,O
have,O
endometrial,B-Entity
cancer,I-Entity
diagnosed,O
than,O
those,O
who,O
had,O
not,O
(,O
crude,O
relative,O
risk,O
=,O
4.9,O
",",O
p,O
=,O
0.0001,O
),O
.,O
Univariate,O
and,O
adjusted,O
analyses,O
showed,O
that,O
the,O
risk,O
increased,O
with,O
the,O
length,O
of,O
treatment,O
(,O
p,O
=,O
0.0001,O
),O
or,O
the,O
cumulative,O
dose,O
of,O
tamoxifen,I-Entity
received,O
(,O
p,O
=,O
0.0001,O
),O
",",O
irrespective,O
of,O
the,O
daily,O
dose,O
.,O
After,O
adjusting,O
for,O
confounding,O
factors,O
",",O
the,O
risk,O
was,O
higher,O
for,O
tamoxifen,I-Entity
users,O
(,O
p,O
=,O
0.0012,O
),O
",",O
Women,O
who,O
had,O
endometrial,B-Entity
cancer,I-Entity
and,O
had,O
received,O
tamoxifen,I-Entity
had,O
more,O
advanced,B-Entity
disease,I-Entity
and,O
poorer,O
prognosis,O
than,O
those,O
with,O
endometrial,B-Entity
cancer,I-Entity
who,O
had,O
not,O
received,O
this,O
treatment,O
.,O
Our,O
results,O
suggest,O
a,O
causal,O
role,O
of,O
tamoxifen,I-Entity
in,O
endometrial,B-Entity
cancer,I-Entity
",",O
particularly,O
when,O
used,O
as,O
currently,O
proposed,O
for,O
breast,B-Entity
cancer,I-Entity
prevention,O
.,O
Pelvic,O
radiotherapy,O
may,O
be,O
an,O
additional,O
iatrogenic,O
factor,O
for,O
women,O
with,O
breast,B-Entity
cancer,I-Entity
.,O
Endometrial,B-Entity
cancers,I-Entity
diagnosed,O
in,O
women,O
treated,O
with,O
tamoxifen,I-Entity
have,O
poorer,O
prognosis,O
.,O
Women,O
who,O
receive,O
tamoxifen,I-Entity
for,O
breast,B-Entity
cancer,I-Entity
should,O
be,O
offered,O
gynaecological,O
surveillance,O
during,O
and,O
after,O
treatment,O
.,O
A,O
long,O
-,O
term,O
evaluation,O
of,O
the,O
risk,O
-,O
benefit,O
ratio,O
of,O
tamoxifen,I-Entity
as,O
a,O
preventive,O
treatment,O
for,O
breast,B-Entity
cancer,I-Entity
is,O
clearly,O
warranted,O
.,O
Granulosa,B-Entity
cell,I-Entity
tumor,I-Entity
of,I-Entity
the,I-Entity
ovary,I-Entity
associated,O
with,O
antecedent,O
tamoxifen,I-Entity
use,O
.,O
BACKGROUND,O
:,O
Increased,O
attention,O
has,O
been,O
focused,O
recently,O
on,O
the,O
estrogenic,O
effects,O
of,O
tamoxifen,I-Entity
.,O
Review,O
of,O
the,O
literature,O
reveals,O
an,O
association,O
between,O
tamoxifen,I-Entity
use,O
and,O
gynecologic,O
tumors,I-Entity
.,O
A,O
52-year,O
-,O
old,O
postmenopausal,O
woman,O
was,O
treated,O
with,O
tamoxifen,I-Entity
for,O
stage,O
II,O
estrogen,I-Entity
receptor,O
-,O
positive,O
breast,B-Entity
carcinoma,I-Entity
.,O
Her,O
aspartate,I-Entity
transaminase,O
and,O
alanine,I-Entity
transaminase,O
levels,O
increase,O
markedly,O
after,O
6,O
months,O
of,O
tamoxifen,I-Entity
use,O
.,O
After,O
an,O
additional,O
17,O
months,O
of,O
elevated,O
serum,O
transaminases,O
",",O
the,O
patient,O
was,O
found,O
to,O
have,O
a,O
stage,O
Ic,O
granulosa,B-Entity
cell,I-Entity
tumor,I-Entity
of,I-Entity
the,I-Entity
ovary,I-Entity
.,O
Patients,O
with,O
tamoxifen,I-Entity
-,O
induced,O
liver,B-Entity
dysfunction,I-Entity
may,O
be,O
at,O
increased,O
risk,O
for,O
granulosa,B-Entity
cell,I-Entity
tumors,I-Entity
because,O
of,O
alterations,O
in,O
tamoxifen,I-Entity
metabolism,O
.,O
A,O
murine,O
model,O
of,O
adenomyosis,I-Entity
:,O
the,O
effects,O
of,O
hyperprolactinemia,I-Entity
induced,O
by,O
fluoxetine,B-Entity
hydrochloride,I-Entity
",",O
a,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitor,O
",",O
on,O
adenomyosis,I-Entity
induction,O
in,O
Wistar,O
albino,O
rats,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
investigate,O
whether,O
fluoxetine,I-Entity
given,O
to,O
castrated,O
and,O
noncastrated,O
rats,O
caused,O
hyperprolactinemia,I-Entity
and,O
its,O
effects,O
with,O
respect,O
to,O
adenomyosis,I-Entity
.,O
Fluoxetine,I-Entity
",",O
a,O
serotonin,I-Entity
reuptake,O
inhibitor,O
",",O
was,O
given,O
to,O
Wistar,O
Albino,O
rats,O
for,O
98,O
days,O
to,O
produce,O
hyperprolactinemia,I-Entity
.,O
The,O
prolactin,O
levels,O
of,O
castrated,O
and,O
noncastrated,O
groups,O
treated,O
with,O
fluoxetine,I-Entity
were,O
statistically,O
significantly,O
higher,O
when,O
compared,O
to,O
their,O
respective,O
control,O
groups,O
.,O
Histological,O
studies,O
revealed,O
11,O
cases,O
of,O
adenomyosis,I-Entity
",",O
all,O
within,O
the,O
noncastrated,O
group,O
receiving,O
fluoxetine,I-Entity
.,O
It,O
was,O
suggested,O
that,O
high,O
serum,O
prolactin,O
levels,O
cause,O
degeneration,O
of,O
myometrial,O
cells,O
in,O
the,O
presence,O
of,O
ovarian,O
steroids,I-Entity
that,O
results,O
in,O
a,O
myometrial,O
invasion,O
by,O
endometrial,O
stroma,O
.,O
This,O
invasion,O
eventually,O
progresses,O
to,O
adenomyosis,I-Entity
.,O
Effects,O
of,O
deliberate,O
hypotension,I-Entity
induced,O
by,O
labetalol,I-Entity
with,O
isoflurane,I-Entity
on,O
neuropsychological,O
function,O
.,O
The,O
effect,O
of,O
deliberate,O
hypotension,I-Entity
on,O
brain,O
function,O
measured,O
by,O
neuropsychological,O
tests,O
was,O
studied,O
in,O
41,O
adult,O
patients,O
.,O
Twenty,O
-,O
four,O
patients,O
were,O
anaesthetized,O
for,O
middle,O
-,O
ear,O
surgery,O
with,O
deliberate,O
hypotension,I-Entity
induced,O
by,O
labetalol,I-Entity
with,O
isoflurane,I-Entity
(,O
hypotensive,I-Entity
group,O
),O
.,O
Seventeen,O
patients,O
without,O
hypotension,I-Entity
served,O
as,O
a,O
control,O
group,O
.,O
0.3,O
kPa,O
),O
before,O
hypotension,I-Entity
and,O
50,O
+,O
/-,O
0.0,O
kPa,O
),O
during,O
hypotension,I-Entity
in,O
the,O
hypotensive,I-Entity
group,O
",",O
and,O
86,O
+,O
/-,O
The,O
following,O
psychological,O
tests,O
were,O
performed,O
:,O
four,O
subtests,O
of,O
the,O
Wechsler,O
Adult,O
Intelligence,O
Scale,O
(,O
similarities,O
",",O
digit,O
span,O
",",O
vocabulary,O
and,O
digit,O
symbol,O
),O
",",O
Trail,O
-,O
Making,O
tests,O
A,O
and,O
B,O
",",O
Zung,O
tests,O
(,O
self,O
-,O
rating,O
anxiety,I-Entity
scale,O
and,O
self,O
-,O
rating,O
depression,I-Entity
scale,O
),O
and,O
two,O
-,O
part,O
memory,O
test,O
battery,O
with,O
immediate,O
and,O
delayed,O
recall,O
.,O
The,O
results,O
indicate,O
that,O
hypotension,I-Entity
induced,O
by,O
labetalol,I-Entity
with,O
isoflurane,I-Entity
has,O
no,O
significant,O
harmful,O
effects,O
on,O
mental,O
functions,O
compared,O
to,O
normotensive,O
anaesthesia,O
.,O
Bupivacaine,I-Entity
0.75%,O
with,O
adrenaline,I-Entity
was,O
given,O
followed,O
by,O
a,O
24-hr,O
continuous,O
infusion,O
of,O
0.25%,O
bupivacaine,I-Entity
.,O
In,O
four,O
patients,O
hearing,B-Entity
impairment,I-Entity
on,O
the,O
side,O
of,O
the,O
block,O
was,O
demonstrated,O
after,O
operation,O
",",O
in,O
three,O
measurements,O
on,O
the,O
day,O
of,O
surgery,O
and,O
in,O
one,O
on,O
the,O
following,O
day,O
.,O
The,O
maximum,O
change,O
in,O
threshold,O
was,O
35,O
dB,O
at,O
6,O
kHz,O
measured,O
at,O
the,O
end,O
of,O
the,O
continuous,O
infusion,O
of,O
bupivacaine,I-Entity
.,O
IBPB,O
may,O
cause,O
transient,O
auditory,B-Entity
dysfunction,I-Entity
in,O
the,O
ipsilateral,O
ear,O
",",O
possibly,O
via,O
an,O
effect,O
on,O
sympathetic,O
innervation,O
.,O
Midazolam,I-Entity
compared,O
with,O
thiopentone,I-Entity
as,O
an,O
induction,O
agent,O
.,O
In,O
patients,O
premedicated,O
with,O
scopolamine,I-Entity
+,O
morphine,I-Entity
(,O
+,O
5,O
mg,O
nitrazepam,I-Entity
the,O
evening,O
before,O
surgery,O
),O
",",O
the,O
sleep,O
-,O
inducing,O
effect,O
of,O
midazolam,I-Entity
0.15,O
mg,O
/,O
kg,O
i.v,O
.,O
was,O
clearly,O
slower,O
in,O
onset,O
than,O
that,O
of,O
thiopentone,I-Entity
4.67,O
mg,O
/,O
kg,O
i.v,O
.,O
Somewhat,O
fewer,O
cardiovascular,O
and,O
local,O
sequelae,O
were,O
found,O
in,O
the,O
midazolam,I-Entity
group,O
",",O
but,O
",",O
although,O
apnoea,I-Entity
occurred,O
less,O
often,O
in,O
the,O
midazolam,I-Entity
group,O
it,O
lasted,O
longer,O
.,O
On,O
the,O
whole,O
",",O
the,O
differences,O
between,O
midazolam,I-Entity
and,O
thiopentone,I-Entity
had,O
no,O
apparent,O
clinical,O
consequences,O
.,O
Midazolam,I-Entity
is,O
a,O
new,O
alternative,O
agent,O
for,O
induction,O
in,O
combination,O
anaesthesia,O
.,O
Cardiotoxic,I-Entity
and,O
possible,O
leukemogenic,O
effects,O
of,O
adriamycin,I-Entity
in,O
nonhuman,O
primates,O
.,O
10,O
monkeys,O
(,O
macaques,O
),O
received,O
adriamycin,I-Entity
by,O
monthly,O
intravenous,O
injections,O
at,O
12,O
mg,O
/,O
m2,O
(,O
1,O
mg,O
/,O
kg,O
),O
.,O
8,O
of,O
the,O
10,O
monkeys,O
developed,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
at,O
an,O
average,O
cumulative,O
adriamycin,I-Entity
dose,O
(,O
310,O
mg,O
/,O
m2,O
),O
well,O
below,O
that,O
considered,O
the,O
safe,O
upper,O
limit,O
(,O
550,O
mg,O
/,O
m2,O
),O
in,O
man,O
.,O
Histologically,O
",",O
the,O
myocardial,B-Entity
lesions,I-Entity
resembled,O
those,O
found,O
in,O
human,O
anthracycline,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
.,O
1,O
of,O
the,O
10,O
monkeys,O
developed,O
acute,B-Entity
myeloblastic,I-Entity
leukemia,I-Entity
after,O
receiving,O
324,O
mg,O
/,O
m2,O
of,O
adriamycin,I-Entity
;,O
the,O
10th,O
monkey,O
is,O
alive,O
and,O
well,O
26,O
months,O
after,O
the,O
last,O
dose,O
of,O
drug,O
.,O
Our,O
results,O
suggest,O
that,O
adriamycin,I-Entity
is,O
a,O
more,O
potent,O
cardiotoxin,O
in,O
monkeys,O
than,O
in,O
man,O
",",O
and,O
that,O
leukemia,I-Entity
may,O
be,O
a,O
consequence,O
of,O
prolonged,O
treatment,O
with,O
this,O
drug,O
.,O
Doxorubicin,I-Entity
cardiomyopathy,I-Entity
in,O
children,O
with,O
left,O
-,O
sided,O
Wilms,B-Entity
tumor,I-Entity
.,O
Two,O
children,O
with,O
Wilms,B-Entity
tumor,I-Entity
of,O
the,O
left,O
kidney,O
experienced,O
severe,O
anthracycline,I-Entity
cardiomyopathy,I-Entity
after,O
irradiation,O
to,O
the,O
tumor,I-Entity
bed,O
and,O
conventional,O
dosage,O
of,O
doxorubicin,I-Entity
.,O
The,O
cardiomyopathy,I-Entity
is,O
attributed,O
1,O
),O
to,O
the,O
fact,O
that,O
radiation,O
fields,O
for,O
left,O
Wilms,B-Entity
tumor,I-Entity
include,O
the,O
lower,O
portion,O
of,O
the,O
heart,O
and,O
2,O
),O
to,O
the,O
interaction,O
of,O
doxorubicin,I-Entity
and,O
irradiation,O
on,O
cardiac,O
muscle,O
.,O
It,O
is,O
recommended,O
that,O
doxorubicin,I-Entity
dosage,O
be,O
sharply,O
restricted,O
in,O
children,O
with,O
Wilms,B-Entity
tumor,I-Entity
of,O
the,O
left,O
kidney,O
who,O
receive,O
postoperative,O
irradiation,O
.,O
Promotional,O
effects,O
of,O
testosterone,I-Entity
and,O
dietary,O
fat,O
on,O
prostate,O
carcinogenesis,I-Entity
in,O
genetically,O
susceptible,O
rats,O
.,O
Wistar,O
(,O
LW,O
),O
rats,O
",",O
fed,O
vegetable,O
diet,O
L-485,O
",",O
have,O
developed,O
prostate,B-Entity
adenocarcinomas,I-Entity
spontaneously,O
(,O
10%,O
incidence,O
),O
at,O
average,O
age,O
34,O
months,O
.,O
Conventional,O
LW,O
rats,O
",",O
implanted,O
with,O
testosterone,I-Entity
at,O
age,O
4,O
months,O
",",O
developed,O
a,O
higher,O
incidence,O
of,O
prostate,B-Entity
cancer,I-Entity
after,O
an,O
average,O
interval,O
of,O
14,O
months,O
:,O
24%,O
had,O
developed,O
gross,O
tumors,I-Entity
",",O
and,O
40%,O
when,O
it,O
included,O
microscopic,O
tumors,I-Entity
.,O
Preliminary,O
results,O
indicate,O
that,O
testosterone,I-Entity
-,O
treated,O
LW,O
rats,O
that,O
were,O
fed,O
the,O
same,O
diet,O
",",O
which,O
was,O
supplemented,O
with,O
corn,O
oil,O
up,O
to,O
20%,O
fat,O
",",O
developed,O
prostate,B-Entity
cancer,I-Entity
after,O
intervals,O
of,O
6,O
-,O
12,O
months,O
.,O
rats,O
have,O
not,O
developed,O
prostate,B-Entity
cancer,I-Entity
spontaneously,O
.,O
Conventional,O
SD,O
rats,O
fed,O
diet,O
L-485,O
and,O
treated,O
with,O
testosterone,I-Entity
developed,O
only,O
prostatitis,I-Entity
.,O
Experimental,O
designs,O
should,O
consider,O
genetic,O
susceptibility,O
as,O
a,O
basic,O
prerequisite,O
for,O
studies,O
on,O
experimental,O
prostate,B-Entity
cancer,I-Entity
.,O
Mitomycin,B-Entity
C,I-Entity
associated,O
hemolytic,B-Entity
uremic,I-Entity
syndrome,I-Entity
.,O
Mitomycin,B-Entity
C,I-Entity
associated,O
Hemolytic,B-Entity
Uremic,I-Entity
Syndrome,I-Entity
(,O
HUS,I-Entity
),O
is,O
a,O
potentially,O
fatal,O
but,O
uncommon,O
condition,O
that,O
is,O
not,O
yet,O
widely,O
recognised,O
.,O
It,O
consists,O
of,O
microangiopathic,O
hemolytic,B-Entity
anemia,I-Entity
",",O
thrombocytopenia,I-Entity
and,O
progressive,O
renal,B-Entity
failure,I-Entity
associated,O
with,O
mitomycin,B-Entity
C,I-Entity
treatment,O
and,O
affects,O
about,O
10%,O
of,O
patients,O
treated,O
with,O
this,O
agent,O
.,O
The,O
renal,B-Entity
failure,I-Entity
usually,O
develops,O
about,O
8,O
-,O
10,O
mth,O
after,O
start,O
of,O
mitomycin,B-Entity
C,I-Entity
treatment,O
and,O
the,O
mortality,O
is,O
approximately,O
60%,O
from,O
renal,B-Entity
failure,I-Entity
or,O
pulmonary,B-Entity
edema,I-Entity
.,O
Renal,B-Entity
lesions,I-Entity
are,O
similar,O
to,O
those,O
seen,O
in,O
idiopathic,O
HUS,I-Entity
and,O
include,O
arteriolar,O
fibrin,O
thrombi,I-Entity
",",O
expanded,O
subendothelial,O
zones,O
in,O
glomerular,O
capillary,O
walls,O
",",O
ischemic,I-Entity
wrinkling,O
of,O
glomerular,O
basement,O
membranes,O
and,O
mesangiolysis,O
.,O
The,O
mechanism,O
of,O
action,O
is,O
postulated,O
as,O
mitomycin,B-Entity
C,I-Entity
-,O
induced,O
endothelial,O
cell,O
damage,O
.,O
We,O
describe,O
the,O
clinical,O
course,O
and,O
pathological,O
findings,O
in,O
a,O
65,O
yr,O
-,O
old,O
man,O
with,O
gastric,B-Entity
adenocarcinoma,I-Entity
who,O
developed,O
renal,B-Entity
failure,I-Entity
and,O
thrombocytopenia,I-Entity
while,O
on,O
treatment,O
with,O
mitomycin,B-Entity
C,I-Entity
and,O
died,O
in,O
pulmonary,B-Entity
edema,I-Entity
.,O
Continuous,O
ambulatory,O
ECG,O
monitoring,O
during,O
fluorouracil,I-Entity
therapy,O
:,O
a,O
prospective,O
study,O
.,O
Although,O
there,O
have,O
been,O
anecdotal,O
reports,O
of,O
cardiac,B-Entity
toxicity,I-Entity
associated,O
with,O
fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
therapy,O
",",O
this,O
phenomenon,O
has,O
not,O
been,O
studied,O
in,O
a,O
systematic,O
fashion,O
.,O
We,O
prospectively,O
performed,O
continuous,O
ambulatory,O
ECG,O
monitoring,O
on,O
25,O
patients,O
undergoing,O
5-FU,I-Entity
infusion,O
for,O
treatment,O
of,O
solid,O
tumors,I-Entity
in,O
order,O
to,O
assess,O
the,O
incidence,O
of,O
ischemic,I-Entity
ST,O
changes,O
.,O
4,O
hours,O
before,O
5-FU,I-Entity
infusion,O
",",O
and,O
98,O
+,O
/-,O
9,O
hours,O
during,O
5-FU,I-Entity
infusion,O
.,O
Anginal,I-Entity
episodes,O
were,O
rare,O
:,O
only,O
one,O
patient,O
had,O
angina,I-Entity
(,O
during,O
5-FU,I-Entity
infusion,O
),O
.,O
However,O
",",O
asymptomatic,O
ST,O
changes,O
(,O
greater,O
than,O
or,O
equal,O
to,O
1,O
mm,O
ST,O
deviation,O
),O
were,O
common,O
:,O
six,O
of,O
25,O
patients,O
(,O
24%,O
),O
had,O
ST,O
changes,O
before,O
5-FU,I-Entity
infusion,O
v,O
17,O
(,O
68%,O
),O
during,O
5-FU,I-Entity
infusion,O
(,O
P,O
less,O
than,O
.002,O
),O
.,O
The,O
incidence,O
of,O
ischemic,I-Entity
episodes,O
per,O
patient,O
per,O
hour,O
was,O
0.05,O
+,O
/-,O
0.02,O
prior,O
to,O
5-FU,I-Entity
infusion,O
v,O
0.13,O
+,O
/-,O
0.03,O
during,O
5-FU,I-Entity
infusion,O
(,O
P,O
less,O
than,O
.001,O
),O
;,O
the,O
duration,O
of,O
ECG,O
changes,O
was,O
0.6,O
+,O
/-,O
0.3,O
minutes,O
per,O
patient,O
per,O
hour,O
before,O
5-FU,I-Entity
v,O
1.9,O
+,O
/-,O
0.5,O
minutes,O
per,O
patient,O
per,O
hour,O
during,O
5-FU,I-Entity
(,O
P,O
less,O
than,O
.01,O
),O
.,O
ECG,O
changes,O
were,O
more,O
common,O
among,O
patients,O
with,O
known,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
.,O
There,O
were,O
two,O
cases,O
of,O
sudden,B-Entity
death,I-Entity
",",O
both,O
of,O
which,O
occurred,O
at,O
the,O
end,O
of,O
the,O
chemotherapy,O
course,O
.,O
We,O
conclude,O
that,O
5-FU,I-Entity
infusion,O
is,O
associated,O
with,O
a,O
significant,O
increase,O
in,O
silent,O
ST,O
segment,O
deviation,O
suggestive,O
of,O
ischemia,I-Entity
",",O
particularly,O
among,O
patients,O
with,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
.,O
Lethal,O
anuria,I-Entity
complicating,O
high,O
dose,O
ifosfamide,I-Entity
chemotherapy,O
in,O
a,O
breast,B-Entity
cancer,I-Entity
patient,O
with,O
an,O
impaired,B-Entity
renal,I-Entity
function,I-Entity
.,O
A,O
sixty,O
-,O
year,O
-,O
old,O
woman,O
with,O
advanced,O
breast,B-Entity
cancer,I-Entity
",",O
previously,O
treated,O
with,O
cisplatin,I-Entity
",",O
developed,O
an,O
irreversible,O
lethal,O
renal,B-Entity
failure,I-Entity
with,O
anuria,I-Entity
",",O
the,O
day,O
after,O
5,O
g,O
/,O
m2,O
bolus,O
ifosfamide,I-Entity
.,O
Postrenal,B-Entity
failure,I-Entity
was,O
excluded,O
by,O
echography,O
.,O
A,O
prerenal,O
component,O
could,O
have,O
contributed,O
to,O
renal,B-Entity
failure,I-Entity
because,O
of,O
a,O
transient,O
hypotension,I-Entity
",",O
due,O
to,O
an,O
increasing,O
ascitis,O
",",O
occurring,O
just,O
before,O
anuria,I-Entity
.,O
Ifosfamide,I-Entity
is,O
a,O
known,O
nephrotoxic,I-Entity
drug,O
with,O
demonstrated,O
tubulopathies,I-Entity
.,O
We,O
strongly,O
suspect,O
that,O
this,O
lethal,O
anuria,I-Entity
was,O
mainly,O
due,O
to,O
ifosfamide,I-Entity
",",O
occurring,O
in,O
a,O
patient,O
having,O
received,O
previous,O
cisplatin,I-Entity
chemotherapy,O
and,O
with,O
poor,O
kidney,O
perfusion,O
due,O
to,O
transient,O
hypotension,I-Entity
.,O
We,O
recommend,O
careful,O
use,O
of,O
ifosfamide,I-Entity
in,O
patients,O
pretreated,O
with,O
nephrotoxic,I-Entity
chemotherapy,O
and,O
inadequate,O
renal,O
perfusion,O
.,O
Central,O
vein,B-Entity
thrombosis,I-Entity
and,O
topical,O
dipivalyl,B-Entity
epinephrine,I-Entity
.,O
A,O
report,O
is,O
given,O
on,O
an,O
83-year,O
-,O
old,O
female,O
who,O
acquired,O
central,O
vein,B-Entity
thrombosis,I-Entity
in,O
her,O
seeing,O
eye,O
one,O
day,O
after,O
having,O
started,O
topical,O
medication,O
with,O
dipivalyl,B-Entity
epinephrine,I-Entity
for,O
advanced,O
glaucoma,I-Entity
discovered,O
in,O
the,O
other,O
eye,O
.,O
Amelioration,O
of,O
bendrofluazide,I-Entity
-,O
induced,O
hypokalemia,I-Entity
by,O
timolol,I-Entity
.,O
The,O
beta,O
adrenergic,O
blocking,O
drug,O
",",O
timolol,I-Entity
",",O
tended,O
to,O
correct,O
the,O
hypokalemia,I-Entity
of,O
short,O
-,O
term,O
bendrofluazide,I-Entity
treatment,O
in,O
6,O
healthy,O
male,O
subjects,O
and,O
although,O
the,O
effect,O
was,O
small,O
it,O
was,O
significant,O
.,O
Timolol,I-Entity
also,O
reduced,O
the,O
rise,O
in,O
plasma,O
aldosterone,I-Entity
and,O
urine,O
potassium,I-Entity
excretion,O
following,O
bendrofluazide,I-Entity
and,O
increased,O
the,O
urine,O
sodium,I-Entity
/,O
potassium,I-Entity
ratio,O
.,O
There,O
was,O
no,O
evidence,O
of,O
a,O
shift,O
of,O
potassium,I-Entity
from,O
the,O
intracellular,O
to,O
the,O
extracellular,O
space,O
.,O
A,O
cross,O
-,O
sectional,O
evaluation,O
of,O
the,O
effect,O
of,O
risperidone,I-Entity
and,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitors,O
on,O
bone,O
mineral,O
density,O
in,O
boys,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
effect,O
of,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
on,O
trabecular,O
bone,O
mineral,O
density,O
(,O
BMD,O
),O
in,O
children,O
and,O
adolescents,O
.,O
Medically,O
healthy,O
7-,O
to,O
17-year,O
-,O
old,O
males,O
chronically,O
treated,O
",",O
in,O
a,O
naturalistic,O
setting,O
",",O
with,O
risperidone,I-Entity
were,O
recruited,O
for,O
this,O
cross,O
-,O
sectional,O
study,O
through,O
child,O
psychiatry,O
outpatient,O
clinics,O
between,O
November,O
2005,O
and,O
June,O
2007,O
.,O
Hyperprolactinemia,I-Entity
was,O
present,O
in,O
49%,O
of,O
83,O
boys,O
(,O
n,O
=,O
41,O
),O
treated,O
with,O
risperidone,I-Entity
for,O
a,O
mean,O
of,O
2.9,O
years,O
.,O
Serum,O
testosterone,I-Entity
concentration,O
increased,O
with,O
pubertal,O
status,O
but,O
was,O
not,O
affected,O
by,O
hyperprolactinemia,I-Entity
.,O
Controlling,O
for,O
relevant,O
covariates,O
",",O
we,O
also,O
found,O
treatment,O
with,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitors,O
(,O
SSRIs,O
),O
to,O
be,O
associated,O
with,O
lower,O
trabecular,O
BMD,O
at,O
the,O
radius,O
(,O
P,O
=,O
.03,O
),O
and,O
BMD,O
z,O
score,O
at,O
the,O
lumbar,O
spine,O
(,O
P,O
<,O
.05,O
),O
.,O
Of,O
13,O
documented,O
fractures,I-Entity
",",O
3,O
occurred,O
after,O
risperidone,I-Entity
and,O
SSRIs,O
were,O
started,O
",",O
and,O
none,O
occurred,O
in,O
patients,O
with,O
hyperprolactinemia,I-Entity
.,O
This,O
is,O
the,O
first,O
study,O
to,O
link,O
risperidone,I-Entity
-,O
induced,O
hyperprolactinemia,I-Entity
and,O
SSRI,O
treatment,O
to,O
lower,O
BMD,O
in,O
children,O
and,O
adolescents,O
.,O
Seizures,I-Entity
associated,O
with,O
levofloxacin,I-Entity
:,O
case,O
presentation,O
and,O
literature,O
review,O
.,O
PURPOSE,O
:,O
We,O
present,O
a,O
case,O
of,O
a,O
patient,O
who,O
developed,O
seizures,I-Entity
shortly,O
after,O
initiating,O
treatment,O
with,O
levofloxacin,I-Entity
and,O
to,O
discuss,O
the,O
potential,O
drug,O
-,O
drug,O
interactions,O
related,O
to,O
the,O
inhibition,O
of,O
cytochrome,O
P450,O
(,O
CYP,O
),O
1A2,O
in,O
this,O
case,O
",",O
as,O
well,O
as,O
in,O
other,O
cases,O
",",O
of,O
levofloxacin,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
The,O
main,O
search,O
terms,O
utilized,O
were,O
case,O
report,O
and,O
levofloxacin,I-Entity
.,O
Six,O
cases,O
of,O
levofloxacin,I-Entity
-,O
induced,O
seizures,I-Entity
have,O
been,O
reported,O
in,O
the,O
literature,O
.,O
Drug,O
-,O
drug,O
interactions,O
related,O
to,O
the,O
inhibition,O
of,O
CYP1A2,O
by,O
levofloxacin,I-Entity
are,O
likely,O
involved,O
in,O
the,O
clinical,O
outcome,O
of,O
these,O
cases,O
.,O
Clinicians,O
are,O
exhorted,O
to,O
pay,O
close,O
attention,O
when,O
initiating,O
levofloxacin,I-Entity
therapy,O
in,O
patients,O
taking,O
medications,O
with,O
epileptogenic,O
properties,O
that,O
are,O
CYP1A2,O
substrates,O
.,O
Mice,O
lacking,O
mPGES-1,O
are,O
resistant,O
to,O
lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
.,O
Cyclooxygenase-2,O
activity,O
is,O
required,O
for,O
the,O
development,O
of,O
lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
.,O
However,O
",",O
the,O
involvement,O
of,O
a,O
specific,O
",",O
terminal,O
prostaglandin,I-Entity
(,O
PG,I-Entity
),O
isomerase,O
has,O
not,O
been,O
evaluated,O
.,O
The,O
present,O
study,O
was,O
undertaken,O
to,O
assess,O
lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
in,O
mice,O
deficient,O
in,O
microsomal,O
prostaglandin,B-Entity
E,I-Entity
synthase-1,O
(,O
mPGES-1,O
),O
.,O
A,O
2-wk,O
administration,O
of,O
LiCl,I-Entity
(,O
4,O
mmol.kg(-1).day(-1,O
),O
ip,O
),O
in,O
mPGES-1,O
+,O
/+,O
mice,O
led,O
to,O
a,O
marked,O
polyuria,I-Entity
with,O
hyposmotic,O
urine,O
.,O
This,O
was,O
associated,O
with,O
elevated,O
renal,O
mPGES-1,O
protein,O
expression,O
and,O
increased,O
urine,O
PGE(2,B-Entity
),I-Entity
In,O
contrast,O
",",O
mPGES-1,O
-/-,O
mice,O
were,O
largely,O
resistant,O
to,O
lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
and,O
a,O
urine,O
concentrating,O
defect,O
",",O
accompanied,O
by,O
nearly,O
complete,O
blockade,O
of,O
high,O
urine,O
PGE(2,B-Entity
),I-Entity
and,O
cAMP,O
output,O
.,O
RT,O
-,O
PCR,O
consistently,O
detected,O
a,O
significant,O
decrease,O
in,O
aquaporin-2,O
(,O
AQP2,O
),O
protein,O
expression,O
in,O
both,O
the,O
renal,O
cortex,O
and,O
medulla,O
of,O
lithium,I-Entity
-,O
treated,O
+,O
/+,O
mice,O
.,O
Similarly,O
",",O
the,O
total,O
protein,O
abundance,O
of,O
the,O
Na,I-Entity
-,O
K-2Cl,I-Entity
cotransporter,O
(,O
NKCC2,O
),O
in,O
the,O
medulla,O
but,O
not,O
in,O
the,O
cortex,O
of,O
the,O
+,O
/+,O
mice,O
was,O
significantly,O
reduced,O
by,O
lithium,I-Entity
treatment,O
.,O
We,O
conclude,O
that,O
mPGES-1-derived,O
PGE(2,B-Entity
),I-Entity
mediates,O
lithium,I-Entity
-,O
induced,O
polyuria,I-Entity
likely,O
via,O
inhibition,O
of,O
AQP2,O
and,O
NKCC2,O
expression,O
.,O
Identification,O
of,O
a,O
simple,O
and,O
sensitive,O
microplate,O
method,O
for,O
the,O
detection,O
of,O
oversulfated,O
chondroitin,B-Entity
sulfate,I-Entity
in,O
heparin,I-Entity
products,O
.,O
Heparin,I-Entity
is,O
a,O
commonly,O
implemented,O
anticoagulant,O
used,O
to,O
treat,O
critically,O
ill,O
patients,O
.,O
Recently,O
",",O
a,O
number,O
of,O
commercial,O
lots,O
of,O
heparin,I-Entity
products,O
were,O
found,O
to,O
be,O
contaminated,O
with,O
an,O
oversulfated,O
chondroitin,B-Entity
sulfate,I-Entity
(,O
OSCS,O
),O
derivative,O
that,O
could,O
elicit,O
a,O
hypotensive,I-Entity
response,O
in,O
pigs,O
following,O
a,O
single,O
high,O
-,O
dose,O
infusion,O
.,O
Using,O
both,O
contaminated,O
heparin,I-Entity
products,O
and,O
the,O
synthetically,O
produced,O
derivative,O
",",O
we,O
showed,O
that,O
the,O
OSCS,O
produces,O
dose,O
-,O
dependent,O
hypotension,I-Entity
in,O
pigs,O
.,O
We,O
also,O
demonstrated,O
that,O
OSCS,O
can,O
be,O
identified,O
in,O
heparin,I-Entity
products,O
using,O
a,O
simple,O
",",O
inexpensive,O
",",O
commercially,O
available,O
heparin,I-Entity
enzyme,O
immunoassay,O
(,O
EIA,O
),O
kit,O
that,O
has,O
a,O
limit,O
of,O
detection,O
of,O
approximately,O
0.1%,O
",",O
well,O
below,O
the,O
NOEL,O
.,O
This,O
kit,O
may,O
provide,O
a,O
useful,O
method,O
to,O
test,O
heparin,I-Entity
products,O
for,O
contamination,O
with,O
oversulfated,O
GAG,O
derivatives,O
.,O
Doxorubicin,I-Entity
cardiomyopathy,I-Entity
-,O
induced,O
inflammation,I-Entity
and,O
apoptosis,O
are,O
attenuated,O
by,O
gene,O
deletion,O
of,O
the,O
kinin,O
B1,O
receptor,O
.,O
Clinical,O
use,O
of,O
the,O
anthracycline,I-Entity
doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
is,O
limited,O
by,O
its,O
cardiotoxic,I-Entity
effects,O
",",O
which,O
are,O
attributed,O
to,O
the,O
induction,O
of,O
apoptosis,O
.,O
To,O
elucidate,O
the,O
possible,O
role,O
of,O
the,O
kinin,O
B1,O
receptor,O
(,O
B1R,O
),O
during,O
the,O
development,O
of,O
DOX,I-Entity
cardiomyopathy,I-Entity
",",O
we,O
studied,O
B1R,O
knockout,O
mice,O
(,O
B1R(-/-,O
),O
),O
by,O
investigating,O
cardiac,O
inflammation,I-Entity
and,O
apoptosis,O
after,O
induction,O
of,O
DOX,I-Entity
-,O
induced,O
cardiomyopathy,I-Entity
.,O
DOX,I-Entity
control,O
mice,O
showed,O
cardiac,B-Entity
dysfunction,I-Entity
measured,O
by,O
pressure,O
-,O
volume,O
loops,O
in,O
vivo,O
.,O
This,O
was,O
associated,O
with,O
a,O
reduced,O
activation,O
state,O
of,O
AKT,O
",",O
as,O
well,O
as,O
an,O
increased,O
bax,O
/,O
bcl2,O
ratio,O
in,O
Western,O
blots,O
",",O
indicating,O
cardiac,B-Entity
apoptosis,I-Entity
.,O
In,O
DOX,I-Entity
B1R(-/-,O
),O
mice,O
",",O
cardiac,B-Entity
dysfunction,I-Entity
was,O
improved,O
compared,O
to,O
DOX,I-Entity
control,O
mice,O
",",O
which,O
was,O
associated,O
with,O
normalization,O
of,O
the,O
bax,O
/,O
bcl-2,O
ratio,O
and,O
interleukin,O
6,O
",",O
as,O
well,O
as,O
AKT,O
activation,O
state,O
.,O
These,O
findings,O
suggest,O
that,O
B1R,O
is,O
detrimental,O
in,O
DOX,I-Entity
cardiomyopathy,I-Entity
in,O
that,O
it,O
mediates,O
the,O
inflammatory,O
response,O
and,O
apoptosis,O
.,O
These,O
insights,O
might,O
have,O
useful,O
implications,O
for,O
future,O
studies,O
utilizing,O
B1R,O
antagonists,O
for,O
treatment,O
of,O
human,O
DOX,I-Entity
cardiomyopathy,I-Entity
.,O
Hepatotoxicity,I-Entity
associated,O
with,O
sulfasalazine,I-Entity
in,O
inflammatory,O
arthritis,I-Entity
:,O
We,O
report,O
an,O
investigation,O
from,O
a,O
local,O
surveillance,O
for,O
serious,O
adverse,O
drug,O
reactions,O
associated,O
with,O
disease,O
modifying,O
anti,O
-,O
rheumatic,O
drugs,O
that,O
was,O
triggered,O
by,O
the,O
occurrence,O
of,O
liver,B-Entity
failure,I-Entity
in,O
two,O
of,O
our,O
patients,O
.,O
Patients,O
',O
",",O
who,O
had,O
hepatotoxicity,I-Entity
on,O
sulfasalazine,I-Entity
and,O
met,O
a,O
definition,O
of,O
a,O
serious,O
ADR,O
",",O
were,O
identified,O
.,O
The,O
likely,O
frequency,O
of,O
hepatotoxicity,I-Entity
with,O
sulfasalazine,I-Entity
was,O
estimated,O
by,O
making,O
a,O
series,O
of,O
conservative,O
assumptions,O
.,O
Eight,O
patients,O
were,O
hospitalised,O
",",O
two,O
in,O
hepatic,B-Entity
failure,I-Entity
-,O
one,O
died,O
after,O
a,O
liver,O
transplant,O
.,O
Seven,O
patients,O
had,O
a,O
skin,B-Entity
rash,I-Entity
",",O
three,O
eosinophilia,I-Entity
and,O
one,O
interstitial,B-Entity
nephritis,I-Entity
.,O
Drug,O
-,O
related,O
hepatotoxicity,I-Entity
was,O
judged,O
probable,O
or,O
highly,O
probable,O
in,O
8,O
patients,O
.,O
The,O
likely,O
frequency,O
of,O
serious,O
hepatotoxicity,I-Entity
with,O
sulfasalazine,I-Entity
was,O
estimated,O
at,O
0.4%,O
of,O
treated,O
patients,O
.,O
CONCLUSION,O
:,O
Serious,O
hepatotoxicity,I-Entity
associated,O
with,O
sulfasalazine,I-Entity
appears,O
to,O
be,O
under,O
-,O
appreciated,O
and,O
intensive,O
monitoring,O
and,O
vigilance,O
in,O
the,O
first,O
6,O
weeks,O
of,O
treatment,O
is,O
especially,O
important,O
.,O
An,O
evaluation,O
of,O
amikacin,I-Entity
nephrotoxicity,I-Entity
in,O
the,O
hematology,O
/,O
oncology,O
population,O
.,O
Amikacin,I-Entity
is,O
an,O
aminoglycoside,I-Entity
commonly,O
used,O
to,O
provide,O
empirical,O
double,O
gram,O
-,O
negative,O
treatment,O
for,O
febrile,B-Entity
neutropenia,I-Entity
and,O
other,O
suspected,O
infections,I-Entity
.,O
To,O
evaluate,O
amikacin,I-Entity
-,O
associated,O
nephrotoxicity,I-Entity
in,O
an,O
adult,O
hematology,O
/,O
oncology,O
population,O
",",O
a,O
prospective,O
",",O
randomized,O
",",O
open,O
-,O
label,O
trial,O
was,O
conducted,O
at,O
a,O
university,O
-,O
affiliated,O
medical,O
center,O
.,O
Forty,O
patients,O
with,O
a,O
diagnosis,O
consistent,O
with,O
a,O
hematologic,B-Entity
/,I-Entity
oncologic,I-Entity
disorder,I-Entity
that,O
required,O
treatment,O
with,O
an,O
aminoglycoside,I-Entity
were,O
randomized,O
to,O
either,O
conventional,O
or,O
extended,O
-,O
interval,O
amikacin,I-Entity
.,O
The,O
occurrence,O
of,O
nephrotoxicity,I-Entity
by,O
means,O
of,O
an,O
increase,O
in,O
serum,O
creatinine,I-Entity
and,O
evaluation,O
of,O
efficacy,O
via,O
amikacin,I-Entity
serum,O
concentrations,O
with,O
respective,O
pathogens,O
were,O
assessed,O
.,O
The,O
occurrence,O
of,O
nephrotoxicity,I-Entity
was,O
similar,O
between,O
the,O
conventional,O
and,O
extended,O
-,O
interval,O
groups,O
",",O
at,O
10%,O
and,O
5%,O
",",O
respectively,O
(,O
P,O
=,O
1.00,O
),O
.,O
The,O
occurrence,O
of,O
nephrotoxicity,I-Entity
was,O
similar,O
between,O
the,O
two,O
dosing,O
regimens,O
",",O
but,O
the,O
distribution,O
of,O
risk,O
factors,O
was,O
variable,O
between,O
the,O
two,O
groups,O
.,O
Memory,O
function,O
and,O
serotonin,I-Entity
transporter,O
promoter,O
gene,O
polymorphism,O
in,O
ecstasy,I-Entity
(,O
MDMA,I-Entity
),O
users,O
.,O
Although,O
"3,4-methylenedioxymethamphetamine",I-Entity
(,O
MDMA,I-Entity
or,O
ecstasy,I-Entity
),O
has,O
been,O
shown,O
to,O
damage,O
brain,O
serotonin,I-Entity
(,O
5-HT,I-Entity
),O
neurons,O
in,O
animals,O
and,O
possibly,O
humans,O
",",O
little,O
is,O
known,O
about,O
the,O
long,O
-,O
term,O
consequences,O
of,O
MDMA,I-Entity
-,O
induced,O
5-HT,I-Entity
neurotoxic,B-Entity
lesions,I-Entity
on,O
functions,O
in,O
which,O
5-HT,I-Entity
is,O
involved,O
",",O
such,O
as,O
cognitive,O
function,O
.,O
Because,O
5-HT,I-Entity
transporters,O
play,O
a,O
key,O
element,O
in,O
the,O
regulation,O
of,O
synaptic,O
5-HT,I-Entity
transmission,O
it,O
may,O
be,O
important,O
to,O
control,O
for,O
the,O
potential,O
covariance,O
effect,O
of,O
a,O
polymorphism,O
in,O
the,O
5-HT,I-Entity
transporter,O
promoter,O
gene,O
region,O
(,O
5-HTTLPR,O
),O
when,O
studying,O
the,O
effects,O
of,O
MDMA,I-Entity
as,O
well,O
as,O
cognitive,O
functioning,O
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
investigate,O
the,O
effects,O
of,O
moderate,O
and,O
heavy,O
MDMA,I-Entity
use,O
on,O
cognitive,O
function,O
",",O
as,O
well,O
as,O
the,O
effects,O
of,O
long,O
-,O
term,O
abstention,O
from,O
MDMA,I-Entity
",",O
in,O
subjects,O
genotyped,O
for,O
5-HTTLPR,O
.,O
Fifteen,O
moderate,O
MDMA,I-Entity
users,O
(,O
<,O
55,O
lifetime,O
tablets,O
),O
",",O
22,O
heavy,O
MDMA+,I-Entity
users,O
(,O
>,O
55,O
lifetime,O
tablets,O
),O
",",O
16,O
ex,O
-,O
MDMA+,I-Entity
users,O
(,O
last,O
tablet,O
>,O
1,O
year,O
ago,O
),O
and,O
13,O
controls,O
were,O
compared,O
on,O
a,O
battery,O
of,O
neuropsychological,O
tests,O
.,O
Heavy,O
and,O
ex,O
-,O
MDMA+,I-Entity
users,O
performed,O
significantly,O
poorer,O
on,O
memory,O
tasks,O
than,O
controls,O
.,O
In,O
contrast,O
",",O
no,O
evidence,O
of,O
memory,B-Entity
impairment,I-Entity
was,O
observed,O
in,O
moderate,O
MDMA,I-Entity
users,O
.,O
While,O
the,O
use,O
of,O
MDMA,I-Entity
in,O
quantities,O
that,O
may,O
be,O
considered,O
"""",O
moderate,O
"""",O
is,O
not,O
associated,O
with,O
impaired,B-Entity
memory,I-Entity
functioning,I-Entity
",",O
heavy,O
use,O
of,O
MDMA,I-Entity
use,O
may,O
lead,O
to,O
long,O
lasting,O
memory,B-Entity
impairments,I-Entity
.,O
No,O
effect,O
of,O
5-HTTLPR,O
or,O
gender,O
on,O
memory,O
function,O
or,O
MDMA,I-Entity
use,O
was,O
observed,O
.,O
Aging,O
process,O
of,O
epithelial,O
cells,O
of,O
the,O
rat,O
prostate,O
lateral,O
lobe,O
in,O
experimental,O
hyperprolactinemia,I-Entity
induced,O
by,O
haloperidol,I-Entity
.,O
The,O
aim,O
of,O
the,O
study,O
was,O
to,O
examine,O
the,O
influence,O
of,O
hyperprolactinemia,I-Entity
",",O
induced,O
by,O
haloperidol,I-Entity
(,O
HAL,I-Entity
),O
on,O
age,O
related,O
morphology,O
and,O
function,O
changes,O
of,O
epithelial,O
cells,O
in,O
rat,O
prostate,O
lateral,O
lobe,O
.,O
Serum,O
concentrations,O
of,O
prolactin,O
(,O
PRL,I-Entity
),O
and,O
testosterone,I-Entity
(,O
T,I-Entity
),O
were,O
measured,O
.,O
In,O
rats,O
of,O
the,O
experimental,O
group,O
",",O
the,O
mean,O
concentration,O
of,O
:,O
PRL,I-Entity
was,O
more,O
than,O
twice,O
higher,O
",",O
whereas,O
T,I-Entity
concentration,O
was,O
almost,O
twice,O
lower,O
than,O
that,O
in,O
the,O
control,O
group,O
.,O
Light,O
microscopy,O
visualized,O
the,O
following,O
:,O
hypertrophy,I-Entity
and,O
epithelium,O
hyperplasia,I-Entity
of,O
the,O
glandular,O
ducts,O
",",O
associated,O
with,O
increased,O
PCNA,O
expression,O
.,O
Does,O
supplemental,O
vitamin,B-Entity
C,I-Entity
increase,O
cardiovascular,B-Entity
disease,I-Entity
risk,O
in,O
women,O
with,O
diabetes,I-Entity
?,O
Vitamin,B-Entity
C,I-Entity
acts,O
as,O
a,O
potent,O
antioxidant,O
;,O
however,O
",",O
it,O
can,O
also,O
be,O
a,O
prooxidant,O
and,O
glycate,O
protein,O
under,O
certain,O
circumstances,O
in,O
vitro,O
.,O
These,O
observations,O
led,O
us,O
to,O
hypothesize,O
that,O
a,O
high,O
intake,O
of,O
vitamin,B-Entity
C,I-Entity
in,O
diabetic,I-Entity
persons,O
might,O
promote,O
atherosclerosis,I-Entity
.,O
The,O
objective,O
was,O
to,O
examine,O
the,O
relation,O
between,O
vitamin,B-Entity
C,I-Entity
intake,O
and,O
mortality,O
from,O
cardiovascular,B-Entity
disease,I-Entity
.,O
DESIGN,O
:,O
We,O
studied,O
the,O
relation,O
between,O
vitamin,B-Entity
C,I-Entity
intake,O
and,O
mortality,O
from,O
total,O
cardiovascular,B-Entity
disease,I-Entity
(,O
n,O
=,O
281,O
),O
",",O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
(,O
n,O
=,O
175,O
),O
",",O
and,O
stroke,I-Entity
(,O
n,O
=,O
57,O
),O
in,O
1923,O
postmenopausal,O
women,O
who,O
reported,O
being,O
diabetic,I-Entity
at,O
baseline,O
.,O
Diet,O
was,O
assessed,O
with,O
a,O
food,O
-,O
frequency,O
questionnaire,O
at,O
baseline,O
",",O
and,O
subjects,O
initially,O
free,O
of,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
were,O
prospectively,O
followed,O
for,O
15,O
y.,O
RESULTS,O
:,O
After,O
adjustment,O
for,O
cardiovascular,B-Entity
disease,I-Entity
risk,O
factors,O
",",O
type,O
of,O
diabetes,I-Entity
medication,O
used,O
",",O
duration,O
of,O
diabetes,I-Entity
",",O
and,O
intakes,O
of,O
folate,I-Entity
",",O
vitamin,B-Entity
E,I-Entity
",",O
and,O
beta,B-Entity
-,I-Entity
carotene,I-Entity
",",O
the,O
adjusted,O
relative,O
risks,O
of,O
total,O
cardiovascular,B-Entity
disease,I-Entity
mortality,O
were,O
1.0,O
",",O
0.97,O
",",O
1.11,O
",",O
1.47,O
",",O
and,O
1.84,O
(,O
P,O
for,O
trend,O
<,O
0.01,O
),O
across,O
quintiles,O
of,O
total,O
vitamin,B-Entity
C,I-Entity
intake,O
from,O
food,O
and,O
supplements,O
.,O
Adjusted,O
relative,O
risks,O
of,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
were,O
1.0,O
",",O
0.81,O
",",O
0.99,O
",",O
1.26,O
",",O
and,O
1.91,O
(,O
P,O
for,O
trend,O
=,O
0.01,O
),O
and,O
of,O
stroke,I-Entity
were,O
1.0,O
",",O
0.52,O
",",O
1.23,O
",",O
2.22,O
",",O
and,O
2.57,O
(,O
P,O
for,O
trend,O
<,O
0.01,O
),O
.,O
When,O
dietary,O
and,O
supplemental,O
vitamin,B-Entity
C,I-Entity
were,O
analyzed,O
separately,O
",",O
only,O
supplemental,O
vitamin,B-Entity
C,I-Entity
showed,O
a,O
positive,O
association,O
with,O
mortality,O
endpoints,O
.,O
Vitamin,B-Entity
C,I-Entity
intake,O
was,O
unrelated,O
to,O
mortality,O
from,O
cardiovascular,B-Entity
disease,I-Entity
in,O
the,O
nondiabetic,O
subjects,O
at,O
baseline,O
.,O
CONCLUSION,O
:,O
A,O
high,O
vitamin,B-Entity
C,I-Entity
intake,O
from,O
supplements,O
is,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
cardiovascular,B-Entity
disease,I-Entity
mortality,O
in,O
postmenopausal,O
women,O
with,O
diabetes,I-Entity
.,O
Absolute,O
and,O
attributable,O
risk,O
of,O
venous,B-Entity
thromboembolism,I-Entity
in,O
women,O
on,O
combined,O
cyproterone,B-Entity
acetate,I-Entity
and,O
ethinylestradiol,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
achieve,O
absolute,O
risk,O
estimates,O
of,O
venous,B-Entity
thromboembolism,I-Entity
(,O
VTE,I-Entity
),O
among,O
women,O
on,O
cyproterone,B-Entity
acetate,I-Entity
plus,O
ethinylestradiol,I-Entity
(,O
CPA,I-Entity
/,O
EE,I-Entity
),O
",",O
and,O
among,O
women,O
on,O
combined,B-Entity
oral,I-Entity
contraceptives,I-Entity
(,O
COCs,I-Entity
),O
.,O
From,O
the,O
Danish,O
National,O
Register,O
of,O
Patients,O
(,O
NRP,O
),O
",",O
1996,O
to,O
1998,O
",",O
the,O
records,O
of,O
1.1,O
million,O
Danish,O
women,O
",",O
ages,O
15,O
to,O
44,O
years,O
",",O
were,O
searched,O
for,O
evidence,O
of,O
VTE,I-Entity
.,O
COC,I-Entity
use,O
was,O
ascertained,O
through,O
mailed,O
questionnaires,O
.,O
Sales,O
statistics,O
of,O
COCs,I-Entity
and,O
CPA,I-Entity
/,O
EE,I-Entity
were,O
provided,O
through,O
Danish,O
Drug,O
Statistics,O
.,O
During,O
the,O
time,O
frame,O
of,O
the,O
study,O
",",O
330,O
women,O
were,O
found,O
to,O
have,O
had,O
VTE,I-Entity
while,O
on,O
COCs,I-Entity
.,O
Of,O
these,O
women,O
",",O
67,O
were,O
on,O
levonorgestrel,I-Entity
-,O
containing,O
COCs,I-Entity
.,O
Eleven,O
were,O
on,O
CPA,I-Entity
/,O
EE,I-Entity
.,O
The,O
corresponding,O
absolute,O
risk,O
of,O
VTE,I-Entity
was,O
3.4,O
(,O
range,O
",",O
3.1,O
-,O
3.8,O
),O
per,O
10,O
000,O
women,O
years,O
among,O
the,O
women,O
on,O
COCs,I-Entity
",",O
4.2,O
(,O
range,O
",",O
3.2,O
-,O
5.2,O
),O
per,O
10,O
000,O
women,O
years,O
among,O
women,O
on,O
levonorgestrel,I-Entity
-,O
containing,O
COCs,I-Entity
",",O
and,O
3.1,O
(,O
range,O
",",O
1.3,O
-,O
4.9,O
),O
per,O
10,O
000,O
women,O
years,O
among,O
the,O
women,O
on,O
CPA,I-Entity
/,O
EE,I-Entity
.,O
CONCLUSION,O
:,O
Our,O
results,O
suggest,O
the,O
absolute,O
risk,O
of,O
VTE,I-Entity
among,O
Danish,O
women,O
on,O
COCs,I-Entity
is,O
similar,O
to,O
that,O
among,O
women,O
taking,O
CPA,I-Entity
/,O
EE,I-Entity
.,O
Effect,O
of,O
lindane,I-Entity
on,O
hepatic,O
and,O
brain,O
cytochrome,O
P450s,O
and,O
influence,O
of,O
P450,O
modulation,O
in,O
lindane,I-Entity
induced,O
neurotoxicity,I-Entity
.,O
Oral,O
administration,O
of,O
lindane,I-Entity
(,O
2.5,O
",",O
5,O
",",O
10,O
and,O
15,O
mg,O
/,O
kg,O
",",O
body,O
weight,O
),O
for,O
5,O
days,O
was,O
found,O
to,O
produce,O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
activity,O
of,O
P450,O
dependent,O
7-ethoxyresorufin,O
-,O
O,O
-,O
deethylase,O
(,O
EROD,O
),O
",",O
7-pentoxyresorufin,O
-,O
O,O
-,O
dealkylase,O
(,O
PROD,O
),O
and,O
N,B-Entity
-,I-Entity
nitrosodimethylamine,I-Entity
demethylase,O
(,O
NDMA,I-Entity
-,O
d,O
),O
in,O
rat,O
brain,O
and,O
liver,O
.,O
brain,O
P450,O
monooxygenases,O
was,O
also,O
observed,O
when,O
the,O
duration,O
of,O
exposure,O
of,O
low,O
dose,O
(,O
2.5,O
mg,O
/,O
kg,O
),O
of,O
lindane,I-Entity
was,O
increased,O
from,O
5,O
days,O
to,O
15,O
or,O
21,O
days,O
.,O
In,O
vitro,O
studies,O
using,O
organic,O
inhibitors,O
specific,O
for,O
individual,O
P450,O
isoenzymes,O
and,O
antibody,O
inhibition,O
experiments,O
have,O
further,O
demonstrated,O
that,O
the,O
increase,O
in,O
the,O
activity,O
of,O
PROD,O
",",O
EROD,O
and,O
NDMA,I-Entity
-,O
d,O
are,O
due,O
to,O
the,O
increase,O
in,O
the,O
levels,O
of,O
P450,O
2B1/2B2,O
",",O
1A1/1A2,O
and,O
2E1,O
isoenzymes,O
",",O
respectively,O
.,O
Induction,O
studies,O
have,O
further,O
shown,O
that,O
while,O
pretreatment,O
of,O
3-methylcholanthrene,I-Entity
(,O
MC,I-Entity
),O
",",O
an,O
inducer,O
of,O
P4501A1/1A2,O
",",O
did,O
not,O
produce,O
any,O
significant,O
effect,O
in,O
the,O
incidence,O
of,O
lindane,I-Entity
induced,O
convulsions,I-Entity
",",O
pretreatment,O
with,O
phenobarbital,I-Entity
(,O
PB,O
),O
",",O
an,O
inducer,O
of,O
P450,O
2B1/2B2,O
or,O
ethanol,I-Entity
",",O
an,O
inducer,O
of,O
P450,O
2E1,O
catalysed,O
reactions,O
",",O
significantly,O
increased,O
the,O
incidence,O
of,O
lindane,I-Entity
induced,O
convulsions,I-Entity
.,O
Similarly,O
",",O
when,O
the,O
P450-mediated,O
metabolism,O
of,O
lindane,I-Entity
was,O
blocked,O
by,O
cobalt,B-Entity
chloride,I-Entity
incidence,O
of,O
convulsions,I-Entity
was,O
increased,O
in,O
animals,O
treated,O
with,O
lindane,I-Entity
indicating,O
that,O
lindane,I-Entity
per,O
se,O
or,O
its,O
metabolites,O
formed,O
by,O
PB,O
or,O
ethanol,I-Entity
inducible,O
P450,O
isoenzymes,O
are,O
involved,O
in,O
its,O
neurobehavioral,O
toxicity,I-Entity
.,O
Seizure,I-Entity
associated,O
with,O
sleep,B-Entity
deprivation,I-Entity
and,O
sustained,O
-,O
release,O
bupropion,I-Entity
.,O
This,O
case,O
report,O
describes,O
a,O
generalized,O
seizure,I-Entity
associated,O
with,O
sustained,O
-,O
release,O
bupropion,I-Entity
use,O
and,O
sleep,B-Entity
deprivation,I-Entity
.,O
The,O
subject,O
",",O
a,O
31-year,O
-,O
old,O
female,O
smoker,O
",",O
was,O
participating,O
in,O
a,O
clinical,O
trial,O
evaluating,O
an,O
investigational,O
medication,O
for,O
smoking,O
cessation,O
that,O
used,O
sustained,O
-,O
release,O
bupropion,I-Entity
as,O
an,O
active,O
control,O
.,O
After,O
5,O
weeks,O
of,O
bupropion,I-Entity
use,O
",",O
the,O
subject,O
experienced,O
a,O
generalized,O
tonic,O
clonic,O
seizure,I-Entity
after,O
staying,O
up,O
nearly,O
all,O
night,O
packing,O
and,O
moving,O
to,O
a,O
new,O
residence,O
.,O
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
seizures,I-Entity
.,O
We,O
suggest,O
that,O
sleep,B-Entity
deprivation,I-Entity
may,O
add,O
to,O
the,O
risk,O
of,O
bupropion,I-Entity
-,O
associated,O
seizures,I-Entity
.,O
Nephrotoxic,I-Entity
effects,O
in,O
high,O
-,O
risk,O
patients,O
undergoing,O
angiography,O
.,O
:,O
The,O
use,O
of,O
iodinated,O
contrast,O
medium,O
can,O
result,O
in,O
nephropathy,I-Entity
.,O
Whether,O
iso,O
-,O
osmolar,O
contrast,O
medium,O
is,O
less,O
nephrotoxic,I-Entity
than,O
low,O
-,O
osmolar,O
contrast,O
medium,O
in,O
high,O
-,O
risk,O
patients,O
is,O
uncertain,O
.,O
METHODS,O
:,O
We,O
conducted,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
",",O
prospective,O
",",O
multicenter,O
study,O
comparing,O
the,O
nephrotoxic,I-Entity
effects,O
of,O
an,O
iso,O
-,O
osmolar,O
",",O
dimeric,O
",",O
nonionic,O
contrast,O
medium,O
",",O
iodixanol,I-Entity
",",O
with,O
those,O
of,O
a,O
low,O
-,O
osmolar,O
",",O
nonionic,O
",",O
monomeric,O
contrast,O
medium,O
",",O
iohexol,I-Entity
.,O
The,O
study,O
involved,O
129,O
patients,O
with,O
diabetes,I-Entity
with,O
serum,O
creatinine,I-Entity
concentrations,O
of,O
1.5,O
to,O
3.5,O
mg,O
per,O
deciliter,O
who,O
underwent,O
coronary,O
or,O
aortofemoral,O
angiography,O
.,O
The,O
primary,O
end,O
point,O
was,O
the,O
peak,O
increase,O
from,O
base,O
line,O
in,O
the,O
creatinine,I-Entity
concentration,O
during,O
the,O
three,O
days,O
after,O
angiography,O
.,O
Other,O
end,O
points,O
were,O
an,O
increase,O
in,O
the,O
creatinine,I-Entity
concentration,O
of,O
0.5,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
an,O
increase,O
of,O
1.0,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
and,O
a,O
change,O
in,O
the,O
creatinine,I-Entity
concentration,O
from,O
day,O
0,O
to,O
day,O
7,O
.,O
The,O
creatinine,I-Entity
concentration,O
increased,O
significantly,O
less,O
in,O
patients,O
who,O
received,O
iodixanol,I-Entity
.,O
From,O
day,O
0,O
to,O
day,O
3,O
",",O
the,O
mean,O
peak,O
increase,O
in,O
creatinine,I-Entity
was,O
0.13,O
mg,O
per,O
deciliter,O
in,O
the,O
iodixanol,I-Entity
group,O
and,O
0.55,O
mg,O
per,O
deciliter,O
in,O
the,O
iohexol,I-Entity
group,O
(,O
P=0.001,O
;,O
the,O
increase,O
with,O
iodixanol,I-Entity
minus,O
the,O
increase,O
with,O
iohexol,I-Entity
",",O
-0.42,O
mg,O
per,O
deciliter,O
[,O
95,O
percent,O
confidence,O
interval,O
",",O
-0.73,O
to,O
-0.22,O
],O
),O
.,O
Two,O
of,O
the,O
64,O
patients,O
in,O
the,O
iodixanol,I-Entity
group,O
(,O
3,O
percent,O
),O
had,O
an,O
increase,O
in,O
the,O
creatinine,I-Entity
concentration,O
of,O
0.5,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
as,O
compared,O
with,O
17,O
of,O
the,O
65,O
patients,O
in,O
the,O
iohexol,I-Entity
group,O
(,O
26,O
percent,O
),O
(,O
P=0.002,O
;,O
odds,O
ratio,O
for,O
such,O
an,O
increase,O
in,O
the,O
iodixanol,I-Entity
group,O
",",O
0.09,O
[,O
95,O
percent,O
confidence,O
interval,O
",",O
0.02,O
to,O
0.41,O
],O
),O
.,O
No,O
patient,O
receiving,O
iodixanol,I-Entity
had,O
an,O
increase,O
of,O
1.0,O
mg,O
per,O
deciliter,O
or,O
more,O
",",O
but,O
10,O
patients,O
in,O
the,O
iohexol,I-Entity
group,O
(,O
15,O
percent,O
),O
did,O
.,O
The,O
mean,O
change,O
in,O
the,O
creatinine,I-Entity
concentration,O
from,O
day,O
0,O
to,O
day,O
7,O
was,O
0.07,O
mg,O
per,O
deciliter,O
in,O
the,O
iodixanol,I-Entity
group,O
and,O
0.24,O
mg,O
per,O
deciliter,O
in,O
the,O
iohexol,I-Entity
group,O
(,O
P=0.003,O
;,O
value,O
in,O
the,O
iodixanol,I-Entity
group,O
minus,O
the,O
value,O
in,O
the,O
iohexol,I-Entity
group,O
",",O
-0.17,O
mg,O
per,O
deciliter,O
[,O
95,O
percent,O
confidence,O
interval,O
",",O
-0.34,O
to,O
-0.07,O
],O
),O
.,O
Nephropathy,I-Entity
induced,O
by,O
contrast,O
medium,O
may,O
be,O
less,O
likely,O
to,O
develop,O
in,O
high,O
-,O
risk,O
patients,O
when,O
iodixanol,I-Entity
is,O
used,O
rather,O
than,O
a,O
low,O
-,O
osmolar,O
",",O
nonionic,O
contrast,O
medium,O
.,O
Experimental,O
cranial,O
pain,I-Entity
elicited,O
by,O
capsaicin,I-Entity
:,O
a,O
PET,O
study,O
.,O
Using,O
a,O
positron,O
emission,O
tomography,O
(,O
PET,O
),O
study,O
it,O
was,O
shown,O
recently,O
that,O
in,O
migraine,I-Entity
without,O
aura,O
certain,O
areas,O
in,O
the,O
brain,O
stem,O
were,O
activated,O
during,O
the,O
headache,I-Entity
state,O
",",O
but,O
not,O
in,O
the,O
headache,I-Entity
free,O
interval,O
.,O
It,O
was,O
suggested,O
that,O
this,O
brain,O
stem,O
activation,O
is,O
inherent,O
to,O
the,O
migraine,I-Entity
attack,O
itself,O
and,O
represents,O
the,O
so,O
called,O
',O
migraine,I-Entity
generator,O
',O
.,O
To,O
test,O
this,O
hypothesis,O
we,O
performed,O
an,O
experimental,O
pain,I-Entity
study,O
in,O
seven,O
healthy,O
volunteers,O
",",O
using,O
the,O
same,O
positioning,O
in,O
the,O
PET,O
scanner,O
as,O
in,O
the,O
migraine,I-Entity
patients,O
.,O
A,O
small,O
amount,O
of,O
capsaicin,I-Entity
was,O
administered,O
subcutaneously,O
in,O
the,O
right,O
forehead,O
to,O
evoke,O
a,O
burning,O
painful,I-Entity
sensation,O
in,O
the,O
first,O
division,O
of,O
the,O
trigeminal,O
nerve,O
.,O
Using,O
the,O
same,O
stereotactic,O
space,O
limits,O
as,O
in,O
the,O
above,O
mentioned,O
migraine,I-Entity
study,O
no,O
brain,O
stem,O
activation,O
was,O
found,O
in,O
the,O
acute,O
pain,I-Entity
state,O
compared,O
to,O
the,O
pain,I-Entity
free,O
state,O
.,O
The,O
increase,O
of,O
activation,O
in,O
the,O
region,O
of,O
the,O
cavernous,O
sinus,O
however,O
",",O
suggests,O
that,O
this,O
structure,O
is,O
more,O
likely,O
to,O
be,O
involved,O
in,O
trigeminal,O
transmitted,O
pain,I-Entity
as,O
such,O
",",O
rather,O
than,O
in,O
a,O
specific,O
type,O
of,O
headache,I-Entity
as,O
was,O
suggested,O
for,O
cluster,B-Entity
headache,I-Entity
.,O
Neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
with,O
risperidone,I-Entity
.,O
Neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
is,O
thought,O
to,O
be,O
a,O
result,O
of,O
dopamine,I-Entity
D2,O
receptor,O
blockade,O
in,O
the,O
striatum,O
of,O
the,O
basal,O
ganglia,O
.,O
Risperidone,I-Entity
",",O
a,O
benzisoxazole,I-Entity
derivative,O
antipsychotic,O
",",O
has,O
high,O
serotonin,I-Entity
5-HT2,O
receptor,O
blockade,O
and,O
dose,O
-,O
related,O
D2,O
receptor,O
blockade,O
.,O
The,O
high,O
ratio,O
is,O
believed,O
to,O
impart,O
the,O
low,O
frequency,O
of,O
extrapyramidal,B-Entity
symptoms,I-Entity
with,O
risperidone,I-Entity
at,O
low,O
dosages,O
.,O
With,O
this,O
low,O
frequency,O
of,O
extrapyramidal,B-Entity
symptoms,I-Entity
",",O
it,O
was,O
thought,O
the,O
frequency,O
of,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
might,O
also,O
be,O
lowered,O
.,O
A,O
73-year,O
-,O
old,O
woman,O
developed,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
after,O
monotherapy,O
with,O
risperidone,I-Entity
.,O
The,O
syndrome,O
reversed,O
after,O
discontinuing,O
risperidone,I-Entity
and,O
starting,O
treatment,O
with,O
dantrolene,I-Entity
and,O
bromocriptine,I-Entity
.,O
It,O
appears,O
that,O
the,O
protection,O
from,O
extrapyramidal,O
side,O
effects,O
observed,O
with,O
risperidone,I-Entity
does,O
not,O
ensure,O
protection,O
from,O
neuroleptic,B-Entity
malignant,I-Entity
syndrome,I-Entity
.,O
Hepatic,O
and,O
extrahepatic,O
angiotensinogen,O
gene,O
expression,O
in,O
rats,O
with,O
acute,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
Plasma,O
concentration,O
and,O
urine,O
excretion,O
of,O
the,O
renin,O
-,O
angiotensin,I-Entity
system,O
proteins,O
are,O
altered,O
in,O
rats,O
with,O
nephrotic,B-Entity
syndrome,I-Entity
(,O
NS,I-Entity
),O
.,O
In,O
this,O
work,O
the,O
messenger,O
ribonucleic,O
acid,O
(,O
mRNA,O
),O
levels,O
of,O
angiotensinogen,O
(,O
Ao,O
),O
were,O
analyzed,O
with,O
the,O
slot,O
-,O
blot,O
hybridization,O
technique,O
in,O
liver,O
and,O
other,O
extrahepatic,O
tissues,O
:,O
kidney,O
",",O
heart,O
",",O
brain,O
",",O
and,O
adrenal,O
gland,O
from,O
control,O
",",O
nephrotic,I-Entity
",",O
and,O
pair,O
-,O
fed,O
(,O
PF,O
),O
rats,O
.,O
NS,I-Entity
was,O
induced,O
by,O
a,O
single,O
injection,O
of,O
puromycin,B-Entity
amino,I-Entity
-,I-Entity
nucleoside,I-Entity
(,O
PAN,I-Entity
),O
.,O
Although,O
a,O
great,O
urinary,O
excretion,O
and,O
half,O
-,O
normal,O
plasma,O
levels,O
of,O
Ao,O
were,O
observed,O
on,O
day,O
6,O
after,O
PAN,I-Entity
injection,O
",",O
when,O
NS,I-Entity
was,O
clearly,O
established,O
",",O
hepatic,O
Ao,O
mRNA,O
levels,O
did,O
not,O
change,O
.,O
Furthermore,O
",",O
the,O
Ao,O
mRNA,O
levels,O
did,O
not,O
change,O
in,O
any,O
of,O
the,O
extrahepatic,O
tissues,O
studied,O
on,O
day,O
6,O
",",O
nor,O
did,O
its,O
hepatic,O
levels,O
at,O
days,O
1,O
",",O
3,O
",",O
5,O
",",O
or,O
7,O
after,O
PAN,I-Entity
injection,O
.,O
These,O
data,O
suggest,O
that,O
the,O
hepatic,O
and,O
extrahepatic,O
Ao,O
mRNA,O
levels,O
are,O
unaltered,O
during,O
the,O
development,O
of,O
the,O
acute,O
NS,I-Entity
induced,O
by,O
PAN,I-Entity
.,O
Cyclophosphamide,I-Entity
associated,O
bladder,B-Entity
cancer,I-Entity
--,O
a,O
highly,O
aggressive,O
disease,O
:,O
analysis,O
of,O
12,O
cases,O
.,O
We,O
gained,O
knowledge,O
of,O
the,O
etiology,O
",",O
treatment,O
and,O
prevention,O
of,O
cyclophosphamide,I-Entity
associated,O
urothelial,B-Entity
cancer,I-Entity
.,O
The,O
medical,O
records,O
of,O
6,O
men,O
and,O
6,O
women,O
(,O
mean,O
age,O
55,O
years,O
),O
with,O
cyclophosphamide,I-Entity
associated,O
bladder,B-Entity
cancer,I-Entity
were,O
reviewed,O
.,O
RESULTS,O
:,O
All,O
tumors,I-Entity
were,O
grade,O
3,O
or,O
4,O
transitional,O
cell,O
carcinoma,I-Entity
.,O
The,O
remaining,O
patient,O
with,O
extensive,O
cancer,I-Entity
underwent,O
partial,O
cystectomy,O
for,O
palliation,O
and,O
died,O
3,O
months,O
later,O
.,O
Cyclophosphamide,I-Entity
associated,O
bladder,B-Entity
tumor,I-Entity
is,O
an,O
aggressive,O
disease,O
.,O
However,O
",",O
long,O
-,O
term,O
survival,O
is,O
possible,O
when,O
radical,O
cystectomy,O
is,O
performed,O
for,O
bladder,B-Entity
tumors,I-Entity
with,O
any,O
sign,O
of,O
invasion,O
and,O
for,O
recurrent,O
high,O
grade,O
disease,O
",",O
even,O
when,O
noninvasive,O
.,O
Leg,B-Entity
and,I-Entity
back,I-Entity
pain,I-Entity
after,O
spinal,O
anaesthesia,O
involving,O
hyperbaric,O
5%,O
lignocaine,I-Entity
.,O
Fifty,O
-,O
four,O
patients,O
",",O
aged,O
27,O
-,O
90,O
years,O
",",O
who,O
were,O
given,O
lignocaine,I-Entity
5%,O
in,O
6.8%,O
glucose,I-Entity
solution,O
for,O
spinal,O
anaesthesia,O
were,O
studied,O
.,O
Thirteen,O
of,O
these,O
patients,O
experienced,O
pain,B-Entity
in,I-Entity
the,I-Entity
legs,I-Entity
and/or,I-Entity
back,I-Entity
after,O
recovery,O
from,O
anaesthesia,O
.,O
The,O
patients,O
affected,O
were,O
younger,O
(,O
p,O
<,O
0.05,O
),O
and,O
the,O
site,O
of,O
the,O
dural,O
puncture,O
was,O
higher,O
(,O
p,O
<,O
0.01,O
),O
than,O
those,O
individuals,O
without,O
pain,I-Entity
.,O
Five,O
of,O
the,O
13,O
patients,O
(,O
38%,O
),O
with,O
pain,I-Entity
and,O
seven,O
of,O
the,O
41,O
patients,O
(,O
17%,O
),O
without,O
pain,I-Entity
admitted,O
to,O
a,O
high,O
alcohol,I-Entity
intake,O
",",O
which,O
might,O
be,O
a,O
contributing,O
factor,O
.,O
Leg,B-Entity
and/or,I-Entity
back,I-Entity
pain,I-Entity
is,O
associated,O
with,O
the,O
intrathecal,O
use,O
of,O
hyperbaric,O
5%,O
lignocaine,I-Entity
.,O
Acute,O
blood,O
pressure,O
elevations,O
with,O
caffeine,I-Entity
in,O
men,O
with,O
borderline,O
systemic,O
hypertension,I-Entity
.,O
Whether,O
the,O
vasoconstrictive,O
actions,O
of,O
caffeine,I-Entity
are,O
enhanced,O
in,O
hypertensive,I-Entity
persons,O
has,O
not,O
been,O
demonstrated,O
.,O
Thus,O
",",O
caffeine,I-Entity
(,O
3.3,O
mg,O
/,O
kg,O
),O
versus,O
placebo,O
was,O
tested,O
in,O
48,O
healthy,O
men,O
(,O
aged,O
20,O
to,O
35,O
years,O
),O
selected,O
after,O
screening,O
on,O
2,O
separate,O
occasions,O
.,O
Borderline,O
hypertensive,I-Entity
men,O
(,O
n,O
=,O
24,O
),O
were,O
selected,O
with,O
screening,O
systolic,O
blood,O
pressure,O
(,O
BP,O
),O
of,O
140,O
to,O
160,O
mm,O
Hg,O
and/or,O
diastolic,O
BP,O
90,O
to,O
99,O
mm,O
Hg,O
.,O
Low,O
-,O
risk,O
controls,O
(,O
n,O
=,O
24,O
),O
reported,O
no,O
parental,O
history,O
of,O
hypertension,I-Entity
and,O
had,O
screening,O
BP,O
<,O
130/85,O
mm,O
Hg,O
.,O
Participants,O
were,O
then,O
tested,O
on,O
2,O
occasions,O
after,O
12-hour,O
abstinence,O
from,O
caffeine,I-Entity
in,O
each,O
of,O
2,O
protocols,O
;,O
this,O
required,O
a,O
total,O
of,O
4,O
laboratory,O
visits,O
.,O
Caffeine,I-Entity
-,O
induced,O
changes,O
in,O
diastolic,O
BP,O
were,O
2,O
to,O
3,O
times,O
larger,O
in,O
borderline,O
subjects,O
than,O
in,O
controls,O
(,O
+,O
8.4,O
vs,O
+,O
3.8,O
mm,O
Hg,O
",",O
p,O
<,O
0.0001,O
),O
",",O
and,O
were,O
attributable,O
to,O
larger,O
changes,O
in,O
impedance,O
-,O
derived,O
measures,O
of,O
systemic,O
vascular,O
resistance,O
(,O
+,O
135,O
vs,O
+,O
45,O
dynes.s.cm-5,O
",",O
p,O
Consequently,O
",",O
whereas,O
all,O
participants,O
exhibited,O
normotensive,O
levels,O
during,O
the,O
resting,O
predrug,O
baseline,O
",",O
33%,O
of,O
borderline,O
subjects,O
achieved,O
hypertensive,I-Entity
BP,O
levels,O
after,O
caffeine,I-Entity
ingestion,O
.,O
Thus,O
",",O
in,O
borderline,O
hypertensive,I-Entity
men,O
",",O
exaggerated,O
responses,O
to,O
caffeine,I-Entity
were,O
:,O
selective,O
for,O
diastolic,O
BP,O
",",O
consistent,O
with,O
greater,O
vasoconstriction,O
",",O
replicated,O
in,O
2,O
protocols,O
",",O
and,O
representative,O
of,O
nearly,O
all,O
borderline,O
hypertensives,I-Entity
.,O
We,O
suspect,O
that,O
the,O
potential,O
for,O
caffeine,I-Entity
to,O
stabilize,O
high,O
resistance,O
states,O
in,O
susceptible,O
persons,O
suggests,O
that,O
its,O
use,O
may,O
facilitate,O
their,O
disease,O
progression,O
",",O
as,O
well,O
as,O
hinder,O
accurate,O
diagnosis,O
and,O
treatment,O
.,O
Hallucinations,I-Entity
and,O
ifosfamide,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
.,O
Hallucinations,I-Entity
as,O
a,O
symptom,O
of,O
central,O
neurotoxicity,I-Entity
are,O
a,O
known,O
but,O
poorly,O
described,O
side,O
effect,O
of,O
ifosfamide,I-Entity
.,O
Most,O
cases,O
of,O
ifosfamide,I-Entity
-,O
induced,O
hallucinations,I-Entity
have,O
been,O
reported,O
with,O
other,O
mental,O
status,O
changes,O
.,O
:,O
The,O
authors,O
interviewed,O
six,O
persons,O
with,O
ifosfamide,I-Entity
-,O
induced,O
hallucinations,I-Entity
in,O
the,O
presence,O
of,O
a,O
clear,O
sensorium,O
.,O
All,O
patients,O
were,O
receiving,O
high,O
-,O
dose,O
ifosfamide,I-Entity
as,O
part,O
of,O
their,O
bone,O
marrow,O
transplant,O
procedure,O
.,O
Hallucinations,I-Entity
occurred,O
only,O
when,O
the,O
patient,O
's,O
eyes,O
were,O
closed,O
and,O
",",O
in,O
all,O
but,O
one,O
case,O
",",O
were,O
reported,O
as,O
disturbing,O
or,O
frightening,O
.,O
Underreporting,O
of,O
these,O
hallucinations,I-Entity
by,O
patients,O
is,O
likely,O
.,O
Hallucinations,I-Entity
may,O
be,O
the,O
sole,O
or,O
first,O
manifestation,O
of,O
neurotoxicity,I-Entity
.,O
The,O
clinician,O
should,O
be,O
alerted,O
for,O
possible,O
ifosfamide,I-Entity
-,O
induced,O
hallucinations,I-Entity
",",O
which,O
may,O
occur,O
without,O
other,O
signs,O
of,O
neurotoxicity,I-Entity
.,O
"""",O
Eyes,O
-,O
closed,O
"""",O
hallucinatory,I-Entity
experiences,O
appear,O
to,O
be,O
an,O
unusual,O
feature,O
of,O
this,O
presentation,O
.,O
If,O
agitation,I-Entity
becomes,O
marked,O
",",O
high,O
-,O
potency,O
neuroleptics,O
(,O
i.e.,O
",",O
haloperidol,I-Entity
),O
may,O
be,O
effective,O
.,O
Chlorpropamide,I-Entity
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
.,O
A,O
65-year,O
-,O
old,O
woman,O
with,O
adult,B-Entity
-,I-Entity
onset,I-Entity
diabetes,I-Entity
treated,O
with,O
chlorpropamide,I-Entity
(,O
Diabenese,I-Entity
),O
had,O
a,O
toxic,B-Entity
optic,I-Entity
neuropathy,I-Entity
that,O
resolved,O
with,O
discontinuation,O
of,O
chlorpropamide,I-Entity
therapy,O
.,O
Visual,B-Entity
loss,I-Entity
occurs,O
in,O
diabetics,I-Entity
for,O
a,O
variety,O
of,O
reasons,O
",",O
and,O
accurate,O
diagnosis,O
is,O
necessary,O
to,O
institute,O
appropriate,O
therapy,O
.,O
The,O
possibility,O
of,O
a,O
drug,O
-,O
induced,O
optic,B-Entity
neuropathy,I-Entity
should,O
be,O
considered,O
in,O
the,O
differential,O
diagnosis,O
of,O
visual,B-Entity
loss,I-Entity
in,O
diabetics,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
and,O
thalamotomy,O
.,O
Levodopa,I-Entity
-,O
induced,O
dyskinesia,I-Entity
of,O
the,O
limbs,O
in,O
thirteen,O
cases,O
of,O
Parkinsonism,I-Entity
",",O
which,O
was,O
choreic,O
",",O
ballistic,O
or,O
dystonic,I-Entity
in,O
type,O
",",O
was,O
alleviated,O
almost,O
completely,O
by,O
stereotaxic,O
surgery,O
using,O
a,O
microelectrode,O
technique,O
for,O
the,O
ventralis,O
oralis,O
anterior,O
and,O
posterior,O
nuclei,O
of,O
the,O
thalamus,O
",",O
but,O
much,O
less,O
by,O
the,O
ventralis,O
intermedius,O
nucleus,O
.,O
Control,O
of,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
by,O
thalamic,B-Entity
lesions,I-Entity
in,O
the,O
course,O
of,O
routine,O
treatment,O
of,O
Parkinsonism,I-Entity
is,O
discussed,O
.,O
Factors,O
associated,O
with,O
nephrotoxicity,I-Entity
and,O
clinical,O
outcome,O
in,O
patients,O
receiving,O
amikacin,I-Entity
.,O
Data,O
from,O
60,O
patients,O
treated,O
with,O
amikacin,I-Entity
were,O
analyzed,O
for,O
factors,O
associated,O
with,O
nephrotoxicity,I-Entity
.,O
Variables,O
evaluated,O
included,O
patient,O
weight,O
",",O
age,O
",",O
sex,O
",",O
serum,O
creatinine,I-Entity
level,O
",",O
creatinine,I-Entity
clearance,O
",",O
duration,O
of,O
therapy,O
",",O
total,O
dose,O
",",O
mean,O
daily,O
dose,O
",",O
organism,O
minimum,O
inhibitory,O
concentration,O
(,O
MIC,O
),O
",",O
mean,O
peak,O
levels,O
",",O
mean,O
trough,O
levels,O
",",O
When,O
the,O
parameters,O
were,O
examined,O
individually,O
",",O
duration,O
of,O
therapy,O
and,O
total,O
AUC,O
correlated,O
significantly,O
(,O
P,O
less,O
than,O
.05,O
),O
with,O
nephrotoxicity,I-Entity
.,O
Based,O
on,O
this,O
model,O
and,O
on,O
Bayes,O
',O
theorem,O
",",O
the,O
predictive,O
accuracy,O
of,O
identifying,O
"""",O
nephrotoxic,I-Entity
"""",O
patients,O
increased,O
from,O
0.17,O
to,O
0.39,O
.,O
In,O
group,O
I,O
",",O
cyclosporine,I-Entity
was,O
given,O
before,O
the,O
procedure,O
at,O
a,O
loading,O
dose,O
of,O
17.5,O
mg,O
/,O
kg,O
and,O
then,O
continued,O
after,O
the,O
procedure,O
to,O
keep,O
a,O
whole,O
blood,O
level,O
about,O
1000,O
ng,O
/,O
ml,O
.,O
In,O
group,O
II,O
",",O
cyclosporine,I-Entity
was,O
started,O
only,O
after,O
the,O
procedure,O
at,O
a,O
lower,O
dosage,O
and,O
was,O
complemented,O
by,O
azathioprine,I-Entity
",",O
which,O
was,O
used,O
for,O
the,O
first,O
postoperative,O
week,O
.,O
Group,O
II,O
showed,O
a,O
better,O
perioperative,O
renal,O
function,O
as,O
determined,O
by,O
serum,O
blood,O
urea,B-Entity
nitrogen,I-Entity
and,O
serum,O
creatinine,I-Entity
levels,O
.,O
Group,O
II,O
also,O
showed,O
a,O
significant,O
decrease,O
of,O
chronic,O
nephrotoxicity,I-Entity
secondary,O
to,O
long,O
-,O
term,O
therapy,O
with,O
cyclosporine,I-Entity
.,O
Despite,O
this,O
improvement,O
in,O
late,O
renal,O
function,O
",",O
group,O
II,O
still,O
shows,O
a,O
slow,O
rise,O
in,O
serum,O
creatinine,I-Entity
.,O
We,O
think,O
that,O
even,O
these,O
lower,O
dosages,O
of,O
cyclosporine,I-Entity
can,O
cause,O
chronic,O
nephrotoxicity,I-Entity
and,O
that,O
further,O
modification,O
of,O
the,O
immunosuppressive,O
regimen,O
is,O
required,O
to,O
completely,O
abolish,O
this,O
toxic,O
side,O
effect,O
.,O
Reversible,O
cholestasis,I-Entity
with,O
bile,B-Entity
duct,I-Entity
injury,I-Entity
following,O
azathioprine,I-Entity
therapy,O
.,O
A,O
67-year,O
-,O
old,O
patient,O
",",O
with,O
primary,O
polymyositis,I-Entity
and,O
without,O
previous,O
evidence,O
of,O
liver,B-Entity
disease,I-Entity
",",O
developed,O
clinical,O
and,O
biochemical,O
features,O
of,O
severe,O
cholestasis,I-Entity
3,O
months,O
after,O
initiation,O
of,O
azathioprine,I-Entity
therapy,O
.,O
Liver,O
biopsy,O
showed,O
cholestasis,I-Entity
with,O
both,O
cytological,O
and,O
architectural,O
alterations,O
of,O
interlobular,O
bile,O
ducts,O
.,O
Azathioprine,I-Entity
withdrawal,O
resulted,O
after,O
7,O
weeks,O
in,O
the,O
resolution,O
of,O
clinical,O
and,O
biochemical,O
abnormalities,O
.,O
It,O
is,O
believed,O
that,O
this,O
is,O
the,O
first,O
reported,O
case,O
of,O
reversible,O
azathioprine,I-Entity
-,O
induced,O
cholestasis,I-Entity
associated,O
with,O
histological,O
evidence,O
of,O
bile,B-Entity
duct,I-Entity
injury,I-Entity
.,O
Renal,O
function,O
and,O
hemodynamics,O
during,O
prolonged,O
isoflurane,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
humans,O
.,O
The,O
effect,O
of,O
isoflurane,I-Entity
-,O
induced,O
hypotension,I-Entity
on,O
glomerular,O
function,O
and,O
renal,O
blood,O
flow,O
was,O
investigated,O
in,O
20,O
human,O
subjects,O
.,O
Glomerular,O
filtration,O
rate,O
(,O
GFR,O
),O
and,O
effective,O
renal,O
plasma,O
flow,O
(,O
ERPF,O
),O
were,O
measured,O
by,O
inulin,O
and,O
para,B-Entity
-,I-Entity
aminohippurate,I-Entity
(,O
PAH,I-Entity
),O
clearance,O
",",O
respectively,O
.,O
Anesthesia,O
was,O
maintained,O
with,O
fentanyl,I-Entity
",",O
nitrous,B-Entity
oxide,I-Entity
",",O
oxygen,I-Entity
",",O
and,O
isoflurane,I-Entity
.,O
Hypotension,I-Entity
was,O
induced,O
for,O
236.9,O
+,O
/-,O
15.1,O
min,O
by,O
increasing,O
the,O
isoflurane,I-Entity
inspired,O
concentration,O
to,O
maintain,O
a,O
mean,O
arterial,O
pressure,O
of,O
59.8,O
+,O
/-,O
GFR,O
and,O
ERPF,O
decreased,O
with,O
the,O
induction,O
of,O
anesthesia,O
but,O
not,O
significantly,O
more,O
during,O
hypotension,I-Entity
.,O
Renal,O
vascular,O
resistance,O
increased,O
during,O
anesthesia,O
but,O
decreased,O
when,O
hypotension,I-Entity
was,O
induced,O
",",O
allowing,O
the,O
maintenance,O
of,O
renal,O
blood,O
flow,O
.,O
We,O
conclude,O
that,O
renal,O
compensatory,O
mechanisms,O
are,O
preserved,O
during,O
isoflurane,I-Entity
-,O
induced,O
hypotension,I-Entity
and,O
that,O
renal,O
function,O
and,O
hemodynamics,O
quickly,O
return,O
to,O
normal,O
when,O
normotension,O
is,O
resumed,O
.,O
Debrisoquine,I-Entity
phenotype,O
and,O
the,O
pharmacokinetics,O
and,O
beta-2,O
receptor,O
pharmacodynamics,O
of,O
metoprolol,I-Entity
and,O
its,O
enantiomers,O
.,O
The,O
metabolism,O
of,O
the,O
cardioselective,O
beta,O
-,O
blocker,O
metoprolol,I-Entity
is,O
under,O
genetic,O
control,O
of,O
the,O
debrisoquine,I-Entity
/,O
sparteine,I-Entity
type,O
.,O
The,O
two,O
metabolic,O
phenotypes,O
",",O
extensive,O
(,O
EM,O
),O
and,O
poor,O
metabolizers,O
(,O
PM,O
),O
",",O
show,O
different,O
stereoselective,O
metabolism,O
",",O
resulting,O
in,O
apparently,O
higher,O
beta-1,O
adrenoceptor,O
antagonistic,O
potency,O
of,O
racemic,O
metoprolol,I-Entity
in,O
EMs,O
.,O
We,O
investigated,O
if,O
the,O
latter,O
also,O
applies,O
to,O
the,O
beta-2,O
adrenoceptor,O
antagonism,O
by,O
metoprolol,I-Entity
.,O
The,O
drug,O
effect,O
studied,O
was,O
the,O
antagonism,O
by,O
metoprolol,I-Entity
of,O
terbutaline,I-Entity
-,O
induced,O
hypokalemia,I-Entity
.,O
By,O
using,O
pharmacokinetic,O
pharmacodynamic,O
modeling,O
the,O
pharmacodynamics,O
of,O
racemic,O
metoprolol,I-Entity
and,O
the,O
active,O
S,O
-,O
isomer,O
",",O
were,O
quantitated,O
in,O
EMs,O
and,O
PMs,O
in,O
terms,O
of,O
IC50,O
values,O
",",O
representing,O
metoprolol,I-Entity
plasma,O
concentrations,O
resulting,O
in,O
half,O
-,O
maximum,O
receptor,O
occupancy,O
.,O
Six,O
EMs,O
received,O
0.5,O
mg,O
of,O
terbutaline,I-Entity
s.c,O
.,O
on,O
two,O
different,O
occasions,O
:,O
1,O
),O
1,O
hr,O
after,O
administration,O
of,O
a,O
placebo,O
and,O
2,O
),O
1,O
hr,O
after,O
150,O
mg,O
of,O
metoprolol,I-Entity
p.o,O
.,O
Five,O
PMs,O
were,O
studied,O
according,O
to,O
the,O
same,O
protocol,O
",",O
except,O
for,O
a,O
higher,O
terbutaline,I-Entity
dose,O
(,O
0.75,O
mg,O
),O
on,O
day,O
2,O
.,O
Blood,O
samples,O
for,O
the,O
analysis,O
of,O
plasma,O
potassium,I-Entity
",",O
terbutaline,I-Entity
",",O
metoprolol,I-Entity
(,O
racemic,O
",",O
R-,O
and,O
S,O
-,O
isomer,O
),O
",",O
and,O
alpha,B-Entity
-,I-Entity
hydroxymetoprolol,I-Entity
concentrations,O
were,O
taken,O
at,O
regular,O
time,O
intervals,O
",",O
during,O
8,O
hr,O
after,O
metoprolol,I-Entity
.,O
In,O
PMs,O
",",O
metoprolol,I-Entity
increased,O
the,O
terbutaline,I-Entity
area,O
under,O
the,O
plasma,O
concentration,O
vs.,O
time,O
curve,O
(,O
+,O
67%,O
),O
.,O
Higher,O
metoprolol,I-Entity
/,O
alpha,B-Entity
-,I-Entity
hydroxymetoprolol,I-Entity
ratios,O
in,O
PMs,O
were,O
predictive,O
for,O
higher,O
R-/S,O
-,O
isomer,O
ratios,O
of,O
unchanged,O
drug,O
.,O
There,O
was,O
a,O
difference,O
in,O
metoprolol,I-Entity
potency,O
with,O
higher,O
racemic,O
metoprolol,I-Entity
IC50,O
values,O
in,O
PMs,O
(,O
72,O
+,O
/-,O
Cefotetan,I-Entity
-,O
induced,O
immune,O
hemolytic,B-Entity
anemia,I-Entity
.,O
Immune,O
hemolytic,B-Entity
anemia,I-Entity
due,O
to,O
a,O
drug,O
-,O
adsorption,O
mechanism,O
has,O
been,O
described,O
primarily,O
in,O
patients,O
receiving,O
penicillins,I-Entity
and,O
first,O
-,O
generation,O
cephalosporins,I-Entity
.,O
We,O
describe,O
a,O
patient,O
who,O
developed,O
anemia,I-Entity
while,O
receiving,O
intravenous,O
cefotetan,I-Entity
.,O
Cefotetan,I-Entity
-,O
dependent,O
antibodies,O
were,O
detected,O
in,O
the,O
patient,O
's,O
serum,O
and,O
in,O
an,O
eluate,O
prepared,O
from,O
his,O
red,O
blood,O
cells,O
.,O
The,O
eluate,O
also,O
reacted,O
weakly,O
with,O
red,O
blood,O
cells,O
in,O
the,O
absence,O
of,O
cefotetan,I-Entity
",",O
suggesting,O
the,O
concomitant,O
formation,O
of,O
warm,O
-,O
reactive,O
autoantibodies,O
.,O
These,O
observations,O
",",O
in,O
conjunction,O
with,O
clinical,O
and,O
laboratory,O
evidence,O
of,O
extravascular,O
hemolysis,I-Entity
",",O
are,O
consistent,O
with,O
drug,O
-,O
induced,O
hemolytic,B-Entity
anemia,I-Entity
",",O
possibly,O
involving,O
both,O
drug,O
-,O
adsorption,O
and,O
autoantibody,O
formation,O
mechanisms,O
.,O
This,O
case,O
emphasizes,O
the,O
need,O
for,O
increased,O
awareness,O
of,O
hemolytic,O
reactions,O
to,O
all,O
cephalosporins,I-Entity
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
subsequent,O
to,O
the,O
administration,O
of,O
rifampicin,I-Entity
.,O
A,O
clinical,O
presentation,O
is,O
made,O
of,O
a,O
2,O
-,O
3,O
year,O
follow,O
-,O
up,O
of,O
six,O
cases,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
that,O
have,O
been,O
reported,O
earlier,O
.,O
The,O
patients,O
had,O
developed,O
transient,O
renal,B-Entity
failure,I-Entity
after,O
the,O
intermittent,O
administration,O
of,O
rifampicin,I-Entity
.,O
The,O
stage,O
of,O
olig,O
-,O
anuria,I-Entity
lasted,O
for,O
1,O
-,O
3,O
weeks,O
",",O
and,O
five,O
of,O
the,O
patients,O
were,O
treated,O
by,O
hemodialysis,O
.,O
Although,O
in,O
the,O
acute,O
stage,O
the,O
renal,B-Entity
lesions,I-Entity
histologically,O
appeared,O
toxic,O
",",O
evidence,O
suggestive,O
of,O
an,O
immunological,O
mechanism,O
can,O
not,O
be,O
excluded,O
.,O
Type,B-Entity
B,I-Entity
hepatitis,I-Entity
after,O
needle,O
-,O
stick,O
exposure,O
:,O
prevention,O
with,O
hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
.,O
Hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
(,O
HBIG,O
),O
and,O
immune,O
serum,O
globulin,O
(,O
ISG,O
),O
were,O
examined,O
in,O
a,O
randomized,O
",",O
double,O
-,O
blind,O
trial,O
to,O
assess,O
their,O
relative,O
efficacies,O
in,O
preventing,O
type,B-Entity
B,I-Entity
hepatitis,I-Entity
after,O
needle,O
-,O
stick,O
exposure,O
to,O
hepatitis,B-Entity
B,I-Entity
surface,I-Entity
antigen,I-Entity
(,O
HBsAG)-positive,I-Entity
donors,O
.,O
Clinical,O
hepatitis,I-Entity
developed,O
in,O
1.4%,O
of,O
HBIG,O
and,O
in,O
5.9%,O
of,O
ISG,O
recipients,O
(,O
Available,O
donor,O
sera,O
were,O
examined,O
for,O
DNA,O
polymerase,O
(,O
DNAP,O
),O
and,O
e,O
antigen,O
and,O
antibody,O
(,O
HBeAg,I-Entity
;,O
anti,O
-,O
HBE,O
),O
.,O
Both,O
DNAP,O
and,O
HBeAg,I-Entity
showed,O
a,O
highly,O
statistically,O
significant,O
correlation,O
with,O
the,O
infectivity,O
of,O
HBsAg,I-Entity
-,O
positive,O
donors,O
.,O
Hepatitis,B-Entity
B,I-Entity
immune,O
globulin,O
remained,O
significantly,O
superior,O
to,O
ISG,O
in,O
preventing,O
type,B-Entity
B,I-Entity
hepatitis,I-Entity
even,O
when,O
the,O
analysis,O
was,O
confined,O
to,O
these,O
two,O
high,O
-,O
risk,O
subgroups,O
.,O
The,O
efficacy,O
of,O
ISG,O
in,O
preventing,O
type,B-Entity
B,I-Entity
hepatitis,I-Entity
can,O
not,O
be,O
ascertained,O
because,O
a,O
true,O
placebo,O
group,O
was,O
not,O
included,O
.,O
Serotonin,B-Entity
syndrome,I-Entity
from,O
venlafaxine,I-Entity
-,O
tranylcypromine,I-Entity
interaction,O
.,O
Excessive,O
stimulation,O
of,O
serotonin,I-Entity
5HT1A,O
receptors,O
causes,O
a,O
syndrome,O
of,O
serotonin,I-Entity
excess,O
that,O
consists,O
of,O
shivering,O
",",O
muscle,B-Entity
rigidity,I-Entity
",",O
salivation,I-Entity
",",O
confusion,I-Entity
",",O
agitation,I-Entity
and,O
hyperthermia,I-Entity
.,O
The,O
most,O
common,O
cause,O
of,O
this,O
syndrome,O
is,O
an,O
interaction,O
between,O
a,O
monoamine,O
oxidase,O
inhibitor,O
(,O
MAOI,O
),O
and,O
a,O
specific,O
serotonin,I-Entity
reuptake,O
inhibitor,O
.,O
Venlafaxine,I-Entity
is,O
a,O
new,O
antidepressant,O
agent,O
that,O
inhibits,O
the,O
reuptake,O
of,O
serotonin,I-Entity
and,O
norepinephrine,I-Entity
.,O
We,O
report,O
a,O
venlafaxine,I-Entity
-,O
MAOI,O
interaction,O
that,O
resulted,O
in,O
the,O
serotonin,B-Entity
syndrome,I-Entity
in,O
a,O
23-y,O
-,O
old,O
male,O
who,O
was,O
taking,O
tranylcypromine,I-Entity
for,O
depression,I-Entity
.,O
He,O
had,O
been,O
well,O
until,O
the,O
morning,O
of,O
presentation,O
when,O
he,O
took,O
1/2,O
tab,O
of,O
venlafaxine,I-Entity
.,O
Within,O
2,O
h,O
he,O
became,O
confused,O
with,O
jerking,O
movements,O
of,O
his,O
extremities,O
",",O
tremors,I-Entity
and,O
rigidity,I-Entity
.,O
He,O
was,O
brought,O
directly,O
to,O
a,O
hospital,O
where,O
he,O
was,O
found,O
to,O
be,O
agitated,O
and,O
confused,O
with,O
shivering,O
",",O
myoclonic,B-Entity
jerks,I-Entity
",",O
rigidity,I-Entity
",",O
salivation,I-Entity
and,O
diaphoresis,O
.,O
After,O
180,O
mg,O
of,O
diazepam,I-Entity
i.v,O
.,O
he,O
remained,O
tremulous,O
with,O
muscle,B-Entity
rigidity,I-Entity
and,O
clenched,O
jaws,O
.,O
He,O
was,O
intubated,O
for,O
airway,O
protection,O
and,O
because,O
of,O
hypoventilation,I-Entity
",",O
and,O
was,O
paralyzed,I-Entity
to,O
control,O
muscle,B-Entity
rigidity,I-Entity
.,O
His,O
subsequent,O
course,O
was,O
remarkable,O
for,O
non,O
-,O
immune,O
thrombocytopenia,I-Entity
which,O
resolved,O
.,O
The,O
patient,O
's,O
maximal,O
temperature,O
was,O
101.2,O
F,O
and,O
his,O
CPK,O
remained,O
<,O
500,O
units,O
/,O
L,O
with,O
no,O
other,O
evidence,O
of,O
rhabdomyolysis,I-Entity
.,O
This,O
patient,O
survived,O
without,O
sequelae,O
due,O
to,O
the,O
aggressive,O
sedation,O
and,O
neuromuscular,O
paralysis,I-Entity
.,O
Effect,O
of,O
nondopaminergic,O
drugs,O
on,O
L,B-Entity
-,I-Entity
dopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
in,O
MPTP,I-Entity
-,O
treated,O
monkeys,O
.,O
A,O
group,O
of,O
four,O
monkeys,O
was,O
rendered,O
parkinsonian,I-Entity
with,O
the,O
toxin,O
MPTP,I-Entity
.,O
They,O
were,O
then,O
treated,O
chronically,O
with,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
/,I-Entity
benserazide,I-Entity
50/12.5,O
mg,O
/,O
kg,O
given,O
orally,O
daily,O
for,O
2,O
months,O
.,O
This,O
dose,O
produced,O
a,O
striking,O
antiparkinsonian,O
effect,O
",",O
but,O
all,O
animals,O
manifested,O
dyskinesia,I-Entity
.,O
A,O
series,O
of,O
agents,O
acting,O
primarily,O
on,O
neurotransmitters,O
other,O
than,O
dopamine,I-Entity
were,O
then,O
tested,O
in,O
combination,O
with,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
to,O
see,O
if,O
the,O
dyskinetic,I-Entity
movements,O
would,O
be,O
modified,O
.,O
Several,O
drugs,O
",",O
including,O
clonidine,I-Entity
",",O
physostigmine,I-Entity
",",O
methysergide,I-Entity
",",O
5-MDOT,I-Entity
",",O
propranolol,I-Entity
",",O
and,O
MK-801,I-Entity
",",O
markedly,O
reduced,O
the,O
dyskinetic,I-Entity
movements,O
but,O
at,O
the,O
cost,O
of,O
a,O
return,O
of,O
parkinsonian,I-Entity
symptomatology,O
.,O
However,O
",",O
yohimbine,I-Entity
and,O
meperidine,I-Entity
reduced,O
predominantly,O
the,O
dyskinetic,I-Entity
movements,O
.,O
Baclofen,I-Entity
was,O
also,O
useful,O
in,O
one,O
monkey,O
against,O
a,O
more,O
dystonic,I-Entity
form,O
of,O
dyskinesia,I-Entity
.,O
Atropine,I-Entity
converted,O
the,O
dystonic,I-Entity
movements,O
into,O
chorea,I-Entity
.,O
CCNU,I-Entity
(,O
lomustine,I-Entity
),O
toxicity,I-Entity
in,O
dogs,O
:,O
a,O
retrospective,O
study,O
(,O
2002,O
-,O
07,O
),O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
the,O
incidence,O
of,O
haematological,B-Entity
",",I-Entity
renal,I-Entity
",",I-Entity
hepatic,I-Entity
and,I-Entity
gastrointestinal,I-Entity
toxicities,I-Entity
in,O
tumour,O
-,O
bearing,O
dogs,O
receiving,O
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,I-Entity
(,O
CCNU,I-Entity
),O
.,O
The,O
medical,O
records,O
of,O
206,O
dogs,O
that,O
were,O
treated,O
with,O
CCNU,I-Entity
at,O
the,O
Melbourne,O
Veterinary,O
Specialist,O
Centre,O
between,O
February,O
2002,O
and,O
December,O
2007,O
were,O
retrospectively,O
evaluated,O
.,O
Of,O
the,O
206,O
dogs,O
treated,O
with,O
CCNU,I-Entity
",",O
185,O
met,O
the,O
inclusion,O
criteria,O
for,O
at,O
least,O
one,O
class,O
of,O
toxicity,I-Entity
.,O
CCNU,I-Entity
was,O
used,O
most,O
commonly,O
in,O
the,O
treatment,O
of,O
lymphoma,I-Entity
",",O
mast,B-Entity
cell,I-Entity
tumour,I-Entity
",",O
brain,B-Entity
tumour,I-Entity
",",O
histiocytic,B-Entity
tumours,I-Entity
and,O
epitheliotropic,B-Entity
lymphoma,I-Entity
.,O
experienced,O
neutropenia,I-Entity
",",O
34.2%,O
experienced,O
anaemia,I-Entity
and,O
14.2%,O
experienced,O
thrombocytopenia,I-Entity
.,O
Gastrointestinal,B-Entity
toxicosis,I-Entity
was,O
detected,O
in,O
37.8%,O
of,O
dogs,O
",",O
the,O
most,O
common,O
sign,O
of,O
which,O
was,O
vomiting,I-Entity
(,O
24.3%,O
),O
.,O
Potential,O
renal,O
toxicity,I-Entity
and,O
elevated,O
alanine,I-Entity
transaminase,O
(,O
ALT,O
),O
The,O
incidence,O
of,O
hepatic,B-Entity
failure,I-Entity
was,O
1.2%,O
.,O
CONCLUSIONS,O
:,O
CCNU,I-Entity
-,O
associated,O
toxicity,I-Entity
in,O
dogs,O
is,O
common,O
",",O
but,O
is,O
usually,O
not,O
life,O
threatening,O
.,O
Neuroactive,O
steroids,I-Entity
protect,O
against,O
pilocarpine-,I-Entity
and,O
kainic,B-Entity
acid,I-Entity
-,O
induced,O
limbic,O
seizures,I-Entity
and,O
status,B-Entity
epilepticus,I-Entity
in,O
mice,O
.,O
Several,O
structurally,O
related,O
metabolites,O
of,O
progesterone,I-Entity
(,O
3,B-Entity
alpha,I-Entity
-,I-Entity
hydroxy,I-Entity
pregnane-20-ones,I-Entity
),O
and,O
deoxycorticosterone,I-Entity
(,O
3,B-Entity
alpha,I-Entity
-,I-Entity
hydroxy,I-Entity
pregnane-21-diol-20-ones,I-Entity
),O
and,O
their,O
3,O
beta,O
-,O
epimers,O
were,O
evaluated,O
for,O
protective,O
activity,O
against,O
pilocarpine-,I-Entity
",",O
kainic,B-Entity
acid-,I-Entity
and,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA)-induced,I-Entity
seizures,I-Entity
in,O
mice,O
.,O
Steroids,I-Entity
with,O
the,O
3-hydroxy,O
group,O
in,O
the,O
alpha,O
-,O
position,O
and,O
5-H,O
in,O
the,O
alpha-,O
or,O
beta,O
-,O
configurations,O
were,O
highly,O
effective,O
in,O
protecting,O
against,O
pilocarpine,I-Entity
(,O
416,O
mg,O
/,O
kg,O
",",O
s.c.)-induced,O
limbic,O
motor,O
seizures,I-Entity
and,O
status,B-Entity
epilepticus,I-Entity
(,O
ED50,O
values,O
",",O
7.0,O
-,O
18.7,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
Although,O
the,O
neuroactive,O
steroids,I-Entity
were,O
considerably,O
less,O
potent,O
than,O
the,O
benzodiazepine,I-Entity
clonazepam,I-Entity
in,O
protecting,O
against,O
pilocarpine,I-Entity
seizures,I-Entity
",",O
steroids,I-Entity
with,O
the,O
5,O
"alpha,3",O
alpha,O
-,O
configuration,O
had,O
comparable,O
or,O
higher,O
protective,O
index,O
values,O
(,O
TD50,O
for,O
motor,O
impairment,O
divided,O
by,O
ED50,O
for,O
seizure,I-Entity
protection,O
),O
than,O
clonazepam,I-Entity
",",O
indicating,O
that,O
some,O
neuroactive,O
steroids,I-Entity
may,O
have,O
lower,O
relative,O
toxicity,I-Entity
.,O
Steroids,I-Entity
with,O
the,O
5,O
"alpha,3",O
alpha-,O
or,O
5,O
"beta,3",O
alpha,O
-,O
configurations,O
also,O
produced,O
a,O
dose,O
-,O
dependent,O
delay,O
in,O
the,O
onset,O
of,O
limbic,O
seizures,I-Entity
induced,O
by,O
kainic,B-Entity
acid,I-Entity
(,O
32,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
",",O
but,O
did,O
not,O
completely,O
protect,O
against,O
the,O
seizures,I-Entity
.,O
However,O
",",O
when,O
a,O
second,O
dose,O
of,O
the,O
steroid,I-Entity
was,O
administered,O
1,O
hr,O
after,O
the,O
first,O
dose,O
",",O
complete,O
protection,O
from,O
the,O
kainic,B-Entity
acid,I-Entity
-,O
induced,O
limbic,O
seizures,I-Entity
and,O
status,B-Entity
epilepticus,I-Entity
was,O
obtained,O
.,O
The,O
steroids,I-Entity
also,O
caused,O
a,O
dose,O
-,O
dependent,O
delay,O
in,O
NMDA,I-Entity
(,O
257,O
mg,O
/,O
kg,O
",",O
s.c.)-induced,O
lethality,O
",",O
but,O
did,O
not,O
completely,O
protect,O
against,O
NMDA,I-Entity
seizures,I-Entity
or,O
lethality,O
.,O
We,O
conclude,O
that,O
neuroactive,O
steroids,I-Entity
are,O
highly,O
effective,O
in,O
protecting,O
against,O
pilocarpine-,I-Entity
and,O
kainic,B-Entity
acid,I-Entity
-,O
induced,O
seizures,I-Entity
and,O
status,B-Entity
epilepticus,I-Entity
in,O
mice,O
",",O
and,O
may,O
be,O
of,O
utility,O
in,O
the,O
treatment,O
of,O
some,O
forms,O
of,O
status,B-Entity
epilepticus,I-Entity
in,O
humans,O
.,O
The,O
safety,O
and,O
efficacy,O
of,O
combination,O
N,B-Entity
-,I-Entity
butyl,I-Entity
-,I-Entity
deoxynojirimycin,I-Entity
(,O
SC-48334,I-Entity
),O
and,O
zidovudine,I-Entity
in,O
patients,O
with,O
HIV-1,B-Entity
infection,I-Entity
and,O
200,O
-,O
500,O
CD4,O
cells,O
/,O
mm3,O
.,O
We,O
conducted,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
phase,O
II,O
study,O
to,O
evaluate,O
the,O
safety,O
and,O
activity,O
of,O
combination,O
therapy,O
with,O
N,B-Entity
-,I-Entity
butyl,I-Entity
-,I-Entity
deoxynojirimycin,I-Entity
(,O
SC-48334,I-Entity
),O
(,O
an,O
alpha,O
-,O
glucosidase,O
I,O
inhibitor,O
),O
and,O
zidovudine,I-Entity
versus,O
zidovudine,I-Entity
alone,O
.,O
mm3,O
who,O
tolerated,O
<,O
or,O
=,O
12,O
weeks,O
of,O
prior,O
zidovudine,I-Entity
therapy,O
received,O
SC-48334,I-Entity
(,O
1000,O
mg,O
every,O
8,O
h,O
),O
and,O
zidovudine,I-Entity
(,O
100,O
mg,O
every,O
8,O
h,O
),O
or,O
zidovudine,I-Entity
and,O
placebo,O
.,O
Sixty,O
patients,O
received,O
combination,O
therapy,O
and,O
58,O
",",O
zidovudine,I-Entity
and,O
placebo,O
.,O
Twenty,O
-,O
three,O
patients,O
(,O
38%,O
),O
and,O
15,O
(,O
26%,O
),O
",",O
in,O
the,O
combination,O
and,O
zidovudine,I-Entity
groups,O
",",O
respectively,O
",",O
discontinued,O
therapy,O
(,O
p,O
=,O
0.15,O
),O
.,O
The,O
mean,O
SC-48334,I-Entity
steady,O
-,O
state,O
trough,O
level,O
(,O
4.04,O
+,O
/-,O
0.99,O
micrograms,O
/,O
ml,O
),O
was,O
below,O
the,O
in,O
vitro,O
inhibitory,O
concentration,O
for,O
human,O
immunodeficiency,I-Entity
virus,O
(,O
HIV,O
),O
.,O
/,O
mm3,O
for,O
the,O
combination,O
and,O
zidovudine,I-Entity
groups,O
",",O
respectively,O
(,O
p,O
>,O
0.36,O
),O
.,O
For,O
patients,O
with,O
prior,O
zidovudine,I-Entity
therapy,O
",",O
the,O
mean,O
change,O
in,O
CD4,O
cells,O
in,O
the,O
combination,O
and,O
zidovudine,I-Entity
groups,O
was,O
63.7,O
cells,O
/,O
mm3,O
and,O
4.9,O
cells,O
/,O
mm3,O
at,O
week,O
8,O
and,O
6.8,O
cells,O
/,O
mm3,O
and,O
-45.1,O
cells,O
/,O
mm3,O
at,O
week,O
16,O
",",O
respectively,O
.,O
The,O
number,O
of,O
patients,O
with,O
suppression,O
of,O
HIV,O
p24,O
antigenemia,O
in,O
the,O
combination,O
and,O
zidovudine,I-Entity
groups,O
was,O
six,O
(,O
40%,O
),O
and,O
two,O
(,O
11%,O
),O
at,O
week,O
4,O
(,O
p,O
=,O
0.10,O
),O
and,O
five,O
(,O
45%,O
),O
and,O
two,O
(,O
14%,O
),O
at,O
week,O
24,O
(,O
p,O
=,O
0.08,O
),O
",",O
respectively,O
.,O
Diarrhea,I-Entity
",",O
flatulence,I-Entity
",",O
abdominal,B-Entity
pain,I-Entity
",",O
and,O
weight,B-Entity
loss,I-Entity
were,O
common,O
for,O
combination,O
recipients.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Recent,O
preclinical,O
and,O
clinical,O
studies,O
with,O
the,O
thymidylate,O
synthase,O
inhibitor,O
"N10-propargyl-5,8-dideazafolic",B-Entity
acid,I-Entity
(,O
CB,B-Entity
3717,I-Entity
),O
.,O
CB,B-Entity
3717,I-Entity
",",O
"N10-propargyl-5,8-dideazafolic",B-Entity
acid,I-Entity
",",O
is,O
a,O
tight,O
-,O
binding,O
inhibitor,O
of,O
thymidylate,O
synthase,O
(,O
TS,O
),O
whose,O
cytotoxicity,I-Entity
is,O
mediated,O
solely,O
through,O
the,O
inhibition,O
of,O
this,O
enzyme,O
.,O
Recent,O
preclinical,O
studies,O
have,O
focused,O
on,O
the,O
intracellular,O
formation,O
of,O
CB,B-Entity
3717,I-Entity
polyglutamates,O
.,O
Following,O
a,O
12-hour,O
exposure,O
of,O
L1210,O
cells,O
to,O
50,O
microM,O
[,O
3H]CB,B-Entity
3717,I-Entity
",",O
30%,O
of,O
the,O
extractable,O
radioactivity,O
could,O
be,O
accounted,O
for,O
as,O
CB,B-Entity
3717,I-Entity
tetra-,O
and,O
pentaglutamate,O
",",O
as,O
determined,O
by,O
high,O
-,O
pressure,O
liquid,O
chromatography,O
(,O
HPLC,O
),O
analyses,O
.,O
As,O
inhibitors,O
of,O
isolated,O
L1210,O
TS,O
",",O
CB,O
3717,O
di-,O
",",O
tri-,O
",",O
tetra-,O
and,O
pentaglutamate,O
are,O
26-,O
",",O
87-,O
",",O
119-,O
and,O
114-fold,O
more,O
potent,O
than,O
CB,B-Entity
3717,I-Entity
",",O
respectively,O
",",O
and,O
their,O
formation,O
may,O
",",O
therefore,O
",",O
be,O
an,O
important,O
determinant,O
of,O
CB,B-Entity
3717,I-Entity
cytotoxicity,I-Entity
.,O
In,O
early,O
clinical,O
studies,O
with,O
CB,B-Entity
3717,I-Entity
",",O
activity,O
has,O
been,O
seen,O
in,O
breast,B-Entity
cancer,I-Entity
",",O
ovarian,B-Entity
cancer,I-Entity
",",O
hepatoma,I-Entity
",",O
and,O
mesothelioma,I-Entity
.,O
Toxicities,I-Entity
included,O
hepatotoxicity,I-Entity
",",O
malaise,I-Entity
",",O
and,O
dose,O
-,O
limiting,O
nephrotoxicity,I-Entity
.,O
This,O
latter,O
effect,O
is,O
thought,O
to,O
be,O
due,O
to,O
drug,O
precipitation,O
within,O
the,O
renal,O
tubule,O
as,O
a,O
result,O
of,O
the,O
poor,O
solubility,O
of,O
CB,B-Entity
3717,I-Entity
under,O
acidic,O
conditions,O
.,O
In,O
an,O
attempt,O
to,O
overcome,O
this,O
problem,O
",",O
a,O
clinical,O
trial,O
of,O
CB,B-Entity
3717,I-Entity
administered,O
with,O
alkaline,O
diuresis,O
is,O
under,O
way,O
.,O
Preliminary,O
results,O
at,O
400,O
and,O
500,O
mg,O
/,O
m2,O
suggest,O
that,O
a,O
reduction,O
in,O
nephrotoxicity,I-Entity
may,O
have,O
been,O
achieved,O
with,O
only,O
1,O
instance,O
of,O
renal,B-Entity
toxicity,I-Entity
in,O
10,O
patients,O
.,O
Hepatotoxicity,I-Entity
and,O
malaise,I-Entity
are,O
again,O
the,O
most,O
frequent,O
side,O
effects,O
.,O
Pharmacokinetic,O
investigations,O
have,O
shown,O
that,O
alkaline,O
diuresis,O
does,O
not,O
alter,O
CB,B-Entity
3717,I-Entity
plasma,O
levels,O
or,O
urinary,O
excretion,O
and,O
that,O
satisfactory,O
urinary,O
alkalinization,O
can,O
be,O
readily,O
achieved,O
.,O
Ethopropazine,I-Entity
and,O
benztropine,I-Entity
in,O
neuroleptic,O
-,O
induced,O
parkinsonism,I-Entity
.,O
In,O
a,O
12-week,O
controlled,O
study,O
ethopropazine,I-Entity
was,O
compared,O
to,O
benztropine,I-Entity
in,O
the,O
treatment,O
of,O
parkinsonism,I-Entity
induced,O
by,O
fluphenazine,B-Entity
enanthate,I-Entity
in,O
60,O
schizophrenic,I-Entity
outpatients,O
.,O
Ethopropazine,I-Entity
and,O
benztropine,I-Entity
were,O
found,O
to,O
be,O
equally,O
effective,O
in,O
controlling,O
parkinsonian,B-Entity
symptoms,I-Entity
and,O
were,O
as,O
efficacious,O
as,O
procyclidine,I-Entity
",",O
their,O
previous,O
antiparkinsonian,O
drug,O
.,O
However,O
",",O
benztropine,I-Entity
treated,O
patients,O
had,O
a,O
significant,O
increase,O
in,O
tardive,B-Entity
dyskinesia,I-Entity
compared,O
to,O
their,O
condition,O
during,O
procyclindine,I-Entity
treatment,O
",",O
and,O
significantly,O
more,O
anxiety,I-Entity
and,O
depression,I-Entity
than,O
ethopropazine,I-Entity
treated,O
patients,O
.,O
This,O
suggests,O
that,O
benztropine,I-Entity
is,O
not,O
the,O
anticholinergic,O
drug,O
of,O
choice,O
in,O
the,O
treatment,O
of,O
neuroleptic,O
-,O
induced,O
parkinsonian,B-Entity
symptoms,I-Entity
",",O
because,O
of,O
its,O
more,O
toxic,O
central,O
and,O
peripheral,O
atropinic,O
effect,O
.,O
Effect,O
of,O
alpha,B-Entity
-,I-Entity
tocopherol,I-Entity
and,O
deferoxamine,I-Entity
on,O
methamphetamine,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
.,O
Methamphetamine,I-Entity
(,O
MA)-induced,I-Entity
dopaminergic,O
neurotoxicity,I-Entity
is,O
believed,O
to,O
be,O
associated,O
with,O
the,O
increased,O
formation,O
of,O
free,O
radicals,O
.,O
This,O
study,O
examined,O
the,O
effect,O
of,O
alpha,B-Entity
-,I-Entity
tocopherol,I-Entity
(,O
alpha,B-Entity
-,I-Entity
TC,I-Entity
),O
",",O
a,O
scavenger,O
of,O
reactive,O
oxygen,I-Entity
species,O
",",O
and,O
deferoxamine,I-Entity
(,O
DFO,I-Entity
),O
",",O
an,O
iron,I-Entity
chelator,O
",",O
on,O
the,O
MA,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
.,O
Male,O
rats,O
were,O
treated,O
with,O
MA,I-Entity
(,O
10,O
mg,O
/,O
kg,O
",",O
every,O
2,O
h,O
for,O
four,O
injections,O
),O
.,O
The,O
rat,O
received,O
either,O
alpha,B-Entity
-,I-Entity
TC,I-Entity
(,O
20,O
mg,O
/,O
kg,O
),O
intraperitoneally,O
for,O
3,O
days,O
and,O
30,O
min,O
prior,O
to,O
MA,I-Entity
administration,O
or,O
DFO,I-Entity
(,O
50,O
mg,O
/,O
kg,O
),O
min,O
before,O
MA,I-Entity
administration,O
.,O
The,O
concentrations,O
of,O
dopamine,I-Entity
(,O
DA,I-Entity
),O
",",O
serotonin,I-Entity
and,O
their,O
metabolites,O
decreased,O
significantly,O
after,O
MA,I-Entity
administration,O
",",O
which,O
was,O
inhibited,O
by,O
the,O
alpha,B-Entity
-,I-Entity
TC,I-Entity
and,O
DFO,I-Entity
pretreatment,O
.,O
alpha,B-Entity
-,I-Entity
TC,I-Entity
and,O
DFO,I-Entity
attenuated,O
the,O
MA,I-Entity
-,O
induced,O
hyperthermia,I-Entity
as,O
well,O
as,O
the,O
alterations,O
in,O
the,O
locomotor,O
activity,O
.,O
The,O
level,O
of,O
lipid,O
peroxidation,O
was,O
higher,O
and,O
the,O
reduced,O
glutathione,I-Entity
concentration,O
was,O
lower,O
in,O
the,O
MA,I-Entity
-,O
treated,O
rats,O
.,O
These,O
changes,O
were,O
significantly,O
attenuated,O
by,O
alpha,B-Entity
-,I-Entity
TC,I-Entity
and,O
DFO,I-Entity
.,O
This,O
suggests,O
that,O
alpha,B-Entity
-,I-Entity
TC,I-Entity
and,O
DFO,I-Entity
ameliorate,O
the,O
MA,I-Entity
-,O
induced,O
neuronal,B-Entity
damage,I-Entity
by,O
decreasing,O
the,O
level,O
of,O
oxidative,O
stress,O
.,O
Use,O
of,O
dexamethasone,I-Entity
with,O
mesna,I-Entity
for,O
the,O
prevention,O
of,O
ifosfamide,I-Entity
-,O
induced,O
hemorrhagic,B-Entity
cystitis,I-Entity
.,O
AIM,O
:,O
Hemorrhagic,B-Entity
cystitis,I-Entity
(,O
HC,I-Entity
),O
is,O
a,O
limiting,O
side,O
-,O
effect,O
of,O
chemotherapy,O
with,O
ifosfamide,I-Entity
(,O
IFS,I-Entity
),O
.,O
In,O
the,O
study,O
presented,O
here,O
",",O
we,O
investigated,O
the,O
use,O
of,O
dexamethasone,I-Entity
in,O
combination,O
with,O
mesna,I-Entity
for,O
the,O
prevention,O
of,O
IFS,I-Entity
-,O
induced,O
HC,I-Entity
.,O
Male,O
Wistar,O
rats,O
(,O
150,O
-,O
200,O
g,O
;,O
6,O
rats,O
per,O
group,O
),O
were,O
treated,O
with,O
saline,O
or,O
mesna,I-Entity
5,O
min,O
(,O
i.p,O
.,O
),O
before,O
and,O
2,O
and,O
6,O
h,O
after,O
(,O
v.o,O
.,O
),O
administration,O
of,O
IFS,I-Entity
.,O
One,O
",",O
two,O
or,O
three,O
doses,O
of,O
mesna,I-Entity
were,O
replaced,O
with,O
dexamethasone,I-Entity
alone,O
or,O
with,O
dexamethasone,I-Entity
plus,O
mesna,I-Entity
.,O
Cystitis,I-Entity
was,O
evaluated,O
24,O
h,O
after,O
its,O
induction,O
by,O
the,O
changes,O
in,O
bladder,O
wet,O
weight,O
and,O
by,O
macroscopic,O
and,O
microscopic,O
analysis,O
.,O
The,O
replacement,O
of,O
the,O
last,O
dose,O
or,O
the,O
last,O
two,O
doses,O
of,O
mesna,I-Entity
with,O
dexamethasone,I-Entity
reduced,O
the,O
increase,O
in,O
bladder,O
wet,O
weight,O
induced,O
by,O
IFS,I-Entity
by,O
84.79%,O
and,O
89.13%,O
",",O
respectively,O
.,O
In,O
addition,O
",",O
it,O
almost,O
abolished,O
the,O
macroscopic,O
and,O
microscopic,O
alterations,O
induced,O
by,O
IFS,I-Entity
.,O
Moreover,O
",",O
the,O
addition,O
of,O
dexamethasone,I-Entity
to,O
the,O
last,O
two,O
doses,O
of,O
mesna,I-Entity
was,O
more,O
efficient,O
than,O
three,O
doses,O
of,O
mesna,I-Entity
alone,O
when,O
evaluated,O
microscopically,O
.,O
CONCLUSION,O
:,O
Dexamethasone,I-Entity
in,O
combination,O
with,O
mesna,I-Entity
was,O
efficient,O
in,O
blocking,O
IFS,I-Entity
-,O
induced,O
HC,I-Entity
.,O
However,O
",",O
the,O
replacement,O
of,O
last,O
two,O
doses,O
of,O
mesna,I-Entity
with,O
saline,O
or,O
all,O
of,O
the,O
mesna,I-Entity
doses,O
with,O
dexamethasone,I-Entity
did,O
not,O
prevent,O
HC,I-Entity
.,O
Behavioral,O
effects,O
of,O
MK-801,I-Entity
on,O
reserpine,I-Entity
-,O
treated,O
mice,O
.,O
The,O
effects,O
of,O
dizocilpine,I-Entity
(,O
MK-801,I-Entity
),O
",",O
a,O
noncompetitive,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
antagonist,O
",",O
were,O
studied,O
on,O
dopamine,I-Entity
-,O
related,O
behaviors,O
induced,O
by,O
reserpine,I-Entity
treatments,O
.,O
This,O
study,O
focuses,O
on,O
behavioral,O
syndromes,O
that,O
may,O
used,O
as,O
models,O
for,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
",",O
or,O
tardive,B-Entity
dyskinesia,I-Entity
",",O
and,O
its,O
response,O
after,O
glutamatergic,O
blockage,O
.,O
Reserpine,I-Entity
(,O
1,O
mg,O
/,O
kg,O
),O
",",O
administered,O
once,O
every,O
other,O
day,O
for,O
4,O
days,O
",",O
produced,O
increases,O
in,O
orofacial,B-Entity
dyskinesia,I-Entity
",",O
tongue,O
protrusion,O
and,O
vacuous,O
chewing,O
in,O
mice,O
",",O
which,O
are,O
signs,O
indicative,O
of,O
tardive,B-Entity
dyskinesia,I-Entity
.,O
Reserpine,I-Entity
also,O
produced,O
tremor,I-Entity
and,O
catalepsy,I-Entity
",",O
which,O
are,O
signs,O
suggestive,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
MK-801,I-Entity
(,O
0.1,O
mg,O
/,O
kg,O
),O
",",O
administered,O
30,O
min,O
before,O
the,O
observation,O
test,O
",",O
prevented,O
the,O
vacuous,O
chewing,O
movements,O
",",O
tongue,O
protrusions,O
and,O
catalepsy,I-Entity
induced,O
by,O
reserpine,I-Entity
.,O
However,O
",",O
MK-801,I-Entity
injection,O
produced,O
a,O
significant,O
increase,O
of,O
tremor,I-Entity
in,O
reserpine,I-Entity
-,O
treated,O
mice,O
.,O
Reserpine,I-Entity
(,O
1,O
mg,O
/,O
kg,O
),O
",",O
administered,O
90,O
min,O
before,O
the,O
test,O
and,O
followed,O
by,O
apomophine,I-Entity
injection,O
(,O
0.1,O
mg,O
/,O
kg,O
),O
5,O
min,O
before,O
the,O
test,O
",",O
did,O
not,O
produce,O
oral,B-Entity
dyskinesia,I-Entity
in,O
mice,O
.,O
On,O
the,O
other,O
hand,O
",",O
reserpine,I-Entity
induced,O
increases,O
in,O
tremor,I-Entity
and,O
catalepsy,I-Entity
compared,O
to,O
control,O
mice,O
.,O
MK-801,I-Entity
(,O
0.1,O
mg,O
/,O
kg,O
),O
administration,O
attenuated,O
the,O
catalepsy,I-Entity
and,O
tremor,I-Entity
induced,O
by,O
reserpine,I-Entity
.,O
Pretreatment,O
with,O
reserpine,I-Entity
(,O
1,O
mg,O
/,O
kg,O
),O
24,O
h,O
before,O
the,O
observation,O
test,O
produced,O
increases,O
in,O
vacuous,O
chewing,O
movements,O
and,O
tongue,O
protrusion,O
",",O
as,O
well,O
as,O
increases,O
in,O
tremor,I-Entity
and,O
catalepsy,I-Entity
",",O
whereas,O
MK-801,I-Entity
(,O
0.1,O
mg,O
/,O
kg,O
),O
injection,O
90,O
min,O
before,O
the,O
test,O
reversed,O
the,O
effects,O
of,O
reserpine,I-Entity
.,O
These,O
results,O
show,O
that,O
reserpine,I-Entity
produces,O
different,O
and,O
abnormal,B-Entity
movements,I-Entity
",",O
which,O
are,O
related,O
to,O
dose,O
and,O
schedule,O
employed,O
and,O
can,O
be,O
considered,O
as,O
parkinsonian,I-Entity
-,O
like,O
and,O
tardive,B-Entity
dsykinesia,I-Entity
signs,O
.,O
The,O
glutamatergic,O
blockage,O
produced,O
by,O
NMDA,I-Entity
can,O
restore,O
these,O
signs,O
",",O
such,O
as,O
vacuous,O
chewing,O
movements,O
",",O
tongue,O
protrusions,O
",",O
catalepsy,I-Entity
and,O
tremor,I-Entity
according,O
to,O
the,O
employed,O
model,O
.,O
Effect,O
of,O
glyceryl,B-Entity
trinitrate,I-Entity
on,O
the,O
sphincter,B-Entity
of,I-Entity
Oddi,I-Entity
spasm,I-Entity
evoked,O
by,O
prostigmine,I-Entity
-,O
morphine,I-Entity
administration,O
.,O
In,O
this,O
study,O
the,O
effect,O
of,O
glyceryl,B-Entity
trinitrate,I-Entity
on,O
the,O
prostigmine,I-Entity
-,O
morphine,I-Entity
-,O
induced,O
sphincter,B-Entity
of,I-Entity
Oddi,I-Entity
spasm,I-Entity
was,O
evaluated,O
in,O
nine,O
female,O
patients,O
with,O
sphincter,B-Entity
of,I-Entity
Oddi,I-Entity
dyskinesia,I-Entity
.,O
METHOD,O
:,O
Sphincter,B-Entity
of,I-Entity
Oddi,I-Entity
spasm,I-Entity
was,O
induced,O
by,O
prostigmine,I-Entity
-,O
morphine,I-Entity
administration,O
(,O
0.5,O
mg,O
prostigmine,I-Entity
intramuscularly,O
and,O
10,O
mg,O
morphine,I-Entity
subcutaneously,O
),O
and,O
visualized,O
by,O
quantitative,O
hepatobiliary,O
scintigraphy,O
.,O
The,O
entire,O
procedure,O
was,O
repeated,O
during,O
glyceryl,B-Entity
trinitrate,I-Entity
infusion,O
(,O
Nitrolingual,I-Entity
1,O
RESULTS,O
:,O
Prostigmine,I-Entity
-,O
morphine,I-Entity
provocation,O
caused,O
significant,O
increases,O
in,O
the,O
time,O
to,O
peak,O
activity,O
(,O
Tmax,O
),O
over,O
the,O
hepatic,O
hilum,O
(,O
HH,O
:,O
34.33,O
+,O
/-,O
6.24,O
),O
",",O
indicating,O
a,O
complete,O
spasm,I-Entity
at,O
the,O
level,O
of,O
the,O
sphincter,O
of,O
Oddi,O
.,O
Glyceryl,B-Entity
trinitrate,I-Entity
infusion,O
completely,O
normalized,O
the,O
prostigmine,I-Entity
-,O
morphine,I-Entity
-,O
induced,O
alterations,O
in,O
these,O
quantitative,O
parameters,O
(,O
TmaX,O
over,O
the,O
LP,O
:,O
11.33,O
+,O
/-,O
6.33,O
),O
",",O
suggesting,O
an,O
effective,O
sphincter,O
-,O
relaxing,O
effect,O
of,O
glyceryl,B-Entity
trinitrate,I-Entity
.,O
CONCLUSION,O
:,O
These,O
results,O
provide,O
the,O
first,O
evidence,O
of,O
the,O
effectiveness,O
of,O
glyceryl,B-Entity
trinitrate,I-Entity
on,O
the,O
morphine,I-Entity
-,O
induced,O
sphincter,B-Entity
of,I-Entity
Oddi,I-Entity
spasm,I-Entity
in,O
humans,O
.,O
Since,O
glyceryl,B-Entity
trinitrate,I-Entity
is,O
able,O
to,O
overcome,O
even,O
the,O
drastic,O
effect,O
of,O
morphine,I-Entity
",",O
it,O
might,O
be,O
of,O
relevance,O
in,O
the,O
treatment,O
of,O
sphincter,B-Entity
of,I-Entity
Oddi,I-Entity
dyskinesia,I-Entity
.,O
Effects,O
of,O
acute,O
steroid,I-Entity
administration,O
on,O
ventilatory,O
and,O
peripheral,O
muscles,O
in,O
rats,O
.,O
Occasional,O
case,O
reports,O
have,O
shown,O
that,O
acute,O
myopathy,I-Entity
may,O
occur,O
in,O
patients,O
treated,O
with,O
massive,O
doses,O
of,O
corticosteroids,I-Entity
.,O
The,O
mechanism,O
of,O
this,O
myopathy,I-Entity
is,O
poorly,O
understood,O
.,O
Therefore,O
",",O
60,O
male,O
rats,O
were,O
randomly,O
assigned,O
to,O
receive,O
daily,O
injection,O
of,O
saline,O
(,O
C,O
),O
",",O
methylprednisolone,I-Entity
(,O
M,I-Entity
),O
",",O
or,O
triamcinolone,I-Entity
(,O
T,I-Entity
),O
80,O
mg,O
/,O
kg,O
/,O
d,O
for,O
5,O
d.,O
Nutritional,O
intake,O
",",O
measured,O
daily,O
in,O
15,O
animals,O
",",O
showed,O
a,O
significant,O
reduction,B-Entity
of,I-Entity
food,I-Entity
intake,I-Entity
in,O
the,O
steroid,I-Entity
-,O
treated,O
groups,O
(,O
-50,O
and,O
-79%,O
in,O
M,I-Entity
and,O
T,I-Entity
",",O
respectively,O
),O
.,O
This,O
was,O
associated,O
with,O
a,O
similar,O
loss,B-Entity
in,I-Entity
body,I-Entity
weight,I-Entity
.,O
Weights,O
of,O
respiratory,O
and,O
peripheral,O
muscles,O
were,O
similarly,O
decreased,O
after,O
steroid,I-Entity
treatment,O
.,O
174,O
g,O
/,O
cm(2,O
),O
),O
than,O
in,O
the,O
M,I-Entity
group,O
(,O
837,O
+,O
/-,O
p,O
<,O
0.05,O
),O
and,O
the,O
T,I-Entity
group,O
(,O
765,O
+,O
/-,O
Half,O
-,O
relaxation,O
time,O
was,O
prolonged,O
in,O
both,O
steroid,I-Entity
groups,O
",",O
and,O
time,O
to,O
peak,O
tension,O
was,O
longer,O
with,O
M,I-Entity
",",O
whereas,O
tetanic,I-Entity
tensions,O
were,O
similar,O
.,O
Steroid,I-Entity
treatment,O
also,O
induced,O
a,O
leftward,O
shift,O
of,O
the,O
force,O
-,O
frequency,O
curve,O
at,O
25,O
and,O
50,O
Hz,O
when,O
compared,O
with,O
saline,O
treatment,O
(,O
p,O
<,O
0.05,O
),O
.,O
ATPase,O
staining,O
of,O
the,O
diaphragm,O
",",O
scalenus,O
medius,O
",",O
and,O
gastrocnemius,O
showed,O
type,O
IIb,O
fiber,O
atrophy,I-Entity
in,O
the,O
steroid,I-Entity
groups,O
and,O
also,O
diaphragmatic,O
type,O
IIa,O
atrophy,I-Entity
with,O
T,I-Entity
",",O
whereas,O
histologic,O
examinations,O
revealed,O
a,O
normal,O
muscular,O
pattern,O
with,O
absence,O
of,O
necrosis,I-Entity
.,O
Finally,O
",",O
a,O
pair,O
-,O
fed,O
(,O
PF,O
),O
study,O
",",O
performed,O
in,O
18,O
rats,O
(,O
C,O
",",O
T,I-Entity
",",O
and,O
PF,O
),O
",",O
showed,O
that,O
muscle,B-Entity
atrophy,I-Entity
was,O
considerably,O
less,O
pronounced,O
in,O
PF,O
animals,O
than,O
in,O
T,I-Entity
-,O
treated,O
animals,O
.,O
We,O
conclude,O
that,O
(,O
1,O
),O
short,O
-,O
term,O
treatment,O
with,O
massive,O
doses,O
of,O
steroids,I-Entity
induced,O
severe,O
respiratory,O
and,O
limb,O
muscle,O
wasting,O
;,O
(,O
2,O
),O
both,O
types,O
of,O
steroids,I-Entity
induced,O
predominantly,O
type,O
IIb,O
atrophy,I-Entity
",",O
resulting,O
in,O
the,O
expected,O
alterations,O
in,O
diaphragm,O
contractile,O
properties,O
;,O
(,O
3,O
),O
neither,O
steroid,I-Entity
caused,O
muscle,O
necrosis,I-Entity
;,O
(,O
4,O
),O
type,O
IIb,O
atrophy,I-Entity
was,O
not,O
caused,O
by,O
acute,O
nutritional,O
deprivation,O
alone,O
.,O
Refractory,O
cardiogenic,B-Entity
shock,I-Entity
and,O
complete,O
heart,B-Entity
block,I-Entity
after,O
verapamil,I-Entity
SR,O
and,O
metoprolol,I-Entity
treatment,O
.,O
A,O
seventy,O
-,O
eight,O
-,O
year,O
-,O
old,O
woman,O
presented,O
with,O
complete,O
heart,B-Entity
block,I-Entity
and,O
refractory,O
hypotension,I-Entity
two,O
days,O
after,O
a,O
therapeutic,O
dose,O
of,O
sustained,O
-,O
release,O
verapamil,I-Entity
with,O
concomitant,O
use,O
of,O
metoprolol,I-Entity
.,O
The,O
patient,O
continued,O
to,O
remain,O
hypotensive,I-Entity
with,O
complete,O
heart,B-Entity
block,I-Entity
",",O
even,O
with,O
multiple,O
uses,O
of,O
intravenous,O
atropine,I-Entity
as,O
well,O
as,O
high,O
doses,O
of,O
pressor,O
agents,O
such,O
as,O
dopamine,I-Entity
and,O
dobutamine,I-Entity
.,O
However,O
",",O
shortly,O
after,O
the,O
use,O
of,O
intravenous,O
calcium,B-Entity
chloride,I-Entity
",",O
the,O
refractory,O
hypotension,I-Entity
and,O
complete,O
heart,B-Entity
block,I-Entity
resolved,O
.,O
A,O
phase,O
I,O
clinical,O
study,O
of,O
the,O
antipurine,I-Entity
antifolate,O
lometrexol,I-Entity
(,O
DDATHF,I-Entity
),O
given,O
with,O
oral,O
folic,B-Entity
acid,I-Entity
.,O
Lometrexol,I-Entity
is,O
an,O
antifolate,O
which,O
inhibits,O
glycinamide,B-Entity
ribonucleotide,I-Entity
formyltransferase,O
(,O
GARFT,O
),O
",",O
an,O
enzyme,O
essential,O
for,O
de,O
novo,O
purine,I-Entity
synthesis,O
.,O
Extensive,O
experimental,O
and,O
limited,O
clinical,O
data,O
have,O
shown,O
that,O
lometrexol,I-Entity
has,O
activity,O
against,O
tumours,I-Entity
which,O
are,O
refractory,O
to,O
other,O
drugs,O
",",O
notably,O
methotrexate,I-Entity
.,O
However,O
",",O
the,O
initial,O
clinical,O
development,O
of,O
lometrexol,I-Entity
was,O
curtailed,O
because,O
of,O
severe,O
and,O
cumulative,O
antiproliferative,O
toxicities,I-Entity
.,O
Preclinical,O
murine,O
studies,O
demonstrated,O
that,O
the,O
toxicity,I-Entity
of,O
lometrexol,I-Entity
can,O
be,O
prevented,O
by,O
low,O
dose,O
folic,B-Entity
acid,I-Entity
administration,O
",",O
i.e.,O
for,O
7,O
days,O
prior,O
to,O
and,O
7,O
days,O
following,O
a,O
single,O
bolus,O
dose,O
.,O
This,O
observation,O
prompted,O
a,O
Phase,O
I,O
clinical,O
study,O
of,O
lometrexol,I-Entity
given,O
with,O
folic,B-Entity
acid,I-Entity
supplementation,O
which,O
has,O
confirmed,O
that,O
the,O
toxicity,I-Entity
of,O
lometrexol,I-Entity
can,O
be,O
markedly,O
reduced,O
by,O
folic,B-Entity
acid,I-Entity
supplementation,O
.,O
Thrombocytopenia,I-Entity
and,O
mucositis,I-Entity
were,O
the,O
major,O
toxicities,I-Entity
.,O
There,O
was,O
no,O
clear,O
relationship,O
between,O
clinical,O
toxicity,I-Entity
and,O
the,O
extent,O
of,O
plasma,O
folate,I-Entity
elevation,O
.,O
Associated,O
studies,O
demonstrated,O
that,O
lometrexol,I-Entity
plasma,O
pharmacokinetics,O
were,O
not,O
altered,O
by,O
folic,B-Entity
acid,I-Entity
administration,O
indicating,O
that,O
supplementation,O
is,O
unlikely,O
to,O
reduce,O
toxicity,I-Entity
by,O
enhancing,O
lometrexol,I-Entity
plasma,O
clearance,O
.,O
This,O
information,O
will,O
facilitate,O
the,O
future,O
evaluation,O
of,O
this,O
class,O
of,O
compounds,O
in,O
cancer,I-Entity
therapy,O
.,O
Involvement,O
of,O
the,O
mu,O
-,O
opiate,O
receptor,O
in,O
peripheral,O
analgesia,I-Entity
.,O
The,O
intradermal,O
injection,O
of,O
mu,O
(,O
morphine,I-Entity
",",O
Tyr,B-Entity
-,I-Entity
D,I-Entity
-,I-Entity
Ala,I-Entity
-,I-Entity
Gly,I-Entity
-,I-Entity
NMe,I-Entity
-,I-Entity
Phe,I-Entity
-,I-Entity
Gly,I-Entity
-,I-Entity
ol,I-Entity
and,O
morphiceptin,I-Entity
),O
",",O
kappa,O
(,O
"trans-3,4-dichloro",B-Entity
-,I-Entity
N,I-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
N[2-(1-pyrrolidinyl,I-Entity
),I-Entity
cyclohexyl]benzeneactemide,I-Entity
),O
and,O
delta,O
(,O
[,B-Entity
D,I-Entity
-,I-Entity
Pen2.5]-enkephalin,I-Entity
and,O
[,B-Entity
D,I-Entity
-,I-Entity
Ser2]-[Leu]enkephalin,I-Entity
-,I-Entity
Thr,I-Entity
),O
selective,O
opioid,O
-,O
agonists,O
",",O
by,O
themselves,O
",",O
did,O
not,O
significantly,O
affect,O
the,O
mechanical,O
nociceptive,O
threshold,O
in,O
the,O
hindpaw,O
of,O
the,O
rat,O
.,O
",",O
however,O
",",O
produced,O
dose,O
-,O
dependent,O
inhibition,O
of,O
prostaglandin,B-Entity
E2-induced,I-Entity
hyperalgesia,I-Entity
.,O
The,O
analgesic,O
effect,O
of,O
the,O
mu,O
-,O
agonist,O
morphine,I-Entity
was,O
dose,O
-,O
dependently,O
antagonized,O
by,O
naloxone,I-Entity
and,O
prevented,O
by,O
co,O
-,O
injection,O
of,O
pertussis,O
toxin,O
.,O
Morphine,I-Entity
did,O
not,O
",",O
however,O
",",O
alter,O
the,O
hyperalgesia,I-Entity
induced,O
by,O
8-bromo,B-Entity
cyclic,I-Entity
adenosine,I-Entity
monophosphate,I-Entity
.,O
We,O
conclude,O
that,O
the,O
analgesic,O
action,O
of,O
opioids,O
on,O
the,O
peripheral,O
terminals,O
of,O
primary,O
afferents,O
is,O
via,O
a,O
binding,O
site,O
with,O
characteristics,O
of,O
the,O
mu,O
-,O
opioid,O
receptor,O
and,O
that,O
this,O
action,O
is,O
mediated,O
by,O
inhibition,O
of,O
the,O
cyclic,B-Entity
adenosine,I-Entity
monophosphate,I-Entity
second,O
messenger,O
system,O
.,O
Adequate,O
timing,O
of,O
ribavirin,I-Entity
reduction,O
in,O
patients,O
with,O
hemolysis,I-Entity
during,O
combination,O
therapy,O
of,O
interferon,I-Entity
and,O
ribavirin,I-Entity
for,O
chronic,B-Entity
hepatitis,I-Entity
C.,I-Entity
BACKGROUND,O
:,O
Hemolytic,B-Entity
anemia,I-Entity
is,O
one,O
of,O
the,O
major,O
adverse,O
events,O
of,O
the,O
combination,O
therapy,O
of,O
interferon,I-Entity
and,O
ribavirin,I-Entity
.,O
Because,O
of,O
ribavirin,I-Entity
-,O
related,O
hemolytic,B-Entity
anemia,I-Entity
",",O
dose,O
reduction,O
is,O
a,O
common,O
event,O
in,O
this,O
therapy,O
.,O
In,O
this,O
clinical,O
retrospective,O
cohort,O
study,O
we,O
have,O
examined,O
the,O
suitable,O
timing,O
of,O
ribavirin,I-Entity
reduction,O
in,O
patients,O
with,O
hemolysis,I-Entity
during,O
combination,O
therapy,O
.,O
METHODS,O
:,O
Thirty,O
-,O
seven,O
of,O
160,O
patients,O
who,O
had,O
HCV,O
-,O
genotype,O
1b,O
",",O
had,O
high,O
virus,O
load,O
",",O
and,O
received,O
24-week,O
combination,O
therapy,O
developed,O
anemia,I-Entity
with,O
hemoglobin,O
level,O
<,O
10,O
g,O
/,O
dl,O
or,O
anemia,I-Entity
-,O
related,O
signs,O
during,O
therapy,O
.,O
After,O
that,O
",",O
these,O
37,O
patients,O
were,O
reduced,O
one,O
tablet,O
of,O
ribavirin,I-Entity
(,O
200,O
mg,O
),O
per,O
day,O
.,O
After,O
reduction,O
of,O
ribavirin,I-Entity
",",O
27,O
of,O
37,O
patients,O
could,O
continue,O
combination,O
therapy,O
for,O
a,O
total,O
of,O
24,O
weeks,O
(,O
group,O
A,O
),O
.,O
However,O
",",O
10,O
of,O
37,O
patients,O
with,O
reduction,O
of,O
ribavirin,I-Entity
could,O
not,O
continue,O
combination,O
therapy,O
because,O
their,O
<,O
8.5,O
g,O
/,O
dl,O
hemoglobin,O
values,O
decreased,O
to,O
or,O
anemia,I-Entity
-,O
related,O
severe,O
side,O
effects,O
occurred,O
(,O
group,O
B,O
),O
.,O
We,O
assessed,O
the,O
final,O
efficacy,O
and,O
safety,O
after,O
reduction,O
of,O
ribavirin,I-Entity
in,O
groups,O
A,O
and,O
B.,O
RESULTS,O
:,O
With,O
respect,O
to,O
hemoglobin,O
level,O
at,O
the,O
time,O
of,O
ribavirin,I-Entity
reduction,O
",",O
a,O
rate,O
of,O
continuation,O
of,O
therapy,O
in,O
patients,O
with,O
>,O
or,O
=,O
10,O
g,O
/,O
dl,O
hemoglobin,O
was,O
higher,O
than,O
that,O
in,O
patients,O
with,O
<,O
10,O
g,O
/,O
dl,O
(,O
P,O
=,O
0.036,O
),O
.,O
Reduction,O
of,O
ribavirin,I-Entity
at,O
hemoglobin,O
level,O
>,O
or,O
=,O
Increased,O
expression,O
and,O
apical,O
targeting,O
of,O
renal,O
ENaC,O
subunits,O
in,O
puromycin,B-Entity
aminonucleoside,I-Entity
-,O
induced,O
nephrotic,B-Entity
syndrome,I-Entity
in,O
rats,O
.,O
Nephrotic,B-Entity
syndrome,I-Entity
is,O
often,O
accompanied,O
by,O
sodium,I-Entity
retention,O
and,O
generalized,O
edema,I-Entity
.,O
However,O
",",O
the,O
molecular,O
basis,O
for,O
the,O
decreased,O
renal,O
sodium,I-Entity
excretion,O
remains,O
undefined,O
.,O
We,O
hypothesized,O
that,O
epithelial,O
Na,I-Entity
channel,O
(,O
ENaC,O
),O
subunit,O
dysregulation,O
may,O
be,O
responsible,O
for,O
the,O
increased,O
sodium,I-Entity
retention,O
.,O
An,O
experimental,O
group,O
of,O
rats,O
was,O
treated,O
with,O
puromycin,B-Entity
aminonucleoside,I-Entity
(,O
PAN,I-Entity
;,O
180,O
mg,O
/,O
kg,O
iv,O
),O
",",O
whereas,O
the,O
control,O
group,O
received,O
only,O
vehicle,O
.,O
After,O
7,O
days,O
",",O
PAN,I-Entity
treatment,O
induced,O
significant,O
proteinuria,I-Entity
",",O
hypoalbuminemia,I-Entity
",",O
decreased,O
urinary,O
sodium,I-Entity
excretion,O
",",O
and,O
extensive,O
ascites,I-Entity
.,O
Immunoelectron,O
microscopy,O
further,O
revealed,O
an,O
increased,O
labeling,O
of,O
alpha,O
-,O
ENaC,O
in,O
the,O
apical,O
plasma,O
membrane,O
of,O
cortical,O
collecting,O
duct,O
principal,O
cells,O
of,O
PAN,I-Entity
-,O
treated,O
rats,O
",",O
indicating,O
enhanced,O
apical,O
targeting,O
of,O
alpha,O
-,O
ENaC,O
subunits,O
.,O
In,O
contrast,O
",",O
the,O
protein,O
abundances,O
of,O
Na(+)/H(+,I-Entity
),O
exchanger,O
type,O
3,O
(,O
NHE3,O
),O
",",O
Na(+)-K(+)-2Cl(-,I-Entity
),O
cotransporter,O
(,O
BSC-1,O
),O
",",O
and,O
thiazide,I-Entity
-,O
sensitive,O
Na(+)-Cl(-,I-Entity
),O
Moreover,O
",",O
the,O
abundance,O
of,O
the,O
alpha(1)-subunit,O
of,O
the,O
Na,I-Entity
-,O
K,I-Entity
-,O
ATPase,O
was,O
decreased,O
in,O
the,O
cortex,O
and,O
ISOM,O
",",O
but,O
it,O
remained,O
unchanged,O
in,O
the,O
IM,O
.,O
In,O
conclusion,O
",",O
the,O
increased,O
or,O
sustained,O
expression,O
of,O
ENaC,O
subunits,O
combined,O
with,O
increased,O
apical,O
targeting,O
in,O
the,O
DCT2,O
",",O
connecting,O
tubule,O
",",O
and,O
collecting,O
duct,O
are,O
likely,O
to,O
play,O
a,O
role,O
in,O
the,O
sodium,I-Entity
retention,O
associated,O
with,O
PAN,I-Entity
-,O
induced,O
nephrotic,B-Entity
syndrome,I-Entity
.,O
The,O
decreased,O
abundance,O
of,O
NHE3,O
",",O
BSC-1,O
",",O
TSC,O
",",O
and,O
Na,I-Entity
-,O
K,I-Entity
-,O
ATPase,O
may,O
play,O
a,O
compensatory,O
role,O
to,O
promote,O
sodium,I-Entity
excretion,O
.,O
Does,O
hormone,O
therapy,O
for,O
the,O
treatment,O
of,O
breast,B-Entity
cancer,I-Entity
have,O
a,O
detrimental,B-Entity
effect,I-Entity
on,I-Entity
memory,I-Entity
and,I-Entity
cognition,I-Entity
?,O
This,O
pilot,O
study,O
examines,O
whether,O
hormone,O
therapy,O
for,O
breast,B-Entity
cancer,I-Entity
affects,O
cognition,O
.,O
Patients,O
participating,O
in,O
a,O
randomised,O
trial,O
of,O
anastrozole,I-Entity
",",O
tamoxifen,I-Entity
alone,O
or,O
combined,O
(,O
ATAC,O
),O
(,O
n=94,O
),O
and,O
a,O
group,O
of,O
women,O
without,O
breast,B-Entity
cancer,I-Entity
(,O
n=35,O
),O
completed,O
a,O
battery,O
of,O
neuropsychological,O
measures,O
.,O
The,O
results,O
showed,O
specific,O
impairments,O
in,O
processing,O
speed,O
and,O
verbal,O
memory,O
in,O
women,O
receiving,O
hormonal,O
therapy,O
for,O
the,O
treatment,O
of,O
breast,B-Entity
cancer,I-Entity
.,O
Verbal,O
memory,O
may,O
be,O
especially,O
sensitive,O
to,O
changes,O
in,O
oestrogen,I-Entity
levels,O
",",O
a,O
finding,O
commonly,O
reported,O
in,O
studies,O
of,O
hormone,O
replacement,O
therapy,O
in,O
healthy,O
women,O
.,O
Association,O
of,O
nitric,B-Entity
oxide,I-Entity
production,O
and,O
apoptosis,O
in,O
a,O
model,O
of,O
experimental,O
nephropathy,I-Entity
.,O
In,O
recent,O
studies,O
increased,O
amounts,O
of,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
and,O
apoptosis,O
have,O
been,O
implicated,O
in,O
various,O
pathological,O
conditions,O
in,O
the,O
kidney,O
.,O
We,O
have,O
studied,O
the,O
role,O
of,O
NO,I-Entity
and,O
its,O
association,O
with,O
apoptosis,O
in,O
an,O
experimental,O
model,O
of,O
nephrotic,B-Entity
syndrome,I-Entity
induced,O
by,O
a,O
single,O
injection,O
of,O
adriamycin,I-Entity
(,O
ADR,I-Entity
),O
.,O
The,O
alteration,O
in,O
the,O
NO,I-Entity
pathway,O
was,O
assessed,O
by,O
measuring,O
nitrite,I-Entity
levels,O
in,O
serum,O
/,O
urine,O
and,O
by,O
evaluating,O
the,O
changes,O
in,O
vascular,O
reactivity,O
of,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
(,O
IPRK,O
),O
system,O
.,O
Rats,O
were,O
stratified,O
into,O
control,O
groups,O
and,O
ADR,I-Entity
-,O
induced,O
nephropathy,I-Entity
groups,O
.,O
These,O
two,O
groups,O
were,O
then,O
divided,O
into,O
:,O
group,O
1,O
",",O
animals,O
receiving,O
saline,O
;,O
and,O
group,O
2,O
",",O
animals,O
receiving,O
aminoguanidine,I-Entity
(,O
AG,I-Entity
),O
which,O
is,O
a,O
specific,O
inhibitor,O
of,O
inducible,O
-,O
NO,I-Entity
synthase,O
.,O
RESULTS,O
:,O
Histopathological,O
examination,O
of,O
the,O
kidneys,O
of,O
rats,O
treated,O
with,O
ADR,I-Entity
revealed,O
focal,O
areas,O
of,O
mesangial,B-Entity
proliferation,I-Entity
and,O
mild,O
tubulointerstitial,B-Entity
inflammation,I-Entity
.,O
They,O
also,O
had,O
significantly,O
higher,O
levels,O
of,O
proteinuria,I-Entity
compared,O
with,O
control,O
and,O
treatment,O
groups,O
(,O
P,O
<,O
0.05,O
),O
.,O
Urine,O
nitrite,I-Entity
levels,O
were,O
significantly,O
increased,O
in,O
the,O
ADR,I-Entity
-,O
nephropathy,I-Entity
group,O
(,O
P,O
<,O
0.05,O
),O
.,O
In,O
the,O
IPRK,O
phenylephrine,I-Entity
and,O
acetylcholine,I-Entity
related,O
responses,O
were,O
significantly,O
impaired,O
in,O
the,O
ADR,I-Entity
-,O
nephropathy,I-Entity
group,O
.,O
However,O
",",O
in,O
the,O
ADR,I-Entity
-,O
nephropathy,I-Entity
group,O
",",O
numerous,O
apoptotic,O
cells,O
were,O
identified,O
in,O
the,O
tubulointerstitial,O
areas,O
.,O
Treatment,O
with,O
AG,I-Entity
prevented,O
the,O
impairment,O
of,O
renal,O
vascular,O
bed,O
responses,O
and,O
reduced,O
both,O
urine,O
nitrite,I-Entity
levels,O
and,O
apoptosis,O
to,O
control,O
levels,O
.,O
:,O
We,O
suggest,O
that,O
interactions,O
between,O
NO,I-Entity
and,O
apoptosis,O
are,O
important,O
in,O
the,O
pathogenesis,O
of,O
the,O
ADR,I-Entity
-,O
induced,O
nephrosis,I-Entity
.,O
The,O
attenuating,O
effect,O
of,O
carteolol,B-Entity
hydrochloride,I-Entity
",",O
a,O
beta,O
-,O
adrenoceptor,O
antagonist,O
",",O
on,O
neuroleptic,O
-,O
induced,O
catalepsy,I-Entity
in,O
rats,O
.,O
It,O
is,O
known,O
that,O
beta,O
-,O
adrenoceptor,O
antagonists,O
are,O
effective,O
in,O
the,O
treatment,O
of,O
akathisia,I-Entity
",",O
one,O
of,O
the,O
extrapyramidal,O
side,O
effects,O
that,O
occur,O
during,O
neuroleptic,O
treatment,O
.,O
Neuroleptic,O
-,O
induced,O
catalepsy,I-Entity
",",O
a,O
model,O
of,O
neuroleptic,O
-,O
induced,O
extrapyramidal,O
side,O
effects,O
",",O
was,O
considered,O
suitable,O
as,O
a,O
model,O
for,O
predicting,O
neuroleptic,O
-,O
induced,O
akathisia,I-Entity
in,O
humans,O
",",O
although,O
neuroleptic,O
-,O
induced,O
catalepsy,I-Entity
was,O
not,O
considered,O
a,O
specific,O
test,O
for,O
neuroleptic,O
-,O
induced,O
akathisia,I-Entity
.,O
Therefore,O
",",O
the,O
effects,O
of,O
carteolol,I-Entity
",",O
a,O
beta,O
-,O
adrenoceptor,O
antagonist,O
",",O
on,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
in,O
rats,O
were,O
behaviorally,O
studied,O
and,O
compared,O
with,O
those,O
of,O
propranolol,I-Entity
and,O
biperiden,I-Entity
",",O
a,O
muscarinic,O
receptor,O
antagonist,O
.,O
Carteolol,I-Entity
",",O
as,O
well,O
as,O
propranolol,I-Entity
and,O
biperiden,I-Entity
",",O
inhibited,O
the,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
.,O
The,O
inhibitory,O
effect,O
of,O
carteolol,I-Entity
was,O
almost,O
comparable,O
to,O
that,O
of,O
propranolol,I-Entity
",",O
but,O
was,O
weaker,O
than,O
that,O
of,O
biperiden,I-Entity
.,O
Carteolol,I-Entity
did,O
not,O
evoke,O
postsynaptic,O
dopamine,I-Entity
receptor,O
-,O
stimulating,O
behavioral,O
signs,O
such,O
as,O
stereotypy,O
and,O
hyperlocomotion,I-Entity
in,O
rats,O
.,O
Carteolol,I-Entity
did,O
not,O
antagonize,O
the,O
inhibitory,O
effects,O
of,O
haloperidol,I-Entity
on,O
apomorphine,I-Entity
-,O
induced,O
stereotypy,O
and,O
locomotor,O
activity,O
in,O
rats,O
.,O
In,O
addition,O
",",O
carteolol,I-Entity
did,O
not,O
evoke,O
5-HT1A,O
receptor,O
-,O
stimulating,O
behavioral,O
signs,O
such,O
as,O
flat,O
body,O
posture,O
and,O
forepaw,O
treading,O
and,O
did,O
not,O
inhibit,O
5-hydroxytryptophan,I-Entity
-,O
induced,O
head,O
twitch,O
in,O
rats,O
.,O
Finally,O
",",O
carteolol,I-Entity
did,O
not,O
inhibit,O
physostigmine,I-Entity
-,O
induced,O
lethality,O
in,O
rats,O
.,O
These,O
results,O
strongly,O
suggest,O
that,O
carteolol,I-Entity
improves,O
haloperidol,I-Entity
-,O
induced,O
catalepsy,I-Entity
via,O
its,O
beta,O
-,O
adrenoceptor,O
antagonistic,O
activity,O
and,O
is,O
expected,O
to,O
be,O
effective,O
in,O
the,O
treatment,O
of,O
akathisia,I-Entity
without,O
attenuating,O
neuroleptic,O
-,O
induced,O
antipsychotic,O
effects,O
due,O
to,O
its,O
postsynaptic,O
dopamine,I-Entity
receptor,O
antagonistic,O
activity,O
.,O
Penicillamine,I-Entity
-,O
induced,O
rapidly,O
progressive,O
glomerulonephritis,I-Entity
in,O
a,O
patient,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
A,O
67-year,O
-,O
old,O
woman,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
presented,O
rapidly,O
progressive,O
glomerulonephritis,I-Entity
(,O
RPGN,I-Entity
),O
after,O
5,O
months,O
of,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
(,O
250,O
mg,O
/,O
day,O
),O
treatment,O
.,O
Light,O
microscopy,O
study,O
showed,O
severe,O
glomerulonephritis,I-Entity
with,O
crescent,O
formation,O
in,O
60%,O
of,O
the,O
glomeruli,O
and,O
infiltration,O
of,O
inflammatory,O
cells,O
in,O
the,O
wall,O
of,O
an,O
arteriole,O
.,O
The,O
patient,O
was,O
treated,O
with,O
steroid,I-Entity
pulse,O
",",O
plasmapheresis,O
",",O
cyclophosphamide,I-Entity
and,O
antiplatelet,B-Entity
agents,I-Entity
.,O
This,O
new,O
case,O
of,O
RPGN,I-Entity
in,O
the,O
course,O
of,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
treatment,O
emphasizes,O
the,O
need,O
for,O
frequent,O
monitoring,O
of,O
renal,O
function,O
and,O
evaluation,O
of,O
urinary,O
sediment,O
and,O
proteinuria,I-Entity
in,O
these,O
patients,O
.,O
The,O
prompt,O
discontinuation,O
of,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
and,O
vigorous,O
treatment,O
measures,O
could,O
allow,O
for,O
a,O
good,O
prognosis,O
as,O
in,O
this,O
case,O
.,O
Nature,O
",",O
time,O
course,O
and,O
dose,O
dependence,O
of,O
zidovudine,I-Entity
-,O
related,O
side,O
effects,O
:,O
results,O
from,O
the,O
Multicenter,O
Canadian,O
Azidothymidine,I-Entity
Trial,O
.,O
To,O
characterize,O
the,O
nature,O
",",O
time,O
course,O
and,O
dose,O
dependency,O
of,O
zidovudine,I-Entity
-,O
related,O
side,O
effects,O
",",O
we,O
undertook,O
a,O
multicenter,O
",",O
prospective,O
",",O
dose,O
-,O
range,O
finding,O
study,O
.,O
Our,O
study,O
group,O
consisted,O
of,O
74,O
HIV,O
-,O
positive,O
homosexual,O
men,O
belonging,O
to,O
groups,O
II,O
B,O
",",O
III,O
and,O
IV,O
C2,O
from,O
the,O
Centers,O
for,O
Disease,O
Control,O
(,O
CDC,O
),O
classification,O
of,O
HIV,B-Entity
disease,I-Entity
.,O
Following,O
a,O
3-week,O
observation,O
period,O
",",O
volunteers,O
were,O
treated,O
with,O
zidovudine,I-Entity
600,O
mg,O
/,O
day,O
for,O
18,O
weeks,O
",",O
900,O
mg,O
/,O
day,O
for,O
9,O
weeks,O
and,O
1200,O
mg,O
Symptomatic,O
adverse,O
effects,O
were,O
present,O
in,O
96%,O
of,O
subjects,O
",",O
most,O
commonly,O
nausea,I-Entity
(,O
64%,O
),O
",",O
fatigue,I-Entity
(,O
55%,O
),O
and,O
headache,I-Entity
(,O
49%,O
),O
.,O
Bone,O
marrow,O
changes,O
occurred,O
rapidly,O
as,O
demonstrated,O
by,O
megaloblastosis,I-Entity
in,O
95%,O
of,O
65,O
specimens,O
at,O
week,O
18.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Bilateral,B-Entity
optic,I-Entity
neuropathy,I-Entity
due,O
to,O
combined,O
ethambutol,I-Entity
and,O
isoniazid,I-Entity
treatment,O
.,O
The,O
case,O
of,O
a,O
40-year,O
-,O
old,O
patient,O
who,O
underwent,O
an,O
unsuccessful,O
cadaver,O
kidney,O
transplantation,O
and,O
was,O
treated,O
with,O
ethambutol,I-Entity
and,O
isoniazid,I-Entity
is,O
reported,O
.,O
A,O
bilateral,B-Entity
retrobulbar,I-Entity
neuropathy,I-Entity
with,O
an,O
unusual,O
central,O
bitemporal,O
hemianopic,O
scotoma,I-Entity
was,O
found,O
.,O
Ethambutol,I-Entity
was,O
stopped,O
and,O
only,O
small,O
improvement,O
of,O
the,O
visual,O
acuity,O
followed,O
.,O
Isoniazid,I-Entity
was,O
discontinued,O
later,O
",",O
followed,O
by,O
a,O
dramatic,O
improvement,O
in,O
the,O
visual,O
acuity,O
.,O
The,O
hazards,O
of,O
optic,O
nerve,O
toxicity,I-Entity
due,O
to,O
ethambutol,I-Entity
are,O
known,O
.,O
We,O
emphasize,O
the,O
potential,O
danger,O
in,O
the,O
use,O
of,O
ethambutol,I-Entity
and,O
isoniazid,I-Entity
.,O
Progestational,O
agents,O
and,O
blood,B-Entity
coagulation,I-Entity
.,O
Thromboembolic,I-Entity
and,O
other,O
complications,O
of,O
oral,B-Entity
contraceptive,I-Entity
therapy,O
in,O
relationship,O
to,O
pretreatment,O
levels,O
of,O
blood,B-Entity
coagulation,I-Entity
factors,O
:,O
summary,O
report,O
of,O
a,O
ten,O
-,O
year,O
study,O
.,O
During,O
a,O
ten,O
-,O
year,O
period,O
",",O
348,O
women,O
were,O
studied,O
for,O
a,O
total,O
of,O
"5,877",O
patient,O
months,O
in,O
four,O
separate,O
studies,O
relating,O
oral,B-Entity
contraceptives,I-Entity
to,O
changes,O
in,O
hematologic,O
parameters,O
.,O
Significant,O
increases,O
in,O
certain,O
factors,O
of,O
the,O
blood,B-Entity
coagulation,I-Entity
and,O
fibrinolysin,O
systems,O
(,O
factors,O
I,O
",",O
II,O
",",O
VII,O
",",O
VIII,O
",",O
IX,O
",",O
and,O
X,O
and,O
plasminogen,O
),O
were,O
observed,O
in,O
the,O
treated,O
groups,O
.,O
All,O
four,O
had,O
an,O
abnormal,O
blood,B-Entity
coagulation,I-Entity
profile,O
",",O
suggesting,O
"""",O
hypercoagulability,I-Entity
"""",O
before,O
initiation,O
of,O
therapy,O
.,O
One,O
of,O
these,O
patients,O
developed,O
a,O
myocardial,B-Entity
infarction,I-Entity
before,O
receiving,O
any,O
medication,O
",",O
shortly,O
after,O
the,O
base,O
-,O
line,O
values,O
were,O
obtained,O
.,O
One,O
patient,O
developed,O
retinopathy,I-Entity
19,O
months,O
after,O
she,O
began,O
therapy,O
",",O
and,O
another,O
developed,O
thrombophlebitis,I-Entity
after,O
27,O
months,O
of,O
therapy,O
.,O
The,O
fourth,O
patient,O
developed,O
thrombophlebitis,I-Entity
14,O
days,O
after,O
initiation,O
of,O
contraceptive,O
therapy,O
.,O
Previous,O
studies,O
suggested,O
the,O
possiblility,O
of,O
increased,O
propensity,O
for,O
thromboembolic,B-Entity
episodes,I-Entity
in,O
patients,O
possessing,O
the,O
A,O
antigen,O
.,O
It,O
appears,O
from,O
these,O
data,O
that,O
hematologic,O
work,O
-,O
ups,O
may,O
be,O
useful,O
in,O
women,O
who,O
are,O
about,O
to,O
start,O
long,O
-,O
term,O
oral,B-Entity
contraceptive,I-Entity
therapy,O
.,O
Cardiac,B-Entity
arrest,I-Entity
in,O
a,O
child,O
with,O
cerebral,B-Entity
palsy,I-Entity
undergoing,O
sevoflurane,I-Entity
induction,O
of,O
anesthesia,O
after,O
preoperative,O
clonidine,I-Entity
.,O
Clonidine,I-Entity
is,O
a,O
frequently,O
administered,O
alpha2-adrenergic,O
agonist,O
which,O
can,O
decrease,O
heart,O
rate,O
and,O
blood,O
pressure,O
.,O
We,O
present,O
a,O
case,O
of,O
a,O
5-year,O
-,O
old,O
child,O
with,O
cerebral,B-Entity
palsy,I-Entity
and,O
seizure,B-Entity
disorder,I-Entity
",",O
receiving,O
clonidine,I-Entity
for,O
restlessness,I-Entity
",",O
who,O
presented,O
for,O
placement,O
of,O
a,O
baclofen,I-Entity
pump,O
.,O
Without,O
the,O
knowledge,O
of,O
the,O
medical,O
personnel,O
",",O
the,O
patient,O
's,O
mother,O
administered,O
three,O
doses,O
of,O
clonidine,I-Entity
during,O
the,O
evening,O
before,O
and,O
morning,O
of,O
surgery,O
to,O
reduce,O
anxiety,I-Entity
.,O
During,O
induction,O
of,O
anesthesia,O
",",O
the,O
patient,O
developed,O
bradycardia,I-Entity
and,O
hypotension,I-Entity
requiring,O
cardiac,O
resuscitation,O
.,O
There,O
are,O
no,O
previous,O
reports,O
of,O
clonidine,I-Entity
-,O
associated,O
cardiac,B-Entity
arrest,I-Entity
in,O
a,O
child,O
undergoing,O
induction,O
of,O
anesthesia,O
.,O
Effects,O
of,O
UMB24,I-Entity
and,O
(,O
+,O
/-)-SM,B-Entity
21,I-Entity
",",O
putative,O
sigma2-preferring,O
antagonists,O
",",O
on,O
behavioral,O
toxic,O
and,O
stimulant,O
effects,O
of,O
cocaine,I-Entity
in,O
mice,O
.,O
Earlier,O
studies,O
have,O
demonstrated,O
that,O
antagonism,O
of,O
sigma1,O
receptors,O
attenuates,O
the,O
convulsive,I-Entity
",",O
lethal,O
",",O
locomotor,O
stimulatory,O
and,O
rewarding,O
actions,O
of,O
cocaine,I-Entity
in,O
mice,O
.,O
To,O
begin,O
addressing,O
this,O
need,O
",",O
we,O
characterized,O
UMB24,I-Entity
(,O
1-(2-phenethyl)-4-(2-pyridyl)-piperazine,I-Entity
),O
and,O
(,O
+,O
/-)-SM,B-Entity
21,I-Entity
(,O
3alpha,B-Entity
-,I-Entity
tropanyl-2-(4-chorophenoxy)butyrate,I-Entity
),O
in,O
receptor,O
binding,O
and,O
behavioral,O
studies,O
.,O
Receptor,O
binding,O
studies,O
confirmed,O
that,O
UMB24,I-Entity
and,O
(,O
+,O
/-)-SM,B-Entity
21,I-Entity
display,O
preferential,O
affinity,O
for,O
sigma2,O
over,O
sigma1,O
receptors,O
.,O
In,O
behavioral,O
studies,O
",",O
pretreatment,O
of,O
Swiss,O
Webster,O
mice,O
with,O
UMB24,I-Entity
or,O
(,O
+,O
/-)-SM,B-Entity
21,I-Entity
significantly,O
attenuated,O
cocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
and,O
locomotor,O
activity,O
",",O
but,O
not,O
lethality,O
.,O
When,O
administered,O
alone,O
",",O
(,O
+,O
/-)-SM,B-Entity
21,I-Entity
produced,O
no,O
significant,O
effects,O
compared,O
to,O
control,O
injections,O
of,O
saline,O
",",O
but,O
UMB24,I-Entity
had,O
locomotor,O
depressant,O
actions,O
.,O
Together,O
",",O
the,O
data,O
suggest,O
that,O
sigma2,O
receptor,O
antagonists,O
have,O
the,O
potential,O
to,O
attenuate,O
some,O
of,O
the,O
behavioral,O
effects,O
of,O
cocaine,I-Entity
",",O
and,O
further,O
development,O
of,O
more,O
selective,O
",",O
high,O
affinity,O
ligands,O
are,O
warranted,O
.,O
Methimazole,I-Entity
-,O
induced,O
cholestatic,B-Entity
jaundice,I-Entity
.,O
Methimazole,I-Entity
is,O
a,O
widely,O
used,O
and,O
generally,O
well,O
-,O
tolerated,O
antithyroid,O
agent,O
.,O
A,O
43-year,O
-,O
old,O
woman,O
had,O
severe,O
jaundice,I-Entity
and,O
itching,I-Entity
1,O
month,O
after,O
receiving,O
methimazole,I-Entity
(,O
10,O
mg,O
tid,O
),O
and,O
propranolol,I-Entity
(,O
20,O
mg,O
tid,O
),O
for,O
treatment,O
of,O
hyperthyroidism,I-Entity
.,O
The,O
patient,O
continued,O
treatment,O
for,O
another,O
4,O
days,O
after,O
the,O
appearance,O
of,O
jaundice,I-Entity
until,O
she,O
finished,O
both,O
medications,O
.,O
When,O
seen,O
at,O
the,O
emergency,O
department,O
2,O
weeks,O
later,O
",",O
she,O
still,O
had,O
severe,O
icterus,I-Entity
",",O
pruritus,I-Entity
",",O
and,O
hyperbilirubinemia,I-Entity
",",O
formed,O
mainly,O
of,O
the,O
conjugated,O
fraction,O
.,O
Methimazole,I-Entity
-,O
induced,O
cholestasis,I-Entity
was,O
diagnosed,O
",",O
and,O
propranolol,I-Entity
therapy,O
was,O
resumed,O
.,O
Over,O
the,O
following,O
9,O
days,O
",",O
the,O
symptoms,O
improved,O
and,O
plasma,O
bilirubin,I-Entity
levels,O
were,O
normal,O
after,O
12,O
weeks,O
without,O
methimazole,I-Entity
.,O
In,O
rare,O
cases,O
within,O
the,O
first,O
few,O
weeks,O
of,O
therapy,O
",",O
this,O
drug,O
can,O
cause,O
severe,O
and,O
reversible,O
cholestatic,B-Entity
jaundice,I-Entity
.,O
Physicians,O
and,O
patients,O
should,O
be,O
aware,O
of,O
this,O
adverse,O
effect,O
so,O
that,O
",",O
upon,O
occurrence,O
",",O
they,O
can,O
discontinue,O
methimazole,I-Entity
therapy,O
and,O
avoid,O
unnecessary,O
invasive,O
procedures,O
.,O
Ciprofloxacin,I-Entity
-,O
induced,O
acute,O
interstitial,B-Entity
nephritis,I-Entity
and,O
autoimmune,B-Entity
hemolytic,I-Entity
anemia,I-Entity
.,O
Ciprofloxacin,I-Entity
has,O
been,O
associated,O
with,O
several,O
side,O
effects,O
including,O
interstitial,B-Entity
nephritis,I-Entity
and,O
hemolytic,B-Entity
anemia,I-Entity
.,O
In,O
this,O
report,O
",",O
we,O
describe,O
a,O
case,O
of,O
ciprofloxacin,I-Entity
-,O
induced,O
interstitial,B-Entity
nephritis,I-Entity
and,O
autoimmune,B-Entity
hemolytic,I-Entity
anemia,I-Entity
.,O
Hemolytic,B-Entity
anemia,I-Entity
improved,O
after,O
stopping,O
the,O
drug,O
and,O
initiation,O
of,O
steroid,I-Entity
therapy,O
.,O
Unfortunately,O
",",O
acute,O
interstitial,B-Entity
nephritis,I-Entity
was,O
irreversible,O
and,O
the,O
patient,O
developed,O
end,B-Entity
-,I-Entity
stage,I-Entity
renal,I-Entity
disease,I-Entity
.,O
Contribution,O
of,O
sodium,B-Entity
valproate,I-Entity
to,O
the,O
syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
secretion,I-Entity
of,I-Entity
antidiuretic,I-Entity
hormone,I-Entity
.,O
We,O
report,O
the,O
case,O
of,O
a,O
62-year,O
-,O
old,O
man,O
who,O
was,O
administered,O
sodium,B-Entity
valproate,I-Entity
(,O
VPA,I-Entity
),O
and,O
who,O
subsequently,O
developed,O
the,O
syndrome,B-Entity
of,I-Entity
inappropriate,I-Entity
secretion,I-Entity
of,I-Entity
antidiuretic,I-Entity
hormone,I-Entity
(,O
SIADH,I-Entity
),O
.,O
He,O
had,O
been,O
taking,O
VPA,I-Entity
for,O
treatment,O
of,O
idiopathic,O
generalized,O
tonic,B-Entity
-,I-Entity
clonic,I-Entity
convulsions,I-Entity
since,O
he,O
was,O
56,O
years,O
old,O
.,O
After,O
substituting,O
VPA,I-Entity
with,O
zonisamide,I-Entity
",",O
the,O
serum,O
sodium,I-Entity
level,O
returned,O
to,O
normal,O
.,O
We,O
consider,O
this,O
episode,O
of,O
SIADH,I-Entity
to,O
be,O
the,O
result,O
of,O
a,O
combination,O
of,O
factors,O
including,O
a,O
weakness,B-Entity
of,I-Entity
the,I-Entity
central,I-Entity
nervous,I-Entity
system,I-Entity
and,O
the,O
long,O
-,O
term,O
administration,O
of,O
VPA,I-Entity
.,O
Vasopressin,I-Entity
in,O
the,O
treatment,O
of,O
milrinone,I-Entity
-,O
induced,O
hypotension,I-Entity
in,O
severe,O
heart,B-Entity
failure,I-Entity
.,O
The,O
use,O
of,O
phosphodiesterase,O
inhibitors,O
such,O
as,O
milrinone,I-Entity
in,O
the,O
treatment,O
of,O
severe,O
heart,B-Entity
failure,I-Entity
is,O
frequently,O
restricted,O
because,O
they,O
cause,O
vasodilation,O
and,O
hypotension,I-Entity
.,O
In,O
patients,O
with,O
decompensated,O
heart,B-Entity
failure,I-Entity
with,O
hypotension,I-Entity
after,O
treatment,O
with,O
milrinone,I-Entity
",",O
low,O
doses,O
of,O
vasopressin,I-Entity
restored,O
blood,O
pressure,O
without,O
inhibiting,O
the,O
inotropic,O
effect,O
of,O
milrinone,I-Entity
.,O
Halogenated,O
anesthetics,O
form,O
liver,O
adducts,O
and,O
antigens,O
that,O
cross,O
-,O
react,O
with,O
halothane,I-Entity
-,O
induced,O
antibodies,O
.,O
Two,O
halogenated,O
anesthetics,O
",",O
enflurane,I-Entity
and,O
isoflurane,I-Entity
",",O
have,O
been,O
associated,O
with,O
an,O
allergic,O
-,O
type,O
hepatic,B-Entity
injury,I-Entity
both,O
alone,O
and,O
following,O
previous,O
exposure,O
to,O
halothane,I-Entity
.,O
Halothane,I-Entity
hepatitis,I-Entity
appears,O
to,O
involve,O
an,O
aberrant,O
immune,O
response,O
.,O
An,O
antibody,O
response,O
to,O
a,O
protein,O
-,O
bound,O
biotransformation,O
product,O
(,O
trifluoroacetyl,I-Entity
adduct,O
),O
has,O
been,O
detected,O
on,O
halothane,I-Entity
hepatitis,I-Entity
patients,O
.,O
This,O
study,O
was,O
performed,O
to,O
determine,O
cross,O
-,O
reactivity,O
between,O
enflurane,I-Entity
and,O
isoflurane,I-Entity
with,O
the,O
hypersensitivity,I-Entity
induced,O
by,O
halothane,I-Entity
.,O
The,O
subcellular,O
and,O
lobular,O
production,O
of,O
hepatic,O
neoantigens,O
recognized,O
by,O
halothane,I-Entity
-,O
induced,O
antibodies,O
following,O
enflurane,I-Entity
and,O
isoflurane,I-Entity
",",O
and,O
the,O
biochemical,O
nature,O
of,O
these,O
neoantigens,O
was,O
investigated,O
in,O
two,O
animal,O
models,O
.,O
Enflurane,I-Entity
administration,O
resulted,O
in,O
neoantigens,O
detected,O
in,O
both,O
the,O
microsomal,O
and,O
cytosolic,O
fraction,O
of,O
liver,O
homogenates,O
and,O
in,O
the,O
centrilobular,O
region,O
of,O
the,O
liver,O
.,O
This,O
supports,O
and,O
extends,O
previous,O
evidence,O
for,O
a,O
mechanism,O
by,O
which,O
enflurane,I-Entity
and/or,O
isoflurane,I-Entity
could,O
produce,O
a,O
hypersensitivity,I-Entity
condition,O
similar,O
to,O
that,O
of,O
halothane,I-Entity
hepatitis,I-Entity
either,O
alone,O
or,O
subsequent,O
to,O
halothane,I-Entity
administration,O
.,O
Induction,O
by,O
paracetamol,I-Entity
of,O
bladder,B-Entity
and,I-Entity
liver,I-Entity
tumours,I-Entity
in,O
the,O
rat,O
.,O
Groups,O
of,O
male,O
and,O
female,O
inbred,O
Leeds,O
strain,O
rats,O
were,O
fed,O
diets,O
containing,O
either,O
0.5%,O
or,O
1.0%,O
paracetamol,I-Entity
by,O
weight,O
for,O
up,O
to,O
18,O
months,O
.,O
Papillomas,I-Entity
of,O
the,O
transitional,O
epithelium,O
of,O
the,O
bladder,O
developed,O
in,O
all,O
paracetamol,I-Entity
-,O
treated,O
groups,O
",",O
and,O
three,O
rats,O
bore,O
bladder,B-Entity
carcinomas,I-Entity
.,O
However,O
",",O
significant,O
yields,O
of,O
bladder,B-Entity
tumours,I-Entity
were,O
only,O
obtained,O
from,O
low,O
dosage,O
females,O
and,O
high,O
dosage,O
males,O
.,O
Additionally,O
",",O
20,O
to,O
25%,O
of,O
paracetamol,I-Entity
-,O
treated,O
rats,O
developed,O
hyperplasia,I-Entity
of,O
the,O
bladder,O
epithelium,O
",",O
which,O
was,O
not,O
coincident,O
with,O
the,O
presence,O
of,O
bladder,B-Entity
calculi,I-Entity
.,O
A,O
low,O
yield,O
of,O
tumours,I-Entity
at,O
various,O
other,O
sites,O
also,O
arose,O
following,O
paracetamol,I-Entity
feeding,O
.,O
An,O
electron,O
microscope,O
study,O
of,O
the,O
livers,O
of,O
paracetamol,I-Entity
-,O
treated,O
rats,O
revealed,O
ultrastructural,O
changes,O
in,O
the,O
hepatocytes,O
that,O
resemble,O
those,O
that,O
result,O
from,O
exposure,O
to,O
a,O
variety,O
of,O
known,O
hepatocarcinogens,I-Entity
.,O
Local,O
anesthetics,O
that,O
are,O
commonly,O
used,O
in,O
ophthalmic,O
surgery,O
(,O
0.75%,O
bupivacaine,B-Entity
hydrochloride,I-Entity
",",O
2.0%,O
mepivacaine,B-Entity
hydrochloride,I-Entity
",",O
and,O
2.0%,O
lidocaine,B-Entity
hydrochloride,I-Entity
plus,O
"1:100,000",O
epinephrine,I-Entity
),O
were,O
injected,O
into,O
the,O
retrobulbar,O
area,O
of,O
rat,O
eyes,O
.,O
Muscle,B-Entity
degeneration,I-Entity
is,O
followed,O
by,O
regeneration,O
of,O
the,O
damaged,O
muscle,O
fibers,O
.,O
In,O
addition,O
to,O
muscle,B-Entity
damage,I-Entity
",",O
severe,O
damage,O
was,O
also,O
seen,O
in,O
harderian,O
glands,O
",",O
especially,O
after,O
exposure,O
to,O
mepivacaine,I-Entity
and,O
lidocaine,I-Entity
plus,O
epinephrine,I-Entity
.,O
With,O
these,O
findings,O
in,O
rats,O
",",O
it,O
is,O
hypothesized,O
that,O
the,O
temporary,O
diplopia,I-Entity
sometimes,O
seen,O
in,O
patients,O
after,O
ophthalmic,O
surgery,O
might,O
be,O
due,O
to,O
anesthetic,O
-,O
induced,O
damage,O
to,O
the,O
extraocular,O
muscles,O
.,O
Reversal,O
of,O
neuroleptic,O
-,O
induced,O
catalepsy,I-Entity
by,O
novel,O
aryl,B-Entity
-,I-Entity
piperazine,I-Entity
anxiolytic,O
drugs,O
.,O
The,O
novel,O
anxiolytic,O
drug,O
",",O
buspirone,I-Entity
",",O
reverses,O
catalepsy,I-Entity
induced,O
by,O
haloperidol,I-Entity
.,O
A,O
series,O
of,O
aryl,B-Entity
-,I-Entity
piperazine,I-Entity
analogues,O
of,O
buspirone,I-Entity
and,O
other,O
5-hydroxytryptaminergic,B-Entity
agonists,I-Entity
were,O
tested,O
for,O
their,O
ability,O
to,O
reverse,O
haloperidol,I-Entity
induced,O
catalepsy,I-Entity
.,O
Those,O
drugs,O
with,O
strong,O
affinity,O
for,O
5-hydroxytryptamine1a,I-Entity
receptors,O
were,O
able,O
to,O
reverse,O
catalepsy,I-Entity
.,O
Drugs,O
with,O
affinity,O
for,O
other,O
5-HT,I-Entity
receptors,O
or,O
weak,O
affinity,O
were,O
ineffective,O
.,O
However,O
",",O
inhibition,O
of,O
postsynaptic,O
5-HT,I-Entity
receptors,O
neither,O
inhibited,O
nor,O
potentiated,O
reversal,O
of,O
catalepsy,I-Entity
and,O
leaves,O
open,O
the,O
question,O
as,O
to,O
the,O
site,O
or,O
mechanism,O
for,O
this,O
effect,O
.,O
Diazepam,I-Entity
facilitates,O
reflex,O
bradycardia,I-Entity
in,O
conscious,O
rats,O
.,O
The,O
effects,O
of,O
diazepam,I-Entity
on,O
cardiovascular,O
function,O
were,O
assessed,O
in,O
conscious,O
rats,O
.,O
Intravenous,O
administration,O
of,O
diazepam,I-Entity
(,O
1,O
-,O
30,O
mg,O
kg-1,O
),O
produced,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
both,O
the,O
mean,O
arterial,O
pressure,O
and,O
the,O
heart,O
rate,O
.,O
Also,O
",",O
reflex,O
bradycardia,I-Entity
was,O
produced,O
in,O
rats,O
by,O
intravenous,O
infusion,O
of,O
adrenaline,I-Entity
(,O
1.25,O
-,O
2.5,O
micrograms,O
kg-1,O
),O
.,O
Intravenous,O
pretreatment,O
of,O
the,O
rats,O
with,O
diazepam,I-Entity
",",O
although,O
causing,O
no,O
change,O
in,O
the,O
adrenaline,I-Entity
-,O
induced,O
pressor,O
effect,O
",",O
did,O
enhance,O
the,O
adrenaline,I-Entity
-,O
induced,O
reflex,O
bradycardia,I-Entity
.,O
However,O
",",O
the,O
diazepam,I-Entity
enhancement,O
of,O
adrenaline,I-Entity
-,O
induced,O
reflex,O
bradycardia,I-Entity
was,O
antagonized,O
by,O
pretreatment,O
of,O
rats,O
with,O
an,O
intravenous,O
dose,O
of,O
picrotoxin,I-Entity
(,O
an,O
agent,O
blocks,O
chloride,I-Entity
channels,O
by,O
binding,O
to,O
sites,O
associated,O
with,O
the,O
benzodiazepine,I-Entity
-,O
GABA,I-Entity
-,O
chloride,I-Entity
channel,O
macromolecular,O
complex,O
),O
.,O
The,O
data,O
indicate,O
that,O
diazepam,I-Entity
acts,O
through,O
the,O
benzodiazepine,I-Entity
-,O
GABA,I-Entity
-,O
chloride,I-Entity
channel,O
macromolecular,O
complex,O
within,O
the,O
central,O
nervous,O
system,O
to,O
facilitate,O
reflex,O
bradycardia,I-Entity
mediated,O
through,O
baroreceptor,O
reflexes,O
in,O
response,O
to,O
an,O
acute,O
increase,O
in,O
arterial,O
pressure,O
.,O
Chronic,O
carbamazepine,I-Entity
inhibits,O
the,O
development,O
of,O
local,O
anesthetic,O
seizures,I-Entity
kindled,O
by,O
cocaine,I-Entity
and,O
lidocaine,I-Entity
.,O
The,O
effects,O
of,O
carbamazepine,I-Entity
(,O
CBZ,I-Entity
),O
treatment,O
on,O
local,O
anesthetic,O
-,O
kindled,O
seizures,I-Entity
and,O
lethality,O
were,O
evaluated,O
in,O
different,O
stages,O
of,O
the,O
kindling,O
process,O
and,O
under,O
different,O
methods,O
of,O
CBZ,I-Entity
administration,O
.,O
Chronic,O
oral,O
CBZ,I-Entity
inhibited,O
the,O
development,O
of,O
both,O
lidocaine-,I-Entity
and,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
",",O
but,O
had,O
little,O
effect,O
on,O
the,O
fully,O
developed,O
local,O
anesthetic,O
seizures,I-Entity
.,O
Chronic,O
CBZ,I-Entity
also,O
decreased,O
the,O
incidence,O
of,O
seizure,I-Entity
-,O
related,O
mortality,O
in,O
the,O
cocaine,I-Entity
-,O
injected,O
rats,O
.,O
Acute,O
CBZ,I-Entity
over,O
a,O
range,O
of,O
doses,O
(,O
15,O
-,O
50,O
mg,O
/,O
kg,O
),O
had,O
no,O
effect,O
on,O
completed,O
lidocaine,I-Entity
-,O
kindled,O
or,O
acute,O
cocaine,I-Entity
-,O
induced,O
seizures,I-Entity
.,O
injection,O
of,O
CBZ,I-Entity
(,O
15,O
mg,O
/,O
kg,O
),O
also,O
was,O
without,O
effect,O
on,O
the,O
development,O
of,O
lidocaine-,I-Entity
or,O
cocaine,I-Entity
-,O
kindled,O
seizures,I-Entity
.,O
The,O
differential,O
effects,O
of,O
CBZ,I-Entity
depending,O
upon,O
stage,O
of,O
seizure,I-Entity
development,O
suggest,O
that,O
distinct,O
mechanisms,O
underlie,O
the,O
development,O
versus,O
maintenance,O
of,O
local,O
anesthetic,O
-,O
kindled,O
seizures,I-Entity
.,O
The,O
effectiveness,O
of,O
chronic,O
but,O
not,O
repeated,O
",",O
intermittent,O
injections,O
of,O
CBZ,I-Entity
suggests,O
that,O
different,O
biochemical,O
consequences,O
result,O
from,O
the,O
different,O
treatment,O
regimens,O
.,O
The,O
possible,O
utility,O
of,O
chronic,O
CBZ,I-Entity
in,O
preventing,O
the,O
development,O
of,O
toxic,O
side,O
effects,O
in,O
human,O
cocaine,I-Entity
users,O
is,O
suggested,O
by,O
these,O
data,O
",",O
but,O
remains,O
to,O
be,O
directly,O
evaluated,O
.,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
in,O
the,O
treatment,O
of,O
localized,B-Entity
scleroderma,I-Entity
.,O
Localized,B-Entity
scleroderma,I-Entity
has,O
no,O
recognized,O
internal,O
organ,O
involvement,O
but,O
may,O
be,O
disfiguring,O
and,O
disabling,O
when,O
the,O
cutaneous,O
lesions,O
are,O
extensive,O
or,O
affect,O
children,O
.,O
There,O
is,O
no,O
accepted,O
or,O
proven,O
treatment,O
for,O
localized,B-Entity
scleroderma,I-Entity
.,O
Case,O
reports,O
of,O
11,O
patients,O
with,O
severe,O
",",O
extensive,O
localized,B-Entity
scleroderma,I-Entity
who,O
were,O
treated,O
with,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
are,O
summarized,O
in,O
this,O
article,O
.,O
Joint,O
stiffness,O
and,O
contractures,I-Entity
also,O
improved,O
.,O
The,O
dose,O
of,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
associated,O
with,O
a,O
favorable,O
response,O
was,O
as,O
low,O
as,O
2,O
to,O
5,O
mg,O
/,O
kg,O
per,O
day,O
given,O
over,O
a,O
period,O
ranging,O
from,O
15,O
to,O
53,O
months,O
.,O
D,B-Entity
-,I-Entity
Penicillamine,I-Entity
caused,O
nephrotic,B-Entity
syndrome,I-Entity
in,O
1,O
patient,O
and,O
milder,O
reversible,O
proteinuria,I-Entity
in,O
3,O
other,O
patients,O
;,O
none,O
developed,O
renal,B-Entity
insufficiency,I-Entity
.,O
These,O
data,O
suggest,O
that,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
may,O
be,O
effective,O
in,O
severe,O
cases,O
of,O
localized,B-Entity
scleroderma,I-Entity
.,O
Preservation,O
of,O
renal,O
blood,O
flow,O
during,O
hypotension,I-Entity
induced,O
with,O
fenoldopam,I-Entity
in,O
dogs,O
.,O
The,O
introduction,O
of,O
drugs,O
that,O
could,O
induce,O
hypotension,I-Entity
with,O
different,O
pharmacological,O
actions,O
would,O
be,O
advantageous,O
because,O
side,O
effects,O
unique,O
to,O
a,O
specific,O
drug,O
could,O
be,O
minimized,O
by,O
selecting,O
appropriate,O
therapy,O
.,O
Specific,O
dopamine-1,I-Entity
",",O
(,O
DA1,I-Entity
),O
and,O
dopamine-2,I-Entity
(,O
DA2,I-Entity
),O
Fenoldopam,B-Entity
mesylate,I-Entity
is,O
a,O
specific,O
DA1,O
receptor,O
agonist,O
that,O
lowers,O
blood,O
pressure,O
by,O
vasodilatation,O
.,O
The,O
hypothesis,O
that,O
fenoldopam,I-Entity
could,O
be,O
used,O
to,O
induce,O
hypotension,I-Entity
and,O
preserve,O
blood,O
flow,O
to,O
the,O
kidney,O
was,O
tested,O
.,O
Systemic,O
aortic,O
blood,O
pressure,O
and,O
renal,O
blood,O
flow,O
were,O
measured,O
continuously,O
with,O
a,O
carotid,O
arterial,O
catheter,O
and,O
an,O
electromagnetic,O
flow,O
probe,O
respectively,O
",",O
in,O
order,O
to,O
compare,O
the,O
cardiovascular,O
and,O
renal,O
vascular,O
effects,O
of,O
fenoldopam,I-Entity
and,O
sodium,I-Entity
nitroprusside,I-Entity
in,O
ten,O
dogs,O
under,O
halothane,I-Entity
general,O
anaesthesia,O
.,O
8,O
per,O
cent,O
from,O
control,O
with,O
infusion,O
of,O
fenoldopam,I-Entity
(,O
3.4,O
+,O
/-,O
4,O
per,O
cent,O
with,O
infusion,O
of,O
sodium,I-Entity
nitroprusside,I-Entity
(,O
5.9,O
micrograms.kg-1.min-1,O
),O
(,O
NS,O
),O
.,O
Renal,O
blood,O
flow,O
(,O
RBF,O
),O
increased,O
during,O
fenoldopam,I-Entity
-,O
induced,O
hypotension,I-Entity
11,O
+,O
/-,O
8,O
per,O
cent,O
during,O
sodium,I-Entity
nitroprusside,I-Entity
-,O
induced,O
hypotension,I-Entity
(,O
P,O
less,O
than,O
0.01,O
),O
.,O
Sodium,O
nitroprusside,I-Entity
is,O
a,O
non,O
-,O
selective,O
arteriolar,O
and,O
venous,O
vasodilator,O
that,O
can,O
produce,O
redistribution,O
of,O
blood,O
flow,O
away,O
from,O
the,O
kidney,O
during,O
induced,O
hypotension,I-Entity
.,O
Fenoldopam,O
is,O
a,O
selective,O
dopamine-1,I-Entity
(,O
DA1,O
),O
receptor,O
agonist,O
that,O
causes,O
vasodilatation,O
to,O
the,O
kidney,O
and,O
other,O
organs,O
with,O
DA1,O
receptors,O
and,O
preserves,O
blood,O
flow,O
to,O
the,O
kidney,O
during,O
induced,O
hypotension,I-Entity
.,O
Antiarrhythmic,O
effects,O
of,O
optical,O
isomers,O
of,O
cibenzoline,I-Entity
on,O
canine,O
ventricular,B-Entity
arrhythmias,I-Entity
.,O
Antiarrhythmic,O
effects,O
of,O
(,O
+,O
),O
-cibenzoline,I-Entity
and,O
(,O
-)-cibenzoline,I-Entity
were,O
examined,O
using,O
two,O
canine,O
ventricular,B-Entity
arrhythmia,I-Entity
models,O
.,O
Digitalis,I-Entity
arrhythmia,I-Entity
",",O
which,O
is,O
suppressed,O
by,O
Na,I-Entity
channel,O
blockers,O
",",O
was,O
induced,O
by,O
intermittent,O
intravenous,O
(,O
i.v,O
.,O
),O
injection,O
of,O
ouabain,I-Entity
in,O
pentobarbital,I-Entity
-,O
anesthetized,O
dogs,O
.,O
Adrenaline,B-Entity
arrhythmia,I-Entity
",",O
which,O
is,O
suppressed,O
by,O
Ca,I-Entity
channel,O
blockers,O
",",O
was,O
induced,O
by,O
adrenaline,I-Entity
infusion,O
in,O
halothane,I-Entity
-,O
anesthetized,O
dogs,O
.,O
(,O
+,O
),O
-cibenzoline,I-Entity
suppressed,O
digitalis-,I-Entity
and,O
adrenaline,I-Entity
-,O
induced,O
arrhythmias,I-Entity
",",O
respectively,O
.,O
The,O
minimum,O
effective,O
plasma,O
concentrations,O
of,O
(,O
+,O
),O
-cibenzoline,I-Entity
for,O
digitalis-,I-Entity
and,O
adrenaline,I-Entity
-,O
induced,O
arrhythmias,I-Entity
were,O
1.4,O
+,O
/-,O
(,O
-)-cibenzoline,I-Entity
suppressed,O
the,O
digitalis,I-Entity
-,O
induced,O
arrhythmia,I-Entity
",",O
whereas,O
5,O
mg,O
/,O
kg,O
i.v,O
.,O
was,O
needed,O
to,O
suppress,O
adrenaline,I-Entity
-,O
induced,O
arrhythmias,I-Entity
.,O
The,O
minimum,O
effective,O
plasma,O
concentrations,O
of,O
(,O
-)-cibenzoline,I-Entity
for,O
digitalis-,I-Entity
and,O
adrenaline,I-Entity
-,O
induced,O
arrhythmia,I-Entity
were,O
0.06,O
+,O
/-,O
The,O
stronger,O
antiarrhythmic,O
effect,O
of,O
(,O
-)-cibenzoline,I-Entity
indicates,O
that,O
(,O
-)-isomer,O
may,O
have,O
an,O
effect,O
nearly,O
5,O
-,O
20,O
times,O
stronger,O
in,O
suppressing,O
Na,I-Entity
channels,O
",",O
but,O
effects,O
of,O
both,O
drugs,O
on,O
Ca,I-Entity
channels,O
may,O
be,O
almost,O
equipotent,O
.,O
Effect,O
of,O
Hibiscus,B-Entity
rosa,I-Entity
sinensis,I-Entity
on,O
reserpine,I-Entity
-,O
induced,O
neurobehavioral,O
and,O
biochemical,O
alterations,O
in,O
rats,O
.,O
Effect,O
of,O
methanolic,O
extract,O
of,O
Hibiscus,B-Entity
rosa,I-Entity
sinensis,I-Entity
(,O
100,O
-,O
300,O
mg,O
/,O
kg,O
),O
was,O
studied,O
on,O
reserpine,I-Entity
-,O
induced,O
orofacial,O
dyskinesia,I-Entity
and,O
neurochemical,O
alterations,O
.,O
The,O
rats,O
were,O
treated,O
with,O
intraperitoneal,O
reserpine,I-Entity
Reserpine,I-Entity
treated,O
rats,O
significantly,O
developed,O
vacuous,O
chewing,O
movements,O
and,O
tongue,O
protrusions,O
however,O
",",O
coadministration,O
of,O
Hibiscus,B-Entity
rosa,I-Entity
sinensis,I-Entity
roots,O
extract,O
(,O
100,O
",",O
200,O
and,O
300,O
mg,O
/,O
kg,O
",",O
per,O
orally,O
),O
attenuated,O
the,O
effects,O
.,O
Biochemical,O
analysis,O
of,O
brain,O
revealed,O
that,O
the,O
reserpine,I-Entity
treatment,O
significantly,O
increased,O
lipid,O
peroxidation,O
and,O
decreased,O
levels,O
of,O
superoxide,I-Entity
dismutase,O
(,O
SOD,O
),O
",",O
catalase,O
(,O
CAT,O
),O
and,O
glutathione,I-Entity
reductase,O
(,O
GSH,O
),O
",",O
an,O
index,O
of,O
oxidative,O
stress,O
process,O
.,O
The,O
results,O
of,O
the,O
present,O
study,O
suggested,O
that,O
Hibiscus,B-Entity
rosa,I-Entity
sinensis,I-Entity
had,O
a,O
protective,O
role,O
against,O
reserpine,I-Entity
-,O
induced,O
orofacial,O
dyskinesia,I-Entity
and,O
oxidative,O
stress,O
.,O
Comparison,O
of,O
aqueous,O
and,O
gellan,O
ophthalmic,O
timolol,I-Entity
with,O
placebo,O
on,O
the,O
24-hour,O
heart,O
rate,O
response,O
in,O
patients,O
on,O
treatment,O
for,O
glaucoma,I-Entity
.,O
Topical,O
beta,O
-,O
blocker,O
treatment,O
is,O
routine,O
therapy,O
in,O
the,O
management,O
of,O
patients,O
with,O
glaucoma,I-Entity
.,O
This,O
trial,O
evaluated,O
the,O
effect,O
of,O
placebo,O
",",O
0.5%,O
aqueous,O
timolol,I-Entity
(,O
timolol,I-Entity
solution,O
),O
and,O
a,O
0.5%,O
timolol,I-Entity
suspension,O
that,O
forms,O
a,O
gel,O
on,O
application,O
to,O
the,O
conjunctiva,O
(,O
timolol,I-Entity
gellan,O
),O
on,O
the,O
24-hour,O
heart,O
rate,O
in,O
patients,O
currently,O
being,O
treated,O
for,O
glaucoma,I-Entity
to,O
quantify,O
the,O
reduction,O
in,O
mean,O
heart,O
rate,O
.,O
METHODS,O
:,O
Forty,O
-,O
three,O
Caucasian,O
patients,O
with,O
primary,O
open,B-Entity
-,I-Entity
angle,I-Entity
glaucoma,I-Entity
or,O
ocular,B-Entity
hypertension,I-Entity
with,O
a,O
mean,O
(,O
+,O
/-SD,O
),O
age,O
of,O
63,O
(,O
+,O
/-8,O
),O
years,O
were,O
randomized,O
and,O
crossed,O
over,O
in,O
a,O
double,O
-,O
masked,O
manner,O
to,O
14,O
days,O
of,O
treatment,O
with,O
placebo,O
(,O
morning,O
and,O
evening,O
in,O
both,O
eyes,O
),O
",",O
timolol,I-Entity
solution,O
(,O
morning,O
and,O
evening,O
in,O
both,O
eyes,O
),O
",",O
or,O
timolol,I-Entity
gellan,O
(,O
morning,O
in,O
both,O
eyes,O
with,O
placebo,O
in,O
the,O
evening,O
),O
.,O
Both,O
timolol,I-Entity
solution,O
and,O
timolol,I-Entity
gellan,O
reduced,O
the,O
mean,O
24-hour,O
heart,O
rate,O
compared,O
with,O
placebo,O
(,O
P,O
<,O
or,O
=,O
.001,O
),O
",",O
and,O
this,O
reduction,O
was,O
most,O
pronounced,O
during,O
the,O
daytime,O
(,O
-7.5%,O
change,O
in,O
mean,O
heart,O
rate,O
Timolol,I-Entity
gellan,O
showed,O
a,O
numerically,O
but,O
not,O
significantly,O
smaller,O
reduction,O
in,O
24-hour,O
heart,O
rate,O
",",O
compared,O
with,O
timolol,I-Entity
solution,O
.,O
During,O
the,O
night,O
",",O
the,O
mean,O
12-hour,O
heart,O
rate,O
on,O
placebo,O
and,O
timolol,I-Entity
gellan,O
were,O
both,O
significantly,O
less,O
than,O
on,O
timolol,I-Entity
solution,O
;,O
the,O
difference,O
between,O
solution,O
and,O
gellan,O
treatments,O
was,O
statistically,O
significant,O
(,O
P,O
=,O
.01,O
),O
.,O
Both,O
timolol,I-Entity
solution,O
and,O
timolol,I-Entity
gellan,O
decrease,O
the,O
mean,O
24-hour,O
heart,O
rate,O
compared,O
with,O
placebo,O
.,O
These,O
data,O
quantify,O
the,O
modest,O
bradycardia,I-Entity
associated,O
with,O
ophthalmic,O
beta,O
-,O
blocker,O
therapy,O
in,O
a,O
typical,O
patient,O
population,O
on,O
therapy,O
for,O
glaucoma,I-Entity
.,O
5,B-Entity
flourouracil,I-Entity
-,O
induced,O
apical,B-Entity
ballooning,I-Entity
syndrome,I-Entity
:,O
a,O
case,O
report,O
.,O
The,O
apical,B-Entity
ballooning,I-Entity
syndrome,I-Entity
(,O
ABS,I-Entity
),O
is,O
a,O
recently,O
described,O
stress,O
-,O
mediated,O
acute,B-Entity
cardiac,I-Entity
syndrome,I-Entity
characterized,O
by,O
transient,O
wall,O
-,O
motion,O
abnormalities,O
involving,O
the,O
apex,O
and,O
midventricle,O
with,O
hyperkinesis,I-Entity
of,O
the,O
basal,O
left,O
ventricular,O
(,O
LV,O
),O
segments,O
without,O
obstructive,O
epicardial,B-Entity
coronary,I-Entity
disease,I-Entity
.,O
Cardiotoxicity,I-Entity
is,O
not,O
an,O
uncommon,O
adverse,O
effect,O
of,O
chemotherapeutic,O
agents,O
.,O
However,O
",",O
there,O
are,O
no,O
reports,O
of,O
ABS,I-Entity
secondary,O
to,O
chemotherapeutic,O
agents,O
.,O
We,O
describe,O
the,O
case,O
of,O
a,O
woman,O
who,O
developed,O
the,O
syndrome,O
after,O
chemotherapy,O
for,O
metastatic,O
cancer,I-Entity
.,O
A,O
79-year,O
-,O
old,O
woman,O
presented,O
with,O
typical,O
ischemic,I-Entity
chest,B-Entity
pain,I-Entity
",",O
elevated,O
cardiac,O
enzymes,O
with,O
significant,O
ST,O
-,O
segment,O
abnormalities,O
on,O
her,O
electrocardiogram,O
.,O
She,O
underwent,O
recent,O
chemotherapy,O
with,O
fluorouracil,I-Entity
for,O
metastatic,O
colorectal,B-Entity
cancer,I-Entity
.,O
Echocardiography,O
revealed,O
a,O
wall,O
-,O
motion,O
abnormality,O
involving,O
the,O
apical,O
and,O
periapical,O
segments,O
which,O
appeared,O
akinetic,I-Entity
.,O
Echocardiogram,O
revealed,O
a,O
normal,O
ejection,O
fraction,O
and,O
a,O
resolution,O
of,O
the,O
apical,O
akinesis,I-Entity
.,O
Pathogenetic,O
mechanisms,O
of,O
cardiac,B-Entity
complications,I-Entity
in,O
cancer,I-Entity
patients,O
undergoing,O
chemotherapy,O
include,O
coronary,B-Entity
vasospasm,I-Entity
",",O
endothelial,O
damage,O
and,O
consequent,O
thrombus,I-Entity
formation,O
.,O
In,O
our,O
patient,O
",",O
both,O
supraphysiologic,O
levels,O
of,O
plasma,O
catecholamines,I-Entity
and,O
stress,O
related,O
neuropeptides,O
caused,O
by,O
cancer,I-Entity
diagnosis,O
as,O
well,O
as,O
chemotherapy,O
may,O
have,O
contributed,O
the,O
development,O
of,O
ABS,I-Entity
.,O
Reduction,O
of,O
pain,I-Entity
during,O
induction,O
with,O
target,O
-,O
controlled,O
propofol,I-Entity
and,O
remifentanil,I-Entity
.,O
Pain,I-Entity
on,O
injection,O
of,O
propofol,I-Entity
is,O
unpleasant,O
.,O
We,O
hypothesized,O
that,O
propofol,I-Entity
infusion,O
pain,I-Entity
might,O
be,O
prevented,O
by,O
infusing,O
remifentanil,I-Entity
before,O
starting,O
the,O
propofol,I-Entity
infusion,O
in,O
a,O
clinical,O
setting,O
where,O
target,O
-,O
controlled,O
infusions,O
(,O
TCI,O
),O
of,O
both,O
drugs,O
were,O
used,O
.,O
A,O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
was,O
performed,O
to,O
determine,O
the,O
effect,O
-,O
site,O
concentration,O
(,O
Ce,O
),O
of,O
remifentanil,I-Entity
to,O
prevent,O
the,O
pain,I-Entity
without,O
producing,O
complications,O
.,O
A,O
total,O
of,O
128,O
patients,O
undergoing,O
general,O
surgery,O
were,O
randomly,O
allocated,O
to,O
receive,O
normal,O
saline,O
(,O
control,O
),O
or,O
remifentanil,I-Entity
to,O
a,O
target,O
Ce,O
of,O
2,O
ng,O
ml(-1,O
),O
(,O
R2,O
),O
",",O
4,O
ng,O
ml(-1,O
),O
(,O
R4,O
),O
",",O
or,O
6,O
ng,O
ml(-1,O
),O
(,O
R6,O
),O
administered,O
via,O
TCI,O
.,O
After,O
the,O
target,O
Ce,O
was,O
achieved,O
",",O
the,O
infusion,O
of,O
propofol,I-Entity
was,O
started,O
.,O
Remifentanil,I-Entity
-,O
related,O
complications,O
were,O
assessed,O
during,O
the,O
remifentanil,I-Entity
infusion,O
",",O
and,O
pain,I-Entity
caused,O
by,O
propofol,I-Entity
was,O
evaluated,O
using,O
a,O
four,O
-,O
point,O
scale,O
during,O
the,O
propofol,I-Entity
infusion,O
.,O
The,O
incidence,O
of,O
pain,I-Entity
was,O
significantly,O
lower,O
in,O
Groups,O
R4,O
and,O
R6,O
than,O
in,O
the,O
control,O
and,O
R2,O
groups,O
(,O
12/32,O
and,O
6/31,O
vs,O
26/31,O
and,O
25/32,O
",",O
respectively,O
",",O
P<0.001,O
),O
.,O
Pain,I-Entity
was,O
less,O
severe,O
in,O
Groups,O
R4,O
and,O
R6,O
than,O
in,O
the,O
control,O
and,O
R2,O
groups,O
(,O
P<0.001,O
),O
.,O
However,O
",",O
both,O
incidence,O
and,O
severity,O
of,O
pain,I-Entity
were,O
not,O
different,O
between,O
Groups,O
R4,O
and,O
R6,O
.,O
During,O
induction,O
of,O
anaesthesia,O
with,O
TCI,O
of,O
propofol,I-Entity
and,O
remifentanil,I-Entity
",",O
a,O
significant,O
reduction,O
in,O
propofol,I-Entity
infusion,O
pain,I-Entity
was,O
achieved,O
without,O
significant,O
complications,O
by,O
prior,O
administration,O
of,O
remifentanil,I-Entity
at,O
a,O
target,O
Ce,O
of,O
4,O
ng,O
ml(-1,O
),O
.,O
Prenatal,O
exposure,O
to,O
fluoxetine,I-Entity
induces,O
fetal,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
in,O
the,O
rat,O
.,O
Fluoxetine,I-Entity
is,O
a,O
selective,O
serotonin,I-Entity
reuptake,O
inhibitor,O
antidepressant,O
widely,O
used,O
by,O
pregnant,O
women,O
.,O
Epidemiological,O
data,O
suggest,O
that,O
fluoxetine,I-Entity
exposure,O
prenatally,O
increases,O
the,O
prevalence,O
of,O
persistent,O
pulmonary,B-Entity
hypertension,I-Entity
syndrome,I-Entity
of,O
the,O
newborn,O
.,O
The,O
mechanism,O
responsible,O
for,O
this,O
effect,O
is,O
unclear,O
and,O
paradoxical,O
",",O
considering,O
the,O
current,O
evidence,O
of,O
a,O
pulmonary,B-Entity
hypertension,I-Entity
protective,O
fluoxetine,I-Entity
effect,O
in,O
adult,O
rodents,O
.,O
To,O
evaluate,O
the,O
fluoxetine,I-Entity
effect,O
on,O
fetal,O
rat,O
pulmonary,O
vascular,O
smooth,O
muscle,O
mechanical,O
properties,O
and,O
cell,O
proliferation,O
rate,O
.,O
Pregnant,O
rats,O
were,O
treated,O
with,O
fluoxetine,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
from,O
Day,O
11,O
through,O
Day,O
21,O
of,O
gestation,O
.,O
As,O
compared,O
with,O
controls,O
",",O
fluoxetine,I-Entity
exposure,O
resulted,O
in,O
fetal,B-Entity
pulmonary,I-Entity
hypertension,I-Entity
as,O
evidenced,O
by,O
an,O
increase,O
in,O
the,O
weight,O
ratio,O
of,O
the,O
right,O
ventricle,O
to,O
the,O
left,O
ventricle,O
plus,O
septum,O
(,O
P,O
=,O
0.02,O
),O
and,O
by,O
an,O
increase,O
in,O
pulmonary,O
arterial,O
medial,O
thickness,O
(,O
P,O
<,O
0.01,O
),O
.,O
Postnatal,O
mortality,O
was,O
increased,O
among,O
experimental,O
animals,O
",",O
and,O
arterial,O
oxygen,I-Entity
saturation,O
was,O
96,O
+,O
/-,O
1%,O
in,O
1-day,O
-,O
old,O
control,O
animals,O
and,O
significantly,O
lower,O
(,O
P,O
<,O
0.01,O
),O
in,O
fluoxetine,I-Entity
-,O
exposed,O
pups,O
(,O
79,O
+,O
/-,O
In,O
vitro,O
",",O
fluoxetine,I-Entity
induced,O
pulmonary,O
arterial,O
muscle,O
contraction,O
in,O
fetal,O
",",O
but,O
not,O
adult,O
",",O
animals,O
(,O
P,O
<,O
0.01,O
),O
and,O
reduced,O
serotonin,I-Entity
-,O
induced,O
contraction,O
at,O
both,O
ages,O
(,O
P,O
<,O
0.01,O
),O
.,O
After,O
in,O
utero,O
exposure,O
to,O
a,O
low,O
fluoxetine,I-Entity
concentration,O
the,O
pulmonary,O
arterial,O
smooth,O
muscle,O
cell,O
proliferation,O
rate,O
was,O
significantly,O
increased,O
in,O
fetal,O
",",O
but,O
not,O
adult,O
",",O
cells,O
(,O
P,O
<,O
0.01,O
),O
.,O
In,O
contrast,O
to,O
the,O
adult,O
",",O
fluoxetine,I-Entity
exposure,O
in,O
utero,O
induces,O
pulmonary,B-Entity
hypertension,I-Entity
in,O
the,O
fetal,O
rat,O
as,O
a,O
result,O
of,O
a,O
developmentally,O
regulated,O
increase,O
in,O
pulmonary,O
vascular,O
smooth,O
muscle,O
proliferation,O
.,O
Syncope,I-Entity
and,O
QT,B-Entity
prolongation,I-Entity
among,O
patients,O
treated,O
with,O
methadone,I-Entity
for,O
heroin,I-Entity
dependence,O
in,O
the,O
city,O
of,O
Copenhagen,O
.,O
Methadone,I-Entity
is,O
prescribed,O
to,O
heroin,I-Entity
addicts,O
to,O
decrease,O
illicit,O
opioid,O
use,O
.,O
Prolongation,O
of,O
the,O
QT,O
interval,O
in,O
the,O
ECG,O
of,O
patients,O
with,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
(,O
TdP,I-Entity
),O
has,O
been,O
reported,O
in,O
methadone,I-Entity
users,O
.,O
As,O
heroin,I-Entity
addicts,O
sometimes,O
faint,O
while,O
using,O
illicit,O
drugs,O
",",O
doctors,O
might,O
attribute,O
too,O
many,O
episodes,O
of,O
syncope,I-Entity
to,O
illicit,O
drug,O
use,O
and,O
thereby,O
underestimate,O
the,O
incidence,O
of,O
TdP,I-Entity
in,O
this,O
special,O
population,O
",",O
and,O
the,O
high,O
mortality,O
in,O
this,O
population,O
may,O
",",O
in,O
part,O
",",O
be,O
caused,O
by,O
the,O
proarrhythmic,O
effect,O
of,O
methadone,I-Entity
.,O
In,O
this,O
cross,O
-,O
sectional,O
study,O
interview,O
",",O
ECGs,O
and,O
blood,O
samples,O
were,O
collected,O
in,O
a,O
population,O
of,O
adult,O
heroin,I-Entity
addicts,O
treated,O
with,O
methadone,I-Entity
or,O
buprenorphine,I-Entity
on,O
a,O
daily,O
basis,O
.,O
All,O
participants,O
were,O
interviewed,O
about,O
any,O
experience,O
of,O
syncope,I-Entity
.,O
The,O
association,O
between,O
opioid,O
dose,O
and,O
QT,O
",",O
and,O
methadone,I-Entity
dose,O
and,O
reporting,O
of,O
syncope,I-Entity
was,O
assessed,O
using,O
multivariate,O
linear,O
regression,O
and,O
logistic,O
regression,O
",",O
respectively,O
.,O
Methadone,I-Entity
dose,O
was,O
associated,O
with,O
longer,O
QT,O
interval,O
of,O
0.140,O
ms,O
/,O
mg,O
(,O
p,O
=,O
0.002,O
),O
.,O
No,O
association,O
between,O
buprenorphine,I-Entity
and,O
QTc,O
was,O
found,O
.,O
Among,O
the,O
subjects,O
treated,O
with,O
methadone,I-Entity
",",O
28%,O
men,O
and,O
32%,O
women,O
had,O
prolonged,B-Entity
QTc,I-Entity
interval,I-Entity
.,O
None,O
of,O
the,O
subjects,O
treated,O
with,O
buprenorphine,I-Entity
had,O
QTc,O
interval,O
>,O
0.440,O
s((1/2,O
),O
),O
.,O
A,O
50,O
mg,O
higher,O
methadone,I-Entity
dose,O
was,O
associated,O
with,O
a,O
1.2,O
(,O
95%,O
CI,O
1.1,O
to,O
1.4,O
),O
times,O
higher,O
odds,O
for,O
syncope,I-Entity
.,O
Methadone,I-Entity
is,O
associated,O
with,O
QT,B-Entity
prolongation,I-Entity
and,O
higher,O
reporting,O
of,O
syncope,I-Entity
in,O
a,O
population,O
of,O
heroin,I-Entity
addicts,O
.,O
Peripheral,B-Entity
neuropathy,I-Entity
caused,O
by,O
high,O
-,O
dose,O
cytosine,B-Entity
arabinoside,I-Entity
treatment,O
in,O
a,O
patient,O
with,O
acute,B-Entity
myeloid,I-Entity
leukemia,I-Entity
.,O
The,O
central,O
nervous,O
system,O
toxicity,I-Entity
of,O
high,O
-,O
dose,O
cytosine,B-Entity
arabinoside,I-Entity
is,O
well,O
recognized,O
",",O
but,O
the,O
toxicity,I-Entity
of,O
cytosine,B-Entity
arabinoside,I-Entity
in,O
the,O
peripheral,O
nervous,O
system,O
has,O
been,O
infrequently,O
reported,O
.,O
A,O
49-year,O
-,O
old,O
Japanese,O
man,O
was,O
diagnosed,O
with,O
acute,B-Entity
myeloid,I-Entity
leukemia,I-Entity
.,O
After,O
he,O
achieved,O
complete,O
remission,O
",",O
he,O
received,O
high,O
-,O
dose,O
cytosine,B-Entity
arabinoside,I-Entity
treatment,O
(,O
2,O
g,O
/,O
m2,O
twice,O
a,O
day,O
for,O
5,O
days,O
;,O
total,O
",",O
20,O
g,O
/,O
m2,O
),O
as,O
consolidation,O
therapy,O
.,O
The,O
first,O
course,O
of,O
high,O
-,O
dose,O
cytosine,B-Entity
arabinoside,I-Entity
resulted,O
in,O
no,O
unusual,O
symptoms,O
",",O
but,O
on,O
day,O
21,O
of,O
the,O
second,O
course,O
of,O
treatment,O
",",O
the,O
patient,O
complained,O
of,O
numbness,I-Entity
in,O
his,O
right,O
foot,O
.,O
Electromyogram,O
and,O
nerve,O
-,O
conduction,O
studies,O
showed,O
peripheral,B-Entity
neuropathy,I-Entity
in,O
both,O
peroneal,O
nerves,O
.,O
This,O
neuropathy,I-Entity
was,O
gradually,O
resolving,O
;,O
however,O
",",O
after,O
the,O
patient,O
received,O
allogeneic,O
bone,O
marrow,O
transplantation,O
",",O
the,O
symptoms,O
worsened,O
",",O
with,O
the,O
development,O
of,O
graft,B-Entity
-,I-Entity
versus,I-Entity
-,I-Entity
host,I-Entity
disease,I-Entity
",",O
and,O
the,O
symptoms,O
subsequently,O
responded,O
to,O
methylprednisolone,I-Entity
.,O
Although,O
the,O
mechanisms,O
of,O
peripheral,B-Entity
neuropathy,I-Entity
are,O
still,O
unclear,O
",",O
high,O
-,O
dose,O
cytosine,B-Entity
arabinoside,I-Entity
is,O
a,O
therapy,O
that,O
is,O
potentially,O
toxic,O
to,O
the,O
peripheral,O
nervous,O
system,O
",",O
and,O
auto,O
/,O
alloimmunity,O
may,O
play,O
an,O
important,O
role,O
in,O
these,O
mechanisms,O
.,O
Atorvastatin,I-Entity
prevented,O
and,O
reversed,O
dexamethasone,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
the,O
rat,O
.,O
To,O
assess,O
the,O
antioxidant,O
effects,O
of,O
atorvastatin,I-Entity
(,O
atorva,I-Entity
),O
on,O
dexamethasone,I-Entity
(,O
dex)-induced,I-Entity
hypertension,I-Entity
",",O
60,O
male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
treated,O
with,O
atorva,I-Entity
30,O
mg,O
/,O
kg,O
/,O
day,O
or,O
tap,O
water,O
for,O
15,O
days,O
.,O
Dex,I-Entity
increased,O
systolic,O
blood,O
pressure,O
(,O
SBP,O
),O
from,O
109,O
+,O
/-,O
0.6,O
mmHg,O
and,O
plasma,O
superoxide,I-Entity
(,O
5711,O
+,O
/-,O
392.8,O
U,O
/,O
ml,O
dex,I-Entity
",",O
P,O
<,O
0.001,O
),O
.,O
In,O
this,O
prevention,O
study,O
",",O
SBP,O
in,O
the,O
atorva,I-Entity
+,O
dex,I-Entity
group,O
was,O
increased,O
from,O
115,O
+,O
/-,O
1.5,O
mmHg,O
",",O
but,O
this,O
was,O
significantly,O
lower,O
than,O
in,O
the,O
dex,I-Entity
-,O
only,O
group,O
(,O
Atorva,I-Entity
reversed,O
dex,I-Entity
-,O
induced,O
hypertension,I-Entity
(,O
129,O
+,O
/-,O
0.6,O
mmHg,O
P,O
',O
<,O
0.05,O
),O
and,O
decreased,O
plasma,O
superoxide,I-Entity
(,O
7931,O
+,O
/-,O
392.8,O
dex,I-Entity
",",O
1187,O
441.2,O
atorva,I-Entity
+,O
dex,I-Entity
",",O
P,O
<,O
0.0001,O
),O
.,O
Plasma,O
nitrate,I-Entity
/,O
nitrite,I-Entity
(,O
NOx,O
),O
was,O
decreased,O
in,O
dex,I-Entity
-,O
treated,O
rats,O
compared,O
to,O
saline,O
-,O
treated,O
rats,O
(,O
11.2,O
+,O
/-,O
Atorva,I-Entity
affected,O
neither,O
plasma,O
NOx,O
nor,O
thymus,O
weight,O
.,O
Thus,O
",",O
atorvastatin,I-Entity
prevented,O
and,O
reversed,O
dexamethasone,I-Entity
-,O
induced,O
hypertension,I-Entity
in,O
the,O
rat,O
.,O
Two,O
prodrugs,O
of,O
potent,O
and,O
selective,O
GluR5,O
kainate,I-Entity
receptor,O
antagonists,O
actives,O
in,O
three,O
animal,O
models,O
of,O
pain,I-Entity
.,O
Amino,O
acids,O
5,O
and,O
7,O
",",O
two,O
potent,O
and,O
selective,O
competitive,O
GluR5,O
KA,I-Entity
receptor,O
antagonists,O
",",O
exhibited,O
high,O
GluR5,O
receptor,O
affinity,O
over,O
other,O
glutamate,I-Entity
receptors,O
.,O
Their,O
ester,O
prodrugs,O
6,O
and,O
8,O
were,O
orally,O
active,O
in,O
three,O
models,O
of,O
pain,I-Entity
:,O
reversal,O
of,O
formalin,I-Entity
-,O
induced,O
paw,O
licking,O
",",O
carrageenan,I-Entity
-,O
induced,O
thermal,B-Entity
hyperalgesia,I-Entity
",",O
and,O
capsaicin,I-Entity
-,O
induced,O
mechanical,B-Entity
hyperalgesia,I-Entity
.,O
Sirolimus,I-Entity
and,O
mycophenolate,B-Entity
mofetil,I-Entity
for,O
calcineurin,O
-,O
free,O
immunosuppression,O
in,O
renal,O
transplant,O
recipients,O
.,O
Calcineurin,O
inhibitors,O
",",O
such,O
as,O
cyclosporine,I-Entity
and,O
tacrolimus,I-Entity
",",O
have,O
been,O
available,O
for,O
almost,O
20,O
years,O
.,O
Although,O
these,O
drugs,O
are,O
highly,O
effective,O
and,O
represent,O
the,O
mainstay,O
of,O
transplant,O
immunosuppression,O
",",O
they,O
are,O
associated,O
with,O
acute,O
and,O
chronic,O
nephrotoxicity,I-Entity
.,O
Acute,O
nephrotoxicity,I-Entity
",",O
which,O
occurs,O
in,O
the,O
early,O
period,O
after,O
transplantation,O
",",O
leads,O
to,O
a,O
higher,O
rate,O
of,O
dialysis,O
",",O
and,O
chronic,O
nephrotoxicity,I-Entity
may,O
eventually,O
result,O
in,O
graft,O
loss,O
.,O
Acute,O
and,O
chronic,O
nephrotoxicity,I-Entity
is,O
becoming,O
more,O
common,O
as,O
the,O
use,O
of,O
marginal,O
kidneys,O
for,O
transplantation,O
increases,O
.,O
Two,O
recently,O
available,O
immunosuppressive,O
agents,O
",",O
mycophenolate,B-Entity
mofetil,I-Entity
and,O
sirolimus,I-Entity
(,O
rapamycin,I-Entity
),O
",",O
have,O
no,O
nephrotoxicity,I-Entity
.,O
Erythropoietin,O
restores,O
the,O
anemia,I-Entity
-,O
induced,O
reduction,O
in,O
cyclophosphamide,I-Entity
cytotoxicity,I-Entity
in,O
rat,O
tumors,I-Entity
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
examine,O
the,O
impact,O
of,O
anemia,I-Entity
prevention,O
by,O
recombinant,O
human,O
erythropoietin,O
(,O
rHuEPO,O
),O
treatment,O
on,O
the,O
cytotoxicity,I-Entity
of,O
cyclophosphamide,I-Entity
in,O
solid,O
experimental,O
tumors,I-Entity
.,O
Anemia,I-Entity
was,O
induced,O
using,O
a,O
single,O
dose,O
of,O
carboplatin,I-Entity
(,O
50,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
In,O
a,O
second,O
group,O
",",O
the,O
development,O
of,O
anemia,I-Entity
was,O
prevented,O
by,O
rHuEPO,O
(,O
1000,O
IU,O
/,O
kg,O
),O
administered,O
s.c,O
.,O
three,O
times,O
/,O
week,O
starting,O
7,O
days,O
before,O
carboplatin,I-Entity
application,O
.,O
Four,O
days,O
after,O
carboplatin,I-Entity
treatment,O
",",O
tumors,I-Entity
(,O
DS,O
-,O
sarcoma,I-Entity
of,O
the,O
rat,O
),O
were,O
implanted,O
s.c,O
.,O
Neither,O
carboplatin,I-Entity
nor,O
rHuEPO,O
treatment,O
influenced,O
tumor,I-Entity
growth,O
rate,O
per,O
se,O
.,O
When,O
tumors,I-Entity
were,O
treated,O
with,O
a,O
single,O
dose,O
of,O
cyclophosphamide,I-Entity
(,O
60,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
5,O
days,O
after,O
implantation,O
",",O
a,O
growth,O
delay,O
with,O
a,O
subsequent,O
regrowth,O
of,O
the,O
tumors,I-Entity
was,O
observed,O
.,O
In,O
the,O
anemia,I-Entity
group,O
",",O
the,O
growth,O
delay,O
was,O
significantly,O
shorter,O
compared,O
with,O
nonanemic,O
controls,O
(,O
13.3,O
days,O
versus,O
8.6,O
days,O
),O
.,O
In,O
the,O
group,O
where,O
anemia,I-Entity
was,O
prevented,O
by,O
rHuEPO,O
treatment,O
",",O
growth,O
delay,O
was,O
comparable,O
with,O
that,O
of,O
nonanemic,O
controls,O
(,O
13.3,O
days,O
),O
.,O
These,O
results,O
suggest,O
that,O
chemotherapy,O
-,O
induced,O
anemia,I-Entity
reduces,O
cytotoxicity,I-Entity
of,O
cyclophosphamide,I-Entity
in,O
tumors,I-Entity
",",O
whereas,O
correction,O
of,O
anemia,I-Entity
by,O
rHuEPO,O
treatment,O
(,O
epoetin,O
alpha,O
),O
increases,O
the,O
sensitivity,O
",",O
probably,O
as,O
a,O
result,O
of,O
an,O
improved,O
oxygen,I-Entity
supply,O
to,O
tumor,I-Entity
tissue,O
.,O
The,O
role,O
of,O
nitrergic,O
system,O
in,O
lidocaine,I-Entity
-,O
induced,O
convulsion,I-Entity
in,O
the,O
mouse,O
.,O
The,O
effects,O
of,O
N,B-Entity
-,I-Entity
nitro,I-Entity
-,I-Entity
L,I-Entity
-,I-Entity
arginine,I-Entity
-,I-Entity
methyl,I-Entity
ester,I-Entity
(,O
L,B-Entity
-,I-Entity
NAME,I-Entity
),O
a,O
nitric,B-Entity
oxide,I-Entity
(,O
NO,I-Entity
),O
synthase,O
inhibitor,O
and,O
L,B-Entity
-,I-Entity
arginine,I-Entity
",",O
a,O
NO,I-Entity
precursor,O
",",O
were,O
investigated,O
on,O
lidocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
.,O
In,O
the,O
first,O
experiment,O
",",O
four,O
groups,O
of,O
mice,O
received,O
physiological,O
saline,O
(,O
0.9%,O
),O
",",O
L,B-Entity
-,I-Entity
arginine,I-Entity
(,O
300,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
",",O
L,B-Entity
-,I-Entity
NAME,I-Entity
(,O
100,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
and,O
diazepam,I-Entity
(,O
2,O
mg,O
/,O
kg,O
),O
",",O
respectively,O
.,O
Thirty,O
minutes,O
after,O
these,O
injections,O
",",O
all,O
mice,O
received,O
lidocaine,I-Entity
(,O
50,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
.,O
In,O
the,O
second,O
experiment,O
",",O
four,O
groups,O
of,O
mice,O
received,O
similar,O
treatment,O
in,O
the,O
first,O
experiment,O
",",O
and,O
30,O
min,O
after,O
these,O
injections,O
",",O
all,O
mice,O
received,O
a,O
higher,O
dose,O
of,O
lidocaine,I-Entity
(,O
80,O
mg,O
/,O
kg,O
),O
.,O
L,B-Entity
-,I-Entity
NAME,I-Entity
(,O
100,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
and,O
diazepam,I-Entity
(,O
2,O
mg,O
/,O
kg,O
),O
significantly,O
decreased,O
the,O
incidence,O
of,O
lidocaine,I-Entity
(,O
50,O
mg,O
/,O
kg)-induced,O
convulsions,I-Entity
.,O
In,O
contrast,O
",",O
the,O
L,B-Entity
-,I-Entity
arginine,I-Entity
treatment,O
increased,O
the,O
incidence,O
of,O
lidocaine,I-Entity
(,O
80,O
mg,O
/,O
kg,O
",",O
i.p.)-induced,O
convulsions,I-Entity
significantly,O
.,O
These,O
results,O
may,O
suggest,O
that,O
NO,I-Entity
is,O
a,O
proconvulsant,O
mediator,O
in,O
lidocaine,I-Entity
-,O
induced,O
convulsions,I-Entity
.,O
Effect,O
of,O
intravenous,O
metoprolol,I-Entity
or,O
intravenous,O
metoprolol,I-Entity
plus,O
glucagon,O
on,O
dobutamine,I-Entity
-,O
induced,O
myocardial,B-Entity
ischemia,I-Entity
.,O
STUDY,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
effect,O
of,O
metoprolol,I-Entity
on,O
dobutamine,I-Entity
stress,O
testing,O
with,O
technetium-99,B-Entity
m,I-Entity
sestamibi,I-Entity
single,O
-,O
photon,O
emission,O
computed,O
tomography,O
imaging,O
and,O
ST,O
-,O
segment,O
monitoring,O
",",O
and,O
to,O
assess,O
the,O
impact,O
of,O
intravenous,O
glucagon,O
on,O
metoprolol,I-Entity
's,O
effects,O
.,O
Patients,O
underwent,O
dobutamine,I-Entity
stress,O
tests,O
per,O
standard,O
protocol,O
.,O
Before,O
dobutamine,I-Entity
was,O
begun,O
",",O
no,O
therapy,O
was,O
given,O
during,O
the,O
first,O
visit,O
",",O
and,O
patients,O
were,O
randomized,O
on,O
subsequent,O
visits,O
to,O
receive,O
metoprolol,I-Entity
or,O
metoprolol,I-Entity
plus,O
glucagon,O
1,O
mg,O
.,O
Metoprolol,I-Entity
was,O
dosed,O
to,O
achieve,O
a,O
resting,O
predobutamine,I-Entity
heart,O
rate,O
below,O
65,O
beats,O
/,O
minute,O
or,O
a,O
total,O
intravenous,O
dose,O
of,O
20,O
mg,O
.,O
Metoprolol,I-Entity
reduced,O
maximum,O
heart,O
rate,O
31%,O
",",O
summed,O
stress,O
scores,O
29%,O
",",O
and,O
summed,O
difference,O
scores,O
43%,O
versus,O
control,O
.,O
Metoprolol,I-Entity
plus,O
glucagon,O
also,O
reduced,O
the,O
maximum,O
heart,O
rate,O
29%,O
versus,O
control,O
.,O
No,O
significant,O
differences,O
were,O
found,O
in,O
any,O
parameter,O
between,O
metoprolol,I-Entity
and,O
metoprolol,I-Entity
-,O
glucagon,O
.,O
During,O
dobutamine,I-Entity
stress,O
testing,O
",",O
metoprolol,I-Entity
attenuates,O
or,O
eliminates,O
evidence,O
of,O
myocardial,B-Entity
ischemia,I-Entity
.,O
Prednisolone,I-Entity
-,O
induced,O
muscle,B-Entity
dysfunction,I-Entity
is,O
caused,O
more,O
by,O
atrophy,I-Entity
than,O
by,O
altered,O
acetylcholine,I-Entity
receptor,O
expression,O
.,O
We,O
investigated,O
the,O
effects,O
of,O
moderate,O
and,O
large,O
doses,O
of,O
prednisolone,I-Entity
on,O
muscle,O
function,O
and,O
pharmacology,O
",",O
and,O
their,O
relationship,O
to,O
changes,O
in,O
muscle,O
size,O
and,O
acetylcholine,I-Entity
receptor,O
(,O
AChR,O
),O
expression,O
.,O
With,O
institutional,O
approval,O
",",O
35,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
randomly,O
allocated,O
to,O
receive,O
daily,O
subcutaneous,O
doses,O
of,O
10,O
mg,O
/,O
kg,O
prednisolone,I-Entity
(,O
P10,O
group,O
),O
",",O
100,O
mg,O
/,O
kg,O
prednisolone,I-Entity
(,O
P100,O
group,O
),O
",",O
or,O
an,O
equal,O
volume,O
of,O
saline,O
(,O
S,O
group,O
),O
for,O
7,O
days,O
.,O
On,O
Day,O
8,O
",",O
the,O
nerve,O
-,O
evoked,O
peak,O
twitch,O
tensions,O
",",O
tetanic,I-Entity
tensions,O
",",O
and,O
fatigability,O
",",O
and,O
the,O
dose,O
-,O
response,O
curves,O
of,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
in,O
the,O
tibialis,O
cranialis,O
muscle,O
were,O
measured,O
in,O
vivo,O
and,O
related,O
to,O
muscle,O
mass,O
or,O
expression,O
of,O
AChRs,O
.,O
The,O
evoked,O
peak,O
twitch,O
and,O
tetanic,I-Entity
tensions,O
were,O
less,O
in,O
the,O
P100,O
group,O
than,O
in,O
the,O
P10,O
or,O
S,O
groups,O
",",O
however,O
",",O
tension,O
per,O
milligram,O
of,O
muscle,O
mass,O
was,O
greater,O
in,O
the,O
P100,O
group,O
than,O
in,O
the,O
S,O
group,O
.,O
The,O
50%,O
effective,O
dose,O
of,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
(,O
microg,O
/,O
kg,O
),O
in,O
the,O
tibialis,O
muscle,O
was,O
smaller,O
in,O
the,O
P10,O
(,O
33.6,O
+,O
/-,O
The,O
50%,O
effective,O
dose,O
of,O
d,B-Entity
-,I-Entity
tubocurarine,I-Entity
did,O
not,O
correlate,O
with,O
muscle,O
mass,O
or,O
AChR,O
expression,O
.,O
Our,O
results,O
suggest,O
that,O
the,O
neuromuscular,B-Entity
dysfunction,I-Entity
after,O
prednisolone,I-Entity
is,O
dose,O
-,O
dependent,O
",",O
and,O
derives,O
primarily,O
from,O
muscle,B-Entity
atrophy,I-Entity
and,O
derives,O
less,O
so,O
from,O
changes,O
in,O
AChR,O
expression,O
.,O
We,O
suggest,O
that,O
the,O
observed,O
effects,O
are,O
dose,O
-,O
dependent,O
and,O
derive,O
primarily,O
from,O
muscle,B-Entity
atrophy,I-Entity
and,O
derive,O
less,O
from,O
changes,O
in,O
acetylcholine,I-Entity
receptor,O
expression,O
.,O
Rapid,O
reversal,O
of,O
life,O
-,O
threatening,O
diltiazem,I-Entity
-,O
induced,O
tetany,I-Entity
with,O
calcium,B-Entity
chloride,I-Entity
.,O
We,O
describe,O
a,O
patient,O
who,O
developed,O
tetany,I-Entity
with,O
sudden,O
respiratory,B-Entity
arrest,I-Entity
after,O
the,O
infusion,O
of,O
intravenous,O
diltiazem,I-Entity
.,O
The,O
administration,O
of,O
calcium,B-Entity
chloride,I-Entity
rapidly,O
resolved,O
the,O
patient,O
's,O
tetany,I-Entity
with,O
prompt,O
recovery,O
of,O
respiratory,O
function,O
",",O
averting,O
the,O
need,O
for,O
more,O
aggressive,O
airway,O
management,O
and,O
ventilatory,O
support,O
.,O
The,O
emergency,O
physician,O
should,O
be,O
aware,O
that,O
life,O
-,O
threatening,O
tetany,I-Entity
may,O
accompany,O
the,O
administration,O
of,O
intravenous,O
diltiazem,I-Entity
and,O
that,O
calcium,B-Entity
chloride,I-Entity
may,O
be,O
a,O
rapid,O
and,O
effective,O
remedy,O
.,O
Effects,O
of,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
on,O
hemostasis,O
in,O
patients,O
with,O
aneurysmal,B-Entity
subarachnoid,I-Entity
hemorrhage,I-Entity
.,O
Patients,O
with,O
aneurysmal,B-Entity
subarachnoid,I-Entity
hemorrhage,I-Entity
(,O
SAH,I-Entity
),O
were,O
randomized,O
to,O
receive,O
either,O
ketoprofen,I-Entity
",",O
100,O
mg,O
",",O
three,O
times,O
a,O
day,O
(,O
ketoprofen,I-Entity
group,O
",",O
n,O
=,O
9,O
),O
or,O
a,O
weak,O
NSAID,O
",",O
acetaminophen,I-Entity
",",O
1,O
g,O
",",O
three,O
times,O
a,O
day,O
(,O
acetaminophen,I-Entity
group,O
",",O
n,O
=,O
9,O
),O
starting,O
immediately,O
after,O
the,O
diagnosis,O
of,O
aneurysmal,I-Entity
SAH,I-Entity
.,O
Maximal,O
platelet,B-Entity
aggregation,I-Entity
induced,O
by,O
6,O
microM,O
of,O
adenosine,B-Entity
diphosphate,I-Entity
decreased,O
after,O
administration,O
of,O
ketoprofen,I-Entity
.,O
Aggregation,O
was,O
lower,O
(,O
P,O
<,O
.05,O
),O
in,O
the,O
ketoprofen,I-Entity
group,O
than,O
in,O
the,O
acetaminophen,I-Entity
group,O
just,O
before,O
surgery,O
and,O
on,O
the,O
third,O
postoperative,O
day,O
.,O
In,O
contrast,O
",",O
maximal,O
platelet,B-Entity
aggregation,I-Entity
increased,O
in,O
the,O
acetaminophen,I-Entity
group,O
on,O
the,O
third,O
postoperative,O
day,O
as,O
compared,O
with,O
the,O
pretreatment,O
platelet,B-Entity
aggregation,I-Entity
results,O
(,O
P,O
<,O
.05,O
),O
.,O
One,O
patient,O
in,O
the,O
ketoprofen,I-Entity
group,O
developed,O
a,O
postoperative,O
intracranial,O
hematoma,I-Entity
.,O
Ketoprofen,I-Entity
but,O
not,O
acetaminophen,I-Entity
impaired,O
platelet,O
function,O
in,O
patients,O
with,O
SAH,I-Entity
.,O
If,O
ketoprofen,I-Entity
is,O
used,O
before,O
surgery,O
on,O
cerebral,O
artery,B-Entity
aneurysms,I-Entity
",",O
it,O
may,O
pose,O
an,O
additional,O
risk,O
factor,O
for,O
hemorrhage,I-Entity
.,O
Value,O
of,O
methylprednisolone,I-Entity
in,O
prevention,O
of,O
the,O
arthralgia,I-Entity
-,O
myalgia,I-Entity
syndrome,O
associated,O
with,O
the,O
total,O
dose,O
infusion,O
of,O
iron,B-Entity
dextran,I-Entity
:,O
a,O
double,O
blind,O
randomized,O
trial,O
.,O
The,O
safety,O
and,O
efficacy,O
of,O
total,O
dose,O
infusion,O
(,O
TDI,O
),O
of,O
iron,B-Entity
dextran,I-Entity
has,O
been,O
well,O
documented,O
.,O
In,O
40%,O
of,O
treated,O
patients,O
",",O
an,O
arthralgia,I-Entity
-,O
myalgia,I-Entity
syndrome,O
develops,O
.,O
administration,O
of,O
methylprednisolone,I-Entity
(,O
MP,I-Entity
),O
prevents,O
this,O
complication,O
.,O
MP,I-Entity
before,O
and,O
saline,O
after,O
TDI,O
(,O
group,O
2,O
),O
",",O
or,O
125,O
mg,O
i.v,O
.,O
MP,I-Entity
before,O
and,O
after,O
TDI,O
(,O
group,O
3,O
),O
.,O
These,O
data,O
demonstrate,O
that,O
administration,O
of,O
MP,I-Entity
before,O
and,O
after,O
TDI,O
reduces,O
the,O
frequency,O
and,O
severity,O
of,O
the,O
arthralgia,I-Entity
-,O
myalgia,I-Entity
syndrome,O
.,O
MP,I-Entity
should,O
be,O
given,O
routinely,O
before,O
and,O
after,O
TDI,O
of,O
iron,B-Entity
dextran,I-Entity
.,O
Long,O
-,O
term,O
effects,O
of,O
vincristine,I-Entity
on,O
the,O
peripheral,O
nervous,O
system,O
.,O
Forty,O
patients,O
with,O
Non,B-Entity
-,I-Entity
Hodgkin,I-Entity
's,I-Entity
Lymphoma,I-Entity
treated,O
with,O
vincristine,I-Entity
between,O
1984,O
and,O
1990,O
(,O
cumulative,O
dose,O
12,O
mg,O
in,O
18,O
-,O
24,O
weeks,O
),O
were,O
investigated,O
in,O
order,O
to,O
evaluate,O
the,O
long,O
term,O
effects,O
of,O
vincristine,I-Entity
on,O
the,O
peripheral,O
nervous,O
system,O
.,O
The,O
patients,O
were,O
interviewed,O
with,O
emphasis,O
on,O
neuropathic,B-Entity
symptoms,I-Entity
.,O
Physical,O
and,O
quantitative,O
sensory,O
examination,O
with,O
determination,O
of,O
vibratory,O
perception,O
and,O
thermal,O
discrimination,O
thresholds,O
were,O
performed,O
",",O
four,O
to,O
77,O
months,O
(,O
median,O
34,O
months,O
),O
after,O
vincristine,I-Entity
treatment,O
.,O
Twenty,O
-,O
seven,O
patients,O
reported,O
neuropathic,B-Entity
symptoms,I-Entity
.,O
It,O
is,O
concluded,O
that,O
with,O
the,O
above,O
mentioned,O
vincristine,I-Entity
dose,O
schedule,O
signs,O
and,O
symptoms,O
of,O
vincristine,I-Entity
neuropathy,I-Entity
are,O
reversible,O
for,O
a,O
great,O
deal,O
and,O
prognosis,O
is,O
fairly,O
good,O
.,O
A,O
case,O
of,O
polymyositis,I-Entity
in,O
a,O
patient,O
with,O
primary,B-Entity
biliary,I-Entity
cirrhosis,I-Entity
treated,O
with,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
.,O
Although,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
has,O
been,O
used,O
for,O
many,O
rheumatologic,B-Entity
diseases,I-Entity
",",O
toxicity,I-Entity
limits,O
its,O
usefulness,O
in,O
many,O
patients,O
.,O
Polymyositis,I-Entity
/,O
dermatomyositis,I-Entity
can,O
develop,O
as,O
one,O
of,O
the,O
autoimmune,O
complications,O
of,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
treatment,O
",",O
but,O
its,O
exact,O
pathogenesis,O
remains,O
unclear,O
.,O
We,O
report,O
a,O
patient,O
with,O
primary,B-Entity
biliary,I-Entity
cirrhosis,I-Entity
",",O
who,O
developed,O
polymyositis,I-Entity
while,O
receiving,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
therapy,O
.,O
Patients,O
receiving,O
D,B-Entity
-,I-Entity
penicillamine,I-Entity
therapy,O
should,O
be,O
followed,O
carefully,O
for,O
the,O
development,O
of,O
autoimmune,O
complications,O
like,O
polymyositis,I-Entity
/,O
dermatomyositis,I-Entity
.,O
Photodistributed,O
nifedipine,I-Entity
-,O
induced,O
facial,O
telangiectasia,I-Entity
.,O
Five,O
months,O
after,O
starting,O
nifedipine,I-Entity
(,O
Adalat,I-Entity
),O
",",O
two,O
patients,O
developed,O
photodistributed,O
facial,O
telangiectasia,I-Entity
",",O
which,O
became,O
more,O
noticeable,O
with,O
time,O
.,O
Neither,O
patient,O
complained,O
of,O
photosensitivity,O
or,O
flushing,I-Entity
.,O
One,O
commenced,O
the,O
closely,O
related,O
drug,O
amlodipine,I-Entity
3,O
years,O
later,O
",",O
with,O
recurrence,O
of,O
telangiectasia,I-Entity
.,O
The,O
photodistribution,O
of,O
the,O
telangiectasia,I-Entity
suggests,O
a,O
significant,O
drug,O
/,O
light,O
interaction,O
.,O
Nephrotoxicity,I-Entity
of,O
cyclosporin,B-Entity
A,I-Entity
and,O
FK506,I-Entity
:,O
inhibition,O
of,O
calcineurin,O
phosphatase,O
.,O
Cyclosporin,B-Entity
A,I-Entity
(,O
CsA,I-Entity
;,O
50,O
mg,O
/,O
kg,O
),O
and,O
Fujimycine,I-Entity
(,O
FK506,I-Entity
;,O
5,O
mg,O
/,O
kg,O
),O
",",O
but,O
not,O
the,O
related,O
macrolide,I-Entity
immunosuppressant,O
rapamycin,I-Entity
(,O
5,O
mg,O
/,O
kg,O
),O
",",O
caused,O
a,O
reduction,O
of,O
glomerular,O
filtration,O
rate,O
",",O
degenerative,O
changes,O
of,O
proximal,O
tubular,O
epithelium,O
",",O
and,O
hypertrophy,I-Entity
of,O
the,O
juxtaglomerular,O
apparatus,O
in,O
male,O
Wistar,O
rats,O
when,O
given,O
for,O
10,O
days,O
.,O
The,O
molecular,O
mechanisms,O
of,O
CsA,I-Entity
and,O
FK506,I-Entity
toxicity,I-Entity
were,O
investigated,O
.,O
Cyclophilin,O
A,O
and,O
FK506-binding,I-Entity
protein,O
",",O
the,O
main,O
intracytoplasmic,O
receptors,O
for,O
CsA,I-Entity
and,O
FK506,I-Entity
",",O
respectively,O
",",O
were,O
each,O
detected,O
in,O
renal,O
tissue,O
extract,O
.,O
In,O
the,O
kidney,O
",",O
high,O
levels,O
of,O
immunoreactive,O
and,O
enzymatically,O
active,O
calcineurin,O
were,O
found,O
which,O
were,O
inhibited,O
by,O
the,O
immunosuppressants,O
CsA,I-Entity
and,O
FK506,I-Entity
",",O
but,O
not,O
by,O
rapamycin,I-Entity
.,O
Finally,O
",",O
specific,O
immunophilin,O
-,O
drug,O
-,O
calcineurin,O
complexes,O
formed,O
only,O
in,O
the,O
presence,O
of,O
CsA,I-Entity
and,O
FK506,I-Entity
",",O
but,O
not,O
rapamycin,I-Entity
.,O
These,O
results,O
suggest,O
that,O
the,O
nephrotoxic,I-Entity
effects,O
of,O
CsA,I-Entity
and,O
FK506,I-Entity
is,O
likely,O
mediated,O
through,O
binding,O
to,O
renal,O
immunophilin,O
and,O
inhibiting,O
calcineurin,O
phosphatase,O
.,O
Massive,O
cerebral,B-Entity
edema,I-Entity
associated,O
with,O
fulminant,O
hepatic,B-Entity
failure,I-Entity
in,O
acetaminophen,I-Entity
overdose,I-Entity
:,O
possible,O
role,O
of,O
cranial,O
decompression,O
.,O
Cerebral,B-Entity
edema,I-Entity
may,O
complicate,O
the,O
course,O
of,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
.,O
We,O
present,O
a,O
patient,O
with,O
fatal,O
acetaminophen,I-Entity
-,O
induced,O
fulminant,B-Entity
hepatic,I-Entity
failure,I-Entity
",",O
with,O
signs,O
and,O
symptoms,O
of,O
cerebral,B-Entity
edema,I-Entity
",",O
unresponsive,O
to,O
conventional,O
medical,O
therapy,O
.,O
Gentamicin,I-Entity
nephropathy,I-Entity
in,O
a,O
neonate,O
.,O
The,O
clinical,O
and,O
autopsy,O
findings,O
in,O
a,O
premature,O
baby,O
who,O
died,O
of,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
after,O
therapy,O
with,O
gentamicin,I-Entity
(,O
5,O
mg,O
/,O
kg,O
/,O
day,O
),O
and,O
penicillin,I-Entity
are,O
presented,O
.,O
The,O
serum,O
gentamicin,I-Entity
concentration,O
had,O
reached,O
toxic,O
levels,O
when,O
anuria,I-Entity
developed,O
.,O
Numerous,O
periodic,B-Entity
acid,I-Entity
Schiff,O
(,O
PAS,O
),O
positive,O
",",O
diastase,O
resistant,O
cytoplasmic,O
inclusion,O
bodies,O
which,O
appeared,O
as,O
myelin,O
figures,O
in,O
cytosegresomes,O
under,O
the,O
electron,O
microscope,O
were,O
identified,O
in,O
the,O
proximal,O
convoluted,O
tubules,O
.,O
The,O
pathological,O
changes,O
induced,O
by,O
gentamicin,I-Entity
in,O
the,O
human,O
neonatal,O
kidneys,O
have,O
not,O
been,O
previously,O
reported,O
.,O
Anti,O
-,O
carcinogenic,I-Entity
action,O
of,O
phenobarbital,I-Entity
given,O
simultaneously,O
with,O
diethylnitrosamine,I-Entity
in,O
the,O
rat,O
.,O
The,O
present,O
work,O
has,O
been,O
planned,O
in,O
order,O
to,O
elucidate,O
the,O
effect,O
of,O
phenobarbital,I-Entity
(,O
PB,I-Entity
:,O
15,O
mg,O
per,O
rat,O
of,O
ingested,O
dose,O
),O
on,O
carcinogenesis,I-Entity
when,O
it,O
is,O
administered,O
simultaneously,O
with,O
diethylnitrosamine,I-Entity
(,O
DEN,I-Entity
:,O
10,O
mg,O
/,O
kg,O
/,O
day,O
),O
.,O
Wistar,O
rats,O
(,O
180,O
g,O
),O
were,O
treated,O
by,O
DEN,I-Entity
alone,O
or,O
by,O
DEN,I-Entity
+,O
PB,I-Entity
during,O
2,O
",",O
4,O
and,O
6,O
weeks,O
according,O
to,O
our,O
schedule,O
for,O
hepatocarcinogenesis,I-Entity
.,O
After,O
the,O
end,O
of,O
the,O
treatment,O
",",O
the,O
number,O
and,O
the,O
size,O
of,O
induced,O
PAS,O
positive,O
preneoplastic,B-Entity
foci,I-Entity
was,O
significantly,O
reduced,O
when,O
PB,I-Entity
was,O
given,O
simultaneously,O
with,O
DEN,I-Entity
for,O
4,O
and,O
6,O
weeks,O
.,O
The,O
mitotic,O
inhibition,O
and,O
the,O
production,O
of,O
micronuclei,O
normally,O
observed,O
after,O
partial,O
hepatectomy,O
in,O
DEN,I-Entity
treated,O
rats,O
were,O
also,O
significantly,O
decreased,O
in,O
DEN,I-Entity
+,O
PB,I-Entity
treated,O
rats,O
.,O
When,O
the,O
treatment,O
last,O
only,O
2,O
weeks,O
",",O
the,O
presence,O
of,O
PB,I-Entity
did,O
not,O
change,O
significantly,O
the,O
last,O
parameters,O
.,O
In,O
DEN,I-Entity
+,O
PB,I-Entity
treated,O
rats,O
",",O
the,O
survival,O
was,O
prolonged,O
and,O
the,O
tumor,I-Entity
incidence,O
decreased,O
as,O
compared,O
with,O
the,O
results,O
obtained,O
by,O
DEN,I-Entity
alone,O
.,O
It,O
is,O
concluded,O
that,O
PB,I-Entity
",",O
which,O
promotes,O
carcinogenesis,I-Entity
when,O
administered,O
after,O
the,O
DEN,I-Entity
treatment,O
",",O
reduces,O
the,O
carcinogen,O
effect,O
when,O
given,O
simultaneously,O
with,O
DEN,I-Entity
.,O
This,O
',O
anti,O
-,O
carcinogen,O
',O
effect,O
acts,O
on,O
the,O
initiation,O
as,O
well,O
as,O
on,O
the,O
promotion,O
of,O
the,O
precancerous,B-Entity
lesions,I-Entity
.,O
Biochemical,O
investigations,O
are,O
in,O
progress,O
to,O
obtain,O
more,O
information,O
about,O
this,O
',O
paradoxical,O
',O
PB,I-Entity
effect,O
.,O
Post,O
-,O
operative,O
rigidity,I-Entity
after,O
fentanyl,I-Entity
administration,O
.,O
A,O
case,O
of,O
thoraco,O
-,O
abdominal,O
rigidity,I-Entity
leading,O
to,O
respiratory,B-Entity
failure,I-Entity
is,O
described,O
in,O
the,O
post,O
-,O
operative,O
period,O
in,O
an,O
elderly,O
patient,O
who,O
received,O
a,O
moderate,O
dose,O
of,O
fentanyl,I-Entity
.,O
This,O
was,O
successfully,O
reversed,O
by,O
naloxone,I-Entity
.,O
Postpartum,O
psychosis,I-Entity
induced,O
by,O
bromocriptine,I-Entity
.,O
Two,O
multigravida,O
patients,O
with,O
no,O
prior,O
psychiatric,I-Entity
history,O
were,O
seen,O
with,O
postpartum,O
psychosis,I-Entity
",",O
having,O
received,O
bromocriptine,I-Entity
for,O
inhibition,B-Entity
of,I-Entity
lactation,I-Entity
.,O
Bromocriptine,I-Entity
given,O
in,O
high,O
doses,O
has,O
been,O
associated,O
with,O
psychosis,I-Entity
in,O
patients,O
receiving,O
the,O
drug,O
for,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
These,O
cases,O
demonstrate,O
that,O
bromocriptine,I-Entity
may,O
cause,O
psychosis,I-Entity
even,O
when,O
given,O
in,O
low,O
doses,O
.,O
A,O
prospective,O
study,O
on,O
the,O
dose,O
dependency,O
of,O
cardiotoxicity,I-Entity
induced,O
by,O
mitomycin,B-Entity
C.,I-Entity
Since,O
1975,O
mitomycin,B-Entity
C,I-Entity
(,O
MMC,I-Entity
),O
has,O
been,O
suggested,O
to,O
be,O
cardiotoxic,I-Entity
",",O
especially,O
when,O
combined,O
with,O
or,O
given,O
following,O
doxorubicin,I-Entity
.,O
Forty,O
-,O
four,O
MMC,I-Entity
-,O
treated,O
patients,O
were,O
studied,O
",",O
37,O
of,O
them,O
could,O
be,O
evaluated,O
.,O
One,O
of,O
the,O
patients,O
developed,O
cardiac,B-Entity
failure,I-Entity
after,O
30,O
mg,O
m-2,O
MMC,I-Entity
and,O
only,O
150,O
mg,O
m-2,O
doxorubicin,I-Entity
.,O
The,O
cardiac,B-Entity
failure,I-Entity
was,O
predicted,O
by,O
a,O
drop,O
in,O
EF,O
determined,O
during,O
a,O
cold,O
pressor,O
test,O
.,O
None,O
of,O
the,O
other,O
patients,O
developed,O
clinical,O
cardiotoxicity,I-Entity
",",O
nor,O
did,O
the,O
studied,O
parameters,O
change,O
.,O
Based,O
on,O
the,O
combined,O
data,O
from,O
the,O
present,O
study,O
and,O
the,O
literature,O
",",O
we,O
suggest,O
that,O
MMC,I-Entity
-,O
related,O
cardiotoxicity,I-Entity
is,O
dose,O
dependent,O
",",O
occurring,O
at,O
cumulative,O
dose,O
levels,O
of,O
30,O
mg,O
m-2,O
or,O
more,O
",",O
mainly,O
in,O
patients,O
also,O
(,O
previously,O
or,O
simultaneously,O
),O
treated,O
with,O
doxorubicin,I-Entity
.,O
Phlorizin,I-Entity
-,O
induced,O
glycosuria,I-Entity
does,O
not,O
prevent,O
gentamicin,I-Entity
nephrotoxicity,I-Entity
in,O
rats,O
.,O
Because,O
rats,O
with,O
streptozotocin,I-Entity
-,O
induced,O
diabetes,B-Entity
mellitus,I-Entity
(,O
DM,I-Entity
),O
have,O
a,O
high,O
solute,O
diuresis,O
(,O
glycosuria,I-Entity
of,O
10,O
to,O
12,O
g,O
/,O
day,O
),O
",",O
we,O
have,O
suggested,O
that,O
this,O
may,O
in,O
part,O
be,O
responsible,O
for,O
their,O
resistance,O
to,O
gentamicin,I-Entity
-,O
induced,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
(,O
ARF,I-Entity
),O
.,O
The,O
protection,O
from,O
gentamicin,I-Entity
nephrotoxicity,I-Entity
was,O
studied,O
in,O
non,O
-,O
diabetic,I-Entity
rats,O
with,O
chronic,O
solute,O
diuresis,O
induced,O
by,O
blockage,O
of,O
tubular,O
glucose,I-Entity
reabsorption,O
with,O
phlorizin,I-Entity
(,O
P,I-Entity
),O
.,O
DM,I-Entity
rats,O
with,O
mild,O
glycosuria,I-Entity
(,O
similar,O
in,O
degree,O
to,O
that,O
of,O
the,O
P,I-Entity
treated,O
animals,O
),O
were,O
also,O
studied,O
.,O
Group,O
1,O
(,O
P,I-Entity
alone,O
),O
received,O
P,I-Entity
",",O
360,O
mg,O
/,O
day,O
",",O
for,O
15,O
days,O
;,O
Group,O
II,O
(,O
P,I-Entity
+,O
gentamicin,I-Entity
),O
;,O
Group,O
III,O
(,O
gentamicin,I-Entity
alone,O
),O
and,O
Group,O
IV,O
(,O
mild,O
DM,I-Entity
+,O
gentamicin,I-Entity
),O
.,O
Nephrotoxic,I-Entity
doses,O
(,O
40,O
mg,O
/,O
kg,O
body,O
wt,O
/,O
day,O
),O
of,O
gentamicin,I-Entity
were,O
injected,O
during,O
the,O
last,O
nine,O
days,O
of,O
study,O
to,O
the,O
animals,O
of,O
groups,O
II,O
to,O
IV,O
.,O
In,O
Group,O
I,O
",",O
P,I-Entity
induced,O
a,O
moderate,O
and,O
stable,O
glycosuria,I-Entity
(,O
3.9,O
+,O
/-,O
0.1,O
g,O
/,O
day,O
",",O
SE,O
),O
",",O
and,O
no,O
functional,O
or,O
morphologic,O
evidence,O
of,O
renal,B-Entity
dysfunction,I-Entity
(,O
baseline,O
CCr,O
2.1,O
+,O
/-,O
ml,O
/,O
min,O
",",O
undetectable,O
lysozymuria,O
),O
or,O
damage,O
(,O
tubular,B-Entity
necrosis,I-Entity
score,O
[,O
maximum,O
4,O
],O
",",O
zero,O
),O
.,O
In,O
Group,O
II,O
",",O
P,I-Entity
did,O
not,O
prevent,O
gentamicin,I-Entity
-,O
ARF,I-Entity
(,O
maximal,O
decrease,O
in,O
CCr,O
at,O
day,O
9.89%,O
",",O
P,I-Entity
less,O
than,O
0.001,O
;,O
peak,O
lysozymuria,O
",",O
1863,O
+,O
/-,O
321,O
micrograms,O
/,O
day,O
;,O
and,O
tubular,B-Entity
necrosis,I-Entity
score,O
",",O
3.9,O
+,O
/-,O
These,O
values,O
were,O
not,O
different,O
from,O
those,O
of,O
Group,O
III,O
:,O
maximal,O
decrease,O
in,O
CCr,O
73%,O
(,O
P,I-Entity
less,O
than,O
0.001,O
),O
;,O
lysozymuria,O
",",O
2147,O
+,O
/-,O
701,O
micrograms,O
/,O
day,O
;,O
tubular,B-Entity
necrosis,I-Entity
score,O
",",O
3.8,O
+,O
/-,O
Tiapride,I-Entity
in,O
levodopa,I-Entity
-,O
induced,O
involuntary,B-Entity
movements,I-Entity
.,O
Tiapride,I-Entity
",",O
a,O
substituted,O
benzamide,I-Entity
derivative,O
closely,O
related,O
to,O
metoclopramide,I-Entity
",",O
reduced,O
levodopa,I-Entity
-,O
induced,O
peak,O
dose,O
involuntary,B-Entity
movements,I-Entity
in,O
16,O
patients,O
with,O
idiopathic,B-Entity
Parkinson,I-Entity
's,I-Entity
disease,I-Entity
.,O
However,O
",",O
an,O
unacceptable,O
increase,O
in,O
disability,O
from,O
Parkinsonism,I-Entity
with,O
aggravation,O
of,O
end,O
-,O
of,O
-,O
dose,O
akinesia,I-Entity
led,O
to,O
its,O
cessation,O
in,O
14,O
patients,O
.,O
Tiapride,I-Entity
had,O
no,O
effect,O
on,O
levodopa,I-Entity
-,O
induced,O
early,O
morning,O
of,O
"""",O
off,O
-,O
period,O
"""",O
segmental,O
dystonia,I-Entity
.,O
These,O
results,O
fail,O
to,O
support,O
the,O
notion,O
that,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
are,O
caused,O
by,O
overstimulation,O
of,O
a,O
separate,O
group,O
of,O
dopamine,I-Entity
receptors,O
.,O
Effects,O
of,O
the,O
hippocampal,O
deep,O
brain,O
stimulation,O
on,O
cortical,O
epileptic,I-Entity
discharges,O
in,O
penicillin,I-Entity
-,O
induced,O
epilepsy,I-Entity
model,O
in,O
rats,O
.,O
AIM,O
:,O
Experimental,O
and,O
clinical,O
studies,O
have,O
revealed,O
that,O
hippocampal,O
DBS,O
can,O
control,O
epileptic,I-Entity
activity,O
",",O
but,O
the,O
mechanism,O
of,O
action,O
is,O
obscure,O
and,O
optimal,O
stimulation,O
parameters,O
are,O
not,O
clearly,O
defined,O
.,O
The,O
aim,O
was,O
to,O
evaluate,O
the,O
effects,O
of,O
high,O
frequency,O
hippocampal,O
stimulation,O
on,O
cortical,O
epileptic,I-Entity
activity,O
in,O
penicillin,I-Entity
-,O
induced,O
epilepsy,I-Entity
model,O
.,O
In,O
group-1,O
(,O
n=10,O
),O
hippocampal,O
DBS,O
was,O
off,O
and,O
in,O
the,O
group-2,O
(,O
n=10,O
),O
hippocampal,O
DBS,O
was,O
on,O
(,O
185,O
Hz,O
",",O
0.5V,O
",",O
1V,O
",",O
2V,O
",",O
and,O
5V,O
for,O
60,O
sec,O
),O
following,O
penicillin,B-Entity
G,I-Entity
injection,O
intracortically,O
.,O
EEG,O
recordings,O
were,O
obtained,O
before,O
and,O
15,O
minutes,O
following,O
penicillin,B-Entity
-,I-Entity
G,I-Entity
injection,O
",",O
and,O
at,O
10th,O
minutes,O
following,O
each,O
stimulus,O
for,O
analysis,O
in,O
terms,O
of,O
frequency,O
",",O
amplitude,O
",",O
and,O
power,O
spectrum,O
.,O
High,O
frequency,O
hippocampal,O
DBS,O
suppressed,O
the,O
acute,O
penicillin,I-Entity
-,O
induced,O
cortical,O
epileptic,I-Entity
activity,O
independent,O
from,O
stimulus,O
intensity,O
.,O
CONCLUSION,O
:,O
Our,O
results,O
revealed,O
that,O
continuous,O
high,O
frequency,O
stimulation,O
of,O
the,O
hippocampus,O
suppressed,O
acute,O
cortical,O
epileptic,I-Entity
activity,O
effectively,O
without,O
causing,O
secondary,O
epileptic,I-Entity
discharges,O
.,O
These,O
results,O
are,O
important,O
in,O
terms,O
of,O
defining,O
the,O
optimal,O
parameters,O
of,O
hippocampal,O
DBS,O
in,O
patients,O
with,O
epilepsy,I-Entity
.,O
Neural,O
correlates,O
of,O
S,B-Entity
-,I-Entity
ketamine,I-Entity
induced,O
psychosis,I-Entity
during,O
overt,O
continuous,O
verbal,O
fluency,O
.,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
D,I-Entity
-,I-Entity
aspartate,I-Entity
(,O
NMDA,I-Entity
),O
receptor,O
has,O
been,O
implicated,O
in,O
the,O
pathophysiology,O
of,O
schizophrenia,I-Entity
.,O
Administered,O
to,O
healthy,O
volunteers,O
",",O
a,O
subanesthetic,O
dose,O
of,O
the,O
non,O
-,O
competitive,O
NMDA,I-Entity
receptor,O
antagonist,O
ketamine,I-Entity
leads,O
to,O
psychopathological,O
symptoms,O
similar,O
to,O
those,O
observed,O
in,O
schizophrenia,I-Entity
.,O
In,O
patients,O
with,O
schizophrenia,I-Entity
",",O
ketamine,I-Entity
exacerbates,O
the,O
core,O
symptoms,O
of,O
illness,O
",",O
supporting,O
the,O
hypothesis,O
of,O
a,O
glutamatergic,B-Entity
dysfunction,I-Entity
.,O
In,O
a,O
counterbalanced,O
",",O
placebo,O
-,O
controlled,O
",",O
double,O
-,O
blind,O
study,O
design,O
",",O
healthy,O
subjects,O
were,O
administered,O
a,O
continuous,O
subanesthetic,O
S,B-Entity
-,I-Entity
ketamine,I-Entity
infusion,O
while,O
differences,O
in,O
BOLD,O
responses,O
measured,O
with,O
fMRI,O
were,O
detected,O
.,O
Ketamine,I-Entity
-,O
induced,O
psychopathological,O
symptoms,O
were,O
assessed,O
with,O
the,O
Positive,O
and,O
Negative,O
Syndrome,O
Scale,O
(,O
PANSS,O
),O
.,O
Ketamine,I-Entity
elicited,O
psychosis,I-Entity
like,O
psychopathology,O
.,O
Post,O
-,O
hoc,O
t,O
-,O
tests,O
revealed,O
significant,O
differences,O
between,O
placebo,O
and,O
ketamine,I-Entity
for,O
the,O
amounts,O
of,O
words,O
generated,O
during,O
lexical,O
and,O
semantic,O
verbal,O
fluency,O
",",O
while,O
the,O
phonological,O
domain,O
remained,O
unaffected,O
.,O
Ketamine,I-Entity
led,O
to,O
enhanced,O
cortical,O
activations,O
in,O
supramarginal,O
and,O
frontal,O
brain,O
regions,O
for,O
phonological,O
and,O
lexical,O
verbal,O
fluency,O
",",O
but,O
not,O
for,O
semantic,O
verbal,O
fluency,O
.,O
Ketamine,I-Entity
induces,O
activation,O
changes,O
in,O
healthy,O
subjects,O
similar,O
to,O
those,O
observed,O
in,O
patients,O
with,O
schizophrenia,I-Entity
",",O
particularly,O
in,O
frontal,O
and,O
temporal,O
brain,O
regions,O
.,O
Our,O
results,O
provide,O
further,O
support,O
for,O
the,O
hypothesis,O
of,O
an,O
NMDA,I-Entity
receptor,O
dysfunction,O
in,O
the,O
pathophysiology,O
of,O
schizophrenia,I-Entity
.,O
Dopamine,I-Entity
is,O
not,O
essential,O
for,O
the,O
development,O
of,O
methamphetamine,I-Entity
-,O
induced,O
neurotoxicity,I-Entity
.,O
It,O
is,O
widely,O
believed,O
that,O
dopamine,I-Entity
(,O
DA,I-Entity
),O
mediates,O
methamphetamine,I-Entity
(,O
METH)-induced,I-Entity
toxicity,I-Entity
to,O
brain,O
dopaminergic,O
neurons,O
",",O
because,O
drugs,O
that,O
interfere,O
with,O
DA,I-Entity
neurotransmission,O
decrease,O
toxicity,I-Entity
",",O
whereas,O
drugs,O
that,O
increase,O
DA,I-Entity
neurotransmission,O
enhance,O
toxicity,I-Entity
.,O
However,O
",",O
temperature,O
effects,O
of,O
drugs,O
that,O
have,O
been,O
used,O
to,O
manipulate,O
brain,O
DA,I-Entity
neurotransmission,O
confound,O
interpretation,O
of,O
the,O
data,O
.,O
Here,O
we,O
show,O
that,O
the,O
recently,O
reported,O
ability,O
of,O
L,B-Entity
-,I-Entity
dihydroxyphenylalanine,I-Entity
to,O
reverse,O
the,O
protective,O
effect,O
of,O
alpha,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
para,I-Entity
-,I-Entity
tyrosine,I-Entity
on,O
METH,I-Entity
-,O
induced,O
DA,I-Entity
neurotoxicity,I-Entity
is,O
also,O
confounded,O
by,O
drug,O
effects,O
on,O
body,O
temperature,O
.,O
Further,O
",",O
we,O
show,O
that,O
mice,O
genetically,O
engineered,O
to,O
be,O
deficient,O
in,O
brain,O
DA,I-Entity
develop,O
METH,I-Entity
neurotoxicity,I-Entity
",",O
as,O
long,O
as,O
the,O
thermic,O
effects,O
of,O
METH,I-Entity
are,O
preserved,O
.,O
In,O
addition,O
",",O
we,O
demonstrate,O
that,O
mice,O
genetically,O
engineered,O
to,O
have,O
unilateral,O
brain,O
DA,I-Entity
deficits,O
develop,O
METH,I-Entity
-,O
induced,O
dopaminergic,B-Entity
deficits,I-Entity
that,O
are,O
of,O
comparable,O
magnitude,O
on,O
both,O
sides,O
of,O
the,O
brain,O
.,O
Taken,O
together,O
",",O
these,O
findings,O
demonstrate,O
that,O
DA,I-Entity
is,O
not,O
essential,O
for,O
the,O
development,O
of,O
METH,I-Entity
-,O
induced,O
dopaminergic,O
neurotoxicity,I-Entity
and,O
suggest,O
that,O
mechanisms,O
independent,O
of,O
DA,I-Entity
warrant,O
more,O
intense,O
investigation,O
.,O
Brainstem,B-Entity
dysgenesis,I-Entity
in,O
an,O
infant,O
prenatally,O
exposed,O
to,O
cocaine,I-Entity
.,O
Many,O
authors,O
described,O
the,O
effects,O
on,O
the,O
fetus,O
of,O
maternal,O
cocaine,B-Entity
abuse,I-Entity
during,O
pregnancy,O
.,O
Vasoconstriction,O
appears,O
to,O
be,O
the,O
common,O
mechanism,O
of,O
action,O
leading,O
to,O
a,O
wide,O
range,O
of,O
fetal,B-Entity
anomalies,I-Entity
.,O
We,O
report,O
on,O
an,O
infant,O
with,O
multiple,B-Entity
cranial,I-Entity
-,I-Entity
nerve,I-Entity
involvement,I-Entity
attributable,O
to,O
brainstem,B-Entity
dysgenesis,I-Entity
",",O
born,O
to,O
a,O
cocaine,B-Entity
-,I-Entity
addicted,I-Entity
mother,O
.,O
The,O
protective,O
role,O
of,O
Nrf2,O
in,O
streptozotocin,I-Entity
-,O
induced,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
Diabetic,B-Entity
nephropathy,I-Entity
is,O
one,O
of,O
the,O
major,O
causes,O
of,O
renal,B-Entity
failure,I-Entity
",",O
which,O
is,O
accompanied,O
by,O
the,O
production,O
of,O
reactive,O
oxygen,I-Entity
species,O
(,O
ROS,O
),O
.,O
Here,O
",",O
we,O
report,O
our,O
findings,O
demonstrating,O
a,O
protective,O
role,O
of,O
Nrf2,O
against,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
We,O
explore,O
the,O
protective,O
role,O
of,O
Nrf2,O
against,O
diabetic,B-Entity
nephropathy,I-Entity
using,O
human,O
kidney,O
biopsy,O
tissues,O
from,O
diabetic,B-Entity
nephropathy,I-Entity
patients,O
",",O
a,O
streptozotocin,I-Entity
-,O
induced,O
diabetic,B-Entity
nephropathy,I-Entity
model,O
in,O
Nrf2(-/-,O
),O
mice,O
",",O
and,O
cultured,O
human,O
mesangial,O
cells,O
.,O
The,O
glomeruli,O
of,O
human,O
diabetic,B-Entity
nephropathy,I-Entity
patients,O
were,O
under,O
oxidative,O
stress,O
and,O
had,O
elevated,O
Nrf2,O
levels,O
.,O
In,O
the,O
animal,O
study,O
",",O
Nrf2,O
was,O
demonstrated,O
to,O
be,O
crucial,O
in,O
ameliorating,O
streptozotocin,I-Entity
-,O
induced,O
renal,B-Entity
damage,I-Entity
.,O
This,O
is,O
evident,O
by,O
Nrf2(-/-,O
),O
mice,O
having,O
higher,O
ROS,O
production,O
and,O
suffering,O
from,O
greater,O
oxidative,O
DNA,O
damage,O
and,O
renal,B-Entity
injury,I-Entity
compared,O
with,O
Nrf2(+/+,O
),O
mice,O
.,O
Mechanistic,O
studies,O
in,O
both,O
in,O
vivo,O
and,O
in,O
vitro,O
systems,O
showed,O
that,O
the,O
Nrf2-mediated,O
protection,O
against,O
diabetic,B-Entity
nephropathy,I-Entity
is,O
",",O
at,O
least,O
",",O
partially,O
through,O
inhibition,O
of,O
transforming,O
growth,O
factor,O
-,O
beta1,O
(,O
TGF,O
-,O
beta1,O
),O
and,O
reduction,O
of,O
extracellular,O
matrix,O
production,O
.,O
In,O
human,O
renal,O
mesangial,O
cells,O
",",O
high,O
glucose,I-Entity
induced,O
ROS,O
production,O
and,O
activated,O
expression,O
of,O
Nrf2,O
and,O
its,O
downstream,O
genes,O
.,O
This,O
work,O
clearly,O
indicates,O
a,O
protective,O
role,O
of,O
Nrf2,O
in,O
diabetic,B-Entity
nephropathy,I-Entity
",",O
suggesting,O
that,O
dietary,O
or,O
therapeutic,O
activation,O
of,O
Nrf2,O
could,O
be,O
used,O
as,O
a,O
strategy,O
to,O
prevent,O
or,O
slow,O
down,O
the,O
progression,O
of,O
diabetic,B-Entity
nephropathy,I-Entity
.,O
High,O
-,O
dose,O
tranexamic,B-Entity
Acid,I-Entity
is,O
associated,O
with,O
nonischemic,O
clinical,O
seizures,I-Entity
in,O
cardiac,O
surgical,O
patients,O
.,O
In,O
2,O
separate,O
centers,O
",",O
we,O
observed,O
a,O
notable,O
increase,O
in,O
the,O
incidence,O
of,O
postoperative,O
convulsive,I-Entity
seizures,I-Entity
from,O
1.3%,O
to,O
3.8%,O
in,O
patients,O
having,O
undergone,O
major,O
cardiac,O
surgical,O
procedures,O
.,O
These,O
events,O
were,O
temporally,O
coincident,O
with,O
the,O
initial,O
use,O
of,O
high,O
-,O
dose,O
tranexamic,B-Entity
acid,I-Entity
(,O
TXA,I-Entity
),O
therapy,O
after,O
withdrawal,O
of,O
aprotinin,O
from,O
general,O
clinical,O
usage,O
.,O
The,O
purpose,O
of,O
this,O
review,O
was,O
to,O
perform,O
a,O
retrospective,O
analysis,O
to,O
examine,O
whether,O
there,O
was,O
a,O
relation,O
between,O
TXA,I-Entity
usage,O
and,O
seizures,I-Entity
after,O
cardiac,O
surgery,O
.,O
An,O
in,O
-,O
depth,O
chart,O
review,O
was,O
undertaken,O
in,O
all,O
24,O
patients,O
who,O
developed,O
perioperative,O
seizures,I-Entity
.,O
Twenty,O
-,O
one,O
of,O
the,O
24,O
patients,O
did,O
not,O
have,O
evidence,O
of,O
new,O
cerebral,B-Entity
ischemic,I-Entity
injury,I-Entity
",",O
but,O
seizures,I-Entity
were,O
likely,O
due,O
to,O
ischemic,B-Entity
brain,I-Entity
injury,I-Entity
in,O
3,O
patients,O
.,O
All,O
patients,O
with,O
seizures,I-Entity
did,O
not,O
have,O
permanent,O
neurological,B-Entity
abnormalities,I-Entity
.,O
All,O
24,O
patients,O
with,O
seizures,I-Entity
received,O
high,O
doses,O
of,O
TXA,I-Entity
intraoperatively,O
ranging,O
from,O
61,O
to,O
259,O
mg,O
/,O
kg,O
",",O
had,O
a,O
mean,O
age,O
of,O
69.9,O
years,O
",",O
and,O
21,O
of,O
24,O
had,O
undergone,O
open,O
chamber,O
rather,O
than,O
coronary,O
bypass,O
procedures,O
.,O
No,O
evidence,O
of,O
brain,B-Entity
ischemic,I-Entity
",",O
metabolic,O
",",O
or,O
hyperthermia,I-Entity
-,O
induced,O
causes,O
for,O
their,O
seizures,I-Entity
was,O
apparent,O
.,O
:,O
Our,O
results,O
suggest,O
that,O
use,O
of,O
high,O
-,O
dose,O
TXA,I-Entity
in,O
older,O
patients,O
in,O
conjunction,O
with,O
cardiopulmonary,O
bypass,O
and,O
open,O
-,O
chamber,O
cardiac,O
surgery,O
is,O
associated,O
with,O
clinical,O
seizures,I-Entity
in,O
susceptible,O
patients,O
.,O
Recurrent,O
dysosmia,I-Entity
induced,O
by,O
pyrazinamide,I-Entity
.,O
Pyrazinamide,I-Entity
can,O
have,O
adverse,O
effects,O
such,O
as,O
hepatic,B-Entity
toxicity,I-Entity
",",O
hyperuricemia,I-Entity
or,O
digestive,O
disorders,O
.,O
In,O
rare,O
cases,O
",",O
alterations,O
in,O
taste,O
and,O
smell,O
function,O
have,O
been,O
reported,O
for,O
pyrazinamide,I-Entity
when,O
combined,O
with,O
other,O
drugs,O
.,O
We,O
report,O
a,O
case,O
of,O
reversible,O
olfactory,B-Entity
disorder,I-Entity
related,O
to,O
pyrazinamide,I-Entity
in,O
a,O
woman,O
",",O
with,O
a,O
positive,O
rechallenge,O
.,O
Dysosmia,I-Entity
disappeared,O
completely,O
after,O
pyrazinamide,I-Entity
withdrawal,O
and,O
recurred,O
after,O
its,O
rechallenge,O
.,O
Longitudinal,O
assessment,O
of,O
air,O
conduction,O
audiograms,O
in,O
a,O
phase,O
III,O
clinical,O
trial,O
of,O
difluoromethylornithine,I-Entity
and,O
sulindac,I-Entity
for,O
prevention,O
of,O
sporadic,O
colorectal,B-Entity
adenomas,I-Entity
.,O
A,O
phase,O
III,O
clinical,O
trial,O
assessed,O
the,O
recurrence,O
of,O
adenomatous,B-Entity
polyps,I-Entity
after,O
treatment,O
for,O
36,O
months,O
with,O
difluoromethylornithine,I-Entity
(,O
DFMO,I-Entity
),O
plus,O
sulindac,I-Entity
or,O
matched,O
placebos,O
.,O
Temporary,O
hearing,B-Entity
loss,I-Entity
is,O
a,O
known,O
toxicity,I-Entity
of,O
treatment,O
with,O
DFMO,I-Entity
",",O
thus,O
a,O
comprehensive,O
approach,O
was,O
developed,O
to,O
analyze,O
serial,O
air,O
conduction,O
audiograms,O
.,O
Based,O
on,O
290,O
subjects,O
",",O
there,O
was,O
an,O
average,O
difference,O
of,O
0.50,O
dB,O
between,O
subjects,O
treated,O
with,O
DFMO,I-Entity
plus,O
sulindac,I-Entity
compared,O
with,O
those,O
treated,O
with,O
placebo,O
(,O
95%,O
confidence,O
interval,O
",",O
-0.64,O
to,O
1.63,O
dB,O
;,O
P,O
=,O
0.39,O
),O
",",O
adjusted,O
for,O
baseline,O
values,O
",",O
age,O
",",O
and,O
frequencies,O
.,O
There,O
were,O
14,O
of,O
151,O
(,O
9.3%,O
),O
in,O
the,O
DFMO,I-Entity
plus,O
sulindac,I-Entity
group,O
and,O
4,O
of,O
139,O
(,O
2.9%,O
),O
in,O
the,O
placebo,O
group,O
who,O
experienced,O
at,O
least,O
15,O
dB,O
hearing,O
reduction,O
from,O
baseline,O
in,O
2,O
or,O
more,O
consecutive,O
frequencies,O
across,O
the,O
entire,O
range,O
tested,O
(,O
P,O
=,O
0.02,O
),O
.,O
There,O
was,O
no,O
significant,O
difference,O
in,O
the,O
proportion,O
of,O
subjects,O
in,O
the,O
DFMO,I-Entity
plus,O
sulindac,I-Entity
group,O
who,O
experienced,O
clinically,O
significant,O
hearing,B-Entity
loss,I-Entity
compared,O
with,O
the,O
placebo,O
group,O
.,O
The,O
estimated,O
attributable,O
risk,O
of,O
ototoxicity,I-Entity
from,O
exposure,O
to,O
the,O
drug,O
is,O
8.4%,O
(,O
95%,O
confidence,O
interval,O
",",O
-2.0%,O
to,O
18.8%,O
;,O
P,O
=,O
0.12,O
),O
.,O
There,O
is,O
a,O
<,O
2,O
dB,O
difference,O
in,O
mean,O
threshold,O
for,O
patients,O
treated,O
with,O
DFMO,I-Entity
plus,O
sulindac,I-Entity
compared,O
with,O
those,O
treated,O
with,O
placebo,O
.,O
Increased,O
mental,B-Entity
slowing,I-Entity
associated,O
with,O
the,O
APOE,O
epsilon4,O
allele,O
after,O
trihexyphenidyl,I-Entity
oral,O
anticholinergic,O
challenge,O
in,O
healthy,O
elderly,O
.,O
The,O
objectives,O
of,O
this,O
study,O
were,O
to,O
examine,O
the,O
relationship,O
between,O
APOE,O
epsilon4,O
and,O
subjective,O
effects,O
of,O
trihexyphenidyl,I-Entity
on,O
measures,O
reflecting,O
sedation,O
and,O
confusion,I-Entity
and,O
to,O
investigate,O
the,O
relationship,O
between,O
trihexyphenidyl,I-Entity
-,O
induced,O
subjective,O
effects,O
and,O
objective,O
memory,O
performance,O
.,O
All,O
participants,O
received,O
1.0,O
mg,O
or,O
2.0,O
mg,O
trihexyphenidyl,I-Entity
or,O
placebo,O
administered,O
in,O
counterbalanced,O
sequences,O
over,O
a,O
period,O
of,O
three,O
consecutive,O
weeks,O
.,O
A,O
2.0-mg,O
oral,O
dose,O
of,O
trihexyphenidyl,I-Entity
resulted,O
in,O
increased,O
subjective,O
ratings,O
of,O
mental,B-Entity
slowness,I-Entity
in,O
carriers,O
of,O
the,O
APOE,O
epsilon4,O
allele,O
only,O
.,O
Drug,O
effects,O
as,O
determined,O
by,O
difference,O
scores,O
between,O
2.0,O
mg,O
trihexyphenidyl,I-Entity
and,O
placebo,O
on,O
ratings,O
of,O
mental,B-Entity
slowness,I-Entity
significantly,O
correlated,O
with,O
total,O
and,O
delayed,O
recall,O
on,O
the,O
Buschke,O
Selective,O
Reminding,O
Test,O
in,O
carriers,O
of,O
the,O
APOE,O
epsilon4,O
allele,O
only,O
.,O
The,O
epsilon4,O
allele,O
in,O
healthy,O
elderly,O
was,O
associated,O
with,O
increased,O
subjective,O
mental,B-Entity
slowing,I-Entity
after,O
trihexyphenidyl,I-Entity
anticholinergic,O
challenge,O
.,O
Behavioral,O
effects,O
of,O
pubertal,O
anabolic,O
androgenic,O
steroid,I-Entity
exposure,O
in,O
male,O
rats,O
with,O
low,O
serotonin,I-Entity
.,O
The,O
goal,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
interactive,O
effects,O
of,O
chronic,O
anabolic,O
androgenic,O
steroid,I-Entity
(,O
AAS,O
),O
exposure,O
and,O
brain,O
serotonin,I-Entity
(,O
5-hydroxytryptamine,I-Entity
",",O
5-HT,I-Entity
),O
depletion,O
on,O
behavior,O
of,O
pubertal,O
male,O
rats,O
.,O
Serotonin,I-Entity
was,O
depleted,O
beginning,O
on,O
postnatal,O
day,O
26,O
with,O
parachlorophenylalanine,I-Entity
(,O
PCPA,I-Entity
100,O
mg,O
/,O
kg,O
",",O
every,O
other,O
day,O
),O
;,O
controls,O
received,O
saline,O
.,O
At,O
puberty,O
(,O
P40,O
),O
",",O
half,O
the,O
PCPA,I-Entity
-,O
treated,O
rats,O
and,O
half,O
the,O
saline,O
-,O
treated,O
rats,O
began,O
treatment,O
with,O
testosterone,I-Entity
(,O
T,I-Entity
",",O
5,O
mg,O
/,O
kg,O
",",O
5,O
days,O
/,O
week,O
),O
.,O
Behavioral,O
measures,O
included,O
locomotion,O
",",O
irritability,I-Entity
",",O
copulation,O
",",O
partner,O
preference,O
",",O
and,O
aggression,I-Entity
.,O
Animals,O
were,O
tested,O
for,O
aggression,I-Entity
in,O
their,O
home,O
cage,O
",",O
both,O
with,O
and,O
without,O
physical,O
provocation,O
(,O
mild,O
tail,O
pinch,O
),O
.,O
Brain,O
levels,O
of,O
5-HT,I-Entity
and,O
its,O
metabolite,O
",",O
5-hydroxyindoleacetic,B-Entity
acid,I-Entity
(,O
5-HIAA,I-Entity
),O
",",O
were,O
determined,O
using,O
HPLC,O
.,O
PCPA,I-Entity
significantly,O
and,O
substantially,O
depleted,O
5-HT,I-Entity
and,O
5-HIAA,I-Entity
in,O
all,O
brain,O
regions,O
examined,O
.,O
Chronic,O
T,I-Entity
treatment,O
significantly,O
decreased,O
5-HT,I-Entity
and,O
5-HIAA,I-Entity
in,O
certain,O
brain,O
areas,O
",",O
but,O
to,O
a,O
much,O
lesser,O
extent,O
than,O
PCPA,I-Entity
.,O
Chronic,O
exposure,O
to,O
PCPA,I-Entity
alone,O
significantly,O
decreased,O
locomotor,O
activity,O
and,O
increased,O
irritability,I-Entity
but,O
had,O
no,O
effect,O
on,O
sexual,O
behavior,O
",",O
partner,O
preference,O
",",O
or,O
aggression,I-Entity
.,O
T,I-Entity
alone,O
had,O
no,O
effect,O
on,O
locomotion,O
",",O
irritability,I-Entity
",",O
or,O
sexual,O
behavior,O
but,O
increased,O
partner,O
preference,O
and,O
aggression,I-Entity
.,O
The,O
most,O
striking,O
effect,O
of,O
combining,O
T+PCPA,I-Entity
was,O
a,O
significant,O
increase,O
in,O
attack,O
frequency,O
as,O
well,O
as,O
a,O
significant,O
decrease,O
in,O
the,O
latency,O
to,O
attack,O
",",O
particularly,O
following,O
physical,O
provocation,O
.,O
Based,O
on,O
these,O
data,O
",",O
it,O
can,O
be,O
speculated,O
that,O
pubertal,O
AAS,O
users,O
with,O
low,O
central,O
5-HT,I-Entity
may,O
be,O
especially,O
prone,O
to,O
exhibit,O
aggressive,B-Entity
behavior,I-Entity
.,O
Intracavitary,O
chemotherapy,O
(,O
paclitaxel,I-Entity
/,O
carboplatin,I-Entity
liquid,O
crystalline,O
cubic,O
phases,O
),O
for,O
recurrent,O
glioblastoma,I-Entity
--,O
clinical,O
observations,O
.,O
Human,O
malignant,O
brain,B-Entity
tumors,I-Entity
have,O
a,O
poor,O
prognosis,O
in,O
spite,O
of,O
surgery,O
and,O
radiation,O
therapy,O
.,O
For,O
human,O
glioblastoma,I-Entity
recurrences,O
",",O
the,O
feasibility,O
",",O
safety,O
",",O
and,O
short,O
-,O
term,O
effects,O
of,O
a,O
surgical,O
intracavitary,O
application,O
of,O
paclitaxel,I-Entity
and,O
carboplatin,I-Entity
encapsulated,O
by,O
liquid,O
crystalline,O
cubic,O
phases,O
are,O
examined,O
in,O
a,O
pilot,O
study,O
.,O
A,O
total,O
of,O
12,O
patients,O
with,O
a,O
recurrence,O
of,O
a,O
glioblastoma,I-Entity
multiforme,O
underwent,O
re,O
-,O
resection,O
and,O
received,O
an,O
intracavitary,O
application,O
of,O
paclitaxel,I-Entity
and,O
carboplatin,I-Entity
cubic,O
phases,O
in,O
different,O
dosages,O
.,O
Six,O
of,O
the,O
patients,O
received,O
more,O
than,O
15,O
mg,O
paclitaxel,I-Entity
and,O
suffered,O
from,O
moderate,O
to,O
severe,O
brain,B-Entity
edema,I-Entity
",",O
while,O
the,O
remaining,O
patients,O
received,O
only,O
a,O
total,O
of,O
15,O
mg,O
paclitaxel,I-Entity
.,O
In,O
the,O
latter,O
group,O
",",O
brain,B-Entity
edema,I-Entity
was,O
markedly,O
reduced,O
and,O
dealt,O
medically,O
.,O
Intracavitary,O
chemotherapy,O
in,O
recurrent,O
glioblastoma,I-Entity
using,O
cubic,O
phases,O
is,O
feasible,O
and,O
safe,O
",",O
yet,O
the,O
clinical,O
benefit,O
remains,O
to,O
be,O
examined,O
in,O
a,O
clinical,O
phase,O
II,O
study,O
.,O
Methylphenidate,I-Entity
-,O
induced,O
obsessive,B-Entity
-,I-Entity
compulsive,I-Entity
symptoms,I-Entity
in,O
an,O
elderly,O
man,O
.,O
An,O
82-year,O
-,O
old,O
man,O
with,O
treatment,B-Entity
-,I-Entity
resistant,I-Entity
depression,I-Entity
and,O
early,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
was,O
started,O
on,O
methylphenidate,I-Entity
.,O
Significant,O
obsessive,B-Entity
-,I-Entity
compulsive,I-Entity
behavior,I-Entity
ensued,O
but,O
diminished,O
over,O
several,O
weeks,O
when,O
methylphenidate,I-Entity
was,O
replaced,O
by,O
fluvoxamine,I-Entity
.,O
The,O
patient,O
had,O
no,O
prior,O
psychiatric,I-Entity
history,O
",",O
but,O
he,O
had,O
a,O
sister,O
with,O
obsessive,B-Entity
-,I-Entity
compulsive,I-Entity
disorder,I-Entity
.,O
It,O
appears,O
that,O
methylphenidate,I-Entity
precipitated,O
the,O
patient,O
's,O
pathological,O
behavior,O
.,O
Cardiac,B-Entity
arrest,I-Entity
after,O
intravenous,O
metoclopramide,I-Entity
-,O
a,O
case,O
of,O
five,O
repeated,O
injections,O
of,O
metoclopramide,I-Entity
causing,O
five,O
episodes,O
of,O
cardiac,B-Entity
arrest,I-Entity
.,O
We,O
describe,O
a,O
patient,O
where,O
intravenous,O
injection,O
of,O
metoclopramide,I-Entity
was,O
immediately,O
followed,O
by,O
asystole,I-Entity
repeatedly,O
.,O
The,O
patient,O
received,O
metoclopramide,I-Entity
10,O
mg,O
i.v,O
.,O
After,O
interviewing,O
the,O
attending,O
nurses,O
and,O
reviewing,O
the,O
written,O
documentation,O
",",O
it,O
is,O
clear,O
that,O
every,O
administration,O
of,O
metoclopramide,I-Entity
was,O
immediately,O
(,O
within,O
s,O
),O
followed,O
by,O
asystole,I-Entity
.,O
The,O
asystole,I-Entity
lasted,O
15,O
-,O
30,O
s,O
on,O
four,O
occasions,O
",",O
on,O
one,O
occasion,O
it,O
lasted,O
2,O
min,O
.,O
The,O
patient,O
received,O
atropine,I-Entity
0.5,O
-,O
1,O
mg,O
and,O
chest,O
compressions,O
",",O
before,O
sinus,O
rhythm,O
again,O
took,O
over,O
.,O
We,O
interpret,O
this,O
as,O
episodes,O
of,O
cardiac,B-Entity
arrest,I-Entity
caused,O
by,O
metoclopramide,I-Entity
.,O
The,O
rapid,O
injection,O
via,O
the,O
central,O
venous,O
route,O
and,O
the,O
concomitant,O
tapering,O
of,O
dopamine,I-Entity
infusion,O
might,O
have,O
contributed,O
in,O
precipitating,O
the,O
adverse,O
drug,O
reaction,O
.,O
Severe,O
immune,O
hemolytic,B-Entity
anemia,I-Entity
associated,O
with,O
prophylactic,O
use,O
of,O
cefotetan,I-Entity
in,O
obstetric,O
and,O
gynecologic,O
procedures,O
.,O
Second-,O
and,O
third,O
-,O
generation,O
cephalosporins,I-Entity
",",O
especially,O
cefotetan,I-Entity
",",O
are,O
increasingly,O
associated,O
with,O
severe,O
",",O
sometimes,O
fatal,O
immune,O
hemolytic,B-Entity
anemia,I-Entity
.,O
We,O
noticed,O
that,O
10,O
of,O
our,O
35,O
cases,O
of,O
cefotetan,I-Entity
-,O
induced,O
hemolytic,B-Entity
anemias,I-Entity
were,O
in,O
patients,O
who,O
had,O
received,O
cefotetan,I-Entity
prophylactically,O
for,O
obstetric,O
and,O
gynecologic,O
procedures,O
.,O
Eight,O
of,O
these,O
cases,O
of,O
severe,O
immune,O
hemolytic,B-Entity
anemia,I-Entity
are,O
described,O
.,O
Cauda,B-Entity
equina,I-Entity
syndrome,I-Entity
after,O
spinal,O
anaesthesia,O
with,O
hyperbaric,O
5%,O
lignocaine,I-Entity
:,O
a,O
review,O
of,O
six,O
cases,O
of,O
cauda,B-Entity
equina,I-Entity
syndrome,I-Entity
reported,O
to,O
the,O
Swedish,O
Pharmaceutical,O
Insurance,O
1993,O
-,O
1997,O
.,O
Six,O
cases,O
of,O
cauda,B-Entity
equina,I-Entity
syndrome,I-Entity
with,O
varying,O
severity,O
were,O
reported,O
to,O
the,O
Swedish,O
Pharmaceutical,O
Insurance,O
during,O
the,O
period,O
1993,O
-,O
1997,O
.,O
All,O
were,O
associated,O
with,O
spinal,O
anaesthesia,O
using,O
hyperbaric,O
5%,O
lignocaine,I-Entity
.,O
The,O
dose,O
of,O
hyperbaric,O
5%,O
lignocaine,I-Entity
administered,O
ranged,O
from,O
60,O
to,O
120,O
mg,O
.,O
Three,O
of,O
the,O
cases,O
were,O
most,O
likely,O
caused,O
by,O
direct,O
neurotoxicity,I-Entity
of,O
hyperbaric,O
5%,O
lignocaine,I-Entity
.,O
In,O
the,O
other,O
3,O
cases,O
",",O
direct,O
neurotoxicity,I-Entity
was,O
also,O
probable,O
",",O
but,O
unfortunately,O
radiological,O
investigations,O
were,O
not,O
done,O
to,O
definitely,O
exclude,O
a,O
compressive,O
aetiology,O
.,O
All,O
cases,O
sustained,O
permanent,O
neurological,B-Entity
deficits,I-Entity
.,O
We,O
recommend,O
that,O
hyperbaric,O
lignocaine,I-Entity
should,O
be,O
administered,O
in,O
concentrations,O
not,O
greater,O
than,O
2%,O
and,O
at,O
a,O
total,O
dose,O
preferably,O
not,O
exceeding,O
60,O
mg,O
.,O
Cortical,O
motor,O
overactivation,O
in,O
parkinsonian,I-Entity
patients,O
with,O
L,B-Entity
-,I-Entity
dopa,I-Entity
-,O
induced,O
peak,O
-,O
dose,O
dyskinesia,I-Entity
.,O
We,O
have,O
studied,O
the,O
regional,O
cerebral,O
blood,O
flow,O
(,O
rCBF,O
),O
changes,O
induced,O
by,O
the,O
execution,O
of,O
a,O
finger,O
-,O
to,O
-,O
thumb,O
opposition,O
motor,O
task,O
in,O
the,O
supplementary,O
and,O
primary,O
motor,O
cortex,O
of,O
two,O
groups,O
of,O
parkinsonian,I-Entity
patients,O
on,O
L,B-Entity
-,I-Entity
dopa,I-Entity
medication,O
",",O
the,O
first,O
one,O
without,O
L,B-Entity
-,I-Entity
dopa,I-Entity
induced,O
dyskinesia,I-Entity
(,O
n,O
=,O
23,O
),O
and,O
the,O
other,O
with,O
moderate,O
peak,O
-,O
dose,O
dyskinesia,I-Entity
(,O
n,O
=,O
15,O
),O
",",O
and,O
of,O
a,O
group,O
of,O
14,O
normal,O
subjects,O
.,O
The,O
dyskinetic,I-Entity
parkinsonian,I-Entity
patients,O
exhibited,O
a,O
pattern,O
of,O
response,O
which,O
was,O
markedly,O
different,O
from,O
those,O
of,O
the,O
normal,O
subjects,O
and,O
non,O
-,O
dyskinetic,I-Entity
parkinsonian,I-Entity
patients,O
",",O
with,O
a,O
significant,O
overactivation,O
in,O
the,O
supplementary,O
motor,O
area,O
and,O
the,O
ipsi-,O
and,O
contralateral,O
primary,O
motor,O
areas,O
.,O
These,O
results,O
are,O
compatible,O
with,O
the,O
hypothesis,O
that,O
an,O
hyperkinetic,I-Entity
abnormal,B-Entity
involuntary,I-Entity
movement,I-Entity
",",O
like,O
L,B-Entity
-,I-Entity
dopa,I-Entity
-,O
induced,O
peak,O
dose,O
dyskinesia,I-Entity
",",O
is,O
due,O
to,O
a,O
disinhibition,O
of,O
the,O
primary,O
and,O
associated,O
motor,O
cortex,O
secondary,O
to,O
an,O
excessive,O
outflow,O
of,O
the,O
pallidothalamocortical,O
motor,O
loop,O
.,O
Dexamethasone,I-Entity
-,O
induced,O
ocular,B-Entity
hypertension,I-Entity
in,O
perfusion,O
-,O
cultured,O
human,O
eyes,O
.,O
Glucocorticoid,O
administration,O
can,O
lead,O
to,O
the,O
development,O
of,O
ocular,B-Entity
hypertension,I-Entity
and,O
corticosteroid,B-Entity
glaucoma,I-Entity
in,O
a,O
subset,O
of,O
the,O
population,O
through,O
a,O
decrease,O
in,O
the,O
aqueous,O
humor,O
outflow,O
facility,O
.,O
M,O
dexamethasone,I-Entity
for,O
12,O
days,O
.,O
A,O
significant,O
increase,O
in,O
intraocular,O
pressure,O
developed,O
in,O
13,O
of,O
the,O
44,O
pairs,O
of,O
eyes,O
perfused,O
with,O
dexamethasone,I-Entity
with,O
an,O
average,O
pressure,O
rise,O
of,O
17.5,O
+,O
/-,O
3.8,O
mm,O
Hg,O
after,O
12,O
days,O
of,O
dexamethasone,I-Entity
exposure,O
.,O
The,O
contralateral,O
control,O
eyes,O
",",O
which,O
did,O
not,O
receive,O
dexamethasone,I-Entity
",",O
maintained,O
a,O
stable,O
intraocular,O
pressure,O
during,O
the,O
same,O
period,O
.,O
In,O
contrast,O
",",O
the,O
dexamethasone,I-Entity
-,O
treated,O
hypertensive,B-Entity
eyes,I-Entity
had,O
thickened,O
trabecular,O
beams,O
",",O
decreased,O
intertrabecular,O
spaces,O
",",O
thickened,O
juxtacanalicular,O
tissue,O
",",O
activated,O
trabecular,O
meshwork,O
cells,O
",",O
and,O
increased,O
amounts,O
of,O
amorphogranular,O
extracellular,O
material,O
",",O
especially,O
in,O
the,O
juxtacanalicular,O
tissue,O
and,O
beneath,O
the,O
endothelial,O
lining,O
of,O
the,O
canal,O
of,O
Schlemm,O
.,O
The,O
dexamethasone,I-Entity
-,O
treated,O
nonresponder,O
eyes,O
appeared,O
to,O
be,O
morphologically,O
similar,O
to,O
the,O
untreated,O
eyes,O
",",O
although,O
several,O
subtle,O
dexamethasone,I-Entity
-,O
induced,O
morphologic,O
changes,O
were,O
evident,O
.,O
Dexamethasone,I-Entity
treatment,O
of,O
isolated,O
",",O
perfusion,O
-,O
cultured,O
human,O
eyes,O
led,O
to,O
the,O
generation,O
of,O
ocular,B-Entity
hypertension,I-Entity
in,O
approximately,O
30%,O
of,O
the,O
dexamethasone,I-Entity
-,O
treated,O
eyes,O
.,O
Steroid,I-Entity
treatment,O
resulted,O
in,O
morphologic,O
changes,O
in,O
the,O
trabecular,O
meshwork,O
similar,O
to,O
those,O
reported,O
for,O
corticosteroid,B-Entity
glaucoma,I-Entity
and,O
open,B-Entity
angle,I-Entity
glaucoma,I-Entity
.,O
This,O
system,O
may,O
provide,O
an,O
acute,O
model,O
in,O
which,O
to,O
study,O
the,O
pathogenic,O
mechanisms,O
involved,O
in,O
steroid,B-Entity
glaucoma,I-Entity
and,O
primary,B-Entity
open,I-Entity
angle,I-Entity
glaucoma,I-Entity
.,O
Cognitive,B-Entity
deterioration,I-Entity
from,O
long,O
-,O
term,O
abuse,O
of,O
dextromethorphan,I-Entity
:,O
a,O
case,O
report,O
.,O
Dextromethorphan,I-Entity
(,O
DM,I-Entity
),O
",",O
the,O
dextrorotatory,O
isomer,O
of,O
3-hydroxy,B-Entity
-,I-Entity
N,I-Entity
-,I-Entity
methylmorphinan,I-Entity
",",O
is,O
the,O
main,O
ingredient,O
in,O
a,O
number,O
of,O
widely,O
available,O
",",O
over,O
-,O
the,O
-,O
counter,O
antitussives,O
.,O
The,O
drug,O
is,O
known,O
to,O
cause,O
a,O
variety,O
of,O
acute,O
toxic,O
effects,O
",",O
ranging,O
from,O
nausea,I-Entity
",",O
restlessness,I-Entity
",",O
insomnia,I-Entity
",",O
ataxia,I-Entity
",",O
slurred,O
speech,O
and,O
nystagmus,I-Entity
to,O
mood,O
changes,O
",",O
perceptual,O
alterations,O
",",O
inattention,O
",",O
disorientation,O
and,O
aggressive,B-Entity
behavior,I-Entity
(,O
Rammer,O
et,O
al,O
1988,O
;,O
Katona,O
and,O
Watson,O
1986,O
;,O
Isbell,O
and,O
Fraser,O
1953,O
;,O
There,O
have,O
also,O
been,O
two,O
reported,O
fatalities,O
from,O
DM,I-Entity
overdoses,O
(,O
Fleming,O
1986,O
),O
.,O
This,O
report,O
describes,O
a,O
case,O
of,O
cognitive,B-Entity
deterioration,I-Entity
resulting,O
from,O
prolonged,O
use,O
of,O
DM,I-Entity
.,O
Long,O
-,O
term,O
lithium,I-Entity
treatment,O
and,O
the,O
kidney,O
.,O
This,O
is,O
a,O
report,O
on,O
the,O
first,O
part,O
of,O
our,O
study,O
of,O
the,O
effects,O
of,O
long,O
-,O
term,O
lithium,I-Entity
treatment,O
on,O
the,O
kidney,O
.,O
Creatinine,I-Entity
clearance,O
",",O
maximum,O
urinary,O
osmolality,O
and,O
24,O
hour,O
urine,O
volume,O
have,O
been,O
tested,O
in,O
50,O
affectively,O
ill,O
patients,O
who,O
have,O
been,O
on,O
long,O
-,O
term,O
lithium,I-Entity
for,O
more,O
than,O
one,O
year,O
.,O
These,O
findings,O
have,O
been,O
compared,O
with,O
norms,O
and,O
with,O
values,O
of,O
the,O
same,O
tests,O
from,O
screening,O
prior,O
to,O
lithium,I-Entity
",",O
available,O
for,O
most,O
of,O
our,O
patients,O
.,O
No,O
evidence,O
was,O
found,O
for,O
any,O
reduction,O
of,O
glomerular,O
filtration,O
during,O
lithium,I-Entity
treatment,O
.,O
Low,O
clearance,O
values,O
found,O
in,O
several,O
patients,O
could,O
be,O
accounted,O
for,O
by,O
their,O
age,O
and,O
their,O
pre,O
-,O
lithium,I-Entity
values,O
.,O
Polyuria,I-Entity
above,O
3,O
litres/24,O
hours,O
was,O
found,O
in,O
10%,O
of,O
patients,O
.,O
Complete,O
heart,B-Entity
block,I-Entity
following,O
a,O
single,O
dose,O
of,O
trazodone,I-Entity
.,O
Forty,O
minutes,O
after,O
receiving,O
a,O
single,O
starting,O
dose,O
of,O
trazodone,I-Entity
",",O
a,O
patient,O
developed,O
complete,O
heart,B-Entity
block,I-Entity
.,O
The,O
case,O
illustrates,O
that,O
",",O
despite,O
the,O
results,O
of,O
earlier,O
studies,O
",",O
trazodone,I-Entity
's,O
effect,O
on,O
cardiac,O
conduction,O
may,O
be,O
severe,O
in,O
individuals,O
at,O
risk,O
for,O
conduction,O
delay,O
.,O
Quinidine,B-Entity
phenylethylbarbiturate,I-Entity
-,O
induced,O
fulminant,O
hepatitis,I-Entity
in,O
a,O
pregnant,O
woman,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
19-year,O
-,O
old,O
Laotian,O
patient,O
affected,O
by,O
fulminant,O
hepatitis,I-Entity
during,O
the,O
third,O
trimester,O
of,O
her,O
pregnancy,O
after,O
a,O
1-month,O
administration,O
of,O
quinidine,B-Entity
phenylethylbarbiturate,I-Entity
.,O
Quinidine,I-Entity
itself,O
or,O
phenylethylbarbiturate,I-Entity
may,O
be,O
responsible,O
for,O
fulminant,O
hepatitis,I-Entity
in,O
this,O
patient,O
.,O
The,O
epidemiology,O
of,O
the,O
acute,O
flank,B-Entity
pain,I-Entity
syndrome,O
from,O
suprofen,I-Entity
.,O
Suprofen,I-Entity
",",O
a,O
new,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drug,O
",",O
was,O
marketed,O
in,O
early,O
1986,O
as,O
an,O
analgesic,O
agent,O
.,O
Until,O
physicians,O
began,O
reporting,O
an,O
unusual,O
acute,O
flank,B-Entity
pain,I-Entity
syndrome,O
to,O
the,O
spontaneous,O
reporting,O
system,O
",",O
"700,000",O
persons,O
used,O
the,O
drug,O
in,O
the,O
United,O
States,O
.,O
To,O
elucidate,O
the,O
epidemiology,O
of,O
the,O
syndrome,O
",",O
a,O
case,O
-,O
control,O
study,O
was,O
performed,O
",",O
comparing,O
62,O
of,O
the,O
case,O
patients,O
who,O
had,O
been,O
reported,O
to,O
the,O
spontaneous,O
reporting,O
system,O
to,O
185,O
suprofen,I-Entity
-,O
exposed,O
control,O
subjects,O
who,O
did,O
not,O
have,O
the,O
syndrome,O
.,O
Case,O
patients,O
were,O
more,O
likely,O
to,O
be,O
men,O
(,O
odds,O
ratio,O
",",O
3.8,O
;,O
95%,O
confidence,O
interval,O
",",O
1.2,O
-,O
12.1,O
),O
",",O
suffer,O
from,O
hay,B-Entity
fever,I-Entity
and,O
asthma,I-Entity
(,O
odds,O
ratio,O
",",O
3.4,O
;,O
95%,O
confidence,O
interval,O
",",O
1.0,O
-,O
11.9,O
),O
;,O
to,O
participate,O
in,O
regular,O
exercise,O
(,O
odds,O
ratio,O
",",O
5.9,O
;,O
95%,O
confidence,O
interval,O
",",O
1.1,O
-,O
30.7,O
),O
",",O
especially,O
in,O
the,O
use,O
of,O
Nautilus,O
equipment,O
(,O
p,O
=,O
0.02,O
),O
;,O
and,O
to,O
use,O
alcohol,I-Entity
(,O
odds,O
ratio,O
",",O
4.4,O
;,O
95%,O
confidence,O
interval,O
",",O
1.1,O
-,O
17.5,O
),O
.,O
Possible,O
risk,O
factors,O
included,O
young,O
age,O
",",O
concurrent,O
use,O
of,O
other,O
analgesic,O
agents,O
(,O
especially,O
ibuprofen,I-Entity
),O
",",O
preexisting,O
renal,B-Entity
disease,I-Entity
",",O
a,O
history,O
of,O
kidney,B-Entity
stones,I-Entity
",",O
a,O
history,O
of,O
gout,I-Entity
",",O
a,O
recent,O
increase,O
in,O
activity,O
",",O
a,O
recent,O
increase,O
in,O
sun,O
exposure,O
",",O
and,O
residence,O
in,O
the,O
Sunbelt,O
.,O
These,O
findings,O
are,O
consistent,O
with,O
the,O
postulated,O
mechanism,O
for,O
this,O
unusual,O
syndrome,O
:,O
acute,O
diffuse,O
crystallization,O
of,O
uric,B-Entity
acid,I-Entity
in,O
renal,O
tubules,O
.,O
Hemolytic,B-Entity
-,I-Entity
uremic,I-Entity
syndrome,I-Entity
associated,O
with,O
ingestion,O
of,O
quinine,I-Entity
.,O
Hemolytic,B-Entity
-,I-Entity
uremic,I-Entity
syndrome,I-Entity
following,O
quinine,I-Entity
ingestion,O
is,O
a,O
newly,O
described,O
phenomenon,O
",",O
with,O
just,O
two,O
previous,O
descriptions,O
of,O
4,O
cases,O
in,O
the,O
literature,O
.,O
The,O
reaction,O
may,O
be,O
mediated,O
by,O
the,O
presence,O
of,O
antibodies,O
reactive,O
against,O
platelets,O
in,O
the,O
presence,O
of,O
quinine,I-Entity
.,O
Treatment,O
has,O
included,O
use,O
of,O
plasma,O
exchange,O
",",O
prednisone,I-Entity
",",O
aspirin,I-Entity
",",O
and,O
dipyridamole,I-Entity
.,O
Quinine,I-Entity
-,O
associated,O
hemolytic,B-Entity
-,I-Entity
uremic,I-Entity
syndrome,I-Entity
probably,O
occurs,O
more,O
often,O
than,O
is,O
recognized,O
.,O
It,O
is,O
important,O
to,O
recognize,O
this,O
reaction,O
when,O
it,O
occurs,O
and,O
to,O
avoid,O
further,O
quinine,I-Entity
exposure,O
",",O
since,O
the,O
reaction,O
seems,O
to,O
be,O
recurrent,O
.,O
The,O
etiology,O
of,O
pyeloureteritis,B-Entity
cystica,I-Entity
has,O
long,O
been,O
attributed,O
to,O
chronic,O
infection,I-Entity
and,O
inflammation,I-Entity
.,O
There,O
is,O
no,O
evidence,O
of,O
antecedent,O
or,O
concurrent,O
infection,I-Entity
in,O
this,O
patient,O
.,O
The,O
disease,O
occurred,O
subsequent,O
to,O
the,O
initiation,O
of,O
heparin,I-Entity
therapy,O
for,O
suspected,O
pelvic,O
thrombophlebitis,I-Entity
and,O
cleared,O
rapidly,O
subsequent,O
to,O
its,O
discontinuation,O
.,O
The,O
rate,O
of,O
resolution,O
of,O
the,O
radiographic,O
findings,O
may,O
be,O
helpful,O
in,O
distinguishing,O
between,O
true,O
pyeloureteritis,B-Entity
cystica,I-Entity
and,O
submucosal,B-Entity
hemorrhage,I-Entity
.,O
Changes,O
in,O
peroxisomes,O
in,O
preneoplastic,O
liver,O
and,O
hepatoma,I-Entity
of,O
mice,O
induced,O
by,O
alpha,B-Entity
-,I-Entity
benzene,I-Entity
hexachloride,I-Entity
.,O
Peroxisomes,O
in,O
hepatomas,I-Entity
and,O
hyperplastic,O
preneoplastic,O
liver,B-Entity
lesions,I-Entity
induced,O
in,O
mice,O
by,O
500,O
ppm,O
alpha,B-Entity
-,I-Entity
benzene,I-Entity
hexachloride,I-Entity
were,O
examined,O
histochemically,O
and,O
electron,O
microscopically,O
.,O
Although,O
most,O
of,O
the,O
hepatomas,I-Entity
were,O
well,O
-,O
differentiated,O
tumors,I-Entity
and,O
contained,O
a,O
considerable,O
number,O
of,O
peroxisomes,O
",",O
the,O
tumor,I-Entity
cells,O
did,O
not,O
respond,O
to,O
ethyl,B-Entity
-,I-Entity
alpha,I-Entity
-,I-Entity
p,I-Entity
-,I-Entity
chlorophenoxyisobutyrate,I-Entity
with,O
proliferation,O
of,O
peroxisomes,O
.,O
These,O
cells,O
proliferated,O
further,O
",",O
replacing,O
the,O
most,O
part,O
of,O
the,O
nodules,O
",",O
and,O
with,O
this,O
process,O
hepatomas,I-Entity
appeared,O
to,O
have,O
been,O
formed,O
.,O
No,O
abnormal,O
matrical,O
inclusions,O
of,O
peroxisomes,O
were,O
formed,O
in,O
the,O
cells,O
of,O
hyperplastic,O
nodules,O
by,O
ethyl,B-Entity
-,I-Entity
alpha,I-Entity
-,I-Entity
p,I-Entity
-,I-Entity
chlorophenoxyisobutyrate,I-Entity
unlike,O
in,O
the,O
case,O
of,O
rats,O
.,O
Quinidine,I-Entity
hepatitis,I-Entity
.,O
Long,O
-,O
term,O
administration,O
of,O
quinidine,I-Entity
was,O
associated,O
with,O
persistent,O
elevation,O
of,O
serum,O
concentrations,O
of,O
SGOT,O
",",O
lactic,B-Entity
acid,I-Entity
dehydrogenase,O
",",O
and,O
alkaline,O
phosphatase,O
.,O
Liver,O
biopsy,O
showed,O
active,O
hepatitis,I-Entity
.,O
Discontinuance,O
of,O
quinidine,I-Entity
therapy,O
led,O
to,O
normalization,O
of,O
liver,O
function,O
tests,O
.,O
A,O
challenge,O
dose,O
of,O
quinidine,I-Entity
caused,O
clinical,O
symptoms,O
and,O
abrupt,O
elevation,O
of,O
SGOT,O
",",O
alkaline,O
phosphatase,O
",",O
and,O
lactic,B-Entity
acid,I-Entity
dehydrogenase,O
values,O
.,O
We,O
concluded,O
that,O
this,O
patient,O
had,O
quinidine,I-Entity
hepatotoxicity,I-Entity
and,O
believe,O
that,O
this,O
is,O
the,O
first,O
case,O
reported,O
with,O
liver,O
biopsy,O
documentation,O
.,O
This,O
report,O
also,O
suggests,O
that,O
",",O
even,O
after,O
long,O
-,O
term,O
administration,O
",",O
the,O
hepatic,B-Entity
toxicity,I-Entity
is,O
reversible,O
.,O
Cholesteryl,B-Entity
hemisuccinate,I-Entity
treatment,O
protects,O
rodents,O
from,O
the,O
toxic,O
effects,O
of,O
acetaminophen,I-Entity
",",O
adriamycin,I-Entity
",",O
carbon,B-Entity
tetrachloride,I-Entity
",",O
chloroform,I-Entity
and,O
galactosamine,I-Entity
.,O
In,O
addition,O
to,O
its,O
use,O
as,O
a,O
stabilizer,O
/,O
rigidifier,O
of,O
membranes,O
",",O
cholesteryl,B-Entity
hemisuccinate,I-Entity
",",O
tris,B-Entity
salt,I-Entity
(,O
CS,I-Entity
),O
administration,O
has,O
also,O
been,O
shown,O
to,O
protect,O
rats,O
from,O
the,O
hepatotoxic,I-Entity
effects,O
of,O
carbon,B-Entity
tetrachloride,I-Entity
(,O
CCl4,I-Entity
),O
.,O
To,O
further,O
our,O
understanding,O
of,O
the,O
mechanism,O
of,O
CS,I-Entity
cytoprotection,O
",",O
we,O
examined,O
in,O
rats,O
and,O
mice,O
the,O
protective,O
abilities,O
of,O
CS,I-Entity
and,O
the,O
non,O
-,O
hydrolyzable,O
ether,O
form,O
of,O
CS,I-Entity
",",O
gamma,B-Entity
-,I-Entity
cholesteryloxybutyric,I-Entity
acid,I-Entity
",",O
tris,B-Entity
salt,I-Entity
(,O
CSE,I-Entity
),O
against,O
acetaminophen-,I-Entity
",",O
adriamycin-,I-Entity
",",O
carbon,B-Entity
tetrachloride-,I-Entity
",",O
chloroform-,I-Entity
and,O
galactosamine,I-Entity
-,O
induced,O
toxicity,I-Entity
.,O
The,O
results,O
of,O
these,O
studies,O
demonstrated,O
that,O
CS,I-Entity
-,O
mediated,O
protection,O
is,O
not,O
selective,O
for,O
a,O
particular,O
species,O
",",O
organ,O
system,O
or,O
toxic,O
chemical,O
.,O
A,O
24-h,O
pretreatment,O
of,O
both,O
rats,O
and,O
mice,O
with,O
a,O
single,O
dose,O
of,O
CS,I-Entity
(,O
100mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
",",O
resulted,O
in,O
significant,O
protection,O
against,O
the,O
hepatotoxic,I-Entity
effects,O
of,O
CCl4,I-Entity
",",O
CHCl3,I-Entity
",",O
acetaminophen,I-Entity
and,O
galactosamine,I-Entity
and,O
against,O
the,O
lethal,O
(,O
and,O
presumably,O
cardiotoxic,I-Entity
),O
effect,O
of,O
adriamycin,I-Entity
administration,O
.,O
Maximal,O
CS,I-Entity
-,O
mediated,O
protection,O
was,O
observed,O
in,O
experimental,O
animals,O
pretreated,O
24,O
h,O
prior,O
to,O
the,O
toxic,O
insult,O
.,O
These,O
data,O
suggest,O
that,O
CS,I-Entity
intervenes,O
in,O
a,O
critical,O
cellular,O
event,O
that,O
is,O
an,O
important,O
common,O
pathway,O
to,O
toxic,O
cell,O
death,O
.,O
The,O
mechanism,O
of,O
CS,I-Entity
protection,O
does,O
not,O
appear,O
to,O
be,O
dependent,O
on,O
the,O
inhibition,O
of,O
chemical,O
bioactivation,O
to,O
a,O
toxic,O
reactive,O
intermediate,O
(,O
in,O
light,O
of,O
the,O
protection,O
observed,O
against,O
galactosamine,I-Entity
hepatotoxicity,I-Entity
),O
.,O
However,O
",",O
based,O
on,O
the,O
data,O
presented,O
",",O
we,O
can,O
not,O
exclude,O
the,O
possibility,O
that,O
CS,I-Entity
administration,O
inhibits,O
chemical,O
bioactivation,O
.,O
Our,O
findings,O
do,O
suggest,O
that,O
CS,I-Entity
-,O
mediated,O
protection,O
is,O
dependent,O
on,O
the,O
action,O
of,O
the,O
intact,O
anionic,O
CS,I-Entity
molecule,O
(,O
non,O
-,O
hydrolyzable,O
CSE,I-Entity
was,O
as,O
protective,O
as,O
CS,I-Entity
),O
",",O
whose,O
mechanism,O
has,O
yet,O
to,O
be,O
defined,O
.,O
DSMM,O
XI,O
study,O
:,O
dose,O
definition,O
for,O
intravenous,O
cyclophosphamide,I-Entity
in,O
combination,O
with,O
bortezomib,I-Entity
/,O
dexamethasone,I-Entity
for,O
remission,O
induction,O
in,O
patients,O
with,O
newly,O
diagnosed,O
myeloma,I-Entity
.,O
A,O
clinical,O
trial,O
was,O
initiated,O
to,O
evaluate,O
the,O
recommended,O
dose,O
of,O
cyclophosphamide,I-Entity
in,O
combination,O
with,O
bortezomib,I-Entity
and,O
dexamethasone,I-Entity
as,O
induction,O
treatment,O
before,O
stem,O
cell,O
transplantation,O
for,O
younger,O
patients,O
with,O
newly,O
diagnosed,O
multiple,B-Entity
myeloma,I-Entity
(,O
MM,I-Entity
),O
.,O
Thirty,O
patients,O
were,O
treated,O
with,O
three,O
21-day,O
cycles,O
of,O
bortezomib,I-Entity
1.3,O
mg,O
/,O
m(2,O
),O
on,O
days,O
1,O
",",O
4,O
",",O
8,O
",",O
and,O
11,O
plus,O
dexamethasone,I-Entity
40,O
mg,O
on,O
the,O
day,O
of,O
bortezomib,I-Entity
injection,O
and,O
the,O
day,O
after,O
plus,O
cyclophosphamide,I-Entity
at,O
900,O
",",O
"1,200",O
",",O
or,O
"1,500",O
mg,O
/,O
m(2,O
),O
on,O
day,O
1,O
.,O
The,O
maximum,O
tolerated,O
dose,O
of,O
cyclophosphamide,I-Entity
was,O
defined,O
as,O
900,O
mg,O
/,O
m(2,O
),O
.,O
The,O
most,O
frequent,O
adverse,O
events,O
were,O
hematological,B-Entity
and,I-Entity
gastrointestinal,I-Entity
toxicities,I-Entity
as,O
well,O
as,O
neuropathy,I-Entity
.,O
The,O
results,O
suggest,O
that,O
bortezomib,I-Entity
in,O
combination,O
with,O
cyclophosphamide,I-Entity
at,O
900,O
mg,O
/,O
m(2,O
),O
and,O
dexamethasone,I-Entity
is,O
an,O
effective,O
induction,O
treatment,O
for,O
patients,O
with,O
newly,O
diagnosed,O
MM,I-Entity
that,O
warrants,O
further,O
investigation,O
.,O
Results,O
of,O
a,O
comparative,O
",",O
phase,O
III,O
",",O
12-week,O
",",O
multicenter,O
",",O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
assessment,O
of,O
the,O
efficacy,O
and,O
tolerability,O
of,O
a,O
fixed,O
-,O
dose,O
combination,O
of,O
telmisartan,I-Entity
and,O
amlodipine,I-Entity
versus,O
amlodipine,I-Entity
monotherapy,O
in,O
Indian,O
adults,O
with,O
stage,O
II,O
hypertension,I-Entity
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
evaluate,O
the,O
efficacy,O
and,O
tolerability,O
of,O
a,O
new,O
fixed,O
-,O
dose,O
combination,O
(,O
FDC,O
),O
of,O
telmisartan,I-Entity
40,O
mg,O
+,O
amlodipine,I-Entity
5,O
mg,O
(,O
T+A,O
),O
compared,O
with,O
amlodipine,I-Entity
5-mg,O
monotherapy,O
(,O
A,O
),O
in,O
adult,O
Indian,O
patients,O
with,O
stage,O
II,O
hypertension,I-Entity
.,O
This,O
comparative,O
",",O
Phase,O
III,O
",",O
12-week,O
",",O
multicenter,O
",",O
prospective,O
",",O
randomized,O
",",O
double,O
-,O
blind,O
study,O
was,O
conducted,O
in,O
Indian,O
patients,O
aged,O
18,O
to,O
65,O
years,O
with,O
established,O
stage,O
II,O
hypertension,I-Entity
.,O
Peripheral,O
edema,I-Entity
was,O
reported,O
in,O
8.5%,O
patients,O
(,O
9/106,O
),O
in,O
the,O
T+A,O
group,O
compared,O
with,O
13.5%,O
(,O
14/104,O
),O
in,O
the,O
A,O
group,O
",",O
and,O
cough,I-Entity
was,O
reported,O
in,O
3.8%,O
patients,O
(,O
4/106,O
),O
in,O
the,O
T+A,O
group,O
and,O
1.0%,O
(,O
1/104,O
),O
patients,O
in,O
the,O
A,O
group,O
;,O
these,O
differences,O
did,O
not,O
reach,O
statistical,O
significance,O
.,O
The,O
incidences,O
of,O
headache,I-Entity
",",O
dizziness,I-Entity
",",O
and,O
diarrhea,I-Entity
were,O
similar,O
between,O
the,O
2,O
groups,O
.,O
CONCLUSIONS,O
:,O
Among,O
these,O
Indian,O
patients,O
with,O
stage,O
II,O
hypertension,I-Entity
",",O
the,O
FDC,O
of,O
T+A,O
was,O
found,O
to,O
be,O
significantly,O
more,O
effective,O
",",O
with,O
regard,O
to,O
BP,O
reductions,O
",",O
than,O
A,O
",",O
and,O
both,O
treatments,O
were,O
well,O
tolerated,O
.,O
Cutaneous,B-Entity
leucocytoclastic,I-Entity
vasculitis,I-Entity
associated,O
with,O
oxacillin,I-Entity
.,O
A,O
67-year,O
-,O
old,O
man,O
who,O
was,O
treated,O
with,O
oxacillin,I-Entity
for,O
one,O
week,O
because,O
of,O
Staphylococcus,B-Entity
aureus,I-Entity
bacteremia,I-Entity
",",O
developed,O
renal,B-Entity
failure,I-Entity
and,O
diffuse,O
",",O
symmetric,O
",",O
palpable,O
purpuric,B-Entity
lesions,I-Entity
on,O
his,O
feet,O
.,O
Necrotic,B-Entity
blisters,I-Entity
were,O
noted,O
on,O
his,O
fingers,O
.,O
Skin,O
biopsies,O
showed,O
findings,O
diagnostic,O
of,O
leucocytoclastic,B-Entity
vasculitis,I-Entity
.,O
Oxacillin,I-Entity
was,O
discontinued,O
and,O
patient,O
was,O
treated,O
with,O
corticosteroids,I-Entity
.,O
The,O
rash,I-Entity
disappeared,O
after,O
three,O
weeks,O
and,O
renal,O
function,O
returned,O
to,O
normal,O
.,O
Leucocytoclastic,B-Entity
vasculitis,I-Entity
presents,O
as,O
palpable,O
purpura,I-Entity
of,O
the,O
lower,O
extremities,O
often,O
accompanied,O
by,O
abdominal,B-Entity
pain,I-Entity
",",O
arthralgia,I-Entity
",",O
and,O
renal,B-Entity
involvement,I-Entity
.,O
Etiologic,O
factors,O
or,O
associated,O
disorders,O
include,O
infections,I-Entity
",",O
medications,O
",",O
collagen,B-Entity
vascular,I-Entity
disease,I-Entity
and,O
neoplasia,I-Entity
.,O
Usually,O
it,O
is,O
a,O
self,O
-,O
limited,O
disorder,O
",",O
but,O
corticosteroid,I-Entity
therapy,O
may,O
be,O
needed,O
in,O
life,O
-,O
threatening,O
cases,O
since,O
early,O
treatment,O
with,O
corticosteroids,I-Entity
in,O
severe,O
cases,O
can,O
prevent,O
complications,O
.,O
Oxacillin,I-Entity
should,O
be,O
included,O
among,O
the,O
drugs,O
that,O
can,O
cause,O
leucocytoclastic,B-Entity
vasculitis,I-Entity
.,O
Naloxazone,I-Entity
pretreatment,O
modifies,O
cardiorespiratory,O
",",O
temperature,O
",",O
and,O
behavioral,O
effects,O
of,O
morphine,I-Entity
.,O
Behavioral,O
and,O
cardiorespiratory,O
responses,O
to,O
a,O
lethal,O
dose,O
of,O
morphine,I-Entity
were,O
evaluated,O
in,O
rats,O
pretreated,O
with,O
saline,O
or,O
naloxazone,I-Entity
",",O
an,O
antagonist,O
of,O
high,O
-,O
affinity,O
mu,O
1,O
opioid,O
receptors,O
.,O
Pretreatment,O
with,O
naloxazone,I-Entity
significantly,O
blocked,O
morphine,I-Entity
analgesia,I-Entity
",",O
catalepsy,I-Entity
and,O
hypothermia,I-Entity
at,O
a,O
dose,O
which,O
completely,O
eliminated,O
high,O
-,O
affinity,O
binding,O
in,O
brain,O
membranes,O
.,O
Moreover,O
",",O
naloxazone,I-Entity
significantly,O
attenuated,O
the,O
morphine,I-Entity
-,O
induced,O
hypotension,I-Entity
and,O
respiratory,B-Entity
depression,I-Entity
",",O
whereas,O
morphine,I-Entity
-,O
induced,O
bradycardia,I-Entity
was,O
less,O
affected,O
.,O
Results,O
indicate,O
that,O
subpopulations,O
of,O
mu,O
receptors,O
may,O
mediate,O
selective,O
behavioral,O
and,O
cardiorespiratory,O
responses,O
to,O
morphine,I-Entity
.,O
Dexrazoxane,I-Entity
protects,O
against,O
myelosuppression,I-Entity
from,O
the,O
DNA,O
cleavage,O
-,O
enhancing,O
drugs,O
etoposide,I-Entity
and,O
daunorubicin,I-Entity
but,O
not,O
doxorubicin,I-Entity
.,O
The,O
anthracyclines,I-Entity
daunorubicin,I-Entity
and,O
doxorubicin,I-Entity
and,O
the,O
epipodophyllotoxin,I-Entity
etoposide,I-Entity
are,O
potent,O
DNA,O
cleavage,O
-,O
enhancing,O
drugs,O
that,O
are,O
widely,O
used,O
in,O
clinical,O
oncology,O
;,O
however,O
",",O
myelosuppression,I-Entity
and,O
cardiac,B-Entity
toxicity,I-Entity
limit,O
their,O
use,O
.,O
Dexrazoxane,I-Entity
(,O
ICRF-187,I-Entity
),O
is,O
recommended,O
for,O
protection,O
against,O
anthracycline,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Because,O
of,O
their,O
widespread,O
use,O
",",O
the,O
hematologic,B-Entity
toxicity,I-Entity
following,O
coadministration,O
of,O
dexrazoxane,I-Entity
and,O
these,O
three,O
structurally,O
different,O
DNA,O
cleavage,O
enhancers,O
was,O
investigated,O
:,O
Sensitivity,O
of,O
human,O
and,O
murine,O
blood,O
progenitor,O
cells,O
to,O
etoposide,I-Entity
",",O
daunorubicin,I-Entity
",",O
and,O
doxorubicin,I-Entity
+,O
/-,O
dexrazoxane,I-Entity
was,O
determined,O
in,O
granulocyte,O
-,O
macrophage,O
colony,O
forming,O
assays,O
.,O
Likewise,O
",",O
in,O
vivo,O
",",O
B6D2F1,O
mice,O
were,O
treated,O
with,O
etoposide,I-Entity
",",O
daunorubicin,I-Entity
",",O
and,O
doxorubicin,I-Entity
",",O
with,O
or,O
without,O
dexrazoxane,I-Entity
over,O
a,O
wide,O
range,O
of,O
doses,O
:,O
posttreatment,O
",",O
a,O
full,O
hematologic,O
evaluation,O
was,O
done,O
.,O
RESULTS,O
:,O
Nontoxic,O
doses,O
of,O
dexrazoxane,I-Entity
reduced,O
myelosuppression,I-Entity
and,O
weight,B-Entity
loss,I-Entity
from,O
daunorubicin,I-Entity
and,O
etoposide,I-Entity
in,O
mice,O
and,O
antagonized,O
their,O
antiproliferative,O
effects,O
in,O
the,O
colony,O
assay,O
;,O
however,O
",",O
dexrazoxane,I-Entity
neither,O
reduced,O
myelosuppression,I-Entity
",",O
weight,B-Entity
loss,I-Entity
",",O
nor,O
the,O
in,O
vitro,O
cytotoxicity,I-Entity
from,O
doxorubicin,I-Entity
.,O
CONCLUSION,O
:,O
Although,O
our,O
findings,O
support,O
the,O
observation,O
that,O
dexrazoxane,I-Entity
reduces,O
neither,O
hematologic,O
activity,O
nor,O
antitumor,O
activity,O
from,O
doxorubicin,I-Entity
clinically,O
",",O
the,O
potent,O
antagonism,O
of,O
daunorubicin,I-Entity
activity,O
raises,O
concern,O
;,O
a,O
possible,O
interference,O
with,O
anticancer,O
efficacy,O
certainly,O
would,O
call,O
for,O
renewed,O
attention,O
.,O
Our,O
data,O
also,O
suggest,O
that,O
significant,O
etoposide,I-Entity
dose,O
escalation,O
is,O
perhaps,O
possible,O
by,O
the,O
use,O
of,O
dexrazoxane,I-Entity
.,O
Clinical,O
trials,O
in,O
patients,O
with,O
brain,O
metastases,I-Entity
combining,O
dexrazoxane,I-Entity
and,O
high,O
doses,O
of,O
etoposide,I-Entity
is,O
ongoing,O
with,O
the,O
aim,O
of,O
improving,O
efficacy,O
without,O
aggravating,O
hematologic,B-Entity
toxicity,I-Entity
.,O
Effects,O
of,O
the,O
novel,O
compound,O
aniracetam,I-Entity
(,O
Ro,B-Entity
13,I-Entity
-,I-Entity
5057,I-Entity
),O
upon,O
impaired,B-Entity
learning,I-Entity
and,I-Entity
memory,I-Entity
in,O
rodents,O
.,O
The,O
effect,O
of,O
aniracetam,I-Entity
(,O
Ro,B-Entity
13,I-Entity
-,I-Entity
5057,I-Entity
",",O
1-anisoyl-2-pyrrolidinone,I-Entity
),O
was,O
studied,O
on,O
various,O
forms,O
of,O
experimentally,O
impaired,B-Entity
cognitive,I-Entity
functions,I-Entity
(,O
learning,O
and,O
memory,O
),O
in,O
rodents,O
and,O
produced,O
the,O
following,O
effects,O
:,O
(,O
1,O
),O
almost,O
complete,O
prevention,O
of,O
the,O
incapacity,O
to,O
learn,O
a,O
discrete,O
escape,O
response,O
in,O
rats,O
exposed,O
to,O
sublethal,O
hypercapnia,I-Entity
immediately,O
before,O
the,O
acquisition,O
session,O
;,O
(,O
2,O
),O
partial,O
(,O
rats,O
),O
or,O
complete,O
(,O
mice,O
),O
prevention,O
of,O
the,O
scopolamine,I-Entity
-,O
induced,O
short,O
-,O
term,O
amnesia,I-Entity
for,O
a,O
passive,O
avoidance,O
task,O
;,O
(,O
3,O
),O
complete,O
protection,O
against,O
amnesia,I-Entity
for,O
a,O
passive,O
avoidance,O
task,O
in,O
rats,O
submitted,O
to,O
electroconvulsive,O
shock,O
immediately,O
after,O
avoidance,O
acquisition,O
;,O
(,O
4,O
),O
prevention,O
of,O
the,O
long,O
-,O
term,O
retention-,O
or,O
retrieval,O
-,O
deficit,O
for,O
a,O
passive,O
avoidance,O
task,O
induced,O
in,O
rats,O
and,O
mice,O
by,O
chloramphenicol,I-Entity
or,O
cycloheximide,I-Entity
administered,O
immediately,O
after,O
acquisition,O
;,O
(,O
5,O
),O
reversal,O
",",O
when,O
administered,O
as,O
late,O
as,O
1,O
h,O
before,O
the,O
retention,O
test,O
",",O
of,O
the,O
deficit,O
in,O
retention,O
or,O
retrieval,O
of,O
a,O
passive,O
avoidance,O
task,O
induced,O
by,O
cycloheximide,I-Entity
injected,O
2,O
days,O
previously,O
;,O
(,O
6,O
),O
prevention,O
of,O
the,O
deficit,O
in,O
the,O
retrieval,O
of,O
an,O
active,O
avoidance,O
task,O
induced,O
in,O
mice,O
by,O
subconvulsant,O
electroshock,O
or,O
hypercapnia,I-Entity
applied,O
immediately,O
before,O
retrieval,O
testing,O
(,O
24,O
h,O
after,O
acquisition,O
),O
.,O
These,O
improvements,O
or,O
normalizations,O
of,O
impaired,B-Entity
cognitive,I-Entity
functions,I-Entity
were,O
seen,O
at,O
oral,O
aniracetam,I-Entity
doses,O
of,O
10,O
-,O
100,O
mg,O
/,O
kg,O
.,O
The,O
mechanisms,O
underlying,O
the,O
activity,O
of,O
aniracetam,I-Entity
and,O
its,O
',O
therapeutic,O
window,O
',O
are,O
unknown,O
.,O
Piracetam,I-Entity
",",O
another,O
pyrrolidinone,I-Entity
derivative,O
was,O
used,O
for,O
comparison,O
.,O
It,O
was,O
active,O
only,O
in,O
six,O
of,O
nine,O
tests,O
and,O
had,O
about,O
one,O
-,O
tenth,O
the,O
potency,O
of,O
aniracetam,I-Entity
.,O
The,O
results,O
indicate,O
that,O
aniracetam,I-Entity
improves,O
cognitive,O
functions,O
which,O
are,O
impaired,O
by,O
different,O
procedure,O
and,O
in,O
different,O
phases,O
of,O
the,O
learning,O
and,O
memory,O
process,O
.,O
Nicotine,I-Entity
potentiation,O
of,O
morphine,I-Entity
-,O
induced,O
catalepsy,I-Entity
in,O
mice,O
.,O
In,O
the,O
present,O
study,O
",",O
effects,O
of,O
nicotine,I-Entity
on,O
catalepsy,I-Entity
induced,O
by,O
morphine,I-Entity
in,O
mice,O
have,O
been,O
investigated,O
.,O
Morphine,I-Entity
but,O
not,O
nicotine,I-Entity
induced,O
a,O
dose,O
-,O
dependent,O
catalepsy,I-Entity
.,O
The,O
response,O
of,O
morphine,I-Entity
was,O
potentiated,O
by,O
nicotine,I-Entity
.,O
Intraperitoneal,O
administration,O
of,O
atropine,I-Entity
",",O
naloxone,I-Entity
",",O
mecamylamine,I-Entity
",",O
and,O
hexamethonium,I-Entity
to,O
mice,O
reduced,O
catalepsy,I-Entity
induced,O
by,O
a,O
combination,O
of,O
morphine,I-Entity
with,O
nicotine,I-Entity
.,O
Intracerebroventricular,O
injection,O
of,O
atropine,I-Entity
",",O
hexamethonium,I-Entity
",",O
and,O
naloxone,I-Entity
also,O
decreased,O
catalepsy,I-Entity
induced,O
by,O
morphine,I-Entity
plus,O
nicotine,I-Entity
.,O
Intraperitoneal,O
administration,O
of,O
atropine,I-Entity
",",O
but,O
not,O
intraperitoneal,O
or,O
intracerebroventricular,O
injection,O
of,O
hexamethonium,I-Entity
",",O
decreased,O
the,O
effect,O
of,O
a,O
single,O
dose,O
of,O
morphine,I-Entity
.,O
It,O
was,O
concluded,O
that,O
morphine,I-Entity
catalepsy,I-Entity
can,O
be,O
elicited,O
by,O
opioid,O
and,O
cholinergic,O
receptors,O
",",O
and,O
the,O
potentiation,O
of,O
morphine,I-Entity
induced,O
by,O
nicotine,I-Entity
may,O
also,O
be,O
mediated,O
through,O
cholinergic,O
receptor,O
mechanisms,O
.,O
Reduced,O
cardiotoxicity,I-Entity
and,O
preserved,O
antitumor,O
efficacy,O
of,O
liposome,O
-,O
encapsulated,O
doxorubicin,I-Entity
and,O
cyclophosphamide,I-Entity
compared,O
with,O
conventional,O
doxorubicin,I-Entity
and,O
cyclophosphamide,I-Entity
in,O
a,O
randomized,O
",",O
multicenter,O
trial,O
of,O
metastatic,O
breast,B-Entity
cancer,I-Entity
.,O
To,O
determine,O
whether,O
Myocet,I-Entity
(,O
liposome,O
-,O
encapsulated,O
doxorubicin,I-Entity
;,O
The,O
Liposome,O
Company,O
",",O
Elan,O
Corporation,O
",",O
Princeton,O
",",O
NJ,O
),O
in,O
combination,O
with,O
cyclophosphamide,I-Entity
significantly,O
reduces,O
doxorubicin,I-Entity
cardiotoxicity,I-Entity
while,O
providing,O
comparable,O
antitumor,O
efficacy,O
in,O
first,O
-,O
line,O
treatment,O
of,O
metastatic,O
breast,B-Entity
cancer,I-Entity
(,O
MBC,I-Entity
),O
.,O
Two,O
hundred,O
ninety,O
-,O
seven,O
patients,O
with,O
MBC,I-Entity
and,O
no,O
prior,O
chemotherapy,O
for,O
metastatic,O
disease,O
were,O
randomized,O
to,O
receive,O
either,O
60,O
mg,O
/,O
m(2,O
),O
of,O
Myocet,I-Entity
(,O
M,O
),O
or,O
conventional,O
doxorubicin,I-Entity
(,O
A,O
),O
",",O
in,O
combination,O
with,O
600,O
mg,O
/,O
m(2,O
),O
of,O
cyclophosphamide,I-Entity
(,O
C,O
),O
",",O
every,O
3,O
weeks,O
until,O
disease,O
progression,O
or,O
unacceptable,O
toxicity,I-Entity
.,O
Cardiotoxicity,I-Entity
was,O
defined,O
by,O
reductions,O
in,O
left,O
-,O
ventricular,O
ejection,O
fraction,O
",",O
assessed,O
by,O
serial,O
multigated,O
radionuclide,O
angiography,O
scans,O
",",O
or,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
(,O
CHF,I-Entity
),O
.,O
Antitumor,O
efficacy,O
was,O
assessed,O
by,O
objective,O
tumor,I-Entity
response,O
rates,O
(,O
World,O
Health,O
Organization,O
criteria,O
),O
",",O
time,O
to,O
progression,O
",",O
and,O
survival,O
.,O
Six,O
percent,O
of,O
MC,O
patients,O
versus,O
21%,O
(,O
including,O
five,O
cases,O
of,O
CHF,I-Entity
),O
of,O
AC,O
patients,O
developed,O
cardiotoxicity,I-Entity
(,O
P,O
=,O
.0002,O
),O
.,O
Median,O
cumulative,O
doxorubicin,I-Entity
dose,O
at,O
onset,O
was,O
more,O
than,O
"2,220",O
mg,O
/,O
m(2,O
),O
for,O
MC,O
versus,O
480,O
mg,O
/,O
m(2,O
),O
for,O
AC,O
(,O
P,O
=,O
.0001,O
",",O
hazard,O
ratio,O
",",O
5.04,O
),O
.,O
MC,O
patients,O
also,O
experienced,O
less,O
grade,O
4,O
neutropenia,I-Entity
.,O
CONCLUSION,O
:,O
Myocet,I-Entity
improves,O
the,O
therapeutic,O
index,O
of,O
doxorubicin,I-Entity
by,O
significantly,O
reducing,O
cardiotoxicity,I-Entity
and,O
grade,O
4,O
neutropenia,I-Entity
and,O
provides,O
comparable,O
antitumor,O
efficacy,O
",",O
when,O
used,O
in,O
combination,O
with,O
cyclophosphamide,I-Entity
as,O
first,O
-,O
line,O
therapy,O
for,O
MBC,I-Entity
.,O
Protective,O
effect,O
of,O
a,O
specific,O
platelet,O
-,O
activating,O
factor,O
antagonist,O
",",O
BN,B-Entity
52021,I-Entity
",",O
on,O
bupivacaine,I-Entity
-,O
induced,O
cardiovascular,B-Entity
impairments,I-Entity
in,O
rats,O
.,O
Administration,O
of,O
the,O
local,O
anaesthetic,O
bupivacaine,I-Entity
(,O
1.5,O
or,O
2,O
mg,O
/,O
kg,O
",",O
i.v,O
.,O
),O
to,O
rats,O
elicited,O
a,O
marked,O
decrease,B-Entity
of,I-Entity
mean,I-Entity
arterial,I-Entity
blood,I-Entity
pressure,I-Entity
(,I-Entity
MBP,I-Entity
),I-Entity
and,I-Entity
heart,I-Entity
rate,I-Entity
(,I-Entity
HR,I-Entity
),I-Entity
leading,O
to,O
death,O
(,O
in,O
67%,O
or,O
90%,O
of,O
animals,O
respectively,O
),O
.,O
Intravenous,O
injection,O
of,O
the,O
specific,O
platelet,O
-,O
activating,O
factor,O
(,O
PAF,O
),O
antagonist,O
BN,B-Entity
52021,I-Entity
(,O
10,O
mg,O
/,O
kg,O
),O
",",O
30,O
min,O
before,O
bupivacaine,I-Entity
administration,O
(,O
2,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
suppressed,O
both,O
the,O
decrease,B-Entity
of,I-Entity
MBP,I-Entity
and,I-Entity
HR,I-Entity
.,O
In,O
contrast,O
",",O
doses,O
of,O
1,O
mg,O
/,O
kg,O
BN,B-Entity
52021,I-Entity
given,O
30,O
min,O
before,O
or,O
10,O
mg,O
/,O
kg,O
administered,O
5,O
min,O
before,O
i.v,O
.,O
injection,O
of,O
bupivacaine,I-Entity
were,O
ineffective,O
.,O
When,O
BN,B-Entity
52021,I-Entity
(,O
20,O
mg,O
was,O
injected,O
immediately,O
after,O
bupivacaine,I-Entity
(,O
2,O
mg,O
/,O
kg,O
),O
",",O
a,O
partial,O
reversion,O
of,O
the,O
decrease,B-Entity
of,I-Entity
MBP,I-Entity
and,I-Entity
HR,I-Entity
was,O
observed,O
",",O
whereas,O
the,O
dose,O
of,O
10,O
mg,O
/,O
kg,O
was,O
ineffective,O
.,O
A,O
partial,O
recovery,O
of,O
bupivacaine,I-Entity
-,O
induced,O
ECG,O
alterations,O
was,O
observed,O
after,O
pretreatment,O
of,O
the,O
rats,O
with,O
BN,B-Entity
52021,I-Entity
.,O
Since,O
the,O
administration,O
of,O
BN,B-Entity
52021,I-Entity
",",O
at,O
all,O
doses,O
studied,O
",",O
did,O
not,O
alter,O
MBP,O
and,O
HR,O
at,O
the,O
doses,O
used,O
",",O
the,O
bulk,O
of,O
these,O
results,O
clearly,O
demonstrate,O
a,O
protective,O
action,O
of,O
BN,B-Entity
52021,I-Entity
",",O
a,O
specific,O
antagonist,O
of,O
PAF,O
",",O
against,O
bupivacaine,I-Entity
-,O
induced,O
cardiovascular,B-Entity
toxicity,I-Entity
.,O
Thus,O
",",O
consistent,O
with,O
its,O
direct,O
effect,O
on,O
heart,O
",",O
PAF,O
appears,O
to,O
be,O
implicated,O
in,O
bupivacaine,I-Entity
-,O
induced,O
cardiovascular,B-Entity
alterations,I-Entity
.,O
Benzylacyclouridine,I-Entity
reverses,O
azidothymidine,I-Entity
-,O
induced,O
marrow,B-Entity
suppression,I-Entity
without,O
impairment,O
of,O
anti,O
-,O
human,O
immunodeficiency,I-Entity
virus,O
activity,O
.,O
Increased,O
extracellular,O
concentrations,O
of,O
uridine,I-Entity
(,O
Urd,I-Entity
),O
have,O
been,O
reported,O
to,O
reduce,O
",",O
in,O
vitro,O
",",O
azidothymidine,I-Entity
(,O
AZT)-induced,I-Entity
inhibition,O
of,O
human,O
granulocyte,O
-,O
macrophage,O
progenitor,O
cells,O
without,O
impairment,O
of,O
its,O
antihuman,O
immunodeficiency,I-Entity
virus,O
(,O
HIV,O
),O
activity,O
.,O
Because,O
of,O
the,O
clinical,O
toxicities,I-Entity
associated,O
with,O
chronic,O
Urd,I-Entity
administration,O
",",O
the,O
ability,O
of,O
benzylacyclouridine,I-Entity
(,O
BAU,I-Entity
),O
to,O
effect,O
",",O
in,O
vivo,O
",",O
AZT,I-Entity
-,O
induced,O
anemia,I-Entity
and,O
leukopenia,I-Entity
was,O
assessed,O
.,O
This,O
agent,O
inhibits,O
Urd,I-Entity
catabolism,O
and,O
",",O
in,O
vivo,O
",",O
increases,O
the,O
plasma,O
concentration,O
of,O
Urd,I-Entity
in,O
a,O
dose,O
-,O
dependent,O
manner,O
",",O
without,O
Urd,I-Entity
-,O
related,O
toxicity,I-Entity
.,O
In,O
mice,O
rendered,O
anemic,I-Entity
and,O
leukopenic,I-Entity
by,O
the,O
administration,O
of,O
AZT,I-Entity
for,O
28,O
days,O
in,O
drinking,O
water,O
(,O
1.5,O
mg,O
/,O
mL,O
),O
",",O
the,O
continued,O
administration,O
of,O
AZT,I-Entity
plus,O
daily,O
BAU,I-Entity
(,O
300,O
mg,O
/,O
kg,O
",",O
orally,O
),O
partially,O
reversed,O
AZT,I-Entity
-,O
induced,O
anemia,I-Entity
and,O
leukopenia,I-Entity
(,O
P,O
less,O
than,O
.05,O
),O
",",O
increased,O
peripheral,O
reticulocytes,O
(,O
to,O
4.9%,O
",",O
P,O
less,O
than,O
.01,O
),O
",",O
increased,O
cellularity,O
in,O
the,O
marrow,O
",",O
and,O
improved,O
megaloblastosis,I-Entity
.,O
When,O
coadministered,O
with,O
AZT,I-Entity
from,O
the,O
onset,O
of,O
drug,O
administration,O
",",O
BAU,I-Entity
reduced,O
AZT,I-Entity
-,O
induced,O
marrow,B-Entity
toxicity,I-Entity
.,O
In,O
vitro,O
",",O
at,O
a,O
concentration,O
of,O
100,O
mumol,O
/,O
L,O
",",O
BAU,I-Entity
possesses,O
minimal,O
anti,O
-,O
HIV,O
activity,O
and,O
has,O
no,O
effect,O
on,O
the,O
ability,O
of,O
AZT,I-Entity
to,O
reverse,O
the,O
HIV,O
-,O
induced,O
cytopathic,O
effect,O
in,O
MT4,O
cells,O
.,O
Cyclophosphamide,I-Entity
-,O
induced,O
cystitis,I-Entity
in,O
freely,O
-,O
moving,O
conscious,O
rats,O
:,O
behavioral,O
approach,O
to,O
a,O
new,O
model,O
of,O
visceral,B-Entity
pain,I-Entity
.,O
PURPOSE,O
:,O
To,O
develop,O
a,O
model,O
of,O
visceral,B-Entity
pain,I-Entity
in,O
rats,O
using,O
a,O
behavioral,O
approach,O
.,O
Cyclophosphamide,I-Entity
(,O
CP,I-Entity
),O
",",O
an,O
antitumoral,O
agent,O
known,O
to,O
produce,O
toxic,O
effects,O
on,O
the,O
bladder,O
wall,O
through,O
its,O
main,O
toxic,O
metabolite,O
acrolein,I-Entity
",",O
was,O
used,O
to,O
induce,O
cystitis,I-Entity
.,O
CP,I-Entity
was,O
administered,O
at,O
doses,O
of,O
50,O
",",O
100,O
and,O
200,O
mg./kg,O
.,O
The,O
effects,O
of,O
morphine,I-Entity
(,O
0.5,O
to,O
4,O
mg./kg,O
.,O
i.v,O
.,O
),O
on,O
CP,I-Entity
-,O
induced,O
behavioral,O
modifications,O
were,O
tested,O
administered,O
alone,O
and,O
after,O
naloxone,I-Entity
(,O
1,O
mg./kg,O
.,O
In,O
addition,O
",",O
90,O
minutes,O
after,O
CP,I-Entity
injection,O
",",O
that,O
is,O
",",O
at,O
the,O
time,O
of,O
administration,O
of,O
morphine,I-Entity
",",O
the,O
bladder,O
was,O
removed,O
in,O
some,O
rats,O
for,O
histological,O
examination,O
.,O
Finally,O
",",O
to,O
show,O
that,O
the,O
bladder,O
is,O
essential,O
for,O
the,O
CP,I-Entity
-,O
induced,O
behavioral,O
modifications,O
",",O
female,O
rats,O
also,O
received,O
CP,I-Entity
at,O
doses,O
of,O
200,O
mg./kg,O
.,O
by,O
the,O
intravesical,O
route,O
",",O
and,O
acrolein,I-Entity
at,O
doses,O
of,O
0.5,O
mg,O
.,O
CP,I-Entity
dose,O
-,O
relatedly,O
induced,O
marked,O
behavioral,O
modifications,O
in,O
male,O
rats,O
:,O
breathing,O
rate,O
decrease,O
",",O
closing,O
of,O
the,O
eyes,O
and,O
occurrence,O
of,O
specific,O
postures,O
.,O
Morphine,I-Entity
dose,O
-,O
dependently,O
reversed,O
these,O
behavioral,B-Entity
disorders,I-Entity
.,O
produced,O
a,O
reduction,O
of,O
almost,O
50%,O
of,O
the,O
behavioral,O
score,O
induced,O
by,O
CP,I-Entity
200,O
mg./kg,O
.,O
This,O
effect,O
was,O
completely,O
prevented,O
by,O
pretreatment,O
with,O
naloxone,I-Entity
.,O
At,O
the,O
time,O
of,O
administration,O
of,O
morphine,I-Entity
",",O
histological,O
modifications,O
of,O
the,O
bladder,O
wall,O
",",O
such,O
as,O
chorionic,O
and,O
muscle,O
layer,O
edema,I-Entity
",",O
were,O
observed,O
.,O
In,O
female,O
rats,O
",",O
CP,I-Entity
200,O
mg./kg,O
.,O
intravesically,O
",",O
CP,I-Entity
did,O
not,O
produce,O
any,O
behavioral,O
effects,O
",",O
whereas,O
acrolein,I-Entity
at,O
0.5,O
mg,O
.,O
intravesically,O
induced,O
behavioral,O
modifications,O
identical,O
to,O
those,O
under,O
CP,I-Entity
200,O
mg./kg,O
.,O
Conversely,O
",",O
acrolein,I-Entity
5,O
mg./kg,O
.,O
Overall,O
",",O
these,O
results,O
indicate,O
that,O
this,O
experimental,O
model,O
of,O
CP,I-Entity
-,O
induced,O
cystitis,I-Entity
may,O
be,O
an,O
interesting,O
new,O
behavioral,O
model,O
of,O
inflammatory,O
visceral,B-Entity
pain,I-Entity
",",O
allowing,O
a,O
better,O
understanding,O
of,O
these,O
painful,B-Entity
syndromes,I-Entity
and,O
thus,O
a,O
better,O
therapeutic,O
approach,O
to,O
them,O
.,O
Hyperalgesia,I-Entity
and,O
myoclonus,I-Entity
in,O
terminal,O
cancer,I-Entity
patients,O
treated,O
with,O
continuous,O
intravenous,O
morphine,I-Entity
.,O
Eight,O
cancer,I-Entity
patients,O
in,O
the,O
terminal,O
stages,O
of,O
the,O
disease,O
treated,O
with,O
high,O
doses,O
of,O
intravenous,O
morphine,I-Entity
developed,O
hyperalgesia,I-Entity
.,O
Five,O
patients,O
developed,O
universal,O
hyperalgesia,I-Entity
and,O
hyperesthesia,I-Entity
which,O
in,O
2,O
cases,O
were,O
accompanied,O
by,O
myoclonus,I-Entity
.,O
In,O
3,O
patients,O
a,O
pre,O
-,O
existing,O
neuralgia,I-Entity
increased,O
to,O
excruciating,O
intensity,O
and,O
in,O
2,O
of,O
these,O
cases,O
myoclonus,I-Entity
occurred,O
simultaneously,O
.,O
Although,O
only,O
few,O
clinical,O
descriptions,O
of,O
the,O
relationship,O
between,O
hyperalgesia,I-Entity
/,O
myoclonus,I-Entity
and,O
high,O
doses,O
of,O
morphine,I-Entity
are,O
available,O
",",O
experimental,O
support,O
from,O
animal,O
studies,O
indicates,O
that,O
morphine,I-Entity
",",O
or,O
its,O
metabolites,O
",",O
plays,O
a,O
causative,O
role,O
for,O
the,O
observed,O
behavioural,O
syndrome,O
.,O
A,O
prospective,O
study,O
of,O
adverse,O
reactions,O
associated,O
with,O
vancomycin,I-Entity
therapy,O
.,O
A,O
prospective,O
evaluation,O
of,O
the,O
efficacy,O
and,O
safety,O
of,O
vancomycin,I-Entity
was,O
conducted,O
in,O
54,O
consecutive,O
patients,O
over,O
a,O
16-month,O
period,O
.,O
Vancomycin,I-Entity
was,O
curative,O
in,O
95%,O
of,O
43,O
patients,O
with,O
proven,O
infection,I-Entity
.,O
Drugs,O
were,O
ceased,O
in,O
six,O
patients,O
because,O
of,O
adverse,O
reactions,O
;,O
in,O
three,O
of,O
these,O
vancomycin,I-Entity
was,O
considered,O
the,O
likely,O
cause,O
.,O
Reactions,O
included,O
thrombophlebitis,I-Entity
(,O
20,O
of,O
54,O
patients,O
),O
",",O
rash,I-Entity
(,O
4,O
of,O
54,O
),O
",",O
nephrotoxicity,I-Entity
(,O
4,O
of,O
50,O
),O
",",O
proteinuria,I-Entity
(,O
1,O
of,O
50,O
),O
and,O
ototoxicity,I-Entity
(,O
1,O
of,O
11,O
patients,O
tested,O
by,O
audiometry,O
),O
.,O
Thrombophlebitis,I-Entity
occurred,O
only,O
with,O
infusion,O
through,O
peripheral,O
cannulae,O
;,O
nephrotoxicity,I-Entity
and,O
ototoxicity,I-Entity
were,O
confined,O
to,O
patients,O
receiving,O
an,O
aminoglycoside,I-Entity
plus,O
vancomycin,I-Entity
.,O
We,O
conclude,O
that,O
vancomycin,I-Entity
",",O
administered,O
appropriately,O
",",O
constitutes,O
safe,O
",",O
effective,O
therapy,O
for,O
infections,I-Entity
caused,O
by,O
susceptible,O
bacteria,O
.,O
Blockade,O
of,O
both,O
D-1,O
and,O
D-2,O
dopamine,I-Entity
receptors,O
may,O
induce,O
catalepsy,I-Entity
in,O
mice,O
.,O
The,O
catalepsy,I-Entity
induced,O
by,O
dopamine,I-Entity
antagonists,O
has,O
been,O
tested,O
and,O
the,O
possible,O
dopamine,I-Entity
subtypes,O
involved,O
in,O
catalepsy,I-Entity
was,O
determined,O
.,O
Dopamine,I-Entity
antagonist,O
fluphenazine,I-Entity
",",O
D-1,O
antagonist,O
SCH,B-Entity
23390,I-Entity
or,O
D-2,O
antagonist,O
sulpiride,I-Entity
induced,O
catalepsy,I-Entity
.,O
The,O
effect,O
of,O
fluphenazine,I-Entity
and,O
sulpiride,I-Entity
was,O
dose,O
-,O
dependent,O
.,O
Combination,O
of,O
SCH,B-Entity
23390,I-Entity
with,O
sulpiride,I-Entity
did,O
not,O
induce,O
catalepsy,I-Entity
potentiation,O
.,O
SKF,B-Entity
38393,I-Entity
or,O
D-2,O
agonist,O
quinpirole,I-Entity
decreased,O
the,O
catalepsy,I-Entity
induced,O
by,O
fluphenazine,I-Entity
",",O
SCH,B-Entity
23390,I-Entity
or,O
sulpiride,I-Entity
.,O
4,O
.,O
Combination,O
of,O
SKF,B-Entity
38393,I-Entity
with,O
quinpirole,I-Entity
did,O
not,O
cause,O
potentiated,O
inhibitory,O
effect,O
on,O
catalepsy,I-Entity
induced,O
by,O
dopamine,I-Entity
antagonists,O
.,O
The,O
data,O
may,O
indicate,O
that,O
although,O
D-2,O
receptor,O
blockade,O
is,O
involved,O
in,O
catalepsy,I-Entity
",",O
the,O
D-1,O
receptor,O
may,O
plan,O
a,O
role,O
.,O
Dextran,I-Entity
-,O
etodolac,I-Entity
conjugates,O
:,O
synthesis,O
",",O
in,O
vitro,O
and,O
in,O
vivo,O
evaluation,O
.,O
Etodolac,I-Entity
(,O
E,I-Entity
),O
",",O
is,O
a,O
non,O
-,O
narcotic,O
analgesic,O
and,O
antiinflammatory,O
drug,O
.,O
A,O
biodegradable,O
polymer,O
dextran,I-Entity
has,O
been,O
utilized,O
as,O
a,O
carrier,O
for,O
synthesis,O
of,O
etodolac,I-Entity
-,O
dextran,I-Entity
conjugates,O
(,O
ED,O
),O
to,O
improve,O
its,O
aqueous,O
solubility,O
and,O
reduce,O
gastrointestinal,O
side,O
effects,O
.,O
An,O
activated,O
moiety,O
",",O
i.e.,O
N,B-Entity
-,I-Entity
acylimidazole,I-Entity
derivative,O
of,O
etodolac,I-Entity
(,O
EAI,I-Entity
),O
",",O
was,O
condensed,O
with,O
the,O
polysaccharide,O
polymer,O
dextran,I-Entity
of,O
different,O
molecular,O
weights,O
(,O
40000,O
",",O
60000,O
",",O
110000,O
and,O
200000,O
),O
.,O
Etodolac,I-Entity
contents,O
were,O
evaluated,O
by,O
UV,O
-,O
spectrophotometric,O
analysis,O
.,O
At,O
pH,O
9,O
",",O
a,O
higher,O
rate,O
of,O
etodolac,I-Entity
release,O
from,O
ED,O
was,O
observed,O
as,O
compared,O
to,O
aqueous,O
buffer,O
of,O
pH,O
7.4,O
and,O
80%,O
human,O
plasma,O
(,O
pH,O
7.4,O
),O
",",O
following,O
first,O
-,O
order,O
kinetics,O
.,O
Acute,O
analgesic,O
and,O
antiinflammatory,O
activities,O
were,O
ascertained,O
using,O
acetic,B-Entity
acid,I-Entity
induced,O
writhing,I-Entity
model,O
(,O
mice,O
),O
and,O
carrageenan,I-Entity
-,O
induced,O
rat,O
paw,O
edema,I-Entity
model,O
",",O
respectively,O
.,O
In,O
comparison,O
to,O
control,O
",",O
E,I-Entity
and,O
ED1-ED4,O
showed,O
highly,O
significant,O
analgesic,O
and,O
antiinflammatory,O
activities,O
(,O
p,O
<,O
0.001,O
),O
.,O
Biological,O
evaluation,O
suggested,O
that,O
conjugates,O
(,O
ED1-ED4,O
),O
retained,O
comparable,O
analgesic,O
and,O
antiinflammatory,O
activities,O
with,O
remarkably,O
reduced,O
ulcerogenicity,O
as,O
compared,O
to,O
their,O
parent,O
drug,O
--,O
etodolac,I-Entity
.,O
Hypersensitivity,I-Entity
myocarditis,I-Entity
complicating,O
hypertrophic,B-Entity
cardiomyopathy,I-Entity
heart,O
.,O
The,O
present,O
report,O
describes,O
a,O
case,O
of,O
eosinophilic,B-Entity
myocarditis,I-Entity
complicating,O
hypertrophic,B-Entity
cardiomyopathy,I-Entity
.,O
The,O
47-year,O
-,O
old,O
female,O
patient,O
",",O
known,O
to,O
have,O
hypertrophic,B-Entity
cardiomyopathy,I-Entity
",",O
was,O
admitted,O
with,O
biventricular,B-Entity
failure,I-Entity
and,O
managed,O
aggressively,O
with,O
dobutamine,I-Entity
infusion,O
and,O
other,O
drugs,O
while,O
being,O
assessed,O
for,O
heart,O
transplantation,O
.,O
On,O
transthoracic,O
echocardiogram,O
",",O
she,O
had,O
moderate,O
left,B-Entity
ventricular,I-Entity
dysfunction,I-Entity
with,O
regional,O
variability,O
and,O
moderate,O
mitral,B-Entity
regurgitation,I-Entity
.,O
The,O
recipient,O
's,O
heart,O
showed,O
the,O
features,O
of,O
apical,O
hypertrophic,B-Entity
cardiomyopathy,I-Entity
and,O
myocarditis,I-Entity
with,O
abundant,O
eosinophils,O
.,O
Myocarditis,I-Entity
is,O
rare,O
and,O
eosinophilic,B-Entity
myocarditis,I-Entity
is,O
rarer,O
.,O
It,O
is,O
likely,O
that,O
the,O
hypersensitivity,I-Entity
(,O
eosinophilic,I-Entity
),O
myocarditis,I-Entity
was,O
related,O
to,O
dobutamine,I-Entity
infusion,O
therapy,O
.,O
Eosinophilic,B-Entity
myocarditis,I-Entity
has,O
been,O
reported,O
with,O
an,O
incidence,O
of,O
2.4%,O
to,O
7.2%,O
in,O
explanted,O
hearts,O
and,O
may,O
be,O
related,O
to,O
multidrug,O
therapy,O
.,O
All-,B-Entity
trans,I-Entity
-,I-Entity
retinoic,I-Entity
acid,I-Entity
-,O
induced,O
erythema,B-Entity
nodosum,I-Entity
in,O
patients,O
with,O
acute,B-Entity
promyelocytic,I-Entity
leukemia,I-Entity
.,O
Erythema,B-Entity
nodosum,I-Entity
associated,O
with,O
all-,B-Entity
trans,I-Entity
-,I-Entity
retinoic,I-Entity
acid,I-Entity
(,O
ATRA,I-Entity
),O
for,O
acute,B-Entity
promyelocytic,I-Entity
leukemia,I-Entity
(,O
APL,I-Entity
),O
is,O
very,O
rare,O
.,O
We,O
describe,O
four,O
patients,O
with,O
classic,O
APL,I-Entity
who,O
developed,O
erythema,B-Entity
nodosum,I-Entity
during,O
ATRA,I-Entity
therapy,O
.,O
Fever,I-Entity
and,O
subsequent,O
multiple,O
painful,I-Entity
erythematous,B-Entity
nodules,I-Entity
over,O
extremities,O
developed,O
on,O
D11,O
",",O
D16,O
",",O
D17,O
",",O
and,O
D19,O
",",O
respectively,O
",",O
after,O
ATRA,I-Entity
therapy,O
.,O
The,O
skin,O
biopsy,O
taken,O
from,O
each,O
patient,O
was,O
consistent,O
with,O
erythema,B-Entity
nodosum,I-Entity
.,O
All,O
patients,O
received,O
short,O
course,O
of,O
steroids,I-Entity
.,O
Fever,I-Entity
subsided,O
rapidly,O
and,O
the,O
skin,O
lesions,O
regressed,O
completely,O
.,O
All,O
patients,O
achieved,O
complete,O
remission,O
without,O
withdrawal,O
of,O
ATRA,I-Entity
.,O
ATRA,I-Entity
seemed,O
to,O
be,O
the,O
most,O
possible,O
etiology,O
of,O
erythema,B-Entity
nodosum,I-Entity
in,O
our,O
patients,O
.,O
Short,O
-,O
term,O
use,O
of,O
steroid,I-Entity
is,O
very,O
effective,O
in,O
ATRA,I-Entity
-,O
induced,O
erythema,B-Entity
nodosum,I-Entity
.,O
Delayed,O
-,O
onset,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
presents,O
5,O
to,O
12,O
days,O
after,O
heparin,I-Entity
exposure,O
",",O
with,O
or,O
without,O
arterial,B-Entity
or,I-Entity
venous,I-Entity
thromboemboli,I-Entity
.,O
Delayed,O
recognition,O
and,O
treatment,O
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
contribute,O
to,O
poor,O
patient,O
outcomes,O
.,O
OBJECTIVE,O
:,O
To,O
describe,O
and,O
increase,O
awareness,O
of,O
a,O
clinical,O
scenario,O
in,O
which,O
the,O
onset,O
or,O
manifestations,O
of,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
are,O
delayed,O
.,O
PATIENTS,O
:,O
14,O
patients,O
seen,O
over,O
a,O
3-year,O
period,O
in,O
whom,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
became,O
apparent,O
on,O
delayed,O
presentation,O
with,O
thromboembolic,I-Entity
complications,O
.,O
MEASUREMENTS,O
:,O
Platelet,O
counts,O
",",O
onset,O
of,O
objectively,O
determined,O
thromboembolism,I-Entity
",",O
results,O
of,O
heparin,I-Entity
-,O
induced,O
platelet,O
factor,O
4,O
antibody,O
tests,O
",",O
and,O
outcomes,O
.,O
Patients,O
went,O
home,O
after,O
hospitalizations,O
that,O
had,O
included,O
heparin,I-Entity
exposure,O
--,O
in,O
most,O
cases,O
",",O
with,O
no,O
thrombocytopenia,I-Entity
recognized,O
--,O
only,O
to,O
return,O
to,O
the,O
hospital,O
(,O
median,O
",",O
day,O
14,O
),O
with,O
thromboembolic,I-Entity
complications,O
.,O
Thromboemboli,I-Entity
were,O
venous,O
(,O
12,O
patients,O
",",O
7,O
with,O
pulmonary,B-Entity
emboli,I-Entity
),O
or,O
arterial,O
(,O
4,O
patients,O
),O
or,O
both,O
.,O
On,O
readmission,O
",",O
11,O
patients,O
received,O
therapeutic,O
heparin,I-Entity
",",O
which,O
worsened,O
the,O
patients,O
',O
clinical,O
condition,O
and,O
",",O
in,O
all,O
11,O
cases,O
",",O
decreased,O
the,O
platelet,O
count,O
(,O
mean,O
at,O
readmission,O
",",O
143,O
x,O
10(9,O
),O
cells,O
/,O
L,O
;,O
mean,O
nadir,O
after,O
heparin,I-Entity
re,O
-,O
exposure,O
",",O
39,O
x,O
10(9,O
),O
cells,O
/,O
L,O
),O
.,O
Results,O
of,O
serologic,O
tests,O
for,O
heparin,I-Entity
-,O
induced,O
antibodies,O
were,O
positive,O
in,O
all,O
patients,O
.,O
Subsequent,O
treatments,O
included,O
alternative,O
anticoagulants,O
(,O
11,O
patients,O
),O
",",O
thrombolytic,O
drugs,O
(,O
3,O
patients,O
),O
",",O
inferior,O
vena,O
cava,O
filters,O
(,O
3,O
patients,O
),O
and,O
",",O
eventually,O
",",O
warfarin,I-Entity
(,O
11,O
patients,O
),O
.,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
is,O
increasingly,O
being,O
recognized,O
.,O
To,O
avoid,O
disastrous,O
outcomes,O
",",O
physicians,O
must,O
consider,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
whenever,O
a,O
recently,O
hospitalized,O
patient,O
returns,O
with,O
thromboembolism,I-Entity
;,O
therapy,O
with,O
alternative,O
anticoagulants,O
",",O
not,O
heparin,I-Entity
",",O
should,O
be,O
initiated,O
.,O
Valsartan,I-Entity
",",O
a,O
new,O
angiotensin,B-Entity
II,I-Entity
antagonist,O
for,O
the,O
treatment,O
of,O
essential,O
hypertension,I-Entity
:,O
a,O
comparative,O
study,O
of,O
the,O
efficacy,O
and,O
safety,O
against,O
amlodipine,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
compare,O
the,O
antihypertensive,O
efficacy,O
of,O
a,O
new,O
angiotensin,B-Entity
II,I-Entity
antagonist,O
",",O
valsartan,I-Entity
",",O
with,O
a,O
reference,O
therapy,O
",",O
amlodipine,I-Entity
.,O
One,O
hundred,O
sixty,O
-,O
eight,O
adult,O
outpatients,O
with,O
mild,O
to,O
moderate,O
hypertension,I-Entity
were,O
randomly,O
allocated,O
in,O
double,O
-,O
blind,O
fashion,O
and,O
equal,O
number,O
to,O
receive,O
80,O
mg,O
valsartan,I-Entity
or,O
5,O
mg,O
amlodipine,I-Entity
for,O
12,O
weeks,O
.,O
After,O
8,O
weeks,O
of,O
therapy,O
",",O
in,O
patients,O
whose,O
blood,O
pressure,O
remained,O
uncontrolled,O
",",O
5,O
mg,O
amlodipine,I-Entity
was,O
added,O
to,O
the,O
initial,O
therapy,O
.,O
Both,O
valsartan,I-Entity
and,O
amlodipine,I-Entity
were,O
effective,O
at,O
lowering,O
blood,O
pressure,O
at,O
4,O
",",O
8,O
",",O
and,O
12,O
weeks,O
.,O
For,O
the,O
primary,O
variable,O
the,O
difference,O
was,O
0.5,O
mm,O
Hg,O
in,O
favor,O
of,O
valsartan,I-Entity
(,O
p,O
=,O
0.68,O
;,O
95%,O
confidence,O
interval,O
",",O
-2.7,O
to,O
1.7,O
),O
.,O
Responder,O
rates,O
at,O
8,O
weeks,O
were,O
66.7%,O
for,O
valsartan,I-Entity
and,O
60.2%,O
for,O
amlodipine,I-Entity
The,O
incidence,O
of,O
drug,O
-,O
related,O
dependent,O
edema,I-Entity
was,O
somewhat,O
higher,O
in,O
the,O
amlodipine,I-Entity
group,O
",",O
particularly,O
at,O
a,O
dose,O
of,O
10,O
mg,O
per,O
day,O
(,O
2.4%,O
for,O
80,O
mg,O
valsartan,I-Entity
;,O
3.6%,O
for,O
5,O
mg,O
amlodipine,I-Entity
;,O
0%,O
for,O
valsartan,I-Entity
plus,O
5,O
mg,O
amlodipine,I-Entity
;,O
14.3%,O
for,O
10,O
mg,O
amlodipine,I-Entity
),O
.,O
CONCLUSIONS,O
:,O
The,O
data,O
show,O
that,O
valsartan,I-Entity
is,O
at,O
least,O
as,O
effective,O
as,O
amlodipine,I-Entity
in,O
the,O
treatment,O
of,O
mild,O
to,O
moderate,O
hypertension,I-Entity
.,O
The,O
results,O
also,O
show,O
valsartan,I-Entity
to,O
be,O
well,O
tolerated,O
and,O
suggest,O
that,O
it,O
is,O
not,O
associated,O
with,O
side,O
effects,O
characteristic,O
of,O
this,O
comparator,O
class,O
",",O
dihydropyridine,I-Entity
calcium,I-Entity
antagonists,O
.,O
KF17837,I-Entity
:,O
a,O
novel,O
selective,O
adenosine,I-Entity
A2A,O
receptor,O
antagonist,O
with,O
anticataleptic,O
activity,O
.,O
KF17837,I-Entity
is,O
a,O
novel,O
selective,O
adenosine,I-Entity
A2A,O
receptor,O
antagonist,O
.,O
Oral,O
administration,O
of,O
KF17837,I-Entity
(,O
2.5,O
",",O
10.0,O
and,O
30.0,O
mg,O
/,O
kg,O
),O
significantly,O
ameliorated,O
the,O
cataleptic,I-Entity
responses,O
induced,O
by,O
intracerebroventricular,O
administration,O
of,O
an,O
adenosine,I-Entity
A2A,O
receptor,O
agonist,O
",",O
CGS,B-Entity
21680,I-Entity
(,O
10,O
micrograms,O
),O
",",O
in,O
a,O
dose,O
-,O
dependent,O
manner,O
.,O
KF17837,I-Entity
also,O
reduced,O
the,O
catalepsy,I-Entity
induced,O
by,O
haloperidol,I-Entity
(,O
1,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
and,O
by,O
reserpine,I-Entity
(,O
5,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
.,O
Moreover,O
",",O
KF17837,I-Entity
(,O
0.625,O
mg,O
/,O
kg,O
p.o,O
.,O
),O
potentiated,O
the,O
anticataleptic,O
effects,O
of,O
a,O
subthreshold,O
dose,O
of,O
"L-3,4-dihydroxyphenylalanine",I-Entity
(,O
L,B-Entity
-,I-Entity
DOPA,I-Entity
;,O
25,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
plus,O
benserazide,I-Entity
(,O
6.25,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
.,O
These,O
results,O
suggested,O
that,O
KF17837,I-Entity
is,O
a,O
centrally,O
active,O
adenosine,I-Entity
A2A,O
receptor,O
antagonist,O
and,O
that,O
the,O
dopaminergic,O
function,O
of,O
the,O
nigrostriatal,O
pathway,O
is,O
potentiated,O
by,O
adenosine,I-Entity
A2A,O
receptor,O
antagonists,O
.,O
Furthermore,O
",",O
KF17837,I-Entity
may,O
be,O
a,O
useful,O
drug,O
in,O
the,O
treatment,O
of,O
parkinsonism,I-Entity
.,O
Some,O
central,O
effects,O
of,O
repeated,O
treatment,O
with,O
fluvoxamine,I-Entity
.,O
We,O
investigated,O
the,O
effect,O
of,O
repeated,O
treatment,O
with,O
fluvoxamine,I-Entity
",",O
a,O
selective,O
serotonin,I-Entity
uptake,O
inhibitor,O
",",O
on,O
behavioral,O
effects,O
of,O
dopaminomimetics,O
and,O
methoxamine,I-Entity
and,O
on,O
the,O
animal,O
behavior,O
in,O
the,O
"""",O
behavioral,O
despair,O
"""",O
test,O
.,O
A,O
repeated,O
treatment,O
with,O
fluvoxamine,I-Entity
(,O
twice,O
daily,O
for,O
14,O
days,O
),O
potentiated,O
in,O
mice,O
and,O
in,O
rats,O
(,O
weaker,O
),O
the,O
amphetamine,I-Entity
-,O
induced,O
hyperactivity,I-Entity
.,O
The,O
hyperactivity,I-Entity
induced,O
by,O
nomifensine,I-Entity
in,O
mice,O
remained,O
unaffected,O
by,O
fluvoxamine,I-Entity
.,O
The,O
stimulation,O
of,O
locomotor,O
activity,O
by,O
intracerebroventricularly,O
administered,O
methoxamine,I-Entity
was,O
not,O
affected,O
by,O
repeated,O
treatment,O
with,O
fluvoxamine,I-Entity
.,O
Given,O
three,O
times,O
fluvoxamine,I-Entity
had,O
no,O
effect,O
on,O
the,O
immobilization,O
time,O
in,O
the,O
"""",O
behavioral,O
despair,O
"""",O
test,O
in,O
rats,O
.,O
The,O
results,O
indicate,O
that,O
fluvoxamine,I-Entity
given,O
repeatedly,O
acts,O
differently,O
than,O
citalopram,I-Entity
",",O
another,O
selective,O
serotonin,I-Entity
uptake,O
inhibitor,O
",",O
and,O
differs,O
also,O
from,O
other,O
antidepressant,O
drugs,O
.,O
Severe,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
patient,O
on,O
amiodarone,I-Entity
presenting,O
with,O
myxedemic,B-Entity
coma,I-Entity
:,O
a,O
case,O
report,O
.,O
This,O
is,O
a,O
case,O
report,O
of,O
myxedema,B-Entity
coma,I-Entity
secondary,O
to,O
amiodarone,I-Entity
-,O
induced,O
hypothyroidism,I-Entity
in,O
a,O
patient,O
with,O
severe,O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
(,O
CHF,I-Entity
),O
.,O
To,O
our,O
knowledge,O
and,O
after,O
reviewing,O
the,O
literature,O
there,O
is,O
one,O
case,O
report,O
of,O
myxedema,B-Entity
coma,I-Entity
during,O
long,O
term,O
amiodarone,I-Entity
therapy,O
.,O
Myxedema,B-Entity
coma,I-Entity
is,O
a,O
life,O
threatening,O
condition,O
that,O
carries,O
a,O
mortality,O
reaching,O
as,O
high,O
as,O
20%,O
with,O
treatment,O
.,O
The,O
condition,O
is,O
treated,O
with,O
intravenous,O
thyroxine,I-Entity
(,O
T4,I-Entity
),O
or,O
intravenous,O
tri,B-Entity
-,I-Entity
iodo,I-Entity
-,I-Entity
thyronine,I-Entity
(,O
T3,I-Entity
),O
.,O
Patients,O
with,O
CHF,I-Entity
on,O
amiodarone,I-Entity
may,O
suffer,O
serious,O
morbidity,O
and,O
mortality,O
from,O
hypothyroidism,I-Entity
",",O
and,O
thus,O
may,O
deserve,O
closer,O
follow,O
up,O
for,O
thyroid,O
stimulating,O
hormone,O
(,O
TSH,O
),O
levels,O
.,O
This,O
case,O
report,O
carries,O
an,O
important,O
clinical,O
application,O
given,O
the,O
frequent,O
usage,O
of,O
amiodarone,I-Entity
among,O
CHF,I-Entity
patients,O
.,O
The,O
myriad,O
clinical,O
presentation,O
of,O
myxedema,B-Entity
coma,I-Entity
and,O
its,O
serious,O
morbidity,O
and,O
mortality,O
stresses,O
the,O
need,O
to,O
suspect,O
this,O
clinical,O
syndrome,O
among,O
CHF,I-Entity
patients,O
presenting,O
with,O
hypotension,I-Entity
",",O
weakness,I-Entity
or,O
other,O
unexplained,O
symptoms,O
.,O
Fear,O
-,O
potentiated,O
startle,I-Entity
",",O
but,O
not,O
light,O
-,O
enhanced,O
startle,I-Entity
",",O
is,O
enhanced,O
by,O
anxiogenic,O
drugs,O
.,O
The,O
light,O
-,O
enhanced,O
startle,I-Entity
paradigm,O
(,O
LES,O
),O
is,O
suggested,O
to,O
model,O
anxiety,I-Entity
",",O
because,O
of,O
the,O
non,O
-,O
specific,O
cue,O
and,O
the,O
long,O
-,O
term,O
effect,O
.,O
In,O
contrast,O
",",O
the,O
fear,O
-,O
potentiated,O
startle,I-Entity
(,O
FPS,O
),O
is,O
suggested,O
to,O
model,O
conditioned,O
fear,O
.,O
Male,O
Wistar,O
rats,O
received,O
each,O
dose,O
of,O
the,O
alpha(2)-adrenoceptor,O
antagonist,O
yohimbine,I-Entity
(,O
0.25,O
-,O
1.0mg,O
/,O
kg,O
),O
",",O
the,O
5-HT(2C,I-Entity
),O
receptor,O
agonist,O
m,B-Entity
-,I-Entity
chlorophenylpiperazine,I-Entity
(,O
mCPP,I-Entity
",",O
0.5,O
-,O
2.0mg,O
/,O
kg,O
),O
or,O
the,O
GABA(A,I-Entity
),O
inverse,O
receptor,O
agonist,O
pentylenetetrazole,I-Entity
(,O
PTZ,I-Entity
",",O
3,O
-,O
30mg,O
/,O
kg,O
),O
and,O
were,O
subsequently,O
tested,O
in,O
either,O
LES,O
or,O
FPS,O
.,O
None,O
of,O
the,O
drugs,O
enhanced,O
LES,O
",",O
whereas,O
mCPP,I-Entity
increased,O
percentage,O
FPS,O
and,O
yohimbine,I-Entity
increased,O
absolute,O
FPS,O
values,O
.,O
Furthermore,O
",",O
yohimbine,I-Entity
increased,O
baseline,O
startle,I-Entity
amplitude,O
in,O
the,O
LES,O
",",O
while,O
mCPP,I-Entity
suppressed,O
baseline,O
startle,I-Entity
in,O
both,O
the,O
LES,O
and,O
FPS,O
and,O
PTZ,I-Entity
suppressed,O
baseline,O
startle,I-Entity
in,O
the,O
FPS,O
.,O
Proteinase,O
3-antineutrophil,O
cytoplasmic,O
antibody-(PR3-ANCA,O
),O
positive,O
necrotizing,O
glomerulonephritis,I-Entity
after,O
restarting,O
sulphasalazine,I-Entity
treatment,O
.,O
A,O
59-year,O
-,O
old,O
woman,O
with,O
ulcerative,B-Entity
colitis,I-Entity
developed,O
red,B-Entity
eyes,I-Entity
",",O
pleural,B-Entity
effusion,I-Entity
",",O
eosinophilia,I-Entity
and,O
urinary,B-Entity
abnormalities,I-Entity
after,O
restarting,O
of,O
sulphasalazine,I-Entity
treatment,O
.,O
Light,O
microscopy,O
of,O
a,O
kidney,O
biopsy,O
revealed,O
segmental,B-Entity
necrotizing,I-Entity
glomerulonephritis,I-Entity
without,O
deposition,O
of,O
immunoglobulin,O
or,O
complement,O
.,O
PR3-ANCA,O
titer,O
was,O
250,O
and,O
"1,070",O
EU,O
in,O
pleural,B-Entity
effusions,I-Entity
on,O
right,O
and,O
left,O
side,O
",",O
respectively,O
.,O
Although,O
cessation,O
of,O
sulphasalazine,I-Entity
treatment,O
resulted,O
in,O
improvements,O
in,O
fever,I-Entity
",",O
red,B-Entity
eyes,I-Entity
",",O
chest,B-Entity
pain,I-Entity
",",O
titer,O
of,O
C,O
-,O
reactive,O
protein,O
and,O
volume,O
of,O
the,O
pleural,B-Entity
effusions,I-Entity
",",O
we,O
initiated,O
steroid,I-Entity
therapy,O
",",O
because,O
PR3-ANCA,O
titer,O
rose,O
to,O
320,O
EU,O
",",O
eosinophil,O
count,O
increased,O
to,O
"1,100",O
cells,O
/,O
microl,O
",",O
and,O
the,O
pleural,B-Entity
effusion,I-Entity
remained,O
.,O
One,O
month,O
after,O
steroid,I-Entity
therapy,O
",",O
the,O
pleural,B-Entity
effusion,I-Entity
disappeared,O
",",O
and,O
PR3-ANCA,O
titer,O
normalized,O
3,O
months,O
later,O
.,O
This,O
case,O
suggests,O
that,O
sulphasalazine,I-Entity
can,O
induce,O
PR3-ANCA,O
-,O
positive,O
necrotizing,O
glomerulonephritis,I-Entity
.,O
Is,O
phenytoin,I-Entity
administration,O
safe,O
in,O
a,O
hypothermic,I-Entity
child,O
?,O
A,O
male,O
neonate,O
with,O
a,O
Chiari,B-Entity
malformation,I-Entity
and,O
a,O
leaking,O
myelomeningocoele,O
underwent,O
ventriculoperitoneal,O
shunt,O
insertion,O
followed,O
by,O
repair,O
of,O
myelomeningocoele,O
.,O
During,O
anaesthesia,O
and,O
surgery,O
",",O
he,O
inadvertently,O
became,O
moderately,O
hypothermic,I-Entity
.,O
Intravenous,O
phenytoin,I-Entity
was,O
administered,O
during,O
the,O
later,O
part,O
of,O
the,O
surgery,O
for,O
seizure,I-Entity
prophylaxis,O
.,O
Following,O
phenytoin,I-Entity
administration,O
",",O
the,O
patient,O
developed,O
acute,O
severe,O
bradycardia,I-Entity
",",O
refractory,O
to,O
atropine,I-Entity
and,O
adrenaline,I-Entity
.,O
The,O
cardiac,O
depressant,O
actions,O
of,O
phenytoin,I-Entity
and,O
hypothermia,I-Entity
can,O
be,O
additive,O
.,O
Administration,O
of,O
phenytoin,I-Entity
in,O
the,O
presence,O
of,O
hypothermia,I-Entity
may,O
lead,O
to,O
an,O
adverse,O
cardiac,O
event,O
in,O
children,O
.,O
As,O
phenytoin,I-Entity
is,O
a,O
commonly,O
used,O
drug,O
",",O
clinicians,O
need,O
to,O
be,O
aware,O
of,O
this,O
interaction,O
.,O
Amisulpride,I-Entity
related,O
tic,B-Entity
-,I-Entity
like,I-Entity
symptoms,I-Entity
in,O
an,O
adolescent,O
schizophrenic,I-Entity
.,O
Tic,B-Entity
disorders,I-Entity
can,O
be,O
effectively,O
treated,O
by,O
atypical,O
antipsychotics,O
such,O
as,O
risperidone,I-Entity
",",O
olanzapine,I-Entity
and,O
ziprasidone,I-Entity
.,O
However,O
",",O
there,O
are,O
two,O
case,O
reports,O
that,O
show,O
tic,B-Entity
-,I-Entity
like,I-Entity
symptoms,I-Entity
",",O
including,O
motor,O
and,O
phonic,O
variants,O
",",O
occurring,O
during,O
treatment,O
with,O
quetiapine,I-Entity
or,O
clozapine,I-Entity
.,O
We,O
present,O
a,O
15-year,O
-,O
old,O
girl,O
schizophrenic,I-Entity
who,O
developed,O
frequent,O
involuntary,B-Entity
eye,I-Entity
-,I-Entity
blinking,I-Entity
movements,I-Entity
after,O
5,O
months,O
of,O
amisulpride,I-Entity
treatment,O
(,O
1000,O
mg,O
per,O
day,O
),O
.,O
The,O
tic,B-Entity
-,I-Entity
like,I-Entity
symptoms,I-Entity
resolved,O
completely,O
after,O
we,O
reduced,O
the,O
dose,O
of,O
amisulpride,I-Entity
down,O
to,O
800,O
mg,O
per,O
day,O
.,O
However,O
",",O
her,O
psychosis,I-Entity
recurred,O
after,O
the,O
dose,O
reduction,O
.,O
We,O
then,O
placed,O
her,O
on,O
an,O
additional,O
100,O
mg,O
per,O
day,O
of,O
quetiapine,I-Entity
.,O
No,O
more,O
tic,B-Entity
-,I-Entity
like,I-Entity
symptoms,I-Entity
or,O
other,O
side,O
effects,O
have,O
been,O
reported,O
.,O
Together,O
with,O
previously,O
reported,O
cases,O
",",O
our,O
patient,O
suggests,O
that,O
tic,B-Entity
-,I-Entity
like,I-Entity
symptoms,I-Entity
might,O
occur,O
in,O
certain,O
vulnerable,O
individuals,O
during,O
treatment,O
with,O
atypical,O
antipsychotics,O
such,O
as,O
quetiapine,I-Entity
",",O
clozapine,I-Entity
",",O
or,O
amisulpride,I-Entity
.,O
Comparison,O
of,O
developmental,O
toxicology,O
of,O
aspirin,I-Entity
(,O
acetylsalicylic,B-Entity
acid,I-Entity
),O
in,O
rats,O
using,O
selected,O
dosing,O
paradigms,O
.,O
Analysis,O
of,O
the,O
literature,O
for,O
nonsteroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,O
),O
suggests,O
that,O
a,O
low,O
incidence,O
of,O
developmental,B-Entity
anomalies,I-Entity
occurs,O
in,O
rats,O
given,O
NSAIDs,O
on,O
specific,O
days,O
during,O
organogenesis,O
.,O
Aspirin,I-Entity
(,O
acetylsalicylic,B-Entity
acid,I-Entity
[,O
ASA,I-Entity
],O
),O
",",O
an,O
irreversible,O
cyclooxygenase,O
1,O
and,O
2,O
inhibitor,O
",",O
induces,O
developmental,B-Entity
anomalies,I-Entity
when,O
administered,O
to,O
Wistar,O
rats,O
on,O
gestational,O
day,O
(,O
GD,O
),O
9,O
",",O
10,O
",",O
or,O
11,O
There,O
are,O
no,O
published,O
ASA,I-Entity
studies,O
using,O
the,O
multiple,O
dosing,O
paradigm,O
of,O
GDs,O
6,O
to,O
17,O
.,O
Objectives,O
of,O
the,O
current,O
study,O
were,O
to,O
compare,O
results,O
between,O
Sprague,O
-,O
Dawley,O
(,O
SD,O
),O
and,O
Wistar,O
strains,O
when,O
ASA,I-Entity
is,O
administered,O
on,O
GD,O
9,O
",",O
10,O
",",O
or,O
11,O
;,O
to,O
compare,O
the,O
malformation,O
patterns,O
following,O
single,O
and,O
multiple,O
dosings,O
during,O
organogenesis,O
in,O
SD,O
rats,O
;,O
and,O
to,O
test,O
the,O
hypothesis,O
that,O
maternal,O
gastrointestinal,B-Entity
toxicity,I-Entity
confounds,O
the,O
detection,O
of,O
low,O
incidence,O
malformations,I-Entity
with,O
ASA,I-Entity
when,O
a,O
multiple,O
dosing,O
paradigm,O
is,O
used,O
.,O
ASA,I-Entity
was,O
administered,O
as,O
a,O
single,O
dose,O
on,O
GD,O
9,O
(,O
0,O
",",O
250,O
",",O
500,O
",",O
or,O
625,O
mg,O
/,O
kg,O
),O
",",O
10,O
(,O
0,O
",",O
500,O
",",O
625,O
",",O
or,O
750,O
mg,O
/,O
kg,O
),O
",",O
or,O
11,O
(,O
0,O
",",O
500,O
",",O
750,O
",",O
or,O
1000,O
mg,O
/,O
kg,O
),O
and,O
from,O
GD,O
6,O
to,O
GD,O
17,O
(,O
0,O
",",O
50,O
",",O
125,O
",",O
or,O
250,O
mg,O
/,O
kg,O
a,O
day,O
),O
in,O
the,O
multiple,O
dose,O
study,O
to,O
SD,O
rats,O
.,O
The,O
literature,O
evaluation,O
suggested,O
that,O
NSAIDs,O
induce,O
ventricular,B-Entity
septal,I-Entity
defects,I-Entity
(,O
VSDs,I-Entity
),O
and,O
midline,B-Entity
defects,I-Entity
(,O
MDs,I-Entity
),O
in,O
rats,O
and,O
diaphragmatic,B-Entity
hernia,I-Entity
(,O
DH,I-Entity
),O
",",O
MDs,I-Entity
",",O
and,O
VSDs,I-Entity
in,O
rabbits,O
;,O
hence,O
",",O
the,O
present,O
study,O
focused,O
on,O
these,O
malformations,I-Entity
",",O
even,O
though,O
ASA,I-Entity
induces,O
several,O
other,O
low,O
-,O
incidence,O
malformations,I-Entity
.,O
In,O
single,O
dose,O
studies,O
",",O
DH,I-Entity
",",O
MD,I-Entity
",",O
and,O
VSD,I-Entity
were,O
induced,O
on,O
GDs,O
9,O
and,O
10,O
.,O
VSD,I-Entity
also,O
was,O
noted,O
following,O
treatment,O
on,O
GD,O
11,O
.,O
In,O
contrast,O
",",O
DH,I-Entity
and,O
MD,I-Entity
were,O
noted,O
in,O
the,O
multiple,O
dose,O
study,O
design,O
only,O
in,O
the,O
high,O
-,O
dose,O
group,O
",",O
and,O
VSD,I-Entity
was,O
noted,O
across,O
all,O
dose,O
groups,O
.,O
CONCLUSIONS,O
:,O
High,O
concordance,O
in,O
major,O
developmental,B-Entity
anomalies,I-Entity
between,O
Wistar,O
and,O
SD,O
rats,O
were,O
noted,O
with,O
the,O
exception,O
of,O
VSD,I-Entity
in,O
the,O
SD,O
rats,O
and,O
hydrocephalus,I-Entity
in,O
the,O
Wistar,O
rats,O
.,O
Variations,O
and,O
malformations,I-Entity
were,O
similar,O
when,O
ASA,I-Entity
was,O
administered,O
as,O
a,O
single,O
dose,O
or,O
during,O
the,O
period,O
of,O
organogenesis,O
(,O
GDs,O
6,O
to,O
17,O
),O
.,O
It,O
was,O
also,O
evident,O
that,O
",",O
by,O
titrating,O
the,O
dose,O
to,O
achieve,O
a,O
maximum,O
tolerated,O
dose,O
",",O
malformations,I-Entity
that,O
normally,O
occur,O
at,O
low,O
incidence,O
",",O
as,O
reported,O
from,O
previous,O
single,O
dose,O
studies,O
",",O
could,O
also,O
be,O
induced,O
with,O
ASA,I-Entity
given,O
at,O
multiple,O
doses,O
.,O
Torsade,B-Entity
de,I-Entity
pointes,I-Entity
induced,O
by,O
metoclopramide,I-Entity
in,O
an,O
elderly,O
woman,O
with,O
preexisting,O
complete,O
left,B-Entity
bundle,I-Entity
branch,I-Entity
block,I-Entity
.,O
There,O
is,O
a,O
growing,O
list,O
of,O
drugs,O
implicated,O
in,O
acquired,O
long,B-Entity
QT,I-Entity
syndrome,I-Entity
and,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
.,O
However,O
",",O
the,O
torsadogenic,O
potential,O
of,O
metoclopramide,I-Entity
",",O
a,O
commonly,O
used,O
antiemetic,O
and,O
prokinetic,O
drug,O
",",O
has,O
not,O
been,O
reported,O
in,O
the,O
literature,O
",",O
despite,O
its,O
chemical,O
similarity,O
to,O
procainamide,I-Entity
.,O
We,O
report,O
on,O
a,O
92-year,O
-,O
old,O
woman,O
with,O
preexisting,O
complete,O
left,B-Entity
bundle,I-Entity
branch,I-Entity
block,I-Entity
who,O
developed,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
after,O
intravenous,O
and,O
oral,O
administration,O
of,O
metoclopramide,I-Entity
.,O
This,O
patient,O
also,O
developed,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
when,O
cisapride,I-Entity
and,O
erythromycin,I-Entity
were,O
given,O
simultaneously,O
.,O
This,O
is,O
the,O
first,O
documentation,O
that,O
metoclopramide,I-Entity
provokes,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
clinically,O
.,O
Metoclopramide,I-Entity
should,O
be,O
used,O
cautiously,O
in,O
patients,O
with,O
a,O
risk,O
of,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
.,O
Apomorphine,I-Entity
:,O
an,O
underutilized,O
therapy,O
for,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
Apomorphine,I-Entity
was,O
the,O
first,O
dopaminergic,O
drug,O
ever,O
used,O
to,O
treat,O
symptoms,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
.,O
While,O
powerful,O
antiparkinsonian,O
effects,O
had,O
been,O
observed,O
as,O
early,O
as,O
1951,O
",",O
the,O
potential,O
of,O
treating,O
fluctuating,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
by,O
subcutaneous,O
administration,O
of,O
apomorphine,I-Entity
has,O
only,O
recently,O
become,O
the,O
subject,O
of,O
systematic,O
study,O
.,O
A,O
number,O
of,O
small,O
scale,O
clinical,O
trials,O
have,O
unequivocally,O
shown,O
that,O
intermittent,O
subcutaneous,O
apomorphine,I-Entity
injections,O
produce,O
antiparkinsonian,O
benefit,O
close,O
if,O
not,O
identical,O
to,O
that,O
seen,O
with,O
levodopa,I-Entity
and,O
that,O
apomorphine,I-Entity
rescue,O
injections,O
can,O
reliably,O
revert,O
off,O
-,O
periods,O
even,O
in,O
patients,O
with,O
complex,O
on,O
-,O
off,O
motor,O
swings,O
.,O
Continuous,O
subcutaneous,O
apomorphine,I-Entity
infusions,O
can,O
reduce,O
daily,O
off,O
-,O
time,O
by,O
more,O
than,O
50%,O
in,O
this,O
group,O
of,O
patients,O
",",O
which,O
appears,O
to,O
be,O
a,O
stronger,O
effect,O
than,O
that,O
generally,O
seen,O
with,O
add,O
-,O
on,O
therapy,O
with,O
oral,O
dopamine,I-Entity
agonists,O
or,O
COMT,O
inhibitors,O
.,O
Extended,O
follow,O
-,O
up,O
studies,O
of,O
up,O
to,O
8,O
years,O
have,O
demonstrated,O
long,O
-,O
term,O
persistence,O
of,O
apomorphine,I-Entity
efficacy,O
.,O
In,O
addition,O
",",O
there,O
is,O
convincing,O
clinical,O
evidence,O
that,O
monotherapy,O
with,O
continuous,O
subcutaneous,O
apomorphine,I-Entity
infusions,O
is,O
associated,O
with,O
marked,O
reductions,O
of,O
preexisting,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
The,O
main,O
side,O
effects,O
of,O
subcutaneous,O
apomorphine,I-Entity
treatment,O
are,O
related,O
to,O
cutaneous,O
tolerability,O
problems,O
",",O
whereas,O
sedation,O
and,O
psychiatric,I-Entity
complications,O
play,O
a,O
lesser,O
role,O
.,O
Given,O
the,O
marked,O
degree,O
of,O
efficacy,O
of,O
subcutaneous,O
apomorphine,I-Entity
treatment,O
in,O
fluctuating,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
",",O
this,O
approach,O
seems,O
to,O
deserve,O
more,O
widespread,O
clinical,O
use,O
.,O
Fatal,O
excited,O
delirium,I-Entity
following,O
cocaine,I-Entity
use,O
:,O
epidemiologic,O
findings,O
provide,O
new,O
evidence,O
for,O
mechanisms,O
of,O
cocaine,I-Entity
toxicity,I-Entity
.,O
We,O
describe,O
an,O
outbreak,O
of,O
deaths,O
from,O
cocaine,I-Entity
-,O
induced,O
excited,O
delirium,I-Entity
(,O
EDDs,I-Entity
),O
in,O
Dade,O
County,O
",",O
Florida,O
between,O
1979,O
and,O
1990,O
.,O
From,O
a,O
registry,O
of,O
all,O
cocaine,I-Entity
-,O
related,O
deaths,O
in,O
Dade,O
County,O
",",O
Florida,O
",",O
from,O
1969,O
-,O
1990,O
",",O
58,O
EDDs,I-Entity
were,O
compared,O
with,O
125,O
victims,O
of,O
accidental,O
cocaine,I-Entity
overdose,I-Entity
without,O
excited,O
delirium,I-Entity
.,O
Compared,O
with,O
controls,O
",",O
EDDs,I-Entity
were,O
more,O
frequently,O
black,O
",",O
male,O
",",O
and,O
younger,O
.,O
They,O
were,O
less,O
likely,O
to,O
have,O
a,O
low,O
body,O
mass,O
index,O
",",O
and,O
more,O
likely,O
to,O
have,O
died,O
in,O
police,O
custody,O
",",O
to,O
have,O
received,O
medical,O
treatment,O
immediately,O
before,O
death,O
",",O
to,O
have,O
survived,O
for,O
a,O
longer,O
period,O
",",O
to,O
have,O
developed,O
hyperthermia,I-Entity
",",O
and,O
to,O
have,O
died,O
in,O
summer,O
months,O
.,O
EDDs,I-Entity
had,O
concentrations,O
of,O
cocaine,I-Entity
and,O
benzoylecgonine,I-Entity
in,O
autopsy,O
blood,O
that,O
were,O
similar,O
to,O
those,O
for,O
controls,O
.,O
The,O
epidemiologic,O
findings,O
are,O
most,O
consistent,O
with,O
the,O
hypothesis,O
that,O
chronic,O
cocaine,I-Entity
use,O
disrupts,O
dopaminergic,O
function,O
and,O
",",O
when,O
coupled,O
with,O
recent,O
cocaine,I-Entity
use,O
",",O
may,O
precipitate,O
agitation,I-Entity
",",O
delirium,I-Entity
",",O
aberrant,O
thermoregulation,O
",",O
rhabdomyolysis,I-Entity
",",O
and,O
sudden,B-Entity
death,I-Entity
.,O
Heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
",",O
thrombosis,I-Entity
",",O
and,O
hemorrhage,I-Entity
.,O
Sixty,O
-,O
two,O
patients,O
with,O
a,O
heparin,I-Entity
-,O
induced,O
thrombocytopenia,I-Entity
are,O
reported,O
.,O
Clinical,O
manifestations,O
of,O
this,O
disorder,O
include,O
hemorrhage,I-Entity
or,O
",",O
more,O
frequently,O
",",O
thromboembolic,I-Entity
events,O
in,O
patients,O
receiving,O
heparin,I-Entity
.,O
Laboratory,O
testing,O
has,O
revealed,O
a,B-Entity
falling,I-Entity
platelet,I-Entity
count,I-Entity
",",O
increased,O
resistance,O
to,O
heparin,I-Entity
",",O
and,O
aggregation,O
of,O
platelets,O
by,O
the,O
patient,O
's,O
plasma,O
when,O
heparin,I-Entity
is,O
added,O
.,O
Immunologic,O
testing,O
has,O
demonstrated,O
the,O
presence,O
of,O
a,O
heparin,I-Entity
-,O
dependent,O
platelet,O
membrane,O
antibody,O
.,O
The,O
20,O
deaths,O
",",O
52,O
hemorrhagic,B-Entity
and,I-Entity
thromboembolic,I-Entity
complications,I-Entity
",",O
and,O
21,O
surgical,O
procedures,O
to,O
manage,O
the,O
complications,O
confirm,O
the,O
seriousness,O
of,O
the,O
disorder,O
.,O
Specific,O
risk,O
factors,O
have,O
not,O
been,O
identified,O
;,O
therefore,O
",",O
all,O
patients,O
receiving,O
heparin,I-Entity
should,O
be,O
monitored,O
.,O
If,O
the,O
platelet,O
count,O
falls,O
to,O
less,O
than,O
"100,000/mm3",O
",",O
while,O
the,O
patient,O
is,O
receiving,O
heparin,I-Entity
",",O
platelet,B-Entity
aggregation,I-Entity
testing,O
",",O
using,O
the,O
patient,O
's,O
plasma,O
",",O
is,O
indicated,O
.,O
Management,O
consists,O
of,O
cessation,O
of,O
heparin,I-Entity
",",O
platelet,O
anti,O
-,O
aggregating,O
agents,O
",",O
and,O
alternate,O
forms,O
of,O
anticoagulation,O
when,O
indicated,O
.,O
Cardiac,B-Entity
toxicity,I-Entity
of,O
5-fluorouracil,I-Entity
.,O
Report,O
of,O
a,O
case,O
of,O
spontaneous,O
angina,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
a,O
patient,O
with,O
colon,B-Entity
carcinoma,I-Entity
and,O
liver,O
metastasis,I-Entity
who,O
presented,O
chest,B-Entity
pain,I-Entity
after,O
5-fluorouracil,I-Entity
(,O
5-FU,I-Entity
),O
administration,O
.,O
Clinical,O
electrocardiographic,O
evolution,O
was,O
similar,O
to,O
that,O
observed,O
in,O
Prinzmetal,B-Entity
's,I-Entity
angina,I-Entity
",",O
and,O
chest,B-Entity
pain,I-Entity
promptly,O
resolved,O
with,O
nifedipine,I-Entity
.,O
These,O
data,O
suggest,O
that,O
coronary,B-Entity
spasm,I-Entity
may,O
be,O
the,O
cause,O
of,O
cardiotoxicity,I-Entity
due,O
to,O
5-FU,I-Entity
",",O
and,O
that,O
calcium,I-Entity
antagonists,O
may,O
probably,O
be,O
used,O
in,O
the,O
prevention,O
or,O
treatment,O
of,O
5-FU,I-Entity
cardiotoxicity,I-Entity
.,O
Toxicity,I-Entity
due,O
to,O
remission,O
inducing,O
drugs,O
in,O
rheumatoid,B-Entity
arthritis,I-Entity
.,O
Twenty,O
-,O
five,O
patients,O
with,O
rheumatoid,B-Entity
arthritis,I-Entity
(,O
RA,I-Entity
),O
who,O
developed,O
toxicity,I-Entity
while,O
taking,O
remission,O
inducing,O
drugs,O
and,O
30,O
without,O
toxicity,I-Entity
were,O
studied,O
for,O
possible,O
associations,O
with,O
class,O
I,O
and,O
II,O
HLA,O
antigens,O
.,O
A,O
strong,O
association,O
has,O
been,O
found,O
between,O
nephritis,I-Entity
and,O
dermatitis,I-Entity
due,O
to,O
Tiopronin,I-Entity
(,O
a,O
D,B-Entity
-,I-Entity
Penicillamine,I-Entity
like,O
compound,O
),O
and,O
class,O
I,O
antigens,O
B35-Cw4,O
",",O
and,O
between,O
dermatitis,I-Entity
due,O
to,O
gold,I-Entity
thiosulphate,I-Entity
and,O
B35,O
.,O
Compared,O
to,O
healthy,O
controls,O
a,O
lower,O
DR5,O
frequency,O
was,O
observed,O
in,O
patients,O
with,O
RA,I-Entity
except,O
for,O
the,O
Tiopronin,I-Entity
related,O
nephritis,I-Entity
group,O
.,O
Transient,O
hemiparesis,I-Entity
:,O
a,O
rare,O
manifestation,O
of,O
diphenylhydantoin,I-Entity
toxicity,I-Entity
.,O
Among,O
the,O
common,O
side,O
effects,O
of,O
diphenylhydantoin,I-Entity
(,O
DPH,I-Entity
),O
overdose,I-Entity
",",O
the,O
most,O
frequently,O
encountered,O
neurological,O
signs,O
are,O
those,O
of,O
cerebellar,B-Entity
dysfunction,I-Entity
.,O
Two,O
patients,O
are,O
presented,O
who,O
suffered,O
progressive,O
hemiparesis,I-Entity
due,O
to,O
DPH,I-Entity
overdose,I-Entity
.,O
Both,O
had,O
brain,O
surgery,O
before,O
DPH,I-Entity
treatment,O
.,O
It,O
is,O
assumed,O
that,O
patients,O
with,O
some,O
cerebral,B-Entity
damage,I-Entity
are,O
liable,O
to,O
manifest,O
DPH,I-Entity
toxicity,I-Entity
as,O
focal,O
neurological,O
signs,O
.,O
Nerve,O
growth,O
factor,O
and,O
prostaglandins,I-Entity
in,O
the,O
urine,O
of,O
female,O
patients,O
with,O
overactive,B-Entity
bladder,I-Entity
.,O
NGF,O
and,O
PGs,I-Entity
in,O
the,O
bladder,O
can,O
be,O
affected,O
by,O
pathological,O
changes,O
in,O
the,O
bladder,O
and,O
these,O
changes,O
can,O
be,O
detected,O
in,O
urine,O
.,O
We,O
investigated,O
changes,O
in,O
urinary,O
NGF,O
and,O
PGs,I-Entity
in,O
women,O
with,O
OAB,I-Entity
.,O
The,O
study,O
groups,O
included,O
65,O
women,O
with,O
OAB,I-Entity
and,O
20,O
without,O
bladder,O
symptoms,O
who,O
served,O
as,O
controls,O
.,O
NGF,O
",",O
PGE2,I-Entity
",",O
PGF2alpha,I-Entity
and,O
PGI2,I-Entity
were,O
measured,O
using,O
enzyme,O
-,O
linked,O
immunosorbent,O
assay,O
and,O
compared,O
between,O
the,O
groups,O
.,O
In,O
addition,O
",",O
correlations,O
between,O
urinary,O
NGF,O
and,O
PG,I-Entity
",",O
and,O
urodynamic,O
parameters,O
in,O
patients,O
with,O
OAB,I-Entity
were,O
examined,O
.,O
Urinary,O
NGF,O
",",O
PGE2,I-Entity
and,O
PGF2alpha,I-Entity
were,O
significantly,O
increased,O
in,O
patients,O
with,O
OAB,I-Entity
compared,O
with,O
controls,O
(,O
p,O
<,O
0.05,O
),O
.,O
However,O
",",O
urinary,O
PGI2,I-Entity
was,O
not,O
different,O
between,O
controls,O
and,O
patients,O
with,O
OAB,I-Entity
.,O
In,O
patients,O
with,O
OAB,I-Entity
urinary,O
PGE2,I-Entity
positively,O
correlated,O
with,O
volume,O
at,O
first,O
desire,O
to,O
void,O
and,O
maximum,O
cystometric,O
capacity,O
(,O
p,O
<,O
0.05,O
),O
.,O
Urinary,O
NGF,O
",",O
PGF2alpha,I-Entity
and,O
PGI2,I-Entity
did,O
not,O
correlate,O
with,O
urodynamic,O
parameters,O
in,O
patients,O
with,O
OAB,I-Entity
.,O
NGF,O
and,O
PGs,I-Entity
have,O
important,O
roles,O
in,O
the,O
development,O
of,O
OAB,I-Entity
symptoms,O
in,O
female,O
patients,O
.,O
Urinary,O
levels,O
of,O
these,O
factors,O
may,O
be,O
used,O
as,O
markers,O
to,O
evaluate,O
OAB,I-Entity
symptoms,O
.,O
Acute,O
low,B-Entity
back,I-Entity
pain,I-Entity
during,O
intravenous,O
administration,O
of,O
amiodarone,I-Entity
:,O
a,O
report,O
of,O
two,O
cases,O
.,O
Amiodarone,I-Entity
represents,O
an,O
effective,O
antiarrhythmic,O
drug,O
for,O
cardioversion,O
of,O
recent,O
-,O
onset,O
atrial,B-Entity
fibrillation,I-Entity
(,O
AF,I-Entity
),O
and,O
maintenance,O
of,O
sinus,O
rhythm,O
.,O
We,O
briefly,O
describe,O
two,O
patients,O
suffering,O
from,O
recent,O
-,O
onset,O
atrial,B-Entity
fibrillation,I-Entity
",",O
who,O
experienced,O
an,O
acute,O
devastating,O
low,B-Entity
back,I-Entity
pain,I-Entity
a,O
few,O
minutes,O
after,O
initiation,O
of,O
intravenous,O
amiodarone,I-Entity
loading,O
.,O
Postoperative,B-Entity
myalgia,I-Entity
after,O
succinylcholine,I-Entity
:,O
no,O
evidence,O
for,O
an,O
inflammatory,O
origin,O
.,O
A,O
common,O
side,O
effect,O
associated,O
with,O
succinylcholine,I-Entity
is,O
postoperative,B-Entity
myalgia,I-Entity
.,O
The,O
pathogenesis,O
of,O
this,O
myalgia,I-Entity
is,O
still,O
unclear,O
;,O
inflammation,I-Entity
has,O
been,O
suggested,O
but,O
without,O
convincing,O
evidence,O
.,O
We,O
designed,O
the,O
present,O
study,O
to,O
investigate,O
whether,O
an,O
inflammatory,O
reaction,O
contributes,O
to,O
this,O
myalgia,I-Entity
.,O
The,O
incidence,O
and,O
severity,O
of,O
succinylcholine,I-Entity
-,O
associated,O
myalgia,I-Entity
was,O
determined,O
in,O
64,O
patients,O
pretreated,O
with,O
saline,O
or,O
dexamethasone,I-Entity
before,O
succinylcholine,I-Entity
(,O
n,O
=,O
32,O
for,O
each,O
),O
.,O
Incidence,O
and,O
severity,O
of,O
myalgia,I-Entity
did,O
not,O
differ,O
significantly,O
between,O
the,O
two,O
groups,O
:,O
15,O
patients,O
in,O
the,O
dexamethasone,I-Entity
group,O
complained,O
of,O
myalgia,I-Entity
compared,O
with,O
18,O
patients,O
in,O
the,O
saline,O
group,O
",",O
and,O
severe,O
myalgia,I-Entity
was,O
reported,O
by,O
five,O
patients,O
and,O
three,O
patients,O
",",O
respectively,O
(,O
not,O
significant,O
),O
.,O
At,O
48,O
h,O
after,O
surgery,O
",",O
12,O
patients,O
in,O
both,O
groups,O
still,O
suffered,O
from,O
myalgia,I-Entity
(,O
not,O
significant,O
),O
.,O
In,O
addition,O
",",O
interleukin-6,O
(,O
IL-6,O
),O
as,O
an,O
early,O
marker,O
of,O
inflammation,I-Entity
was,O
assessed,O
in,O
a,O
subgroup,O
of,O
10,O
patients,O
pretreated,O
with,O
saline,O
.,O
We,O
found,O
an,O
increase,O
of,O
IL-6,O
for,O
only,O
three,O
patients,O
",",O
but,O
only,O
one,O
patient,O
reported,O
myalgia,I-Entity
;,O
no,O
relationship,O
between,O
myalgia,I-Entity
and,O
the,O
increase,O
of,O
IL-6,O
was,O
found,O
.,O
In,O
conclusion,O
",",O
there,O
is,O
no,O
evidence,O
for,O
an,O
inflammatory,O
origin,O
of,O
succinylcholine,I-Entity
-,O
associated,O
myalgia,I-Entity
.,O
Administration,O
of,O
dexamethasone,I-Entity
before,O
succinylcholine,I-Entity
was,O
not,O
effective,O
in,O
decreasing,O
the,O
incidence,O
or,O
the,O
severity,O
of,O
succinylcholine,I-Entity
-,O
induced,O
postoperative,B-Entity
myalgia,I-Entity
.,O
Furthermore,O
",",O
there,O
was,O
no,O
significant,O
relationship,O
between,O
postoperative,B-Entity
myalgia,I-Entity
and,O
time,O
course,O
of,O
interleukin-6,O
concentrations,O
",",O
a,O
marker,O
of,O
inflammation,I-Entity
.,O
Pretreatment,O
with,O
dexamethasone,I-Entity
is,O
not,O
justified,O
to,O
prevent,O
postoperative,B-Entity
myalgia,I-Entity
after,O
succinylcholine,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
oromandibular,O
dystonia,I-Entity
in,O
progressive,B-Entity
supranuclear,I-Entity
palsy,I-Entity
.,O
Levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
have,O
been,O
reported,O
in,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
and,O
multiple,B-Entity
system,I-Entity
atrophy,I-Entity
.,O
Cranial,O
dystonias,I-Entity
are,O
rare,O
in,O
patients,O
with,O
progressive,B-Entity
supranuclear,I-Entity
palsy,I-Entity
(,O
PSP,I-Entity
),O
.,O
In,O
this,O
report,O
we,O
describe,O
an,O
unusual,O
case,O
of,O
reversible,O
levodopa,I-Entity
-,O
induced,O
Oromandibular,B-Entity
dystonia,I-Entity
(,O
OMD,I-Entity
),O
in,O
a,O
PSP,I-Entity
patient,O
to,O
highlight,O
the,O
importance,O
of,O
recognizing,O
this,O
drug,O
related,O
complication,O
in,O
the,O
management,O
of,O
PSP,I-Entity
",",O
and,O
discuss,O
the,O
possible,O
underlying,O
pathophysiology,O
.,O
Protective,O
effect,O
of,O
edaravone,I-Entity
against,O
streptomycin,I-Entity
-,O
induced,O
vestibulotoxicity,I-Entity
in,O
the,O
guinea,O
pig,O
.,O
This,O
study,O
investigated,O
alleviation,O
of,O
streptomycin,I-Entity
-,O
induced,O
vestibulotoxicity,I-Entity
by,O
edaravone,I-Entity
in,O
guinea,O
pigs,O
.,O
Edaravone,I-Entity
",",O
a,O
free,O
radical,O
scavenger,O
",",O
has,O
potent,O
free,O
radical,O
quenching,O
action,O
and,O
is,O
used,O
in,O
clinical,O
practice,O
to,O
treat,O
cerebral,B-Entity
infarction,I-Entity
.,O
Streptomycin,I-Entity
was,O
administered,O
to,O
the,O
inner,O
ear,O
by,O
osmotic,O
pump,O
for,O
24,O
h,O
",",O
and,O
edaravone,I-Entity
(,O
n=8,O
),O
or,O
saline,O
(,O
n=6,O
),O
was,O
intraperitoneally,O
injected,O
once,O
a,O
day,O
for,O
7,O
days,O
.,O
Animals,O
injected,O
with,O
saline,O
showed,O
statistically,O
smaller,O
gains,O
than,O
those,O
injected,O
with,O
edaravone,I-Entity
.,O
These,O
results,O
suggest,O
that,O
edaravone,I-Entity
suppresses,O
streptomycin,I-Entity
-,O
induced,O
vestibulotoxicity,I-Entity
.,O
Ketamine,I-Entity
in,O
war,O
/,O
tropical,O
surgery,O
(,O
a,O
final,O
tribute,O
to,O
the,O
racemic,O
mixture,O
),O
.,O
A,O
technique,O
of,O
continuous,O
intravenous,O
anaesthesia,O
with,O
ketamine,I-Entity
was,O
used,O
successfully,O
during,O
the,O
Somalia,O
civil,O
war,O
in,O
1994,O
and,O
in,O
north,O
Uganda,O
in,O
1999,O
for,O
64,O
operations,O
in,O
62,O
patients,O
",",O
aged,O
from,O
6,O
weeks,O
to,O
70,O
years,O
",",O
undergoing,O
limb,O
and,O
abdominal,O
surgery,O
including,O
caesarian,O
sections,O
and,O
interventions,O
in,O
neonates,O
.,O
Operations,O
lasting,O
up,O
to,O
2h,O
could,O
be,O
performed,O
in,O
the,O
absence,O
of,O
sophisticated,O
equipment,O
such,O
as,O
pulse,O
oximeters,O
or,O
ventilators,O
in,O
patients,O
on,O
spontaneous,O
ventilation,O
breathing,O
air,O
/,O
oxygen,I-Entity
only,O
.,O
After,O
premedication,O
with,O
diazepam,I-Entity
",",O
glycopyrrolate,I-Entity
and,O
local,O
anaesthesia,O
",",O
and,O
induction,O
with,O
standard,O
doses,O
of,O
ketamine,I-Entity
",",O
a,O
maintenance,O
dose,O
of,O
10,O
-,O
20,O
microg,O
/,O
kg,O
/,O
min,O
of,O
ketamine,I-Entity
proved,O
safe,O
and,O
effective,O
.,O
Diazepam,I-Entity
",",O
unless,O
contraindicated,O
or,O
risky,O
",",O
remains,O
the,O
only,O
necessary,O
complementary,O
drug,O
to,O
ketamine,I-Entity
as,O
it,O
buffers,O
its,O
cardiovascular,O
response,O
and,O
decreases,O
the,O
duration,O
and,O
intensity,O
of,O
operative,O
and,O
postoperative,O
hallucinations,I-Entity
.,O
Local,O
anaesthetic,O
blocks,O
were,O
useful,O
in,O
decreasing,O
the,O
requirement,O
for,O
postoperative,O
analgesia,I-Entity
.,O
An,O
antisialogue,O
was,O
usually,O
unnecessary,O
in,O
operations,O
lasting,O
up,O
to,O
2,O
h,O
",",O
glycopyrrolate,I-Entity
being,O
the,O
best,O
choice,O
for,O
its,O
lowest,O
psychotropic,O
and,O
chronotropic,O
effects,O
",",O
especially,O
in,O
a,O
hot,O
climate,O
.,O
Steroid,I-Entity
structure,O
and,O
pharmacological,O
properties,O
determine,O
the,O
anti,O
-,O
amnesic,I-Entity
effects,O
of,O
pregnenolone,B-Entity
sulphate,I-Entity
in,O
the,O
passive,O
avoidance,O
task,O
in,O
rats,O
.,O
Pregnenolone,B-Entity
sulphate,I-Entity
(,O
PREGS,I-Entity
),O
has,O
generated,O
interest,O
as,O
one,O
of,O
the,O
most,O
potent,O
memory,O
-,O
enhancing,O
neurosteroids,O
to,O
be,O
examined,O
in,O
rodent,O
learning,O
studies,O
",",O
with,O
particular,O
importance,O
in,O
the,O
ageing,O
process,O
.,O
The,O
mechanism,O
by,O
which,O
this,O
endogenous,O
steroid,I-Entity
enhances,O
memory,O
formation,O
is,O
hypothesized,O
to,O
involve,O
actions,O
on,O
glutamatergic,O
and,O
GABAergic,O
systems,O
.,O
This,O
hypothesis,O
stems,O
from,O
findings,O
that,O
PREGS,I-Entity
is,O
a,O
potent,O
positive,O
modulator,O
of,O
N,B-Entity
-,I-Entity
methyl,I-Entity
-,I-Entity
d,I-Entity
-,I-Entity
aspartate,I-Entity
receptors,O
(,O
NMDARs,O
),O
and,O
a,O
negative,O
modulator,O
of,O
gamma,B-Entity
-,I-Entity
aminobutyric,I-Entity
acid(A,I-Entity
),O
receptors,O
(,O
GABA(A)Rs,I-Entity
),O
.,O
Moreover,O
",",O
PREGS,I-Entity
is,O
able,O
to,O
reverse,O
the,O
amnesic,I-Entity
-,O
like,O
effects,O
of,O
NMDAR,O
and,O
GABA(A)R,I-Entity
ligands,O
.,O
To,O
investigate,O
this,O
hypothesis,O
",",O
the,O
present,O
study,O
in,O
rats,O
examined,O
the,O
memory,O
-,O
altering,O
abilities,O
of,O
structural,O
analogs,O
of,O
PREGS,I-Entity
",",O
which,O
differ,O
in,O
their,O
modulation,O
of,O
NMDAR,O
and/or,O
GABA(A)R,I-Entity
function,O
.,O
The,O
analogs,O
tested,O
were,O
:,O
11-ketopregnenolone,B-Entity
sulphate,I-Entity
(,O
an,O
agent,O
that,O
is,O
inactive,O
at,O
GABA(A)Rs,I-Entity
and,O
NMDARs,O
),O
",",O
epipregnanolone,B-Entity
(,I-Entity
[,I-Entity
3beta,I-Entity
-,I-Entity
hydroxy-5beta,I-Entity
-,I-Entity
pregnan-20-one,I-Entity
],I-Entity
sulphate,I-Entity
",",O
an,O
inhibitor,O
of,O
both,O
GABA(A)Rs,I-Entity
and,O
NMDARs,O
),O
",",O
and,O
a,O
newly,O
synthesized,O
(,O
-,O
),O
PREGS,I-Entity
enantiomer,O
(,O
which,O
is,O
identical,O
to,O
PREGS,I-Entity
in,O
effects,O
on,O
GABA(A)Rs,I-Entity
and,O
NMDARs,O
),O
.,O
The,O
memory,O
-,O
enhancing,O
effects,O
of,O
PREGS,I-Entity
and,O
its,O
analogs,O
were,O
tested,O
in,O
the,O
passive,O
avoidance,O
task,O
using,O
the,O
model,O
of,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
Both,O
PREGS,I-Entity
and,O
its,O
(,O
-,O
),O
enantiomer,O
blocked,O
the,O
effects,O
of,O
scopolamine,I-Entity
.,O
The,O
results,O
show,O
that,O
",",O
unlike,O
PREGS,I-Entity
",",O
11-ketopregnenolone,B-Entity
sulphate,I-Entity
and,O
epipregnanolone,B-Entity
sulphate,I-Entity
failed,O
to,O
block,O
the,O
effect,O
of,O
scopolamine,I-Entity
",",O
suggesting,O
that,O
altering,O
the,O
modulation,O
of,O
NMDA,I-Entity
receptors,O
diminishes,O
the,O
memory,O
-,O
enhancing,O
effects,O
of,O
PREGS,I-Entity
.,O
Moreover,O
",",O
enantioselectivity,O
was,O
demonstrated,O
by,O
the,O
ability,O
of,O
natural,O
PREGS,I-Entity
to,O
be,O
an,O
order,O
of,O
magnitude,O
more,O
effective,O
than,O
its,O
synthetic,O
enantiomer,O
in,O
reversing,O
scopolamine,I-Entity
-,O
induced,O
amnesia,I-Entity
.,O
These,O
results,O
identify,O
a,O
novel,O
neuropharmacological,O
site,O
for,O
the,O
modulation,O
of,O
memory,O
processes,O
by,O
neuroactive,O
steroids,I-Entity
.,O
Preliminary,O
efficacy,O
assessment,O
of,O
intrathecal,O
injection,O
of,O
an,O
American,O
formulation,O
of,O
adenosine,I-Entity
in,O
humans,O
.,O
Preclinical,O
studies,O
of,O
intrathecal,O
adenosine,I-Entity
suggest,O
it,O
may,O
be,O
effective,O
in,O
the,O
treatment,O
of,O
acute,B-Entity
and,I-Entity
chronic,I-Entity
pain,I-Entity
in,O
humans,O
",",O
and,O
preliminary,O
studies,O
in,O
volunteers,O
and,O
patients,O
with,O
a,O
Swedish,O
formulation,O
of,O
adenosine,I-Entity
suggests,O
it,O
may,O
be,O
effective,O
in,O
hypersensitivity,I-Entity
states,O
but,O
not,O
with,O
acute,O
noxious,O
stimulation,O
.,O
The,O
purpose,O
of,O
this,O
study,O
was,O
to,O
screen,O
for,O
efficacy,O
of,O
a,O
different,O
formulation,O
of,O
adenosine,I-Entity
marketed,O
in,O
the,O
US,O
",",O
using,O
both,O
acute,O
noxious,O
stimulation,O
and,O
capsaicin,I-Entity
-,O
evoked,O
mechanical,O
hypersensitivity,I-Entity
.,O
Following,O
Food,O
and,O
Drug,O
Administration,O
and,O
institutional,O
review,O
board,O
approval,O
and,O
written,O
informed,O
consent,O
",",O
65,O
volunteers,O
were,O
studied,O
in,O
two,O
trials,O
:,O
an,O
open,O
-,O
label,O
",",O
dose,O
-,O
escalating,O
trial,O
with,O
intrathecal,O
adenosine,I-Entity
doses,O
of,O
0.25,O
-,O
2.0,O
mg,O
and,O
a,O
double,O
-,O
blind,O
",",O
placebo,O
-,O
controlled,O
trial,O
of,O
adenosine,I-Entity
",",O
2,O
mg,O
.,O
Cerebrospinal,O
fluid,O
was,O
obtained,O
for,O
pharmacokinetic,O
analysis,O
",",O
and,O
pain,I-Entity
ratings,O
in,O
response,O
to,O
acute,O
heat,O
stimuli,O
and,O
areas,O
of,O
mechanical,B-Entity
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
after,O
intradermal,O
capsaicin,I-Entity
injection,O
were,O
determined,O
.,O
Adenosine,I-Entity
produced,O
no,O
effect,O
on,O
pain,I-Entity
report,O
to,O
acute,O
noxious,O
thermal,O
or,O
chemical,O
stimulation,O
but,O
reduced,O
mechanical,B-Entity
hyperalgesia,I-Entity
and,O
allodynia,I-Entity
from,O
intradermal,O
capsaicin,I-Entity
injection,O
for,O
at,O
least,O
24,O
h.,O
In,O
contrast,O
",",O
residence,O
time,O
of,O
adenosine,I-Entity
in,O
cerebrospinal,O
fluid,O
was,O
short,O
(,O
<,O
4,O
h,O
),O
.,O
These,O
results,O
show,O
selective,O
inhibition,O
by,O
intrathecal,O
adenosine,I-Entity
of,O
hypersensitivity,I-Entity
",",O
presumed,O
to,O
reflect,O
central,O
sensitization,O
in,O
humans,O
after,O
peripheral,O
capsaicin,I-Entity
injection,O
.,O
The,O
long,O
-,O
lasting,O
effect,O
is,O
consistent,O
with,O
that,O
observed,O
in,O
preliminary,O
reports,O
of,O
patients,O
with,O
chronic,O
neuropathic,B-Entity
pain,I-Entity
and,O
is,O
not,O
due,O
to,O
prolonged,O
residence,O
of,O
adenosine,I-Entity
in,O
cerebrospinal,O
fluid,O
.,O
Effect,O
of,O
lithium,I-Entity
maintenance,O
therapy,O
on,O
thyroid,O
and,O
parathyroid,O
function,O
.,O
To,O
assess,O
changes,O
induced,O
by,O
lithium,I-Entity
maintenance,O
therapy,O
on,O
the,O
incidence,O
of,O
thyroid,O
",",O
parathyroid,O
and,O
ion,O
alterations,O
.,O
These,O
were,O
evaluated,O
with,O
respect,O
to,O
the,O
duration,O
of,O
lithium,I-Entity
therapy,O
",",O
age,O
",",O
sex,O
",",O
and,O
family,O
history,O
(,O
whether,O
or,O
not,O
the,O
patient,O
had,O
a,O
first,O
-,O
degree,O
relative,O
with,O
thyroid,B-Entity
disease,I-Entity
),O
.,O
One,O
hundred,O
and,O
one,O
patients,O
(,O
28,O
men,O
and,O
73,O
women,O
),O
with,O
bipolar,B-Entity
disorder,I-Entity
receiving,O
lithium,I-Entity
maintenance,O
therapy,O
ranging,O
from,O
1,O
year,O
's,O
to,O
32,O
years,O
',O
duration,O
.,O
The,O
control,O
group,O
consisted,O
of,O
82,O
patients,O
with,O
no,O
psychiatric,I-Entity
or,O
endocrinological,O
diagnoses,O
from,O
the,O
hospital,O
's,O
out,O
-,O
patient,O
clinics,O
.,O
Laboratory,O
analyses,O
of,O
calcium,I-Entity
",",O
magnesium,I-Entity
and,O
thyroid,O
-,O
stimulating,O
hormone,O
levels,O
performed,O
before,O
beginning,O
lithium,I-Entity
therapy,O
and,O
at,O
biannual,O
follow,O
-,O
up,O
.,O
Hypothyroidism,I-Entity
developed,O
in,O
40,O
patients,O
",",O
excluding,O
8,O
patients,O
who,O
were,O
hypothyroid,I-Entity
at,O
baseline,O
.,O
All,O
patients,O
having,O
first,O
-,O
degree,O
relatives,O
affected,O
by,O
thyroid,B-Entity
illness,I-Entity
had,O
accelerated,O
onset,O
of,O
hypothyroidism,I-Entity
(,O
3.7,O
years,O
after,O
onset,O
of,O
lithium,I-Entity
therapy,O
),O
compared,O
with,O
patients,O
without,O
a,O
family,O
history,O
(,O
8.6,O
years,O
after,O
onset,O
of,O
lithium,I-Entity
therapy,O
),O
.,O
Women,O
over,O
60,O
years,O
of,O
age,O
were,O
more,O
often,O
affected,O
by,O
hypothyroidism,I-Entity
than,O
women,O
under,O
60,O
years,O
of,O
age,O
(,O
34.6%,O
versus,O
31.9%,O
),O
.,O
Magnesium,I-Entity
levels,O
in,O
patients,O
on,O
lithium,I-Entity
treatment,O
were,O
unchanged,O
from,O
baseline,O
levels,O
.,O
After,O
lithium,I-Entity
treatment,O
",",O
calcium,I-Entity
levels,O
were,O
higher,O
than,O
either,O
baseline,O
levels,O
or,O
control,O
levels,O
.,O
Thus,O
",",O
lithium,I-Entity
treatment,O
counteracted,O
the,O
decrease,O
in,O
plasma,O
calcium,I-Entity
levels,O
associated,O
with,O
aging,O
.,O
CONCLUSIONS,O
:,O
Familial,O
thyroid,B-Entity
illness,I-Entity
is,O
a,O
risk,O
factor,O
for,O
hypothyroidism,I-Entity
and,O
hypercalcemia,I-Entity
during,O
lithium,I-Entity
therapy,O
.,O
Systemic,O
toxicity,I-Entity
following,O
administration,O
of,O
sirolimus,I-Entity
(,O
formerly,O
rapamycin,I-Entity
),O
for,O
psoriasis,I-Entity
:,O
association,O
of,O
capillary,B-Entity
leak,I-Entity
syndrome,I-Entity
with,O
apoptosis,O
of,O
lesional,O
lymphocytes,O
.,O
BACKGROUND,O
:,O
Sirolimus,I-Entity
(,O
formerly,O
rapamycin,I-Entity
),O
is,O
an,O
immunosuppressive,O
agent,O
that,O
interferes,O
with,O
T,O
-,O
cell,O
activation,O
.,O
After,O
2,O
individuals,O
with,O
psoriasis,I-Entity
developed,O
a,O
capillary,B-Entity
leak,I-Entity
syndrome,I-Entity
following,O
treatment,O
with,O
oral,O
sirolimus,I-Entity
lesional,O
skin,O
cells,O
and,O
activated,O
peripheral,O
blood,O
cells,O
were,O
analyzed,O
for,O
induction,O
of,O
apoptosis,O
.,O
A,O
keratome,O
skin,O
specimen,O
from,O
1,O
patient,O
with,O
sirolimus,I-Entity
-,O
induced,O
capillary,B-Entity
leak,I-Entity
syndrome,I-Entity
had,O
a,O
2.3-fold,O
increase,O
in,O
percentage,O
of,O
apoptotic,O
cells,O
(,O
to,O
48%,O
),O
compared,O
with,O
an,O
unaffected,O
sirolimus,I-Entity
-,O
treated,O
patient,O
with,O
psoriasis,I-Entity
(,O
21%,O
),O
.,O
Activated,O
peripheral,O
blood,O
T,O
cells,O
from,O
patients,O
with,O
psoriasis,I-Entity
tended,O
to,O
exhibit,O
greater,O
spontaneous,O
or,O
dexamethasone,I-Entity
-,O
induced,O
apoptosis,O
than,O
did,O
normal,O
T,O
cells,O
",",O
particularly,O
in,O
the,O
presence,O
of,O
sirolimus,I-Entity
.,O
Severe,O
adverse,O
effects,O
of,O
sirolimus,I-Entity
include,O
fever,I-Entity
",",O
anemia,I-Entity
",",O
and,O
capillary,B-Entity
leak,I-Entity
syndrome,I-Entity
.,O
Because,O
patients,O
with,O
severe,O
psoriasis,I-Entity
may,O
develop,O
capillary,B-Entity
leak,I-Entity
from,O
various,O
systemic,O
therapies,O
",",O
clinical,O
monitoring,O
is,O
advisable,O
for,O
patients,O
with,O
inflammatory,B-Entity
diseases,I-Entity
who,O
are,O
treated,O
with,O
immune,O
modulators,O
.,O
Contribution,O
of,O
the,O
glycine,I-Entity
site,O
of,O
NMDA,I-Entity
receptors,O
in,O
rostral,O
and,O
intermediate,O
-,O
caudal,O
parts,O
of,O
the,O
striatum,O
to,O
the,O
regulation,O
of,O
muscle,O
tone,O
in,O
rats,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
assess,O
the,O
contribution,O
of,O
the,O
glycine,I-Entity
site,O
of,O
NMDA,I-Entity
receptors,O
in,O
the,O
striatum,O
to,O
the,O
regulation,O
of,O
muscle,O
tone,O
.,O
Muscle,B-Entity
rigidity,I-Entity
was,O
induced,O
by,O
haloperidol,I-Entity
(,O
2.5,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
.,O
"5,7-dichlorokynurenic",B-Entity
acid,I-Entity
(,O
"5,7-DCKA",I-Entity
),O
",",O
a,O
selective,O
glycine,I-Entity
site,O
antagonist,O
",",O
injected,O
in,O
doses,O
of,O
2.5,O
and,O
4.5,O
microg/0.5,O
microl,O
bilaterally,O
",",O
into,O
the,O
rostral,O
region,O
of,O
the,O
striatum,O
",",O
decreased,O
both,O
the,O
haloperidol,I-Entity
-,O
induced,O
muscle,B-Entity
rigidity,I-Entity
(,O
MMG,O
),O
and,O
the,O
enhanced,O
electromyographic,O
activity,O
(,O
EMG,O
),O
.,O
"5,7-DCKA",I-Entity
injected,O
bilaterally,O
in,O
a,O
dose,O
of,O
4.5,O
microg/0.5,O
microl,O
into,O
the,O
intermediate,O
-,O
caudal,O
region,O
of,O
the,O
striatum,O
of,O
rats,O
not,O
pretreated,O
with,O
haloperidol,I-Entity
had,O
no,O
effect,O
on,O
the,O
muscle,O
tone,O
.,O
The,O
present,O
results,O
suggest,O
that,O
blockade,O
of,O
the,O
glycine,I-Entity
site,O
of,O
NMDA,I-Entity
receptors,O
in,O
the,O
rostral,O
part,O
of,O
the,O
striatum,O
may,O
be,O
mainly,O
responsible,O
for,O
the,O
antiparkinsonian,O
action,O
of,O
this,O
drug,O
.,O
Efficacy,O
and,O
tolerability,O
of,O
lovastatin,I-Entity
in,O
3390,O
women,O
with,O
moderate,O
hypercholesterolemia,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
efficacy,O
and,O
safety,O
of,O
lovastatin,I-Entity
in,O
women,O
with,O
moderate,O
hypercholesterolemia,I-Entity
.,O
The,O
Expanded,O
Clinical,O
Evaluation,O
of,O
Lovastatin,I-Entity
(,O
EXCEL,O
),O
Study,O
",",O
a,O
multicenter,O
",",O
double,O
-,O
blind,O
",",O
diet-,O
and,O
placebo,O
-,O
controlled,O
trial,O
",",O
in,O
which,O
participants,O
were,O
randomly,O
assigned,O
to,O
receive,O
placebo,O
or,O
lovastatin,I-Entity
at,O
doses,O
of,O
20,O
or,O
40,O
mg,O
once,O
daily,O
",",O
or,O
20,O
or,O
40,O
mg,O
twice,O
daily,O
for,O
48,O
weeks,O
.,O
MEASUREMENTS,O
:,O
Plasma,O
total,O
",",O
low,O
-,O
density,O
lipoprotein,O
(,O
LDL,O
),O
",",O
and,O
high,O
-,O
density,O
lipoprotein,O
(,O
HDL,O
),O
cholesterol,I-Entity
",",O
and,O
triglycerides,I-Entity
;,O
and,O
laboratory,O
and,O
clinical,O
evidence,O
of,O
adverse,O
events,O
monitored,O
periodically,O
throughout,O
the,O
study,O
.,O
Among,O
women,O
",",O
lovastatin,I-Entity
(,O
20,O
to,O
80,O
mg,O
/,O
d,O
),O
produced,O
sustained,O
(,O
12-,O
to,O
48-week,O
),O
",",O
dose,O
-,O
related,O
changes,O
(,O
P,O
<,O
0.001,O
),O
:,O
decreases,O
in,O
LDL,O
cholesterol,I-Entity
(,O
24%,O
to,O
40%,O
),O
and,O
triglycerides,I-Entity
(,O
9%,O
to,O
18%,O
),O
",",O
and,O
increases,O
in,O
HDL,O
cholesterol,I-Entity
(,O
6.7%,O
to,O
8.6%,O
),O
.,O
Depending,O
on,O
the,O
dose,O
",",O
from,O
82%,O
to,O
95%,O
of,O
lovastatin,I-Entity
-,O
treated,O
women,O
achieved,O
the,O
National,O
Cholesterol,I-Entity
Education,O
Program,O
goal,O
of,O
LDL,O
cholesterol,I-Entity
levels,O
less,O
than,O
4.14,O
mmol,O
/,O
L,O
(,O
160,O
mg,O
/,O
dL,O
),O
",",O
and,O
40%,O
to,O
87%,O
achieved,O
the,O
goal,O
of,O
3.36,O
mmol,O
/,O
L,O
(,O
130,O
mg,O
/,O
dL,O
),O
.,O
Myopathy,I-Entity
",",O
defined,O
as,O
muscle,O
symptoms,O
with,O
creatine,I-Entity
kinase,O
elevations,O
greater,O
than,O
10,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
",",O
was,O
rare,O
and,O
associated,O
with,O
the,O
highest,O
recommended,O
daily,O
dose,O
of,O
lovastatin,I-Entity
(,O
80,O
mg,O
),O
.,O
Estrogen,O
-,O
replacement,O
therapy,O
appeared,O
to,O
have,O
no,O
effect,O
on,O
either,O
the,O
efficacy,O
or,O
safety,O
profile,O
of,O
lovastatin,I-Entity
.,O
CONCLUSION,O
:,O
Lovastatin,I-Entity
is,O
highly,O
effective,O
and,O
generally,O
well,O
tolerated,O
as,O
therapy,O
for,O
primary,O
hypercholesterolemia,I-Entity
in,O
women,O
.,O
REM,B-Entity
sleep,I-Entity
deprivation,I-Entity
changes,O
behavioral,O
response,O
to,O
catecholaminergic,O
and,O
serotonergic,O
receptor,O
activation,O
in,O
rats,O
.,O
The,O
effects,O
of,O
REM,B-Entity
sleep,I-Entity
deprivation,I-Entity
(,O
REMD,I-Entity
),O
on,O
apomorphine,I-Entity
-,O
induced,O
aggressiveness,I-Entity
and,O
quipazine,I-Entity
-,O
induced,O
head,B-Entity
twitches,I-Entity
in,O
rats,O
were,O
determined,O
.,O
hr,O
of,O
REMD,I-Entity
increased,O
apomorphine,I-Entity
-,O
induced,O
aggressiveness,I-Entity
",",O
and,O
reduced,O
(,O
immediately,O
after,O
completing,O
of,O
REMD,I-Entity
),O
or,O
increased,O
(,O
96,O
hr,O
after,O
completing,O
of,O
REMD,I-Entity
),O
quipazine,I-Entity
-,O
induced,O
head,B-Entity
twitches,I-Entity
.,O
Extrapyramidal,O
side,O
effects,O
and,O
oral,O
haloperidol,I-Entity
:,O
an,O
analysis,O
of,O
explanatory,O
patient,O
and,O
treatment,O
characteristics,O
.,O
The,O
incidence,O
of,O
extrapyramidal,O
side,O
effects,O
(,O
EPS,O
),O
was,O
evaluated,O
in,O
98,O
patients,O
treated,O
with,O
haloperidol,I-Entity
.,O
The,O
incidence,O
of,O
parkinsonism,I-Entity
was,O
higher,O
at,O
higher,O
doses,O
of,O
haloperidol,I-Entity
and,O
in,O
younger,O
patients,O
.,O
However,O
",",O
these,O
medications,O
were,O
more,O
effective,O
in,O
both,O
young,O
and,O
old,O
patients,O
when,O
given,O
after,O
parkinsonism,I-Entity
developed,O
.,O
Akathisia,I-Entity
was,O
controlled,O
by,O
the,O
benzodiazepine,I-Entity
lorazepam,I-Entity
in,O
14,O
out,O
of,O
16,O
patients,O
",",O
while,O
prophylactic,O
antiparkinsonians,O
were,O
ineffective,O
.,O
The,O
present,O
study,O
points,O
to,O
patient,O
characteristics,O
that,O
may,O
be,O
of,O
significance,O
in,O
the,O
development,O
of,O
EPS,O
due,O
to,O
haloperidol,I-Entity
.,O
Hepatic,B-Entity
veno,I-Entity
-,I-Entity
occlusive,I-Entity
disease,I-Entity
caused,O
by,O
6-thioguanine,I-Entity
.,O
Clinically,O
reversible,O
veno,B-Entity
-,I-Entity
occlusive,I-Entity
disease,I-Entity
of,I-Entity
the,I-Entity
liver,I-Entity
developed,O
in,O
a,O
23-year,O
-,O
old,O
man,O
with,O
acute,B-Entity
lymphocytic,I-Entity
leukemia,I-Entity
after,O
10,O
months,O
of,O
maintenance,O
therapy,O
with,O
6-thioguanine,I-Entity
.,O
Although,O
this,O
disease,O
was,O
clinically,O
reversible,O
",",O
some,O
subintimal,O
fibrosis,I-Entity
about,O
the,O
terminal,O
hepatic,O
veins,O
persisted,O
.,O
This,O
case,O
presented,O
a,O
unique,O
opportunity,O
to,O
observe,O
the,O
histologic,O
features,O
of,O
clinically,O
reversible,O
hepatic,B-Entity
veno,I-Entity
-,I-Entity
occlusive,I-Entity
disease,I-Entity
over,O
time,O
",",O
and,O
may,O
be,O
the,O
first,O
case,O
of,O
veno,O
-,O
occlusive,O
related,O
solely,O
to,O
6-thioguanine,I-Entity
.,O
Treatment,O
of,O
ifosfamide,I-Entity
-,O
induced,O
urothelial,B-Entity
toxicity,I-Entity
by,O
oral,O
administration,O
of,O
sodium,B-Entity
2-mercaptoethane,I-Entity
sulphonate,I-Entity
(,O
MESNA,I-Entity
),O
to,O
patients,O
with,O
inoperable,O
lung,B-Entity
cancer,I-Entity
.,O
The,O
protective,O
effect,O
of,O
oral,O
administration,O
of,O
the,O
thiol,I-Entity
compound,O
sodium,B-Entity
2-mercaptoethane,I-Entity
sulphonate,I-Entity
(,O
MESNA,I-Entity
),O
against,O
urothelial,B-Entity
toxicity,I-Entity
induced,O
by,O
ifosfamide,I-Entity
(,O
IF,I-Entity
),O
was,O
tested,O
in,O
a,O
group,O
of,O
45,O
patients,O
with,O
inoperable,O
lung,B-Entity
cancer,I-Entity
under,O
treatment,O
with,O
IF,I-Entity
(,O
2250,O
mg,O
/,O
m2,O
on,O
days,O
2,O
-,O
5,O
),O
as,O
part,O
of,O
a,O
polychemotherapy,O
regimen,O
repeated,O
in,O
a,O
4-week,O
cycle,O
.,O
MESNA,I-Entity
was,O
given,O
orally,O
on,O
the,O
days,O
of,O
treatment,O
with,O
IF,I-Entity
in,O
3,O
doses,O
of,O
840,O
mg,O
/,O
m2,O
",",O
each,O
administered,O
at,O
0,O
hr,O
(=,O
injection,O
of,O
IF,I-Entity
),O
",",O
4,O
hr,O
and,O
8,O
hr,O
p.i,O
.,O
Out,O
of,O
a,O
total,O
of,O
88,O
courses,O
of,O
this,O
treatment,O
we,O
observed,O
10,O
episodes,O
of,O
asymptomatic,O
microscopic,O
haematuria,I-Entity
and,O
no,O
episodes,O
of,O
gross,O
haematuria,I-Entity
.,O
In,O
this,O
group,O
of,O
45,O
patients,O
under,O
protection,O
with,O
MESNA,I-Entity
there,O
were,O
5,O
complete,O
remissions,O
and,O
9,O
partial,O
remissions,O
(,O
total,O
31%,O
),O
.,O
A,O
further,O
group,O
of,O
25,O
patients,O
under,O
polychemotherapy,O
with,O
IF,I-Entity
were,O
treated,O
by,O
conventional,O
prophylactic,O
measures,O
(,O
raised,O
fluid,O
intake,O
and,O
forced,O
diuresis,O
),O
.,O
In,O
this,O
group,O
there,O
were,O
1,O
complete,O
and,O
5,O
partial,O
remissions,O
(,O
total,O
24%,O
),O
",",O
but,O
nearly,O
all,O
patients,O
developed,O
either,O
gross,O
haematuria,I-Entity
and/or,O
symptoms,O
of,O
bladder,B-Entity
irritation,I-Entity
(,O
cystitis,I-Entity
and,O
pollakisuria,I-Entity
),O
.,O
There,O
were,O
no,O
appreciable,O
differences,O
between,O
the,O
MESNA,I-Entity
series,O
and,O
the,O
conventional,O
prophylaxis,O
series,O
with,O
respect,O
to,O
either,O
haematological,O
or,O
systemic,O
toxicity,I-Entity
of,O
the,O
cytostatic,O
treatment,O
.,O
Our,O
results,O
support,O
the,O
view,O
that,O
MESNA,I-Entity
",",O
given,O
orally,O
in,O
conjunction,O
with,O
combined,O
cytostatic,O
regimens,O
which,O
include,O
IF,I-Entity
",",O
simplifies,O
the,O
treatment,O
and,O
provides,O
optimum,O
protection,O
for,O
the,O
urinary,O
epithelium,O
.,O
Protection,O
with,O
oral,O
MESNA,I-Entity
is,O
particularly,O
suitable,O
for,O
outpatients,O
.,O
Time,O
course,O
alterations,O
of,O
QTC,O
interval,O
due,O
to,O
hypaque,B-Entity
76,I-Entity
.,O
Sequential,O
measurement,O
of,O
QT,O
interval,O
during,O
left,O
ventricular,O
angiography,O
was,O
made,O
30,O
seconds,O
and,O
one,O
",",O
three,O
",",O
five,O
and,O
ten,O
minutes,O
after,O
injection,O
of,O
hypaque,B-Entity
76,I-Entity
.,O
Significant,O
QTC,B-Entity
prolongation,I-Entity
occurred,O
in,O
30,O
seconds,O
to,O
one,O
minute,O
in,O
association,O
with,O
marked,O
hypotension,I-Entity
and,O
elevation,O
of,O
cardiac,O
output,O
.,O
Production,O
of,O
autochthonous,O
prostate,B-Entity
cancer,I-Entity
in,O
Lobund,O
-,O
Wistar,O
rats,O
by,O
treatments,O
with,O
N,B-Entity
-,I-Entity
nitroso,I-Entity
-,I-Entity
N,I-Entity
-,I-Entity
methylurea,I-Entity
and,O
testosterone,I-Entity
.,O
strain,O
rats,O
developed,O
large,O
",",O
palpable,O
prostate,B-Entity
adenocarcinomas,I-Entity
(,O
PAs,I-Entity
),O
following,O
treatments,O
with,O
N,B-Entity
-,I-Entity
nitroso,I-Entity
-,I-Entity
N,I-Entity
-,I-Entity
methylurea,I-Entity
(,O
CAS,O
:,O
684,O
-,O
93,O
-,O
5,O
),O
and,O
testosterone,B-Entity
propionate,I-Entity
[,O
(,O
TP,I-Entity
),O
CAS,O
:,O
57,O
-,O
85,O
-,O
2,O
],O
",",O
and,O
most,O
of,O
the,O
tumor,I-Entity
-,O
bearing,O
rats,O
manifested,O
metastatic,O
lesions,O
.,O
Within,O
the,O
same,O
timeframe,O
",",O
no,O
L,O
-,O
W,O
rat,O
developed,O
a,O
similar,O
palpable,O
PA,I-Entity
when,O
treated,O
only,O
with,O
TP,I-Entity
.,O
In,O
L,O
-,O
W,O
rats,O
",",O
TP,I-Entity
acted,O
as,O
a,O
tumor,I-Entity
enhancement,O
agent,O
",",O
with,O
primary,O
emphasis,O
on,O
the,O
development,O
of,O
prostate,B-Entity
cancer,I-Entity
.,O
A,O
dystonia,I-Entity
-,O
like,O
syndrome,O
after,O
neuropeptide,O
(,O
MSH,I-Entity
/,O
ACTH,I-Entity
),O
stimulation,O
of,O
the,O
rat,O
locus,O
ceruleus,O
.,O
The,O
movement,B-Entity
disorder,I-Entity
investigated,O
in,O
these,O
studies,O
has,O
some,O
features,O
in,O
common,O
with,O
human,O
idiopathic,O
dystonia,I-Entity
",",O
and,O
information,O
obtained,O
in,O
these,O
studies,O
may,O
be,O
of,O
potential,O
clinical,O
benefit,O
.,O
However,O
",",O
it,O
is,O
not,O
certain,O
as,O
to,O
the,O
following,O
:,O
(,O
a,O
),O
what,O
receptors,O
were,O
stimulated,O
by,O
the,O
ACTH,I-Entity
N,O
-,O
terminal,O
fragments,O
at,O
the,O
LC,O
that,O
resulted,O
in,O
this,O
disorder,O
;,O
(,O
b,O
),O
whether,O
NE,O
",",O
released,O
onto,O
Purkinje,O
cell,O
synapses,O
located,O
at,O
terminals,O
of,O
the,O
ceruleo,O
-,O
cerebellar,O
pathway,O
",",O
did,O
indeed,O
cause,O
the,O
long,O
-,O
term,O
depression,I-Entity
at,O
Purkinje,O
cell,O
synapses,O
(,O
previously,O
described,O
by,O
others,O
),O
that,O
resulted,O
in,O
the,O
long,O
duration,O
of,O
the,O
movement,B-Entity
disorder,I-Entity
;,O
(,O
c,O
),O
whether,O
the,O
inhibition,O
of,O
inhibitory,O
Purkinje,O
cells,O
resulted,O
in,O
disinhibition,O
or,O
increased,O
excitability,O
of,O
the,O
unilateral,O
cerebellar,O
Dexmedetomidine,I-Entity
",",O
acting,O
through,O
central,O
alpha-2,O
adrenoceptors,O
",",O
prevents,O
opiate,O
-,O
induced,O
muscle,B-Entity
rigidity,I-Entity
in,O
the,O
rat,O
.,O
The,O
highly,O
-,O
selective,O
alpha-2,O
adrenergic,O
agonist,O
dexmedetomidine,I-Entity
(,O
D,B-Entity
-,I-Entity
MED,I-Entity
),O
is,O
capable,O
of,O
inducing,O
muscle,B-Entity
flaccidity,I-Entity
and,O
anesthesia,O
in,O
rats,O
and,O
dogs,O
.,O
Intense,O
generalized,O
muscle,B-Entity
rigidity,I-Entity
is,O
an,O
undesirable,O
side,O
effect,O
of,O
potent,O
opiate,O
agonists,O
.,O
Although,O
the,O
neurochemistry,O
of,O
opiate,O
-,O
induced,O
rigidity,I-Entity
has,O
yet,O
to,O
be,O
fully,O
elucidated,O
",",O
recent,O
work,O
suggests,O
a,O
role,O
for,O
a,O
central,O
adrenergic,O
mechanism,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
authors,O
determined,O
if,O
treatment,O
with,O
D,B-Entity
-,I-Entity
MED,I-Entity
prevents,O
the,O
muscle,B-Entity
rigidity,I-Entity
caused,O
by,O
high,O
-,O
dose,O
alfentanil,I-Entity
anesthesia,O
in,O
the,O
rat,O
.,O
Animals,O
(,O
n,O
=,O
42,O
),O
were,O
treated,O
intraperitoneally,O
with,O
one,O
of,O
the,O
following,O
six,O
regimens,O
:,O
1,O
),O
L,O
-,O
MED,O
(,O
the,O
inactive,O
L,O
-,O
isomer,O
of,O
medetomidine,I-Entity
),O
",",O
30,O
micrograms,O
/,O
kg,O
;,O
2,O
),O
D,B-Entity
-,I-Entity
MED,I-Entity
",",O
10,O
micrograms,O
/,O
kg,O
;,O
3,O
),O
D,B-Entity
-,I-Entity
MED,I-Entity
",",O
30,O
micrograms,O
/,O
kg,O
;,O
4,O
),O
D,B-Entity
-,I-Entity
MED,I-Entity
[,O
30,O
micrograms,O
/,O
kg,O
],O
and,O
the,O
central,O
-,O
acting,O
alpha-2,O
antagonist,O
",",O
idazoxan,I-Entity
[,O
10,O
mg,O
/,O
kg,O
],O
;,O
5,O
),O
D,B-Entity
-,I-Entity
MED,I-Entity
[,O
30,O
micrograms,O
/,O
kg,O
],O
and,O
the,O
peripheral,O
-,O
acting,O
alpha-2,O
antagonist,O
DG-5128,I-Entity
[,O
10,O
mg,O
/,O
kg,O
],O
",",O
or,O
;,O
6,O
),O
Each,O
rat,O
was,O
then,O
injected,O
with,O
alfentanil,I-Entity
(,O
ALF,I-Entity
",",O
0.5,O
mg,O
/,O
kg,O
sc,O
),O
.,O
ALF,I-Entity
injection,O
resulted,O
in,O
a,O
marked,O
increase,O
in,O
hindlimb,O
EMG,O
activity,O
in,O
the,O
L,O
-,O
MED,O
treatment,O
group,O
which,O
was,O
indistinguishable,O
from,O
that,O
seen,O
in,O
animals,O
treated,O
with,O
saline,O
.,O
In,O
contrast,O
",",O
D,B-Entity
-,I-Entity
MED,I-Entity
prevented,O
alfentanil,I-Entity
-,O
induced,O
muscle,B-Entity
rigidity,I-Entity
in,O
a,O
dose,O
-,O
dependent,O
fashion,O
.,O
The,O
small,O
EMG,O
values,O
obtained,O
in,O
the,O
high,O
-,O
dose,O
D,B-Entity
-,I-Entity
MED,I-Entity
group,O
were,O
comparable,O
with,O
those,O
recorded,O
in,O
earlier,O
studies,O
from,O
control,O
animals,O
not,O
given,O
any,O
opiate,O
.,O
The,O
high,O
-,O
dose,O
D,B-Entity
-,I-Entity
MED,I-Entity
animals,O
were,O
flaccid,O
",",O
akinetic,I-Entity
",",O
and,O
lacked,O
a,O
startle,I-Entity
response,O
during,O
the,O
entire,O
experimental,O
period.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Seizure,I-Entity
activity,O
with,O
imipenem,I-Entity
therapy,O
:,O
incidence,O
and,O
risk,O
factors,O
.,O
Two,O
elderly,O
patients,O
with,O
a,O
history,O
of,O
either,O
cerebral,B-Entity
vascular,I-Entity
accident,I-Entity
(,O
CVA,I-Entity
),O
or,O
head,B-Entity
trauma,I-Entity
and,O
no,O
evidence,O
of,O
renal,B-Entity
disease,I-Entity
developed,O
seizures,I-Entity
while,O
receiving,O
maximum,O
doses,O
of,O
imipenem,B-Entity
/,I-Entity
cilastatin,I-Entity
.,O
Neither,O
patient,O
had,O
reported,O
previous,O
seizures,I-Entity
or,O
seizure,I-Entity
-,O
like,O
activity,O
nor,O
was,O
receiving,O
anticonvulsant,O
agents,O
.,O
All,O
seizures,I-Entity
were,O
controlled,O
with,O
therapeutic,O
doses,O
of,O
phenytoin,I-Entity
.,O
Both,O
patients,O
had,O
received,O
maximum,O
doses,O
of,O
other,O
beta,B-Entity
-,I-Entity
lactam,I-Entity
antibiotics,O
without,O
evidence,O
of,O
seizure,I-Entity
activity,O
.,O
The,O
ability,O
of,O
insulin,O
treatment,O
to,O
reverse,O
or,O
prevent,O
the,O
changes,O
in,O
urinary,O
bladder,O
function,O
caused,O
by,O
streptozotocin,I-Entity
-,O
induced,O
diabetes,B-Entity
mellitus,I-Entity
.,O
1,O
.,O
The,O
effects,O
of,O
insulin,O
treatment,O
on,O
in,O
vivo,O
and,O
in,O
vitro,O
urinary,O
bladder,O
function,O
in,O
streptozotocin,I-Entity
-,O
diabetic,I-Entity
rats,O
were,O
investigated,O
.,O
Diabetes,I-Entity
of,O
2,O
months,O
duration,O
resulted,O
in,O
decreases,O
in,O
body,O
weight,O
and,O
increases,O
in,O
fluid,O
consumption,O
",",O
urine,O
volume,O
",",O
frequency,O
of,O
micturition,O
",",O
and,O
average,O
volume,O
per,O
micturition,O
;,O
effects,O
which,O
were,O
prevented,O
by,O
insulin,O
treatment,O
.,O
3,O
.,O
Insulin,O
treatment,O
also,O
prevented,O
the,O
increases,O
in,O
contractile,O
responses,O
of,O
bladder,O
body,O
strips,O
from,O
diabetic,I-Entity
rats,O
to,O
nerve,O
stimulation,O
",",O
ATP,I-Entity
",",O
and,O
bethanechol,I-Entity
.,O
Diabetes,I-Entity
of,O
4,O
months,O
duration,O
also,O
resulted,O
in,O
decreases,O
in,O
body,O
weight,O
",",O
and,O
increases,O
in,O
fluid,O
consumption,O
",",O
urine,O
volume,O
",",O
frequency,O
of,O
micturition,O
",",O
and,O
average,O
volume,O
per,O
micturition,O
",",O
effects,O
which,O
were,O
reversed,O
by,O
insulin,O
treatment,O
for,O
the,O
final,O
2,O
months,O
of,O
the,O
study,O
.,O
Insulin,O
treatment,O
reversed,O
the,O
increases,O
in,O
contractile,O
responses,O
of,O
bladder,O
body,O
strips,O
from,O
diabetic,I-Entity
rats,O
to,O
nerve,O
stimulation,O
",",O
ATP,I-Entity
",",O
and,O
bethanechol,I-Entity
.,O
The,O
data,O
indicate,O
that,O
the,O
effects,O
of,O
streptozotocin,I-Entity
-,O
induced,O
diabetes,I-Entity
on,O
urinary,O
bladder,O
function,O
are,O
both,O
prevented,O
and,O
reversed,O
by,O
insulin,O
treatment,O
.,O
Delayed,O
institution,O
of,O
hypertension,I-Entity
during,O
focal,O
cerebral,B-Entity
ischemia,I-Entity
:,O
effect,O
on,O
brain,B-Entity
edema,I-Entity
.,O
The,O
effect,O
of,O
induced,O
hypertension,I-Entity
instituted,O
after,O
a,O
2-h,O
delay,O
following,O
middle,B-Entity
cerebral,I-Entity
artery,I-Entity
occlusion,I-Entity
(,O
MCAO,I-Entity
),O
on,O
brain,B-Entity
edema,I-Entity
formation,O
and,O
histochemical,O
injury,O
was,O
studied,O
.,O
Under,O
isoflurane,I-Entity
anesthesia,O
",",O
the,O
MCA,O
of,O
14,O
spontaneously,O
hypertensive,I-Entity
rats,O
was,O
occluded,O
.,O
In,O
the,O
hypertensive,I-Entity
group,O
(,O
n,O
=,O
7,O
),O
",",O
the,O
MAP,O
was,O
elevated,O
by,O
25,O
-,O
30,O
mm,O
Hg,O
beginning,O
2,O
h,O
after,O
MCAO,I-Entity
.,O
Four,O
hours,O
after,O
MCAO,I-Entity
",",O
the,O
rats,O
were,O
killed,O
and,O
the,O
brains,O
harvested,O
.,O
The,O
brains,O
were,O
sectioned,O
along,O
coronal,O
planes,O
spanning,O
the,O
distribution,O
of,O
ischemia,I-Entity
produced,O
by,O
MCAO,I-Entity
.,O
Specific,O
gravity,O
(,O
SG,O
),O
was,O
determined,O
in,O
the,O
subcortex,O
and,O
in,O
two,O
sites,O
in,O
the,O
cortex,O
(,O
core,O
and,O
periphery,O
of,O
the,O
ischemic,I-Entity
territory,O
),O
.,O
The,O
extent,O
of,O
neuronal,B-Entity
injury,I-Entity
was,O
determined,O
by,O
"2,3,5-triphenyltetrazolium",I-Entity
staining,O
.,O
In,O
the,O
ischemic,I-Entity
core,O
",",O
there,O
was,O
no,O
difference,O
in,O
SG,O
in,O
the,O
subcortex,O
and,O
cortex,O
in,O
the,O
two,O
groups,O
.,O
In,O
the,O
periphery,O
of,O
the,O
ischemic,I-Entity
territory,O
",",O
SG,O
in,O
the,O
cortex,O
was,O
greater,O
(,O
less,O
edema,I-Entity
accumulation,O
),O
in,O
the,O
hypertensive,I-Entity
group,O
(,O
1.041,O
+,O
/-,O
The,O
area,O
of,O
histochemical,O
injury,O
(,O
as,O
a,O
percent,O
of,O
the,O
cross,O
-,O
sectional,O
area,O
of,O
the,O
hemisphere,O
),O
was,O
less,O
in,O
the,O
hypertensive,I-Entity
group,O
(,O
33,O
+,O
/-,O
The,O
data,O
indicate,O
that,O
phenylephrine,I-Entity
-,O
induced,O
hypertension,I-Entity
instituted,O
2,O
h,O
after,O
MCAO,I-Entity
does,O
not,O
aggravate,O
edema,I-Entity
in,O
the,O
ischemic,I-Entity
core,O
",",O
that,O
it,O
improves,O
edema,I-Entity
in,O
the,O
periphery,O
of,O
the,O
ischemic,I-Entity
territory,O
",",O
and,O
that,O
it,O
reduces,O
the,O
area,O
of,O
histochemical,O
neuronal,B-Entity
dysfunction,I-Entity
.,O
Amiodarone,I-Entity
pulmonary,B-Entity
toxicity,I-Entity
.,O
Amiodarone,I-Entity
is,O
an,O
effective,O
antiarrhythmic,O
agent,O
whose,O
utility,O
is,O
limited,O
by,O
many,O
side,O
-,O
effects,O
",",O
the,O
most,O
problematic,O
being,O
pneumonitis,I-Entity
.,O
The,O
pulmonary,B-Entity
toxicity,I-Entity
of,O
amiodarone,I-Entity
is,O
thought,O
to,O
result,O
from,O
direct,O
injury,O
related,O
to,O
the,O
intracellular,O
accumulation,O
of,O
phospholipid,O
and,O
T,O
cell,O
-,O
mediated,O
hypersensitivity,B-Entity
pneumonitis,I-Entity
.,O
The,O
clinical,O
and,O
radiographic,O
features,O
of,O
amiodarone,I-Entity
-,O
induced,O
pulmonary,B-Entity
toxicity,I-Entity
are,O
characteristic,O
but,O
nonspecific,O
.,O
The,O
diagnosis,O
depends,O
on,O
exclusion,O
of,O
other,O
entities,O
",",O
such,O
as,O
heart,B-Entity
failure,I-Entity
",",O
infection,I-Entity
",",O
and,O
malignancy,I-Entity
.,O
While,O
withdrawal,O
of,O
amiodarone,I-Entity
leads,O
to,O
clinical,O
improvement,O
in,O
majority,O
of,O
cases,O
",",O
this,O
is,O
not,O
always,O
possible,O
or,O
advisable,O
.,O
Dose,O
reduction,O
or,O
concomitant,O
steroid,I-Entity
therapy,O
may,O
have,O
a,O
role,O
in,O
selected,O
patients,O
.,O
Light,O
chain,O
proteinuria,I-Entity
and,O
cellular,O
mediated,O
immunity,O
in,O
rifampin,I-Entity
treated,O
patients,O
with,O
tuberculosis,I-Entity
.,O
Light,O
chain,O
proteinuria,I-Entity
was,O
found,O
in,O
9,O
of,O
17,O
tuberculosis,I-Entity
patients,O
treated,O
with,O
rifampin,I-Entity
.,O
Response,O
to,O
Varidase,O
skin,O
test,O
antigen,O
was,O
negative,O
for,O
all,O
eight,O
tuberculosis,I-Entity
patients,O
tested,O
",",O
but,O
there,O
occurred,O
a,O
hyper,O
-,O
responsiveness,O
of,O
the,O
lymphocytes,O
of,O
these,O
eight,O
patients,O
to,O
phytomitogen,O
(,O
PHA,O
-,O
P,O
),O
.,O
as,O
well,O
as,O
of,O
those,O
of,O
seven,O
other,O
tuberculous,I-Entity
patients,O
.,O
This,O
last,O
finding,O
may,O
be,O
related,O
to,O
time,O
of,O
testing,O
and/or,O
endogenous,O
serum,O
binding,O
of,O
rifampin,I-Entity
which,O
could,O
have,O
inhibited,O
mitogen,O
activity,O
for,O
the,O
lymphocyte,O
.,O
Initial,O
potassium,I-Entity
loss,O
and,O
hypokalaemia,I-Entity
during,O
chlorthalidone,I-Entity
administration,O
in,O
patients,O
with,O
essential,O
hypertension,I-Entity
:,O
the,O
influence,O
of,O
dietary,O
sodium,I-Entity
restriction,O
.,O
To,O
investigate,O
the,O
initial,O
potassium,I-Entity
loss,O
and,O
development,O
of,O
hypokalaemia,I-Entity
during,O
the,O
administration,O
of,O
an,O
oral,O
diuretic,O
",",O
metabolic,O
balance,O
studies,O
were,O
performed,O
in,O
ten,O
patients,O
with,O
essential,O
hypertension,I-Entity
who,O
had,O
shown,O
hypokalaemia,I-Entity
under,O
prior,O
oral,O
diuretic,O
treatment,O
.,O
Chlorthalidone,I-Entity
(,O
50,O
mg,O
daily,O
),O
was,O
given,O
for,O
14,O
days,O
.,O
Six,O
patients,O
received,O
a,O
normal,O
-,O
sodium,I-Entity
diet,O
and,O
four,O
a,O
low,O
-,O
sodium,I-Entity
(,O
17,O
mmol,O
/,O
day,O
),O
diet,O
.,O
All,O
patients,O
had,O
a,O
normal,O
initial,O
total,O
body,O
potassium,I-Entity
(,O
40,O
K,O
),O
.,O
The,O
electrolyte,O
balances,O
",",O
weight,O
",",O
bromide,O
space,O
",",O
plasma,O
renin,O
activity,O
",",O
and,O
aldosterone,I-Entity
secretion,O
rate,O
were,O
measured,O
.,O
In,O
both,O
groups,O
a,O
potassium,I-Entity
deficit,O
developed,O
",",O
with,O
proportionally,O
larger,O
losses,O
from,O
the,O
extracellular,O
than,O
from,O
the,O
intracellular,O
compartment,O
.,O
In,O
the,O
normal,O
-,O
sodium,I-Entity
group,O
the,O
highest,O
mean,O
potassium,I-Entity
deficit,O
was,O
176,O
mmol,O
on,O
day,O
9,O
",",O
after,O
which,O
some,O
potassium,I-Entity
was,O
regained,O
;,O
in,O
the,O
low,O
-,O
sodium,I-Entity
group,O
the,O
highest,O
deficit,O
was,O
276,O
mmol,O
on,O
day,O
13,O
.,O
The,O
normal,O
-,O
sodium,I-Entity
group,O
showed,O
an,O
immediate,O
but,O
temporary,O
rise,O
of,O
the,O
renin,O
and,O
aldosterone,I-Entity
levels,O
;,O
in,O
the,O
low,O
-,O
sodium,I-Entity
group,O
renin,O
and,O
aldosterone,I-Entity
increased,O
more,O
slowly,O
but,O
remained,O
elevated,O
.,O
It,O
is,O
concluded,O
that,O
dietary,O
sodium,I-Entity
restriction,O
increases,O
diuretic,O
-,O
induced,O
potassium,I-Entity
loss,O
",",O
presumably,O
by,O
an,O
increased,O
activity,O
of,O
the,O
renin,O
-,O
angiotensin,I-Entity
-,O
aldosterone,I-Entity
system,O
",",O
while,O
sodium,I-Entity
delivery,O
to,O
the,O
distal,O
renal,O
tubules,O
remains,O
sufficiently,O
high,O
to,O
allow,O
increased,O
potassium,I-Entity
secretion,O
.,O
Dynamic,O
response,O
of,O
blood,O
vessel,O
in,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
In,O
this,O
study,O
we,O
postulated,O
that,O
during,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
induced,O
by,O
gentamicin,I-Entity
the,O
transient,O
or,O
dynamic,O
response,O
of,O
blood,O
vessels,O
could,O
be,O
affected,O
",",O
and,O
that,O
antioxidants,O
can,O
prevent,O
the,O
changes,O
in,O
dynamic,O
responses,O
of,O
blood,O
vessels,O
.,O
Our,O
results,O
confirm,O
the,O
alteration,O
in,O
dynamic,O
response,O
of,O
blood,O
vessels,O
during,O
the,O
change,O
of,O
pressure,O
in,O
gentamicin,I-Entity
-,O
treated,O
animals,O
.,O
The,O
beneficial,O
effects,O
of,O
vitamin,B-Entity
C,I-Entity
administration,O
to,O
gentamicin,I-Entity
-,O
treated,O
animals,O
are,O
also,O
confirmed,O
through,O
:,O
lower,O
level,O
of,O
blood,O
urea,I-Entity
and,O
creatinine,I-Entity
and,O
higher,O
level,O
of,O
potassium,I-Entity
.,O
The,O
pressure,O
dynamic,O
responses,O
of,O
isolated,O
blood,O
vessels,O
show,O
a,O
faster,O
pressure,O
change,O
in,O
gentamicin,I-Entity
-,O
treated,O
animals,O
(,O
8.07,O
+,O
/-,O
Vitamin,B-Entity
C,I-Entity
administration,O
induced,O
slowdown,O
of,O
pressure,O
change,O
back,O
to,O
the,O
control,O
values,O
.,O
The,O
pressure,O
dynamic,O
properties,O
",",O
quantitatively,O
defined,O
by,O
comparative,O
pressure,O
dynamic,O
and,O
total,O
pressure,O
dynamic,O
",",O
confirm,O
the,O
alteration,O
in,O
dynamic,O
response,O
of,O
blood,O
vessels,O
during,O
the,O
change,O
of,O
pressure,O
in,O
gentamicin,I-Entity
-,O
treated,O
animals,O
and,O
beneficial,O
effects,O
of,O
vitamin,B-Entity
C,I-Entity
administration,O
.,O
The,O
hemodynamics,O
of,O
oxytocin,I-Entity
and,O
other,O
vasoactive,O
agents,O
during,O
neuraxial,O
anesthesia,O
for,O
cesarean,O
delivery,O
:,O
findings,O
in,O
six,O
cases,O
.,O
Oxytocin,I-Entity
is,O
a,O
commonly,O
used,O
uterotonic,O
that,O
can,O
cause,O
significant,O
and,O
even,O
fatal,O
hypotension,I-Entity
",",O
particularly,O
when,O
given,O
as,O
a,O
bolus,O
.,O
The,O
resulting,O
hypotension,I-Entity
can,O
be,O
produced,O
by,O
a,O
decrease,O
in,O
systemic,O
vascular,O
resistance,O
or,O
cardiac,O
output,O
through,O
a,O
decrease,O
in,O
venous,O
return,O
.,O
Parturients,O
with,O
normal,O
volume,O
status,O
",",O
heart,O
valves,O
and,O
pulmonary,O
vasculature,O
most,O
often,O
respond,O
to,O
this,O
hypotension,I-Entity
with,O
a,O
compensatory,O
increase,O
in,O
heart,O
rate,O
and,O
stroke,I-Entity
volume,O
.,O
Oxytocin,I-Entity
-,O
induced,O
hypotension,I-Entity
at,O
cesarean,O
delivery,O
may,O
be,O
incorrectly,O
attributed,O
to,O
blood,B-Entity
loss,I-Entity
.,O
Hypotension,I-Entity
in,O
response,O
to,O
oxytocin,I-Entity
was,O
associated,O
with,O
a,O
decrease,O
in,O
systemic,O
vascular,O
resistance,O
and,O
a,O
compensatory,O
increase,O
in,O
stroke,I-Entity
volume,O
",",O
heart,O
rate,O
and,O
cardiac,O
output,O
.,O
Pulse,O
power,O
analysis,O
may,O
be,O
helpful,O
in,O
determining,O
the,O
etiology,O
of,O
and,O
treating,O
hypotension,I-Entity
during,O
cesarean,O
delivery,O
under,O
neuraxial,O
anesthesia,O
.,O
Exaggerated,O
expression,O
of,O
inflammatory,O
mediators,O
in,O
vasoactive,O
intestinal,O
polypeptide,O
knockout,O
(,O
VIP-/-,O
),O
mice,O
with,O
cyclophosphamide,I-Entity
(,O
CYP)-induced,I-Entity
cystitis,I-Entity
.,O
VIP(-/-,O
),O
mice,O
exhibit,O
altered,O
bladder,O
function,O
and,O
neurochemical,O
properties,O
in,O
micturition,O
pathways,O
after,O
cyclophosphamide,I-Entity
(,O
CYP)-induced,I-Entity
cystitis,I-Entity
.,O
Given,O
VIP,O
's,O
role,O
as,O
an,O
anti,O
-,O
inflammatory,O
mediator,O
",",O
we,O
hypothesized,O
that,O
VIP(-/-,O
),O
mice,O
would,O
exhibit,O
enhanced,O
inflammatory,O
mediator,O
expression,O
after,O
cystitis,I-Entity
.,O
A,O
mouse,O
inflammatory,O
cytokine,O
and,O
receptor,O
RT2,O
profiler,O
array,O
was,O
used,O
to,O
determine,O
regulated,O
transcripts,O
in,O
the,O
urinary,O
bladder,O
of,O
wild,O
type,O
(,O
WT,O
),O
and,O
VIP(-/-,O
),O
mice,O
with,O
or,O
without,O
CYP,I-Entity
-,O
induced,O
cystitis,I-Entity
(,O
150,O
mg,O
/,O
kg,O
;,O
i.p,O
.,O
;,O
48,O
h,O
),O
.,O
Four,O
binary,O
comparisons,O
were,O
made,O
:,O
WT,O
control,O
versus,O
CYP,I-Entity
treatment,O
(,O
48,O
h,O
),O
",",O
VIP(-/-,O
),O
control,O
versus,O
CYP,I-Entity
treatment,O
(,O
48,O
h,O
),O
",",O
WT,O
control,O
versus,O
VIP(-/-,O
),O
control,O
",",O
and,O
WT,O
with,O
CYP,I-Entity
treatment,O
(,O
48,O
h,O
),O
versus,O
VIP(-/-,O
),O
with,O
CYP,I-Entity
treatment,O
(,O
48,O
h,O
),O
.,O
CYP,I-Entity
treatment,O
significantly,O
(,O
p,O
<,O
or,O
=,O
0.001,O
),O
increased,O
expression,O
of,O
CXCL1,O
and,O
IL-1beta,O
in,O
the,O
urinary,O
bladder,O
of,O
WT,O
and,O
VIP(-/-,O
),O
mice,O
",",O
but,O
expression,O
in,O
VIP(-/-,O
),O
mice,O
with,O
CYP,I-Entity
treatment,O
was,O
significantly,O
(,O
p,O
<,O
or,O
=,O
0.001,O
),O
greater,O
(,O
4.2-,O
to,O
13-fold,O
increase,O
),O
than,O
that,O
observed,O
in,O
WT,O
urinary,O
bladder,O
(,O
3.6-,O
to,O
5-fold,O
increase,O
),O
.,O
The,O
data,O
suggest,O
that,O
in,O
VIP(-/-,O
),O
mice,O
with,O
bladder,B-Entity
inflammation,I-Entity
",",O
inflammatory,O
mediators,O
are,O
increased,O
above,O
that,O
observed,O
in,O
WT,O
with,O
CYP,I-Entity
.,O
This,O
shift,O
in,O
balance,O
may,O
contribute,O
to,O
increased,O
bladder,B-Entity
dysfunction,I-Entity
in,O
VIP(-/-,O
),O
mice,O
with,O
bladder,B-Entity
inflammation,I-Entity
and,O
altered,O
neurochemical,O
expression,O
in,O
micturition,O
pathways,O
.,O
Intraocular,O
pressure,O
in,O
patients,O
with,O
uveitis,I-Entity
treated,O
with,O
fluocinolone,B-Entity
acetonide,I-Entity
implants,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
the,O
incidence,O
and,O
management,O
of,O
elevated,B-Entity
intraocular,I-Entity
pressure,I-Entity
(,O
IOP,O
),O
in,O
patients,O
with,O
uveitis,I-Entity
treated,O
with,O
the,O
fluocinolone,B-Entity
acetonide,I-Entity
(,O
FA,I-Entity
),O
DESIGN,O
:,O
Pooled,O
data,O
from,O
3,O
multicenter,O
",",O
double,O
-,O
masked,O
",",O
randomized,O
",",O
controlled,O
",",O
phase,O
2b/3,O
clinical,O
trials,O
evaluating,O
the,O
safety,O
and,O
efficacy,O
of,O
the,O
0.59-mg,O
or,O
2.1-mg,O
FA,I-Entity
intravitreal,O
implant,O
or,O
standard,O
therapy,O
were,O
analyzed,O
.,O
The,O
rate,O
of,O
hypotony,I-Entity
(,O
IOP,O
<,O
/=,O
5,O
mm,O
Hg,O
),O
following,O
IOP,O
-,O
lowering,O
surgery,O
(,O
42.5%,O
),O
was,O
not,O
different,O
from,O
that,O
of,O
implanted,O
eyes,O
not,O
subjected,O
to,O
surgery,O
(,O
35.4%,O
),O
A,O
resurgence,O
of,O
interest,O
in,O
the,O
surgical,O
treatment,O
of,O
Parkinson,B-Entity
's,I-Entity
disease,I-Entity
(,O
PD,I-Entity
),O
came,O
with,O
the,O
rediscovery,O
of,O
posteroventral,O
pallidotomy,O
by,O
Laitinen,O
in,O
1985,O
.,O
Laitinen,O
's,O
procedure,O
improved,O
most,O
symptoms,O
in,O
drug,O
-,O
resistant,O
PD,I-Entity
",",O
which,O
engendered,O
wide,O
interest,O
in,O
the,O
neurosurgical,O
community,O
.,O
According,O
to,O
the,O
literature,O
pallidotomy,O
improves,O
the,O
"""",O
on,O
"""",O
symptoms,O
of,O
PD,I-Entity
",",O
such,O
as,O
dyskinesias,I-Entity
",",O
as,O
well,O
as,O
the,O
"""",O
off,O
"""",O
symptoms,O
",",O
such,O
as,O
rigidity,I-Entity
",",O
bradykinesia,I-Entity
",",O
and,O
on,O
-,O
off,O
fluctuations,O
.,O
Pallidal,O
stimulation,O
improves,O
bradykinesia,I-Entity
and,O
rigidity,I-Entity
to,O
a,O
minor,O
extent,O
;,O
however,O
",",O
its,O
strength,O
seems,O
to,O
be,O
in,O
improving,O
levodopa,I-Entity
-,O
induced,O
dyskinesias,I-Entity
.,O
Stimulation,O
often,O
produces,O
an,O
improvement,O
in,O
the,O
hyper-,B-Entity
or,I-Entity
dyskinetic,I-Entity
upper,O
limbs,O
",",O
but,O
increases,O
the,O
"""",O
freezing,O
"""",O
phenomenon,O
in,O
the,O
lower,O
limbs,O
at,O
the,O
same,O
time,O
.,O
Case,O
report,O
:,O
Dexatrim,I-Entity
(,O
Phenylpropanolamine,I-Entity
),O
as,O
a,O
cause,O
of,O
myocardial,B-Entity
infarction,I-Entity
.,O
Phenylpropanolamine,I-Entity
(,O
PPA,I-Entity
),O
is,O
a,O
sympathetic,O
amine,I-Entity
used,O
in,O
over,O
-,O
the,O
-,O
counter,O
cold,O
remedies,O
and,O
weight,O
-,O
control,O
preparations,O
worldwide,O
.,O
Its,O
use,O
has,O
been,O
associated,O
with,O
hypertensive,I-Entity
episodes,O
and,O
hemorrhagic,B-Entity
strokes,I-Entity
in,O
younger,O
women,O
.,O
Several,O
reports,O
have,O
linked,O
the,O
abuse,O
of,O
PPA,I-Entity
with,O
myocardial,B-Entity
injury,I-Entity
",",O
especially,O
when,O
overdose,I-Entity
is,O
involved,O
.,O
We,O
report,O
here,O
the,O
first,O
case,O
of,O
Dexatrim,I-Entity
(,O
PPA)-induced,I-Entity
myocardial,B-Entity
injury,I-Entity
in,O
a,O
young,O
woman,O
who,O
was,O
using,O
it,O
at,O
recommended,O
doses,O
for,O
weight,O
control,O
.,O
In,O
addition,O
",",O
we,O
review,O
the,O
7,O
other,O
cases,O
of,O
PPA,I-Entity
related,O
myocardial,B-Entity
injury,I-Entity
that,O
have,O
been,O
reported,O
so,O
far,O
.,O
Physicians,O
and,O
patients,O
should,O
be,O
alert,O
to,O
the,O
potential,O
cardiac,O
risk,O
associated,O
with,O
the,O
use,O
of,O
PPA,I-Entity
",",O
even,O
at,O
doses,O
generally,O
considered,O
to,O
be,O
safe,O
.,O
Risperidone,I-Entity
-,O
associated,O
",",O
benign,O
transient,O
visual,B-Entity
disturbances,I-Entity
in,O
schizophrenic,I-Entity
patients,O
with,O
a,O
past,O
history,O
of,O
LSD,I-Entity
abuse,O
.,O
Two,O
schizophrenic,I-Entity
patients,O
",",O
who,O
had,O
a,O
prior,O
history,O
of,O
LSD,I-Entity
abuse,O
and,O
who,O
had,O
previously,O
developed,O
EPS,I-Entity
with,O
classic,O
antipsychotics,O
",",O
were,O
successfully,O
treated,O
with,O
risperidone,I-Entity
.,O
They,O
both,O
reported,O
short,O
episodes,O
of,O
transient,O
visual,B-Entity
disturbances,I-Entity
",",O
which,O
appeared,O
immediately,O
after,O
starting,O
treatment,O
with,O
risperidone,I-Entity
.,O
This,O
imagery,O
resembled,O
visual,B-Entity
disturbances,I-Entity
previously,O
experienced,O
as,O
"""",O
flashbacks,O
"""",O
related,O
to,O
prior,O
LSD,I-Entity
consumption,O
.,O
Risperidone,I-Entity
administration,O
was,O
continued,O
and,O
the,O
visual,B-Entity
disturbances,I-Entity
gradually,O
wore,O
off,O
.,O
During,O
a,O
six,O
-,O
month,O
follow,O
-,O
up,O
period,O
",",O
there,O
was,O
no,O
recurrence,O
of,O
visual,B-Entity
disturbances,I-Entity
.,O
This,O
phenomenon,O
may,O
be,O
interpreted,O
as,O
a,O
benign,O
",",O
short,O
-,O
term,O
and,O
self,O
-,O
limiting,O
side,O
effect,O
which,O
does,O
not,O
contraindicate,O
the,O
use,O
of,O
risperidone,I-Entity
or,O
interfere,O
with,O
treatment,O
.,O
Activation,O
of,O
poly(ADP,B-Entity
-,I-Entity
ribose,I-Entity
),I-Entity
polymerase,O
contributes,O
to,O
development,O
of,O
doxorubicin,I-Entity
-,O
induced,O
heart,B-Entity
failure,I-Entity
.,O
Activation,O
of,O
the,O
nuclear,O
enzyme,O
poly(ADP,B-Entity
-,I-Entity
ribose,I-Entity
),I-Entity
polymerase,O
(,O
PARP,O
),O
by,O
oxidant,O
-,O
mediated,O
DNA,O
damage,O
is,O
an,O
important,O
pathway,O
of,O
cell,O
dysfunction,O
and,O
tissue,O
injury,O
in,O
conditions,O
associated,O
with,O
oxidative,O
stress,O
.,O
Increased,O
oxidative,O
stress,O
is,O
a,O
major,O
factor,O
implicated,O
in,O
the,O
cardiotoxicity,I-Entity
of,O
doxorubicin,I-Entity
(,O
DOX,I-Entity
),O
",",O
a,O
widely,O
used,O
antitumor,O
anthracycline,I-Entity
antibiotic,O
.,O
Thus,O
",",O
we,O
hypothesized,O
that,O
the,O
activation,O
of,O
PARP,O
may,O
contribute,O
to,O
the,O
DOX,I-Entity
-,O
induced,O
cardiotoxicity,I-Entity
.,O
Using,O
a,O
dual,O
approach,O
of,O
PARP-1,O
suppression,O
",",O
by,O
genetic,O
deletion,O
or,O
pharmacological,O
inhibition,O
with,O
the,O
phenanthridinone,O
PARP,O
inhibitor,O
PJ34,I-Entity
",",O
we,O
now,O
demonstrate,O
the,O
role,O
of,O
PARP,O
in,O
the,O
development,O
of,O
cardiac,B-Entity
dysfunction,I-Entity
induced,O
by,O
DOX,I-Entity
.,O
PARP-1+/+,O
and,O
PARP-1-/-,O
mice,O
received,O
a,O
single,O
injection,O
of,O
DOX,I-Entity
(,O
25,O
mg,O
/,O
kg,O
i.p,O
),O
.,O
Five,O
days,O
after,O
DOX,I-Entity
administration,O
",",O
left,O
ventricular,O
performance,O
was,O
significantly,O
depressed,O
in,O
PARP-1+/+,O
mice,O
",",O
but,O
only,O
to,O
a,O
smaller,O
extent,O
in,O
PARP-1-/-,O
ones,O
.,O
Similar,O
experiments,O
were,O
conducted,O
in,O
BALB,O
/,O
c,O
mice,O
treated,O
with,O
PJ34,I-Entity
or,O
vehicle,O
.,O
Treatment,O
with,O
a,O
PJ34,I-Entity
significantly,O
improved,O
cardiac,B-Entity
dysfunction,I-Entity
and,O
increased,O
the,O
survival,O
of,O
the,O
animals,O
.,O
In,O
addition,O
PJ34,I-Entity
significantly,O
reduced,O
the,O
DOX,I-Entity
-,O
induced,O
increase,O
in,O
the,O
serum,O
lactate,I-Entity
dehydrogenase,O
and,O
creatine,I-Entity
kinase,O
activities,O
but,O
not,O
metalloproteinase,O
activation,O
in,O
the,O
heart,O
.,O
Thus,O
",",O
PARP,O
activation,O
contributes,O
to,O
the,O
cardiotoxicity,I-Entity
of,O
DOX,I-Entity
.,O
PARP,O
inhibitors,O
may,O
exert,O
protective,O
effects,O
against,O
the,O
development,O
of,O
severe,O
cardiac,B-Entity
complications,I-Entity
associated,O
with,O
the,O
DOX,I-Entity
treatment,O
.,O
Fluconazole,I-Entity
-,O
induced,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
.,O
OBJECTIVE,O
:,O
To,O
present,O
a,O
case,O
of,O
fluconazole,I-Entity
-,O
associated,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
(,O
TDP,I-Entity
),O
and,O
discuss,O
fluconazole,I-Entity
's,O
role,O
in,O
causing,O
TDP,I-Entity
.,O
A,O
68-year,O
-,O
old,O
white,O
woman,O
with,O
Candida,O
glabrata,O
isolated,O
from,O
a,O
presacral,O
abscess,O
developed,O
TDP,I-Entity
eight,O
days,O
after,O
commencing,O
oral,O
fluconazole,I-Entity
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
TDP,I-Entity
",",O
including,O
coronary,B-Entity
artery,I-Entity
disease,I-Entity
",",O
cardiomyopathy,I-Entity
",",O
congestive,B-Entity
heart,I-Entity
failure,I-Entity
",",O
and,O
electrolyte,O
abnormalities,O
There,O
was,O
a,O
temporal,O
association,O
between,O
the,O
initiation,O
of,O
fluconazole,I-Entity
and,O
TDP,I-Entity
.,O
The,O
TDP,I-Entity
resolved,O
when,O
fluconazole,I-Entity
was,O
discontinued,O
;,O
however,O
",",O
the,O
patient,O
continued,O
to,O
have,O
premature,B-Entity
ventricular,I-Entity
contractions,I-Entity
and,O
nonsustained,O
ventricular,B-Entity
tachycardia,I-Entity
(,O
NSVT,I-Entity
),O
until,O
six,O
days,O
after,O
drug,O
cessation,O
DISCUSSION,O
:,O
Use,O
of,O
the,O
Naranjo,O
probability,O
scale,O
indicates,O
a,O
probable,O
relationship,O
between,O
the,O
use,O
of,O
fluconazole,I-Entity
and,O
the,O
development,O
of,O
TDP,I-Entity
.,O
The,O
possible,O
mechanism,O
is,O
depression,I-Entity
of,O
rapidly,O
activating,O
delayed,O
rectifier,O
potassium,I-Entity
currents,O
.,O
In,O
our,O
patient,O
",",O
there,O
was,O
no,O
other,O
etiology,O
identified,O
that,O
could,O
explain,O
QT,B-Entity
prolongation,I-Entity
or,O
TDP,I-Entity
The,O
complete,O
disappearance,O
of,O
NSVT,I-Entity
and,O
premature,B-Entity
ventricular,I-Entity
contractions,I-Entity
followed,O
by,O
normalization,O
of,O
QT,O
interval,O
after,O
the,O
drug,O
was,O
stopped,O
strongly,O
suggests,O
fluconazole,I-Entity
as,O
the,O
etiology,O
.,O
Clinicians,O
should,O
be,O
aware,O
that,O
fluconazole,I-Entity
",",O
even,O
at,O
low,O
doses,O
",",O
may,O
cause,O
prolongation,B-Entity
of,I-Entity
the,I-Entity
QT,I-Entity
interval,I-Entity
",",O
leading,O
to,O
TDP,I-Entity
.,O
Serial,O
electrocardiographic,O
monitoring,O
may,O
be,O
considered,O
when,O
fluconazole,I-Entity
is,O
administered,O
in,O
patients,O
who,O
are,O
at,O
risk,O
for,O
ventricular,B-Entity
arrhythmias,I-Entity
.,O
High,O
-,O
dose,O
methylprednisolone,I-Entity
may,O
do,O
more,O
harm,O
for,O
spinal,B-Entity
cord,I-Entity
injury,I-Entity
.,O
Because,O
of,O
the,O
National,O
Acute,O
Spinal,B-Entity
Cord,I-Entity
Injury,I-Entity
Studies,O
(,O
NASCIS,O
),O
",",O
high,O
-,O
dose,O
methylprednisolone,I-Entity
became,O
the,O
standard,O
of,O
care,O
for,O
the,O
acute,O
spinal,B-Entity
cord,I-Entity
injury,I-Entity
.,O
In,O
the,O
NASCIS,O
",",O
there,O
was,O
no,O
mention,O
regarding,O
the,O
possibility,O
of,O
acute,O
corticosteroid,I-Entity
myopathy,I-Entity
that,O
high,O
-,O
dose,O
methylprednisolone,I-Entity
may,O
cause,O
.,O
The,O
dosage,O
of,O
methylprednisolone,I-Entity
recommended,O
by,O
the,O
NASCIS,O
3,O
is,O
the,O
highest,O
dose,O
of,O
steroids,I-Entity
ever,O
being,O
used,O
during,O
a,O
2-day,O
period,O
for,O
any,O
clinical,O
condition,O
.,O
We,O
hypothesize,O
that,O
it,O
may,O
cause,O
some,O
damage,B-Entity
to,I-Entity
the,I-Entity
muscle,I-Entity
of,O
spinal,B-Entity
cord,I-Entity
injury,I-Entity
patients,O
.,O
Further,O
",",O
steroid,I-Entity
myopathy,I-Entity
recovers,O
naturally,O
and,O
the,O
neurological,O
improvement,O
shown,O
in,O
the,O
NASCIS,O
may,O
be,O
just,O
a,O
recording,O
of,O
this,O
natural,O
motor,O
recovery,O
from,O
the,O
steroid,I-Entity
myopathy,I-Entity
",",O
instead,O
of,O
any,O
protection,O
that,O
methylprednisolone,I-Entity
offers,O
to,O
the,O
spinal,B-Entity
cord,I-Entity
injury,I-Entity
.,O
To,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
discussion,O
considering,O
the,O
possibility,O
that,O
the,O
methylprednisolone,I-Entity
recommended,O
by,O
NASCIS,O
may,O
cause,O
acute,O
corticosteroid,I-Entity
myopathy,I-Entity
.,O
The,O
pharmacological,O
response,O
to,O
drugs,O
that,O
act,O
on,O
the,O
cholinergic,O
system,O
of,O
the,O
iris,O
has,O
been,O
used,O
to,O
predict,O
deficits,O
in,O
central,O
cholinergic,O
functioning,O
due,O
to,O
diseases,O
such,O
as,O
Alzheimer,B-Entity
's,I-Entity
disease,I-Entity
",",O
yet,O
correlations,O
between,O
central,O
and,O
peripheral,O
responses,O
have,O
not,O
been,O
properly,O
studied,O
.,O
This,O
study,O
assessed,O
the,O
effect,O
of,O
normal,O
aging,O
on,O
(,O
1,O
),O
the,O
tropicamide,I-Entity
-,O
induced,O
increase,O
in,O
pupil,O
diameter,O
",",O
and,O
(,O
2,O
),O
the,O
reversal,O
of,O
this,O
effect,O
with,O
pilocarpine,I-Entity
.,O
Scopolamine,I-Entity
was,O
used,O
as,O
a,O
positive,O
control,O
to,O
detect,O
age,O
-,O
dependent,O
changes,O
in,O
central,O
cholinergic,O
functioning,O
in,O
the,O
elderly,O
.,O
In,O
1,O
session,O
",",O
tropicamide,I-Entity
(,O
20,O
microL,O
",",O
0.01%,O
),O
was,O
administered,O
to,O
one,O
eye,O
and,O
placebo,O
to,O
the,O
other,O
.,O
In,O
another,O
session,O
",",O
tropicamide,I-Entity
(,O
20,O
microL,O
",",O
0.01%,O
),O
was,O
administered,O
to,O
both,O
eyes,O
",",O
followed,O
23,O
minutes,O
later,O
by,O
the,O
application,O
of,O
pilocarpine,I-Entity
(,O
20,O
microL,O
",",O
0.1%,O
),O
to,O
one,O
eye,O
and,O
placebo,O
to,O
the,O
other,O
.,O
In,O
2,O
separate,O
sessions,O
",",O
a,O
single,O
dose,O
of,O
scopolamine,I-Entity
(,O
0.5,O
mg,O
",",O
intravenously,O
),O
or,O
placebo,O
was,O
administered,O
",",O
and,O
the,O
effects,O
on,O
word,O
recall,O
were,O
measured,O
using,O
the,O
Buschke,O
Selective,O
Reminding,O
Test,O
over,O
2,O
hours,O
.,O
Pupil,O
size,O
at,O
time,O
points,O
after,O
administration,O
of,O
tropicamide,I-Entity
and,O
pilocarpine,I-Entity
;,O
scopolamine,I-Entity
-,O
induced,O
impairment,B-Entity
in,I-Entity
word,I-Entity
recall,I-Entity
.,O
There,O
was,O
no,O
significant,O
difference,O
between,O
elderly,O
and,O
young,O
volunteers,O
in,O
pupillary,O
response,O
to,O
tropicamide,I-Entity
at,O
any,O
time,O
point,O
(,O
p,O
>,O
0.05,O
),O
.,O
The,O
elderly,O
group,O
had,O
a,O
significantly,O
greater,O
pilocarpine,I-Entity
-,O
induced,O
net,O
decrease,O
in,O
pupil,O
size,O
85,O
",",O
125,O
",",O
165,O
and,O
215,O
minutes,O
after,O
administration,O
",",O
compared,O
with,O
the,O
young,O
group,O
(,O
p,O
<,O
0.05,O
),O
.,O
Compared,O
with,O
the,O
young,O
group,O
",",O
the,O
elderly,O
group,O
had,O
greater,O
scopolamine,I-Entity
-,O
induced,O
impairment,B-Entity
in,I-Entity
word,I-Entity
recall,I-Entity
60,O
",",O
90,O
and,O
120,O
minutes,O
after,O
administration,O
(,O
CONCLUSION,O
:,O
There,O
is,O
an,O
age,O
-,O
related,O
pupillary,O
response,O
to,O
pilocarpine,I-Entity
that,O
is,O
not,O
found,O
with,O
tropicamide,I-Entity
.,O
Thus,O
",",O
pilocarpine,I-Entity
may,O
be,O
useful,O
to,O
assess,O
variations,O
in,O
central,O
cholinergic,O
function,O
in,O
elderly,O
patients,O
.,O
Acetazolamide,I-Entity
-,O
induced,O
Gerstmann,B-Entity
syndrome,I-Entity
.,O
Acute,O
confusion,I-Entity
induced,O
by,O
acetazolamide,I-Entity
is,O
a,O
well,O
known,O
adverse,O
drug,O
reaction,O
in,O
patients,O
with,O
renal,B-Entity
impairment,I-Entity
.,O
We,O
report,O
a,O
case,O
of,O
acetazolamide,I-Entity
-,O
induced,O
Gerstmann,B-Entity
syndrome,I-Entity
in,O
a,O
patient,O
with,O
normal,O
renal,O
function,O
",",O
to,O
highlight,O
predisposing,O
factors,O
that,O
are,O
frequently,O
overlooked,O
.,O
Hypomania,I-Entity
-,O
like,O
syndrome,O
induced,O
by,O
olanzapine,I-Entity
.,O
We,O
report,O
a,O
female,O
patient,O
with,O
a,O
diagnosis,O
of,O
a,O
not,O
otherwise,O
specified,O
psychotic,B-Entity
disorder,I-Entity
(,O
DSM,O
-,O
IV,O
),O
who,O
developed,O
hypomania,I-Entity
shortly,O
after,O
the,O
introduction,O
of,O
olanzapine,I-Entity
treatment,O
.,O
Neutrophil,O
superoxide,I-Entity
and,O
hydrogen,B-Entity
peroxide,I-Entity
production,O
in,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
.,O
Defects,O
in,O
superoxide,I-Entity
and,O
hydrogen,B-Entity
peroxide,I-Entity
production,O
may,O
be,O
implicated,O
in,O
the,O
high,O
incidence,O
of,O
bacterial,B-Entity
infections,I-Entity
in,O
patients,O
with,O
acute,B-Entity
liver,I-Entity
failure,I-Entity
(,O
ALF,I-Entity
),O
.,O
In,O
the,O
present,O
study,O
",",O
oxygen,I-Entity
radical,O
production,O
in,O
patients,O
with,O
ALF,I-Entity
due,O
to,O
paracetamol,I-Entity
overdose,I-Entity
was,O
compared,O
with,O
that,O
of,O
healthy,O
volunteers,O
.,O
Neutrophils,O
from,O
14,O
ALF,I-Entity
patients,O
were,O
stimulated,O
via,O
the,O
complement,O
receptors,O
using,O
zymosan,O
opsonized,O
with,O
ALF,I-Entity
or,O
control,O
serum,O
.,O
Superoxide,I-Entity
and,O
hydrogen,B-Entity
peroxide,I-Entity
production,O
by,O
ALF,I-Entity
neutrophils,O
stimulated,O
with,O
zymosan,O
opsonized,O
with,O
ALF,I-Entity
serum,O
was,O
significantly,O
reduced,O
compared,O
with,O
the,O
control,O
subjects,O
(,O
P,O
<,O
0.01,O
),O
.,O
Superoxide,I-Entity
and,O
hydrogen,B-Entity
peroxide,I-Entity
production,O
in,O
neutrophils,O
stimulated,O
with,O
formyl,B-Entity
-,I-Entity
methionyl,I-Entity
-,I-Entity
leucyl,I-Entity
-,I-Entity
phenylalanine,I-Entity
(,O
fMLP,I-Entity
),O
from,O
a,O
further,O
18,O
ALF,I-Entity
patients,O
was,O
unaffected,O
compared,O
with,O
control,O
neutrophils,O
.,O
Serum,O
C3,O
complement,O
levels,O
were,O
significantly,O
reduced,O
in,O
ALF,I-Entity
patients,O
compared,O
with,O
control,O
subjects,O
(,O
P,O
<,O
0.0005,O
),O
.,O
These,O
results,O
demonstrate,O
a,O
neutrophil,O
defect,O
in,O
ALF,I-Entity
due,O
to,O
paracetamol,I-Entity
overdose,I-Entity
",",O
that,O
is,O
complement,O
dependent,O
but,O
independent,O
of,O
serum,O
complement,O
",",O
possibly,O
connected,O
to,O
the,O
complement,O
receptor,O
.,O
Absence,O
of,O
effect,O
of,O
sertraline,I-Entity
on,O
time,O
-,O
based,O
sensitization,O
of,O
cognitive,B-Entity
impairment,I-Entity
with,O
haloperidol,I-Entity
.,O
This,O
double,O
-,O
blind,O
",",O
randomized,O
",",O
placebo,O
-,O
controlled,O
study,O
evaluated,O
the,O
effects,O
of,O
haloperidol,I-Entity
alone,O
and,O
haloperidol,I-Entity
plus,O
sertraline,I-Entity
on,O
cognitive,O
and,O
psychomotor,O
function,O
in,O
24,O
healthy,O
male,O
subjects,O
.,O
All,O
subjects,O
received,O
placebo,O
on,O
Day,O
1,O
and,O
haloperidol,I-Entity
2,O
mg,O
on,O
Days,O
2,O
and,O
25,O
.,O
From,O
Days,O
9,O
to,O
25,O
",",O
subjects,O
were,O
randomly,O
assigned,O
to,O
either,O
sertraline,I-Entity
(,O
12,O
subjects,O
),O
or,O
placebo,O
(,O
12,O
subjects,O
),O
;,O
the,O
sertraline,I-Entity
dose,O
was,O
titrated,O
from,O
50,O
to,O
200,O
mg,O
/,O
day,O
from,O
Days,O
9,O
to,O
16,O
",",O
and,O
remained,O
at,O
200,O
mg,O
/,O
day,O
for,O
the,O
final,O
10,O
days,O
of,O
the,O
drug,O
administration,O
period,O
.,O
RESULTS,O
:,O
Impairment,B-Entity
of,I-Entity
cognitive,I-Entity
function,I-Entity
was,O
observed,O
6,O
to,O
8,O
hours,O
after,O
administration,O
of,O
haloperidol,I-Entity
on,O
Day,O
2,O
but,O
was,O
not,O
evident,O
23,O
hours,O
after,O
dosing,O
.,O
When,O
single,O
-,O
dose,O
haloperidol,I-Entity
was,O
given,O
again,O
25,O
days,O
later,O
",",O
greater,O
impairment,O
with,O
earlier,O
onset,O
was,O
noted,O
in,O
several,O
tests,O
in,O
both,O
treatment,O
groups,O
",",O
suggesting,O
enhancement,O
of,O
this,O
effect,O
.,O
There,O
was,O
no,O
indication,O
that,O
sertraline,I-Entity
exacerbated,O
the,O
impairment,O
produced,O
by,O
haloperidol,I-Entity
since,O
an,O
equivalent,O
effect,O
also,O
occurred,O
in,O
the,O
placebo,O
group,O
.,O
Three,O
subjects,O
(,O
2,O
on,O
sertraline,I-Entity
and,O
1,O
on,O
placebo,O
),O
withdrew,O
from,O
the,O
study,O
because,O
of,O
side,O
effects,O
.,O
The,O
side,O
effect,O
profiles,O
of,O
sertraline,I-Entity
and,O
of,O
placebo,O
were,O
similar,O
.,O
Haloperidol,I-Entity
produced,O
a,O
clear,O
profile,O
of,O
cognitive,B-Entity
impairment,I-Entity
that,O
was,O
not,O
worsened,O
by,O
concomitant,O
sertraline,I-Entity
administration,O
.,O
Ciprofloxacin,I-Entity
-,O
induced,O
nephrotoxicity,I-Entity
in,O
patients,O
with,O
cancer,I-Entity
.,O
Nephrotoxicity,I-Entity
associated,O
with,O
ciprofloxacin,I-Entity
is,O
uncommon,O
.,O
Five,O
patients,O
with,O
cancer,I-Entity
who,O
developed,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
that,O
followed,O
treatment,O
with,O
ciprofloxacin,I-Entity
are,O
described,O
and,O
an,O
additional,O
15,O
cases,O
reported,O
in,O
the,O
literature,O
are,O
reviewed,O
.,O
Other,O
than,O
elevation,O
of,O
serum,O
creatinine,I-Entity
levels,O
",",O
characteristic,O
clinical,O
manifestations,O
and,O
abnormal,O
laboratory,O
findings,O
are,O
not,O
frequently,O
present,O
.,O
Allergic,O
interstitial,B-Entity
nephritis,I-Entity
is,O
believed,O
to,O
be,O
the,O
underlying,O
pathological,O
-,O
process,O
.,O
An,O
improvement,O
in,O
renal,O
function,O
that,O
followed,O
the,O
discontinuation,O
of,O
the,O
offending,O
antibiotic,O
supports,O
the,O
presumptive,O
diagnosis,O
of,O
ciprofloxacin,I-Entity
-,O
induced,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
.,O
Case,O
report,O
:,O
pentamidine,I-Entity
and,O
polymorphic,O
ventricular,B-Entity
tachycardia,I-Entity
revisited,O
.,O
Pentamidine,B-Entity
isethionate,I-Entity
has,O
been,O
associated,O
with,O
ventricular,B-Entity
tachyarrhythmias,I-Entity
",",O
including,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
.,O
Pentamidine,I-Entity
-,O
induced,O
torsade,B-Entity
de,I-Entity
pointes,I-Entity
may,O
be,O
related,O
to,O
serum,O
magnesium,I-Entity
levels,O
and,O
hypomagnesemia,I-Entity
may,O
synergistically,O
induce,O
torsade,O
.,O
Torsade,B-Entity
de,I-Entity
pointes,I-Entity
occurred,O
after,O
an,O
average,O
of,O
10,O
days,O
of,O
treatment,O
with,O
pentamidine,I-Entity
.,O
In,O
these,O
patients,O
",",O
no,O
other,O
acute,O
side,O
effects,O
of,O
pentamidine,I-Entity
were,O
observed,O
.,O
Torsade,B-Entity
de,I-Entity
pointes,I-Entity
can,O
be,O
treated,O
when,O
recognized,O
early,O
",",O
possibly,O
without,O
discontinuation,O
of,O
pentamidine,I-Entity
.,O
When,O
QTc,B-Entity
interval,I-Entity
prolongation,I-Entity
is,O
observed,O
",",O
early,O
magnesium,I-Entity
supplementation,O
is,O
advocated,O
.,O
Time,O
dependence,O
of,O
plasma,O
malondialdehyde,I-Entity
",",O
oxypurines,I-Entity
",",O
and,O
nucleosides,I-Entity
during,O
incomplete,O
cerebral,B-Entity
ischemia,I-Entity
in,O
the,O
rat,O
.,O
Incomplete,O
cerebral,B-Entity
ischemia,I-Entity
(,O
30,O
min,O
),O
was,O
induced,O
in,O
the,O
rat,O
by,O
bilaterally,O
clamping,O
the,O
common,O
carotid,O
arteries,O
.,O
Peripheral,O
venous,O
blood,O
samples,O
were,O
withdrawn,O
from,O
the,O
femoral,O
vein,O
four,O
times,O
(,O
once,O
every,O
5,O
min,O
),O
before,O
ischemia,I-Entity
(,O
0,O
time,O
),O
and,O
5,O
",",O
15,O
",",O
and,O
30,O
min,O
after,O
ischemia,I-Entity
.,O
Plasma,O
extracts,O
were,O
analyzed,O
by,O
a,O
highly,O
sensitive,O
high,O
-,O
performance,O
liquid,O
chromatographic,O
method,O
for,O
the,O
direct,O
determination,O
of,O
malondialdehyde,I-Entity
",",O
oxypurines,I-Entity
",",O
and,O
nucleosides,I-Entity
.,O
During,O
ischemia,I-Entity
",",O
a,O
time,O
-,O
dependent,O
increase,O
of,O
plasma,O
oxypurines,I-Entity
and,O
nucleosides,I-Entity
was,O
observed,O
.,O
Plasma,O
malondialdehyde,I-Entity
",",O
which,O
was,O
present,O
in,O
minimal,O
amount,O
at,O
zero,O
time,O
(,O
0.058,O
mumol,O
/,O
liter,O
plasma,O
;,O
SD,O
0.015,O
),O
",",O
increased,O
after,O
5,O
min,O
of,O
ischemia,I-Entity
",",O
resulting,O
in,O
a,O
fivefold,O
increase,O
after,O
30,O
min,O
of,O
carotid,O
occlusion,O
(,O
0.298,O
mumol,O
/,O
liter,O
plasma,O
;,O
SD,O
0.078,O
),O
.,O
Increased,O
plasma,O
malondialdehyde,I-Entity
was,O
also,O
recorded,O
in,O
two,O
other,O
groups,O
of,O
animals,O
subjected,O
to,O
the,O
same,O
experimental,O
model,O
",",O
one,O
receiving,O
20,O
mg,O
/,O
kg,O
b.w,O
.,O
of,O
the,O
cyclooxygenase,O
inhibitor,O
acetylsalicylate,I-Entity
intravenously,O
immediately,O
before,O
ischemia,I-Entity
",",O
the,O
other,O
receiving,O
650,O
micrograms,O
/,O
kg,O
b.w,O
.,O
of,O
the,O
hypotensive,I-Entity
drug,O
nitroprusside,I-Entity
at,O
a,O
flow,O
rate,O
of,O
103,O
microliters,O
/,O
min,O
intravenously,O
during,O
ischemia,I-Entity
",",O
although,O
in,O
this,O
latter,O
group,O
malondialdehyde,I-Entity
was,O
significantly,O
higher,O
.,O
The,O
present,O
data,O
indicate,O
that,O
the,O
determination,O
of,O
malondialdehyde,I-Entity
",",O
oxypurines,I-Entity
",",O
and,O
nucleosides,I-Entity
in,O
peripheral,O
blood,O
",",O
may,O
be,O
used,O
to,O
monitor,O
the,O
metabolic,O
alterations,O
of,O
tissues,O
occurring,O
during,O
ischemic,I-Entity
phenomena.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Cholinergic,O
toxicity,I-Entity
resulting,O
from,O
ocular,O
instillation,O
of,O
echothiophate,B-Entity
iodide,I-Entity
eye,O
drops,O
.,O
A,O
patient,O
developed,O
a,O
severe,O
cholinergic,O
syndrome,O
from,O
the,O
use,O
of,O
echothiophate,B-Entity
iodide,I-Entity
ophthalmic,O
drops,O
",",O
presented,O
with,O
profound,O
muscle,B-Entity
weakness,I-Entity
and,O
was,O
initially,O
given,O
the,O
diagnosis,O
of,O
myasthenia,B-Entity
gravis,I-Entity
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
in,O
high,O
dose,O
carboplatin,I-Entity
chemotherapy,O
.,O
Carboplatin,I-Entity
has,O
been,O
reported,O
to,O
cause,O
acute,B-Entity
renal,I-Entity
failure,I-Entity
when,O
administered,O
in,O
high,O
doses,O
to,O
adult,O
patients,O
.,O
We,O
report,O
a,O
4,O
1/2-year,O
-,O
old,O
girl,O
who,O
was,O
treated,O
with,O
high,O
-,O
dose,O
carboplatin,I-Entity
for,O
metastatic,O
parameningeal,O
embryonal,B-Entity
rhabdomyosarcoma,I-Entity
.,O
Acute,B-Entity
renal,I-Entity
failure,I-Entity
developed,O
followed,O
by,O
a,O
slow,O
partial,O
recovery,O
of,O
renal,O
function,O
.,O
Endometrial,B-Entity
carcinoma,I-Entity
after,O
Hodgkin,B-Entity
disease,I-Entity
in,O
childhood,O
.,O
A,O
34-year,O
-,O
old,O
patient,O
developed,O
metastic,O
endometrial,B-Entity
carcinoma,I-Entity
after,O
Hodgkin,B-Entity
disease,I-Entity
in,O
childhood,O
.,O
She,O
had,O
ovarian,B-Entity
failure,I-Entity
after,O
abdominal,O
irradiation,O
and,O
chemotherapy,O
for,O
Hodgkin,B-Entity
disease,I-Entity
",",O
and,O
received,O
exogenous,O
estrogens,I-Entity
",",O
a,O
treatment,O
implicated,O
in,O
the,O
development,O
of,O
endometrial,B-Entity
cancer,I-Entity
in,O
menopausal,O
women,O
.,O
Young,O
women,O
on,O
replacement,O
estrogens,I-Entity
for,O
ovarian,B-Entity
failure,I-Entity
after,O
cancer,I-Entity
therapy,O
may,O
also,O
have,O
increased,O
risk,O
of,O
endometrial,B-Entity
carcinoma,I-Entity
and,O
should,O
be,O
examined,O
periodically,O
.,O
Induction,O
of,O
the,O
obstructive,B-Entity
sleep,I-Entity
apnea,I-Entity
syndrome,I-Entity
in,O
a,O
woman,O
by,O
exogenous,O
androgen,I-Entity
administration,O
.,O
We,O
documented,O
airway,O
occlusion,O
during,O
sleep,O
and,O
an,O
abnormally,O
high,O
supraglottic,O
resistance,O
while,O
awake,O
in,O
a,O
54-yr,O
-,O
old,O
woman,O
who,O
had,O
developed,O
physical,O
changes,O
and,O
the,O
syndrome,B-Entity
of,I-Entity
obstructive,I-Entity
sleep,I-Entity
apnea,I-Entity
while,O
being,O
administered,O
exogenous,O
androgens,I-Entity
.,O
When,O
the,O
androgens,I-Entity
were,O
withdrawn,O
",",O
the,O
patient,O
's,O
physical,O
changes,O
",",O
symptoms,O
",",O
sleep,O
study,O
",",O
and,O
supraglottic,O
resistance,O
all,O
returned,O
to,O
normal,O
.,O
A,O
rechallenge,O
with,O
androgen,I-Entity
produced,O
symptoms,O
of,O
obstructive,B-Entity
sleep,I-Entity
apnea,I-Entity
that,O
abated,O
upon,O
withdrawal,O
of,O
the,O
hormone,O
.,O
Previous,O
reports,O
have,O
favored,O
a,O
role,O
of,O
androgens,I-Entity
in,O
the,O
pathogenesis,O
of,O
sleep,B-Entity
apnea,I-Entity
.,O
Structural,O
and,O
functional,O
measurements,O
indicate,O
that,O
androgens,I-Entity
exert,O
a,O
permissive,O
or,O
necessary,O
action,O
on,O
the,O
structural,O
configuration,O
of,O
the,O
oropharynx,O
that,O
predisposes,O
to,O
obstruction,O
during,O
sleep,O
.,O
Development,O
of,O
the,O
obstructive,B-Entity
sleep,I-Entity
apnea,I-Entity
syndrome,I-Entity
must,O
be,O
considered,O
a,O
possible,O
side,O
effect,O
of,O
androgen,I-Entity
therapy,O
.,O
Effect,O
of,O
captopril,I-Entity
on,O
pre,O
-,O
existing,O
and,O
aminonucleoside,I-Entity
-,O
induced,O
proteinuria,I-Entity
in,O
spontaneously,O
hypertensive,I-Entity
rats,O
.,O
Proteinuria,I-Entity
is,O
a,O
side,O
effect,O
of,O
captopril,I-Entity
treatment,O
in,O
hypertensive,I-Entity
patients,O
.,O
The,O
possibility,O
of,O
reproducing,O
the,O
same,O
renal,B-Entity
abnormality,I-Entity
with,O
captopril,I-Entity
was,O
examined,O
in,O
SHR,O
.,O
Oral,O
administration,O
of,O
captopril,I-Entity
at,O
100,O
mg,O
/,O
kg,O
for,O
14,O
days,O
failed,O
to,O
aggravate,O
proteinuria,I-Entity
pre,O
-,O
existing,O
in,O
SHR,O
.,O
Also,O
",",O
captopril,I-Entity
treatment,O
failed,O
to,O
potentiate,O
or,O
facilitate,O
development,O
of,O
massive,O
proteinuria,I-Entity
invoked,O
by,O
puromycin,B-Entity
aminonucleoside,I-Entity
in,O
SHR,O
.,O
Captopril,I-Entity
had,O
little,O
or,O
no,O
demonstrable,O
effects,O
on,O
serum,O
electrolyte,O
concentrations,O
",",O
excretion,O
of,O
urine,O
",",O
sodium,I-Entity
and,O
potassium,I-Entity
",",O
endogenous,O
creatinine,I-Entity
clearance,O
",",O
body,O
weight,O
",",O
and,O
food,O
and,O
water,O
consumption,O
.,O
However,O
",",O
ketone,I-Entity
bodies,O
were,O
consistently,O
present,O
in,O
urine,O
and,O
several,O
lethalities,O
occurred,O
during,O
multiple,O
dosing,O
of,O
captopril,I-Entity
in,O
SHR,O
.,O
Epileptogenic,O
properties,O
of,O
enflurane,I-Entity
and,O
their,O
clinical,O
interpretation,O
.,O
Three,O
cases,O
of,O
EEG,O
changes,O
induced,O
by,O
single,O
exposure,O
to,O
enflurane,I-Entity
anesthesia,O
are,O
reported,O
.,O
In,O
one,O
patient,O
",",O
enflurane,I-Entity
administered,O
during,O
a,O
donor,O
nephrectomy,O
resulted,O
in,O
unexpected,O
partial,O
motor,O
seizures,I-Entity
.,O
Until,O
the,O
cause,O
of,O
the,O
seizures,I-Entity
was,O
correctly,O
identified,O
",",O
the,O
patient,O
was,O
inappropriately,O
treated,O
with,O
anticonvulsants,O
.,O
Two,O
other,O
patients,O
suffered,O
from,O
partial,O
",",O
complex,O
and,O
generalized,O
seizures,I-Entity
uncontrolled,O
by,O
medication,O
.,O
Epileptic,I-Entity
foci,O
delineated,O
and,O
activated,O
by,O
enflurane,I-Entity
were,O
surgically,O
ablated,O
and,O
the,O
patients,O
are,O
now,O
seizure,I-Entity
-,O
free,O
.,O
Previous,O
exposures,O
to,O
enflurane,I-Entity
have,O
to,O
be,O
disclosed,O
to,O
avoid,O
mistakes,O
in,O
clinical,O
interpretation,O
of,O
the,O
EEG,O
.,O
On,O
the,O
other,O
hand,O
",",O
enflurane,I-Entity
may,O
prove,O
to,O
be,O
a,O
safe,O
fast,O
acting,O
activator,O
of,O
epileptic,I-Entity
foci,O
during,O
corticography,O
or,O
depth,O
electrode,O
intraoperative,O
recordings,O
.,O
Reversible,O
cerebral,B-Entity
lesions,I-Entity
associated,O
with,O
tiazofurin,I-Entity
usage,O
:,O
MR,O
demonstration,O
.,O
Tiazofurin,I-Entity
is,O
an,O
experimental,O
chemotherapeutic,O
agent,O
currently,O
undergoing,O
clinical,O
evaluation,O
.,O
We,O
report,O
our,O
results,O
with,O
magnetic,O
resonance,O
(,O
MR,O
),O
in,O
demonstrating,O
reversible,O
cerebral,B-Entity
abnormalities,I-Entity
concurrent,O
with,O
the,O
use,O
of,O
this,O
drug,O
.,O
Antagonism,O
of,O
diazepam,I-Entity
-,O
induced,O
sedative,O
effects,O
by,O
Ro15,B-Entity
-,I-Entity
1788,I-Entity
in,O
patients,O
after,O
surgery,O
under,O
lumbar,O
epidural,O
block,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
assess,O
the,O
efficacy,O
of,O
Ro15,B-Entity
-,I-Entity
1788,I-Entity
and,O
a,O
placebo,O
in,O
reversing,O
diazepam,I-Entity
-,O
induced,O
effects,O
after,O
surgery,O
under,O
epidural,O
block,O
",",O
and,O
to,O
evaluate,O
the,O
local,O
tolerance,O
and,O
general,O
safety,O
of,O
Ro15,B-Entity
-,I-Entity
1788,I-Entity
.,O
Fifty,O
-,O
seven,O
patients,O
were,O
sedated,O
with,O
diazepam,I-Entity
for,O
surgery,O
under,O
epidural,O
anaesthesia,O
.,O
Antagonism,O
of,O
diazepam,I-Entity
-,O
induced,O
effects,O
by,O
Ro15,B-Entity
-,I-Entity
1788,I-Entity
was,O
investigated,O
postoperatively,O
in,O
a,O
double,O
-,O
blind,O
placebo,O
-,O
controlled,O
trial,O
.,O
The,O
patient,O
's,O
subjective,O
assessment,O
of,O
mood,O
rating,O
",",O
an,O
objective,O
test,O
of,O
performance,O
",",O
a,O
test,O
for,O
amnesia,I-Entity
",",O
and,O
vital,O
signs,O
were,O
recorded,O
for,O
up,O
to,O
300,O
min,O
after,O
administration,O
of,O
the,O
trial,O
drug,O
.,O
No,O
significant,O
differences,O
between,O
the,O
two,O
groups,O
were,O
observed,O
for,O
mood,O
rating,O
",",O
amnesia,I-Entity
",",O
or,O
vital,O
signs,O
.,O
The,O
Ro15,B-Entity
-,I-Entity
1788,I-Entity
group,O
showed,O
a,O
significant,O
improvement,O
in,O
the,O
performance,O
test,O
up,O
to,O
120,O
min,O
after,O
administration,O
of,O
the,O
drug,O
.,O
Enhanced,O
stimulus,O
-,O
induced,O
neurotransmitter,O
overflow,O
in,O
epinephrine,I-Entity
-,O
induced,O
hypertensive,I-Entity
rats,O
is,O
not,O
mediated,O
by,O
prejunctional,O
beta,O
-,O
adrenoceptor,O
activation,O
.,O
The,O
present,O
study,O
examines,O
the,O
effect,O
of,O
6-day,O
epinephrine,I-Entity
treatment,O
(,O
100,O
micrograms,O
/,O
kg,O
per,O
h,O
",",O
s.c,O
.,O
),O
endogenous,O
neurotransmitter,O
overflow,O
from,O
the,O
isolated,O
perfused,O
kidney,O
of,O
vehicle-,O
and,O
epinephrine,I-Entity
-,O
treated,O
rats,O
.,O
Renal,O
catecholamine,I-Entity
stores,O
and,O
stimulus,O
-,O
induced,O
overflow,O
in,O
the,O
vehicle,O
-,O
treated,O
group,O
consisted,O
of,O
norepinephrine,I-Entity
only,O
.,O
However,O
",",O
epinephrine,I-Entity
treatment,O
resulted,O
in,O
the,O
incorporation,O
of,O
epinephrine,I-Entity
into,O
renal,O
catecholamine,I-Entity
stores,O
such,O
that,O
approximately,O
40%,O
of,O
the,O
catecholamine,I-Entity
present,O
was,O
epinephrine,I-Entity
while,O
the,O
norepinephrine,I-Entity
content,O
was,O
reduced,O
by,O
a,O
similar,O
degree,O
.,O
Total,O
tissue,O
catecholamine,I-Entity
content,O
of,O
the,O
kidney,O
on,O
a,O
molar,O
basis,O
was,O
unchanged,O
.,O
Stimulus,O
-,O
induced,O
fractional,O
overflow,O
of,O
neurotransmitter,O
from,O
the,O
epinephrine,I-Entity
-,O
treated,O
kidneys,O
was,O
approximately,O
twice,O
normal,O
and,O
consisted,O
of,O
both,O
norepinephrine,I-Entity
and,O
epinephrine,I-Entity
in,O
proportions,O
similar,O
to,O
those,O
found,O
in,O
the,O
kidney,O
.,O
Propranolol,I-Entity
had,O
no,O
effect,O
on,O
stimulus,O
-,O
induced,O
overflow,O
in,O
either,O
group,O
.,O
Phentolamine,I-Entity
increased,O
stimulus,O
-,O
induced,O
overflow,O
in,O
both,O
groups,O
although,O
the,O
increment,O
in,O
overflow,O
was,O
greater,O
in,O
the,O
epinephrine,I-Entity
-,O
treated,O
group,O
.,O
In,O
conclusion,O
",",O
chronic,O
epinephrine,I-Entity
treatment,O
results,O
in,O
enhanced,O
fractional,O
neurotransmitter,O
overflow,O
.,O
Furthermore,O
",",O
data,O
obtained,O
with,O
phentolamine,I-Entity
alone,O
do,O
not,O
suggest,O
alpha,O
-,O
adrenoceptor,O
desensitization,O
as,O
the,O
cause,O
of,O
the,O
enhanced,O
neurotransmitter,O
overflow,O
after,O
epinephrine,I-Entity
treatment,O
.,O
Ocular,O
manifestations,O
of,O
juvenile,B-Entity
rheumatoid,I-Entity
arthritis,I-Entity
.,O
We,O
followed,O
210,O
cases,O
of,O
juvenile,B-Entity
rheumatoid,I-Entity
arthritis,I-Entity
closely,O
for,O
eleven,O
years,O
.,O
Thirty,O
-,O
six,O
of,O
the,O
210,O
patients,O
(,O
17.2%,O
),O
developed,O
iridocyclitis,I-Entity
.,O
Iridocyclitis,I-Entity
was,O
seen,O
most,O
frequently,O
in,O
young,O
female,O
patients,O
(,O
0,O
to,O
4,O
years,O
),O
with,O
the,O
monoarticular,O
or,O
pauciatricular,O
form,O
of,O
the,O
arthritis,I-Entity
.,O
However,O
",",O
30%,O
of,O
the,O
patients,O
developed,O
uveitis,I-Entity
after,O
16,O
years,O
of,O
age,O
.,O
Although,O
61%,O
of,O
patients,O
had,O
a,O
noncontributory,O
ocular,O
history,O
on,O
entry,O
",",O
42%,O
had,O
active,O
uveitis,I-Entity
on,O
entry,O
.,O
Our,O
approach,O
was,O
effective,O
in,O
detecting,O
uveitis,I-Entity
in,O
new,O
cases,O
and,O
exacerbations,O
of,O
uveitis,I-Entity
in,O
established,O
cases,O
.,O
Forty,O
-,O
four,O
percent,O
of,O
patients,O
with,O
uveitis,I-Entity
had,O
one,O
or,O
more,O
identifiable,O
signs,O
or,O
symptoms,O
",",O
such,O
as,O
red,O
eye,O
",",O
ocular,B-Entity
pain,I-Entity
",",O
decreased,B-Entity
visual,I-Entity
acuity,I-Entity
",",O
or,O
photophobia,I-Entity
",",O
in,O
order,O
of,O
decreasing,O
frequency,O
.,O
Even,O
after,O
early,O
detection,O
and,O
prompt,O
treatment,O
",",O
41%,O
of,O
cases,O
of,O
uveitis,I-Entity
did,O
not,O
respond,O
to,O
more,O
than,O
six,O
months,O
of,O
intensive,O
topical,O
treatment,O
with,O
corticosteroids,I-Entity
and,O
mydriatics,O
.,O
Despite,O
this,O
",",O
there,O
was,O
a,O
dramatic,O
decrease,O
in,O
the,O
50%,O
incidence,O
of,O
blinding,O
complications,O
of,O
uveitis,I-Entity
cited,O
in,O
earlier,O
studies,O
.,O
Cataract,I-Entity
and,O
band,B-Entity
keratopathy,I-Entity
occurred,O
in,O
only,O
22,O
and,O
13%,O
of,O
our,O
group,O
",",O
respectively,O
.,O
We,O
used,O
chloroquine,I-Entity
or,O
hydroxychloroquine,I-Entity
in,O
173,O
of,O
210,O
cases,O
and,O
found,O
only,O
one,O
case,O
of,O
chorioretinopathy,I-Entity
attributable,O
to,O
these,O
drugs,O
.,O
Systemically,O
administered,O
corticosteroids,I-Entity
were,O
used,O
in,O
75,O
of,O
210,O
cases,O
;,O
a,O
significant,O
number,O
of,O
posterior,O
subcapsular,O
cataracts,I-Entity
was,O
found,O
.,O
Typical,O
keratoconjunctivitis,I-Entity
sicca,O
developed,O
in,O
three,O
of,O
the,O
uveitis,I-Entity
cases,O
.,O
This,O
association,O
with,O
uveitis,I-Entity
and,O
JRA,O
was,O
not,O
noted,O
previously,O
.,O
Surgical,O
treatment,O
of,O
cataracts,I-Entity
",",O
band,B-Entity
keratopathy,I-Entity
",",O
and,O
glaucoma,I-Entity
achieved,O
uniformly,O
discouraging,O
results,O
.,O
Water,B-Entity
intoxication,I-Entity
associated,O
with,O
oxytocin,I-Entity
administration,O
during,O
saline,O
-,O
induced,O
abortion,I-Entity
.,O
Four,O
cases,O
of,O
water,B-Entity
intoxication,I-Entity
in,O
connection,O
with,O
oxytocin,I-Entity
administration,O
during,O
saline,O
-,O
induced,O
abortions,I-Entity
are,O
described,O
.,O
The,O
mechanism,O
of,O
water,B-Entity
intoxication,I-Entity
is,O
discussed,O
in,O
regard,O
to,O
these,O
cases,O
.,O
Oxytocin,I-Entity
administration,O
during,O
midtrimester,O
-,O
induced,O
abortions,I-Entity
is,O
advocated,O
only,O
if,O
it,O
can,O
be,O
carried,O
out,O
under,O
careful,O
observations,O
of,O
an,O
alert,O
nursing,O
staff,O
",",O
aware,O
of,O
the,O
symptoms,O
of,O
water,B-Entity
intoxication,I-Entity
and,O
instructed,O
to,O
watch,O
the,O
diuresis,O
and,O
report,O
such,O
early,O
signs,O
of,O
the,O
syndrome,O
as,O
asthenia,I-Entity
",",O
muscular,O
irritability,I-Entity
",",O
or,O
headaches,I-Entity
.,O
The,O
oxytocin,I-Entity
should,O
be,O
given,O
only,O
in,O
Ringers,O
lactate,I-Entity
or,O
",",O
alternately,O
",",O
in,O
Ringers,O
lactate,I-Entity
and,O
a,O
5,O
per,O
cent,O
dextrose,I-Entity
and,O
water,O
solutions,O
.,O
The,O
urinary,O
output,O
should,O
be,O
monitored,O
and,O
the,O
oxytocin,I-Entity
administration,O
discontinued,O
and,O
the,O
serum,O
electrolytes,O
checked,O
if,O
the,O
urinary,O
output,O
decreases,O
.,O
The,O
oxytocin,I-Entity
should,O
not,O
be,O
administered,O
in,O
excess,O
of,O
36,O
hours,O
.,O
If,O
the,O
patient,O
has,O
not,O
aborted,O
by,O
then,O
the,O
oxytocin,I-Entity
should,O
be,O
discontinued,O
for,O
10,O
to,O
12,O
hours,O
in,O
order,O
to,O
perform,O
electrolyte,O
determinations,O
and,O
correct,O
any,O
electrolyte,O
imbalance,O
.,O
